<SEC-DOCUMENT>0000722830-20-000003.txt : 20200227
<SEC-HEADER>0000722830-20-000003.hdr.sgml : 20200227
<ACCEPTANCE-DATETIME>20200227160606
ACCESSION NUMBER: 0000722830-20-000003
CONFORMED SUBMISSION TYPE: 10-K
PUBLIC DOCUMENT COUNT: 95
CONFORMED PERIOD OF REPORT: 20191231
FILED AS OF DATE: 20200227
DATE AS OF CHANGE: 20200227
FILER:
COMPANY DATA:
COMPANY CONFORMED NAME: IMMUNOMEDICS INC
CENTRAL INDEX KEY: 0000722830
STANDARD INDUSTRIAL CLASSIFICATION: IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES [2835]
IRS NUMBER: 611009366
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
FILING VALUES:
FORM TYPE: 10-K
SEC ACT: 1934 Act
SEC FILE NUMBER: 000-12104
FILM NUMBER: 20661954
BUSINESS ADDRESS:
STREET 1: 300 AMERICAN RD
CITY: MORRIS PLAINS
STATE: NJ
ZIP: 07950
BUSINESS PHONE: 9736058200
MAIL ADDRESS:
STREET 1: 300 AMERICAN ROAD
CITY: MORRIS PLAINS
STATE: NJ
ZIP: 07950
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-K
<SEQUENCE>1
<FILENAME>immu201910-k.htm
<DESCRIPTION>10-K - 12/31/2019
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>
<!--XBRL Document Created with Wdesk from Workiva-->
<!--p:1AA2916889EC5DF9A45659BE8C4A13AE,x:a77d249ff6e1498bb3f4832259286dc3-->
<!-- Document created using Wdesk -->
<!-- Copyright 2020 Workiva -->
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:schedoi-fednote="http://fasb.org/dis/schedoi-fednote/2019-01-31" xmlns:fs-interest="http://fasb.org/dis/fs-interest/2019-01-31" xmlns:sfp-ibo="http://fasb.org/stm/sfp-ibo/2019-01-31" xmlns:sfp-sbo="http://fasb.org/stm/sfp-sbo/2019-01-31" xmlns:sic-std="http://xbrl.sec.gov/sic-std/2011-01-31" xmlns:stpr-std="http://xbrl.sec.gov/stpr-std-std-std/2018-01-31" xmlns:currency-ent-std="http://xbrl.sec.gov/currency-ent-std/2019-01-31" xmlns:lea="http://fasb.org/dis/lea/2019-01-31" xmlns:ctbl="http://fasb.org/dis/ctbl/2019-01-31" xmlns:guar="http://fasb.org/dis/guar/2019-01-31" xmlns:ru="http://fasb.org/dis/ru/2019-01-31" xmlns:stpr-all="http://xbrl.sec.gov/stpr-all-all-all/2018-01-31" xmlns:leas="http://fasb.org/dis/leas/2019-01-31" xmlns:sfp-clreo="http://fasb.org/stm/sfp-clreo/2019-01-31" xmlns:iaoi="http://fasb.org/dis/iaoi/2019-01-31" xmlns:soi-ins="http://fasb.org/stm/soi-ins/2019-01-31" xmlns:country-ent-std="http://xbrl.sec.gov/country-ent-std/2017-01-31" xmlns:country="http://xbrl.sec.gov/country/2017-01-31" xmlns:fs-insa="http://fasb.org/dis/fs-insa/2019-01-31" xmlns:naics="http://xbrl.sec.gov/naics/2017-01-31" xmlns:cce="http://fasb.org/dis/cce/2019-01-31" xmlns:inv="http://fasb.org/dis/inv/2019-01-31" xmlns:naics-ent-std="http://xbrl.sec.gov/naics-ent-std/2017-01-31" xmlns:srt-std="http://fasb.org/srt-std/2019-01-31" xmlns:stpr-ent-all="http://xbrl.sec.gov/stpr-ent-all-all-all/2018-01-31" xmlns:stpr-ent-std="http://xbrl.sec.gov/stpr-ent-std-std-std/2018-01-31" xmlns:schedoi-iiaa="http://fasb.org/dis/schedoi-iiaa/2019-01-31" xmlns:us-arcroles="http://fasb.org/us-arcroles/2019-01-31" xmlns:dccpoa="http://fasb.org/dis/dccpoa/2019-01-31" xmlns:soi-sbi="http://fasb.org/stm/soi-sbi/2019-01-31" xmlns:us-gaap-all="http://fasb.org/us-gaap-all/2019-01-31" xmlns:scf-sd="http://fasb.org/stm/scf-sd/2019-01-31" xmlns:ceclcalc3l="http://fasb.org/dis/ceclcalc3l/2019-01-31" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:dei-ent-all="http://xbrl.sec.gov/dei-ent-all/2019-01-31" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:deprecated="http://www.xbrl.org/2009/arcrole/deprecated" xmlns:naics-all="http://xbrl.sec.gov/naics-all/2017-01-31" xmlns:re="http://fasb.org/dis/re/2019-01-31" xmlns:srt-types="http://fasb.org/srt-types/2019-01-31" xmlns:reorg="http://fasb.org/dis/reorg/2019-01-31" xmlns:invco="http://fasb.org/dis/invco/2019-01-31" xmlns:currency-ent-all="http://xbrl.sec.gov/currency-ent-all/2019-01-31" xmlns:currency-std="http://xbrl.sec.gov/currency-std/2019-01-31" xmlns:currency-ent-dep="http://xbrl.sec.gov/currency-ent-dep/2019-01-31" xmlns:aro="http://fasb.org/dis/aro/2019-01-31" xmlns:exch="http://xbrl.sec.gov/exch/2019-01-31" xmlns:ocpfs="http://fasb.org/dis/ocpfs/2019-01-31" xmlns:currency="http://xbrl.sec.gov/currency/2019-01-31" xmlns:naics-std="http://xbrl.sec.gov/naics-std/2017-01-31" xmlns:srt-all="http://fasb.org/srt-all/2019-01-31" xmlns:codification-part="http://fasb.org/codification-part/2019-01-31" xmlns:srt="http://fasb.org/srt/2019-01-31" xmlns:deprecated1="http://www.xbrl.org/2009/role/deprecated" xmlns:sec-re="http://fasb.org/dis/sec-re/2019-01-31" xmlns:soi-int="http://fasb.org/stm/soi-int/2019-01-31" xmlns:emjv="http://fasb.org/dis/emjv/2019-01-31" xmlns:sec-suppc="http://fasb.org/dis/sec-suppc/2019-01-31" xmlns:equity="http://fasb.org/dis/equity/2019-01-31" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:se="http://fasb.org/dis/se/2019-01-31" xmlns:crcrb="http://fasb.org/dis/crcrb/2019-01-31" xmlns:edco="http://fasb.org/dis/edco/2019-01-31" xmlns:te="http://fasb.org/dis/te/2019-01-31" xmlns:dei-all="http://xbrl.sec.gov/dei-all/2019-01-31" xmlns:fs-bd="http://fasb.org/dis/fs-bd/2019-01-31" xmlns:invest-all="http://xbrl.sec.gov/invest-all/2013-01-31" xmlns:hco="http://fasb.org/dis/hco/2019-01-31" xmlns:fs-bt="http://fasb.org/dis/fs-bt/2019-01-31" xmlns:us-roles="http://fasb.org/us-roles/2019-01-31" xmlns:dr="http://fasb.org/dis/dr/2019-01-31" xmlns:ero="http://fasb.org/dis/ero/2019-01-31" xmlns:country-ent-all="http://xbrl.sec.gov/country-ent-all/2017-01-31" xmlns:schedoi-oocw="http://fasb.org/dis/schedoi-oocw/2019-01-31" xmlns:cecl="http://fasb.org/dis/cecl/2019-01-31" xmlns:rpd="http://fasb.org/dis/rpd/2019-01-31" xmlns:schedoi-sumhold="http://fasb.org/dis/schedoi-sumhold/2019-01-31" xmlns:ceclcalc2="http://fasb.org/dis/ceclcalc2/2019-01-31" xmlns:othliab="http://fasb.org/dis/othliab/2019-01-31" xmlns:soi-egm="http://fasb.org/stm/soi-egm/2019-01-31" xmlns:schedoi-shorthold="http://fasb.org/dis/schedoi-shorthold/2019-01-31" xmlns:soi="http://fasb.org/stm/soi/2019-01-31" xmlns:diha="http://fasb.org/dis/diha/2019-01-31" xmlns:debt="http://fasb.org/dis/debt/2019-01-31" xmlns:schedoi-hold="http://fasb.org/dis/schedoi-hold/2019-01-31" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:invest-std="http://xbrl.sec.gov/invest-std/2013-01-31" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:us-gaap-ent-std="http://fasb.org/us-gaap-ent-std/2019-01-31" xmlns:bc="http://fasb.org/dis/bc/2019-01-31" xmlns:sic-ent-all="http://xbrl.sec.gov/sic-ent-all/2011-01-31" xmlns:exch-ent-std="http://xbrl.sec.gov/exch-ent-std/2019-01-31" xmlns:invest-ent-all="http://xbrl.sec.gov/invest-ent-all/2013-01-31" xmlns:rcc="http://fasb.org/dis/rcc/2019-01-31" xmlns:rd="http://fasb.org/dis/rd/2019-01-31" xmlns:sfp-ucreo="http://fasb.org/stm/sfp-ucreo/2019-01-31" xmlns:immu="http://www.immunomedics.com/20191231" xmlns:eui="http://fasb.org/dis/eui/2019-01-31" xmlns:dei="http://xbrl.sec.gov/dei/2019-01-31" xmlns:ap="http://fasb.org/dis/ap/2019-01-31" xmlns:soi-reit="http://fasb.org/stm/soi-reit/2019-01-31" xmlns:fs-mort="http://fasb.org/dis/fs-mort/2019-01-31" xmlns:sec-reins="http://fasb.org/dis/sec-reins/2019-01-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:sec-cndfir="http://fasb.org/dis/sec-cndfir/2019-01-31" xmlns:sr="http://fasb.org/dis/sr/2019-01-31" xmlns:currency-all="http://xbrl.sec.gov/currency-all/2019-01-31" xmlns:scf-dbo="http://fasb.org/stm/scf-dbo/2019-01-31" xmlns:fs-fhlb="http://fasb.org/dis/fs-fhlb/2019-01-31" xmlns:crcpb="http://fasb.org/dis/crcpb/2019-01-31" xmlns:dei-ent-std="http://xbrl.sec.gov/dei-ent-std/2019-01-31" xmlns:us-types="http://fasb.org/us-types/2019-01-31" xmlns:scf-inv="http://fasb.org/stm/scf-inv/2019-01-31" xmlns:scf-indira="http://fasb.org/stm/scf-indira/2019-01-31" xmlns:bsoff="http://fasb.org/dis/bsoff/2019-01-31" xmlns:exch-ent-all="http://xbrl.sec.gov/exch-ent-all/2019-01-31" xmlns:oi="http://fasb.org/dis/oi/2019-01-31" xmlns:soi-indira="http://fasb.org/stm/soi-indira/2019-01-31" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:schedoi-otsh="http://fasb.org/dis/schedoi-otsh/2019-01-31" xmlns:sfp-dbo="http://fasb.org/stm/sfp-dbo/2019-01-31" xmlns:cc="http://fasb.org/dis/cc/2019-01-31" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:crcsbp="http://fasb.org/dis/crcsbp/2019-01-31" xmlns:disops="http://fasb.org/dis/disops/2019-01-31" xmlns:reference="http://www.xbrl.org/2009/role/reference" xmlns:cn-part="http://fasb.org/cn-part/2019-01-31" xmlns:us-gaap="http://fasb.org/us-gaap/2019-01-31" xmlns:srt-roles="http://fasb.org/srt-roles/2019-01-31" xmlns:country-std="http://xbrl.sec.gov/country-std/2017-01-31" xmlns:net="http://www.xbrl.org/2009/role/net" xmlns:scf-indir="http://fasb.org/stm/scf-indir/2019-01-31" xmlns:rlnro="http://fasb.org/dis/rlnro/2019-01-31" xmlns:ts="http://fasb.org/dis/ts/2019-01-31" xmlns:us-gaap-std="http://fasb.org/us-gaap-std/2019-01-31" xmlns:naics-ent-all="http://xbrl.sec.gov/naics-ent-all/2017-01-31" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:scf-dir="http://fasb.org/stm/scf-dir/2019-01-31" xmlns:dei-std="http://xbrl.sec.gov/dei-std/2019-01-31" xmlns:ni="http://fasb.org/dis/ni/2019-01-31" xmlns:sec-mort="http://fasb.org/dis/sec-mort/2019-01-31" xmlns:fifvd="http://fasb.org/dis/fifvd/2019-01-31" xmlns:otherexp="http://fasb.org/dis/otherexp/2019-01-31" xmlns:scf-re="http://fasb.org/stm/scf-re/2019-01-31" xmlns:sec-vq="http://fasb.org/dis/sec-vq/2019-01-31" xmlns:sec-sum="http://fasb.org/dis/sec-sum/2019-01-31" xmlns:exch-std="http://xbrl.sec.gov/exch-std/2019-01-31" xmlns:invest="http://xbrl.sec.gov/invest/2013-01-31" xmlns:ir="http://fasb.org/dis/ir/2019-01-31" xmlns:sheci="http://fasb.org/stm/sheci/2019-01-31" xmlns:foct="http://fasb.org/dis/foct/2019-01-31" xmlns:soc="http://fasb.org/stm/soc/2019-01-31" xmlns:scf-sbo="http://fasb.org/stm/scf-sbo/2019-01-31" xmlns:inctax="http://fasb.org/dis/inctax/2019-01-31" xmlns:ppe="http://fasb.org/dis/ppe/2019-01-31" xmlns:country-all="http://xbrl.sec.gov/country-all/2017-01-31" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:con="http://fasb.org/dis/con/2019-01-31" xmlns:sic-ent-std="http://xbrl.sec.gov/sic-ent-std/2011-01-31" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:invest-ent-std="http://xbrl.sec.gov/invest-ent-std/2013-01-31" xmlns:fs-ins="http://fasb.org/dis/fs-ins/2019-01-31" xmlns:eps="http://fasb.org/dis/eps/2019-01-31" xmlns:stpr="http://xbrl.sec.gov/stpr/2018-01-31" xmlns:iago="http://fasb.org/dis/iago/2019-01-31" xmlns:pay="http://fasb.org/dis/pay/2019-01-31" xmlns:sic="http://xbrl.sec.gov/sic/2011-01-31" xmlns:tin-part="http://fasb.org/tin-part/2019-01-31" xmlns:acec="http://fasb.org/dis/acec/2019-01-31" xmlns:us-gaap-entryPoint-all="http://fasb.org/us-gaap-entryPoint-all/2019-01-31" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:nt="http://fasb.org/dis/nt/2019-01-31" xmlns:spc="http://fasb.org/stm/spc/2019-01-31" xmlns:exch-all="http://xbrl.sec.gov/exch-all/2019-01-31" xmlns:ides="http://fasb.org/dis/ides/2019-01-31" xmlns:sec-supins="http://fasb.org/dis/sec-supins/2019-01-31" xmlns:sic-all="http://xbrl.sec.gov/sic-all/2011-01-31" xmlns:xl="http://www.xbrl.org/2003/XLink" xmlns:regop="http://fasb.org/dis/regop/2019-01-31" xmlns:sfp-cls="http://fasb.org/stm/sfp-cls/2019-01-31" xmlns:com="http://fasb.org/stm/com/2019-01-31" xmlns:soi-re="http://fasb.org/stm/soi-re/2019-01-31" xmlns:crcgen="http://fasb.org/dis/crcgen/2019-01-31" xmlns:exch-ent-dep="http://xbrl.sec.gov/exch-ent-dep/2019-01-31" xmlns:negated="http://www.xbrl.org/2009/role/negated" xmlns:ei="http://fasb.org/dis/ei/2019-01-31" xmlns:xbrldt="http://xbrl.org/2005/xbrldt">
<head>
<meta http-equiv="Content-Type" content="text/html" />
<title>Document</title>
</head>
<body><div style="font-family:Times New Roman;font-size:10pt;">
<div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="FD2019Q4YTD" name="dei:AmendmentFlag" id="Fact-A7ED97D1522841A5D150D1D0180BC50D-wk-Fact-A7ED97D1522841A5D150D1D0180BC50D" format="ixt:booleanfalse">false</ix:nonNumeric><ix:nonNumeric contextRef="FD2019Q4YTD" name="dei:CurrentFiscalYearEndDate" id="Fact-6D26DEC0D558C2419AAAD1D0182AA2F8-wk-Fact-6D26DEC0D558C2419AAAD1D0182AA2F8">--12-31</ix:nonNumeric><ix:nonNumeric contextRef="FD2019Q4YTD" name="dei:DocumentFiscalPeriodFocus" id="Fact-34211CACF3D3AE7AFCAED1D0182ADA02-wk-Fact-34211CACF3D3AE7AFCAED1D0182ADA02">FY</ix:nonNumeric><ix:nonNumeric contextRef="FD2019Q4YTD" name="dei:DocumentFiscalYearFocus" id="Fact-61FC478C35788B3FF839D1D0183CD355-wk-Fact-61FC478C35788B3FF839D1D0183CD355">2019</ix:nonNumeric><ix:nonNumeric contextRef="FD2019Q4YTD" name="dei:EntityCentralIndexKey" id="Fact-5178AE335880E3EBF516D1D0181BF030-wk-Fact-5178AE335880E3EBF516D1D0181BF030">0000722830</ix:nonNumeric><ix:nonFraction decimals="-3" unitRef="usd" contextRef="FI2019Q4_srt_CounterpartyNameAxis_immu_RpiFinanceTrustMember_us-gaap_DeferredRevenueArrangementTypeAxis_us-gaap_RoyaltyArrangementMember" name="immu:LiabilitiesRelatedToTheSaleOfFutureRoyaltiesCurrent" id="Fact-39ECAF244C156AB47C9179F5015E81CE-wk-Fact-39ECAF244C156AB47C9179F5015E81CE">3455000</ix:nonFraction><ix:nonFraction decimals="-3" unitRef="usd" contextRef="D2017Q4Jul012016toJun302017" name="immu:OperatingLossCarryforwardResultingFromSale" id="Fact-D4FFF04AA2D0FAACC69CD1D0180B787C-wk-Fact-D4FFF04AA2D0FAACC69CD1D0180B787C">0</ix:nonFraction><ix:nonFraction decimals="-3" unitRef="usd" contextRef="D2018Q4Jul01-Dec31" name="immu:OperatingLossCarryforwardResultingFromSale" id="Fact-57923928CEC3D2FA06FDD1D0180BCB12-wk-Fact-57923928CEC3D2FA06FDD1D0180BCB12">0</ix:nonFraction><ix:nonNumeric contextRef="FD2019Q4YTD_srt_TitleOfIndividualAxis_srt_ChiefExecutiveOfficerMember" name="immu:SupplementalUnemploymentBenefitsSeveranceBenefitsPaymentTerm" id="Fact-2AFBE0F36BDB270D9B2E7D11E460BCF3-wk-Fact-2AFBE0F36BDB270D9B2E7D11E460BCF3">P18M</ix:nonNumeric><ix:nonFraction decimals="-3" unitRef="usd" contextRef="FI2019Q4" name="us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent" id="Fact-F22614965E2A8C15D444D705B07F4628-wk-Fact-F22614965E2A8C15D444D705B07F4628">0</ix:nonFraction><ix:nonFraction decimals="INF" unitRef="usdPerShare" contextRef="FI2018Q4" name="us-gaap:CommonStockParOrStatedValuePerShare" id="Fact-72A1C5BDA1F915B4856BD1D0184BB1F5-wk-Fact-72A1C5BDA1F915B4856BD1D0184BB1F5">0.01</ix:nonFraction><ix:nonFraction decimals="INF" unitRef="usdPerShare" contextRef="FI2019Q4" name="us-gaap:CommonStockParOrStatedValuePerShare" id="Fact-B296A6C9EE4BAE19647ED1D0184BADAE-wk-Fact-B296A6C9EE4BAE19647ED1D0184BADAE">0.01</ix:nonFraction><ix:nonFraction decimals="INF" unitRef="shares" contextRef="FI2018Q4" name="us-gaap:CommonStockSharesAuthorized" id="Fact-07FCE8C270B3BDB90324D1D0184BCE6A-wk-Fact-07FCE8C270B3BDB90324D1D0184BCE6A">250000000</ix:nonFraction><ix:nonFraction decimals="INF" unitRef="shares" contextRef="FI2019Q4" name="us-gaap:CommonStockSharesAuthorized" id="Fact-07E34C26D1D09BC194A7D1D0184BEC81-wk-Fact-07E34C26D1D09BC194A7D1D0184BEC81">250000000</ix:nonFraction><ix:nonFraction decimals="INF" unitRef="shares" contextRef="FI2018Q4" name="us-gaap:CommonStockSharesIssued" id="Fact-6F0B1B4EAE9E268D14D4D1D0184B55F2-wk-Fact-6F0B1B4EAE9E268D14D4D1D0184B55F2">190445795</ix:nonFraction><ix:nonFraction decimals="INF" unitRef="shares" contextRef="FI2019Q4" name="us-gaap:CommonStockSharesIssued" id="Fact-082991A6B0F12CC2258FD1D0184B7DE9-wk-Fact-082991A6B0F12CC2258FD1D0184B7DE9">212529313</ix:nonFraction><ix:nonFraction decimals="INF" unitRef="shares" contextRef="FI2018Q4" name="us-gaap:CommonStockSharesOutstanding" id="Fact-352369FBB236E3001FABD1D0184BD16E-wk-Fact-352369FBB236E3001FABD1D0184BD16E">190411070</ix:nonFraction><ix:nonFraction decimals="INF" unitRef="shares" contextRef="FI2019Q4" name="us-gaap:CommonStockSharesOutstanding" id="Fact-16ECE8B36A54E6116210D1D0184BD7C9-wk-Fact-16ECE8B36A54E6116210D1D0184BD7C9">212409692</ix:nonFraction><ix:nonNumeric contextRef="D2017Q3Feb10-Feb10_srt_CounterpartyNameAxis_immu_SeattleGeneticsIncMember_us-gaap_TypeOfArrangementAxis_immu_SecuritiesPurchaseAgreementMember" name="us-gaap:DebtInstrumentTerm" id="Fact-BE9B8FFC929585B1D7CA454A8E13CBDA-wk-Fact-BE9B8FFC929585B1D7CA454A8E13CBDA">P3Y</ix:nonNumeric><ix:nonFraction decimals="-5" unitRef="usd" contextRef="D2017Q4Jul012016toJun302017" name="us-gaap:DefinedBenefitPlanContributionsByEmployer" id="Fact-5CBE9B8D3ABAB124085E63716174017B-wk-Fact-5CBE9B8D3ABAB124085E63716174017B">100000</ix:nonFraction><ix:nonFraction decimals="-5" unitRef="usd" contextRef="D2018Q4Jul12017toJun302018" name="us-gaap:DefinedBenefitPlanContributionsByEmployer" id="Fact-CE1461802A0C335E9D3D63715629B431-wk-Fact-CE1461802A0C335E9D3D63715629B431">100000</ix:nonFraction><ix:nonFraction decimals="INF" unitRef="usdPerShare" contextRef="FI2018Q4_us-gaap_StatementClassOfStockAxis_us-gaap_ConvertiblePreferredStockMember" name="us-gaap:PreferredStockParOrStatedValuePerShare" id="Fact-3404D2B2E98069147F8CD1D0184BFDB1-wk-Fact-3404D2B2E98069147F8CD1D0184BFDB1">0.01</ix:nonFraction><ix:nonFraction decimals="INF" unitRef="usdPerShare" contextRef="FI2019Q4_us-gaap_StatementClassOfStockAxis_us-gaap_ConvertiblePreferredStockMember" name="us-gaap:PreferredStockParOrStatedValuePerShare" id="Fact-647522B2D6A369FBC5DDD1D0184BD8B1-wk-Fact-647522B2D6A369FBC5DDD1D0184BD8B1">0.01</ix:nonFraction><ix:nonFraction decimals="INF" unitRef="shares" contextRef="FI2018Q4_us-gaap_StatementClassOfStockAxis_us-gaap_ConvertiblePreferredStockMember" name="us-gaap:PreferredStockSharesAuthorized" id="Fact-872AACA4AA08EDB0198ED1D0184B41D4-wk-Fact-872AACA4AA08EDB0198ED1D0184B41D4">10000000</ix:nonFraction><ix:nonFraction decimals="INF" unitRef="shares" contextRef="FI2019Q4_us-gaap_StatementClassOfStockAxis_us-gaap_ConvertiblePreferredStockMember" name="us-gaap:PreferredStockSharesAuthorized" id="Fact-23A5205ADADE42E75B15D1D0184B2452-wk-Fact-23A5205ADADE42E75B15D1D0184B2452">10000000</ix:nonFraction><ix:nonFraction decimals="INF" unitRef="shares" contextRef="FI2018Q4_us-gaap_StatementClassOfStockAxis_us-gaap_ConvertiblePreferredStockMember" name="us-gaap:PreferredStockSharesIssued" id="Fact-CBEC72BB42FF73F5F8A1D704C1894CCA-wk-Fact-CBEC72BB42FF73F5F8A1D704C1894CCA">0</ix:nonFraction><ix:nonFraction decimals="INF" unitRef="shares" contextRef="FI2019Q4_us-gaap_StatementClassOfStockAxis_us-gaap_ConvertiblePreferredStockMember" name="us-gaap:PreferredStockSharesIssued" id="Fact-CA34D697574D6AC492CAD704C160E73D-wk-Fact-CA34D697574D6AC492CAD704C160E73D">0</ix:nonFraction><ix:nonFraction decimals="INF" unitRef="shares" contextRef="FI2018Q4_us-gaap_StatementClassOfStockAxis_us-gaap_ConvertiblePreferredStockMember" name="us-gaap:PreferredStockSharesOutstanding" id="Fact-5F6B7F3669A30E367ABCD704D7B0FE5B-wk-Fact-5F6B7F3669A30E367ABCD704D7B0FE5B">0</ix:nonFraction><ix:nonFraction decimals="INF" unitRef="shares" contextRef="FI2019Q4_us-gaap_StatementClassOfStockAxis_us-gaap_ConvertiblePreferredStockMember" name="us-gaap:PreferredStockSharesOutstanding" id="Fact-180D1B7715506AE0A952D704D7B07073-wk-Fact-180D1B7715506AE0A952D704D7B07073">0</ix:nonFraction><ix:nonFraction decimals="4" unitRef="number" contextRef="D2017Q4Jul012016toJun302017_srt_RangeAxis_srt_MaximumMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" id="Fact-F04A0F79EE45EBF5D04CD1D0181BDBA0-wk-Fact-F04A0F79EE45EBF5D04CD1D0181BDBA0">0.0215</ix:nonFraction><ix:nonFraction decimals="4" unitRef="number" contextRef="D2017Q4Jul012016toJun302017_srt_RangeAxis_srt_MinimumMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" id="Fact-A9D5BFA60F5C865B14CDD1D0181B6103-wk-Fact-A9D5BFA60F5C865B14CDD1D0181B6103">0.0116</ix:nonFraction><ix:nonFraction decimals="4" unitRef="number" contextRef="D2018Q4Jul01-Dec31_srt_RangeAxis_srt_MaximumMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" id="Fact-5CE7C6AED3E35887862ED1D0182A4C71-wk-Fact-5CE7C6AED3E35887862ED1D0182A4C71">0.0306</ix:nonFraction><ix:nonFraction decimals="4" unitRef="number" contextRef="D2018Q4Jul01-Dec31_srt_RangeAxis_srt_MinimumMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" id="Fact-CD5262D1B993A1AEC157D1D0181B1C0F-wk-Fact-CD5262D1B993A1AEC157D1D0181B1C0F">0.0269</ix:nonFraction><ix:nonFraction decimals="4" unitRef="number" contextRef="D2018Q4Jul12017toJun302018_srt_RangeAxis_srt_MaximumMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" id="Fact-08CF791FF5DE3B4673F6D1D0181B9D67-wk-Fact-08CF791FF5DE3B4673F6D1D0181B9D67">0.0289</ix:nonFraction><ix:nonFraction decimals="4" unitRef="number" contextRef="D2018Q4Jul12017toJun302018_srt_RangeAxis_srt_MinimumMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" id="Fact-29339EDF21FB4F9C3678D1D0181B2FC7-wk-Fact-29339EDF21FB4F9C3678D1D0181B2FC7">0.0172</ix:nonFraction><ix:nonFraction decimals="4" unitRef="number" contextRef="FD2019Q4YTD_srt_RangeAxis_srt_MaximumMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" id="Fact-C4487818F169E75E5052D1D0180BC5A7-wk-Fact-C4487818F169E75E5052D1D0180BC5A7">0.0258</ix:nonFraction><ix:nonFraction decimals="4" unitRef="number" contextRef="FD2019Q4YTD_srt_RangeAxis_srt_MinimumMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" id="Fact-85F70D3379BD181B66F2D1D0181BCC77-wk-Fact-85F70D3379BD181B66F2D1D0181BCC77">0.0139</ix:nonFraction><ix:nonFraction decimals="INF" unitRef="shares" contextRef="D2017Q4Jul012016toJun302017_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" id="Fact-15EB1D31C1405747630ED1D0182A4F45-wk-Fact-15EB1D31C1405747630ED1D0182A4F45">0</ix:nonFraction><ix:nonFraction decimals="INF" unitRef="shares" contextRef="FD2016Q4YTD_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" id="Fact-0BFF1F8D7CCB6AF211D6D1D0182A6F87-wk-Fact-0BFF1F8D7CCB6AF211D6D1D0182A6F87">0</ix:nonFraction><ix:nonNumeric contextRef="FD2019Q4YTD_srt_TitleOfIndividualAxis_immu_ExecutiveDirectorMember" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" id="Fact-3A2872FE26E015689271454D4CF53C5B-wk-Fact-3A2872FE26E015689271454D4CF53C5B">P7Y</ix:nonNumeric><ix:nonFraction decimals="INF" unitRef="shares" contextRef="FI2018Q4" name="us-gaap:TreasuryStockShares" id="Fact-7A32521110195736DBB1D1D0184B9B9A-wk-Fact-7A32521110195736DBB1D1D0184B9B9A">34725</ix:nonFraction><ix:nonFraction decimals="INF" unitRef="shares" contextRef="FI2019Q4" name="us-gaap:TreasuryStockShares" id="Fact-0F5FE4FA3BFAAF62BA34D1D0184B7AE2-wk-Fact-0F5FE4FA3BFAAF62BA34D1D0184B7AE2">119621</ix:nonFraction><ix:nonFraction decimals="INF" unitRef="usd" contextRef="FI2018Q4" name="us-gaap:UndistributedEarningsOfForeignSubsidiaries" id="Fact-4F75A8AB5D78ADF4FD5CD1D0181B2B8E-wk-Fact-4F75A8AB5D78ADF4FD5CD1D0181B2B8E">0</ix:nonFraction></ix:hidden><ix:references><link:schemaRef xlink:href="immu-20191231.xsd" xlink:type="simple"></link:schemaRef></ix:references><ix:resources><xbrli:context id="FD2019Q4YTD">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000722830</xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2019-01-01</xbrli:startDate>
<xbrli:endDate>2019-12-31</xbrli:endDate>
</xbrli:period>
</xbrli:context><xbrli:context id="I2020Q1SharesOutstanding">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000722830</xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>2020-02-21</xbrli:instant>
</xbrli:period>
</xbrli:context><xbrli:context id="FI2019Q2">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000722830</xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>2019-06-30</xbrli:instant>
</xbrli:period>
</xbrli:context><xbrli:context id="FI2018Q4">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000722830</xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>2018-12-31</xbrli:instant>
</xbrli:period>
</xbrli:context><xbrli:context id="FI2019Q4">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000722830</xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>2019-12-31</xbrli:instant>
</xbrli:period>
</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_StatementClassOfStockAxis_us-gaap_ConvertiblePreferredStockMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000722830</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>2018-12-31</xbrli:instant>
</xbrli:period>
</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_StatementClassOfStockAxis_us-gaap_ConvertiblePreferredStockMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000722830</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>2019-12-31</xbrli:instant>
</xbrli:period>
</xbrli:context><xbrli:context id="D2018Q4Jul01-Dec31">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000722830</xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2018-07-01</xbrli:startDate>
<xbrli:endDate>2018-12-31</xbrli:endDate>
</xbrli:period>
</xbrli:context><xbrli:context id="FD2019Q4YTD_srt_ProductOrServiceAxis_immu_ResearchandDevelopmentMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000722830</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">immu:ResearchandDevelopmentMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2019-01-01</xbrli:startDate>
<xbrli:endDate>2019-12-31</xbrli:endDate>
</xbrli:period>
</xbrli:context><xbrli:context id="FD2019Q4YTD_srt_ProductOrServiceAxis_immu_LicenseFreeAndOtherRevenueMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000722830</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">immu:LicenseFreeAndOtherRevenueMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2019-01-01</xbrli:startDate>
<xbrli:endDate>2019-12-31</xbrli:endDate>
</xbrli:period>
</xbrli:context><xbrli:context id="D2018Q4Jul12017toJun302018_srt_ProductOrServiceAxis_immu_ProductSalesMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000722830</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">immu:ProductSalesMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2017-07-01</xbrli:startDate>
<xbrli:endDate>2018-06-30</xbrli:endDate>
</xbrli:period>
</xbrli:context><xbrli:context id="D2018Q4Jul12017toJun302018">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000722830</xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2017-07-01</xbrli:startDate>
<xbrli:endDate>2018-06-30</xbrli:endDate>
</xbrli:period>
</xbrli:context><xbrli:context id="D2017Q4Jul012016toJun302017">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000722830</xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2016-07-01</xbrli:startDate>
<xbrli:endDate>2017-06-30</xbrli:endDate>
</xbrli:period>
</xbrli:context><xbrli:context id="D2018Q4Jul12017toJun302018_srt_ProductOrServiceAxis_immu_LicenseFreeAndOtherRevenueMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000722830</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">immu:LicenseFreeAndOtherRevenueMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2017-07-01</xbrli:startDate>
<xbrli:endDate>2018-06-30</xbrli:endDate>
</xbrli:period>
</xbrli:context><xbrli:context id="D2018Q4Jul01-Dec31_srt_ProductOrServiceAxis_immu_ProductSalesMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000722830</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">immu:ProductSalesMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2018-07-01</xbrli:startDate>
<xbrli:endDate>2018-12-31</xbrli:endDate>
</xbrli:period>
</xbrli:context><xbrli:context id="D2017Q4Jul012016toJun302017_srt_ProductOrServiceAxis_immu_ResearchandDevelopmentMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000722830</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">immu:ResearchandDevelopmentMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2016-07-01</xbrli:startDate>
<xbrli:endDate>2017-06-30</xbrli:endDate>
</xbrli:period>
</xbrli:context><xbrli:context id="D2017Q4Jul012016toJun302017_srt_ProductOrServiceAxis_immu_ProductSalesMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000722830</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">immu:ProductSalesMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2016-07-01</xbrli:startDate>
<xbrli:endDate>2017-06-30</xbrli:endDate>
</xbrli:period>
</xbrli:context><xbrli:context id="D2018Q4Jul01-Dec31_srt_ProductOrServiceAxis_immu_ResearchandDevelopmentMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000722830</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">immu:ResearchandDevelopmentMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2018-07-01</xbrli:startDate>
<xbrli:endDate>2018-12-31</xbrli:endDate>
</xbrli:period>
</xbrli:context><xbrli:context id="D2017Q4Jul012016toJun302017_srt_ProductOrServiceAxis_immu_LicenseFreeAndOtherRevenueMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000722830</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">immu:LicenseFreeAndOtherRevenueMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2016-07-01</xbrli:startDate>
<xbrli:endDate>2017-06-30</xbrli:endDate>
</xbrli:period>
</xbrli:context><xbrli:context id="D2018Q4Jul01-Dec31_srt_ProductOrServiceAxis_immu_LicenseFreeAndOtherRevenueMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000722830</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">immu:LicenseFreeAndOtherRevenueMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2018-07-01</xbrli:startDate>
<xbrli:endDate>2018-12-31</xbrli:endDate>
</xbrli:period>
</xbrli:context><xbrli:context id="FD2019Q4YTD_srt_ProductOrServiceAxis_immu_ProductSalesMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000722830</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">immu:ProductSalesMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2019-01-01</xbrli:startDate>
<xbrli:endDate>2019-12-31</xbrli:endDate>
</xbrli:period>
</xbrli:context><xbrli:context id="D2018Q4Jul12017toJun302018_srt_ProductOrServiceAxis_immu_ResearchandDevelopmentMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000722830</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">immu:ResearchandDevelopmentMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2017-07-01</xbrli:startDate>
<xbrli:endDate>2018-06-30</xbrli:endDate>
</xbrli:period>
</xbrli:context><xbrli:context id="D2018Q4Jul01-Dec31_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000722830</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2018-07-01</xbrli:startDate>
<xbrli:endDate>2018-12-31</xbrli:endDate>
</xbrli:period>
</xbrli:context><xbrli:context id="D2017Q4Jul012016toJun302017_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000722830</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2016-07-01</xbrli:startDate>
<xbrli:endDate>2017-06-30</xbrli:endDate>
</xbrli:period>
</xbrli:context><xbrli:context id="D2017Q4Jul012016toJun302017_srt_CounterpartyNameAxis_immu_SeattleGeneticsIncMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000722830</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">immu:SeattleGeneticsIncMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2016-07-01</xbrli:startDate>
<xbrli:endDate>2017-06-30</xbrli:endDate>
</xbrli:period>
</xbrli:context><xbrli:context id="FI2017Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000722830</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>2017-06-30</xbrli:instant>
</xbrli:period>
</xbrli:context><xbrli:context id="D2017Q4Jul012016toJun302017_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000722830</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2016-07-01</xbrli:startDate>
<xbrli:endDate>2017-06-30</xbrli:endDate>
</xbrli:period>
</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000722830</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>2019-12-31</xbrli:instant>
</xbrli:period>
</xbrli:context><xbrli:context id="FI2016Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000722830</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>2016-06-30</xbrli:instant>
</xbrli:period>
</xbrli:context><xbrli:context id="D2018Q4Jul12017toJun302018_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000722830</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2017-07-01</xbrli:startDate>
<xbrli:endDate>2018-06-30</xbrli:endDate>
</xbrli:period>
</xbrli:context><xbrli:context id="FD2019Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000722830</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2019-01-01</xbrli:startDate>
<xbrli:endDate>2019-12-31</xbrli:endDate>
</xbrli:period>
</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000722830</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>2019-12-31</xbrli:instant>
</xbrli:period>
</xbrli:context><xbrli:context id="D2018Q4Jul01-Dec31_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000722830</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2018-07-01</xbrli:startDate>
<xbrli:endDate>2018-12-31</xbrli:endDate>
</xbrli:period>
</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000722830</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>2018-12-31</xbrli:instant>
</xbrli:period>
</xbrli:context><xbrli:context id="D2018Q4Jul12017toJun302018_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000722830</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2017-07-01</xbrli:startDate>
<xbrli:endDate>2018-06-30</xbrli:endDate>
</xbrli:period>
</xbrli:context><xbrli:context id="FI2016Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000722830</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>2016-06-30</xbrli:instant>
</xbrli:period>
</xbrli:context><xbrli:context id="D2017Q4Jul012016toJun302017_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000722830</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2016-07-01</xbrli:startDate>
<xbrli:endDate>2017-06-30</xbrli:endDate>
</xbrli:period>
</xbrli:context><xbrli:context id="D2018Q4Jul01-Dec31_srt_CounterpartyNameAxis_immu_RpiFinanceTrustMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000722830</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">immu:RpiFinanceTrustMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2018-07-01</xbrli:startDate>
<xbrli:endDate>2018-12-31</xbrli:endDate>
</xbrli:period>
</xbrli:context><xbrli:context id="FI2016Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000722830</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>2016-06-30</xbrli:instant>
</xbrli:period>
</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000722830</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>2019-12-31</xbrli:instant>
</xbrli:period>
</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000722830</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>2018-12-31</xbrli:instant>
</xbrli:period>
</xbrli:context><xbrli:context id="FI2018Q2_us-gaap_StatementClassOfStockAxis_us-gaap_ConvertiblePreferredStockMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000722830</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>2018-06-30</xbrli:instant>
</xbrli:period>
</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000722830</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>2018-12-31</xbrli:instant>
</xbrli:period>
</xbrli:context><xbrli:context id="D2018Q4Jul12017toJun302018_us-gaap_StatementClassOfStockAxis_us-gaap_ConvertiblePreferredStockMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000722830</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2017-07-01</xbrli:startDate>
<xbrli:endDate>2018-06-30</xbrli:endDate>
</xbrli:period>
</xbrli:context><xbrli:context id="FD2019Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000722830</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2019-01-01</xbrli:startDate>
<xbrli:endDate>2019-12-31</xbrli:endDate>
</xbrli:period>
</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000722830</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>2018-12-31</xbrli:instant>
</xbrli:period>
</xbrli:context><xbrli:context id="D2018Q4Jul12017toJun302018_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000722830</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2017-07-01</xbrli:startDate>
<xbrli:endDate>2018-06-30</xbrli:endDate>
</xbrli:period>
</xbrli:context><xbrli:context id="FD2019Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000722830</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2019-01-01</xbrli:startDate>
<xbrli:endDate>2019-12-31</xbrli:endDate>
</xbrli:period>
</xbrli:context><xbrli:context id="D2018Q4Jul12017toJun302018_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000722830</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2017-07-01</xbrli:startDate>
<xbrli:endDate>2018-06-30</xbrli:endDate>
</xbrli:period>
</xbrli:context><xbrli:context id="FI2018Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000722830</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>2018-06-30</xbrli:instant>
</xbrli:period>
</xbrli:context><xbrli:context id="D2017Q4Jul012016toJun302017_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000722830</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2016-07-01</xbrli:startDate>
<xbrli:endDate>2017-06-30</xbrli:endDate>
</xbrli:period>
</xbrli:context><xbrli:context id="FI2017Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000722830</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>2017-06-30</xbrli:instant>
</xbrli:period>
</xbrli:context><xbrli:context id="FI2018Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000722830</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>2018-06-30</xbrli:instant>
</xbrli:period>
</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000722830</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>2019-12-31</xbrli:instant>
</xbrli:period>
</xbrli:context><xbrli:context id="FI2017Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000722830</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>2017-06-30</xbrli:instant>
</xbrli:period>
</xbrli:context><xbrli:context id="FI2016Q4_us-gaap_StatementClassOfStockAxis_us-gaap_ConvertiblePreferredStockMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000722830</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>2016-06-30</xbrli:instant>
</xbrli:period>
</xbrli:context><xbrli:context id="FI2017Q2">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000722830</xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>2017-06-30</xbrli:instant>
</xbrli:period>
</xbrli:context><xbrli:context id="FI2016Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000722830</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>2016-06-30</xbrli:instant>
</xbrli:period>
</xbrli:context><xbrli:context id="D2017Q4Jul012016toJun302017_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000722830</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2016-07-01</xbrli:startDate>
<xbrli:endDate>2017-06-30</xbrli:endDate>
</xbrli:period>
</xbrli:context><xbrli:context id="D2017Q4Jul012016toJun302017_srt_CounterpartyNameAxis_immu_SeattleGeneticsIncMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000722830</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">immu:SeattleGeneticsIncMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2016-07-01</xbrli:startDate>
<xbrli:endDate>2017-06-30</xbrli:endDate>
</xbrli:period>
</xbrli:context><xbrli:context id="D2017Q4Jul012016toJun302017_srt_CounterpartyNameAxis_immu_SeattleGeneticsIncMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000722830</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">immu:SeattleGeneticsIncMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2016-07-01</xbrli:startDate>
<xbrli:endDate>2017-06-30</xbrli:endDate>
</xbrli:period>
</xbrli:context><xbrli:context id="FI2018Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000722830</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>2018-06-30</xbrli:instant>
</xbrli:period>
</xbrli:context><xbrli:context id="FD2019Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000722830</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2019-01-01</xbrli:startDate>
<xbrli:endDate>2019-12-31</xbrli:endDate>
</xbrli:period>
</xbrli:context><xbrli:context id="FI2017Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000722830</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>2017-06-30</xbrli:instant>
</xbrli:period>
</xbrli:context><xbrli:context id="FD2019Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_us-gaap_SubsidiarySaleOfStockAxis_immu_MarketOfferingMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000722830</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">immu:MarketOfferingMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2019-01-01</xbrli:startDate>
<xbrli:endDate>2019-12-31</xbrli:endDate>
</xbrli:period>
</xbrli:context><xbrli:context id="D2018Q4Jul01-Dec31_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000722830</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2018-07-01</xbrli:startDate>
<xbrli:endDate>2018-12-31</xbrli:endDate>
</xbrli:period>
</xbrli:context><xbrli:context id="FI2017Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000722830</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>2017-06-30</xbrli:instant>
</xbrli:period>
</xbrli:context><xbrli:context id="FD2019Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000722830</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2019-01-01</xbrli:startDate>
<xbrli:endDate>2019-12-31</xbrli:endDate>
</xbrli:period>
</xbrli:context><xbrli:context id="D2018Q4Jul01-Dec31_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000722830</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2018-07-01</xbrli:startDate>
<xbrli:endDate>2018-12-31</xbrli:endDate>
</xbrli:period>
</xbrli:context><xbrli:context id="FI2017Q2_us-gaap_StatementClassOfStockAxis_us-gaap_ConvertiblePreferredStockMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000722830</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>2017-06-30</xbrli:instant>
</xbrli:period>
</xbrli:context><xbrli:context id="D2018Q4Jul01-Dec31_srt_CounterpartyNameAxis_immu_RpiFinanceTrustMember_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000722830</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">immu:RpiFinanceTrustMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2018-07-01</xbrli:startDate>
<xbrli:endDate>2018-12-31</xbrli:endDate>
</xbrli:period>
</xbrli:context><xbrli:context id="D2018Q4Jul01-Dec31_srt_CounterpartyNameAxis_immu_RpiFinanceTrustMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000722830</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">immu:RpiFinanceTrustMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2018-07-01</xbrli:startDate>
<xbrli:endDate>2018-12-31</xbrli:endDate>
</xbrli:period>
</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000722830</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>2018-12-31</xbrli:instant>
</xbrli:period>
</xbrli:context><xbrli:context id="FD2019Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_us-gaap_SubsidiarySaleOfStockAxis_immu_MarketOfferingMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000722830</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">immu:MarketOfferingMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2019-01-01</xbrli:startDate>
<xbrli:endDate>2019-12-31</xbrli:endDate>
</xbrli:period>
</xbrli:context><xbrli:context id="D2018Q4Jul12017toJun302018_srt_CounterpartyNameAxis_immu_RpiFinanceTrustMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000722830</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">immu:RpiFinanceTrustMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2017-07-01</xbrli:startDate>
<xbrli:endDate>2018-06-30</xbrli:endDate>
</xbrli:period>
</xbrli:context><xbrli:context id="FD2019Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000722830</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2019-01-01</xbrli:startDate>
<xbrli:endDate>2019-12-31</xbrli:endDate>
</xbrli:period>
</xbrli:context><xbrli:context id="D2017Q4Jul012016toJun302017_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000722830</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2016-07-01</xbrli:startDate>
<xbrli:endDate>2017-06-30</xbrli:endDate>
</xbrli:period>
</xbrli:context><xbrli:context id="D2018Q4Jul01-Dec31_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000722830</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2018-07-01</xbrli:startDate>
<xbrli:endDate>2018-12-31</xbrli:endDate>
</xbrli:period>
</xbrli:context><xbrli:context id="D2017Q4Jul012016toJun302017_us-gaap_StatementClassOfStockAxis_us-gaap_ConvertiblePreferredStockMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000722830</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2016-07-01</xbrli:startDate>
<xbrli:endDate>2017-06-30</xbrli:endDate>
</xbrli:period>
</xbrli:context><xbrli:context id="FD2019Q4YTD_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000722830</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2019-01-01</xbrli:startDate>
<xbrli:endDate>2019-12-31</xbrli:endDate>
</xbrli:period>
</xbrli:context><xbrli:context id="FI2017Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000722830</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>2017-06-30</xbrli:instant>
</xbrli:period>
</xbrli:context><xbrli:context id="FI2016Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000722830</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>2016-06-30</xbrli:instant>
</xbrli:period>
</xbrli:context><xbrli:context id="D2018Q4Jul12017toJun302018_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000722830</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2017-07-01</xbrli:startDate>
<xbrli:endDate>2018-06-30</xbrli:endDate>
</xbrli:period>
</xbrli:context><xbrli:context id="FI2018Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000722830</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>2018-06-30</xbrli:instant>
</xbrli:period>
</xbrli:context><xbrli:context id="D2017Q4Jul012016toJun302017_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000722830</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2016-07-01</xbrli:startDate>
<xbrli:endDate>2017-06-30</xbrli:endDate>
</xbrli:period>
</xbrli:context><xbrli:context id="D2018Q4Jul01-Dec31_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000722830</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2018-07-01</xbrli:startDate>
<xbrli:endDate>2018-12-31</xbrli:endDate>
</xbrli:period>
</xbrli:context><xbrli:context id="FI2018Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000722830</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>2018-06-30</xbrli:instant>
</xbrli:period>
</xbrli:context><xbrli:context id="FD2019Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000722830</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2019-01-01</xbrli:startDate>
<xbrli:endDate>2019-12-31</xbrli:endDate>
</xbrli:period>
</xbrli:context><xbrli:context id="D2018Q4Jul12017toJun302018_srt_CounterpartyNameAxis_immu_RpiFinanceTrustMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000722830</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">immu:RpiFinanceTrustMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2017-07-01</xbrli:startDate>
<xbrli:endDate>2018-06-30</xbrli:endDate>
</xbrli:period>
</xbrli:context><xbrli:context id="FI2018Q2">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000722830</xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>2018-06-30</xbrli:instant>
</xbrli:period>
</xbrli:context><xbrli:context id="FD2019Q4YTD_us-gaap_SubsidiarySaleOfStockAxis_immu_MarketOfferingMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000722830</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">immu:MarketOfferingMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2019-01-01</xbrli:startDate>
<xbrli:endDate>2019-12-31</xbrli:endDate>
</xbrli:period>
</xbrli:context><xbrli:context id="D2018Q4Jul12017toJun302018_srt_CounterpartyNameAxis_immu_RpiFinanceTrustMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000722830</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">immu:RpiFinanceTrustMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2017-07-01</xbrli:startDate>
<xbrli:endDate>2018-06-30</xbrli:endDate>
</xbrli:period>
</xbrli:context><xbrli:context id="FI2018Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000722830</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>2018-06-30</xbrli:instant>
</xbrli:period>
</xbrli:context><xbrli:context id="D2018Q4Jul01-Dec31_srt_CounterpartyNameAxis_immu_RpiFinanceTrustMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000722830</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">immu:RpiFinanceTrustMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2018-07-01</xbrli:startDate>
<xbrli:endDate>2018-12-31</xbrli:endDate>
</xbrli:period>
</xbrli:context><xbrli:context id="D2018Q4Jul12017toJun302018_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000722830</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2017-07-01</xbrli:startDate>
<xbrli:endDate>2018-06-30</xbrli:endDate>
</xbrli:period>
</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000722830</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>2018-12-31</xbrli:instant>
</xbrli:period>
</xbrli:context><xbrli:context id="D2017Q4Jul012016toJun302017_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000722830</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2016-07-01</xbrli:startDate>
<xbrli:endDate>2017-06-30</xbrli:endDate>
</xbrli:period>
</xbrli:context><xbrli:context id="D2018Q4Jul12017toJun302018_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000722830</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2017-07-01</xbrli:startDate>
<xbrli:endDate>2018-06-30</xbrli:endDate>
</xbrli:period>
</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000722830</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>2019-12-31</xbrli:instant>
</xbrli:period>
</xbrli:context><xbrli:context id="FI2016Q4">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000722830</xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>2016-06-30</xbrli:instant>
</xbrli:period>
</xbrli:context><xbrli:context id="D2018Q4Jul12017toJun302018_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000722830</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2017-07-01</xbrli:startDate>
<xbrli:endDate>2018-06-30</xbrli:endDate>
</xbrli:period>
</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000722830</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>2019-12-31</xbrli:instant>
</xbrli:period>
</xbrli:context><xbrli:context id="FI2016Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000722830</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>2016-06-30</xbrli:instant>
</xbrli:period>
</xbrli:context><xbrli:context id="FD2019Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000722830</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2019-01-01</xbrli:startDate>
<xbrli:endDate>2019-12-31</xbrli:endDate>
</xbrli:period>
</xbrli:context><xbrli:context id="D2018Q4Jul12017toJun302018_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000722830</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2017-07-01</xbrli:startDate>
<xbrli:endDate>2018-06-30</xbrli:endDate>
</xbrli:period>
</xbrli:context><xbrli:context id="D2017Q4Jul012016toJun302017_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000722830</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2016-07-01</xbrli:startDate>
<xbrli:endDate>2017-06-30</xbrli:endDate>
</xbrli:period>
</xbrli:context><xbrli:context id="D2017Q4Jul012016toJun302017_us-gaap_SubsidiarySaleOfStockAxis_immu_MarketOfferingMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000722830</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">immu:MarketOfferingMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2016-07-01</xbrli:startDate>
<xbrli:endDate>2017-06-30</xbrli:endDate>
</xbrli:period>
</xbrli:context><xbrli:context id="D2018Q4Jul01-Dec31_us-gaap_SubsidiarySaleOfStockAxis_immu_MarketOfferingMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000722830</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">immu:MarketOfferingMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2018-07-01</xbrli:startDate>
<xbrli:endDate>2018-12-31</xbrli:endDate>
</xbrli:period>
</xbrli:context><xbrli:context id="D2018Q4Jul01-Dec31_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000722830</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2018-07-01</xbrli:startDate>
<xbrli:endDate>2018-12-31</xbrli:endDate>
</xbrli:period>
</xbrli:context><xbrli:context id="FD2019Q4YTD_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000722830</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2019-01-01</xbrli:startDate>
<xbrli:endDate>2019-12-31</xbrli:endDate>
</xbrli:period>
</xbrli:context><xbrli:context id="D2018Q4Jul12017toJun302018_us-gaap_SubsidiarySaleOfStockAxis_immu_MarketOfferingMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000722830</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">immu:MarketOfferingMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2017-07-01</xbrli:startDate>
<xbrli:endDate>2018-06-30</xbrli:endDate>
</xbrli:period>
</xbrli:context><xbrli:context id="I2019Q1Jan01_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201602Member">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000722830</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201602Member</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>2019-01-01</xbrli:instant>
</xbrli:period>
</xbrli:context><xbrli:context id="FD2019Q4YTD_srt_RangeAxis_srt_MaximumMember_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_LeaseholdImprovementsMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000722830</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2019-01-01</xbrli:startDate>
<xbrli:endDate>2019-12-31</xbrli:endDate>
</xbrli:period>
</xbrli:context><xbrli:context id="FD2019Q4YTD_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_ComputerEquipmentMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000722830</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2019-01-01</xbrli:startDate>
<xbrli:endDate>2019-12-31</xbrli:endDate>
</xbrli:period>
</xbrli:context><xbrli:context id="FD2019Q4YTD_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_FurnitureAndFixturesMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000722830</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2019-01-01</xbrli:startDate>
<xbrli:endDate>2019-12-31</xbrli:endDate>
</xbrli:period>
</xbrli:context><xbrli:context id="FD2019Q4YTD_srt_RangeAxis_srt_MinimumMember_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_MachineryAndEquipmentMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000722830</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:MachineryAndEquipmentMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2019-01-01</xbrli:startDate>
<xbrli:endDate>2019-12-31</xbrli:endDate>
</xbrli:period>
</xbrli:context><xbrli:context id="FD2019Q4YTD_srt_RangeAxis_srt_MinimumMember_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_LeaseholdImprovementsMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000722830</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2019-01-01</xbrli:startDate>
<xbrli:endDate>2019-12-31</xbrli:endDate>
</xbrli:period>
</xbrli:context><xbrli:context id="FD2019Q4YTD_srt_RangeAxis_srt_MaximumMember_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_MachineryAndEquipmentMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000722830</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:MachineryAndEquipmentMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2019-01-01</xbrli:startDate>
<xbrli:endDate>2019-12-31</xbrli:endDate>
</xbrli:period>
</xbrli:context><xbrli:context id="I2019Q2Apr29_srt_MajorCustomersAxis_immu_EverestMedicinesIILimitedMember_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain_2019-04-30">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000722830</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="srt:MajorCustomersAxis">immu:EverestMedicinesIILimitedMember</xbrldi:explicitMember>
<xbrldi:typedMember dimension="us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis">
<us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain>2019-04-30</us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain>
</xbrldi:typedMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>2019-04-29</xbrli:instant>
</xbrli:period>
</xbrli:context><xbrli:context id="D2019Q2Apr29_srt_MajorCustomersAxis_immu_EverestMedicinesIILimitedMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000722830</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="srt:MajorCustomersAxis">immu:EverestMedicinesIILimitedMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2019-04-29</xbrli:startDate>
<xbrli:endDate>2019-04-29</xbrli:endDate>
</xbrli:period>
</xbrli:context><xbrli:context id="D2019Q2Apr29_srt_MajorCustomersAxis_immu_EverestMedicinesIILimitedMember_srt_RangeAxis_srt_MaximumMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000722830</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="srt:MajorCustomersAxis">immu:EverestMedicinesIILimitedMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2019-04-29</xbrli:startDate>
<xbrli:endDate>2019-04-29</xbrli:endDate>
</xbrli:period>
</xbrli:context><xbrli:context id="I2019Q2Apr29_srt_MajorCustomersAxis_immu_EverestMedicinesIILimitedMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000722830</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="srt:MajorCustomersAxis">immu:EverestMedicinesIILimitedMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>2019-04-29</xbrli:instant>
</xbrli:period>
</xbrli:context><xbrli:context id="D2019Q1Apr5-Apr5_srt_MajorCustomersAxis_immu_JanssenBiotechIncMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000722830</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="srt:MajorCustomersAxis">immu:JanssenBiotechIncMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2019-04-05</xbrli:startDate>
<xbrli:endDate>2019-04-05</xbrli:endDate>
</xbrli:period>
</xbrli:context><xbrli:context id="D2019Q2Apr29_srt_MajorCustomersAxis_immu_EverestMedicinesIILimitedMember_srt_RangeAxis_srt_MinimumMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000722830</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="srt:MajorCustomersAxis">immu:EverestMedicinesIILimitedMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2019-04-29</xbrli:startDate>
<xbrli:endDate>2019-04-29</xbrli:endDate>
</xbrli:period>
</xbrli:context><xbrli:context id="FD2019Q4YTD_srt_MajorCustomersAxis_immu_JanssenBiotechIncMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000722830</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="srt:MajorCustomersAxis">immu:JanssenBiotechIncMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2019-01-01</xbrli:startDate>
<xbrli:endDate>2019-12-31</xbrli:endDate>
</xbrli:period>
</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000722830</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>2018-12-31</xbrli:instant>
</xbrli:period>
</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000722830</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>2019-12-31</xbrli:instant>
</xbrli:period>
</xbrli:context><xbrli:context id="D2018Q3Jan07_srt_CounterpartyNameAxis_immu_RpiFinanceTrustMember_us-gaap_DeferredRevenueArrangementTypeAxis_us-gaap_RoyaltyArrangementMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000722830</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">immu:RpiFinanceTrustMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:DeferredRevenueArrangementTypeAxis">us-gaap:RoyaltyArrangementMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2018-01-07</xbrli:startDate>
<xbrli:endDate>2018-01-07</xbrli:endDate>
</xbrli:period>
</xbrli:context><xbrli:context id="FD2019Q4YTD_us-gaap_DebtInstrumentAxis_immu_FourPointSevenFivePercentConvertibleSeniorNotesMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000722830</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">immu:FourPointSevenFivePercentConvertibleSeniorNotesMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2019-01-01</xbrli:startDate>
<xbrli:endDate>2019-12-31</xbrli:endDate>
</xbrli:period>
</xbrli:context><xbrli:context id="D2019Q1Jan7">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000722830</xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2019-01-01</xbrli:startDate>
<xbrli:endDate>2019-01-01</xbrli:endDate>
</xbrli:period>
</xbrli:context><xbrli:context id="D2018Q4Jul12017toJun302018_us-gaap_DebtInstrumentAxis_immu_FourPointSevenFivePercentConvertibleSeniorNotesMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000722830</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">immu:FourPointSevenFivePercentConvertibleSeniorNotesMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2017-07-01</xbrli:startDate>
<xbrli:endDate>2018-06-30</xbrli:endDate>
</xbrli:period>
</xbrli:context><xbrli:context id="D2015Q3Feb01-Feb28_us-gaap_DebtInstrumentAxis_immu_FourPointSevenFivePercentConvertibleSeniorNotesMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000722830</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">immu:FourPointSevenFivePercentConvertibleSeniorNotesMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2015-02-01</xbrli:startDate>
<xbrli:endDate>2015-02-28</xbrli:endDate>
</xbrli:period>
</xbrli:context><xbrli:context id="D2020Q1Feb14-Feb14_us-gaap_DebtInstrumentAxis_immu_FourPointSevenFivePercentConvertibleSeniorNotesMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000722830</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">immu:FourPointSevenFivePercentConvertibleSeniorNotesMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2020-02-14</xbrli:startDate>
<xbrli:endDate>2020-02-14</xbrli:endDate>
</xbrli:period>
</xbrli:context><xbrli:context id="D2018Q1Sept21_us-gaap_DebtInstrumentAxis_immu_FourPointSevenFivePercentConvertibleSeniorNotesMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000722830</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">immu:FourPointSevenFivePercentConvertibleSeniorNotesMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2017-09-21</xbrli:startDate>
<xbrli:endDate>2017-09-21</xbrli:endDate>
</xbrli:period>
</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_DebtInstrumentAxis_immu_FourPointSevenFivePercentConvertibleSeniorNotesMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000722830</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">immu:FourPointSevenFivePercentConvertibleSeniorNotesMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>2019-12-31</xbrli:instant>
</xbrli:period>
</xbrli:context><xbrli:context id="I2020Q1Feb14_us-gaap_DebtInstrumentAxis_immu_FourPointSevenFivePercentConvertibleSeniorNotesMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000722830</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">immu:FourPointSevenFivePercentConvertibleSeniorNotesMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>2020-02-14</xbrli:instant>
</xbrli:period>
</xbrli:context><xbrli:context id="D2018Q4Jul01-Dec31_us-gaap_DebtInstrumentAxis_immu_FourPointSevenFivePercentConvertibleSeniorNotesMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000722830</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">immu:FourPointSevenFivePercentConvertibleSeniorNotesMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2018-07-01</xbrli:startDate>
<xbrli:endDate>2018-12-31</xbrli:endDate>
</xbrli:period>
</xbrli:context><xbrli:context id="I2015Q3Feb28_us-gaap_DebtInstrumentAxis_immu_FourPointSevenFivePercentConvertibleSeniorNotesMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000722830</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">immu:FourPointSevenFivePercentConvertibleSeniorNotesMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>2015-02-28</xbrli:instant>
</xbrli:period>
</xbrli:context><xbrli:context id="D2018Q4Oct02_us-gaap_DebtInstrumentAxis_immu_October2018ExchangeAgreementMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000722830</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">immu:October2018ExchangeAgreementMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2018-10-02</xbrli:startDate>
<xbrli:endDate>2018-10-02</xbrli:endDate>
</xbrli:period>
</xbrli:context><xbrli:context id="D2018Q4Oct02_us-gaap_DebtInstrumentAxis_immu_FourPointSevenFivePercentConvertibleSeniorNotesMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000722830</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">immu:FourPointSevenFivePercentConvertibleSeniorNotesMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2018-10-02</xbrli:startDate>
<xbrli:endDate>2018-10-02</xbrli:endDate>
</xbrli:period>
</xbrli:context><xbrli:context id="I2018Q3Jan07_srt_CounterpartyNameAxis_immu_RpiFinanceTrustMember_us-gaap_DeferredRevenueArrangementTypeAxis_us-gaap_RoyaltyArrangementMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000722830</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">immu:RpiFinanceTrustMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:DeferredRevenueArrangementTypeAxis">us-gaap:RoyaltyArrangementMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>2018-01-07</xbrli:instant>
</xbrli:period>
</xbrli:context><xbrli:context id="FD2019Q4YTD_srt_CounterpartyNameAxis_immu_RpiFinanceTrustMember_us-gaap_DeferredRevenueArrangementTypeAxis_us-gaap_RoyaltyArrangementMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000722830</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">immu:RpiFinanceTrustMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:DeferredRevenueArrangementTypeAxis">us-gaap:RoyaltyArrangementMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2019-01-01</xbrli:startDate>
<xbrli:endDate>2019-12-31</xbrli:endDate>
</xbrli:period>
</xbrli:context><xbrli:context id="D2017Q4Jul012016toJun302017_us-gaap_DebtInstrumentAxis_immu_FourPointSevenFivePercentConvertibleSeniorNotesMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000722830</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">immu:FourPointSevenFivePercentConvertibleSeniorNotesMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2016-07-01</xbrli:startDate>
<xbrli:endDate>2017-06-30</xbrli:endDate>
</xbrli:period>
</xbrli:context><xbrli:context id="D2018Q3Jan07_srt_CounterpartyNameAxis_immu_RpiFinanceTrustMember_us-gaap_DeferredRevenueArrangementTypeAxis_us-gaap_RoyaltyArrangementMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000722830</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">immu:RpiFinanceTrustMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:DeferredRevenueArrangementTypeAxis">us-gaap:RoyaltyArrangementMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2018-01-07</xbrli:startDate>
<xbrli:endDate>2018-01-07</xbrli:endDate>
</xbrli:period>
</xbrli:context><xbrli:context id="D2018Q4Jul01-Dec31_srt_CounterpartyNameAxis_immu_RpiFinanceTrustMember_us-gaap_DeferredRevenueArrangementTypeAxis_us-gaap_RoyaltyArrangementMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000722830</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">immu:RpiFinanceTrustMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:DeferredRevenueArrangementTypeAxis">us-gaap:RoyaltyArrangementMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2018-07-01</xbrli:startDate>
<xbrli:endDate>2018-12-31</xbrli:endDate>
</xbrli:period>
</xbrli:context><xbrli:context id="D2018Q4Jul12017toJun302018_srt_CounterpartyNameAxis_immu_RpiFinanceTrustMember_us-gaap_DeferredRevenueArrangementTypeAxis_us-gaap_RoyaltyArrangementMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000722830</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">immu:RpiFinanceTrustMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:DeferredRevenueArrangementTypeAxis">us-gaap:RoyaltyArrangementMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2017-07-01</xbrli:startDate>
<xbrli:endDate>2018-06-30</xbrli:endDate>
</xbrli:period>
</xbrli:context><xbrli:context id="FI2018Q4_srt_CounterpartyNameAxis_immu_RpiFinanceTrustMember_us-gaap_DeferredRevenueArrangementTypeAxis_us-gaap_RoyaltyArrangementMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000722830</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">immu:RpiFinanceTrustMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:DeferredRevenueArrangementTypeAxis">us-gaap:RoyaltyArrangementMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>2018-12-31</xbrli:instant>
</xbrli:period>
</xbrli:context><xbrli:context id="FI2018Q2_srt_CounterpartyNameAxis_immu_RpiFinanceTrustMember_us-gaap_DeferredRevenueArrangementTypeAxis_us-gaap_RoyaltyArrangementMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000722830</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">immu:RpiFinanceTrustMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:DeferredRevenueArrangementTypeAxis">us-gaap:RoyaltyArrangementMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>2018-06-30</xbrli:instant>
</xbrli:period>
</xbrli:context><xbrli:context id="I2018Q3Jan07_srt_CounterpartyNameAxis_immu_RpiFinanceTrustMember_us-gaap_DeferredRevenueArrangementTypeAxis_us-gaap_RoyaltyArrangementMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000722830</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">immu:RpiFinanceTrustMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:DeferredRevenueArrangementTypeAxis">us-gaap:RoyaltyArrangementMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>2018-01-07</xbrli:instant>
</xbrli:period>
</xbrli:context><xbrli:context id="D2018Q3Jan08-Jun30_srt_CounterpartyNameAxis_immu_RpiFinanceTrustMember_us-gaap_DeferredRevenueArrangementTypeAxis_us-gaap_RoyaltyArrangementMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000722830</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">immu:RpiFinanceTrustMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:DeferredRevenueArrangementTypeAxis">us-gaap:RoyaltyArrangementMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2018-01-08</xbrli:startDate>
<xbrli:endDate>2018-06-30</xbrli:endDate>
</xbrli:period>
</xbrli:context><xbrli:context id="FI2019Q4_srt_CounterpartyNameAxis_immu_RpiFinanceTrustMember_us-gaap_DeferredRevenueArrangementTypeAxis_us-gaap_RoyaltyArrangementMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000722830</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">immu:RpiFinanceTrustMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:DeferredRevenueArrangementTypeAxis">us-gaap:RoyaltyArrangementMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>2019-12-31</xbrli:instant>
</xbrli:period>
</xbrli:context><xbrli:context id="FI2018Q2_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000722830</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>2018-06-30</xbrli:instant>
</xbrli:period>
</xbrli:context><xbrli:context id="D2018Q4Jul01-Dec31_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000722830</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2018-07-01</xbrli:startDate>
<xbrli:endDate>2018-12-31</xbrli:endDate>
</xbrli:period>
</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000722830</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>2018-12-31</xbrli:instant>
</xbrli:period>
</xbrli:context><xbrli:context id="FD2019Q4YTD_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000722830</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2019-01-01</xbrli:startDate>
<xbrli:endDate>2019-12-31</xbrli:endDate>
</xbrli:period>
</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000722830</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>2019-12-31</xbrli:instant>
</xbrli:period>
</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000722830</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>2018-12-31</xbrli:instant>
</xbrli:period>
</xbrli:context><xbrli:context id="FD2018Q4YTD_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000722830</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2018-01-01</xbrli:startDate>
<xbrli:endDate>2018-12-31</xbrli:endDate>
</xbrli:period>
</xbrli:context><xbrli:context id="FI2018Q2_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000722830</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>2018-06-30</xbrli:instant>
</xbrli:period>
</xbrli:context><xbrli:context id="D2018Q4Jul01-Dec31_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000722830</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2018-07-01</xbrli:startDate>
<xbrli:endDate>2018-12-31</xbrli:endDate>
</xbrli:period>
</xbrli:context><xbrli:context id="D2018Q4Jul12017toJun302018_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000722830</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2017-07-01</xbrli:startDate>
<xbrli:endDate>2018-06-30</xbrli:endDate>
</xbrli:period>
</xbrli:context><xbrli:context id="FD2019Q4YTD_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000722830</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2019-01-01</xbrli:startDate>
<xbrli:endDate>2019-12-31</xbrli:endDate>
</xbrli:period>
</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000722830</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>2019-12-31</xbrli:instant>
</xbrli:period>
</xbrli:context><xbrli:context id="D2017Q4Jul012016toJun302017_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000722830</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2016-07-01</xbrli:startDate>
<xbrli:endDate>2017-06-30</xbrli:endDate>
</xbrli:period>
</xbrli:context><xbrli:context id="D2018Q4Jul01-Dec31_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000722830</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2018-07-01</xbrli:startDate>
<xbrli:endDate>2018-12-31</xbrli:endDate>
</xbrli:period>
</xbrli:context><xbrli:context id="FD2019Q4YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000722830</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2019-01-01</xbrli:startDate>
<xbrli:endDate>2019-12-31</xbrli:endDate>
</xbrli:period>
</xbrli:context><xbrli:context id="D2018Q4Jul12017toJun302018_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000722830</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2017-07-01</xbrli:startDate>
<xbrli:endDate>2018-06-30</xbrli:endDate>
</xbrli:period>
</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000722830</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>2019-12-31</xbrli:instant>
</xbrli:period>
</xbrli:context><xbrli:context id="FD2018Q4YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000722830</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2018-01-01</xbrli:startDate>
<xbrli:endDate>2018-12-31</xbrli:endDate>
</xbrli:period>
</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000722830</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>2018-12-31</xbrli:instant>
</xbrli:period>
</xbrli:context><xbrli:context id="FI2018Q2_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000722830</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>2018-06-30</xbrli:instant>
</xbrli:period>
</xbrli:context><xbrli:context id="D2018Q4Jul12017toJun302018_srt_RangeAxis_srt_MaximumMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000722830</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2017-07-01</xbrli:startDate>
<xbrli:endDate>2018-06-30</xbrli:endDate>
</xbrli:period>
</xbrli:context><xbrli:context id="D2017Q4Jul012016toJun302017_srt_RangeAxis_srt_MinimumMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000722830</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2016-07-01</xbrli:startDate>
<xbrli:endDate>2017-06-30</xbrli:endDate>
</xbrli:period>
</xbrli:context><xbrli:context id="D2018Q4Jul01-Dec31_srt_RangeAxis_srt_MaximumMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000722830</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2018-07-01</xbrli:startDate>
<xbrli:endDate>2018-12-31</xbrli:endDate>
</xbrli:period>
</xbrli:context><xbrli:context id="D2018Q4Jul12017toJun302018_srt_RangeAxis_srt_MinimumMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000722830</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2017-07-01</xbrli:startDate>
<xbrli:endDate>2018-06-30</xbrli:endDate>
</xbrli:period>
</xbrli:context><xbrli:context id="D2017Q4Jul012016toJun302017_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000722830</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2016-07-01</xbrli:startDate>
<xbrli:endDate>2017-06-30</xbrli:endDate>
</xbrli:period>
</xbrli:context><xbrli:context id="D2017Q4Jul012016toJun302017_srt_RangeAxis_srt_MaximumMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000722830</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2016-07-01</xbrli:startDate>
<xbrli:endDate>2017-06-30</xbrli:endDate>
</xbrli:period>
</xbrli:context><xbrli:context id="FD2019Q4YTD_srt_RangeAxis_srt_MaximumMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000722830</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2019-01-01</xbrli:startDate>
<xbrli:endDate>2019-12-31</xbrli:endDate>
</xbrli:period>
</xbrli:context><xbrli:context id="D2018Q4Jul01-Dec31_srt_RangeAxis_srt_MinimumMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000722830</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2018-07-01</xbrli:startDate>
<xbrli:endDate>2018-12-31</xbrli:endDate>
</xbrli:period>
</xbrli:context><xbrli:context id="FD2016Q4YTD_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000722830</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2015-07-01</xbrli:startDate>
<xbrli:endDate>2016-06-30</xbrli:endDate>
</xbrli:period>
</xbrli:context><xbrli:context id="FD2019Q4YTD_srt_RangeAxis_srt_MinimumMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000722830</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2019-01-01</xbrli:startDate>
<xbrli:endDate>2019-12-31</xbrli:endDate>
</xbrli:period>
</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000722830</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>2018-12-31</xbrli:instant>
</xbrli:period>
</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FinancialInstrumentAxis_us-gaap_MoneyMarketFundsMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000722830</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>2018-12-31</xbrli:instant>
</xbrli:period>
</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000722830</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>2018-12-31</xbrli:instant>
</xbrli:period>
</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000722830</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>2018-12-31</xbrli:instant>
</xbrli:period>
</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FinancialInstrumentAxis_us-gaap_MoneyMarketFundsMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000722830</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>2018-12-31</xbrli:instant>
</xbrli:period>
</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_FinancialInstrumentAxis_us-gaap_MoneyMarketFundsMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000722830</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>2018-12-31</xbrli:instant>
</xbrli:period>
</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000722830</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>2018-12-31</xbrli:instant>
</xbrli:period>
</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FinancialInstrumentAxis_us-gaap_MoneyMarketFundsMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000722830</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>2018-12-31</xbrli:instant>
</xbrli:period>
</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000722830</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>2018-12-31</xbrli:instant>
</xbrli:period>
</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000722830</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>2018-12-31</xbrli:instant>
</xbrli:period>
</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FinancialInstrumentAxis_us-gaap_MoneyMarketFundsMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000722830</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>2019-12-31</xbrli:instant>
</xbrli:period>
</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FinancialInstrumentAxis_us-gaap_MoneyMarketFundsMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000722830</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>2019-12-31</xbrli:instant>
</xbrli:period>
</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FinancialInstrumentAxis_us-gaap_MoneyMarketFundsMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000722830</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>2019-12-31</xbrli:instant>
</xbrli:period>
</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000722830</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>2019-12-31</xbrli:instant>
</xbrli:period>
</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000722830</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>2019-12-31</xbrli:instant>
</xbrli:period>
</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000722830</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>2019-12-31</xbrli:instant>
</xbrli:period>
</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000722830</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>2019-12-31</xbrli:instant>
</xbrli:period>
</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000722830</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>2019-12-31</xbrli:instant>
</xbrli:period>
</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_FinancialInstrumentAxis_us-gaap_MoneyMarketFundsMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000722830</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>2019-12-31</xbrli:instant>
</xbrli:period>
</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000722830</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>2019-12-31</xbrli:instant>
</xbrli:period>
</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_EstimateOfFairValueFairValueDisclosureMember_us-gaap_LongtermDebtTypeAxis_us-gaap_SeniorNotesMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000722830</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>2018-12-31</xbrli:instant>
</xbrli:period>
</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_CarryingReportedAmountFairValueDisclosureMember_us-gaap_LongtermDebtTypeAxis_us-gaap_SeniorNotesMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000722830</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>2018-12-31</xbrli:instant>
</xbrli:period>
</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_EstimateOfFairValueFairValueDisclosureMember_us-gaap_LongtermDebtTypeAxis_us-gaap_SeniorNotesMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000722830</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>2019-12-31</xbrli:instant>
</xbrli:period>
</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_CarryingReportedAmountFairValueDisclosureMember_us-gaap_LongtermDebtTypeAxis_us-gaap_SeniorNotesMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000722830</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>2019-12-31</xbrli:instant>
</xbrli:period>
</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_MachineryAndEquipmentMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000722830</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:MachineryAndEquipmentMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>2018-12-31</xbrli:instant>
</xbrli:period>
</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_FurnitureAndFixturesMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000722830</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>2019-12-31</xbrli:instant>
</xbrli:period>
</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_ConstructionInProgressMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000722830</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>2018-12-31</xbrli:instant>
</xbrli:period>
</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_FurnitureAndFixturesMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000722830</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>2018-12-31</xbrli:instant>
</xbrli:period>
</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_LeaseholdImprovementsMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000722830</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>2019-12-31</xbrli:instant>
</xbrli:period>
</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_ComputerEquipmentMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000722830</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>2019-12-31</xbrli:instant>
</xbrli:period>
</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_ConstructionInProgressMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000722830</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>2019-12-31</xbrli:instant>
</xbrli:period>
</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_LeaseholdImprovementsMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000722830</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>2018-12-31</xbrli:instant>
</xbrli:period>
</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_ComputerEquipmentMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000722830</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>2018-12-31</xbrli:instant>
</xbrli:period>
</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_MachineryAndEquipmentMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000722830</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:MachineryAndEquipmentMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>2019-12-31</xbrli:instant>
</xbrli:period>
</xbrli:context><xbrli:context id="I2017Q4May10_us-gaap_StatementClassOfStockAxis_us-gaap_ConvertiblePreferredStockMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000722830</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>2017-05-10</xbrli:instant>
</xbrli:period>
</xbrli:context><xbrli:context id="D2019Q4Dec09-Dec09_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_OverAllotmentOptionMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000722830</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2019-12-09</xbrli:startDate>
<xbrli:endDate>2019-12-09</xbrli:endDate>
</xbrli:period>
</xbrli:context><xbrli:context id="I2017Q4June28">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000722830</xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>2017-06-28</xbrli:instant>
</xbrli:period>
</xbrli:context><xbrli:context id="D2018Q2Dec05_srt_CounterpartyNameAxis_immu_SeattleGeneticsIncMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000722830</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">immu:SeattleGeneticsIncMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2017-12-05</xbrli:startDate>
<xbrli:endDate>2017-12-05</xbrli:endDate>
</xbrli:period>
</xbrli:context><xbrli:context id="D2017Q4May10_us-gaap_StatementClassOfStockAxis_us-gaap_ConvertiblePreferredStockMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000722830</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2017-05-10</xbrli:startDate>
<xbrli:endDate>2017-05-10</xbrli:endDate>
</xbrli:period>
</xbrli:context><xbrli:context id="D2018Q2_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_OverAllotmentOptionMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000722830</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2018-06-15</xbrli:startDate>
<xbrli:endDate>2018-06-15</xbrli:endDate>
</xbrli:period>
</xbrli:context><xbrli:context id="I2017Q2Oct11_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000722830</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>2016-10-11</xbrli:instant>
</xbrli:period>
</xbrli:context><xbrli:context id="D2019Q4Dec09-Dec09_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000722830</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2019-12-09</xbrli:startDate>
<xbrli:endDate>2019-12-09</xbrli:endDate>
</xbrli:period>
</xbrli:context><xbrli:context id="I2017Q4June29">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000722830</xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>2017-06-29</xbrli:instant>
</xbrli:period>
</xbrli:context><xbrli:context id="D2018Q2">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000722830</xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2018-06-15</xbrli:startDate>
<xbrli:endDate>2018-06-15</xbrli:endDate>
</xbrli:period>
</xbrli:context><xbrli:context id="D2018Q1July31_srt_CounterpartyNameAxis_immu_SeattleGeneticsIncMember_us-gaap_TypeOfArrangementAxis_immu_SecuritiesPurchaseAgreementMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000722830</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">immu:SeattleGeneticsIncMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">immu:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2017-07-31</xbrli:startDate>
<xbrli:endDate>2017-07-31</xbrli:endDate>
</xbrli:period>
</xbrli:context><xbrli:context id="I2017Q3Feb10_srt_CounterpartyNameAxis_immu_SeattleGeneticsIncMember_us-gaap_TypeOfArrangementAxis_immu_SecuritiesPurchaseAgreementMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000722830</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">immu:SeattleGeneticsIncMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">immu:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>2017-02-10</xbrli:instant>
</xbrli:period>
</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000722830</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>2019-12-31</xbrli:instant>
</xbrli:period>
</xbrli:context><xbrli:context id="I2017Q1Jul31_srt_CounterpartyNameAxis_immu_SeattleGeneticsIncMember_us-gaap_TypeOfArrangementAxis_immu_SecuritiesPurchaseAgreementMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000722830</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">immu:SeattleGeneticsIncMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">immu:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>2017-07-31</xbrli:instant>
</xbrli:period>
</xbrli:context><xbrli:context id="D2016Q1Oct11-Oct11_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000722830</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2016-10-11</xbrli:startDate>
<xbrli:endDate>2016-10-11</xbrli:endDate>
</xbrli:period>
</xbrli:context><xbrli:context id="I2017Q3Feb16_srt_CounterpartyNameAxis_immu_SeattleGeneticsIncMember_us-gaap_TypeOfArrangementAxis_immu_SecuritiesPurchaseAgreementMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000722830</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">immu:SeattleGeneticsIncMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">immu:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>2017-02-16</xbrli:instant>
</xbrli:period>
</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000722830</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>2018-12-31</xbrli:instant>
</xbrli:period>
</xbrli:context><xbrli:context id="D2018Q1July31_us-gaap_StatementClassOfStockAxis_us-gaap_ConvertiblePreferredStockMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000722830</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2017-07-31</xbrli:startDate>
<xbrli:endDate>2017-07-31</xbrli:endDate>
</xbrli:period>
</xbrli:context><xbrli:context id="D2017Q3Feb10-Feb10_srt_CounterpartyNameAxis_immu_SeattleGeneticsIncMember_us-gaap_TypeOfArrangementAxis_immu_SecuritiesPurchaseAgreementMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000722830</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">immu:SeattleGeneticsIncMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">immu:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2017-02-10</xbrli:startDate>
<xbrli:endDate>2017-02-10</xbrli:endDate>
</xbrli:period>
</xbrli:context><xbrli:context id="I2018Q4_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000722830</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>2018-06-15</xbrli:instant>
</xbrli:period>
</xbrli:context><xbrli:context id="I2019Q4Dec09_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000722830</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>2019-12-09</xbrli:instant>
</xbrli:period>
</xbrli:context><xbrli:context id="D2018Q4Jul01-Dec31_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000722830</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2018-07-01</xbrli:startDate>
<xbrli:endDate>2018-12-31</xbrli:endDate>
</xbrli:period>
</xbrli:context><xbrli:context id="I2019Q1Mar29_us-gaap_SubsidiarySaleOfStockAxis_immu_ATMAgreementMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000722830</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">immu:ATMAgreementMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>2019-03-29</xbrli:instant>
</xbrli:period>
</xbrli:context><xbrli:context id="D2018Q2_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000722830</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2018-06-15</xbrli:startDate>
<xbrli:endDate>2018-06-15</xbrli:endDate>
</xbrli:period>
</xbrli:context><xbrli:context id="FI2019Q4_srt_RangeAxis_srt_WeightedAverageMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000722830</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="srt:RangeAxis">srt:WeightedAverageMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>2019-12-31</xbrli:instant>
</xbrli:period>
</xbrli:context><xbrli:context id="D2019Q1Mar29-29_us-gaap_SubsidiarySaleOfStockAxis_immu_ATMAgreementMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000722830</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">immu:ATMAgreementMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2019-03-29</xbrli:startDate>
<xbrli:endDate>2019-03-29</xbrli:endDate>
</xbrli:period>
</xbrli:context><xbrli:context id="D2018Q4Jul12017toJun302018_us-gaap_FairValueByLiabilityClassAxis_us-gaap_WarrantMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000722830</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2017-07-01</xbrli:startDate>
<xbrli:endDate>2018-06-30</xbrli:endDate>
</xbrli:period>
</xbrli:context><xbrli:context id="I2017Q2Oct11_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember_us-gaap_TypeOfArrangementAxis_immu_SecuritiesPurchaseAgreementMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000722830</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">immu:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>2016-10-11</xbrli:instant>
</xbrli:period>
</xbrli:context><xbrli:context id="D2019Q4Dec09-Dec09">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000722830</xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2019-12-09</xbrli:startDate>
<xbrli:endDate>2019-12-09</xbrli:endDate>
</xbrli:period>
</xbrli:context><xbrli:context id="I2018Q2Dec05_srt_CounterpartyNameAxis_immu_SeattleGeneticsIncMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000722830</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">immu:SeattleGeneticsIncMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>2017-12-05</xbrli:instant>
</xbrli:period>
</xbrli:context><xbrli:context id="FD2019Q4YTD_us-gaap_SubsidiarySaleOfStockAxis_immu_ATMAgreementMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000722830</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">immu:ATMAgreementMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2019-01-01</xbrli:startDate>
<xbrli:endDate>2019-12-31</xbrli:endDate>
</xbrli:period>
</xbrli:context><xbrli:context id="FD2019Q4YTD_us-gaap_SubsidiarySaleOfStockAxis_immu_SalesAgreementMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000722830</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">immu:SalesAgreementMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2019-01-01</xbrli:startDate>
<xbrli:endDate>2019-12-31</xbrli:endDate>
</xbrli:period>
</xbrli:context><xbrli:context id="D2018Q4Jul12017toJun302018_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000722830</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2017-07-01</xbrli:startDate>
<xbrli:endDate>2018-06-30</xbrli:endDate>
</xbrli:period>
</xbrli:context><xbrli:context id="FD2019Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000722830</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2019-01-01</xbrli:startDate>
<xbrli:endDate>2019-12-31</xbrli:endDate>
</xbrli:period>
</xbrli:context><xbrli:context id="FD2019Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedTranslationAdjustmentMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000722830</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2019-01-01</xbrli:startDate>
<xbrli:endDate>2019-12-31</xbrli:endDate>
</xbrli:period>
</xbrli:context><xbrli:context id="D2018Q4Jul01-Dec31_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000722830</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2018-07-01</xbrli:startDate>
<xbrli:endDate>2018-12-31</xbrli:endDate>
</xbrli:period>
</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000722830</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>2018-12-31</xbrli:instant>
</xbrli:period>
</xbrli:context><xbrli:context id="FI2017Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedTranslationAdjustmentMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000722830</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>2017-06-30</xbrli:instant>
</xbrli:period>
</xbrli:context><xbrli:context id="D2017Q4Jul012016toJun302017_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedTranslationAdjustmentMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000722830</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2016-07-01</xbrli:startDate>
<xbrli:endDate>2017-06-30</xbrli:endDate>
</xbrli:period>
</xbrli:context><xbrli:context id="D2018Q4Jul12017toJun302018_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedTranslationAdjustmentMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000722830</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2017-07-01</xbrli:startDate>
<xbrli:endDate>2018-06-30</xbrli:endDate>
</xbrli:period>
</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedTranslationAdjustmentMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000722830</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>2019-12-31</xbrli:instant>
</xbrli:period>
</xbrli:context><xbrli:context id="D2018Q4Jul01-Dec31_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedTranslationAdjustmentMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000722830</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2018-07-01</xbrli:startDate>
<xbrli:endDate>2018-12-31</xbrli:endDate>
</xbrli:period>
</xbrli:context><xbrli:context id="D2017Q4Jul012016toJun302017_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000722830</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2016-07-01</xbrli:startDate>
<xbrli:endDate>2017-06-30</xbrli:endDate>
</xbrli:period>
</xbrli:context><xbrli:context id="FI2016Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000722830</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>2016-06-30</xbrli:instant>
</xbrli:period>
</xbrli:context><xbrli:context id="FI2016Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedTranslationAdjustmentMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000722830</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>2016-06-30</xbrli:instant>
</xbrli:period>
</xbrli:context><xbrli:context id="FI2017Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000722830</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>2017-06-30</xbrli:instant>
</xbrli:period>
</xbrli:context><xbrli:context id="FI2018Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedTranslationAdjustmentMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000722830</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>2018-06-30</xbrli:instant>
</xbrli:period>
</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedTranslationAdjustmentMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000722830</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>2018-12-31</xbrli:instant>
</xbrli:period>
</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000722830</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>2019-12-31</xbrli:instant>
</xbrli:period>
</xbrli:context><xbrli:context id="FI2018Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000722830</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>2018-06-30</xbrli:instant>
</xbrli:period>
</xbrli:context><xbrli:context id="FD2016Q4YTD">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000722830</xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2015-07-01</xbrli:startDate>
<xbrli:endDate>2016-06-30</xbrli:endDate>
</xbrli:period>
</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_IncomeTaxAuthorityAxis_us-gaap_DomesticCountryMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000722830</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>2019-12-31</xbrli:instant>
</xbrli:period>
</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_IncomeTaxAuthorityAxis_us-gaap_StateAndLocalJurisdictionMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000722830</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>2019-12-31</xbrli:instant>
</xbrli:period>
</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_IncomeTaxAuthorityAxis_us-gaap_StateAndLocalJurisdictionMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000722830</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>2018-12-31</xbrli:instant>
</xbrli:period>
</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_IncomeTaxAuthorityAxis_us-gaap_DomesticCountryMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000722830</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>2018-12-31</xbrli:instant>
</xbrli:period>
</xbrli:context><xbrli:context id="I2018Q1Jan06">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000722830</xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>2018-01-06</xbrli:instant>
</xbrli:period>
</xbrli:context><xbrli:context id="D2019Q4Nov19-Nov19_srt_TitleOfIndividualAxis_srt_BoardOfDirectorsChairmanMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000722830</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:BoardOfDirectorsChairmanMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2019-11-19</xbrli:startDate>
<xbrli:endDate>2019-11-19</xbrli:endDate>
</xbrli:period>
</xbrli:context><xbrli:context id="D2019Q1Mar5-Mar5_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_srt_DirectorMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000722830</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:DirectorMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2019-03-05</xbrli:startDate>
<xbrli:endDate>2019-03-05</xbrli:endDate>
</xbrli:period>
</xbrli:context><xbrli:context id="D2018Q3Jan08-Jun30_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_immu_MRosenbergBioPharmaConsultingLlcMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000722830</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">immu:MRosenbergBioPharmaConsultingLlcMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2018-01-08</xbrli:startDate>
<xbrli:endDate>2018-06-30</xbrli:endDate>
</xbrli:period>
</xbrli:context><xbrli:context id="FD2019Q4YTD_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_srt_DirectorMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000722830</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:DirectorMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2019-01-01</xbrli:startDate>
<xbrli:endDate>2019-12-31</xbrli:endDate>
</xbrli:period>
</xbrli:context><xbrli:context id="D2018Q3May05-Jan06_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_immu_MRosenbergBioPharmaConsultingLlcMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000722830</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">immu:MRosenbergBioPharmaConsultingLlcMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2017-05-05</xbrli:startDate>
<xbrli:endDate>2018-01-06</xbrli:endDate>
</xbrli:period>
</xbrli:context><xbrli:context id="D2019Q1Mar5-Mar5_srt_TitleOfIndividualAxis_immu_ExecutiveDirectorMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000722830</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">immu:ExecutiveDirectorMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2019-03-05</xbrli:startDate>
<xbrli:endDate>2019-03-05</xbrli:endDate>
</xbrli:period>
</xbrli:context><xbrli:context id="D2018Q4Jul01-Dec31_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_immu_MRosenbergBioPharmaConsultingLlcMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000722830</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">immu:MRosenbergBioPharmaConsultingLlcMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2018-07-01</xbrli:startDate>
<xbrli:endDate>2018-12-31</xbrli:endDate>
</xbrli:period>
</xbrli:context><xbrli:context id="D2018Q3Jan08-Jun30_srt_TitleOfIndividualAxis_immu_ChiefTechnologyOfficerMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000722830</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">immu:ChiefTechnologyOfficerMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2018-01-08</xbrli:startDate>
<xbrli:endDate>2018-06-30</xbrli:endDate>
</xbrli:period>
</xbrli:context><xbrli:context id="D2018Q3Jan08-Jun30">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000722830</xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2018-01-08</xbrli:startDate>
<xbrli:endDate>2018-06-30</xbrli:endDate>
</xbrli:period>
</xbrli:context><xbrli:context id="FD2019Q4YTD_srt_TitleOfIndividualAxis_immu_ExecutiveDirectorMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000722830</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">immu:ExecutiveDirectorMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2019-01-01</xbrli:startDate>
<xbrli:endDate>2019-12-31</xbrli:endDate>
</xbrli:period>
</xbrli:context><xbrli:context id="D2018Q3May05-Jan06_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_immu_MRosenbergBioPharmaConsultingLlcMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000722830</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">immu:MRosenbergBioPharmaConsultingLlcMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2017-05-05</xbrli:startDate>
<xbrli:endDate>2018-01-06</xbrli:endDate>
</xbrli:period>
</xbrli:context><xbrli:context id="FD2019Q4YTD_immu_CollaborationAgreementAxis_immu_CBGForschungsGmbHMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000722830</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="immu:CollaborationAgreementAxis">immu:CBGForschungsGmbHMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2019-01-01</xbrli:startDate>
<xbrli:endDate>2019-12-31</xbrli:endDate>
</xbrli:period>
</xbrli:context><xbrli:context id="D2018Q2Apr04-Apr04_srt_CounterpartyNameAxis_immu_TheScrippsResearchInstituteMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000722830</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">immu:TheScrippsResearchInstituteMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2018-04-04</xbrli:startDate>
<xbrli:endDate>2018-04-04</xbrli:endDate>
</xbrli:period>
</xbrli:context><xbrli:context id="FD2019Q4YTD_srt_LitigationCaseAxis_immu_InsuranceCoverageArbitrationMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000722830</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="srt:LitigationCaseAxis">immu:InsuranceCoverageArbitrationMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2019-01-01</xbrli:startDate>
<xbrli:endDate>2019-12-31</xbrli:endDate>
</xbrli:period>
</xbrli:context><xbrli:context id="D2018Q2Apr04-Apr04">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000722830</xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2018-04-04</xbrli:startDate>
<xbrli:endDate>2018-04-04</xbrli:endDate>
</xbrli:period>
</xbrli:context><xbrli:context id="D2019Q1Jan015_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_EmploymentContractsMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_immu_GoldenbergAgreementMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000722830</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:EmploymentContractsMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">immu:GoldenbergAgreementMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2019-01-15</xbrli:startDate>
<xbrli:endDate>2019-01-15</xbrli:endDate>
</xbrli:period>
</xbrli:context><xbrli:context id="FD2019Q4YTD_srt_TitleOfIndividualAxis_srt_ChiefExecutiveOfficerMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000722830</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2019-01-01</xbrli:startDate>
<xbrli:endDate>2019-12-31</xbrli:endDate>
</xbrli:period>
</xbrli:context><xbrli:context id="D2019Q1Jan015_us-gaap_AwardTypeAxis_immu_RestrictedUnitsWithVestingMarketConditionsMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_immu_GoldenbergAgreementMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000722830</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">immu:RestrictedUnitsWithVestingMarketConditionsMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">immu:GoldenbergAgreementMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2019-01-15</xbrli:startDate>
<xbrli:endDate>2019-01-15</xbrli:endDate>
</xbrli:period>
</xbrli:context><xbrli:context id="I2019Q1Mar13_srt_TitleOfIndividualAxis_srt_ChiefExecutiveOfficerMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000722830</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>2019-03-13</xbrli:instant>
</xbrli:period>
</xbrli:context><xbrli:context id="FD2019Q4YTD_srt_CounterpartyNameAxis_immu_TheScrippsResearchInstituteMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000722830</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">immu:TheScrippsResearchInstituteMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2019-01-01</xbrli:startDate>
<xbrli:endDate>2019-12-31</xbrli:endDate>
</xbrli:period>
</xbrli:context><xbrli:context id="FI2019Q4_srt_TitleOfIndividualAxis_srt_ChiefExecutiveOfficerMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000722830</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>2019-12-31</xbrli:instant>
</xbrli:period>
</xbrli:context><xbrli:context id="FD2019Q2QTD">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000722830</xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2019-04-01</xbrli:startDate>
<xbrli:endDate>2019-06-30</xbrli:endDate>
</xbrli:period>
</xbrli:context><xbrli:context id="FD2019Q3QTD">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000722830</xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2019-07-01</xbrli:startDate>
<xbrli:endDate>2019-09-30</xbrli:endDate>
</xbrli:period>
</xbrli:context><xbrli:context id="FD2019Q4QTD">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000722830</xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2019-10-01</xbrli:startDate>
<xbrli:endDate>2019-12-31</xbrli:endDate>
</xbrli:period>
</xbrli:context><xbrli:context id="FD2019Q1QTD">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000722830</xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2019-01-01</xbrli:startDate>
<xbrli:endDate>2019-03-31</xbrli:endDate>
</xbrli:period>
</xbrli:context><xbrli:context id="FD2018Q3QTD">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000722830</xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2018-07-01</xbrli:startDate>
<xbrli:endDate>2018-09-30</xbrli:endDate>
</xbrli:period>
</xbrli:context><xbrli:context id="FD2018Q4QTD">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000722830</xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2018-10-01</xbrli:startDate>
<xbrli:endDate>2018-12-31</xbrli:endDate>
</xbrli:period>
</xbrli:context><xbrli:context id="FD2018Q1QTD">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000722830</xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2018-01-01</xbrli:startDate>
<xbrli:endDate>2018-03-31</xbrli:endDate>
</xbrli:period>
</xbrli:context><xbrli:context id="FD2018Q2QTD">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000722830</xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2018-04-01</xbrli:startDate>
<xbrli:endDate>2018-06-30</xbrli:endDate>
</xbrli:period>
</xbrli:context><xbrli:unit id="usdPerShare">
<xbrli:divide>
<xbrli:unitNumerator>
<xbrli:measure>iso4217:USD</xbrli:measure>
</xbrli:unitNumerator>
<xbrli:unitDenominator>
<xbrli:measure>xbrli:shares</xbrli:measure>
</xbrli:unitDenominator>
</xbrli:divide>
</xbrli:unit><xbrli:unit id="usd">
<xbrli:measure>iso4217:USD</xbrli:measure>
</xbrli:unit><xbrli:unit id="shares">
<xbrli:measure>xbrli:shares</xbrli:measure>
</xbrli:unit><xbrli:unit id="number">
<xbrli:measure>xbrli:pure</xbrli:measure>
</xbrli:unit><xbrli:unit id="eur">
<xbrli:measure>iso4217:EUR</xbrli:measure>
</xbrli:unit><xbrli:unit id="patient">
<xbrli:measure>immu:patient</xbrli:measure>
</xbrli:unit></ix:resources></ix:header></div><div><a id="sF4CCC47CF539588ABFD1BD0CBC6ED114"></a></div><div></div><div><br/></div><div style="line-height:120%;text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">UNITED STATES</span></div><div style="line-height:120%;text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">SECURITIES AND EXCHANGE COMMISSION</span></div><div style="line-height:120%;text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Washington, D.C.  20549</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:37.5%;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td style="width:52%;"></td><td style="width:48%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">FORM </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span><ix:nonNumeric id="d22891554e658-wk-Fact-8D880E696AF074AECB18D1D0183C4FFD" name="dei:DocumentType" contextRef="FD2019Q4YTD">10-K</ix:nonNumeric></span></span></div></td></tr></table></div></div><div style="line-height:120%;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">(Mark one)</span></div><div style="line-height:120%;text-align:center;font-size:9pt;"><span><ix:nonNumeric id="d22891554e664-wk-Fact-E8F3E2EFF3D2176ED5B0D1D0184BE6D0" name="dei:DocumentAnnualReport" contextRef="FD2019Q4YTD" format="ixt-sec:boolballotbox"><span style="font-family:Arial Unicode MS;font-size:9pt;">☑</span></ix:nonNumeric></span><span style="font-family:inherit;font-size:9pt;font-weight:bold;">  ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE</span></div><div style="line-height:120%;text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">SECURITIES EXCHANGE ACT OF 1934</span></div><div style="line-height:120%;text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">For the fiscal year ended </span><span style="font-family:inherit;font-size:9pt;"><span><span style="white-space:nowrap"><ix:nonNumeric id="d22891554e677-wk-Fact-F43B970BBDC8137EBCFCD1D01865A1CE" name="dei:DocumentPeriodEndDate" contextRef="FD2019Q4YTD" format="ixt:datemonthdayyearen">December 31, 2019</ix:nonNumeric></span></span></span><span style="font-family:inherit;font-size:9pt;"> </span></div><div style="line-height:120%;text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:9pt;"><span><ix:nonNumeric id="d22891554e684-wk-Fact-39CA96C5C50B426B4792D1D0180B050E" name="dei:DocumentTransitionReport" contextRef="FD2019Q4YTD" format="ixt-sec:boolballotbox"><span style="font-family:Arial Unicode MS;font-size:9pt;">☐</span></ix:nonNumeric></span><span style="font-family:inherit;font-size:9pt;font-weight:bold;"> TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d)</span></div><div style="line-height:120%;text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">OF THE SECURITIES EXCHANGE ACT OF 1934</span></div><div style="line-height:120%;font-size:6pt;"><span style="font-family:inherit;font-size:6pt;"> </span></div><div style="line-height:120%;text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">For the transition period from ________to________</span></div><div style="line-height:120%;font-size:6pt;"><span style="font-family:inherit;font-size:6pt;"> </span></div><div style="line-height:120%;text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Commission file number</span><span style="font-family:inherit;font-size:9pt;">:   </span><span><ix:nonNumeric id="d22891554e707-wk-Fact-9E00E8740D5527690EABD1D0181B88C3" name="dei:EntityFileNumber" contextRef="FD2019Q4YTD"><span style="font-size:9pt;font-weight:bold;">0-12104</span></ix:nonNumeric></span><span style="font-family:inherit;font-size:9pt;"> </span></div><div style="line-height:120%;text-align:center;padding-left:0px;text-indent:0px;font-size:9pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:37.5%;border-collapse:collapse;text-align:left;"><tr><td colspan="1"></td></tr><tr><td style="width:100%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;"><span><ix:nonNumeric id="d22891554e723-wk-Fact-924FBFFC01ED5426B20FD1D0185BC3D3" name="dei:EntityRegistrantName" contextRef="FD2019Q4YTD">IMMUNOMEDICS, INC.</ix:nonNumeric></span></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-bottom:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">(Exact name of registrant as specified in its charter)</span></div></td></tr></table></div></div><div style="line-height:120%;padding-left:0px;text-indent:0px;font-size:8pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td style="width:50%;"></td><td style="width:50%;"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;"><span><ix:nonNumeric id="d22891554e743-wk-Fact-E8897AE4B1A115298312D1D0183C85C8" name="dei:EntityIncorporationStateCountryCode" contextRef="FD2019Q4YTD" format="ixt-sec:stateprovnameen">Delaware</ix:nonNumeric></span></span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;"><span><ix:nonNumeric id="d22891554e748-wk-Fact-81EFE41CF3E73B7B57D0D1D0181BDB67" name="dei:EntityTaxIdentificationNumber" contextRef="FD2019Q4YTD">61-1009366</ix:nonNumeric></span></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">(State or other jurisdiction of incorporation or organization)</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">(I.R.S. Employer Identification No.)</span></div></td></tr></table></div></div><div style="line-height:120%;font-size:6pt;"><span style="font-family:inherit;font-size:6pt;"> </span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span><ix:nonNumeric id="d22891554e765-wk-Fact-6F31DAEAAFD9B8F2AE66D1D0185B493E" name="dei:EntityAddressAddressLine1" contextRef="FD2019Q4YTD"><span style="font-size:8pt;font-weight:bold;">300 The American Road</span></ix:nonNumeric></span><span style="font-family:inherit;font-size:8pt;font-weight:bold;">, </span><span><ix:nonNumeric id="d22891554e770-wk-Fact-CEE899471446EB3A86C7D1D0184A3DEE" name="dei:EntityAddressCityOrTown" contextRef="FD2019Q4YTD"><span style="font-size:8pt;font-weight:bold;">Morris Plains,</span></ix:nonNumeric></span><span style="font-family:inherit;font-size:8pt;font-weight:bold;"> </span><span><ix:nonNumeric id="d22891554e775-wk-Fact-DB90F9AAF7BAA240526CD1D0184B2147" name="dei:EntityAddressStateOrProvince" contextRef="FD2019Q4YTD" format="ixt-sec:stateprovnameen"><span style="font-size:8pt;font-weight:bold;">New Jersey</span></ix:nonNumeric></span><span style="font-family:inherit;font-size:8pt;font-weight:bold;"> </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonNumeric id="d22891554e780-wk-Fact-CC63824FC2E413391553D1D01865C580" name="dei:EntityAddressPostalZipCode" contextRef="FD2019Q4YTD">07950</ix:nonNumeric></span></span><span style="font-family:inherit;font-size:8pt;font-weight:bold;"> </span></div><div style="line-height:120%;text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">(Address of principal executive offices) (Zip Code)</span></div><div style="line-height:120%;text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">(</span><span><ix:nonNumeric id="d22891554e793-wk-Fact-F2132F534FF1C5C4F24DD1D0185BE5CB" name="dei:CityAreaCode" contextRef="FD2019Q4YTD"><span style="font-size:8pt;font-weight:bold;">973</span></ix:nonNumeric></span><span style="font-family:inherit;font-size:8pt;font-weight:bold;">) </span><span><ix:nonNumeric id="d22891554e798-wk-Fact-493A8845D49FC88373E2D1D0184B9656" name="dei:LocalPhoneNumber" contextRef="FD2019Q4YTD"><span style="font-size:8pt;font-weight:bold;">605-8200</span></ix:nonNumeric></span><span style="font-family:inherit;font-size:8pt;font-weight:bold;"> </span></div><div style="line-height:120%;text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">(Registrant's Telephone Number, Including Area Code)</span><span style="font-family:inherit;font-size:8pt;font-weight:bold;"> </span></div><div style="line-height:120%;text-align:center;font-size:6pt;"><span style="font-family:inherit;font-size:6pt;"> </span></div><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;text-decoration:underline;">Securities registered pursuant to Section 12(b) of the Act:</span></div><div style="line-height:120%;padding-left:0px;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="5"></td></tr><tr><td style="width:39%;"></td><td style="width:1%;"></td><td style="width:18%;"></td><td style="width:1%;"></td><td style="width:41%;"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-bottom:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Title of each class</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-bottom:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Trading Symbol</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-bottom:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Name of each exchange on which registered</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;"><span><ix:nonNumeric id="d22891554e855-wk-Fact-D0F0E7216C9C5EE29217D1D0182A6217" name="dei:Security12bTitle" contextRef="FD2019Q4YTD">Common Stock, $0.01 par value</ix:nonNumeric></span></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;"><span><ix:nonNumeric id="d22891554e865-wk-Fact-405ACB6AAB427643E8FDD1D0183CD7C8" name="dei:TradingSymbol" contextRef="FD2019Q4YTD">IMMU</ix:nonNumeric></span></span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;"><span><ix:nonNumeric id="d22891554e875-wk-Fact-E2E91DB403C166A30CABD1D0180B2289" name="dei:SecurityExchangeName" contextRef="FD2019Q4YTD" format="ixt-sec:exchnameen">Nasdaq Stock Market LLC</ix:nonNumeric></span></span></div></td></tr></table></div></div><div style="line-height:120%;font-size:6pt;"><span style="font-family:inherit;font-size:6pt;"> </span></div><div style="line-height:120%;text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Securities registered pursuant to Section 12(g) of the Act: None</span></div><div style="line-height:120%;text-align:center;font-size:6pt;"><span style="font-family:inherit;font-size:6pt;"> </span></div><div style="line-height:120%;text-indent:48px;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act.    </span><span><ix:nonNumeric id="d22891554e890-wk-Fact-CBD06DCFBFF4999A8EC0D1D01865D34E" name="dei:EntityWellKnownSeasonedIssuer" contextRef="FD2019Q4YTD"><span style="font-size:8pt;">Yes</span></ix:nonNumeric></span><span style="font-family:inherit;font-size:8pt;">  </span><span style="font-family:Wingdings;font-size:8pt;">þ</span><span style="font-family:inherit;font-size:8pt;">    No  </span><span style="font-family:Wingdings;font-size:8pt;">¨</span></div><div style="line-height:120%;font-size:6pt;"><span style="font-family:inherit;font-size:6pt;"> </span></div><div style="line-height:120%;text-indent:48px;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.    Yes  </span><span style="font-family:Wingdings;font-size:8pt;">¨</span><span style="font-family:inherit;font-size:8pt;">    </span><span><ix:nonNumeric id="d22891554e912-wk-Fact-9F1A13D425AB33E79F94D1D0180B79A4" name="dei:EntityVoluntaryFilers" contextRef="FD2019Q4YTD"><span style="font-size:8pt;">No</span></ix:nonNumeric></span><span style="font-family:inherit;font-size:8pt;">  </span><span style="font-family:Wingdings;font-size:8pt;">þ</span></div><div style="line-height:120%;font-size:6pt;"><span style="font-family:inherit;font-size:6pt;"> </span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirement for the past 90 days.  </span><span><ix:nonNumeric id="d22891554e927-wk-Fact-E37AD66695F22F24A9AAD1D0181BB219" name="dei:EntityCurrentReportingStatus" contextRef="FD2019Q4YTD"><span style="font-size:8pt;">Yes</span></ix:nonNumeric></span><span style="font-family:inherit;font-size:8pt;"> </span><span style="font-family:Wingdings;font-size:8pt;">þ </span><span style="font-family:inherit;font-size:8pt;"> No </span><span style="font-family:Wingdings;font-size:8pt;">¨</span></div><div style="line-height:120%;font-size:6pt;"><span style="font-family:inherit;font-size:6pt;"> </span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files).  </span><span><ix:nonNumeric id="d22891554e945-wk-Fact-B8B70F444047D76CFB3FD1D0180B6E6B" name="dei:EntityInteractiveDataCurrent" contextRef="FD2019Q4YTD"><span style="font-size:8pt;">Yes</span></ix:nonNumeric></span><span style="font-family:inherit;font-size:8pt;"> </span><span style="font-family:Wingdings;font-size:8pt;">þ </span><span style="font-family:inherit;font-size:7pt;"> </span><span style="font-family:inherit;font-size:8pt;">No </span><span style="font-family:Wingdings;font-size:8pt;">¨</span></div><div style="line-height:120%;font-size:6pt;"><span style="font-family:inherit;font-size:6pt;"> </span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See definitions of “large accelerated filer”, “accelerated filer”, “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act. (Check one):</span></div><div style="line-height:120%;text-align:justify;font-size:6pt;"><span style="font-family:inherit;font-size:6pt;"> </span></div><div style="line-height:120%;padding-left:0px;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"></td></tr><tr><td style="width:45%;"></td><td style="width:5%;"></td><td style="width:45%;"></td><td style="width:5%;"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonNumeric id="d22891554e982-wk-Fact-632F198FD0F017624DFDD1D0180B8518" name="dei:EntityFilerCategory" contextRef="FD2019Q4YTD" format="ixt-sec:entityfilercategoryen">Large Accelerated Filer</ix:nonNumeric></span></span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial Unicode MS;font-size:8pt;">☑</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Accelerated Filer</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial Unicode MS;font-size:8pt;">☐</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Non-Accelerated Filer</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial Unicode MS;font-size:8pt;">☐</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Smaller Reporting Company</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial Unicode MS;font-size:8pt;"><span><ix:nonNumeric id="d22891554e1018-wk-Fact-C67912C6396CF5857F46D1D0185BAF72" name="dei:EntitySmallBusiness" contextRef="FD2019Q4YTD" format="ixt-sec:boolballotbox">☐</ix:nonNumeric></span></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Emerging Growth Company</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial Unicode MS;font-size:8pt;"><span><ix:nonNumeric id="d22891554e1039-wk-Fact-2D08B5685A9AF5CB3E4BD1D0184B285A" name="dei:EntityEmergingGrowthCompany" contextRef="FD2019Q4YTD" format="ixt-sec:boolballotbox">☐</ix:nonNumeric></span></span></div></td></tr></table></div></div><div style="line-height:120%;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"> </span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. </span><span style="font-family:Wingdings;font-size:8pt;">¨</span></div><div style="line-height:120%;text-align:left;font-size:6pt;"><span style="font-family:inherit;font-size:6pt;"> </span></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Indicate by check mark whether the registrant is a shell company (as defined in Exchange Act Rule 12b-2 of the Act). Yes   </span><span><ix:nonNumeric id="d22891554e1058-wk-Fact-51683AD76CA4F6BA2EBA7E5C6C9ED1AF" name="dei:EntityShellCompany" contextRef="FD2019Q4YTD" format="ixt-sec:boolballotbox"><span style="font-family:Arial Unicode MS;font-size:8pt;">☐</span></ix:nonNumeric></span><span style="font-family:inherit;font-size:8pt;">   No   </span><span style="font-family:Wingdings;font-size:8pt;">þ</span></div><div style="line-height:120%;font-size:6pt;"><span style="font-family:inherit;font-size:6pt;"> </span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">The aggregate market value of the registrant’s common stock held by non-affiliates computed by reference to the price at which the common stock was last sold on the Nasdaq Global Select Market as of June 30, 2019 was </span><span style="font-family:inherit;font-size:8pt;"><span>$<ix:nonFraction id="d22891554e1072-wk-Fact-DE2D71583DA959E9E373D1D0184BCBF6" name="dei:EntityPublicFloat" contextRef="FI2019Q2" unitRef="usd" decimals="0" scale="0" format="ixt:numdotdecimal">2,660,996,949</ix:nonFraction></span></span><span style="font-family:inherit;font-size:8pt;">. The number of shares of the registrant’s common stock outstanding as of February 21, 2020 was </span><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d22891554e1076-wk-Fact-7B6132A1C663422099D0D1D0186574B2" name="dei:EntityCommonStockSharesOutstanding" contextRef="I2020Q1SharesOutstanding" unitRef="shares" decimals="INF" scale="0" format="ixt:numdotdecimal">213,929,505</ix:nonFraction></span></span><span style="font-family:inherit;font-size:8pt;">.</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><br/></span></div><div style="line-height:120%;font-size:6pt;"><span style="font-family:inherit;font-size:6pt;"> </span></div><div style="line-height:120%;text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Documents Incorporated by Reference:</span></div><div style="line-height:120%;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"> </span></div><ix:nonNumeric contextRef="FD2019Q4YTD" name="dei:DocumentsIncorporatedByReferenceTextBlock" id="TextSelection-8C352722E0F9DBD6CEF1D1D01865AD4E-0-wk-Fact-D432D860F1049290B4D0D1D018658445" escape="true"><div style="line-height:120%;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Specified portions of the registrant’s proxy statement, which will be filed with the Commission pursuant to Regulation 14A within 120 days of the end of the fiscal year ended </span><span style="font-family:inherit;font-size:8pt;">December 31, 2019</span><span style="font-family:inherit;font-size:8pt;"> in connection with the registrant’s 2020 Annual Meeting of Stockholders, are incorporated by reference into Part III of this annual report on Form 10-K.</span></div></ix:nonNumeric><div style="line-height:120%;text-align:justify;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><br/></span></div><div style="line-height:120%;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"> </span></div><div style="line-height:120%;text-align:justify;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">In this Form 10-K, we use the words "Immunomedics, Inc." to refer to Immunomedics, Inc., a Delaware corporation, and we use the words the "Company," "Immunomedics," "Immunomedics, Inc.," "we," "us" and "our" to refer to Immunomedics, Inc. and its subsidiaries.</span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">1</span></div></div><hr style="page-break-after:always"></hr><div><a id="sfb86787ac8304dffbb4bfe7ffcfa7b54"></a></div><div></div><div><br/></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Immunomedics, Inc.</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Annual Report on Form 10-K</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Table of Contents</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"></td></tr><tr><td style="width:9%;"></td><td style="width:11%;"></td><td style="width:75%;"></td><td style="width:5%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;" href="#s1287F7A29BF85670A125052C33A43E05"><span style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">Part I</span></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;" href="#sD88FB3DCB09359FDBFDE826CA37D7299"><span style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">Item 1.</span></a></div></td><td style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;" href="#sD88FB3DCB09359FDBFDE826CA37D7299"><span style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">Business </span></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;" href="#sD88FB3DCB09359FDBFDE826CA37D7299">4</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;" href="#s931E08D0A1D957A6B72594D176FE2C49"><span style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">Item 1A.</span></a></div></td><td style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;" href="#s931E08D0A1D957A6B72594D176FE2C49"><span style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">Risk Factors</span></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;" href="#s931E08D0A1D957A6B72594D176FE2C49">19</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;" href="#s01F8EB8D9CC252B4903CA9F8B3F04FAA"><span style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">Item 1B.</span></a></div></td><td style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;" href="#s01F8EB8D9CC252B4903CA9F8B3F04FAA"><span style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">Unresolved Staff Comments</span></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;" href="#s01F8EB8D9CC252B4903CA9F8B3F04FAA">39</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;" href="#sEA7ACF572884574782926CE339C93C98"><span style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">Item 2.</span></a></div></td><td style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;" href="#sEA7ACF572884574782926CE339C93C98"><span style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">Properties</span></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;" href="#sEA7ACF572884574782926CE339C93C98">40</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;" href="#s48E5F676E90A5389AE648AD1F7125177"><span style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">Item 3.</span></a></div></td><td style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;" href="#s48E5F676E90A5389AE648AD1F7125177"><span style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">Legal Proceedings</span></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;" href="#s48E5F676E90A5389AE648AD1F7125177">40</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;" href="#s663FD1E8F42E502B91733C65710BE25C"><span style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">Item 4.</span></a></div></td><td style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;" href="#s663FD1E8F42E502B91733C65710BE25C"><span style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">Mine Safety Disclosures</span></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;" href="#s663FD1E8F42E502B91733C65710BE25C">42</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;" href="#sB843E213E54B503897780A7C1EA24AFF"><span style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">Part II</span></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;" href="#sE6707278AA655630A22C90B3D2EF9291"><span style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">Item 5.</span></a></div></td><td style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;" href="#sE6707278AA655630A22C90B3D2EF9291"><span style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">Market For Registrant’s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities</span></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;" href="#sE6707278AA655630A22C90B3D2EF9291">43</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;" href="#s3AA20388715F53D0AD804BF27E9AC0BA"><span style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">Item 6.</span></a></div></td><td style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;" href="#s3AA20388715F53D0AD804BF27E9AC0BA"><span style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">Selected Financial Data</span></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;" href="#s3AA20388715F53D0AD804BF27E9AC0BA">44</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;" href="#sA6CC3F09E422530DB6C0B9582C397CCC"><span style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">Item 7.</span></a></div></td><td style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;" href="#sA6CC3F09E422530DB6C0B9582C397CCC"><span style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">Management’s Discussion and Analysis of Financial Condition and Results of Operations</span></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;" href="#sA6CC3F09E422530DB6C0B9582C397CCC">45</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;" href="#s64CE80BC57B655E58D13682F3A5FA16A"><span style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">Item 7A.</span></a></div></td><td style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;" href="#s64CE80BC57B655E58D13682F3A5FA16A"><span style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">Quantitative and Qualitative Disclosures About Market Risk</span></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;" href="#s64CE80BC57B655E58D13682F3A5FA16A">54</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;" href="#sAB1A2881EFD35C9E9182717103603243"><span style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">Item 8.</span></a></div></td><td style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;" href="#sAB1A2881EFD35C9E9182717103603243"><span style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">Financial Statements and Supplementary Data</span></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;" href="#sAB1A2881EFD35C9E9182717103603243">55</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;" href="#s3BC1695089135603B302FF81A27F9B72"><span style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">Item 9.</span></a></div></td><td style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;" href="#s3BC1695089135603B302FF81A27F9B72"><span style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">Changes in and Disagreements with Accountants on Accounting and Financial Disclosure</span></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;" href="#s3BC1695089135603B302FF81A27F9B72">87</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;" href="#s6B4112BD0305559BBC7821EA6D2D9EE7"><span style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">Item 9A.</span></a></div></td><td style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;" href="#s6B4112BD0305559BBC7821EA6D2D9EE7"><span style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">Controls and Procedures</span></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;" href="#s6B4112BD0305559BBC7821EA6D2D9EE7">87</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;" href="#s58758530FCC955CF9243354D01A7680C"><span style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">Item 9B.</span></a></div></td><td style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;" href="#s58758530FCC955CF9243354D01A7680C"><span style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">Other Information</span></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;" href="#s58758530FCC955CF9243354D01A7680C">87</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;" href="#sA682473C3FAD5594A612BE6AE05D826C"><span style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">Part III</span></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;" href="#s48DEBEDF264A51D98F0AEACA688789F7"><span style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">Item 10.</span></a></div></td><td style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;" href="#s48DEBEDF264A51D98F0AEACA688789F7"><span style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">Directors, Executive Officers, and Corporate Governance</span></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;" href="#s48DEBEDF264A51D98F0AEACA688789F7">88</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;" href="#s0BED532A06535006A6E288EA0599F57A"><span style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">Item 11.</span></a></div></td><td style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;" href="#s0BED532A06535006A6E288EA0599F57A"><span style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">Executive Compensation</span></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;" href="#s0BED532A06535006A6E288EA0599F57A">88</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;" href="#sD07CC60DE97854F68CF914B30282FE47"><span style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">Item 12.</span></a></div></td><td style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;" href="#sD07CC60DE97854F68CF914B30282FE47"><span style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters</span></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;" href="#sD07CC60DE97854F68CF914B30282FE47">88</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;" href="#s1145738D0B755CA2806CC9EA884298BB"><span style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">Item 13.</span></a></div></td><td style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;" href="#s1145738D0B755CA2806CC9EA884298BB"><span style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">Certain Relationships and Related Transactions and Director Independence</span></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;" href="#s1145738D0B755CA2806CC9EA884298BB">88</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;" href="#s1A584D1CAD6954258A066CDE8A246C91"><span style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">Item 14.</span></a></div></td><td style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;" href="#s1A584D1CAD6954258A066CDE8A246C91"><span style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">Principal Accounting Fees and Services</span></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;" href="#s1A584D1CAD6954258A066CDE8A246C91">88</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;" href="#s789D9C5B1AF852AFA4B469AA7FBC6A6C"><span style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">Part IV</span></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;" href="#sD6E8CDD5B84D5CEF873128CA517227AB"><span style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">Item 15.</span></a></div></td><td style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;" href="#sD6E8CDD5B84D5CEF873128CA517227AB"><span style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">Exhibits, Financial Statement Schedules</span></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;" href="#sD6E8CDD5B84D5CEF873128CA517227AB">88</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;" href="#saf81f7d3746e4a37ac924f89e19da6ed"><span style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">Item 16.</span></a></div></td><td style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;" href="#saf81f7d3746e4a37ac924f89e19da6ed"><span style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">Form 10-K Summary</span></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;" href="#saf81f7d3746e4a37ac924f89e19da6ed">91</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;" href="#s237FCEAA66A55C47B272B6578E9E8E67"><span style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">Signatures</span></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;" href="#s237FCEAA66A55C47B272B6578E9E8E67">92</a></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2</span></div></div><hr style="page-break-after:always"></hr><div><a id="s1287F7A29BF85670A125052C33A43E05"></a></div><div><div style="line-height:120%;text-align:justify;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;" href="#sfb86787ac8304dffbb4bfe7ffcfa7b54"><span style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">Table of Contents</span></a></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></div><div><br/></div><div style="line-height:120%;padding-bottom:16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">PART I</span></div><div><a id="sD88FB3DCB09359FDBFDE826CA37D7299"></a></div><div style="line-height:120%;padding-bottom:16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Item 1.    BUSINESS</span></div><div><a id="s60B0E90A5B1B543EB997360F37311D63"></a></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Transition Period</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">On December 14, 2018, the Company's Board of Directors approved a change in the Company's fiscal year end from June 30 to December 31. In connection with this change, we previously filed a Transition Report on Form 10-K to report the results of the six-month transition period from July 1, 2018 to December 31, 2018 (which we sometimes refer to as the "Transition Period"). In this Annual Report, the periods presented are the year ended December 31, 2019, the Transition Period ended December 31, 2018 and our fiscal years ended June 30, 2018 and 2017 (which are referred to as “fiscal 2018,” and "fiscal 2017", as if we had not changed our fiscal year to a calendar year). For comparison purposes, we have also included unaudited data for the year ended December 31, 2018.</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Overview</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Immunomedics is a clinical-stage biopharmaceutical company developing monoclonal antibody-based products for the targeted treatment of cancer. Our advanced proprietary technologies allow us to create humanized antibodies that can be used either alone in unlabeled or “naked” form, or conjugated with chemotherapeutics, cytokines or toxins. Our most advanced product candidate is sacituzumab govitecan ("IMMU-132"), an antibody-drug conjugate (“ADC”) that has received Breakthrough Therapy Designation (“BTD”) from the United States Food and Drug Administration for the treatment of patients with metastatic triple-negative breast cancer (“mTNBC”) who previously received at least two prior therapies for metastatic disease.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Our current focus is to commercialize sacituzumab govitecan as a third-line therapy for patients with mTNBC in the United States. </span><span style="font-family:inherit;font-size:10pt;">In May 2018, we submitted a Biologics License Application (“BLA”) to the United States Food and Drug Administration ("FDA") for sacituzumab govitecan for the treatment of patients with mTNBC who have received at least two prior therapies for metastatic disease. In July 2018, we received notification from the FDA that the BLA was accepted for filing and the original application was granted Priority Review with a Prescription Drug User Fee Act ("PDUFA") target action date in January 2019. In January 2019, we received a Complete Response Letter ("CRL") from the FDA for the BLA. We subsequently met with the FDA in May 2019 to review the FDA’s findings and discussed our BLA resubmission. Since then, we have developed a detailed plan to address the chemistry, manufacturing, and controls (“CMC”) matters raised in the CRL and in our pre-approval inspection. We held another meeting with the FDA in September 2019 to update the FDA on our progress in addressing these matters and to receive feedback from the FDA on our approach. On November 30, 2019, we resubmitted our BLA to the FDA and on December 23, 2019 we received notification from the FDA that the BLA was accepted for filing and further assigned a new PDUFA target action date as June 2, 2020. We have dedicated, and continue to commit, significant resources to address the CMC matters identified by the FDA, while, in parallel, preparing our manufacturing facility to be ready for re-inspection by the FDA. Our Phase 3 confirmatory ASCENT study for sacituzumab govitecan has reached its target enrollment for mTNBC patients previously treated with at least two systemic chemotherapy regimens. Top-line data for the ASCENT study is expected to be available around mid-2020. </span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">On March 29, 2019, the Company entered into a sales agreement (the "ATM Agreement") with Cowen and Company, LLC ("Cowen") to issue and sell shares of the Company’s common stock, par value $0.01 per share, having an aggregate offering price of up to $150.0 million, from time to time during the term of the ATM Agreement, through an “at-the-market” equity offering program at the Company's sole discretion, under which Cowen will act as the Company’s agent and/or principal. The Company will pay Cowen a commission up to 3.0% of the gross sales proceeds of any common stock sold through Cowen under the ATM Agreement. During the year ended December 31, 2019, the Company sold 4,432,416 shares of common stock with net proceeds of $71.6 million at a weighted average price of $16.40 (excluding commissions) under the ATM Agreement. </span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">On April 5, 2019, the Company entered into a promotion agreement (the “Promotion Agreement”) with Janssen Biotech Inc., ("Janssen") pursuant to which the Company will provide non-exclusive product detailing services to Janssen for erdafitinib (the “Product”). Pursuant to the Promotion Agreement, the Company will provide a dedicated sales team to detail the Product to oncologists and other targeted health care providers in the United States. Under the terms of the Promotion Agreement, Janssen maintains ownership of the New Drug Application for the Product as well as legal, regulatory, distribution, commercialization and manufacturing responsibilities for the Product, while the Company will provide product detailing services to Janssen.  Following the achievement of certain sales targets in 2019 and 2020, Janssen will pay the Company (a) a service fee equal to a percentage in the low double digits of the portion of Cumulative Net Sales (as defined in the Promotion Agreement) in excess of a baseline amount during each of 2019 and 2020, and (b) potential milestone payments of up to $15.0 million when Cumulative Net Sales exceed certain thresholds during each of 2019 and 2020. On April 12, 2019, the Company was informed that the FDA granted accelerated approval to Janssen's Balversa</span><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">®</sup></span><span style="font-family:inherit;font-size:10pt;"> (erdafitinib) for the treatment of adult patients with locally advanced or </span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">4</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;text-align:justify;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;" href="#sfb86787ac8304dffbb4bfe7ffcfa7b54"><span style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">Table of Contents</span></a></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></div><div><br/></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">metastatic urothelial carcinoma that has a type of susceptible genetic alteration known as FGFR3 or FGFR2, and that has progressed during or following prior platinum-containing chemotherapy. Refer to "Note 2 - Revenue Recognition" for additional information.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">On April 29, 2019, we entered into a license agreement (the “License Agreement”) with Everest Medicines II Limited, a China limited company (“Everest”). Pursuant to the License Agreement, we granted Everest an exclusive license to develop and commercialize sacituzumab govitecan in the People’s Republic of China, Taiwan, Hong Kong, Macao, Indonesia, Philippines, Vietnam, Thailand, South Korea, Malaysia, Singapore and Mongolia (the "Territory"). In consideration for entering into the License Agreement, Everest made a one-time, non-refundable upfront payment to us in the aggregate amount of $65.0 million which is recorded as deferred revenue on the consolidated balance sheet as of </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;">. The License Agreement contains a development milestone payment of $60.0 million based upon our achievement of FDA approval for sacituzumab govitecan. The License Agreement also contains additional development milestone payments in a total amount of up to $180.0 million based upon the achievement of certain other development milestones. In addition, the License Agreement contains sales milestone payments in a total amount of up to $530.0 million based upon the achievement of certain sales milestones. Everest will make royalty payments to us based upon percentages of net sales of sacituzumab govitecan, ranging from 14% to 20%. Refer to "Note 2 - Revenue Recognition" for additional information.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">On December 9, 2019, we closed an underwritten public offering of 14,285,715 shares of common stock at a public offering with a price of $17.50 per share, representing gross proceeds of approximately $250.0 million. In addition, the Company granted the underwriters a 30-day option to purchase up to 2,142,857 additional shares of common stock for a total of 16,428,572 shares. We received gross proceeds of $287.5 million and net proceeds of $273.0 million after deducting the underwriting discounts and commissions and expenses related to the offering. We intend to use the net proceeds from this offering primarily to accelerate commercial launch readiness, pending FDA approval, of sacituzumab govitecan in the United States in mTNBC, continue to expand the clinical development programs for sacituzumab govitecan, invest in the broader clinical development of the platform (including IMMU-130 and IMMU-140), continued scale-up of manufacturing and manufacturing process improvements, as well as for working capital and general corporate purposes.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">     </span><span style="font-family:inherit;font-size:10pt;">As of December 31, 2019</span><span style="font-family:inherit;font-size:10pt;">, we had </span><span style="font-family:inherit;font-size:10pt;">$613.2 million</span><span style="font-family:inherit;font-size:10pt;"> in cash, cash equivalents and marketable securities. </span><span style="font-family:inherit;font-size:10pt;">We believe our projected financial resources are adequate to (i) accelerate commercial launch readiness, pending FDA approval, of sacituzumab govitecan in the United States in mTNBC, (ii) continue to expand the clinical development programs for developing sacituzumab govitecan in mTNBC, metastatic urothelial cancer ("mUC"), hormone receptor-positive ("HR+")/human epidermal growth factor receptor 2-negative ("HER2-") metastatic breast cancer ("mBC"), and other indications of high medical need, (iii) invest in the broader clinical development of the platform (including IMMU-130 and IMMU-140), (iv) continued scale up of manufacturing and manufacturing process improvements, and (v) general working capital requirements. However, in case of regulatory delays or other unforeseen events, we may require additional funding.</span><span style="font-family:inherit;font-size:10pt;"> </span><span style="font-family:inherit;font-size:10pt;">Potential sources of funding in such a case could include (i) the entrance into potential development and commercial partnerships to advance and maximize our full pipeline for mTNBC and beyond in the United States and globally, and (ii) potential private and public capital markets financing. Refer to "Note 9 - Stockholders' Equity" for additional information. </span><span style="font-family:inherit;font-size:10pt;"> </span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">    </span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">For 2020, our strategic priorities for sacituzumab govitecan include:</span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:72px;"><span style="font-family:inherit;font-size:10pt;">1.</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">FDA approval of sacituzumab govitecan for the treatment of patients with mTNBC who have received at least two prior therapies for metastatic disease under the FDA's Accelerated Approval Pathway;</span></div></td></tr></table><div style="line-height:120%;text-align:justify;padding-left:96px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:72px;"><span style="font-family:inherit;font-size:10pt;">2.</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Commercial launch of sacituzumab govitecan, pending FDA approval, in the United States;</span></div></td></tr></table><div style="line-height:120%;text-align:justify;padding-left:96px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:72px;"><span style="font-family:inherit;font-size:10pt;">3.</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Execution of our clinical development plan, which includes: </span></div></td></tr></table><div style="line-height:120%;text-align:justify;padding-left:96px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:144px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:120px;"><span style="font-family:inherit;font-size:10pt;">a.</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Complete patient enrollment into registrational Phase 3 TROPiCS-02 study in HR+/HER2- mBC;</span></div></td></tr></table><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:144px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:120px;"><span style="font-family:inherit;font-size:10pt;">b.</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Complete enrolling cisplatin-ineligible patients into cohort 2 of the pivotal Phase 2 TROPHY U-01 study in mUC and report top-line results from full 100 cohort 1 patients with prior platinum-based and immune checkpoint inhibitor therapies; </span></div></td></tr></table><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:144px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:120px;"><span style="font-family:inherit;font-size:10pt;">c.</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Include an additional exploratory cohort of patients who have relapsed or are refractory to platinum-based therapies but naïve to immuno-oncology therapies to evaluate sacituzumab govitecan in combination with pembrolizumab in the ongoing TROPHY U-01 study;</span></div></td></tr></table><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">5</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;text-align:justify;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;" href="#sfb86787ac8304dffbb4bfe7ffcfa7b54"><span style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">Table of Contents</span></a></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></div><div><br/></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:144px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:120px;"><span style="font-family:inherit;font-size:10pt;">d.</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Report initial results in non small cell lung cancer ("NSCLC") from the TROPiCS-03 study, a Trop-2-enriched Phase 2 multi-cohort study in refractory adeno- and squamous NSCLC, head and neck cancer, and endometrial cancer; and</span></div></td></tr></table><div style="line-height:120%;text-align:justify;padding-left:144px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:144px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:120px;"><span style="font-family:inherit;font-size:10pt;">e.</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Report top-line results from the confirmatory Phase 3 ASCENT study in mTNBC.</span></div></td></tr></table><div style="line-height:120%;text-align:justify;padding-left:144px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:72px;"><span style="font-family:inherit;font-size:10pt;">4.</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Establishing Samsung BioLogics Co., Ltd. as our primary source of commercial antibody in the supply chain for sacituzumab govitecan, while also investing in the scale up of our global supply chain.</span></div></td></tr></table><div style="line-height:120%;text-align:justify;padding-left:96px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div><a id="s33D97413A3BF5113927751F4D4F4AD19"></a></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Our Clinical and Preclinical Programs</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We believe that our antibodies have therapeutic potential, in some cases as a naked antibody or when conjugated with chemotherapeutics, cytokines or other toxins to create unique and potentially more effective treatment options. The attachment of effective anti-tumor compounds to antibodies is intended to allow the delivery of these therapeutic agents to tumor sites with better specificity than conventional chemotherapy. This treatment method is designed to optimize the therapeutic window through reducing the systemic exposure of the patient to the therapeutic agents, which ideally minimizes debilitating side effects while maximizing the concentration of the therapeutic agent at the tumor, potentially leading to better efficacy.</span><span style="font-family:inherit;font-size:10pt;"> </span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Our portfolio of investigational products includes ADCs that are designed to deliver a specific payload of a chemotherapeutic directly to the tumor while reducing overall toxicities that are usually associated with conventional administration of these chemotherapeutic agents. Sacituzumab govitecan is our most advanced ADC and our lead product candidate that has received Breakthrough Therapy Designation from the FDA for the treatment of patients with mTNBC who have received at least two prior therapies for metastatic disease.</span><span style="font-family:inherit;font-size:10pt;"> </span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">To accelerate the clinical and preclinical development of sacituzumab govitecan, we have entered into the following clinical collaborations: with AstraZeneca PLC ("AstraZeneca") to investigate sacituzumab govitecan in combination with the checkpoint inhibitor, durvalumab (Imfinzi</span><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">®</sup></span><span style="font-family:inherit;font-size:10pt;">), in earlier lines of therapy for mTNBC, advanced urothelial cancer ("UC") and metastatic NSCLC ("mNSCLC"); with Clovis Oncology, Inc. ("Clovis") to combine sacituzumab govitecan with its poly (ADP-ribose) polymerase (PARP) inhibitor, rucaparib (Rubraca</span><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">®</sup></span><span style="font-family:inherit;font-size:10pt;">), in mTNBC, advanced UC and ovarian cancer; and with Roche to initiate a Phase 1b/2 study (MORPHEUS) comparing the safety and efficacy of the combination of atezolizumab (Tecentriq</span><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">®</sup></span><span style="font-family:inherit;font-size:10pt;">) and sacituzumab govitecan as a frontline treatment for patients with metastatic or inoperable locally advanced mTNBC versus atezolizumab plus nab-paclitaxel as standard of care. Additionally, we have entered into a collaboration with the German Breast Group ("GBG") to conduct a multinational, post-neoadjuvant registrational Phase 3 study (SASCIA) that will evaluate sacituzumab govitecan as a treatment for newly-diagnosed breast cancer patients who do not achieve a pathological complete response ("pCR") following standard neoadjuvant therapy. </span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We are also working with (i) Massachusetts General Hospital ("MGH") on a Phase 1b/2 study of sacituzumab govitecan combining with Pfizer’s PARP inhibitor, talazoparib (TALZENNA</span><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">®</sup></span><span style="font-family:inherit;font-size:10pt;">), in patients with mTNBC previously treated with no more than one prior therapeutic regimen for metastatic disease; (ii) Yale University on a Phase 2 study of sacituzumab govitecan in patients with persistent and recurrent endometrial cancer; and (iii) the University of Wisconsin in patients with metastatic castration-resistant prostate cancer who have progressed on second generation androgen receptor-directed therapy on a Phase 2 study. Refer to "Corporate Collaboration" and "Other Collaborations" below for additional information.</span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">6</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;text-align:justify;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;" href="#sfb86787ac8304dffbb4bfe7ffcfa7b54"><span style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">Table of Contents</span></a></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></div><div><br/></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Below is our development timeline for sacituzumab govitecan across indications: </span></div><div style="line-height:120%;text-align:justify;"><img src="immupipeline21020.jpg" alt="immupipeline21020.jpg" style="height:225px;width:682px;"></img></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Sacituzumab govitecan has been studied in over 1,000 cancer patients in more than 15 types of solid cancers. Sacituzumab govitecan received BTD from the FDA for the treatment of patients with mTNBC who have received at least two prior therapies for metastatic disease. The FDA has also granted sacituzumab govitecan fast track designation, designed to expedite the development and review of applications for products intended for the treatment of a serious or life-threatening disease or condition, for the same indication and for patients with NSCLC or small-cell lung cancer ("SCLC"). Sacituzumab govitecan has also been designated an orphan drug by the FDA for the treatment of patients with SCLC or pancreatic cancer and by the European Medicines Agency (“EMA”) for the treatment of patients with pancreatic cancer.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In February 2019, updated data from the Phase 1/2 trial of sacituzumab govitecan in patients with mTNBC were published in the New England Journal of Medicine. The data (from 108 subjects with mTNBC) showed an overall response rate of 33% and continue to support a favorable benefit/risk profile of the ADC in the mTNBC cohort. The confirmatory Phase 3 ASCENT study in patients with mTNBC with at least two prior therapies for metastatic disease has completed enrollment. Top-line data for the ASCENT study is expected to be available around mid-2020.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">HR+/HER2- mBC is another breast cancer indication that is a key strategic focus for the Company. Phase 1/2 results of sacituzumab govitecan in this treatment-refractory cohort, a population with the distinct need for better treatment options, showed a confirmed overall response rate of 31%. Median duration of response was 7.4 months, the clinical benefit rate was 48% and median progression-free survival was 6.8 months. The safety profile in this cohort was consistent with previous reports. </span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Updated results from the Phase 1/2 study of sacituzumab govitecan in the cohort of patients with previously treated mUC was presented in an oral presentation at the 2019 Genitourinary Cancers Symposium. The results showed an overall response rate of 31% and a median duration of response of 12.9 months in 45 relapsed/refractory patients. Further supportive clinical data was reported in the interim analysis of the first 35 patients from cohort 1 of the pivotal TROPHY-U-01 study and confirmed the safety and efficacy profile of sacituzumab govitecan with an overall response rate of 29% in mUC patients who progressed after both platinum-based chemotherapy and immune checkpoint inhibitor therapy.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The February 2019, New England Journal of Medicine publication also provided additional information on safety from 420 patients with a variety of epithelial cancers from the Phase 1/2 study. The adverse event profile from this overall safety population of the trial was generally consistent with those observed from various cohorts at earlier stages with low discontinuation rates and key adverse events of neutropenia, nausea and diarrhea.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">With the promising efficacy and safety findings, the Company has strategically decided to broaden the development of sacituzumab govitecan beyond mTNBC by launching a Trop-2-enriched Phase 2 basket study in refractory NSCLC, head and neck cancer, and endometrial cancer.</span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">    </span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We have an extensive intellectual property portfolio protecting sacituzumab govitecan. Specifically, 57 patents were issued in the United States and 35 foreign patents were issued covering composition of matter, synthesis and uses. Certain patents relating to the protein sequence of the hRS7 antibody used in sacituzumab govitecan expired in 2017 in the United States and will expire in 2023 overseas. Patents to compositions and use of the CL2A linker incorporated in sacituzumab govitecan expire between 2023 and 2029 in the United States and overseas. Other patents relating to methods of cancer therapy with the SN-38 conjugated form of hRS7 used in sacituzumab govitecan extend to 2033. Additionally, we are entitled to extend the term of our key patent for up to five more years in the United States and certain foreign countries. Outside the United States, patents were issued in Australia, Canada, China, Europe, Israel, Japan, Mexico, South Korea and other key global markets.</span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">7</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;text-align:justify;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;" href="#sfb86787ac8304dffbb4bfe7ffcfa7b54"><span style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">Table of Contents</span></a></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></div><div><br/></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div><a id="s50D74013D96A56D8B6D9F13D7500916D"></a></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Our Platform Technologies</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In our drive to improve targeted therapies of diseases, we have built significant expertise in antibody engineering, particularly proprietary complementarity determining region (CDR)-grafting (antibody humanization) methods, antibody production and formulation, immunochemistry, molecular biology, antibody conjugation, peptide chemistry, synthetic organic chemistry, and protein engineering.</span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Beginning with our unique grafting technique to engineer humanized antibodies, our antibody humanization platform has produced a diverse portfolio of therapeutic agents that are well tolerated and also have a low incidence of immunogenicity.</span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">With the successful humanized antibody platform as a foundation, we have built a robust ADC program using our own proprietary ADC linker technology. </span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;font-style:italic;font-weight:bold;">ADC Linker Technology</span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We developed a novel ADC platform using our proprietary linker, CL2A, which was designed with targeted delivery of SN-38 in mind. SN-38 is about 3 orders of magnitude (100 to 1,000 times) more potent than irinotecan, its parent drug, but it cannot be administered systemically to patients because of its poor water solubility and toxicity. Our linker, CL2A, allows us to produce SN-38 conjugates that are soluble in water with excellent yields while preserving antibody binding and drug activity.</span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">CL2A contains an antibody coupling group on one end and a chemical group on the other for binding with a drug. We have also added a short polyethylene glycol to improve the solubility of CL2A.</span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;"><img src="immu20170630x10k002a01.jpg" alt="immu20170630x10k002a01.jpg" style="height:259px;width:682px;"></img></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Furthermore, because SN-38 can be converted from its active lactone form to the inactive carboxylate form, CL2A was designed to attach close to the lactone ring to prevent it from opening up, thereby maintaining the activity of SN-38. Another key feature of our ADC platform is that the linkage between CL2A and SN-38 is hydrolyzable and will allow the detachment of SN-38 at a rate of about 50% per day </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">in vivo</span><span style="font-family:inherit;font-size:10pt;">.</span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;"><img src="immu20170630x10k003a01.jpg" alt="immu20170630x10k003a01.jpg" style="height:192px;width:682px;"></img></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">8</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;text-align:justify;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;" href="#sfb86787ac8304dffbb4bfe7ffcfa7b54"><span style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">Table of Contents</span></a></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></div><div><br/></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The final structure of our ADC is depicted below, with the hydrolysable linker indicated. What differentiates our ADC platform from those of other companies is the high drug-to-antibody ratio of about seven to eight molecules of drug per antibody. That is to say, when our ADCs bind to their targets on cancer cells, they are delivering up to eight molecules of SN-38 per antibody molecule into the blood or at the vicinity of the tumor, which may explain why our ADCs can deliver more than 120-times the amount of SN-38 to the tumor when studied in an animal model, as compared to irinotecan, the parent compound. We can deliver this drug concentration because our drug is not supertoxic, thus permitting us to give higher antibody doses, in repeated therapy cycles, that we believe provide a better therapeutic index. </span></div><div style="line-height:120%;text-align:left;"><img src="a10kchecmicallinkerimage.jpg" alt="a10kchecmicallinkerimage.jpg" style="height:390px;width:588px;"></img></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div><a id="s37822DE983EB57EA9B7F9F59E88D990C"></a></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Patents and Proprietary Rights</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Our Patents</span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We have accumulated a sizable portfolio of patents and patent applications in the course of our research, which we believe constitutes a valuable business asset. Our key patents relate primarily to our therapeutic product candidates as well as our technologies and other discoveries for which no product candidate has yet been identified. As of </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;">, our portfolio included approximately 285 active United States patents. In addition, as of such date, the portfolio included approximately 384 foreign patents, with a number of United States and foreign patent applications pending.</span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The chart below highlights our material patents and product groups as of </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;">, the major jurisdictions, and relevant expiration periods. Additional patents have been filed to extend the patent life on some of these products, but there can be no assurance that these will be issued as filed.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="7"></td></tr><tr><td style="width:34%;"></td><td style="width:1%;"></td><td style="width:35%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:18%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Program & Product Group</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Targeted</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Antigen/Description</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Patent</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Expiration</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Major</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Jurisdictions</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Antibody-Drug Conjugates</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Trop-2, CEA/CEACAM5 and HLA-DR</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2023-2033</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">U.S., Europe, Japan</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Subcutaneous Formulation</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">All Antibodies</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2032</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">U.S., Europe, Japan</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Epratuzumab</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">CD22</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2020</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">U.S., Europe</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Veltuzumab</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">CD20</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2023-2029</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">U.S., Europe, Japan</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Milatuzumab</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">CD74</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2023-2032</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">U.S., Europe, Japan</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">IMMU-114</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">HLA-DR</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2026-2027</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">U.S., Europe, Japan</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">DNL</span><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">®</sup></span><span style="font-family:inherit;font-size:10pt;"> Program - (E1)-3s</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Trop-2</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2033</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">U.S., Japan</span><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">+</sup></span></div></td></tr></table></div></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">+</sup></span><span style="font-family:inherit;font-size:10pt;"> pending in Europe</span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">9</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;text-align:justify;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;" href="#sfb86787ac8304dffbb4bfe7ffcfa7b54"><span style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">Table of Contents</span></a></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></div><div><br/></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">License</span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">On April 4, 2018, we entered into a license agreement with The Scripps Research Institute ("TSRI"). Pursuant to the license agreement, TSRI granted to us an exclusive, worldwide, sub-licensable, royalty-bearing license to use certain patent rights relating to our ADC sacituzumab govitecan. The license agreement expires on a country-by-country basis on the expiration date of the last to expire licensed patent rights in such country covering a licensed product. The license agreement may be terminated by the mutual written consent of us and TSRI, and TSRI may terminate the license agreement upon the occurrence of certain events, including, but not limited to, if we do not make a payment due pursuant to the license agreement and fail to cure such non-payment within 30 days after the date of TSRI's written notice of such non-payment. As consideration for the license granted, we made a cash payment of $250,000 to TSRI. Additionally, we will pay TRSI (i) product development milestone payments that range from the mid-six digit dollar figure to the low-seven digit dollar figure and (ii) royalties on net sales of licensed products in the low-single digit percentage figure range capped at an annual amount. We have agreed to use reasonable efforts to develop and market the licensed products. During the year ended December 31, 2019, we recognized a $0.5 million milestone payment expense.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"></span><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Our Trademarks</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The mark “IMMUNOMEDICS” is registered in the United States and 21 foreign countries and a European Community Trademark has been granted. Our logo is also registered in the United States and in one foreign country. The mark “IMMUSTRIP” is registered in the United States and Canada. The mark “LEUKOSCAN” is registered in eight foreign countries, and a European Community Trademark has been granted. In addition, we have applied for registration in the United States for several other trademarks for use on products now in development or testing, and for corresponding foreign and/or European Community Trademarks for certain of those marks. The marks “EPRATUCYN,” “VELTUCYN” and “MILATUCYN” have been registered in the United States and International Trademark Registrations which claim priority to the respective United States applications have been filed for “EPRATUCYN” and “VELTUCYN.” The International Registrations request registration in China, Japan and the European Union. The marks “DOCK-AND-LOCK,” “DNL,” and “PANCRIT” have been registered in the United States. Registrations for “SCIGOVI,” “TRODELVY” and “HUMANLY” have been filed in the United States and internationally and for “TUMIMI” in the United States. The U.S. Patent and Trademark Office has issued Notices of Allowance for the marks “TRODELVY,” “SCIGOVI,” “HUMANLY” and “TUMIMI”. </span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Our Trade Secrets</span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We also rely upon unpatented trade secrets, and there is no assurance that others will not independently develop substantially equivalent proprietary information and techniques or otherwise gain access to our trade secrets or disclose such technology, or that such rights can be meaningfully protected. We require our employees, consultants, outside scientific collaborators, sponsored researchers and other advisers to execute confidentiality agreements upon the commencement of employment or consulting relationships with us. These agreements provide that all confidential information developed or made known to the individual during the course of the individual's relationship with us is to be kept confidential and not disclosed to third parties except in specific circumstances. In the case of our employees, the agreement provides that all inventions conceived by such employees shall be our exclusive property. There can be no assurance, however, that these agreements will provide meaningful protection or adequate remedies for our trade secrets in the event of unauthorized use or disclosure of such information.</span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Third Party Rights</span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Our success also depends in part on our ability to gain access to third party patent and proprietary rights and to operate our business without infringing on third party patent rights. We may be required to obtain licenses to patents or other proprietary rights from third parties to develop, manufacture and commercialize our product candidates. Licenses required under third-party patents or proprietary rights may not be available on terms acceptable to us, if at all. If we do not obtain the required licenses, we could encounter delays in product development while we attempt to redesign products or methods or we could be unable to develop, manufacture or sell products requiring these licenses at all.</span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">10</span></div></div><hr style="page-break-after:always"></hr><div><a id="sEE601E27378753FFAC25471C4ECCB98E"></a></div><div><div style="line-height:120%;text-align:justify;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;" href="#sfb86787ac8304dffbb4bfe7ffcfa7b54"><span style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">Table of Contents</span></a></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></div><div><br/></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Corporate Collaborations</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">AstraZeneca/MedImmune</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In June 2018, we entered into a clinical collaboration with AstraZeneca and its global biologics research and development arm, MedImmune, to evaluate in Phase 1/2 studies the safety and efficacy of combining AstraZeneca’s Imfinzi</span><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">®</sup></span><span style="font-family:inherit;font-size:10pt;"> (durvalumab), a human monoclonal antibody directed against programmed cell death ligand 1 ("PD-L1"), with sacituzumab govitecan as a treatment of patients with TNBC and UC, which was broadened in October 2018 to include second-line mNSCLC. </span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"></span><span style="font-family:inherit;font-size:10pt;">Part one of the two-part Phase 1/2 studies will be co-funded by the two companies. Immunomedics will supply the study drug and AstraZeneca will utilize its existing clinical trial infrastructure to accelerate the enrollment of the sacituzumab govitecan and durvalumab combination. The trial design allows for rapid transition into randomized Phase 2 studies should the first part of these studies show promising data and the companies agree to proceed based on efficacy and safety results obtained. </span><span style="font-family:inherit;font-size:10pt;"> </span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">    </span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Clovis Oncology</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In June 2018, we signed a letter of intent with Clovis, and in December 2018, we entered into a clinical collaboration to investigate the combination of Clovis’ Rubraca</span><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">®</sup></span><span style="font-family:inherit;font-size:10pt;"> (rucaparib), a poly (ADP ribose) polymerase inhibitor (PARPi), and sacituzumab govitecan as a second-line treatment of patients with mTNBC and mUC in a phase 1/2 study (SEASTAR), which has been expanded to include platinum resistant ovarian cancer. The dose escalation phase of the study is currently enrolling patients.</span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">    </span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"></span><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">GBG Forschungs GmbH</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In September 2019, we entered into a clinical collaboration with GBG, Neu-Isenburg, Germany, to develop sacituzumab govitecan as a treatment for newly-diagnosed breast cancer patients who do not achieve a pCR following standard neoadjuvant therapy.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The multinational, post-neoadjuvant Phase 3 SASCIA study developed by GBG will be conducted under the sponsorship of GBG. Approximately </span><span style="font-family:inherit;font-size:10pt;">1,200</span><span style="font-family:inherit;font-size:10pt;"> high-risk patients with newly-diagnosed HER2- breast cancer not achieving a pCR following standard neoadjuvant therapy will be randomized to receive either sacituzumab govitecan or treatment of physician’s choice. Primary endpoint is invasive disease-free survival with overall survival, patient reported outcome/quality of life, circulating tumor DNA clearance, and safety serving as secondary endpoints.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Under the terms of the agreement, GBG is eligible to receive up to </span><span style="font-family:inherit;font-size:10pt;">€33.0 million</span><span style="font-family:inherit;font-size:10pt;"> in potential clinical and regulatory milestone payments over a span of approximately six years, of which </span><span style="font-family:inherit;font-size:10pt;">€0.5 million</span><span style="font-family:inherit;font-size:10pt;"> was paid during the year ended </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;">. </span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">F. Hoffman-La Roche Ltd</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In September 2019, we entered into a clinical collaboration with F. Hoffman-La Roche Ltd ("Roche") to compare the safety and efficacy of the combination of atezolizumab (Tecentriq</span><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">®</sup></span><span style="font-family:inherit;font-size:10pt;">), a programmed cell death ligand 1 blocking checkpoint inhibitor, and sacituzumab govitecan, as a frontline treatment of patients with metastatic or inoperable locally advanced TNBC versus atezolizumab plus nab-paclitaxel as standard of care. Roche will be responsible for conducting the randomized trial.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div><a id="s413D7FB33F2E58598F10E6F6769E477C"></a></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Other Collaborations</span></div><div style="line-height:120%;text-align:justify;text-indent:96px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">    </span><span style="font-family:inherit;font-size:10pt;">    </span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In breast cancer, we are collaborating with MGH on a Phase 1b/2 study of sacituzumab govitecan combining with Pfizer’s PARP inhibitor, TALZENNA</span><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">®</sup></span><span style="font-family:inherit;font-size:10pt;">, in patients with mTNBC previously treated with no more than one prior therapeutic regimens for metastatic disease. In endometrial cancer, we are collaborating with Yale University on a Phase 2 study of sacituzumab govitecan in patients with persistent and recurrent endometrial cancer. Through an agreement with The Prostate Cancer Clinical Trials Consortium, we are collaborating with the University of Wisconsin Carbone Cancer Center to investigate sacituzumab govitecan in a Phase 2 study to assess whether targeting Trop-2 with sacituzumab govitecan is promising in prostate cancer patients. In addition to the Phase 2 study, Dr. Lang, the lead investigator at the University of Wisconsin, is also leading a broad translational program integrated into the clinical study to further validate the expression and importance of Trop-2 as a therapeutic target in various stages of prostate cancer. </span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">A separate research collaboration was also established with Fred Hutchinson Cancer Research Center to investigate sacituzumab govitecan and IMMU-130 as a single agent and in combination in prostate cancer xenograft models.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">11</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;text-align:justify;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;" href="#sfb86787ac8304dffbb4bfe7ffcfa7b54"><span style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">Table of Contents</span></a></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></div><div><br/></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Funding Agreement</span><span style="font-family:inherit;font-size:10pt;"> </span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">On January 7, 2018, we entered into a funding agreement (the “Funding Agreement”) with RPI Finance Trust, a Delaware statutory trust (“RPI”). Pursuant to the Funding Agreement, we granted RPI the right to receive certain royalty amounts, subject to certain reductions, based on the net sales of the antibody-drug conjugate IMMU-132 (sacituzumab govitecan) (the “Product”), for each calendar quarter during the term of the Funding Agreement (“Revenue Participation Right”), in exchange for $175,000,000 in cash (the “Purchase Price”). Specifically, the royalty rate commences at 4.15 percent on net annual sales of up to $2 billion, declining step-wise based on sales tiers to 1.75 percent on net global annual sales exceeding $6 billion. In addition, after the seventh anniversary of the First Commercial Sale (as defined in the Funding Agreement) in the United States and following a change of control of the Company, we shall have the option to repurchase fifty percent (50%) of the Revenue Participation Right from RPI, at the net present value (calculated using a 5% discount rate) of the projected royalty payments based upon the then projected sales of the Product.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div><a id="s31DF47E326715806A706F76A89CFE63A"></a></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Government Regulation</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Regulatory Compliance</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Our research and development activities, including testing in laboratory animals and in humans, our manufacture of antibodies and oversight of suppliers and contract manufacturers involved in the production of our product candidates, as well as the design, manufacturing, safety, efficacy, handling, labeling, storage, record-keeping, advertising, promotion and marketing of the product candidates that we are developing, are all subject to stringent regulation, primarily by the FDA in the United States under the Federal Food, Drug, and Cosmetic Act (the "FDCA") and its implementing regulations, and the Public Health Service Act ("PHS Act") and its implementing regulations, and by comparable authorities under similar laws and regulations in other countries. If, for any reason, we do not comply with applicable requirements, such noncompliance can result in various adverse consequences, including one or more delays in approval of, or even the refusal to approve, product licenses or other applications, the suspension or termination of clinical investigations, the revocation of approvals previously granted, as well as fines, criminal prosecution, recall or seizure of products, injunctions against shipping products and total or partial suspension of production and/or refusal to allow us to enter into or termination of governmental supply contracts.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Product Approval</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In the United States, our product candidates are regulated as biologic pharmaceuticals, or biologics. The FDA's regulatory authority for the approval of biologics resides in the PHS Act. However, biologics are also subject to regulation under the FDCA because most biological products also meet the FDCA's definition of "drugs." Most pharmaceuticals or "conventional drugs" consist of pure chemical substances and their structures are known. Most biologics, however, are complex mixtures that are not easily identified or characterized. Biological products differ from conventional drugs in that they tend to be heat-sensitive and susceptible to microbial contamination, thus requiring sterile manufacturing processes. The process required by the FDA before biologic product candidates may be marketed in the United States generally involves the following:</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:inherit;font-size:10pt;">•</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">completion of preclinical laboratory tests and animal studies performed in accordance with the FDA’s current Good Laboratory Practices regulations;</span></div></td></tr></table><div style="line-height:120%;text-align:justify;padding-left:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:inherit;font-size:10pt;">•</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">submission to the FDA of an Investigational New Drug Application (“IND”), which must become effective before human clinical trials may begin and must be updated annually;</span></div></td></tr></table><div style="line-height:120%;text-align:justify;padding-left:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:inherit;font-size:10pt;">•</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">approval by an independent Institutional Review Board (“IRB”) ethics committee at each clinical site before the trial is initiated;</span></div></td></tr></table><div style="line-height:120%;text-align:justify;padding-left:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:inherit;font-size:10pt;">•</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">performance of adequate and well-controlled clinical trials to establish the safety, purity and potency of the proposed biologic, and its safety and efficacy for each indication;</span></div></td></tr></table><div style="line-height:120%;text-align:justify;padding-left:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:inherit;font-size:10pt;">•</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">preparation of and submission to the FDA of a BLA for a new biologic, after completion of all pivotal clinical trials;</span></div></td></tr></table><div style="line-height:120%;text-align:justify;padding-left:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:inherit;font-size:10pt;">•</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">satisfactory completion of an FDA Advisory Committee review, if applicable;</span></div></td></tr></table><div style="line-height:120%;text-align:justify;padding-left:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:inherit;font-size:10pt;">•</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">a determination by the FDA within 60 days of its receipt of a BLA to file the application for review;</span></div></td></tr></table><div style="line-height:120%;text-align:justify;padding-left:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:inherit;font-size:10pt;">•</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">satisfactory completion of an FDA pre-approval inspection of the manufacturing facilities to assess compliance with current Good Manufacturing Practice (“cGMP”) regulations; and</span></div></td></tr></table><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">12</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;text-align:justify;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;" href="#sfb86787ac8304dffbb4bfe7ffcfa7b54"><span style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">Table of Contents</span></a></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></div><div><br/></div><div style="line-height:120%;text-align:justify;padding-left:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:inherit;font-size:10pt;">•</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">FDA review and approval of a BLA for a new biologic, prior to any commercial marketing or sale of the product in the United States.</span></div></td></tr></table><div style="line-height:120%;text-align:justify;padding-left:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Preclinical tests assess the potential safety and efficacy of a product candidate in animal models. Clinical trials involve the administration of the investigational product to human subjects under the supervision of qualified investigators in accordance with current Good Clinical Practices (“cGCPs”), which include the requirement that all research subjects provide their informed consent for their participation in any clinical trial. A protocol for each clinical trial and any subsequent protocol amendments must be submitted to the FDA as part of the IND. Additionally, approval must also be obtained from each clinical trial site’s IRB before the trials may be initiated, and the IRB must monitor the study until completed. There are also requirements governing the reporting of ongoing clinical trials and clinical trial results to public registries.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The clinical investigation of a pharmaceutical, including a biologic, is generally divided into three phases. Although the phases are usually conducted sequentially, they may overlap or be combined.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:inherit;font-size:10pt;">•</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Phase 1 studies are designed to evaluate the safety, dosage tolerance, metabolism and pharmacologic actions of the investigational product in humans, the side effects associated with increasing doses, and if possible, to gain early evidence on effectiveness.</span></div></td></tr></table><div style="line-height:120%;text-align:justify;padding-left:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:inherit;font-size:10pt;">•</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Phase 2 includes controlled clinical trials conducted to preliminarily or further evaluate the effectiveness of the investigational product for a particular indication(s) in patients with the disease or condition under study, to determine dosage tolerance and optimal dosage, and to identify possible adverse side effects and safety risks associated with the product.</span></div></td></tr></table><div style="line-height:120%;text-align:justify;padding-left:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:inherit;font-size:10pt;">•</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Phase 3 clinical trials are generally controlled clinical trials conducted in an expanded patient population generally at geographically dispersed clinical trial sites, and are intended to further evaluate dosage, clinical effectiveness and safety, to establish the overall benefit-risk relationship of the investigational product, and to provide an adequate basis for product approval.</span></div></td></tr></table><div style="line-height:120%;text-align:justify;padding-left:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The FDA may place clinical trials on hold at any point in this process if, among other reasons, it concludes that clinical subjects are being exposed to an unacceptable health risk. Trials may also be terminated by IRBs, which must review and approve all research involving human subjects. Side effects or adverse events that are reported during clinical trials can delay, impede or prevent marketing authorization.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The results of the preclinical and clinical testing, along with information regarding the manufacturing of the product and proposed product labeling, are evaluated and, if determined appropriate, submitted to the FDA through a BLA. The application includes all relevant data available from pertinent preclinical and clinical trials, including negative or ambiguous results as well as positive findings, together with detailed information relating to the product’s chemistry, manufacturing, controls and proposed labeling, among other things. Once the BLA submission has been accepted for filing, the FDA’s standard goal is to review applications within ten months of the filing date or, if the application relates to a drug that treats a serious condition and would provide a significant improvement in safety or effectiveness qualifying for Priority Review, six months from the filing date. The review process is often significantly extended by FDA requests for additional information or clarification.</span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">    </span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The FDA offers certain programs, such as BTD and Fast Track designation, designed to expedite the development and review of applications for products intended for the treatment of a serious or life-threatening disease or condition. For BTD, preliminary clinical evidence of the product indicates that it may demonstrate substantial improvement over existing therapies on one or more clinically significant endpoints, such as substantial treatment effects observed early in clinical development. If BTD or Fast Track designation is obtained, the FDA may initiate review of sections of a BLA before the application is complete, and the product may be eligible for accelerated approval. However, receipt of BTD or Fast Track designation for a product candidate does not ensure that a product will be developed or approved on an expedited basis, and such designation may be rescinded if the product candidate is found to no longer meet the qualifying criteria.</span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">    </span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The FDA reviews the BLA to determine, among other things, whether the proposed product is safe, pure and potent, which includes determining whether it is effective for its intended use, and whether the product is being manufactured in accordance with cGMP, to assure and preserve the product’s identity, strength, quality, potency and purity. The FDA may refer an application to an advisory committee for review, evaluation and recommendation as to whether the application should be approved, and applications for new molecular entities and original BLAs are generally discussed at advisory committee meetings unless the FDA determines that this type of consultation is not needed under the circumstances. The FDA is not bound by the recommendation of an advisory committee, but it typically follows such recommendations.</span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">13</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;text-align:justify;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;" href="#sfb86787ac8304dffbb4bfe7ffcfa7b54"><span style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">Table of Contents</span></a></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></div><div><br/></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">    </span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">After the FDA evaluates the BLA and conducts inspections of manufacturing facilities, it may issue an approval letter or a CRL. An approval letter authorizes commercial marketing of the biologic with specific prescribing information for specific indications. A CRL indicates that the review cycle of the application is complete, and the application is not ready for approval. A CRL may require additional inspections, and/or other significant, expensive and time-consuming requirements related to clinical trials, preclinical studies or manufacturing. Even if such additional information is submitted, the FDA may ultimately decide that the BLA does not satisfy the criteria for approval. The FDA could approve the BLA with a Risk Evaluation and Mitigation Strategy ("REMS") to mitigate risks, which could include medication guides, physician communication plans, or elements to assure safe use, such as restricted distribution methods, patient registries and other risk minimization tools. The FDA also may condition approval on, among other things, changes to proposed labeling, development of adequate controls and specifications, or a commitment to conduct one or more post-market studies or clinical trials. Such post-market testing may include Phase 4 clinical trials and surveillance to further assess and monitor the product’s safety and effectiveness after commercialization.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Biologics Price Competition and Innovation Act of 2009 (“BPCIA”) created an abbreviated pathway for the approval of biosimilar and interchangeable biologic products. The abbreviated pathway establishes legal authority for the FDA to review and approve biosimilar biologics, including the possible designation of a biosimilar as “interchangeable” based on its similarity to an existing brand product. Under the BPCIA, an application for a biosimilar product cannot be approved by the FDA until 12 years after the original branded product was approved under a BLA. In March 2015, the FDA approved Novartis’s Zarxio as a biosimilar product to Amgen’s Neupogen. Since then, as of January 2019, twenty-six biosimilar drugs have received FDA approval. </span><span style="font-family:inherit;font-size:10pt;">In 2020, the FDA and FTC announced collaborative regulatory efforts to support the adoption of biosimilars and interchangeable products and indicated that they will take measures to discourage anti-competitive behavior and promotional statements that they deem false and misleading.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"></span><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Expedited Review and Approval</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The FDA has four program designations/approval pathways — Fast Track, BTD, Accelerated Approval, and Priority Review — to facilitate and expedite development and review of new drugs and biologics to address unmet medical needs in the treatment of serious or life-threatening conditions. The Fast Track designation provides pharmaceutical manufacturers with opportunities for frequent interactions with FDA reviewers during the product’s development and the ability for the manufacturer to do a rolling submission of the BLA. A rolling submission allows completed portions of the application to be submitted and reviewed by the FDA on an ongoing basis. The BTD provides manufacturers with all of the features of the Fast Track designation as well as intensive guidance on implementing an efficient development program for the product and a commitment by the FDA to involve senior managers and experienced review staff in the review. The Accelerated Approval designation allows the FDA to approve a product based on an effect on a surrogate or intermediate endpoint that is reasonably likely to predict a product’s clinical benefit and generally requires the manufacturer to conduct required post-approval confirmatory trials to verify the clinical benefit. The Priority Review designation means that the FDA’s goal is to take action on the BLA within six months, compared to ten months under standard review. The BLA submitted in 2018 for sacituzumab govitecan in patients with mTNBC was accepted by the FDA and the original application was granted Priority Review. On January 17, 2019, we received a CRL from the FDA for the sacituzumab govitecan BLA. We requested a meeting with the FDA to gain a full understanding of its requirements and the resulting timelines for preparation of the resubmission, agency review, and an agency decision on the resubmission. On November 30, 2019 we resubmitted our BLA to the FDA and on December 23, 2019 we received notification from the FDA that the BLA was accepted for filing and further assigned a new PDUFA target action date as June 2, 2020. Refer to "Overview" above for additional information.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Post-Approval Requirements</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Any products manufactured or distributed by us or on our behalf pursuant to FDA approvals are subject to continuing regulation by the FDA and certain state agencies, including requirements for record-keeping, reporting of adverse experiences with the biologic, submitting biological product deviation reports to notify the FDA of unanticipated changes in distributed products, establishment registration, compliance with cGMP standards (including investigation and correction of any deviations from cGMP), and certain state licensing requirements. Additionally, any significant change in the approved product or in how it is manufactured, including changes in formulation or the site of manufacture, generally require prior FDA approval, and even changes that may seem less significant must be evaluated under change control procedures to assess their potential impact on product quality and relative to the specifications on file with the FDA, and whether they trigger notification or approval requirements. The packaging and labeling of all products developed by us are also subject to FDA approval and ongoing regulation. Noncompliance with any regulatory requirements can result in, among other things, issuance of warning letters, civil and criminal penalties, seizures, and injunctive action. Accordingly, manufacturers must continue to expend time, money and effort in the area of production and quality control to maintain compliance with cGMP and other aspects of regulatory compliance.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">14</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;text-align:justify;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;" href="#sfb86787ac8304dffbb4bfe7ffcfa7b54"><span style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">Table of Contents</span></a></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></div><div><br/></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The commercial distribution of prescription drugs is subject to the Drug Supply Chain Security Act ("DSCSA"), which regulates the distribution of the products at the federal level, and sets certain standards for federal or state registration and compliance of entities in the supply chain (manufacturers and packagers, wholesale distributors, third-party logistics providers, and dispensers). The DSCSA preempts certain previously enacted state laws and the pedigree requirements of the Prescription Drug Marketing Act ("PDMA"). Trading partners within the drug supply chain must now ensure certain product tracing requirements are met, and are required to exchange transaction information, transaction history, and transaction statements. Further, the DSCSA limits the distribution of prescription biopharmaceutical products and imposes requirements to ensure overall accountability and security in the drug supply chain. </span><span style="font-family:inherit;font-size:10pt;">Product identifier information (an aspect of the product tracing scheme) is also now required.</span><span style="font-family:inherit;font-size:10pt;color:#333333;"> The DSCSA requirements, development of standards, and the system for product tracing have been and will continue to be phased in over a period of years through 2023, and subject companies will need to continue their implementation efforts.</span><span style="font-family:inherit;font-size:10pt;"> The distribution of product samples continues to be regulated under the PDMA, and some states also impose regulations on drug sample distribution.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">From time to time, legislation is drafted, introduced and passed in Congress that could significantly change the statutory provisions governing the approval, manufacturing and marketing of products regulated by the FDA. In addition to new legislation, FDA regulations, guidance documents, and policies are often revised or reinterpreted by the agency in ways that may significantly affect our business and our product candidates. It is impossible to predict whether further legislative or FDA regulation or policy changes will be enacted or implemented and what the impact of such changes, if any, may be.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"></span><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Orphan Drug Act</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We have successfully obtained Orphan Drug designation by the FDA under the Orphan Drug Act of 1983 for sacituzumab govitecan for SCLC and pancreatic cancer. Under the Orphan Drug Act, FDA may grant Orphan Drug designation to drugs intended to treat a rare disease or condition, which is generally defined as a disease or condition that affects fewer than 200,000 individuals in the United States. Orphan Drug designation must be requested before submitting a BLA. In the United States, Orphan Drug designation entitles a party to financial incentives such as opportunities for grant funding towards clinical trial costs, tax advantages, and user-fee waivers. Orphan Drug designation does not convey any advantage in, or shorten the duration of, the regulatory review and approval process. The first BLA applicant to receive FDA approval for a particular active ingredient to treat a particular disease with FDA Orphan Drug designation is entitled to a seven-year exclusive marketing period in the United States for that product, for that indication. During the seven-year exclusivity period, FDA may not approve any other applications to market the same drug for the same orphan indication, except in limited circumstances, such as a showing of clinical superiority to the product with orphan exclusivity or where the manufacturer of the approved product cannot assure sufficient quantities. As a result, there can be no assurance that our competitors will not receive approval of drugs or biologics that have a different active ingredient for treatment of the diseases for which our products and product candidates are targeted.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"></span><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Foreign Regulation</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In addition to regulations in the United States, we are subject to a variety of foreign regulations governing clinical trials and commercial sales and distribution of our product candidates being developed, and products being marketed outside of the United States. We must obtain approval by the comparable regulatory authorities of foreign countries before we can commence clinical trials or marketing of our products in those countries. The approval process varies from country to country, and the time may be longer or shorter than required by the FDA for BLA licensure. The requirements governing the conduct of clinical trials, product licensing, pricing and reimbursement vary greatly from country to country. As in the United States, we are subject to post-approval regulatory requirements, such as those regarding product manufacturing, marketing, or distribution.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"></span><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Other Regulatory Considerations</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We are also subject to regulation under the Occupational Safety and Health Act, the Toxic Substances Control Act, the Resource Conservation and Recovery Act, The Clean Air Act, New Jersey Department of Environmental Protection and other current and potential future federal, state, or local regulations. Our research and development activities involve the controlled use of hazardous materials, chemicals, biological materials and various radioactive compounds. We believe that our procedures comply with the standards prescribed by state and federal regulations; however, the risk of injury or accidental contamination cannot be completely eliminated.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We may also be subject to healthcare regulation and enforcement by the federal government and the states and foreign governments where we may market our products and product candidates, if approved. These laws and regulations include, without limitation, state and federal anti-kickback, fraud and abuse, false claims, data privacy and security, aggregate spend reporting, and product price advertising.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">15</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;text-align:justify;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;" href="#sfb86787ac8304dffbb4bfe7ffcfa7b54"><span style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">Table of Contents</span></a></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></div><div><br/></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The federal Anti-Kickback Statute, which prohibits, among other things, persons and entities including pharmaceutical manufacturers from knowingly and willfully soliciting, receiving, offering or paying remuneration, directly or indirectly, overtly or covertly, in case or in kind, to induce or reward, or in return for, or either the referral of an individual for, or the purchase, lease or order or recommendation of an item or service reimbursable, in whole or in part, under a federal healthcare program, such as the Medicare and Medicaid programs. This statute has been interpreted broadly to apply to, among other things, arrangements between pharmaceutical manufacturers on the one hand and prescribers, purchasers and formulary managers on the other hand. The term “remuneration” expressly includes kickbacks, bribes or rebates and also has been broadly interpreted to include anything of value. There are a number of statutory exceptions and regulatory safe harbors protecting certain common activities from prosecution or other regulatory sanctions; however, the exceptions and safe harbors are drawn narrowly, and practices that do not fit squarely within an exception or safe harbor may be subject to scrutiny. The failure to meet all of the requirements of a particular applicable statutory exception or regulatory safe harbor does not make the conduct per se illegal under the federal Anti-Kickback Statute. Instead, the legality of the arrangement will be evaluated on a case-by-case basis based on a cumulative review of all of its facts and circumstances. Our practices may not meet all of the criteria for safe harbor protection from federal Anti-Kickback Statute liability in all cases. A person or entity does not need to have actual knowledge of the federal Anti-Kickback Statute or specific intent to violate it to have committed a violation. In addition, Patient Protection and Affordable Care Act of 2010, as amended ("ACA") codified cash law that a claim including items or services resulting from a violation of the federal Anti-Kickback Statute constitutes a false or fraudulent claim for purposes of the federal civil False Claims Act.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The federal civil False Claims Act prohibits individuals or entities from, among other things, knowingly presenting or causing the presentation of a claims payment to, or approval by, the federal government that are false, fictitious or fraudulent, or knowingly making, using or causing to be made or used, a false record or statement material to a false or fraudulent claim to avoid, decrease or conceal an obligation to pay money to the federal government. As a result of a modification made by the Fraud Enforcement and Recovery Act of 2009, a claim includes "any request or demand" for money or property presented to the federal government. Although we do not submit claims directly to payors, manufacturers can be held liable under these laws if they are deemed to "cause" the submission of false or fraudulent claims by, for example, providing inaccurate billing or coding information to customers, promoting a product for unapproved uses (also known as "off-label promotion"), marketing products of sub-standard quality, or, as noted above, paying a kickback that results in a claim for items or services in violation of the Anti-Kickback Statute. In addition, our activities relating to the reporting of wholesaler or estimated retail prices for our products, the reporting of prices used to calculate Medicaid rebate information and other information affecting federal, state and third-party reimbursement for our products, and the sale and marketing of our products, are subject to scrutiny under the False Claims Act. For example, several pharmaceutical and other healthcare companies have faced enforcement actions under these laws for allegedly inflating drug prices they report to pricing services, which in turn were used by the government to set Medicare and Medicaid reimbursement rates, and for allegedly providing free product to customers with the expectation that the customers would bill federal healthcare programs for the product. The federal civil False Claims Act also permits a private individual acting as a "whistleblower" to bring actions on behalf of the federal government alleging violations of the False Claims Act and to share in any monetary recovery. In addition, certain marketing practices, including off-label promotion, may also implicate the False Claims Act. Although the False Claims Act is a civil statute, conduct that results in a False Claims Act violation may also implicate various federal criminal statutes. </span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In addition to the Anti-Kickback Statute and False Claims Act, there are state statutes and regulations equivalent or substantially similar to the federal laws which may extend to items and services reimbursed by commercial insurers and/or by patients directly. State law equivalents to the Anti-Kickback Statute and False Claims Act may not have adopted exceptions and safe harbors available at the federal level and therefore, may implicate a broader range of activities. </span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">To the extent we obtain coverage for our products by state Medicaid programs, we may be required to pay a rebate to each state Medicaid program for any covered outpatient drugs that are dispensed to Medicaid beneficiaries and paid for by a state Medicaid program, and to comply with all Medicaid rebate requirements of the Omnibus Budget Reconciliation Act of 1990 and the Veterans Healthcare Act of 1992. Moreover, federal law requires that any company participating in the Medicaid Drug Rebate program also participate in the Public Health Service’s 340B Program, which impose additional reporting requirements and price concessions. Manufacturer compliance with 340B Program requirements can be costly. In addition, if our products are made available to authorized users of the Federal Supply Schedule of the General Services Administration or to low income patients of certain hospitals, additional laws and requirements may apply.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The federal Health Insurance Portability and Accountability Act of 1996 (“HIPAA”) imposes criminal and civil liability for knowingly and willfully executing, or attempting to execute, a scheme to defraud or obtain, by any means of false or fraudulent pretenses, representations or promises, any money or property owned by, or under the control or custody of, any healthcare benefit program, including private third-party payors, and knowingly and willfully falsifying, concealing or covering up by trick, scheme or device, a material fact or making any materially false, fictitious or fraudulent statement in connection with the delivery of or payment for healthcare benefits, items or services. Similar to the federal Anti-Kickback Statute, a person or entity does not need to have actual knowledge of the statute or specific intent to violate it in order to have committed a violation.</span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">16</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;text-align:justify;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;" href="#sfb86787ac8304dffbb4bfe7ffcfa7b54"><span style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">Table of Contents</span></a></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></div><div><br/></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">    </span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">There has also been a recent trend of increased federal and state regulation of payments made to physicians and other healthcare providers. The federal physician payment transparency requirements, sometimes referred to as the “Physician Payments Sunshine Act,” created under the ACA, and its implementing regulations, which requires applicable manufacturers of covered drugs, devices, biologics and medical supplies for which payment is available under Medicare, Medicaid or the State Children’s Health Insurance Program (with certain exceptions) to annually report to the United States Department of Health and Human Services, or HHS, information related to certain payments or other transfers of value made or distributed to physicians and teaching hospitals, or to entities or individuals at the request of, or designated on behalf of, the physicians and teaching hospitals, as well as ownership and investment interests held by physicians and their immediate family members. Under recent legislation, the Sunshine Act will extend to payments and transfers of value to physician assistants, nurse practitioners, and other mid-level healthcare providers (with reporting requirements going into effect in 2022 for payments and transfers made in 2021). Centers for Medicare and Medicaid Services ("CMS") has the potential to impose penalties of up to $1.15 million per year for violations of the Sunshine Act, depending on the circumstances, and payments reported under the Sunshine Act also have the potential to draw scrutiny on payments to and relationships with physicians and teaching hospitals, which may have implications under the Anti-Kickback Statute and other healthcare laws.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We may also be subject to data privacy and security regulation by both the federal government and the state governments in which we conduct our business. HIPAA, as amended by the Health Information Technology and Clinical Health Act of 2009 ("HITECH") and their respective implementing regulations, including the Final Omnibus Rule published on January 25, 2013, imposes, among other things, obligations, including mandatory contractual terms with respect to safeguarding the privacy, security and transmission of individually identifiable health information held by certain healthcare providers, health plans and healthcare clearinghouses, known as covered entities, and business associates. Among other things, HITECH made certain aspects of HIPAA’s rules (notably the Security Rule) directly applicable to business associates, defined as independent contractors or agents of covered entities that receive or obtain individually identifiable health information in connection with providing a service for or on behalf of a covered entity. HITECH created four tiers of civil monetary penalties, amended HIPAA to make civil and criminal penalties directly applicable to business associates, and gave state attorneys general new authority to file civil actions for damages or injunctions in federal court to enforce the federal HIPAA laws and seek attorney’s fees and costs associated with pursuing federal civil actions. The Department of Health and Human Services Office of Civil Rights ("OCR") has increased its focus on compliance and continues to train state attorneys general for enforcement purposes. The OCR has recently increased both its efforts to audit HIPAA compliance and its level of enforcement, with one recent penalty exceeding $5.0 million. </span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Even where HIPAA does not apply, according to the United States Federal Trade Commission ("FTC"), failing to take appropriate steps to keep consumers' personal information secure constitutes unfair acts or practices in or affecting commerce in violation of Section 5(a) of the Federal Trade Commission Act ("FTCA"), 15 United States C § 45(a). The FTC expects a company's data security measures to be reasonable and appropriate in light of the sensitivity and volume of consumer information it holds, the size and complexity of its business, and the cost of available tools to improve security and reduce vulnerabilities. Medical data is considered sensitive data that merits stronger safeguards. The FTC's guidance for appropriately securing consumers' personal information is similar to what is required by the HIPAA Security Rule.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">There are numerous other laws and legislative and regulatory initiatives at the federal and state levels addressing privacy and security concerns, and some state privacy laws apply in broader circumstances than HIPAA. California recently enacted legislation – the California Consumer Privacy Act ("CCPA"), which took effect January 1, 2020. The CCPA, among other things, created new data privacy obligations for covered companies and provided new privacy rights to California residents, including the right to opt out of certain disclosures of their information. The CCPA also created a private right of action with statutory damages for certain data breaches, thereby potentially increasing risks associated with a data breach. The California Attorney General will issue clarifying regulations. Although the law, as initially enacted, included certain limited exceptions, including for information collected as part of clinical trials as specified in the law, it remains unclear what language the final Attorney General regulations will contain or how the statue and regulations will be interpreted.    </span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We are subject to the United States Foreign Corrupt Practices Act ("FCPA"), which prohibits corporations and individuals from engaging in certain activities to obtain or retain business or to influence a person working in an official capacity. Under this act, it is illegal to pay, offer to pay, or authorize the payment of anything of value to any foreign government official, government staff member, political party or political candidate in an attempt to obtain or retain business or to otherwise influence a person working in an official capacity. Our present and future business has been and will continue to be subject to various other laws and regulations. </span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">17</span></div></div><hr style="page-break-after:always"></hr><div><a id="sE07E1705998C58D39CE1DD0D8286B737"></a></div><div><div style="line-height:120%;text-align:justify;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;" href="#sfb86787ac8304dffbb4bfe7ffcfa7b54"><span style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">Table of Contents</span></a></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></div><div><br/></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Marketing, Sales and Distribution</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">As noted above, we intend to bring sacituzumab govitecan to the United States market on our own for patients with mTNBC. In anticipation of bringing sacituzumab govitecan to market, we have built a commercial operation with a total sales force of approximately 56 colleagues. We also have maintained a core commercial infrastructure preparing for launch readiness. </span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In April 2019, we entered into the Promotion Agreement with Janssen pursuant to which we will provide non-exclusive product detailing services to Janssen. Pursuant to the Promotion Agreement, we will provide a dedicated sales team to market Janssen's Balversa (erdafitinib) to oncologists and other targeted health care providers in the United States. Under the terms of the Promotion Agreement, Janssen maintains ownership of the New Drug Application for the product as well as legal, regulatory, distribution, commercialization and manufacturing responsibilities for the product, while we will provide product detailing services to Janssen. Refer to "Note 2 - Revenue Recognition" for additional information.</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div><a id="s17119892D39D5BC6940AB880E76DE786"></a></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Manufacturing</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We operate a cGMP manufacturing facility in Morris Plains, New Jersey for the production of ADC product candidates for clinical trials, as well as, potentially, for commercial use.</span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Presently, we believe our Morris Plains facility has enough capacity to produce sufficient quantities of hRS7, the anti-Trop-2 antibody used in sacituzumab govitecan, to support the initial commercial launch of sacituzumab govitecan in the United States, pending FDA approval. To meet our projected future demand of sacituzumab govitecan, we have contracted with Samsung Biologics Co., Ltd. for commercial-scale antibody production. Our global supply chain also includes two outside contract manufacturing organizations: Johnson Matthey Pharma Services of Devens, Massachusetts for the manufacture of the linker-drug payload, and BSP Pharmaceuticals of Latina Scalo, Italy for the conjugation of the antibody with the linker-drug and fill/finish of the sacituzumab govitecan drug product. Together, our end-to-end supply chain has capacity to support the potential commercial launch of sacituzumab govitecan in the United States, as well as the multitude of clinical development programs globally. </span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div><a id="s21718177CE895932B5B47602B801F7B4"></a></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Manufacturing Regulatory Considerations</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In addition to regulating and auditing human clinical trials, the FDA regulates and inspects equipment, facilities and processes used in the manufacturing of such products prior to providing approval to market a product. If, after receiving approval from the FDA, a material change is made in manufacturing equipment, location, or process related to an approved product, additional regulatory review may be required. We must also adhere to cGMP and product-specific regulations enforced by the FDA through its facilities inspection program. The FDA also conducts regular, periodic visits to re-inspect equipment, facilities, and processes following the initial approval. If, as a result of these inspections, the FDA determines that our equipment, facilities or processes do not comply with applicable FDA regulations and conditions of product approval, the FDA may seek civil, criminal or administrative sanctions and/or remedies against us, including the suspension of our manufacturing operations.</span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div><a id="sCBB910AB95905B27ACEB8341754D276A"></a></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Employees</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">As of </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;">, we employed 366 persons on a full-time basis, 71 of whom were engaged in research, clinical research and regulatory affairs, 182 of whom were engaged in operations and manufacturing and quality control, and 113 of whom were engaged in finance, administration, sales and marketing. We believe that while we have been successful to date in attracting skilled and experienced scientific personnel, competition for such personnel continues to be intense and there can be no assurance that we will continue to be able to attract and retain the professionals we will need to grow our business. Our employees are not covered by a collective bargaining agreement and we believe that our relationship with our employees is excellent.</span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div><a id="s76EFA8A30D355D15A3E4ED1DDF6F2614"></a></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Corporate Information</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We were incorporated in Delaware in 1982. Our principal offices are located at 300 The American Road, Morris Plains, New Jersey 07950 and 410 The American Road, Morris Plains, New Jersey 07950. Our telephone number is (973) 605-8200. </span><span style="font-family:inherit;font-size:10pt;font-weight:bold;"> </span><span style="font-family:inherit;font-size:10pt;">In addition, to our majority-owned subsidiary, IBC Pharmaceuticals, Inc. (“IBC”), we also have one foreign subsidiary, Immunomedics GmbH in Rodermark, Germany, to assist us in managing sales and marketing efforts, coordinating clinical trials in Europe, and providing related regulatory affairs support. Immunomedics has incurred expenses on behalf of the IBC operations, including interest, over the past fifteen years. As of </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;">, IBC has a liability to Immunomedics Inc. of approximately $18.1 million, which is eliminated in consolidation. Our web address is www.immunomedics.com. We have not incorporated by reference into this Annual Report on Form 10-K the information on our website and you should not consider it to be a part of this document.</span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">18</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;text-align:justify;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;" href="#sfb86787ac8304dffbb4bfe7ffcfa7b54"><span style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">Table of Contents</span></a></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></div><div><br/></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Our reports that have been filed with the Securities and Exchange Commission (“SEC”), are available on our website free of charge, including our transition report and annual reports on Form 10-K, quarterly reports on Form 10-Q, current reports on Form 8-K, Forms 3, 4 and 5 filed on behalf of directors and executive officers and any amendments to such reports filed pursuant to Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended (the “Exchange Act”). Copies of this Annual Report on Form 10-K may also be obtained without charge electronically or by paper by contacting Investor Relations, Immunomedics, Inc., 300 The American Road, Morris Plains, New Jersey 07950 or by calling (973) 605-8200.</span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In addition, we make available on our website (i) the charters for the committees of the Board of Directors, including the Audit Committee, Compensation Committee and Governance and Nominating Committee, and (ii) the Company’s Code of Business Conduct (the “Code of Conduct”) governing our directors, officers and employees. Within the time period required by the SEC, we will post on our website any modifications to the Code of Conduct, as required by the Sarbanes-Oxley Act of 2002, (“Sarbanes-Oxley Act”). The SEC maintains a web site at http://www.sec.gov that contains reports, proxy and information statements and other information regarding companies that file electronically with the SEC. </span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div><a id="s931E08D0A1D957A6B72594D176FE2C49"></a></div><div style="line-height:120%;padding-bottom:16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Item 1A.    RISK FACTORS</span></div><div><a id="sA105B0DE51ED58AD8239B77534311AFA"></a></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"></span><span style="font-family:inherit;font-size:10pt;">Investing in our common stock involves a high degree of risk. You should carefully consider the risks described below, as well as the other information in this Annual Report on Form 10-K, including our financial statements and the related notes and “Management’s Discussion and Analysis of Financial Condition and Results of Operations,” before deciding whether to invest in our common stock. The occurrence of any of the events or developments described below could harm our business, financial condition, results of operations and growth prospects. In such an event, the market price of our common stock could decline, and you may lose all or part of your investment. Additional risks and uncertainties not presently known to us or that we currently deem immaterial also may impair our business operations</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Risks Relating to Our Business, Operations and Product Development</span><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"> </span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">We have a long history of operating losses and it is likely that our operating expenses will continue to exceed our revenues for the foreseeable future.</span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We have incurred significant operating losses since our formation in 1982. We continue to spend our cash resources to fund our research and development programs and, subject to adequate funding, we expect these expenses to increase for the foreseeable future. There can be no assurance that we will be profitable in future quarters or other periods. Further, we have made the strategic decision to focus on our therapeutic pipeline. We have never had product sales of any therapeutic product. We expect to experience significant operating losses as we invest further in our research and development activities while simultaneously attempting to develop and commercialize our other therapeutic product candidates. Even if we are able to develop commercially viable therapeutic products, certain obligations the Company has to third parties, including, without limitation, our obligation to pay RPI Finance Trust, a Delaware statutory trust ("RPI"), royalties on certain sacituzumab govitecan revenues pursuant to the Royalty Agreement may erode profitability of such products. If we are unable to develop commercially viable therapeutic products or to license them to third parties, it is likely that we will never achieve significant revenues or become profitable, either of which would jeopardize our ability to continue as a going concern.</span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">We have significant future capital needs and may be unable to raise capital when needed, which could force us to delay or reduce our clinical development efforts.</span></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We believe our projected financial resources are adequate to (i) accelerate commercial launch readiness, pending FDA approval, of sacituzumab govitecan in the United States in mTNBC, (ii) continue to expand the clinical development programs for developing sacituzumab govitecan in mTNBC, metastatic urothelial cancer ("mUC"), hormone receptor-positive ("HR+")/human epidermal growth factor receptor 2-negative ("HER2-") metastatic breast cancer ("mBC"), and other indications of high medical need, (iii) invest in the broader clinical development of the platform (including IMMU-130 and IMMU-140), (iv) continued scale up of manufacturing and manufacturing process improvements, and (v) general working capital requirements. However, in case of regulatory delays or other unforeseen events, we may require additional funding.</span></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We may require additional funding in the future to complete our clinical trials currently planned or underway, continue research and new development programs, and continue operations. Potential sources of funding include (i) the entrance into various potential strategic partnerships targeted at advancing and maximizing our full pipeline for mTNBC and beyond, (ii) the sales and marketing of sacituzumab govitecan as a third-line therapy for mTNBC in the United States (pending FDA approval), and (iii) potential equity and debt financing transactions. Refer to "Note 9 - Stockholders' Equity" for additional information.</span></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">19</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;text-align:justify;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;" href="#sfb86787ac8304dffbb4bfe7ffcfa7b54"><span style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">Table of Contents</span></a></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></div><div><br/></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Until we can generate significant cash through (i) the entrance into various potential strategic partnerships towards advancing and maximizing our full pipeline for mTNBC and beyond, or (ii) the sales and marketing of sacituzumab govitecan as a third-line therapy for mTNBC in the United States (pending FDA approval), we expect to continue to fund our operations with our current financial resources. In the future, if we cannot obtain sufficient funding through the above methods, we could be required to finance future cash needs through the sale of additional equity and/or issuance of debt. However, there can be no assurance that we will be able to raise the additional capital needed to complete our pipeline of research and development programs on commercially acceptable terms, if at all. The capital markets have experienced volatility in recent years, which has resulted in uncertainty with respect to availability of capital and hence the timing to meet an entity’s liquidity needs. Our existing debt may also negatively impact our ability to raise additional capital. If we are unable to raise capital on acceptable terms, our ability to continue our business would be materially and adversely affected. </span></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">    </span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Other than our pending BLA resubmission for sacituzumab govitecan for patients with metastatic triple-negative breast cancer, our other most advanced therapeutic product candidates are still only in the clinical development stage, and may require us to raise capital in the future in order to fund further expensive and time-consuming studies before they can even be submitted for final regulatory approval. A failure of a clinical trial could severely harm our business and results of operations.</span></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Clinical trials involve the administration of a product candidate to patients who are already extremely ill, making patient enrollment often difficult and expensive. Moreover, even in ideal circumstances where the patients can be enrolled and then followed for the several months or more required to complete the study, the trials can be suspended, terminated, delayed or otherwise fail for any number of reasons, including:</span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:inherit;font-size:10pt;">•</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">later-stage clinical trials may raise safety or efficacy concerns not readily apparent in earlier trials or fail to meet the primary endpoint;</span></div></td></tr></table><div style="line-height:120%;padding-left:4px;text-align:justify;padding-left:48px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:inherit;font-size:10pt;">•</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">unforeseen difficulties in manufacturing the product candidate in compliance with all regulatory requirements and in the quantities needed to complete the trial which may become cost-prohibitive;</span></div></td></tr></table><div style="line-height:120%;padding-left:4px;text-align:justify;padding-left:48px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:inherit;font-size:10pt;">•</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">we or any of our collaboration partners may experience delays in obtaining, or be unable to obtain, agreement for the conduct of our clinical trials from the FDA, IRBs, or other reviewing entities at clinical sites selected for participation in our clinical trials;</span></div></td></tr></table><div style="line-height:120%;padding-left:4px;text-align:justify;padding-left:48px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:inherit;font-size:10pt;">•</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">while underway, the continuation of clinical trials may be delayed, suspended or terminated due to modifications to the clinical trial’s protocols based on interim results obtained or changes required or conditions imposed by the FDA, an IRB, a data and safety monitoring board (“DSMB”), or any other regulatory authority;</span></div></td></tr></table><div style="line-height:120%;padding-left:4px;text-align:justify;padding-left:48px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:inherit;font-size:10pt;">•</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">our third-party contractors may fail to meet their contractual obligations to us in a timely manner;</span></div></td></tr></table><div style="line-height:120%;padding-left:4px;text-align:justify;padding-left:48px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:inherit;font-size:10pt;">•</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">the FDA or other regulatory authorities may impose a clinical hold, for example based on an inspection of the clinical trial operations or trial sites;</span></div></td></tr></table><div style="line-height:120%;padding-left:4px;text-align:justify;padding-left:48px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:inherit;font-size:10pt;">•</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">we or any of our collaboration partners may suspend or cease trials in our or their sole discretion;</span></div></td></tr></table><div style="line-height:120%;padding-left:4px;text-align:justify;padding-left:48px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:inherit;font-size:10pt;">•</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">during the long trial process alternative therapies may become available which make further development of the product candidate impracticable; and</span></div></td></tr></table><div style="line-height:120%;padding-left:4px;text-align:justify;padding-left:48px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:inherit;font-size:10pt;">•</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">if we are unable to obtain the additional capital we need to fund all of the clinical trials we foresee, we may be forced to cancel or otherwise curtail such trials and other studies.</span></div></td></tr></table><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Any substantial delay in successfully completing clinical trials for our product candidates, sacituzumab govitecan and labetuzumab govitecan, could severely harm our business and results of operations.</span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Our clinical trials may not adequately show that our drugs are safe or effective, and a failure to achieve the planned endpoints could result in termination of product development.</span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Progression of our drug products through the clinical development process is dependent upon our trials indicating our drugs have adequate safety and efficacy in the patients being treated by achieving pre-determined safety and efficacy endpoints according to the trial protocols. Failure to achieve either of these endpoints could result in delays in our trials; require the performance of additional unplanned trials or require termination of any further development of the product for the intended indication.</span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">20</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;text-align:justify;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;" href="#sfb86787ac8304dffbb4bfe7ffcfa7b54"><span style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">Table of Contents</span></a></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></div><div><br/></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">These factors could result in delays in the development of our product candidates and could result in significant unexpected costs or the termination of programs.</span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Information obtained from our Expanded Access Program launched in January 2020 may not reliably predict the efficacy of our product candidates in company-sponsored clinical trials and may lead to adverse events that could limit approval.</span></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In January 2020, we instituted an Expanded Access Program for mTNBC patients. Expanded access studies conducted under this program are uncontrolled, carried out by individual investigators and not typically conducted in strict compliance with cGCPs, all of which can lead to a treatment effect which may differ from that in placebo-controlled trials. These studies provide only anecdotal evidence of efficacy for regulatory review. These studies contain no control or comparator group for reference and these patient data are not designed to be aggregated or reported as study results. Moreover, data from such small numbers of patients may be highly variable. </span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Expanded access programs provide supportive safety information for regulatory review. Physicians conducting these studies may use sacituzumab govitecan in a manner inconsistent with the protocol. Any adverse events or reactions experienced by subjects in the expanded access program may be attributed to sacituzumab govitecan and may limit our ability to obtain regulatory approval with labeling that we consider desirable, or at all.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Should the clinical development process be successfully completed, our ability to derive revenues from the sale of therapeutics will depend upon our first obtaining FDA as well as foreign regulatory approvals, all of which are subject to a number of unique risks and uncertainties.</span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Even if we are able to demonstrate the safety and efficacy of our product candidates in clinical trials, if we fail to gain timely approval to commercialize our product candidates from the FDA and other foreign regulatory authorities, we will be unable to generate the revenues we will need to build our business. The FDA or comparable regulatory authorities in other countries may delay, limit or deny approval of our product candidates for various reasons. For example, such authorities may disagree with the design, scope or implementation of our clinical trials; or with our interpretation of data from our preclinical studies or clinical trials; or may otherwise take the position that our product candidates fail to meet the requirements and standards for regulatory approval. There is limited FDA precedent or guidance on ADCs, and ADC product candidates may present more complex review considerations than conventional drugs, given their biologic (antibody), drug, and linker components. There are numerous FDA personnel assigned to review different aspects of a BLA, and uncertainties can be presented by their ability to exercise judgment and discretion during the review process. During the course of review, the FDA may request or require additional preclinical, clinical, chemistry, manufacturing, and controls ("CMC"), or other data and information, and the development and provision of these data and information may be time consuming and expensive. Regulatory approvals may not be granted on a timely basis, if at all, and even if and when they are granted, they may not cover all the indications for which we seek approval. On May 21, 2018, we submitted a Biologics License Application (“BLA”) to the FDA for sacituzumab govitecan for the treatment of patients with mTNBC who have received at least two prior therapies for metastatic disease. On July 18, 2018, we received notification from the FDA that the BLA was accepted for filing and the original application was granted Priority Review with a PDUFA target action date of January 18, 2019. In January 2019, we received a Complete Response Letter ("CRL") from the FDA for the BLA, which identified CMC matters for the Company to address to place our application in condition for approval. In February 2019, we received a written communication from the FDA enclosing the Establishment Inspection Report (“EIR”) from the chemistry, manufacturing and controls BLA pre-approval inspection conducted by the FDA at the Company’s Morris Plains, New Jersey antibody manufacturing facility for our ADC product candidate sacituzumab govitecan, which took place from August 6, 2018 through August 14, 2018. The FDA also notified the Company that the FDA will be conducting a re-inspection of the Company’s Morris Plains, New Jersey antibody manufacturing facility as part of the BLA resubmission process. The Company met with the FDA on May 2, 2019 to review the FDA’s findings and discussed the Company's BLA resubmission and held another meeting with the FDA in September 2019 to update the FDA on our progress in addressing the items identified in the CRL and in our pre-approval inspection and to receive feedback from FDA on our approach. On November 30, 2019 we resubmitted our BLA to the FDA and on December 23, 2019 we received notification from the FDA that the BLA was accepted for filing and further assigned a new PDUFA target action date as June 2, 2020. The Company has developed a detailed plan and has dedicated, and continues to commit, significant resources to addressing the CMC matters identified by the FDA, while, in parallel, preparing our manufacturing facility to be ready for re-inspection by the FDA. If the FDA determines that these actions were not sufficient, or based on the re-inspection FDA officials do not recommend approval relative to our manufacturing facility, or if information deemed necessary by the FDA cannot be provided as part of our BLA submission or during the review period as deemed appropriate on a timely basis, such events could further delay the progress of our BLA and could require additional Company actions that cannot be completed during the review period which may adversely impact our business. Further, while we may develop a product candidate with the intention of addressing a large, unmet medical need, the FDA may only approve the use of the drug for indications affecting a relatively small number of patients, thus greatly reducing the market size and our potential revenues. The approvals </span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">21</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;text-align:justify;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;" href="#sfb86787ac8304dffbb4bfe7ffcfa7b54"><span style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">Table of Contents</span></a></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></div><div><br/></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">may also contain significant limitations in the form of warnings, precautions or contraindications with respect to conditions of use, which could further narrow the size of the market. In certain countries, even if the health regulatory authorities approve a drug, it cannot be marketed until pricing for the drug is also approved. Finally, even after approval can be obtained, we may be required to recall or withdraw a product as a result of newly discovered safety or efficacy concerns, either of which would have a materially adverse effect on our business and results of operations.</span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">In order to fund future operations, we will need to raise significant amounts of additional capital. Because it can be difficult for a mid-cap company like ours to raise equity capital on acceptable terms, we cannot assure you that we will be able to obtain the necessary capital when we need it, or on acceptable terms, if at all.</span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Even if our technologies and product candidates are superior, if we lack the capital needed to bring our future products to market, we may not be successful. We have obtained the capital necessary to fund our research and development programs to date primarily from the following sources:</span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:inherit;font-size:10pt;">•</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">upfront payments, milestone payments, and payments for limited amounts of our antibodies received from licensing partners;</span></div></td></tr></table><div style="line-height:120%;padding-left:4px;text-align:justify;padding-left:48px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:inherit;font-size:10pt;">•</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">proceeds from the public and private sale of our equity or debt securities; and</span></div></td></tr></table><div style="line-height:120%;padding-left:4px;text-align:justify;padding-left:48px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:inherit;font-size:10pt;">•</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">licenses and interest income from our investments.</span></div></td></tr></table><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Over the long term, we expect to commercialize sacituzumab govitecan in mTNBC in the United States and globally, to expand sacituzumab govitecan to treat patients with other solid tumors, including UC, HR+/HER2- mBC, NSCLC and other serious cancers, to expand research and development activities to continue to expand and we do not believe we will have adequate cash to continue commercial expansion and development of sacituzumab govitecan, or to complete development of product candidates in line with our pipeline included in our long term corporate strategy. Our capital requirements are dependent on numerous factors, including:</span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:inherit;font-size:10pt;">•</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">the rate of progress of commercialization of sacituzumab govitecan in mTNBC and our ability to develop it for other cancers;</span></div></td></tr></table><div style="line-height:120%;padding-left:4px;text-align:justify;padding-left:48px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:inherit;font-size:10pt;">•</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">the rate at which we progress our research programs and the number of product candidates we have in preclinical and clinical development at any one time;</span></div></td></tr></table><div style="line-height:120%;padding-left:4px;text-align:justify;padding-left:48px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:inherit;font-size:10pt;">•</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">the cost of conducting clinical trials involving patients in the United States, Europe and possibly elsewhere;</span></div></td></tr></table><div style="line-height:120%;padding-left:4px;text-align:justify;padding-left:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:inherit;font-size:10pt;">•</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">our need to establish the manufacturing capabilities necessary to produce the quantities of our product candidates we project we will need;</span></div></td></tr></table><div style="line-height:120%;padding-left:4px;text-align:justify;padding-left:48px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:inherit;font-size:10pt;">•</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">the time and costs involved in obtaining FDA and foreign regulatory approvals;</span></div></td></tr></table><div style="line-height:120%;padding-left:4px;text-align:justify;padding-left:48px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:inherit;font-size:10pt;">•</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">the cost of first obtaining, and then defending, our patent claims and other intellectual property rights; and</span></div></td></tr></table><div style="line-height:120%;padding-left:4px;text-align:justify;padding-left:48px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:inherit;font-size:10pt;">•</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">our ability to enter into licensing and other collaborative agreements to help offset some of these costs.</span></div></td></tr></table><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">There may be additional cash requirements for many reasons, including, but not limited to, changes in our commercial expansion plans, our research and development plans, the need for unexpected capital expenditures or costs associated with any acquisitions of other businesses, assets or technologies that we may choose to undertake and marketing and commercialization of our product candidates. If we deplete our existing capital resources, we will be required to either obtain additional capital quickly, or significantly reduce our operating expenses and capital expenditures, either of which could have a material adverse effect on us.</span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Until we can generate significant cash through either (i) the entrance into various potential strategic partnerships targeted at advancing and maximizing the Company’s full pipeline for mTNBC and beyond, or (ii) the sales and marketing of sacituzumab govitecan as a third-line therapy for mTNBC </span><span style="font-family:inherit;font-size:10pt;">We believe our projected financial resources are adequate to (i) accelerate commercial launch readiness, pending FDA approval, of sacituzumab govitecan in the United States in mTNBC, (ii) continue to expand the clinical development programs for developing sacituzumab govitecan in mTNBC, metastatic urothelial cancer ("mUC"), hormone receptor-positive ("HR+")/human epidermal growth factor receptor 2-negative ("HER2-") metastatic breast cancer ("mBC"), and other indications of high medical need, (iii) invest in the broader clinical development of the platform (including IMMU-130 and </span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">22</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;text-align:justify;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;" href="#sfb86787ac8304dffbb4bfe7ffcfa7b54"><span style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">Table of Contents</span></a></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></div><div><br/></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">IMMU-140), (iv) continued scale up of manufacturing and manufacturing process improvements, and (v) general working capital requirements. However, in case of regulatory delays or other unforeseen events, we may require additional funding.</span><span style="font-family:inherit;font-size:10pt;"> If, however, we cannot obtain sufficient funding through the entrance into various potential strategic partnerships targeted at advancing and maximizing the Company’s full pipeline for mTNBC and beyond, we could be required to finance future cash needs through the sale of additional equity securities and/or the issuance of debt. However, there can be no assurance that we will be able to raise the additional capital needed to complete our pipeline of research and development programs on commercially acceptable terms, if at all. The capital markets have experienced volatility in recent years, which has resulted in uncertainty with respect to availability of capital and hence the timing to meet an entity’s liquidity needs. The Company’s existing debt will also negatively impact the Company’s ability to raise additional capital. If the Company is unable to raise capital on acceptable terms, its ability to continue its business would be materially and adversely affected. Having insufficient funds may require us to delay, scale-back, or eliminate some or all of our programs, or renegotiate less favorable terms than we would otherwise choose. Failure to obtain adequate financing also may adversely affect our ability to operate as a going concern.</span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Additionally, if we raise funds by issuing equity securities, dilution to existing stockholders would result; and if we raise funds by incurring additional debt financing, the terms of the debt may involve future cash payment obligations and/or conversion to equity as well as restrictions that may limit our ability to operate our business.</span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">If we, or any of our collaboration partners, or our or their contract manufacturers, cannot successfully and efficiently manufacture the compounds that make up our products and product candidates, our ability, and the ability of our collaboration partners, to sell products and conduct clinical trials will be impaired.</span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Our ability to conduct our preclinical and clinical research and development programs depends, in large part, upon our ability to manufacture our proprietary compounds in accordance with the FDA and other regulatory requirements. We have limited historical experience in manufacturing these compounds in significant quantities, and we may not be able to do so in the quantities required to commercialize these products. Any interruption in manufacturing across the supply chain, whether by natural disasters, global disease outbreaks such as COVID-19 (coronavirus) or otherwise, could significantly and adversely affect our operations, and delay our research and development programs.</span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We and our collaboration partners also depend on third parties to provide certain raw materials, and contract manufacturing and processing services. All manufacturers of biopharmaceutical products must comply with current cGMP standards, required by the FDA and other regulatory agencies. Such regulations address, among other matters, controls in manufacturing processes, quality control and quality assurance requirements and the maintenance of proper records and documentation. The FDA and other regulatory agencies routinely inspect manufacturing facilities, including in connection with the review of a BLA. The FDA generally will issue a notice on Form 483 if it finds issues with respect to its inspections, to which the facility must adequately respond in order to avoid escalated regulatory concerns. If our manufacturing facility or those facilities of our collaboration partners and our respective contract manufacturers or processors do not comply with applicable cGMP standards and other regulatory requirements, in addition to regulatory enforcement, we may be subject to product liability claims, we may be unable to meet clinical demand for our products, and we could suffer delays in the progress of clinical trials for products under development and of potential approval and commercialization.</span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Although historically we have been a research and development company, we currently plan to commercialize our lead product candidate internally rather than license such asset. There can be no assurance that we will be successful in developing and expanding commercial operations or balancing our research and development activities with our commercialization activities.</span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We have historically been engaged primarily in research and development activities, but plan to commercialize our lead product candidate, sacituzumab govitecan, ourselves. There can be no assurance that we will be able to successfully manage the balance of our research and development operations with our planned commercialization activities. Potential investors should be aware of the problems, delays, expenses and difficulties frequently encountered by companies balancing development of product candidates, which can include problems such as unanticipated issues relating to clinical trials and receipt of approvals from the FDA and foreign regulatory bodies, with commercialization efforts, which can include problems relating to managing manufacturing and supply, reimbursement, marketing problems and additional costs. Our product candidates will require significant additional research and clinical trials, and we will need to overcome significant regulatory burdens prior to commercialization in the United States and other countries. In addition, we may be required to spend significant funds on building out our commercial operations. </span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Factors that may impact our efforts to commercialize our current or future product candidates and generate product revenues include:</span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">23</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;text-align:justify;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;" href="#sfb86787ac8304dffbb4bfe7ffcfa7b54"><span style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">Table of Contents</span></a></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></div><div><br/></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:inherit;font-size:10pt;">•</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">the need to recruit, train, manage, and retain adequate numbers of effective sales and marketing personnel over a large geographic area;</span></div></td></tr></table><div style="line-height:120%;text-align:justify;padding-left:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:inherit;font-size:10pt;">•</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">the costs and time associated with the initial and ongoing training of sales and marketing personnel on legal and regulatory compliance matters and monitoring their actions;</span></div></td></tr></table><div style="line-height:120%;text-align:justify;padding-left:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:inherit;font-size:10pt;">•</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">the clinical indications for which the products are approved and the claims that we may make for the products;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:inherit;font-size:10pt;">•</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">limitations or warnings, including distribution or use restrictions, contained in the products’ approved labeling;</span></div></td></tr></table><div style="line-height:120%;text-align:justify;padding-left:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:inherit;font-size:10pt;">•</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">any distribution and use restrictions imposed by the FDA or to which we agree; </span></div></td></tr></table><div style="line-height:120%;text-align:justify;padding-left:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:inherit;font-size:10pt;">•</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">understanding and training relevant personnel on the limitations on, and the transparency and reporting requirements applicable to, remuneration provided to actual and potential referral sources; and</span></div></td></tr></table><div style="line-height:120%;text-align:justify;padding-left:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:inherit;font-size:10pt;">•</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">liability for sales or marketing personnel who fail to comply with the applicable legal and regulatory requirements.</span></div></td></tr></table><div style="line-height:120%;text-align:justify;padding-left:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Additionally, commercial products must now meet the requirements of the DSCSA, which imposes obligations on manufacturers of prescription drug products for commercial distribution, regulating the distribution of the products at the federal level, and sets certain standards for federal or state registration and compliance of entities in the supply chain (manufacturers and repackagers, wholesale distributors, third-party logistics providers, and dispensers). The DSCSA preempts previously enacted state pedigree laws and the pedigree requirements of the PDMA. Trading partners within the drug supply chain must now ensure certain product tracing requirements are met that they are doing business with other authorized trading partners; and they are required to exchange transaction information, transaction history, and transaction statements. Further, the DSCSA limits the distribution of prescription pharmaceutical products and imposes requirements to ensure overall accountability and security in the drug supply chain. Product identifier information (an aspect of the product tracing scheme) is also now required. The DSCSA </span><span style="font-family:inherit;font-size:10pt;color:#333333;">requirements, development of standards, and the system for product tracing have been and will continue to be phased in over a period of years through 2023, and subject companies will need to continue their implementation efforts. </span><span style="font-family:inherit;font-size:10pt;">The distribution of product samples continues to be regulated under the PDMA, and some states also impose regulations on drug sample distribution.</span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">If we are unable to develop commercially viable therapeutic products, certain obligations the Company has to third parties, including, without limitation, our obligation to pay RPI royalties on certain sacituzumab govitecan revenues pursuant to the funding agreement may also erode profitability of this product. There can be no assurance that after the expenditure of substantial funds and efforts, we will successfully develop and commercialize any of our product candidates, generate any significant revenues or ever achieve and maintain a substantial level of sales of our products.</span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">We may not successfully establish and maintain collaborative and licensing arrangements, which could adversely affect our ability to develop and commercialize certain of our product candidates. Any of our collaboration partners may not adequately perform their responsibilities under our agreements, which could adversely affect our development and commercialization program.</span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">A key element of our business strategy has been to develop, market and commercialize our product candidates through collaborations with more established pharmaceutical companies, including, but not limited to, our collaborations with Everest, Clovis, Roche and AstraZeneca. To the extent we continue to rely on this business strategy, we may not be able to maintain or expand these licenses and collaborations or establish additional licensing and collaboration arrangements necessary to develop and commercialize any of our product candidates. Even if we are able to maintain or establish licensing or collaboration arrangements, these arrangements may not be on favorable terms and may contain provisions that will restrict our ability to develop, test and market our product candidates. Any failure to maintain or establish licensing or collaboration arrangements on favorable terms could adversely affect our business prospects, financial condition or ability to develop and commercialize our product candidates.</span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We expect to rely at least in part on third party collaborators to perform a number of activities relating to the development and commercialization of certain of our product candidates, including the manufacturing of product materials, the design and conduct of clinical trials for certain of our product candidates, and potentially the obtaining of regulatory approvals and marketing and distribution of any successfully developed products. Our collaborative partners may also have or acquire rights to control aspects of our product development and clinical programs. As a result, we may not be able to conduct these programs in the manner or on the time schedule we currently contemplate. In addition, if any of these collaborative partners withdraw support for our programs or product candidates or otherwise impair their development, our business could be negatively affected. Our expenses may also increase as a result of our plan to undertake these activities internally to commercialize sacituzumab govitecan.</span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">24</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;text-align:justify;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;" href="#sfb86787ac8304dffbb4bfe7ffcfa7b54"><span style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">Table of Contents</span></a></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></div><div><br/></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In addition, our success depends on the performance of our collaborators of their responsibilities under these arrangements. Some potential collaborators may not perform their obligations in a timely fashion or in a manner satisfactory to us. Because such agreements may be exclusive, we may not be able to enter into a collaboration agreement with any other company covering the same product field during the applicable collaborative period. In addition, our collaborators’ competitors may not wish to do business with us at all due to our relationship with our collaborators. If we are unable to enter into additional product discovery and development collaborations, our ability to sustain or expand our business will be significantly diminished.</span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Our future success will depend upon our ability to first obtain and then adequately protect our patent and other intellectual property rights, as well as avoiding the infringement of the rights of others.</span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Our future success will be highly dependent upon our ability to first obtain and then defend the patent and other intellectual property rights necessary for the commercialization of our product candidates. We have filed numerous patent applications on the technologies and processes that we use in the United States and certain foreign countries. Although we have obtained a number of issued United States patents to date, the patent applications owned or licensed by us may not result in additional patents being issued. Moreover, these patents may not afford us the protection we need against competitors with similar technologies or products. A number of jurisdictions where we have sought, or may in the future choose to seek, intellectual property protection, have intellectual property laws and patent offices which are still developing. Accordingly, we may have difficulty obtaining intellectual property protection in these markets, and any intellectual property protections which we do obtain may be less protective than in the United States, which could have an adverse effect on our operations and financial prospects.</span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The successful development of therapeutic products frequently requires the application of multiple technologies that may be subject to the patent or other intellectual property rights of third parties. Although we believe it is likely we will need to license technologies and processes from third parties in the ordinary course of our business, we are not currently aware of any material conflict involving our technologies and processes with any valid patents or other intellectual property rights owned or licensed by others that would affect commercial sales of sacituzumab govitecan or other products starting in 2020. In the event that a third party was to claim such a conflict existed, they could sue us for damages as well as seek to prevent us from commercializing our product candidates. It is possible that a third party could successfully claim that our products infringe on their intellectual property rights. Uncertainties resulting from the litigation and continuation of patent litigation or other proceedings could have a material adverse effect on our ability to compete in the marketplace. Any patent litigation or other proceeding, even if resolved in our favor, would require significant financial resources and management time.</span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Some of our competitors may be able to sustain these costs more effectively than we can because of their substantially greater financial and managerial resources. If a patent litigation or other proceeding is resolved unfavorably to us, we may be enjoined from manufacturing or selling our products without a license from the other party, in addition to being held liable for significant damages. We may not be able to obtain any such license on commercially acceptable terms, if at all.</span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In addition to our reliance on patents, we attempt to protect our proprietary technologies and processes by relying on trade secret laws, nondisclosure and confidentiality agreements and licensing arrangements with our employees and other persons who have access to our proprietary information. These agreements and arrangements may not provide meaningful protection for our proprietary technologies and processes in the event of unauthorized use or disclosure of such information. In addition, our competitors may independently develop substantially equivalent technologies and processes or otherwise gain access to our trade secrets or technology, either of which could materially and adversely affect our competitive position.</span></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Expiry of our intellectual property rights could lead to increased competition.</span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Even where we are able to obtain and then defend patent and other intellectual property rights necessary for research, development and commercialization of our product candidates, such intellectual property rights will be for a limited term. Where patents which we own or license expire, the technology comprising the subject of the patent may be utilized by third parties in research and development or competing products (for example, biosimilars of a patented product may be manufactured by third parties once the patent expires). While we endeavor to maintain robust intellectual property protection, as our existing issued patents expire, it may materially and adversely affect our competitive position.</span></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">We face substantial competition in the biotechnology industry and may not be able to compete successfully against one or more of our competitors.</span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The biotechnology industry is highly competitive, particularly in the area of therapeutic oncology products. In recent years, there have been extensive technological innovations achieved in short periods of time, and it is possible that future technological changes and discoveries by others could result in our products and product candidates quickly becoming uncompetitive or obsolete. A number of companies, including ADC Therapeutics, AbbVie, Astellas Pharma, AstraZeneca, Bristol-</span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">25</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;text-align:justify;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;" href="#sfb86787ac8304dffbb4bfe7ffcfa7b54"><span style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">Table of Contents</span></a></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></div><div><br/></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Myers Squibb, Daiichi Sankyo, GlaxoSmithKline, Immunogen, Merck, Novartis, Pfizer, Roche, Sanofi, Seattle Genetics, and Zyme Works, are engaged in the development of therapeutic ADC and/or oncology products. Many of these companies have significantly greater financial, technical and marketing resources than we do. In addition, many of these companies have more established positions in the pharmaceutical industry and are therefore better equipped to develop, commercialize and market oncology products. Even some smaller competitors may obtain a significant competitive advantage over us if they are able to discover or otherwise acquire patentable inventions, form collaborative arrangements or merge with larger pharmaceutical companies. Further, even if we are able to successfully develop and commercialize products, other manufacturers operating in emerging markets may also have a competitive advantage over us with respect to competing products due to their ability to manufacture with a lower cost base.</span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We expect to face increasing competition from universities and other non-profit research organizations. These institutions carry out a significant amount of research and development in the field of antibody-based technologies and they are increasingly aware of the commercial value of their findings. As a result, they are demanding greater patent and other proprietary rights, as well as licensing and future royalty revenues. It is possible that such competition could come from universities with which we have, or have previously had, collaborative research and development relationships, notwithstanding our efforts to protect our intellectual property in the course of such relationships.</span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">We may be liable for contamination or other harm caused by hazardous materials that we use in the operations of our business.</span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In addition to laws and regulations enforced by the FDA, we are also subject to regulation under various other foreign, federal, state and local laws and regulations. Our manufacturing and research and development programs involve the controlled use of viruses, hazardous materials, chemicals and various radioactive compounds. The risk of accidental contamination or injury from these materials can never be completely eliminated, and if an accident occurs we could be held liable for any damages that result, which could exceed our available resources.</span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">The nature of our business exposes us to significant liability claims, and our insurance coverage may not be adequate to cover any future claims.</span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The use of our compounds in clinical trials and any future sale exposes us to liability claims that could be substantial. These claims might be made directly by healthcare providers, medical personnel, patients, consumers, pharmaceutical companies, and others selling or distributing our compounds. While we currently have product liability insurance that we consider adequate for our current needs, we may not be able to continue to obtain comparable insurance in the future at an acceptable cost, if at all. If for any reason we cannot maintain our existing or comparable liability insurance, our ability to clinically test and market products could be significantly impaired. Moreover, the amount and scope of our insurance coverage, as well as the indemnification arrangements with third parties upon which we rely, may be inadequate to protect us in the event of a successful product liability claim. Any successful claim in excess of our insurance coverage could materially and adversely affect our financial condition and operating results.</span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Certain potential for conflicts of interest, both real and perceived, exist which could result in expensive and time-consuming litigation.</span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Certain of our former officers and directors have relationships and agreements, both with us as well as among themselves and their respective affiliates, which create the potential for both real, as well as perceived, conflicts of interest. These include Dr. David M. Goldenberg, our former Chairman of our Board of Directors, our former Chief Scientific Officer and our former Chief Patent Officer, and Ms. Cynthia L. Sullivan, a former Director and our former President and Chief Executive Officer (who is also the wife of Dr. Goldenberg). Dr. Goldenberg is also a minority stockholder of our majority-owned subsidiary, IBC. Dr. Goldenberg was the primary inventor of new intellectual property for Immunomedics and IBC and was largely responsible for allocating ownership between the two companies. Immunomedics has incurred expenses on behalf of the IBC operations, including interest, over the past fifteen years. </span><span style="font-family:inherit;font-size:10pt;">As of December 31, 2019</span><span style="font-family:inherit;font-size:10pt;">, IBC has a liability to Immunomedics Inc. which is eliminated in consolidation. </span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">On January 8, 2018, Morris Rosenberg joined the Company as Chief Technology Officer and became a full-time employee and was permitted to continue to provide certain limited outside consulting services through M Rosenberg BioPharma Consulting LLC.</span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">On March 5, 2019, we entered into a Letter Agreement with Scott Canute, a member of our Board of Directors, in connection with his appointment as Executive Director of the Company.</span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">26</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;text-align:justify;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;" href="#sfb86787ac8304dffbb4bfe7ffcfa7b54"><span style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">Table of Contents</span></a></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></div><div><br/></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">On November 19, 2019, pursuant to the Plan, the Board of Directors approved a stock option grant to Behzad Aghazadeh, Executive Chairman of the Board of Directors of the Company, to purchase 150,000 shares of the Company's common stock (the "Performance-Based Option") for certain duties performing this role; including providing consulting and advisory services to the Company. The Performance-Based Option will be a nonqualified stock option and one third vested upon FDA acceptance of the BLA resubmission, and two thirds shall vest upon approval from the FDA for the Company’s BLA for sacituzumab govitecan.</span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">As a result of these and other relationships, the potential for both real and perceived conflicts of interest exist and disputes could arise over the allocation of funds, research projects and ownership of intellectual property rights. In addition, in the event that we become involved in stockholder litigation regarding these potential conflicts, we might be required to devote significant resources and management time defending the Company from these claims, which could adversely affect our results of operations.</span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">The commercial success of our product candidates depends on the availability and sufficiency of third-party payor coverage and reimbursement. Given that recent cancer therapeutics for solid cancers such as the ones we are developing can cost approximately in the range of $13,000 to $30,000 a month, even if our product candidates become available for sale it is likely that federal and state governments, insurance companies and other payors of health care costs will try to first limit the use of these drugs to certain patients, and may be reluctant to provide a level of reimbursement that permits us to earn a significant profit on our investment, if any.</span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Our ability to successfully commercialize therapeutic products will depend, in significant part, on the extent to which hospitals and physicians can obtain appropriate reimbursement levels for the cost of our products and related treatment. Third-party payors are increasingly challenging the prices charged for diagnostic and therapeutic products and related services. Many commercial payors employ “new-to-market blocks” for newly launched medications and other products until the payors have the opportunity to make a coverage decision based upon their internal review of such products. When a medication or other product is not covered, the patient is responsible to pay the full price, which can significantly limit utilization. In addition, legislative proposals to reform health care or reduce government insurance programs may result in lower prices or the actual inability of prospective customers to purchase our products. Furthermore, even if reimbursement is available, it may not be available at price levels sufficient for us to realize a positive return on our investment.</span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The United States government, state legislatures and foreign governmental entities have shown significant interest in implementing cost containment programs to limit the growth of government-paid healthcare costs, including price controls, restrictions on reimbursement and coverage and requirements for substitution of generic products for branded prescription drugs. Adoption of government controls and measures and tightening of restrictive policies in jurisdictions with existing controls and measures, could exclude or limit our product candidates from coverage and limit payments for pharmaceuticals. We continue to monitor the potential impact of proposals to lower prescription drug costs at the federal and state level. For example, on May 11, 2018, President Trump laid out his administration’s “Blueprint” to lower drug prices and reduce out of pocket costs of drugs, as well as additional proposals to increase drug manufacturer competition, increase the negotiating power of certain federal healthcare programs, and incentivize manufacturers to lower the list price of their products. Although some proposals related to the administration’s Blueprint require additional authorization to become effective, may ultimately be withdrawn, or may face challenges in the courts, the U.S. Congress and the Trump administration have indicated that they will continue to seek new legislative and administrative measures to control drug costs. Drug pricing remains a key bipartisan issue and drug pricing legislation has been introduced in both the Senate and the House. The Senate Finance Committee released “The Prescription Drug Pricing Reduction Act of 2019” in late July 2019 which includes changes to Medicare and Medicaid drug pricing and targets certain pharmacy benefit manager (“PBM”) and pharmaceutical manufacturer pricing practices such as: (i) revisions to Medicare Part D benefit design and capping beneficiary out-of-pocket costs at $3,100; (ii) an inflationary rebate policy that would require pharmaceutical manufacturers to pay rebates when the price of their drug or biologic increases faster than inflation; (iii) manufacturer reporting requirement to HHS for certain drug price increases; and (iv) PGM transparency requirements and a ban on spread pricing in Medicaid. In December 2019, the House passed a drug pricing bill, “Lower Drug Costs Now Act of 2019), which features Medicare Parts B and D direct negotiation with manufacturers, inflationary rebates and a restructuring of the Part D benefit. Direct price negotiations would occur for at least 50 of the most costly drugs to Medicare and would target drugs without a comparable generic or biosimilar on the market. Negotiated prices under the House bill could be used by any payor, both governmental and commercial. Republicans in both chambers have opposed the drug pricing bills but the Trump administration has expressed support for the Senate bill and continues to push for drug pricing controls. If drug pricing reform is not meaningfully addressed before the 2020 election, policies to be pursued in the future may be more aggressive, regardless of which party controls the White House. </span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">At the state level, legislatures have increasingly passed legislation and implemented regulations designed to control pharmaceutical and biological product pricing, including price or patient reimbursement constraints, discounts, restrictions on certain product access and marketing cost disclosure and transparency measures, and, in some cases, designed to encourage importation from other countries and bulk purchasing.</span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">27</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;text-align:justify;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;" href="#sfb86787ac8304dffbb4bfe7ffcfa7b54"><span style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">Table of Contents</span></a></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></div><div><br/></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In addition, we expect that increased emphasis on managed care and cost containment measures in the United States by third-party payors and government authorities to continue and will place pressure on pharmaceutical pricing and coverage. Coverage policies and third-party reimbursement rates may change at any time. Even if favorable coverage and reimbursement status is attained for one or more product candidates for which we receive regulatory approval, less favorable coverage policies and reimbursement rates may be implemented in the future. </span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">If we are unable to obtain and maintain sufficient third-party coverage and adequate reimbursement for our product candidates, the commercial success of our product candidates may be greatly hindered, and our financial condition and results of operations may be materially and adversely affected.</span></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Our products may not achieve market acceptance</span><span style="font-family:inherit;font-size:10pt;font-weight:bold;">. </span></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">If any of our product candidates fail to achieve sufficient market acceptance, we may not be able to generate sufficient revenue to become profitable. The degree of market acceptance of our product candidates, if and when they are approved for commercial sale, will depend on a number of factors, including but not limited to:</span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:inherit;font-size:10pt;">•</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">the timing of our receipt of marketing approvals, the terms of such approvals and the countries in which such approvals are obtained;</span></div></td></tr></table><div style="line-height:120%;text-align:justify;padding-left:48px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:inherit;font-size:10pt;">•</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">the safety, efficacy, reliability and ease of administration of our product candidates;</span></div></td></tr></table><div style="line-height:120%;text-align:left;padding-left:48px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:inherit;font-size:10pt;">•</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">the prevalence and severity of undesirable side effects and adverse events;</span></div></td></tr></table><div style="line-height:120%;text-align:left;padding-left:48px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:inherit;font-size:10pt;">•</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">the extent of the limitations or warnings required by the FDA or comparable regulatory authorities in other countries to be contained in the labeling of our product candidates;</span></div></td></tr></table><div style="line-height:120%;text-align:left;padding-left:48px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:inherit;font-size:10pt;">•</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">the clinical indications for which our product candidates are approved;</span></div></td></tr></table><div style="line-height:120%;text-align:left;padding-left:48px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:inherit;font-size:10pt;">•</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">the availability and perceived advantages of alternative therapies;</span></div></td></tr></table><div style="line-height:120%;text-align:left;padding-left:48px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:inherit;font-size:10pt;">•</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">any publicity related to our product candidates or those of our competitors;</span></div></td></tr></table><div style="line-height:120%;text-align:left;padding-left:48px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:inherit;font-size:10pt;">•</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">the quality and price of competing products;</span></div></td></tr></table><div style="line-height:120%;text-align:left;padding-left:48px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:inherit;font-size:10pt;">•</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">our ability to obtain third-party payor coverage and sufficient reimbursement;</span></div></td></tr></table><div style="line-height:120%;text-align:left;padding-left:48px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:inherit;font-size:10pt;">•</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">the willingness of patients to pay out of pocket in the absence of third-party payor coverage; and </span></div></td></tr></table><div style="line-height:120%;text-align:left;padding-left:48px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:inherit;font-size:10pt;">•</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">the selling efforts and commitment of our commercialization collaborators.</span></div></td></tr></table><div style="line-height:120%;text-align:left;padding-left:48px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">If our approved product candidates fail to receive a sufficient level of market acceptance, our ability to generate revenue from sales of our product candidates will be limited, and our business and results of operations may be materially and adversely affected. </span></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">A portion of our funding has come from federal government grants and research contracts. Due to reductions in funding, we may not be able to rely on these grants or contracts as a continuing source of funds.</span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">During the last few years, we have generated revenues from awards made to us by the National Institutes of Health and the Department of Defense to partially fund some of our programs. We cannot rely on grants or additional contracts as a continuing source of funds. Funds available under these grants and contracts must be applied by us toward the research and development programs specified by the government rather than for all our programs generally. The government’s obligation to make payments under these grants and contracts is subject to appropriation by the United States Congress for funding in each year. It is possible that Congress or the government agencies that administer these government research programs will continue to scale back these programs or terminate them due to their own budgetary constraints, as they have recently been doing. Additionally, these grants and research contracts are subject to adjustment based upon the results of periodic audits performed on behalf of the granting authority. Consequently, the government may not award grants or research contracts to us in the future, and any amounts that we derive from existing awards may be less than those received to date. In those circumstances, we would need to provide funding on our own, obtain other funding, or scale back or terminate the affected program. In particular, we cannot assure you that any </span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">28</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;text-align:justify;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;" href="#sfb86787ac8304dffbb4bfe7ffcfa7b54"><span style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">Table of Contents</span></a></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></div><div><br/></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">currently-contemplated or future efforts to obtain funding for our product candidate programs through government grants or contracts will be successful, or that any such arrangements which we do conclude will supply us with sufficient funds to complete our development programs without providing additional funding on our own or obtaining other funding. Where funding is obtained from government agencies or research bodies, our intellectual property rights in the research or technology funded by the grant are typically subject to certain licenses to such agencies or bodies, which could have an impact on our utilization of such intellectual property in the future.</span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">We face a number of risks relating to the maintenance of our information systems and our use of information relating to clinical trials.</span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In managing our operations, we rely on computer systems and electronic communications, including systems relating to record keeping, financial information, sourcing, and back-up and the Internet (“Information Systems”). Our Information Systems include the electronic storage of financial, operational, research, patient and other data. Our Information Systems may be subject to interruption or damage from a variety of causes, including power outages, computer and communications failures, system capacity constraints, catastrophic events (such as fires, tornadoes and other natural disasters), cyber risks, computer viruses and security breaches. If our Information Systems cease to function properly, are damaged or are subject to unauthorized access, we may suffer interruptions in our operations, be required to make significant investments to fix or replace systems and/or be subject to fines, penalties, lawsuits, or government action. The realization of any of these risks could have a material adverse effect on our business, financial condition and results of operations. Our clinical trials information and patient data (which may include personally identifiable information) is part of our Information Systems and is therefore subject to all of the risks set forth above, notwithstanding our efforts to code and protect such information.</span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div><a id="s40F5F90B3C305C48815138DAB459BCF0"></a></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Risks Related to Government Regulation of Our Industry</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Legislative or regulatory reform of the healthcare system may affect our ability to sell our products profitably.</span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In recent years, there have been numerous initiatives on the federal and state levels in the United States for comprehensive reforms affecting the payment for, the availability of, and reimbursement for, healthcare services. As discussed above, there have been a number of federal and state proposals during the last few years regarding the pricing of pharmaceutical and biopharmaceutical products, limiting coverage and reimbursement for drugs and other medical products, government control and other changes to the healthcare system in the United States. For example, the Patient Protection and Affordable Care Act (“ACA”) and the Health Care and Education Reconciliation Act of 2010, which amends the ACA, collectively, the United States Health Reform Laws, were signed into law in the United States in March 2010. </span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Among the provisions of the ACA of importance to the pharmaceutical industry are the following:</span></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:inherit;font-size:10pt;">•</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">the Medicaid Drug Rebate Program requires pharmaceutical manufacturers to enter into and have in effect a national rebate agreement with the Secretary of the Department of Health and Human Services as a condition of Medicare Part B and Medicaid coverage of the manufacturer's outpatient drugs furnished to Medicaid patients. Effective in 2010, the ACA made several changes to the Medicaid Drug Rebate Program, including increasing pharmaceutical manufacturers' rebate liability by raising the minimum basic Medicaid rebate on most branded prescription drugs from 15.1% of average manufacturer price, or AMP, to 23.1% of AMP, establishing new methodologies by which AMP is calculated and rebates owed by manufacturers under the Medicaid Drug Rebate Program are collected for drugs that are inhaled, infused, instilled, implanted or injected, adding a new rebate calculation for "line extensions" (i.e., new formulations, such as extended release formulations) of solid oral dosage forms of branded products, expanding the universe of Medicaid utilization subject to drug rebates to covered drugs dispensed to individuals who are enrolled in Medicaid managed care organizations, and expanding the population potentially eligible for Medicaid drug benefits;</span></div></td></tr></table><div style="line-height:120%;text-align:justify;padding-left:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:inherit;font-size:10pt;">•</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">the expansion of eligibility criteria for Medicaid programs by, among other things, allowing states to offer Medicaid coverage to additional individuals beginning in April 2010 and by adding new mandatory eligibility categories for certain individuals with income at or below 133.0% of the federal poverty level beginning in 2014, thereby potentially increasing both the volume of sales and manufacturers' Medicaid rebate liability; </span></div></td></tr></table><div style="line-height:120%;text-align:justify;padding-left:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:inherit;font-size:10pt;">•</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">in order for a pharmaceutical product to receive federal reimbursement under the Medicare Part B and Medicaid programs or to be sold directly to United States government agencies, the manufacturer must extend discounts to entities eligible to participate in the 340B drug pricing program. The required 340B discount on a given product is calculated based on the AMP and Medicaid rebate amounts reported by the manufacturer. Effective in 2010, the ACA expanded the types of entities eligible to receive discounted 340B pricing, although, under the current state of the law, with the exception of children's hospitals, these newly eligible entities will not be eligible to receive discounted 340B pricing on orphan drugs </span></div></td></tr></table><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">29</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;text-align:justify;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;" href="#sfb86787ac8304dffbb4bfe7ffcfa7b54"><span style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">Table of Contents</span></a></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></div><div><br/></div><div style="line-height:120%;padding-left:48px;text-align:justify;"><span style="font-family:inherit;font-size:10pt;">when used for the orphan indication. In addition, as 340B drug pricing is determined based on AMP and Medicaid rebate data, the revisions to the Medicaid rebate formula and AMP definition described above could cause the required 340B discount to increase. Proposed guidance from the United States Department of Health and Human Services Health Resources and Services Administration, if adopted in its current form, may affect manufacturers' rights and liabilities in conducting audits and resolving disputes under the 340B program; </span></div><div style="line-height:120%;text-align:justify;padding-left:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:inherit;font-size:10pt;">•</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">the ACA imposed a requirement on manufacturers of branded drugs to provide a 50%, which increased to 70% on January 1, 2019, discount off the negotiated price of branded drugs dispensed to Medicare Part D patients in the coverage gap (i.e., the "donut hole"); </span></div></td></tr></table><div style="line-height:120%;text-align:justify;padding-left:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:inherit;font-size:10pt;">•</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">the ACA imposed an annual, nondeductible fee on any entity that manufactures or imports certain branded prescription drugs, apportioned among these entities according to their market share in certain government healthcare programs, although this fee would not apply to sales of certain products approved exclusively for orphan indications; </span></div></td></tr></table><div style="line-height:120%;text-align:justify;padding-left:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:inherit;font-size:10pt;">•</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">the ACA implemented the Physician Payments Sunshine Act; </span></div></td></tr></table><div style="line-height:120%;text-align:left;padding-left:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:inherit;font-size:10pt;">•</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">the ACA requires annual reporting of drug samples that manufacturers and distributors provide to physicians; </span></div></td></tr></table><div style="line-height:120%;text-align:left;padding-left:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:inherit;font-size:10pt;">•</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">the ACA expanded healthcare fraud and abuse laws in the United States, including the False Claims Act and the federal Anti-Kickback Statute, new government investigative powers and enhanced penalties for non-compliance; </span></div></td></tr></table><div style="line-height:120%;text-align:justify;padding-left:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:inherit;font-size:10pt;">•</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">the ACA established a licensing framework for follow-on biologics; </span></div></td></tr></table><div style="line-height:120%;text-align:left;padding-left:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:inherit;font-size:10pt;">•</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">the ACA established the Patient-Centered Outcomes Research Institute to oversee, identify priorities in and conduct comparative clinical effectiveness research, along with the funding for such research. The research conducted by the Patient-Centered Outcomes Research Institute may affect the market for certain pharmaceutical products by influencing decisions relating to coverage and reimbursement rates; and </span></div></td></tr></table><div style="line-height:120%;text-align:justify;padding-left:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:inherit;font-size:10pt;">•</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">the ACA established the Center for Medicare & Medicaid Innovation within the Centers for Medicare & Medicaid Services ("Innovation Center"), to test innovative payment and service delivery models to lower Medicare and Medicaid spending, potentially including prescription drug spending. The Innovation Center was funded through 2019, and funding will be automatically renewed for each 10-year budget window thereafter.</span></div></td></tr></table><div style="line-height:120%;text-align:justify;padding-left:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Some of the provisions of the ACA have yet to be implemented, and there have been judicial and Congressional challenges to certain aspects of the ACA, as well as recent efforts by the Trump administration to repeal or replace certain aspects of the ACA. Since January 2017, President Trump has signed two Executive Orders and other directives designed to delay the implementation of certain provisions of the ACA or otherwise circumvent some of the requirements for health insurance mandated by the ACA. Concurrently, Congress has considered legislation that would repeal or repeal and replace all or part of the ACA. While Congress has not passed comprehensive repeal legislation, two bills affecting the implementation of certain taxes under the ACA have been signed into law. The Tax Cuts and Jobs Act of 2017 ("TCJA"), includes a provision repealing, effective January 1, 2019, the tax-based shared responsibility payment imposed by the ACA on certain individuals who fail to maintain qualifying health coverage for all or part of a year that is commonly referred to as the "individual mandate". Additionally, on January 22, 2018, President Trump signed a continuing resolution on appropriations for fiscal year 2018 that delayed the implementation of certain ACA-mandated fees, including the so-called "Cadillac" tax on certain high cost employer-sponsored insurance plans, the annual fee imposed on certain health insurance providers based on market share, and the medical device excise tax on non-exempt medical devices. Further, the Bipartisan Budget Act of 2018, or the BBA, among other things, amends the ACA, effective January 1, 2019, to close the coverage gap in most Medicare drug plans, commonly referred to as the "donut hole". In July 2018, CMS published a final rule permitting further collections and payments to and from certain ACA qualified health plans and health insurance issuers under the ACA risk adjustment program in response to the outcome of federal district court litigation regarding the method CMS uses to determine this risk adjustment. Congress may consider additional legislation to repeal or repeal and replace other elements of the ACA. On December 14, 2018, the U.S. District Court for the Northern District of Texas struck down the ACA in </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Texas v. Azar</span><span style="font-family:inherit;font-size:10pt;">, deeming it unconstitutional given that Congress repealed the individual mandate in 2017; on July 9, 2019, the U.S. Court of Appeals for the Fifth Circuit heard arguments on appeal in this matter. On December 18, 2019, the Fifth Circuit ruled that the ACA’s individual mandate is unconstitutional. In concluding that the individual mandate is unconstitutional, the question remains whether, or how much of, the rest of the ACA is severable from that constitutional defect. The Fifth Circuit further remanded the case to the U.S. District Court for the Northern District of Texas to further analyze whether the other provisions of the ACA are severable as they currently exist under the law.  It is unclear how the eventual decision from this appeal, subsequent appeals, and other efforts to repeal and replace the ACA will impact the ACA and our business.</span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">30</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;text-align:justify;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;" href="#sfb86787ac8304dffbb4bfe7ffcfa7b54"><span style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">Table of Contents</span></a></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></div><div><br/></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In addition, other legislative changes have been proposed and adopted since the ACA was enacted. For example, in August 2011, the Budget Control Act of 2011, among other things, created measures for spending reductions by Congress. A Joint Select Committee on Deficit Reduction, tasked with recommending a targeted deficit reduction of at least $1.2 trillion for the years 2013 through 2021, was unable to reach required goals, thereby triggering the legislation's automatic reduction to several government programs. This includes aggregate reductions to Medicare payments to providers of up to 2.0% per fiscal year, which went into effect in 2013, and due to subsequent legislative amendments to the statute, including the BBA, will remain in effect through 2027 unless additional Congressional action is taken. In January 2013, then-President Barack Obama signed into law the American Taxpayer Relief Act of 2012 ("ATRA"), which, among other things, delayed for another two months the budget cuts mandated by these sequestration provisions of the Budget Control Act of 2011. The ATRA also reduced Medicare payments to several providers, including hospitals, imaging centers and cancer treatment centers, and increased the statute of limitations period for the government to recover over-payments to providers from three to five years. Moreover, CMS has promulgated or amended a number of cost containment and value based reimbursement measures in the ordinary course of business, and it is expected to continue revising its regulations and policies in response to market conditions and administration directives. These new laws may result in additional reductions in Medicare and other healthcare funding, which could have a material and adverse effect on our customers and accordingly, our financial operations. </span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Further, there has been increasing legislative and enforcement interest in the United States with respect to specialty drug pricing practices. Specifically, there have been several recent United States Congressional inquiries and proposed and enacted federal and state legislation designed to, among other things, bring more transparency to drug pricing, reduce the cost of prescription drugs under Medicare, review the relationship between pricing and manufacturer patient programs, and reform government program reimbursement methodologies for drugs. </span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In addition, there have been a number of other policy, legislative, and regulatory proposals aimed at changing the pharmaceutical industry. For instance, on May 11, 2018, President Trump laid out his administration’s “Blueprint” to lower drug prices and reduce out of pocket costs of drugs, as well as additional proposals to increase drug manufacturer competition, increase the negotiating power of certain federal healthcare programs, and incentivize manufacturers to lower the list price of their products. Although some proposals related to the administration’s Blueprint may require additional authorization to become effective, may ultimately be withdrawn, or may face challenges in the courts, the U.S. Congress and the Trump administration have indicated that they will continue to seek new legislative and administrative measures to control drug costs, including by addressing the role of pharmacy benefit managers in the supply chain.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">At the state level, legislatures have increasingly passed legislation and implemented regulations designed to control pharmaceutical and biological product pricing, including price or patient reimbursement constraints, discounts, restrictions on certain product access and marketing cost disclosure and transparency measures, and, in some cases, designed to encourage importation from other countries and bulk purchasing. We are unable to predict the future course of federal or state healthcare legislation in the United States directed at broadening the availability of healthcare and containing or lowering the cost of healthcare. The ACA and any further changes in the law or regulatory framework that reduce our revenue or increase our costs could also have a material and adverse effect on our business, financial condition and results of operations.</span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">On May 30, 2018, the Trickett Wendler, Frank Mongiello, Jordan McLinn, and Matthew Bellina Right to Try Act of 2017, or Right to Try Act, was signed into law. The law, among other things, provides a federal framework for patients to access certain investigational new product candidates that have completed a Phase I clinical trial. Under certain circumstances, eligible patients can seek treatment without enrolling in clinical trials and without obtaining FDA approval under the FDA expanded access program. The Right to Try Act did not establish any new entitlement or positive right to any party or individual, nor did it create any new mandates, directives, or additional regulations requiring a manufacturer or sponsor of an eligible investigational new product candidates to provide expanded access. </span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We are unable to predict the future course of federal or state healthcare legislation in the United States directed at broadening the availability of healthcare and containing or lowering the cost of healthcare. The United States Health Reform Laws and any further changes in the law or regulatory framework that reduce our revenue or increase our costs could also have a material and adverse effect on our business, financial condition and results of operations. </span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Healthcare laws and regulations may affect the pricing of our product candidates and may affect our profitability. </span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In certain countries, the government may provide healthcare at a subsidized cost to consumers and regulate prices, patient eligibility or third-party payor reimbursement policies to control the cost of product candidates. Such a system may lead to inconsistent pricing of our product candidates from one country to another. The availability of our product candidates at lower prices in certain countries may undermine our sales in other countries where our product candidates are more expensive. In addition, certain countries may set prices by reference to the prices of our product candidates in other countries. Our inability to secure </span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">31</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;text-align:justify;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;" href="#sfb86787ac8304dffbb4bfe7ffcfa7b54"><span style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">Table of Contents</span></a></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></div><div><br/></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">adequate prices in a particular country may adversely affect our ability to obtain an acceptable price for our product candidates in existing and potential markets. If we are unable to obtain a price for our product candidates that provides an appropriate return on our investment, our profitability may be materially and adversely affected. </span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Our industry and we are subject to intense regulation from the United States Government and other governments and quasi-official authorities regulating where our products are and product candidates may be sold.</span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Both before and after regulatory approval to market a particular product candidate, including our biologic product candidates, the manufacturing, labeling, packaging, adverse event reporting, storage, advertising, promotion, distribution and record keeping related to the product are subject to extensive, ongoing regulatory requirements, including, without limitation, submissions of safety and other post-marketing information and reports, registration, as well as continued compliance with cGMP requirements and good clinical practice requirements for any clinical trials that we conduct post-approval. As a result, we are subject to a number of governmental and other regulatory risks, which include:</span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:inherit;font-size:10pt;">•</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">clinical development is a long, expensive and uncertain process; delay and failure can occur at any stage of our clinical trials;</span></div></td></tr></table><div style="line-height:120%;text-align:justify;padding-left:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:inherit;font-size:10pt;">•</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">our clinical trials are dependent on patient enrollment and regulatory approvals; we do not know whether our planned trials will begin on time, or at all, or will be completed on schedule, or at all;</span></div></td></tr></table><div style="line-height:120%;text-align:justify;padding-left:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:inherit;font-size:10pt;">•</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">the FDA or other regulatory authorities may not approve a clinical trial protocol or may place a clinical trial on hold;</span></div></td></tr></table><div style="line-height:120%;text-align:justify;padding-left:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:inherit;font-size:10pt;">•</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">we rely on third parties, such as consultants, contract research organizations, medical institutions, and clinical investigators, to conduct clinical trials for our drug candidates and if we or any of our third-party contractors fail to comply with applicable regulatory requirements, such as cGCP requirements, the clinical data generated in our clinical trials may be deemed unreliable and the FDA, EMA or comparable foreign regulatory authorities may require us to perform additional clinical trials;</span></div></td></tr></table><div style="line-height:120%;text-align:justify;padding-left:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:inherit;font-size:10pt;">•</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">if the clinical development process is completed successfully, our ability to derive revenues from the sale of therapeutics will depend on our first obtaining FDA or other comparable foreign regulatory approvals, each of which is subject to unique risks and uncertainties;</span></div></td></tr></table><div style="line-height:120%;text-align:justify;padding-left:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:inherit;font-size:10pt;">•</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">there is no assurance that we will receive FDA or corollary foreign approval for any of our product candidates for any indication; we are subject to government regulation for the commercialization of our product candidates;</span></div></td></tr></table><div style="line-height:120%;text-align:justify;padding-left:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:inherit;font-size:10pt;">•</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">we have not received regulatory approval in the United States for the commercial sale of any of our biologic product candidates;</span></div></td></tr></table><div style="line-height:120%;text-align:justify;padding-left:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:inherit;font-size:10pt;">•</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">even if one or more of our product candidates does obtain approval, regulatory authorities may approve such product candidate for fewer or more limited indications than we request, may not approve the price we intend to charge for our products, may grant approval contingent on the performance of costly post-marketing clinical trials, or may approve with a label that does not include the labeling claims necessary or desirable for the successful commercialization of that product candidate;</span></div></td></tr></table><div style="line-height:120%;text-align:justify;padding-left:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:inherit;font-size:10pt;">•</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">undesirable side effects caused by our product candidates could cause us or regulatory authorities to interrupt, delay or halt clinical trials and could result in a more restrictive label or the delay or denial of regulatory approval by the FDA or other comparable foreign authorities;</span></div></td></tr></table><div style="line-height:120%;text-align:justify;padding-left:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:inherit;font-size:10pt;">•</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">later discovery of previously unknown problems with a product, including adverse events of unanticipated severity or frequency, or with our third-party manufacturers or manufacturing processes, or failure to comply with the regulatory requirements of FDA and other applicable United States and foreign regulatory authorities could subject us to administrative or judicially imposed sanctions;</span></div></td></tr></table><div style="line-height:120%;text-align:justify;padding-left:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:inherit;font-size:10pt;">•</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">although several of our product candidates have received orphan drug designation in the United States and the European Union ("EU"), for particular indications, we may not receive orphan drug exclusivity for any or all of those product candidates or indications upon approval, and even if we do obtain orphan drug exclusivity, that exclusivity may not effectively protect the product from competition; and</span></div></td></tr></table><div style="line-height:120%;text-align:justify;padding-left:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">32</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;text-align:justify;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;" href="#sfb86787ac8304dffbb4bfe7ffcfa7b54"><span style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">Table of Contents</span></a></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></div><div><br/></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:inherit;font-size:10pt;">•</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">even if one or more of our product candidates is approved in the United States, it may not obtain the 12 years of exclusivity from biosimilars for which innovator biologics are eligible, and even if it does obtain such exclusivity, that exclusivity may not effectively protect the product from competition; the FDA’s policies may change and additional government regulations may be enacted that could prevent, limit or delay regulatory approval of our drug candidates, and if we are slow or unable to adapt to changes in existing requirements or the adoption of new requirements or policies, or if we are not able to maintain regulatory compliance, we may lose any marketing approval that we may have obtained; and we may be liable for contamination or other harm caused by hazardous materials used in the operations of our business.</span></div></td></tr></table><div style="line-height:120%;text-align:justify;padding-left:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Healthcare providers, physicians and third-party payors often play a primary role in the recommendation and prescription of any currently marketed products and product candidates for which we may obtain marketing approval. Our current and future arrangements with healthcare providers, physicians, third-party payors and customers, and our sales, marketing and educational activities, may expose us to broadly applicable fraud and abuse and other healthcare laws and regulations (at the federal and state level) that may constrain our business or financial arrangements and relationships through which we market, sell and distribute our products for which we obtain marketing approval. In addition, our operations are also subject to various federal and state fraud and abuse, physician payment transparency and privacy and security laws, including, without limitation:</span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:inherit;font-size:10pt;">•</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The federal Anti-Kickback Statute, which prohibits, among other things, persons and entities including pharmaceutical manufacturers from knowingly and willfully soliciting, receiving, offering or paying remuneration, directly or indirectly, overtly or covertly, in case or in kind, to induce or reward, or in return for, or either the referral of an individual for, or the purchase, lease, order or recommendation of, an item or service reimbursable, in whole or in part, under a federal healthcare program, such as the Medicare or Medicaid programs. This statute has interpreted broadly to apply to, among other things, arrangements between pharmaceutical manufacturers on the one hand and prescribers, purchasers and formulary managers on the other hand. The term "remuneration" expressly includes kickbacks, bribes or rebates and also has been broadly interpreted to include anything of value, including, for example, gifts, discounts, waivers of payment, ownership interest and providing anything at less than its fair market value. There are a number of statutory exceptions and regulatory safe harbors protecting certain common activities from prosecution or other regulatory sanctions, however, the exceptions and safe harbors are drawn narrowly, and practices that do not fit squarely within an exception or safe harbor may be subject to scrutiny. The failure to meet all of the requirements of a particular applicable statutory exception or regulatory safe harbor does not make the conduct per se illegal under the federal Anti-Kickback Statute. Instead, the legality of the arrangement will be evaluated on a case-by-case basis based on a cumulative review of all of its facts and circumstances. Our practices may not meet all of the criteria for safe harbor protection from federal Anti-Kickback Statute liability in all cases. A person or entity does not need to have actual knowledge of the federal Anti-Kickback Statute or specific intent to violate it to have committed a violation. In addition, the ACA codified case law supporting that a claim including items or services resulting from a violation of the federal Anti-Kickback Statute constitutes a false or fraudulent claim for purposes of the False Claims Act. </span></div></td></tr></table><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:inherit;font-size:10pt;">•</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Federal enforcement agencies and private whistleblowers recently have shown interest in pharmaceutical companies’ product and patient assistance programs (PAPs), including reimbursement support, co-pay support, nursing, adherence and educational services, referrals to other providers, donations to independent patient assistance charities, and relationships with specialty pharmacies. Co-pay assistance programs are intended to assist qualified patients with private insurance with any out-of-pocket financial obligations but must exclude any government healthcare program beneficiaries. Several investigations into patient assistance practices have resulted in significant civil and criminal settlements. Recently, the HHS-Office of the Inspector General has released several industry guidance documents, special bulletins, and advisory opinions addressing PAPs. Failure to implement certain measures and safeguards may be found by government agencies to courts to be evidence of intent to induce the purchase of drugs paid for by federal programs, in violations of the Anti-Kickback Statute. PAPs have also been the subject of recent Congressional review.</span></div></td></tr></table><div style="line-height:120%;text-align:justify;padding-left:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:inherit;font-size:10pt;">•</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The federal civil and criminal false claims laws and civil monetary penalty laws, including the False Claims Act, which prohibits individuals or entities from, among other things, knowingly presenting, or causing to be presented, claims for payment to, or approval by, the federal government that are false, fictitious or fraudulent or knowingly making, using or causing to be made or used, a false record or statement material to a false or fraudulent claim to avoid, decrease or conceal an obligation to pay money to the federal government. As a result of a modification made by the Fraud Enforcement and Recovery Act of 2009, a claim includes "any request or demand" for money or property presented to the federal government. Although we do not submit claims directly to payors, manufacturers can be held liable under these laws if they are deemed to "cause" the submission of false or fraudulent claims by, for example, providing inaccurate billing or coding information to customers, promoting a product off-label, marketing products of sub-standard quality, or, as noted above, paying a kickback that results in a claim for items or services in violation of the Anti-Kickback Statue. In addition, our activities relating to the reporting of wholesaler or estimated retail prices for our products, the reporting of prices used to calculate Medicaid rebate information and other information affecting federal, state and third-party reimbursement for our products, </span></div></td></tr></table><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">33</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;text-align:justify;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;" href="#sfb86787ac8304dffbb4bfe7ffcfa7b54"><span style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">Table of Contents</span></a></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></div><div><br/></div><div style="line-height:120%;padding-left:48px;text-align:justify;"><span style="font-family:inherit;font-size:10pt;">and the sale and marketing of our products, are subject to scrutiny under this law. For example, several pharmaceutical and other healthcare companies have faced enforcement actions under these laws for allegedly inflating drug prices they report to pricing services, which in turn were used by the government to set Medicare and Medicaid reimbursement rates, and for allegedly providing free product to customers with the expectation that the customers would bill federal programs for the product. The False Claims Act also permits a private individual acting as a "whistleblower" to bring actions on behalf of the federal government alleging violations of the False Claims Act and to share in any monetary recovery. In addition, certain marketing practices, including off-label promotion, may also implicate the False Claims Act. Although the False Claims Act is a civil statute, conduct that results in a False Claims Act violation may also implicate various federal criminal statutes. </span></div><div style="line-height:120%;text-align:justify;padding-left:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:inherit;font-size:10pt;">•</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Federal Health Insurance Portability and Accountability Act of 1996 ("HIPAA"), which imposes criminal and civil liability for knowingly and willfully executing, or attempting to execute, a scheme to defraud or to obtain, by means of false or fraudulent pretenses, representations or promises, any money or property owned by, or under the control or custody of, any healthcare benefit program, including private third-party payors and knowingly and willfully falsifying, concealing or covering up by trick, scheme or device, a material fact or making any materially false, fictitious or fraudulent statement in connection with the delivery of or payment for healthcare benefits, items or services. Similar to the federal Anti-Kickback Statute, a person or entity does not need to have actual knowledge of the statute or specific intent to violate it to have committed a violation.</span></div></td></tr></table><div style="line-height:120%;text-align:justify;padding-left:48px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:inherit;font-size:10pt;">•</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act of 2009 ("HITECH"), and their respective implementing regulations, including the Final Omnibus Rule published on January 25, 2013, impose, among other things, obligations, including mandatory contractual terms, with respect to safeguarding the privacy, security and transmission of individually identifiable health information held by certain healthcare providers, health plans and healthcare clearinghouses, known as covered entities, and business associates. Among other things, HITECH made certain aspects of HIPAA's rules (notably the Security Rule) directly applicable to business associates - independent contractors or agents of covered entities that receive or obtain individually identifiable health information in connection with providing a service on behalf of a covered entity. HITECH also created four new tiers of civil monetary penalties, amended HIPAA to make civil and criminal penalties directly applicable to business associates, and gave state attorneys general new authority to file civil actions for damages or injunctions in federal court to enforce the federal HIPAA laws and seek attorney's fees and costs associated with pursuing federal civil actions. The Department of Health and Human Services Office of Civil Rights ("OCR"), has increased its focus on compliance and continues to train state attorneys general for enforcement purposes. The OCR has recently increased both its efforts to audit HIPAA compliance and its level of enforcement, with one recent penalty exceeding $5 million. </span></div></td></tr></table><div style="line-height:120%;text-align:justify;padding-left:48px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:inherit;font-size:10pt;">•</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The federal physician payment transparency requirements, sometimes referred to as the "Physician Payments Sunshine Act," created under the United States Patient Protection and Affordable Care Act of 2010, as amended, or the ACA, and its implementing regulations, which requires applicable manufacturers of covered drugs, devices, biologics and medical supplies for which payment is available under Medicare, Medicaid or the State Children's Health Insurance Program (with certain exceptions) to annually report to the United States Department of Health and Human Services ("HHS"), information related to certain payments or other transfers of value made or distributed to physicians (defined to include doctors, dentists, optometrists, podiatrists and chiropractors) and teaching hospitals, or to entities or individuals at the request of, or designated on behalf of, the physicians and teaching hospitals, as well as ownership and investment interests held by physicians and their immediate family members. In 2022, the Sunshine Act will be extended to payments and transfers of value to physician assistants, nurse practitioners, and other mid-level practitioners (with reporting requirements going into effect in 2022 for payments made in 2021). In addition, Section 6004 of the ACA requires annual reporting of information about drug samples that manufacturers and authorized distributors provide to healthcare providers. </span></div></td></tr></table><div style="line-height:120%;text-align:justify;padding-left:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:inherit;font-size:10pt;">•</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">On October 25, 2018, President Trump signed into law the “Substance Use-Disorder Prevention that Promoted Opioid Recovery and Treatment for Patients and Communities Act.” This law, in part (under a provision entitled “Fighting the Opioid Epidemic with Sunshine”), will extend the Sunshine Act to payments and transfers of value to physician assistants, nurse practitioners, and other mid-level healthcare providers (with reporting requirements going into effect in 2022 for payments made in 2021).</span></div></td></tr></table><div style="line-height:120%;text-align:justify;padding-left:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:inherit;font-size:10pt;">•</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">According to the United States Federal Trade Commission ("FTC"), failing to take appropriate steps to keep consumers' personal information secure constitutes unfair acts or practices in or affecting commerce in violation of Section 5(a) of the Federal Trade Commission Act, or the FTCA, 15 USC § 45(a). The FTC expects a company's data security measures to be reasonable and appropriate in light of the sensitivity and volume of consumer information it holds, the size and complexity of its business, and the cost of available tools to improve security and reduce vulnerabilities. Medical data is considered sensitive data that merits stronger safeguards. The FTC's guidance for appropriately securing consumers' </span></div></td></tr></table><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">34</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;text-align:justify;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;" href="#sfb86787ac8304dffbb4bfe7ffcfa7b54"><span style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">Table of Contents</span></a></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></div><div><br/></div><div style="line-height:120%;padding-left:48px;text-align:justify;"><span style="font-family:inherit;font-size:10pt;">personal information is similar to what is required by the HIPAA Security Rule. </span></div><div style="line-height:120%;text-align:justify;padding-left:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:inherit;font-size:10pt;">•</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">To the extent we obtain coverage for our products by state Medicaid programs, we may be required to pay a rebate to each state Medicaid program for any covered outpatient drugs that are dispensed to Medicaid beneficiaries and paid for by a state Medicaid program, and to comply with all Medicaid rebate requirements of the Omnibus Budget Reconciliation Act of 1990 and the Veterans Healthcare Act of 1992. Moreover, federal law requires that any company participating in the Medicaid Drug Rebate program also participate in the Public Health Service’s 340B Program, which impose additional reporting requirements and price concessions. Manufacturer compliance with 340B Program requirements can be costly. In addition, if our products are made available to authorized users of the Federal Supply Schedule of the General Services Administration or to low income patients of certain hospitals, additional laws and requirements may apply.</span></div></td></tr></table><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:inherit;font-size:10pt;">•</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Analogous state laws and regulations, such as state anti-kickback and false claims laws, and other states laws addressing the pharmaceutical and healthcare industries, which may apply to items or services reimbursed by any third-party payor, including commercial insurers, and in some cases that may apply regardless of payor, i.e., even if reimbursement is not available; some state laws require pharmaceutical companies to comply with the pharmaceutical industry's voluntary compliance guidelines (the PhRMA Code) and the relevant compliance program guidance promulgated by the federal government (HHS-OIG) in addition to requiring drug manufacturers to report pricing and marketing information, including, among other things, information related to gifts, payments, or other remuneration to physicians and other healthcare providers , state and local laws that require the registration of pharmaceutical sales representatives, and state laws governing the privacy and security of health information and the use of prescriber-identifiable data in certain circumstances, many of which differ from each other in significant ways and may not have the same effect, thus complicating compliance efforts. For example, California enacted legislation - the California Consumer Privacy Act (“CCPA”) - which goes into effect January 1, 2020. The CCPA, among other things, creates new data privacy obligations for covered companies and provides new privacy rights to California residents, including the right to opt out of certain disclosures of their information. The CCPA also creates a private right of action with statutory damages for certain data breaches, thereby potentially increasing risks associated with a data breach. The California Attorney General will issue clarifying regulations. Although the law includes limited exceptions, including for certain information collected as part of clinical trials as specified in the law and for protected health information collected by covered entities or business associates subject to HIPAA as specified in the law, it may regulate or impact our processing of personal information depending on the context. It remains unclear what language the final Attorney General regulations will contain or how the statue and regulations will be interpreted. </span></div></td></tr></table><div style="line-height:120%;text-align:justify;padding-left:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Because of the breadth of these laws and the narrowness of the statutory exceptions and safe harbors available under such laws, it is possible that certain business activities could be subject to challenge under one or more of such laws. The scope and enforcement of each of these laws is uncertain and subject to rapid change in the current environment of healthcare reform, especially in light of the lack of applicable precedent and regulations. Federal and state enforcement bodies have recently increased their scrutiny of interactions between healthcare companies and healthcare providers, which has led to a number of investigations, prosecutions, convictions and settlements in the healthcare industry. Ensuring that business arrangements with third parties comply with applicable healthcare laws, as well as responding to possible investigations by government authorities, can be time- and resource-consuming and can divert management's attention from the business. </span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">If our operations are found to be in violation of any of the health regulatory laws described above or any other laws that apply to us, we may be subject to penalties, including, but not limited to, criminal, civil and administrative penalties, damages, fines, disgorgement, individual imprisonment, possible exclusion from participation in government healthcare programs, injunctions, private qui tam actions brought by individual whistleblowers in the name of the government and the curtailment or restructuring of our operations, as well as additional reporting obligations and oversight if we become subject to a corporate integrity agreement or other agreement to resolve allegations of non-compliance with these laws, any of which could adversely affect our ability to operate our business and our results of operations. Any action against us for violation of these laws, even if we successfully defend against it, could cause us to incur significant legal expenses, divert our management’s attention from the operation of our business, and damage our reputation.</span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Many aspects of these laws have not been definitively interpreted by the regulatory authorities or the courts, and their provisions are open to a variety of subjective interpretations that increases the risk of potential violations. In addition, these laws and their interpretations are subject to change. In addition, from time to time in the future, we may become subject to additional laws or regulations administered by the FDA, the FTC, HHS, or by other federal, state, local, or foreign regulatory authorities, or the repeal of laws or regulations that we generally consider favorable, or to more stringent interpretations of current laws or regulations. We are not able to predict the nature of such future laws, regulations, repeals, or interpretations, and we cannot predict what effect additional governmental regulation, if and when it occurs, would have on our business in the future. </span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">35</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;text-align:justify;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;" href="#sfb86787ac8304dffbb4bfe7ffcfa7b54"><span style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">Table of Contents</span></a></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></div><div><br/></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Our failure to comply with foreign data protection laws and regulations could lead to government enforcement actions and significant penalties against us, and adversely impact our operating results.</span></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">EU member states and other foreign jurisdictions, including Switzerland, have adopted data protection laws and regulations which impose significant compliance obligations. Moreover, the collection and use of personal health data in the EU, which was formerly governed by the provisions of the European Union Data Protection Directive, was replaced with the European Union General Data Protection Regulation ("GDPR"), in May 2018. The GDPR, which is wide-ranging in scope, imposes several requirements relating to the consent of the individuals to whom the personal data relates, the information provided to the individuals, the security and confidentiality of the personal data, data breach notification and the use of third party processors in connection with the processing of personal data. The GDPR also imposes strict rules on the transfer of personal data out of the EU to the United States, provides an enforcement authority and imposes large penalties for noncompliance, including the potential for fines of up to €20 million or 4% of the annual global revenues of the non-compliant company, whichever is greater. The recent implementation of the GDPR has increased our responsibility and liability in relation to personal data that we process, including in clinical trials, and we may in the future be required to put in place additional mechanisms to ensure compliance with the GDPR, which could divert management's attention and increase our cost of doing business. In addition, new regulation or legislative actions regarding data privacy and security (together with applicable industry standards) may increase our costs of doing business. In this regard, we expect that there will continue to be new proposed laws, regulations and industry standards relating to privacy and data protection in the United States, the EU and other jurisdictions, and we cannot determine the impact such future laws, regulations and standards may have on our business.</span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Our employees and our independent contractors, principal investigators, consultants or commercial collaborators, as well as their respective sub-contractors, if any, may engage in misconduct or fail to comply with certain regulatory standards and requirements, which could expose us to liability and adversely affect our reputation.</span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Our employees and our independent contractors, principal investigators, consultants or commercial collaborators, as well as their respective sub-contractors, if any, may engage in fraudulent conduct or other illegal activity, which may include intentional, reckless or negligent conduct that violates, among others, (a) FDA laws and regulations, or those of comparable regulatory authorities in other countries, including those laws that require the reporting of true, complete and accurate information to the FDA, (b) manufacturing standards, (c) healthcare fraud and abuse laws (d) anti-bribery and anti-corruption laws, including the FCPA, or (e) laws that require the true, complete and accurate reporting of financial information or data. For example, such persons may improperly use or misrepresent information obtained in the course of our clinical trials, create fraudulent data in our preclinical studies or clinical trials or misappropriate our drug products, which could result in regulatory sanctions being imposed on us and cause serious harm to our reputation. It is not always possible for us to identify or deter misconduct by our employees and third parties, and any precautions we may take to detect or prevent such misconduct may not be effective. Any misconduct or failure by our employees and our independent contractors, principal investigators, consultants or commercial collaborators, as well as their respective sub-contractors, if any, to comply with the applicable laws or regulations may expose us to governmental investigations, other regulatory action or lawsuits. If any action is instituted against us as a result of the alleged misconduct of our employees or other third parties, regardless of the final outcome, our reputation may be adversely affected, and our business may suffer as a result. If we are unsuccessful in defending against any such action, we may also be liable to significant fines or other sanctions, which could have a material and adverse effect on us.</span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Inadequate funding for the FDA, the SEC and other government agencies could hinder their ability to hire and retain key leadership and other personnel, prevent new products and services from being developed or commercialized in a timely manner or otherwise prevent those agencies from performing normal business functions on which the operation of our business may rely, which could negatively impact our business.</span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The ability of the FDA to review and approve new products can be affected by a variety of factors, including government budget and funding levels, ability to hire and retain key personnel and accept the payment of user fees, and statutory, regulatory, and policy changes. Average review times at the FDA have fluctuated in recent years as a result. In addition, government funding of the SEC and other government agencies on which our operations may rely, including those that fund research and development activities is subject to the political process, which is inherently fluid and unpredictable.</span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Disruptions at the FDA and other agencies may also slow the time necessary for new drugs to be reviewed and/or approved by necessary government agencies, which would adversely affect our business. For example, over the last several years, including from December 22, 2018 until January 25, 2019, the U.S. government has shut down several times and certain regulatory agencies, such as the FDA and the SEC, have had to furlough critical FDA, SEC and other government employees and stop critical activities. If a prolonged government shutdown occurs, it could significantly impact the ability of the FDA to timely review and process our regulatory submissions, which could have a material adverse effect on our business. Further, in our operations as a public company, </span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">36</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;text-align:justify;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;" href="#sfb86787ac8304dffbb4bfe7ffcfa7b54"><span style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">Table of Contents</span></a></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></div><div><br/></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">future government shutdowns could impact our ability to access the public markets and obtain necessary capital in order to properly capitalize and continue our operations.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div><a id="sA7CF5E89099653FF889981FE8E8CA6E2"></a></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Risks Related to Our Securities</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Our indebtedness and debt service obligations may adversely affect our cash flow.</span></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We intend to fulfill our current debt service obligations, including repayment of the principal from our existing cash and investments, as well as the proceeds from potential licensing agreements and any additional financing from equity or debt transactions. However, our ability to make scheduled payments of the principal of, to pay interest on, or to refinance, our indebtedness, depends on our future performance, which is subject to economic, financial, competitive and other factors beyond our control. Our business may not generate cash flow from operations in the future sufficient to service our debt and make necessary capital expenditures. If we are unable to generate such cash flow to meet these obligations, we may be required to adopt one or more alternatives, such as selling assets, restructuring debt or obtaining additional equity capital on terms that may be onerous or highly dilutive, or delaying or curtailing research and development programs. Our ability to refinance our indebtedness will depend on the capital markets and our financial condition at such time. We may not be able to engage in any of these activities or engage in these activities on desirable terms, which could result in a default on our debt obligations.</span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">We may add lease lines to finance capital expenditures and may obtain additional long‑term debt and lines of credit. If we issue other debt securities in the future, our debt service obligations will increase further.</span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Our indebtedness could have significant additional negative consequences, including, but not limited to:</span></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:inherit;font-size:10pt;">•</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">requiring the dedication of a substantial portion of our existing cash and marketable securities balances and, if available, future cash flow from operations to service our indebtedness, thereby reducing the amount of our expected cash flow available for other purposes, including capital expenditures;</span></div></td></tr></table><div style="line-height:120%;text-align:left;padding-left:48px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:inherit;font-size:10pt;">•</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">increasing our vulnerability to general adverse economic and industry conditions;</span></div></td></tr></table><div style="line-height:120%;text-align:left;padding-left:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:inherit;font-size:10pt;">•</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">limiting our ability to obtain additional financing;</span></div></td></tr></table><div style="line-height:120%;text-align:left;padding-left:48px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:inherit;font-size:10pt;">•</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">limiting our ability to sell assets if deemed necessary;</span></div></td></tr></table><div style="line-height:120%;text-align:left;padding-left:48px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:inherit;font-size:10pt;">•</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">limiting our flexibility in planning for, or reacting to, changes in our business and the industry in which we compete; and</span></div></td></tr></table><div style="line-height:120%;text-align:left;padding-left:48px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:inherit;font-size:10pt;">•</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">placing us at a possible competitive disadvantage to less leveraged competitors and competitors that have better access to capital resources.</span></div></td></tr></table><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Shares eligible for future sale may adversely affect our ability to sell equity securities.</span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Sales of our common stock (including the issuance of shares upon conversion of convertible debt) in the public market could materially and adversely affect the market price of shares. </span><span style="font-family:inherit;font-size:10pt;">As of December 31, 2019</span><span style="font-family:inherit;font-size:10pt;"> we had 212,529,313 shares of common stock issued, plus (1) outstanding options to purchase 5,900,099 shares of common stock with a weighted-average exercise price of $16.54 per share, (2) 58,002 outstanding restricted stock units held by certain directors of the Company, (3) 836,769 outstanding performance stock options held by certain executive officers and employees of the Company, (4) 4,588,632 shares of common stock reserved for potential future grant under the Plan, and (5) $7.1 million of principal amount of Convertible Senior Notes convertible into approximately 1,393,160 shares of common stock at the conversion rate of $5.11 subject to adjustment as described in the indenture. Of the 250,000,000 shares of common stock authorized under our Certificate of Incorporation, there are 24,694,025 shares of common stock that remain available for future issuance.</span></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">    </span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Our outstanding options may adversely affect our ability to consummate future equity‑based financings due to the dilution potential to future investors.</span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Due to the number of shares of common stock we are obligated to issue pursuant to outstanding options, potential investors may not purchase our future equity offerings at market price because of the potential dilution such investors may suffer as a result of the exercise of the outstanding options.</span></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">The market price of our common stock has fluctuated widely in the past and is likely to continue to fluctuate widely based on a number of factors, many of which are beyond our control.</span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">37</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;text-align:justify;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;" href="#sfb86787ac8304dffbb4bfe7ffcfa7b54"><span style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">Table of Contents</span></a></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></div><div><br/></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The market price of our common stock has been, and is likely to continue to be, highly volatile. Furthermore, the stock market and the market for stocks of comparable biopharmaceutical companies like ours have from time to time experienced, and likely will again experience, significant price and volume fluctuations that are unrelated to actual operating performance.</span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">From time to time, stock market analysts publish research reports or otherwise comment upon our business and future prospects. Due to a number of factors, we may fail to meet the expectations of securities analysts or investors and our stock price would likely decline as a result. These factors include:</span></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:inherit;font-size:10pt;">•</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Announcements by us, any collaboration partners, any future alliance partners or our competitors of pre-clinical studies and clinical trial results, regulatory developments, technological innovations or new therapeutic products, product sales, new products or product candidates and product development timelines;</span></div></td></tr></table><div style="line-height:120%;text-align:justify;padding-left:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:inherit;font-size:10pt;">•</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The formation or termination of corporate alliances;</span></div></td></tr></table><div style="line-height:120%;text-align:justify;padding-left:48px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:inherit;font-size:10pt;">•</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Developments in patent or other proprietary rights by us or our respective competitors, including litigation;</span></div></td></tr></table><div style="line-height:120%;text-align:justify;padding-left:48px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:inherit;font-size:10pt;">•</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Developments or disputes concerning our patent or other proprietary rights, and the issuance of patents in our field of business to others;</span></div></td></tr></table><div style="line-height:120%;text-align:justify;padding-left:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:inherit;font-size:10pt;">•</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Government regulatory action;</span></div></td></tr></table><div style="line-height:120%;text-align:justify;padding-left:48px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:inherit;font-size:10pt;">•</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Period-to-period fluctuations in the results of our operations; and</span></div></td></tr></table><div style="line-height:120%;text-align:justify;padding-left:48px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:inherit;font-size:10pt;">•</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Developments and market conditions for emerging growth companies and biopharmaceutical companies, in general.</span></div></td></tr></table><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In addition, Internet “chat rooms” have provided forums where investors make predictions about our business and prospects, oftentimes without any real basis in fact, that readers may trade on.</span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In the past, following periods of volatility in the market prices of the securities of companies in our industry, securities class action litigation has often been instituted against those companies. Refer to “Legal Proceedings” for more information. If we face such litigation in the future, it would result in substantial costs and a diversion of management’s attention and resources, which could negatively impact our business.</span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">    </span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Our principal stockholders can significantly influence all matters requiring the approval by our stockholders.</span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">As of December 31, 2019</span><span style="font-family:inherit;font-size:10pt;">, Avoro Capital Advisors LLC, (“Avoro”) is the beneficial owner of approximately 11.5% of our outstanding common stock. Avoro is our largest stockholder, and Dr. Behzad Aghazadeh, the portfolio manager and controlling person of Avoro, serves as Executive Chairman of our Board of Directors.</span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">    </span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">As a result of this voting power, Avoro has the ability to significantly influence the outcome of substantially all matters that may be put to a vote of our stockholders, including the election of our directors.</span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">There are limitations on the liability of our directors, and we may have to indemnify our officers and directors in certain instances.</span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Our certificate of incorporation limits, to the maximum extent permitted under Delaware law, the personal liability of our directors for monetary damages for breach of their fiduciary duties as directors. Our bylaws provide that we will indemnify our officers and directors and may indemnify our employees and other agents to the fullest extent permitted by law. These provisions may be in some respects broader than the specific indemnification provisions under Delaware law. The indemnification provisions may require us, among other things, to indemnify such officers and directors against certain liabilities that may arise by reason of their status or service as directors or officers (other than liabilities arising from willful misconduct of a culpable nature), to advance their expenses incurred as a result of certain proceedings against them as to which they could be indemnified and to obtain directors’ and officers’ insurance. Section 145 of the Delaware General Corporation Law provides that a corporation may indemnify a director, officer, employee or agent made or threatened to be made a party to an action by reason of the fact that he or she was a director, officer, employee or agent of the corporation or was serving at the request of the corporation, against expenses actually and reasonably incurred in connection with such action if he or she acted in good faith and in a manner he or she reasonably believed to be in, or not opposed to, the best interests of the corporation, and, with respect to any criminal action or proceeding, had no reasonable cause to believe his or her conduct was unlawful. Delaware law does not permit a corporation to eliminate a </span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">38</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;text-align:justify;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;" href="#sfb86787ac8304dffbb4bfe7ffcfa7b54"><span style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">Table of Contents</span></a></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></div><div><br/></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">director’s duty of care and the provisions of our certificate of incorporation have no effect on the availability of equitable remedies, such as injunction or rescission, for a director’s breach of the duty of care.</span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We believe that our limitation of officer and director liability assists us to attract and retain qualified employees and directors. However, in the event an officer, a director or the board of directors commits an act that may legally be indemnified under Delaware law, we will be responsible to pay for such officer(s) or director(s) legal defense and potentially any damages resulting there from. Furthermore, the limitation on director liability may reduce the likelihood of derivative litigation against directors and may discourage or deter stockholders from instituting litigation against directors for breach of their fiduciary duties, even though such an action, if successful, might benefit our stockholders and us. Given the difficult environment and potential for incurring liabilities currently facing directors of publicly-held corporations, we believe that director indemnification is in our and our stockholders’ best interests because it enhances our ability to attract and retain highly qualified directors and reduce a possible deterrent to entrepreneurial decision-making.</span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Nevertheless, limitations of director liability may be viewed as limiting the rights of stockholders, and the broad scope of the indemnification provisions contained in our certificate of incorporation and bylaws could result in increased expenses. Our board of directors believes, however, that these provisions will provide a better balancing of the legal obligations of, and protections for, directors and will contribute positively to the quality and stability of our corporate governance. Our board of directors has concluded that the benefit to stockholders of improved corporate governance outweighs any possible adverse effects on stockholders of reducing the exposure of directors to liability and broadened indemnification rights.</span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">We are exposed to potential risks from legislation requiring companies to evaluate controls under Section 404 of the Sarbanes-Oxley Act.</span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Sarbanes-Oxley Act requires that we maintain effective internal controls over financial reporting and disclosure controls and procedures. Among other things, we must perform system and process evaluation and testing of our internal controls over financial reporting to allow management to report on, and our independent registered public accounting firm to attest to, our internal controls over financial reporting, as required by Section 404 of the Sarbanes-Oxley Act (“Section 404”). Compliance with Section 404 requires substantial accounting expense and significant management efforts. Our testing, or the subsequent review by our independent registered public accounting firm, may reveal deficiencies in our internal controls that would require us to remediate in a timely manner so as to be able to comply with the requirements of Section 404 each year. If we are not able to comply with the requirements of Section 404 in a timely manner each year, we could be subject to sanctions or investigations by the SEC, the Nasdaq Stock Market or other regulatory authorities that would require additional financial and management resources and could adversely affect the market price of our common stock.</span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">    </span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">We do not intend to pay dividends on our common stock. Until such time as we pay cash dividends, our stockholders, must rely on increases in our stock price for appreciation.</span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We have never declared or paid dividends on our common stock. We intend to retain future earnings to develop and commercialize our product candidates and therefore we do not intend to pay cash dividends in the foreseeable future. Until such time as we determine to pay cash dividends on our common stock, our stockholders must rely on increases in the market price of our common stock for appreciation of their investment.</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div><a id="s01F8EB8D9CC252B4903CA9F8B3F04FAA"></a></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Item 1B. </span><span style="font-family:inherit;font-size:10pt;"> </span><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Unresolved Staff Comments</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">None.</span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">39</span></div></div><hr style="page-break-after:always"></hr><div><a id="sEA7ACF572884574782926CE339C93C98"></a></div><div><div style="line-height:120%;text-align:justify;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;" href="#sfb86787ac8304dffbb4bfe7ffcfa7b54"><span style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">Table of Contents</span></a></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></div><div><br/></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Item 2. </span><span style="font-family:inherit;font-size:10pt;"> </span><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Properties</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Our corporate headquarters is located in Morris Plains, New Jersey. Summarized below are the locations, primary usage and approximate square footage of the facilities we lease. Under these lease agreements, we may be required to reimburse the lessors for real estate taxes, insurance, utilities, maintenance and other operating costs. All leases are with unaffiliated parties.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="5"></td></tr><tr><td style="width:34%;"></td><td style="width:1%;"></td><td style="width:40%;"></td><td style="width:1%;"></td><td style="width:24%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Location</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Primary Usage</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Approximate Square Feet</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">300 The American Road, Morris Plains, New Jersey</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Office space, research, manufacturing and clinical trial management</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">85,000</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">400 The American Road, Morris Plains, New Jersey</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Office space, warehouse, research and clinical trial management</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">45,700</span></div></td></tr></table></div></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div><a id="s48E5F676E90A5389AE648AD1F7125177"></a></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Item 3. </span><span style="font-family:inherit;font-size:10pt;"> </span><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Legal Proceedings</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"></span><span style="font-family:inherit;font-size:10pt;">The following is a summary of legal matters that are outstanding.</span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">    </span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Stockholder Complaints:</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Class Action Stockholder Federal Securities Cases</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"></span><span style="font-family:inherit;font-size:10pt;color:#000000;">Two purported class action cases were filed in the United States District Court for the District of New Jersey; namely, Fergus v. Immunomedics, Inc., et al., filed June 9, 2016; and Becker v. Immunomedics, Inc., et al., filed June 10, 2016. These cases arise from the same alleged facts and circumstances and seek class certification on behalf of purchasers of our common stock between April 20, 2016 and June 2, 2016 (with respect to the Fergus matter) and between April 20, 2016 and June 3, 2016 (with respect to the Becker matter). These cases concern the Company’s statements in press releases, investor conference calls, and filings with the U.S. Securities and Exchange Commission (the "SEC") beginning in April 2016 that the Company would present updated information regarding its IMMU-132 breast cancer drug at the 2016 American Society of Clinical Oncology (“ASCO”) conference in Chicago, Illinois. The complaints allege that these statements were false and misleading in light of June 2, 2016 reports that ASCO had canceled the presentation because it contained previously reported information. The complaints further allege that these statements resulted in artificially inflated prices for our common stock, and that the Company and certain of its officers are thus liable under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934, as amended (the "Exchange Act"). An order of voluntary dismissal without prejudice was entered on November 10, 2016 in the Becker matter. An order granting motion to consolidate cases, appoint lead plaintiff, and approve lead and liaison counsel was entered on February 7, 2017 in the Fergus matter. A consolidated complaint was filed on October 4, 2017. The Company filed a motion to dismiss the consolidated complaint on January 26, 2018. On March 31, 2019, the court granted the Company's motion to dismiss, without prejudice, and left plaintiffs with the ability to file an amended complaint within thirty (30) days. Counsel for the Company has consented to an extension of time for plaintiffs to file the proposed amended complaint for an additional thirty (30) days. On May 30, 2019, plaintiffs filed an amended complaint alleging many of the same allegations that were set forth in the previously filed complaints, and the Company has filed a motion to dismiss.</span><span style="font-family:inherit;font-size:10pt;"> </span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"></span><span style="font-family:inherit;font-size:10pt;color:#000000;">A third purported class action case was filed in the United States District Court for the District of New Jersey; namely, Odeh v. Immunomedics, Inc., et al., filed December 27, 2018. The complaint in this action alleges that the Company failed to disclose the results of observations made by the FDA during an inspection of the Company’s manufacturing facility in Morris Plains, New Jersey in August 2018. The complaint alleges that Immunomedics misled investors by failing to disclose the Form 483 inspection report issued by the FDA which set forth the observations of the FDA inspector during the inspection. Such observations purportedly included, inter alia, manipulated bioburden samples, misrepresentation of an integrity test procedure in the batch record, and backdating of batch records. The complaint further alleges that the Company’s failure to disclose the Form 483 resulted in an artificially inflated price for our common stock, and that the Company and certain of its officers are thus liable under Sections 10(b) and 20(a) of the Exchange Act. </span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"></span><span style="font-family:inherit;font-size:10pt;">On February 8, 2019, a purported class action case was filed in the United States District Court for the District of New Jersey; namely, Choi v. Immunomedics, Inc., et al. The complaint asserts violations of the federal securities laws based on claims that the Company violated the federal securities laws by making alleged misstatements in various press releases and securities filings from February 8, 2018 to November 7, 2018 and by failing to disclose the substance of its interactions with the FDA in connection with the Company's submission of its BLA for sacituzumab govitecan.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"></span><span style="font-family:inherit;font-size:10pt;">Motions for the appointment of a lead plaintiff and lead counsel and to consolidate the Odeh and Choi actions were granted on September 10, 2019. Pursuant to a scheduling order entered by the court on October 7, 2019, the plaintiffs filed an </span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">40</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;text-align:justify;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;" href="#sfb86787ac8304dffbb4bfe7ffcfa7b54"><span style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">Table of Contents</span></a></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></div><div><br/></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">amended complaint on November 18, 2019. The Company filed a motion to dismiss the consolidated, amended complaint on January 17, 2020. The motion has a return date of April 20, 2020. </span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"></span><span style="font-family:inherit;font-size:10pt;">On April 8, 2019, a putative stockholder of the Company filed a derivative action purportedly on behalf of the Company and against the Company’s board of directors and certain Company current and former officers, in the Superior Court of New Jersey, Law Division (Morris County); namely, Crow v. Aghazadeh, et al. The Crow complaint alleges that the individual defendants breached their fiduciary duties and committed other violations of law based on the same core allegations in the Odeh and Choi actions. The Crow complaint was served on the Company and other defendants on July 18, 2019. On August 13, 2019, the parties submitted to the court a stipulation and proposed order to stay the action until either the entry of an order denying all motions to dismiss the now-consolidated federal actions or the entry of an order dismissing the federal actions with prejudice. That stipulation is currently pending court approval.</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Stockholder Claim in the Court of Chancery of the State of Delaware</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"></span><span style="font-family:inherit;font-size:10pt;color:#000000;">On February 13, 2017, venBio commenced an action captioned venBio Select Advisor LLC v. Goldenberg, et al., C.A. (Del. Ch.) (the “venBio Action”), alleging that Company’s Board breached their fiduciary duties when the Board (i) amended the Company’s Amended and Restated By-laws (the “By-Laws”) to call for a plurality voting regime for the election of directors instead of majority voting, and providing for mandatory advancement of attorneys’ fees and costs for the Company’s directors and officers, (ii) rescheduled the Company’s 2016 Annual Meeting of Stockholders (the “2016 Annual Meeting”) from December 14, 2016 to February 16, 2017, and then again to March 3, 2017, and (iii) agreed to the proposed Licensing Transaction with Seattle Genetics. venBio also named Seattle Genetics as a defendant and sought an injunction preventing the Company from closing the licensing transaction with Seattle Genetics. On March 6, 2017, venBio amended its complaint, adding further allegations. The Court of Chancery entered a temporary restraining order on March 9, 2017, enjoining the closing of the Licensing Transaction. venBio amended its complaint a second time on April 19, 2017, this time adding Greenhill & Co. Inc. and Greenhill & Co. LLC (together “Greenhill”), the Company’s financial advisor on the Licensing Transaction, as an additional defendant. On May 3, 2017, venBio and the Company and individual defendants Dr. Goldenberg, Ms. Sullivan and Mr. Brian A. Markison, a director of the Company (collectively, the “Individual Defendants”) entered into the Initial Term Sheet. On June 8, 2017, venBio the Company and Greenhill entered into the Greenhill Term Sheet. On February 9, 2018, the Court of Chancery approved the Settlement, and entered an order and partial judgment releasing all claims that were asserted by venBio against the Individual Defendants and Greenhill in the venBio Action and awarding venBio fees and expenses. On May 24, 2018 the remaining parties to the venBio Action participated in a mediation of the claims against Geoff Cox, Robert Forrester, Bob Oliver, and Jason Aryeh (the "Remaining Defendants"). The mediation was unsuccessful. The Remaining Defendants filed submitted motions to dismiss the claims against them in the venBio Action. On March 18, 2019, venBio amended its complaint, adding further allegations. The Remaining Defendants filed a motion to dismiss the claims against them on May 1, 2019. The Court of Chancery held oral arguments for the motion to dismiss on November 13, 2019 and following arguments, denied Defendants' motion to dismiss on that same date. The parties are now engaged in discovery activities.</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Insurance Coverage Arbitration:</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"></span><span style="font-family:inherit;font-size:10pt;">The Company has initiated an arbitration with two of its management liability insurers: Starr Indemnity & Liability Company (“Starr”), and Liberty Insurance Underwriters Inc. (“Liberty”) (collectively, “Insurers”).  The arbitration arises from the 2015 Insurers’ refusal to cover</span><span style="font-family:inherit;font-size:10pt;"> $3.4 million </span><span style="font-family:inherit;font-size:10pt;">in attorneys’ fees and expenses paid to venBio pursuant to a December 1, 2017, settlement agreement between venBio, the Company, Dr. Goldenberg, Ms. Sullivan, Mr. Markison, and Greenhill to partially settle the venBio Action and fully settle the Federal Action and the Delaware Section 225 Action (the “venBio Fee Award”).  </span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"></span><span style="font-family:inherit;font-size:10pt;">The Insurers argue that the venBio Fee Award does not satisfy their policies’ definitions of covered “loss” because the policies only cover defense costs incurred by the Company.  The Company counters that the venBio Fee Award is a covered settlement, not a claim for defense costs.  Insurers also argue that they have no obligation to pay any defense costs or settlement incurred in the Federal Action or 225 Action because Immunomedics initiated those lawsuits.  The Company’s position is that the Federal Action and 225 Action were defensive in nature and therefore covered because they were initiated to further the defense of the venBio Action.  Additionally, Insurers argue the venBio Fee Award is not covered because the Company was required to obtain Insurers’ consent to enter into a binding term sheet in the venBio Action and to agree to pay the venBio Fee Award and that the Company failed to do so.  The Company takes the position that Insurers at all times were aware of the developments in the venBio Action, that they sought consent to enter into the settlement, and that Insurers cannot show they were prejudiced by an any alleged failure to obtain Insurers’ consent. </span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"></span><span style="font-family:inherit;font-size:10pt;">The Insurers argue that the venBio Fee Award does not satisfy their policies’ definitions of covered “loss” because the policies only cover defense costs incurred by the Company.  The Company counters that the venBio Fee Award is a covered settlement, not a claim for defense costs.  Insurers also argue that they have no obligation to pay any defense costs or settlement </span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">41</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;text-align:justify;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;" href="#sfb86787ac8304dffbb4bfe7ffcfa7b54"><span style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">Table of Contents</span></a></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></div><div><br/></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">incurred in the Federal Action or 225 Action because Immunomedics initiated those lawsuits.  The Company’s position is that the Federal Action and 225 Action were defensive in nature and therefore covered because they were initiated to further the defense of the venBio Action.  Additionally, Insurers argue the venBio Fee Award is not covered because the Company was required to obtain Insurers’ consent to enter into a binding term sheet in the venBio Action and to agree to pay the venBio Fee Award and that the Company failed to do so.  The Company takes the position that Insurers at all times were aware of the developments in the venBio Action, that they sought consent to enter into the settlement, and that Insurers cannot show they were prejudiced by an any alleged failure to obtain Insurers’ consent. </span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"></span><span style="font-family:inherit;font-size:10pt;">In the event Insurers prevail on their argument that the venBio Fee Award is covered by a subsequent policy year, the Company will pursue coverage under its other insurance policies.</span><span style="font-family:inherit;font-size:10pt;">    </span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">    </span><span>Starr is presently advancing the costs to defend the remaining claims in the venBio Action, </span><span style="font-style:italic;">i.e., </span><span>those against the Company as Nominal Defendant and individual defendants Aryeh, Cox, Forrester, and Oliver.  However, all Insurers have reserved their rights to contest coverage for any potential settlement of those claims.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Arbitration of Disputed Matters:</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">On January 15, 2019, the Company received an Arbitrator’s Findings of Fact and Conclusions of Law and Final Award (the “Final Award”) in the arbitration matter in which Dr. David M. Goldenberg, the Company’s former Chief Scientific Officer, Chief Patent Officer and Chairman of the Company’s Board of Directors, claimed entitlement to certain equity awards and severance payments, and Dr. Goldenberg and Ms. Cynthia Sullivan, a former director of the Company and former President and Chief Executive Officer, claimed rights to certain bonus payments. The Final Award (i) denied Dr. Goldenberg’s claim that he was entitled to an award of 1.5 million restricted stock units, (ii) denied each of Dr. Goldenberg’s and Ms. Sullivan’s claims that they were entitled to certain discretionary cash bonuses relating to the Company’s 2017 fiscal year, and (iii) granted Dr. Goldenberg an award of approximately $1 million relating to certain claimed severance payments which was paid in March 2019. The arbitration took place pursuant to the Delaware Rapid Arbitration Act.  Although the Delaware Rapid Arbitration Act permits challenges to arbitration awards in limited circumstances, pursuant to that certain stipulation and agreement of settlement, compromise, and release dated November 2, 2017, the Company, Dr. Goldenberg and Ms. Sullivan agreed that the Final Award would be the sole and exclusive final and binding remedy between and among the parties with respect to the matters disputed in the arbitration. </span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Other Matters:</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"></span><span style="font-family:inherit;font-size:10pt;color:#000000;">Immunomedics is also a party to various claims and litigation arising in the normal course of business.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div><a id="s663FD1E8F42E502B91733C65710BE25C"></a></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Item 4. </span><span style="font-family:inherit;font-size:10pt;"> </span><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Mine Safety Disclosures</span><span style="font-family:inherit;font-size:10pt;"> </span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Not applicable.</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">42</span></div></div><hr style="page-break-after:always"></hr><div><a id="sB843E213E54B503897780A7C1EA24AFF"></a></div><div><div style="line-height:120%;text-align:justify;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;" href="#sfb86787ac8304dffbb4bfe7ffcfa7b54"><span style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">Table of Contents</span></a></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></div><div><br/></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">PART II</span></div><div><a id="sE6707278AA655630A22C90B3D2EF9291"></a></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Item 5. </span><span style="font-family:inherit;font-size:10pt;"> </span><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Market For Registrant’s Common Equity, Related Stockholder Matters</span><span style="font-family:inherit;font-size:10pt;font-style:italic;"> </span><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">and Issuer Purchases of Equity Securities</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Market Price and Dividend Information</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Our common stock is quoted on the Nasdaq Global Market under the symbol “IMMU.” As of February 21, 2020, the closing sales price of our common stock on the Nasdaq Global Market was $18.03 and there were approximately 328 stockholders of record of our common stock. We have not paid dividends on our common stock since inception and do not plan to pay cash dividends in the foreseeable future. </span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Stock Performance Graph</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">This graph is not “soliciting material,” and is not deemed filed with the SEC and not to be incorporated by reference in any filing by our Company under the Securities Act of 1933, as amended, or the Exchange Act, whether made before or after the date hereof and irrespective of any general incorporation language in any such filing. The total return values data is prepared by the Nasdaq OMX Global Index Group. Total Return Indexes are posted on Nasdaq Online on a monthly basis.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following graph compares the yearly change in cumulative total stockholder return on the Company’s common stock for the prior five years with the total cumulative return of the Nasdaq Composite Index and the Nasdaq Pharmaceutical Index.  The returns are indexed to a value of $100.00 at December 31, 2014. </span></div><div style="line-height:120%;text-align:center;"><img src="chart-e9c6128662635b0daca.jpg" alt="chart-e9c6128662635b0daca.jpg" style="height:428px;width:601px;"></img></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="18"></td></tr><tr><td style="width:52%;"></td><td style="width:6%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:6%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:7%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:6%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:6%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:6%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="17" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Indexed Returns (years ending)</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Company/Index</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">12/31/14</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">12/31/15</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">12/31/16</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">12/31/17</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">12/31/18</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">12/31/19</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Immunomedics</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">100</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">64</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">76</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">337</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">297</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">441</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Nasdaq Composite</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">100</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">100</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">114</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">138</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">130</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">171</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Nasdaq Pharmaceutical</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">100</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">105</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">104</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">124</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">134</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">154</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">43</span></div></div><hr style="page-break-after:always"></hr><div><a id="s3AA20388715F53D0AD804BF27E9AC0BA"></a></div><div><div style="line-height:120%;text-align:justify;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;" href="#sfb86787ac8304dffbb4bfe7ffcfa7b54"><span style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">Table of Contents</span></a></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></div><div><br/></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Item 6. </span><span style="font-family:inherit;font-size:10pt;"> </span><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Selected Financial Data</span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following table sets forth our consolidated financial data for the year ended December 31, 2019, the Transition Period ended December 31, 2018 as well as for each of the four fiscal years ended June 30, 2018, 2017, 2016 and 2015, which has been derived from our audited consolidated financial statements. The audited consolidated financial statements for the year ended December 31, 2019, the Transition Period ended December 31, 2018, as well as the two fiscal years ended June 30, 2018 and 2017, are included elsewhere in this Annual Report on Form 10-K. The information below should be read in conjunction with the consolidated financial statements (and notes thereon) and Item 7,</span><span style="font-family:inherit;font-size:10pt;font-style:italic;"> </span><span style="font-family:inherit;font-size:10pt;">Management’s Discussion and Analysis of Financial Condition and Results of Operations.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="24"></td></tr><tr><td style="width:29%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:8%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:8%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:8%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:8%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"> </span></div></td><td colspan="3" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Year Ended December 31, 2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;"> Transition Period Ended December 31, 2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Fiscal Years Ended June 30,</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-style:italic;font-weight:bold;">($ in thousands, except per share </span></div><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-style:italic;font-weight:bold;">amounts)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">2017</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">2016</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">2015</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Total revenues</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">295</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">—</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">2,156</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">3,091</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">3,233</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">5,653</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Total costs and expenses</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">325,133</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">144,535</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">143,203</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">82,241</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">62,241</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">51,873</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Operating loss</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">(324,838</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">(144,535</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">(141,047</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">(79,150</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">(59,008</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">(46,220</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Changes in fair market value of warrant liabilities</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">—</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">1,404</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">(108,636</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">(61,074</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">—</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">—</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Warrant related expenses</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">—</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">—</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">—</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">(7,649</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">—</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">—</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Interest expense </span><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(1)</sup></span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">(40,337</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">(20,017</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">(23,255</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">(5,480</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">(5,480</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">(2,091</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Interest and other income</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">7,856</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">6,106</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">5,493</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">431</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">338</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">246</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Loss on induced exchanges of debt</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">—</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">(897</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">(13,005</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">—</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">—</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">—</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Other financing expenses</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">—</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">—</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">—</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">(347</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">—</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">—</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Insurance reimbursement</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">—</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">190</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">6,638</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">—</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">—</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">—</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Foreign currency transaction gain (loss), net</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">—</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">—</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">81</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">23</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">(40</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">(1</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Loss before income tax</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">(357,319</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">(157,749</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">(273,731</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">(153,246</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">(64,190</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">(48,066</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Income tax (expense) benefit</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">—</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">—</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">(156</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">(20</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">5,054</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">(58</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Net loss</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">(357,319</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">(157,749</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">(273,887</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">(153,266</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">(59,136</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">(48,124</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Net loss attributable to noncontrolling interest</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">(129</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">(81</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">(50</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">(60</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">(99</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">(122</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Net loss attributable to Immunomedics, Inc. stockholders</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">(357,190</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">(157,668</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">(273,837</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">(153,206</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">(59,037</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">(48,002</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Loss per common share attributable to Immunomedics, Inc. stockholders (basic and diluted):</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">(1.84</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">(0.84</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">(1.78</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">(1.47</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">(0.62</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">(0.51</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Weighted average shares used to calculate loss per common share (basic and diluted)</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">193,617</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">188,554</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">153,475</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">104,536</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">94,770</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">93,315</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;text-align:justify;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="24"></td></tr><tr><td style="width:29%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:8%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:8%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:8%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:8%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"> </span></div></td><td colspan="3" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">As of December 31, 2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">For the Transition Period As of December 31, 2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">As of June 30,</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-style:italic;"> </span><span style="font-family:inherit;font-size:9pt;font-style:italic;font-weight:bold;">($ in thousands)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">2017</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">2016</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">2015</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Total cash, cash equivalents and marketable securities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">613,178</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">497,801</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">638,802</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">154,902</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">50,628</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">99,618</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Total assets</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">671,722</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">528,040</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">664,173</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">162,573</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">56,950</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">105,780</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Liability related to sale of future royalties</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">261,224</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">221,295</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">202,007</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">—</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">—</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">—</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Convertible senior notes, net</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">7,106</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">7,055</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">19,763</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">98,084</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">97,354</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">96,625</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Warrant liabilities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">—</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">—</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">8,973</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">90,706</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">—</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">—</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Total stockholders' equity </span><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(2)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">267,230</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">265,849</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">399,686</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">(59,464</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">(57,527</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">(4,525</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td></tr></table></div></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">44</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;text-align:justify;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;" href="#sfb86787ac8304dffbb4bfe7ffcfa7b54"><span style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">Table of Contents</span></a></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></div><div><br/></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:inherit;font-size:10pt;">(1)</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Interest expense represents interest on liability related to sale of future royalties of </span><span style="font-family:inherit;font-size:10pt;">$39.9 million</span><span style="font-family:inherit;font-size:10pt;"> for the year ended December 31, 2019, </span><span style="font-family:inherit;font-size:10pt;">$19.3 million</span><span style="font-family:inherit;font-size:10pt;"> for the Transition Period ended December 31, 2018, </span><span style="font-family:inherit;font-size:10pt;">$19.8 million</span><span style="font-family:inherit;font-size:10pt;"> for fiscal 2018, the Convertible Senior Notes interest expense (</span><span style="font-family:inherit;font-size:10pt;">$0.3 million</span><span style="font-family:inherit;font-size:10pt;">, </span><span style="font-family:inherit;font-size:10pt;">$0.3 million</span><span style="font-family:inherit;font-size:10pt;">, </span><span style="font-family:inherit;font-size:10pt;">$1.8 million</span><span style="font-family:inherit;font-size:10pt;">, and </span><span style="font-family:inherit;font-size:10pt;">$4.8 million</span><span style="font-family:inherit;font-size:10pt;"> for the year ended December 31, 2019, the Transition Period, fiscal 2018, and fiscal 2017, respectively) and amortized debt issuance costs (</span><span style="font-family:inherit;font-size:10pt;">$0.1 million</span><span style="font-family:inherit;font-size:10pt;">, </span><span style="font-family:inherit;font-size:10pt;">$0.2 million</span><span style="font-family:inherit;font-size:10pt;">, </span><span style="font-family:inherit;font-size:10pt;">$1.7 million</span><span style="font-family:inherit;font-size:10pt;">, and </span><span style="font-family:inherit;font-size:10pt;">$0.7 million</span><span style="font-family:inherit;font-size:10pt;"> for the year ended December 31, 2019, the Transition Period ended December 31, 2018, fiscal 2018, and fiscal 2017, respectively).</span></div></td></tr></table><div style="line-height:120%;padding-left:4px;text-align:justify;padding-left:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:inherit;font-size:10pt;">(2)</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We have never paid cash dividends on our common stock. Stockholders’ equity represents Immunomedics, Inc. stockholders' equity and the non-controlling interest in our subsidiary.  </span></div></td></tr></table><div style="line-height:120%;padding-left:4px;text-align:justify;padding-left:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div><a id="sA6CC3F09E422530DB6C0B9582C397CCC"></a></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Item 7.</span><span style="font-family:inherit;font-size:10pt;">    </span><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Management’s Discussion and Analysis of Financial Condition and Results of</span><span style="font-family:inherit;font-size:10pt;"> </span><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Operations</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Cautionary Note Regarding Forward-Looking Statements</span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The SEC encourages companies to disclose forward-looking information so that investors can better understand a company’s future prospects and make informed investment decisions. This Annual Report on Form 10-K contains such “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. These statements may be made directly in this Annual Report, and they may also be made a part of this Annual Report by reference to other documents filed with the SEC, which is known as “incorporation by reference.”</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Words such as “may,” “anticipate,” “estimate,” “expects,” “projects,” “intends,” “plans,” “believes” and words and terms of similar substance used in connection with any discussion of future operating or financial performance are intended to identify forward-looking statements. All forward-looking statements are management’s present expectations of future events and are subject to a number of risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. These risks and uncertainties include, among other things: expectations for the outcome of our resubmission of our BLA for sacituzumab govitecan for the treatment of patients with mTNBC who have received at least two prior therapies for metastatic disease; the FDA re-inspection of the Company’s manufacturing facility where we manufacture the monoclonal antibody for further manufacture into our ADC candidate sacituzumab govitecan; potential approval and commercial launch of sacituzumab govitecan for that indication and the Company’s development of sacituzumab govitecan for additional indications; clinical trials (including the funding therefor, anticipated patient enrollment, trial outcomes, timing or associated costs); regulatory applications and related timelines, including the filing and approval timelines for BLAs, BLA resubmissions, and BLA supplements; out-licensing arrangements; forecasts of future operating results, potential collaborations, capital raising activities, and the timing for bringing any product candidate to market; our inability to further identify, develop and achieve commercial success for new products and technologies; the possibility of delays in the research and development necessary to select drug development candidates and delays in clinical trials; the risk that clinical trials may not result in marketable products; the risk that we may be unable to obtain additional capital through strategic collaborations, licensing, convertible debt securities or equity financing in order to continue our research and development programs as well as secure regulatory approval of and market our drug candidates; our dependence upon pharmaceutical and biotechnology collaborations; the levels and timing of payments under our collaborative agreements; uncertainties about our ability to obtain new corporate collaborations and acquire new technologies on satisfactory terms, if at all; the development of competing products; our ability to protect our proprietary technologies; patent infringement claims; and risks of new, changing and competitive technologies and regulations in the United States and internationally, as well as the risks discussed in the Company’s filings with the SEC. The Company is not under any obligation, and the Company expressly disclaims any obligation, to update or alter any forward-looking statements, whether as a result of new information, future events or otherwise. Refer to Item 1A “Risk Factors” in this Annual Report on Form 10-K for more information.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In light of these assumptions, risks and uncertainties, the results and events discussed in the forward-looking statements contained in this Annual Report on Form 10-K or in any document incorporated by reference might not occur. Stockholders are cautioned not to place undue reliance on the forward-looking statements, which speak only as of the date of this Annual Report on Form 10-K or the date of the document incorporated by reference in this Annual Report on Form 10-K, as applicable. We are not under any obligation, and we expressly disclaim any obligation, to update or alter any forward-looking statements, whether as a result of new information, future events or otherwise except as may be required by applicable law. All subsequent forward-looking statements attributable to the Company or to any person acting on our behalf are expressly qualified in their entirety by the cautionary statements contained or referred to in this section</span><span style="font-family:inherit;font-size:10pt;font-style:italic;">.</span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Historically, our fiscal years ended on June 30. On December 14, 2018, the Company's Board of Directors approved a change in the Company's fiscal year end from June 30 to December 31. In connection with this change, we previously filed a Transition Report on Form 10-K to report the results of the six-month transition period from July 1, 2018 to December 31, 2018 (which we sometimes refer to as the "Transition Period"). In this Annual Report, the periods presented are the year ended December 31, 2019, the Transition Period ended December 31, 2018 and our fiscal years ended June 30, 2018 and 2017 (which are referred </span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">45</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;text-align:justify;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;" href="#sfb86787ac8304dffbb4bfe7ffcfa7b54"><span style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">Table of Contents</span></a></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></div><div><br/></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">to as “fiscal 2018,” and "fiscal 2017", as if we had not changed our fiscal year to a calendar year). For comparison purposes, we have also included unaudited data for the year ended December 31, 2018.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following Management’s Discussion and Analysis (“MD&A”) provides a narrative of our results of operations for the year ended December 31, 2019 and unaudited data for the comparable period ended December 31, 2018. The MD&A should be read together with our consolidated financial statements and related notes included in Item 8 in this Annual Report on Form 10-K.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div><a id="s65D5F2A717995F11B5C535BC3A47BC89"></a></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Overview</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We are a clinical-stage biopharmaceutical company developing monoclonal antibody-based products for the targeted treatment of cancer. Our advanced proprietary technologies allow us to create humanized antibodies that can be used either alone in unlabeled or “naked” form, or conjugated with chemotherapeutics, cytokines or toxins. </span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We believe that our antibodies have therapeutic potential, in some cases as a naked antibody or when conjugated with chemotherapeutics, cytokines or other toxins to create unique and potentially more effective treatment options. The attachment of effective anti-tumor compounds to antibodies is intended to allow the delivery of these therapeutic agents to tumor sites with better specificity than conventional chemotherapy. This treatment method is designed to optimize the therapeutic window through reducing the systemic exposure of the patient to the therapeutic agents, which ideally minimizes debilitating side effects while maximizing the concentration of the therapeutic agent at the tumor, potentially leading to better efficacy.</span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"></span><span style="font-family:inherit;font-size:10pt;">Our portfolio of investigational products includes ADCs that are designed to deliver a specific payload of a chemotherapeutic directly to the tumor while reducing overall toxicities that are usually associated with conventional administration of these chemotherapeutic agents. Sacituzumab govitecan is our most advanced ADC and our lead product candidate that has received Breakthrough Therapy Designation from the FDA for the treatment of patients with mTNBC who have received at least two prior therapies for metastatic disease.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Our corporate strategy is to become a fully-integrated biopharmaceutical company and a leader in the field of ADCs. </span><span style="font-family:inherit;font-size:10pt;">In May 2018, we submitted a Biologics License Application (“BLA”) to the United States Food and Drug Administration ("FDA") for sacituzumab govitecan for the treatment of patients with mTNBC who have received at least two prior therapies for metastatic disease. In July 2018, we received notification from the FDA that the BLA was accepted for filing and the original application was granted Priority Review with a Prescription Drug User Fee Act ("PDUFA") target action date in January 2019. In January 2019, we received a Complete Response Letter ("CRL") from the FDA for the BLA. We subsequently met with the FDA in May 2019 to review the FDA’s findings and discussed our BLA resubmission. Since then, we have developed a detailed plan to address the chemistry, manufacturing, and controls (“CMC”) matters raised in the CRL and in our pre-approval inspection. We held another meeting with the FDA in September 2019 to update the FDA on our progress in addressing these matters and to receive feedback from the FDA on our approach. On November 30, 2019, we resubmitted our BLA to the FDA and on December 23, 2019 we received notification from the FDA that the BLA was accepted for filing and further assigned a new PDUFA target action date as June 2, 2020. We have dedicated, and continue to commit, significant resources to address the CMC matters identified by the FDA, while, in parallel, preparing our manufacturing facility to be ready for re-inspection by the FDA. Our Phase 3 confirmatory ASCENT study for sacituzumab govitecan has reached its target enrollment for mTNBC patients previously treated with at least two systemic chemotherapy regimens. Top-line data for the ASCENT study is expected to be available around mid-2020. </span></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">On March 29, 2019, the Company entered into the ATM Agreement with Cowen to issue and sell shares of the Company’s common stock, par value $0.01 per share, having an aggregate offering price of up to $150.0 million, from time to time during the term of the ATM Agreement, through an “at-the-market” equity offering program at the Company's sole discretion, under which Cowen will act as the Company’s agent and/or principal. The Company will pay Cowen a commission up to 3.0% of the gross sales proceeds of any common stock sold through Cowen under the ATM Agreement. During the year ended </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;">, the Company sold 4,432,416 shares of common stock with net proceeds of $71.6 million at a weighted average price of $16.40 (excluding commissions) under the ATM Agreement. </span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">On April 5, 2019, the Company entered into the Promotion Agreement with Janssen pursuant to which the Company will provide non-exclusive product detailing services to Janssen for the product. Pursuant to the Promotion Agreement, the Company will provide a dedicated sales team to detail the Product to oncologists and other targeted health care providers in the United States. Under the terms of the Promotion Agreement, Janssen maintains ownership of the New Drug Application for the product as well as legal, regulatory, distribution, commercialization and manufacturing responsibilities for the product, while the Company will provide product detailing services to Janssen.  Following the achievement of certain sales targets in 2019 and 2020, Janssen will pay the Company (a) a service fee equal to a percentage in the low double digits of the portion of Cumulative Net Sales (as defined in the Promotion Agreement) in excess of a baseline amount during each of 2019 and 2020, and (b) potential milestone payments </span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">46</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;text-align:justify;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;" href="#sfb86787ac8304dffbb4bfe7ffcfa7b54"><span style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">Table of Contents</span></a></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></div><div><br/></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">of up to $15.0 million when Cumulative Net Sales exceed certain thresholds during each of 2019 and 2020. On April 12, 2019, the Company was informed that the FDA granted accelerated approval to Janssen's Balversa</span><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">®</sup></span><span style="font-family:inherit;font-size:10pt;"> (erdafitinib) for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma that has a type of susceptible genetic alteration known as FGFR3 or FGFR2, and that has progressed during or following prior platinum-containing chemotherapy. Refer to "Note 2 - Revenue Recognition" for additional information.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">On April 29, 2019, we entered into the License Agreement with Everest. Pursuant to the License Agreement, we granted Everest an exclusive license to develop and commercialize sacituzumab govitecan in the People’s Republic of China, Taiwan, Hong Kong, Macao, Indonesia, Philippines, Vietnam, Thailand, South Korea, Malaysia, Singapore and Mongolia (the "Territory"). In consideration for entering into the License Agreement, Everest made a one-time, non-refundable upfront payment to us in the aggregate amount of $65.0 million which is recorded as deferred revenue on the consolidated balance sheet as of </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;">. The License Agreement contains a development milestone payment of $60.0 million based upon our achievement of FDA approval for sacituzumab govitecan. The License Agreement also contains additional development milestone payments in a total amount of up to $180.0 million based upon the achievement of certain other development milestones. In addition, the License Agreement contains sales milestone payments in a total amount of up to $530.0 million based upon the achievement of certain sales milestones. Everest will make royalty payments to us based upon percentages of net sales of sacituzumab govitecan, ranging from 14% to 20%. Refer to "Note 2 - Revenue Recognition" for additional information.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">On December 9, 2019, we closed an underwritten public offering of 14,285,715 shares of common stock at a public offering with a price of $17.50 per share, representing gross proceeds of approximately $250.0 million. In addition, the Company granted the underwriters a 30-day option to purchase up to 2,142,857 additional shares of common stock for a total of 16,428,572 shares. We received gross proceeds of $287.5 million and net proceeds of $273.0 million after deducting the underwriting discounts and commissions and expenses related to the offering. We intend to use the net proceeds from this offering primarily to accelerate commercial launch readiness, pending FDA approval, of sacituzumab govitecan in the United States in mTNBC, continue to expand the clinical development programs for sacituzumab govitecan, invest in the broader clinical development of the platform (including IMMU-130 and IMMU-140), continued scale-up of manufacturing and manufacturing process improvements, as well as for working capital and general corporate purposes.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">As of </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;">, we had </span><span style="font-family:inherit;font-size:10pt;">$613.2 million</span><span style="font-family:inherit;font-size:10pt;"> in cash, cash equivalents and marketable securities. </span><span style="font-family:inherit;font-size:10pt;">We believe our projected financial resources are adequate to (i) accelerate commercial launch readiness, pending FDA approval, of sacituzumab govitecan in the United States in mTNBC, (ii) continue to expand the clinical development programs for developing sacituzumab govitecan in mTNBC, metastatic urothelial cancer ("mUC"), hormone receptor-positive ("HR+")/human epidermal growth factor receptor 2-negative ("HER2-") metastatic breast cancer ("mBC"), and other indications of high medical need, (iii) invest in the broader clinical development of the platform (including IMMU-130 and IMMU-140), (iv) continued scale up of manufacturing and manufacturing process improvements, and (v) general working capital requirements. However, in case of regulatory delays or other unforeseen events, we may require additional funding.</span><span style="font-family:inherit;font-size:10pt;"> </span><span style="font-family:inherit;font-size:10pt;">Potential sources of funding in such a case could include (i) the entrance into potential development and commercial partnerships to advance and maximize our full pipeline for mTNBC and beyond in the United States and globally, and (ii) potential private and public capital markets financing. Refer to "Note 9 - Stockholders' Equity" for additional information. </span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">As part of our commitment to invest in and scale our global supply capacity with world-class partners in each component of its supply-chain, on September 11, 2018, we entered into a Master Services Agreement (the “MSA”) with Samsung BioLogics Co., Ltd. (“Samsung”), pursuant to which Samsung provides the Company with certain biologics manufacturing and development services in accordance with one or more product specific agreements. In connection with the MSA, on September 11, 2018, we also entered into a product specific agreement with Samsung for the production of hRS7, the antibody used in the Company’s lead antibody drug conjugate candidate, sacituzumab govitecan. In addition, on December 26, 2018, we expanded our long-term master supply agreement with Johnson Matthey who will continue to scale the manufacturing of CL2A-SN-38, the drug-linker that is a key component of sacituzumab govitecan. </span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">To accelerate the clinical development of sacituzumab govitecan, we are collaborating with Roche to evaluate the safety and efficacy of the combination of its programmed cell death ligand 1 blocking checkpoint inhibitor and sacituzumab govitecan in frontline mTNBC. In the post-neoadjuvant setting in HER2- mBC, we are collaborating with the German Breast Group to assess sacituzumab govitecan as a single agent. We are also collaborating with AstraZeneca to investigate our ADC in earlier lines of therapy for mTNBC, advanced UC and mNSCLC in combination with its checkpoint inhibitor, and with Clovis, Inc. to combine with its PARP inhibitor in mTNBC, advanced UC and ovarian cancer. In addition, Massachusetts General Hospital is working on a study combining sacituzumab govitecan with Pfizer's PARP inhibitor in patients with mTNBC, University of Wisconsin is working on a clinical study of sacituzumab govitecan as a monotherapy in prostate cancer, and Yale University has a Phase 2 study of sacituzumab govitecan in patients with persistent and recurrent endometrial cancer. </span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">47</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;text-align:justify;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;" href="#sfb86787ac8304dffbb4bfe7ffcfa7b54"><span style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">Table of Contents</span></a></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></div><div><br/></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We also have a number of other product candidates, which target solid tumors and hematologic malignancies in various stages of clinical and preclinical development. They include other ADCs such as labetuzumab govitecan, which binds the CEACAM5 antigen expressed on CRC and other solid cancers, and IMMU-140 that targets HLA-DR for the potential treatment of hematologic malignancies. We believe that our portfolio of intellectual property provides commercially reasonable protection for our product candidates and technologies.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The development and commercialization of successful therapeutic products is subject to numerous risks and uncertainties including, without limitation, the following:</span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:inherit;font-size:10pt;">•</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">the time and expense required for us to comply with all applicable federal, state and foreign legal requirements, including, without limitation, our receipt of the necessary approvals of the FDA (which receipt is uncertain);</span></div></td></tr></table><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:inherit;font-size:10pt;">•</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">the time and expense required for us to establish and maintain compliant operations for commercial manufacturing, sale, and distribution of products (if approved) under FDA and healthcare law requirements, and risks of non-compliance;</span></div></td></tr></table><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:inherit;font-size:10pt;">•</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">we may be unable to obtain additional capital through strategic collaborations, licensing, or potential private and public capital markets financings, including the use of the ATM Agreement, in order to continue our research and secure regulatory approval of and market our lead drug candidate;</span></div></td></tr></table><div style="line-height:120%;text-align:justify;padding-left:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:inherit;font-size:10pt;">•</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">challenges based on the type of therapeutic compound under investigation and nature of the disease in connection with which the compound is being studied;</span></div></td></tr></table><div style="line-height:120%;text-align:justify;padding-left:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:inherit;font-size:10pt;">•</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">our ability, as well as the ability of our partners, to conduct and complete clinical trials on a timely basis;</span></div></td></tr></table><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:inherit;font-size:10pt;">•</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">the financial resources available to us during any particular period; and</span></div></td></tr></table><div style="line-height:120%;text-align:justify;padding-left:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:inherit;font-size:10pt;">•</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">many other factors associated with the commercial development of therapeutic products outside of our control.</span></div></td></tr></table><div style="line-height:120%;text-align:justify;padding-left:72px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;padding-left:72px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">(Refer to "Risk Factors" under Item 1A in this Annual Report on Form 10-K for more information.)</span></div><div style="line-height:120%;text-align:justify;padding-left:72px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div><a id="sA6D144398B7454ECA6520DA787BBAB4A"></a></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Critical Accounting Policies and Accounting Estimates</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">A critical accounting policy is one that is both important to the portrayal of our financial condition and results of operation and requires management's most difficult, subjective or complex judgments, often as a result of the need to make estimates about the effect of matters that are inherently uncertain.</span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Our critical accounting estimates and assumptions impacting the consolidated financial statements relate to stock-based compensation expenses, the fair value for the liability related to sale of future royalties and related interest expense. Refer to "Note 1 - Business Overview and Summary of Significant Accounting Policies", "Note 4 - Debt", and "Note 6 - Estimated Fair Value of Financial Instruments", respectively, for more information.</span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">48</span></div></div><hr style="page-break-after:always"></hr><div><a id="s6A10421701E2571390FB5FE9A17060EA"></a></div><div><div style="line-height:120%;text-align:justify;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;" href="#sfb86787ac8304dffbb4bfe7ffcfa7b54"><span style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">Table of Contents</span></a></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></div><div><br/></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Results of Operations</span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">    </span></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Revenues</span></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="14"></td></tr><tr><td style="width:49%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="5" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-style:italic;">($ in thousands)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">(Decrease)/Increase</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">For the Year Ended December 31,</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">(unaudited 2018)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">2019 vs (unaudited 2018)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Product sales</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">—</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">450</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">(450</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">nm</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">License fee and other revenues</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">295</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">265</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">30</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">11.3%</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Research and development</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">—</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">153</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">(153</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">nm</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Total revenues</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">295</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">868</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">(573</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">nm</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">nm - not meaningful</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total revenue for the year ended </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;"> decreased compared to the comparable period ended December 31, 2018, primarily due to the discontinued sale of LeukoScan</span><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">® </sup></span><span style="font-family:inherit;font-size:10pt;">during February 2018 to focus on our ADC business. Revenues for the year ended </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;"> are service fee revenues earned related to the Janssen Promotion Agreement.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Costs and Expenses</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following table summarizes our costs and expenses for the year ended </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;"> and the comparable period ended December 31, 2018:</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="15"></td></tr><tr><td style="width:45%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="6" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-style:italic;">($ in thousands)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">(unaudited) 2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="6" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Increase/(Decrease)</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">For the Year Ended December 31,</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="6" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">2019 vs (unaudited) 2018</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Costs of goods sold</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">—</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">47</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">(47</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">nm</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Research and development</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">254,871</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">150,333</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">104,538</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">69.5</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"> %</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Sales and marketing</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">26,459</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">25,239</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">1,220</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">4.8</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"> %</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">General and administrative</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">43,803</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">59,807</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">(16,004</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">(26.8</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)%</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Total costs and expenses</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">325,133</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">235,426</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">89,707</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">38.1</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"> %</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">nm - not meaningful</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr></table></div></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">    </span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total costs and expenses for the year ended December 31, 2019 increased compared to the comparable period ended December 31, 2018, primarily due to an increase in research and development expenses and an increase in sales and marketing expenses. The increase was partially offset by a decrease in general and administrative expenses.</span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">    </span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Research and Development</span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">    </span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We do not track expenses on the basis of each individual compound under investigation and therefore we do not provide a breakdown of such historical information in that format. We evaluate projects under development from an operational perspective, including such factors as results of individual compounds from laboratory/animal testing, patient results and enrollment statistics in clinical trials. It is important to note that multiple product candidates are often tested simultaneously. It is not possible to calculate each antibody’s supply costs. There are many different development processes and test methods that examine multiple product candidates at the same time. We have, historically, tracked our costs in the categories discussed below, specifically “research costs” and “product development costs” and by the types of costs outlined below.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Our research costs consist of outside costs associated with animal studies and costs associated with research and testing of our product candidates prior to reaching the clinical stage. Such research costs primarily include personnel costs, facilities, including depreciation, lab supplies, funding of outside contracted research and license fees. Our product development costs consist of costs from preclinical development (including manufacturing), conducting and administering clinical trials and patent expenses.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">    </span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">49</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;text-align:justify;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;" href="#sfb86787ac8304dffbb4bfe7ffcfa7b54"><span style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">Table of Contents</span></a></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></div><div><br/></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following table summarizes our research and development costs for the year ended </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;"> and the comparable period ended December 31, 2018:</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="15"></td></tr><tr><td style="width:45%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="6" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-style:italic;">($ in thousands)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">(unaudited) 2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="6" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Increase/(Decrease)</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">For the Year Ended December 31,</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="6" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">2019 vs (unaudited) 2018</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Labor</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">48,285</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">27,026</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">21,259</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">78.7</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"> %</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Manufacturing and quality costs</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">154,249</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">77,772</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">76,477</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">98.3</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"> %</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Clinical development and operations</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">40,627</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">24,011</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">16,616</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">69.2</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"> %</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Other</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">11,710</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">21,524</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">(9,814</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">(45.6</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)%</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Total research and development costs</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">254,871</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">150,333</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">104,538</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">69.5</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"> %</span></div></td></tr></table></div></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Research and development costs increased for the year ended </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;"> by approximately </span><span style="font-family:inherit;font-size:10pt;">$104.5 million</span><span style="font-family:inherit;font-size:10pt;"> to </span><span style="font-family:inherit;font-size:10pt;">$254.9 million</span><span style="font-family:inherit;font-size:10pt;"> compared to the comparable period ended December 31, 2018. The increase in research and development costs relate primarily to preparations for the approval and launch of sacituzumab govitecan in the United States for patients with mTNBC, CRL remediation costs including outside manufacturers' organizations services costs, and outside consulting services to improve our manufacturing and regulatory functions. </span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">    </span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Completion of clinical trials may take several years or more. The length of time varies according to the type, complexity and the disease indication of the product candidate. We estimate that clinical trials of the type we generally conduct are typically completed over the following periods:</span></div><div style="line-height:120%;text-align:justify;text-indent:6px;font-size:9pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.21875%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:64%;"></td><td style="width:4%;"></td><td style="width:32%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">    </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Estimated Completion Period</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Clinical Phase</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">(Years)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">I</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">0-1</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">II</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">1-2</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">III</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">1-4</span></div></td></tr></table></div></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The duration and cost of clinical trials through each of the clinical phases may vary significantly over the life of a particular project as a result of, among other things, the following factors:</span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:inherit;font-size:10pt;">•</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">the length of time required to recruit qualified patients for clinical trials;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:inherit;font-size:10pt;">•</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">the duration of patient follow-up in light of trial results;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:inherit;font-size:10pt;">•</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">the number of clinical sites required for trials; and</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:inherit;font-size:10pt;">•</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">the number of patients that ultimately participate.</span></div></td></tr></table><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Sales and Marketing</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following table summarizes our sales and marketing expenses for the year ended </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;"> and the comparable period ended December 31, 2018:</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.609375%;border-collapse:collapse;text-align:left;"><tr><td colspan="15"></td></tr><tr><td style="width:45%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="6" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-style:italic;">($ in thousands)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">(unaudited) 2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="6" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Increase/(Decrease)</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">For the Year Ended December 31, </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="6" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">2019 vs (unaudited) 2018</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Labor costs</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">21,928</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">7,825</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">14,103</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">nm</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Marketing and promotions</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">1,440</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">10,821</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">(9,381</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">(86.7</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)%</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Consulting services</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">208</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">2,626</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">(2,418</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">(92.1</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)%</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Other</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">2,883</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">3,967</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">(1,084</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">(27.3</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)%</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Total sales and marketing</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">26,459</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">25,239</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">1,220</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">4.8</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"> %</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">nm- not meaningful</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr></table></div></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Sales and marketing expenses increased during the year ended </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;"> by approximately $1.2 million compared to the comparable period ended December 31, 2018, primarily due to an increase in labor costs due to a full year of expenses relating to our sales force, offset by a decrease in marketing and promotions as well as consulting services.</span><span style="font-family:inherit;font-size:10pt;color:#ee2724;"> </span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">50</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;text-align:justify;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;" href="#sfb86787ac8304dffbb4bfe7ffcfa7b54"><span style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">Table of Contents</span></a></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></div><div><br/></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">General and Administrative Expenses</span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">    </span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following table summarizes our general and administrative expenses for the year ended </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;"> and the comparable period ended December 31, 2018:</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="15"></td></tr><tr><td style="width:45%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="6" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-style:italic;">($ in thousands)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">(unaudited) 2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="6" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">(Decrease)/Increase</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">For the Year Ended December 31, </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="6" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">2019 vs (unaudited) 2018</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Labor costs</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">19,393</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">17,397</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">1,996</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">11.5</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"> %</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Legal and advisory fees</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">7,839</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">16,824</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">(8,985</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">(53.4</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)%</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Consulting services</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">5,064</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">8,177</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">(3,113</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">(38.1</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)%</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Other</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">11,507</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">17,409</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">(5,902</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">(33.9</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)%</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Total general and administrative</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">43,803</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">59,807</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">(16,004</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">(26.8</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)%</span></div></td></tr></table></div></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">    </span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">General and administrative expenses for the year ended </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;"> decreased by approximately $16.0 million compared to the comparable period ended December 31, 2018, primarily due to decreased legal and advisory expenses due to reduced reliance on outside legal counsel, as well as a decrease in other and consulting services, partially offset by an increase in labor costs. </span></div><div style="line-height:120%;text-align:justify;text-indent:96px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">        </span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Changes in fair market value of warrant liabilities </span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We have no non-cash income or expense for the year ended </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;">, compared to </span><span style="font-family:inherit;font-size:10pt;">$47.6 million</span><span style="font-family:inherit;font-size:10pt;"> in non-cash expense for the comparable period ended December 31, 2018, as a result of the net appreciation in the fair value of the then outstanding warrants. There were no warrants outstanding at </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;"> and 2018. Refer to "Note 9 - Stockholders' Equity" for more information.</span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">    </span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Interest expense</span><span style="font-family:inherit;font-size:10pt;font-weight:bold;"> </span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Interest expense for the year ended </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;"> was </span><span style="font-family:inherit;font-size:10pt;">$40.3 million</span><span style="font-family:inherit;font-size:10pt;"> compared to </span><span style="font-family:inherit;font-size:10pt;">$40.4 million</span><span style="font-family:inherit;font-size:10pt;"> for the comparable period ended December 31, 2018. The $0.1 million decrease was due primarily to changes in the fair value of our debt balances as a result of the RPI agreement. Refer to "Note 4 - Debt" for more information. </span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Loss on induced exchanges of debt </span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"></span><span style="font-family:inherit;font-size:10pt;">On October 2, 2018, the Company entered into privately negotiated exchange agreements (the "October 2018 Exchange Agreements"), with a limited number of holders of the Convertible Senior Notes. As a result of the October 2018 Exchange Agreements, the Company recognized a non-cash loss on induced exchanges of debt of </span><span style="font-family:inherit;font-size:10pt;">$0.9 million</span><span style="font-family:inherit;font-size:10pt;"> representing the fair value of the incremental consideration paid to induce the holders to exchange their Convertible Senior Notes for equity (i.e., 0.1 million shares of common stock), based on the closing market price of the Company's Common Stock on the date of the October 2018 Exchange Agreements. Refer to "Note 4 - Debt" for more information.</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Insurance reimbursement </span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We received no insurance reimbursements for the year ended </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;">, compared to </span><span style="font-family:inherit;font-size:10pt;">$2.5 million</span><span style="font-family:inherit;font-size:10pt;"> we received for the comparable period ended December 31, 2018, due to insurance reimbursements related to legal costs incurred during our proxy contest during fiscal 2017. Refer to "Note 14 - Commitments and Contingencies" for more information.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Income tax expense</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">There was no income tax expense for the year ended </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;">, and </span><span style="font-family:inherit;font-size:10pt;">$0.2 million</span><span style="font-family:inherit;font-size:10pt;"> of income tax expense for the comparable period ended December 31, 2018. </span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Net Loss Attributable to Immunomedics, Inc. Stockholders </span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"></span><span style="font-family:inherit;font-size:10pt;">Net loss attributable to Immunomedics, Inc. common stockholders for the year ended </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;"> was </span><span style="font-family:inherit;font-size:10pt;">$357.2 million</span><span style="font-family:inherit;font-size:10pt;">, or </span><span style="font-family:inherit;font-size:10pt;">$1.84</span><span style="font-family:inherit;font-size:10pt;"> per share, compared to a net loss of approximately </span><span style="font-family:inherit;font-size:10pt;">$310.2 million</span><span style="font-family:inherit;font-size:10pt;">, or </span><span style="font-family:inherit;font-size:10pt;">$1.74</span><span style="font-family:inherit;font-size:10pt;"> per share, for the comparable period ended December 31, 2018, an </span><span style="font-family:inherit;font-size:10pt;">increase</span><span style="font-family:inherit;font-size:10pt;"> in the loss of $47.0 million due primarily to a </span><span style="font-family:inherit;font-size:10pt;">$89.7 million</span><span style="font-family:inherit;font-size:10pt;"> </span><span style="font-family:inherit;font-size:10pt;">increase</span><span style="font-family:inherit;font-size:10pt;"> in costs and expenses related to preparations for the approval and launch of sacituzumab govitecan in the United States for patients with mTNBC, along </span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">51</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;text-align:justify;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;" href="#sfb86787ac8304dffbb4bfe7ffcfa7b54"><span style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">Table of Contents</span></a></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></div><div><br/></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">with a reduction of interest and other income of </span><span style="font-family:inherit;font-size:10pt;">$2.9 million</span><span style="font-family:inherit;font-size:10pt;"> , a reduction of </span><span style="font-family:inherit;font-size:10pt;">$2.5 million</span><span style="font-family:inherit;font-size:10pt;"> in non-recurring insurance reimbursement related to the proxy contest, offset by a </span><span style="font-family:inherit;font-size:10pt;">decrease</span><span style="font-family:inherit;font-size:10pt;"> in the expense from the change in fair value of warrant liabilities of </span><span style="font-family:inherit;font-size:10pt;">$47.6 million</span><span style="font-family:inherit;font-size:10pt;">, in the comparable period ended December 31, 2018.</span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">    </span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Transition Period Ended December 31, 2018 and the Comparable Period Ended December 31, 2017, and Fiscal Year Ended June 30, 2018 Compared to the Fiscal Year Ended June 30, 2017</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Management’s discussion and analysis of our results of operations for the Transition Period ended December 31, 2018, the comparable period ended December 31, 2017, and fiscal year ended June 30, 2018 compared to the fiscal year ended June 30, 2017 may be found in the “Management’s Discussion and Analysis of Financial Condition and Results of Operations sections of our Transition Report on Form 10-K for the transition period ended December 31, 2018, filed with the SEC on February 25, 2019.</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div><a id="s0E33530CBB7C52D7B4F94D1B25DAD401"></a></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Liquidity and Capital Resources </span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Since its inception in 1982, Immunomedics’ principal sources of funds have been the private and public sale of equity and debt securities, and revenues from licensing agreements, including up-front and milestone payments, funding of development programs, and other forms of funding from collaborations.</span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">As of </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;">, we had </span><span style="font-family:inherit;font-size:10pt;">$613.2 million</span><span style="font-family:inherit;font-size:10pt;"> in cash, cash equivalents and marketable securities. </span><span style="font-family:inherit;font-size:10pt;">We believe our projected financial resources are adequate to (i) accelerate commercial launch readiness, pending FDA approval, of sacituzumab govitecan in the United States in mTNBC, (ii) continue to expand the clinical development programs for developing sacituzumab govitecan in mTNBC, metastatic urothelial cancer ("mUC"), hormone receptor-positive ("HR+")/human epidermal growth factor receptor 2-negative ("HER2-") metastatic breast cancer ("mBC"), and other indications of high medical need, (iii) invest in the broader clinical development of the platform (including IMMU-130 and IMMU-140), (iv) continued scale up of manufacturing and manufacturing process improvements, and (v) general working capital requirements. However, in case of regulatory delays or other unforeseen events, we may require additional funding.</span><span style="font-family:inherit;font-size:10pt;"> </span><span style="font-family:inherit;font-size:10pt;">Potential sources of funding in such a case could include (i) the entrance into potential development and commercial partnerships to advance and maximize our full pipeline for mTNBC and beyond in the United States and globally, and (ii) potential private and public capital markets financing. Refer to "Note 9 - Stockholders' Equity" for additional information. </span></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Actual results could differ materially from our expectations as a result of a number of risks and uncertainties, including the risks described in Item 1A Risk Factors, “Factors That May Affect Our Business and Results of Operations,” and elsewhere in this Annual Report on Form 10-K. Our working capital and working capital requirements are affected by numerous factors and such factors may have a negative impact on our liquidity. Principal among these are the success of product commercialization and marketing products, the technological advantages and pricing of our products, the impact of the regulatory requirements applicable to us, and access to capital markets that can provide us with the resources, when necessary, to fund our strategic priorities.</span></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Discussion of Cash Flows</span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following table summarizes our cash flows for the years ended </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;"> and 2018:</span></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"></td></tr><tr><td style="width:59%;"></td><td style="width:1%;"></td><td style="width:18%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:18%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-style:italic;">($ in thousands)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">For the Year Ended December 31,</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">2018 (unaudited)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Net cash used in operating activities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">(222,442</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">(200,311</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Net cash (used in)/provided by investing activities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">(6,849</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">54,635</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Net cash provided by financing activities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">347,181</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">579,010</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:21px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Cash flows used in operating activities</span><span style="font-family:inherit;font-size:10pt;"> </span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net cash used in operating activities for the year ended </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;"> was approximately </span><span style="font-family:inherit;font-size:10pt;">$222.4 million</span><span style="font-family:inherit;font-size:10pt;">, compared to $200.3 million in the prior year. The increase in cash of $22.1 million used in operating for the period was primarily due to increased research and development expenses primarily relate to preparations for the approval and launch of sacituzumab govitecan in the United States for patients with mTNBC, CRL remediation costs including outside manufacturers' organizations services costs, and outside consulting services to improve our manufacturing and regulatory functions.</span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">52</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;text-align:justify;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;" href="#sfb86787ac8304dffbb4bfe7ffcfa7b54"><span style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">Table of Contents</span></a></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></div><div><br/></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:21px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Cash flows (used in)/provided by investing activities</span><span style="font-family:inherit;font-size:10pt;"> </span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net cash used in investing activities for the year ended </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;"> was </span><span style="font-family:inherit;font-size:10pt;">$6.8 million</span><span style="font-family:inherit;font-size:10pt;">, compared to $54.6 million of cash provided by investing activities in prior year. The decrease of $61.4 million was due primarily to a decrease in proceeds from sales or maturities of marketable securities of $73.8 million, offset by purchases of property and equipment of $12.3 million.</span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:21px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Cash flows provided by financing activities</span><span style="font-family:inherit;font-size:10pt;"> </span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net cash provided by financing activities for the year ended </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;">, was </span><span style="font-family:inherit;font-size:10pt;">$347.2 million</span><span style="font-family:inherit;font-size:10pt;">, compared to $579.0 million of cash provided by financing activities during the year ended December 31, 2018. The decrease of $231.8 million was primarily due to receipt of approximately $182.2 million in net proceeds from the issuance of non-recourse debt, warrant exercises of $29.4 million, and lower proceeds from the sale of our common stock of $22.6 million in the comparable period ended December 31, 2018. </span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Working Capital and Cash Requirements</span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Working capital was </span><span style="font-family:inherit;font-size:10pt;">$566.9 million</span><span style="font-family:inherit;font-size:10pt;"> as of </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;"> compared to </span><span style="font-family:inherit;font-size:10pt;">$472.8 million</span><span style="font-family:inherit;font-size:10pt;"> as of December 31, 2018, a $94.1 million </span><span style="font-family:inherit;font-size:10pt;">increase</span><span style="font-family:inherit;font-size:10pt;">. The </span><span style="font-family:inherit;font-size:10pt;">increase</span><span style="font-family:inherit;font-size:10pt;"> in cash was primarily due to net proceeds received from public offering and the at-the-marketing offering offset by increased research and development expenses primarily relate to preparations for the approval and launch of sacituzumab govitecan in the United States for patients with mTNBC, CRL remediation costs including outside manufacturers' organizations services costs, and outside consulting services to improve our manufacturing and regulatory functions.</span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We expect to continue to fund our operations with our current financial resources. Potential sources of funding include (i) the entrance into various potential strategic partnerships targeted at advancing and maximizing our full pipeline for mTNBC and beyond, (ii) the sales and marketing of sacituzumab govitecan as a third-line therapy for mTNBC in the United States (pending FDA approval), and (iii) potential equity and debt financing transactions. </span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">    </span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"></span><span style="font-family:inherit;font-size:10pt;">Until we can generate significant cash through (i) the entrance into various potential strategic partnerships towards advancing and maximizing our full pipeline for mTNBC and beyond, or (ii) the sales and marketing of sacituzumab govitecan as a third-line therapy for mTNBC in the United States (pending FDA approval), we expect to continue to fund our operations with our current financial resources. In the future, if we cannot obtain sufficient funding through the above methods, we could be required to finance future cash needs through the sale of additional equity and/or debt securities in capital markets. However, there can be no assurance that we will be able to raise the additional capital needed to complete our pipeline of research and development programs on commercially acceptable terms, if at all. The capital markets have experienced volatility in recent years, which has resulted in uncertainty with respect to availability of capital and hence the timing to meet an entity’s liquidity needs. Our existing debt may also negatively impact our ability to raise additional capital. If we are unable to raise capital on acceptable terms, our ability to continue our business would be materially and adversely affected.</span><span style="font-family:inherit;font-size:10pt;"> Actual results could differ materially from our expectations as a result of a number of risks and uncertainties, including the risks described in Item 1A Risk Factors, “Factors That May Affect Our Business and Results of Operations,” and elsewhere in our Annual Report on Form 10-K. Our working capital and working capital requirements are affected by numerous factors and such factors may have a negative impact on our liquidity. Principal among these are the success of product commercialization and marketing products, the technological advantages and pricing of our products, the impact of the regulatory requirements applicable to us, and access to capital markets that can provide us with the resources, when necessary, to fund our strategic priorities.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Transition Period Ended December 31, 2018 and the Comparable Period Ended December 31, 2017, and Fiscal Year Ended June 30, 2018 Compared to the Fiscal Year Ended June 30, 2017</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Management’s discussion and analysis of our cash flows for the Transition Period ended December 31, 2018, the comparable period ended December 31, 2017, and fiscal year ended June 30, 2018 compared to the fiscal year ended June 30, 2017 may be found in the “Management’s Discussion and Analysis of Financial Condition and Results of Operations—Cash Flows—section of our Transition Report on Form 10-K for the transition period ended December 31, 2018, filed with the SEC on February 25, 2019.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Off-Balance Sheet Arrangements</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We did not have during the periods presented in this Annual Report on Form 10-K, and we do not currently have, any off-balance sheet arrangements, as defined in the rules and regulations of the SEC.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">53</span></div></div><hr style="page-break-after:always"></hr><div><a id="s5429A53043BF5A57BE33BA4E591BE070"></a></div><div><div style="line-height:120%;text-align:justify;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;" href="#sfb86787ac8304dffbb4bfe7ffcfa7b54"><span style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">Table of Contents</span></a></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></div><div><br/></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Contractual Commitments</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"></span><span style="font-family:inherit;font-size:10pt;">The following table summarizes our outstanding contractual obligations as of the year ended December 31, 2019:</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="29"></td></tr><tr><td style="width:35%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:6%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:6%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:6%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:6%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:6%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:7%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:7%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"> </span></div></td><td colspan="28" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">($ in thousands)</span></div></td><td colspan="28" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Contractual Obligations</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">2020</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">2021</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">2022</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">2023</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">2024</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Thereafter</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Total</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Convertible senior notes</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">7,106</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">—</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">—</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">—</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">—</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">—</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">7,106</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Interest on long-term debt</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">453</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">—</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">—</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">—</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">—</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">—</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">453</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">   Total long-term debt</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">7,559</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">—</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">—</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">—</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">—</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">—</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">7,559</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Purchase obligations </span><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(1)</sup></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">90,015</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">59,765</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">40,796</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">40,796</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">33,026</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">33,026</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">297,424</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Other </span><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(2)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">1,958</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">592</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">100</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">26</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">24</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">23</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">2,723</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Total</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">99,532</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">60,357</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">40,896</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">40,822</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">33,050</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">33,049</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">307,706</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;padding-left:4px;text-align:justify;padding-left:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:inherit;font-size:10pt;">(1)</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Purchase obligations are</span><span style="font-family:inherit;font-size:10pt;"> primarily to purchase commercial manufacturing services including minimum purchase commitments related to product supply contracts and e-sourcing software</span><span style="font-family:inherit;font-size:10pt;">.</span></div></td></tr></table><div style="line-height:120%;padding-left:4px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:inherit;font-size:10pt;">(2)</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other contractual commitments represent vehicles, printers, clinical supply agreements, facility and maintenance agreements, and other equipment. </span></div></td></tr></table><div style="line-height:120%;padding-left:4px;text-align:justify;padding-left:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-left:4px;text-align:justify;padding-left:6px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Effective January 1, 2019, operating lease obligations are presented on our consolidated balance sheet as a right-of-use asset and lease liability for leases with a duration of greater than one year. See Note 1 of Notes to Consolidated Financial Statements contained elsewhere in this report for additional details related to adoption of this change in accounting standard. For more information on the facilities that we occupy under lease arrangements refer to Part I, Item 2. "Properties" of this report.</span></div><div style="line-height:120%;padding-left:4px;text-align:justify;padding-left:24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-left:4px;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The above amounts exclude potential payments related to the sale of future royalties pursuant to our agreement with RPI, under which we are required to make certain royalty payments based on estimated future sales of sacituzumab govitecan. Due to the nature of this arrangement, the future potential payments related to the attainment of regulatory approval and sales-based milestones over a period of several years are inherently uncertain, and accordingly, no amounts have been presented for these future potential payments.</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div><a id="s64CE80BC57B655E58D13682F3A5FA16A"></a></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Item 7A.  Quantitative and Qualitative Disclosures About Market Risk</span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following discussion about our exposure to market risk of financial instruments contains forward-looking statements under the Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those described due to a number of factors, including uncertainties associated with general economic conditions and conditions impacting our industry.</span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">As of the year ended December 31, 2019, we had </span><span style="font-family:inherit;font-size:10pt;">$613.2 million</span><span style="font-family:inherit;font-size:10pt;"> in cash, cash equivalents and marketable securities. Such interest-earning instruments carry a degree of interest rate risk. We do not invest for trading or speculative purposes. We do not have any derivative financial instruments to manage our interest rate risk exposure. A hypothetical 1% change in interest rates at December 31, 2019, would not result in a significant change in the fair market value of our portfolio.</span></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We may be exposed to fluctuations in foreign currencies with regard to certain agreements with service providers. Depending on the strengthening or weakening of the United States dollar, realized and unrealized currency fluctuations could be significant.</span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">54</span></div></div><hr style="page-break-after:always"></hr><div><a id="sAB1A2881EFD35C9E9182717103603243"></a></div><div><div style="line-height:120%;text-align:justify;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;" href="#sfb86787ac8304dffbb4bfe7ffcfa7b54"><span style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">Table of Contents</span></a></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></div><div><br/></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Item 8. </span><span style="font-family:inherit;font-size:10pt;"> </span><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Financial Statements and Supplementary Data</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div><div><a id="s90B45FF4B98A558A8FDFED74DDEB1D2D"></a></div><div style="line-height:120%;padding-bottom:10px;text-align:center;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;font-weight:bold;">Report of Independent Registered Public Accounting Firm</span></div><div style="line-height:120%;padding-bottom:10px;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">To the Stockholders and Board of Directors </span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Immunomedics, Inc.: </span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Opinion on the Consolidated Financial Statements</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We have audited the accompanying consolidated balance sheets of Immunomedics, Inc. and subsidiaries (the Company) as of December 31, 2019 and 2018, the related consolidated statements of comprehensive loss, changes in stockholders’ equity, and cash flows for the year ended December 31, 2019, the six-month transition period ended December 31, 2018, and each of the years in the two-year period ended June 30, 2018, and the related notes (collectively, the consolidated financial statements). In our opinion, the consolidated financial statements present fairly, in all material respects, the financial position of the Company as of December 31, 2019 and 2018, and the results of its operations and its cash flows for the year ended December 31, 2019, the six-month transition period ended December 31, 2018 and each of the years in the two-year period ended June 30, 2018, in conformity with U.S. generally accepted accounting principles. </span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We also have audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States) (PCAOB), the Company’s internal control over financial reporting as of December 31, 2019, based on criteria established in </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Internal Control - Integrated Framework (2013)</span><span style="font-family:inherit;font-size:10pt;"> issued by the Committee of Sponsoring Organizations of the Treadway Commission, and our report dated </span><span style="font-family:inherit;font-size:10pt;">February 27, 2020</span><span style="font-family:inherit;font-size:10pt;"> expressed an unqualified opinion on the effectiveness of the Company’s internal control over financial reporting.</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Basis for Opinion</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">These consolidated financial statements are the responsibility of the Company’s management. Our responsibility is to express an opinion on these consolidated financial statements based on our audits. We are a public accounting firm registered with the PCAOB and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the consolidated financial statements are free of material misstatement, whether due to error or fraud. Our audits included performing procedures to assess the risks of material misstatement of the consolidated financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the consolidated financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the consolidated financial statements. We believe that our audits provide a reasonable basis for our opinion. </span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:6px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Critical Audit Matter</span></div><div style="line-height:120%;padding-bottom:13px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The critical audit matter communicated below is a matter arising from the current period audit of the consolidated financial statements that was communicated or required to be communicated to the audit committee and that: (1) relates to accounts or disclosures that are material to the consolidated financial statements and (2) involved our especially challenging, subjective, or complex judgment. The communication of a critical audit matter does not alter in any way our opinion on the consolidated financial statements, taken as a whole, and we are not, by communicating the critical audit matter below, providing a separate opinion on the critical audit matter or on the accounts or disclosures to which it relates.</span></div><div style="line-height:120%;padding-bottom:13px;text-align:justify;padding-left:41px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Evaluation of liability related to the sale of future royalties</span></div><div style="line-height:120%;padding-bottom:13px;text-align:justify;padding-left:41px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">As discussed in Notes 1, 4, and 6 to the consolidated financial statements, on January 7, 2018, the Company entered into a funding agreement with RPI Finance Trust. The Company accounts for the liability related to the sale of future royalties as a debt financing. The Company estimates the amount of future royalty payments and expected interest expense using the effective interest rate method over the life of the agreement. The carrying value of the liability related to the sale of future royalties at December 31, 2019 was $261.2 million.</span></div><div style="line-height:120%;padding-bottom:13px;text-align:justify;padding-left:41px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We identified the evaluation of the liability related to the sale of future royalties as a critical audit matter because evaluating the estimates of future royalties involved challenging auditor judgment. These estimates involve significant judgment and inherent uncertainties as it relates to the Company's estimate of future sales for which royalties will be paid. Specifically, </span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">55</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;text-align:justify;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;" href="#sfb86787ac8304dffbb4bfe7ffcfa7b54"><span style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">Table of Contents</span></a></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></div><div><br/></div><div style="line-height:120%;padding-bottom:13px;text-align:justify;padding-left:41px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">the date of planned commercialization, anticipated pricing and the patient population assumptions used to calculate the revenue projections involved significant estimation uncertainty.</span></div><div style="line-height:120%;padding-bottom:13px;padding-top:13px;text-align:justify;padding-left:41px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The primary procedures we performed to address this critical audit matter included the following. We tested certain internal controls over the measurement of the liability related to the sale of future royalties, including controls related to the Company’s estimate of future sales and use of third party analysis in developing underlying assumptions. We evaluated the amount recorded for the liability, including classification between current and non-current. In addition, we evaluated the Company’s estimate of future sales, including the date of planned commercialization, anticipated pricing and the patient population, by comparing to available peer data and market research. We recalculated the current year interest expense based on the amortization schedule and estimate of royalties using the effective interest method.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:13px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:10px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">/s/KPMG LLP</span></div><div style="line-height:120%;padding-bottom:13px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:13px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We have served as the Company’s auditor since 2013.</span></div><div style="line-height:120%;padding-bottom:13px;padding-top:13px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">New York, NY</span></div><div style="line-height:120%;padding-bottom:13px;padding-top:13px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">February 27, 2020</span><span style="font-family:inherit;font-size:10pt;"> </span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">56</span></div></div><hr style="page-break-after:always"></hr><div><a id="sBF05D4A5210E5318894EE64B209C0773"></a></div><div><div style="line-height:120%;text-align:justify;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;" href="#sfb86787ac8304dffbb4bfe7ffcfa7b54"><span style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">Table of Contents</span></a></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></div><div><br/></div><div style="line-height:120%;padding-bottom:10px;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Report of Independent Registered Public Accounting Firm</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">To the Stockholders and Board of Directors </span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Immunomedics, Inc.: </span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:6px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Opinion on Internal Control Over Financial Reporting </span></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We have audited Immunomedics, Inc.’s and subsidiaries (the Company) internal control over financial reporting as of December 31, 2019, based on criteria established in </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Internal Control - Integrated Framework (2013)</span><span style="font-family:inherit;font-size:10pt;"> issued by the Committee of Sponsoring Organizations of the Treadway Commission. In our opinion, the Company maintained, in all material respects, effective internal control over financial reporting as of December 31, 2019, based on criteria established in </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Internal Control - Integrated Framework (2013)</span><span style="font-family:inherit;font-size:10pt;"> issued by the Committee of Sponsoring Organizations of the Treadway Commission.</span></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We also have audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States) (PCAOB), the consolidated balance sheets of the Company as of December 31, 2019 and 2018, the related consolidated statements of comprehensive loss, changes in stockholders’ equity, and cash flows for the year ended December 31, 2019, the six-month transition period ended December 31, 2018, and each of the years in the two-year period ended June 30, 2018, and the related notes (collectively, the consolidated financial statements), and our report dated </span><span style="font-family:inherit;font-size:10pt;">February 27, 2020</span><span style="font-family:inherit;font-size:10pt;"> expressed an unqualified opinion on those consolidated financial statements.</span></div><div style="line-height:120%;padding-bottom:6px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Basis for Opinion </span></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company’s management is responsible for maintaining effective internal control over financial reporting and for its assessment of the effectiveness of internal control over financial reporting, included in the accompanying Management’s Report on Internal Control Over Financial Reporting. Our responsibility is to express an opinion on the Company’s internal control over financial reporting based on our audit. We are a public accounting firm registered with the PCAOB and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.</span></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We conducted our audit in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether effective internal control over financial reporting was maintained in all material respects. Our audit of internal control over financial reporting included obtaining an understanding of internal control over financial reporting, assessing the risk that a material weakness exists, and testing and evaluating the design and operating effectiveness of internal control based on the assessed risk. Our audit also included performing such other procedures as we considered necessary in the circumstances. We believe that our audit provides a reasonable basis for our opinion.</span></div><div style="line-height:120%;padding-bottom:6px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Definition and Limitations of Internal Control Over Financial Reporting </span></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">A company’s internal control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. A company’s internal control over financial reporting includes those policies and procedures that (1) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the company; (2) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the company are being made only in accordance with authorizations of management and directors of the company; and (3) provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use, or disposition of the company’s assets that could have a material effect on the financial statements. </span></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate. </span></div><div style="line-height:120%;padding-bottom:10px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:10px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">/s/ KPMG LLP</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">New York, NY</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">February 27, 2020</span><span style="font-family:inherit;font-size:10pt;"> </span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">57</span></div></div><hr style="page-break-after:always"></hr><div><a id="s25104645997655BC92AB9A0BAD1CCC72"></a></div><div><div style="line-height:120%;text-align:justify;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;" href="#sfb86787ac8304dffbb4bfe7ffcfa7b54"><span style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">Table of Contents</span></a></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></div><div><br/></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">IMMUNOMEDICS, INC. AND SUBSIDIARIES</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">CONSOLIDATED BALANCE SHEETS</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">(Dollars in thousands, except per share amounts)</span><span style="font-family:inherit;font-size:10pt;"> </span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="9"></td></tr><tr><td style="width:60%;"></td><td style="width:8%;"></td><td style="width:1%;"></td><td style="width:13%;"></td><td style="width:1%;"></td><td style="width:2%;"></td><td style="width:1%;"></td><td style="width:13%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">December 31,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">2018</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">ASSETS</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Current Assets:</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Cash and cash equivalents</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d22909209e861-wk-Fact-DC4AE9A8FE4AE0112236D1D0184B774F" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="FI2019Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">608,628</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d22909209e880-wk-Fact-71ACCBE1F94A85D78382D1D0184B1F30" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="FI2018Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">492,860</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Marketable securities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d22909209e900-wk-Fact-A83535AA97BD4D1198A0D1D0184B1567" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" contextRef="FI2019Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">4,550</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d22909209e919-wk-Fact-E55C8926040E78940F72D1D0184BA09B" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" contextRef="FI2018Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">4,941</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Accounts receivable, net of allowances of $0 at December 31, 2019</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d22909209e944-wk-Fact-A1469DD4CFE6B9712277D1D0180B0BAB" name="us-gaap:AccountsReceivableNetCurrent" contextRef="FI2019Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">295</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d22909209e963-wk-Fact-1D5DCD038A71F97E0153D1D0181BE42A" name="us-gaap:AccountsReceivableNetCurrent" contextRef="FI2018Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">—</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Prepaid expenses</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d22909209e988-wk-Fact-A4208F98B347CFB27FA6D1D0184BEF32" name="us-gaap:PrepaidExpenseCurrent" contextRef="FI2019Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">21,818</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d22909209e1007-wk-Fact-7135DAEA87FF6F71EE6BD1D0184B74D8" name="us-gaap:PrepaidExpenseCurrent" contextRef="FI2018Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">5,354</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Other current assets</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d22909209e1032-wk-Fact-5FD8820299B30BE9B4C2D1D0185BF435" name="us-gaap:OtherAssetsCurrent" contextRef="FI2019Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">3,413</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d22909209e1051-wk-Fact-9555C1EB841AAC68D155D1D0185B86B4" name="us-gaap:OtherAssetsCurrent" contextRef="FI2018Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">1,348</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Total current assets</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d22909209e1076-wk-Fact-1C8D17C3369AE885A18AD1D0185BC208" name="us-gaap:AssetsCurrent" contextRef="FI2019Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">638,704</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d22909209e1095-wk-Fact-4F67B160758AA362C8A5D1D0184B4028" name="us-gaap:AssetsCurrent" contextRef="FI2018Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">504,503</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Property and equipment, net of accumulated depreciation and amortization of $7,925 and $4,316 at December 31, 2019 and 2018, respectively</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d22909209e1120-wk-Fact-E3C75C1700F42C00467BD1D0184B9605" name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="FI2019Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">32,762</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d22909209e1139-wk-Fact-10C952140E4204F13D7BD1D0184B37BF" name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="FI2018Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">23,469</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Other long-term assets</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d22909209e1165-wk-Fact-7051C4AAC3558AAC8642D1D0184B472D" name="us-gaap:OtherAssetsNoncurrent" contextRef="FI2019Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">256</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d22909209e1184-wk-Fact-1A2763FDD1D0DD9F0C6CD1D0184B4C83" name="us-gaap:OtherAssetsNoncurrent" contextRef="FI2018Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">68</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Total Assets</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d22909209e1214-wk-Fact-80C553DD9A54032E3C78D1D0184BC218" name="us-gaap:Assets" contextRef="FI2019Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">671,722</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d22909209e1233-wk-Fact-47299FFA8AE4C494972ED1D0185BB94A" name="us-gaap:Assets" contextRef="FI2018Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">528,040</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">LIABILITIES AND STOCKHOLDERS' EQUITY </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Current Liabilities:</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Accounts payable and accrued expenses</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d22909209e1396-wk-Fact-7C2A859B877F0F655F76D6F43C09A49D" name="us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent" contextRef="FI2019Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">60,860</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d22909209e1415-wk-Fact-228C40E00DEB07C9D25AD1D0185B2721" name="us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent" contextRef="FI2018Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">31,722</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Liability related to sale of future royalties - current</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d22909209e1435-wk-Fact-43384EACEC23B8D45E88D6F43C5C946E" name="immu:LiabilitiesRelatedToTheSaleOfFutureRoyaltiesCurrent" contextRef="FI2019Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">3,455</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d22909209e1454-wk-Fact-B0F60D4AEBFD1B158EF5D1D0184B60FE" name="immu:LiabilitiesRelatedToTheSaleOfFutureRoyaltiesCurrent" contextRef="FI2018Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">—</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Lease liability - current</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d22909209e1479-wk-Fact-F784E40002191509ACB0D6EF61131A61" name="us-gaap:OperatingLeaseLiabilityCurrent" contextRef="FI2019Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">337</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">—</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Convertible senior notes, net</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d22909209e1523-wk-Fact-C99BB883EF6A99D6095639991F3EDE2D" name="us-gaap:ConvertibleDebtCurrent" contextRef="FI2019Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">7,106</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d22909209e1542-wk-Fact-06BBEA18318A0EE351D43999452EAD94" name="us-gaap:ConvertibleDebtCurrent" contextRef="FI2018Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">—</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:44px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Total current liabilities</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d22909209e1567-wk-Fact-85F2508459CCE488A4FBD6F43DA928A8" name="us-gaap:LiabilitiesCurrent" contextRef="FI2019Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">71,758</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d22909209e1586-wk-Fact-BEF0B9381A2BF0D5D374D1D0183C3C08" name="us-gaap:LiabilitiesCurrent" contextRef="FI2018Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">31,722</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Convertible senior notes, net</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d22909209e1611-wk-Fact-ABFE52DA7DA2682A9E4A3998D248E88A" name="us-gaap:ConvertibleDebtNoncurrent" contextRef="FI2019Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">—</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d22909209e1630-wk-Fact-3A1B4E3AF80548BB44BFD1D0184BA3DD" name="us-gaap:ConvertibleDebtNoncurrent" contextRef="FI2018Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">7,055</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Liability related to sale of future royalties - non-current</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d22909209e1656-wk-Fact-187BAD387A11001FED70D6F43E165A34" name="immu:LiabilitiesRelatedToTheSaleOfFutureRoyaltiesNoncurrent" contextRef="FI2019Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">257,769</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d22909209e1675-wk-Fact-527EDD58BB7E9BE310DAD1D0184B1531" name="immu:LiabilitiesRelatedToTheSaleOfFutureRoyaltiesNoncurrent" contextRef="FI2018Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">221,295</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Deferred revenues</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d22909209e1700-wk-Fact-B0756F150582F0979660D6F06A9A83B3" name="us-gaap:ContractWithCustomerLiabilityNoncurrent" contextRef="FI2019Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">65,000</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d22909209e1719-wk-Fact-82FD8FE0EB15FA74DD07D1D0184BB963" name="us-gaap:ContractWithCustomerLiabilityNoncurrent" contextRef="FI2018Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">—</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Other long-term liabilities</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d22909209e1744-wk-Fact-D2CEE59A32500E97367CD6F43EA9ECCC" name="us-gaap:OtherLiabilitiesNoncurrent" contextRef="FI2019Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">9,965</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d22909209e1763-wk-Fact-58CDC7E3063990F900ADD1D0184B597C" name="us-gaap:OtherLiabilitiesNoncurrent" contextRef="FI2018Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">2,119</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Total Liabilities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d22909209e1788-wk-Fact-214265571E5A5CEB1964D6F43EFF16E6" name="us-gaap:Liabilities" contextRef="FI2019Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">404,492</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d22909209e1807-wk-Fact-53110366302F72C99EA1D1D0184B0A93" name="us-gaap:Liabilities" contextRef="FI2018Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">262,191</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Commitments and Contingencies (Note 14)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d22909209e1832-wk-Fact-741E6098A5A97DC4C6BAD1D0184ACEE5" name="us-gaap:CommitmentsAndContingencies" contextRef="FI2019Q4" unitRef="usd" xsi:nil="true" scale="0" format="ixt:nocontent"></ix:nonFraction></span><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d22909209e1850-wk-Fact-680F6FE3AF52F300BE34D1D0184A42DB" name="us-gaap:CommitmentsAndContingencies" contextRef="FI2018Q4" unitRef="usd" xsi:nil="true" scale="0" format="ixt:nocontent"></ix:nonFraction></span><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Stockholders' Equity:</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Convertible preferred stock, $0.01 par value; authorized 10,000,000 shares; no shares issued and outstanding at December 31, 2019 and 2018</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d22909209e1920-wk-Fact-DA59FC4E132BEC863F12D1D0184BC4EB" name="us-gaap:ConvertiblePreferredStockNonredeemableOrRedeemableIssuerOptionValue" contextRef="FI2019Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">—</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d22909209e1939-wk-Fact-CC17A2E44C85903DED4CD1D0184B0057" name="us-gaap:ConvertiblePreferredStockNonredeemableOrRedeemableIssuerOptionValue" contextRef="FI2018Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">—</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Common stock, $0.01 par value; authorized 250,000,000 shares; issued 212,529,313 shares and outstanding 212,409,692 shares at December 31, 2019; issued 190,445,795 shares and outstanding 190,411,070 shares at December 31, 2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d22909209e1964-wk-Fact-B8CA1105BAA6A50FB566D1D0184BD52E" name="us-gaap:CommonStockValue" contextRef="FI2019Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">2,125</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d22909209e1983-wk-Fact-E6B46C8E9F9421C7E93CD1D0185B44F2" name="us-gaap:CommonStockValue" contextRef="FI2018Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">1,905</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Capital contributed in excess of par</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d22909209e2008-wk-Fact-0B2E5AE6FF9EEFB4D148D1D0184B8831" name="us-gaap:AdditionalPaidInCapitalCommonStock" contextRef="FI2019Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">1,579,205</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d22909209e2027-wk-Fact-5238DE08BC981CFA2DB6D1D0184BFCBE" name="us-gaap:AdditionalPaidInCapitalCommonStock" contextRef="FI2018Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">1,219,237</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Treasury stock, at cost: 119,621 shares at December 31, 2019 and 34,725 shares at December 31, 2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(<ix:nonFraction id="d22909209e2052-wk-Fact-6832AA0BD09019B3A452D1D0184BD7E5" name="us-gaap:TreasuryStockValue" contextRef="FI2019Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">2,095</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(<ix:nonFraction id="d22909209e2072-wk-Fact-837F7A4A4EFC4A029988D1D0184BC8F8" name="us-gaap:TreasuryStockValue" contextRef="FI2018Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">824</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Accumulated deficit</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(<ix:nonFraction id="d22909209e2098-wk-Fact-38CD3235136A96B5013ED1D0185BE7F9" name="us-gaap:RetainedEarningsAccumulatedDeficit" contextRef="FI2019Q4" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">1,310,406</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(<ix:nonFraction id="d22909209e2118-wk-Fact-816A33B8BEF48FA4F723D1D0184B19AE" name="us-gaap:RetainedEarningsAccumulatedDeficit" contextRef="FI2018Q4" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">953,216</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Accumulated other comprehensive loss</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(<ix:nonFraction id="d22909209e2145-wk-Fact-49954B6AB2E9E8F572FED1D0184B71CA" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" contextRef="FI2019Q4" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">568</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(<ix:nonFraction id="d22909209e2165-wk-Fact-B2259B9501A45FF8FFA3D1D0184BF8F0" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" contextRef="FI2018Q4" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">351</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Total Immunomedics, Inc. stockholders' equity</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d22909209e2191-wk-Fact-B8A81A216826F9E8600DD1D0184B17BF" name="us-gaap:StockholdersEquity" contextRef="FI2019Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">268,261</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d22909209e2210-wk-Fact-958C727F7AC1A85077B4D1D0185B081F" name="us-gaap:StockholdersEquity" contextRef="FI2018Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">266,751</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Noncontrolling interest in subsidiary</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(<ix:nonFraction id="d22909209e2235-wk-Fact-5625D0ABF40EF7CE6A44D1D0184B42D7" name="us-gaap:MinorityInterest" contextRef="FI2019Q4" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">1,031</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(<ix:nonFraction id="d22909209e2255-wk-Fact-4875B5458E2F189891CAD1D0184B9A42" name="us-gaap:MinorityInterest" contextRef="FI2018Q4" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">902</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Total Stockholders' Equity</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d22909209e2281-wk-Fact-506CDA3CCB6716A29946D1D0184B0B3B" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="FI2019Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">267,230</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d22909209e2300-wk-Fact-82C9BC65B21B97B100C5D1D0184B8D2C" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="FI2018Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">265,849</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Total Liabilities and Stockholders' Equity</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d22909209e2330-wk-Fact-AE58C2CD0AA2D69AF270D1D0183C7921" name="us-gaap:LiabilitiesAndStockholdersEquity" contextRef="FI2019Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">671,722</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d22909209e2349-wk-Fact-B97BD1E8CA270EA60E13D1D0184B0E07" name="us-gaap:LiabilitiesAndStockholdersEquity" contextRef="FI2018Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">528,040</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;padding-top:10px;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">See accompanying notes to consolidated financial statements.</span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">58</span></div></div><hr style="page-break-after:always"></hr><div><a id="s4AA0C616ADE65A8BA6F55E0AEFB671DB"></a></div><div><div style="line-height:120%;text-align:justify;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;" href="#sfb86787ac8304dffbb4bfe7ffcfa7b54"><span style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">Table of Contents</span></a></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></div><div><br/></div><div style="line-height:120%;text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">IMMUNOMEDICS, INC. AND SUBSIDIARIES</span></div><div style="line-height:120%;text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">CONSOLIDATED STATEMENTS OF</span></div><div style="line-height:120%;text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">COMPREHENSIVE LOSS</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">(Dollars in thousands, except per share amounts)</span><span style="font-family:inherit;font-size:10pt;"> </span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"></td></tr><tr><td style="width:41%;"></td><td style="width:1%;"></td><td style="width:13%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:13%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"> </span></div></td><td colspan="3" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Year Ended December 31, 2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">For the Transition Period Ended December 31, 2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Years Ended June 30,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">2017</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Revenues:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Product sales</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d22912578e928-wk-Fact-849307BE2C2CD3186A6ED71306A09326" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2019Q4YTD_srt_ProductOrServiceAxis_immu_ProductSalesMember" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">—</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d22912578e947-wk-Fact-0C066261783ADD1F0B3ED1D0184BE183" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="D2018Q4Jul01-Dec31_srt_ProductOrServiceAxis_immu_ProductSalesMember" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">—</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d22912578e966-wk-Fact-6FC762CDD646E7C09EF0D1D0185B1329" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="D2018Q4Jul12017toJun302018_srt_ProductOrServiceAxis_immu_ProductSalesMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">1,501</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d22912578e986-wk-Fact-6BAED3D9F7E84118916BD1D0185B2530" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="D2017Q4Jul012016toJun302017_srt_ProductOrServiceAxis_immu_ProductSalesMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">2,443</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">License fee and other revenues</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d22912578e1001-wk-Fact-8BCE2A850F609D812959D713090D74E0" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2019Q4YTD_srt_ProductOrServiceAxis_immu_LicenseFreeAndOtherRevenueMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">295</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d22912578e1020-wk-Fact-E620504A2B4D663BB59ED1D0185BA0EE" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="D2018Q4Jul01-Dec31_srt_ProductOrServiceAxis_immu_LicenseFreeAndOtherRevenueMember" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">—</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d22912578e1039-wk-Fact-33CD22EEB4CF1C9D2EC9D1D01865A44E" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="D2018Q4Jul12017toJun302018_srt_ProductOrServiceAxis_immu_LicenseFreeAndOtherRevenueMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">330</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d22912578e1059-wk-Fact-954F00B17E6FF93F9AD9D1D0184BC7C4" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="D2017Q4Jul012016toJun302017_srt_ProductOrServiceAxis_immu_LicenseFreeAndOtherRevenueMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">284</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Research and development</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d22912578e1079-wk-Fact-B967A541E52B74E1F92DD7130AD3A9AD" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2019Q4YTD_srt_ProductOrServiceAxis_immu_ResearchandDevelopmentMember" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">—</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d22912578e1098-wk-Fact-96102BA3DFA71F2AC990D1D0185B5DEC" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="D2018Q4Jul01-Dec31_srt_ProductOrServiceAxis_immu_ResearchandDevelopmentMember" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">—</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d22912578e1117-wk-Fact-6338BB5F750EA369909DD1D0185B97AB" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="D2018Q4Jul12017toJun302018_srt_ProductOrServiceAxis_immu_ResearchandDevelopmentMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">325</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d22912578e1137-wk-Fact-84B823585AAADDB57909D1D0180BDFC6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="D2017Q4Jul012016toJun302017_srt_ProductOrServiceAxis_immu_ResearchandDevelopmentMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">364</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Total revenues</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d22912578e1157-wk-Fact-BE0339946F50338D197BD7130D1D6330" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">295</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d22912578e1176-wk-Fact-2E4FA2FEB6C1E00677A8D1D0185B2147" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="D2018Q4Jul01-Dec31" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">—</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d22912578e1195-wk-Fact-6AA171CFEB17092C01B8D1D0185B165F" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="D2018Q4Jul12017toJun302018" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">2,156</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d22912578e1215-wk-Fact-B9CB6F1C411F3D42094ED1D018642B18" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="D2017Q4Jul012016toJun302017" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">3,091</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Costs and expenses:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Costs of goods sold</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d22912578e1399-wk-Fact-D96853E3535829A15A7ED713D1E90369" name="us-gaap:CostOfRevenue" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">—</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d22912578e1418-wk-Fact-D7A81EF6C3BBFF9ABDD8D1D0185BD9F0" name="us-gaap:CostOfRevenue" contextRef="D2018Q4Jul01-Dec31" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">—</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d22912578e1437-wk-Fact-F91439BB83BA1B1BF2F0D1D0185BAA11" name="us-gaap:CostOfRevenue" contextRef="D2018Q4Jul12017toJun302018" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">613</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d22912578e1457-wk-Fact-30B02726B27AF75E5B85D1D0185B7765" name="us-gaap:CostOfRevenue" contextRef="D2017Q4Jul012016toJun302017" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">483</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Research and development</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d22912578e1477-wk-Fact-B11FDF4ADA5C9F46A3E2D713D2BF53AF" name="us-gaap:ResearchAndDevelopmentExpense" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">254,871</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d22912578e1496-wk-Fact-E7B9D3701A1EC92A4331D1D018659239" name="us-gaap:ResearchAndDevelopmentExpense" contextRef="D2018Q4Jul01-Dec31" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">93,887</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d22912578e1515-wk-Fact-1658CE7B1021821A9ED4D1D0184BB922" name="us-gaap:ResearchAndDevelopmentExpense" contextRef="D2018Q4Jul12017toJun302018" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">99,283</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d22912578e1535-wk-Fact-8DD50C65D904A7967D5BD1D0180BDBB9" name="us-gaap:ResearchAndDevelopmentExpense" contextRef="D2017Q4Jul012016toJun302017" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">51,776</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Sales and marketing</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d22912578e1556-wk-Fact-3910843FD69E0648ED42D713D3A776AB" name="us-gaap:SellingAndMarketingExpense" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">26,459</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d22912578e1575-wk-Fact-BA56985542020B20470ED1D018650FED" name="us-gaap:SellingAndMarketingExpense" contextRef="D2018Q4Jul01-Dec31" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">19,834</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d22912578e1594-wk-Fact-7D85183C7160CAF5FF77D1D0184B150F" name="us-gaap:SellingAndMarketingExpense" contextRef="D2018Q4Jul12017toJun302018" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">6,822</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d22912578e1614-wk-Fact-ECA0FE7699DA13B71737D1D0185B6DC3" name="us-gaap:SellingAndMarketingExpense" contextRef="D2017Q4Jul012016toJun302017" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">873</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">General and administrative</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d22912578e1634-wk-Fact-2BC47F20F787BA724609D713D45A454C" name="us-gaap:GeneralAndAdministrativeExpense" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">43,803</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d22912578e1653-wk-Fact-A8429C6D7C690F620C60D1D0184B8513" name="us-gaap:GeneralAndAdministrativeExpense" contextRef="D2018Q4Jul01-Dec31" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">30,814</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d22912578e1672-wk-Fact-02E40748F19333AA1661D1D0185B7B1D" name="us-gaap:GeneralAndAdministrativeExpense" contextRef="D2018Q4Jul12017toJun302018" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">36,485</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d22912578e1692-wk-Fact-0BAE8D6BF3442F357E3FD1D0185BFF20" name="us-gaap:GeneralAndAdministrativeExpense" contextRef="D2017Q4Jul012016toJun302017" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">29,109</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Total costs and expenses</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d22912578e1712-wk-Fact-88AD0497CD31D47BCF2AD713D57AEA2E" name="us-gaap:CostsAndExpenses" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">325,133</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d22912578e1731-wk-Fact-EF12E63A7E33163ADE83D1D0184BD97E" name="us-gaap:CostsAndExpenses" contextRef="D2018Q4Jul01-Dec31" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">144,535</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d22912578e1750-wk-Fact-74E82701703D0AB64498D1D0184B68C6" name="us-gaap:CostsAndExpenses" contextRef="D2018Q4Jul12017toJun302018" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">143,203</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d22912578e1770-wk-Fact-7D884864882DD0188911D1D0185B6D18" name="us-gaap:CostsAndExpenses" contextRef="D2017Q4Jul012016toJun302017" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">82,241</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Operating loss</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(<ix:nonFraction id="d22912578e1790-wk-Fact-2568334275D383D7F60FD713D620B870" name="us-gaap:OperatingIncomeLoss" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">324,838</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(<ix:nonFraction id="d22912578e1810-wk-Fact-6A7566400D8A7373C6A9D1D0185BF0A5" name="us-gaap:OperatingIncomeLoss" contextRef="D2018Q4Jul01-Dec31" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">144,535</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(<ix:nonFraction id="d22912578e1830-wk-Fact-2D77134220E2B92918C3D1D0185BD470" name="us-gaap:OperatingIncomeLoss" contextRef="D2018Q4Jul12017toJun302018" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">141,047</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(<ix:nonFraction id="d22912578e1851-wk-Fact-8494A2DF4A52A832E0A6D1D01865C60C" name="us-gaap:OperatingIncomeLoss" contextRef="D2017Q4Jul012016toJun302017" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">79,150</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Changes in fair market value of warrant liabilities</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d22912578e1872-wk-Fact-D2E66984117CBB450CBED713D6D0FE4C" name="us-gaap:FairValueAdjustmentOfWarrants" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">—</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d22912578e1891-wk-Fact-1D5D4506E00364D1DE67D1D0180B6BBD" name="us-gaap:FairValueAdjustmentOfWarrants" contextRef="D2018Q4Jul01-Dec31" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">1,404</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(<ix:nonFraction id="d22912578e1910-wk-Fact-E26CFE363B06D151ED08D1D0185B3F62" name="us-gaap:FairValueAdjustmentOfWarrants" contextRef="D2018Q4Jul12017toJun302018" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">108,636</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(<ix:nonFraction id="d22912578e1931-wk-Fact-F37ECCDD6B19E07A84DED1D0184BF9B9" name="us-gaap:FairValueAdjustmentOfWarrants" contextRef="D2017Q4Jul012016toJun302017" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">61,074</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Warrant related expenses</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d22912578e1952-wk-Fact-19C533DBB7AA881D2E4ED713D76EE172" name="us-gaap:AdjustmentOfWarrantsGrantedForServices" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">—</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d22912578e1971-wk-Fact-02AC75F1B59F9F5CF65BD1D0180B5321" name="us-gaap:AdjustmentOfWarrantsGrantedForServices" contextRef="D2018Q4Jul01-Dec31" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">—</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d22912578e1990-wk-Fact-98B95CF860F0B356D8DDD1D0185B395E" name="us-gaap:AdjustmentOfWarrantsGrantedForServices" contextRef="D2018Q4Jul12017toJun302018" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">—</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(<ix:nonFraction id="d22912578e2010-wk-Fact-797C88AEF9ED2C7F4EE3D1D0184B05E0" name="us-gaap:AdjustmentOfWarrantsGrantedForServices" contextRef="D2017Q4Jul012016toJun302017" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">7,649</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Interest expense</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(<ix:nonFraction id="d22912578e2031-wk-Fact-30DB59B73DB242E363E4D713D8165D09" name="us-gaap:InterestExpense" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">40,337</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(<ix:nonFraction id="d22912578e2051-wk-Fact-72BD364920F18DA1D99FD1D0184BF821" name="us-gaap:InterestExpense" contextRef="D2018Q4Jul01-Dec31" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">20,017</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(<ix:nonFraction id="d22912578e2071-wk-Fact-3B66A61233A9BCBFD3C6D1D0184B14CE" name="us-gaap:InterestExpense" contextRef="D2018Q4Jul12017toJun302018" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">23,255</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(<ix:nonFraction id="d22912578e2092-wk-Fact-64CD7BD68675331EA7D7D1D0184BC04E" name="us-gaap:InterestExpense" contextRef="D2017Q4Jul012016toJun302017" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">5,480</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Interest and other income</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d22912578e2113-wk-Fact-E6EFA523230B1891F546D713D8C5C87B" name="us-gaap:InterestAndOtherIncome" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">7,856</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d22912578e2132-wk-Fact-CD1DEAA5D3CB0A9A2D0CD1D0185B05F9" name="us-gaap:InterestAndOtherIncome" contextRef="D2018Q4Jul01-Dec31" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">6,106</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d22912578e2151-wk-Fact-E3CC4A7B8168960651CDD1D0184BD62C" name="us-gaap:InterestAndOtherIncome" contextRef="D2018Q4Jul12017toJun302018" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">5,493</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d22912578e2171-wk-Fact-22FC6DDEA7D24B3DFE08D1D018653AB2" name="us-gaap:InterestAndOtherIncome" contextRef="D2017Q4Jul012016toJun302017" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">431</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Loss on induced exchanges of debt</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d22912578e2191-wk-Fact-CA82D7B93B7BC5D63761D713D96D415C" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">—</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(<ix:nonFraction id="d22912578e2210-wk-Fact-9369F26ACFE94B195D3AD1D0184B6189" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" contextRef="D2018Q4Jul01-Dec31" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">897</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(<ix:nonFraction id="d22912578e2230-wk-Fact-AF53D3B24B925925A685D1D0184B9F0E" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" contextRef="D2018Q4Jul12017toJun302018" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">13,005</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d22912578e2251-wk-Fact-ABDED49C91AE1FDB5EEED1D0185B4263" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" contextRef="D2017Q4Jul012016toJun302017" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">—</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Other financing expenses</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d22912578e2271-wk-Fact-9FF5F26A0EBF2991A6EDD713DA20D6E6" name="immu:OtherFinancingExpenseIncome" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">—</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d22912578e2290-wk-Fact-8B448EE696535CF40EFBD1D0180B65F2" name="immu:OtherFinancingExpenseIncome" contextRef="D2018Q4Jul01-Dec31" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">—</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d22912578e2309-wk-Fact-94AA403DF954FBF14CEAD1D0185B029B" name="immu:OtherFinancingExpenseIncome" contextRef="D2018Q4Jul12017toJun302018" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">—</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(<ix:nonFraction id="d22912578e2329-wk-Fact-6F29950E9C7A54D4FC47D1D0184BD95B" name="immu:OtherFinancingExpenseIncome" contextRef="D2017Q4Jul012016toJun302017" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">347</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Insurance reimbursement</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d22912578e2350-wk-Fact-5E4FB2AC018E1393D369D713DACB3286" name="us-gaap:GainOnBusinessInterruptionInsuranceRecovery" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">—</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d22912578e2369-wk-Fact-C6656772A985441CF9A5D1D01865D74C" name="us-gaap:GainOnBusinessInterruptionInsuranceRecovery" contextRef="D2018Q4Jul01-Dec31" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">190</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d22912578e2388-wk-Fact-ACCD4355D74144BD1A93D1D0185BD31D" name="us-gaap:GainOnBusinessInterruptionInsuranceRecovery" contextRef="D2018Q4Jul12017toJun302018" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">6,638</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d22912578e2408-wk-Fact-EFB91C217296D207904AD1D0185BD28C" name="us-gaap:GainOnBusinessInterruptionInsuranceRecovery" contextRef="D2017Q4Jul012016toJun302017" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">—</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Foreign currency transaction gain, net</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d22912578e2429-wk-Fact-DED3ACC95C175ADA7E4AD713DB6B9BD3" name="us-gaap:ForeignCurrencyTransactionGainLossBeforeTax" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">—</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d22912578e2448-wk-Fact-4B99F3A7086D3766FA07D1D0180BC974" name="us-gaap:ForeignCurrencyTransactionGainLossBeforeTax" contextRef="D2018Q4Jul01-Dec31" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">—</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d22912578e2467-wk-Fact-65CEFCDA87E6033DD4F7D1D0184B28A7" name="us-gaap:ForeignCurrencyTransactionGainLossBeforeTax" contextRef="D2018Q4Jul12017toJun302018" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">81</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d22912578e2487-wk-Fact-BCB0F6F64A867205F2ECD1D0184B9E46" name="us-gaap:ForeignCurrencyTransactionGainLossBeforeTax" contextRef="D2017Q4Jul012016toJun302017" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">23</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Loss before income tax</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(<ix:nonFraction id="d22912578e2507-wk-Fact-2A0CA103AC2C49597E93D713DBFF3115" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">357,319</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(<ix:nonFraction id="d22912578e2527-wk-Fact-44EE05DB67B05FD87789D1D0184B91BD" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" contextRef="D2018Q4Jul01-Dec31" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">157,749</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(<ix:nonFraction id="d22912578e2547-wk-Fact-5CE89222731660B2B1BFD1D0184B3DBE" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" contextRef="D2018Q4Jul12017toJun302018" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">273,731</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(<ix:nonFraction id="d22912578e2568-wk-Fact-EF5770EEDA0F69E63917D1D01864AC18" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" contextRef="D2017Q4Jul012016toJun302017" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">153,246</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Income tax expense</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d22912578e2589-wk-Fact-3CC832BF5EF3C97185F1D713DCC31FBC" name="us-gaap:IncomeTaxExpenseBenefit" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">—</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d22912578e2608-wk-Fact-32780205060E315B26CED1D0185B11B7" name="us-gaap:IncomeTaxExpenseBenefit" contextRef="D2018Q4Jul01-Dec31" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">—</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(<ix:nonFraction id="d22912578e2627-wk-Fact-5584AB2B0AA443CB47F2D1D0180B2C0B" name="us-gaap:IncomeTaxExpenseBenefit" contextRef="D2018Q4Jul12017toJun302018" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">156</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(<ix:nonFraction id="d22912578e2648-wk-Fact-B3DF2F8B547FC4AC0F35D1D0184B2343" name="us-gaap:IncomeTaxExpenseBenefit" contextRef="D2017Q4Jul012016toJun302017" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">20</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Net loss</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(<ix:nonFraction id="d22912578e2669-wk-Fact-29F9B6EF360FC370699FD713DDBDA593" name="us-gaap:ProfitLoss" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">357,319</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(<ix:nonFraction id="d22912578e2689-wk-Fact-5ACF8E8FD2F7A88E6F00D1D0184B9305" name="us-gaap:ProfitLoss" contextRef="D2018Q4Jul01-Dec31" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">157,749</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(<ix:nonFraction id="d22912578e2709-wk-Fact-6CE3D07A35B1D83DEB81D1D0184B1FFE" name="us-gaap:ProfitLoss" contextRef="D2018Q4Jul12017toJun302018" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">273,887</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(<ix:nonFraction id="d22912578e2730-wk-Fact-AC988A2DC8A22FB48CBDD1D018651B52" name="us-gaap:ProfitLoss" contextRef="D2017Q4Jul012016toJun302017" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">153,266</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Net loss attributable to noncontrolling interest</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(<ix:nonFraction id="d22912578e2751-wk-Fact-299E907197C83C6AC3A5D713DEA358C6" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">129</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(<ix:nonFraction id="d22912578e2771-wk-Fact-E993EB3C6C253F4641ECD1D0184BBB7B" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" contextRef="D2018Q4Jul01-Dec31" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">81</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(<ix:nonFraction id="d22912578e2791-wk-Fact-8809DF416D0B3AF3681DD1D0184B3665" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" contextRef="D2018Q4Jul12017toJun302018" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">50</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(<ix:nonFraction id="d22912578e2812-wk-Fact-8457D6CBD4E1DE0EBDB0D1D0184B4095" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" contextRef="D2017Q4Jul012016toJun302017" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">60</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Net loss attributable to Immunomedics, Inc. stockholders</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(<ix:nonFraction id="d22912578e2838-wk-Fact-3F7D94E4DE1AC85D3DD4D713DFB524CA" name="us-gaap:NetIncomeLoss" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">357,190</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(<ix:nonFraction id="d22912578e2858-wk-Fact-9C21D92CEF83CA62B07BD1D0184B6F86" name="us-gaap:NetIncomeLoss" contextRef="D2018Q4Jul01-Dec31" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">157,668</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(<ix:nonFraction id="d22912578e2878-wk-Fact-3D5D8EF8B296CD34AF8AD1D0184B6D05" name="us-gaap:NetIncomeLoss" contextRef="D2018Q4Jul12017toJun302018" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">273,837</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(<ix:nonFraction id="d22912578e2899-wk-Fact-AB40936ABCF6162B822DD1D0185B6E17" name="us-gaap:NetIncomeLoss" contextRef="D2017Q4Jul012016toJun302017" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">153,206</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Loss per common share attributable to Immunomedics, Inc. stockholders (basic and diluted):</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(<ix:nonFraction id="d22912578e2920-wk-Fact-1E182124567E5A939773D713E086B425" name="us-gaap:EarningsPerShareBasicAndDiluted" contextRef="FD2019Q4YTD" unitRef="usdPerShare" decimals="2" scale="0" sign="-" format="ixt:numdotdecimal">1.84</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(<ix:nonFraction id="d22912578e2940-wk-Fact-503C5F49D656E570EF19D1D0184B3CD7" name="us-gaap:EarningsPerShareBasicAndDiluted" contextRef="D2018Q4Jul01-Dec31" unitRef="usdPerShare" decimals="2" scale="0" sign="-" format="ixt:numdotdecimal">0.84</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(<ix:nonFraction id="d22912578e2960-wk-Fact-6152D000FB974A9716FED1D0184B167D" name="us-gaap:EarningsPerShareBasicAndDiluted" contextRef="D2018Q4Jul12017toJun302018" unitRef="usdPerShare" decimals="2" scale="0" sign="-" format="ixt:numdotdecimal">1.78</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(<ix:nonFraction id="d22912578e2981-wk-Fact-15593DF1B21B85A3D63BD1D01865C103" name="us-gaap:EarningsPerShareBasicAndDiluted" contextRef="D2017Q4Jul012016toJun302017" unitRef="usdPerShare" decimals="2" scale="0" sign="-" format="ixt:numdotdecimal">1.47</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Weighted average shares used to calculate loss per common share (basic and diluted)</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d22912578e2997-wk-Fact-2B1B8810A6E12D1E9555D713E12B856F" name="us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted" contextRef="FD2019Q4YTD" unitRef="shares" decimals="-3" scale="3" format="ixt:numdotdecimal">193,617</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d22912578e3016-wk-Fact-B9734C406F4E5C1740AAD1D0185BD208" name="us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted" contextRef="D2018Q4Jul01-Dec31" unitRef="shares" decimals="-3" scale="3" format="ixt:numdotdecimal">188,554</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d22912578e3035-wk-Fact-C1017F6E4A80C820BFDBD1D0184BDD1D" name="us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted" contextRef="D2018Q4Jul12017toJun302018" unitRef="shares" decimals="-3" scale="3" format="ixt:numdotdecimal">153,475</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d22912578e3055-wk-Fact-D45257CFA82E94991ADED1D0184B09B0" name="us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted" contextRef="D2017Q4Jul012016toJun302017" unitRef="shares" decimals="-3" scale="3" format="ixt:numdotdecimal">104,536</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Other comprehensive (loss) income, net of tax:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Foreign currency translation adjustments</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d22912578e3157-wk-Fact-64F61827888127DA9CE5D714166325C1" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">174</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(<ix:nonFraction id="d22912578e3176-wk-Fact-241CC7A97083AD10E426D1D0180B4B86" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" contextRef="D2018Q4Jul01-Dec31" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(<ix:nonFraction id="d22912578e3196-wk-Fact-354906819C21877A706ED1D0180B75B0" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" contextRef="D2018Q4Jul12017toJun302018" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">105</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(<ix:nonFraction id="d22912578e3217-wk-Fact-2217B4ADC7FF49ED8FFDD1D0180B7908" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" contextRef="D2017Q4Jul012016toJun302017" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">62</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Unrealized gain (loss) on securities available for sale</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(<ix:nonFraction id="d22912578e3238-wk-Fact-CDE46A60F0AD907354B6D714170C011D" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">391</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d22912578e3258-wk-Fact-2D7DAC56897B17192D1ED1D0185B2FE9" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" contextRef="D2018Q4Jul01-Dec31" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">10</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d22912578e3277-wk-Fact-8CB34EFDB3FF61B72480D1D0184BAD04" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" contextRef="D2018Q4Jul12017toJun302018" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">55</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(<ix:nonFraction id="d22912578e3297-wk-Fact-2387014B7A4308282AD4D1D0185B1B2A" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" contextRef="D2017Q4Jul012016toJun302017" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">109</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Other comprehensive income (loss), net of tax:</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(<ix:nonFraction id="d22912578e3319-wk-Fact-A6C1E2230EF5DC9F423AD71417BAA3B2" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">217</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d22912578e3339-wk-Fact-8BE8CC99A112976EF87AD1D018643C0B" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" contextRef="D2018Q4Jul01-Dec31" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">2</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(<ix:nonFraction id="d22912578e3358-wk-Fact-1ECA80141594AC8AB006D1D0180BF0F8" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" contextRef="D2018Q4Jul12017toJun302018" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">50</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(<ix:nonFraction id="d22912578e3379-wk-Fact-E76D21D8C9058DC7E880D1D0185B55B6" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" contextRef="D2017Q4Jul012016toJun302017" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">171</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Comprehensive loss</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(<ix:nonFraction id="d22912578e3400-wk-Fact-E16FF6B81A3AEA0591F4D71418667B6B" name="us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">357,536</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(<ix:nonFraction id="d22912578e3420-wk-Fact-B9166124E1B8323315C9D1D0184BC8DD" name="us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" contextRef="D2018Q4Jul01-Dec31" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">157,747</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(<ix:nonFraction id="d22912578e3440-wk-Fact-6FD15BED102CB32E118ED1D018650531" name="us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" contextRef="D2018Q4Jul12017toJun302018" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">273,937</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(<ix:nonFraction id="d22912578e3461-wk-Fact-10C975ED81C3A179394DD1D01865FB4F" name="us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" contextRef="D2017Q4Jul012016toJun302017" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">153,437</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Comprehensive loss attributable to noncontrolling interest</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(<ix:nonFraction id="d22912578e3482-wk-Fact-95094446A4E26AACC45CD7141919617A" name="us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">129</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(<ix:nonFraction id="d22912578e3502-wk-Fact-0DDB5EC59D2DE3DD1DC8D1D01865913A" name="us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" contextRef="D2018Q4Jul01-Dec31" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">81</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(<ix:nonFraction id="d22912578e3522-wk-Fact-3C60FCADDEC2AD213D1FD1D0184B4070" name="us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" contextRef="D2018Q4Jul12017toJun302018" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">50</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(<ix:nonFraction id="d22912578e3543-wk-Fact-B6F356B6EC1F96C21675D1D0184B0CD9" name="us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" contextRef="D2017Q4Jul012016toJun302017" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">60</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Comprehensive loss attributable to Immunomedics, Inc. stockholders</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(<ix:nonFraction id="d22912578e3569-wk-Fact-5355A796CC6E7390D03BD71419C2106B" name="us-gaap:ComprehensiveIncomeNetOfTax" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">357,407</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(<ix:nonFraction id="d22912578e3589-wk-Fact-AD97A9353DBD452590BED1D018658987" name="us-gaap:ComprehensiveIncomeNetOfTax" contextRef="D2018Q4Jul01-Dec31" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">157,666</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(<ix:nonFraction id="d22912578e3609-wk-Fact-06305F149F3E5546440DD1D0184B9228" name="us-gaap:ComprehensiveIncomeNetOfTax" contextRef="D2018Q4Jul12017toJun302018" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">273,887</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(<ix:nonFraction id="d22912578e3630-wk-Fact-FC2BDBA6017F5C354F5CD1D0185B57FC" name="us-gaap:ComprehensiveIncomeNetOfTax" contextRef="D2017Q4Jul012016toJun302017" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">153,377</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td></tr></table></div></div><div style="line-height:120%;padding-top:16px;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">See accompanying notes to consolidated financial statements.</span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">59</span></div></div><hr style="page-break-after:always"></hr><div><a id="s6FED0107C012592CA75321B966F9F921"></a></div><div><div style="line-height:120%;text-align:justify;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;" href="#sfb86787ac8304dffbb4bfe7ffcfa7b54"><span style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">Table of Contents</span></a></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></div><div><br/></div><div style="line-height:120%;text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">IMMUNOMEDICS, INC. AND SUBSIDIARIES</span></div><div style="line-height:120%;text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS’ EQUITY </span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">(in thousands)</span><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="38"></td></tr><tr><td style="width:18%;"></td><td style="width:5%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:4%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:6%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:5%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:7%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:4%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:6%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:7%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:5%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:6%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"> </span></div></td><td colspan="29" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Immunomedics, Inc. Stockholders' Equity </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"> </span></div></td><td colspan="6" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;font-weight:bold;">Convertible Preferred Stock</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" rowspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;font-weight:bold;">Capital Contributed in Excess of Par</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" rowspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;font-weight:bold;">Accumulated Other Comprehensive Income (Loss)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="6" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;font-weight:bold;">Common Stock</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;font-weight:bold;">Treasury Stock</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;font-weight:bold;">Accumulated Deficit</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;font-weight:bold;">Noncontrolling Interest</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;font-weight:bold;">Shares</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;font-weight:bold;">Amount</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;font-weight:bold;">Shares</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;font-weight:bold;">Amount</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;font-weight:bold;">Total</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">Balance at June 30, 2016</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span><ix:nonFraction id="d22922455e1469-wk-Fact-A228FF53951493EC1D73DB1A34391273" name="us-gaap:SharesIssued" contextRef="FI2016Q4_us-gaap_StatementClassOfStockAxis_us-gaap_ConvertiblePreferredStockMember" unitRef="shares" decimals="-3" scale="3" format="ixt:zerodash">—</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span><ix:nonFraction id="d22922455e1488-wk-Fact-88FCAE56074F90C692BADB1A34487677" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="FI2016Q4_us-gaap_StatementClassOfStockAxis_us-gaap_ConvertiblePreferredStockMember" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">—</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span><ix:nonFraction id="d22922455e1502-wk-Fact-5887A7B81BA5D696D587DB1A34962BB1" name="us-gaap:SharesIssued" contextRef="FI2016Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="shares" decimals="-3" scale="3" format="ixt:numdotdecimal">95,868</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span><ix:nonFraction id="d22922455e1522-wk-Fact-8CA16E2F9C6DC38642A0DB1A34F4B388" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="FI2016Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">958</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span><ix:nonFraction id="d22922455e1541-wk-Fact-CBAE0CDA6EF8FDAFAA9DDB1A35A01494" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="FI2016Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">311,320</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>(<ix:nonFraction id="d22922455e1560-wk-Fact-CFAD4F325349791A5B59DB1A361DDC9B" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="FI2016Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">458</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>(<ix:nonFraction id="d22922455e1581-wk-Fact-AA86C2F9F278C2D1A9C3DB1A36D8E105" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="FI2016Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">368,505</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>(<ix:nonFraction id="d22922455e1601-wk-Fact-758529E64C065EDFFFCCDB1A3736EEC9" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="FI2016Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">132</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>(<ix:nonFraction id="d22922455e1621-wk-Fact-33195E48254081FC35E0DB1A37C3B5C2" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="FI2016Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">711</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>(<ix:nonFraction id="d22922455e1642-wk-Fact-42A7BF2368C2F8F556F7DB1A37FC1F61" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="FI2016Q4" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">57,528</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">Issuance of preferred stock, net</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span><ix:nonFraction id="d22922455e1658-wk-Fact-178DB0833555C0288B0DDB1A3822595A" name="immu:PreferredStockIssuedDuringPeriodSharesNewIssues" contextRef="D2017Q4Jul012016toJun302017_us-gaap_StatementClassOfStockAxis_us-gaap_ConvertiblePreferredStockMember" unitRef="shares" decimals="-3" scale="3" format="ixt:numdotdecimal">1,000</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span><ix:nonFraction id="d22922455e1672-wk-Fact-C607F434E4B9F414AC23DB1A3861F27E" name="immu:PreferredStockIssuedDuringPeriodValueNewIssues" contextRef="D2017Q4Jul012016toJun302017_us-gaap_StatementClassOfStockAxis_us-gaap_ConvertiblePreferredStockMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">10</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">—</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">—</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span><ix:nonFraction id="d22922455e1725-wk-Fact-A39E490FD33D3330AFEBDB1A388B5944" name="immu:PreferredStockIssuedDuringPeriodValueNewIssues" contextRef="D2017Q4Jul012016toJun302017_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">121,772</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">—</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">—</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">—</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">—</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span><ix:nonFraction id="d22922455e1822-wk-Fact-46D11CF9762BEF05FA0FDB1A3926079B" name="immu:PreferredStockIssuedDuringPeriodValueNewIssues" contextRef="D2017Q4Jul012016toJun302017" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">121,782</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">Issuance of common stock in public offering, net</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">—</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">—</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span><ix:nonFraction id="d22922455e1875-wk-Fact-61D43C9ACDD32C666934DB1A398DF64C" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="D2017Q4Jul012016toJun302017_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember" unitRef="shares" decimals="-3" scale="3" format="ixt:numdotdecimal">10,000</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span><ix:nonFraction id="d22922455e1890-wk-Fact-6DFE38B0335E3293E171DB1A32771D27" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="D2017Q4Jul012016toJun302017_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">100</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span><ix:nonFraction id="d22922455e1909-wk-Fact-D4FBDDEDF3125F850D0EDB1A325CC4A2" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="D2017Q4Jul012016toJun302017_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">28,478</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">—</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">—</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">—</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">—</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span><ix:nonFraction id="d22922455e2006-wk-Fact-0E9D2971ACD3649EAEA4DB1A336B9CD4" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="D2017Q4Jul012016toJun302017_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">28,578</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">Proceeds of public offering allocated to warrant liability</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">—</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">—</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">—</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">—</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>(<ix:nonFraction id="d22922455e2093-wk-Fact-D3F52AFB4CB6876B471DDB1A33A0CE85" name="immu:AdjustmentstoAdditionalPaidinCapitalProceedsFromOfferingWarrants" contextRef="D2017Q4Jul012016toJun302017_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">6,966</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">—</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">—</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">—</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">—</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>(<ix:nonFraction id="d22922455e2191-wk-Fact-7485F83B70501FF6525CDB1A33B8D288" name="immu:AdjustmentstoAdditionalPaidinCapitalProceedsFromOfferingWarrants" contextRef="D2017Q4Jul012016toJun302017" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">6,966</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">Issuance of common stock to Seattle Genetics, Inc.</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">—</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">—</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span><ix:nonFraction id="d22922455e2245-wk-Fact-41AB8B902A7BCB26A2AADB1A340AD9E0" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="D2017Q4Jul012016toJun302017_srt_CounterpartyNameAxis_immu_SeattleGeneticsIncMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember" unitRef="shares" decimals="-3" scale="3" format="ixt:numdotdecimal">3,000</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span><ix:nonFraction id="d22922455e2260-wk-Fact-76ADFB0ECD5D445C28EEDB1A3429C50E" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="D2017Q4Jul012016toJun302017_srt_CounterpartyNameAxis_immu_SeattleGeneticsIncMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">30</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span><ix:nonFraction id="d22922455e2279-wk-Fact-355DB0ED5AB07F4D315CDB1A3439F48B" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="D2017Q4Jul012016toJun302017_srt_CounterpartyNameAxis_immu_SeattleGeneticsIncMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">14,670</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">—</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">—</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">—</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">—</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span><ix:nonFraction id="d22922455e2376-wk-Fact-C109A21874BBFBA10134DB1A3513A124" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="D2017Q4Jul012016toJun302017_srt_CounterpartyNameAxis_immu_SeattleGeneticsIncMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">14,700</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">Proceeds of share issuance to Seattle Genetics, Inc. allocated to warrant liability</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">—</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">—</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">—</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">—</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>(<ix:nonFraction id="d22922455e2463-wk-Fact-5C126682E18BB29EF614DB1A37B32D38" name="immu:AdjustmentstoAdditionalPaidinCapitalProceedsFromOfferingWarrants" contextRef="D2017Q4Jul012016toJun302017_srt_CounterpartyNameAxis_immu_SeattleGeneticsIncMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">14,670</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">—</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">—</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">—</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">—</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>(<ix:nonFraction id="d22922455e2561-wk-Fact-6E2BF2CC1D827777EAFADB1A38327B75" name="immu:AdjustmentstoAdditionalPaidinCapitalProceedsFromOfferingWarrants" contextRef="D2017Q4Jul012016toJun302017_srt_CounterpartyNameAxis_immu_SeattleGeneticsIncMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">14,670</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">Exercise of stock options, net</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">—</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">—</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span><ix:nonFraction id="d22922455e2615-wk-Fact-E43519A3C4571190A20EDB1A38A55797" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" contextRef="D2017Q4Jul012016toJun302017_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="shares" decimals="-3" scale="3" format="ixt:numdotdecimal">1,279</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span><ix:nonFraction id="d22922455e2630-wk-Fact-53D83D0B495E49ED89EBDB1A38BFA027" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="D2017Q4Jul012016toJun302017_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">13</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span><ix:nonFraction id="d22922455e2649-wk-Fact-D28335E6EDA15C68767BDB1A39159649" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="D2017Q4Jul012016toJun302017_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">4,277</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">—</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">—</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">—</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">—</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span><ix:nonFraction id="d22922455e2746-wk-Fact-BCBD0953759B0069EFB2DB1A39597D43" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="D2017Q4Jul012016toJun302017" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">4,290</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">Stock-based compensation</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">—</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">—</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span><ix:nonFraction id="d22922455e2800-wk-Fact-52A752F8BD553FE392DBDB1A328E5246" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" contextRef="D2017Q4Jul012016toJun302017_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="shares" decimals="-3" scale="3" format="ixt:numdotdecimal">198</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span><ix:nonFraction id="d22922455e2815-wk-Fact-AC7E4E3A08EE16992166DB1A32D92CED" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" contextRef="D2017Q4Jul012016toJun302017_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">2</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span><ix:nonFraction id="d22922455e2834-wk-Fact-B9B7EE813175781F3F6BDB1A32E48DC5" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" contextRef="D2017Q4Jul012016toJun302017_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">3,785</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">—</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">—</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">—</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">—</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span><ix:nonFraction id="d22922455e2931-wk-Fact-FAD7653E8F7629F6C063DB1A33768A4B" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" contextRef="D2017Q4Jul012016toJun302017" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">3,787</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">Other comprehensive loss</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">—</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">—</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">—</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">—</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">—</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">—</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">—</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>(<ix:nonFraction id="d22922455e3076-wk-Fact-41522A8060540A8B032ADB1A33C9BB3D" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" contextRef="D2017Q4Jul012016toJun302017_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">171</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">—</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>(<ix:nonFraction id="d22922455e3116-wk-Fact-E76D21D8C9058DC7E880D1D0185B55B6" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" contextRef="D2017Q4Jul012016toJun302017" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">171</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">Net loss</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">—</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">—</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">—</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">—</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">—</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">—</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>(<ix:nonFraction id="d22922455e3243-wk-Fact-E6166577EACDCD72D74CDB1A35FE9B28" name="us-gaap:ProfitLoss" contextRef="D2017Q4Jul012016toJun302017_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">153,206</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>(<ix:nonFraction id="d22922455e3283-wk-Fact-5415C1BB72020B1D990FDB1A36B95436" name="us-gaap:ProfitLoss" contextRef="D2017Q4Jul012016toJun302017_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">60</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>(<ix:nonFraction id="d22922455e3304-wk-Fact-AC988A2DC8A22FB48CBDD1D018651B52" name="us-gaap:ProfitLoss" contextRef="D2017Q4Jul012016toJun302017" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">153,266</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">Balance at June 30, 2017</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span><ix:nonFraction id="d22922455e3325-wk-Fact-DC232591C496E06AD56ADB1A37E283AE" name="us-gaap:SharesIssued" contextRef="FI2017Q2_us-gaap_StatementClassOfStockAxis_us-gaap_ConvertiblePreferredStockMember" unitRef="shares" decimals="-3" scale="3" format="ixt:numdotdecimal">1,000</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span><ix:nonFraction id="d22922455e3344-wk-Fact-569D07F8B7886CC3E641DB1A380BF04D" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="FI2017Q2_us-gaap_StatementClassOfStockAxis_us-gaap_ConvertiblePreferredStockMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">10</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span><ix:nonFraction id="d22922455e3358-wk-Fact-4F60F980CD721D1943F7DB1A3849F952" name="us-gaap:SharesIssued" contextRef="FI2017Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="shares" decimals="-3" scale="3" format="ixt:numdotdecimal">110,345</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span><ix:nonFraction id="d22922455e3378-wk-Fact-6006DC0666129A72781BDB1A3859FED1" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="FI2017Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">1,103</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span><ix:nonFraction id="d22922455e3397-wk-Fact-14247BDA1650AF255671DB1A386911F7" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="FI2017Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">462,666</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>(<ix:nonFraction id="d22922455e3416-wk-Fact-1268BDE9E2F8E4BD25F9DB1A389D4837" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="FI2017Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">458</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>(<ix:nonFraction id="d22922455e3437-wk-Fact-1700F63F6A0812A161D9DB1A38AE1709" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="FI2017Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">521,711</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>(<ix:nonFraction id="d22922455e3457-wk-Fact-C250495353646701D3F8DB1A38D1AAF4" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="FI2017Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">303</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>(<ix:nonFraction id="d22922455e3477-wk-Fact-77973AB87400221D4B8DDB1A38F45A1E" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="FI2017Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">771</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>(<ix:nonFraction id="d22922455e3498-wk-Fact-894520B5C9B760872CA6DB1A39372D98" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="FI2017Q2" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">59,464</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">Reclassification of warrant liability to equity</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">—</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">—</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">—</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">—</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span><ix:nonFraction id="d22922455e3581-wk-Fact-5A9E010A0A5AD759B13FDB1A323BFCA8" name="immu:ReclassificationofWarrantLiabilitytoEquity" contextRef="D2018Q4Jul12017toJun302018_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">190,369</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">—</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">—</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">—</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">—</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span><ix:nonFraction id="d22922455e3678-wk-Fact-AD9715B1063DB2C6B6E9DB1A32EF5E80" name="immu:ReclassificationofWarrantLiabilitytoEquity" contextRef="D2018Q4Jul12017toJun302018" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">190,369</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">Exercise of common stock warrants</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">—</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">—</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span><ix:nonFraction id="d22922455e3731-wk-Fact-EA7169FC780F2B95CEA1DB1A33824448" name="immu:SharebasedCompensationArrangementbySharebasedPaymentAwardWarrantsExercisesinPeriod" contextRef="D2018Q4Jul12017toJun302018_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="shares" decimals="-3" scale="3" format="ixt:numdotdecimal">18,206</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span><ix:nonFraction id="d22922455e3746-wk-Fact-5D744DC9B2C5678D6C81DB1A3388D819" name="immu:StockIssuedDuringPeriodValueWarrantsExercised" contextRef="D2018Q4Jul12017toJun302018_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">182</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span><ix:nonFraction id="d22922455e3765-wk-Fact-73EA3BF187A2A7FC7FE1DB1A3394B13C" name="immu:StockIssuedDuringPeriodValueWarrantsExercised" contextRef="D2018Q4Jul12017toJun302018_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">78,044</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">—</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">—</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">—</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">—</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span><ix:nonFraction id="d22922455e3862-wk-Fact-EB0DD7A8AD727D836DB1DB1A33C42F2D" name="immu:StockIssuedDuringPeriodValueWarrantsExercised" contextRef="D2018Q4Jul12017toJun302018" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">78,226</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">Exercise of stock options, net</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">—</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">—</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span><ix:nonFraction id="d22922455e3915-wk-Fact-DAA6963965024C43DB1ADB1A340AF299" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" contextRef="D2018Q4Jul12017toJun302018_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="shares" decimals="-3" scale="3" format="ixt:numdotdecimal">586</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span><ix:nonFraction id="d22922455e3930-wk-Fact-85A94CE600AA631703F6DB1A341A3EA6" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="D2018Q4Jul12017toJun302018_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">6</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span><ix:nonFraction id="d22922455e3949-wk-Fact-1AE04C6BB6CC860B338EDB1A341A9655" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="D2018Q4Jul12017toJun302018_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">2,255</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">—</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">—</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">—</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">—</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span><ix:nonFraction id="d22922455e4046-wk-Fact-20AEEE871EDC933B6758DB1A34B6345F" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="D2018Q4Jul12017toJun302018" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">2,261</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">Issuance of common stock to RPI Finance Trust</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">—</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">—</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span><ix:nonFraction id="d22922455e4099-wk-Fact-CCAD31FE206AD598FA06DB1A369AADBE" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="D2018Q4Jul12017toJun302018_srt_CounterpartyNameAxis_immu_RpiFinanceTrustMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="shares" decimals="-3" scale="3" format="ixt:numdotdecimal">4,373</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span><ix:nonFraction id="d22922455e4114-wk-Fact-6A2E27CBBDEE9C0716A5DB1A371758B1" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="D2018Q4Jul12017toJun302018_srt_CounterpartyNameAxis_immu_RpiFinanceTrustMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">44</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span><ix:nonFraction id="d22922455e4133-wk-Fact-C956E00647699D663DDADB1A373664D2" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="D2018Q4Jul12017toJun302018_srt_CounterpartyNameAxis_immu_RpiFinanceTrustMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">67,740</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">—</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">—</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">—</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">—</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span><ix:nonFraction id="d22922455e4230-wk-Fact-26FD7DE1205BED40DB8FDB1A381B7E38" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="D2018Q4Jul12017toJun302018_srt_CounterpartyNameAxis_immu_RpiFinanceTrustMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">67,784</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">Issuance of common stock in public offering, net</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">—</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">—</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span><ix:nonFraction id="d22922455e4283-wk-Fact-D674818A4088772D2118DB1A37A4EC45" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="D2018Q4Jul12017toJun302018_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember" unitRef="shares" decimals="-3" scale="3" format="ixt:numdotdecimal">13,225</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span><ix:nonFraction id="d22922455e4298-wk-Fact-B9D6690BFA9A5EA6A0C0DB1A34D530D2" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="D2018Q4Jul12017toJun302018_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">132</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span><ix:nonFraction id="d22922455e4317-wk-Fact-B4DEC0C5BF902A7FE251DB1A339AD6D6" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="D2018Q4Jul12017toJun302018_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">299,335</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">—</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">—</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">—</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">—</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span><ix:nonFraction id="d22922455e4414-wk-Fact-7B7D779FA7A8362A15CADB1A3879A8D5" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="D2018Q4Jul12017toJun302018_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">299,467</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">Conversion of preferred stock</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>(<ix:nonFraction id="d22922455e4434-wk-Fact-C6D124497FC01429C75BDB1A38C88B3C" name="us-gaap:StockIssuedDuringPeriodSharesConversionOfUnits" contextRef="D2018Q4Jul12017toJun302018_us-gaap_StatementClassOfStockAxis_us-gaap_ConvertiblePreferredStockMember" unitRef="shares" decimals="-3" scale="3" format="ixt:numdotdecimal">1,000</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>(<ix:nonFraction id="d22922455e4449-wk-Fact-43A49EA247EB0D8F7B62DB1A38E2CFD3" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecuritiesNetOfAdjustments" contextRef="D2018Q4Jul12017toJun302018_us-gaap_StatementClassOfStockAxis_us-gaap_ConvertiblePreferredStockMember" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">10</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span><ix:nonFraction id="d22922455e4469-wk-Fact-946688E43C4E7119208FDB1A392E8D2D" name="us-gaap:StockIssuedDuringPeriodSharesConversionOfUnits" contextRef="D2018Q4Jul12017toJun302018_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="shares" decimals="-3" scale="3" format="ixt:numdotdecimal">23,105</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span><ix:nonFraction id="d22922455e4484-wk-Fact-82FA74FAB817852BC51DDB1A390C8A69" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecuritiesNetOfAdjustments" contextRef="D2018Q4Jul12017toJun302018_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">231</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>(<ix:nonFraction id="d22922455e4503-wk-Fact-65585779EDCE8CD3F870DB1A39DC783A" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecuritiesNetOfAdjustments" contextRef="D2018Q4Jul12017toJun302018_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">221</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">—</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">—</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">—</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">—</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span><ix:nonFraction id="d22922455e4601-wk-Fact-66E21C8357F68E5819E2DB1A3A14975F" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecuritiesNetOfAdjustments" contextRef="D2018Q4Jul12017toJun302018" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">—</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">Issuance of common stock due to debt conversion</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">—</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">—</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span><ix:nonFraction id="d22922455e4654-wk-Fact-A979096C24D5C23D858EDB1A35718257" name="us-gaap:DebtConversionConvertedInstrumentSharesIssued1" contextRef="D2018Q4Jul12017toJun302018_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="shares" decimals="-3" scale="3" format="ixt:numdotdecimal">16,800</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span><ix:nonFraction id="d22922455e4669-wk-Fact-0EFB495985B9843D8A5CDB1A367B1E61" name="us-gaap:DebtConversionConvertedInstrumentAmount1" contextRef="D2018Q4Jul12017toJun302018_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">168</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span><ix:nonFraction id="d22922455e4688-wk-Fact-142EB4D1395EF0F43CFFDB1A36F87EB1" name="us-gaap:DebtConversionConvertedInstrumentAmount1" contextRef="D2018Q4Jul12017toJun302018_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">92,307</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">—</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">—</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">—</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">—</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span><ix:nonFraction id="d22922455e4785-wk-Fact-BB66D9AB8A69F82D7FC0DB1A37D26911" name="us-gaap:DebtConversionConvertedInstrumentAmount1" contextRef="D2018Q4Jul12017toJun302018" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">92,475</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">Stock-based compensation</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">—</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">—</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span><ix:nonFraction id="d22922455e4839-wk-Fact-8BFB71AD64D0ADFBACF6DB1A383A00B0" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" contextRef="D2018Q4Jul12017toJun302018_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="shares" decimals="-3" scale="3" format="ixt:numdotdecimal">331</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span><ix:nonFraction id="d22922455e4854-wk-Fact-04266B8D16D7A205BABCDB1A3851BC12" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" contextRef="D2018Q4Jul12017toJun302018_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">3</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span><ix:nonFraction id="d22922455e4873-wk-Fact-5384D2B3252F547402A4DB1A3871AE61" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" contextRef="D2018Q4Jul12017toJun302018_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">4,024</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">—</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">—</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">—</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">—</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span><ix:nonFraction id="d22922455e4970-wk-Fact-415E090F48B97C9D0BFCDB1A39059A07" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" contextRef="D2018Q4Jul12017toJun302018" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">4,027</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">Conversion of RSU's for tax withholding payments</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">—</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">—</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>(<ix:nonFraction id="d22922455e5023-wk-Fact-CAC084D54571C6A20004DB1A397BBF8B" name="us-gaap:SharesPaidForTaxWithholdingForShareBasedCompensation" contextRef="D2018Q4Jul12017toJun302018_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="shares" decimals="-3" scale="3" format="ixt:numdotdecimal">170</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>(<ix:nonFraction id="d22922455e5039-wk-Fact-46AA6B63E82EDC39D36CDB1A398340BA" name="us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" contextRef="D2018Q4Jul12017toJun302018_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>(<ix:nonFraction id="d22922455e5059-wk-Fact-79251B9941D8DAF2EFF2DB1A3997B07B" name="us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" contextRef="D2018Q4Jul12017toJun302018_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">1,521</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">—</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">—</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">—</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">—</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>(<ix:nonFraction id="d22922455e5157-wk-Fact-23CE170113E776D71EBEDB1A363C6226" name="us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" contextRef="D2018Q4Jul12017toJun302018" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">1,522</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">Other comprehensive loss</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">—</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">—</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">—</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">—</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">—</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">—</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">—</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>(<ix:nonFraction id="d22922455e5303-wk-Fact-AB5E70C4483A1DE69C98DB1A3813DD50" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" contextRef="D2018Q4Jul12017toJun302018_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">50</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">—</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>(<ix:nonFraction id="d22922455e5343-wk-Fact-1ECA80141594AC8AB006D1D0180BF0F8" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" contextRef="D2018Q4Jul12017toJun302018" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">50</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">Net loss</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">—</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">—</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">—</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">—</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">—</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">—</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>(<ix:nonFraction id="d22922455e5470-wk-Fact-18A6CED1342045E12F6ADB1A391D44FA" name="us-gaap:ProfitLoss" contextRef="D2018Q4Jul12017toJun302018_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">273,837</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">—</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>(<ix:nonFraction id="d22922455e5509-wk-Fact-CBA95FC35F2D22807768DB1A3947B9FB" name="us-gaap:ProfitLoss" contextRef="D2018Q4Jul12017toJun302018_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">50</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>(<ix:nonFraction id="d22922455e5530-wk-Fact-6CE3D07A35B1D83DEB81D1D0184B1FFE" name="us-gaap:ProfitLoss" contextRef="D2018Q4Jul12017toJun302018" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">273,887</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">Balance at June 30, 2018</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span><ix:nonFraction id="d22922455e5551-wk-Fact-C134259EB5AB2C48EBA3DB1A3A2C2F71" name="us-gaap:SharesIssued" contextRef="FI2018Q2_us-gaap_StatementClassOfStockAxis_us-gaap_ConvertiblePreferredStockMember" unitRef="shares" decimals="-3" scale="3" format="ixt:zerodash">—</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span><ix:nonFraction id="d22922455e5570-wk-Fact-FE2899D8184CA487BC44DB1A3552C90B" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="FI2018Q2_us-gaap_StatementClassOfStockAxis_us-gaap_ConvertiblePreferredStockMember" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">—</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span><ix:nonFraction id="d22922455e5584-wk-Fact-9E1FB3DAAA6BBBFF3457DB1A35333466" name="us-gaap:SharesIssued" contextRef="FI2018Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="shares" decimals="-3" scale="3" format="ixt:numdotdecimal">186,801</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span><ix:nonFraction id="d22922455e5604-wk-Fact-AD60146677BD42CE81FEDB1A35CF1BC1" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="FI2018Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">1,868</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span><ix:nonFraction id="d22922455e5623-wk-Fact-0CEB8110D18C8F6FBC41DB1A365B3B35" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="FI2018Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">1,194,998</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>(<ix:nonFraction id="d22922455e5642-wk-Fact-DB323081C326F2ED0571DB1A37275A21" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="FI2018Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">458</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>(<ix:nonFraction id="d22922455e5663-wk-Fact-3E9BA2F69F795113AB2ADB1A37B36E81" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="FI2018Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">795,548</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>(<ix:nonFraction id="d22922455e5683-wk-Fact-7CD7C9D8D384C483DBEADB1A37C32986" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="FI2018Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">353</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>(<ix:nonFraction id="d22922455e5703-wk-Fact-3F6901B10BA605A59DABDB1A37E2E6A0" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="FI2018Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">821</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span><ix:nonFraction id="d22922455e5724-wk-Fact-8D06FCED55F03AC4C6F8DB1A37F288CE" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="FI2018Q2" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">399,686</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">Reclassification of warrant liability to equity</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">—</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">—</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">—</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">—</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span><ix:nonFraction id="d22922455e5806-wk-Fact-6338A29699F3B14BDB39DB1A38D9A838" name="immu:ReclassificationofWarrantLiabilitytoEquity" contextRef="D2018Q4Jul01-Dec31_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">7,569</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">—</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">—</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">—</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">—</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span><ix:nonFraction id="d22922455e5903-wk-Fact-207AD62C3915B0E6A8ADDB1A38FDA626" name="immu:ReclassificationofWarrantLiabilitytoEquity" contextRef="D2018Q4Jul01-Dec31" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">7,569</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">Exercise of common stock warrants</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">—</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">—</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span><ix:nonFraction id="d22922455e5956-wk-Fact-79494612ECA232A37878DB1A3950C5E2" name="immu:SharebasedCompensationArrangementbySharebasedPaymentAwardWarrantsExercisesinPeriod" contextRef="D2018Q4Jul01-Dec31_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="shares" decimals="-3" scale="3" format="ixt:numdotdecimal">450</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span><ix:nonFraction id="d22922455e5971-wk-Fact-33A86064B144A57F390DDB1A39698BEE" name="immu:StockIssuedDuringPeriodValueWarrantsExercised" contextRef="D2018Q4Jul01-Dec31_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">5</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span><ix:nonFraction id="d22922455e5990-wk-Fact-F32DB8ABBA658C7761CCDB1A3972202A" name="immu:StockIssuedDuringPeriodValueWarrantsExercised" contextRef="D2018Q4Jul01-Dec31_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">1,683</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">—</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">—</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">—</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span><ix:nonFraction id="d22922455e6088-wk-Fact-A08C1E79F200350364F2DB1A35BFC13C" name="immu:StockIssuedDuringPeriodValueWarrantsExercised" contextRef="D2018Q4Jul01-Dec31" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">1,688</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">Exercise of stock options, net</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">—</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">—</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span><ix:nonFraction id="d22922455e6141-wk-Fact-C3CCC4713C0B9C83CFF0DB1A37276675" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" contextRef="D2018Q4Jul01-Dec31_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="shares" decimals="-3" scale="3" format="ixt:numdotdecimal">706</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span><ix:nonFraction id="d22922455e6156-wk-Fact-FD6FDFCC2691C135115FDB1A3803FDA2" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="D2018Q4Jul01-Dec31_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">7</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span><ix:nonFraction id="d22922455e6175-wk-Fact-33C7A1EDE6F65E7C34ACDB1A37A495F1" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="D2018Q4Jul01-Dec31_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">2,619</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>(<ix:nonFraction id="d22922455e6194-wk-Fact-7BDC108E4B64649C8035DB1A37D26358" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="D2018Q4Jul01-Dec31_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">2,450</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">—</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">—</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">—</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span><ix:nonFraction id="d22922455e6273-wk-Fact-5AA6E3D9AB361B4991A6DB1A382AE3C5" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="D2018Q4Jul01-Dec31" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">176</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">Retirement of treasury stock</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">—</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">—</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>(<ix:nonFraction id="d22922455e6326-wk-Fact-434E0C0454C92A056EC7DB1A3881E7F1" name="us-gaap:StockRepurchasedAndRetiredDuringPeriodShares" contextRef="D2018Q4Jul01-Dec31_srt_CounterpartyNameAxis_immu_RpiFinanceTrustMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="shares" decimals="-3" scale="3" format="ixt:numdotdecimal">106</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>(<ix:nonFraction id="d22922455e6342-wk-Fact-F888A5BA91B92D45A04FDB1A38936529" name="us-gaap:StockRepurchasedAndRetiredDuringPeriodValue" contextRef="D2018Q4Jul01-Dec31_srt_CounterpartyNameAxis_immu_RpiFinanceTrustMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>(<ix:nonFraction id="d22922455e6362-wk-Fact-89B276ADEC1EAA74C155DB1A38B67080" name="us-gaap:StockRepurchasedAndRetiredDuringPeriodValue" contextRef="D2018Q4Jul01-Dec31_srt_CounterpartyNameAxis_immu_RpiFinanceTrustMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">2,083</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span><ix:nonFraction id="d22922455e6382-wk-Fact-64CDA05FBBF3A1A0533EDB1A38EBD3D1" name="us-gaap:StockRepurchasedAndRetiredDuringPeriodValue" contextRef="D2018Q4Jul01-Dec31_srt_CounterpartyNameAxis_immu_RpiFinanceTrustMember_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">2,084</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">—</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">—</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">—</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span><ix:nonFraction id="d22922455e6460-wk-Fact-9441FEBA9D0985FE39BDDB1A393E015C" name="us-gaap:StockRepurchasedAndRetiredDuringPeriodValue" contextRef="D2018Q4Jul01-Dec31_srt_CounterpartyNameAxis_immu_RpiFinanceTrustMember" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">—</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">Issuance of common stock due to debt conversion</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">—</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">—</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span><ix:nonFraction id="d22922455e6513-wk-Fact-9AB29318C83AC9004B93DB1A39BD2C4E" name="us-gaap:DebtConversionConvertedInstrumentSharesIssued1" contextRef="D2018Q4Jul01-Dec31_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="shares" decimals="-3" scale="3" format="ixt:numdotdecimal">2,568</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span><ix:nonFraction id="d22922455e6528-wk-Fact-A47C1EA74E813F829D3ADB1A39F5C5A5" name="us-gaap:DebtConversionConvertedInstrumentAmount1" contextRef="D2018Q4Jul01-Dec31_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">26</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span><ix:nonFraction id="d22922455e6547-wk-Fact-AB087089441F773BD023DB1A32A8DFA6" name="us-gaap:DebtConversionConvertedInstrumentAmount1" contextRef="D2018Q4Jul01-Dec31_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">13,757</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">—</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">—</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">—</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">—</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span><ix:nonFraction id="d22922455e6644-wk-Fact-44E6D0030383E00EA8CFDB1A32F47F95" name="us-gaap:DebtConversionConvertedInstrumentAmount1" contextRef="D2018Q4Jul01-Dec31" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">13,783</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">Stock-based compensation</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">—</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">—</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span><ix:nonFraction id="d22922455e6697-wk-Fact-7337E6AE1F691C0AD237DB1A337C8817" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" contextRef="D2018Q4Jul01-Dec31_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="shares" decimals="-3" scale="3" format="ixt:numdotdecimal">36</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">—</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span><ix:nonFraction id="d22922455e6731-wk-Fact-9C61C9CE4F0F1D661676DB1A338DFB5F" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" contextRef="D2018Q4Jul01-Dec31_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">886</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">—</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">—</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">—</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">—</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span><ix:nonFraction id="d22922455e6828-wk-Fact-9B9ED98A693589C5AA9EDB1A33AC7080" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" contextRef="D2018Q4Jul01-Dec31" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">886</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">Conversion of RSU's for tax withholding payments</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">—</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">—</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>(<ix:nonFraction id="d22922455e6882-wk-Fact-06D88D1F562BF86AB490DB1A33CFCA7C" name="us-gaap:SharesPaidForTaxWithholdingForShareBasedCompensation" contextRef="D2018Q4Jul01-Dec31_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="shares" decimals="-3" scale="3" format="ixt:numdotdecimal">9</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">—</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>(<ix:nonFraction id="d22922455e6917-wk-Fact-7631E684054514533642DB1A33EF3175" name="us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" contextRef="D2018Q4Jul01-Dec31_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">192</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">—</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">—</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">—</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">—</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>(<ix:nonFraction id="d22922455e7015-wk-Fact-A0F40B8EFDEF0171E27FDB1A344864FE" name="us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" contextRef="D2018Q4Jul01-Dec31" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">192</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">Other comprehensive income</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">—</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">—</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">—</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">—</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">—</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">—</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">—</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span><ix:nonFraction id="d22922455e7161-wk-Fact-6412DDF91EE459E13C19DB1A3365D6EE" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" contextRef="D2018Q4Jul01-Dec31_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">2</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">—</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span><ix:nonFraction id="d22922455e7200-wk-Fact-8BE8CC99A112976EF87AD1D018643C0B" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" contextRef="D2018Q4Jul01-Dec31" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">2</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">Net loss</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">—</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">—</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">—</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">—</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">—</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">—</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>(<ix:nonFraction id="d22922455e7326-wk-Fact-B3465BD810D5EBC02921DB1A33A6F84E" name="us-gaap:ProfitLoss" contextRef="D2018Q4Jul01-Dec31_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">157,668</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>(<ix:nonFraction id="d22922455e7366-wk-Fact-97BAEE797D6938FA7468DB1A33B21718" name="us-gaap:ProfitLoss" contextRef="D2018Q4Jul01-Dec31_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">81</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>(<ix:nonFraction id="d22922455e7387-wk-Fact-5ACF8E8FD2F7A88E6F00D1D0184B9305" name="us-gaap:ProfitLoss" contextRef="D2018Q4Jul01-Dec31" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">157,749</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">Balance at December 31, 2018</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span><ix:nonFraction id="d22922455e7408-wk-Fact-34276AFB4FC86A1178A4DB1A33D6CF8B" name="us-gaap:SharesIssued" contextRef="FI2018Q4_us-gaap_StatementClassOfStockAxis_us-gaap_ConvertiblePreferredStockMember" unitRef="shares" decimals="-3" scale="3" format="ixt:zerodash">—</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span><ix:nonFraction id="d22922455e7427-wk-Fact-D8BD7D786A88E93487EBDB1A33E97150" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="FI2018Q4_us-gaap_StatementClassOfStockAxis_us-gaap_ConvertiblePreferredStockMember" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">—</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span><ix:nonFraction id="d22922455e7441-wk-Fact-67214A7B1CE5ABF3EA11DB1A33FC4ACF" name="us-gaap:SharesIssued" contextRef="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="shares" decimals="-3" scale="3" format="ixt:numdotdecimal">190,446</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span><ix:nonFraction id="d22922455e7461-wk-Fact-A7FC0995A8AEBEE92D15DB1A341A815B" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">1,905</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span><ix:nonFraction id="d22922455e7480-wk-Fact-76A2D1DFA701CA8C6880DB1A34295F72" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">1,219,237</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>(<ix:nonFraction id="d22922455e7499-wk-Fact-6F1E8115D1B5B1C86E92DB1A34481A84" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">824</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>(<ix:nonFraction id="d22922455e7520-wk-Fact-20814BF9D248359A344EDB1A347716B1" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">953,216</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>(<ix:nonFraction id="d22922455e7540-wk-Fact-562F6001069369D84768DB1A32C37129" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">351</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>(<ix:nonFraction id="d22922455e7560-wk-Fact-EDF8707C7ABB7E2C3D9ADB1A32DFCE05" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">902</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span><ix:nonFraction id="d22922455e7581-wk-Fact-82C9BC65B21B97B100C5D1D0184B8D2C" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="FI2018Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">265,849</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">Exercise of stock options, net</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">—</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">—</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span><ix:nonFraction id="d22922455e7629-wk-Fact-6ADB63583FDC17EED36AE0171C999F3D" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" contextRef="FD2019Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="shares" decimals="-3" scale="3" format="ixt:numdotdecimal">1,207</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span><ix:nonFraction id="d22922455e7644-wk-Fact-91E6D8158AAD11676781E0171E19DA1C" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="FD2019Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">12</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span><ix:nonFraction id="d22922455e7663-wk-Fact-4A531C3AF5ABFF79425CE0171F88B28D" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="FD2019Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">3,812</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>(<ix:nonFraction id="d22922455e7682-wk-Fact-FE80A5BA53B2FB9DE573E0179BF9B84D" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="FD2019Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">1,271</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">—</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">—</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">—</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span><ix:nonFraction id="d22922455e7761-wk-Fact-E36C8C0C6C8DB4384D73E0172567DC39" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">2,553</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">Issuance of common stock in public offering, net</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">—</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">—</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span><ix:nonFraction id="d22922455e7814-wk-Fact-17EF308A0FE33AE3309DE0189C49A69A" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="FD2019Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember" unitRef="shares" decimals="-3" scale="3" format="ixt:numdotdecimal">16,429</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span><ix:nonFraction id="d22922455e7829-wk-Fact-789CE102F96988BFD128E0189EDC4B95" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="FD2019Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">164</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span><ix:nonFraction id="d22922455e7848-wk-Fact-4000A1B2DCE46DFD6593E018A179D642" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="FD2019Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">272,867</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">—</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">—</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">—</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">—</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span><ix:nonFraction id="d22922455e7945-wk-Fact-885847366CB4D0077E51E018AB642955" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="FD2019Q4YTD_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">273,031</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">Stock-based compensation</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">—</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">—</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span><ix:nonFraction id="d22922455e7998-wk-Fact-B30D6F1CA8BCB4BEA753E0193F59A74E" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" contextRef="FD2019Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="shares" decimals="-3" scale="3" format="ixt:numdotdecimal">15</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">—</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span><ix:nonFraction id="d22922455e8032-wk-Fact-9A1651F113BE49E50647E01942449541" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" contextRef="FD2019Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">11,736</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">—</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">—</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">—</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">—</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span><ix:nonFraction id="d22922455e8129-wk-Fact-43E52E5311509C4DD4F0E019479C45DF" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">11,736</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">Issuance of common stock in at-the-market offering, net</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">—</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">—</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span><ix:nonFraction id="d22922455e8182-wk-Fact-DCBB2FA4C7DE3AA80401E0226E38F11A" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="FD2019Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_us-gaap_SubsidiarySaleOfStockAxis_immu_MarketOfferingMember" unitRef="shares" decimals="-3" scale="3" format="ixt:numdotdecimal">4,432</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span><ix:nonFraction id="d22922455e8197-wk-Fact-A821D07063F18F3FA45EE0227161BE54" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="FD2019Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_us-gaap_SubsidiarySaleOfStockAxis_immu_MarketOfferingMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">44</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span><ix:nonFraction id="d22922455e8216-wk-Fact-F222BE7870F9D334374FE022746DC81A" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="FD2019Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_us-gaap_SubsidiarySaleOfStockAxis_immu_MarketOfferingMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">71,553</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">—</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">—</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">—</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">—</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span><ix:nonFraction id="d22922455e8313-wk-Fact-7BA23B140E9B754F2274E02283833BAB" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="FD2019Q4YTD_us-gaap_SubsidiarySaleOfStockAxis_immu_MarketOfferingMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">71,597</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">Other comprehensive loss</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">—</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">—</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">—</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">—</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">—</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">—</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">—</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>(<ix:nonFraction id="d22922455e8458-wk-Fact-DD9474BEB6B88C2EC211E01B9DDAC906" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" contextRef="FD2019Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">217</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">—</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>(<ix:nonFraction id="d22922455e8498-wk-Fact-A6C1E2230EF5DC9F423AD71417BAA3B2" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">217</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">Net loss</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">—</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">—</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">—</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">—</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">—</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">—</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>(<ix:nonFraction id="d22922455e8625-wk-Fact-D59B78AAE5CA59EF330BE01BD5405CD4" name="us-gaap:ProfitLoss" contextRef="FD2019Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">357,190</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">—</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>(<ix:nonFraction id="d22922455e8664-wk-Fact-1DA3F7A5EE15BA97FD65E01BD810D643" name="us-gaap:ProfitLoss" contextRef="FD2019Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">129</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>(<ix:nonFraction id="d22922455e8685-wk-Fact-29F9B6EF360FC370699FD713DDBDA593" name="us-gaap:ProfitLoss" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">357,319</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">Balance at December 31, 2019</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span><ix:nonFraction id="d22922455e8706-wk-Fact-4D91E5BC752B0EF014B4E01C2724CAD4" name="us-gaap:SharesIssued" contextRef="FI2019Q4_us-gaap_StatementClassOfStockAxis_us-gaap_ConvertiblePreferredStockMember" unitRef="shares" decimals="-3" scale="3" format="ixt:zerodash">—</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span><ix:nonFraction id="d22922455e8725-wk-Fact-2EF83A51D107D60EA816E01C289606F8" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="FI2019Q4_us-gaap_StatementClassOfStockAxis_us-gaap_ConvertiblePreferredStockMember" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">—</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span><ix:nonFraction id="d22922455e8739-wk-Fact-351E87437DA2C208F602E01C2A121598" name="us-gaap:SharesIssued" contextRef="FI2019Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="shares" decimals="-3" scale="3" format="ixt:numdotdecimal">212,529</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span><ix:nonFraction id="d22922455e8759-wk-Fact-F378FDBF492BA0B35961E01C2B82A3EF" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="FI2019Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">2,125</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span><ix:nonFraction id="d22922455e8778-wk-Fact-0153367734B82FD76113E01C2CFE5025" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="FI2019Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">1,579,205</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>(<ix:nonFraction id="d22922455e8797-wk-Fact-943E06949CDDB37031D5E01C2E71A7D8" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="FI2019Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">2,095</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>(<ix:nonFraction id="d22922455e8818-wk-Fact-E4C7EC056A034D54D906E01C2FEE1F96" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="FI2019Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">1,310,406</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>(<ix:nonFraction id="d22922455e8838-wk-Fact-E05F826E7FC2B3955FA6E01C315FCF80" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="FI2019Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">568</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>(<ix:nonFraction id="d22922455e8858-wk-Fact-012C9C92FE5184C3BED0E01C32DDBA4E" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="FI2019Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">1,031</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span><ix:nonFraction id="d22922455e8879-wk-Fact-506CDA3CCB6716A29946D1D0184B0B3B" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="FI2019Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">267,230</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;padding-top:16px;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">See accompanying notes to consolidated financial statements.</span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">60</span></div></div><hr style="page-break-after:always"></hr><div><a id="sC53F1EBE702F5B08B49050D77056F4B8"></a></div><div><div style="line-height:120%;text-align:justify;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;" href="#sfb86787ac8304dffbb4bfe7ffcfa7b54"><span style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">Table of Contents</span></a></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></div><div><br/></div><div style="line-height:120%;text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">IMMUNOMEDICS, INC. AND SUBSIDIARIES</span></div><div style="line-height:120%;text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">CONSOLIDATED STATEMENTS OF CASH FLOWS</span></div><div style="line-height:120%;text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">(Dollars in thousands)</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"></td></tr><tr><td style="width:45%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"> </span></div></td><td colspan="3" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Year Ended December 31, 2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">For the Transition Period Ended December 31, 2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Years Ended June 30, </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">2017</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Cash flows from operating activities:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Net loss</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>(<ix:nonFraction id="d22927408e922-wk-Fact-29F9B6EF360FC370699FD713DDBDA593" name="us-gaap:ProfitLoss" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">357,319</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>(<ix:nonFraction id="d22927408e942-wk-Fact-5ACF8E8FD2F7A88E6F00D1D0184B9305" name="us-gaap:ProfitLoss" contextRef="D2018Q4Jul01-Dec31" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">157,749</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>(<ix:nonFraction id="d22927408e962-wk-Fact-6CE3D07A35B1D83DEB81D1D0184B1FFE" name="us-gaap:ProfitLoss" contextRef="D2018Q4Jul12017toJun302018" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">273,887</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>(<ix:nonFraction id="d22927408e983-wk-Fact-AC988A2DC8A22FB48CBDD1D018651B52" name="us-gaap:ProfitLoss" contextRef="D2017Q4Jul012016toJun302017" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">153,266</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Adjustments to reconcile net loss to net cash used in operating activities:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:44px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Changes in fair value of warrant liabilities</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d22927408e1081-wk-Fact-D2E66984117CBB450CBED713D6D0FE4C" name="us-gaap:FairValueAdjustmentOfWarrants" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">—</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>(<ix:nonFraction id="d22927408e1100-wk-Fact-1D5D4506E00364D1DE67D1D0180B6BBD" name="us-gaap:FairValueAdjustmentOfWarrants" contextRef="D2018Q4Jul01-Dec31" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">1,404</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d22927408e1120-wk-Fact-E26CFE363B06D151ED08D1D0185B3F62" name="us-gaap:FairValueAdjustmentOfWarrants" contextRef="D2018Q4Jul12017toJun302018" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">108,636</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d22927408e1140-wk-Fact-F37ECCDD6B19E07A84DED1D0184BF9B9" name="us-gaap:FairValueAdjustmentOfWarrants" contextRef="D2017Q4Jul012016toJun302017" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">61,074</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:44px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Warrant related expense</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d22927408e1160-wk-Fact-19C533DBB7AA881D2E4ED713D76EE172" name="us-gaap:AdjustmentOfWarrantsGrantedForServices" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">—</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d22927408e1179-wk-Fact-02AC75F1B59F9F5CF65BD1D0180B5321" name="us-gaap:AdjustmentOfWarrantsGrantedForServices" contextRef="D2018Q4Jul01-Dec31" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">—</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d22927408e1198-wk-Fact-98B95CF860F0B356D8DDD1D0185B395E" name="us-gaap:AdjustmentOfWarrantsGrantedForServices" contextRef="D2018Q4Jul12017toJun302018" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">—</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d22927408e1218-wk-Fact-797C88AEF9ED2C7F4EE3D1D0184B05E0" name="us-gaap:AdjustmentOfWarrantsGrantedForServices" contextRef="D2017Q4Jul012016toJun302017" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">7,649</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:44px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Depreciation and amortization</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d22927408e1238-wk-Fact-796F20817C8F559229CAE03DED5163C9" name="us-gaap:DepreciationAndAmortization" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">3,822</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d22927408e1257-wk-Fact-5E7A83E518B41047DEE3D1D0182AC33E" name="us-gaap:DepreciationAndAmortization" contextRef="D2018Q4Jul01-Dec31" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">2,099</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d22927408e1276-wk-Fact-61ABE4EE1D9A402E6FEBD1D0181BFFC5" name="us-gaap:DepreciationAndAmortization" contextRef="D2018Q4Jul12017toJun302018" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">1,297</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d22927408e1296-wk-Fact-2BC04E4166F6D3520588D1D0183CB85C" name="us-gaap:DepreciationAndAmortization" contextRef="D2017Q4Jul012016toJun302017" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">923</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:44px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Loss on disposal of property and equipment</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d22927408e1316-wk-Fact-72005A0951F951DF966EE047E5F650F8" name="us-gaap:GainLossOnSaleOfPropertyPlantEquipment" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">1,003</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d22927408e1335-wk-Fact-352C2491E5806EE9148BE047E6078AE1" name="us-gaap:GainLossOnSaleOfPropertyPlantEquipment" contextRef="D2018Q4Jul01-Dec31" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">—</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d22927408e1354-wk-Fact-A4EC20A8B78FADB20566E047E602B51B" name="us-gaap:GainLossOnSaleOfPropertyPlantEquipment" contextRef="D2018Q4Jul12017toJun302018" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">—</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d22927408e1374-wk-Fact-14204F7CF92813D54F90E047E5FD4AA4" name="us-gaap:GainLossOnSaleOfPropertyPlantEquipment" contextRef="D2017Q4Jul012016toJun302017" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">—</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:44px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Interest on non-recourse debt</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d22927408e1394-wk-Fact-55D0CC5B9F74C0B7E003E03DEE735F4D" name="us-gaap:InterestExpenseDebt" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">39,929</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d22927408e1413-wk-Fact-FE0C65C47E78AE3AD99ED1D0181B1F93" name="us-gaap:InterestExpenseDebt" contextRef="D2018Q4Jul01-Dec31" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">19,288</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d22927408e1432-wk-Fact-C4C4DC191010160FB8D3D1D0185B657D" name="us-gaap:InterestExpenseDebt" contextRef="D2018Q4Jul12017toJun302018" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">19,791</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d22927408e1452-wk-Fact-9FD98E6EECA57E0E1697D1D0180B81DF" name="us-gaap:InterestExpenseDebt" contextRef="D2017Q4Jul012016toJun302017" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">—</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:44px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Loss on induced exchanges of debt</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d22927408e1472-wk-Fact-6F0080A18CB0CED25E92E03DEF194A94" name="immu:LossOnInducedExchangesOfDebt" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">—</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d22927408e1491-wk-Fact-E47672E3C80DDAD70C01D1D0180B0F49" name="immu:LossOnInducedExchangesOfDebt" contextRef="D2018Q4Jul01-Dec31" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">897</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d22927408e1510-wk-Fact-17D8CE6622ACEC880707D1D01865B031" name="immu:LossOnInducedExchangesOfDebt" contextRef="D2018Q4Jul12017toJun302018" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">13,005</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d22927408e1530-wk-Fact-E600B3AE91A97B17EC25D1D0183B6E8F" name="immu:LossOnInducedExchangesOfDebt" contextRef="D2017Q4Jul012016toJun302017" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">—</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:44px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Amortization of deferred revenue</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d22927408e1551-wk-Fact-00B2B7A1E6125CB5CB26E03DEFBAE70F" name="us-gaap:ContractWithCustomerLiabilityRevenueRecognized" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">—</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>(<ix:nonFraction id="d22927408e1570-wk-Fact-2E811D4E8954A7DB753AD1D0181B41CA" name="us-gaap:ContractWithCustomerLiabilityRevenueRecognized" contextRef="D2018Q4Jul01-Dec31" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">94</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>(<ix:nonFraction id="d22927408e1590-wk-Fact-ED74FD1E7A242DCD0A48D1D0181BA805" name="us-gaap:ContractWithCustomerLiabilityRevenueRecognized" contextRef="D2018Q4Jul12017toJun302018" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">77</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>(<ix:nonFraction id="d22927408e1611-wk-Fact-10CF2DF7F9BC2B6D2ED9D1D0182A2F0A" name="us-gaap:ContractWithCustomerLiabilityRevenueRecognized" contextRef="D2017Q4Jul012016toJun302017" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">64</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:44px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Amortization of bond premiums</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d22927408e1632-wk-Fact-315F871BAE6F3E575D65E03DF0665C28" name="us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">—</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d22927408e1651-wk-Fact-363F775B1E771FE6569BD1D0180BE83C" name="us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments" contextRef="D2018Q4Jul01-Dec31" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">3</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d22927408e1670-wk-Fact-9C9400B76971994CA4FFD1D0182A0F22" name="us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments" contextRef="D2018Q4Jul12017toJun302018" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">31</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d22927408e1690-wk-Fact-9BC21C1D3C9C418CC1A4D1D0183C27C7" name="us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments" contextRef="D2017Q4Jul012016toJun302017" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">218</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:44px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Amortization of debt issuance costs</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d22927408e1710-wk-Fact-38085602BB09E587F549E03DF1079925" name="us-gaap:AmortizationOfFinancingCosts" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">50</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d22927408e1729-wk-Fact-269E3818309893EB8304D1D0186540E4" name="us-gaap:AmortizationOfFinancingCosts" contextRef="D2018Q4Jul01-Dec31" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">179</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d22927408e1748-wk-Fact-07AF50940B45C6D84A2FD1D0181B8B7F" name="us-gaap:AmortizationOfFinancingCosts" contextRef="D2018Q4Jul12017toJun302018" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">1,679</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d22927408e1768-wk-Fact-A2FDABF98AFACA5099E8D1D0181B22CF" name="us-gaap:AmortizationOfFinancingCosts" contextRef="D2017Q4Jul012016toJun302017" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">730</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:44px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Amortization of deferred rent</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d22927408e1788-wk-Fact-427E98B389C0E980DDF4E03DF1AEC5C9" name="us-gaap:IncreaseDecreaseInDeferredCharges" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">—</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d22927408e1807-wk-Fact-687B1B63DE151E2F3C2BD1D0183C5FB5" name="us-gaap:IncreaseDecreaseInDeferredCharges" contextRef="D2018Q4Jul01-Dec31" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">132</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d22927408e1826-wk-Fact-7AA6FA362DCD7A43235FD1D01865632E" name="us-gaap:IncreaseDecreaseInDeferredCharges" contextRef="D2018Q4Jul12017toJun302018" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">279</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d22927408e1846-wk-Fact-6DE7623FEC6B072E7251D1D0182AA220" name="us-gaap:IncreaseDecreaseInDeferredCharges" contextRef="D2017Q4Jul012016toJun302017" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">10</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:44px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Non-cash lease expense</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d22927408e1866-wk-Fact-0461DCA6A3DFAFDA7C1AE0477722A0F8" name="us-gaap:FinanceLeaseRightOfUseAssetAmortization" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">264</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d22927408e1885-wk-Fact-29E3D6D1AF209B06B96BE04777274B72" name="us-gaap:FinanceLeaseRightOfUseAssetAmortization" contextRef="D2018Q4Jul01-Dec31" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">—</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d22927408e1904-wk-Fact-C5656CAAE3D775C3873CE047772C267C" name="us-gaap:FinanceLeaseRightOfUseAssetAmortization" contextRef="D2018Q4Jul12017toJun302018" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">—</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d22927408e1924-wk-Fact-80B9230093CBA5B31C81E047771DED51" name="us-gaap:FinanceLeaseRightOfUseAssetAmortization" contextRef="D2017Q4Jul012016toJun302017" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">—</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:44px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Loss on sale of marketable securities</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d22927408e1944-wk-Fact-3FA7CECAA7B0125B4476E03DF2DCAFCC" name="us-gaap:DebtAndEquitySecuritiesGainLoss" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">—</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d22927408e1963-wk-Fact-50D9B060540A9217ABE4D1D0183CA9D9" name="us-gaap:DebtAndEquitySecuritiesGainLoss" contextRef="D2018Q4Jul01-Dec31" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">—</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d22927408e1982-wk-Fact-C4E935E5407DC22D5D36D1D0185B42D1" name="us-gaap:DebtAndEquitySecuritiesGainLoss" contextRef="D2018Q4Jul12017toJun302018" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">—</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d22927408e2002-wk-Fact-BCFDF14072B79812794BD1D0181B639C" name="us-gaap:DebtAndEquitySecuritiesGainLoss" contextRef="D2017Q4Jul012016toJun302017" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">16</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:44px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Decrease in allowance for doubtful accounts</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d22927408e2022-wk-Fact-C476D201DD89814BC935E03DF3881200" name="us-gaap:ProvisionForDoubtfulAccounts" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">—</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d22927408e2041-wk-Fact-525457B19BBC6B61A1B5D1D0181B3E7A" name="us-gaap:ProvisionForDoubtfulAccounts" contextRef="D2018Q4Jul01-Dec31" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">—</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>(<ix:nonFraction id="d22927408e2060-wk-Fact-A499D78C396F5BB9AA1ED1D0182A5F1F" name="us-gaap:ProvisionForDoubtfulAccounts" contextRef="D2018Q4Jul12017toJun302018" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">9</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>(<ix:nonFraction id="d22927408e2081-wk-Fact-6E7F0983A9E2CB2CD08DD1D0185BC28F" name="us-gaap:ProvisionForDoubtfulAccounts" contextRef="D2017Q4Jul012016toJun302017" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">62</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:44px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Non-cash expense related to stock-based compensation</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d22927408e2102-wk-Fact-3153A3E94C9F98F8B14BE03DF428872E" name="us-gaap:ShareBasedCompensation" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">11,736</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d22927408e2121-wk-Fact-2357B96370D886723F5CD1D0182A5C6F" name="us-gaap:ShareBasedCompensation" contextRef="D2018Q4Jul01-Dec31" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">886</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d22927408e2140-wk-Fact-28AABABF5E384C3D2AE9D1D0181B4266" name="us-gaap:ShareBasedCompensation" contextRef="D2018Q4Jul12017toJun302018" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">4,024</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d22927408e2160-wk-Fact-6B4B93CD6EF7A42B450FD1D0183CC8E7" name="us-gaap:ShareBasedCompensation" contextRef="D2017Q4Jul012016toJun302017" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">4,333</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:44px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Non-cash financing expenses</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d22927408e2180-wk-Fact-A069CC3B7ADE1506E2BBE03DF6C54057" name="us-gaap:OtherNoncashExpense" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">—</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d22927408e2199-wk-Fact-1962DED19E8A8AB89DCFD1D0180B059C" name="us-gaap:OtherNoncashExpense" contextRef="D2018Q4Jul01-Dec31" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">—</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d22927408e2218-wk-Fact-C7C5B57B5CCB58A0932BD1D0182A1881" name="us-gaap:OtherNoncashExpense" contextRef="D2018Q4Jul12017toJun302018" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">—</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d22927408e2238-wk-Fact-B08B0B44F05FA383581ED1D0183C3753" name="us-gaap:OtherNoncashExpense" contextRef="D2017Q4Jul012016toJun302017" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">347</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Changes in operating assets and liabilities</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:44px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Accounts receivable, net</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>(<ix:nonFraction id="d22927408e2340-wk-Fact-1F3E892E630ADCC147D7E03DF7DD26EE" name="us-gaap:IncreaseDecreaseInAccountsReceivable" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">295</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d22927408e2360-wk-Fact-5063F3BEC0BBC08062E5D1D0181B1EC5" name="us-gaap:IncreaseDecreaseInAccountsReceivable" contextRef="D2018Q4Jul01-Dec31" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">46</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d22927408e2379-wk-Fact-93D84D449AE5A845E444D1D01865EB58" name="us-gaap:IncreaseDecreaseInAccountsReceivable" contextRef="D2018Q4Jul12017toJun302018" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">452</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d22927408e2399-wk-Fact-48B029B0A4DA7B0EED00D1D0181BD835" name="us-gaap:IncreaseDecreaseInAccountsReceivable" contextRef="D2017Q4Jul012016toJun302017" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">103</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:44px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Inventories, net</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d22927408e2420-wk-Fact-1E70C9B811B92D4A7B43E03DF90A300E" name="us-gaap:IncreaseDecreaseInInventories" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">—</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d22927408e2439-wk-Fact-CF5D647F10C26F0968F0D1D0181BF89B" name="us-gaap:IncreaseDecreaseInInventories" contextRef="D2018Q4Jul01-Dec31" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">—</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d22927408e2458-wk-Fact-764FCBE86670B845D7FAD1D0182A6446" name="us-gaap:IncreaseDecreaseInInventories" contextRef="D2018Q4Jul12017toJun302018" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">580</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>(<ix:nonFraction id="d22927408e2478-wk-Fact-6031D805A7BC190787CAD1D0185B36DE" name="us-gaap:IncreaseDecreaseInInventories" contextRef="D2017Q4Jul012016toJun302017" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">196</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:44px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Other receivables</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d22927408e2499-wk-Fact-A33B6E7F9AF4E6D507B7E03DF9CDE4E0" name="us-gaap:IncreaseDecreaseInOtherReceivables" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">—</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d22927408e2518-wk-Fact-7F4B769A9CC117685186D1D0183CF81C" name="us-gaap:IncreaseDecreaseInOtherReceivables" contextRef="D2018Q4Jul01-Dec31" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">—</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>(<ix:nonFraction id="d22927408e2537-wk-Fact-0F0E243CF6AEE727184ED1D0182A9D78" name="us-gaap:IncreaseDecreaseInOtherReceivables" contextRef="D2018Q4Jul12017toJun302018" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">30</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d22927408e2558-wk-Fact-CFB94900FCC471373741D1D0180BF7E3" name="us-gaap:IncreaseDecreaseInOtherReceivables" contextRef="D2017Q4Jul012016toJun302017" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">223</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:44px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Prepaid expenses and other current assets</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>(<ix:nonFraction id="d22927408e2578-wk-Fact-0E53CE49A7C9D148358BE03DFAA27027" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">16,423</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d22927408e2598-wk-Fact-BAA4E071CF39ABFE6912D1D0181B2BC5" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" contextRef="D2018Q4Jul01-Dec31" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">3,617</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>(<ix:nonFraction id="d22927408e2617-wk-Fact-31681F45B63E4BD6FB52D1D0182AB5C3" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" contextRef="D2018Q4Jul12017toJun302018" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">7,679</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>(<ix:nonFraction id="d22927408e2638-wk-Fact-6D3CBF9B31E69EC49082D1D0185BD770" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" contextRef="D2017Q4Jul012016toJun302017" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">97</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:44px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Accounts payable and accrued expenses</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d22927408e2659-wk-Fact-85C04B9330B2518EF98FE03DFC9CF2AA" name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">29,977</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d22927408e2678-wk-Fact-E3FC29AC548FFA912DEFD1D0183CD5B5" name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" contextRef="D2018Q4Jul01-Dec31" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">1,436</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>(<ix:nonFraction id="d22927408e2697-wk-Fact-C43717E4AD0EF0E50A22D1D0185B052A" name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" contextRef="D2018Q4Jul12017toJun302018" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">1,518</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d22927408e2718-wk-Fact-63343A911680AED40207D1D0182ABF4E" name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" contextRef="D2017Q4Jul012016toJun302017" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">15,809</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:44px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Other liabilities</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>(<ix:nonFraction id="d22927408e2738-wk-Fact-8165F26AFB80EE0B36BAE042DA252EC1" name="us-gaap:IncreaseDecreaseInOtherOperatingLiabilities" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">186</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d22927408e2758-wk-Fact-1A4A8BB9759CDACDE464E042DA2F4F43" name="us-gaap:IncreaseDecreaseInOtherOperatingLiabilities" contextRef="D2018Q4Jul01-Dec31" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">—</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d22927408e2777-wk-Fact-35337C344C0CBC544DD8E042DA2AA3C9" name="us-gaap:IncreaseDecreaseInOtherOperatingLiabilities" contextRef="D2018Q4Jul12017toJun302018" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">—</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d22927408e2797-wk-Fact-186B5C23720975FA2405E042DA1F28CB" name="us-gaap:IncreaseDecreaseInOtherOperatingLiabilities" contextRef="D2017Q4Jul012016toJun302017" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">—</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:44px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Deferred revenue</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d22927408e2817-wk-Fact-E9A7481E9DA23DB31181E04382CCF9F0" name="us-gaap:IncreaseDecreaseInDeferredRevenue" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">65,000</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d22927408e2836-wk-Fact-7BEBA1D145A1EB5C429EE043842AED24" name="us-gaap:IncreaseDecreaseInDeferredRevenue" contextRef="D2018Q4Jul01-Dec31" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">—</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d22927408e2855-wk-Fact-3E2F6328F2929A42A10FE04385E527C9" name="us-gaap:IncreaseDecreaseInDeferredRevenue" contextRef="D2018Q4Jul12017toJun302018" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">—</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d22927408e2875-wk-Fact-F3031886EC60F9A6448AE04387B6A345" name="us-gaap:IncreaseDecreaseInDeferredRevenue" contextRef="D2017Q4Jul012016toJun302017" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">—</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:44px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Net cash used in operating activities</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>(<ix:nonFraction id="d22927408e2895-wk-Fact-105F176A1DB59041C3C1E03DFE41A474" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">222,442</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>(<ix:nonFraction id="d22927408e2915-wk-Fact-9881C2E57624659D5270D1D0182AE11A" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" contextRef="D2018Q4Jul01-Dec31" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">130,664</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>(<ix:nonFraction id="d22927408e2935-wk-Fact-4035B20C58F079D3A7C7D1D0182A3DC9" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" contextRef="D2018Q4Jul12017toJun302018" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">133,426</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>(<ix:nonFraction id="d22927408e2956-wk-Fact-E728F2285F609C16FC95D1D0181B4F7A" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" contextRef="D2017Q4Jul012016toJun302017" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">62,250</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Cash flows from investing activities:</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Purchases of marketable securities</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d22927408e3059-wk-Fact-DC22795EE41646A9F03FE03DFFB12850" name="us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">—</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d22927408e3078-wk-Fact-DFF5F997DED8A72F25FCD1D0180B60C1" name="us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt" contextRef="D2018Q4Jul01-Dec31" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">—</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>(<ix:nonFraction id="d22927408e3097-wk-Fact-90CCB689DA444C4657FCD1D0185BB712" name="us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt" contextRef="D2018Q4Jul12017toJun302018" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">10,380</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>(<ix:nonFraction id="d22927408e3118-wk-Fact-0AE8125908315C0960FFD1D0181B6A73" name="us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt" contextRef="D2017Q4Jul012016toJun302017" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">131,610</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Proceeds from sales/maturities of marketable securities</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d22927408e3139-wk-Fact-A2F9302707D8DCDDA31DE03E0058CB9E" name="us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">—</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d22927408e3158-wk-Fact-3F5A7910746DAAA9BBD0D1D0181B8A7F" name="us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" contextRef="D2018Q4Jul01-Dec31" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">21,818</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d22927408e3177-wk-Fact-1B33929C329F74A06CAED1D0183BA628" name="us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" contextRef="D2018Q4Jul12017toJun302018" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">95,112</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d22927408e3197-wk-Fact-BB7F696DDC4C1CF56302D1D01865F0B9" name="us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" contextRef="D2017Q4Jul012016toJun302017" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">57,183</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Purchases of property and equipment</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>(<ix:nonFraction id="d22927408e3217-wk-Fact-D501140860E88A996C8DE03E0108D380" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">6,849</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>(<ix:nonFraction id="d22927408e3237-wk-Fact-DF901A1823C5EC6B4AC1D1D018646EA5" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" contextRef="D2018Q4Jul01-Dec31" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">11,213</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>(<ix:nonFraction id="d22927408e3257-wk-Fact-0DD4A17A158FD0FD55CFD1D018655460" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" contextRef="D2018Q4Jul12017toJun302018" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">9,975</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>(<ix:nonFraction id="d22927408e3278-wk-Fact-5BAB0E3555C5B8798566D1D0180B3584" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" contextRef="D2017Q4Jul012016toJun302017" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">1,837</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:44px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Net cash (used in) provided by investing activities</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>(<ix:nonFraction id="d22927408e3300-wk-Fact-127C2563439CE49154B5E03E026B0AC8" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">6,849</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d22927408e3320-wk-Fact-AE7D93389679985B1D1CD1D0180B6614" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" contextRef="D2018Q4Jul01-Dec31" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">10,605</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d22927408e3339-wk-Fact-9A06E4822D7686C58CBFD1D0182A5ACA" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" contextRef="D2018Q4Jul12017toJun302018" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">74,757</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>(<ix:nonFraction id="d22927408e3359-wk-Fact-0A3444E6989A87FB4A5ED1D0181BE447" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" contextRef="D2017Q4Jul012016toJun302017" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">76,264</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Cash flows from financing activities:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Exercise of stock options, net</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d22927408e3462-wk-Fact-855876B006BD995C61BCE03E0373EC35" name="us-gaap:ProceedsFromStockOptionsExercised" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">2,553</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d22927408e3481-wk-Fact-68CF32679C55162FF6D5D1D01865F663" name="us-gaap:ProceedsFromStockOptionsExercised" contextRef="D2018Q4Jul01-Dec31" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">176</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d22927408e3500-wk-Fact-E5FC720EEA81334A98BAD1D0180BE418" name="us-gaap:ProceedsFromStockOptionsExercised" contextRef="D2018Q4Jul12017toJun302018" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">2,261</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d22927408e3520-wk-Fact-8DFD961D07AD6B5F0541D1D0183CA52F" name="us-gaap:ProceedsFromStockOptionsExercised" contextRef="D2017Q4Jul012016toJun302017" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">4,290</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Exercise of warrants</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d22927408e3540-wk-Fact-35B39B3B4A1E85D292EAE03E0418D5EB" name="us-gaap:ProceedsFromWarrantExercises" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">—</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d22927408e3559-wk-Fact-4278239C42C56611E0A2D1D0182A0A9D" name="us-gaap:ProceedsFromWarrantExercises" contextRef="D2018Q4Jul01-Dec31" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">1,688</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d22927408e3578-wk-Fact-0F29532860D2209B0E4DD1D0182A5123" name="us-gaap:ProceedsFromWarrantExercises" contextRef="D2018Q4Jul12017toJun302018" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">78,226</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d22927408e3598-wk-Fact-4B0F366850EEBC0595AAD1D0181B803A" name="us-gaap:ProceedsFromWarrantExercises" contextRef="D2017Q4Jul012016toJun302017" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">—</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Sale of preferred stock, net of related expenses</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d22927408e3618-wk-Fact-62CE1B148A156791E279E03E04C2795E" name="us-gaap:ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">—</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d22927408e3637-wk-Fact-DCA1AA1912B5933CD947D1D0182A7185" name="us-gaap:ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" contextRef="D2018Q4Jul01-Dec31" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">—</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d22927408e3656-wk-Fact-70713572B3E7DCF81F14D1D0182A763F" name="us-gaap:ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" contextRef="D2018Q4Jul12017toJun302018" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">—</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d22927408e3676-wk-Fact-94E2B71FAA90A5537401D1D0181B0EA0" name="us-gaap:ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" contextRef="D2017Q4Jul012016toJun302017" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">121,782</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Proceeds from public offering of common stock</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d22927408e3696-wk-Fact-3169E29DE0388E2B20A5E03E05697637" name="us-gaap:ProceedsFromIssuanceInitialPublicOffering" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">273,031</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d22927408e3715-wk-Fact-324654F3E82C89488BF5D1D0181BF1DE" name="us-gaap:ProceedsFromIssuanceInitialPublicOffering" contextRef="D2018Q4Jul01-Dec31" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">—</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d22927408e3734-wk-Fact-4B0DE5A19551B9C48F61D1D0182A9BB0" name="us-gaap:ProceedsFromIssuanceInitialPublicOffering" contextRef="D2018Q4Jul12017toJun302018" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">299,467</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d22927408e3754-wk-Fact-90A2B33FCB01F079D047D1D0183A06DA" name="us-gaap:ProceedsFromIssuanceInitialPublicOffering" contextRef="D2017Q4Jul012016toJun302017" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">28,578</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Proceeds from the issuance of common stock in at-the-market offering, net</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d22927408e3774-wk-Fact-570DE8390E8718F4222EE03E060FFE72" name="us-gaap:ProceedsFromIssuanceOfCommonStock" contextRef="FD2019Q4YTD_us-gaap_SubsidiarySaleOfStockAxis_immu_MarketOfferingMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">71,597</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d22927408e3793-wk-Fact-C3DAC846230131E426CF39BAC1CFCA81" name="us-gaap:ProceedsFromIssuanceOfCommonStock" contextRef="D2018Q4Jul01-Dec31_us-gaap_SubsidiarySaleOfStockAxis_immu_MarketOfferingMember" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">—</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d22927408e3812-wk-Fact-5AB400EA4B3A3C2A43BC39BACD3314B1" name="us-gaap:ProceedsFromIssuanceOfCommonStock" contextRef="D2018Q4Jul12017toJun302018_us-gaap_SubsidiarySaleOfStockAxis_immu_MarketOfferingMember" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">—</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d22927408e3832-wk-Fact-3E8897258591B299137C39BAD7B9CFBF" name="us-gaap:ProceedsFromIssuanceOfCommonStock" contextRef="D2017Q4Jul012016toJun302017_us-gaap_SubsidiarySaleOfStockAxis_immu_MarketOfferingMember" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">—</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Proceeds from private offering of common stock</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d22927408e3852-wk-Fact-F5D27E2C267B2BBAEEE739B36007FDBE" name="us-gaap:ProceedsFromIssuanceOfCommonStock" contextRef="FD2019Q4YTD_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">—</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d22927408e3871-wk-Fact-F010E73EE4CF54D14A36D1D0181B7C91" name="us-gaap:ProceedsFromIssuanceOfCommonStock" contextRef="D2018Q4Jul01-Dec31_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">—</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d22927408e3890-wk-Fact-08CF94FD00BFEDF1F28BD1D0183CC149" name="us-gaap:ProceedsFromIssuanceOfCommonStock" contextRef="D2018Q4Jul12017toJun302018_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">67,784</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d22927408e3910-wk-Fact-E565E3A9F9612F750AFBD1D0181BED10" name="us-gaap:ProceedsFromIssuanceOfCommonStock" contextRef="D2017Q4Jul012016toJun302017_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">14,700</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Proceeds from the issuance of non-recourse debt</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d22927408e3930-wk-Fact-C430B25CDD13101E63CBE03E06B5D264" name="immu:ProceedsFromIssuanceOfNonRecourseDebt" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">—</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d22927408e3949-wk-Fact-CE3E5AE84C4DDBB2A3CCD1D0182A9C2C" name="immu:ProceedsFromIssuanceOfNonRecourseDebt" contextRef="D2018Q4Jul01-Dec31" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">—</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d22927408e3968-wk-Fact-D7A5F0F5003D6359599ED1D0182A304A" name="immu:ProceedsFromIssuanceOfNonRecourseDebt" contextRef="D2018Q4Jul12017toJun302018" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">182,216</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d22927408e3988-wk-Fact-B2FD821B5351485AB039D1D0181BCD1E" name="immu:ProceedsFromIssuanceOfNonRecourseDebt" contextRef="D2017Q4Jul012016toJun302017" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">—</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Debt conversion fees</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d22927408e4008-wk-Fact-C8EB7029A2C48C158D62E03E075DD939" name="immu:PaymentOfDebtConversionFees" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">—</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d22927408e4027-wk-Fact-EA6CE8C13C97B7729570D1D0182A80FB" name="immu:PaymentOfDebtConversionFees" contextRef="D2018Q4Jul01-Dec31" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">—</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>(<ix:nonFraction id="d22927408e4046-wk-Fact-55AE829804B9A5A60AE5D1D0185B1F9F" name="immu:PaymentOfDebtConversionFees" contextRef="D2018Q4Jul12017toJun302018" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">530</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d22927408e4067-wk-Fact-9A050A083EE9207883E3D1D0185B3A55" name="immu:PaymentOfDebtConversionFees" contextRef="D2017Q4Jul012016toJun302017" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">—</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Tax withholding payments for stock-based compensation</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d22927408e4087-wk-Fact-516CB4AB5F6B90908F93E03E0808C15F" name="us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">—</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>(<ix:nonFraction id="d22927408e4106-wk-Fact-D514A232A8B9A92B0B61D1D0183A25B4" name="us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation" contextRef="D2018Q4Jul01-Dec31" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">192</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>(<ix:nonFraction id="d22927408e4126-wk-Fact-2D985B48416D06503477D1D0182A9EA9" name="us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation" contextRef="D2018Q4Jul12017toJun302018" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">1,521</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>(<ix:nonFraction id="d22927408e4147-wk-Fact-DA230C32032D17FE1704D1D0182AC248" name="us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation" contextRef="D2017Q4Jul012016toJun302017" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">546</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:44px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Net cash provided by financing activities</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d22927408e4169-wk-Fact-15AA4D7D8B6FBCF6193EE03E08D30F81" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">347,181</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d22927408e4188-wk-Fact-E3A215C08CCA35FF7B0DD1D0182A4CE2" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" contextRef="D2018Q4Jul01-Dec31" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">1,672</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d22927408e4207-wk-Fact-85FB1EB10DCB43C77CB2D1D0182A1988" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" contextRef="D2018Q4Jul12017toJun302018" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">627,903</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d22927408e4227-wk-Fact-1B7E58CF0D22542D9DF1D1D01865F893" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" contextRef="D2017Q4Jul012016toJun302017" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">168,804</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Effect of changes in exchange rates on cash, cash equivalents and restricted cash</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>(<ix:nonFraction id="d22927408e4247-wk-Fact-CD00A591E3EA6681559439B35FFFB72F" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">22</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>(<ix:nonFraction id="d22927408e4267-wk-Fact-F5F2479C60AE1BD47CE9D1D0180B27FB" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" contextRef="D2018Q4Jul01-Dec31" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">22</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>(<ix:nonFraction id="d22927408e4287-wk-Fact-505C4B84AA5D4C316DAED1D01865F32C" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" contextRef="D2018Q4Jul12017toJun302018" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">46</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>(<ix:nonFraction id="d22927408e4308-wk-Fact-6E437A14B2B947BF9690D1D0185BB818" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" contextRef="D2017Q4Jul012016toJun302017" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">100</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Net increase (decrease) in cash, cash equivalents and restricted cash</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d22927408e4329-wk-Fact-B95CAAC91F70AA1E1AD2E03E0A476FC3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">117,868</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span>(<ix:nonFraction id="d22927408e4348-wk-Fact-6EC15A1D90930728ED44D1D0180BDEC2" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" contextRef="D2018Q4Jul01-Dec31" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">118,409</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d22927408e4368-wk-Fact-B1510DCB162D7F3BEDBFD1D018651E70" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" contextRef="D2018Q4Jul12017toJun302018" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">569,188</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d22927408e4388-wk-Fact-742881101562FF38427BD1D0180B7FCE" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" contextRef="D2017Q4Jul012016toJun302017" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">30,190</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Cash, cash equivalents, and restricted cash beginning of period</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d22927408e4408-wk-Fact-6D5B14D1F6D6938CB26AD1D018659C29" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="FI2018Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">494,173</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d22927408e4427-wk-Fact-718066546B34804E2C42D1D0185B0EC6" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="FI2018Q2" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">612,582</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d22927408e4446-wk-Fact-CF0AB14AC23CEEB46858D1D0182A1CA9" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="FI2017Q2" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">43,394</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d22927408e4466-wk-Fact-9CB258C2A7D45DE20F36D1D01865A3D6" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="FI2016Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">13,204</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Cash, cash equivalents, and restricted cash end of period</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d22927408e4491-wk-Fact-AF9460368D0650E51B54E03E0BB96189" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="FI2019Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">612,041</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d22927408e4510-wk-Fact-6D5B14D1F6D6938CB26AD1D018659C29" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="FI2018Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">494,173</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d22927408e4529-wk-Fact-718066546B34804E2C42D1D0185B0EC6" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="FI2018Q2" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">612,582</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d22927408e4549-wk-Fact-CF0AB14AC23CEEB46858D1D0182A1CA9" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="FI2017Q2" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">43,394</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Supplemental disclosure of cash flow information:</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:44px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Interest paid</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d22927408e4651-wk-Fact-2D3BE16986E793E84712E03E0CE3EC33" name="us-gaap:InterestPaidNet" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">338</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d22927408e4670-wk-Fact-454B7204524D8B3874AFD1D0183CB9AE" name="us-gaap:InterestPaidNet" contextRef="D2018Q4Jul01-Dec31" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">475</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d22927408e4689-wk-Fact-98A3EC35F0430866D085D1D0180B4AE4" name="us-gaap:InterestPaidNet" contextRef="D2018Q4Jul12017toJun302018" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">2,850</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d22927408e4709-wk-Fact-BCFC44F6B49818AA74D5D1D018653E0F" name="us-gaap:InterestPaidNet" contextRef="D2017Q4Jul012016toJun302017" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">4,750</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:44px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Income taxes paid</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d22927408e4729-wk-Fact-A155B91EE56DE38B9B1FE03E0D8EE85D" name="us-gaap:IncomeTaxesPaidNet" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">—</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d22927408e4748-wk-Fact-613BC2F958AC56B30B96D1D0183BBD5C" name="us-gaap:IncomeTaxesPaidNet" contextRef="D2018Q4Jul01-Dec31" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">—</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d22927408e4767-wk-Fact-A5674B8510B9356F6766D1D0181BC1C6" name="us-gaap:IncomeTaxesPaidNet" contextRef="D2018Q4Jul12017toJun302018" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">—</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d22927408e4787-wk-Fact-8DA866395C026C8C94E8D1D0183C12E8" name="us-gaap:IncomeTaxesPaidNet" contextRef="D2017Q4Jul012016toJun302017" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">24</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Schedule of non-cash investing and financing activities:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:44px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Issuance of common shares for debt conversion</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d22927408e4889-wk-Fact-BC4B5D3A1BFFD83CDBFDE03E0EA706EF" name="us-gaap:DebtConversionOriginalDebtAmount1" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">—</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d22927408e4908-wk-Fact-FD40D3203A3AB49C3046D1D0182A2315" name="us-gaap:DebtConversionOriginalDebtAmount1" contextRef="D2018Q4Jul01-Dec31" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">13,757</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d22927408e4927-wk-Fact-BCAAA96C0D98FB904106D1D0181BD813" name="us-gaap:DebtConversionOriginalDebtAmount1" contextRef="D2018Q4Jul12017toJun302018" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">92,307</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d22927408e4947-wk-Fact-50000F7DEF97E0D0282AD1D0185B96FE" name="us-gaap:DebtConversionOriginalDebtAmount1" contextRef="D2017Q4Jul012016toJun302017" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">—</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:44px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Accrued capital expenditures</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d22927408e4967-wk-Fact-19B9A5D46FC6F777A6EBE03E0F4C1447" name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">101</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d22927408e4986-wk-Fact-723D145BA68A07E35DD7D1D0183C1642" name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" contextRef="D2018Q4Jul01-Dec31" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">795</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d22927408e5005-wk-Fact-C2DEE5DE86402AA98AFBD1D0181B2590" name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" contextRef="D2018Q4Jul12017toJun302018" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">2,173</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d22927408e5025-wk-Fact-F38C0A5F93FFB6DA4F51D1D0182A5984" name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" contextRef="D2017Q4Jul012016toJun302017" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">—</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:44px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Non-cash component of warrant exercise</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d22927408e5046-wk-Fact-CB87C24A0EC65ED46208E03E0FF7BBD7" name="immu:ReclassOfWarrantLiabilityToCapitalContributedInExcessOfPar" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">—</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d22927408e5065-wk-Fact-624BA810BAA5A6534EC6D1D0182A59C0" name="immu:ReclassOfWarrantLiabilityToCapitalContributedInExcessOfPar" contextRef="D2018Q4Jul01-Dec31" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">7,569</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d22927408e5084-wk-Fact-A1D735BEFD4BBC202CD2D1D0185BACB7" name="immu:ReclassOfWarrantLiabilityToCapitalContributedInExcessOfPar" contextRef="D2018Q4Jul12017toJun302018" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">—</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d22927408e5104-wk-Fact-0E7A2A6E3E242813BB52D1D0180B2540" name="immu:ReclassOfWarrantLiabilityToCapitalContributedInExcessOfPar" contextRef="D2017Q4Jul012016toJun302017" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">—</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:44px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Shares received in cashless exercise</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d22927408e5124-wk-Fact-5DF0496CE18BDE23074AE03E109ECBE3" name="us-gaap:StockIssued1" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">1,271</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d22927408e5143-wk-Fact-EF398E3D05DEB45E6BB4D1D0186499B4" name="us-gaap:StockIssued1" contextRef="D2018Q4Jul01-Dec31" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">2,450</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d22927408e5162-wk-Fact-2791EAB3155BFB730D33D1D0180BC1C1" name="us-gaap:StockIssued1" contextRef="D2018Q4Jul12017toJun302018" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">—</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d22927408e5182-wk-Fact-AA31417070BFC2CCAF4FD1D0181BFF42" name="us-gaap:StockIssued1" contextRef="D2017Q4Jul012016toJun302017" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">—</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">61</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;text-align:justify;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;" href="#sfb86787ac8304dffbb4bfe7ffcfa7b54"><span style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">Table of Contents</span></a></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></div><div><br/></div><div style="line-height:120%;padding-top:16px;text-align:justify;text-indent:48px;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">The following table provides a reconciliation of cash, cash equivalents and restricted cash reported within our consolidated balance sheets that sum to the total of the same amounts shown in the consolidated statements of cash flows:</span></div><div style="line-height:120%;padding-top:16px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.609375%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"></td></tr><tr><td style="width:38%;"></td><td style="width:1%;"></td><td style="width:20%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:17%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:17%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Year Ended December 31, 2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">For the Transition Period Ended December 31, 2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Year Ended June 30, 2018</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Cash and cash equivalents</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d22927408e5350-wk-Fact-DC4AE9A8FE4AE0112236D1D0184B774F" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="FI2019Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">608,628</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d22927408e5369-wk-Fact-71ACCBE1F94A85D78382D1D0184B1F30" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="FI2018Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">492,860</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d22927408e5388-wk-Fact-80EF5A48784EB236CEFBD1D0181B2035" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="FI2018Q2" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">612,057</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Restricted cash in other current assets</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d22927408e5404-wk-Fact-9D7DA728DDC623261698E03EB93965FE" name="us-gaap:RestrictedCashCurrent" contextRef="FI2019Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">3,413</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d22927408e5423-wk-Fact-35E0C66E965F74B667ABD1D0182A2292" name="us-gaap:RestrictedCashCurrent" contextRef="FI2018Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">1,313</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d22927408e5442-wk-Fact-BA12B45D4859B1EE014DD1D0182A8274" name="us-gaap:RestrictedCashCurrent" contextRef="FI2018Q2" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">525</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Total cash, cash equivalents and restricted cash</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d22927408e5468-wk-Fact-AF9460368D0650E51B54E03E0BB96189" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="FI2019Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">612,041</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d22927408e5487-wk-Fact-6D5B14D1F6D6938CB26AD1D018659C29" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="FI2018Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">494,173</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"><span><ix:nonFraction id="d22927408e5506-wk-Fact-718066546B34804E2C42D1D0185B0EC6" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="FI2018Q2" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">612,582</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;padding-top:16px;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">See accompanying notes to consolidated financial statements.</span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">62</span></div></div><hr style="page-break-after:always"></hr><div><a id="s366E033A4F835251860BAF50950C5D0A"></a></div><div><div style="line-height:120%;text-align:justify;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;" href="#sfb86787ac8304dffbb4bfe7ffcfa7b54"><span style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">Table of Contents</span></a></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></div><div><br/></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">IMMUNOMEDICS, INC. AND SUBSIDIARIES</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Notes to Consolidated Financial Statements</span></div><div><a id="sFDBAD78758B152089F2A9B2E04A55E0A"></a></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">1.         <ix:nonNumeric contextRef="FD2019Q4YTD" name="us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock" id="TextSelection-233697280A886946CB74D1D0186581DF-0-wk-Fact-2CB3DE235F0C10149D15D1D0182A1681" continuedAt="TextSelection-233697280A886946CB74D1D0186581DF-1" escape="true">Business Overview and Summary of Significant Accounting Policies</ix:nonNumeric></span></div><ix:continuation id="TextSelection-233697280A886946CB74D1D0186581DF-1" continuedAt="TextSelection-233697280A886946CB74D1D0186581DF-2"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Immunomedics, Inc., a Delaware corporation, together with its subsidiaries (collectively "we," "our," "us," "Immunomedics", or the "Company"), is a clinical-stage biopharmaceutical company that develops monoclonal antibody-based products for the targeted treatment of cancer. Immunomedics manages its operations as one line of business of researching, developing, manufacturing and marketing biopharmaceutical products, particularly antibody-based products for patients with difficult to treat solid tumor and blood cancers. The Company currently reports as a single industry segment with substantially all business conducted in the United States. Immunomedics conducts its research activities in the United States and runs its development studies in the United States and selected European countries. Our corporate objective is to become a fully-integrated biopharmaceutical company and a leader in the field of antibody-drug conjugates (“ADCs”). To that end, our immediate priority is to commercialize our most advanced ADC product candidate, sacituzumab govitecan ("IMMU-132"), beginning in the United States, with metastatic triple-negative breast cancer (“mTNBC”) as the first indication. </span><span style="font-family:inherit;font-size:10pt;">In May 2018, we submitted a Biologics License Application (“BLA”) to the United States Food and Drug Administration ("FDA") for sacituzumab govitecan for the treatment of patients with mTNBC who have received at least two prior therapies for metastatic disease. In July 2018, we received notification from the FDA that the BLA was accepted for filing and the original application was granted Priority Review with a Prescription Drug User Fee Act ("PDUFA") target action date in January 2019. In January 2019, we received a Complete Response Letter ("CRL") from the FDA for the BLA. We subsequently met with the FDA in May 2019 to review the FDA’s findings and discussed our BLA resubmission. Since then, we have developed a detailed plan to address the chemistry, manufacturing, and controls (“CMC”) matters raised in the CRL and in our pre-approval inspection. We held another meeting with the FDA in September 2019 to update the FDA on our progress in addressing these matters and to receive feedback from the FDA on our approach. On November 30, 2019, we resubmitted our BLA to the FDA and on December 23, 2019 we received notification from the FDA that the BLA was accepted for filing and further assigned a new PDUFA target action date as June 2, 2020. We have dedicated, and continue to commit, significant resources to address the CMC matters identified by the FDA, while, in parallel, preparing our manufacturing facility to be ready for re-inspection by the FDA. Our Phase 3 confirmatory ASCENT study for sacituzumab govitecan has reached its target enrollment for mTNBC patients previously treated with at least two systemic chemotherapy regimens. Top-line data for the ASCENT study is expected to be available around mid-2020. </span><span style="font-family:inherit;font-size:10pt;"> </span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company has a foreign subsidiary, Immunomedics GmbH in Rodermark, Germany, that assists the Company in managing sales and marketing efforts and coordinating clinical trials in Europe. The accompanying consolidated financial statements include results for its foreign subsidiary and its majority-owned United States subsidiary, IBC Pharmaceuticals, Inc. ("IBC"). </span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Immunomedics is subject to significant risks and uncertainties, including, without limitation, the Company's inability to further identify, develop and achieve commercial success for new products and technologies; the possibility of delays in the research and development necessary to select drug development candidates and delays in clinical trials; the risk that clinical trials may not result in marketable products; the risk that the Company may be unable to secure regulatory approval of and market its drug candidates; the development or regulatory approval of competing products; the Company's ability to protect its proprietary technologies; patent infringement claims; and risks of new, changing and competitive technologies, and regulations in the United States and internationally.</span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Since its inception in 1982, Immunomedics’ principal sources of funds have been the private and public sale of equity and debt securities, and revenues from licensing agreements, including up-front and milestone payments, funding of development programs, and other forms of funding from collaborations. </span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company expects to continue to fund its operations with its current financial resources. </span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></ix:continuation><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">63</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;text-align:justify;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;" href="#sfb86787ac8304dffbb4bfe7ffcfa7b54"><span style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">Table of Contents</span></a></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></div><div><br/></div><ix:continuation id="TextSelection-233697280A886946CB74D1D0186581DF-2" continuedAt="TextSelection-233697280A886946CB74D1D0186581DF-3"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Summary of Significant Accounting Policies:</span></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><ix:nonNumeric contextRef="FD2019Q4YTD" name="us-gaap:BasisOfAccountingPolicyPolicyTextBlock" id="TextSelection-F568666CD837EE6DD33AE082EED1E298-0-wk-Fact-64F3FC42E2475FF77D57E08540066094" escape="true"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Basis of Presentation</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The consolidated financial statements include the accounts of Immunomedics and its subsidiaries. Noncontrolling interests in consolidated subsidiaries in the consolidated balance sheets represent minority stockholders' proportionate share of the equity (deficit) in such subsidiaries. All intercompany balances and transactions have been eliminated in consolidation. In this Annual Report, the periods presented are the year ended December 31, 2019, the six-month transition period from July 1, 2018 to December 31, 2018 (which we sometimes refer to as the "Transition Period") and our fiscal years ended June 30, 2018 and 2017 (which are referred to as “fiscal 2018,” and "fiscal 2017", as if we had not changed our fiscal year to a calendar year).</span></div></ix:nonNumeric><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><ix:nonNumeric contextRef="FD2019Q4YTD" name="us-gaap:UseOfEstimates" id="TextSelection-9924BB4C5C3E3B324110E085A64A6CE7-0-wk-Fact-FB3E568B33BA58DB06EFE085E3AE746E" escape="true"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Use of Estimates</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The preparation of consolidated financial statements in conformity with United States generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reported period. Actual results could differ from those estimates. The Company’s significant estimates and assumptions relate to stock-based compensation expenses, the fair value for the liability related to sale of future royalties and related interest expense.</span></div></ix:nonNumeric><div style="line-height:120%;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><ix:nonNumeric contextRef="FD2019Q4YTD" name="us-gaap:DebtPolicyTextBlock" id="TextSelection-0FDD55E87D2C7D9876E8E0868B22A197-0-wk-Fact-08DC171E09D825D2FF9BE086BBC11B25" escape="true"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Interest Expense on Liability Related to Sale of Future Royalties</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company accounts for the liability related to the sale of future royalties as a debt financing. The Company has a significant continuing involvement in the generation of related royalty streams. The Company accretes this liability and recognizes expected interest expense using the effective interest rate method over the life of the related royalty stream, based on our current estimates of future royalty payments. These estimates include projections the Company makes and projections from outside the Company and involves significant judgment and inherent uncertainties. The Company periodically re-assesses the projections and, to the extent our future projections are greater or less than its previous estimates or the estimated timing of such payments is materially different than its previous estimates, the Company will adjust the effective interest calculation.</span></div></ix:nonNumeric><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><ix:nonNumeric contextRef="FD2019Q4YTD" name="us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" id="TextSelection-429E2D8ACA2E24608CC0E08709083661-0-wk-Fact-D1DF11012F863A0CD9EBE0873CFBD47C" escape="true"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Foreign Currencies</span><span style="font-family:inherit;font-size:10pt;font-style:italic;"> </span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">For our German subsidiary which operates in a local currency environment, income and expense items are translated to United States dollars at the monthly average rates of exchange prevailing during the year, assets and liabilities are translated at year-end exchange rates and equity accounts are translated at historical exchange rates. Translation adjustments are accumulated in a separate component of stockholders' equity in the consolidated balance sheets and the consolidated statements of changes in stockholders’ equity and are included in the determination of comprehensive (loss) income in the consolidated statements of comprehensive loss. Transaction gains and losses are included in the determination of net loss in the consolidated statements of comprehensive loss.</span></div></ix:nonNumeric><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><ix:nonNumeric contextRef="FD2019Q4YTD" name="us-gaap:FairValueOfFinancialInstrumentsPolicy" id="TextSelection-C01A23B1A896230BB137E0877EE5F10B-0-wk-Fact-FB925445C0A043C534CEE087AF5646CA" escape="true"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Financial Instruments</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The carrying amount of cash and cash equivalents, prepaid expenses, other current assets and current liabilities approximate fair value due to the short-term maturity of these instruments. The Company considers all highly liquid investments with an original maturity of three months or less when purchased to be cash equivalents.</span></div></ix:nonNumeric><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><ix:nonNumeric contextRef="FD2019Q4YTD" name="us-gaap:MarketableSecuritiesPolicy" id="TextSelection-2F7F988F2BD860CF39E3E088021956F0-0-wk-Fact-F61B0426AD862C779CD0E088321D26BC" escape="true"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Marketable Securities</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Marketable securities, all of which are available-for-sale, consist of United States Government sponsored agencies which are carried at fair value, with unrealized gains and losses, net of related income taxes, reported as accumulated other comprehensive loss, except for losses from impairments which are determined to be other-than-temporary. Realized gains and losses and declines in value judged to be other-than-temporary on available-for-sale securities are included in the determination of net loss and are included in interest and other income (net), at which time the average cost basis of these securities are adjusted to fair value. Fair values are based on quoted market prices at the reporting date. Interest and dividends on available-for-sale securities are included in interest and other income (net).</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></ix:nonNumeric></ix:continuation><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">64</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;text-align:justify;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;" href="#sfb86787ac8304dffbb4bfe7ffcfa7b54"><span style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">Table of Contents</span></a></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></div><div><br/></div><ix:continuation id="TextSelection-233697280A886946CB74D1D0186581DF-3" continuedAt="TextSelection-233697280A886946CB74D1D0186581DF-4"><ix:nonNumeric contextRef="FD2019Q4YTD" name="us-gaap:PropertyPlantAndEquipmentPolicyTextBlock" id="TextSelection-AB78A56E0E619C2EE54BE0894ED7CDFF-0-wk-Fact-3458984F52CDF6898AD0E08A91C08FAF" escape="true"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Property and Equipment</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Property and equipment are stated at cost less accumulated depreciation and amortization. Depreciation expense is computed using the straight-line method over the estimated useful lives of the assets, including leasehold improvements and capital lease assets that are amortized over the shorter of their useful lives or the terms of the respective leases. The Company generally uses the following range of useful lives for its property and equipment categories: leasehold improvements—</span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonNumeric id="d22928294e768-wk-Fact-8FA34FA0C0400679BA48D78245CDFFC8" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" contextRef="FD2019Q4YTD_srt_RangeAxis_srt_MinimumMember_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_LeaseholdImprovementsMember" format="ixt-sec:duryear">7</ix:nonNumeric></span></span><span style="font-family:inherit;font-size:10pt;"> to </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonNumeric id="d22928294e772-wk-Fact-97639741B319D8ED7BD0D7825672E2B8" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" contextRef="FD2019Q4YTD_srt_RangeAxis_srt_MaximumMember_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_LeaseholdImprovementsMember" format="ixt-sec:duryear">10</ix:nonNumeric> years</span></span><span style="font-family:inherit;font-size:10pt;">; computer equipment—</span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonNumeric id="d22928294e776-wk-Fact-233486708D76020C2BD4D783AC6BA9E6" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" contextRef="FD2019Q4YTD_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_ComputerEquipmentMember" format="ixt-sec:duryear">5</ix:nonNumeric> years</span></span><span style="font-family:inherit;font-size:10pt;">; machinery and equipment—</span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonNumeric id="d22928294e780-wk-Fact-4445C8DE7C0D5D4025B9D7826578D31B" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" contextRef="FD2019Q4YTD_srt_RangeAxis_srt_MinimumMember_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_MachineryAndEquipmentMember" format="ixt-sec:duryear">5</ix:nonNumeric></span></span><span style="font-family:inherit;font-size:10pt;"> to </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonNumeric id="d22928294e784-wk-Fact-39C4BCE463D50DAA8242D78273110DBA" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" contextRef="FD2019Q4YTD_srt_RangeAxis_srt_MaximumMember_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_MachineryAndEquipmentMember" format="ixt-sec:duryear">10</ix:nonNumeric> years</span></span><span style="font-family:inherit;font-size:10pt;">; and furniture and fixtures—</span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonNumeric id="d22928294e789-wk-Fact-31F8CD64AC14C1F56995D78282EDF70A" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" contextRef="FD2019Q4YTD_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_FurnitureAndFixturesMember" format="ixt-sec:duryear">10</ix:nonNumeric> years</span></span><span style="font-family:inherit;font-size:10pt;">. Depreciation expense includes amortization of assets related to capital leases. The Company charges repairs and maintenance costs to expense as incurred. </span></div></ix:nonNumeric><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><ix:nonNumeric contextRef="FD2019Q4YTD" name="us-gaap:ConcentrationRiskCreditRisk" id="TextSelection-743447A55CDBC1F7B754E08AE6AA57D3-0-wk-Fact-A6CA0098CCCCD110EFFCE08B13FF58D6" continuedAt="TextSelection-743447A55CDBC1F7B754E08AE6AA57D3-1" escape="true"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Concentration of Credit Risk</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></ix:nonNumeric><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><ix:continuation id="TextSelection-743447A55CDBC1F7B754E08AE6AA57D3-1">Cash, cash equivalents, and marketable securities are financial instruments that potentially subject the Company to concentration of credit risk. Our investment policy is to invest only in institutions that meet high credit quality standards and establishes limits on the amount and time to maturity of investments with any individual counterparty. The policy also requires that investments are only entered into with corporate and financial institutions that meet high credit quality standards. Restricted cash represents funds the Company is required to set aside to cover vehicle operating leases and other purposes.</ix:continuation> </span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><ix:nonNumeric contextRef="FD2019Q4YTD" name="us-gaap:RevenueRecognitionPolicyTextBlock" id="TextSelection-0AA05DB69DDE3F3D223FE08B736A8951-0-wk-Fact-F01D59D6DDBFD1242367E08B9C16A639" continuedAt="TextSelection-0AA05DB69DDE3F3D223FE08B736A8951-1" escape="true"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Revenue Recognition</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Pursuant to Topic 606, we recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. To achieve this core principle, Topic 606 includes provisions within a five step model that includes i) identifying the contract with a customer, ii) identifying the performance obligations in the contract, iii) determining the transaction price, iv) allocating the transaction price to the performance obligations, and v) recognizing revenue when, or as, an entity satisfies a performance obligation.</span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">At contract inception, we assess the goods or services promised within each contract and assess whether each promised good or service is distinct and determine those that are performance obligations. We then recognize as revenue the amount of the transaction price that is allocated to the respective performance obligation when the performance obligation is satisfied.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></ix:nonNumeric><ix:nonNumeric contextRef="FD2019Q4YTD" name="us-gaap:ResearchAndDevelopmentExpensePolicy" id="TextSelection-DAA1BDD14BDF506F3E27E08BE5135173-0-wk-Fact-818754D466F57B953B14E08C0F43AE7D" escape="true"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"><ix:continuation id="TextSelection-0AA05DB69DDE3F3D223FE08B736A8951-1"></ix:continuation>Research and Development Costs</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Research and development costs are expensed as incurred. Costs incurred for clinical trials for patients and investigators are expensed as services are performed in accordance with the agreements in place with the institutions. Research and development costs include salaries and benefits, costs associated with producing biopharmaceutical compounds, laboratory supplies, the costs of conducting clinical trials, and facilities costs. In addition, the Company uses clinical research organizations and contract manufacturing operations to outsource portions of our research and development activities.</span></div></ix:nonNumeric><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><ix:nonNumeric contextRef="FD2019Q4YTD" name="immu:TreasuryStockPolicyPolicyTextBlock" id="TextSelection-FDD722EF0D0558D5B46AE08C728F3260-0-wk-Fact-90206E810195C16B7417E08CE9065B86" escape="true"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Treasury Shares</span><span style="font-family:inherit;font-size:10pt;">    </span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company records treasury stock at the cost to acquire it and includes treasury stock as a component of Stockholders’ Equity. In determining the cost of the treasury shares when either sold or issued, the Company uses the first-in, first-out method ("FIFO"). If the proceeds from the sale of the treasury shares are greater than the cost of the shares sold, the excess proceeds are recorded as additional paid-in capital. If the proceeds from the sale of the treasury shares are less than the original cost of the shares sold, the excess cost reduces any additional paid-in capital arising from previous sales of treasury shares for that class of stock.</span></div></ix:nonNumeric><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><ix:nonNumeric contextRef="FD2019Q4YTD" name="us-gaap:FairValueMeasurementPolicyPolicyTextBlock" id="TextSelection-60B6D4B40A9A28330841E08D4BFDDF04-0-wk-Fact-489D80FCC3957FF3D0DDE08D7B322C6B" continuedAt="TextSelection-60B6D4B40A9A28330841E08D4BFDDF04-1" escape="true"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Fair Value Measurements</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"></span><span style="font-family:inherit;font-size:10pt;">The Company categorizes its financial instruments measured at fair value into a three-level fair value hierarchy that prioritizes the inputs used in determining the fair value of the asset or liability. The three levels of the fair value hierarchy are as follows:</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">•</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Level 1 - </span><span style="font-family:inherit;font-size:10pt;">Financial instruments whose values are based on unadjusted quoted prices for identical assets or liabilities in an active market which the company has the ability to access at the measurement date (examples include active exchange-traded securities and most United States Government and agency securities).</span></div></td></tr></table><div style="line-height:120%;text-align:justify;padding-left:96px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><span style="font-family:inherit;font-size:10pt;">•</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Level 2 -</span><span style="font-family:inherit;font-size:10pt;"> Financial instruments whose value are based on quoted market prices in markets where trading occurs infrequently or whose values are based on quoted prices of instruments with similar attributes in active markets.</span></div></td></tr></table><div style="line-height:120%;text-align:justify;padding-left:96px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></ix:nonNumeric></ix:continuation><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">65</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;text-align:justify;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;" href="#sfb86787ac8304dffbb4bfe7ffcfa7b54"><span style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">Table of Contents</span></a></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></div><div><br/></div><ix:continuation id="TextSelection-233697280A886946CB74D1D0186581DF-4" continuedAt="TextSelection-233697280A886946CB74D1D0186581DF-5"><ix:continuation id="TextSelection-60B6D4B40A9A28330841E08D4BFDDF04-1"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><span style="font-family:inherit;font-size:10pt;">•</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Level 3 -</span><span style="font-family:inherit;font-size:10pt;"> Financial instruments whose values are based on prices or valuation techniques that require inputs that are both unobservable and significant to the overall fair value measurement. These inputs reflect management's own assumptions about the assumptions a market participant would use in pricing the asset.</span></div></td></tr></table><div style="line-height:120%;text-align:justify;padding-left:72px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company’s financial instruments consist of cash and cash equivalents, marketable securities, prepaid expenses, other current assets, accounts payable and accrued expenses, convertible senior notes, liabilities related to the sale of future royalties and Convertible Senior Notes. The carrying amount of prepaid expenses, other current assets, accounts payable and accrued expenses and certain other liabilities are generally considered to be representative of their respective fair values because of the short-term nature of those instruments.</span></div></ix:continuation><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><ix:nonNumeric contextRef="FD2019Q4YTD" name="us-gaap:IncomeTaxPolicyTextBlock" id="TextSelection-C472F536E842E5DD5AA2E08F369FE541-0-wk-Fact-2D61EA321E24D3F2072AE08F9DA82BD9" continuedAt="TextSelection-C472F536E842E5DD5AA2E08F369FE541-1" escape="true"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Income Taxes</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company uses the asset and liability method to account for income taxes, including the recognition of deferred tax assets and deferred tax liabilities for the anticipated future tax consequences attributable to differences between financial statements amounts and their respective tax bases. The Company reviews its deferred tax assets for recovery. A valuation allowance is established when the Company believes that it is more likely than not that its deferred tax assets will not be realized. Changes in valuation allowances from period to period are included in the Company’s tax provision in the period of change. The Company has recorded a full valuation allowance against its net deferred tax assets as of </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">2018</span><span style="font-family:inherit;font-size:10pt;">.</span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></ix:nonNumeric><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><ix:continuation id="TextSelection-C472F536E842E5DD5AA2E08F369FE541-1" continuedAt="TextSelection-C472F536E842E5DD5AA2E08F369FE541-2"><span style="font-family:inherit;font-size:10pt;">The Tax Cuts and Jobs Act (the "Act") was signed into law on December 22, 2017. Among its numerous changes to the Internal Revenue Code, the Act reduces United States corporate rates from 35% to 21%. Additionally, the Act limits the use of net operating loss carry backs, however any future net operating losses will instead be carried forward indefinitely. Only 80% of current income will be able to be offset with a net operating loss carryforward, with the remainder of the net operating loss continuing to carry forward. As a result of the reduction in the U.S. corporate income tax rate, the Company revalued its ending net deferred tax assets as of June 30, 2018, which resulted in a provisional expense of </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d22928294e934-wk-Fact-597DF60237726C170D565EE29F497720" name="us-gaap:TaxCutsAndJobsActOf2017IncompleteAccountingChangeInTaxRateDeferredTaxAssetProvisionalIncomeTaxExpense" contextRef="D2018Q4Jul01-Dec31" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">59.5</ix:nonFraction> million</span></span></ix:continuation><span style="font-family:inherit;font-size:10pt;"><ix:continuation id="TextSelection-C472F536E842E5DD5AA2E08F369FE541-2"> which was offset by an associated change in valuation allowance. In the second quarter of the Transition Period, the Company completed its analysis to determine the effect of the Tax Act and recorded no further adjustments.</ix:continuation> </span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><ix:nonNumeric contextRef="FD2019Q4YTD" name="us-gaap:EarningsPerSharePolicyTextBlock" id="TextSelection-F86ED3B13D2DD92F6C39E08FEFA33C64-0-wk-Fact-762F6B4A3C46090FAC66E0907829B65C" escape="true"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Net Loss Per Share Allocable to Common Stockholders</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net loss per basic and diluted common share allocable to common stockholders is based on the net loss for the relevant period, divided by the weighted-average number of common shares outstanding during the period. For purposes of the diluted net loss per common share calculations, the exercise or exchange of all potential common shares is not included because their effect would have been anti-dilutive, due to the net loss recorded for the year ended </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;">, the Transition Period and fiscal years ended June 2018, and 2017, respectively. The common stock equivalents excluded from the earnings per share calculation are </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d22928294e956-wk-Fact-9E9427FA31C2403FBD09D7785EBE8E5A" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="FD2019Q4YTD" unitRef="shares" decimals="-5" scale="6" format="ixt:numdotdecimal">8.2</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;">, </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d22928294e960-wk-Fact-50F0ADE9DE987807177AD77591DCE286" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="D2018Q4Jul01-Dec31" unitRef="shares" decimals="-5" scale="6" format="ixt:numdotdecimal">6.7</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;">, </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d22928294e964-wk-Fact-1CB44CED46CEAD38C394D775A11E96AB" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="D2018Q4Jul12017toJun302018" unitRef="shares" decimals="-5" scale="6" format="ixt:numdotdecimal">10.0</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;">, and </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d22928294e968-wk-Fact-3CD8CEB572B3D9E4F999D775B239AEA9" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="D2017Q4Jul012016toJun302017" unitRef="shares" decimals="-5" scale="6" format="ixt:numdotdecimal">66.1</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> for the year ended </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;">, the Transition Period and the fiscal years ended June 2018, and 2017, respectively.</span></div></ix:nonNumeric><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><ix:nonNumeric contextRef="FD2019Q4YTD" name="us-gaap:ComprehensiveIncomePolicyPolicyTextBlock" id="TextSelection-901D758F3758E3CB05ADE090F58C2D75-0-wk-Fact-EA6E7F890E7DD6BA9A60E0912BBF02FD" escape="true"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Net Comprehensive Loss</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net comprehensive loss consists of net loss, unrealized gain (loss) on available for sale securities and foreign exchange translation adjustments and is presented in the consolidated statements of comprehensive loss.</span></div></ix:nonNumeric><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><ix:nonNumeric contextRef="FD2019Q4YTD" name="us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy" id="TextSelection-15910446B6FF1333E6E5E09168889018-0-wk-Fact-D0072F6BDBDBD39E1C46E09192221961" continuedAt="TextSelection-15910446B6FF1333E6E5E09168889018-1" escape="true"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Stock-Based Compensation</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company utilizes stock-based compensation in the form of stock options, stock appreciation rights, stock awards, stock unit awards, performance shares, cash-based performance units and other stock-based awards, each of which may be granted separately or in tandem with other awards.</span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The grant-date fair value of stock awards is based upon the underlying price of the stock on the date of grant. The grant-date fair value of stock option awards must be determined using an option pricing model. Option pricing models require the use of estimates and assumptions as to (a) the expected term of the option, (b) the expected volatility of the price of the underlying stock and (c) the risk-free interest rate for the expected term of the option. The Company uses the Black-Scholes option pricing formula for determining the grant-date fair value of such awards. The fair value of option awards that vest based on achievement of certain market conditions are determined using a Monte Carlo simulation technique.</span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The expected term of the option is based upon the contractual term and expected employee exercise and expected post-vesting employment termination behavior. The expected volatility of the price of the underlying stock is based upon the historical volatility of the Company’s stock computed over a period of time equal to the expected term of the option. The risk-free interest </span></div></ix:nonNumeric></ix:continuation><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">66</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;text-align:justify;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;" href="#sfb86787ac8304dffbb4bfe7ffcfa7b54"><span style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">Table of Contents</span></a></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></div><div><br/></div><ix:continuation id="TextSelection-233697280A886946CB74D1D0186581DF-5"><ix:continuation id="TextSelection-15910446B6FF1333E6E5E09168889018-1"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">rate is based upon the implied yields currently available from the United States Treasury yield curve in effect at the time of the grant. Forfeitures are recorded as incurred.</span></div></ix:continuation><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><ix:nonNumeric contextRef="FD2019Q4YTD" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" id="TextSelection-3CC03DEF0563C512A420E09251913891-0-wk-Fact-009A7727F41E28CBE744E092848F04AA" escape="true"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Recently Issued Accounting Pronouncements</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Accounting Pronouncements adopted during the year</span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) 2019-01, “Leases Topic 842,” requiring entities to recognize assets and liabilities on the balance sheet for all leases, with certain exceptions. Topic 842 allows for a modified retrospective application and is effective as of the first quarter of 2019. Entities are allowed to apply the new guidance using a modified retrospective approach at the beginning of the year in which new lease standard is adopted, rather than to the earliest comparative period presented in their financial statements. The modified retrospective approach includes a number of optional practical expedients that entities may elect to apply. We elected the modified retrospective approach under the new guidance and elected the available practical expedients on adoption. Upon adoption, we recognized additional operating lease liabilities of </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d22928294e1035-wk-Fact-0747AF242BA734722F96D751F0F78EE3" name="us-gaap:OperatingLeaseLiability" contextRef="I2019Q1Jan01_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201602Member" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">8.4</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> with a corresponding right-of-use assets of </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d22928294e1039-wk-Fact-EF41DE1A18F5412A868DD752629C1DD9" name="us-gaap:OperatingLeaseRightOfUseAsset" contextRef="I2019Q1Jan01_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201602Member" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">8.4</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> based on the present value of the remaining lease payments under existing operating leases. As of December 31, 2018, we had </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d22928294e1043-wk-Fact-D5D48CC33AC413899C9AD752D5A45019" name="us-gaap:OtherLiabilitiesNoncurrent" contextRef="FI2018Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">2.1</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> in deferred charges related to our real estate leases that were recorded against the lease liability asset as part of the transition, resulting in </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d22928294e1047-wk-Fact-9E74F6CE672198B62B81D75335774656" name="us-gaap:OtherLiabilitiesNoncurrent" contextRef="I2019Q1Jan01_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201602Member" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">10.5</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> included in other long-term liabilities on our consolidated balance sheets. In addition, the new guidance resulted in additional lease-related disclosures in the footnotes to our consolidated financial statements. Our leasing portfolio is comprised entirely of operating leases, and we do not recognize right-of-use assets or related lease liabilities with a lease term of twelve months or less on our consolidated balance sheets. Adoption of Topic 842 has required changes to our business processes and controls to comply with the provisions of the standard. Refer to Note 14 "Commitments and Contingencies" for additional information.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In June 2018, the FASB issued ASU 2018-07, "Compensation-Stock Compensation," to improve the usefulness of information provided to users of financial statements while reducing cost and complexity in financial reporting and provide guidance aligning the measurement and classification for share-based payments to nonemployees with the guidance for share-based payments to employees. Under the guidance, the measurement of equity-classified nonemployee awards will be fixed at the grant date. This standard is effective for fiscal years beginning after December 15, 2018, and interim periods within those annual periods. Early adoption is permitted, but no earlier than an entity's adoption date of ASU 2014-09, “Revenue from Contracts with Customers (Topic 606).” We adopted ASU 2018-07 during the first quarter of 2019 and the adoption did not have a material impact to our consolidated financial statements.</span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Accounting Pronouncements yet to be adopted</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In November 2018, the FASB issued ASU 2018-18, "Collaborative Arrangements (Topic 808): Clarifying the Interaction between Topic 808 and Topic 606,"    to clarify when ASC 606 should be used for collaborative arrangements when the counterparty is a customer. The guidance precludes an entity from presenting consideration from a transaction in a collaborative arrangement as revenue from contracts with customers if the counterparty is not a customer for that transaction. The guidance is effective for public business entities in fiscal years beginning after December 15, 2019, and interim periods therein. Early adoption is permitted to entities that have adopted ASC 606. We are currently assessing the impact of ASU 2018-18.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In August 2018, the FASB issued ASU 2018-13, "Fair Value measurement (Topic 820): Disclosure Framework - Changes to the Disclosure Requirements for Fair Value Measurement," to no longer require public companies to disclose transfers between Level 1 and Level 2 of the fair value hierarchy, and to require disclosure about the range and weighted average used to develop significant unobservable inputs for Level 3 fair value measurements. The guidance is effective for fiscal years beginning after December 15, 2019, and for interim periods within those fiscal years. Entities are permitted to early adopt either the entire standard or only the provisions that eliminate or modify the requirements. We are currently assessing the impact of ASU 2018-13.</span></div></ix:nonNumeric></ix:continuation><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div><a id="sB6124EDCD6CC5E88AA37430224861510"></a></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">2.         <ix:nonNumeric contextRef="FD2019Q4YTD" name="us-gaap:RevenueFromContractWithCustomerTextBlock" id="TextSelection-8C8F6DD7313BA9FA5DCED78E963BBAAD-0-wk-Fact-7D67033580E8C63EE616D78FB71D14AF" continuedAt="TextSelection-8C8F6DD7313BA9FA5DCED78E963BBAAD-1" escape="true">Revenue Recognition</ix:nonNumeric></span></div><ix:continuation id="TextSelection-8C8F6DD7313BA9FA5DCED78E963BBAAD-1" continuedAt="TextSelection-8C8F6DD7313BA9FA5DCED78E963BBAAD-2"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Everest Medicines II Limited</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">On April 29, 2019, we entered into a license agreement (the "License Agreement") with Everest Medicines II Limited, a China limited company ("Everest"). Pursuant to the License Agreement, we granted Everest an exclusive license to develop and commercialize sacituzumab govitecan in the People's Republic of China, Taiwan, Hong Kong, Macao, Indonesia, Philippines, Vietnam, Thailand, South Korea, Malaysia, Singapore and Mongolia (the "Territory"). In consideration for entering into the License Agreement, Everest made a one-time, non-refundable upfront payment to us in the aggregate amount of </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d22928493e862-wk-Fact-DF8A068B5B59AE38C63CD79478C3190F" name="immu:LicenseAgreementUpfrontFeesPaid" contextRef="D2019Q2Apr29_srt_MajorCustomersAxis_immu_EverestMedicinesIILimitedMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">65.0</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> which is recorded as deferred revenue on the consolidated balance sheet as of </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;">. The License Agreement contains a development milestone payment of </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d22928493e870-wk-Fact-6E2E1A990ADCC8E055B5D795B988BFE8" name="immu:LicenseAgreementMilestonePaymentUponAchievementofFDAApproval" contextRef="D2019Q2Apr29_srt_MajorCustomersAxis_immu_EverestMedicinesIILimitedMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">60.0</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> based upon our achievement of FDA approval for sacituzumab govitecan. The </span></div></ix:continuation><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">67</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;text-align:justify;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;" href="#sfb86787ac8304dffbb4bfe7ffcfa7b54"><span style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">Table of Contents</span></a></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></div><div><br/></div><ix:continuation id="TextSelection-8C8F6DD7313BA9FA5DCED78E963BBAAD-2" continuedAt="TextSelection-8C8F6DD7313BA9FA5DCED78E963BBAAD-3"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">License Agreement also contains additional development milestone payments in a total amount of up to </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d22928493e877-wk-Fact-3BFC0B35EBF03F09DDF2D79758641AD0" name="immu:LicenseAgreementMilestoneDevelopmentTotalPayments" contextRef="D2019Q2Apr29_srt_MajorCustomersAxis_immu_EverestMedicinesIILimitedMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">180.0</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> based upon the achievement of certain other development milestones. In addition, the License Agreement contains sales milestone payments in a total amount of up to </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d22928493e881-wk-Fact-6750CE1BFAD2A176AC2FD79692ECEC6C" name="immu:LicenseAgreementMilestoneSalesTotalPayments" contextRef="D2019Q2Apr29_srt_MajorCustomersAxis_immu_EverestMedicinesIILimitedMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">530.0</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> based upon the achievement of certain sales milestones. Everest will make royalty payments to us based upon percentages of net sales of sacituzumab govitecan, ranging from </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d22928493e885-wk-Fact-FC466D5D97B0FF2027DAD79871424F17" name="immu:RoyaltyPaymentsPercentage" contextRef="D2019Q2Apr29_srt_MajorCustomersAxis_immu_EverestMedicinesIILimitedMember_srt_RangeAxis_srt_MinimumMember" unitRef="number" decimals="INF" scale="-2" format="ixt:numdotdecimal">14</ix:nonFraction>%</span></span><span style="font-family:inherit;font-size:10pt;"> to </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d22928493e889-wk-Fact-A61CB577CE92CFD0570BD798A1DD9F46" name="immu:RoyaltyPaymentsPercentage" contextRef="D2019Q2Apr29_srt_MajorCustomersAxis_immu_EverestMedicinesIILimitedMember_srt_RangeAxis_srt_MaximumMember" unitRef="number" decimals="INF" scale="-2" format="ixt:numdotdecimal">20</ix:nonFraction>%</span></span><span style="font-family:inherit;font-size:10pt;">. </span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company assessed the arrangement in accordance with ASC 606 and concluded that the contract counterparty, Everest, is a customer based on the arrangement structure. The Company identified two material promises to deliver under the contract: (1) grant of license and the (2) clinical and commercial supply of the product. However, given the nature of the manufacturing of the product the license is not considered to be distinct from the clinical and commercial supply promise. The Company therefore concluded that there is one combined performance obligation.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company initially deferred and will recognize the </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d22928493e905-wk-Fact-EBC5624C00CF3A375C4CD79BE3CB0AF5" name="us-gaap:RevenueRemainingPerformanceObligation" contextRef="I2019Q2Apr29_srt_MajorCustomersAxis_immu_EverestMedicinesIILimitedMember_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain_2019-04-30" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">65.0</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> over the performance obligation period of the combined performance obligation. As it relates to the upfront consideration, the </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d22928493e909-wk-Fact-C733B02AD5739BEBEBE1D79B2A61513A" name="us-gaap:ContractWithCustomerLiabilityNoncurrent" contextRef="I2019Q2Apr29_srt_MajorCustomersAxis_immu_EverestMedicinesIILimitedMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">65.0</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> is recorded as deferred revenue and will be recognized over the term of the of the contract performance obligation period, which the Company has concluded to be </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonNumeric id="d22928493e913-wk-Fact-8BBA9930F39910216520D79C9F7C2BC0" name="us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1" contextRef="I2019Q2Apr29_srt_MajorCustomersAxis_immu_EverestMedicinesIILimitedMember_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain_2019-04-30" format="ixt-sec:duryear">15</ix:nonNumeric> years</span></span><span style="font-family:inherit;font-size:10pt;"> after initial sale of the product in the territory. As concluded above, the Company has a combined performance obligation, which includes delivering the license and clinical and commercial supply to Everest. As such, because the clinical and commercial supply obligation occur throughout the period of the License Agreement, the </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d22928493e917-wk-Fact-EBC5624C00CF3A375C4CD79BE3CB0AF5" name="us-gaap:RevenueRemainingPerformanceObligation" contextRef="I2019Q2Apr29_srt_MajorCustomersAxis_immu_EverestMedicinesIILimitedMember_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain_2019-04-30" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">65.0</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> fixed consideration is recognized over the period in which commercial and clinical supply of product is delivered (over-time). </span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The future potential milestone payments are excluded from the transaction price, as the achievement of the milestone events require considerable judgment in determining whether it is probable of being achieved, and that a significant revenue reversal would not occur. As such, all milestone payments are fully constrained. The Company will reevaluate the transaction price at the end of each reporting period and as uncertain events are resolved or other changes in circumstances occur, and, if necessary, adjust its estimate of the transaction price.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Janssen Biotech Inc.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></ix:continuation><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><ix:continuation id="TextSelection-8C8F6DD7313BA9FA5DCED78E963BBAAD-3" continuedAt="TextSelection-8C8F6DD7313BA9FA5DCED78E963BBAAD-4"><span style="font-family:inherit;font-size:10pt;">On April 5, 2019, the Company entered into a promotion agreement (the "Promotion Agreement") with Janssen Biotech Inc., ("Janssen") pursuant to which the Company will provide non-exclusive product detailing services to Janssen for erdafitinib (the "Product"). Pursuant to the Promotion Agreement, the Company will provide a dedicated sales team to detail the Product to oncologists and other targeted health care providers in the United States. Under the terms of the Promotion Agreement, Janssen maintains ownership of the New Drug Application for the Product as well as legal, regulatory, distribution, commercialization and manufacturing responsibilities for the Product, while the Company will provide product detailing services to Janssen.  Following the achievement of certain sales targets in 2019 and 2020, Janssen will pay the Company (a) a service fee equal to a percentage in the low double digits of the portion of Cumulative Net Sales (as defined in the Promotion Agreement) in excess of a baseline amount during each of 2019 and 2020, and (b) potential milestone payments of up to </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d22928493e939-wk-Fact-1BD245C692593D058017D79DAEE061BF" name="immu:LicenseAgreementMilestoneSalesTotalPayments" contextRef="D2019Q1Apr5-Apr5_srt_MajorCustomersAxis_immu_JanssenBiotechIncMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">15.0</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> when Cumulative Net Sales exceed certain thresholds during each of 2019 and 2020. On April 12, 2019, the Company was informed that the FDA granted accelerated approval to Janssen's Balversa</span><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">® </sup></span><span style="font-family:inherit;font-size:10pt;">(erdafitinib) for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma that has a type of susceptible genetic alteration known as FGFR3 or FGFR2, and that has progressed during or following prior platinum-containing chemotherapy. During the year ended </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;">, </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d22928493e951-wk-Fact-4274AA58226EFA569EC3D79E7E695F6E" name="us-gaap:Revenues" contextRef="FD2019Q4YTD_srt_MajorCustomersAxis_immu_JanssenBiotechIncMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">0.3</ix:nonFraction> million</span></span></ix:continuation><span style="font-family:inherit;font-size:10pt;"><ix:continuation id="TextSelection-8C8F6DD7313BA9FA5DCED78E963BBAAD-4"> of service fee revenues were recorded relating to the Promotion Agreement.</ix:continuation> </span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">68</span></div></div><hr style="page-break-after:always"></hr><div><a id="s1547CD745C3F5B16A2B77CDE8612C7CB"></a></div><div><div style="line-height:120%;text-align:justify;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;" href="#sfb86787ac8304dffbb4bfe7ffcfa7b54"><span style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">Table of Contents</span></a></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></div><div><br/></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">3.         <ix:nonNumeric contextRef="FD2019Q4YTD" name="us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" id="TextSelection-5626F08A98EB97B4E60ED1D018754DA3-0-wk-Fact-748190D6F5C93AB98E63D1D0185B6734" continuedAt="TextSelection-5626F08A98EB97B4E60ED1D018754DA3-1" escape="true">Marketable Securities</ix:nonNumeric></span></div><ix:continuation id="TextSelection-5626F08A98EB97B4E60ED1D018754DA3-1"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Immunomedics considers all of its current investments to be available-for-sale. Marketable securities are carried at fair value, with unrealized gains and losses, net of related income taxes, reported as accumulated other comprehensive (loss) income, except for losses from impairments which are determined to be other-than-temporary. Realized gains and losses and declines in value judged to be other-than-temporary on available-for-sale securities are included in the determination of net loss and are included in interest and other income (net), at which time the average cost basis of these securities are adjusted to fair value. Fair values are based on quoted market prices at the reporting date. Interest and dividends on available-for-sale securities are included in interest and other income (net). As of December 31, 2019, and 2018, the carrying value of our current investments due after one year or more are </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d22929044e648-wk-Fact-AFDAF810C5E432B1D5D7D7B2F62CFE04" name="immu:AvailableForSaleSecuritiesDebtMaturitiesAfterOneYearormoreCarryingValue" contextRef="FI2019Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">4.5</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d22929044e652-wk-Fact-94AAC381CD95D9A0CBE4D7B31883B655" name="immu:AvailableForSaleSecuritiesDebtMaturitiesAfterOneYearormoreCarryingValue" contextRef="FI2018Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">4.9</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;">, respectively. </span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><ix:nonNumeric contextRef="FD2019Q4YTD" name="us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock" id="TextSelection-E1B11B24340238329CDDD1D01875D4D6-0-wk-Fact-D4694B111840E3AF5ADAD1D0180B85D0" escape="true"><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following table summarizes the marketable securities held as of </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;"> and 2018 (in thousands):</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"></td></tr><tr><td style="width:38%;"></td><td style="width:1%;"></td><td style="width:13%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:13%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:13%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"> December 31, 2019</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Amortized Cost</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Gross Unrealized Gain</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Gross Unrealized (Loss)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Fair Value</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">U.S. Government Sponsored Agencies</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d22929044e789-wk-Fact-4A58C57EDEE8BFB85293D1D0182A55F6" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" contextRef="FI2019Q4_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">4,941</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d22929044e808-wk-Fact-700D19C87CCD90549255D1D0182A376E" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" contextRef="FI2019Q4_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">—</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(<ix:nonFraction id="d22929044e827-wk-Fact-EE281F4CA618BB5D0122D1D0182AE5A0" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" contextRef="FI2019Q4_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">391</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d22929044e848-wk-Fact-6925F06F6C4C9B1C7110D1D0182AFD14" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="FI2019Q4_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">4,550</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;padding-left:0px;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"></td></tr><tr><td style="width:38%;"></td><td style="width:1%;"></td><td style="width:13%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:13%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:13%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"> December 31, 2018</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Amortized Cost</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Gross Unrealized Gain</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Gross Unrealized (Loss)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Fair Value</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">U.S. Government Sponsored Agencies</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d22929044e989-wk-Fact-3CD83E68B6B15BFE491AD7AF42DA449B" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" contextRef="FI2018Q4_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">4,941</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d22929044e1008-wk-Fact-486C56E6EC78B9BE4107D7AF42F9514F" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" contextRef="FI2018Q4_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">—</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d22929044e1027-wk-Fact-99CBEA59ABF5FD6173C4D7AF42EAFE35" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" contextRef="FI2018Q4_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">—</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d22929044e1047-wk-Fact-19DDF8199E1F6CF08D52D7AF42EA193E" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="FI2018Q4_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">4,941</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div></ix:nonNumeric></ix:continuation><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div><a id="s1397F49B2A3E53FAA4775CE51EF24B2C"></a></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">4.         <ix:nonNumeric contextRef="FD2019Q4YTD" name="us-gaap:DebtDisclosureTextBlock" id="TextSelection-58784F48271978614545D1D0187553FD-0-wk-Fact-49800ED299C7EABF4DDED1D0181BB9E6" continuedAt="TextSelection-58784F48271978614545D1D0187553FD-1" escape="true">Debt</ix:nonNumeric></span></div><ix:continuation id="TextSelection-58784F48271978614545D1D0187553FD-1" continuedAt="TextSelection-58784F48271978614545D1D0187553FD-2"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Liability related to sale of future royalties</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"></span><span style="font-family:inherit;font-size:10pt;">On </span><span style="font-family:inherit;font-size:10pt;">January 7, 2018</span><span style="font-family:inherit;font-size:10pt;">, the Company entered into a funding agreement (the "Funding Agreement") with RPI Finance Trust, a Delaware statutory trust ("RPI"). Pursuant to the Funding Agreement, the Company issued to RPI the right to receive certain royalty amounts, subject to certain reductions, based on the net sales of the ADC sacituzumab govitecan, for each calendar quarter during the term of the Funding Agreement ("Revenue Participation Right"), in exchange for </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d22929576e658-wk-Fact-54CD9DC64C87871AA5A4D1D0180BC084" name="immu:PaymentsForFutureRoyalties" contextRef="D2018Q3Jan07_srt_CounterpartyNameAxis_immu_RpiFinanceTrustMember_us-gaap_DeferredRevenueArrangementTypeAxis_us-gaap_RoyaltyArrangementMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">175.0</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> in cash (the "Purchase Price"). Specifically, the royalty rate commences at </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d22929576e662-wk-Fact-2E6529BC8E40A640C9F3D1D0181B0B67" name="immu:RoyaltyPurchaseArrangementRoyaltyRateasPercentageofNetSales" contextRef="D2018Q3Jan07_srt_CounterpartyNameAxis_immu_RpiFinanceTrustMember_us-gaap_DeferredRevenueArrangementTypeAxis_us-gaap_RoyaltyArrangementMember" unitRef="number" decimals="4" scale="-2" format="ixt:numdotdecimal">4.15</ix:nonFraction> percent</span></span><span style="font-family:inherit;font-size:10pt;"> on net annual sales of up to </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d22929576e666-wk-Fact-7035369352B29A4829ACD1D0181B59AC" name="immu:RoyaltyPurchaseArrangementAnnualSalesLimitMaximum" contextRef="D2018Q3Jan07_srt_CounterpartyNameAxis_immu_RpiFinanceTrustMember_us-gaap_DeferredRevenueArrangementTypeAxis_us-gaap_RoyaltyArrangementMember" unitRef="usd" decimals="INF" scale="9" format="ixt:numdotdecimal">2.0</ix:nonFraction> billion</span></span><span style="font-family:inherit;font-size:10pt;">, declining step-wise based on sales tiers to </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d22929576e670-wk-Fact-7306D996BED6BEF995C9D1D0185B771B" name="immu:RoyaltyPurchaseArrangementRoyaltyRateasPercentageofExcessofGlobalAnnualSalesThresholdLimit" contextRef="D2018Q3Jan07_srt_CounterpartyNameAxis_immu_RpiFinanceTrustMember_us-gaap_DeferredRevenueArrangementTypeAxis_us-gaap_RoyaltyArrangementMember" unitRef="number" decimals="4" scale="-2" format="ixt:numdotdecimal">1.75</ix:nonFraction> percent</span></span><span style="font-family:inherit;font-size:10pt;"> on net global annual sales exceeding </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d22929576e675-wk-Fact-87F4C65FAA17A28EE9CAD1D0181BB86D" name="immu:RoyaltyPurchaseArrangementExcessGlobalAnnualSalesLimitMinimum" contextRef="D2018Q3Jan07_srt_CounterpartyNameAxis_immu_RpiFinanceTrustMember_us-gaap_DeferredRevenueArrangementTypeAxis_us-gaap_RoyaltyArrangementMember" unitRef="usd" decimals="INF" scale="9" format="ixt:numdotdecimal">6.0</ix:nonFraction> billion</span></span><span style="font-family:inherit;font-size:10pt;">.</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">On </span><span style="font-family:inherit;font-size:10pt;">January 7, 2018</span><span style="font-family:inherit;font-size:10pt;">, in connection with the Funding Agreement, the Company entered into a common stock purchase agreement (the "Purchase Agreement") with RPI, pursuant to which the Company, in a private placement, issued and sold to RPI approximately </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d22929576e689-wk-Fact-994FDD5EFB1015822490DCE2318AC1DB" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="D2019Q1Jan7" unitRef="shares" decimals="-5" scale="6" format="ixt:numdotdecimal">4.4</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> unregistered shares (the "Shares") of the Company's Common Stock, at a price of </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d22929576e693-wk-Fact-A7EDC4B4270AD2F27136D1D0184BCC30" name="us-gaap:SharePrice" contextRef="I2018Q3Jan07_srt_CounterpartyNameAxis_immu_RpiFinanceTrustMember_us-gaap_DeferredRevenueArrangementTypeAxis_us-gaap_RoyaltyArrangementMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember" unitRef="usdPerShare" decimals="INF" scale="0" format="ixt:numdotdecimal">17.15</ix:nonFraction></span></span><span style="font-family:inherit;font-size:10pt;"> per share for gross proceeds to the Company of </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d22929576e697-wk-Fact-9F481AFA117AD3963C89D1D0181BE8B3" name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" contextRef="D2018Q3Jan07_srt_CounterpartyNameAxis_immu_RpiFinanceTrustMember_us-gaap_DeferredRevenueArrangementTypeAxis_us-gaap_RoyaltyArrangementMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">75.0</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> before deducting fees and expenses (the "Financing").</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company concluded that there were two units of accounting in the transaction. <ix:nonNumeric contextRef="FD2019Q4YTD" name="immu:AllocationofFairValuetoLiabilityTableTextBlock" id="TextSelection-B87D5A5A9A886F981391D1D018759849-0-wk-Fact-82200CF6ABB08D69E1E0D1D0180BB5F3" continuedAt="TextSelection-B87D5A5A9A886F981391D1D018759849-1" escape="true">The Company allocated the transaction consideration on a relative fair value to the liability and common stock in accordance with ASC 470-10 as follows (in thousands):</ix:nonNumeric></span></div><ix:continuation id="TextSelection-B87D5A5A9A886F981391D1D018759849-1"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="5"></td></tr><tr><td style="width:2%;"></td><td style="width:78%;"></td><td style="width:1%;"></td><td style="width:18%;"></td><td style="width:1%;"></td></tr><tr><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Units of Accounting:</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Allocated Consideration</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Liability related to sale of future royalties</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d22929576e773-wk-Fact-FAFCEA6073D4F0B07F2039CD1FA246BA" name="immu:FairValueForLiabilityRelatedtoSaleofFutureRoyalties" contextRef="I2018Q3Jan07_srt_CounterpartyNameAxis_immu_RpiFinanceTrustMember_us-gaap_DeferredRevenueArrangementTypeAxis_us-gaap_RoyaltyArrangementMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">182,216</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Common stock</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d22929576e793-wk-Fact-26E7614FCD07D4FE2F7E39CD1AADA641" name="us-gaap:CommonStockValue" contextRef="I2018Q3Jan07_srt_CounterpartyNameAxis_immu_RpiFinanceTrustMember_us-gaap_DeferredRevenueArrangementTypeAxis_us-gaap_RoyaltyArrangementMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">67,784</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d22929576e823-wk-Fact-C68B680BFE5A0D97535D39CD1A81B842" name="immu:RoyaltyPurchaseAgreementArrangementsConsideration" contextRef="I2018Q3Jan07_srt_CounterpartyNameAxis_immu_RpiFinanceTrustMember_us-gaap_DeferredRevenueArrangementTypeAxis_us-gaap_RoyaltyArrangementMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">250,000</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div></ix:continuation><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Interest will be recognized using the effective interest method over a period of </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonNumeric id="d22929576e840-wk-Fact-C53187AE1E129F63E002DCE15344F553" name="immu:PeriodWhichCompanyWillAccreteLiability" contextRef="FD2019Q4YTD" format="ixt-sec:duryear">20</ix:nonNumeric> years</span></span><span style="font-family:inherit;font-size:10pt;">. The effective interest rate under the Funding Agreement, including issuance costs, is approximately </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d22929576e844-wk-Fact-9F79ABF09422AA9A2C88DCE3F9D7CC30" name="immu:AnnualInterestRateInCalculatingLiabilityRelatedToSaleOfFutureRoyalties" contextRef="FD2019Q4YTD" unitRef="number" decimals="INF" scale="-2" format="ixt:numdotdecimal">16.0</ix:nonFraction>%</span></span><span style="font-family:inherit;font-size:10pt;"> as of </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;">. During the year ended </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;">, the Transition Period, and the fiscal year ended </span><span style="font-family:inherit;font-size:10pt;">June 30, 2018</span><span style="font-family:inherit;font-size:10pt;">, the Company recognized </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d22929576e861-wk-Fact-AD81B21DC8736B2EE80BD7B45C5561AA" name="immu:NonCashInterestExpenseRelatedToSaleOfFutureRoyalties" contextRef="FD2019Q4YTD_srt_CounterpartyNameAxis_immu_RpiFinanceTrustMember_us-gaap_DeferredRevenueArrangementTypeAxis_us-gaap_RoyaltyArrangementMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">39.9</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;">, </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d22929576e865-wk-Fact-D2938A39563021AFDE71D1D0180B89C8" name="immu:NonCashInterestExpenseRelatedToSaleOfFutureRoyalties" contextRef="D2018Q4Jul01-Dec31_srt_CounterpartyNameAxis_immu_RpiFinanceTrustMember_us-gaap_DeferredRevenueArrangementTypeAxis_us-gaap_RoyaltyArrangementMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">19.3</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;">, and </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d22929576e869-wk-Fact-29B17B74BB3F7D6D53A3D7B46B57B0C8" name="immu:NonCashInterestExpenseRelatedToSaleOfFutureRoyalties" contextRef="D2018Q4Jul12017toJun302018_srt_CounterpartyNameAxis_immu_RpiFinanceTrustMember_us-gaap_DeferredRevenueArrangementTypeAxis_us-gaap_RoyaltyArrangementMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">19.8</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> in interest expense, respectively.</span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></ix:continuation><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">69</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;text-align:justify;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;" href="#sfb86787ac8304dffbb4bfe7ffcfa7b54"><span style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">Table of Contents</span></a></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></div><div><br/></div><ix:continuation id="TextSelection-58784F48271978614545D1D0187553FD-2" continuedAt="TextSelection-58784F48271978614545D1D0187553FD-3"><ix:nonNumeric contextRef="FD2019Q4YTD" name="us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock" id="TextSelection-FC74E42A79BA51350E60D1D01875C061-0-wk-Fact-45CFEF396EA1B9D77574D1D0180BA8E8" escape="true"><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following table shows the activity within the liability related to sale of future royalties during the year ended </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;">, the Transition Period and at the fiscal year ended June 30, 2018 (in thousands):</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"></td></tr><tr><td style="width:80%;"></td><td style="width:1%;"></td><td style="width:18%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Liability related to sale of future royalties at January 7, 2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d22929576e913-wk-Fact-FAFCEA6073D4F0B07F2039CD1FA246BA" name="immu:FairValueForLiabilityRelatedtoSaleofFutureRoyalties" contextRef="I2018Q3Jan07_srt_CounterpartyNameAxis_immu_RpiFinanceTrustMember_us-gaap_DeferredRevenueArrangementTypeAxis_us-gaap_RoyaltyArrangementMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">182,216</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Interest expense recognized</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d22929576e928-wk-Fact-A56EA7DB28E612D6D02539CD1FA90A38" name="immu:NonCashInterestExpenseRelatedToSaleOfFutureRoyalties" contextRef="D2018Q3Jan08-Jun30_srt_CounterpartyNameAxis_immu_RpiFinanceTrustMember_us-gaap_DeferredRevenueArrangementTypeAxis_us-gaap_RoyaltyArrangementMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">19,791</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Carrying value of liability related to sale of future royalties at June 30, 2018</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d22929576e953-wk-Fact-1F2A4EDC36D7468DDC4939CD1F45CA08" name="immu:FairValueForLiabilityRelatedtoSaleofFutureRoyalties" contextRef="FI2018Q2_srt_CounterpartyNameAxis_immu_RpiFinanceTrustMember_us-gaap_DeferredRevenueArrangementTypeAxis_us-gaap_RoyaltyArrangementMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">202,007</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Interest expense recognized</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d22929576e968-wk-Fact-1E5DF9BF77803116D17FD1D0183CFDF3" name="immu:NonCashInterestExpenseRelatedToSaleOfFutureRoyalties" contextRef="D2018Q4Jul01-Dec31_srt_CounterpartyNameAxis_immu_RpiFinanceTrustMember_us-gaap_DeferredRevenueArrangementTypeAxis_us-gaap_RoyaltyArrangementMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">19,288</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Carrying value of liability related to sale of future royalties at December 31, 2018 </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d22929576e993-wk-Fact-1B74D96A73D100729493D1D0183C4E06" name="immu:FairValueForLiabilityRelatedtoSaleofFutureRoyalties" contextRef="FI2018Q4_srt_CounterpartyNameAxis_immu_RpiFinanceTrustMember_us-gaap_DeferredRevenueArrangementTypeAxis_us-gaap_RoyaltyArrangementMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">221,295</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Interest expense recognized</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d22929576e1008-wk-Fact-5036BB16364A99C9849DDCE73F5999E7" name="immu:NonCashInterestExpenseRelatedToSaleOfFutureRoyalties" contextRef="FD2019Q4YTD_srt_CounterpartyNameAxis_immu_RpiFinanceTrustMember_us-gaap_DeferredRevenueArrangementTypeAxis_us-gaap_RoyaltyArrangementMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">39,929</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Carrying value of liability related to sale of future royalties at December 31, 2019 (includes current portion of $3,455)</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d22929576e1033-wk-Fact-CDEE26BEC02196546FE3DCE9C68463B8" name="immu:FairValueForLiabilityRelatedtoSaleofFutureRoyalties" contextRef="FI2019Q4_srt_CounterpartyNameAxis_immu_RpiFinanceTrustMember_us-gaap_DeferredRevenueArrangementTypeAxis_us-gaap_RoyaltyArrangementMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">261,224</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div></ix:nonNumeric><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Convertible Senior Notes</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In February 2015, the Company issued </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d22929576e1057-wk-Fact-39BB0540D0441A880594D1D0184B807B" name="us-gaap:DebtInstrumentFaceAmount" contextRef="I2015Q3Feb28_us-gaap_DebtInstrumentAxis_immu_FourPointSevenFivePercentConvertibleSeniorNotesMember" unitRef="usd" decimals="INF" scale="6" format="ixt:numdotdecimal">100.0</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> of Convertible Senior Notes (the "Convertible Senior Notes") (net proceeds of approximately </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d22929576e1061-wk-Fact-F6012EF370623FA1E236D1D0180B04D2" name="us-gaap:ProceedsFromDebtNetOfIssuanceCosts" contextRef="D2015Q3Feb01-Feb28_us-gaap_DebtInstrumentAxis_immu_FourPointSevenFivePercentConvertibleSeniorNotesMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">96.3</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> after deducting the initial purchasers’ fees and offering expenses) in a private offering exempt from registration under the Securities Act of 1933, as amended (the “Securities Act”), in reliance upon Rule 144A under the Securities Act. The Convertible Senior Notes had a maturity date of </span><span style="font-family:inherit;font-size:10pt;">February 15, 2020</span><span style="font-family:inherit;font-size:10pt;">, unless earlier purchased or converted. The debt issuance costs of approximately </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d22929576e1069-wk-Fact-9D35B69BCD759D85B301D1D0181B3A94" name="us-gaap:PaymentsOfDebtIssuanceCosts" contextRef="D2015Q3Feb01-Feb28_us-gaap_DebtInstrumentAxis_immu_FourPointSevenFivePercentConvertibleSeniorNotesMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">3.7</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;">, primarily consisting of underwriting, legal and other professional fees, and are amortized over the term of the Convertible Senior Notes. The Convertible Senior Notes are senior unsecured obligations of the Company. Interest at </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d22929576e1073-wk-Fact-8250E54BFDC25F74BBBDD1D0181B6405" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" contextRef="I2015Q3Feb28_us-gaap_DebtInstrumentAxis_immu_FourPointSevenFivePercentConvertibleSeniorNotesMember" unitRef="number" decimals="INF" scale="-2" format="ixt:numdotdecimal">4.75</ix:nonFraction>%</span></span><span style="font-family:inherit;font-size:10pt;"> is payable semiannually on </span><span style="font-family:inherit;font-size:10pt;">February 15</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">August 15</span><span style="font-family:inherit;font-size:10pt;"> of each year. The effective interest rate on the Convertible Senior Notes was </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d22929576e1086-wk-Fact-D00436D83C97EE7BFC3DD1D01865A105" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" contextRef="FI2019Q4_us-gaap_DebtInstrumentAxis_immu_FourPointSevenFivePercentConvertibleSeniorNotesMember" unitRef="number" decimals="4" scale="-2" format="ixt:numdotdecimal">5.48</ix:nonFraction>%</span></span><span style="font-family:inherit;font-size:10pt;"> for the period from the date of issuance through the year ended </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;">.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Convertible Senior Notes are convertible at the option of holders into approximately </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d22929576e1101-wk-Fact-E684A61F74EF22FCC9F8D1D0180BD27A" name="us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion" contextRef="I2015Q3Feb28_us-gaap_DebtInstrumentAxis_immu_FourPointSevenFivePercentConvertibleSeniorNotesMember" unitRef="shares" decimals="-5" scale="6" format="ixt:numdotdecimal">19.6</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> shares of common stock at any time prior to the close of business on the day immediately preceding the maturity date. The exchange rate will initially be </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d22929576e1105-wk-Fact-520C77FA6382008E685CD1D0184B1A46" name="us-gaap:DebtInstrumentConvertibleConversionRatio1" contextRef="D2015Q3Feb01-Feb28_us-gaap_DebtInstrumentAxis_immu_FourPointSevenFivePercentConvertibleSeniorNotesMember" unitRef="number" decimals="INF" scale="0" format="ixt:numdotdecimal">195.8336</ix:nonFraction></span></span><span style="font-family:inherit;font-size:10pt;"> shares of common stock per </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d22929576e1109-wk-Fact-1807AD01AB36B644D601D1D0181B2496" name="us-gaap:DebtInstrumentConvertibleConversionPrice1" contextRef="FI2019Q4_us-gaap_DebtInstrumentAxis_immu_FourPointSevenFivePercentConvertibleSeniorNotesMember" unitRef="usdPerShare" decimals="INF" scale="0" format="ixt:numdotdecimal">1,000</ix:nonFraction></span></span><span style="font-family:inherit;font-size:10pt;"> principal amount of Convertible Senior Notes (equivalent to an initial conversion price of approximately </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d22929576e1113-wk-Fact-9FECAE8EFECD0D11FDF1D1D0181BC2C1" name="us-gaap:DebtInstrumentConvertibleConversionPrice1" contextRef="I2015Q3Feb28_us-gaap_DebtInstrumentAxis_immu_FourPointSevenFivePercentConvertibleSeniorNotesMember" unitRef="usdPerShare" decimals="2" scale="0" format="ixt:numdotdecimal">5.11</ix:nonFraction></span></span><span style="font-family:inherit;font-size:10pt;"> per share of common stock).</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">If the Company undergoes a fundamental change (as defined in the indenture governing the Convertible Senior Notes), holders may require Immunomedics to purchase for cash all or part of the Convertible Senior Notes at a purchase price equal to </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d22929576e1123-wk-Fact-1818B8F9CF2B9E5F8945D1D0181B76B0" name="us-gaap:DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed" contextRef="D2015Q3Feb01-Feb28_us-gaap_DebtInstrumentAxis_immu_FourPointSevenFivePercentConvertibleSeniorNotesMember" unitRef="number" decimals="INF" scale="-2" format="ixt:numdotdecimal">100</ix:nonFraction>%</span></span><span style="font-family:inherit;font-size:10pt;"> of the principal amount of the Convertible Senior Notes to be purchased, plus accrued and unpaid interest, if any, to, but excluding, the fundamental change purchase date, subject to certain exceptions. In addition, if certain make-whole fundamental changes (as defined in the indenture governing the Convertible Senior Notes) occur, Immunomedics will, in certain circumstances, increase the conversion rate for any Convertible Note converted in connection with such make-whole fundamental change.</span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The indenture does not limit the amount of debt which may be issued by the Company under the indenture or otherwise, does not contain any financial covenants or restrict the Company from paying dividends, selling or disposing of assets, or issuing or repurchasing its other securities, provided that such event is not deemed to be a fundamental change (as defined in the indenture governing the Convertible Senior Notes). The indenture contains customary terms and covenants and events of default.</span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">If an event of default with respect to the Convertible Senior Notes occurs, holders may, upon satisfaction of certain conditions, accelerate the principal amount of the Convertible Senior Notes plus premium, if any, and accrued and unpaid interest, if any. In addition, the principal amount of the Convertible Senior Notes plus premium, if any, and accrued and unpaid interest, if any, will automatically become due and payable in the case of certain types of bankruptcy or insolvency events of default involving the Company.</span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">On </span><span style="font-family:inherit;font-size:10pt;">September 21, 2017</span><span style="font-family:inherit;font-size:10pt;">, the Company entered into separate, privately negotiated exchange agreements, (the "September Exchange Agreements") with certain holders of the Convertible Senior Notes. Under the Exchange Agreements, such holders agreed to convert an aggregate </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d22929576e1146-wk-Fact-07FB96E283FB3E3A3CC0D1D0181BCE74" name="us-gaap:DebtConversionOriginalDebtAmount1" contextRef="D2018Q1Sept21_us-gaap_DebtInstrumentAxis_immu_FourPointSevenFivePercentConvertibleSeniorNotesMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">80.0</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> of Convertible Senior Notes held by them. In total, the Company issued an aggregate </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d22929576e1150-wk-Fact-5E7A89197A99C4ABB80DD1D0181B9856" name="us-gaap:DebtConversionConvertedInstrumentSharesIssued1" contextRef="D2018Q1Sept21_us-gaap_DebtInstrumentAxis_immu_FourPointSevenFivePercentConvertibleSeniorNotesMember" unitRef="shares" decimals="-5" scale="6" format="ixt:numdotdecimal">16.8</ix:nonFraction></span></span><span style="font-family:inherit;font-size:10pt;"> million shares of common stock in the September Exchange Agreements. The shares represent an aggregate of </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d22929576e1154-wk-Fact-1C2C74F160B55BC0F822D1D0181BB64E" name="immu:DebtInstrumentConvertibleBeneficialConversionFeatureAggregateNumberOfShares" contextRef="D2018Q1Sept21_us-gaap_DebtInstrumentAxis_immu_FourPointSevenFivePercentConvertibleSeniorNotesMember" unitRef="shares" decimals="-5" scale="6" format="ixt:numdotdecimal">1.1</ix:nonFraction></span></span><span style="font-family:inherit;font-size:10pt;"> million shares more than the number of shares into which the exchanged Convertible Senior Notes were convertible under their original terms. As a result of the September Exchange Agreements, the Company recognized a loss on induced exchanges of debt of </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d22929576e1158-wk-Fact-9A7F6E65C187B9C0DFD7D1D0185B24F9" name="us-gaap:InducedConversionOfConvertibleDebtExpense" contextRef="D2018Q1Sept21_us-gaap_DebtInstrumentAxis_immu_FourPointSevenFivePercentConvertibleSeniorNotesMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">13.0</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> representing the fair value of the incremental consideration paid to induce the holders to exchange their Convertible Senior Notes for equity (i.e., </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d22929576e1163-wk-Fact-1C2C74F160B55BC0F822D1D0181BB64E" name="immu:DebtInstrumentConvertibleBeneficialConversionFeatureAggregateNumberOfShares" contextRef="D2018Q1Sept21_us-gaap_DebtInstrumentAxis_immu_FourPointSevenFivePercentConvertibleSeniorNotesMember" unitRef="shares" decimals="-5" scale="6" format="ixt:numdotdecimal">1.1</ix:nonFraction></span></span><span style="font-family:inherit;font-size:10pt;"> million shares of common stock), based on the closing market price of the Company's Common Stock on the date of the September 2017 Exchange Agreements.</span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></ix:continuation><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">70</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;text-align:justify;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;" href="#sfb86787ac8304dffbb4bfe7ffcfa7b54"><span style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">Table of Contents</span></a></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></div><div><br/></div><ix:continuation id="TextSelection-58784F48271978614545D1D0187553FD-3"><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">On October 2, 2018, the Company entered into privately negotiated exchange agreements (the "October 2018 Exchange Agreements"), with a limited number of holders of the Convertible Senior Notes. Under the Exchange Agreements, such holders agreed to convert an aggregate </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d22929576e1172-wk-Fact-1FC5C224F9D44C28F682D1D0185B6A0D" name="us-gaap:DebtConversionOriginalDebtAmount1" contextRef="D2018Q4Oct02_us-gaap_DebtInstrumentAxis_immu_October2018ExchangeAgreementMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">12.9</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> of Convertible Senior Notes held by them. In total, the Company issued an aggregate </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d22929576e1176-wk-Fact-A57E91C0980A95BAA732D1D0180B595B" name="us-gaap:DebtConversionConvertedInstrumentSharesIssued1" contextRef="D2018Q4Oct02_us-gaap_DebtInstrumentAxis_immu_October2018ExchangeAgreementMember" unitRef="shares" decimals="-5" scale="6" format="ixt:numdotdecimal">2.6</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> shares of common stock in the October 2018 Exchange Agreements. The shares represent an aggregate of </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d22929576e1180-wk-Fact-61F1B77ADC72EE70E6FED1D0186528DF" name="immu:DebtInstrumentConvertibleBeneficialConversionFeatureAggregateNumberOfShares" contextRef="D2018Q4Oct02_us-gaap_DebtInstrumentAxis_immu_FourPointSevenFivePercentConvertibleSeniorNotesMember" unitRef="shares" decimals="-5" scale="6" format="ixt:numdotdecimal">0.1</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> shares more than the number of shares into which the exchanged Convertible Senior Notes were convertible under their original terms. As a result of the October 2018 Exchange Agreements, the Company recognized a loss on induced exchanges of debt of </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d22929576e1184-wk-Fact-139F0177BEE2CC86F759D1D0180BCC4A" name="us-gaap:InducedConversionOfConvertibleDebtExpense" contextRef="D2018Q4Oct02_us-gaap_DebtInstrumentAxis_immu_FourPointSevenFivePercentConvertibleSeniorNotesMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">0.9</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> representing the fair value of the incremental consideration paid to induce the holders to exchange their Convertible Senior Notes for equity (i.e., </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d22929576e1188-wk-Fact-61F1B77ADC72EE70E6FED1D0186528DF" name="immu:DebtInstrumentConvertibleBeneficialConversionFeatureAggregateNumberOfShares" contextRef="D2018Q4Oct02_us-gaap_DebtInstrumentAxis_immu_FourPointSevenFivePercentConvertibleSeniorNotesMember" unitRef="shares" decimals="-5" scale="6" format="ixt:numdotdecimal">0.1</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> shares of common stock), based on the closing market price of the Company's Common Stock on the date of the October 2018 Exchange Agreements. As a result of the October 2018 Exchange Agreements, the balance of the outstanding Convertible Senior Notes was </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d22929576e1193-wk-Fact-79D2B5AF41A7A8552383D1D0181BD3A2" name="immu:DebtConversionOutstandingBalance" contextRef="FI2019Q4_us-gaap_DebtInstrumentAxis_immu_FourPointSevenFivePercentConvertibleSeniorNotesMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">7.1</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> at </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">2018</span><span style="font-family:inherit;font-size:10pt;">. As of February 14, 2020, the remaining </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d22929576e1205-wk-Fact-F3415A8ECEABE24D0B4A456402C6EA70" name="immu:DebtConversionOutstandingBalance" contextRef="I2020Q1Feb14_us-gaap_DebtInstrumentAxis_immu_FourPointSevenFivePercentConvertibleSeniorNotesMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">7.1</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> of Convertible Senior Notes converted into </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d22929576e1209-wk-Fact-62F311FED758F5A6D7C145624F9A4714" name="us-gaap:DebtConversionConvertedInstrumentSharesIssued1" contextRef="D2020Q1Feb14-Feb14_us-gaap_DebtInstrumentAxis_immu_FourPointSevenFivePercentConvertibleSeniorNotesMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember" unitRef="shares" decimals="-5" scale="6" format="ixt:numdotdecimal">1.4</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> shares of common stock based on the initial conversion price of approximately </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d22929576e1213-wk-Fact-C8021A098E040EFCA0844565BCA3E985" name="us-gaap:DebtInstrumentConvertibleConversionPrice1" contextRef="I2020Q1Feb14_us-gaap_DebtInstrumentAxis_immu_FourPointSevenFivePercentConvertibleSeniorNotesMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember" unitRef="usdPerShare" decimals="2" scale="0" format="ixt:numdotdecimal">5.11</ix:nonFraction></span></span><span style="font-family:inherit;font-size:10pt;"> per share of common stock.</span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total interest expense for the Convertible Senior Notes were </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d22929576e1224-wk-Fact-F73063966F9C5B35271ED7B3ECE002B7" name="us-gaap:InterestExpenseDebt" contextRef="FD2019Q4YTD_us-gaap_DebtInstrumentAxis_immu_FourPointSevenFivePercentConvertibleSeniorNotesMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">0.4</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;">, </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d22929576e1228-wk-Fact-0051548EE71F5854037ED1D0181B152A" name="us-gaap:InterestExpenseDebt" contextRef="D2018Q4Jul01-Dec31_us-gaap_DebtInstrumentAxis_immu_FourPointSevenFivePercentConvertibleSeniorNotesMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">0.5</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;">, </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d22929576e1232-wk-Fact-75F25B0545B713219A54D1D0180B2222" name="us-gaap:InterestExpenseDebt" contextRef="D2018Q4Jul12017toJun302018_us-gaap_DebtInstrumentAxis_immu_FourPointSevenFivePercentConvertibleSeniorNotesMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">3.5</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;">, and </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d22929576e1236-wk-Fact-6C3E7BC71A9DDC8DFF07D1D0181BCD00" name="us-gaap:InterestExpenseDebt" contextRef="D2017Q4Jul012016toJun302017_us-gaap_DebtInstrumentAxis_immu_FourPointSevenFivePercentConvertibleSeniorNotesMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">5.5</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;">, for the year ended </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;">, the Transition Period and the fiscal years ended 2018 and 2017, respectively. Included in interest expense is the amortization of debt issuance costs of </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d22929576e1245-wk-Fact-59956610D69A082D1769DB3BBABC2EB5" name="us-gaap:AmortizationOfFinancingCosts" contextRef="FD2019Q4YTD_us-gaap_DebtInstrumentAxis_immu_FourPointSevenFivePercentConvertibleSeniorNotesMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">0.1</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> for the year ended </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;">, </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d22929576e1253-wk-Fact-3C2F714F899E7BA3051BD1D0181B8DC7" name="us-gaap:AmortizationOfFinancingCosts" contextRef="D2018Q4Jul01-Dec31_us-gaap_DebtInstrumentAxis_immu_FourPointSevenFivePercentConvertibleSeniorNotesMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">0.2</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> in the Transition Period (</span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d22929576e1257-wk-Fact-F29D16C394FC1AF7CBCAD1D0185B4552" name="immu:AcceleratedAmortizationOfFinancingCosts" contextRef="D2018Q4Jul01-Dec31_us-gaap_DebtInstrumentAxis_immu_FourPointSevenFivePercentConvertibleSeniorNotesMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">0.1</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> of which related to the accelerated amortization of debt issuance costs associated with the October 2018 Exchange Agreements), </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d22929576e1261-wk-Fact-ACAA2614C19DCA975C47D1D0181B6BA6" name="us-gaap:AmortizationOfFinancingCosts" contextRef="D2018Q4Jul12017toJun302018_us-gaap_DebtInstrumentAxis_immu_FourPointSevenFivePercentConvertibleSeniorNotesMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1.7</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> in fiscal 2018 (</span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d22929576e1265-wk-Fact-03784594C491DD1B94E6D1D0180B068B" name="immu:AcceleratedAmortizationOfFinancingCosts" contextRef="D2018Q4Jul12017toJun302018_us-gaap_DebtInstrumentAxis_immu_FourPointSevenFivePercentConvertibleSeniorNotesMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1.4</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> of which related to the accelerated amortization of debt issuance costs associated with the September Exchange Agreements), and </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d22929576e1270-wk-Fact-A7900FB0625568436B32D1D0181B38B3" name="us-gaap:AmortizationOfFinancingCosts" contextRef="D2017Q4Jul012016toJun302017_us-gaap_DebtInstrumentAxis_immu_FourPointSevenFivePercentConvertibleSeniorNotesMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">0.7</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> in fiscal 2017.</span></div></ix:continuation><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div><a id="s531AA7EA7572598C86BB71900DB544E1"></a></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">5.     <ix:nonNumeric contextRef="FD2019Q4YTD" name="us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" id="TextSelection-E7DF875311C5AEEADAA0D1D0187552B7-0-wk-Fact-EE129F5E60CC1E22C1CCD1D0182AEC98" continuedAt="TextSelection-E7DF875311C5AEEADAA0D1D0187552B7-1" escape="true">Stock-Based Compensation</ix:nonNumeric></span></div><ix:continuation id="TextSelection-E7DF875311C5AEEADAA0D1D0187552B7-1" continuedAt="TextSelection-E7DF875311C5AEEADAA0D1D0187552B7-2"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Stock Incentive Plan</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company has a stock incentive plan, the Immunomedics, Inc. 2014 Long-Term Incentive Plan (the “Plan”). The Plan was established to promote the long-term financial interests and growth of the Company, by attracting and retaining management and other personnel and key service providers with the training, experience and ability to enable them to make a substantial contribution to the success of the Company's business. The Plan is designed to motivate management personnel by means of growth-related incentives to achieve long-range goals and further the alignment of interests with those of the stockholders of the Company through opportunities for increased stock or stock-based ownership in the Company. Toward these objectives, the Company may grant stock options, stock appreciation rights, stock awards, stock units, performance shares, performance options, performance units, and other stock-based awards to eligible individuals on the terms and subject to the conditions set forth in the Plan. There have been no significant modifications to the Plan during the year ended December 31, 2019, the Transition Period or fiscal years ended June 30, 2018, or 2017.</span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Stock-based compensation expense was </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d22935527e661-wk-Fact-CF22244D0AF0067F54FADB3D87317669" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">11.7</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;">, </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d22935527e665-wk-Fact-3321BA2ABD198B8EE601D1D0182AD623" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="D2018Q4Jul01-Dec31" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">0.9</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;">, </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d22935527e669-wk-Fact-395E09A4CBEB70DF4166D1D0181BE883" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="D2018Q4Jul12017toJun302018" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">4.0</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;">, and </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d22935527e673-wk-Fact-BD76F750AFE14BAFB074D1D0182AB205" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="D2017Q4Jul012016toJun302017" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">4.3</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> for the year ended </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;">, the Transition Period, and fiscal years ended </span><span style="font-family:inherit;font-size:10pt;">June 30, 2018</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">2017</span><span style="font-family:inherit;font-size:10pt;">, respectively. On January 15, 2019, the Company received a final award finding from an arbitrator that denied Dr. Goldenberg </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d22935527e690-wk-Fact-F9F6A94E5A1BB7535F46D1D0182A33A0" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" contextRef="D2018Q4Jul01-Dec31_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember" unitRef="shares" decimals="-5" scale="6" format="ixt:numdotdecimal">1.5</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> of RSU's. As a result, during the Transition Period, </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d22935527e694-wk-Fact-5DBA3EC9B4DC577F53F8D1D0182A2BC3" name="immu:AllocatedSharebasedCompensationExpenseAmountReversed" contextRef="D2018Q4Jul01-Dec31" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">3.4</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> of the stock-based compensation expense was reversed. Refer to "Note 14 - Commitments and Contingencies" for more information.</span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Stock Options</span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Stock option grants provide the right to purchase a specified number of shares of Common Stock from the Company at a specified price during a specified period of time. The stock option exercise price per share is the fair market value of one share of Common Stock on the date of the grant of the stock option and generally have a vesting period of </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonNumeric id="d22935527e709-wk-Fact-2F0562EDE165A092A300D1D0182A3BE8" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" contextRef="D2018Q4Jul01-Dec31_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" format="ixt-sec:durwordsen">four years</ix:nonNumeric></span></span><span style="font-family:inherit;font-size:10pt;">. </span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">As of December 31, 2019</span><span style="font-family:inherit;font-size:10pt;">, there was </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d22935527e721-wk-Fact-3C6B602C580AB54A6D88DB95EDD4DCE8" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" contextRef="FI2019Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">40.6</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> of total unrecognized compensation cost related to non-vested stock-based compensation arrangements granted under the plan. That cost is being recognized over a weighted-average period of </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonNumeric id="d22935527e725-wk-Fact-ADBF165C8A1E70761278DB978B0A1834" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" contextRef="FD2019Q4YTD" format="ixt-sec:duryear">3</ix:nonNumeric> years</span></span><span style="font-family:inherit;font-size:10pt;">. </span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The weighted average grant date fair value of the stock options granted during the year ended </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;">, the Transition Period, and fiscal years ended </span><span style="font-family:inherit;font-size:10pt;">June 30, 2018</span><span style="font-family:inherit;font-size:10pt;">, and </span><span style="font-family:inherit;font-size:10pt;">2017</span><span style="font-family:inherit;font-size:10pt;"> was </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d22935527e746-wk-Fact-914C4424CB27CE207397DB4F3CDBC215" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" contextRef="FI2019Q4" unitRef="usdPerShare" decimals="2" scale="0" format="ixt:numdotdecimal">8.81</ix:nonFraction></span></span><span style="font-family:inherit;font-size:10pt;"> per share, </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d22935527e750-wk-Fact-3A4E9F0A1E6F439E9CC7DB4FC4844164" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" contextRef="FI2018Q4" unitRef="usdPerShare" decimals="2" scale="0" format="ixt:numdotdecimal">12.90</ix:nonFraction></span></span><span style="font-family:inherit;font-size:10pt;"> per share, </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d22935527e755-wk-Fact-6C6617812D9F619DAC66DB4FD5117173" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" contextRef="FI2018Q2" unitRef="usdPerShare" decimals="2" scale="0" format="ixt:numdotdecimal">8.76</ix:nonFraction></span></span><span style="font-family:inherit;font-size:10pt;"> per share, and </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d22935527e759-wk-Fact-1BDB7322491C29D38C82DB4FE3E0B7EA" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" contextRef="FI2017Q2" unitRef="usdPerShare" decimals="2" scale="0" format="ixt:numdotdecimal">2.21</ix:nonFraction></span></span><span style="font-family:inherit;font-size:10pt;"> per share, respectively. The weighted average grant date fair value of the performance-based stock options granted during the year ended December 31, 2019, the Transition Period, and fiscal years ended </span><span style="font-family:inherit;font-size:10pt;">June 30, 2018</span><span style="font-family:inherit;font-size:10pt;">, and 2017 was </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d22935527e767-wk-Fact-8C7030E047ED26ADEA1CDBC1378D701B" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" contextRef="FD2019Q4YTD" unitRef="usdPerShare" decimals="2" scale="0" format="ixt:numdotdecimal">9.50</ix:nonFraction></span></span><span style="font-family:inherit;font-size:10pt;">, </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d22935527e771-wk-Fact-4DED5CAC7F92D5D900FEDBC1464B29A3" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" contextRef="D2018Q4Jul01-Dec31" unitRef="usdPerShare" decimals="2" scale="0" format="ixt:numdotdecimal">0.00</ix:nonFraction></span></span><span style="font-family:inherit;font-size:10pt;">, </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d22935527e775-wk-Fact-FE4FFE090EF52F98DE5339D6E13125D7" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" contextRef="D2018Q4Jul12017toJun302018" unitRef="usdPerShare" decimals="2" scale="0" format="ixt:numdotdecimal">7.29</ix:nonFraction></span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d22935527e780-wk-Fact-B027EC513220E2EA025DDBC15C2504B9" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" contextRef="D2017Q4Jul012016toJun302017" unitRef="usdPerShare" decimals="2" scale="0" format="ixt:numdotdecimal">0.00</ix:nonFraction></span></span><span style="font-family:inherit;font-size:10pt;"> per share, respectively. There were no performance-based stock options granted during the Transition Period, or for the fiscal year ended </span><span style="font-family:inherit;font-size:10pt;">June 30, 2017</span><span style="font-family:inherit;font-size:10pt;">. </span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></ix:continuation><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">71</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;text-align:justify;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;" href="#sfb86787ac8304dffbb4bfe7ffcfa7b54"><span style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">Table of Contents</span></a></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></div><div><br/></div><ix:continuation id="TextSelection-E7DF875311C5AEEADAA0D1D0187552B7-2" continuedAt="TextSelection-E7DF875311C5AEEADAA0D1D0187552B7-3"><ix:nonNumeric contextRef="FD2019Q4YTD" name="us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" id="TextSelection-DEFD4F890AF42B8509D1D1D018755B47-0-wk-Fact-B74485BA018BCF8F60BDD1D0182AE43F" escape="true"><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We estimated the fair value of options granted using a Black-Scholes option pricing model with the following assumptions:</span></div><div style="line-height:120%;text-align:center;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:98.6328125%;border-collapse:collapse;text-align:left;"><tr><td colspan="10"></td></tr><tr><td style="width:31%;"></td><td style="width:1%;"></td><td style="width:16%;"></td><td style="width:1%;"></td><td style="width:16%;"></td><td style="width:1%;"></td><td style="width:16%;"></td><td style="width:1%;"></td><td style="width:16%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Year Ended </span></div><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">December 31, 2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Transition Period December 31, 2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="4" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Fiscal Years Ended June 30,</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">2017</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Expected dividend yield</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d22935527e933-wk-Fact-133FC494FA0F0913EFC6DB543E0FB5B2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" contextRef="FD2019Q4YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" unitRef="number" decimals="INF" scale="-2" format="ixt:zerodash">—</ix:nonFraction>%</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d22935527e943-wk-Fact-DA3E92660817591781E7D1D0181B7A1E" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" contextRef="D2018Q4Jul01-Dec31_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" unitRef="number" decimals="INF" scale="-2" format="ixt:zerodash">—</ix:nonFraction>%</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d22935527e953-wk-Fact-DA8CE10E3EFB59B6A696DB3EAEB0FABF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" contextRef="D2018Q4Jul12017toJun302018_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" unitRef="number" decimals="INF" scale="-2" format="ixt:zerodash">—</ix:nonFraction>%</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d22935527e963-wk-Fact-9D93327B2BCD07FC82CFDB3EAEE652C5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" contextRef="D2017Q4Jul012016toJun302017_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" unitRef="number" decimals="INF" scale="-2" format="ixt:zerodash">—</ix:nonFraction>%</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Expected option term (years)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonNumeric id="d22935527e984-wk-Fact-94CCA5FDD30A39EF11B7DB5440A312F3" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" contextRef="FD2019Q4YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" format="ixt-sec:duryear">4.52</ix:nonNumeric></span></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonNumeric id="d22935527e994-wk-Fact-28C453D120EA43AE77F6D1D0182A1324" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" contextRef="D2018Q4Jul01-Dec31_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" format="ixt-sec:duryear">4.76</ix:nonNumeric></span></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonNumeric id="d22935527e1004-wk-Fact-EEE1987791021A8612E6DB3EAF4B086B" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" contextRef="D2018Q4Jul12017toJun302018_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" format="ixt-sec:duryear">4.84</ix:nonNumeric></span></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonNumeric id="d22935527e1014-wk-Fact-B4266E5941B9E1CD78F5DB3EAE9F0DB7" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" contextRef="D2017Q4Jul012016toJun302017_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" format="ixt-sec:duryear">5.04</ix:nonNumeric></span></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Expected stock price volatility</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d22935527e1035-wk-Fact-18E985A0FD5B0D8440C6DB54429E10DE" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" contextRef="FD2019Q4YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" unitRef="number" decimals="2" scale="-2" format="ixt:numdotdecimal">71</ix:nonFraction>%</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d22935527e1045-wk-Fact-B499E292079BBF3A8436D1D0181B6EAD" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" contextRef="D2018Q4Jul01-Dec31_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" unitRef="number" decimals="INF" scale="-2" format="ixt:numdotdecimal">69</ix:nonFraction>%</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d22935527e1055-wk-Fact-53F8E8A06211EAA14EE2DB3EAF1AF7C8" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" contextRef="D2018Q4Jul12017toJun302018_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" unitRef="number" decimals="INF" scale="-2" format="ixt:numdotdecimal">70</ix:nonFraction>%</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d22935527e1065-wk-Fact-905EBCBAAF47B4650DC0DB3EAE63C552" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" contextRef="D2017Q4Jul012016toJun302017_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" unitRef="number" decimals="INF" scale="-2" format="ixt:numdotdecimal">63</ix:nonFraction>%</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Risk-free interest rate</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">1.39% - 2.58%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">2.69% - 3.06%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">1.72% - 2.89%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">1.16% - 2.15%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div></ix:nonNumeric><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">    </span></div><ix:nonNumeric contextRef="FD2019Q4YTD" name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" id="TextSelection-F5A3BED674556E057988D1D0187527D1-0-wk-Fact-A1FF0DEF023182B87A7BD1D0182A3635" escape="true"><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following table summarizes all stock option activity for the ended </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;">:</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="13"></td></tr><tr><td style="width:27%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:16%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:21%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:16%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Options</span></div><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">(in thousands)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Weighted Average Exercise Price Per Option</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Weighted Average Remaining Contractual Term (Years)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Aggregate Intrinsic Value (in thousands)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Options outstanding, January 1, 2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d22935527e1240-wk-Fact-1C792F6AAA8EC074ECDBDB556B759DD1" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="FI2018Q4_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" unitRef="shares" decimals="-3" scale="3" format="ixt:numdotdecimal">4,757</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d22935527e1259-wk-Fact-2A606CC8D444DD7D3F67DB556F59F9A6" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="FI2018Q4_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" unitRef="usdPerShare" decimals="2" scale="0" format="ixt:numdotdecimal">14.30</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonNumeric id="d22935527e1273-wk-Fact-B8CB532A8ACA068820C8DB557269DAF8" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" contextRef="FD2018Q4YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" format="ixt-sec:duryear">5.42</ix:nonNumeric></span></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d22935527e1289-wk-Fact-4FFC07C05595B985EEFCDB5575523F7C" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" contextRef="FI2018Q4_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">18,618</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">   Changes during the year:</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">   Granted</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d22935527e1371-wk-Fact-1C913DFD7AC8320C025ADB557ABE4904" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" contextRef="FD2019Q4YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" unitRef="shares" decimals="-3" scale="3" format="ixt:numdotdecimal">3,614</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d22935527e1385-wk-Fact-04B8E954B9711769CC40DB557D35E1EB" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" contextRef="FD2019Q4YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" unitRef="usdPerShare" decimals="2" scale="0" format="ixt:numdotdecimal">15.46</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">   Exercised</span></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(<ix:nonFraction id="d22935527e1436-wk-Fact-7613A19B8E4ED25B4F8DDB5581B11A2B" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" contextRef="FD2019Q4YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" unitRef="shares" decimals="-3" scale="3" format="ixt:numdotdecimal">1,207</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d22935527e1451-wk-Fact-6E4DDD960264BE70F5B2DB5584A3BE01" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" contextRef="FD2019Q4YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" unitRef="usdPerShare" decimals="2" scale="0" format="ixt:numdotdecimal">3.17</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">   Expired or forfeited</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(<ix:nonFraction id="d22935527e1502-wk-Fact-590CFA8C091E2F5B6B75DB5589049715" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" contextRef="FD2019Q4YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" unitRef="shares" decimals="-3" scale="3" format="ixt:numdotdecimal">1,263</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d22935527e1517-wk-Fact-BA844CE21592A55C7376DB558BC6B6B3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" contextRef="FD2019Q4YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" unitRef="usdPerShare" decimals="2" scale="0" format="ixt:numdotdecimal">17.78</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Options outstanding, end of year</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d22935527e1568-wk-Fact-0B0B170319B69B6E9A22DB558FDF5994" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="FI2019Q4_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" unitRef="shares" decimals="-3" scale="3" format="ixt:numdotdecimal">5,901</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#bfe4ff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#bfe4ff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d22935527e1587-wk-Fact-E71A5C84199BD5C15A38DB55927BC2C5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="FI2019Q4_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" unitRef="usdPerShare" decimals="2" scale="0" format="ixt:numdotdecimal">16.54</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonNumeric id="d22935527e1601-wk-Fact-BE671EC649F2BF0FAD4EDB559497B3DD" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" contextRef="FD2019Q4YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" format="ixt-sec:duryear">5.90</ix:nonNumeric></span></span></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#bfe4ff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d22935527e1617-wk-Fact-0DF916CE4F42A8486746DB559762A0BB" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" contextRef="FI2019Q4_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">30,145</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Vested as of December 31, 2019</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d22935527e1632-wk-Fact-2B07F810209443AEF5CBDB5599AC38F2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" contextRef="FI2019Q4_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" unitRef="shares" decimals="-3" scale="3" format="ixt:numdotdecimal">1,150</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d22935527e1651-wk-Fact-31DDC6BB160F1BF8C2E2DB559BF39363" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" contextRef="FI2019Q4_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" unitRef="usdPerShare" decimals="2" scale="0" format="ixt:numdotdecimal">14.72</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonNumeric id="d22935527e1665-wk-Fact-E3F795809D339B0E8BB1DB559EA85DFE" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" contextRef="FD2019Q4YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" format="ixt-sec:duryear">4.61</ix:nonNumeric></span></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d22935527e1681-wk-Fact-AF1CBB11F050412BDF9BDB55A0F3E766" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" contextRef="FI2019Q4_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">8,276</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following table summarizes all stock option activity for the Transition Period ended </span><span style="font-family:inherit;font-size:10pt;">December 31, 2018</span><span style="font-family:inherit;font-size:10pt;">:</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="13"></td></tr><tr><td style="width:27%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:16%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:21%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:16%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Options</span></div><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">(in thousands)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Weighted Average Exercise Price Per Option</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Weighted Average Remaining Contractual Term (Years)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Aggregate Intrinsic Value (in thousands)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Options outstanding, July 1, 2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d22935527e1801-wk-Fact-98284B64524AFB41AAF1D1D0184BA082" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="FI2018Q2_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" unitRef="shares" decimals="-3" scale="3" format="ixt:numdotdecimal">3,549</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d22935527e1820-wk-Fact-5FAAF80DC0E39C561098D1D0183C7E71" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="FI2018Q2_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" unitRef="usdPerShare" decimals="2" scale="0" format="ixt:numdotdecimal">7.58</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonNumeric id="d22935527e1834-wk-Fact-9BA1EEF6466F632C2C71D1D0183C130B" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" contextRef="D2018Q4Jul12017toJun302018_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" format="ixt-sec:duryear">4.43</ix:nonNumeric></span></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d22935527e1850-wk-Fact-537B155E383607207CBAD1D0183C3480" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" contextRef="FI2018Q2_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">57,123</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">   Changes during the year:</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">   Granted</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d22935527e1932-wk-Fact-0EF102DC6D95EE00CFF9D1D0183CDC37" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" contextRef="D2018Q4Jul01-Dec31_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" unitRef="shares" decimals="-3" scale="3" format="ixt:numdotdecimal">2,002</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d22935527e1946-wk-Fact-AF08077D8914F3A99C77D1D0184A3E30" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" contextRef="D2018Q4Jul01-Dec31_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" unitRef="usdPerShare" decimals="2" scale="0" format="ixt:numdotdecimal">22.54</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">   Exercised</span></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(<ix:nonFraction id="d22935527e1997-wk-Fact-BFB8200B58FA105FA7BBD1D0183C40BB" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" contextRef="D2018Q4Jul01-Dec31_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" unitRef="shares" decimals="-3" scale="3" format="ixt:numdotdecimal">706</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d22935527e2012-wk-Fact-FB1617602A2450A8963AD1D0183C67F8" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" contextRef="D2018Q4Jul01-Dec31_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" unitRef="usdPerShare" decimals="2" scale="0" format="ixt:numdotdecimal">3.71</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">   Expired or forfeited</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(<ix:nonFraction id="d22935527e2063-wk-Fact-EF856CBBB5CC73F2D99DD1D0181B4A71" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" contextRef="D2018Q4Jul01-Dec31_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" unitRef="shares" decimals="-3" scale="3" format="ixt:numdotdecimal">88</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d22935527e2078-wk-Fact-B95DEC4607D799D90BF2D1D0181B91CD" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" contextRef="D2018Q4Jul01-Dec31_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" unitRef="usdPerShare" decimals="2" scale="0" format="ixt:numdotdecimal">15.57</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Options outstanding, end of year</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d22935527e2129-wk-Fact-1C792F6AAA8EC074ECDBDB556B759DD1" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="FI2018Q4_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" unitRef="shares" decimals="-3" scale="3" format="ixt:numdotdecimal">4,757</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#bfe4ff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#bfe4ff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d22935527e2148-wk-Fact-2A606CC8D444DD7D3F67DB556F59F9A6" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="FI2018Q4_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" unitRef="usdPerShare" decimals="2" scale="0" format="ixt:numdotdecimal">14.30</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonNumeric id="d22935527e2162-wk-Fact-0D5E502B471CAFB6DC11D1D0183C6079" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" contextRef="D2018Q4Jul01-Dec31_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" format="ixt-sec:duryear">5.42</ix:nonNumeric></span></span></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#bfe4ff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d22935527e2178-wk-Fact-4FFC07C05595B985EEFCDB5575523F7C" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" contextRef="FI2018Q4_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">18,618</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Vested as of December 31, 2018</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d22935527e2193-wk-Fact-127FA6BBFEB10C08861ED1D0183C9DDB" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" contextRef="FI2018Q4_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" unitRef="shares" decimals="-3" scale="3" format="ixt:numdotdecimal">1,504</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d22935527e2212-wk-Fact-97746BBA3654ED473FF1D1D0184B40C6" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" contextRef="FI2018Q4_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" unitRef="usdPerShare" decimals="2" scale="0" format="ixt:numdotdecimal">4.23</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonNumeric id="d22935527e2226-wk-Fact-40B4DC342A0E322A766AD1D0184ADDF9" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" contextRef="D2018Q4Jul01-Dec31_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" format="ixt-sec:duryear">3.41</ix:nonNumeric></span></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d22935527e2242-wk-Fact-08B31E957AA311DC98B7D1D0183CF945" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" contextRef="FI2018Q4_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">15,098</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div></ix:nonNumeric><div style="line-height:120%;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">    </span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The total fair value of shares vested during the year ended </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;">, the Transition Period, and fiscal years ended </span><span style="font-family:inherit;font-size:10pt;">June 30, 2018</span><span style="font-family:inherit;font-size:10pt;">, and </span><span style="font-family:inherit;font-size:10pt;">2017</span><span style="font-family:inherit;font-size:10pt;"> was </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d22935527e2272-wk-Fact-3EC650DC5D322A9B05AADBBDF7C57C18" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" contextRef="FD2019Q4YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">8.9</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;">, </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d22935527e2276-wk-Fact-AEC82A26AEFDA5A63317DBBE0F930AA7" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" contextRef="D2018Q4Jul01-Dec31_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1.3</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;">, </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d22935527e2281-wk-Fact-1EE0066702EFD52C6FCDDBBE1B3DA520" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" contextRef="D2018Q4Jul12017toJun302018_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">0.3</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;">, and </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d22935527e2285-wk-Fact-518DAF61AD9814C02E89DBBE2591E6E5" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" contextRef="D2017Q4Jul012016toJun302017_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1.4</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;">, respectively. The total intrinsic value of stock options exercised during the fiscal year ended </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;">, the Transition Period, and fiscal years ended </span><span style="font-family:inherit;font-size:10pt;">June 30, 2018</span><span style="font-family:inherit;font-size:10pt;">, and </span><span style="font-family:inherit;font-size:10pt;">2017</span><span style="font-family:inherit;font-size:10pt;"> was </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d22935527e2301-wk-Fact-AB94AB74D691D7E7D899DBBE57246357" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" contextRef="FD2019Q4YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">14.7</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;">, </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d22935527e2306-wk-Fact-1334D2B7D8A485A226DCDBBE6746B7C1" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" contextRef="D2018Q4Jul01-Dec31_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">13.3</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;">, </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d22935527e2310-wk-Fact-1D155FFBD36902966D79DBBE784226F2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" contextRef="D2018Q4Jul12017toJun302018_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">7.8</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;">, and </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d22935527e2314-wk-Fact-F8357CCE57C305B936B7DBBE85968A0D" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" contextRef="D2017Q4Jul012016toJun302017_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">2.6</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;">, respectively.    </span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></ix:continuation><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">72</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;text-align:justify;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;" href="#sfb86787ac8304dffbb4bfe7ffcfa7b54"><span style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">Table of Contents</span></a></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></div><div><br/></div><ix:continuation id="TextSelection-E7DF875311C5AEEADAA0D1D0187552B7-3" continuedAt="TextSelection-E7DF875311C5AEEADAA0D1D0187552B7-4"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Restricted Stock Units ("RSU's")</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"></span><span style="font-family:inherit;font-size:10pt;">The Company may grant awards of RSU's to eligible individuals. An RSU represents a contractual obligation by the Company to deliver a number of shares of Common Stock equal to the fair market value of the specified number of shares subject to the award, or a combination of shares of Common Stock and cash. Vesting requirements may include performance goals, the attainment of performance goals with continued service, or both. </span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><ix:nonNumeric contextRef="FD2019Q4YTD" name="us-gaap:ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" id="TextSelection-1D36418EE871A8FF00A7DBB21823150B-0-wk-Fact-3C320DE10204D98A4046DBB22800ECC7" continuedAt="TextSelection-35C8AD7274B30B2CD632D1D0187569DE-0" escape="true"><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Information regarding the Company's RSU's for the year ended </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;"> is as follows:</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"></td></tr><tr><td style="width:38%;"></td><td style="width:1%;"></td><td style="width:29%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:28%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Non-Vested Restricted Stock Units</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Share Equivalent</span></div><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">(in thousands)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Weighted Average Grant Date Fair Value</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Non-vested at January 1, 2019</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d22935527e2415-wk-Fact-5A29927AAB2979432B7DD1D0183C3877" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" contextRef="FI2018Q4_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember" unitRef="shares" decimals="-3" scale="3" format="ixt:numdotdecimal">15</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d22935527e2434-wk-Fact-DC139A030FC5AEE9E49AD1D0183CECBC" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" contextRef="FI2018Q4_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember" unitRef="usdPerShare" decimals="2" scale="0" format="ixt:numdotdecimal">14.29</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Changes during the period:</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">   Restricted Units Granted </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d22935527e2495-wk-Fact-FA84444566D026DF73BBDBAABACFDB20" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" contextRef="FD2019Q4YTD_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember" unitRef="shares" decimals="-3" scale="3" format="ixt:numdotdecimal">58</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d22935527e2509-wk-Fact-0569D4887364015CD141DBAABCF9C9CB" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" contextRef="FD2019Q4YTD_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember" unitRef="usdPerShare" decimals="2" scale="0" format="ixt:numdotdecimal">12.93</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">   Vested/Exercised</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(<ix:nonFraction id="d22935527e2534-wk-Fact-18129F032C4025FE2DF7DBAABE4539E7" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" contextRef="FD2019Q4YTD_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember" unitRef="shares" decimals="-3" scale="3" format="ixt:numdotdecimal">15</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d22935527e2549-wk-Fact-188EB6FFED4384BA3143DBAAC05911C9" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" contextRef="FD2019Q4YTD_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember" unitRef="usdPerShare" decimals="2" scale="0" format="ixt:numdotdecimal">14.29</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">   Forfeited</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d22935527e2574-wk-Fact-BCE9D3A4C118D4046735DBAAC1EF62FE" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" contextRef="FD2019Q4YTD_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember" unitRef="shares" decimals="-3" scale="3" format="ixt:zerodash">—</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d22935527e2588-wk-Fact-F071D40F609114ECF2B7DBAAC35AD0FD" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" contextRef="FD2019Q4YTD_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember" unitRef="usdPerShare" decimals="2" scale="0" format="ixt:zerodash">—</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Non-vested at December 31, 2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d22935527e2613-wk-Fact-190942A48DB0727D31EADBAAC536CFD2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" contextRef="FI2019Q4_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember" unitRef="shares" decimals="-3" scale="3" format="ixt:numdotdecimal">58</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d22935527e2632-wk-Fact-5F25C2999C018089AD76DBAAC6B7D200" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" contextRef="FI2019Q4_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember" unitRef="usdPerShare" decimals="2" scale="0" format="ixt:numdotdecimal">12.93</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div></ix:nonNumeric><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">As of the year ended </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;">, there was </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d22935527e2651-wk-Fact-D1E45BE1A024CB7032E1DBC003C01917" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" contextRef="FI2019Q4_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">0.3</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> of total unrecognized compensation costs related to the awards. The cost is being recognized over a weighted-average period of </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonNumeric id="d22935527e2655-wk-Fact-C92BDA4C1A7D4F5000E8DBEDBBBFBF8B" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" contextRef="FD2019Q4YTD_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember" format="ixt-sec:duryear">0.4</ix:nonNumeric></span></span><span style="font-family:inherit;font-size:10pt;"> years. </span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><ix:continuation id="TextSelection-35C8AD7274B30B2CD632D1D0187569DE-0"><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Information regarding the Company's RSU's for the Transition Period ended </span><span style="font-family:inherit;font-size:10pt;">December 31, 2018</span><span style="font-family:inherit;font-size:10pt;"> is as follows:</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"></td></tr><tr><td style="width:38%;"></td><td style="width:1%;"></td><td style="width:29%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:28%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Non-Vested Restricted Stock Units</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Share Equivalent</span></div><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">(in thousands)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Weighted Average Grant Date Fair Value</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Non-vested at July 1, 2018</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d22935527e2746-wk-Fact-829789ECDA46A8F3C8A1D1D0183C474D" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" contextRef="FI2018Q2_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember" unitRef="shares" decimals="-3" scale="3" format="ixt:numdotdecimal">1,535</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d22935527e2765-wk-Fact-C542BF61545CAAC3CB7FD1D0183C2BA2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" contextRef="FI2018Q2_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember" unitRef="usdPerShare" decimals="2" scale="0" format="ixt:numdotdecimal">2.83</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Changes during the period:</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">   Restricted Units Granted </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d22935527e2826-wk-Fact-F901E15CB43E71A9B98CD1D0183CB801" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" contextRef="D2018Q4Jul01-Dec31_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember" unitRef="shares" decimals="-3" scale="3" format="ixt:numdotdecimal">15</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d22935527e2840-wk-Fact-B79A07FB95FA4BBAF4D3D1D0183CBA1C" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" contextRef="D2018Q4Jul01-Dec31_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember" unitRef="usdPerShare" decimals="2" scale="0" format="ixt:numdotdecimal">14.29</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">   Vested/Exercised</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(<ix:nonFraction id="d22935527e2865-wk-Fact-7B7B9BA96C1827A8A782D1D0183C61B3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" contextRef="D2018Q4Jul01-Dec31_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember" unitRef="shares" decimals="-3" scale="3" format="ixt:numdotdecimal">35</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d22935527e2880-wk-Fact-E1CFAAF6926D12F4B422D1D0183CB608" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" contextRef="D2018Q4Jul01-Dec31_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember" unitRef="usdPerShare" decimals="2" scale="0" format="ixt:numdotdecimal">8.46</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">   Forfeited</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(<ix:nonFraction id="d22935527e2905-wk-Fact-CC674E24B3548058149CD1D0183C8356" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" contextRef="D2018Q4Jul01-Dec31_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember" unitRef="shares" decimals="-3" scale="3" format="ixt:numdotdecimal">1,500</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d22935527e2920-wk-Fact-D5C880D02C170AD2C437D1D0183C9DCB" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" contextRef="D2018Q4Jul01-Dec31_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember" unitRef="usdPerShare" decimals="2" scale="0" format="ixt:numdotdecimal">2.28</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Non-vested at December 31, 2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d22935527e2945-wk-Fact-5A29927AAB2979432B7DD1D0183C3877" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" contextRef="FI2018Q4_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember" unitRef="shares" decimals="-3" scale="3" format="ixt:numdotdecimal">15</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d22935527e2964-wk-Fact-DC139A030FC5AEE9E49AD1D0183CECBC" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" contextRef="FI2018Q4_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember" unitRef="usdPerShare" decimals="2" scale="0" format="ixt:numdotdecimal">14.29</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div></ix:continuation><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">As of </span><span style="font-family:inherit;font-size:10pt;">December 31, 2018</span><span style="font-family:inherit;font-size:10pt;">, there was </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d22935527e2982-wk-Fact-60FD9BFF3E23F12275DFD1D0182AF852" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" contextRef="FI2018Q4_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">0.3</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> of total unrecognized compensation costs related to the awards. The cost was being recognized over a weighted-average period of </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonNumeric id="d22935527e2986-wk-Fact-6ABB5EB6D8B61A62EE46D1D0181BE563" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" contextRef="D2018Q4Jul01-Dec31_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember" format="ixt-sec:duryear">1.18</ix:nonNumeric> years</span></span><span style="font-family:inherit;font-size:10pt;">. During the Transition Period, the Company received a final award finding from an arbitrator that denied Dr. Goldenberg </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d22935527e2990-wk-Fact-F9F6A94E5A1BB7535F46D1D0182A33A0" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" contextRef="D2018Q4Jul01-Dec31_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember" unitRef="shares" decimals="-5" scale="6" format="ixt:numdotdecimal">1.5</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> of RSU's that are included as forfeited in the table above. Refer to "Note 14 - Commitments and Contingencies" for more information.</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Performance Stock Options ("PSO's")</span></div><div style="line-height:120%;padding-left:4px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-left:4px;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"></span><span style="font-family:inherit;font-size:10pt;">The Company may grant awards of PSO's to eligible individuals. PSO's are shares of Common Stock that vest based on performance measured against predetermined objectives that could include performance goals, continued employment, or a combination of both over a specified performance period. PSO's may be settled in shares of Common Stock, cash, or both as determined on the settlement date. </span></div><div style="line-height:120%;padding-left:4px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">On March 14, 2019, performance stock options were granted to certain individuals that vest upon the Company’s receipt of approval from the FDA for the Company’s BLA for sacituzumab govitecan for the treatment of patients with metastatic triple-negative breast cancer who have received at least two prior therapies for metastatic disease under the Prescription Drug User Fee Act. There were additional stock options that were granted to certain eligible individuals that vest on the second anniversary of the date of grant. In addition, on April 17, 2019 performance stock options were granted to certain individuals that vest upon achievement of defined sales performance milestones.</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-left:4px;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">    </span></div></ix:continuation><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">73</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;text-align:justify;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;" href="#sfb86787ac8304dffbb4bfe7ffcfa7b54"><span style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">Table of Contents</span></a></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></div><div><br/></div><ix:continuation id="TextSelection-E7DF875311C5AEEADAA0D1D0187552B7-4"><ix:nonNumeric contextRef="FD2019Q4YTD" name="immu:ScheduleofSharebasedCompensationPerformanceStockandPerformanceStockUnitsActivityTableTextBlock" id="TextSelection-92E9E4ED2D3F64DC3DC6DBB2B6D41DC0-0-wk-Fact-7A724DF6BF014C556DEFDBB2C315FC79" continuedAt="TextSelection-59730475C80636EB3F58D1D018759BE8-0" escape="true"><div style="line-height:120%;padding-left:4px;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following table summarizes the Company's performance-based stock option activity for the year ended </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;"> is as follows:</span><span style="font-family:inherit;font-size:10pt;font-weight:bold;"> </span></div><div style="line-height:120%;padding-left:4px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:98.4375%;border-collapse:collapse;text-align:left;"><tr><td colspan="13"></td></tr><tr><td style="width:28%;"></td><td style="width:13%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:15%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:20%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:16%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Options</span></div><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">(in thousands)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Weighted Average Exercise Price Per Option</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Weighted Average Remaining Contractual Term (Years)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Aggregate Intrinsic Value (in thousands)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Options outstanding, January 1, 2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d22935527e3132-wk-Fact-5AC99E349B43B172FF9DDB573B174CD4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="FI2018Q4_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember" unitRef="shares" decimals="-3" scale="3" format="ixt:numdotdecimal">538</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d22935527e3151-wk-Fact-3655AA100DF4D062C35EDB573DD7AB49" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="FI2018Q4_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember" unitRef="usdPerShare" decimals="2" scale="0" format="ixt:numdotdecimal">13.09</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonNumeric id="d22935527e3165-wk-Fact-64512B8C91E62763AC6DDB57401D3697" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" contextRef="FD2018Q4YTD_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember" format="ixt-sec:duryear">6.04</ix:nonNumeric></span></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d22935527e3181-wk-Fact-4E284582162198798B2FDB5742E6EEE5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" contextRef="FI2018Q4_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">772</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">   Changes during the year:</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">   Granted</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d22935527e3263-wk-Fact-B606A52BAEB4139C2324DB57489160E9" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" contextRef="FD2019Q4YTD_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember" unitRef="shares" decimals="-3" scale="3" format="ixt:numdotdecimal">800</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d22935527e3277-wk-Fact-C3EC3F5928A232082974DB574AF2013F" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" contextRef="FD2019Q4YTD_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember" unitRef="usdPerShare" decimals="2" scale="0" format="ixt:numdotdecimal">17.18</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">   Exercised</span></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d22935527e3328-wk-Fact-41C86C4B006414377916DB574F6D6C54" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" contextRef="FD2019Q4YTD_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember" unitRef="shares" decimals="-3" scale="3" format="ixt:zerodash">—</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d22935527e3342-wk-Fact-E8C791BA04C0FAA81E76DB5752941D13" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" contextRef="FD2019Q4YTD_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember" unitRef="usdPerShare" decimals="2" scale="0" format="ixt:zerodash">—</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">   Expired or forfeited</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(<ix:nonFraction id="d22935527e3393-wk-Fact-18D730412290368663A2DB57571B1314" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" contextRef="FD2019Q4YTD_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember" unitRef="shares" decimals="-3" scale="3" format="ixt:numdotdecimal">501</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d22935527e3408-wk-Fact-C14A5AC032D0EA032C96DB575A24E427" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" contextRef="FD2019Q4YTD_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember" unitRef="usdPerShare" decimals="2" scale="0" format="ixt:numdotdecimal">13.05</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Options outstanding, end of year</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d22935527e3459-wk-Fact-46EEC875D417E38D47A9DB575E0F93C5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="FI2019Q4_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember" unitRef="shares" decimals="-3" scale="3" format="ixt:numdotdecimal">837</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#bfe4ff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#bfe4ff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d22935527e3478-wk-Fact-10FFCADBB31C246F4C73DB5760FA9BC2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="FI2019Q4_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember" unitRef="usdPerShare" decimals="2" scale="0" format="ixt:numdotdecimal">17.03</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonNumeric id="d22935527e3492-wk-Fact-10AF66E292B381288592DB576420821C" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" contextRef="FD2019Q4YTD_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember" format="ixt-sec:duryear">6.26</ix:nonNumeric></span></span></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#bfe4ff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d22935527e3508-wk-Fact-829A9E4335F6EFFBB1C5DB5766DB8275" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" contextRef="FI2019Q4_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">3,456</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Vested as of December 31, 2019</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d22935527e3523-wk-Fact-C1780054BDA4A17A7814DB5769519F7D" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" contextRef="FI2019Q4_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember" unitRef="shares" decimals="-3" scale="3" format="ixt:numdotdecimal">50</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d22935527e3542-wk-Fact-870B4CE69C3A6227B317DB576C0B9928" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" contextRef="FI2019Q4_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember" unitRef="usdPerShare" decimals="2" scale="0" format="ixt:numdotdecimal">18.74</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonNumeric id="d22935527e3556-wk-Fact-F6E27EFA3309DBBEA732DB576ED8683B" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" contextRef="FD2019Q4YTD_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember" format="ixt-sec:duryear">6.88</ix:nonNumeric></span></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d22935527e3572-wk-Fact-A646E39571D8A5BFF473DB577194156A" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" contextRef="FI2019Q4_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">121</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div></ix:nonNumeric><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The total fair value of shares vested during the year ended </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;"> was </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d22935527e3590-wk-Fact-9E6963BE7D29CB5AA60539DBC02C7780" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" contextRef="FD2019Q4YTD_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1.1</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;">. As of the year ended </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;">, there was </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d22935527e3598-wk-Fact-9D2E115565174276FFFCDBBF3BC8E735" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" contextRef="FI2019Q4_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">4.9</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> of total unrecognized compensation costs related to the awards. The cost is being recognized over a remaining weighted-average period of </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonNumeric id="d22935527e3602-wk-Fact-A2B0714C4BB10327E678DBE9FA0D5109" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" contextRef="FD2019Q4YTD_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember" format="ixt-sec:duryear">0.8</ix:nonNumeric></span></span><span style="font-family:inherit;font-size:10pt;"> years. </span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><ix:continuation id="TextSelection-59730475C80636EB3F58D1D018759BE8-0"><div style="line-height:120%;padding-left:4px;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following table summarizes the Company's performance-based stock option activity for the Transition Period ended </span><span style="font-family:inherit;font-size:10pt;">December 31, 2018</span><span style="font-family:inherit;font-size:10pt;"> is as follows:</span><span style="font-family:inherit;font-size:10pt;font-weight:bold;"> </span></div><div style="line-height:120%;padding-left:4px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:98.4375%;border-collapse:collapse;text-align:left;"><tr><td colspan="13"></td></tr><tr><td style="width:28%;"></td><td style="width:13%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:15%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:20%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:16%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Options</span></div><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">(in thousands)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Weighted Average Exercise Price Per Option</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Weighted Average Remaining Contractual Term (Years)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Aggregate Intrinsic Value (in thousands)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Options outstanding, July 1, 2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d22935527e3722-wk-Fact-0530DCB8AEA3050C5419D1D0182A9207" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="FI2018Q2_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember" unitRef="shares" decimals="-3" scale="3" format="ixt:numdotdecimal">538</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d22935527e3741-wk-Fact-FED8593404B4AA5A8FA8D1D0183CE432" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="FI2018Q2_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember" unitRef="usdPerShare" decimals="2" scale="0" format="ixt:numdotdecimal">13.09</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonNumeric id="d22935527e3755-wk-Fact-97099399C4E18DFC661AD1D0182A8D44" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" contextRef="D2018Q4Jul12017toJun302018_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember" format="ixt-sec:duryear">6.54</ix:nonNumeric></span></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d22935527e3771-wk-Fact-F1B33105695F61A9DCDDD1D0182AB690" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" contextRef="FI2018Q2_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">5,688</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">   Changes during the year:</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">   Granted</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d22935527e3853-wk-Fact-F6F8A525EA2E750C12ACD1D0183C03D4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" contextRef="D2018Q4Jul01-Dec31_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember" unitRef="shares" decimals="-3" scale="3" format="ixt:zerodash">—</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d22935527e3867-wk-Fact-470FE9C68154C399140FD1D0183BA643" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" contextRef="D2018Q4Jul01-Dec31_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember" unitRef="usdPerShare" decimals="2" scale="0" format="ixt:zerodash">—</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">   Exercised</span></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d22935527e3918-wk-Fact-486240C6793FBA82663CD1D0182AA165" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" contextRef="D2018Q4Jul01-Dec31_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember" unitRef="shares" decimals="-3" scale="3" format="ixt:zerodash">—</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d22935527e3932-wk-Fact-072459DE90AD7ACE49E6D1D0183A36EF" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" contextRef="D2018Q4Jul01-Dec31_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember" unitRef="usdPerShare" decimals="2" scale="0" format="ixt:zerodash">—</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">   Expired or forfeited</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d22935527e3983-wk-Fact-CBA1E8C4CF06C0B38414D1D0182AFDB8" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" contextRef="D2018Q4Jul01-Dec31_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember" unitRef="shares" decimals="-3" scale="3" format="ixt:zerodash">—</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d22935527e3997-wk-Fact-C732CAC4DAE7250BED57D1D0182A2CA6" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" contextRef="D2018Q4Jul01-Dec31_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember" unitRef="usdPerShare" decimals="2" scale="0" format="ixt:zerodash">—</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Options outstanding, end of year</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d22935527e4048-wk-Fact-5AC99E349B43B172FF9DDB573B174CD4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="FI2018Q4_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember" unitRef="shares" decimals="-3" scale="3" format="ixt:numdotdecimal">538</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#bfe4ff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#bfe4ff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d22935527e4067-wk-Fact-3655AA100DF4D062C35EDB573DD7AB49" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="FI2018Q4_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember" unitRef="usdPerShare" decimals="2" scale="0" format="ixt:numdotdecimal">13.09</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonNumeric id="d22935527e4081-wk-Fact-2030C1B7EE1D2A00149ED1D0182AF069" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" contextRef="D2018Q4Jul01-Dec31_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember" format="ixt-sec:duryear">6.04</ix:nonNumeric></span></span></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#bfe4ff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d22935527e4097-wk-Fact-4E284582162198798B2FDB5742E6EEE5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" contextRef="FI2018Q4_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">772</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Vested as of December 31, 2018</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d22935527e4112-wk-Fact-FD797D7B83F91BD887CCD1D0183B294D" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" contextRef="FI2018Q4_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember" unitRef="shares" decimals="-3" scale="3" format="ixt:numdotdecimal">38</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d22935527e4131-wk-Fact-7BEAA9A520042585409FD1D0183BEF5E" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" contextRef="FI2018Q4_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember" unitRef="usdPerShare" decimals="2" scale="0" format="ixt:numdotdecimal">11.86</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonNumeric id="d22935527e4145-wk-Fact-281EDBF7406F2EF61150D1D0183CD95F" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" contextRef="D2018Q4Jul01-Dec31_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember" format="ixt-sec:duryear">5.94</ix:nonNumeric></span></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d22935527e4161-wk-Fact-14C03E0F617B4A8C3D60D1D0183C19CE" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" contextRef="FI2018Q4_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">91</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div></ix:continuation><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">As of </span><span style="font-family:inherit;font-size:10pt;">December 31, 2018</span><span style="font-family:inherit;font-size:10pt;">, there was </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d22935527e4183-wk-Fact-84D0F05DE8E37EEEB78CDBBF89A9D61E" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" contextRef="FI2018Q4_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">3.0</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> of total unrecognized compensation costs related to the awards. The cost was being recognized over a remaining weighted-average period of </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonNumeric id="d22935527e4187-wk-Fact-B10C9B1DFC4E81EED4E1DBEB360F4135" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" contextRef="D2018Q4Jul01-Dec31_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember" format="ixt-sec:duryear">3.05</ix:nonNumeric></span></span><span style="font-family:inherit;font-size:10pt;">. There were no performance stock options granted during the Transition Period.</span></div></ix:continuation><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">74</span></div></div><hr style="page-break-after:always"></hr><div><a id="s7E05BF24B67B5760842CB8ECFDCFB008"></a></div><div><div style="line-height:120%;text-align:justify;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;" href="#sfb86787ac8304dffbb4bfe7ffcfa7b54"><span style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">Table of Contents</span></a></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></div><div><br/></div><div style="line-height:120%;padding-bottom:16px;padding-top:16px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">6.         <ix:nonNumeric contextRef="FD2019Q4YTD" name="us-gaap:FairValueDisclosuresTextBlock" id="TextSelection-3C424B79A445199A782AD1D01875601F-0-wk-Fact-EE2070A80E26FD9E8462D1D0182AB9A6" continuedAt="TextSelection-3C424B79A445199A782AD1D01875601F-1" escape="true">Estimated Fair Value of Financial Instruments</ix:nonNumeric></span></div><ix:continuation id="TextSelection-3C424B79A445199A782AD1D01875601F-1"><ix:nonNumeric contextRef="FD2019Q4YTD" name="us-gaap:FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" id="TextSelection-E9716D53F81AC559DD59D1D018756F4B-0-wk-Fact-3E542CE1BD21860F6617D1D0184B6187" escape="true"><div style="line-height:120%;padding-top:16px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Cash Equivalents and Marketable Securities</span></div><div style="line-height:120%;padding-top:16px;text-align:justify;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.609375%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"></td></tr><tr><td style="width:53%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="15" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-style:italic;font-weight:bold;">($ in thousands)</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">As of December 31, 2019</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Level 1</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Level 2</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Level 3</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Total</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Money Market Funds Note (a)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d22931120e850-wk-Fact-4691B2143E28C877E457D1D0181B285B" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" contextRef="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FinancialInstrumentAxis_us-gaap_MoneyMarketFundsMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">550,788</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d22931120e869-wk-Fact-4186F3C569A627391497D1D0181B044B" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" contextRef="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FinancialInstrumentAxis_us-gaap_MoneyMarketFundsMember" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">—</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d22931120e888-wk-Fact-514C7F00212683FB863ED1D0181B6626" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" contextRef="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FinancialInstrumentAxis_us-gaap_MoneyMarketFundsMember" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">—</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d22931120e908-wk-Fact-ED44A04F0F8966B4A14CD1D0181B1844" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" contextRef="FI2019Q4_us-gaap_FinancialInstrumentAxis_us-gaap_MoneyMarketFundsMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">550,788</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Marketable Securities:</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">U.S. Government Sponsored Agencies</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d22931120e1005-wk-Fact-4D18208EFF249433BAF0D1D0181BC49C" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">4,550</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d22931120e1024-wk-Fact-863865C23B2A31F77B1ED1D0181BCC1A" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">—</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d22931120e1043-wk-Fact-B90460F0BBBD8315129CD1D0181B596B" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">—</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d22931120e1063-wk-Fact-6925F06F6C4C9B1C7110D1D0182AFD14" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="FI2019Q4_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">4,550</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Total</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d22931120e1088-wk-Fact-026CB44386DFED309601D1D0182A85C4" name="us-gaap:AssetsFairValueDisclosure" contextRef="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">555,338</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d22931120e1107-wk-Fact-55B1ED8098E1B5E8D315D1D0181BCF78" name="us-gaap:AssetsFairValueDisclosure" contextRef="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">—</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d22931120e1126-wk-Fact-2941BC00A30EE117EB60D1D0182AD8CE" name="us-gaap:AssetsFairValueDisclosure" contextRef="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">—</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d22931120e1146-wk-Fact-FD8584D0D337183C39CED1D0181BC332" name="us-gaap:AssetsFairValueDisclosure" contextRef="FI2019Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">555,338</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"></td></tr><tr><td style="width:53%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="15" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-style:italic;font-weight:bold;">($ in thousands)</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">As of December 31, 2018</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Level 1</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Level 2</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Level 3</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Total</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Money Market Funds Note (a)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d22931120e1354-wk-Fact-60AAC78D31A03115748F39E56907A462" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" contextRef="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FinancialInstrumentAxis_us-gaap_MoneyMarketFundsMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">326,239</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d22931120e1373-wk-Fact-11D2AA157735560C1A3A39E567898E29" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" contextRef="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FinancialInstrumentAxis_us-gaap_MoneyMarketFundsMember" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">—</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d22931120e1392-wk-Fact-4252752844F821CF5BA939E5691C7485" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" contextRef="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FinancialInstrumentAxis_us-gaap_MoneyMarketFundsMember" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">—</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d22931120e1412-wk-Fact-E415CA2F42824A326F9A39E568022827" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" contextRef="FI2018Q4_us-gaap_FinancialInstrumentAxis_us-gaap_MoneyMarketFundsMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">326,239</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Marketable Securities:</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">U.S. Government Sponsored Agencies</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d22931120e1509-wk-Fact-42D163FC812A216B1B6139E568090729" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">4,941</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d22931120e1528-wk-Fact-5BE1508F573ACA57EAFD39E567D0A364" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">—</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d22931120e1547-wk-Fact-3017332B69E18F88E35139E5681192BB" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">—</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d22931120e1567-wk-Fact-19DDF8199E1F6CF08D52D7AF42EA193E" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="FI2018Q4_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">4,941</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Total</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d22931120e1592-wk-Fact-AF8DF3388F43D385AC4839E567F157A6" name="us-gaap:AssetsFairValueDisclosure" contextRef="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">331,180</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d22931120e1611-wk-Fact-3C0AEE0037CD8ED2413239E568248A43" name="us-gaap:AssetsFairValueDisclosure" contextRef="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">—</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d22931120e1630-wk-Fact-0424473D01966E67E89539E568186B1B" name="us-gaap:AssetsFairValueDisclosure" contextRef="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">—</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d22931120e1650-wk-Fact-52207698BCC44F1EFB5939E5681E7E5E" name="us-gaap:AssetsFairValueDisclosure" contextRef="FI2018Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">331,180</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;padding-left:4px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-left:0px;text-align:justify;text-indent:48px;"><span style="text-align:justify;font-family:inherit;font-size:10pt;padding-right:48px;">(a)</span><span style="font-family:inherit;font-size:10pt;">The money market funds noted above are included in cash and cash equivalents.</span></div></ix:nonNumeric><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Convertible Senior Notes</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><ix:nonNumeric contextRef="FD2019Q4YTD" name="us-gaap:ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock" id="TextSelection-FB4E9A338F4D77B53BDBD1D018754332-0-wk-Fact-E5B21B9463B2E1B4768AD1D0184B0C53" escape="true"><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The carrying amounts and estimated fair values (Level 2) of debt instruments are as follows (in thousands):</span></div><div style="line-height:120%;text-align:justify;padding-left:0px;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"></td></tr><tr><td style="width:47%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">As of December 31, 2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">As of December 31, 2018</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Carrying Amount</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Estimated Fair Value</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Carrying Amount</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Estimated Fair Value</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Convertible Senior Notes</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d22931120e1886-wk-Fact-E1D963B5BF176843E9A8D1D0182A56FC" name="us-gaap:ConvertibleDebtFairValueDisclosures" contextRef="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_CarryingReportedAmountFairValueDisclosureMember_us-gaap_LongtermDebtTypeAxis_us-gaap_SeniorNotesMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">7,106</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d22931120e1905-wk-Fact-3475F014A1B23BAD0AF5D1D0182A0A69" name="us-gaap:ConvertibleDebtFairValueDisclosures" contextRef="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_EstimateOfFairValueFairValueDisclosureMember_us-gaap_LongtermDebtTypeAxis_us-gaap_SeniorNotesMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">28,900</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d22931120e1924-wk-Fact-CDB060014703E9380292D1D0182A364D" name="us-gaap:ConvertibleDebtFairValueDisclosures" contextRef="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_CarryingReportedAmountFairValueDisclosureMember_us-gaap_LongtermDebtTypeAxis_us-gaap_SeniorNotesMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">7,055</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d22931120e1944-wk-Fact-77C1D497BB9CF373B9C2D1D0182AD9A1" name="us-gaap:ConvertibleDebtFairValueDisclosures" contextRef="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_EstimateOfFairValueFairValueDisclosureMember_us-gaap_LongtermDebtTypeAxis_us-gaap_SeniorNotesMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">20,100</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div></ix:nonNumeric><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The fair value of the Convertible Senior Notes, which differs from their carrying values, is influenced by interest rates, the Company’s stock price and stock price volatility and is determined by prices for the Convertible Senior Notes observed in market trading which are Level 2 inputs.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Liability Related to the Sale of Future Royalties</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"></span><span style="font-family:inherit;font-size:10pt;">The Company has determined the fair value of the liability related to the sale of future royalties is based on the Company's current estimates of future royalties expected to be paid to RPI, over the life of the arrangement, which are considered Level 3 (See Note 4 - "Debt").</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">There were no transfers between Level 1, Level 2, and Level 3 during the periods presented.</span></div></ix:continuation><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">75</span></div></div><hr style="page-break-after:always"></hr><div><a id="s783AA86DB59E5F969ADCD02670ADA21A"></a></div><div><div style="line-height:120%;text-align:justify;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;" href="#sfb86787ac8304dffbb4bfe7ffcfa7b54"><span style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">Table of Contents</span></a></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></div><div><br/></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">7.        <ix:nonNumeric contextRef="FD2019Q4YTD" name="us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock" id="TextSelection-0AAAAD1E3296F3BD9E9CD1D0186585A9-0-wk-Fact-8FEEE9B3FEF1D84CC938D1D0185BFB52" continuedAt="TextSelection-0AAAAD1E3296F3BD9E9CD1D0186585A9-1" escape="true">Property and Equipment</ix:nonNumeric></span></div><ix:continuation id="TextSelection-0AAAAD1E3296F3BD9E9CD1D0186585A9-1"><ix:nonNumeric contextRef="FD2019Q4YTD" name="us-gaap:PropertyPlantAndEquipmentTextBlock" id="TextSelection-7B2CF42039CCBA2D0772D1D018654DB0-0-wk-Fact-7CF5306DD40C9413D31AD1D0185BD954" escape="true"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Property and equipment consisted of the following as of December 31, (in thousands):</span></div><div style="line-height:120%;text-align:justify;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"></td></tr><tr><td style="width:73%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">2018</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Machinery and equipment</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d22931655e721-wk-Fact-2ABB620438BB34E3E0E6DC232E0D3545" name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="FI2019Q4_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_MachineryAndEquipmentMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">14,331</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d22931655e740-wk-Fact-51FDB320DDB0EEB099DCD1D0183C6852" name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="FI2018Q4_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_MachineryAndEquipmentMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">16,048</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Leasehold improvements</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d22931655e755-wk-Fact-2CD1F15E54293FF8A0B6DC232FC55FCF" name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="FI2019Q4_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_LeaseholdImprovementsMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">11,535</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d22931655e774-wk-Fact-DDAF61EA32F45C75A33ED1D0181B7458" name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="FI2018Q4_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_LeaseholdImprovementsMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">6,365</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Right-of-use asset</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d22931655e794-wk-Fact-2F796DD821798DFDA045DC26DB107659" name="immu:FinanceLeaseRightofUseAssetBeforeAccumulatedAmortization" contextRef="FI2019Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">8,368</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">—</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Furniture and fixtures</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d22931655e833-wk-Fact-36DAF61E4FB8C88EFD4FD1D0183CA562" name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="FI2019Q4_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_FurnitureAndFixturesMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">1,190</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d22931655e852-wk-Fact-64CC24FE6354B7D07118D1D0183CAACC" name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="FI2018Q4_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_FurnitureAndFixturesMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">291</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Computer equipment</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d22931655e872-wk-Fact-7E668CE23E799D967D23D1D01865B003" name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="FI2019Q4_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_ComputerEquipmentMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">2,596</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d22931655e891-wk-Fact-983C0C5C9081CEDD528ED1D0180BA4FC" name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="FI2018Q4_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_ComputerEquipmentMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">1,850</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Construction in progress</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d22931655e911-wk-Fact-3EC9A5E4F332EAC269DADC2334027C5E" name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="FI2019Q4_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_ConstructionInProgressMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">2,667</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d22931655e930-wk-Fact-07D37FF946BBED8D1477D1D0183C8460" name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="FI2018Q4_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_ConstructionInProgressMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">3,231</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d22931655e950-wk-Fact-70FD5425CC4A42909782DC2334DBEB3A" name="immu:PropertyPlantAndEquipmentAndFinanceLeaseRightofUseAssetBeforeAccumulatedDepreciationAndAmortization" contextRef="FI2019Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">40,687</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d22931655e969-wk-Fact-A0735FE0E9B278D8C171D1D018652089" name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="FI2018Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">27,785</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Accumulated depreciation and amortization</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(<ix:nonFraction id="d22931655e989-wk-Fact-BA3142CCBDBC635BF3EDD1D0184B4830" name="immu:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization" contextRef="FI2019Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">7,925</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(<ix:nonFraction id="d22931655e1009-wk-Fact-B16C960460B57D54D585D1D0184B43D1" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" contextRef="FI2018Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">4,316</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d22931655e1035-wk-Fact-EE43CD49E45AC72CA17EDC2335823FD1" name="immu:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization" contextRef="FI2019Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">32,762</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d22931655e1054-wk-Fact-10C952140E4204F13D7BD1D0184B37BF" name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="FI2018Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">23,469</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div></ix:nonNumeric><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Depreciation and amortization expense for the year ended </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;">, the Transition Period, and the fiscal years ended June 30, 2018 and 2017, was </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d22931655e1076-wk-Fact-254ADED3A81BE8581353DC2C513819A4" name="us-gaap:DepreciationAndAmortization" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">3.8</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;">, </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d22931655e1080-wk-Fact-9D3E5509FD63016A1559D1D0185B0D78" name="us-gaap:DepreciationAndAmortization" contextRef="D2018Q4Jul01-Dec31" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">2.1</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;">, $</span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d22931655e1084-wk-Fact-E1F1FF43EC7DFFFF1328D1D0185B436C" name="us-gaap:DepreciationAndAmortization" contextRef="D2018Q4Jul12017toJun302018" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1.3</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d22931655e1088-wk-Fact-344143FDFC7B9CFC9EECD1D0185B4AFE" name="us-gaap:DepreciationAndAmortization" contextRef="D2017Q4Jul012016toJun302017" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">0.9</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;">, respectively. </span></div></ix:continuation><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div><a id="s71E6291577E558A190DB633E6398736A"></a></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">8.    <ix:nonNumeric contextRef="FD2019Q4YTD" name="us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" id="TextSelection-E1C31154866ABB5378E7D1D018756E4F-0-wk-Fact-5245735B663039DDECC9D1D0184BA72D" continuedAt="TextSelection-E1C31154866ABB5378E7D1D018756E4F-1" escape="true">Accounts Payable and Accrued Expenses</ix:nonNumeric></span></div><ix:nonNumeric contextRef="FD2019Q4YTD" name="us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" id="TextSelection-4D05772FD1D0E9FBE174D1D018751894-0-wk-Fact-C96B6766D4ED9A68B571D1D0184B3F17" escape="true"><ix:continuation id="TextSelection-E1C31154866ABB5378E7D1D018756E4F-1"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Accounts payable and accrued expenses consisted of the following as of December 31, (in thousands):</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"></td></tr><tr><td style="width:73%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">2018 </span><span style="font-family:inherit;font-size:9pt;font-weight:bold;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(a)</sup></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Trade accounts payable</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d22936016e726-wk-Fact-15FDC18F635518BD8F17DC30BF8452F5" name="us-gaap:AccountsPayableTradeCurrent" contextRef="FI2019Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">37,758</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d22936016e745-wk-Fact-25CFEAA8166ECBAED0B7DC30BFA26297" name="us-gaap:AccountsPayableTradeCurrent" contextRef="FI2018Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">20,125</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Accrued contract manufacturing expenses</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d22936016e760-wk-Fact-D1D437D3DDCBC2425FE95EEE1F61F7F1" name="immu:AccruedContractManufacturingExpenses" contextRef="FI2019Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">11,663</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d22936016e779-wk-Fact-4B876B8FE663120B5B1F5EEE1F5BA807" name="immu:AccruedContractManufacturingExpenses" contextRef="FI2018Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">—</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Accrued employee related expenses</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d22936016e799-wk-Fact-0A15252A0385186E72E85EEF16F74ED3" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" contextRef="FI2019Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">7,403</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d22936016e818-wk-Fact-4E5406264E2BDAEA3A2A5EEF16F2BD9B" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" contextRef="FI2018Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">315</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Clinical trial accruals</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d22936016e838-wk-Fact-D7B3EDCC36D64CE67C15DC30BFA7D9A9" name="immu:ClinicalTrials" contextRef="FI2019Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">2,225</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d22936016e857-wk-Fact-F2721495462E238E075DDC30BFACCB58" name="immu:ClinicalTrials" contextRef="FI2018Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">5,114</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Executive severance liabilities</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d22936016e877-wk-Fact-CAA0A6E59C1CAA3196BADC30BF9302F2" name="us-gaap:SupplementalUnemploymentBenefitsSeveranceBenefits" contextRef="FI2019Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">561</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d22936016e896-wk-Fact-62DB42B9058DEC62A7B0DC30BF9D0EAA" name="us-gaap:SupplementalUnemploymentBenefitsSeveranceBenefits" contextRef="FI2018Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">2,198</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Miscellaneous other current liabilities</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d22936016e916-wk-Fact-06F54F6CACE5FD661076DC30BF989CCA" name="immu:OtherCurrentLiabilities" contextRef="FI2019Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">1,250</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d22936016e935-wk-Fact-FC32F67F11D6F3EC0C47DC30BFBE0B35" name="immu:OtherCurrentLiabilities" contextRef="FI2018Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">3,970</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d22936016e960-wk-Fact-7C2A859B877F0F655F76D6F43C09A49D" name="us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent" contextRef="FI2019Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">60,860</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d22936016e979-wk-Fact-228C40E00DEB07C9D25AD1D0185B2721" name="us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent" contextRef="FI2018Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">31,722</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(a)</sup></span><span style="font-family:inherit;font-size:10pt;"> </span><span style="font-family:inherit;font-size:9pt;">Certain 2018 amounts have been reclassified to conform with current year presentation.</span></div></ix:continuation></ix:nonNumeric><div style="line-height:120%;text-align:justify;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><br/></span></div><div><a id="s52E53916EEF55345A872B0D391985FD0"></a></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">9.         <ix:nonNumeric contextRef="FD2019Q4YTD" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock" id="TextSelection-2EB876058512C5BA3848D1D01875A12F-0-wk-Fact-D7266ED348457E80536ED1D0181B1DF6" continuedAt="TextSelection-2EB876058512C5BA3848D1D01875A12F-1" escape="true">Stockholders’ Equity </ix:nonNumeric></span></div><ix:continuation id="TextSelection-2EB876058512C5BA3848D1D01875A12F-1" continuedAt="TextSelection-2EB876058512C5BA3848D1D01875A12F-2"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">At the June 29, 2017 Special Meeting, the Company’s stockholders approved the amendment and restatement of the Company’s Certificate of Incorporation to increase the maximum number of shares of the Company’s stock authorized up to </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d22936210e647-wk-Fact-45B6FFF53D3B3514ED1FD1D0182A81E2" name="immu:CommonAndPreferredSharesAuthorized" contextRef="I2017Q4June29" unitRef="shares" decimals="INF" scale="0" format="ixt:numdotdecimal">260,000,000</ix:nonFraction></span></span><span style="font-family:inherit;font-size:10pt;"> shares of stock consisting of </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d22936210e651-wk-Fact-6832264F99936087887CD1D0182ABB1E" name="us-gaap:CommonStockSharesAuthorized" contextRef="I2017Q4June29" unitRef="shares" decimals="INF" scale="0" format="ixt:numdotdecimal">250,000,000</ix:nonFraction></span></span><span style="font-family:inherit;font-size:10pt;"> shares of common stock and </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d22936210e655-wk-Fact-7506D8D8E3F5AC3306DFD1D0181B1CC1" name="us-gaap:PreferredStockSharesAuthorized" contextRef="I2017Q4June29" unitRef="shares" decimals="INF" scale="0" format="ixt:numdotdecimal">10,000,000</ix:nonFraction></span></span><span style="font-family:inherit;font-size:10pt;"> shares of preferred stock. Previously the Company’s Certificate of Incorporation authorized up to </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d22936210e659-wk-Fact-82991E9AC9AEF9860216D1D0182A0538" name="immu:CommonAndPreferredSharesAuthorized" contextRef="I2017Q4June28" unitRef="shares" decimals="INF" scale="0" format="ixt:numdotdecimal">165,000,000</ix:nonFraction></span></span><span style="font-family:inherit;font-size:10pt;"> shares of capital stock, consisting of </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d22936210e663-wk-Fact-C56DEE55F527529AB6FBD1D0182A9418" name="us-gaap:CommonStockSharesAuthorized" contextRef="I2017Q4June28" unitRef="shares" decimals="INF" scale="0" format="ixt:numdotdecimal">155,000,000</ix:nonFraction></span></span><span style="font-family:inherit;font-size:10pt;"> shares of common stock and </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d22936210e668-wk-Fact-DEA2961F2FD3331CEC8CD1D0182AA02F" name="us-gaap:PreferredStockSharesAuthorized" contextRef="I2017Q4June28" unitRef="shares" decimals="INF" scale="0" format="ixt:numdotdecimal">10,000,000</ix:nonFraction></span></span><span style="font-family:inherit;font-size:10pt;"> shares of preferred stock.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Preferred Stock</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Certificate of Incorporation of the Company authorizes </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d22936210e683-wk-Fact-79943D91E04C4EE456B7D1D0182A1B6C" name="us-gaap:PreferredStockSharesAuthorized" contextRef="FI2019Q4" unitRef="shares" decimals="INF" scale="0" format="ixt:numdotdecimal">10,000,000</ix:nonFraction></span></span><span style="font-family:inherit;font-size:10pt;"> shares of preferred stock, </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d22936210e687-wk-Fact-82A02BBE73A541BE2865D1D0182A6F71" name="us-gaap:PreferredStockParOrStatedValuePerShare" contextRef="FI2019Q4" unitRef="usdPerShare" decimals="INF" scale="0">.01</ix:nonFraction></span></span><span style="font-family:inherit;font-size:10pt;"> par value per share. The preferred stock may be issued from time to time in one or more series, with such distinctive serial designations, rights and preferences as shall be determined by the Board of Directors.</span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">On May 10, 2017, the Company issued in a private placement </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d22936210e696-wk-Fact-89CDE4A24DCCDF4BE2FAD1D0182A91C2" name="us-gaap:PreferredStockSharesIssued" contextRef="I2017Q4May10_us-gaap_StatementClassOfStockAxis_us-gaap_ConvertiblePreferredStockMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember" unitRef="shares" decimals="INF" scale="0" format="ixt:numdotdecimal">1,000,000</ix:nonFraction></span></span><span style="font-family:inherit;font-size:10pt;"> shares (the “Preferred Shares”) of the Company’s Series A-1 Convertible Preferred Stock at a price of </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d22936210e700-wk-Fact-2418863D60065DC2E71AD1D0182A00A2" name="immu:IssuanceofConvertiblePreferredStockPerShare" contextRef="D2017Q4May10_us-gaap_StatementClassOfStockAxis_us-gaap_ConvertiblePreferredStockMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember" unitRef="usdPerShare" decimals="INF" scale="0" format="ixt:numdotdecimal">125</ix:nonFraction></span></span><span style="font-family:inherit;font-size:10pt;"> per share for gross proceeds to the Company of </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d22936210e704-wk-Fact-9E74712E09BC6A2619B1D1D0182A4D1A" name="us-gaap:ProceedsFromIssuanceOfConvertiblePreferredStock" contextRef="D2017Q4May10_us-gaap_StatementClassOfStockAxis_us-gaap_ConvertiblePreferredStockMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">125.0</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;">, before deducting fees and expenses (the “Financing”). Each Preferred Share will be convertible into </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d22936210e708-wk-Fact-70C852941E089C9BA45BD1D0183C827B" name="immu:ConvertiblePreferredStockConversionRatio" contextRef="I2017Q4May10_us-gaap_StatementClassOfStockAxis_us-gaap_ConvertiblePreferredStockMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember" unitRef="number" decimals="INF" scale="0" format="ixt:numdotdecimal">23.10536</ix:nonFraction></span></span><span style="font-family:inherit;font-size:10pt;"> shares of common stock (or an aggregate of </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d22936210e712-wk-Fact-A630F079D9843F1B3C44D1D0182A39BD" name="us-gaap:ConversionOfStockSharesIssued1" contextRef="D2017Q4May10_us-gaap_StatementClassOfStockAxis_us-gaap_ConvertiblePreferredStockMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember" unitRef="shares" decimals="INF" scale="0" format="ixt:numdotdecimal">23,105,348</ix:nonFraction></span></span><span style="font-family:inherit;font-size:10pt;"> shares of common stock). The conversion price per share of common stock is </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d22936210e717-wk-Fact-FB71EA5019E4AFB75CBED1D0183B20E0" name="us-gaap:SharePrice" contextRef="I2017Q4May10_us-gaap_StatementClassOfStockAxis_us-gaap_ConvertiblePreferredStockMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember" unitRef="usdPerShare" decimals="INF" scale="0" format="ixt:numdotdecimal">5.41</ix:nonFraction></span></span><span style="font-family:inherit;font-size:10pt;">. At </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;"> and 2018, the Company had no preferred stock outstanding.</span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></ix:continuation><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">76</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;text-align:justify;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;" href="#sfb86787ac8304dffbb4bfe7ffcfa7b54"><span style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">Table of Contents</span></a></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></div><div><br/></div><ix:continuation id="TextSelection-2EB876058512C5BA3848D1D01875A12F-2" continuedAt="TextSelection-2EB876058512C5BA3848D1D01875A12F-3"><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Following the June 29, 2017 Special Meeting and filing the Charter Amendment with the State of Delaware, the Company had authorized a sufficient number of unreserved shares of common stock to permit the exchange of the Preferred Shares. On July 31, 2017, the Company filed a registration statement on Form S-3 to register for resale the </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d22936210e730-wk-Fact-B517B19E61876DA9E87ED1D0182A8D5A" name="us-gaap:ConversionOfStockSharesIssued1" contextRef="D2018Q1July31_us-gaap_StatementClassOfStockAxis_us-gaap_ConvertiblePreferredStockMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember" unitRef="shares" decimals="INF" scale="0" format="ixt:numdotdecimal">23,105,348</ix:nonFraction></span></span><span style="font-family:inherit;font-size:10pt;"> shares of the Company's common stock issuable upon the exchange of the Series A-1 Convertible Preferred Stock. The Preferred Shares converted to shares of common stock on August 24, 2017. The registration statement was declared effective on September 19, 2017.</span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Common Stock</span><span style="font-family:inherit;font-size:10pt;"> </span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">On October 11, 2016, the Company completed an underwritten public offering of </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d22936210e747-wk-Fact-CA377FABA92202C1A0BE1C31121081AA" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="I2017Q2Oct11_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember" unitRef="shares" decimals="INF" scale="0" format="ixt:numdotdecimal">10,000,000</ix:nonFraction></span></span><span style="font-family:inherit;font-size:10pt;"> shares of its common stock and accompanying warrants to purchase </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d22936210e751-wk-Fact-CA377FABA92202C1A0BE1C31121081AA" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="I2017Q2Oct11_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember" unitRef="shares" decimals="INF" scale="0" format="ixt:numdotdecimal">10,000,000</ix:nonFraction></span></span><span style="font-family:inherit;font-size:10pt;"> shares of common stock at a purchase price of </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d22936210e755-wk-Fact-FDE4F8C18AE1680A36C11C341AB9BBE4" name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="I2017Q2Oct11_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember" unitRef="usdPerShare" decimals="INF" scale="0" format="ixt:numdotdecimal">3.00</ix:nonFraction></span></span><span style="font-family:inherit;font-size:10pt;"> per unit, comprising of one share of common stock and one warrant. The Company received gross and net proceeds of </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d22936210e759-wk-Fact-04C912FB10BF5236899A1C363C6EABD5" name="immu:GrossProceedsFromIssuanceOfCommonStock" contextRef="D2016Q1Oct11-Oct11_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">30.0</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> and approximately </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d22936210e763-wk-Fact-EEF601EF978CE25073401C37EC844AA9" name="us-gaap:ProceedsFromIssuanceOfCommonStock" contextRef="D2016Q1Oct11-Oct11_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">28.6</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;">, respectively after deducting the underwriting discounts and commissions and estimated expenses related to the offering payable. The warrants became exercisable nine months following the date of issuance and will expire on the second anniversary of the date of issuance and have an exercise price of </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d22936210e768-wk-Fact-D30CE0E89FFCA4269A3A1C38C6C6848A" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="I2017Q2Oct11_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember" unitRef="usdPerShare" decimals="INF" scale="0" format="ixt:numdotdecimal">3.75</ix:nonFraction></span></span><span style="font-family:inherit;font-size:10pt;">. On the date of issuance, the fair value of these warrants was determined to be </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d22936210e772-wk-Fact-BB0DFBA3203A42702A671C3986F10B13" name="immu:ClassOfWarrantOrRightFairValue" contextRef="I2017Q2Oct11_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember_us-gaap_TypeOfArrangementAxis_immu_SecuritiesPurchaseAgreementMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">7.3</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> and recognized as a liability. The warrants under certain situations require cash settlement by the Company. During fiscal 2018 there were </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d22936210e776-wk-Fact-71C729C678B9B5B0186F1C3AACDC2BB0" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" contextRef="D2018Q4Jul12017toJun302018_us-gaap_FairValueByLiabilityClassAxis_us-gaap_WarrantMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember" unitRef="shares" decimals="INF" scale="0" format="ixt:numdotdecimal">9,550,000</ix:nonFraction></span></span><span style="font-family:inherit;font-size:10pt;"> warrants exercised. The fair value of the </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d22936210e780-wk-Fact-71C729C678B9B5B0186F1C3AACDC2BB0" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" contextRef="D2018Q4Jul12017toJun302018_us-gaap_FairValueByLiabilityClassAxis_us-gaap_WarrantMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember" unitRef="shares" decimals="INF" scale="0" format="ixt:numdotdecimal">9,550,000</ix:nonFraction></span></span><span style="font-family:inherit;font-size:10pt;"> exercised warrants increased </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d22936210e784-wk-Fact-48FAF65673FE27C9223D1C3E2255FA5D" name="immu:IncreaseDecreaseinFairValueOfWarrantsExercised" contextRef="D2018Q4Jul12017toJun302018_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">102.1</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> from June 30, 2017 to the dates of exercise which has been recognized in the accompanying consolidated statements of comprehensive loss. As of the fiscal year ended June 30, 2018, there were </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d22936210e788-wk-Fact-BC0CF1AAB91BF08ED5DB1C3FE5AE5B49" name="us-gaap:ClassOfWarrantOrRightOutstanding" contextRef="FI2019Q4_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember" unitRef="shares" decimals="INF" scale="0" format="ixt:numdotdecimal">450,000</ix:nonFraction></span></span><span style="font-family:inherit;font-size:10pt;"> warrants outstanding. During the transition period ended December 31, 2018, the remaining </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d22936210e793-wk-Fact-FD1B1D493B2E3CBB1F6B1C4093227871" name="immu:ExerciseOfWarrants" contextRef="FI2018Q4_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember" unitRef="shares" decimals="INF" scale="0" format="ixt:numdotdecimal">450,000</ix:nonFraction></span></span><span style="font-family:inherit;font-size:10pt;"> warrants were exercised for which we received </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d22936210e797-wk-Fact-6294C5B9DAFED9FD2C671C414095C466" name="us-gaap:ProceedsFromWarrantExercises" contextRef="D2018Q4Jul01-Dec31_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1.7</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> in cash. As of December 31, 2019, and 2018, there were </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d22936210e801-wk-Fact-6C29CCF4EDF14F2E9EE51C3D2F53A9BC" name="us-gaap:ClassOfWarrantOrRightOutstanding" contextRef="FI2018Q4_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember" unitRef="shares" decimals="INF" scale="0" format="ixt-sec:numwordsen">no</ix:nonFraction></span></span><span style="font-family:inherit;font-size:10pt;"> warrants outstanding.</span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">On February 10, 2017, in connection with the execution of a License Agreement, the Company entered into the Securities Purchase Agreement (“SPA”) with Seattle Genetics. Under the SPA, Seattle Genetics purchased </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d22936210e811-wk-Fact-D09722DCB6489A19C5B1D1D0182A20D6" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="D2017Q3Feb10-Feb10_srt_CounterpartyNameAxis_immu_SeattleGeneticsIncMember_us-gaap_TypeOfArrangementAxis_immu_SecuritiesPurchaseAgreementMember" unitRef="shares" decimals="INF" scale="0" format="ixt:numdotdecimal">3,000,000</ix:nonFraction></span></span><span style="font-family:inherit;font-size:10pt;"> shares (the “Common Shares”) of the Company’s common stock at a price of </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d22936210e815-wk-Fact-C2447F89BD1441EAAFE6D1D0183C4649" name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="I2017Q3Feb10_srt_CounterpartyNameAxis_immu_SeattleGeneticsIncMember_us-gaap_TypeOfArrangementAxis_immu_SecuritiesPurchaseAgreementMember" unitRef="usdPerShare" decimals="INF" scale="0" format="ixt:numdotdecimal">4.90</ix:nonFraction></span></span><span style="font-family:inherit;font-size:10pt;"> per share, for aggregate proceeds of </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d22936210e819-wk-Fact-31C37614CD20FF803343D1D0181B583D" name="immu:GrossProceedsFromIssuanceOfCommonStock" contextRef="D2017Q3Feb10-Feb10_srt_CounterpartyNameAxis_immu_SeattleGeneticsIncMember_us-gaap_TypeOfArrangementAxis_immu_SecuritiesPurchaseAgreementMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">14.7</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;">. Concurrently with the sale of the Common Shares, pursuant to the SPA, the Company also agreed to issue the </span><span style="font-family:inherit;font-size:10pt;">three</span><span style="font-family:inherit;font-size:10pt;">-year warrant to purchase an aggregate of </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d22936210e827-wk-Fact-8248ECF955F00E66FD42D1D0182A0294" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="I2017Q3Feb10_srt_CounterpartyNameAxis_immu_SeattleGeneticsIncMember_us-gaap_TypeOfArrangementAxis_immu_SecuritiesPurchaseAgreementMember" unitRef="shares" decimals="INF" scale="0" format="ixt:numdotdecimal">8,655,804</ix:nonFraction></span></span><span style="font-family:inherit;font-size:10pt;"> shares of common stock. On July 31, 2017, the Company filed a registration statement on Form S-3 to register the </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d22936210e832-wk-Fact-35FA47A74C8D683722D0D1D0183CCB8C" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="D2018Q1July31_srt_CounterpartyNameAxis_immu_SeattleGeneticsIncMember_us-gaap_TypeOfArrangementAxis_immu_SecuritiesPurchaseAgreementMember" unitRef="shares" decimals="INF" scale="0" format="ixt:numdotdecimal">3,000,000</ix:nonFraction></span></span><span style="font-family:inherit;font-size:10pt;"> shares of Company’s common stock and </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d22936210e836-wk-Fact-9F200665D6C5B3101B3FD1D0181BCB31" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="I2017Q1Jul31_srt_CounterpartyNameAxis_immu_SeattleGeneticsIncMember_us-gaap_TypeOfArrangementAxis_immu_SecuritiesPurchaseAgreementMember" unitRef="shares" decimals="INF" scale="0" format="ixt:numdotdecimal">8,655,804</ix:nonFraction></span></span><span style="font-family:inherit;font-size:10pt;"> shares of common stock issuable upon the exercise of the warrants (in addition to the shares issuable upon the conversion of our Series A-1 Convertible Preferred Stock, as discussed above). The warrant became exercisable for cash on February 16, 2017 and expired on January 31, 2018. The warrant was issued on </span><span style="font-family:inherit;font-size:10pt;">February 16, 2017</span><span style="font-family:inherit;font-size:10pt;"> and was originally exercisable until February 10, 2020. On the date of issuance, the fair value of these warrants was determined to be </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d22936210e844-wk-Fact-5B7F9F0209E6FE8F65C7D1D0183CED41" name="immu:ClassOfWarrantOrRightFairValue" contextRef="I2017Q3Feb16_srt_CounterpartyNameAxis_immu_SeattleGeneticsIncMember_us-gaap_TypeOfArrangementAxis_immu_SecuritiesPurchaseAgreementMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">22.3</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;">. The difference between such fair value and the proceeds of </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d22936210e848-wk-Fact-31C37614CD20FF803343D1D0181B583D" name="immu:GrossProceedsFromIssuanceOfCommonStock" contextRef="D2017Q3Feb10-Feb10_srt_CounterpartyNameAxis_immu_SeattleGeneticsIncMember_us-gaap_TypeOfArrangementAxis_immu_SecuritiesPurchaseAgreementMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">14.7</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> has been recognized as an expense and presented in the consolidated statements of comprehensive loss as a “warrant related expense.” On May 4, 2017, the Company and Seattle Genetics entered into the Termination Agreement, pursuant to which the Company and Seattle Genetics relinquished their respective rights under the License Agreement and agreed to amend the terms of the warrant to amend the expiration date from February 10, 2020 to December 31, 2017. On December 5, 2017, Seattle Genetics exercised the Warrants they held in full to acquire </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d22936210e852-wk-Fact-C7A8F2F5842644731C2ED1D0182A3DF8" name="immu:ExerciseOfWarrants" contextRef="I2018Q2Dec05_srt_CounterpartyNameAxis_immu_SeattleGeneticsIncMember" unitRef="shares" decimals="INF" scale="0" format="ixt:numdotdecimal">8,655,804</ix:nonFraction></span></span><span style="font-family:inherit;font-size:10pt;"> shares of Common Stock for an aggregate purchase price of </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d22936210e857-wk-Fact-F91045A93D51470194D0D1D0183C676C" name="immu:AggregateOfferingPriceofCommonStock" contextRef="D2018Q2Dec05_srt_CounterpartyNameAxis_immu_SeattleGeneticsIncMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">42.4</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;">.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> On June 15, 2018, we announced the closing of our public offering of </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d22936210e866-wk-Fact-526BBCE691B0F5FC0B7E632D394F82B6" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" contextRef="D2018Q2_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember" unitRef="shares" decimals="INF" scale="0" format="ixt:numdotdecimal">11,500,000</ix:nonFraction></span></span><span style="font-family:inherit;font-size:10pt;"> shares of our common stock at a price of </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d22936210e870-wk-Fact-75EBD9EBF74083B6D4DE6331F7CCED7B" name="us-gaap:SaleOfStockPricePerShare" contextRef="I2018Q4_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember" unitRef="usdPerShare" decimals="2" scale="0" format="ixt:numdotdecimal">24.00</ix:nonFraction></span></span><span style="font-family:inherit;font-size:10pt;"> per share. Pursuant to the underwriter's full exercise of the over-allotment option granted by us, on June 22, 2018, we closed on the sale of an additional </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d22936210e874-wk-Fact-C430E3B0005EE2E3DB996332B571977D" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" contextRef="D2018Q2_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_OverAllotmentOptionMember" unitRef="shares" decimals="INF" scale="0" format="ixt:numdotdecimal">1,725,000</ix:nonFraction></span></span><span style="font-family:inherit;font-size:10pt;"> shares of our common stock for a total of </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d22936210e878-wk-Fact-2CB91452EB166DE309A36335A046503C" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" contextRef="D2018Q2" unitRef="shares" decimals="INF" scale="0" format="ixt:numdotdecimal">13,225,000</ix:nonFraction></span></span><span style="font-family:inherit;font-size:10pt;"> shares. The total net proceeds from the offering, including the exercise of the over-allotment option, were </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d22936210e882-wk-Fact-9B7E3396E508CA8846AE633684A222EB" name="us-gaap:ProceedsFromIssuanceInitialPublicOffering" contextRef="D2018Q2_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_OverAllotmentOptionMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">299.5</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;">, after deducting </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d22936210e887-wk-Fact-CFAF04308AE403EBEB9963388D95A308" name="us-gaap:PaymentsOfStockIssuanceCosts" contextRef="D2018Q4Jul12017toJun302018" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">17.4</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> in underwriting discounts and commissions and other offering expenses payable by the Company. </span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">On December 9, 2019, we closed an underwritten public offering of </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d22936210e897-wk-Fact-F0332BC9A453C680D712633BD392A20F" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" contextRef="D2019Q4Dec09-Dec09_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember" unitRef="shares" decimals="INF" scale="0" format="ixt:numdotdecimal">14,285,715</ix:nonFraction></span></span><span style="font-family:inherit;font-size:10pt;"> shares of its common stock at a public offering price of </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d22936210e901-wk-Fact-78CC9314544187EAD739633C04E463EF" name="us-gaap:SaleOfStockPricePerShare" contextRef="I2019Q4Dec09_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember" unitRef="usdPerShare" decimals="2" scale="0" format="ixt:numdotdecimal">17.50</ix:nonFraction></span></span><span style="font-family:inherit;font-size:10pt;"> per share, representing gross proceeds of approximately $</span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d22936210e905-wk-Fact-2F64A1BBD05B09E26941633C61B6475A" name="us-gaap:ProceedsFromIssuanceInitialPublicOffering" contextRef="D2019Q4Dec09-Dec09_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">250.0</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;">. In addition, the Company granted the underwriters a 30-day option to purchase up to </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d22936210e909-wk-Fact-D9616CD1096D4B6F63C3633D712C223C" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" contextRef="D2019Q4Dec09-Dec09_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_OverAllotmentOptionMember" unitRef="shares" decimals="INF" scale="0" format="ixt:numdotdecimal">2,142,857</ix:nonFraction></span></span><span style="font-family:inherit;font-size:10pt;"> additional shares of common stock for a total of </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d22936210e913-wk-Fact-14F6BA2D2E3D11BC1C08633F0553D571" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" contextRef="D2019Q4Dec09-Dec09" unitRef="shares" decimals="INF" scale="0" format="ixt:numdotdecimal">16,428,572</ix:nonFraction></span></span><span style="font-family:inherit;font-size:10pt;"> shares. We received gross proceeds of </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d22936210e918-wk-Fact-17D9A88D432D6B3FC3AE633F72974931" name="immu:ProceedsfromIssuanceInitialPublicOfferingGross" contextRef="D2019Q4Dec09-Dec09_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_OverAllotmentOptionMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">287.5</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> and net proceeds of </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d22936210e922-wk-Fact-7DF55AC6B2B9208F6BC4633F7E6C8B2A" name="us-gaap:ProceedsFromIssuanceInitialPublicOffering" contextRef="D2019Q4Dec09-Dec09_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_OverAllotmentOptionMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">273.0</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> after deducting the underwriting discounts and commissions and expenses related to the offering. </span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">At-the-Market Offering</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">On March 29, 2019, the Company entered into a sales agreement (the "ATM Agreement") with Cowen and Company, LLC ("Cowen") to issue and sell shares of the Company’s common stock, par value </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d22936210e938-wk-Fact-9D72EF0102F6A7256F5EDB6043510D47" name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="I2019Q1Mar29_us-gaap_SubsidiarySaleOfStockAxis_immu_ATMAgreementMember" unitRef="usdPerShare" decimals="INF" scale="0" format="ixt:numdotdecimal">0.01</ix:nonFraction></span></span><span style="font-family:inherit;font-size:10pt;"> per share, having an aggregate offering price of up to </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d22936210e942-wk-Fact-491A6C9788EE24741465DB617C797421" name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" contextRef="D2019Q1Mar29-29_us-gaap_SubsidiarySaleOfStockAxis_immu_ATMAgreementMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">150.0</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;">, from time to time during the term of the ATM Agreement, through an “at-the-market” equity offering program at the Company's sole discretion, under which Cowen will act as the Company’s agent and/or principal. The Company will pay Cowen a commission up to </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d22936210e946-wk-Fact-CD98C2DC559F7F2ACCB8DB6302D2BCA1" name="immu:PaymentsforStockIssuanceCostsPercentage" contextRef="D2019Q1Mar29-29_us-gaap_SubsidiarySaleOfStockAxis_immu_ATMAgreementMember" unitRef="number" decimals="3" scale="-2" format="ixt:numdotdecimal">3.0</ix:nonFraction>%</span></span><span style="font-family:inherit;font-size:10pt;"> of the gross sales proceeds of any common stock sold through Cowen under the ATM Agreement. During the year ended </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;">, the Company sold </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d22936210e954-wk-Fact-680C9932260B481522AFDC3A49BA9900" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" contextRef="FD2019Q4YTD_us-gaap_SubsidiarySaleOfStockAxis_immu_ATMAgreementMember" unitRef="shares" decimals="INF" scale="0" format="ixt:numdotdecimal">4,432,416</ix:nonFraction></span></span><span style="font-family:inherit;font-size:10pt;"> shares of common stock with net proceeds of </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d22936210e959-wk-Fact-DAD842A588E0177AEDC1DC3722428B78" name="us-gaap:SaleOfStockConsiderationReceivedPerTransaction" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">71.6</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> at a weighted average price of </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d22936210e963-wk-Fact-DF9268E83D9D48D0A3B6DC37B5E23418" name="us-gaap:SharesIssuedPricePerShare" contextRef="FI2019Q4_srt_RangeAxis_srt_WeightedAverageMember" unitRef="usdPerShare" decimals="2" scale="0" format="ixt:numdotdecimal">16.40</ix:nonFraction></span></span><span style="font-family:inherit;font-size:10pt;"> (excluding commissions) under the ATM Agreement. </span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></ix:continuation><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">77</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;text-align:justify;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;" href="#sfb86787ac8304dffbb4bfe7ffcfa7b54"><span style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">Table of Contents</span></a></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></div><div><br/></div><ix:continuation id="TextSelection-2EB876058512C5BA3848D1D01875A12F-3"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Treasury Stock</span></div><div style="line-height:120%;text-align:justify;text-indent:84px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"></span><span style="font-family:inherit;font-size:10pt;">During the year ended </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;">, there were </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d22936210e1003-wk-Fact-F49DBC1184173886B47DDC3B7BBF285E" name="us-gaap:TreasuryStockSharesAcquired" contextRef="FD2019Q4YTD_us-gaap_SubsidiarySaleOfStockAxis_immu_SalesAgreementMember" unitRef="shares" decimals="INF" scale="0" format="ixt:numdotdecimal">84,896</ix:nonFraction></span></span><span style="font-family:inherit;font-size:10pt;"> shares received in connection with a non-cash equity transaction related to the Company's Plan. During the Transition Period, there were </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d22936210e1007-wk-Fact-E628101C54303A2B0372D1D0183C7A71" name="us-gaap:StockRepurchasedAndRetiredDuringPeriodShares" contextRef="D2018Q4Jul01-Dec31" unitRef="shares" decimals="INF" scale="0" format="ixt:numdotdecimal">105,959</ix:nonFraction></span></span><span style="font-family:inherit;font-size:10pt;"> treasury shares received in connection with a non-cash equity transaction related to the Company's Plan and the shares were subsequently retired.</span></div></ix:continuation><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div><a id="s644A0D82DB3859F8BC60102DCB65E4E8"></a></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">10.         <ix:nonNumeric contextRef="FD2019Q4YTD" name="us-gaap:ComprehensiveIncomeNoteTextBlock" id="TextSelection-EE2C37E3B955FED1DA8AD1D018755E2A-0-wk-Fact-190F697323E06EA4E3C2D1D0182A9267" continuedAt="TextSelection-EE2C37E3B955FED1DA8AD1D018755E2A-1" escape="true">Accumulated Other Comprehensive (Loss) Income</ix:nonNumeric></span></div><ix:continuation id="TextSelection-EE2C37E3B955FED1DA8AD1D018755E2A-1"><ix:nonNumeric contextRef="FD2019Q4YTD" name="us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" id="TextSelection-5439C4042288341A898ED1D01875AFF4-0-wk-Fact-2CEB1BE97FF5681C7E7FD1D0182A38BD" continuedAt="TextSelection-5439C4042288341A898ED1D01875AFF4-1" escape="true"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The components of accumulated other comprehensive (loss) income were as follows (in thousands):</span></div><div style="line-height:120%;text-align:justify;padding-left:0px;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"></td></tr><tr><td style="width:53%;"></td><td style="width:1%;"></td><td style="width:13%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:13%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:13%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Currency Translation Adjustments</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;"> Net Unrealized Gains (Losses) on Available-for-Sale Securities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Accumulated Other Comprehensive (Loss) Income</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Balance at June 30, 2016</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(<ix:nonFraction id="d22937505e748-wk-Fact-69A41CC636BAF12CFD88D1D0182AA531" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="FI2016Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedTranslationAdjustmentMember" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">172</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d22937505e768-wk-Fact-28831C631BF69B491B03D1D0182A7A36" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="FI2016Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">40</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(<ix:nonFraction id="d22937505e787-wk-Fact-758529E64C065EDFFFCCDB1A3736EEC9" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="FI2016Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">132</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Other comprehensive loss before reclassifications</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(<ix:nonFraction id="d22937505e804-wk-Fact-D302243CC71471A94C8CD1D0182AD009" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" contextRef="D2017Q4Jul012016toJun302017_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedTranslationAdjustmentMember" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">62</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(<ix:nonFraction id="d22937505e824-wk-Fact-781CE5DD6F6AB081F4ECD1D0183C5E28" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" contextRef="D2017Q4Jul012016toJun302017_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">125</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(<ix:nonFraction id="d22937505e844-wk-Fact-CA0DC944E510F40C7B1ED1D0182A26BF" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" contextRef="D2017Q4Jul012016toJun302017" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">187</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">   Amounts reclassified from accumulated other comprehensive income</span><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(a)</sup></span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d22937505e868-wk-Fact-5F85E73AD8ED8362EBB6D1D0183C0496" name="us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" contextRef="D2017Q4Jul012016toJun302017_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedTranslationAdjustmentMember" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">—</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d22937505e887-wk-Fact-72DB2B6AB9888F159BD7D1D0182A91A4" name="us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" contextRef="D2017Q4Jul012016toJun302017_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">16</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d22937505e906-wk-Fact-3A6E5577C6D497575631DC50E7357379" name="us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" contextRef="D2017Q4Jul012016toJun302017" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">16</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Net other comprehensive loss for the year</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(<ix:nonFraction id="d22937505e927-wk-Fact-98D1361342D9E233633BD1D0183C0AEF" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" contextRef="D2017Q4Jul012016toJun302017_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedTranslationAdjustmentMember" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">62</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(<ix:nonFraction id="d22937505e947-wk-Fact-E1CDF8D779B96774F5A4D1D0183C5F49" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" contextRef="D2017Q4Jul012016toJun302017_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">109</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(<ix:nonFraction id="d22937505e967-wk-Fact-E76D21D8C9058DC7E880D1D0185B55B6" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" contextRef="D2017Q4Jul012016toJun302017" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">171</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Balance at June 30, 2017</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(<ix:nonFraction id="d22937505e989-wk-Fact-84B96639888668A05906D1D0182A224E" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="FI2017Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedTranslationAdjustmentMember" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">234</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(<ix:nonFraction id="d22937505e1009-wk-Fact-02B14842F86C8AAFBC43D1D0182A0201" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="FI2017Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">69</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(<ix:nonFraction id="d22937505e1029-wk-Fact-C250495353646701D3F8DB1A38D1AAF4" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="FI2017Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">303</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Other comprehensive income (loss) before reclassifications</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(<ix:nonFraction id="d22937505e1051-wk-Fact-4F8F1DBBA38D074BDB5BD1D0182AEF2D" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" contextRef="D2018Q4Jul12017toJun302018_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedTranslationAdjustmentMember" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">105</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d22937505e1071-wk-Fact-A07F27DA01E0C1D6C06FD1D0183C32D7" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" contextRef="D2018Q4Jul12017toJun302018_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">55</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(<ix:nonFraction id="d22937505e1090-wk-Fact-031B0933C65F98045177D1D0183CD4A6" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" contextRef="D2018Q4Jul12017toJun302018" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">50</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">  Amounts reclassified from accumulated other comprehensive income</span><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(a)</sup></span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d22937505e1114-wk-Fact-0AA95B250CD40620949CD1D0183B0D37" name="us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" contextRef="D2018Q4Jul12017toJun302018_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedTranslationAdjustmentMember" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">—</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d22937505e1133-wk-Fact-402580D74DA95CA7F32CD1D0183AD4BB" name="us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" contextRef="D2018Q4Jul12017toJun302018_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">—</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d22937505e1152-wk-Fact-4030CB4D23F5D5A6D944D1D0183C994E" name="us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" contextRef="D2018Q4Jul12017toJun302018" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">—</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Net other comprehensive (loss) income for the year</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(<ix:nonFraction id="d22937505e1173-wk-Fact-9FA07D5F7DE2A37F08C9D1D0182AC64D" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" contextRef="D2018Q4Jul12017toJun302018_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedTranslationAdjustmentMember" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">105</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d22937505e1193-wk-Fact-AC42CDFFFCBE8D3F18B7D1D0183CD24C" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" contextRef="D2018Q4Jul12017toJun302018_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">55</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(<ix:nonFraction id="d22937505e1212-wk-Fact-1ECA80141594AC8AB006D1D0180BF0F8" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" contextRef="D2018Q4Jul12017toJun302018" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">50</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Balance at June 30, 2018</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(<ix:nonFraction id="d22937505e1234-wk-Fact-7923125F0FDFCEEAE872D1D0183C87B6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="FI2018Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedTranslationAdjustmentMember" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">339</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(<ix:nonFraction id="d22937505e1254-wk-Fact-F9BAF01C4A9F71EF2978D1D0183A570D" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="FI2018Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">14</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(<ix:nonFraction id="d22937505e1274-wk-Fact-7CD7C9D8D384C483DBEADB1A37C32986" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="FI2018Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">353</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Other comprehensive income (loss) before reclassifications</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(<ix:nonFraction id="d22937505e1296-wk-Fact-F008E482CD4BA8C99FD1D1D0182A0A24" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" contextRef="D2018Q4Jul01-Dec31_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedTranslationAdjustmentMember" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d22937505e1316-wk-Fact-5614A2AA8BA9855FDD05D1D0183CE7B8" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" contextRef="D2018Q4Jul01-Dec31_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">10</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d22937505e1335-wk-Fact-E50051A926B55E49D246D1D0182AE8BC" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" contextRef="D2018Q4Jul01-Dec31" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">2</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">  Amounts reclassified from accumulated other comprehensive income</span><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(a)</sup></span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d22937505e1359-wk-Fact-50A702721470BEB5666FD1D0183C5D7D" name="us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" contextRef="D2018Q4Jul01-Dec31_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedTranslationAdjustmentMember" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">—</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d22937505e1378-wk-Fact-1D7ED0605A98AA8DF692D1D0183C6DD9" name="us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" contextRef="D2018Q4Jul01-Dec31_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">—</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d22937505e1397-wk-Fact-DE696552741AB42F4BC7D1D0183CF444" name="us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" contextRef="D2018Q4Jul01-Dec31" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">—</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Net other comprehensive (loss) income for the year</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(<ix:nonFraction id="d22937505e1418-wk-Fact-CBFD424BF5F970E208A7D1D0183CA033" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" contextRef="D2018Q4Jul01-Dec31_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedTranslationAdjustmentMember" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d22937505e1438-wk-Fact-52F5407797BB167A0CF8D1D0182A335E" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" contextRef="D2018Q4Jul01-Dec31_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">10</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d22937505e1457-wk-Fact-8BE8CC99A112976EF87AD1D018643C0B" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" contextRef="D2018Q4Jul01-Dec31" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">2</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Balance at December 31, 2018</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(<ix:nonFraction id="d22937505e1478-wk-Fact-22A57ADF086EF16E789FD1D0183C9A28" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedTranslationAdjustmentMember" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">347</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(<ix:nonFraction id="d22937505e1498-wk-Fact-325F9C036E62CE07A95BD1D0182ADEFE" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">4</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(<ix:nonFraction id="d22937505e1518-wk-Fact-562F6001069369D84768DB1A32C37129" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">351</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Other comprehensive loss before reclassifications</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(<ix:nonFraction id="d22937505e1540-wk-Fact-D0A16C13B1B1CED6BD7FD1D0183CDF72" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" contextRef="FD2019Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedTranslationAdjustmentMember" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">21</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(<ix:nonFraction id="d22937505e1560-wk-Fact-7ECD19337F4F1289B85DD1D0183C974C" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" contextRef="FD2019Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">391</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(<ix:nonFraction id="d22937505e1580-wk-Fact-632D4A8DF392D0DFCDFFD1D0183BB7C2" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">412</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">  Amounts reclassified from accumulated other comprehensive income</span><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(a)</sup></span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d22937505e1604-wk-Fact-768C58521265B0FD2569D1D0183CFB6C" name="us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" contextRef="FD2019Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedTranslationAdjustmentMember" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">195</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d22937505e1623-wk-Fact-4E2134E3D62C2C6E59E6D1D0183C2357" name="us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" contextRef="FD2019Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">—</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d22937505e1642-wk-Fact-7C901C90262E301A7B1BD1D0183C2D58" name="us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">195</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Net other comprehensive (loss) income for the year</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d22937505e1663-wk-Fact-5350F471704C66E89FAFD1D0183C803C" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" contextRef="FD2019Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedTranslationAdjustmentMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">174</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(<ix:nonFraction id="d22937505e1682-wk-Fact-946B4A69FE1DF2A56A9DD1D0182A6E48" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" contextRef="FD2019Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">391</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(<ix:nonFraction id="d22937505e1702-wk-Fact-A6C1E2230EF5DC9F423AD71417BAA3B2" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">217</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Balance at December 31, 2019</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(<ix:nonFraction id="d22937505e1729-wk-Fact-81BE774949614206946ED1D0182A6731" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="FI2019Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedTranslationAdjustmentMember" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">173</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(<ix:nonFraction id="d22937505e1749-wk-Fact-9B686CE7ABC430BC78CAD1D0183CA39B" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="FI2019Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">395</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(<ix:nonFraction id="d22937505e1769-wk-Fact-E05F826E7FC2B3955FA6E01C315FCF80" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="FI2019Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">568</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td></tr></table></div></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></ix:nonNumeric><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><ix:continuation id="TextSelection-5439C4042288341A898ED1D01875AFF4-1" continuedAt="TextSelection-5439C4042288341A898ED1D01875AFF4-2"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:inherit;font-size:10pt;">(a)</span></div></ix:continuation></td><td style="vertical-align:top;"><ix:continuation id="TextSelection-5439C4042288341A898ED1D01875AFF4-2"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">For the year ended </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;">, the Transition Period ended December 31, 2018, and the fiscal years ended June 30, 2018 and 2017, </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d22937505e1790-wk-Fact-5B0D1D814A94666101CDDC50B4ACE9D4" name="us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">0.2</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;">, </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d22937505e1794-wk-Fact-C732B3BD1E4498E13474DC50B4B0C2C2" name="us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" contextRef="D2018Q4Jul01-Dec31" unitRef="usd" decimals="0" scale="0" format="ixt:numdotdecimal">0</ix:nonFraction></span></span><span style="font-family:inherit;font-size:10pt;">, </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d22937505e1798-wk-Fact-1301539E54C2C25DFF4FDC50D84A75C4" name="us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" contextRef="D2018Q4Jul12017toJun302018" unitRef="usd" decimals="0" scale="0" format="ixt:numdotdecimal">0</ix:nonFraction></span></span><span style="font-family:inherit;font-size:10pt;">, and </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d22937505e1802-wk-Fact-3A6E5577C6D497575631DC50E7357379" name="us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" contextRef="D2017Q4Jul012016toJun302017" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">16</ix:nonFraction> thousand</span></span><span style="font-family:inherit;font-size:10pt;">, respectively, were reclassified from accumulated other comprehensive (loss) income to interest and other income.</span></div></ix:continuation></td></tr></table><div style="line-height:120%;padding-left:4px;text-align:justify;padding-left:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">All components of accumulated other comprehensive (loss) income are net of tax, except currency translation adjustments, which exclude income taxes related to indefinite investments in foreign subsidiaries.</span></div></ix:continuation><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">78</span></div></div><hr style="page-break-after:always"></hr><div><a id="s1DCB79167C4D548EBCCD74AB5EC2C100"></a></div><div><div style="line-height:120%;text-align:justify;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;" href="#sfb86787ac8304dffbb4bfe7ffcfa7b54"><span style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">Table of Contents</span></a></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></div><div><br/></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">11.         <ix:nonNumeric contextRef="FD2019Q4YTD" name="us-gaap:IncomeTaxDisclosureTextBlock" id="TextSelection-ABC34BED1808A8EF29D0D1D01875AE37-0-wk-Fact-6FF43F79E98C7180F56FD1D0181BBE52" continuedAt="TextSelection-ABC34BED1808A8EF29D0D1D01875AE37-1" escape="true">Income Taxes</ix:nonNumeric></span></div><ix:continuation id="TextSelection-ABC34BED1808A8EF29D0D1D01875AE37-1" continuedAt="TextSelection-ABC34BED1808A8EF29D0D1D01875AE37-2"><ix:nonNumeric contextRef="FD2019Q4YTD" name="us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" id="TextSelection-C4A02C75CB0581101797D1D01875D8E9-0-wk-Fact-BE88A8DDD252857A5D56D1D0181BC4F3" escape="true"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Income tax expense for income taxes is as follows (in thousands):</span></div><div style="line-height:120%;text-align:justify;padding-left:0px;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"></td></tr><tr><td style="width:31%;"></td><td style="width:1%;"></td><td style="width:15%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:15%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:14%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:14%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"> </span></div></td><td colspan="3" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Year Ended </span></div><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">December 31, 2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Transition Period Ended </span></div><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">December 31, 2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Fiscal Year Ended June 30,</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">2017</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Federal</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">    </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">    </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Current</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d22940884e942-wk-Fact-496DE05C6A273194A88DDC5BC946E954" name="us-gaap:CurrentFederalTaxExpenseBenefit" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">—</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d22940884e961-wk-Fact-680DFC230A0973C6C298D1D0181B4DF7" name="us-gaap:CurrentFederalTaxExpenseBenefit" contextRef="D2018Q4Jul01-Dec31" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">—</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d22940884e980-wk-Fact-D553D24BDB982683B0E539EFBDA04BD0" name="us-gaap:CurrentFederalTaxExpenseBenefit" contextRef="D2018Q4Jul12017toJun302018" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">—</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d22940884e1000-wk-Fact-A24D1DD48055A2200B3E39EFBDCD201E" name="us-gaap:CurrentFederalTaxExpenseBenefit" contextRef="D2017Q4Jul012016toJun302017" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">—</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Deferred</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d22940884e1015-wk-Fact-12A7A2A7317AA5D94DF7DC5BC9DF2FF9" name="us-gaap:DeferredFederalIncomeTaxExpenseBenefit" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">—</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d22940884e1034-wk-Fact-94878538272480C20B0AD1D0181BFA6B" name="us-gaap:DeferredFederalIncomeTaxExpenseBenefit" contextRef="D2018Q4Jul01-Dec31" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">—</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d22940884e1053-wk-Fact-8CB19FE6D79BD0C1CB6B39EFBE110E06" name="us-gaap:DeferredFederalIncomeTaxExpenseBenefit" contextRef="D2018Q4Jul12017toJun302018" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">—</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d22940884e1073-wk-Fact-5CA24DF9FD9FA1AA92BE39EFBDB334E9" name="us-gaap:DeferredFederalIncomeTaxExpenseBenefit" contextRef="D2017Q4Jul012016toJun302017" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">—</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Total Federal</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d22940884e1093-wk-Fact-A348F2F046361480DD1BDC5BCA628A74" name="us-gaap:FederalIncomeTaxExpenseBenefitContinuingOperations" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">—</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d22940884e1112-wk-Fact-7D0CB9FB5E7F948CE5B4D1D0181B3DC8" name="us-gaap:FederalIncomeTaxExpenseBenefitContinuingOperations" contextRef="D2018Q4Jul01-Dec31" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">—</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d22940884e1131-wk-Fact-953191293EFB7CAA7D4939EFBDA6ABCD" name="us-gaap:FederalIncomeTaxExpenseBenefitContinuingOperations" contextRef="D2018Q4Jul12017toJun302018" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">—</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d22940884e1151-wk-Fact-E991132203E8DAF2B50639EFBEF1FD9D" name="us-gaap:FederalIncomeTaxExpenseBenefitContinuingOperations" contextRef="D2017Q4Jul012016toJun302017" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">—</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">State</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Current</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d22940884e1253-wk-Fact-1B7B37EF2FFE8E48C5E6DC5BCADA3089" name="us-gaap:CurrentStateAndLocalTaxExpenseBenefit" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">—</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d22940884e1272-wk-Fact-476B99CF8A3253815613D1D0181B6810" name="us-gaap:CurrentStateAndLocalTaxExpenseBenefit" contextRef="D2018Q4Jul01-Dec31" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">—</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d22940884e1291-wk-Fact-73B17112DDC07F747FCD39EFBD8C4A86" name="us-gaap:CurrentStateAndLocalTaxExpenseBenefit" contextRef="D2018Q4Jul12017toJun302018" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">2</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d22940884e1311-wk-Fact-5F586B3236590725B41839EFBDD42785" name="us-gaap:CurrentStateAndLocalTaxExpenseBenefit" contextRef="D2017Q4Jul012016toJun302017" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Deferred</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d22940884e1331-wk-Fact-2EF85CBADBF56DA35E71DC5BCB5C7593" name="us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">—</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d22940884e1350-wk-Fact-17F962D0A6CF3267B314D1D0181B4961" name="us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit" contextRef="D2018Q4Jul01-Dec31" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">—</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d22940884e1369-wk-Fact-6BE761AB9BE8D53151D039EFBDC65E80" name="us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit" contextRef="D2018Q4Jul12017toJun302018" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">—</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d22940884e1389-wk-Fact-2456FCE72139F762374439EFBDBF9C19" name="us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit" contextRef="D2017Q4Jul012016toJun302017" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">—</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Total State</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d22940884e1409-wk-Fact-7F62DD64CFBF5FBE7120DC5BCBE254AE" name="us-gaap:StateAndLocalIncomeTaxExpenseBenefitContinuingOperations" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">—</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d22940884e1428-wk-Fact-EFF005038DCA1138A738D1D0181B0F1B" name="us-gaap:StateAndLocalIncomeTaxExpenseBenefitContinuingOperations" contextRef="D2018Q4Jul01-Dec31" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">—</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d22940884e1447-wk-Fact-2E3D49884CD6306D51A039EFBD86A839" name="us-gaap:StateAndLocalIncomeTaxExpenseBenefitContinuingOperations" contextRef="D2018Q4Jul12017toJun302018" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">2</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d22940884e1467-wk-Fact-7DC99E5B1B2C863CA98039EFBE3E7D9E" name="us-gaap:StateAndLocalIncomeTaxExpenseBenefitContinuingOperations" contextRef="D2017Q4Jul012016toJun302017" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Foreign</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Current</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d22940884e1570-wk-Fact-C2B9E890A689B0EA3A40DC5BCC77D062" name="us-gaap:CurrentForeignTaxExpenseBenefit" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">—</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d22940884e1589-wk-Fact-9127F5C6BFA0D4FC4ECFD1D0181B7466" name="us-gaap:CurrentForeignTaxExpenseBenefit" contextRef="D2018Q4Jul01-Dec31" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">—</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d22940884e1608-wk-Fact-1DD4DFB6E5EDA5E2232039EFBE9A2986" name="us-gaap:CurrentForeignTaxExpenseBenefit" contextRef="D2018Q4Jul12017toJun302018" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">154</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d22940884e1628-wk-Fact-C8DE266F7A450429433439EFBD7B9E25" name="us-gaap:CurrentForeignTaxExpenseBenefit" contextRef="D2017Q4Jul012016toJun302017" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">19</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Deferred</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d22940884e1648-wk-Fact-93D086DA010648D53C7DDC5BCD010AED" name="us-gaap:DeferredForeignIncomeTaxExpenseBenefit" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">—</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d22940884e1667-wk-Fact-0F38A66122DD40173373D1D0181B0DF3" name="us-gaap:DeferredForeignIncomeTaxExpenseBenefit" contextRef="D2018Q4Jul01-Dec31" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">—</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d22940884e1686-wk-Fact-0BAA0D76D1722A6FD3C939EFBD99CEEE" name="us-gaap:DeferredForeignIncomeTaxExpenseBenefit" contextRef="D2018Q4Jul12017toJun302018" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">—</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d22940884e1706-wk-Fact-EA4D9DA67C02181AB14639EFBE69D3F7" name="us-gaap:DeferredForeignIncomeTaxExpenseBenefit" contextRef="D2017Q4Jul012016toJun302017" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">—</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Total Foreign</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d22940884e1726-wk-Fact-A6EE4D74E82019F9D9A8DC5BCD8E1FF3" name="us-gaap:ForeignIncomeTaxExpenseBenefitContinuingOperations" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">—</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d22940884e1745-wk-Fact-A09C7EF9382AFB33C30CD1D0181B6308" name="us-gaap:ForeignIncomeTaxExpenseBenefitContinuingOperations" contextRef="D2018Q4Jul01-Dec31" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">—</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d22940884e1764-wk-Fact-1F4D45C0FD54E4D047B539EFBEC57D3F" name="us-gaap:ForeignIncomeTaxExpenseBenefitContinuingOperations" contextRef="D2018Q4Jul12017toJun302018" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">154</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d22940884e1784-wk-Fact-57288D2C09D32011E81D39EFBDB83E1E" name="us-gaap:ForeignIncomeTaxExpenseBenefitContinuingOperations" contextRef="D2017Q4Jul012016toJun302017" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">19</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Total income tax expense</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d22940884e1809-wk-Fact-3CC832BF5EF3C97185F1D713DCC31FBC" name="us-gaap:IncomeTaxExpenseBenefit" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">—</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d22940884e1828-wk-Fact-32780205060E315B26CED1D0185B11B7" name="us-gaap:IncomeTaxExpenseBenefit" contextRef="D2018Q4Jul01-Dec31" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">—</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d22940884e1847-wk-Fact-5584AB2B0AA443CB47F2D1D0180B2C0B" name="us-gaap:IncomeTaxExpenseBenefit" contextRef="D2018Q4Jul12017toJun302018" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">156</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d22940884e1867-wk-Fact-B3DF2F8B547FC4AC0F35D1D0184B2343" name="us-gaap:IncomeTaxExpenseBenefit" contextRef="D2017Q4Jul012016toJun302017" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">20</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div></ix:nonNumeric><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><ix:nonNumeric contextRef="FD2019Q4YTD" name="us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" id="TextSelection-0F0E0F87219DEBEC42BAD1D01875F9EB-0-wk-Fact-A18AFB6197E4884D2C5FD1D0181BD580" escape="true"><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">A reconciliation of the statutory tax rates and the effective tax rates for the year ended </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;">, the transition period ended December 31, 2018 and fiscal years ended June 30, 2018 and 2017 is as follows:</span></div><div style="line-height:120%;text-align:justify;padding-left:0px;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"></td></tr><tr><td style="width:31%;"></td><td style="width:16%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:16%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:15%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:15%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Year Ended </span></div><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">December 31, 2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Transition Period Ended </span></div><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">December 31, 2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Fiscal Year Ended June 30,</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">2017</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Statutory rate</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(<ix:nonFraction id="d22940884e2051-wk-Fact-D7D322AFCFFC39BBFEA345687DB7D232" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" contextRef="FD2019Q4YTD" unitRef="number" decimals="INF" scale="-2" format="ixt:numdotdecimal">21.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)%</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(<ix:nonFraction id="d22940884e2066-wk-Fact-0E31CF2DE3FDAFB6F432D1D0183CC6B5" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" contextRef="D2018Q4Jul01-Dec31" unitRef="number" decimals="INF" scale="-2" format="ixt:numdotdecimal">21.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)%</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(<ix:nonFraction id="d22940884e2081-wk-Fact-72324324A7E2347FD21C39EFCAEE2940" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" contextRef="D2018Q4Jul12017toJun302018" unitRef="number" decimals="INF" scale="-2" format="ixt:numdotdecimal">28.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)%</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(<ix:nonFraction id="d22940884e2096-wk-Fact-35D6E49200267D8C563739EFCAE75C0B" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" contextRef="D2017Q4Jul012016toJun302017" unitRef="number" decimals="INF" scale="-2" format="ixt:numdotdecimal">34.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)%</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Foreign income tax</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d22940884e2113-wk-Fact-4AE5BFAA72DD01A5D66845687E5D710E" name="us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" contextRef="FD2019Q4YTD" unitRef="number" decimals="3" scale="-2" format="ixt:zerodash">—</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"> %</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d22940884e2128-wk-Fact-AA5C4B5BB7CA67B9E865D1D0183C811F" name="us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" contextRef="D2018Q4Jul01-Dec31" unitRef="number" decimals="3" scale="-2" format="ixt:zerodash">—</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"> %</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d22940884e2143-wk-Fact-28CED200EA55A90BC80739EFCAD9AADB" name="us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" contextRef="D2018Q4Jul12017toJun302018" unitRef="number" decimals="3" scale="-2" format="ixt:zerodash">—</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"> %</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d22940884e2158-wk-Fact-39543BB0611B0045F9AE39EFCAB7AA79" name="us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" contextRef="D2017Q4Jul012016toJun302017" unitRef="number" decimals="3" scale="-2" format="ixt:zerodash">—</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"> %</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Change in valuation allowance</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d22940884e2175-wk-Fact-11AF0E27BB1FFA04BBF945687F07E45C" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" contextRef="FD2019Q4YTD" unitRef="number" decimals="3" scale="-2" sign="-" format="ixt:numdotdecimal">29.9</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"> %</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d22940884e2190-wk-Fact-A649AEEEF482586FEFA6D1D0183CE9B6" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" contextRef="D2018Q4Jul01-Dec31" unitRef="number" decimals="3" scale="-2" sign="-" format="ixt:numdotdecimal">34.4</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"> %</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d22940884e2205-wk-Fact-E852850A0F8C4462E1DB39EFCAAFE716" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" contextRef="D2018Q4Jul12017toJun302018" unitRef="number" decimals="3" scale="-2" sign="-" format="ixt:numdotdecimal">21.1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"> %</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d22940884e2220-wk-Fact-535075CB892E40347F3D39EFCAC99FA9" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" contextRef="D2017Q4Jul012016toJun302017" unitRef="number" decimals="3" scale="-2" sign="-" format="ixt:numdotdecimal">21.9</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"> %</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">State income taxes, (net of federal tax benefit)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(<ix:nonFraction id="d22940884e2237-wk-Fact-A216E09EEC13EF18B63445687FA9E50F" name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" contextRef="FD2019Q4YTD" unitRef="number" decimals="3" scale="-2" format="ixt:numdotdecimal">7.5</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(<ix:nonFraction id="d22940884e2252-wk-Fact-813A34C1A998BAD5E909D1D0183C678E" name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" contextRef="D2018Q4Jul01-Dec31" unitRef="number" decimals="3" scale="-2" format="ixt:numdotdecimal">8.8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(<ix:nonFraction id="d22940884e2267-wk-Fact-152B13266C2A439AC4A639EFCAA88AFF" name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" contextRef="D2018Q4Jul12017toJun302018" unitRef="number" decimals="3" scale="-2" format="ixt:numdotdecimal">4.3</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(<ix:nonFraction id="d22940884e2282-wk-Fact-672AC44BB2DD0B1FDACE39EFCA9B01F2" name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" contextRef="D2017Q4Jul012016toJun302017" unitRef="number" decimals="3" scale="-2" format="ixt:numdotdecimal">4.8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)%</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Permanent differences, (primarily warrant-related expenses)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(<ix:nonFraction id="d22940884e2299-wk-Fact-41BFF3BF5AF582FEB02B4568804FACC4" name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpense" contextRef="FD2019Q4YTD" unitRef="number" decimals="3" scale="-2" format="ixt:numdotdecimal">1.4</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)%</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(<ix:nonFraction id="d22940884e2314-wk-Fact-A7782178ADA57966387CD1D0184AEDF4" name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpense" contextRef="D2018Q4Jul01-Dec31" unitRef="number" decimals="3" scale="-2" format="ixt:numdotdecimal">4.2</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)%</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d22940884e2329-wk-Fact-B70466D486E2E7F2742C39EFCA92B5AF" name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpense" contextRef="D2018Q4Jul12017toJun302018" unitRef="number" decimals="3" scale="-2" sign="-" format="ixt:numdotdecimal">11.3</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"> %</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d22940884e2344-wk-Fact-3F46B4110B2E25B636EF39EFCAE07C75" name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpense" contextRef="D2017Q4Jul012016toJun302017" unitRef="number" decimals="3" scale="-2" sign="-" format="ixt:numdotdecimal">15.3</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"> %</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Other</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d22940884e2361-wk-Fact-AB0B2733BB1FED4A67EC456880FDC19E" name="us-gaap:EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent" contextRef="FD2019Q4YTD" unitRef="number" decimals="3" scale="-2" format="ixt:zerodash">—</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"> %</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(<ix:nonFraction id="d22940884e2376-wk-Fact-FC48E18F45F90BA9348FD1D0184A94ED" name="us-gaap:EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent" contextRef="D2018Q4Jul01-Dec31" unitRef="number" decimals="3" scale="-2" format="ixt:numdotdecimal">0.4</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d22940884e2391-wk-Fact-03F2516EDA856A90DA1A39EFCAD12216" name="us-gaap:EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent" contextRef="D2018Q4Jul12017toJun302018" unitRef="number" decimals="3" scale="-2" format="ixt:zerodash">—</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"> %</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d22940884e2406-wk-Fact-31BBB01A05E564E6F3D139EFCABFC451" name="us-gaap:EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent" contextRef="D2017Q4Jul012016toJun302017" unitRef="number" decimals="3" scale="-2" sign="-" format="ixt:numdotdecimal">1.6</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"> %</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Effective rate</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d22940884e2423-wk-Fact-4F547C109F9E297A9E74456881A1EE74" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" contextRef="FD2019Q4YTD" unitRef="number" decimals="3" scale="-2" format="ixt:zerodash">—</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"> %</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d22940884e2438-wk-Fact-1663136871A275185B55D1D0183CB0C3" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" contextRef="D2018Q4Jul01-Dec31" unitRef="number" decimals="3" scale="-2" format="ixt:zerodash">—</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"> %</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d22940884e2453-wk-Fact-D9004BEFEA7D67752D8939EFCAF635D0" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" contextRef="D2018Q4Jul12017toJun302018" unitRef="number" decimals="3" scale="-2" sign="-" format="ixt:numdotdecimal">0.1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"> %</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d22940884e2468-wk-Fact-4568B3CA0778A88B0EE039EFCAA17AB4" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" contextRef="D2017Q4Jul012016toJun302017" unitRef="number" decimals="3" scale="-2" format="ixt:zerodash">—</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"> %</span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div></ix:nonNumeric><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><ix:nonNumeric contextRef="FD2019Q4YTD" name="us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" id="TextSelection-266838FAD6D07DF70A33D1D01875FF04-0-wk-Fact-F311DB4E217D76950B6FD1D0181BB98B" continuedAt="TextSelection-266838FAD6D07DF70A33D1D01875FF04-1" escape="true"><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The tax effects of temporary differences that give rise to significant portions of the Company’s deferred tax assets and liabilities as of December 31, (in thousands):</span></div></ix:nonNumeric><div style="line-height:120%;text-align:justify;padding-left:0px;text-indent:0px;font-size:10pt;"><ix:continuation id="TextSelection-266838FAD6D07DF70A33D1D01875FF04-1"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"></td></tr><tr><td style="width:59%;"></td><td style="width:1%;"></td><td style="width:18%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:18%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">2018</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Deferred tax assets:</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">NOL carryforwards</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d22940884e2603-wk-Fact-B7DE3E1927D42A3E58FD4568F9AFD735" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" contextRef="FI2019Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">203,928</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d22940884e2622-wk-Fact-52C8401DC9DF2BFBEA26D1D0183C3B20" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" contextRef="FI2018Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">132,841</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Research and development credits</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d22940884e2637-wk-Fact-CA373FF793B867D8A70F4568FA7292B6" name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch" contextRef="FI2019Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">28,535</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d22940884e2656-wk-Fact-AF6B376E2CD0B1DE19F9D1D0183C7FE4" name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch" contextRef="FI2018Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">23,118</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Liability related to sale of future royalties</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d22940884e2676-wk-Fact-44718362666C4937FADC4568FAF794F2" name="us-gaap:DeferredTaxAssetsDeferredIncome" contextRef="FI2019Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">49,228</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d22940884e2695-wk-Fact-8EE0AD00DED97203731FD1D0183CF4F7" name="us-gaap:DeferredTaxAssetsDeferredIncome" contextRef="FI2018Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">49,217</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Deferred revenue</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d22940884e2715-wk-Fact-D1C19118301AF2B508B1456DB0484D1F" name="immu:DeferredTaxAssetsDeferredRevenue" contextRef="FI2019Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">18,286</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d22940884e2734-wk-Fact-0015B0220F3723C43FFB456DB043D543" name="immu:DeferredTaxAssetsDeferredRevenue" contextRef="FI2018Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">—</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Disallowed interest expense </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d22940884e2754-wk-Fact-D7E72C03BB6D43B2A359456ECF021579" name="immu:DeferredTaxAssetDisallowedInterestExpense" contextRef="FI2019Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">13,474</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d22940884e2773-wk-Fact-CFF629138BE1BD57B035456ECF9C05C2" name="immu:DeferredTaxAssetDisallowedInterestExpense" contextRef="FI2018Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">—</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Other</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d22940884e2793-wk-Fact-6254DA1EE7125CE8876C4568FCA2EB6E" name="us-gaap:DeferredTaxAssetsOther" contextRef="FI2019Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">5,807</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d22940884e2812-wk-Fact-9702276AA73BECD9F363D1D0183C02BC" name="us-gaap:DeferredTaxAssetsOther" contextRef="FI2018Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">3,088</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Total</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d22940884e2832-wk-Fact-AA658F8A547E351822DD4568FD635936" name="us-gaap:DeferredTaxAssetsGross" contextRef="FI2019Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">319,258</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d22940884e2851-wk-Fact-9643F23FAC7388DA5BA4D1D0183C3B44" name="us-gaap:DeferredTaxAssetsGross" contextRef="FI2018Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">208,264</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Valuation allowance</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(<ix:nonFraction id="d22940884e2871-wk-Fact-333FB33F85D9B69D578D4568FDFC9156" name="us-gaap:DeferredTaxAssetsValuationAllowance" contextRef="FI2019Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">317,828</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(<ix:nonFraction id="d22940884e2891-wk-Fact-84412C6129C5BE7CF2DFD1D0183C639E" name="us-gaap:DeferredTaxAssetsValuationAllowance" contextRef="FI2018Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">206,397</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Net deferred assets</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d22940884e2917-wk-Fact-C5072B48C92B3F54696D4568FE9C36F9" name="us-gaap:DeferredTaxAssetsNet" contextRef="FI2019Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">1,430</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d22940884e2936-wk-Fact-4EFE15A1BA2A3CDB3CC8D1D0183CE64F" name="us-gaap:DeferredTaxAssetsNet" contextRef="FI2018Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">1,867</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Deferred tax liabilities:</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Property and equipment</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(<ix:nonFraction id="d22940884e2998-wk-Fact-7A189DDD6E29DD2C88384569002D1FBA" name="us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment" contextRef="FI2019Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">1,430</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(<ix:nonFraction id="d22940884e3018-wk-Fact-00CE299868A67ED8E495D1D0183C5B15" name="us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment" contextRef="FI2018Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">1,867</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Net deferred assets and liabilities</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d22940884e3039-wk-Fact-E2D4A48ABFD7F6545B08DC5C7C61056E" name="us-gaap:DeferredTaxAssetsLiabilitiesNet" contextRef="FI2019Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">—</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d22940884e3058-wk-Fact-D35E335751DD73ECAE35D1D0182AC844" name="us-gaap:DeferredTaxAssetsLiabilitiesNet" contextRef="FI2018Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">—</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></ix:continuation><span style="font-family:inherit;font-size:10pt;"> </span></div></ix:continuation><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">79</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;text-align:justify;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;" href="#sfb86787ac8304dffbb4bfe7ffcfa7b54"><span style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">Table of Contents</span></a></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></div><div><br/></div><ix:continuation id="TextSelection-ABC34BED1808A8EF29D0D1D01875AE37-2" continuedAt="TextSelection-ABC34BED1808A8EF29D0D1D01875AE37-3"><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">A valuation allowance is provided when it is more likely than not that some portion or all of the deferred tax assets will not be realized. The valuation allowances for the year ended </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;">, and the Transition Period ended December 31, 2018 have been applied to offset the deferred tax assets in recognition of the uncertainty that such tax benefits will be realized as the Company continues to incur losses. The differences between book income and tax income primarily relate to the temporary differences from depreciation and stock compensation expenses, and deferred book income that is realized for tax.</span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">At </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;">, and the Transition Period ended December 31, 2018, the Company has available net operating loss carry forwards for federal income tax reporting purposes of approximately </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d22940884e3088-wk-Fact-0609E184088CE249368845732F6D3DAF" name="us-gaap:OperatingLossCarryforwards" contextRef="FI2019Q4_us-gaap_IncomeTaxAuthorityAxis_us-gaap_DomesticCountryMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">769.1</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d22940884e3092-wk-Fact-B6BE4C0CB6E03205FC1F45732F710BF4" name="us-gaap:OperatingLossCarryforwards" contextRef="FI2018Q4_us-gaap_IncomeTaxAuthorityAxis_us-gaap_DomesticCountryMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">516.6</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> for state income tax reporting purposes of approximately </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d22940884e3096-wk-Fact-DF8E9FD6214D35145EC8457378636195" name="us-gaap:OperatingLossCarryforwards" contextRef="FI2019Q4_us-gaap_IncomeTaxAuthorityAxis_us-gaap_StateAndLocalJurisdictionMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">593.6</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d22940884e3100-wk-Fact-31EF5E98066FD913DFB5457377CFE68B" name="us-gaap:OperatingLossCarryforwards" contextRef="FI2018Q4_us-gaap_IncomeTaxAuthorityAxis_us-gaap_StateAndLocalJurisdictionMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">343.0</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;">, respectively, which expire at various dates between 2020 and 2038. For tax years 2018 onward, Federal net operating losses have an indefinite life but are limited to annual utilization by 80% taxable income. </span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company accounts for uncertain tax benefits in accordance with the provisions of section 740-10 of the Accounting for Uncertainty in Income Taxes Topic of the FASB ASC. Of the total unrecognized tax benefits at </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;"> and 2018, approximately </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d22940884e3113-wk-Fact-BF46BE1BE6FFC89CC4CEDC64648FCC43" name="us-gaap:UnrecognizedTaxBenefits" contextRef="FI2019Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">2.5</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> was recorded in both years as a reduction to deferred tax assets, which caused a corresponding reduction in the Company’s valuation allowance of </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d22940884e3117-wk-Fact-9403BADFA846939DE6A4DC651F58585D" name="us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">2.5</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> in both years. The Company does not anticipate that the amount of unrecognized tax benefits as of </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;"> will change materially within the 12-month period following </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;">. <ix:nonNumeric contextRef="FD2019Q4YTD" name="us-gaap:SummaryOfIncomeTaxContingenciesTextBlock" id="TextSelection-DEFE9C81E645254C3C5BD1D018756BAB-0-wk-Fact-67B32928107950305421D1D0181BCB80" continuedAt="TextSelection-DEFE9C81E645254C3C5BD1D018756BAB-1" escape="true">The change in unrecognized tax benefits are presented below (in thousands):</ix:nonNumeric></span></div><ix:continuation id="TextSelection-DEFE9C81E645254C3C5BD1D018756BAB-1"><div style="line-height:120%;text-align:left;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"></td></tr><tr><td style="width:66%;"></td><td style="width:1%;"></td><td style="width:14%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:15%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Year Ended </span></div><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">December 31, 2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Transition Period Ended </span></div><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">December 31, 2018</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Change in unrecognized tax benefits</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Balance at beginning of year</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d22940884e3292-wk-Fact-E394AE8D6E74415EC455D1D0183CA33E" name="us-gaap:UnrecognizedTaxBenefits" contextRef="FI2018Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">2,521</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d22940884e3311-wk-Fact-62574EC5593AAF751439D1D0183CCC85" name="us-gaap:UnrecognizedTaxBenefits" contextRef="FI2018Q2" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">—</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Gross increases related to current period tax positions</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d22940884e3326-wk-Fact-8E743BCA150769311F49DC5FBC9001BC" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">—</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d22940884e3345-wk-Fact-FA94629836D70D5151EFD1D0183CA1E3" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" contextRef="D2018Q4Jul01-Dec31" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">—</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Gross increases related to prior periods tax positions</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d22940884e3365-wk-Fact-CCE1277A0D0E431E2466DC5FBD45D52C" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">—</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d22940884e3384-wk-Fact-9BE094958C81B371E3BCD1D0182A8DCF" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" contextRef="D2018Q4Jul01-Dec31" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">2,521</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Gross decreases in tax positions</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d22940884e3404-wk-Fact-72674BC2674F6990B4A8DC5FBDD528ED" name="us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">—</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d22940884e3423-wk-Fact-7D81328AB6AE8C3328FDD1D0183C9E58" name="us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" contextRef="D2018Q4Jul01-Dec31" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">—</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Expiration of the statute of limitations</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d22940884e3443-wk-Fact-4F475E515D0AA0865A47DC5FBE4E2A9E" name="us-gaap:UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">—</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d22940884e3462-wk-Fact-89F3010C737C2624B302D1D0183C1C36" name="us-gaap:UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations" contextRef="D2018Q4Jul01-Dec31" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">—</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Balance at end of year</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d22940884e3487-wk-Fact-558791BBFEF1FA2DD1B0DC5FBF027D2E" name="us-gaap:UnrecognizedTaxBenefits" contextRef="FI2019Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">2,521</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d22940884e3506-wk-Fact-E394AE8D6E74415EC455D1D0183CA33E" name="us-gaap:UnrecognizedTaxBenefits" contextRef="FI2018Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">2,521</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div></ix:continuation><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company will recognize potential interest and penalties related to income tax positions as a component of the provision for income taxes on the Consolidated Statements of Comprehensive Loss in any future periods in which the Company must record a liability. The Company is subject to examination for United States Federal and Foreign tax purposes for 2013 and forward and for New Jersey 2015 and forward. The Company conducts business and files tax returns in New Jersey.</span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">For fiscal year 2016, the Company sold certain State of New Jersey State Net Operating Losses (“NOL”) and Research and Development (“R&D”) tax credits through the New Jersey Economic Development Authority Technology Business Tax Certificate Transfer Program. Pursuant to such sale, for the year ended June 30, 2016, the Company recorded a tax benefit of </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d22940884e3528-wk-Fact-0EE111B38411DE68FFA5D1D0181BE8F9" name="us-gaap:IncomeTaxExpenseBenefit" contextRef="FD2016Q4YTD" unitRef="usd" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">5.1</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;">, as a result of its sale of approximately </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d22940884e3532-wk-Fact-82C819B0541C2BE7F6D8D1D0181BFBF9" name="immu:OperatingLossCarryforwardResultingFromSale" contextRef="FD2016Q4YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">66.2</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;">, of New Jersey State NOL and </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d22940884e3536-wk-Fact-57A13B0AF94DB4B08DCFD1D0181BDF1C" name="immu:DeferredTaxAssetsTaxCreditCarryforwardsResearchAndDevelopment" contextRef="FD2016Q4YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1.5</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> of New Jersey R&D tax credits. There were </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d22940884e3540-wk-Fact-3930A84BAE0E81760140D1D0181BB1A9" name="immu:OperatingLossCarryforwardResultingFromSale" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-3" scale="0" format="ixt-sec:numwordsen">no</ix:nonFraction></span></span><span style="font-family:inherit;font-size:10pt;"> sales of NOL or R&D for the year ended </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;">, the Transition Period or 2018 or 2017 fiscal years.</span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Global Intangible Low-tax Income ("GILTI") provisions of the 2017 Tax Act require the Company to include in its United States income tax return foreign subsidiary earnings in excess of an allowable return on the foreign subsidiary’s tangible assets. The Company expects that it may be subject to incremental United States tax on GILTI income in the future but not for the for the year ended </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;">. The Company has elected to account for GILTI tax in the period in which it is incurred, and therefore has not provided any deferred tax impacts of GILTI in its consolidated financial statements. </span></div><div style="line-height:120%;padding-top:10px;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">As a result of U.S. tax reform legislation, distributions of profits from non-U.S. subsidiaries are not expected to cause a significant incremental U.S. tax impact in the future. However, distributions may be subject to non-U.S. withholding taxes if profits are distributed from certain jurisdictions. U.S. federal income taxes have not been provided on undistributed earnings of our international subsidiaries as it is our intention to reinvest any earnings into the respective subsidiaries. It is not practicable to estimate the amount of tax that might be payable if some or all of such earnings were to be repatriated due to the legal structure and complexity of U.S. and local tax laws. As of </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;">, and 2018, there are </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d22940884e3566-wk-Fact-643E569C3520B120778DD1D0181BC18F" name="us-gaap:UndistributedEarningsOfForeignSubsidiaries" contextRef="FI2019Q4" unitRef="usd" decimals="INF" scale="0" format="ixt-sec:numwordsen">no</ix:nonFraction></span></span><span style="font-family:inherit;font-size:10pt;"> undistributed earnings.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></ix:continuation><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><ix:continuation id="TextSelection-ABC34BED1808A8EF29D0D1D01875AE37-3" continuedAt="TextSelection-ABC34BED1808A8EF29D0D1D01875AE37-4"><span style="font-family:inherit;font-size:10pt;">As a result of the reduction in the U.S. corporate income tax rate, the Company revalued its ending net deferred tax assets as of June 30, 2018, which resulted in a provisional expense of </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d22940884e3576-wk-Fact-7062C5E8F3186725C7C1D1D0181B50B6" name="us-gaap:TaxCutsAndJobsActOf2017IncompleteAccountingProvisionalIncomeTaxExpenseBenefit" contextRef="D2018Q4Jul12017toJun302018" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">59.5</ix:nonFraction> million</span></span></ix:continuation><span style="font-family:inherit;font-size:10pt;"><ix:continuation id="TextSelection-ABC34BED1808A8EF29D0D1D01875AE37-4"> which was offset by an associated change in valuation allowance. In the second quarter of the Transition Period, the Company completed its analysis to determine the effect of the Tax Act and recorded no further adjustments.</ix:continuation> </span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">80</span></div></div><hr style="page-break-after:always"></hr><div><a id="s5EE716399DFB5E6CBB798C7DB90A8C75"></a></div><div><div style="line-height:120%;text-align:justify;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;" href="#sfb86787ac8304dffbb4bfe7ffcfa7b54"><span style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">Table of Contents</span></a></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></div><div><br/></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">12.         <ix:nonNumeric contextRef="FD2019Q4YTD" name="us-gaap:RelatedPartyTransactionsDisclosureTextBlock" id="TextSelection-001CB464BD6A0AABC002D1D01875478B-0-wk-Fact-2F092288625A09B56EACD1D0184B5D2B" continuedAt="TextSelection-001CB464BD6A0AABC002D1D01875478B-1" escape="true">Related Party Transactions</ix:nonNumeric></span></div><ix:continuation id="TextSelection-001CB464BD6A0AABC002D1D01875478B-1"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">On </span><span style="font-family:inherit;font-size:10pt;">January 8, 2018</span><span style="font-family:inherit;font-size:10pt;">, Morris Rosenberg joined the Company as Chief Technology Officer and became a full-time employee. Between </span><span style="font-family:inherit;font-size:10pt;">May 5, 2017</span><span style="font-family:inherit;font-size:10pt;">, and </span><span style="font-family:inherit;font-size:10pt;">January 7, 2018</span><span style="font-family:inherit;font-size:10pt;">, Mr. Rosenberg was engaged by the Company as an independent consultant pursuant to a consulting agreement between the Company and Mr. Rosenberg’s consulting company, M Rosenberg BioPharma Consulting LLC. The Company paid M Rosenberg BioPharma Consulting LLC </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d22940986e660-wk-Fact-2C7F19983AAF717A8CFFD1D0183C832B" name="us-gaap:ProfessionalAndContractServicesExpense" contextRef="D2018Q3May05-Jan06_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_immu_MRosenbergBioPharmaConsultingLlcMember" unitRef="usd" decimals="INF" scale="6" format="ixt:numdotdecimal">0.6</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> during this time and Morris Rosenberg was also granted stock options to purchase </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d22940986e664-wk-Fact-19B9613511E3A604322ED1D0183C657A" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" contextRef="D2018Q3May05-Jan06_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_immu_MRosenbergBioPharmaConsultingLlcMember" unitRef="shares" decimals="INF" scale="0" format="ixt:numdotdecimal">45,000</ix:nonFraction></span></span><span style="font-family:inherit;font-size:10pt;"> shares of the Company's common stock pursuant to the Immunomedics, Inc. 2014 Long-Term Incentive Plan. From </span><span style="font-family:inherit;font-size:10pt;">January 8, 2018</span><span style="font-family:inherit;font-size:10pt;">, through </span><span style="font-family:inherit;font-size:10pt;">June 30, 2018</span><span style="font-family:inherit;font-size:10pt;">, the Company paid M Rosenberg BioPharma </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d22940986e677-wk-Fact-05A7F73F7FF5BE60DDF2D1D0183A3799" name="us-gaap:ProfessionalAndContractServicesExpense" contextRef="D2018Q3Jan08-Jun30_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_immu_MRosenbergBioPharmaConsultingLlcMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">0.8</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;">, and from July 1, 2018, through the transition period ending December 31, 2018, the Company paid M Rosenberg BioPharma </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d22940986e681-wk-Fact-A528A87490C170AEF396D1D0183C17D7" name="us-gaap:ProfessionalAndContractServicesExpense" contextRef="D2018Q4Jul01-Dec31_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_immu_MRosenbergBioPharmaConsultingLlcMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">0.3</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> for services agreed upon prior to Mr. Rosenberg becoming a full-time employee. As part of his employment contract, </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d22940986e685-wk-Fact-0979655EBE23574F811ED1D0183C3C71" name="immu:PercentOfSharesForfeitedEmploymentCommencement" contextRef="I2018Q1Jan06" unitRef="number" decimals="2" scale="-2" format="ixt:numdotdecimal">50</ix:nonFraction>%</span></span><span style="font-family:inherit;font-size:10pt;"> of the </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d22940986e689-wk-Fact-19B9613511E3A604322ED1D0183C657A" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" contextRef="D2018Q3May05-Jan06_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_immu_MRosenbergBioPharmaConsultingLlcMember" unitRef="shares" decimals="INF" scale="0" format="ixt:numdotdecimal">45,000</ix:nonFraction></span></span><span style="font-family:inherit;font-size:10pt;"> shares granted to Mr. Rosenberg as a consultant were forfeited, the remaining </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d22940986e694-wk-Fact-246F642283E10D7F9795D1D0183C2E1D" name="immu:PercentOfSharesVestedEmploymentCommencement" contextRef="D2018Q3Jan08-Jun30" unitRef="number" decimals="2" scale="-2" format="ixt:numdotdecimal">50</ix:nonFraction>%</span></span><span style="font-family:inherit;font-size:10pt;"> continue to vest. Mr. Rosenberg received </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d22940986e698-wk-Fact-EBC813B97CC3F763A7B0D1D0183A4D15" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" contextRef="D2018Q3Jan08-Jun30_srt_TitleOfIndividualAxis_immu_ChiefTechnologyOfficerMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" unitRef="shares" decimals="INF" scale="0" format="ixt:numdotdecimal">104,389</ix:nonFraction></span></span><span style="font-family:inherit;font-size:10pt;"> stock options and was permitted to continue to provide certain limited outside consulting services through M Rosenberg BioPharma Consulting LLC based on certain restrictions outlined in the contract. Additionally, during his employment period, except with the prior written consent of the Board of Directors, Mr. Rosenberg is not permitted to enter into any contract, agreement or other transaction arrangement to provide goods and/or services to the Company through M Rosenberg BioPharma Consulting LLC.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">On March 5, 2019, the Company appointed Scott Canute, a member of the Company’s Board, as the Company’s Executive Director. Upon recommendation of the Compensation Committee, the Board approved that Mr. Canute will be paid </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d22940986e720-wk-Fact-7399AA42D2BC0B56F3BFDC7480D6FE16" name="immu:SalaryandWageOfficerMonthlySalary" contextRef="D2019Q1Mar5-Mar5_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_srt_DirectorMember" unitRef="usd" decimals="0" scale="0" format="ixt:numdotdecimal">16,667</ix:nonFraction></span></span><span style="font-family:inherit;font-size:10pt;"> per month for his service as Executive Director and was granted a nonqualified stock option to purchase </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d22940986e724-wk-Fact-D6CC6B0F4E5F48D5BA9ADC768A411AA2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" contextRef="D2019Q1Mar5-Mar5_srt_TitleOfIndividualAxis_immu_ExecutiveDirectorMember" unitRef="shares" decimals="INF" scale="0" format="ixt:numdotdecimal">79,818</ix:nonFraction></span></span><span style="font-family:inherit;font-size:10pt;"> shares of the Company’s common stock (the “Initial Canute Compensation”). The Compensation Committee determined that in order to reflect the scope of his role and the significant time that Mr. Canute will be devoting to his role as Executive Director, Mr. Canute’s cash compensation shall be increased to </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d22940986e728-wk-Fact-4430DF262B273498ABB1DC77783D029B" name="immu:SalaryandWageOfficerMonthlySalary" contextRef="FD2019Q4YTD_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_srt_DirectorMember" unitRef="usd" decimals="0" scale="0" format="ixt:numdotdecimal">21,372</ix:nonFraction></span></span><span style="font-family:inherit;font-size:10pt;"> per month, and Mr. Canute was granted an additional nonqualified stock option to purchase </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d22940986e732-wk-Fact-E732B4E1128557E764BBDC7808A2E5B0" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" contextRef="FD2019Q4YTD_srt_TitleOfIndividualAxis_immu_ExecutiveDirectorMember" unitRef="shares" decimals="INF" scale="0" format="ixt:numdotdecimal">22,854</ix:nonFraction></span></span><span style="font-family:inherit;font-size:10pt;"> shares of the Company’s common stock (the “Revised Canute Compensation”). The options have a </span><span style="font-family:inherit;font-size:10pt;">seven</span><span style="font-family:inherit;font-size:10pt;">-year term and an exercise price equal to the fair market value of the Company’s common stock based on the closing price of the Company’s common stock on each date of grant and will be subject to the terms of a nonqualified stock option agreement (the “Canute NQSO Agreement”). Such options will vest in full upon the Company’s receipt of approval from the FDA for the Company’s BLA resubmission for sacituzumab govitecan for the treatment of patients with mTNBC who have received at least two prior therapies for metastatic disease under the PDUFA. The Company and Mr. Canute entered into a letter agreement (the “Canute Letter Agreement”) to memorialize his appointment as the Company’s Executive Director, and the Initial Canute Compensation. The Canute Letter Agreement may be terminated by either party at any time upon written notice to the other party. During the year ended </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;">, the Company paid Mr. Canute </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d22940986e745-wk-Fact-EFEE0356ABFC457D6D82DC79D67A6488" name="us-gaap:SalariesWagesAndOfficersCompensation" contextRef="FD2019Q4YTD_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_srt_DirectorMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">0.4</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> for such services. </span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">On November 19, 2019, pursuant to the Plan, the Board of Directors approved a stock option grant to Behzad Aghazadeh, Executive Chairman of the Board of Directors of the Company, to purchase </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d22940986e755-wk-Fact-6266D00C7C0C6284FC0745518407094C" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" contextRef="D2019Q4Nov19-Nov19_srt_TitleOfIndividualAxis_srt_BoardOfDirectorsChairmanMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" unitRef="shares" decimals="-3" scale="0" format="ixt:numdotdecimal">150,000</ix:nonFraction></span></span><span style="font-family:inherit;font-size:10pt;"> shares of the Company's common stock (the "Performance-Based Option") for certain duties performing this role; including providing consulting and advisory services to the Company. The Performance-Based Option will be a nonqualified stock option and one third vested upon FDA acceptance of the BLA resubmission in December 2019, and two thirds shall vest upon approval from the FDA for the Company’s BLA for sacituzumab govitecan.</span></div></ix:continuation><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div><a id="s5A5E65B2CDFF50E2A94B2CE64DB9D128"></a></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">13.         <ix:nonNumeric contextRef="FD2019Q4YTD" name="immu:LicenseAndCollaborationAgreementsTextBlock" id="TextSelection-61D4E645DA71893A6C43D1D018753009-0-wk-Fact-10DA48AC884A565258DFD1D0183CF8C8" continuedAt="TextSelection-61D4E645DA71893A6C43D1D018753009-1" escape="true">Collaboration Agreements</ix:nonNumeric></span></div><ix:continuation id="TextSelection-61D4E645DA71893A6C43D1D018753009-1" continuedAt="TextSelection-61D4E645DA71893A6C43D1D018753009-2"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">AstraZeneca/MedImmune </span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span>In June 2018, we entered into a clinical collaboration with AstraZeneca PLC ("AstraZeneca") and its global biologics research and development arm, MedImmune, to evaluate in Phase 1/2 studies the safety and efficacy of combining AstraZeneca’s Imfinzi</span><span><sup style="vertical-align:top;line-height:120%;font-size:7pt">®</sup></span><span> (durvalumab), a human monoclonal antibody directed against programmed cell death ligand 1 ("PD-L1"), with sacituzumab govitecan as a treatment of patients with triple-negative breast cancer (“TNBC”) and urothelial cancer ("UC"), which was broadened in October 2018 to include second-line metastatic non-small cell lung cancer ("NSCLC"). </span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Part one of the two-part Phase 1/2 studies will be co-funded by the two companies. Immunomedics will supply the study drug and AstraZeneca will utilize its existing clinical trial infrastructure to accelerate the enrollment of the sacituzumab govitecan and durvalumab combination. The trial design allows for rapid transition into randomized Phase 2 studies should the first part of these studies show promising data and the companies agree to proceed based on efficacy and safety results obtained. </span><span style="font-family:inherit;font-size:10pt;"> </span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></ix:continuation><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">81</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;text-align:justify;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;" href="#sfb86787ac8304dffbb4bfe7ffcfa7b54"><span style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">Table of Contents</span></a></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></div><div><br/></div><ix:continuation id="TextSelection-61D4E645DA71893A6C43D1D018753009-2"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">GBG Forschungs GmbH</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In September 2019, we entered into a clinical collaboration with the German Breast Group Forschungs-GmbH ("GBG"), Neu-Isenburg, Germany, to develop sacituzumab govitecan as a treatment for newly-diagnosed breast cancer patients who do not achieve a pathological complete response ("pCR") following standard neoadjuvant therapy.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The multinational, post-neoadjuvant Phase 3 SASCIA study developed by GBG will be conducted under the sponsorship of GBG. Approximately </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d22941100e682-wk-Fact-0CAEF6808B49899B2230DC997488DF15" name="immu:NumberofPatients" contextRef="FD2019Q4YTD_immu_CollaborationAgreementAxis_immu_CBGForschungsGmbHMember" unitRef="patient" decimals="INF" scale="0" format="ixt:numdotdecimal">1,200</ix:nonFraction></span></span><span style="font-family:inherit;font-size:10pt;"> high-risk patients with newly-diagnosed HER2-negative breast cancer not achieving a pCR following standard neoadjuvant therapy will be randomized to receive either sacituzumab govitecan or treatment of physician’s choice. Primary endpoint is invasive DFS with overall survival, patient reported outcome/quality of life, circulating tumor DNA clearance, and safety serving as secondary endpoints.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Under the terms of the agreement, GBG is eligible to receive up to </span><span style="font-family:inherit;font-size:10pt;"><span>€<ix:nonFraction id="d22941100e692-wk-Fact-B926B691882FFFE56930DC9A56183155" name="immu:AgreementPotentialMilestonePayment" contextRef="FI2019Q4" unitRef="eur" decimals="-5" scale="6" format="ixt:numdotdecimal">33.0</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> in potential clinical and regulatory milestone payments over a span of approximately </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonNumeric id="d22941100e696-wk-Fact-11A7B442CAE5587060C47D0797A6894B" name="immu:AgreementPotentialMilestonePaymentTerm" contextRef="FD2019Q4YTD" format="ixt-sec:durwordsen">six years</ix:nonNumeric></span></span><span style="font-family:inherit;font-size:10pt;">, of which </span><span style="font-family:inherit;font-size:10pt;"><span>€<ix:nonFraction id="d22941100e700-wk-Fact-777DA46735E6C3052DC5DC9ACE791B4C" name="us-gaap:IncreaseDecreaseInAccruedLiabilities" contextRef="FD2019Q4YTD" unitRef="eur" decimals="-5" scale="6" format="ixt:numdotdecimal">0.5</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> was paid during the year ended </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;">. </span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></ix:continuation><div><a id="s8E4FEF688EBF569BBE82E1AE7B521389"></a></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">14.         <ix:nonNumeric contextRef="FD2019Q4YTD" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" id="TextSelection-57DD292AF8EA62BC2189D1D01875463E-0-wk-Fact-8BB4E50D571B74535A97D1D0184A70BE" continuedAt="TextSelection-57DD292AF8EA62BC2189D1D01875463E-1" escape="true">Commitments and Contingencies</ix:nonNumeric></span></div><ix:continuation id="TextSelection-57DD292AF8EA62BC2189D1D01875463E-1" continuedAt="TextSelection-57DD292AF8EA62BC2189D1D01875463E-2"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">a. Legal Matters</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Arbitration of Disputed Matters:</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">On January 15, 2019, the Company received an Arbitrator’s Findings of Fact and Conclusions of Law and Final Award (the “Final Award”) in the arbitration matter in which Dr. David M. Goldenberg, the Company’s former Chief Scientific Officer, Chief Patent Officer and Chairman of the Company’s Board of Directors, claimed entitlement to certain equity awards and severance payments, and Dr. Goldenberg and Ms. Cynthia Sullivan, a former director of the Company and former President and Chief Executive Officer, claimed rights to certain bonus payments. The Final Award (i) denied Dr. Goldenberg’s claim that he was entitled to an award of </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d22942323e662-wk-Fact-B789D3D01F23F8BE95A3D1D0181BBA75" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" contextRef="D2019Q1Jan015_us-gaap_AwardTypeAxis_immu_RestrictedUnitsWithVestingMarketConditionsMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_immu_GoldenbergAgreementMember" unitRef="shares" decimals="INF" scale="6" format="ixt:numdotdecimal">1.5</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> restricted stock units, (ii) denied each of Dr. Goldenberg’s and Ms. Sullivan’s claims that they were entitled to certain discretionary cash bonuses relating to the Company’s 2017 fiscal year, and (iii) granted Dr. Goldenberg an award of approximately </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d22942323e666-wk-Fact-0227E2342FF89DEAF3D3D1D0181B2A6B" name="us-gaap:SeveranceCosts1" contextRef="D2019Q1Jan015_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_EmploymentContractsMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_immu_GoldenbergAgreementMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1.0</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> relating to certain claimed severance payments which was paid in March 2019. The arbitration took place pursuant to the Delaware Rapid Arbitration Act.  Although the Delaware Rapid Arbitration Act permits challenges to arbitration awards in limited circumstances, pursuant to that certain stipulation and agreement of settlement, compromise, and release dated November 2, 2017, the Company, Dr. Goldenberg and Ms. Sullivan agreed that the Final Award would be the sole and exclusive final and binding remedy between and among the parties with respect to the matters disputed in the arbitration. </span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Stockholder Complaints:</span></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Class Action Stockholder Federal Securities Cases</span></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Two purported class action cases were filed in the United States District Court for the District of New Jersey; namely, Fergus v. Immunomedics, Inc., et al., filed June 9, 2016; and Becker v. Immunomedics, Inc., et al., filed June 10, 2016. These cases arise from the same alleged facts and circumstances and seek class certification on behalf of purchasers of our common stock between April 20, 2016 and June 2, 2016 (with respect to the Fergus matter) and between April 20, 2016 and June 3, 2016 (with respect to the Becker matter). These cases concern the Company’s statements in press releases, investor conference calls, and filings with the U.S. Securities and Exchange Commission (the "SEC") beginning in April 2016 that the Company would present updated information regarding its IMMU-132 breast cancer drug at the 2016 American Society of Clinical Oncology (“ASCO”) conference in Chicago, Illinois. The complaints allege that these statements were false and misleading in light of June 2, 2016 reports that ASCO had canceled the presentation because it contained previously reported information. The complaints further allege that these statements resulted in artificially inflated prices for our common stock, and that the Company and certain of its officers are thus liable under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934, as amended (the "Exchange Act"). An order of voluntary dismissal without prejudice was entered on November 10, 2016 in the Becker matter. An order granting motion to consolidate cases, appoint lead plaintiff, and approve lead and liaison counsel was entered on February 7, 2017 in the Fergus matter. A consolidated complaint was filed on October 4, 2017. The Company filed a motion to dismiss the consolidated complaint on January 26, 2018. On March 31, 2019, the court granted the Company's motion to dismiss, without prejudice, and left plaintiffs with the ability to file an amended complaint within thirty (30) days. Counsel for the Company has consented to an extension of time for plaintiffs to file the proposed amended complaint for an additional thirty (30) days. On May 30, 2019, plaintiffs filed an amended complaint alleging many of the same allegations that were set forth in the previously filed complaints, and the Company has filed a motion to dismiss.</span><span style="font-family:inherit;font-size:10pt;"> </span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></ix:continuation><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">82</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;text-align:justify;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;" href="#sfb86787ac8304dffbb4bfe7ffcfa7b54"><span style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">Table of Contents</span></a></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></div><div><br/></div><ix:continuation id="TextSelection-57DD292AF8EA62BC2189D1D01875463E-2" continuedAt="TextSelection-57DD292AF8EA62BC2189D1D01875463E-3"><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">A third purported class action case was filed in the United States District Court for the District of New Jersey; namely, Odeh v. Immunomedics, Inc., et al., filed December 27, 2018. The complaint in this action alleges that the Company failed to disclose the results of observations made by the FDA during an inspection of the Company’s manufacturing facility in Morris Plains, New Jersey in August 2018. The complaint alleges that Immunomedics misled investors by failing to disclose the Form 483 inspection report issued by the FDA which set forth the observations of the FDA inspector during the inspection. Such observations purportedly included, inter alia, manipulated bioburden samples, misrepresentation of an integrity test procedure in the batch record, and backdating of batch records. The complaint further alleges that the Company’s failure to disclose the Form 483 resulted in an artificially inflated price for our common stock, and that the Company and certain of its officers are thus liable under Sections 10(b) and 20(a) of the Exchange Act. </span><span style="font-family:inherit;font-size:10pt;"> </span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"></span><span style="font-family:inherit;font-size:10pt;">On February 8, 2019, a purported class action case was filed in the United States District Court for the District of New Jersey; namely, Choi v. Immunomedics, Inc., et al. The complaint asserts violations of the federal securities laws based on claims that the Company violated the federal securities laws by making alleged misstatements in various press releases and securities filings from February 8, 2018 to November 7, 2018 and by failing to disclose the substance of its interactions with the FDA in connection with the Company's submission of its BLA for sacituzumab govitecan.</span><span style="font-family:inherit;font-size:10pt;">  </span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"></span><span style="font-family:inherit;font-size:10pt;">Motions for the appointment of a lead plaintiff and lead counsel and to consolidate the Odeh and Choi actions were granted on September 10, 2019. Pursuant to a scheduling order entered by the court on October 7, 2019, the plaintiffs filed an amended complaint on November 18, 2019. The Company filed a motion to dismiss the consolidated, amended complaint on January 17, 2020. The motion has a return date of April 20, 2020. </span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"></span><span style="font-family:inherit;font-size:10pt;">On April 8, 2019, a putative stockholder of the Company filed a derivative action purportedly on behalf of the Company and against the Company’s board of directors and certain Company current and former officers, in the Superior Court of New Jersey, Law Division (Morris County); namely, Crow v. Aghazadeh, et al. The Crow complaint alleges that the individual defendants breached their fiduciary duties and committed other violations of law based on the same core allegations in the Odeh and Choi actions. The Crow complaint was served on the Company and other defendants on July 18, 2019. On August 13, 2019, the parties submitted to the court a stipulation and proposed order to stay the action until either the entry of an order denying all motions to dismiss the now-consolidated federal actions or the entry of an order dismissing the federal actions with prejudice. That stipulation is currently pending court approval.</span><span style="font-family:inherit;font-size:10pt;"> </span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Stockholder Claim in the Court of Chancery of the State of Delaware</span></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">On February 13, 2017, venBio commenced an action captioned venBio Select Advisor LLC v. Goldenberg, et al., C.A. (Del. Ch.) (the “venBio Action”), alleging that Company’s Board breached their fiduciary duties when the Board (i) amended the Company’s Amended and Restated By-laws (the “By-Laws”) to call for a plurality voting regime for the election of directors instead of majority voting, and providing for mandatory advancement of attorneys’ fees and costs for the Company’s directors and officers, (ii) rescheduled the Company’s 2016 Annual Meeting of Stockholders (the “2016 Annual Meeting”) from December 14, 2016 to February 16, 2017, and then again to March 3, 2017, and (iii) agreed to the proposed Licensing Transaction with Seattle Genetics. venBio also named Seattle Genetics as a defendant and sought an injunction preventing the Company from closing the licensing transaction with Seattle Genetics. On March 6, 2017, venBio amended its complaint, adding further allegations. The Court of Chancery entered a temporary restraining order on March 9, 2017, enjoining the closing of the Licensing Transaction. venBio amended its complaint a second time on April 19, 2017, this time adding Greenhill & Co. Inc. and Greenhill & Co. LLC (together “Greenhill”), the Company’s financial advisor on the Licensing Transaction, as an additional defendant. On May 3, 2017, venBio and the Company and individual defendants Dr. Goldenberg, Ms. Sullivan and Mr. Brian A. Markison, a director of the Company (collectively, the “Individual Defendants”) entered into the Initial Term Sheet. On June 8, 2017, venBio the Company and Greenhill entered into the Greenhill Term Sheet. On February 9, 2018, the Court of Chancery approved the Settlement, and entered an order and partial judgment releasing all claims that were asserted by venBio against the Individual Defendants and Greenhill in the venBio Action and awarding venBio fees and expenses. On May 24, 2018 the remaining parties to the venBio Action participated in a mediation of the claims against Geoff Cox, Robert Forrester, Bob Oliver, and Jason Aryeh (the "Remaining Defendants"). The mediation was unsuccessful. The Remaining Defendants filed submitted motions to dismiss the claims against them in the venBio Action. On March 18, 2019, venBio amended its complaint, adding further allegations. The Remaining Defendants filed a motion to dismiss the claims against them on May 1, 2019. The Court of Chancery held oral arguments for the motion to dismiss on November 13, 2019 and following arguments, denied Defendants' motion to dismiss on that same date. The parties are now engaged in discovery activities.</span><span style="font-family:inherit;font-size:10pt;"> </span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Insurance Coverage Arbitration:</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"></span><span style="font-family:inherit;font-size:10pt;">The Company has initiated an arbitration with two of its management liability insurers: Starr Indemnity & Liability Company (“Starr”), and Liberty Insurance Underwriters Inc. (“Liberty”) (collectively, “Insurers”).  The arbitration arises from </span></div></ix:continuation><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">83</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;text-align:justify;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;" href="#sfb86787ac8304dffbb4bfe7ffcfa7b54"><span style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">Table of Contents</span></a></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></div><div><br/></div><ix:continuation id="TextSelection-57DD292AF8EA62BC2189D1D01875463E-3" continuedAt="TextSelection-57DD292AF8EA62BC2189D1D01875463E-4"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">the 2015 Insurers’ refusal to cover</span><span style="font-family:inherit;font-size:10pt;"> </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d22942323e750-wk-Fact-B7F107E640020176C1035F0B01902FE9" name="us-gaap:LossContingencyDamagesSoughtValue" contextRef="FD2019Q4YTD_srt_LitigationCaseAxis_immu_InsuranceCoverageArbitrationMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">3.4</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> </span><span style="font-family:inherit;font-size:10pt;">in attorneys’ fees and expenses paid to venBio pursuant to a December 1, 2017, settlement agreement between venBio, the Company, Dr. Goldenberg, Ms. Sullivan, Mr. Markison, and Greenhill to partially settle the venBio Action and fully settle the Federal Action and the Delaware Section 225 Action (the “venBio Fee Award”).  </span><span style="font-family:inherit;font-size:10pt;"> </span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"></span><span style="font-family:inherit;font-size:10pt;">The Insurers argue that the venBio Fee Award does not satisfy their policies’ definitions of covered “loss” because the policies only cover defense costs incurred by the Company.  The Company counters that the venBio Fee Award is a covered settlement, not a claim for defense costs.  Insurers also argue that they have no obligation to pay any defense costs or settlement incurred in the Federal Action or 225 Action because Immunomedics initiated those lawsuits.  The Company’s position is that the Federal Action and 225 Action were defensive in nature and therefore covered because they were initiated to further the defense of the venBio Action.  Additionally, Insurers argue the venBio Fee Award is not covered because the Company was required to obtain Insurers’ consent to enter into a binding term sheet in the venBio Action and to agree to pay the venBio Fee Award and that the Company failed to do so.  The Company takes the position that Insurers at all times were aware of the developments in the venBio Action, that they sought consent to enter into the settlement, and that Insurers cannot show they were prejudiced by an any alleged failure to obtain Insurers’ consent. </span><span style="font-family:inherit;font-size:10pt;"> </span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"></span><span style="font-family:inherit;font-size:10pt;">Liberty also contends that the Company’s insurance claim is not covered by Liberty’s 2015-16 insurance policy and should be covered by another company’s policy in a later policy period. The Company takes the position that the policies treat the venBio Action as a related claim to the Fergus v. Immunomedics class action stockholder federal securities case, which was filed in 2016 and that because of the similar allegation in the venBio Action and Fergus, the policies deem the venBio Action claim to be made at the same time as Fergus and covered by the 2015-16 policies. In the arbitration, Starr contends it will have the benefit of any finding that the claim is covered in a later policy period, even though Starr had agreed with the Company’s position prior to the arbitration.</span><span style="font-family:inherit;font-size:10pt;"> </span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"></span><span style="font-family:inherit;font-size:10pt;">In the event Insurers prevail on their argument that the venBio Fee Award is covered by a subsequent policy year, the Company will pursue coverage under its other insurance policies.</span><span style="font-family:inherit;font-size:10pt;"> </span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"></span><span>Starr is presently advancing the costs to defend the remaining claims in the venBio Action, </span><span style="font-style:italic;">i.e., </span><span>those against the Company as Nominal Defendant and individual defendants Aryeh, Cox, Forrester, and Oliver.  However, all Insurers have reserved their rights to contest coverage for any potential settlement of those claims.</span><span style="font-family:inherit;font-size:10pt;"> </span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">b. Other Matters</span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Immunomedics is also a party to various claims and litigation arising in the normal course of business.</span><span style="font-family:inherit;font-size:10pt;"> </span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">c. Leases</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Our operating lease assets primarily represent manufacturing and research and development facilities, warehouses, and offices. Our finance leases primarily represent computer equipment and are not significant. For the year ended </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;">, cash payments against operating lease liabilities totaled </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d22942323e829-wk-Fact-D0790C8228E78C767B2ADCBDC9A32835" name="us-gaap:OperatingLeasePayments" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1.3</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;">. The discount rate used to determine the net present value of the leases at inception was </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d22942323e833-wk-Fact-4761459E029D5F018342DCBA4CB7558F" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" contextRef="FI2019Q4" unitRef="number" decimals="2" scale="-2" format="ixt:numdotdecimal">11.0</ix:nonFraction>%</span></span><span style="font-family:inherit;font-size:10pt;">. This is the incremental borrowing rate that represents the rate of interest that the Company would expect to pay to borrow an amount equal to the lease payments under similar terms. Our leases both share a remaining lease term of </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonNumeric id="d22942323e837-wk-Fact-A354FBE4AC7287BA0021DCB9E58951D7" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" contextRef="FI2019Q4" format="ixt-sec:duryear">11.8</ix:nonNumeric> years</span></span><span style="font-family:inherit;font-size:10pt;">, some of which may include options to extend the leases further. The Company considers these options in determining the lease term used to establish the right-of-use assets and lease liabilities. </span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><ix:nonNumeric contextRef="FD2019Q4YTD" name="us-gaap:LeaseCostTableTextBlock" id="TextSelection-5062DDBAE80010FC14B6326A42FFC278-0-wk-Fact-D9C249ECD97F1A9980E3326BCCEAA7C1" continuedAt="TextSelection-5062DDBAE80010FC14B6326A42FFC278-1" escape="true"><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Supplemental consolidated balance sheet information related to leases are as follows (in thousands):</span></div><div style="line-height:120%;text-align:center;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="6"></td></tr><tr><td style="width:3%;"></td><td style="width:67%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:27%;"></td><td style="width:1%;"></td></tr><tr><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Operating leases:</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">December 31, 2019</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Operating lease right-of-use assets, net</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d22942323e916-wk-Fact-C2AAA92F5C6EBB9346DF32A1FEC74008" name="us-gaap:OperatingLeaseRightOfUseAsset" contextRef="FI2019Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">8,105</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Current portion of lease liabilities</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d22942323e977-wk-Fact-F784E40002191509ACB0D6EF61131A61" name="us-gaap:OperatingLeaseLiabilityCurrent" contextRef="FI2019Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">337</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Non-current portion of lease liabilities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d22942323e1007-wk-Fact-F2DCC6BE5BFB5F40AAF932A40E538A89" name="us-gaap:OperatingLeaseLiabilityNoncurrent" contextRef="FI2019Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">9,965</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Total operating lease liabilities</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d22942323e1037-wk-Fact-E9F4ECBB3A839BDF8A243338B3B142F0" name="us-gaap:OperatingLeaseLiability" contextRef="FI2019Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">10,302</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Weighted average remaining lease term (years)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonNumeric id="d22942323e1093-wk-Fact-A354FBE4AC7287BA0021DCB9E58951D7" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" contextRef="FI2019Q4" format="ixt-sec:duryear">11.8</ix:nonNumeric></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Weighted average discount rate</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d22942323e1123-wk-Fact-1B72E9A423A9CBBFAFA332A56B36932D" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" contextRef="FI2019Q4" unitRef="number" decimals="3" scale="-2" format="ixt:numdotdecimal">11.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">%</span></div></td></tr></table></div></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></ix:nonNumeric></ix:continuation><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">84</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;text-align:justify;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;" href="#sfb86787ac8304dffbb4bfe7ffcfa7b54"><span style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">Table of Contents</span></a></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></div><div><br/></div><ix:continuation id="TextSelection-57DD292AF8EA62BC2189D1D01875463E-4" continuedAt="TextSelection-57DD292AF8EA62BC2189D1D01875463E-5"><ix:continuation id="TextSelection-5062DDBAE80010FC14B6326A42FFC278-1"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Operating lease right-of-use asset is a component of property and equipment on the consolidated balance sheet. The non-current portion of lease liabilities is a component of other long-term liabilities on the consolidated balance sheet.</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-indent:48px;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"></span><span style="font-family:inherit;font-size:10pt;">Supplemental cash flow information related to leases are as follows (in thousands):</span></div><div style="line-height:120%;text-align:center;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="5"></td></tr><tr><td style="width:67%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:30%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Year Ended December 31, 2019</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Non-cash lease expense</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d22942323e1204-wk-Fact-D4AD94765C96E78EF0CA32AABC773A14" name="immu:NonCashLeaseExpense" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">264</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Change in operating lease liabilities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d22942323e1229-wk-Fact-E9C3C38D4429EDE2FC5032ABCB39050B" name="immu:ChangeinOperatingLeaseLiability" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">186</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div></ix:continuation><div style="line-height:120%;padding-left:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><ix:nonNumeric contextRef="FD2019Q4YTD" name="us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock" id="TextSelection-CE7223671A51297C2A75326C71DF1A7A-0-wk-Fact-EC04F2647ED27C75DF73326CCD482E89" escape="true"><div style="line-height:120%;padding-left:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Maturities of lease liabilities as of </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;"> are as follows (in thousands): </span></div><div style="line-height:120%;text-align:center;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="6"></td></tr><tr><td style="width:3%;"></td><td style="width:77%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:17%;"></td><td style="width:1%;"></td></tr><tr><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Year 1</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d22942323e1285-wk-Fact-339C83550A3AE6C47AE33336B6CB2A6F" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" contextRef="FI2019Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">1,453</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Year 2</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d22942323e1310-wk-Fact-40BA21DA47825EE5FE013336F98C02A7" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" contextRef="FI2019Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">1,465</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Year 3</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d22942323e1340-wk-Fact-5096B8102E99BF834F7E333747C39E19" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree" contextRef="FI2019Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">1,523</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Year 4</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d22942323e1370-wk-Fact-FD52D6A66A72B7201261333782CE2109" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour" contextRef="FI2019Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">1,531</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Year 5</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d22942323e1400-wk-Fact-88D4DA861CEC2CEC8F083337BFF90CA5" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive" contextRef="FI2019Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">1,567</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Thereafter</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d22942323e1430-wk-Fact-129D5CAD76C5540A006B33380402AC3A" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" contextRef="FI2019Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">11,333</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Total lease payments</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d22942323e1460-wk-Fact-44D43D1450205FAA7D5633383BC0200F" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" contextRef="FI2019Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">18,872</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Less imputed interest</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(<ix:nonFraction id="d22942323e1490-wk-Fact-AFB0EEF5889F84DF5FAA333874D9E41D" name="us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" contextRef="FI2019Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">8,570</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td></tr><tr><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Total</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d22942323e1526-wk-Fact-E9F4ECBB3A839BDF8A243338B3B142F0" name="us-gaap:OperatingLeaseLiability" contextRef="FI2019Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">10,302</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div></ix:nonNumeric><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Operating lease expense was approximately </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d22942323e1548-wk-Fact-509E58F832D43D32832ADCB0B84B6516" name="us-gaap:LeaseCost" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1.4</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;">, </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d22942323e1552-wk-Fact-4564A8156D8145F8F982328B97E5E5DC" name="us-gaap:LeaseCost" contextRef="D2018Q4Jul01-Dec31" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">0.7</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;">, </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d22942323e1556-wk-Fact-94FE5F736A5D0D53593B328B97E862CC" name="us-gaap:LeaseCost" contextRef="D2018Q4Jul12017toJun302018" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1.3</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;">, and </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d22942323e1560-wk-Fact-21C9FA50A9747D838E96328B97DFC7DC" name="us-gaap:LeaseCost" contextRef="D2017Q4Jul012016toJun302017" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">0.9</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> for the year ended </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;">, the transition period ended December 31, 2018 and fiscal years ended June 30, 2018, and 2017, respectively.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">d. Purchase Obligations</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We have several commitments</span><span style="font-family:inherit;font-size:10pt;"> primarily to purchase commercial manufacturing services including minimum purchase commitments related to product supply contracts and e-sourcing software</span><span style="font-family:inherit;font-size:10pt;"> totaling </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d22942323e1583-wk-Fact-E3F818D86B84D7838A925F0DC4063914" name="us-gaap:PurchaseObligationDueInNextTwelveMonths" contextRef="FI2019Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">90.0</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> in 2020, </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d22942323e1587-wk-Fact-F5D6E2FF9F60152ECA2B5F0EA04748A6" name="us-gaap:PurchaseObligationDueInSecondYear" contextRef="FI2019Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">59.8</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> in 2021, </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d22942323e1591-wk-Fact-E74E75BB47C21E87B63A5F0FA3428BA2" name="us-gaap:PurchaseObligationDueInThirdYear" contextRef="FI2019Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">40.8</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> in 2022, </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d22942323e1595-wk-Fact-8BFB33C76493549DFB595F0FE73A88A4" name="us-gaap:PurchaseObligationDueInFourthYear" contextRef="FI2019Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">40.8</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> in 2023, </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d22942323e1600-wk-Fact-604FA0644277F97070035F104A3641A7" name="us-gaap:PurchaseObligationDueInFifthYear" contextRef="FI2019Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">33.0</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> in 2024 and </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d22942323e1604-wk-Fact-D96298D8E888A9447D255F11D8B54416" name="us-gaap:PurchaseObligationDueAfterFifthYear" contextRef="FI2019Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">33.0</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> thereafter. </span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">e. License</span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">On April 4, 2018, we entered into a license agreement with The Scripps Research Institute ("TSRI"). Pursuant to the license agreement, TSRI granted to us an exclusive, worldwide, sub-licensable, royalty-bearing license to use certain patent rights relating to our ADC sacituzumab govitecan. The license agreement expires on a country-by-country basis on the expiration date of the last to expire licensed patent rights in such country covering a licensed product. The license agreement may be terminated by the mutual written consent of us and TSRI, and TSRI may terminate the license agreement upon the occurrence of certain events, including but not limited to if we do not make a payment due pursuant to the license agreement and fail to cure such non-payment within </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonNumeric id="d22942323e1620-wk-Fact-9967C31AEA3505E78240D1D0184B1997" name="immu:NumberofDaysLicenseCancellableAfterNonPayment" contextRef="D2018Q2Apr04-Apr04_srt_CounterpartyNameAxis_immu_TheScrippsResearchInstituteMember" format="ixt-sec:durday">30</ix:nonNumeric></span></span><span style="font-family:inherit;font-size:10pt;"> days after the date of TSRI's written notice of such non-payment. As consideration for the license granted, we made a cash payment of </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d22942323e1624-wk-Fact-1C436FAFF9C1B3F1E9CDDCB4672DE42B" name="us-gaap:PaymentForContingentConsiderationLiabilityInvestingActivities" contextRef="D2018Q2Apr04-Apr04" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">0.3</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> to TSRI. Additionally, we will pay TRSI (i) product development milestone payments that range from the </span><span style="font-family:inherit;font-size:10pt;">mid-six digit dollar figure</span><span style="font-family:inherit;font-size:10pt;"> to the </span><span style="font-family:inherit;font-size:10pt;">low-seven digit dollar figure</span><span style="font-family:inherit;font-size:10pt;"> and (ii) royalties on net sales of licensed products in the </span><span style="font-family:inherit;font-size:10pt;">low-single digit</span><span style="font-family:inherit;font-size:10pt;"> percentage figure range capped at an annual amount. We have agreed to use reasonable efforts to develop and market the licensed products. During the year ended December 31, 2019, we recognized a </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d22942323e1641-wk-Fact-742BD9488406FA57F2085F07DF0B8E01" name="immu:LicenseAgreementMilestoneExpense" contextRef="FD2019Q4YTD_srt_CounterpartyNameAxis_immu_TheScrippsResearchInstituteMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">0.5</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> milestone payment expense.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">f. Michael Pehl Separation</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></ix:continuation><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><ix:continuation id="TextSelection-57DD292AF8EA62BC2189D1D01875463E-5" continuedAt="TextSelection-57DD292AF8EA62BC2189D1D01875463E-6"><span style="font-family:inherit;font-size:10pt;">On March 13, 2019, the Company entered into a separation agreement (the “Separation Agreement”) with Michael Pehl, the Company’s former Chief Executive Officer, President and member of the Company’s Board. Mr. Pehl resigned as Chief Executive Officer, President and member of the Company’s Board effective February 23, 2019. Pursuant to the Separation Agreement, Mr. Pehl will receive cash payments of approximately </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d22942323e1656-wk-Fact-A1369DD790225E556A6C32937629F2E3" name="us-gaap:SupplementalUnemploymentBenefitsSeveranceBenefits" contextRef="I2019Q1Mar13_srt_TitleOfIndividualAxis_srt_ChiefExecutiveOfficerMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1.0</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> over an </span><span style="font-family:inherit;font-size:10pt;">eighteen-month</span><span style="font-family:inherit;font-size:10pt;"> period. During the year ended </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;">, the Company paid approximately </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d22942323e1668-wk-Fact-537A7FA0A70157361D9132943C7C5E86" name="us-gaap:SalariesWagesAndOfficersCompensation" contextRef="FD2019Q4YTD_srt_TitleOfIndividualAxis_srt_ChiefExecutiveOfficerMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">0.5</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> to Mr. Pehl, and </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d22942323e1672-wk-Fact-41082A749EEBCD98948C3294C982BB3C" name="us-gaap:SupplementalUnemploymentBenefitsSalaryContinuation" contextRef="FI2019Q4_srt_TitleOfIndividualAxis_srt_ChiefExecutiveOfficerMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">0.6</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> was accrued for as of </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span></ix:continuation><span style="font-family:inherit;font-size:10pt;"><ix:continuation id="TextSelection-57DD292AF8EA62BC2189D1D01875463E-6">. Mr. Pehl also released the Company from any and all claims with respect to all matters arising out of or related to Mr. Pehl’s employment by the Company and his resignation.</ix:continuation> </span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">85</span></div></div><hr style="page-break-after:always"></hr><div><a id="sC60CC37B3AE059528C7798502851139B"></a></div><div><div style="line-height:120%;text-align:justify;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;" href="#sfb86787ac8304dffbb4bfe7ffcfa7b54"><span style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">Table of Contents</span></a></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></div><div><br/></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">15.         <ix:nonNumeric contextRef="FD2019Q4YTD" name="us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock" id="TextSelection-D5998D84EC88BF99BA2ED1D0187558E0-0-wk-Fact-CDDF3639576C20F8CCBED1D0183C4186" continuedAt="TextSelection-D5998D84EC88BF99BA2ED1D0187558E0-1" escape="true">Defined Contribution Plans </ix:nonNumeric></span></div><ix:continuation id="TextSelection-D5998D84EC88BF99BA2ED1D0187558E0-1"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Eligible employees are able to participate in the Company’s 401(k) plan. Effective January 1, 2019, the Company increased the employer non-discretionary matching contributions in an amount equal to </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d22942380e647-wk-Fact-D4DF8DE7976841508EC363765577B21F" name="us-gaap:DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" contextRef="FD2019Q4YTD" unitRef="number" decimals="INF" scale="-2" format="ixt:numdotdecimal">100</ix:nonFraction>%</span></span><span style="font-family:inherit;font-size:10pt;"> of deferral contributions up to a maximum of </span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d22942380e651-wk-Fact-8E127891BF36254CAB2A6376E56FE300" name="us-gaap:DefinedContributionPlanEmployerMatchingContributionPercent" contextRef="FD2019Q4YTD" unitRef="number" decimals="INF" scale="-2" format="ixt:numdotdecimal">5</ix:nonFraction>%</span></span><span style="font-family:inherit;font-size:10pt;"> of eligible compensation contributed to the 401(k) plan. Company contributions to the 401(k) plan totaled approximately $</span><span style="font-family:inherit;font-size:10pt;"><span><ix:nonFraction id="d22942380e655-wk-Fact-2BB828CA11739A71967CDCD5AC9F642B" name="us-gaap:DefinedBenefitPlanContributionsByEmployer" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1.9</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> for the year ended December 31, 2019, and </span><span style="font-family:inherit;font-size:10pt;"><span>$<ix:nonFraction id="d22942380e659-wk-Fact-9C59CA3B0467F864D046DCD59C5F7180" name="us-gaap:DefinedBenefitPlanContributionsByEmployer" contextRef="D2018Q4Jul01-Dec31" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">0.1</ix:nonFraction> million</span></span><span style="font-family:inherit;font-size:10pt;"> for the Transition Period and for each of the fiscal years ended June 30, 2018 and 2017.</span></div></ix:continuation><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div><a id="sB57CD4EE8BF15F04AC95008289641458"></a></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">16</span><span style="font-family:inherit;font-size:10pt;">. </span><span style="font-family:inherit;font-size:10pt;font-weight:bold;">        <ix:nonNumeric contextRef="FD2019Q4YTD" name="us-gaap:QuarterlyFinancialInformationTextBlock" id="TextSelection-04A2A534C5873769321DD1D018756FF3-0-wk-Fact-3801D7334A807FDF6CEDD1D0184B900A" continuedAt="TextSelection-04A2A534C5873769321DD1D018756FF3-1" escape="true">Quarterly Results of Operations (Unaudited)</ix:nonNumeric></span></div><ix:nonNumeric contextRef="FD2019Q4YTD" name="us-gaap:ScheduleOfQuarterlyFinancialInformationTableTextBlock" id="TextSelection-931B069BC07EA57C6E74D1D0187567EA-0-wk-Fact-3D69FC162B74609F7A0DD1D0180B8F0B" escape="true"><ix:continuation id="TextSelection-04A2A534C5873769321DD1D018756FF3-1"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following table summarizes unaudited quarterly financial data:</span></div><div style="line-height:120%;text-align:justify;padding-left:0px;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"></td></tr><tr><td style="width:37%;"></td><td style="width:1%;"></td><td style="width:13%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:14%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:13%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"> </span></div></td><td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Three Months Ended</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-style:italic;"> </span><span style="font-family:inherit;font-size:9pt;font-style:italic;font-weight:bold;">($ in thousands, except for per share amounts)</span></div></td><td colspan="3" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">December 31, 2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">September 30, 2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">June 30, 2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">March 31, 2019</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Consolidated Statements of Comprehensive Loss Data:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">    </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">    </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Revenues</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d22943746e941-wk-Fact-77362C02FC77BB87CF72D1D0183C2984" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2019Q4QTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">295</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d22943746e960-wk-Fact-DF35748002A4A142F63DD1D0184B8ACE" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2019Q3QTD" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">—</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d22943746e979-wk-Fact-115A07C79E0F2A6CC29939FF4D883D4F" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2019Q2QTD" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">—</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d22943746e999-wk-Fact-776B26B817696A99B0A239FF4D6D73F1" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2019Q1QTD" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">—</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Net loss attributable to Immunomedics, Inc. stockholders </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(<ix:nonFraction id="d22943746e1019-wk-Fact-E390D4B75C621147D15FD1D0183C1A5F" name="us-gaap:NetIncomeLoss" contextRef="FD2019Q4QTD" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">99,608</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(<ix:nonFraction id="d22943746e1039-wk-Fact-4A15CF4F294EB2D00332D1D0183C849F" name="us-gaap:NetIncomeLoss" contextRef="FD2019Q3QTD" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">94,292</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(<ix:nonFraction id="d22943746e1059-wk-Fact-CBA8D14399C0B39DB9B639FF4D8F3480" name="us-gaap:NetIncomeLoss" contextRef="FD2019Q2QTD" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">75,953</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(<ix:nonFraction id="d22943746e1080-wk-Fact-DB56F365395D71333ABA39FF4D94A1CD" name="us-gaap:NetIncomeLoss" contextRef="FD2019Q1QTD" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">87,337</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Loss per common share attributable to Immunomedics Inc. stockholders – (basic and diluted) </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(<ix:nonFraction id="d22943746e1101-wk-Fact-23EAFBAEEA3B9C3E8D68D1D0184ADC21" name="us-gaap:EarningsPerShareBasicAndDiluted" contextRef="FD2019Q4QTD" unitRef="usdPerShare" decimals="2" scale="0" sign="-" format="ixt:numdotdecimal">0.50</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(<ix:nonFraction id="d22943746e1121-wk-Fact-45BCB1C0AF74A6A3FD5FD1D0183C5C38" name="us-gaap:EarningsPerShareBasicAndDiluted" contextRef="FD2019Q3QTD" unitRef="usdPerShare" decimals="2" scale="0" sign="-" format="ixt:numdotdecimal">0.49</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(<ix:nonFraction id="d22943746e1141-wk-Fact-10074A27231F69E7192839FF4D7EB602" name="us-gaap:EarningsPerShareBasicAndDiluted" contextRef="FD2019Q2QTD" unitRef="usdPerShare" decimals="2" scale="0" sign="-" format="ixt:numdotdecimal">0.40</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(<ix:nonFraction id="d22943746e1162-wk-Fact-733934D0CADC0573B75539FF4D833C8E" name="us-gaap:EarningsPerShareBasicAndDiluted" contextRef="FD2019Q1QTD" unitRef="usdPerShare" decimals="2" scale="0" sign="-" format="ixt:numdotdecimal">0.46</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Weighted average shares used to calculate loss per common share – (basic and diluted)</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d22943746e1178-wk-Fact-CB95FDAF206BF3E6C51ED1D0183CFF93" name="us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted" contextRef="FD2019Q4QTD" unitRef="shares" decimals="-3" scale="3" format="ixt:numdotdecimal">199,614</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d22943746e1197-wk-Fact-F0D047DC00FB163C5AB2D1D0184BF3AE" name="us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted" contextRef="FD2019Q3QTD" unitRef="shares" decimals="-3" scale="3" format="ixt:numdotdecimal">191,981</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d22943746e1216-wk-Fact-B8F7E8A9248863F3613039FF4D78B51C" name="us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted" contextRef="FD2019Q2QTD" unitRef="shares" decimals="-3" scale="3" format="ixt:numdotdecimal">191,745</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d22943746e1236-wk-Fact-77E3E34BE1C81363E4A039FF4D9BB745" name="us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted" contextRef="FD2019Q1QTD" unitRef="shares" decimals="-3" scale="3" format="ixt:numdotdecimal">191,052</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;padding-left:0px;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"></td></tr><tr><td style="width:37%;"></td><td style="width:1%;"></td><td style="width:13%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:14%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:13%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"> </span></div></td><td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Three Months Ended</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-style:italic;"> </span><span style="font-family:inherit;font-size:9pt;font-style:italic;font-weight:bold;">($ in thousands, except for per share amounts)</span></div></td><td colspan="3" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">December 31, 2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">September 30, 2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">June 30, 2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">March 31, 2018</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Consolidated Statements of Comprehensive Loss Data:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">    </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">    </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Revenues</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d22943746e1534-wk-Fact-7350DE79683D901C1101DCD826A8E4B2" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2018Q4QTD" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">—</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d22943746e1553-wk-Fact-84A78FFF0B38741C717ADCD8281B72D0" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2018Q3QTD" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">—</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d22943746e1572-wk-Fact-50E58E3653AAC70DBDD7DCD829BD370E" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2018Q2QTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">387</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d22943746e1592-wk-Fact-86F74E606A4FB4D7B2E6DCD82BB50A75" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2018Q1QTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">482</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Net loss attributable to Immunomedics, Inc. stockholders </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(<ix:nonFraction id="d22943746e1612-wk-Fact-C97483C086C51E119916DCD82C912254" name="us-gaap:NetIncomeLoss" contextRef="FD2018Q4QTD" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">93,499</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(<ix:nonFraction id="d22943746e1632-wk-Fact-D1449235EB53D9DC0375DCD82DBBD2B2" name="us-gaap:NetIncomeLoss" contextRef="FD2018Q3QTD" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">64,169</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(<ix:nonFraction id="d22943746e1652-wk-Fact-5177149168D0BAC4BBAEDCD82F84A575" name="us-gaap:NetIncomeLoss" contextRef="FD2018Q2QTD" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">117,032</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(<ix:nonFraction id="d22943746e1673-wk-Fact-A2489E73716CFADFC0F1DCD830B113F3" name="us-gaap:NetIncomeLoss" contextRef="FD2018Q1QTD" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">35,546</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Loss per common share attributable to Immunomedics Inc. stockholders – (basic and diluted) </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(<ix:nonFraction id="d22943746e1694-wk-Fact-B886381348F0BFD15885DCD8315D84F6" name="us-gaap:EarningsPerShareBasicAndDiluted" contextRef="FD2018Q4QTD" unitRef="usdPerShare" decimals="2" scale="0" sign="-" format="ixt:numdotdecimal">0.50</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(<ix:nonFraction id="d22943746e1714-wk-Fact-E26915AF0B153B4611EEDCD83271344E" name="us-gaap:EarningsPerShareBasicAndDiluted" contextRef="FD2018Q3QTD" unitRef="usdPerShare" decimals="2" scale="0" sign="-" format="ixt:numdotdecimal">0.34</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(<ix:nonFraction id="d22943746e1734-wk-Fact-44B52BD5F0C0678F3A6EDCD8339724C5" name="us-gaap:EarningsPerShareBasicAndDiluted" contextRef="FD2018Q2QTD" unitRef="usdPerShare" decimals="2" scale="0" sign="-" format="ixt:numdotdecimal">0.68</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(<ix:nonFraction id="d22943746e1755-wk-Fact-D5E1D592B1DB59787450DCD834B4ED2C" name="us-gaap:EarningsPerShareBasicAndDiluted" contextRef="FD2018Q1QTD" unitRef="usdPerShare" decimals="2" scale="0" sign="-" format="ixt:numdotdecimal">0.21</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Weighted average shares used to calculate loss per common share – (basic and diluted)</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d22943746e1771-wk-Fact-0B3046530795FA2D5BA8DCD8355DAF3D" name="us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted" contextRef="FD2018Q4QTD" unitRef="shares" decimals="-3" scale="3" format="ixt:numdotdecimal">190,171</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d22943746e1790-wk-Fact-E8BC978CF77FA0E88FC6DCD8368EC128" name="us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted" contextRef="FD2018Q3QTD" unitRef="shares" decimals="-3" scale="3" format="ixt:numdotdecimal">186,937</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d22943746e1809-wk-Fact-F29F8E93DD82F8DFBCE8DCD837A31596" name="us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted" contextRef="FD2018Q2QTD" unitRef="shares" decimals="-3" scale="3" format="ixt:numdotdecimal">171,124</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span><ix:nonFraction id="d22943746e1829-wk-Fact-DEAB44E6A9576E70F7ACDCD838D70678" name="us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted" contextRef="FD2018Q1QTD" unitRef="shares" decimals="-3" scale="3" format="ixt:numdotdecimal">166,054</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div></ix:continuation></ix:nonNumeric><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">86</span></div></div><hr style="page-break-after:always"></hr><div><a id="s3BC1695089135603B302FF81A27F9B72"></a></div><div><div style="line-height:120%;text-align:justify;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;" href="#sfb86787ac8304dffbb4bfe7ffcfa7b54"><span style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">Table of Contents</span></a></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></div><div><br/></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Item 9. </span><span style="font-family:inherit;font-size:10pt;"> </span><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Changes in and Disagreements with Accountants on Accounting and Financial Disclosure</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">None.</span></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div><a id="s6B4112BD0305559BBC7821EA6D2D9EE7"></a></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Item 9A. </span><span style="font-family:inherit;font-size:10pt;"> </span><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Controls and Procedures: </span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Disclosure Controls and Procedures:</span><span style="font-family:inherit;font-size:10pt;">  We maintain controls and procedures designed to ensure that we are able to collect the information we are required to disclose in the reports we file with the SEC, and to record, process, summarize and disclose this information within the time periods specified in the rules promulgated by the SEC. Our Chief Financial Officer, who serves as our principal executive officer and principal financial officer, and our Principal Accounting Officer are responsible for establishing and maintaining these disclosure controls and procedures and as required by the rules of the SEC, to evaluate their effectiveness. Based on their evaluation of our disclosure controls and procedures as of the end of the period covered by this Annual Report on Form 10-K, our Chief Financial Officer and Principal Accounting Officer believe that these procedures are functioning effectively to provide reasonable assurance that the information required to be disclosed by us in reports filed under the Securities Exchange Act of 1934 is (i) recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and forms and (ii) accumulated and communicated to our management, including our Chief Financial Officer and Principal Accounting Officer, as appropriate to allow timely decisions regarding disclosures.</span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Management’s Report on Internal Control Over Financial Reporting:</span><span style="font-family:inherit;font-size:10pt;"> Our management is responsible for establishing and maintaining adequate internal control over financial reporting as defined in Rules 13a-15(f) and 15d-15(f) under the Securities Exchange Act of 1934. Our internal control over financial reporting is designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. Our internal control over financial reporting includes those policies and procedures that: (i) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of Immunomedics; (ii) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that our receipts and expenditures are being made only in accordance with authorizations of our management and our directors; and (iii) provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use or disposition of our assets that could have a material effect on the financial statements. </span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.</span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Our management assessed the effectiveness of our internal control over financial reporting as of </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;">. In making this assessment, management used the criteria in the </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Internal Control-Integrated Framework (2013)</span><span style="font-family:inherit;font-size:10pt;"> issued by the Committee of Sponsoring Organizations of the Treadway Commission (“COSO”). Based on its assessment and those criteria, our management has concluded we maintained effective internal control over financial reporting as of </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;">.</span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Our independent registered public accounting firm has issued an attestation report on the effectiveness of Immunomedics’ internal control over financial reporting.</span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Changes in internal controls over financial reporting:</span><span style="font-family:inherit;font-size:10pt;">  There were no changes in our internal control over financial reporting (as defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act), identified in connection with the evaluation of such internal control that occurred during our last fiscal quarter, that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div><a id="s58758530FCC955CF9243354D01A7680C"></a></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Item 9B</span><span style="font-family:inherit;font-size:10pt;">.  </span><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Other Information</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">None.</span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">87</span></div></div><hr style="page-break-after:always"></hr><div><a id="sA682473C3FAD5594A612BE6AE05D826C"></a></div><div><div style="line-height:120%;text-align:justify;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;" href="#sfb86787ac8304dffbb4bfe7ffcfa7b54"><span style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">Table of Contents</span></a></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></div><div><br/></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">PART III</span></div><div><a id="s48DEBEDF264A51D98F0AEACA688789F7"></a></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Item 10. </span><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Directors, Executive Officers, and Corporate Governance</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Pursuant to Paragraph G(3) of the General Instructions to Form 10-K, the information required by Part III (Items 10, 11, 12, 13 and 14) is being incorporated by reference herein from our definitive proxy statement to be filed with the SEC within 120 days after the end of the fiscal year ended December 31, 2019 in connection with our 2020 Annual Meeting of Stockholders.</span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The text of our Code of Business Conduct, which applies to our directors and employees (including our principal executive officer, principal financial officer, principal accounting officer or controller, or persons performing similar functions) is posted in the “Corporate Governance” section of our website, www.immunomedics.com. A copy of the Code of Business Conduct can be obtained free of charge on our website. We intend to disclose on our website any amendments to, or waivers from, our Code of Business Conduct that are required to be disclosed pursuant to the rules of the SEC and Nasdaq.</span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div><a id="s0BED532A06535006A6E288EA0599F57A"></a></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Item 11. </span><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Executive Compensation</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">See Item 10.</span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div><a id="sD07CC60DE97854F68CF914B30282FE47"></a></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Item 12. </span><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">See Item 10.</span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div><a id="s1145738D0B755CA2806CC9EA884298BB"></a></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Item 13. </span><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Certain Relationships and Related Transactions and Director Independence</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">See Item 10.</span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div><a id="s1A584D1CAD6954258A066CDE8A246C91"></a></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Item 14. </span><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Principal Accounting Fees and Services</span><span style="font-family:inherit;font-size:10pt;font-weight:bold;"> </span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">See Item 10.</span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div><a id="s789D9C5B1AF852AFA4B469AA7FBC6A6C"></a></div><div style="line-height:120%;padding-bottom:16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">PART IV</span></div><div><a id="sD6E8CDD5B84D5CEF873128CA517227AB"></a></div><div style="line-height:120%;text-align:left;-sec-extract:summary;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Item 15. </span><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Exhibits, Financial Statement Schedules</span></div><div style="line-height:120%;text-align:center;font-size:12pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.609375%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:5%;"></td><td style="width:6%;"></td><td style="width:89%;"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">(a) </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Documents filed as part of this report</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:6px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:6px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">(1)</span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Consolidated Financial Statements</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:6px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:6px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Index to Consolidated Financial Statements</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:6px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:6px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:6px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:12pt;"><span style="font-family:inherit;font-size:12pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:12pt;"><span style="font-family:inherit;font-size:12pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Consolidated Balance Sheets – as of December 31, 2019 and 2018</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:6px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:6px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:6px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:12pt;"><span style="font-family:inherit;font-size:12pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:12pt;"><span style="font-family:inherit;font-size:12pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Consolidated Statements of Comprehensive Loss for the Year Ended December 31, 2019, the Transition Period Ended December 31, 2018 and the Fiscal Years Ended June 30, 2018 and 2017</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:6px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:6px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:6px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:12pt;"><span style="font-family:inherit;font-size:12pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:12pt;"><span style="font-family:inherit;font-size:12pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Consolidated Statements of Changes in Stockholders’ Equity for the Year Ended December 31, 2019, the Transition Period Ended December 31, 2018 and Fiscal Years Ended June 30, 2018 and 2017</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:6px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:6px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:6px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:12pt;"><span style="font-family:inherit;font-size:12pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:12pt;"><span style="font-family:inherit;font-size:12pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Consolidated Statements of Cash Flows for the Year Ended December 31, 2019, the Transition Period Ended December 31, 2018 and Fiscal Years Ended June 30, 2018 and 2017</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:6px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:6px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:6px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:12pt;"><span style="font-family:inherit;font-size:12pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:12pt;"><span style="font-family:inherit;font-size:12pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Notes to Consolidated Financial Statements</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:6px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:6px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:6px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:12pt;"><span style="font-family:inherit;font-size:12pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:12pt;"><span style="font-family:inherit;font-size:12pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Reports of Independent Registered Public Accounting Firm – KPMG LLP</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:6px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:6px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:6px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">(b)</span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Financial Statement Schedules</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">None.</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:6px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:6px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">(3)</span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">List of Exhibits</span></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">88</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;text-align:justify;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;" href="#sfb86787ac8304dffbb4bfe7ffcfa7b54"><span style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">Table of Contents</span></a></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></div><div><br/></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:15%;"></td><td style="width:4%;"></td><td style="width:81%;"></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Exhibit No.</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">    </span></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Description</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">3.(i).1</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="font-size:10pt;"><a style="text-decoration:none;color:#000000;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/722830/000110465917042576/a17-14555_7ex3d1.htm"><span style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">Amended and Restated Certificate of Incorporation, incorporated by reference from Exhibit 3.1 to the Company’s Current Report on Form 8-K as filed with the Commission on June 29, 2017.</span></a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">3.(i).2</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="text-decoration:none;color:#000000;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/722830/000110465917030082/a17-12537_1ex3d1.htm"><span style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">Form of Certificate of Designation of Series A-1 Convertible Preferred Stock, incorporated by reference from Exhibit 3.1 to the Company’s Current Report on Form 8-K, as filed with the Commission on May 5, 2017.</span></a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">3.(iii).1</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="text-decoration:none;color:#000000;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/722830/000110465919021967/a19-8517_18k.htm"><span style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">By-Laws of Immunomedics, Inc., incorporated by reference from Exhibit 3.1 to the Company’s Current Report on Form 8-K, as filed with the Commission on April 17, 2019.</span></a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">4.1*</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="text-decoration:none;color:#000000;-sec-extract:exhibit;" href="immu201910kex41.htm"><span style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">Description of Securities of the Registrant, dated as of December 31, 2019.</span></a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">4.2</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="text-decoration:none;color:#000000;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/722830/000117184315000761/exh_41.htm"><span style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">Indenture, dated as of February 11, 2015, by and between the Company and Wells Fargo Bank, National Association, incorporated by reference from Exhibit 4.1 to the Company’s Current Report on Form 8-K as filed with the Commission on February 12, 2015.</span></a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">4.3</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="text-decoration:none;color:#000000;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/722830/000117184315000761/exh_41.htm"><span style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">Form of 4.75% Convertible Senior Note due 2020 incorporated by reference from Exhibit 4.1 to the Company’s Current Report on Form 8-K as filed with the Commission on February 12, 2015.</span></a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">10.1</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="text-decoration:none;color:#000000;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/722830/0000722830-99-000006.txt"><span style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">License Agreement, dated March 5, 1999, between the Company and IBC Pharmaceuticals, incorporated by reference from Exhibit 10.2 to the Company’s Current Report on Form 8-K as filed with the Commission on March 24, 1999.</span></a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">10.2</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Lease Agreement with Baker Properties Limited Partnership, dated January 16, 1992, incorporated by reference from the Exhibits to the Company’s Registration Statement on Form S-2 (Commission File No. 33-44750), effective January 30, 1992. (P)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">10.3</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="text-decoration:none;color:#000000;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/722830/000119312507200675/dex1031.htm"><span style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">First Addendum, dated May 5, 1993, of the Lease Agreement with Baker Properties Limited Partnership, dated January 16, 1992, incorporated by reference from Exhibit 10.31 to the Company’s Annual Report on Form 10-K for the fiscal year ended June 30, 2007.</span></a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">10.4</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="text-decoration:none;color:#000000;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/722830/000119312507200675/dex1032.htm"><span style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">Second Addendum, dated March 29, 1995, of the Lease Agreement with Baker Properties Limited Partnership, dated January 16, 1992, incorporated by reference from Exhibit 10.32 to the Company’s Annual Report on Form 10-K for the fiscal year ended June 30, 2007.</span></a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">10.5</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="text-decoration:none;color:#000000;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/722830/000119312507200675/dex1033.htm"><span style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">Letter Amendment, dated October 5, 1998, of the Lease Agreement with Baker Properties Limited Partnership, dated January 16, 1992, incorporated by reference from Exhibit 10.33 to the Company’s Annual Report on Form 10-K for the fiscal year ended June 30, 2007.</span></a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">10.6</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="text-decoration:none;color:#000000;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/722830/000119312507200675/dex1034.htm"><span style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">Fourth Amendment Expansion/Extension Agreement dated August 15, 2001, of the Lease Agreement with Baker Properties Limited Partnership, dated January 16, 1992, incorporated by reference from Exhibit 10.34 to the Company’s Annual Report on Form 10-K for the fiscal year ended June 30, 2007.</span></a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">10.7</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="text-decoration:none;color:#000000;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/722830/000119312509182946/dex1036.htm"><span style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">Fifth Amendment Expansion Agreement dated June 18, 2009 of the Lease with WU/LH 300 American L.L.C. a successor-in-interest to Baker Properties Limited Partnership, incorporated by reference from Exhibit 10.36 to the Company’s Annual Report on Form 10-K for the fiscal year ended June 30, 2009.</span></a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">10.8</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="text-decoration:none;color:#000000;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/722830/000119312511133817/dex101.htm"><span style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">Sixth Amendment Extension Agreement dated February 11, 2011 of the Lease with WU/LH 300 American L.L.C. a successor-in-interest to Baker Properties Limited Partnership, incorporated by reference from Exhibit 10.1 to the Company’s Quarterly Report on Form 10-Q for the fiscal quarter ended March 31, 2011.</span></a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">10.9*</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="text-decoration:none;color:#000000;-sec-extract:exhibit;" href="immu201910k1231ex109.htm"><span style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">Lease Agreement dated October 27, 2017 with WU/LH 400 American L.L.C.</span></a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">10.10#</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="text-decoration:none;color:#000000;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/722830/000119312515009400/d850467dex991.htm"><span style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">Immunomedics, Inc. 2014 Long-Term Incentive Plan, incorporated by reference from Exhibit 99.1 to the Company’s Registration Statement on Form S-8 (Commission File Number 333-201470), as filed with the Commission on January 13, 2015.</span></a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">10.11#</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="text-decoration:none;color:#000000;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/722830/000119312515009400/d850467dex992.htm"><span style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">Forms of Incentive Stock Option Notice and Incentive Stock Option Agreement under the Immunomedics, Inc. 2014 Long-Term Incentive Plan, incorporated by reference from Exhibit 99.2 to the Company’s Registration Statement on Form S-8 (Commission File Number 333-201470),  as filed with the Commission on January 13, 2015.</span></a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">10.12#</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="text-decoration:none;color:#000000;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/722830/000119312515009400/d850467dex993.htm"><span style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">Forms of Nonqualified Stock Option Notice and Nonqualified Stock Option Agreement under the Immunomedics, Inc. 2014 Long-Term Incentive Plan, incorporated by reference from Exhibit 99.3 to the Company’s Registration Statement on Form S-8 as filed with the Commission on January 13, 2015.</span></a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">10.13#</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="text-decoration:none;color:#000000;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/722830/000119312515009400/d850467dex994.htm"><span style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">Forms of Restricted Stock Units Notice and Restricted Stock Units Agreement (for Officers/Employees) under the Immunomedics, Inc. 2014 Long-Term Incentive Plan, incorporated by reference from Exhibit 99.4 to the Company’s Registration Statement on Form S-8 as filed with the Commission on January 13, 2015.</span></a></div></td></tr></table></div></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">89</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;text-align:justify;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;" href="#sfb86787ac8304dffbb4bfe7ffcfa7b54"><span style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">Table of Contents</span></a></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></div><div><br/></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:15%;"></td><td style="width:4%;"></td><td style="width:81%;"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">10.14#</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="text-decoration:none;color:#000000;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/722830/000119312515009400/d850467dex995.htm"><span style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">Forms of Restricted Stock Units Notice and Restricted Stock Units Agreement (for Directors) under the Immunomedics, Inc. 2014 Long-Term Incentive Plan, incorporated by reference from Exhibit 99.5 to the Company’s Registration Statement on Form S-8 as filed with the Commission on January 13, 2015.</span></a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">10.15</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="text-decoration:none;color:#000000;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/722830/000110465917009919/a17-4579_1ex10d1.htm"><span style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">Form of Indemnification Agreement by and between the Company and each of its directors, executive officers, and certain of its former directors and executive officers, incorporated by reference to exhibit 10.1 to the Company’s current report on Form 8-K, as filed with the Commission on February 16, 2017.</span></a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">10.16</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="text-decoration:none;color:#000000;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/722830/000104746917004865/a2232826zex-10_3.htm"><span style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">Securities Purchase Agreement between the Company and the Purchasers, dated as of May 4, 2017, incorporated by reference to Exhibit 10.3 to the Company’s Registration Statement on Form S-3, as filed with the Commission on July 31, 2017 (Commission File No. 333-219594).</span></a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">10.17 †</span></div><div style="font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="text-decoration:none;color:#000000;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/722830/000155837017008736/immu-20170930ex102a57faf.htm"><span style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">Master Services Agreement, dated as of July 3, 2017, by and between the Company and Covance, Inc., incorporated by reference to Exhibit 10.2 to the Company’s quarterly report on Form 10-Q, as filed with the Commission on November 9, 2017.</span></a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">10.18 †</span></div><div style="font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="text-decoration:none;color:#000000;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/722830/000155837017008736/immu-20170930ex1035f6dcd.htm"><span style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">Work Order, dated as of July 3, 2017, by and between the Company and Covance, Inc., incorporated by reference to Exhibit 10.3 to the Company’s quarterly report on Form 10-Q, as filed with the Commission on November 9, 2017.</span></a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">10.19</span></div><div style="font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:10px;font-size:10pt;"><a style="text-decoration:none;color:#000000;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/722830/000110465917067010/a17-26175_1ex10d1.htm"><span style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">Stipulation and Agreement of Settlement, Compromise, and Release, dated November 2, 2017, by and among the Company, venBio Select Advisor LLC, Dr. David M. Goldenberg, Cynthia L. Sullivan, Brian A. Markison, Greenhill & Co., Inc., and Greenhill & Co., LLC., incorporated by reference to Exhibit 10.1 to the Company’s current report on Form 8-K, as filed with the Commission on November 8, 2017.</span></a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">10.20</span></div><div style="font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="text-decoration:none;color:#000000;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/722830/000110465917072044/a17-28048_1ex10d1.htm"><span style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">Form of Indemnification Agreement, incorporated by reference to Exhibit 10.1 to the Company’s current report on Form 8-K, as filed with the Commission on December 6, 2017.</span></a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">10.21 #</span></div><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="text-decoration:none;color:#000000;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/722830/000155837018000528/immu-20171231ex10583048a.htm"><span style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">Executive Employment Agreement, dated as of November 8, 2017, between the Company and Brendan Delaney, incorporated by reference to Exhibit 10.5 to the Company’s quarterly report on Form 10-Q, as filed with the Commission on February 8, 2018.</span></a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">10.22 #</span></div><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="text-decoration:none;color:#000000;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/722830/000155837018000528/immu-20171231ex1060d12b0.htm"><span style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">Incentive Stock Option Grant, dated as of November 10, 2017, between the Company and Brendan Delaney, incorporated by reference to Exhibit 10.6 to the Company’s quarterly report on Form 10-Q, as filed with the Commission on February 8, 2018.</span></a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">10.23 †</span></div><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="text-decoration:none;color:#000000;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/722830/000155837018004502/immu-20180331ex101be05bb.htm"><span style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">Funding Agreement, dated as of January 7, 2018, between the Company and RPI Finance Trust, incorporated by reference to Exhibit 10.1 to the Company’s quarterly report on Form 10-Q, as filed with the Commission on May 9, 2018.</span></a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">10.24</span></div><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="text-decoration:none;color:#000000;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/722830/000155837018004502/immu-20180331ex1026c778d.htm"><span style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">Common Stock Purchase Agreement, dated as of January 7, 2018, between the Company and RPI Finance Trust, incorporated by reference to Exhibit 10.2 to the Company’s quarterly report on Form 10-Q, as filed with the Commission on May 9, 2018.</span></a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">10.25 </span><span style="font-family:inherit;font-size:9pt;">† </span></div><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="text-decoration:none;color:#000000;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/722830/000072283018000006/immu20180630ex1055.htm"><span style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">Letter Agreement, dated as of July 6, 2018, by and between the Company and BSP Pharmaceuticals S.p.A., incorporated by reference to Exhibit 10.55 to the Company’s annual report on Form 10K/A, as filed with the Commission on December 6, 2018.</span></a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">10.26 </span><span style="font-family:inherit;font-size:9pt;">† </span></div><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="text-decoration:none;color:#000000;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/722830/000072283018000006/immu20180630ex1056.htm"><span style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">License Agreement, dated as of April 4, 2018, by and between the Company and The Scripps Research Institute, incorporated by reference to Exhibit 10.56 to the Company’s annual report on Form 10-K/A, as filed with the Commission on December 6, 2018.</span></a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">10.27 </span><span style="font-family:inherit;font-size:9pt;">† </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="text-decoration:none;color:#000000;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/722830/000072283018000012/immu-09302018ex1059.htm"><span style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">Master Services Agreement, dated as of September 11, 2018, between the Company and Samsung BioLogics Co., Ltd, incorporated by reference to Exhibit 10.59 to the Company’s quarterly report on Form 10-Q, as filed with the Commission on November 7, 2018.</span></a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">10.28 </span><span style="font-family:inherit;font-size:9pt;">†</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="text-decoration:none;color:#000000;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/722830/000072283018000012/immu-9302018ex1060.htm"><span style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">Product Specific Agreement, dated as of September 11, 2018, between the Company and Samsung BioLogics Co., Ltd, incorporated by reference to Exhibit 10.60 to the Company’s quarterly report on Form 10-Q, as filed with the Commission on November 7, 2018.</span></a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">10.29</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="text-decoration:none;color:#000000;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/722830/000072283018000012/immu-09302018ex1061.htm"><span style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">Executive Employment Agreement, dated as of September 24, 2018, between the Company and Jared Freedberg, incorporated by reference to Exhibit 10.61 to the Company’s quarterly report on Form 10-Q, as filed with the Commission on November 7, 2018.</span></a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">10.30</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="text-decoration:none;color:#000000;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/722830/000072283018000012/immu-09302018ex1062.htm"><span style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">Nonqualified Stock Option Grant, dated as of September 24, 2018, between the Company and Jared Freedberg, incorporated by reference to Exhibit 10.62 to the Company's quarterly report on Form 10-Q, as filed with the Commission on November 7, 2018.</span></a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">10.31</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="text-decoration:none;color:#000000;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/722830/000072283018000012/immu-09302018ex1063.htm"><span style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">Executive Employment Agreement, dated as of September 26, 2018, between the Company and Kurt Andrews, incorporated by reference to Exhibit 10.63 to the Company’s quarterly report on Form 10-Q, as filed with the Commission on November 7, 2018.</span></a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">10.32</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="text-decoration:none;color:#000000;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/722830/000072283018000012/immu-09302018ex1064.htm"><span style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">Nonqualified Stock Option Grant, dated as of July 11, 2018, between the Company and Kurt Andrews, incorporated by reference to Exhibit 10.64 to the Company’s quarterly report on Form 10-Q, as filed with the Commission on November 7, 2018.</span></a></div></td></tr></table></div></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">90</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;text-align:justify;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;" href="#sfb86787ac8304dffbb4bfe7ffcfa7b54"><span style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">Table of Contents</span></a></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></div><div><br/></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:15%;"></td><td style="width:4%;"></td><td style="width:81%;"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">10.33</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="text-decoration:none;color:#000000;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/722830/000072283018000012/immu-09302018ex1065.htm"><span style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">Immunomedics, Inc. Annual Cash Bonus Plan, incorporated by reference to Exhibit 10.65 to the Company’s quarterly report on Form 10-Q, as filed with the Commission on November 7, 2018.</span></a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">10.34 </span><span style="font-family:inherit;font-size:9pt;">†</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="text-decoration:none;color:#000000;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/722830/000072283019000005/immu201810kt1231ex1066.htm"><span style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">Manufacturing Services Agreement, dated as of December 17, 2018, by and between the Company and Johnson Matthey Pharmaceutical Materials, Inc., incorporated by reference to Exhibit 10.66 to the Company's annual report on Form 10-K, as filed with the Commission on February 25, 2019.</span></a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">10.35</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="text-decoration:none;color:#000000;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/722830/000072283019000012/immu-03312019ex101.htm"><span style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">Letter Agreement, dated as of March 5, 2019, by and between the Company and Scott Canute, incorporated by reference to Exhibit 10.1 to the Company's quarterly report on Form 10-Q, as filed with the Commission on May 9, 2019.</span></a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">10.36</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="text-decoration:none;color:#000000;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/722830/000072283019000012/immu-03312019ex102.htm"><span style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">Separation Agreement, dated as of March 13, 2019, by and between the Company and Michael Pehl, incorporated by reference to Exhibit 10.2 to the Company's quarterly report on Form 10-Q, as filed with the Commission on May 9, 2019.</span></a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">10.37</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="text-decoration:none;color:#000000;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/722830/000072283019000012/immu-03312019ex103.htm"><span style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">Executive Employment Agreement, dated as of August 7, 2017, by and between the Company and Usama Malik, incorporated by reference to Exhibit 10.3 to the Company's quarterly report on Form 10-Q, as filed with the Commission on May 9, 2019.</span></a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">10.38 </span><span style="font-family:inherit;font-size:9pt;">†</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="text-decoration:none;color:#000000;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/722830/000072283019000016/exhibit101.htm"><span style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">Promotion Agreement, dated as of April 5, 2019, by and between Immunomedics, Inc. and Janssen Biotech, Inc., incorporated by reference to Exhibit 10.1 to the Company's quarterly report on Form 10-Q, as filed with the Commission on August 7, 2019.</span></a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">10.39 </span><span style="font-family:inherit;font-size:9pt;">†</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="text-decoration:none;color:#000000;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/722830/000072283019000016/exhibit102.htm"><span style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">License Agreement, dated as of April 29, 2019, by and between Immunomedics, Inc. and Everest Medicines II Limited., incorporated by reference to Exhibit 10.2 to the Company's quarterly report on Form 10-Q, as filed with the Commission on August 7, 2019.</span></a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">10.40</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="text-decoration:none;color:#000000;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/722830/000072283019000016/exhibit103.htm"><span style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">Consulting Agreement, dated as of May 28, 2019, by and between Immunomedics, Inc. and Dr. Robert Iannone, incorporated by reference to Exhibit 10.3 to the Company's quarterly report on Form 10-Q, as filed with the Commission on August 7, 2019.</span></a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">21.1*</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="text-decoration:none;color:#000000;-sec-extract:exhibit;" href="immu201910k1231ex2111.htm"><span style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">Subsidiaries of the Company.</span></a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">23.1*</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="text-decoration:none;color:#000000;-sec-extract:exhibit;" href="immu201910k1231ex2311.htm"><span style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">Consent of Independent Registered Public Accounting Firm – KPMG LLP.</span></a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">31.1*</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="text-decoration:none;color:#000000;-sec-extract:exhibit;" href="immu201910k1231ex3111.htm"><span style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">Certification of the Principal Executive Officer pursuant to Section 302(a) of the Sarbanes-Oxley Act of 2002.</span></a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">31.2*</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="text-decoration:none;color:#000000;-sec-extract:exhibit;" href="immu201910k1231ex3121.htm"><span style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">Certification of the Principal Financial Officer pursuant to Section 302(a) of the Sarbanes-Oxley Act of 2002.</span></a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">32.1**</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="text-decoration:none;color:#000000;-sec-extract:exhibit;" href="immu201910k1231ex3211.htm"><span style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">Certification of the Principal Executive Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.</span></a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">32.2**</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="text-decoration:none;color:#000000;-sec-extract:exhibit;" href="immu201910k1231ex3221.htm"><span style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">Certification of the Principal Financial Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.</span></a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">101*</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following financial information from the Annual Report on Form 10-K for the year ended December 31, 2019, formatted in Inline XBRL (eXtensible Business Reporting Language) and furnished electronically herewith: (i) the Consolidated Balance Sheets; (ii) the Consolidated Statements of Comprehensive Loss; (iii) the Consolidated Statements of Changes in Stockholders’ Equity; (iv) the Consolidated Statements of Cash Flows; and (v) the Notes to Consolidated Financial Statements. </span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">104*</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The cover page of this Annual Report on Form 10-K for the year ended December 31, 2019, formatted in Inline XBRL, included in the Exhibit 101 Inline XBRL Document Set.</span></div></td></tr></table></div></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">*            Filed herewith.</span></div><div style="line-height:120%;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">**    Furnished herewith</span></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9pt;padding-left:0px;"><span style="font-family:inherit;font-size:9pt;">#        </span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Management contract or compensatory plan or arrangement required to be filed as an exhibit to this Annual Report on Form 10-K pursuant to Item 15(a)(3) of Form 10-K.</span></div></td></tr></table><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:9pt;">†           Confidential treatment has been granted for certain portions of this exhibit.</span><span style="font-family:inherit;font-size:10pt;">    </span></div><div style="line-height:120%;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">P    Paper copy only.</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">(Exhibits available upon request)</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div><a id="saf81f7d3746e4a37ac924f89e19da6ed"></a></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Item 16. </span><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Form 10-K Summary</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"></span><span style="font-family:inherit;font-size:10pt;">None.</span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">91</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;text-align:justify;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;" href="#sfb86787ac8304dffbb4bfe7ffcfa7b54"><span style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">Table of Contents</span></a></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></div><div><br/></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div><a id="s237FCEAA66A55C47B272B6578E9E8E67"></a></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">SIGNATURES</span></div><div style="line-height:120%;padding-bottom:16px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.</span></div><div style="line-height:120%;font-size:12pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="5"></td></tr><tr><td style="width:41%;"></td><td style="width:8%;"></td><td style="width:17%;"></td><td style="width:17%;"></td><td style="width:17%;"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="4" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">IMMUNOMEDICS, INC.</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Date: February 27, 2020</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">By:</span></div></td><td colspan="3" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">/s/Usama Malik</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Usama Malik</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:12pt;"><span style="font-family:inherit;font-size:12pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:12pt;"><span style="font-family:inherit;font-size:12pt;"> </span></div></td><td colspan="3" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Chief Financial Officer</span></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:8px;padding-top:16px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the registrant and in the capacities and on the dates indicated.</span></div><div style="line-height:120%;font-size:12pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="5"></td></tr><tr><td style="width:29%;"></td><td style="width:1%;"></td><td style="width:46%;"></td><td style="width:1%;"></td><td style="width:23%;"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Signature</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">    </span></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Title</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">    </span></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Date</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">/s/Dr. Behzad Aghazadeh</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Chairman of the Board, Director</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">February 27, 2020</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Dr. Behzad Aghazadeh</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">/s/Charles M. Baum</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Director</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">February 27, 2020</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Charles M. Baum, M.D., Ph.D.</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">/s/Barbara G. Duncan</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Director</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">February 27, 2020</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Ms. Barbara G. Duncan</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">/s/Dr. Khalid Islam</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Director</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">February 27, 2020</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Dr. Khalid Islam</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">/s/Scott Canute</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Director</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">February 27, 2020</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Scott Canute</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:12pt;"><span style="font-family:inherit;font-size:12pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:12pt;"><span style="font-family:inherit;font-size:12pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:12pt;"><span style="font-family:inherit;font-size:12pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:12pt;"><span style="font-family:inherit;font-size:12pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:12pt;"><span style="font-family:inherit;font-size:12pt;"> </span></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">/s/Peter Barton Hutt</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Director</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">February 27, 2020</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Peter Barton Hutt</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">/s/Usama Malik</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Chief Financial Officer</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">February 27, 2020</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Usama Malik</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">(Principal Executive Officer and Principal Financial Officer)</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">/s/William Fricker</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Corporate Controller</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">February 27, 2020</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">William Fricker</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">(Principal Accounting Officer)</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">92</span></div></div> </div></body>
</html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-4.1
<SEQUENCE>2
<FILENAME>immu201910kex41.htm
<DESCRIPTION>EXHIBIT 4.1 DESCRIPTION OF SECURITIES OF THE REGISTRANT
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
<head>
<!-- Document created using Wdesk 1 -->
<!-- Copyright 2020 Workiva -->
<title>Exhibit</title>
</head>
<body><div style="font-family:Times New Roman;font-size:10pt;">
<div><a name="s89f914326bb44b0b95bda22f63d43e7c"></a></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:right;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">Exhibit 4.1</font></div><div style="line-height:120%;text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">DESCRIPTION OF THE REGISTRANT’S SECURITIES</font></div><div style="line-height:120%;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">REGISTERED PURSUANT TO SECTION 12 OF THE</font></div><div style="line-height:120%;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">SECURITIES EXCHANGE ACT OF 1934</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">As of December 31, 2019, Immunomedics, Inc. (the “Company”) had one class of securities registered under Section 12 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”): Common Stock</font><font style="font-family:inherit;font-size:11pt;font-weight:bold;">, </font><font style="font-family:inherit;font-size:11pt;">$0.01 par value per share (“Common Stock”). Shares of the Company’s Common Stock registered under Section 12 of the Exchange Act are listed on The Nasdaq Stock Market LLC.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">DESCRIPTION OF COMMON STOCK</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-style:italic;">Authorized Capital Stock</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:11pt;"><font style="font-family:inherit;font-size:10pt;"></font><font style="font-family:inherit;font-size:11pt;">The Company’s authorized capital stock consists of 250,000,000 shares of Common Stock and 10,000,000 shares of preferred stock, $0.01 par value per share.</font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"> </font></div><div style="line-height:120%;text-align:left;padding-left:13px;text-indent:-14px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-style:italic;">Dividends, Voting Rights and Liquidation</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Each stockholder of record is entitled to one vote for each outstanding share of Common Stock owned by that stockholder on every matter properly submitted to the stockholders for their vote. After satisfaction of the dividend rights of holders of any preferred stock, holders of Common Stock are entitled to any dividend declared by the Board of Directors out of funds legally available for that purpose. After the payment of liquidation preferences to holders of any preferred stock, holders of Common Stock are entitled to receive, on a pro rata basis, all remaining assets available for distribution to stockholders in the event of the Company’s liquidation, dissolution or winding up. The rights, preferences and privileges of holders of Common Stock are subject to, and may be injured by, the rights of the holders of shares of any series of preferred stock that the Company may designate and issue in the future.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-style:italic;">No Preemptive or Similar Rights</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">The Company’s Common Stock has no preemptive or other subscription rights, and there are no conversion rights or redemption or sinking fund provisions with respect to such shares of Common Stock.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:13px;text-indent:-14px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-style:italic;">Transfer Agent and Registrar</font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"> </font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Philadelphia Stock Transfer, Inc. is the transfer agent and registrar for the Company’s Common Stock.</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-style:italic;">Listing</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">The Company’s Common Stock is listed on The Nasdaq Stock Market LLC under the trading symbol “IMMU.”</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div> </div></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.9
<SEQUENCE>3
<FILENAME>immu201910k1231ex109.htm
<DESCRIPTION>EXHIBIT 10.9 LEASE AGREEMENT
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
<head>
<!-- Document created using Wdesk 1 -->
<!-- Copyright 2020 Workiva -->
<title>Exhibit</title>
</head>
<body><div style="font-family:Times New Roman;font-size:10pt;">
<div><a name="se7f6a401f583439a8e836974a53ee1fd"></a></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;padding-top:2px;text-align:center;padding-left:214px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;color:#2d2d2d;">LEASE AGREEMENT</font></div><div style="line-height:120%;padding-top:0px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:center;padding-left:260px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;color:#2d2d2d;">Between</font></div><div style="line-height:120%;padding-top:0px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:center;padding-left:178px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;color:#2d2d2d;">WU/LH 400 AMERICAN L.L.C.,</font></div><div style="line-height:120%;padding-top:0px;text-align:center;padding-left:252px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;color:#2d2d2d;">as Landlord</font></div><div style="line-height:120%;padding-top:0px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:center;padding-left:268px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;color:#2d2d2d;">-and-</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;padding-top:1px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;padding-top:1px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:center;padding-left:202px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;color:#2d2d2d;">IMMUNOMEDICS, INC.,</font></div><div style="line-height:120%;padding-top:0px;text-align:center;padding-left:260px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;color:#2d2d2d;">as Tenant</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;padding-top:2px;text-align:center;padding-left:220px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;padding-top:2px;text-align:center;padding-left:220px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div><br></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-top:2px;text-align:center;padding-left:220px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;color:#34363a;text-decoration:underline;">TABLE OF CONTENT</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;color:#34363a;">ARTICLE 1. DEFINITIONS ................</font><font style="font-family:inherit;font-size:12pt;color:#54565d;">.</font><font style="font-family:inherit;font-size:12pt;color:#34363a;">........................................................................................1</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;padding-top:1px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;color:#34363a;">ARTICLE 2. GRANTING CLAUSE .............................................................................................4</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;padding-top:1px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;color:#34363a;">ARTICLE 3. POSSESSION AND CONSTRUCTION .................................................................5</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;padding-top:1px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;color:#34363a;">ARTICLE 4. TENANT PAYMENTS ............................................................................................6</font></div><div style="line-height:120%;text-align:left;padding-left:6px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:6px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;color:#34363a;">ARTICLE 5. TENANT'S WORK ..............................................................................................13</font></div><div style="line-height:120%;text-align:left;padding-left:6px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:6px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;color:#34363a;">ARTICLE 6. USE OF TIIE PREMISES ....................................................................................15</font></div><div style="line-height:120%;text-align:left;padding-left:6px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:6px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;color:#34363a;">ARTICLE 7. COMMON FACILITIES .........</font><font style="font-family:inherit;font-size:12pt;color:#54565d;">.</font><font style="font-family:inherit;font-size:12pt;color:#34363a;">....................................</font><font style="font-family:inherit;font-size:12pt;color:#54565d;">.</font><font style="font-family:inherit;font-size:12pt;color:#34363a;">....</font><font style="font-family:inherit;font-size:12pt;color:#54565d;">.</font><font style="font-family:inherit;font-size:12pt;color:#34363a;">..................................17</font></div><div style="line-height:120%;text-align:left;padding-left:6px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:6px;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;color:#34363a;">    </font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;color:#34363a;">ARTICLE 8. UTILITIES.........................</font><font style="font-family:inherit;font-size:12pt;color:#54565d;">.</font><font style="font-family:inherit;font-size:12pt;color:#34363a;">..................................................................................18</font></div><div style="line-height:120%;text-align:left;padding-left:6px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:6px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;color:#34363a;">ARTICLE 9. LIENS ..........................................................</font><font style="font-family:inherit;font-size:12pt;color:#54565d;">.</font><font style="font-family:inherit;font-size:12pt;color:#34363a;">.........</font><font style="font-family:inherit;font-size:12pt;color:#54565d;">.</font><font style="font-family:inherit;font-size:12pt;color:#34363a;">..............................................19</font></div><div style="line-height:120%;text-align:left;padding-left:6px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:6px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;color:#34363a;">ARTICLE 10. MA</font><font style="font-family:inherit;font-size:12pt;color:#54565d;">IN</font><font style="font-family:inherit;font-size:12pt;color:#34363a;">TENANCE, REPAIR AND ALTERATIONS .........................................20</font></div><div style="line-height:120%;text-align:left;padding-left:6px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:6px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;color:#34363a;">ARTICLE 11. ENTRY, INSPECTION, POSTING AND DISPLAY........................................22</font></div><div style="line-height:120%;text-align:left;padding-left:6px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:6px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;color:#34363a;">ARTICLE 12. LAWS AND INSURANCE STANDARDS .......................................................23</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;color:#34363a;">ARTICLE 13. INDEMNIFICATION OF LANDLORD AND LIABILITY INSURANCE .......</font><font style="font-family:inherit;font-size:12pt;color:#54565d;">.</font><font style="font-family:inherit;font-size:12pt;color:#34363a;">...</font><font style="font-family:inherit;font-size:12pt;color:#54565d;">.</font><font style="font-family:inherit;font-size:12pt;color:#34363a;">.......</font><font style="font-family:inherit;font-size:12pt;color:#54565d;">.</font><font style="font-family:inherit;font-size:12pt;color:#34363a;">..</font><font style="font-family:inherit;font-size:12pt;color:#54565d;">.</font><font style="font-family:inherit;font-size:12pt;color:#34363a;">............................................................................................23</font></div><div style="line-height:120%;text-align:left;padding-left:53px;text-indent:-46px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:53px;text-indent:-46px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;color:#34363a;">ARTICLE 14. FIRE INSURANCE</font><font style="font-family:inherit;font-size:12pt;color:#54565d;">, </font><font style="font-family:inherit;font-size:12pt;color:#34363a;">DAMAGE AND DESTRUCTION ..................................27</font></div><div style="line-height:120%;text-align:left;padding-left:53px;text-indent:-46px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:53px;text-indent:-46px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;color:#34363a;">ARTICLE 15. EMINENT DOMAIN ..</font><font style="font-family:inherit;font-size:12pt;color:#54565d;">.</font><font style="font-family:inherit;font-size:12pt;color:#34363a;">......................................................................................31</font></div><div style="line-height:120%;padding-top:2px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;padding-top:2px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;color:#2f2f2f;">ARTICLE 16. FINANCIAL INFORMATION; STATEMENT OF TENANT; AMENDMENT TO LEASE..........................................................................................32</font></div><div style="line-height:120%;padding-top:2px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div><br></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;color:#2f2f2f;">ARTICLE 17. ASSIGNMENT, SUBLETTING AND HYPOTHECATION OF LEASE ........33</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;color:#2f2f2f;">ARTICLE 18. INTENTIONALLY DELETED .........................................................................42</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;color:#2f2f2f;">ARTICLE 19. SURRENDER OF PREMISES...........................................................................42</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;color:#2f2f2f;">ARTICLE 20. HOLDOVER BY TENANT ...............................................................................42</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;color:#2f2f2f;">ARTICLE 21. ADDITIONAL CONSTRUCTION ....................................................................42</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;color:#2f2f2f;">ARTICLE 22. DEFAULT; REMEDIES ....................................................................................43</font></div><div style="line-height:120%;text-align:left;padding-left:8px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:8px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;color:#2f2f2f;">ARTICLE 23. NO WAIVER ......................................................................................................48</font></div><div style="line-height:120%;text-align:left;padding-left:8px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:8px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;color:#2f2f2f;">ARTICLE 24. NOTICES............................................................................................................48</font></div><div style="line-height:120%;text-align:left;padding-left:8px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:8px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;color:#2f2f2f;">ARTICLE 25. SUBORDINATION AND ATTORNMENT........................................................49</font></div><div style="line-height:120%;text-align:left;padding-left:8px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:8px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;color:#2f2f2f;">ARTICLE 26. HAZARDOUS MATERIALS ...........................................................................50</font></div><div style="line-height:120%;text-align:left;padding-left:8px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:8px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;color:#2f2f2f;">ARTICLE 27. MISCELLANEOUS PROVISIONS ..................................................................53</font></div><div style="line-height:120%;text-align:left;padding-left:8px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:8px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;color:#2f2f2f;">ARTICLE 28. SECURITY DEPOSIT........................................................................................56</font></div><div style="line-height:120%;text-align:left;padding-left:8px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;color:#2f2f2f;">ARTICLE 29. RIGHT OF FIRST OFFER ................................................................................57</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;color:#2f2f2f;">ARTICLE 30. TENANT'S SINGLE RENEWAL OPTION ......................................................60</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;color:#2f2f2f;">ARTICLE 31. TENANT'S SELF-HELP ...................................................................................62</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;color:#2f2f2f;">ARTICLE 32. LANDORD'S REPRESENTATIONS ...............................................................62</font></div><div style="line-height:120%;padding-top:1px;text-align:center;padding-left:269px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;color:#2f2f2f;text-decoration:underline;">EXHIBITS</font></div><div style="line-height:120%;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div><br></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:2px;text-align:left;padding-left:188px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;padding-top:2px;text-align:left;padding-left:188px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;padding-top:2px;text-align:left;padding-left:188px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;padding-top:2px;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;padding-top:2px;text-align:center;padding-left:188px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;padding-top:2px;text-align:center;padding-left:188px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;padding-top:2px;text-align:center;padding-left:188px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;color:#2f343a;">Exhibit "A" </font><font style="font-family:inherit;font-size:12pt;">    </font><font style="font-family:inherit;font-size:12pt;color:#2f343a;">Site Plan</font></div><div style="line-height:120%;padding-top:0px;text-align:center;padding-left:188px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;color:#2f343a;">Exhibit "B" </font><font style="font-family:inherit;font-size:12pt;">    </font><font style="font-family:inherit;font-size:12pt;color:#2f343a;">Rules and Regulations</font></div><div style="line-height:120%;padding-top:0px;text-align:center;padding-left:188px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;color:#2f343a;">Exhibit "C" </font><font style="font-family:inherit;font-size:12pt;">    </font><font style="font-family:inherit;font-size:12pt;color:#2f343a;">Intentionally Deleted</font></div><div style="line-height:120%;padding-top:0px;text-align:center;padding-left:188px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;color:#2f343a;">Exhibit "D" </font><font style="font-family:inherit;font-size:12pt;">    </font><font style="font-family:inherit;font-size:12pt;color:#2f343a;">Tenant Move-In and Lease Renewal Environmental</font></div><div style="line-height:120%;padding-top:0px;text-align:center;padding-left:276px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;color:#2f343a;">Questionnaire</font></div><div style="line-height:120%;padding-top:0px;text-align:center;padding-left:188px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;color:#2f343a;">Exhibit "E" </font><font style="font-family:inherit;font-size:12pt;">    </font><font style="font-family:inherit;font-size:12pt;color:#2f343a;">Tenant Move-Out Environmental Questionnaire</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;padding-top:2px;text-align:center;padding-left:221px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;color:#262626;font-weight:bold;text-decoration:underline;">LEASE AGREEMENT</font></div><div style="line-height:120%;text-align:justify;padding-left:6px;text-indent:89px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:justify;padding-left:6px;text-indent:89px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;color:#262626;">INDENTURE made this </font><font style="font-family:inherit;font-size:12pt;color:#262626;text-decoration:underline;">27</font><font style="font-family:inherit;font-size:12pt;color:#262626;font-style:italic;"> </font><font style="font-family:inherit;font-size:12pt;color:#262626;">day of October 2017 (the "Effective Date"), by and between </font><font style="font-family:inherit;font-size:12pt;color:#262626;font-weight:bold;">WU/LH 400 AMERICAN L.L.C.</font><font style="font-family:inherit;font-size:12pt;color:#262626;">, a Delaware limited liability company, with offices c/o GTJ Management, LLC, 60 Hempstead Avenue, Suite 718, West Hempstead, NY 11552, hereinafter referred to as "</font><font style="font-family:inherit;font-size:12pt;color:#262626;text-decoration:underline;">Landlord"</font><font style="font-family:inherit;font-size:12pt;color:#262626;">, and </font><font style="font-family:inherit;font-size:12pt;color:#262626;font-weight:bold;">IMMUNOMEDICS, INC.,</font><font style="font-family:inherit;font-size:12pt;color:#262626;">  a Delaware corporation, with offices at 300 American Road, Morris Plains, New Jersey 07950, hereinafter referred to as "</font><font style="font-family:inherit;font-size:12pt;color:#262626;text-decoration:underline;">Tenant</font><font style="font-family:inherit;font-size:12pt;color:#262626;">".</font></div><div style="line-height:120%;text-align:justify;padding-left:6px;text-indent:89px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:center;padding-left:201px;text-indent:-2px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;color:#262626;">W IT N E S S E T H: </font></div><div style="line-height:120%;text-align:center;padding-left:201px;text-indent:-2px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:center;padding-left:201px;text-indent:-2px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;color:#262626;font-weight:bold;text-decoration:underline;">ARTICLE 1. DEFINITIONS</font></div><div style="line-height:120%;text-align:center;padding-left:201px;text-indent:-2px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:52px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;color:#262626;font-weight:bold;text-decoration:underline;">Section 1.1.</font><font style="font-family:inherit;font-size:12pt;color:#262626;"> </font><font style="font-family:inherit;font-size:12pt;">    </font><font style="font-family:inherit;font-size:12pt;color:#262626;text-decoration:underline;">Additional Rent</font><font style="font-family:inherit;font-size:12pt;color:#262626;">. In addition to the Minimum Rent, all other payments to</font></div><div style="line-height:120%;padding-top:0px;text-align:justify;padding-left:6px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;color:#262626;">be made by Tenant to Landlord, shall be deemed to be and shall become additional rent hereunder whether or not the same be designated as such (such amounts as may become due, collectively, "</font><font style="font-family:inherit;font-size:12pt;color:#262626;text-decoration:underline;">Additional Rent</font><font style="font-family:inherit;font-size:12pt;color:#262626;">"); and shall be due and payable within thirty (30) days following receipt of a reasonably detailed invoice therefor. Landlord shall have the same remedies for failure to pay Additional Rent as for a nonpayment of Minimum Rent. All payments required to be made by Tenant to Landlord pursuant to this Lease shall be delivered to the office of the Landlord at the address set forth on the first page of this Lease or at such place or places as Landlord may from time to time designate by notice to Tenant, all without prior demand for same.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:justify;padding-left:6px;text-indent:45px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;color:#262626;font-weight:bold;text-decoration:underline;">Section 1.2.</font><font style="font-family:inherit;font-size:12pt;color:#262626;font-weight:bold;">  </font><font style="font-family:inherit;font-size:12pt;color:#262626;">  </font><font style="font-family:inherit;font-size:12pt;color:#262626;text-decoration:underline;">Commencement Date</font><font style="font-family:inherit;font-size:12pt;color:#262626;text-decoration:underline;">   </font><font style="font-family:inherit;font-size:12pt;color:#262626;font-style:italic;text-decoration:underline;">I</font><font style="font-family:inherit;font-size:12pt;color:#262626;font-style:italic;text-decoration:underline;">  </font><font style="font-family:inherit;font-size:12pt;color:#262626;text-decoration:underline;">Expiration Date.</font><font style="font-family:inherit;font-size:12pt;color:#262626;">      A. As used herein, "</font><font style="font-family:inherit;font-size:12pt;color:#262626;text-decoration:underline;">Commencement Date</font><font style="font-family:inherit;font-size:12pt;color:#262626;">" shall mean the date of execution and delivery of this Lease and "</font><font style="font-family:inherit;font-size:12pt;color:#262626;text-decoration:underline;">Expiration Date</font><font style="font-family:inherit;font-size:12pt;color:#262626;">" shall mean October 31, 2031, unless the Lease Term shall sooner terminate pursuant to any of the terms, covenants or conditions of this Lease or pursuant to law.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:justify;padding-left:8px;text-indent:89px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;color:#262626;">B. If requested by either party, each of Landlord and Tenant agrees, upon such request, to execute, acknowledge and deliver to the other, an instrument, in form satisfactory to Landlord and Tenant, setting forth said Commencement Date and the Expiration Date.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:justify;padding-left:8px;text-indent:45px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;color:#262626;font-weight:bold;text-decoration:underline;">Section 1.3.</font><font style="font-family:inherit;font-size:12pt;color:#262626;font-weight:bold;"> </font><font style="font-family:inherit;font-size:12pt;color:#262626;">   </font><font style="font-family:inherit;font-size:12pt;color:#262626;text-decoration:underline;">Common Facilities</font><font style="font-family:inherit;font-size:12pt;color:#262626;">. As used herein shall mean all facilities furnished in the Industrial Center (as defined herein) and designated for the general use, in common, of all occupants of the Industrial Center, including the Tenant hereunder, its officers, agents, employees and customers. Common Facilities shall include, but are not limited to, parking areas, streets, sidewalks, canopies, roadways, washrooms, shelter, ramps, landscaped areas and other similar facilities.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:justify;padding-left:8px;text-indent:45px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;color:#262626;font-weight:bold;text-decoration:underline;">Section 1.4.</font><font style="font-family:inherit;font-size:12pt;color:#262626;">    </font><font style="font-family:inherit;font-size:12pt;color:#262626;text-decoration:underline;">Demised Premises</font><font style="font-family:inherit;font-size:12pt;color:#262626;">. As used herein shall mean approximately 45,654 aggre­ gate square feet consisting of approximately 31,726 square feet located on the ground floor the ("Ground Floor Space") and approximately 13,928 square feet located on mezzanine (the "Mezzanine Space") of the building commonly known as 400 American Road, American Enterprise Park, Morris Plains, New Jersey (the "</font><font style="font-family:inherit;font-size:12pt;color:#262626;text-decoration:underline;">Building"</font><font style="font-family:inherit;font-size:12pt;color:#262626;">), designated by cross-hatching on</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:16px;font-size:7pt;"><font style="font-family:inherit;font-size:7pt;"><br></font></div><div><br></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;padding-top:2px;text-align:justify;padding-left:6px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;padding-top:2px;text-align:justify;padding-left:6px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;padding-top:2px;text-align:justify;padding-left:6px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;color:#2a2a31;text-decoration:underline;">Exhibit A</font><font style="font-family:inherit;font-size:12pt;color:#2a2a31;"> attached hereto and made a part hereof. The Demised Premises do not include any exterior of the Building, or any space above the bottom of the structural framework supporting the roof or below the finished floor level of the area demised.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:justify;padding-left:6px;text-indent:45px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;color:#2a2a31;font-weight:bold;text-decoration:underline;">Section 1.5.</font><font style="font-family:inherit;font-size:12pt;color:#2a2a31;font-weight:bold;"> </font><font style="font-family:inherit;font-size:12pt;color:#2a2a31;font-weight:bold;">   </font><font style="font-family:inherit;font-size:12pt;color:#2a2a31;text-decoration:underline;">Industrial Center</font><font style="font-family:inherit;font-size:12pt;color:#2a2a31;">. As used herein, the Industrial Center shall mean the land depicted on </font><font style="font-family:inherit;font-size:12pt;color:#2a2a31;text-decoration:underline;">Exhibit A</font><font style="font-family:inherit;font-size:12pt;color:#2a2a31;"> attached hereto and by this reference incorporated herein and the Building and all related common areas and common facilities located thereon, less any deletion by Landlord pursuant hereto, plus such additions and extensions as Landlord may from time to time designate as included with the Industrial Center pursuant hereto. </font><font style="font-family:inherit;font-size:12pt;color:#2a2a31;text-decoration:underline;">Exhibit A</font><font style="font-family:inherit;font-size:12pt;color:#2a2a31;"> embodies the proposed outline of the Industrial Center of which the Demised Premises will be a part. Landlord may amend </font><font style="font-family:inherit;font-size:12pt;color:#2a2a31;text-decoration:underline;">Exhibit A</font><font style="font-family:inherit;font-size:12pt;color:#2a2a31;"> </font><font style="font-family:inherit;font-size:12pt;color:#2a2a31;">at any time and make such departures therefrom as Landlord in its sole discretion may from time to time deem proper, including the minor relocation of the Demised Premises as a result of construction.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:justify;padding-left:6px;text-indent:45px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;color:#2a2a31;font-weight:bold;text-decoration:underline;">Section 1.6.</font><font style="font-family:inherit;font-size:12pt;color:#2a2a31;font-weight:bold;">    </font><font style="font-family:inherit;font-size:12pt;color:#2a2a31;text-decoration:underline;">Lease Term</font><font style="font-family:inherit;font-size:12pt;color:#2a2a31;">. The initial Lease Term shall be approximately fourteen (14) Lease Years, commencing on the Commencement Date, and ending, unless extended or sooner terminated pursuant to any of the terms, covenants or conditions of the Lease or pursuant to law, at midnight on October 31, 2031 (the "</font><font style="font-family:inherit;font-size:12pt;color:#2a2a31;text-decoration:underline;">Initial Lease Term</font><font style="font-family:inherit;font-size:12pt;color:#2a2a31;">" and together with any Renewal Term, the "</font><font style="font-family:inherit;font-size:12pt;color:#2a2a31;text-decoration:underline;">Lease Term</font><font style="font-family:inherit;font-size:12pt;color:#2a2a31;">").</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:justify;padding-left:6px;text-indent:44px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;color:#2a2a31;font-weight:bold;text-decoration:underline;">Section 1.7.</font><font style="font-family:inherit;font-size:12pt;color:#2a2a31;font-weight:bold;">    </font><font style="font-family:inherit;font-size:12pt;color:#2a2a31;text-decoration:underline;">Lease Year.</font><font style="font-family:inherit;font-size:12pt;color:#2a2a31;">   Shall mean each period of twelve (12) consecutive months during the Lease Term commencing on the Commencement Date, except that the first Lease Year shall be extended by the number of days, if any, required for said first Lease Year to end on the last day of a calendar month. For example, if the Commencement Date is August 15,2017, the first Lease Year shall commence upon such date, the second Lease Year shall commence upon September 1, 2018 and so on.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:53px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;color:#2a2a31;font-weight:bold;text-decoration:underline;">Section 1.8.</font><font style="font-family:inherit;font-size:12pt;color:#2a2a31;font-weight:bold;"> </font><font style="font-family:inherit;font-size:12pt;">    </font><font style="font-family:inherit;font-size:12pt;color:#2a2a31;text-decoration:underline;">Minimum Rent</font><font style="font-family:inherit;font-size:12pt;color:#2a2a31;">.</font></div><div style="line-height:120%;text-align:justify;padding-left:6px;text-indent:89px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;color:#2a2a31;">A. The annual Minimum Rent for the Initial Term is shown on Schedule "1" annexed hereto and made a part hereof and, subject to the provisions of Section l.C. below, shall be payable commencing on the Rent Commencement Date with respect to the Ground Floor Space and the Complete Rent Commencement Date with respect to the Mezzanine Space.</font></div><div style="line-height:120%;padding-top:1px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:justify;padding-left:6px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;color:#2a2a31;">B. Tenant covenants and agrees to pay to Landlord the Minimum Rent, determined in accordance with this Section 1.8, in advance on the first day of each calendar month during the Lease Term, in equal monthly installments as set forth in Subsection A above, without deduction or set-off except as expressly set forth herein. In the event that the Complete Rent Commencement Date shall occur on a date other than the first (1st) day of any calendar month, Tenant shall pay to Landlord, on the first (1st) day of the month next succeeding the month during which the Complete Rent Commencement Date shall occur, a sum equal to the pro-rata amount applicable to the period from the Complete Rent Commencement Date to the last day of the calendar month in which the Complete Rent Commencement Date shall occur. Such payment, together with the sum paid by Tenant upon the execution of this Lease, shall constitute payment of the Minimum Rent for the period from the Complete Rent Commencement Date to and including the last day of the next succeeding calendar month.</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div><br></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;padding-top:2px;text-align:justify;padding-left:6px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;padding-top:2px;text-align:justify;padding-left:6px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;padding-top:2px;text-align:justify;padding-left:6px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;color:#242424;">C. Provided Tenant is not then in default in the observance and performance of any of the terms, covenants and conditions of this Lease on Tenant's part to be observed and performed beyond applicable notice and cure periods, then Tenant shall be entitled to a conditional rent holiday, and not be required to pay, the Minimum Rent otherwise due during each month in the period (the "</font><font style="font-family:inherit;font-size:12pt;color:#242424;text-decoration:underline;">Rent Holiday Period"</font><font style="font-family:inherit;font-size:12pt;color:#242424;">) commencing on the Commencement Date and ending on the day immediately preceding the twelfth (12th) month anniversary of the Commencement Date, both dates inclusive. The date next following the expiration of the Rent Holiday Period is referred to as the "</font><font style="font-family:inherit;font-size:12pt;color:#242424;text-decoration:underline;">Rent Commencement Date</font><font style="font-family:inherit;font-size:12pt;color:#242424;">". During such period, Tenant shall otherwise be required to comply with all of the other terms, covenants and conditions of this Lease on Tenant's part to be observed and performed, including, but not limited to, the obligation to make all payments pursuant to Article 4 hereof. In addition, subject to the terms and provisions of the last sentence of this subdivision C., provided Tenant is not then in default in the observance and performance of any of the terms, covenants and conditions of this Lease on Tenant's part to be observed and performed beyond applicable notice and cure periods, then Tenant shall be entitled to a conditional rent holiday, and not be required to pay, the Minimum Rent with respect to the Mezzanine Space otherwise due during each month in the period (the "</font><font style="font-family:inherit;font-size:12pt;color:#242424;text-decoration:underline;">Additional Rent Holiday Period</font><font style="font-family:inherit;font-size:12pt;color:#242424;">") commencing on the Rent Commencement Date and ending on day immediately preceding the twelfth (12th) month anniversary of the Rent Commencement Date, both dates inclusive. The date next following the expiration of the Additional Rent Holiday Period is referred to as the "</font><font style="font-family:inherit;font-size:12pt;color:#242424;text-decoration:underline;">Complete Rent Commencement Date</font><font style="font-family:inherit;font-size:12pt;color:#242424;">". If at any time during the Lease Term, Tenant shall be in default in the observance and performance of any of the terms, covenants and conditions of this Lease on Tenant's part to be observed and performed beyond applicable notice and cure periods, then the total unamortized sum of the Minimum Rent so conditionally excused by operation of the foregoing provisions of this Subsection C shall become immediately due and payable by Tenant to Landlord. If, as of the Expiration Date, Tenant shall not then be in default in the observance and performance of any of the terms, covenants and conditions of this Lease on Tenant's part to be observed and performed, Landlord shall waive payment of all such Minimum Rent so conditionally excused.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:justify;padding-left:8px;text-indent:45px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;color:#242424;font-weight:bold;text-decoration:underline;">Section 1.9.</font><font style="font-family:inherit;font-size:12pt;color:#242424;font-weight:bold;">     </font><font style="font-family:inherit;font-size:12pt;color:#242424;text-decoration:underline;">Permitted Use.</font><font style="font-family:inherit;font-size:12pt;color:#242424;">     Tenant shall use the Demised Premises solely for biopharmaceutical research and development, the manufacture of biopharmaceutical and other pharmaceutical products, for general office and business use including selling, warehousing and distribution and for other activities normally associated with the operation of a biopharmaceutical business.</font></div><div style="line-height:120%;padding-top:1px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;padding-top:1px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:justify;padding-left:8px;text-indent:45px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;color:#242424;font-weight:bold;text-decoration:underline;">Section 1.10.</font><font style="font-family:inherit;font-size:12pt;color:#242424;font-weight:bold;">   </font><font style="font-family:inherit;font-size:12pt;color:#242424;text-decoration:underline;">Real Estate Taxes.</font><font style="font-family:inherit;font-size:12pt;color:#242424;">    As used herein shall mean all real estate taxes, assessments, water and sewer rents or charges and other governmental impositions and charges of every kind and nature whatsoever, extraordinary as well as ordinary, foreseen and unforeseen, and each and every installment thereof, which shall or may during the Lease Term be assessed, imposed, become due and payable or be levied by the lawful taxing authorities against the land, buildings and all other improvements in the Industrial Center, or liens upon or arising in connection with the use or occupancy or possession of, or becoming due or payable out of or for, the Industrial Center or any part thereof or any land, buildings or other improvements therein, including all commercially reasonable costs and fees incurred by Landlord in contesting same or in negotiating with the appropriate governmental authorities as to same.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div><br></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;padding-top:2px;text-align:justify;padding-left:6px;text-indent:90px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;color:#2a2a31;">Except as otherwise set forth in the immediately succeeding paragraph of this Section 1.10, nothing herein contained shall be construed to include as a Real Estate Tax any inheri­ tance, estate, succession, transfer, gift, franchise, corporation, income or profit tax that is or may be imposed upon Landlord; provided, however, that, if at any time during the Lease Term the methods of taxation prevailing at the commencement of the Lease Term shall be altered so that in lieu of or as a substitute for the whole or any part of the taxes now levied, assessed or imposed, there shall be levied, assessed or imposed an income or other tax of whatever nature, then the same shall be included in the computation of Real Estate Taxes hereunder. As used in this Lease, the term "Tenant's Pro-rata Share of Complex Operating Costs" shall include any excise, transaction, sales or privilege tax hereafter imposed by any government or governmental agency upon Landlord on account of, attributed to, or measured by rent or other charges payable by Tenant, or levied by reason of the public parking made available by Landlord in the Industrial Center. Tenant shall not have the right to contest the amount or application of any Real Estate Taxes with any governmental authority.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:justify;padding-left:6px;text-indent:45px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;color:#2a2a31;font-weight:bold;text-decoration:underline;">Section 1.11.</font><font style="font-family:inherit;font-size:12pt;color:#2a2a31;">  </font><font style="font-family:inherit;font-size:12pt;color:#2a2a31;text-decoration:underline;">Tenant's Pro-rata Share.</font><font style="font-family:inherit;font-size:12pt;color:#2a2a31;"> As used herein shall mean a fraction, the numerator of which shall be the gross rentable area of the Demised Premises and the denominator of which shall be the gross rentable area of all buildings in the Industrial Center. As of the Commencement Date, Tenant's Pro-rata Share shall be 46.7216%. Notwithstanding anything to the contrary contained herein, Landlord has agreed that for the period from the Commencement Date to and including the Complete Rent Commencement Date, Tenant shall not be required to pay Tenant's Pro-rata Share of Real Estate Taxes nor Tenant's Pro-rata Share of Complex Operating Costs with respect to the Mezzanine Space unless Tenant occupies or stores any materials in the Mezzanine Space in which case, from and after the date that Tenant occupies the Mezzanine Space, Tenant shall be required to pay Tenant's Pro-rata Share of Real Estate Taxes and Tenant's Pro-rata Share of Complex Operating Costs with respect to the Mezzanine Space. Accordingly, provided that Tenant does not occupy or store any materials in the Mezzanine Space during the Additional Rent Holiday Period, Tenant's Pro-rata Share shall be reduced to 32.4679% during the Additional Rent Holiday Period.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:center;padding-left:177px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;color:#2a2a31;font-weight:bold;text-decoration:underline;">ARTICLE 2. GRANTING CLAUSE</font></div><div style="line-height:120%;padding-top:1px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:justify;padding-left:6px;text-indent:45px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;color:#2a2a31;font-weight:bold;text-decoration:underline;">Section 2.1.</font><font style="font-family:inherit;font-size:12pt;color:#2a2a31;font-weight:bold;"> </font><font style="font-family:inherit;font-size:12pt;color:#2a2a31;">    </font><font style="font-family:inherit;font-size:12pt;color:#2a2a31;text-decoration:underline;">Lease of Demised Premises</font><font style="font-family:inherit;font-size:12pt;color:#2a2a31;">. In consideration of the obligation of Tenant to pay rent as herein provided and in consideration of the other terms, covenants and conditions hereof, Landlord hereby leases and rents to Tenant</font><font style="font-family:inherit;font-size:12pt;color:#545660;">, </font><font style="font-family:inherit;font-size:12pt;color:#2a2a31;">and Tenant hereby leases and rents from Landlord, the Demised Premises TO HAVE AND TO HOLD said Demised Premises for the Lease Term.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:center;padding-left:122px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;color:#2a2a31;font-weight:bold;text-decoration:underline;">ARTICLE 3. POSSESSION AND CONSTRUCTION</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:justify;padding-left:8px;text-indent:45px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;color:#2a2a31;font-weight:bold;text-decoration:underline;">Section 3.1.</font><font style="font-family:inherit;font-size:12pt;color:#2a2a31;font-weight:bold;"> </font><font style="font-family:inherit;font-size:12pt;color:#2a2a31;">    </font><font style="font-family:inherit;font-size:12pt;color:#2a2a31;text-decoration:underline;">Demise Includes Use of Common Facilities.</font><font style="font-family:inherit;font-size:12pt;color:#2a2a31;">    The demise to Tenant shall include, in addition to the Demised Premises</font><font style="font-family:inherit;font-size:12pt;color:#545660;">, </font><font style="font-family:inherit;font-size:12pt;color:#2a2a31;">the right to the nonexclusive use in common with others of the Common Facilities, subject, however</font><font style="font-family:inherit;font-size:12pt;color:#545660;">, </font><font style="font-family:inherit;font-size:12pt;color:#2a2a31;">to the terms and conditions of this Lease and to the rules and regulations set forth in </font><font style="font-family:inherit;font-size:12pt;color:#2a2a31;text-decoration:underline;">Exhibit B</font><font style="font-family:inherit;font-size:12pt;color:#2a2a31;"> which is attached hereto and made a part hereof.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:justify;padding-left:8px;text-indent:44px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;color:#2a2a31;font-weight:bold;text-decoration:underline;">Section 3.2.</font><font style="font-family:inherit;font-size:12pt;color:#2a2a31;">     </font><font style="font-family:inherit;font-size:12pt;color:#2a2a31;text-decoration:underline;">Quiet Enjoyment</font><font style="font-family:inherit;font-size:12pt;color:#2a2a31;">. Tenant</font><font style="font-family:inherit;font-size:12pt;color:#545660;">, </font><font style="font-family:inherit;font-size:12pt;color:#2a2a31;">upon paying the rent and performing Tenant's obligations in this Lease, shall peacefully and quietly have</font><font style="font-family:inherit;font-size:12pt;color:#545660;">, </font><font style="font-family:inherit;font-size:12pt;color:#2a2a31;">hold and enjoy the Demised Premises</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;padding-top:2px;text-align:left;padding-left:8px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div><br></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;padding-top:2px;text-align:justify;padding-left:6px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;color:#262626;">and the appurtenances thereunto appertaining throughout the Lease Term, subject, however, to the provisions of this Lease, to all other agreements, conditions, restrictions and encumbrances and mortgages to which this Lease is subject and subordinate.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:justify;padding-left:8px;text-indent:44px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;color:#262626;font-weight:bold;text-decoration:underline;">Section 3.3.</font><font style="font-family:inherit;font-size:12pt;color:#262626;">    </font><font style="font-family:inherit;font-size:12pt;color:#262626;text-decoration:underline;">Industrial Center</font><font style="font-family:inherit;font-size:12pt;color:#262626;">. Tenant acknowledges that </font><font style="font-family:inherit;font-size:12pt;color:#262626;text-decoration:underline;">Exhibit A</font><font style="font-family:inherit;font-size:12pt;color:#262626;"> attached hereto is a site plan which generally depicts the layout of the Industrial Center.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:53px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;color:#262626;font-weight:bold;text-decoration:underline;">Section 3.4.</font><font style="font-family:inherit;font-size:12pt;color:#262626;font-weight:bold;"> </font><font style="font-family:inherit;font-size:12pt;">    </font><font style="font-family:inherit;font-size:12pt;color:#262626;text-decoration:underline;">No Preparation of Demised Premises by Landlord.</font></div><div style="line-height:120%;padding-top:1px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:justify;padding-left:8px;text-indent:89px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;color:#262626;">A. Tenant shall take possession of the Demised Premises on the Commencement Date in a strictly "as is", "where is" condition, and Landlord shall have no obligation to alter, improve, decorate or otherwise prepare the Demised Premises for Tenant's occupancy. The taking of possession of the Demised Premises by Tenant shall be deemed a delivery of the Demised Premises by Landlord and an absolute and unconditional acceptance of same by Tenant provided, however, nothing contained in this subdivision shall limit Landlord's obligations to make structural repairs pursuant to Article 10.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:justify;padding-left:8px;text-indent:89px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;color:#262626;">B. The parties agree that Tenant shall be solely responsible for performing any alteration or other work necessary or desired by Tenant for its occupancy of the Demised Premises.</font></div><div style="line-height:120%;padding-top:1px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:justify;padding-left:8px;text-indent:90px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;color:#262626;">C. Landlord has made no representations, warranties or promises with respect to this Lease, to the Demised Premises, to any fixtures, equipment or other property therein or to any matter related thereto, whether express or implied and Tenant acknowledges that it has not relied upon any representations, warranties or promises, whether from Landlord or from any of Landlord's employees, agents or representatives. ALL IMPLIED WARRANTIES ARE EXCLUDED, INCLUDING IMPLIED WARRANTIES OF MERCHANTABILITY AND FITNESS, IF ANY. Tenant waives any right to rescind this Lease under the laws of the State of New Jersey and further waives any damages which may result from any lack of completion of the Demised Premises.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:justify;padding-left:8px;text-indent:45px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;color:#262626;font-weight:bold;text-decoration:underline;">Section 3.5</font><font style="font-family:inherit;font-size:12pt;color:#262626;">. </font><font style="font-family:inherit;font-size:12pt;color:#262626;"> </font><font style="font-family:inherit;font-size:12pt;color:#262626;text-decoration:underline;">Initial Tenant's Work</font><font style="font-family:inherit;font-size:12pt;color:#262626;">. Tenant shall, following the Commencement Date, have the right to perform all work necessary to prepare the Demised Premises for Tenant's occupancy (the "</font><font style="font-family:inherit;font-size:12pt;color:#262626;text-decoration:underline;">Initial Tenant's Work</font><font style="font-family:inherit;font-size:12pt;color:#262626;">") at its sole cost, expense and risk in accordance with plans and specifications therefor which shall be subject to Landlord's approval, such approval not to be unreasonably withheld, conditioned or delayed; provided, however, that Tenant shall make any changes in Tenant's Initial Work required by any governmental department or bureau having jurisdiction of the Center and Landlord's approval shall not be required with respect to any such changes. The Initial Tenant's Work shall be performed by Tenant in full compliance with the terms, provisions of conditions set forth below in Article 5.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:178px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;color:#262626;font-weight:bold;text-decoration:underline;">ARTICLE 4. TENANT PAYMENTS</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:justify;padding-left:9px;text-indent:45px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;color:#262626;font-weight:bold;">Section 4.1. </font><font style="font-family:inherit;font-size:12pt;color:#262626;text-decoration:underline;">Tenant's Obligations To Pay Minimum Rent and Other Charges</font><font style="font-family:inherit;font-size:12pt;color:#262626;">. During the Lease Term, Tenant shall pay to Landlord without any prior demand and without any deduction or set-off whatsoever (except as expressly set forth herein), Minimum Rent in the manner hereinafter set forth. In addition to Tenant's obligation to pay Minimum Rent, Tenant shall pay any tax, whether a sales tax or otherwise, which is or shall be imposed on Tenant's payment of</font></div><div><br></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;padding-top:2px;text-align:justify;padding-left:8px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;color:#2d2f36;">rent hereunder. Tenant further covenants and agrees to pay, as set forth below, Tenant's Pro-rata Share of Complex Operating Costs and Tenant's Pro-rata Share of Real Estate Taxes, both of which are included within the term "</font><font style="font-family:inherit;font-size:12pt;color:#2d2f36;text-decoration:underline;">Additional Rent"</font><font style="font-family:inherit;font-size:12pt;color:#2d2f36;">. The obligations of Landlord and Tenant under the provisions of this Article with respect to (i) the payment by Tenant of Minimum Rent and Additional Rent, including, without limitation, any deficiencies with respect to previous payments by Tenant on account of Tenant's Pro-rata Share of Complex Operating Costs or Tenant's Pro-rata Share of Real Estate Taxes, or (ii) any credit to which Tenant may be entitled on account of such aforesaid previous payments, shall survive the expiration or any sooner termination of the Lease Term</font><font style="font-family:inherit;font-size:12pt;color:#46464b;">.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:53px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;color:#2d2f36;font-weight:bold;text-decoration:underline;">Section 4.2.</font><font style="font-family:inherit;font-size:12pt;color:#2d2f36;font-weight:bold;"> </font><font style="font-family:inherit;font-size:12pt;">    </font><font style="font-family:inherit;font-size:12pt;color:#2d2f36;text-decoration:underline;">Intentionally Omitted</font><font style="font-family:inherit;font-size:12pt;color:#2d2f36;">.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:53px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;color:#2d2f36;font-weight:bold;text-decoration:underline;">Section 4.3.</font><font style="font-family:inherit;font-size:12pt;color:#2d2f36;font-weight:bold;"> </font><font style="font-family:inherit;font-size:12pt;">    </font><font style="font-family:inherit;font-size:12pt;color:#2d2f36;text-decoration:underline;">Intentionally Omitted.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:justify;padding-left:8px;text-indent:45px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;color:#2d2f36;font-weight:bold;text-decoration:underline;">Section 4.4</font><font style="font-family:inherit;font-size:12pt;color:#2d2f36;font-weight:bold;">. </font><font style="font-family:inherit;font-size:12pt;color:#2d2f36;text-decoration:underline;">Tenant's Pro-rata Share of Complex Operating Costs</font><font style="font-family:inherit;font-size:12pt;color:#46464b;">. </font><font style="font-family:inherit;font-size:12pt;color:#2d2f36;">Commencing with </font><font style="font-family:inherit;font-size:12pt;color:#46464b;">th</font><font style="font-family:inherit;font-size:12pt;color:#2d2f36;">e Commencement Date, and continuing thereafter during the Lease Term, Tenant will pay to Landlord, Tenant's Pro-rata Share of Landlord's operating cost of the Common Facilities ("</font><font style="font-family:inherit;font-size:12pt;color:#2d2f36;text-decoration:underline;">Tenant</font><font style="font-family:inherit;font-size:12pt;color:#46464b;text-decoration:underline;">'</font><font style="font-family:inherit;font-size:12pt;color:#2d2f36;text-decoration:underline;">s Pro-rata Share of Complex Operating Costs</font><font style="font-family:inherit;font-size:12pt;color:#2d2f36;">")</font><font style="font-family:inherit;font-size:12pt;color:#46464b;">. </font><font style="font-family:inherit;font-size:12pt;color:#2d2f36;">Tenant</font><font style="font-family:inherit;font-size:12pt;color:#46464b;">'</font><font style="font-family:inherit;font-size:12pt;color:#2d2f36;">s Pro-rata Share of Complex Operating costs shall be a monthly charge to be paid in advance, on the first day of each month, without deduction or set-off(except as expressly set forth herein)</font><font style="font-family:inherit;font-size:12pt;color:#46464b;">. </font><font style="font-family:inherit;font-size:12pt;color:#2d2f36;">Tenant's initial Pro-rata Share of Complex Operating Costs shall be estimated by Landlord and the amount of such estimate shall be furnished to Tenant on or about the Commencement Date. Within one hundred twenty (120) days after the end of each calendar year of the Lease Term, Landlord will furnish to Tenant a statement (the "Operating Costs Statement") of the amount of Landlord's operating costs of the Common Facilities for the immediately preceding Calendar year, Landlord's estimate of Landlord's cost of operating the Common Facilities for the then calendar year and Tenant's Pro­ rata Share of Complex Operating Costs for the then calendar year</font><font style="font-family:inherit;font-size:12pt;color:#46464b;">. </font><font style="font-family:inherit;font-size:12pt;color:#2d2f36;">Tenant shall pay any deficiency in Tenant's Pro-rata Share of Complex Operating Costs with respect to both the preceding calendar year and the then calendar year (as a result of any delay in adjusting the monthly Tenant's Pro-rata Share of Complex Operating Costs for the then calendar year) within thirty (30) days after Landlord sends the Operating Costs Statement to Tenant. Landlord may increase the monthly payment of Tenant's Pro-rata Share of Complex Operating Costs to compensate for increased expenses including, but not limited to, snow removal during periods of unusual snow fall. Landlord shall credit any excess payments made by Tenant against the next regular installment of Tenant's Pro-rata Share of Complex Operating Costs. Nothing herein shall prevent Landlord from making retroactive adjustments to Tenant's Pro-rata Share of Complex Operating Costs in the event that errors are discovered with respect to such calculations for past calendar years.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:justify;padding-left:6px;text-indent:89px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;color:#2d2f36;">Tenant's Pro-rata Share of Complex Operating Costs shall be based on the cost and expense of operating, maintaining and managing the Common Facilities in a manner deemed by Landlord reasonable and appropriate and for the best interest of the Industrial Center, including without limitation:</font></div><div style="line-height:120%;padding-top:1px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:justify;padding-left:6px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;color:#2d2f36;">(a) All costs and expenses, including capital expenses (the cost of each capital expense, plus interest charges paid thereon, shall be amortized on a straight-line basis over its estimated useful life and only the annual amortization cost of such capital expense shall be included in Tenant</font><font style="font-family:inherit;font-size:12pt;color:#46464b;">'</font><font style="font-family:inherit;font-size:12pt;color:#2d2f36;">s Pro-rata Share of Complex Operating Costs for each calendar year until the cost of such</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div><br></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;padding-top:2px;text-align:justify;padding-left:6px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;color:#282828;">capital expense is fully amortized), of operating, repairing, lighting, cleaning, painting, striping, securing (including cost of uniforms, equipment and all employment taxes) and insuring (including liability insurance for personal injury, umbrella coverage, death and property damage, insurance and extended coverage against fire, theft or other casualty, worker's compensation insurance covering personnel, fidelity bonds for personnel, insurance against liability for defamation and claims of false arrest occurring in or about the Common Facilities, and plate glass insurance for glass exclusively serving the Common Facilities) the Common Facilities;</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:justify;padding-left:6px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;color:#282828;">(b) All costs and expenses incurred by Landlord in making the Landlord's Repairs as set forth in Section 10.1 hereof;</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:justify;padding-left:6px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;color:#282828;">(c) All costs and expenses of paying all personnel employed on a full or part-time basis in the operation, maintenance or repair of the Common Facilities;</font></div><div style="line-height:120%;text-align:justify;padding-left:6px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:8px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:6px;"><font style="font-family:inherit;font-size:12pt;color:#282828;">(d) </font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;color:#282828;">All costs and expenses of removal of rubbish and debris; </font></div></td></tr></table><div style="line-height:120%;text-align:left;padding-left:8px;text-indent:-2px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:justify;padding-left:6px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;color:#282828;">(e)     All costs and expenses of regulating traffic;</font></div><div style="line-height:120%;text-align:justify;padding-left:6px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:justify;padding-left:6px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;color:#282828;">(f) All costs and expenses of inspecting and depreciation on (straight-line) machinery and equipment used in the operation and maintenance of the Common Facilities and personal property taxes and other charges incurred in connection with such equipment;</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:justify;padding-left:8px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;color:#282828;">(g) All costs and expenses of the maintenance and replacement of paving, curbs, walkways, drainage and lighting facilities in the Common Facilities including, without limitation, a reserve equal to eight percent (8%) of the estimated cost for resurfacing the parking area;</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:justify;padding-left:8px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;color:#282828;">(h) All costs and expenses of planting, replanting and replacing flowers, shrubbery and planters in the Common Facilities and the supplies required therefor;</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:justify;padding-left:8px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;color:#282828;">(i) All costs and expenses in the maintenance and replacement of the built-up roof system and all items in connection therewith, including but not limited to, flashing, expansion joints, pitch boxes, curbs, gutters, leaders and skylights;</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:justify;padding-left:8px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;color:#282828;">(j) The cost of all utilities, including the cost of standby water for fire protection, used in connection with the operation of the Common Facilities;</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:justify;padding-left:8px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;color:#282828;">(k) The cost of snow and ice removal from the Common Facilities;</font></div><div style="line-height:120%;padding-top:1px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:justify;padding-left:8px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;color:#282828;">(1) The cost of property management services incurred by Landlord; and</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:justify;padding-left:8px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;color:#282828;">(m) The cost of compliance with laws including, but not limited to, energy management systems and/or other costs and expenditures pursuant to Leadership in Energy and Environmental Design ("LEED") compliance.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:justify;padding-left:8px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;color:#282828;">Notwithstanding anything to the contrary contained herein, the following items are excluded from</font></div><div style="line-height:120%;padding-top:0px;text-align:justify;padding-left:8px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;color:#282828;">Complex Operating Costs:</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:2px;text-align:justify;padding-left:8px;text-indent:120px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;color:#2f3138;">(i) the cost of any work performed (such as preparing a tenant's space for occupancy, including painting and decorating) or services provided (such as separately metered electricity) for any tenant (including Tenant) at such tenant's cost, or provided by Landlord without charge as an inducement to lease (such as free rent or improvement allowances);</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:125px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;color:#2f3138;">(ii) </font><font style="font-family:inherit;font-size:12pt;">    </font><font style="font-family:inherit;font-size:12pt;color:#2f3138;">the cost of correcting defects in construction;</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:justify;padding-left:8px;text-indent:112px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;color:#2f3138;">(iii) salaries of Landlord's officers and partners, its Building engineer and its headquarters staff;</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:justify;padding-left:8px;text-indent:112px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;color:#2f3138;">(iv) the cost of any work performed or service provided for any tenant of the Building (other than Tenant) to a materially greater extent or in a materially more favorable manner than that furnished generally to the other tenants and occupants (such as electricity and cleaning services provided to retail tenants);</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:126px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;color:#2f3138;">(v) </font><font style="font-family:inherit;font-size:12pt;">    </font><font style="font-family:inherit;font-size:12pt;color:#2f3138;">the cost of any work performed or service provided (such as electricity)</font></div><div style="line-height:120%;padding-top:0px;text-align:left;padding-left:8px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;color:#2f3138;">for any facility other than the Building (such as a garage) for which fees are charged;</font></div><div style="line-height:120%;padding-top:1px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:justify;padding-left:8px;text-indent:113px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;color:#2f3138;">(vi) the cost of any items for which Landlord is reimbursed by insurance proceeds, condemnation awards, a tenant of the Industrial Center, or otherwise;</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:117px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;color:#2f3138;">(vii) </font><font style="font-family:inherit;font-size:12pt;">    </font><font style="font-family:inherit;font-size:12pt;color:#2f3138;">the cost of any additions to the Industrial Center, or Complex Operating</font></div><div style="line-height:120%;padding-top:0px;text-align:left;padding-left:8px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;color:#2f3138;">Costs generated by such additions, after the date of this Lease;</font></div><div style="line-height:120%;padding-top:1px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:justify;padding-left:8px;text-indent:110px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;color:#2f3138;">(viii) the cost of any repairs, alterations, additions, changes, replacements and the like which under generally accepted accounting principles are properly classified as capital expenditures;</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:121px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;color:#2f3138;">(ix) </font><font style="font-family:inherit;font-size:12pt;">    </font><font style="font-family:inherit;font-size:12pt;color:#2f3138;">the cost of any repair made in accordance with Articles 14 and 15 of this</font></div><div style="line-height:120%;padding-top:0px;text-align:left;padding-left:8px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;color:#2f3138;">Lease entitled "Damage or Destruction" and "Condemnation";</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:justify;padding-left:8px;text-indent:117px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;color:#2f3138;">(x) insurance premiums to the extent any tenant causes Landlord's existing insurance premiums to increase or requires Landlord to purchase additional insurance;</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:justify;padding-left:8px;text-indent:113px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;color:#2f3138;">(xi) interest and principal payments on any debt, depreciation and rental under any ground lease or other underlying lease;</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:justify;padding-left:8px;text-indent:109px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;color:#2f3138;">(xii) any real estate brokerage comrmss1ons or other cost incurred m procuring tenants, or any fee in lieu of commission;</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:113px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;color:#2f3138;">(xiii) </font><font style="font-family:inherit;font-size:12pt;">    </font><font style="font-family:inherit;font-size:12pt;color:#2f3138;">any advertising expenses;</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:justify;padding-left:8px;text-indent:105px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;color:#2f3138;">(xiv) any costs representing an amount paid to a related or affiliated person of Landlord which is in excess of the amount which would have been paid in the absence of such relationship:</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:justify;padding-left:8px;text-indent:110px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;color:#2f3138;">(xv) payments for rented equipment, the cost of which equipment would constitute a capital expenditure if the equipment were purchased;</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div><br></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;padding-top:2px;text-align:justify;padding-left:6px;text-indent:106px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;padding-top:2px;text-align:justify;padding-left:6px;text-indent:106px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;color:#262626;">(xvi) any expenses for repairs or maintenance which are covered by warranties, guaranties or service contracts (excluding any mandatory deductibles);</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:justify;padding-left:6px;text-indent:101px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;color:#262626;">(xvii) legal expenses arising out of the construction, operation, use, occupation or maintenance of the Industrial Center, or the enforcement of the provisions of any agreements affecting the Industrial Center, including this Lease;</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:105px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;color:#262626;">(xviii) </font><font style="font-family:inherit;font-size:12pt;">    </font><font style="font-family:inherit;font-size:12pt;color:#262626;">franchise taxes or income taxes of Landlord;</font></div><table cellpadding="0" cellspacing="0" style="padding-top:3px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:117px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:112px;"><font style="font-family:inherit;font-size:12pt;color:#262626;">(xix) </font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;color:#262626;">refinancing costs and mortgage interest and amortization payments; (xx)</font><font style="font-family:inherit;font-size:12pt;">    </font><font style="font-family:inherit;font-size:12pt;color:#262626;">cost of abating, removing, testing for or treating any environmental</font></div></td></tr></table><div style="line-height:120%;text-align:left;padding-left:6px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;color:#262626;">condition in the Demised Premises, Building or the Industrial Center unless such condition was</font></div><div style="line-height:120%;padding-top:0px;text-align:left;padding-left:6px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;color:#262626;">caused by Tenant;</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:justify;padding-left:6px;text-indent:105px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;color:#262626;">(xxi) the cost of any work for which Landlord is fully reimbursed by another tenant of the Industrial Center; and</font></div><div style="line-height:120%;padding-top:1px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:6px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;color:#262626;">any costs that are reimbursed or refunded to Landlord pursuant to any warranty or insurance policy concerning the Industrial Center.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:justify;padding-left:6px;text-indent:45px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;color:#262626;font-weight:bold;text-decoration:underline;">Section 4.5.</font><font style="font-family:inherit;font-size:12pt;color:#262626;font-weight:bold;">    </font><font style="font-family:inherit;font-size:12pt;color:#262626;text-decoration:underline;">Net Lease.</font><font style="font-family:inherit;font-size:12pt;color:#262626;">  It is the intention of the parties that the rent payable hereunder shall be absolutely net to Landlord, so that this Lease shall yield to Landlord the net annual basic Minimum Rent specified herein during the term of this Lease, and that all costs, expenses and obligations of every kind and nature whatsoever relating to the Demised Premises shall be paid by Tenant and shall be deemed to be and shall become Additional Rent hereunder whether or not the same be designated as such.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:justify;padding-left:8px;text-indent:45px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;color:#262626;font-weight:bold;text-decoration:underline;">Section 4.6.</font><font style="font-family:inherit;font-size:12pt;color:#262626;font-weight:bold;"> </font><font style="font-family:inherit;font-size:12pt;color:#262626;font-weight:bold;">   </font><font style="font-family:inherit;font-size:12pt;color:#262626;"> </font><font style="font-family:inherit;font-size:12pt;color:#262626;text-decoration:underline;">Utility Service Charges.</font><font style="font-family:inherit;font-size:12pt;color:#262626;">  Tenant shall pay all utility charges in accordance with the provisions of Article 8.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:justify;padding-left:8px;text-indent:45px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;color:#262626;font-weight:bold;text-decoration:underline;">Section 4.7.</font><font style="font-family:inherit;font-size:12pt;color:#262626;font-weight:bold;"> </font><font style="font-family:inherit;font-size:12pt;color:#262626;font-weight:bold;">   </font><font style="font-family:inherit;font-size:12pt;color:#262626;text-decoration:underline;">Taxes</font><font style="font-family:inherit;font-size:12pt;color:#262626;">. Commencing with the Commencement Date and continuing thereafter during the term of this Lease, Tenant agrees to pay to Landlord on the first day of each month, in advance, and without deduction or set-off except as expressly set forth herein, Tenant </font><font style="font-family:inherit;font-size:12pt;color:#4f4f4f;">'</font><font style="font-family:inherit;font-size:12pt;color:#262626;">s Pro-rata Share of Real Estate Taxes. Tenant’s initial monthly charge for Real Estate Taxes shall be based on Landlord's estimate of Real Estate Taxes, written notice of which charge for the initial tax year (as that term is hereinafter defined) shall be furnished to Tenant at or around the Commencement Date. Such monthly charge may be periodically adjusted by Landlord to more accurately reflect Tenant's Pro-rata Share of Real Estate Taxes.</font></div><div style="line-height:120%;padding-top:1px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:justify;padding-left:8px;text-indent:89px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;color:#262626;">Within ninety (90) days of receipt of the tax bills for each tax year, Landlord shall mail to Tenant a statement setting forth the Real Estate Taxes and the amount of Tenant’s Pro-rata Share of Real Estate Taxes. Tenant's Pro-rata Share of Real Estate Taxes paid or payable for each tax year during the Lease Term shall be adjusted between Landlord and Tenant, each party hereby agreeing to pay to the other, within thirty (30) days of the mailing of the aforesaid statement to Tenant, such amount as may be necessary to effect Tenant's Pro-rata Share of Real Estate Taxes based upon actual amounts due. The term "tax year" as used herein shall mean the twelve-month</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div><br></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-top:1px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;padding-top:1px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;padding-top:2px;text-align:left;padding-left:6px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;color:#2a2b33;">period established as the real estate tax year by the taxing authorities having jurisdiction over the</font></div><div style="line-height:120%;padding-top:1px;text-align:left;padding-left:6px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;color:#2a2b33;">Industrial Center.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:justify;padding-left:6px;text-indent:90px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;color:#2a2b33;">Should Tenant's obligation for the payment of Real Estate Taxes pursuant to this Lease originate or terminate for less than a full tax year, Tenant's liability for Real Estate Taxes shall be subject to a pro rata adjustment based on the number of months of said tax year for which Tenant's obligation to pay Real Estate Taxes is in effect.</font></div><div style="line-height:120%;padding-top:1px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:justify;padding-left:6px;text-indent:90px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;color:#2a2b33;">Landlord shall pay Real Estate Taxes on or before when same are due. Tenant shall pay promptly when due all taxes directly or indirectly imposed or assessed on Tenant's business operations, machinery, equipment, improvements, inventory and other personal property or assets, whether such taxes are assessed against Tenant, Landlord or the Industrial Center as a single entity. In the event that such taxes are imposed or assessed against Landlord or the Industrial Center, Landlord, upon request, shall furnish Tenant with all applicable tax bills, public charges and other assessments or impositions.</font></div><div style="line-height:120%;padding-top:1px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:justify;padding-left:8px;text-indent:89px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;color:#2a2b33;">Notwithstanding the foregoing, Tenant shall pay during the Lease Term its pro-rata share of water and sewer charges for the Industrial Center. These charges shall be billed in a manner similar to that set forth above for Real Estate Taxes.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:justify;padding-left:8px;text-indent:44px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;color:#2a2b33;font-weight:bold;">Section 4.8. </font><font style="font-family:inherit;font-size:12pt;color:#2a2b33;text-decoration:underline;">Insurance Premiums</font><font style="font-family:inherit;font-size:12pt;color:#2a2b33;">. In addition to paying Tenant's Pro-rata Share of Landlord's insurance premiums as part of Tenant’s Pro-rata Share of Complex Operating Costs, Tenant agrees to pay, within thirty (30) days after demand, any increase in premiums that may be charged on insurance carried by Landlord resulting from Tenant's use or occupancy of the Demised Premises or the Industrial Center (the "</font><font style="font-family:inherit;font-size:12pt;color:#2a2b33;text-decoration:underline;">Insurance Premium Charge"</font><font style="font-family:inherit;font-size:12pt;color:#2a2b33;">). In determining whether increased premiums are the result of Tenant’s use or occupancy of the Demised Premises, a schedule or </font><font style="font-family:inherit;font-size:12pt;color:#565d66;">"</font><font style="font-family:inherit;font-size:12pt;color:#2a2b33;">make-up" rate of the organization issuing the fire insurance, extended coverage, vandalism and malicious mischief, special extended coverage or any all-risk insurance rates for the Demised Premises or Industrial Center or any rule books issued by the rating organization or similar bodies or rating procedures or rules of Landlord's insurance companies shall be conclusive evidence of the several items and charges which make up the insurance rates and premiums on the Demised Premises and the Industrial Center. If due to the Tenant's failure to occupy the Demised Premises, as herein provided, any such insurance shall be canceled by the insurance carrier, then Tenant shall indemnify and hold Landlord harmless against any loss which would have been covered by such insurance. Tenant also shall pay any increase in premiums on rent insurance as may be carried by Landlord for its protection against rent loss through fire or other casualty, if such increase shall result from Tenant's occupancy or failure to occupy.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:justify;padding-left:8px;text-indent:44px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;color:#2a2b33;font-weight:bold;text-decoration:underline;">Section 4.9.</font><font style="font-family:inherit;font-size:12pt;color:#2a2b33;font-weight:bold;">    </font><font style="font-family:inherit;font-size:12pt;color:#2a2b33;">A. Tenant or its usual auditors of its normal books and records (provided same are certified public accountants and are not compensated on a contingent basis) in each case at Tenant's expense (except as otherwise set forth in this Section 4.9), shall have the right to examine those portions of Landlord's records (the "</font><font style="font-family:inherit;font-size:12pt;color:#2a2b33;text-decoration:underline;">Records</font><font style="font-family:inherit;font-size:12pt;color:#2a2b33;">") which are reasonably required to verify the accuracy of any amounts shown on any Operating Costs Statement provided Tenant shall notify Landlord of its desire to so examine such records within ninety (90) days next following rendition to Tenant of such Operating Costs Statement. Upon Tenant's timely request, Landlord shall make such Records available and any such examination shall be conducted at the office of Landlord's accountants or at such other reasonable place designated by Landlord during</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:9px;font-size:7pt;"><font style="font-family:inherit;font-size:7pt;"><br></font></div><div><br></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:2px;text-align:justify;padding-left:6px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;padding-top:2px;text-align:justify;padding-left:6px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;padding-top:2px;text-align:justify;padding-left:6px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;color:#242424;">normal office hours. Tenant acknowledges and agrees that not more than three (3) of its employees or three (3) persons employed by such auditors shall be entitled to entry to the offices of Landlord at any one time for the purposes of such review and inspection. Tenant hereby recognizes the confidential, privileged and proprietary nature of such Records and the information and data contained therein, as well as any compromise, settlement or adjustment reached between Landlord and Tenant relating to the results of such examination, and Tenant covenants and agrees for itself, and its employees, agents and representatives (including, but not limited to, such auditors, and any attorneys or consultants retained by Tenant as hereinafter provided), that such books, Records, information, data, compromise, settlement and adjustment which are identified to Tenant or its auditors as confidential will be held in confidence and not be divulged, disclosed or revealed to any other person except (x) to the extent required by law, court order or directive of any governmental authority or (y) to such auditors or any attorneys retained by Tenant or consultants retained by Tenant in connection with any action or proceeding between Landlord and Tenant as to Complex Operating Costs or any Operating Costs Statement and no examination of any such Records shall be permitted unless and until such auditors, attorneys and consultants affirmatively agree and consent to be bound by the confidentiality provisions of this Section 4.9. This obligation of Tenant and its employees, agents and representatives (including, but not limited to, any such auditors, attorneys or consultants) shall survive the expiration or sooner termination of the Lease Term.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:justify;padding-left:6px;text-indent:89px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;color:#242424;">B. In the event that Tenant, after having reasonable opportunity to examine the Records (but in no event more than ninety (90) days from the date on which the Records are made available to Tenant), shall disagree with the applicable Operating Costs Statement, then Tenant may send a written notice ("</font><font style="font-family:inherit;font-size:12pt;color:#242424;text-decoration:underline;">Tenant's Statement"</font><font style="font-family:inherit;font-size:12pt;color:#242424;">) to Landlord of such disagreement, specifying in reasonable detail the basis for Tenant's disagreement and the specific amount which Tenant believes is due. If Tenant fails to send Tenant's Statement to Landlord within such ninety (90) day period, then the Operating Costs Statement shall be conclusive and binding upon Tenant. In all instances, Tenant, pending the resolution of any contest pursuant to the terms hereof, shall continue to pay all sums as determined to be due in the first instance by such Operating Costs Statement at the time the same are otherwise due and payable under the provisions in this Lease, subject to adjustment upon the resolution of any dispute pursuant to the last sentence of this paragraph. Landlord and Tenant shall attempt to resolve such disagreement. If they are unable to do so within thirty (30) days following delivery of Tenant's Statement, then Landlord and Tenant shall agree upon a certified public accountant (the "</font><font style="font-family:inherit;font-size:12pt;color:#242424;text-decoration:underline;">Arbiter</font><font style="font-family:inherit;font-size:12pt;color:#242424;">") whose determination made in accordance with this paragraph shall be binding upon the parties. The cost of the Arbiter shall be borne equally by Landlord and Tenant (unless the Complex Operating Expenses were overstated by more than four percent (4%), in which case Landlord shall bear the </font><font style="font-family:inherit;font-size:12pt;color:#383838;">full </font><font style="font-family:inherit;font-size:12pt;color:#242424;">cost of the Arbiter). The Arbiter shall be a member of an independent certified public accounting firm having at least three (3) accounting professionals and having at least fifteen (15) years of experience in commercial real estate accounting. In the event that Landlord and Tenant shall be unable to agree upon the designation of the Arbiter within thirty (30) days after receipt of notice from the other party requesting agreement as to the designation of the Arbiter, which notice shall contain the names and addresses of two or more certified public accountants who are acceptable to the party sending such notice (any one of whom, if acceptable to the party receiving such notice as shall be evidenced by notice given by the receiving party to the other party within such thirty (30) day period, shall be the agreed upon Arbiter), then either party shall have the right to request the American Arbitration Association (the "</font><font style="font-family:inherit;font-size:12pt;color:#242424;text-decoration:underline;">AAA"</font><font style="font-family:inherit;font-size:12pt;color:#242424;">) (or any organization which is the successor</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:justify;padding-left:8px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div><br></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;padding-top:2px;text-align:justify;padding-left:6px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;padding-top:2px;text-align:justify;padding-left:6px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;padding-top:2px;text-align:justify;padding-left:6px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;color:#2d2d34;">thereto) to designate as the Arbiter a certified public accountant whose determination made in accordance with this paragraph shall be conclusive and binding upon the parties, and the cost charged by the AAA (or any organization which is the successor thereto), for designating such Arbiter, shall be shared equally by Landlord and Tenant. The Arbiter shall determine the issue and render its decision as promptly as practicable choosing either Landlord's or Tenant's determination as to the amount of Tenant's Pro-Rata Share of Complex Operating Costs due and payable to Landlord</font><font style="font-family:inherit;font-size:12pt;color:#464449;">. </font><font style="font-family:inherit;font-size:12pt;color:#2d2d34;">Landlord and Tenant hereby agree that any determination made by an Arbiter designated pursuant to this paragraph shall not exceed the amount(s) as determined to be due in the first instance by the Operating Costs Statement, nor shall such determination be less than the amount(s) claimed to be due by Tenant in Tenant's Statement, and that any determination which does not comply with the foregoing shall be null and void and not binding on the parties. In rendering such determination such Arbiter shall not add to, subtract from or otherwise modify the provisions of this Lease, including the immediately preceding sentence. Until the resolution of such contest, Tenant shall timely pay Tenant's Pro-Rata Share of Complex Operating Costs as determined by Landlord. Upon the resolution of such contest, any suitable adjustments to the amounts due on account of Tenant’s Pro-Rata Share of Complex Operating Costs shall be made, with any appropriate refund to be made by Landlord to Tenant within thirty (30) days after the resolution of such contest if required thereby and any underpayment by Tenant to be paid to Landlord within thirty (30) days after resolution of such contest. If the Arbiter determines (or Landlord and Tenant otherwise agree) that Landlord's calculation of Complex Operating Costs for the calendar year under inspection was overstated by more than four percent (4%), then Landlord shall pay Tenant's actual reasonable out-of-pocket audit and inspection applicable to the review of said calendar year statement within thirty (30) days after receipt of Tenant's invoice therefor.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:189px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;color:#2d2d34;font-weight:bold;text-decoration:underline;">ARTICLE 5. TENANT'S WORK</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:justify;padding-left:6px;text-indent:45px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;color:#2d2d34;font-weight:bold;text-decoration:underline;">Section 5.1.</font><font style="font-family:inherit;font-size:12pt;color:#2d2d34;font-weight:bold;"> </font><font style="font-family:inherit;font-size:12pt;color:#2d2d34;">   Except as expressly set forth herein, Tenant shall not, without Landlord's prior written approval, in each instance, make (i) structural changes or alterations in or to the Demised Premises of any nature, (ii) changes or alterations which affect the Building</font><font style="font-family:inherit;font-size:12pt;color:#5d6067;">'</font><font style="font-family:inherit;font-size:12pt;color:#2d2d34;">s systems</font><font style="font-family:inherit;font-size:12pt;color:#464449;">, </font><font style="font-family:inherit;font-size:12pt;color:#2d2d34;">which te</font><font style="font-family:inherit;font-size:12pt;color:#464449;">r</font><font style="font-family:inherit;font-size:12pt;color:#2d2d34;">m shall include, without limitation, the Building's utility</font><font style="font-family:inherit;font-size:12pt;color:#464449;">, </font><font style="font-family:inherit;font-size:12pt;color:#2d2d34;">plumbing, ventilating, electrical, air conditioning or heating systems or (iii) non-structural changes or alterations costing more than $75,000 in the aggregate in any twelve (12) month period</font><font style="font-family:inherit;font-size:12pt;color:#464449;">. </font><font style="font-family:inherit;font-size:12pt;color:#2d2d34;">Prior to Tenant's commencing the Initial Tenant's Work described in Section 3.5 above, or any other work in the Demised Premises for which Landlord's prior approval is required, Tenant shall submit to Landlord for Landlord's written approval (which approval shall not be unreasonably withheld for non-structural work which does not affect any Building systems), complete drawings, plans and specifications, if any, (herein collectively referred to as "</font><font style="font-family:inherit;font-size:12pt;color:#2d2d34;text-decoration:underline;">Tenant's Plan</font><font style="font-family:inherit;font-size:12pt;color:#464449;">"</font><font style="font-family:inherit;font-size:12pt;color:#2d2d34;">) for the improvements and installations to be made by Tenant (said Initial Tenant's Work</font><font style="font-family:inherit;font-size:12pt;color:#464449;">, </font><font style="font-family:inherit;font-size:12pt;color:#2d2d34;">together with all other work contemplated in this Article 5 is herein collectively referred to as "</font><font style="font-family:inherit;font-size:12pt;color:#2d2d34;text-decoration:underline;">Tenant's Work"</font><font style="font-family:inherit;font-size:12pt;color:#2d2d34;">). Tenant shall also submit to Landlord for Landlord's written approval (x) the proposed budget (updated as any work progresses) for all Tenant's Work to be made by Tenant and (y) a list of contractors and subcontractors for Tenant's Work. Upon request, Tenant agrees to employ Landlord's contractor to perform any part of Tenant’s Work with respect to the Building's systems or the exterior of the Demised Premises and/or any structural aspect of Tenant’s Work</font><font style="font-family:inherit;font-size:12pt;color:#464449;">. </font><font style="font-family:inherit;font-size:12pt;color:#2d2d34;">Tenant acknowledges that said Landlord's contractor may be a related party to Landlord and Tenant has no objection thereto so long as the cost of such work does not exceed that which Tenant would be obligated to pay an unrelated party</font><font style="font-family:inherit;font-size:12pt;color:#5d6067;">. </font><font style="font-family:inherit;font-size:12pt;color:#2d2d34;">Tenant's Plan shall be fully detailed</font><font style="font-family:inherit;font-size:12pt;color:#464449;">, </font><font style="font-family:inherit;font-size:12pt;color:#2d2d34;">shall show complete dimensions</font><font style="font-family:inherit;font-size:12pt;color:#5d6067;">, </font><font style="font-family:inherit;font-size:12pt;color:#2d2d34;">shall not</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div><br></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:justify;padding-left:8px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;padding-top:1px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;padding-top:2px;text-align:justify;padding-left:6px;text-indent:-2px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;padding-top:2px;text-align:justify;padding-left:6px;text-indent:-2px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;color:#262626;">require any changes in the structure of the Building (except as expressly permitted pursuant hereto) and shall not be in violation of any laws, order, rules or regulations of any governmental department or bureau having jurisdiction of the Demised Premises.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:justify;padding-left:6px;text-indent:45px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;color:#262626;font-weight:bold;text-decoration:underline;">Section 5.2.</font><font style="font-family:inherit;font-size:12pt;color:#262626;font-weight:bold;"> </font><font style="font-family:inherit;font-size:12pt;color:#262626;font-weight:bold;">   </font><font style="font-family:inherit;font-size:12pt;color:#262626;">Within ten (10) days after submission to Landlord of Tenant's Plan, Landlord shall either approve same or shall set forth in writing the particulars in which Landlord does not approve same, in which latter case Tenant shall, within ten (10) days after Landlord's notification, return to Landlord appropriate corrections thereto. Such corrections shall be subject to Landlord's approval not to be unreasonably withheld. Tenant shall pay to Landlord, promptly upon being billed, any reasonable charges or expenses of Landlord's architects and engineers in reviewing Tenant's Plan and/or insuring compliance therewith as well as a construction management fee of two and one/half (2.5%) percent of the aggregate hard costs for such work as set forth in Tenant's proposed budget for any Tenant's Work required to be supervised or monitored by Landlord.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:justify;padding-left:6px;text-indent:45px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;color:#262626;font-weight:bold;text-decoration:underline;">Section 5.3.</font><font style="font-family:inherit;font-size:12pt;color:#262626;">    Tenant further agrees that Tenant shall not make any changes in Tenant's Plan subsequent to approval by Landlord unless Landlord consents to such changes; provided, however, Landlord's consent shall not be required in connection with any changes required by any governmental entity or agency. Tenant shall pay to Landlord all costs and expenses caused by such change which Landlord may incur or sustain in the performance by Landlord of any construction or work in the Building. Landlord shall have the right to refuse to consent to any such changes if in the reasonable judgment of Landlord or Landlord's architect such changes materially deviate from Tenant's Plan theretofore approved by Landlord or otherwise violate the terms of this Lease. Any charges payable under this subparagraph 5.3 shall be paid by Tenant from time to time upon demand as Additional Rent, whether or not the Lease Term shall have commenced.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:justify;padding-left:8px;text-indent:45px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;color:#262626;font-weight:bold;text-decoration:underline;">Section 5.4.</font><font style="font-family:inherit;font-size:12pt;color:#262626;font-weight:bold;">    </font><font style="font-family:inherit;font-size:12pt;color:#262626;">Following compliance by Tenant with its obligations under the foregoing subparagraphs and approval of Tenant’s Plan by Landlord, Tenant shall commence Tenant's Work and it shall proceed diligently with same in a good and workmanlike manner using first-class materials in order to complete same within a reasonable period of time.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:justify;padding-left:8px;text-indent:45px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;color:#262626;font-weight:bold;text-decoration:underline;">Section 5.5.</font><font style="font-family:inherit;font-size:12pt;color:#262626;">    Tenant agrees that in the performance of Tenant's Work (i) neither Tenant nor its agents or employees shall interfere with any work being done at the Industrial Center by other tenants or occupants thereof or by Landlord and its contractors, agents and employees, (ii) intentionally omitted, (iii) that Tenant shall comply with any reasonable rules and regulations proposed by Landlord, its agents, contractors or employees, (iv) that all that all contractors, subcontractors and personnel employed by Tenant shall be harmonious and compatible with the labor employed by Landlord and other tenants in the Industrial Center, it being agreed that if in Landlord's judgment the labor is incompatible with the labor employed by Landlord or construction labor employed by other tenants in the Industrial Center, Tenant shall immediately resolve such incompatibility, or upon Landlord's demand immediately withdraw such labor from the premises, (v) that prior to commencing Tenant's Work, Tenant shall procure and deliver to Landlord worker's compensation, public liability, property damage and such other insurance policies, in such form and amounts as shall be reasonably acceptable to Landlord in connection with Tenant's Work, and shall upon Landlord's request cause Landlord, any mortgagee of the Industrial Center and such other entities as Landlord shall designate to be named as an insured</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div><br></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:justify;padding-left:9px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;padding-top:2px;text-align:justify;padding-left:8px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;color:#2d2f36;">thereunder, (vi) that Tenant shall hold Landlord, any mortgagee of the Industrial Center and such other entities as Landlord shall designate harmless from and against any and all claims arising from or in connection with any act or omission of Tenant or its agents, contractors and employees, (viii) that Tenant's Work shall be performed in accordance with the approved Tenant's Plan and in compliance with the laws, orders, rules and regulations of any governmental department or bureau having jurisdiction over the Industrial Center and Tenant shall immediately correct any non-conforming work, and (vii) that Tenant shall promptly pay for Tenant's Work in full and shall not permit any lien to attach to the Demised Premises or the land and/or Industrial Center.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:justify;padding-left:8px;text-indent:44px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;color:#2d2f36;font-weight:bold;text-decoration:underline;">Section 5.6.</font><font style="font-family:inherit;font-size:12pt;color:#2d2f36;font-weight:bold;"> </font><font style="font-family:inherit;font-size:12pt;color:#2d2f36;">   In the event that Tenant shall not diligently perform and fully pay for Tenant's Work and/or causes or permits any liens to attach to </font><font style="font-family:inherit;font-size:12pt;color:#464649;">the </font><font style="font-family:inherit;font-size:12pt;color:#2d2f36;">Demised Premises or the building containing the Demised Premises, as determined by Landlord, then, in addition to any other remedies of Landlord in this Lease contained, by law or otherwise, Landlord shall, to the extent Landlord deems necessary, be entitled</font><font style="font-family:inherit;font-size:12pt;color:#575d67;">, </font><font style="font-family:inherit;font-size:12pt;color:#2d2f36;">at Tenant's expense, to restore and/or protect the Demised Premises or the Industrial Center, and to pay or satisfy any costs, damages or expenses in connection with the foregoing and/or Tenant's obligations under </font><font style="font-family:inherit;font-size:12pt;color:#2d2f36;font-style:italic;">this </font><font style="font-family:inherit;font-size:12pt;color:#2d2f36;">Lease.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:justify;padding-left:8px;text-indent:44px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;color:#2d2f36;font-weight:bold;text-decoration:underline;">Section 5.7.</font><font style="font-family:inherit;font-size:12pt;color:#2d2f36;">    All trade fixtures and equipment installed or used by Tenant in the Demised Premises shall be fully paid for by Tenant in cash and shall not be subject to conditional bills of sale, chattel mortgage or other title retention agreements, unless such conditional bill of sale, chattel mortgage or other title retention interest does not affect Landlord's interest in the Demised Premises or the Industrial Center.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:justify;padding-left:8px;text-indent:44px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;color:#2d2f36;font-weight:bold;text-decoration:underline;">Section 5.8.</font><font style="font-family:inherit;font-size:12pt;color:#2d2f36;font-weight:bold;"> </font><font style="font-family:inherit;font-size:12pt;color:#2d2f36;">   Notice is hereby given that the Landlord shall not be liable for any labor or materials furnished or to be furnished to the Tenant upon credit, and that no mechanic's or other lien for any such labor or materials shall attach to or affect the reversion or other estate or interest of the Landlord in and to the Demised Premises or the Industrial Center.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:justify;padding-left:8px;text-indent:44px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;color:#2d2f36;font-weight:bold;text-decoration:underline;">Section 5.9.</font><font style="font-family:inherit;font-size:12pt;color:#2d2f36;">    Notwithstanding anything to the contrary contained herein, Landlord shall not be obligated to give its consent or approval regarding Tenant's Work in the event that such consent or approval is required of, and not given by, Landlord's mortgagee. Tenant's Work shall in all respects conform to the requirements, if any, imposed by any mortgage on the Industrial Center with respect to such alterations and improvements.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:justify;padding-left:8px;text-indent:45px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;color:#2d2f36;font-weight:bold;text-decoration:underline;">Section 5.10.</font><font style="font-family:inherit;font-size:12pt;color:#2d2f36;">  Landlord may, at any time and from time to time but upon reasonable advance notice, in addition to any other right of access given to Landlord pursuant to the terms of this Lease, enter upon the Demised Premises with one or more engineers and/or architects of Landlord's selection to determine the course and degree of completion of Tenant's Work and its compliance with Tenant's Plan and the terms and conditions of this Lease.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:justify;padding-left:8px;text-indent:45px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;color:#2d2f36;font-weight:bold;text-decoration:underline;">Section 5.11.</font><font style="font-family:inherit;font-size:12pt;color:#2d2f36;">  At the time Landlord approves the Tenant's Plan, Landlord, by notice to Tenant, shall have the right to require Tenant to remove prior to the Expiration Date any or all Tenant's Work performed by Tenant and restore the Demised Premises to the condition it existed prior to the performance of said Tenant's Work (such Tenant's Work which Landlord requires Tenant to remove, "</font><font style="font-family:inherit;font-size:12pt;color:#2d2f36;text-decoration:underline;">Designated Alterations"</font><font style="font-family:inherit;font-size:12pt;color:#2d2f36;">).</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div><br></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;padding-top:1px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;padding-top:2px;text-align:left;padding-left:169px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;color:#262626;font-weight:bold;text-decoration:underline;">ARTICLE 6. USE OF THE PREMISES</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:justify;padding-left:6px;text-indent:45px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;color:#262626;font-weight:bold;text-decoration:underline;">Section 6.1.</font><font style="font-family:inherit;font-size:12pt;color:#262626;font-weight:bold;">    </font><font style="font-family:inherit;font-size:12pt;color:#262626;"> </font><font style="font-family:inherit;font-size:12pt;color:#262626;text-decoration:underline;">Permitted Use.</font><font style="font-family:inherit;font-size:12pt;color:#262626;"> During the Lease Term the Demised Premises shall be used and occupied solely for the purposes set forth in Section 1.9 and for no other purposes without the written consent of Landlord. Upon the Commencement Date, Tenant shall commence the conduct of its business and shall continuously, actively and diligently thereafter operate its business at the Demised Premises in a high-grade and reputable manner and in accordance with the terms, provisions and conditions of this Lease.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:53px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;color:#262626;font-weight:bold;text-decoration:underline;">Section 6.2.</font><font style="font-family:inherit;font-size:12pt;color:#262626;font-weight:bold;"> </font><font style="font-family:inherit;font-size:12pt;">    </font><font style="font-family:inherit;font-size:12pt;color:#262626;text-decoration:underline;">Operation of Demised Premises.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:justify;padding-left:8px;text-indent:89px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;color:#262626;">A. If any governmental license or permit shall be required for the proper and lawful conduct of Tenant's business in the Demised Premises or any part thereof, Tenant, at its expense, shall duly procure and thereafter maintain such license or permit and submit the same to Landlord for inspection. Tenant shall at all times comply with the terms and conditions of each such license or permit. Without limiting the generality of the forgoing, Tenant (and not Landlord) shall be responsible at its own cost, expense and risk to obtain a certificate of occupancy for Tenant's use and occupancy of the Demised Premises, it being agreed, however, that Landlord shall reasonably cooperate with Tenant's obtaining any local permitting relating to Tenant's use of the Demised Premises as herein contemplated, and Tenant shall pay Landlord's out-of-pocket expenses paid or incurred in connection therewith.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:justify;padding-left:8px;text-indent:90px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;color:#262626;font-weight:bold;">B. </font><font style="font-family:inherit;font-size:12pt;color:#262626;">Tenant shall not at any time use or occupy the Demised Premises, or suffer or permit anyone to use or occupy the Demised Premises, or do anything to be done in, brought into or kept on the Demised Premises, which in any manner (a) violates the Certificate of Occupancy for the Demised Premises; (b) causes or is liable to cause injury to the Demised Premises or the Industrial Center or any equipment, facilities or systems therein; (c) constitutes a violation of the laws and requirements of any public authorities or the requirements of insurance bodies; (d) constitutes a nuisance, public or private; (e) makes unobtainable from reputable insurance companies authorized to do business in the State of New Jersey any fire insurance with extended coverage, or liability, elevator, boiler or other insurance at standard rates required to be furnished by Landlord under the terms of any mortgages covering the Demised Premises; (f) discharges objectionable fumes, vapors or odors into the Demised Premises and/or Industrial Center's flues or vents or otherwise in such manner as may offend other tenants or occupants of the Industrial Center; or (g) is in violation of laws or any regulation of any governmental authority.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:justify;padding-left:9px;text-indent:90px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;color:#262626;">C. Tenant, at Tenant's expense, shall at all times cause all portions of the Demised Premises to be kept in a clean and safe condition, including, without limitation, the windows, doors and loading docks thereof, in a manner reasonably satisfactory to Landlord and in compliance with the requirements of all governmental authorities having jurisdiction therein.</font></div><div style="line-height:120%;padding-top:1px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:100px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;color:#262626;">D.</font><font style="font-family:inherit;font-size:12pt;color:#262626;font-weight:bold;"> </font><font style="font-family:inherit;font-size:12pt;">    </font><font style="font-family:inherit;font-size:12pt;color:#262626;">Intentionally Omitted.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:justify;padding-left:9px;text-indent:90px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;color:#262626;">E. Tenant covenants and agrees that no part of the loading docks, drives, sidewalks or walkways abutting or leading to the Demised Premises, nor the Demised Premises itself, has been leased to Tenant for retail, commercial or sale purposes and that Tenant shall use no part thereof for such purposes.</font></div><div><br></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;padding-top:2px;text-align:justify;padding-left:8px;text-indent:89px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;color:#2d2f36;">F. Tenant covenants at all times to exterminate and keep the Demised Premises in a clean, sanitary and wholesome condition at its own cost and expense</font><font style="font-family:inherit;font-size:12pt;color:#4d4d50;">.</font></div><div style="line-height:120%;padding-top:1px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:justify;padding-left:6px;text-indent:90px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;color:#2d2f36;">G. Tenant shall store all of Tenant's refuse and rubbish in the Demised Premises enclosed areas and in sanitary containers and arrange for it to be removed from the Demised Premises at Tenant's sole cost and expense. Landlord shall not be required to furnish any services or equipment for the removal of such refuse and rubbish. Tenant further agrees that the refuse and rubbish to be collected or disposed of from the Demised Premises shall be removed only in accordance with the present or future regulations established by Landlord. If the use of plastic bags for external refuse storage and disposal is unsatisfactory due to vandalism or other cause, Tenant will place refuse, at Landlord's request, in metal containers.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:justify;padding-left:6px;text-indent:90px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;color:#2d2f36;">H. Tenant shall not place any item, merchandise, inventory, fixture or equipment within the Demised Premises which will have a weight in excess of the floor load of the Demised Premises. Tenant shall not (i) stack merchandise or materials against the walls so as to create a load or weight factor upon the walls, (ii) tie in Tenant's racking systems with such walls or (iii) hang equipment from (or otherwise load) the roof or structural members of the Building, in any such case, without the express written consent of Landlord in each instance which may be withheld by Landlord in its sole and absolute discretion.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:justify;padding-left:6px;text-indent:45px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;color:#2d2f36;font-weight:bold;text-decoration:underline;">Section 6.3.</font><font style="font-family:inherit;font-size:12pt;color:#2d2f36;font-weight:bold;"> </font><font style="font-family:inherit;font-size:12pt;color:#2d2f36;">   </font><font style="font-family:inherit;font-size:12pt;color:#2d2f36;text-decoration:underline;">Rules and Regulations.</font><font style="font-family:inherit;font-size:12pt;color:#2d2f36;"> </font><font style="font-family:inherit;font-size:12pt;color:#2d2f36;"> The rules and regulations set forth in </font><font style="font-family:inherit;font-size:12pt;color:#2d2f36;text-decoration:underline;">Exhibit B</font><font style="font-family:inherit;font-size:12pt;color:#2d2f36;"> are made a part of this Lease, and Tenant agrees to comply with and observe the same. Tenant's failure to keep and observe the rules and regulations shall constitute a breach of the terms of this Lease in the manner as if the same were contained herein as covenants. Landlord reserves the right from time to time to reasonably amend or supplement said rules and regulations and to adopt and promulgate additional reasonable rules and regulations applicable to the Demised Premises and the Industrial Center so long as such amended and/or supplemented rules and regulations are reasonable and do not prohibit Tenant's use of the Demised Premises for Tenant's intended purpose. Notice of such additional rules and regulations, and amendments and supplements, if any, shall be given to Tenant, and Tenant agrees to comply with and observe all such amendments and supplements from and after the date of such notice.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:justify;padding-left:6px;text-indent:45px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;color:#2d2f36;font-weight:bold;text-decoration:underline;">Section 6.4.</font><font style="font-family:inherit;font-size:12pt;color:#2d2f36;">    </font><font style="font-family:inherit;font-size:12pt;color:#2d2f36;text-decoration:underline;">Parking.</font><font style="font-family:inherit;font-size:12pt;color:#2d2f36;">  Tenant shall have the right to use in common with other tenants at the Industrial Center, up to seventy-five (75) automobile parking spaces in the parking areas of the Industrial Center on a non-exclusive first-come, first serve basis. In no event may cars or trucks owned or operated by Tenant, its agent, contractors, employees or invitees (collectively, "Tenant's Vehicles") (i) obstruct or restrict access or passage over or through the parking areas, roadways or accessways of the Industrial Center, or (ii) be parked in any parking spaces which are for the exclusive use of any other occupant of the Industrial Center. Tenant shall not have the right to park Tenant's Vehicles in any other areas of the Industrial Center except as set forth in this Section 6.4.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:170px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;color:#2d2f36;font-weight:bold;text-decoration:underline;">ARTICLE 7. COMMON FACILITIES.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:justify;padding-left:6px;text-indent:45px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;color:#2d2f36;font-weight:bold;text-decoration:underline;">Section 7.1.</font><font style="font-family:inherit;font-size:12pt;color:#2d2f36;font-weight:bold;"> </font><font style="font-family:inherit;font-size:12pt;color:#2d2f36;">   </font><font style="font-family:inherit;font-size:12pt;color:#2d2f36;text-decoration:underline;">Common Facilities Under Control of Landlord</font><font style="font-family:inherit;font-size:12pt;color:#2d2f36;">. The Common Facilities shall at all times be subject to the exclusive control and management of Landlord, and Landlord shall have the right from time to time, and provided that the visibility of and the access to the</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div><br></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:left;padding-left:8px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;padding-top:1px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;padding-top:2px;text-align:justify;padding-left:6px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;color:#262626;">Demised Premises are not materially and adversely affected, to do any of the following: add, alter or construct upon any portion of the Industrial Center; change the area, level, location and arrange­ ment of such parking areas and other facilities comprising the Common Facilities; restrict parking by Tenant and its employees to employee parking areas; do such things as in Landlord's reasonable discretion may be necessary regarding said facilities; and make all reasonable rules and regulations pertaining to and necessary for the proper operation and maintenance of the Common Facilities. Except as in this Lease specifically provided, Tenant shall have no right or interest in the Common Facilities. If the Common Facilities shall be changed or diminished in accordance with the terms hereof, Landlord shall not be subject to any liability to Tenant and Tenant shall not be entitled to any compensation or abatement of rent nor shall any change or diminution of such areas be deemed constructive or actual eviction. Tenant agrees not to hinder, block or deny access of vehicular ingress and egress of any other tenant to and from the Building.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:justify;padding-left:8px;text-indent:45px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;color:#262626;font-weight:bold;text-decoration:underline;">Section 7.2.</font><font style="font-family:inherit;font-size:12pt;color:#262626;font-weight:bold;">     </font><font style="font-family:inherit;font-size:12pt;color:#262626;text-decoration:underline;">Industrial Center as Private Property</font><font style="font-family:inherit;font-size:12pt;color:#262626;">. In order to establish that the Industrial Center, and any portion thereof is and will continue to remain private property, the Landlord shall have the unrestricted right in the Landlord's sole discretion, with respect to the entire Industrial Center and/or any portion thereof owned or controlled by the Landlord, to close the same to the general public for one (1) non-business day in each calendar year and, in connection therewith, to seal off all entrances to the Industrial Center or any portion thereof.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:center;padding-left:213px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;color:#262626;font-weight:bold;text-decoration:underline;">ARTICLE 8. UTILITIES</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:justify;padding-left:8px;text-indent:45px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;color:#262626;font-weight:bold;text-decoration:underline;">Section 8.1.</font><font style="font-family:inherit;font-size:12pt;color:#262626;font-weight:bold;"> </font><font style="font-family:inherit;font-size:12pt;color:#262626;font-weight:bold;">    </font><font style="font-family:inherit;font-size:12pt;color:#262626;text-decoration:underline;">Obtaining Utilities</font><font style="font-family:inherit;font-size:12pt;color:#262626;">. Tenant shall make application for, arrange for and pay or cause to be paid and shall be solely responsible for all charges for utility services and shall indemnify Landlord and save it harmless against any liability or charges on account thereof. In the event any such utility charges are not paid by Tenant when due, Landlord may pay the same to the utility company or department furnishing the same and any amount so paid by Landlord shall be paid by Tenant as Additional Rent for the month next following such payment by Landlord.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:justify;padding-left:8px;text-indent:45px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;color:#262626;font-weight:bold;text-decoration:underline;">Section 8.2.</font><font style="font-family:inherit;font-size:12pt;color:#262626;font-weight:bold;">    </font><font style="font-family:inherit;font-size:12pt;color:#262626;text-decoration:underline;">Installation of Equipment by Tenant.</font><font style="font-family:inherit;font-size:12pt;color:#262626;">  Tenant further agrees that it will not install any equipment which will exceed or overload the capacity of any utility facilities. If Landlord approves the installation of any equipment to be installed by Tenant that would require additional utility facilities, the same shall be installed at Tenant's expense in accordance with plans and specifications to be approved in writing by Landlord. Any additional feeders or risers to supply Tenant's additional electrical requirements, and all other equipment proper and necessary in connection with such feeders or risers shall be installed by Landlord or, at Landlord's election, by Tenant, at the sole cost and expense of Tenant, provided, that, in Landlord's judgment, such additional feeders or risers are necessary and are permissible under applicable laws and insurance regulations and the installation of such feeders or riders will not cause permanent damage or injury to the Building or the Demised Premises or cause or create a dangerous or hazardous condition or entail excessive or unreasonable alterations or repairs to or interfere with or disturb other tenants or occupants of the Building.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:justify;padding-left:8px;text-indent:45px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;color:#262626;font-weight:bold;text-decoration:underline;">Section 8.3.</font><font style="font-family:inherit;font-size:12pt;color:#262626;">    </font><font style="font-family:inherit;font-size:12pt;color:#262626;text-decoration:underline;">Cessation of Utilities.</font><font style="font-family:inherit;font-size:12pt;color:#262626;"> </font><font style="font-family:inherit;font-size:12pt;color:#262626;">   Landlord shall not be liable to Tenant for any damages should the furnishing of any utilities by any utility company be interrupted or required to be terminated because of necessary repairs or improvements or any cause beyond the control of Landlord. Nor shall any such interruption or cessation relieve Tenant from the performance of</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div><br></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:justify;padding-left:9px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;padding-top:2px;text-align:justify;padding-left:6px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;color:#2a2b33;">any of Tenant’s covenants, conditions and agreements under this Lease. Notwithstanding anything to the contrary, if (i) all or any substantial portion of the Demised Premises are rendered untenantable by reason of the fact that, as a result of Landlord’s negligence or willful misconduct (or the negligence or willful misconduct of Landlord's employees, contractors or agents), electrical, water, HVAC or other critical service to the Demised Premises (or a material portion thereof) are unavailable or inoperative or are at a materially reduced capacity or level, (ii) Tenant shall give to Landlord notice of such failure, interruption, cessation or reduction and such resulting untenantability, (iii) Landlord shall fail within five (5) business days from the date Landlord receives Tenant's notice of such failure of the aforesaid service and resulting untenantability to cause such matter to be resolved or cured or perform such maintenance or repair to the extent necessary to again render tenantable the Demised Premises or a portion thereof so previously rendered untenantable as hereinabove provided, and (iv) the Demised Premises or the applicable portion thereof as described above shall continue to be untenantable by reason of such in operation or unavailability of such aforesaid service for the purposes for which the Demised Premises are leased, and (v) Tenant shall not then using or occupying all or such portion of the Demised Premises so rendered untenantable, then, upon the occurrence of all the aforesaid events, as Tenant's sole remedy therefor, commencing on the day after the expiration of such five (5) business day period, the Minimum Rent shall abate until the Demised Premises, or such substantial portion thereof so previously rendered untenantable are rendered tenantable; with it understood that if less than substantially all of the Demised Premises are untenantable, then Tenant shall continue to pay Minimum Rent with respect to the tenantable portion of the Demised Premises based on the proportion that the rentable square feet of the tenantable portion of the Demised Premises bears to the total rentable square feet of the Demised Premises.</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:justify;padding-left:8px;text-indent:45px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;color:#2a2b33;font-weight:bold;text-decoration:underline;">Section 8.4.</font><font style="font-family:inherit;font-size:12pt;color:#2a2b33;font-weight:bold;">    </font><font style="font-family:inherit;font-size:12pt;color:#2a2b33;text-decoration:underline;">Demised Premises Heating and Air-Conditioning</font><font style="font-family:inherit;font-size:12pt;color:#2a2b33;">. Tenant agrees to operate any heating and air-conditioning servicing the Demised Premises in such a manner so as to maintain an adequate temperature within the Demised Premises during Tenant's business hours and at such temperatures during non-business hours to prevent the freezing of any pipes or plumbing facilities. Tenant agrees to keep in force a standard maintenance agreement, at the sole expense of Tenant, and to furnish a copy of such agreement to Landlord upon request. If Tenant does not provide such maintenance agreement, Landlord shall have the right to enter into such agreement on behalf of Tenant at Tenant's sole cost and expense.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:justify;padding-left:8px;text-indent:45px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;color:#2a2b33;font-weight:bold;text-decoration:underline;">Section 8.5.</font><font style="font-family:inherit;font-size:12pt;color:#2a2b33;font-weight:bold;">    </font><font style="font-family:inherit;font-size:12pt;color:#2a2b33;text-decoration:underline;">Electricity and other Meters.</font><font style="font-family:inherit;font-size:12pt;color:#2a2b33;">      Meters to measure electricity and gas consumed at the Demised Premises have been installed in the Demised Premises so that electricity and gas may be measured separately. Tenant shall make its own arrangements with the utility company supplying the utilities for service. Tenant shall take good care of any meter which measures the consumption of utilities at the Demised Premises and all equipment installed in connection therewith, at Tenant's sole cost and expense, and make all repairs thereto as and when necessary to insure that any such meter is, at all times during the Lease Term, in good working order. Tenant shall make all appropriate applications to the local utility companies at such times as shall be necessary to ensure that utilities are available at the Demised Premises, and shall pay all required deposits, connection fees and/or charges for meters within the applicable time period set by the local utility company. Tenant shall be solely responsible for and promptly pay all charges for heat, water, electricity, sewer rents or charges, and any other utility used or consumed in the Demised Premises or in providing heating and air-conditioning to the Demised Premises, including in each instance</font><font style="font-family:inherit;font-size:12pt;color:#505962;">, </font><font style="font-family:inherit;font-size:12pt;color:#2a2b33;">all sales and other taxes applicable to the sale or supply of such utilities,</font></div><div style="line-height:120%;padding-top:1px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:justify;padding-left:9px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div><br></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-top:1px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;padding-top:2px;text-align:left;padding-left:8px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;padding-top:2px;text-align:left;padding-left:8px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;padding-top:2px;text-align:left;padding-left:8px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;color:#262626;">said responsibility commencing on the earlier of the Commencement Date or the date Tenant first enters the Demised Premises for any reason.</font></div><div style="line-height:120%;padding-top:1px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:center;padding-left:228px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;color:#262626;font-weight:bold;text-decoration:underline;">ARTICLE 9. LIENS</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:justify;padding-left:6px;text-indent:45px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;color:#262626;font-weight:bold;text-decoration:underline;">Section 9.1</font><font style="font-family:inherit;font-size:12pt;color:#262626;font-weight:bold;">. </font><font style="font-family:inherit;font-size:12pt;color:#262626;text-decoration:underline;">Discharge of Lien.</font><font style="font-family:inherit;font-size:12pt;color:#262626;">  Tenant shall, prior to the commencement of any work upon the Demised Premises, do all things necessary to prevent the filing of any mechanics' or other liens against the Industrial Center, the Demised Premises or any part thereof by reason of work, labor, services or materials supplied or claimed to have been supplied to Tenant or anyone holding the Demised Premises, or any part thereof, through or under Tenant. If any such lien or notice thereof shall at any time be filed against the Demised Premises, then Tenant shall either cause the same to be discharged of record within twenty (20) days after notice of the date of filing of the same or, if Tenant, in Tenant's discretion and in good faith, determines that such lien should be contested, furnish such security as may be necessary or required, as determined by Landlord, to prevent any enforcement or foreclosure proceedings against the Demised Premises during the pendency of such contest. If Tenant shall fail to discharge such lien within such period or fail to furnish such security, then, in addition to any other right or remedy of Landlord resulting from such default, Landlord may, but shall not be obligated to, discharge the same either by paying the amount claimed to be due or by procuring the discharge of such lien in such manner as is, or may be, prescribed by law. Tenant shall repay to Landlord, as Additional Rent, all sums disbursed or deposited by Landlord pursuant to the foregoing provisions of this Section 9.1, including interest and the costs, expenses and reasonable attorneys' fees incurred by Landlord in connection therewith.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:center;padding-left:82px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;color:#262626;font-weight:bold;text-decoration:underline;">ARTICLE 10. MAINTENANCE.REPAIRANDALTERATIONS</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:justify;padding-left:9px;text-indent:45px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;color:#262626;font-weight:bold;text-decoration:underline;">Section 10.1.</font><font style="font-family:inherit;font-size:12pt;color:#262626;font-weight:bold;"> </font><font style="font-family:inherit;font-size:12pt;color:#262626;font-weight:bold;"> </font><font style="font-family:inherit;font-size:12pt;color:#262626;text-decoration:underline;">Landlord and Tenant Repair</font><font style="font-family:inherit;font-size:12pt;color:#262626;">. Landlord shall (i) make structural repairs to the exterior walls, common exterior facade, roof and foundation of the Building, (ii) maintain the Common Facilities in good order and conditions and properly lighted, to include prompt repair and restriping when required in the parking area, prompt cleaning and removal of snow and ice, landscaping (grass cutting, weed control, shrub replacement and maintenance) and all other services necessary to operate a first-class Industrial Center, and (iii) maintain utility lines, drains, and related facilities, serving all tenants of the Industrial Center), (iv) clean the exterior of the Building, including glass, and (v) replace any cracked or broken glass ("</font><font style="font-family:inherit;font-size:12pt;color:#262626;text-decoration:underline;">Landlord's Repairs"</font><font style="font-family:inherit;font-size:12pt;color:#262626;">) excepting, in each case, any work done by Tenant or by Landlord for Tenant; provided, however, that in each case Tenant shall have given Landlord prior written notice of the necessity of such repairs. The cost of all repairs made by Landlord shall be included in the Tenant's Pro-rata Share of Complex Operating Costs pursuant to Paragraph 4.4 of this Lease. If any such repair is required by reason of the act, omission or negligence, improper conduct of Tenant or any of its contractors, agents, invitees, delivery men, vendors, distributors, employees or other person using the Demised Premises with Tenant's consent, express or implied, or Tenant's failure to perform any of its obligations under this Lease, then Landlord may, at its option, make such repair and Tenant shall pay to Landlord, as Additional Rent, upon demand, the reasonable cost of such repairs plus interest from the date of such repair by Landlord until such payment is made by Tenant to Landlord. Except as hereinbefore provided, Tenant covenants and agrees to keep and maintain in good working order, condition and repair the Demised Premises and every part thereof, including fixtures and equipment therein, the exterior and interior portions of all loading docks, doors, door</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div><br></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:left;padding-left:10px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;padding-top:2px;text-align:justify;padding-left:8px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;color:#2b2d34;">checks, security gates, all Building systems, including plumbing and sewage facilities within the Demised Premises (and the free flow of sewer lines therein) and all sprinkler, heating</font><font style="font-family:inherit;font-size:12pt;color:#505964;">, </font><font style="font-family:inherit;font-size:12pt;color:#2b2d34;">air­ conditioning, ventilation, mechanical, electrical and lighting systems and all fixtures, interior walls, floors and ceilings within the Demised Premises. Tenant shall accomplish any and all repairs, alterations, replacements and modifications at its own expense, using materials and labor of kind and quality equal to the original work. As a material inducement to Landlord to enter into this Lease and to accept Tenant's use of the Demised Premises as herein permitted, Tenant covenants and agrees to and with Landlord that Tenant shall, at its sole cost and expense, surrender the Demised Premises and all areas of the Industrial Center subjected to Tenant's use at the expiration or earlier termination of this Lease broom clean, with Tenant's personal property, furniture, fixtures and equipment and all Designated Alterations removed. Landlord and Tenant's obligations under this Section 10.1 shall be subject to the provisions of Section 13.6(b) and the so­ called "</font><font style="font-family:inherit;font-size:12pt;color:#2b2d34;text-decoration:underline;">waiver of subrogation</font><font style="font-family:inherit;font-size:12pt;color:#2b2d34;">" provisions referred to therein.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:justify;padding-left:8px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;color:#2b2d34;">If any repairs required to be made by Tenant hereunder are not made within twenty (20) days after written notice delivered to Tenant by Landlord, or if such repairs are of a nature that they cannot be completed within twenty (20) days, then if Tenant, within such twenty (20) day period has not commenced such repair or having commenced such repairs, thereafter fails to diligently complete such repairs, then Landlord may, at its option, make such repairs without liability to Tenant for any loss or damage which may result to its inventory or business by reason of such repairs, and Tenant shall pay to Landlord, as Additional Rent, upon demand, the reasonable cost of such repairs plus interest from the date of payment by Landlord until repaid by Tenant.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:justify;padding-left:8px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;color:#2b2d34;">Except as provided herein, Landlord shall have no obligation to repair or maintain the Demised Premises, or any part thereof, or any Building system therein, including, without limitation, the plumbing, heating, electrical, air-conditioning or other mechanical installations therein.</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;padding-top:1px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:justify;padding-left:8px;text-indent:45px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;color:#2b2d34;font-weight:bold;text-decoration:underline;">Section 10.2.</font><font style="font-family:inherit;font-size:12pt;color:#2b2d34;font-weight:bold;">   </font><font style="font-family:inherit;font-size:12pt;color:#2b2d34;text-decoration:underline;">Fixtures and Signs</font><font style="font-family:inherit;font-size:12pt;color:#505964;text-decoration:underline;">.</font><font style="font-family:inherit;font-size:12pt;color:#505964;"> </font><font style="font-family:inherit;font-size:12pt;color:#2b2d34;">Tenant shall not install or fix any sign, device, fixture or attachment on or to the exterior or interior of the Demised Premises or Building, nor place any vents, structure, building, improvement, sign or advertising device or obstruction of any type or kind upon the Common Facilities or on or to the exterior or interior of the Demised Premises, without first obtaining Landlord's written consent, which may be withheld in Landlord's sole and absolute discretion. If Tenant shall do any of the foregoing acts in contravention of this provision, then Landlord shall have the right to remove any such decoration, paint, alteration, sign, device, fixture or attachment, etc., and restore the Demised Premises and/or the Common Facilities to the condition thereof prior to such act, and the cost of such removal and restoration shall be paid by Tenant as an additional charge. Any signage approved for Tenant shall be installed, maintained and at the termination or expiration of this Lease removed by Tenant at Tenant's sole cost, expense and risk.</font></div><div style="line-height:120%;padding-top:1px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:justify;padding-left:8px;text-indent:89px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;color:#2b2d34;">Throughout the term of this Lease, Landlord reserves the right to remodel or renovate the Building facade and to require Tenant to replace, at its sole expense, its existing signage once during the original term of this Lease to conform to Landlord's common signage scheme for the Building as to sign size, location and material, but using Tenant's standard logo and sign colors.</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div><br></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:justify;padding-left:9px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:justify;padding-left:9px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;padding-top:2px;text-align:justify;padding-left:6px;text-indent:45px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;color:#242424;font-weight:bold;text-decoration:underline;">Section 10.3.</font><font style="font-family:inherit;font-size:12pt;color:#242424;font-weight:bold;">  </font><font style="font-family:inherit;font-size:12pt;color:#242424;text-decoration:underline;">Construction Standards.</font><font style="font-family:inherit;font-size:12pt;color:#242424;">  All construction work done by Tenant within the Demised Premises shall be performed in compliance with Article 5 hereof. Tenant shall, at Tenant's sole cost and expense, erect and install a temporary enclosure, subject to Landlord's reasonable approval, which structure shall enclose all of the Demised Premises during construction therein, and which enclosure shall meet all state and local fire codes and Landlord's insurance standards.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;color:#242424;font-weight:bold;text-decoration:underline;">ARTICLE 11. ENTRY, INSPECTION, POSTING AND DISPLAY</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:justify;padding-left:8px;text-indent:44px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;color:#242424;font-weight:bold;text-decoration:underline;">Section 11.1.</font><font style="font-family:inherit;font-size:12pt;color:#242424;font-weight:bold;"> </font><font style="font-family:inherit;font-size:12pt;color:#242424;font-weight:bold;"> </font><font style="font-family:inherit;font-size:12pt;color:#242424;text-decoration:underline;">Posting Notices.</font><font style="font-family:inherit;font-size:12pt;color:#242424;">  With not less than two (2) business days' prior notice and, at Tenant's option accompanied by a representative of Tenant, Tenant shall permit Landlord and any authorized representative of Landlord to enter the Demised Premises at all reasonable times during business hours for any of the following purposes: serving or posting or keeping posted thereon notices required by any law or which Landlord may reasonably deem necessary or appropriate for the protection of Landlord or its interest; inspecting the Demised Premises; inspecting the heating and air-conditioning service facilities and sprinkler facilities; any other reason that may be necessary to comply with any laws, ordinances, rules, regulations or requirements of any public authority or any applicable standards that may from time to time be established by all carriers of insurance on the Demised Premises, any Board of Underwriters, Rating Bureau or similar bodies or that Landlord may deem necessary to prevent waste, loss, damage, or deterioration to or in connection with the Demised Premises. Nothing herein shall imply any duty upon the part of Landlord to do any work which, under any provision of this Lease, Tenant may be required to perform, and the performance thereof by Landlord shall not constitute a waiver of Tenant's default in failing to perform the same. Landlord may, during the progress of any work on the Demised Premises, keep and store upon the Demised Premises all necessary materials, tools and equipment without the same constituting a constructive eviction of Tenant in whole or in part, and the rents reserved shall not abate while said work is in progress by reason of loss or interruption of Tenant's business or otherwise. Landlord shall not in any event be liable for inconvenience, annoyance, disturbance, loss of business or other damage of Tenant by reason of the performance of any work on the Demised Premises, or on account of bringing materials, supplies and equipment into or through the Demised Premises during the course of work on or in or under the Demised Premises, and the obligations of the Tenant under this Lease shall not thereby be affected in any manner whatsoever. However, Landlord, in connection with the doing of any such work, shall use reasonable efforts to minimize interference with Tenant's business without any obligation to utilize labor at overtime or other premium pay rates.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:justify;padding-left:9px;text-indent:45px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;color:#242424;font-weight:bold;text-decoration:underline;">Section 11.2.</font><font style="font-family:inherit;font-size:12pt;color:#242424;font-weight:bold;">  </font><font style="font-family:inherit;font-size:12pt;color:#242424;text-decoration:underline;">Entry to Demised Premises.</font><font style="font-family:inherit;font-size:12pt;color:#242424;">  With not less than two (2) business days' prior notice and, at Tenant's option accompanied by a representative of Tenant, Landlord and any authorized representative of Landlord may enter the Demised Premises at all reasonable times during business hours for the purpose of exhibiting the same to prospective purchasers, mortgagees, and, during the final twelve (12) months of the Lease Term, may exhibit the Demised Premises for hire.</font></div><div style="line-height:120%;padding-top:1px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:justify;padding-left:9px;text-indent:45px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;color:#242424;font-weight:bold;text-decoration:underline;">Section 11.3.</font><font style="font-family:inherit;font-size:12pt;color:#242424;font-weight:bold;">  </font><font style="font-family:inherit;font-size:12pt;color:#242424;font-weight:bold;"> </font><font style="font-family:inherit;font-size:12pt;color:#242424;text-decoration:underline;">Landlord's Easement.</font><font style="font-family:inherit;font-size:12pt;color:#242424;">  Tenant hereby grants to Landlord such licenses and easements in, over or under the Demised Premises or any portion or portions thereof as shall be reasonably required for the installation or maintenance of mains, conduits, pipes, ducts or other facilities to serve the Industrial Center, or any part thereof, including, but not by way of limitation,</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div><br></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;padding-top:2px;text-align:justify;padding-left:8px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;color:#2a2b33;">the premises of any other tenant or occupant; provided, however, that no exercise, occupancy under or enjoyment of any such license or easement shall result in the permanent unreasonable interference with Tenant's use of the Demised Premises as contemplated by this Lease.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:center;padding-left:113px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;color:#2a2b33;font-weight:bold;text-decoration:underline;">ARTICLE 12. LAWS AND INSURANCE STANDARDS</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:justify;padding-left:8px;text-indent:44px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;color:#2a2b33;font-weight:bold;text-decoration:underline;">Section 12.1.</font><font style="font-family:inherit;font-size:12pt;color:#2a2b33;">  </font><font style="font-family:inherit;font-size:12pt;color:#2a2b33;text-decoration:underline;">Tenant's Compliance With Laws and Insurance Standards.</font><font style="font-family:inherit;font-size:12pt;color:#2a2b33;">   Tenant shall, during the Lease Term and at Tenant's sole cost and expense, promptly comply in every respect with the following: all codes, laws, ordinances, rules and regulations of all federal, state, county and municipal governments, including without limitation, all Environmental Laws (hereinafter defined) now in force or that may be enacted hereafter; all requirements of the American with Disabilities Act of 1990, as the same may be hereafter modified from time to time; all directions, rules and regulations of the fire marshal, health officer, building inspector, zoning official and/or other proper officers of the governmental agencies having jurisdiction over the Demised Premises; all carriers of insurance on the Demised Premises, any Board of Underwriters, Rating Bureau and any similar bodies, which are applicable to Tenant's use and occupancy of the Demised Premises. Tenant shall, at Tenant's sole cost and expense, make all changes to the Demised Premises which are or hereafter may be required in order to comply with the foregoing. Tenant expressly covenants and agrees to indemnify and save Landlord harmless from any penalties, damages or charges imposed for any violation of any and all laws, ordinances, rules or regulations or violations of the covenants herein expressed, whether occasioned by Tenant or any person upon the Demised Premises. Tenant shall not do, suffer or permit anything to be done in or about the Demised Premises or the Industrial Center which would: (a) subject Landlord to any liability for injury to any person or property, (b) cause any increase in the insurance rates applicable to the Industrial Center, or (c) result in the cancellation of, or the assertion of any defense by any insurer to any claim under, any policy of insurance maintained by or for the benefit of Landlord.</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:justify;padding-left:8px;text-indent:44px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;color:#2a2b33;font-weight:bold;text-decoration:underline;">Section 12.2.</font><font style="font-family:inherit;font-size:12pt;color:#2a2b33;font-weight:bold;"> </font><font style="font-family:inherit;font-size:12pt;color:#2a2b33;"> </font><font style="font-family:inherit;font-size:12pt;color:#2a2b33;text-decoration:underline;">Tenant's Use of Demised Premises Impaired</font><font style="font-family:inherit;font-size:12pt;color:#2a2b33;">. Tenant shall have no claim against Landlord for any damages should Tenant's use and occupancy of the Demised Premises for the purpose set forth in this Lease be prohibited or substantially impaired by reason of any law, ordinance or regulation of federal, state, county or municipal governments or by reason of any act of any legal or governmental or other public authority.</font></div><div style="line-height:120%;text-align:justify;padding-left:8px;text-indent:44px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:center;padding-left:53px;text-indent:-39px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;color:#2a2b33;font-weight:bold;">ARTICLE 13. INDEMNIFICATION OF LANDLORD AND LIABILITY INSURANCE </font></div><div style="line-height:120%;padding-top:0px;text-align:center;padding-left:53px;text-indent:-39px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:left;padding-left:53px;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;color:#2a2b33;"></font><font style="font-family:inherit;font-size:12pt;color:#2a2b33;font-weight:bold;text-decoration:underline;">Section 13.1.</font><font style="font-family:inherit;font-size:12pt;color:#2a2b33;font-weight:bold;"> </font><font style="font-family:inherit;font-size:12pt;color:#2a2b33;"> </font><font style="font-family:inherit;font-size:12pt;color:#2a2b33;text-decoration:underline;">Tenant Indemnity</font><font style="font-family:inherit;font-size:12pt;color:#2a2b33;">. Except to the extent caused by the negligence or willful</font></div><div style="line-height:120%;text-align:justify;padding-left:8px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;color:#2a2b33;">misconduct of Landlord</font><font style="font-family:inherit;font-size:12pt;color:#595d64;">, </font><font style="font-family:inherit;font-size:12pt;color:#2a2b33;">its agents, employees or contractors, (a) Tenant hereby indemnifies and</font></div><div style="line-height:120%;padding-top:0px;text-align:justify;padding-left:8px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;color:#2a2b33;">agrees to defend and hold Landlord and its lenders, managing agents and its and their respective members</font><font style="font-family:inherit;font-size:12pt;color:#4b4952;">, </font><font style="font-family:inherit;font-size:12pt;color:#2a2b33;">partners, affiliates</font><font style="font-family:inherit;font-size:12pt;color:#595d64;">, </font><font style="font-family:inherit;font-size:12pt;color:#2a2b33;">principals, shareholders, officers, directors, members, trustees, fiduciaries, servants, agents and employees free and harmless from and against all suits, causes, actions, damages, liabilities, penalties, costs, charges, fees and expenses (including without limitation</font><font style="font-family:inherit;font-size:12pt;color:#595d64;">, </font><font style="font-family:inherit;font-size:12pt;color:#2a2b33;">attorneys' fees and disbursements), including without limitation, any claim relating to with loss of life, personal injury or property damage incurred in connection with or arising from (i) a breach by Tenant under this Lease or (ii) any occurrence in, upon, at or from the Demised Premises or (iii) the occupancy or use by Tenant of the Demised Premises or (iv) subject, to Section 13.5(b) below</font><font style="font-family:inherit;font-size:12pt;color:#4b4952;">, </font><font style="font-family:inherit;font-size:12pt;color:#2a2b33;">any act or omission by Tenant, its agents, contractors, employees, invitees, licensees or concessionaires</font><font style="font-family:inherit;font-size:12pt;color:#595d64;">, </font><font style="font-family:inherit;font-size:12pt;color:#2a2b33;">whether or not occurring or resulting in damage or injury within the</font></div><div><br></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;padding-top:1px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;padding-top:2px;text-align:justify;padding-left:6px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;color:#242424;">Demised Premises or upon the Common Facilities and whether or not any such act or omission constitutes a violation of law or this Lease; (b) Tenant shall store its property in and shall occupy the Demised Premises and all other portions of the Industrial Center at its own risk; Landlord shall not be responsible or liable at any time for any loss or damage to Tenant's merchandise, equipment, fixtures or other personal property of Tenant or to Tenant's business; (c) Landlord shall not be responsible or liable to Tenant, or to those claiming by, through or under Tenant, for any loss or damage to either the person or property of Tenant, or of those claiming by, through or under Tenant, that may be occasioned by or through the acts or omissions of persons occupying adjacent, connecting or adjoining premises; (d) Landlord shall not be responsible or liable for any defect, latent or otherwise, in any building in the Industrial Center or in any of the equipment, machinery, utilities, appliances or apparatus therein (provided that the foregoing shall not in any way reduce Landlord's repair, maintenance, replacement and restoration obligations set forth in this Lease); (e) Landlord shall not be responsible or liable for any injury, loss or damage to any person or to any property of Tenant or other person caused by or resulting from bursting, breakage or leakage, steam or snow or ice, running, backing up, seepage, or the overflow of water or sewage in any part of the Industrial Center or for any injury or damage caused by or resulting from any defect or negligence in the occupancy, construction or use of any building in the Industrial Center, or machinery, apparatus or equipment therein or thereon; or (f) by or from the acts of negligence of any occupant of the Industrial Center building. Providing Tenant has knowledge of same, Tenant shall give prompt notice to Landlord in case of fire or accidents in the Demised Premises or in the building of which the Demised Premises are a part and of defects therein or in any fixtures or equipment. Landlord shall in no event be liable for any damages arising from any act, omission or negligence of any other tenant at the Industrial Center. In case Landlord shall be made a party to any litigation commenced by or against Tenant through no fault of Landlord, its agents, contractors or employees, Tenant shall protect and hold Landlord harmless and shall pay all reasonable costs, expenses and attorney's fees in connection therewith. The obligations of Tenant under this Section shall survive the expiration or earlier termination of this Lease.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:justify;padding-left:8px;text-indent:45px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;color:#242424;font-weight:bold;text-decoration:underline;">Section 13.2.</font><font style="font-family:inherit;font-size:12pt;color:#242424;font-weight:bold;">  </font><font style="font-family:inherit;font-size:12pt;color:#242424;"> </font><font style="font-family:inherit;font-size:12pt;color:#242424;text-decoration:underline;">Tenant Liability Insurance.</font><font style="font-family:inherit;font-size:12pt;color:#242424;"> Tenant shall at all times during the Lease Term maintain in full force and effect the following insurance in standard form generally in use in the state in which the Industrial Center is located with insurance companies with an AM Best rating of A/VII or better (or a comparable rating in the event that the AM Best rating is no longer published) and authorized to do business in said state:</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:justify;padding-left:8px;text-indent:45px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;color:#242424;">(a) Commercial general liability insurance in the amount of at least One Million Dollars ($1,000,000) per any occurrence resulting in bodily injury, personal injury or property damage and fire legal liability in the amount of at least $500,000 per occurrence.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:justify;padding-left:8px;text-indent:45px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;color:#242424;">(b) Commercial Automobile Insurance covering all owned, non-owned and hired automobiles of Tenant including the loading and unloading of any automobile, truck or other vehicle with limits of liability not less than $1,000,000 combined single limit for bodily injury liability and property damage liability.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:justify;padding-left:8px;text-indent:45px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;color:#242424;">(c) umbrella Liability coverage with minimum limits of at least $10,000,000 each occurrence and $10,000,000 general aggregate, in excess of the general liability, commercial auto liability and employer's liability programs</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div><br></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:justify;padding-left:9px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;padding-top:2px;text-align:justify;padding-left:6px;text-indent:45px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;color:#2d2f36;">(d) Tenant shall require that all Contractor/Vendors (as defined in Section 13.5 below) Tenant hires to perform any alterations to the Demised Premises shall furnish Landlord and Tenant with certificates showing evidence of commercial general liability and damage insurance in the amount of at least $3,000,000 plus required workmen's compensation and employer's liability insurance coverage to the extent required by law.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:justify;padding-left:6px;text-indent:44px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;color:#2d2f36;">(e) If Tenant uses, stores, handles, processes or disposes of Hazardous Materials in the ordinary course of its business, then Tenant shall maintain in full force and effect throughout the Lease Term, Environmental Impairment Liability Insurance (including coverage for claims involving infectious waste, biological agents, bacteria and viruses) with limits of not less than Five Million Dollars ($5,000,000.00) naming Tenant as insured, and Landlord as an additional insured, and providing coverage for bodily injury, property damage or injury or damage of actual, alleged or threatened emission, discharge, dispersal, seepage, release or escape of Hazardous Materials, including any loss, cost or expense incurred as a result of any cleanup of Hazardous Materials or in the investigation, settlement or defense of any claim, suit, or proceedings against Landlord or its management company arising from Tenant's use, storage, handling, processing or disposal of Hazardous Materials. This paragraph is not intended to limit or modify any of the prohibitions set forth in Article 26 in any way.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:justify;padding-left:8px;text-indent:44px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;color:#2d2f36;">(f) Worker's compensation and employer's liability insurance to comply with the applicable laws of the state in which the Industrial Center is located.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:justify;padding-left:6px;text-indent:45px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;color:#2d2f36;font-weight:bold;text-decoration:underline;">Section 13.3.</font><font style="font-family:inherit;font-size:12pt;color:#2d2f36;">  </font><font style="font-family:inherit;font-size:12pt;color:#2d2f36;text-decoration:underline;">Landlord Indemnity</font><font style="font-family:inherit;font-size:12pt;color:#2d2f36;">. Except to the extent caused by the gross negligence or willful misconduct of Tenant, its agents, employees or contractors, Landlord hereby indemnifies and agrees to defend and hold Tenant and its managing agents and its and their respective members, partners, affiliates, principals, shareholders, officers, directors</font><font style="font-family:inherit;font-size:12pt;color:#525762;">, </font><font style="font-family:inherit;font-size:12pt;color:#2d2f36;">members, trustees, fiduciaries, servants, agents and employees free and harmless from and against all suits, causes, actions, damages, liabilities, penalties, costs, charges, fees and expenses (including without limitation, attorneys' fees and disbursements)</font><font style="font-family:inherit;font-size:12pt;color:#525762;">, </font><font style="font-family:inherit;font-size:12pt;color:#2d2f36;">including without limitation, any claim relating to with loss of life, personal injury or property damage incurred in connection with or arising from (i) a breach by Landlord under this Lease or (ii) arising out of loss of life or personal injury upon, at or from the Common Facilities which is caused by acts, failures, omissions or negligence of Landlord, its agents, employees or contractors</font><font style="font-family:inherit;font-size:12pt;color:#525762;">. </font><font style="font-family:inherit;font-size:12pt;color:#2d2f36;">The obligations of Landlord under this Section shall survive the expiration or earlier termination of this Lease</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:justify;padding-left:6px;text-indent:45px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;color:#2d2f36;font-weight:bold;text-decoration:underline;">Section 13.4.</font><font style="font-family:inherit;font-size:12pt;color:#2d2f36;font-weight:bold;">  </font><font style="font-family:inherit;font-size:12pt;color:#2d2f36;text-decoration:underline;">Landlord Liability Insurance</font><font style="font-family:inherit;font-size:12pt;color:#2d2f36;">. During the Lease Term, Landlord, at its own expense, shall maintain comprehensive general public liability insurance against any claims upon Landlord arising from the ownership, operation or control of the Industrial Center with respect to bodily injury, death, property damage or other risks of similar nature with combined limits as Landlord deems appropriate, but in no event less than Five Million and 00</font><font style="font-family:inherit;font-size:12pt;color:#525762;">/</font><font style="font-family:inherit;font-size:12pt;color:#2d2f36;">100 ($5,000,000) Dollars per occurrence.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:justify;padding-left:8px;text-indent:44px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;color:#2d2f36;font-weight:bold;text-decoration:underline;">Section 13.5.</font><font style="font-family:inherit;font-size:12pt;color:#2d2f36;">  </font><font style="font-family:inherit;font-size:12pt;color:#2d2f36;text-decoration:underline;">Contractors and Vendors.</font><font style="font-family:inherit;font-size:12pt;color:#2d2f36;">     Prior to allowing a contractor or vendor (collectively and individually, </font><font style="font-family:inherit;font-size:12pt;color:#44444b;">"</font><font style="font-family:inherit;font-size:12pt;color:#44444b;text-decoration:underline;">Contractor/V</font><font style="font-family:inherit;font-size:12pt;color:#2d2f36;text-decoration:underline;">endor"</font><font style="font-family:inherit;font-size:12pt;color:#2d2f36;">) to perform work or services on the premises, the Tenant shall comply with the following requirements:</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div><br></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:8px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;padding-top:2px;text-align:justify;padding-left:6px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;color:#262626;">(a) Tenant shall require that Contractor/Vendor shall provide indemnification and insurance in accordance this Lease and any additional and reasonable insurance requirements by Landlord on an ad hoc basis; and</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:justify;padding-left:6px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;color:#262626;">(b) To the extent permitted by applicable law and subject to the terms of this section, Tenant agrees to indemnify the Landlord and its lenders, managing agents and its and their respective members, partners, affiliates, principals, shareholders, officers, directors, members, trustees, fiduciaries, servants, agents and employees for any suits, damages, liabilities, professional fees, including attorneys' fees, costs, court costs, expenses and disbursements related to death, personal injuries or property damage (including loss of use thereof) brought or assumed against any of the Landlord and its lenders, managing agents and its and their respective members, partners, affiliates, principals, shareholders, officers, directors, members, trustees, fiduciaries, servants, agents and employees by any person or firm, arising out of or in connection with or as a result of or consequence of the Contractor/Vendor's presence on the premises or the performance of the work or services, whether or not caused in whole or in part by the Tenant or any person or entity employed/engaged, either directly or indirectly, by the Tenant, including any Contractor/Vendor and their employees. The parties expressly agree that this indemnification agreement contemplates (i) full indemnity in the event of liability imposed against Landlord and its lenders, managing agents and its and their respective members, partners, affiliates, principals, shareholders, officers, directors, members, trustees, fiduciaries, servants, agents and employees without negligence and solely by reason of statute, operation of law or otherwise; and (ii) partial indemnity in the event of any actual negligence on the part of Landlord and its lenders, managing agents and its and their respective members, partners, affiliates, principals, shareholders, officers, directors, members, trustees, fiduciaries, servants, agents and employees either causing or contributing to the underlying claim in which case, indemnification will be limited to any liability imposed over and above that percentage attributable to actual fault whether by statute, by operation of law, or otherwise. Where partial indemnity is provided under this agreement, costs, professional fees, attorneys' fees, expenses, disbursements, etc. shall be indemnified on a pro rata basis. Attorneys' fees, court costs, expenses and disbursements shall be defined without limit to include those fees, costs, etc. incurred in defending the underlying claim and those fees, costs, etc. incurred in connection with the enforcement of this Section 13.5 by way of cross-claim, third-party claim, declaratory action or otherwise.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:53px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;color:#262626;font-weight:bold;text-decoration:underline;">Section 13.6.</font><font style="font-family:inherit;font-size:12pt;color:#262626;font-weight:bold;">   </font><font style="font-family:inherit;font-size:12pt;color:#262626;text-decoration:underline;">General Insurance Requirements.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:6px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:5px;"><font style="font-family:inherit;font-size:12pt;color:#262626;">(a) </font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;color:#262626;">The insurance and certificates required in subsections 13.2(a) through (c) above shall be endorsed (using form CG 2010 (11/85) or its equivalent) to include Landlord (and any other parties requested by Landlord) as an additional insured for the full amount of the insurance herein required, contain a Primary and not Contributory Endorsement, and confirm that such policy provides coverage for damages which the Tenant is obligated to pay by reason of the assumption of liability in the indemnity agreement(s) within this Lease. Each policy required to be maintained by Tenant or any Contractor/Vendor under this Lease shall contain an endorsement requiring the insurer to give Landlord (30) days' prior written notice of cancellations, nonrenewal of or material changes in such policy. With respect to each and every policy of such insurance required to be maintained by Tenant and each renewal thereof, Tenant</font><font style="font-family:inherit;font-size:12pt;color:#606060;">, </font><font style="font-family:inherit;font-size:12pt;color:#262626;">at least five (5) days prior to the beginning of the Lease Term (and prior to Tenant entering on the Demised Premises) and thereafter not less than twenty (20) days prior to the expiration of any such policy, shall furnish Landlord with a</font></div></td></tr></table><div style="line-height:120%;padding-top:0px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div><br></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:justify;padding-left:9px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;padding-top:2px;text-align:justify;padding-left:6px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;color:#2a2b33;">certificate of insurance executed by the insurer evidencing the insurance required to be maintained by Tenant under this Lease.</font></div><div style="line-height:120%;padding-top:1px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:justify;padding-left:8px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;color:#2a2b33;">(b) Notwithstanding anything to the contrary contained in this Lease, each party hereto, on behalf of itself and on behalf of anyone claiming under or through it by way of subrogation or otherwise, waives all rights and causes of action against the other party, and the officers, directors or employees of the other party, for any liability arising out of any loss or damage in or to the Building, the Demised Premises and their contents caused by</font></div><div style="line-height:120%;padding-top:1px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:justify;padding-left:8px;text-indent:181px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;color:#2a2b33;">(1) any peril normally covered under "all-risk" or "Special Form" policies issued in the State of New Jersey (whether or not such party actually carries such insurance policies and without giving effect to any deductibles or self-insurance retainage), or</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:justify;padding-left:8px;text-indent:181px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;color:#2a2b33;">(2) if the scope of coverage is broader than in (1) above, then any peril actually covered under the insurance maintained by such party.</font></div><div style="line-height:120%;padding-top:1px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:justify;padding-left:8px;text-indent:90px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;color:#2a2b33;">To the extent permitted by applicable laws, this release and waiver shall be complete and total even if such loss or damage may have been caused by the negligence of the other party, its officers, employees, agents, directors, contractors or invitees and shall not be affected or limited by the amount of insurance proceeds available to the waiving party, regardless of the reason for such deficiency in proceeds. If any additional charge or increase in premium is made by the insurer because of this waiver of subrogation, then the party in whose favor the waiver was obtained shall pay such additional charge or increase in premium; failure to pay the increase in premium will void the release and waiver benefiting such party but shall not affect the benefit of the corresponding release and waiver enjoyed by the other party. However, if one party's insurance carrier prohibits waiver of subrogation regardless of premium, then the other party's release and waiver shall become null and void, it being understood that in this instance each waiver is given in consideration for the other. Each party covenants that from and after the date possession of the Leased Premises is delivered to Tenant its property damage insurance policies will contain waiver of subrogation endorsements, and that if such endorsements, for any reason whatsoever, are about to become unavailable, it will give the other party not less than thirty (30) days prior written notice of such impending unavailability. In the event of such unavailability each party shall use its commercially reasonable efforts to name the other party as an additional insured (but not loss payee) on its property damage insurance policies.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:73px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;color:#2a2b33;font-weight:bold;">ARTICLE 14. FIRE INSURANCE. DAMAGE AND DESTRUCTION</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:justify;padding-left:8px;text-indent:45px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;color:#2a2b33;font-weight:bold;text-decoration:underline;">Section 14.1.</font><font style="font-family:inherit;font-size:12pt;color:#2a2b33;font-weight:bold;"> </font><font style="font-family:inherit;font-size:12pt;color:#2a2b33;font-weight:bold;">  </font><font style="font-family:inherit;font-size:12pt;color:#2a2b33;text-decoration:underline;">Landlord Insurance.</font><font style="font-family:inherit;font-size:12pt;color:#2a2b33;">   At all times during the Lease Term, Landlord shall maintain in effect with a responsible insurance company or companies with an AM Best rating of A or better (or a comparable rating in the event that the AM Best rating is no longer published), policies of insurance covering the building of which the Demised Premises constitute a part, providing protection to the extent of not less than the full replacement cost of the Building against all casualties included under standard insurance industry practices within the classification "All Risk". Nothing in this Section shall prevent the taking out of policies of blanket insurance, which may cover real and/or personal property and improvements in addition to the building of which the Demised Premises constitutes a part; provided, however, that in all other respects each such policy shall comply with the other provisions of this Section 14.1.</font></div><div style="line-height:120%;padding-top:1px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div><br></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:justify;padding-left:9px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;padding-top:1px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;padding-top:2px;text-align:justify;padding-left:6px;text-indent:45px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;color:#262626;font-weight:bold;text-decoration:underline;">Section 14.2.</font><font style="font-family:inherit;font-size:12pt;color:#262626;font-weight:bold;">  </font><font style="font-family:inherit;font-size:12pt;color:#262626;text-decoration:underline;">Tenant Insurance.</font><font style="font-family:inherit;font-size:12pt;color:#262626;">  At all times during the Lease Term, Tenant shall pay all premiums for and maintain in effect, with a responsible insurance company or companies with an AM Best rating of ANII or better (or a comparable rating in the event that the AM Best rating is no longer published) licensed to do business within the state in which the Industrial Center is located, policies of insurance for the benefit of Tenant, as follows:</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:justify;padding-left:8px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;color:#262626;">(a) Insurance covering Tenant's trade fixtures, furniture, furnishings, equipment and other installations of Tenant not otherwise covered under Landlord's insurance coverage as described in Section 14.1 above, providing protection to the extent of not less than the full replacement cost thereof against all casualties included under standard insurance industry practices within the classification "All Risk" (including terrorism, flood and earthquake) and insurance covering sprinkler leakage, unless Tenant's insurance otherwise includes sprinkler leakage coverage.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:justify;padding-left:8px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;color:#262626;">(b) Plate glass insurance covering the plate glass in the Demised Premises; provided, however, Tenant may satisfy this requirement by self-insuring and in the event of damage or de­ struction to said plate glass immediately replacing same.</font></div><div style="line-height:120%;padding-top:1px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:justify;padding-left:8px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;color:#262626;">(c) Insurance covering the full replacement cost of any Tenant's Work against all casualties included under standard insurance industry practices within the classification "All Risk" which insurance shall be maintained, and under no circumstances terminated by Tenant.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:justify;padding-left:9px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;color:#262626;">(d) Such other insurance against such other hazards and in such amounts as may be customarily carried by tenants, owners and operators of similar properties as Landlord may reasonably require for its protection from time to time during the Lease Term.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:justify;padding-left:9px;text-indent:45px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;color:#262626;font-weight:bold;text-decoration:underline;">Section 14.3.</font><font style="font-family:inherit;font-size:12pt;color:#262626;font-weight:bold;">  </font><font style="font-family:inherit;font-size:12pt;color:#262626;text-decoration:underline;">Landlord Repair.</font><font style="font-family:inherit;font-size:12pt;color:#262626;">  If the Demised Premises shall be damaged by any fire or casualty covered under the Landlord's insurance policy pursuant to Section 14.1 and Landlord shall not elect to cancel this Lease pursuant to the provisions of Section 14.4, Landlord shall, upon receipt of the insurance proceeds, repair the same; provided, however, the obligation of Landlord to restore the Demised Premises as herein provided shall be limited to such restoration as can be financed by such insurance proceeds as shall actually be received by Landlord, free and clear from collection by any mortgagees and after deducting the cost and expense, if any, including attorneys' fees of settling with the insurer. In the event the proceeds received are not sufficient to fully restore the Demised Premises and Landlord elects not to fully restore the Demised Premises, Tenant shall have the right to terminate this Lease upon notice to Landlord. In no event shall Landlord be required to insure Tenant's personal property, Tenant's Work or any work performed by Landlord on Tenant's behalf (other than Landlord's Work) and Landlord shall have no obligation to repair or restore the same.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:justify;padding-left:9px;text-indent:45px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;color:#262626;font-weight:bold;text-decoration:underline;">Section 14.4.</font><font style="font-family:inherit;font-size:12pt;color:#262626;font-weight:bold;">   </font><font style="font-family:inherit;font-size:12pt;color:#262626;text-decoration:underline;">Lease Termination</font><font style="font-family:inherit;font-size:12pt;color:#262626;">. If the Demised Premises (a) by reason of a loss are rendered untenantable or (b) should be damaged as a result of a risk which is not covered by Landlord's insurance or (c) should be damaged in whole or in part during the last twelve (12) months of the Lease Term or any renewal term thereof or (d) if any or all of the buildings or Common Facilities of the Industrial Center are damaged, whether or not the Demised Premises are damaged, to such an extent that the Industrial Center cannot, in the reasonable judgment of Landlord, be operated as an integral unit, then, or in any such event, Landlord may either elect to repair the damage or may cancel this Lease (provided if Landlord elects to cancel this Lease,</font></div><div><br></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:justify;padding-left:10px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;padding-top:2px;text-align:justify;padding-left:8px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;color:#2a2b33;">Landlord must have also elected to cancel or terminate all other similarly affected leases in the Building). Landlord shall give the Tenant written notice of its election to terminate or to continue the Lease within ninety (90) days after such event. In the event of termination, this Lease shall expire at the end of the calendar month in which such notice of termination is given, and Tenant shall vacate and surrender the Demised Premises to the Landlord. In the event of notice by Landlord that Landlord has elected to continue this Lease, Landlord and Tenant shall commence their respective obligations for repair as soon as is reasonably possible and prosecute the same to completion with all due diligence.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:justify;padding-left:8px;text-indent:45px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;color:#2a2b33;font-weight:bold;text-decoration:underline;">Section 14.5.</font><font style="font-family:inherit;font-size:12pt;color:#2a2b33;font-weight:bold;">   </font><font style="font-family:inherit;font-size:12pt;color:#2a2b33;text-decoration:underline;">Rent Abatement</font><font style="font-family:inherit;font-size:12pt;color:#2a2b33;">. The Minimum Rent and all Additional Rent shall be abated proportionately with the degree in which Tenant's use of the Demised Premises is impaired during the period of any damage, repair or restoration provided for in this Article 14; provided that in the event Landlord elects to repair the damage insurable under Landlord's policies, any abate­ ment of rent shall end five (5) days after notice by Landlord to Tenant that the Demised Premises have been repaired. Tenant shall continue the operation of its business on the Demised Premises during any such period to the extent reasonably practicable from the standpoint of prudent business management. Except for the abatement of Minimum Rent and Additional Rent hereinabove provided, Tenant shall not be entitled to any compensation or damage for loss in the use of the whole or any part of the Demised Premises and/or any inconvenience or annoyance occasioned by any damage, destruction, repair or restoration.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:justify;padding-left:8px;text-indent:45px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;color:#2a2b33;font-weight:bold;text-decoration:underline;">Section 14.6.</font><font style="font-family:inherit;font-size:12pt;color:#2a2b33;font-weight:bold;">  </font><font style="font-family:inherit;font-size:12pt;color:#2a2b33;"> </font><font style="font-family:inherit;font-size:12pt;color:#2a2b33;text-decoration:underline;">Tenant Repairs</font><font style="font-family:inherit;font-size:12pt;color:#2a2b33;">. Unless this Lease is terminated by Landlord or Tenant, Tenant shall repair, restore and refixture all parts of the Demised Premises which Landlord is not obligated to restore pursuant to Section 14.3 in a manner and to a condition substantially equal to that existing prior to its destruction or casualty, including, but not by way of limitation, all exterior signs, trade fixtures, equipment, display cases, furniture, furnishings and other installations of personalty of Tenant.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:justify;padding-left:8px;text-indent:45px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;color:#2a2b33;font-weight:bold;text-decoration:underline;">Section 14.7.</font><font style="font-family:inherit;font-size:12pt;color:#2a2b33;font-weight:bold;"> </font><font style="font-family:inherit;font-size:12pt;color:#2a2b33;font-weight:bold;">        </font><font style="font-family:inherit;font-size:12pt;color:#2a2b33;text-decoration:underline;">Tenant Termination Right</font><font style="font-family:inherit;font-size:12pt;color:#2a2b33;">. A. In the event (a) the Demised Premises or Building shall be damaged by fire or other casualty and Tenant shall be unable to use the Demised Premises for the Permitted Use (set forth in Section 1.9) or Tenant shall be denied reasonable access to the Demised Premises as a result of such damage and (b) Landlord shall give Tenant notice of its election to continue the Lease rather than terminate same pursuant to Section</font></div><div style="line-height:120%;padding-top:0px;text-align:justify;padding-left:8px;text-indent:1px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;color:#2a2b33;">14.4, then, if such damage is not repaired within the Casualty Restoration Period (as defined herein), Tenant shall have the following options:</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:justify;padding-left:8px;text-indent:181px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;color:#2a2b33;">(i) to give to Landlord, within ten (10) days next following the expiration of the Casualty Restoration Period, a five (5) days’ notice of termination of this Lease, or</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:justify;padding-left:6px;text-indent:181px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;color:#2a2b33;">(ii) to extend the Casualty Restoration Period for a further period of three (3) months by notice given to Landlord within ten (10) days after the expiration of the initial Casualty Restoration Period. In the event Tenant shall have given such notice to Landlord extending the initial Casualty Restoration Period and if such damage shall not have been repaired by Landlord within any extended Casualty Restoration Period, Tenant shall have the options to (a) further extend the Casualty Restoration Period for further successive periods of three (3) months, by notice given to Landlord within twenty (20) days after the expiration of any extended Casualty</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div><br></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:justify;padding-left:8px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;padding-top:2px;text-align:left;padding-left:6px;text-indent:-2px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;color:#262626;">Restoration Period or (b) to give Landlord, within twenty (20) days after the expiration of any such extended Casualty Restoration Period a five (5) days' notice of termination of this Lease.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:6px;text-indent:44px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;color:#262626;">The term "</font><font style="font-family:inherit;font-size:12pt;color:#262626;text-decoration:underline;">Casualty Restoration Period</font><font style="font-family:inherit;font-size:12pt;color:#262626;">" shall mean twelve (12) months after the date of such fire or other casualty.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:justify;padding-left:6px;text-indent:89px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;color:#262626;">B. Notwithstanding anything to the contrary contained in the provisions of Subsection A of this Section 14.7, in the event (a) the Demised Premises or Building shall be damaged by fire or other casualty and Tenant shall be unable to use the Demised Premises as a result of such damage and (b) Landlord shall not exercise the right to terminate this Lease in accordance with the provisions of Section 14.4, and (c) Landlord, in the opinion of Landlord's independent architect, shall determine that the repair of such damage to the Demised Premises or Building will reasonably require a period longer than twelve (12)months, Landlord shall within ninety (90) days after the date of such fire or casualty, give a notice to Tenant extending the initial Casualty Restoration Period to the date upon which Landlord estimates that such repair to the Demised Premises or Building shall be completed. In the event Landlord shall give such a notice under this Subsection B, then, the initial Casualty Restoration Period set forth in Paragraph A of this Section 14.7, shall be so extended and (b) Tenant shall have the further option to give to Landlord a five (5) days' notice of termination of this Lease within twenty (20) days next following the giving of such notice under this Subsection B by Landlord to Tenant extending the initial Casualty Restoration Period.</font></div><div style="line-height:120%;padding-top:1px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:justify;padding-left:8px;text-indent:89px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;color:#262626;">C. Time is of the essence with respect to the giving by Tenant to Landlord of any notice in accordance with the provisions of Subsections A and B of this Section 14.7 and in the event that Tenant shall fail to give any such notice within the time periods set forth therein, Tenant shall be deemed to have given to Landlord a notice pursuant to subdivision (ii) of Subsection A of this Section 14.7 extending the Casualty Restoration Period provided, however, that any five (5) days' notice of termination given by Tenant pursuant to the provisions of Subsection A or B of this Section 14.7 beyond the twenty (20) day period provided therein shall be void and of no force and effect.</font></div><div style="line-height:120%;padding-top:1px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:justify;padding-left:9px;text-indent:89px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;color:#262626;">D. In the event that Tenant shall give to Landlord within the applicable time periods set forth in the foregoing provisions of this Section a five (5) days' notice of termination of this Lease, this Lease and the Lease Term shall come to an end and expire upon the expiration of said five (5) days with the same effect as if the date of expiration of said five (5) days were the Expiration Date, the Minimum Rent and all increases thereof and Additional Rent shall be apportioned as of such date, and any prepaid portion of Minimum Rent and increases thereof or Additional Rent for any period after such date shall be refunded by Landlord to Tenant.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:justify;padding-left:9px;text-indent:89px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;color:#262626;">E. Nothing contained in the foregoing provisions of this Section 14.7 shall be deemed to affect the rights of Landlord to give to Tenant a notice of termination of this Lease in accordance with the provisions of Section 14.4.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:justify;padding-left:9px;text-indent:89px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;color:#262626;">F. Supplementing the foregoing, Landlord shall, within ninety (90) days after the occurrence of any of the type of casualty referred to in Section 14.7A.(a), notify Tenant whether or not the repair therefor will reasonably require a period of longer than twelve (12) months to complete. If Landlord notifies Tenant that, in the opinion of Landlord's independent architect,</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div><br></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:10px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;padding-top:2px;text-align:justify;padding-left:8px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;color:#2b2d34;">reasonably determined, such repair will take more than twelve (12) months to complete or in the event the occurrence of any type of casualty referred to in Section 14.7(A)(a) shall occur during the last two (2) years of the Lease Term or any renewal term thereof, Tenant shall have the single right to give to Landlord, within twenty (20) days' next following Landlord's notice, a five (5) day notice of termination of this Lease, time being of the essence with respect thereto. If Tenant fails to give such notice, Tenant shall not have the right to terminate this Lease except as otherwise expressly set forth in this Section and the foregoing provisions of this Section shall apply.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:180px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;color:#2b2d34;font-weight:bold;text-decoration:underline;">ARTICLE 15. EMINENT DOMAIN</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:justify;padding-left:8px;text-indent:44px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;color:#2b2d34;font-weight:bold;text-decoration:underline;">Section 15.1.</font><font style="font-family:inherit;font-size:12pt;color:#2b2d34;font-weight:bold;">  </font><font style="font-family:inherit;font-size:12pt;color:#2b2d34;text-decoration:underline;">Entire Taking</font><font style="font-family:inherit;font-size:12pt;color:#2b2d34;">. In the event that the whole of the Demised Premises shall be taken under the power of eminent domain, this Lease shall thereupon terminate as of the date possession shall be so taken.</font></div><div style="line-height:120%;padding-top:1px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:justify;padding-left:8px;text-indent:44px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;color:#2b2d34;font-weight:bold;text-decoration:underline;">Section 15.2.</font><font style="font-family:inherit;font-size:12pt;color:#2b2d34;font-weight:bold;"> </font><font style="font-family:inherit;font-size:12pt;color:#2b2d34;font-weight:bold;"> </font><font style="font-family:inherit;font-size:12pt;color:#2b2d34;text-decoration:underline;">Partial Taking Other than Demised Premises</font><font style="font-family:inherit;font-size:12pt;color:#2b2d34;">. If more than ten percent (10%) of the floor area of the Building in which the Demised Premises is located, whether or not any portion of the Demised Premises is included therein, is taken as aforesaid, then Landlord may, by written notice to Tenant, terminate this Lease, such termination to be effective as of the date possession shall be so taken.</font></div><div style="line-height:120%;padding-top:1px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:justify;padding-left:8px;text-indent:44px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;color:#2b2d34;font-weight:bold;text-decoration:underline;">Section 15.3.</font><font style="font-family:inherit;font-size:12pt;color:#2b2d34;font-weight:bold;">   </font><font style="font-family:inherit;font-size:12pt;color:#2b2d34;text-decoration:underline;">Partial Taking Demised Premises.</font><font style="font-family:inherit;font-size:12pt;color:#2b2d34;">    In the event that a portion of the Demised Premises shall be taken under the power of eminent domain and the portion not so taken will not, in the reasonable business judgment of both Landlord and Tenant, be suitable for the operation of Tenant's business notwithstanding Landlord's performance of restoration as hereinafter set out in this Section, this Lease shall thereupon terminate as of the date possession of said portion is taken. In the event of any taking under the power of eminent domain which is not sufficiently extensive to render the Demised Premises unsuitable for the business of the Tenant, the provisions of this Lease shall remain in full force and effect, except that the Minimum Rent shall be reduced in the same proportion that the amount of Demised Premises taken bears to the original total Demised Premises immediately prior to such taking, and Landlord shall, upon receipt of the award in condemnation, make all necessary repairs or alterations to the building in which the Demised Premises are located so as to constitute the portion of the building not taken a complete architectural unit, but Landlord shall not be required to spend for such work an amount in excess of the amount received by Landlord as damages for the part of the Demised Premises so taken. "Amount received by Landlord" shall mean that part of the award in condemnation which is free and clear to Landlord of any collection by mortgagees for the value of the diminished fee, and after payment of all costs involved in collection including but not limited to attorneys fees. Tenant, at its own cost and expense, shall, with respect to all exterior signs, trade fixtures, equip­ ment, display cases, furniture, furnishings and other installations of personality of Tenant, restore such part of the Demised Premises as is not taken to as near its former condition as the circumstances will permit.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:justify;padding-left:8px;text-indent:44px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;color:#2b2d34;font-weight:bold;text-decoration:underline;">Section 15.4.</font><font style="font-family:inherit;font-size:12pt;color:#2b2d34;font-weight:bold;">   </font><font style="font-family:inherit;font-size:12pt;color:#2b2d34;text-decoration:underline;">Condemnation Award.</font><font style="font-family:inherit;font-size:12pt;color:#2b2d34;">   In the event the Demised Premises or any part thereof shall be taken or condemned either permanently or temporarily for any public or quasi­ public use or purpose by any competent authority in appropriate proceedings or by any right of eminent domain, the entire compensation award for both leasehold and reversion shall belong to the Landlord without any deduction therefrom for any present or future estate of Tenant, and</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div><br></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:justify;padding-left:9px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;padding-top:2px;text-align:justify;padding-left:6px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;color:#242424;">Tenant hereby expressly waives any claim and assigns to Landlord all its right, title and interest to any such award. However, Tenant shall be entitled to claim in such condemnation proceedings such award as may be allowed for relocation costs, fixtures and other equipment installed by it, but only to the extent that the same shall not reduce Landlord's award and only if such award shall be in addition to the award for the land and building (or portion thereof) containing the Demised Premises. To the extent that the Tenant has a claim in condemnation proceedings, as aforesaid, Tenant may claim for condemnors, but not from Landlord, such compensation as may be recoverable by Tenant.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:justify;padding-left:8px;text-indent:45px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;color:#242424;font-weight:bold;text-decoration:underline;">Section 15.5.</font><font style="font-family:inherit;font-size:12pt;color:#242424;">  </font><font style="font-family:inherit;font-size:12pt;color:#242424;text-decoration:underline;">Rent Proration.</font><font style="font-family:inherit;font-size:12pt;color:#242424;">  If the Lease is terminated as provided in this Article 15, all rent and other charges shall be paid up to the date that possession is taken by public authority, and Landlord shall make refund of any rent and other charges paid by Tenant in advance and not yet earned. Further, in the event the square footage of the Demised Premises is reduced as a result of any such condemnation or taking, Tenant's Pro-Rata Share shall be reduced accordingly.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:justify;padding-left:8px;text-indent:45px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;color:#242424;font-weight:bold;text-decoration:underline;">Section 15.6.</font><font style="font-family:inherit;font-size:12pt;color:#242424;font-weight:bold;"> </font><font style="font-family:inherit;font-size:12pt;color:#242424;"> </font><font style="font-family:inherit;font-size:12pt;color:#242424;text-decoration:underline;">Temporary Taking.</font><font style="font-family:inherit;font-size:12pt;color:#242424;">     Notwithstanding anything to the contrary in the foregoing provisions of this Article 15, the requisitioning of the Demised Premises or any part thereof by military or other public authority for purposes arising out of a temporary emergency or other temporary situation shall constitute a taking of the Demised Premises by eminent domain only when the use and occupancy by the requisitioning authority has continued for thirty (30) consecutive days. During such thirty (30) day period, and if this Lease is not terminated under the foregoing provisions of this Article 15, then for the duration of the use and occupancy of the Demised Premises by the requisitioning authority, the provisions of this Lease shall remain in full force and effect, except that the Minimum Rent shall be reduced in the same proportion that the amount of the Demised Premises requisitioned bears to the total Demised Premises, and Landlord shall be entitled to whatever compensation may be payable from the requisitioning authority.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:178px;text-indent:-94px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;color:#242424;font-weight:bold;">ARTICLE 16. FINANCIAL INFORMATION; STATEMENT OF TENANT;AMENDMENT TO LEASE</font></div><div style="line-height:120%;padding-top:1px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:justify;padding-left:9px;text-indent:45px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;color:#242424;font-weight:bold;text-decoration:underline;">Section 16.1.</font><font style="font-family:inherit;font-size:12pt;color:#242424;">  </font><font style="font-family:inherit;font-size:12pt;color:#242424;text-decoration:underline;">Delivery of Information</font><font style="font-family:inherit;font-size:12pt;color:#242424;">. Tenant shall, at any time and from time to time within ten (10) days of written request by Landlord, deliver to Landlord any and all of the following:</font></div><div style="line-height:120%;padding-top:1px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:justify;padding-left:9px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;color:#242424;">(a) Such financial information concerning Tenant and Tenant's business operations as may reasonably be requested by a mortgagee or prospective mortgagee or purchaser of the Industrial Center or any part thereof; provided, however, Tenant shall not be required to deliver such financial information more than once in a twelve (12) month period and shall not be required to deliver any financial information if Tenant’s financial statements are publicly available.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:justify;padding-left:9px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;color:#242424;">(b) An executed and acknowledged written declaration, prepared by Landlord and reasonably acceptable to Tenant: (1) ratifying this Lease; (2) expressing the commencement and termination dates hereof; (3) certifying that this Lease is in full force and effect and has not been assigned, modified, supplemented or amended (except by such writings as shall be stated and attached); (4) certifying that, to the extent of Tenant's knowledge, and if the same be true, that all conditions under this Lease to be performed by Landlord have been satisfied; (5) certifying that there are no known defenses or offsets against the enforcement of this Lease by the Landlord, or</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div><br></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:justify;padding-left:10px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:justify;padding-left:10px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;padding-top:2px;text-align:justify;padding-left:6px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;color:#2d2f36;">stating those claimed by Tenant; (6) stating the amount of advance rental if any (or none if such is the case), paid by Tenant; (7) stating the date to which rental has been paid; and (8) certifying such other matters as shall be requested by Landlord or Landlord's lender or any superior lessor.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:justify;padding-left:6px;text-indent:92px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;color:#2d2f36;">(c) </font><font style="font-family:inherit;font-size:12pt;color:#44464b;">An </font><font style="font-family:inherit;font-size:12pt;color:#2d2f36;">executed and acknowledged instrument, prepared by Landlord, amending this Lease in such respects as may be required by any mortgagee or prospective mortgagee, provided that any such amendment shall not alter or impair any of the rights and remedies of Tenant under this Lease or increase Tenant's financial obligations under this Lease in each case by more than a deminimis degree and Landlord pays Tenant's reasonable out of pocket attorneys' fees, in connection with any such amendment.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:justify;padding-left:6px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;color:#2d2f36;">(d) </font><font style="font-family:inherit;font-size:12pt;color:#2d2f36;"> </font><font style="font-family:inherit;font-size:12pt;color:#2d2f36;text-decoration:underline;">Use of Information.</font><font style="font-family:inherit;font-size:12pt;color:#2d2f36;">   Any financial information delivered pursuant to Section 16.1(a) and any statement delivered pursuant to Section 16.1(b) may be relied upon by any mortgagee or prospective mortgagee or purchaser; provided, however, that any such financial information and any such statement shall be utilized only for bona fide business reasons related to such mortgage or purchase.</font></div><div style="line-height:232%;padding-top:0px;text-align:center;padding-left:52px;text-indent:-35px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;color:#2d2f36;font-weight:bold;text-decoration:underline;">ARTICLE 17. ASSIGNMENT.SUBLETTING AND HYPOTHECATION OF LEASE </font></div><div style="line-height:232%;padding-top:0px;text-align:justify;padding-left:52px;text-indent:-35px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;color:#2d2f36;font-weight:bold;text-decoration:underline;">Section 17.1.</font><font style="font-family:inherit;font-size:12pt;color:#2d2f36;">  </font><font style="font-family:inherit;font-size:12pt;color:#2d2f36;text-decoration:underline;">Assignment and Subletting.</font><font style="font-family:inherit;font-size:12pt;color:#2d2f36;">   Except as herein provided, Tenant shall not,</font></div><div style="line-height:120%;padding-top:0px;text-align:justify;padding-left:6px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;color:#2d2f36;">and shall not have the power to, transfer, assign, sublet, enter into license or concession agreements, change ownership, mortgage or hypothecate this Lease or Tenant's interest in and to the Demised Premises without first procuring the written consent of Landlord, which consent shall not be unreasonably withheld, conditioned or delayed. Any attempted or purported transfer, assignment, subletting, license or concession agreement, change of ownership, mortgage or hypothecation without Landlord's written consent pursuant to this Section 17.1 or Section 17.2 shall be void and confer no rights upon any third person. The consent by Landlord to any assignment or subletting shall not constitute a waiver of the necessity for such consent to any subsequent assignment or subletting. If this Lease be assigned or if the Demised Premises or any part thereof be occupied by anybody other than Tenant, Landlord may collect rent from the assignee, or (with respect to a subletting, during the pendency of any uncured Default hereunder) the occupant, and apply the net amount collected to the rent reserved, but no such assignment, underletting, occupancy or collection shall be deemed a waiver of this provision or the acceptance of the assignee, undertenant or occupant as Tenant. Nothing herein contained shall relieve Tenant or any Guarantor from its covenants and obligations for the term of this Lease. Tenant agrees to reimburse Landlord for Landlord's reasonable attorney's fees incurred in conjunction with the processing and documentation of any such requested transfer, assignment, subletting, license or concession agreement, change of ownership, mortgage or hypothecation of this Lease by Tenant or Tenant's interest in and to the Demised Premises up to a maximum of $3,500.00.</font></div><div style="line-height:120%;padding-top:0px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:justify;padding-left:6px;text-indent:45px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;color:#2d2f36;font-weight:bold;text-decoration:underline;">Section 17.2.</font><font style="font-family:inherit;font-size:12pt;color:#2d2f36;font-weight:bold;"> </font><font style="font-family:inherit;font-size:12pt;color:#2d2f36;"> </font><font style="font-family:inherit;font-size:12pt;color:#2d2f36;text-decoration:underline;">Documentation Required.</font><font style="font-family:inherit;font-size:12pt;color:#2d2f36;">  Each transfer, assignment, subletting, license, concession agreement, mortgage or hypothecation to which there has been consent shall be by an instrument in writing in form reasonably satisfactory to Landlord, and shall be executed by the transferor, assignor, sublessor, licensor, concessionaire, hypothecator or mortgagor and the transferee, assignee, sublessee, licensee, concessionaire or mortgagee in each instance, as the case may be; and each assignee shall agree in writing for the benefit of Landlord herein to assume, to be bound by, and to perform the terms, covenants and conditions of this Lease to be done, kept</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div><br></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:justify;padding-left:6px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;padding-top:2px;text-align:justify;padding-left:6px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;color:#262626;">and performed by Tenant, including the payment of all amounts due or to become due under this Lease directly to Landlord. Failure to first obtain in writing Landlord's consent or failure to comply with the provisions of this Section shall operate to prevent any such transfer, assignment, subletting, license, concession agreement or hypothecation from becoming effective.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:justify;padding-left:6px;text-indent:45px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;color:#262626;font-weight:bold;text-decoration:underline;">Section 17.3.</font><font style="font-family:inherit;font-size:12pt;color:#262626;font-weight:bold;">   </font><font style="font-family:inherit;font-size:12pt;color:#262626;text-decoration:underline;">Voting Control</font><font style="font-family:inherit;font-size:12pt;color:#262626;">. In the event the Tenant is a corporation, any dissolution, merger, consolidation or other reorganization of such corporation or the sale or other transfer of a controlling percentage of the corporate stock of Tenant shall constitute an assignment of this Lease for all purposes of this Article 17; provided, however, that any transfer by inheritance or by any transaction in Tenant's stock or the stock of a corporation owning or controlling a majority of Tenant's stock which occurs on a major security exchange (including, but not limited to, NASDAQ or any successor thereto) shall not be considered an assignment hereunder. The term "</font><font style="font-family:inherit;font-size:12pt;color:#262626;text-decoration:underline;">controlling percentage"</font><font style="font-family:inherit;font-size:12pt;color:#262626;">, for the purpose of this Article 17, means the ownership of stock possessing, and of the right to exercise voting power of all classes of stock of such corporation issued, outstanding and entitled to vote for the election of directors, whether such ownership be direct or indirect ownership through ownership of stock possessing, and of the right to exercise, at least fifty-one percent (51%) of the total combined voting power of all classes of stock of another corporation or corporations.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:justify;padding-left:6px;text-indent:89px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;color:#262626;">In the event Tenant is a partnership or entity other than a corporation, any dissolution, merger, consolidation or other reorganization of such partnership or entity or the sale or transfer of a controlling percentage of such partnership or entity shall constitute an assignment of this Lease for all purposes of this Article 17; provided, however, that any transfer by inheritance shall not be considered an assignment hereunder. The term "controlling percentage," for the purpose of this Article 17 means the ownership of, and the right to exercise, at least fifty-one percent (51%) of the total combined voting rights of said partnership or entity, whether such ownership be direct or indirect.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:justify;padding-left:8px;text-indent:45px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;color:#262626;font-weight:bold;text-decoration:underline;">Section 17.4.</font><font style="font-family:inherit;font-size:12pt;color:#262626;font-weight:bold;"> </font><font style="font-family:inherit;font-size:12pt;color:#262626;font-weight:bold;">  </font><font style="font-family:inherit;font-size:12pt;color:#262626;text-decoration:underline;">Tenant Includes Approved Assignees and Subtenants.</font><font style="font-family:inherit;font-size:12pt;color:#262626;">    In the event that Landlord shall agree to any transfer of Tenant’s interest in this Lease, then the term "Tenant" shall thereafter be deemed to include, without further reference, the party to whom such interest is transferred, which is, for example, but without limiting the generality thereof, any subtenant, assignee, concessionaire or licensee. Except as otherwise expressly set forth herein, if the Lease be assigned or if the Demised Premises or any part thereof be occupied by anybody other than Tenant, then Landlord may collect rent from the assignee or occupant in accordance with the provisions of Section 17.1 above. Notwithstanding any assignment or sublease, Tenant shall remain fully liable and shall not be released from performing any of the terms of this Lease.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:justify;padding-left:8px;text-indent:45px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;color:#262626;font-weight:bold;text-decoration:underline;">Section 17.5.</font><font style="font-family:inherit;font-size:12pt;color:#262626;font-weight:bold;"> </font><font style="font-family:inherit;font-size:12pt;color:#262626;font-weight:bold;">  </font><font style="font-family:inherit;font-size:12pt;color:#262626;text-decoration:underline;">Tenant Include Successors.</font><font style="font-family:inherit;font-size:12pt;color:#262626;">   All rights, obligations and liabilities herein given to, or imposed upon, the respective parties hereto shall extend to and bind the several and respective heirs, executors, administrators, successors, subtenants, licensees, concessionaires and assigns of the named Tenant herein, except as expressly provided in this Article; and if there shall be more than one Tenant they shall all be bound jointly and severally by the terms, covenants, conditions and agreements herein and the word "Tenant" shall be deemed and taken to mean each and every person or party mentioned as a Tenant herein, be the same one or more; and if there shall be more than one Tenant, any notice required or permitted by the terms of this Lease may be given by or to any one thereof. No rights, however, shall inure to the benefit of any assignee of</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div><br></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:justify;padding-left:9px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;padding-top:2px;text-align:justify;padding-left:6px;text-indent:-2px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;color:#2d2f36;">Tenant unless the assignment to such assignee has been approved by Landlord in writing as aforesaid. The use of the neuter singular pronoun to refer to Landlord or Tenant shall be deemed a proper reference even though Landlord or Tenant may be an individual, a partnership, a corporation, a group of two or more individuals or corporations. The necessary grammatical changes required to make the provisions of this Lease apply in the plural sense where there is more than one Landlord or Tenant and to either corporations, associations, partnerships, or individuals, males or females, shall in all instances be assumed as though in each case fully expressed.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:justify;padding-left:6px;text-indent:46px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;color:#2d2f36;font-weight:bold;text-decoration:underline;">Section 17.6.</font><font style="font-family:inherit;font-size:12pt;color:#2d2f36;">  </font><font style="font-family:inherit;font-size:12pt;color:#2d2f36;text-decoration:underline;">Successor to Landlord Interest.</font><font style="font-family:inherit;font-size:12pt;color:#2d2f36;"> The term "</font><font style="font-family:inherit;font-size:12pt;color:#2d2f36;text-decoration:underline;">Landlord,</font><font style="font-family:inherit;font-size:12pt;color:#2d2f36;">" as used in this Lease, so far as covenants, conditions and agreements on the part of the said Landlord are concerned, shall be limited to mean the party executing this Lease as Landlord, its successors and assigns, and in the event of any transfer or transfers of the interest of Landlord in the Industrial Center, the said Landlord (and in case of any subsequent transfers or conveyances, the then grantor) shall be automatically freed and relieved from and after the date of such transfer or conveyance of all liability as respects the performance of any covenants, conditions and agreements on the part of said Landlord contained in this Lease thereafter to be performed, provided that any amount then due and payable to Tenant by Landlord, or the then grantor, under any provisions of this Lease, shall be paid to Tenant. It being intended by Landlord and Tenant that the covenants, conditions and agreements contained in this Lease on the part of the Landlord shall, subject as aforesaid, be binding on Landlord, its successors and assigns, only during and in respect of their respective successive periods of ownership. Further, Landlord's liability under this Lease shall be limited to and include only the interest of Landlord in the Industrial Center.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:justify;padding-left:6px;text-indent:81px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;color:#2d2f36;font-weight:bold;text-decoration:underline;">Section 17.7.</font><font style="font-family:inherit;font-size:12pt;color:#2d2f36;">     </font><font style="font-family:inherit;font-size:12pt;color:#2d2f36;text-decoration:underline;">Transfer Premium.</font><font style="font-family:inherit;font-size:12pt;color:#2d2f36;">  If Landlord consents to any assignment of this Lease, or subletting of the Demised Premises or parts thereof (a "</font><font style="font-family:inherit;font-size:12pt;color:#2d2f36;text-decoration:underline;">Transfer"</font><font style="font-family:inherit;font-size:12pt;color:#2d2f36;">) then, as a condition thereto, which the parties hereby agree is reasonable, Tenant shall pay Landlord fifty percent (50%) of the Minimum Rent and Tenant's Pro-Rata Share of Complex Operating Costs received by Tenant from such Transfer in excess of the Minimum Rent and Tenant's Pro-Rata Share of Complex Operating Costs payable by Tenant under this Lease with respect to the Demised Premises or the portion thereof that is the subject of the Transfer, after deducting the reasonable expenses incurred by Tenant in connection with the Transfer (the "Transfer Premium"). Such Transfer Premium shall be paid promptly by Tenant upon Tenant's receipt from time to time of periodic payments from such transferee or such other time as Tenant shall realize a Transfer Premium from such transferee.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:justify;padding-left:6px;text-indent:46px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;color:#2d2f36;font-weight:bold;text-decoration:underline;">Section 17.8.</font><font style="font-family:inherit;font-size:12pt;color:#2d2f36;">   </font><font style="font-family:inherit;font-size:12pt;color:#2d2f36;text-decoration:underline;">Sublet Rights.</font><font style="font-family:inherit;font-size:12pt;color:#2d2f36;">   A. (1) As long as Tenant is not in default under any of the terms, covenants or conditions of this Lease on Tenant's part to be observed and performed, Landlord agrees not to unreasonably withhold Landlord's prior consent to sublettings by Tenant of all or portions of the Demised Premises to not more than three (3) subtenants. Each such subletting shall be for undivided occupancy by the subtenant for that part of the Demised Premises affected thereby, for the use expressly permitted in this Lease, and at no time shall there be more than three (3) occupants (inclusive of Tenant) in the Demised Premises, it being understood that any such occupant shall have a self-contained separately demised space with demising walls furnished and supplied by Tenant at Tenant's expense;</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:6px;text-indent:273px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;color:#2d2f36;">(2) </font><font style="font-family:inherit;font-size:12pt;">    </font><font style="font-family:inherit;font-size:12pt;color:#2d2f36;">Without Landlord's prior consent, Tenant shall not (a) negotiate or enter into a proposed subletting with any tenant, subtenant or occupant</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div><br></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:justify;padding-left:6px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;padding-top:1px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;padding-top:2px;text-align:justify;padding-left:6px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;color:#262626;">of any space in the Building or (b) list or otherwise publicly advertise the Demised Premises or any part thereof for subletting at a rental lower than the Minimum Rent then in effect under this Lease;</font></div><div style="line-height:120%;padding-top:2px;text-align:justify;padding-left:6px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:278px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;color:#262626;">(3) </font><font style="font-family:inherit;font-size:12pt;">    </font><font style="font-family:inherit;font-size:12pt;color:#262626;">At least thirty (30) days prior to any proposed</font></div><div style="line-height:120%;padding-top:0px;text-align:justify;padding-left:6px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;color:#262626;">subletting, Tenant shall submit to Landlord a statement (the "</font><font style="font-family:inherit;font-size:12pt;color:#262626;text-decoration:underline;">Proposed Sublet Statement</font><font style="font-family:inherit;font-size:12pt;color:#262626;">") containing the name and address of the proposed subtenant, the nature of the proposed subtenant's business and its current </font><font style="font-family:inherit;font-size:12pt;color:#2d2f36;">financial </font><font style="font-family:inherit;font-size:12pt;color:#262626;">status, and all of the principal terms and conditions of the proposed subletting including, but not limited to, the proposed commencement and expiration dates of the term thereof; and</font></div><div style="line-height:120%;padding-top:0px;text-align:justify;padding-left:6px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:justify;padding-left:8px;text-indent:270px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;color:#262626;">(4) Landlord may arbitrarily withhold consent to a proposed subletting if, (a) in Landlord's reasonable judgment, the occupancy of the proposed</font></div><div style="line-height:120%;padding-top:0px;text-align:justify;padding-left:8px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;color:#262626;">subtenant will tend to impair the character or dignity of the Building or impose any additional burden upon Landlord in the operation of the Building, or (b) the proposed subtenant shall be a person or entity with whom Landlord is then negotiating or discussing to lease space in the Building or (c) the proposed sublet rent is less than the fair rental value of the Demised Premises or (d) the proposed use of the Demised Premises is reasonably objectionable to Landlord; and</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:justify;padding-left:8px;text-indent:270px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;color:#262626;">(5) Any Sublease consented to by Landlord must conform to the information contained in the Proposed Sublet Statement and shall expressly provide that (a) the subtenant shall obtain the provisions in its insurance policies to the effect that such policies shall not be invalidated should the insured waive, in writing, prior to a loss, any or all right of recovery against any party for loss occasioned by fire or other casualty which is an insured risk under such policies, as set forth in Article 14, and (b) in the event of the termination, re-entry or dispossess of Tenant by Landlord under this Lease, Landlord may, at its option, take over all of the right, title and interest of Tenant, as sublessor under the sublease, and such subtenant shall, at Landlord's option, attorn to Landlord pursuant to the then executory provisions of such sublease, except that Landlord shall not (i) be liable for any previous act or omission of Tenant under such sublease, (ii) be subject to any offset which accrued to such subtenant against Tenant, (iii) be bound by any previous modification of such sublease or by any previous prepayment of more than one month's rent unless such modification or prepayment was previously approved by Landlord, (iv) be bound by any covenant to undertake or complete any construction of the premises, or any portion thereof, demised by such sublease and (v) be bound by any obligation to make any payment to or on behalf of the subtenant, except for services, repairs, maintenance and restoration provided for under the sublease to be performed after the date of such termination, re-entry or dispossess by Landlord under this Lease and to which Landlord is expressly required to perform under this Lease with respect to the subleased space at Landlord's expense, it being expressly understood, however, that Landlord shall not be bound by any obligation to make payment to or on behalf of a subtenant with respect to construction performed by or on behalf of such subtenant in the subleased premises. Tenant shall reimburse Landlord on demand for any reasonable out of pocket costs or expense that may be actually incurred by Landlord's review of any Proposed Sublet Statement or in connection with any sublease consented to by Landlord, including, without limitation, any reasonable processing fee, reasonable attorneys' fees and disbursements and the reasonable costs of making investigations as to the acceptability of the proposed subtenant up to a maximum of $3,500.00. Further, the provisions of Section 17.7 with respect to payment of a Transfer Premium shall apply to each and every subletting consented to by Landlord.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div><br></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:justify;padding-left:10px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;padding-top:2px;text-align:justify;padding-left:6px;text-indent:134px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;color:#2a2b33;">B. Notwithstanding the foregoing provisions set forth in A hereof, Landlord shall have the following rights with respect to each proposed subletting by Tenant other than a subletting in accordance with the provisions of Section 17.10:</font></div><div style="line-height:120%;padding-top:1px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:justify;padding-left:6px;text-indent:225px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;color:#2a2b33;">(1) In the event Tenant proposes to sublet all or any portion of the Demised Premises pursuant to a transaction for which Landlord's consent is required, prior to entering into such sublease, Tenant shall have the right to advise Landlord in writing of its intention to sublet all or such portion of the Premises (hereinafter referred to as the "</font><font style="font-family:inherit;font-size:12pt;color:#2a2b33;text-decoration:underline;">Prior Notice</font><font style="font-family:inherit;font-size:12pt;color:#2a2b33;">"). If Landlord does not notify Tenant within twenty (20) days after receipt of the Prior Notice that it intends to cancel this Lease with respect to the Demised Premises or the portion thereof intended to be sublet or to recapture the portion of the Demised Premises or portion thereof for the portion of the term described in the Prior Notice, Tenant shall have the right to sublet the Demised Premises or portion thereof described in the Prior Notice in subject to the terms and conditions of this Article 17, however, Landlord shall not have the right to terminate this Lease with respect to the Demised Premises or the portion thereof described in the Prior Notice.</font></div><div style="line-height:120%;padding-top:1px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:justify;padding-left:6px;text-indent:226px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;color:#2a2b33;">(2) In the event Tenant proposes to sublet all or substantially of the Demised Premises for all or substantially all of the remainder of the Demised Term pursuant to a transaction for which Landlord's consent is required and Tenant has not given Landlord a Prior Notice, Landlord, at Landlord's option, may give to Tenant, within thirty (30) days after the submission by Tenant to Landlord of the Proposed Sublet Statement, a notice terminating this Lease on the date (referred to as the "</font><font style="font-family:inherit;font-size:12pt;color:#2a2b33;text-decoration:underline;">Earlier Termination Date"</font><font style="font-family:inherit;font-size:12pt;color:#2a2b33;">) immediately prior to the proposed commencement date of the term of the proposed subletting, as set forth in the Proposed Sublet Statement, and, in the event such notice is given, this Lease and the Lease Term shall come to an end and expire on the Earlier Termination Date with the same effect as if it were the Expiration Date, the Minimum Rent shall be apportioned as of said Earlier Termination Date and any prepaid portion of Minimum Rent and Additional Rent for any period after such date shall be refunded by Landlord to Tenant</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:justify;padding-left:6px;text-indent:226px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;color:#2a2b33;">(3) In the event Tenant proposes to sublet all or any portion of the Demised Premises for less than all or substantially all of the remainder of the Term pursuant to a transaction for which Landlord's consent is required and Tenant has not given Landlord a Prior Notice, Landlord, at Landlord's option, may give to Tenant, within thirty (30) days after the submission by Tenant to Landlord, of the Proposed Sublet Statement required to be submitted in connection with such proposed subletting, a notice electing to recapture the portion of the Demised Premises proposed to be sublet as designated on a plan (the "</font><font style="font-family:inherit;font-size:12pt;color:#2a2b33;text-decoration:underline;">Recapture Premises"</font><font style="font-family:inherit;font-size:12pt;color:#2a2b33;">) during the period (referred to as the "Recapture Period") commencing on the date (referred to as "Recapture Date") immediately prior to the proposed commencement date of the term of the proposed subletting, as set forth in the Proposed Sublet Statement, and ending on the proposed expiration date of the term of the proposed subletting, as set forth in the Proposed Sublet Statement, and in the event such notice is given the following shall apply:</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:justify;padding-left:6px;text-indent:226px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;color:#2a2b33;">(a) Tenant shall, at Tenant's cost, demise any such Recapture Premises prior to the commencement of the Recapture Period and the Recapture Premises shall be recaptured by Landlord during the Recapture Period;</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div><br></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:8px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;color:#525966;">00355322.4</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;padding-top:2px;text-align:justify;padding-left:6px;text-indent:225px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;color:#262626;">(b) Tenant shall surrender the Recapture Premises to Landlord on or prior to the Recapture Date in the same manner as if said Recapture Date were the Expiration Date;</font></div><div style="line-height:120%;text-align:left;padding-left:233px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;color:#262626;">(c) </font><font style="font-family:inherit;font-size:12pt;">    </font><font style="font-family:inherit;font-size:12pt;color:#262626;">During the Recapture Period, Tenant shall have no</font></div><div style="line-height:120%;padding-top:0px;text-align:justify;padding-left:6px;text-indent:-2px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;color:#262626;">rights with respect to the Recapture Premises nor any obligations with respect to the Recapture Premises, including, but not limited to, any obligations to pay Minimum Rent or Additional Rent, applicable to the Recapture Premises and any prepaid portion of Minimum Rent allocable to the Recapture Period for the Recapture Premises shall be refunded by Landlord to Tenant;</font></div><div style="line-height:120%;padding-top:1px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:233px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;color:#262626;">(d) </font><font style="font-family:inherit;font-size:12pt;">    </font><font style="font-family:inherit;font-size:12pt;color:#262626;">There shall be an equitable apportionment of any</font></div><div style="line-height:120%;padding-top:0px;text-align:justify;padding-left:8px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;color:#262626;">Additional Rent pursuant to Article 4 for the Lease Year in which said Recapture Date shall occur;</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:justify;padding-left:8px;text-indent:225px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;color:#262626;">(e) Upon the expiration of the Recapture Period, the Recapture Premises shall be restored to Tenant, in the condition which existed immediately prior to the Recapture Date, ordinary wear and tear excepted, and Tenant shall have all rights with respect to the Recapture Premises which are set forth in this Lease and all obligations with respect to the Recapture Premises which are set forth in this Lease, including, but not limited to, the obligations for the payment of Minimum Rent and Additional Rent (as they would have been adjusted if Tenant occupied the Recapture Premises during the Recapture Period) during the period (referred to as the "</font><font style="font-family:inherit;font-size:12pt;color:#262626;text-decoration:underline;">Recapture Restoration Period</font><font style="font-family:inherit;font-size:12pt;color:#262626;">") commencing on the date next following the expiration of the Recapture Period and ending on the Expiration Date, except in the event that Landlord is unable to give Tenant possession of the Recapture Premises at the expiration of the Recapture Period by reason of the holding over or retention of possession of any tenant or other occupant, in which event (x) the Recapture Restoration Period shall not commence and the Recapture Premises shall not be deemed available for Tenant's occupancy and Tenant shall not be required to comply with the obligations of Tenant under this Lease until the date upon which Landlord shall give Tenant possession of the Recapture Premises free of occupancies, (y) neither the Expiration Date nor the validity of this Lease nor the obligations of Tenant under this Lease shall be affected thereby, and (z) Tenant waives any rights to rescind this Lease and to recover any damages which may result from the failure by Landlord to deliver possession of the Recapture Premises at the end of the Recapture Period; Landlord agrees to institute, within thirty (30) days after the expiration of the Recapture Period, possession proceedings against any tenants and occupants who have not so vacated and surrendered all or any portions of the Recapture Premises and agrees to prosecute such proceedings with reasonable diligence; and</font></div><div style="line-height:120%;padding-top:1px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:justify;padding-left:9px;text-indent:225px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;color:#262626;">(f) There shall be an equitable apportionment of any Additional Rent pursuant to Article 4 for the Lease Year in which the Recapture Restoration Period shall commence. At the request of Landlord, Tenant shall execute and deliver an instrument or instruments, in form and substance reasonably satisfactory to Landlord, setting forth any modifications to this Lease contemplated in or resulting from the operation of the foregoing provisions hereof; however, neither Landlord's failure to request any such instrument nor Tenant's failure to execute or deliver any such instrument shall vitiate the effect of the foregoing provisions of this Section. The failure by Landlord to exercise any option under this Section with respect to any subletting shall not be deemed a waiver of such option with respect to any extension of such subletting or any subsequent subletting of the premises affected thereby or any other portion of the Demised Premises. Tenant shall indemnify Landlord from all loss, cost, liability, damage and</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div><br></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-top:1px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:justify;padding-left:10px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;padding-top:2px;text-align:justify;padding-left:6px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;color:#2a2b33;">expense, including, but not limited to, reasonable counsel fees and disbursements, arising from any claims against Landlord by any broker or other person, for a brokerage commission or other similar compensation in connection with any such proposed subletting, in the event (a) Landlord shall (i) fail or refuse to consent to any proposed subletting, or (ii) exercise any of its options under this Section, or (b) any proposed subletting shall fail to be consummated for any reason whatsoever.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:justify;padding-left:6px;text-indent:45px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;color:#2a2b33;font-weight:bold;text-decoration:underline;">Section 17.9.</font><font style="font-family:inherit;font-size:12pt;color:#2a2b33;font-weight:bold;">  </font><font style="font-family:inherit;font-size:12pt;color:#2a2b33;font-weight:bold;text-decoration:underline;">Merger/Consolidation/Asset or Stock Sale.</font><font style="font-family:inherit;font-size:12pt;color:#2a2b33;font-weight:bold;">   </font><font style="font-family:inherit;font-size:12pt;color:#2a2b33;">Notwithstanding anything contained in this Article 17 to the contrary, as long as Tenant is not in default under any of the terms, covenants or conditions of this Lease on Tenant's part to be observed and performed, beyond applicable notice and cure periods, Tenant shall have the right, without the prior consent of Landlord, to assign Tenant's interest in this Lease to any person, corporation</font><font style="font-family:inherit;font-size:12pt;color:#576069;">, </font><font style="font-family:inherit;font-size:12pt;color:#2a2b33;">partnership, or other business entity which is a successor of Tenant, either by (i) merger or consolidation or (ii) the purchase of all or substantially all of the (x) assets or stock, and (y) business and goodwill of Tenant, provided that said person, corporation, partnership or other business entity which shall be Tenant following such merger, consolidation or asset purchase or Tenant following the transfer of stock, as the case may be, (the "</font><font style="font-family:inherit;font-size:12pt;color:#2a2b33;text-decoration:underline;">Proposed Assignee</font><font style="font-family:inherit;font-size:12pt;color:#2a2b33;">") shall have a tangible net worth, as determined in accordance with generally accepted accounting principles consistently applied following the consummation of such transaction, at least equal to the greater of (x) that of Tenant named hereunder as of the date of this Lease and (y) that of Tenant immediately prior to such transaction (such required net worth, the "</font><font style="font-family:inherit;font-size:12pt;color:#2a2b33;text-decoration:underline;">Required Net Worth</font><font style="font-family:inherit;font-size:12pt;color:#2a2b33;">") and provided further that such Proposed Assignee shall continue to operate the same business conducted by Tenant in the Demised Premises immediately prior to the transaction and the interest of Tenant in this Lease is not the sole asset of Tenant named herein and such assignment shall be for a bone fide business purpose and shall not be intended to circumvent the restrictions on assignment set forth in this Lease. At the time of said proposed assignment, Tenant shall deliver to Landlord a reasonably detailed statement of the </font><font style="font-family:inherit;font-size:12pt;color:#2d2f36;">financial </font><font style="font-family:inherit;font-size:12pt;color:#2a2b33;">condition of the aforesaid Proposed Assignee, prepared in accordance with generally accepted accounting principles applied on a consistent basis, sworn to by an executive officer or principal or partner of Tenant and the Proposed Assignee, and certified without qualification by a firm of reputable independent certified public accountants which statement shall reflect the financial condition of the aforesaid proposed assignee at that time after taking into account the consummation of the assignment of this Lease and any other transactions related thereto. Notwithstanding anything contained in this Section to the contrary, such assignment shall not be valid if the Proposed Assignee shall not have a tangible net worth following the cons</font><font style="font-family:inherit;font-size:12pt;color:#49494f;">umm</font><font style="font-family:inherit;font-size:12pt;color:#2a2b33;">ation of such transaction at least equal to the Required Net Worth or the interest of Tenant named herein in this Lease is the sole or principal asset of Tenant named herein or such assignment is not made for a bona fide business purpose. Furthermore, no such assignment in connection with an asset sale shall be valid, unless, within ten (10) days after the execution thereof, Tenant shall deliver to Landlord (I) a duplicate original instrument of assignment in form and substance reasonably satisfactory to Landlord duly executed by Tenant, acknowledged before a notary public, in which Tenant shall (a) waive Tenant's right to receive all notices of default given to the assignee and all other notices of every kind or description, now or hereafter provided in this Lease, by statute or by rule of law; (b) acknowledge that Tenant's obligations with respect to this Lease shall not be discharged, released or impaired by (i) such assignment; (ii) any amendment or modification of this Lease (whether or not the obligations of the tenant under the Lease are increased thereby); (iii) any further assignment or transfer of the tenant's interest in this Lease;</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;padding-top:1px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:justify;padding-left:8px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div><br></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;padding-top:2px;text-align:justify;padding-left:6px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;padding-top:2px;text-align:justify;padding-left:6px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;padding-top:2px;text-align:justify;padding-left:6px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;color:#262626;">(iv) any exercise, non- exercise or waiver by Landlord of any right, remedy, power or privilege under or with respect to this Lease; (v) any waiver, consent, extension, indulgence or other act or omission with respect to any of the obligations of Tenant under this Lease; (vi) any act or thing which, but for the provisions of such assignment, might be deemed a legal or equitable discharge of a surety or assignor, to all of which Tenant shall consent in advance; and (c) expressly waive and surrender any then existing defense to its liability thereunder; it being the purpose and intent of Landlord and Tenant that the obligations of Tenant hereunder as assignor shall be absolute and unconditional under any and all circumstances; and {II) an instrument in form and substance reasonably satisfactory to Landlord, duly executed by the Proposed Assignee, acknowledged before a notary public, in which such Proposed Assignee shall assume observance and performance of, and agree to be personally bound by, all of the terms, covenants and conditions of this Lease on Tenant's part to be performed. In addition, no such assignment in connection with a merger, consolidation or sale of stock or other equity interests in Tenant shall be valid unless within ten (10) business days after the consummation thereof, Tenant shall deliver to Landlord (xx) a copy of the certificate of merger or consolidation which was filed in the relevant jurisdiction, in the event the assignment was in connection with a merger or consolidation, or (yy) a statement identifying the purchaser(s) of the stock or other equity interests in Tenant, in the event the assignment was in connection with a sale of the stock or other equity interests in Tenant. The provisions of Section 17.7 relating to assignment consideration shall not be applicable to any proposed assignment of this Lease made in accordance with the provisions of this Section 17.9. In the event of any dispute between Landlord and Tenant as to the validity of any such assignment such dispute shall be determined by arbitration where designated by Landlord. Any such determination shall be final and binding upon the parties whether or not a judgment shall be entered in any court. If the determination of any such arbitration shall be adverse to Landlord, Landlord, nevertheless, shall not be liable for damages to Tenant and Tenant's sole remedy in such event shall be to have the proposed assignment deemed valid.</font></div><div style="line-height:120%;padding-top:1px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:justify;padding-left:8px;text-indent:45px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;color:#262626;font-weight:bold;text-decoration:underline;">Section 17.10.</font><font style="font-family:inherit;font-size:12pt;color:#262626;font-weight:bold;"> </font><font style="font-family:inherit;font-size:12pt;color:#262626;">Notwithstanding anything contained in this Article 17 to the contrary, as long as Tenant is not then in default (x) under any of the non-monetary terms, covenants or conditions of this Lease on Tenant's part to be observed or performed beyond the applicable notice and grace periods set forth in this Lease or (y) under the monetary terms, covenants or conditions of this Lease on Tenant's part to be observed or performed, Tenant shall have the right, without the prior consent of Landlord, to sublet to, or permit the use or occupancy of, all or any part of the Demised Premises by any subsidiary or affiliate (as said terms are defined in Subsection A above) of Tenant named herein for the use permitted in this Lease provided that such subsidiary or affiliate is in the same general line of business as the Tenant named herein and only for such period as it shall remain a subsidiary or affiliate of, and in the same general line of business as, the Tenant named herein. However, no such subletting shall be valid unless, prior to the execution thereof, Tenant shall give notice to Landlord of the proposed subletting, and within ten (10) days prior the commencement of said subletting, Tenant shall deliver to Landlord an agreement, in form and substance satisfactory to Landlord, duly executed by Tenant and said subtenant, in which said subtenant shall assume performance of and agree to be personally bound by, all of the terms, covenants and conditions of this Lease which are applicable to said subtenant and such subletting. Tenant shall give prompt notice to Landlord of any such use or occupancy of all or any part of the Demised Premises and such use or occupancy shall be subject and subordinate to all of the terms, covenants and conditions of this Lease. No such use or occupancy shall operate to vest in the user or occupant any right or interest in this Lease or the Demised Premises. The provisions of Section</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div><br></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:justify;padding-left:9px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;padding-top:2px;text-align:justify;padding-left:6px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;color:#2d2f36;">17.7 relating to Landlord's rights to the Transfer Premium shall not be applicable to any proposed subletting to any such subsidiary or affiliate of Tenant pursuant to the provisions of this Section</font></div><div style="line-height:120%;text-align:justify;padding-left:8px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;color:#2d2f36;">17.10.</font></div><div style="line-height:120%;padding-top:1px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:center;padding-left:146px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;color:#2d2f36;font-weight:bold;text-decoration:underline;">ARTICLE 18. INTENTIONALLY DELETED</font></div><div style="line-height:120%;text-align:center;padding-left:146px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:center;padding-left:146px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;color:#2d2f36;font-weight:bold;text-decoration:underline;"> ARTICLE 19. SURRENDER OF PREMISES</font></div><div style="line-height:120%;text-align:center;padding-left:146px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:52px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;color:#2d2f36;font-weight:bold;text-decoration:underline;">Section 19.1.</font><font style="font-family:inherit;font-size:12pt;color:#2d2f36;font-weight:bold;">  </font><font style="font-family:inherit;font-size:12pt;color:#2d2f36;">Upon the expiration or sooner termination of this Lease, Tenant shall</font></div><div style="line-height:120%;padding-top:0px;text-align:justify;padding-left:6px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;color:#2d2f36;">surrender to Landlord the Demised Premises, including, without limitation, all carpeting, additions, alterations, </font><font style="font-family:inherit;font-size:12pt;color:#46464d;">improvements, </font><font style="font-family:inherit;font-size:12pt;color:#2d2f36;">apparatus and fixtures, in good and broom clean condition and repair, as aforesaid in Section 10.1 hereof; provided, however, that Tenant (i) shall be required to remove unattached and moveable and trade fixtures and furniture and other personal property installed by Tenant and all Designated Alterations; and (ii) may be permitted to remove, upon written approval by Landlord, which approval shall not be unreasonably withheld, such other alterations, additions, improvements and fixtures installed by Tenant, and which are removable without material damage to the Demised Premises, and, in each instance, Tenant shall remove any Tenant's Work which has been designated in any notice from Landlord to Tenant in accordance with the provision of Section 5.11 and restore the affected portion of the Demised Premises to their original condition at Tenant's expense.. Any unattached moveable fixtures and furniture installed by Tenant not removed by Tenant upon the expiration or sooner termination of the Lease as aforesaid for any reason whatsoever shall become the property of Landlord, and Landlord may thereafter, at Tenant's sole cost and expense, cause such property to be removed from the Demised Premises. Landlord shall not in any manner or to any extent be obligated to reimburse Tenant for any property which becomes the property of Landlord as a result of such expiration or earlier termination nor shall Landlord's retention or sale of such property waive any of Landlord's rights with respect to any default by Tenant under the foregoing provisions of this Section.</font></div><div style="line-height:120%;padding-top:1px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:center;padding-left:158px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;color:#2d2f36;font-weight:bold;text-decoration:underline;">ARTICLE 20. HOLDOVER BY TENANT</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:justify;padding-left:6px;text-indent:45px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;color:#2d2f36;font-weight:bold;text-decoration:underline;">Section 20.1.</font><font style="font-family:inherit;font-size:12pt;color:#2d2f36;font-weight:bold;">   </font><font style="font-family:inherit;font-size:12pt;color:#2d2f36;text-decoration:underline;">Rent In The Event Of Holdover.</font><font style="font-family:inherit;font-size:12pt;color:#2d2f36;"> </font><font style="font-family:inherit;font-size:12pt;color:#2d2f36;">  In the event that Tenant shall hold the Demised Premises after the expiration of </font><font style="font-family:inherit;font-size:12pt;color:#46464d;">the </font><font style="font-family:inherit;font-size:12pt;color:#2d2f36;">Lease Term without the express written consent of the Landlord, such holding shall be deemed to have created a tenancy from month to month terminable on thirty (30) days' written notice by either party to the other, upon a monthly rental basis, and otherwise subject to all terms and provisions of this Article 20. Such monthly rental shall be the greater of (i) 150% of the monthly rental in effect immediately prior to the expiration of the Lease Term or (ii) fair rental value.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:justify;padding-left:6px;text-indent:45px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;color:#2d2f36;font-weight:bold;text-decoration:underline;">Section 20.2.</font><font style="font-family:inherit;font-size:12pt;color:#2d2f36;font-weight:bold;">   </font><font style="font-family:inherit;font-size:12pt;color:#2d2f36;text-decoration:underline;">Liability In The Event Of Holdover.</font><font style="font-family:inherit;font-size:12pt;color:#2d2f36;">   If the Tenant fails to surrender the Demised Premises within ninety (90) days after the expiration or earlier termination of this Lease, then Tenant shall, in addition to any other liabilities to Landlord accruing therefrom, indemnify and hold Landlord harmless from loss or liability resulting from such failure, including, without limiting the generality of the foregoing, any claims made by any succeeding tenant founded on such failure.</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:justify;padding-left:6px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div><br></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:justify;padding-left:6px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:justify;padding-left:6px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;padding-top:2px;text-align:center;padding-left:133px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;color:#262626;font-weight:bold;">ARTICLE 21. ADDITIONAL CONSTRUCTION</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:justify;padding-left:6px;text-indent:45px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;color:#262626;font-weight:bold;text-decoration:underline;">Section 21.1.</font><font style="font-family:inherit;font-size:12pt;color:#262626;font-weight:bold;">   </font><font style="font-family:inherit;font-size:12pt;color:#262626;text-decoration:underline;">Construction By Landlord.</font><font style="font-family:inherit;font-size:12pt;color:#262626;">  Landlord hereby reserves the right, at any time and from time to time, providing reasonable access to the Demised Premises is not materially and adversely affected, to make alterations or additions to the Industrial Center, to build additional stories on the building in which the Demised Premises are contained and to build adjoining same and to construct other or add to other buildings or improvements in the Industrial Center; provided, however, that such construction or additions shall not unreasonably interfere with Tenant's use of the Demised Premises as permitted hereunder, except when such work is necessitated by emergency or required by structural need.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:justify;padding-left:6px;text-indent:45px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;color:#262626;font-weight:bold;text-decoration:underline;">Section 21.2.</font><font style="font-family:inherit;font-size:12pt;color:#262626;font-weight:bold;">  </font><font style="font-family:inherit;font-size:12pt;color:#262626;text-decoration:underline;">Excavation.</font><font style="font-family:inherit;font-size:12pt;color:#262626;">    If an excavation shall be made upon land adjacent to the Demised Premises, then, Tenant shall permit the person authorized to cause such excavation license to enter upon the Demised Premises for the purpose of doing such work as such person deems necessary to preserve the wall or the building of which the Demised Premises form a part from damage and to support the same by proper foundations and Tenant shall not be entitled to any claim for damages or indemnification against Landlord nor shall Tenant be entitled to an abatement of rent. Reasonable efforts shall be taken to preserve vehicular and personnel access during any such work.</font></div><div style="line-height:232%;text-align:left;padding-left:53px;text-indent:116px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;color:#262626;font-weight:bold;text-decoration:underline;">ARTICLE 22. DEFAULT; REMEDIES</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;color:#262626;font-weight:bold;"> </font><font style="font-family:inherit;font-size:12pt;color:#262626;font-weight:bold;text-decoration:underline;">Section 22.1.</font><font style="font-family:inherit;font-size:12pt;color:#262626;font-weight:bold;">   </font><font style="font-family:inherit;font-size:12pt;color:#262626;text-decoration:underline;">Defaults. Conditional Limitation.</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:left;padding-left:8px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;color:#262626;">(a) </font><font style="font-family:inherit;font-size:12pt;">    </font><font style="font-family:inherit;font-size:12pt;color:#262626;">Each of the following events shall constitute a default under this Lease (each, a</font></div><div style="line-height:120%;padding-top:0px;text-align:left;padding-left:8px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;color:#262626;">"Default"):</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:justify;padding-left:8px;text-indent:76px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;color:#262626;">(i) If Tenant, or any guarantor of Tenant's obligations hereunder (any such guarantor, a "Guarantor"), shall: (x) make an assignment for the benefit of creditors; or (y) file or acquiesce to a petition in any court (whether or not pursuant to any statute of the United States or of any State) in any bankruptcy, reorganization, composition, extension, arrangement or insolvency proceedings; or (z) make an application in any such proceedings for or acquiesce to the appointment of a trustee or receiver for it or all of any portion of its property.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:justify;padding-left:8px;text-indent:72px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;color:#262626;">(ii) If any petition shall be filed against Tenant, or any Guarantor, to which neither of them acquiesce in any court (whether or not pursuant to any statute of the United States or any State) in any bankruptcy, reorganization, composition, extension, arrangement or insolvency proceedings, and: (x) Tenant or any Guarantor shall thereafter be adjudicated a bankrupt;, or (y) such petition shall be approved by any such court; or (z) such proceedings shall not be dismissed, discontinued or vacated within sixty (60) days.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:justify;padding-left:8px;text-indent:66px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;color:#262626;">(iii) If, in any proceeding, pursuant to the application of any Person other than Tenant, or any Guarantor to which neither of them acquiesce, a receiver or trustee shall be appointed for Tenant, or any Guarantor or for all or any portion of the property of either and such receivership or trusteeship shall not be set aside within sixty (60) days after such appointment.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:justify;padding-left:9px;text-indent:68px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;color:#262626;">(iv) If Tenant shall refuse to take possession of the Demised Premises within sixty (60) days after the Commencement Date.</font></div><div><br></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;padding-top:2px;text-align:justify;padding-left:6px;text-indent:73px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;color:#2b2d34;">(v) If Tenant shall fail to pay any Minimum or Additional Rent (collectively, "</font><font style="font-family:inherit;font-size:12pt;color:#2b2d34;text-decoration:underline;">Rent</font><font style="font-family:inherit;font-size:12pt;color:#2b2d34;">"), or any other charge required to be paid by Tenant hereunder, when the same shall become due and payable, and such failure shall continue for five (5) days after receipt of written notice that such payment was not received by Landlord.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:justify;padding-left:6px;text-indent:69px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;color:#2b2d34;">(vi) If Tenant shall fail to perform or observe any other requirement of this Lease to be performed or observed by Tenant but not specifically referred to in this Section, and such failure shall continue for thirty (30) days after Landlord shall give written notice of the failure to Tenant. However, if Tenant's failure to comply cannot reasonably be cured within thirty (30) days, Tenant shall be allowed additional time as is reasonably necessary to cure the failure so long as: (1) Tenant commences to cure the failure within thirty (30) days of receipt of Landlord's notice, and (2) Tenant diligently pursues a course of action that will cure the failure and bring Tenant back into compliance with the Lease.</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:justify;padding-left:6px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;color:#2b2d34;">(b) This Lease is subject to the following limitation: If at any time, a Default shall occur, then upon the happening of any one or more of the aforementioned Defaults, Landlord may give to Tenant a notice of intention to end the Term of this Lease at the expiration of five (5) days from the date of service of such notice of termination. At the expiration of such five (5) days, this Lease and the Term as well as all of the right, title and interest of Tenant hereunder shall wholly cease and expire, and Tenant shall then quit and surrender the Demised Premises to Landlord. But notwithstanding such termination, surrender, and the expiration of Tenant’s right, title and interest, Tenant's liability under all of the provisions of this Lease shall continue.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:justify;padding-left:6px;text-indent:45px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;color:#2b2d34;font-weight:bold;">Section 22.2. </font><font style="font-family:inherit;font-size:12pt;color:#2b2d34;">Landlord's Re-Entry. In the event of a Default by Tenant hereunder, Landlord, or its agents or employees, may re-enter the Demised Premises at any time and remove therefrom Tenant, Tenant's Agents, subtenants, and any licensees, concessionaires or invitees, together with any of its or their property, either by summary dispossess proceedings or by any suitable action or proceeding at law or by force or otherwise and, in connection therewith, Landlord may repossess and enjoy the Demised Premises. Landlord shall be entitled to the benefits of all provisions of law respecting the speedy recovery of lands and tenements held over by Tenant, or proceedings in forcible entry and detainer. Tenant waives any rights to the service of any notice of Landlord's intention to re-enter provided for by any present or future law. Landlord shall not be liable in any way in connection with any action it takes pursuant to the foregoing. Notwithstanding any such re-entry, repossession, dispossession or removal, Tenant's liability under all of the provisions of this Lease shall continue. No such re-entry or taking possession of the Demised Premises by Landlord shall be construed as an election on its part to terminate this Lease unless notice of such intention be given to Tenant or unless the termination thereof shall result as a matter of law or be decreed by a court of competent jurisdiction. Notwithstanding any re-letting without termination, Landlord may at any time thereafter, elect to terminate this Lease for such previous breach.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:53px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;color:#2b2d34;font-weight:bold;text-decoration:underline;">Section 22.3.</font><font style="font-family:inherit;font-size:12pt;color:#2b2d34;font-weight:bold;">  </font><font style="font-family:inherit;font-size:12pt;color:#2b2d34;text-decoration:underline;">Deficiency.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:justify;padding-left:6px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;color:#2b2d34;">(a) In case of re-entry, repossession or termination of this Lease, whether the same is the result of the institution of summary or other proceedings or not, Tenant shall remain liable (in addition to accrued liabilities) to the extent legally permissible for: (i) (x) the Rent, and all other charges provided for herein until the date this Lease would have expired (or, in the alternative, as</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div><br></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:justify;padding-left:8px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;padding-top:2px;text-align:justify;padding-left:6px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;color:#262626;">liquidated damages, an amount equal to the Rent and such other charges) had such termination, re-entry or repossession not occurred; and (y) expenses to which Landlord may be put in re-entering the Demised Premises, repossessing the same, making good any Default of Tenant, painting, altering or dividing the Demised Premises, combining or placing the same in proper repair, protecting and preserving the same by placing therein watchmen and caretakers, reletting the same (including attorney's fees and disbursements, marshal's fees and broker's fees, in so doing), and any expenses which Landlord may incur during the occupancy of any new tenant; minus (ii) the net proceeds of any re-letting. Tenant agrees to pay to Landlord the difference between items (i) and (ii) hereinabove with respect to each month, at the end of such month. Any suit brought by Landlord to enforce collection of such difference for any one month shall not prejudice Landlord's right to enforce the collection of any difference for any subsequent month. In addition to the foregoing, Tenant shall pay to Landlord such sums as the court which has jurisdiction thereover may adjudge reasonable as attorneys' fees with respect to any successful lawsuit or action instituted by Landlord to enforce the provisions hereof.</font></div><div style="line-height:120%;padding-top:1px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:justify;padding-left:8px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;color:#262626;">(b) Landlord, at Landlord's option, may re-let the whole or any part of said Demised Premises for the whole of the unexpired Lease Term, or longer, or from time to time for shorter period, for any rental then obtainable, giving such concessions of rent and making such special repairs, alterations, decorations and paintings for any new tenant as it may, in its sole and absolute discretion deem advisable. Landlord shall have no obligation to relet the Demised Premises or any part thereof and shall in no event be liable for refusal or failure to relet the Demised Premises or any part thereof, or, in the event of any such reletting, for refusal or failure to collect any rent due upon any such reletting, and no such refusal or failure shall operate to relieve Tenant of any liability under this Lease or otherwise to affect any such liability; Landlord, at Landlord's option, may make such repairs, replacements, alterations, additions, improvements, decorations and other physical changes in and to the Demised Premises as Landlord, in its sole discretion, considers advisable or necessary in connection with any such reletting or proposed reletting, without relieving Tenant of any liability under this Lease or otherwise affecting any such liability. Tenant's liability as aforesaid shall survive the institution of summary proceedings and the issuance of any warrant thereunder.</font></div><div style="line-height:120%;padding-top:1px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:justify;padding-left:9px;text-indent:45px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;color:#262626;font-weight:bold;text-decoration:underline;">Section 22.4.</font><font style="font-family:inherit;font-size:12pt;color:#262626;font-weight:bold;"> </font><font style="font-family:inherit;font-size:12pt;color:#262626;font-weight:bold;"> </font><font style="font-family:inherit;font-size:12pt;color:#262626;text-decoration:underline;">Agreed Final Damages.</font><font style="font-family:inherit;font-size:12pt;color:#262626;">  If Landlord so elects, Tenant shall pay Landlord, on demand, as liquidated and agreed final damages, the Rent and all other charges which would have been payable by Tenant from the date of such demand to the date when this Lease would have expired if it had not been terminated as aforesaid, minus the fair rental value of the Demised Premises for the same period with such sums discounted to present value. Upon payment of such liquidated and agreed final damages, Tenant shall be under no further liability with respect to the period after the date of such demand.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:justify;padding-left:9px;text-indent:45px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;color:#262626;font-weight:bold;text-decoration:underline;">Section 22.5.</font><font style="font-family:inherit;font-size:12pt;color:#262626;font-weight:bold;">   </font><font style="font-family:inherit;font-size:12pt;color:#262626;text-decoration:underline;">Waiver of Right of Redemption</font><font style="font-family:inherit;font-size:12pt;color:#262626;">. Tenant hereby expressly waives (to the extent legally permissible), for itself and all persons claiming by, though, or under it, any right of redemption or for the restoration of the operation of this Lease under any present or future law in case Tenant shall be dispossessed for any cause, or in case Landlord shall obtain possession of the Demised Premises as herein provided. In the event Landlord commences any action or proceeding for non-payment of Minimum Rent or any items of Additional Rent due hereunder, Tenant shall not interpose any counterclaim of any nature or description in any such action or proceeding. The</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:justify;padding-left:10px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div><br></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;padding-top:2px;text-align:justify;padding-left:8px;text-indent:-2px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;padding-top:2px;text-align:justify;padding-left:8px;text-indent:-2px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;padding-top:2px;text-align:justify;padding-left:8px;text-indent:-2px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;color:#2a2b33;">foregoing, however, shall not be construed as a waiver of Tenant's right to assert such claim in a separate action or proceeding instituted by Tenant.</font></div><div style="line-height:120%;padding-top:1px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:justify;padding-left:8px;text-indent:44px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;color:#2a2b33;font-weight:bold;text-decoration:underline;">Section 22.6.</font><font style="font-family:inherit;font-size:12pt;color:#2a2b33;">   </font><font style="font-family:inherit;font-size:12pt;color:#2a2b33;text-decoration:underline;">Landlord's Right to Perform for Account of Tenant.</font><font style="font-family:inherit;font-size:12pt;color:#2a2b33;">   If Tenant shall be in default hereunder after expiration of applicable notice and cure periods, Landlord or any mortgagee may, at any time thereafter, cure said default for the account and at the expense of Tenant. Tenant shall pay, with interest at the maximum legal rate, on demand, to Landlord, the amount so paid, expended, or incurred by Landlord or any mortgagee and any expense of Landlord or any mortgagee including attorneys' fees incurred in connection with such default plus administrative costs of Landlord or any mortgagee in an amount equal to ten (10%) percent of such costs and expenses, and all of the same shall be deemed to be Additional Rent.</font></div><div style="line-height:120%;padding-top:1px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:justify;padding-left:8px;text-indent:44px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;color:#2a2b33;font-weight:bold;text-decoration:underline;">Section 22.7.</font><font style="font-family:inherit;font-size:12pt;color:#2a2b33;">   </font><font style="font-family:inherit;font-size:12pt;color:#2a2b33;text-decoration:underline;">Additional Remedies, Waivers.</font><font style="font-family:inherit;font-size:12pt;color:#2a2b33;"> Etc. With respect to the rights and remedies of and waivers by Landlord: (a) the rights and remedies of Landlord set forth herein shall be in addition to any other right and remedy now and hereafter provided by law. Landlord may exercise such rights and remedies at such times, in such order, to such extent, and as often as Landlord deems advisable without regard to whether the exercise of one right or remedy precedes, concurs with or succeeds the exercise of another, (b) single or partial exercise of a right or remedy shall not preclude: (i) a further exercise thereof; or (ii) the exercise of another right or remedy, from time to time; (c) no delay or omission by Landlord in exercising a right or remedy shall exhaust or impair the same or constitute a waiver of, or acquiescence to a Default; (d) no waiver of a Default shall extend to or affect any other Default or impair any right or remedy with respect thereto; (e) no action or inaction by Landlord shall constitute a waiver of a Default; and (f) no waiver of a Default shall be effective, unless it is in writing.</font></div><div style="line-height:120%;padding-top:1px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:justify;padding-left:8px;text-indent:44px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;color:#2a2b33;font-weight:bold;text-decoration:underline;">Section 22.8.</font><font style="font-family:inherit;font-size:12pt;color:#2a2b33;">   </font><font style="font-family:inherit;font-size:12pt;color:#2a2b33;text-decoration:underline;">Distraint.</font><font style="font-family:inherit;font-size:12pt;color:#2a2b33;">  In addition to all other rights and remedies, if Tenant shall be in Default hereunder, Landlord shall, to the extent permitted by law, have a right of distress for Rent and a lien on all of Tenant's fixtures, merchandise and equipment in the Demised Premises, as security for Rent and all other charges payable hereunder</font><font style="font-family:inherit;font-size:12pt;color:#565b67;">.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:53px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;color:#2a2b33;font-weight:bold;text-decoration:underline;">Section 22.9.</font><font style="font-family:inherit;font-size:12pt;color:#2a2b33;">   </font><font style="font-family:inherit;font-size:12pt;color:#2a2b33;text-decoration:underline;">Miscellaneous.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:justify;padding-left:6px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;color:#2a2b33;">(a) No waiver of any covenant or condition or of the breach of any covenant or condition of this Lease by either Landlord or Tenant shall be taken to constitute a waiver of any subsequent breach of such covenant or condition or to justify or authorize the non-observance on any other occasion of the same or of any other covenant or condition hereof, nor shall the acceptance of Minimum Rent or any item of Additional Rent by Landlord at any time when Tenant is in Default under any covenant or condition hereof be construed as a waiver of such Default or of Landlord's right to terminate this Lease on account of such Default, nor shall any waiver or indulgence granted by Landlord to Tenant be taken as an estoppel against Landlord, nor shall any waiver or indulgence granted by Tenant to Landlord be taken as an estoppel against Landlord; it being expressly understood that if at any time Tenant shall be in Default in any of its covenants or conditions hereunder, an acceptance by Landlord of Minimum Rent or any item of Additional Rent during the continuance of such Default or the failure on the part of Landlord promptly to avail itself of such other rights or remedies as Landlord may have, shall not be construed as a waiver of such</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div><br></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;padding-top:2px;text-align:justify;padding-left:6px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;color:#262626;">Default, but Landlord may at any time thereafter, if such Default continues, terminate this Lease on account of such Default in the manner herein provided.</font></div><div style="line-height:120%;padding-top:1px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:justify;padding-left:6px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;color:#262626;">(b) In the event of any breach by Landlord or Tenant of any of the terms and provisions of this Lease, the non-defaulting party shall have the right to injunctive relief as if no other remedies were provided herein for such breach.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:justify;padding-left:6px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;color:#262626;">(c) The rights and remedies herein reserved by, or granted to, Landlord are distinct, separate and cumulative, and the exercise of any one of them shall not be deemed to preclude, waive or prejudice Landlord's right to exercise any or all others.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:justify;padding-left:6px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;color:#262626;">(d) Tenant hereby expressly waives any right to assert a defense based on merger and agrees that neither the commencement of any action or proceeding, nor the settlement thereof, nor the entry of judgment therein, shall bar Landlord from bringing any subsequent actions or proceedings from time to time.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:justify;padding-left:6px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;color:#262626;">(e) Tenant hereby waives the benefit of any provisions of the applicable statute of limitations as a defense in any action for collection of rentals or other charges accrued under this Lease which may be filed by Landlord against Tenant.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:justify;padding-left:8px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;color:#262626;">(f) Intentionally omitted.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:justify;padding-left:8px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;color:#262626;">(g) Wherever in this Lease, Landlord has reserved or is granted the right of "re-entry" into the Demised Premises, the use of such word is not intended, nor shall it be construed, to be limited to its technical legal meaning.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:justify;padding-left:8px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;color:#262626;">(h) In the event of any lawsuit or court action between Landlord and Tenant arising out of or under this Lease or the terms and conditions stated herein, the prevailing party in such lawsuit or court action shall be entitled to and shall collect from the non-prevailing party the reasonable attorney's fees and court costs actually incurred by the prevailing party with respect to said lawsuit or court action.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:justify;padding-left:6px;text-indent:1px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;color:#262626;">(i) Any action, suit or proceeding relating to, arising out of or in connection with the terms, conditions and covenants of this Lease may be brought in the courts of the State in which the Industrial Center is located. Each of Landlord and Tenant hereby waives any objection to jurisdiction or venue in any proceeding before said courts.</font></div><div style="line-height:120%;padding-top:1px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:justify;padding-left:8px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;color:#262626;">(j) </font><font style="font-family:inherit;font-size:12pt;color:#262626;font-weight:bold;">LANDLORD AND TENANT HEREBY WAIVE TRIAL BY JURY IN ANY ACTION, PROCEEDING OR COUNTERCLAIM BROUGHT BY EITHER PARTY AGAINST THE OTHER ON ANY MATTERS IN ANY WAY ARISING OUT OF OR CONNECTED WITH THIS LEASE, THE RELATIONSHIP OF LANDLORD AND TENANT, TENANT'S USE OR OCCUPANCY OF THE PREMISES, OR THE ENFORCEMENT OF ANY REMEDY UNDER ANY STATUTE, EMERGENCY OR OTHERWISE.</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div><br></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;padding-top:2px;text-align:center;padding-left:204px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;color:#2f2f36;font-weight:bold;text-decoration:underline;">ARTICLE 23. NO WAIVER</font></div><div style="line-height:120%;padding-top:1px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:justify;padding-left:6px;text-indent:44px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;color:#2f2f36;font-weight:bold;text-decoration:underline;">Section 23.1.</font><font style="font-family:inherit;font-size:12pt;color:#2f2f36;">   </font><font style="font-family:inherit;font-size:12pt;color:#2f2f36;text-decoration:underline;">No Waiver Except In Writing.</font><font style="font-family:inherit;font-size:12pt;color:#2f2f36;">  Failure of Landlord or Tenant to insist upon the strict performance of any provisions hereof or of any rules and regulations promulgated hereunder or to exercise any option shall not be construed as a waiver for the future of any such provision or rule or option. The receipt by Landlord of any rent or other charge due hereunder with knowledge of the breach of any provision of this Lease shall not be deemed a waiver of such breach. No provision of this Lease shall be deemed to have been waived unless such waiver be in writing signed by the Landlord. No payment by Tenant or receipt by Landlord of a lesser amount than the monthly rent shall be deemed to be other than on account of the earliest rent then unpaid nor shall any endorsement or statement or any check or any letter accompanying any check or payment as rent be deemed an accord and satisfaction, and Landlord may accept such check or payment without prejudice to Landlord's right to recover the balance of such rent or pursue any other remedy in this Lease, and no waiver by Landlord in respect to one tenant shall constitute a waiver in favor of any other tenant in the Industrial Center.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:center;padding-left:214px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;color:#2f2f36;font-weight:bold;text-decoration:underline;">ARTICLE 24. NOTICES</font></div><div style="line-height:120%;padding-top:1px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:justify;padding-left:6px;text-indent:44px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;color:#2f2f36;font-weight:bold;text-decoration:underline;">Section 24.1.</font><font style="font-family:inherit;font-size:12pt;color:#2f2f36;">  </font><font style="font-family:inherit;font-size:12pt;color:#2f2f36;text-decoration:underline;">Addresses</font><font style="font-family:inherit;font-size:12pt;color:#2f2f36;">. Except as otherwise provided for herein, any notice, demand, request, consent, approval or other communication which either party hereto is required or desires to give, make, or communicate to the other shall be in writing and shall be given, made, or communicated only by nationally recognized courier service (e.g. Federal Express) providing dated evidence of receipt or refusal to accept delivery by the addressee, addressed, in the case of Landlord:</font></div><div style="line-height:120%;padding-top:1px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:280px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;color:#2f2f36;">c</font><font style="font-family:inherit;font-size:12pt;color:#5d606b;">/</font><font style="font-family:inherit;font-size:12pt;color:#2f2f36;">o GTJ Management, LLC</font></div><div style="line-height:120%;padding-top:0px;text-align:left;padding-left:280px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;color:#2f2f36;">60 Hempstead Avenue, Suite 718</font></div><div style="line-height:120%;padding-top:0px;text-align:left;padding-left:280px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;color:#2f2f36;">West Hempstead, NY 11552</font></div><div style="line-height:120%;padding-top:0px;text-align:left;padding-left:280px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;color:#2f2f36;">Attention: Paul Cooper</font></div><div style="line-height:120%;padding-top:2px;text-align:left;padding-left:6px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;color:#2f2f36;">with a copy to:</font></div><div style="line-height:120%;padding-top:1px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:288px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;color:#2f2f36;">Marc J. Becker, Esq. </font></div><div style="line-height:120%;text-align:left;text-indent:288px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;color:#2f2f36;">Goldfarb and Fleece LLP</font></div><div style="line-height:120%;text-align:left;text-indent:288px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;color:#2f2f36;">560 Lexington Avenue, 61h Floor</font></div><div style="line-height:120%;padding-top:0px;text-align:left;text-indent:288px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;color:#2f2f36;">New York, New York 10022</font></div><div style="line-height:120%;padding-top:1px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;padding-top:2px;text-align:justify;padding-left:6px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;color:#2f2f36;">and addressed, in the case of Tenant, to Tenant's address contained in the preamble of this Lease, Attn: CFO, subject to the right of either party to designate a different address by notice similarly given, made or communicated, as the case may be, any such notice to be effective on the date when it shall have been delivered by such courier service or when delivery by such courier service was refused by the addressee. Refusal to accept delivery of any notice shall not limit or negate delivery of such notice or limit, negate or render ineffective any such notice.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:110px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;color:#2f2f36;">ARTICLE 25. SUBORDINATION AND ATTORNMENT</font></div><div style="line-height:120%;padding-top:1px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:6px;text-indent:44px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;color:#2f2f36;font-weight:bold;text-decoration:underline;">Section 25.1.</font><font style="font-family:inherit;font-size:12pt;color:#2f2f36;">   </font><font style="font-family:inherit;font-size:12pt;color:#2f2f36;text-decoration:underline;">Subordination.</font><font style="font-family:inherit;font-size:12pt;color:#2f2f36;">  This Lease and the rights of Tenant hereunder are and shall be automatically subordinate to the lien of any mortgage now or hereafter in force against the land</font></div><div><br></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;padding-top:1px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;padding-top:2px;text-align:justify;padding-left:6px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;color:#262626;">and/or buildings of which the Demised Premises are a part against any buildings hereafter placed upon the land of which the Demised Premises are a part and to all advances made or hereafter to be made upon the security thereof, and to any and all extensions, renewals, modifications or replacements thereof, and to any ground or underlying lease of the land or buildings. The provisions of this Section 25.1 are self-operative and no further instrument of subordination shall be required. However, within ten (10) days of Landlord's written request, Tenant shall execute any commercially reasonable agreement reasonably required by any mortgagee or landlord, confirming the foregoing subordination of this Lease.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:justify;padding-left:6px;text-indent:45px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;color:#262626;font-weight:bold;text-decoration:underline;">Section 25.2.</font><font style="font-family:inherit;font-size:12pt;color:#262626;font-weight:bold;">  </font><font style="font-family:inherit;font-size:12pt;color:#262626;text-decoration:underline;">Attornment.</font><font style="font-family:inherit;font-size:12pt;color:#262626;">    Tenant shall, in the event of the sale or assignment of Landlord's interest in the Building of which the Demised Premises form a part or in the event of any proceedings brought for the foreclosure of, or in the event of exercise of the power of sale under any mortgage made by Landlord covering the Demised Premises, attorn to the purchaser and recognize such purchaser as Landlord under this Lease.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:justify;padding-left:6px;text-indent:45px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;color:#262626;font-weight:bold;text-decoration:underline;">Section 25.3.</font><font style="font-family:inherit;font-size:12pt;color:#262626;font-weight:bold;">  </font><font style="font-family:inherit;font-size:12pt;color:#262626;text-decoration:underline;">Mortgagee Protection Clause.</font><font style="font-family:inherit;font-size:12pt;color:#262626;">  Tenant agrees to give any mortgagee and/or trustees under any deed of trust or land under any ground lease, by registered or certified mail or via a nationally recognized overnight courier service, a copy of any notice of default served upon Landlord under this Lease, provided that prior to such notice Tenant has been notified, in writing, of the address of such mortgagees and/or trust deed holders and/or landlords. Tenant further agrees that if Landlord shall have failed to cure such default within the time provided for in this Lease, then the mortgagees and/or trust deed holders and/or landlords shall have an additional thirty (30) days within which to cure such default or if such default cannot be cured within that time, then such additional time as may be necessary if within such thirty (30) days, any mortgagee and/or trust deed holder and/or landlord has commenced and is diligently pursuing the remedies necessary to cure such default, (including but not limited to commencement of foreclosure proceedings, if necessary to effect such cure) in which event this Lease shall not be terminated while such remedies are being so diligently pursued.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:justify;padding-left:8px;text-indent:45px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;color:#262626;font-weight:bold;text-decoration:underline;">Section 25.4.</font><font style="font-family:inherit;font-size:12pt;color:#262626;font-weight:bold;">  </font><font style="font-family:inherit;font-size:12pt;color:#262626;">Landlord hereby agrees to request from its existing mortgagee of the Industrial Center, at no cost to Landlord, a subordination, non-disturbance and attornment agreement with Tenant which agreement will be on the mortgagee's standard form (with such commercially reasonable modifications as Tenant may request and which are acceptable to the mortgagee). In addition, Landlord hereby agrees to obtain from any such future mortgagee of the Industrial Center, at no cost to Landlord, a subordination, non-disturbance and attornment agreement with Tenant which agreement will be on the mortgagee's standard form (with such commercially reasonable modifications as Tenant may request and which are acceptable to the mortgagee).</font></div><div style="line-height:120%;padding-top:1px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:156px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;color:#262626;font-weight:bold;text-decoration:underline;">ARTICLE 26. HAZARDOUS MATERIALS</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:justify;padding-left:8px;text-indent:45px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;color:#262626;font-weight:bold;text-decoration:underline;">Section 26.1.</font><font style="font-family:inherit;font-size:12pt;color:#262626;font-weight:bold;">  </font><font style="font-family:inherit;font-size:12pt;color:#262626;">Tenant shall not cause any Hazardous Materials, as herein defined, or permit its agents, employees or contractors to cause any Hazardous Materials to be brought upon, stored, treated, used, produced, generated, emitted, disposed, discharged, or released (collectively known as "</font><font style="font-family:inherit;font-size:12pt;color:#262626;text-decoration:underline;">handled</font><font style="font-family:inherit;font-size:12pt;color:#262626;">" or "</font><font style="font-family:inherit;font-size:12pt;color:#262626;text-decoration:underline;">handle</font><font style="font-family:inherit;font-size:12pt;color:#262626;">") upon, about, above or beneath the Demised Premises or the Industrial Center. Notwithstanding the foregoing, (i) normal quantities of those Hazardous Materials customarily used in the conduct of general administrative and executive office activities (e.g.,</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div><br></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;padding-top:2px;text-align:justify;padding-left:6px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;color:#2d2f36;">copier fluids and cleaning supplies) may be used and stored at the Demised Premises without Landlord's prior written consent, and (ii) in connection with the Permitted Use of the Demised Premises, Tenant shall be allowed to receive and send shipments of Hazardous Materials, but only in compliance with all applicable Environmental Laws, as defined herein</font><font style="font-family:inherit;font-size:12pt;color:#494949;">. </font><font style="font-family:inherit;font-size:12pt;color:#2d2f36;">These Hazardous Materials referred to in subdivisions (i) and (ii) of the preceding sentence shall be known as "</font><font style="font-family:inherit;font-size:12pt;color:#2d2f36;text-decoration:underline;">Tenant's Hazardous Materials</font><font style="font-family:inherit;font-size:12pt;color:#2d2f36;">" and shall be handled in accordance with all applicable federal, state and local laws, statutes, ordinances, regulations, codes, rulings, policies, requirements, orders and decrees including, but not limited to, the Resource Conservation Recovery Act of 1976 (42 U.S.C.. 6901 et seq</font><font style="font-family:inherit;font-size:12pt;color:#494949;">.</font><font style="font-family:inherit;font-size:12pt;color:#2d2f36;">), as amended, and the Comprehensive Environmental Response Compensation and Liability Act (42 U.S.C.. 9601 et seq.), as amended (collectively known as "</font><font style="font-family:inherit;font-size:12pt;color:#2d2f36;text-decoration:underline;">Environmental Laws”)</font><font style="font-family:inherit;font-size:12pt;color:#2d2f36;"> </font><font style="font-family:inherit;font-size:12pt;color:#2d2f36;">relating to the industrial hygiene, environmental protection or the handling, use, analysis, generation, manufacture, storage, presence, disposal or transportation of Hazardous Materials, defined below. Tenant hereby agrees to pay the costs of all remediation and corrective measures made necessary or desirable in the event that Tenant shall breach the provisions of this Article</font><font style="font-family:inherit;font-size:12pt;color:#494949;">. </font><font style="font-family:inherit;font-size:12pt;color:#2d2f36;">Tenant hereby indemnifies and agrees to defend and hold harmless, Landlord and its managing agent and its or their respective affiliates, principals, shareholders, officers, directors, partners, members, trustees, fiduciaries, servants, agents and employees from and against any and all liabilities, damages, suits, causes, actions, penalties, costs, charges, fees and expenses, including, without limitation</font><font style="font-family:inherit;font-size:12pt;color:#494949;">, </font><font style="font-family:inherit;font-size:12pt;color:#2d2f36;">attorneys' fees and disbursements, for death or injury to any person or damage to any property whatsoever (including water tables and atmosphere) or otherwise resulting from Tenant's failure to comply with its obligations, duties and responsibilities under this Article. For purposes of this indemnity, Tenant shall have the burden of proof to establish any pre-existing environmental conditions affecting the Demised Premises by conducting an environmental audit of the property. Any acts or omissions of Tenant or its employees, agents, customers, invitees, sub-lessees, assignees, contractors or sub-contractors (whether or not they are negligent, intentional, willful or unlawful) shall be strictly attributable to Tenant hereunder. Tenant agrees to execute affidavits, representations and the like from time to time at Landlord's request conveying Tenant's best knowledge and belief regarding the presence of Hazardous Materials in the Demised Premises.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:justify;padding-left:6px;text-indent:90px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;color:#2d2f36;">Tenant shall at its own expense procure, maintain in effect and comply with all conditions of any and all permits, licenses and other governmental and regulatory approvals required for Tenant's use of the Demised Premises, including, without limitation, discharge of (appropriately treated) materials or waste into or through any sanitary sewer system serving the Demised Premises. Except as discharged in strict accordance and conformity with all applicable Environmental Laws, Tenant shall cause any and all Hazardous Materials handled by or introduced by Tenant to be removed from the Demised Premises and transported solely by duly licensed facilities for final disposal of such Hazardous Materials. Tenant shall in all respects handle any and all Hazardous Materials in, on, under or about the Demised Premises in complete conformity with all applicable Environmental Laws and prudent industry practice regarding the management of such Hazardous Materials. All reporting obligations to the extent imposed upon Tenant by Environmental Laws are solely the responsibility of Tenant. Upon expiration or termination of this Lease, Tenant shall cause all Tenant's Hazardous Materials to be removed from the Demised Premises and transported for use, storage or disposal in accordance and in compliance with all applicable Environmental Laws</font><font style="font-family:inherit;font-size:12pt;color:#494949;">. </font><font style="font-family:inherit;font-size:12pt;color:#2d2f36;">Tenant shall not take any remedial action in response to the presence of Hazardous Materials in, on or about the Demised Premises or in the Industrial Center, nor enter into any settlement agreement</font><font style="font-family:inherit;font-size:12pt;color:#494949;">, </font><font style="font-family:inherit;font-size:12pt;color:#2d2f36;">consent</font><font style="font-family:inherit;font-size:12pt;color:#576069;">, </font><font style="font-family:inherit;font-size:12pt;color:#2d2f36;">decree or other compromise in respect to any</font></div><div style="line-height:120%;padding-top:1px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:justify;padding-left:8px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div><br></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;padding-top:2px;text-align:justify;padding-left:6px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;color:#262626;">claims relating to or in any way connected with the Demised Premises or the Industrial Center without first notifying Landlord of Tenant's intention to do so and affording Landlord thirty (30) days to appear, intervene or otherwise appropriately assert and protect Landlord's interest with respect thereto. In addition, at Landlord's request, at the expiration of the Lease Term, Tenant shall remove all tanks or fixtures which were placed on the Demised Premises during the Lease Term and which contain, have contained or are contaminated with, Hazardous Materials.</font></div><div style="line-height:120%;padding-top:1px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:justify;padding-left:8px;text-indent:90px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;color:#262626;">Tenant shall promptly notify Landlord in writing of (a) any enforcement, clean-up, removal or other governmental or regulatory action instituted, completed or threatened pursuant to any Environmental Laws with respect to the Demised Premises; (b) any claim made or threatened by any person against Landlord or the Demised Premises relating to damage, contribution, cost recovery, compensation, loss or injury resulting from or claimed to result from any Hazardous Materials; and (c) any reports made to any environmental agency arising out of or in, on or about the Demised Premises or in connection with any Hazardous Materials removed from the Demised Premises, including any complaints, notices, warnings, reports or asserted violations in connection therewith. Tenant shall also provide to Landlord, as promptly as possible, and in any event within five (5) business days after Tenant first receives or sends the same, copies of all claims, reports, complaints, notices, warnings or asserted violations relating in any way to the Demised Premises or Tenant's use thereof. Upon written request of Landlord (to enable Landlord to defend itself from any claim or charge related to any Environmental Law), Tenant shall promptly deliver to Landlord lists of Hazardous Materials removed or to be removed from the Demised Premises. All such lists shall list the Tenant or its agent as a responsible party and in no way shall attribute responsibility for any such Hazardous Materials to Landlord.</font></div><div style="line-height:120%;padding-top:1px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:justify;padding-left:9px;text-indent:90px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;color:#262626;">"</font><font style="font-family:inherit;font-size:12pt;color:#262626;text-decoration:underline;">Hazardous Materials</font><font style="font-family:inherit;font-size:12pt;color:#262626;">" means: (a) any material or substance; (i) which is defined or becomes defined as a "</font><font style="font-family:inherit;font-size:12pt;color:#262626;text-decoration:underline;">hazardous substance,</font><font style="font-family:inherit;font-size:12pt;color:#262626;">" "</font><font style="font-family:inherit;font-size:12pt;color:#262626;text-decoration:underline;">hazardous waste</font><font style="font-family:inherit;font-size:12pt;color:#262626;">," "</font><font style="font-family:inherit;font-size:12pt;color:#262626;text-decoration:underline;">infectious waste</font><font style="font-family:inherit;font-size:12pt;color:#262626;">," "</font><font style="font-family:inherit;font-size:12pt;color:#262626;text-decoration:underline;">chemical mixture or substance,</font><font style="font-family:inherit;font-size:12pt;color:#262626;">" or "</font><font style="font-family:inherit;font-size:12pt;color:#262626;text-decoration:underline;">air pollutant</font><font style="font-family:inherit;font-size:12pt;color:#262626;">" under Environmental Laws; (ii) containing asbestos, urea formaldehyde or polychlorinated biphenyls, (iii) which is oil or petroleum product, (iv) which is radioactive; (v) which is infectious waste, biological agents, bacteria and viruses; or (b) any other material or substance displaying toxic, reactive ignitable or corrosive characteristics, as all such terms are used in their broadest sense, and are defined or become defined by Environmental Laws.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:justify;padding-left:9px;text-indent:89px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;color:#262626;">If any lender or governmental agency requires Landlord to test for a release of Hazardous Materials on the Demised Premises, or if Landlord reasonable believes that Tenant may have violated an Environmental Law or the terms of this Article, Tenant shall, within thirty (30) days following Landlord's demand, supply to Landlord at Tenant's sole cost and expense an environmental report of the Demised Premises and the use of the Demised Premises addressing Landlord's concerns and demonstrating whether Tenant's use of the Demised Premises has violated or is violating any Environmental Laws, prepared by a reputable independent licensed environmental contracting firm, in form, substance and detail reasonably satisfactory to Landlord. Such report shall be delivered to Landlord and shall be kept strictly confidential by Landlord and Tenant.</font></div><div style="line-height:120%;padding-top:1px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:justify;padding-left:10px;text-indent:89px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;color:#262626;">Tenant agrees to clean its trucks in compliance with Environmental Laws such that any run off from the cleaning of Tenant’s trucks shall not spill into landscaped areas or drains.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div><br></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-top:2px;text-align:justify;padding-left:13px;text-indent:90px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;padding-top:2px;text-align:justify;padding-left:13px;text-indent:90px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;padding-top:2px;text-align:justify;padding-left:13px;text-indent:90px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;padding-top:2px;text-align:justify;padding-left:13px;text-indent:90px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;color:#2a2b33;">Tenant acknowledges that Landlord has made no representations to Tenant with respect to the compliance of the Demised Premises with Environmental Laws except as otherwise expressly set forth herein.</font></div><div style="line-height:120%;padding-top:1px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:justify;padding-left:13px;text-indent:93px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;color:#2a2b33;">Tenant shall execute and deliver to Landlord a completed questionnaire, in the form attached hereto as </font><font style="font-family:inherit;font-size:12pt;color:#2a2b33;text-decoration:underline;">Exhibit D</font><font style="font-family:inherit;font-size:12pt;color:#2a2b33;">, immediately prior to the Commencement Date and, if applicable, immediately prior to the commencement of any renewal term and Tenant shall execute and deliver to Landlord a completed questionnaire, in the form attached hereto as </font><font style="font-family:inherit;font-size:12pt;color:#2a2b33;text-decoration:underline;">Exhibit E,</font><font style="font-family:inherit;font-size:12pt;color:#2a2b33;"> immediately prior to the expiration of the Lease Term or Tenant's surrender of possession of the Demised Premises, whichever is earlier.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:justify;padding-left:13px;text-indent:90px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;color:#2a2b33;">Tenant represents and warrants that, as of the date hereof, Tenant's North American Industry Classification System ("</font><font style="font-family:inherit;font-size:12pt;color:#2a2b33;text-decoration:underline;">NAICS</font><font style="font-family:inherit;font-size:12pt;color:#2a2b33;">") code is 3254130700 and Tenant agrees that it will promptly advise Landlord of any change in Tenant's NAICS code (or the NAICS code of any assignee or sublessee) during the Lease Term. Prior to any assignment of this Lease or subletting of any portion of the Demised Premises and prior to the expiration or sooner termination of this Lease or any sublease, Tenant, at its sole expense, will take all actions to comply with the New Jersey Industrial Site Recovery Act ("</font><font style="font-family:inherit;font-size:12pt;color:#2a2b33;text-decoration:underline;">ISRA</font><font style="font-family:inherit;font-size:12pt;color:#2a2b33;">"), if applicable, or provide Landlord with reasonable evidence that ISRA is not applicable. Tenant will also provide Landlord with a duplicate original of the affidavit and any and all other information submitted to the New Jersey Department of Environmental Protection ("</font><font style="font-family:inherit;font-size:12pt;color:#2a2b33;text-decoration:underline;">NJDEP</font><font style="font-family:inherit;font-size:12pt;color:#2a2b33;">") in connection with such compliance, if applicable. Prior to the termination of this Lease and the cessation of all of Tenant's operations therein, or cessation of industrial operations as defined by NJDEP, if ISRA is applicable, Tenant shall submit all required ISRA forms, reports, letters, and payments which are required due to Tenant's occupancy of the Premises and/or to the actions of Tenant, its employees, contractors or agents. Tenant shall provide draft copies of all ISRA submittals to Landlord for review prior to submission to regulatory agencies. If remediation is required in order to submit a Response Action Outcome Form, such remediation shall be performed by Tenant to standards required under ISRA. The Response Action Outcome Form shall be issued to Landlord subsequent to the end of the Lease Term and vacation of the Demised Premises by Tenant or in accordance with the schedule required by ISRA. If requested by Tenant at the time of execution of this Lease, Landlord will prepare all ISRA related documents, with it understood that all reasonable costs incurred by Landlord in connection therewith will be reimbursed by Tenant.</font></div><div style="line-height:120%;padding-top:1px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:justify;padding-left:13px;text-indent:89px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;color:#2a2b33;">Landlord represents that as of the Effective Date, it has no actual knowledge of any Hazardous Materials existing on the Building or the Industrial Center other than those Hazardous Materials disclosed in that certain Phase I Environmental Assessment prepared by P.W. Grosser Consulting, Inc. in December 2011, a copy of which was delivered to Tenant's attorney electronically on or about October 23, 2017. Tenant acknowledges receipt of such environmental report and agrees to maintain in confidence such report and not disclose to any third-party the existence of such report and/or the content of such report, except (i) in order to enforce Tenant's rights or Landlord's obligations under this Article 26, (ii) as specifically authorized to do so in writing by Landlord, or (iii) as otherwise required by any legal requirement.</font></div><div style="line-height:120%;padding-top:1px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:13px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;color:#2a2b33;">Landlord hereby indemnifies and agrees to defend and hold harmless, Tenant and its managing agent and its or their respective affiliates, principals, shareholders, officers, directors, partners,</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div><br></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-top:2px;text-align:justify;padding-left:6px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;padding-top:2px;text-align:justify;padding-left:6px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;padding-top:2px;text-align:justify;padding-left:6px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;padding-top:2px;text-align:justify;padding-left:6px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;padding-top:2px;text-align:justify;padding-left:6px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;color:#262626;">members, trustees, fiduciaries, servants, agents and employees from and against any and all liabilities, damages, suits, causes, actions, penalties, costs, charges, fees and expenses, including, without limitation, reasonable attorneys' fees and disbursements, for death or injury to any person or damage to any property whatsoever (including water tables and atmosphere) or otherwise resulting from the presence of Hazardous Materials (i) existing prior to the Commencement Date at the Building or the Industrial Center or (ii) introduced to the Building or the Industrial Center at any time during the Term of this Lease to the extent caused by Landlord, its agents, contractors or employees.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:justify;padding-left:8px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;color:#262626;">The obligations of Landlord and Tenant under this Article shall survive the termination of this</font></div><div style="line-height:120%;padding-top:0px;text-align:justify;padding-left:8px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;color:#262626;">Lease.</font></div><div style="line-height:120%;padding-top:1px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:center;padding-left:132px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;color:#262626;font-weight:bold;text-decoration:underline;">ARTICLE 27. MISCELLANEOUS PROVISIONS</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:justify;padding-left:8px;text-indent:45px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;color:#262626;font-weight:bold;text-decoration:underline;">Section 27.1.</font><font style="font-family:inherit;font-size:12pt;color:#262626;font-weight:bold;">   </font><font style="font-family:inherit;font-size:12pt;color:#262626;text-decoration:underline;">Headings.</font><font style="font-family:inherit;font-size:12pt;color:#262626;">  The captions of the Articles and Sections of this Lease are for convenience only and shall not be considered or referred to in resolving questions of interpretation or construction.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:justify;padding-left:8px;text-indent:45px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;color:#262626;font-weight:bold;text-decoration:underline;">Section 27.2.</font><font style="font-family:inherit;font-size:12pt;color:#262626;font-weight:bold;"> </font><font style="font-family:inherit;font-size:12pt;color:#262626;font-weight:bold;">  </font><font style="font-family:inherit;font-size:12pt;color:#262626;text-decoration:underline;">Time of Essence.</font><font style="font-family:inherit;font-size:12pt;color:#262626;"> Time is of the essence with respect to the performance of each of the covenants and agreements under this Lease.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:justify;padding-left:8px;text-indent:45px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;color:#262626;font-weight:bold;text-decoration:underline;">Section 27.3.</font><font style="font-family:inherit;font-size:12pt;color:#262626;font-weight:bold;">   </font><font style="font-family:inherit;font-size:12pt;color:#262626;text-decoration:underline;">Construction of Lease.</font><font style="font-family:inherit;font-size:12pt;color:#262626;">     Tenant declares that Tenant has read and under­ stands all parts of this Lease. It is agreed that in the construction and interpretation of the terms of this Lease any rule of construction that a document is to be construed most strictly against the party who prepared the same shall not be applied, it being agreed that both parties hereto have participated in the preparation of the final form of this Lease. This Lease may be executed in several counterparts, each of which shall constitute an original, but all of which together shall constitute one and the same instrument. Executed copies of this Lease may be delivered by facsimile or other electronic (e.g., pdf) means, any of which shall be deemed effective to constitute delivery.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:justify;padding-left:9px;text-indent:45px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;color:#262626;font-weight:bold;text-decoration:underline;">Section 27.4.</font><font style="font-family:inherit;font-size:12pt;color:#262626;font-weight:bold;">   </font><font style="font-family:inherit;font-size:12pt;color:#262626;text-decoration:underline;">Governing Law.</font><font style="font-family:inherit;font-size:12pt;color:#262626;"> </font><font style="font-family:inherit;font-size:12pt;color:#262626;"> This Lease and the enforcement hereof shall be governed by the laws of the state in which the Industrial Center is located.</font></div><div style="line-height:120%;padding-top:1px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:justify;padding-left:9px;text-indent:45px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;color:#262626;font-weight:bold;text-decoration:underline;">Section 27.5.</font><font style="font-family:inherit;font-size:12pt;color:#262626;font-weight:bold;">   </font><font style="font-family:inherit;font-size:12pt;color:#262626;text-decoration:underline;">Severability.</font><font style="font-family:inherit;font-size:12pt;color:#262626;">   If any provision of this Lease or any paragraph, sentence, clause, phrase or word appearing herein be judicially or administratively held invalid or unenforceable for any reason whatsoever, such holding shall not be deemed to affect, alter, modify or impair in any manner whatsoever any other term, provision, paragraph, sentence, clause, phrase or word appearing therein.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:justify;padding-left:9px;text-indent:45px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;color:#262626;font-weight:bold;text-decoration:underline;">Section 27.6.</font><font style="font-family:inherit;font-size:12pt;color:#262626;font-weight:bold;">   </font><font style="font-family:inherit;font-size:12pt;color:#262626;text-decoration:underline;">Interest Rate.</font><font style="font-family:inherit;font-size:12pt;color:#262626;"> Where under the terms of this Lease interest shall be provided for, such interest, unless a specific interest rate is set forth, shall be at a rate equal to the prime rate of JP Morgan Chase Manhattan Bank, or any successor thereto, plus seven percent (7%), but in no event greater than the highest lawful rate of interest per annum permissible under the law of the state in which the Industrial Center is located, and shall accrue from the date when the same becomes due and payable by the terms and provisions hereof until paid and shall continue after any judgment until fully satisfied, to which shall be added reasonable attorneys' fees and costs.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div><br></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-top:2px;text-align:justify;padding-left:14px;text-indent:44px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;padding-top:2px;text-align:justify;padding-left:14px;text-indent:44px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;padding-top:2px;text-align:justify;padding-left:14px;text-indent:44px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;padding-top:2px;text-align:justify;padding-left:14px;text-indent:44px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;color:#2d2f36;font-weight:bold;text-decoration:underline;">Section 27.7.</font><font style="font-family:inherit;font-size:12pt;color:#2d2f36;">  </font><font style="font-family:inherit;font-size:12pt;color:#2d2f36;text-decoration:underline;">Consent of Landlord.</font><font style="font-family:inherit;font-size:12pt;color:#2d2f36;">  Where, under the terms of this Lease, the consent of Landlord shall be required, such consent, unless otherwise provided for herein, shall not be unreasonably withheld, conditioned or delayed. If Tenant shall request Landlord's consent and Landlord shall fail or refuse to give such consent, Tenant shall not be entitled to any damages for any withholding by Landlord of its consent, it being intended that Tenant's sole remedy shall be an action for specific performance or injunction, and that such remedy shall be available only in those cases where Landlord has expressly agreed in writing not to unreasonably withhold its consent or where as a matter of law Landlord may not unreasonably withhold its consent.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:justify;padding-left:14px;text-indent:44px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;color:#2d2f36;font-weight:bold;text-decoration:underline;">Section 27.8.</font><font style="font-family:inherit;font-size:12pt;color:#2d2f36;">  </font><font style="font-family:inherit;font-size:12pt;color:#2d2f36;text-decoration:underline;">Entire Agreement.</font><font style="font-family:inherit;font-size:12pt;color:#2d2f36;">  This Lease and the exhibits, riders and/or addenda, if any, attached hereto contain all covenants and agreements between Landlord and Tenant relating in any manner to the rental, use and occupancy of the Demised Premises and the other matters set forth in this Lease. No prior agreement or understanding pertaining to the same shall be valid or of any force or effect, and the covenants and agreements of this Lease cannot be altered, changed, modified or added to, except in writing signed by Landlord and Tenant. No representation, inducement, understanding or anything of any nature whatsoever, made, stated or represented on Landlord's behalf, either orally or in writing (except this Lease), has induced Tenant to enter into this Lease. The submission of this document for examination does not constitute an offer to lease, or a reservation of an option for the Demised Premises and becomes effective only upon execution and delivery thereof by Landlord and Tenant.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:justify;padding-left:14px;text-indent:44px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;color:#2d2f36;font-weight:bold;text-decoration:underline;">Section 27.9.</font><font style="font-family:inherit;font-size:12pt;color:#2d2f36;">  </font><font style="font-family:inherit;font-size:12pt;color:#2d2f36;text-decoration:underline;">Default Under Other Agreements.</font><font style="font-family:inherit;font-size:12pt;color:#2d2f36;">      Any default by Tenant under any instrument, undertaking or agreement executed by Tenant in favor of or with Landlord relating to this Lease, or the tenancy created hereby, shall constitute a breach of this Lease and entitle Landlord to pursue each and all of its rights and remedies hereunder and at law.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:justify;padding-left:14px;text-indent:44px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;color:#2d2f36;font-weight:bold;text-decoration:underline;">Section 27</font><font style="font-family:inherit;font-size:12pt;color:#545b67;font-weight:bold;text-decoration:underline;">.</font><font style="font-family:inherit;font-size:12pt;color:#2d2f36;font-weight:bold;text-decoration:underline;">10.</font><font style="font-family:inherit;font-size:12pt;color:#2d2f36;font-weight:bold;"> </font><font style="font-family:inherit;font-size:12pt;color:#2d2f36;text-decoration:underline;">Objection to Statements.</font><font style="font-family:inherit;font-size:12pt;color:#2d2f36;">     Tenant's failure to object to any statement, invoice or billing rendered by Landlord within a period of ninety (90) days after receipt thereof shall constitute Tenant's acquiescence with respect thereto and shall render such statement, invoice or billing an account stated between Landlord and Tenant.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:justify;padding-left:14px;text-indent:45px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;color:#2d2f36;font-weight:bold;text-decoration:underline;">Section 27.11.</font><font style="font-family:inherit;font-size:12pt;color:#2d2f36;">  </font><font style="font-family:inherit;font-size:12pt;color:#2d2f36;text-decoration:underline;">Brokerage Commission.</font><font style="font-family:inherit;font-size:12pt;color:#2d2f36;">  Tenant and Landlord represent and warrant to the other that there are no claims for brokerage commissions or finder's fees incurred by them, respectively, in connection with the execution of this Lease except for Resource Realty of Northern New Jersey (the "Broker") and each party agrees to indemnify the other against and hold it harmless from all liabilities arising from any such claims other than that of the Broker, including the cost of counsel. Landlord agrees to pay a commission to the Broker pursuant to the terms of a separate agreement between Landlord </font><font style="font-family:inherit;font-size:12pt;color:#444449;">and </font><font style="font-family:inherit;font-size:12pt;color:#2d2f36;">Broker.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:justify;padding-left:14px;text-indent:45px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;color:#2d2f36;font-weight:bold;text-decoration:underline;">Section 27.12.</font><font style="font-family:inherit;font-size:12pt;color:#2d2f36;">  </font><font style="font-family:inherit;font-size:12pt;color:#2d2f36;text-decoration:underline;">Relationship of Parties.</font><font style="font-family:inherit;font-size:12pt;color:#2d2f36;">      Anything in this Lease to the contrary notwithstanding, it is agreed that Landlord shall in no event be deemed to be a partner or engaged in a joint venture with or any associate of Tenant, or any party associated with Tenant in the conduct of its business or otherwise, nor shall Landlord be liable for any debts incurred by Tenant in the conduct of its business. The relationship of Landlord and Tenant as established by this Lease is that of Landlord and Tenant. None of the language or terminology of this Lease shall be construed to create any other form of relationship between Landlord and Tenant.</font></div><div><br></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;padding-top:1px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;padding-top:1px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;padding-top:2px;text-align:justify;padding-left:8px;text-indent:44px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;padding-top:2px;text-align:justify;padding-left:8px;text-indent:44px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;color:#262626;font-weight:bold;text-decoration:underline;">Section 27.13.</font><font style="font-family:inherit;font-size:12pt;color:#262626;"> </font><font style="font-family:inherit;font-size:12pt;color:#262626;text-decoration:underline;">No Recording of Lease.</font><font style="font-family:inherit;font-size:12pt;color:#262626;"> Tenant represents that it shall not record this Lease and acknowledges that such representation is a material term of this Lease.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:justify;padding-left:6px;text-indent:45px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;color:#262626;font-weight:bold;text-decoration:underline;">Section 27.14.</font><font style="font-family:inherit;font-size:12pt;color:#262626;"> </font><font style="font-family:inherit;font-size:12pt;color:#262626;text-decoration:underline;">Past Due Rent.</font><font style="font-family:inherit;font-size:12pt;color:#262626;">  If Landlord shall fail to receive, when the same is due and payable, any Minimum Rent, Additional Rent or other amounts or charges to be paid to Landlord by Tenant, as provided in this Lease, Tenant shall pay as Additional Rent interest thereon until fully paid, which shall continue after any judgment until fully satisfied, and if same is not paid within five (5) days of its due date Tenant shall pay as Additional Rent, a late charge equal to five percent (5%) of each installment past due to cover the administrative costs and expenses involved in administering delinquent accounts.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:justify;padding-left:8px;text-indent:45px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;color:#262626;font-weight:bold;text-decoration:underline;">Section 27.15.</font><font style="font-family:inherit;font-size:12pt;color:#262626;"> </font><font style="font-family:inherit;font-size:12pt;color:#262626;text-decoration:underline;">Limitation of Liability.</font><font style="font-family:inherit;font-size:12pt;color:#262626;">     Anything in this Lease to the contrary notwithstanding, Tenant agrees that it shall look solely to the estate and property of the Landlord in the Industrial Center, and subject to the prior rights of any mortgagee of the Industrial Center and subject to Landlord's rights under a leasehold interest of the Industrial Center or part thereof, if any, for the collection of any judgment (or other judicial process) requiring the payment of money by Landlord in the event of any default or breach by Landlord with respect to any of the terms, covenants and conditions of this Lease to be observed and/or performed by Landlord, and no other assets of the Landlord or its managing agent, and it’s or their respective affiliates, principals, shareholders, officers, directors, partners, members, trustees, fiduciaries, servants, agents and employees, shall be subject to levy, execution or other procedures for the satisfaction of Tenant's remedies. In no event shall Landlord be liable for, and Tenant, hereby waives any claim for, any indirect, consequential or punitive damages, including loss of profits or business opportunity, arising under or in connection with this Lease.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:justify;padding-left:8px;text-indent:45px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;color:#262626;font-weight:bold;text-decoration:underline;">Section 27.16.</font><font style="font-family:inherit;font-size:12pt;color:#262626;"> </font><font style="font-family:inherit;font-size:12pt;color:#262626;text-decoration:underline;">OFAC List Representation.</font><font style="font-family:inherit;font-size:12pt;color:#262626;"> Tenant represents and warrants that it is not listed, nor is it owned or controlled by, or acting for or on behalf of any person or entity, on the list of Specially Designated Nationals and Blocked Persons maintained by the Office of Foreign Assets Control of the United States Department of the Treasury, or any other list of persons or entities with whom Landlord is restricted from doing business with ("</font><font style="font-family:inherit;font-size:12pt;color:#262626;text-decoration:underline;">OFAC List</font><font style="font-family:inherit;font-size:12pt;color:#262626;">"). Notwithstanding anything to the contrary herein contained, Tenant shall not permit the Demised Premises or any portion thereof to be used, occupied or operated by or for the benefit of any person or entity that is on the OFAC List. Tenant shall indemnify and hold Landlord harmless from and against all losses, damages, liabilities, cost and expenses (including, without limitation, reasonable attorneys' fees and expenses) that are incurred by Landlord and/or its affiliate that derive from a claim made by a third party against Landlord and/or its affiliates arising or alleged to arise from a misrepresentation made by Tenant hereunder or a breach of any covenant to be performed by Tenant hereunder. Landlord represents and warrants that it is not listed, nor is it owned or controlled by, or acting for or on behalf of any person or entity, on the OFAC List. Landlord shall indemnify and hold Tenant harmless from and against all losses, damages, liabilities, cost and expenses (including, without limitation, reasonable attorneys' fees and expenses) that are incurred by Tenant that derive from a claim made by a third party against Tenant and/or its affiliates arising or alleged to arise from a misrepresentation made by Landlord hereunder or a breach of any covenant to be performed by Landlord hereunder.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:justify;padding-left:9px;text-indent:44px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;color:#262626;font-weight:bold;text-decoration:underline;">Section 27.17.</font><font style="font-family:inherit;font-size:12pt;color:#262626;"> </font><font style="font-family:inherit;font-size:12pt;color:#262626;text-decoration:underline;">Inability to Perform.</font><font style="font-family:inherit;font-size:12pt;color:#262626;">  If, by reason of strikes or other labor disputes, fire or other casualty (or reasonable delays in adjustment of insurance), accidents, any legal requirements,</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div><br></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-top:2px;text-align:justify;padding-left:14px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;padding-top:2px;text-align:justify;padding-left:14px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;padding-top:2px;text-align:justify;padding-left:14px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;color:#2d2f36;">any orders of any governmental authority or any other cause beyond a party's reasonable control, whether or not such other cause shall be similar in nature to those hereinbefore enumerated (any such event an "</font><font style="font-family:inherit;font-size:12pt;color:#2d2f36;text-decoration:underline;">Unavoidable Delay"</font><font style="font-family:inherit;font-size:12pt;color:#2d2f36;">), the non-performing party is unable to furnish or is delayed in furnishing any utility or service required to be furnished by such party under this Lease, or is unable to perform or make or is delayed in performing or making any installations, decorations, repairs, alterations, additions or improvements, whether or not required to be performed or made under this Lease, or is unable to fulfill or is delayed in fulfilling any of the non-performing party's other obligations under this Lease, the period of time for performance of such obligation shall be extended for the duration of the Unavoidable Delay. Nothing contained in this Section 27.17 shall excuse the payment of any sums required to be paid under this Lease.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:center;padding-left:181px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;color:#2d2f36;font-weight:bold;text-decoration:underline;">ARTICLE 28. SECURITY DEPOSIT</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:justify;padding-left:14px;text-indent:45px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;color:#2d2f36;font-weight:bold;text-decoration:underline;">Section 28.1.</font><font style="font-family:inherit;font-size:12pt;color:#2d2f36;"> Tenant has deposited the sum of Thirty Thousand and 00</font><font style="font-family:inherit;font-size:12pt;color:#56606d;">/</font><font style="font-family:inherit;font-size:12pt;color:#2d2f36;">100 Dollars ($30,000.00) with Landlord as a "</font><font style="font-family:inherit;font-size:12pt;color:#2d2f36;text-decoration:underline;">Security Deposit</font><font style="font-family:inherit;font-size:12pt;color:#2d2f36;">" which shall be held by Landlord as security for the punctual performance by Tenant of each and every obligation of it under this Lease. In the event of any default by Tenant (beyond applicable notice and cure periods), Landlord may apply or retain all or any part of the Security Deposit to cure the default or to reimburse Landlord for any sum which Landlord may spend by reason of the default and for which Tenant is liable under the terms of this Lease, without thereby waiving any other rights or remedies of Landlord with respect to such default. In the case of every such application or retention Tenant shall on demand, pay to Landlord the sum so applied or retained which shall be added to the Security Deposit so that the same shall be restored to Thirty Thousand and 00</font><font style="font-family:inherit;font-size:12pt;color:#56606d;">/</font><font style="font-family:inherit;font-size:12pt;color:#2d2f36;">100 Dollars ($30,000.00). If at the end of the Lease Term, Tenant shall not be in default under this Lease (beyond applicable notice and cure periods), but not otherwise, the Security Deposit shall be returned to Tenant within thirty (30) days to the extent same has not been retained or applied by Landlord in accordance with the provisions of hereof. There shall be no interest payable on the Security Deposit. Tenant agrees that except for an assignment in connection with an assignment of Tenant's interest under this Lease in accordance with the provisions of Article 17</font><font style="font-family:inherit;font-size:12pt;color:#56606d;">, </font><font style="font-family:inherit;font-size:12pt;color:#2d2f36;">Tenant shall not assign or encumber any part of the Security Deposit, and no assignment or encumbrance by Tenant of all or any part of the Security Deposit shall be binding upon Landlord, whether made prior to, during, or after the Lease Term. Landlord shall not be required to exhaust its remedies against Tenant or against the Security Deposit before having recourse to any other form of security held by Landlord and recourse by Landlord to any form of security shall not affect any remedies of Landlord which are provided in this Lease or which are available to Landlord in law or equity. In the event of any sale, assignment or transfer by Landlord named herein (or by any subsequent Landlord) of its interest in the Building or Industrial Center as owner or lessee, Landlord (or such subsequent owner) shall assign or transfer the Security Deposit to its grantee, assignee or transferee and, in the event of such assignment or transfer, Landlord named herein, (or such subsequent Landlord) shall have no liability to Tenant for the return of the Security Deposit and Tenant shall look solely to the grantee, assignee or transferee for such return. A lease of the entire Building or Industrial Center shall be deemed a transfer within the meaning of the foregoing sentence.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:center;padding-left:166px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;color:#2d2f36;font-weight:bold;text-decoration:underline;">ARTICLE 29. RIGHT OF FIRST OFFER</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:justify;padding-left:14px;text-indent:44px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;color:#2d2f36;font-weight:bold;text-decoration:underline;">Section 29.1.</font><font style="font-family:inherit;font-size:12pt;color:#2d2f36;">  </font><font style="font-family:inherit;font-size:12pt;color:#2d2f36;text-decoration:underline;">Tenant's Right of First Offer</font><font style="font-family:inherit;font-size:12pt;color:#2d2f36;">. Provided that (a) Tenant is not then in default under any of the terms, covenants or conditions of this Lease on Tenant's part to be observed or</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div><br></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-top:2px;text-align:justify;padding-left:6px;text-indent:-2px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;padding-top:2px;text-align:justify;padding-left:6px;text-indent:-2px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;padding-top:2px;text-align:justify;padding-left:6px;text-indent:-2px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;padding-top:2px;text-align:justify;padding-left:6px;text-indent:-2px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;color:#262626;">performed beyond applicable notice and cure periods and (b) the original named Tenant of this Lease (i.e., Immunomedics, Inc.) or any assignee or subtenant for which Landlord's consent was not required under the terms of this Lease, in contradistinction to any other subtenants or other occupants, shall then be leasing the entire Demised Premises then Tenant shall have the one-time right (sometimes referred to herein as "Tenant's First Offer Right"), subject to the provisions of this Lease, exercisable in accordance with the provisions of Section 29.2, to lease the entirety of the first space in the Building which is contiguous to the Demised Premises (such space, the "Additional Space"), which becomes "available for leasing" during the Lease Term. No Additional Space shall be deemed "available for leasing" if(a) the then tenant of the Additional Space or any assignee, successor, subtenant or other occupant holding through or under such tenant, shall enter into (i) any Lease with Landlord extending the letting Lease affecting the Additional Space or (ii) any new lease with Landlord affecting the Additional Space, or (b) any other tenant of the Building or any assignee or successor of such other tenant shall have or shall exercise any contractual option or right which it has as of the date of this Lease to lease the Additional Space (whether the Additional Space in question is specifically referred to in any such contractual option or right or Landlord must utilize such Additional Space in question in order to satisfy such contractual option or right). Without limiting the foregoing, so long as a tenant or other occupant leases or occupies a portion of the applicable Additional Space, Landlord shall be free to extend any such tenancy or occupancy, whether or not pursuant to a lease or other Lease, and such space shall not be deemed to be available for leasing. Notwithstanding the foregoing provisions of this Section 29.1, Tenant shall not have the right to lease any Additional Space pursuant to Tenant's First Offer Right which becomes available for leasing if, the Expected Vacancy Date (as defined in Section 29.2A) as set forth in Landlord's Availability Notice (as defined in Section 29.2A) is later than the date two (2) years immediately preceding the then current Expiration Date of the Lease unless Tenant simultaneously with its giving of Tenant's First Offer Notice exercises its Renewal Option (as defined in Section 30.1).</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:54px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;color:#262626;font-weight:bold;text-decoration:underline;">Section 29.2.</font><font style="font-family:inherit;font-size:12pt;color:#262626;font-weight:bold;"> </font><font style="font-family:inherit;font-size:12pt;color:#262626;font-weight:bold;"> </font><font style="font-family:inherit;font-size:12pt;color:#262626;">- </font><font style="font-family:inherit;font-size:12pt;color:#262626;text-decoration:underline;">Notice of Availability and Tenant's Exercise of Option.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:justify;padding-left:9px;text-indent:89px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;color:#262626;">A. In the event that the Additional Space shall become or about to become available for leasing in accordance with the provisions of Section 21.1, Landlord shall give notice thereof to Tenant (any such notice is referred to as an "</font><font style="font-family:inherit;font-size:12pt;color:#262626;text-decoration:underline;">Landlord Availability Notice"</font><font style="font-family:inherit;font-size:12pt;color:#262626;">), which Landlord's Availability Notice shall contain (i) the date such Additional Space is expected to be vacant or available for leasing; (ii) the Minimum Rent and other material financial terms upon which Landlord is willing to Lease the Additional Space to Tenant. Landlord's Availability Notice may be given not more than eighteen (18) months prior to the date set forth in such Landlord's Availability Notice upon which such Additional Space is expected to become vacant and available for leasing (the date set forth in Landlord's Availability Notice on which such Additional Space is expected to become available for leasing is sometimes referred to as an "</font><font style="font-family:inherit;font-size:12pt;color:#262626;text-decoration:underline;">Expected Vacancy Date</font><font style="font-family:inherit;font-size:12pt;color:#444444;">"</font><font style="font-family:inherit;font-size:12pt;color:#262626;">). Upon Landlord giving Tenant a Landlord's Availability Notice, Tenant may exercise Tenant's First Offer Right with respect to the entire Additional Space only and only by notice given to Landlord within twenty (20) days next following the date of the giving of such Landlord's Availability Notice, and by giving such notice Tenant shall thereby lease and add such Additional Space to the Demised Premises for a term to begin, subject to Section 29.3, on the Expected Vacancy Date for a term co-terminous with the Lease Term for the Demised Premises; any notice given by Tenant to Landlord exercising such Tenant's First Offer Right is referred to as "Tenant's </font><font style="font-family:inherit;font-size:12pt;color:#262626;text-decoration:underline;">First Offer Notice"</font><font style="font-family:inherit;font-size:12pt;color:#262626;">.</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div><br></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-top:2px;text-align:justify;padding-left:13px;text-indent:92px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;padding-top:2px;text-align:justify;padding-left:13px;text-indent:92px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;padding-top:2px;text-align:justify;padding-left:13px;text-indent:92px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;padding-top:2px;text-align:justify;padding-left:13px;text-indent:92px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;color:#2d2f36;">B. It is understood and agreed that "time is of the essence" with respect to Tenant's exercise of its Tenant's First Offer Right pursuant to this Article and that if Tenant does not exercise such Tenant's First Offer Right within the twenty (20) day time limitation set forth in Subsection A above, (i) any notice purporting to exercise such Tenant's First Offer Right given after the expiration of such time limitation shall be void and of no force and effect, (ii) Tenant shall have no further right to lease the Additional Space, and (iii) Tenant shall have no further rights under this Article 29. Notwithstanding the foregoing, in the event Landlord offers to lease the Available Space to another party on monetary terms that differ by more than I 0% from those terms set forth in Landlord's Availability Notice, Landlord shall again offer the Available Space to Tenant in accordance with the terms of this Article 29.</font></div><div style="line-height:120%;padding-top:1px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:justify;padding-left:13px;text-indent:92px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;color:#2d2f36;">C. If Tenant exercises Tenant's First Offer Right in accordance with the provisions of this Article 29, then the Additional Space shall be leased by Tenant upon all of the then executory terms, covenants and conditions as are contained in this Lease, except as otherwise set forth herein, and adjusted to reflect (w) the number of rentable square feet contained in the Additional Space, and (x) that the term applicable to the Additional Space shall, commence on the Expected Vacancy Date, as the same may be accelerated or delayed pursuant to the provisions of Section 29.3, and (y) as otherwise provided in Section 29.4.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:60px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;color:#2d2f36;font-weight:bold;">Section 29.3. </font><font style="font-family:inherit;font-size:12pt;color:#2d2f36;">-</font><font style="font-family:inherit;font-size:12pt;color:#2d2f36;text-decoration:underline;">Acceleration of First Offer Vacancy Date.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:justify;padding-left:14px;text-indent:90px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;color:#2d2f36;">A. In the event that the Additional Space shall become available for leasing sooner than the Expected Vacancy Date because of the termination of the term of the lease or occupancy affecting such Additional Space, Landlord shall have the right to accelerate the Expected Vacancy Date to such sooner date upon not less than ten (10) days' notice to Tenant.</font></div><div style="line-height:120%;padding-top:1px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:justify;padding-left:14px;text-indent:90px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;color:#2d2f36;">B. </font><font style="font-family:inherit;font-size:12pt;color:#2d2f36;text-decoration:underline;">Holdover Occupant</font><font style="font-family:inherit;font-size:12pt;color:#2d2f36;">. Landlord and Tenant acknowledge the possibility that all or any of the tenants or occupants of the Additional Space may not have vacated and surrendered the Additional Space to Landlord by the Expected Vacancy Date. Accordingly, notwithstanding anything to the contrary contained in Sections 29.1 or 29.2 or in any Landlord's Availability Notice, if such tenants or occupants shall not have vacated and surrendered the Additional Space to Landlord by the Expected Vacancy Date, then the term applicable to the Additional Space shall commence on the date next following the day upon which the entire Additional Space becomes vacant and Landlord gives notice to Tenant of such vacancy, provided, however, Landlord shall use commercially reasonable efforts to obtain possession of the Additional Space.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:justify;padding-left:13px;text-indent:90px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;color:#2d2f36;">C. </font><font style="font-family:inherit;font-size:12pt;color:#2d2f36;text-decoration:underline;">Lease Not Affected</font><font style="font-family:inherit;font-size:12pt;color:#2d2f36;">. In the event that the provisions of this Section 29.3 shall apply, then, the parties agree that (a) the Expiration Date shall not be affected by operation of the provisions of this Section 29.3; (b) except as expressly set forth in this Section 29.3, neither the validity of this Lease nor the obligations of Tenant under this Article 29 shall be affected by operation of the provisions of this Section 29.3; and (c) Tenant waives any rights under any statute or other law to rescind this Lease or such Tenant's exercise of Tenant's First Offer Right and further waives the right to recover any damages against Landlord which may result from the failure of Landlord to deliver possession of the Additional Space on the Expected Vacancy Date. Notwithstanding the foregoing or anything to the contrary in this Section 29.3</font><font style="font-family:inherit;font-size:12pt;color:#5b6069;">, </font><font style="font-family:inherit;font-size:12pt;color:#2d2f36;">in the event the</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div><br></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;padding-top:2px;text-align:justify;padding-left:6px;text-indent:-2px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;padding-top:2px;text-align:justify;padding-left:6px;text-indent:-2px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;padding-top:2px;text-align:justify;padding-left:6px;text-indent:-2px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;color:#262626;">Additional Space is not delivered to Tenant within one hundred twenty (120) days after the Expected Vacancy Date, Tenant shall have the right to rescind its exercise of Tenant's First Offer Right upon ten (10) days' notice to Landlord.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:justify;padding-left:6px;text-indent:45px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;color:#262626;font-weight:bold;text-decoration:underline;">Section 29.4.</font><font style="font-family:inherit;font-size:12pt;color:#262626;">   - </font><font style="font-family:inherit;font-size:12pt;color:#262626;text-decoration:underline;">Lease of Additional Space</font><font style="font-family:inherit;font-size:12pt;color:#262626;">. If Tenant shall timely exercise Tenant's First Offer Right in accordance with the provisions of this Article then as of the effective commencement date of the term applicable to the Additional Space this Lease shall be modified as follows:</font></div><div style="line-height:120%;padding-top:1px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:justify;padding-left:8px;text-indent:89px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;color:#262626;">A. The Demised Premises shall include the Additional Space (together with all appurtenances, fixtures, improvements, additions and other property attached thereto or installed therein at the commencement of the term applicable to the Additional Space or at any time during said term, other than Tenant's Personal Property) for all purposes of this Lease;</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:98px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;color:#262626;">B. </font><font style="font-family:inherit;font-size:12pt;">    </font><font style="font-family:inherit;font-size:12pt;color:#262626;">The Minimum Rent and Additional Rent shall be increased as specified in</font></div><div style="line-height:120%;padding-top:1px;text-align:justify;padding-left:8px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;color:#262626;">Landlord's Availability Notice;</font></div><div style="line-height:120%;padding-top:1px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:justify;padding-left:9px;text-indent:89px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;color:#262626;">C. The area of the Additional Space and Tenant's Pro-rata Share shall be as set forth in Landlord's Availability Notice; and</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:justify;padding-left:9px;text-indent:89px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;color:#262626;">D. The Lease shall be modified to reflect any such other terms as are specified in Landlord's Availability Notice.</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;padding-top:2px;text-align:left;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;color:#262626;">E. </font><font style="font-family:inherit;font-size:12pt;">    </font><font style="font-family:inherit;font-size:12pt;color:#262626;">The term with respect to the Additional Space shall expire on the Expiration Date.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;padding-top:2px;text-align:justify;padding-left:9px;text-indent:45px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;color:#262626;font-weight:bold;text-decoration:underline;">Section 29.5.</font><font style="font-family:inherit;font-size:12pt;color:#262626;">   - </font><font style="font-family:inherit;font-size:12pt;color:#262626;text-decoration:underline;">Condition of Additional Space.</font><font style="font-family:inherit;font-size:12pt;color:#262626;">  Tenant agrees to accept the Additional Space in the condition which shall exist on the commencement date of the term applicable thereto "as is" and further agrees that Landlord shall have no obligation to perform any work or make any installations in order to prepare the Additional Space for Tenant's occupancy.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:justify;padding-left:9px;text-indent:45px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;color:#262626;font-weight:bold;text-decoration:underline;">Section 29.6.</font><font style="font-family:inherit;font-size:12pt;color:#262626;">   - </font><font style="font-family:inherit;font-size:12pt;color:#262626;text-decoration:underline;">Waiver</font><font style="font-family:inherit;font-size:12pt;color:#262626;">. If Tenant fails to exercise Tenant's First Offer Right within the time period set forth in Section 29.2, Tenant shall be deemed to have waived its right to lease the Additional Space, Tenant shall have no further right to lease the Additional Space and Tenant's right of first offer shall be null and void and of no further force or effect. Notwithstanding the foregoing, in the event Landlord offers to lease the Available Space to another party on monetary terms that differ by more than 10% from those terms set forth in Landlord's Availability Notice, Landlord shall again offer the Available Space to Tenant in accordance with the terms of this Article 29.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;color:#262626;font-weight:bold;text-decoration:underline;">ARTICLE 30. TENANT'S SINGLE RENEWAL OPTION</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:justify;padding-left:10px;text-indent:45px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;color:#262626;font-weight:bold;text-decoration:underline;">Section 30.1.</font><font style="font-family:inherit;font-size:12pt;color:#262626;">   </font><font style="font-family:inherit;font-size:12pt;color:#262626;text-decoration:underline;">Exercise of Option.</font><font style="font-family:inherit;font-size:12pt;color:#262626;">  Tenant shall have the right, to renew the Lease Term for all of the Demised Premises for a single renewal term (the "</font><font style="font-family:inherit;font-size:12pt;color:#262626;text-decoration:underline;">Renewal Term"</font><font style="font-family:inherit;font-size:12pt;color:#262626;">) often (10) years by irrevocable notice (the "Renewal Notice") delivered to Landlord not less than twelve (12) months prior to the Expiration Date of the Initial Lease Term, time being of the essence; provided, however, that (a) Tenant shall not be in default beyond applicable notice and cure periods under</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div><br></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-top:2px;text-align:justify;padding-left:12px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;padding-top:2px;text-align:justify;padding-left:12px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;padding-top:2px;text-align:justify;padding-left:12px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;padding-top:2px;text-align:justify;padding-left:12px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;color:#2a2d34;">any of the terms, covenants or conditions of this Lease on Tenant's part to be observed and performed either on the date the Renewal Notice is given or on the Renewal Term Commencement Date (as hereinafter defined), and (b) the Tenant named herein (i.e., Immunomedics, Inc.) shall not have assigned this Lease other than to an assignee for which Landlord's consent is not required hereunder. Upon the giving of the Renewal Notice, this Lease shall be deemed renewed for the Renewal Term with the same force and effect as if the Renewal Term had originally been included in the Lease Term. The Renewal Term shall commence on the day after the Expiration Date of the Lease Term (the "</font><font style="font-family:inherit;font-size:12pt;color:#2a2d34;text-decoration:underline;">Renewal Term Commencement Date</font><font style="font-family:inherit;font-size:12pt;color:#2a2d34;">") and shall terminate on the day preceding the tenth (10th) anniversary of the Renewal Term Commencement Date or such earlier date as this Lease shall terminate pursuant to any of the terms of this Lease.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:justify;padding-left:12px;text-indent:45px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;color:#2a2d34;font-weight:bold;text-decoration:underline;">Section 30.2.</font><font style="font-family:inherit;font-size:12pt;color:#2a2d34;font-weight:bold;"> </font><font style="font-family:inherit;font-size:12pt;color:#2a2d34;font-weight:bold;"> </font><font style="font-family:inherit;font-size:12pt;color:#2a2d34;text-decoration:underline;">Terms.</font><font style="font-family:inherit;font-size:12pt;color:#2a2d34;">   All of the terms, covenants and conditions of this Lease shall continue in full force and effect during the Renewal Term, except that (a) the Minimum Rent for the first five (5) years of the Renewal Term shall be equal to the greater of (i) the Fair Market Value (as hereinafter defined) and (ii) the annual Minimum Rent then in effect at the expiration of the Initial Lease Term, (b) the Minimum Rent for the remainder of the Renewal Term shall be increased based upon the CPI Increase (as defined in Schedule 1) and (c) Tenant shall have no further right to renew the Lease Term. Any termination, cancellation or surrender of the entire interest of Tenant under this Lease at any time during the Lease Term shall terminate any right of renewal of Tenant hereunder.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:justify;padding-left:12px;text-indent:46px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;color:#2a2d34;font-weight:bold;text-decoration:underline;">Section 30.3.</font><font style="font-family:inherit;font-size:12pt;color:#2a2d34;font-weight:bold;"> </font><font style="font-family:inherit;font-size:12pt;color:#2a2d34;font-weight:bold;"> </font><font style="font-family:inherit;font-size:12pt;color:#2a2d34;"> </font><font style="font-family:inherit;font-size:12pt;color:#2a2d34;text-decoration:underline;">Fair Market Value and Renewal Term Rent.</font><font style="font-family:inherit;font-size:12pt;color:#2a2d34;">   "</font><font style="font-family:inherit;font-size:12pt;color:#2a2d34;text-decoration:underline;">Fair Market Value</font><font style="font-family:inherit;font-size:12pt;color:#2a2d34;">" shall mean the fair market annual rental value of the Demised Premises at the commencement of the Renewal Term for a term equal to the first five (5) years of the Renewal Term, as determined by Landlord based on comparable space in the Building, and other comparable buildings in the market including all of Landlord's services provided for in this Lease, and with the Demised Premises considered as vacant, and in the "as is" condition existing on the Renewal Term Commencement Date. The calculation of Fair Market Value shall also be adjusted to take into account all relevant factors. Prior to the commencement of the Renewal Term, Landlord shall deliver to Tenant Landlord's determination of Minimum Rent during the Renewal Term. If Landlord determines that the Minimum Rent during the Renewal Term is the annual Minimum Rent then in effect at the expiration of the initial Lease Term, such determination shall be binding on Landlord and Tenant and Tenant shall have no right to dispute the same. If Landlord determines that the Minimum Rent during the Renewal Term is Fair Market Value, Tenant may dispute such determination as provided in Section 30.4 below.</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:justify;padding-left:12px;text-indent:45px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;color:#2a2d34;font-weight:bold;text-decoration:underline;">Section 30.4.</font><font style="font-family:inherit;font-size:12pt;color:#2a2d34;font-weight:bold;">  </font><font style="font-family:inherit;font-size:12pt;color:#2a2d34;text-decoration:underline;">Arbitration.</font><font style="font-family:inherit;font-size:12pt;color:#2a2d34;">    If Tenant shall dispute Landlord's determination of Fair Market Value, Tenant shall give notice to Landlord of such dispute within ten (10) business days after the delivery of Landlord's determination to Tenant. Thereafter for a period of thirty (30) days, Landlord and Tenant shall work diligently and in good faith to agree on the Fair Market Value. If no notice of dispute is given by Tenant within such ten (10) business day period (time being of the essence), then Landlord’s determination shall be binding upon Tenant. If Landlord and Tenant fail to agree on the Fair Market Value during such thirty (30) day period, such dispute shall be determined by a single arbitrator appointed in accordance with the American Arbitration Association Arbitration Rules for the Real Estate Industry. The arbitrator shall be impartial and shall have not less than ten (10) years' experience in the County of Morris related to the leasing of commercial warehouse space in comparable buildings in Morris County, and the fees of the</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div><br></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-top:1px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;padding-top:2px;text-align:justify;padding-left:6px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;padding-top:2px;text-align:justify;padding-left:6px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;padding-top:2px;text-align:justify;padding-left:6px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;padding-top:2px;text-align:justify;padding-left:6px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;padding-top:2px;text-align:justify;padding-left:6px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;color:#242424;">arbitrator shall be shared by Landlord and Tenant. Within fifteen (15) days following the appointment of the arbitrator, Landlord and Tenant shall attend a hearing before the arbitrator at which each party shall submit a report setting forth its determination of Fair Market Value, together with such information on comparable rentals and such other evidence as such party shall deem relevant. The arbitrator shall, within 30 days following such hearing and submission of evidence, render his or her decision by selecting the determination of Fair Market Value submitted by either Landlord or Tenant which, in the judgment of the arbitrator, most nearly reflects the Fair Market Value, but in no event less than the annual Minimum Rent then in effect at the expiration of the initial Lease Term. The arbitrator shall have no power or authority to select any Fair Market Value other than a Fair Market Value submitted by Landlord or Tenant or to modify any of the provisions of this Lease, and the decision of the arbitrator shall be final and binding upon Landlord and Tenant. Prior to the determination of the arbitrator, Tenant shall pay Minimum Rent based on Landlord's determination of Fair Market Value submitted to Tenant pursuant to Section 29.3, and following the arbitrator's final determination, the amount of any overpayment or underpayment shall be appropriately adjusted between the parties.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:justify;padding-left:6px;text-indent:45px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;color:#242424;font-weight:bold;text-decoration:underline;">Section 30.5.</font><font style="font-family:inherit;font-size:12pt;color:#242424;">  </font><font style="font-family:inherit;font-size:12pt;color:#242424;text-decoration:underline;">Agreement of Terms.</font><font style="font-family:inherit;font-size:12pt;color:#242424;">  Landlord and Tenant, at either party's request, shall promptly execute and exchange an appropriate agreement evidencing the extension of the Lease Term for the applicable Renewal Term, and the terms thereof in a form reasonably satisfactory to both parties, but no such agreement shall be necessary in order to make the provisions hereof effective.</font></div><div style="line-height:120%;text-align:justify;padding-left:6px;text-indent:45px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;color:#242424;font-weight:bold;text-decoration:underline;">ARTICLE 31. TENANT'S SELF-HELP</font></div><div style="line-height:120%;padding-top:1px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:justify;padding-left:8px;text-indent:45px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;color:#242424;font-weight:bold;text-decoration:underline;">Section 31.1.</font><font style="font-family:inherit;font-size:12pt;color:#242424;">   </font><font style="font-family:inherit;font-size:12pt;color:#242424;text-decoration:underline;">Tenant's Self-Help.</font><font style="font-family:inherit;font-size:12pt;color:#242424;">     If Landlord shall default in the performance or observance of any agreement or condition in this Lease contained on its part to be performed or observed with respect to the Demised Premises that could cause Tenant to be in violation of any legal requirements, and if Landlord shall not cure such default within twenty (20) days after notice from Tenant specifying the default and following five (5) days after a second "reminder" notice from Tenant, (or shall not within said period commence to cure such default and thereafter prosecute the curing of such default to completion with due diligence), Tenant may at its option, without waiving any claim for damages for breach of agreement, at any time thereafter cure such default for the account of Landlord and any reasonable amount paid or any contractual liability incurred by Tenant in so doing shall be deemed paid or incurred for the account of Landlord, and Landlord agrees to reimburse Tenant therefor or save Tenant harmless therefrom; provided that Tenant may cure any such default as aforesaid prior to the expiration of said waiting period, but after notice to Landlord (and in the case of the removal of snow and/or ice from the Common Facilities, prior to said notice to Landlord), if the curing of such default prior to the expiration of said waiting period is reasonably necessary to protect the real estate or Tenant's interest therein, to prevent injury or damage to persons or property, or to enable Tenant to conduct its business in the Demised Premises. Notwithstanding anything to the contrary contained herein, in the case of emergency, notice required pursuant to this Article may be given orally, or in any other reasonably due and sufficient manner having regard to the emergency and the attending circumstances. If any such notice shall not be given in the manner described in this Lease, then, as soon thereafter as</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div><br></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-top:2px;text-align:left;padding-left:14px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;color:#282a31;">may be practicable such notice shall be followed up by notice given in the manner described in herein.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;color:#282a31;font-weight:bold;text-decoration:underline;">ARTICLE 32. LANDORD'S REPRESENTATIONS</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:14px;text-indent:44px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;color:#282a31;font-weight:bold;text-decoration:underline;">Section 32.1.</font><font style="font-family:inherit;font-size:12pt;color:#282a31;">   Landlord hereby represents and warrants to Tenant that as of the date of execution and delivery of this Lease:</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:justify;padding-left:14px;text-indent:89px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;color:#282a31;">(a) Landlord has not received any notice of, any outstanding violation of any governmental law, rule, statute, ordinance, or regulation affecting the Demised Premises, the Building or the Industrial Center in any case which would have an adverse effect upon Tenant.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:justify;padding-left:14px;text-indent:89px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;color:#282a31;">(b) Landlord has not received any notice of any confirmed or unconfirmed special assessments affecting the Demised Premises, the Building or the Industrial Center.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:104px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;color:#282a31;">(c) </font><font style="font-family:inherit;font-size:12pt;">    </font><font style="font-family:inherit;font-size:12pt;color:#282a31;">Landlord has full power and right to enter into and complete this Lease.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:justify;padding-left:14px;text-indent:89px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;color:#282a31;">(e) There is no pending or threatened litigation affecting Landlord, the Demised Premises or the Industrial center which could have a material, adverse impact on Tenant or Tenant's use and occupancy of the Demised Premises for its intended purpose.</font></div><div style="line-height:120%;text-align:justify;padding-left:14px;text-indent:89px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:justify;padding-left:14px;text-indent:89px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;color:#282a31;">(f) </font><font style="font-family:inherit;font-size:12pt;">    </font><font style="font-family:inherit;font-size:12pt;color:#282a31;">Landlord is the owner of the Building and the Industrial Center in fee simple.</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;padding-top:2px;text-align:left;padding-left:146px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;color:#282a31;">[SIGNATURE PAGE IMMEDIATELY FOLLOWS]</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div><br></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;padding-top:2px;text-align:left;padding-left:6px;text-indent:89px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;color:#2f2f2f;">IN WITNESS WHEREOF, the parties hereto have set their hands and seals on the date first written above.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:8px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;color:#2f2f2f;">LANDLORD:</font><font style="font-family:inherit;font-size:12pt;">     </font><font style="font-family:inherit;font-size:12pt;color:#2f2f2f;">TENANT:</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;padding-top:2px;text-align:left;padding-left:8px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;color:#2f2f2f;">Wu/LH 400 American L.L.C.                    IMMUNOMEDICS, INC</font><font style="font-family:inherit;font-size:12pt;color:#646464;">.</font></div><div style="line-height:120%;padding-top:1px;text-align:left;padding-left:8px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;color:#2f2f2f;">By: GTJ Realty LP, the sole member</font></div><div style="line-height:120%;padding-top:1px;text-align:left;padding-left:30px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;color:#2f2f2f;">By: GTJ GP LLC, the general partner</font></div><div style="line-height:120%;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;color:#2f2f2f;">By: GTJ REIT, Inc., the sole member</font></div><div style="line-height:120%;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><img src="signature1.jpg" alt="signature1.jpg" style="font-size:12pt;height:100px;width:252px;"><font style="font-family:inherit;font-size:12pt;">                             </font><img src="signature2.jpg" alt="signature2.jpg" style="font-size:12pt;height:86px;width:246px;"></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div><br></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;padding-top:2px;text-align:center;padding-left:245px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;color:#31343d;text-decoration:underline;">SCHEDULE "1"</font></div><div style="line-height:120%;padding-top:2px;text-align:center;padding-left:245px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;padding-top:3px;text-align:left;text-indent:144px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;color:#31343d;">         </font><font style="font-family:inherit;font-size:12pt;color:#31343d;text-decoration:underline;">MINIMUM RENT FOR ORIGINAL LEASE TERM</font><font style="font-family:inherit;font-size:12pt;color:#31343d;"> </font></div><div style="line-height:120%;padding-top:3px;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:401px;border-collapse:collapse;text-align:left;"><tr><td colspan="7"></td></tr><tr><td style="width:122px;"></td><td style="width:126px;"></td><td style="width:9px;"></td><td style="width:114px;"></td><td style="width:5px;"></td><td style="width:17px;"></td><td style="width:5px;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-top:5px;text-align:center;padding-left:2px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;color:#31343d;text-decoration:underline;">Rent Period</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;color:#31343d;text-decoration:underline;">Annual Rent</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-top:5px;text-align:center;padding-left:28px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;color:#31343d;text-decoration:underline;">Monthly Rent</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-top:5px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;color:#31343d;">1st Lease Year</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;color:#31343d;">$479,367.00</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;color:#31343d;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;color:#31343d;">39,947.25</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;color:#31343d;"><sup style="vertical-align:top;line-height:120%;font-size:8pt">1</sup> </font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;color:#31343d;">2nd Lease Year</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;color:#31343d;">$479,367.00</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;color:#31343d;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;color:#31343d;">39,947.25</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;color:#31343d;"><sup style="vertical-align:top;line-height:120%;font-size:8pt">2</sup> </font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;color:#31343d;">3rd Lease Year</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;color:#31343d;">$479,367.00</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;color:#31343d;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;color:#31343d;">39,947.25</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;color:#31343d;">4th Lease Year</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;color:#31343d;">$479,367.00</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;color:#31343d;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;color:#31343d;">39,947.25</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;color:#31343d;">5th Lease Year</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;color:#31343d;">$479,367.00</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;color:#31343d;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;color:#31343d;">39,947.25</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;color:#31343d;">6th Lease Year</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;color:#31343d;">$522,510.03</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;color:#31343d;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;color:#31343d;">43,542.50</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;color:#31343d;">7th Lease Year</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;color:#31343d;">$522,510.03</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;color:#31343d;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;color:#31343d;">43,542.50</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;color:#31343d;">8th Lease Year</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;color:#31343d;">$522,510.03</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;color:#31343d;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;color:#31343d;">43,542.50</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;color:#31343d;">9th Lease Year</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;color:#31343d;">$522,510.03</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;color:#31343d;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;color:#31343d;">43,542.50</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;color:#31343d;">10th Lease Year</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;color:#31343d;">$522,510.03</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;color:#31343d;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;color:#31343d;">43,542.50</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;padding-top:2px;text-align:justify;padding-left:52px;text-indent:45px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;color:#31343d;">Minimum Rent for the 11th Lease Year shall be increased based upon the percentage increase in the Consumer Price Index (as hereinafter defined) during the preceding twelve (12) month period (the" C.P.I. Increase")and such increased Minimum Rent shall be the Minimum Rent payable by Tenant for the remainder of the Initial Lease Term. The term "Consumer Price Index" shall mean the Consumer Price Index For All Urban Consumers All Items</font><font style="font-family:inherit;font-size:12pt;color:#4b4b50;">, </font><font style="font-family:inherit;font-size:12pt;color:#31343d;">United States (CPI-U) (1985-87 = 100) seasonally adjusted as published by the United States Department of Labor, Bureau of Labor Statistics, or any replacement thereof. If the manner in which the Consumer Price Index is determined by the Department of Labor shall be substantially revised, an adjustment shall be made in such revised index which would have obtained if the Consumer Price Index had not been so revised. If the current yearly average shall no longer be used as an index of 100, such change shall constitute a substantial revision</font><font style="font-family:inherit;font-size:12pt;color:#4b4b50;">. </font><font style="font-family:inherit;font-size:12pt;color:#31343d;">If the Consumer Price Index shall become unavailable to the public because publication is discontinued, or otherwise, Landlord will substitute therefor a comparable index based upon changes in the cost of living or purchasing power of the consumer dollar published by any other governmental agency or, if no such index shall then be available, a comparable index published by a major bank or other financial </font><font style="font-family:inherit;font-size:12pt;color:#4b4b50;">ins</font><font style="font-family:inherit;font-size:12pt;color:#31343d;">titution or by a university or a recognized financial publication shall be substituted</font><font style="font-family:inherit;font-size:12pt;color:#4b4b50;">.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:justify;padding-left:53px;text-indent:44px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;color:#31343d;">Landlord shall submit a statement to Tenant setting forth the amount of the C.P.I. Increase, and if such statement is not submitted until after the commencement of the 11th Lease Year, Tenant shall continue to pay Minimum Rent at the rate thereof at the end of the 1Oth Lease Year and after receipt of said statement the Minimum Rent shall be increased in the amount of the applicable C.P.I. Increase and the first Minimum Rent</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;padding-top:2px;text-align:left;padding-left:9px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;color:#31343d;"><sup style="vertical-align:top;line-height:120%;font-size:8pt">1</sup></font><font style="font-family:inherit;font-size:12pt;color:#31343d;"> See 1. 8C.</font></div><div style="line-height:120%;padding-top:1px;text-align:left;padding-left:9px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;color:#31343d;"><sup style="vertical-align:top;line-height:120%;font-size:8pt">2</sup></font><font style="font-family:inherit;font-size:12pt;color:#31343d;"> See 1. 8C.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:9px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;color:#31343d;">00355322.4</font></div><div><br></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:center;padding-left:297px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;color:#31343d;">2</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;padding-top:1px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;padding-top:2px;text-align:left;padding-left:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;color:#262626;">payment after receipt of said statement shall include payment of any increases due for any prior months.</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div><br></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;padding-top:2px;text-align:center;padding-left:262px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;color:#282a33;text-decoration:underline;">EXHIBIT A</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:6px;text-indent:-2px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;color:#282a33;">This exhibit is annexed to this Lease and made a part hereof solely to delineate by outlining and cross-hatching markings the description of the Demised Premises, Building and the Industrial Center. All areas, dimensions, locations and conditions are approximate.</font></div><div style="line-height:120%;padding-top:1px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:center;padding-left:254px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;color:#282a33;">(See Attached)</font><img src="layout.jpg" alt="layout.jpg" style="color:#282a33;font-size:12pt;height:540px;width:578px;"></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;padding-top:2px;text-align:center;padding-left:226px;text-indent:-2px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;padding-top:2px;text-align:center;padding-left:226px;text-indent:-2px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;color:#232323;font-weight:bold;text-decoration:underline;">EXHIBIT B</font></div><div style="line-height:120%;padding-top:2px;text-align:center;padding-left:226px;text-indent:-2px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;color:#232323;font-weight:bold;text-decoration:underline;"> (Rules and Regulations)</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div><br></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:justify;padding-left:6px;text-indent:46px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;color:#232323;">1. Tenant shall advise and cause its vendors and distributors to deliver all merchandise in a manner that does not interfere with Landlord's and other tenant's use and enjoyment of the Industrial Center.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:justify;padding-left:6px;text-indent:44px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;color:#232323;">2. All deliveries and pick ups are to be made to designated service or receiving areas and Tenant shall request delivery trucks to approach their service or receiving areas by designated service routes and drives.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:justify;padding-left:6px;text-indent:45px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;color:#232323;">3. Tractor trailers which must be unhooked or parked must use steel plates under dolly wheels to prevent damage to the asphalt paving surface. In addition, wheel blocking must be available for use. Tractor trailers are to be removed from the loading areas after unloading.</font></div><div style="line-height:120%;padding-top:1px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:justify;padding-left:6px;text-indent:45px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;color:#232323;">4. Automobiles and other vehicles of Tenant and its employees and agents shall be parked only in areas designated by Landlord from time to time as "employee parking." There shall be absolutely no overnight parking of any kind by Tenant or its employees or agents at the Industrial Center. Landlord shall have the right to remove or cause to be removed any automobile or other vehicle of Tenant, its employees or agents that may be parked in any other area not designated for employee parking or which may be parked overnight. Any such removal shall be without liability of any kind to Landlord, its agents and employees and Tenant hereby indemnifies and agrees to hold Landlord free and harmless against all such liability pursuant to the indemnity provisions contained in this Lease. Tenant shall, from time to time, upon request of Landlord, supply Landlord with a list of all automobile models and license plate numbers owned by its employees and agents.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:justify;padding-left:8px;text-indent:45px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;color:#232323;">5. Tenant is responsible for storage and removal of its trash, refuse and garbage. Tenant shall not dispose of the following items in sinks or commodes: Hazardous Waste; plastic products (plastic bags, straws, boxes); sanitary napkins; tea bags; cooking fats, cooking oils; any meat scraps or cutting residue; petroleum products (gasoline, naphtha, kerosene, lubricating oils); paint products (thinner, brushes); or any other items which the same are not designed to receive. All floor area of the Demised Premises, including vestibules, entrances and returns, loading docks, doors, fixtures, windows and plate glass, shall be maintained in a safe, neat and clean condition.</font></div><div style="line-height:120%;padding-top:1px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:justify;padding-left:8px;text-indent:45px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;color:#232323;">6. Tenant shall not permit or suffer any advertising medium to be placed on the Building's walls, on the Demised Premises' exterior walls or windows, on the sidewalks or on the parking lot areas or light poles. No permission, expressed or implied, is granted to expressed or implied, is granted to exhibit or display any banner, pennant, sign and trade or seasonal decoration of any size, style or material within the </font><font style="font-family:inherit;font-size:12pt;color:#383838;">Industrial </font><font style="font-family:inherit;font-size:12pt;color:#232323;">Center, or outside the Demised Premises.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:justify;padding-left:8px;text-indent:45px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;color:#232323;">7. Tenant shall not permit or suffer the use of any advertising medium which can be heard or experienced outside of the Demised Premises, including, without limiting the generality of the foregoing, flashing lights, searchlights, loud speakers, phonographs, radios or television.</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;padding-top:2px;text-align:justify;padding-left:8px;text-indent:-2px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;padding-top:2px;text-align:justify;padding-left:8px;text-indent:-2px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;padding-top:2px;text-align:justify;padding-left:8px;text-indent:-2px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;padding-top:2px;text-align:justify;padding-left:8px;text-indent:-2px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;color:#2a2d34;">No radio, television or other communication antenna equipment or device is to be mounted, attached, or secured to any part of the roof, exterior surface, or anywhere outside the Demised Premises, unless Landlord has previously given its written consent, which may be arbitrarily withheld.</font></div><div><br></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:justify;padding-left:8px;text-indent:46px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;color:#2a2d34;">8. Tenant shall not permit or suffer merchandise of any kind at any time to be placed, exhibited or displayed outside the Demised Premises, nor shall Tenant use the exterior sidewalks, loading docks or exterior walkways of the Demised Premises to display, store or place any merchandise</font><font style="font-family:inherit;font-size:12pt;color:#444449;">. </font><font style="font-family:inherit;font-size:12pt;color:#2a2d34;">No sale of merchandise by tent sale, truck load sale or the like, shall be permitted on the Industrial Center's drives, parking lot or other Common Facilities</font><font style="font-family:inherit;font-size:12pt;color:#444449;">.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:justify;padding-left:8px;text-indent:45px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;color:#2a2d34;">9. Tenant shall not pe</font><font style="font-family:inherit;font-size:12pt;color:#444449;">rm</font><font style="font-family:inherit;font-size:12pt;color:#2a2d34;">it or suffer any portion of the Demised Premises to be used for retail residential, lodging purposes, sleeping, manufacturing, or any immoral or illegal, purpose.</font></div><div style="line-height:120%;padding-top:1px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:justify;padding-left:8px;text-indent:46px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;color:#2a2d34;">10</font><font style="font-family:inherit;font-size:12pt;color:#444449;">. </font><font style="font-family:inherit;font-size:12pt;color:#2a2d34;">Tenant shall not, in or on any part of the Common Facilities or to other tenants at the Industrial Center</font><font style="font-family:inherit;font-size:12pt;color:#444449;">:</font></div><div style="line-height:120%;text-align:justify;padding-left:8px;text-indent:46px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:98px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;color:#2a2d34;">(a) </font><font style="font-family:inherit;font-size:12pt;">    </font><font style="font-family:inherit;font-size:12pt;color:#2a2d34;">Create a nuisance.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:justify;padding-left:8px;text-indent:90px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;color:#2a2d34;">(b) Throw, discard or deposit any paper, glass or extraneous matter of any kind except in designated receptacles, or create litter or hazards of any kind.</font></div><div style="line-height:120%;padding-top:1px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:justify;padding-left:8px;text-indent:90px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;color:#2a2d34;">(c) Deface, damage, or demolish any sign, light standard or fixture, landscaping materials or other improvements within the Industrial Center, or the property of other tenants, business invitees or employees situated within the Industrial Center</font><font style="font-family:inherit;font-size:12pt;color:#444449;">.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:justify;padding-left:6px;text-indent:46px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;color:#2a2d34;">11. No additional locks or bolts of any kind shall be placed upon any of the entrances, doors or windows by Tenant, nor shall any changes be made in existing locks or the mechanism thereof. Each Tenant must, upon the termination of its tenancy, restore to Landlord all keys of entrances, doors, offices, and toilet rooms, ei</font><font style="font-family:inherit;font-size:12pt;color:#444449;">t</font><font style="font-family:inherit;font-size:12pt;color:#2a2d34;">her </font><font style="font-family:inherit;font-size:12pt;color:#444449;">furn</font><font style="font-family:inherit;font-size:12pt;color:#2a2d34;">ished to, or otherwise procured by, such Tenant, and in the event of the loss of any keys so furnished, such Tenant shall pay to Landlord the cost thereof and the cost of any locksmith or other service required by Landlord to obtain access to the Demised Premises, and in the event safes, closets of other lockable fixtures were installed in the Demised Premises, Tenant shall give all keys or combinations thereto to Landlord.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:justify;padding-left:6px;text-indent:46px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;color:#2a2d34;">12. Landlord shall have the right to prohibit any advertising, signage or other display by any Tenant which, in Landlord's opinion, tends to impair the reputation of the Industrial Center or its desirability as an industrial center, and upon written notice from Landlord, the Tenant shall refrain from or discontinue such advertising, signage or display.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:justify;padding-left:6px;text-indent:46px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;color:#2a2d34;">13. Tenant shall employ only such labor as will not result in jurisdictional disputes with any labor unions or strikes against or involving Landlord or the Industrial Center and which shall not cause any conflict with any union contract to which Landlord or its contractors or </font><font style="font-family:inherit;font-size:11pt;color:#242424;">subcontractors may be a party.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:2px;text-align:left;padding-left:202px;text-indent:57px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#262a2f;">  </font><font style="font-family:inherit;font-size:11pt;color:#262a2f;font-weight:bold;">         </font><font style="font-family:inherit;font-size:11pt;color:#262a2f;font-weight:bold;text-decoration:underline;">EXHIBIT C</font><font style="font-family:inherit;font-size:11pt;color:#262a2f;font-weight:bold;"> </font></div><div style="line-height:120%;padding-top:2px;text-align:left;padding-left:202px;text-indent:57px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;padding-top:2px;text-align:left;text-indent:240px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#262a2f;font-weight:bold;"></font><font style="font-family:inherit;font-size:11pt;color:#3d3f44;font-weight:bold;text-decoration:underline;">INTENTIONALLY</font><font style="font-family:inherit;font-size:11pt;color:#3d3f44;font-weight:bold;text-decoration:underline;"> </font><font style="font-family:inherit;font-size:11pt;color:#262a2f;font-weight:bold;text-decoration:underline;">DELETED</font></div><div><br></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:3px;text-align:left;font-size:7pt;"><font style="font-family:inherit;font-size:7pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:2px;text-align:center;padding-left:249px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#282828;font-weight:bold;text-decoration:underline;">EXHIDIT D</font></div><div style="line-height:120%;padding-top:2px;text-align:center;padding-left:249px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div><br></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-top:0px;text-align:center;padding-left:73px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#282828;font-weight:bold;text-decoration:underline;">TENANT MOVE-IN AND LEASE RENEWAL ENVIRONMENTAL QUESTIONNAIRE</font></div><div style="line-height:120%;padding-top:0px;text-align:center;padding-left:73px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:center;padding-left:73px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:justify;padding-left:17px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#282828;">Property Name: _______________________________________________________________</font></div><div style="line-height:120%;text-align:justify;padding-left:17px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#282828;"> </font></div><div style="line-height:120%;text-align:justify;padding-left:17px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#282828;">Property Address: _____________________________________________________________</font></div><div style="line-height:120%;text-align:justify;padding-left:17px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:justify;padding-left:17px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#282828;">Building/Suite Numbers: _______________________________________________________</font></div><div style="line-height:120%;text-align:justify;padding-left:17px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:justify;padding-left:17px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:justify;padding-left:17px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#282828;">Instructions: The following questionnaire is to be completed by the Tenant Representative with knowledge of the planned/existing operations for the specified building/location. A copy of the completed form must be attached to all new leases and renewals, and forwarded to the Owner's Risk Management Department. Please print clearly and attach additional sheets as necessary.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;padding-left:18px;font-size:11pt;"><font style="font-family:Arial;font-size:10pt;color:#282828;font-weight:bold;">1. </font><font style="font-family:inherit;font-size:11pt;color:#282828;font-weight:bold;">PROCESS INFORMATION</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:17px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#282828;">Describe planned use (new Lease) or existing operations (lease renewal), and include brief description of manufacturing processes employed.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;padding-left:18px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#282828;font-weight:bold;">2. HAZARDOUS MATERIALS</font></div><div style="line-height:120%;padding-top:0px;text-align:left;padding-left:18px;text-indent:-2px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#282828;">Are hazardous materials used or stored? If so, continue with the next question. If not, go to Section 3.0.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;padding-left:18px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#282828;font-weight:bold;">2.1 </font><font style="font-family:inherit;font-size:11pt;color:#282828;">Are any of the following materials handled on the property?</font></div><div style="line-height:120%;padding-top:0px;text-align:left;padding-left:109px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#282828;">Yes___ </font><font style="font-family:inherit;font-size:10pt;">    </font><font style="font-family:inherit;font-size:11pt;color:#282828;">No __</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:18px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#282828;">(A material is handled if it is used, generated, processed, produced, packaged, treated, stored, emitted, discharged, or disposed.) If so, complete this section. If this question is not applicable, skip this section and go on to Section 5.0.</font></div><div style="line-height:120%;text-align:left;padding-left:18px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:18px;text-indent:96px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#282828;">__: Explosives             __: Fuels         __: Oils</font></div><div style="line-height:120%;text-align:left;padding-left:18px;text-indent:96px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#282828;">__:Solvents            __: Oxidizers        __: Organics/Inorganics</font></div><div style="line-height:120%;text-align:left;padding-left:18px;text-indent:96px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#282828;">__ :Acids            __: Bases         __: Pesticides</font></div><div style="line-height:120%;text-align:left;padding-left:18px;text-indent:96px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#282828;">__:Gases            __: PCBs        __: Radioactive Materials</font></div><div style="line-height:120%;padding-top:0px;text-align:left;padding-left:78px;text-indent:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#282828;">__: Other (please specify)</font></div><div style="line-height:120%;padding-top:0px;text-align:left;padding-left:78px;text-indent:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#282828;">    </font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:2px;text-align:left;padding-left:18px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#282828;font-weight:bold;">2.2 </font><font style="font-family:inherit;font-size:10pt;">    </font><font style="font-family:inherit;font-size:11pt;color:#282828;">If any of the groups of materials checked in Section 2.1, please list the specific material(s), use(s), and quantity of each chemical used or stored on the site in the Table below. If convenient, you may substitute a chemical inventory and list the uses of each of the chemicals in each category separately.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:26px;font-size:7pt;"><font style="font-family:inherit;font-size:7pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:center;font-size:11pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:586px;border-collapse:collapse;text-align:left;"><tr><td colspan="6"></td></tr><tr><td style="width:97px;"></td><td style="width:97px;"></td><td style="width:98px;"></td><td style="width:97px;"></td><td style="width:98px;"></td><td style="width:97px;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#31343b;">Material</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="padding-left:6px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#31343b;">Physical</font></div><div style="padding-top:0px;padding-left:6px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#31343b;">State (Solid, Liquid, or Gas)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#31343b;">Usage</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="padding-top:0px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="padding-left:6px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#31343b;">Container</font></div><div style="padding-top:0px;padding-left:6px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#31343b;">Size</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="padding-top:0px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="padding-left:5px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#31343b;">Number of</font></div><div style="padding-top:0px;padding-left:6px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#31343b;">Containers</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="padding-top:0px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="padding-left:6px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#31343b;">Total</font></div><div style="padding-top:0px;padding-left:6px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#31343b;">Quantity</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="overflow:hidden;height:22px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="overflow:hidden;height:22px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="overflow:hidden;height:22px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="overflow:hidden;height:22px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="overflow:hidden;height:22px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="overflow:hidden;height:22px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="overflow:hidden;height:22px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="overflow:hidden;height:22px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="overflow:hidden;height:22px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="overflow:hidden;height:22px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="overflow:hidden;height:22px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="overflow:hidden;height:22px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="overflow:hidden;height:22px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="overflow:hidden;height:22px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="overflow:hidden;height:22px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="overflow:hidden;height:22px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="overflow:hidden;height:22px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="overflow:hidden;height:22px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="overflow:hidden;height:22px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="overflow:hidden;height:22px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="overflow:hidden;height:22px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="overflow:hidden;height:22px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="overflow:hidden;height:22px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="overflow:hidden;height:22px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="overflow:hidden;height:22px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="overflow:hidden;height:22px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="overflow:hidden;height:22px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="overflow:hidden;height:22px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="overflow:hidden;height:22px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="overflow:hidden;height:22px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="padding-top:2px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:29px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:28px;"><font style="font-family:inherit;font-size:11pt;color:#31343b;font-weight:bold;">2.3</font><font style="font-family:inherit;font-size:11pt;color:#31343b;"> </font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#31343b;">Describe the planned storage area location(s) for these materials. Please include site maps and drawings as appropriate.</font></div></td></tr></table><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:29px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#31343b;font-weight:bold;">3 </font><font style="font-family:inherit;font-size:10pt;">    </font><font style="font-family:inherit;font-size:11pt;color:#31343b;font-weight:bold;">HAZARDOUS WASTES</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:29px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#31343b;">Are hazardous wastes generated? </font><font style="font-family:inherit;font-size:10pt;">    </font><font style="font-family:inherit;font-size:11pt;color:#31343b;">Yes__ </font><font style="font-family:inherit;font-size:10pt;">    </font><font style="font-family:inherit;font-size:11pt;color:#31343b;">No__</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:29px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#31343b;">If yes, continue with the next question. If not, skip this section and go to section</font></div><div style="line-height:120%;padding-top:0px;text-align:left;padding-left:29px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#31343b;">4.0.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:29px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:28px;"><font style="font-family:inherit;font-size:11pt;color:#31343b;font-weight:bold;">3.1 </font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#31343b;">Are any of the following wastes generated, handled, or disposed of (where applicable) on the property?</font></div></td></tr></table><div style="line-height:120%;padding-top:1px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:113px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#49464d;">__ : </font><font style="font-family:inherit;font-size:11pt;color:#31343b;">Hazardous Wastes            __ : Industrial Wastewater</font></div><div style="line-height:120%;padding-top:0px;text-align:left;padding-left:113px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#31343b;">__ :Waste Oils                __ :PCBs</font></div><div style="line-height:120%;padding-top:0px;text-align:left;padding-left:113px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#49464d;">__ : </font><font style="font-family:inherit;font-size:11pt;color:#31343b;">Air Emissions                __ :Sludges </font></div><div style="line-height:120%;padding-top:0px;text-align:left;padding-left:113px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#31343b;">__ : Regulated Wastes            __ : Other (please specify)</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:2px;text-align:left;padding-left:29px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#31343b;font-weight:bold;">3.2 </font><font style="font-family:inherit;font-size:10pt;">    </font><font style="font-family:inherit;font-size:11pt;color:#31343b;">List and quantify </font><font style="font-family:inherit;font-size:11pt;color:#49464d;">the </font><font style="font-family:inherit;font-size:11pt;color:#31343b;">materials identified in Question 3-1 of this section.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:11pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:587px;border-collapse:collapse;text-align:left;"><tr><td colspan="6"></td></tr><tr><td style="width:106px;"></td><td style="width:68px;"></td><td style="width:96px;"></td><td style="width:124px;"></td><td style="width:94px;"></td><td style="width:97px;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#31343b;">WASTE GENERATED</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#31343b;">RCRA listed Waste?</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#31343b;">SOURCE</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#31343b;">APPROXIMATE MONTHLY QUANTITY</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="padding-left:6px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#31343b;">WASTE</font></div><div style="padding-top:0px;padding-left:6px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#31343b;">CHARAC- TERIZA- TION</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#31343b;">DISPOSI- TION</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="overflow:hidden;height:22px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="overflow:hidden;height:22px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="overflow:hidden;height:22px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="overflow:hidden;height:22px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="overflow:hidden;height:22px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="overflow:hidden;height:22px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="overflow:hidden;height:22px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="overflow:hidden;height:22px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="overflow:hidden;height:22px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="overflow:hidden;height:22px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="overflow:hidden;height:22px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="overflow:hidden;height:22px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="overflow:hidden;height:22px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="overflow:hidden;height:22px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="overflow:hidden;height:22px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="overflow:hidden;height:22px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="overflow:hidden;height:22px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="overflow:hidden;height:22px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="overflow:hidden;height:22px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="overflow:hidden;height:22px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="overflow:hidden;height:22px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="overflow:hidden;height:22px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="overflow:hidden;height:22px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="overflow:hidden;height:22px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="overflow:hidden;height:22px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="overflow:hidden;height:22px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="overflow:hidden;height:22px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="overflow:hidden;height:22px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="overflow:hidden;height:22px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="overflow:hidden;height:22px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:2px;text-align:left;padding-left:29px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#31343b;">3.3 </font><font style="font-family:inherit;font-size:10pt;">    </font><font style="font-family:inherit;font-size:11pt;color:#31343b;">Please include name, location, and permit number (e.g., EPA ID No.) for transporter and disposal facility, if applicable). Attach separate pages as necessary</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:left;padding-left:36px;font-size:7pt;"><font style="font-family:inherit;font-size:7pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:1px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:11pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:588px;border-collapse:collapse;text-align:left;"><tr><td colspan="4"></td></tr><tr><td style="width:146px;"></td><td style="width:146px;"></td><td style="width:146px;"></td><td style="width:146px;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#31343b;">Transporter/Disposal</font></div><div style="text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#31343b;">Facility Name</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#2f2f2f;">Facility Location</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="padding-left:6px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#2f2f2f;">Transporter (T) or</font></div><div style="padding-top:0px;padding-left:6px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#2f2f2f;">Disposal (D) Facility</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#2f2f2f;">Permit Number</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="overflow:hidden;height:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="overflow:hidden;height:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="overflow:hidden;height:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="overflow:hidden;height:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="overflow:hidden;height:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="overflow:hidden;height:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="overflow:hidden;height:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="overflow:hidden;height:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="overflow:hidden;height:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="overflow:hidden;height:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="overflow:hidden;height:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="overflow:hidden;height:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="overflow:hidden;height:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="overflow:hidden;height:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="overflow:hidden;height:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="overflow:hidden;height:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="overflow:hidden;height:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="overflow:hidden;height:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="overflow:hidden;height:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="overflow:hidden;height:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:2px;text-align:left;padding-left:8px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#2f2f2f;">3.4 </font><font style="font-family:inherit;font-size:10pt;">    </font><font style="font-family:inherit;font-size:11pt;color:#2f2f2f;">Are pollution controls or monitoring employed in the process to prevent or minimize the release of wastes into the environment? </font><font style="font-family:inherit;font-size:10pt;">    </font><font style="font-family:inherit;font-size:11pt;color:#2f2f2f;">Yes __</font><font style="font-family:inherit;font-size:10pt;">    </font><font style="font-family:inherit;font-size:11pt;color:#2f2f2f;">No__</font></div><div style="line-height:120%;text-align:left;padding-left:8px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#2f2f2f;">If so, please describe.</font></div><div style="line-height:120%;padding-top:1px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:8px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#2f2f2f;">4. </font><font style="font-family:inherit;font-size:10pt;">    </font><font style="font-family:inherit;font-size:11pt;color:#2f2f2f;">USTS</font><font style="font-family:inherit;font-size:11pt;color:#6b6b6b;">/</font><font style="font-family:inherit;font-size:11pt;color:#2f2f2f;">ASTS</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:8px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#2f2f2f;">4.1 </font><font style="font-family:inherit;font-size:10pt;">    </font><font style="font-family:inherit;font-size:11pt;color:#2f2f2f;">Are underground storage tanks (USTs), aboveground storage tanks (ASTs), or associated pipelines used for the storage of petroleum products, chemicals, or liquid wastes present on site (lease renewals) or required for planned operations (new tenants)?</font></div><div style="line-height:120%;padding-top:0px;text-align:left;padding-left:8px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#2f2f2f;">Yes __ </font><font style="font-family:inherit;font-size:10pt;">    </font><font style="font-family:inherit;font-size:11pt;color:#2f2f2f;">No __</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:9px;text-indent:-2px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#2f2f2f;">If not, continue with section 5.0. If yes, please describe capacity, contents, age, type of the USTs or ASTs, as well any associated leak detection/spill prevention measures. Please attach additional pages if necessary.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:11pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:585px;border-collapse:collapse;text-align:left;"><tr><td colspan="5"></td></tr><tr><td style="width:117px;"></td><td style="width:117px;"></td><td style="width:117px;"></td><td style="width:117px;"></td><td style="width:117px;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#2f2f2f;">Capacity</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#2f2f2f;">Contents</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#2f2f2f;">Year Installed</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#2f2f2f;">Type (Steel, Fiberglass, etc.)</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="padding-top:0px;padding-left:6px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#2f2f2f;">Associated Leak</font></div><div style="padding-top:0px;padding-left:6px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#2f2f2f;">Detection</font></div><div style="padding-top:0px;padding-left:6px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#2f2f2f;">/Spill Prevention</font></div><div style="padding-top:0px;padding-left:6px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#2f2f2f;">Measures*</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="overflow:hidden;height:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="overflow:hidden;height:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="overflow:hidden;height:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="overflow:hidden;height:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="overflow:hidden;height:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="overflow:hidden;height:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="overflow:hidden;height:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="overflow:hidden;height:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="overflow:hidden;height:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="overflow:hidden;height:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="overflow:hidden;height:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="overflow:hidden;height:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="overflow:hidden;height:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="overflow:hidden;height:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="overflow:hidden;height:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:2px;text-align:left;padding-left:9px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#2f2f2f;">*Note:                 The following are examples of leak detection/spill prevention</font></div><div style="line-height:120%;padding-top:2px;text-align:left;padding-left:9px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#2f2f2f;">measures:                     Inventory reconciliation </font><font style="font-family:inherit;font-size:10pt;">    </font><font style="font-family:inherit;font-size:11pt;color:#2f2f2f;">Leak detection</font></div><div style="line-height:120%;padding-top:2px;text-align:left;padding-left:9px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#2f2f2f;">Integrity testing                 Secondary containment     </font><font style="font-family:inherit;font-size:10pt;">    </font><font style="font-family:inherit;font-size:11pt;color:#2f2f2f;">Cathodic protection        </font></div><div style="line-height:120%;padding-top:2px;text-align:left;padding-left:9px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#2f2f2f;">system</font></div><div style="line-height:120%;padding-top:0px;text-align:left;padding-left:10px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#2f2f2f;">Overfill spill protection</font></div><div style="line-height:120%;padding-top:2px;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="padding-top:2px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:10px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:9px;"><font style="font-family:inherit;font-size:11pt;color:#2f2f2f;font-weight:bold;">4.2 </font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#2f2f2f;">Please provide copies of written tank integrity test results and/or monitoring documentation, if available.</font></div></td></tr></table><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:10px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#2f2f2f;font-weight:bold;">4.3</font><font style="font-family:inherit;font-size:11pt;color:#2f2f2f;"> </font><font style="font-family:inherit;font-size:10pt;">    </font><font style="font-family:inherit;font-size:11pt;color:#2f2f2f;">Is the UST/AST registered and permitted with the appropriate regulatory agencies?</font></div><div style="line-height:120%;padding-top:0px;text-align:left;padding-left:56px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#2f2f2f;">Yes __ </font><font style="font-family:inherit;font-size:10pt;">    </font><font style="font-family:inherit;font-size:11pt;color:#2f2f2f;">No __</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:10px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#2f2f2f;font-weight:bold;">4.4</font><font style="font-family:inherit;font-size:11pt;color:#2f2f2f;"> </font><font style="font-family:inherit;font-size:10pt;">    </font><font style="font-family:inherit;font-size:11pt;color:#2f2f2f;">If so, please attach a copy of the required permits.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;padding-left:10px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#2f2f2f;">If this Questionnaire is being completed for a lease renewal, and if any of the USTs/ASTs have</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:left;padding-left:14px;font-size:7pt;"><font style="font-family:inherit;font-size:7pt;color:#2f2f2f;">00235687.6</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:2px;text-align:left;padding-left:6px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;padding-top:2px;text-align:left;padding-left:6px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;padding-top:2px;text-align:left;padding-left:6px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;padding-top:2px;text-align:left;padding-left:6px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#2d2f36;">leaked, please state the substance released, the media(s) impacted (e.g., soil, water, asphalt, etc.), the actions taken, and al remedial responses to the incident.</font></div><div style="line-height:120%;padding-top:1px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:6px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#2d2f36;font-weight:bold;">4.5 </font><font style="font-family:inherit;font-size:10pt;">    </font><font style="font-family:inherit;font-size:11pt;color:#2d2f36;">If this Questionnaire is being completed for a lease renewal, have USTs</font><font style="font-family:inherit;font-size:11pt;color:#59626e;">/</font><font style="font-family:inherit;font-size:11pt;color:#2d2f36;">ASTs been</font></div><div style="line-height:120%;padding-top:0px;text-align:left;padding-left:6px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#2d2f36;">removed from the property? Yes __</font><font style="font-family:inherit;font-size:10pt;">    </font><font style="font-family:inherit;font-size:11pt;color:#2d2f36;">No __</font></div><div style="line-height:120%;padding-top:1px;text-align:left;padding-left:6px;text-indent:-2px;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;color:#2d2f36;">If </font><font style="font-family:inherit;font-size:11pt;color:#2d2f36;">yes, please provide any official closure letters or reports and supporting documentation (e.g., analytical test results, remediation report results, etc.).</font></div><div style="line-height:120%;padding-top:1px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:6px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:5px;"><font style="font-family:inherit;font-size:11pt;color:#2d2f36;font-weight:bold;">4.6 </font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#2d2f36;">For Lease renewals, are there any above or below ground pipelines on site used to transfer chemicals or wastes? </font><font style="font-family:inherit;font-size:10pt;">    </font><font style="font-family:inherit;font-size:11pt;color:#2d2f36;">Yes __</font><font style="font-family:inherit;font-size:10pt;">    </font><font style="font-family:inherit;font-size:11pt;color:#2d2f36;">No __</font></div></td></tr></table><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:6px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#2d2f36;">For new tenants, are installations of this type required for the planned operations? Yes __ No __</font></div><div style="line-height:120%;padding-top:1px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:6px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#2d2f36;">If yes to either question, please describe.</font></div><div style="line-height:120%;text-align:left;padding-left:6px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:6px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#2d2f36;font-weight:bold;">5. </font><font style="font-family:inherit;font-size:10pt;">    </font><font style="font-family:inherit;font-size:11pt;color:#2d2f36;font-weight:bold;">ASBESTOS CONTAINING BUILDING MATERIALS</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;padding-left:6px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#2d2f36;">Please be advised that this property participates in an Asbestos Operations and Maintenance Program, and that an asbestos survey may have been performed at the Property. If provided, please review the information that identifies the locations of known asbestos containing material or presumed asbestos containing material. All personnel and appropriate subcontractors should be notified of the presence of these materials, and informed not to disturb these materials. Any activity that involves the disturbance or removal of these materials must be done by an appropriately trained individual/contractor.</font></div><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:6px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#2d2f36;font-weight:bold;">6. </font><font style="font-family:inherit;font-size:10pt;">    </font><font style="font-family:inherit;font-size:11pt;color:#2d2f36;font-weight:bold;">REGULATORY</font></div><div style="line-height:120%;text-align:left;padding-left:6px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:6px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#2d2f36;font-weight:bold;">6.1 </font><font style="font-family:inherit;font-size:10pt;">    </font><font style="font-family:inherit;font-size:11pt;color:#2d2f36;">For Lease Renewals, are there any past, current, or pending regulatory actions by federal, state, or local environmental agencies alleging noncompliance with regulations?</font></div><div style="line-height:120%;text-align:left;padding-left:6px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#2d2f36;">Yes __ No __</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:6px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#2d2f36;">If so, please describe.</font></div><div style="line-height:120%;text-align:left;padding-left:6px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:6px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#2d2f36;font-weight:bold;">6.2 </font><font style="font-family:inherit;font-size:10pt;">    </font><font style="font-family:inherit;font-size:11pt;color:#2d2f36;">For lease renewals, are there any past, current, or pending lawsuits or administrative proceedings for alleged environmental damages involving the property, you, or any owner or tenant of the property? </font></div><div style="line-height:120%;text-align:left;padding-left:6px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#2d2f36;">Yes __ No __</font></div><div style="line-height:120%;text-align:left;padding-left:6px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:6px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#2d2f36;">If so, please describe.</font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:6px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#2d2f36;font-weight:bold;">6.3 </font><font style="font-family:inherit;font-size:10pt;">    </font><font style="font-family:inherit;font-size:11pt;color:#2d2f36;">Does the operation have or require a National Pollutant Discharge Elimination System</font></div><div style="line-height:120%;padding-top:0px;text-align:left;padding-left:6px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#2d2f36;">(NPDES) or equivalent permit? Yes __ No __</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:6px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#2d2f36;">If so, please attach a copy of this permit.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-top:2px;text-align:left;padding-left:6px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#282828;font-weight:bold;">6.4 </font><font style="font-family:inherit;font-size:10pt;">    </font><font style="font-family:inherit;font-size:11pt;color:#282828;">For Lease renewals, have there been any complaints from the surrounding community</font></div><div style="line-height:120%;padding-top:0px;text-align:left;padding-left:6px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#282828;">regarding facility operations?     </font><font style="font-family:inherit;font-size:11pt;color:#2d2f36;">Yes __ No __</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:2px;text-align:left;padding-left:6px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#282828;font-weight:bold;">6.5 </font><font style="font-family:inherit;font-size:10pt;">    </font><font style="font-family:inherit;font-size:11pt;color:#282828;">Have there been any worker complaints or regulatory investigations regarding hazardous material exposure at the facility? </font><font style="font-family:inherit;font-size:10pt;">    </font><font style="font-family:inherit;font-size:11pt;color:#2d2f36;">Yes __ No __</font></div><div style="line-height:120%;padding-top:1px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:8px;text-indent:-2px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#282828;">If so, please describe status and any corrective actions taken. Please attach additional pages as necessary.</font></div><div style="line-height:120%;padding-top:1px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;padding-left:8px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#282828;font-weight:bold;">6.6 </font><font style="font-family:inherit;font-size:11pt;color:#282828;">Has a Hazardous Materials Business Plan been developed for the site?    </font><font style="font-family:inherit;font-size:11pt;color:#2d2f36;">Yes __ No __</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;padding-left:8px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#282828;">If so, please attach a copy.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;padding-left:8px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#282828;font-weight:bold;">7. CERTIFICATION</font></div><div style="line-height:120%;padding-top:1px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;padding-left:8px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#282828;">I am familiar with the real property described in this questionnaire. By signing below, I represent and warrant that the answers to the above questions are complete and accurate to the best of my knowledge. I also understand that the Owner will rely on the completeness and accuracy of my answers in assessing any environmental liability risks associated with the property.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;padding-left:9px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#282828;">Signature:</font></div><div style="line-height:174%;text-align:justify;padding-left:9px;text-indent:-2px;font-size:15pt;"><font style="font-family:inherit;font-size:11pt;color:#282828;">Name:__________________________________________</font><font style="font-family:inherit;font-size:15pt;color:#777777;"> </font><font style="font-family:inherit;font-size:11pt;color:#282828;">Title:</font><font style="font-family:inherit;font-size:15pt;color:#777777;">_________________________________ </font><font style="font-family:inherit;font-size:11pt;color:#282828;">Date:</font><font style="font-family:inherit;font-size:15pt;color:#777777;">_________ </font><font style="font-family:inherit;font-size:11pt;color:#282828;">Telephone:___________________</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;padding-left:9px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#282828;font-weight:bold;">PLEASE PROVIDE A COPY OF THE COMPLETED QUESTIONNAIRE TO:</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:2px;text-align:center;padding-left:261px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;padding-top:2px;text-align:center;padding-left:261px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;padding-top:2px;text-align:center;padding-left:261px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;padding-top:2px;text-align:center;padding-left:261px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;padding-top:2px;text-align:center;padding-left:261px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;padding-top:2px;text-align:center;padding-left:261px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;padding-top:2px;text-align:center;padding-left:261px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;padding-top:2px;text-align:center;padding-left:261px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;padding-top:2px;text-align:center;padding-left:261px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;padding-top:2px;text-align:center;padding-left:261px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;padding-top:2px;text-align:center;padding-left:261px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;padding-top:2px;text-align:center;padding-left:261px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;padding-top:2px;text-align:center;padding-left:261px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;padding-top:2px;text-align:center;padding-left:261px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;padding-top:2px;text-align:center;padding-left:261px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;padding-top:2px;text-align:center;padding-left:261px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;padding-top:2px;text-align:center;padding-left:261px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;padding-top:2px;text-align:center;padding-left:261px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div><br></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-top:2px;text-align:center;padding-left:261px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;padding-top:2px;text-align:center;padding-left:261px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;padding-top:2px;text-align:center;padding-left:261px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;padding-top:2px;text-align:center;padding-left:261px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;padding-top:2px;text-align:center;padding-left:261px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#2d2f36;font-weight:bold;">EXHIBIT E</font></div><div style="line-height:120%;padding-top:2px;text-align:center;padding-left:261px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:232%;padding-top:0px;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#2d2f36;font-weight:bold;">TENANT MOVE-OUT ENVIRONMENTAL QUESTIONNAIRE</font></div><div style="line-height:232%;padding-top:0px;text-align:left;padding-left:6px;text-indent:90px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:232%;padding-top:0px;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#2d2f36;"> Property Name: ________________________________________________________________________ </font></div><div style="line-height:232%;padding-top:0px;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#2d2f36;">Property Address: _______________________________________________________________________</font></div><div style="line-height:232%;padding-top:0px;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#2d2f36;">Building </font><font style="font-family:Arial;font-size:11pt;color:#565b64;font-style:italic;">I </font><font style="font-family:inherit;font-size:11pt;color:#2d2f36;">Suite Number(s):_______________________________________________________________</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;padding-left:6px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:justify;padding-left:6px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#2d2f36;">Instructions: The following questionnaire is to be completed by the Property Manager prior to</font><font style="font-family:inherit;font-size:11pt;color:#6b6b70;">/</font><font style="font-family:inherit;font-size:11pt;color:#2d2f36;">after the Tenant vacates a building/suite or location. A copy of the completed form must be forwarded to the Owner's Risk Management Department. Please print clearly and attach additional sheets as necessary.</font></div><div style="line-height:120%;text-align:justify;padding-left:6px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:justify;padding-left:6px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:left;padding-left:6px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#2d2f36;font-weight:bold;">1. </font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">    </font><font style="font-family:inherit;font-size:11pt;color:#2d2f36;font-weight:bold;">GENERAL INFORMATION </font></div><div style="line-height:120%;padding-top:0px;text-align:left;padding-left:6px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:left;padding-left:6px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#2d2f36;">Property Manager:</font></div><div style="line-height:120%;padding-top:0px;text-align:left;padding-left:6px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#2d2f36;">Property Management Company: </font></div><div style="line-height:120%;padding-top:0px;text-align:left;padding-left:6px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#2d2f36;">Regional Manager:</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:6px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:6px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#2d2f36;font-weight:bold;">2. </font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">    </font><font style="font-family:inherit;font-size:11pt;color:#2d2f36;font-weight:bold;">TENANT INFORMATION </font></div><div style="line-height:120%;text-align:left;padding-left:6px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:6px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#2d2f36;">Name of Former Tenant:</font></div><div style="line-height:120%;padding-top:0px;text-align:justify;padding-left:6px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#2d2f36;">Lease Date: _______________________________ Move-out Date: _____________________________</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;padding-left:6px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:justify;padding-left:6px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#2d2f36;font-weight:bold;">3. INDOOR INSPECTION</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:justify;padding-left:6px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;color:#2d2f36;">The Property Manager is expected to inspect the vacant building/suite of the tenant. A pre-vacate "inspection" should be performed in advance of the tenant moving out to ensure that potential environmental issues requiring tenant response are addressed. Areas that are inaccessible should be noted. The Property Manager should check the interior of all closets and storage cabinets for items left by the vacated tenant.</font></div><div style="line-height:120%;padding-top:1px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:justify;padding-left:6px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;color:#2d2f36;">3.1 Upon entering the vacated building(s)</font><font style="font-family:inherit;font-size:12pt;color:#565b64;">/</font><font style="font-family:inherit;font-size:12pt;color:#2d2f36;">suite(s), did you note any unusual odors?</font></div><div style="line-height:120%;text-align:left;padding-left:6px;text-indent:288px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;color:#2d2f36;">Yes __ No __</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:6px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;color:#2d2f36;">If yes, please provide a brief description of the odor (rotten eggs, chemical, etc.), and note possible sources of the odor:</font></div><div style="line-height:120%;text-align:left;padding-left:6px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;color:#2d2f36;">____________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________</font></div><div><br></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;padding-top:2px;text-align:left;padding-left:6px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;color:#282828;">3.2 </font><font style="font-family:inherit;font-size:12pt;">    </font><font style="font-family:inherit;font-size:12pt;color:#282828;">Were any chemicals, including janitorial supplies left in the building/suite(s)?</font></div><div style="line-height:120%;text-align:left;padding-left:6px;text-indent:240px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;color:#2d2f36;">Yes __ No __</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:8px;text-indent:-2px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;color:#282828;">If yes, please provide a list of the items, note their location and note whether any leakage or staining is apparent (please attach additional sheets as necessary):</font></div><div style="line-height:120%;text-align:left;padding-left:6px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;color:#2d2f36;">____________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________</font></div><div style="line-height:120%;padding-top:1px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:8px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:6px;"><font style="font-family:inherit;font-size:12pt;color:#282828;">3.3 </font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;color:#282828;">Are there any known or suspect environmental conditions associated with the tenant's former activities at the building/suite?</font></div></td></tr></table><div style="line-height:120%;text-align:left;padding-left:8px;text-indent:-2px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:8px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;color:#282828;">If yes, please identify the location and nature of the environmental conditions:</font></div><div style="line-height:120%;text-align:left;padding-left:6px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;color:#2d2f36;">____________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:8px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;color:#282828;font-weight:bold;">4. </font><font style="font-family:inherit;font-size:12pt;">    </font><font style="font-family:inherit;font-size:12pt;color:#282828;font-weight:bold;">OUTDOOR INSPECTION</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:8px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;color:#282828;">The Property Manager is expected to inspect the exterior and perimeter of the vacant building/suite of the former tenant.</font></div><div style="line-height:120%;padding-top:1px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:8px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;color:#282828;font-weight:bold;">4.1 </font><font style="font-family:inherit;font-size:12pt;">    </font><font style="font-family:inherit;font-size:12pt;color:#282828;">Please check each of the applicable items, if observed outside the former tenant's building/suite:</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:45px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;color:#282828;">__: Other Containers                Drums __: Leakage from Transformers</font></div><div style="line-height:120%;text-align:left;padding-left:45px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;color:#282828;">__: g of Trash/Debris Wastes             __: Leakage from Trash Compactor Oil    </font></div><div style="line-height:120%;text-align:left;padding-left:45px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;color:#282828;">__: Soils/Pavement                Dumpin Reservoir</font></div><div style="line-height:120%;text-align:left;padding-left:45px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;color:#282828;">__: or Stained Vegetation            Stained __: Other (Specify):__________________</font></div><div style="line-height:120%;text-align:left;padding-left:45px;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;color:#282828;">        </font></div><div style="line-height:120%;text-align:left;padding-left:45px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;padding-top:2px;text-align:left;padding-left:9px;text-indent:-2px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;color:#282828;">For each item checked above, please describe the location, provide a brief description and estimate the approximate quantity or amount (Attach additional sheets as necessary.):</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:justify;padding-left:9px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;color:#282828;font-weight:bold;">4.2 </font><font style="font-family:inherit;font-size:12pt;color:#282828;">Are underground storage tanks (USTs), aboveground storage tanks (ASTs), or associated pipelines used for the storage of either petroleum products, chemicals, or liquid wastes present at the vacating tenant's building/suite?</font></div><div style="line-height:120%;padding-top:0px;text-align:justify;padding-left:9px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;color:#282828;">Yes ___ No ____</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div><br></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:2px;text-align:left;padding-left:8px;text-indent:-2px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;color:#2f3138;">If yes, please describe capacity, contents, age, type of the USTs or ASTs, as well any associated leak detection/spill prevention measures. Please attach additional pages if necessary.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:589px;border-collapse:collapse;text-align:left;"><tr><td colspan="5"></td></tr><tr><td style="width:104px;"></td><td style="width:104px;"></td><td style="width:117px;"></td><td style="width:118px;"></td><td style="width:145px;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #2f2f38;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #2f2f38;border-right:1px solid #2f2f38;border-top:1px solid #2f2f38;"><div style="text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;color:#2f3138;">Capacity</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #2f2f38;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #2f2f38;border-right:1px solid #2f2f38;border-top:1px solid #2f2f38;"><div style="text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;color:#2f3138;">Contents</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #2f2f38;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #2f2f38;border-top:1px solid #2f2f38;"><div style="text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;color:#2f3138;">Year Installed</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;color:#2f3138;">Type ( Steel, Fiberglass, etc.)</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #342f38;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #34343b;border-top:1px solid #2f2f38;"><div style="padding-top:0px;padding-left:6px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;color:#2f3138;">Associated Leak</font></div><div style="padding-top:1px;padding-left:6px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;color:#2f3138;">Detection</font></div><div style="padding-top:1px;padding-left:6px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;color:#676b77;">/</font><font style="font-family:inherit;font-size:12pt;color:#2f3138;">Spill Prevention</font></div><div style="padding-top:1px;padding-left:6px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;color:#2f3138;">Measures*</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #2f2f38;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #2f2f38;border-right:1px solid #2f2f38;border-top:1px solid #2f2f38;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #2f2f38;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #2f2f38;border-right:1px solid #2f2f38;border-top:1px solid #2f2f38;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #2f2f38;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #2f2f38;border-right:1px solid #34343b;border-top:1px solid #2f2f38;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #2f2f38;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #34343b;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #2f2f38;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #2f2f38;border-right:1px solid #34343b;border-top:1px solid #342f38;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #2f2f38;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #2f2f38;border-right:1px solid #2f2f38;border-top:1px solid #2f2f38;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #2f2f38;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #2f2f38;border-right:1px solid #2f2f38;border-top:1px solid #2f2f38;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #2f2f38;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #2f2f38;border-right:1px solid #34343b;border-top:1px solid #2f2f38;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #2f2f38;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #34343b;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #2f2f38;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #2f2f38;border-right:1px solid #34343b;border-top:1px solid #342f38;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #2f2f38;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #2f2f38;border-right:1px solid #2f2f38;border-top:1px solid #2f2f38;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #2f2f38;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #2f2f38;border-right:1px solid #2f2f38;border-top:1px solid #2f2f38;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #2f2f38;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #2f2f38;border-right:1px solid #34343b;border-top:1px solid #2f2f38;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #2f2f38;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #34343b;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #2f2f38;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #2f2f38;border-right:1px solid #34343b;border-top:1px solid #342f38;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td></tr></table></div></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;padding-top:2px;text-align:left;padding-left:6px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;color:#2f3138;">*Note:                 The following are examples of leak detection/spill prevention</font></div><div style="line-height:120%;padding-top:2px;text-align:left;padding-left:6px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;color:#2f3138;">measures:                     Inventory reconciliation</font><font style="font-family:inherit;font-size:12pt;">    </font><font style="font-family:inherit;font-size:12pt;color:#2f3138;">Leak detection</font></div><div style="line-height:120%;padding-top:2px;text-align:left;padding-left:6px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;color:#2f3138;">Integrity testing                 Secondary containment</font><font style="font-family:inherit;font-size:12pt;">    </font><font style="font-family:inherit;font-size:12pt;color:#2f3138;">Cathodic protection</font></div><div style="line-height:120%;padding-top:2px;text-align:left;padding-left:6px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;color:#2f3138;">system </font></div><div style="line-height:120%;text-align:left;padding-left:6px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;color:#2f3138;">Overfill spill protection</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;padding-top:2px;text-align:left;padding-left:6px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;color:#2f3138;">(a) </font><font style="font-family:inherit;font-size:12pt;">                    </font><font style="font-family:inherit;font-size:12pt;color:#2f3138;">Please provide copies of the most recent written tank integrity test results and/or monitoring documentation, if available.</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;padding-top:2px;text-align:left;padding-left:6px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;color:#2f3138;">(b)                     Are there any documented releases associated with the</font></div><div style="line-height:120%;padding-top:2px;text-align:left;padding-left:6px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;color:#2f3138;">USTs</font><font style="font-family:inherit;font-size:12pt;color:#676b77;">/</font><font style="font-family:inherit;font-size:12pt;color:#2f3138;">ASTs?</font></div><div style="line-height:120%;text-align:left;text-indent:240px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;color:#2f3138;">Yes ___No ___</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;padding-top:2px;text-align:left;padding-left:6px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;color:#2f3138;">If so</font><font style="font-family:inherit;font-size:12pt;color:#4f565e;">, </font><font style="font-family:inherit;font-size:12pt;color:#2f3138;">please state the substance released</font><font style="font-family:inherit;font-size:12pt;color:#4f565e;">, </font><font style="font-family:inherit;font-size:12pt;color:#2f3138;">the media(s) impacted (e.g., soil, water, asphalt, etc.), the actions taken, and all remedial responses to the incident (Please attach additional sheets as</font></div><div style="line-height:120%;text-align:justify;padding-left:6px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;color:#2f3138;">necessary.):_______________________________________________________________________</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:justify;padding-left:6px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;color:#2f3138;font-weight:bold;">4.3 </font><font style="font-family:inherit;font-size:12pt;color:#2f3138;">Have USTs</font><font style="font-family:inherit;font-size:12pt;color:#676b77;">/</font><font style="font-family:inherit;font-size:12pt;color:#2f3138;">ASTs been removed from the vacated tenant's building/suite?</font></div><div style="line-height:120%;padding-top:1px;text-align:left;padding-left:52px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;color:#2f3138;">Yes ___ </font><font style="font-family:inherit;font-size:12pt;">    </font><font style="font-family:inherit;font-size:12pt;color:#2f3138;">No ___</font></div><div style="line-height:120%;padding-top:1px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:8px;text-indent:-2px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;color:#2f3138;">If yes, please provide any official closure letters or reports and supporting documentation (e.g., analytical test results, remediation report results, etc.) unless previously provided.</font></div><div style="line-height:120%;padding-top:1px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:justify;padding-left:6px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;color:#2f3138;font-weight:bold;">5. ASBESTOS CONTAINING BUILDING MATERIALS</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:justify;padding-left:6px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;color:#2f3138;">If an asbestos survey is available for the property, please review the information that identifies the locations of known asbestos containing material or presumed asbestos containing material. Please note that any tenant activity that may have involved the disturbance or removal of these materials must be done by an appropriately trained individual/contractor.</font></div><div style="line-height:120%;padding-top:1px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:justify;padding-left:6px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;color:#2f3138;">If the available asbestos survey results indicate that asbestos containing materials (ACMs), and/or</font></div><div><br></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;padding-top:2px;text-align:left;padding-left:6px;text-indent:-2px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;color:#262626;">presumed asbestos containing materials (PACMs) have been identified in the building/suite, please inspect those materials and note those that are damaged in the space below:</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div><br></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;padding-top:2px;text-align:left;padding-left:6px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;color:#2f3138;font-weight:bold;">6.</font><font style="font-family:inherit;font-size:12pt;">    </font><font style="font-family:inherit;font-size:12pt;color:#2f3138;font-weight:bold;">REGULATORY</font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:6px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:5px;"><font style="font-family:inherit;font-size:12pt;color:#2f3138;font-weight:bold;">6.1 </font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;color:#2f3138;">Are there any past, current, or pending regulatory actions by federal, state, or local environmental agencies alleging that the vacated tenant is in noncompliance with regulations?</font></div></td></tr></table><div style="line-height:120%;text-align:left;padding-left:50px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;color:#2f3138;">Yes _____</font><font style="font-family:inherit;font-size:12pt;">    </font><font style="font-family:inherit;font-size:12pt;color:#2f3138;">No______</font></div><div style="line-height:120%;padding-top:1px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:6px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;color:#2f3138;">If so, please describe.</font></div><div style="line-height:120%;text-align:left;padding-left:6px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;color:#2f3138;">________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:309px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:13px;"><font style="font-family:inherit;font-size:10pt;color:#2f3138;font-weight:bold;">PREPARED BY: </font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#2f3138;font-weight:bold;">PLEASE FORWARD THE COMPLETED QUESTIONNAIRE TO:</font></div></td></tr></table><div style="line-height:120%;text-align:left;padding-left:14px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#2f3138;">Signature</font><font style="font-family:inherit;font-size:10pt;color:#4f5054;">: _________________________</font><font style="font-family:inherit;font-size:10pt;color:#2f3138;">__</font></div><div style="line-height:120%;padding-top:3px;text-align:left;padding-left:13px;text-indent:-2px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#2f3138;"> Name: ______________ </font></div><div style="line-height:120%;padding-top:3px;text-align:left;padding-left:13px;text-indent:-2px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#2f3138;"> Date: _______________</font></div><div style="line-height:120%;padding-top:1px;text-align:left;padding-left:13px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#2f3138;">Title</font><font style="font-family:inherit;font-size:10pt;color:#4f5054;">: _________________________________</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:2px;text-align:justify;padding-left:13px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#2f3138;">Company: ______________________________</font></div><div style="line-height:120%;padding-top:2px;text-align:justify;padding-left:13px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#2f3138;">Telephon</font><font style="font-family:inherit;font-size:10pt;color:#4f5054;">e: ______________________________</font></div><div style="line-height:120%;padding-top:2px;text-align:justify;padding-left:13px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#2f3138;">Fax: ___________________________________</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div> </div></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-21.1
<SEQUENCE>4
<FILENAME>immu201910k1231ex2111.htm
<DESCRIPTION>EXHIBIT 21.1 SUBSIDIARIES OF THE COMPANY
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
<head>
<!-- Document created using Wdesk 1 -->
<!-- Copyright 2020 Workiva -->
<title>Exhibit</title>
</head>
<body><div style="font-family:Times New Roman;font-size:10pt;">
<div><a name="sCAD8900CA0CC5BD5A0B94D033DF7CFA9"></a></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:right;text-indent:48px;-sec-extract:summary;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">EXHIBIT 21.1</font></div><div style="line-height:120%;text-indent:96px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;">SUBSIDIARIES OF THE COMPANY AS OF DECEMBER 31, 2019 </font></div><div style="line-height:120%;text-align:center;text-indent:96px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div><div style="line-height:120%;text-align:center;text-indent:96px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:5%;"></td><td style="width:38%;"></td><td style="width:57%;"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">●</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Immunomedics GmbH (Germany)</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Wholly owned subsidiary of Immunomedics, Inc.</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">●</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">IBC Pharmaceuticals, Inc. (Delaware)</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Majority owned subsidiary of Immunomedics, Inc.</font></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div> </div></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.1
<SEQUENCE>5
<FILENAME>immu201910k1231ex2311.htm
<DESCRIPTION>EXHIBIT 23.1 CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING - KPMG LLP
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
<head>
<!-- Document created using Wdesk 1 -->
<!-- Copyright 2020 Workiva -->
<title>Exhibit</title>
</head>
<body><div style="font-family:Times New Roman;font-size:10pt;">
<div><a name="s5FD49FAA4FAC57DEAAF120829AB3190A"></a></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:right;-sec-extract:summary;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">Exhibit 23.1</font></div><div style="line-height:120%;padding-top:12px;text-indent:384px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;padding-top:12px;text-indent:96px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"> </font></div><div style="line-height:120%;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;text-decoration:underline;">Consent of Independent Registered Public Accounting Firm</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">The Board of Directors </font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Immunomedics, Inc. </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">We consent to the incorporation by reference in the Registration Statements Nos. 333-219594, 333-198766, 333-184377, 333-128310, 333-114810, 333-90338 and 333-225550 on Form S-3 and the Registration Statements Nos. 333-201470, 333-143420 and 333-53224 on Form S-8 of Immunomedics, Inc. of our reports dated </font><font style="font-family:inherit;font-size:11pt;">February 27, 2020</font><font style="font-family:inherit;font-size:11pt;">, with respect to the consolidated balance sheets of Immunomedics, Inc. and subsidiaries as of December 31, 2019, December 31, 2018, June 30, 2018 and 2017, the related consolidated statements of comprehensive loss, changes in stockholders’ equity and cash flows for the year ended December 31, 2019, six month transition period ended December 31, 2018 and each of the years in the two-year period ended June 30, 2018, and the effectiveness of internal control over financial reporting as of December 31, 2019, which reports appear in the December 31, 2019 annual report on Form 10-K of Immunomedics, Inc. </font></div><div style="line-height:120%;padding-bottom:10px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:10px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">/s/ KPMG LLP</font></div><div style="line-height:120%;padding-bottom:10px;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">New York, New York</font></div><div style="line-height:120%;padding-bottom:10px;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">February 27, 2020</font><font style="font-family:inherit;font-size:11pt;"> </font></div><div style="line-height:120%;padding-bottom:10px;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;padding-bottom:40px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div> </div></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>6
<FILENAME>immu201910k1231ex3111.htm
<DESCRIPTION>EXHIBIT 31.1 CERT OF THE PRINCIPAL EXECUTIVE OFFICER PURSUANT TO SECTION 302(A)
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
<head>
<!-- Document created using Wdesk 1 -->
<!-- Copyright 2020 Workiva -->
<title>Exhibit</title>
</head>
<body><div style="font-family:Times New Roman;font-size:10pt;">
<div><a name="s9D8E10B00B1F5354B8BD7B03BDC7EEC0"></a></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:10px;text-align:right;-sec-extract:summary;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">Exhibit 31.1</font></div><div style="line-height:120%;padding-bottom:10px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">CERTIFICATION</font></div><div style="line-height:120%;padding-bottom:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#231f20;">I, Usama Malik,  Principal Executive Officer of Immunomedics, Inc., certify that:</font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:10px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;color:#231f20;">1.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">I have reviewed the Annual Report on Form 10-K of Immunomedics, Inc.;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:10px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;">2.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:10px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;">3.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:10px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;">4.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)), for the registrant and have:</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">(a)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">(b)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">(c)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">(d)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;">5.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">(a)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">(b)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.</font></div></td></tr></table><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td style="width:24%;"></td><td style="width:76%;"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Date: February 27, 2020</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">/s/Usama Malik</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Usama Malik</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Principal Executive Officer</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div> </div></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>7
<FILENAME>immu201910k1231ex3121.htm
<DESCRIPTION>EXHIBIT 31.2 CERT OF THE PRINCIPAL FINANCIAL OFFICER PURSUANT TO SECTION 302(A)
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
<head>
<!-- Document created using Wdesk 1 -->
<!-- Copyright 2020 Workiva -->
<title>Exhibit</title>
</head>
<body><div style="font-family:Times New Roman;font-size:10pt;">
<div><a name="s607E11E5FDB5516383D94CFC8EB9D69B"></a></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:10px;text-align:right;text-indent:84px;-sec-extract:summary;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Exhibit 31.2</font></div><div style="line-height:120%;padding-bottom:10px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">CERTIFICATION</font></div><div style="line-height:120%;padding-bottom:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#231f20;">I, Usama Malik, Chief Financial Officer of Immunomedics, Inc., certify that:</font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;">1.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">I have reviewed the Annual Report on Form 10-K of Immunomedics, Inc.;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;">2.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;">3.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;">4.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)), for the registrant and have:</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">(a)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">(b)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">(c)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">(d)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;">5.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">(a)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">(b)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.</font></div></td></tr></table><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td style="width:24%;"></td><td style="width:76%;"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Date: February 27, 2020</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">/s/Usama Malik</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Usama Malik</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Chief Financial Officer</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div> </div></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>8
<FILENAME>immu201910k1231ex3211.htm
<DESCRIPTION>EXHIBIT 32.1 CERT OF THE PRINCIPAL EXECUTIVE OFFICER PURSUANT TO SECTION 906
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
<head>
<!-- Document created using Wdesk 1 -->
<!-- Copyright 2020 Workiva -->
<title>Exhibit</title>
</head>
<body><div style="font-family:Times New Roman;font-size:10pt;">
<div><a name="s83F3CDE8DFEB582D83C97403DCD13778"></a></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:8px;padding-top:6px;text-align:right;-sec-extract:summary;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Exhibit 32.1</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Certification</font></div><div style="line-height:120%;text-align:center;text-indent:96px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002</font></div><div style="line-height:120%;text-align:center;text-indent:96px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(Subsections (a) and (b) of Section 1350, Chapter 63 of Title 18, United States Code)</font></div><div style="line-height:120%;text-align:center;text-indent:96px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:8px;padding-top:6px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Pursuant to section 906 of the Sarbanes-Oxley Act of 2002 (subsections (a) and (b) of section 1350, chapter 63 of title 18, United States Code), the undersigned officer of Immunomedics. Inc., a Delaware corporation (the “Company”), does hereby certify, to such officer’s knowledge, that:</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:6px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:8px;padding-top:6px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Annual Report on Form 10-K for the fiscal year ended </font><font style="font-family:inherit;font-size:10pt;">December 31,</font><font style="font-family:inherit;font-size:10pt;"> 2019 (the “Form 10-K”) of the Company fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, and the information contained in the Form 10-K fairly presents, in all material respects, the financial condition and results of operations of the Company.</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:6px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:13px;padding-top:6px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Dated: </font><font style="font-family:inherit;font-size:10pt;">February 27, 2020</font><font style="font-family:inherit;font-size:10pt;"> </font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:226px;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td style="width:46px;"></td><td style="width:178px;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">/s/Usama Malik</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Usama Malik</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Principal Executive Officer</font></div></td></tr></table></div></div><div style="line-height:120%;text-align:center;text-indent:96px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">A signed original of this written statement required by Section 906 has been provided to the Company and will be retained by the Company and furnished to the Securities and Exchange Commission or its staff upon request.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div> </div></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.2
<SEQUENCE>9
<FILENAME>immu201910k1231ex3221.htm
<DESCRIPTION>EXHIBIT 32.2 CERT OF THE FINANCIAL EXECUTIVE OFFICER PURSUANT TO SECTION 906
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
<head>
<!-- Document created using Wdesk 1 -->
<!-- Copyright 2020 Workiva -->
<title>Exhibit</title>
</head>
<body><div style="font-family:Times New Roman;font-size:10pt;">
<div><a name="sB1F45A0BDE8C5358BA4CB0A4B2D6C042"></a></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:8px;padding-top:6px;text-align:right;-sec-extract:summary;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Exhibit 32.2</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:6px;text-align:center;text-indent:144px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Certification</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(Subsections (a) and (b) of Section 1350, Chapter 63 of Title 18, United States Code)</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:8px;padding-top:6px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Pursuant to section 906 of the Sarbanes-Oxley Act of 2002 (subsections (a) and (b) of section 1350, chapter 63 of title 18, United States Code), the undersigned officer of Immunomedics. Inc., a Delaware corporation (the “Company”), does hereby certify, to such officer’s knowledge, that:</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:6px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:8px;padding-top:6px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Annual Report on Form 10-K for the fiscal year ended </font><font style="font-family:inherit;font-size:10pt;">December 31,</font><font style="font-family:inherit;font-size:10pt;"> 2019 (the “Form 10-K”) of the Company fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, and the information contained in the Form 10-K fairly presents, in all material respects, the financial condition and results of operations of the Company.</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:6px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:13px;padding-top:6px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Dated: </font><font style="font-family:inherit;font-size:10pt;">February 27, 2020</font><font style="font-family:inherit;font-size:10pt;"> </font></div><div style="line-height:120%;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:228px;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td style="width:49px;"></td><td style="width:178px;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">/s/Usama Malik</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Usama Malik</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Chief Financial Officer</font></div></td></tr></table></div></div><div style="line-height:120%;text-align:center;text-indent:96px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div><div style="line-height:120%;padding-bottom:8px;padding-top:4px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">A signed original of this written statement required by Section 906 has been provided to the Company and will be retained by the Company and furnished to the Securities and Exchange Commission or its staff upon request.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div> </div></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>10
<FILENAME>immu-20191231.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!--XBRL Document Created with Wdesk from Workiva-->
<!-- -->
<xsd:schema attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.immunomedics.com/20191231" xmlns:immu="http://www.immunomedics.com/20191231" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:us-types="http://fasb.org/us-types/2019-01-31" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsd="http://www.w3.org/2001/XMLSchema">
<xsd:import namespace="http://fasb.org/srt-types/2019-01-31" schemaLocation="http://xbrl.fasb.org/srt/2019/elts/srt-types-2019-01-31.xsd" />
<xsd:import namespace="http://fasb.org/srt/2019-01-31" schemaLocation="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd" />
<xsd:import namespace="http://fasb.org/us-gaap/2019-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd" />
<xsd:import namespace="http://fasb.org/us-roles/2019-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2019/elts/us-roles-2019-01-31.xsd" />
<xsd:import namespace="http://fasb.org/us-types/2019-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2019/elts/us-types-2019-01-31.xsd" />
<xsd:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
<xsd:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" />
<xsd:import namespace="http://www.xbrl.org/2009/arcrole/fact-explanatoryFact" schemaLocation="http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd" />
<xsd:import namespace="http://www.xbrl.org/2009/role/negated" schemaLocation="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd" />
<xsd:import namespace="http://www.xbrl.org/2009/role/net" schemaLocation="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd" />
<xsd:import namespace="http://www.xbrl.org/dtr/type/non-numeric" schemaLocation="http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd" />
<xsd:import namespace="http://www.xbrl.org/dtr/type/numeric" schemaLocation="http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd" />
<xsd:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" />
<xsd:import namespace="http://xbrl.sec.gov/country/2017-01-31" schemaLocation="https://xbrl.sec.gov/country/2017/country-2017-01-31.xsd" />
<xsd:import namespace="http://xbrl.sec.gov/currency/2019-01-31" schemaLocation="https://xbrl.sec.gov/currency/2019/currency-2019-01-31.xsd" />
<xsd:import namespace="http://xbrl.sec.gov/dei/2019-01-31" schemaLocation="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd" />
<xsd:import namespace="http://xbrl.sec.gov/exch/2019-01-31" schemaLocation="https://xbrl.sec.gov/exch/2019/exch-2019-01-31.xsd" />
<xsd:import namespace="http://xbrl.sec.gov/invest/2013-01-31" schemaLocation="http://xbrl.sec.gov/invest/2013/invest-2013-01-31.xsd" />
<xsd:import namespace="http://xbrl.sec.gov/naics/2017-01-31" schemaLocation="http://xbrl.sec.gov/naics/2017/naics-2017-01-31.xsd" />
<xsd:import namespace="http://xbrl.sec.gov/sic/2011-01-31" schemaLocation="http://xbrl.sec.gov/sic/2011/sic-2011-01-31.xsd" />
<xsd:import namespace="http://xbrl.sec.gov/stpr/2018-01-31" schemaLocation="https://xbrl.sec.gov/stpr/2018/stpr-2018-01-31.xsd" />
<xsd:annotation>
<xsd:appinfo>
<link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="immu-20191231_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:type="simple" />
<link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="immu-20191231_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple" />
<link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="immu-20191231_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple" />
<link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="immu-20191231_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple" />
<link:roleType id="AccountsPayableAndAccruedExpenses" roleURI="http://www.immunomedics.com/role/AccountsPayableAndAccruedExpenses">
<link:definition>2109100 - Disclosure - Accounts Payable and Accrued Expenses</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
</link:roleType>
<link:roleType id="AccountsPayableAndAccruedExpensesDetails" roleURI="http://www.immunomedics.com/role/AccountsPayableAndAccruedExpensesDetails">
<link:definition>2409402 - Disclosure - Accounts Payable and Accrued Expenses (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
</link:roleType>
<link:roleType id="AccountsPayableAndAccruedExpensesTables" roleURI="http://www.immunomedics.com/role/AccountsPayableAndAccruedExpensesTables">
<link:definition>2309301 - Disclosure - Accounts Payable and Accrued Expenses (Tables)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
</link:roleType>
<link:roleType id="AccumulatedOtherComprehensiveLossIncome" roleURI="http://www.immunomedics.com/role/AccumulatedOtherComprehensiveLossIncome">
<link:definition>2111100 - Disclosure - Accumulated Other Comprehensive (Loss) Income</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
</link:roleType>
<link:roleType id="AccumulatedOtherComprehensiveLossIncomeDetails" roleURI="http://www.immunomedics.com/role/AccumulatedOtherComprehensiveLossIncomeDetails">
<link:definition>2411402 - Disclosure - Accumulated Other Comprehensive (Loss) Income (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
</link:roleType>
<link:roleType id="AccumulatedOtherComprehensiveLossIncomeTables" roleURI="http://www.immunomedics.com/role/AccumulatedOtherComprehensiveLossIncomeTables">
<link:definition>2311301 - Disclosure - Accumulated Other Comprehensive (Loss) Income (Tables)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
</link:roleType>
<link:roleType id="BusinessOverviewAndSummaryOfSignificantAccountingPolices" roleURI="http://www.immunomedics.com/role/BusinessOverviewAndSummaryOfSignificantAccountingPolices">
<link:definition>2101100 - Disclosure - Business Overview and Summary of Significant Accounting Polices</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
</link:roleType>
<link:roleType id="BusinessOverviewAndSummaryOfSignificantAccountingPolicesRecentAccountingPronouncementsDetails" roleURI="http://www.immunomedics.com/role/BusinessOverviewAndSummaryOfSignificantAccountingPolicesRecentAccountingPronouncementsDetails">
<link:definition>2401402 - Disclosure - Business Overview and Summary of Significant Accounting Polices - Recent Accounting Pronouncements (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
</link:roleType>
<link:roleType id="BusinessOverviewSummaryOfSignificantAccountingPolicesPolicies" roleURI="http://www.immunomedics.com/role/BusinessOverviewSummaryOfSignificantAccountingPolicesPolicies">
<link:definition>2201201 - Disclosure - Business Overview, Summary of Significant Accounting Polices (Policies)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
</link:roleType>
<link:roleType id="CollaborationAgreements" roleURI="http://www.immunomedics.com/role/CollaborationAgreements">
<link:definition>2114100 - Disclosure - Collaboration Agreements</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
</link:roleType>
<link:roleType id="CollaborationAgreementsDetails" roleURI="http://www.immunomedics.com/role/CollaborationAgreementsDetails">
<link:definition>2414401 - Disclosure - Collaboration Agreements (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
</link:roleType>
<link:roleType id="CommitmentsAndContingencies" roleURI="http://www.immunomedics.com/role/CommitmentsAndContingencies">
<link:definition>2115100 - Disclosure - Commitments and Contingencies</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
</link:roleType>
<link:roleType id="CommitmentsAndContingenciesMaturitiesOfLeaseLiabilitiesDetails" roleURI="http://www.immunomedics.com/role/CommitmentsAndContingenciesMaturitiesOfLeaseLiabilitiesDetails">
<link:definition>2415404 - Disclosure - Commitments and Contingencies - Maturities of Lease Liabilities (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
</link:roleType>
<link:roleType id="CommitmentsAndContingenciesMaturitiesOfLeaseLiabilitiesDetailsCalc2" roleURI="http://www.immunomedics.com/role/CommitmentsAndContingenciesMaturitiesOfLeaseLiabilitiesDetailsCalc2">
<link:definition>2415404 - Disclosure - Commitments and Contingencies - Maturities of Lease Liabilities (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
</link:roleType>
<link:roleType id="CommitmentsAndContingenciesNarrativeDetails" roleURI="http://www.immunomedics.com/role/CommitmentsAndContingenciesNarrativeDetails">
<link:definition>2415402 - Disclosure - Commitments and Contingencies - Narrative (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
</link:roleType>
<link:roleType id="CommitmentsAndContingenciesSupplementalConsolidatedBalanceSheetInformationRelatedToLeasesDetails" roleURI="http://www.immunomedics.com/role/CommitmentsAndContingenciesSupplementalConsolidatedBalanceSheetInformationRelatedToLeasesDetails">
<link:definition>2415403 - Disclosure - Commitments and Contingencies - Supplemental Consolidated Balance Sheet Information Related to Leases (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
</link:roleType>
<link:roleType id="CommitmentsAndContingenciesTables" roleURI="http://www.immunomedics.com/role/CommitmentsAndContingenciesTables">
<link:definition>2315301 - Disclosure - Commitments and Contingencies (Tables)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
</link:roleType>
<link:roleType id="ConsolidatedBalanceSheets" roleURI="http://www.immunomedics.com/role/ConsolidatedBalanceSheets">
<link:definition>1001000 - Statement - CONSOLIDATED BALANCE SHEETS</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
</link:roleType>
<link:roleType id="ConsolidatedBalanceSheetsParenthetical" roleURI="http://www.immunomedics.com/role/ConsolidatedBalanceSheetsParenthetical">
<link:definition>1001501 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
</link:roleType>
<link:roleType id="ConsolidatedStatementsOfCashFlows" roleURI="http://www.immunomedics.com/role/ConsolidatedStatementsOfCashFlows">
<link:definition>1004000 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
</link:roleType>
<link:roleType id="ConsolidatedStatementsOfChangesInStockholdersEquity" roleURI="http://www.immunomedics.com/role/ConsolidatedStatementsOfChangesInStockholdersEquity">
<link:definition>1003000 - Statement - CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS’ EQUITY</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
</link:roleType>
<link:roleType id="ConsolidatedStatementsOfComprehensiveLoss" roleURI="http://www.immunomedics.com/role/ConsolidatedStatementsOfComprehensiveLoss">
<link:definition>1002000 - Statement - CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
</link:roleType>
<link:roleType id="CoverPage" roleURI="http://www.immunomedics.com/role/CoverPage">
<link:definition>0001000 - Document - COVER PAGE</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
</link:roleType>
<link:roleType id="Debt" roleURI="http://www.immunomedics.com/role/Debt">
<link:definition>2105100 - Disclosure - Debt</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
</link:roleType>
<link:roleType id="DebtConsiderationAllocationDetails" roleURI="http://www.immunomedics.com/role/DebtConsiderationAllocationDetails">
<link:definition>2405403 - Disclosure - Debt - Consideration Allocation (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
</link:roleType>
<link:roleType id="DebtConvertibleSeniorNotesDetails" roleURI="http://www.immunomedics.com/role/DebtConvertibleSeniorNotesDetails">
<link:definition>2405405 - Disclosure - Debt - Convertible Senior Notes (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
</link:roleType>
<link:roleType id="DebtLiabilityRelatedToSaleOfFutureRoyaltiesDetails" roleURI="http://www.immunomedics.com/role/DebtLiabilityRelatedToSaleOfFutureRoyaltiesDetails">
<link:definition>2405402 - Disclosure - Debt - Liability Related to Sale of Future Royalties (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
</link:roleType>
<link:roleType id="DebtScheduleOfLiabilityRelatedToSaleOfFutureRoyaltiesDetails" roleURI="http://www.immunomedics.com/role/DebtScheduleOfLiabilityRelatedToSaleOfFutureRoyaltiesDetails">
<link:definition>2405404 - Disclosure - Debt - Schedule of Liability Related to Sale of Future Royalties (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
</link:roleType>
<link:roleType id="DebtTables" roleURI="http://www.immunomedics.com/role/DebtTables">
<link:definition>2305301 - Disclosure - Debt (Tables)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
</link:roleType>
<link:roleType id="DefinedContributionPlans" roleURI="http://www.immunomedics.com/role/DefinedContributionPlans">
<link:definition>2116100 - Disclosure - Defined Contribution Plans</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
</link:roleType>
<link:roleType id="DefinedContributionPlansDetails" roleURI="http://www.immunomedics.com/role/DefinedContributionPlansDetails">
<link:definition>2416401 - Disclosure - Defined Contribution Plans (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
</link:roleType>
<link:roleType id="EstimatedFairValueOfFinancialInstruments" roleURI="http://www.immunomedics.com/role/EstimatedFairValueOfFinancialInstruments">
<link:definition>2107100 - Disclosure - Estimated Fair Value of Financial Instruments</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
</link:roleType>
<link:roleType id="EstimatedFairValueOfFinancialInstrumentsDebtInstrumentsDetails" roleURI="http://www.immunomedics.com/role/EstimatedFairValueOfFinancialInstrumentsDebtInstrumentsDetails">
<link:definition>2407403 - Disclosure - Estimated Fair Value of Financial Instruments - Debt Instruments (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
</link:roleType>
<link:roleType id="EstimatedFairValueOfFinancialInstrumentsNarrativeDetails" roleURI="http://www.immunomedics.com/role/EstimatedFairValueOfFinancialInstrumentsNarrativeDetails">
<link:definition>2407402 - Disclosure - Estimated Fair Value of Financial Instruments - Narrative (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
</link:roleType>
<link:roleType id="EstimatedFairValueOfFinancialInstrumentsTables" roleURI="http://www.immunomedics.com/role/EstimatedFairValueOfFinancialInstrumentsTables">
<link:definition>2307301 - Disclosure - Estimated Fair Value of Financial Instruments (Tables)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
</link:roleType>
<link:roleType id="IncomeTaxes" roleURI="http://www.immunomedics.com/role/IncomeTaxes">
<link:definition>2112100 - Disclosure - Income Taxes</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
</link:roleType>
<link:roleType id="IncomeTaxesChangeInUnrecognizedTaxBenefitsDetails" roleURI="http://www.immunomedics.com/role/IncomeTaxesChangeInUnrecognizedTaxBenefitsDetails">
<link:definition>2412406 - Disclosure - Income Taxes - Change in Unrecognized Tax Benefits (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
</link:roleType>
<link:roleType id="IncomeTaxesExpenseBenefitFromIncomeTaxesDetails" roleURI="http://www.immunomedics.com/role/IncomeTaxesExpenseBenefitFromIncomeTaxesDetails">
<link:definition>2412402 - Disclosure - Income Taxes - Expense (Benefit) from Income Taxes (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
</link:roleType>
<link:roleType id="IncomeTaxesNarrativeDetails" roleURI="http://www.immunomedics.com/role/IncomeTaxesNarrativeDetails">
<link:definition>2412405 - Disclosure - Income Taxes - Narrative (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
</link:roleType>
<link:roleType id="IncomeTaxesReconciliationOfStatutoryTaxRatesAndEffectiveTaxRatesDetails" roleURI="http://www.immunomedics.com/role/IncomeTaxesReconciliationOfStatutoryTaxRatesAndEffectiveTaxRatesDetails">
<link:definition>2412403 - Disclosure - Income Taxes - Reconciliation of Statutory Tax Rates and Effective Tax Rates (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
</link:roleType>
<link:roleType id="IncomeTaxesTables" roleURI="http://www.immunomedics.com/role/IncomeTaxesTables">
<link:definition>2312301 - Disclosure - Income Taxes (Tables)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
</link:roleType>
<link:roleType id="IncomeTaxesTaxEffectsOfTemporaryDifferencesInDeferredTaxAssetsDetails" roleURI="http://www.immunomedics.com/role/IncomeTaxesTaxEffectsOfTemporaryDifferencesInDeferredTaxAssetsDetails">
<link:definition>2412404 - Disclosure - Income Taxes - Tax Effects of Temporary Differences in Deferred Tax Assets (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
</link:roleType>
<link:roleType id="MarketableSecurities" roleURI="http://www.immunomedics.com/role/MarketableSecurities">
<link:definition>2103100 - Disclosure - Marketable Securities</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
</link:roleType>
<link:roleType id="MarketableSecuritiesAmortizedCostToFairValueDetails" roleURI="http://www.immunomedics.com/role/MarketableSecuritiesAmortizedCostToFairValueDetails">
<link:definition>2403402 - Disclosure - Marketable Securities - Amortized Cost to Fair Value (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
</link:roleType>
<link:roleType id="MarketableSecuritiesTables" roleURI="http://www.immunomedics.com/role/MarketableSecuritiesTables">
<link:definition>2303301 - Disclosure - Marketable Securities (Tables)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
</link:roleType>
<link:roleType id="PropertyAndEquipment" roleURI="http://www.immunomedics.com/role/PropertyAndEquipment">
<link:definition>2108100 - Disclosure - Property and Equipment</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
</link:roleType>
<link:roleType id="PropertyAndEquipmentAdditionalInformationDetails" roleURI="http://www.immunomedics.com/role/PropertyAndEquipmentAdditionalInformationDetails">
<link:definition>2408403 - Disclosure - Property and Equipment - Additional Information (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
</link:roleType>
<link:roleType id="PropertyAndEquipmentSchedulesOfPropertyAndEquipmentDetails" roleURI="http://www.immunomedics.com/role/PropertyAndEquipmentSchedulesOfPropertyAndEquipmentDetails">
<link:definition>2408402 - Disclosure - Property and Equipment - Schedules of Property and Equipment (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
</link:roleType>
<link:roleType id="PropertyAndEquipmentTables" roleURI="http://www.immunomedics.com/role/PropertyAndEquipmentTables">
<link:definition>2308301 - Disclosure - Property and Equipment (Tables)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
</link:roleType>
<link:roleType id="QuarterlyResultsOfOperationsDetails" roleURI="http://www.immunomedics.com/role/QuarterlyResultsOfOperationsDetails">
<link:definition>2417402 - Disclosure - Quarterly Results of Operations (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
</link:roleType>
<link:roleType id="QuarterlyResultsOfOperationsTables" roleURI="http://www.immunomedics.com/role/QuarterlyResultsOfOperationsTables">
<link:definition>2317301 - Disclosure - Quarterly Results of Operations (Tables)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
</link:roleType>
<link:roleType id="QuarterlyResultsOfOperationsUnaudited" roleURI="http://www.immunomedics.com/role/QuarterlyResultsOfOperationsUnaudited">
<link:definition>2117100 - Disclosure - Quarterly Results of Operations (Unaudited)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
</link:roleType>
<link:roleType id="RelatedPartyTransactions" roleURI="http://www.immunomedics.com/role/RelatedPartyTransactions">
<link:definition>2113100 - Disclosure - Related Party Transactions</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
</link:roleType>
<link:roleType id="RelatedPartyTransactionsDetails" roleURI="http://www.immunomedics.com/role/RelatedPartyTransactionsDetails">
<link:definition>2413401 - Disclosure - Related Party Transactions (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
</link:roleType>
<link:roleType id="RevenueRecognition" roleURI="http://www.immunomedics.com/role/RevenueRecognition">
<link:definition>2102100 - Disclosure - Revenue Recognition</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
</link:roleType>
<link:roleType id="RevenueRecognitionAdditionalInformationDetails" roleURI="http://www.immunomedics.com/role/RevenueRecognitionAdditionalInformationDetails">
<link:definition>2402401 - Disclosure - Revenue Recognition - Additional Information (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
</link:roleType>
<link:roleType id="RevenueRecognitionPerformanceObligationDetails" roleURI="http://www.immunomedics.com/role/RevenueRecognitionPerformanceObligationDetails">
<link:definition>2402402 - Disclosure - Revenue Recognition - Performance Obligation (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
</link:roleType>
<link:roleType id="StockBasedCompensation" roleURI="http://www.immunomedics.com/role/StockBasedCompensation">
<link:definition>2106100 - Disclosure - Stock-Based Compensation</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
</link:roleType>
<link:roleType id="StockBasedCompensationFairValueAssumptionsDetails" roleURI="http://www.immunomedics.com/role/StockBasedCompensationFairValueAssumptionsDetails">
<link:definition>2406404 - Disclosure - Stock-Based Compensation - Fair Value Assumptions (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
</link:roleType>
<link:roleType id="StockBasedCompensationNarrativeDetails" roleURI="http://www.immunomedics.com/role/StockBasedCompensationNarrativeDetails">
<link:definition>2406403 - Disclosure - Stock-Based Compensation - Narrative (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
</link:roleType>
<link:roleType id="StockBasedCompensationRestrictedStockUnitActivityDetails" roleURI="http://www.immunomedics.com/role/StockBasedCompensationRestrictedStockUnitActivityDetails">
<link:definition>2406406 - Disclosure - Stock-Based Compensation - Restricted Stock Unit Activity (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
</link:roleType>
<link:roleType id="StockBasedCompensationStockIncentivePlanDetails" roleURI="http://www.immunomedics.com/role/StockBasedCompensationStockIncentivePlanDetails">
<link:definition>2406402 - Disclosure - Stock-Based Compensation - Stock Incentive Plan (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
</link:roleType>
<link:roleType id="StockBasedCompensationStockOptionActivityDetails" roleURI="http://www.immunomedics.com/role/StockBasedCompensationStockOptionActivityDetails">
<link:definition>2406405 - Disclosure - Stock-Based Compensation - Stock Option Activity (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
</link:roleType>
<link:roleType id="StockBasedCompensationTables" roleURI="http://www.immunomedics.com/role/StockBasedCompensationTables">
<link:definition>2306301 - Disclosure - Stock-Based Compensation (Tables)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
</link:roleType>
<link:roleType id="StockholdersEquity" roleURI="http://www.immunomedics.com/role/StockholdersEquity">
<link:definition>2110100 - Disclosure - Stockholders’ Equity</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
</link:roleType>
<link:roleType id="StockholdersEquityDetails" roleURI="http://www.immunomedics.com/role/StockholdersEquityDetails">
<link:definition>2410401 - Disclosure - Stockholders’ Equity (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
</link:roleType>
</xsd:appinfo>
</xsd:annotation>
<xsd:element abstract="true" id="immu_ATMAgreementMember" name="ATMAgreementMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
<xsd:element id="immu_AcceleratedAmortizationOfFinancingCosts" name="AcceleratedAmortizationOfFinancingCosts" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
<xsd:element id="immu_AccruedContractManufacturingExpenses" name="AccruedContractManufacturingExpenses" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant" />
<xsd:element id="immu_AdjustmentstoAdditionalPaidinCapitalProceedsFromOfferingWarrants" name="AdjustmentstoAdditionalPaidinCapitalProceedsFromOfferingWarrants" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
<xsd:element id="immu_AggregateOfferingPriceofCommonStock" name="AggregateOfferingPriceofCommonStock" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
<xsd:element id="immu_AgreementPotentialMilestonePayment" name="AgreementPotentialMilestonePayment" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant" />
<xsd:element id="immu_AgreementPotentialMilestonePaymentTerm" name="AgreementPotentialMilestonePaymentTerm" nillable="true" substitutionGroup="xbrli:item" type="xbrli:durationItemType" xbrli:periodType="duration" />
<xsd:element id="immu_AllocatedSharebasedCompensationExpenseAmountReversed" name="AllocatedSharebasedCompensationExpenseAmountReversed" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
<xsd:element id="immu_AllocationofFairValuetoLiabilityTableTextBlock" name="AllocationofFairValuetoLiabilityTableTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration" />
<xsd:element id="immu_AnnualInterestRateInCalculatingLiabilityRelatedToSaleOfFutureRoyalties" name="AnnualInterestRateInCalculatingLiabilityRelatedToSaleOfFutureRoyalties" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="duration" />
<xsd:element id="immu_AvailableForSaleSecuritiesDebtMaturitiesAfterOneYearormoreCarryingValue" name="AvailableForSaleSecuritiesDebtMaturitiesAfterOneYearormoreCarryingValue" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant" />
<xsd:element abstract="true" id="immu_CBGForschungsGmbHMember" name="CBGForschungsGmbHMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
<xsd:element id="immu_ChangeinOperatingLeaseLiability" name="ChangeinOperatingLeaseLiability" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
<xsd:element abstract="true" id="immu_ChiefTechnologyOfficerMember" name="ChiefTechnologyOfficerMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
<xsd:element id="immu_ClassOfWarrantOrRightFairValue" name="ClassOfWarrantOrRightFairValue" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant" />
<xsd:element id="immu_ClinicalTrials" name="ClinicalTrials" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant" />
<xsd:element abstract="true" id="immu_CollaborationAgreementAxis" name="CollaborationAgreementAxis" nillable="true" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType" xbrli:periodType="duration" />
<xsd:element abstract="true" id="immu_CollaborationAgreementDomain" name="CollaborationAgreementDomain" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
<xsd:element id="immu_CommonAndPreferredSharesAuthorized" name="CommonAndPreferredSharesAuthorized" nillable="true" substitutionGroup="xbrli:item" type="xbrli:sharesItemType" xbrli:periodType="instant" />
<xsd:element abstract="true" id="immu_ConsolidatedStatementOfOperationsAbstract" name="ConsolidatedStatementOfOperationsAbstract" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration" />
<xsd:element id="immu_ConvertiblePreferredStockConversionRatio" name="ConvertiblePreferredStockConversionRatio" nillable="true" substitutionGroup="xbrli:item" type="xbrli:pureItemType" xbrli:periodType="instant" />
<xsd:element id="immu_DebtConversionOutstandingBalance" name="DebtConversionOutstandingBalance" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant" />
<xsd:element id="immu_DebtInstrumentConvertibleBeneficialConversionFeatureAggregateNumberOfShares" name="DebtInstrumentConvertibleBeneficialConversionFeatureAggregateNumberOfShares" nillable="true" substitutionGroup="xbrli:item" type="xbrli:sharesItemType" xbrli:periodType="duration" />
<xsd:element id="immu_DeferredTaxAssetDisallowedInterestExpense" name="DeferredTaxAssetDisallowedInterestExpense" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant" />
<xsd:element id="immu_DeferredTaxAssetsDeferredRevenue" name="DeferredTaxAssetsDeferredRevenue" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant" />
<xsd:element id="immu_DeferredTaxAssetsTaxCreditCarryforwardsResearchAndDevelopment" name="DeferredTaxAssetsTaxCreditCarryforwardsResearchAndDevelopment" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
<xsd:element abstract="true" id="immu_EverestMedicinesIILimitedMember" name="EverestMedicinesIILimitedMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
<xsd:element abstract="true" id="immu_ExecutiveDirectorMember" name="ExecutiveDirectorMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
<xsd:element id="immu_ExerciseOfWarrants" name="ExerciseOfWarrants" nillable="true" substitutionGroup="xbrli:item" type="xbrli:sharesItemType" xbrli:periodType="instant" />
<xsd:element id="immu_FairValueForLiabilityRelatedtoSaleofFutureRoyalties" name="FairValueForLiabilityRelatedtoSaleofFutureRoyalties" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant" />
<xsd:element id="immu_FinanceLeaseRightofUseAssetBeforeAccumulatedAmortization" name="FinanceLeaseRightofUseAssetBeforeAccumulatedAmortization" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant" />
<xsd:element abstract="true" id="immu_FourPointSevenFivePercentConvertibleSeniorNotesMember" name="FourPointSevenFivePercentConvertibleSeniorNotesMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
<xsd:element abstract="true" id="immu_GoldenbergAgreementMember" name="GoldenbergAgreementMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
<xsd:element id="immu_GrossProceedsFromIssuanceOfCommonStock" name="GrossProceedsFromIssuanceOfCommonStock" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
<xsd:element id="immu_IncreaseDecreaseinFairValueOfWarrantsExercised" name="IncreaseDecreaseinFairValueOfWarrantsExercised" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
<xsd:element abstract="true" id="immu_InsuranceCoverageArbitrationMember" name="InsuranceCoverageArbitrationMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
<xsd:element abstract="true" id="immu_IntrinsicvalueRollForward" name="IntrinsicvalueRollForward" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration" />
<xsd:element id="immu_IssuanceofConvertiblePreferredStockPerShare" name="IssuanceofConvertiblePreferredStockPerShare" nillable="true" substitutionGroup="xbrli:item" type="num:perShareItemType" xbrli:periodType="duration" />
<xsd:element abstract="true" id="immu_JanssenBiotechIncMember" name="JanssenBiotechIncMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
<xsd:element id="immu_LiabilitiesRelatedToTheSaleOfFutureRoyaltiesCurrent" name="LiabilitiesRelatedToTheSaleOfFutureRoyaltiesCurrent" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant" />
<xsd:element id="immu_LiabilitiesRelatedToTheSaleOfFutureRoyaltiesNoncurrent" name="LiabilitiesRelatedToTheSaleOfFutureRoyaltiesNoncurrent" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant" />
<xsd:element id="immu_LicenseAgreementMilestoneDevelopmentTotalPayments" name="LicenseAgreementMilestoneDevelopmentTotalPayments" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
<xsd:element id="immu_LicenseAgreementMilestoneExpense" name="LicenseAgreementMilestoneExpense" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
<xsd:element id="immu_LicenseAgreementMilestonePaymentUponAchievementofFDAApproval" name="LicenseAgreementMilestonePaymentUponAchievementofFDAApproval" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
<xsd:element id="immu_LicenseAgreementMilestoneSalesTotalPayments" name="LicenseAgreementMilestoneSalesTotalPayments" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
<xsd:element id="immu_LicenseAgreementUpfrontFeesPaid" name="LicenseAgreementUpfrontFeesPaid" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
<xsd:element abstract="true" id="immu_LicenseAndCollaborationAgreementsAbstract" name="LicenseAndCollaborationAgreementsAbstract" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration" />
<xsd:element id="immu_LicenseAndCollaborationAgreementsTextBlock" name="LicenseAndCollaborationAgreementsTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration" />
<xsd:element abstract="true" id="immu_LicenseFreeAndOtherRevenueMember" name="LicenseFreeAndOtherRevenueMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
<xsd:element id="immu_LossOnInducedExchangesOfDebt" name="LossOnInducedExchangesOfDebt" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
<xsd:element abstract="true" id="immu_MRosenbergBioPharmaConsultingLlcMember" name="MRosenbergBioPharmaConsultingLlcMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
<xsd:element abstract="true" id="immu_MarketOfferingMember" name="MarketOfferingMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
<xsd:element id="immu_NonCashInterestExpenseRelatedToSaleOfFutureRoyalties" name="NonCashInterestExpenseRelatedToSaleOfFutureRoyalties" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
<xsd:element id="immu_NonCashLeaseExpense" name="NonCashLeaseExpense" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
<xsd:element id="immu_NumberofDaysLicenseCancellableAfterNonPayment" name="NumberofDaysLicenseCancellableAfterNonPayment" nillable="true" substitutionGroup="xbrli:item" type="us-types:durationStringItemType" xbrli:periodType="duration" />
<xsd:element id="immu_NumberofPatients" name="NumberofPatients" nillable="true" substitutionGroup="xbrli:item" type="xbrli:integerItemType" xbrli:periodType="duration" />
<xsd:element abstract="true" id="immu_October2018ExchangeAgreementMember" name="October2018ExchangeAgreementMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
<xsd:element id="immu_OperatingLossCarryforwardResultingFromSale" name="OperatingLossCarryforwardResultingFromSale" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
<xsd:element id="immu_OtherCurrentLiabilities" name="OtherCurrentLiabilities" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant" />
<xsd:element id="immu_OtherFinancingExpenseIncome" name="OtherFinancingExpenseIncome" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
<xsd:element id="immu_PaymentOfDebtConversionFees" name="PaymentOfDebtConversionFees" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
<xsd:element id="immu_PaymentsForFutureRoyalties" name="PaymentsForFutureRoyalties" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
<xsd:element id="immu_PaymentsforStockIssuanceCostsPercentage" name="PaymentsforStockIssuanceCostsPercentage" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="duration" />
<xsd:element id="immu_PercentOfSharesForfeitedEmploymentCommencement" name="PercentOfSharesForfeitedEmploymentCommencement" nillable="true" substitutionGroup="xbrli:item" type="xbrli:pureItemType" xbrli:periodType="instant" />
<xsd:element id="immu_PercentOfSharesVestedEmploymentCommencement" name="PercentOfSharesVestedEmploymentCommencement" nillable="true" substitutionGroup="xbrli:item" type="xbrli:pureItemType" xbrli:periodType="duration" />
<xsd:element id="immu_PeriodWhichCompanyWillAccreteLiability" name="PeriodWhichCompanyWillAccreteLiability" nillable="true" substitutionGroup="xbrli:item" type="xbrli:durationItemType" xbrli:periodType="duration" />
<xsd:element id="immu_PreferredStockIssuedDuringPeriodSharesNewIssues" name="PreferredStockIssuedDuringPeriodSharesNewIssues" nillable="true" substitutionGroup="xbrli:item" type="xbrli:sharesItemType" xbrli:periodType="duration" />
<xsd:element id="immu_PreferredStockIssuedDuringPeriodValueNewIssues" name="PreferredStockIssuedDuringPeriodValueNewIssues" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
<xsd:element id="immu_ProceedsFromIssuanceOfNonRecourseDebt" name="ProceedsFromIssuanceOfNonRecourseDebt" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
<xsd:element id="immu_ProceedsfromIssuanceInitialPublicOfferingGross" name="ProceedsfromIssuanceInitialPublicOfferingGross" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
<xsd:element abstract="true" id="immu_ProductSalesMember" name="ProductSalesMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
<xsd:element id="immu_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization" name="PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant" />
<xsd:element id="immu_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization" name="PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant" />
<xsd:element id="immu_PropertyPlantAndEquipmentAndFinanceLeaseRightofUseAssetBeforeAccumulatedDepreciationAndAmortization" name="PropertyPlantAndEquipmentAndFinanceLeaseRightofUseAssetBeforeAccumulatedDepreciationAndAmortization" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant" />
<xsd:element id="immu_ReclassOfWarrantLiabilityToCapitalContributedInExcessOfPar" name="ReclassOfWarrantLiabilityToCapitalContributedInExcessOfPar" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
<xsd:element id="immu_ReclassificationofWarrantLiabilitytoEquity" name="ReclassificationofWarrantLiabilitytoEquity" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
<xsd:element abstract="true" id="immu_ResearchandDevelopmentMember" name="ResearchandDevelopmentMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
<xsd:element abstract="true" id="immu_RestrictedUnitsWithVestingMarketConditionsMember" name="RestrictedUnitsWithVestingMarketConditionsMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
<xsd:element id="immu_RoyaltyPaymentsPercentage" name="RoyaltyPaymentsPercentage" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="duration" />
<xsd:element id="immu_RoyaltyPurchaseAgreementArrangementsConsideration" name="RoyaltyPurchaseAgreementArrangementsConsideration" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant" />
<xsd:element id="immu_RoyaltyPurchaseArrangementAnnualSalesLimitMaximum" name="RoyaltyPurchaseArrangementAnnualSalesLimitMaximum" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
<xsd:element id="immu_RoyaltyPurchaseArrangementExcessGlobalAnnualSalesLimitMinimum" name="RoyaltyPurchaseArrangementExcessGlobalAnnualSalesLimitMinimum" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
<xsd:element id="immu_RoyaltyPurchaseArrangementRoyaltyRateasPercentageofExcessofGlobalAnnualSalesThresholdLimit" name="RoyaltyPurchaseArrangementRoyaltyRateasPercentageofExcessofGlobalAnnualSalesThresholdLimit" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="duration" />
<xsd:element id="immu_RoyaltyPurchaseArrangementRoyaltyRateasPercentageofNetSales" name="RoyaltyPurchaseArrangementRoyaltyRateasPercentageofNetSales" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="duration" />
<xsd:element abstract="true" id="immu_RpiFinanceTrustMember" name="RpiFinanceTrustMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
<xsd:element id="immu_SalaryandWageOfficerMonthlySalary" name="SalaryandWageOfficerMonthlySalary" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
<xsd:element abstract="true" id="immu_SalesAgreementMember" name="SalesAgreementMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
<xsd:element id="immu_ScheduleofSharebasedCompensationPerformanceStockandPerformanceStockUnitsActivityTableTextBlock" name="ScheduleofSharebasedCompensationPerformanceStockandPerformanceStockUnitsActivityTableTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration" />
<xsd:element abstract="true" id="immu_SeattleGeneticsIncMember" name="SeattleGeneticsIncMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
<xsd:element abstract="true" id="immu_SecuritiesPurchaseAgreementMember" name="SecuritiesPurchaseAgreementMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
<xsd:element id="immu_SharebasedCompensationArrangementbySharebasedPaymentAwardWarrantsExercisesinPeriod" name="SharebasedCompensationArrangementbySharebasedPaymentAwardWarrantsExercisesinPeriod" nillable="true" substitutionGroup="xbrli:item" type="xbrli:sharesItemType" xbrli:periodType="duration" />
<xsd:element id="immu_StockIssuedDuringPeriodValueWarrantsExercised" name="StockIssuedDuringPeriodValueWarrantsExercised" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
<xsd:element id="immu_SupplementalUnemploymentBenefitsSeveranceBenefitsPaymentTerm" name="SupplementalUnemploymentBenefitsSeveranceBenefitsPaymentTerm" nillable="true" substitutionGroup="xbrli:item" type="xbrli:durationItemType" xbrli:periodType="duration" />
<xsd:element abstract="true" id="immu_TheScrippsResearchInstituteMember" name="TheScrippsResearchInstituteMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
<xsd:element id="immu_TreasuryStockPolicyPolicyTextBlock" name="TreasuryStockPolicyPolicyTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration" />
<xsd:element abstract="true" id="immu_WeightedaveragegrantdatefairvalueRollForward" name="WeightedaveragegrantdatefairvalueRollForward" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration" />
<xsd:element abstract="true" id="immu_WeightedaverageremainingcontractualtermyearsRollForward" name="WeightedaverageremainingcontractualtermyearsRollForward" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration" />
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>11
<FILENAME>immu-20191231_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!--XBRL Document Created with Wdesk from Workiva-->
<!-- -->
<link:linkbase xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<link:roleRef roleURI="http://www.immunomedics.com/role/AccountsPayableAndAccruedExpenses" xlink:href="immu-20191231.xsd#AccountsPayableAndAccruedExpenses" xlink:type="simple" />
<link:roleRef roleURI="http://www.immunomedics.com/role/AccountsPayableAndAccruedExpensesDetails" xlink:href="immu-20191231.xsd#AccountsPayableAndAccruedExpensesDetails" xlink:type="simple" />
<link:roleRef roleURI="http://www.immunomedics.com/role/AccountsPayableAndAccruedExpensesTables" xlink:href="immu-20191231.xsd#AccountsPayableAndAccruedExpensesTables" xlink:type="simple" />
<link:roleRef roleURI="http://www.immunomedics.com/role/AccumulatedOtherComprehensiveLossIncome" xlink:href="immu-20191231.xsd#AccumulatedOtherComprehensiveLossIncome" xlink:type="simple" />
<link:roleRef roleURI="http://www.immunomedics.com/role/AccumulatedOtherComprehensiveLossIncomeDetails" xlink:href="immu-20191231.xsd#AccumulatedOtherComprehensiveLossIncomeDetails" xlink:type="simple" />
<link:roleRef roleURI="http://www.immunomedics.com/role/AccumulatedOtherComprehensiveLossIncomeTables" xlink:href="immu-20191231.xsd#AccumulatedOtherComprehensiveLossIncomeTables" xlink:type="simple" />
<link:roleRef roleURI="http://www.immunomedics.com/role/BusinessOverviewAndSummaryOfSignificantAccountingPolices" xlink:href="immu-20191231.xsd#BusinessOverviewAndSummaryOfSignificantAccountingPolices" xlink:type="simple" />
<link:roleRef roleURI="http://www.immunomedics.com/role/BusinessOverviewAndSummaryOfSignificantAccountingPolicesRecentAccountingPronouncementsDetails" xlink:href="immu-20191231.xsd#BusinessOverviewAndSummaryOfSignificantAccountingPolicesRecentAccountingPronouncementsDetails" xlink:type="simple" />
<link:roleRef roleURI="http://www.immunomedics.com/role/BusinessOverviewSummaryOfSignificantAccountingPolicesPolicies" xlink:href="immu-20191231.xsd#BusinessOverviewSummaryOfSignificantAccountingPolicesPolicies" xlink:type="simple" />
<link:roleRef roleURI="http://www.immunomedics.com/role/CollaborationAgreements" xlink:href="immu-20191231.xsd#CollaborationAgreements" xlink:type="simple" />
<link:roleRef roleURI="http://www.immunomedics.com/role/CollaborationAgreementsDetails" xlink:href="immu-20191231.xsd#CollaborationAgreementsDetails" xlink:type="simple" />
<link:roleRef roleURI="http://www.immunomedics.com/role/CommitmentsAndContingencies" xlink:href="immu-20191231.xsd#CommitmentsAndContingencies" xlink:type="simple" />
<link:roleRef roleURI="http://www.immunomedics.com/role/CommitmentsAndContingenciesMaturitiesOfLeaseLiabilitiesDetails" xlink:href="immu-20191231.xsd#CommitmentsAndContingenciesMaturitiesOfLeaseLiabilitiesDetails" xlink:type="simple" />
<link:roleRef roleURI="http://www.immunomedics.com/role/CommitmentsAndContingenciesMaturitiesOfLeaseLiabilitiesDetailsCalc2" xlink:href="immu-20191231.xsd#CommitmentsAndContingenciesMaturitiesOfLeaseLiabilitiesDetailsCalc2" xlink:type="simple" />
<link:roleRef roleURI="http://www.immunomedics.com/role/CommitmentsAndContingenciesNarrativeDetails" xlink:href="immu-20191231.xsd#CommitmentsAndContingenciesNarrativeDetails" xlink:type="simple" />
<link:roleRef roleURI="http://www.immunomedics.com/role/CommitmentsAndContingenciesSupplementalConsolidatedBalanceSheetInformationRelatedToLeasesDetails" xlink:href="immu-20191231.xsd#CommitmentsAndContingenciesSupplementalConsolidatedBalanceSheetInformationRelatedToLeasesDetails" xlink:type="simple" />
<link:roleRef roleURI="http://www.immunomedics.com/role/CommitmentsAndContingenciesTables" xlink:href="immu-20191231.xsd#CommitmentsAndContingenciesTables" xlink:type="simple" />
<link:roleRef roleURI="http://www.immunomedics.com/role/ConsolidatedBalanceSheets" xlink:href="immu-20191231.xsd#ConsolidatedBalanceSheets" xlink:type="simple" />
<link:roleRef roleURI="http://www.immunomedics.com/role/ConsolidatedBalanceSheetsParenthetical" xlink:href="immu-20191231.xsd#ConsolidatedBalanceSheetsParenthetical" xlink:type="simple" />
<link:roleRef roleURI="http://www.immunomedics.com/role/ConsolidatedStatementsOfCashFlows" xlink:href="immu-20191231.xsd#ConsolidatedStatementsOfCashFlows" xlink:type="simple" />
<link:roleRef roleURI="http://www.immunomedics.com/role/ConsolidatedStatementsOfChangesInStockholdersEquity" xlink:href="immu-20191231.xsd#ConsolidatedStatementsOfChangesInStockholdersEquity" xlink:type="simple" />
<link:roleRef roleURI="http://www.immunomedics.com/role/ConsolidatedStatementsOfComprehensiveLoss" xlink:href="immu-20191231.xsd#ConsolidatedStatementsOfComprehensiveLoss" xlink:type="simple" />
<link:roleRef roleURI="http://www.immunomedics.com/role/CoverPage" xlink:href="immu-20191231.xsd#CoverPage" xlink:type="simple" />
<link:roleRef roleURI="http://www.immunomedics.com/role/Debt" xlink:href="immu-20191231.xsd#Debt" xlink:type="simple" />
<link:roleRef roleURI="http://www.immunomedics.com/role/DebtConsiderationAllocationDetails" xlink:href="immu-20191231.xsd#DebtConsiderationAllocationDetails" xlink:type="simple" />
<link:roleRef roleURI="http://www.immunomedics.com/role/DebtConvertibleSeniorNotesDetails" xlink:href="immu-20191231.xsd#DebtConvertibleSeniorNotesDetails" xlink:type="simple" />
<link:roleRef roleURI="http://www.immunomedics.com/role/DebtLiabilityRelatedToSaleOfFutureRoyaltiesDetails" xlink:href="immu-20191231.xsd#DebtLiabilityRelatedToSaleOfFutureRoyaltiesDetails" xlink:type="simple" />
<link:roleRef roleURI="http://www.immunomedics.com/role/DebtScheduleOfLiabilityRelatedToSaleOfFutureRoyaltiesDetails" xlink:href="immu-20191231.xsd#DebtScheduleOfLiabilityRelatedToSaleOfFutureRoyaltiesDetails" xlink:type="simple" />
<link:roleRef roleURI="http://www.immunomedics.com/role/DebtTables" xlink:href="immu-20191231.xsd#DebtTables" xlink:type="simple" />
<link:roleRef roleURI="http://www.immunomedics.com/role/DefinedContributionPlans" xlink:href="immu-20191231.xsd#DefinedContributionPlans" xlink:type="simple" />
<link:roleRef roleURI="http://www.immunomedics.com/role/DefinedContributionPlansDetails" xlink:href="immu-20191231.xsd#DefinedContributionPlansDetails" xlink:type="simple" />
<link:roleRef roleURI="http://www.immunomedics.com/role/EstimatedFairValueOfFinancialInstruments" xlink:href="immu-20191231.xsd#EstimatedFairValueOfFinancialInstruments" xlink:type="simple" />
<link:roleRef roleURI="http://www.immunomedics.com/role/EstimatedFairValueOfFinancialInstrumentsDebtInstrumentsDetails" xlink:href="immu-20191231.xsd#EstimatedFairValueOfFinancialInstrumentsDebtInstrumentsDetails" xlink:type="simple" />
<link:roleRef roleURI="http://www.immunomedics.com/role/EstimatedFairValueOfFinancialInstrumentsNarrativeDetails" xlink:href="immu-20191231.xsd#EstimatedFairValueOfFinancialInstrumentsNarrativeDetails" xlink:type="simple" />
<link:roleRef roleURI="http://www.immunomedics.com/role/EstimatedFairValueOfFinancialInstrumentsTables" xlink:href="immu-20191231.xsd#EstimatedFairValueOfFinancialInstrumentsTables" xlink:type="simple" />
<link:roleRef roleURI="http://www.immunomedics.com/role/IncomeTaxes" xlink:href="immu-20191231.xsd#IncomeTaxes" xlink:type="simple" />
<link:roleRef roleURI="http://www.immunomedics.com/role/IncomeTaxesChangeInUnrecognizedTaxBenefitsDetails" xlink:href="immu-20191231.xsd#IncomeTaxesChangeInUnrecognizedTaxBenefitsDetails" xlink:type="simple" />
<link:roleRef roleURI="http://www.immunomedics.com/role/IncomeTaxesExpenseBenefitFromIncomeTaxesDetails" xlink:href="immu-20191231.xsd#IncomeTaxesExpenseBenefitFromIncomeTaxesDetails" xlink:type="simple" />
<link:roleRef roleURI="http://www.immunomedics.com/role/IncomeTaxesNarrativeDetails" xlink:href="immu-20191231.xsd#IncomeTaxesNarrativeDetails" xlink:type="simple" />
<link:roleRef roleURI="http://www.immunomedics.com/role/IncomeTaxesReconciliationOfStatutoryTaxRatesAndEffectiveTaxRatesDetails" xlink:href="immu-20191231.xsd#IncomeTaxesReconciliationOfStatutoryTaxRatesAndEffectiveTaxRatesDetails" xlink:type="simple" />
<link:roleRef roleURI="http://www.immunomedics.com/role/IncomeTaxesTables" xlink:href="immu-20191231.xsd#IncomeTaxesTables" xlink:type="simple" />
<link:roleRef roleURI="http://www.immunomedics.com/role/IncomeTaxesTaxEffectsOfTemporaryDifferencesInDeferredTaxAssetsDetails" xlink:href="immu-20191231.xsd#IncomeTaxesTaxEffectsOfTemporaryDifferencesInDeferredTaxAssetsDetails" xlink:type="simple" />
<link:roleRef roleURI="http://www.immunomedics.com/role/MarketableSecurities" xlink:href="immu-20191231.xsd#MarketableSecurities" xlink:type="simple" />
<link:roleRef roleURI="http://www.immunomedics.com/role/MarketableSecuritiesAmortizedCostToFairValueDetails" xlink:href="immu-20191231.xsd#MarketableSecuritiesAmortizedCostToFairValueDetails" xlink:type="simple" />
<link:roleRef roleURI="http://www.immunomedics.com/role/MarketableSecuritiesTables" xlink:href="immu-20191231.xsd#MarketableSecuritiesTables" xlink:type="simple" />
<link:roleRef roleURI="http://www.immunomedics.com/role/PropertyAndEquipment" xlink:href="immu-20191231.xsd#PropertyAndEquipment" xlink:type="simple" />
<link:roleRef roleURI="http://www.immunomedics.com/role/PropertyAndEquipmentAdditionalInformationDetails" xlink:href="immu-20191231.xsd#PropertyAndEquipmentAdditionalInformationDetails" xlink:type="simple" />
<link:roleRef roleURI="http://www.immunomedics.com/role/PropertyAndEquipmentSchedulesOfPropertyAndEquipmentDetails" xlink:href="immu-20191231.xsd#PropertyAndEquipmentSchedulesOfPropertyAndEquipmentDetails" xlink:type="simple" />
<link:roleRef roleURI="http://www.immunomedics.com/role/PropertyAndEquipmentTables" xlink:href="immu-20191231.xsd#PropertyAndEquipmentTables" xlink:type="simple" />
<link:roleRef roleURI="http://www.immunomedics.com/role/QuarterlyResultsOfOperationsDetails" xlink:href="immu-20191231.xsd#QuarterlyResultsOfOperationsDetails" xlink:type="simple" />
<link:roleRef roleURI="http://www.immunomedics.com/role/QuarterlyResultsOfOperationsTables" xlink:href="immu-20191231.xsd#QuarterlyResultsOfOperationsTables" xlink:type="simple" />
<link:roleRef roleURI="http://www.immunomedics.com/role/QuarterlyResultsOfOperationsUnaudited" xlink:href="immu-20191231.xsd#QuarterlyResultsOfOperationsUnaudited" xlink:type="simple" />
<link:roleRef roleURI="http://www.immunomedics.com/role/RelatedPartyTransactions" xlink:href="immu-20191231.xsd#RelatedPartyTransactions" xlink:type="simple" />
<link:roleRef roleURI="http://www.immunomedics.com/role/RelatedPartyTransactionsDetails" xlink:href="immu-20191231.xsd#RelatedPartyTransactionsDetails" xlink:type="simple" />
<link:roleRef roleURI="http://www.immunomedics.com/role/RevenueRecognition" xlink:href="immu-20191231.xsd#RevenueRecognition" xlink:type="simple" />
<link:roleRef roleURI="http://www.immunomedics.com/role/RevenueRecognitionAdditionalInformationDetails" xlink:href="immu-20191231.xsd#RevenueRecognitionAdditionalInformationDetails" xlink:type="simple" />
<link:roleRef roleURI="http://www.immunomedics.com/role/RevenueRecognitionPerformanceObligationDetails" xlink:href="immu-20191231.xsd#RevenueRecognitionPerformanceObligationDetails" xlink:type="simple" />
<link:roleRef roleURI="http://www.immunomedics.com/role/StockBasedCompensation" xlink:href="immu-20191231.xsd#StockBasedCompensation" xlink:type="simple" />
<link:roleRef roleURI="http://www.immunomedics.com/role/StockBasedCompensationFairValueAssumptionsDetails" xlink:href="immu-20191231.xsd#StockBasedCompensationFairValueAssumptionsDetails" xlink:type="simple" />
<link:roleRef roleURI="http://www.immunomedics.com/role/StockBasedCompensationNarrativeDetails" xlink:href="immu-20191231.xsd#StockBasedCompensationNarrativeDetails" xlink:type="simple" />
<link:roleRef roleURI="http://www.immunomedics.com/role/StockBasedCompensationRestrictedStockUnitActivityDetails" xlink:href="immu-20191231.xsd#StockBasedCompensationRestrictedStockUnitActivityDetails" xlink:type="simple" />
<link:roleRef roleURI="http://www.immunomedics.com/role/StockBasedCompensationStockIncentivePlanDetails" xlink:href="immu-20191231.xsd#StockBasedCompensationStockIncentivePlanDetails" xlink:type="simple" />
<link:roleRef roleURI="http://www.immunomedics.com/role/StockBasedCompensationStockOptionActivityDetails" xlink:href="immu-20191231.xsd#StockBasedCompensationStockOptionActivityDetails" xlink:type="simple" />
<link:roleRef roleURI="http://www.immunomedics.com/role/StockBasedCompensationTables" xlink:href="immu-20191231.xsd#StockBasedCompensationTables" xlink:type="simple" />
<link:roleRef roleURI="http://www.immunomedics.com/role/StockholdersEquity" xlink:href="immu-20191231.xsd#StockholdersEquity" xlink:type="simple" />
<link:roleRef roleURI="http://www.immunomedics.com/role/StockholdersEquityDetails" xlink:href="immu-20191231.xsd#StockholdersEquityDetails" xlink:type="simple" />
<link:calculationLink xlink:role="http://www.immunomedics.com/role/AccountsPayableAndAccruedExpenses" xlink:type="extended" />
<link:calculationLink xlink:role="http://www.immunomedics.com/role/AccountsPayableAndAccruedExpensesDetails" xlink:type="extended">
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_9a34fc5e-00bc-420c-8698-6e19b92b8e39" xlink:type="locator" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountsPayableTradeCurrent" xlink:label="loc_us-gaap_AccountsPayableTradeCurrent_51b23810-9c40-7332-bdd2-99200011c44c" xlink:type="locator" />
<link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_9a34fc5e-00bc-420c-8698-6e19b92b8e39" xlink:to="loc_us-gaap_AccountsPayableTradeCurrent_51b23810-9c40-7332-bdd2-99200011c44c" xlink:type="arc" />
<link:loc xlink:href="immu-20191231.xsd#immu_AccruedContractManufacturingExpenses" xlink:label="loc_immu_AccruedContractManufacturingExpenses_27E675E3A0EAF80093065EEE10FD6F08" xlink:type="locator" />
<link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_9a34fc5e-00bc-420c-8698-6e19b92b8e39" xlink:to="loc_immu_AccruedContractManufacturingExpenses_27E675E3A0EAF80093065EEE10FD6F08" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_a2b836a7-cc87-0e4f-38a0-c91a29535622" xlink:type="locator" />
<link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_9a34fc5e-00bc-420c-8698-6e19b92b8e39" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_a2b836a7-cc87-0e4f-38a0-c91a29535622" xlink:type="arc" />
<link:loc xlink:href="immu-20191231.xsd#immu_ClinicalTrials" xlink:label="loc_immu_ClinicalTrials_5d03d3bc-5855-46b9-640e-d1d02a43e08f" xlink:type="locator" />
<link:calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_9a34fc5e-00bc-420c-8698-6e19b92b8e39" xlink:to="loc_immu_ClinicalTrials_5d03d3bc-5855-46b9-640e-d1d02a43e08f" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SupplementalUnemploymentBenefitsSeveranceBenefits" xlink:label="loc_us-gaap_SupplementalUnemploymentBenefitsSeveranceBenefits_59a23c5f-d19e-44f6-6529-eabb5bf66d50" xlink:type="locator" />
<link:calculationArc order="5" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_9a34fc5e-00bc-420c-8698-6e19b92b8e39" xlink:to="loc_us-gaap_SupplementalUnemploymentBenefitsSeveranceBenefits_59a23c5f-d19e-44f6-6529-eabb5bf66d50" xlink:type="arc" />
<link:loc xlink:href="immu-20191231.xsd#immu_OtherCurrentLiabilities" xlink:label="loc_immu_OtherCurrentLiabilities_f8999feb-48a5-95a8-9cfa-d1d029e7ec4c" xlink:type="locator" />
<link:calculationArc order="6" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_9a34fc5e-00bc-420c-8698-6e19b92b8e39" xlink:to="loc_immu_OtherCurrentLiabilities_f8999feb-48a5-95a8-9cfa-d1d029e7ec4c" xlink:type="arc" />
</link:calculationLink>
<link:calculationLink xlink:role="http://www.immunomedics.com/role/AccountsPayableAndAccruedExpensesTables" xlink:type="extended" />
<link:calculationLink xlink:role="http://www.immunomedics.com/role/AccumulatedOtherComprehensiveLossIncome" xlink:type="extended" />
<link:calculationLink xlink:role="http://www.immunomedics.com/role/AccumulatedOtherComprehensiveLossIncomeDetails" xlink:type="extended">
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_1ed26a82-dd4b-490f-d61a-b04c5d44793e" xlink:type="locator" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax_78f9a384-d8cc-c622-a09d-cab78e8426f5" xlink:type="locator" />
<link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_1ed26a82-dd4b-490f-d61a-b04c5d44793e" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax_78f9a384-d8cc-c622-a09d-cab78e8426f5" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" xlink:label="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax_33fd7cc6-9d16-3ba3-ad10-286b2340fef5" xlink:type="locator" />
<link:calculationArc order="2" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_1ed26a82-dd4b-490f-d61a-b04c5d44793e" xlink:to="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax_33fd7cc6-9d16-3ba3-ad10-286b2340fef5" xlink:type="arc" />
</link:calculationLink>
<link:calculationLink xlink:role="http://www.immunomedics.com/role/AccumulatedOtherComprehensiveLossIncomeTables" xlink:type="extended" />
<link:calculationLink xlink:role="http://www.immunomedics.com/role/BusinessOverviewAndSummaryOfSignificantAccountingPolices" xlink:type="extended" />
<link:calculationLink xlink:role="http://www.immunomedics.com/role/BusinessOverviewAndSummaryOfSignificantAccountingPolicesRecentAccountingPronouncementsDetails" xlink:type="extended" />
<link:calculationLink xlink:role="http://www.immunomedics.com/role/BusinessOverviewSummaryOfSignificantAccountingPolicesPolicies" xlink:type="extended" />
<link:calculationLink xlink:role="http://www.immunomedics.com/role/CollaborationAgreements" xlink:type="extended" />
<link:calculationLink xlink:role="http://www.immunomedics.com/role/CollaborationAgreementsDetails" xlink:type="extended" />
<link:calculationLink xlink:role="http://www.immunomedics.com/role/CommitmentsAndContingencies" xlink:type="extended" />
<link:calculationLink xlink:role="http://www.immunomedics.com/role/CommitmentsAndContingenciesMaturitiesOfLeaseLiabilitiesDetails" xlink:type="extended">
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_1c2cd15f-6a97-015f-b126-1d0a0750698b" xlink:type="locator" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_07815ffa-512a-3133-dcbb-38e09d2626b9" xlink:type="locator" />
<link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_1c2cd15f-6a97-015f-b126-1d0a0750698b" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_07815ffa-512a-3133-dcbb-38e09d2626b9" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseLiability" xlink:label="loc_us-gaap_OperatingLeaseLiability_b983c2d8-8318-0a7e-1a5c-6ab2933f7be5" xlink:type="locator" />
<link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_1c2cd15f-6a97-015f-b126-1d0a0750698b" xlink:to="loc_us-gaap_OperatingLeaseLiability_b983c2d8-8318-0a7e-1a5c-6ab2933f7be5" xlink:type="arc" />
</link:calculationLink>
<link:calculationLink xlink:role="http://www.immunomedics.com/role/CommitmentsAndContingenciesMaturitiesOfLeaseLiabilitiesDetailsCalc2" xlink:type="extended">
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_5EF0A044ECF7FA43A4A53A2FF4A679C6_1c2cd15f-6a97-015f-b126-1d0a0750698b" xlink:type="locator" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_5EF0A044ECF7FA43A4A53A2FF4A679C6_48abcf97-737b-2b2c-8a8c-c74539d0b215" xlink:type="locator" />
<link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_5EF0A044ECF7FA43A4A53A2FF4A679C6_1c2cd15f-6a97-015f-b126-1d0a0750698b" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_5EF0A044ECF7FA43A4A53A2FF4A679C6_48abcf97-737b-2b2c-8a8c-c74539d0b215" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_5EF0A044ECF7FA43A4A53A2FF4A679C6_9b040bc1-f43c-735d-05f7-679f319d2bb6" xlink:type="locator" />
<link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_5EF0A044ECF7FA43A4A53A2FF4A679C6_1c2cd15f-6a97-015f-b126-1d0a0750698b" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_5EF0A044ECF7FA43A4A53A2FF4A679C6_9b040bc1-f43c-735d-05f7-679f319d2bb6" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_5EF0A044ECF7FA43A4A53A2FF4A679C6_2f0ec234-4f20-7099-efb3-3c0ab4d024dd" xlink:type="locator" />
<link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_5EF0A044ECF7FA43A4A53A2FF4A679C6_1c2cd15f-6a97-015f-b126-1d0a0750698b" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_5EF0A044ECF7FA43A4A53A2FF4A679C6_2f0ec234-4f20-7099-efb3-3c0ab4d024dd" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_5EF0A044ECF7FA43A4A53A2FF4A679C6_1ed751b1-5f94-4f6f-41e9-ef873c9f2bab" xlink:type="locator" />
<link:calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_5EF0A044ECF7FA43A4A53A2FF4A679C6_1c2cd15f-6a97-015f-b126-1d0a0750698b" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_5EF0A044ECF7FA43A4A53A2FF4A679C6_1ed751b1-5f94-4f6f-41e9-ef873c9f2bab" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_5EF0A044ECF7FA43A4A53A2FF4A679C6_8a8de21f-aadc-3af7-8c96-d54cf42b401b" xlink:type="locator" />
<link:calculationArc order="5" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_5EF0A044ECF7FA43A4A53A2FF4A679C6_1c2cd15f-6a97-015f-b126-1d0a0750698b" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_5EF0A044ECF7FA43A4A53A2FF4A679C6_8a8de21f-aadc-3af7-8c96-d54cf42b401b" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_5EF0A044ECF7FA43A4A53A2FF4A679C6_b411eec9-2a0a-356b-e751-bd0680ab4d58" xlink:type="locator" />
<link:calculationArc order="6" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_5EF0A044ECF7FA43A4A53A2FF4A679C6_1c2cd15f-6a97-015f-b126-1d0a0750698b" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_5EF0A044ECF7FA43A4A53A2FF4A679C6_b411eec9-2a0a-356b-e751-bd0680ab4d58" xlink:type="arc" />
</link:calculationLink>
<link:calculationLink xlink:role="http://www.immunomedics.com/role/CommitmentsAndContingenciesNarrativeDetails" xlink:type="extended" />
<link:calculationLink xlink:role="http://www.immunomedics.com/role/CommitmentsAndContingenciesSupplementalConsolidatedBalanceSheetInformationRelatedToLeasesDetails" xlink:type="extended" />
<link:calculationLink xlink:role="http://www.immunomedics.com/role/CommitmentsAndContingenciesTables" xlink:type="extended" />
<link:calculationLink xlink:role="http://www.immunomedics.com/role/ConsolidatedBalanceSheets" xlink:type="extended">
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_d7f1ad03-6ed4-706a-15fc-eae794dee33a" xlink:type="locator" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_2605fa18-bbd8-c7d7-35fc-aace43a8c019" xlink:type="locator" />
<link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_d7f1ad03-6ed4-706a-15fc-eae794dee33a" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_2605fa18-bbd8-c7d7-35fc-aace43a8c019" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_4b9904d8-8624-0dbb-a949-29ff2cf808a8" xlink:type="locator" />
<link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_2605fa18-bbd8-c7d7-35fc-aace43a8c019" xlink:to="loc_us-gaap_StockholdersEquity_4b9904d8-8624-0dbb-a949-29ff2cf808a8" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConvertiblePreferredStockNonredeemableOrRedeemableIssuerOptionValue" xlink:label="loc_us-gaap_ConvertiblePreferredStockNonredeemableOrRedeemableIssuerOptionValue_b07445bf-4f8f-1562-6305-4efc9d9115ba" xlink:type="locator" />
<link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_4b9904d8-8624-0dbb-a949-29ff2cf808a8" xlink:to="loc_us-gaap_ConvertiblePreferredStockNonredeemableOrRedeemableIssuerOptionValue_b07445bf-4f8f-1562-6305-4efc9d9115ba" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaap_CommonStockValue_f05ab245-2bd1-7865-e7ed-1461a5a6155f" xlink:type="locator" />
<link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_4b9904d8-8624-0dbb-a949-29ff2cf808a8" xlink:to="loc_us-gaap_CommonStockValue_f05ab245-2bd1-7865-e7ed-1461a5a6155f" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock_9a00ddef-ccc2-f99c-735a-66b1e1849bbf" xlink:type="locator" />
<link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_4b9904d8-8624-0dbb-a949-29ff2cf808a8" xlink:to="loc_us-gaap_AdditionalPaidInCapitalCommonStock_9a00ddef-ccc2-f99c-735a-66b1e1849bbf" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TreasuryStockValue" xlink:label="loc_us-gaap_TreasuryStockValue_e6069c8d-dfec-45ff-4b3f-643d125d5b29" xlink:type="locator" />
<link:calculationArc order="4" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_4b9904d8-8624-0dbb-a949-29ff2cf808a8" xlink:to="loc_us-gaap_TreasuryStockValue_e6069c8d-dfec-45ff-4b3f-643d125d5b29" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_62305d8f-d807-0fe8-d0ab-f2c2b3d03011" xlink:type="locator" />
<link:calculationArc order="5" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_4b9904d8-8624-0dbb-a949-29ff2cf808a8" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_62305d8f-d807-0fe8-d0ab-f2c2b3d03011" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_988c1346-b444-a867-fe80-f3aec1443d54" xlink:type="locator" />
<link:calculationArc order="6" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_4b9904d8-8624-0dbb-a949-29ff2cf808a8" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_988c1346-b444-a867-fe80-f3aec1443d54" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MinorityInterest" xlink:label="loc_us-gaap_MinorityInterest_3070eb63-b0f5-1f18-a22f-cc54a94922d9" xlink:type="locator" />
<link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_2605fa18-bbd8-c7d7-35fc-aace43a8c019" xlink:to="loc_us-gaap_MinorityInterest_3070eb63-b0f5-1f18-a22f-cc54a94922d9" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="loc_us-gaap_CommitmentsAndContingencies_4d934b0d-59bc-ae5c-ffb9-b6ced82ff9f8" xlink:type="locator" />
<link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_d7f1ad03-6ed4-706a-15fc-eae794dee33a" xlink:to="loc_us-gaap_CommitmentsAndContingencies_4d934b0d-59bc-ae5c-ffb9-b6ced82ff9f8" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaap_Liabilities_44863786-cbc4-bac4-e070-0a1f19314584" xlink:type="locator" />
<link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_d7f1ad03-6ed4-706a-15fc-eae794dee33a" xlink:to="loc_us-gaap_Liabilities_44863786-cbc4-bac4-e070-0a1f19314584" xlink:type="arc" />
<link:loc xlink:href="immu-20191231.xsd#immu_LiabilitiesRelatedToTheSaleOfFutureRoyaltiesNoncurrent" xlink:label="loc_immu_LiabilitiesRelatedToTheSaleOfFutureRoyaltiesNoncurrent_c3f1c31d-350d-27d8-ffd2-d1d029e2a2b0" xlink:type="locator" />
<link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_44863786-cbc4-bac4-e070-0a1f19314584" xlink:to="loc_immu_LiabilitiesRelatedToTheSaleOfFutureRoyaltiesNoncurrent_c3f1c31d-350d-27d8-ffd2-d1d029e2a2b0" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_2bf7259d-4c54-f092-3b62-ad288c59c828" xlink:type="locator" />
<link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_44863786-cbc4-bac4-e070-0a1f19314584" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_2bf7259d-4c54-f092-3b62-ad288c59c828" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_8c850143-cd0c-0f85-9038-e19d8c4f7808" xlink:type="locator" />
<link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_44863786-cbc4-bac4-e070-0a1f19314584" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_8c850143-cd0c-0f85-9038-e19d8c4f7808" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaap_LiabilitiesCurrent_30dca50d-a7bd-cff0-949a-3d7ae869c50d" xlink:type="locator" />
<link:calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_44863786-cbc4-bac4-e070-0a1f19314584" xlink:to="loc_us-gaap_LiabilitiesCurrent_30dca50d-a7bd-cff0-949a-3d7ae869c50d" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_9a34fc5e-00bc-420c-8698-6e19b92b8e39" xlink:type="locator" />
<link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_30dca50d-a7bd-cff0-949a-3d7ae869c50d" xlink:to="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_9a34fc5e-00bc-420c-8698-6e19b92b8e39" xlink:type="arc" />
<link:loc xlink:href="immu-20191231.xsd#immu_LiabilitiesRelatedToTheSaleOfFutureRoyaltiesCurrent" xlink:label="loc_immu_LiabilitiesRelatedToTheSaleOfFutureRoyaltiesCurrent_cb9b460d-e9e9-9347-bce3-d1d02a37f36e" xlink:type="locator" />
<link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_30dca50d-a7bd-cff0-949a-3d7ae869c50d" xlink:to="loc_immu_LiabilitiesRelatedToTheSaleOfFutureRoyaltiesCurrent_cb9b460d-e9e9-9347-bce3-d1d02a37f36e" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_b91d2f01-85c2-f9fb-3250-26a4b1b39c5e" xlink:type="locator" />
<link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_30dca50d-a7bd-cff0-949a-3d7ae869c50d" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_b91d2f01-85c2-f9fb-3250-26a4b1b39c5e" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConvertibleDebtCurrent" xlink:label="loc_us-gaap_ConvertibleDebtCurrent_41825e0e-2672-912d-3c5f-e31b87262266" xlink:type="locator" />
<link:calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_30dca50d-a7bd-cff0-949a-3d7ae869c50d" xlink:to="loc_us-gaap_ConvertibleDebtCurrent_41825e0e-2672-912d-3c5f-e31b87262266" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConvertibleDebtNoncurrent" xlink:label="loc_us-gaap_ConvertibleDebtNoncurrent_11cb9e8d-a660-6f46-5f9d-84486199528b" xlink:type="locator" />
<link:calculationArc order="5" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_44863786-cbc4-bac4-e070-0a1f19314584" xlink:to="loc_us-gaap_ConvertibleDebtNoncurrent_11cb9e8d-a660-6f46-5f9d-84486199528b" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Assets" xlink:label="loc_us-gaap_Assets_17ef3f41-42f7-52c0-cba1-93e7e0e1116a" xlink:type="locator" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaap_AssetsCurrent_0b3bd361-d592-2906-279e-2682647fdd27" xlink:type="locator" />
<link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_17ef3f41-42f7-52c0-cba1-93e7e0e1116a" xlink:to="loc_us-gaap_AssetsCurrent_0b3bd361-d592-2906-279e-2682647fdd27" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_1de780cc-9607-daa3-0bed-03c88ae94769" xlink:type="locator" />
<link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_0b3bd361-d592-2906-279e-2682647fdd27" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_1de780cc-9607-daa3-0bed-03c88ae94769" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_e2b10c93-5dbd-d345-d7e4-6144b8287c24" xlink:type="locator" />
<link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_0b3bd361-d592-2906-279e-2682647fdd27" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_e2b10c93-5dbd-d345-d7e4-6144b8287c24" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_dd2cbe99-77d2-db20-3c91-750589881c79" xlink:type="locator" />
<link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_0b3bd361-d592-2906-279e-2682647fdd27" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_dd2cbe99-77d2-db20-3c91-750589881c79" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PrepaidExpenseCurrent" xlink:label="loc_us-gaap_PrepaidExpenseCurrent_f68f267d-78ad-b62f-6b0e-44daadd4feda" xlink:type="locator" />
<link:calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_0b3bd361-d592-2906-279e-2682647fdd27" xlink:to="loc_us-gaap_PrepaidExpenseCurrent_f68f267d-78ad-b62f-6b0e-44daadd4feda" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherAssetsCurrent" xlink:label="loc_us-gaap_OtherAssetsCurrent_7832082e-fa39-48cc-a655-249c101debf9" xlink:type="locator" />
<link:calculationArc order="5" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_0b3bd361-d592-2906-279e-2682647fdd27" xlink:to="loc_us-gaap_OtherAssetsCurrent_7832082e-fa39-48cc-a655-249c101debf9" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_4246ec24-1a4c-19dd-57c9-32d4a8e0cbaa" xlink:type="locator" />
<link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_17ef3f41-42f7-52c0-cba1-93e7e0e1116a" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_4246ec24-1a4c-19dd-57c9-32d4a8e0cbaa" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_bd8545de-cfc2-6f31-bff6-ed0d4012c357" xlink:type="locator" />
<link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_17ef3f41-42f7-52c0-cba1-93e7e0e1116a" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_bd8545de-cfc2-6f31-bff6-ed0d4012c357" xlink:type="arc" />
</link:calculationLink>
<link:calculationLink xlink:role="http://www.immunomedics.com/role/ConsolidatedBalanceSheetsParenthetical" xlink:type="extended" />
<link:calculationLink xlink:role="http://www.immunomedics.com/role/ConsolidatedStatementsOfCashFlows" xlink:type="extended">
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_21c019f0-62e8-3b20-07d1-495695054dce" xlink:type="locator" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_1de780cc-9607-daa3-0bed-03c88ae94769" xlink:type="locator" />
<link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_21c019f0-62e8-3b20-07d1-495695054dce" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_1de780cc-9607-daa3-0bed-03c88ae94769" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestrictedCashCurrent" xlink:label="loc_us-gaap_RestrictedCashCurrent_61f9319a-6aae-8e2f-f7d0-f41809896476" xlink:type="locator" />
<link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_21c019f0-62e8-3b20-07d1-495695054dce" xlink:to="loc_us-gaap_RestrictedCashCurrent_61f9319a-6aae-8e2f-f7d0-f41809896476" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_50231013-f048-89e7-0e20-ba139224c5f7" xlink:type="locator" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ce0d7b63-a366-bc9b-79e1-780981e428fe" xlink:type="locator" />
<link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_50231013-f048-89e7-0e20-ba139224c5f7" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ce0d7b63-a366-bc9b-79e1-780981e428fe" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProfitLoss" xlink:label="loc_us-gaap_ProfitLoss_8b582348-a62e-cdfb-bc53-d5894b42e091" xlink:type="locator" />
<link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ce0d7b63-a366-bc9b-79e1-780981e428fe" xlink:to="loc_us-gaap_ProfitLoss_8b582348-a62e-cdfb-bc53-d5894b42e091" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="loc_us-gaap_FairValueAdjustmentOfWarrants_dcf39713-2bbe-ebf2-2d75-3bc1c2f5ba99" xlink:type="locator" />
<link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ce0d7b63-a366-bc9b-79e1-780981e428fe" xlink:to="loc_us-gaap_FairValueAdjustmentOfWarrants_dcf39713-2bbe-ebf2-2d75-3bc1c2f5ba99" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdjustmentOfWarrantsGrantedForServices" xlink:label="loc_us-gaap_AdjustmentOfWarrantsGrantedForServices_2f904c20-67ab-dbad-e785-423ce21ac2c0" xlink:type="locator" />
<link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ce0d7b63-a366-bc9b-79e1-780981e428fe" xlink:to="loc_us-gaap_AdjustmentOfWarrantsGrantedForServices_2f904c20-67ab-dbad-e785-423ce21ac2c0" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DepreciationAndAmortization" xlink:label="loc_us-gaap_DepreciationAndAmortization_9f9b2594-efaa-e1fa-01db-e194221f432f" xlink:type="locator" />
<link:calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ce0d7b63-a366-bc9b-79e1-780981e428fe" xlink:to="loc_us-gaap_DepreciationAndAmortization_9f9b2594-efaa-e1fa-01db-e194221f432f" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:label="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_ae064a9e-7563-5fa2-95b8-bfe0f620685d" xlink:type="locator" />
<link:calculationArc order="5" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ce0d7b63-a366-bc9b-79e1-780981e428fe" xlink:to="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_ae064a9e-7563-5fa2-95b8-bfe0f620685d" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InterestExpenseDebt" xlink:label="loc_us-gaap_InterestExpenseDebt_67350937-b93b-8ace-3db0-138d5fe4c955" xlink:type="locator" />
<link:calculationArc order="6" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ce0d7b63-a366-bc9b-79e1-780981e428fe" xlink:to="loc_us-gaap_InterestExpenseDebt_67350937-b93b-8ace-3db0-138d5fe4c955" xlink:type="arc" />
<link:loc xlink:href="immu-20191231.xsd#immu_LossOnInducedExchangesOfDebt" xlink:label="loc_immu_LossOnInducedExchangesOfDebt_b50f3f41-27e7-b008-c853-d1d029de0f46" xlink:type="locator" />
<link:calculationArc order="7" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ce0d7b63-a366-bc9b-79e1-780981e428fe" xlink:to="loc_immu_LossOnInducedExchangesOfDebt_b50f3f41-27e7-b008-c853-d1d029de0f46" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_57cbd7df-7e25-c8b5-2eaa-6ac8279f4bf6" xlink:type="locator" />
<link:calculationArc order="8" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ce0d7b63-a366-bc9b-79e1-780981e428fe" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_57cbd7df-7e25-c8b5-2eaa-6ac8279f4bf6" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:label="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_94f5ae99-7bd8-4f8c-5311-9522abc2f1bd" xlink:type="locator" />
<link:calculationArc order="9" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ce0d7b63-a366-bc9b-79e1-780981e428fe" xlink:to="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_94f5ae99-7bd8-4f8c-5311-9522abc2f1bd" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AmortizationOfFinancingCosts" xlink:label="loc_us-gaap_AmortizationOfFinancingCosts_149d6655-b7f8-5049-ef74-296db479f8f9" xlink:type="locator" />
<link:calculationArc order="10" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ce0d7b63-a366-bc9b-79e1-780981e428fe" xlink:to="loc_us-gaap_AmortizationOfFinancingCosts_149d6655-b7f8-5049-ef74-296db479f8f9" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInDeferredCharges" xlink:label="loc_us-gaap_IncreaseDecreaseInDeferredCharges_ed4c1c9d-dcee-1661-2ae4-cfaaba657145" xlink:type="locator" />
<link:calculationArc order="11" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ce0d7b63-a366-bc9b-79e1-780981e428fe" xlink:to="loc_us-gaap_IncreaseDecreaseInDeferredCharges_ed4c1c9d-dcee-1661-2ae4-cfaaba657145" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FinanceLeaseRightOfUseAssetAmortization" xlink:label="loc_us-gaap_FinanceLeaseRightOfUseAssetAmortization_e6bc46d1-fec7-6b3b-527e-4ad756896790" xlink:type="locator" />
<link:calculationArc order="12" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ce0d7b63-a366-bc9b-79e1-780981e428fe" xlink:to="loc_us-gaap_FinanceLeaseRightOfUseAssetAmortization_e6bc46d1-fec7-6b3b-527e-4ad756896790" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtAndEquitySecuritiesGainLoss" xlink:label="loc_us-gaap_DebtAndEquitySecuritiesGainLoss_621f303c-751b-9349-bcf4-ad4fd6948d9c" xlink:type="locator" />
<link:calculationArc order="13" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ce0d7b63-a366-bc9b-79e1-780981e428fe" xlink:to="loc_us-gaap_DebtAndEquitySecuritiesGainLoss_621f303c-751b-9349-bcf4-ad4fd6948d9c" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProvisionForDoubtfulAccounts" xlink:label="loc_us-gaap_ProvisionForDoubtfulAccounts_5ae19a9f-6de6-075a-2c5a-a587d82ebad5" xlink:type="locator" />
<link:calculationArc order="14" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ce0d7b63-a366-bc9b-79e1-780981e428fe" xlink:to="loc_us-gaap_ProvisionForDoubtfulAccounts_5ae19a9f-6de6-075a-2c5a-a587d82ebad5" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaap_ShareBasedCompensation_f0b9d825-b0b9-37fd-4d25-9294a8598890" xlink:type="locator" />
<link:calculationArc order="15" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ce0d7b63-a366-bc9b-79e1-780981e428fe" xlink:to="loc_us-gaap_ShareBasedCompensation_f0b9d825-b0b9-37fd-4d25-9294a8598890" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherNoncashExpense" xlink:label="loc_us-gaap_OtherNoncashExpense_7f62bca4-bc86-c978-3a6e-11978d8407f3" xlink:type="locator" />
<link:calculationArc order="16" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ce0d7b63-a366-bc9b-79e1-780981e428fe" xlink:to="loc_us-gaap_OtherNoncashExpense_7f62bca4-bc86-c978-3a6e-11978d8407f3" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_09b7b41a-f5a1-c45e-d61b-846fff462802" xlink:type="locator" />
<link:calculationArc order="17" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ce0d7b63-a366-bc9b-79e1-780981e428fe" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_09b7b41a-f5a1-c45e-d61b-846fff462802" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInInventories" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories_f2b34f8d-2445-12ee-2c68-fa0c5409d5e0" xlink:type="locator" />
<link:calculationArc order="18" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ce0d7b63-a366-bc9b-79e1-780981e428fe" xlink:to="loc_us-gaap_IncreaseDecreaseInInventories_f2b34f8d-2445-12ee-2c68-fa0c5409d5e0" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInOtherReceivables" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherReceivables_6990de1f-0b35-2b76-52bb-4b0ce17b5e4e" xlink:type="locator" />
<link:calculationArc order="19" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ce0d7b63-a366-bc9b-79e1-780981e428fe" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherReceivables_6990de1f-0b35-2b76-52bb-4b0ce17b5e4e" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_dfcbd6f7-83fa-00c2-bd9e-6c5c1de7d890" xlink:type="locator" />
<link:calculationArc order="20" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ce0d7b63-a366-bc9b-79e1-780981e428fe" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_dfcbd6f7-83fa-00c2-bd9e-6c5c1de7d890" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_7c1c3153-d95c-50b8-10ed-a75d1f3d7a68" xlink:type="locator" />
<link:calculationArc order="21" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ce0d7b63-a366-bc9b-79e1-780981e428fe" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_7c1c3153-d95c-50b8-10ed-a75d1f3d7a68" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_d7de2883-fea4-6e7c-2c8b-7fee9aa34369" xlink:type="locator" />
<link:calculationArc order="22" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ce0d7b63-a366-bc9b-79e1-780981e428fe" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_d7de2883-fea4-6e7c-2c8b-7fee9aa34369" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:label="loc_us-gaap_IncreaseDecreaseInDeferredRevenue_6cfa827d-143a-2a96-d20d-4ed339c92bf3" xlink:type="locator" />
<link:calculationArc order="23" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ce0d7b63-a366-bc9b-79e1-780981e428fe" xlink:to="loc_us-gaap_IncreaseDecreaseInDeferredRevenue_6cfa827d-143a-2a96-d20d-4ed339c92bf3" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_0f07a806-a2da-6d18-a7a9-d734fad1f3b0" xlink:type="locator" />
<link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_50231013-f048-89e7-0e20-ba139224c5f7" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_0f07a806-a2da-6d18-a7a9-d734fad1f3b0" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:label="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_8b51ae5f-8f14-ae0e-00e7-8f4e716f2f96" xlink:type="locator" />
<link:calculationArc order="1" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_0f07a806-a2da-6d18-a7a9-d734fad1f3b0" xlink:to="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_8b51ae5f-8f14-ae0e-00e7-8f4e716f2f96" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_83cf65a5-9616-b748-1d6c-92f0b7da6e69" xlink:type="locator" />
<link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_0f07a806-a2da-6d18-a7a9-d734fad1f3b0" xlink:to="loc_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_83cf65a5-9616-b748-1d6c-92f0b7da6e69" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_0f8df60b-841f-6df5-83c3-e4049d366459" xlink:type="locator" />
<link:calculationArc order="3" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_0f07a806-a2da-6d18-a7a9-d734fad1f3b0" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_0f8df60b-841f-6df5-83c3-e4049d366459" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_1efd93c0-bb90-2a64-a997-3a70afaa3faa" xlink:type="locator" />
<link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_50231013-f048-89e7-0e20-ba139224c5f7" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_1efd93c0-bb90-2a64-a997-3a70afaa3faa" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_f73833cd-0af4-c4d5-a7c4-1151269f1da3" xlink:type="locator" />
<link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_1efd93c0-bb90-2a64-a997-3a70afaa3faa" xlink:to="loc_us-gaap_ProceedsFromStockOptionsExercised_f73833cd-0af4-c4d5-a7c4-1151269f1da3" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="loc_us-gaap_ProceedsFromWarrantExercises_a88ea9da-fe15-25d5-e7ed-084f1843cf38" xlink:type="locator" />
<link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_1efd93c0-bb90-2a64-a997-3a70afaa3faa" xlink:to="loc_us-gaap_ProceedsFromWarrantExercises_a88ea9da-fe15-25d5-e7ed-084f1843cf38" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock_d58ff834-f6f4-d17f-9a5a-a8f17b05a983" xlink:type="locator" />
<link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_1efd93c0-bb90-2a64-a997-3a70afaa3faa" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock_d58ff834-f6f4-d17f-9a5a-a8f17b05a983" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:label="loc_us-gaap_ProceedsFromIssuanceInitialPublicOffering_505a1499-71a2-e5de-2af8-1565f94fa52c" xlink:type="locator" />
<link:calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_1efd93c0-bb90-2a64-a997-3a70afaa3faa" xlink:to="loc_us-gaap_ProceedsFromIssuanceInitialPublicOffering_505a1499-71a2-e5de-2af8-1565f94fa52c" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_0f0975d6-8500-76a0-c74f-5d2f0ed8b620" xlink:type="locator" />
<link:calculationArc order="5" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_1efd93c0-bb90-2a64-a997-3a70afaa3faa" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_0f0975d6-8500-76a0-c74f-5d2f0ed8b620" xlink:type="arc" />
<link:loc xlink:href="immu-20191231.xsd#immu_ProceedsFromIssuanceOfNonRecourseDebt" xlink:label="loc_immu_ProceedsFromIssuanceOfNonRecourseDebt_91170f86-37e4-b880-b483-d1d02a27e376" xlink:type="locator" />
<link:calculationArc order="6" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_1efd93c0-bb90-2a64-a997-3a70afaa3faa" xlink:to="loc_immu_ProceedsFromIssuanceOfNonRecourseDebt_91170f86-37e4-b880-b483-d1d02a27e376" xlink:type="arc" />
<link:loc xlink:href="immu-20191231.xsd#immu_PaymentOfDebtConversionFees" xlink:label="loc_immu_PaymentOfDebtConversionFees_d4084036-4c20-56ef-5c64-d1d02a2b6714" xlink:type="locator" />
<link:calculationArc order="7" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_1efd93c0-bb90-2a64-a997-3a70afaa3faa" xlink:to="loc_immu_PaymentOfDebtConversionFees_d4084036-4c20-56ef-5c64-d1d02a2b6714" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:label="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_07e50027-f2db-6d1b-93ed-b22d6bd39351" xlink:type="locator" />
<link:calculationArc order="8" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_1efd93c0-bb90-2a64-a997-3a70afaa3faa" xlink:to="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_07e50027-f2db-6d1b-93ed-b22d6bd39351" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_62f6f07e-4449-59c4-74ee-766defbf8a2f" xlink:type="locator" />
<link:calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_50231013-f048-89e7-0e20-ba139224c5f7" xlink:to="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_62f6f07e-4449-59c4-74ee-766defbf8a2f" xlink:type="arc" />
</link:calculationLink>
<link:calculationLink xlink:role="http://www.immunomedics.com/role/ConsolidatedStatementsOfChangesInStockholdersEquity" xlink:type="extended" />
<link:calculationLink xlink:role="http://www.immunomedics.com/role/ConsolidatedStatementsOfComprehensiveLoss" xlink:type="extended">
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_e170ce1e-c3a8-e8ee-88b0-37e8dd7b1d11" xlink:type="locator" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProfitLoss" xlink:label="loc_us-gaap_ProfitLoss_8b582348-a62e-cdfb-bc53-d5894b42e091" xlink:type="locator" />
<link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_e170ce1e-c3a8-e8ee-88b0-37e8dd7b1d11" xlink:to="loc_us-gaap_ProfitLoss_8b582348-a62e-cdfb-bc53-d5894b42e091" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_489b61b6-7c39-240c-7f68-1c1675bca3b7" xlink:type="locator" />
<link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ProfitLoss_8b582348-a62e-cdfb-bc53-d5894b42e091" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_489b61b6-7c39-240c-7f68-1c1675bca3b7" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaap_OperatingIncomeLoss_8db01d6d-ae17-523f-94b9-8ab4add4a22e" xlink:type="locator" />
<link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_489b61b6-7c39-240c-7f68-1c1675bca3b7" xlink:to="loc_us-gaap_OperatingIncomeLoss_8db01d6d-ae17-523f-94b9-8ab4add4a22e" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_b88c060f-09b3-b6c0-4cdb-a77cb8e75ec8" xlink:type="locator" />
<link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_8db01d6d-ae17-523f-94b9-8ab4add4a22e" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_b88c060f-09b3-b6c0-4cdb-a77cb8e75ec8" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CostsAndExpenses" xlink:label="loc_us-gaap_CostsAndExpenses_76d25f63-60a6-4deb-1fd0-84a3d98fe881" xlink:type="locator" />
<link:calculationArc order="2" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_8db01d6d-ae17-523f-94b9-8ab4add4a22e" xlink:to="loc_us-gaap_CostsAndExpenses_76d25f63-60a6-4deb-1fd0-84a3d98fe881" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CostOfRevenue" xlink:label="loc_us-gaap_CostOfRevenue_b362f93c-0412-ea6c-3d48-01ede1ed7f3f" xlink:type="locator" />
<link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_76d25f63-60a6-4deb-1fd0-84a3d98fe881" xlink:to="loc_us-gaap_CostOfRevenue_b362f93c-0412-ea6c-3d48-01ede1ed7f3f" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_ef2ac9e8-006f-b467-3389-9a8ceec4bee5" xlink:type="locator" />
<link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_76d25f63-60a6-4deb-1fd0-84a3d98fe881" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_ef2ac9e8-006f-b467-3389-9a8ceec4bee5" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SellingAndMarketingExpense" xlink:label="loc_us-gaap_SellingAndMarketingExpense_731c29d0-c256-edba-6ba9-ec31b7c2ca7b" xlink:type="locator" />
<link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_76d25f63-60a6-4deb-1fd0-84a3d98fe881" xlink:to="loc_us-gaap_SellingAndMarketingExpense_731c29d0-c256-edba-6ba9-ec31b7c2ca7b" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_58462a12-ec5e-da2d-89ad-2d8b2ce76259" xlink:type="locator" />
<link:calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_76d25f63-60a6-4deb-1fd0-84a3d98fe881" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_58462a12-ec5e-da2d-89ad-2d8b2ce76259" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="loc_us-gaap_FairValueAdjustmentOfWarrants_dcf39713-2bbe-ebf2-2d75-3bc1c2f5ba99" xlink:type="locator" />
<link:calculationArc order="2" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_489b61b6-7c39-240c-7f68-1c1675bca3b7" xlink:to="loc_us-gaap_FairValueAdjustmentOfWarrants_dcf39713-2bbe-ebf2-2d75-3bc1c2f5ba99" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdjustmentOfWarrantsGrantedForServices" xlink:label="loc_us-gaap_AdjustmentOfWarrantsGrantedForServices_2f904c20-67ab-dbad-e785-423ce21ac2c0" xlink:type="locator" />
<link:calculationArc order="3" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_489b61b6-7c39-240c-7f68-1c1675bca3b7" xlink:to="loc_us-gaap_AdjustmentOfWarrantsGrantedForServices_2f904c20-67ab-dbad-e785-423ce21ac2c0" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InterestExpense" xlink:label="loc_us-gaap_InterestExpense_16e9f6a6-5524-a7b1-7e7c-73ee97610ec6" xlink:type="locator" />
<link:calculationArc order="4" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_489b61b6-7c39-240c-7f68-1c1675bca3b7" xlink:to="loc_us-gaap_InterestExpense_16e9f6a6-5524-a7b1-7e7c-73ee97610ec6" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InterestAndOtherIncome" xlink:label="loc_us-gaap_InterestAndOtherIncome_96f7f20e-e49e-0553-3bc6-1ab6e52eead0" xlink:type="locator" />
<link:calculationArc order="5" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_489b61b6-7c39-240c-7f68-1c1675bca3b7" xlink:to="loc_us-gaap_InterestAndOtherIncome_96f7f20e-e49e-0553-3bc6-1ab6e52eead0" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_d385978f-69ad-b055-896a-51e9bbc23743" xlink:type="locator" />
<link:calculationArc order="6" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_489b61b6-7c39-240c-7f68-1c1675bca3b7" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_d385978f-69ad-b055-896a-51e9bbc23743" xlink:type="arc" />
<link:loc xlink:href="immu-20191231.xsd#immu_OtherFinancingExpenseIncome" xlink:label="loc_immu_OtherFinancingExpenseIncome_4b6728b9-84e7-6977-4766-d1d029f38fe4" xlink:type="locator" />
<link:calculationArc order="7" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_489b61b6-7c39-240c-7f68-1c1675bca3b7" xlink:to="loc_immu_OtherFinancingExpenseIncome_4b6728b9-84e7-6977-4766-d1d029f38fe4" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GainOnBusinessInterruptionInsuranceRecovery" xlink:label="loc_us-gaap_GainOnBusinessInterruptionInsuranceRecovery_0b694126-6834-dff2-98d9-42194c90297c" xlink:type="locator" />
<link:calculationArc order="8" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_489b61b6-7c39-240c-7f68-1c1675bca3b7" xlink:to="loc_us-gaap_GainOnBusinessInterruptionInsuranceRecovery_0b694126-6834-dff2-98d9-42194c90297c" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:label="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_96cf6261-5089-1df3-fbfc-c8c8918673b4" xlink:type="locator" />
<link:calculationArc order="9" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_489b61b6-7c39-240c-7f68-1c1675bca3b7" xlink:to="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_96cf6261-5089-1df3-fbfc-c8c8918673b4" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_666ca9f0-28f1-b21a-025e-36222808a6c3" xlink:type="locator" />
<link:calculationArc order="2" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ProfitLoss_8b582348-a62e-cdfb-bc53-d5894b42e091" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_666ca9f0-28f1-b21a-025e-36222808a6c3" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_a3a6becb-cb5c-3f3c-51b9-6edd8011ed69" xlink:type="locator" />
<link:calculationArc order="2" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_e170ce1e-c3a8-e8ee-88b0-37e8dd7b1d11" xlink:to="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_a3a6becb-cb5c-3f3c-51b9-6edd8011ed69" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_5c8b3520-1ca2-0a91-0912-70d62831826c" xlink:type="locator" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_c4761fa8-dc2a-e270-4b5c-921deca83ad0" xlink:type="locator" />
<link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_5c8b3520-1ca2-0a91-0912-70d62831826c" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_c4761fa8-dc2a-e270-4b5c-921deca83ad0" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_51cce957-7438-47fa-f5b3-33f2b5e56016" xlink:type="locator" />
<link:calculationArc order="2" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_5c8b3520-1ca2-0a91-0912-70d62831826c" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_51cce957-7438-47fa-f5b3-33f2b5e56016" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_1ed26a82-dd4b-490f-d61a-b04c5d44793e" xlink:type="locator" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_68a2669c-01f8-c962-bf95-0b4231cd45da" xlink:type="locator" />
<link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_1ed26a82-dd4b-490f-d61a-b04c5d44793e" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_68a2669c-01f8-c962-bf95-0b4231cd45da" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_e88bd855-1cc4-7d92-7586-c29e344f0391" xlink:type="locator" />
<link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_1ed26a82-dd4b-490f-d61a-b04c5d44793e" xlink:to="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_e88bd855-1cc4-7d92-7586-c29e344f0391" xlink:type="arc" />
</link:calculationLink>
<link:calculationLink xlink:role="http://www.immunomedics.com/role/CoverPage" xlink:type="extended" />
<link:calculationLink xlink:role="http://www.immunomedics.com/role/Debt" xlink:type="extended" />
<link:calculationLink xlink:role="http://www.immunomedics.com/role/DebtConsiderationAllocationDetails" xlink:type="extended" />
<link:calculationLink xlink:role="http://www.immunomedics.com/role/DebtConvertibleSeniorNotesDetails" xlink:type="extended" />
<link:calculationLink xlink:role="http://www.immunomedics.com/role/DebtLiabilityRelatedToSaleOfFutureRoyaltiesDetails" xlink:type="extended" />
<link:calculationLink xlink:role="http://www.immunomedics.com/role/DebtScheduleOfLiabilityRelatedToSaleOfFutureRoyaltiesDetails" xlink:type="extended" />
<link:calculationLink xlink:role="http://www.immunomedics.com/role/DebtTables" xlink:type="extended" />
<link:calculationLink xlink:role="http://www.immunomedics.com/role/DefinedContributionPlans" xlink:type="extended" />
<link:calculationLink xlink:role="http://www.immunomedics.com/role/DefinedContributionPlansDetails" xlink:type="extended" />
<link:calculationLink xlink:role="http://www.immunomedics.com/role/EstimatedFairValueOfFinancialInstruments" xlink:type="extended" />
<link:calculationLink xlink:role="http://www.immunomedics.com/role/EstimatedFairValueOfFinancialInstrumentsDebtInstrumentsDetails" xlink:type="extended" />
<link:calculationLink xlink:role="http://www.immunomedics.com/role/EstimatedFairValueOfFinancialInstrumentsNarrativeDetails" xlink:type="extended">
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsFairValueDisclosure" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_a0a5801b-c8ce-1793-dd5f-edbcde4cc5a3" xlink:type="locator" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_554f95d2-cb4f-eb2c-68b3-7e12c8578a72" xlink:type="locator" />
<link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsFairValueDisclosure_a0a5801b-c8ce-1793-dd5f-edbcde4cc5a3" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_554f95d2-cb4f-eb2c-68b3-7e12c8578a72" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_e562c48b-3e99-2c57-8e96-c3b81056b58c" xlink:type="locator" />
<link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsFairValueDisclosure_a0a5801b-c8ce-1793-dd5f-edbcde4cc5a3" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_e562c48b-3e99-2c57-8e96-c3b81056b58c" xlink:type="arc" />
</link:calculationLink>
<link:calculationLink xlink:role="http://www.immunomedics.com/role/EstimatedFairValueOfFinancialInstrumentsTables" xlink:type="extended" />
<link:calculationLink xlink:role="http://www.immunomedics.com/role/IncomeTaxes" xlink:type="extended" />
<link:calculationLink xlink:role="http://www.immunomedics.com/role/IncomeTaxesChangeInUnrecognizedTaxBenefitsDetails" xlink:type="extended" />
<link:calculationLink xlink:role="http://www.immunomedics.com/role/IncomeTaxesExpenseBenefitFromIncomeTaxesDetails" xlink:type="extended">
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_666ca9f0-28f1-b21a-025e-36222808a6c3" xlink:type="locator" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StateAndLocalIncomeTaxExpenseBenefitContinuingOperations" xlink:label="loc_us-gaap_StateAndLocalIncomeTaxExpenseBenefitContinuingOperations_c5bea251-d8cc-63c6-2a45-28fbbaf81f71" xlink:type="locator" />
<link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_666ca9f0-28f1-b21a-025e-36222808a6c3" xlink:to="loc_us-gaap_StateAndLocalIncomeTaxExpenseBenefitContinuingOperations_c5bea251-d8cc-63c6-2a45-28fbbaf81f71" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:label="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_7f37ab3b-992e-e1ba-f578-2c503524d7e4" xlink:type="locator" />
<link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StateAndLocalIncomeTaxExpenseBenefitContinuingOperations_c5bea251-d8cc-63c6-2a45-28fbbaf81f71" xlink:to="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_7f37ab3b-992e-e1ba-f578-2c503524d7e4" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_ca5c17e6-16a0-bee8-1413-d316d82a8942" xlink:type="locator" />
<link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StateAndLocalIncomeTaxExpenseBenefitContinuingOperations_c5bea251-d8cc-63c6-2a45-28fbbaf81f71" xlink:to="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_ca5c17e6-16a0-bee8-1413-d316d82a8942" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ForeignIncomeTaxExpenseBenefitContinuingOperations" xlink:label="loc_us-gaap_ForeignIncomeTaxExpenseBenefitContinuingOperations_8feaf7d2-18e4-e500-3156-ff9a4033818b" xlink:type="locator" />
<link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_666ca9f0-28f1-b21a-025e-36222808a6c3" xlink:to="loc_us-gaap_ForeignIncomeTaxExpenseBenefitContinuingOperations_8feaf7d2-18e4-e500-3156-ff9a4033818b" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CurrentForeignTaxExpenseBenefit" xlink:label="loc_us-gaap_CurrentForeignTaxExpenseBenefit_dbb037c2-04c0-fa14-65e6-8ccd12d2a855" xlink:type="locator" />
<link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ForeignIncomeTaxExpenseBenefitContinuingOperations_8feaf7d2-18e4-e500-3156-ff9a4033818b" xlink:to="loc_us-gaap_CurrentForeignTaxExpenseBenefit_dbb037c2-04c0-fa14-65e6-8ccd12d2a855" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredForeignIncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_DeferredForeignIncomeTaxExpenseBenefit_8caef893-a841-2be2-863f-e20b53026f02" xlink:type="locator" />
<link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ForeignIncomeTaxExpenseBenefitContinuingOperations_8feaf7d2-18e4-e500-3156-ff9a4033818b" xlink:to="loc_us-gaap_DeferredForeignIncomeTaxExpenseBenefit_8caef893-a841-2be2-863f-e20b53026f02" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperations" xlink:label="loc_us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperations_c4db70dd-653d-338f-7465-7cd2417ef806" xlink:type="locator" />
<link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_666ca9f0-28f1-b21a-025e-36222808a6c3" xlink:to="loc_us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperations_c4db70dd-653d-338f-7465-7cd2417ef806" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CurrentFederalTaxExpenseBenefit" xlink:label="loc_us-gaap_CurrentFederalTaxExpenseBenefit_1007d9fe-6d83-c6c6-eef9-c29803b14ec7" xlink:type="locator" />
<link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperations_c4db70dd-653d-338f-7465-7cd2417ef806" xlink:to="loc_us-gaap_CurrentFederalTaxExpenseBenefit_1007d9fe-6d83-c6c6-eef9-c29803b14ec7" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_db02e614-93e7-eddf-abe0-a58cca48e685" xlink:type="locator" />
<link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperations_c4db70dd-653d-338f-7465-7cd2417ef806" xlink:to="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_db02e614-93e7-eddf-abe0-a58cca48e685" xlink:type="arc" />
</link:calculationLink>
<link:calculationLink xlink:role="http://www.immunomedics.com/role/IncomeTaxesNarrativeDetails" xlink:type="extended" />
<link:calculationLink xlink:role="http://www.immunomedics.com/role/IncomeTaxesReconciliationOfStatutoryTaxRatesAndEffectiveTaxRatesDetails" xlink:type="extended">
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_aa9fb8cf-e50d-6d5b-0236-a084fee29894" xlink:type="locator" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_5ef0c8c5-04c5-1c10-a59e-3eaa9cf923b4" xlink:type="locator" />
<link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_aa9fb8cf-e50d-6d5b-0236-a084fee29894" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_5ef0c8c5-04c5-1c10-a59e-3eaa9cf923b4" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_cb745973-9398-b1e8-0b84-89b40fb91052" xlink:type="locator" />
<link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_aa9fb8cf-e50d-6d5b-0236-a084fee29894" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_cb745973-9398-b1e8-0b84-89b40fb91052" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_77b9f787-6596-82cb-4698-f0991c80113b" xlink:type="locator" />
<link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_aa9fb8cf-e50d-6d5b-0236-a084fee29894" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_77b9f787-6596-82cb-4698-f0991c80113b" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_fa285cf0-c43f-6ef0-a0f2-c37d958f2fe4" xlink:type="locator" />
<link:calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_aa9fb8cf-e50d-6d5b-0236-a084fee29894" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_fa285cf0-c43f-6ef0-a0f2-c37d958f2fe4" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense_d9df7d3d-b9dd-e868-b078-e2e03ba315bc" xlink:type="locator" />
<link:calculationArc order="5" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_aa9fb8cf-e50d-6d5b-0236-a084fee29894" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense_d9df7d3d-b9dd-e868-b078-e2e03ba315bc" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent_816488b8-0d56-395f-9159-c39b85761bc4" xlink:type="locator" />
<link:calculationArc order="6" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_aa9fb8cf-e50d-6d5b-0236-a084fee29894" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent_816488b8-0d56-395f-9159-c39b85761bc4" xlink:type="arc" />
</link:calculationLink>
<link:calculationLink xlink:role="http://www.immunomedics.com/role/IncomeTaxesTables" xlink:type="extended" />
<link:calculationLink xlink:role="http://www.immunomedics.com/role/IncomeTaxesTaxEffectsOfTemporaryDifferencesInDeferredTaxAssetsDetails" xlink:type="extended">
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:label="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_0bdbea13-bfd8-228d-43ea-fae0c1330aaa" xlink:type="locator" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="loc_us-gaap_DeferredTaxAssetsNet_e6f5d9f5-2430-5e17-896c-5e4d69815366" xlink:type="locator" />
<link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_0bdbea13-bfd8-228d-43ea-fae0c1330aaa" xlink:to="loc_us-gaap_DeferredTaxAssetsNet_e6f5d9f5-2430-5e17-896c-5e4d69815366" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_55b78dfc-faa8-3c71-752a-e6857318d516" xlink:type="locator" />
<link:calculationArc order="1" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsNet_e6f5d9f5-2430-5e17-896c-5e4d69815366" xlink:to="loc_us-gaap_DeferredTaxAssetsValuationAllowance_55b78dfc-faa8-3c71-752a-e6857318d516" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="loc_us-gaap_DeferredTaxAssetsGross_e54f6543-25d5-ceb9-ff71-ca6ba1b37623" xlink:type="locator" />
<link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsNet_e6f5d9f5-2430-5e17-896c-5e4d69815366" xlink:to="loc_us-gaap_DeferredTaxAssetsGross_e54f6543-25d5-ceb9-ff71-ca6ba1b37623" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_bc5d002e-802f-bf1e-7d7d-9f1d1a7551a7" xlink:type="locator" />
<link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_e54f6543-25d5-ceb9-ff71-ca6ba1b37623" xlink:to="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_bc5d002e-802f-bf1e-7d7d-9f1d1a7551a7" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_2923c663-d6ea-ecbc-ca18-63a6f8140ce1" xlink:type="locator" />
<link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_e54f6543-25d5-ceb9-ff71-ca6ba1b37623" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_2923c663-d6ea-ecbc-ca18-63a6f8140ce1" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxAssetsDeferredIncome" xlink:label="loc_us-gaap_DeferredTaxAssetsDeferredIncome_646908de-2c79-6268-8484-e0575f967d9d" xlink:type="locator" />
<link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_e54f6543-25d5-ceb9-ff71-ca6ba1b37623" xlink:to="loc_us-gaap_DeferredTaxAssetsDeferredIncome_646908de-2c79-6268-8484-e0575f967d9d" xlink:type="arc" />
<link:loc xlink:href="immu-20191231.xsd#immu_DeferredTaxAssetDisallowedInterestExpense" xlink:label="loc_immu_DeferredTaxAssetDisallowedInterestExpense_4BB07B508D7AF6CC90DF456EC4380078" xlink:type="locator" />
<link:calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_e54f6543-25d5-ceb9-ff71-ca6ba1b37623" xlink:to="loc_immu_DeferredTaxAssetDisallowedInterestExpense_4BB07B508D7AF6CC90DF456EC4380078" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxAssetsOther" xlink:label="loc_us-gaap_DeferredTaxAssetsOther_a87b79d6-1ed8-a71d-1843-5c0769713f28" xlink:type="locator" />
<link:calculationArc order="5" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_e54f6543-25d5-ceb9-ff71-ca6ba1b37623" xlink:to="loc_us-gaap_DeferredTaxAssetsOther_a87b79d6-1ed8-a71d-1843-5c0769713f28" xlink:type="arc" />
<link:loc xlink:href="immu-20191231.xsd#immu_DeferredTaxAssetsDeferredRevenue" xlink:label="loc_immu_DeferredTaxAssetsDeferredRevenue_95386FA8D493428D8712456DA518392A" xlink:type="locator" />
<link:calculationArc order="6" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_e54f6543-25d5-ceb9-ff71-ca6ba1b37623" xlink:to="loc_immu_DeferredTaxAssetsDeferredRevenue_95386FA8D493428D8712456DA518392A" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_fee9ac69-74b7-a6ae-6ad8-e6860d7cdb9d" xlink:type="locator" />
<link:calculationArc order="2" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_0bdbea13-bfd8-228d-43ea-fae0c1330aaa" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_fee9ac69-74b7-a6ae-6ad8-e6860d7cdb9d" xlink:type="arc" />
</link:calculationLink>
<link:calculationLink xlink:role="http://www.immunomedics.com/role/MarketableSecurities" xlink:type="extended" />
<link:calculationLink xlink:role="http://www.immunomedics.com/role/MarketableSecuritiesAmortizedCostToFairValueDetails" xlink:type="extended">
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_27940abc-0cb4-eab4-8ef0-df4a4c0bb415" xlink:type="locator" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_9fbaf9cb-468f-3b91-9cf2-18d26152173d" xlink:type="locator" />
<link:calculationArc order="1" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_27940abc-0cb4-eab4-8ef0-df4a4c0bb415" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_9fbaf9cb-468f-3b91-9cf2-18d26152173d" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_a23ab896-034e-8e96-1a84-63ffb40e496e" xlink:type="locator" />
<link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_27940abc-0cb4-eab4-8ef0-df4a4c0bb415" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_a23ab896-034e-8e96-1a84-63ffb40e496e" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_e562c48b-3e99-2c57-8e96-c3b81056b58c" xlink:type="locator" />
<link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_27940abc-0cb4-eab4-8ef0-df4a4c0bb415" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_e562c48b-3e99-2c57-8e96-c3b81056b58c" xlink:type="arc" />
</link:calculationLink>
<link:calculationLink xlink:role="http://www.immunomedics.com/role/MarketableSecuritiesTables" xlink:type="extended" />
<link:calculationLink xlink:role="http://www.immunomedics.com/role/PropertyAndEquipment" xlink:type="extended" />
<link:calculationLink xlink:role="http://www.immunomedics.com/role/PropertyAndEquipmentAdditionalInformationDetails" xlink:type="extended" />
<link:calculationLink xlink:role="http://www.immunomedics.com/role/PropertyAndEquipmentSchedulesOfPropertyAndEquipmentDetails" xlink:type="extended">
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_4246ec24-1a4c-19dd-57c9-32d4a8e0cbaa" xlink:type="locator" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_94cd7971-9d17-1c6e-6642-d4d38fb682b6" xlink:type="locator" />
<link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet_4246ec24-1a4c-19dd-57c9-32d4a8e0cbaa" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_94cd7971-9d17-1c6e-6642-d4d38fb682b6" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_7b7a3a8d-eb3d-0c85-68cc-b3d4d184ff23" xlink:type="locator" />
<link:calculationArc order="2" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet_4246ec24-1a4c-19dd-57c9-32d4a8e0cbaa" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_7b7a3a8d-eb3d-0c85-68cc-b3d4d184ff23" xlink:type="arc" />
<link:loc xlink:href="immu-20191231.xsd#immu_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization" xlink:label="loc_immu_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization_D5529FD1947BDD014A4D6366EC59CD19" xlink:type="locator" />
<link:loc xlink:href="immu-20191231.xsd#immu_PropertyPlantAndEquipmentAndFinanceLeaseRightofUseAssetBeforeAccumulatedDepreciationAndAmortization" xlink:label="loc_immu_PropertyPlantAndEquipmentAndFinanceLeaseRightofUseAssetBeforeAccumulatedDepreciationAndAmortization_2CF57464F3A78B69C078636461040C82" xlink:type="locator" />
<link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_immu_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization_D5529FD1947BDD014A4D6366EC59CD19" xlink:to="loc_immu_PropertyPlantAndEquipmentAndFinanceLeaseRightofUseAssetBeforeAccumulatedDepreciationAndAmortization_2CF57464F3A78B69C078636461040C82" xlink:type="arc" />
<link:loc xlink:href="immu-20191231.xsd#immu_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization" xlink:label="loc_immu_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization_21914AAA6A2EEE46674F6365C4FAF75E" xlink:type="locator" />
<link:calculationArc order="2" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_immu_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization_D5529FD1947BDD014A4D6366EC59CD19" xlink:to="loc_immu_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization_21914AAA6A2EEE46674F6365C4FAF75E" xlink:type="arc" />
</link:calculationLink>
<link:calculationLink xlink:role="http://www.immunomedics.com/role/PropertyAndEquipmentTables" xlink:type="extended" />
<link:calculationLink xlink:role="http://www.immunomedics.com/role/QuarterlyResultsOfOperationsDetails" xlink:type="extended" />
<link:calculationLink xlink:role="http://www.immunomedics.com/role/QuarterlyResultsOfOperationsTables" xlink:type="extended" />
<link:calculationLink xlink:role="http://www.immunomedics.com/role/QuarterlyResultsOfOperationsUnaudited" xlink:type="extended" />
<link:calculationLink xlink:role="http://www.immunomedics.com/role/RelatedPartyTransactions" xlink:type="extended" />
<link:calculationLink xlink:role="http://www.immunomedics.com/role/RelatedPartyTransactionsDetails" xlink:type="extended" />
<link:calculationLink xlink:role="http://www.immunomedics.com/role/RevenueRecognition" xlink:type="extended" />
<link:calculationLink xlink:role="http://www.immunomedics.com/role/RevenueRecognitionAdditionalInformationDetails" xlink:type="extended" />
<link:calculationLink xlink:role="http://www.immunomedics.com/role/RevenueRecognitionPerformanceObligationDetails" xlink:type="extended" />
<link:calculationLink xlink:role="http://www.immunomedics.com/role/StockBasedCompensation" xlink:type="extended" />
<link:calculationLink xlink:role="http://www.immunomedics.com/role/StockBasedCompensationFairValueAssumptionsDetails" xlink:type="extended" />
<link:calculationLink xlink:role="http://www.immunomedics.com/role/StockBasedCompensationNarrativeDetails" xlink:type="extended" />
<link:calculationLink xlink:role="http://www.immunomedics.com/role/StockBasedCompensationRestrictedStockUnitActivityDetails" xlink:type="extended" />
<link:calculationLink xlink:role="http://www.immunomedics.com/role/StockBasedCompensationStockIncentivePlanDetails" xlink:type="extended" />
<link:calculationLink xlink:role="http://www.immunomedics.com/role/StockBasedCompensationStockOptionActivityDetails" xlink:type="extended" />
<link:calculationLink xlink:role="http://www.immunomedics.com/role/StockBasedCompensationTables" xlink:type="extended" />
<link:calculationLink xlink:role="http://www.immunomedics.com/role/StockholdersEquity" xlink:type="extended" />
<link:calculationLink xlink:role="http://www.immunomedics.com/role/StockholdersEquityDetails" xlink:type="extended" />
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>12
<FILENAME>immu-20191231_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!--XBRL Document Created with Wdesk from Workiva-->
<!-- -->
<link:linkbase xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<link:roleRef roleURI="http://www.immunomedics.com/role/AccountsPayableAndAccruedExpenses" xlink:href="immu-20191231.xsd#AccountsPayableAndAccruedExpenses" xlink:type="simple" />
<link:roleRef roleURI="http://www.immunomedics.com/role/AccountsPayableAndAccruedExpensesDetails" xlink:href="immu-20191231.xsd#AccountsPayableAndAccruedExpensesDetails" xlink:type="simple" />
<link:roleRef roleURI="http://www.immunomedics.com/role/AccountsPayableAndAccruedExpensesTables" xlink:href="immu-20191231.xsd#AccountsPayableAndAccruedExpensesTables" xlink:type="simple" />
<link:roleRef roleURI="http://www.immunomedics.com/role/AccumulatedOtherComprehensiveLossIncome" xlink:href="immu-20191231.xsd#AccumulatedOtherComprehensiveLossIncome" xlink:type="simple" />
<link:roleRef roleURI="http://www.immunomedics.com/role/AccumulatedOtherComprehensiveLossIncomeDetails" xlink:href="immu-20191231.xsd#AccumulatedOtherComprehensiveLossIncomeDetails" xlink:type="simple" />
<link:roleRef roleURI="http://www.immunomedics.com/role/AccumulatedOtherComprehensiveLossIncomeTables" xlink:href="immu-20191231.xsd#AccumulatedOtherComprehensiveLossIncomeTables" xlink:type="simple" />
<link:roleRef roleURI="http://www.immunomedics.com/role/BusinessOverviewAndSummaryOfSignificantAccountingPolices" xlink:href="immu-20191231.xsd#BusinessOverviewAndSummaryOfSignificantAccountingPolices" xlink:type="simple" />
<link:roleRef roleURI="http://www.immunomedics.com/role/BusinessOverviewAndSummaryOfSignificantAccountingPolicesRecentAccountingPronouncementsDetails" xlink:href="immu-20191231.xsd#BusinessOverviewAndSummaryOfSignificantAccountingPolicesRecentAccountingPronouncementsDetails" xlink:type="simple" />
<link:roleRef roleURI="http://www.immunomedics.com/role/BusinessOverviewSummaryOfSignificantAccountingPolicesPolicies" xlink:href="immu-20191231.xsd#BusinessOverviewSummaryOfSignificantAccountingPolicesPolicies" xlink:type="simple" />
<link:roleRef roleURI="http://www.immunomedics.com/role/CollaborationAgreements" xlink:href="immu-20191231.xsd#CollaborationAgreements" xlink:type="simple" />
<link:roleRef roleURI="http://www.immunomedics.com/role/CollaborationAgreementsDetails" xlink:href="immu-20191231.xsd#CollaborationAgreementsDetails" xlink:type="simple" />
<link:roleRef roleURI="http://www.immunomedics.com/role/CommitmentsAndContingencies" xlink:href="immu-20191231.xsd#CommitmentsAndContingencies" xlink:type="simple" />
<link:roleRef roleURI="http://www.immunomedics.com/role/CommitmentsAndContingenciesMaturitiesOfLeaseLiabilitiesDetails" xlink:href="immu-20191231.xsd#CommitmentsAndContingenciesMaturitiesOfLeaseLiabilitiesDetails" xlink:type="simple" />
<link:roleRef roleURI="http://www.immunomedics.com/role/CommitmentsAndContingenciesNarrativeDetails" xlink:href="immu-20191231.xsd#CommitmentsAndContingenciesNarrativeDetails" xlink:type="simple" />
<link:roleRef roleURI="http://www.immunomedics.com/role/CommitmentsAndContingenciesSupplementalConsolidatedBalanceSheetInformationRelatedToLeasesDetails" xlink:href="immu-20191231.xsd#CommitmentsAndContingenciesSupplementalConsolidatedBalanceSheetInformationRelatedToLeasesDetails" xlink:type="simple" />
<link:roleRef roleURI="http://www.immunomedics.com/role/CommitmentsAndContingenciesTables" xlink:href="immu-20191231.xsd#CommitmentsAndContingenciesTables" xlink:type="simple" />
<link:roleRef roleURI="http://www.immunomedics.com/role/ConsolidatedBalanceSheets" xlink:href="immu-20191231.xsd#ConsolidatedBalanceSheets" xlink:type="simple" />
<link:roleRef roleURI="http://www.immunomedics.com/role/ConsolidatedBalanceSheetsParenthetical" xlink:href="immu-20191231.xsd#ConsolidatedBalanceSheetsParenthetical" xlink:type="simple" />
<link:roleRef roleURI="http://www.immunomedics.com/role/ConsolidatedStatementsOfCashFlows" xlink:href="immu-20191231.xsd#ConsolidatedStatementsOfCashFlows" xlink:type="simple" />
<link:roleRef roleURI="http://www.immunomedics.com/role/ConsolidatedStatementsOfChangesInStockholdersEquity" xlink:href="immu-20191231.xsd#ConsolidatedStatementsOfChangesInStockholdersEquity" xlink:type="simple" />
<link:roleRef roleURI="http://www.immunomedics.com/role/ConsolidatedStatementsOfComprehensiveLoss" xlink:href="immu-20191231.xsd#ConsolidatedStatementsOfComprehensiveLoss" xlink:type="simple" />
<link:roleRef roleURI="http://www.immunomedics.com/role/CoverPage" xlink:href="immu-20191231.xsd#CoverPage" xlink:type="simple" />
<link:roleRef roleURI="http://www.immunomedics.com/role/Debt" xlink:href="immu-20191231.xsd#Debt" xlink:type="simple" />
<link:roleRef roleURI="http://www.immunomedics.com/role/DebtConsiderationAllocationDetails" xlink:href="immu-20191231.xsd#DebtConsiderationAllocationDetails" xlink:type="simple" />
<link:roleRef roleURI="http://www.immunomedics.com/role/DebtConvertibleSeniorNotesDetails" xlink:href="immu-20191231.xsd#DebtConvertibleSeniorNotesDetails" xlink:type="simple" />
<link:roleRef roleURI="http://www.immunomedics.com/role/DebtLiabilityRelatedToSaleOfFutureRoyaltiesDetails" xlink:href="immu-20191231.xsd#DebtLiabilityRelatedToSaleOfFutureRoyaltiesDetails" xlink:type="simple" />
<link:roleRef roleURI="http://www.immunomedics.com/role/DebtScheduleOfLiabilityRelatedToSaleOfFutureRoyaltiesDetails" xlink:href="immu-20191231.xsd#DebtScheduleOfLiabilityRelatedToSaleOfFutureRoyaltiesDetails" xlink:type="simple" />
<link:roleRef roleURI="http://www.immunomedics.com/role/DebtTables" xlink:href="immu-20191231.xsd#DebtTables" xlink:type="simple" />
<link:roleRef roleURI="http://www.immunomedics.com/role/DefinedContributionPlans" xlink:href="immu-20191231.xsd#DefinedContributionPlans" xlink:type="simple" />
<link:roleRef roleURI="http://www.immunomedics.com/role/DefinedContributionPlansDetails" xlink:href="immu-20191231.xsd#DefinedContributionPlansDetails" xlink:type="simple" />
<link:roleRef roleURI="http://www.immunomedics.com/role/EstimatedFairValueOfFinancialInstruments" xlink:href="immu-20191231.xsd#EstimatedFairValueOfFinancialInstruments" xlink:type="simple" />
<link:roleRef roleURI="http://www.immunomedics.com/role/EstimatedFairValueOfFinancialInstrumentsDebtInstrumentsDetails" xlink:href="immu-20191231.xsd#EstimatedFairValueOfFinancialInstrumentsDebtInstrumentsDetails" xlink:type="simple" />
<link:roleRef roleURI="http://www.immunomedics.com/role/EstimatedFairValueOfFinancialInstrumentsNarrativeDetails" xlink:href="immu-20191231.xsd#EstimatedFairValueOfFinancialInstrumentsNarrativeDetails" xlink:type="simple" />
<link:roleRef roleURI="http://www.immunomedics.com/role/EstimatedFairValueOfFinancialInstrumentsTables" xlink:href="immu-20191231.xsd#EstimatedFairValueOfFinancialInstrumentsTables" xlink:type="simple" />
<link:roleRef roleURI="http://www.immunomedics.com/role/IncomeTaxes" xlink:href="immu-20191231.xsd#IncomeTaxes" xlink:type="simple" />
<link:roleRef roleURI="http://www.immunomedics.com/role/IncomeTaxesChangeInUnrecognizedTaxBenefitsDetails" xlink:href="immu-20191231.xsd#IncomeTaxesChangeInUnrecognizedTaxBenefitsDetails" xlink:type="simple" />
<link:roleRef roleURI="http://www.immunomedics.com/role/IncomeTaxesExpenseBenefitFromIncomeTaxesDetails" xlink:href="immu-20191231.xsd#IncomeTaxesExpenseBenefitFromIncomeTaxesDetails" xlink:type="simple" />
<link:roleRef roleURI="http://www.immunomedics.com/role/IncomeTaxesNarrativeDetails" xlink:href="immu-20191231.xsd#IncomeTaxesNarrativeDetails" xlink:type="simple" />
<link:roleRef roleURI="http://www.immunomedics.com/role/IncomeTaxesReconciliationOfStatutoryTaxRatesAndEffectiveTaxRatesDetails" xlink:href="immu-20191231.xsd#IncomeTaxesReconciliationOfStatutoryTaxRatesAndEffectiveTaxRatesDetails" xlink:type="simple" />
<link:roleRef roleURI="http://www.immunomedics.com/role/IncomeTaxesTables" xlink:href="immu-20191231.xsd#IncomeTaxesTables" xlink:type="simple" />
<link:roleRef roleURI="http://www.immunomedics.com/role/IncomeTaxesTaxEffectsOfTemporaryDifferencesInDeferredTaxAssetsDetails" xlink:href="immu-20191231.xsd#IncomeTaxesTaxEffectsOfTemporaryDifferencesInDeferredTaxAssetsDetails" xlink:type="simple" />
<link:roleRef roleURI="http://www.immunomedics.com/role/MarketableSecurities" xlink:href="immu-20191231.xsd#MarketableSecurities" xlink:type="simple" />
<link:roleRef roleURI="http://www.immunomedics.com/role/MarketableSecuritiesAmortizedCostToFairValueDetails" xlink:href="immu-20191231.xsd#MarketableSecuritiesAmortizedCostToFairValueDetails" xlink:type="simple" />
<link:roleRef roleURI="http://www.immunomedics.com/role/MarketableSecuritiesTables" xlink:href="immu-20191231.xsd#MarketableSecuritiesTables" xlink:type="simple" />
<link:roleRef roleURI="http://www.immunomedics.com/role/PropertyAndEquipment" xlink:href="immu-20191231.xsd#PropertyAndEquipment" xlink:type="simple" />
<link:roleRef roleURI="http://www.immunomedics.com/role/PropertyAndEquipmentAdditionalInformationDetails" xlink:href="immu-20191231.xsd#PropertyAndEquipmentAdditionalInformationDetails" xlink:type="simple" />
<link:roleRef roleURI="http://www.immunomedics.com/role/PropertyAndEquipmentSchedulesOfPropertyAndEquipmentDetails" xlink:href="immu-20191231.xsd#PropertyAndEquipmentSchedulesOfPropertyAndEquipmentDetails" xlink:type="simple" />
<link:roleRef roleURI="http://www.immunomedics.com/role/PropertyAndEquipmentTables" xlink:href="immu-20191231.xsd#PropertyAndEquipmentTables" xlink:type="simple" />
<link:roleRef roleURI="http://www.immunomedics.com/role/QuarterlyResultsOfOperationsDetails" xlink:href="immu-20191231.xsd#QuarterlyResultsOfOperationsDetails" xlink:type="simple" />
<link:roleRef roleURI="http://www.immunomedics.com/role/QuarterlyResultsOfOperationsTables" xlink:href="immu-20191231.xsd#QuarterlyResultsOfOperationsTables" xlink:type="simple" />
<link:roleRef roleURI="http://www.immunomedics.com/role/QuarterlyResultsOfOperationsUnaudited" xlink:href="immu-20191231.xsd#QuarterlyResultsOfOperationsUnaudited" xlink:type="simple" />
<link:roleRef roleURI="http://www.immunomedics.com/role/RelatedPartyTransactions" xlink:href="immu-20191231.xsd#RelatedPartyTransactions" xlink:type="simple" />
<link:roleRef roleURI="http://www.immunomedics.com/role/RelatedPartyTransactionsDetails" xlink:href="immu-20191231.xsd#RelatedPartyTransactionsDetails" xlink:type="simple" />
<link:roleRef roleURI="http://www.immunomedics.com/role/RevenueRecognition" xlink:href="immu-20191231.xsd#RevenueRecognition" xlink:type="simple" />
<link:roleRef roleURI="http://www.immunomedics.com/role/RevenueRecognitionAdditionalInformationDetails" xlink:href="immu-20191231.xsd#RevenueRecognitionAdditionalInformationDetails" xlink:type="simple" />
<link:roleRef roleURI="http://www.immunomedics.com/role/RevenueRecognitionPerformanceObligationDetails" xlink:href="immu-20191231.xsd#RevenueRecognitionPerformanceObligationDetails" xlink:type="simple" />
<link:roleRef roleURI="http://www.immunomedics.com/role/StockBasedCompensation" xlink:href="immu-20191231.xsd#StockBasedCompensation" xlink:type="simple" />
<link:roleRef roleURI="http://www.immunomedics.com/role/StockBasedCompensationFairValueAssumptionsDetails" xlink:href="immu-20191231.xsd#StockBasedCompensationFairValueAssumptionsDetails" xlink:type="simple" />
<link:roleRef roleURI="http://www.immunomedics.com/role/StockBasedCompensationNarrativeDetails" xlink:href="immu-20191231.xsd#StockBasedCompensationNarrativeDetails" xlink:type="simple" />
<link:roleRef roleURI="http://www.immunomedics.com/role/StockBasedCompensationRestrictedStockUnitActivityDetails" xlink:href="immu-20191231.xsd#StockBasedCompensationRestrictedStockUnitActivityDetails" xlink:type="simple" />
<link:roleRef roleURI="http://www.immunomedics.com/role/StockBasedCompensationStockIncentivePlanDetails" xlink:href="immu-20191231.xsd#StockBasedCompensationStockIncentivePlanDetails" xlink:type="simple" />
<link:roleRef roleURI="http://www.immunomedics.com/role/StockBasedCompensationStockOptionActivityDetails" xlink:href="immu-20191231.xsd#StockBasedCompensationStockOptionActivityDetails" xlink:type="simple" />
<link:roleRef roleURI="http://www.immunomedics.com/role/StockBasedCompensationTables" xlink:href="immu-20191231.xsd#StockBasedCompensationTables" xlink:type="simple" />
<link:roleRef roleURI="http://www.immunomedics.com/role/StockholdersEquity" xlink:href="immu-20191231.xsd#StockholdersEquity" xlink:type="simple" />
<link:roleRef roleURI="http://www.immunomedics.com/role/StockholdersEquityDetails" xlink:href="immu-20191231.xsd#StockholdersEquityDetails" xlink:type="simple" />
<link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" xlink:type="simple" />
<link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" xlink:type="simple" />
<link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" xlink:type="simple" />
<link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" xlink:type="simple" />
<link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" xlink:type="simple" />
<link:definitionLink xlink:role="http://www.immunomedics.com/role/AccountsPayableAndAccruedExpenses" xlink:type="extended" />
<link:definitionLink xlink:role="http://www.immunomedics.com/role/AccountsPayableAndAccruedExpensesDetails" xlink:type="extended" />
<link:definitionLink xlink:role="http://www.immunomedics.com/role/AccountsPayableAndAccruedExpensesTables" xlink:type="extended" />
<link:definitionLink xlink:role="http://www.immunomedics.com/role/AccumulatedOtherComprehensiveLossIncome" xlink:type="extended" />
<link:definitionLink xlink:role="http://www.immunomedics.com/role/AccumulatedOtherComprehensiveLossIncomeDetails" xlink:type="extended">
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_505398F0237C88D0B7053991D1D137BA" xlink:type="locator" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_3BBAC288AE6ECCDEE78C3991D1D033F7" xlink:type="locator" />
<link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_505398F0237C88D0B7053991D1D137BA" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_3BBAC288AE6ECCDEE78C3991D1D033F7" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_8F4A9C99B2BD2E75E4673991D1D093C3" xlink:type="locator" />
<link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_3BBAC288AE6ECCDEE78C3991D1D033F7" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_8F4A9C99B2BD2E75E4673991D1D093C3" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_A65AA8620ED49C60D7BC3991D1D07596_default" xlink:type="locator" />
<link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_8F4A9C99B2BD2E75E4673991D1D093C3" xlink:to="loc_us-gaap_EquityComponentDomain_A65AA8620ED49C60D7BC3991D1D07596_default" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_A65AA8620ED49C60D7BC3991D1D07596" xlink:type="locator" />
<link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_8F4A9C99B2BD2E75E4673991D1D093C3" xlink:to="loc_us-gaap_EquityComponentDomain_A65AA8620ED49C60D7BC3991D1D07596" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedTranslationAdjustmentMember" xlink:label="loc_us-gaap_AccumulatedTranslationAdjustmentMember_6EDCE1B68C010B705DE93991D1D039F6" xlink:type="locator" />
<link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_A65AA8620ED49C60D7BC3991D1D07596" xlink:to="loc_us-gaap_AccumulatedTranslationAdjustmentMember_6EDCE1B68C010B705DE93991D1D039F6" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember" xlink:label="loc_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_FF154B1687E35F422C613991D1D12A2D" xlink:type="locator" />
<link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_A65AA8620ED49C60D7BC3991D1D07596" xlink:to="loc_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_FF154B1687E35F422C613991D1D12A2D" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_84072F3D901B8B44D7A03991D1D17A05" xlink:type="locator" />
<link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_A65AA8620ED49C60D7BC3991D1D07596" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_84072F3D901B8B44D7A03991D1D17A05" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AOCIAttributableToParentNetOfTaxRollForward" xlink:label="loc_us-gaap_AOCIAttributableToParentNetOfTaxRollForward_4B0B813418EB2CF10C613991D1D1B1B4" xlink:type="locator" />
<link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_505398F0237C88D0B7053991D1D137BA" xlink:to="loc_us-gaap_AOCIAttributableToParentNetOfTaxRollForward_4B0B813418EB2CF10C613991D1D1B1B4" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_A125CCF656771326A2323991D1D1DDAF" xlink:type="locator" />
<link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AOCIAttributableToParentNetOfTaxRollForward_4B0B813418EB2CF10C613991D1D1B1B4" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_A125CCF656771326A2323991D1D1DDAF" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax_8A5CC61054E0837D25143A207EFC16F3" xlink:type="locator" />
<link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AOCIAttributableToParentNetOfTaxRollForward_4B0B813418EB2CF10C613991D1D1B1B4" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax_8A5CC61054E0837D25143A207EFC16F3" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" xlink:label="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax_9E8518171A73EB4F66A63991D1D255A5" xlink:type="locator" />
<link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AOCIAttributableToParentNetOfTaxRollForward_4B0B813418EB2CF10C613991D1D1B1B4" xlink:to="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax_9E8518171A73EB4F66A63991D1D255A5" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_6060EB093112DB3DA5573991D1D2EC4F" xlink:type="locator" />
<link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AOCIAttributableToParentNetOfTaxRollForward_4B0B813418EB2CF10C613991D1D1B1B4" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_6060EB093112DB3DA5573991D1D2EC4F" xlink:type="arc" />
</link:definitionLink>
<link:definitionLink xlink:role="http://www.immunomedics.com/role/AccumulatedOtherComprehensiveLossIncomeTables" xlink:type="extended" />
<link:definitionLink xlink:role="http://www.immunomedics.com/role/BusinessOverviewAndSummaryOfSignificantAccountingPolices" xlink:type="extended" />
<link:definitionLink xlink:role="http://www.immunomedics.com/role/BusinessOverviewAndSummaryOfSignificantAccountingPolicesRecentAccountingPronouncementsDetails" xlink:type="extended">
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeLeaseDescriptionLineItems" xlink:label="loc_us-gaap_LesseeLeaseDescriptionLineItems_69767A1FF71C85471FDB5EDE15325B15" xlink:type="locator" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeLeaseDescriptionTable" xlink:label="loc_us-gaap_LesseeLeaseDescriptionTable_17BF163483C2B2821FAA5EDE152E7FC6" xlink:type="locator" />
<link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_69767A1FF71C85471FDB5EDE15325B15" xlink:to="loc_us-gaap_LesseeLeaseDescriptionTable_17BF163483C2B2821FAA5EDE152E7FC6" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_5F6744B6A7FFB94AFF245EDE152F1776" xlink:type="locator" />
<link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_17BF163483C2B2821FAA5EDE152E7FC6" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_5F6744B6A7FFB94AFF245EDE152F1776" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_1E0814C45C37E775B45C5EDE152FD575_default" xlink:type="locator" />
<link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_5F6744B6A7FFB94AFF245EDE152F1776" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_1E0814C45C37E775B45C5EDE152FD575_default" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_1E0814C45C37E775B45C5EDE152FD575" xlink:type="locator" />
<link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_5F6744B6A7FFB94AFF245EDE152F1776" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_1E0814C45C37E775B45C5EDE152FD575" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="loc_us-gaap_LeaseholdImprovementsMember_A7190697615A690D6D285EDE152FDC79" xlink:type="locator" />
<link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_1E0814C45C37E775B45C5EDE152FD575" xlink:to="loc_us-gaap_LeaseholdImprovementsMember_A7190697615A690D6D285EDE152FDC79" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ComputerEquipmentMember" xlink:label="loc_us-gaap_ComputerEquipmentMember_7D14B48447A448395C1F5EDE1530698B" xlink:type="locator" />
<link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_1E0814C45C37E775B45C5EDE152FD575" xlink:to="loc_us-gaap_ComputerEquipmentMember_7D14B48447A448395C1F5EDE1530698B" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MachineryAndEquipmentMember" xlink:label="loc_us-gaap_MachineryAndEquipmentMember_3026492A25C588D58E395EDE1530464F" xlink:type="locator" />
<link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_1E0814C45C37E775B45C5EDE152FD575" xlink:to="loc_us-gaap_MachineryAndEquipmentMember_3026492A25C588D58E395EDE1530464F" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="loc_us-gaap_FurnitureAndFixturesMember_0453F08815378007D8575EDE1530A396" xlink:type="locator" />
<link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_1E0814C45C37E775B45C5EDE152FD575" xlink:to="loc_us-gaap_FurnitureAndFixturesMember_0453F08815378007D8575EDE1530A396" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_FCB8767D7C08743D3AFB5EDE1530454C" xlink:type="locator" />
<link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_17BF163483C2B2821FAA5EDE152E7FC6" xlink:to="loc_srt_RangeAxis_FCB8767D7C08743D3AFB5EDE1530454C" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_43D7DF79919A04A4CB5C5EDE1530D5B9_default" xlink:type="locator" />
<link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_FCB8767D7C08743D3AFB5EDE1530454C" xlink:to="loc_srt_RangeMember_43D7DF79919A04A4CB5C5EDE1530D5B9_default" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_43D7DF79919A04A4CB5C5EDE1530D5B9" xlink:type="locator" />
<link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_FCB8767D7C08743D3AFB5EDE1530454C" xlink:to="loc_srt_RangeMember_43D7DF79919A04A4CB5C5EDE1530D5B9" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MinimumMember" xlink:label="loc_srt_MinimumMember_683669AD6EFA9AD517C35EDE1531F193" xlink:type="locator" />
<link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_43D7DF79919A04A4CB5C5EDE1530D5B9" xlink:to="loc_srt_MinimumMember_683669AD6EFA9AD517C35EDE1531F193" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_7C88B0A9EA29EB8652155EDE153143D5" xlink:type="locator" />
<link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_43D7DF79919A04A4CB5C5EDE1530D5B9" xlink:to="loc_srt_MaximumMember_7C88B0A9EA29EB8652155EDE153143D5" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:label="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_6450A0DECC83B2C635425EDE15312ECA" xlink:type="locator" />
<link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_17BF163483C2B2821FAA5EDE152E7FC6" xlink:to="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_6450A0DECC83B2C635425EDE15312ECA" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="loc_us-gaap_TypeOfAdoptionMember_5E688A29B22AA47609A15EDE1531E9A4_default" xlink:type="locator" />
<link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_6450A0DECC83B2C635425EDE15312ECA" xlink:to="loc_us-gaap_TypeOfAdoptionMember_5E688A29B22AA47609A15EDE1531E9A4_default" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="loc_us-gaap_TypeOfAdoptionMember_5E688A29B22AA47609A15EDE1531E9A4" xlink:type="locator" />
<link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_6450A0DECC83B2C635425EDE15312ECA" xlink:to="loc_us-gaap_TypeOfAdoptionMember_5E688A29B22AA47609A15EDE1531E9A4" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountingStandardsUpdate201602Member" xlink:label="loc_us-gaap_AccountingStandardsUpdate201602Member_B0B74ECE3D11AE4CE61C5EDE15326639" xlink:type="locator" />
<link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TypeOfAdoptionMember_5E688A29B22AA47609A15EDE1531E9A4" xlink:to="loc_us-gaap_AccountingStandardsUpdate201602Member_B0B74ECE3D11AE4CE61C5EDE15326639" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_91408CC4FF4ADEBBC58A5EDE15323851" xlink:type="locator" />
<link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_69767A1FF71C85471FDB5EDE15325B15" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_91408CC4FF4ADEBBC58A5EDE15323851" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TaxCutsAndJobsActOf2017IncompleteAccountingChangeInTaxRateDeferredTaxAssetProvisionalIncomeTaxExpense" xlink:label="loc_us-gaap_TaxCutsAndJobsActOf2017IncompleteAccountingChangeInTaxRateDeferredTaxAssetProvisionalIncomeTaxExpense_26CBEA58E62C87C4FEFF5EE29F257DA7" xlink:type="locator" />
<link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_69767A1FF71C85471FDB5EDE15325B15" xlink:to="loc_us-gaap_TaxCutsAndJobsActOf2017IncompleteAccountingChangeInTaxRateDeferredTaxAssetProvisionalIncomeTaxExpense_26CBEA58E62C87C4FEFF5EE29F257DA7" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_82F5459FFD5856EEB7CD5EDE153265A3" xlink:type="locator" />
<link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_69767A1FF71C85471FDB5EDE15325B15" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_82F5459FFD5856EEB7CD5EDE153265A3" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseLiability" xlink:label="loc_us-gaap_OperatingLeaseLiability_90F37937B74A883A11835EDE153227D8" xlink:type="locator" />
<link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_69767A1FF71C85471FDB5EDE15325B15" xlink:to="loc_us-gaap_OperatingLeaseLiability_90F37937B74A883A11835EDE153227D8" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_F5F2EB1CBD6531D46BB75EDE15336DB5" xlink:type="locator" />
<link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_69767A1FF71C85471FDB5EDE15325B15" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_F5F2EB1CBD6531D46BB75EDE15336DB5" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_1A63D63E3C3FD7B2E7485EDE1533A583" xlink:type="locator" />
<link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_69767A1FF71C85471FDB5EDE15325B15" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_1A63D63E3C3FD7B2E7485EDE1533A583" xlink:type="arc" />
</link:definitionLink>
<link:definitionLink xlink:role="http://www.immunomedics.com/role/BusinessOverviewSummaryOfSignificantAccountingPolicesPolicies" xlink:type="extended" />
<link:definitionLink xlink:role="http://www.immunomedics.com/role/CollaborationAgreements" xlink:type="extended" />
<link:definitionLink xlink:role="http://www.immunomedics.com/role/CollaborationAgreementsDetails" xlink:type="extended">
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GuaranteeObligationsLineItems" xlink:label="loc_us-gaap_GuaranteeObligationsLineItems_59D312A86D862DC0892C7D0659DF7F65" xlink:type="locator" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfGuaranteeObligationsTable" xlink:label="loc_us-gaap_ScheduleOfGuaranteeObligationsTable_CE495FD42BB0EC9A916B7D0659DE55BD" xlink:type="locator" />
<link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_GuaranteeObligationsLineItems_59D312A86D862DC0892C7D0659DF7F65" xlink:to="loc_us-gaap_ScheduleOfGuaranteeObligationsTable_CE495FD42BB0EC9A916B7D0659DE55BD" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
<link:loc xlink:href="immu-20191231.xsd#immu_CollaborationAgreementAxis" xlink:label="loc_immu_CollaborationAgreementAxis_42181E63B0465340B0447D0659DFBFEF" xlink:type="locator" />
<link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfGuaranteeObligationsTable_CE495FD42BB0EC9A916B7D0659DE55BD" xlink:to="loc_immu_CollaborationAgreementAxis_42181E63B0465340B0447D0659DFBFEF" xlink:type="arc" />
<link:loc xlink:href="immu-20191231.xsd#immu_CollaborationAgreementDomain" xlink:label="loc_immu_CollaborationAgreementDomain_7D49EAABA91DEA2E5B127D0659DF6AA0_default" xlink:type="locator" />
<link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_immu_CollaborationAgreementAxis_42181E63B0465340B0447D0659DFBFEF" xlink:to="loc_immu_CollaborationAgreementDomain_7D49EAABA91DEA2E5B127D0659DF6AA0_default" xlink:type="arc" />
<link:loc xlink:href="immu-20191231.xsd#immu_CollaborationAgreementDomain" xlink:label="loc_immu_CollaborationAgreementDomain_7D49EAABA91DEA2E5B127D0659DF6AA0" xlink:type="locator" />
<link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_immu_CollaborationAgreementAxis_42181E63B0465340B0447D0659DFBFEF" xlink:to="loc_immu_CollaborationAgreementDomain_7D49EAABA91DEA2E5B127D0659DF6AA0" xlink:type="arc" />
<link:loc xlink:href="immu-20191231.xsd#immu_CBGForschungsGmbHMember" xlink:label="loc_immu_CBGForschungsGmbHMember_584AB8C3C3D9750314EF7D0659DF3928" xlink:type="locator" />
<link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_immu_CollaborationAgreementDomain_7D49EAABA91DEA2E5B127D0659DF6AA0" xlink:to="loc_immu_CBGForschungsGmbHMember_584AB8C3C3D9750314EF7D0659DF3928" xlink:type="arc" />
<link:loc xlink:href="immu-20191231.xsd#immu_NumberofPatients" xlink:label="loc_immu_NumberofPatients_802AAC05DB627584C5E97D0659E0434A" xlink:type="locator" />
<link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GuaranteeObligationsLineItems_59D312A86D862DC0892C7D0659DF7F65" xlink:to="loc_immu_NumberofPatients_802AAC05DB627584C5E97D0659E0434A" xlink:type="arc" />
<link:loc xlink:href="immu-20191231.xsd#immu_AgreementPotentialMilestonePayment" xlink:label="loc_immu_AgreementPotentialMilestonePayment_BE8E93B0CC57BF6044857D0659E0758B" xlink:type="locator" />
<link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GuaranteeObligationsLineItems_59D312A86D862DC0892C7D0659DF7F65" xlink:to="loc_immu_AgreementPotentialMilestonePayment_BE8E93B0CC57BF6044857D0659E0758B" xlink:type="arc" />
<link:loc xlink:href="immu-20191231.xsd#immu_AgreementPotentialMilestonePaymentTerm" xlink:label="loc_immu_AgreementPotentialMilestonePaymentTerm_1F69D85CA2F25AE4D86A7D079737F782" xlink:type="locator" />
<link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GuaranteeObligationsLineItems_59D312A86D862DC0892C7D0659DF7F65" xlink:to="loc_immu_AgreementPotentialMilestonePaymentTerm_1F69D85CA2F25AE4D86A7D079737F782" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_DB0976E4D317949B39DA7D0659E0F6C2" xlink:type="locator" />
<link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GuaranteeObligationsLineItems_59D312A86D862DC0892C7D0659DF7F65" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_DB0976E4D317949B39DA7D0659E0F6C2" xlink:type="arc" />
</link:definitionLink>
<link:definitionLink xlink:role="http://www.immunomedics.com/role/CommitmentsAndContingencies" xlink:type="extended" />
<link:definitionLink xlink:role="http://www.immunomedics.com/role/CommitmentsAndContingenciesMaturitiesOfLeaseLiabilitiesDetails" xlink:type="extended" />
<link:definitionLink xlink:role="http://www.immunomedics.com/role/CommitmentsAndContingenciesNarrativeDetails" xlink:type="extended">
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GuaranteeObligationsLineItems" xlink:label="loc_us-gaap_GuaranteeObligationsLineItems_5ADA2F1A6585A6453F65850F474A18DA" xlink:type="locator" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfGuaranteeObligationsTable" xlink:label="loc_us-gaap_ScheduleOfGuaranteeObligationsTable_E7726D3968F9585FE727850F47441C00" xlink:type="locator" />
<link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_GuaranteeObligationsLineItems_5ADA2F1A6585A6453F65850F474A18DA" xlink:to="loc_us-gaap_ScheduleOfGuaranteeObligationsTable_E7726D3968F9585FE727850F47441C00" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_BC313587271DDD4AB380850F474529B5" xlink:type="locator" />
<link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfGuaranteeObligationsTable_E7726D3968F9585FE727850F47441C00" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_BC313587271DDD4AB380850F474529B5" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_0E0CE576C169D42AD03B850F47455F11_default" xlink:type="locator" />
<link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_BC313587271DDD4AB380850F474529B5" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_0E0CE576C169D42AD03B850F47455F11_default" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_0E0CE576C169D42AD03B850F47455F11" xlink:type="locator" />
<link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_BC313587271DDD4AB380850F474529B5" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_0E0CE576C169D42AD03B850F47455F11" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaap_SubsequentEventMember_3B18C89D2AF06ADB7E28850F4745A893" xlink:type="locator" />
<link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_0E0CE576C169D42AD03B850F47455F11" xlink:to="loc_us-gaap_SubsequentEventMember_3B18C89D2AF06ADB7E28850F4745A893" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_CounterpartyNameAxis" xlink:label="loc_srt_CounterpartyNameAxis_F3286F6B9BAD5F69771E850F4745766A" xlink:type="locator" />
<link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfGuaranteeObligationsTable_E7726D3968F9585FE727850F47441C00" xlink:to="loc_srt_CounterpartyNameAxis_F3286F6B9BAD5F69771E850F4745766A" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_55C87A8F02BD746EBF8C850F47453582_default" xlink:type="locator" />
<link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_F3286F6B9BAD5F69771E850F4745766A" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_55C87A8F02BD746EBF8C850F47453582_default" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_55C87A8F02BD746EBF8C850F47453582" xlink:type="locator" />
<link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_F3286F6B9BAD5F69771E850F4745766A" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_55C87A8F02BD746EBF8C850F47453582" xlink:type="arc" />
<link:loc xlink:href="immu-20191231.xsd#immu_TheScrippsResearchInstituteMember" xlink:label="loc_immu_TheScrippsResearchInstituteMember_D02242A86CEB0767E654850F47467FBF" xlink:type="locator" />
<link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_55C87A8F02BD746EBF8C850F47453582" xlink:to="loc_immu_TheScrippsResearchInstituteMember_D02242A86CEB0767E654850F47467FBF" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_LitigationCaseAxis" xlink:label="loc_srt_LitigationCaseAxis_53F9DDF6B17FDDA34DAC850F4746A5B5" xlink:type="locator" />
<link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfGuaranteeObligationsTable_E7726D3968F9585FE727850F47441C00" xlink:to="loc_srt_LitigationCaseAxis_53F9DDF6B17FDDA34DAC850F4746A5B5" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_LitigationCaseTypeDomain" xlink:label="loc_srt_LitigationCaseTypeDomain_7305AC435EDA2B81570A850F4746BE99_default" xlink:type="locator" />
<link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_LitigationCaseAxis_53F9DDF6B17FDDA34DAC850F4746A5B5" xlink:to="loc_srt_LitigationCaseTypeDomain_7305AC435EDA2B81570A850F4746BE99_default" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_LitigationCaseTypeDomain" xlink:label="loc_srt_LitigationCaseTypeDomain_7305AC435EDA2B81570A850F4746BE99" xlink:type="locator" />
<link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_LitigationCaseAxis_53F9DDF6B17FDDA34DAC850F4746A5B5" xlink:to="loc_srt_LitigationCaseTypeDomain_7305AC435EDA2B81570A850F4746BE99" xlink:type="arc" />
<link:loc xlink:href="immu-20191231.xsd#immu_InsuranceCoverageArbitrationMember" xlink:label="loc_immu_InsuranceCoverageArbitrationMember_A92C2D42782767A9EDC1850F47479BF6" xlink:type="locator" />
<link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_LitigationCaseTypeDomain_7305AC435EDA2B81570A850F4746BE99" xlink:to="loc_immu_InsuranceCoverageArbitrationMember_A92C2D42782767A9EDC1850F47479BF6" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_7FA6E5B85171D86491C1850F4747636D" xlink:type="locator" />
<link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfGuaranteeObligationsTable_E7726D3968F9585FE727850F47441C00" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_7FA6E5B85171D86491C1850F4747636D" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_51366888B45043F08DB9850F47477B2A_default" xlink:type="locator" />
<link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_7FA6E5B85171D86491C1850F4747636D" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_51366888B45043F08DB9850F47477B2A_default" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_51366888B45043F08DB9850F47477B2A" xlink:type="locator" />
<link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_7FA6E5B85171D86491C1850F4747636D" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_51366888B45043F08DB9850F47477B2A" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmploymentContractsMember" xlink:label="loc_us-gaap_EmploymentContractsMember_F170CDAFECA94CDE3993850F4747587E" xlink:type="locator" />
<link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_51366888B45043F08DB9850F47477B2A" xlink:to="loc_us-gaap_EmploymentContractsMember_F170CDAFECA94CDE3993850F4747587E" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_55F1B4EBE385242E9265850F474702D1" xlink:type="locator" />
<link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfGuaranteeObligationsTable_E7726D3968F9585FE727850F47441C00" xlink:to="loc_us-gaap_AwardTypeAxis_55F1B4EBE385242E9265850F474702D1" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_857DF7ED9DBBBA856DCB850F47487EBA_default" xlink:type="locator" />
<link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_55F1B4EBE385242E9265850F474702D1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_857DF7ED9DBBBA856DCB850F47487EBA_default" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_857DF7ED9DBBBA856DCB850F47487EBA" xlink:type="locator" />
<link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_55F1B4EBE385242E9265850F474702D1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_857DF7ED9DBBBA856DCB850F47487EBA" xlink:type="arc" />
<link:loc xlink:href="immu-20191231.xsd#immu_RestrictedUnitsWithVestingMarketConditionsMember" xlink:label="loc_immu_RestrictedUnitsWithVestingMarketConditionsMember_548A856D4564E86F573D850F47485B66" xlink:type="locator" />
<link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_857DF7ED9DBBBA856DCB850F47487EBA" xlink:to="loc_immu_RestrictedUnitsWithVestingMarketConditionsMember_548A856D4564E86F573D850F47485B66" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_1FFBAFB04A7E1FD98481850F474974FA" xlink:type="locator" />
<link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfGuaranteeObligationsTable_E7726D3968F9585FE727850F47441C00" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_1FFBAFB04A7E1FD98481850F474974FA" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain_9FCE8CE4D153C4B740BE850F47492ECE_default" xlink:type="locator" />
<link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_1FFBAFB04A7E1FD98481850F474974FA" xlink:to="loc_us-gaap_RelatedPartyDomain_9FCE8CE4D153C4B740BE850F47492ECE_default" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain_9FCE8CE4D153C4B740BE850F47492ECE" xlink:type="locator" />
<link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_1FFBAFB04A7E1FD98481850F474974FA" xlink:to="loc_us-gaap_RelatedPartyDomain_9FCE8CE4D153C4B740BE850F47492ECE" xlink:type="arc" />
<link:loc xlink:href="immu-20191231.xsd#immu_GoldenbergAgreementMember" xlink:label="loc_immu_GoldenbergAgreementMember_A51ACD98FE41C350A1A5850F47493F30" xlink:type="locator" />
<link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_9FCE8CE4D153C4B740BE850F47492ECE" xlink:to="loc_immu_GoldenbergAgreementMember_A51ACD98FE41C350A1A5850F47493F30" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_TitleOfIndividualAxis" xlink:label="loc_srt_TitleOfIndividualAxis_43490DB8081F974C479F850F474995E9" xlink:type="locator" />
<link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfGuaranteeObligationsTable_E7726D3968F9585FE727850F47441C00" xlink:to="loc_srt_TitleOfIndividualAxis_43490DB8081F974C479F850F474995E9" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_9A21E4427FF67C5DF939850F474959F0_default" xlink:type="locator" />
<link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_TitleOfIndividualAxis_43490DB8081F974C479F850F474995E9" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_9A21E4427FF67C5DF939850F474959F0_default" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_9A21E4427FF67C5DF939850F474959F0" xlink:type="locator" />
<link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_TitleOfIndividualAxis_43490DB8081F974C479F850F474995E9" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_9A21E4427FF67C5DF939850F474959F0" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ChiefExecutiveOfficerMember" xlink:label="loc_srt_ChiefExecutiveOfficerMember_27977EC00981FCAC22C7850F474A7D72" xlink:type="locator" />
<link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_9A21E4427FF67C5DF939850F474959F0" xlink:to="loc_srt_ChiefExecutiveOfficerMember_27977EC00981FCAC22C7850F474A7D72" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_A5D0DDF4B0D2FAD71637850F474A758F" xlink:type="locator" />
<link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GuaranteeObligationsLineItems_5ADA2F1A6585A6453F65850F474A18DA" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_A5D0DDF4B0D2FAD71637850F474A758F" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SeveranceCosts1" xlink:label="loc_us-gaap_SeveranceCosts1_260AAC05678B8422ADCE850F474AA2D6" xlink:type="locator" />
<link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GuaranteeObligationsLineItems_5ADA2F1A6585A6453F65850F474A18DA" xlink:to="loc_us-gaap_SeveranceCosts1_260AAC05678B8422ADCE850F474AA2D6" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LossContingencyDamagesSoughtValue" xlink:label="loc_us-gaap_LossContingencyDamagesSoughtValue_C29CF9DAB622DAD9EB2E850F474B838C" xlink:type="locator" />
<link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GuaranteeObligationsLineItems_5ADA2F1A6585A6453F65850F474A18DA" xlink:to="loc_us-gaap_LossContingencyDamagesSoughtValue_C29CF9DAB622DAD9EB2E850F474B838C" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeasePayments" xlink:label="loc_us-gaap_OperatingLeasePayments_A7BBD7A78B98821F75C3850F474B1B7B" xlink:type="locator" />
<link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GuaranteeObligationsLineItems_5ADA2F1A6585A6453F65850F474A18DA" xlink:to="loc_us-gaap_OperatingLeasePayments_A7BBD7A78B98821F75C3850F474B1B7B" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_250B02C5A6374FAD72C5850F474B7F47" xlink:type="locator" />
<link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GuaranteeObligationsLineItems_5ADA2F1A6585A6453F65850F474A18DA" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_250B02C5A6374FAD72C5850F474B7F47" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_3840C26F8723C73FFB60850F474BA0D5" xlink:type="locator" />
<link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GuaranteeObligationsLineItems_5ADA2F1A6585A6453F65850F474A18DA" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_3840C26F8723C73FFB60850F474BA0D5" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LeaseCost" xlink:label="loc_us-gaap_LeaseCost_E818EAA8F2E4A080286B850F474B6919" xlink:type="locator" />
<link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GuaranteeObligationsLineItems_5ADA2F1A6585A6453F65850F474A18DA" xlink:to="loc_us-gaap_LeaseCost_E818EAA8F2E4A080286B850F474B6919" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PurchaseObligationDueInNextTwelveMonths" xlink:label="loc_us-gaap_PurchaseObligationDueInNextTwelveMonths_AC3B2A7655FA2E5F27DD850F474B533B" xlink:type="locator" />
<link:definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GuaranteeObligationsLineItems_5ADA2F1A6585A6453F65850F474A18DA" xlink:to="loc_us-gaap_PurchaseObligationDueInNextTwelveMonths_AC3B2A7655FA2E5F27DD850F474B533B" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PurchaseObligationDueInSecondYear" xlink:label="loc_us-gaap_PurchaseObligationDueInSecondYear_647302C8F424C964A636850F474C2CDD" xlink:type="locator" />
<link:definitionArc order="9" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GuaranteeObligationsLineItems_5ADA2F1A6585A6453F65850F474A18DA" xlink:to="loc_us-gaap_PurchaseObligationDueInSecondYear_647302C8F424C964A636850F474C2CDD" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PurchaseObligationDueInThirdYear" xlink:label="loc_us-gaap_PurchaseObligationDueInThirdYear_1ED3933733761292C567850F474C45B7" xlink:type="locator" />
<link:definitionArc order="10" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GuaranteeObligationsLineItems_5ADA2F1A6585A6453F65850F474A18DA" xlink:to="loc_us-gaap_PurchaseObligationDueInThirdYear_1ED3933733761292C567850F474C45B7" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PurchaseObligationDueInFourthYear" xlink:label="loc_us-gaap_PurchaseObligationDueInFourthYear_2CE21846F5D15265D8C6850F474CABB0" xlink:type="locator" />
<link:definitionArc order="11" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GuaranteeObligationsLineItems_5ADA2F1A6585A6453F65850F474A18DA" xlink:to="loc_us-gaap_PurchaseObligationDueInFourthYear_2CE21846F5D15265D8C6850F474CABB0" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PurchaseObligationDueInFifthYear" xlink:label="loc_us-gaap_PurchaseObligationDueInFifthYear_2E86AB6D75C997385ECD850F474C40E8" xlink:type="locator" />
<link:definitionArc order="12" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GuaranteeObligationsLineItems_5ADA2F1A6585A6453F65850F474A18DA" xlink:to="loc_us-gaap_PurchaseObligationDueInFifthYear_2E86AB6D75C997385ECD850F474C40E8" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PurchaseObligationDueAfterFifthYear" xlink:label="loc_us-gaap_PurchaseObligationDueAfterFifthYear_646C93F1A48A867BCB08850F474C60BC" xlink:type="locator" />
<link:definitionArc order="13" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GuaranteeObligationsLineItems_5ADA2F1A6585A6453F65850F474A18DA" xlink:to="loc_us-gaap_PurchaseObligationDueAfterFifthYear_646C93F1A48A867BCB08850F474C60BC" xlink:type="arc" />
<link:loc xlink:href="immu-20191231.xsd#immu_NumberofDaysLicenseCancellableAfterNonPayment" xlink:label="loc_immu_NumberofDaysLicenseCancellableAfterNonPayment_447D0ED523899122A486850F474C9A3F" xlink:type="locator" />
<link:definitionArc order="14" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GuaranteeObligationsLineItems_5ADA2F1A6585A6453F65850F474A18DA" xlink:to="loc_immu_NumberofDaysLicenseCancellableAfterNonPayment_447D0ED523899122A486850F474C9A3F" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentForContingentConsiderationLiabilityInvestingActivities" xlink:label="loc_us-gaap_PaymentForContingentConsiderationLiabilityInvestingActivities_226A6BC275F7EA47BAED850F474C4BE2" xlink:type="locator" />
<link:definitionArc order="15" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GuaranteeObligationsLineItems_5ADA2F1A6585A6453F65850F474A18DA" xlink:to="loc_us-gaap_PaymentForContingentConsiderationLiabilityInvestingActivities_226A6BC275F7EA47BAED850F474C4BE2" xlink:type="arc" />
<link:loc xlink:href="immu-20191231.xsd#immu_LicenseAgreementMilestoneExpense" xlink:label="loc_immu_LicenseAgreementMilestoneExpense_F031B3F84AFD2D4F30CD850F474D464B" xlink:type="locator" />
<link:definitionArc order="16" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GuaranteeObligationsLineItems_5ADA2F1A6585A6453F65850F474A18DA" xlink:to="loc_immu_LicenseAgreementMilestoneExpense_F031B3F84AFD2D4F30CD850F474D464B" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SupplementalUnemploymentBenefitsSeveranceBenefits" xlink:label="loc_us-gaap_SupplementalUnemploymentBenefitsSeveranceBenefits_704320BF00AB89F9071B850F474DFFAA" xlink:type="locator" />
<link:definitionArc order="17" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GuaranteeObligationsLineItems_5ADA2F1A6585A6453F65850F474A18DA" xlink:to="loc_us-gaap_SupplementalUnemploymentBenefitsSeveranceBenefits_704320BF00AB89F9071B850F474DFFAA" xlink:type="arc" />
<link:loc xlink:href="immu-20191231.xsd#immu_SupplementalUnemploymentBenefitsSeveranceBenefitsPaymentTerm" xlink:label="loc_immu_SupplementalUnemploymentBenefitsSeveranceBenefitsPaymentTerm_FB012E23005E35A8821F850F474D4A3E" xlink:type="locator" />
<link:definitionArc order="18" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GuaranteeObligationsLineItems_5ADA2F1A6585A6453F65850F474A18DA" xlink:to="loc_immu_SupplementalUnemploymentBenefitsSeveranceBenefitsPaymentTerm_FB012E23005E35A8821F850F474D4A3E" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SalariesWagesAndOfficersCompensation" xlink:label="loc_us-gaap_SalariesWagesAndOfficersCompensation_3A26831790DCD0A1D852850F474D5924" xlink:type="locator" />
<link:definitionArc order="19" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GuaranteeObligationsLineItems_5ADA2F1A6585A6453F65850F474A18DA" xlink:to="loc_us-gaap_SalariesWagesAndOfficersCompensation_3A26831790DCD0A1D852850F474D5924" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SupplementalUnemploymentBenefitsSalaryContinuation" xlink:label="loc_us-gaap_SupplementalUnemploymentBenefitsSalaryContinuation_D616856A9F3C6E1AA683850F474D08CA" xlink:type="locator" />
<link:definitionArc order="20" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GuaranteeObligationsLineItems_5ADA2F1A6585A6453F65850F474A18DA" xlink:to="loc_us-gaap_SupplementalUnemploymentBenefitsSalaryContinuation_D616856A9F3C6E1AA683850F474D08CA" xlink:type="arc" />
</link:definitionLink>
<link:definitionLink xlink:role="http://www.immunomedics.com/role/CommitmentsAndContingenciesSupplementalConsolidatedBalanceSheetInformationRelatedToLeasesDetails" xlink:type="extended" />
<link:definitionLink xlink:role="http://www.immunomedics.com/role/CommitmentsAndContingenciesTables" xlink:type="extended" />
<link:definitionLink xlink:role="http://www.immunomedics.com/role/ConsolidatedBalanceSheets" xlink:type="extended" />
<link:definitionLink xlink:role="http://www.immunomedics.com/role/ConsolidatedBalanceSheetsParenthetical" xlink:type="extended">
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_BC49A111ACD3EC96C7AC853A88E2A3E3" xlink:type="locator" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_EADA282B7E1E1CFC76BA853A88E10422" xlink:type="locator" />
<link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_BC49A111ACD3EC96C7AC853A88E2A3E3" xlink:to="loc_us-gaap_StatementTable_EADA282B7E1E1CFC76BA853A88E10422" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_CBE30CAEF014942CFFB0853A88E25312" xlink:type="locator" />
<link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_EADA282B7E1E1CFC76BA853A88E10422" xlink:to="loc_us-gaap_StatementClassOfStockAxis_CBE30CAEF014942CFFB0853A88E25312" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_218216FD708ED50C9732853A88E24FEB_default" xlink:type="locator" />
<link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_CBE30CAEF014942CFFB0853A88E25312" xlink:to="loc_us-gaap_ClassOfStockDomain_218216FD708ED50C9732853A88E24FEB_default" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_218216FD708ED50C9732853A88E24FEB" xlink:type="locator" />
<link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_CBE30CAEF014942CFFB0853A88E25312" xlink:to="loc_us-gaap_ClassOfStockDomain_218216FD708ED50C9732853A88E24FEB" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConvertiblePreferredStockMember" xlink:label="loc_us-gaap_ConvertiblePreferredStockMember_5A591AEE08A4CD7E7578853A88E22171" xlink:type="locator" />
<link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_218216FD708ED50C9732853A88E24FEB" xlink:to="loc_us-gaap_ConvertiblePreferredStockMember_5A591AEE08A4CD7E7578853A88E22171" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_24538307D55A5CF7B81E853A88E2B205" xlink:type="locator" />
<link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_BC49A111ACD3EC96C7AC853A88E2A3E3" xlink:to="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_24538307D55A5CF7B81E853A88E2B205" xlink:type="arc" />
<link:loc xlink:href="immu-20191231.xsd#immu_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization" xlink:label="loc_immu_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization_B0748FE1746C3B70CACD8549B6EFB658" xlink:type="locator" />
<link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_BC49A111ACD3EC96C7AC853A88E2A3E3" xlink:to="loc_immu_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization_B0748FE1746C3B70CACD8549B6EFB658" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_0BE2B1399145F54C945E853A88E38EDB" xlink:type="locator" />
<link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_BC49A111ACD3EC96C7AC853A88E2A3E3" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_0BE2B1399145F54C945E853A88E38EDB" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_ECE973E6B7963DF9ECC4853A88E39DC1" xlink:type="locator" />
<link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_BC49A111ACD3EC96C7AC853A88E2A3E3" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_ECE973E6B7963DF9ECC4853A88E39DC1" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_554409BE0EBEFF2CB40E853A88E3DDFE" xlink:type="locator" />
<link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_BC49A111ACD3EC96C7AC853A88E2A3E3" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_554409BE0EBEFF2CB40E853A88E3DDFE" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="loc_us-gaap_PreferredStockSharesIssued_B172F567A08B83D32174853A88E34156" xlink:type="locator" />
<link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_BC49A111ACD3EC96C7AC853A88E2A3E3" xlink:to="loc_us-gaap_PreferredStockSharesIssued_B172F567A08B83D32174853A88E34156" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_174FF7DE750CC8BC90CD853A88E3D7F4" xlink:type="locator" />
<link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_BC49A111ACD3EC96C7AC853A88E2A3E3" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_174FF7DE750CC8BC90CD853A88E3D7F4" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_905FDA7F60332DB2BDDC853A88E3F072" xlink:type="locator" />
<link:definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_BC49A111ACD3EC96C7AC853A88E2A3E3" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_905FDA7F60332DB2BDDC853A88E3F072" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_9D84C570F925426A0724853A88E4E0D7" xlink:type="locator" />
<link:definitionArc order="9" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_BC49A111ACD3EC96C7AC853A88E2A3E3" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_9D84C570F925426A0724853A88E4E0D7" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaap_CommonStockSharesIssued_657FC67CC9C6ABDE2EC7853A88E4D133" xlink:type="locator" />
<link:definitionArc order="10" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_BC49A111ACD3EC96C7AC853A88E2A3E3" xlink:to="loc_us-gaap_CommonStockSharesIssued_657FC67CC9C6ABDE2EC7853A88E4D133" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_3CF630060A5DE0AFC14C853A88E46973" xlink:type="locator" />
<link:definitionArc order="11" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_BC49A111ACD3EC96C7AC853A88E2A3E3" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_3CF630060A5DE0AFC14C853A88E46973" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TreasuryStockShares" xlink:label="loc_us-gaap_TreasuryStockShares_FA04EF86755F3F2BC217853A88E41478" xlink:type="locator" />
<link:definitionArc order="12" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_BC49A111ACD3EC96C7AC853A88E2A3E3" xlink:to="loc_us-gaap_TreasuryStockShares_FA04EF86755F3F2BC217853A88E41478" xlink:type="arc" />
</link:definitionLink>
<link:definitionLink xlink:role="http://www.immunomedics.com/role/ConsolidatedStatementsOfCashFlows" xlink:type="extended">
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_D98B9FD5B538F7B7C6D6850F48C286FA" xlink:type="locator" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_3AB4C66D03C7F0454A1F850F48C152DA" xlink:type="locator" />
<link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_D98B9FD5B538F7B7C6D6850F48C286FA" xlink:to="loc_us-gaap_StatementTable_3AB4C66D03C7F0454A1F850F48C152DA" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_28ADC66E74A7501C8244850F48C13309" xlink:type="locator" />
<link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_3AB4C66D03C7F0454A1F850F48C152DA" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_28ADC66E74A7501C8244850F48C13309" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_1E421A88D26CAAB15566850F48C19054_default" xlink:type="locator" />
<link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_28ADC66E74A7501C8244850F48C13309" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_1E421A88D26CAAB15566850F48C19054_default" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_1E421A88D26CAAB15566850F48C19054" xlink:type="locator" />
<link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_28ADC66E74A7501C8244850F48C13309" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_1E421A88D26CAAB15566850F48C19054" xlink:type="arc" />
<link:loc xlink:href="immu-20191231.xsd#immu_MarketOfferingMember" xlink:label="loc_immu_MarketOfferingMember_2E1EC3A1C131BAD4AE9F850F48C21EC1" xlink:type="locator" />
<link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_1E421A88D26CAAB15566850F48C19054" xlink:to="loc_immu_MarketOfferingMember_2E1EC3A1C131BAD4AE9F850F48C21EC1" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PrivatePlacementMember" xlink:label="loc_us-gaap_PrivatePlacementMember_CAAF9AE49E1DC83F3422850F48C2C4ED" xlink:type="locator" />
<link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_1E421A88D26CAAB15566850F48C19054" xlink:to="loc_us-gaap_PrivatePlacementMember_CAAF9AE49E1DC83F3422850F48C2C4ED" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_5A41C9BE0A0408732CB3850F48C2A86A" xlink:type="locator" />
<link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_D98B9FD5B538F7B7C6D6850F48C286FA" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_5A41C9BE0A0408732CB3850F48C2A86A" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProfitLoss" xlink:label="loc_us-gaap_ProfitLoss_B1A96B0FB036EA0AAFB3850F48C39A43" xlink:type="locator" />
<link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_5A41C9BE0A0408732CB3850F48C2A86A" xlink:to="loc_us-gaap_ProfitLoss_B1A96B0FB036EA0AAFB3850F48C39A43" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_3F0C2A970F792AD09A03850F48C368FE" xlink:type="locator" />
<link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_5A41C9BE0A0408732CB3850F48C2A86A" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_3F0C2A970F792AD09A03850F48C368FE" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="loc_us-gaap_FairValueAdjustmentOfWarrants_3E46BF4294D11B252086850F48C3330B" xlink:type="locator" />
<link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_3F0C2A970F792AD09A03850F48C368FE" xlink:to="loc_us-gaap_FairValueAdjustmentOfWarrants_3E46BF4294D11B252086850F48C3330B" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdjustmentOfWarrantsGrantedForServices" xlink:label="loc_us-gaap_AdjustmentOfWarrantsGrantedForServices_C556857E0EB81C7DF87B850F48C34FAD" xlink:type="locator" />
<link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_3F0C2A970F792AD09A03850F48C368FE" xlink:to="loc_us-gaap_AdjustmentOfWarrantsGrantedForServices_C556857E0EB81C7DF87B850F48C34FAD" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DepreciationAndAmortization" xlink:label="loc_us-gaap_DepreciationAndAmortization_185656F56B677453935C850F48C4D0C0" xlink:type="locator" />
<link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_3F0C2A970F792AD09A03850F48C368FE" xlink:to="loc_us-gaap_DepreciationAndAmortization_185656F56B677453935C850F48C4D0C0" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:label="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_01D54B5BE28D507922C1850F48C44FB8" xlink:type="locator" />
<link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_3F0C2A970F792AD09A03850F48C368FE" xlink:to="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_01D54B5BE28D507922C1850F48C44FB8" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InterestExpenseDebt" xlink:label="loc_us-gaap_InterestExpenseDebt_9316FB172638206F425A850F48C4891A" xlink:type="locator" />
<link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_3F0C2A970F792AD09A03850F48C368FE" xlink:to="loc_us-gaap_InterestExpenseDebt_9316FB172638206F425A850F48C4891A" xlink:type="arc" />
<link:loc xlink:href="immu-20191231.xsd#immu_LossOnInducedExchangesOfDebt" xlink:label="loc_immu_LossOnInducedExchangesOfDebt_AE678E273FB7136C2943850F48C4BC3B" xlink:type="locator" />
<link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_3F0C2A970F792AD09A03850F48C368FE" xlink:to="loc_immu_LossOnInducedExchangesOfDebt_AE678E273FB7136C2943850F48C4BC3B" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_79FFA159748CE593C81E850F48C4DE92" xlink:type="locator" />
<link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_3F0C2A970F792AD09A03850F48C368FE" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_79FFA159748CE593C81E850F48C4DE92" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:label="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_DA87B72F3CBD78D5C8EE850F48C4BBB4" xlink:type="locator" />
<link:definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_3F0C2A970F792AD09A03850F48C368FE" xlink:to="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_DA87B72F3CBD78D5C8EE850F48C4BBB4" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AmortizationOfFinancingCosts" xlink:label="loc_us-gaap_AmortizationOfFinancingCosts_5AE5033CD6F7EE6A94E9850F48C444BB" xlink:type="locator" />
<link:definitionArc order="9" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_3F0C2A970F792AD09A03850F48C368FE" xlink:to="loc_us-gaap_AmortizationOfFinancingCosts_5AE5033CD6F7EE6A94E9850F48C444BB" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInDeferredCharges" xlink:label="loc_us-gaap_IncreaseDecreaseInDeferredCharges_E6514D657E24BFD55B22850F48C5D684" xlink:type="locator" />
<link:definitionArc order="10" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_3F0C2A970F792AD09A03850F48C368FE" xlink:to="loc_us-gaap_IncreaseDecreaseInDeferredCharges_E6514D657E24BFD55B22850F48C5D684" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FinanceLeaseRightOfUseAssetAmortization" xlink:label="loc_us-gaap_FinanceLeaseRightOfUseAssetAmortization_2B90A1F77421510BBBD9850F48C5A717" xlink:type="locator" />
<link:definitionArc order="11" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_3F0C2A970F792AD09A03850F48C368FE" xlink:to="loc_us-gaap_FinanceLeaseRightOfUseAssetAmortization_2B90A1F77421510BBBD9850F48C5A717" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtAndEquitySecuritiesGainLoss" xlink:label="loc_us-gaap_DebtAndEquitySecuritiesGainLoss_573F1A7A06C80AE2E16E850F48C5BCBB" xlink:type="locator" />
<link:definitionArc order="12" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_3F0C2A970F792AD09A03850F48C368FE" xlink:to="loc_us-gaap_DebtAndEquitySecuritiesGainLoss_573F1A7A06C80AE2E16E850F48C5BCBB" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProvisionForDoubtfulAccounts" xlink:label="loc_us-gaap_ProvisionForDoubtfulAccounts_BD5AB4E81564CAED13D6850F48C5C45A" xlink:type="locator" />
<link:definitionArc order="13" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_3F0C2A970F792AD09A03850F48C368FE" xlink:to="loc_us-gaap_ProvisionForDoubtfulAccounts_BD5AB4E81564CAED13D6850F48C5C45A" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaap_ShareBasedCompensation_BDC67034B1822EF503FE850F48C512B6" xlink:type="locator" />
<link:definitionArc order="14" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_3F0C2A970F792AD09A03850F48C368FE" xlink:to="loc_us-gaap_ShareBasedCompensation_BDC67034B1822EF503FE850F48C512B6" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherNoncashExpense" xlink:label="loc_us-gaap_OtherNoncashExpense_F4B666EF61B22134B65D850F48C68208" xlink:type="locator" />
<link:definitionArc order="15" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_3F0C2A970F792AD09A03850F48C368FE" xlink:to="loc_us-gaap_OtherNoncashExpense_F4B666EF61B22134B65D850F48C68208" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_6812207EE24F0446651D850F48C67CDF" xlink:type="locator" />
<link:definitionArc order="16" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_3F0C2A970F792AD09A03850F48C368FE" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_6812207EE24F0446651D850F48C67CDF" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_3FFDE7E6BD89D01E7FFE850F48C62427" xlink:type="locator" />
<link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_6812207EE24F0446651D850F48C67CDF" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_3FFDE7E6BD89D01E7FFE850F48C62427" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInInventories" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories_58AAE17805E1049E5608850F48C6AA76" xlink:type="locator" />
<link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_6812207EE24F0446651D850F48C67CDF" xlink:to="loc_us-gaap_IncreaseDecreaseInInventories_58AAE17805E1049E5608850F48C6AA76" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInOtherReceivables" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherReceivables_7B7CE881622B2AD67A2C850F48C6AC1A" xlink:type="locator" />
<link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_6812207EE24F0446651D850F48C67CDF" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherReceivables_7B7CE881622B2AD67A2C850F48C6AC1A" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_5834EA9F1E70AB50369A850F48C6622F" xlink:type="locator" />
<link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_6812207EE24F0446651D850F48C67CDF" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_5834EA9F1E70AB50369A850F48C6622F" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_76A790CC4B7DFFF533C4850F48C730DF" xlink:type="locator" />
<link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_6812207EE24F0446651D850F48C67CDF" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_76A790CC4B7DFFF533C4850F48C730DF" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_CCBD27721B9AEBDE6447850F48C7D5B4" xlink:type="locator" />
<link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_6812207EE24F0446651D850F48C67CDF" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_CCBD27721B9AEBDE6447850F48C7D5B4" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:label="loc_us-gaap_IncreaseDecreaseInDeferredRevenue_EA42B9C922F09160A7A1850F48C768E7" xlink:type="locator" />
<link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_6812207EE24F0446651D850F48C67CDF" xlink:to="loc_us-gaap_IncreaseDecreaseInDeferredRevenue_EA42B9C922F09160A7A1850F48C768E7" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_EB0D803AA16ABF722606850F48C786BA" xlink:type="locator" />
<link:definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_6812207EE24F0446651D850F48C67CDF" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_EB0D803AA16ABF722606850F48C786BA" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_54933EFCB3382B26072D850F48C7DA19" xlink:type="locator" />
<link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_D98B9FD5B538F7B7C6D6850F48C286FA" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_54933EFCB3382B26072D850F48C7DA19" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:label="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_4884A8A43B8C203596C4850F48C77006" xlink:type="locator" />
<link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_54933EFCB3382B26072D850F48C7DA19" xlink:to="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_4884A8A43B8C203596C4850F48C77006" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_15445853E04ED86E9090850F48C8591A" xlink:type="locator" />
<link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_54933EFCB3382B26072D850F48C7DA19" xlink:to="loc_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_15445853E04ED86E9090850F48C8591A" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_162ECA08E46DC74D63DB850F48C89DE6" xlink:type="locator" />
<link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_54933EFCB3382B26072D850F48C7DA19" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_162ECA08E46DC74D63DB850F48C89DE6" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_44B91DD09CE6893D0527850F48C808B6" xlink:type="locator" />
<link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_54933EFCB3382B26072D850F48C7DA19" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_44B91DD09CE6893D0527850F48C808B6" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_DB4641840B53276FC068850F48C8D1FE" xlink:type="locator" />
<link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_D98B9FD5B538F7B7C6D6850F48C286FA" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_DB4641840B53276FC068850F48C8D1FE" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_17C53D9E6EE4F9F914EC850F48C82F9F" xlink:type="locator" />
<link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_DB4641840B53276FC068850F48C8D1FE" xlink:to="loc_us-gaap_ProceedsFromStockOptionsExercised_17C53D9E6EE4F9F914EC850F48C82F9F" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="loc_us-gaap_ProceedsFromWarrantExercises_8CCF5DE880DD0C7C388F850F48C9ECB8" xlink:type="locator" />
<link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_DB4641840B53276FC068850F48C8D1FE" xlink:to="loc_us-gaap_ProceedsFromWarrantExercises_8CCF5DE880DD0C7C388F850F48C9ECB8" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock_D04F35AF3C633066D370850F48C96BF8" xlink:type="locator" />
<link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_DB4641840B53276FC068850F48C8D1FE" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock_D04F35AF3C633066D370850F48C96BF8" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:label="loc_us-gaap_ProceedsFromIssuanceInitialPublicOffering_E69C3BA7AF8AAA0E8A2A850F48C98448" xlink:type="locator" />
<link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_DB4641840B53276FC068850F48C8D1FE" xlink:to="loc_us-gaap_ProceedsFromIssuanceInitialPublicOffering_E69C3BA7AF8AAA0E8A2A850F48C98448" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_170286333CFBF7AAE01A850F48C9FC67" xlink:type="locator" />
<link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_DB4641840B53276FC068850F48C8D1FE" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_170286333CFBF7AAE01A850F48C9FC67" xlink:type="arc" />
<link:loc xlink:href="immu-20191231.xsd#immu_ProceedsFromIssuanceOfNonRecourseDebt" xlink:label="loc_immu_ProceedsFromIssuanceOfNonRecourseDebt_89A80BEBF0FAF6CAB8E8850F48C96885" xlink:type="locator" />
<link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_DB4641840B53276FC068850F48C8D1FE" xlink:to="loc_immu_ProceedsFromIssuanceOfNonRecourseDebt_89A80BEBF0FAF6CAB8E8850F48C96885" xlink:type="arc" />
<link:loc xlink:href="immu-20191231.xsd#immu_PaymentOfDebtConversionFees" xlink:label="loc_immu_PaymentOfDebtConversionFees_C9394921E15BCD099F10850F48C9FB0D" xlink:type="locator" />
<link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_DB4641840B53276FC068850F48C8D1FE" xlink:to="loc_immu_PaymentOfDebtConversionFees_C9394921E15BCD099F10850F48C9FB0D" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:label="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_DE426E616F7B1D17987B850F48CA2F58" xlink:type="locator" />
<link:definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_DB4641840B53276FC068850F48C8D1FE" xlink:to="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_DE426E616F7B1D17987B850F48CA2F58" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_D7E291371D366E4B41A6850F48CAC80F" xlink:type="locator" />
<link:definitionArc order="9" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_DB4641840B53276FC068850F48C8D1FE" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_D7E291371D366E4B41A6850F48CAC80F" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_13F8537322C5FD7CA770850F48CAB3AA" xlink:type="locator" />
<link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_D98B9FD5B538F7B7C6D6850F48C286FA" xlink:to="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_13F8537322C5FD7CA770850F48CAB3AA" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_04AA55A0A9F7909025F2850F48CAFA35" xlink:type="locator" />
<link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_D98B9FD5B538F7B7C6D6850F48C286FA" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_04AA55A0A9F7909025F2850F48CAFA35" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_6676EABE3A59074AF404850F48CA6487" xlink:type="locator" />
<link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_D98B9FD5B538F7B7C6D6850F48C286FA" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_6676EABE3A59074AF404850F48CA6487" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract_33B642340BC7803CFCEF850F48CB8F7E" xlink:type="locator" />
<link:definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_D98B9FD5B538F7B7C6D6850F48C286FA" xlink:to="loc_us-gaap_SupplementalCashFlowInformationAbstract_33B642340BC7803CFCEF850F48CB8F7E" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InterestPaidNet" xlink:label="loc_us-gaap_InterestPaidNet_94057D2DE29F9C268532850F48CB8AB8" xlink:type="locator" />
<link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_33B642340BC7803CFCEF850F48CB8F7E" xlink:to="loc_us-gaap_InterestPaidNet_94057D2DE29F9C268532850F48CB8AB8" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxesPaidNet" xlink:label="loc_us-gaap_IncomeTaxesPaidNet_3BC0E6713D91BC060DE5850F48CB8C0A" xlink:type="locator" />
<link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_33B642340BC7803CFCEF850F48CB8F7E" xlink:to="loc_us-gaap_IncomeTaxesPaidNet_3BC0E6713D91BC060DE5850F48CB8C0A" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:label="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_79595872D16BFDE61B95850F48CB4631" xlink:type="locator" />
<link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_33B642340BC7803CFCEF850F48CB8F7E" xlink:to="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_79595872D16BFDE61B95850F48CB4631" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtConversionOriginalDebtAmount1" xlink:label="loc_us-gaap_DebtConversionOriginalDebtAmount1_7D2A300F177CEB28CAB9850F48CB952B" xlink:type="locator" />
<link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_79595872D16BFDE61B95850F48CB4631" xlink:to="loc_us-gaap_DebtConversionOriginalDebtAmount1_7D2A300F177CEB28CAB9850F48CB952B" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:label="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid_38024077610C863FC7F7850F48CC9EB8" xlink:type="locator" />
<link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_79595872D16BFDE61B95850F48CB4631" xlink:to="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid_38024077610C863FC7F7850F48CC9EB8" xlink:type="arc" />
<link:loc xlink:href="immu-20191231.xsd#immu_ReclassOfWarrantLiabilityToCapitalContributedInExcessOfPar" xlink:label="loc_immu_ReclassOfWarrantLiabilityToCapitalContributedInExcessOfPar_B70C52440131664DB50D850F48CCA733" xlink:type="locator" />
<link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_33B642340BC7803CFCEF850F48CB8F7E" xlink:to="loc_immu_ReclassOfWarrantLiabilityToCapitalContributedInExcessOfPar_B70C52440131664DB50D850F48CCA733" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssued1" xlink:label="loc_us-gaap_StockIssued1_196DCF8CD1933035B28E850F48CC9EDD" xlink:type="locator" />
<link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_33B642340BC7803CFCEF850F48CB8F7E" xlink:to="loc_us-gaap_StockIssued1_196DCF8CD1933035B28E850F48CC9EDD" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_5502F03DB48A1EAD9BED850F48CC72B2" xlink:type="locator" />
<link:definitionArc order="9" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_D98B9FD5B538F7B7C6D6850F48C286FA" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_5502F03DB48A1EAD9BED850F48CC72B2" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestrictedCashCurrent" xlink:label="loc_us-gaap_RestrictedCashCurrent_FED23580107C4D9E6065850F48CCAD4D" xlink:type="locator" />
<link:definitionArc order="10" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_D98B9FD5B538F7B7C6D6850F48C286FA" xlink:to="loc_us-gaap_RestrictedCashCurrent_FED23580107C4D9E6065850F48CCAD4D" xlink:type="arc" />
</link:definitionLink>
<link:definitionLink xlink:role="http://www.immunomedics.com/role/ConsolidatedStatementsOfChangesInStockholdersEquity" xlink:type="extended">
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_87A5F0DCA73FC9570251850F48E3D4A1" xlink:type="locator" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_A9A06ED6D8261C34DDBF850F48DDF8F4" xlink:type="locator" />
<link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_87A5F0DCA73FC9570251850F48E3D4A1" xlink:to="loc_us-gaap_StatementTable_A9A06ED6D8261C34DDBF850F48DDF8F4" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_15756B7A2D16B8E43178850F48DE611C" xlink:type="locator" />
<link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_A9A06ED6D8261C34DDBF850F48DDF8F4" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_15756B7A2D16B8E43178850F48DE611C" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_E789B41A1DB48DFD9079850F48DE3E26_default" xlink:type="locator" />
<link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_15756B7A2D16B8E43178850F48DE611C" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_E789B41A1DB48DFD9079850F48DE3E26_default" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_E789B41A1DB48DFD9079850F48DE3E26" xlink:type="locator" />
<link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_15756B7A2D16B8E43178850F48DE611C" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_E789B41A1DB48DFD9079850F48DE3E26" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IPOMember" xlink:label="loc_us-gaap_IPOMember_95AC806F7D19F0EB11CA850F48DF3621" xlink:type="locator" />
<link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_E789B41A1DB48DFD9079850F48DE3E26" xlink:to="loc_us-gaap_IPOMember_95AC806F7D19F0EB11CA850F48DF3621" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PrivatePlacementMember" xlink:label="loc_us-gaap_PrivatePlacementMember_FD0A23D578E537774A03850F48DF117A" xlink:type="locator" />
<link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_E789B41A1DB48DFD9079850F48DE3E26" xlink:to="loc_us-gaap_PrivatePlacementMember_FD0A23D578E537774A03850F48DF117A" xlink:type="arc" />
<link:loc xlink:href="immu-20191231.xsd#immu_MarketOfferingMember" xlink:label="loc_immu_MarketOfferingMember_387C0703280AC1E7B9D3850F48DF0D7F" xlink:type="locator" />
<link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_E789B41A1DB48DFD9079850F48DE3E26" xlink:to="loc_immu_MarketOfferingMember_387C0703280AC1E7B9D3850F48DF0D7F" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_294C1F252204E5C637B2850F48DFB621" xlink:type="locator" />
<link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_A9A06ED6D8261C34DDBF850F48DDF8F4" xlink:to="loc_us-gaap_StatementClassOfStockAxis_294C1F252204E5C637B2850F48DFB621" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_C659201D059723760708850F48DFB9D8_default" xlink:type="locator" />
<link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_294C1F252204E5C637B2850F48DFB621" xlink:to="loc_us-gaap_ClassOfStockDomain_C659201D059723760708850F48DFB9D8_default" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_C659201D059723760708850F48DFB9D8" xlink:type="locator" />
<link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_294C1F252204E5C637B2850F48DFB621" xlink:to="loc_us-gaap_ClassOfStockDomain_C659201D059723760708850F48DFB9D8" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConvertiblePreferredStockMember" xlink:label="loc_us-gaap_ConvertiblePreferredStockMember_D5B2D3184A88C0E61C17850F48E01640" xlink:type="locator" />
<link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_C659201D059723760708850F48DFB9D8" xlink:to="loc_us-gaap_ConvertiblePreferredStockMember_D5B2D3184A88C0E61C17850F48E01640" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_0F208F313B781FECB022850F48E0598A" xlink:type="locator" />
<link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_A9A06ED6D8261C34DDBF850F48DDF8F4" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_0F208F313B781FECB022850F48E0598A" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_14EBFC8826C2D87A3EE6850F48E07D75_default" xlink:type="locator" />
<link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_0F208F313B781FECB022850F48E0598A" xlink:to="loc_us-gaap_EquityComponentDomain_14EBFC8826C2D87A3EE6850F48E07D75_default" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_14EBFC8826C2D87A3EE6850F48E07D75" xlink:type="locator" />
<link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_0F208F313B781FECB022850F48E0598A" xlink:to="loc_us-gaap_EquityComponentDomain_14EBFC8826C2D87A3EE6850F48E07D75" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_437CBBCB70CB1EBD1F3E850F48E11515" xlink:type="locator" />
<link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_14EBFC8826C2D87A3EE6850F48E07D75" xlink:to="loc_us-gaap_CommonStockMember_437CBBCB70CB1EBD1F3E850F48E11515" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_EA66A60DA9B643BF757C850F48E16D31" xlink:type="locator" />
<link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_14EBFC8826C2D87A3EE6850F48E07D75" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_EA66A60DA9B643BF757C850F48E16D31" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TreasuryStockMember" xlink:label="loc_us-gaap_TreasuryStockMember_EDC648369AD0F435CF24850F48E14504" xlink:type="locator" />
<link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_14EBFC8826C2D87A3EE6850F48E07D75" xlink:to="loc_us-gaap_TreasuryStockMember_EDC648369AD0F435CF24850F48E14504" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaap_RetainedEarningsMember_BAE714DC0477DD395D65850F48E1CCBB" xlink:type="locator" />
<link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_14EBFC8826C2D87A3EE6850F48E07D75" xlink:to="loc_us-gaap_RetainedEarningsMember_BAE714DC0477DD395D65850F48E1CCBB" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_FAF480ECC546AFDC927E850F48E167E8" xlink:type="locator" />
<link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_14EBFC8826C2D87A3EE6850F48E07D75" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_FAF480ECC546AFDC927E850F48E167E8" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NoncontrollingInterestMember" xlink:label="loc_us-gaap_NoncontrollingInterestMember_BA494BD541B0533196F5850F48E2D5FD" xlink:type="locator" />
<link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_14EBFC8826C2D87A3EE6850F48E07D75" xlink:to="loc_us-gaap_NoncontrollingInterestMember_BA494BD541B0533196F5850F48E2D5FD" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_CounterpartyNameAxis" xlink:label="loc_srt_CounterpartyNameAxis_E5E2CBB5F996E0C17E16850F48E2492B" xlink:type="locator" />
<link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_A9A06ED6D8261C34DDBF850F48DDF8F4" xlink:to="loc_srt_CounterpartyNameAxis_E5E2CBB5F996E0C17E16850F48E2492B" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_77E293748596D62200C1850F48E27DBC_default" xlink:type="locator" />
<link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_E5E2CBB5F996E0C17E16850F48E2492B" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_77E293748596D62200C1850F48E27DBC_default" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_77E293748596D62200C1850F48E27DBC" xlink:type="locator" />
<link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_E5E2CBB5F996E0C17E16850F48E2492B" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_77E293748596D62200C1850F48E27DBC" xlink:type="arc" />
<link:loc xlink:href="immu-20191231.xsd#immu_SeattleGeneticsIncMember" xlink:label="loc_immu_SeattleGeneticsIncMember_8C34F696C8DF1B4F6523850F48E262BB" xlink:type="locator" />
<link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_77E293748596D62200C1850F48E27DBC" xlink:to="loc_immu_SeattleGeneticsIncMember_8C34F696C8DF1B4F6523850F48E262BB" xlink:type="arc" />
<link:loc xlink:href="immu-20191231.xsd#immu_RpiFinanceTrustMember" xlink:label="loc_immu_RpiFinanceTrustMember_3423230DE51DFAF8DDFD850F48E30A07" xlink:type="locator" />
<link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_77E293748596D62200C1850F48E27DBC" xlink:to="loc_immu_RpiFinanceTrustMember_3423230DE51DFAF8DDFD850F48E30A07" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_A12D4BD358632C8D685E850F48E3F4B3" xlink:type="locator" />
<link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_87A5F0DCA73FC9570251850F48E3D4A1" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_A12D4BD358632C8D685E850F48E3F4B3" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharesIssued" xlink:label="loc_us-gaap_SharesIssued_4A453983E0984B9A43BE850F48E39E07" xlink:type="locator" />
<link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_A12D4BD358632C8D685E850F48E3F4B3" xlink:to="loc_us-gaap_SharesIssued_4A453983E0984B9A43BE850F48E39E07" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_BBFD876070595A1BD882850F48E357EC" xlink:type="locator" />
<link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_A12D4BD358632C8D685E850F48E3F4B3" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_BBFD876070595A1BD882850F48E357EC" xlink:type="arc" />
<link:loc xlink:href="immu-20191231.xsd#immu_ReclassificationofWarrantLiabilitytoEquity" xlink:label="loc_immu_ReclassificationofWarrantLiabilitytoEquity_C69945798460F35A0E09850F48E47CED" xlink:type="locator" />
<link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_A12D4BD358632C8D685E850F48E3F4B3" xlink:to="loc_immu_ReclassificationofWarrantLiabilitytoEquity_C69945798460F35A0E09850F48E47CED" xlink:type="arc" />
<link:loc xlink:href="immu-20191231.xsd#immu_PreferredStockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_immu_PreferredStockIssuedDuringPeriodSharesNewIssues_D8342A9C590697F3E00A850F48E4E410" xlink:type="locator" />
<link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_A12D4BD358632C8D685E850F48E3F4B3" xlink:to="loc_immu_PreferredStockIssuedDuringPeriodSharesNewIssues_D8342A9C590697F3E00A850F48E4E410" xlink:type="arc" />
<link:loc xlink:href="immu-20191231.xsd#immu_PreferredStockIssuedDuringPeriodValueNewIssues" xlink:label="loc_immu_PreferredStockIssuedDuringPeriodValueNewIssues_6FB76EADC68491CC8FC1850F48E46180" xlink:type="locator" />
<link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_A12D4BD358632C8D685E850F48E3F4B3" xlink:to="loc_immu_PreferredStockIssuedDuringPeriodValueNewIssues_6FB76EADC68491CC8FC1850F48E46180" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_8ADD141794E7CC15B600850F48E43469" xlink:type="locator" />
<link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_A12D4BD358632C8D685E850F48E3F4B3" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_8ADD141794E7CC15B600850F48E43469" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_3802BC977357ADE17F2A850F48E4437C" xlink:type="locator" />
<link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_A12D4BD358632C8D685E850F48E3F4B3" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_3802BC977357ADE17F2A850F48E4437C" xlink:type="arc" />
<link:loc xlink:href="immu-20191231.xsd#immu_AdjustmentstoAdditionalPaidinCapitalProceedsFromOfferingWarrants" xlink:label="loc_immu_AdjustmentstoAdditionalPaidinCapitalProceedsFromOfferingWarrants_04138668A5E69C0DB8F7850F48E4F5EF" xlink:type="locator" />
<link:definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_A12D4BD358632C8D685E850F48E3F4B3" xlink:to="loc_immu_AdjustmentstoAdditionalPaidinCapitalProceedsFromOfferingWarrants_04138668A5E69C0DB8F7850F48E4F5EF" xlink:type="arc" />
<link:loc xlink:href="immu-20191231.xsd#immu_SharebasedCompensationArrangementbySharebasedPaymentAwardWarrantsExercisesinPeriod" xlink:label="loc_immu_SharebasedCompensationArrangementbySharebasedPaymentAwardWarrantsExercisesinPeriod_9EEC82250E188ADE056C850F48E4E6E8" xlink:type="locator" />
<link:definitionArc order="9" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_A12D4BD358632C8D685E850F48E3F4B3" xlink:to="loc_immu_SharebasedCompensationArrangementbySharebasedPaymentAwardWarrantsExercisesinPeriod_9EEC82250E188ADE056C850F48E4E6E8" xlink:type="arc" />
<link:loc xlink:href="immu-20191231.xsd#immu_StockIssuedDuringPeriodValueWarrantsExercised" xlink:label="loc_immu_StockIssuedDuringPeriodValueWarrantsExercised_992AAE67CA6E289D4C7E850F48E53AC3" xlink:type="locator" />
<link:definitionArc order="10" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_A12D4BD358632C8D685E850F48E3F4B3" xlink:to="loc_immu_StockIssuedDuringPeriodValueWarrantsExercised_992AAE67CA6E289D4C7E850F48E53AC3" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_1CDA7B53D2CBC0F42281850F48E51E76" xlink:type="locator" />
<link:definitionArc order="11" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_A12D4BD358632C8D685E850F48E3F4B3" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_1CDA7B53D2CBC0F42281850F48E51E76" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_E6FC38FC84E7D8185F2D850F48E5DFF0" xlink:type="locator" />
<link:definitionArc order="12" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_A12D4BD358632C8D685E850F48E3F4B3" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_E6FC38FC84E7D8185F2D850F48E5DFF0" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockRepurchasedAndRetiredDuringPeriodShares" xlink:label="loc_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares_2AF90E976E0A321AB2F6850F48E5C9A7" xlink:type="locator" />
<link:definitionArc order="13" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_A12D4BD358632C8D685E850F48E3F4B3" xlink:to="loc_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares_2AF90E976E0A321AB2F6850F48E5C9A7" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockRepurchasedAndRetiredDuringPeriodValue" xlink:label="loc_us-gaap_StockRepurchasedAndRetiredDuringPeriodValue_887486DA5BC550402115850F48E53209" xlink:type="locator" />
<link:definitionArc order="14" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_A12D4BD358632C8D685E850F48E3F4B3" xlink:to="loc_us-gaap_StockRepurchasedAndRetiredDuringPeriodValue_887486DA5BC550402115850F48E53209" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits_DA3269606B708A297FA3850F48E59800" xlink:type="locator" />
<link:definitionArc order="15" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_A12D4BD358632C8D685E850F48E3F4B3" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits_DA3269606B708A297FA3850F48E59800" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecuritiesNetOfAdjustments" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecuritiesNetOfAdjustments_7E83FCCCE8B849ECA82F850F48E6158C" xlink:type="locator" />
<link:definitionArc order="16" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_A12D4BD358632C8D685E850F48E3F4B3" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecuritiesNetOfAdjustments_7E83FCCCE8B849ECA82F850F48E6158C" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xlink:label="loc_us-gaap_DebtConversionConvertedInstrumentSharesIssued1_187BCF77647D53F7B9B4850F48E694E0" xlink:type="locator" />
<link:definitionArc order="17" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_A12D4BD358632C8D685E850F48E3F4B3" xlink:to="loc_us-gaap_DebtConversionConvertedInstrumentSharesIssued1_187BCF77647D53F7B9B4850F48E694E0" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtConversionConvertedInstrumentAmount1" xlink:label="loc_us-gaap_DebtConversionConvertedInstrumentAmount1_FF207936941DB371E8C9850F48E6A3AE" xlink:type="locator" />
<link:definitionArc order="18" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_A12D4BD358632C8D685E850F48E3F4B3" xlink:to="loc_us-gaap_DebtConversionConvertedInstrumentAmount1_FF207936941DB371E8C9850F48E6A3AE" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_46CBF5E7A9B3DDA4B9B6850F48E64F4D" xlink:type="locator" />
<link:definitionArc order="19" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_A12D4BD358632C8D685E850F48E3F4B3" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_46CBF5E7A9B3DDA4B9B6850F48E64F4D" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_C51B3FFFFC9B210094CF850F48E6B0DE" xlink:type="locator" />
<link:definitionArc order="20" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_A12D4BD358632C8D685E850F48E3F4B3" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_C51B3FFFFC9B210094CF850F48E6B0DE" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation" xlink:label="loc_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation_4FCB2713E25854ADD7B1850F48E7ECD9" xlink:type="locator" />
<link:definitionArc order="21" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_A12D4BD358632C8D685E850F48E3F4B3" xlink:to="loc_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation_4FCB2713E25854ADD7B1850F48E7ECD9" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:label="loc_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation_A2B092E90D16EAAC49B2850F48E70AB0" xlink:type="locator" />
<link:definitionArc order="22" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_A12D4BD358632C8D685E850F48E3F4B3" xlink:to="loc_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation_A2B092E90D16EAAC49B2850F48E70AB0" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_BD93D9EAC0AFA298A9F6850F48E72C9D" xlink:type="locator" />
<link:definitionArc order="23" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_A12D4BD358632C8D685E850F48E3F4B3" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_BD93D9EAC0AFA298A9F6850F48E72C9D" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProfitLoss" xlink:label="loc_us-gaap_ProfitLoss_3C98C26798907127CDA1850F48E70D0D" xlink:type="locator" />
<link:definitionArc order="24" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_A12D4BD358632C8D685E850F48E3F4B3" xlink:to="loc_us-gaap_ProfitLoss_3C98C26798907127CDA1850F48E70D0D" xlink:type="arc" />
</link:definitionLink>
<link:definitionLink xlink:role="http://www.immunomedics.com/role/ConsolidatedStatementsOfComprehensiveLoss" xlink:type="extended">
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_64808253156529864DB73991D2EE9751" xlink:type="locator" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_3825C0A03532CAE333323991D2ED7BE8" xlink:type="locator" />
<link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_64808253156529864DB73991D2EE9751" xlink:to="loc_us-gaap_StatementTable_3825C0A03532CAE333323991D2ED7BE8" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
<link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="loc_srt_ProductOrServiceAxis_22CF8D6FA4D195CFB0A23991D2EDA726" xlink:type="locator" />
<link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_3825C0A03532CAE333323991D2ED7BE8" xlink:to="loc_srt_ProductOrServiceAxis_22CF8D6FA4D195CFB0A23991D2EDA726" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain_49B4A8F93F2BE7F95EC83991D2EE4186_default" xlink:type="locator" />
<link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_22CF8D6FA4D195CFB0A23991D2EDA726" xlink:to="loc_srt_ProductsAndServicesDomain_49B4A8F93F2BE7F95EC83991D2EE4186_default" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain_49B4A8F93F2BE7F95EC83991D2EE4186" xlink:type="locator" />
<link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_22CF8D6FA4D195CFB0A23991D2EDA726" xlink:to="loc_srt_ProductsAndServicesDomain_49B4A8F93F2BE7F95EC83991D2EE4186" xlink:type="arc" />
<link:loc xlink:href="immu-20191231.xsd#immu_ProductSalesMember" xlink:label="loc_immu_ProductSalesMember_45A60C0F21551244EA603991D2EE2686" xlink:type="locator" />
<link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_49B4A8F93F2BE7F95EC83991D2EE4186" xlink:to="loc_immu_ProductSalesMember_45A60C0F21551244EA603991D2EE2686" xlink:type="arc" />
<link:loc xlink:href="immu-20191231.xsd#immu_LicenseFreeAndOtherRevenueMember" xlink:label="loc_immu_LicenseFreeAndOtherRevenueMember_0B44C7717F9249711D103991D2EEE4A0" xlink:type="locator" />
<link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_49B4A8F93F2BE7F95EC83991D2EE4186" xlink:to="loc_immu_LicenseFreeAndOtherRevenueMember_0B44C7717F9249711D103991D2EEE4A0" xlink:type="arc" />
<link:loc xlink:href="immu-20191231.xsd#immu_ResearchandDevelopmentMember" xlink:label="loc_immu_ResearchandDevelopmentMember_21F77234471BFC2EF67D3991D2EE395C" xlink:type="locator" />
<link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_49B4A8F93F2BE7F95EC83991D2EE4186" xlink:to="loc_immu_ResearchandDevelopmentMember_21F77234471BFC2EF67D3991D2EE395C" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_6306CCA70B26123DEA0B3991D2EEA6C9" xlink:type="locator" />
<link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_64808253156529864DB73991D2EE9751" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_6306CCA70B26123DEA0B3991D2EEA6C9" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingCostsAndExpensesAbstract" xlink:label="loc_us-gaap_OperatingCostsAndExpensesAbstract_B0A834C896BE79AA3C943991D2EF6DE2" xlink:type="locator" />
<link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_64808253156529864DB73991D2EE9751" xlink:to="loc_us-gaap_OperatingCostsAndExpensesAbstract_B0A834C896BE79AA3C943991D2EF6DE2" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CostOfRevenue" xlink:label="loc_us-gaap_CostOfRevenue_CC8BF2DAC8FFA253B10E3991D2EF784A" xlink:type="locator" />
<link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingCostsAndExpensesAbstract_B0A834C896BE79AA3C943991D2EF6DE2" xlink:to="loc_us-gaap_CostOfRevenue_CC8BF2DAC8FFA253B10E3991D2EF784A" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_6BE5C575300BDA7173053991D2EF16C1" xlink:type="locator" />
<link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingCostsAndExpensesAbstract_B0A834C896BE79AA3C943991D2EF6DE2" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_6BE5C575300BDA7173053991D2EF16C1" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SellingAndMarketingExpense" xlink:label="loc_us-gaap_SellingAndMarketingExpense_B19B5F04389E85B2AAC23991D2EF2FD3" xlink:type="locator" />
<link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingCostsAndExpensesAbstract_B0A834C896BE79AA3C943991D2EF6DE2" xlink:to="loc_us-gaap_SellingAndMarketingExpense_B19B5F04389E85B2AAC23991D2EF2FD3" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_B6FD0A604E52D8847AB83991D2F0B458" xlink:type="locator" />
<link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingCostsAndExpensesAbstract_B0A834C896BE79AA3C943991D2EF6DE2" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_B6FD0A604E52D8847AB83991D2F0B458" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CostsAndExpenses" xlink:label="loc_us-gaap_CostsAndExpenses_A0DB6A50253584EF4E613991D2F01F7A" xlink:type="locator" />
<link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingCostsAndExpensesAbstract_B0A834C896BE79AA3C943991D2EF6DE2" xlink:to="loc_us-gaap_CostsAndExpenses_A0DB6A50253584EF4E613991D2F01F7A" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaap_OperatingIncomeLoss_F77C73B193B830DC98D23991D2F0FDB6" xlink:type="locator" />
<link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_64808253156529864DB73991D2EE9751" xlink:to="loc_us-gaap_OperatingIncomeLoss_F77C73B193B830DC98D23991D2F0FDB6" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="loc_us-gaap_FairValueAdjustmentOfWarrants_07807BE17701BA7D655C3991D2F0EC35" xlink:type="locator" />
<link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_64808253156529864DB73991D2EE9751" xlink:to="loc_us-gaap_FairValueAdjustmentOfWarrants_07807BE17701BA7D655C3991D2F0EC35" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdjustmentOfWarrantsGrantedForServices" xlink:label="loc_us-gaap_AdjustmentOfWarrantsGrantedForServices_8FB3BFAE946622C778683991D2F09B24" xlink:type="locator" />
<link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_64808253156529864DB73991D2EE9751" xlink:to="loc_us-gaap_AdjustmentOfWarrantsGrantedForServices_8FB3BFAE946622C778683991D2F09B24" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InterestExpense" xlink:label="loc_us-gaap_InterestExpense_2B792A808FCECD48E3103991D2F012BD" xlink:type="locator" />
<link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_64808253156529864DB73991D2EE9751" xlink:to="loc_us-gaap_InterestExpense_2B792A808FCECD48E3103991D2F012BD" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InterestAndOtherIncome" xlink:label="loc_us-gaap_InterestAndOtherIncome_48115CA82FF3FA7913C83991D2F05F9C" xlink:type="locator" />
<link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_64808253156529864DB73991D2EE9751" xlink:to="loc_us-gaap_InterestAndOtherIncome_48115CA82FF3FA7913C83991D2F05F9C" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_343F36BBA1351D4307503991D2F1A9D9" xlink:type="locator" />
<link:definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_64808253156529864DB73991D2EE9751" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_343F36BBA1351D4307503991D2F1A9D9" xlink:type="arc" />
<link:loc xlink:href="immu-20191231.xsd#immu_OtherFinancingExpenseIncome" xlink:label="loc_immu_OtherFinancingExpenseIncome_1A249C92A1AD8D640FB23991D2F125B7" xlink:type="locator" />
<link:definitionArc order="9" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_64808253156529864DB73991D2EE9751" xlink:to="loc_immu_OtherFinancingExpenseIncome_1A249C92A1AD8D640FB23991D2F125B7" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GainOnBusinessInterruptionInsuranceRecovery" xlink:label="loc_us-gaap_GainOnBusinessInterruptionInsuranceRecovery_934167A48ABC430009B43991D2F1EF4B" xlink:type="locator" />
<link:definitionArc order="10" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_64808253156529864DB73991D2EE9751" xlink:to="loc_us-gaap_GainOnBusinessInterruptionInsuranceRecovery_934167A48ABC430009B43991D2F1EF4B" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:label="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_6D00024E1D56B1A069B73991D2F1A04B" xlink:type="locator" />
<link:definitionArc order="11" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_64808253156529864DB73991D2EE9751" xlink:to="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_6D00024E1D56B1A069B73991D2F1A04B" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_37D2660895D0FDE20A8E3991D2F1FDDC" xlink:type="locator" />
<link:definitionArc order="12" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_64808253156529864DB73991D2EE9751" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_37D2660895D0FDE20A8E3991D2F1FDDC" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_C7AF9F997E338E8448DD3991D2F23A3B" xlink:type="locator" />
<link:definitionArc order="13" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_64808253156529864DB73991D2EE9751" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_C7AF9F997E338E8448DD3991D2F23A3B" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProfitLoss" xlink:label="loc_us-gaap_ProfitLoss_5A6E14ED519E24FDF5193991D2F20BD9" xlink:type="locator" />
<link:definitionArc order="14" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_64808253156529864DB73991D2EE9751" xlink:to="loc_us-gaap_ProfitLoss_5A6E14ED519E24FDF5193991D2F20BD9" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_835D025D4EDD419966A43991D2F27E72" xlink:type="locator" />
<link:definitionArc order="15" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_64808253156529864DB73991D2EE9751" xlink:to="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_835D025D4EDD419966A43991D2F27E72" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_F99ECE8B1B9C2A7D1EAF3991D2F28FE6" xlink:type="locator" />
<link:definitionArc order="16" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_64808253156529864DB73991D2EE9751" xlink:to="loc_us-gaap_NetIncomeLoss_F99ECE8B1B9C2A7D1EAF3991D2F28FE6" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDiluted_93C4BC00FC5DDA6180643991D2F2E687" xlink:type="locator" />
<link:definitionArc order="17" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_64808253156529864DB73991D2EE9751" xlink:to="loc_us-gaap_EarningsPerShareBasicAndDiluted_93C4BC00FC5DDA6180643991D2F2E687" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:label="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_A45B79CD9CC922FE84A33991D2F2BAAA" xlink:type="locator" />
<link:definitionArc order="18" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_64808253156529864DB73991D2EE9751" xlink:to="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_A45B79CD9CC922FE84A33991D2F2BAAA" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_D81D592D3CEE8D11603E3991D2F29E1B" xlink:type="locator" />
<link:definitionArc order="19" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_64808253156529864DB73991D2EE9751" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_D81D592D3CEE8D11603E3991D2F29E1B" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_CCA16121786BAC259F223991D2F32C88" xlink:type="locator" />
<link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_D81D592D3CEE8D11603E3991D2F29E1B" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_CCA16121786BAC259F223991D2F32C88" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_78131803F2859990C7943991D2F3EBDE" xlink:type="locator" />
<link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_D81D592D3CEE8D11603E3991D2F29E1B" xlink:to="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_78131803F2859990C7943991D2F3EBDE" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_27F826F1BEB8FA2318F93991D2F3BFF4" xlink:type="locator" />
<link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_D81D592D3CEE8D11603E3991D2F29E1B" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_27F826F1BEB8FA2318F93991D2F3BFF4" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_B25BA9D06E81AEDB075B3991D2F3FCDD" xlink:type="locator" />
<link:definitionArc order="20" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_64808253156529864DB73991D2EE9751" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_B25BA9D06E81AEDB075B3991D2F3FCDD" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_45C840BA398E4E3D4B913991D2F33518" xlink:type="locator" />
<link:definitionArc order="21" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_64808253156529864DB73991D2EE9751" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_45C840BA398E4E3D4B913991D2F33518" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_F3B9419815158C25580A3991D2F3D24D" xlink:type="locator" />
<link:definitionArc order="22" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_64808253156529864DB73991D2EE9751" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTax_F3B9419815158C25580A3991D2F3D24D" xlink:type="arc" />
</link:definitionLink>
<link:definitionLink xlink:role="http://www.immunomedics.com/role/CoverPage" xlink:type="extended" />
<link:definitionLink xlink:role="http://www.immunomedics.com/role/Debt" xlink:type="extended" />
<link:definitionLink xlink:role="http://www.immunomedics.com/role/DebtConsiderationAllocationDetails" xlink:type="extended">
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredRevenueArrangementLineItems" xlink:label="loc_us-gaap_DeferredRevenueArrangementLineItems_CA3758CB21B1BD02862DDC8C25265E0D" xlink:type="locator" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredRevenueArrangementByTypeTable" xlink:label="loc_us-gaap_DeferredRevenueArrangementByTypeTable_21DD3A5BE1049858A70BDC8C25240E9E" xlink:type="locator" />
<link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DeferredRevenueArrangementLineItems_CA3758CB21B1BD02862DDC8C25265E0D" xlink:to="loc_us-gaap_DeferredRevenueArrangementByTypeTable_21DD3A5BE1049858A70BDC8C25240E9E" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
<link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_CounterpartyNameAxis" xlink:label="loc_srt_CounterpartyNameAxis_C276CB6187B98FBBB678DC8C2524FE7B" xlink:type="locator" />
<link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DeferredRevenueArrangementByTypeTable_21DD3A5BE1049858A70BDC8C25240E9E" xlink:to="loc_srt_CounterpartyNameAxis_C276CB6187B98FBBB678DC8C2524FE7B" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_C747660E21FE22C1ABA4DC8C25253739_default" xlink:type="locator" />
<link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_C276CB6187B98FBBB678DC8C2524FE7B" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_C747660E21FE22C1ABA4DC8C25253739_default" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_C747660E21FE22C1ABA4DC8C25253739" xlink:type="locator" />
<link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_C276CB6187B98FBBB678DC8C2524FE7B" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_C747660E21FE22C1ABA4DC8C25253739" xlink:type="arc" />
<link:loc xlink:href="immu-20191231.xsd#immu_RpiFinanceTrustMember" xlink:label="loc_immu_RpiFinanceTrustMember_3489A6D92C293A8A20AEDC8C252522FD" xlink:type="locator" />
<link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_C747660E21FE22C1ABA4DC8C25253739" xlink:to="loc_immu_RpiFinanceTrustMember_3489A6D92C293A8A20AEDC8C252522FD" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredRevenueArrangementTypeAxis" xlink:label="loc_us-gaap_DeferredRevenueArrangementTypeAxis_81832223976D9C8D3C60DC8C25252006" xlink:type="locator" />
<link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DeferredRevenueArrangementByTypeTable_21DD3A5BE1049858A70BDC8C25240E9E" xlink:to="loc_us-gaap_DeferredRevenueArrangementTypeAxis_81832223976D9C8D3C60DC8C25252006" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredRevenueArrangementTypeDomain" xlink:label="loc_us-gaap_DeferredRevenueArrangementTypeDomain_64ABE74EC10ED1C2E578DC8C25255A4D_default" xlink:type="locator" />
<link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DeferredRevenueArrangementTypeAxis_81832223976D9C8D3C60DC8C25252006" xlink:to="loc_us-gaap_DeferredRevenueArrangementTypeDomain_64ABE74EC10ED1C2E578DC8C25255A4D_default" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredRevenueArrangementTypeDomain" xlink:label="loc_us-gaap_DeferredRevenueArrangementTypeDomain_64ABE74EC10ED1C2E578DC8C25255A4D" xlink:type="locator" />
<link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DeferredRevenueArrangementTypeAxis_81832223976D9C8D3C60DC8C25252006" xlink:to="loc_us-gaap_DeferredRevenueArrangementTypeDomain_64ABE74EC10ED1C2E578DC8C25255A4D" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RoyaltyArrangementMember" xlink:label="loc_us-gaap_RoyaltyArrangementMember_7C95D0A56F83BAE24010DC8C252638D3" xlink:type="locator" />
<link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DeferredRevenueArrangementTypeDomain_64ABE74EC10ED1C2E578DC8C25255A4D" xlink:to="loc_us-gaap_RoyaltyArrangementMember_7C95D0A56F83BAE24010DC8C252638D3" xlink:type="arc" />
<link:loc xlink:href="immu-20191231.xsd#immu_FairValueForLiabilityRelatedtoSaleofFutureRoyalties" xlink:label="loc_immu_FairValueForLiabilityRelatedtoSaleofFutureRoyalties_0EC8EEEFE6F416932FCBDC8C25261090" xlink:type="locator" />
<link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DeferredRevenueArrangementLineItems_CA3758CB21B1BD02862DDC8C25265E0D" xlink:to="loc_immu_FairValueForLiabilityRelatedtoSaleofFutureRoyalties_0EC8EEEFE6F416932FCBDC8C25261090" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaap_CommonStockValue_F81EB7A42FE090241B6FDC8C252617E2" xlink:type="locator" />
<link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DeferredRevenueArrangementLineItems_CA3758CB21B1BD02862DDC8C25265E0D" xlink:to="loc_us-gaap_CommonStockValue_F81EB7A42FE090241B6FDC8C252617E2" xlink:type="arc" />
<link:loc xlink:href="immu-20191231.xsd#immu_RoyaltyPurchaseAgreementArrangementsConsideration" xlink:label="loc_immu_RoyaltyPurchaseAgreementArrangementsConsideration_49946F7D07095DFDDD82DC8C25271750" xlink:type="locator" />
<link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DeferredRevenueArrangementLineItems_CA3758CB21B1BD02862DDC8C25265E0D" xlink:to="loc_immu_RoyaltyPurchaseAgreementArrangementsConsideration_49946F7D07095DFDDD82DC8C25271750" xlink:type="arc" />
</link:definitionLink>
<link:definitionLink xlink:role="http://www.immunomedics.com/role/DebtConvertibleSeniorNotesDetails" xlink:type="extended">
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredRevenueArrangementLineItems" xlink:label="loc_us-gaap_DeferredRevenueArrangementLineItems_A61291F657DA9B9C03647E59E3B5E4B1" xlink:type="locator" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredRevenueArrangementByTypeTable" xlink:label="loc_us-gaap_DeferredRevenueArrangementByTypeTable_63CD53B0BE48C3BAAB857E59E3B3D37C" xlink:type="locator" />
<link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DeferredRevenueArrangementLineItems_A61291F657DA9B9C03647E59E3B5E4B1" xlink:to="loc_us-gaap_DeferredRevenueArrangementByTypeTable_63CD53B0BE48C3BAAB857E59E3B3D37C" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_C7BAC0E8E59C5A8C8E137E59E3B4C3E7" xlink:type="locator" />
<link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DeferredRevenueArrangementByTypeTable_63CD53B0BE48C3BAAB857E59E3B3D37C" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_C7BAC0E8E59C5A8C8E137E59E3B4C3E7" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_D040975D839636F11E367E59E3B4604C_default" xlink:type="locator" />
<link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_C7BAC0E8E59C5A8C8E137E59E3B4C3E7" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_D040975D839636F11E367E59E3B4604C_default" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_D040975D839636F11E367E59E3B4604C" xlink:type="locator" />
<link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_C7BAC0E8E59C5A8C8E137E59E3B4C3E7" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_D040975D839636F11E367E59E3B4604C" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaap_SubsequentEventMember_3D35FB42BBDCA9FDF9D67E59E3B4FA2C" xlink:type="locator" />
<link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_D040975D839636F11E367E59E3B4604C" xlink:to="loc_us-gaap_SubsequentEventMember_3D35FB42BBDCA9FDF9D67E59E3B4FA2C" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaap_DebtInstrumentAxis_E63FFDC7A2A22EE8A6D27E59E3B56F1D" xlink:type="locator" />
<link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DeferredRevenueArrangementByTypeTable_63CD53B0BE48C3BAAB857E59E3B3D37C" xlink:to="loc_us-gaap_DebtInstrumentAxis_E63FFDC7A2A22EE8A6D27E59E3B56F1D" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_98440B5079A09B026A3A7E59E3B5C0D5_default" xlink:type="locator" />
<link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_E63FFDC7A2A22EE8A6D27E59E3B56F1D" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_98440B5079A09B026A3A7E59E3B5C0D5_default" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_98440B5079A09B026A3A7E59E3B5C0D5" xlink:type="locator" />
<link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_E63FFDC7A2A22EE8A6D27E59E3B56F1D" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_98440B5079A09B026A3A7E59E3B5C0D5" xlink:type="arc" />
<link:loc xlink:href="immu-20191231.xsd#immu_FourPointSevenFivePercentConvertibleSeniorNotesMember" xlink:label="loc_immu_FourPointSevenFivePercentConvertibleSeniorNotesMember_66084863CD5A2CBA72847E59E3B58383" xlink:type="locator" />
<link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_98440B5079A09B026A3A7E59E3B5C0D5" xlink:to="loc_immu_FourPointSevenFivePercentConvertibleSeniorNotesMember_66084863CD5A2CBA72847E59E3B58383" xlink:type="arc" />
<link:loc xlink:href="immu-20191231.xsd#immu_October2018ExchangeAgreementMember" xlink:label="loc_immu_October2018ExchangeAgreementMember_644BD44DCF6FFD39050B7E59E3B52D08" xlink:type="locator" />
<link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_98440B5079A09B026A3A7E59E3B5C0D5" xlink:to="loc_immu_October2018ExchangeAgreementMember_644BD44DCF6FFD39050B7E59E3B52D08" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_9E6D5114BA1FCF6817E67E59E3B6B7A7" xlink:type="locator" />
<link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DeferredRevenueArrangementLineItems_A61291F657DA9B9C03647E59E3B5E4B1" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_9E6D5114BA1FCF6817E67E59E3B6B7A7" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromDebtNetOfIssuanceCosts" xlink:label="loc_us-gaap_ProceedsFromDebtNetOfIssuanceCosts_F3C1ACD8B16A6414CA567E59E3B6250A" xlink:type="locator" />
<link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DeferredRevenueArrangementLineItems_A61291F657DA9B9C03647E59E3B5E4B1" xlink:to="loc_us-gaap_ProceedsFromDebtNetOfIssuanceCosts_F3C1ACD8B16A6414CA567E59E3B6250A" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsOfDebtIssuanceCosts" xlink:label="loc_us-gaap_PaymentsOfDebtIssuanceCosts_F3A1AF6149122C39732F7E59E3B64D84" xlink:type="locator" />
<link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DeferredRevenueArrangementLineItems_A61291F657DA9B9C03647E59E3B5E4B1" xlink:to="loc_us-gaap_PaymentsOfDebtIssuanceCosts_F3A1AF6149122C39732F7E59E3B64D84" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_9A76A9E09C4A22F5A9D57E59E3B61AA6" xlink:type="locator" />
<link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DeferredRevenueArrangementLineItems_A61291F657DA9B9C03647E59E3B5E4B1" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_9A76A9E09C4A22F5A9D57E59E3B61AA6" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:label="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage_3B3119A6BD18932053947E59E3B625A2" xlink:type="locator" />
<link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DeferredRevenueArrangementLineItems_A61291F657DA9B9C03647E59E3B5E4B1" xlink:to="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage_3B3119A6BD18932053947E59E3B625A2" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:label="loc_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_551A5FB0E4E22F6C67A27E59E3B6E386" xlink:type="locator" />
<link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DeferredRevenueArrangementLineItems_A61291F657DA9B9C03647E59E3B5E4B1" xlink:to="loc_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_551A5FB0E4E22F6C67A27E59E3B6E386" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentConvertibleConversionRatio1" xlink:label="loc_us-gaap_DebtInstrumentConvertibleConversionRatio1_9AF338F0E6E64A1452C27E59E3B73FE3" xlink:type="locator" />
<link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DeferredRevenueArrangementLineItems_A61291F657DA9B9C03647E59E3B5E4B1" xlink:to="loc_us-gaap_DebtInstrumentConvertibleConversionRatio1_9AF338F0E6E64A1452C27E59E3B73FE3" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:label="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1_62BD5DA267C1B3F2C3107E59E3B7F61B" xlink:type="locator" />
<link:definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DeferredRevenueArrangementLineItems_A61291F657DA9B9C03647E59E3B5E4B1" xlink:to="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1_62BD5DA267C1B3F2C3107E59E3B7F61B" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed_7B2E5642F278CF950E5C7E59E3B7DFE7" xlink:type="locator" />
<link:definitionArc order="9" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DeferredRevenueArrangementLineItems_A61291F657DA9B9C03647E59E3B5E4B1" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed_7B2E5642F278CF950E5C7E59E3B7DFE7" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtConversionOriginalDebtAmount1" xlink:label="loc_us-gaap_DebtConversionOriginalDebtAmount1_893FE425634EC0867D227E59E3B7C8AD" xlink:type="locator" />
<link:definitionArc order="10" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DeferredRevenueArrangementLineItems_A61291F657DA9B9C03647E59E3B5E4B1" xlink:to="loc_us-gaap_DebtConversionOriginalDebtAmount1_893FE425634EC0867D227E59E3B7C8AD" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xlink:label="loc_us-gaap_DebtConversionConvertedInstrumentSharesIssued1_C24622FD9E54DBC1D87F7E59E3B793B6" xlink:type="locator" />
<link:definitionArc order="11" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DeferredRevenueArrangementLineItems_A61291F657DA9B9C03647E59E3B5E4B1" xlink:to="loc_us-gaap_DebtConversionConvertedInstrumentSharesIssued1_C24622FD9E54DBC1D87F7E59E3B793B6" xlink:type="arc" />
<link:loc xlink:href="immu-20191231.xsd#immu_DebtInstrumentConvertibleBeneficialConversionFeatureAggregateNumberOfShares" xlink:label="loc_immu_DebtInstrumentConvertibleBeneficialConversionFeatureAggregateNumberOfShares_571170204A9C7C40B37C7E59E3B8F583" xlink:type="locator" />
<link:definitionArc order="12" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DeferredRevenueArrangementLineItems_A61291F657DA9B9C03647E59E3B5E4B1" xlink:to="loc_immu_DebtInstrumentConvertibleBeneficialConversionFeatureAggregateNumberOfShares_571170204A9C7C40B37C7E59E3B8F583" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InducedConversionOfConvertibleDebtExpense" xlink:label="loc_us-gaap_InducedConversionOfConvertibleDebtExpense_86854216D775AAC3CF547E59E3B8178B" xlink:type="locator" />
<link:definitionArc order="13" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DeferredRevenueArrangementLineItems_A61291F657DA9B9C03647E59E3B5E4B1" xlink:to="loc_us-gaap_InducedConversionOfConvertibleDebtExpense_86854216D775AAC3CF547E59E3B8178B" xlink:type="arc" />
<link:loc xlink:href="immu-20191231.xsd#immu_DebtConversionOutstandingBalance" xlink:label="loc_immu_DebtConversionOutstandingBalance_04AD3A053866F435BE1A7E59E3B82922" xlink:type="locator" />
<link:definitionArc order="14" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DeferredRevenueArrangementLineItems_A61291F657DA9B9C03647E59E3B5E4B1" xlink:to="loc_immu_DebtConversionOutstandingBalance_04AD3A053866F435BE1A7E59E3B82922" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InterestExpenseDebt" xlink:label="loc_us-gaap_InterestExpenseDebt_77BBC79310EED63CCC097E59E3B84CC1" xlink:type="locator" />
<link:definitionArc order="15" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DeferredRevenueArrangementLineItems_A61291F657DA9B9C03647E59E3B5E4B1" xlink:to="loc_us-gaap_InterestExpenseDebt_77BBC79310EED63CCC097E59E3B84CC1" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AmortizationOfFinancingCosts" xlink:label="loc_us-gaap_AmortizationOfFinancingCosts_5F1936C24502EDC59BDE7E59E3B8F856" xlink:type="locator" />
<link:definitionArc order="16" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DeferredRevenueArrangementLineItems_A61291F657DA9B9C03647E59E3B5E4B1" xlink:to="loc_us-gaap_AmortizationOfFinancingCosts_5F1936C24502EDC59BDE7E59E3B8F856" xlink:type="arc" />
<link:loc xlink:href="immu-20191231.xsd#immu_AcceleratedAmortizationOfFinancingCosts" xlink:label="loc_immu_AcceleratedAmortizationOfFinancingCosts_AB1A0C23699916F901817E59E3B82291" xlink:type="locator" />
<link:definitionArc order="17" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DeferredRevenueArrangementLineItems_A61291F657DA9B9C03647E59E3B5E4B1" xlink:to="loc_immu_AcceleratedAmortizationOfFinancingCosts_AB1A0C23699916F901817E59E3B82291" xlink:type="arc" />
</link:definitionLink>
<link:definitionLink xlink:role="http://www.immunomedics.com/role/DebtLiabilityRelatedToSaleOfFutureRoyaltiesDetails" xlink:type="extended">
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="loc_us-gaap_DebtInstrumentLineItems_F01CB6FE0F8B09FD122E4551CEF10957" xlink:type="locator" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentTable" xlink:label="loc_us-gaap_DebtInstrumentTable_5053D60EE07AB24FB50F4551CEEF99C7" xlink:type="locator" />
<link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_F01CB6FE0F8B09FD122E4551CEF10957" xlink:to="loc_us-gaap_DebtInstrumentTable_5053D60EE07AB24FB50F4551CEEF99C7" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_CBC0288E70003AE4164B4551CEEFAA09" xlink:type="locator" />
<link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_5053D60EE07AB24FB50F4551CEEF99C7" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_CBC0288E70003AE4164B4551CEEFAA09" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_81E6FA7DE6DFF2600B404551CEEF4417_default" xlink:type="locator" />
<link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_CBC0288E70003AE4164B4551CEEFAA09" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_81E6FA7DE6DFF2600B404551CEEF4417_default" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_81E6FA7DE6DFF2600B404551CEEF4417" xlink:type="locator" />
<link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_CBC0288E70003AE4164B4551CEEFAA09" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_81E6FA7DE6DFF2600B404551CEEF4417" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PrivatePlacementMember" xlink:label="loc_us-gaap_PrivatePlacementMember_790E4FCF8EA6FBB42F954551CEF0834A" xlink:type="locator" />
<link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_81E6FA7DE6DFF2600B404551CEEF4417" xlink:to="loc_us-gaap_PrivatePlacementMember_790E4FCF8EA6FBB42F954551CEF0834A" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_CounterpartyNameAxis" xlink:label="loc_srt_CounterpartyNameAxis_88DD390B3CA0A5DFAE664551CEF0F8E5" xlink:type="locator" />
<link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_5053D60EE07AB24FB50F4551CEEF99C7" xlink:to="loc_srt_CounterpartyNameAxis_88DD390B3CA0A5DFAE664551CEF0F8E5" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_7982E0C66D9D913C5A9F4551CEF0C8DA_default" xlink:type="locator" />
<link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_88DD390B3CA0A5DFAE664551CEF0F8E5" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_7982E0C66D9D913C5A9F4551CEF0C8DA_default" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_7982E0C66D9D913C5A9F4551CEF0C8DA" xlink:type="locator" />
<link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_88DD390B3CA0A5DFAE664551CEF0F8E5" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_7982E0C66D9D913C5A9F4551CEF0C8DA" xlink:type="arc" />
<link:loc xlink:href="immu-20191231.xsd#immu_RpiFinanceTrustMember" xlink:label="loc_immu_RpiFinanceTrustMember_CB6667FEDB5EE23D5DE54551CEF0DC7E" xlink:type="locator" />
<link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_7982E0C66D9D913C5A9F4551CEF0C8DA" xlink:to="loc_immu_RpiFinanceTrustMember_CB6667FEDB5EE23D5DE54551CEF0DC7E" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredRevenueArrangementTypeAxis" xlink:label="loc_us-gaap_DeferredRevenueArrangementTypeAxis_DC562DCF2C850555977B4551CEF1AEA7" xlink:type="locator" />
<link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_5053D60EE07AB24FB50F4551CEEF99C7" xlink:to="loc_us-gaap_DeferredRevenueArrangementTypeAxis_DC562DCF2C850555977B4551CEF1AEA7" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredRevenueArrangementTypeDomain" xlink:label="loc_us-gaap_DeferredRevenueArrangementTypeDomain_A3383D540D7C3FA981B24551CEF16431_default" xlink:type="locator" />
<link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DeferredRevenueArrangementTypeAxis_DC562DCF2C850555977B4551CEF1AEA7" xlink:to="loc_us-gaap_DeferredRevenueArrangementTypeDomain_A3383D540D7C3FA981B24551CEF16431_default" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredRevenueArrangementTypeDomain" xlink:label="loc_us-gaap_DeferredRevenueArrangementTypeDomain_A3383D540D7C3FA981B24551CEF16431" xlink:type="locator" />
<link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DeferredRevenueArrangementTypeAxis_DC562DCF2C850555977B4551CEF1AEA7" xlink:to="loc_us-gaap_DeferredRevenueArrangementTypeDomain_A3383D540D7C3FA981B24551CEF16431" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RoyaltyArrangementMember" xlink:label="loc_us-gaap_RoyaltyArrangementMember_875E93CE0061AC48C9CE4551CEF1DF14" xlink:type="locator" />
<link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DeferredRevenueArrangementTypeDomain_A3383D540D7C3FA981B24551CEF16431" xlink:to="loc_us-gaap_RoyaltyArrangementMember_875E93CE0061AC48C9CE4551CEF1DF14" xlink:type="arc" />
<link:loc xlink:href="immu-20191231.xsd#immu_PaymentsForFutureRoyalties" xlink:label="loc_immu_PaymentsForFutureRoyalties_8AB96DCEDB7FCEE3859E4551CEF1F814" xlink:type="locator" />
<link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_F01CB6FE0F8B09FD122E4551CEF10957" xlink:to="loc_immu_PaymentsForFutureRoyalties_8AB96DCEDB7FCEE3859E4551CEF1F814" xlink:type="arc" />
<link:loc xlink:href="immu-20191231.xsd#immu_RoyaltyPurchaseArrangementRoyaltyRateasPercentageofNetSales" xlink:label="loc_immu_RoyaltyPurchaseArrangementRoyaltyRateasPercentageofNetSales_34370556009D3D7CFBEF4551CEF2DD34" xlink:type="locator" />
<link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_F01CB6FE0F8B09FD122E4551CEF10957" xlink:to="loc_immu_RoyaltyPurchaseArrangementRoyaltyRateasPercentageofNetSales_34370556009D3D7CFBEF4551CEF2DD34" xlink:type="arc" />
<link:loc xlink:href="immu-20191231.xsd#immu_RoyaltyPurchaseArrangementAnnualSalesLimitMaximum" xlink:label="loc_immu_RoyaltyPurchaseArrangementAnnualSalesLimitMaximum_4BF2090984B904EA1C314551CEF2D53F" xlink:type="locator" />
<link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_F01CB6FE0F8B09FD122E4551CEF10957" xlink:to="loc_immu_RoyaltyPurchaseArrangementAnnualSalesLimitMaximum_4BF2090984B904EA1C314551CEF2D53F" xlink:type="arc" />
<link:loc xlink:href="immu-20191231.xsd#immu_RoyaltyPurchaseArrangementRoyaltyRateasPercentageofExcessofGlobalAnnualSalesThresholdLimit" xlink:label="loc_immu_RoyaltyPurchaseArrangementRoyaltyRateasPercentageofExcessofGlobalAnnualSalesThresholdLimit_35E5FBE8A0E448C3C1A14551CEF2EE34" xlink:type="locator" />
<link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_F01CB6FE0F8B09FD122E4551CEF10957" xlink:to="loc_immu_RoyaltyPurchaseArrangementRoyaltyRateasPercentageofExcessofGlobalAnnualSalesThresholdLimit_35E5FBE8A0E448C3C1A14551CEF2EE34" xlink:type="arc" />
<link:loc xlink:href="immu-20191231.xsd#immu_RoyaltyPurchaseArrangementExcessGlobalAnnualSalesLimitMinimum" xlink:label="loc_immu_RoyaltyPurchaseArrangementExcessGlobalAnnualSalesLimitMinimum_837598AC27EE4F9DA6614551CEF2194E" xlink:type="locator" />
<link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_F01CB6FE0F8B09FD122E4551CEF10957" xlink:to="loc_immu_RoyaltyPurchaseArrangementExcessGlobalAnnualSalesLimitMinimum_837598AC27EE4F9DA6614551CEF2194E" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_479D2D6024A2F16DD79A4551CEF2077C" xlink:type="locator" />
<link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_F01CB6FE0F8B09FD122E4551CEF10957" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_479D2D6024A2F16DD79A4551CEF2077C" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharePrice" xlink:label="loc_us-gaap_SharePrice_5688FEF0BA068425A9AA4551CEF2485B" xlink:type="locator" />
<link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_F01CB6FE0F8B09FD122E4551CEF10957" xlink:to="loc_us-gaap_SharePrice_5688FEF0BA068425A9AA4551CEF2485B" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_2D57F9823B3269F540514551CEF3E517" xlink:type="locator" />
<link:definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_F01CB6FE0F8B09FD122E4551CEF10957" xlink:to="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_2D57F9823B3269F540514551CEF3E517" xlink:type="arc" />
<link:loc xlink:href="immu-20191231.xsd#immu_PeriodWhichCompanyWillAccreteLiability" xlink:label="loc_immu_PeriodWhichCompanyWillAccreteLiability_67EF7CCEE80DE0A6FC8B4551CEF33138" xlink:type="locator" />
<link:definitionArc order="9" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_F01CB6FE0F8B09FD122E4551CEF10957" xlink:to="loc_immu_PeriodWhichCompanyWillAccreteLiability_67EF7CCEE80DE0A6FC8B4551CEF33138" xlink:type="arc" />
<link:loc xlink:href="immu-20191231.xsd#immu_AnnualInterestRateInCalculatingLiabilityRelatedToSaleOfFutureRoyalties" xlink:label="loc_immu_AnnualInterestRateInCalculatingLiabilityRelatedToSaleOfFutureRoyalties_343F008535B92953A44C4551CEF3CC92" xlink:type="locator" />
<link:definitionArc order="10" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_F01CB6FE0F8B09FD122E4551CEF10957" xlink:to="loc_immu_AnnualInterestRateInCalculatingLiabilityRelatedToSaleOfFutureRoyalties_343F008535B92953A44C4551CEF3CC92" xlink:type="arc" />
<link:loc xlink:href="immu-20191231.xsd#immu_NonCashInterestExpenseRelatedToSaleOfFutureRoyalties" xlink:label="loc_immu_NonCashInterestExpenseRelatedToSaleOfFutureRoyalties_EBC138D80FFF09644C854551CEF34752" xlink:type="locator" />
<link:definitionArc order="11" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_F01CB6FE0F8B09FD122E4551CEF10957" xlink:to="loc_immu_NonCashInterestExpenseRelatedToSaleOfFutureRoyalties_EBC138D80FFF09644C854551CEF34752" xlink:type="arc" />
</link:definitionLink>
<link:definitionLink xlink:role="http://www.immunomedics.com/role/DebtScheduleOfLiabilityRelatedToSaleOfFutureRoyaltiesDetails" xlink:type="extended">
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredRevenueArrangementLineItems" xlink:label="loc_us-gaap_DeferredRevenueArrangementLineItems_17A8037B46D0DCAB52D679F70C1F46F9" xlink:type="locator" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredRevenueArrangementByTypeTable" xlink:label="loc_us-gaap_DeferredRevenueArrangementByTypeTable_E5BFF701801B04BDD19F79F70C1DABEC" xlink:type="locator" />
<link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DeferredRevenueArrangementLineItems_17A8037B46D0DCAB52D679F70C1F46F9" xlink:to="loc_us-gaap_DeferredRevenueArrangementByTypeTable_E5BFF701801B04BDD19F79F70C1DABEC" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
<link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_CounterpartyNameAxis" xlink:label="loc_srt_CounterpartyNameAxis_39765065DF207F6413B279F70C1DDBDD" xlink:type="locator" />
<link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DeferredRevenueArrangementByTypeTable_E5BFF701801B04BDD19F79F70C1DABEC" xlink:to="loc_srt_CounterpartyNameAxis_39765065DF207F6413B279F70C1DDBDD" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_8331CAA28045C5B2BC1279F70C1D9C58_default" xlink:type="locator" />
<link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_39765065DF207F6413B279F70C1DDBDD" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_8331CAA28045C5B2BC1279F70C1D9C58_default" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_8331CAA28045C5B2BC1279F70C1D9C58" xlink:type="locator" />
<link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_39765065DF207F6413B279F70C1DDBDD" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_8331CAA28045C5B2BC1279F70C1D9C58" xlink:type="arc" />
<link:loc xlink:href="immu-20191231.xsd#immu_RpiFinanceTrustMember" xlink:label="loc_immu_RpiFinanceTrustMember_D3ADB92ECDE725A545A279F70C1DA4EF" xlink:type="locator" />
<link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_8331CAA28045C5B2BC1279F70C1D9C58" xlink:to="loc_immu_RpiFinanceTrustMember_D3ADB92ECDE725A545A279F70C1DA4EF" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredRevenueArrangementTypeAxis" xlink:label="loc_us-gaap_DeferredRevenueArrangementTypeAxis_58D8A8CD3242A9B4D6FB79F70C1E9FC2" xlink:type="locator" />
<link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DeferredRevenueArrangementByTypeTable_E5BFF701801B04BDD19F79F70C1DABEC" xlink:to="loc_us-gaap_DeferredRevenueArrangementTypeAxis_58D8A8CD3242A9B4D6FB79F70C1E9FC2" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredRevenueArrangementTypeDomain" xlink:label="loc_us-gaap_DeferredRevenueArrangementTypeDomain_248D924A4AD95D77D6B979F70C1E3973_default" xlink:type="locator" />
<link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DeferredRevenueArrangementTypeAxis_58D8A8CD3242A9B4D6FB79F70C1E9FC2" xlink:to="loc_us-gaap_DeferredRevenueArrangementTypeDomain_248D924A4AD95D77D6B979F70C1E3973_default" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredRevenueArrangementTypeDomain" xlink:label="loc_us-gaap_DeferredRevenueArrangementTypeDomain_248D924A4AD95D77D6B979F70C1E3973" xlink:type="locator" />
<link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DeferredRevenueArrangementTypeAxis_58D8A8CD3242A9B4D6FB79F70C1E9FC2" xlink:to="loc_us-gaap_DeferredRevenueArrangementTypeDomain_248D924A4AD95D77D6B979F70C1E3973" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RoyaltyArrangementMember" xlink:label="loc_us-gaap_RoyaltyArrangementMember_2F0E3B33309F72CB923A79F70C1E06DE" xlink:type="locator" />
<link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DeferredRevenueArrangementTypeDomain_248D924A4AD95D77D6B979F70C1E3973" xlink:to="loc_us-gaap_RoyaltyArrangementMember_2F0E3B33309F72CB923A79F70C1E06DE" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MovementInDeferredRevenueRollForward" xlink:label="loc_us-gaap_MovementInDeferredRevenueRollForward_6809D139BF522FD52EA079F70C1FA6A9" xlink:type="locator" />
<link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DeferredRevenueArrangementLineItems_17A8037B46D0DCAB52D679F70C1F46F9" xlink:to="loc_us-gaap_MovementInDeferredRevenueRollForward_6809D139BF522FD52EA079F70C1FA6A9" xlink:type="arc" />
<link:loc xlink:href="immu-20191231.xsd#immu_FairValueForLiabilityRelatedtoSaleofFutureRoyalties" xlink:label="loc_immu_FairValueForLiabilityRelatedtoSaleofFutureRoyalties_B194EE0EDA2813FCF06579F70C1F6CF3" xlink:type="locator" />
<link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MovementInDeferredRevenueRollForward_6809D139BF522FD52EA079F70C1FA6A9" xlink:to="loc_immu_FairValueForLiabilityRelatedtoSaleofFutureRoyalties_B194EE0EDA2813FCF06579F70C1F6CF3" xlink:type="arc" />
<link:loc xlink:href="immu-20191231.xsd#immu_NonCashInterestExpenseRelatedToSaleOfFutureRoyalties" xlink:label="loc_immu_NonCashInterestExpenseRelatedToSaleOfFutureRoyalties_EAE42A93470CD93BDE0B79F70C1F1D1A" xlink:type="locator" />
<link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MovementInDeferredRevenueRollForward_6809D139BF522FD52EA079F70C1FA6A9" xlink:to="loc_immu_NonCashInterestExpenseRelatedToSaleOfFutureRoyalties_EAE42A93470CD93BDE0B79F70C1F1D1A" xlink:type="arc" />
<link:loc xlink:href="immu-20191231.xsd#immu_LiabilitiesRelatedToTheSaleOfFutureRoyaltiesCurrent" xlink:label="loc_immu_LiabilitiesRelatedToTheSaleOfFutureRoyaltiesCurrent_20CE025FF8B91D1E964E79F70C1FDCBE" xlink:type="locator" />
<link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DeferredRevenueArrangementLineItems_17A8037B46D0DCAB52D679F70C1F46F9" xlink:to="loc_immu_LiabilitiesRelatedToTheSaleOfFutureRoyaltiesCurrent_20CE025FF8B91D1E964E79F70C1FDCBE" xlink:type="arc" />
</link:definitionLink>
<link:definitionLink xlink:role="http://www.immunomedics.com/role/DebtTables" xlink:type="extended" />
<link:definitionLink xlink:role="http://www.immunomedics.com/role/DefinedContributionPlans" xlink:type="extended" />
<link:definitionLink xlink:role="http://www.immunomedics.com/role/DefinedContributionPlansDetails" xlink:type="extended" />
<link:definitionLink xlink:role="http://www.immunomedics.com/role/EstimatedFairValueOfFinancialInstruments" xlink:type="extended" />
<link:definitionLink xlink:role="http://www.immunomedics.com/role/EstimatedFairValueOfFinancialInstrumentsDebtInstrumentsDetails" xlink:type="extended">
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:label="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_C773DC9E184F3A7D6F9CD1D062A91686" xlink:type="locator" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueByBalanceSheetGroupingTable" xlink:label="loc_us-gaap_FairValueByBalanceSheetGroupingTable_22B437A3922012F0FB84D1D062A53E67" xlink:type="locator" />
<link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_C773DC9E184F3A7D6F9CD1D062A91686" xlink:to="loc_us-gaap_FairValueByBalanceSheetGroupingTable_22B437A3922012F0FB84D1D062A53E67" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_547C5CF6185AA73CA7B9D1D062A5B59B" xlink:type="locator" />
<link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_22B437A3922012F0FB84D1D062A53E67" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_547C5CF6185AA73CA7B9D1D062A5B59B" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_54D8AB1ECB880A97ADD6D1D062A57A40_default" xlink:type="locator" />
<link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_547C5CF6185AA73CA7B9D1D062A5B59B" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_54D8AB1ECB880A97ADD6D1D062A57A40_default" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_54D8AB1ECB880A97ADD6D1D062A57A40" xlink:type="locator" />
<link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_547C5CF6185AA73CA7B9D1D062A5B59B" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_54D8AB1ECB880A97ADD6D1D062A57A40" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SeniorNotesMember" xlink:label="loc_us-gaap_SeniorNotesMember_8195555F200070B96763D1D062A564AF" xlink:type="locator" />
<link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_54D8AB1ECB880A97ADD6D1D062A57A40" xlink:to="loc_us-gaap_SeniorNotesMember_8195555F200070B96763D1D062A564AF" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_0DD493AEFDD7A1AB6987D1D062A5E0B5" xlink:type="locator" />
<link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_22B437A3922012F0FB84D1D062A53E67" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_0DD493AEFDD7A1AB6987D1D062A5E0B5" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_57BFCBD7A92A3EE11706D1D062A5F54D_default" xlink:type="locator" />
<link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_0DD493AEFDD7A1AB6987D1D062A5E0B5" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_57BFCBD7A92A3EE11706D1D062A5F54D_default" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_57BFCBD7A92A3EE11706D1D062A5F54D" xlink:type="locator" />
<link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_0DD493AEFDD7A1AB6987D1D062A5E0B5" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_57BFCBD7A92A3EE11706D1D062A5F54D" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_F045EF858EE73A7F54A0D1D062A585CE" xlink:type="locator" />
<link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_57BFCBD7A92A3EE11706D1D062A5F54D" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_F045EF858EE73A7F54A0D1D062A585CE" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueByMeasurementBasisAxis" xlink:label="loc_us-gaap_FairValueByMeasurementBasisAxis_51E07BA817291853F990D1D062A57F06" xlink:type="locator" />
<link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_22B437A3922012F0FB84D1D062A53E67" xlink:to="loc_us-gaap_FairValueByMeasurementBasisAxis_51E07BA817291853F990D1D062A57F06" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PortionAtFairValueFairValueDisclosureMember" xlink:label="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_278CB9189DFA6F87A402D1D062A9F579_default" xlink:type="locator" />
<link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByMeasurementBasisAxis_51E07BA817291853F990D1D062A57F06" xlink:to="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_278CB9189DFA6F87A402D1D062A9F579_default" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueDisclosureItemAmountsDomain" xlink:label="loc_us-gaap_FairValueDisclosureItemAmountsDomain_368328E73CE8EC50CE9FD1D062A5766F" xlink:type="locator" />
<link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByMeasurementBasisAxis_51E07BA817291853F990D1D062A57F06" xlink:to="loc_us-gaap_FairValueDisclosureItemAmountsDomain_368328E73CE8EC50CE9FD1D062A5766F" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PortionAtFairValueFairValueDisclosureMember" xlink:label="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_278CB9189DFA6F87A402D1D062A9F579" xlink:type="locator" />
<link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueDisclosureItemAmountsDomain_368328E73CE8EC50CE9FD1D062A5766F" xlink:to="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_278CB9189DFA6F87A402D1D062A9F579" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CarryingReportedAmountFairValueDisclosureMember" xlink:label="loc_us-gaap_CarryingReportedAmountFairValueDisclosureMember_EBAC510E1438A1BC72B6D1D062A936EB" xlink:type="locator" />
<link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueDisclosureItemAmountsDomain_368328E73CE8EC50CE9FD1D062A5766F" xlink:to="loc_us-gaap_CarryingReportedAmountFairValueDisclosureMember_EBAC510E1438A1BC72B6D1D062A936EB" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EstimateOfFairValueFairValueDisclosureMember" xlink:label="loc_us-gaap_EstimateOfFairValueFairValueDisclosureMember_0E63A278249976AC67FCD1D062A96902" xlink:type="locator" />
<link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueDisclosureItemAmountsDomain_368328E73CE8EC50CE9FD1D062A5766F" xlink:to="loc_us-gaap_EstimateOfFairValueFairValueDisclosureMember_0E63A278249976AC67FCD1D062A96902" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConvertibleDebtFairValueDisclosures" xlink:label="loc_us-gaap_ConvertibleDebtFairValueDisclosures_17115F1EE2D1297C8A92D1D062A94960" xlink:type="locator" />
<link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_C773DC9E184F3A7D6F9CD1D062A91686" xlink:to="loc_us-gaap_ConvertibleDebtFairValueDisclosures_17115F1EE2D1297C8A92D1D062A94960" xlink:type="arc" />
</link:definitionLink>
<link:definitionLink xlink:role="http://www.immunomedics.com/role/EstimatedFairValueOfFinancialInstrumentsNarrativeDetails" xlink:type="extended">
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_1B18A48DFA2C9B5309E03991D21D28A4" xlink:type="locator" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_7A84A7191EE18E97725F3991D21BFD2B" xlink:type="locator" />
<link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_1B18A48DFA2C9B5309E03991D21D28A4" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_7A84A7191EE18E97725F3991D21BFD2B" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_6888A5B661D7D189EB1E3991D21B3E3C" xlink:type="locator" />
<link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_7A84A7191EE18E97725F3991D21BFD2B" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_6888A5B661D7D189EB1E3991D21B3E3C" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_F2BC3C14289B0DB634F83991D21C2D0F_default" xlink:type="locator" />
<link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_6888A5B661D7D189EB1E3991D21B3E3C" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_F2BC3C14289B0DB634F83991D21C2D0F_default" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_F2BC3C14289B0DB634F83991D21C2D0F" xlink:type="locator" />
<link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_6888A5B661D7D189EB1E3991D21B3E3C" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_F2BC3C14289B0DB634F83991D21C2D0F" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_310D57561001F762D5D63991D21C06D4" xlink:type="locator" />
<link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_F2BC3C14289B0DB634F83991D21C2D0F" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_310D57561001F762D5D63991D21C06D4" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_CE878E650049789556E53991D21CCCFC" xlink:type="locator" />
<link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_F2BC3C14289B0DB634F83991D21C2D0F" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_CE878E650049789556E53991D21CCCFC" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_A592D90CC1264F5EA4043991D21C7C13" xlink:type="locator" />
<link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_F2BC3C14289B0DB634F83991D21C2D0F" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_A592D90CC1264F5EA4043991D21C7C13" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="loc_us-gaap_FinancialInstrumentAxis_DB6E5FABBA8D812638EC3991D21D8BD1" xlink:type="locator" />
<link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_7A84A7191EE18E97725F3991D21BFD2B" xlink:to="loc_us-gaap_FinancialInstrumentAxis_DB6E5FABBA8D812638EC3991D21D8BD1" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_526709F63B0CABCE619F3991D21D875D_default" xlink:type="locator" />
<link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FinancialInstrumentAxis_DB6E5FABBA8D812638EC3991D21D8BD1" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_526709F63B0CABCE619F3991D21D875D_default" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_526709F63B0CABCE619F3991D21D875D" xlink:type="locator" />
<link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FinancialInstrumentAxis_DB6E5FABBA8D812638EC3991D21D8BD1" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_526709F63B0CABCE619F3991D21D875D" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="loc_us-gaap_MoneyMarketFundsMember_05F20A83D504DB4A6E253991D21D7A19" xlink:type="locator" />
<link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_526709F63B0CABCE619F3991D21D875D" xlink:to="loc_us-gaap_MoneyMarketFundsMember_05F20A83D504DB4A6E253991D21D7A19" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember" xlink:label="loc_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember_A8DB543EC88D7DF444573991D21D5920" xlink:type="locator" />
<link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_526709F63B0CABCE619F3991D21D875D" xlink:to="loc_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember_A8DB543EC88D7DF444573991D21D5920" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_E7F2F8F281353C61A35A3991D21EF53B" xlink:type="locator" />
<link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_1B18A48DFA2C9B5309E03991D21D28A4" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_E7F2F8F281353C61A35A3991D21EF53B" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_62A34529823E4BD54DAF3991D21E2C3C" xlink:type="locator" />
<link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_1B18A48DFA2C9B5309E03991D21D28A4" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_62A34529823E4BD54DAF3991D21E2C3C" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsFairValueDisclosure" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_7BA9841294FF6D0A6EC03991D21E3CEB" xlink:type="locator" />
<link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_1B18A48DFA2C9B5309E03991D21D28A4" xlink:to="loc_us-gaap_AssetsFairValueDisclosure_7BA9841294FF6D0A6EC03991D21E3CEB" xlink:type="arc" />
</link:definitionLink>
<link:definitionLink xlink:role="http://www.immunomedics.com/role/EstimatedFairValueOfFinancialInstrumentsTables" xlink:type="extended" />
<link:definitionLink xlink:role="http://www.immunomedics.com/role/IncomeTaxes" xlink:type="extended" />
<link:definitionLink xlink:role="http://www.immunomedics.com/role/IncomeTaxesChangeInUnrecognizedTaxBenefitsDetails" xlink:type="extended" />
<link:definitionLink xlink:role="http://www.immunomedics.com/role/IncomeTaxesExpenseBenefitFromIncomeTaxesDetails" xlink:type="extended" />
<link:definitionLink xlink:role="http://www.immunomedics.com/role/IncomeTaxesNarrativeDetails" xlink:type="extended">
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLossCarryforwardsLineItems" xlink:label="loc_us-gaap_OperatingLossCarryforwardsLineItems_6D391C67D484970224E569B4D08D9F73" xlink:type="locator" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLossCarryforwardsTable" xlink:label="loc_us-gaap_OperatingLossCarryforwardsTable_D5E2B8D5F18698CC4D0769B4D08C4BA2" xlink:type="locator" />
<link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_6D391C67D484970224E569B4D08D9F73" xlink:to="loc_us-gaap_OperatingLossCarryforwardsTable_D5E2B8D5F18698CC4D0769B4D08C4BA2" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis_25F0DCD4BED95389B72769B4D08C2334" xlink:type="locator" />
<link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable_D5E2B8D5F18698CC4D0769B4D08C4BA2" xlink:to="loc_us-gaap_IncomeTaxAuthorityAxis_25F0DCD4BED95389B72769B4D08C2334" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_5447170E9FD17BB25EA869B4D08C85F6_default" xlink:type="locator" />
<link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_25F0DCD4BED95389B72769B4D08C2334" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_5447170E9FD17BB25EA869B4D08C85F6_default" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_5447170E9FD17BB25EA869B4D08C85F6" xlink:type="locator" />
<link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_25F0DCD4BED95389B72769B4D08C2334" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_5447170E9FD17BB25EA869B4D08C85F6" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DomesticCountryMember" xlink:label="loc_us-gaap_DomesticCountryMember_5C4F00DB7A628B796DFD69B4D08C1B77" xlink:type="locator" />
<link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_5447170E9FD17BB25EA869B4D08C85F6" xlink:to="loc_us-gaap_DomesticCountryMember_5C4F00DB7A628B796DFD69B4D08C1B77" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="loc_us-gaap_StateAndLocalJurisdictionMember_E9C900CFABB8DF565C6369B4D08D7C82" xlink:type="locator" />
<link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_5447170E9FD17BB25EA869B4D08C85F6" xlink:to="loc_us-gaap_StateAndLocalJurisdictionMember_E9C900CFABB8DF565C6369B4D08D7C82" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="loc_us-gaap_OperatingLossCarryforwards_B76669AD0CFD82D881ED69B4D08DFD20" xlink:type="locator" />
<link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_6D391C67D484970224E569B4D08D9F73" xlink:to="loc_us-gaap_OperatingLossCarryforwards_B76669AD0CFD82D881ED69B4D08DFD20" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits_6AA7AE0201BAB005B2C869BEC0E2E51F" xlink:type="locator" />
<link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_6D391C67D484970224E569B4D08D9F73" xlink:to="loc_us-gaap_UnrecognizedTaxBenefits_6AA7AE0201BAB005B2C869BEC0E2E51F" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_BED917FFEAEC15E7399169B4D08DEF4F" xlink:type="locator" />
<link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_6D391C67D484970224E569B4D08D9F73" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_BED917FFEAEC15E7399169B4D08DEF4F" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:label="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_DE2B098A3984EFCF8F5469B4D08D930B" xlink:type="locator" />
<link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_6D391C67D484970224E569B4D08D9F73" xlink:to="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_DE2B098A3984EFCF8F5469B4D08D930B" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_91DAE56D75FD9E5EDA8069B4D08EB621" xlink:type="locator" />
<link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_6D391C67D484970224E569B4D08D9F73" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_91DAE56D75FD9E5EDA8069B4D08EB621" xlink:type="arc" />
<link:loc xlink:href="immu-20191231.xsd#immu_OperatingLossCarryforwardResultingFromSale" xlink:label="loc_immu_OperatingLossCarryforwardResultingFromSale_88A679BA6BEAF27902C769B4D08EEE44" xlink:type="locator" />
<link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_6D391C67D484970224E569B4D08D9F73" xlink:to="loc_immu_OperatingLossCarryforwardResultingFromSale_88A679BA6BEAF27902C769B4D08EEE44" xlink:type="arc" />
<link:loc xlink:href="immu-20191231.xsd#immu_DeferredTaxAssetsTaxCreditCarryforwardsResearchAndDevelopment" xlink:label="loc_immu_DeferredTaxAssetsTaxCreditCarryforwardsResearchAndDevelopment_143E42E1965233B4991D69B4D08EF6E7" xlink:type="locator" />
<link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_6D391C67D484970224E569B4D08D9F73" xlink:to="loc_immu_DeferredTaxAssetsTaxCreditCarryforwardsResearchAndDevelopment_143E42E1965233B4991D69B4D08EF6E7" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_UndistributedEarningsOfForeignSubsidiaries" xlink:label="loc_us-gaap_UndistributedEarningsOfForeignSubsidiaries_E7C1E10D3C9DB8C5A65269B4D08E42F0" xlink:type="locator" />
<link:definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_6D391C67D484970224E569B4D08D9F73" xlink:to="loc_us-gaap_UndistributedEarningsOfForeignSubsidiaries_E7C1E10D3C9DB8C5A65269B4D08E42F0" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TaxCutsAndJobsActOf2017IncompleteAccountingProvisionalIncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_TaxCutsAndJobsActOf2017IncompleteAccountingProvisionalIncomeTaxExpenseBenefit_03817D2788B72BDC290169B4D08E4F10" xlink:type="locator" />
<link:definitionArc order="9" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_6D391C67D484970224E569B4D08D9F73" xlink:to="loc_us-gaap_TaxCutsAndJobsActOf2017IncompleteAccountingProvisionalIncomeTaxExpenseBenefit_03817D2788B72BDC290169B4D08E4F10" xlink:type="arc" />
</link:definitionLink>
<link:definitionLink xlink:role="http://www.immunomedics.com/role/IncomeTaxesReconciliationOfStatutoryTaxRatesAndEffectiveTaxRatesDetails" xlink:type="extended" />
<link:definitionLink xlink:role="http://www.immunomedics.com/role/IncomeTaxesTables" xlink:type="extended" />
<link:definitionLink xlink:role="http://www.immunomedics.com/role/IncomeTaxesTaxEffectsOfTemporaryDifferencesInDeferredTaxAssetsDetails" xlink:type="extended" />
<link:definitionLink xlink:role="http://www.immunomedics.com/role/MarketableSecurities" xlink:type="extended" />
<link:definitionLink xlink:role="http://www.immunomedics.com/role/MarketableSecuritiesAmortizedCostToFairValueDetails" xlink:type="extended">
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_6012AD4D345BB19050CD3991D284B262" xlink:type="locator" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_E415A2A1CBB006EF66073991D2837379" xlink:type="locator" />
<link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_6012AD4D345BB19050CD3991D284B262" xlink:to="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_E415A2A1CBB006EF66073991D2837379" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="loc_us-gaap_FinancialInstrumentAxis_126BF9B58810F2D6D5483991D2844ACE" xlink:type="locator" />
<link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_E415A2A1CBB006EF66073991D2837379" xlink:to="loc_us-gaap_FinancialInstrumentAxis_126BF9B58810F2D6D5483991D2844ACE" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_F3B53A7162D06F4E67093991D2845899_default" xlink:type="locator" />
<link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FinancialInstrumentAxis_126BF9B58810F2D6D5483991D2844ACE" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_F3B53A7162D06F4E67093991D2845899_default" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_F3B53A7162D06F4E67093991D2845899" xlink:type="locator" />
<link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FinancialInstrumentAxis_126BF9B58810F2D6D5483991D2844ACE" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_F3B53A7162D06F4E67093991D2845899" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember" xlink:label="loc_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember_B23B21643218C7FBF1EA3991D2847FAF" xlink:type="locator" />
<link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_F3B53A7162D06F4E67093991D2845899" xlink:to="loc_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember_B23B21643218C7FBF1EA3991D2847FAF" xlink:type="arc" />
<link:loc xlink:href="immu-20191231.xsd#immu_AvailableForSaleSecuritiesDebtMaturitiesAfterOneYearormoreCarryingValue" xlink:label="loc_immu_AvailableForSaleSecuritiesDebtMaturitiesAfterOneYearormoreCarryingValue_9291349186795373BECD3991D285C6A2" xlink:type="locator" />
<link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_6012AD4D345BB19050CD3991D284B262" xlink:to="loc_immu_AvailableForSaleSecuritiesDebtMaturitiesAfterOneYearormoreCarryingValue_9291349186795373BECD3991D285C6A2" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_9A1324DB69BFCAE357D73991D28513EB" xlink:type="locator" />
<link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_6012AD4D345BB19050CD3991D284B262" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_9A1324DB69BFCAE357D73991D28513EB" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_E52421C5094607DC888F3991D285C18A" xlink:type="locator" />
<link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_6012AD4D345BB19050CD3991D284B262" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_E52421C5094607DC888F3991D285C18A" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_48DA9E2371A57265E2AE3991D285E536" xlink:type="locator" />
<link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_6012AD4D345BB19050CD3991D284B262" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_48DA9E2371A57265E2AE3991D285E536" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_6D436F18B75EBA986CE03991D28536B5" xlink:type="locator" />
<link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_6012AD4D345BB19050CD3991D284B262" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_6D436F18B75EBA986CE03991D28536B5" xlink:type="arc" />
</link:definitionLink>
<link:definitionLink xlink:role="http://www.immunomedics.com/role/MarketableSecuritiesTables" xlink:type="extended" />
<link:definitionLink xlink:role="http://www.immunomedics.com/role/PropertyAndEquipment" xlink:type="extended" />
<link:definitionLink xlink:role="http://www.immunomedics.com/role/PropertyAndEquipmentAdditionalInformationDetails" xlink:type="extended" />
<link:definitionLink xlink:role="http://www.immunomedics.com/role/PropertyAndEquipmentSchedulesOfPropertyAndEquipmentDetails" xlink:type="extended">
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_8DE427629B54A6D803EC853A877D3F17" xlink:type="locator" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_4D63321AB22AD9013453853A877B15FA" xlink:type="locator" />
<link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_8DE427629B54A6D803EC853A877D3F17" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_4D63321AB22AD9013453853A877B15FA" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_22ED0A765BDCE7B68E05853A877C084C" xlink:type="locator" />
<link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_4D63321AB22AD9013453853A877B15FA" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_22ED0A765BDCE7B68E05853A877C084C" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_00365D813F93995C5903853A877C46F5_default" xlink:type="locator" />
<link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_22ED0A765BDCE7B68E05853A877C084C" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_00365D813F93995C5903853A877C46F5_default" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_00365D813F93995C5903853A877C46F5" xlink:type="locator" />
<link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_22ED0A765BDCE7B68E05853A877C084C" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_00365D813F93995C5903853A877C46F5" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MachineryAndEquipmentMember" xlink:label="loc_us-gaap_MachineryAndEquipmentMember_3967AB313E1E39D325D4853A877CB73C" xlink:type="locator" />
<link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_00365D813F93995C5903853A877C46F5" xlink:to="loc_us-gaap_MachineryAndEquipmentMember_3967AB313E1E39D325D4853A877CB73C" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="loc_us-gaap_LeaseholdImprovementsMember_9F4A897E34D8546E22E3853A877C2955" xlink:type="locator" />
<link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_00365D813F93995C5903853A877C46F5" xlink:to="loc_us-gaap_LeaseholdImprovementsMember_9F4A897E34D8546E22E3853A877C2955" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="loc_us-gaap_FurnitureAndFixturesMember_F4F35E62B2B4487894B5853A877DB7AA" xlink:type="locator" />
<link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_00365D813F93995C5903853A877C46F5" xlink:to="loc_us-gaap_FurnitureAndFixturesMember_F4F35E62B2B4487894B5853A877DB7AA" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ComputerEquipmentMember" xlink:label="loc_us-gaap_ComputerEquipmentMember_81DDC19214490D9A4F70853A877DE79A" xlink:type="locator" />
<link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_00365D813F93995C5903853A877C46F5" xlink:to="loc_us-gaap_ComputerEquipmentMember_81DDC19214490D9A4F70853A877DE79A" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConstructionInProgressMember" xlink:label="loc_us-gaap_ConstructionInProgressMember_4E71809F704B96FAB51C853A877DD9D9" xlink:type="locator" />
<link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_00365D813F93995C5903853A877C46F5" xlink:to="loc_us-gaap_ConstructionInProgressMember_4E71809F704B96FAB51C853A877DD9D9" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_0D30A6F5EF78DAC1CFD5853A877D84F2" xlink:type="locator" />
<link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_8DE427629B54A6D803EC853A877D3F17" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_0D30A6F5EF78DAC1CFD5853A877D84F2" xlink:type="arc" />
<link:loc xlink:href="immu-20191231.xsd#immu_FinanceLeaseRightofUseAssetBeforeAccumulatedAmortization" xlink:label="loc_immu_FinanceLeaseRightofUseAssetBeforeAccumulatedAmortization_569A7945E7E440F96D6D853A877D8137" xlink:type="locator" />
<link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_8DE427629B54A6D803EC853A877D3F17" xlink:to="loc_immu_FinanceLeaseRightofUseAssetBeforeAccumulatedAmortization_569A7945E7E440F96D6D853A877D8137" xlink:type="arc" />
<link:loc xlink:href="immu-20191231.xsd#immu_PropertyPlantAndEquipmentAndFinanceLeaseRightofUseAssetBeforeAccumulatedDepreciationAndAmortization" xlink:label="loc_immu_PropertyPlantAndEquipmentAndFinanceLeaseRightofUseAssetBeforeAccumulatedDepreciationAndAmortization_97A5523681CEF27B4870853A877E8E40" xlink:type="locator" />
<link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_8DE427629B54A6D803EC853A877D3F17" xlink:to="loc_immu_PropertyPlantAndEquipmentAndFinanceLeaseRightofUseAssetBeforeAccumulatedDepreciationAndAmortization_97A5523681CEF27B4870853A877E8E40" xlink:type="arc" />
<link:loc xlink:href="immu-20191231.xsd#immu_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization" xlink:label="loc_immu_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization_6A46FF2408D8FB5A9BC4853A877E61C5" xlink:type="locator" />
<link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_8DE427629B54A6D803EC853A877D3F17" xlink:to="loc_immu_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization_6A46FF2408D8FB5A9BC4853A877E61C5" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_6A2AB5215C99F14E67EA853A877E331B" xlink:type="locator" />
<link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_8DE427629B54A6D803EC853A877D3F17" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_6A2AB5215C99F14E67EA853A877E331B" xlink:type="arc" />
<link:loc xlink:href="immu-20191231.xsd#immu_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization" xlink:label="loc_immu_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization_FB080B6EB50EF437BC7C853A877E5F59" xlink:type="locator" />
<link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_8DE427629B54A6D803EC853A877D3F17" xlink:to="loc_immu_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization_FB080B6EB50EF437BC7C853A877E5F59" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_6F5C9B295B3EA656C698853A877EF908" xlink:type="locator" />
<link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_8DE427629B54A6D803EC853A877D3F17" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_6F5C9B295B3EA656C698853A877EF908" xlink:type="arc" />
</link:definitionLink>
<link:definitionLink xlink:role="http://www.immunomedics.com/role/PropertyAndEquipmentTables" xlink:type="extended" />
<link:definitionLink xlink:role="http://www.immunomedics.com/role/QuarterlyResultsOfOperationsDetails" xlink:type="extended" />
<link:definitionLink xlink:role="http://www.immunomedics.com/role/QuarterlyResultsOfOperationsTables" xlink:type="extended" />
<link:definitionLink xlink:role="http://www.immunomedics.com/role/QuarterlyResultsOfOperationsUnaudited" xlink:type="extended" />
<link:definitionLink xlink:role="http://www.immunomedics.com/role/RelatedPartyTransactions" xlink:type="extended" />
<link:definitionLink xlink:role="http://www.immunomedics.com/role/RelatedPartyTransactionsDetails" xlink:type="extended">
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems_4F0A09EF5C1EB6170559454D85764216" xlink:type="locator" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_D48F28D818B708A15DC3454D8573D6A8" xlink:type="locator" />
<link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_4F0A09EF5C1EB6170559454D85764216" xlink:to="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_D48F28D818B708A15DC3454D8573D6A8" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_153CF61DAF92B99799B5454D8573B92F" xlink:type="locator" />
<link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_D48F28D818B708A15DC3454D8573D6A8" xlink:to="loc_us-gaap_AwardTypeAxis_153CF61DAF92B99799B5454D8573B92F" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_6227319A64CDCB10E44A454D85738E36_default" xlink:type="locator" />
<link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_153CF61DAF92B99799B5454D8573B92F" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_6227319A64CDCB10E44A454D85738E36_default" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_6227319A64CDCB10E44A454D85738E36" xlink:type="locator" />
<link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_153CF61DAF92B99799B5454D8573B92F" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_6227319A64CDCB10E44A454D85738E36" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaap_EmployeeStockOptionMember_F1C638CDE8C4BA1BF02C454D85746A52" xlink:type="locator" />
<link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_6227319A64CDCB10E44A454D85738E36" xlink:to="loc_us-gaap_EmployeeStockOptionMember_F1C638CDE8C4BA1BF02C454D85746A52" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_TitleOfIndividualAxis" xlink:label="loc_srt_TitleOfIndividualAxis_F700DD8D65AE796AA41A454D85746996" xlink:type="locator" />
<link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_D48F28D818B708A15DC3454D8573D6A8" xlink:to="loc_srt_TitleOfIndividualAxis_F700DD8D65AE796AA41A454D85746996" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_9AC367E14248D30B63B3454D8574AAD9_default" xlink:type="locator" />
<link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_TitleOfIndividualAxis_F700DD8D65AE796AA41A454D85746996" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_9AC367E14248D30B63B3454D8574AAD9_default" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_9AC367E14248D30B63B3454D8574AAD9" xlink:type="locator" />
<link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_TitleOfIndividualAxis_F700DD8D65AE796AA41A454D85746996" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_9AC367E14248D30B63B3454D8574AAD9" xlink:type="arc" />
<link:loc xlink:href="immu-20191231.xsd#immu_ChiefTechnologyOfficerMember" xlink:label="loc_immu_ChiefTechnologyOfficerMember_BC9C5329332BB6953973454D857408F5" xlink:type="locator" />
<link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_9AC367E14248D30B63B3454D8574AAD9" xlink:to="loc_immu_ChiefTechnologyOfficerMember_BC9C5329332BB6953973454D857408F5" xlink:type="arc" />
<link:loc xlink:href="immu-20191231.xsd#immu_ExecutiveDirectorMember" xlink:label="loc_immu_ExecutiveDirectorMember_0B166C8AE4059C13AAC5454D85758891" xlink:type="locator" />
<link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_9AC367E14248D30B63B3454D8574AAD9" xlink:to="loc_immu_ExecutiveDirectorMember_0B166C8AE4059C13AAC5454D85758891" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_BoardOfDirectorsChairmanMember" xlink:label="loc_srt_BoardOfDirectorsChairmanMember_8A65A3722CA02672053345546C13CCB2" xlink:type="locator" />
<link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_9AC367E14248D30B63B3454D8574AAD9" xlink:to="loc_srt_BoardOfDirectorsChairmanMember_8A65A3722CA02672053345546C13CCB2" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_A4A291188135E9662F04454D8575FA4A" xlink:type="locator" />
<link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_D48F28D818B708A15DC3454D8573D6A8" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_A4A291188135E9662F04454D8575FA4A" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain_33D9556EA95504090841454D8575CFE2_default" xlink:type="locator" />
<link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_A4A291188135E9662F04454D8575FA4A" xlink:to="loc_us-gaap_RelatedPartyDomain_33D9556EA95504090841454D8575CFE2_default" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain_33D9556EA95504090841454D8575CFE2" xlink:type="locator" />
<link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_A4A291188135E9662F04454D8575FA4A" xlink:to="loc_us-gaap_RelatedPartyDomain_33D9556EA95504090841454D8575CFE2" xlink:type="arc" />
<link:loc xlink:href="immu-20191231.xsd#immu_MRosenbergBioPharmaConsultingLlcMember" xlink:label="loc_immu_MRosenbergBioPharmaConsultingLlcMember_6D2D2530303492A8CE97454D857559F9" xlink:type="locator" />
<link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_33D9556EA95504090841454D8575CFE2" xlink:to="loc_immu_MRosenbergBioPharmaConsultingLlcMember_6D2D2530303492A8CE97454D857559F9" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_DirectorMember" xlink:label="loc_srt_DirectorMember_D281A408959672E55FEE454D8576E926" xlink:type="locator" />
<link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_33D9556EA95504090841454D8575CFE2" xlink:to="loc_srt_DirectorMember_D281A408959672E55FEE454D8576E926" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProfessionalAndContractServicesExpense" xlink:label="loc_us-gaap_ProfessionalAndContractServicesExpense_8ED33DE68964D3F00940454D85767385" xlink:type="locator" />
<link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_4F0A09EF5C1EB6170559454D85764216" xlink:to="loc_us-gaap_ProfessionalAndContractServicesExpense_8ED33DE68964D3F00940454D85767385" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_26293CCD8B470D11936F454D85761674" xlink:type="locator" />
<link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_4F0A09EF5C1EB6170559454D85764216" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_26293CCD8B470D11936F454D85761674" xlink:type="arc" />
<link:loc xlink:href="immu-20191231.xsd#immu_PercentOfSharesForfeitedEmploymentCommencement" xlink:label="loc_immu_PercentOfSharesForfeitedEmploymentCommencement_23577B37F8BD73215F67454D85765860" xlink:type="locator" />
<link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_4F0A09EF5C1EB6170559454D85764216" xlink:to="loc_immu_PercentOfSharesForfeitedEmploymentCommencement_23577B37F8BD73215F67454D85765860" xlink:type="arc" />
<link:loc xlink:href="immu-20191231.xsd#immu_PercentOfSharesVestedEmploymentCommencement" xlink:label="loc_immu_PercentOfSharesVestedEmploymentCommencement_82E9E17024F7DCC0470E454D8576F058" xlink:type="locator" />
<link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_4F0A09EF5C1EB6170559454D85764216" xlink:to="loc_immu_PercentOfSharesVestedEmploymentCommencement_82E9E17024F7DCC0470E454D8576F058" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_4E6DDC8D7BB2E1A90B6D454D85777DEB" xlink:type="locator" />
<link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_4F0A09EF5C1EB6170559454D85764216" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_4E6DDC8D7BB2E1A90B6D454D85777DEB" xlink:type="arc" />
<link:loc xlink:href="immu-20191231.xsd#immu_SalaryandWageOfficerMonthlySalary" xlink:label="loc_immu_SalaryandWageOfficerMonthlySalary_F391BB5DBD3195381408454D8577BC52" xlink:type="locator" />
<link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_4F0A09EF5C1EB6170559454D85764216" xlink:to="loc_immu_SalaryandWageOfficerMonthlySalary_F391BB5DBD3195381408454D8577BC52" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SalariesWagesAndOfficersCompensation" xlink:label="loc_us-gaap_SalariesWagesAndOfficersCompensation_969D940F4822EEB5145D454D85775024" xlink:type="locator" />
<link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_4F0A09EF5C1EB6170559454D85764216" xlink:to="loc_us-gaap_SalariesWagesAndOfficersCompensation_969D940F4822EEB5145D454D85775024" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_0F3A51A99079A240ECF0454D8577A3B6" xlink:type="locator" />
<link:definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_4F0A09EF5C1EB6170559454D85764216" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_0F3A51A99079A240ECF0454D8577A3B6" xlink:type="arc" />
</link:definitionLink>
<link:definitionLink xlink:role="http://www.immunomedics.com/role/RevenueRecognition" xlink:type="extended" />
<link:definitionLink xlink:role="http://www.immunomedics.com/role/RevenueRecognitionAdditionalInformationDetails" xlink:type="extended">
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1DBDCC40AA7342E0D7D5600A1655AF53" xlink:type="locator" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_D1B50C3E582007C79188600A16526012" xlink:type="locator" />
<link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1DBDCC40AA7342E0D7D5600A1655AF53" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_D1B50C3E582007C79188600A16526012" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
<link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_A12BBBE3E798750CE14F600A1653163A" xlink:type="locator" />
<link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_D1B50C3E582007C79188600A16526012" xlink:to="loc_srt_RangeAxis_A12BBBE3E798750CE14F600A1653163A" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_90C878E15A2D5DA40382600A1653F34F_default" xlink:type="locator" />
<link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_A12BBBE3E798750CE14F600A1653163A" xlink:to="loc_srt_RangeMember_90C878E15A2D5DA40382600A1653F34F_default" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_90C878E15A2D5DA40382600A1653F34F" xlink:type="locator" />
<link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_A12BBBE3E798750CE14F600A1653163A" xlink:to="loc_srt_RangeMember_90C878E15A2D5DA40382600A1653F34F" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MinimumMember" xlink:label="loc_srt_MinimumMember_97A4131D6AA236B451FC600A1654A4F0" xlink:type="locator" />
<link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_90C878E15A2D5DA40382600A1653F34F" xlink:to="loc_srt_MinimumMember_97A4131D6AA236B451FC600A1654A4F0" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_0843F8EE82892DE4A556600A1654367F" xlink:type="locator" />
<link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_90C878E15A2D5DA40382600A1653F34F" xlink:to="loc_srt_MaximumMember_0843F8EE82892DE4A556600A1654367F" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MajorCustomersAxis" xlink:label="loc_srt_MajorCustomersAxis_D2B4966F6BB63CD66656600A16545DC6" xlink:type="locator" />
<link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_D1B50C3E582007C79188600A16526012" xlink:to="loc_srt_MajorCustomersAxis_D2B4966F6BB63CD66656600A16545DC6" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_NameOfMajorCustomerDomain" xlink:label="loc_srt_NameOfMajorCustomerDomain_F8E94BBB1CE4CD8FD11A600A165533EC_default" xlink:type="locator" />
<link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_MajorCustomersAxis_D2B4966F6BB63CD66656600A16545DC6" xlink:to="loc_srt_NameOfMajorCustomerDomain_F8E94BBB1CE4CD8FD11A600A165533EC_default" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_NameOfMajorCustomerDomain" xlink:label="loc_srt_NameOfMajorCustomerDomain_F8E94BBB1CE4CD8FD11A600A165533EC" xlink:type="locator" />
<link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_MajorCustomersAxis_D2B4966F6BB63CD66656600A16545DC6" xlink:to="loc_srt_NameOfMajorCustomerDomain_F8E94BBB1CE4CD8FD11A600A165533EC" xlink:type="arc" />
<link:loc xlink:href="immu-20191231.xsd#immu_EverestMedicinesIILimitedMember" xlink:label="loc_immu_EverestMedicinesIILimitedMember_37EDB7656211658CA0FC600A16555470" xlink:type="locator" />
<link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_F8E94BBB1CE4CD8FD11A600A165533EC" xlink:to="loc_immu_EverestMedicinesIILimitedMember_37EDB7656211658CA0FC600A16555470" xlink:type="arc" />
<link:loc xlink:href="immu-20191231.xsd#immu_JanssenBiotechIncMember" xlink:label="loc_immu_JanssenBiotechIncMember_539D7A71C595FF03DE74600A16551E8A" xlink:type="locator" />
<link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_F8E94BBB1CE4CD8FD11A600A165533EC" xlink:to="loc_immu_JanssenBiotechIncMember_539D7A71C595FF03DE74600A16551E8A" xlink:type="arc" />
<link:loc xlink:href="immu-20191231.xsd#immu_LicenseAgreementUpfrontFeesPaid" xlink:label="loc_immu_LicenseAgreementUpfrontFeesPaid_7370011645711C8646F9600A1656BD38" xlink:type="locator" />
<link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1DBDCC40AA7342E0D7D5600A1655AF53" xlink:to="loc_immu_LicenseAgreementUpfrontFeesPaid_7370011645711C8646F9600A1656BD38" xlink:type="arc" />
<link:loc xlink:href="immu-20191231.xsd#immu_LicenseAgreementMilestonePaymentUponAchievementofFDAApproval" xlink:label="loc_immu_LicenseAgreementMilestonePaymentUponAchievementofFDAApproval_1AB7EBD853E908205207600A16564630" xlink:type="locator" />
<link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1DBDCC40AA7342E0D7D5600A1655AF53" xlink:to="loc_immu_LicenseAgreementMilestonePaymentUponAchievementofFDAApproval_1AB7EBD853E908205207600A16564630" xlink:type="arc" />
<link:loc xlink:href="immu-20191231.xsd#immu_LicenseAgreementMilestoneDevelopmentTotalPayments" xlink:label="loc_immu_LicenseAgreementMilestoneDevelopmentTotalPayments_AF47BF19638BB147E1C6600A1656E37E" xlink:type="locator" />
<link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1DBDCC40AA7342E0D7D5600A1655AF53" xlink:to="loc_immu_LicenseAgreementMilestoneDevelopmentTotalPayments_AF47BF19638BB147E1C6600A1656E37E" xlink:type="arc" />
<link:loc xlink:href="immu-20191231.xsd#immu_LicenseAgreementMilestoneSalesTotalPayments" xlink:label="loc_immu_LicenseAgreementMilestoneSalesTotalPayments_8875A3B1139BEE577714600A16560AB1" xlink:type="locator" />
<link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1DBDCC40AA7342E0D7D5600A1655AF53" xlink:to="loc_immu_LicenseAgreementMilestoneSalesTotalPayments_8875A3B1139BEE577714600A16560AB1" xlink:type="arc" />
<link:loc xlink:href="immu-20191231.xsd#immu_RoyaltyPaymentsPercentage" xlink:label="loc_immu_RoyaltyPaymentsPercentage_3A3555046E5FA3205B54600A1656895B" xlink:type="locator" />
<link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1DBDCC40AA7342E0D7D5600A1655AF53" xlink:to="loc_immu_RoyaltyPaymentsPercentage_3A3555046E5FA3205B54600A1656895B" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_67C476BE482536C1CF8A600A16576498" xlink:type="locator" />
<link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1DBDCC40AA7342E0D7D5600A1655AF53" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_67C476BE482536C1CF8A600A16576498" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Revenues" xlink:label="loc_us-gaap_Revenues_140CA064DA642700FF98600A1657DB51" xlink:type="locator" />
<link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1DBDCC40AA7342E0D7D5600A1655AF53" xlink:to="loc_us-gaap_Revenues_140CA064DA642700FF98600A1657DB51" xlink:type="arc" />
</link:definitionLink>
<link:definitionLink xlink:role="http://www.immunomedics.com/role/RevenueRecognitionPerformanceObligationDetails" xlink:type="extended">
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems_921FCF5FBA7D1E1CD70560442EBFEB5D" xlink:type="locator" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable_F4694D1FF242B00E15A560442EBD23BA" xlink:type="locator" />
<link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems_921FCF5FBA7D1E1CD70560442EBFEB5D" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable_F4694D1FF242B00E15A560442EBD23BA" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
<link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MajorCustomersAxis" xlink:label="loc_srt_MajorCustomersAxis_FA9E55C5BCAD54F286BE60442EBDF618" xlink:type="locator" />
<link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable_F4694D1FF242B00E15A560442EBD23BA" xlink:to="loc_srt_MajorCustomersAxis_FA9E55C5BCAD54F286BE60442EBDF618" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_NameOfMajorCustomerDomain" xlink:label="loc_srt_NameOfMajorCustomerDomain_32D104BBB2478BE035DC60442EBE18FE_default" xlink:type="locator" />
<link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_MajorCustomersAxis_FA9E55C5BCAD54F286BE60442EBDF618" xlink:to="loc_srt_NameOfMajorCustomerDomain_32D104BBB2478BE035DC60442EBE18FE_default" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_NameOfMajorCustomerDomain" xlink:label="loc_srt_NameOfMajorCustomerDomain_32D104BBB2478BE035DC60442EBE18FE" xlink:type="locator" />
<link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_MajorCustomersAxis_FA9E55C5BCAD54F286BE60442EBDF618" xlink:to="loc_srt_NameOfMajorCustomerDomain_32D104BBB2478BE035DC60442EBE18FE" xlink:type="arc" />
<link:loc xlink:href="immu-20191231.xsd#immu_EverestMedicinesIILimitedMember" xlink:label="loc_immu_EverestMedicinesIILimitedMember_AACB2332F4046898F56260442EBEB9C6" xlink:type="locator" />
<link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_32D104BBB2478BE035DC60442EBE18FE" xlink:to="loc_immu_EverestMedicinesIILimitedMember_AACB2332F4046898F56260442EBEB9C6" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis_3AF2DADEDCA1E9A7621560442EBE7F0F" xlink:type="locator" />
<link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable_F4694D1FF242B00E15A560442EBD23BA" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis_3AF2DADEDCA1E9A7621560442EBE7F0F" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligation" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligation_094F2AF318DA8860924560442EBF48A0" xlink:type="locator" />
<link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems_921FCF5FBA7D1E1CD70560442EBFEB5D" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligation_094F2AF318DA8860924560442EBF48A0" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1_A2BAF008799865F61CB060442EBFA562" xlink:type="locator" />
<link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems_921FCF5FBA7D1E1CD70560442EBFEB5D" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1_A2BAF008799865F61CB060442EBFA562" xlink:type="arc" />
</link:definitionLink>
<link:definitionLink xlink:role="http://www.immunomedics.com/role/StockBasedCompensation" xlink:type="extended" />
<link:definitionLink xlink:role="http://www.immunomedics.com/role/StockBasedCompensationFairValueAssumptionsDetails" xlink:type="extended">
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_FBBA194E86769ED2E37BDB3A5B46FC67" xlink:type="locator" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_5D6475A6855A9E99AE6EDB3A5B44149D" xlink:type="locator" />
<link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_FBBA194E86769ED2E37BDB3A5B46FC67" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_5D6475A6855A9E99AE6EDB3A5B44149D" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
<link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_60F903A44F5DAF0A887BDB3A5B44FEC0" xlink:type="locator" />
<link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_5D6475A6855A9E99AE6EDB3A5B44149D" xlink:to="loc_srt_RangeAxis_60F903A44F5DAF0A887BDB3A5B44FEC0" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_58D440EBA43F1375F27CDB3A5B44EDB2_default" xlink:type="locator" />
<link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_60F903A44F5DAF0A887BDB3A5B44FEC0" xlink:to="loc_srt_RangeMember_58D440EBA43F1375F27CDB3A5B44EDB2_default" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_58D440EBA43F1375F27CDB3A5B44EDB2" xlink:type="locator" />
<link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_60F903A44F5DAF0A887BDB3A5B44FEC0" xlink:to="loc_srt_RangeMember_58D440EBA43F1375F27CDB3A5B44EDB2" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MinimumMember" xlink:label="loc_srt_MinimumMember_8F2B3F58CF5F52576F46DB3A5B4533A0" xlink:type="locator" />
<link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_58D440EBA43F1375F27CDB3A5B44EDB2" xlink:to="loc_srt_MinimumMember_8F2B3F58CF5F52576F46DB3A5B4533A0" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_3C76837C63825C7DB32DDB3A5B457108" xlink:type="locator" />
<link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_58D440EBA43F1375F27CDB3A5B44EDB2" xlink:to="loc_srt_MaximumMember_3C76837C63825C7DB32DDB3A5B457108" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_BA0D1FFE5AFA1CDBEC74DB3A5B45C36C" xlink:type="locator" />
<link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_5D6475A6855A9E99AE6EDB3A5B44149D" xlink:to="loc_us-gaap_AwardTypeAxis_BA0D1FFE5AFA1CDBEC74DB3A5B45C36C" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_586D6A299E128D39D0ECDB3A5B4528D7_default" xlink:type="locator" />
<link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_BA0D1FFE5AFA1CDBEC74DB3A5B45C36C" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_586D6A299E128D39D0ECDB3A5B4528D7_default" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_586D6A299E128D39D0ECDB3A5B4528D7" xlink:type="locator" />
<link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_BA0D1FFE5AFA1CDBEC74DB3A5B45C36C" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_586D6A299E128D39D0ECDB3A5B4528D7" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaap_EmployeeStockOptionMember_62719B727184CBF5A047DB3A5B46D42F" xlink:type="locator" />
<link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_586D6A299E128D39D0ECDB3A5B4528D7" xlink:to="loc_us-gaap_EmployeeStockOptionMember_62719B727184CBF5A047DB3A5B46D42F" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_9BDD3CBF16CEC1159BB5DB3A5B4658DD" xlink:type="locator" />
<link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_FBBA194E86769ED2E37BDB3A5B46FC67" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_9BDD3CBF16CEC1159BB5DB3A5B4658DD" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_D0587A8AAF695E71C278DB3A5B46557E" xlink:type="locator" />
<link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_FBBA194E86769ED2E37BDB3A5B46FC67" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_D0587A8AAF695E71C278DB3A5B46557E" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_9E0D51C039E5D2138D14DB3A5B477571" xlink:type="locator" />
<link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_FBBA194E86769ED2E37BDB3A5B46FC67" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_9E0D51C039E5D2138D14DB3A5B477571" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_59E1D67A98DAD414A740DB3A5B4734D7" xlink:type="locator" />
<link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_FBBA194E86769ED2E37BDB3A5B46FC67" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_59E1D67A98DAD414A740DB3A5B4734D7" xlink:type="arc" />
</link:definitionLink>
<link:definitionLink xlink:role="http://www.immunomedics.com/role/StockBasedCompensationNarrativeDetails" xlink:type="extended">
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2FCEBC1E6F4075E1DA1A3991D2446CDA" xlink:type="locator" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_8123148D82AE94D2BE083991D2439319" xlink:type="locator" />
<link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2FCEBC1E6F4075E1DA1A3991D2446CDA" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_8123148D82AE94D2BE083991D2439319" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_F042FBCC4465C45B9BCA3991D24376A1" xlink:type="locator" />
<link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_8123148D82AE94D2BE083991D2439319" xlink:to="loc_us-gaap_AwardTypeAxis_F042FBCC4465C45B9BCA3991D24376A1" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_30CFCC05505077EFAA7D3991D2436058_default" xlink:type="locator" />
<link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_F042FBCC4465C45B9BCA3991D24376A1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_30CFCC05505077EFAA7D3991D2436058_default" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_30CFCC05505077EFAA7D3991D2436058" xlink:type="locator" />
<link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_F042FBCC4465C45B9BCA3991D24376A1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_30CFCC05505077EFAA7D3991D2436058" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaap_EmployeeStockOptionMember_C2E5B865773FA49F3A5D3991D243EE0F" xlink:type="locator" />
<link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_30CFCC05505077EFAA7D3991D2436058" xlink:to="loc_us-gaap_EmployeeStockOptionMember_C2E5B865773FA49F3A5D3991D243EE0F" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_64B19240C2B31C27EC4B3991D244179E" xlink:type="locator" />
<link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_30CFCC05505077EFAA7D3991D2436058" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_64B19240C2B31C27EC4B3991D244179E" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PerformanceSharesMember" xlink:label="loc_us-gaap_PerformanceSharesMember_2FBC58B100DE1FE4AE6039DC3FA70277" xlink:type="locator" />
<link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_30CFCC05505077EFAA7D3991D2436058" xlink:to="loc_us-gaap_PerformanceSharesMember_2FBC58B100DE1FE4AE6039DC3FA70277" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_235E7196232A4C4692833991D244DB40" xlink:type="locator" />
<link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2FCEBC1E6F4075E1DA1A3991D2446CDA" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_235E7196232A4C4692833991D244DB40" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_7EA07F7FC98927746BBF3991D245F8D3" xlink:type="locator" />
<link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2FCEBC1E6F4075E1DA1A3991D2446CDA" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_7EA07F7FC98927746BBF3991D245F8D3" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_976D676FE780709929473991D245D52B" xlink:type="locator" />
<link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2FCEBC1E6F4075E1DA1A3991D2446CDA" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_976D676FE780709929473991D245D52B" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_18F2D8F7019099C518D73991D2452561" xlink:type="locator" />
<link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2FCEBC1E6F4075E1DA1A3991D2446CDA" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_18F2D8F7019099C518D73991D2452561" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_2B5F295CD125034D9BA83991D2454A77" xlink:type="locator" />
<link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2FCEBC1E6F4075E1DA1A3991D2446CDA" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_2B5F295CD125034D9BA83991D2454A77" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_0F46A9630622E31D92463991D245C157" xlink:type="locator" />
<link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2FCEBC1E6F4075E1DA1A3991D2446CDA" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_0F46A9630622E31D92463991D245C157" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_7B4A8C45D0E991B0A64A3991D245AE8A" xlink:type="locator" />
<link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2FCEBC1E6F4075E1DA1A3991D2446CDA" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_7B4A8C45D0E991B0A64A3991D245AE8A" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_ADC8845C9F4891302D063991D24555BE" xlink:type="locator" />
<link:definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2FCEBC1E6F4075E1DA1A3991D2446CDA" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_ADC8845C9F4891302D063991D24555BE" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_B53655B1E376993F351939D4E372026B" xlink:type="locator" />
<link:definitionArc order="9" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2FCEBC1E6F4075E1DA1A3991D2446CDA" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_B53655B1E376993F351939D4E372026B" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StateAndLocalIncomeTaxExpenseBenefitContinuingOperations" xlink:label="loc_us-gaap_StateAndLocalIncomeTaxExpenseBenefitContinuingOperations_07F8B3BCC28D12D6EE0F39EC99A63F93" xlink:type="locator" />
<link:definitionArc order="10" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2FCEBC1E6F4075E1DA1A3991D2446CDA" xlink:to="loc_us-gaap_StateAndLocalIncomeTaxExpenseBenefitContinuingOperations_07F8B3BCC28D12D6EE0F39EC99A63F93" xlink:type="arc" />
</link:definitionLink>
<link:definitionLink xlink:role="http://www.immunomedics.com/role/StockBasedCompensationRestrictedStockUnitActivityDetails" xlink:type="extended">
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_415370AEF46F004DE3A43991D22802C9" xlink:type="locator" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_D708CAB03C4F686D30603991D227FE04" xlink:type="locator" />
<link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_415370AEF46F004DE3A43991D22802C9" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_D708CAB03C4F686D30603991D227FE04" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_4DDD91272168A84268C03991D227685D" xlink:type="locator" />
<link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_D708CAB03C4F686D30603991D227FE04" xlink:to="loc_us-gaap_AwardTypeAxis_4DDD91272168A84268C03991D227685D" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0D3AD342E7A26D3BD20F3991D2279672_default" xlink:type="locator" />
<link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_4DDD91272168A84268C03991D227685D" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0D3AD342E7A26D3BD20F3991D2279672_default" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0D3AD342E7A26D3BD20F3991D2279672" xlink:type="locator" />
<link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_4DDD91272168A84268C03991D227685D" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0D3AD342E7A26D3BD20F3991D2279672" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_B9CAC079C1417D283B153991D2285C9B" xlink:type="locator" />
<link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0D3AD342E7A26D3BD20F3991D2279672" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_B9CAC079C1417D283B153991D2285C9B" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_D87433532962FBD7B8803991D228186D" xlink:type="locator" />
<link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_415370AEF46F004DE3A43991D22802C9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_D87433532962FBD7B8803991D228186D" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_3EAD8D7715A3B29478A43991D229E6C6" xlink:type="locator" />
<link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_D87433532962FBD7B8803991D228186D" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_3EAD8D7715A3B29478A43991D229E6C6" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_21CAC48053750F29AEA53991D229E83E" xlink:type="locator" />
<link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_D87433532962FBD7B8803991D228186D" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_21CAC48053750F29AEA53991D229E83E" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_63BAD3AD7AB7CF1665E23991D2291875" xlink:type="locator" />
<link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_D87433532962FBD7B8803991D228186D" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_63BAD3AD7AB7CF1665E23991D2291875" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_8FC1F861EE84D69E18953991D229C39B" xlink:type="locator" />
<link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_D87433532962FBD7B8803991D228186D" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_8FC1F861EE84D69E18953991D229C39B" xlink:type="arc" />
<link:loc xlink:href="immu-20191231.xsd#immu_WeightedaveragegrantdatefairvalueRollForward" xlink:label="loc_immu_WeightedaveragegrantdatefairvalueRollForward_0B159BB2FEE53AF19F863991D22AFE9F" xlink:type="locator" />
<link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_415370AEF46F004DE3A43991D22802C9" xlink:to="loc_immu_WeightedaveragegrantdatefairvalueRollForward_0B159BB2FEE53AF19F863991D22AFE9F" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_4E78933187C83BE24FB03991D22AAF26" xlink:type="locator" />
<link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_immu_WeightedaveragegrantdatefairvalueRollForward_0B159BB2FEE53AF19F863991D22AFE9F" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_4E78933187C83BE24FB03991D22AAF26" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_7BEAAC0017085B0D34E23991D22A815F" xlink:type="locator" />
<link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_immu_WeightedaveragegrantdatefairvalueRollForward_0B159BB2FEE53AF19F863991D22AFE9F" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_7BEAAC0017085B0D34E23991D22A815F" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_B05C97F255D7808305BF3991D22AC652" xlink:type="locator" />
<link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_immu_WeightedaveragegrantdatefairvalueRollForward_0B159BB2FEE53AF19F863991D22AFE9F" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_B05C97F255D7808305BF3991D22AC652" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_1B6AE5896B1AFD85B19D3991D22A7F29" xlink:type="locator" />
<link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_immu_WeightedaveragegrantdatefairvalueRollForward_0B159BB2FEE53AF19F863991D22AFE9F" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_1B6AE5896B1AFD85B19D3991D22A7F29" xlink:type="arc" />
</link:definitionLink>
<link:definitionLink xlink:role="http://www.immunomedics.com/role/StockBasedCompensationStockIncentivePlanDetails" xlink:type="extended">
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_64A8B36E0B9994CC2CC039D1BC3A79ED" xlink:type="locator" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_7E51634C0597C526F08939D1BC31FBB2" xlink:type="locator" />
<link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_64A8B36E0B9994CC2CC039D1BC3A79ED" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_7E51634C0597C526F08939D1BC31FBB2" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_2CF71EA8D879456B8F1B39D1BD38AACA" xlink:type="locator" />
<link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_7E51634C0597C526F08939D1BC31FBB2" xlink:to="loc_us-gaap_AwardTypeAxis_2CF71EA8D879456B8F1B39D1BD38AACA" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_138A2E1C48342EB2A7E939D1BD386D04_default" xlink:type="locator" />
<link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_2CF71EA8D879456B8F1B39D1BD38AACA" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_138A2E1C48342EB2A7E939D1BD386D04_default" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_138A2E1C48342EB2A7E939D1BD386D04" xlink:type="locator" />
<link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_2CF71EA8D879456B8F1B39D1BD38AACA" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_138A2E1C48342EB2A7E939D1BD386D04" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_6E1664D25DCF2A00F39139D1BE0E63A4" xlink:type="locator" />
<link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_138A2E1C48342EB2A7E939D1BD386D04" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_6E1664D25DCF2A00F39139D1BE0E63A4" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_893F440C627BD9A54F9D3991D249836E" xlink:type="locator" />
<link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_64A8B36E0B9994CC2CC039D1BC3A79ED" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_893F440C627BD9A54F9D3991D249836E" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_B2C9857716BCBF0E935C3991D2490D6F" xlink:type="locator" />
<link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_64A8B36E0B9994CC2CC039D1BC3A79ED" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_B2C9857716BCBF0E935C3991D2490D6F" xlink:type="arc" />
<link:loc xlink:href="immu-20191231.xsd#immu_AllocatedSharebasedCompensationExpenseAmountReversed" xlink:label="loc_immu_AllocatedSharebasedCompensationExpenseAmountReversed_3CF2C1FDEBA0F90A6B473991D2496AF7" xlink:type="locator" />
<link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_64A8B36E0B9994CC2CC039D1BC3A79ED" xlink:to="loc_immu_AllocatedSharebasedCompensationExpenseAmountReversed_3CF2C1FDEBA0F90A6B473991D2496AF7" xlink:type="arc" />
</link:definitionLink>
<link:definitionLink xlink:role="http://www.immunomedics.com/role/StockBasedCompensationStockOptionActivityDetails" xlink:type="extended">
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_68F9E4B5E3E63931CF97DB3A1D3F583E" xlink:type="locator" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_03D95BA6414F33B86706DB3A1D3D476C" xlink:type="locator" />
<link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_68F9E4B5E3E63931CF97DB3A1D3F583E" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_03D95BA6414F33B86706DB3A1D3D476C" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_AE7EEFC6F2FF16D804F7DB3A1D3E1BAC" xlink:type="locator" />
<link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_03D95BA6414F33B86706DB3A1D3D476C" xlink:to="loc_us-gaap_AwardTypeAxis_AE7EEFC6F2FF16D804F7DB3A1D3E1BAC" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_E10056EFAE86D5FAA212DB3A1D3E6953_default" xlink:type="locator" />
<link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_AE7EEFC6F2FF16D804F7DB3A1D3E1BAC" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_E10056EFAE86D5FAA212DB3A1D3E6953_default" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_E10056EFAE86D5FAA212DB3A1D3E6953" xlink:type="locator" />
<link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_AE7EEFC6F2FF16D804F7DB3A1D3E1BAC" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_E10056EFAE86D5FAA212DB3A1D3E6953" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaap_EmployeeStockOptionMember_EA02E793F5BDFFFF3F38DB3A1D3F1E35" xlink:type="locator" />
<link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_E10056EFAE86D5FAA212DB3A1D3E6953" xlink:to="loc_us-gaap_EmployeeStockOptionMember_EA02E793F5BDFFFF3F38DB3A1D3F1E35" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PerformanceSharesMember" xlink:label="loc_us-gaap_PerformanceSharesMember_4342E3ADC48F2382FC9EDB3A1D3FF9C9" xlink:type="locator" />
<link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_E10056EFAE86D5FAA212DB3A1D3E6953" xlink:to="loc_us-gaap_PerformanceSharesMember_4342E3ADC48F2382FC9EDB3A1D3FF9C9" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_7988743A8E36D7DE7FB7DB3A1D403328" xlink:type="locator" />
<link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_68F9E4B5E3E63931CF97DB3A1D3F583E" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_7988743A8E36D7DE7FB7DB3A1D403328" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_B1563FEB14EC24B5F17BDB3A1D4065C3" xlink:type="locator" />
<link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_7988743A8E36D7DE7FB7DB3A1D403328" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_B1563FEB14EC24B5F17BDB3A1D4065C3" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_F086F89D242753A0C7AFDB3A1D4034AD" xlink:type="locator" />
<link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_7988743A8E36D7DE7FB7DB3A1D403328" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_F086F89D242753A0C7AFDB3A1D4034AD" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_BDD5713DA37532C8BC9ADB3A1D40C7CA" xlink:type="locator" />
<link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_7988743A8E36D7DE7FB7DB3A1D403328" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_BDD5713DA37532C8BC9ADB3A1D40C7CA" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_5960C6A3AC773CF31B77DB3A1D402C5E" xlink:type="locator" />
<link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_7988743A8E36D7DE7FB7DB3A1D403328" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_5960C6A3AC773CF31B77DB3A1D402C5E" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_BF6FD067942DCFE09D5ADB3A1D415CD3" xlink:type="locator" />
<link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_68F9E4B5E3E63931CF97DB3A1D3F583E" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_BF6FD067942DCFE09D5ADB3A1D415CD3" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward_4B9F3FBBA60C48160F8ADB3A1D418DBB" xlink:type="locator" />
<link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_68F9E4B5E3E63931CF97DB3A1D3F583E" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward_4B9F3FBBA60C48160F8ADB3A1D418DBB" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_7C2B091AEAAD05CE0854DB3A1D412BFB" xlink:type="locator" />
<link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward_4B9F3FBBA60C48160F8ADB3A1D418DBB" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_7C2B091AEAAD05CE0854DB3A1D412BFB" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_ADA279D2706A72FF4EE0DB3A1D416B9C" xlink:type="locator" />
<link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward_4B9F3FBBA60C48160F8ADB3A1D418DBB" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_ADA279D2706A72FF4EE0DB3A1D416B9C" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_C548497D931A0EFC9286DB3A1D41B655" xlink:type="locator" />
<link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward_4B9F3FBBA60C48160F8ADB3A1D418DBB" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_C548497D931A0EFC9286DB3A1D41B655" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_C72156D9E6E28AD2A505DB3A1D4210CF" xlink:type="locator" />
<link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward_4B9F3FBBA60C48160F8ADB3A1D418DBB" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_C72156D9E6E28AD2A505DB3A1D4210CF" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_7CE89DCD55E99B216EC8DB3A1D423EDB" xlink:type="locator" />
<link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_68F9E4B5E3E63931CF97DB3A1D3F583E" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_7CE89DCD55E99B216EC8DB3A1D423EDB" xlink:type="arc" />
<link:loc xlink:href="immu-20191231.xsd#immu_WeightedaverageremainingcontractualtermyearsRollForward" xlink:label="loc_immu_WeightedaverageremainingcontractualtermyearsRollForward_FBC1992349DF0CC00340DB3A1D42BB0C" xlink:type="locator" />
<link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_68F9E4B5E3E63931CF97DB3A1D3F583E" xlink:to="loc_immu_WeightedaverageremainingcontractualtermyearsRollForward_FBC1992349DF0CC00340DB3A1D42BB0C" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_B922E1ABDA68C98CBF59DB3A1D42CD9F" xlink:type="locator" />
<link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_immu_WeightedaverageremainingcontractualtermyearsRollForward_FBC1992349DF0CC00340DB3A1D42BB0C" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_B922E1ABDA68C98CBF59DB3A1D42CD9F" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_EE9E951C68225F1ECE98DB3A1D4314FC" xlink:type="locator" />
<link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_68F9E4B5E3E63931CF97DB3A1D3F583E" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_EE9E951C68225F1ECE98DB3A1D4314FC" xlink:type="arc" />
<link:loc xlink:href="immu-20191231.xsd#immu_IntrinsicvalueRollForward" xlink:label="loc_immu_IntrinsicvalueRollForward_4303B084DCECAA9F2D34DB3A1D43AD3C" xlink:type="locator" />
<link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_68F9E4B5E3E63931CF97DB3A1D3F583E" xlink:to="loc_immu_IntrinsicvalueRollForward_4303B084DCECAA9F2D34DB3A1D43AD3C" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_C7C792C30FEB260E2FB7DB3A1D4366B4" xlink:type="locator" />
<link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_immu_IntrinsicvalueRollForward_4303B084DCECAA9F2D34DB3A1D43AD3C" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_C7C792C30FEB260E2FB7DB3A1D4366B4" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_4C380E9857667B9DB0C4DB3A1D4374D9" xlink:type="locator" />
<link:definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_68F9E4B5E3E63931CF97DB3A1D3F583E" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_4C380E9857667B9DB0C4DB3A1D4374D9" xlink:type="arc" />
</link:definitionLink>
<link:definitionLink xlink:role="http://www.immunomedics.com/role/StockBasedCompensationTables" xlink:type="extended" />
<link:definitionLink xlink:role="http://www.immunomedics.com/role/StockholdersEquity" xlink:type="extended" />
<link:definitionLink xlink:role="http://www.immunomedics.com/role/StockholdersEquityDetails" xlink:type="extended">
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfWarrantOrRightLineItems" xlink:label="loc_us-gaap_ClassOfWarrantOrRightLineItems_41B54B431001DB193B43850F47E921A5" xlink:type="locator" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfWarrantOrRightTable" xlink:label="loc_us-gaap_ClassOfWarrantOrRightTable_5A50C1824C482DD38108850F47E3B754" xlink:type="locator" />
<link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_41B54B431001DB193B43850F47E921A5" xlink:to="loc_us-gaap_ClassOfWarrantOrRightTable_5A50C1824C482DD38108850F47E3B754" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
<link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_D10F3776ACAEEC5EE58D850F47E3D620" xlink:type="locator" />
<link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_5A50C1824C482DD38108850F47E3B754" xlink:to="loc_srt_RangeAxis_D10F3776ACAEEC5EE58D850F47E3D620" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_A6CE1182B46968E3B82A850F47E4953A_default" xlink:type="locator" />
<link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_D10F3776ACAEEC5EE58D850F47E3D620" xlink:to="loc_srt_RangeMember_A6CE1182B46968E3B82A850F47E4953A_default" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_A6CE1182B46968E3B82A850F47E4953A" xlink:type="locator" />
<link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_D10F3776ACAEEC5EE58D850F47E3D620" xlink:to="loc_srt_RangeMember_A6CE1182B46968E3B82A850F47E4953A" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_WeightedAverageMember" xlink:label="loc_srt_WeightedAverageMember_F83CAA7750A045BD2246850F47E4511F" xlink:type="locator" />
<link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_A6CE1182B46968E3B82A850F47E4953A" xlink:to="loc_srt_WeightedAverageMember_F83CAA7750A045BD2246850F47E4511F" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueByLiabilityClassAxis" xlink:label="loc_us-gaap_FairValueByLiabilityClassAxis_24F069FDB21AD3A17EA2850F47E4792C" xlink:type="locator" />
<link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_5A50C1824C482DD38108850F47E3B754" xlink:to="loc_us-gaap_FairValueByLiabilityClassAxis_24F069FDB21AD3A17EA2850F47E4792C" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_93D0C374BB337497CBC4850F47E51B0E_default" xlink:type="locator" />
<link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByLiabilityClassAxis_24F069FDB21AD3A17EA2850F47E4792C" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_93D0C374BB337497CBC4850F47E51B0E_default" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_93D0C374BB337497CBC4850F47E51B0E" xlink:type="locator" />
<link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByLiabilityClassAxis_24F069FDB21AD3A17EA2850F47E4792C" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_93D0C374BB337497CBC4850F47E51B0E" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaap_WarrantMember_33C4AFA262D511CBE402850F47E5C193" xlink:type="locator" />
<link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_93D0C374BB337497CBC4850F47E51B0E" xlink:to="loc_us-gaap_WarrantMember_33C4AFA262D511CBE402850F47E5C193" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_B077B03334465223E455850F47E52C46" xlink:type="locator" />
<link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_5A50C1824C482DD38108850F47E3B754" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_B077B03334465223E455850F47E52C46" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_88AA6A50083DA36A6D3D850F47E57C9B_default" xlink:type="locator" />
<link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_B077B03334465223E455850F47E52C46" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_88AA6A50083DA36A6D3D850F47E57C9B_default" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_88AA6A50083DA36A6D3D850F47E57C9B" xlink:type="locator" />
<link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_B077B03334465223E455850F47E52C46" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_88AA6A50083DA36A6D3D850F47E57C9B" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PrivatePlacementMember" xlink:label="loc_us-gaap_PrivatePlacementMember_37B4B2FC953837583FDF850F47E67F0C" xlink:type="locator" />
<link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_88AA6A50083DA36A6D3D850F47E57C9B" xlink:to="loc_us-gaap_PrivatePlacementMember_37B4B2FC953837583FDF850F47E67F0C" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IPOMember" xlink:label="loc_us-gaap_IPOMember_ED41F9D2B0B88E3F0F79850F47E67B88" xlink:type="locator" />
<link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_88AA6A50083DA36A6D3D850F47E57C9B" xlink:to="loc_us-gaap_IPOMember_ED41F9D2B0B88E3F0F79850F47E67B88" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OverAllotmentOptionMember" xlink:label="loc_us-gaap_OverAllotmentOptionMember_36AF5CD8640A31F20761850F47E6F069" xlink:type="locator" />
<link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_88AA6A50083DA36A6D3D850F47E57C9B" xlink:to="loc_us-gaap_OverAllotmentOptionMember_36AF5CD8640A31F20761850F47E6F069" xlink:type="arc" />
<link:loc xlink:href="immu-20191231.xsd#immu_ATMAgreementMember" xlink:label="loc_immu_ATMAgreementMember_F86213B8FBA8032424BE850F47E6D596" xlink:type="locator" />
<link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_88AA6A50083DA36A6D3D850F47E57C9B" xlink:to="loc_immu_ATMAgreementMember_F86213B8FBA8032424BE850F47E6D596" xlink:type="arc" />
<link:loc xlink:href="immu-20191231.xsd#immu_SalesAgreementMember" xlink:label="loc_immu_SalesAgreementMember_42C26528926A0DEFF5C5850F47E6DD22" xlink:type="locator" />
<link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_88AA6A50083DA36A6D3D850F47E57C9B" xlink:to="loc_immu_SalesAgreementMember_42C26528926A0DEFF5C5850F47E6DD22" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis_409ECE1F14A283FF61E2850F47E7FF68" xlink:type="locator" />
<link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_5A50C1824C482DD38108850F47E3B754" xlink:to="loc_us-gaap_TypeOfArrangementAxis_409ECE1F14A283FF61E2850F47E7FF68" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_838F02D6EE7005DB9632850F47E75B04_default" xlink:type="locator" />
<link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_409ECE1F14A283FF61E2850F47E7FF68" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_838F02D6EE7005DB9632850F47E75B04_default" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_838F02D6EE7005DB9632850F47E75B04" xlink:type="locator" />
<link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_409ECE1F14A283FF61E2850F47E7FF68" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_838F02D6EE7005DB9632850F47E75B04" xlink:type="arc" />
<link:loc xlink:href="immu-20191231.xsd#immu_SecuritiesPurchaseAgreementMember" xlink:label="loc_immu_SecuritiesPurchaseAgreementMember_AF223CF58A6E21D1AFDB850F47E743BC" xlink:type="locator" />
<link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_838F02D6EE7005DB9632850F47E75B04" xlink:to="loc_immu_SecuritiesPurchaseAgreementMember_AF223CF58A6E21D1AFDB850F47E743BC" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_CounterpartyNameAxis" xlink:label="loc_srt_CounterpartyNameAxis_C832E7872DE3F498858B850F47E7A497" xlink:type="locator" />
<link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_5A50C1824C482DD38108850F47E3B754" xlink:to="loc_srt_CounterpartyNameAxis_C832E7872DE3F498858B850F47E7A497" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_E82BF005FE97775E2BC8850F47E7A3DB_default" xlink:type="locator" />
<link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_C832E7872DE3F498858B850F47E7A497" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_E82BF005FE97775E2BC8850F47E7A3DB_default" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_E82BF005FE97775E2BC8850F47E7A3DB" xlink:type="locator" />
<link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_C832E7872DE3F498858B850F47E7A497" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_E82BF005FE97775E2BC8850F47E7A3DB" xlink:type="arc" />
<link:loc xlink:href="immu-20191231.xsd#immu_SeattleGeneticsIncMember" xlink:label="loc_immu_SeattleGeneticsIncMember_092583072F73922BB441850F47E853B9" xlink:type="locator" />
<link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_E82BF005FE97775E2BC8850F47E7A3DB" xlink:to="loc_immu_SeattleGeneticsIncMember_092583072F73922BB441850F47E853B9" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_6D8CC3904CD88BFAAC9D850F47E87621" xlink:type="locator" />
<link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_5A50C1824C482DD38108850F47E3B754" xlink:to="loc_us-gaap_StatementClassOfStockAxis_6D8CC3904CD88BFAAC9D850F47E87621" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_3EF5DC41CDF892B40927850F47E855A0_default" xlink:type="locator" />
<link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_6D8CC3904CD88BFAAC9D850F47E87621" xlink:to="loc_us-gaap_ClassOfStockDomain_3EF5DC41CDF892B40927850F47E855A0_default" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_3EF5DC41CDF892B40927850F47E855A0" xlink:type="locator" />
<link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_6D8CC3904CD88BFAAC9D850F47E87621" xlink:to="loc_us-gaap_ClassOfStockDomain_3EF5DC41CDF892B40927850F47E855A0" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConvertiblePreferredStockMember" xlink:label="loc_us-gaap_ConvertiblePreferredStockMember_3A02A184B09DF64DA62D850F47E908B1" xlink:type="locator" />
<link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_3EF5DC41CDF892B40927850F47E855A0" xlink:to="loc_us-gaap_ConvertiblePreferredStockMember_3A02A184B09DF64DA62D850F47E908B1" xlink:type="arc" />
<link:loc xlink:href="immu-20191231.xsd#immu_CommonAndPreferredSharesAuthorized" xlink:label="loc_immu_CommonAndPreferredSharesAuthorized_6AEE6862DE86A533B9E1850F47E9E292" xlink:type="locator" />
<link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_41B54B431001DB193B43850F47E921A5" xlink:to="loc_immu_CommonAndPreferredSharesAuthorized_6AEE6862DE86A533B9E1850F47E9E292" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_F1EC7734E7C61223B94F850F47E9FF23" xlink:type="locator" />
<link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_41B54B431001DB193B43850F47E921A5" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_F1EC7734E7C61223B94F850F47E9FF23" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_61733BD4016BB6C49831850F47EA843F" xlink:type="locator" />
<link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_41B54B431001DB193B43850F47E921A5" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_61733BD4016BB6C49831850F47EA843F" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_2BD9CCAC9820EB00AF42850F47EA0AA9" xlink:type="locator" />
<link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_41B54B431001DB193B43850F47E921A5" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_2BD9CCAC9820EB00AF42850F47EA0AA9" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="loc_us-gaap_PreferredStockSharesIssued_16E086653E6C9C058F10850F47EA2C6F" xlink:type="locator" />
<link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_41B54B431001DB193B43850F47E921A5" xlink:to="loc_us-gaap_PreferredStockSharesIssued_16E086653E6C9C058F10850F47EA2C6F" xlink:type="arc" />
<link:loc xlink:href="immu-20191231.xsd#immu_IssuanceofConvertiblePreferredStockPerShare" xlink:label="loc_immu_IssuanceofConvertiblePreferredStockPerShare_35BB2233F02AD1DD1A9A850F47EA6C11" xlink:type="locator" />
<link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_41B54B431001DB193B43850F47E921A5" xlink:to="loc_immu_IssuanceofConvertiblePreferredStockPerShare_35BB2233F02AD1DD1A9A850F47EA6C11" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock_78DEBE2E2AE2ADC57FBA850F47EAC9CF" xlink:type="locator" />
<link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_41B54B431001DB193B43850F47E921A5" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock_78DEBE2E2AE2ADC57FBA850F47EAC9CF" xlink:type="arc" />
<link:loc xlink:href="immu-20191231.xsd#immu_ConvertiblePreferredStockConversionRatio" xlink:label="loc_immu_ConvertiblePreferredStockConversionRatio_01A184EF89FCDA9C01FC850F47EAEAE6" xlink:type="locator" />
<link:definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_41B54B431001DB193B43850F47E921A5" xlink:to="loc_immu_ConvertiblePreferredStockConversionRatio_01A184EF89FCDA9C01FC850F47EAEAE6" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConversionOfStockSharesIssued1" xlink:label="loc_us-gaap_ConversionOfStockSharesIssued1_2CCF6829D25EC1EE1D8D850F47EB1F7A" xlink:type="locator" />
<link:definitionArc order="9" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_41B54B431001DB193B43850F47E921A5" xlink:to="loc_us-gaap_ConversionOfStockSharesIssued1_2CCF6829D25EC1EE1D8D850F47EB1F7A" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharePrice" xlink:label="loc_us-gaap_SharePrice_0C5CB3695874285C3B7C850F47EB932A" xlink:type="locator" />
<link:definitionArc order="10" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_41B54B431001DB193B43850F47E921A5" xlink:to="loc_us-gaap_SharePrice_0C5CB3695874285C3B7C850F47EB932A" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_21EA5940FFF38DC81306850F47EB2428" xlink:type="locator" />
<link:definitionArc order="11" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_41B54B431001DB193B43850F47E921A5" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_21EA5940FFF38DC81306850F47EB2428" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_2E41EC97CE61FF5D00BF850F47EB098A" xlink:type="locator" />
<link:definitionArc order="12" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_41B54B431001DB193B43850F47E921A5" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_2E41EC97CE61FF5D00BF850F47EB098A" xlink:type="arc" />
<link:loc xlink:href="immu-20191231.xsd#immu_GrossProceedsFromIssuanceOfCommonStock" xlink:label="loc_immu_GrossProceedsFromIssuanceOfCommonStock_90AED044F33BF1D4471D850F47EB1F30" xlink:type="locator" />
<link:definitionArc order="13" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_41B54B431001DB193B43850F47E921A5" xlink:to="loc_immu_GrossProceedsFromIssuanceOfCommonStock_90AED044F33BF1D4471D850F47EB1F30" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentTerm" xlink:label="loc_us-gaap_DebtInstrumentTerm_A61474B9EB28143748BD850F47EC7EF6" xlink:type="locator" />
<link:definitionArc order="14" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_41B54B431001DB193B43850F47E921A5" xlink:to="loc_us-gaap_DebtInstrumentTerm_A61474B9EB28143748BD850F47EC7EF6" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_91DAEE9A6F7BF5DD4E41850F47ECD966" xlink:type="locator" />
<link:definitionArc order="15" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_41B54B431001DB193B43850F47E921A5" xlink:to="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_91DAEE9A6F7BF5DD4E41850F47ECD966" xlink:type="arc" />
<link:loc xlink:href="immu-20191231.xsd#immu_ClassOfWarrantOrRightFairValue" xlink:label="loc_immu_ClassOfWarrantOrRightFairValue_C54AF79D6DBE361D4E69850F47EC092E" xlink:type="locator" />
<link:definitionArc order="16" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_41B54B431001DB193B43850F47E921A5" xlink:to="loc_immu_ClassOfWarrantOrRightFairValue_C54AF79D6DBE361D4E69850F47EC092E" xlink:type="arc" />
<link:loc xlink:href="immu-20191231.xsd#immu_ExerciseOfWarrants" xlink:label="loc_immu_ExerciseOfWarrants_CE9B4B113ACA7946DB04850F47ECBA61" xlink:type="locator" />
<link:definitionArc order="17" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_41B54B431001DB193B43850F47E921A5" xlink:to="loc_immu_ExerciseOfWarrants_CE9B4B113ACA7946DB04850F47ECBA61" xlink:type="arc" />
<link:loc xlink:href="immu-20191231.xsd#immu_AggregateOfferingPriceofCommonStock" xlink:label="loc_immu_AggregateOfferingPriceofCommonStock_DC155101CFD294A2A126850F47EC451F" xlink:type="locator" />
<link:definitionArc order="18" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_41B54B431001DB193B43850F47E921A5" xlink:to="loc_immu_AggregateOfferingPriceofCommonStock_DC155101CFD294A2A126850F47EC451F" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_4CD5E532202817ED8B59850F47EC6514" xlink:type="locator" />
<link:definitionArc order="19" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_41B54B431001DB193B43850F47E921A5" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_4CD5E532202817ED8B59850F47EC6514" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_EA6065A0DD062D619B48850F47EDE783" xlink:type="locator" />
<link:definitionArc order="20" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_41B54B431001DB193B43850F47E921A5" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_EA6065A0DD062D619B48850F47EDE783" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_30A04D579EC847712FAF850F47ED669E" xlink:type="locator" />
<link:definitionArc order="21" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_41B54B431001DB193B43850F47E921A5" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_30A04D579EC847712FAF850F47ED669E" xlink:type="arc" />
<link:loc xlink:href="immu-20191231.xsd#immu_IncreaseDecreaseinFairValueOfWarrantsExercised" xlink:label="loc_immu_IncreaseDecreaseinFairValueOfWarrantsExercised_B2503160710146E5BC59850F47ED07EC" xlink:type="locator" />
<link:definitionArc order="22" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_41B54B431001DB193B43850F47E921A5" xlink:to="loc_immu_IncreaseDecreaseinFairValueOfWarrantsExercised_B2503160710146E5BC59850F47ED07EC" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="loc_us-gaap_ClassOfWarrantOrRightOutstanding_60BB1972C4CF5556F1B1850F47EDDD06" xlink:type="locator" />
<link:definitionArc order="23" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_41B54B431001DB193B43850F47E921A5" xlink:to="loc_us-gaap_ClassOfWarrantOrRightOutstanding_60BB1972C4CF5556F1B1850F47EDDD06" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="loc_us-gaap_ProceedsFromWarrantExercises_5519F3305EA7F5D121A9850F47EDD92B" xlink:type="locator" />
<link:definitionArc order="24" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_41B54B431001DB193B43850F47E921A5" xlink:to="loc_us-gaap_ProceedsFromWarrantExercises_5519F3305EA7F5D121A9850F47EDD92B" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_3F447CF427C30BAD418F850F47ED51F6" xlink:type="locator" />
<link:definitionArc order="25" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_41B54B431001DB193B43850F47E921A5" xlink:to="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_3F447CF427C30BAD418F850F47ED51F6" xlink:type="arc" />
<link:loc xlink:href="immu-20191231.xsd#immu_PaymentsforStockIssuanceCostsPercentage" xlink:label="loc_immu_PaymentsforStockIssuanceCostsPercentage_BF07775D46C76641E8D3850F47EE3625" xlink:type="locator" />
<link:definitionArc order="26" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_41B54B431001DB193B43850F47E921A5" xlink:to="loc_immu_PaymentsforStockIssuanceCostsPercentage_BF07775D46C76641E8D3850F47EE3625" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_81D8410D64B54D860620850F47EEC435" xlink:type="locator" />
<link:definitionArc order="27" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_41B54B431001DB193B43850F47E921A5" xlink:to="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_81D8410D64B54D860620850F47EEC435" xlink:type="arc" />
<link:loc xlink:href="immu-20191231.xsd#immu_ProceedsfromIssuanceInitialPublicOfferingGross" xlink:label="loc_immu_ProceedsfromIssuanceInitialPublicOfferingGross_41A0652CC90FECF9C94C850F47EE0055" xlink:type="locator" />
<link:definitionArc order="28" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_41B54B431001DB193B43850F47E921A5" xlink:to="loc_immu_ProceedsfromIssuanceInitialPublicOfferingGross_41A0652CC90FECF9C94C850F47EE0055" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:label="loc_us-gaap_ProceedsFromIssuanceInitialPublicOffering_A037A04E8DABACBC5DCB850F47EE8D4D" xlink:type="locator" />
<link:definitionArc order="29" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_41B54B431001DB193B43850F47E921A5" xlink:to="loc_us-gaap_ProceedsFromIssuanceInitialPublicOffering_A037A04E8DABACBC5DCB850F47EE8D4D" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="loc_us-gaap_PaymentsOfStockIssuanceCosts_F9F32C6E033BDC7C221A850F47EE93BB" xlink:type="locator" />
<link:definitionArc order="30" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_41B54B431001DB193B43850F47E921A5" xlink:to="loc_us-gaap_PaymentsOfStockIssuanceCosts_F9F32C6E033BDC7C221A850F47EE93BB" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="loc_us-gaap_SaleOfStockPricePerShare_85E2B55364A04D8CC420850F47EEB8CD" xlink:type="locator" />
<link:definitionArc order="31" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_41B54B431001DB193B43850F47E921A5" xlink:to="loc_us-gaap_SaleOfStockPricePerShare_85E2B55364A04D8CC420850F47EEB8CD" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SaleOfStockConsiderationReceivedPerTransaction" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedPerTransaction_E0D0B4C26ECEE2C9F288850F47EFBC29" xlink:type="locator" />
<link:definitionArc order="32" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_41B54B431001DB193B43850F47E921A5" xlink:to="loc_us-gaap_SaleOfStockConsiderationReceivedPerTransaction_E0D0B4C26ECEE2C9F288850F47EFBC29" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="loc_us-gaap_SharesIssuedPricePerShare_C6D23EC728ECAF6F6D62850F47EFA06C" xlink:type="locator" />
<link:definitionArc order="33" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_41B54B431001DB193B43850F47E921A5" xlink:to="loc_us-gaap_SharesIssuedPricePerShare_C6D23EC728ECAF6F6D62850F47EFA06C" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TreasuryStockSharesAcquired" xlink:label="loc_us-gaap_TreasuryStockSharesAcquired_F7363FF27DF4F82D1479850F47EF3FE0" xlink:type="locator" />
<link:definitionArc order="34" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_41B54B431001DB193B43850F47E921A5" xlink:to="loc_us-gaap_TreasuryStockSharesAcquired_F7363FF27DF4F82D1479850F47EF3FE0" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockRepurchasedAndRetiredDuringPeriodShares" xlink:label="loc_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares_9030732EFE2942362108850F47EFB2DF" xlink:type="locator" />
<link:definitionArc order="35" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_41B54B431001DB193B43850F47E921A5" xlink:to="loc_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares_9030732EFE2942362108850F47EFB2DF" xlink:type="arc" />
</link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>13
<FILENAME>immu-20191231_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!--XBRL Document Created with Wdesk from Workiva-->
<!-- -->
<link:linkbase xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" xlink:type="simple" />
<link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" xlink:type="simple" />
<link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" xlink:type="simple" />
<link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" xlink:type="simple" />
<link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" xlink:type="simple" />
<link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" xlink:type="simple" />
<link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" xlink:type="simple" />
<link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
<link:label id="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_748DAAF2BA0ACA69FA3D3991D283D95D_label_en-US" xlink:label="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_748DAAF2BA0ACA69FA3D3991D283D95D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investments, Debt and Equity Securities [Abstract]</link:label>
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_748DAAF2BA0ACA69FA3D3991D283D95D" xlink:type="locator" />
<link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_748DAAF2BA0ACA69FA3D3991D283D95D" xlink:to="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_748DAAF2BA0ACA69FA3D3991D283D95D" xlink:type="arc" />
<link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_E415A2A1CBB006EF66073991D2837379_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_E415A2A1CBB006EF66073991D2837379" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Available-for-sale Securities [Table]</link:label>
<link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_E415A2A1CBB006EF66073991D2837379_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_E415A2A1CBB006EF66073991D2837379" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Available-for-sale Securities [Table]</link:label>
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_E415A2A1CBB006EF66073991D2837379" xlink:type="locator" />
<link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_E415A2A1CBB006EF66073991D2837379" xlink:to="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_E415A2A1CBB006EF66073991D2837379" xlink:type="arc" />
<link:label id="lab_us-gaap_FinancialInstrumentAxis_126BF9B58810F2D6D5483991D2844ACE_terseLabel_en-US" xlink:label="lab_us-gaap_FinancialInstrumentAxis_126BF9B58810F2D6D5483991D2844ACE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Financial Instrument [Axis]</link:label>
<link:label id="lab_us-gaap_FinancialInstrumentAxis_126BF9B58810F2D6D5483991D2844ACE_label_en-US" xlink:label="lab_us-gaap_FinancialInstrumentAxis_126BF9B58810F2D6D5483991D2844ACE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Financial Instrument [Axis]</link:label>
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="loc_us-gaap_FinancialInstrumentAxis_126BF9B58810F2D6D5483991D2844ACE" xlink:type="locator" />
<link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinancialInstrumentAxis_126BF9B58810F2D6D5483991D2844ACE" xlink:to="lab_us-gaap_FinancialInstrumentAxis_126BF9B58810F2D6D5483991D2844ACE" xlink:type="arc" />
<link:label id="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_F3B53A7162D06F4E67093991D2845899_terseLabel_en-US" xlink:label="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_F3B53A7162D06F4E67093991D2845899" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Financial Instruments [Domain]</link:label>
<link:label id="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_F3B53A7162D06F4E67093991D2845899_label_en-US" xlink:label="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_F3B53A7162D06F4E67093991D2845899" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Financial Instruments [Domain]</link:label>
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_F3B53A7162D06F4E67093991D2845899" xlink:type="locator" />
<link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_F3B53A7162D06F4E67093991D2845899" xlink:to="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_F3B53A7162D06F4E67093991D2845899" xlink:type="arc" />
<link:label id="lab_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember_B23B21643218C7FBF1EA3991D2847FAF_terseLabel_en-US" xlink:label="lab_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember_B23B21643218C7FBF1EA3991D2847FAF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">U.S. Government Sponsored Agencies</link:label>
<link:label id="lab_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember_B23B21643218C7FBF1EA3991D2847FAF_label_en-US" xlink:label="lab_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember_B23B21643218C7FBF1EA3991D2847FAF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">US Government-sponsored Enterprises Debt Securities [Member]</link:label>
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember" xlink:label="loc_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember_B23B21643218C7FBF1EA3991D2847FAF" xlink:type="locator" />
<link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember_B23B21643218C7FBF1EA3991D2847FAF" xlink:to="lab_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember_B23B21643218C7FBF1EA3991D2847FAF" xlink:type="arc" />
<link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_6012AD4D345BB19050CD3991D284B262_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_6012AD4D345BB19050CD3991D284B262" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-sale [Line Items]</link:label>
<link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_6012AD4D345BB19050CD3991D284B262_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_6012AD4D345BB19050CD3991D284B262" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-sale [Line Items]</link:label>
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_6012AD4D345BB19050CD3991D284B262" xlink:type="locator" />
<link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_6012AD4D345BB19050CD3991D284B262" xlink:to="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_6012AD4D345BB19050CD3991D284B262" xlink:type="arc" />
<link:label id="lab_immu_AvailableForSaleSecuritiesDebtMaturitiesAfterOneYearormoreCarryingValue_9291349186795373BECD3991D285C6A2_terseLabel_en-US" xlink:label="lab_immu_AvailableForSaleSecuritiesDebtMaturitiesAfterOneYearormoreCarryingValue_9291349186795373BECD3991D285C6A2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value</link:label>
<link:label id="lab_immu_AvailableForSaleSecuritiesDebtMaturitiesAfterOneYearormoreCarryingValue_9291349186795373BECD3991D285C6A2_label_en-US" xlink:label="lab_immu_AvailableForSaleSecuritiesDebtMaturitiesAfterOneYearormoreCarryingValue_9291349186795373BECD3991D285C6A2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Available For Sale Securities Debt Maturities After One Year or more Carrying Value</link:label>
<link:label id="lab_immu_AvailableForSaleSecuritiesDebtMaturitiesAfterOneYearormoreCarryingValue_9291349186795373BECD3991D285C6A2_documentation_en-US" xlink:label="lab_immu_AvailableForSaleSecuritiesDebtMaturitiesAfterOneYearormoreCarryingValue_9291349186795373BECD3991D285C6A2" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Available For Sale Securities Debt Maturities After One Year or more Carrying Value</link:label>
<link:loc xlink:href="immu-20191231.xsd#immu_AvailableForSaleSecuritiesDebtMaturitiesAfterOneYearormoreCarryingValue" xlink:label="loc_immu_AvailableForSaleSecuritiesDebtMaturitiesAfterOneYearormoreCarryingValue_9291349186795373BECD3991D285C6A2" xlink:type="locator" />
<link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_immu_AvailableForSaleSecuritiesDebtMaturitiesAfterOneYearormoreCarryingValue_9291349186795373BECD3991D285C6A2" xlink:to="lab_immu_AvailableForSaleSecuritiesDebtMaturitiesAfterOneYearormoreCarryingValue_9291349186795373BECD3991D285C6A2" xlink:type="arc" />
<link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_9A1324DB69BFCAE357D73991D28513EB_totalLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_9A1324DB69BFCAE357D73991D28513EB" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Amortized Cost</link:label>
<link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_9A1324DB69BFCAE357D73991D28513EB_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_9A1324DB69BFCAE357D73991D28513EB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-sale, Amortized Cost</link:label>
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_9A1324DB69BFCAE357D73991D28513EB" xlink:type="locator" />
<link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_9A1324DB69BFCAE357D73991D28513EB" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_9A1324DB69BFCAE357D73991D28513EB" xlink:type="arc" />
<link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_E52421C5094607DC888F3991D285C18A_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_E52421C5094607DC888F3991D285C18A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Gross Unrealized Gain</link:label>
<link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_E52421C5094607DC888F3991D285C18A_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_E52421C5094607DC888F3991D285C18A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-sale, Accumulated Gross Unrealized Gain, before Tax</link:label>
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_E52421C5094607DC888F3991D285C18A" xlink:type="locator" />
<link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_E52421C5094607DC888F3991D285C18A" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_E52421C5094607DC888F3991D285C18A" xlink:type="arc" />
<link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_48DA9E2371A57265E2AE3991D285E536_negatedLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_48DA9E2371A57265E2AE3991D285E536" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Gross Unrealized (Loss)</link:label>
<link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_48DA9E2371A57265E2AE3991D285E536_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_48DA9E2371A57265E2AE3991D285E536" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax</link:label>
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_48DA9E2371A57265E2AE3991D285E536" xlink:type="locator" />
<link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_48DA9E2371A57265E2AE3991D285E536" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_48DA9E2371A57265E2AE3991D285E536" xlink:type="arc" />
<link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_6D436F18B75EBA986CE03991D28536B5_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_6D436F18B75EBA986CE03991D28536B5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value</link:label>
<link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_6D436F18B75EBA986CE03991D28536B5_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_6D436F18B75EBA986CE03991D28536B5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-sale</link:label>
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_6D436F18B75EBA986CE03991D28536B5" xlink:type="locator" />
<link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_6D436F18B75EBA986CE03991D28536B5" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_6D436F18B75EBA986CE03991D28536B5" xlink:type="arc" />
<link:label id="lab_us-gaap_IncomeTaxDisclosureAbstract_7DA3A40D7AED6D14B7D23991D1C3C7CD_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureAbstract_7DA3A40D7AED6D14B7D23991D1C3C7CD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_7DA3A40D7AED6D14B7D23991D1C3C7CD" xlink:type="locator" />
<link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_7DA3A40D7AED6D14B7D23991D1C3C7CD" xlink:to="lab_us-gaap_IncomeTaxDisclosureAbstract_7DA3A40D7AED6D14B7D23991D1C3C7CD" xlink:type="arc" />
<link:label id="lab_us-gaap_CurrentFederalTaxExpenseBenefit_5607347BE2D6E68A0BE83991D1C48808_terseLabel_en-US" xlink:label="lab_us-gaap_CurrentFederalTaxExpenseBenefit_5607347BE2D6E68A0BE83991D1C48808" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current</link:label>
<link:label id="lab_us-gaap_CurrentFederalTaxExpenseBenefit_5607347BE2D6E68A0BE83991D1C48808_label_en-US" xlink:label="lab_us-gaap_CurrentFederalTaxExpenseBenefit_5607347BE2D6E68A0BE83991D1C48808" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current Federal Tax Expense (Benefit)</link:label>
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CurrentFederalTaxExpenseBenefit" xlink:label="loc_us-gaap_CurrentFederalTaxExpenseBenefit_5607347BE2D6E68A0BE83991D1C48808" xlink:type="locator" />
<link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrentFederalTaxExpenseBenefit_5607347BE2D6E68A0BE83991D1C48808" xlink:to="lab_us-gaap_CurrentFederalTaxExpenseBenefit_5607347BE2D6E68A0BE83991D1C48808" xlink:type="arc" />
<link:label id="lab_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_400C4E4B89ED75428EF93991D1C43D0D_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_400C4E4B89ED75428EF93991D1C43D0D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred</link:label>
<link:label id="lab_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_400C4E4B89ED75428EF93991D1C43D0D_label_en-US" xlink:label="lab_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_400C4E4B89ED75428EF93991D1C43D0D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Federal Income Tax Expense (Benefit)</link:label>
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_400C4E4B89ED75428EF93991D1C43D0D" xlink:type="locator" />
<link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_400C4E4B89ED75428EF93991D1C43D0D" xlink:to="lab_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_400C4E4B89ED75428EF93991D1C43D0D" xlink:type="arc" />
<link:label id="lab_us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperations_29DA8882FECF691B4A9D3991D1C4E0CC_totalLabel_en-US" xlink:label="lab_us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperations_29DA8882FECF691B4A9D3991D1C4E0CC" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total Federal</link:label>
<link:label id="lab_us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperations_29DA8882FECF691B4A9D3991D1C4E0CC_label_en-US" xlink:label="lab_us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperations_29DA8882FECF691B4A9D3991D1C4E0CC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Federal Income Tax Expense (Benefit), Continuing Operations</link:label>
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperations" xlink:label="loc_us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperations_29DA8882FECF691B4A9D3991D1C4E0CC" xlink:type="locator" />
<link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperations_29DA8882FECF691B4A9D3991D1C4E0CC" xlink:to="lab_us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperations_29DA8882FECF691B4A9D3991D1C4E0CC" xlink:type="arc" />
<link:label id="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_E81E6416312850CA74DD3991D1C42BFF_terseLabel_en-US" xlink:label="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_E81E6416312850CA74DD3991D1C42BFF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current</link:label>
<link:label id="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_E81E6416312850CA74DD3991D1C42BFF_label_en-US" xlink:label="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_E81E6416312850CA74DD3991D1C42BFF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current State and Local Tax Expense (Benefit)</link:label>
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:label="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_E81E6416312850CA74DD3991D1C42BFF" xlink:type="locator" />
<link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_E81E6416312850CA74DD3991D1C42BFF" xlink:to="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_E81E6416312850CA74DD3991D1C42BFF" xlink:type="arc" />
<link:label id="lab_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_69A4AD8E6323E5C556693991D1C4B4F0_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_69A4AD8E6323E5C556693991D1C4B4F0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred</link:label>
<link:label id="lab_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_69A4AD8E6323E5C556693991D1C4B4F0_label_en-US" xlink:label="lab_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_69A4AD8E6323E5C556693991D1C4B4F0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred State and Local Income Tax Expense (Benefit)</link:label>
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_69A4AD8E6323E5C556693991D1C4B4F0" xlink:type="locator" />
<link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_69A4AD8E6323E5C556693991D1C4B4F0" xlink:to="lab_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_69A4AD8E6323E5C556693991D1C4B4F0" xlink:type="arc" />
<link:label id="lab_us-gaap_StateAndLocalIncomeTaxExpenseBenefitContinuingOperations_669E6917CCAD67E4ACF639ED5BFF2E5A_totalLabel_en-US" xlink:label="lab_us-gaap_StateAndLocalIncomeTaxExpenseBenefitContinuingOperations_669E6917CCAD67E4ACF639ED5BFF2E5A" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total State</link:label>
<link:label id="lab_us-gaap_StateAndLocalIncomeTaxExpenseBenefitContinuingOperations_669E6917CCAD67E4ACF639ED5BFF2E5A_label_en-US" xlink:label="lab_us-gaap_StateAndLocalIncomeTaxExpenseBenefitContinuingOperations_669E6917CCAD67E4ACF639ED5BFF2E5A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">State and Local Income Tax Expense (Benefit), Continuing Operations</link:label>
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StateAndLocalIncomeTaxExpenseBenefitContinuingOperations" xlink:label="loc_us-gaap_StateAndLocalIncomeTaxExpenseBenefitContinuingOperations_669E6917CCAD67E4ACF639ED5BFF2E5A" xlink:type="locator" />
<link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StateAndLocalIncomeTaxExpenseBenefitContinuingOperations_669E6917CCAD67E4ACF639ED5BFF2E5A" xlink:to="lab_us-gaap_StateAndLocalIncomeTaxExpenseBenefitContinuingOperations_669E6917CCAD67E4ACF639ED5BFF2E5A" xlink:type="arc" />
<link:label id="lab_us-gaap_CurrentForeignTaxExpenseBenefit_9B31FBE30D5FED7428E93991D1C53101_terseLabel_en-US" xlink:label="lab_us-gaap_CurrentForeignTaxExpenseBenefit_9B31FBE30D5FED7428E93991D1C53101" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current</link:label>
<link:label id="lab_us-gaap_CurrentForeignTaxExpenseBenefit_9B31FBE30D5FED7428E93991D1C53101_label_en-US" xlink:label="lab_us-gaap_CurrentForeignTaxExpenseBenefit_9B31FBE30D5FED7428E93991D1C53101" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current Foreign Tax Expense (Benefit)</link:label>
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CurrentForeignTaxExpenseBenefit" xlink:label="loc_us-gaap_CurrentForeignTaxExpenseBenefit_9B31FBE30D5FED7428E93991D1C53101" xlink:type="locator" />
<link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrentForeignTaxExpenseBenefit_9B31FBE30D5FED7428E93991D1C53101" xlink:to="lab_us-gaap_CurrentForeignTaxExpenseBenefit_9B31FBE30D5FED7428E93991D1C53101" xlink:type="arc" />
<link:label id="lab_us-gaap_DeferredForeignIncomeTaxExpenseBenefit_6CE221DEC27ACD6C2C933991D1C53753_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredForeignIncomeTaxExpenseBenefit_6CE221DEC27ACD6C2C933991D1C53753" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred</link:label>
<link:label id="lab_us-gaap_DeferredForeignIncomeTaxExpenseBenefit_6CE221DEC27ACD6C2C933991D1C53753_label_en-US" xlink:label="lab_us-gaap_DeferredForeignIncomeTaxExpenseBenefit_6CE221DEC27ACD6C2C933991D1C53753" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Foreign Income Tax Expense (Benefit)</link:label>
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredForeignIncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_DeferredForeignIncomeTaxExpenseBenefit_6CE221DEC27ACD6C2C933991D1C53753" xlink:type="locator" />
<link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredForeignIncomeTaxExpenseBenefit_6CE221DEC27ACD6C2C933991D1C53753" xlink:to="lab_us-gaap_DeferredForeignIncomeTaxExpenseBenefit_6CE221DEC27ACD6C2C933991D1C53753" xlink:type="arc" />
<link:label id="lab_us-gaap_ForeignIncomeTaxExpenseBenefitContinuingOperations_B38F76EE2AF2C46999193991D1C57C1A_totalLabel_en-US" xlink:label="lab_us-gaap_ForeignIncomeTaxExpenseBenefitContinuingOperations_B38F76EE2AF2C46999193991D1C57C1A" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total Foreign</link:label>
<link:label id="lab_us-gaap_ForeignIncomeTaxExpenseBenefitContinuingOperations_B38F76EE2AF2C46999193991D1C57C1A_label_en-US" xlink:label="lab_us-gaap_ForeignIncomeTaxExpenseBenefitContinuingOperations_B38F76EE2AF2C46999193991D1C57C1A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Foreign Income Tax Expense (Benefit), Continuing Operations</link:label>
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ForeignIncomeTaxExpenseBenefitContinuingOperations" xlink:label="loc_us-gaap_ForeignIncomeTaxExpenseBenefitContinuingOperations_B38F76EE2AF2C46999193991D1C57C1A" xlink:type="locator" />
<link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignIncomeTaxExpenseBenefitContinuingOperations_B38F76EE2AF2C46999193991D1C57C1A" xlink:to="lab_us-gaap_ForeignIncomeTaxExpenseBenefitContinuingOperations_B38F76EE2AF2C46999193991D1C57C1A" xlink:type="arc" />
<link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_8D2D65F5D36806F720E13991D1C56400_totalLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit_8D2D65F5D36806F720E13991D1C56400" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total income tax expense</link:label>
<link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_8D2D65F5D36806F720E13991D1C56400_label_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit_8D2D65F5D36806F720E13991D1C56400" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Expense (Benefit)</link:label>
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_8D2D65F5D36806F720E13991D1C56400" xlink:type="locator" />
<link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_8D2D65F5D36806F720E13991D1C56400" xlink:to="lab_us-gaap_IncomeTaxExpenseBenefit_8D2D65F5D36806F720E13991D1C56400" xlink:type="arc" />
<link:label id="lab_dei_CoverAbstract_EA6F80DC35A952F1E4887E59E4CA4181_label_en-US" xlink:label="lab_dei_CoverAbstract_EA6F80DC35A952F1E4887E59E4CA4181" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cover page.</link:label>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CoverAbstract" xlink:label="loc_dei_CoverAbstract_EA6F80DC35A952F1E4887E59E4CA4181" xlink:type="locator" />
<link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract_EA6F80DC35A952F1E4887E59E4CA4181" xlink:to="lab_dei_CoverAbstract_EA6F80DC35A952F1E4887E59E4CA4181" xlink:type="arc" />
<link:label id="lab_dei_DocumentType_CFC168DFDA8435D5AEEF7E59E4CA6A9B_terseLabel_en-US" xlink:label="lab_dei_DocumentType_CFC168DFDA8435D5AEEF7E59E4CA6A9B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Type</link:label>
<link:label id="lab_dei_DocumentType_CFC168DFDA8435D5AEEF7E59E4CA6A9B_label_en-US" xlink:label="lab_dei_DocumentType_CFC168DFDA8435D5AEEF7E59E4CA6A9B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Type</link:label>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentType" xlink:label="loc_dei_DocumentType_CFC168DFDA8435D5AEEF7E59E4CA6A9B" xlink:type="locator" />
<link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType_CFC168DFDA8435D5AEEF7E59E4CA6A9B" xlink:to="lab_dei_DocumentType_CFC168DFDA8435D5AEEF7E59E4CA6A9B" xlink:type="arc" />
<link:label id="lab_dei_DocumentAnnualReport_3931EC4AB87F7793F4D67E59E4CAB74C_terseLabel_en-US" xlink:label="lab_dei_DocumentAnnualReport_3931EC4AB87F7793F4D67E59E4CAB74C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Annual Report</link:label>
<link:label id="lab_dei_DocumentAnnualReport_3931EC4AB87F7793F4D67E59E4CAB74C_label_en-US" xlink:label="lab_dei_DocumentAnnualReport_3931EC4AB87F7793F4D67E59E4CAB74C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Annual Report</link:label>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentAnnualReport" xlink:label="loc_dei_DocumentAnnualReport_3931EC4AB87F7793F4D67E59E4CAB74C" xlink:type="locator" />
<link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentAnnualReport_3931EC4AB87F7793F4D67E59E4CAB74C" xlink:to="lab_dei_DocumentAnnualReport_3931EC4AB87F7793F4D67E59E4CAB74C" xlink:type="arc" />
<link:label id="lab_dei_DocumentPeriodEndDate_E3119447EB32A8BB81F57E59E4CACE89_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate_E3119447EB32A8BB81F57E59E4CACE89" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Period End Date</link:label>
<link:label id="lab_dei_DocumentPeriodEndDate_E3119447EB32A8BB81F57E59E4CACE89_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate_E3119447EB32A8BB81F57E59E4CACE89" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Period End Date</link:label>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_dei_DocumentPeriodEndDate_E3119447EB32A8BB81F57E59E4CACE89" xlink:type="locator" />
<link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate_E3119447EB32A8BB81F57E59E4CACE89" xlink:to="lab_dei_DocumentPeriodEndDate_E3119447EB32A8BB81F57E59E4CACE89" xlink:type="arc" />
<link:label id="lab_dei_DocumentTransitionReport_B6945A303E37CD7DA5AF7E59E4CA9D14_terseLabel_en-US" xlink:label="lab_dei_DocumentTransitionReport_B6945A303E37CD7DA5AF7E59E4CA9D14" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Transition Report</link:label>
<link:label id="lab_dei_DocumentTransitionReport_B6945A303E37CD7DA5AF7E59E4CA9D14_label_en-US" xlink:label="lab_dei_DocumentTransitionReport_B6945A303E37CD7DA5AF7E59E4CA9D14" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Transition Report</link:label>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentTransitionReport" xlink:label="loc_dei_DocumentTransitionReport_B6945A303E37CD7DA5AF7E59E4CA9D14" xlink:type="locator" />
<link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentTransitionReport_B6945A303E37CD7DA5AF7E59E4CA9D14" xlink:to="lab_dei_DocumentTransitionReport_B6945A303E37CD7DA5AF7E59E4CA9D14" xlink:type="arc" />
<link:label id="lab_dei_EntityFileNumber_9994590247217BF8A8367E59E4CB0779_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber_9994590247217BF8A8367E59E4CB0779" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity File Number</link:label>
<link:label id="lab_dei_EntityFileNumber_9994590247217BF8A8367E59E4CB0779_label_en-US" xlink:label="lab_dei_EntityFileNumber_9994590247217BF8A8367E59E4CB0779" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity File Number</link:label>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityFileNumber" xlink:label="loc_dei_EntityFileNumber_9994590247217BF8A8367E59E4CB0779" xlink:type="locator" />
<link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber_9994590247217BF8A8367E59E4CB0779" xlink:to="lab_dei_EntityFileNumber_9994590247217BF8A8367E59E4CB0779" xlink:type="arc" />
<link:label id="lab_dei_EntityRegistrantName_A98076C696DE0666D5947E59E4CB6A88_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName_A98076C696DE0666D5947E59E4CB6A88" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Registrant Name</link:label>
<link:label id="lab_dei_EntityRegistrantName_A98076C696DE0666D5947E59E4CB6A88_label_en-US" xlink:label="lab_dei_EntityRegistrantName_A98076C696DE0666D5947E59E4CB6A88" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Registrant Name</link:label>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityRegistrantName" xlink:label="loc_dei_EntityRegistrantName_A98076C696DE0666D5947E59E4CB6A88" xlink:type="locator" />
<link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName_A98076C696DE0666D5947E59E4CB6A88" xlink:to="lab_dei_EntityRegistrantName_A98076C696DE0666D5947E59E4CB6A88" xlink:type="arc" />
<link:label id="lab_dei_EntityIncorporationStateCountryCode_21357F6AA2FC500563487E59E4CBF511_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode_21357F6AA2FC500563487E59E4CBF511" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
<link:label id="lab_dei_EntityIncorporationStateCountryCode_21357F6AA2FC500563487E59E4CBF511_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode_21357F6AA2FC500563487E59E4CBF511" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="loc_dei_EntityIncorporationStateCountryCode_21357F6AA2FC500563487E59E4CBF511" xlink:type="locator" />
<link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode_21357F6AA2FC500563487E59E4CBF511" xlink:to="lab_dei_EntityIncorporationStateCountryCode_21357F6AA2FC500563487E59E4CBF511" xlink:type="arc" />
<link:label id="lab_dei_EntityTaxIdentificationNumber_371F07EEE8E7407DF6DB7E59E4CB7194_terseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber_371F07EEE8E7407DF6DB7E59E4CB7194" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Tax Identification Number</link:label>
<link:label id="lab_dei_EntityTaxIdentificationNumber_371F07EEE8E7407DF6DB7E59E4CB7194_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber_371F07EEE8E7407DF6DB7E59E4CB7194" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Tax Identification Number</link:label>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityTaxIdentificationNumber" xlink:label="loc_dei_EntityTaxIdentificationNumber_371F07EEE8E7407DF6DB7E59E4CB7194" xlink:type="locator" />
<link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber_371F07EEE8E7407DF6DB7E59E4CB7194" xlink:to="lab_dei_EntityTaxIdentificationNumber_371F07EEE8E7407DF6DB7E59E4CB7194" xlink:type="arc" />
<link:label id="lab_dei_EntityAddressAddressLine1_19A7BFB89CD516726CF27E59E4CB5ED6_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1_19A7BFB89CD516726CF27E59E4CB5ED6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, Address Line One</link:label>
<link:label id="lab_dei_EntityAddressAddressLine1_19A7BFB89CD516726CF27E59E4CB5ED6_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1_19A7BFB89CD516726CF27E59E4CB5ED6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, Address Line One</link:label>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressAddressLine1" xlink:label="loc_dei_EntityAddressAddressLine1_19A7BFB89CD516726CF27E59E4CB5ED6" xlink:type="locator" />
<link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1_19A7BFB89CD516726CF27E59E4CB5ED6" xlink:to="lab_dei_EntityAddressAddressLine1_19A7BFB89CD516726CF27E59E4CB5ED6" xlink:type="arc" />
<link:label id="lab_dei_EntityAddressCityOrTown_12C815816E56370B66CA7E59E4CB7A27_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown_12C815816E56370B66CA7E59E4CB7A27" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, City or Town</link:label>
<link:label id="lab_dei_EntityAddressCityOrTown_12C815816E56370B66CA7E59E4CB7A27_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown_12C815816E56370B66CA7E59E4CB7A27" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, City or Town</link:label>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressCityOrTown" xlink:label="loc_dei_EntityAddressCityOrTown_12C815816E56370B66CA7E59E4CB7A27" xlink:type="locator" />
<link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown_12C815816E56370B66CA7E59E4CB7A27" xlink:to="lab_dei_EntityAddressCityOrTown_12C815816E56370B66CA7E59E4CB7A27" xlink:type="arc" />
<link:label id="lab_dei_EntityAddressStateOrProvince_30530D96EAB66AB3F5AE7E59E4CC1BC1_terseLabel_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince_30530D96EAB66AB3F5AE7E59E4CC1BC1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, State or Province</link:label>
<link:label id="lab_dei_EntityAddressStateOrProvince_30530D96EAB66AB3F5AE7E59E4CC1BC1_label_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince_30530D96EAB66AB3F5AE7E59E4CC1BC1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, State or Province</link:label>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressStateOrProvince" xlink:label="loc_dei_EntityAddressStateOrProvince_30530D96EAB66AB3F5AE7E59E4CC1BC1" xlink:type="locator" />
<link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince_30530D96EAB66AB3F5AE7E59E4CC1BC1" xlink:to="lab_dei_EntityAddressStateOrProvince_30530D96EAB66AB3F5AE7E59E4CC1BC1" xlink:type="arc" />
<link:label id="lab_dei_EntityAddressPostalZipCode_1BCEA833A2FF33702D6E7E59E4CCC31D_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode_1BCEA833A2FF33702D6E7E59E4CCC31D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
<link:label id="lab_dei_EntityAddressPostalZipCode_1BCEA833A2FF33702D6E7E59E4CCC31D_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode_1BCEA833A2FF33702D6E7E59E4CCC31D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressPostalZipCode" xlink:label="loc_dei_EntityAddressPostalZipCode_1BCEA833A2FF33702D6E7E59E4CCC31D" xlink:type="locator" />
<link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode_1BCEA833A2FF33702D6E7E59E4CCC31D" xlink:to="lab_dei_EntityAddressPostalZipCode_1BCEA833A2FF33702D6E7E59E4CCC31D" xlink:type="arc" />
<link:label id="lab_dei_CityAreaCode_F6F3164FCDE20CFF5DB97E59E4CCF272_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode_F6F3164FCDE20CFF5DB97E59E4CCF272" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">City Area Code</link:label>
<link:label id="lab_dei_CityAreaCode_F6F3164FCDE20CFF5DB97E59E4CCF272_label_en-US" xlink:label="lab_dei_CityAreaCode_F6F3164FCDE20CFF5DB97E59E4CCF272" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">City Area Code</link:label>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CityAreaCode" xlink:label="loc_dei_CityAreaCode_F6F3164FCDE20CFF5DB97E59E4CCF272" xlink:type="locator" />
<link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode_F6F3164FCDE20CFF5DB97E59E4CCF272" xlink:to="lab_dei_CityAreaCode_F6F3164FCDE20CFF5DB97E59E4CCF272" xlink:type="arc" />
<link:label id="lab_dei_LocalPhoneNumber_0E773D2CF342577978007E59E4CC37BB_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber_0E773D2CF342577978007E59E4CC37BB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Local Phone Number</link:label>
<link:label id="lab_dei_LocalPhoneNumber_0E773D2CF342577978007E59E4CC37BB_label_en-US" xlink:label="lab_dei_LocalPhoneNumber_0E773D2CF342577978007E59E4CC37BB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Local Phone Number</link:label>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LocalPhoneNumber" xlink:label="loc_dei_LocalPhoneNumber_0E773D2CF342577978007E59E4CC37BB" xlink:type="locator" />
<link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber_0E773D2CF342577978007E59E4CC37BB" xlink:to="lab_dei_LocalPhoneNumber_0E773D2CF342577978007E59E4CC37BB" xlink:type="arc" />
<link:label id="lab_dei_Security12bTitle_8C30A90A57F7537194067E59E4CC6B1F_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle_8C30A90A57F7537194067E59E4CC6B1F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Title of 12(b) Security</link:label>
<link:label id="lab_dei_Security12bTitle_8C30A90A57F7537194067E59E4CC6B1F_label_en-US" xlink:label="lab_dei_Security12bTitle_8C30A90A57F7537194067E59E4CC6B1F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Title of 12(b) Security</link:label>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_Security12bTitle" xlink:label="loc_dei_Security12bTitle_8C30A90A57F7537194067E59E4CC6B1F" xlink:type="locator" />
<link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle_8C30A90A57F7537194067E59E4CC6B1F" xlink:to="lab_dei_Security12bTitle_8C30A90A57F7537194067E59E4CC6B1F" xlink:type="arc" />
<link:label id="lab_dei_TradingSymbol_A5EC51EA4D7F32B97C1D7E59E4CCACCB_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol_A5EC51EA4D7F32B97C1D7E59E4CCACCB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Trading Symbol</link:label>
<link:label id="lab_dei_TradingSymbol_A5EC51EA4D7F32B97C1D7E59E4CCACCB_label_en-US" xlink:label="lab_dei_TradingSymbol_A5EC51EA4D7F32B97C1D7E59E4CCACCB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Symbol</link:label>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_TradingSymbol" xlink:label="loc_dei_TradingSymbol_A5EC51EA4D7F32B97C1D7E59E4CCACCB" xlink:type="locator" />
<link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol_A5EC51EA4D7F32B97C1D7E59E4CCACCB" xlink:to="lab_dei_TradingSymbol_A5EC51EA4D7F32B97C1D7E59E4CCACCB" xlink:type="arc" />
<link:label id="lab_dei_SecurityExchangeName_56003D725C56ECCA6CC87E59E4CD2524_terseLabel_en-US" xlink:label="lab_dei_SecurityExchangeName_56003D725C56ECCA6CC87E59E4CD2524" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Security Exchange Name</link:label>
<link:label id="lab_dei_SecurityExchangeName_56003D725C56ECCA6CC87E59E4CD2524_label_en-US" xlink:label="lab_dei_SecurityExchangeName_56003D725C56ECCA6CC87E59E4CD2524" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Security Exchange Name</link:label>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_SecurityExchangeName" xlink:label="loc_dei_SecurityExchangeName_56003D725C56ECCA6CC87E59E4CD2524" xlink:type="locator" />
<link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName_56003D725C56ECCA6CC87E59E4CD2524" xlink:to="lab_dei_SecurityExchangeName_56003D725C56ECCA6CC87E59E4CD2524" xlink:type="arc" />
<link:label id="lab_dei_EntityWellKnownSeasonedIssuer_BE13B4B041013B9BB66F7E59E4CD3902_terseLabel_en-US" xlink:label="lab_dei_EntityWellKnownSeasonedIssuer_BE13B4B041013B9BB66F7E59E4CD3902" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
<link:label id="lab_dei_EntityWellKnownSeasonedIssuer_BE13B4B041013B9BB66F7E59E4CD3902_label_en-US" xlink:label="lab_dei_EntityWellKnownSeasonedIssuer_BE13B4B041013B9BB66F7E59E4CD3902" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="loc_dei_EntityWellKnownSeasonedIssuer_BE13B4B041013B9BB66F7E59E4CD3902" xlink:type="locator" />
<link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityWellKnownSeasonedIssuer_BE13B4B041013B9BB66F7E59E4CD3902" xlink:to="lab_dei_EntityWellKnownSeasonedIssuer_BE13B4B041013B9BB66F7E59E4CD3902" xlink:type="arc" />
<link:label id="lab_dei_EntityVoluntaryFilers_0152253F74093EDFCCA57E59E4CDEF30_terseLabel_en-US" xlink:label="lab_dei_EntityVoluntaryFilers_0152253F74093EDFCCA57E59E4CDEF30" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Voluntary Filers</link:label>
<link:label id="lab_dei_EntityVoluntaryFilers_0152253F74093EDFCCA57E59E4CDEF30_label_en-US" xlink:label="lab_dei_EntityVoluntaryFilers_0152253F74093EDFCCA57E59E4CDEF30" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Voluntary Filers</link:label>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityVoluntaryFilers" xlink:label="loc_dei_EntityVoluntaryFilers_0152253F74093EDFCCA57E59E4CDEF30" xlink:type="locator" />
<link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityVoluntaryFilers_0152253F74093EDFCCA57E59E4CDEF30" xlink:to="lab_dei_EntityVoluntaryFilers_0152253F74093EDFCCA57E59E4CDEF30" xlink:type="arc" />
<link:label id="lab_dei_EntityCurrentReportingStatus_4EE42BF191956F853E5F7E59E4CDD19C_terseLabel_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus_4EE42BF191956F853E5F7E59E4CDD19C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Current Reporting Status</link:label>
<link:label id="lab_dei_EntityCurrentReportingStatus_4EE42BF191956F853E5F7E59E4CDD19C_label_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus_4EE42BF191956F853E5F7E59E4CDD19C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Current Reporting Status</link:label>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCurrentReportingStatus" xlink:label="loc_dei_EntityCurrentReportingStatus_4EE42BF191956F853E5F7E59E4CDD19C" xlink:type="locator" />
<link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCurrentReportingStatus_4EE42BF191956F853E5F7E59E4CDD19C" xlink:to="lab_dei_EntityCurrentReportingStatus_4EE42BF191956F853E5F7E59E4CDD19C" xlink:type="arc" />
<link:label id="lab_dei_EntityInteractiveDataCurrent_CA61AE2F4A794B2672DA7E59E4CD8378_terseLabel_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent_CA61AE2F4A794B2672DA7E59E4CD8378" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Interactive Data Current</link:label>
<link:label id="lab_dei_EntityInteractiveDataCurrent_CA61AE2F4A794B2672DA7E59E4CD8378_label_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent_CA61AE2F4A794B2672DA7E59E4CD8378" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Interactive Data Current</link:label>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityInteractiveDataCurrent" xlink:label="loc_dei_EntityInteractiveDataCurrent_CA61AE2F4A794B2672DA7E59E4CD8378" xlink:type="locator" />
<link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityInteractiveDataCurrent_CA61AE2F4A794B2672DA7E59E4CD8378" xlink:to="lab_dei_EntityInteractiveDataCurrent_CA61AE2F4A794B2672DA7E59E4CD8378" xlink:type="arc" />
<link:label id="lab_dei_EntityShellCompany_E16D14538EE7A4AE31DB7E5C6B50501F_terseLabel_en-US" xlink:label="lab_dei_EntityShellCompany_E16D14538EE7A4AE31DB7E5C6B50501F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Shell Company</link:label>
<link:label id="lab_dei_EntityShellCompany_E16D14538EE7A4AE31DB7E5C6B50501F_label_en-US" xlink:label="lab_dei_EntityShellCompany_E16D14538EE7A4AE31DB7E5C6B50501F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Shell Company</link:label>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityShellCompany" xlink:label="loc_dei_EntityShellCompany_E16D14538EE7A4AE31DB7E5C6B50501F" xlink:type="locator" />
<link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityShellCompany_E16D14538EE7A4AE31DB7E5C6B50501F" xlink:to="lab_dei_EntityShellCompany_E16D14538EE7A4AE31DB7E5C6B50501F" xlink:type="arc" />
<link:label id="lab_dei_EntityFilerCategory_8A9AEDFB76331A184D657E59E4CD015B_terseLabel_en-US" xlink:label="lab_dei_EntityFilerCategory_8A9AEDFB76331A184D657E59E4CD015B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Filer Category</link:label>
<link:label id="lab_dei_EntityFilerCategory_8A9AEDFB76331A184D657E59E4CD015B_label_en-US" xlink:label="lab_dei_EntityFilerCategory_8A9AEDFB76331A184D657E59E4CD015B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Filer Category</link:label>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityFilerCategory" xlink:label="loc_dei_EntityFilerCategory_8A9AEDFB76331A184D657E59E4CD015B" xlink:type="locator" />
<link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFilerCategory_8A9AEDFB76331A184D657E59E4CD015B" xlink:to="lab_dei_EntityFilerCategory_8A9AEDFB76331A184D657E59E4CD015B" xlink:type="arc" />
<link:label id="lab_dei_EntitySmallBusiness_051DF2EA6668A189F9DF7E59E4CD7F50_terseLabel_en-US" xlink:label="lab_dei_EntitySmallBusiness_051DF2EA6668A189F9DF7E59E4CD7F50" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Small Business</link:label>
<link:label id="lab_dei_EntitySmallBusiness_051DF2EA6668A189F9DF7E59E4CD7F50_label_en-US" xlink:label="lab_dei_EntitySmallBusiness_051DF2EA6668A189F9DF7E59E4CD7F50" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Small Business</link:label>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntitySmallBusiness" xlink:label="loc_dei_EntitySmallBusiness_051DF2EA6668A189F9DF7E59E4CD7F50" xlink:type="locator" />
<link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntitySmallBusiness_051DF2EA6668A189F9DF7E59E4CD7F50" xlink:to="lab_dei_EntitySmallBusiness_051DF2EA6668A189F9DF7E59E4CD7F50" xlink:type="arc" />
<link:label id="lab_dei_EntityEmergingGrowthCompany_DC6945B444D9E69160217E59E4CE26B7_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany_DC6945B444D9E69160217E59E4CE26B7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Emerging Growth Company</link:label>
<link:label id="lab_dei_EntityEmergingGrowthCompany_DC6945B444D9E69160217E59E4CE26B7_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany_DC6945B444D9E69160217E59E4CE26B7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Emerging Growth Company</link:label>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityEmergingGrowthCompany" xlink:label="loc_dei_EntityEmergingGrowthCompany_DC6945B444D9E69160217E59E4CE26B7" xlink:type="locator" />
<link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany_DC6945B444D9E69160217E59E4CE26B7" xlink:to="lab_dei_EntityEmergingGrowthCompany_DC6945B444D9E69160217E59E4CE26B7" xlink:type="arc" />
<link:label id="lab_dei_EntityPublicFloat_6F6129761753420F79237E59E4CE16CE_terseLabel_en-US" xlink:label="lab_dei_EntityPublicFloat_6F6129761753420F79237E59E4CE16CE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Public Float</link:label>
<link:label id="lab_dei_EntityPublicFloat_6F6129761753420F79237E59E4CE16CE_label_en-US" xlink:label="lab_dei_EntityPublicFloat_6F6129761753420F79237E59E4CE16CE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Public Float</link:label>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityPublicFloat" xlink:label="loc_dei_EntityPublicFloat_6F6129761753420F79237E59E4CE16CE" xlink:type="locator" />
<link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityPublicFloat_6F6129761753420F79237E59E4CE16CE" xlink:to="lab_dei_EntityPublicFloat_6F6129761753420F79237E59E4CE16CE" xlink:type="arc" />
<link:label id="lab_dei_EntityCommonStockSharesOutstanding_7230C916E958236933947E59E4CEB119_terseLabel_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding_7230C916E958236933947E59E4CEB119" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
<link:label id="lab_dei_EntityCommonStockSharesOutstanding_7230C916E958236933947E59E4CEB119_label_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding_7230C916E958236933947E59E4CEB119" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_7230C916E958236933947E59E4CEB119" xlink:type="locator" />
<link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCommonStockSharesOutstanding_7230C916E958236933947E59E4CEB119" xlink:to="lab_dei_EntityCommonStockSharesOutstanding_7230C916E958236933947E59E4CEB119" xlink:type="arc" />
<link:label id="lab_dei_DocumentsIncorporatedByReferenceTextBlock_1386838E78E7140B3C007E59E4CEF815_terseLabel_en-US" xlink:label="lab_dei_DocumentsIncorporatedByReferenceTextBlock_1386838E78E7140B3C007E59E4CEF815" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Documents Incorporated by Reference</link:label>
<link:label id="lab_dei_DocumentsIncorporatedByReferenceTextBlock_1386838E78E7140B3C007E59E4CEF815_label_en-US" xlink:label="lab_dei_DocumentsIncorporatedByReferenceTextBlock_1386838E78E7140B3C007E59E4CEF815" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Documents Incorporated by Reference [Text Block]</link:label>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="loc_dei_DocumentsIncorporatedByReferenceTextBlock_1386838E78E7140B3C007E59E4CEF815" xlink:type="locator" />
<link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentsIncorporatedByReferenceTextBlock_1386838E78E7140B3C007E59E4CEF815" xlink:to="lab_dei_DocumentsIncorporatedByReferenceTextBlock_1386838E78E7140B3C007E59E4CEF815" xlink:type="arc" />
<link:label id="lab_dei_EntityCentralIndexKey_2B37F4EEA9AB1EB9A27F7E59E4CE0881_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey_2B37F4EEA9AB1EB9A27F7E59E4CE0881" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Central Index Key</link:label>
<link:label id="lab_dei_EntityCentralIndexKey_2B37F4EEA9AB1EB9A27F7E59E4CE0881_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey_2B37F4EEA9AB1EB9A27F7E59E4CE0881" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Central Index Key</link:label>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="loc_dei_EntityCentralIndexKey_2B37F4EEA9AB1EB9A27F7E59E4CE0881" xlink:type="locator" />
<link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey_2B37F4EEA9AB1EB9A27F7E59E4CE0881" xlink:to="lab_dei_EntityCentralIndexKey_2B37F4EEA9AB1EB9A27F7E59E4CE0881" xlink:type="arc" />
<link:label id="lab_dei_CurrentFiscalYearEndDate_D6BA800749AA684DD20F7E59E4CE9FC2_terseLabel_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate_D6BA800749AA684DD20F7E59E4CE9FC2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current Fiscal Year End Date</link:label>
<link:label id="lab_dei_CurrentFiscalYearEndDate_D6BA800749AA684DD20F7E59E4CE9FC2_label_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate_D6BA800749AA684DD20F7E59E4CE9FC2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current Fiscal Year End Date</link:label>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_dei_CurrentFiscalYearEndDate_D6BA800749AA684DD20F7E59E4CE9FC2" xlink:type="locator" />
<link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CurrentFiscalYearEndDate_D6BA800749AA684DD20F7E59E4CE9FC2" xlink:to="lab_dei_CurrentFiscalYearEndDate_D6BA800749AA684DD20F7E59E4CE9FC2" xlink:type="arc" />
<link:label id="lab_dei_DocumentFiscalYearFocus_A9E301F16839812958857E59E4D430B3_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus_A9E301F16839812958857E59E4D430B3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Fiscal Year Focus</link:label>
<link:label id="lab_dei_DocumentFiscalYearFocus_A9E301F16839812958857E59E4D430B3_label_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus_A9E301F16839812958857E59E4D430B3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Fiscal Year Focus</link:label>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_dei_DocumentFiscalYearFocus_A9E301F16839812958857E59E4D430B3" xlink:type="locator" />
<link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalYearFocus_A9E301F16839812958857E59E4D430B3" xlink:to="lab_dei_DocumentFiscalYearFocus_A9E301F16839812958857E59E4D430B3" xlink:type="arc" />
<link:label id="lab_dei_DocumentFiscalPeriodFocus_6E9375C9452DCD92F2357E59E4D4D22B_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus_6E9375C9452DCD92F2357E59E4D4D22B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Fiscal Period Focus</link:label>
<link:label id="lab_dei_DocumentFiscalPeriodFocus_6E9375C9452DCD92F2357E59E4D4D22B_label_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus_6E9375C9452DCD92F2357E59E4D4D22B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Fiscal Period Focus</link:label>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_dei_DocumentFiscalPeriodFocus_6E9375C9452DCD92F2357E59E4D4D22B" xlink:type="locator" />
<link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalPeriodFocus_6E9375C9452DCD92F2357E59E4D4D22B" xlink:to="lab_dei_DocumentFiscalPeriodFocus_6E9375C9452DCD92F2357E59E4D4D22B" xlink:type="arc" />
<link:label id="lab_dei_AmendmentFlag_2359E165651EBF5A05907E59E4D44451_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag_2359E165651EBF5A05907E59E4D44451" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amendment Flag</link:label>
<link:label id="lab_dei_AmendmentFlag_2359E165651EBF5A05907E59E4D44451_label_en-US" xlink:label="lab_dei_AmendmentFlag_2359E165651EBF5A05907E59E4D44451" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amendment Flag</link:label>
<link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_AmendmentFlag" xlink:label="loc_dei_AmendmentFlag_2359E165651EBF5A05907E59E4D44451" xlink:type="locator" />
<link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag_2359E165651EBF5A05907E59E4D44451" xlink:to="lab_dei_AmendmentFlag_2359E165651EBF5A05907E59E4D44451" xlink:type="arc" />
<link:label id="lab_us-gaap_FairValueDisclosuresAbstract_E272DD645964CDB65E87D1D06279D12F_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract_E272DD645964CDB65E87D1D06279D12F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_E272DD645964CDB65E87D1D06279D12F" xlink:type="locator" />
<link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_E272DD645964CDB65E87D1D06279D12F" xlink:to="lab_us-gaap_FairValueDisclosuresAbstract_E272DD645964CDB65E87D1D06279D12F" xlink:type="arc" />
<link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_A3F2835DDB1C11E90D91D1D062799F49_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock_A3F2835DDB1C11E90D91D1D062799F49" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Estimated Fair Value of Financial Instruments</link:label>
<link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_A3F2835DDB1C11E90D91D1D062799F49_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock_A3F2835DDB1C11E90D91D1D062799F49" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Disclosures [Text Block]</link:label>
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock_A3F2835DDB1C11E90D91D1D062799F49" xlink:type="locator" />
<link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresTextBlock_A3F2835DDB1C11E90D91D1D062799F49" xlink:to="lab_us-gaap_FairValueDisclosuresTextBlock_A3F2835DDB1C11E90D91D1D062799F49" xlink:type="arc" />
<link:label id="lab_us-gaap_PayablesAndAccrualsAbstract_BB91CC3FD9426303BF82D1D06182F210_label_en-US" xlink:label="lab_us-gaap_PayablesAndAccrualsAbstract_BB91CC3FD9426303BF82D1D06182F210" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payables and Accruals [Abstract]</link:label>
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract_BB91CC3FD9426303BF82D1D06182F210" xlink:type="locator" />
<link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_BB91CC3FD9426303BF82D1D06182F210" xlink:to="lab_us-gaap_PayablesAndAccrualsAbstract_BB91CC3FD9426303BF82D1D06182F210" xlink:type="arc" />
<link:label id="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_24A271CDE8E188AEBFA0D1D06182E401_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_24A271CDE8E188AEBFA0D1D06182E401" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounts Payable and Accrued Expenses</link:label>
<link:label id="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_24A271CDE8E188AEBFA0D1D06182E401_label_en-US" xlink:label="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_24A271CDE8E188AEBFA0D1D06182E401" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounts Payable and Accrued Liabilities Disclosure [Text Block]</link:label>
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_24A271CDE8E188AEBFA0D1D06182E401" xlink:type="locator" />
<link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_24A271CDE8E188AEBFA0D1D06182E401" xlink:to="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_24A271CDE8E188AEBFA0D1D06182E401" xlink:type="arc" />
<link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_6DC2CAD38381C6CFF8DFDB9A48957F5D_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_6DC2CAD38381C6CFF8DFDB9A48957F5D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Payment Arrangement [Abstract]</link:label>
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_6DC2CAD38381C6CFF8DFDB9A48957F5D" xlink:type="locator" />
<link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_6DC2CAD38381C6CFF8DFDB9A48957F5D" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_6DC2CAD38381C6CFF8DFDB9A48957F5D" xlink:type="arc" />
<link:label id="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_5FCEEB89B1C91F1F1A4CDB9A4895A776_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_5FCEEB89B1C91F1F1A4CDB9A4895A776" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions</link:label>
<link:label id="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_5FCEEB89B1C91F1F1A4CDB9A4895A776_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_5FCEEB89B1C91F1F1A4CDB9A4895A776" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]</link:label>
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_5FCEEB89B1C91F1F1A4CDB9A4895A776" xlink:type="locator" />
<link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_5FCEEB89B1C91F1F1A4CDB9A4895A776" xlink:to="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_5FCEEB89B1C91F1F1A4CDB9A4895A776" xlink:type="arc" />
<link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_7DE8FF0E0CF04BD0A2D8DB9A4895CC13_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_7DE8FF0E0CF04BD0A2D8DB9A4895CC13" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based Compensation, Stock Options, Activity</link:label>
<link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_7DE8FF0E0CF04BD0A2D8DB9A4895CC13_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_7DE8FF0E0CF04BD0A2D8DB9A4895CC13" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Payment Arrangement, Option, Activity [Table Text Block]</link:label>
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_7DE8FF0E0CF04BD0A2D8DB9A4895CC13" xlink:type="locator" />
<link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_7DE8FF0E0CF04BD0A2D8DB9A4895CC13" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_7DE8FF0E0CF04BD0A2D8DB9A4895CC13" xlink:type="arc" />
<link:label id="lab_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock_D4A8EA6157C45FF13DA2DB9A4896FA4C_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock_D4A8EA6157C45FF13DA2DB9A4896FA4C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Share-based Compensation, Restricted Stock and Restricted Stock Units Activity</link:label>
<link:label id="lab_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock_D4A8EA6157C45FF13DA2DB9A4896FA4C_label_en-US" xlink:label="lab_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock_D4A8EA6157C45FF13DA2DB9A4896FA4C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Payment Arrangement, Restricted Stock and Restricted Stock Unit, Activity [Table Text Block]</link:label>
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock_D4A8EA6157C45FF13DA2DB9A4896FA4C" xlink:type="locator" />
<link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock_D4A8EA6157C45FF13DA2DB9A4896FA4C" xlink:to="lab_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock_D4A8EA6157C45FF13DA2DB9A4896FA4C" xlink:type="arc" />
<link:label id="lab_immu_ScheduleofSharebasedCompensationPerformanceStockandPerformanceStockUnitsActivityTableTextBlock_44520D6A5C96AAF805D0DB9A4896F214_terseLabel_en-US" xlink:label="lab_immu_ScheduleofSharebasedCompensationPerformanceStockandPerformanceStockUnitsActivityTableTextBlock_44520D6A5C96AAF805D0DB9A4896F214" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Share-based Compensation, Performance Stock and Performance Stock Units Activity</link:label>
<link:label id="lab_immu_ScheduleofSharebasedCompensationPerformanceStockandPerformanceStockUnitsActivityTableTextBlock_44520D6A5C96AAF805D0DB9A4896F214_label_en-US" xlink:label="lab_immu_ScheduleofSharebasedCompensationPerformanceStockandPerformanceStockUnitsActivityTableTextBlock_44520D6A5C96AAF805D0DB9A4896F214" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Share-based Compensation, Performance Stock and Performance Stock Units Activity [Table Text Block]</link:label>
<link:label id="lab_immu_ScheduleofSharebasedCompensationPerformanceStockandPerformanceStockUnitsActivityTableTextBlock_44520D6A5C96AAF805D0DB9A4896F214_documentation_en-US" xlink:label="lab_immu_ScheduleofSharebasedCompensationPerformanceStockandPerformanceStockUnitsActivityTableTextBlock_44520D6A5C96AAF805D0DB9A4896F214" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Schedule of Share-based Compensation, Performance Stock and Performance Stock Units Activity [Table Text Block]</link:label>
<link:loc xlink:href="immu-20191231.xsd#immu_ScheduleofSharebasedCompensationPerformanceStockandPerformanceStockUnitsActivityTableTextBlock" xlink:label="loc_immu_ScheduleofSharebasedCompensationPerformanceStockandPerformanceStockUnitsActivityTableTextBlock_44520D6A5C96AAF805D0DB9A4896F214" xlink:type="locator" />
<link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_immu_ScheduleofSharebasedCompensationPerformanceStockandPerformanceStockUnitsActivityTableTextBlock_44520D6A5C96AAF805D0DB9A4896F214" xlink:to="lab_immu_ScheduleofSharebasedCompensationPerformanceStockandPerformanceStockUnitsActivityTableTextBlock_44520D6A5C96AAF805D0DB9A4896F214" xlink:type="arc" />
<link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_9063E597FE9A01F343645EDE152C93BE_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_9063E597FE9A01F343645EDE152C93BE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_9063E597FE9A01F343645EDE152C93BE" xlink:type="locator" />
<link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_9063E597FE9A01F343645EDE152C93BE" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_9063E597FE9A01F343645EDE152C93BE" xlink:type="arc" />
<link:label id="lab_us-gaap_LesseeLeaseDescriptionTable_17BF163483C2B2821FAA5EDE152E7FC6_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionTable_17BF163483C2B2821FAA5EDE152E7FC6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Lessee, Lease, Description [Table]</link:label>
<link:label id="lab_us-gaap_LesseeLeaseDescriptionTable_17BF163483C2B2821FAA5EDE152E7FC6_label_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionTable_17BF163483C2B2821FAA5EDE152E7FC6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Lease, Description [Table]</link:label>
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeLeaseDescriptionTable" xlink:label="loc_us-gaap_LesseeLeaseDescriptionTable_17BF163483C2B2821FAA5EDE152E7FC6" xlink:type="locator" />
<link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_17BF163483C2B2821FAA5EDE152E7FC6" xlink:to="lab_us-gaap_LesseeLeaseDescriptionTable_17BF163483C2B2821FAA5EDE152E7FC6" xlink:type="arc" />
<link:label id="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_5F6744B6A7FFB94AFF245EDE152F1776_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_5F6744B6A7FFB94AFF245EDE152F1776" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Type [Axis]</link:label>
<link:label id="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_5F6744B6A7FFB94AFF245EDE152F1776_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_5F6744B6A7FFB94AFF245EDE152F1776" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Type [Axis]</link:label>
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_5F6744B6A7FFB94AFF245EDE152F1776" xlink:type="locator" />
<link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_5F6744B6A7FFB94AFF245EDE152F1776" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_5F6744B6A7FFB94AFF245EDE152F1776" xlink:type="arc" />
<link:label id="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_1E0814C45C37E775B45C5EDE152FD575_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_1E0814C45C37E775B45C5EDE152FD575" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Type [Domain]</link:label>
<link:label id="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_1E0814C45C37E775B45C5EDE152FD575_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_1E0814C45C37E775B45C5EDE152FD575" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Type [Domain]</link:label>
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_1E0814C45C37E775B45C5EDE152FD575" xlink:type="locator" />
<link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_1E0814C45C37E775B45C5EDE152FD575" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_1E0814C45C37E775B45C5EDE152FD575" xlink:type="arc" />
<link:label id="lab_us-gaap_LeaseholdImprovementsMember_A7190697615A690D6D285EDE152FDC79_verboseLabel_en-US" xlink:label="lab_us-gaap_LeaseholdImprovementsMember_A7190697615A690D6D285EDE152FDC79" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Leasehold Improvements</link:label>
<link:label id="lab_us-gaap_LeaseholdImprovementsMember_A7190697615A690D6D285EDE152FDC79_label_en-US" xlink:label="lab_us-gaap_LeaseholdImprovementsMember_A7190697615A690D6D285EDE152FDC79" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Leasehold Improvements [Member]</link:label>
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="loc_us-gaap_LeaseholdImprovementsMember_A7190697615A690D6D285EDE152FDC79" xlink:type="locator" />
<link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseholdImprovementsMember_A7190697615A690D6D285EDE152FDC79" xlink:to="lab_us-gaap_LeaseholdImprovementsMember_A7190697615A690D6D285EDE152FDC79" xlink:type="arc" />
<link:label id="lab_us-gaap_ComputerEquipmentMember_7D14B48447A448395C1F5EDE1530698B_verboseLabel_en-US" xlink:label="lab_us-gaap_ComputerEquipmentMember_7D14B48447A448395C1F5EDE1530698B" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Computer Equipment</link:label>
<link:label id="lab_us-gaap_ComputerEquipmentMember_7D14B48447A448395C1F5EDE1530698B_label_en-US" xlink:label="lab_us-gaap_ComputerEquipmentMember_7D14B48447A448395C1F5EDE1530698B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Computer Equipment [Member]</link:label>
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ComputerEquipmentMember" xlink:label="loc_us-gaap_ComputerEquipmentMember_7D14B48447A448395C1F5EDE1530698B" xlink:type="locator" />
<link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComputerEquipmentMember_7D14B48447A448395C1F5EDE1530698B" xlink:to="lab_us-gaap_ComputerEquipmentMember_7D14B48447A448395C1F5EDE1530698B" xlink:type="arc" />
<link:label id="lab_us-gaap_MachineryAndEquipmentMember_3026492A25C588D58E395EDE1530464F_verboseLabel_en-US" xlink:label="lab_us-gaap_MachineryAndEquipmentMember_3026492A25C588D58E395EDE1530464F" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Machinery and Equipment</link:label>
<link:label id="lab_us-gaap_MachineryAndEquipmentMember_3026492A25C588D58E395EDE1530464F_label_en-US" xlink:label="lab_us-gaap_MachineryAndEquipmentMember_3026492A25C588D58E395EDE1530464F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Machinery and Equipment [Member]</link:label>
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MachineryAndEquipmentMember" xlink:label="loc_us-gaap_MachineryAndEquipmentMember_3026492A25C588D58E395EDE1530464F" xlink:type="locator" />
<link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MachineryAndEquipmentMember_3026492A25C588D58E395EDE1530464F" xlink:to="lab_us-gaap_MachineryAndEquipmentMember_3026492A25C588D58E395EDE1530464F" xlink:type="arc" />
<link:label id="lab_us-gaap_FurnitureAndFixturesMember_0453F08815378007D8575EDE1530A396_verboseLabel_en-US" xlink:label="lab_us-gaap_FurnitureAndFixturesMember_0453F08815378007D8575EDE1530A396" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Furniture and Fixtures</link:label>
<link:label id="lab_us-gaap_FurnitureAndFixturesMember_0453F08815378007D8575EDE1530A396_label_en-US" xlink:label="lab_us-gaap_FurnitureAndFixturesMember_0453F08815378007D8575EDE1530A396" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Furniture and Fixtures [Member]</link:label>
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="loc_us-gaap_FurnitureAndFixturesMember_0453F08815378007D8575EDE1530A396" xlink:type="locator" />
<link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FurnitureAndFixturesMember_0453F08815378007D8575EDE1530A396" xlink:to="lab_us-gaap_FurnitureAndFixturesMember_0453F08815378007D8575EDE1530A396" xlink:type="arc" />
<link:label id="lab_srt_RangeAxis_FCB8767D7C08743D3AFB5EDE1530454C_terseLabel_en-US" xlink:label="lab_srt_RangeAxis_FCB8767D7C08743D3AFB5EDE1530454C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
<link:label id="lab_srt_RangeAxis_FCB8767D7C08743D3AFB5EDE1530454C_label_en-US" xlink:label="lab_srt_RangeAxis_FCB8767D7C08743D3AFB5EDE1530454C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
<link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_FCB8767D7C08743D3AFB5EDE1530454C" xlink:type="locator" />
<link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeAxis_FCB8767D7C08743D3AFB5EDE1530454C" xlink:to="lab_srt_RangeAxis_FCB8767D7C08743D3AFB5EDE1530454C" xlink:type="arc" />
<link:label id="lab_srt_RangeMember_43D7DF79919A04A4CB5C5EDE1530D5B9_terseLabel_en-US" xlink:label="lab_srt_RangeMember_43D7DF79919A04A4CB5C5EDE1530D5B9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
<link:label id="lab_srt_RangeMember_43D7DF79919A04A4CB5C5EDE1530D5B9_label_en-US" xlink:label="lab_srt_RangeMember_43D7DF79919A04A4CB5C5EDE1530D5B9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
<link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_43D7DF79919A04A4CB5C5EDE1530D5B9" xlink:type="locator" />
<link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeMember_43D7DF79919A04A4CB5C5EDE1530D5B9" xlink:to="lab_srt_RangeMember_43D7DF79919A04A4CB5C5EDE1530D5B9" xlink:type="arc" />
<link:label id="lab_srt_MinimumMember_683669AD6EFA9AD517C35EDE1531F193_terseLabel_en-US" xlink:label="lab_srt_MinimumMember_683669AD6EFA9AD517C35EDE1531F193" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Minimum</link:label>
<link:label id="lab_srt_MinimumMember_683669AD6EFA9AD517C35EDE1531F193_label_en-US" xlink:label="lab_srt_MinimumMember_683669AD6EFA9AD517C35EDE1531F193" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Minimum [Member]</link:label>
<link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MinimumMember" xlink:label="loc_srt_MinimumMember_683669AD6EFA9AD517C35EDE1531F193" xlink:type="locator" />
<link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MinimumMember_683669AD6EFA9AD517C35EDE1531F193" xlink:to="lab_srt_MinimumMember_683669AD6EFA9AD517C35EDE1531F193" xlink:type="arc" />
<link:label id="lab_srt_MaximumMember_7C88B0A9EA29EB8652155EDE153143D5_terseLabel_en-US" xlink:label="lab_srt_MaximumMember_7C88B0A9EA29EB8652155EDE153143D5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Maximum</link:label>
<link:label id="lab_srt_MaximumMember_7C88B0A9EA29EB8652155EDE153143D5_label_en-US" xlink:label="lab_srt_MaximumMember_7C88B0A9EA29EB8652155EDE153143D5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Maximum [Member]</link:label>
<link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_7C88B0A9EA29EB8652155EDE153143D5" xlink:type="locator" />
<link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MaximumMember_7C88B0A9EA29EB8652155EDE153143D5" xlink:to="lab_srt_MaximumMember_7C88B0A9EA29EB8652155EDE153143D5" xlink:type="arc" />
<link:label id="lab_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_6450A0DECC83B2C635425EDE15312ECA_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_6450A0DECC83B2C635425EDE15312ECA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Adjustments for New Accounting Pronouncements [Axis]</link:label>
<link:label id="lab_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_6450A0DECC83B2C635425EDE15312ECA_label_en-US" xlink:label="lab_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_6450A0DECC83B2C635425EDE15312ECA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustments for New Accounting Pronouncements [Axis]</link:label>
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:label="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_6450A0DECC83B2C635425EDE15312ECA" xlink:type="locator" />
<link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_6450A0DECC83B2C635425EDE15312ECA" xlink:to="lab_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_6450A0DECC83B2C635425EDE15312ECA" xlink:type="arc" />
<link:label id="lab_us-gaap_TypeOfAdoptionMember_5E688A29B22AA47609A15EDE1531E9A4_terseLabel_en-US" xlink:label="lab_us-gaap_TypeOfAdoptionMember_5E688A29B22AA47609A15EDE1531E9A4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Type of Adoption [Domain]</link:label>
<link:label id="lab_us-gaap_TypeOfAdoptionMember_5E688A29B22AA47609A15EDE1531E9A4_label_en-US" xlink:label="lab_us-gaap_TypeOfAdoptionMember_5E688A29B22AA47609A15EDE1531E9A4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Type of Adoption [Domain]</link:label>
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="loc_us-gaap_TypeOfAdoptionMember_5E688A29B22AA47609A15EDE1531E9A4" xlink:type="locator" />
<link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TypeOfAdoptionMember_5E688A29B22AA47609A15EDE1531E9A4" xlink:to="lab_us-gaap_TypeOfAdoptionMember_5E688A29B22AA47609A15EDE1531E9A4" xlink:type="arc" />
<link:label id="lab_us-gaap_AccountingStandardsUpdate201602Member_B0B74ECE3D11AE4CE61C5EDE15326639_terseLabel_en-US" xlink:label="lab_us-gaap_AccountingStandardsUpdate201602Member_B0B74ECE3D11AE4CE61C5EDE15326639" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounting Standards Update 2016-02</link:label>
<link:label id="lab_us-gaap_AccountingStandardsUpdate201602Member_B0B74ECE3D11AE4CE61C5EDE15326639_label_en-US" xlink:label="lab_us-gaap_AccountingStandardsUpdate201602Member_B0B74ECE3D11AE4CE61C5EDE15326639" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounting Standards Update 2016-02 [Member]</link:label>
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountingStandardsUpdate201602Member" xlink:label="loc_us-gaap_AccountingStandardsUpdate201602Member_B0B74ECE3D11AE4CE61C5EDE15326639" xlink:type="locator" />
<link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingStandardsUpdate201602Member_B0B74ECE3D11AE4CE61C5EDE15326639" xlink:to="lab_us-gaap_AccountingStandardsUpdate201602Member_B0B74ECE3D11AE4CE61C5EDE15326639" xlink:type="arc" />
<link:label id="lab_us-gaap_LesseeLeaseDescriptionLineItems_69767A1FF71C85471FDB5EDE15325B15_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionLineItems_69767A1FF71C85471FDB5EDE15325B15" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Lessee, Lease, Description [Line Items]</link:label>
<link:label id="lab_us-gaap_LesseeLeaseDescriptionLineItems_69767A1FF71C85471FDB5EDE15325B15_label_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionLineItems_69767A1FF71C85471FDB5EDE15325B15" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Lease, Description [Line Items]</link:label>
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeLeaseDescriptionLineItems" xlink:label="loc_us-gaap_LesseeLeaseDescriptionLineItems_69767A1FF71C85471FDB5EDE15325B15" xlink:type="locator" />
<link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_69767A1FF71C85471FDB5EDE15325B15" xlink:to="lab_us-gaap_LesseeLeaseDescriptionLineItems_69767A1FF71C85471FDB5EDE15325B15" xlink:type="arc" />
<link:label id="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife_91408CC4FF4ADEBBC58A5EDE15323851_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife_91408CC4FF4ADEBBC58A5EDE15323851" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property, plant and equipment, useful life</link:label>
<link:label id="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife_91408CC4FF4ADEBBC58A5EDE15323851_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife_91408CC4FF4ADEBBC58A5EDE15323851" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Useful Life</link:label>
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_91408CC4FF4ADEBBC58A5EDE15323851" xlink:type="locator" />
<link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_91408CC4FF4ADEBBC58A5EDE15323851" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife_91408CC4FF4ADEBBC58A5EDE15323851" xlink:type="arc" />
<link:label id="lab_us-gaap_TaxCutsAndJobsActOf2017IncompleteAccountingChangeInTaxRateDeferredTaxAssetProvisionalIncomeTaxExpense_26CBEA58E62C87C4FEFF5EE29F257DA7_terseLabel_en-US" xlink:label="lab_us-gaap_TaxCutsAndJobsActOf2017IncompleteAccountingChangeInTaxRateDeferredTaxAssetProvisionalIncomeTaxExpense_26CBEA58E62C87C4FEFF5EE29F257DA7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Provisional expense from revaluation in deferred tax asset due to TCJA</link:label>
<link:label id="lab_us-gaap_TaxCutsAndJobsActOf2017IncompleteAccountingChangeInTaxRateDeferredTaxAssetProvisionalIncomeTaxExpense_26CBEA58E62C87C4FEFF5EE29F257DA7_label_en-US" xlink:label="lab_us-gaap_TaxCutsAndJobsActOf2017IncompleteAccountingChangeInTaxRateDeferredTaxAssetProvisionalIncomeTaxExpense_26CBEA58E62C87C4FEFF5EE29F257DA7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Tax Cuts and Jobs Act, Incomplete Accounting, Change in Tax Rate, Deferred Tax Asset, Provisional Income Tax Expense</link:label>
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TaxCutsAndJobsActOf2017IncompleteAccountingChangeInTaxRateDeferredTaxAssetProvisionalIncomeTaxExpense" xlink:label="loc_us-gaap_TaxCutsAndJobsActOf2017IncompleteAccountingChangeInTaxRateDeferredTaxAssetProvisionalIncomeTaxExpense_26CBEA58E62C87C4FEFF5EE29F257DA7" xlink:type="locator" />
<link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TaxCutsAndJobsActOf2017IncompleteAccountingChangeInTaxRateDeferredTaxAssetProvisionalIncomeTaxExpense_26CBEA58E62C87C4FEFF5EE29F257DA7" xlink:to="lab_us-gaap_TaxCutsAndJobsActOf2017IncompleteAccountingChangeInTaxRateDeferredTaxAssetProvisionalIncomeTaxExpense_26CBEA58E62C87C4FEFF5EE29F257DA7" xlink:type="arc" />
<link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_82F5459FFD5856EEB7CD5EDE153265A3_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_82F5459FFD5856EEB7CD5EDE153265A3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Antidilutive securities excluded from computation of earnings per share</link:label>
<link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_82F5459FFD5856EEB7CD5EDE153265A3_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_82F5459FFD5856EEB7CD5EDE153265A3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</link:label>
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_82F5459FFD5856EEB7CD5EDE153265A3" xlink:type="locator" />
<link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_82F5459FFD5856EEB7CD5EDE153265A3" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_82F5459FFD5856EEB7CD5EDE153265A3" xlink:type="arc" />
<link:label id="lab_us-gaap_OperatingLeaseLiability_90F37937B74A883A11835EDE153227D8_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability_90F37937B74A883A11835EDE153227D8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating lease, liability</link:label>
<link:label id="lab_us-gaap_OperatingLeaseLiability_90F37937B74A883A11835EDE153227D8_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability_90F37937B74A883A11835EDE153227D8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Liability</link:label>
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseLiability" xlink:label="loc_us-gaap_OperatingLeaseLiability_90F37937B74A883A11835EDE153227D8" xlink:type="locator" />
<link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiability_90F37937B74A883A11835EDE153227D8" xlink:to="lab_us-gaap_OperatingLeaseLiability_90F37937B74A883A11835EDE153227D8" xlink:type="arc" />
<link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_F5F2EB1CBD6531D46BB75EDE15336DB5_verboseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset_F5F2EB1CBD6531D46BB75EDE15336DB5" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Right-of-use asset</link:label>
<link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_F5F2EB1CBD6531D46BB75EDE15336DB5_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset_F5F2EB1CBD6531D46BB75EDE15336DB5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Right-of-Use Asset</link:label>
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_F5F2EB1CBD6531D46BB75EDE15336DB5" xlink:type="locator" />
<link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseRightOfUseAsset_F5F2EB1CBD6531D46BB75EDE15336DB5" xlink:to="lab_us-gaap_OperatingLeaseRightOfUseAsset_F5F2EB1CBD6531D46BB75EDE15336DB5" xlink:type="arc" />
<link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_1A63D63E3C3FD7B2E7485EDE1533A583_terseLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent_1A63D63E3C3FD7B2E7485EDE1533A583" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other liabilities, noncurrent</link:label>
<link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_1A63D63E3C3FD7B2E7485EDE1533A583_label_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent_1A63D63E3C3FD7B2E7485EDE1533A583" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Liabilities, Noncurrent</link:label>
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_1A63D63E3C3FD7B2E7485EDE1533A583" xlink:type="locator" />
<link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesNoncurrent_1A63D63E3C3FD7B2E7485EDE1533A583" xlink:to="lab_us-gaap_OtherLiabilitiesNoncurrent_1A63D63E3C3FD7B2E7485EDE1533A583" xlink:type="arc" />
<link:label id="lab_us-gaap_EquityAbstract_035FD1494609B3B22FC8D1D06163C672_label_en-US" xlink:label="lab_us-gaap_EquityAbstract_035FD1494609B3B22FC8D1D06163C672" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity [Abstract]</link:label>
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaap_EquityAbstract_035FD1494609B3B22FC8D1D06163C672" xlink:type="locator" />
<link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityAbstract_035FD1494609B3B22FC8D1D06163C672" xlink:to="lab_us-gaap_EquityAbstract_035FD1494609B3B22FC8D1D06163C672" xlink:type="arc" />
<link:label id="lab_us-gaap_ComprehensiveIncomeNoteTextBlock_F0C99087DFD7FB14F13AD1D0616384FD_terseLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNoteTextBlock_F0C99087DFD7FB14F13AD1D0616384FD" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accumulated Other Comprehensive (Loss) Income</link:label>
<link:label id="lab_us-gaap_ComprehensiveIncomeNoteTextBlock_F0C99087DFD7FB14F13AD1D0616384FD_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNoteTextBlock_F0C99087DFD7FB14F13AD1D0616384FD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Comprehensive Income (Loss) Note [Text Block]</link:label>
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ComprehensiveIncomeNoteTextBlock" xlink:label="loc_us-gaap_ComprehensiveIncomeNoteTextBlock_F0C99087DFD7FB14F13AD1D0616384FD" xlink:type="locator" />
<link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNoteTextBlock_F0C99087DFD7FB14F13AD1D0616384FD" xlink:to="lab_us-gaap_ComprehensiveIncomeNoteTextBlock_F0C99087DFD7FB14F13AD1D0616384FD" xlink:type="arc" />
<link:label id="lab_us-gaap_DebtDisclosureAbstract_29B7CA3880EACBE2B48479F70C1C2C1A_label_en-US" xlink:label="lab_us-gaap_DebtDisclosureAbstract_29B7CA3880EACBE2B48479F70C1C2C1A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Disclosure [Abstract]</link:label>
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="loc_us-gaap_DebtDisclosureAbstract_29B7CA3880EACBE2B48479F70C1C2C1A" xlink:type="locator" />
<link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtDisclosureAbstract_29B7CA3880EACBE2B48479F70C1C2C1A" xlink:to="lab_us-gaap_DebtDisclosureAbstract_29B7CA3880EACBE2B48479F70C1C2C1A" xlink:type="arc" />
<link:label id="lab_us-gaap_DeferredRevenueArrangementByTypeTable_E5BFF701801B04BDD19F79F70C1DABEC_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredRevenueArrangementByTypeTable_E5BFF701801B04BDD19F79F70C1DABEC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred Revenue Arrangement, by Type [Table]</link:label>
<link:label id="lab_us-gaap_DeferredRevenueArrangementByTypeTable_E5BFF701801B04BDD19F79F70C1DABEC_label_en-US" xlink:label="lab_us-gaap_DeferredRevenueArrangementByTypeTable_E5BFF701801B04BDD19F79F70C1DABEC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Revenue Arrangement, by Type [Table]</link:label>
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredRevenueArrangementByTypeTable" xlink:label="loc_us-gaap_DeferredRevenueArrangementByTypeTable_E5BFF701801B04BDD19F79F70C1DABEC" xlink:type="locator" />
<link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredRevenueArrangementByTypeTable_E5BFF701801B04BDD19F79F70C1DABEC" xlink:to="lab_us-gaap_DeferredRevenueArrangementByTypeTable_E5BFF701801B04BDD19F79F70C1DABEC" xlink:type="arc" />
<link:label id="lab_srt_CounterpartyNameAxis_39765065DF207F6413B279F70C1DDBDD_terseLabel_en-US" xlink:label="lab_srt_CounterpartyNameAxis_39765065DF207F6413B279F70C1DDBDD" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Counterparty Name [Axis]</link:label>
<link:label id="lab_srt_CounterpartyNameAxis_39765065DF207F6413B279F70C1DDBDD_label_en-US" xlink:label="lab_srt_CounterpartyNameAxis_39765065DF207F6413B279F70C1DDBDD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Counterparty Name [Axis]</link:label>
<link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_CounterpartyNameAxis" xlink:label="loc_srt_CounterpartyNameAxis_39765065DF207F6413B279F70C1DDBDD" xlink:type="locator" />
<link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_CounterpartyNameAxis_39765065DF207F6413B279F70C1DDBDD" xlink:to="lab_srt_CounterpartyNameAxis_39765065DF207F6413B279F70C1DDBDD" xlink:type="arc" />
<link:label id="lab_srt_RepurchaseAgreementCounterpartyNameDomain_8331CAA28045C5B2BC1279F70C1D9C58_terseLabel_en-US" xlink:label="lab_srt_RepurchaseAgreementCounterpartyNameDomain_8331CAA28045C5B2BC1279F70C1D9C58" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Counterparty Name [Domain]</link:label>
<link:label id="lab_srt_RepurchaseAgreementCounterpartyNameDomain_8331CAA28045C5B2BC1279F70C1D9C58_label_en-US" xlink:label="lab_srt_RepurchaseAgreementCounterpartyNameDomain_8331CAA28045C5B2BC1279F70C1D9C58" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Counterparty Name [Domain]</link:label>
<link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_8331CAA28045C5B2BC1279F70C1D9C58" xlink:type="locator" />
<link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_8331CAA28045C5B2BC1279F70C1D9C58" xlink:to="lab_srt_RepurchaseAgreementCounterpartyNameDomain_8331CAA28045C5B2BC1279F70C1D9C58" xlink:type="arc" />
<link:label id="lab_immu_RpiFinanceTrustMember_D3ADB92ECDE725A545A279F70C1DA4EF_terseLabel_en-US" xlink:label="lab_immu_RpiFinanceTrustMember_D3ADB92ECDE725A545A279F70C1DA4EF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Rpi Finance Trust</link:label>
<link:label id="lab_immu_RpiFinanceTrustMember_D3ADB92ECDE725A545A279F70C1DA4EF_label_en-US" xlink:label="lab_immu_RpiFinanceTrustMember_D3ADB92ECDE725A545A279F70C1DA4EF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Rpi Finance Trust [Member]</link:label>
<link:label id="lab_immu_RpiFinanceTrustMember_D3ADB92ECDE725A545A279F70C1DA4EF_documentation_en-US" xlink:label="lab_immu_RpiFinanceTrustMember_D3ADB92ECDE725A545A279F70C1DA4EF" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">This member stands for RPI Finance Trust, a Delaware statutory trust.</link:label>
<link:loc xlink:href="immu-20191231.xsd#immu_RpiFinanceTrustMember" xlink:label="loc_immu_RpiFinanceTrustMember_D3ADB92ECDE725A545A279F70C1DA4EF" xlink:type="locator" />
<link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_immu_RpiFinanceTrustMember_D3ADB92ECDE725A545A279F70C1DA4EF" xlink:to="lab_immu_RpiFinanceTrustMember_D3ADB92ECDE725A545A279F70C1DA4EF" xlink:type="arc" />
<link:label id="lab_us-gaap_DeferredRevenueArrangementTypeAxis_58D8A8CD3242A9B4D6FB79F70C1E9FC2_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredRevenueArrangementTypeAxis_58D8A8CD3242A9B4D6FB79F70C1E9FC2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred Revenue Arrangement Type [Axis]</link:label>
<link:label id="lab_us-gaap_DeferredRevenueArrangementTypeAxis_58D8A8CD3242A9B4D6FB79F70C1E9FC2_label_en-US" xlink:label="lab_us-gaap_DeferredRevenueArrangementTypeAxis_58D8A8CD3242A9B4D6FB79F70C1E9FC2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Revenue Arrangement Type [Axis]</link:label>
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredRevenueArrangementTypeAxis" xlink:label="loc_us-gaap_DeferredRevenueArrangementTypeAxis_58D8A8CD3242A9B4D6FB79F70C1E9FC2" xlink:type="locator" />
<link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredRevenueArrangementTypeAxis_58D8A8CD3242A9B4D6FB79F70C1E9FC2" xlink:to="lab_us-gaap_DeferredRevenueArrangementTypeAxis_58D8A8CD3242A9B4D6FB79F70C1E9FC2" xlink:type="arc" />
<link:label id="lab_us-gaap_DeferredRevenueArrangementTypeDomain_248D924A4AD95D77D6B979F70C1E3973_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredRevenueArrangementTypeDomain_248D924A4AD95D77D6B979F70C1E3973" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred Revenue [Domain]</link:label>
<link:label id="lab_us-gaap_DeferredRevenueArrangementTypeDomain_248D924A4AD95D77D6B979F70C1E3973_label_en-US" xlink:label="lab_us-gaap_DeferredRevenueArrangementTypeDomain_248D924A4AD95D77D6B979F70C1E3973" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Revenue [Domain]</link:label>
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredRevenueArrangementTypeDomain" xlink:label="loc_us-gaap_DeferredRevenueArrangementTypeDomain_248D924A4AD95D77D6B979F70C1E3973" xlink:type="locator" />
<link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredRevenueArrangementTypeDomain_248D924A4AD95D77D6B979F70C1E3973" xlink:to="lab_us-gaap_DeferredRevenueArrangementTypeDomain_248D924A4AD95D77D6B979F70C1E3973" xlink:type="arc" />
<link:label id="lab_us-gaap_RoyaltyArrangementMember_2F0E3B33309F72CB923A79F70C1E06DE_terseLabel_en-US" xlink:label="lab_us-gaap_RoyaltyArrangementMember_2F0E3B33309F72CB923A79F70C1E06DE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Royalty Arrangement</link:label>
<link:label id="lab_us-gaap_RoyaltyArrangementMember_2F0E3B33309F72CB923A79F70C1E06DE_label_en-US" xlink:label="lab_us-gaap_RoyaltyArrangementMember_2F0E3B33309F72CB923A79F70C1E06DE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Royalty Arrangement [Member]</link:label>
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RoyaltyArrangementMember" xlink:label="loc_us-gaap_RoyaltyArrangementMember_2F0E3B33309F72CB923A79F70C1E06DE" xlink:type="locator" />
<link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RoyaltyArrangementMember_2F0E3B33309F72CB923A79F70C1E06DE" xlink:to="lab_us-gaap_RoyaltyArrangementMember_2F0E3B33309F72CB923A79F70C1E06DE" xlink:type="arc" />
<link:label id="lab_us-gaap_DeferredRevenueArrangementLineItems_17A8037B46D0DCAB52D679F70C1F46F9_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredRevenueArrangementLineItems_17A8037B46D0DCAB52D679F70C1F46F9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred Revenue Arrangement [Line Items]</link:label>
<link:label id="lab_us-gaap_DeferredRevenueArrangementLineItems_17A8037B46D0DCAB52D679F70C1F46F9_label_en-US" xlink:label="lab_us-gaap_DeferredRevenueArrangementLineItems_17A8037B46D0DCAB52D679F70C1F46F9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Revenue Arrangement [Line Items]</link:label>
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredRevenueArrangementLineItems" xlink:label="loc_us-gaap_DeferredRevenueArrangementLineItems_17A8037B46D0DCAB52D679F70C1F46F9" xlink:type="locator" />
<link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredRevenueArrangementLineItems_17A8037B46D0DCAB52D679F70C1F46F9" xlink:to="lab_us-gaap_DeferredRevenueArrangementLineItems_17A8037B46D0DCAB52D679F70C1F46F9" xlink:type="arc" />
<link:label id="lab_us-gaap_MovementInDeferredRevenueRollForward_6809D139BF522FD52EA079F70C1FA6A9_terseLabel_en-US" xlink:label="lab_us-gaap_MovementInDeferredRevenueRollForward_6809D139BF522FD52EA079F70C1FA6A9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Movement in Deferred Revenue [Roll Forward]</link:label>
<link:label id="lab_us-gaap_MovementInDeferredRevenueRollForward_6809D139BF522FD52EA079F70C1FA6A9_label_en-US" xlink:label="lab_us-gaap_MovementInDeferredRevenueRollForward_6809D139BF522FD52EA079F70C1FA6A9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Movement in Deferred Revenue [Roll Forward]</link:label>
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MovementInDeferredRevenueRollForward" xlink:label="loc_us-gaap_MovementInDeferredRevenueRollForward_6809D139BF522FD52EA079F70C1FA6A9" xlink:type="locator" />
<link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MovementInDeferredRevenueRollForward_6809D139BF522FD52EA079F70C1FA6A9" xlink:to="lab_us-gaap_MovementInDeferredRevenueRollForward_6809D139BF522FD52EA079F70C1FA6A9" xlink:type="arc" />
<link:label id="lab_immu_FairValueForLiabilityRelatedtoSaleofFutureRoyalties_B194EE0EDA2813FCF06579F70C1F6CF3_periodStartLabel_en-US" xlink:label="lab_immu_FairValueForLiabilityRelatedtoSaleofFutureRoyalties_B194EE0EDA2813FCF06579F70C1F6CF3" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Fair value, liability related to sale of future royalties, beginning balance</link:label>
<link:label id="lab_immu_FairValueForLiabilityRelatedtoSaleofFutureRoyalties_B194EE0EDA2813FCF06579F70C1F6CF3_label_en-US" xlink:label="lab_immu_FairValueForLiabilityRelatedtoSaleofFutureRoyalties_B194EE0EDA2813FCF06579F70C1F6CF3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value For Liability Related to Sale of Future Royalties</link:label>
<link:label id="lab_immu_FairValueForLiabilityRelatedtoSaleofFutureRoyalties_B194EE0EDA2813FCF06579F70C1F6CF3_documentation_en-US" xlink:label="lab_immu_FairValueForLiabilityRelatedtoSaleofFutureRoyalties_B194EE0EDA2813FCF06579F70C1F6CF3" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Fair Value For Liability Related to Sale of Future Royalties</link:label>
<link:loc xlink:href="immu-20191231.xsd#immu_FairValueForLiabilityRelatedtoSaleofFutureRoyalties" xlink:label="loc_immu_FairValueForLiabilityRelatedtoSaleofFutureRoyalties_B194EE0EDA2813FCF06579F70C1F6CF3" xlink:type="locator" />
<link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_immu_FairValueForLiabilityRelatedtoSaleofFutureRoyalties_B194EE0EDA2813FCF06579F70C1F6CF3" xlink:to="lab_immu_FairValueForLiabilityRelatedtoSaleofFutureRoyalties_B194EE0EDA2813FCF06579F70C1F6CF3" xlink:type="arc" />
<link:label id="lab_immu_NonCashInterestExpenseRelatedToSaleOfFutureRoyalties_EAE42A93470CD93BDE0B79F70C1F1D1A_terseLabel_en-US" xlink:label="lab_immu_NonCashInterestExpenseRelatedToSaleOfFutureRoyalties_EAE42A93470CD93BDE0B79F70C1F1D1A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-cash interest expenses</link:label>
<link:label id="lab_immu_NonCashInterestExpenseRelatedToSaleOfFutureRoyalties_EAE42A93470CD93BDE0B79F70C1F1D1A_label_en-US" xlink:label="lab_immu_NonCashInterestExpenseRelatedToSaleOfFutureRoyalties_EAE42A93470CD93BDE0B79F70C1F1D1A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non Cash Interest Expense Related To Sale Of Future Royalties</link:label>
<link:label id="lab_immu_NonCashInterestExpenseRelatedToSaleOfFutureRoyalties_EAE42A93470CD93BDE0B79F70C1F1D1A_documentation_en-US" xlink:label="lab_immu_NonCashInterestExpenseRelatedToSaleOfFutureRoyalties_EAE42A93470CD93BDE0B79F70C1F1D1A" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Non Cash Interest Expense Related To Sale Of Future Royalties</link:label>
<link:loc xlink:href="immu-20191231.xsd#immu_NonCashInterestExpenseRelatedToSaleOfFutureRoyalties" xlink:label="loc_immu_NonCashInterestExpenseRelatedToSaleOfFutureRoyalties_EAE42A93470CD93BDE0B79F70C1F1D1A" xlink:type="locator" />
<link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_immu_NonCashInterestExpenseRelatedToSaleOfFutureRoyalties_EAE42A93470CD93BDE0B79F70C1F1D1A" xlink:to="lab_immu_NonCashInterestExpenseRelatedToSaleOfFutureRoyalties_EAE42A93470CD93BDE0B79F70C1F1D1A" xlink:type="arc" />
<link:label id="lab_immu_FairValueForLiabilityRelatedtoSaleofFutureRoyalties_6ECD9BF50827322C329079F70C1FB936_periodEndLabel_en-US" xlink:label="lab_immu_FairValueForLiabilityRelatedtoSaleofFutureRoyalties_6ECD9BF50827322C329079F70C1FB936" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Fair value, liability related to sale of future royalties, ending balance</link:label>
<link:loc xlink:href="immu-20191231.xsd#immu_FairValueForLiabilityRelatedtoSaleofFutureRoyalties" xlink:label="loc_immu_FairValueForLiabilityRelatedtoSaleofFutureRoyalties_6ECD9BF50827322C329079F70C1FB936" xlink:type="locator" />
<link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_immu_FairValueForLiabilityRelatedtoSaleofFutureRoyalties_6ECD9BF50827322C329079F70C1FB936" xlink:to="lab_immu_FairValueForLiabilityRelatedtoSaleofFutureRoyalties_6ECD9BF50827322C329079F70C1FB936" xlink:type="arc" />
<link:label id="lab_immu_LiabilitiesRelatedToTheSaleOfFutureRoyaltiesCurrent_20CE025FF8B91D1E964E79F70C1FDCBE_terseLabel_en-US" xlink:label="lab_immu_LiabilitiesRelatedToTheSaleOfFutureRoyaltiesCurrent_20CE025FF8B91D1E964E79F70C1FDCBE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Liability related to sale of future royalties - current</link:label>
<link:label id="lab_immu_LiabilitiesRelatedToTheSaleOfFutureRoyaltiesCurrent_20CE025FF8B91D1E964E79F70C1FDCBE_label_en-US" xlink:label="lab_immu_LiabilitiesRelatedToTheSaleOfFutureRoyaltiesCurrent_20CE025FF8B91D1E964E79F70C1FDCBE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities Related To The Sale Of Future Royalties, Current</link:label>
<link:label id="lab_immu_LiabilitiesRelatedToTheSaleOfFutureRoyaltiesCurrent_20CE025FF8B91D1E964E79F70C1FDCBE_documentation_en-US" xlink:label="lab_immu_LiabilitiesRelatedToTheSaleOfFutureRoyaltiesCurrent_20CE025FF8B91D1E964E79F70C1FDCBE" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Liabilities Related To The Sale Of Future Royalties, Current</link:label>
<link:loc xlink:href="immu-20191231.xsd#immu_LiabilitiesRelatedToTheSaleOfFutureRoyaltiesCurrent" xlink:label="loc_immu_LiabilitiesRelatedToTheSaleOfFutureRoyaltiesCurrent_20CE025FF8B91D1E964E79F70C1FDCBE" xlink:type="locator" />
<link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_immu_LiabilitiesRelatedToTheSaleOfFutureRoyaltiesCurrent_20CE025FF8B91D1E964E79F70C1FDCBE" xlink:to="lab_immu_LiabilitiesRelatedToTheSaleOfFutureRoyaltiesCurrent_20CE025FF8B91D1E964E79F70C1FDCBE" xlink:type="arc" />
<link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_F623DAEBB62FCB958E1F3991D308277A_label_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract_F623DAEBB62FCB958E1F3991D308277A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_F623DAEBB62FCB958E1F3991D308277A" xlink:type="locator" />
<link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_F623DAEBB62FCB958E1F3991D308277A" xlink:to="lab_us-gaap_StatementOfFinancialPositionAbstract_F623DAEBB62FCB958E1F3991D308277A" xlink:type="arc" />
<link:label id="lab_us-gaap_AssetsAbstract_94274A213341EA4F5D573991D309F89B_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsAbstract_94274A213341EA4F5D573991D309F89B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">ASSETS</link:label>
<link:label id="lab_us-gaap_AssetsAbstract_94274A213341EA4F5D573991D309F89B_label_en-US" xlink:label="lab_us-gaap_AssetsAbstract_94274A213341EA4F5D573991D309F89B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets [Abstract]</link:label>
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="loc_us-gaap_AssetsAbstract_94274A213341EA4F5D573991D309F89B" xlink:type="locator" />
<link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsAbstract_94274A213341EA4F5D573991D309F89B" xlink:to="lab_us-gaap_AssetsAbstract_94274A213341EA4F5D573991D309F89B" xlink:type="arc" />
<link:label id="lab_us-gaap_AssetsCurrentAbstract_D1FAC9758DE7944B5B213991D30932EE_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract_D1FAC9758DE7944B5B213991D30932EE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current Assets:</link:label>
<link:label id="lab_us-gaap_AssetsCurrentAbstract_D1FAC9758DE7944B5B213991D30932EE_label_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract_D1FAC9758DE7944B5B213991D30932EE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets, Current [Abstract]</link:label>
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="loc_us-gaap_AssetsCurrentAbstract_D1FAC9758DE7944B5B213991D30932EE" xlink:type="locator" />
<link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrentAbstract_D1FAC9758DE7944B5B213991D30932EE" xlink:to="lab_us-gaap_AssetsCurrentAbstract_D1FAC9758DE7944B5B213991D30932EE" xlink:type="arc" />
<link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_65D37DABC8FCC17FE1803991D3091B75_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_65D37DABC8FCC17FE1803991D3091B75" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash and cash equivalents</link:label>
<link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_65D37DABC8FCC17FE1803991D3091B75_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_65D37DABC8FCC17FE1803991D3091B75" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents, at Carrying Value</link:label>
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_65D37DABC8FCC17FE1803991D3091B75" xlink:type="locator" />
<link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_65D37DABC8FCC17FE1803991D3091B75" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_65D37DABC8FCC17FE1803991D3091B75" xlink:type="arc" />
<link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_4D7827CD8AE7894EA3553991D30961F2_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_4D7827CD8AE7894EA3553991D30961F2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Marketable securities</link:label>
<link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_4D7827CD8AE7894EA3553991D30961F2_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_4D7827CD8AE7894EA3553991D30961F2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-sale, Current</link:label>
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_4D7827CD8AE7894EA3553991D30961F2" xlink:type="locator" />
<link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_4D7827CD8AE7894EA3553991D30961F2" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_4D7827CD8AE7894EA3553991D30961F2" xlink:type="arc" />
<link:label id="lab_us-gaap_AccountsReceivableNetCurrent_56CF615F09132B6796623991D30AB268_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent_56CF615F09132B6796623991D30AB268" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounts receivable, net of allowances of $0 at December 31, 2019</link:label>
<link:label id="lab_us-gaap_AccountsReceivableNetCurrent_56CF615F09132B6796623991D30AB268_label_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent_56CF615F09132B6796623991D30AB268" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounts Receivable, after Allowance for Credit Loss, Current</link:label>
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_56CF615F09132B6796623991D30AB268" xlink:type="locator" />
<link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableNetCurrent_56CF615F09132B6796623991D30AB268" xlink:to="lab_us-gaap_AccountsReceivableNetCurrent_56CF615F09132B6796623991D30AB268" xlink:type="arc" />
<link:label id="lab_us-gaap_PrepaidExpenseCurrent_5D5DCBA80D71F97114273991D30A3FB2_terseLabel_en-US" xlink:label="lab_us-gaap_PrepaidExpenseCurrent_5D5DCBA80D71F97114273991D30A3FB2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Prepaid expenses</link:label>
<link:label id="lab_us-gaap_PrepaidExpenseCurrent_5D5DCBA80D71F97114273991D30A3FB2_label_en-US" xlink:label="lab_us-gaap_PrepaidExpenseCurrent_5D5DCBA80D71F97114273991D30A3FB2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Prepaid Expense, Current</link:label>
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PrepaidExpenseCurrent" xlink:label="loc_us-gaap_PrepaidExpenseCurrent_5D5DCBA80D71F97114273991D30A3FB2" xlink:type="locator" />
<link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidExpenseCurrent_5D5DCBA80D71F97114273991D30A3FB2" xlink:to="lab_us-gaap_PrepaidExpenseCurrent_5D5DCBA80D71F97114273991D30A3FB2" xlink:type="arc" />
<link:label id="lab_us-gaap_OtherAssetsCurrent_60144D953CFEC917E9703991D30A7CA3_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsCurrent_60144D953CFEC917E9703991D30A7CA3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other current assets</link:label>
<link:label id="lab_us-gaap_OtherAssetsCurrent_60144D953CFEC917E9703991D30A7CA3_label_en-US" xlink:label="lab_us-gaap_OtherAssetsCurrent_60144D953CFEC917E9703991D30A7CA3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Assets, Current</link:label>
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherAssetsCurrent" xlink:label="loc_us-gaap_OtherAssetsCurrent_60144D953CFEC917E9703991D30A7CA3" xlink:type="locator" />
<link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsCurrent_60144D953CFEC917E9703991D30A7CA3" xlink:to="lab_us-gaap_OtherAssetsCurrent_60144D953CFEC917E9703991D30A7CA3" xlink:type="arc" />
<link:label id="lab_us-gaap_AssetsCurrent_B6D62AFA8081FAD0E5523991D30A4A47_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrent_B6D62AFA8081FAD0E5523991D30A4A47" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total current assets</link:label>
<link:label id="lab_us-gaap_AssetsCurrent_B6D62AFA8081FAD0E5523991D30A4A47_label_en-US" xlink:label="lab_us-gaap_AssetsCurrent_B6D62AFA8081FAD0E5523991D30A4A47" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets, Current</link:label>
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaap_AssetsCurrent_B6D62AFA8081FAD0E5523991D30A4A47" xlink:type="locator" />
<link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrent_B6D62AFA8081FAD0E5523991D30A4A47" xlink:to="lab_us-gaap_AssetsCurrent_B6D62AFA8081FAD0E5523991D30A4A47" xlink:type="arc" />
<link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_A3B5C198E63C505C745E3991D30A05D4_verboseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet_A3B5C198E63C505C745E3991D30A05D4" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Property and equipment, net of accumulated depreciation and amortization of $7,925 and $4,316 at December 31, 2019 and 2018, respectively</link:label>
<link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_A3B5C198E63C505C745E3991D30A05D4_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet_A3B5C198E63C505C745E3991D30A05D4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Net</link:label>
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_A3B5C198E63C505C745E3991D30A05D4" xlink:type="locator" />
<link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet_A3B5C198E63C505C745E3991D30A05D4" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentNet_A3B5C198E63C505C745E3991D30A05D4" xlink:type="arc" />
<link:label id="lab_us-gaap_OtherAssetsNoncurrent_952CD8F9569D4B93B2403991D30A35D6_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent_952CD8F9569D4B93B2403991D30A35D6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other long-term assets</link:label>
<link:label id="lab_us-gaap_OtherAssetsNoncurrent_952CD8F9569D4B93B2403991D30A35D6_label_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent_952CD8F9569D4B93B2403991D30A35D6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Assets, Noncurrent</link:label>
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_952CD8F9569D4B93B2403991D30A35D6" xlink:type="locator" />
<link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsNoncurrent_952CD8F9569D4B93B2403991D30A35D6" xlink:to="lab_us-gaap_OtherAssetsNoncurrent_952CD8F9569D4B93B2403991D30A35D6" xlink:type="arc" />
<link:label id="lab_us-gaap_Assets_EC5D16BADD081039696E3991D30A08BF_totalLabel_en-US" xlink:label="lab_us-gaap_Assets_EC5D16BADD081039696E3991D30A08BF" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total Assets</link:label>
<link:label id="lab_us-gaap_Assets_EC5D16BADD081039696E3991D30A08BF_label_en-US" xlink:label="lab_us-gaap_Assets_EC5D16BADD081039696E3991D30A08BF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets</link:label>
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Assets" xlink:label="loc_us-gaap_Assets_EC5D16BADD081039696E3991D30A08BF" xlink:type="locator" />
<link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Assets_EC5D16BADD081039696E3991D30A08BF" xlink:to="lab_us-gaap_Assets_EC5D16BADD081039696E3991D30A08BF" xlink:type="arc" />
<link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_77C3BB8610D1AD3443193991D30B2EB1_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_77C3BB8610D1AD3443193991D30B2EB1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">LIABILITIES AND STOCKHOLDERS' EQUITY</link:label>
<link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_77C3BB8610D1AD3443193991D30B2EB1_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_77C3BB8610D1AD3443193991D30B2EB1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities and Equity [Abstract]</link:label>
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_77C3BB8610D1AD3443193991D30B2EB1" xlink:type="locator" />
<link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_77C3BB8610D1AD3443193991D30B2EB1" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_77C3BB8610D1AD3443193991D30B2EB1" xlink:type="arc" />
<link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_DEBEF4CF538D2DAC1B763991D30B61F5_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract_DEBEF4CF538D2DAC1B763991D30B61F5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current Liabilities:</link:label>
<link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_DEBEF4CF538D2DAC1B763991D30B61F5_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract_DEBEF4CF538D2DAC1B763991D30B61F5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities, Current [Abstract]</link:label>
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_DEBEF4CF538D2DAC1B763991D30B61F5" xlink:type="locator" />
<link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_DEBEF4CF538D2DAC1B763991D30B61F5" xlink:to="lab_us-gaap_LiabilitiesCurrentAbstract_DEBEF4CF538D2DAC1B763991D30B61F5" xlink:type="arc" />
<link:label id="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_9CA7DD8D66964577DF903991D30B99ED_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_9CA7DD8D66964577DF903991D30B99ED" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounts payable and accrued expenses</link:label>
<link:label id="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_9CA7DD8D66964577DF903991D30B99ED_label_en-US" xlink:label="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_9CA7DD8D66964577DF903991D30B99ED" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounts Payable and Accrued Liabilities, Current</link:label>
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_9CA7DD8D66964577DF903991D30B99ED" xlink:type="locator" />
<link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_9CA7DD8D66964577DF903991D30B99ED" xlink:to="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_9CA7DD8D66964577DF903991D30B99ED" xlink:type="arc" />
<link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_0C63364903903D1E2A403991D30C82DD_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent_0C63364903903D1E2A403991D30C82DD" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Lease liability - current</link:label>
<link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_0C63364903903D1E2A403991D30C82DD_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent_0C63364903903D1E2A403991D30C82DD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Liability, Current</link:label>
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_0C63364903903D1E2A403991D30C82DD" xlink:type="locator" />
<link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityCurrent_0C63364903903D1E2A403991D30C82DD" xlink:to="lab_us-gaap_OperatingLeaseLiabilityCurrent_0C63364903903D1E2A403991D30C82DD" xlink:type="arc" />
<link:label id="lab_us-gaap_ConvertibleDebtCurrent_458F5F68A34A6557A13639991EF8DF59_terseLabel_en-US" xlink:label="lab_us-gaap_ConvertibleDebtCurrent_458F5F68A34A6557A13639991EF8DF59" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Convertible senior notes, net</link:label>
<link:label id="lab_us-gaap_ConvertibleDebtCurrent_458F5F68A34A6557A13639991EF8DF59_label_en-US" xlink:label="lab_us-gaap_ConvertibleDebtCurrent_458F5F68A34A6557A13639991EF8DF59" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Convertible Debt, Current</link:label>
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConvertibleDebtCurrent" xlink:label="loc_us-gaap_ConvertibleDebtCurrent_458F5F68A34A6557A13639991EF8DF59" xlink:type="locator" />
<link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConvertibleDebtCurrent_458F5F68A34A6557A13639991EF8DF59" xlink:to="lab_us-gaap_ConvertibleDebtCurrent_458F5F68A34A6557A13639991EF8DF59" xlink:type="arc" />
<link:label id="lab_us-gaap_LiabilitiesCurrent_A9995D2A23F3BF4101C93991D30C48E9_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent_A9995D2A23F3BF4101C93991D30C48E9" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total current liabilities</link:label>
<link:label id="lab_us-gaap_LiabilitiesCurrent_A9995D2A23F3BF4101C93991D30C48E9_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent_A9995D2A23F3BF4101C93991D30C48E9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities, Current</link:label>
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaap_LiabilitiesCurrent_A9995D2A23F3BF4101C93991D30C48E9" xlink:type="locator" />
<link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrent_A9995D2A23F3BF4101C93991D30C48E9" xlink:to="lab_us-gaap_LiabilitiesCurrent_A9995D2A23F3BF4101C93991D30C48E9" xlink:type="arc" />
<link:label id="lab_us-gaap_ConvertibleDebtNoncurrent_557A26864094AD1B90C33991D30C3734_terseLabel_en-US" xlink:label="lab_us-gaap_ConvertibleDebtNoncurrent_557A26864094AD1B90C33991D30C3734" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Convertible senior notes, net</link:label>
<link:label id="lab_us-gaap_ConvertibleDebtNoncurrent_557A26864094AD1B90C33991D30C3734_label_en-US" xlink:label="lab_us-gaap_ConvertibleDebtNoncurrent_557A26864094AD1B90C33991D30C3734" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Convertible Debt, Noncurrent</link:label>
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConvertibleDebtNoncurrent" xlink:label="loc_us-gaap_ConvertibleDebtNoncurrent_557A26864094AD1B90C33991D30C3734" xlink:type="locator" />
<link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConvertibleDebtNoncurrent_557A26864094AD1B90C33991D30C3734" xlink:to="lab_us-gaap_ConvertibleDebtNoncurrent_557A26864094AD1B90C33991D30C3734" xlink:type="arc" />
<link:label id="lab_immu_LiabilitiesRelatedToTheSaleOfFutureRoyaltiesNoncurrent_378F95F04551FF9B7FB83991D30CFFDB_terseLabel_en-US" xlink:label="lab_immu_LiabilitiesRelatedToTheSaleOfFutureRoyaltiesNoncurrent_378F95F04551FF9B7FB83991D30CFFDB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Liability related to sale of future royalties - non-current</link:label>
<link:label id="lab_immu_LiabilitiesRelatedToTheSaleOfFutureRoyaltiesNoncurrent_378F95F04551FF9B7FB83991D30CFFDB_label_en-US" xlink:label="lab_immu_LiabilitiesRelatedToTheSaleOfFutureRoyaltiesNoncurrent_378F95F04551FF9B7FB83991D30CFFDB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities Related To The Sale Of Future Royalties, Noncurrent</link:label>
<link:label id="lab_immu_LiabilitiesRelatedToTheSaleOfFutureRoyaltiesNoncurrent_378F95F04551FF9B7FB83991D30CFFDB_documentation_en-US" xlink:label="lab_immu_LiabilitiesRelatedToTheSaleOfFutureRoyaltiesNoncurrent_378F95F04551FF9B7FB83991D30CFFDB" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Liabilities Related To The Sale Of Future Royalties, Noncurrent</link:label>
<link:loc xlink:href="immu-20191231.xsd#immu_LiabilitiesRelatedToTheSaleOfFutureRoyaltiesNoncurrent" xlink:label="loc_immu_LiabilitiesRelatedToTheSaleOfFutureRoyaltiesNoncurrent_378F95F04551FF9B7FB83991D30CFFDB" xlink:type="locator" />
<link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_immu_LiabilitiesRelatedToTheSaleOfFutureRoyaltiesNoncurrent_378F95F04551FF9B7FB83991D30CFFDB" xlink:to="lab_immu_LiabilitiesRelatedToTheSaleOfFutureRoyaltiesNoncurrent_378F95F04551FF9B7FB83991D30CFFDB" xlink:type="arc" />
<link:label id="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent_2CCD54AF555040BF0A323991D30C692C_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent_2CCD54AF555040BF0A323991D30C692C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred revenues</link:label>
<link:label id="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent_2CCD54AF555040BF0A323991D30C692C_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent_2CCD54AF555040BF0A323991D30C692C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contract with Customer, Liability, Noncurrent</link:label>
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_2CCD54AF555040BF0A323991D30C692C" xlink:type="locator" />
<link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_2CCD54AF555040BF0A323991D30C692C" xlink:to="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent_2CCD54AF555040BF0A323991D30C692C" xlink:type="arc" />
<link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_E625283631607EB69AD43991D30C256A_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent_E625283631607EB69AD43991D30C256A" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Other long-term liabilities</link:label>
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_E625283631607EB69AD43991D30C256A" xlink:type="locator" />
<link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesNoncurrent_E625283631607EB69AD43991D30C256A" xlink:to="lab_us-gaap_OtherLiabilitiesNoncurrent_E625283631607EB69AD43991D30C256A" xlink:type="arc" />
<link:label id="lab_us-gaap_Liabilities_B780A7E07800ADE12C583991D30DBF3B_totalLabel_en-US" xlink:label="lab_us-gaap_Liabilities_B780A7E07800ADE12C583991D30DBF3B" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total Liabilities</link:label>
<link:label id="lab_us-gaap_Liabilities_B780A7E07800ADE12C583991D30DBF3B_label_en-US" xlink:label="lab_us-gaap_Liabilities_B780A7E07800ADE12C583991D30DBF3B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities</link:label>
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaap_Liabilities_B780A7E07800ADE12C583991D30DBF3B" xlink:type="locator" />
<link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Liabilities_B780A7E07800ADE12C583991D30DBF3B" xlink:to="lab_us-gaap_Liabilities_B780A7E07800ADE12C583991D30DBF3B" xlink:type="arc" />
<link:label id="lab_us-gaap_CommitmentsAndContingencies_A638E8178B4C8E82DD643991D30D7B4D_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies_A638E8178B4C8E82DD643991D30D7B4D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Commitments and Contingencies (Note 14)</link:label>
<link:label id="lab_us-gaap_CommitmentsAndContingencies_A638E8178B4C8E82DD643991D30D7B4D_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies_A638E8178B4C8E82DD643991D30D7B4D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Commitments and Contingencies</link:label>
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="loc_us-gaap_CommitmentsAndContingencies_A638E8178B4C8E82DD643991D30D7B4D" xlink:type="locator" />
<link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingencies_A638E8178B4C8E82DD643991D30D7B4D" xlink:to="lab_us-gaap_CommitmentsAndContingencies_A638E8178B4C8E82DD643991D30D7B4D" xlink:type="arc" />
<link:label id="lab_us-gaap_StockholdersEquityAbstract_4B92C69D6A88EEFCEB5C3991D30D6648_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract_4B92C69D6A88EEFCEB5C3991D30D6648" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stockholders' Equity:</link:label>
<link:label id="lab_us-gaap_StockholdersEquityAbstract_4B92C69D6A88EEFCEB5C3991D30D6648_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract_4B92C69D6A88EEFCEB5C3991D30D6648" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stockholders' Equity Attributable to Parent [Abstract]</link:label>
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="loc_us-gaap_StockholdersEquityAbstract_4B92C69D6A88EEFCEB5C3991D30D6648" xlink:type="locator" />
<link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityAbstract_4B92C69D6A88EEFCEB5C3991D30D6648" xlink:to="lab_us-gaap_StockholdersEquityAbstract_4B92C69D6A88EEFCEB5C3991D30D6648" xlink:type="arc" />
<link:label id="lab_us-gaap_ConvertiblePreferredStockNonredeemableOrRedeemableIssuerOptionValue_C0951EA06D3BC0555F893991D30D41FA_terseLabel_en-US" xlink:label="lab_us-gaap_ConvertiblePreferredStockNonredeemableOrRedeemableIssuerOptionValue_C0951EA06D3BC0555F893991D30D41FA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Convertible preferred stock, $0.01 par value; authorized 10,000,000 shares; no shares issued and outstanding at December 31, 2019 and 2018</link:label>
<link:label id="lab_us-gaap_ConvertiblePreferredStockNonredeemableOrRedeemableIssuerOptionValue_C0951EA06D3BC0555F893991D30D41FA_label_en-US" xlink:label="lab_us-gaap_ConvertiblePreferredStockNonredeemableOrRedeemableIssuerOptionValue_C0951EA06D3BC0555F893991D30D41FA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Convertible Preferred Stock, Nonredeemable or Redeemable, Issuer Option, Value</link:label>
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConvertiblePreferredStockNonredeemableOrRedeemableIssuerOptionValue" xlink:label="loc_us-gaap_ConvertiblePreferredStockNonredeemableOrRedeemableIssuerOptionValue_C0951EA06D3BC0555F893991D30D41FA" xlink:type="locator" />
<link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConvertiblePreferredStockNonredeemableOrRedeemableIssuerOptionValue_C0951EA06D3BC0555F893991D30D41FA" xlink:to="lab_us-gaap_ConvertiblePreferredStockNonredeemableOrRedeemableIssuerOptionValue_C0951EA06D3BC0555F893991D30D41FA" xlink:type="arc" />
<link:label id="lab_us-gaap_CommonStockValue_D20B9AACEA82F577794C3991D30DF269_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockValue_D20B9AACEA82F577794C3991D30DF269" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock, $0.01 par value; authorized 250,000,000 shares; issued 212,529,313 shares and outstanding 212,409,692 shares at December 31, 2019; issued 190,445,795 shares and outstanding 190,411,070 shares at December 31, 2018</link:label>
<link:label id="lab_us-gaap_CommonStockValue_D20B9AACEA82F577794C3991D30DF269_label_en-US" xlink:label="lab_us-gaap_CommonStockValue_D20B9AACEA82F577794C3991D30DF269" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Value, Issued</link:label>
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaap_CommonStockValue_D20B9AACEA82F577794C3991D30DF269" xlink:type="locator" />
<link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockValue_D20B9AACEA82F577794C3991D30DF269" xlink:to="lab_us-gaap_CommonStockValue_D20B9AACEA82F577794C3991D30DF269" xlink:type="arc" />
<link:label id="lab_us-gaap_AdditionalPaidInCapitalCommonStock_8D58F6DE22CADCFDDCE33991D30D65E9_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalCommonStock_8D58F6DE22CADCFDDCE33991D30D65E9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Capital contributed in excess of par</link:label>
<link:label id="lab_us-gaap_AdditionalPaidInCapitalCommonStock_8D58F6DE22CADCFDDCE33991D30D65E9_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalCommonStock_8D58F6DE22CADCFDDCE33991D30D65E9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Additional Paid in Capital, Common Stock</link:label>
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock_8D58F6DE22CADCFDDCE33991D30D65E9" xlink:type="locator" />
<link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalCommonStock_8D58F6DE22CADCFDDCE33991D30D65E9" xlink:to="lab_us-gaap_AdditionalPaidInCapitalCommonStock_8D58F6DE22CADCFDDCE33991D30D65E9" xlink:type="arc" />
<link:label id="lab_us-gaap_TreasuryStockValue_8199BD55FCCF973953D43991D30E782C_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockValue_8199BD55FCCF973953D43991D30E782C" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Treasury stock, at cost: 119,621 shares at December 31, 2019 and 34,725 shares at December 31, 2018</link:label>
<link:label id="lab_us-gaap_TreasuryStockValue_8199BD55FCCF973953D43991D30E782C_label_en-US" xlink:label="lab_us-gaap_TreasuryStockValue_8199BD55FCCF973953D43991D30E782C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Treasury Stock, Value</link:label>
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TreasuryStockValue" xlink:label="loc_us-gaap_TreasuryStockValue_8199BD55FCCF973953D43991D30E782C" xlink:type="locator" />
<link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockValue_8199BD55FCCF973953D43991D30E782C" xlink:to="lab_us-gaap_TreasuryStockValue_8199BD55FCCF973953D43991D30E782C" xlink:type="arc" />
<link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_380E4C18C3F46539BB493991D30E1334_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit_380E4C18C3F46539BB493991D30E1334" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accumulated deficit</link:label>
<link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_380E4C18C3F46539BB493991D30E1334_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit_380E4C18C3F46539BB493991D30E1334" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</link:label>
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_380E4C18C3F46539BB493991D30E1334" xlink:type="locator" />
<link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsAccumulatedDeficit_380E4C18C3F46539BB493991D30E1334" xlink:to="lab_us-gaap_RetainedEarningsAccumulatedDeficit_380E4C18C3F46539BB493991D30E1334" xlink:type="arc" />
<link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_4CA7FC1097A5CE126D253991D30EFCEC_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_4CA7FC1097A5CE126D253991D30EFCEC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accumulated other comprehensive loss</link:label>
<link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_4CA7FC1097A5CE126D253991D30EFCEC_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_4CA7FC1097A5CE126D253991D30EFCEC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss), Net of Tax</link:label>
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_4CA7FC1097A5CE126D253991D30EFCEC" xlink:type="locator" />
<link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_4CA7FC1097A5CE126D253991D30EFCEC" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_4CA7FC1097A5CE126D253991D30EFCEC" xlink:type="arc" />
<link:label id="lab_us-gaap_StockholdersEquity_A97BF343F49B8250D22E3991D30ECDBB_totalLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity_A97BF343F49B8250D22E3991D30ECDBB" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total Immunomedics, Inc. stockholders' equity</link:label>
<link:label id="lab_us-gaap_StockholdersEquity_A97BF343F49B8250D22E3991D30ECDBB_label_en-US" xlink:label="lab_us-gaap_StockholdersEquity_A97BF343F49B8250D22E3991D30ECDBB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stockholders' Equity Attributable to Parent</link:label>
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_A97BF343F49B8250D22E3991D30ECDBB" xlink:type="locator" />
<link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity_A97BF343F49B8250D22E3991D30ECDBB" xlink:to="lab_us-gaap_StockholdersEquity_A97BF343F49B8250D22E3991D30ECDBB" xlink:type="arc" />
<link:label id="lab_us-gaap_MinorityInterest_844432DFD3790274C3053991D30E158E_terseLabel_en-US" xlink:label="lab_us-gaap_MinorityInterest_844432DFD3790274C3053991D30E158E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Noncontrolling interest in subsidiary</link:label>
<link:label id="lab_us-gaap_MinorityInterest_844432DFD3790274C3053991D30E158E_label_en-US" xlink:label="lab_us-gaap_MinorityInterest_844432DFD3790274C3053991D30E158E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stockholders' Equity Attributable to Noncontrolling Interest</link:label>
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MinorityInterest" xlink:label="loc_us-gaap_MinorityInterest_844432DFD3790274C3053991D30E158E" xlink:type="locator" />
<link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MinorityInterest_844432DFD3790274C3053991D30E158E" xlink:to="lab_us-gaap_MinorityInterest_844432DFD3790274C3053991D30E158E" xlink:type="arc" />
<link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_565A739BEFF0A98CA09B3991D30E2219_totalLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_565A739BEFF0A98CA09B3991D30E2219" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total Stockholders' Equity</link:label>
<link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_565A739BEFF0A98CA09B3991D30E2219_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_565A739BEFF0A98CA09B3991D30E2219" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest</link:label>
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_565A739BEFF0A98CA09B3991D30E2219" xlink:type="locator" />
<link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_565A739BEFF0A98CA09B3991D30E2219" xlink:to="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_565A739BEFF0A98CA09B3991D30E2219" xlink:type="arc" />
<link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_344DF847DB06DEB5A1ED3991D30F920F_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity_344DF847DB06DEB5A1ED3991D30F920F" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total Liabilities and Stockholders' Equity</link:label>
<link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_344DF847DB06DEB5A1ED3991D30F920F_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity_344DF847DB06DEB5A1ED3991D30F920F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities and Equity</link:label>
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_344DF847DB06DEB5A1ED3991D30F920F" xlink:type="locator" />
<link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_344DF847DB06DEB5A1ED3991D30F920F" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquity_344DF847DB06DEB5A1ED3991D30F920F" xlink:type="arc" />
<link:label id="lab_us-gaap_RelatedPartyTransactionsAbstract_D8F9F2EECEA0152D6568D1D0627DF742_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsAbstract_D8F9F2EECEA0152D6568D1D0627DF742" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Related Party Transactions [Abstract]</link:label>
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract_D8F9F2EECEA0152D6568D1D0627DF742" xlink:type="locator" />
<link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract_D8F9F2EECEA0152D6568D1D0627DF742" xlink:to="lab_us-gaap_RelatedPartyTransactionsAbstract_D8F9F2EECEA0152D6568D1D0627DF742" xlink:type="arc" />
<link:label id="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_39FC415335A195A0796CD1D0627DECE7_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_39FC415335A195A0796CD1D0627DECE7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Related Party Transactions</link:label>
<link:label id="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_39FC415335A195A0796CD1D0627DECE7_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_39FC415335A195A0796CD1D0627DECE7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Related Party Transactions Disclosure [Text Block]</link:label>
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:label="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_39FC415335A195A0796CD1D0627DECE7" xlink:type="locator" />
<link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_39FC415335A195A0796CD1D0627DECE7" xlink:to="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_39FC415335A195A0796CD1D0627DECE7" xlink:type="arc" />
<link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_8123148D82AE94D2BE083991D2439319_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_8123148D82AE94D2BE083991D2439319" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
<link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_8123148D82AE94D2BE083991D2439319_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_8123148D82AE94D2BE083991D2439319" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_8123148D82AE94D2BE083991D2439319" xlink:type="locator" />
<link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_8123148D82AE94D2BE083991D2439319" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_8123148D82AE94D2BE083991D2439319" xlink:type="arc" />
<link:label id="lab_us-gaap_AwardTypeAxis_F042FBCC4465C45B9BCA3991D24376A1_terseLabel_en-US" xlink:label="lab_us-gaap_AwardTypeAxis_F042FBCC4465C45B9BCA3991D24376A1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Award Type [Axis]</link:label>
<link:label id="lab_us-gaap_AwardTypeAxis_F042FBCC4465C45B9BCA3991D24376A1_label_en-US" xlink:label="lab_us-gaap_AwardTypeAxis_F042FBCC4465C45B9BCA3991D24376A1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Type [Axis]</link:label>
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_F042FBCC4465C45B9BCA3991D24376A1" xlink:type="locator" />
<link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AwardTypeAxis_F042FBCC4465C45B9BCA3991D24376A1" xlink:to="lab_us-gaap_AwardTypeAxis_F042FBCC4465C45B9BCA3991D24376A1" xlink:type="arc" />
<link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_30CFCC05505077EFAA7D3991D2436058_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_30CFCC05505077EFAA7D3991D2436058" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Award Type [Domain]</link:label>
<link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_30CFCC05505077EFAA7D3991D2436058_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_30CFCC05505077EFAA7D3991D2436058" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Type [Domain]</link:label>
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_30CFCC05505077EFAA7D3991D2436058" xlink:type="locator" />
<link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_30CFCC05505077EFAA7D3991D2436058" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_30CFCC05505077EFAA7D3991D2436058" xlink:type="arc" />
<link:label id="lab_us-gaap_EmployeeStockOptionMember_C2E5B865773FA49F3A5D3991D243EE0F_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember_C2E5B865773FA49F3A5D3991D243EE0F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Employee Stock Option</link:label>
<link:label id="lab_us-gaap_EmployeeStockOptionMember_C2E5B865773FA49F3A5D3991D243EE0F_label_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember_C2E5B865773FA49F3A5D3991D243EE0F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Payment Arrangement, Option [Member]</link:label>
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaap_EmployeeStockOptionMember_C2E5B865773FA49F3A5D3991D243EE0F" xlink:type="locator" />
<link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeStockOptionMember_C2E5B865773FA49F3A5D3991D243EE0F" xlink:to="lab_us-gaap_EmployeeStockOptionMember_C2E5B865773FA49F3A5D3991D243EE0F" xlink:type="arc" />
<link:label id="lab_us-gaap_RestrictedStockUnitsRSUMember_64B19240C2B31C27EC4B3991D244179E_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember_64B19240C2B31C27EC4B3991D244179E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restricted Stock Units (RSUs)</link:label>
<link:label id="lab_us-gaap_RestrictedStockUnitsRSUMember_64B19240C2B31C27EC4B3991D244179E_label_en-US" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember_64B19240C2B31C27EC4B3991D244179E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restricted Stock Units (RSUs) [Member]</link:label>
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_64B19240C2B31C27EC4B3991D244179E" xlink:type="locator" />
<link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedStockUnitsRSUMember_64B19240C2B31C27EC4B3991D244179E" xlink:to="lab_us-gaap_RestrictedStockUnitsRSUMember_64B19240C2B31C27EC4B3991D244179E" xlink:type="arc" />
<link:label id="lab_us-gaap_PerformanceSharesMember_2FBC58B100DE1FE4AE6039DC3FA70277_terseLabel_en-US" xlink:label="lab_us-gaap_PerformanceSharesMember_2FBC58B100DE1FE4AE6039DC3FA70277" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Performance Shares</link:label>
<link:label id="lab_us-gaap_PerformanceSharesMember_2FBC58B100DE1FE4AE6039DC3FA70277_label_en-US" xlink:label="lab_us-gaap_PerformanceSharesMember_2FBC58B100DE1FE4AE6039DC3FA70277" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Performance Shares [Member]</link:label>
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PerformanceSharesMember" xlink:label="loc_us-gaap_PerformanceSharesMember_2FBC58B100DE1FE4AE6039DC3FA70277" xlink:type="locator" />
<link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PerformanceSharesMember_2FBC58B100DE1FE4AE6039DC3FA70277" xlink:to="lab_us-gaap_PerformanceSharesMember_2FBC58B100DE1FE4AE6039DC3FA70277" xlink:type="arc" />
<link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2FCEBC1E6F4075E1DA1A3991D2446CDA_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2FCEBC1E6F4075E1DA1A3991D2446CDA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
<link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2FCEBC1E6F4075E1DA1A3991D2446CDA_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2FCEBC1E6F4075E1DA1A3991D2446CDA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2FCEBC1E6F4075E1DA1A3991D2446CDA" xlink:type="locator" />
<link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2FCEBC1E6F4075E1DA1A3991D2446CDA" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2FCEBC1E6F4075E1DA1A3991D2446CDA" xlink:type="arc" />
<link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_235E7196232A4C4692833991D244DB40_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_235E7196232A4C4692833991D244DB40" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Vesting period</link:label>
<link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_235E7196232A4C4692833991D244DB40_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_235E7196232A4C4692833991D244DB40" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period</link:label>
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_235E7196232A4C4692833991D244DB40" xlink:type="locator" />
<link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_235E7196232A4C4692833991D244DB40" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_235E7196232A4C4692833991D244DB40" xlink:type="arc" />
<link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_7EA07F7FC98927746BBF3991D245F8D3_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_7EA07F7FC98927746BBF3991D245F8D3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Nonvested, compensation not yet recognized, stock options</link:label>
<link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_7EA07F7FC98927746BBF3991D245F8D3_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_7EA07F7FC98927746BBF3991D245F8D3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount</link:label>
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_7EA07F7FC98927746BBF3991D245F8D3" xlink:type="locator" />
<link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_7EA07F7FC98927746BBF3991D245F8D3" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_7EA07F7FC98927746BBF3991D245F8D3" xlink:type="arc" />
<link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_976D676FE780709929473991D245D52B_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_976D676FE780709929473991D245D52B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Nonvested, compensation not yet recognized, period</link:label>
<link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_976D676FE780709929473991D245D52B_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_976D676FE780709929473991D245D52B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition</link:label>
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_976D676FE780709929473991D245D52B" xlink:type="locator" />
<link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_976D676FE780709929473991D245D52B" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_976D676FE780709929473991D245D52B" xlink:type="arc" />
<link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_18F2D8F7019099C518D73991D2452561_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_18F2D8F7019099C518D73991D2452561" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Arrangement by share-based payment award (in USD per share)</link:label>
<link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_18F2D8F7019099C518D73991D2452561_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_18F2D8F7019099C518D73991D2452561" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Option, Nonvested, Weighted Average Exercise Price</link:label>
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_18F2D8F7019099C518D73991D2452561" xlink:type="locator" />
<link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_18F2D8F7019099C518D73991D2452561" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_18F2D8F7019099C518D73991D2452561" xlink:type="arc" />
<link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_2B5F295CD125034D9BA83991D2454A77_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_2B5F295CD125034D9BA83991D2454A77" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Granted (in USD per share)</link:label>
<link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_2B5F295CD125034D9BA83991D2454A77_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_2B5F295CD125034D9BA83991D2454A77" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</link:label>
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_2B5F295CD125034D9BA83991D2454A77" xlink:type="locator" />
<link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_2B5F295CD125034D9BA83991D2454A77" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_2B5F295CD125034D9BA83991D2454A77" xlink:type="arc" />
<link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_0F46A9630622E31D92463991D245C157_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_0F46A9630622E31D92463991D245C157" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair value of shares vested</link:label>
<link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_0F46A9630622E31D92463991D245C157_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_0F46A9630622E31D92463991D245C157" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value</link:label>
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_0F46A9630622E31D92463991D245C157" xlink:type="locator" />
<link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_0F46A9630622E31D92463991D245C157" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_0F46A9630622E31D92463991D245C157" xlink:type="arc" />
<link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_7B4A8C45D0E991B0A64A3991D245AE8A_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_7B4A8C45D0E991B0A64A3991D245AE8A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Intrinsic value of stock-options exercised</link:label>
<link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_7B4A8C45D0E991B0A64A3991D245AE8A_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_7B4A8C45D0E991B0A64A3991D245AE8A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value</link:label>
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_7B4A8C45D0E991B0A64A3991D245AE8A" xlink:type="locator" />
<link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_7B4A8C45D0E991B0A64A3991D245AE8A" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_7B4A8C45D0E991B0A64A3991D245AE8A" xlink:type="arc" />
<link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_ADC8845C9F4891302D063991D24555BE_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_ADC8845C9F4891302D063991D24555BE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Unrecognized compensation costs</link:label>
<link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_ADC8845C9F4891302D063991D24555BE_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_ADC8845C9F4891302D063991D24555BE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not yet Recognized, Amount</link:label>
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_ADC8845C9F4891302D063991D24555BE" xlink:type="locator" />
<link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_ADC8845C9F4891302D063991D24555BE" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_ADC8845C9F4891302D063991D24555BE" xlink:type="arc" />
<link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_B53655B1E376993F351939D4E372026B_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_B53655B1E376993F351939D4E372026B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">RSUs forfeited in period (in shares)</link:label>
<link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_B53655B1E376993F351939D4E372026B_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_B53655B1E376993F351939D4E372026B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period</link:label>
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_B53655B1E376993F351939D4E372026B" xlink:type="locator" />
<link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_B53655B1E376993F351939D4E372026B" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_B53655B1E376993F351939D4E372026B" xlink:type="arc" />
<link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_8ACDE04314CF2E6FBAD033A13C6226EA_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_8ACDE04314CF2E6FBAD033A13C6226EA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_8ACDE04314CF2E6FBAD033A13C6226EA" xlink:type="locator" />
<link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_8ACDE04314CF2E6FBAD033A13C6226EA" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_8ACDE04314CF2E6FBAD033A13C6226EA" xlink:type="arc" />
<link:label id="lab_us-gaap_LeaseCostTableTextBlock_F45F61F605B6A0FF398033A13C623998_terseLabel_en-US" xlink:label="lab_us-gaap_LeaseCostTableTextBlock_F45F61F605B6A0FF398033A13C623998" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Supplemental Lease Information</link:label>
<link:label id="lab_us-gaap_LeaseCostTableTextBlock_F45F61F605B6A0FF398033A13C623998_label_en-US" xlink:label="lab_us-gaap_LeaseCostTableTextBlock_F45F61F605B6A0FF398033A13C623998" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lease, Cost [Table Text Block]</link:label>
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LeaseCostTableTextBlock" xlink:label="loc_us-gaap_LeaseCostTableTextBlock_F45F61F605B6A0FF398033A13C623998" xlink:type="locator" />
<link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseCostTableTextBlock_F45F61F605B6A0FF398033A13C623998" xlink:to="lab_us-gaap_LeaseCostTableTextBlock_F45F61F605B6A0FF398033A13C623998" xlink:type="arc" />
<link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_D2F77307989B0ECD45BA33A13C62E45C_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_D2F77307989B0ECD45BA33A13C62E45C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Maturities of Lease Liabilities</link:label>
<link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_D2F77307989B0ECD45BA33A13C62E45C_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_D2F77307989B0ECD45BA33A13C62E45C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, Maturity [Table Text Block]</link:label>
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_D2F77307989B0ECD45BA33A13C62E45C" xlink:type="locator" />
<link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_D2F77307989B0ECD45BA33A13C62E45C" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_D2F77307989B0ECD45BA33A13C62E45C" xlink:type="arc" />
<link:label id="lab_us-gaap_RevenueFromContractWithCustomerAbstract_E1B4E902CBE10A762E483991D2985686_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerAbstract_E1B4E902CBE10A762E483991D2985686" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue from Contract with Customer [Abstract]</link:label>
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueFromContractWithCustomerAbstract" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_E1B4E902CBE10A762E483991D2985686" xlink:type="locator" />
<link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_E1B4E902CBE10A762E483991D2985686" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerAbstract_E1B4E902CBE10A762E483991D2985686" xlink:type="arc" />
<link:label id="lab_us-gaap_RevenueFromContractWithCustomerTextBlock_5EB23711DC3E2FCBBA1C3991D298B575_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerTextBlock_5EB23711DC3E2FCBBA1C3991D298B575" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenue Recognition</link:label>
<link:label id="lab_us-gaap_RevenueFromContractWithCustomerTextBlock_5EB23711DC3E2FCBBA1C3991D298B575_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerTextBlock_5EB23711DC3E2FCBBA1C3991D298B575" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue from Contract with Customer [Text Block]</link:label>
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerTextBlock_5EB23711DC3E2FCBBA1C3991D298B575" xlink:type="locator" />
<link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerTextBlock_5EB23711DC3E2FCBBA1C3991D298B575" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerTextBlock_5EB23711DC3E2FCBBA1C3991D298B575" xlink:type="arc" />
<link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock_B48B161AC54FF4686A7CDB5CE7ADAE73_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock_B48B161AC54FF4686A7CDB5CE7ADAE73" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Available-for-sale Securities</link:label>
<link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock_B48B161AC54FF4686A7CDB5CE7ADAE73_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock_B48B161AC54FF4686A7CDB5CE7ADAE73" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-sale [Table Text Block]</link:label>
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock_B48B161AC54FF4686A7CDB5CE7ADAE73" xlink:type="locator" />
<link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock_B48B161AC54FF4686A7CDB5CE7ADAE73" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock_B48B161AC54FF4686A7CDB5CE7ADAE73" xlink:type="arc" />
<link:label id="lab_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_8A84B25C219DEE0C75A53991D2B1E743_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_8A84B25C219DEE0C75A53991D2B1E743" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Business Overview and Summary of Significant Accounting Policies</link:label>
<link:label id="lab_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_8A84B25C219DEE0C75A53991D2B1E743_label_en-US" xlink:label="lab_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_8A84B25C219DEE0C75A53991D2B1E743" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Description and Basis of Presentation [Text Block]</link:label>
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:label="loc_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_8A84B25C219DEE0C75A53991D2B1E743" xlink:type="locator" />
<link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_8A84B25C219DEE0C75A53991D2B1E743" xlink:to="lab_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_8A84B25C219DEE0C75A53991D2B1E743" xlink:type="arc" />
<link:label id="lab_us-gaap_StockholdersEquityNoteAbstract_25E889D9FB0CFB76B1A5E022A670FECB_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteAbstract_25E889D9FB0CFB76B1A5E022A670FECB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stockholders' Equity Note [Abstract]</link:label>
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="loc_us-gaap_StockholdersEquityNoteAbstract_25E889D9FB0CFB76B1A5E022A670FECB" xlink:type="locator" />
<link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_25E889D9FB0CFB76B1A5E022A670FECB" xlink:to="lab_us-gaap_StockholdersEquityNoteAbstract_25E889D9FB0CFB76B1A5E022A670FECB" xlink:type="arc" />
<link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_07575616F2AE72FB07B3E022A67005FA_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_07575616F2AE72FB07B3E022A67005FA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stockholders’ Equity</link:label>
<link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_07575616F2AE72FB07B3E022A67005FA_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_07575616F2AE72FB07B3E022A67005FA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stockholders' Equity Note Disclosure [Text Block]</link:label>
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_07575616F2AE72FB07B3E022A67005FA" xlink:type="locator" />
<link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_07575616F2AE72FB07B3E022A67005FA" xlink:to="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_07575616F2AE72FB07B3E022A67005FA" xlink:type="arc" />
<link:label id="lab_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock_A3883F57DB3E1F343E97D1D06163F6C8_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock_A3883F57DB3E1F343E97D1D06163F6C8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Components of Accumulated Other Comprehensive (Loss) Income</link:label>
<link:label id="lab_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock_A3883F57DB3E1F343E97D1D06163F6C8_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock_A3883F57DB3E1F343E97D1D06163F6C8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block]</link:label>
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock_A3883F57DB3E1F343E97D1D06163F6C8" xlink:type="locator" />
<link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock_A3883F57DB3E1F343E97D1D06163F6C8" xlink:to="lab_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock_A3883F57DB3E1F343E97D1D06163F6C8" xlink:type="arc" />
<link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_34883BA79701873C6B914551CE521D4C_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_34883BA79701873C6B914551CE521D4C" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Statutory rate</link:label>
<link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_34883BA79701873C6B914551CE521D4C_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_34883BA79701873C6B914551CE521D4C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent</link:label>
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_34883BA79701873C6B914551CE521D4C" xlink:type="locator" />
<link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_34883BA79701873C6B914551CE521D4C" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_34883BA79701873C6B914551CE521D4C" xlink:type="arc" />
<link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_FC7932092496F100E2544551CE52B2EC_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_FC7932092496F100E2544551CE52B2EC" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Foreign income tax</link:label>
<link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_FC7932092496F100E2544551CE52B2EC_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_FC7932092496F100E2544551CE52B2EC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Foreign Income Tax Rate Differential, Percent</link:label>
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_FC7932092496F100E2544551CE52B2EC" xlink:type="locator" />
<link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_FC7932092496F100E2544551CE52B2EC" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_FC7932092496F100E2544551CE52B2EC" xlink:type="arc" />
<link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_D4FD5D1BAC5E1B4DDCAF4551CE527461_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_D4FD5D1BAC5E1B4DDCAF4551CE527461" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Change in valuation allowance</link:label>
<link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_D4FD5D1BAC5E1B4DDCAF4551CE527461_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_D4FD5D1BAC5E1B4DDCAF4551CE527461" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent</link:label>
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_D4FD5D1BAC5E1B4DDCAF4551CE527461" xlink:type="locator" />
<link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_D4FD5D1BAC5E1B4DDCAF4551CE527461" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_D4FD5D1BAC5E1B4DDCAF4551CE527461" xlink:type="arc" />
<link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_1F74F2029C26566E34774551CE530B8D_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_1F74F2029C26566E34774551CE530B8D" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">State income taxes, (net of federal tax benefit)</link:label>
<link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_1F74F2029C26566E34774551CE530B8D_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_1F74F2029C26566E34774551CE530B8D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent</link:label>
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_1F74F2029C26566E34774551CE530B8D" xlink:type="locator" />
<link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_1F74F2029C26566E34774551CE530B8D" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_1F74F2029C26566E34774551CE530B8D" xlink:type="arc" />
<link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense_B9EAEE3246EBE3DAF49A4551CE5352BB_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense_B9EAEE3246EBE3DAF49A4551CE5352BB" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Permanent differences, (primarily warrant-related expenses)</link:label>
<link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense_B9EAEE3246EBE3DAF49A4551CE5352BB_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense_B9EAEE3246EBE3DAF49A4551CE5352BB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Nondeductible Expense, Percent</link:label>
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense_B9EAEE3246EBE3DAF49A4551CE5352BB" xlink:type="locator" />
<link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense_B9EAEE3246EBE3DAF49A4551CE5352BB" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense_B9EAEE3246EBE3DAF49A4551CE5352BB" xlink:type="arc" />
<link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent_2385AD64D3CA091EEA7A4551CE539978_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent_2385AD64D3CA091EEA7A4551CE539978" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Other</link:label>
<link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent_2385AD64D3CA091EEA7A4551CE539978_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent_2385AD64D3CA091EEA7A4551CE539978" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation,Other Reconciling Items, Percent</link:label>
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent_2385AD64D3CA091EEA7A4551CE539978" xlink:type="locator" />
<link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent_2385AD64D3CA091EEA7A4551CE539978" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent_2385AD64D3CA091EEA7A4551CE539978" xlink:type="arc" />
<link:label id="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations_0AC7867D3B56AE1E004E4551CE53200F_negatedTotalLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations_0AC7867D3B56AE1E004E4551CE53200F" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="resource" xml:lang="en-US">Effective rate</link:label>
<link:label id="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations_0AC7867D3B56AE1E004E4551CE53200F_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations_0AC7867D3B56AE1E004E4551CE53200F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Percent</link:label>
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_0AC7867D3B56AE1E004E4551CE53200F" xlink:type="locator" />
<link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_0AC7867D3B56AE1E004E4551CE53200F" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations_0AC7867D3B56AE1E004E4551CE53200F" xlink:type="arc" />
<link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_DD2FB6CA5F7F682FCF88E022A5AEF7FC_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset_DD2FB6CA5F7F682FCF88E022A5AEF7FC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating lease right-of-use assets, net</link:label>
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_DD2FB6CA5F7F682FCF88E022A5AEF7FC" xlink:type="locator" />
<link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseRightOfUseAsset_DD2FB6CA5F7F682FCF88E022A5AEF7FC" xlink:to="lab_us-gaap_OperatingLeaseRightOfUseAsset_DD2FB6CA5F7F682FCF88E022A5AEF7FC" xlink:type="arc" />
<link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_326D1919B583C796D9E1E022A5AF3009_verboseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent_326D1919B583C796D9E1E022A5AF3009" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Current portion of lease liabilities</link:label>
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_326D1919B583C796D9E1E022A5AF3009" xlink:type="locator" />
<link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityCurrent_326D1919B583C796D9E1E022A5AF3009" xlink:to="lab_us-gaap_OperatingLeaseLiabilityCurrent_326D1919B583C796D9E1E022A5AF3009" xlink:type="arc" />
<link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_A1DE02290BBF4471213DE022A5AF90FA_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_A1DE02290BBF4471213DE022A5AF90FA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-current portion of lease liabilities</link:label>
<link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_A1DE02290BBF4471213DE022A5AF90FA_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_A1DE02290BBF4471213DE022A5AF90FA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Liability, Noncurrent</link:label>
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_A1DE02290BBF4471213DE022A5AF90FA" xlink:type="locator" />
<link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_A1DE02290BBF4471213DE022A5AF90FA" xlink:to="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_A1DE02290BBF4471213DE022A5AF90FA" xlink:type="arc" />
<link:label id="lab_us-gaap_OperatingLeaseLiability_297FED56EC21B282BC6EE022A5AF35EB_netLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability_297FED56EC21B282BC6EE022A5AF35EB" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:type="resource" xml:lang="en-US">Total operating lease liabilities</link:label>
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseLiability" xlink:label="loc_us-gaap_OperatingLeaseLiability_297FED56EC21B282BC6EE022A5AF35EB" xlink:type="locator" />
<link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiability_297FED56EC21B282BC6EE022A5AF35EB" xlink:to="lab_us-gaap_OperatingLeaseLiability_297FED56EC21B282BC6EE022A5AF35EB" xlink:type="arc" />
<link:label id="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_A3935C7F7C40D9D0575EE022A5B1E848_verboseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_A3935C7F7C40D9D0575EE022A5B1E848" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Weighted average remaining lease term (years)</link:label>
<link:label id="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_A3935C7F7C40D9D0575EE022A5B1E848_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_A3935C7F7C40D9D0575EE022A5B1E848" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Weighted Average Remaining Lease Term</link:label>
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_A3935C7F7C40D9D0575EE022A5B1E848" xlink:type="locator" />
<link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_A3935C7F7C40D9D0575EE022A5B1E848" xlink:to="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_A3935C7F7C40D9D0575EE022A5B1E848" xlink:type="arc" />
<link:label id="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_96D058DE37DFE6914FD3E022A5B16491_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_96D058DE37DFE6914FD3E022A5B16491" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted average discount rate</link:label>
<link:label id="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_96D058DE37DFE6914FD3E022A5B16491_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_96D058DE37DFE6914FD3E022A5B16491" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Weighted Average Discount Rate, Percent</link:label>
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_96D058DE37DFE6914FD3E022A5B16491" xlink:type="locator" />
<link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_96D058DE37DFE6914FD3E022A5B16491" xlink:to="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_96D058DE37DFE6914FD3E022A5B16491" xlink:type="arc" />
<link:label id="lab_immu_NonCashLeaseExpense_35CB89126D3E45BF6C08E022A5B1CDB3_terseLabel_en-US" xlink:label="lab_immu_NonCashLeaseExpense_35CB89126D3E45BF6C08E022A5B1CDB3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-cash lease expense</link:label>
<link:label id="lab_immu_NonCashLeaseExpense_35CB89126D3E45BF6C08E022A5B1CDB3_label_en-US" xlink:label="lab_immu_NonCashLeaseExpense_35CB89126D3E45BF6C08E022A5B1CDB3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non Cash Lease Expense</link:label>
<link:label id="lab_immu_NonCashLeaseExpense_35CB89126D3E45BF6C08E022A5B1CDB3_documentation_en-US" xlink:label="lab_immu_NonCashLeaseExpense_35CB89126D3E45BF6C08E022A5B1CDB3" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Non Cash Lease Expense</link:label>
<link:loc xlink:href="immu-20191231.xsd#immu_NonCashLeaseExpense" xlink:label="loc_immu_NonCashLeaseExpense_35CB89126D3E45BF6C08E022A5B1CDB3" xlink:type="locator" />
<link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_immu_NonCashLeaseExpense_35CB89126D3E45BF6C08E022A5B1CDB3" xlink:to="lab_immu_NonCashLeaseExpense_35CB89126D3E45BF6C08E022A5B1CDB3" xlink:type="arc" />
<link:label id="lab_immu_ChangeinOperatingLeaseLiability_EFA82F2FE307663AB743E022A5B1E544_terseLabel_en-US" xlink:label="lab_immu_ChangeinOperatingLeaseLiability_EFA82F2FE307663AB743E022A5B1E544" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Change in operating lease liabilities</link:label>
<link:label id="lab_immu_ChangeinOperatingLeaseLiability_EFA82F2FE307663AB743E022A5B1E544_label_en-US" xlink:label="lab_immu_ChangeinOperatingLeaseLiability_EFA82F2FE307663AB743E022A5B1E544" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Change in Operating Lease Liability</link:label>
<link:label id="lab_immu_ChangeinOperatingLeaseLiability_EFA82F2FE307663AB743E022A5B1E544_documentation_en-US" xlink:label="lab_immu_ChangeinOperatingLeaseLiability_EFA82F2FE307663AB743E022A5B1E544" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Change in Operating Lease Liability</link:label>
<link:loc xlink:href="immu-20191231.xsd#immu_ChangeinOperatingLeaseLiability" xlink:label="loc_immu_ChangeinOperatingLeaseLiability_EFA82F2FE307663AB743E022A5B1E544" xlink:type="locator" />
<link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_immu_ChangeinOperatingLeaseLiability_EFA82F2FE307663AB743E022A5B1E544" xlink:to="lab_immu_ChangeinOperatingLeaseLiability_EFA82F2FE307663AB743E022A5B1E544" xlink:type="arc" />
<link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_7988743A8E36D7DE7FB7DB3A1D403328_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_7988743A8E36D7DE7FB7DB3A1D403328" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Share Equivalent</link:label>
<link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_7988743A8E36D7DE7FB7DB3A1D403328_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_7988743A8E36D7DE7FB7DB3A1D403328" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]</link:label>
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_7988743A8E36D7DE7FB7DB3A1D403328" xlink:type="locator" />
<link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_7988743A8E36D7DE7FB7DB3A1D403328" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_7988743A8E36D7DE7FB7DB3A1D403328" xlink:type="arc" />
<link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_B1563FEB14EC24B5F17BDB3A1D4065C3_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_B1563FEB14EC24B5F17BDB3A1D4065C3" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Options outstanding, start of year (in shares)</link:label>
<link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_B1563FEB14EC24B5F17BDB3A1D4065C3_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_B1563FEB14EC24B5F17BDB3A1D4065C3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number</link:label>
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_B1563FEB14EC24B5F17BDB3A1D4065C3" xlink:type="locator" />
<link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_B1563FEB14EC24B5F17BDB3A1D4065C3" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_B1563FEB14EC24B5F17BDB3A1D4065C3" xlink:type="arc" />
<link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_F086F89D242753A0C7AFDB3A1D4034AD_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_F086F89D242753A0C7AFDB3A1D4034AD" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Granted (in shares)</link:label>
<link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_F086F89D242753A0C7AFDB3A1D4034AD_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_F086F89D242753A0C7AFDB3A1D4034AD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross</link:label>
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_F086F89D242753A0C7AFDB3A1D4034AD" xlink:type="locator" />
<link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_F086F89D242753A0C7AFDB3A1D4034AD" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_F086F89D242753A0C7AFDB3A1D4034AD" xlink:type="arc" />
<link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_BDD5713DA37532C8BC9ADB3A1D40C7CA_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_BDD5713DA37532C8BC9ADB3A1D40C7CA" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Exercise of stock options (in shares)</link:label>
<link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_BDD5713DA37532C8BC9ADB3A1D40C7CA_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_BDD5713DA37532C8BC9ADB3A1D40C7CA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period</link:label>
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_BDD5713DA37532C8BC9ADB3A1D40C7CA" xlink:type="locator" />
<link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_BDD5713DA37532C8BC9ADB3A1D40C7CA" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_BDD5713DA37532C8BC9ADB3A1D40C7CA" xlink:type="arc" />
<link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_5960C6A3AC773CF31B77DB3A1D402C5E_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_5960C6A3AC773CF31B77DB3A1D402C5E" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Expired or forfeited (in shares)</link:label>
<link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_5960C6A3AC773CF31B77DB3A1D402C5E_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_5960C6A3AC773CF31B77DB3A1D402C5E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period</link:label>
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_5960C6A3AC773CF31B77DB3A1D402C5E" xlink:type="locator" />
<link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_5960C6A3AC773CF31B77DB3A1D402C5E" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_5960C6A3AC773CF31B77DB3A1D402C5E" xlink:type="arc" />
<link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_C1F0722357D57805BDDEDB3A1D410C57_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_C1F0722357D57805BDDEDB3A1D410C57" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Options outstanding, end of year (in shares)</link:label>
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_C1F0722357D57805BDDEDB3A1D410C57" xlink:type="locator" />
<link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_C1F0722357D57805BDDEDB3A1D410C57" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_C1F0722357D57805BDDEDB3A1D410C57" xlink:type="arc" />
<link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_BF6FD067942DCFE09D5ADB3A1D415CD3_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_BF6FD067942DCFE09D5ADB3A1D415CD3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Vested, end of year (in shares)</link:label>
<link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_BF6FD067942DCFE09D5ADB3A1D415CD3_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_BF6FD067942DCFE09D5ADB3A1D415CD3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number</link:label>
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_BF6FD067942DCFE09D5ADB3A1D415CD3" xlink:type="locator" />
<link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_BF6FD067942DCFE09D5ADB3A1D415CD3" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_BF6FD067942DCFE09D5ADB3A1D415CD3" xlink:type="arc" />
<link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward_4B9F3FBBA60C48160F8ADB3A1D418DBB_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward_4B9F3FBBA60C48160F8ADB3A1D418DBB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted Average Exercise Price [Roll Forward]</link:label>
<link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward_4B9F3FBBA60C48160F8ADB3A1D418DBB_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward_4B9F3FBBA60C48160F8ADB3A1D418DBB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested, Number of Shares [Roll Forward]</link:label>
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward_4B9F3FBBA60C48160F8ADB3A1D418DBB" xlink:type="locator" />
<link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward_4B9F3FBBA60C48160F8ADB3A1D418DBB" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward_4B9F3FBBA60C48160F8ADB3A1D418DBB" xlink:type="arc" />
<link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_7C2B091AEAAD05CE0854DB3A1D412BFB_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_7C2B091AEAAD05CE0854DB3A1D412BFB" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Weighted average exercise price, options outstanding, start of year (in USD per share)</link:label>
<link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_7C2B091AEAAD05CE0854DB3A1D412BFB_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_7C2B091AEAAD05CE0854DB3A1D412BFB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price</link:label>
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_7C2B091AEAAD05CE0854DB3A1D412BFB" xlink:type="locator" />
<link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_7C2B091AEAAD05CE0854DB3A1D412BFB" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_7C2B091AEAAD05CE0854DB3A1D412BFB" xlink:type="arc" />
<link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_C548497D931A0EFC9286DB3A1D41B655_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_C548497D931A0EFC9286DB3A1D41B655" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Exercised (in USD per share)</link:label>
<link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_C548497D931A0EFC9286DB3A1D41B655_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_C548497D931A0EFC9286DB3A1D41B655" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price</link:label>
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_C548497D931A0EFC9286DB3A1D41B655" xlink:type="locator" />
<link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_C548497D931A0EFC9286DB3A1D41B655" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_C548497D931A0EFC9286DB3A1D41B655" xlink:type="arc" />
<link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_C72156D9E6E28AD2A505DB3A1D4210CF_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_C72156D9E6E28AD2A505DB3A1D4210CF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Expired or forfeited (in USD per share)</link:label>
<link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_C72156D9E6E28AD2A505DB3A1D4210CF_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_C72156D9E6E28AD2A505DB3A1D4210CF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price</link:label>
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_C72156D9E6E28AD2A505DB3A1D4210CF" xlink:type="locator" />
<link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_C72156D9E6E28AD2A505DB3A1D4210CF" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_C72156D9E6E28AD2A505DB3A1D4210CF" xlink:type="arc" />
<link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_B5268C8D1DAA6FA9D625DB3A1D4283CF_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_B5268C8D1DAA6FA9D625DB3A1D4283CF" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Weighted average exercise price, options outstanding, end of year (in USD per share)</link:label>
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_B5268C8D1DAA6FA9D625DB3A1D4283CF" xlink:type="locator" />
<link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_B5268C8D1DAA6FA9D625DB3A1D4283CF" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_B5268C8D1DAA6FA9D625DB3A1D4283CF" xlink:type="arc" />
<link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_7CE89DCD55E99B216EC8DB3A1D423EDB_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_7CE89DCD55E99B216EC8DB3A1D423EDB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Vested, end of year (in USD per share)</link:label>
<link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_7CE89DCD55E99B216EC8DB3A1D423EDB_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_7CE89DCD55E99B216EC8DB3A1D423EDB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price</link:label>
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_7CE89DCD55E99B216EC8DB3A1D423EDB" xlink:type="locator" />
<link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_7CE89DCD55E99B216EC8DB3A1D423EDB" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_7CE89DCD55E99B216EC8DB3A1D423EDB" xlink:type="arc" />
<link:label id="lab_immu_WeightedaverageremainingcontractualtermyearsRollForward_FBC1992349DF0CC00340DB3A1D42BB0C_terseLabel_en-US" xlink:label="lab_immu_WeightedaverageremainingcontractualtermyearsRollForward_FBC1992349DF0CC00340DB3A1D42BB0C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted average remaining contractual term (years) [Roll Forward]</link:label>
<link:label id="lab_immu_WeightedaverageremainingcontractualtermyearsRollForward_FBC1992349DF0CC00340DB3A1D42BB0C_label_en-US" xlink:label="lab_immu_WeightedaverageremainingcontractualtermyearsRollForward_FBC1992349DF0CC00340DB3A1D42BB0C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted average remaining contractual term (years) [Roll Forward]</link:label>
<link:label id="lab_immu_WeightedaverageremainingcontractualtermyearsRollForward_FBC1992349DF0CC00340DB3A1D42BB0C_documentation_en-US" xlink:label="lab_immu_WeightedaverageremainingcontractualtermyearsRollForward_FBC1992349DF0CC00340DB3A1D42BB0C" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Weighted average remaining contractual term (years) [Roll Forward]</link:label>
<link:loc xlink:href="immu-20191231.xsd#immu_WeightedaverageremainingcontractualtermyearsRollForward" xlink:label="loc_immu_WeightedaverageremainingcontractualtermyearsRollForward_FBC1992349DF0CC00340DB3A1D42BB0C" xlink:type="locator" />
<link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_immu_WeightedaverageremainingcontractualtermyearsRollForward_FBC1992349DF0CC00340DB3A1D42BB0C" xlink:to="lab_immu_WeightedaverageremainingcontractualtermyearsRollForward_FBC1992349DF0CC00340DB3A1D42BB0C" xlink:type="arc" />
<link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_B922E1ABDA68C98CBF59DB3A1D42CD9F_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_B922E1ABDA68C98CBF59DB3A1D42CD9F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted average remaining contractual term</link:label>
<link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_B922E1ABDA68C98CBF59DB3A1D42CD9F_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_B922E1ABDA68C98CBF59DB3A1D42CD9F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term</link:label>
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_B922E1ABDA68C98CBF59DB3A1D42CD9F" xlink:type="locator" />
<link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_B922E1ABDA68C98CBF59DB3A1D42CD9F" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_B922E1ABDA68C98CBF59DB3A1D42CD9F" xlink:type="arc" />
<link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_EE9E951C68225F1ECE98DB3A1D4314FC_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_EE9E951C68225F1ECE98DB3A1D4314FC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted average remaining contractual term, end of year</link:label>
<link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_EE9E951C68225F1ECE98DB3A1D4314FC_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_EE9E951C68225F1ECE98DB3A1D4314FC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term</link:label>
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_EE9E951C68225F1ECE98DB3A1D4314FC" xlink:type="locator" />
<link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_EE9E951C68225F1ECE98DB3A1D4314FC" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_EE9E951C68225F1ECE98DB3A1D4314FC" xlink:type="arc" />
<link:label id="lab_immu_IntrinsicvalueRollForward_4303B084DCECAA9F2D34DB3A1D43AD3C_terseLabel_en-US" xlink:label="lab_immu_IntrinsicvalueRollForward_4303B084DCECAA9F2D34DB3A1D43AD3C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Intrinsic value [Roll Forward]</link:label>
<link:label id="lab_immu_IntrinsicvalueRollForward_4303B084DCECAA9F2D34DB3A1D43AD3C_label_en-US" xlink:label="lab_immu_IntrinsicvalueRollForward_4303B084DCECAA9F2D34DB3A1D43AD3C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Intrinsic value [Roll Forward]</link:label>
<link:label id="lab_immu_IntrinsicvalueRollForward_4303B084DCECAA9F2D34DB3A1D43AD3C_documentation_en-US" xlink:label="lab_immu_IntrinsicvalueRollForward_4303B084DCECAA9F2D34DB3A1D43AD3C" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Intrinsic value [Roll Forward]</link:label>
<link:loc xlink:href="immu-20191231.xsd#immu_IntrinsicvalueRollForward" xlink:label="loc_immu_IntrinsicvalueRollForward_4303B084DCECAA9F2D34DB3A1D43AD3C" xlink:type="locator" />
<link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_immu_IntrinsicvalueRollForward_4303B084DCECAA9F2D34DB3A1D43AD3C" xlink:to="lab_immu_IntrinsicvalueRollForward_4303B084DCECAA9F2D34DB3A1D43AD3C" xlink:type="arc" />
<link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_C7C792C30FEB260E2FB7DB3A1D4366B4_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_C7C792C30FEB260E2FB7DB3A1D4366B4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Options, outstanding, intrinsic value</link:label>
<link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_C7C792C30FEB260E2FB7DB3A1D4366B4_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_C7C792C30FEB260E2FB7DB3A1D4366B4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value</link:label>
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_C7C792C30FEB260E2FB7DB3A1D4366B4" xlink:type="locator" />
<link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_C7C792C30FEB260E2FB7DB3A1D4366B4" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_C7C792C30FEB260E2FB7DB3A1D4366B4" xlink:type="arc" />
<link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_4C380E9857667B9DB0C4DB3A1D4374D9_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_4C380E9857667B9DB0C4DB3A1D4374D9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Options, vested, outstanding, intrinsic value end of year</link:label>
<link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_4C380E9857667B9DB0C4DB3A1D4374D9_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_4C380E9857667B9DB0C4DB3A1D4374D9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value</link:label>
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_4C380E9857667B9DB0C4DB3A1D4374D9" xlink:type="locator" />
<link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_4C380E9857667B9DB0C4DB3A1D4374D9" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_4C380E9857667B9DB0C4DB3A1D4374D9" xlink:type="arc" />
<link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_9BDD3CBF16CEC1159BB5DB3A5B4658DD_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_9BDD3CBF16CEC1159BB5DB3A5B4658DD" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Expected dividend yield</link:label>
<link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_9BDD3CBF16CEC1159BB5DB3A5B4658DD_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_9BDD3CBF16CEC1159BB5DB3A5B4658DD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate</link:label>
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_9BDD3CBF16CEC1159BB5DB3A5B4658DD" xlink:type="locator" />
<link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_9BDD3CBF16CEC1159BB5DB3A5B4658DD" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_9BDD3CBF16CEC1159BB5DB3A5B4658DD" xlink:type="arc" />
<link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_D0587A8AAF695E71C278DB3A5B46557E_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_D0587A8AAF695E71C278DB3A5B46557E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Expected option term (years)</link:label>
<link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_D0587A8AAF695E71C278DB3A5B46557E_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_D0587A8AAF695E71C278DB3A5B46557E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term</link:label>
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_D0587A8AAF695E71C278DB3A5B46557E" xlink:type="locator" />
<link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_D0587A8AAF695E71C278DB3A5B46557E" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_D0587A8AAF695E71C278DB3A5B46557E" xlink:type="arc" />
<link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_9E0D51C039E5D2138D14DB3A5B477571_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_9E0D51C039E5D2138D14DB3A5B477571" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Expected stock price volatility</link:label>
<link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_9E0D51C039E5D2138D14DB3A5B477571_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_9E0D51C039E5D2138D14DB3A5B477571" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate</link:label>
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_9E0D51C039E5D2138D14DB3A5B477571" xlink:type="locator" />
<link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_9E0D51C039E5D2138D14DB3A5B477571" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_9E0D51C039E5D2138D14DB3A5B477571" xlink:type="arc" />
<link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_59E1D67A98DAD414A740DB3A5B4734D7_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_59E1D67A98DAD414A740DB3A5B4734D7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Risk-free interest rate</link:label>
<link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_59E1D67A98DAD414A740DB3A5B4734D7_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_59E1D67A98DAD414A740DB3A5B4734D7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate</link:label>
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_59E1D67A98DAD414A740DB3A5B4734D7" xlink:type="locator" />
<link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_59E1D67A98DAD414A740DB3A5B4734D7" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_59E1D67A98DAD414A740DB3A5B4734D7" xlink:type="arc" />
<link:label id="lab_us-gaap_PropertyPlantAndEquipmentAbstract_F28A057436C61B6FC6B4D1D062254A38_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentAbstract_F28A057436C61B6FC6B4D1D062254A38" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment [Abstract]</link:label>
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_F28A057436C61B6FC6B4D1D062254A38" xlink:type="locator" />
<link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_F28A057436C61B6FC6B4D1D062254A38" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentAbstract_F28A057436C61B6FC6B4D1D062254A38" xlink:type="arc" />
<link:label id="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_107C98C8C33F9443645BD1D062250447_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_107C98C8C33F9443645BD1D062250447" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Summary of Property and Equipment</link:label>
<link:label id="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_107C98C8C33F9443645BD1D062250447_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_107C98C8C33F9443645BD1D062250447" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment [Table Text Block]</link:label>
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_107C98C8C33F9443645BD1D062250447" xlink:type="locator" />
<link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_107C98C8C33F9443645BD1D062250447" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_107C98C8C33F9443645BD1D062250447" xlink:type="arc" />
<link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_C708FA86EF0DC060F4FD850F48C1790F_label_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract_C708FA86EF0DC060F4FD850F48C1790F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_C708FA86EF0DC060F4FD850F48C1790F" xlink:type="locator" />
<link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_C708FA86EF0DC060F4FD850F48C1790F" xlink:to="lab_us-gaap_StatementOfCashFlowsAbstract_C708FA86EF0DC060F4FD850F48C1790F" xlink:type="arc" />
<link:label id="lab_us-gaap_StatementTable_3AB4C66D03C7F0454A1F850F48C152DA_terseLabel_en-US" xlink:label="lab_us-gaap_StatementTable_3AB4C66D03C7F0454A1F850F48C152DA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statement [Table]</link:label>
<link:label id="lab_us-gaap_StatementTable_3AB4C66D03C7F0454A1F850F48C152DA_label_en-US" xlink:label="lab_us-gaap_StatementTable_3AB4C66D03C7F0454A1F850F48C152DA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement [Table]</link:label>
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_3AB4C66D03C7F0454A1F850F48C152DA" xlink:type="locator" />
<link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementTable_3AB4C66D03C7F0454A1F850F48C152DA" xlink:to="lab_us-gaap_StatementTable_3AB4C66D03C7F0454A1F850F48C152DA" xlink:type="arc" />
<link:label id="lab_us-gaap_SubsidiarySaleOfStockAxis_28ADC66E74A7501C8244850F48C13309_terseLabel_en-US" xlink:label="lab_us-gaap_SubsidiarySaleOfStockAxis_28ADC66E74A7501C8244850F48C13309" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Sale of Stock [Axis]</link:label>
<link:label id="lab_us-gaap_SubsidiarySaleOfStockAxis_28ADC66E74A7501C8244850F48C13309_label_en-US" xlink:label="lab_us-gaap_SubsidiarySaleOfStockAxis_28ADC66E74A7501C8244850F48C13309" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sale of Stock [Axis]</link:label>
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_28ADC66E74A7501C8244850F48C13309" xlink:type="locator" />
<link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_28ADC66E74A7501C8244850F48C13309" xlink:to="lab_us-gaap_SubsidiarySaleOfStockAxis_28ADC66E74A7501C8244850F48C13309" xlink:type="arc" />
<link:label id="lab_us-gaap_SaleOfStockNameOfTransactionDomain_1E421A88D26CAAB15566850F48C19054_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockNameOfTransactionDomain_1E421A88D26CAAB15566850F48C19054" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Sale of Stock [Domain]</link:label>
<link:label id="lab_us-gaap_SaleOfStockNameOfTransactionDomain_1E421A88D26CAAB15566850F48C19054_label_en-US" xlink:label="lab_us-gaap_SaleOfStockNameOfTransactionDomain_1E421A88D26CAAB15566850F48C19054" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sale of Stock [Domain]</link:label>
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_1E421A88D26CAAB15566850F48C19054" xlink:type="locator" />
<link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_1E421A88D26CAAB15566850F48C19054" xlink:to="lab_us-gaap_SaleOfStockNameOfTransactionDomain_1E421A88D26CAAB15566850F48C19054" xlink:type="arc" />
<link:label id="lab_immu_MarketOfferingMember_2E1EC3A1C131BAD4AE9F850F48C21EC1_terseLabel_en-US" xlink:label="lab_immu_MarketOfferingMember_2E1EC3A1C131BAD4AE9F850F48C21EC1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Market Offering</link:label>
<link:label id="lab_immu_MarketOfferingMember_2E1EC3A1C131BAD4AE9F850F48C21EC1_label_en-US" xlink:label="lab_immu_MarketOfferingMember_2E1EC3A1C131BAD4AE9F850F48C21EC1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Market Offering [Member]</link:label>
<link:label id="lab_immu_MarketOfferingMember_2E1EC3A1C131BAD4AE9F850F48C21EC1_documentation_en-US" xlink:label="lab_immu_MarketOfferingMember_2E1EC3A1C131BAD4AE9F850F48C21EC1" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Market Offering [Member]</link:label>
<link:loc xlink:href="immu-20191231.xsd#immu_MarketOfferingMember" xlink:label="loc_immu_MarketOfferingMember_2E1EC3A1C131BAD4AE9F850F48C21EC1" xlink:type="locator" />
<link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_immu_MarketOfferingMember_2E1EC3A1C131BAD4AE9F850F48C21EC1" xlink:to="lab_immu_MarketOfferingMember_2E1EC3A1C131BAD4AE9F850F48C21EC1" xlink:type="arc" />
<link:label id="lab_us-gaap_PrivatePlacementMember_CAAF9AE49E1DC83F3422850F48C2C4ED_terseLabel_en-US" xlink:label="lab_us-gaap_PrivatePlacementMember_CAAF9AE49E1DC83F3422850F48C2C4ED" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Private placement</link:label>
<link:label id="lab_us-gaap_PrivatePlacementMember_CAAF9AE49E1DC83F3422850F48C2C4ED_label_en-US" xlink:label="lab_us-gaap_PrivatePlacementMember_CAAF9AE49E1DC83F3422850F48C2C4ED" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Private Placement [Member]</link:label>
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PrivatePlacementMember" xlink:label="loc_us-gaap_PrivatePlacementMember_CAAF9AE49E1DC83F3422850F48C2C4ED" xlink:type="locator" />
<link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrivatePlacementMember_CAAF9AE49E1DC83F3422850F48C2C4ED" xlink:to="lab_us-gaap_PrivatePlacementMember_CAAF9AE49E1DC83F3422850F48C2C4ED" xlink:type="arc" />
<link:label id="lab_us-gaap_StatementLineItems_D98B9FD5B538F7B7C6D6850F48C286FA_terseLabel_en-US" xlink:label="lab_us-gaap_StatementLineItems_D98B9FD5B538F7B7C6D6850F48C286FA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statement [Line Items]</link:label>
<link:label id="lab_us-gaap_StatementLineItems_D98B9FD5B538F7B7C6D6850F48C286FA_label_en-US" xlink:label="lab_us-gaap_StatementLineItems_D98B9FD5B538F7B7C6D6850F48C286FA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement [Line Items]</link:label>
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_D98B9FD5B538F7B7C6D6850F48C286FA" xlink:type="locator" />
<link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementLineItems_D98B9FD5B538F7B7C6D6850F48C286FA" xlink:to="lab_us-gaap_StatementLineItems_D98B9FD5B538F7B7C6D6850F48C286FA" xlink:type="arc" />
<link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_5A41C9BE0A0408732CB3850F48C2A86A_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_5A41C9BE0A0408732CB3850F48C2A86A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash flows from operating activities:</link:label>
<link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_5A41C9BE0A0408732CB3850F48C2A86A_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_5A41C9BE0A0408732CB3850F48C2A86A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_5A41C9BE0A0408732CB3850F48C2A86A" xlink:type="locator" />
<link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_5A41C9BE0A0408732CB3850F48C2A86A" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_5A41C9BE0A0408732CB3850F48C2A86A" xlink:type="arc" />
<link:label id="lab_us-gaap_ProfitLoss_B1A96B0FB036EA0AAFB3850F48C39A43_terseLabel_en-US" xlink:label="lab_us-gaap_ProfitLoss_B1A96B0FB036EA0AAFB3850F48C39A43" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net loss</link:label>
<link:label id="lab_us-gaap_ProfitLoss_B1A96B0FB036EA0AAFB3850F48C39A43_label_en-US" xlink:label="lab_us-gaap_ProfitLoss_B1A96B0FB036EA0AAFB3850F48C39A43" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Income (Loss), Including Portion Attributable to Noncontrolling Interest</link:label>
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProfitLoss" xlink:label="loc_us-gaap_ProfitLoss_B1A96B0FB036EA0AAFB3850F48C39A43" xlink:type="locator" />
<link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProfitLoss_B1A96B0FB036EA0AAFB3850F48C39A43" xlink:to="lab_us-gaap_ProfitLoss_B1A96B0FB036EA0AAFB3850F48C39A43" xlink:type="arc" />
<link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_3F0C2A970F792AD09A03850F48C368FE_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_3F0C2A970F792AD09A03850F48C368FE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Adjustments to reconcile net loss to net cash used in operating activities:</link:label>
<link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_3F0C2A970F792AD09A03850F48C368FE_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_3F0C2A970F792AD09A03850F48C368FE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_3F0C2A970F792AD09A03850F48C368FE" xlink:type="locator" />
<link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_3F0C2A970F792AD09A03850F48C368FE" xlink:to="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_3F0C2A970F792AD09A03850F48C368FE" xlink:type="arc" />
<link:label id="lab_us-gaap_FairValueAdjustmentOfWarrants_3E46BF4294D11B252086850F48C3330B_verboseLabel_en-US" xlink:label="lab_us-gaap_FairValueAdjustmentOfWarrants_3E46BF4294D11B252086850F48C3330B" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Changes in fair value of warrant liabilities</link:label>
<link:label id="lab_us-gaap_FairValueAdjustmentOfWarrants_3E46BF4294D11B252086850F48C3330B_label_en-US" xlink:label="lab_us-gaap_FairValueAdjustmentOfWarrants_3E46BF4294D11B252086850F48C3330B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Adjustment of Warrants</link:label>
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="loc_us-gaap_FairValueAdjustmentOfWarrants_3E46BF4294D11B252086850F48C3330B" xlink:type="locator" />
<link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAdjustmentOfWarrants_3E46BF4294D11B252086850F48C3330B" xlink:to="lab_us-gaap_FairValueAdjustmentOfWarrants_3E46BF4294D11B252086850F48C3330B" xlink:type="arc" />
<link:label id="lab_us-gaap_AdjustmentOfWarrantsGrantedForServices_C556857E0EB81C7DF87B850F48C34FAD_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentOfWarrantsGrantedForServices_C556857E0EB81C7DF87B850F48C34FAD" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Warrant related expense</link:label>
<link:label id="lab_us-gaap_AdjustmentOfWarrantsGrantedForServices_C556857E0EB81C7DF87B850F48C34FAD_label_en-US" xlink:label="lab_us-gaap_AdjustmentOfWarrantsGrantedForServices_C556857E0EB81C7DF87B850F48C34FAD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustment of Warrants Granted for Services</link:label>
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdjustmentOfWarrantsGrantedForServices" xlink:label="loc_us-gaap_AdjustmentOfWarrantsGrantedForServices_C556857E0EB81C7DF87B850F48C34FAD" xlink:type="locator" />
<link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentOfWarrantsGrantedForServices_C556857E0EB81C7DF87B850F48C34FAD" xlink:to="lab_us-gaap_AdjustmentOfWarrantsGrantedForServices_C556857E0EB81C7DF87B850F48C34FAD" xlink:type="arc" />
<link:label id="lab_us-gaap_DepreciationAndAmortization_185656F56B677453935C850F48C4D0C0_terseLabel_en-US" xlink:label="lab_us-gaap_DepreciationAndAmortization_185656F56B677453935C850F48C4D0C0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Depreciation and amortization</link:label>
<link:label id="lab_us-gaap_DepreciationAndAmortization_185656F56B677453935C850F48C4D0C0_label_en-US" xlink:label="lab_us-gaap_DepreciationAndAmortization_185656F56B677453935C850F48C4D0C0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Depreciation, Depletion and Amortization, Nonproduction</link:label>
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DepreciationAndAmortization" xlink:label="loc_us-gaap_DepreciationAndAmortization_185656F56B677453935C850F48C4D0C0" xlink:type="locator" />
<link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DepreciationAndAmortization_185656F56B677453935C850F48C4D0C0" xlink:to="lab_us-gaap_DepreciationAndAmortization_185656F56B677453935C850F48C4D0C0" xlink:type="arc" />
<link:label id="lab_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_01D54B5BE28D507922C1850F48C44FB8_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_01D54B5BE28D507922C1850F48C44FB8" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Loss on disposal of property and equipment</link:label>
<link:label id="lab_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_01D54B5BE28D507922C1850F48C44FB8_label_en-US" xlink:label="lab_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_01D54B5BE28D507922C1850F48C44FB8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Gain (Loss) on Disposition of Property Plant Equipment</link:label>
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:label="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_01D54B5BE28D507922C1850F48C44FB8" xlink:type="locator" />
<link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_01D54B5BE28D507922C1850F48C44FB8" xlink:to="lab_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_01D54B5BE28D507922C1850F48C44FB8" xlink:type="arc" />
<link:label id="lab_us-gaap_InterestExpenseDebt_9316FB172638206F425A850F48C4891A_terseLabel_en-US" xlink:label="lab_us-gaap_InterestExpenseDebt_9316FB172638206F425A850F48C4891A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Interest on non-recourse debt</link:label>
<link:label id="lab_us-gaap_InterestExpenseDebt_9316FB172638206F425A850F48C4891A_label_en-US" xlink:label="lab_us-gaap_InterestExpenseDebt_9316FB172638206F425A850F48C4891A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interest Expense, Debt</link:label>
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InterestExpenseDebt" xlink:label="loc_us-gaap_InterestExpenseDebt_9316FB172638206F425A850F48C4891A" xlink:type="locator" />
<link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestExpenseDebt_9316FB172638206F425A850F48C4891A" xlink:to="lab_us-gaap_InterestExpenseDebt_9316FB172638206F425A850F48C4891A" xlink:type="arc" />
<link:label id="lab_immu_LossOnInducedExchangesOfDebt_AE678E273FB7136C2943850F48C4BC3B_terseLabel_en-US" xlink:label="lab_immu_LossOnInducedExchangesOfDebt_AE678E273FB7136C2943850F48C4BC3B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Loss on induced exchanges of debt</link:label>
<link:label id="lab_immu_LossOnInducedExchangesOfDebt_AE678E273FB7136C2943850F48C4BC3B_label_en-US" xlink:label="lab_immu_LossOnInducedExchangesOfDebt_AE678E273FB7136C2943850F48C4BC3B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Loss On Induced Exchanges Of Debt</link:label>
<link:label id="lab_immu_LossOnInducedExchangesOfDebt_AE678E273FB7136C2943850F48C4BC3B_documentation_en-US" xlink:label="lab_immu_LossOnInducedExchangesOfDebt_AE678E273FB7136C2943850F48C4BC3B" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Loss On Induced Exchanges Of Debt</link:label>
<link:loc xlink:href="immu-20191231.xsd#immu_LossOnInducedExchangesOfDebt" xlink:label="loc_immu_LossOnInducedExchangesOfDebt_AE678E273FB7136C2943850F48C4BC3B" xlink:type="locator" />
<link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_immu_LossOnInducedExchangesOfDebt_AE678E273FB7136C2943850F48C4BC3B" xlink:to="lab_immu_LossOnInducedExchangesOfDebt_AE678E273FB7136C2943850F48C4BC3B" xlink:type="arc" />
<link:label id="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_79FFA159748CE593C81E850F48C4DE92_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_79FFA159748CE593C81E850F48C4DE92" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Amortization of deferred revenue</link:label>
<link:label id="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_79FFA159748CE593C81E850F48C4DE92_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_79FFA159748CE593C81E850F48C4DE92" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contract with Customer, Liability, Revenue Recognized</link:label>
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_79FFA159748CE593C81E850F48C4DE92" xlink:type="locator" />
<link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_79FFA159748CE593C81E850F48C4DE92" xlink:to="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_79FFA159748CE593C81E850F48C4DE92" xlink:type="arc" />
<link:label id="lab_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_DA87B72F3CBD78D5C8EE850F48C4BBB4_negatedLabel_en-US" xlink:label="lab_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_DA87B72F3CBD78D5C8EE850F48C4BBB4" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Amortization of bond premiums</link:label>
<link:label id="lab_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_DA87B72F3CBD78D5C8EE850F48C4BBB4_label_en-US" xlink:label="lab_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_DA87B72F3CBD78D5C8EE850F48C4BBB4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accretion (Amortization) of Discounts and Premiums, Investments</link:label>
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:label="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_DA87B72F3CBD78D5C8EE850F48C4BBB4" xlink:type="locator" />
<link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_DA87B72F3CBD78D5C8EE850F48C4BBB4" xlink:to="lab_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_DA87B72F3CBD78D5C8EE850F48C4BBB4" xlink:type="arc" />
<link:label id="lab_us-gaap_AmortizationOfFinancingCosts_5AE5033CD6F7EE6A94E9850F48C444BB_terseLabel_en-US" xlink:label="lab_us-gaap_AmortizationOfFinancingCosts_5AE5033CD6F7EE6A94E9850F48C444BB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amortization of debt issuance costs</link:label>
<link:label id="lab_us-gaap_AmortizationOfFinancingCosts_5AE5033CD6F7EE6A94E9850F48C444BB_label_en-US" xlink:label="lab_us-gaap_AmortizationOfFinancingCosts_5AE5033CD6F7EE6A94E9850F48C444BB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amortization of Debt Issuance Costs</link:label>
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AmortizationOfFinancingCosts" xlink:label="loc_us-gaap_AmortizationOfFinancingCosts_5AE5033CD6F7EE6A94E9850F48C444BB" xlink:type="locator" />
<link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AmortizationOfFinancingCosts_5AE5033CD6F7EE6A94E9850F48C444BB" xlink:to="lab_us-gaap_AmortizationOfFinancingCosts_5AE5033CD6F7EE6A94E9850F48C444BB" xlink:type="arc" />
<link:label id="lab_us-gaap_IncreaseDecreaseInDeferredCharges_E6514D657E24BFD55B22850F48C5D684_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInDeferredCharges_E6514D657E24BFD55B22850F48C5D684" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Amortization of deferred rent</link:label>
<link:label id="lab_us-gaap_IncreaseDecreaseInDeferredCharges_E6514D657E24BFD55B22850F48C5D684_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInDeferredCharges_E6514D657E24BFD55B22850F48C5D684" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Deferred Charges</link:label>
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInDeferredCharges" xlink:label="loc_us-gaap_IncreaseDecreaseInDeferredCharges_E6514D657E24BFD55B22850F48C5D684" xlink:type="locator" />
<link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInDeferredCharges_E6514D657E24BFD55B22850F48C5D684" xlink:to="lab_us-gaap_IncreaseDecreaseInDeferredCharges_E6514D657E24BFD55B22850F48C5D684" xlink:type="arc" />
<link:label id="lab_us-gaap_FinanceLeaseRightOfUseAssetAmortization_2B90A1F77421510BBBD9850F48C5A717_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseRightOfUseAssetAmortization_2B90A1F77421510BBBD9850F48C5A717" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-cash lease expense</link:label>
<link:label id="lab_us-gaap_FinanceLeaseRightOfUseAssetAmortization_2B90A1F77421510BBBD9850F48C5A717_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseRightOfUseAssetAmortization_2B90A1F77421510BBBD9850F48C5A717" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finance Lease, Right-of-Use Asset, Amortization</link:label>
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FinanceLeaseRightOfUseAssetAmortization" xlink:label="loc_us-gaap_FinanceLeaseRightOfUseAssetAmortization_2B90A1F77421510BBBD9850F48C5A717" xlink:type="locator" />
<link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseRightOfUseAssetAmortization_2B90A1F77421510BBBD9850F48C5A717" xlink:to="lab_us-gaap_FinanceLeaseRightOfUseAssetAmortization_2B90A1F77421510BBBD9850F48C5A717" xlink:type="arc" />
<link:label id="lab_us-gaap_DebtAndEquitySecuritiesGainLoss_573F1A7A06C80AE2E16E850F48C5BCBB_negatedLabel_en-US" xlink:label="lab_us-gaap_DebtAndEquitySecuritiesGainLoss_573F1A7A06C80AE2E16E850F48C5BCBB" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Loss on sale of marketable securities</link:label>
<link:label id="lab_us-gaap_DebtAndEquitySecuritiesGainLoss_573F1A7A06C80AE2E16E850F48C5BCBB_label_en-US" xlink:label="lab_us-gaap_DebtAndEquitySecuritiesGainLoss_573F1A7A06C80AE2E16E850F48C5BCBB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt and Equity Securities, Gain (Loss)</link:label>
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtAndEquitySecuritiesGainLoss" xlink:label="loc_us-gaap_DebtAndEquitySecuritiesGainLoss_573F1A7A06C80AE2E16E850F48C5BCBB" xlink:type="locator" />
<link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtAndEquitySecuritiesGainLoss_573F1A7A06C80AE2E16E850F48C5BCBB" xlink:to="lab_us-gaap_DebtAndEquitySecuritiesGainLoss_573F1A7A06C80AE2E16E850F48C5BCBB" xlink:type="arc" />
<link:label id="lab_us-gaap_ProvisionForDoubtfulAccounts_BD5AB4E81564CAED13D6850F48C5C45A_terseLabel_en-US" xlink:label="lab_us-gaap_ProvisionForDoubtfulAccounts_BD5AB4E81564CAED13D6850F48C5C45A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Decrease in allowance for doubtful accounts</link:label>
<link:label id="lab_us-gaap_ProvisionForDoubtfulAccounts_BD5AB4E81564CAED13D6850F48C5C45A_label_en-US" xlink:label="lab_us-gaap_ProvisionForDoubtfulAccounts_BD5AB4E81564CAED13D6850F48C5C45A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounts Receivable, Credit Loss Expense (Reversal)</link:label>
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProvisionForDoubtfulAccounts" xlink:label="loc_us-gaap_ProvisionForDoubtfulAccounts_BD5AB4E81564CAED13D6850F48C5C45A" xlink:type="locator" />
<link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProvisionForDoubtfulAccounts_BD5AB4E81564CAED13D6850F48C5C45A" xlink:to="lab_us-gaap_ProvisionForDoubtfulAccounts_BD5AB4E81564CAED13D6850F48C5C45A" xlink:type="arc" />
<link:label id="lab_us-gaap_ShareBasedCompensation_BDC67034B1822EF503FE850F48C512B6_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation_BDC67034B1822EF503FE850F48C512B6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-cash expense related to stock-based compensation</link:label>
<link:label id="lab_us-gaap_ShareBasedCompensation_BDC67034B1822EF503FE850F48C512B6_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation_BDC67034B1822EF503FE850F48C512B6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Payment Arrangement, Noncash Expense</link:label>
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaap_ShareBasedCompensation_BDC67034B1822EF503FE850F48C512B6" xlink:type="locator" />
<link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensation_BDC67034B1822EF503FE850F48C512B6" xlink:to="lab_us-gaap_ShareBasedCompensation_BDC67034B1822EF503FE850F48C512B6" xlink:type="arc" />
<link:label id="lab_us-gaap_OtherNoncashExpense_F4B666EF61B22134B65D850F48C68208_terseLabel_en-US" xlink:label="lab_us-gaap_OtherNoncashExpense_F4B666EF61B22134B65D850F48C68208" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-cash financing expenses</link:label>
<link:label id="lab_us-gaap_OtherNoncashExpense_F4B666EF61B22134B65D850F48C68208_label_en-US" xlink:label="lab_us-gaap_OtherNoncashExpense_F4B666EF61B22134B65D850F48C68208" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Noncash Expense</link:label>
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherNoncashExpense" xlink:label="loc_us-gaap_OtherNoncashExpense_F4B666EF61B22134B65D850F48C68208" xlink:type="locator" />
<link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNoncashExpense_F4B666EF61B22134B65D850F48C68208" xlink:to="lab_us-gaap_OtherNoncashExpense_F4B666EF61B22134B65D850F48C68208" xlink:type="arc" />
<link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_6812207EE24F0446651D850F48C67CDF_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_6812207EE24F0446651D850F48C67CDF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Changes in operating assets and liabilities</link:label>
<link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_6812207EE24F0446651D850F48C67CDF_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_6812207EE24F0446651D850F48C67CDF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Operating Capital [Abstract]</link:label>
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_6812207EE24F0446651D850F48C67CDF" xlink:type="locator" />
<link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_6812207EE24F0446651D850F48C67CDF" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_6812207EE24F0446651D850F48C67CDF" xlink:type="arc" />
<link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_3FFDE7E6BD89D01E7FFE850F48C62427_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_3FFDE7E6BD89D01E7FFE850F48C62427" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Accounts receivable, net</link:label>
<link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_3FFDE7E6BD89D01E7FFE850F48C62427_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_3FFDE7E6BD89D01E7FFE850F48C62427" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Accounts Receivable</link:label>
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_3FFDE7E6BD89D01E7FFE850F48C62427" xlink:type="locator" />
<link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_3FFDE7E6BD89D01E7FFE850F48C62427" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_3FFDE7E6BD89D01E7FFE850F48C62427" xlink:type="arc" />
<link:label id="lab_us-gaap_IncreaseDecreaseInInventories_58AAE17805E1049E5608850F48C6AA76_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInInventories_58AAE17805E1049E5608850F48C6AA76" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Inventories, net</link:label>
<link:label id="lab_us-gaap_IncreaseDecreaseInInventories_58AAE17805E1049E5608850F48C6AA76_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInInventories_58AAE17805E1049E5608850F48C6AA76" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Inventories</link:label>
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInInventories" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories_58AAE17805E1049E5608850F48C6AA76" xlink:type="locator" />
<link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInInventories_58AAE17805E1049E5608850F48C6AA76" xlink:to="lab_us-gaap_IncreaseDecreaseInInventories_58AAE17805E1049E5608850F48C6AA76" xlink:type="arc" />
<link:label id="lab_us-gaap_IncreaseDecreaseInOtherReceivables_7B7CE881622B2AD67A2C850F48C6AC1A_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherReceivables_7B7CE881622B2AD67A2C850F48C6AC1A" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Other receivables</link:label>
<link:label id="lab_us-gaap_IncreaseDecreaseInOtherReceivables_7B7CE881622B2AD67A2C850F48C6AC1A_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherReceivables_7B7CE881622B2AD67A2C850F48C6AC1A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Other Receivables</link:label>
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInOtherReceivables" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherReceivables_7B7CE881622B2AD67A2C850F48C6AC1A" xlink:type="locator" />
<link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherReceivables_7B7CE881622B2AD67A2C850F48C6AC1A" xlink:to="lab_us-gaap_IncreaseDecreaseInOtherReceivables_7B7CE881622B2AD67A2C850F48C6AC1A" xlink:type="arc" />
<link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_5834EA9F1E70AB50369A850F48C6622F_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_5834EA9F1E70AB50369A850F48C6622F" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
<link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_5834EA9F1E70AB50369A850F48C6622F_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_5834EA9F1E70AB50369A850F48C6622F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Prepaid Expense and Other Assets</link:label>
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_5834EA9F1E70AB50369A850F48C6622F" xlink:type="locator" />
<link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_5834EA9F1E70AB50369A850F48C6622F" xlink:to="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_5834EA9F1E70AB50369A850F48C6622F" xlink:type="arc" />
<link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_76A790CC4B7DFFF533C4850F48C730DF_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_76A790CC4B7DFFF533C4850F48C730DF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounts payable and accrued expenses</link:label>
<link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_76A790CC4B7DFFF533C4850F48C730DF_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_76A790CC4B7DFFF533C4850F48C730DF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Accounts Payable and Accrued Liabilities</link:label>
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_76A790CC4B7DFFF533C4850F48C730DF" xlink:type="locator" />
<link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_76A790CC4B7DFFF533C4850F48C730DF" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_76A790CC4B7DFFF533C4850F48C730DF" xlink:type="arc" />
<link:label id="lab_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_CCBD27721B9AEBDE6447850F48C7D5B4_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_CCBD27721B9AEBDE6447850F48C7D5B4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other liabilities</link:label>
<link:label id="lab_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_CCBD27721B9AEBDE6447850F48C7D5B4_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_CCBD27721B9AEBDE6447850F48C7D5B4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Other Operating Liabilities</link:label>
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_CCBD27721B9AEBDE6447850F48C7D5B4" xlink:type="locator" />
<link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_CCBD27721B9AEBDE6447850F48C7D5B4" xlink:to="lab_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_CCBD27721B9AEBDE6447850F48C7D5B4" xlink:type="arc" />
<link:label id="lab_us-gaap_IncreaseDecreaseInDeferredRevenue_EA42B9C922F09160A7A1850F48C768E7_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInDeferredRevenue_EA42B9C922F09160A7A1850F48C768E7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred revenue</link:label>
<link:label id="lab_us-gaap_IncreaseDecreaseInDeferredRevenue_EA42B9C922F09160A7A1850F48C768E7_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInDeferredRevenue_EA42B9C922F09160A7A1850F48C768E7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Deferred Revenue</link:label>
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:label="loc_us-gaap_IncreaseDecreaseInDeferredRevenue_EA42B9C922F09160A7A1850F48C768E7" xlink:type="locator" />
<link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInDeferredRevenue_EA42B9C922F09160A7A1850F48C768E7" xlink:to="lab_us-gaap_IncreaseDecreaseInDeferredRevenue_EA42B9C922F09160A7A1850F48C768E7" xlink:type="arc" />
<link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_EB0D803AA16ABF722606850F48C786BA_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_EB0D803AA16ABF722606850F48C786BA" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net cash used in operating activities</link:label>
<link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_EB0D803AA16ABF722606850F48C786BA_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_EB0D803AA16ABF722606850F48C786BA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</link:label>
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_EB0D803AA16ABF722606850F48C786BA" xlink:type="locator" />
<link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_EB0D803AA16ABF722606850F48C786BA" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_EB0D803AA16ABF722606850F48C786BA" xlink:type="arc" />
<link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_54933EFCB3382B26072D850F48C7DA19_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_54933EFCB3382B26072D850F48C7DA19" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash flows from investing activities:</link:label>
<link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_54933EFCB3382B26072D850F48C7DA19_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_54933EFCB3382B26072D850F48C7DA19" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities [Abstract]</link:label>
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_54933EFCB3382B26072D850F48C7DA19" xlink:type="locator" />
<link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_54933EFCB3382B26072D850F48C7DA19" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_54933EFCB3382B26072D850F48C7DA19" xlink:type="arc" />
<link:label id="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_4884A8A43B8C203596C4850F48C77006_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_4884A8A43B8C203596C4850F48C77006" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Purchases of marketable securities</link:label>
<link:label id="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_4884A8A43B8C203596C4850F48C77006_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_4884A8A43B8C203596C4850F48C77006" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments to Acquire Debt Securities, Available-for-sale</link:label>
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:label="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_4884A8A43B8C203596C4850F48C77006" xlink:type="locator" />
<link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_4884A8A43B8C203596C4850F48C77006" xlink:to="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_4884A8A43B8C203596C4850F48C77006" xlink:type="arc" />
<link:label id="lab_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_15445853E04ED86E9090850F48C8591A_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_15445853E04ED86E9090850F48C8591A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from sales/maturities of marketable securities</link:label>
<link:label id="lab_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_15445853E04ED86E9090850F48C8591A_label_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_15445853E04ED86E9090850F48C8591A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Sale and Maturity of Debt Securities, Available-for-sale</link:label>
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_15445853E04ED86E9090850F48C8591A" xlink:type="locator" />
<link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_15445853E04ED86E9090850F48C8591A" xlink:to="lab_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_15445853E04ED86E9090850F48C8591A" xlink:type="arc" />
<link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_162ECA08E46DC74D63DB850F48C89DE6_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_162ECA08E46DC74D63DB850F48C89DE6" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Purchases of property and equipment</link:label>
<link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_162ECA08E46DC74D63DB850F48C89DE6_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_162ECA08E46DC74D63DB850F48C89DE6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</link:label>
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_162ECA08E46DC74D63DB850F48C89DE6" xlink:type="locator" />
<link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_162ECA08E46DC74D63DB850F48C89DE6" xlink:to="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_162ECA08E46DC74D63DB850F48C89DE6" xlink:type="arc" />
<link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_44B91DD09CE6893D0527850F48C808B6_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_44B91DD09CE6893D0527850F48C808B6" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net cash (used in) provided by investing activities</link:label>
<link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_44B91DD09CE6893D0527850F48C808B6_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_44B91DD09CE6893D0527850F48C808B6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</link:label>
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_44B91DD09CE6893D0527850F48C808B6" xlink:type="locator" />
<link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_44B91DD09CE6893D0527850F48C808B6" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_44B91DD09CE6893D0527850F48C808B6" xlink:type="arc" />
<link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_DB4641840B53276FC068850F48C8D1FE_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_DB4641840B53276FC068850F48C8D1FE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash flows from financing activities:</link:label>
<link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_DB4641840B53276FC068850F48C8D1FE_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_DB4641840B53276FC068850F48C8D1FE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities [Abstract]</link:label>
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_DB4641840B53276FC068850F48C8D1FE" xlink:type="locator" />
<link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_DB4641840B53276FC068850F48C8D1FE" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_DB4641840B53276FC068850F48C8D1FE" xlink:type="arc" />
<link:label id="lab_us-gaap_ProceedsFromStockOptionsExercised_17C53D9E6EE4F9F914EC850F48C82F9F_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromStockOptionsExercised_17C53D9E6EE4F9F914EC850F48C82F9F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Exercise of stock options, net</link:label>
<link:label id="lab_us-gaap_ProceedsFromStockOptionsExercised_17C53D9E6EE4F9F914EC850F48C82F9F_label_en-US" xlink:label="lab_us-gaap_ProceedsFromStockOptionsExercised_17C53D9E6EE4F9F914EC850F48C82F9F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Stock Options Exercised</link:label>
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_17C53D9E6EE4F9F914EC850F48C82F9F" xlink:type="locator" />
<link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromStockOptionsExercised_17C53D9E6EE4F9F914EC850F48C82F9F" xlink:to="lab_us-gaap_ProceedsFromStockOptionsExercised_17C53D9E6EE4F9F914EC850F48C82F9F" xlink:type="arc" />
<link:label id="lab_us-gaap_ProceedsFromWarrantExercises_8CCF5DE880DD0C7C388F850F48C9ECB8_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromWarrantExercises_8CCF5DE880DD0C7C388F850F48C9ECB8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Exercise of warrants</link:label>
<link:label id="lab_us-gaap_ProceedsFromWarrantExercises_8CCF5DE880DD0C7C388F850F48C9ECB8_label_en-US" xlink:label="lab_us-gaap_ProceedsFromWarrantExercises_8CCF5DE880DD0C7C388F850F48C9ECB8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Warrant Exercises</link:label>
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="loc_us-gaap_ProceedsFromWarrantExercises_8CCF5DE880DD0C7C388F850F48C9ECB8" xlink:type="locator" />
<link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromWarrantExercises_8CCF5DE880DD0C7C388F850F48C9ECB8" xlink:to="lab_us-gaap_ProceedsFromWarrantExercises_8CCF5DE880DD0C7C388F850F48C9ECB8" xlink:type="arc" />
<link:label id="lab_us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock_D04F35AF3C633066D370850F48C96BF8_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock_D04F35AF3C633066D370850F48C96BF8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Sale of preferred stock, net of related expenses</link:label>
<link:label id="lab_us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock_D04F35AF3C633066D370850F48C96BF8_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock_D04F35AF3C633066D370850F48C96BF8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Issuance of Preferred Stock and Preference Stock</link:label>
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock_D04F35AF3C633066D370850F48C96BF8" xlink:type="locator" />
<link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock_D04F35AF3C633066D370850F48C96BF8" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock_D04F35AF3C633066D370850F48C96BF8" xlink:type="arc" />
<link:label id="lab_us-gaap_ProceedsFromIssuanceInitialPublicOffering_E69C3BA7AF8AAA0E8A2A850F48C98448_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceInitialPublicOffering_E69C3BA7AF8AAA0E8A2A850F48C98448" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from public offering of common stock</link:label>
<link:label id="lab_us-gaap_ProceedsFromIssuanceInitialPublicOffering_E69C3BA7AF8AAA0E8A2A850F48C98448_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceInitialPublicOffering_E69C3BA7AF8AAA0E8A2A850F48C98448" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Issuance Initial Public Offering</link:label>
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:label="loc_us-gaap_ProceedsFromIssuanceInitialPublicOffering_E69C3BA7AF8AAA0E8A2A850F48C98448" xlink:type="locator" />
<link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceInitialPublicOffering_E69C3BA7AF8AAA0E8A2A850F48C98448" xlink:to="lab_us-gaap_ProceedsFromIssuanceInitialPublicOffering_E69C3BA7AF8AAA0E8A2A850F48C98448" xlink:type="arc" />
<link:label id="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_170286333CFBF7AAE01A850F48C9FC67_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_170286333CFBF7AAE01A850F48C9FC67" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from private offering of common stock</link:label>
<link:label id="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_170286333CFBF7AAE01A850F48C9FC67_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_170286333CFBF7AAE01A850F48C9FC67" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Issuance of Common Stock</link:label>
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_170286333CFBF7AAE01A850F48C9FC67" xlink:type="locator" />
<link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_170286333CFBF7AAE01A850F48C9FC67" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_170286333CFBF7AAE01A850F48C9FC67" xlink:type="arc" />
<link:label id="lab_immu_ProceedsFromIssuanceOfNonRecourseDebt_89A80BEBF0FAF6CAB8E8850F48C96885_terseLabel_en-US" xlink:label="lab_immu_ProceedsFromIssuanceOfNonRecourseDebt_89A80BEBF0FAF6CAB8E8850F48C96885" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from the issuance of non-recourse debt</link:label>
<link:label id="lab_immu_ProceedsFromIssuanceOfNonRecourseDebt_89A80BEBF0FAF6CAB8E8850F48C96885_label_en-US" xlink:label="lab_immu_ProceedsFromIssuanceOfNonRecourseDebt_89A80BEBF0FAF6CAB8E8850F48C96885" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Issuance of Non-Recourse Debt</link:label>
<link:label id="lab_immu_ProceedsFromIssuanceOfNonRecourseDebt_89A80BEBF0FAF6CAB8E8850F48C96885_documentation_en-US" xlink:label="lab_immu_ProceedsFromIssuanceOfNonRecourseDebt_89A80BEBF0FAF6CAB8E8850F48C96885" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The cash inflows from amounts received from a non-recourse debt.</link:label>
<link:loc xlink:href="immu-20191231.xsd#immu_ProceedsFromIssuanceOfNonRecourseDebt" xlink:label="loc_immu_ProceedsFromIssuanceOfNonRecourseDebt_89A80BEBF0FAF6CAB8E8850F48C96885" xlink:type="locator" />
<link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_immu_ProceedsFromIssuanceOfNonRecourseDebt_89A80BEBF0FAF6CAB8E8850F48C96885" xlink:to="lab_immu_ProceedsFromIssuanceOfNonRecourseDebt_89A80BEBF0FAF6CAB8E8850F48C96885" xlink:type="arc" />
<link:label id="lab_immu_PaymentOfDebtConversionFees_C9394921E15BCD099F10850F48C9FB0D_negatedTerseLabel_en-US" xlink:label="lab_immu_PaymentOfDebtConversionFees_C9394921E15BCD099F10850F48C9FB0D" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Debt conversion fees</link:label>
<link:label id="lab_immu_PaymentOfDebtConversionFees_C9394921E15BCD099F10850F48C9FB0D_label_en-US" xlink:label="lab_immu_PaymentOfDebtConversionFees_C9394921E15BCD099F10850F48C9FB0D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payment of Debt Conversion Fees</link:label>
<link:label id="lab_immu_PaymentOfDebtConversionFees_C9394921E15BCD099F10850F48C9FB0D_documentation_en-US" xlink:label="lab_immu_PaymentOfDebtConversionFees_C9394921E15BCD099F10850F48C9FB0D" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The cash outflow associated with debt conversion fees.</link:label>
<link:loc xlink:href="immu-20191231.xsd#immu_PaymentOfDebtConversionFees" xlink:label="loc_immu_PaymentOfDebtConversionFees_C9394921E15BCD099F10850F48C9FB0D" xlink:type="locator" />
<link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_immu_PaymentOfDebtConversionFees_C9394921E15BCD099F10850F48C9FB0D" xlink:to="lab_immu_PaymentOfDebtConversionFees_C9394921E15BCD099F10850F48C9FB0D" xlink:type="arc" />
<link:label id="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_DE426E616F7B1D17987B850F48CA2F58_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_DE426E616F7B1D17987B850F48CA2F58" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Tax withholding payments for stock-based compensation</link:label>
<link:label id="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_DE426E616F7B1D17987B850F48CA2F58_label_en-US" xlink:label="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_DE426E616F7B1D17987B850F48CA2F58" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payment, Tax Withholding, Share-based Payment Arrangement</link:label>
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:label="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_DE426E616F7B1D17987B850F48CA2F58" xlink:type="locator" />
<link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_DE426E616F7B1D17987B850F48CA2F58" xlink:to="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_DE426E616F7B1D17987B850F48CA2F58" xlink:type="arc" />
<link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_D7E291371D366E4B41A6850F48CAC80F_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_D7E291371D366E4B41A6850F48CAC80F" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net cash provided by financing activities</link:label>
<link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_D7E291371D366E4B41A6850F48CAC80F_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_D7E291371D366E4B41A6850F48CAC80F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</link:label>
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_D7E291371D366E4B41A6850F48CAC80F" xlink:type="locator" />
<link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_D7E291371D366E4B41A6850F48CAC80F" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_D7E291371D366E4B41A6850F48CAC80F" xlink:type="arc" />
<link:label id="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_13F8537322C5FD7CA770850F48CAB3AA_terseLabel_en-US" xlink:label="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_13F8537322C5FD7CA770850F48CAB3AA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Effect of changes in exchange rates on cash, cash equivalents and restricted cash</link:label>
<link:label id="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_13F8537322C5FD7CA770850F48CAB3AA_label_en-US" xlink:label="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_13F8537322C5FD7CA770850F48CAB3AA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations</link:label>
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_13F8537322C5FD7CA770850F48CAB3AA" xlink:type="locator" />
<link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_13F8537322C5FD7CA770850F48CAB3AA" xlink:to="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_13F8537322C5FD7CA770850F48CAB3AA" xlink:type="arc" />
<link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_04AA55A0A9F7909025F2850F48CAFA35_totalLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_04AA55A0A9F7909025F2850F48CAFA35" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net increase (decrease) in cash, cash equivalents and restricted cash</link:label>
<link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_04AA55A0A9F7909025F2850F48CAFA35_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_04AA55A0A9F7909025F2850F48CAFA35" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</link:label>
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_04AA55A0A9F7909025F2850F48CAFA35" xlink:type="locator" />
<link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_04AA55A0A9F7909025F2850F48CAFA35" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_04AA55A0A9F7909025F2850F48CAFA35" xlink:type="arc" />
<link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_6676EABE3A59074AF404850F48CA6487_periodStartLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_6676EABE3A59074AF404850F48CA6487" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Cash, cash equivalents, and restricted cash beginning of period</link:label>
<link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_6676EABE3A59074AF404850F48CA6487_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_6676EABE3A59074AF404850F48CA6487" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents</link:label>
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_6676EABE3A59074AF404850F48CA6487" xlink:type="locator" />
<link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_6676EABE3A59074AF404850F48CA6487" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_6676EABE3A59074AF404850F48CA6487" xlink:type="arc" />
<link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_63520ED89ADDBED734AF850F48CB9513_periodEndLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_63520ED89ADDBED734AF850F48CB9513" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Cash, cash equivalents, and restricted cash end of period</link:label>
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_63520ED89ADDBED734AF850F48CB9513" xlink:type="locator" />
<link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_63520ED89ADDBED734AF850F48CB9513" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_63520ED89ADDBED734AF850F48CB9513" xlink:type="arc" />
<link:label id="lab_us-gaap_SupplementalCashFlowInformationAbstract_33B642340BC7803CFCEF850F48CB8F7E_terseLabel_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract_33B642340BC7803CFCEF850F48CB8F7E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Supplemental disclosure of cash flow information:</link:label>
<link:label id="lab_us-gaap_SupplementalCashFlowInformationAbstract_33B642340BC7803CFCEF850F48CB8F7E_label_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract_33B642340BC7803CFCEF850F48CB8F7E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Supplemental Cash Flow Information [Abstract]</link:label>
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract_33B642340BC7803CFCEF850F48CB8F7E" xlink:type="locator" />
<link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_33B642340BC7803CFCEF850F48CB8F7E" xlink:to="lab_us-gaap_SupplementalCashFlowInformationAbstract_33B642340BC7803CFCEF850F48CB8F7E" xlink:type="arc" />
<link:label id="lab_us-gaap_InterestPaidNet_94057D2DE29F9C268532850F48CB8AB8_terseLabel_en-US" xlink:label="lab_us-gaap_InterestPaidNet_94057D2DE29F9C268532850F48CB8AB8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Interest paid</link:label>
<link:label id="lab_us-gaap_InterestPaidNet_94057D2DE29F9C268532850F48CB8AB8_label_en-US" xlink:label="lab_us-gaap_InterestPaidNet_94057D2DE29F9C268532850F48CB8AB8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interest Paid, Excluding Capitalized Interest, Operating Activities</link:label>
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InterestPaidNet" xlink:label="loc_us-gaap_InterestPaidNet_94057D2DE29F9C268532850F48CB8AB8" xlink:type="locator" />
<link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestPaidNet_94057D2DE29F9C268532850F48CB8AB8" xlink:to="lab_us-gaap_InterestPaidNet_94057D2DE29F9C268532850F48CB8AB8" xlink:type="arc" />
<link:label id="lab_us-gaap_IncomeTaxesPaidNet_3BC0E6713D91BC060DE5850F48CB8C0A_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxesPaidNet_3BC0E6713D91BC060DE5850F48CB8C0A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income taxes paid</link:label>
<link:label id="lab_us-gaap_IncomeTaxesPaidNet_3BC0E6713D91BC060DE5850F48CB8C0A_label_en-US" xlink:label="lab_us-gaap_IncomeTaxesPaidNet_3BC0E6713D91BC060DE5850F48CB8C0A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Taxes Paid, Net</link:label>
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxesPaidNet" xlink:label="loc_us-gaap_IncomeTaxesPaidNet_3BC0E6713D91BC060DE5850F48CB8C0A" xlink:type="locator" />
<link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxesPaidNet_3BC0E6713D91BC060DE5850F48CB8C0A" xlink:to="lab_us-gaap_IncomeTaxesPaidNet_3BC0E6713D91BC060DE5850F48CB8C0A" xlink:type="arc" />
<link:label id="lab_us-gaap_NoncashInvestingAndFinancingItemsAbstract_79595872D16BFDE61B95850F48CB4631_terseLabel_en-US" xlink:label="lab_us-gaap_NoncashInvestingAndFinancingItemsAbstract_79595872D16BFDE61B95850F48CB4631" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of non-cash investing and financing activities:</link:label>
<link:label id="lab_us-gaap_NoncashInvestingAndFinancingItemsAbstract_79595872D16BFDE61B95850F48CB4631_label_en-US" xlink:label="lab_us-gaap_NoncashInvestingAndFinancingItemsAbstract_79595872D16BFDE61B95850F48CB4631" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Noncash Investing and Financing Items [Abstract]</link:label>
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:label="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_79595872D16BFDE61B95850F48CB4631" xlink:type="locator" />
<link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_79595872D16BFDE61B95850F48CB4631" xlink:to="lab_us-gaap_NoncashInvestingAndFinancingItemsAbstract_79595872D16BFDE61B95850F48CB4631" xlink:type="arc" />
<link:label id="lab_us-gaap_DebtConversionOriginalDebtAmount1_7D2A300F177CEB28CAB9850F48CB952B_terseLabel_en-US" xlink:label="lab_us-gaap_DebtConversionOriginalDebtAmount1_7D2A300F177CEB28CAB9850F48CB952B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Issuance of common shares for debt conversion</link:label>
<link:label id="lab_us-gaap_DebtConversionOriginalDebtAmount1_7D2A300F177CEB28CAB9850F48CB952B_label_en-US" xlink:label="lab_us-gaap_DebtConversionOriginalDebtAmount1_7D2A300F177CEB28CAB9850F48CB952B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Conversion, Original Debt, Amount</link:label>
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtConversionOriginalDebtAmount1" xlink:label="loc_us-gaap_DebtConversionOriginalDebtAmount1_7D2A300F177CEB28CAB9850F48CB952B" xlink:type="locator" />
<link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtConversionOriginalDebtAmount1_7D2A300F177CEB28CAB9850F48CB952B" xlink:to="lab_us-gaap_DebtConversionOriginalDebtAmount1_7D2A300F177CEB28CAB9850F48CB952B" xlink:type="arc" />
<link:label id="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid_38024077610C863FC7F7850F48CC9EB8_terseLabel_en-US" xlink:label="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid_38024077610C863FC7F7850F48CC9EB8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued capital expenditures</link:label>
<link:label id="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid_38024077610C863FC7F7850F48CC9EB8_label_en-US" xlink:label="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid_38024077610C863FC7F7850F48CC9EB8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Capital Expenditures Incurred but Not yet Paid</link:label>
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:label="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid_38024077610C863FC7F7850F48CC9EB8" xlink:type="locator" />
<link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid_38024077610C863FC7F7850F48CC9EB8" xlink:to="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid_38024077610C863FC7F7850F48CC9EB8" xlink:type="arc" />
<link:label id="lab_immu_ReclassOfWarrantLiabilityToCapitalContributedInExcessOfPar_B70C52440131664DB50D850F48CCA733_terseLabel_en-US" xlink:label="lab_immu_ReclassOfWarrantLiabilityToCapitalContributedInExcessOfPar_B70C52440131664DB50D850F48CCA733" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-cash component of warrant exercise</link:label>
<link:label id="lab_immu_ReclassOfWarrantLiabilityToCapitalContributedInExcessOfPar_B70C52440131664DB50D850F48CCA733_label_en-US" xlink:label="lab_immu_ReclassOfWarrantLiabilityToCapitalContributedInExcessOfPar_B70C52440131664DB50D850F48CCA733" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Reclass of Warrant Liability to Capital Contributed in Excess of Par</link:label>
<link:label id="lab_immu_ReclassOfWarrantLiabilityToCapitalContributedInExcessOfPar_B70C52440131664DB50D850F48CCA733_documentation_en-US" xlink:label="lab_immu_ReclassOfWarrantLiabilityToCapitalContributedInExcessOfPar_B70C52440131664DB50D850F48CCA733" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Reclass of warrant liability to capital contributed in excess of par.</link:label>
<link:loc xlink:href="immu-20191231.xsd#immu_ReclassOfWarrantLiabilityToCapitalContributedInExcessOfPar" xlink:label="loc_immu_ReclassOfWarrantLiabilityToCapitalContributedInExcessOfPar_B70C52440131664DB50D850F48CCA733" xlink:type="locator" />
<link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_immu_ReclassOfWarrantLiabilityToCapitalContributedInExcessOfPar_B70C52440131664DB50D850F48CCA733" xlink:to="lab_immu_ReclassOfWarrantLiabilityToCapitalContributedInExcessOfPar_B70C52440131664DB50D850F48CCA733" xlink:type="arc" />
<link:label id="lab_us-gaap_StockIssued1_196DCF8CD1933035B28E850F48CC9EDD_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssued1_196DCF8CD1933035B28E850F48CC9EDD" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Shares received in cashless exercise</link:label>
<link:label id="lab_us-gaap_StockIssued1_196DCF8CD1933035B28E850F48CC9EDD_label_en-US" xlink:label="lab_us-gaap_StockIssued1_196DCF8CD1933035B28E850F48CC9EDD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued</link:label>
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssued1" xlink:label="loc_us-gaap_StockIssued1_196DCF8CD1933035B28E850F48CC9EDD" xlink:type="locator" />
<link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssued1_196DCF8CD1933035B28E850F48CC9EDD" xlink:to="lab_us-gaap_StockIssued1_196DCF8CD1933035B28E850F48CC9EDD" xlink:type="arc" />
<link:label id="lab_us-gaap_RestrictedCashCurrent_FED23580107C4D9E6065850F48CCAD4D_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedCashCurrent_FED23580107C4D9E6065850F48CCAD4D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restricted cash in other current assets</link:label>
<link:label id="lab_us-gaap_RestrictedCashCurrent_FED23580107C4D9E6065850F48CCAD4D_label_en-US" xlink:label="lab_us-gaap_RestrictedCashCurrent_FED23580107C4D9E6065850F48CCAD4D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restricted Cash, Current</link:label>
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestrictedCashCurrent" xlink:label="loc_us-gaap_RestrictedCashCurrent_FED23580107C4D9E6065850F48CCAD4D" xlink:type="locator" />
<link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCashCurrent_FED23580107C4D9E6065850F48CCAD4D" xlink:to="lab_us-gaap_RestrictedCashCurrent_FED23580107C4D9E6065850F48CCAD4D" xlink:type="arc" />
<link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_8428117B78A6022E4576850F48CDE055_totalLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_8428117B78A6022E4576850F48CDE055" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total cash, cash equivalents and restricted cash</link:label>
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_8428117B78A6022E4576850F48CDE055" xlink:type="locator" />
<link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_8428117B78A6022E4576850F48CDE055" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_8428117B78A6022E4576850F48CDE055" xlink:type="arc" />
<link:label id="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_6B1182AF19D69F4DB860D1D06216872F_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_6B1182AF19D69F4DB860D1D06216872F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Expense for Income Taxes</link:label>
<link:label id="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_6B1182AF19D69F4DB860D1D06216872F_label_en-US" xlink:label="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_6B1182AF19D69F4DB860D1D06216872F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]</link:label>
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_6B1182AF19D69F4DB860D1D06216872F" xlink:type="locator" />
<link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_6B1182AF19D69F4DB860D1D06216872F" xlink:to="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_6B1182AF19D69F4DB860D1D06216872F" xlink:type="arc" />
<link:label id="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_FB6C7D616F9A8944FD0DD1D062166647_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_FB6C7D616F9A8944FD0DD1D062166647" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Reconciliation of Statutory Tax Rates and Effective Tax Rates</link:label>
<link:label id="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_FB6C7D616F9A8944FD0DD1D062166647_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_FB6C7D616F9A8944FD0DD1D062166647" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]</link:label>
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_FB6C7D616F9A8944FD0DD1D062166647" xlink:type="locator" />
<link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_FB6C7D616F9A8944FD0DD1D062166647" xlink:to="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_FB6C7D616F9A8944FD0DD1D062166647" xlink:type="arc" />
<link:label id="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_C59383D24A93D2ABEAA5D1D06216C66B_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_C59383D24A93D2ABEAA5D1D06216C66B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Tax Effects of Temporary Differences in Deferred Tax Assets</link:label>
<link:label id="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_C59383D24A93D2ABEAA5D1D06216C66B_label_en-US" xlink:label="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_C59383D24A93D2ABEAA5D1D06216C66B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Deferred Tax Assets and Liabilities [Table Text Block]</link:label>
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_C59383D24A93D2ABEAA5D1D06216C66B" xlink:type="locator" />
<link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_C59383D24A93D2ABEAA5D1D06216C66B" xlink:to="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_C59383D24A93D2ABEAA5D1D06216C66B" xlink:type="arc" />
<link:label id="lab_us-gaap_SummaryOfIncomeTaxContingenciesTextBlock_185C06E4055FB7EAEA73D1D062163AB4_terseLabel_en-US" xlink:label="lab_us-gaap_SummaryOfIncomeTaxContingenciesTextBlock_185C06E4055FB7EAEA73D1D062163AB4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Summary of Unrecognized Tax Benefits</link:label>
<link:label id="lab_us-gaap_SummaryOfIncomeTaxContingenciesTextBlock_185C06E4055FB7EAEA73D1D062163AB4_label_en-US" xlink:label="lab_us-gaap_SummaryOfIncomeTaxContingenciesTextBlock_185C06E4055FB7EAEA73D1D062163AB4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Summary of Income Tax Contingencies [Table Text Block]</link:label>
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SummaryOfIncomeTaxContingenciesTextBlock" xlink:label="loc_us-gaap_SummaryOfIncomeTaxContingenciesTextBlock_185C06E4055FB7EAEA73D1D062163AB4" xlink:type="locator" />
<link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SummaryOfIncomeTaxContingenciesTextBlock_185C06E4055FB7EAEA73D1D062163AB4" xlink:to="lab_us-gaap_SummaryOfIncomeTaxContingenciesTextBlock_185C06E4055FB7EAEA73D1D062163AB4" xlink:type="arc" />
<link:label id="lab_us-gaap_FairValueByBalanceSheetGroupingTable_22B437A3922012F0FB84D1D062A53E67_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByBalanceSheetGroupingTable_22B437A3922012F0FB84D1D062A53E67" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value, by Balance Sheet Grouping [Table]</link:label>
<link:label id="lab_us-gaap_FairValueByBalanceSheetGroupingTable_22B437A3922012F0FB84D1D062A53E67_label_en-US" xlink:label="lab_us-gaap_FairValueByBalanceSheetGroupingTable_22B437A3922012F0FB84D1D062A53E67" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, by Balance Sheet Grouping [Table]</link:label>
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueByBalanceSheetGroupingTable" xlink:label="loc_us-gaap_FairValueByBalanceSheetGroupingTable_22B437A3922012F0FB84D1D062A53E67" xlink:type="locator" />
<link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_22B437A3922012F0FB84D1D062A53E67" xlink:to="lab_us-gaap_FairValueByBalanceSheetGroupingTable_22B437A3922012F0FB84D1D062A53E67" xlink:type="arc" />
<link:label id="lab_us-gaap_LongtermDebtTypeAxis_547C5CF6185AA73CA7B9D1D062A5B59B_terseLabel_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeAxis_547C5CF6185AA73CA7B9D1D062A5B59B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Long-term Debt, Type [Axis]</link:label>
<link:label id="lab_us-gaap_LongtermDebtTypeAxis_547C5CF6185AA73CA7B9D1D062A5B59B_label_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeAxis_547C5CF6185AA73CA7B9D1D062A5B59B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-term Debt, Type [Axis]</link:label>
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_547C5CF6185AA73CA7B9D1D062A5B59B" xlink:type="locator" />
<link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_547C5CF6185AA73CA7B9D1D062A5B59B" xlink:to="lab_us-gaap_LongtermDebtTypeAxis_547C5CF6185AA73CA7B9D1D062A5B59B" xlink:type="arc" />
<link:label id="lab_us-gaap_LongtermDebtTypeDomain_54D8AB1ECB880A97ADD6D1D062A57A40_terseLabel_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeDomain_54D8AB1ECB880A97ADD6D1D062A57A40" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Long-term Debt, Type [Domain]</link:label>
<link:label id="lab_us-gaap_LongtermDebtTypeDomain_54D8AB1ECB880A97ADD6D1D062A57A40_label_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeDomain_54D8AB1ECB880A97ADD6D1D062A57A40" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-term Debt, Type [Domain]</link:label>
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_54D8AB1ECB880A97ADD6D1D062A57A40" xlink:type="locator" />
<link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_54D8AB1ECB880A97ADD6D1D062A57A40" xlink:to="lab_us-gaap_LongtermDebtTypeDomain_54D8AB1ECB880A97ADD6D1D062A57A40" xlink:type="arc" />
<link:label id="lab_us-gaap_SeniorNotesMember_8195555F200070B96763D1D062A564AF_terseLabel_en-US" xlink:label="lab_us-gaap_SeniorNotesMember_8195555F200070B96763D1D062A564AF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Senior Notes</link:label>
<link:label id="lab_us-gaap_SeniorNotesMember_8195555F200070B96763D1D062A564AF_label_en-US" xlink:label="lab_us-gaap_SeniorNotesMember_8195555F200070B96763D1D062A564AF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Senior Notes [Member]</link:label>
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SeniorNotesMember" xlink:label="loc_us-gaap_SeniorNotesMember_8195555F200070B96763D1D062A564AF" xlink:type="locator" />
<link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SeniorNotesMember_8195555F200070B96763D1D062A564AF" xlink:to="lab_us-gaap_SeniorNotesMember_8195555F200070B96763D1D062A564AF" xlink:type="arc" />
<link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_0DD493AEFDD7A1AB6987D1D062A5E0B5_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_0DD493AEFDD7A1AB6987D1D062A5E0B5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
<link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_0DD493AEFDD7A1AB6987D1D062A5E0B5_label_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_0DD493AEFDD7A1AB6987D1D062A5E0B5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_0DD493AEFDD7A1AB6987D1D062A5E0B5" xlink:type="locator" />
<link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_0DD493AEFDD7A1AB6987D1D062A5E0B5" xlink:to="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_0DD493AEFDD7A1AB6987D1D062A5E0B5" xlink:type="arc" />
<link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_57BFCBD7A92A3EE11706D1D062A5F54D_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_57BFCBD7A92A3EE11706D1D062A5F54D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
<link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_57BFCBD7A92A3EE11706D1D062A5F54D_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_57BFCBD7A92A3EE11706D1D062A5F54D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_57BFCBD7A92A3EE11706D1D062A5F54D" xlink:type="locator" />
<link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_57BFCBD7A92A3EE11706D1D062A5F54D" xlink:to="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_57BFCBD7A92A3EE11706D1D062A5F54D" xlink:type="arc" />
<link:label id="lab_us-gaap_FairValueInputsLevel2Member_F045EF858EE73A7F54A0D1D062A585CE_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member_F045EF858EE73A7F54A0D1D062A585CE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Level 2</link:label>
<link:label id="lab_us-gaap_FairValueInputsLevel2Member_F045EF858EE73A7F54A0D1D062A585CE_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member_F045EF858EE73A7F54A0D1D062A585CE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Inputs, Level 2 [Member]</link:label>
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_F045EF858EE73A7F54A0D1D062A585CE" xlink:type="locator" />
<link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel2Member_F045EF858EE73A7F54A0D1D062A585CE" xlink:to="lab_us-gaap_FairValueInputsLevel2Member_F045EF858EE73A7F54A0D1D062A585CE" xlink:type="arc" />
<link:label id="lab_us-gaap_FairValueByMeasurementBasisAxis_51E07BA817291853F990D1D062A57F06_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementBasisAxis_51E07BA817291853F990D1D062A57F06" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Measurement Basis [Axis]</link:label>
<link:label id="lab_us-gaap_FairValueByMeasurementBasisAxis_51E07BA817291853F990D1D062A57F06_label_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementBasisAxis_51E07BA817291853F990D1D062A57F06" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Measurement Basis [Axis]</link:label>
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueByMeasurementBasisAxis" xlink:label="loc_us-gaap_FairValueByMeasurementBasisAxis_51E07BA817291853F990D1D062A57F06" xlink:type="locator" />
<link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByMeasurementBasisAxis_51E07BA817291853F990D1D062A57F06" xlink:to="lab_us-gaap_FairValueByMeasurementBasisAxis_51E07BA817291853F990D1D062A57F06" xlink:type="arc" />
<link:label id="lab_us-gaap_FairValueDisclosureItemAmountsDomain_368328E73CE8EC50CE9FD1D062A5766F_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosureItemAmountsDomain_368328E73CE8EC50CE9FD1D062A5766F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value Measurement [Domain]</link:label>
<link:label id="lab_us-gaap_FairValueDisclosureItemAmountsDomain_368328E73CE8EC50CE9FD1D062A5766F_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosureItemAmountsDomain_368328E73CE8EC50CE9FD1D062A5766F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Measurement [Domain]</link:label>
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueDisclosureItemAmountsDomain" xlink:label="loc_us-gaap_FairValueDisclosureItemAmountsDomain_368328E73CE8EC50CE9FD1D062A5766F" xlink:type="locator" />
<link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosureItemAmountsDomain_368328E73CE8EC50CE9FD1D062A5766F" xlink:to="lab_us-gaap_FairValueDisclosureItemAmountsDomain_368328E73CE8EC50CE9FD1D062A5766F" xlink:type="arc" />
<link:label id="lab_us-gaap_PortionAtFairValueFairValueDisclosureMember_278CB9189DFA6F87A402D1D062A9F579_terseLabel_en-US" xlink:label="lab_us-gaap_PortionAtFairValueFairValueDisclosureMember_278CB9189DFA6F87A402D1D062A9F579" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Portion at Fair Value Measurement [Member]</link:label>
<link:label id="lab_us-gaap_PortionAtFairValueFairValueDisclosureMember_278CB9189DFA6F87A402D1D062A9F579_label_en-US" xlink:label="lab_us-gaap_PortionAtFairValueFairValueDisclosureMember_278CB9189DFA6F87A402D1D062A9F579" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Portion at Fair Value Measurement [Member]</link:label>
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PortionAtFairValueFairValueDisclosureMember" xlink:label="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_278CB9189DFA6F87A402D1D062A9F579" xlink:type="locator" />
<link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_278CB9189DFA6F87A402D1D062A9F579" xlink:to="lab_us-gaap_PortionAtFairValueFairValueDisclosureMember_278CB9189DFA6F87A402D1D062A9F579" xlink:type="arc" />
<link:label id="lab_us-gaap_CarryingReportedAmountFairValueDisclosureMember_EBAC510E1438A1BC72B6D1D062A936EB_terseLabel_en-US" xlink:label="lab_us-gaap_CarryingReportedAmountFairValueDisclosureMember_EBAC510E1438A1BC72B6D1D062A936EB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Carrying Amount</link:label>
<link:label id="lab_us-gaap_CarryingReportedAmountFairValueDisclosureMember_EBAC510E1438A1BC72B6D1D062A936EB_label_en-US" xlink:label="lab_us-gaap_CarryingReportedAmountFairValueDisclosureMember_EBAC510E1438A1BC72B6D1D062A936EB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Reported Value Measurement [Member]</link:label>
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CarryingReportedAmountFairValueDisclosureMember" xlink:label="loc_us-gaap_CarryingReportedAmountFairValueDisclosureMember_EBAC510E1438A1BC72B6D1D062A936EB" xlink:type="locator" />
<link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CarryingReportedAmountFairValueDisclosureMember_EBAC510E1438A1BC72B6D1D062A936EB" xlink:to="lab_us-gaap_CarryingReportedAmountFairValueDisclosureMember_EBAC510E1438A1BC72B6D1D062A936EB" xlink:type="arc" />
<link:label id="lab_us-gaap_EstimateOfFairValueFairValueDisclosureMember_0E63A278249976AC67FCD1D062A96902_terseLabel_en-US" xlink:label="lab_us-gaap_EstimateOfFairValueFairValueDisclosureMember_0E63A278249976AC67FCD1D062A96902" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Estimated Fair Value</link:label>
<link:label id="lab_us-gaap_EstimateOfFairValueFairValueDisclosureMember_0E63A278249976AC67FCD1D062A96902_label_en-US" xlink:label="lab_us-gaap_EstimateOfFairValueFairValueDisclosureMember_0E63A278249976AC67FCD1D062A96902" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Estimate of Fair Value Measurement [Member]</link:label>
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EstimateOfFairValueFairValueDisclosureMember" xlink:label="loc_us-gaap_EstimateOfFairValueFairValueDisclosureMember_0E63A278249976AC67FCD1D062A96902" xlink:type="locator" />
<link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EstimateOfFairValueFairValueDisclosureMember_0E63A278249976AC67FCD1D062A96902" xlink:to="lab_us-gaap_EstimateOfFairValueFairValueDisclosureMember_0E63A278249976AC67FCD1D062A96902" xlink:type="arc" />
<link:label id="lab_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_C773DC9E184F3A7D6F9CD1D062A91686_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_C773DC9E184F3A7D6F9CD1D062A91686" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</link:label>
<link:label id="lab_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_C773DC9E184F3A7D6F9CD1D062A91686_label_en-US" xlink:label="lab_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_C773DC9E184F3A7D6F9CD1D062A91686" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</link:label>
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:label="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_C773DC9E184F3A7D6F9CD1D062A91686" xlink:type="locator" />
<link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_C773DC9E184F3A7D6F9CD1D062A91686" xlink:to="lab_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_C773DC9E184F3A7D6F9CD1D062A91686" xlink:type="arc" />
<link:label id="lab_us-gaap_ConvertibleDebtFairValueDisclosures_17115F1EE2D1297C8A92D1D062A94960_terseLabel_en-US" xlink:label="lab_us-gaap_ConvertibleDebtFairValueDisclosures_17115F1EE2D1297C8A92D1D062A94960" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Convertible debt, fair value</link:label>
<link:label id="lab_us-gaap_ConvertibleDebtFairValueDisclosures_17115F1EE2D1297C8A92D1D062A94960_label_en-US" xlink:label="lab_us-gaap_ConvertibleDebtFairValueDisclosures_17115F1EE2D1297C8A92D1D062A94960" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Convertible Debt, Fair Value Disclosures</link:label>
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConvertibleDebtFairValueDisclosures" xlink:label="loc_us-gaap_ConvertibleDebtFairValueDisclosures_17115F1EE2D1297C8A92D1D062A94960" xlink:type="locator" />
<link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConvertibleDebtFairValueDisclosures_17115F1EE2D1297C8A92D1D062A94960" xlink:to="lab_us-gaap_ConvertibleDebtFairValueDisclosures_17115F1EE2D1297C8A92D1D062A94960" xlink:type="arc" />
<link:label id="lab_us-gaap_DebtDisclosureTextBlock_DF837FA62C8C1BD38670D1D06261D8DA_terseLabel_en-US" xlink:label="lab_us-gaap_DebtDisclosureTextBlock_DF837FA62C8C1BD38670D1D06261D8DA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt</link:label>
<link:label id="lab_us-gaap_DebtDisclosureTextBlock_DF837FA62C8C1BD38670D1D06261D8DA_label_en-US" xlink:label="lab_us-gaap_DebtDisclosureTextBlock_DF837FA62C8C1BD38670D1D06261D8DA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Disclosure [Text Block]</link:label>
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtDisclosureTextBlock" xlink:label="loc_us-gaap_DebtDisclosureTextBlock_DF837FA62C8C1BD38670D1D06261D8DA" xlink:type="locator" />
<link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtDisclosureTextBlock_DF837FA62C8C1BD38670D1D06261D8DA" xlink:to="lab_us-gaap_DebtDisclosureTextBlock_DF837FA62C8C1BD38670D1D06261D8DA" xlink:type="arc" />
<link:label id="lab_us-gaap_QuarterlyFinancialInformationDisclosureAbstract_DD5FFBB2EAAFA86614743991D16F6B21_label_en-US" xlink:label="lab_us-gaap_QuarterlyFinancialInformationDisclosureAbstract_DD5FFBB2EAAFA86614743991D16F6B21" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Quarterly Financial Information Disclosure [Abstract]</link:label>
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_QuarterlyFinancialInformationDisclosureAbstract" xlink:label="loc_us-gaap_QuarterlyFinancialInformationDisclosureAbstract_DD5FFBB2EAAFA86614743991D16F6B21" xlink:type="locator" />
<link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_QuarterlyFinancialInformationDisclosureAbstract_DD5FFBB2EAAFA86614743991D16F6B21" xlink:to="lab_us-gaap_QuarterlyFinancialInformationDisclosureAbstract_DD5FFBB2EAAFA86614743991D16F6B21" xlink:type="arc" />
<link:label id="lab_us-gaap_QuarterlyFinancialInformationTextBlock_D5C66C068ECBEE4D8C723991D1703C1A_terseLabel_en-US" xlink:label="lab_us-gaap_QuarterlyFinancialInformationTextBlock_D5C66C068ECBEE4D8C723991D1703C1A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Quarterly Results of Operations (Unaudited)</link:label>
<link:label id="lab_us-gaap_QuarterlyFinancialInformationTextBlock_D5C66C068ECBEE4D8C723991D1703C1A_label_en-US" xlink:label="lab_us-gaap_QuarterlyFinancialInformationTextBlock_D5C66C068ECBEE4D8C723991D1703C1A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Quarterly Financial Information [Text Block]</link:label>
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_QuarterlyFinancialInformationTextBlock" xlink:label="loc_us-gaap_QuarterlyFinancialInformationTextBlock_D5C66C068ECBEE4D8C723991D1703C1A" xlink:type="locator" />
<link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_QuarterlyFinancialInformationTextBlock_D5C66C068ECBEE4D8C723991D1703C1A" xlink:to="lab_us-gaap_QuarterlyFinancialInformationTextBlock_D5C66C068ECBEE4D8C723991D1703C1A" xlink:type="arc" />
<link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_D1A3D31F912466309A27850F48DDA644_label_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract_D1A3D31F912466309A27850F48DDA644" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_D1A3D31F912466309A27850F48DDA644" xlink:type="locator" />
<link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_D1A3D31F912466309A27850F48DDA644" xlink:to="lab_us-gaap_StatementOfStockholdersEquityAbstract_D1A3D31F912466309A27850F48DDA644" xlink:type="arc" />
<link:label id="lab_us-gaap_IPOMember_95AC806F7D19F0EB11CA850F48DF3621_terseLabel_en-US" xlink:label="lab_us-gaap_IPOMember_95AC806F7D19F0EB11CA850F48DF3621" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">IPO</link:label>
<link:label id="lab_us-gaap_IPOMember_95AC806F7D19F0EB11CA850F48DF3621_label_en-US" xlink:label="lab_us-gaap_IPOMember_95AC806F7D19F0EB11CA850F48DF3621" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">IPO [Member]</link:label>
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IPOMember" xlink:label="loc_us-gaap_IPOMember_95AC806F7D19F0EB11CA850F48DF3621" xlink:type="locator" />
<link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IPOMember_95AC806F7D19F0EB11CA850F48DF3621" xlink:to="lab_us-gaap_IPOMember_95AC806F7D19F0EB11CA850F48DF3621" xlink:type="arc" />
<link:label id="lab_us-gaap_StatementClassOfStockAxis_294C1F252204E5C637B2850F48DFB621_terseLabel_en-US" xlink:label="lab_us-gaap_StatementClassOfStockAxis_294C1F252204E5C637B2850F48DFB621" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Class of Stock [Axis]</link:label>
<link:label id="lab_us-gaap_StatementClassOfStockAxis_294C1F252204E5C637B2850F48DFB621_label_en-US" xlink:label="lab_us-gaap_StatementClassOfStockAxis_294C1F252204E5C637B2850F48DFB621" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Stock [Axis]</link:label>
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_294C1F252204E5C637B2850F48DFB621" xlink:type="locator" />
<link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementClassOfStockAxis_294C1F252204E5C637B2850F48DFB621" xlink:to="lab_us-gaap_StatementClassOfStockAxis_294C1F252204E5C637B2850F48DFB621" xlink:type="arc" />
<link:label id="lab_us-gaap_ClassOfStockDomain_C659201D059723760708850F48DFB9D8_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfStockDomain_C659201D059723760708850F48DFB9D8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Class of Stock [Domain]</link:label>
<link:label id="lab_us-gaap_ClassOfStockDomain_C659201D059723760708850F48DFB9D8_label_en-US" xlink:label="lab_us-gaap_ClassOfStockDomain_C659201D059723760708850F48DFB9D8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Stock [Domain]</link:label>
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_C659201D059723760708850F48DFB9D8" xlink:type="locator" />
<link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfStockDomain_C659201D059723760708850F48DFB9D8" xlink:to="lab_us-gaap_ClassOfStockDomain_C659201D059723760708850F48DFB9D8" xlink:type="arc" />
<link:label id="lab_us-gaap_ConvertiblePreferredStockMember_D5B2D3184A88C0E61C17850F48E01640_terseLabel_en-US" xlink:label="lab_us-gaap_ConvertiblePreferredStockMember_D5B2D3184A88C0E61C17850F48E01640" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Convertible preferred stock</link:label>
<link:label id="lab_us-gaap_ConvertiblePreferredStockMember_D5B2D3184A88C0E61C17850F48E01640_label_en-US" xlink:label="lab_us-gaap_ConvertiblePreferredStockMember_D5B2D3184A88C0E61C17850F48E01640" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Convertible Preferred Stock [Member]</link:label>
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConvertiblePreferredStockMember" xlink:label="loc_us-gaap_ConvertiblePreferredStockMember_D5B2D3184A88C0E61C17850F48E01640" xlink:type="locator" />
<link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConvertiblePreferredStockMember_D5B2D3184A88C0E61C17850F48E01640" xlink:to="lab_us-gaap_ConvertiblePreferredStockMember_D5B2D3184A88C0E61C17850F48E01640" xlink:type="arc" />
<link:label id="lab_us-gaap_StatementEquityComponentsAxis_0F208F313B781FECB022850F48E0598A_terseLabel_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis_0F208F313B781FECB022850F48E0598A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Components [Axis]</link:label>
<link:label id="lab_us-gaap_StatementEquityComponentsAxis_0F208F313B781FECB022850F48E0598A_label_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis_0F208F313B781FECB022850F48E0598A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Components [Axis]</link:label>
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_0F208F313B781FECB022850F48E0598A" xlink:type="locator" />
<link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_0F208F313B781FECB022850F48E0598A" xlink:to="lab_us-gaap_StatementEquityComponentsAxis_0F208F313B781FECB022850F48E0598A" xlink:type="arc" />
<link:label id="lab_us-gaap_EquityComponentDomain_14EBFC8826C2D87A3EE6850F48E07D75_terseLabel_en-US" xlink:label="lab_us-gaap_EquityComponentDomain_14EBFC8826C2D87A3EE6850F48E07D75" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Component [Domain]</link:label>
<link:label id="lab_us-gaap_EquityComponentDomain_14EBFC8826C2D87A3EE6850F48E07D75_label_en-US" xlink:label="lab_us-gaap_EquityComponentDomain_14EBFC8826C2D87A3EE6850F48E07D75" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Component [Domain]</link:label>
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_14EBFC8826C2D87A3EE6850F48E07D75" xlink:type="locator" />
<link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityComponentDomain_14EBFC8826C2D87A3EE6850F48E07D75" xlink:to="lab_us-gaap_EquityComponentDomain_14EBFC8826C2D87A3EE6850F48E07D75" xlink:type="arc" />
<link:label id="lab_us-gaap_CommonStockMember_437CBBCB70CB1EBD1F3E850F48E11515_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockMember_437CBBCB70CB1EBD1F3E850F48E11515" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common Stock</link:label>
<link:label id="lab_us-gaap_CommonStockMember_437CBBCB70CB1EBD1F3E850F48E11515_label_en-US" xlink:label="lab_us-gaap_CommonStockMember_437CBBCB70CB1EBD1F3E850F48E11515" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock [Member]</link:label>
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_437CBBCB70CB1EBD1F3E850F48E11515" xlink:type="locator" />
<link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockMember_437CBBCB70CB1EBD1F3E850F48E11515" xlink:to="lab_us-gaap_CommonStockMember_437CBBCB70CB1EBD1F3E850F48E11515" xlink:type="arc" />
<link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_EA66A60DA9B643BF757C850F48E16D31_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember_EA66A60DA9B643BF757C850F48E16D31" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Capital Contributed in Excess of Par</link:label>
<link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_EA66A60DA9B643BF757C850F48E16D31_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember_EA66A60DA9B643BF757C850F48E16D31" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Additional Paid-in Capital [Member]</link:label>
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_EA66A60DA9B643BF757C850F48E16D31" xlink:type="locator" />
<link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalMember_EA66A60DA9B643BF757C850F48E16D31" xlink:to="lab_us-gaap_AdditionalPaidInCapitalMember_EA66A60DA9B643BF757C850F48E16D31" xlink:type="arc" />
<link:label id="lab_us-gaap_TreasuryStockMember_EDC648369AD0F435CF24850F48E14504_terseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockMember_EDC648369AD0F435CF24850F48E14504" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Treasury Stock</link:label>
<link:label id="lab_us-gaap_TreasuryStockMember_EDC648369AD0F435CF24850F48E14504_label_en-US" xlink:label="lab_us-gaap_TreasuryStockMember_EDC648369AD0F435CF24850F48E14504" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Treasury Stock [Member]</link:label>
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TreasuryStockMember" xlink:label="loc_us-gaap_TreasuryStockMember_EDC648369AD0F435CF24850F48E14504" xlink:type="locator" />
<link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockMember_EDC648369AD0F435CF24850F48E14504" xlink:to="lab_us-gaap_TreasuryStockMember_EDC648369AD0F435CF24850F48E14504" xlink:type="arc" />
<link:label id="lab_us-gaap_RetainedEarningsMember_BAE714DC0477DD395D65850F48E1CCBB_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember_BAE714DC0477DD395D65850F48E1CCBB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accumulated Deficit</link:label>
<link:label id="lab_us-gaap_RetainedEarningsMember_BAE714DC0477DD395D65850F48E1CCBB_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember_BAE714DC0477DD395D65850F48E1CCBB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Retained Earnings [Member]</link:label>
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaap_RetainedEarningsMember_BAE714DC0477DD395D65850F48E1CCBB" xlink:type="locator" />
<link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsMember_BAE714DC0477DD395D65850F48E1CCBB" xlink:to="lab_us-gaap_RetainedEarningsMember_BAE714DC0477DD395D65850F48E1CCBB" xlink:type="arc" />
<link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_FAF480ECC546AFDC927E850F48E167E8_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_FAF480ECC546AFDC927E850F48E167E8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accumulated Other Comprehensive (Loss) Income</link:label>
<link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_FAF480ECC546AFDC927E850F48E167E8_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_FAF480ECC546AFDC927E850F48E167E8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">AOCI Attributable to Parent [Member]</link:label>
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_FAF480ECC546AFDC927E850F48E167E8" xlink:type="locator" />
<link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_FAF480ECC546AFDC927E850F48E167E8" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_FAF480ECC546AFDC927E850F48E167E8" xlink:type="arc" />
<link:label id="lab_us-gaap_NoncontrollingInterestMember_BA494BD541B0533196F5850F48E2D5FD_terseLabel_en-US" xlink:label="lab_us-gaap_NoncontrollingInterestMember_BA494BD541B0533196F5850F48E2D5FD" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Noncontrolling Interest</link:label>
<link:label id="lab_us-gaap_NoncontrollingInterestMember_BA494BD541B0533196F5850F48E2D5FD_label_en-US" xlink:label="lab_us-gaap_NoncontrollingInterestMember_BA494BD541B0533196F5850F48E2D5FD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Noncontrolling Interest [Member]</link:label>
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NoncontrollingInterestMember" xlink:label="loc_us-gaap_NoncontrollingInterestMember_BA494BD541B0533196F5850F48E2D5FD" xlink:type="locator" />
<link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NoncontrollingInterestMember_BA494BD541B0533196F5850F48E2D5FD" xlink:to="lab_us-gaap_NoncontrollingInterestMember_BA494BD541B0533196F5850F48E2D5FD" xlink:type="arc" />
<link:label id="lab_immu_SeattleGeneticsIncMember_8C34F696C8DF1B4F6523850F48E262BB_terseLabel_en-US" xlink:label="lab_immu_SeattleGeneticsIncMember_8C34F696C8DF1B4F6523850F48E262BB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Seattle Genetics, Inc., (“SGEN”)</link:label>
<link:label id="lab_immu_SeattleGeneticsIncMember_8C34F696C8DF1B4F6523850F48E262BB_label_en-US" xlink:label="lab_immu_SeattleGeneticsIncMember_8C34F696C8DF1B4F6523850F48E262BB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Seattle Genetics Inc [Member]</link:label>
<link:label id="lab_immu_SeattleGeneticsIncMember_8C34F696C8DF1B4F6523850F48E262BB_documentation_en-US" xlink:label="lab_immu_SeattleGeneticsIncMember_8C34F696C8DF1B4F6523850F48E262BB" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents the information pertaining to Seattle Genetics, Inc.</link:label>
<link:loc xlink:href="immu-20191231.xsd#immu_SeattleGeneticsIncMember" xlink:label="loc_immu_SeattleGeneticsIncMember_8C34F696C8DF1B4F6523850F48E262BB" xlink:type="locator" />
<link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_immu_SeattleGeneticsIncMember_8C34F696C8DF1B4F6523850F48E262BB" xlink:to="lab_immu_SeattleGeneticsIncMember_8C34F696C8DF1B4F6523850F48E262BB" xlink:type="arc" />
<link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_A12D4BD358632C8D685E850F48E3F4B3_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_A12D4BD358632C8D685E850F48E3F4B3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
<link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_A12D4BD358632C8D685E850F48E3F4B3_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_A12D4BD358632C8D685E850F48E3F4B3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_A12D4BD358632C8D685E850F48E3F4B3" xlink:type="locator" />
<link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_A12D4BD358632C8D685E850F48E3F4B3" xlink:to="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_A12D4BD358632C8D685E850F48E3F4B3" xlink:type="arc" />
<link:label id="lab_us-gaap_SharesIssued_4A453983E0984B9A43BE850F48E39E07_periodStartLabel_en-US" xlink:label="lab_us-gaap_SharesIssued_4A453983E0984B9A43BE850F48E39E07" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Beginning balance (in shares)</link:label>
<link:label id="lab_us-gaap_SharesIssued_4A453983E0984B9A43BE850F48E39E07_label_en-US" xlink:label="lab_us-gaap_SharesIssued_4A453983E0984B9A43BE850F48E39E07" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Shares, Issued</link:label>
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharesIssued" xlink:label="loc_us-gaap_SharesIssued_4A453983E0984B9A43BE850F48E39E07" xlink:type="locator" />
<link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharesIssued_4A453983E0984B9A43BE850F48E39E07" xlink:to="lab_us-gaap_SharesIssued_4A453983E0984B9A43BE850F48E39E07" xlink:type="arc" />
<link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_BBFD876070595A1BD882850F48E357EC_periodStartLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_BBFD876070595A1BD882850F48E357EC" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Beginning balance</link:label>
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_BBFD876070595A1BD882850F48E357EC" xlink:type="locator" />
<link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_BBFD876070595A1BD882850F48E357EC" xlink:to="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_BBFD876070595A1BD882850F48E357EC" xlink:type="arc" />
<link:label id="lab_immu_ReclassificationofWarrantLiabilitytoEquity_C69945798460F35A0E09850F48E47CED_terseLabel_en-US" xlink:label="lab_immu_ReclassificationofWarrantLiabilitytoEquity_C69945798460F35A0E09850F48E47CED" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Reclassification of warrant liability to equity</link:label>
<link:label id="lab_immu_ReclassificationofWarrantLiabilitytoEquity_C69945798460F35A0E09850F48E47CED_label_en-US" xlink:label="lab_immu_ReclassificationofWarrantLiabilitytoEquity_C69945798460F35A0E09850F48E47CED" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Reclassification of Warrant Liability to Equity</link:label>
<link:label id="lab_immu_ReclassificationofWarrantLiabilitytoEquity_C69945798460F35A0E09850F48E47CED_documentation_en-US" xlink:label="lab_immu_ReclassificationofWarrantLiabilitytoEquity_C69945798460F35A0E09850F48E47CED" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Reclassification of Warrant Liability to Equity</link:label>
<link:loc xlink:href="immu-20191231.xsd#immu_ReclassificationofWarrantLiabilitytoEquity" xlink:label="loc_immu_ReclassificationofWarrantLiabilitytoEquity_C69945798460F35A0E09850F48E47CED" xlink:type="locator" />
<link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_immu_ReclassificationofWarrantLiabilitytoEquity_C69945798460F35A0E09850F48E47CED" xlink:to="lab_immu_ReclassificationofWarrantLiabilitytoEquity_C69945798460F35A0E09850F48E47CED" xlink:type="arc" />
<link:label id="lab_immu_PreferredStockIssuedDuringPeriodSharesNewIssues_D8342A9C590697F3E00A850F48E4E410_terseLabel_en-US" xlink:label="lab_immu_PreferredStockIssuedDuringPeriodSharesNewIssues_D8342A9C590697F3E00A850F48E4E410" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Issuance of preferred stock (in shares)</link:label>
<link:label id="lab_immu_PreferredStockIssuedDuringPeriodSharesNewIssues_D8342A9C590697F3E00A850F48E4E410_label_en-US" xlink:label="lab_immu_PreferredStockIssuedDuringPeriodSharesNewIssues_D8342A9C590697F3E00A850F48E4E410" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred Stock Issued During Period Shares New Issues</link:label>
<link:label id="lab_immu_PreferredStockIssuedDuringPeriodSharesNewIssues_D8342A9C590697F3E00A850F48E4E410_documentation_en-US" xlink:label="lab_immu_PreferredStockIssuedDuringPeriodSharesNewIssues_D8342A9C590697F3E00A850F48E4E410" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt</link:label>
<link:loc xlink:href="immu-20191231.xsd#immu_PreferredStockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_immu_PreferredStockIssuedDuringPeriodSharesNewIssues_D8342A9C590697F3E00A850F48E4E410" xlink:type="locator" />
<link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_immu_PreferredStockIssuedDuringPeriodSharesNewIssues_D8342A9C590697F3E00A850F48E4E410" xlink:to="lab_immu_PreferredStockIssuedDuringPeriodSharesNewIssues_D8342A9C590697F3E00A850F48E4E410" xlink:type="arc" />
<link:label id="lab_immu_PreferredStockIssuedDuringPeriodValueNewIssues_6FB76EADC68491CC8FC1850F48E46180_terseLabel_en-US" xlink:label="lab_immu_PreferredStockIssuedDuringPeriodValueNewIssues_6FB76EADC68491CC8FC1850F48E46180" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Issuance of preferred stock, net</link:label>
<link:label id="lab_immu_PreferredStockIssuedDuringPeriodValueNewIssues_6FB76EADC68491CC8FC1850F48E46180_label_en-US" xlink:label="lab_immu_PreferredStockIssuedDuringPeriodValueNewIssues_6FB76EADC68491CC8FC1850F48E46180" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred Stock Issued During Period Value New Issues</link:label>
<link:label id="lab_immu_PreferredStockIssuedDuringPeriodValueNewIssues_6FB76EADC68491CC8FC1850F48E46180_documentation_en-US" xlink:label="lab_immu_PreferredStockIssuedDuringPeriodValueNewIssues_6FB76EADC68491CC8FC1850F48E46180" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Value of all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by shareholders, which is net of related treasury stock. May be all or a portion of the number of preferred shares authorized. These shares represent the ownership interest of the preferred shareholders.</link:label>
<link:loc xlink:href="immu-20191231.xsd#immu_PreferredStockIssuedDuringPeriodValueNewIssues" xlink:label="loc_immu_PreferredStockIssuedDuringPeriodValueNewIssues_6FB76EADC68491CC8FC1850F48E46180" xlink:type="locator" />
<link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_immu_PreferredStockIssuedDuringPeriodValueNewIssues_6FB76EADC68491CC8FC1850F48E46180" xlink:to="lab_immu_PreferredStockIssuedDuringPeriodValueNewIssues_6FB76EADC68491CC8FC1850F48E46180" xlink:type="arc" />
<link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_8ADD141794E7CC15B600850F48E43469_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_8ADD141794E7CC15B600850F48E43469" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Issuance of common stock (in shares)</link:label>
<link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_8ADD141794E7CC15B600850F48E43469_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_8ADD141794E7CC15B600850F48E43469" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Shares, New Issues</link:label>
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_8ADD141794E7CC15B600850F48E43469" xlink:type="locator" />
<link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_8ADD141794E7CC15B600850F48E43469" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_8ADD141794E7CC15B600850F48E43469" xlink:type="arc" />
<link:label id="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues_3802BC977357ADE17F2A850F48E4437C_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues_3802BC977357ADE17F2A850F48E4437C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Issuance of common stock, net</link:label>
<link:label id="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues_3802BC977357ADE17F2A850F48E4437C_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues_3802BC977357ADE17F2A850F48E4437C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Value, New Issues</link:label>
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_3802BC977357ADE17F2A850F48E4437C" xlink:type="locator" />
<link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_3802BC977357ADE17F2A850F48E4437C" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues_3802BC977357ADE17F2A850F48E4437C" xlink:type="arc" />
<link:label id="lab_immu_AdjustmentstoAdditionalPaidinCapitalProceedsFromOfferingWarrants_04138668A5E69C0DB8F7850F48E4F5EF_negatedTerseLabel_en-US" xlink:label="lab_immu_AdjustmentstoAdditionalPaidinCapitalProceedsFromOfferingWarrants_04138668A5E69C0DB8F7850F48E4F5EF" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Proceeds of public offering allocated to warrant liability</link:label>
<link:label id="lab_immu_AdjustmentstoAdditionalPaidinCapitalProceedsFromOfferingWarrants_04138668A5E69C0DB8F7850F48E4F5EF_label_en-US" xlink:label="lab_immu_AdjustmentstoAdditionalPaidinCapitalProceedsFromOfferingWarrants_04138668A5E69C0DB8F7850F48E4F5EF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustments to Additional Paid in Capital, Proceeds From Offering Warrants</link:label>
<link:label id="lab_immu_AdjustmentstoAdditionalPaidinCapitalProceedsFromOfferingWarrants_04138668A5E69C0DB8F7850F48E4F5EF_documentation_en-US" xlink:label="lab_immu_AdjustmentstoAdditionalPaidinCapitalProceedsFromOfferingWarrants_04138668A5E69C0DB8F7850F48E4F5EF" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Adjustments to Additional Paid in Capital, Proceeds From Offering Warrants</link:label>
<link:loc xlink:href="immu-20191231.xsd#immu_AdjustmentstoAdditionalPaidinCapitalProceedsFromOfferingWarrants" xlink:label="loc_immu_AdjustmentstoAdditionalPaidinCapitalProceedsFromOfferingWarrants_04138668A5E69C0DB8F7850F48E4F5EF" xlink:type="locator" />
<link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_immu_AdjustmentstoAdditionalPaidinCapitalProceedsFromOfferingWarrants_04138668A5E69C0DB8F7850F48E4F5EF" xlink:to="lab_immu_AdjustmentstoAdditionalPaidinCapitalProceedsFromOfferingWarrants_04138668A5E69C0DB8F7850F48E4F5EF" xlink:type="arc" />
<link:label id="lab_immu_SharebasedCompensationArrangementbySharebasedPaymentAwardWarrantsExercisesinPeriod_9EEC82250E188ADE056C850F48E4E6E8_terseLabel_en-US" xlink:label="lab_immu_SharebasedCompensationArrangementbySharebasedPaymentAwardWarrantsExercisesinPeriod_9EEC82250E188ADE056C850F48E4E6E8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Exercise of common stock warrants (in shares)</link:label>
<link:label id="lab_immu_SharebasedCompensationArrangementbySharebasedPaymentAwardWarrantsExercisesinPeriod_9EEC82250E188ADE056C850F48E4E6E8_label_en-US" xlink:label="lab_immu_SharebasedCompensationArrangementbySharebasedPaymentAwardWarrantsExercisesinPeriod_9EEC82250E188ADE056C850F48E4E6E8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Warrants, Exercises in Period</link:label>
<link:label id="lab_immu_SharebasedCompensationArrangementbySharebasedPaymentAwardWarrantsExercisesinPeriod_9EEC82250E188ADE056C850F48E4E6E8_documentation_en-US" xlink:label="lab_immu_SharebasedCompensationArrangementbySharebasedPaymentAwardWarrantsExercisesinPeriod_9EEC82250E188ADE056C850F48E4E6E8" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Warrants, Exercises in Period</link:label>
<link:loc xlink:href="immu-20191231.xsd#immu_SharebasedCompensationArrangementbySharebasedPaymentAwardWarrantsExercisesinPeriod" xlink:label="loc_immu_SharebasedCompensationArrangementbySharebasedPaymentAwardWarrantsExercisesinPeriod_9EEC82250E188ADE056C850F48E4E6E8" xlink:type="locator" />
<link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_immu_SharebasedCompensationArrangementbySharebasedPaymentAwardWarrantsExercisesinPeriod_9EEC82250E188ADE056C850F48E4E6E8" xlink:to="lab_immu_SharebasedCompensationArrangementbySharebasedPaymentAwardWarrantsExercisesinPeriod_9EEC82250E188ADE056C850F48E4E6E8" xlink:type="arc" />
<link:label id="lab_immu_StockIssuedDuringPeriodValueWarrantsExercised_992AAE67CA6E289D4C7E850F48E53AC3_terseLabel_en-US" xlink:label="lab_immu_StockIssuedDuringPeriodValueWarrantsExercised_992AAE67CA6E289D4C7E850F48E53AC3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Exercise of common stock warrants</link:label>
<link:label id="lab_immu_StockIssuedDuringPeriodValueWarrantsExercised_992AAE67CA6E289D4C7E850F48E53AC3_label_en-US" xlink:label="lab_immu_StockIssuedDuringPeriodValueWarrantsExercised_992AAE67CA6E289D4C7E850F48E53AC3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Value, Warrants Exercised</link:label>
<link:label id="lab_immu_StockIssuedDuringPeriodValueWarrantsExercised_992AAE67CA6E289D4C7E850F48E53AC3_documentation_en-US" xlink:label="lab_immu_StockIssuedDuringPeriodValueWarrantsExercised_992AAE67CA6E289D4C7E850F48E53AC3" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Value, Warrants Exercised</link:label>
<link:loc xlink:href="immu-20191231.xsd#immu_StockIssuedDuringPeriodValueWarrantsExercised" xlink:label="loc_immu_StockIssuedDuringPeriodValueWarrantsExercised_992AAE67CA6E289D4C7E850F48E53AC3" xlink:type="locator" />
<link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_immu_StockIssuedDuringPeriodValueWarrantsExercised_992AAE67CA6E289D4C7E850F48E53AC3" xlink:to="lab_immu_StockIssuedDuringPeriodValueWarrantsExercised_992AAE67CA6E289D4C7E850F48E53AC3" xlink:type="arc" />
<link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_1CDA7B53D2CBC0F42281850F48E51E76_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_1CDA7B53D2CBC0F42281850F48E51E76" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Exercise of stock options (in shares)</link:label>
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_1CDA7B53D2CBC0F42281850F48E51E76" xlink:type="locator" />
<link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_1CDA7B53D2CBC0F42281850F48E51E76" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_1CDA7B53D2CBC0F42281850F48E51E76" xlink:type="arc" />
<link:label id="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_E6FC38FC84E7D8185F2D850F48E5DFF0_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_E6FC38FC84E7D8185F2D850F48E5DFF0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Exercise of stock options, net</link:label>
<link:label id="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_E6FC38FC84E7D8185F2D850F48E5DFF0_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_E6FC38FC84E7D8185F2D850F48E5DFF0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Value, Stock Options Exercised</link:label>
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_E6FC38FC84E7D8185F2D850F48E5DFF0" xlink:type="locator" />
<link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_E6FC38FC84E7D8185F2D850F48E5DFF0" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_E6FC38FC84E7D8185F2D850F48E5DFF0" xlink:type="arc" />
<link:label id="lab_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares_2AF90E976E0A321AB2F6850F48E5C9A7_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares_2AF90E976E0A321AB2F6850F48E5C9A7" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Retirement of treasury stock (in shares)</link:label>
<link:label id="lab_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares_2AF90E976E0A321AB2F6850F48E5C9A7_label_en-US" xlink:label="lab_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares_2AF90E976E0A321AB2F6850F48E5C9A7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Repurchased and Retired During Period, Shares</link:label>
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockRepurchasedAndRetiredDuringPeriodShares" xlink:label="loc_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares_2AF90E976E0A321AB2F6850F48E5C9A7" xlink:type="locator" />
<link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares_2AF90E976E0A321AB2F6850F48E5C9A7" xlink:to="lab_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares_2AF90E976E0A321AB2F6850F48E5C9A7" xlink:type="arc" />
<link:label id="lab_us-gaap_StockRepurchasedAndRetiredDuringPeriodValue_887486DA5BC550402115850F48E53209_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_StockRepurchasedAndRetiredDuringPeriodValue_887486DA5BC550402115850F48E53209" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Retirement of treasury stock</link:label>
<link:label id="lab_us-gaap_StockRepurchasedAndRetiredDuringPeriodValue_887486DA5BC550402115850F48E53209_label_en-US" xlink:label="lab_us-gaap_StockRepurchasedAndRetiredDuringPeriodValue_887486DA5BC550402115850F48E53209" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Repurchased and Retired During Period, Value</link:label>
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockRepurchasedAndRetiredDuringPeriodValue" xlink:label="loc_us-gaap_StockRepurchasedAndRetiredDuringPeriodValue_887486DA5BC550402115850F48E53209" xlink:type="locator" />
<link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockRepurchasedAndRetiredDuringPeriodValue_887486DA5BC550402115850F48E53209" xlink:to="lab_us-gaap_StockRepurchasedAndRetiredDuringPeriodValue_887486DA5BC550402115850F48E53209" xlink:type="arc" />
<link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits_DA3269606B708A297FA3850F48E59800_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits_DA3269606B708A297FA3850F48E59800" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Conversion of preferred shares (in shares)</link:label>
<link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits_DA3269606B708A297FA3850F48E59800_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits_DA3269606B708A297FA3850F48E59800" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Shares, Conversion of Units</link:label>
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits_DA3269606B708A297FA3850F48E59800" xlink:type="locator" />
<link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits_DA3269606B708A297FA3850F48E59800" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits_DA3269606B708A297FA3850F48E59800" xlink:type="arc" />
<link:label id="lab_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecuritiesNetOfAdjustments_7E83FCCCE8B849ECA82F850F48E6158C_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecuritiesNetOfAdjustments_7E83FCCCE8B849ECA82F850F48E6158C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Conversion of preferred stock</link:label>
<link:label id="lab_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecuritiesNetOfAdjustments_7E83FCCCE8B849ECA82F850F48E6158C_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecuritiesNetOfAdjustments_7E83FCCCE8B849ECA82F850F48E6158C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Value, Conversion of Convertible Securities, Net of Adjustments</link:label>
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecuritiesNetOfAdjustments" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecuritiesNetOfAdjustments_7E83FCCCE8B849ECA82F850F48E6158C" xlink:type="locator" />
<link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecuritiesNetOfAdjustments_7E83FCCCE8B849ECA82F850F48E6158C" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecuritiesNetOfAdjustments_7E83FCCCE8B849ECA82F850F48E6158C" xlink:type="arc" />
<link:label id="lab_us-gaap_DebtConversionConvertedInstrumentSharesIssued1_187BCF77647D53F7B9B4850F48E694E0_terseLabel_en-US" xlink:label="lab_us-gaap_DebtConversionConvertedInstrumentSharesIssued1_187BCF77647D53F7B9B4850F48E694E0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Issuance of common stock due to debt conversion (in shares)</link:label>
<link:label id="lab_us-gaap_DebtConversionConvertedInstrumentSharesIssued1_187BCF77647D53F7B9B4850F48E694E0_label_en-US" xlink:label="lab_us-gaap_DebtConversionConvertedInstrumentSharesIssued1_187BCF77647D53F7B9B4850F48E694E0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Conversion, Converted Instrument, Shares Issued</link:label>
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xlink:label="loc_us-gaap_DebtConversionConvertedInstrumentSharesIssued1_187BCF77647D53F7B9B4850F48E694E0" xlink:type="locator" />
<link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtConversionConvertedInstrumentSharesIssued1_187BCF77647D53F7B9B4850F48E694E0" xlink:to="lab_us-gaap_DebtConversionConvertedInstrumentSharesIssued1_187BCF77647D53F7B9B4850F48E694E0" xlink:type="arc" />
<link:label id="lab_us-gaap_DebtConversionConvertedInstrumentAmount1_FF207936941DB371E8C9850F48E6A3AE_terseLabel_en-US" xlink:label="lab_us-gaap_DebtConversionConvertedInstrumentAmount1_FF207936941DB371E8C9850F48E6A3AE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Issuance of common stock due to debt conversion</link:label>
<link:label id="lab_us-gaap_DebtConversionConvertedInstrumentAmount1_FF207936941DB371E8C9850F48E6A3AE_label_en-US" xlink:label="lab_us-gaap_DebtConversionConvertedInstrumentAmount1_FF207936941DB371E8C9850F48E6A3AE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Conversion, Converted Instrument, Amount</link:label>
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtConversionConvertedInstrumentAmount1" xlink:label="loc_us-gaap_DebtConversionConvertedInstrumentAmount1_FF207936941DB371E8C9850F48E6A3AE" xlink:type="locator" />
<link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtConversionConvertedInstrumentAmount1_FF207936941DB371E8C9850F48E6A3AE" xlink:to="lab_us-gaap_DebtConversionConvertedInstrumentAmount1_FF207936941DB371E8C9850F48E6A3AE" xlink:type="arc" />
<link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_46CBF5E7A9B3DDA4B9B6850F48E64F4D_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_46CBF5E7A9B3DDA4B9B6850F48E64F4D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock based compensation (in shares)</link:label>
<link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_46CBF5E7A9B3DDA4B9B6850F48E64F4D_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_46CBF5E7A9B3DDA4B9B6850F48E64F4D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Shares Issued, Shares, Share-based Payment Arrangement, after Forfeiture</link:label>
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_46CBF5E7A9B3DDA4B9B6850F48E64F4D" xlink:type="locator" />
<link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_46CBF5E7A9B3DDA4B9B6850F48E64F4D" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_46CBF5E7A9B3DDA4B9B6850F48E64F4D" xlink:type="arc" />
<link:label id="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_C51B3FFFFC9B210094CF850F48E6B0DE_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_C51B3FFFFC9B210094CF850F48E6B0DE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock-based compensation</link:label>
<link:label id="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_C51B3FFFFC9B210094CF850F48E6B0DE_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_C51B3FFFFC9B210094CF850F48E6B0DE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Shares Issued, Value, Share-based Payment Arrangement, after Forfeiture</link:label>
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_C51B3FFFFC9B210094CF850F48E6B0DE" xlink:type="locator" />
<link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_C51B3FFFFC9B210094CF850F48E6B0DE" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_C51B3FFFFC9B210094CF850F48E6B0DE" xlink:type="arc" />
<link:label id="lab_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation_4FCB2713E25854ADD7B1850F48E7ECD9_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation_4FCB2713E25854ADD7B1850F48E7ECD9" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Conversion of RSU's for tax withholding payments (in shares)</link:label>
<link:label id="lab_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation_4FCB2713E25854ADD7B1850F48E7ECD9_label_en-US" xlink:label="lab_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation_4FCB2713E25854ADD7B1850F48E7ECD9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Payment Arrangement, Shares Withheld for Tax Withholding Obligation</link:label>
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation" xlink:label="loc_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation_4FCB2713E25854ADD7B1850F48E7ECD9" xlink:type="locator" />
<link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation_4FCB2713E25854ADD7B1850F48E7ECD9" xlink:to="lab_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation_4FCB2713E25854ADD7B1850F48E7ECD9" xlink:type="arc" />
<link:label id="lab_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation_A2B092E90D16EAAC49B2850F48E70AB0_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation_A2B092E90D16EAAC49B2850F48E70AB0" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Conversion of RSU's for tax withholding payments</link:label>
<link:label id="lab_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation_A2B092E90D16EAAC49B2850F48E70AB0_label_en-US" xlink:label="lab_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation_A2B092E90D16EAAC49B2850F48E70AB0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Payment Arrangement, Decrease for Tax Withholding Obligation</link:label>
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:label="loc_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation_A2B092E90D16EAAC49B2850F48E70AB0" xlink:type="locator" />
<link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation_A2B092E90D16EAAC49B2850F48E70AB0" xlink:to="lab_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation_A2B092E90D16EAAC49B2850F48E70AB0" xlink:type="arc" />
<link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax_BD93D9EAC0AFA298A9F6850F48E72C9D_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax_BD93D9EAC0AFA298A9F6850F48E72C9D" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Other comprehensive income (loss)</link:label>
<link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax_BD93D9EAC0AFA298A9F6850F48E72C9D_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax_BD93D9EAC0AFA298A9F6850F48E72C9D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Comprehensive Income (Loss), Net of Tax</link:label>
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_BD93D9EAC0AFA298A9F6850F48E72C9D" xlink:type="locator" />
<link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_BD93D9EAC0AFA298A9F6850F48E72C9D" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax_BD93D9EAC0AFA298A9F6850F48E72C9D" xlink:type="arc" />
<link:label id="lab_us-gaap_SharesIssued_27D56B2D50C72A29AA4B850F48E7D665_periodEndLabel_en-US" xlink:label="lab_us-gaap_SharesIssued_27D56B2D50C72A29AA4B850F48E7D665" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Ending balance (in shares)</link:label>
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharesIssued" xlink:label="loc_us-gaap_SharesIssued_27D56B2D50C72A29AA4B850F48E7D665" xlink:type="locator" />
<link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharesIssued_27D56B2D50C72A29AA4B850F48E7D665" xlink:to="lab_us-gaap_SharesIssued_27D56B2D50C72A29AA4B850F48E7D665" xlink:type="arc" />
<link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_C8480ACC8A33849C0D1D850F48E7252C_periodEndLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_C8480ACC8A33849C0D1D850F48E7252C" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Ending balance</link:label>
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_C8480ACC8A33849C0D1D850F48E7252C" xlink:type="locator" />
<link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_C8480ACC8A33849C0D1D850F48E7252C" xlink:to="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_C8480ACC8A33849C0D1D850F48E7252C" xlink:type="arc" />
<link:label id="lab_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_1DE9EE52BD7CCB6AD4C4D1D0626D59BB_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_1DE9EE52BD7CCB6AD4C4D1D0626D59BB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Accounts Payable and Accrued Expenses</link:label>
<link:label id="lab_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_1DE9EE52BD7CCB6AD4C4D1D0626D59BB_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_1DE9EE52BD7CCB6AD4C4D1D0626D59BB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Accounts Payable and Accrued Liabilities [Table Text Block]</link:label>
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_1DE9EE52BD7CCB6AD4C4D1D0626D59BB" xlink:type="locator" />
<link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_1DE9EE52BD7CCB6AD4C4D1D0626D59BB" xlink:to="lab_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_1DE9EE52BD7CCB6AD4C4D1D0626D59BB" xlink:type="arc" />
<link:label id="lab_immu_LicenseAndCollaborationAgreementsAbstract_B4EBBB1516BF582351947D0659DE4A6D_label_en-US" xlink:label="lab_immu_LicenseAndCollaborationAgreementsAbstract_B4EBBB1516BF582351947D0659DE4A6D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaboration Agreement</link:label>
<link:label id="lab_immu_LicenseAndCollaborationAgreementsAbstract_B4EBBB1516BF582351947D0659DE4A6D_documentation_en-US" xlink:label="lab_immu_LicenseAndCollaborationAgreementsAbstract_B4EBBB1516BF582351947D0659DE4A6D" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">License and Collaboration Agreements [Abstract]</link:label>
<link:loc xlink:href="immu-20191231.xsd#immu_LicenseAndCollaborationAgreementsAbstract" xlink:label="loc_immu_LicenseAndCollaborationAgreementsAbstract_B4EBBB1516BF582351947D0659DE4A6D" xlink:type="locator" />
<link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_immu_LicenseAndCollaborationAgreementsAbstract_B4EBBB1516BF582351947D0659DE4A6D" xlink:to="lab_immu_LicenseAndCollaborationAgreementsAbstract_B4EBBB1516BF582351947D0659DE4A6D" xlink:type="arc" />
<link:label id="lab_us-gaap_ScheduleOfGuaranteeObligationsTable_CE495FD42BB0EC9A916B7D0659DE55BD_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfGuaranteeObligationsTable_CE495FD42BB0EC9A916B7D0659DE55BD" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Guarantor Obligations [Table]</link:label>
<link:label id="lab_us-gaap_ScheduleOfGuaranteeObligationsTable_CE495FD42BB0EC9A916B7D0659DE55BD_label_en-US" xlink:label="lab_us-gaap_ScheduleOfGuaranteeObligationsTable_CE495FD42BB0EC9A916B7D0659DE55BD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Guarantor Obligations [Table]</link:label>
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfGuaranteeObligationsTable" xlink:label="loc_us-gaap_ScheduleOfGuaranteeObligationsTable_CE495FD42BB0EC9A916B7D0659DE55BD" xlink:type="locator" />
<link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfGuaranteeObligationsTable_CE495FD42BB0EC9A916B7D0659DE55BD" xlink:to="lab_us-gaap_ScheduleOfGuaranteeObligationsTable_CE495FD42BB0EC9A916B7D0659DE55BD" xlink:type="arc" />
<link:label id="lab_immu_CollaborationAgreementAxis_42181E63B0465340B0447D0659DFBFEF_terseLabel_en-US" xlink:label="lab_immu_CollaborationAgreementAxis_42181E63B0465340B0447D0659DFBFEF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Collaboration Agreement [Axis]</link:label>
<link:label id="lab_immu_CollaborationAgreementAxis_42181E63B0465340B0447D0659DFBFEF_label_en-US" xlink:label="lab_immu_CollaborationAgreementAxis_42181E63B0465340B0447D0659DFBFEF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaboration Agreement [Axis]</link:label>
<link:label id="lab_immu_CollaborationAgreementAxis_42181E63B0465340B0447D0659DFBFEF_documentation_en-US" xlink:label="lab_immu_CollaborationAgreementAxis_42181E63B0465340B0447D0659DFBFEF" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Collaboration Agreement [Axis]</link:label>
<link:loc xlink:href="immu-20191231.xsd#immu_CollaborationAgreementAxis" xlink:label="loc_immu_CollaborationAgreementAxis_42181E63B0465340B0447D0659DFBFEF" xlink:type="locator" />
<link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_immu_CollaborationAgreementAxis_42181E63B0465340B0447D0659DFBFEF" xlink:to="lab_immu_CollaborationAgreementAxis_42181E63B0465340B0447D0659DFBFEF" xlink:type="arc" />
<link:label id="lab_immu_CollaborationAgreementDomain_7D49EAABA91DEA2E5B127D0659DF6AA0_terseLabel_en-US" xlink:label="lab_immu_CollaborationAgreementDomain_7D49EAABA91DEA2E5B127D0659DF6AA0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Collaboration Agreement [Domain]</link:label>
<link:label id="lab_immu_CollaborationAgreementDomain_7D49EAABA91DEA2E5B127D0659DF6AA0_label_en-US" xlink:label="lab_immu_CollaborationAgreementDomain_7D49EAABA91DEA2E5B127D0659DF6AA0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaboration Agreement [Domain]</link:label>
<link:label id="lab_immu_CollaborationAgreementDomain_7D49EAABA91DEA2E5B127D0659DF6AA0_documentation_en-US" xlink:label="lab_immu_CollaborationAgreementDomain_7D49EAABA91DEA2E5B127D0659DF6AA0" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">[Domain] for Collaboration Agreement [Axis]</link:label>
<link:loc xlink:href="immu-20191231.xsd#immu_CollaborationAgreementDomain" xlink:label="loc_immu_CollaborationAgreementDomain_7D49EAABA91DEA2E5B127D0659DF6AA0" xlink:type="locator" />
<link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_immu_CollaborationAgreementDomain_7D49EAABA91DEA2E5B127D0659DF6AA0" xlink:to="lab_immu_CollaborationAgreementDomain_7D49EAABA91DEA2E5B127D0659DF6AA0" xlink:type="arc" />
<link:label id="lab_immu_CBGForschungsGmbHMember_584AB8C3C3D9750314EF7D0659DF3928_terseLabel_en-US" xlink:label="lab_immu_CBGForschungsGmbHMember_584AB8C3C3D9750314EF7D0659DF3928" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">CBG Forschungs GmbH</link:label>
<link:label id="lab_immu_CBGForschungsGmbHMember_584AB8C3C3D9750314EF7D0659DF3928_label_en-US" xlink:label="lab_immu_CBGForschungsGmbHMember_584AB8C3C3D9750314EF7D0659DF3928" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">CBG Forschungs GmbH [Member]</link:label>
<link:label id="lab_immu_CBGForschungsGmbHMember_584AB8C3C3D9750314EF7D0659DF3928_documentation_en-US" xlink:label="lab_immu_CBGForschungsGmbHMember_584AB8C3C3D9750314EF7D0659DF3928" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">CBG Forschungs GmbH [Member]</link:label>
<link:loc xlink:href="immu-20191231.xsd#immu_CBGForschungsGmbHMember" xlink:label="loc_immu_CBGForschungsGmbHMember_584AB8C3C3D9750314EF7D0659DF3928" xlink:type="locator" />
<link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_immu_CBGForschungsGmbHMember_584AB8C3C3D9750314EF7D0659DF3928" xlink:to="lab_immu_CBGForschungsGmbHMember_584AB8C3C3D9750314EF7D0659DF3928" xlink:type="arc" />
<link:label id="lab_us-gaap_GuaranteeObligationsLineItems_59D312A86D862DC0892C7D0659DF7F65_terseLabel_en-US" xlink:label="lab_us-gaap_GuaranteeObligationsLineItems_59D312A86D862DC0892C7D0659DF7F65" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Guarantor Obligations [Line Items]</link:label>
<link:label id="lab_us-gaap_GuaranteeObligationsLineItems_59D312A86D862DC0892C7D0659DF7F65_label_en-US" xlink:label="lab_us-gaap_GuaranteeObligationsLineItems_59D312A86D862DC0892C7D0659DF7F65" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Guarantor Obligations [Line Items]</link:label>
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GuaranteeObligationsLineItems" xlink:label="loc_us-gaap_GuaranteeObligationsLineItems_59D312A86D862DC0892C7D0659DF7F65" xlink:type="locator" />
<link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GuaranteeObligationsLineItems_59D312A86D862DC0892C7D0659DF7F65" xlink:to="lab_us-gaap_GuaranteeObligationsLineItems_59D312A86D862DC0892C7D0659DF7F65" xlink:type="arc" />
<link:label id="lab_immu_NumberofPatients_802AAC05DB627584C5E97D0659E0434A_terseLabel_en-US" xlink:label="lab_immu_NumberofPatients_802AAC05DB627584C5E97D0659E0434A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of patients in clinical collaboration (in patients)</link:label>
<link:label id="lab_immu_NumberofPatients_802AAC05DB627584C5E97D0659E0434A_label_en-US" xlink:label="lab_immu_NumberofPatients_802AAC05DB627584C5E97D0659E0434A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number of Patients</link:label>
<link:label id="lab_immu_NumberofPatients_802AAC05DB627584C5E97D0659E0434A_documentation_en-US" xlink:label="lab_immu_NumberofPatients_802AAC05DB627584C5E97D0659E0434A" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Number of Patients</link:label>
<link:loc xlink:href="immu-20191231.xsd#immu_NumberofPatients" xlink:label="loc_immu_NumberofPatients_802AAC05DB627584C5E97D0659E0434A" xlink:type="locator" />
<link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_immu_NumberofPatients_802AAC05DB627584C5E97D0659E0434A" xlink:to="lab_immu_NumberofPatients_802AAC05DB627584C5E97D0659E0434A" xlink:type="arc" />
<link:label id="lab_immu_AgreementPotentialMilestonePayment_BE8E93B0CC57BF6044857D0659E0758B_terseLabel_en-US" xlink:label="lab_immu_AgreementPotentialMilestonePayment_BE8E93B0CC57BF6044857D0659E0758B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Potential milestone payment</link:label>
<link:label id="lab_immu_AgreementPotentialMilestonePayment_BE8E93B0CC57BF6044857D0659E0758B_label_en-US" xlink:label="lab_immu_AgreementPotentialMilestonePayment_BE8E93B0CC57BF6044857D0659E0758B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Agreement Potential Milestone Payment</link:label>
<link:label id="lab_immu_AgreementPotentialMilestonePayment_BE8E93B0CC57BF6044857D0659E0758B_documentation_en-US" xlink:label="lab_immu_AgreementPotentialMilestonePayment_BE8E93B0CC57BF6044857D0659E0758B" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Agreement Potential Milestone Payment</link:label>
<link:loc xlink:href="immu-20191231.xsd#immu_AgreementPotentialMilestonePayment" xlink:label="loc_immu_AgreementPotentialMilestonePayment_BE8E93B0CC57BF6044857D0659E0758B" xlink:type="locator" />
<link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_immu_AgreementPotentialMilestonePayment_BE8E93B0CC57BF6044857D0659E0758B" xlink:to="lab_immu_AgreementPotentialMilestonePayment_BE8E93B0CC57BF6044857D0659E0758B" xlink:type="arc" />
<link:label id="lab_immu_AgreementPotentialMilestonePaymentTerm_1F69D85CA2F25AE4D86A7D079737F782_terseLabel_en-US" xlink:label="lab_immu_AgreementPotentialMilestonePaymentTerm_1F69D85CA2F25AE4D86A7D079737F782" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Potential milestone payment terms (in years)</link:label>
<link:label id="lab_immu_AgreementPotentialMilestonePaymentTerm_1F69D85CA2F25AE4D86A7D079737F782_label_en-US" xlink:label="lab_immu_AgreementPotentialMilestonePaymentTerm_1F69D85CA2F25AE4D86A7D079737F782" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Agreement, Potential Milestone Payment Term</link:label>
<link:label id="lab_immu_AgreementPotentialMilestonePaymentTerm_1F69D85CA2F25AE4D86A7D079737F782_documentation_en-US" xlink:label="lab_immu_AgreementPotentialMilestonePaymentTerm_1F69D85CA2F25AE4D86A7D079737F782" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Agreement, Potential Milestone Payment Term</link:label>
<link:loc xlink:href="immu-20191231.xsd#immu_AgreementPotentialMilestonePaymentTerm" xlink:label="loc_immu_AgreementPotentialMilestonePaymentTerm_1F69D85CA2F25AE4D86A7D079737F782" xlink:type="locator" />
<link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_immu_AgreementPotentialMilestonePaymentTerm_1F69D85CA2F25AE4D86A7D079737F782" xlink:to="lab_immu_AgreementPotentialMilestonePaymentTerm_1F69D85CA2F25AE4D86A7D079737F782" xlink:type="arc" />
<link:label id="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities_DB0976E4D317949B39DA7D0659E0F6C2_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities_DB0976E4D317949B39DA7D0659E0F6C2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued expenses</link:label>
<link:label id="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities_DB0976E4D317949B39DA7D0659E0F6C2_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities_DB0976E4D317949B39DA7D0659E0F6C2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Accrued Liabilities</link:label>
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_DB0976E4D317949B39DA7D0659E0F6C2" xlink:type="locator" />
<link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_DB0976E4D317949B39DA7D0659E0F6C2" xlink:to="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities_DB0976E4D317949B39DA7D0659E0F6C2" xlink:type="arc" />
<link:label id="lab_us-gaap_SubsequentEventTypeAxis_BC313587271DDD4AB380850F474529B5_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeAxis_BC313587271DDD4AB380850F474529B5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Subsequent Event Type [Axis]</link:label>
<link:label id="lab_us-gaap_SubsequentEventTypeAxis_BC313587271DDD4AB380850F474529B5_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeAxis_BC313587271DDD4AB380850F474529B5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsequent Event Type [Axis]</link:label>
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_BC313587271DDD4AB380850F474529B5" xlink:type="locator" />
<link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_BC313587271DDD4AB380850F474529B5" xlink:to="lab_us-gaap_SubsequentEventTypeAxis_BC313587271DDD4AB380850F474529B5" xlink:type="arc" />
<link:label id="lab_us-gaap_SubsequentEventTypeDomain_0E0CE576C169D42AD03B850F47455F11_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeDomain_0E0CE576C169D42AD03B850F47455F11" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Subsequent Event Type [Domain]</link:label>
<link:label id="lab_us-gaap_SubsequentEventTypeDomain_0E0CE576C169D42AD03B850F47455F11_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeDomain_0E0CE576C169D42AD03B850F47455F11" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsequent Event Type [Domain]</link:label>
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_0E0CE576C169D42AD03B850F47455F11" xlink:type="locator" />
<link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_0E0CE576C169D42AD03B850F47455F11" xlink:to="lab_us-gaap_SubsequentEventTypeDomain_0E0CE576C169D42AD03B850F47455F11" xlink:type="arc" />
<link:label id="lab_us-gaap_SubsequentEventMember_3B18C89D2AF06ADB7E28850F4745A893_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventMember_3B18C89D2AF06ADB7E28850F4745A893" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Subsequent Event</link:label>
<link:label id="lab_us-gaap_SubsequentEventMember_3B18C89D2AF06ADB7E28850F4745A893_label_en-US" xlink:label="lab_us-gaap_SubsequentEventMember_3B18C89D2AF06ADB7E28850F4745A893" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsequent Event [Member]</link:label>
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaap_SubsequentEventMember_3B18C89D2AF06ADB7E28850F4745A893" xlink:type="locator" />
<link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventMember_3B18C89D2AF06ADB7E28850F4745A893" xlink:to="lab_us-gaap_SubsequentEventMember_3B18C89D2AF06ADB7E28850F4745A893" xlink:type="arc" />
<link:label id="lab_immu_TheScrippsResearchInstituteMember_D02242A86CEB0767E654850F47467FBF_terseLabel_en-US" xlink:label="lab_immu_TheScrippsResearchInstituteMember_D02242A86CEB0767E654850F47467FBF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">TSRI</link:label>
<link:label id="lab_immu_TheScrippsResearchInstituteMember_D02242A86CEB0767E654850F47467FBF_label_en-US" xlink:label="lab_immu_TheScrippsResearchInstituteMember_D02242A86CEB0767E654850F47467FBF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">The Scripps Research Institute [Member]</link:label>
<link:label id="lab_immu_TheScrippsResearchInstituteMember_D02242A86CEB0767E654850F47467FBF_documentation_en-US" xlink:label="lab_immu_TheScrippsResearchInstituteMember_D02242A86CEB0767E654850F47467FBF" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The Scripps Research Institute [Member]</link:label>
<link:loc xlink:href="immu-20191231.xsd#immu_TheScrippsResearchInstituteMember" xlink:label="loc_immu_TheScrippsResearchInstituteMember_D02242A86CEB0767E654850F47467FBF" xlink:type="locator" />
<link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_immu_TheScrippsResearchInstituteMember_D02242A86CEB0767E654850F47467FBF" xlink:to="lab_immu_TheScrippsResearchInstituteMember_D02242A86CEB0767E654850F47467FBF" xlink:type="arc" />
<link:label id="lab_srt_LitigationCaseAxis_53F9DDF6B17FDDA34DAC850F4746A5B5_terseLabel_en-US" xlink:label="lab_srt_LitigationCaseAxis_53F9DDF6B17FDDA34DAC850F4746A5B5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Litigation Case [Axis]</link:label>
<link:label id="lab_srt_LitigationCaseAxis_53F9DDF6B17FDDA34DAC850F4746A5B5_label_en-US" xlink:label="lab_srt_LitigationCaseAxis_53F9DDF6B17FDDA34DAC850F4746A5B5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Litigation Case [Axis]</link:label>
<link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_LitigationCaseAxis" xlink:label="loc_srt_LitigationCaseAxis_53F9DDF6B17FDDA34DAC850F4746A5B5" xlink:type="locator" />
<link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_LitigationCaseAxis_53F9DDF6B17FDDA34DAC850F4746A5B5" xlink:to="lab_srt_LitigationCaseAxis_53F9DDF6B17FDDA34DAC850F4746A5B5" xlink:type="arc" />
<link:label id="lab_srt_LitigationCaseTypeDomain_7305AC435EDA2B81570A850F4746BE99_terseLabel_en-US" xlink:label="lab_srt_LitigationCaseTypeDomain_7305AC435EDA2B81570A850F4746BE99" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Litigation Case [Domain]</link:label>
<link:label id="lab_srt_LitigationCaseTypeDomain_7305AC435EDA2B81570A850F4746BE99_label_en-US" xlink:label="lab_srt_LitigationCaseTypeDomain_7305AC435EDA2B81570A850F4746BE99" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Litigation Case [Domain]</link:label>
<link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_LitigationCaseTypeDomain" xlink:label="loc_srt_LitigationCaseTypeDomain_7305AC435EDA2B81570A850F4746BE99" xlink:type="locator" />
<link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_LitigationCaseTypeDomain_7305AC435EDA2B81570A850F4746BE99" xlink:to="lab_srt_LitigationCaseTypeDomain_7305AC435EDA2B81570A850F4746BE99" xlink:type="arc" />
<link:label id="lab_immu_InsuranceCoverageArbitrationMember_A92C2D42782767A9EDC1850F47479BF6_terseLabel_en-US" xlink:label="lab_immu_InsuranceCoverageArbitrationMember_A92C2D42782767A9EDC1850F47479BF6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Insurance Coverage Arbitration</link:label>
<link:label id="lab_immu_InsuranceCoverageArbitrationMember_A92C2D42782767A9EDC1850F47479BF6_label_en-US" xlink:label="lab_immu_InsuranceCoverageArbitrationMember_A92C2D42782767A9EDC1850F47479BF6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Insurance Coverage Arbitration [Member]</link:label>
<link:label id="lab_immu_InsuranceCoverageArbitrationMember_A92C2D42782767A9EDC1850F47479BF6_documentation_en-US" xlink:label="lab_immu_InsuranceCoverageArbitrationMember_A92C2D42782767A9EDC1850F47479BF6" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Insurance Coverage Arbitration [Member]</link:label>
<link:loc xlink:href="immu-20191231.xsd#immu_InsuranceCoverageArbitrationMember" xlink:label="loc_immu_InsuranceCoverageArbitrationMember_A92C2D42782767A9EDC1850F47479BF6" xlink:type="locator" />
<link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_immu_InsuranceCoverageArbitrationMember_A92C2D42782767A9EDC1850F47479BF6" xlink:to="lab_immu_InsuranceCoverageArbitrationMember_A92C2D42782767A9EDC1850F47479BF6" xlink:type="arc" />
<link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_7FA6E5B85171D86491C1850F4747636D_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_7FA6E5B85171D86491C1850F4747636D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets by Major Class [Axis]</link:label>
<link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_7FA6E5B85171D86491C1850F4747636D_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_7FA6E5B85171D86491C1850F4747636D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets by Major Class [Axis]</link:label>
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_7FA6E5B85171D86491C1850F4747636D" xlink:type="locator" />
<link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_7FA6E5B85171D86491C1850F4747636D" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_7FA6E5B85171D86491C1850F4747636D" xlink:type="arc" />
<link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_51366888B45043F08DB9850F47477B2A_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_51366888B45043F08DB9850F47477B2A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets, Major Class Name [Domain]</link:label>
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_51366888B45043F08DB9850F47477B2A" xlink:type="locator" />
<link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_51366888B45043F08DB9850F47477B2A" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_51366888B45043F08DB9850F47477B2A" xlink:type="arc" />
<link:label id="lab_us-gaap_EmploymentContractsMember_F170CDAFECA94CDE3993850F4747587E_terseLabel_en-US" xlink:label="lab_us-gaap_EmploymentContractsMember_F170CDAFECA94CDE3993850F4747587E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Employment Agreement</link:label>
<link:label id="lab_us-gaap_EmploymentContractsMember_F170CDAFECA94CDE3993850F4747587E_label_en-US" xlink:label="lab_us-gaap_EmploymentContractsMember_F170CDAFECA94CDE3993850F4747587E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Employment Contracts [Member]</link:label>
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmploymentContractsMember" xlink:label="loc_us-gaap_EmploymentContractsMember_F170CDAFECA94CDE3993850F4747587E" xlink:type="locator" />
<link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmploymentContractsMember_F170CDAFECA94CDE3993850F4747587E" xlink:to="lab_us-gaap_EmploymentContractsMember_F170CDAFECA94CDE3993850F4747587E" xlink:type="arc" />
<link:label id="lab_immu_RestrictedUnitsWithVestingMarketConditionsMember_548A856D4564E86F573D850F47485B66_terseLabel_en-US" xlink:label="lab_immu_RestrictedUnitsWithVestingMarketConditionsMember_548A856D4564E86F573D850F47485B66" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restricted Units Vesting Based on Certain Market Conditions</link:label>
<link:label id="lab_immu_RestrictedUnitsWithVestingMarketConditionsMember_548A856D4564E86F573D850F47485B66_label_en-US" xlink:label="lab_immu_RestrictedUnitsWithVestingMarketConditionsMember_548A856D4564E86F573D850F47485B66" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restricted Units With Vesting Market Conditions [Member]</link:label>
<link:label id="lab_immu_RestrictedUnitsWithVestingMarketConditionsMember_548A856D4564E86F573D850F47485B66_documentation_en-US" xlink:label="lab_immu_RestrictedUnitsWithVestingMarketConditionsMember_548A856D4564E86F573D850F47485B66" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Restricted Units with Vesting Market Conditions [Member]</link:label>
<link:loc xlink:href="immu-20191231.xsd#immu_RestrictedUnitsWithVestingMarketConditionsMember" xlink:label="loc_immu_RestrictedUnitsWithVestingMarketConditionsMember_548A856D4564E86F573D850F47485B66" xlink:type="locator" />
<link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_immu_RestrictedUnitsWithVestingMarketConditionsMember_548A856D4564E86F573D850F47485B66" xlink:to="lab_immu_RestrictedUnitsWithVestingMarketConditionsMember_548A856D4564E86F573D850F47485B66" xlink:type="arc" />
<link:label id="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_1FFBAFB04A7E1FD98481850F474974FA_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_1FFBAFB04A7E1FD98481850F474974FA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Related Party [Axis]</link:label>
<link:label id="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_1FFBAFB04A7E1FD98481850F474974FA_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_1FFBAFB04A7E1FD98481850F474974FA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Related Party [Axis]</link:label>
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_1FFBAFB04A7E1FD98481850F474974FA" xlink:type="locator" />
<link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_1FFBAFB04A7E1FD98481850F474974FA" xlink:to="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_1FFBAFB04A7E1FD98481850F474974FA" xlink:type="arc" />
<link:label id="lab_us-gaap_RelatedPartyDomain_9FCE8CE4D153C4B740BE850F47492ECE_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyDomain_9FCE8CE4D153C4B740BE850F47492ECE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Related Party [Domain]</link:label>
<link:label id="lab_us-gaap_RelatedPartyDomain_9FCE8CE4D153C4B740BE850F47492ECE_label_en-US" xlink:label="lab_us-gaap_RelatedPartyDomain_9FCE8CE4D153C4B740BE850F47492ECE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Related Party [Domain]</link:label>
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain_9FCE8CE4D153C4B740BE850F47492ECE" xlink:type="locator" />
<link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyDomain_9FCE8CE4D153C4B740BE850F47492ECE" xlink:to="lab_us-gaap_RelatedPartyDomain_9FCE8CE4D153C4B740BE850F47492ECE" xlink:type="arc" />
<link:label id="lab_immu_GoldenbergAgreementMember_A51ACD98FE41C350A1A5850F47493F30_terseLabel_en-US" xlink:label="lab_immu_GoldenbergAgreementMember_A51ACD98FE41C350A1A5850F47493F30" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Goldenberg Agreement</link:label>
<link:label id="lab_immu_GoldenbergAgreementMember_A51ACD98FE41C350A1A5850F47493F30_label_en-US" xlink:label="lab_immu_GoldenbergAgreementMember_A51ACD98FE41C350A1A5850F47493F30" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Goldenberg Agreement [Member]</link:label>
<link:label id="lab_immu_GoldenbergAgreementMember_A51ACD98FE41C350A1A5850F47493F30_documentation_en-US" xlink:label="lab_immu_GoldenbergAgreementMember_A51ACD98FE41C350A1A5850F47493F30" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Goldenberg Agreement [Member]</link:label>
<link:loc xlink:href="immu-20191231.xsd#immu_GoldenbergAgreementMember" xlink:label="loc_immu_GoldenbergAgreementMember_A51ACD98FE41C350A1A5850F47493F30" xlink:type="locator" />
<link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_immu_GoldenbergAgreementMember_A51ACD98FE41C350A1A5850F47493F30" xlink:to="lab_immu_GoldenbergAgreementMember_A51ACD98FE41C350A1A5850F47493F30" xlink:type="arc" />
<link:label id="lab_srt_TitleOfIndividualAxis_43490DB8081F974C479F850F474995E9_terseLabel_en-US" xlink:label="lab_srt_TitleOfIndividualAxis_43490DB8081F974C479F850F474995E9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Title of Individual [Axis]</link:label>
<link:label id="lab_srt_TitleOfIndividualAxis_43490DB8081F974C479F850F474995E9_label_en-US" xlink:label="lab_srt_TitleOfIndividualAxis_43490DB8081F974C479F850F474995E9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Title of Individual [Axis]</link:label>
<link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_TitleOfIndividualAxis" xlink:label="loc_srt_TitleOfIndividualAxis_43490DB8081F974C479F850F474995E9" xlink:type="locator" />
<link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_TitleOfIndividualAxis_43490DB8081F974C479F850F474995E9" xlink:to="lab_srt_TitleOfIndividualAxis_43490DB8081F974C479F850F474995E9" xlink:type="arc" />
<link:label id="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain_9A21E4427FF67C5DF939850F474959F0_terseLabel_en-US" xlink:label="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain_9A21E4427FF67C5DF939850F474959F0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Title of Individual [Domain]</link:label>
<link:label id="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain_9A21E4427FF67C5DF939850F474959F0_label_en-US" xlink:label="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain_9A21E4427FF67C5DF939850F474959F0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Title of Individual [Domain]</link:label>
<link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_9A21E4427FF67C5DF939850F474959F0" xlink:type="locator" />
<link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_9A21E4427FF67C5DF939850F474959F0" xlink:to="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain_9A21E4427FF67C5DF939850F474959F0" xlink:type="arc" />
<link:label id="lab_srt_ChiefExecutiveOfficerMember_27977EC00981FCAC22C7850F474A7D72_terseLabel_en-US" xlink:label="lab_srt_ChiefExecutiveOfficerMember_27977EC00981FCAC22C7850F474A7D72" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Chief Executive Officer</link:label>
<link:label id="lab_srt_ChiefExecutiveOfficerMember_27977EC00981FCAC22C7850F474A7D72_label_en-US" xlink:label="lab_srt_ChiefExecutiveOfficerMember_27977EC00981FCAC22C7850F474A7D72" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Chief Executive Officer [Member]</link:label>
<link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ChiefExecutiveOfficerMember" xlink:label="loc_srt_ChiefExecutiveOfficerMember_27977EC00981FCAC22C7850F474A7D72" xlink:type="locator" />
<link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ChiefExecutiveOfficerMember_27977EC00981FCAC22C7850F474A7D72" xlink:to="lab_srt_ChiefExecutiveOfficerMember_27977EC00981FCAC22C7850F474A7D72" xlink:type="arc" />
<link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_A5D0DDF4B0D2FAD71637850F474A758F_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_A5D0DDF4B0D2FAD71637850F474A758F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restricted stock units granted (in shares)</link:label>
<link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_A5D0DDF4B0D2FAD71637850F474A758F_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_A5D0DDF4B0D2FAD71637850F474A758F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period</link:label>
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_A5D0DDF4B0D2FAD71637850F474A758F" xlink:type="locator" />
<link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_A5D0DDF4B0D2FAD71637850F474A758F" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_A5D0DDF4B0D2FAD71637850F474A758F" xlink:type="arc" />
<link:label id="lab_us-gaap_SeveranceCosts1_260AAC05678B8422ADCE850F474AA2D6_terseLabel_en-US" xlink:label="lab_us-gaap_SeveranceCosts1_260AAC05678B8422ADCE850F474AA2D6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Severance costs</link:label>
<link:label id="lab_us-gaap_SeveranceCosts1_260AAC05678B8422ADCE850F474AA2D6_label_en-US" xlink:label="lab_us-gaap_SeveranceCosts1_260AAC05678B8422ADCE850F474AA2D6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Severance Costs</link:label>
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SeveranceCosts1" xlink:label="loc_us-gaap_SeveranceCosts1_260AAC05678B8422ADCE850F474AA2D6" xlink:type="locator" />
<link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SeveranceCosts1_260AAC05678B8422ADCE850F474AA2D6" xlink:to="lab_us-gaap_SeveranceCosts1_260AAC05678B8422ADCE850F474AA2D6" xlink:type="arc" />
<link:label id="lab_us-gaap_LossContingencyDamagesSoughtValue_C29CF9DAB622DAD9EB2E850F474B838C_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingencyDamagesSoughtValue_C29CF9DAB622DAD9EB2E850F474B838C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Legal fees</link:label>
<link:label id="lab_us-gaap_LossContingencyDamagesSoughtValue_C29CF9DAB622DAD9EB2E850F474B838C_label_en-US" xlink:label="lab_us-gaap_LossContingencyDamagesSoughtValue_C29CF9DAB622DAD9EB2E850F474B838C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Loss Contingency, Damages Sought, Value</link:label>
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LossContingencyDamagesSoughtValue" xlink:label="loc_us-gaap_LossContingencyDamagesSoughtValue_C29CF9DAB622DAD9EB2E850F474B838C" xlink:type="locator" />
<link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingencyDamagesSoughtValue_C29CF9DAB622DAD9EB2E850F474B838C" xlink:to="lab_us-gaap_LossContingencyDamagesSoughtValue_C29CF9DAB622DAD9EB2E850F474B838C" xlink:type="arc" />
<link:label id="lab_us-gaap_OperatingLeasePayments_A7BBD7A78B98821F75C3850F474B1B7B_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeasePayments_A7BBD7A78B98821F75C3850F474B1B7B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating lease, liability</link:label>
<link:label id="lab_us-gaap_OperatingLeasePayments_A7BBD7A78B98821F75C3850F474B1B7B_label_en-US" xlink:label="lab_us-gaap_OperatingLeasePayments_A7BBD7A78B98821F75C3850F474B1B7B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Payments</link:label>
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeasePayments" xlink:label="loc_us-gaap_OperatingLeasePayments_A7BBD7A78B98821F75C3850F474B1B7B" xlink:type="locator" />
<link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasePayments_A7BBD7A78B98821F75C3850F474B1B7B" xlink:to="lab_us-gaap_OperatingLeasePayments_A7BBD7A78B98821F75C3850F474B1B7B" xlink:type="arc" />
<link:label id="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_250B02C5A6374FAD72C5850F474B7F47_verboseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_250B02C5A6374FAD72C5850F474B7F47" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Weighted average discount rate, percent</link:label>
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_250B02C5A6374FAD72C5850F474B7F47" xlink:type="locator" />
<link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_250B02C5A6374FAD72C5850F474B7F47" xlink:to="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_250B02C5A6374FAD72C5850F474B7F47" xlink:type="arc" />
<link:label id="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_3840C26F8723C73FFB60850F474BA0D5_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_3840C26F8723C73FFB60850F474BA0D5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted average remaining lease term</link:label>
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_3840C26F8723C73FFB60850F474BA0D5" xlink:type="locator" />
<link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_3840C26F8723C73FFB60850F474BA0D5" xlink:to="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_3840C26F8723C73FFB60850F474BA0D5" xlink:type="arc" />
<link:label id="lab_us-gaap_LeaseCost_E818EAA8F2E4A080286B850F474B6919_terseLabel_en-US" xlink:label="lab_us-gaap_LeaseCost_E818EAA8F2E4A080286B850F474B6919" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Lease cost</link:label>
<link:label id="lab_us-gaap_LeaseCost_E818EAA8F2E4A080286B850F474B6919_label_en-US" xlink:label="lab_us-gaap_LeaseCost_E818EAA8F2E4A080286B850F474B6919" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lease, Cost</link:label>
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LeaseCost" xlink:label="loc_us-gaap_LeaseCost_E818EAA8F2E4A080286B850F474B6919" xlink:type="locator" />
<link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseCost_E818EAA8F2E4A080286B850F474B6919" xlink:to="lab_us-gaap_LeaseCost_E818EAA8F2E4A080286B850F474B6919" xlink:type="arc" />
<link:label id="lab_us-gaap_PurchaseObligationDueInNextTwelveMonths_AC3B2A7655FA2E5F27DD850F474B533B_terseLabel_en-US" xlink:label="lab_us-gaap_PurchaseObligationDueInNextTwelveMonths_AC3B2A7655FA2E5F27DD850F474B533B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Purchase commitments due 2020</link:label>
<link:label id="lab_us-gaap_PurchaseObligationDueInNextTwelveMonths_AC3B2A7655FA2E5F27DD850F474B533B_label_en-US" xlink:label="lab_us-gaap_PurchaseObligationDueInNextTwelveMonths_AC3B2A7655FA2E5F27DD850F474B533B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Purchase Obligation, Due in Next Twelve Months</link:label>
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PurchaseObligationDueInNextTwelveMonths" xlink:label="loc_us-gaap_PurchaseObligationDueInNextTwelveMonths_AC3B2A7655FA2E5F27DD850F474B533B" xlink:type="locator" />
<link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PurchaseObligationDueInNextTwelveMonths_AC3B2A7655FA2E5F27DD850F474B533B" xlink:to="lab_us-gaap_PurchaseObligationDueInNextTwelveMonths_AC3B2A7655FA2E5F27DD850F474B533B" xlink:type="arc" />
<link:label id="lab_us-gaap_PurchaseObligationDueInSecondYear_647302C8F424C964A636850F474C2CDD_terseLabel_en-US" xlink:label="lab_us-gaap_PurchaseObligationDueInSecondYear_647302C8F424C964A636850F474C2CDD" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Purchase commitments due 2021</link:label>
<link:label id="lab_us-gaap_PurchaseObligationDueInSecondYear_647302C8F424C964A636850F474C2CDD_label_en-US" xlink:label="lab_us-gaap_PurchaseObligationDueInSecondYear_647302C8F424C964A636850F474C2CDD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Purchase Obligation, Due in Second Year</link:label>
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PurchaseObligationDueInSecondYear" xlink:label="loc_us-gaap_PurchaseObligationDueInSecondYear_647302C8F424C964A636850F474C2CDD" xlink:type="locator" />
<link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PurchaseObligationDueInSecondYear_647302C8F424C964A636850F474C2CDD" xlink:to="lab_us-gaap_PurchaseObligationDueInSecondYear_647302C8F424C964A636850F474C2CDD" xlink:type="arc" />
<link:label id="lab_us-gaap_PurchaseObligationDueInThirdYear_1ED3933733761292C567850F474C45B7_terseLabel_en-US" xlink:label="lab_us-gaap_PurchaseObligationDueInThirdYear_1ED3933733761292C567850F474C45B7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Purchase commitments due 2022</link:label>
<link:label id="lab_us-gaap_PurchaseObligationDueInThirdYear_1ED3933733761292C567850F474C45B7_label_en-US" xlink:label="lab_us-gaap_PurchaseObligationDueInThirdYear_1ED3933733761292C567850F474C45B7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Purchase Obligation, Due in Third Year</link:label>
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PurchaseObligationDueInThirdYear" xlink:label="loc_us-gaap_PurchaseObligationDueInThirdYear_1ED3933733761292C567850F474C45B7" xlink:type="locator" />
<link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PurchaseObligationDueInThirdYear_1ED3933733761292C567850F474C45B7" xlink:to="lab_us-gaap_PurchaseObligationDueInThirdYear_1ED3933733761292C567850F474C45B7" xlink:type="arc" />
<link:label id="lab_us-gaap_PurchaseObligationDueInFourthYear_2CE21846F5D15265D8C6850F474CABB0_terseLabel_en-US" xlink:label="lab_us-gaap_PurchaseObligationDueInFourthYear_2CE21846F5D15265D8C6850F474CABB0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Purchase commitments due 2023</link:label>
<link:label id="lab_us-gaap_PurchaseObligationDueInFourthYear_2CE21846F5D15265D8C6850F474CABB0_label_en-US" xlink:label="lab_us-gaap_PurchaseObligationDueInFourthYear_2CE21846F5D15265D8C6850F474CABB0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Purchase Obligation, Due in Fourth Year</link:label>
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PurchaseObligationDueInFourthYear" xlink:label="loc_us-gaap_PurchaseObligationDueInFourthYear_2CE21846F5D15265D8C6850F474CABB0" xlink:type="locator" />
<link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PurchaseObligationDueInFourthYear_2CE21846F5D15265D8C6850F474CABB0" xlink:to="lab_us-gaap_PurchaseObligationDueInFourthYear_2CE21846F5D15265D8C6850F474CABB0" xlink:type="arc" />
<link:label id="lab_us-gaap_PurchaseObligationDueInFifthYear_2E86AB6D75C997385ECD850F474C40E8_terseLabel_en-US" xlink:label="lab_us-gaap_PurchaseObligationDueInFifthYear_2E86AB6D75C997385ECD850F474C40E8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Purchase commitments due 2024</link:label>
<link:label id="lab_us-gaap_PurchaseObligationDueInFifthYear_2E86AB6D75C997385ECD850F474C40E8_label_en-US" xlink:label="lab_us-gaap_PurchaseObligationDueInFifthYear_2E86AB6D75C997385ECD850F474C40E8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Purchase Obligation, Due in Fifth Year</link:label>
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PurchaseObligationDueInFifthYear" xlink:label="loc_us-gaap_PurchaseObligationDueInFifthYear_2E86AB6D75C997385ECD850F474C40E8" xlink:type="locator" />
<link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PurchaseObligationDueInFifthYear_2E86AB6D75C997385ECD850F474C40E8" xlink:to="lab_us-gaap_PurchaseObligationDueInFifthYear_2E86AB6D75C997385ECD850F474C40E8" xlink:type="arc" />
<link:label id="lab_us-gaap_PurchaseObligationDueAfterFifthYear_646C93F1A48A867BCB08850F474C60BC_terseLabel_en-US" xlink:label="lab_us-gaap_PurchaseObligationDueAfterFifthYear_646C93F1A48A867BCB08850F474C60BC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Purchase commitments due thereafter</link:label>
<link:label id="lab_us-gaap_PurchaseObligationDueAfterFifthYear_646C93F1A48A867BCB08850F474C60BC_label_en-US" xlink:label="lab_us-gaap_PurchaseObligationDueAfterFifthYear_646C93F1A48A867BCB08850F474C60BC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Purchase Obligation, Due after Fifth Year</link:label>
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PurchaseObligationDueAfterFifthYear" xlink:label="loc_us-gaap_PurchaseObligationDueAfterFifthYear_646C93F1A48A867BCB08850F474C60BC" xlink:type="locator" />
<link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PurchaseObligationDueAfterFifthYear_646C93F1A48A867BCB08850F474C60BC" xlink:to="lab_us-gaap_PurchaseObligationDueAfterFifthYear_646C93F1A48A867BCB08850F474C60BC" xlink:type="arc" />
<link:label id="lab_immu_NumberofDaysLicenseCancellableAfterNonPayment_447D0ED523899122A486850F474C9A3F_terseLabel_en-US" xlink:label="lab_immu_NumberofDaysLicenseCancellableAfterNonPayment_447D0ED523899122A486850F474C9A3F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of days license cancellable after non-payment</link:label>
<link:label id="lab_immu_NumberofDaysLicenseCancellableAfterNonPayment_447D0ED523899122A486850F474C9A3F_label_en-US" xlink:label="lab_immu_NumberofDaysLicenseCancellableAfterNonPayment_447D0ED523899122A486850F474C9A3F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number of Days License Cancellable After Non-Payment</link:label>
<link:label id="lab_immu_NumberofDaysLicenseCancellableAfterNonPayment_447D0ED523899122A486850F474C9A3F_documentation_en-US" xlink:label="lab_immu_NumberofDaysLicenseCancellableAfterNonPayment_447D0ED523899122A486850F474C9A3F" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Number of Days License Cancellable After Non-Payment</link:label>
<link:loc xlink:href="immu-20191231.xsd#immu_NumberofDaysLicenseCancellableAfterNonPayment" xlink:label="loc_immu_NumberofDaysLicenseCancellableAfterNonPayment_447D0ED523899122A486850F474C9A3F" xlink:type="locator" />
<link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_immu_NumberofDaysLicenseCancellableAfterNonPayment_447D0ED523899122A486850F474C9A3F" xlink:to="lab_immu_NumberofDaysLicenseCancellableAfterNonPayment_447D0ED523899122A486850F474C9A3F" xlink:type="arc" />
<link:label id="lab_us-gaap_PaymentForContingentConsiderationLiabilityInvestingActivities_226A6BC275F7EA47BAED850F474C4BE2_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentForContingentConsiderationLiabilityInvestingActivities_226A6BC275F7EA47BAED850F474C4BE2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Payment for contingent consideration liability</link:label>
<link:label id="lab_us-gaap_PaymentForContingentConsiderationLiabilityInvestingActivities_226A6BC275F7EA47BAED850F474C4BE2_label_en-US" xlink:label="lab_us-gaap_PaymentForContingentConsiderationLiabilityInvestingActivities_226A6BC275F7EA47BAED850F474C4BE2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payment for Contingent Consideration Liability, Investing Activities</link:label>
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentForContingentConsiderationLiabilityInvestingActivities" xlink:label="loc_us-gaap_PaymentForContingentConsiderationLiabilityInvestingActivities_226A6BC275F7EA47BAED850F474C4BE2" xlink:type="locator" />
<link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentForContingentConsiderationLiabilityInvestingActivities_226A6BC275F7EA47BAED850F474C4BE2" xlink:to="lab_us-gaap_PaymentForContingentConsiderationLiabilityInvestingActivities_226A6BC275F7EA47BAED850F474C4BE2" xlink:type="arc" />
<link:label id="lab_immu_LicenseAgreementMilestoneExpense_F031B3F84AFD2D4F30CD850F474D464B_terseLabel_en-US" xlink:label="lab_immu_LicenseAgreementMilestoneExpense_F031B3F84AFD2D4F30CD850F474D464B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Milestone expense</link:label>
<link:label id="lab_immu_LicenseAgreementMilestoneExpense_F031B3F84AFD2D4F30CD850F474D464B_label_en-US" xlink:label="lab_immu_LicenseAgreementMilestoneExpense_F031B3F84AFD2D4F30CD850F474D464B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">License Agreement Milestone Expense</link:label>
<link:label id="lab_immu_LicenseAgreementMilestoneExpense_F031B3F84AFD2D4F30CD850F474D464B_documentation_en-US" xlink:label="lab_immu_LicenseAgreementMilestoneExpense_F031B3F84AFD2D4F30CD850F474D464B" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">License Agreement Milestone Expense</link:label>
<link:loc xlink:href="immu-20191231.xsd#immu_LicenseAgreementMilestoneExpense" xlink:label="loc_immu_LicenseAgreementMilestoneExpense_F031B3F84AFD2D4F30CD850F474D464B" xlink:type="locator" />
<link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_immu_LicenseAgreementMilestoneExpense_F031B3F84AFD2D4F30CD850F474D464B" xlink:to="lab_immu_LicenseAgreementMilestoneExpense_F031B3F84AFD2D4F30CD850F474D464B" xlink:type="arc" />
<link:label id="lab_us-gaap_SupplementalUnemploymentBenefitsSeveranceBenefits_704320BF00AB89F9071B850F474DFFAA_verboseLabel_en-US" xlink:label="lab_us-gaap_SupplementalUnemploymentBenefitsSeveranceBenefits_704320BF00AB89F9071B850F474DFFAA" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Severance benefits</link:label>
<link:label id="lab_us-gaap_SupplementalUnemploymentBenefitsSeveranceBenefits_704320BF00AB89F9071B850F474DFFAA_label_en-US" xlink:label="lab_us-gaap_SupplementalUnemploymentBenefitsSeveranceBenefits_704320BF00AB89F9071B850F474DFFAA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Supplemental Unemployment Benefits, Severance Benefits</link:label>
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SupplementalUnemploymentBenefitsSeveranceBenefits" xlink:label="loc_us-gaap_SupplementalUnemploymentBenefitsSeveranceBenefits_704320BF00AB89F9071B850F474DFFAA" xlink:type="locator" />
<link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SupplementalUnemploymentBenefitsSeveranceBenefits_704320BF00AB89F9071B850F474DFFAA" xlink:to="lab_us-gaap_SupplementalUnemploymentBenefitsSeveranceBenefits_704320BF00AB89F9071B850F474DFFAA" xlink:type="arc" />
<link:label id="lab_immu_SupplementalUnemploymentBenefitsSeveranceBenefitsPaymentTerm_FB012E23005E35A8821F850F474D4A3E_terseLabel_en-US" xlink:label="lab_immu_SupplementalUnemploymentBenefitsSeveranceBenefitsPaymentTerm_FB012E23005E35A8821F850F474D4A3E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Severance benefits payment term (in months)</link:label>
<link:label id="lab_immu_SupplementalUnemploymentBenefitsSeveranceBenefitsPaymentTerm_FB012E23005E35A8821F850F474D4A3E_label_en-US" xlink:label="lab_immu_SupplementalUnemploymentBenefitsSeveranceBenefitsPaymentTerm_FB012E23005E35A8821F850F474D4A3E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Supplemental Unemployment Benefits, Severance Benefits, Payment Term</link:label>
<link:label id="lab_immu_SupplementalUnemploymentBenefitsSeveranceBenefitsPaymentTerm_FB012E23005E35A8821F850F474D4A3E_documentation_en-US" xlink:label="lab_immu_SupplementalUnemploymentBenefitsSeveranceBenefitsPaymentTerm_FB012E23005E35A8821F850F474D4A3E" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Supplemental Unemployment Benefits, Severance Benefits, Payment Term</link:label>
<link:loc xlink:href="immu-20191231.xsd#immu_SupplementalUnemploymentBenefitsSeveranceBenefitsPaymentTerm" xlink:label="loc_immu_SupplementalUnemploymentBenefitsSeveranceBenefitsPaymentTerm_FB012E23005E35A8821F850F474D4A3E" xlink:type="locator" />
<link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_immu_SupplementalUnemploymentBenefitsSeveranceBenefitsPaymentTerm_FB012E23005E35A8821F850F474D4A3E" xlink:to="lab_immu_SupplementalUnemploymentBenefitsSeveranceBenefitsPaymentTerm_FB012E23005E35A8821F850F474D4A3E" xlink:type="arc" />
<link:label id="lab_us-gaap_SalariesWagesAndOfficersCompensation_3A26831790DCD0A1D852850F474D5924_verboseLabel_en-US" xlink:label="lab_us-gaap_SalariesWagesAndOfficersCompensation_3A26831790DCD0A1D852850F474D5924" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Officers' compensation</link:label>
<link:label id="lab_us-gaap_SalariesWagesAndOfficersCompensation_3A26831790DCD0A1D852850F474D5924_label_en-US" xlink:label="lab_us-gaap_SalariesWagesAndOfficersCompensation_3A26831790DCD0A1D852850F474D5924" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Salary and Wage, Excluding Cost of Good and Service Sold</link:label>
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SalariesWagesAndOfficersCompensation" xlink:label="loc_us-gaap_SalariesWagesAndOfficersCompensation_3A26831790DCD0A1D852850F474D5924" xlink:type="locator" />
<link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SalariesWagesAndOfficersCompensation_3A26831790DCD0A1D852850F474D5924" xlink:to="lab_us-gaap_SalariesWagesAndOfficersCompensation_3A26831790DCD0A1D852850F474D5924" xlink:type="arc" />
<link:label id="lab_us-gaap_SupplementalUnemploymentBenefitsSalaryContinuation_D616856A9F3C6E1AA683850F474D08CA_terseLabel_en-US" xlink:label="lab_us-gaap_SupplementalUnemploymentBenefitsSalaryContinuation_D616856A9F3C6E1AA683850F474D08CA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Salary accrued</link:label>
<link:label id="lab_us-gaap_SupplementalUnemploymentBenefitsSalaryContinuation_D616856A9F3C6E1AA683850F474D08CA_label_en-US" xlink:label="lab_us-gaap_SupplementalUnemploymentBenefitsSalaryContinuation_D616856A9F3C6E1AA683850F474D08CA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Supplemental Unemployment Benefits, Salary Continuation</link:label>
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SupplementalUnemploymentBenefitsSalaryContinuation" xlink:label="loc_us-gaap_SupplementalUnemploymentBenefitsSalaryContinuation_D616856A9F3C6E1AA683850F474D08CA" xlink:type="locator" />
<link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SupplementalUnemploymentBenefitsSalaryContinuation_D616856A9F3C6E1AA683850F474D08CA" xlink:to="lab_us-gaap_SupplementalUnemploymentBenefitsSalaryContinuation_D616856A9F3C6E1AA683850F474D08CA" xlink:type="arc" />
<link:label id="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_24538307D55A5CF7B81E853A88E2B205_terseLabel_en-US" xlink:label="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_24538307D55A5CF7B81E853A88E2B205" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Allowances for doubtful accounts</link:label>
<link:label id="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_24538307D55A5CF7B81E853A88E2B205_label_en-US" xlink:label="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_24538307D55A5CF7B81E853A88E2B205" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounts Receivable, Allowance for Credit Loss, Current</link:label>
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_24538307D55A5CF7B81E853A88E2B205" xlink:type="locator" />
<link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_24538307D55A5CF7B81E853A88E2B205" xlink:to="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_24538307D55A5CF7B81E853A88E2B205" xlink:type="arc" />
<link:label id="lab_immu_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization_B0748FE1746C3B70CACD8549B6EFB658_terseLabel_en-US" xlink:label="lab_immu_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization_B0748FE1746C3B70CACD8549B6EFB658" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accumulated depreciation</link:label>
<link:label id="lab_immu_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization_B0748FE1746C3B70CACD8549B6EFB658_label_en-US" xlink:label="lab_immu_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization_B0748FE1746C3B70CACD8549B6EFB658" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant, And Equipment And Finance Lease Right-Of-Use Asset, Accumulated Depreciation And Amortization</link:label>
<link:label id="lab_immu_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization_B0748FE1746C3B70CACD8549B6EFB658_documentation_en-US" xlink:label="lab_immu_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization_B0748FE1746C3B70CACD8549B6EFB658" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Property, Plant, And Equipment And Finance Lease Right-Of-Use Asset, Accumulated Depreciation And Amortization</link:label>
<link:loc xlink:href="immu-20191231.xsd#immu_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization" xlink:label="loc_immu_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization_B0748FE1746C3B70CACD8549B6EFB658" xlink:type="locator" />
<link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_immu_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization_B0748FE1746C3B70CACD8549B6EFB658" xlink:to="lab_immu_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization_B0748FE1746C3B70CACD8549B6EFB658" xlink:type="arc" />
<link:label id="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_0BE2B1399145F54C945E853A88E38EDB_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_0BE2B1399145F54C945E853A88E38EDB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accumulated depreciation</link:label>
<link:label id="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_0BE2B1399145F54C945E853A88E38EDB_label_en-US" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_0BE2B1399145F54C945E853A88E38EDB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment</link:label>
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_0BE2B1399145F54C945E853A88E38EDB" xlink:type="locator" />
<link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_0BE2B1399145F54C945E853A88E38EDB" xlink:to="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_0BE2B1399145F54C945E853A88E38EDB" xlink:type="arc" />
<link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_ECE973E6B7963DF9ECC4853A88E39DC1_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare_ECE973E6B7963DF9ECC4853A88E39DC1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Preferred stock, par value (in USD per share)</link:label>
<link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_ECE973E6B7963DF9ECC4853A88E39DC1_label_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare_ECE973E6B7963DF9ECC4853A88E39DC1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred Stock, Par or Stated Value Per Share</link:label>
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_ECE973E6B7963DF9ECC4853A88E39DC1" xlink:type="locator" />
<link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockParOrStatedValuePerShare_ECE973E6B7963DF9ECC4853A88E39DC1" xlink:to="lab_us-gaap_PreferredStockParOrStatedValuePerShare_ECE973E6B7963DF9ECC4853A88E39DC1" xlink:type="arc" />
<link:label id="lab_us-gaap_PreferredStockSharesAuthorized_554409BE0EBEFF2CB40E853A88E3DDFE_verboseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized_554409BE0EBEFF2CB40E853A88E3DDFE" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Preferred stock, shares authorized (in shares)</link:label>
<link:label id="lab_us-gaap_PreferredStockSharesAuthorized_554409BE0EBEFF2CB40E853A88E3DDFE_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized_554409BE0EBEFF2CB40E853A88E3DDFE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred Stock, Shares Authorized</link:label>
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_554409BE0EBEFF2CB40E853A88E3DDFE" xlink:type="locator" />
<link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesAuthorized_554409BE0EBEFF2CB40E853A88E3DDFE" xlink:to="lab_us-gaap_PreferredStockSharesAuthorized_554409BE0EBEFF2CB40E853A88E3DDFE" xlink:type="arc" />
<link:label id="lab_us-gaap_PreferredStockSharesIssued_B172F567A08B83D32174853A88E34156_verboseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesIssued_B172F567A08B83D32174853A88E34156" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Preferred stock, shares issued (in shares)</link:label>
<link:label id="lab_us-gaap_PreferredStockSharesIssued_B172F567A08B83D32174853A88E34156_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesIssued_B172F567A08B83D32174853A88E34156" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred Stock, Shares Issued</link:label>
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="loc_us-gaap_PreferredStockSharesIssued_B172F567A08B83D32174853A88E34156" xlink:type="locator" />
<link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesIssued_B172F567A08B83D32174853A88E34156" xlink:to="lab_us-gaap_PreferredStockSharesIssued_B172F567A08B83D32174853A88E34156" xlink:type="arc" />
<link:label id="lab_us-gaap_PreferredStockSharesOutstanding_174FF7DE750CC8BC90CD853A88E3D7F4_verboseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding_174FF7DE750CC8BC90CD853A88E3D7F4" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Preferred stock, shares outstanding (in shares)</link:label>
<link:label id="lab_us-gaap_PreferredStockSharesOutstanding_174FF7DE750CC8BC90CD853A88E3D7F4_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding_174FF7DE750CC8BC90CD853A88E3D7F4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred Stock, Shares Outstanding</link:label>
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_174FF7DE750CC8BC90CD853A88E3D7F4" xlink:type="locator" />
<link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesOutstanding_174FF7DE750CC8BC90CD853A88E3D7F4" xlink:to="lab_us-gaap_PreferredStockSharesOutstanding_174FF7DE750CC8BC90CD853A88E3D7F4" xlink:type="arc" />
<link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_905FDA7F60332DB2BDDC853A88E3F072_verboseLabel_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare_905FDA7F60332DB2BDDC853A88E3F072" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Common stock, par value (in USD per share)</link:label>
<link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_905FDA7F60332DB2BDDC853A88E3F072_label_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare_905FDA7F60332DB2BDDC853A88E3F072" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Par or Stated Value Per Share</link:label>
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_905FDA7F60332DB2BDDC853A88E3F072" xlink:type="locator" />
<link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockParOrStatedValuePerShare_905FDA7F60332DB2BDDC853A88E3F072" xlink:to="lab_us-gaap_CommonStockParOrStatedValuePerShare_905FDA7F60332DB2BDDC853A88E3F072" xlink:type="arc" />
<link:label id="lab_us-gaap_CommonStockSharesAuthorized_9D84C570F925426A0724853A88E4E0D7_verboseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized_9D84C570F925426A0724853A88E4E0D7" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Common stock, shares authorized (in shares)</link:label>
<link:label id="lab_us-gaap_CommonStockSharesAuthorized_9D84C570F925426A0724853A88E4E0D7_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized_9D84C570F925426A0724853A88E4E0D7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Shares Authorized</link:label>
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_9D84C570F925426A0724853A88E4E0D7" xlink:type="locator" />
<link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesAuthorized_9D84C570F925426A0724853A88E4E0D7" xlink:to="lab_us-gaap_CommonStockSharesAuthorized_9D84C570F925426A0724853A88E4E0D7" xlink:type="arc" />
<link:label id="lab_us-gaap_CommonStockSharesIssued_657FC67CC9C6ABDE2EC7853A88E4D133_verboseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued_657FC67CC9C6ABDE2EC7853A88E4D133" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Common stock, shares issued (in shares)</link:label>
<link:label id="lab_us-gaap_CommonStockSharesIssued_657FC67CC9C6ABDE2EC7853A88E4D133_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued_657FC67CC9C6ABDE2EC7853A88E4D133" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Shares, Issued</link:label>
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaap_CommonStockSharesIssued_657FC67CC9C6ABDE2EC7853A88E4D133" xlink:type="locator" />
<link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesIssued_657FC67CC9C6ABDE2EC7853A88E4D133" xlink:to="lab_us-gaap_CommonStockSharesIssued_657FC67CC9C6ABDE2EC7853A88E4D133" xlink:type="arc" />
<link:label id="lab_us-gaap_CommonStockSharesOutstanding_3CF630060A5DE0AFC14C853A88E46973_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding_3CF630060A5DE0AFC14C853A88E46973" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock, shares outstanding (in shares)</link:label>
<link:label id="lab_us-gaap_CommonStockSharesOutstanding_3CF630060A5DE0AFC14C853A88E46973_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding_3CF630060A5DE0AFC14C853A88E46973" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Shares, Outstanding</link:label>
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_3CF630060A5DE0AFC14C853A88E46973" xlink:type="locator" />
<link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesOutstanding_3CF630060A5DE0AFC14C853A88E46973" xlink:to="lab_us-gaap_CommonStockSharesOutstanding_3CF630060A5DE0AFC14C853A88E46973" xlink:type="arc" />
<link:label id="lab_us-gaap_TreasuryStockShares_FA04EF86755F3F2BC217853A88E41478_terseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockShares_FA04EF86755F3F2BC217853A88E41478" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Treasury stock, shares (in shares)</link:label>
<link:label id="lab_us-gaap_TreasuryStockShares_FA04EF86755F3F2BC217853A88E41478_label_en-US" xlink:label="lab_us-gaap_TreasuryStockShares_FA04EF86755F3F2BC217853A88E41478" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Treasury Stock, Shares</link:label>
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TreasuryStockShares" xlink:label="loc_us-gaap_TreasuryStockShares_FA04EF86755F3F2BC217853A88E41478" xlink:type="locator" />
<link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockShares_FA04EF86755F3F2BC217853A88E41478" xlink:to="lab_us-gaap_TreasuryStockShares_FA04EF86755F3F2BC217853A88E41478" xlink:type="arc" />
<link:label id="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_4D63321AB22AD9013453853A877B15FA_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_4D63321AB22AD9013453853A877B15FA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment [Table]</link:label>
<link:label id="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_4D63321AB22AD9013453853A877B15FA_label_en-US" xlink:label="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_4D63321AB22AD9013453853A877B15FA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment [Table]</link:label>
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_4D63321AB22AD9013453853A877B15FA" xlink:type="locator" />
<link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_4D63321AB22AD9013453853A877B15FA" xlink:to="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_4D63321AB22AD9013453853A877B15FA" xlink:type="arc" />
<link:label id="lab_us-gaap_MachineryAndEquipmentMember_3967AB313E1E39D325D4853A877CB73C_terseLabel_en-US" xlink:label="lab_us-gaap_MachineryAndEquipmentMember_3967AB313E1E39D325D4853A877CB73C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Machinery and equipment</link:label>
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MachineryAndEquipmentMember" xlink:label="loc_us-gaap_MachineryAndEquipmentMember_3967AB313E1E39D325D4853A877CB73C" xlink:type="locator" />
<link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MachineryAndEquipmentMember_3967AB313E1E39D325D4853A877CB73C" xlink:to="lab_us-gaap_MachineryAndEquipmentMember_3967AB313E1E39D325D4853A877CB73C" xlink:type="arc" />
<link:label id="lab_us-gaap_LeaseholdImprovementsMember_9F4A897E34D8546E22E3853A877C2955_terseLabel_en-US" xlink:label="lab_us-gaap_LeaseholdImprovementsMember_9F4A897E34D8546E22E3853A877C2955" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Leasehold improvements</link:label>
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="loc_us-gaap_LeaseholdImprovementsMember_9F4A897E34D8546E22E3853A877C2955" xlink:type="locator" />
<link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseholdImprovementsMember_9F4A897E34D8546E22E3853A877C2955" xlink:to="lab_us-gaap_LeaseholdImprovementsMember_9F4A897E34D8546E22E3853A877C2955" xlink:type="arc" />
<link:label id="lab_us-gaap_FurnitureAndFixturesMember_F4F35E62B2B4487894B5853A877DB7AA_terseLabel_en-US" xlink:label="lab_us-gaap_FurnitureAndFixturesMember_F4F35E62B2B4487894B5853A877DB7AA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Furniture and fixtures</link:label>
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="loc_us-gaap_FurnitureAndFixturesMember_F4F35E62B2B4487894B5853A877DB7AA" xlink:type="locator" />
<link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FurnitureAndFixturesMember_F4F35E62B2B4487894B5853A877DB7AA" xlink:to="lab_us-gaap_FurnitureAndFixturesMember_F4F35E62B2B4487894B5853A877DB7AA" xlink:type="arc" />
<link:label id="lab_us-gaap_ComputerEquipmentMember_81DDC19214490D9A4F70853A877DE79A_terseLabel_en-US" xlink:label="lab_us-gaap_ComputerEquipmentMember_81DDC19214490D9A4F70853A877DE79A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Computer equipment</link:label>
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ComputerEquipmentMember" xlink:label="loc_us-gaap_ComputerEquipmentMember_81DDC19214490D9A4F70853A877DE79A" xlink:type="locator" />
<link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComputerEquipmentMember_81DDC19214490D9A4F70853A877DE79A" xlink:to="lab_us-gaap_ComputerEquipmentMember_81DDC19214490D9A4F70853A877DE79A" xlink:type="arc" />
<link:label id="lab_us-gaap_ConstructionInProgressMember_4E71809F704B96FAB51C853A877DD9D9_terseLabel_en-US" xlink:label="lab_us-gaap_ConstructionInProgressMember_4E71809F704B96FAB51C853A877DD9D9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Construction in progress</link:label>
<link:label id="lab_us-gaap_ConstructionInProgressMember_4E71809F704B96FAB51C853A877DD9D9_label_en-US" xlink:label="lab_us-gaap_ConstructionInProgressMember_4E71809F704B96FAB51C853A877DD9D9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Construction in Progress [Member]</link:label>
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConstructionInProgressMember" xlink:label="loc_us-gaap_ConstructionInProgressMember_4E71809F704B96FAB51C853A877DD9D9" xlink:type="locator" />
<link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConstructionInProgressMember_4E71809F704B96FAB51C853A877DD9D9" xlink:to="lab_us-gaap_ConstructionInProgressMember_4E71809F704B96FAB51C853A877DD9D9" xlink:type="arc" />
<link:label id="lab_us-gaap_PropertyPlantAndEquipmentLineItems_8DE427629B54A6D803EC853A877D3F17_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentLineItems_8DE427629B54A6D803EC853A877D3F17" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment [Line Items]</link:label>
<link:label id="lab_us-gaap_PropertyPlantAndEquipmentLineItems_8DE427629B54A6D803EC853A877D3F17_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentLineItems_8DE427629B54A6D803EC853A877D3F17" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment [Line Items]</link:label>
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_8DE427629B54A6D803EC853A877D3F17" xlink:type="locator" />
<link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_8DE427629B54A6D803EC853A877D3F17" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentLineItems_8DE427629B54A6D803EC853A877D3F17" xlink:type="arc" />
<link:label id="lab_us-gaap_PropertyPlantAndEquipmentGross_0D30A6F5EF78DAC1CFD5853A877D84F2_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentGross_0D30A6F5EF78DAC1CFD5853A877D84F2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property and equipment, gross</link:label>
<link:label id="lab_us-gaap_PropertyPlantAndEquipmentGross_0D30A6F5EF78DAC1CFD5853A877D84F2_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentGross_0D30A6F5EF78DAC1CFD5853A877D84F2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Gross</link:label>
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_0D30A6F5EF78DAC1CFD5853A877D84F2" xlink:type="locator" />
<link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentGross_0D30A6F5EF78DAC1CFD5853A877D84F2" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentGross_0D30A6F5EF78DAC1CFD5853A877D84F2" xlink:type="arc" />
<link:label id="lab_immu_FinanceLeaseRightofUseAssetBeforeAccumulatedAmortization_569A7945E7E440F96D6D853A877D8137_terseLabel_en-US" xlink:label="lab_immu_FinanceLeaseRightofUseAssetBeforeAccumulatedAmortization_569A7945E7E440F96D6D853A877D8137" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Right-of-use asset</link:label>
<link:label id="lab_immu_FinanceLeaseRightofUseAssetBeforeAccumulatedAmortization_569A7945E7E440F96D6D853A877D8137_label_en-US" xlink:label="lab_immu_FinanceLeaseRightofUseAssetBeforeAccumulatedAmortization_569A7945E7E440F96D6D853A877D8137" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finance Lease, Right-of-Use Asset, Before Accumulated Amortization</link:label>
<link:label id="lab_immu_FinanceLeaseRightofUseAssetBeforeAccumulatedAmortization_569A7945E7E440F96D6D853A877D8137_documentation_en-US" xlink:label="lab_immu_FinanceLeaseRightofUseAssetBeforeAccumulatedAmortization_569A7945E7E440F96D6D853A877D8137" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Finance Lease, Right-of-Use Asset, Before Accumulated Amortization</link:label>
<link:loc xlink:href="immu-20191231.xsd#immu_FinanceLeaseRightofUseAssetBeforeAccumulatedAmortization" xlink:label="loc_immu_FinanceLeaseRightofUseAssetBeforeAccumulatedAmortization_569A7945E7E440F96D6D853A877D8137" xlink:type="locator" />
<link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_immu_FinanceLeaseRightofUseAssetBeforeAccumulatedAmortization_569A7945E7E440F96D6D853A877D8137" xlink:to="lab_immu_FinanceLeaseRightofUseAssetBeforeAccumulatedAmortization_569A7945E7E440F96D6D853A877D8137" xlink:type="arc" />
<link:label id="lab_immu_PropertyPlantAndEquipmentAndFinanceLeaseRightofUseAssetBeforeAccumulatedDepreciationAndAmortization_97A5523681CEF27B4870853A877E8E40_terseLabel_en-US" xlink:label="lab_immu_PropertyPlantAndEquipmentAndFinanceLeaseRightofUseAssetBeforeAccumulatedDepreciationAndAmortization_97A5523681CEF27B4870853A877E8E40" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property, plant, and equipment and finance lease right-of-use asset, before accumulated depreciation and amortization</link:label>
<link:label id="lab_immu_PropertyPlantAndEquipmentAndFinanceLeaseRightofUseAssetBeforeAccumulatedDepreciationAndAmortization_97A5523681CEF27B4870853A877E8E40_label_en-US" xlink:label="lab_immu_PropertyPlantAndEquipmentAndFinanceLeaseRightofUseAssetBeforeAccumulatedDepreciationAndAmortization_97A5523681CEF27B4870853A877E8E40" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant, And Equipment And Finance Lease Right-of-Use Asset, Before Accumulated Depreciation And Amortization</link:label>
<link:label id="lab_immu_PropertyPlantAndEquipmentAndFinanceLeaseRightofUseAssetBeforeAccumulatedDepreciationAndAmortization_97A5523681CEF27B4870853A877E8E40_documentation_en-US" xlink:label="lab_immu_PropertyPlantAndEquipmentAndFinanceLeaseRightofUseAssetBeforeAccumulatedDepreciationAndAmortization_97A5523681CEF27B4870853A877E8E40" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Property, Plant, And Equipment And Finance Lease Right-of-Use Asset, Before Accumulated Depreciation And Amortization</link:label>
<link:loc xlink:href="immu-20191231.xsd#immu_PropertyPlantAndEquipmentAndFinanceLeaseRightofUseAssetBeforeAccumulatedDepreciationAndAmortization" xlink:label="loc_immu_PropertyPlantAndEquipmentAndFinanceLeaseRightofUseAssetBeforeAccumulatedDepreciationAndAmortization_97A5523681CEF27B4870853A877E8E40" xlink:type="locator" />
<link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_immu_PropertyPlantAndEquipmentAndFinanceLeaseRightofUseAssetBeforeAccumulatedDepreciationAndAmortization_97A5523681CEF27B4870853A877E8E40" xlink:to="lab_immu_PropertyPlantAndEquipmentAndFinanceLeaseRightofUseAssetBeforeAccumulatedDepreciationAndAmortization_97A5523681CEF27B4870853A877E8E40" xlink:type="arc" />
<link:label id="lab_immu_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization_6A46FF2408D8FB5A9BC4853A877E61C5_verboseLabel_en-US" xlink:label="lab_immu_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization_6A46FF2408D8FB5A9BC4853A877E61C5" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Accumulated depreciation and amortization</link:label>
<link:loc xlink:href="immu-20191231.xsd#immu_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization" xlink:label="loc_immu_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization_6A46FF2408D8FB5A9BC4853A877E61C5" xlink:type="locator" />
<link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_immu_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization_6A46FF2408D8FB5A9BC4853A877E61C5" xlink:to="lab_immu_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization_6A46FF2408D8FB5A9BC4853A877E61C5" xlink:type="arc" />
<link:label id="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_6A2AB5215C99F14E67EA853A877E331B_negatedLabel_en-US" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_6A2AB5215C99F14E67EA853A877E331B" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Accumulated depreciation and amortization</link:label>
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_6A2AB5215C99F14E67EA853A877E331B" xlink:type="locator" />
<link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_6A2AB5215C99F14E67EA853A877E331B" xlink:to="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_6A2AB5215C99F14E67EA853A877E331B" xlink:type="arc" />
<link:label id="lab_immu_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization_FB080B6EB50EF437BC7C853A877E5F59_totalLabel_en-US" xlink:label="lab_immu_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization_FB080B6EB50EF437BC7C853A877E5F59" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Property, plant, and equipment and finance lease right-of-use asset, after accumulated depreciation and amortization</link:label>
<link:label id="lab_immu_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization_FB080B6EB50EF437BC7C853A877E5F59_label_en-US" xlink:label="lab_immu_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization_FB080B6EB50EF437BC7C853A877E5F59" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant, And Equipment And Finance Lease Right-Of-Use Asset, After Accumulated Depreciation And Amortization</link:label>
<link:label id="lab_immu_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization_FB080B6EB50EF437BC7C853A877E5F59_documentation_en-US" xlink:label="lab_immu_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization_FB080B6EB50EF437BC7C853A877E5F59" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Property, Plant, And Equipment And Finance Lease Right-Of-Use Asset, After Accumulated Depreciation And Amortization</link:label>
<link:loc xlink:href="immu-20191231.xsd#immu_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization" xlink:label="loc_immu_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization_FB080B6EB50EF437BC7C853A877E5F59" xlink:type="locator" />
<link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_immu_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization_FB080B6EB50EF437BC7C853A877E5F59" xlink:to="lab_immu_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization_FB080B6EB50EF437BC7C853A877E5F59" xlink:type="arc" />
<link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_6F5C9B295B3EA656C698853A877EF908_totalLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet_6F5C9B295B3EA656C698853A877EF908" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Property, plant and equipment, net</link:label>
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_6F5C9B295B3EA656C698853A877EF908" xlink:type="locator" />
<link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet_6F5C9B295B3EA656C698853A877EF908" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentNet_6F5C9B295B3EA656C698853A877EF908" xlink:type="arc" />
<link:label id="lab_us-gaap_DebtInstrumentAxis_E63FFDC7A2A22EE8A6D27E59E3B56F1D_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentAxis_E63FFDC7A2A22EE8A6D27E59E3B56F1D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Instrument [Axis]</link:label>
<link:label id="lab_us-gaap_DebtInstrumentAxis_E63FFDC7A2A22EE8A6D27E59E3B56F1D_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentAxis_E63FFDC7A2A22EE8A6D27E59E3B56F1D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument [Axis]</link:label>
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaap_DebtInstrumentAxis_E63FFDC7A2A22EE8A6D27E59E3B56F1D" xlink:type="locator" />
<link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentAxis_E63FFDC7A2A22EE8A6D27E59E3B56F1D" xlink:to="lab_us-gaap_DebtInstrumentAxis_E63FFDC7A2A22EE8A6D27E59E3B56F1D" xlink:type="arc" />
<link:label id="lab_us-gaap_DebtInstrumentNameDomain_98440B5079A09B026A3A7E59E3B5C0D5_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentNameDomain_98440B5079A09B026A3A7E59E3B5C0D5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Instrument, Name [Domain]</link:label>
<link:label id="lab_us-gaap_DebtInstrumentNameDomain_98440B5079A09B026A3A7E59E3B5C0D5_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentNameDomain_98440B5079A09B026A3A7E59E3B5C0D5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Name [Domain]</link:label>
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_98440B5079A09B026A3A7E59E3B5C0D5" xlink:type="locator" />
<link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_98440B5079A09B026A3A7E59E3B5C0D5" xlink:to="lab_us-gaap_DebtInstrumentNameDomain_98440B5079A09B026A3A7E59E3B5C0D5" xlink:type="arc" />
<link:label id="lab_immu_FourPointSevenFivePercentConvertibleSeniorNotesMember_66084863CD5A2CBA72847E59E3B58383_terseLabel_en-US" xlink:label="lab_immu_FourPointSevenFivePercentConvertibleSeniorNotesMember_66084863CD5A2CBA72847E59E3B58383" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Four Point Seven Five Percent Convertible Senior Notes</link:label>
<link:label id="lab_immu_FourPointSevenFivePercentConvertibleSeniorNotesMember_66084863CD5A2CBA72847E59E3B58383_label_en-US" xlink:label="lab_immu_FourPointSevenFivePercentConvertibleSeniorNotesMember_66084863CD5A2CBA72847E59E3B58383" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Four Point Seven Five Percent Convertible Senior Notes [Member]</link:label>
<link:label id="lab_immu_FourPointSevenFivePercentConvertibleSeniorNotesMember_66084863CD5A2CBA72847E59E3B58383_documentation_en-US" xlink:label="lab_immu_FourPointSevenFivePercentConvertibleSeniorNotesMember_66084863CD5A2CBA72847E59E3B58383" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Four point seven five percent convertible senior notes.</link:label>
<link:loc xlink:href="immu-20191231.xsd#immu_FourPointSevenFivePercentConvertibleSeniorNotesMember" xlink:label="loc_immu_FourPointSevenFivePercentConvertibleSeniorNotesMember_66084863CD5A2CBA72847E59E3B58383" xlink:type="locator" />
<link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_immu_FourPointSevenFivePercentConvertibleSeniorNotesMember_66084863CD5A2CBA72847E59E3B58383" xlink:to="lab_immu_FourPointSevenFivePercentConvertibleSeniorNotesMember_66084863CD5A2CBA72847E59E3B58383" xlink:type="arc" />
<link:label id="lab_immu_October2018ExchangeAgreementMember_644BD44DCF6FFD39050B7E59E3B52D08_terseLabel_en-US" xlink:label="lab_immu_October2018ExchangeAgreementMember_644BD44DCF6FFD39050B7E59E3B52D08" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">October 2018 Exchange Agreement</link:label>
<link:label id="lab_immu_October2018ExchangeAgreementMember_644BD44DCF6FFD39050B7E59E3B52D08_label_en-US" xlink:label="lab_immu_October2018ExchangeAgreementMember_644BD44DCF6FFD39050B7E59E3B52D08" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">October 2018 Exchange Agreement [Member]</link:label>
<link:label id="lab_immu_October2018ExchangeAgreementMember_644BD44DCF6FFD39050B7E59E3B52D08_documentation_en-US" xlink:label="lab_immu_October2018ExchangeAgreementMember_644BD44DCF6FFD39050B7E59E3B52D08" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">October 2018 Exchange Agreement [Member]</link:label>
<link:loc xlink:href="immu-20191231.xsd#immu_October2018ExchangeAgreementMember" xlink:label="loc_immu_October2018ExchangeAgreementMember_644BD44DCF6FFD39050B7E59E3B52D08" xlink:type="locator" />
<link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_immu_October2018ExchangeAgreementMember_644BD44DCF6FFD39050B7E59E3B52D08" xlink:to="lab_immu_October2018ExchangeAgreementMember_644BD44DCF6FFD39050B7E59E3B52D08" xlink:type="arc" />
<link:label id="lab_us-gaap_DebtInstrumentFaceAmount_9E6D5114BA1FCF6817E67E59E3B6B7A7_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentFaceAmount_9E6D5114BA1FCF6817E67E59E3B6B7A7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt instrument, face amount</link:label>
<link:label id="lab_us-gaap_DebtInstrumentFaceAmount_9E6D5114BA1FCF6817E67E59E3B6B7A7_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentFaceAmount_9E6D5114BA1FCF6817E67E59E3B6B7A7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Face Amount</link:label>
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_9E6D5114BA1FCF6817E67E59E3B6B7A7" xlink:type="locator" />
<link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentFaceAmount_9E6D5114BA1FCF6817E67E59E3B6B7A7" xlink:to="lab_us-gaap_DebtInstrumentFaceAmount_9E6D5114BA1FCF6817E67E59E3B6B7A7" xlink:type="arc" />
<link:label id="lab_us-gaap_ProceedsFromDebtNetOfIssuanceCosts_F3C1ACD8B16A6414CA567E59E3B6250A_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromDebtNetOfIssuanceCosts_F3C1ACD8B16A6414CA567E59E3B6250A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from debt, net of issuance costs</link:label>
<link:label id="lab_us-gaap_ProceedsFromDebtNetOfIssuanceCosts_F3C1ACD8B16A6414CA567E59E3B6250A_label_en-US" xlink:label="lab_us-gaap_ProceedsFromDebtNetOfIssuanceCosts_F3C1ACD8B16A6414CA567E59E3B6250A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Debt, Net of Issuance Costs</link:label>
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromDebtNetOfIssuanceCosts" xlink:label="loc_us-gaap_ProceedsFromDebtNetOfIssuanceCosts_F3C1ACD8B16A6414CA567E59E3B6250A" xlink:type="locator" />
<link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromDebtNetOfIssuanceCosts_F3C1ACD8B16A6414CA567E59E3B6250A" xlink:to="lab_us-gaap_ProceedsFromDebtNetOfIssuanceCosts_F3C1ACD8B16A6414CA567E59E3B6250A" xlink:type="arc" />
<link:label id="lab_us-gaap_PaymentsOfDebtIssuanceCosts_F3A1AF6149122C39732F7E59E3B64D84_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentsOfDebtIssuanceCosts_F3A1AF6149122C39732F7E59E3B64D84" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Payments of debt issuance costs</link:label>
<link:label id="lab_us-gaap_PaymentsOfDebtIssuanceCosts_F3A1AF6149122C39732F7E59E3B64D84_label_en-US" xlink:label="lab_us-gaap_PaymentsOfDebtIssuanceCosts_F3A1AF6149122C39732F7E59E3B64D84" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments of Debt Issuance Costs</link:label>
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsOfDebtIssuanceCosts" xlink:label="loc_us-gaap_PaymentsOfDebtIssuanceCosts_F3A1AF6149122C39732F7E59E3B64D84" xlink:type="locator" />
<link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsOfDebtIssuanceCosts_F3A1AF6149122C39732F7E59E3B64D84" xlink:to="lab_us-gaap_PaymentsOfDebtIssuanceCosts_F3A1AF6149122C39732F7E59E3B64D84" xlink:type="arc" />
<link:label id="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_9A76A9E09C4A22F5A9D57E59E3B61AA6_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_9A76A9E09C4A22F5A9D57E59E3B61AA6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt instrument, interest rate, stated percentage</link:label>
<link:label id="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_9A76A9E09C4A22F5A9D57E59E3B61AA6_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_9A76A9E09C4A22F5A9D57E59E3B61AA6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Interest Rate, Stated Percentage</link:label>
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_9A76A9E09C4A22F5A9D57E59E3B61AA6" xlink:type="locator" />
<link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_9A76A9E09C4A22F5A9D57E59E3B61AA6" xlink:to="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_9A76A9E09C4A22F5A9D57E59E3B61AA6" xlink:type="arc" />
<link:label id="lab_us-gaap_DebtInstrumentInterestRateEffectivePercentage_3B3119A6BD18932053947E59E3B625A2_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateEffectivePercentage_3B3119A6BD18932053947E59E3B625A2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt instrument, interest rate, effective percentage</link:label>
<link:label id="lab_us-gaap_DebtInstrumentInterestRateEffectivePercentage_3B3119A6BD18932053947E59E3B625A2_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateEffectivePercentage_3B3119A6BD18932053947E59E3B625A2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Interest Rate, Effective Percentage</link:label>
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:label="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage_3B3119A6BD18932053947E59E3B625A2" xlink:type="locator" />
<link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage_3B3119A6BD18932053947E59E3B625A2" xlink:to="lab_us-gaap_DebtInstrumentInterestRateEffectivePercentage_3B3119A6BD18932053947E59E3B625A2" xlink:type="arc" />
<link:label id="lab_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_551A5FB0E4E22F6C67A27E59E3B6E386_verboseLabel_en-US" xlink:label="lab_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_551A5FB0E4E22F6C67A27E59E3B6E386" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Convertible preferred stock, shares issued upon conversion (in shares)</link:label>
<link:label id="lab_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_551A5FB0E4E22F6C67A27E59E3B6E386_label_en-US" xlink:label="lab_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_551A5FB0E4E22F6C67A27E59E3B6E386" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Convertible Preferred Stock, Shares Issued upon Conversion</link:label>
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:label="loc_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_551A5FB0E4E22F6C67A27E59E3B6E386" xlink:type="locator" />
<link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_551A5FB0E4E22F6C67A27E59E3B6E386" xlink:to="lab_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_551A5FB0E4E22F6C67A27E59E3B6E386" xlink:type="arc" />
<link:label id="lab_us-gaap_DebtInstrumentConvertibleConversionRatio1_9AF338F0E6E64A1452C27E59E3B73FE3_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleConversionRatio1_9AF338F0E6E64A1452C27E59E3B73FE3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Conversion ratio</link:label>
<link:label id="lab_us-gaap_DebtInstrumentConvertibleConversionRatio1_9AF338F0E6E64A1452C27E59E3B73FE3_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleConversionRatio1_9AF338F0E6E64A1452C27E59E3B73FE3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Convertible, Conversion Ratio</link:label>
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentConvertibleConversionRatio1" xlink:label="loc_us-gaap_DebtInstrumentConvertibleConversionRatio1_9AF338F0E6E64A1452C27E59E3B73FE3" xlink:type="locator" />
<link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentConvertibleConversionRatio1_9AF338F0E6E64A1452C27E59E3B73FE3" xlink:to="lab_us-gaap_DebtInstrumentConvertibleConversionRatio1_9AF338F0E6E64A1452C27E59E3B73FE3" xlink:type="arc" />
<link:label id="lab_us-gaap_DebtInstrumentConvertibleConversionPrice1_62BD5DA267C1B3F2C3107E59E3B7F61B_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleConversionPrice1_62BD5DA267C1B3F2C3107E59E3B7F61B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Conversion price (in USD per share)</link:label>
<link:label id="lab_us-gaap_DebtInstrumentConvertibleConversionPrice1_62BD5DA267C1B3F2C3107E59E3B7F61B_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleConversionPrice1_62BD5DA267C1B3F2C3107E59E3B7F61B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Convertible, Conversion Price</link:label>
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:label="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1_62BD5DA267C1B3F2C3107E59E3B7F61B" xlink:type="locator" />
<link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1_62BD5DA267C1B3F2C3107E59E3B7F61B" xlink:to="lab_us-gaap_DebtInstrumentConvertibleConversionPrice1_62BD5DA267C1B3F2C3107E59E3B7F61B" xlink:type="arc" />
<link:label id="lab_us-gaap_DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed_7B2E5642F278CF950E5C7E59E3B7DFE7_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed_7B2E5642F278CF950E5C7E59E3B7DFE7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Percentage of principal amount redeemed</link:label>
<link:label id="lab_us-gaap_DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed_7B2E5642F278CF950E5C7E59E3B7DFE7_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed_7B2E5642F278CF950E5C7E59E3B7DFE7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Redemption Price, Percentage of Principal Amount Redeemed</link:label>
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed_7B2E5642F278CF950E5C7E59E3B7DFE7" xlink:type="locator" />
<link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed_7B2E5642F278CF950E5C7E59E3B7DFE7" xlink:to="lab_us-gaap_DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed_7B2E5642F278CF950E5C7E59E3B7DFE7" xlink:type="arc" />
<link:label id="lab_immu_DebtInstrumentConvertibleBeneficialConversionFeatureAggregateNumberOfShares_571170204A9C7C40B37C7E59E3B8F583_terseLabel_en-US" xlink:label="lab_immu_DebtInstrumentConvertibleBeneficialConversionFeatureAggregateNumberOfShares_571170204A9C7C40B37C7E59E3B8F583" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Convertible beneficial conversion feature (in shares)</link:label>
<link:label id="lab_immu_DebtInstrumentConvertibleBeneficialConversionFeatureAggregateNumberOfShares_571170204A9C7C40B37C7E59E3B8F583_label_en-US" xlink:label="lab_immu_DebtInstrumentConvertibleBeneficialConversionFeatureAggregateNumberOfShares_571170204A9C7C40B37C7E59E3B8F583" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument Convertible Beneficial Conversion Feature, Aggregate Number of Shares</link:label>
<link:label id="lab_immu_DebtInstrumentConvertibleBeneficialConversionFeatureAggregateNumberOfShares_571170204A9C7C40B37C7E59E3B8F583_documentation_en-US" xlink:label="lab_immu_DebtInstrumentConvertibleBeneficialConversionFeatureAggregateNumberOfShares_571170204A9C7C40B37C7E59E3B8F583" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The amount of shares by which the convertible debt's if-converted value exceeds its principle amount of shares at the balance sheet date, regardless of whether the instrument is currently convertible. This element applies to public companies only.</link:label>
<link:loc xlink:href="immu-20191231.xsd#immu_DebtInstrumentConvertibleBeneficialConversionFeatureAggregateNumberOfShares" xlink:label="loc_immu_DebtInstrumentConvertibleBeneficialConversionFeatureAggregateNumberOfShares_571170204A9C7C40B37C7E59E3B8F583" xlink:type="locator" />
<link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_immu_DebtInstrumentConvertibleBeneficialConversionFeatureAggregateNumberOfShares_571170204A9C7C40B37C7E59E3B8F583" xlink:to="lab_immu_DebtInstrumentConvertibleBeneficialConversionFeatureAggregateNumberOfShares_571170204A9C7C40B37C7E59E3B8F583" xlink:type="arc" />
<link:label id="lab_us-gaap_InducedConversionOfConvertibleDebtExpense_86854216D775AAC3CF547E59E3B8178B_terseLabel_en-US" xlink:label="lab_us-gaap_InducedConversionOfConvertibleDebtExpense_86854216D775AAC3CF547E59E3B8178B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Induced conversion of convertible debt expense</link:label>
<link:label id="lab_us-gaap_InducedConversionOfConvertibleDebtExpense_86854216D775AAC3CF547E59E3B8178B_label_en-US" xlink:label="lab_us-gaap_InducedConversionOfConvertibleDebtExpense_86854216D775AAC3CF547E59E3B8178B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Induced Conversion of Convertible Debt Expense</link:label>
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InducedConversionOfConvertibleDebtExpense" xlink:label="loc_us-gaap_InducedConversionOfConvertibleDebtExpense_86854216D775AAC3CF547E59E3B8178B" xlink:type="locator" />
<link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InducedConversionOfConvertibleDebtExpense_86854216D775AAC3CF547E59E3B8178B" xlink:to="lab_us-gaap_InducedConversionOfConvertibleDebtExpense_86854216D775AAC3CF547E59E3B8178B" xlink:type="arc" />
<link:label id="lab_immu_DebtConversionOutstandingBalance_04AD3A053866F435BE1A7E59E3B82922_terseLabel_en-US" xlink:label="lab_immu_DebtConversionOutstandingBalance_04AD3A053866F435BE1A7E59E3B82922" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Outstanding balance</link:label>
<link:label id="lab_immu_DebtConversionOutstandingBalance_04AD3A053866F435BE1A7E59E3B82922_label_en-US" xlink:label="lab_immu_DebtConversionOutstandingBalance_04AD3A053866F435BE1A7E59E3B82922" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Conversion, Outstanding Balance</link:label>
<link:label id="lab_immu_DebtConversionOutstandingBalance_04AD3A053866F435BE1A7E59E3B82922_documentation_en-US" xlink:label="lab_immu_DebtConversionOutstandingBalance_04AD3A053866F435BE1A7E59E3B82922" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Debt Conversion, Outstanding Balance</link:label>
<link:loc xlink:href="immu-20191231.xsd#immu_DebtConversionOutstandingBalance" xlink:label="loc_immu_DebtConversionOutstandingBalance_04AD3A053866F435BE1A7E59E3B82922" xlink:type="locator" />
<link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_immu_DebtConversionOutstandingBalance_04AD3A053866F435BE1A7E59E3B82922" xlink:to="lab_immu_DebtConversionOutstandingBalance_04AD3A053866F435BE1A7E59E3B82922" xlink:type="arc" />
<link:label id="lab_immu_AcceleratedAmortizationOfFinancingCosts_AB1A0C23699916F901817E59E3B82291_terseLabel_en-US" xlink:label="lab_immu_AcceleratedAmortizationOfFinancingCosts_AB1A0C23699916F901817E59E3B82291" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accelerated amortization of financing costs</link:label>
<link:label id="lab_immu_AcceleratedAmortizationOfFinancingCosts_AB1A0C23699916F901817E59E3B82291_label_en-US" xlink:label="lab_immu_AcceleratedAmortizationOfFinancingCosts_AB1A0C23699916F901817E59E3B82291" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accelerated Amortization Of Financing Costs</link:label>
<link:label id="lab_immu_AcceleratedAmortizationOfFinancingCosts_AB1A0C23699916F901817E59E3B82291_documentation_en-US" xlink:label="lab_immu_AcceleratedAmortizationOfFinancingCosts_AB1A0C23699916F901817E59E3B82291" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Amount of accelerated amortization of financing costs attributable to debt issuance costs.</link:label>
<link:loc xlink:href="immu-20191231.xsd#immu_AcceleratedAmortizationOfFinancingCosts" xlink:label="loc_immu_AcceleratedAmortizationOfFinancingCosts_AB1A0C23699916F901817E59E3B82291" xlink:type="locator" />
<link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_immu_AcceleratedAmortizationOfFinancingCosts_AB1A0C23699916F901817E59E3B82291" xlink:to="lab_immu_AcceleratedAmortizationOfFinancingCosts_AB1A0C23699916F901817E59E3B82291" xlink:type="arc" />
<link:label id="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_EF688BF1BEF9AE53264DD1D062E16A3B_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_EF688BF1BEF9AE53264DD1D062E16A3B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property and Equipment</link:label>
<link:label id="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_EF688BF1BEF9AE53264DD1D062E16A3B_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_EF688BF1BEF9AE53264DD1D062E16A3B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment Disclosure [Text Block]</link:label>
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_EF688BF1BEF9AE53264DD1D062E16A3B" xlink:type="locator" />
<link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_EF688BF1BEF9AE53264DD1D062E16A3B" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_EF688BF1BEF9AE53264DD1D062E16A3B" xlink:type="arc" />
<link:label id="lab_us-gaap_DebtInstrumentTable_5053D60EE07AB24FB50F4551CEEF99C7_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentTable_5053D60EE07AB24FB50F4551CEEF99C7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Long-term Debt Instruments [Table]</link:label>
<link:label id="lab_us-gaap_DebtInstrumentTable_5053D60EE07AB24FB50F4551CEEF99C7_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentTable_5053D60EE07AB24FB50F4551CEEF99C7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Long-term Debt Instruments [Table]</link:label>
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentTable" xlink:label="loc_us-gaap_DebtInstrumentTable_5053D60EE07AB24FB50F4551CEEF99C7" xlink:type="locator" />
<link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentTable_5053D60EE07AB24FB50F4551CEEF99C7" xlink:to="lab_us-gaap_DebtInstrumentTable_5053D60EE07AB24FB50F4551CEEF99C7" xlink:type="arc" />
<link:label id="lab_us-gaap_DebtInstrumentLineItems_F01CB6FE0F8B09FD122E4551CEF10957_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentLineItems_F01CB6FE0F8B09FD122E4551CEF10957" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Instrument [Line Items]</link:label>
<link:label id="lab_us-gaap_DebtInstrumentLineItems_F01CB6FE0F8B09FD122E4551CEF10957_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentLineItems_F01CB6FE0F8B09FD122E4551CEF10957" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument [Line Items]</link:label>
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="loc_us-gaap_DebtInstrumentLineItems_F01CB6FE0F8B09FD122E4551CEF10957" xlink:type="locator" />
<link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentLineItems_F01CB6FE0F8B09FD122E4551CEF10957" xlink:to="lab_us-gaap_DebtInstrumentLineItems_F01CB6FE0F8B09FD122E4551CEF10957" xlink:type="arc" />
<link:label id="lab_immu_PaymentsForFutureRoyalties_8AB96DCEDB7FCEE3859E4551CEF1F814_terseLabel_en-US" xlink:label="lab_immu_PaymentsForFutureRoyalties_8AB96DCEDB7FCEE3859E4551CEF1F814" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Collaborative arrangement purchase price</link:label>
<link:label id="lab_immu_PaymentsForFutureRoyalties_8AB96DCEDB7FCEE3859E4551CEF1F814_label_en-US" xlink:label="lab_immu_PaymentsForFutureRoyalties_8AB96DCEDB7FCEE3859E4551CEF1F814" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments For Future Royalties</link:label>
<link:label id="lab_immu_PaymentsForFutureRoyalties_8AB96DCEDB7FCEE3859E4551CEF1F814_documentation_en-US" xlink:label="lab_immu_PaymentsForFutureRoyalties_8AB96DCEDB7FCEE3859E4551CEF1F814" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Payments For Future Royalties</link:label>
<link:loc xlink:href="immu-20191231.xsd#immu_PaymentsForFutureRoyalties" xlink:label="loc_immu_PaymentsForFutureRoyalties_8AB96DCEDB7FCEE3859E4551CEF1F814" xlink:type="locator" />
<link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_immu_PaymentsForFutureRoyalties_8AB96DCEDB7FCEE3859E4551CEF1F814" xlink:to="lab_immu_PaymentsForFutureRoyalties_8AB96DCEDB7FCEE3859E4551CEF1F814" xlink:type="arc" />
<link:label id="lab_immu_RoyaltyPurchaseArrangementRoyaltyRateasPercentageofNetSales_34370556009D3D7CFBEF4551CEF2DD34_terseLabel_en-US" xlink:label="lab_immu_RoyaltyPurchaseArrangementRoyaltyRateasPercentageofNetSales_34370556009D3D7CFBEF4551CEF2DD34" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Collaborative arrangement royalty rate as percent of net sales</link:label>
<link:label id="lab_immu_RoyaltyPurchaseArrangementRoyaltyRateasPercentageofNetSales_34370556009D3D7CFBEF4551CEF2DD34_label_en-US" xlink:label="lab_immu_RoyaltyPurchaseArrangementRoyaltyRateasPercentageofNetSales_34370556009D3D7CFBEF4551CEF2DD34" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Royalty Purchase Arrangement, Royalty Rate as Percentage of Net Sales</link:label>
<link:label id="lab_immu_RoyaltyPurchaseArrangementRoyaltyRateasPercentageofNetSales_34370556009D3D7CFBEF4551CEF2DD34_documentation_en-US" xlink:label="lab_immu_RoyaltyPurchaseArrangementRoyaltyRateasPercentageofNetSales_34370556009D3D7CFBEF4551CEF2DD34" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The percentage of collaborative arrangement royalty rate on net sales.</link:label>
<link:loc xlink:href="immu-20191231.xsd#immu_RoyaltyPurchaseArrangementRoyaltyRateasPercentageofNetSales" xlink:label="loc_immu_RoyaltyPurchaseArrangementRoyaltyRateasPercentageofNetSales_34370556009D3D7CFBEF4551CEF2DD34" xlink:type="locator" />
<link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_immu_RoyaltyPurchaseArrangementRoyaltyRateasPercentageofNetSales_34370556009D3D7CFBEF4551CEF2DD34" xlink:to="lab_immu_RoyaltyPurchaseArrangementRoyaltyRateasPercentageofNetSales_34370556009D3D7CFBEF4551CEF2DD34" xlink:type="arc" />
<link:label id="lab_immu_RoyaltyPurchaseArrangementAnnualSalesLimitMaximum_4BF2090984B904EA1C314551CEF2D53F_terseLabel_en-US" xlink:label="lab_immu_RoyaltyPurchaseArrangementAnnualSalesLimitMaximum_4BF2090984B904EA1C314551CEF2D53F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Collaborative arrangement maximum royalty amount</link:label>
<link:label id="lab_immu_RoyaltyPurchaseArrangementAnnualSalesLimitMaximum_4BF2090984B904EA1C314551CEF2D53F_label_en-US" xlink:label="lab_immu_RoyaltyPurchaseArrangementAnnualSalesLimitMaximum_4BF2090984B904EA1C314551CEF2D53F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Royalty Purchase Arrangement, Annual Sales Limit, Maximum</link:label>
<link:label id="lab_immu_RoyaltyPurchaseArrangementAnnualSalesLimitMaximum_4BF2090984B904EA1C314551CEF2D53F_documentation_en-US" xlink:label="lab_immu_RoyaltyPurchaseArrangementAnnualSalesLimitMaximum_4BF2090984B904EA1C314551CEF2D53F" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The amount of collaborative arrangement royalty.</link:label>
<link:loc xlink:href="immu-20191231.xsd#immu_RoyaltyPurchaseArrangementAnnualSalesLimitMaximum" xlink:label="loc_immu_RoyaltyPurchaseArrangementAnnualSalesLimitMaximum_4BF2090984B904EA1C314551CEF2D53F" xlink:type="locator" />
<link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_immu_RoyaltyPurchaseArrangementAnnualSalesLimitMaximum_4BF2090984B904EA1C314551CEF2D53F" xlink:to="lab_immu_RoyaltyPurchaseArrangementAnnualSalesLimitMaximum_4BF2090984B904EA1C314551CEF2D53F" xlink:type="arc" />
<link:label id="lab_immu_RoyaltyPurchaseArrangementRoyaltyRateasPercentageofExcessofGlobalAnnualSalesThresholdLimit_35E5FBE8A0E448C3C1A14551CEF2EE34_terseLabel_en-US" xlink:label="lab_immu_RoyaltyPurchaseArrangementRoyaltyRateasPercentageofExcessofGlobalAnnualSalesThresholdLimit_35E5FBE8A0E448C3C1A14551CEF2EE34" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Collaborative arrangement royalty rate as percentage of excess of global annual sales threshold limit</link:label>
<link:label id="lab_immu_RoyaltyPurchaseArrangementRoyaltyRateasPercentageofExcessofGlobalAnnualSalesThresholdLimit_35E5FBE8A0E448C3C1A14551CEF2EE34_label_en-US" xlink:label="lab_immu_RoyaltyPurchaseArrangementRoyaltyRateasPercentageofExcessofGlobalAnnualSalesThresholdLimit_35E5FBE8A0E448C3C1A14551CEF2EE34" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Royalty Purchase Arrangement, Royalty Rate as Percentage of Excess of Global Annual Sales Threshold Limit</link:label>
<link:label id="lab_immu_RoyaltyPurchaseArrangementRoyaltyRateasPercentageofExcessofGlobalAnnualSalesThresholdLimit_35E5FBE8A0E448C3C1A14551CEF2EE34_documentation_en-US" xlink:label="lab_immu_RoyaltyPurchaseArrangementRoyaltyRateasPercentageofExcessofGlobalAnnualSalesThresholdLimit_35E5FBE8A0E448C3C1A14551CEF2EE34" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The percentage of collaborative arrangement royalty rate on excess of global annual sales threshold limit.</link:label>
<link:loc xlink:href="immu-20191231.xsd#immu_RoyaltyPurchaseArrangementRoyaltyRateasPercentageofExcessofGlobalAnnualSalesThresholdLimit" xlink:label="loc_immu_RoyaltyPurchaseArrangementRoyaltyRateasPercentageofExcessofGlobalAnnualSalesThresholdLimit_35E5FBE8A0E448C3C1A14551CEF2EE34" xlink:type="locator" />
<link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_immu_RoyaltyPurchaseArrangementRoyaltyRateasPercentageofExcessofGlobalAnnualSalesThresholdLimit_35E5FBE8A0E448C3C1A14551CEF2EE34" xlink:to="lab_immu_RoyaltyPurchaseArrangementRoyaltyRateasPercentageofExcessofGlobalAnnualSalesThresholdLimit_35E5FBE8A0E448C3C1A14551CEF2EE34" xlink:type="arc" />
<link:label id="lab_immu_RoyaltyPurchaseArrangementExcessGlobalAnnualSalesLimitMinimum_837598AC27EE4F9DA6614551CEF2194E_terseLabel_en-US" xlink:label="lab_immu_RoyaltyPurchaseArrangementExcessGlobalAnnualSalesLimitMinimum_837598AC27EE4F9DA6614551CEF2194E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Collaborative arrangement excess of global annual sales threshold limit</link:label>
<link:label id="lab_immu_RoyaltyPurchaseArrangementExcessGlobalAnnualSalesLimitMinimum_837598AC27EE4F9DA6614551CEF2194E_label_en-US" xlink:label="lab_immu_RoyaltyPurchaseArrangementExcessGlobalAnnualSalesLimitMinimum_837598AC27EE4F9DA6614551CEF2194E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Royalty Purchase Arrangement, Excess Global Annual Sales Limit, Minimum</link:label>
<link:label id="lab_immu_RoyaltyPurchaseArrangementExcessGlobalAnnualSalesLimitMinimum_837598AC27EE4F9DA6614551CEF2194E_documentation_en-US" xlink:label="lab_immu_RoyaltyPurchaseArrangementExcessGlobalAnnualSalesLimitMinimum_837598AC27EE4F9DA6614551CEF2194E" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US" />
<link:loc xlink:href="immu-20191231.xsd#immu_RoyaltyPurchaseArrangementExcessGlobalAnnualSalesLimitMinimum" xlink:label="loc_immu_RoyaltyPurchaseArrangementExcessGlobalAnnualSalesLimitMinimum_837598AC27EE4F9DA6614551CEF2194E" xlink:type="locator" />
<link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_immu_RoyaltyPurchaseArrangementExcessGlobalAnnualSalesLimitMinimum_837598AC27EE4F9DA6614551CEF2194E" xlink:to="lab_immu_RoyaltyPurchaseArrangementExcessGlobalAnnualSalesLimitMinimum_837598AC27EE4F9DA6614551CEF2194E" xlink:type="arc" />
<link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_479D2D6024A2F16DD79A4551CEF2077C_verboseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_479D2D6024A2F16DD79A4551CEF2077C" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Agreement purchase shares of common stock (in shares)</link:label>
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_479D2D6024A2F16DD79A4551CEF2077C" xlink:type="locator" />
<link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_479D2D6024A2F16DD79A4551CEF2077C" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_479D2D6024A2F16DD79A4551CEF2077C" xlink:type="arc" />
<link:label id="lab_us-gaap_SharePrice_5688FEF0BA068425A9AA4551CEF2485B_verboseLabel_en-US" xlink:label="lab_us-gaap_SharePrice_5688FEF0BA068425A9AA4551CEF2485B" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Share price (in USD per share)</link:label>
<link:label id="lab_us-gaap_SharePrice_5688FEF0BA068425A9AA4551CEF2485B_label_en-US" xlink:label="lab_us-gaap_SharePrice_5688FEF0BA068425A9AA4551CEF2485B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share Price</link:label>
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharePrice" xlink:label="loc_us-gaap_SharePrice_5688FEF0BA068425A9AA4551CEF2485B" xlink:type="locator" />
<link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharePrice_5688FEF0BA068425A9AA4551CEF2485B" xlink:to="lab_us-gaap_SharePrice_5688FEF0BA068425A9AA4551CEF2485B" xlink:type="arc" />
<link:label id="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_2D57F9823B3269F540514551CEF3E517_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_2D57F9823B3269F540514551CEF3E517" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Sale of stock, consideration received on transaction</link:label>
<link:label id="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_2D57F9823B3269F540514551CEF3E517_label_en-US" xlink:label="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_2D57F9823B3269F540514551CEF3E517" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sale of Stock, Consideration Received on Transaction</link:label>
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_2D57F9823B3269F540514551CEF3E517" xlink:type="locator" />
<link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_2D57F9823B3269F540514551CEF3E517" xlink:to="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_2D57F9823B3269F540514551CEF3E517" xlink:type="arc" />
<link:label id="lab_immu_PeriodWhichCompanyWillAccreteLiability_67EF7CCEE80DE0A6FC8B4551CEF33138_terseLabel_en-US" xlink:label="lab_immu_PeriodWhichCompanyWillAccreteLiability_67EF7CCEE80DE0A6FC8B4551CEF33138" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Period which company will accrete liability</link:label>
<link:label id="lab_immu_PeriodWhichCompanyWillAccreteLiability_67EF7CCEE80DE0A6FC8B4551CEF33138_label_en-US" xlink:label="lab_immu_PeriodWhichCompanyWillAccreteLiability_67EF7CCEE80DE0A6FC8B4551CEF33138" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Period Which Company Will Accrete Liability</link:label>
<link:label id="lab_immu_PeriodWhichCompanyWillAccreteLiability_67EF7CCEE80DE0A6FC8B4551CEF33138_documentation_en-US" xlink:label="lab_immu_PeriodWhichCompanyWillAccreteLiability_67EF7CCEE80DE0A6FC8B4551CEF33138" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Period Which Company Will Accrete Liability</link:label>
<link:loc xlink:href="immu-20191231.xsd#immu_PeriodWhichCompanyWillAccreteLiability" xlink:label="loc_immu_PeriodWhichCompanyWillAccreteLiability_67EF7CCEE80DE0A6FC8B4551CEF33138" xlink:type="locator" />
<link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_immu_PeriodWhichCompanyWillAccreteLiability_67EF7CCEE80DE0A6FC8B4551CEF33138" xlink:to="lab_immu_PeriodWhichCompanyWillAccreteLiability_67EF7CCEE80DE0A6FC8B4551CEF33138" xlink:type="arc" />
<link:label id="lab_immu_AnnualInterestRateInCalculatingLiabilityRelatedToSaleOfFutureRoyalties_343F008535B92953A44C4551CEF3CC92_terseLabel_en-US" xlink:label="lab_immu_AnnualInterestRateInCalculatingLiabilityRelatedToSaleOfFutureRoyalties_343F008535B92953A44C4551CEF3CC92" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Annual interest rate in calculating liability related to sale of future royalties</link:label>
<link:label id="lab_immu_AnnualInterestRateInCalculatingLiabilityRelatedToSaleOfFutureRoyalties_343F008535B92953A44C4551CEF3CC92_label_en-US" xlink:label="lab_immu_AnnualInterestRateInCalculatingLiabilityRelatedToSaleOfFutureRoyalties_343F008535B92953A44C4551CEF3CC92" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Annual Interest Rate In Calculating Liability Related To Sale Of Future Royalties</link:label>
<link:label id="lab_immu_AnnualInterestRateInCalculatingLiabilityRelatedToSaleOfFutureRoyalties_343F008535B92953A44C4551CEF3CC92_documentation_en-US" xlink:label="lab_immu_AnnualInterestRateInCalculatingLiabilityRelatedToSaleOfFutureRoyalties_343F008535B92953A44C4551CEF3CC92" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Annual Interest Rate In Calculating Liability Related To Sale Of Future Royalties</link:label>
<link:loc xlink:href="immu-20191231.xsd#immu_AnnualInterestRateInCalculatingLiabilityRelatedToSaleOfFutureRoyalties" xlink:label="loc_immu_AnnualInterestRateInCalculatingLiabilityRelatedToSaleOfFutureRoyalties_343F008535B92953A44C4551CEF3CC92" xlink:type="locator" />
<link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_immu_AnnualInterestRateInCalculatingLiabilityRelatedToSaleOfFutureRoyalties_343F008535B92953A44C4551CEF3CC92" xlink:to="lab_immu_AnnualInterestRateInCalculatingLiabilityRelatedToSaleOfFutureRoyalties_343F008535B92953A44C4551CEF3CC92" xlink:type="arc" />
<link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_3EAD8D7715A3B29478A43991D229E6C6_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_3EAD8D7715A3B29478A43991D229E6C6" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Non-vested, start of year (in shares)</link:label>
<link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_3EAD8D7715A3B29478A43991D229E6C6_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_3EAD8D7715A3B29478A43991D229E6C6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number</link:label>
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_3EAD8D7715A3B29478A43991D229E6C6" xlink:type="locator" />
<link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_3EAD8D7715A3B29478A43991D229E6C6" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_3EAD8D7715A3B29478A43991D229E6C6" xlink:type="arc" />
<link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_21CAC48053750F29AEA53991D229E83E_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_21CAC48053750F29AEA53991D229E83E" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Granted (in shares)</link:label>
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_21CAC48053750F29AEA53991D229E83E" xlink:type="locator" />
<link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_21CAC48053750F29AEA53991D229E83E" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_21CAC48053750F29AEA53991D229E83E" xlink:type="arc" />
<link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_63BAD3AD7AB7CF1665E23991D2291875_negatedLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_63BAD3AD7AB7CF1665E23991D2291875" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Vested/Exercised (in shares)</link:label>
<link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_63BAD3AD7AB7CF1665E23991D2291875_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_63BAD3AD7AB7CF1665E23991D2291875" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period</link:label>
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_63BAD3AD7AB7CF1665E23991D2291875" xlink:type="locator" />
<link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_63BAD3AD7AB7CF1665E23991D2291875" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_63BAD3AD7AB7CF1665E23991D2291875" xlink:type="arc" />
<link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_8FC1F861EE84D69E18953991D229C39B_negatedLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_8FC1F861EE84D69E18953991D229C39B" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Forfeited (in shares)</link:label>
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_8FC1F861EE84D69E18953991D229C39B" xlink:type="locator" />
<link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_8FC1F861EE84D69E18953991D229C39B" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_8FC1F861EE84D69E18953991D229C39B" xlink:type="arc" />
<link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_7AAE52D42DB09648E5083991D2295770_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_7AAE52D42DB09648E5083991D2295770" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Non-vested, end of year (in shares)</link:label>
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_7AAE52D42DB09648E5083991D2295770" xlink:type="locator" />
<link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_7AAE52D42DB09648E5083991D2295770" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_7AAE52D42DB09648E5083991D2295770" xlink:type="arc" />
<link:label id="lab_immu_WeightedaveragegrantdatefairvalueRollForward_0B159BB2FEE53AF19F863991D22AFE9F_terseLabel_en-US" xlink:label="lab_immu_WeightedaveragegrantdatefairvalueRollForward_0B159BB2FEE53AF19F863991D22AFE9F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted Average Grant Date Fair Value</link:label>
<link:label id="lab_immu_WeightedaveragegrantdatefairvalueRollForward_0B159BB2FEE53AF19F863991D22AFE9F_label_en-US" xlink:label="lab_immu_WeightedaveragegrantdatefairvalueRollForward_0B159BB2FEE53AF19F863991D22AFE9F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted average grant date fair value [Roll Forward]</link:label>
<link:label id="lab_immu_WeightedaveragegrantdatefairvalueRollForward_0B159BB2FEE53AF19F863991D22AFE9F_documentation_en-US" xlink:label="lab_immu_WeightedaveragegrantdatefairvalueRollForward_0B159BB2FEE53AF19F863991D22AFE9F" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Weighted average grant date fair value [Roll Forward]</link:label>
<link:loc xlink:href="immu-20191231.xsd#immu_WeightedaveragegrantdatefairvalueRollForward" xlink:label="loc_immu_WeightedaveragegrantdatefairvalueRollForward_0B159BB2FEE53AF19F863991D22AFE9F" xlink:type="locator" />
<link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_immu_WeightedaveragegrantdatefairvalueRollForward_0B159BB2FEE53AF19F863991D22AFE9F" xlink:to="lab_immu_WeightedaveragegrantdatefairvalueRollForward_0B159BB2FEE53AF19F863991D22AFE9F" xlink:type="arc" />
<link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_4E78933187C83BE24FB03991D22AAF26_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_4E78933187C83BE24FB03991D22AAF26" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Nonvested, weighted average grant date fair value, start of year (in USD per share)</link:label>
<link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_4E78933187C83BE24FB03991D22AAF26_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_4E78933187C83BE24FB03991D22AAF26" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value</link:label>
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_4E78933187C83BE24FB03991D22AAF26" xlink:type="locator" />
<link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_4E78933187C83BE24FB03991D22AAF26" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_4E78933187C83BE24FB03991D22AAF26" xlink:type="arc" />
<link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_7BEAAC0017085B0D34E23991D22A815F_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_7BEAAC0017085B0D34E23991D22A815F" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Grants in period, weighted average grant date fair value (in USD per share)</link:label>
<link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_7BEAAC0017085B0D34E23991D22A815F_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_7BEAAC0017085B0D34E23991D22A815F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_7BEAAC0017085B0D34E23991D22A815F" xlink:type="locator" />
<link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_7BEAAC0017085B0D34E23991D22A815F" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_7BEAAC0017085B0D34E23991D22A815F" xlink:type="arc" />
<link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_B05C97F255D7808305BF3991D22AC652_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_B05C97F255D7808305BF3991D22AC652" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Vested/exercised, weighted average grant date fair value (in USD per share)</link:label>
<link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_B05C97F255D7808305BF3991D22AC652_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_B05C97F255D7808305BF3991D22AC652" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value</link:label>
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_B05C97F255D7808305BF3991D22AC652" xlink:type="locator" />
<link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_B05C97F255D7808305BF3991D22AC652" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_B05C97F255D7808305BF3991D22AC652" xlink:type="arc" />
<link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_1B6AE5896B1AFD85B19D3991D22A7F29_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_1B6AE5896B1AFD85B19D3991D22A7F29" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Forfeited, weighted average grant fate fair value (in USD per share)</link:label>
<link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_1B6AE5896B1AFD85B19D3991D22A7F29_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_1B6AE5896B1AFD85B19D3991D22A7F29" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value</link:label>
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_1B6AE5896B1AFD85B19D3991D22A7F29" xlink:type="locator" />
<link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_1B6AE5896B1AFD85B19D3991D22A7F29" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_1B6AE5896B1AFD85B19D3991D22A7F29" xlink:type="arc" />
<link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_CA1DBE4B3C051AC6D7253991D22A7990_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_CA1DBE4B3C051AC6D7253991D22A7990" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Nonvested, weighted average grant date fair value, end of year (in USD per share)</link:label>
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_CA1DBE4B3C051AC6D7253991D22A7990" xlink:type="locator" />
<link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_CA1DBE4B3C051AC6D7253991D22A7990" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_CA1DBE4B3C051AC6D7253991D22A7990" xlink:type="arc" />
<link:label id="lab_us-gaap_CompensationAndRetirementDisclosureAbstract_9E55CFFD9684533C9928D1D0623791AC_label_en-US" xlink:label="lab_us-gaap_CompensationAndRetirementDisclosureAbstract_9E55CFFD9684533C9928D1D0623791AC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Retirement Benefits [Abstract]</link:label>
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:label="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_9E55CFFD9684533C9928D1D0623791AC" xlink:type="locator" />
<link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_9E55CFFD9684533C9928D1D0623791AC" xlink:to="lab_us-gaap_CompensationAndRetirementDisclosureAbstract_9E55CFFD9684533C9928D1D0623791AC" xlink:type="arc" />
<link:label id="lab_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_B1E4078F7553FC41C6E3D1D062470EFB_terseLabel_en-US" xlink:label="lab_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_B1E4078F7553FC41C6E3D1D062470EFB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Defined Contribution Plans</link:label>
<link:label id="lab_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_B1E4078F7553FC41C6E3D1D062470EFB_label_en-US" xlink:label="lab_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_B1E4078F7553FC41C6E3D1D062470EFB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pension and Other Postretirement Benefits Disclosure [Text Block]</link:label>
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:label="loc_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_B1E4078F7553FC41C6E3D1D062470EFB" xlink:type="locator" />
<link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_B1E4078F7553FC41C6E3D1D062470EFB" xlink:to="lab_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_B1E4078F7553FC41C6E3D1D062470EFB" xlink:type="arc" />
<link:label id="lab_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_BB276CE63601025F9CFCD1D0633433B0_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_BB276CE63601025F9CFCD1D0633433B0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Marketable Securities</link:label>
<link:label id="lab_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_BB276CE63601025F9CFCD1D0633433B0_label_en-US" xlink:label="lab_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_BB276CE63601025F9CFCD1D0633433B0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investments in Debt and Marketable Equity Securities (and Certain Trading Assets) Disclosure [Text Block]</link:label>
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:label="loc_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_BB276CE63601025F9CFCD1D0633433B0" xlink:type="locator" />
<link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_BB276CE63601025F9CFCD1D0633433B0" xlink:to="lab_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_BB276CE63601025F9CFCD1D0633433B0" xlink:type="arc" />
<link:label id="lab_us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock_881AB52636EFC19CC43B3991D16E632E_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock_881AB52636EFC19CC43B3991D16E632E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Summarized Unaudited Quarterly Financial Data</link:label>
<link:label id="lab_us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock_881AB52636EFC19CC43B3991D16E632E_label_en-US" xlink:label="lab_us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock_881AB52636EFC19CC43B3991D16E632E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Quarterly Financial Information [Table Text Block]</link:label>
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock_881AB52636EFC19CC43B3991D16E632E" xlink:type="locator" />
<link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock_881AB52636EFC19CC43B3991D16E632E" xlink:to="lab_us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock_881AB52636EFC19CC43B3991D16E632E" xlink:type="arc" />
<link:label id="lab_srt_MajorCustomersAxis_D2B4966F6BB63CD66656600A16545DC6_terseLabel_en-US" xlink:label="lab_srt_MajorCustomersAxis_D2B4966F6BB63CD66656600A16545DC6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Customer [Axis]</link:label>
<link:label id="lab_srt_MajorCustomersAxis_D2B4966F6BB63CD66656600A16545DC6_label_en-US" xlink:label="lab_srt_MajorCustomersAxis_D2B4966F6BB63CD66656600A16545DC6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Customer [Axis]</link:label>
<link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MajorCustomersAxis" xlink:label="loc_srt_MajorCustomersAxis_D2B4966F6BB63CD66656600A16545DC6" xlink:type="locator" />
<link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MajorCustomersAxis_D2B4966F6BB63CD66656600A16545DC6" xlink:to="lab_srt_MajorCustomersAxis_D2B4966F6BB63CD66656600A16545DC6" xlink:type="arc" />
<link:label id="lab_srt_NameOfMajorCustomerDomain_F8E94BBB1CE4CD8FD11A600A165533EC_terseLabel_en-US" xlink:label="lab_srt_NameOfMajorCustomerDomain_F8E94BBB1CE4CD8FD11A600A165533EC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Customer [Domain]</link:label>
<link:label id="lab_srt_NameOfMajorCustomerDomain_F8E94BBB1CE4CD8FD11A600A165533EC_label_en-US" xlink:label="lab_srt_NameOfMajorCustomerDomain_F8E94BBB1CE4CD8FD11A600A165533EC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Customer [Domain]</link:label>
<link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_NameOfMajorCustomerDomain" xlink:label="loc_srt_NameOfMajorCustomerDomain_F8E94BBB1CE4CD8FD11A600A165533EC" xlink:type="locator" />
<link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_NameOfMajorCustomerDomain_F8E94BBB1CE4CD8FD11A600A165533EC" xlink:to="lab_srt_NameOfMajorCustomerDomain_F8E94BBB1CE4CD8FD11A600A165533EC" xlink:type="arc" />
<link:label id="lab_immu_EverestMedicinesIILimitedMember_37EDB7656211658CA0FC600A16555470_terseLabel_en-US" xlink:label="lab_immu_EverestMedicinesIILimitedMember_37EDB7656211658CA0FC600A16555470" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Everest Medicines II Limited</link:label>
<link:label id="lab_immu_EverestMedicinesIILimitedMember_37EDB7656211658CA0FC600A16555470_label_en-US" xlink:label="lab_immu_EverestMedicinesIILimitedMember_37EDB7656211658CA0FC600A16555470" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Everest Medicines II Limited [Member]</link:label>
<link:label id="lab_immu_EverestMedicinesIILimitedMember_37EDB7656211658CA0FC600A16555470_documentation_en-US" xlink:label="lab_immu_EverestMedicinesIILimitedMember_37EDB7656211658CA0FC600A16555470" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Everest Medicines II Limited [Member]</link:label>
<link:loc xlink:href="immu-20191231.xsd#immu_EverestMedicinesIILimitedMember" xlink:label="loc_immu_EverestMedicinesIILimitedMember_37EDB7656211658CA0FC600A16555470" xlink:type="locator" />
<link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_immu_EverestMedicinesIILimitedMember_37EDB7656211658CA0FC600A16555470" xlink:to="lab_immu_EverestMedicinesIILimitedMember_37EDB7656211658CA0FC600A16555470" xlink:type="arc" />
<link:label id="lab_immu_JanssenBiotechIncMember_539D7A71C595FF03DE74600A16551E8A_terseLabel_en-US" xlink:label="lab_immu_JanssenBiotechIncMember_539D7A71C595FF03DE74600A16551E8A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Janssen Biotech Inc</link:label>
<link:label id="lab_immu_JanssenBiotechIncMember_539D7A71C595FF03DE74600A16551E8A_label_en-US" xlink:label="lab_immu_JanssenBiotechIncMember_539D7A71C595FF03DE74600A16551E8A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Janssen Biotech Inc [Member]</link:label>
<link:label id="lab_immu_JanssenBiotechIncMember_539D7A71C595FF03DE74600A16551E8A_documentation_en-US" xlink:label="lab_immu_JanssenBiotechIncMember_539D7A71C595FF03DE74600A16551E8A" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Janssen Biotech Inc [Member]</link:label>
<link:loc xlink:href="immu-20191231.xsd#immu_JanssenBiotechIncMember" xlink:label="loc_immu_JanssenBiotechIncMember_539D7A71C595FF03DE74600A16551E8A" xlink:type="locator" />
<link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_immu_JanssenBiotechIncMember_539D7A71C595FF03DE74600A16551E8A" xlink:to="lab_immu_JanssenBiotechIncMember_539D7A71C595FF03DE74600A16551E8A" xlink:type="arc" />
<link:label id="lab_immu_LicenseAgreementUpfrontFeesPaid_7370011645711C8646F9600A1656BD38_terseLabel_en-US" xlink:label="lab_immu_LicenseAgreementUpfrontFeesPaid_7370011645711C8646F9600A1656BD38" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Upfront fees paid</link:label>
<link:label id="lab_immu_LicenseAgreementUpfrontFeesPaid_7370011645711C8646F9600A1656BD38_label_en-US" xlink:label="lab_immu_LicenseAgreementUpfrontFeesPaid_7370011645711C8646F9600A1656BD38" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">License Agreement Upfront Fees Paid</link:label>
<link:label id="lab_immu_LicenseAgreementUpfrontFeesPaid_7370011645711C8646F9600A1656BD38_documentation_en-US" xlink:label="lab_immu_LicenseAgreementUpfrontFeesPaid_7370011645711C8646F9600A1656BD38" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">License Agreement Upfront Fees Paid</link:label>
<link:loc xlink:href="immu-20191231.xsd#immu_LicenseAgreementUpfrontFeesPaid" xlink:label="loc_immu_LicenseAgreementUpfrontFeesPaid_7370011645711C8646F9600A1656BD38" xlink:type="locator" />
<link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_immu_LicenseAgreementUpfrontFeesPaid_7370011645711C8646F9600A1656BD38" xlink:to="lab_immu_LicenseAgreementUpfrontFeesPaid_7370011645711C8646F9600A1656BD38" xlink:type="arc" />
<link:label id="lab_immu_LicenseAgreementMilestonePaymentUponAchievementofFDAApproval_1AB7EBD853E908205207600A16564630_terseLabel_en-US" xlink:label="lab_immu_LicenseAgreementMilestonePaymentUponAchievementofFDAApproval_1AB7EBD853E908205207600A16564630" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Payment upon achievement of FDA approval</link:label>
<link:label id="lab_immu_LicenseAgreementMilestonePaymentUponAchievementofFDAApproval_1AB7EBD853E908205207600A16564630_label_en-US" xlink:label="lab_immu_LicenseAgreementMilestonePaymentUponAchievementofFDAApproval_1AB7EBD853E908205207600A16564630" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">License Agreement Milestone Payment Upon Achievement of FDA Approval</link:label>
<link:label id="lab_immu_LicenseAgreementMilestonePaymentUponAchievementofFDAApproval_1AB7EBD853E908205207600A16564630_documentation_en-US" xlink:label="lab_immu_LicenseAgreementMilestonePaymentUponAchievementofFDAApproval_1AB7EBD853E908205207600A16564630" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">License Agreement Milestone Payment Upon Achievement of FDA Approval</link:label>
<link:loc xlink:href="immu-20191231.xsd#immu_LicenseAgreementMilestonePaymentUponAchievementofFDAApproval" xlink:label="loc_immu_LicenseAgreementMilestonePaymentUponAchievementofFDAApproval_1AB7EBD853E908205207600A16564630" xlink:type="locator" />
<link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_immu_LicenseAgreementMilestonePaymentUponAchievementofFDAApproval_1AB7EBD853E908205207600A16564630" xlink:to="lab_immu_LicenseAgreementMilestonePaymentUponAchievementofFDAApproval_1AB7EBD853E908205207600A16564630" xlink:type="arc" />
<link:label id="lab_immu_LicenseAgreementMilestoneDevelopmentTotalPayments_AF47BF19638BB147E1C6600A1656E37E_terseLabel_en-US" xlink:label="lab_immu_LicenseAgreementMilestoneDevelopmentTotalPayments_AF47BF19638BB147E1C6600A1656E37E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Development total payments</link:label>
<link:label id="lab_immu_LicenseAgreementMilestoneDevelopmentTotalPayments_AF47BF19638BB147E1C6600A1656E37E_label_en-US" xlink:label="lab_immu_LicenseAgreementMilestoneDevelopmentTotalPayments_AF47BF19638BB147E1C6600A1656E37E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">License Agreement Milestone Development Total Payments</link:label>
<link:label id="lab_immu_LicenseAgreementMilestoneDevelopmentTotalPayments_AF47BF19638BB147E1C6600A1656E37E_documentation_en-US" xlink:label="lab_immu_LicenseAgreementMilestoneDevelopmentTotalPayments_AF47BF19638BB147E1C6600A1656E37E" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">License Agreement Milestone Development Total Payments</link:label>
<link:loc xlink:href="immu-20191231.xsd#immu_LicenseAgreementMilestoneDevelopmentTotalPayments" xlink:label="loc_immu_LicenseAgreementMilestoneDevelopmentTotalPayments_AF47BF19638BB147E1C6600A1656E37E" xlink:type="locator" />
<link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_immu_LicenseAgreementMilestoneDevelopmentTotalPayments_AF47BF19638BB147E1C6600A1656E37E" xlink:to="lab_immu_LicenseAgreementMilestoneDevelopmentTotalPayments_AF47BF19638BB147E1C6600A1656E37E" xlink:type="arc" />
<link:label id="lab_immu_LicenseAgreementMilestoneSalesTotalPayments_8875A3B1139BEE577714600A16560AB1_verboseLabel_en-US" xlink:label="lab_immu_LicenseAgreementMilestoneSalesTotalPayments_8875A3B1139BEE577714600A16560AB1" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Sales total payments</link:label>
<link:label id="lab_immu_LicenseAgreementMilestoneSalesTotalPayments_8875A3B1139BEE577714600A16560AB1_label_en-US" xlink:label="lab_immu_LicenseAgreementMilestoneSalesTotalPayments_8875A3B1139BEE577714600A16560AB1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">License Agreement Milestone Sales Total Payments</link:label>
<link:label id="lab_immu_LicenseAgreementMilestoneSalesTotalPayments_8875A3B1139BEE577714600A16560AB1_documentation_en-US" xlink:label="lab_immu_LicenseAgreementMilestoneSalesTotalPayments_8875A3B1139BEE577714600A16560AB1" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">License Agreement Milestone Sales Total Payments</link:label>
<link:loc xlink:href="immu-20191231.xsd#immu_LicenseAgreementMilestoneSalesTotalPayments" xlink:label="loc_immu_LicenseAgreementMilestoneSalesTotalPayments_8875A3B1139BEE577714600A16560AB1" xlink:type="locator" />
<link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_immu_LicenseAgreementMilestoneSalesTotalPayments_8875A3B1139BEE577714600A16560AB1" xlink:to="lab_immu_LicenseAgreementMilestoneSalesTotalPayments_8875A3B1139BEE577714600A16560AB1" xlink:type="arc" />
<link:label id="lab_immu_RoyaltyPaymentsPercentage_3A3555046E5FA3205B54600A1656895B_terseLabel_en-US" xlink:label="lab_immu_RoyaltyPaymentsPercentage_3A3555046E5FA3205B54600A1656895B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Royalty payments percentage</link:label>
<link:label id="lab_immu_RoyaltyPaymentsPercentage_3A3555046E5FA3205B54600A1656895B_label_en-US" xlink:label="lab_immu_RoyaltyPaymentsPercentage_3A3555046E5FA3205B54600A1656895B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Royalty Payments Percentage</link:label>
<link:label id="lab_immu_RoyaltyPaymentsPercentage_3A3555046E5FA3205B54600A1656895B_documentation_en-US" xlink:label="lab_immu_RoyaltyPaymentsPercentage_3A3555046E5FA3205B54600A1656895B" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Royalty Payments Percentage</link:label>
<link:loc xlink:href="immu-20191231.xsd#immu_RoyaltyPaymentsPercentage" xlink:label="loc_immu_RoyaltyPaymentsPercentage_3A3555046E5FA3205B54600A1656895B" xlink:type="locator" />
<link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_immu_RoyaltyPaymentsPercentage_3A3555046E5FA3205B54600A1656895B" xlink:to="lab_immu_RoyaltyPaymentsPercentage_3A3555046E5FA3205B54600A1656895B" xlink:type="arc" />
<link:label id="lab_us-gaap_Revenues_140CA064DA642700FF98600A1657DB51_terseLabel_en-US" xlink:label="lab_us-gaap_Revenues_140CA064DA642700FF98600A1657DB51" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenues</link:label>
<link:label id="lab_us-gaap_Revenues_140CA064DA642700FF98600A1657DB51_label_en-US" xlink:label="lab_us-gaap_Revenues_140CA064DA642700FF98600A1657DB51" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenues</link:label>
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Revenues" xlink:label="loc_us-gaap_Revenues_140CA064DA642700FF98600A1657DB51" xlink:type="locator" />
<link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Revenues_140CA064DA642700FF98600A1657DB51" xlink:to="lab_us-gaap_Revenues_140CA064DA642700FF98600A1657DB51" xlink:type="arc" />
<link:label id="lab_us-gaap_AccountsPayableTradeCurrent_668E763C5D6A2A4FD5BF5EE4648775DD_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableTradeCurrent_668E763C5D6A2A4FD5BF5EE4648775DD" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Trade accounts payable</link:label>
<link:label id="lab_us-gaap_AccountsPayableTradeCurrent_668E763C5D6A2A4FD5BF5EE4648775DD_label_en-US" xlink:label="lab_us-gaap_AccountsPayableTradeCurrent_668E763C5D6A2A4FD5BF5EE4648775DD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounts Payable, Trade, Current</link:label>
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountsPayableTradeCurrent" xlink:label="loc_us-gaap_AccountsPayableTradeCurrent_668E763C5D6A2A4FD5BF5EE4648775DD" xlink:type="locator" />
<link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableTradeCurrent_668E763C5D6A2A4FD5BF5EE4648775DD" xlink:to="lab_us-gaap_AccountsPayableTradeCurrent_668E763C5D6A2A4FD5BF5EE4648775DD" xlink:type="arc" />
<link:label id="lab_immu_AccruedContractManufacturingExpenses_C121B89B9BCD95FDA0F45EEE23F06A43_terseLabel_en-US" xlink:label="lab_immu_AccruedContractManufacturingExpenses_C121B89B9BCD95FDA0F45EEE23F06A43" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued contract manufacturing expenses</link:label>
<link:label id="lab_immu_AccruedContractManufacturingExpenses_C121B89B9BCD95FDA0F45EEE23F06A43_label_en-US" xlink:label="lab_immu_AccruedContractManufacturingExpenses_C121B89B9BCD95FDA0F45EEE23F06A43" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accrued Contract Manufacturing Expenses</link:label>
<link:label id="lab_immu_AccruedContractManufacturingExpenses_C121B89B9BCD95FDA0F45EEE23F06A43_documentation_en-US" xlink:label="lab_immu_AccruedContractManufacturingExpenses_C121B89B9BCD95FDA0F45EEE23F06A43" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Accrued Manufacturing Expenses</link:label>
<link:loc xlink:href="immu-20191231.xsd#immu_AccruedContractManufacturingExpenses" xlink:label="loc_immu_AccruedContractManufacturingExpenses_C121B89B9BCD95FDA0F45EEE23F06A43" xlink:type="locator" />
<link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_immu_AccruedContractManufacturingExpenses_C121B89B9BCD95FDA0F45EEE23F06A43" xlink:to="lab_immu_AccruedContractManufacturingExpenses_C121B89B9BCD95FDA0F45EEE23F06A43" xlink:type="arc" />
<link:label id="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_D0927ACC8EAC66FC18715EEF16E55B5F_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_D0927ACC8EAC66FC18715EEF16E55B5F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued employee related expenses</link:label>
<link:label id="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_D0927ACC8EAC66FC18715EEF16E55B5F_label_en-US" xlink:label="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_D0927ACC8EAC66FC18715EEF16E55B5F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Employee-related Liabilities, Current</link:label>
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_D0927ACC8EAC66FC18715EEF16E55B5F" xlink:type="locator" />
<link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_D0927ACC8EAC66FC18715EEF16E55B5F" xlink:to="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_D0927ACC8EAC66FC18715EEF16E55B5F" xlink:type="arc" />
<link:label id="lab_immu_ClinicalTrials_C29B6826CEFAB93305555EE464881878_terseLabel_en-US" xlink:label="lab_immu_ClinicalTrials_C29B6826CEFAB93305555EE464881878" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Clinical trial accruals</link:label>
<link:label id="lab_immu_ClinicalTrials_C29B6826CEFAB93305555EE464881878_label_en-US" xlink:label="lab_immu_ClinicalTrials_C29B6826CEFAB93305555EE464881878" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Clinical Trials</link:label>
<link:label id="lab_immu_ClinicalTrials_C29B6826CEFAB93305555EE464881878_documentation_en-US" xlink:label="lab_immu_ClinicalTrials_C29B6826CEFAB93305555EE464881878" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Clinical Trials</link:label>
<link:loc xlink:href="immu-20191231.xsd#immu_ClinicalTrials" xlink:label="loc_immu_ClinicalTrials_C29B6826CEFAB93305555EE464881878" xlink:type="locator" />
<link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_immu_ClinicalTrials_C29B6826CEFAB93305555EE464881878" xlink:to="lab_immu_ClinicalTrials_C29B6826CEFAB93305555EE464881878" xlink:type="arc" />
<link:label id="lab_us-gaap_SupplementalUnemploymentBenefitsSeveranceBenefits_C880EA6F77ADC92346475EE464885A42_terseLabel_en-US" xlink:label="lab_us-gaap_SupplementalUnemploymentBenefitsSeveranceBenefits_C880EA6F77ADC92346475EE464885A42" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Executive severance liabilities</link:label>
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SupplementalUnemploymentBenefitsSeveranceBenefits" xlink:label="loc_us-gaap_SupplementalUnemploymentBenefitsSeveranceBenefits_C880EA6F77ADC92346475EE464885A42" xlink:type="locator" />
<link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SupplementalUnemploymentBenefitsSeveranceBenefits_C880EA6F77ADC92346475EE464885A42" xlink:to="lab_us-gaap_SupplementalUnemploymentBenefitsSeveranceBenefits_C880EA6F77ADC92346475EE464885A42" xlink:type="arc" />
<link:label id="lab_immu_OtherCurrentLiabilities_3004943FD3FE5D272C625EE46488415B_terseLabel_en-US" xlink:label="lab_immu_OtherCurrentLiabilities_3004943FD3FE5D272C625EE46488415B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Miscellaneous other current liabilities</link:label>
<link:label id="lab_immu_OtherCurrentLiabilities_3004943FD3FE5D272C625EE46488415B_label_en-US" xlink:label="lab_immu_OtherCurrentLiabilities_3004943FD3FE5D272C625EE46488415B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Current Liabilities</link:label>
<link:label id="lab_immu_OtherCurrentLiabilities_3004943FD3FE5D272C625EE46488415B_documentation_en-US" xlink:label="lab_immu_OtherCurrentLiabilities_3004943FD3FE5D272C625EE46488415B" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Other Current Liabilities</link:label>
<link:loc xlink:href="immu-20191231.xsd#immu_OtherCurrentLiabilities" xlink:label="loc_immu_OtherCurrentLiabilities_3004943FD3FE5D272C625EE46488415B" xlink:type="locator" />
<link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_immu_OtherCurrentLiabilities_3004943FD3FE5D272C625EE46488415B" xlink:to="lab_immu_OtherCurrentLiabilities_3004943FD3FE5D272C625EE46488415B" xlink:type="arc" />
<link:label id="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_21B5C0994C51007861A55EE46488FCE9_totalLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_21B5C0994C51007861A55EE46488FCE9" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Accounts payable and accrued expenses</link:label>
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_21B5C0994C51007861A55EE46488FCE9" xlink:type="locator" />
<link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_21B5C0994C51007861A55EE46488FCE9" xlink:to="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_21B5C0994C51007861A55EE46488FCE9" xlink:type="arc" />
<link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_C956FEA9B3A95A446E48D1D06334A983_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_C956FEA9B3A95A446E48D1D06334A983" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Commitments and Contingencies</link:label>
<link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_C956FEA9B3A95A446E48D1D06334A983_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_C956FEA9B3A95A446E48D1D06334A983" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Commitments and Contingencies Disclosure [Text Block]</link:label>
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_C956FEA9B3A95A446E48D1D06334A983" xlink:type="locator" />
<link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_C956FEA9B3A95A446E48D1D06334A983" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_C956FEA9B3A95A446E48D1D06334A983" xlink:type="arc" />
<link:label id="lab_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch_76768F4BB1D38441E24763765547FD59_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch_76768F4BB1D38441E24763765547FD59" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Employer matching contribution (as percent)</link:label>
<link:label id="lab_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch_76768F4BB1D38441E24763765547FD59_label_en-US" xlink:label="lab_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch_76768F4BB1D38441E24763765547FD59" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Defined Contribution Plan, Employer Matching Contribution, Percent of Match</link:label>
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" xlink:label="loc_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch_76768F4BB1D38441E24763765547FD59" xlink:type="locator" />
<link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch_76768F4BB1D38441E24763765547FD59" xlink:to="lab_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch_76768F4BB1D38441E24763765547FD59" xlink:type="arc" />
<link:label id="lab_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent_9B49F616A3B584A49B9D6376E52CF4F3_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent_9B49F616A3B584A49B9D6376E52CF4F3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Employer matching contribution, percent of employee's pay (as percent)</link:label>
<link:label id="lab_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent_9B49F616A3B584A49B9D6376E52CF4F3_label_en-US" xlink:label="lab_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent_9B49F616A3B584A49B9D6376E52CF4F3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Defined Contribution Plan, Employer Matching Contribution, Percent of Employees' Gross Pay</link:label>
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent" xlink:label="loc_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent_9B49F616A3B584A49B9D6376E52CF4F3" xlink:type="locator" />
<link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent_9B49F616A3B584A49B9D6376E52CF4F3" xlink:to="lab_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent_9B49F616A3B584A49B9D6376E52CF4F3" xlink:type="arc" />
<link:label id="lab_us-gaap_DefinedBenefitPlanContributionsByEmployer_1053037299173A742AF7635C88421F7D_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanContributionsByEmployer_1053037299173A742AF7635C88421F7D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Aggregate company contributions to its benefit plans</link:label>
<link:label id="lab_us-gaap_DefinedBenefitPlanContributionsByEmployer_1053037299173A742AF7635C88421F7D_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanContributionsByEmployer_1053037299173A742AF7635C88421F7D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Defined Benefit Plan, Plan Assets, Contributions by Employer</link:label>
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DefinedBenefitPlanContributionsByEmployer" xlink:label="loc_us-gaap_DefinedBenefitPlanContributionsByEmployer_1053037299173A742AF7635C88421F7D" xlink:type="locator" />
<link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanContributionsByEmployer_1053037299173A742AF7635C88421F7D" xlink:to="lab_us-gaap_DefinedBenefitPlanContributionsByEmployer_1053037299173A742AF7635C88421F7D" xlink:type="arc" />
<link:label id="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable_F4694D1FF242B00E15A560442EBD23BA_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable_F4694D1FF242B00E15A560442EBD23BA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Table]</link:label>
<link:label id="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable_F4694D1FF242B00E15A560442EBD23BA_label_en-US" xlink:label="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable_F4694D1FF242B00E15A560442EBD23BA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Table]</link:label>
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable_F4694D1FF242B00E15A560442EBD23BA" xlink:type="locator" />
<link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable_F4694D1FF242B00E15A560442EBD23BA" xlink:to="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable_F4694D1FF242B00E15A560442EBD23BA" xlink:type="arc" />
<link:label id="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis_3AF2DADEDCA1E9A7621560442EBE7F0F_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis_3AF2DADEDCA1E9A7621560442EBE7F0F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]</link:label>
<link:label id="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis_3AF2DADEDCA1E9A7621560442EBE7F0F_label_en-US" xlink:label="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis_3AF2DADEDCA1E9A7621560442EBE7F0F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]</link:label>
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis_3AF2DADEDCA1E9A7621560442EBE7F0F" xlink:type="locator" />
<link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis_3AF2DADEDCA1E9A7621560442EBE7F0F" xlink:to="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis_3AF2DADEDCA1E9A7621560442EBE7F0F" xlink:type="arc" />
<link:label id="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems_921FCF5FBA7D1E1CD70560442EBFEB5D_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems_921FCF5FBA7D1E1CD70560442EBFEB5D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]</link:label>
<link:label id="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems_921FCF5FBA7D1E1CD70560442EBFEB5D_label_en-US" xlink:label="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems_921FCF5FBA7D1E1CD70560442EBFEB5D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]</link:label>
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems_921FCF5FBA7D1E1CD70560442EBFEB5D" xlink:type="locator" />
<link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems_921FCF5FBA7D1E1CD70560442EBFEB5D" xlink:to="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems_921FCF5FBA7D1E1CD70560442EBFEB5D" xlink:type="arc" />
<link:label id="lab_us-gaap_RevenueRemainingPerformanceObligation_094F2AF318DA8860924560442EBF48A0_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueRemainingPerformanceObligation_094F2AF318DA8860924560442EBF48A0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Performance obligation</link:label>
<link:label id="lab_us-gaap_RevenueRemainingPerformanceObligation_094F2AF318DA8860924560442EBF48A0_label_en-US" xlink:label="lab_us-gaap_RevenueRemainingPerformanceObligation_094F2AF318DA8860924560442EBF48A0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue, Remaining Performance Obligation, Amount</link:label>
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligation" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligation_094F2AF318DA8860924560442EBF48A0" xlink:type="locator" />
<link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligation_094F2AF318DA8860924560442EBF48A0" xlink:to="lab_us-gaap_RevenueRemainingPerformanceObligation_094F2AF318DA8860924560442EBF48A0" xlink:type="arc" />
<link:label id="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1_A2BAF008799865F61CB060442EBFA562_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1_A2BAF008799865F61CB060442EBFA562" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Remaining performance obligation period</link:label>
<link:label id="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1_A2BAF008799865F61CB060442EBFA562_label_en-US" xlink:label="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1_A2BAF008799865F61CB060442EBFA562" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Period</link:label>
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1_A2BAF008799865F61CB060442EBFA562" xlink:type="locator" />
<link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1_A2BAF008799865F61CB060442EBFA562" xlink:to="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1_A2BAF008799865F61CB060442EBFA562" xlink:type="arc" />
<link:label id="lab_us-gaap_FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_B894E9BC299FDAFE931ADB9A483D8F6A_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_B894E9BC299FDAFE931ADB9A483D8F6A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Financial Instruments Recorded on Condensed Consolidated Balance Sheets</link:label>
<link:label id="lab_us-gaap_FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_B894E9BC299FDAFE931ADB9A483D8F6A_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_B894E9BC299FDAFE931ADB9A483D8F6A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Assets Measured on Recurring and Nonrecurring Basis [Table Text Block]</link:label>
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_B894E9BC299FDAFE931ADB9A483D8F6A" xlink:type="locator" />
<link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_B894E9BC299FDAFE931ADB9A483D8F6A" xlink:to="lab_us-gaap_FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_B894E9BC299FDAFE931ADB9A483D8F6A" xlink:type="arc" />
<link:label id="lab_us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock_64EEB5D0BD954CC02249DB9A483DA72F_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock_64EEB5D0BD954CC02249DB9A483DA72F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Carrying Amounts and Estimated Fair Values (Level 2) of Debt Instruments</link:label>
<link:label id="lab_us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock_64EEB5D0BD954CC02249DB9A483DA72F_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock_64EEB5D0BD954CC02249DB9A483DA72F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Carrying Values and Estimated Fair Values of Debt Instruments [Table Text Block]</link:label>
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock_64EEB5D0BD954CC02249DB9A483DA72F" xlink:type="locator" />
<link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock_64EEB5D0BD954CC02249DB9A483DA72F" xlink:to="lab_us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock_64EEB5D0BD954CC02249DB9A483DA72F" xlink:type="arc" />
<link:label id="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_D48F28D818B708A15DC3454D8573D6A8_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_D48F28D818B708A15DC3454D8573D6A8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Related Party Transactions, by Related Party [Table]</link:label>
<link:label id="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_D48F28D818B708A15DC3454D8573D6A8_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_D48F28D818B708A15DC3454D8573D6A8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Related Party Transactions, by Related Party [Table]</link:label>
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_D48F28D818B708A15DC3454D8573D6A8" xlink:type="locator" />
<link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_D48F28D818B708A15DC3454D8573D6A8" xlink:to="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_D48F28D818B708A15DC3454D8573D6A8" xlink:type="arc" />
<link:label id="lab_immu_ChiefTechnologyOfficerMember_BC9C5329332BB6953973454D857408F5_terseLabel_en-US" xlink:label="lab_immu_ChiefTechnologyOfficerMember_BC9C5329332BB6953973454D857408F5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Chief Technology Officer</link:label>
<link:label id="lab_immu_ChiefTechnologyOfficerMember_BC9C5329332BB6953973454D857408F5_label_en-US" xlink:label="lab_immu_ChiefTechnologyOfficerMember_BC9C5329332BB6953973454D857408F5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Chief Technology Officer [Member]</link:label>
<link:label id="lab_immu_ChiefTechnologyOfficerMember_BC9C5329332BB6953973454D857408F5_documentation_en-US" xlink:label="lab_immu_ChiefTechnologyOfficerMember_BC9C5329332BB6953973454D857408F5" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents information pertaining to chief technology officer.</link:label>
<link:loc xlink:href="immu-20191231.xsd#immu_ChiefTechnologyOfficerMember" xlink:label="loc_immu_ChiefTechnologyOfficerMember_BC9C5329332BB6953973454D857408F5" xlink:type="locator" />
<link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_immu_ChiefTechnologyOfficerMember_BC9C5329332BB6953973454D857408F5" xlink:to="lab_immu_ChiefTechnologyOfficerMember_BC9C5329332BB6953973454D857408F5" xlink:type="arc" />
<link:label id="lab_immu_ExecutiveDirectorMember_0B166C8AE4059C13AAC5454D85758891_terseLabel_en-US" xlink:label="lab_immu_ExecutiveDirectorMember_0B166C8AE4059C13AAC5454D85758891" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Executive Director</link:label>
<link:label id="lab_immu_ExecutiveDirectorMember_0B166C8AE4059C13AAC5454D85758891_label_en-US" xlink:label="lab_immu_ExecutiveDirectorMember_0B166C8AE4059C13AAC5454D85758891" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Executive Director [Member]</link:label>
<link:label id="lab_immu_ExecutiveDirectorMember_0B166C8AE4059C13AAC5454D85758891_documentation_en-US" xlink:label="lab_immu_ExecutiveDirectorMember_0B166C8AE4059C13AAC5454D85758891" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Executive Directorr [Member]</link:label>
<link:loc xlink:href="immu-20191231.xsd#immu_ExecutiveDirectorMember" xlink:label="loc_immu_ExecutiveDirectorMember_0B166C8AE4059C13AAC5454D85758891" xlink:type="locator" />
<link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_immu_ExecutiveDirectorMember_0B166C8AE4059C13AAC5454D85758891" xlink:to="lab_immu_ExecutiveDirectorMember_0B166C8AE4059C13AAC5454D85758891" xlink:type="arc" />
<link:label id="lab_srt_BoardOfDirectorsChairmanMember_8A65A3722CA02672053345546C13CCB2_terseLabel_en-US" xlink:label="lab_srt_BoardOfDirectorsChairmanMember_8A65A3722CA02672053345546C13CCB2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Board of Directors Chairman</link:label>
<link:label id="lab_srt_BoardOfDirectorsChairmanMember_8A65A3722CA02672053345546C13CCB2_label_en-US" xlink:label="lab_srt_BoardOfDirectorsChairmanMember_8A65A3722CA02672053345546C13CCB2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Board of Directors Chairman [Member]</link:label>
<link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_BoardOfDirectorsChairmanMember" xlink:label="loc_srt_BoardOfDirectorsChairmanMember_8A65A3722CA02672053345546C13CCB2" xlink:type="locator" />
<link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_BoardOfDirectorsChairmanMember_8A65A3722CA02672053345546C13CCB2" xlink:to="lab_srt_BoardOfDirectorsChairmanMember_8A65A3722CA02672053345546C13CCB2" xlink:type="arc" />
<link:label id="lab_immu_MRosenbergBioPharmaConsultingLlcMember_6D2D2530303492A8CE97454D857559F9_terseLabel_en-US" xlink:label="lab_immu_MRosenbergBioPharmaConsultingLlcMember_6D2D2530303492A8CE97454D857559F9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">M Rosenberg Bio Pharma Consulting Llc</link:label>
<link:label id="lab_immu_MRosenbergBioPharmaConsultingLlcMember_6D2D2530303492A8CE97454D857559F9_label_en-US" xlink:label="lab_immu_MRosenbergBioPharmaConsultingLlcMember_6D2D2530303492A8CE97454D857559F9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">M Rosenberg Bio Pharma Consulting Llc [Member]</link:label>
<link:label id="lab_immu_MRosenbergBioPharmaConsultingLlcMember_6D2D2530303492A8CE97454D857559F9_documentation_en-US" xlink:label="lab_immu_MRosenbergBioPharmaConsultingLlcMember_6D2D2530303492A8CE97454D857559F9" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents information pertaining to consulting agreement.</link:label>
<link:loc xlink:href="immu-20191231.xsd#immu_MRosenbergBioPharmaConsultingLlcMember" xlink:label="loc_immu_MRosenbergBioPharmaConsultingLlcMember_6D2D2530303492A8CE97454D857559F9" xlink:type="locator" />
<link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_immu_MRosenbergBioPharmaConsultingLlcMember_6D2D2530303492A8CE97454D857559F9" xlink:to="lab_immu_MRosenbergBioPharmaConsultingLlcMember_6D2D2530303492A8CE97454D857559F9" xlink:type="arc" />
<link:label id="lab_srt_DirectorMember_D281A408959672E55FEE454D8576E926_terseLabel_en-US" xlink:label="lab_srt_DirectorMember_D281A408959672E55FEE454D8576E926" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Director</link:label>
<link:label id="lab_srt_DirectorMember_D281A408959672E55FEE454D8576E926_label_en-US" xlink:label="lab_srt_DirectorMember_D281A408959672E55FEE454D8576E926" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Director [Member]</link:label>
<link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_DirectorMember" xlink:label="loc_srt_DirectorMember_D281A408959672E55FEE454D8576E926" xlink:type="locator" />
<link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_DirectorMember_D281A408959672E55FEE454D8576E926" xlink:to="lab_srt_DirectorMember_D281A408959672E55FEE454D8576E926" xlink:type="arc" />
<link:label id="lab_us-gaap_RelatedPartyTransactionLineItems_4F0A09EF5C1EB6170559454D85764216_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionLineItems_4F0A09EF5C1EB6170559454D85764216" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Related Party Transaction [Line Items]</link:label>
<link:label id="lab_us-gaap_RelatedPartyTransactionLineItems_4F0A09EF5C1EB6170559454D85764216_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionLineItems_4F0A09EF5C1EB6170559454D85764216" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Related Party Transaction [Line Items]</link:label>
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems_4F0A09EF5C1EB6170559454D85764216" xlink:type="locator" />
<link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_4F0A09EF5C1EB6170559454D85764216" xlink:to="lab_us-gaap_RelatedPartyTransactionLineItems_4F0A09EF5C1EB6170559454D85764216" xlink:type="arc" />
<link:label id="lab_us-gaap_ProfessionalAndContractServicesExpense_8ED33DE68964D3F00940454D85767385_terseLabel_en-US" xlink:label="lab_us-gaap_ProfessionalAndContractServicesExpense_8ED33DE68964D3F00940454D85767385" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Professional and contract services expense</link:label>
<link:label id="lab_us-gaap_ProfessionalAndContractServicesExpense_8ED33DE68964D3F00940454D85767385_label_en-US" xlink:label="lab_us-gaap_ProfessionalAndContractServicesExpense_8ED33DE68964D3F00940454D85767385" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Professional and Contract Services Expense</link:label>
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProfessionalAndContractServicesExpense" xlink:label="loc_us-gaap_ProfessionalAndContractServicesExpense_8ED33DE68964D3F00940454D85767385" xlink:type="locator" />
<link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProfessionalAndContractServicesExpense_8ED33DE68964D3F00940454D85767385" xlink:to="lab_us-gaap_ProfessionalAndContractServicesExpense_8ED33DE68964D3F00940454D85767385" xlink:type="arc" />
<link:label id="lab_immu_PercentOfSharesForfeitedEmploymentCommencement_23577B37F8BD73215F67454D85765860_terseLabel_en-US" xlink:label="lab_immu_PercentOfSharesForfeitedEmploymentCommencement_23577B37F8BD73215F67454D85765860" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Percent of shares forfeited upon employment commencement</link:label>
<link:label id="lab_immu_PercentOfSharesForfeitedEmploymentCommencement_23577B37F8BD73215F67454D85765860_label_en-US" xlink:label="lab_immu_PercentOfSharesForfeitedEmploymentCommencement_23577B37F8BD73215F67454D85765860" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Percent Of Shares Forfeited, Employment Commencement</link:label>
<link:label id="lab_immu_PercentOfSharesForfeitedEmploymentCommencement_23577B37F8BD73215F67454D85765860_documentation_en-US" xlink:label="lab_immu_PercentOfSharesForfeitedEmploymentCommencement_23577B37F8BD73215F67454D85765860" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Percent Of Shares Forfeited, Employment Commencement</link:label>
<link:loc xlink:href="immu-20191231.xsd#immu_PercentOfSharesForfeitedEmploymentCommencement" xlink:label="loc_immu_PercentOfSharesForfeitedEmploymentCommencement_23577B37F8BD73215F67454D85765860" xlink:type="locator" />
<link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_immu_PercentOfSharesForfeitedEmploymentCommencement_23577B37F8BD73215F67454D85765860" xlink:to="lab_immu_PercentOfSharesForfeitedEmploymentCommencement_23577B37F8BD73215F67454D85765860" xlink:type="arc" />
<link:label id="lab_immu_PercentOfSharesVestedEmploymentCommencement_82E9E17024F7DCC0470E454D8576F058_terseLabel_en-US" xlink:label="lab_immu_PercentOfSharesVestedEmploymentCommencement_82E9E17024F7DCC0470E454D8576F058" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Percent of shares vested upon employment commencement</link:label>
<link:label id="lab_immu_PercentOfSharesVestedEmploymentCommencement_82E9E17024F7DCC0470E454D8576F058_label_en-US" xlink:label="lab_immu_PercentOfSharesVestedEmploymentCommencement_82E9E17024F7DCC0470E454D8576F058" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Percent Of Shares Vested, Employment Commencement</link:label>
<link:label id="lab_immu_PercentOfSharesVestedEmploymentCommencement_82E9E17024F7DCC0470E454D8576F058_documentation_en-US" xlink:label="lab_immu_PercentOfSharesVestedEmploymentCommencement_82E9E17024F7DCC0470E454D8576F058" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Percent Of Shares Vested, Employment Commencement</link:label>
<link:loc xlink:href="immu-20191231.xsd#immu_PercentOfSharesVestedEmploymentCommencement" xlink:label="loc_immu_PercentOfSharesVestedEmploymentCommencement_82E9E17024F7DCC0470E454D8576F058" xlink:type="locator" />
<link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_immu_PercentOfSharesVestedEmploymentCommencement_82E9E17024F7DCC0470E454D8576F058" xlink:to="lab_immu_PercentOfSharesVestedEmploymentCommencement_82E9E17024F7DCC0470E454D8576F058" xlink:type="arc" />
<link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_4E6DDC8D7BB2E1A90B6D454D85777DEB_verboseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_4E6DDC8D7BB2E1A90B6D454D85777DEB" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Stock issued during period, net of forfeitures (in shares)</link:label>
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_4E6DDC8D7BB2E1A90B6D454D85777DEB" xlink:type="locator" />
<link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_4E6DDC8D7BB2E1A90B6D454D85777DEB" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_4E6DDC8D7BB2E1A90B6D454D85777DEB" xlink:type="arc" />
<link:label id="lab_immu_SalaryandWageOfficerMonthlySalary_F391BB5DBD3195381408454D8577BC52_terseLabel_en-US" xlink:label="lab_immu_SalaryandWageOfficerMonthlySalary_F391BB5DBD3195381408454D8577BC52" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Monthly salary</link:label>
<link:label id="lab_immu_SalaryandWageOfficerMonthlySalary_F391BB5DBD3195381408454D8577BC52_label_en-US" xlink:label="lab_immu_SalaryandWageOfficerMonthlySalary_F391BB5DBD3195381408454D8577BC52" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Salary and Wage, Officer, Monthly Salary</link:label>
<link:label id="lab_immu_SalaryandWageOfficerMonthlySalary_F391BB5DBD3195381408454D8577BC52_documentation_en-US" xlink:label="lab_immu_SalaryandWageOfficerMonthlySalary_F391BB5DBD3195381408454D8577BC52" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Salary and Wage, Officer, Monthly Salary</link:label>
<link:loc xlink:href="immu-20191231.xsd#immu_SalaryandWageOfficerMonthlySalary" xlink:label="loc_immu_SalaryandWageOfficerMonthlySalary_F391BB5DBD3195381408454D8577BC52" xlink:type="locator" />
<link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_immu_SalaryandWageOfficerMonthlySalary_F391BB5DBD3195381408454D8577BC52" xlink:to="lab_immu_SalaryandWageOfficerMonthlySalary_F391BB5DBD3195381408454D8577BC52" xlink:type="arc" />
<link:label id="lab_us-gaap_SalariesWagesAndOfficersCompensation_969D940F4822EEB5145D454D85775024_terseLabel_en-US" xlink:label="lab_us-gaap_SalariesWagesAndOfficersCompensation_969D940F4822EEB5145D454D85775024" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Salary and wage</link:label>
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SalariesWagesAndOfficersCompensation" xlink:label="loc_us-gaap_SalariesWagesAndOfficersCompensation_969D940F4822EEB5145D454D85775024" xlink:type="locator" />
<link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SalariesWagesAndOfficersCompensation_969D940F4822EEB5145D454D85775024" xlink:to="lab_us-gaap_SalariesWagesAndOfficersCompensation_969D940F4822EEB5145D454D85775024" xlink:type="arc" />
<link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_0F3A51A99079A240ECF0454D8577A3B6_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_0F3A51A99079A240ECF0454D8577A3B6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based payment award</link:label>
<link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_0F3A51A99079A240ECF0454D8577A3B6_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_0F3A51A99079A240ECF0454D8577A3B6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period</link:label>
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_0F3A51A99079A240ECF0454D8577A3B6" xlink:type="locator" />
<link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_0F3A51A99079A240ECF0454D8577A3B6" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_0F3A51A99079A240ECF0454D8577A3B6" xlink:type="arc" />
<link:label id="lab_immu_AllocationofFairValuetoLiabilityTableTextBlock_02C71681413280E547583991D270E19E_terseLabel_en-US" xlink:label="lab_immu_AllocationofFairValuetoLiabilityTableTextBlock_02C71681413280E547583991D270E19E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of allocation of fair value to liability</link:label>
<link:label id="lab_immu_AllocationofFairValuetoLiabilityTableTextBlock_02C71681413280E547583991D270E19E_label_en-US" xlink:label="lab_immu_AllocationofFairValuetoLiabilityTableTextBlock_02C71681413280E547583991D270E19E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Allocation of Fair Value to Liability [Table Text Block]</link:label>
<link:label id="lab_immu_AllocationofFairValuetoLiabilityTableTextBlock_02C71681413280E547583991D270E19E_documentation_en-US" xlink:label="lab_immu_AllocationofFairValuetoLiabilityTableTextBlock_02C71681413280E547583991D270E19E" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Allocation of Fair Value to Liability [Table Text Block]</link:label>
<link:loc xlink:href="immu-20191231.xsd#immu_AllocationofFairValuetoLiabilityTableTextBlock" xlink:label="loc_immu_AllocationofFairValuetoLiabilityTableTextBlock_02C71681413280E547583991D270E19E" xlink:type="locator" />
<link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_immu_AllocationofFairValuetoLiabilityTableTextBlock_02C71681413280E547583991D270E19E" xlink:to="lab_immu_AllocationofFairValuetoLiabilityTableTextBlock_02C71681413280E547583991D270E19E" xlink:type="arc" />
<link:label id="lab_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock_A8EA8E396197E3F62EA13991D2701036_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock_A8EA8E396197E3F62EA13991D2701036" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of deferred revenue, by arrangement</link:label>
<link:label id="lab_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock_A8EA8E396197E3F62EA13991D2701036_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock_A8EA8E396197E3F62EA13991D2701036" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contract with Customer, Asset and Liability [Table Text Block]</link:label>
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock" xlink:label="loc_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock_A8EA8E396197E3F62EA13991D2701036" xlink:type="locator" />
<link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock_A8EA8E396197E3F62EA13991D2701036" xlink:to="lab_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock_A8EA8E396197E3F62EA13991D2701036" xlink:type="arc" />
<link:label id="lab_us-gaap_ClassOfWarrantOrRightTable_5A50C1824C482DD38108850F47E3B754_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightTable_5A50C1824C482DD38108850F47E3B754" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right [Table]</link:label>
<link:label id="lab_us-gaap_ClassOfWarrantOrRightTable_5A50C1824C482DD38108850F47E3B754_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightTable_5A50C1824C482DD38108850F47E3B754" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right [Table]</link:label>
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfWarrantOrRightTable" xlink:label="loc_us-gaap_ClassOfWarrantOrRightTable_5A50C1824C482DD38108850F47E3B754" xlink:type="locator" />
<link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_5A50C1824C482DD38108850F47E3B754" xlink:to="lab_us-gaap_ClassOfWarrantOrRightTable_5A50C1824C482DD38108850F47E3B754" xlink:type="arc" />
<link:label id="lab_srt_WeightedAverageMember_F83CAA7750A045BD2246850F47E4511F_terseLabel_en-US" xlink:label="lab_srt_WeightedAverageMember_F83CAA7750A045BD2246850F47E4511F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted Average</link:label>
<link:label id="lab_srt_WeightedAverageMember_F83CAA7750A045BD2246850F47E4511F_label_en-US" xlink:label="lab_srt_WeightedAverageMember_F83CAA7750A045BD2246850F47E4511F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted Average [Member]</link:label>
<link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_WeightedAverageMember" xlink:label="loc_srt_WeightedAverageMember_F83CAA7750A045BD2246850F47E4511F" xlink:type="locator" />
<link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_WeightedAverageMember_F83CAA7750A045BD2246850F47E4511F" xlink:to="lab_srt_WeightedAverageMember_F83CAA7750A045BD2246850F47E4511F" xlink:type="arc" />
<link:label id="lab_us-gaap_FairValueByLiabilityClassAxis_24F069FDB21AD3A17EA2850F47E4792C_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByLiabilityClassAxis_24F069FDB21AD3A17EA2850F47E4792C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Liability Class [Axis]</link:label>
<link:label id="lab_us-gaap_FairValueByLiabilityClassAxis_24F069FDB21AD3A17EA2850F47E4792C_label_en-US" xlink:label="lab_us-gaap_FairValueByLiabilityClassAxis_24F069FDB21AD3A17EA2850F47E4792C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liability Class [Axis]</link:label>
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueByLiabilityClassAxis" xlink:label="loc_us-gaap_FairValueByLiabilityClassAxis_24F069FDB21AD3A17EA2850F47E4792C" xlink:type="locator" />
<link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByLiabilityClassAxis_24F069FDB21AD3A17EA2850F47E4792C" xlink:to="lab_us-gaap_FairValueByLiabilityClassAxis_24F069FDB21AD3A17EA2850F47E4792C" xlink:type="arc" />
<link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_93D0C374BB337497CBC4850F47E51B0E_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_93D0C374BB337497CBC4850F47E51B0E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value by Liability Class [Domain]</link:label>
<link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_93D0C374BB337497CBC4850F47E51B0E_label_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_93D0C374BB337497CBC4850F47E51B0E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value by Liability Class [Domain]</link:label>
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_93D0C374BB337497CBC4850F47E51B0E" xlink:type="locator" />
<link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_93D0C374BB337497CBC4850F47E51B0E" xlink:to="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_93D0C374BB337497CBC4850F47E51B0E" xlink:type="arc" />
<link:label id="lab_us-gaap_WarrantMember_33C4AFA262D511CBE402850F47E5C193_verboseLabel_en-US" xlink:label="lab_us-gaap_WarrantMember_33C4AFA262D511CBE402850F47E5C193" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Warrant</link:label>
<link:label id="lab_us-gaap_WarrantMember_33C4AFA262D511CBE402850F47E5C193_label_en-US" xlink:label="lab_us-gaap_WarrantMember_33C4AFA262D511CBE402850F47E5C193" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Warrant [Member]</link:label>
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaap_WarrantMember_33C4AFA262D511CBE402850F47E5C193" xlink:type="locator" />
<link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WarrantMember_33C4AFA262D511CBE402850F47E5C193" xlink:to="lab_us-gaap_WarrantMember_33C4AFA262D511CBE402850F47E5C193" xlink:type="arc" />
<link:label id="lab_us-gaap_OverAllotmentOptionMember_36AF5CD8640A31F20761850F47E6F069_terseLabel_en-US" xlink:label="lab_us-gaap_OverAllotmentOptionMember_36AF5CD8640A31F20761850F47E6F069" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Over-Allotment Option [Member]</link:label>
<link:label id="lab_us-gaap_OverAllotmentOptionMember_36AF5CD8640A31F20761850F47E6F069_label_en-US" xlink:label="lab_us-gaap_OverAllotmentOptionMember_36AF5CD8640A31F20761850F47E6F069" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Over-Allotment Option [Member]</link:label>
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OverAllotmentOptionMember" xlink:label="loc_us-gaap_OverAllotmentOptionMember_36AF5CD8640A31F20761850F47E6F069" xlink:type="locator" />
<link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OverAllotmentOptionMember_36AF5CD8640A31F20761850F47E6F069" xlink:to="lab_us-gaap_OverAllotmentOptionMember_36AF5CD8640A31F20761850F47E6F069" xlink:type="arc" />
<link:label id="lab_immu_ATMAgreementMember_F86213B8FBA8032424BE850F47E6D596_terseLabel_en-US" xlink:label="lab_immu_ATMAgreementMember_F86213B8FBA8032424BE850F47E6D596" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">ATM Agreement</link:label>
<link:label id="lab_immu_ATMAgreementMember_F86213B8FBA8032424BE850F47E6D596_label_en-US" xlink:label="lab_immu_ATMAgreementMember_F86213B8FBA8032424BE850F47E6D596" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">ATM Agreement [Member]</link:label>
<link:label id="lab_immu_ATMAgreementMember_F86213B8FBA8032424BE850F47E6D596_documentation_en-US" xlink:label="lab_immu_ATMAgreementMember_F86213B8FBA8032424BE850F47E6D596" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">ATM Agreement [Member]</link:label>
<link:loc xlink:href="immu-20191231.xsd#immu_ATMAgreementMember" xlink:label="loc_immu_ATMAgreementMember_F86213B8FBA8032424BE850F47E6D596" xlink:type="locator" />
<link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_immu_ATMAgreementMember_F86213B8FBA8032424BE850F47E6D596" xlink:to="lab_immu_ATMAgreementMember_F86213B8FBA8032424BE850F47E6D596" xlink:type="arc" />
<link:label id="lab_immu_SalesAgreementMember_42C26528926A0DEFF5C5850F47E6DD22_terseLabel_en-US" xlink:label="lab_immu_SalesAgreementMember_42C26528926A0DEFF5C5850F47E6DD22" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Sales Agreement</link:label>
<link:label id="lab_immu_SalesAgreementMember_42C26528926A0DEFF5C5850F47E6DD22_label_en-US" xlink:label="lab_immu_SalesAgreementMember_42C26528926A0DEFF5C5850F47E6DD22" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sales Agreement [Member]</link:label>
<link:label id="lab_immu_SalesAgreementMember_42C26528926A0DEFF5C5850F47E6DD22_documentation_en-US" xlink:label="lab_immu_SalesAgreementMember_42C26528926A0DEFF5C5850F47E6DD22" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Sales Agreement [Member]</link:label>
<link:loc xlink:href="immu-20191231.xsd#immu_SalesAgreementMember" xlink:label="loc_immu_SalesAgreementMember_42C26528926A0DEFF5C5850F47E6DD22" xlink:type="locator" />
<link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_immu_SalesAgreementMember_42C26528926A0DEFF5C5850F47E6DD22" xlink:to="lab_immu_SalesAgreementMember_42C26528926A0DEFF5C5850F47E6DD22" xlink:type="arc" />
<link:label id="lab_us-gaap_TypeOfArrangementAxis_409ECE1F14A283FF61E2850F47E7FF68_terseLabel_en-US" xlink:label="lab_us-gaap_TypeOfArrangementAxis_409ECE1F14A283FF61E2850F47E7FF68" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</link:label>
<link:label id="lab_us-gaap_TypeOfArrangementAxis_409ECE1F14A283FF61E2850F47E7FF68_label_en-US" xlink:label="lab_us-gaap_TypeOfArrangementAxis_409ECE1F14A283FF61E2850F47E7FF68" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</link:label>
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis_409ECE1F14A283FF61E2850F47E7FF68" xlink:type="locator" />
<link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TypeOfArrangementAxis_409ECE1F14A283FF61E2850F47E7FF68" xlink:to="lab_us-gaap_TypeOfArrangementAxis_409ECE1F14A283FF61E2850F47E7FF68" xlink:type="arc" />
<link:label id="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_838F02D6EE7005DB9632850F47E75B04_terseLabel_en-US" xlink:label="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_838F02D6EE7005DB9632850F47E75B04" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Domain]</link:label>
<link:label id="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_838F02D6EE7005DB9632850F47E75B04_label_en-US" xlink:label="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_838F02D6EE7005DB9632850F47E75B04" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Domain]</link:label>
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_838F02D6EE7005DB9632850F47E75B04" xlink:type="locator" />
<link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_838F02D6EE7005DB9632850F47E75B04" xlink:to="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_838F02D6EE7005DB9632850F47E75B04" xlink:type="arc" />
<link:label id="lab_immu_SecuritiesPurchaseAgreementMember_AF223CF58A6E21D1AFDB850F47E743BC_terseLabel_en-US" xlink:label="lab_immu_SecuritiesPurchaseAgreementMember_AF223CF58A6E21D1AFDB850F47E743BC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Securities Purchase Agreement</link:label>
<link:label id="lab_immu_SecuritiesPurchaseAgreementMember_AF223CF58A6E21D1AFDB850F47E743BC_label_en-US" xlink:label="lab_immu_SecuritiesPurchaseAgreementMember_AF223CF58A6E21D1AFDB850F47E743BC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Securities Purchase Agreement [Member]</link:label>
<link:label id="lab_immu_SecuritiesPurchaseAgreementMember_AF223CF58A6E21D1AFDB850F47E743BC_documentation_en-US" xlink:label="lab_immu_SecuritiesPurchaseAgreementMember_AF223CF58A6E21D1AFDB850F47E743BC" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents information pertaining to purchase agreement.</link:label>
<link:loc xlink:href="immu-20191231.xsd#immu_SecuritiesPurchaseAgreementMember" xlink:label="loc_immu_SecuritiesPurchaseAgreementMember_AF223CF58A6E21D1AFDB850F47E743BC" xlink:type="locator" />
<link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_immu_SecuritiesPurchaseAgreementMember_AF223CF58A6E21D1AFDB850F47E743BC" xlink:to="lab_immu_SecuritiesPurchaseAgreementMember_AF223CF58A6E21D1AFDB850F47E743BC" xlink:type="arc" />
<link:label id="lab_us-gaap_ClassOfWarrantOrRightLineItems_41B54B431001DB193B43850F47E921A5_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightLineItems_41B54B431001DB193B43850F47E921A5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right [Line Items]</link:label>
<link:label id="lab_us-gaap_ClassOfWarrantOrRightLineItems_41B54B431001DB193B43850F47E921A5_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightLineItems_41B54B431001DB193B43850F47E921A5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right [Line Items]</link:label>
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfWarrantOrRightLineItems" xlink:label="loc_us-gaap_ClassOfWarrantOrRightLineItems_41B54B431001DB193B43850F47E921A5" xlink:type="locator" />
<link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_41B54B431001DB193B43850F47E921A5" xlink:to="lab_us-gaap_ClassOfWarrantOrRightLineItems_41B54B431001DB193B43850F47E921A5" xlink:type="arc" />
<link:label id="lab_immu_CommonAndPreferredSharesAuthorized_6AEE6862DE86A533B9E1850F47E9E292_terseLabel_en-US" xlink:label="lab_immu_CommonAndPreferredSharesAuthorized_6AEE6862DE86A533B9E1850F47E9E292" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common and preferred shares authorized (in shares)</link:label>
<link:label id="lab_immu_CommonAndPreferredSharesAuthorized_6AEE6862DE86A533B9E1850F47E9E292_label_en-US" xlink:label="lab_immu_CommonAndPreferredSharesAuthorized_6AEE6862DE86A533B9E1850F47E9E292" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common And Preferred Shares Authorized</link:label>
<link:label id="lab_immu_CommonAndPreferredSharesAuthorized_6AEE6862DE86A533B9E1850F47E9E292_documentation_en-US" xlink:label="lab_immu_CommonAndPreferredSharesAuthorized_6AEE6862DE86A533B9E1850F47E9E292" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Common and preferred shares authorized.</link:label>
<link:loc xlink:href="immu-20191231.xsd#immu_CommonAndPreferredSharesAuthorized" xlink:label="loc_immu_CommonAndPreferredSharesAuthorized_6AEE6862DE86A533B9E1850F47E9E292" xlink:type="locator" />
<link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_immu_CommonAndPreferredSharesAuthorized_6AEE6862DE86A533B9E1850F47E9E292" xlink:to="lab_immu_CommonAndPreferredSharesAuthorized_6AEE6862DE86A533B9E1850F47E9E292" xlink:type="arc" />
<link:label id="lab_immu_IssuanceofConvertiblePreferredStockPerShare_35BB2233F02AD1DD1A9A850F47EA6C11_terseLabel_en-US" xlink:label="lab_immu_IssuanceofConvertiblePreferredStockPerShare_35BB2233F02AD1DD1A9A850F47EA6C11" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Issuance of convertible preferred stock (in USD per share)</link:label>
<link:label id="lab_immu_IssuanceofConvertiblePreferredStockPerShare_35BB2233F02AD1DD1A9A850F47EA6C11_label_en-US" xlink:label="lab_immu_IssuanceofConvertiblePreferredStockPerShare_35BB2233F02AD1DD1A9A850F47EA6C11" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Issuance of Convertible Preferred Stock, Per Share</link:label>
<link:label id="lab_immu_IssuanceofConvertiblePreferredStockPerShare_35BB2233F02AD1DD1A9A850F47EA6C11_documentation_en-US" xlink:label="lab_immu_IssuanceofConvertiblePreferredStockPerShare_35BB2233F02AD1DD1A9A850F47EA6C11" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Issuance of Convertible Preferred Stock, Per Share</link:label>
<link:loc xlink:href="immu-20191231.xsd#immu_IssuanceofConvertiblePreferredStockPerShare" xlink:label="loc_immu_IssuanceofConvertiblePreferredStockPerShare_35BB2233F02AD1DD1A9A850F47EA6C11" xlink:type="locator" />
<link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_immu_IssuanceofConvertiblePreferredStockPerShare_35BB2233F02AD1DD1A9A850F47EA6C11" xlink:to="lab_immu_IssuanceofConvertiblePreferredStockPerShare_35BB2233F02AD1DD1A9A850F47EA6C11" xlink:type="arc" />
<link:label id="lab_us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock_78DEBE2E2AE2ADC57FBA850F47EAC9CF_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock_78DEBE2E2AE2ADC57FBA850F47EAC9CF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from issuance of convertible preferred stock</link:label>
<link:label id="lab_us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock_78DEBE2E2AE2ADC57FBA850F47EAC9CF_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock_78DEBE2E2AE2ADC57FBA850F47EAC9CF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Issuance of Convertible Preferred Stock</link:label>
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock_78DEBE2E2AE2ADC57FBA850F47EAC9CF" xlink:type="locator" />
<link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock_78DEBE2E2AE2ADC57FBA850F47EAC9CF" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock_78DEBE2E2AE2ADC57FBA850F47EAC9CF" xlink:type="arc" />
<link:label id="lab_immu_ConvertiblePreferredStockConversionRatio_01A184EF89FCDA9C01FC850F47EAEAE6_verboseLabel_en-US" xlink:label="lab_immu_ConvertiblePreferredStockConversionRatio_01A184EF89FCDA9C01FC850F47EAEAE6" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Convertible preferred stock, shares issued upon conversion (in shares)</link:label>
<link:label id="lab_immu_ConvertiblePreferredStockConversionRatio_01A184EF89FCDA9C01FC850F47EAEAE6_label_en-US" xlink:label="lab_immu_ConvertiblePreferredStockConversionRatio_01A184EF89FCDA9C01FC850F47EAEAE6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Convertible Preferred Stock, Conversion Ratio</link:label>
<link:label id="lab_immu_ConvertiblePreferredStockConversionRatio_01A184EF89FCDA9C01FC850F47EAEAE6_documentation_en-US" xlink:label="lab_immu_ConvertiblePreferredStockConversionRatio_01A184EF89FCDA9C01FC850F47EAEAE6" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Convertible Preferred Stock, Conversion Ratio</link:label>
<link:loc xlink:href="immu-20191231.xsd#immu_ConvertiblePreferredStockConversionRatio" xlink:label="loc_immu_ConvertiblePreferredStockConversionRatio_01A184EF89FCDA9C01FC850F47EAEAE6" xlink:type="locator" />
<link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_immu_ConvertiblePreferredStockConversionRatio_01A184EF89FCDA9C01FC850F47EAEAE6" xlink:to="lab_immu_ConvertiblePreferredStockConversionRatio_01A184EF89FCDA9C01FC850F47EAEAE6" xlink:type="arc" />
<link:label id="lab_us-gaap_ConversionOfStockSharesIssued1_2CCF6829D25EC1EE1D8D850F47EB1F7A_terseLabel_en-US" xlink:label="lab_us-gaap_ConversionOfStockSharesIssued1_2CCF6829D25EC1EE1D8D850F47EB1F7A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Conversion of shares (in shares)</link:label>
<link:label id="lab_us-gaap_ConversionOfStockSharesIssued1_2CCF6829D25EC1EE1D8D850F47EB1F7A_label_en-US" xlink:label="lab_us-gaap_ConversionOfStockSharesIssued1_2CCF6829D25EC1EE1D8D850F47EB1F7A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Conversion of Stock, Shares Issued</link:label>
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConversionOfStockSharesIssued1" xlink:label="loc_us-gaap_ConversionOfStockSharesIssued1_2CCF6829D25EC1EE1D8D850F47EB1F7A" xlink:type="locator" />
<link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConversionOfStockSharesIssued1_2CCF6829D25EC1EE1D8D850F47EB1F7A" xlink:to="lab_us-gaap_ConversionOfStockSharesIssued1_2CCF6829D25EC1EE1D8D850F47EB1F7A" xlink:type="arc" />
<link:label id="lab_immu_GrossProceedsFromIssuanceOfCommonStock_90AED044F33BF1D4471D850F47EB1F30_terseLabel_en-US" xlink:label="lab_immu_GrossProceedsFromIssuanceOfCommonStock_90AED044F33BF1D4471D850F47EB1F30" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Gross proceeds from sale of common stock</link:label>
<link:label id="lab_immu_GrossProceedsFromIssuanceOfCommonStock_90AED044F33BF1D4471D850F47EB1F30_label_en-US" xlink:label="lab_immu_GrossProceedsFromIssuanceOfCommonStock_90AED044F33BF1D4471D850F47EB1F30" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Gross Proceeds From Issuance Of Common Stock</link:label>
<link:label id="lab_immu_GrossProceedsFromIssuanceOfCommonStock_90AED044F33BF1D4471D850F47EB1F30_documentation_en-US" xlink:label="lab_immu_GrossProceedsFromIssuanceOfCommonStock_90AED044F33BF1D4471D850F47EB1F30" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents gross proceeds from issuance of common stock before deducting underwriting discounts and commissions and estimated expense.</link:label>
<link:loc xlink:href="immu-20191231.xsd#immu_GrossProceedsFromIssuanceOfCommonStock" xlink:label="loc_immu_GrossProceedsFromIssuanceOfCommonStock_90AED044F33BF1D4471D850F47EB1F30" xlink:type="locator" />
<link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_immu_GrossProceedsFromIssuanceOfCommonStock_90AED044F33BF1D4471D850F47EB1F30" xlink:to="lab_immu_GrossProceedsFromIssuanceOfCommonStock_90AED044F33BF1D4471D850F47EB1F30" xlink:type="arc" />
<link:label id="lab_us-gaap_DebtInstrumentTerm_A61474B9EB28143748BD850F47EC7EF6_verboseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentTerm_A61474B9EB28143748BD850F47EC7EF6" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Warrants term</link:label>
<link:label id="lab_us-gaap_DebtInstrumentTerm_A61474B9EB28143748BD850F47EC7EF6_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentTerm_A61474B9EB28143748BD850F47EC7EF6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Term</link:label>
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentTerm" xlink:label="loc_us-gaap_DebtInstrumentTerm_A61474B9EB28143748BD850F47EC7EF6" xlink:type="locator" />
<link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentTerm_A61474B9EB28143748BD850F47EC7EF6" xlink:to="lab_us-gaap_DebtInstrumentTerm_A61474B9EB28143748BD850F47EC7EF6" xlink:type="arc" />
<link:label id="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_91DAEE9A6F7BF5DD4E41850F47ECD966_verboseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_91DAEE9A6F7BF5DD4E41850F47ECD966" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Shares that warrants can purchase (in shares)</link:label>
<link:label id="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_91DAEE9A6F7BF5DD4E41850F47ECD966_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_91DAEE9A6F7BF5DD4E41850F47ECD966" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right, Number of Securities Called by Warrants or Rights</link:label>
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_91DAEE9A6F7BF5DD4E41850F47ECD966" xlink:type="locator" />
<link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_91DAEE9A6F7BF5DD4E41850F47ECD966" xlink:to="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_91DAEE9A6F7BF5DD4E41850F47ECD966" xlink:type="arc" />
<link:label id="lab_immu_ClassOfWarrantOrRightFairValue_C54AF79D6DBE361D4E69850F47EC092E_terseLabel_en-US" xlink:label="lab_immu_ClassOfWarrantOrRightFairValue_C54AF79D6DBE361D4E69850F47EC092E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair value of warrants</link:label>
<link:label id="lab_immu_ClassOfWarrantOrRightFairValue_C54AF79D6DBE361D4E69850F47EC092E_label_en-US" xlink:label="lab_immu_ClassOfWarrantOrRightFairValue_C54AF79D6DBE361D4E69850F47EC092E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right, Fair Value</link:label>
<link:label id="lab_immu_ClassOfWarrantOrRightFairValue_C54AF79D6DBE361D4E69850F47EC092E_documentation_en-US" xlink:label="lab_immu_ClassOfWarrantOrRightFairValue_C54AF79D6DBE361D4E69850F47EC092E" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Fair value of warrants during the reporting period.</link:label>
<link:loc xlink:href="immu-20191231.xsd#immu_ClassOfWarrantOrRightFairValue" xlink:label="loc_immu_ClassOfWarrantOrRightFairValue_C54AF79D6DBE361D4E69850F47EC092E" xlink:type="locator" />
<link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_immu_ClassOfWarrantOrRightFairValue_C54AF79D6DBE361D4E69850F47EC092E" xlink:to="lab_immu_ClassOfWarrantOrRightFairValue_C54AF79D6DBE361D4E69850F47EC092E" xlink:type="arc" />
<link:label id="lab_immu_ExerciseOfWarrants_CE9B4B113ACA7946DB04850F47ECBA61_terseLabel_en-US" xlink:label="lab_immu_ExerciseOfWarrants_CE9B4B113ACA7946DB04850F47ECBA61" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Exercise of warrants (in shares)</link:label>
<link:label id="lab_immu_ExerciseOfWarrants_CE9B4B113ACA7946DB04850F47ECBA61_label_en-US" xlink:label="lab_immu_ExerciseOfWarrants_CE9B4B113ACA7946DB04850F47ECBA61" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Exercise of Warrants</link:label>
<link:label id="lab_immu_ExerciseOfWarrants_CE9B4B113ACA7946DB04850F47ECBA61_documentation_en-US" xlink:label="lab_immu_ExerciseOfWarrants_CE9B4B113ACA7946DB04850F47ECBA61" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Number of warrants exercised.</link:label>
<link:loc xlink:href="immu-20191231.xsd#immu_ExerciseOfWarrants" xlink:label="loc_immu_ExerciseOfWarrants_CE9B4B113ACA7946DB04850F47ECBA61" xlink:type="locator" />
<link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_immu_ExerciseOfWarrants_CE9B4B113ACA7946DB04850F47ECBA61" xlink:to="lab_immu_ExerciseOfWarrants_CE9B4B113ACA7946DB04850F47ECBA61" xlink:type="arc" />
<link:label id="lab_immu_AggregateOfferingPriceofCommonStock_DC155101CFD294A2A126850F47EC451F_terseLabel_en-US" xlink:label="lab_immu_AggregateOfferingPriceofCommonStock_DC155101CFD294A2A126850F47EC451F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Aggregate purchase price of common stock</link:label>
<link:label id="lab_immu_AggregateOfferingPriceofCommonStock_DC155101CFD294A2A126850F47EC451F_label_en-US" xlink:label="lab_immu_AggregateOfferingPriceofCommonStock_DC155101CFD294A2A126850F47EC451F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Aggregate Offering Price of Common Stock</link:label>
<link:label id="lab_immu_AggregateOfferingPriceofCommonStock_DC155101CFD294A2A126850F47EC451F_documentation_en-US" xlink:label="lab_immu_AggregateOfferingPriceofCommonStock_DC155101CFD294A2A126850F47EC451F" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The amount of aggregate offering price of common stock.</link:label>
<link:loc xlink:href="immu-20191231.xsd#immu_AggregateOfferingPriceofCommonStock" xlink:label="loc_immu_AggregateOfferingPriceofCommonStock_DC155101CFD294A2A126850F47EC451F" xlink:type="locator" />
<link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_immu_AggregateOfferingPriceofCommonStock_DC155101CFD294A2A126850F47EC451F" xlink:to="lab_immu_AggregateOfferingPriceofCommonStock_DC155101CFD294A2A126850F47EC451F" xlink:type="arc" />
<link:label id="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_4CD5E532202817ED8B59850F47EC6514_verboseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_4CD5E532202817ED8B59850F47EC6514" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Net proceeds from sale of common stock</link:label>
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_4CD5E532202817ED8B59850F47EC6514" xlink:type="locator" />
<link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_4CD5E532202817ED8B59850F47EC6514" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_4CD5E532202817ED8B59850F47EC6514" xlink:type="arc" />
<link:label id="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_EA6065A0DD062D619B48850F47EDE783_verboseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_EA6065A0DD062D619B48850F47EDE783" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Exercise price of warrant (in USD per share)</link:label>
<link:label id="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_EA6065A0DD062D619B48850F47EDE783_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_EA6065A0DD062D619B48850F47EDE783" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right, Exercise Price of Warrants or Rights</link:label>
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_EA6065A0DD062D619B48850F47EDE783" xlink:type="locator" />
<link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_EA6065A0DD062D619B48850F47EDE783" xlink:to="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_EA6065A0DD062D619B48850F47EDE783" xlink:type="arc" />
<link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_30A04D579EC847712FAF850F47ED669E_verboseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_30A04D579EC847712FAF850F47ED669E" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Warrants exercised (in shares)</link:label>
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_30A04D579EC847712FAF850F47ED669E" xlink:type="locator" />
<link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_30A04D579EC847712FAF850F47ED669E" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_30A04D579EC847712FAF850F47ED669E" xlink:type="arc" />
<link:label id="lab_immu_IncreaseDecreaseinFairValueOfWarrantsExercised_B2503160710146E5BC59850F47ED07EC_terseLabel_en-US" xlink:label="lab_immu_IncreaseDecreaseinFairValueOfWarrantsExercised_B2503160710146E5BC59850F47ED07EC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Increase in fair value of warrants exercised</link:label>
<link:label id="lab_immu_IncreaseDecreaseinFairValueOfWarrantsExercised_B2503160710146E5BC59850F47ED07EC_label_en-US" xlink:label="lab_immu_IncreaseDecreaseinFairValueOfWarrantsExercised_B2503160710146E5BC59850F47ED07EC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Fair Value Of Warrants Exercised</link:label>
<link:label id="lab_immu_IncreaseDecreaseinFairValueOfWarrantsExercised_B2503160710146E5BC59850F47ED07EC_documentation_en-US" xlink:label="lab_immu_IncreaseDecreaseinFairValueOfWarrantsExercised_B2503160710146E5BC59850F47ED07EC" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Fair Value Of Warrants Exercised</link:label>
<link:loc xlink:href="immu-20191231.xsd#immu_IncreaseDecreaseinFairValueOfWarrantsExercised" xlink:label="loc_immu_IncreaseDecreaseinFairValueOfWarrantsExercised_B2503160710146E5BC59850F47ED07EC" xlink:type="locator" />
<link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_immu_IncreaseDecreaseinFairValueOfWarrantsExercised_B2503160710146E5BC59850F47ED07EC" xlink:to="lab_immu_IncreaseDecreaseinFairValueOfWarrantsExercised_B2503160710146E5BC59850F47ED07EC" xlink:type="arc" />
<link:label id="lab_us-gaap_ClassOfWarrantOrRightOutstanding_60BB1972C4CF5556F1B1850F47EDDD06_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightOutstanding_60BB1972C4CF5556F1B1850F47EDDD06" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Warrants outstanding (in shares)</link:label>
<link:label id="lab_us-gaap_ClassOfWarrantOrRightOutstanding_60BB1972C4CF5556F1B1850F47EDDD06_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightOutstanding_60BB1972C4CF5556F1B1850F47EDDD06" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right, Outstanding</link:label>
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="loc_us-gaap_ClassOfWarrantOrRightOutstanding_60BB1972C4CF5556F1B1850F47EDDD06" xlink:type="locator" />
<link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightOutstanding_60BB1972C4CF5556F1B1850F47EDDD06" xlink:to="lab_us-gaap_ClassOfWarrantOrRightOutstanding_60BB1972C4CF5556F1B1850F47EDDD06" xlink:type="arc" />
<link:label id="lab_immu_PaymentsforStockIssuanceCostsPercentage_BF07775D46C76641E8D3850F47EE3625_verboseLabel_en-US" xlink:label="lab_immu_PaymentsforStockIssuanceCostsPercentage_BF07775D46C76641E8D3850F47EE3625" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Payments for stock issuance costs percentage (as percent)</link:label>
<link:label id="lab_immu_PaymentsforStockIssuanceCostsPercentage_BF07775D46C76641E8D3850F47EE3625_label_en-US" xlink:label="lab_immu_PaymentsforStockIssuanceCostsPercentage_BF07775D46C76641E8D3850F47EE3625" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments for Stock Issuance Costs Percentage</link:label>
<link:label id="lab_immu_PaymentsforStockIssuanceCostsPercentage_BF07775D46C76641E8D3850F47EE3625_documentation_en-US" xlink:label="lab_immu_PaymentsforStockIssuanceCostsPercentage_BF07775D46C76641E8D3850F47EE3625" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Payments for Stock Issuance Costs Percentage</link:label>
<link:loc xlink:href="immu-20191231.xsd#immu_PaymentsforStockIssuanceCostsPercentage" xlink:label="loc_immu_PaymentsforStockIssuanceCostsPercentage_BF07775D46C76641E8D3850F47EE3625" xlink:type="locator" />
<link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_immu_PaymentsforStockIssuanceCostsPercentage_BF07775D46C76641E8D3850F47EE3625" xlink:to="lab_immu_PaymentsforStockIssuanceCostsPercentage_BF07775D46C76641E8D3850F47EE3625" xlink:type="arc" />
<link:label id="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_81D8410D64B54D860620850F47EEC435_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_81D8410D64B54D860620850F47EEC435" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of shares issued in transaction (in shares)</link:label>
<link:label id="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_81D8410D64B54D860620850F47EEC435_label_en-US" xlink:label="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_81D8410D64B54D860620850F47EEC435" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sale of Stock, Number of Shares Issued in Transaction</link:label>
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_81D8410D64B54D860620850F47EEC435" xlink:type="locator" />
<link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_81D8410D64B54D860620850F47EEC435" xlink:to="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_81D8410D64B54D860620850F47EEC435" xlink:type="arc" />
<link:label id="lab_immu_ProceedsfromIssuanceInitialPublicOfferingGross_41A0652CC90FECF9C94C850F47EE0055_terseLabel_en-US" xlink:label="lab_immu_ProceedsfromIssuanceInitialPublicOfferingGross_41A0652CC90FECF9C94C850F47EE0055" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from initial public offering, gross</link:label>
<link:label id="lab_immu_ProceedsfromIssuanceInitialPublicOfferingGross_41A0652CC90FECF9C94C850F47EE0055_label_en-US" xlink:label="lab_immu_ProceedsfromIssuanceInitialPublicOfferingGross_41A0652CC90FECF9C94C850F47EE0055" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Issuance Initial Public Offering, Gross</link:label>
<link:label id="lab_immu_ProceedsfromIssuanceInitialPublicOfferingGross_41A0652CC90FECF9C94C850F47EE0055_documentation_en-US" xlink:label="lab_immu_ProceedsfromIssuanceInitialPublicOfferingGross_41A0652CC90FECF9C94C850F47EE0055" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Proceeds from Issuance Initial Public Offering, Gross</link:label>
<link:loc xlink:href="immu-20191231.xsd#immu_ProceedsfromIssuanceInitialPublicOfferingGross" xlink:label="loc_immu_ProceedsfromIssuanceInitialPublicOfferingGross_41A0652CC90FECF9C94C850F47EE0055" xlink:type="locator" />
<link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_immu_ProceedsfromIssuanceInitialPublicOfferingGross_41A0652CC90FECF9C94C850F47EE0055" xlink:to="lab_immu_ProceedsfromIssuanceInitialPublicOfferingGross_41A0652CC90FECF9C94C850F47EE0055" xlink:type="arc" />
<link:label id="lab_us-gaap_PaymentsOfStockIssuanceCosts_F9F32C6E033BDC7C221A850F47EE93BB_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentsOfStockIssuanceCosts_F9F32C6E033BDC7C221A850F47EE93BB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Payments for stock issuance costs</link:label>
<link:label id="lab_us-gaap_PaymentsOfStockIssuanceCosts_F9F32C6E033BDC7C221A850F47EE93BB_label_en-US" xlink:label="lab_us-gaap_PaymentsOfStockIssuanceCosts_F9F32C6E033BDC7C221A850F47EE93BB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments of Stock Issuance Costs</link:label>
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="loc_us-gaap_PaymentsOfStockIssuanceCosts_F9F32C6E033BDC7C221A850F47EE93BB" xlink:type="locator" />
<link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsOfStockIssuanceCosts_F9F32C6E033BDC7C221A850F47EE93BB" xlink:to="lab_us-gaap_PaymentsOfStockIssuanceCosts_F9F32C6E033BDC7C221A850F47EE93BB" xlink:type="arc" />
<link:label id="lab_us-gaap_SaleOfStockPricePerShare_85E2B55364A04D8CC420850F47EEB8CD_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockPricePerShare_85E2B55364A04D8CC420850F47EEB8CD" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Sale of stock (in USD per share)</link:label>
<link:label id="lab_us-gaap_SaleOfStockPricePerShare_85E2B55364A04D8CC420850F47EEB8CD_label_en-US" xlink:label="lab_us-gaap_SaleOfStockPricePerShare_85E2B55364A04D8CC420850F47EEB8CD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sale of Stock, Price Per Share</link:label>
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="loc_us-gaap_SaleOfStockPricePerShare_85E2B55364A04D8CC420850F47EEB8CD" xlink:type="locator" />
<link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockPricePerShare_85E2B55364A04D8CC420850F47EEB8CD" xlink:to="lab_us-gaap_SaleOfStockPricePerShare_85E2B55364A04D8CC420850F47EEB8CD" xlink:type="arc" />
<link:label id="lab_us-gaap_SaleOfStockConsiderationReceivedPerTransaction_E0D0B4C26ECEE2C9F288850F47EFBC29_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockConsiderationReceivedPerTransaction_E0D0B4C26ECEE2C9F288850F47EFBC29" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Consideration received per transaction</link:label>
<link:label id="lab_us-gaap_SaleOfStockConsiderationReceivedPerTransaction_E0D0B4C26ECEE2C9F288850F47EFBC29_label_en-US" xlink:label="lab_us-gaap_SaleOfStockConsiderationReceivedPerTransaction_E0D0B4C26ECEE2C9F288850F47EFBC29" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sale of Stock, Consideration Received Per Transaction</link:label>
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SaleOfStockConsiderationReceivedPerTransaction" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedPerTransaction_E0D0B4C26ECEE2C9F288850F47EFBC29" xlink:type="locator" />
<link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockConsiderationReceivedPerTransaction_E0D0B4C26ECEE2C9F288850F47EFBC29" xlink:to="lab_us-gaap_SaleOfStockConsiderationReceivedPerTransaction_E0D0B4C26ECEE2C9F288850F47EFBC29" xlink:type="arc" />
<link:label id="lab_us-gaap_SharesIssuedPricePerShare_C6D23EC728ECAF6F6D62850F47EFA06C_terseLabel_en-US" xlink:label="lab_us-gaap_SharesIssuedPricePerShare_C6D23EC728ECAF6F6D62850F47EFA06C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Shares issued, price (USD per share)</link:label>
<link:label id="lab_us-gaap_SharesIssuedPricePerShare_C6D23EC728ECAF6F6D62850F47EFA06C_label_en-US" xlink:label="lab_us-gaap_SharesIssuedPricePerShare_C6D23EC728ECAF6F6D62850F47EFA06C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Shares Issued, Price Per Share</link:label>
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="loc_us-gaap_SharesIssuedPricePerShare_C6D23EC728ECAF6F6D62850F47EFA06C" xlink:type="locator" />
<link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharesIssuedPricePerShare_C6D23EC728ECAF6F6D62850F47EFA06C" xlink:to="lab_us-gaap_SharesIssuedPricePerShare_C6D23EC728ECAF6F6D62850F47EFA06C" xlink:type="arc" />
<link:label id="lab_us-gaap_TreasuryStockSharesAcquired_F7363FF27DF4F82D1479850F47EF3FE0_terseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockSharesAcquired_F7363FF27DF4F82D1479850F47EF3FE0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Treasury stock, acquired (in shares)</link:label>
<link:label id="lab_us-gaap_TreasuryStockSharesAcquired_F7363FF27DF4F82D1479850F47EF3FE0_label_en-US" xlink:label="lab_us-gaap_TreasuryStockSharesAcquired_F7363FF27DF4F82D1479850F47EF3FE0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Treasury Stock, Shares, Acquired</link:label>
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TreasuryStockSharesAcquired" xlink:label="loc_us-gaap_TreasuryStockSharesAcquired_F7363FF27DF4F82D1479850F47EF3FE0" xlink:type="locator" />
<link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockSharesAcquired_F7363FF27DF4F82D1479850F47EF3FE0" xlink:to="lab_us-gaap_TreasuryStockSharesAcquired_F7363FF27DF4F82D1479850F47EF3FE0" xlink:type="arc" />
<link:label id="lab_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares_9030732EFE2942362108850F47EFB2DF_terseLabel_en-US" xlink:label="lab_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares_9030732EFE2942362108850F47EFB2DF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Retired treasury stock (in shares)</link:label>
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockRepurchasedAndRetiredDuringPeriodShares" xlink:label="loc_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares_9030732EFE2942362108850F47EFB2DF" xlink:type="locator" />
<link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares_9030732EFE2942362108850F47EFB2DF" xlink:to="lab_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares_9030732EFE2942362108850F47EFB2DF" xlink:type="arc" />
<link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_893F440C627BD9A54F9D3991D249836E_terseLabel_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense_893F440C627BD9A54F9D3991D249836E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock compensation expense</link:label>
<link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_893F440C627BD9A54F9D3991D249836E_label_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense_893F440C627BD9A54F9D3991D249836E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Payment Arrangement, Expense</link:label>
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_893F440C627BD9A54F9D3991D249836E" xlink:type="locator" />
<link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllocatedShareBasedCompensationExpense_893F440C627BD9A54F9D3991D249836E" xlink:to="lab_us-gaap_AllocatedShareBasedCompensationExpense_893F440C627BD9A54F9D3991D249836E" xlink:type="arc" />
<link:label id="lab_immu_AllocatedSharebasedCompensationExpenseAmountReversed_3CF2C1FDEBA0F90A6B473991D2496AF7_terseLabel_en-US" xlink:label="lab_immu_AllocatedSharebasedCompensationExpenseAmountReversed_3CF2C1FDEBA0F90A6B473991D2496AF7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Reversed stock based compensation expense</link:label>
<link:label id="lab_immu_AllocatedSharebasedCompensationExpenseAmountReversed_3CF2C1FDEBA0F90A6B473991D2496AF7_label_en-US" xlink:label="lab_immu_AllocatedSharebasedCompensationExpenseAmountReversed_3CF2C1FDEBA0F90A6B473991D2496AF7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Allocated Share-based Compensation Expense, Amount Reversed</link:label>
<link:label id="lab_immu_AllocatedSharebasedCompensationExpenseAmountReversed_3CF2C1FDEBA0F90A6B473991D2496AF7_documentation_en-US" xlink:label="lab_immu_AllocatedSharebasedCompensationExpenseAmountReversed_3CF2C1FDEBA0F90A6B473991D2496AF7" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Allocated Share-based Compensation Expense, Amount Reversed</link:label>
<link:loc xlink:href="immu-20191231.xsd#immu_AllocatedSharebasedCompensationExpenseAmountReversed" xlink:label="loc_immu_AllocatedSharebasedCompensationExpenseAmountReversed_3CF2C1FDEBA0F90A6B473991D2496AF7" xlink:type="locator" />
<link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_immu_AllocatedSharebasedCompensationExpenseAmountReversed_3CF2C1FDEBA0F90A6B473991D2496AF7" xlink:to="lab_immu_AllocatedSharebasedCompensationExpenseAmountReversed_3CF2C1FDEBA0F90A6B473991D2496AF7" xlink:type="arc" />
<link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_279D7B0754A69AD98639D1D062D1493E_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock_279D7B0754A69AD98639D1D062D1493E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Taxes</link:label>
<link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_279D7B0754A69AD98639D1D062D1493E_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock_279D7B0754A69AD98639D1D062D1493E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Disclosure [Text Block]</link:label>
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock_279D7B0754A69AD98639D1D062D1493E" xlink:type="locator" />
<link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureTextBlock_279D7B0754A69AD98639D1D062D1493E" xlink:to="lab_us-gaap_IncomeTaxDisclosureTextBlock_279D7B0754A69AD98639D1D062D1493E" xlink:type="arc" />
<link:label id="lab_us-gaap_IncomeStatementAbstract_90F00AFAEF34FF8F63353991D2ED2C6C_label_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract_90F00AFAEF34FF8F63353991D2ED2C6C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Statement [Abstract]</link:label>
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:label="loc_us-gaap_IncomeStatementAbstract_90F00AFAEF34FF8F63353991D2ED2C6C" xlink:type="locator" />
<link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementAbstract_90F00AFAEF34FF8F63353991D2ED2C6C" xlink:to="lab_us-gaap_IncomeStatementAbstract_90F00AFAEF34FF8F63353991D2ED2C6C" xlink:type="arc" />
<link:label id="lab_srt_ProductOrServiceAxis_22CF8D6FA4D195CFB0A23991D2EDA726_terseLabel_en-US" xlink:label="lab_srt_ProductOrServiceAxis_22CF8D6FA4D195CFB0A23991D2EDA726" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Product and Service [Axis]</link:label>
<link:label id="lab_srt_ProductOrServiceAxis_22CF8D6FA4D195CFB0A23991D2EDA726_label_en-US" xlink:label="lab_srt_ProductOrServiceAxis_22CF8D6FA4D195CFB0A23991D2EDA726" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Product and Service [Axis]</link:label>
<link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="loc_srt_ProductOrServiceAxis_22CF8D6FA4D195CFB0A23991D2EDA726" xlink:type="locator" />
<link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductOrServiceAxis_22CF8D6FA4D195CFB0A23991D2EDA726" xlink:to="lab_srt_ProductOrServiceAxis_22CF8D6FA4D195CFB0A23991D2EDA726" xlink:type="arc" />
<link:label id="lab_srt_ProductsAndServicesDomain_49B4A8F93F2BE7F95EC83991D2EE4186_terseLabel_en-US" xlink:label="lab_srt_ProductsAndServicesDomain_49B4A8F93F2BE7F95EC83991D2EE4186" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Product and Service [Domain]</link:label>
<link:label id="lab_srt_ProductsAndServicesDomain_49B4A8F93F2BE7F95EC83991D2EE4186_label_en-US" xlink:label="lab_srt_ProductsAndServicesDomain_49B4A8F93F2BE7F95EC83991D2EE4186" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Product and Service [Domain]</link:label>
<link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain_49B4A8F93F2BE7F95EC83991D2EE4186" xlink:type="locator" />
<link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductsAndServicesDomain_49B4A8F93F2BE7F95EC83991D2EE4186" xlink:to="lab_srt_ProductsAndServicesDomain_49B4A8F93F2BE7F95EC83991D2EE4186" xlink:type="arc" />
<link:label id="lab_immu_ProductSalesMember_45A60C0F21551244EA603991D2EE2686_terseLabel_en-US" xlink:label="lab_immu_ProductSalesMember_45A60C0F21551244EA603991D2EE2686" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Product sales</link:label>
<link:label id="lab_immu_ProductSalesMember_45A60C0F21551244EA603991D2EE2686_label_en-US" xlink:label="lab_immu_ProductSalesMember_45A60C0F21551244EA603991D2EE2686" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Product Sales [Member]</link:label>
<link:label id="lab_immu_ProductSalesMember_45A60C0F21551244EA603991D2EE2686_documentation_en-US" xlink:label="lab_immu_ProductSalesMember_45A60C0F21551244EA603991D2EE2686" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Product Sales [Member]</link:label>
<link:loc xlink:href="immu-20191231.xsd#immu_ProductSalesMember" xlink:label="loc_immu_ProductSalesMember_45A60C0F21551244EA603991D2EE2686" xlink:type="locator" />
<link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_immu_ProductSalesMember_45A60C0F21551244EA603991D2EE2686" xlink:to="lab_immu_ProductSalesMember_45A60C0F21551244EA603991D2EE2686" xlink:type="arc" />
<link:label id="lab_immu_LicenseFreeAndOtherRevenueMember_0B44C7717F9249711D103991D2EEE4A0_terseLabel_en-US" xlink:label="lab_immu_LicenseFreeAndOtherRevenueMember_0B44C7717F9249711D103991D2EEE4A0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">License fee and other revenues</link:label>
<link:label id="lab_immu_LicenseFreeAndOtherRevenueMember_0B44C7717F9249711D103991D2EEE4A0_label_en-US" xlink:label="lab_immu_LicenseFreeAndOtherRevenueMember_0B44C7717F9249711D103991D2EEE4A0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">License Free And Other Revenue [Member]</link:label>
<link:label id="lab_immu_LicenseFreeAndOtherRevenueMember_0B44C7717F9249711D103991D2EEE4A0_documentation_en-US" xlink:label="lab_immu_LicenseFreeAndOtherRevenueMember_0B44C7717F9249711D103991D2EEE4A0" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">License Free And Other Revenue [Member]</link:label>
<link:loc xlink:href="immu-20191231.xsd#immu_LicenseFreeAndOtherRevenueMember" xlink:label="loc_immu_LicenseFreeAndOtherRevenueMember_0B44C7717F9249711D103991D2EEE4A0" xlink:type="locator" />
<link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_immu_LicenseFreeAndOtherRevenueMember_0B44C7717F9249711D103991D2EEE4A0" xlink:to="lab_immu_LicenseFreeAndOtherRevenueMember_0B44C7717F9249711D103991D2EEE4A0" xlink:type="arc" />
<link:label id="lab_immu_ResearchandDevelopmentMember_21F77234471BFC2EF67D3991D2EE395C_terseLabel_en-US" xlink:label="lab_immu_ResearchandDevelopmentMember_21F77234471BFC2EF67D3991D2EE395C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research and development</link:label>
<link:label id="lab_immu_ResearchandDevelopmentMember_21F77234471BFC2EF67D3991D2EE395C_label_en-US" xlink:label="lab_immu_ResearchandDevelopmentMember_21F77234471BFC2EF67D3991D2EE395C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research and Development [Member]</link:label>
<link:label id="lab_immu_ResearchandDevelopmentMember_21F77234471BFC2EF67D3991D2EE395C_documentation_en-US" xlink:label="lab_immu_ResearchandDevelopmentMember_21F77234471BFC2EF67D3991D2EE395C" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Research and Development [Member]</link:label>
<link:loc xlink:href="immu-20191231.xsd#immu_ResearchandDevelopmentMember" xlink:label="loc_immu_ResearchandDevelopmentMember_21F77234471BFC2EF67D3991D2EE395C" xlink:type="locator" />
<link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_immu_ResearchandDevelopmentMember_21F77234471BFC2EF67D3991D2EE395C" xlink:to="lab_immu_ResearchandDevelopmentMember_21F77234471BFC2EF67D3991D2EE395C" xlink:type="arc" />
<link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_6306CCA70B26123DEA0B3991D2EEA6C9_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_6306CCA70B26123DEA0B3991D2EEA6C9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenues</link:label>
<link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_6306CCA70B26123DEA0B3991D2EEA6C9_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_6306CCA70B26123DEA0B3991D2EEA6C9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue from Contract with Customer, Excluding Assessed Tax</link:label>
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_6306CCA70B26123DEA0B3991D2EEA6C9" xlink:type="locator" />
<link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_6306CCA70B26123DEA0B3991D2EEA6C9" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_6306CCA70B26123DEA0B3991D2EEA6C9" xlink:type="arc" />
<link:label id="lab_us-gaap_OperatingCostsAndExpensesAbstract_B0A834C896BE79AA3C943991D2EF6DE2_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingCostsAndExpensesAbstract_B0A834C896BE79AA3C943991D2EF6DE2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Costs and expenses:</link:label>
<link:label id="lab_us-gaap_OperatingCostsAndExpensesAbstract_B0A834C896BE79AA3C943991D2EF6DE2_label_en-US" xlink:label="lab_us-gaap_OperatingCostsAndExpensesAbstract_B0A834C896BE79AA3C943991D2EF6DE2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Costs and Expenses [Abstract]</link:label>
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingCostsAndExpensesAbstract" xlink:label="loc_us-gaap_OperatingCostsAndExpensesAbstract_B0A834C896BE79AA3C943991D2EF6DE2" xlink:type="locator" />
<link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingCostsAndExpensesAbstract_B0A834C896BE79AA3C943991D2EF6DE2" xlink:to="lab_us-gaap_OperatingCostsAndExpensesAbstract_B0A834C896BE79AA3C943991D2EF6DE2" xlink:type="arc" />
<link:label id="lab_us-gaap_CostOfRevenue_CC8BF2DAC8FFA253B10E3991D2EF784A_terseLabel_en-US" xlink:label="lab_us-gaap_CostOfRevenue_CC8BF2DAC8FFA253B10E3991D2EF784A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Costs of goods sold</link:label>
<link:label id="lab_us-gaap_CostOfRevenue_CC8BF2DAC8FFA253B10E3991D2EF784A_label_en-US" xlink:label="lab_us-gaap_CostOfRevenue_CC8BF2DAC8FFA253B10E3991D2EF784A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cost of Revenue</link:label>
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CostOfRevenue" xlink:label="loc_us-gaap_CostOfRevenue_CC8BF2DAC8FFA253B10E3991D2EF784A" xlink:type="locator" />
<link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostOfRevenue_CC8BF2DAC8FFA253B10E3991D2EF784A" xlink:to="lab_us-gaap_CostOfRevenue_CC8BF2DAC8FFA253B10E3991D2EF784A" xlink:type="arc" />
<link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_6BE5C575300BDA7173053991D2EF16C1_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense_6BE5C575300BDA7173053991D2EF16C1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research and development</link:label>
<link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_6BE5C575300BDA7173053991D2EF16C1_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense_6BE5C575300BDA7173053991D2EF16C1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research and Development Expense</link:label>
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_6BE5C575300BDA7173053991D2EF16C1" xlink:type="locator" />
<link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpense_6BE5C575300BDA7173053991D2EF16C1" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpense_6BE5C575300BDA7173053991D2EF16C1" xlink:type="arc" />
<link:label id="lab_us-gaap_SellingAndMarketingExpense_B19B5F04389E85B2AAC23991D2EF2FD3_terseLabel_en-US" xlink:label="lab_us-gaap_SellingAndMarketingExpense_B19B5F04389E85B2AAC23991D2EF2FD3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Sales and marketing</link:label>
<link:label id="lab_us-gaap_SellingAndMarketingExpense_B19B5F04389E85B2AAC23991D2EF2FD3_label_en-US" xlink:label="lab_us-gaap_SellingAndMarketingExpense_B19B5F04389E85B2AAC23991D2EF2FD3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Selling and Marketing Expense</link:label>
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SellingAndMarketingExpense" xlink:label="loc_us-gaap_SellingAndMarketingExpense_B19B5F04389E85B2AAC23991D2EF2FD3" xlink:type="locator" />
<link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SellingAndMarketingExpense_B19B5F04389E85B2AAC23991D2EF2FD3" xlink:to="lab_us-gaap_SellingAndMarketingExpense_B19B5F04389E85B2AAC23991D2EF2FD3" xlink:type="arc" />
<link:label id="lab_us-gaap_GeneralAndAdministrativeExpense_B6FD0A604E52D8847AB83991D2F0B458_terseLabel_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense_B6FD0A604E52D8847AB83991D2F0B458" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">General and administrative</link:label>
<link:label id="lab_us-gaap_GeneralAndAdministrativeExpense_B6FD0A604E52D8847AB83991D2F0B458_label_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense_B6FD0A604E52D8847AB83991D2F0B458" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">General and Administrative Expense</link:label>
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_B6FD0A604E52D8847AB83991D2F0B458" xlink:type="locator" />
<link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpense_B6FD0A604E52D8847AB83991D2F0B458" xlink:to="lab_us-gaap_GeneralAndAdministrativeExpense_B6FD0A604E52D8847AB83991D2F0B458" xlink:type="arc" />
<link:label id="lab_us-gaap_CostsAndExpenses_A0DB6A50253584EF4E613991D2F01F7A_totalLabel_en-US" xlink:label="lab_us-gaap_CostsAndExpenses_A0DB6A50253584EF4E613991D2F01F7A" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total costs and expenses</link:label>
<link:label id="lab_us-gaap_CostsAndExpenses_A0DB6A50253584EF4E613991D2F01F7A_label_en-US" xlink:label="lab_us-gaap_CostsAndExpenses_A0DB6A50253584EF4E613991D2F01F7A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Costs and Expenses</link:label>
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CostsAndExpenses" xlink:label="loc_us-gaap_CostsAndExpenses_A0DB6A50253584EF4E613991D2F01F7A" xlink:type="locator" />
<link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostsAndExpenses_A0DB6A50253584EF4E613991D2F01F7A" xlink:to="lab_us-gaap_CostsAndExpenses_A0DB6A50253584EF4E613991D2F01F7A" xlink:type="arc" />
<link:label id="lab_us-gaap_OperatingIncomeLoss_F77C73B193B830DC98D23991D2F0FDB6_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss_F77C73B193B830DC98D23991D2F0FDB6" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Operating loss</link:label>
<link:label id="lab_us-gaap_OperatingIncomeLoss_F77C73B193B830DC98D23991D2F0FDB6_label_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss_F77C73B193B830DC98D23991D2F0FDB6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Income (Loss)</link:label>
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaap_OperatingIncomeLoss_F77C73B193B830DC98D23991D2F0FDB6" xlink:type="locator" />
<link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingIncomeLoss_F77C73B193B830DC98D23991D2F0FDB6" xlink:to="lab_us-gaap_OperatingIncomeLoss_F77C73B193B830DC98D23991D2F0FDB6" xlink:type="arc" />
<link:label id="lab_us-gaap_FairValueAdjustmentOfWarrants_07807BE17701BA7D655C3991D2F0EC35_negatedLabel_en-US" xlink:label="lab_us-gaap_FairValueAdjustmentOfWarrants_07807BE17701BA7D655C3991D2F0EC35" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Changes in fair market value of warrant liabilities</link:label>
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="loc_us-gaap_FairValueAdjustmentOfWarrants_07807BE17701BA7D655C3991D2F0EC35" xlink:type="locator" />
<link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAdjustmentOfWarrants_07807BE17701BA7D655C3991D2F0EC35" xlink:to="lab_us-gaap_FairValueAdjustmentOfWarrants_07807BE17701BA7D655C3991D2F0EC35" xlink:type="arc" />
<link:label id="lab_us-gaap_AdjustmentOfWarrantsGrantedForServices_8FB3BFAE946622C778683991D2F09B24_negatedLabel_en-US" xlink:label="lab_us-gaap_AdjustmentOfWarrantsGrantedForServices_8FB3BFAE946622C778683991D2F09B24" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Warrant related expenses</link:label>
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdjustmentOfWarrantsGrantedForServices" xlink:label="loc_us-gaap_AdjustmentOfWarrantsGrantedForServices_8FB3BFAE946622C778683991D2F09B24" xlink:type="locator" />
<link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentOfWarrantsGrantedForServices_8FB3BFAE946622C778683991D2F09B24" xlink:to="lab_us-gaap_AdjustmentOfWarrantsGrantedForServices_8FB3BFAE946622C778683991D2F09B24" xlink:type="arc" />
<link:label id="lab_us-gaap_InterestExpense_2B792A808FCECD48E3103991D2F012BD_negatedLabel_en-US" xlink:label="lab_us-gaap_InterestExpense_2B792A808FCECD48E3103991D2F012BD" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Interest expense</link:label>
<link:label id="lab_us-gaap_InterestExpense_2B792A808FCECD48E3103991D2F012BD_label_en-US" xlink:label="lab_us-gaap_InterestExpense_2B792A808FCECD48E3103991D2F012BD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interest Expense</link:label>
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InterestExpense" xlink:label="loc_us-gaap_InterestExpense_2B792A808FCECD48E3103991D2F012BD" xlink:type="locator" />
<link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestExpense_2B792A808FCECD48E3103991D2F012BD" xlink:to="lab_us-gaap_InterestExpense_2B792A808FCECD48E3103991D2F012BD" xlink:type="arc" />
<link:label id="lab_us-gaap_InterestAndOtherIncome_48115CA82FF3FA7913C83991D2F05F9C_terseLabel_en-US" xlink:label="lab_us-gaap_InterestAndOtherIncome_48115CA82FF3FA7913C83991D2F05F9C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Interest and other income</link:label>
<link:label id="lab_us-gaap_InterestAndOtherIncome_48115CA82FF3FA7913C83991D2F05F9C_label_en-US" xlink:label="lab_us-gaap_InterestAndOtherIncome_48115CA82FF3FA7913C83991D2F05F9C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interest and Other Income</link:label>
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InterestAndOtherIncome" xlink:label="loc_us-gaap_InterestAndOtherIncome_48115CA82FF3FA7913C83991D2F05F9C" xlink:type="locator" />
<link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestAndOtherIncome_48115CA82FF3FA7913C83991D2F05F9C" xlink:to="lab_us-gaap_InterestAndOtherIncome_48115CA82FF3FA7913C83991D2F05F9C" xlink:type="arc" />
<link:label id="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt_343F36BBA1351D4307503991D2F1A9D9_terseLabel_en-US" xlink:label="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt_343F36BBA1351D4307503991D2F1A9D9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Loss on induced exchanges of debt</link:label>
<link:label id="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt_343F36BBA1351D4307503991D2F1A9D9_label_en-US" xlink:label="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt_343F36BBA1351D4307503991D2F1A9D9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Gain (Loss) on Extinguishment of Debt</link:label>
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_343F36BBA1351D4307503991D2F1A9D9" xlink:type="locator" />
<link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_343F36BBA1351D4307503991D2F1A9D9" xlink:to="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt_343F36BBA1351D4307503991D2F1A9D9" xlink:type="arc" />
<link:label id="lab_immu_OtherFinancingExpenseIncome_1A249C92A1AD8D640FB23991D2F125B7_negatedTerseLabel_en-US" xlink:label="lab_immu_OtherFinancingExpenseIncome_1A249C92A1AD8D640FB23991D2F125B7" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Other financing expenses</link:label>
<link:label id="lab_immu_OtherFinancingExpenseIncome_1A249C92A1AD8D640FB23991D2F125B7_label_en-US" xlink:label="lab_immu_OtherFinancingExpenseIncome_1A249C92A1AD8D640FB23991D2F125B7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Financing Expense (Income)</link:label>
<link:label id="lab_immu_OtherFinancingExpenseIncome_1A249C92A1AD8D640FB23991D2F125B7_documentation_en-US" xlink:label="lab_immu_OtherFinancingExpenseIncome_1A249C92A1AD8D640FB23991D2F125B7" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Amount of other financing expenses.</link:label>
<link:loc xlink:href="immu-20191231.xsd#immu_OtherFinancingExpenseIncome" xlink:label="loc_immu_OtherFinancingExpenseIncome_1A249C92A1AD8D640FB23991D2F125B7" xlink:type="locator" />
<link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_immu_OtherFinancingExpenseIncome_1A249C92A1AD8D640FB23991D2F125B7" xlink:to="lab_immu_OtherFinancingExpenseIncome_1A249C92A1AD8D640FB23991D2F125B7" xlink:type="arc" />
<link:label id="lab_us-gaap_GainOnBusinessInterruptionInsuranceRecovery_934167A48ABC430009B43991D2F1EF4B_terseLabel_en-US" xlink:label="lab_us-gaap_GainOnBusinessInterruptionInsuranceRecovery_934167A48ABC430009B43991D2F1EF4B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Insurance reimbursement</link:label>
<link:label id="lab_us-gaap_GainOnBusinessInterruptionInsuranceRecovery_934167A48ABC430009B43991D2F1EF4B_label_en-US" xlink:label="lab_us-gaap_GainOnBusinessInterruptionInsuranceRecovery_934167A48ABC430009B43991D2F1EF4B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Gain on Business Interruption Insurance Recovery</link:label>
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GainOnBusinessInterruptionInsuranceRecovery" xlink:label="loc_us-gaap_GainOnBusinessInterruptionInsuranceRecovery_934167A48ABC430009B43991D2F1EF4B" xlink:type="locator" />
<link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainOnBusinessInterruptionInsuranceRecovery_934167A48ABC430009B43991D2F1EF4B" xlink:to="lab_us-gaap_GainOnBusinessInterruptionInsuranceRecovery_934167A48ABC430009B43991D2F1EF4B" xlink:type="arc" />
<link:label id="lab_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_6D00024E1D56B1A069B73991D2F1A04B_terseLabel_en-US" xlink:label="lab_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_6D00024E1D56B1A069B73991D2F1A04B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Foreign currency transaction gain, net</link:label>
<link:label id="lab_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_6D00024E1D56B1A069B73991D2F1A04B_label_en-US" xlink:label="lab_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_6D00024E1D56B1A069B73991D2F1A04B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Foreign Currency Transaction Gain (Loss), before Tax</link:label>
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:label="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_6D00024E1D56B1A069B73991D2F1A04B" xlink:type="locator" />
<link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_6D00024E1D56B1A069B73991D2F1A04B" xlink:to="lab_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_6D00024E1D56B1A069B73991D2F1A04B" xlink:type="arc" />
<link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_37D2660895D0FDE20A8E3991D2F1FDDC_totalLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_37D2660895D0FDE20A8E3991D2F1FDDC" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Loss before income tax</link:label>
<link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_37D2660895D0FDE20A8E3991D2F1FDDC_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_37D2660895D0FDE20A8E3991D2F1FDDC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest</link:label>
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_37D2660895D0FDE20A8E3991D2F1FDDC" xlink:type="locator" />
<link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_37D2660895D0FDE20A8E3991D2F1FDDC" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_37D2660895D0FDE20A8E3991D2F1FDDC" xlink:type="arc" />
<link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_C7AF9F997E338E8448DD3991D2F23A3B_negatedLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit_C7AF9F997E338E8448DD3991D2F23A3B" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Income tax expense</link:label>
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_C7AF9F997E338E8448DD3991D2F23A3B" xlink:type="locator" />
<link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_C7AF9F997E338E8448DD3991D2F23A3B" xlink:to="lab_us-gaap_IncomeTaxExpenseBenefit_C7AF9F997E338E8448DD3991D2F23A3B" xlink:type="arc" />
<link:label id="lab_us-gaap_ProfitLoss_5A6E14ED519E24FDF5193991D2F20BD9_totalLabel_en-US" xlink:label="lab_us-gaap_ProfitLoss_5A6E14ED519E24FDF5193991D2F20BD9" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net loss</link:label>
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProfitLoss" xlink:label="loc_us-gaap_ProfitLoss_5A6E14ED519E24FDF5193991D2F20BD9" xlink:type="locator" />
<link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProfitLoss_5A6E14ED519E24FDF5193991D2F20BD9" xlink:to="lab_us-gaap_ProfitLoss_5A6E14ED519E24FDF5193991D2F20BD9" xlink:type="arc" />
<link:label id="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_835D025D4EDD419966A43991D2F27E72_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_835D025D4EDD419966A43991D2F27E72" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net loss attributable to noncontrolling interest</link:label>
<link:label id="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_835D025D4EDD419966A43991D2F27E72_label_en-US" xlink:label="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_835D025D4EDD419966A43991D2F27E72" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Income (Loss) Attributable to Noncontrolling Interest</link:label>
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_835D025D4EDD419966A43991D2F27E72" xlink:type="locator" />
<link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_835D025D4EDD419966A43991D2F27E72" xlink:to="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_835D025D4EDD419966A43991D2F27E72" xlink:type="arc" />
<link:label id="lab_us-gaap_NetIncomeLoss_F99ECE8B1B9C2A7D1EAF3991D2F28FE6_totalLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss_F99ECE8B1B9C2A7D1EAF3991D2F28FE6" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net loss attributable to Immunomedics, Inc. stockholders</link:label>
<link:label id="lab_us-gaap_NetIncomeLoss_F99ECE8B1B9C2A7D1EAF3991D2F28FE6_label_en-US" xlink:label="lab_us-gaap_NetIncomeLoss_F99ECE8B1B9C2A7D1EAF3991D2F28FE6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Income (Loss) Attributable to Parent</link:label>
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_F99ECE8B1B9C2A7D1EAF3991D2F28FE6" xlink:type="locator" />
<link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss_F99ECE8B1B9C2A7D1EAF3991D2F28FE6" xlink:to="lab_us-gaap_NetIncomeLoss_F99ECE8B1B9C2A7D1EAF3991D2F28FE6" xlink:type="arc" />
<link:label id="lab_us-gaap_EarningsPerShareBasicAndDiluted_93C4BC00FC5DDA6180643991D2F2E687_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasicAndDiluted_93C4BC00FC5DDA6180643991D2F2E687" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Loss per common share attributable to Immunomedics, Inc. stockholders (basic and diluted) (in USD per share)</link:label>
<link:label id="lab_us-gaap_EarningsPerShareBasicAndDiluted_93C4BC00FC5DDA6180643991D2F2E687_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasicAndDiluted_93C4BC00FC5DDA6180643991D2F2E687" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share, Basic and Diluted</link:label>
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDiluted_93C4BC00FC5DDA6180643991D2F2E687" xlink:type="locator" />
<link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasicAndDiluted_93C4BC00FC5DDA6180643991D2F2E687" xlink:to="lab_us-gaap_EarningsPerShareBasicAndDiluted_93C4BC00FC5DDA6180643991D2F2E687" xlink:type="arc" />
<link:label id="lab_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_A45B79CD9CC922FE84A33991D2F2BAAA_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_A45B79CD9CC922FE84A33991D2F2BAAA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted average shares used to calculate loss per common share (basic and diluted) (in shares)</link:label>
<link:label id="lab_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_A45B79CD9CC922FE84A33991D2F2BAAA_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_A45B79CD9CC922FE84A33991D2F2BAAA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic and Diluted</link:label>
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:label="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_A45B79CD9CC922FE84A33991D2F2BAAA" xlink:type="locator" />
<link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_A45B79CD9CC922FE84A33991D2F2BAAA" xlink:to="lab_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_A45B79CD9CC922FE84A33991D2F2BAAA" xlink:type="arc" />
<link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_D81D592D3CEE8D11603E3991D2F29E1B_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_D81D592D3CEE8D11603E3991D2F29E1B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other comprehensive (loss) income, net of tax:</link:label>
<link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_D81D592D3CEE8D11603E3991D2F29E1B_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_D81D592D3CEE8D11603E3991D2F29E1B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Comprehensive Income (Loss), Net of Tax [Abstract]</link:label>
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_D81D592D3CEE8D11603E3991D2F29E1B" xlink:type="locator" />
<link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_D81D592D3CEE8D11603E3991D2F29E1B" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_D81D592D3CEE8D11603E3991D2F29E1B" xlink:type="arc" />
<link:label id="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_CCA16121786BAC259F223991D2F32C88_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_CCA16121786BAC259F223991D2F32C88" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Foreign currency translation adjustments</link:label>
<link:label id="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_CCA16121786BAC259F223991D2F32C88_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_CCA16121786BAC259F223991D2F32C88" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax</link:label>
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_CCA16121786BAC259F223991D2F32C88" xlink:type="locator" />
<link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_CCA16121786BAC259F223991D2F32C88" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_CCA16121786BAC259F223991D2F32C88" xlink:type="arc" />
<link:label id="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_78131803F2859990C7943991D2F3EBDE_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_78131803F2859990C7943991D2F3EBDE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Unrealized gain (loss) on securities available for sale</link:label>
<link:label id="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_78131803F2859990C7943991D2F3EBDE_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_78131803F2859990C7943991D2F3EBDE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Comprehensive Income (Loss), Securities, Available-for-Sale, Unrealized Holding Gain (Loss) Arising During Period, after Tax</link:label>
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_78131803F2859990C7943991D2F3EBDE" xlink:type="locator" />
<link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_78131803F2859990C7943991D2F3EBDE" xlink:to="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_78131803F2859990C7943991D2F3EBDE" xlink:type="arc" />
<link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax_27F826F1BEB8FA2318F93991D2F3BFF4_totalLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax_27F826F1BEB8FA2318F93991D2F3BFF4" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Other comprehensive income (loss), net of tax:</link:label>
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_27F826F1BEB8FA2318F93991D2F3BFF4" xlink:type="locator" />
<link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_27F826F1BEB8FA2318F93991D2F3BFF4" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax_27F826F1BEB8FA2318F93991D2F3BFF4" xlink:type="arc" />
<link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_B25BA9D06E81AEDB075B3991D2F3FCDD_terseLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_B25BA9D06E81AEDB075B3991D2F3FCDD" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Comprehensive loss</link:label>
<link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_B25BA9D06E81AEDB075B3991D2F3FCDD_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_B25BA9D06E81AEDB075B3991D2F3FCDD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest</link:label>
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_B25BA9D06E81AEDB075B3991D2F3FCDD" xlink:type="locator" />
<link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_B25BA9D06E81AEDB075B3991D2F3FCDD" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_B25BA9D06E81AEDB075B3991D2F3FCDD" xlink:type="arc" />
<link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_45C840BA398E4E3D4B913991D2F33518_terseLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_45C840BA398E4E3D4B913991D2F33518" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Comprehensive loss attributable to noncontrolling interest</link:label>
<link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_45C840BA398E4E3D4B913991D2F33518_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_45C840BA398E4E3D4B913991D2F33518" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Attributable to Noncontrolling Interest</link:label>
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_45C840BA398E4E3D4B913991D2F33518" xlink:type="locator" />
<link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_45C840BA398E4E3D4B913991D2F33518" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_45C840BA398E4E3D4B913991D2F33518" xlink:type="arc" />
<link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_F3B9419815158C25580A3991D2F3D24D_totalLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax_F3B9419815158C25580A3991D2F3D24D" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Comprehensive loss attributable to Immunomedics, Inc. stockholders</link:label>
<link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_F3B9419815158C25580A3991D2F3D24D_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax_F3B9419815158C25580A3991D2F3D24D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Attributable to Parent</link:label>
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_F3B9419815158C25580A3991D2F3D24D" xlink:type="locator" />
<link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_F3B9419815158C25580A3991D2F3D24D" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTax_F3B9419815158C25580A3991D2F3D24D" xlink:type="arc" />
<link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_07859EBC9F787C252994D1D062B9B28D_terseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_07859EBC9F787C252994D1D062B9B28D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock-Based Compensation</link:label>
<link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_07859EBC9F787C252994D1D062B9B28D_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_07859EBC9F787C252994D1D062B9B28D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Payment Arrangement [Text Block]</link:label>
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_07859EBC9F787C252994D1D062B9B28D" xlink:type="locator" />
<link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_07859EBC9F787C252994D1D062B9B28D" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_07859EBC9F787C252994D1D062B9B28D" xlink:type="arc" />
<link:label id="lab_immu_ConsolidatedStatementOfOperationsAbstract_336915A68B8170F677E73991D16AB877_terseLabel_en-US" xlink:label="lab_immu_ConsolidatedStatementOfOperationsAbstract_336915A68B8170F677E73991D16AB877" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Consolidated Statements of Comprehensive Loss Data:</link:label>
<link:label id="lab_immu_ConsolidatedStatementOfOperationsAbstract_336915A68B8170F677E73991D16AB877_label_en-US" xlink:label="lab_immu_ConsolidatedStatementOfOperationsAbstract_336915A68B8170F677E73991D16AB877" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Consolidated Statement Of Operations [Abstract]</link:label>
<link:label id="lab_immu_ConsolidatedStatementOfOperationsAbstract_336915A68B8170F677E73991D16AB877_documentation_en-US" xlink:label="lab_immu_ConsolidatedStatementOfOperationsAbstract_336915A68B8170F677E73991D16AB877" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Consolidated Statement Of Operations [Abstract]</link:label>
<link:loc xlink:href="immu-20191231.xsd#immu_ConsolidatedStatementOfOperationsAbstract" xlink:label="loc_immu_ConsolidatedStatementOfOperationsAbstract_336915A68B8170F677E73991D16AB877" xlink:type="locator" />
<link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_immu_ConsolidatedStatementOfOperationsAbstract_336915A68B8170F677E73991D16AB877" xlink:to="lab_immu_ConsolidatedStatementOfOperationsAbstract_336915A68B8170F677E73991D16AB877" xlink:type="arc" />
<link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_D0811422C28110D82DE53991D16A2D64_verboseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_D0811422C28110D82DE53991D16A2D64" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Revenues</link:label>
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_D0811422C28110D82DE53991D16A2D64" xlink:type="locator" />
<link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_D0811422C28110D82DE53991D16A2D64" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_D0811422C28110D82DE53991D16A2D64" xlink:type="arc" />
<link:label id="lab_us-gaap_NetIncomeLoss_1578A38BD35849A7E4CB3991D16A95B5_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss_1578A38BD35849A7E4CB3991D16A95B5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net loss attributable to Immunomedics, Inc. stockholders</link:label>
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_1578A38BD35849A7E4CB3991D16A95B5" xlink:type="locator" />
<link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss_1578A38BD35849A7E4CB3991D16A95B5" xlink:to="lab_us-gaap_NetIncomeLoss_1578A38BD35849A7E4CB3991D16A95B5" xlink:type="arc" />
<link:label id="lab_us-gaap_DepreciationAndAmortization_E2D873D34008E91A9379DB9A47EAB776_verboseLabel_en-US" xlink:label="lab_us-gaap_DepreciationAndAmortization_E2D873D34008E91A9379DB9A47EAB776" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Depreciation and amortization expense</link:label>
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DepreciationAndAmortization" xlink:label="loc_us-gaap_DepreciationAndAmortization_E2D873D34008E91A9379DB9A47EAB776" xlink:type="locator" />
<link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DepreciationAndAmortization_E2D873D34008E91A9379DB9A47EAB776" xlink:to="lab_us-gaap_DepreciationAndAmortization_E2D873D34008E91A9379DB9A47EAB776" xlink:type="arc" />
<link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_7A84A7191EE18E97725F3991D21BFD2B_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_7A84A7191EE18E97725F3991D21BFD2B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value, Recurring and Nonrecurring [Table]</link:label>
<link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_7A84A7191EE18E97725F3991D21BFD2B_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_7A84A7191EE18E97725F3991D21BFD2B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Recurring and Nonrecurring [Table]</link:label>
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_7A84A7191EE18E97725F3991D21BFD2B" xlink:type="locator" />
<link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_7A84A7191EE18E97725F3991D21BFD2B" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_7A84A7191EE18E97725F3991D21BFD2B" xlink:type="arc" />
<link:label id="lab_us-gaap_FairValueInputsLevel1Member_310D57561001F762D5D63991D21C06D4_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member_310D57561001F762D5D63991D21C06D4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Level 1</link:label>
<link:label id="lab_us-gaap_FairValueInputsLevel1Member_310D57561001F762D5D63991D21C06D4_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member_310D57561001F762D5D63991D21C06D4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Inputs, Level 1 [Member]</link:label>
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_310D57561001F762D5D63991D21C06D4" xlink:type="locator" />
<link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel1Member_310D57561001F762D5D63991D21C06D4" xlink:to="lab_us-gaap_FairValueInputsLevel1Member_310D57561001F762D5D63991D21C06D4" xlink:type="arc" />
<link:label id="lab_us-gaap_FairValueInputsLevel3Member_A592D90CC1264F5EA4043991D21C7C13_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member_A592D90CC1264F5EA4043991D21C7C13" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Level 3</link:label>
<link:label id="lab_us-gaap_FairValueInputsLevel3Member_A592D90CC1264F5EA4043991D21C7C13_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member_A592D90CC1264F5EA4043991D21C7C13" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Inputs, Level 3 [Member]</link:label>
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_A592D90CC1264F5EA4043991D21C7C13" xlink:type="locator" />
<link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel3Member_A592D90CC1264F5EA4043991D21C7C13" xlink:to="lab_us-gaap_FairValueInputsLevel3Member_A592D90CC1264F5EA4043991D21C7C13" xlink:type="arc" />
<link:label id="lab_us-gaap_MoneyMarketFundsMember_05F20A83D504DB4A6E253991D21D7A19_terseLabel_en-US" xlink:label="lab_us-gaap_MoneyMarketFundsMember_05F20A83D504DB4A6E253991D21D7A19" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Money Market Funds</link:label>
<link:label id="lab_us-gaap_MoneyMarketFundsMember_05F20A83D504DB4A6E253991D21D7A19_label_en-US" xlink:label="lab_us-gaap_MoneyMarketFundsMember_05F20A83D504DB4A6E253991D21D7A19" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Money Market Funds [Member]</link:label>
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="loc_us-gaap_MoneyMarketFundsMember_05F20A83D504DB4A6E253991D21D7A19" xlink:type="locator" />
<link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MoneyMarketFundsMember_05F20A83D504DB4A6E253991D21D7A19" xlink:to="lab_us-gaap_MoneyMarketFundsMember_05F20A83D504DB4A6E253991D21D7A19" xlink:type="arc" />
<link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_1B18A48DFA2C9B5309E03991D21D28A4_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_1B18A48DFA2C9B5309E03991D21D28A4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
<link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_1B18A48DFA2C9B5309E03991D21D28A4_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_1B18A48DFA2C9B5309E03991D21D28A4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_1B18A48DFA2C9B5309E03991D21D28A4" xlink:type="locator" />
<link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_1B18A48DFA2C9B5309E03991D21D28A4" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_1B18A48DFA2C9B5309E03991D21D28A4" xlink:type="arc" />
<link:label id="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_E7F2F8F281353C61A35A3991D21EF53B_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_E7F2F8F281353C61A35A3991D21EF53B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash and cash equivalents</link:label>
<link:label id="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_E7F2F8F281353C61A35A3991D21EF53B_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_E7F2F8F281353C61A35A3991D21EF53B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents, Fair Value Disclosure</link:label>
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_E7F2F8F281353C61A35A3991D21EF53B" xlink:type="locator" />
<link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_E7F2F8F281353C61A35A3991D21EF53B" xlink:to="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_E7F2F8F281353C61A35A3991D21EF53B" xlink:type="arc" />
<link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_62A34529823E4BD54DAF3991D21E2C3C_verboseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_62A34529823E4BD54DAF3991D21E2C3C" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Marketable Securities</link:label>
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_62A34529823E4BD54DAF3991D21E2C3C" xlink:type="locator" />
<link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_62A34529823E4BD54DAF3991D21E2C3C" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_62A34529823E4BD54DAF3991D21E2C3C" xlink:type="arc" />
<link:label id="lab_us-gaap_AssetsFairValueDisclosure_7BA9841294FF6D0A6EC03991D21E3CEB_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosure_7BA9841294FF6D0A6EC03991D21E3CEB" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Financial assets</link:label>
<link:label id="lab_us-gaap_AssetsFairValueDisclosure_7BA9841294FF6D0A6EC03991D21E3CEB_label_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosure_7BA9841294FF6D0A6EC03991D21E3CEB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets, Fair Value Disclosure</link:label>
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsFairValueDisclosure" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_7BA9841294FF6D0A6EC03991D21E3CEB" xlink:type="locator" />
<link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsFairValueDisclosure_7BA9841294FF6D0A6EC03991D21E3CEB" xlink:to="lab_us-gaap_AssetsFairValueDisclosure_7BA9841294FF6D0A6EC03991D21E3CEB" xlink:type="arc" />
<link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_3BBAC288AE6ECCDEE78C3991D1D033F7_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_3BBAC288AE6ECCDEE78C3991D1D033F7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accumulated Other Comprehensive (Loss) Income [Table]</link:label>
<link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_3BBAC288AE6ECCDEE78C3991D1D033F7_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_3BBAC288AE6ECCDEE78C3991D1D033F7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss) [Table]</link:label>
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_3BBAC288AE6ECCDEE78C3991D1D033F7" xlink:type="locator" />
<link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_3BBAC288AE6ECCDEE78C3991D1D033F7" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_3BBAC288AE6ECCDEE78C3991D1D033F7" xlink:type="arc" />
<link:label id="lab_us-gaap_AccumulatedTranslationAdjustmentMember_6EDCE1B68C010B705DE93991D1D039F6_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedTranslationAdjustmentMember_6EDCE1B68C010B705DE93991D1D039F6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Currency Translation Adjustments</link:label>
<link:label id="lab_us-gaap_AccumulatedTranslationAdjustmentMember_6EDCE1B68C010B705DE93991D1D039F6_label_en-US" xlink:label="lab_us-gaap_AccumulatedTranslationAdjustmentMember_6EDCE1B68C010B705DE93991D1D039F6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accumulated Foreign Currency Adjustment Attributable to Parent [Member]</link:label>
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedTranslationAdjustmentMember" xlink:label="loc_us-gaap_AccumulatedTranslationAdjustmentMember_6EDCE1B68C010B705DE93991D1D039F6" xlink:type="locator" />
<link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedTranslationAdjustmentMember_6EDCE1B68C010B705DE93991D1D039F6" xlink:to="lab_us-gaap_AccumulatedTranslationAdjustmentMember_6EDCE1B68C010B705DE93991D1D039F6" xlink:type="arc" />
<link:label id="lab_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_FF154B1687E35F422C613991D1D12A2D_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_FF154B1687E35F422C613991D1D12A2D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net Unrealized Gains (Losses) on Available-for-Sale Securities</link:label>
<link:label id="lab_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_FF154B1687E35F422C613991D1D12A2D_label_en-US" xlink:label="lab_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_FF154B1687E35F422C613991D1D12A2D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">AOCI, Accumulated Gain (Loss), Debt Securities, Available-for-sale, Parent [Member]</link:label>
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember" xlink:label="loc_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_FF154B1687E35F422C613991D1D12A2D" xlink:type="locator" />
<link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_FF154B1687E35F422C613991D1D12A2D" xlink:to="lab_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_FF154B1687E35F422C613991D1D12A2D" xlink:type="arc" />
<link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_505398F0237C88D0B7053991D1D137BA_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_505398F0237C88D0B7053991D1D137BA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accumulated Other Comprehensive (Loss) Income [Line Items]</link:label>
<link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_505398F0237C88D0B7053991D1D137BA_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_505398F0237C88D0B7053991D1D137BA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss) [Line Items]</link:label>
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_505398F0237C88D0B7053991D1D137BA" xlink:type="locator" />
<link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_505398F0237C88D0B7053991D1D137BA" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_505398F0237C88D0B7053991D1D137BA" xlink:type="arc" />
<link:label id="lab_us-gaap_AOCIAttributableToParentNetOfTaxRollForward_4B0B813418EB2CF10C613991D1D1B1B4_terseLabel_en-US" xlink:label="lab_us-gaap_AOCIAttributableToParentNetOfTaxRollForward_4B0B813418EB2CF10C613991D1D1B1B4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">AOCI Attributable to Parent [Roll Forward]</link:label>
<link:label id="lab_us-gaap_AOCIAttributableToParentNetOfTaxRollForward_4B0B813418EB2CF10C613991D1D1B1B4_label_en-US" xlink:label="lab_us-gaap_AOCIAttributableToParentNetOfTaxRollForward_4B0B813418EB2CF10C613991D1D1B1B4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">AOCI Attributable to Parent, Net of Tax [Roll Forward]</link:label>
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AOCIAttributableToParentNetOfTaxRollForward" xlink:label="loc_us-gaap_AOCIAttributableToParentNetOfTaxRollForward_4B0B813418EB2CF10C613991D1D1B1B4" xlink:type="locator" />
<link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AOCIAttributableToParentNetOfTaxRollForward_4B0B813418EB2CF10C613991D1D1B1B4" xlink:to="lab_us-gaap_AOCIAttributableToParentNetOfTaxRollForward_4B0B813418EB2CF10C613991D1D1B1B4" xlink:type="arc" />
<link:label id="lab_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax_8A5CC61054E0837D25143A207EFC16F3_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax_8A5CC61054E0837D25143A207EFC16F3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other comprehensive loss before reclassifications</link:label>
<link:label id="lab_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax_8A5CC61054E0837D25143A207EFC16F3_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax_8A5CC61054E0837D25143A207EFC16F3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Comprehensive Income (Loss), before Reclassifications, Net of Tax</link:label>
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax_8A5CC61054E0837D25143A207EFC16F3" xlink:type="locator" />
<link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax_8A5CC61054E0837D25143A207EFC16F3" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax_8A5CC61054E0837D25143A207EFC16F3" xlink:type="arc" />
<link:label id="lab_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax_9E8518171A73EB4F66A63991D1D255A5_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax_9E8518171A73EB4F66A63991D1D255A5" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Amounts reclassified from accumulated other comprehensive income (loss)</link:label>
<link:label id="lab_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax_9E8518171A73EB4F66A63991D1D255A5_label_en-US" xlink:label="lab_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax_9E8518171A73EB4F66A63991D1D255A5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Reclassification from Accumulated Other Comprehensive Income, Current Period, Net of Tax</link:label>
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" xlink:label="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax_9E8518171A73EB4F66A63991D1D255A5" xlink:type="locator" />
<link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax_9E8518171A73EB4F66A63991D1D255A5" xlink:to="lab_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax_9E8518171A73EB4F66A63991D1D255A5" xlink:type="arc" />
<link:label id="lab_immu_LicenseAndCollaborationAgreementsTextBlock_4FCD23E7D553255EB893D1D06279D0B2_terseLabel_en-US" xlink:label="lab_immu_LicenseAndCollaborationAgreementsTextBlock_4FCD23E7D553255EB893D1D06279D0B2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Collaboration Agreement</link:label>
<link:label id="lab_immu_LicenseAndCollaborationAgreementsTextBlock_4FCD23E7D553255EB893D1D06279D0B2_label_en-US" xlink:label="lab_immu_LicenseAndCollaborationAgreementsTextBlock_4FCD23E7D553255EB893D1D06279D0B2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">License And Collaboration Agreements [Text Block]</link:label>
<link:label id="lab_immu_LicenseAndCollaborationAgreementsTextBlock_4FCD23E7D553255EB893D1D06279D0B2_documentation_en-US" xlink:label="lab_immu_LicenseAndCollaborationAgreementsTextBlock_4FCD23E7D553255EB893D1D06279D0B2" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">License And Collaboration Agreements [Text Block]</link:label>
<link:loc xlink:href="immu-20191231.xsd#immu_LicenseAndCollaborationAgreementsTextBlock" xlink:label="loc_immu_LicenseAndCollaborationAgreementsTextBlock_4FCD23E7D553255EB893D1D06279D0B2" xlink:type="locator" />
<link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_immu_LicenseAndCollaborationAgreementsTextBlock_4FCD23E7D553255EB893D1D06279D0B2" xlink:to="lab_immu_LicenseAndCollaborationAgreementsTextBlock_4FCD23E7D553255EB893D1D06279D0B2" xlink:type="arc" />
<link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_1CE5C5FFDF8515A921293991D178AF38_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_1CE5C5FFDF8515A921293991D178AF38" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Year 1</link:label>
<link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_1CE5C5FFDF8515A921293991D178AF38_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_1CE5C5FFDF8515A921293991D178AF38" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, Payments, Remainder of Fiscal Year</link:label>
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_1CE5C5FFDF8515A921293991D178AF38" xlink:type="locator" />
<link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_1CE5C5FFDF8515A921293991D178AF38" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_1CE5C5FFDF8515A921293991D178AF38" xlink:type="arc" />
<link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_2C1EABE64481D9EAA8513991D17B5C8B_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_2C1EABE64481D9EAA8513991D17B5C8B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Year 2</link:label>
<link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_2C1EABE64481D9EAA8513991D17B5C8B_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_2C1EABE64481D9EAA8513991D17B5C8B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, Payments, Due Year Two</link:label>
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_2C1EABE64481D9EAA8513991D17B5C8B" xlink:type="locator" />
<link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_2C1EABE64481D9EAA8513991D17B5C8B" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_2C1EABE64481D9EAA8513991D17B5C8B" xlink:type="arc" />
<link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_EBD9D9E0F053B2B9FAEB3991D17B52E3_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_EBD9D9E0F053B2B9FAEB3991D17B52E3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Year 3</link:label>
<link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_EBD9D9E0F053B2B9FAEB3991D17B52E3_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_EBD9D9E0F053B2B9FAEB3991D17B52E3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, Payments, Due Year Three</link:label>
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_EBD9D9E0F053B2B9FAEB3991D17B52E3" xlink:type="locator" />
<link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_EBD9D9E0F053B2B9FAEB3991D17B52E3" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_EBD9D9E0F053B2B9FAEB3991D17B52E3" xlink:type="arc" />
<link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_70970A79EDB292354D663991D17B9927_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_70970A79EDB292354D663991D17B9927" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Year 4</link:label>
<link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_70970A79EDB292354D663991D17B9927_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_70970A79EDB292354D663991D17B9927" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, Payments, Due Year Four</link:label>
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_70970A79EDB292354D663991D17B9927" xlink:type="locator" />
<link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_70970A79EDB292354D663991D17B9927" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_70970A79EDB292354D663991D17B9927" xlink:type="arc" />
<link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_B5AFD39EE48E2CDFFB0C3991D17B9689_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_B5AFD39EE48E2CDFFB0C3991D17B9689" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Year 5</link:label>
<link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_B5AFD39EE48E2CDFFB0C3991D17B9689_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_B5AFD39EE48E2CDFFB0C3991D17B9689" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, Payments, Due Year Five</link:label>
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_B5AFD39EE48E2CDFFB0C3991D17B9689" xlink:type="locator" />
<link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_B5AFD39EE48E2CDFFB0C3991D17B9689" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_B5AFD39EE48E2CDFFB0C3991D17B9689" xlink:type="arc" />
<link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_E48009C68D579DBF44FE3991D17B5707_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_E48009C68D579DBF44FE3991D17B5707" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Thereafter</link:label>
<link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_E48009C68D579DBF44FE3991D17B5707_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_E48009C68D579DBF44FE3991D17B5707" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, Payments, Due after Year Five</link:label>
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_E48009C68D579DBF44FE3991D17B5707" xlink:type="locator" />
<link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_E48009C68D579DBF44FE3991D17B5707" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_E48009C68D579DBF44FE3991D17B5707" xlink:type="arc" />
<link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_EED4EA0FBE7D3039BCB13991D17C9EC6_totalLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_EED4EA0FBE7D3039BCB13991D17C9EC6" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total lease payments</link:label>
<link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_EED4EA0FBE7D3039BCB13991D17C9EC6_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_EED4EA0FBE7D3039BCB13991D17C9EC6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, Payments, Due</link:label>
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_EED4EA0FBE7D3039BCB13991D17C9EC6" xlink:type="locator" />
<link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_EED4EA0FBE7D3039BCB13991D17C9EC6" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_EED4EA0FBE7D3039BCB13991D17C9EC6" xlink:type="arc" />
<link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_51C9152BC630D6079A4C3991D17C2CB2_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_51C9152BC630D6079A4C3991D17C2CB2" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Less imputed interest</link:label>
<link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_51C9152BC630D6079A4C3991D17C2CB2_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_51C9152BC630D6079A4C3991D17C2CB2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, Undiscounted Excess Amount</link:label>
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_51C9152BC630D6079A4C3991D17C2CB2" xlink:type="locator" />
<link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_51C9152BC630D6079A4C3991D17C2CB2" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_51C9152BC630D6079A4C3991D17C2CB2" xlink:type="arc" />
<link:label id="lab_us-gaap_OperatingLeaseLiability_54FE89C7BB5914BAE9843991D17C3940_verboseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability_54FE89C7BB5914BAE9843991D17C3940" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Total</link:label>
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseLiability" xlink:label="loc_us-gaap_OperatingLeaseLiability_54FE89C7BB5914BAE9843991D17C3940" xlink:type="locator" />
<link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiability_54FE89C7BB5914BAE9843991D17C3940" xlink:to="lab_us-gaap_OperatingLeaseLiability_54FE89C7BB5914BAE9843991D17C3940" xlink:type="arc" />
<link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_7D50BB26E42B1FAFD2F33A2EBE0DA9BD_terseLabel_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_7D50BB26E42B1FAFD2F33A2EBE0DA9BD" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Basis of Accounting</link:label>
<link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_7D50BB26E42B1FAFD2F33A2EBE0DA9BD_label_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_7D50BB26E42B1FAFD2F33A2EBE0DA9BD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Basis of Accounting, Policy [Policy Text Block]</link:label>
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_7D50BB26E42B1FAFD2F33A2EBE0DA9BD" xlink:type="locator" />
<link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_7D50BB26E42B1FAFD2F33A2EBE0DA9BD" xlink:to="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_7D50BB26E42B1FAFD2F33A2EBE0DA9BD" xlink:type="arc" />
<link:label id="lab_us-gaap_UseOfEstimates_9D894A0FAD766589277E3A2EBE0EFD32_terseLabel_en-US" xlink:label="lab_us-gaap_UseOfEstimates_9D894A0FAD766589277E3A2EBE0EFD32" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Use of Estimates</link:label>
<link:label id="lab_us-gaap_UseOfEstimates_9D894A0FAD766589277E3A2EBE0EFD32_label_en-US" xlink:label="lab_us-gaap_UseOfEstimates_9D894A0FAD766589277E3A2EBE0EFD32" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Use of Estimates, Policy [Policy Text Block]</link:label>
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_UseOfEstimates" xlink:label="loc_us-gaap_UseOfEstimates_9D894A0FAD766589277E3A2EBE0EFD32" xlink:type="locator" />
<link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UseOfEstimates_9D894A0FAD766589277E3A2EBE0EFD32" xlink:to="lab_us-gaap_UseOfEstimates_9D894A0FAD766589277E3A2EBE0EFD32" xlink:type="arc" />
<link:label id="lab_us-gaap_DebtPolicyTextBlock_7FF9D1070296F1C6DEA63A2EBE0E31B3_terseLabel_en-US" xlink:label="lab_us-gaap_DebtPolicyTextBlock_7FF9D1070296F1C6DEA63A2EBE0E31B3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Interest Expense on Liability Related to Sale of Future Royalties</link:label>
<link:label id="lab_us-gaap_DebtPolicyTextBlock_7FF9D1070296F1C6DEA63A2EBE0E31B3_label_en-US" xlink:label="lab_us-gaap_DebtPolicyTextBlock_7FF9D1070296F1C6DEA63A2EBE0E31B3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt, Policy [Policy Text Block]</link:label>
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtPolicyTextBlock" xlink:label="loc_us-gaap_DebtPolicyTextBlock_7FF9D1070296F1C6DEA63A2EBE0E31B3" xlink:type="locator" />
<link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtPolicyTextBlock_7FF9D1070296F1C6DEA63A2EBE0E31B3" xlink:to="lab_us-gaap_DebtPolicyTextBlock_7FF9D1070296F1C6DEA63A2EBE0E31B3" xlink:type="arc" />
<link:label id="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_A451B25117D99F7D90BD3A2EBE0E22C9_terseLabel_en-US" xlink:label="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_A451B25117D99F7D90BD3A2EBE0E22C9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Foreign Currencies</link:label>
<link:label id="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_A451B25117D99F7D90BD3A2EBE0E22C9_label_en-US" xlink:label="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_A451B25117D99F7D90BD3A2EBE0E22C9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Foreign Currency Transactions and Translations Policy [Policy Text Block]</link:label>
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:label="loc_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_A451B25117D99F7D90BD3A2EBE0E22C9" xlink:type="locator" />
<link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_A451B25117D99F7D90BD3A2EBE0E22C9" xlink:to="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_A451B25117D99F7D90BD3A2EBE0E22C9" xlink:type="arc" />
<link:label id="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy_282D4F4A4E82B4A17E333A2EBE0E7294_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy_282D4F4A4E82B4A17E333A2EBE0E7294" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Financial Instruments</link:label>
<link:label id="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy_282D4F4A4E82B4A17E333A2EBE0E7294_label_en-US" xlink:label="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy_282D4F4A4E82B4A17E333A2EBE0E7294" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value of Financial Instruments, Policy [Policy Text Block]</link:label>
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:label="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy_282D4F4A4E82B4A17E333A2EBE0E7294" xlink:type="locator" />
<link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy_282D4F4A4E82B4A17E333A2EBE0E7294" xlink:to="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy_282D4F4A4E82B4A17E333A2EBE0E7294" xlink:type="arc" />
<link:label id="lab_us-gaap_MarketableSecuritiesPolicy_420CB89CA703CD38BA823A2EBE0F0154_terseLabel_en-US" xlink:label="lab_us-gaap_MarketableSecuritiesPolicy_420CB89CA703CD38BA823A2EBE0F0154" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Marketable Securities</link:label>
<link:label id="lab_us-gaap_MarketableSecuritiesPolicy_420CB89CA703CD38BA823A2EBE0F0154_label_en-US" xlink:label="lab_us-gaap_MarketableSecuritiesPolicy_420CB89CA703CD38BA823A2EBE0F0154" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Marketable Securities, Policy [Policy Text Block]</link:label>
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MarketableSecuritiesPolicy" xlink:label="loc_us-gaap_MarketableSecuritiesPolicy_420CB89CA703CD38BA823A2EBE0F0154" xlink:type="locator" />
<link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MarketableSecuritiesPolicy_420CB89CA703CD38BA823A2EBE0F0154" xlink:to="lab_us-gaap_MarketableSecuritiesPolicy_420CB89CA703CD38BA823A2EBE0F0154" xlink:type="arc" />
<link:label id="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_F46965D912652799F2B93A2EBE0FB755_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_F46965D912652799F2B93A2EBE0FB755" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment</link:label>
<link:label id="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_F46965D912652799F2B93A2EBE0FB755_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_F46965D912652799F2B93A2EBE0FB755" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Policy [Policy Text Block]</link:label>
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_F46965D912652799F2B93A2EBE0FB755" xlink:type="locator" />
<link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_F46965D912652799F2B93A2EBE0FB755" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_F46965D912652799F2B93A2EBE0FB755" xlink:type="arc" />
<link:label id="lab_us-gaap_ConcentrationRiskCreditRisk_0F83EEA9EA9B7D15C4DB3A2EBE0F5DAC_verboseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskCreditRisk_0F83EEA9EA9B7D15C4DB3A2EBE0F5DAC" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Concentration of Credit Risk</link:label>
<link:label id="lab_us-gaap_ConcentrationRiskCreditRisk_0F83EEA9EA9B7D15C4DB3A2EBE0F5DAC_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskCreditRisk_0F83EEA9EA9B7D15C4DB3A2EBE0F5DAC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Concentration Risk, Credit Risk, Policy [Policy Text Block]</link:label>
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:label="loc_us-gaap_ConcentrationRiskCreditRisk_0F83EEA9EA9B7D15C4DB3A2EBE0F5DAC" xlink:type="locator" />
<link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskCreditRisk_0F83EEA9EA9B7D15C4DB3A2EBE0F5DAC" xlink:to="lab_us-gaap_ConcentrationRiskCreditRisk_0F83EEA9EA9B7D15C4DB3A2EBE0F5DAC" xlink:type="arc" />
<link:label id="lab_us-gaap_RevenueRecognitionPolicyTextBlock_E102685B617A093024043A2EBE0FE835_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueRecognitionPolicyTextBlock_E102685B617A093024043A2EBE0FE835" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenue Recognition</link:label>
<link:label id="lab_us-gaap_RevenueRecognitionPolicyTextBlock_E102685B617A093024043A2EBE0FE835_label_en-US" xlink:label="lab_us-gaap_RevenueRecognitionPolicyTextBlock_E102685B617A093024043A2EBE0FE835" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue [Policy Text Block]</link:label>
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueRecognitionPolicyTextBlock" xlink:label="loc_us-gaap_RevenueRecognitionPolicyTextBlock_E102685B617A093024043A2EBE0FE835" xlink:type="locator" />
<link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueRecognitionPolicyTextBlock_E102685B617A093024043A2EBE0FE835" xlink:to="lab_us-gaap_RevenueRecognitionPolicyTextBlock_E102685B617A093024043A2EBE0FE835" xlink:type="arc" />
<link:label id="lab_us-gaap_ResearchAndDevelopmentExpensePolicy_F06757C1C4E534B7B6563A2EBE0F3C38_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpensePolicy_F06757C1C4E534B7B6563A2EBE0F3C38" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research and Development Costs</link:label>
<link:label id="lab_us-gaap_ResearchAndDevelopmentExpensePolicy_F06757C1C4E534B7B6563A2EBE0F3C38_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpensePolicy_F06757C1C4E534B7B6563A2EBE0F3C38" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research and Development Expense, Policy [Policy Text Block]</link:label>
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_F06757C1C4E534B7B6563A2EBE0F3C38" xlink:type="locator" />
<link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_F06757C1C4E534B7B6563A2EBE0F3C38" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpensePolicy_F06757C1C4E534B7B6563A2EBE0F3C38" xlink:type="arc" />
<link:label id="lab_immu_TreasuryStockPolicyPolicyTextBlock_62A31D67BD7E3C2BAA913A2EBE0FA3B9_terseLabel_en-US" xlink:label="lab_immu_TreasuryStockPolicyPolicyTextBlock_62A31D67BD7E3C2BAA913A2EBE0FA3B9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Treasury Shares</link:label>
<link:label id="lab_immu_TreasuryStockPolicyPolicyTextBlock_62A31D67BD7E3C2BAA913A2EBE0FA3B9_label_en-US" xlink:label="lab_immu_TreasuryStockPolicyPolicyTextBlock_62A31D67BD7E3C2BAA913A2EBE0FA3B9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Treasury Stock Policy [Policy Text Block]</link:label>
<link:label id="lab_immu_TreasuryStockPolicyPolicyTextBlock_62A31D67BD7E3C2BAA913A2EBE0FA3B9_documentation_en-US" xlink:label="lab_immu_TreasuryStockPolicyPolicyTextBlock_62A31D67BD7E3C2BAA913A2EBE0FA3B9" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Treasury Stock Policy [Policy Text Block]</link:label>
<link:loc xlink:href="immu-20191231.xsd#immu_TreasuryStockPolicyPolicyTextBlock" xlink:label="loc_immu_TreasuryStockPolicyPolicyTextBlock_62A31D67BD7E3C2BAA913A2EBE0FA3B9" xlink:type="locator" />
<link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_immu_TreasuryStockPolicyPolicyTextBlock_62A31D67BD7E3C2BAA913A2EBE0FA3B9" xlink:to="lab_immu_TreasuryStockPolicyPolicyTextBlock_62A31D67BD7E3C2BAA913A2EBE0FA3B9" xlink:type="arc" />
<link:label id="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_589F113BCDA36D05B5203A2EBE10837B_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_589F113BCDA36D05B5203A2EBE10837B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value Measurements</link:label>
<link:label id="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_589F113BCDA36D05B5203A2EBE10837B_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_589F113BCDA36D05B5203A2EBE10837B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Measurement, Policy [Policy Text Block]</link:label>
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:label="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_589F113BCDA36D05B5203A2EBE10837B" xlink:type="locator" />
<link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_589F113BCDA36D05B5203A2EBE10837B" xlink:to="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_589F113BCDA36D05B5203A2EBE10837B" xlink:type="arc" />
<link:label id="lab_us-gaap_IncomeTaxPolicyTextBlock_5AC54B4911BF363396773A2EBE118C73_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxPolicyTextBlock_5AC54B4911BF363396773A2EBE118C73" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Taxes</link:label>
<link:label id="lab_us-gaap_IncomeTaxPolicyTextBlock_5AC54B4911BF363396773A2EBE118C73_label_en-US" xlink:label="lab_us-gaap_IncomeTaxPolicyTextBlock_5AC54B4911BF363396773A2EBE118C73" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax, Policy [Policy Text Block]</link:label>
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="loc_us-gaap_IncomeTaxPolicyTextBlock_5AC54B4911BF363396773A2EBE118C73" xlink:type="locator" />
<link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxPolicyTextBlock_5AC54B4911BF363396773A2EBE118C73" xlink:to="lab_us-gaap_IncomeTaxPolicyTextBlock_5AC54B4911BF363396773A2EBE118C73" xlink:type="arc" />
<link:label id="lab_us-gaap_EarningsPerSharePolicyTextBlock_6E9006570CB714335E483A2EBE117C21_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerSharePolicyTextBlock_6E9006570CB714335E483A2EBE117C21" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net Loss Per Share Allocable to Common Stockholders</link:label>
<link:label id="lab_us-gaap_EarningsPerSharePolicyTextBlock_6E9006570CB714335E483A2EBE117C21_label_en-US" xlink:label="lab_us-gaap_EarningsPerSharePolicyTextBlock_6E9006570CB714335E483A2EBE117C21" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share, Policy [Policy Text Block]</link:label>
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="loc_us-gaap_EarningsPerSharePolicyTextBlock_6E9006570CB714335E483A2EBE117C21" xlink:type="locator" />
<link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerSharePolicyTextBlock_6E9006570CB714335E483A2EBE117C21" xlink:to="lab_us-gaap_EarningsPerSharePolicyTextBlock_6E9006570CB714335E483A2EBE117C21" xlink:type="arc" />
<link:label id="lab_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_096B0092307E96714A2C3A2EBE114CD2_verboseLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_096B0092307E96714A2C3A2EBE114CD2" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Net Comprehensive Loss</link:label>
<link:label id="lab_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_096B0092307E96714A2C3A2EBE114CD2_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_096B0092307E96714A2C3A2EBE114CD2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Comprehensive Income, Policy [Policy Text Block]</link:label>
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:label="loc_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_096B0092307E96714A2C3A2EBE114CD2" xlink:type="locator" />
<link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_096B0092307E96714A2C3A2EBE114CD2" xlink:to="lab_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_096B0092307E96714A2C3A2EBE114CD2" xlink:type="arc" />
<link:label id="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_CAAD2E91275B9118DB0B3A2EBE11B1E1_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_CAAD2E91275B9118DB0B3A2EBE11B1E1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock-Based Compensation</link:label>
<link:label id="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_CAAD2E91275B9118DB0B3A2EBE11B1E1_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_CAAD2E91275B9118DB0B3A2EBE11B1E1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Payment Arrangement [Policy Text Block]</link:label>
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_CAAD2E91275B9118DB0B3A2EBE11B1E1" xlink:type="locator" />
<link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_CAAD2E91275B9118DB0B3A2EBE11B1E1" xlink:to="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_CAAD2E91275B9118DB0B3A2EBE11B1E1" xlink:type="arc" />
<link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_3436A72705E5C53A11E23A2EBE1240D3_terseLabel_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_3436A72705E5C53A11E23A2EBE1240D3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Recently Issued Accounting Pronouncements</link:label>
<link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_3436A72705E5C53A11E23A2EBE1240D3_label_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_3436A72705E5C53A11E23A2EBE1240D3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">New Accounting Pronouncements, Policy [Policy Text Block]</link:label>
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_3436A72705E5C53A11E23A2EBE1240D3" xlink:type="locator" />
<link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_3436A72705E5C53A11E23A2EBE1240D3" xlink:to="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_3436A72705E5C53A11E23A2EBE1240D3" xlink:type="arc" />
<link:label id="lab_immu_FairValueForLiabilityRelatedtoSaleofFutureRoyalties_0EC8EEEFE6F416932FCBDC8C25261090_terseLabel_en-US" xlink:label="lab_immu_FairValueForLiabilityRelatedtoSaleofFutureRoyalties_0EC8EEEFE6F416932FCBDC8C25261090" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Liability related to sale of future royalties</link:label>
<link:loc xlink:href="immu-20191231.xsd#immu_FairValueForLiabilityRelatedtoSaleofFutureRoyalties" xlink:label="loc_immu_FairValueForLiabilityRelatedtoSaleofFutureRoyalties_0EC8EEEFE6F416932FCBDC8C25261090" xlink:type="locator" />
<link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_immu_FairValueForLiabilityRelatedtoSaleofFutureRoyalties_0EC8EEEFE6F416932FCBDC8C25261090" xlink:to="lab_immu_FairValueForLiabilityRelatedtoSaleofFutureRoyalties_0EC8EEEFE6F416932FCBDC8C25261090" xlink:type="arc" />
<link:label id="lab_us-gaap_CommonStockValue_F81EB7A42FE090241B6FDC8C252617E2_verboseLabel_en-US" xlink:label="lab_us-gaap_CommonStockValue_F81EB7A42FE090241B6FDC8C252617E2" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Common stock</link:label>
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaap_CommonStockValue_F81EB7A42FE090241B6FDC8C252617E2" xlink:type="locator" />
<link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockValue_F81EB7A42FE090241B6FDC8C252617E2" xlink:to="lab_us-gaap_CommonStockValue_F81EB7A42FE090241B6FDC8C252617E2" xlink:type="arc" />
<link:label id="lab_immu_RoyaltyPurchaseAgreementArrangementsConsideration_49946F7D07095DFDDD82DC8C25271750_terseLabel_en-US" xlink:label="lab_immu_RoyaltyPurchaseAgreementArrangementsConsideration_49946F7D07095DFDDD82DC8C25271750" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Royalty purchase agreement arrangements consideration</link:label>
<link:label id="lab_immu_RoyaltyPurchaseAgreementArrangementsConsideration_49946F7D07095DFDDD82DC8C25271750_label_en-US" xlink:label="lab_immu_RoyaltyPurchaseAgreementArrangementsConsideration_49946F7D07095DFDDD82DC8C25271750" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Royalty Purchase Agreement Arrangements Consideration</link:label>
<link:label id="lab_immu_RoyaltyPurchaseAgreementArrangementsConsideration_49946F7D07095DFDDD82DC8C25271750_documentation_en-US" xlink:label="lab_immu_RoyaltyPurchaseAgreementArrangementsConsideration_49946F7D07095DFDDD82DC8C25271750" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Royalty Purchase Agreement Arrangements Consideration</link:label>
<link:loc xlink:href="immu-20191231.xsd#immu_RoyaltyPurchaseAgreementArrangementsConsideration" xlink:label="loc_immu_RoyaltyPurchaseAgreementArrangementsConsideration_49946F7D07095DFDDD82DC8C25271750" xlink:type="locator" />
<link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_immu_RoyaltyPurchaseAgreementArrangementsConsideration_49946F7D07095DFDDD82DC8C25271750" xlink:to="lab_immu_RoyaltyPurchaseAgreementArrangementsConsideration_49946F7D07095DFDDD82DC8C25271750" xlink:type="arc" />
<link:label id="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_B03B37D208FBA0EA7B9D850F4781D6E1_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_B03B37D208FBA0EA7B9D850F4781D6E1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">NOL carryforwards</link:label>
<link:label id="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_B03B37D208FBA0EA7B9D850F4781D6E1_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_B03B37D208FBA0EA7B9D850F4781D6E1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Operating Loss Carryforwards</link:label>
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_B03B37D208FBA0EA7B9D850F4781D6E1" xlink:type="locator" />
<link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_B03B37D208FBA0EA7B9D850F4781D6E1" xlink:to="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_B03B37D208FBA0EA7B9D850F4781D6E1" xlink:type="arc" />
<link:label id="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_2C7C681892C109F3D820850F47816FA3_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_2C7C681892C109F3D820850F47816FA3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research and development credits</link:label>
<link:label id="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_2C7C681892C109F3D820850F47816FA3_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_2C7C681892C109F3D820850F47816FA3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Tax Credit Carryforwards, Research</link:label>
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_2C7C681892C109F3D820850F47816FA3" xlink:type="locator" />
<link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_2C7C681892C109F3D820850F47816FA3" xlink:to="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_2C7C681892C109F3D820850F47816FA3" xlink:type="arc" />
<link:label id="lab_us-gaap_DeferredTaxAssetsDeferredIncome_1E1159C8040E498516E9850F4782AC2A_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsDeferredIncome_1E1159C8040E498516E9850F4782AC2A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Liability related to sale of future royalties</link:label>
<link:label id="lab_us-gaap_DeferredTaxAssetsDeferredIncome_1E1159C8040E498516E9850F4782AC2A_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsDeferredIncome_1E1159C8040E498516E9850F4782AC2A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Deferred Income</link:label>
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxAssetsDeferredIncome" xlink:label="loc_us-gaap_DeferredTaxAssetsDeferredIncome_1E1159C8040E498516E9850F4782AC2A" xlink:type="locator" />
<link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsDeferredIncome_1E1159C8040E498516E9850F4782AC2A" xlink:to="lab_us-gaap_DeferredTaxAssetsDeferredIncome_1E1159C8040E498516E9850F4782AC2A" xlink:type="arc" />
<link:label id="lab_immu_DeferredTaxAssetsDeferredRevenue_AE338F3CA479660BF6BC8523B2B7A602_terseLabel_en-US" xlink:label="lab_immu_DeferredTaxAssetsDeferredRevenue_AE338F3CA479660BF6BC8523B2B7A602" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred revenue</link:label>
<link:label id="lab_immu_DeferredTaxAssetsDeferredRevenue_AE338F3CA479660BF6BC8523B2B7A602_label_en-US" xlink:label="lab_immu_DeferredTaxAssetsDeferredRevenue_AE338F3CA479660BF6BC8523B2B7A602" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Deferred Revenue</link:label>
<link:label id="lab_immu_DeferredTaxAssetsDeferredRevenue_AE338F3CA479660BF6BC8523B2B7A602_documentation_en-US" xlink:label="lab_immu_DeferredTaxAssetsDeferredRevenue_AE338F3CA479660BF6BC8523B2B7A602" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Deferred Revenue</link:label>
<link:loc xlink:href="immu-20191231.xsd#immu_DeferredTaxAssetsDeferredRevenue" xlink:label="loc_immu_DeferredTaxAssetsDeferredRevenue_AE338F3CA479660BF6BC8523B2B7A602" xlink:type="locator" />
<link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_immu_DeferredTaxAssetsDeferredRevenue_AE338F3CA479660BF6BC8523B2B7A602" xlink:to="lab_immu_DeferredTaxAssetsDeferredRevenue_AE338F3CA479660BF6BC8523B2B7A602" xlink:type="arc" />
<link:label id="lab_immu_DeferredTaxAssetDisallowedInterestExpense_2AA5B510C68D23201E11850F47822E56_terseLabel_en-US" xlink:label="lab_immu_DeferredTaxAssetDisallowedInterestExpense_2AA5B510C68D23201E11850F47822E56" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disallowed interest expense</link:label>
<link:label id="lab_immu_DeferredTaxAssetDisallowedInterestExpense_2AA5B510C68D23201E11850F47822E56_label_en-US" xlink:label="lab_immu_DeferredTaxAssetDisallowedInterestExpense_2AA5B510C68D23201E11850F47822E56" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Asset, Disallowed Interest Expense</link:label>
<link:label id="lab_immu_DeferredTaxAssetDisallowedInterestExpense_2AA5B510C68D23201E11850F47822E56_documentation_en-US" xlink:label="lab_immu_DeferredTaxAssetDisallowedInterestExpense_2AA5B510C68D23201E11850F47822E56" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Deferred Tax Asset, Disallowed Interest Expense</link:label>
<link:loc xlink:href="immu-20191231.xsd#immu_DeferredTaxAssetDisallowedInterestExpense" xlink:label="loc_immu_DeferredTaxAssetDisallowedInterestExpense_2AA5B510C68D23201E11850F47822E56" xlink:type="locator" />
<link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_immu_DeferredTaxAssetDisallowedInterestExpense_2AA5B510C68D23201E11850F47822E56" xlink:to="lab_immu_DeferredTaxAssetDisallowedInterestExpense_2AA5B510C68D23201E11850F47822E56" xlink:type="arc" />
<link:label id="lab_us-gaap_DeferredTaxAssetsOther_4E1038BE974242FF3C9A850F47829CD2_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOther_4E1038BE974242FF3C9A850F47829CD2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other</link:label>
<link:label id="lab_us-gaap_DeferredTaxAssetsOther_4E1038BE974242FF3C9A850F47829CD2_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOther_4E1038BE974242FF3C9A850F47829CD2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Other</link:label>
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxAssetsOther" xlink:label="loc_us-gaap_DeferredTaxAssetsOther_4E1038BE974242FF3C9A850F47829CD2" xlink:type="locator" />
<link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsOther_4E1038BE974242FF3C9A850F47829CD2" xlink:to="lab_us-gaap_DeferredTaxAssetsOther_4E1038BE974242FF3C9A850F47829CD2" xlink:type="arc" />
<link:label id="lab_us-gaap_DeferredTaxAssetsGross_C23C24220BD35F543803850F47826162_totalLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsGross_C23C24220BD35F543803850F47826162" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total</link:label>
<link:label id="lab_us-gaap_DeferredTaxAssetsGross_C23C24220BD35F543803850F47826162_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsGross_C23C24220BD35F543803850F47826162" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Gross</link:label>
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="loc_us-gaap_DeferredTaxAssetsGross_C23C24220BD35F543803850F47826162" xlink:type="locator" />
<link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_C23C24220BD35F543803850F47826162" xlink:to="lab_us-gaap_DeferredTaxAssetsGross_C23C24220BD35F543803850F47826162" xlink:type="arc" />
<link:label id="lab_us-gaap_DeferredTaxAssetsValuationAllowance_3529FE8E2EF58B46AC95850F4783B4CE_negatedLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsValuationAllowance_3529FE8E2EF58B46AC95850F4783B4CE" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Valuation allowance</link:label>
<link:label id="lab_us-gaap_DeferredTaxAssetsValuationAllowance_3529FE8E2EF58B46AC95850F4783B4CE_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsValuationAllowance_3529FE8E2EF58B46AC95850F4783B4CE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Valuation Allowance</link:label>
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_3529FE8E2EF58B46AC95850F4783B4CE" xlink:type="locator" />
<link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsValuationAllowance_3529FE8E2EF58B46AC95850F4783B4CE" xlink:to="lab_us-gaap_DeferredTaxAssetsValuationAllowance_3529FE8E2EF58B46AC95850F4783B4CE" xlink:type="arc" />
<link:label id="lab_us-gaap_DeferredTaxAssetsNet_5B3CE593757A23F5015A850F4783E4A5_totalLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsNet_5B3CE593757A23F5015A850F4783E4A5" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net deferred assets</link:label>
<link:label id="lab_us-gaap_DeferredTaxAssetsNet_5B3CE593757A23F5015A850F4783E4A5_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsNet_5B3CE593757A23F5015A850F4783E4A5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Net of Valuation Allowance</link:label>
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="loc_us-gaap_DeferredTaxAssetsNet_5B3CE593757A23F5015A850F4783E4A5" xlink:type="locator" />
<link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsNet_5B3CE593757A23F5015A850F4783E4A5" xlink:to="lab_us-gaap_DeferredTaxAssetsNet_5B3CE593757A23F5015A850F4783E4A5" xlink:type="arc" />
<link:label id="lab_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_A150D5EF00AA47927903850F47838C72_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_A150D5EF00AA47927903850F47838C72" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Property and equipment</link:label>
<link:label id="lab_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_A150D5EF00AA47927903850F47838C72_label_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_A150D5EF00AA47927903850F47838C72" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Liabilities, Property, Plant and Equipment</link:label>
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_A150D5EF00AA47927903850F47838C72" xlink:type="locator" />
<link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_A150D5EF00AA47927903850F47838C72" xlink:to="lab_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_A150D5EF00AA47927903850F47838C72" xlink:type="arc" />
<link:label id="lab_us-gaap_DeferredTaxAssetsLiabilitiesNet_F10777736338F6FF5662850F47831F48_totalLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsLiabilitiesNet_F10777736338F6FF5662850F47831F48" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net deferred assets and liabilities</link:label>
<link:label id="lab_us-gaap_DeferredTaxAssetsLiabilitiesNet_F10777736338F6FF5662850F47831F48_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsLiabilitiesNet_F10777736338F6FF5662850F47831F48" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Net</link:label>
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:label="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_F10777736338F6FF5662850F47831F48" xlink:type="locator" />
<link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_F10777736338F6FF5662850F47831F48" xlink:to="lab_us-gaap_DeferredTaxAssetsLiabilitiesNet_F10777736338F6FF5662850F47831F48" xlink:type="arc" />
<link:label id="lab_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_98459F74CF486271CD0DDB9A474E8609_terseLabel_en-US" xlink:label="lab_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_98459F74CF486271CD0DDB9A474E8609" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]</link:label>
<link:label id="lab_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_98459F74CF486271CD0DDB9A474E8609_label_en-US" xlink:label="lab_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_98459F74CF486271CD0DDB9A474E8609" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]</link:label>
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:label="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_98459F74CF486271CD0DDB9A474E8609" xlink:type="locator" />
<link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_98459F74CF486271CD0DDB9A474E8609" xlink:to="lab_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_98459F74CF486271CD0DDB9A474E8609" xlink:type="arc" />
<link:label id="lab_us-gaap_UnrecognizedTaxBenefits_3E2AEC5BCD1644BAB11BDB9A474E305B_periodStartLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefits_3E2AEC5BCD1644BAB11BDB9A474E305B" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Balance at beginning of year</link:label>
<link:label id="lab_us-gaap_UnrecognizedTaxBenefits_3E2AEC5BCD1644BAB11BDB9A474E305B_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefits_3E2AEC5BCD1644BAB11BDB9A474E305B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Unrecognized Tax Benefits</link:label>
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits_3E2AEC5BCD1644BAB11BDB9A474E305B" xlink:type="locator" />
<link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefits_3E2AEC5BCD1644BAB11BDB9A474E305B" xlink:to="lab_us-gaap_UnrecognizedTaxBenefits_3E2AEC5BCD1644BAB11BDB9A474E305B" xlink:type="arc" />
<link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_3F96FB6751A65BBEA221DB9A47533B0C_terseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_3F96FB6751A65BBEA221DB9A47533B0C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Gross increases related to current period tax positions</link:label>
<link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_3F96FB6751A65BBEA221DB9A47533B0C_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_3F96FB6751A65BBEA221DB9A47533B0C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Unrecognized Tax Benefits, Increase Resulting from Current Period Tax Positions</link:label>
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_3F96FB6751A65BBEA221DB9A47533B0C" xlink:type="locator" />
<link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_3F96FB6751A65BBEA221DB9A47533B0C" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_3F96FB6751A65BBEA221DB9A47533B0C" xlink:type="arc" />
<link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_6D136ECA106AEBC1DD3EDB9A47533F32_terseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_6D136ECA106AEBC1DD3EDB9A47533F32" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Gross increases related to prior periods tax positions</link:label>
<link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_6D136ECA106AEBC1DD3EDB9A47533F32_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_6D136ECA106AEBC1DD3EDB9A47533F32" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Unrecognized Tax Benefits, Increase Resulting from Prior Period Tax Positions</link:label>
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_6D136ECA106AEBC1DD3EDB9A47533F32" xlink:type="locator" />
<link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_6D136ECA106AEBC1DD3EDB9A47533F32" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_6D136ECA106AEBC1DD3EDB9A47533F32" xlink:type="arc" />
<link:label id="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions_081C7496DE218F50A080DB9A475455B9_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions_081C7496DE218F50A080DB9A475455B9" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Gross decreases in tax positions</link:label>
<link:label id="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions_081C7496DE218F50A080DB9A475455B9_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions_081C7496DE218F50A080DB9A475455B9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Unrecognized Tax Benefits, Decrease Resulting from Prior Period Tax Positions</link:label>
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions_081C7496DE218F50A080DB9A475455B9" xlink:type="locator" />
<link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions_081C7496DE218F50A080DB9A475455B9" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions_081C7496DE218F50A080DB9A475455B9" xlink:type="arc" />
<link:label id="lab_us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations_E41B0A8E3FAF99BFD88DDB9A47544EAD_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations_E41B0A8E3FAF99BFD88DDB9A47544EAD" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Expiration of the statute of limitations</link:label>
<link:label id="lab_us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations_E41B0A8E3FAF99BFD88DDB9A47544EAD_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations_E41B0A8E3FAF99BFD88DDB9A47544EAD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Unrecognized Tax Benefits, Reduction Resulting from Lapse of Applicable Statute of Limitations</link:label>
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations_E41B0A8E3FAF99BFD88DDB9A47544EAD" xlink:type="locator" />
<link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations_E41B0A8E3FAF99BFD88DDB9A47544EAD" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations_E41B0A8E3FAF99BFD88DDB9A47544EAD" xlink:type="arc" />
<link:label id="lab_us-gaap_UnrecognizedTaxBenefits_D2A06F1DD2142770D619DB9A475425C3_periodEndLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefits_D2A06F1DD2142770D619DB9A475425C3" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Balance at end of year</link:label>
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits_D2A06F1DD2142770D619DB9A475425C3" xlink:type="locator" />
<link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefits_D2A06F1DD2142770D619DB9A475425C3" xlink:to="lab_us-gaap_UnrecognizedTaxBenefits_D2A06F1DD2142770D619DB9A475425C3" xlink:type="arc" />
<link:label id="lab_us-gaap_OperatingLossCarryforwardsTable_D5E2B8D5F18698CC4D0769B4D08C4BA2_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwardsTable_D5E2B8D5F18698CC4D0769B4D08C4BA2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating Loss Carryforwards [Table]</link:label>
<link:label id="lab_us-gaap_OperatingLossCarryforwardsTable_D5E2B8D5F18698CC4D0769B4D08C4BA2_label_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwardsTable_D5E2B8D5F18698CC4D0769B4D08C4BA2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Loss Carryforwards [Table]</link:label>
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLossCarryforwardsTable" xlink:label="loc_us-gaap_OperatingLossCarryforwardsTable_D5E2B8D5F18698CC4D0769B4D08C4BA2" xlink:type="locator" />
<link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable_D5E2B8D5F18698CC4D0769B4D08C4BA2" xlink:to="lab_us-gaap_OperatingLossCarryforwardsTable_D5E2B8D5F18698CC4D0769B4D08C4BA2" xlink:type="arc" />
<link:label id="lab_us-gaap_IncomeTaxAuthorityAxis_25F0DCD4BED95389B72769B4D08C2334_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityAxis_25F0DCD4BED95389B72769B4D08C2334" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Tax Authority [Axis]</link:label>
<link:label id="lab_us-gaap_IncomeTaxAuthorityAxis_25F0DCD4BED95389B72769B4D08C2334_label_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityAxis_25F0DCD4BED95389B72769B4D08C2334" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Authority [Axis]</link:label>
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis_25F0DCD4BED95389B72769B4D08C2334" xlink:type="locator" />
<link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_25F0DCD4BED95389B72769B4D08C2334" xlink:to="lab_us-gaap_IncomeTaxAuthorityAxis_25F0DCD4BED95389B72769B4D08C2334" xlink:type="arc" />
<link:label id="lab_us-gaap_IncomeTaxAuthorityDomain_5447170E9FD17BB25EA869B4D08C85F6_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityDomain_5447170E9FD17BB25EA869B4D08C85F6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Tax Authority [Domain]</link:label>
<link:label id="lab_us-gaap_IncomeTaxAuthorityDomain_5447170E9FD17BB25EA869B4D08C85F6_label_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityDomain_5447170E9FD17BB25EA869B4D08C85F6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Authority [Domain]</link:label>
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_5447170E9FD17BB25EA869B4D08C85F6" xlink:type="locator" />
<link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_5447170E9FD17BB25EA869B4D08C85F6" xlink:to="lab_us-gaap_IncomeTaxAuthorityDomain_5447170E9FD17BB25EA869B4D08C85F6" xlink:type="arc" />
<link:label id="lab_us-gaap_DomesticCountryMember_5C4F00DB7A628B796DFD69B4D08C1B77_terseLabel_en-US" xlink:label="lab_us-gaap_DomesticCountryMember_5C4F00DB7A628B796DFD69B4D08C1B77" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Domestic Tax Authority</link:label>
<link:label id="lab_us-gaap_DomesticCountryMember_5C4F00DB7A628B796DFD69B4D08C1B77_label_en-US" xlink:label="lab_us-gaap_DomesticCountryMember_5C4F00DB7A628B796DFD69B4D08C1B77" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Domestic Tax Authority [Member]</link:label>
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DomesticCountryMember" xlink:label="loc_us-gaap_DomesticCountryMember_5C4F00DB7A628B796DFD69B4D08C1B77" xlink:type="locator" />
<link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DomesticCountryMember_5C4F00DB7A628B796DFD69B4D08C1B77" xlink:to="lab_us-gaap_DomesticCountryMember_5C4F00DB7A628B796DFD69B4D08C1B77" xlink:type="arc" />
<link:label id="lab_us-gaap_StateAndLocalJurisdictionMember_E9C900CFABB8DF565C6369B4D08D7C82_terseLabel_en-US" xlink:label="lab_us-gaap_StateAndLocalJurisdictionMember_E9C900CFABB8DF565C6369B4D08D7C82" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">State and Local Jurisdiction</link:label>
<link:label id="lab_us-gaap_StateAndLocalJurisdictionMember_E9C900CFABB8DF565C6369B4D08D7C82_label_en-US" xlink:label="lab_us-gaap_StateAndLocalJurisdictionMember_E9C900CFABB8DF565C6369B4D08D7C82" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">State and Local Jurisdiction [Member]</link:label>
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="loc_us-gaap_StateAndLocalJurisdictionMember_E9C900CFABB8DF565C6369B4D08D7C82" xlink:type="locator" />
<link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StateAndLocalJurisdictionMember_E9C900CFABB8DF565C6369B4D08D7C82" xlink:to="lab_us-gaap_StateAndLocalJurisdictionMember_E9C900CFABB8DF565C6369B4D08D7C82" xlink:type="arc" />
<link:label id="lab_us-gaap_OperatingLossCarryforwardsLineItems_6D391C67D484970224E569B4D08D9F73_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwardsLineItems_6D391C67D484970224E569B4D08D9F73" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating Loss Carryforwards [Line Items]</link:label>
<link:label id="lab_us-gaap_OperatingLossCarryforwardsLineItems_6D391C67D484970224E569B4D08D9F73_label_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwardsLineItems_6D391C67D484970224E569B4D08D9F73" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Loss Carryforwards [Line Items]</link:label>
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLossCarryforwardsLineItems" xlink:label="loc_us-gaap_OperatingLossCarryforwardsLineItems_6D391C67D484970224E569B4D08D9F73" xlink:type="locator" />
<link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_6D391C67D484970224E569B4D08D9F73" xlink:to="lab_us-gaap_OperatingLossCarryforwardsLineItems_6D391C67D484970224E569B4D08D9F73" xlink:type="arc" />
<link:label id="lab_us-gaap_OperatingLossCarryforwards_B76669AD0CFD82D881ED69B4D08DFD20_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwards_B76669AD0CFD82D881ED69B4D08DFD20" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating loss carryforwards</link:label>
<link:label id="lab_us-gaap_OperatingLossCarryforwards_B76669AD0CFD82D881ED69B4D08DFD20_label_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwards_B76669AD0CFD82D881ED69B4D08DFD20" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Loss Carryforwards</link:label>
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="loc_us-gaap_OperatingLossCarryforwards_B76669AD0CFD82D881ED69B4D08DFD20" xlink:type="locator" />
<link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLossCarryforwards_B76669AD0CFD82D881ED69B4D08DFD20" xlink:to="lab_us-gaap_OperatingLossCarryforwards_B76669AD0CFD82D881ED69B4D08DFD20" xlink:type="arc" />
<link:label id="lab_us-gaap_UnrecognizedTaxBenefits_6AA7AE0201BAB005B2C869BEC0E2E51F_terseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefits_6AA7AE0201BAB005B2C869BEC0E2E51F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Unrecognized Tax Benefits</link:label>
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits_6AA7AE0201BAB005B2C869BEC0E2E51F" xlink:type="locator" />
<link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefits_6AA7AE0201BAB005B2C869BEC0E2E51F" xlink:to="lab_us-gaap_UnrecognizedTaxBenefits_6AA7AE0201BAB005B2C869BEC0E2E51F" xlink:type="arc" />
<link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_BED917FFEAEC15E7399169B4D08DEF4F_verboseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_BED917FFEAEC15E7399169B4D08DEF4F" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Reduction in deferred tax assets</link:label>
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_BED917FFEAEC15E7399169B4D08DEF4F" xlink:type="locator" />
<link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_BED917FFEAEC15E7399169B4D08DEF4F" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_BED917FFEAEC15E7399169B4D08DEF4F" xlink:type="arc" />
<link:label id="lab_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_DE2B098A3984EFCF8F5469B4D08D930B_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_DE2B098A3984EFCF8F5469B4D08D930B" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Reduction in valuation allowance</link:label>
<link:label id="lab_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_DE2B098A3984EFCF8F5469B4D08D930B_label_en-US" xlink:label="lab_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_DE2B098A3984EFCF8F5469B4D08D930B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount</link:label>
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:label="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_DE2B098A3984EFCF8F5469B4D08D930B" xlink:type="locator" />
<link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_DE2B098A3984EFCF8F5469B4D08D930B" xlink:to="lab_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_DE2B098A3984EFCF8F5469B4D08D930B" xlink:type="arc" />
<link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_91DAE56D75FD9E5EDA8069B4D08EB621_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit_91DAE56D75FD9E5EDA8069B4D08EB621" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Income tax expense (benefit)</link:label>
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_91DAE56D75FD9E5EDA8069B4D08EB621" xlink:type="locator" />
<link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_91DAE56D75FD9E5EDA8069B4D08EB621" xlink:to="lab_us-gaap_IncomeTaxExpenseBenefit_91DAE56D75FD9E5EDA8069B4D08EB621" xlink:type="arc" />
<link:label id="lab_immu_OperatingLossCarryforwardResultingFromSale_88A679BA6BEAF27902C769B4D08EEE44_terseLabel_en-US" xlink:label="lab_immu_OperatingLossCarryforwardResultingFromSale_88A679BA6BEAF27902C769B4D08EEE44" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating loss carryforward resulting from sale</link:label>
<link:label id="lab_immu_OperatingLossCarryforwardResultingFromSale_88A679BA6BEAF27902C769B4D08EEE44_label_en-US" xlink:label="lab_immu_OperatingLossCarryforwardResultingFromSale_88A679BA6BEAF27902C769B4D08EEE44" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Loss Carryforward Resulting From Sale</link:label>
<link:label id="lab_immu_OperatingLossCarryforwardResultingFromSale_88A679BA6BEAF27902C769B4D08EEE44_documentation_en-US" xlink:label="lab_immu_OperatingLossCarryforwardResultingFromSale_88A679BA6BEAF27902C769B4D08EEE44" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws that resulted from a sale of taxing authority certificate(s).</link:label>
<link:loc xlink:href="immu-20191231.xsd#immu_OperatingLossCarryforwardResultingFromSale" xlink:label="loc_immu_OperatingLossCarryforwardResultingFromSale_88A679BA6BEAF27902C769B4D08EEE44" xlink:type="locator" />
<link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_immu_OperatingLossCarryforwardResultingFromSale_88A679BA6BEAF27902C769B4D08EEE44" xlink:to="lab_immu_OperatingLossCarryforwardResultingFromSale_88A679BA6BEAF27902C769B4D08EEE44" xlink:type="arc" />
<link:label id="lab_immu_DeferredTaxAssetsTaxCreditCarryforwardsResearchAndDevelopment_143E42E1965233B4991D69B4D08EF6E7_terseLabel_en-US" xlink:label="lab_immu_DeferredTaxAssetsTaxCreditCarryforwardsResearchAndDevelopment_143E42E1965233B4991D69B4D08EF6E7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research and development tax credits</link:label>
<link:label id="lab_immu_DeferredTaxAssetsTaxCreditCarryforwardsResearchAndDevelopment_143E42E1965233B4991D69B4D08EF6E7_label_en-US" xlink:label="lab_immu_DeferredTaxAssetsTaxCreditCarryforwardsResearchAndDevelopment_143E42E1965233B4991D69B4D08EF6E7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets Tax Credit Carryforwards Research And Development.</link:label>
<link:label id="lab_immu_DeferredTaxAssetsTaxCreditCarryforwardsResearchAndDevelopment_143E42E1965233B4991D69B4D08EF6E7_documentation_en-US" xlink:label="lab_immu_DeferredTaxAssetsTaxCreditCarryforwardsResearchAndDevelopment_143E42E1965233B4991D69B4D08EF6E7" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Amount before allocation of valuation allowances of deferred tax asset attributable to deductible research tax credit carryforwards resulting from a sale of taxing authority certificate(s).</link:label>
<link:loc xlink:href="immu-20191231.xsd#immu_DeferredTaxAssetsTaxCreditCarryforwardsResearchAndDevelopment" xlink:label="loc_immu_DeferredTaxAssetsTaxCreditCarryforwardsResearchAndDevelopment_143E42E1965233B4991D69B4D08EF6E7" xlink:type="locator" />
<link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_immu_DeferredTaxAssetsTaxCreditCarryforwardsResearchAndDevelopment_143E42E1965233B4991D69B4D08EF6E7" xlink:to="lab_immu_DeferredTaxAssetsTaxCreditCarryforwardsResearchAndDevelopment_143E42E1965233B4991D69B4D08EF6E7" xlink:type="arc" />
<link:label id="lab_us-gaap_UndistributedEarningsOfForeignSubsidiaries_E7C1E10D3C9DB8C5A65269B4D08E42F0_terseLabel_en-US" xlink:label="lab_us-gaap_UndistributedEarningsOfForeignSubsidiaries_E7C1E10D3C9DB8C5A65269B4D08E42F0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Undistributed earnings of foreign subsidiaries</link:label>
<link:label id="lab_us-gaap_UndistributedEarningsOfForeignSubsidiaries_E7C1E10D3C9DB8C5A65269B4D08E42F0_label_en-US" xlink:label="lab_us-gaap_UndistributedEarningsOfForeignSubsidiaries_E7C1E10D3C9DB8C5A65269B4D08E42F0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Undistributed Earnings of Foreign Subsidiaries</link:label>
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_UndistributedEarningsOfForeignSubsidiaries" xlink:label="loc_us-gaap_UndistributedEarningsOfForeignSubsidiaries_E7C1E10D3C9DB8C5A65269B4D08E42F0" xlink:type="locator" />
<link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UndistributedEarningsOfForeignSubsidiaries_E7C1E10D3C9DB8C5A65269B4D08E42F0" xlink:to="lab_us-gaap_UndistributedEarningsOfForeignSubsidiaries_E7C1E10D3C9DB8C5A65269B4D08E42F0" xlink:type="arc" />
<link:label id="lab_us-gaap_TaxCutsAndJobsActOf2017IncompleteAccountingProvisionalIncomeTaxExpenseBenefit_03817D2788B72BDC290169B4D08E4F10_terseLabel_en-US" xlink:label="lab_us-gaap_TaxCutsAndJobsActOf2017IncompleteAccountingProvisionalIncomeTaxExpenseBenefit_03817D2788B72BDC290169B4D08E4F10" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Provisional expense</link:label>
<link:label id="lab_us-gaap_TaxCutsAndJobsActOf2017IncompleteAccountingProvisionalIncomeTaxExpenseBenefit_03817D2788B72BDC290169B4D08E4F10_label_en-US" xlink:label="lab_us-gaap_TaxCutsAndJobsActOf2017IncompleteAccountingProvisionalIncomeTaxExpenseBenefit_03817D2788B72BDC290169B4D08E4F10" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Tax Cuts and Jobs Act, Incomplete Accounting, Provisional Income Tax Expense (Benefit)</link:label>
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TaxCutsAndJobsActOf2017IncompleteAccountingProvisionalIncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_TaxCutsAndJobsActOf2017IncompleteAccountingProvisionalIncomeTaxExpenseBenefit_03817D2788B72BDC290169B4D08E4F10" xlink:type="locator" />
<link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TaxCutsAndJobsActOf2017IncompleteAccountingProvisionalIncomeTaxExpenseBenefit_03817D2788B72BDC290169B4D08E4F10" xlink:to="lab_us-gaap_TaxCutsAndJobsActOf2017IncompleteAccountingProvisionalIncomeTaxExpenseBenefit_03817D2788B72BDC290169B4D08E4F10" xlink:type="arc" />
</link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>14
<FILENAME>immu-20191231_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!--XBRL Document Created with Wdesk from Workiva-->
<!-- -->
<link:linkbase xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<link:roleRef roleURI="http://www.immunomedics.com/role/AccountsPayableAndAccruedExpenses" xlink:href="immu-20191231.xsd#AccountsPayableAndAccruedExpenses" xlink:type="simple" />
<link:roleRef roleURI="http://www.immunomedics.com/role/AccountsPayableAndAccruedExpensesDetails" xlink:href="immu-20191231.xsd#AccountsPayableAndAccruedExpensesDetails" xlink:type="simple" />
<link:roleRef roleURI="http://www.immunomedics.com/role/AccountsPayableAndAccruedExpensesTables" xlink:href="immu-20191231.xsd#AccountsPayableAndAccruedExpensesTables" xlink:type="simple" />
<link:roleRef roleURI="http://www.immunomedics.com/role/AccumulatedOtherComprehensiveLossIncome" xlink:href="immu-20191231.xsd#AccumulatedOtherComprehensiveLossIncome" xlink:type="simple" />
<link:roleRef roleURI="http://www.immunomedics.com/role/AccumulatedOtherComprehensiveLossIncomeDetails" xlink:href="immu-20191231.xsd#AccumulatedOtherComprehensiveLossIncomeDetails" xlink:type="simple" />
<link:roleRef roleURI="http://www.immunomedics.com/role/AccumulatedOtherComprehensiveLossIncomeTables" xlink:href="immu-20191231.xsd#AccumulatedOtherComprehensiveLossIncomeTables" xlink:type="simple" />
<link:roleRef roleURI="http://www.immunomedics.com/role/BusinessOverviewAndSummaryOfSignificantAccountingPolices" xlink:href="immu-20191231.xsd#BusinessOverviewAndSummaryOfSignificantAccountingPolices" xlink:type="simple" />
<link:roleRef roleURI="http://www.immunomedics.com/role/BusinessOverviewAndSummaryOfSignificantAccountingPolicesRecentAccountingPronouncementsDetails" xlink:href="immu-20191231.xsd#BusinessOverviewAndSummaryOfSignificantAccountingPolicesRecentAccountingPronouncementsDetails" xlink:type="simple" />
<link:roleRef roleURI="http://www.immunomedics.com/role/BusinessOverviewSummaryOfSignificantAccountingPolicesPolicies" xlink:href="immu-20191231.xsd#BusinessOverviewSummaryOfSignificantAccountingPolicesPolicies" xlink:type="simple" />
<link:roleRef roleURI="http://www.immunomedics.com/role/CollaborationAgreements" xlink:href="immu-20191231.xsd#CollaborationAgreements" xlink:type="simple" />
<link:roleRef roleURI="http://www.immunomedics.com/role/CollaborationAgreementsDetails" xlink:href="immu-20191231.xsd#CollaborationAgreementsDetails" xlink:type="simple" />
<link:roleRef roleURI="http://www.immunomedics.com/role/CommitmentsAndContingencies" xlink:href="immu-20191231.xsd#CommitmentsAndContingencies" xlink:type="simple" />
<link:roleRef roleURI="http://www.immunomedics.com/role/CommitmentsAndContingenciesMaturitiesOfLeaseLiabilitiesDetails" xlink:href="immu-20191231.xsd#CommitmentsAndContingenciesMaturitiesOfLeaseLiabilitiesDetails" xlink:type="simple" />
<link:roleRef roleURI="http://www.immunomedics.com/role/CommitmentsAndContingenciesNarrativeDetails" xlink:href="immu-20191231.xsd#CommitmentsAndContingenciesNarrativeDetails" xlink:type="simple" />
<link:roleRef roleURI="http://www.immunomedics.com/role/CommitmentsAndContingenciesSupplementalConsolidatedBalanceSheetInformationRelatedToLeasesDetails" xlink:href="immu-20191231.xsd#CommitmentsAndContingenciesSupplementalConsolidatedBalanceSheetInformationRelatedToLeasesDetails" xlink:type="simple" />
<link:roleRef roleURI="http://www.immunomedics.com/role/CommitmentsAndContingenciesTables" xlink:href="immu-20191231.xsd#CommitmentsAndContingenciesTables" xlink:type="simple" />
<link:roleRef roleURI="http://www.immunomedics.com/role/ConsolidatedBalanceSheets" xlink:href="immu-20191231.xsd#ConsolidatedBalanceSheets" xlink:type="simple" />
<link:roleRef roleURI="http://www.immunomedics.com/role/ConsolidatedBalanceSheetsParenthetical" xlink:href="immu-20191231.xsd#ConsolidatedBalanceSheetsParenthetical" xlink:type="simple" />
<link:roleRef roleURI="http://www.immunomedics.com/role/ConsolidatedStatementsOfCashFlows" xlink:href="immu-20191231.xsd#ConsolidatedStatementsOfCashFlows" xlink:type="simple" />
<link:roleRef roleURI="http://www.immunomedics.com/role/ConsolidatedStatementsOfChangesInStockholdersEquity" xlink:href="immu-20191231.xsd#ConsolidatedStatementsOfChangesInStockholdersEquity" xlink:type="simple" />
<link:roleRef roleURI="http://www.immunomedics.com/role/ConsolidatedStatementsOfComprehensiveLoss" xlink:href="immu-20191231.xsd#ConsolidatedStatementsOfComprehensiveLoss" xlink:type="simple" />
<link:roleRef roleURI="http://www.immunomedics.com/role/CoverPage" xlink:href="immu-20191231.xsd#CoverPage" xlink:type="simple" />
<link:roleRef roleURI="http://www.immunomedics.com/role/Debt" xlink:href="immu-20191231.xsd#Debt" xlink:type="simple" />
<link:roleRef roleURI="http://www.immunomedics.com/role/DebtConsiderationAllocationDetails" xlink:href="immu-20191231.xsd#DebtConsiderationAllocationDetails" xlink:type="simple" />
<link:roleRef roleURI="http://www.immunomedics.com/role/DebtConvertibleSeniorNotesDetails" xlink:href="immu-20191231.xsd#DebtConvertibleSeniorNotesDetails" xlink:type="simple" />
<link:roleRef roleURI="http://www.immunomedics.com/role/DebtLiabilityRelatedToSaleOfFutureRoyaltiesDetails" xlink:href="immu-20191231.xsd#DebtLiabilityRelatedToSaleOfFutureRoyaltiesDetails" xlink:type="simple" />
<link:roleRef roleURI="http://www.immunomedics.com/role/DebtScheduleOfLiabilityRelatedToSaleOfFutureRoyaltiesDetails" xlink:href="immu-20191231.xsd#DebtScheduleOfLiabilityRelatedToSaleOfFutureRoyaltiesDetails" xlink:type="simple" />
<link:roleRef roleURI="http://www.immunomedics.com/role/DebtTables" xlink:href="immu-20191231.xsd#DebtTables" xlink:type="simple" />
<link:roleRef roleURI="http://www.immunomedics.com/role/DefinedContributionPlans" xlink:href="immu-20191231.xsd#DefinedContributionPlans" xlink:type="simple" />
<link:roleRef roleURI="http://www.immunomedics.com/role/DefinedContributionPlansDetails" xlink:href="immu-20191231.xsd#DefinedContributionPlansDetails" xlink:type="simple" />
<link:roleRef roleURI="http://www.immunomedics.com/role/EstimatedFairValueOfFinancialInstruments" xlink:href="immu-20191231.xsd#EstimatedFairValueOfFinancialInstruments" xlink:type="simple" />
<link:roleRef roleURI="http://www.immunomedics.com/role/EstimatedFairValueOfFinancialInstrumentsDebtInstrumentsDetails" xlink:href="immu-20191231.xsd#EstimatedFairValueOfFinancialInstrumentsDebtInstrumentsDetails" xlink:type="simple" />
<link:roleRef roleURI="http://www.immunomedics.com/role/EstimatedFairValueOfFinancialInstrumentsNarrativeDetails" xlink:href="immu-20191231.xsd#EstimatedFairValueOfFinancialInstrumentsNarrativeDetails" xlink:type="simple" />
<link:roleRef roleURI="http://www.immunomedics.com/role/EstimatedFairValueOfFinancialInstrumentsTables" xlink:href="immu-20191231.xsd#EstimatedFairValueOfFinancialInstrumentsTables" xlink:type="simple" />
<link:roleRef roleURI="http://www.immunomedics.com/role/IncomeTaxes" xlink:href="immu-20191231.xsd#IncomeTaxes" xlink:type="simple" />
<link:roleRef roleURI="http://www.immunomedics.com/role/IncomeTaxesChangeInUnrecognizedTaxBenefitsDetails" xlink:href="immu-20191231.xsd#IncomeTaxesChangeInUnrecognizedTaxBenefitsDetails" xlink:type="simple" />
<link:roleRef roleURI="http://www.immunomedics.com/role/IncomeTaxesExpenseBenefitFromIncomeTaxesDetails" xlink:href="immu-20191231.xsd#IncomeTaxesExpenseBenefitFromIncomeTaxesDetails" xlink:type="simple" />
<link:roleRef roleURI="http://www.immunomedics.com/role/IncomeTaxesNarrativeDetails" xlink:href="immu-20191231.xsd#IncomeTaxesNarrativeDetails" xlink:type="simple" />
<link:roleRef roleURI="http://www.immunomedics.com/role/IncomeTaxesReconciliationOfStatutoryTaxRatesAndEffectiveTaxRatesDetails" xlink:href="immu-20191231.xsd#IncomeTaxesReconciliationOfStatutoryTaxRatesAndEffectiveTaxRatesDetails" xlink:type="simple" />
<link:roleRef roleURI="http://www.immunomedics.com/role/IncomeTaxesTables" xlink:href="immu-20191231.xsd#IncomeTaxesTables" xlink:type="simple" />
<link:roleRef roleURI="http://www.immunomedics.com/role/IncomeTaxesTaxEffectsOfTemporaryDifferencesInDeferredTaxAssetsDetails" xlink:href="immu-20191231.xsd#IncomeTaxesTaxEffectsOfTemporaryDifferencesInDeferredTaxAssetsDetails" xlink:type="simple" />
<link:roleRef roleURI="http://www.immunomedics.com/role/MarketableSecurities" xlink:href="immu-20191231.xsd#MarketableSecurities" xlink:type="simple" />
<link:roleRef roleURI="http://www.immunomedics.com/role/MarketableSecuritiesAmortizedCostToFairValueDetails" xlink:href="immu-20191231.xsd#MarketableSecuritiesAmortizedCostToFairValueDetails" xlink:type="simple" />
<link:roleRef roleURI="http://www.immunomedics.com/role/MarketableSecuritiesTables" xlink:href="immu-20191231.xsd#MarketableSecuritiesTables" xlink:type="simple" />
<link:roleRef roleURI="http://www.immunomedics.com/role/PropertyAndEquipment" xlink:href="immu-20191231.xsd#PropertyAndEquipment" xlink:type="simple" />
<link:roleRef roleURI="http://www.immunomedics.com/role/PropertyAndEquipmentAdditionalInformationDetails" xlink:href="immu-20191231.xsd#PropertyAndEquipmentAdditionalInformationDetails" xlink:type="simple" />
<link:roleRef roleURI="http://www.immunomedics.com/role/PropertyAndEquipmentSchedulesOfPropertyAndEquipmentDetails" xlink:href="immu-20191231.xsd#PropertyAndEquipmentSchedulesOfPropertyAndEquipmentDetails" xlink:type="simple" />
<link:roleRef roleURI="http://www.immunomedics.com/role/PropertyAndEquipmentTables" xlink:href="immu-20191231.xsd#PropertyAndEquipmentTables" xlink:type="simple" />
<link:roleRef roleURI="http://www.immunomedics.com/role/QuarterlyResultsOfOperationsDetails" xlink:href="immu-20191231.xsd#QuarterlyResultsOfOperationsDetails" xlink:type="simple" />
<link:roleRef roleURI="http://www.immunomedics.com/role/QuarterlyResultsOfOperationsTables" xlink:href="immu-20191231.xsd#QuarterlyResultsOfOperationsTables" xlink:type="simple" />
<link:roleRef roleURI="http://www.immunomedics.com/role/QuarterlyResultsOfOperationsUnaudited" xlink:href="immu-20191231.xsd#QuarterlyResultsOfOperationsUnaudited" xlink:type="simple" />
<link:roleRef roleURI="http://www.immunomedics.com/role/RelatedPartyTransactions" xlink:href="immu-20191231.xsd#RelatedPartyTransactions" xlink:type="simple" />
<link:roleRef roleURI="http://www.immunomedics.com/role/RelatedPartyTransactionsDetails" xlink:href="immu-20191231.xsd#RelatedPartyTransactionsDetails" xlink:type="simple" />
<link:roleRef roleURI="http://www.immunomedics.com/role/RevenueRecognition" xlink:href="immu-20191231.xsd#RevenueRecognition" xlink:type="simple" />
<link:roleRef roleURI="http://www.immunomedics.com/role/RevenueRecognitionAdditionalInformationDetails" xlink:href="immu-20191231.xsd#RevenueRecognitionAdditionalInformationDetails" xlink:type="simple" />
<link:roleRef roleURI="http://www.immunomedics.com/role/RevenueRecognitionPerformanceObligationDetails" xlink:href="immu-20191231.xsd#RevenueRecognitionPerformanceObligationDetails" xlink:type="simple" />
<link:roleRef roleURI="http://www.immunomedics.com/role/StockBasedCompensation" xlink:href="immu-20191231.xsd#StockBasedCompensation" xlink:type="simple" />
<link:roleRef roleURI="http://www.immunomedics.com/role/StockBasedCompensationFairValueAssumptionsDetails" xlink:href="immu-20191231.xsd#StockBasedCompensationFairValueAssumptionsDetails" xlink:type="simple" />
<link:roleRef roleURI="http://www.immunomedics.com/role/StockBasedCompensationNarrativeDetails" xlink:href="immu-20191231.xsd#StockBasedCompensationNarrativeDetails" xlink:type="simple" />
<link:roleRef roleURI="http://www.immunomedics.com/role/StockBasedCompensationRestrictedStockUnitActivityDetails" xlink:href="immu-20191231.xsd#StockBasedCompensationRestrictedStockUnitActivityDetails" xlink:type="simple" />
<link:roleRef roleURI="http://www.immunomedics.com/role/StockBasedCompensationStockIncentivePlanDetails" xlink:href="immu-20191231.xsd#StockBasedCompensationStockIncentivePlanDetails" xlink:type="simple" />
<link:roleRef roleURI="http://www.immunomedics.com/role/StockBasedCompensationStockOptionActivityDetails" xlink:href="immu-20191231.xsd#StockBasedCompensationStockOptionActivityDetails" xlink:type="simple" />
<link:roleRef roleURI="http://www.immunomedics.com/role/StockBasedCompensationTables" xlink:href="immu-20191231.xsd#StockBasedCompensationTables" xlink:type="simple" />
<link:roleRef roleURI="http://www.immunomedics.com/role/StockholdersEquity" xlink:href="immu-20191231.xsd#StockholdersEquity" xlink:type="simple" />
<link:roleRef roleURI="http://www.immunomedics.com/role/StockholdersEquityDetails" xlink:href="immu-20191231.xsd#StockholdersEquityDetails" xlink:type="simple" />
<link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" xlink:type="simple" />
<link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" xlink:type="simple" />
<link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" xlink:type="simple" />
<link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" xlink:type="simple" />
<link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" xlink:type="simple" />
<link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" xlink:type="simple" />
<link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" xlink:type="simple" />
<link:presentationLink xlink:role="http://www.immunomedics.com/role/AccountsPayableAndAccruedExpenses" xlink:type="extended">
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract_BB91CC3FD9426303BF82D1D06182F210" xlink:type="locator" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_24A271CDE8E188AEBFA0D1D06182E401" xlink:type="locator" />
<link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_BB91CC3FD9426303BF82D1D06182F210" xlink:to="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_24A271CDE8E188AEBFA0D1D06182E401" xlink:type="arc" />
</link:presentationLink>
<link:presentationLink xlink:role="http://www.immunomedics.com/role/AccountsPayableAndAccruedExpensesDetails" xlink:type="extended">
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract_E9433B67642CC6FE5A975EE4648722E4" xlink:type="locator" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountsPayableTradeCurrent" xlink:label="loc_us-gaap_AccountsPayableTradeCurrent_668E763C5D6A2A4FD5BF5EE4648775DD" xlink:type="locator" />
<link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_E9433B67642CC6FE5A975EE4648722E4" xlink:to="loc_us-gaap_AccountsPayableTradeCurrent_668E763C5D6A2A4FD5BF5EE4648775DD" xlink:type="arc" />
<link:loc xlink:href="immu-20191231.xsd#immu_AccruedContractManufacturingExpenses" xlink:label="loc_immu_AccruedContractManufacturingExpenses_C121B89B9BCD95FDA0F45EEE23F06A43" xlink:type="locator" />
<link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_E9433B67642CC6FE5A975EE4648722E4" xlink:to="loc_immu_AccruedContractManufacturingExpenses_C121B89B9BCD95FDA0F45EEE23F06A43" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_D0927ACC8EAC66FC18715EEF16E55B5F" xlink:type="locator" />
<link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_E9433B67642CC6FE5A975EE4648722E4" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_D0927ACC8EAC66FC18715EEF16E55B5F" xlink:type="arc" />
<link:loc xlink:href="immu-20191231.xsd#immu_ClinicalTrials" xlink:label="loc_immu_ClinicalTrials_C29B6826CEFAB93305555EE464881878" xlink:type="locator" />
<link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_E9433B67642CC6FE5A975EE4648722E4" xlink:to="loc_immu_ClinicalTrials_C29B6826CEFAB93305555EE464881878" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SupplementalUnemploymentBenefitsSeveranceBenefits" xlink:label="loc_us-gaap_SupplementalUnemploymentBenefitsSeveranceBenefits_C880EA6F77ADC92346475EE464885A42" xlink:type="locator" />
<link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_E9433B67642CC6FE5A975EE4648722E4" xlink:to="loc_us-gaap_SupplementalUnemploymentBenefitsSeveranceBenefits_C880EA6F77ADC92346475EE464885A42" xlink:type="arc" />
<link:loc xlink:href="immu-20191231.xsd#immu_OtherCurrentLiabilities" xlink:label="loc_immu_OtherCurrentLiabilities_3004943FD3FE5D272C625EE46488415B" xlink:type="locator" />
<link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_E9433B67642CC6FE5A975EE4648722E4" xlink:to="loc_immu_OtherCurrentLiabilities_3004943FD3FE5D272C625EE46488415B" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_21B5C0994C51007861A55EE46488FCE9" xlink:type="locator" />
<link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_E9433B67642CC6FE5A975EE4648722E4" xlink:to="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_21B5C0994C51007861A55EE46488FCE9" xlink:type="arc" />
</link:presentationLink>
<link:presentationLink xlink:role="http://www.immunomedics.com/role/AccountsPayableAndAccruedExpensesTables" xlink:type="extended">
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract_5E30EE8E8EB3668006CAD1D0626DBE3E" xlink:type="locator" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_1DE9EE52BD7CCB6AD4C4D1D0626D59BB" xlink:type="locator" />
<link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_5E30EE8E8EB3668006CAD1D0626DBE3E" xlink:to="loc_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_1DE9EE52BD7CCB6AD4C4D1D0626D59BB" xlink:type="arc" />
</link:presentationLink>
<link:presentationLink xlink:role="http://www.immunomedics.com/role/AccumulatedOtherComprehensiveLossIncome" xlink:type="extended">
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaap_EquityAbstract_035FD1494609B3B22FC8D1D06163C672" xlink:type="locator" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ComprehensiveIncomeNoteTextBlock" xlink:label="loc_us-gaap_ComprehensiveIncomeNoteTextBlock_F0C99087DFD7FB14F13AD1D0616384FD" xlink:type="locator" />
<link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_035FD1494609B3B22FC8D1D06163C672" xlink:to="loc_us-gaap_ComprehensiveIncomeNoteTextBlock_F0C99087DFD7FB14F13AD1D0616384FD" xlink:type="arc" />
</link:presentationLink>
<link:presentationLink xlink:role="http://www.immunomedics.com/role/AccumulatedOtherComprehensiveLossIncomeDetails" xlink:type="extended">
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaap_EquityAbstract_82EA01FDD18D9CF8711E3991D1CF3D05" xlink:type="locator" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_3BBAC288AE6ECCDEE78C3991D1D033F7" xlink:type="locator" />
<link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_82EA01FDD18D9CF8711E3991D1CF3D05" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_3BBAC288AE6ECCDEE78C3991D1D033F7" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_8F4A9C99B2BD2E75E4673991D1D093C3" xlink:type="locator" />
<link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_3BBAC288AE6ECCDEE78C3991D1D033F7" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_8F4A9C99B2BD2E75E4673991D1D093C3" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_A65AA8620ED49C60D7BC3991D1D07596" xlink:type="locator" />
<link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_8F4A9C99B2BD2E75E4673991D1D093C3" xlink:to="loc_us-gaap_EquityComponentDomain_A65AA8620ED49C60D7BC3991D1D07596" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedTranslationAdjustmentMember" xlink:label="loc_us-gaap_AccumulatedTranslationAdjustmentMember_6EDCE1B68C010B705DE93991D1D039F6" xlink:type="locator" />
<link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_A65AA8620ED49C60D7BC3991D1D07596" xlink:to="loc_us-gaap_AccumulatedTranslationAdjustmentMember_6EDCE1B68C010B705DE93991D1D039F6" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember" xlink:label="loc_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_FF154B1687E35F422C613991D1D12A2D" xlink:type="locator" />
<link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_A65AA8620ED49C60D7BC3991D1D07596" xlink:to="loc_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_FF154B1687E35F422C613991D1D12A2D" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_84072F3D901B8B44D7A03991D1D17A05" xlink:type="locator" />
<link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_A65AA8620ED49C60D7BC3991D1D07596" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_84072F3D901B8B44D7A03991D1D17A05" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_505398F0237C88D0B7053991D1D137BA" xlink:type="locator" />
<link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_3BBAC288AE6ECCDEE78C3991D1D033F7" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_505398F0237C88D0B7053991D1D137BA" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AOCIAttributableToParentNetOfTaxRollForward" xlink:label="loc_us-gaap_AOCIAttributableToParentNetOfTaxRollForward_4B0B813418EB2CF10C613991D1D1B1B4" xlink:type="locator" />
<link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_505398F0237C88D0B7053991D1D137BA" xlink:to="loc_us-gaap_AOCIAttributableToParentNetOfTaxRollForward_4B0B813418EB2CF10C613991D1D1B1B4" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_A125CCF656771326A2323991D1D1DDAF" xlink:type="locator" />
<link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AOCIAttributableToParentNetOfTaxRollForward_4B0B813418EB2CF10C613991D1D1B1B4" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_A125CCF656771326A2323991D1D1DDAF" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax_8A5CC61054E0837D25143A207EFC16F3" xlink:type="locator" />
<link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AOCIAttributableToParentNetOfTaxRollForward_4B0B813418EB2CF10C613991D1D1B1B4" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax_8A5CC61054E0837D25143A207EFC16F3" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" xlink:label="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax_9E8518171A73EB4F66A63991D1D255A5" xlink:type="locator" />
<link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" priority="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AOCIAttributableToParentNetOfTaxRollForward_4B0B813418EB2CF10C613991D1D1B1B4" xlink:to="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax_9E8518171A73EB4F66A63991D1D255A5" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_6060EB093112DB3DA5573991D1D2EC4F" xlink:type="locator" />
<link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AOCIAttributableToParentNetOfTaxRollForward_4B0B813418EB2CF10C613991D1D1B1B4" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_6060EB093112DB3DA5573991D1D2EC4F" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_44608B402CDDE63951473991D1D258EB" xlink:type="locator" />
<link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AOCIAttributableToParentNetOfTaxRollForward_4B0B813418EB2CF10C613991D1D1B1B4" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_44608B402CDDE63951473991D1D258EB" xlink:type="arc" />
</link:presentationLink>
<link:presentationLink xlink:role="http://www.immunomedics.com/role/AccumulatedOtherComprehensiveLossIncomeTables" xlink:type="extended">
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaap_EquityAbstract_601EEE2BF86EB374D9F5D1D061630847" xlink:type="locator" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock_A3883F57DB3E1F343E97D1D06163F6C8" xlink:type="locator" />
<link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_601EEE2BF86EB374D9F5D1D061630847" xlink:to="loc_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock_A3883F57DB3E1F343E97D1D06163F6C8" xlink:type="arc" />
</link:presentationLink>
<link:presentationLink xlink:role="http://www.immunomedics.com/role/BusinessOverviewAndSummaryOfSignificantAccountingPolices" xlink:type="extended">
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_54EEC937D1794AD0873E3991D2B165BA" xlink:type="locator" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:label="loc_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_8A84B25C219DEE0C75A53991D2B1E743" xlink:type="locator" />
<link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_54EEC937D1794AD0873E3991D2B165BA" xlink:to="loc_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_8A84B25C219DEE0C75A53991D2B1E743" xlink:type="arc" />
</link:presentationLink>
<link:presentationLink xlink:role="http://www.immunomedics.com/role/BusinessOverviewAndSummaryOfSignificantAccountingPolicesRecentAccountingPronouncementsDetails" xlink:type="extended">
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_9063E597FE9A01F343645EDE152C93BE" xlink:type="locator" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeLeaseDescriptionTable" xlink:label="loc_us-gaap_LesseeLeaseDescriptionTable_17BF163483C2B2821FAA5EDE152E7FC6" xlink:type="locator" />
<link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_9063E597FE9A01F343645EDE152C93BE" xlink:to="loc_us-gaap_LesseeLeaseDescriptionTable_17BF163483C2B2821FAA5EDE152E7FC6" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_5F6744B6A7FFB94AFF245EDE152F1776" xlink:type="locator" />
<link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_17BF163483C2B2821FAA5EDE152E7FC6" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_5F6744B6A7FFB94AFF245EDE152F1776" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_1E0814C45C37E775B45C5EDE152FD575" xlink:type="locator" />
<link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_5F6744B6A7FFB94AFF245EDE152F1776" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_1E0814C45C37E775B45C5EDE152FD575" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="loc_us-gaap_LeaseholdImprovementsMember_A7190697615A690D6D285EDE152FDC79" xlink:type="locator" />
<link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_1E0814C45C37E775B45C5EDE152FD575" xlink:to="loc_us-gaap_LeaseholdImprovementsMember_A7190697615A690D6D285EDE152FDC79" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ComputerEquipmentMember" xlink:label="loc_us-gaap_ComputerEquipmentMember_7D14B48447A448395C1F5EDE1530698B" xlink:type="locator" />
<link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_1E0814C45C37E775B45C5EDE152FD575" xlink:to="loc_us-gaap_ComputerEquipmentMember_7D14B48447A448395C1F5EDE1530698B" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MachineryAndEquipmentMember" xlink:label="loc_us-gaap_MachineryAndEquipmentMember_3026492A25C588D58E395EDE1530464F" xlink:type="locator" />
<link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_1E0814C45C37E775B45C5EDE152FD575" xlink:to="loc_us-gaap_MachineryAndEquipmentMember_3026492A25C588D58E395EDE1530464F" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="loc_us-gaap_FurnitureAndFixturesMember_0453F08815378007D8575EDE1530A396" xlink:type="locator" />
<link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_1E0814C45C37E775B45C5EDE152FD575" xlink:to="loc_us-gaap_FurnitureAndFixturesMember_0453F08815378007D8575EDE1530A396" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_FCB8767D7C08743D3AFB5EDE1530454C" xlink:type="locator" />
<link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_17BF163483C2B2821FAA5EDE152E7FC6" xlink:to="loc_srt_RangeAxis_FCB8767D7C08743D3AFB5EDE1530454C" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_43D7DF79919A04A4CB5C5EDE1530D5B9" xlink:type="locator" />
<link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_FCB8767D7C08743D3AFB5EDE1530454C" xlink:to="loc_srt_RangeMember_43D7DF79919A04A4CB5C5EDE1530D5B9" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MinimumMember" xlink:label="loc_srt_MinimumMember_683669AD6EFA9AD517C35EDE1531F193" xlink:type="locator" />
<link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_43D7DF79919A04A4CB5C5EDE1530D5B9" xlink:to="loc_srt_MinimumMember_683669AD6EFA9AD517C35EDE1531F193" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_7C88B0A9EA29EB8652155EDE153143D5" xlink:type="locator" />
<link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_43D7DF79919A04A4CB5C5EDE1530D5B9" xlink:to="loc_srt_MaximumMember_7C88B0A9EA29EB8652155EDE153143D5" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:label="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_6450A0DECC83B2C635425EDE15312ECA" xlink:type="locator" />
<link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_17BF163483C2B2821FAA5EDE152E7FC6" xlink:to="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_6450A0DECC83B2C635425EDE15312ECA" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="loc_us-gaap_TypeOfAdoptionMember_5E688A29B22AA47609A15EDE1531E9A4" xlink:type="locator" />
<link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_6450A0DECC83B2C635425EDE15312ECA" xlink:to="loc_us-gaap_TypeOfAdoptionMember_5E688A29B22AA47609A15EDE1531E9A4" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountingStandardsUpdate201602Member" xlink:label="loc_us-gaap_AccountingStandardsUpdate201602Member_B0B74ECE3D11AE4CE61C5EDE15326639" xlink:type="locator" />
<link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfAdoptionMember_5E688A29B22AA47609A15EDE1531E9A4" xlink:to="loc_us-gaap_AccountingStandardsUpdate201602Member_B0B74ECE3D11AE4CE61C5EDE15326639" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeLeaseDescriptionLineItems" xlink:label="loc_us-gaap_LesseeLeaseDescriptionLineItems_69767A1FF71C85471FDB5EDE15325B15" xlink:type="locator" />
<link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_17BF163483C2B2821FAA5EDE152E7FC6" xlink:to="loc_us-gaap_LesseeLeaseDescriptionLineItems_69767A1FF71C85471FDB5EDE15325B15" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_91408CC4FF4ADEBBC58A5EDE15323851" xlink:type="locator" />
<link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_69767A1FF71C85471FDB5EDE15325B15" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_91408CC4FF4ADEBBC58A5EDE15323851" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TaxCutsAndJobsActOf2017IncompleteAccountingChangeInTaxRateDeferredTaxAssetProvisionalIncomeTaxExpense" xlink:label="loc_us-gaap_TaxCutsAndJobsActOf2017IncompleteAccountingChangeInTaxRateDeferredTaxAssetProvisionalIncomeTaxExpense_26CBEA58E62C87C4FEFF5EE29F257DA7" xlink:type="locator" />
<link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_69767A1FF71C85471FDB5EDE15325B15" xlink:to="loc_us-gaap_TaxCutsAndJobsActOf2017IncompleteAccountingChangeInTaxRateDeferredTaxAssetProvisionalIncomeTaxExpense_26CBEA58E62C87C4FEFF5EE29F257DA7" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_82F5459FFD5856EEB7CD5EDE153265A3" xlink:type="locator" />
<link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_69767A1FF71C85471FDB5EDE15325B15" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_82F5459FFD5856EEB7CD5EDE153265A3" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseLiability" xlink:label="loc_us-gaap_OperatingLeaseLiability_90F37937B74A883A11835EDE153227D8" xlink:type="locator" />
<link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_69767A1FF71C85471FDB5EDE15325B15" xlink:to="loc_us-gaap_OperatingLeaseLiability_90F37937B74A883A11835EDE153227D8" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_F5F2EB1CBD6531D46BB75EDE15336DB5" xlink:type="locator" />
<link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_69767A1FF71C85471FDB5EDE15325B15" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_F5F2EB1CBD6531D46BB75EDE15336DB5" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_1A63D63E3C3FD7B2E7485EDE1533A583" xlink:type="locator" />
<link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_69767A1FF71C85471FDB5EDE15325B15" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_1A63D63E3C3FD7B2E7485EDE1533A583" xlink:type="arc" />
</link:presentationLink>
<link:presentationLink xlink:role="http://www.immunomedics.com/role/BusinessOverviewSummaryOfSignificantAccountingPolicesPolicies" xlink:type="extended">
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_5B869D95243F995FA56D3A2EBDFD860A" xlink:type="locator" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_5A2DAA2F059228FDC9B83991D2AB8508" xlink:type="locator" />
<link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_5B869D95243F995FA56D3A2EBDFD860A" xlink:to="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_5A2DAA2F059228FDC9B83991D2AB8508" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_UseOfEstimates" xlink:label="loc_us-gaap_UseOfEstimates_4DC55B290681A2C85CA93991D2AC7BA1" xlink:type="locator" />
<link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_5B869D95243F995FA56D3A2EBDFD860A" xlink:to="loc_us-gaap_UseOfEstimates_4DC55B290681A2C85CA93991D2AC7BA1" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtPolicyTextBlock" xlink:label="loc_us-gaap_DebtPolicyTextBlock_668554BFCBBDC11BC6C43991D2AC4B4E" xlink:type="locator" />
<link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_5B869D95243F995FA56D3A2EBDFD860A" xlink:to="loc_us-gaap_DebtPolicyTextBlock_668554BFCBBDC11BC6C43991D2AC4B4E" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:label="loc_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_0924A1512DB2A900F6DE3991D2ACB042" xlink:type="locator" />
<link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_5B869D95243F995FA56D3A2EBDFD860A" xlink:to="loc_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_0924A1512DB2A900F6DE3991D2ACB042" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:label="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy_F2221F96A7AD443AF9E83991D2ACFDEF" xlink:type="locator" />
<link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_5B869D95243F995FA56D3A2EBDFD860A" xlink:to="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy_F2221F96A7AD443AF9E83991D2ACFDEF" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MarketableSecuritiesPolicy" xlink:label="loc_us-gaap_MarketableSecuritiesPolicy_57C9DA24B6F5C58941D83991D2ACC803" xlink:type="locator" />
<link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_5B869D95243F995FA56D3A2EBDFD860A" xlink:to="loc_us-gaap_MarketableSecuritiesPolicy_57C9DA24B6F5C58941D83991D2ACC803" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_C3F3BB5FB1FCB69ADE5F3991D2ACA01C" xlink:type="locator" />
<link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_5B869D95243F995FA56D3A2EBDFD860A" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_C3F3BB5FB1FCB69ADE5F3991D2ACA01C" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:label="loc_us-gaap_ConcentrationRiskCreditRisk_E236C9334B32E3F4572E3991D2AB214C" xlink:type="locator" />
<link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_5B869D95243F995FA56D3A2EBDFD860A" xlink:to="loc_us-gaap_ConcentrationRiskCreditRisk_E236C9334B32E3F4572E3991D2AB214C" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueRecognitionPolicyTextBlock" xlink:label="loc_us-gaap_RevenueRecognitionPolicyTextBlock_202CED6C11CF01700B353991D2AD26BD" xlink:type="locator" />
<link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_5B869D95243F995FA56D3A2EBDFD860A" xlink:to="loc_us-gaap_RevenueRecognitionPolicyTextBlock_202CED6C11CF01700B353991D2AD26BD" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_5C3E5D284D93AADC9F223991D2AD6810" xlink:type="locator" />
<link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_5B869D95243F995FA56D3A2EBDFD860A" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_5C3E5D284D93AADC9F223991D2AD6810" xlink:type="arc" />
<link:loc xlink:href="immu-20191231.xsd#immu_TreasuryStockPolicyPolicyTextBlock" xlink:label="loc_immu_TreasuryStockPolicyPolicyTextBlock_68FC17183DA9465CB6C93991D2ADB5D4" xlink:type="locator" />
<link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_5B869D95243F995FA56D3A2EBDFD860A" xlink:to="loc_immu_TreasuryStockPolicyPolicyTextBlock_68FC17183DA9465CB6C93991D2ADB5D4" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:label="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_6723F734C59B5A1E5D3F3991D2AD4A4F" xlink:type="locator" />
<link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_5B869D95243F995FA56D3A2EBDFD860A" xlink:to="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_6723F734C59B5A1E5D3F3991D2AD4A4F" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="loc_us-gaap_IncomeTaxPolicyTextBlock_6DB99FF3ACD487BFB5443991D2AD06E3" xlink:type="locator" />
<link:presentationArc order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_5B869D95243F995FA56D3A2EBDFD860A" xlink:to="loc_us-gaap_IncomeTaxPolicyTextBlock_6DB99FF3ACD487BFB5443991D2AD06E3" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="loc_us-gaap_EarningsPerSharePolicyTextBlock_5FFAC4F197A46F8DECD33991D2ADEFB3" xlink:type="locator" />
<link:presentationArc order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_5B869D95243F995FA56D3A2EBDFD860A" xlink:to="loc_us-gaap_EarningsPerSharePolicyTextBlock_5FFAC4F197A46F8DECD33991D2ADEFB3" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:label="loc_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_B28D83C44048C43F87CC3991D2AB04BC" xlink:type="locator" />
<link:presentationArc order="15" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_5B869D95243F995FA56D3A2EBDFD860A" xlink:to="loc_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_B28D83C44048C43F87CC3991D2AB04BC" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_3D414F603BFF433B564B3991D2AE70FF" xlink:type="locator" />
<link:presentationArc order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_5B869D95243F995FA56D3A2EBDFD860A" xlink:to="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_3D414F603BFF433B564B3991D2AE70FF" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_79EDDA5806D5E0776BE83991D2AE9342" xlink:type="locator" />
<link:presentationArc order="17" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_5B869D95243F995FA56D3A2EBDFD860A" xlink:to="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_79EDDA5806D5E0776BE83991D2AE9342" xlink:type="arc" />
</link:presentationLink>
<link:presentationLink xlink:role="http://www.immunomedics.com/role/CollaborationAgreements" xlink:type="extended">
<link:loc xlink:href="immu-20191231.xsd#immu_LicenseAndCollaborationAgreementsAbstract" xlink:label="loc_immu_LicenseAndCollaborationAgreementsAbstract_7B9718297624B292B98FD1D06279F723" xlink:type="locator" />
<link:loc xlink:href="immu-20191231.xsd#immu_LicenseAndCollaborationAgreementsTextBlock" xlink:label="loc_immu_LicenseAndCollaborationAgreementsTextBlock_4FCD23E7D553255EB893D1D06279D0B2" xlink:type="locator" />
<link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_immu_LicenseAndCollaborationAgreementsAbstract_7B9718297624B292B98FD1D06279F723" xlink:to="loc_immu_LicenseAndCollaborationAgreementsTextBlock_4FCD23E7D553255EB893D1D06279D0B2" xlink:type="arc" />
</link:presentationLink>
<link:presentationLink xlink:role="http://www.immunomedics.com/role/CollaborationAgreementsDetails" xlink:type="extended">
<link:loc xlink:href="immu-20191231.xsd#immu_LicenseAndCollaborationAgreementsAbstract" xlink:label="loc_immu_LicenseAndCollaborationAgreementsAbstract_B4EBBB1516BF582351947D0659DE4A6D" xlink:type="locator" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfGuaranteeObligationsTable" xlink:label="loc_us-gaap_ScheduleOfGuaranteeObligationsTable_CE495FD42BB0EC9A916B7D0659DE55BD" xlink:type="locator" />
<link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_immu_LicenseAndCollaborationAgreementsAbstract_B4EBBB1516BF582351947D0659DE4A6D" xlink:to="loc_us-gaap_ScheduleOfGuaranteeObligationsTable_CE495FD42BB0EC9A916B7D0659DE55BD" xlink:type="arc" />
<link:loc xlink:href="immu-20191231.xsd#immu_CollaborationAgreementAxis" xlink:label="loc_immu_CollaborationAgreementAxis_42181E63B0465340B0447D0659DFBFEF" xlink:type="locator" />
<link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfGuaranteeObligationsTable_CE495FD42BB0EC9A916B7D0659DE55BD" xlink:to="loc_immu_CollaborationAgreementAxis_42181E63B0465340B0447D0659DFBFEF" xlink:type="arc" />
<link:loc xlink:href="immu-20191231.xsd#immu_CollaborationAgreementDomain" xlink:label="loc_immu_CollaborationAgreementDomain_7D49EAABA91DEA2E5B127D0659DF6AA0" xlink:type="locator" />
<link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_immu_CollaborationAgreementAxis_42181E63B0465340B0447D0659DFBFEF" xlink:to="loc_immu_CollaborationAgreementDomain_7D49EAABA91DEA2E5B127D0659DF6AA0" xlink:type="arc" />
<link:loc xlink:href="immu-20191231.xsd#immu_CBGForschungsGmbHMember" xlink:label="loc_immu_CBGForschungsGmbHMember_584AB8C3C3D9750314EF7D0659DF3928" xlink:type="locator" />
<link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_immu_CollaborationAgreementDomain_7D49EAABA91DEA2E5B127D0659DF6AA0" xlink:to="loc_immu_CBGForschungsGmbHMember_584AB8C3C3D9750314EF7D0659DF3928" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GuaranteeObligationsLineItems" xlink:label="loc_us-gaap_GuaranteeObligationsLineItems_59D312A86D862DC0892C7D0659DF7F65" xlink:type="locator" />
<link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfGuaranteeObligationsTable_CE495FD42BB0EC9A916B7D0659DE55BD" xlink:to="loc_us-gaap_GuaranteeObligationsLineItems_59D312A86D862DC0892C7D0659DF7F65" xlink:type="arc" />
<link:loc xlink:href="immu-20191231.xsd#immu_NumberofPatients" xlink:label="loc_immu_NumberofPatients_802AAC05DB627584C5E97D0659E0434A" xlink:type="locator" />
<link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GuaranteeObligationsLineItems_59D312A86D862DC0892C7D0659DF7F65" xlink:to="loc_immu_NumberofPatients_802AAC05DB627584C5E97D0659E0434A" xlink:type="arc" />
<link:loc xlink:href="immu-20191231.xsd#immu_AgreementPotentialMilestonePayment" xlink:label="loc_immu_AgreementPotentialMilestonePayment_BE8E93B0CC57BF6044857D0659E0758B" xlink:type="locator" />
<link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GuaranteeObligationsLineItems_59D312A86D862DC0892C7D0659DF7F65" xlink:to="loc_immu_AgreementPotentialMilestonePayment_BE8E93B0CC57BF6044857D0659E0758B" xlink:type="arc" />
<link:loc xlink:href="immu-20191231.xsd#immu_AgreementPotentialMilestonePaymentTerm" xlink:label="loc_immu_AgreementPotentialMilestonePaymentTerm_1F69D85CA2F25AE4D86A7D079737F782" xlink:type="locator" />
<link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GuaranteeObligationsLineItems_59D312A86D862DC0892C7D0659DF7F65" xlink:to="loc_immu_AgreementPotentialMilestonePaymentTerm_1F69D85CA2F25AE4D86A7D079737F782" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_DB0976E4D317949B39DA7D0659E0F6C2" xlink:type="locator" />
<link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GuaranteeObligationsLineItems_59D312A86D862DC0892C7D0659DF7F65" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_DB0976E4D317949B39DA7D0659E0F6C2" xlink:type="arc" />
</link:presentationLink>
<link:presentationLink xlink:role="http://www.immunomedics.com/role/CommitmentsAndContingencies" xlink:type="extended">
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_1AC98376167C18CA1396D1D06334EFA9" xlink:type="locator" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_C956FEA9B3A95A446E48D1D06334A983" xlink:type="locator" />
<link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_1AC98376167C18CA1396D1D06334EFA9" xlink:to="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_C956FEA9B3A95A446E48D1D06334A983" xlink:type="arc" />
</link:presentationLink>
<link:presentationLink xlink:role="http://www.immunomedics.com/role/CommitmentsAndContingenciesMaturitiesOfLeaseLiabilitiesDetails" xlink:type="extended">
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_3D54112F48562A661CBD3991D178573F" xlink:type="locator" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_1CE5C5FFDF8515A921293991D178AF38" xlink:type="locator" />
<link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_3D54112F48562A661CBD3991D178573F" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_1CE5C5FFDF8515A921293991D178AF38" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_2C1EABE64481D9EAA8513991D17B5C8B" xlink:type="locator" />
<link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_3D54112F48562A661CBD3991D178573F" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_2C1EABE64481D9EAA8513991D17B5C8B" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_EBD9D9E0F053B2B9FAEB3991D17B52E3" xlink:type="locator" />
<link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_3D54112F48562A661CBD3991D178573F" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_EBD9D9E0F053B2B9FAEB3991D17B52E3" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_70970A79EDB292354D663991D17B9927" xlink:type="locator" />
<link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_3D54112F48562A661CBD3991D178573F" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_70970A79EDB292354D663991D17B9927" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_B5AFD39EE48E2CDFFB0C3991D17B9689" xlink:type="locator" />
<link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_3D54112F48562A661CBD3991D178573F" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_B5AFD39EE48E2CDFFB0C3991D17B9689" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_E48009C68D579DBF44FE3991D17B5707" xlink:type="locator" />
<link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_3D54112F48562A661CBD3991D178573F" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_E48009C68D579DBF44FE3991D17B5707" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_EED4EA0FBE7D3039BCB13991D17C9EC6" xlink:type="locator" />
<link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_3D54112F48562A661CBD3991D178573F" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_EED4EA0FBE7D3039BCB13991D17C9EC6" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_51C9152BC630D6079A4C3991D17C2CB2" xlink:type="locator" />
<link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_3D54112F48562A661CBD3991D178573F" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_51C9152BC630D6079A4C3991D17C2CB2" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseLiability" xlink:label="loc_us-gaap_OperatingLeaseLiability_54FE89C7BB5914BAE9843991D17C3940" xlink:type="locator" />
<link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_3D54112F48562A661CBD3991D178573F" xlink:to="loc_us-gaap_OperatingLeaseLiability_54FE89C7BB5914BAE9843991D17C3940" xlink:type="arc" />
</link:presentationLink>
<link:presentationLink xlink:role="http://www.immunomedics.com/role/CommitmentsAndContingenciesNarrativeDetails" xlink:type="extended">
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_B90227073DC3E7F0BBB3850F474448E0" xlink:type="locator" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfGuaranteeObligationsTable" xlink:label="loc_us-gaap_ScheduleOfGuaranteeObligationsTable_E7726D3968F9585FE727850F47441C00" xlink:type="locator" />
<link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_B90227073DC3E7F0BBB3850F474448E0" xlink:to="loc_us-gaap_ScheduleOfGuaranteeObligationsTable_E7726D3968F9585FE727850F47441C00" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_BC313587271DDD4AB380850F474529B5" xlink:type="locator" />
<link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfGuaranteeObligationsTable_E7726D3968F9585FE727850F47441C00" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_BC313587271DDD4AB380850F474529B5" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_0E0CE576C169D42AD03B850F47455F11" xlink:type="locator" />
<link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_BC313587271DDD4AB380850F474529B5" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_0E0CE576C169D42AD03B850F47455F11" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaap_SubsequentEventMember_3B18C89D2AF06ADB7E28850F4745A893" xlink:type="locator" />
<link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_0E0CE576C169D42AD03B850F47455F11" xlink:to="loc_us-gaap_SubsequentEventMember_3B18C89D2AF06ADB7E28850F4745A893" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_CounterpartyNameAxis" xlink:label="loc_srt_CounterpartyNameAxis_F3286F6B9BAD5F69771E850F4745766A" xlink:type="locator" />
<link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfGuaranteeObligationsTable_E7726D3968F9585FE727850F47441C00" xlink:to="loc_srt_CounterpartyNameAxis_F3286F6B9BAD5F69771E850F4745766A" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_55C87A8F02BD746EBF8C850F47453582" xlink:type="locator" />
<link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_F3286F6B9BAD5F69771E850F4745766A" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_55C87A8F02BD746EBF8C850F47453582" xlink:type="arc" />
<link:loc xlink:href="immu-20191231.xsd#immu_TheScrippsResearchInstituteMember" xlink:label="loc_immu_TheScrippsResearchInstituteMember_D02242A86CEB0767E654850F47467FBF" xlink:type="locator" />
<link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_55C87A8F02BD746EBF8C850F47453582" xlink:to="loc_immu_TheScrippsResearchInstituteMember_D02242A86CEB0767E654850F47467FBF" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_LitigationCaseAxis" xlink:label="loc_srt_LitigationCaseAxis_53F9DDF6B17FDDA34DAC850F4746A5B5" xlink:type="locator" />
<link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfGuaranteeObligationsTable_E7726D3968F9585FE727850F47441C00" xlink:to="loc_srt_LitigationCaseAxis_53F9DDF6B17FDDA34DAC850F4746A5B5" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_LitigationCaseTypeDomain" xlink:label="loc_srt_LitigationCaseTypeDomain_7305AC435EDA2B81570A850F4746BE99" xlink:type="locator" />
<link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseAxis_53F9DDF6B17FDDA34DAC850F4746A5B5" xlink:to="loc_srt_LitigationCaseTypeDomain_7305AC435EDA2B81570A850F4746BE99" xlink:type="arc" />
<link:loc xlink:href="immu-20191231.xsd#immu_InsuranceCoverageArbitrationMember" xlink:label="loc_immu_InsuranceCoverageArbitrationMember_A92C2D42782767A9EDC1850F47479BF6" xlink:type="locator" />
<link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseTypeDomain_7305AC435EDA2B81570A850F4746BE99" xlink:to="loc_immu_InsuranceCoverageArbitrationMember_A92C2D42782767A9EDC1850F47479BF6" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_7FA6E5B85171D86491C1850F4747636D" xlink:type="locator" />
<link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfGuaranteeObligationsTable_E7726D3968F9585FE727850F47441C00" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_7FA6E5B85171D86491C1850F4747636D" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_51366888B45043F08DB9850F47477B2A" xlink:type="locator" />
<link:presentationArc order="1" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_7FA6E5B85171D86491C1850F4747636D" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_51366888B45043F08DB9850F47477B2A" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmploymentContractsMember" xlink:label="loc_us-gaap_EmploymentContractsMember_F170CDAFECA94CDE3993850F4747587E" xlink:type="locator" />
<link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_51366888B45043F08DB9850F47477B2A" xlink:to="loc_us-gaap_EmploymentContractsMember_F170CDAFECA94CDE3993850F4747587E" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_55F1B4EBE385242E9265850F474702D1" xlink:type="locator" />
<link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfGuaranteeObligationsTable_E7726D3968F9585FE727850F47441C00" xlink:to="loc_us-gaap_AwardTypeAxis_55F1B4EBE385242E9265850F474702D1" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_857DF7ED9DBBBA856DCB850F47487EBA" xlink:type="locator" />
<link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_55F1B4EBE385242E9265850F474702D1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_857DF7ED9DBBBA856DCB850F47487EBA" xlink:type="arc" />
<link:loc xlink:href="immu-20191231.xsd#immu_RestrictedUnitsWithVestingMarketConditionsMember" xlink:label="loc_immu_RestrictedUnitsWithVestingMarketConditionsMember_548A856D4564E86F573D850F47485B66" xlink:type="locator" />
<link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_857DF7ED9DBBBA856DCB850F47487EBA" xlink:to="loc_immu_RestrictedUnitsWithVestingMarketConditionsMember_548A856D4564E86F573D850F47485B66" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_1FFBAFB04A7E1FD98481850F474974FA" xlink:type="locator" />
<link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfGuaranteeObligationsTable_E7726D3968F9585FE727850F47441C00" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_1FFBAFB04A7E1FD98481850F474974FA" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain_9FCE8CE4D153C4B740BE850F47492ECE" xlink:type="locator" />
<link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_1FFBAFB04A7E1FD98481850F474974FA" xlink:to="loc_us-gaap_RelatedPartyDomain_9FCE8CE4D153C4B740BE850F47492ECE" xlink:type="arc" />
<link:loc xlink:href="immu-20191231.xsd#immu_GoldenbergAgreementMember" xlink:label="loc_immu_GoldenbergAgreementMember_A51ACD98FE41C350A1A5850F47493F30" xlink:type="locator" />
<link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_9FCE8CE4D153C4B740BE850F47492ECE" xlink:to="loc_immu_GoldenbergAgreementMember_A51ACD98FE41C350A1A5850F47493F30" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_TitleOfIndividualAxis" xlink:label="loc_srt_TitleOfIndividualAxis_43490DB8081F974C479F850F474995E9" xlink:type="locator" />
<link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfGuaranteeObligationsTable_E7726D3968F9585FE727850F47441C00" xlink:to="loc_srt_TitleOfIndividualAxis_43490DB8081F974C479F850F474995E9" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_9A21E4427FF67C5DF939850F474959F0" xlink:type="locator" />
<link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_TitleOfIndividualAxis_43490DB8081F974C479F850F474995E9" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_9A21E4427FF67C5DF939850F474959F0" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ChiefExecutiveOfficerMember" xlink:label="loc_srt_ChiefExecutiveOfficerMember_27977EC00981FCAC22C7850F474A7D72" xlink:type="locator" />
<link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_9A21E4427FF67C5DF939850F474959F0" xlink:to="loc_srt_ChiefExecutiveOfficerMember_27977EC00981FCAC22C7850F474A7D72" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GuaranteeObligationsLineItems" xlink:label="loc_us-gaap_GuaranteeObligationsLineItems_5ADA2F1A6585A6453F65850F474A18DA" xlink:type="locator" />
<link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfGuaranteeObligationsTable_E7726D3968F9585FE727850F47441C00" xlink:to="loc_us-gaap_GuaranteeObligationsLineItems_5ADA2F1A6585A6453F65850F474A18DA" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_A5D0DDF4B0D2FAD71637850F474A758F" xlink:type="locator" />
<link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GuaranteeObligationsLineItems_5ADA2F1A6585A6453F65850F474A18DA" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_A5D0DDF4B0D2FAD71637850F474A758F" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SeveranceCosts1" xlink:label="loc_us-gaap_SeveranceCosts1_260AAC05678B8422ADCE850F474AA2D6" xlink:type="locator" />
<link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GuaranteeObligationsLineItems_5ADA2F1A6585A6453F65850F474A18DA" xlink:to="loc_us-gaap_SeveranceCosts1_260AAC05678B8422ADCE850F474AA2D6" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LossContingencyDamagesSoughtValue" xlink:label="loc_us-gaap_LossContingencyDamagesSoughtValue_C29CF9DAB622DAD9EB2E850F474B838C" xlink:type="locator" />
<link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GuaranteeObligationsLineItems_5ADA2F1A6585A6453F65850F474A18DA" xlink:to="loc_us-gaap_LossContingencyDamagesSoughtValue_C29CF9DAB622DAD9EB2E850F474B838C" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeasePayments" xlink:label="loc_us-gaap_OperatingLeasePayments_A7BBD7A78B98821F75C3850F474B1B7B" xlink:type="locator" />
<link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GuaranteeObligationsLineItems_5ADA2F1A6585A6453F65850F474A18DA" xlink:to="loc_us-gaap_OperatingLeasePayments_A7BBD7A78B98821F75C3850F474B1B7B" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_250B02C5A6374FAD72C5850F474B7F47" xlink:type="locator" />
<link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GuaranteeObligationsLineItems_5ADA2F1A6585A6453F65850F474A18DA" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_250B02C5A6374FAD72C5850F474B7F47" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_3840C26F8723C73FFB60850F474BA0D5" xlink:type="locator" />
<link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GuaranteeObligationsLineItems_5ADA2F1A6585A6453F65850F474A18DA" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_3840C26F8723C73FFB60850F474BA0D5" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LeaseCost" xlink:label="loc_us-gaap_LeaseCost_E818EAA8F2E4A080286B850F474B6919" xlink:type="locator" />
<link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GuaranteeObligationsLineItems_5ADA2F1A6585A6453F65850F474A18DA" xlink:to="loc_us-gaap_LeaseCost_E818EAA8F2E4A080286B850F474B6919" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PurchaseObligationDueInNextTwelveMonths" xlink:label="loc_us-gaap_PurchaseObligationDueInNextTwelveMonths_AC3B2A7655FA2E5F27DD850F474B533B" xlink:type="locator" />
<link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GuaranteeObligationsLineItems_5ADA2F1A6585A6453F65850F474A18DA" xlink:to="loc_us-gaap_PurchaseObligationDueInNextTwelveMonths_AC3B2A7655FA2E5F27DD850F474B533B" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PurchaseObligationDueInSecondYear" xlink:label="loc_us-gaap_PurchaseObligationDueInSecondYear_647302C8F424C964A636850F474C2CDD" xlink:type="locator" />
<link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GuaranteeObligationsLineItems_5ADA2F1A6585A6453F65850F474A18DA" xlink:to="loc_us-gaap_PurchaseObligationDueInSecondYear_647302C8F424C964A636850F474C2CDD" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PurchaseObligationDueInThirdYear" xlink:label="loc_us-gaap_PurchaseObligationDueInThirdYear_1ED3933733761292C567850F474C45B7" xlink:type="locator" />
<link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GuaranteeObligationsLineItems_5ADA2F1A6585A6453F65850F474A18DA" xlink:to="loc_us-gaap_PurchaseObligationDueInThirdYear_1ED3933733761292C567850F474C45B7" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PurchaseObligationDueInFourthYear" xlink:label="loc_us-gaap_PurchaseObligationDueInFourthYear_2CE21846F5D15265D8C6850F474CABB0" xlink:type="locator" />
<link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GuaranteeObligationsLineItems_5ADA2F1A6585A6453F65850F474A18DA" xlink:to="loc_us-gaap_PurchaseObligationDueInFourthYear_2CE21846F5D15265D8C6850F474CABB0" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PurchaseObligationDueInFifthYear" xlink:label="loc_us-gaap_PurchaseObligationDueInFifthYear_2E86AB6D75C997385ECD850F474C40E8" xlink:type="locator" />
<link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GuaranteeObligationsLineItems_5ADA2F1A6585A6453F65850F474A18DA" xlink:to="loc_us-gaap_PurchaseObligationDueInFifthYear_2E86AB6D75C997385ECD850F474C40E8" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PurchaseObligationDueAfterFifthYear" xlink:label="loc_us-gaap_PurchaseObligationDueAfterFifthYear_646C93F1A48A867BCB08850F474C60BC" xlink:type="locator" />
<link:presentationArc order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GuaranteeObligationsLineItems_5ADA2F1A6585A6453F65850F474A18DA" xlink:to="loc_us-gaap_PurchaseObligationDueAfterFifthYear_646C93F1A48A867BCB08850F474C60BC" xlink:type="arc" />
<link:loc xlink:href="immu-20191231.xsd#immu_NumberofDaysLicenseCancellableAfterNonPayment" xlink:label="loc_immu_NumberofDaysLicenseCancellableAfterNonPayment_447D0ED523899122A486850F474C9A3F" xlink:type="locator" />
<link:presentationArc order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GuaranteeObligationsLineItems_5ADA2F1A6585A6453F65850F474A18DA" xlink:to="loc_immu_NumberofDaysLicenseCancellableAfterNonPayment_447D0ED523899122A486850F474C9A3F" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentForContingentConsiderationLiabilityInvestingActivities" xlink:label="loc_us-gaap_PaymentForContingentConsiderationLiabilityInvestingActivities_226A6BC275F7EA47BAED850F474C4BE2" xlink:type="locator" />
<link:presentationArc order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GuaranteeObligationsLineItems_5ADA2F1A6585A6453F65850F474A18DA" xlink:to="loc_us-gaap_PaymentForContingentConsiderationLiabilityInvestingActivities_226A6BC275F7EA47BAED850F474C4BE2" xlink:type="arc" />
<link:loc xlink:href="immu-20191231.xsd#immu_LicenseAgreementMilestoneExpense" xlink:label="loc_immu_LicenseAgreementMilestoneExpense_F031B3F84AFD2D4F30CD850F474D464B" xlink:type="locator" />
<link:presentationArc order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GuaranteeObligationsLineItems_5ADA2F1A6585A6453F65850F474A18DA" xlink:to="loc_immu_LicenseAgreementMilestoneExpense_F031B3F84AFD2D4F30CD850F474D464B" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SupplementalUnemploymentBenefitsSeveranceBenefits" xlink:label="loc_us-gaap_SupplementalUnemploymentBenefitsSeveranceBenefits_704320BF00AB89F9071B850F474DFFAA" xlink:type="locator" />
<link:presentationArc order="17" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GuaranteeObligationsLineItems_5ADA2F1A6585A6453F65850F474A18DA" xlink:to="loc_us-gaap_SupplementalUnemploymentBenefitsSeveranceBenefits_704320BF00AB89F9071B850F474DFFAA" xlink:type="arc" />
<link:loc xlink:href="immu-20191231.xsd#immu_SupplementalUnemploymentBenefitsSeveranceBenefitsPaymentTerm" xlink:label="loc_immu_SupplementalUnemploymentBenefitsSeveranceBenefitsPaymentTerm_FB012E23005E35A8821F850F474D4A3E" xlink:type="locator" />
<link:presentationArc order="18" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GuaranteeObligationsLineItems_5ADA2F1A6585A6453F65850F474A18DA" xlink:to="loc_immu_SupplementalUnemploymentBenefitsSeveranceBenefitsPaymentTerm_FB012E23005E35A8821F850F474D4A3E" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SalariesWagesAndOfficersCompensation" xlink:label="loc_us-gaap_SalariesWagesAndOfficersCompensation_3A26831790DCD0A1D852850F474D5924" xlink:type="locator" />
<link:presentationArc order="19" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GuaranteeObligationsLineItems_5ADA2F1A6585A6453F65850F474A18DA" xlink:to="loc_us-gaap_SalariesWagesAndOfficersCompensation_3A26831790DCD0A1D852850F474D5924" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SupplementalUnemploymentBenefitsSalaryContinuation" xlink:label="loc_us-gaap_SupplementalUnemploymentBenefitsSalaryContinuation_D616856A9F3C6E1AA683850F474D08CA" xlink:type="locator" />
<link:presentationArc order="20" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GuaranteeObligationsLineItems_5ADA2F1A6585A6453F65850F474A18DA" xlink:to="loc_us-gaap_SupplementalUnemploymentBenefitsSalaryContinuation_D616856A9F3C6E1AA683850F474D08CA" xlink:type="arc" />
</link:presentationLink>
<link:presentationLink xlink:role="http://www.immunomedics.com/role/CommitmentsAndContingenciesSupplementalConsolidatedBalanceSheetInformationRelatedToLeasesDetails" xlink:type="extended">
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_DC2D2616766A35F8641EE022A5AEBE55" xlink:type="locator" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_DD2FB6CA5F7F682FCF88E022A5AEF7FC" xlink:type="locator" />
<link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_DC2D2616766A35F8641EE022A5AEBE55" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_DD2FB6CA5F7F682FCF88E022A5AEF7FC" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_326D1919B583C796D9E1E022A5AF3009" xlink:type="locator" />
<link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_DC2D2616766A35F8641EE022A5AEBE55" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_326D1919B583C796D9E1E022A5AF3009" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_A1DE02290BBF4471213DE022A5AF90FA" xlink:type="locator" />
<link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_DC2D2616766A35F8641EE022A5AEBE55" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_A1DE02290BBF4471213DE022A5AF90FA" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseLiability" xlink:label="loc_us-gaap_OperatingLeaseLiability_297FED56EC21B282BC6EE022A5AF35EB" xlink:type="locator" />
<link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2009/role/netLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_DC2D2616766A35F8641EE022A5AEBE55" xlink:to="loc_us-gaap_OperatingLeaseLiability_297FED56EC21B282BC6EE022A5AF35EB" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_A3935C7F7C40D9D0575EE022A5B1E848" xlink:type="locator" />
<link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_DC2D2616766A35F8641EE022A5AEBE55" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_A3935C7F7C40D9D0575EE022A5B1E848" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_96D058DE37DFE6914FD3E022A5B16491" xlink:type="locator" />
<link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_DC2D2616766A35F8641EE022A5AEBE55" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_96D058DE37DFE6914FD3E022A5B16491" xlink:type="arc" />
<link:loc xlink:href="immu-20191231.xsd#immu_NonCashLeaseExpense" xlink:label="loc_immu_NonCashLeaseExpense_35CB89126D3E45BF6C08E022A5B1CDB3" xlink:type="locator" />
<link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_DC2D2616766A35F8641EE022A5AEBE55" xlink:to="loc_immu_NonCashLeaseExpense_35CB89126D3E45BF6C08E022A5B1CDB3" xlink:type="arc" />
<link:loc xlink:href="immu-20191231.xsd#immu_ChangeinOperatingLeaseLiability" xlink:label="loc_immu_ChangeinOperatingLeaseLiability_EFA82F2FE307663AB743E022A5B1E544" xlink:type="locator" />
<link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_DC2D2616766A35F8641EE022A5AEBE55" xlink:to="loc_immu_ChangeinOperatingLeaseLiability_EFA82F2FE307663AB743E022A5B1E544" xlink:type="arc" />
</link:presentationLink>
<link:presentationLink xlink:role="http://www.immunomedics.com/role/CommitmentsAndContingenciesTables" xlink:type="extended">
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_8ACDE04314CF2E6FBAD033A13C6226EA" xlink:type="locator" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LeaseCostTableTextBlock" xlink:label="loc_us-gaap_LeaseCostTableTextBlock_F45F61F605B6A0FF398033A13C623998" xlink:type="locator" />
<link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_8ACDE04314CF2E6FBAD033A13C6226EA" xlink:to="loc_us-gaap_LeaseCostTableTextBlock_F45F61F605B6A0FF398033A13C623998" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_D2F77307989B0ECD45BA33A13C62E45C" xlink:type="locator" />
<link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_8ACDE04314CF2E6FBAD033A13C6226EA" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_D2F77307989B0ECD45BA33A13C62E45C" xlink:type="arc" />
</link:presentationLink>
<link:presentationLink xlink:role="http://www.immunomedics.com/role/ConsolidatedBalanceSheets" xlink:type="extended">
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_F623DAEBB62FCB958E1F3991D308277A" xlink:type="locator" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="loc_us-gaap_AssetsAbstract_94274A213341EA4F5D573991D309F89B" xlink:type="locator" />
<link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_F623DAEBB62FCB958E1F3991D308277A" xlink:to="loc_us-gaap_AssetsAbstract_94274A213341EA4F5D573991D309F89B" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="loc_us-gaap_AssetsCurrentAbstract_D1FAC9758DE7944B5B213991D30932EE" xlink:type="locator" />
<link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_94274A213341EA4F5D573991D309F89B" xlink:to="loc_us-gaap_AssetsCurrentAbstract_D1FAC9758DE7944B5B213991D30932EE" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_65D37DABC8FCC17FE1803991D3091B75" xlink:type="locator" />
<link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_D1FAC9758DE7944B5B213991D30932EE" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_65D37DABC8FCC17FE1803991D3091B75" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_4D7827CD8AE7894EA3553991D30961F2" xlink:type="locator" />
<link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_D1FAC9758DE7944B5B213991D30932EE" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_4D7827CD8AE7894EA3553991D30961F2" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_56CF615F09132B6796623991D30AB268" xlink:type="locator" />
<link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_D1FAC9758DE7944B5B213991D30932EE" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_56CF615F09132B6796623991D30AB268" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PrepaidExpenseCurrent" xlink:label="loc_us-gaap_PrepaidExpenseCurrent_5D5DCBA80D71F97114273991D30A3FB2" xlink:type="locator" />
<link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_D1FAC9758DE7944B5B213991D30932EE" xlink:to="loc_us-gaap_PrepaidExpenseCurrent_5D5DCBA80D71F97114273991D30A3FB2" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherAssetsCurrent" xlink:label="loc_us-gaap_OtherAssetsCurrent_60144D953CFEC917E9703991D30A7CA3" xlink:type="locator" />
<link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_D1FAC9758DE7944B5B213991D30932EE" xlink:to="loc_us-gaap_OtherAssetsCurrent_60144D953CFEC917E9703991D30A7CA3" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaap_AssetsCurrent_B6D62AFA8081FAD0E5523991D30A4A47" xlink:type="locator" />
<link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_D1FAC9758DE7944B5B213991D30932EE" xlink:to="loc_us-gaap_AssetsCurrent_B6D62AFA8081FAD0E5523991D30A4A47" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_A3B5C198E63C505C745E3991D30A05D4" xlink:type="locator" />
<link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_94274A213341EA4F5D573991D309F89B" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_A3B5C198E63C505C745E3991D30A05D4" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_952CD8F9569D4B93B2403991D30A35D6" xlink:type="locator" />
<link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_94274A213341EA4F5D573991D309F89B" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_952CD8F9569D4B93B2403991D30A35D6" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Assets" xlink:label="loc_us-gaap_Assets_EC5D16BADD081039696E3991D30A08BF" xlink:type="locator" />
<link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_94274A213341EA4F5D573991D309F89B" xlink:to="loc_us-gaap_Assets_EC5D16BADD081039696E3991D30A08BF" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_77C3BB8610D1AD3443193991D30B2EB1" xlink:type="locator" />
<link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_F623DAEBB62FCB958E1F3991D308277A" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_77C3BB8610D1AD3443193991D30B2EB1" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_DEBEF4CF538D2DAC1B763991D30B61F5" xlink:type="locator" />
<link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_77C3BB8610D1AD3443193991D30B2EB1" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_DEBEF4CF538D2DAC1B763991D30B61F5" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_9CA7DD8D66964577DF903991D30B99ED" xlink:type="locator" />
<link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_DEBEF4CF538D2DAC1B763991D30B61F5" xlink:to="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_9CA7DD8D66964577DF903991D30B99ED" xlink:type="arc" />
<link:loc xlink:href="immu-20191231.xsd#immu_LiabilitiesRelatedToTheSaleOfFutureRoyaltiesCurrent" xlink:label="loc_immu_LiabilitiesRelatedToTheSaleOfFutureRoyaltiesCurrent_AA15555F8392CBCEFC123991D30BD106" xlink:type="locator" />
<link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_DEBEF4CF538D2DAC1B763991D30B61F5" xlink:to="loc_immu_LiabilitiesRelatedToTheSaleOfFutureRoyaltiesCurrent_AA15555F8392CBCEFC123991D30BD106" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_0C63364903903D1E2A403991D30C82DD" xlink:type="locator" />
<link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_DEBEF4CF538D2DAC1B763991D30B61F5" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_0C63364903903D1E2A403991D30C82DD" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConvertibleDebtCurrent" xlink:label="loc_us-gaap_ConvertibleDebtCurrent_458F5F68A34A6557A13639991EF8DF59" xlink:type="locator" />
<link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_DEBEF4CF538D2DAC1B763991D30B61F5" xlink:to="loc_us-gaap_ConvertibleDebtCurrent_458F5F68A34A6557A13639991EF8DF59" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaap_LiabilitiesCurrent_A9995D2A23F3BF4101C93991D30C48E9" xlink:type="locator" />
<link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_DEBEF4CF538D2DAC1B763991D30B61F5" xlink:to="loc_us-gaap_LiabilitiesCurrent_A9995D2A23F3BF4101C93991D30C48E9" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConvertibleDebtNoncurrent" xlink:label="loc_us-gaap_ConvertibleDebtNoncurrent_557A26864094AD1B90C33991D30C3734" xlink:type="locator" />
<link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_77C3BB8610D1AD3443193991D30B2EB1" xlink:to="loc_us-gaap_ConvertibleDebtNoncurrent_557A26864094AD1B90C33991D30C3734" xlink:type="arc" />
<link:loc xlink:href="immu-20191231.xsd#immu_LiabilitiesRelatedToTheSaleOfFutureRoyaltiesNoncurrent" xlink:label="loc_immu_LiabilitiesRelatedToTheSaleOfFutureRoyaltiesNoncurrent_378F95F04551FF9B7FB83991D30CFFDB" xlink:type="locator" />
<link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_77C3BB8610D1AD3443193991D30B2EB1" xlink:to="loc_immu_LiabilitiesRelatedToTheSaleOfFutureRoyaltiesNoncurrent_378F95F04551FF9B7FB83991D30CFFDB" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_2CCD54AF555040BF0A323991D30C692C" xlink:type="locator" />
<link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_77C3BB8610D1AD3443193991D30B2EB1" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_2CCD54AF555040BF0A323991D30C692C" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_E625283631607EB69AD43991D30C256A" xlink:type="locator" />
<link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_77C3BB8610D1AD3443193991D30B2EB1" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_E625283631607EB69AD43991D30C256A" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaap_Liabilities_B780A7E07800ADE12C583991D30DBF3B" xlink:type="locator" />
<link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_77C3BB8610D1AD3443193991D30B2EB1" xlink:to="loc_us-gaap_Liabilities_B780A7E07800ADE12C583991D30DBF3B" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="loc_us-gaap_CommitmentsAndContingencies_A638E8178B4C8E82DD643991D30D7B4D" xlink:type="locator" />
<link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_77C3BB8610D1AD3443193991D30B2EB1" xlink:to="loc_us-gaap_CommitmentsAndContingencies_A638E8178B4C8E82DD643991D30D7B4D" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="loc_us-gaap_StockholdersEquityAbstract_4B92C69D6A88EEFCEB5C3991D30D6648" xlink:type="locator" />
<link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_77C3BB8610D1AD3443193991D30B2EB1" xlink:to="loc_us-gaap_StockholdersEquityAbstract_4B92C69D6A88EEFCEB5C3991D30D6648" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConvertiblePreferredStockNonredeemableOrRedeemableIssuerOptionValue" xlink:label="loc_us-gaap_ConvertiblePreferredStockNonredeemableOrRedeemableIssuerOptionValue_C0951EA06D3BC0555F893991D30D41FA" xlink:type="locator" />
<link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_4B92C69D6A88EEFCEB5C3991D30D6648" xlink:to="loc_us-gaap_ConvertiblePreferredStockNonredeemableOrRedeemableIssuerOptionValue_C0951EA06D3BC0555F893991D30D41FA" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaap_CommonStockValue_D20B9AACEA82F577794C3991D30DF269" xlink:type="locator" />
<link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_4B92C69D6A88EEFCEB5C3991D30D6648" xlink:to="loc_us-gaap_CommonStockValue_D20B9AACEA82F577794C3991D30DF269" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock_8D58F6DE22CADCFDDCE33991D30D65E9" xlink:type="locator" />
<link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_4B92C69D6A88EEFCEB5C3991D30D6648" xlink:to="loc_us-gaap_AdditionalPaidInCapitalCommonStock_8D58F6DE22CADCFDDCE33991D30D65E9" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TreasuryStockValue" xlink:label="loc_us-gaap_TreasuryStockValue_8199BD55FCCF973953D43991D30E782C" xlink:type="locator" />
<link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_4B92C69D6A88EEFCEB5C3991D30D6648" xlink:to="loc_us-gaap_TreasuryStockValue_8199BD55FCCF973953D43991D30E782C" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_380E4C18C3F46539BB493991D30E1334" xlink:type="locator" />
<link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_4B92C69D6A88EEFCEB5C3991D30D6648" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_380E4C18C3F46539BB493991D30E1334" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_4CA7FC1097A5CE126D253991D30EFCEC" xlink:type="locator" />
<link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_4B92C69D6A88EEFCEB5C3991D30D6648" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_4CA7FC1097A5CE126D253991D30EFCEC" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_A97BF343F49B8250D22E3991D30ECDBB" xlink:type="locator" />
<link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_4B92C69D6A88EEFCEB5C3991D30D6648" xlink:to="loc_us-gaap_StockholdersEquity_A97BF343F49B8250D22E3991D30ECDBB" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MinorityInterest" xlink:label="loc_us-gaap_MinorityInterest_844432DFD3790274C3053991D30E158E" xlink:type="locator" />
<link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_4B92C69D6A88EEFCEB5C3991D30D6648" xlink:to="loc_us-gaap_MinorityInterest_844432DFD3790274C3053991D30E158E" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_565A739BEFF0A98CA09B3991D30E2219" xlink:type="locator" />
<link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_4B92C69D6A88EEFCEB5C3991D30D6648" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_565A739BEFF0A98CA09B3991D30E2219" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_344DF847DB06DEB5A1ED3991D30F920F" xlink:type="locator" />
<link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_77C3BB8610D1AD3443193991D30B2EB1" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_344DF847DB06DEB5A1ED3991D30F920F" xlink:type="arc" />
</link:presentationLink>
<link:presentationLink xlink:role="http://www.immunomedics.com/role/ConsolidatedBalanceSheetsParenthetical" xlink:type="extended">
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_2E4E440349018967B786853A88E16131" xlink:type="locator" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_EADA282B7E1E1CFC76BA853A88E10422" xlink:type="locator" />
<link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_2E4E440349018967B786853A88E16131" xlink:to="loc_us-gaap_StatementTable_EADA282B7E1E1CFC76BA853A88E10422" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_CBE30CAEF014942CFFB0853A88E25312" xlink:type="locator" />
<link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_EADA282B7E1E1CFC76BA853A88E10422" xlink:to="loc_us-gaap_StatementClassOfStockAxis_CBE30CAEF014942CFFB0853A88E25312" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_218216FD708ED50C9732853A88E24FEB" xlink:type="locator" />
<link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_CBE30CAEF014942CFFB0853A88E25312" xlink:to="loc_us-gaap_ClassOfStockDomain_218216FD708ED50C9732853A88E24FEB" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConvertiblePreferredStockMember" xlink:label="loc_us-gaap_ConvertiblePreferredStockMember_5A591AEE08A4CD7E7578853A88E22171" xlink:type="locator" />
<link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_218216FD708ED50C9732853A88E24FEB" xlink:to="loc_us-gaap_ConvertiblePreferredStockMember_5A591AEE08A4CD7E7578853A88E22171" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_BC49A111ACD3EC96C7AC853A88E2A3E3" xlink:type="locator" />
<link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_EADA282B7E1E1CFC76BA853A88E10422" xlink:to="loc_us-gaap_StatementLineItems_BC49A111ACD3EC96C7AC853A88E2A3E3" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_24538307D55A5CF7B81E853A88E2B205" xlink:type="locator" />
<link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_BC49A111ACD3EC96C7AC853A88E2A3E3" xlink:to="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_24538307D55A5CF7B81E853A88E2B205" xlink:type="arc" />
<link:loc xlink:href="immu-20191231.xsd#immu_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization" xlink:label="loc_immu_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization_B0748FE1746C3B70CACD8549B6EFB658" xlink:type="locator" />
<link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_BC49A111ACD3EC96C7AC853A88E2A3E3" xlink:to="loc_immu_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization_B0748FE1746C3B70CACD8549B6EFB658" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_0BE2B1399145F54C945E853A88E38EDB" xlink:type="locator" />
<link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_BC49A111ACD3EC96C7AC853A88E2A3E3" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_0BE2B1399145F54C945E853A88E38EDB" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_ECE973E6B7963DF9ECC4853A88E39DC1" xlink:type="locator" />
<link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_BC49A111ACD3EC96C7AC853A88E2A3E3" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_ECE973E6B7963DF9ECC4853A88E39DC1" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_554409BE0EBEFF2CB40E853A88E3DDFE" xlink:type="locator" />
<link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_BC49A111ACD3EC96C7AC853A88E2A3E3" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_554409BE0EBEFF2CB40E853A88E3DDFE" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="loc_us-gaap_PreferredStockSharesIssued_B172F567A08B83D32174853A88E34156" xlink:type="locator" />
<link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_BC49A111ACD3EC96C7AC853A88E2A3E3" xlink:to="loc_us-gaap_PreferredStockSharesIssued_B172F567A08B83D32174853A88E34156" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_174FF7DE750CC8BC90CD853A88E3D7F4" xlink:type="locator" />
<link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_BC49A111ACD3EC96C7AC853A88E2A3E3" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_174FF7DE750CC8BC90CD853A88E3D7F4" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_905FDA7F60332DB2BDDC853A88E3F072" xlink:type="locator" />
<link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_BC49A111ACD3EC96C7AC853A88E2A3E3" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_905FDA7F60332DB2BDDC853A88E3F072" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_9D84C570F925426A0724853A88E4E0D7" xlink:type="locator" />
<link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_BC49A111ACD3EC96C7AC853A88E2A3E3" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_9D84C570F925426A0724853A88E4E0D7" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaap_CommonStockSharesIssued_657FC67CC9C6ABDE2EC7853A88E4D133" xlink:type="locator" />
<link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_BC49A111ACD3EC96C7AC853A88E2A3E3" xlink:to="loc_us-gaap_CommonStockSharesIssued_657FC67CC9C6ABDE2EC7853A88E4D133" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_3CF630060A5DE0AFC14C853A88E46973" xlink:type="locator" />
<link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_BC49A111ACD3EC96C7AC853A88E2A3E3" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_3CF630060A5DE0AFC14C853A88E46973" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TreasuryStockShares" xlink:label="loc_us-gaap_TreasuryStockShares_FA04EF86755F3F2BC217853A88E41478" xlink:type="locator" />
<link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_BC49A111ACD3EC96C7AC853A88E2A3E3" xlink:to="loc_us-gaap_TreasuryStockShares_FA04EF86755F3F2BC217853A88E41478" xlink:type="arc" />
</link:presentationLink>
<link:presentationLink xlink:role="http://www.immunomedics.com/role/ConsolidatedStatementsOfCashFlows" xlink:type="extended">
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_C708FA86EF0DC060F4FD850F48C1790F" xlink:type="locator" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_3AB4C66D03C7F0454A1F850F48C152DA" xlink:type="locator" />
<link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_C708FA86EF0DC060F4FD850F48C1790F" xlink:to="loc_us-gaap_StatementTable_3AB4C66D03C7F0454A1F850F48C152DA" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_28ADC66E74A7501C8244850F48C13309" xlink:type="locator" />
<link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_3AB4C66D03C7F0454A1F850F48C152DA" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_28ADC66E74A7501C8244850F48C13309" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_1E421A88D26CAAB15566850F48C19054" xlink:type="locator" />
<link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_28ADC66E74A7501C8244850F48C13309" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_1E421A88D26CAAB15566850F48C19054" xlink:type="arc" />
<link:loc xlink:href="immu-20191231.xsd#immu_MarketOfferingMember" xlink:label="loc_immu_MarketOfferingMember_2E1EC3A1C131BAD4AE9F850F48C21EC1" xlink:type="locator" />
<link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_1E421A88D26CAAB15566850F48C19054" xlink:to="loc_immu_MarketOfferingMember_2E1EC3A1C131BAD4AE9F850F48C21EC1" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PrivatePlacementMember" xlink:label="loc_us-gaap_PrivatePlacementMember_CAAF9AE49E1DC83F3422850F48C2C4ED" xlink:type="locator" />
<link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_1E421A88D26CAAB15566850F48C19054" xlink:to="loc_us-gaap_PrivatePlacementMember_CAAF9AE49E1DC83F3422850F48C2C4ED" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_D98B9FD5B538F7B7C6D6850F48C286FA" xlink:type="locator" />
<link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_3AB4C66D03C7F0454A1F850F48C152DA" xlink:to="loc_us-gaap_StatementLineItems_D98B9FD5B538F7B7C6D6850F48C286FA" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_5A41C9BE0A0408732CB3850F48C2A86A" xlink:type="locator" />
<link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_D98B9FD5B538F7B7C6D6850F48C286FA" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_5A41C9BE0A0408732CB3850F48C2A86A" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProfitLoss" xlink:label="loc_us-gaap_ProfitLoss_B1A96B0FB036EA0AAFB3850F48C39A43" xlink:type="locator" />
<link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_5A41C9BE0A0408732CB3850F48C2A86A" xlink:to="loc_us-gaap_ProfitLoss_B1A96B0FB036EA0AAFB3850F48C39A43" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_3F0C2A970F792AD09A03850F48C368FE" xlink:type="locator" />
<link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_5A41C9BE0A0408732CB3850F48C2A86A" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_3F0C2A970F792AD09A03850F48C368FE" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="loc_us-gaap_FairValueAdjustmentOfWarrants_3E46BF4294D11B252086850F48C3330B" xlink:type="locator" />
<link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_3F0C2A970F792AD09A03850F48C368FE" xlink:to="loc_us-gaap_FairValueAdjustmentOfWarrants_3E46BF4294D11B252086850F48C3330B" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdjustmentOfWarrantsGrantedForServices" xlink:label="loc_us-gaap_AdjustmentOfWarrantsGrantedForServices_C556857E0EB81C7DF87B850F48C34FAD" xlink:type="locator" />
<link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_3F0C2A970F792AD09A03850F48C368FE" xlink:to="loc_us-gaap_AdjustmentOfWarrantsGrantedForServices_C556857E0EB81C7DF87B850F48C34FAD" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DepreciationAndAmortization" xlink:label="loc_us-gaap_DepreciationAndAmortization_185656F56B677453935C850F48C4D0C0" xlink:type="locator" />
<link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_3F0C2A970F792AD09A03850F48C368FE" xlink:to="loc_us-gaap_DepreciationAndAmortization_185656F56B677453935C850F48C4D0C0" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:label="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_01D54B5BE28D507922C1850F48C44FB8" xlink:type="locator" />
<link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_3F0C2A970F792AD09A03850F48C368FE" xlink:to="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_01D54B5BE28D507922C1850F48C44FB8" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InterestExpenseDebt" xlink:label="loc_us-gaap_InterestExpenseDebt_9316FB172638206F425A850F48C4891A" xlink:type="locator" />
<link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_3F0C2A970F792AD09A03850F48C368FE" xlink:to="loc_us-gaap_InterestExpenseDebt_9316FB172638206F425A850F48C4891A" xlink:type="arc" />
<link:loc xlink:href="immu-20191231.xsd#immu_LossOnInducedExchangesOfDebt" xlink:label="loc_immu_LossOnInducedExchangesOfDebt_AE678E273FB7136C2943850F48C4BC3B" xlink:type="locator" />
<link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_3F0C2A970F792AD09A03850F48C368FE" xlink:to="loc_immu_LossOnInducedExchangesOfDebt_AE678E273FB7136C2943850F48C4BC3B" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_79FFA159748CE593C81E850F48C4DE92" xlink:type="locator" />
<link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_3F0C2A970F792AD09A03850F48C368FE" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_79FFA159748CE593C81E850F48C4DE92" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:label="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_DA87B72F3CBD78D5C8EE850F48C4BBB4" xlink:type="locator" />
<link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_3F0C2A970F792AD09A03850F48C368FE" xlink:to="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_DA87B72F3CBD78D5C8EE850F48C4BBB4" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AmortizationOfFinancingCosts" xlink:label="loc_us-gaap_AmortizationOfFinancingCosts_5AE5033CD6F7EE6A94E9850F48C444BB" xlink:type="locator" />
<link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_3F0C2A970F792AD09A03850F48C368FE" xlink:to="loc_us-gaap_AmortizationOfFinancingCosts_5AE5033CD6F7EE6A94E9850F48C444BB" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInDeferredCharges" xlink:label="loc_us-gaap_IncreaseDecreaseInDeferredCharges_E6514D657E24BFD55B22850F48C5D684" xlink:type="locator" />
<link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_3F0C2A970F792AD09A03850F48C368FE" xlink:to="loc_us-gaap_IncreaseDecreaseInDeferredCharges_E6514D657E24BFD55B22850F48C5D684" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FinanceLeaseRightOfUseAssetAmortization" xlink:label="loc_us-gaap_FinanceLeaseRightOfUseAssetAmortization_2B90A1F77421510BBBD9850F48C5A717" xlink:type="locator" />
<link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_3F0C2A970F792AD09A03850F48C368FE" xlink:to="loc_us-gaap_FinanceLeaseRightOfUseAssetAmortization_2B90A1F77421510BBBD9850F48C5A717" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtAndEquitySecuritiesGainLoss" xlink:label="loc_us-gaap_DebtAndEquitySecuritiesGainLoss_573F1A7A06C80AE2E16E850F48C5BCBB" xlink:type="locator" />
<link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_3F0C2A970F792AD09A03850F48C368FE" xlink:to="loc_us-gaap_DebtAndEquitySecuritiesGainLoss_573F1A7A06C80AE2E16E850F48C5BCBB" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProvisionForDoubtfulAccounts" xlink:label="loc_us-gaap_ProvisionForDoubtfulAccounts_BD5AB4E81564CAED13D6850F48C5C45A" xlink:type="locator" />
<link:presentationArc order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_3F0C2A970F792AD09A03850F48C368FE" xlink:to="loc_us-gaap_ProvisionForDoubtfulAccounts_BD5AB4E81564CAED13D6850F48C5C45A" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaap_ShareBasedCompensation_BDC67034B1822EF503FE850F48C512B6" xlink:type="locator" />
<link:presentationArc order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_3F0C2A970F792AD09A03850F48C368FE" xlink:to="loc_us-gaap_ShareBasedCompensation_BDC67034B1822EF503FE850F48C512B6" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherNoncashExpense" xlink:label="loc_us-gaap_OtherNoncashExpense_F4B666EF61B22134B65D850F48C68208" xlink:type="locator" />
<link:presentationArc order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_3F0C2A970F792AD09A03850F48C368FE" xlink:to="loc_us-gaap_OtherNoncashExpense_F4B666EF61B22134B65D850F48C68208" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_6812207EE24F0446651D850F48C67CDF" xlink:type="locator" />
<link:presentationArc order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_3F0C2A970F792AD09A03850F48C368FE" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_6812207EE24F0446651D850F48C67CDF" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_3FFDE7E6BD89D01E7FFE850F48C62427" xlink:type="locator" />
<link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_6812207EE24F0446651D850F48C67CDF" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_3FFDE7E6BD89D01E7FFE850F48C62427" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInInventories" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories_58AAE17805E1049E5608850F48C6AA76" xlink:type="locator" />
<link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_6812207EE24F0446651D850F48C67CDF" xlink:to="loc_us-gaap_IncreaseDecreaseInInventories_58AAE17805E1049E5608850F48C6AA76" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInOtherReceivables" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherReceivables_7B7CE881622B2AD67A2C850F48C6AC1A" xlink:type="locator" />
<link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_6812207EE24F0446651D850F48C67CDF" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherReceivables_7B7CE881622B2AD67A2C850F48C6AC1A" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_5834EA9F1E70AB50369A850F48C6622F" xlink:type="locator" />
<link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_6812207EE24F0446651D850F48C67CDF" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_5834EA9F1E70AB50369A850F48C6622F" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_76A790CC4B7DFFF533C4850F48C730DF" xlink:type="locator" />
<link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_6812207EE24F0446651D850F48C67CDF" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_76A790CC4B7DFFF533C4850F48C730DF" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_CCBD27721B9AEBDE6447850F48C7D5B4" xlink:type="locator" />
<link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_6812207EE24F0446651D850F48C67CDF" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_CCBD27721B9AEBDE6447850F48C7D5B4" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:label="loc_us-gaap_IncreaseDecreaseInDeferredRevenue_EA42B9C922F09160A7A1850F48C768E7" xlink:type="locator" />
<link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_6812207EE24F0446651D850F48C67CDF" xlink:to="loc_us-gaap_IncreaseDecreaseInDeferredRevenue_EA42B9C922F09160A7A1850F48C768E7" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_EB0D803AA16ABF722606850F48C786BA" xlink:type="locator" />
<link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_6812207EE24F0446651D850F48C67CDF" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_EB0D803AA16ABF722606850F48C786BA" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_54933EFCB3382B26072D850F48C7DA19" xlink:type="locator" />
<link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_D98B9FD5B538F7B7C6D6850F48C286FA" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_54933EFCB3382B26072D850F48C7DA19" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:label="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_4884A8A43B8C203596C4850F48C77006" xlink:type="locator" />
<link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_54933EFCB3382B26072D850F48C7DA19" xlink:to="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_4884A8A43B8C203596C4850F48C77006" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_15445853E04ED86E9090850F48C8591A" xlink:type="locator" />
<link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_54933EFCB3382B26072D850F48C7DA19" xlink:to="loc_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_15445853E04ED86E9090850F48C8591A" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_162ECA08E46DC74D63DB850F48C89DE6" xlink:type="locator" />
<link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_54933EFCB3382B26072D850F48C7DA19" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_162ECA08E46DC74D63DB850F48C89DE6" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_44B91DD09CE6893D0527850F48C808B6" xlink:type="locator" />
<link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_54933EFCB3382B26072D850F48C7DA19" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_44B91DD09CE6893D0527850F48C808B6" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_DB4641840B53276FC068850F48C8D1FE" xlink:type="locator" />
<link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_D98B9FD5B538F7B7C6D6850F48C286FA" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_DB4641840B53276FC068850F48C8D1FE" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_17C53D9E6EE4F9F914EC850F48C82F9F" xlink:type="locator" />
<link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_DB4641840B53276FC068850F48C8D1FE" xlink:to="loc_us-gaap_ProceedsFromStockOptionsExercised_17C53D9E6EE4F9F914EC850F48C82F9F" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="loc_us-gaap_ProceedsFromWarrantExercises_8CCF5DE880DD0C7C388F850F48C9ECB8" xlink:type="locator" />
<link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_DB4641840B53276FC068850F48C8D1FE" xlink:to="loc_us-gaap_ProceedsFromWarrantExercises_8CCF5DE880DD0C7C388F850F48C9ECB8" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock_D04F35AF3C633066D370850F48C96BF8" xlink:type="locator" />
<link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_DB4641840B53276FC068850F48C8D1FE" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock_D04F35AF3C633066D370850F48C96BF8" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:label="loc_us-gaap_ProceedsFromIssuanceInitialPublicOffering_E69C3BA7AF8AAA0E8A2A850F48C98448" xlink:type="locator" />
<link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_DB4641840B53276FC068850F48C8D1FE" xlink:to="loc_us-gaap_ProceedsFromIssuanceInitialPublicOffering_E69C3BA7AF8AAA0E8A2A850F48C98448" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_170286333CFBF7AAE01A850F48C9FC67" xlink:type="locator" />
<link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_DB4641840B53276FC068850F48C8D1FE" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_170286333CFBF7AAE01A850F48C9FC67" xlink:type="arc" />
<link:loc xlink:href="immu-20191231.xsd#immu_ProceedsFromIssuanceOfNonRecourseDebt" xlink:label="loc_immu_ProceedsFromIssuanceOfNonRecourseDebt_89A80BEBF0FAF6CAB8E8850F48C96885" xlink:type="locator" />
<link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_DB4641840B53276FC068850F48C8D1FE" xlink:to="loc_immu_ProceedsFromIssuanceOfNonRecourseDebt_89A80BEBF0FAF6CAB8E8850F48C96885" xlink:type="arc" />
<link:loc xlink:href="immu-20191231.xsd#immu_PaymentOfDebtConversionFees" xlink:label="loc_immu_PaymentOfDebtConversionFees_C9394921E15BCD099F10850F48C9FB0D" xlink:type="locator" />
<link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_DB4641840B53276FC068850F48C8D1FE" xlink:to="loc_immu_PaymentOfDebtConversionFees_C9394921E15BCD099F10850F48C9FB0D" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:label="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_DE426E616F7B1D17987B850F48CA2F58" xlink:type="locator" />
<link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_DB4641840B53276FC068850F48C8D1FE" xlink:to="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_DE426E616F7B1D17987B850F48CA2F58" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_D7E291371D366E4B41A6850F48CAC80F" xlink:type="locator" />
<link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_DB4641840B53276FC068850F48C8D1FE" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_D7E291371D366E4B41A6850F48CAC80F" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_13F8537322C5FD7CA770850F48CAB3AA" xlink:type="locator" />
<link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_D98B9FD5B538F7B7C6D6850F48C286FA" xlink:to="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_13F8537322C5FD7CA770850F48CAB3AA" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_04AA55A0A9F7909025F2850F48CAFA35" xlink:type="locator" />
<link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_D98B9FD5B538F7B7C6D6850F48C286FA" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_04AA55A0A9F7909025F2850F48CAFA35" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_6676EABE3A59074AF404850F48CA6487" xlink:type="locator" />
<link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_D98B9FD5B538F7B7C6D6850F48C286FA" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_6676EABE3A59074AF404850F48CA6487" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_63520ED89ADDBED734AF850F48CB9513" xlink:type="locator" />
<link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_D98B9FD5B538F7B7C6D6850F48C286FA" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_63520ED89ADDBED734AF850F48CB9513" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract_33B642340BC7803CFCEF850F48CB8F7E" xlink:type="locator" />
<link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_D98B9FD5B538F7B7C6D6850F48C286FA" xlink:to="loc_us-gaap_SupplementalCashFlowInformationAbstract_33B642340BC7803CFCEF850F48CB8F7E" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InterestPaidNet" xlink:label="loc_us-gaap_InterestPaidNet_94057D2DE29F9C268532850F48CB8AB8" xlink:type="locator" />
<link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_33B642340BC7803CFCEF850F48CB8F7E" xlink:to="loc_us-gaap_InterestPaidNet_94057D2DE29F9C268532850F48CB8AB8" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxesPaidNet" xlink:label="loc_us-gaap_IncomeTaxesPaidNet_3BC0E6713D91BC060DE5850F48CB8C0A" xlink:type="locator" />
<link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_33B642340BC7803CFCEF850F48CB8F7E" xlink:to="loc_us-gaap_IncomeTaxesPaidNet_3BC0E6713D91BC060DE5850F48CB8C0A" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:label="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_79595872D16BFDE61B95850F48CB4631" xlink:type="locator" />
<link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_33B642340BC7803CFCEF850F48CB8F7E" xlink:to="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_79595872D16BFDE61B95850F48CB4631" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtConversionOriginalDebtAmount1" xlink:label="loc_us-gaap_DebtConversionOriginalDebtAmount1_7D2A300F177CEB28CAB9850F48CB952B" xlink:type="locator" />
<link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_79595872D16BFDE61B95850F48CB4631" xlink:to="loc_us-gaap_DebtConversionOriginalDebtAmount1_7D2A300F177CEB28CAB9850F48CB952B" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:label="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid_38024077610C863FC7F7850F48CC9EB8" xlink:type="locator" />
<link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_79595872D16BFDE61B95850F48CB4631" xlink:to="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid_38024077610C863FC7F7850F48CC9EB8" xlink:type="arc" />
<link:loc xlink:href="immu-20191231.xsd#immu_ReclassOfWarrantLiabilityToCapitalContributedInExcessOfPar" xlink:label="loc_immu_ReclassOfWarrantLiabilityToCapitalContributedInExcessOfPar_B70C52440131664DB50D850F48CCA733" xlink:type="locator" />
<link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_33B642340BC7803CFCEF850F48CB8F7E" xlink:to="loc_immu_ReclassOfWarrantLiabilityToCapitalContributedInExcessOfPar_B70C52440131664DB50D850F48CCA733" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssued1" xlink:label="loc_us-gaap_StockIssued1_196DCF8CD1933035B28E850F48CC9EDD" xlink:type="locator" />
<link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_33B642340BC7803CFCEF850F48CB8F7E" xlink:to="loc_us-gaap_StockIssued1_196DCF8CD1933035B28E850F48CC9EDD" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_5502F03DB48A1EAD9BED850F48CC72B2" xlink:type="locator" />
<link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_D98B9FD5B538F7B7C6D6850F48C286FA" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_5502F03DB48A1EAD9BED850F48CC72B2" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestrictedCashCurrent" xlink:label="loc_us-gaap_RestrictedCashCurrent_FED23580107C4D9E6065850F48CCAD4D" xlink:type="locator" />
<link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_D98B9FD5B538F7B7C6D6850F48C286FA" xlink:to="loc_us-gaap_RestrictedCashCurrent_FED23580107C4D9E6065850F48CCAD4D" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_8428117B78A6022E4576850F48CDE055" xlink:type="locator" />
<link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_D98B9FD5B538F7B7C6D6850F48C286FA" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_8428117B78A6022E4576850F48CDE055" xlink:type="arc" />
</link:presentationLink>
<link:presentationLink xlink:role="http://www.immunomedics.com/role/ConsolidatedStatementsOfChangesInStockholdersEquity" xlink:type="extended">
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_D1A3D31F912466309A27850F48DDA644" xlink:type="locator" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_A9A06ED6D8261C34DDBF850F48DDF8F4" xlink:type="locator" />
<link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_D1A3D31F912466309A27850F48DDA644" xlink:to="loc_us-gaap_StatementTable_A9A06ED6D8261C34DDBF850F48DDF8F4" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_15756B7A2D16B8E43178850F48DE611C" xlink:type="locator" />
<link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_A9A06ED6D8261C34DDBF850F48DDF8F4" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_15756B7A2D16B8E43178850F48DE611C" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_E789B41A1DB48DFD9079850F48DE3E26" xlink:type="locator" />
<link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_15756B7A2D16B8E43178850F48DE611C" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_E789B41A1DB48DFD9079850F48DE3E26" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IPOMember" xlink:label="loc_us-gaap_IPOMember_95AC806F7D19F0EB11CA850F48DF3621" xlink:type="locator" />
<link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_E789B41A1DB48DFD9079850F48DE3E26" xlink:to="loc_us-gaap_IPOMember_95AC806F7D19F0EB11CA850F48DF3621" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PrivatePlacementMember" xlink:label="loc_us-gaap_PrivatePlacementMember_FD0A23D578E537774A03850F48DF117A" xlink:type="locator" />
<link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_E789B41A1DB48DFD9079850F48DE3E26" xlink:to="loc_us-gaap_PrivatePlacementMember_FD0A23D578E537774A03850F48DF117A" xlink:type="arc" />
<link:loc xlink:href="immu-20191231.xsd#immu_MarketOfferingMember" xlink:label="loc_immu_MarketOfferingMember_387C0703280AC1E7B9D3850F48DF0D7F" xlink:type="locator" />
<link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_E789B41A1DB48DFD9079850F48DE3E26" xlink:to="loc_immu_MarketOfferingMember_387C0703280AC1E7B9D3850F48DF0D7F" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_294C1F252204E5C637B2850F48DFB621" xlink:type="locator" />
<link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_A9A06ED6D8261C34DDBF850F48DDF8F4" xlink:to="loc_us-gaap_StatementClassOfStockAxis_294C1F252204E5C637B2850F48DFB621" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_C659201D059723760708850F48DFB9D8" xlink:type="locator" />
<link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_294C1F252204E5C637B2850F48DFB621" xlink:to="loc_us-gaap_ClassOfStockDomain_C659201D059723760708850F48DFB9D8" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConvertiblePreferredStockMember" xlink:label="loc_us-gaap_ConvertiblePreferredStockMember_D5B2D3184A88C0E61C17850F48E01640" xlink:type="locator" />
<link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_C659201D059723760708850F48DFB9D8" xlink:to="loc_us-gaap_ConvertiblePreferredStockMember_D5B2D3184A88C0E61C17850F48E01640" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_0F208F313B781FECB022850F48E0598A" xlink:type="locator" />
<link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_A9A06ED6D8261C34DDBF850F48DDF8F4" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_0F208F313B781FECB022850F48E0598A" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_14EBFC8826C2D87A3EE6850F48E07D75" xlink:type="locator" />
<link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_0F208F313B781FECB022850F48E0598A" xlink:to="loc_us-gaap_EquityComponentDomain_14EBFC8826C2D87A3EE6850F48E07D75" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_437CBBCB70CB1EBD1F3E850F48E11515" xlink:type="locator" />
<link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_14EBFC8826C2D87A3EE6850F48E07D75" xlink:to="loc_us-gaap_CommonStockMember_437CBBCB70CB1EBD1F3E850F48E11515" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_EA66A60DA9B643BF757C850F48E16D31" xlink:type="locator" />
<link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_14EBFC8826C2D87A3EE6850F48E07D75" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_EA66A60DA9B643BF757C850F48E16D31" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TreasuryStockMember" xlink:label="loc_us-gaap_TreasuryStockMember_EDC648369AD0F435CF24850F48E14504" xlink:type="locator" />
<link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_14EBFC8826C2D87A3EE6850F48E07D75" xlink:to="loc_us-gaap_TreasuryStockMember_EDC648369AD0F435CF24850F48E14504" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaap_RetainedEarningsMember_BAE714DC0477DD395D65850F48E1CCBB" xlink:type="locator" />
<link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_14EBFC8826C2D87A3EE6850F48E07D75" xlink:to="loc_us-gaap_RetainedEarningsMember_BAE714DC0477DD395D65850F48E1CCBB" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_FAF480ECC546AFDC927E850F48E167E8" xlink:type="locator" />
<link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_14EBFC8826C2D87A3EE6850F48E07D75" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_FAF480ECC546AFDC927E850F48E167E8" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NoncontrollingInterestMember" xlink:label="loc_us-gaap_NoncontrollingInterestMember_BA494BD541B0533196F5850F48E2D5FD" xlink:type="locator" />
<link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_14EBFC8826C2D87A3EE6850F48E07D75" xlink:to="loc_us-gaap_NoncontrollingInterestMember_BA494BD541B0533196F5850F48E2D5FD" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_CounterpartyNameAxis" xlink:label="loc_srt_CounterpartyNameAxis_E5E2CBB5F996E0C17E16850F48E2492B" xlink:type="locator" />
<link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_A9A06ED6D8261C34DDBF850F48DDF8F4" xlink:to="loc_srt_CounterpartyNameAxis_E5E2CBB5F996E0C17E16850F48E2492B" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_77E293748596D62200C1850F48E27DBC" xlink:type="locator" />
<link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_E5E2CBB5F996E0C17E16850F48E2492B" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_77E293748596D62200C1850F48E27DBC" xlink:type="arc" />
<link:loc xlink:href="immu-20191231.xsd#immu_SeattleGeneticsIncMember" xlink:label="loc_immu_SeattleGeneticsIncMember_8C34F696C8DF1B4F6523850F48E262BB" xlink:type="locator" />
<link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_77E293748596D62200C1850F48E27DBC" xlink:to="loc_immu_SeattleGeneticsIncMember_8C34F696C8DF1B4F6523850F48E262BB" xlink:type="arc" />
<link:loc xlink:href="immu-20191231.xsd#immu_RpiFinanceTrustMember" xlink:label="loc_immu_RpiFinanceTrustMember_3423230DE51DFAF8DDFD850F48E30A07" xlink:type="locator" />
<link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_77E293748596D62200C1850F48E27DBC" xlink:to="loc_immu_RpiFinanceTrustMember_3423230DE51DFAF8DDFD850F48E30A07" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_87A5F0DCA73FC9570251850F48E3D4A1" xlink:type="locator" />
<link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_A9A06ED6D8261C34DDBF850F48DDF8F4" xlink:to="loc_us-gaap_StatementLineItems_87A5F0DCA73FC9570251850F48E3D4A1" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_A12D4BD358632C8D685E850F48E3F4B3" xlink:type="locator" />
<link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_87A5F0DCA73FC9570251850F48E3D4A1" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_A12D4BD358632C8D685E850F48E3F4B3" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharesIssued" xlink:label="loc_us-gaap_SharesIssued_4A453983E0984B9A43BE850F48E39E07" xlink:type="locator" />
<link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_A12D4BD358632C8D685E850F48E3F4B3" xlink:to="loc_us-gaap_SharesIssued_4A453983E0984B9A43BE850F48E39E07" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_BBFD876070595A1BD882850F48E357EC" xlink:type="locator" />
<link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_A12D4BD358632C8D685E850F48E3F4B3" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_BBFD876070595A1BD882850F48E357EC" xlink:type="arc" />
<link:loc xlink:href="immu-20191231.xsd#immu_ReclassificationofWarrantLiabilitytoEquity" xlink:label="loc_immu_ReclassificationofWarrantLiabilitytoEquity_C69945798460F35A0E09850F48E47CED" xlink:type="locator" />
<link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_A12D4BD358632C8D685E850F48E3F4B3" xlink:to="loc_immu_ReclassificationofWarrantLiabilitytoEquity_C69945798460F35A0E09850F48E47CED" xlink:type="arc" />
<link:loc xlink:href="immu-20191231.xsd#immu_PreferredStockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_immu_PreferredStockIssuedDuringPeriodSharesNewIssues_D8342A9C590697F3E00A850F48E4E410" xlink:type="locator" />
<link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_A12D4BD358632C8D685E850F48E3F4B3" xlink:to="loc_immu_PreferredStockIssuedDuringPeriodSharesNewIssues_D8342A9C590697F3E00A850F48E4E410" xlink:type="arc" />
<link:loc xlink:href="immu-20191231.xsd#immu_PreferredStockIssuedDuringPeriodValueNewIssues" xlink:label="loc_immu_PreferredStockIssuedDuringPeriodValueNewIssues_6FB76EADC68491CC8FC1850F48E46180" xlink:type="locator" />
<link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_A12D4BD358632C8D685E850F48E3F4B3" xlink:to="loc_immu_PreferredStockIssuedDuringPeriodValueNewIssues_6FB76EADC68491CC8FC1850F48E46180" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_8ADD141794E7CC15B600850F48E43469" xlink:type="locator" />
<link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_A12D4BD358632C8D685E850F48E3F4B3" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_8ADD141794E7CC15B600850F48E43469" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_3802BC977357ADE17F2A850F48E4437C" xlink:type="locator" />
<link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_A12D4BD358632C8D685E850F48E3F4B3" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_3802BC977357ADE17F2A850F48E4437C" xlink:type="arc" />
<link:loc xlink:href="immu-20191231.xsd#immu_AdjustmentstoAdditionalPaidinCapitalProceedsFromOfferingWarrants" xlink:label="loc_immu_AdjustmentstoAdditionalPaidinCapitalProceedsFromOfferingWarrants_04138668A5E69C0DB8F7850F48E4F5EF" xlink:type="locator" />
<link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" priority="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_A12D4BD358632C8D685E850F48E3F4B3" xlink:to="loc_immu_AdjustmentstoAdditionalPaidinCapitalProceedsFromOfferingWarrants_04138668A5E69C0DB8F7850F48E4F5EF" xlink:type="arc" />
<link:loc xlink:href="immu-20191231.xsd#immu_SharebasedCompensationArrangementbySharebasedPaymentAwardWarrantsExercisesinPeriod" xlink:label="loc_immu_SharebasedCompensationArrangementbySharebasedPaymentAwardWarrantsExercisesinPeriod_9EEC82250E188ADE056C850F48E4E6E8" xlink:type="locator" />
<link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_A12D4BD358632C8D685E850F48E3F4B3" xlink:to="loc_immu_SharebasedCompensationArrangementbySharebasedPaymentAwardWarrantsExercisesinPeriod_9EEC82250E188ADE056C850F48E4E6E8" xlink:type="arc" />
<link:loc xlink:href="immu-20191231.xsd#immu_StockIssuedDuringPeriodValueWarrantsExercised" xlink:label="loc_immu_StockIssuedDuringPeriodValueWarrantsExercised_992AAE67CA6E289D4C7E850F48E53AC3" xlink:type="locator" />
<link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_A12D4BD358632C8D685E850F48E3F4B3" xlink:to="loc_immu_StockIssuedDuringPeriodValueWarrantsExercised_992AAE67CA6E289D4C7E850F48E53AC3" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_1CDA7B53D2CBC0F42281850F48E51E76" xlink:type="locator" />
<link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_A12D4BD358632C8D685E850F48E3F4B3" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_1CDA7B53D2CBC0F42281850F48E51E76" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_E6FC38FC84E7D8185F2D850F48E5DFF0" xlink:type="locator" />
<link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_A12D4BD358632C8D685E850F48E3F4B3" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_E6FC38FC84E7D8185F2D850F48E5DFF0" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockRepurchasedAndRetiredDuringPeriodShares" xlink:label="loc_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares_2AF90E976E0A321AB2F6850F48E5C9A7" xlink:type="locator" />
<link:presentationArc order="13" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_A12D4BD358632C8D685E850F48E3F4B3" xlink:to="loc_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares_2AF90E976E0A321AB2F6850F48E5C9A7" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockRepurchasedAndRetiredDuringPeriodValue" xlink:label="loc_us-gaap_StockRepurchasedAndRetiredDuringPeriodValue_887486DA5BC550402115850F48E53209" xlink:type="locator" />
<link:presentationArc order="14" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_A12D4BD358632C8D685E850F48E3F4B3" xlink:to="loc_us-gaap_StockRepurchasedAndRetiredDuringPeriodValue_887486DA5BC550402115850F48E53209" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits_DA3269606B708A297FA3850F48E59800" xlink:type="locator" />
<link:presentationArc order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_A12D4BD358632C8D685E850F48E3F4B3" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits_DA3269606B708A297FA3850F48E59800" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecuritiesNetOfAdjustments" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecuritiesNetOfAdjustments_7E83FCCCE8B849ECA82F850F48E6158C" xlink:type="locator" />
<link:presentationArc order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_A12D4BD358632C8D685E850F48E3F4B3" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecuritiesNetOfAdjustments_7E83FCCCE8B849ECA82F850F48E6158C" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xlink:label="loc_us-gaap_DebtConversionConvertedInstrumentSharesIssued1_187BCF77647D53F7B9B4850F48E694E0" xlink:type="locator" />
<link:presentationArc order="17" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_A12D4BD358632C8D685E850F48E3F4B3" xlink:to="loc_us-gaap_DebtConversionConvertedInstrumentSharesIssued1_187BCF77647D53F7B9B4850F48E694E0" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtConversionConvertedInstrumentAmount1" xlink:label="loc_us-gaap_DebtConversionConvertedInstrumentAmount1_FF207936941DB371E8C9850F48E6A3AE" xlink:type="locator" />
<link:presentationArc order="18" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_A12D4BD358632C8D685E850F48E3F4B3" xlink:to="loc_us-gaap_DebtConversionConvertedInstrumentAmount1_FF207936941DB371E8C9850F48E6A3AE" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_46CBF5E7A9B3DDA4B9B6850F48E64F4D" xlink:type="locator" />
<link:presentationArc order="19" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_A12D4BD358632C8D685E850F48E3F4B3" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_46CBF5E7A9B3DDA4B9B6850F48E64F4D" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_C51B3FFFFC9B210094CF850F48E6B0DE" xlink:type="locator" />
<link:presentationArc order="20" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_A12D4BD358632C8D685E850F48E3F4B3" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_C51B3FFFFC9B210094CF850F48E6B0DE" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation" xlink:label="loc_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation_4FCB2713E25854ADD7B1850F48E7ECD9" xlink:type="locator" />
<link:presentationArc order="21" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_A12D4BD358632C8D685E850F48E3F4B3" xlink:to="loc_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation_4FCB2713E25854ADD7B1850F48E7ECD9" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:label="loc_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation_A2B092E90D16EAAC49B2850F48E70AB0" xlink:type="locator" />
<link:presentationArc order="22" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_A12D4BD358632C8D685E850F48E3F4B3" xlink:to="loc_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation_A2B092E90D16EAAC49B2850F48E70AB0" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_BD93D9EAC0AFA298A9F6850F48E72C9D" xlink:type="locator" />
<link:presentationArc order="23" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_A12D4BD358632C8D685E850F48E3F4B3" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_BD93D9EAC0AFA298A9F6850F48E72C9D" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProfitLoss" xlink:label="loc_us-gaap_ProfitLoss_3C98C26798907127CDA1850F48E70D0D" xlink:type="locator" />
<link:presentationArc order="24" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_A12D4BD358632C8D685E850F48E3F4B3" xlink:to="loc_us-gaap_ProfitLoss_3C98C26798907127CDA1850F48E70D0D" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharesIssued" xlink:label="loc_us-gaap_SharesIssued_27D56B2D50C72A29AA4B850F48E7D665" xlink:type="locator" />
<link:presentationArc order="25" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_A12D4BD358632C8D685E850F48E3F4B3" xlink:to="loc_us-gaap_SharesIssued_27D56B2D50C72A29AA4B850F48E7D665" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_C8480ACC8A33849C0D1D850F48E7252C" xlink:type="locator" />
<link:presentationArc order="26" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_A12D4BD358632C8D685E850F48E3F4B3" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_C8480ACC8A33849C0D1D850F48E7252C" xlink:type="arc" />
</link:presentationLink>
<link:presentationLink xlink:role="http://www.immunomedics.com/role/ConsolidatedStatementsOfComprehensiveLoss" xlink:type="extended">
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:label="loc_us-gaap_IncomeStatementAbstract_90F00AFAEF34FF8F63353991D2ED2C6C" xlink:type="locator" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_3825C0A03532CAE333323991D2ED7BE8" xlink:type="locator" />
<link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_90F00AFAEF34FF8F63353991D2ED2C6C" xlink:to="loc_us-gaap_StatementTable_3825C0A03532CAE333323991D2ED7BE8" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="loc_srt_ProductOrServiceAxis_22CF8D6FA4D195CFB0A23991D2EDA726" xlink:type="locator" />
<link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_3825C0A03532CAE333323991D2ED7BE8" xlink:to="loc_srt_ProductOrServiceAxis_22CF8D6FA4D195CFB0A23991D2EDA726" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain_49B4A8F93F2BE7F95EC83991D2EE4186" xlink:type="locator" />
<link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_22CF8D6FA4D195CFB0A23991D2EDA726" xlink:to="loc_srt_ProductsAndServicesDomain_49B4A8F93F2BE7F95EC83991D2EE4186" xlink:type="arc" />
<link:loc xlink:href="immu-20191231.xsd#immu_ProductSalesMember" xlink:label="loc_immu_ProductSalesMember_45A60C0F21551244EA603991D2EE2686" xlink:type="locator" />
<link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_49B4A8F93F2BE7F95EC83991D2EE4186" xlink:to="loc_immu_ProductSalesMember_45A60C0F21551244EA603991D2EE2686" xlink:type="arc" />
<link:loc xlink:href="immu-20191231.xsd#immu_LicenseFreeAndOtherRevenueMember" xlink:label="loc_immu_LicenseFreeAndOtherRevenueMember_0B44C7717F9249711D103991D2EEE4A0" xlink:type="locator" />
<link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_49B4A8F93F2BE7F95EC83991D2EE4186" xlink:to="loc_immu_LicenseFreeAndOtherRevenueMember_0B44C7717F9249711D103991D2EEE4A0" xlink:type="arc" />
<link:loc xlink:href="immu-20191231.xsd#immu_ResearchandDevelopmentMember" xlink:label="loc_immu_ResearchandDevelopmentMember_21F77234471BFC2EF67D3991D2EE395C" xlink:type="locator" />
<link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_49B4A8F93F2BE7F95EC83991D2EE4186" xlink:to="loc_immu_ResearchandDevelopmentMember_21F77234471BFC2EF67D3991D2EE395C" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_64808253156529864DB73991D2EE9751" xlink:type="locator" />
<link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_3825C0A03532CAE333323991D2ED7BE8" xlink:to="loc_us-gaap_StatementLineItems_64808253156529864DB73991D2EE9751" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_6306CCA70B26123DEA0B3991D2EEA6C9" xlink:type="locator" />
<link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_64808253156529864DB73991D2EE9751" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_6306CCA70B26123DEA0B3991D2EEA6C9" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingCostsAndExpensesAbstract" xlink:label="loc_us-gaap_OperatingCostsAndExpensesAbstract_B0A834C896BE79AA3C943991D2EF6DE2" xlink:type="locator" />
<link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_64808253156529864DB73991D2EE9751" xlink:to="loc_us-gaap_OperatingCostsAndExpensesAbstract_B0A834C896BE79AA3C943991D2EF6DE2" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CostOfRevenue" xlink:label="loc_us-gaap_CostOfRevenue_CC8BF2DAC8FFA253B10E3991D2EF784A" xlink:type="locator" />
<link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingCostsAndExpensesAbstract_B0A834C896BE79AA3C943991D2EF6DE2" xlink:to="loc_us-gaap_CostOfRevenue_CC8BF2DAC8FFA253B10E3991D2EF784A" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_6BE5C575300BDA7173053991D2EF16C1" xlink:type="locator" />
<link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingCostsAndExpensesAbstract_B0A834C896BE79AA3C943991D2EF6DE2" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_6BE5C575300BDA7173053991D2EF16C1" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SellingAndMarketingExpense" xlink:label="loc_us-gaap_SellingAndMarketingExpense_B19B5F04389E85B2AAC23991D2EF2FD3" xlink:type="locator" />
<link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingCostsAndExpensesAbstract_B0A834C896BE79AA3C943991D2EF6DE2" xlink:to="loc_us-gaap_SellingAndMarketingExpense_B19B5F04389E85B2AAC23991D2EF2FD3" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_B6FD0A604E52D8847AB83991D2F0B458" xlink:type="locator" />
<link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingCostsAndExpensesAbstract_B0A834C896BE79AA3C943991D2EF6DE2" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_B6FD0A604E52D8847AB83991D2F0B458" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CostsAndExpenses" xlink:label="loc_us-gaap_CostsAndExpenses_A0DB6A50253584EF4E613991D2F01F7A" xlink:type="locator" />
<link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingCostsAndExpensesAbstract_B0A834C896BE79AA3C943991D2EF6DE2" xlink:to="loc_us-gaap_CostsAndExpenses_A0DB6A50253584EF4E613991D2F01F7A" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaap_OperatingIncomeLoss_F77C73B193B830DC98D23991D2F0FDB6" xlink:type="locator" />
<link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_64808253156529864DB73991D2EE9751" xlink:to="loc_us-gaap_OperatingIncomeLoss_F77C73B193B830DC98D23991D2F0FDB6" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="loc_us-gaap_FairValueAdjustmentOfWarrants_07807BE17701BA7D655C3991D2F0EC35" xlink:type="locator" />
<link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_64808253156529864DB73991D2EE9751" xlink:to="loc_us-gaap_FairValueAdjustmentOfWarrants_07807BE17701BA7D655C3991D2F0EC35" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdjustmentOfWarrantsGrantedForServices" xlink:label="loc_us-gaap_AdjustmentOfWarrantsGrantedForServices_8FB3BFAE946622C778683991D2F09B24" xlink:type="locator" />
<link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_64808253156529864DB73991D2EE9751" xlink:to="loc_us-gaap_AdjustmentOfWarrantsGrantedForServices_8FB3BFAE946622C778683991D2F09B24" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InterestExpense" xlink:label="loc_us-gaap_InterestExpense_2B792A808FCECD48E3103991D2F012BD" xlink:type="locator" />
<link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_64808253156529864DB73991D2EE9751" xlink:to="loc_us-gaap_InterestExpense_2B792A808FCECD48E3103991D2F012BD" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InterestAndOtherIncome" xlink:label="loc_us-gaap_InterestAndOtherIncome_48115CA82FF3FA7913C83991D2F05F9C" xlink:type="locator" />
<link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_64808253156529864DB73991D2EE9751" xlink:to="loc_us-gaap_InterestAndOtherIncome_48115CA82FF3FA7913C83991D2F05F9C" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_343F36BBA1351D4307503991D2F1A9D9" xlink:type="locator" />
<link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_64808253156529864DB73991D2EE9751" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_343F36BBA1351D4307503991D2F1A9D9" xlink:type="arc" />
<link:loc xlink:href="immu-20191231.xsd#immu_OtherFinancingExpenseIncome" xlink:label="loc_immu_OtherFinancingExpenseIncome_1A249C92A1AD8D640FB23991D2F125B7" xlink:type="locator" />
<link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_64808253156529864DB73991D2EE9751" xlink:to="loc_immu_OtherFinancingExpenseIncome_1A249C92A1AD8D640FB23991D2F125B7" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GainOnBusinessInterruptionInsuranceRecovery" xlink:label="loc_us-gaap_GainOnBusinessInterruptionInsuranceRecovery_934167A48ABC430009B43991D2F1EF4B" xlink:type="locator" />
<link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_64808253156529864DB73991D2EE9751" xlink:to="loc_us-gaap_GainOnBusinessInterruptionInsuranceRecovery_934167A48ABC430009B43991D2F1EF4B" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:label="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_6D00024E1D56B1A069B73991D2F1A04B" xlink:type="locator" />
<link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_64808253156529864DB73991D2EE9751" xlink:to="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_6D00024E1D56B1A069B73991D2F1A04B" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_37D2660895D0FDE20A8E3991D2F1FDDC" xlink:type="locator" />
<link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_64808253156529864DB73991D2EE9751" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_37D2660895D0FDE20A8E3991D2F1FDDC" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_C7AF9F997E338E8448DD3991D2F23A3B" xlink:type="locator" />
<link:presentationArc order="13" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_64808253156529864DB73991D2EE9751" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_C7AF9F997E338E8448DD3991D2F23A3B" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProfitLoss" xlink:label="loc_us-gaap_ProfitLoss_5A6E14ED519E24FDF5193991D2F20BD9" xlink:type="locator" />
<link:presentationArc order="14" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_64808253156529864DB73991D2EE9751" xlink:to="loc_us-gaap_ProfitLoss_5A6E14ED519E24FDF5193991D2F20BD9" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_835D025D4EDD419966A43991D2F27E72" xlink:type="locator" />
<link:presentationArc order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_64808253156529864DB73991D2EE9751" xlink:to="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_835D025D4EDD419966A43991D2F27E72" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_F99ECE8B1B9C2A7D1EAF3991D2F28FE6" xlink:type="locator" />
<link:presentationArc order="16" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_64808253156529864DB73991D2EE9751" xlink:to="loc_us-gaap_NetIncomeLoss_F99ECE8B1B9C2A7D1EAF3991D2F28FE6" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDiluted_93C4BC00FC5DDA6180643991D2F2E687" xlink:type="locator" />
<link:presentationArc order="17" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_64808253156529864DB73991D2EE9751" xlink:to="loc_us-gaap_EarningsPerShareBasicAndDiluted_93C4BC00FC5DDA6180643991D2F2E687" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:label="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_A45B79CD9CC922FE84A33991D2F2BAAA" xlink:type="locator" />
<link:presentationArc order="18" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_64808253156529864DB73991D2EE9751" xlink:to="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_A45B79CD9CC922FE84A33991D2F2BAAA" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_D81D592D3CEE8D11603E3991D2F29E1B" xlink:type="locator" />
<link:presentationArc order="19" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_64808253156529864DB73991D2EE9751" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_D81D592D3CEE8D11603E3991D2F29E1B" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_CCA16121786BAC259F223991D2F32C88" xlink:type="locator" />
<link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_D81D592D3CEE8D11603E3991D2F29E1B" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_CCA16121786BAC259F223991D2F32C88" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_78131803F2859990C7943991D2F3EBDE" xlink:type="locator" />
<link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_D81D592D3CEE8D11603E3991D2F29E1B" xlink:to="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_78131803F2859990C7943991D2F3EBDE" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_27F826F1BEB8FA2318F93991D2F3BFF4" xlink:type="locator" />
<link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_D81D592D3CEE8D11603E3991D2F29E1B" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_27F826F1BEB8FA2318F93991D2F3BFF4" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_B25BA9D06E81AEDB075B3991D2F3FCDD" xlink:type="locator" />
<link:presentationArc order="20" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_64808253156529864DB73991D2EE9751" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_B25BA9D06E81AEDB075B3991D2F3FCDD" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_45C840BA398E4E3D4B913991D2F33518" xlink:type="locator" />
<link:presentationArc order="21" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_64808253156529864DB73991D2EE9751" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_45C840BA398E4E3D4B913991D2F33518" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_F3B9419815158C25580A3991D2F3D24D" xlink:type="locator" />
<link:presentationArc order="22" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_64808253156529864DB73991D2EE9751" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTax_F3B9419815158C25580A3991D2F3D24D" xlink:type="arc" />
</link:presentationLink>
<link:presentationLink xlink:role="http://www.immunomedics.com/role/CoverPage" xlink:type="extended">
<link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CoverAbstract" xlink:label="loc_dei_CoverAbstract_EA6F80DC35A952F1E4887E59E4CA4181" xlink:type="locator" />
<link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentType" xlink:label="loc_dei_DocumentType_CFC168DFDA8435D5AEEF7E59E4CA6A9B" xlink:type="locator" />
<link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_EA6F80DC35A952F1E4887E59E4CA4181" xlink:to="loc_dei_DocumentType_CFC168DFDA8435D5AEEF7E59E4CA6A9B" xlink:type="arc" />
<link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentAnnualReport" xlink:label="loc_dei_DocumentAnnualReport_3931EC4AB87F7793F4D67E59E4CAB74C" xlink:type="locator" />
<link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_EA6F80DC35A952F1E4887E59E4CA4181" xlink:to="loc_dei_DocumentAnnualReport_3931EC4AB87F7793F4D67E59E4CAB74C" xlink:type="arc" />
<link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_dei_DocumentPeriodEndDate_E3119447EB32A8BB81F57E59E4CACE89" xlink:type="locator" />
<link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_EA6F80DC35A952F1E4887E59E4CA4181" xlink:to="loc_dei_DocumentPeriodEndDate_E3119447EB32A8BB81F57E59E4CACE89" xlink:type="arc" />
<link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentTransitionReport" xlink:label="loc_dei_DocumentTransitionReport_B6945A303E37CD7DA5AF7E59E4CA9D14" xlink:type="locator" />
<link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_EA6F80DC35A952F1E4887E59E4CA4181" xlink:to="loc_dei_DocumentTransitionReport_B6945A303E37CD7DA5AF7E59E4CA9D14" xlink:type="arc" />
<link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityFileNumber" xlink:label="loc_dei_EntityFileNumber_9994590247217BF8A8367E59E4CB0779" xlink:type="locator" />
<link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_EA6F80DC35A952F1E4887E59E4CA4181" xlink:to="loc_dei_EntityFileNumber_9994590247217BF8A8367E59E4CB0779" xlink:type="arc" />
<link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityRegistrantName" xlink:label="loc_dei_EntityRegistrantName_A98076C696DE0666D5947E59E4CB6A88" xlink:type="locator" />
<link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_EA6F80DC35A952F1E4887E59E4CA4181" xlink:to="loc_dei_EntityRegistrantName_A98076C696DE0666D5947E59E4CB6A88" xlink:type="arc" />
<link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="loc_dei_EntityIncorporationStateCountryCode_21357F6AA2FC500563487E59E4CBF511" xlink:type="locator" />
<link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_EA6F80DC35A952F1E4887E59E4CA4181" xlink:to="loc_dei_EntityIncorporationStateCountryCode_21357F6AA2FC500563487E59E4CBF511" xlink:type="arc" />
<link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityTaxIdentificationNumber" xlink:label="loc_dei_EntityTaxIdentificationNumber_371F07EEE8E7407DF6DB7E59E4CB7194" xlink:type="locator" />
<link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_EA6F80DC35A952F1E4887E59E4CA4181" xlink:to="loc_dei_EntityTaxIdentificationNumber_371F07EEE8E7407DF6DB7E59E4CB7194" xlink:type="arc" />
<link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressAddressLine1" xlink:label="loc_dei_EntityAddressAddressLine1_19A7BFB89CD516726CF27E59E4CB5ED6" xlink:type="locator" />
<link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_EA6F80DC35A952F1E4887E59E4CA4181" xlink:to="loc_dei_EntityAddressAddressLine1_19A7BFB89CD516726CF27E59E4CB5ED6" xlink:type="arc" />
<link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressCityOrTown" xlink:label="loc_dei_EntityAddressCityOrTown_12C815816E56370B66CA7E59E4CB7A27" xlink:type="locator" />
<link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_EA6F80DC35A952F1E4887E59E4CA4181" xlink:to="loc_dei_EntityAddressCityOrTown_12C815816E56370B66CA7E59E4CB7A27" xlink:type="arc" />
<link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressStateOrProvince" xlink:label="loc_dei_EntityAddressStateOrProvince_30530D96EAB66AB3F5AE7E59E4CC1BC1" xlink:type="locator" />
<link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_EA6F80DC35A952F1E4887E59E4CA4181" xlink:to="loc_dei_EntityAddressStateOrProvince_30530D96EAB66AB3F5AE7E59E4CC1BC1" xlink:type="arc" />
<link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressPostalZipCode" xlink:label="loc_dei_EntityAddressPostalZipCode_1BCEA833A2FF33702D6E7E59E4CCC31D" xlink:type="locator" />
<link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_EA6F80DC35A952F1E4887E59E4CA4181" xlink:to="loc_dei_EntityAddressPostalZipCode_1BCEA833A2FF33702D6E7E59E4CCC31D" xlink:type="arc" />
<link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CityAreaCode" xlink:label="loc_dei_CityAreaCode_F6F3164FCDE20CFF5DB97E59E4CCF272" xlink:type="locator" />
<link:presentationArc order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_EA6F80DC35A952F1E4887E59E4CA4181" xlink:to="loc_dei_CityAreaCode_F6F3164FCDE20CFF5DB97E59E4CCF272" xlink:type="arc" />
<link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LocalPhoneNumber" xlink:label="loc_dei_LocalPhoneNumber_0E773D2CF342577978007E59E4CC37BB" xlink:type="locator" />
<link:presentationArc order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_EA6F80DC35A952F1E4887E59E4CA4181" xlink:to="loc_dei_LocalPhoneNumber_0E773D2CF342577978007E59E4CC37BB" xlink:type="arc" />
<link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_Security12bTitle" xlink:label="loc_dei_Security12bTitle_8C30A90A57F7537194067E59E4CC6B1F" xlink:type="locator" />
<link:presentationArc order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_EA6F80DC35A952F1E4887E59E4CA4181" xlink:to="loc_dei_Security12bTitle_8C30A90A57F7537194067E59E4CC6B1F" xlink:type="arc" />
<link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_TradingSymbol" xlink:label="loc_dei_TradingSymbol_A5EC51EA4D7F32B97C1D7E59E4CCACCB" xlink:type="locator" />
<link:presentationArc order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_EA6F80DC35A952F1E4887E59E4CA4181" xlink:to="loc_dei_TradingSymbol_A5EC51EA4D7F32B97C1D7E59E4CCACCB" xlink:type="arc" />
<link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_SecurityExchangeName" xlink:label="loc_dei_SecurityExchangeName_56003D725C56ECCA6CC87E59E4CD2524" xlink:type="locator" />
<link:presentationArc order="17" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_EA6F80DC35A952F1E4887E59E4CA4181" xlink:to="loc_dei_SecurityExchangeName_56003D725C56ECCA6CC87E59E4CD2524" xlink:type="arc" />
<link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="loc_dei_EntityWellKnownSeasonedIssuer_BE13B4B041013B9BB66F7E59E4CD3902" xlink:type="locator" />
<link:presentationArc order="18" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_EA6F80DC35A952F1E4887E59E4CA4181" xlink:to="loc_dei_EntityWellKnownSeasonedIssuer_BE13B4B041013B9BB66F7E59E4CD3902" xlink:type="arc" />
<link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityVoluntaryFilers" xlink:label="loc_dei_EntityVoluntaryFilers_0152253F74093EDFCCA57E59E4CDEF30" xlink:type="locator" />
<link:presentationArc order="19" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_EA6F80DC35A952F1E4887E59E4CA4181" xlink:to="loc_dei_EntityVoluntaryFilers_0152253F74093EDFCCA57E59E4CDEF30" xlink:type="arc" />
<link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCurrentReportingStatus" xlink:label="loc_dei_EntityCurrentReportingStatus_4EE42BF191956F853E5F7E59E4CDD19C" xlink:type="locator" />
<link:presentationArc order="20" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_EA6F80DC35A952F1E4887E59E4CA4181" xlink:to="loc_dei_EntityCurrentReportingStatus_4EE42BF191956F853E5F7E59E4CDD19C" xlink:type="arc" />
<link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityInteractiveDataCurrent" xlink:label="loc_dei_EntityInteractiveDataCurrent_CA61AE2F4A794B2672DA7E59E4CD8378" xlink:type="locator" />
<link:presentationArc order="21" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_EA6F80DC35A952F1E4887E59E4CA4181" xlink:to="loc_dei_EntityInteractiveDataCurrent_CA61AE2F4A794B2672DA7E59E4CD8378" xlink:type="arc" />
<link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityShellCompany" xlink:label="loc_dei_EntityShellCompany_E16D14538EE7A4AE31DB7E5C6B50501F" xlink:type="locator" />
<link:presentationArc order="22" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_EA6F80DC35A952F1E4887E59E4CA4181" xlink:to="loc_dei_EntityShellCompany_E16D14538EE7A4AE31DB7E5C6B50501F" xlink:type="arc" />
<link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityFilerCategory" xlink:label="loc_dei_EntityFilerCategory_8A9AEDFB76331A184D657E59E4CD015B" xlink:type="locator" />
<link:presentationArc order="23" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_EA6F80DC35A952F1E4887E59E4CA4181" xlink:to="loc_dei_EntityFilerCategory_8A9AEDFB76331A184D657E59E4CD015B" xlink:type="arc" />
<link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntitySmallBusiness" xlink:label="loc_dei_EntitySmallBusiness_051DF2EA6668A189F9DF7E59E4CD7F50" xlink:type="locator" />
<link:presentationArc order="24" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_EA6F80DC35A952F1E4887E59E4CA4181" xlink:to="loc_dei_EntitySmallBusiness_051DF2EA6668A189F9DF7E59E4CD7F50" xlink:type="arc" />
<link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityEmergingGrowthCompany" xlink:label="loc_dei_EntityEmergingGrowthCompany_DC6945B444D9E69160217E59E4CE26B7" xlink:type="locator" />
<link:presentationArc order="25" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_EA6F80DC35A952F1E4887E59E4CA4181" xlink:to="loc_dei_EntityEmergingGrowthCompany_DC6945B444D9E69160217E59E4CE26B7" xlink:type="arc" />
<link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityPublicFloat" xlink:label="loc_dei_EntityPublicFloat_6F6129761753420F79237E59E4CE16CE" xlink:type="locator" />
<link:presentationArc order="26" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_EA6F80DC35A952F1E4887E59E4CA4181" xlink:to="loc_dei_EntityPublicFloat_6F6129761753420F79237E59E4CE16CE" xlink:type="arc" />
<link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_7230C916E958236933947E59E4CEB119" xlink:type="locator" />
<link:presentationArc order="27" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_EA6F80DC35A952F1E4887E59E4CA4181" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_7230C916E958236933947E59E4CEB119" xlink:type="arc" />
<link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="loc_dei_DocumentsIncorporatedByReferenceTextBlock_1386838E78E7140B3C007E59E4CEF815" xlink:type="locator" />
<link:presentationArc order="28" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_EA6F80DC35A952F1E4887E59E4CA4181" xlink:to="loc_dei_DocumentsIncorporatedByReferenceTextBlock_1386838E78E7140B3C007E59E4CEF815" xlink:type="arc" />
<link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="loc_dei_EntityCentralIndexKey_2B37F4EEA9AB1EB9A27F7E59E4CE0881" xlink:type="locator" />
<link:presentationArc order="29" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_EA6F80DC35A952F1E4887E59E4CA4181" xlink:to="loc_dei_EntityCentralIndexKey_2B37F4EEA9AB1EB9A27F7E59E4CE0881" xlink:type="arc" />
<link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_dei_CurrentFiscalYearEndDate_D6BA800749AA684DD20F7E59E4CE9FC2" xlink:type="locator" />
<link:presentationArc order="30" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_EA6F80DC35A952F1E4887E59E4CA4181" xlink:to="loc_dei_CurrentFiscalYearEndDate_D6BA800749AA684DD20F7E59E4CE9FC2" xlink:type="arc" />
<link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_dei_DocumentFiscalYearFocus_A9E301F16839812958857E59E4D430B3" xlink:type="locator" />
<link:presentationArc order="31" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_EA6F80DC35A952F1E4887E59E4CA4181" xlink:to="loc_dei_DocumentFiscalYearFocus_A9E301F16839812958857E59E4D430B3" xlink:type="arc" />
<link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_dei_DocumentFiscalPeriodFocus_6E9375C9452DCD92F2357E59E4D4D22B" xlink:type="locator" />
<link:presentationArc order="32" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_EA6F80DC35A952F1E4887E59E4CA4181" xlink:to="loc_dei_DocumentFiscalPeriodFocus_6E9375C9452DCD92F2357E59E4D4D22B" xlink:type="arc" />
<link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_AmendmentFlag" xlink:label="loc_dei_AmendmentFlag_2359E165651EBF5A05907E59E4D44451" xlink:type="locator" />
<link:presentationArc order="33" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_EA6F80DC35A952F1E4887E59E4CA4181" xlink:to="loc_dei_AmendmentFlag_2359E165651EBF5A05907E59E4D44451" xlink:type="arc" />
</link:presentationLink>
<link:presentationLink xlink:role="http://www.immunomedics.com/role/Debt" xlink:type="extended">
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="loc_us-gaap_DebtDisclosureAbstract_F3264AF19924F3FDD1F7D1D062618CB5" xlink:type="locator" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtDisclosureTextBlock" xlink:label="loc_us-gaap_DebtDisclosureTextBlock_DF837FA62C8C1BD38670D1D06261D8DA" xlink:type="locator" />
<link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_F3264AF19924F3FDD1F7D1D062618CB5" xlink:to="loc_us-gaap_DebtDisclosureTextBlock_DF837FA62C8C1BD38670D1D06261D8DA" xlink:type="arc" />
</link:presentationLink>
<link:presentationLink xlink:role="http://www.immunomedics.com/role/DebtConsiderationAllocationDetails" xlink:type="extended">
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="loc_us-gaap_DebtDisclosureAbstract_E3ECD6E7D1451A982C7EDC8C2524CCC8" xlink:type="locator" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredRevenueArrangementByTypeTable" xlink:label="loc_us-gaap_DeferredRevenueArrangementByTypeTable_21DD3A5BE1049858A70BDC8C25240E9E" xlink:type="locator" />
<link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_E3ECD6E7D1451A982C7EDC8C2524CCC8" xlink:to="loc_us-gaap_DeferredRevenueArrangementByTypeTable_21DD3A5BE1049858A70BDC8C25240E9E" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_CounterpartyNameAxis" xlink:label="loc_srt_CounterpartyNameAxis_C276CB6187B98FBBB678DC8C2524FE7B" xlink:type="locator" />
<link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredRevenueArrangementByTypeTable_21DD3A5BE1049858A70BDC8C25240E9E" xlink:to="loc_srt_CounterpartyNameAxis_C276CB6187B98FBBB678DC8C2524FE7B" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_C747660E21FE22C1ABA4DC8C25253739" xlink:type="locator" />
<link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_C276CB6187B98FBBB678DC8C2524FE7B" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_C747660E21FE22C1ABA4DC8C25253739" xlink:type="arc" />
<link:loc xlink:href="immu-20191231.xsd#immu_RpiFinanceTrustMember" xlink:label="loc_immu_RpiFinanceTrustMember_3489A6D92C293A8A20AEDC8C252522FD" xlink:type="locator" />
<link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_C747660E21FE22C1ABA4DC8C25253739" xlink:to="loc_immu_RpiFinanceTrustMember_3489A6D92C293A8A20AEDC8C252522FD" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredRevenueArrangementTypeAxis" xlink:label="loc_us-gaap_DeferredRevenueArrangementTypeAxis_81832223976D9C8D3C60DC8C25252006" xlink:type="locator" />
<link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredRevenueArrangementByTypeTable_21DD3A5BE1049858A70BDC8C25240E9E" xlink:to="loc_us-gaap_DeferredRevenueArrangementTypeAxis_81832223976D9C8D3C60DC8C25252006" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredRevenueArrangementTypeDomain" xlink:label="loc_us-gaap_DeferredRevenueArrangementTypeDomain_64ABE74EC10ED1C2E578DC8C25255A4D" xlink:type="locator" />
<link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredRevenueArrangementTypeAxis_81832223976D9C8D3C60DC8C25252006" xlink:to="loc_us-gaap_DeferredRevenueArrangementTypeDomain_64ABE74EC10ED1C2E578DC8C25255A4D" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RoyaltyArrangementMember" xlink:label="loc_us-gaap_RoyaltyArrangementMember_7C95D0A56F83BAE24010DC8C252638D3" xlink:type="locator" />
<link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredRevenueArrangementTypeDomain_64ABE74EC10ED1C2E578DC8C25255A4D" xlink:to="loc_us-gaap_RoyaltyArrangementMember_7C95D0A56F83BAE24010DC8C252638D3" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredRevenueArrangementLineItems" xlink:label="loc_us-gaap_DeferredRevenueArrangementLineItems_CA3758CB21B1BD02862DDC8C25265E0D" xlink:type="locator" />
<link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredRevenueArrangementByTypeTable_21DD3A5BE1049858A70BDC8C25240E9E" xlink:to="loc_us-gaap_DeferredRevenueArrangementLineItems_CA3758CB21B1BD02862DDC8C25265E0D" xlink:type="arc" />
<link:loc xlink:href="immu-20191231.xsd#immu_FairValueForLiabilityRelatedtoSaleofFutureRoyalties" xlink:label="loc_immu_FairValueForLiabilityRelatedtoSaleofFutureRoyalties_0EC8EEEFE6F416932FCBDC8C25261090" xlink:type="locator" />
<link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredRevenueArrangementLineItems_CA3758CB21B1BD02862DDC8C25265E0D" xlink:to="loc_immu_FairValueForLiabilityRelatedtoSaleofFutureRoyalties_0EC8EEEFE6F416932FCBDC8C25261090" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaap_CommonStockValue_F81EB7A42FE090241B6FDC8C252617E2" xlink:type="locator" />
<link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredRevenueArrangementLineItems_CA3758CB21B1BD02862DDC8C25265E0D" xlink:to="loc_us-gaap_CommonStockValue_F81EB7A42FE090241B6FDC8C252617E2" xlink:type="arc" />
<link:loc xlink:href="immu-20191231.xsd#immu_RoyaltyPurchaseAgreementArrangementsConsideration" xlink:label="loc_immu_RoyaltyPurchaseAgreementArrangementsConsideration_49946F7D07095DFDDD82DC8C25271750" xlink:type="locator" />
<link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredRevenueArrangementLineItems_CA3758CB21B1BD02862DDC8C25265E0D" xlink:to="loc_immu_RoyaltyPurchaseAgreementArrangementsConsideration_49946F7D07095DFDDD82DC8C25271750" xlink:type="arc" />
</link:presentationLink>
<link:presentationLink xlink:role="http://www.immunomedics.com/role/DebtConvertibleSeniorNotesDetails" xlink:type="extended">
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="loc_us-gaap_DebtDisclosureAbstract_E66480FA1C0F2D2AEDD87E59E3B39ADF" xlink:type="locator" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredRevenueArrangementByTypeTable" xlink:label="loc_us-gaap_DeferredRevenueArrangementByTypeTable_63CD53B0BE48C3BAAB857E59E3B3D37C" xlink:type="locator" />
<link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_E66480FA1C0F2D2AEDD87E59E3B39ADF" xlink:to="loc_us-gaap_DeferredRevenueArrangementByTypeTable_63CD53B0BE48C3BAAB857E59E3B3D37C" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_C7BAC0E8E59C5A8C8E137E59E3B4C3E7" xlink:type="locator" />
<link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredRevenueArrangementByTypeTable_63CD53B0BE48C3BAAB857E59E3B3D37C" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_C7BAC0E8E59C5A8C8E137E59E3B4C3E7" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_D040975D839636F11E367E59E3B4604C" xlink:type="locator" />
<link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_C7BAC0E8E59C5A8C8E137E59E3B4C3E7" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_D040975D839636F11E367E59E3B4604C" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaap_SubsequentEventMember_3D35FB42BBDCA9FDF9D67E59E3B4FA2C" xlink:type="locator" />
<link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_D040975D839636F11E367E59E3B4604C" xlink:to="loc_us-gaap_SubsequentEventMember_3D35FB42BBDCA9FDF9D67E59E3B4FA2C" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaap_DebtInstrumentAxis_E63FFDC7A2A22EE8A6D27E59E3B56F1D" xlink:type="locator" />
<link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredRevenueArrangementByTypeTable_63CD53B0BE48C3BAAB857E59E3B3D37C" xlink:to="loc_us-gaap_DebtInstrumentAxis_E63FFDC7A2A22EE8A6D27E59E3B56F1D" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_98440B5079A09B026A3A7E59E3B5C0D5" xlink:type="locator" />
<link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_E63FFDC7A2A22EE8A6D27E59E3B56F1D" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_98440B5079A09B026A3A7E59E3B5C0D5" xlink:type="arc" />
<link:loc xlink:href="immu-20191231.xsd#immu_FourPointSevenFivePercentConvertibleSeniorNotesMember" xlink:label="loc_immu_FourPointSevenFivePercentConvertibleSeniorNotesMember_66084863CD5A2CBA72847E59E3B58383" xlink:type="locator" />
<link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_98440B5079A09B026A3A7E59E3B5C0D5" xlink:to="loc_immu_FourPointSevenFivePercentConvertibleSeniorNotesMember_66084863CD5A2CBA72847E59E3B58383" xlink:type="arc" />
<link:loc xlink:href="immu-20191231.xsd#immu_October2018ExchangeAgreementMember" xlink:label="loc_immu_October2018ExchangeAgreementMember_644BD44DCF6FFD39050B7E59E3B52D08" xlink:type="locator" />
<link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_98440B5079A09B026A3A7E59E3B5C0D5" xlink:to="loc_immu_October2018ExchangeAgreementMember_644BD44DCF6FFD39050B7E59E3B52D08" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredRevenueArrangementLineItems" xlink:label="loc_us-gaap_DeferredRevenueArrangementLineItems_A61291F657DA9B9C03647E59E3B5E4B1" xlink:type="locator" />
<link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredRevenueArrangementByTypeTable_63CD53B0BE48C3BAAB857E59E3B3D37C" xlink:to="loc_us-gaap_DeferredRevenueArrangementLineItems_A61291F657DA9B9C03647E59E3B5E4B1" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_9E6D5114BA1FCF6817E67E59E3B6B7A7" xlink:type="locator" />
<link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredRevenueArrangementLineItems_A61291F657DA9B9C03647E59E3B5E4B1" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_9E6D5114BA1FCF6817E67E59E3B6B7A7" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromDebtNetOfIssuanceCosts" xlink:label="loc_us-gaap_ProceedsFromDebtNetOfIssuanceCosts_F3C1ACD8B16A6414CA567E59E3B6250A" xlink:type="locator" />
<link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredRevenueArrangementLineItems_A61291F657DA9B9C03647E59E3B5E4B1" xlink:to="loc_us-gaap_ProceedsFromDebtNetOfIssuanceCosts_F3C1ACD8B16A6414CA567E59E3B6250A" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsOfDebtIssuanceCosts" xlink:label="loc_us-gaap_PaymentsOfDebtIssuanceCosts_F3A1AF6149122C39732F7E59E3B64D84" xlink:type="locator" />
<link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredRevenueArrangementLineItems_A61291F657DA9B9C03647E59E3B5E4B1" xlink:to="loc_us-gaap_PaymentsOfDebtIssuanceCosts_F3A1AF6149122C39732F7E59E3B64D84" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_9A76A9E09C4A22F5A9D57E59E3B61AA6" xlink:type="locator" />
<link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredRevenueArrangementLineItems_A61291F657DA9B9C03647E59E3B5E4B1" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_9A76A9E09C4A22F5A9D57E59E3B61AA6" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:label="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage_3B3119A6BD18932053947E59E3B625A2" xlink:type="locator" />
<link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredRevenueArrangementLineItems_A61291F657DA9B9C03647E59E3B5E4B1" xlink:to="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage_3B3119A6BD18932053947E59E3B625A2" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:label="loc_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_551A5FB0E4E22F6C67A27E59E3B6E386" xlink:type="locator" />
<link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredRevenueArrangementLineItems_A61291F657DA9B9C03647E59E3B5E4B1" xlink:to="loc_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_551A5FB0E4E22F6C67A27E59E3B6E386" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentConvertibleConversionRatio1" xlink:label="loc_us-gaap_DebtInstrumentConvertibleConversionRatio1_9AF338F0E6E64A1452C27E59E3B73FE3" xlink:type="locator" />
<link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredRevenueArrangementLineItems_A61291F657DA9B9C03647E59E3B5E4B1" xlink:to="loc_us-gaap_DebtInstrumentConvertibleConversionRatio1_9AF338F0E6E64A1452C27E59E3B73FE3" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:label="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1_62BD5DA267C1B3F2C3107E59E3B7F61B" xlink:type="locator" />
<link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredRevenueArrangementLineItems_A61291F657DA9B9C03647E59E3B5E4B1" xlink:to="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1_62BD5DA267C1B3F2C3107E59E3B7F61B" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed_7B2E5642F278CF950E5C7E59E3B7DFE7" xlink:type="locator" />
<link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredRevenueArrangementLineItems_A61291F657DA9B9C03647E59E3B5E4B1" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed_7B2E5642F278CF950E5C7E59E3B7DFE7" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtConversionOriginalDebtAmount1" xlink:label="loc_us-gaap_DebtConversionOriginalDebtAmount1_893FE425634EC0867D227E59E3B7C8AD" xlink:type="locator" />
<link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredRevenueArrangementLineItems_A61291F657DA9B9C03647E59E3B5E4B1" xlink:to="loc_us-gaap_DebtConversionOriginalDebtAmount1_893FE425634EC0867D227E59E3B7C8AD" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xlink:label="loc_us-gaap_DebtConversionConvertedInstrumentSharesIssued1_C24622FD9E54DBC1D87F7E59E3B793B6" xlink:type="locator" />
<link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredRevenueArrangementLineItems_A61291F657DA9B9C03647E59E3B5E4B1" xlink:to="loc_us-gaap_DebtConversionConvertedInstrumentSharesIssued1_C24622FD9E54DBC1D87F7E59E3B793B6" xlink:type="arc" />
<link:loc xlink:href="immu-20191231.xsd#immu_DebtInstrumentConvertibleBeneficialConversionFeatureAggregateNumberOfShares" xlink:label="loc_immu_DebtInstrumentConvertibleBeneficialConversionFeatureAggregateNumberOfShares_571170204A9C7C40B37C7E59E3B8F583" xlink:type="locator" />
<link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredRevenueArrangementLineItems_A61291F657DA9B9C03647E59E3B5E4B1" xlink:to="loc_immu_DebtInstrumentConvertibleBeneficialConversionFeatureAggregateNumberOfShares_571170204A9C7C40B37C7E59E3B8F583" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InducedConversionOfConvertibleDebtExpense" xlink:label="loc_us-gaap_InducedConversionOfConvertibleDebtExpense_86854216D775AAC3CF547E59E3B8178B" xlink:type="locator" />
<link:presentationArc order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredRevenueArrangementLineItems_A61291F657DA9B9C03647E59E3B5E4B1" xlink:to="loc_us-gaap_InducedConversionOfConvertibleDebtExpense_86854216D775AAC3CF547E59E3B8178B" xlink:type="arc" />
<link:loc xlink:href="immu-20191231.xsd#immu_DebtConversionOutstandingBalance" xlink:label="loc_immu_DebtConversionOutstandingBalance_04AD3A053866F435BE1A7E59E3B82922" xlink:type="locator" />
<link:presentationArc order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredRevenueArrangementLineItems_A61291F657DA9B9C03647E59E3B5E4B1" xlink:to="loc_immu_DebtConversionOutstandingBalance_04AD3A053866F435BE1A7E59E3B82922" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InterestExpenseDebt" xlink:label="loc_us-gaap_InterestExpenseDebt_77BBC79310EED63CCC097E59E3B84CC1" xlink:type="locator" />
<link:presentationArc order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredRevenueArrangementLineItems_A61291F657DA9B9C03647E59E3B5E4B1" xlink:to="loc_us-gaap_InterestExpenseDebt_77BBC79310EED63CCC097E59E3B84CC1" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AmortizationOfFinancingCosts" xlink:label="loc_us-gaap_AmortizationOfFinancingCosts_5F1936C24502EDC59BDE7E59E3B8F856" xlink:type="locator" />
<link:presentationArc order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredRevenueArrangementLineItems_A61291F657DA9B9C03647E59E3B5E4B1" xlink:to="loc_us-gaap_AmortizationOfFinancingCosts_5F1936C24502EDC59BDE7E59E3B8F856" xlink:type="arc" />
<link:loc xlink:href="immu-20191231.xsd#immu_AcceleratedAmortizationOfFinancingCosts" xlink:label="loc_immu_AcceleratedAmortizationOfFinancingCosts_AB1A0C23699916F901817E59E3B82291" xlink:type="locator" />
<link:presentationArc order="17" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredRevenueArrangementLineItems_A61291F657DA9B9C03647E59E3B5E4B1" xlink:to="loc_immu_AcceleratedAmortizationOfFinancingCosts_AB1A0C23699916F901817E59E3B82291" xlink:type="arc" />
</link:presentationLink>
<link:presentationLink xlink:role="http://www.immunomedics.com/role/DebtLiabilityRelatedToSaleOfFutureRoyaltiesDetails" xlink:type="extended">
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="loc_us-gaap_DebtDisclosureAbstract_EC2EEED90AB534B8978E4551CEEFD9EC" xlink:type="locator" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentTable" xlink:label="loc_us-gaap_DebtInstrumentTable_5053D60EE07AB24FB50F4551CEEF99C7" xlink:type="locator" />
<link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_EC2EEED90AB534B8978E4551CEEFD9EC" xlink:to="loc_us-gaap_DebtInstrumentTable_5053D60EE07AB24FB50F4551CEEF99C7" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_CBC0288E70003AE4164B4551CEEFAA09" xlink:type="locator" />
<link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_5053D60EE07AB24FB50F4551CEEF99C7" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_CBC0288E70003AE4164B4551CEEFAA09" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_81E6FA7DE6DFF2600B404551CEEF4417" xlink:type="locator" />
<link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_CBC0288E70003AE4164B4551CEEFAA09" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_81E6FA7DE6DFF2600B404551CEEF4417" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PrivatePlacementMember" xlink:label="loc_us-gaap_PrivatePlacementMember_790E4FCF8EA6FBB42F954551CEF0834A" xlink:type="locator" />
<link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_81E6FA7DE6DFF2600B404551CEEF4417" xlink:to="loc_us-gaap_PrivatePlacementMember_790E4FCF8EA6FBB42F954551CEF0834A" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_CounterpartyNameAxis" xlink:label="loc_srt_CounterpartyNameAxis_88DD390B3CA0A5DFAE664551CEF0F8E5" xlink:type="locator" />
<link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_5053D60EE07AB24FB50F4551CEEF99C7" xlink:to="loc_srt_CounterpartyNameAxis_88DD390B3CA0A5DFAE664551CEF0F8E5" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_7982E0C66D9D913C5A9F4551CEF0C8DA" xlink:type="locator" />
<link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_88DD390B3CA0A5DFAE664551CEF0F8E5" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_7982E0C66D9D913C5A9F4551CEF0C8DA" xlink:type="arc" />
<link:loc xlink:href="immu-20191231.xsd#immu_RpiFinanceTrustMember" xlink:label="loc_immu_RpiFinanceTrustMember_CB6667FEDB5EE23D5DE54551CEF0DC7E" xlink:type="locator" />
<link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_7982E0C66D9D913C5A9F4551CEF0C8DA" xlink:to="loc_immu_RpiFinanceTrustMember_CB6667FEDB5EE23D5DE54551CEF0DC7E" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredRevenueArrangementTypeAxis" xlink:label="loc_us-gaap_DeferredRevenueArrangementTypeAxis_DC562DCF2C850555977B4551CEF1AEA7" xlink:type="locator" />
<link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_5053D60EE07AB24FB50F4551CEEF99C7" xlink:to="loc_us-gaap_DeferredRevenueArrangementTypeAxis_DC562DCF2C850555977B4551CEF1AEA7" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredRevenueArrangementTypeDomain" xlink:label="loc_us-gaap_DeferredRevenueArrangementTypeDomain_A3383D540D7C3FA981B24551CEF16431" xlink:type="locator" />
<link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredRevenueArrangementTypeAxis_DC562DCF2C850555977B4551CEF1AEA7" xlink:to="loc_us-gaap_DeferredRevenueArrangementTypeDomain_A3383D540D7C3FA981B24551CEF16431" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RoyaltyArrangementMember" xlink:label="loc_us-gaap_RoyaltyArrangementMember_875E93CE0061AC48C9CE4551CEF1DF14" xlink:type="locator" />
<link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredRevenueArrangementTypeDomain_A3383D540D7C3FA981B24551CEF16431" xlink:to="loc_us-gaap_RoyaltyArrangementMember_875E93CE0061AC48C9CE4551CEF1DF14" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="loc_us-gaap_DebtInstrumentLineItems_F01CB6FE0F8B09FD122E4551CEF10957" xlink:type="locator" />
<link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_5053D60EE07AB24FB50F4551CEEF99C7" xlink:to="loc_us-gaap_DebtInstrumentLineItems_F01CB6FE0F8B09FD122E4551CEF10957" xlink:type="arc" />
<link:loc xlink:href="immu-20191231.xsd#immu_PaymentsForFutureRoyalties" xlink:label="loc_immu_PaymentsForFutureRoyalties_8AB96DCEDB7FCEE3859E4551CEF1F814" xlink:type="locator" />
<link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_F01CB6FE0F8B09FD122E4551CEF10957" xlink:to="loc_immu_PaymentsForFutureRoyalties_8AB96DCEDB7FCEE3859E4551CEF1F814" xlink:type="arc" />
<link:loc xlink:href="immu-20191231.xsd#immu_RoyaltyPurchaseArrangementRoyaltyRateasPercentageofNetSales" xlink:label="loc_immu_RoyaltyPurchaseArrangementRoyaltyRateasPercentageofNetSales_34370556009D3D7CFBEF4551CEF2DD34" xlink:type="locator" />
<link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_F01CB6FE0F8B09FD122E4551CEF10957" xlink:to="loc_immu_RoyaltyPurchaseArrangementRoyaltyRateasPercentageofNetSales_34370556009D3D7CFBEF4551CEF2DD34" xlink:type="arc" />
<link:loc xlink:href="immu-20191231.xsd#immu_RoyaltyPurchaseArrangementAnnualSalesLimitMaximum" xlink:label="loc_immu_RoyaltyPurchaseArrangementAnnualSalesLimitMaximum_4BF2090984B904EA1C314551CEF2D53F" xlink:type="locator" />
<link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_F01CB6FE0F8B09FD122E4551CEF10957" xlink:to="loc_immu_RoyaltyPurchaseArrangementAnnualSalesLimitMaximum_4BF2090984B904EA1C314551CEF2D53F" xlink:type="arc" />
<link:loc xlink:href="immu-20191231.xsd#immu_RoyaltyPurchaseArrangementRoyaltyRateasPercentageofExcessofGlobalAnnualSalesThresholdLimit" xlink:label="loc_immu_RoyaltyPurchaseArrangementRoyaltyRateasPercentageofExcessofGlobalAnnualSalesThresholdLimit_35E5FBE8A0E448C3C1A14551CEF2EE34" xlink:type="locator" />
<link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_F01CB6FE0F8B09FD122E4551CEF10957" xlink:to="loc_immu_RoyaltyPurchaseArrangementRoyaltyRateasPercentageofExcessofGlobalAnnualSalesThresholdLimit_35E5FBE8A0E448C3C1A14551CEF2EE34" xlink:type="arc" />
<link:loc xlink:href="immu-20191231.xsd#immu_RoyaltyPurchaseArrangementExcessGlobalAnnualSalesLimitMinimum" xlink:label="loc_immu_RoyaltyPurchaseArrangementExcessGlobalAnnualSalesLimitMinimum_837598AC27EE4F9DA6614551CEF2194E" xlink:type="locator" />
<link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_F01CB6FE0F8B09FD122E4551CEF10957" xlink:to="loc_immu_RoyaltyPurchaseArrangementExcessGlobalAnnualSalesLimitMinimum_837598AC27EE4F9DA6614551CEF2194E" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_479D2D6024A2F16DD79A4551CEF2077C" xlink:type="locator" />
<link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_F01CB6FE0F8B09FD122E4551CEF10957" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_479D2D6024A2F16DD79A4551CEF2077C" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharePrice" xlink:label="loc_us-gaap_SharePrice_5688FEF0BA068425A9AA4551CEF2485B" xlink:type="locator" />
<link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_F01CB6FE0F8B09FD122E4551CEF10957" xlink:to="loc_us-gaap_SharePrice_5688FEF0BA068425A9AA4551CEF2485B" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_2D57F9823B3269F540514551CEF3E517" xlink:type="locator" />
<link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_F01CB6FE0F8B09FD122E4551CEF10957" xlink:to="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_2D57F9823B3269F540514551CEF3E517" xlink:type="arc" />
<link:loc xlink:href="immu-20191231.xsd#immu_PeriodWhichCompanyWillAccreteLiability" xlink:label="loc_immu_PeriodWhichCompanyWillAccreteLiability_67EF7CCEE80DE0A6FC8B4551CEF33138" xlink:type="locator" />
<link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_F01CB6FE0F8B09FD122E4551CEF10957" xlink:to="loc_immu_PeriodWhichCompanyWillAccreteLiability_67EF7CCEE80DE0A6FC8B4551CEF33138" xlink:type="arc" />
<link:loc xlink:href="immu-20191231.xsd#immu_AnnualInterestRateInCalculatingLiabilityRelatedToSaleOfFutureRoyalties" xlink:label="loc_immu_AnnualInterestRateInCalculatingLiabilityRelatedToSaleOfFutureRoyalties_343F008535B92953A44C4551CEF3CC92" xlink:type="locator" />
<link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_F01CB6FE0F8B09FD122E4551CEF10957" xlink:to="loc_immu_AnnualInterestRateInCalculatingLiabilityRelatedToSaleOfFutureRoyalties_343F008535B92953A44C4551CEF3CC92" xlink:type="arc" />
<link:loc xlink:href="immu-20191231.xsd#immu_NonCashInterestExpenseRelatedToSaleOfFutureRoyalties" xlink:label="loc_immu_NonCashInterestExpenseRelatedToSaleOfFutureRoyalties_EBC138D80FFF09644C854551CEF34752" xlink:type="locator" />
<link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_F01CB6FE0F8B09FD122E4551CEF10957" xlink:to="loc_immu_NonCashInterestExpenseRelatedToSaleOfFutureRoyalties_EBC138D80FFF09644C854551CEF34752" xlink:type="arc" />
</link:presentationLink>
<link:presentationLink xlink:role="http://www.immunomedics.com/role/DebtScheduleOfLiabilityRelatedToSaleOfFutureRoyaltiesDetails" xlink:type="extended">
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="loc_us-gaap_DebtDisclosureAbstract_29B7CA3880EACBE2B48479F70C1C2C1A" xlink:type="locator" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredRevenueArrangementByTypeTable" xlink:label="loc_us-gaap_DeferredRevenueArrangementByTypeTable_E5BFF701801B04BDD19F79F70C1DABEC" xlink:type="locator" />
<link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_29B7CA3880EACBE2B48479F70C1C2C1A" xlink:to="loc_us-gaap_DeferredRevenueArrangementByTypeTable_E5BFF701801B04BDD19F79F70C1DABEC" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_CounterpartyNameAxis" xlink:label="loc_srt_CounterpartyNameAxis_39765065DF207F6413B279F70C1DDBDD" xlink:type="locator" />
<link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredRevenueArrangementByTypeTable_E5BFF701801B04BDD19F79F70C1DABEC" xlink:to="loc_srt_CounterpartyNameAxis_39765065DF207F6413B279F70C1DDBDD" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_8331CAA28045C5B2BC1279F70C1D9C58" xlink:type="locator" />
<link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_39765065DF207F6413B279F70C1DDBDD" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_8331CAA28045C5B2BC1279F70C1D9C58" xlink:type="arc" />
<link:loc xlink:href="immu-20191231.xsd#immu_RpiFinanceTrustMember" xlink:label="loc_immu_RpiFinanceTrustMember_D3ADB92ECDE725A545A279F70C1DA4EF" xlink:type="locator" />
<link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_8331CAA28045C5B2BC1279F70C1D9C58" xlink:to="loc_immu_RpiFinanceTrustMember_D3ADB92ECDE725A545A279F70C1DA4EF" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredRevenueArrangementTypeAxis" xlink:label="loc_us-gaap_DeferredRevenueArrangementTypeAxis_58D8A8CD3242A9B4D6FB79F70C1E9FC2" xlink:type="locator" />
<link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredRevenueArrangementByTypeTable_E5BFF701801B04BDD19F79F70C1DABEC" xlink:to="loc_us-gaap_DeferredRevenueArrangementTypeAxis_58D8A8CD3242A9B4D6FB79F70C1E9FC2" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredRevenueArrangementTypeDomain" xlink:label="loc_us-gaap_DeferredRevenueArrangementTypeDomain_248D924A4AD95D77D6B979F70C1E3973" xlink:type="locator" />
<link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredRevenueArrangementTypeAxis_58D8A8CD3242A9B4D6FB79F70C1E9FC2" xlink:to="loc_us-gaap_DeferredRevenueArrangementTypeDomain_248D924A4AD95D77D6B979F70C1E3973" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RoyaltyArrangementMember" xlink:label="loc_us-gaap_RoyaltyArrangementMember_2F0E3B33309F72CB923A79F70C1E06DE" xlink:type="locator" />
<link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredRevenueArrangementTypeDomain_248D924A4AD95D77D6B979F70C1E3973" xlink:to="loc_us-gaap_RoyaltyArrangementMember_2F0E3B33309F72CB923A79F70C1E06DE" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredRevenueArrangementLineItems" xlink:label="loc_us-gaap_DeferredRevenueArrangementLineItems_17A8037B46D0DCAB52D679F70C1F46F9" xlink:type="locator" />
<link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredRevenueArrangementByTypeTable_E5BFF701801B04BDD19F79F70C1DABEC" xlink:to="loc_us-gaap_DeferredRevenueArrangementLineItems_17A8037B46D0DCAB52D679F70C1F46F9" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MovementInDeferredRevenueRollForward" xlink:label="loc_us-gaap_MovementInDeferredRevenueRollForward_6809D139BF522FD52EA079F70C1FA6A9" xlink:type="locator" />
<link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredRevenueArrangementLineItems_17A8037B46D0DCAB52D679F70C1F46F9" xlink:to="loc_us-gaap_MovementInDeferredRevenueRollForward_6809D139BF522FD52EA079F70C1FA6A9" xlink:type="arc" />
<link:loc xlink:href="immu-20191231.xsd#immu_FairValueForLiabilityRelatedtoSaleofFutureRoyalties" xlink:label="loc_immu_FairValueForLiabilityRelatedtoSaleofFutureRoyalties_B194EE0EDA2813FCF06579F70C1F6CF3" xlink:type="locator" />
<link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MovementInDeferredRevenueRollForward_6809D139BF522FD52EA079F70C1FA6A9" xlink:to="loc_immu_FairValueForLiabilityRelatedtoSaleofFutureRoyalties_B194EE0EDA2813FCF06579F70C1F6CF3" xlink:type="arc" />
<link:loc xlink:href="immu-20191231.xsd#immu_NonCashInterestExpenseRelatedToSaleOfFutureRoyalties" xlink:label="loc_immu_NonCashInterestExpenseRelatedToSaleOfFutureRoyalties_EAE42A93470CD93BDE0B79F70C1F1D1A" xlink:type="locator" />
<link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MovementInDeferredRevenueRollForward_6809D139BF522FD52EA079F70C1FA6A9" xlink:to="loc_immu_NonCashInterestExpenseRelatedToSaleOfFutureRoyalties_EAE42A93470CD93BDE0B79F70C1F1D1A" xlink:type="arc" />
<link:loc xlink:href="immu-20191231.xsd#immu_FairValueForLiabilityRelatedtoSaleofFutureRoyalties" xlink:label="loc_immu_FairValueForLiabilityRelatedtoSaleofFutureRoyalties_6ECD9BF50827322C329079F70C1FB936" xlink:type="locator" />
<link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MovementInDeferredRevenueRollForward_6809D139BF522FD52EA079F70C1FA6A9" xlink:to="loc_immu_FairValueForLiabilityRelatedtoSaleofFutureRoyalties_6ECD9BF50827322C329079F70C1FB936" xlink:type="arc" />
<link:loc xlink:href="immu-20191231.xsd#immu_LiabilitiesRelatedToTheSaleOfFutureRoyaltiesCurrent" xlink:label="loc_immu_LiabilitiesRelatedToTheSaleOfFutureRoyaltiesCurrent_20CE025FF8B91D1E964E79F70C1FDCBE" xlink:type="locator" />
<link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredRevenueArrangementLineItems_17A8037B46D0DCAB52D679F70C1F46F9" xlink:to="loc_immu_LiabilitiesRelatedToTheSaleOfFutureRoyaltiesCurrent_20CE025FF8B91D1E964E79F70C1FDCBE" xlink:type="arc" />
</link:presentationLink>
<link:presentationLink xlink:role="http://www.immunomedics.com/role/DebtTables" xlink:type="extended">
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="loc_us-gaap_DebtDisclosureAbstract_26FA468D8899595245523991D26F7CA2" xlink:type="locator" />
<link:loc xlink:href="immu-20191231.xsd#immu_AllocationofFairValuetoLiabilityTableTextBlock" xlink:label="loc_immu_AllocationofFairValuetoLiabilityTableTextBlock_02C71681413280E547583991D270E19E" xlink:type="locator" />
<link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_26FA468D8899595245523991D26F7CA2" xlink:to="loc_immu_AllocationofFairValuetoLiabilityTableTextBlock_02C71681413280E547583991D270E19E" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock" xlink:label="loc_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock_A8EA8E396197E3F62EA13991D2701036" xlink:type="locator" />
<link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_26FA468D8899595245523991D26F7CA2" xlink:to="loc_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock_A8EA8E396197E3F62EA13991D2701036" xlink:type="arc" />
</link:presentationLink>
<link:presentationLink xlink:role="http://www.immunomedics.com/role/DefinedContributionPlans" xlink:type="extended">
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:label="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_9E55CFFD9684533C9928D1D0623791AC" xlink:type="locator" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:label="loc_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_B1E4078F7553FC41C6E3D1D062470EFB" xlink:type="locator" />
<link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_9E55CFFD9684533C9928D1D0623791AC" xlink:to="loc_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_B1E4078F7553FC41C6E3D1D062470EFB" xlink:type="arc" />
</link:presentationLink>
<link:presentationLink xlink:role="http://www.immunomedics.com/role/DefinedContributionPlansDetails" xlink:type="extended">
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:label="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_520D337B9A6AD241DB5F635C884211F4" xlink:type="locator" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" xlink:label="loc_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch_76768F4BB1D38441E24763765547FD59" xlink:type="locator" />
<link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_520D337B9A6AD241DB5F635C884211F4" xlink:to="loc_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch_76768F4BB1D38441E24763765547FD59" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent" xlink:label="loc_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent_9B49F616A3B584A49B9D6376E52CF4F3" xlink:type="locator" />
<link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_520D337B9A6AD241DB5F635C884211F4" xlink:to="loc_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent_9B49F616A3B584A49B9D6376E52CF4F3" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DefinedBenefitPlanContributionsByEmployer" xlink:label="loc_us-gaap_DefinedBenefitPlanContributionsByEmployer_1053037299173A742AF7635C88421F7D" xlink:type="locator" />
<link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_520D337B9A6AD241DB5F635C884211F4" xlink:to="loc_us-gaap_DefinedBenefitPlanContributionsByEmployer_1053037299173A742AF7635C88421F7D" xlink:type="arc" />
</link:presentationLink>
<link:presentationLink xlink:role="http://www.immunomedics.com/role/EstimatedFairValueOfFinancialInstruments" xlink:type="extended">
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_E272DD645964CDB65E87D1D06279D12F" xlink:type="locator" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock_A3F2835DDB1C11E90D91D1D062799F49" xlink:type="locator" />
<link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_E272DD645964CDB65E87D1D06279D12F" xlink:to="loc_us-gaap_FairValueDisclosuresTextBlock_A3F2835DDB1C11E90D91D1D062799F49" xlink:type="arc" />
</link:presentationLink>
<link:presentationLink xlink:role="http://www.immunomedics.com/role/EstimatedFairValueOfFinancialInstrumentsDebtInstrumentsDetails" xlink:type="extended">
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_570BD1388EC419B0DE30D1D062A59F3E" xlink:type="locator" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueByBalanceSheetGroupingTable" xlink:label="loc_us-gaap_FairValueByBalanceSheetGroupingTable_22B437A3922012F0FB84D1D062A53E67" xlink:type="locator" />
<link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_570BD1388EC419B0DE30D1D062A59F3E" xlink:to="loc_us-gaap_FairValueByBalanceSheetGroupingTable_22B437A3922012F0FB84D1D062A53E67" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_547C5CF6185AA73CA7B9D1D062A5B59B" xlink:type="locator" />
<link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_22B437A3922012F0FB84D1D062A53E67" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_547C5CF6185AA73CA7B9D1D062A5B59B" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_54D8AB1ECB880A97ADD6D1D062A57A40" xlink:type="locator" />
<link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_547C5CF6185AA73CA7B9D1D062A5B59B" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_54D8AB1ECB880A97ADD6D1D062A57A40" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SeniorNotesMember" xlink:label="loc_us-gaap_SeniorNotesMember_8195555F200070B96763D1D062A564AF" xlink:type="locator" />
<link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_54D8AB1ECB880A97ADD6D1D062A57A40" xlink:to="loc_us-gaap_SeniorNotesMember_8195555F200070B96763D1D062A564AF" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_0DD493AEFDD7A1AB6987D1D062A5E0B5" xlink:type="locator" />
<link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_22B437A3922012F0FB84D1D062A53E67" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_0DD493AEFDD7A1AB6987D1D062A5E0B5" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_57BFCBD7A92A3EE11706D1D062A5F54D" xlink:type="locator" />
<link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_0DD493AEFDD7A1AB6987D1D062A5E0B5" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_57BFCBD7A92A3EE11706D1D062A5F54D" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_F045EF858EE73A7F54A0D1D062A585CE" xlink:type="locator" />
<link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_57BFCBD7A92A3EE11706D1D062A5F54D" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_F045EF858EE73A7F54A0D1D062A585CE" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueByMeasurementBasisAxis" xlink:label="loc_us-gaap_FairValueByMeasurementBasisAxis_51E07BA817291853F990D1D062A57F06" xlink:type="locator" />
<link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_22B437A3922012F0FB84D1D062A53E67" xlink:to="loc_us-gaap_FairValueByMeasurementBasisAxis_51E07BA817291853F990D1D062A57F06" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueDisclosureItemAmountsDomain" xlink:label="loc_us-gaap_FairValueDisclosureItemAmountsDomain_368328E73CE8EC50CE9FD1D062A5766F" xlink:type="locator" />
<link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByMeasurementBasisAxis_51E07BA817291853F990D1D062A57F06" xlink:to="loc_us-gaap_FairValueDisclosureItemAmountsDomain_368328E73CE8EC50CE9FD1D062A5766F" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PortionAtFairValueFairValueDisclosureMember" xlink:label="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_278CB9189DFA6F87A402D1D062A9F579" xlink:type="locator" />
<link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosureItemAmountsDomain_368328E73CE8EC50CE9FD1D062A5766F" xlink:to="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_278CB9189DFA6F87A402D1D062A9F579" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CarryingReportedAmountFairValueDisclosureMember" xlink:label="loc_us-gaap_CarryingReportedAmountFairValueDisclosureMember_EBAC510E1438A1BC72B6D1D062A936EB" xlink:type="locator" />
<link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosureItemAmountsDomain_368328E73CE8EC50CE9FD1D062A5766F" xlink:to="loc_us-gaap_CarryingReportedAmountFairValueDisclosureMember_EBAC510E1438A1BC72B6D1D062A936EB" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EstimateOfFairValueFairValueDisclosureMember" xlink:label="loc_us-gaap_EstimateOfFairValueFairValueDisclosureMember_0E63A278249976AC67FCD1D062A96902" xlink:type="locator" />
<link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosureItemAmountsDomain_368328E73CE8EC50CE9FD1D062A5766F" xlink:to="loc_us-gaap_EstimateOfFairValueFairValueDisclosureMember_0E63A278249976AC67FCD1D062A96902" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:label="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_C773DC9E184F3A7D6F9CD1D062A91686" xlink:type="locator" />
<link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_22B437A3922012F0FB84D1D062A53E67" xlink:to="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_C773DC9E184F3A7D6F9CD1D062A91686" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConvertibleDebtFairValueDisclosures" xlink:label="loc_us-gaap_ConvertibleDebtFairValueDisclosures_17115F1EE2D1297C8A92D1D062A94960" xlink:type="locator" />
<link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_C773DC9E184F3A7D6F9CD1D062A91686" xlink:to="loc_us-gaap_ConvertibleDebtFairValueDisclosures_17115F1EE2D1297C8A92D1D062A94960" xlink:type="arc" />
</link:presentationLink>
<link:presentationLink xlink:role="http://www.immunomedics.com/role/EstimatedFairValueOfFinancialInstrumentsNarrativeDetails" xlink:type="extended">
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_50C07B210A870EE4EC7F3991D21B1017" xlink:type="locator" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_7A84A7191EE18E97725F3991D21BFD2B" xlink:type="locator" />
<link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_50C07B210A870EE4EC7F3991D21B1017" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_7A84A7191EE18E97725F3991D21BFD2B" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_6888A5B661D7D189EB1E3991D21B3E3C" xlink:type="locator" />
<link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_7A84A7191EE18E97725F3991D21BFD2B" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_6888A5B661D7D189EB1E3991D21B3E3C" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_F2BC3C14289B0DB634F83991D21C2D0F" xlink:type="locator" />
<link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_6888A5B661D7D189EB1E3991D21B3E3C" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_F2BC3C14289B0DB634F83991D21C2D0F" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_310D57561001F762D5D63991D21C06D4" xlink:type="locator" />
<link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_F2BC3C14289B0DB634F83991D21C2D0F" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_310D57561001F762D5D63991D21C06D4" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_CE878E650049789556E53991D21CCCFC" xlink:type="locator" />
<link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_F2BC3C14289B0DB634F83991D21C2D0F" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_CE878E650049789556E53991D21CCCFC" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_A592D90CC1264F5EA4043991D21C7C13" xlink:type="locator" />
<link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_F2BC3C14289B0DB634F83991D21C2D0F" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_A592D90CC1264F5EA4043991D21C7C13" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="loc_us-gaap_FinancialInstrumentAxis_DB6E5FABBA8D812638EC3991D21D8BD1" xlink:type="locator" />
<link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_7A84A7191EE18E97725F3991D21BFD2B" xlink:to="loc_us-gaap_FinancialInstrumentAxis_DB6E5FABBA8D812638EC3991D21D8BD1" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_526709F63B0CABCE619F3991D21D875D" xlink:type="locator" />
<link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentAxis_DB6E5FABBA8D812638EC3991D21D8BD1" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_526709F63B0CABCE619F3991D21D875D" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="loc_us-gaap_MoneyMarketFundsMember_05F20A83D504DB4A6E253991D21D7A19" xlink:type="locator" />
<link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_526709F63B0CABCE619F3991D21D875D" xlink:to="loc_us-gaap_MoneyMarketFundsMember_05F20A83D504DB4A6E253991D21D7A19" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember" xlink:label="loc_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember_A8DB543EC88D7DF444573991D21D5920" xlink:type="locator" />
<link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_526709F63B0CABCE619F3991D21D875D" xlink:to="loc_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember_A8DB543EC88D7DF444573991D21D5920" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_1B18A48DFA2C9B5309E03991D21D28A4" xlink:type="locator" />
<link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_7A84A7191EE18E97725F3991D21BFD2B" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_1B18A48DFA2C9B5309E03991D21D28A4" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_E7F2F8F281353C61A35A3991D21EF53B" xlink:type="locator" />
<link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_1B18A48DFA2C9B5309E03991D21D28A4" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_E7F2F8F281353C61A35A3991D21EF53B" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_62A34529823E4BD54DAF3991D21E2C3C" xlink:type="locator" />
<link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_1B18A48DFA2C9B5309E03991D21D28A4" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_62A34529823E4BD54DAF3991D21E2C3C" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsFairValueDisclosure" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_7BA9841294FF6D0A6EC03991D21E3CEB" xlink:type="locator" />
<link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_1B18A48DFA2C9B5309E03991D21D28A4" xlink:to="loc_us-gaap_AssetsFairValueDisclosure_7BA9841294FF6D0A6EC03991D21E3CEB" xlink:type="arc" />
</link:presentationLink>
<link:presentationLink xlink:role="http://www.immunomedics.com/role/EstimatedFairValueOfFinancialInstrumentsTables" xlink:type="extended">
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_D3FA99BA34CD88D73E8EDB9A483D3644" xlink:type="locator" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_B894E9BC299FDAFE931ADB9A483D8F6A" xlink:type="locator" />
<link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_D3FA99BA34CD88D73E8EDB9A483D3644" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_B894E9BC299FDAFE931ADB9A483D8F6A" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock_64EEB5D0BD954CC02249DB9A483DA72F" xlink:type="locator" />
<link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_D3FA99BA34CD88D73E8EDB9A483D3644" xlink:to="loc_us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock_64EEB5D0BD954CC02249DB9A483DA72F" xlink:type="arc" />
</link:presentationLink>
<link:presentationLink xlink:role="http://www.immunomedics.com/role/IncomeTaxes" xlink:type="extended">
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_DF421CDCFEBD1B2B73BAD1D062D13105" xlink:type="locator" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock_279D7B0754A69AD98639D1D062D1493E" xlink:type="locator" />
<link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_DF421CDCFEBD1B2B73BAD1D062D13105" xlink:to="loc_us-gaap_IncomeTaxDisclosureTextBlock_279D7B0754A69AD98639D1D062D1493E" xlink:type="arc" />
</link:presentationLink>
<link:presentationLink xlink:role="http://www.immunomedics.com/role/IncomeTaxesChangeInUnrecognizedTaxBenefitsDetails" xlink:type="extended">
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_CD21777152EE478EDBD5DB9A474ECC8E" xlink:type="locator" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:label="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_98459F74CF486271CD0DDB9A474E8609" xlink:type="locator" />
<link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_CD21777152EE478EDBD5DB9A474ECC8E" xlink:to="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_98459F74CF486271CD0DDB9A474E8609" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits_3E2AEC5BCD1644BAB11BDB9A474E305B" xlink:type="locator" />
<link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_98459F74CF486271CD0DDB9A474E8609" xlink:to="loc_us-gaap_UnrecognizedTaxBenefits_3E2AEC5BCD1644BAB11BDB9A474E305B" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_3F96FB6751A65BBEA221DB9A47533B0C" xlink:type="locator" />
<link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_98459F74CF486271CD0DDB9A474E8609" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_3F96FB6751A65BBEA221DB9A47533B0C" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_6D136ECA106AEBC1DD3EDB9A47533F32" xlink:type="locator" />
<link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_98459F74CF486271CD0DDB9A474E8609" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_6D136ECA106AEBC1DD3EDB9A47533F32" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions_081C7496DE218F50A080DB9A475455B9" xlink:type="locator" />
<link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_98459F74CF486271CD0DDB9A474E8609" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions_081C7496DE218F50A080DB9A475455B9" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations_E41B0A8E3FAF99BFD88DDB9A47544EAD" xlink:type="locator" />
<link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_98459F74CF486271CD0DDB9A474E8609" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations_E41B0A8E3FAF99BFD88DDB9A47544EAD" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits_D2A06F1DD2142770D619DB9A475425C3" xlink:type="locator" />
<link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_98459F74CF486271CD0DDB9A474E8609" xlink:to="loc_us-gaap_UnrecognizedTaxBenefits_D2A06F1DD2142770D619DB9A475425C3" xlink:type="arc" />
</link:presentationLink>
<link:presentationLink xlink:role="http://www.immunomedics.com/role/IncomeTaxesExpenseBenefitFromIncomeTaxesDetails" xlink:type="extended">
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_7DA3A40D7AED6D14B7D23991D1C3C7CD" xlink:type="locator" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CurrentFederalTaxExpenseBenefit" xlink:label="loc_us-gaap_CurrentFederalTaxExpenseBenefit_5607347BE2D6E68A0BE83991D1C48808" xlink:type="locator" />
<link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_7DA3A40D7AED6D14B7D23991D1C3C7CD" xlink:to="loc_us-gaap_CurrentFederalTaxExpenseBenefit_5607347BE2D6E68A0BE83991D1C48808" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_400C4E4B89ED75428EF93991D1C43D0D" xlink:type="locator" />
<link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_7DA3A40D7AED6D14B7D23991D1C3C7CD" xlink:to="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_400C4E4B89ED75428EF93991D1C43D0D" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperations" xlink:label="loc_us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperations_29DA8882FECF691B4A9D3991D1C4E0CC" xlink:type="locator" />
<link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_7DA3A40D7AED6D14B7D23991D1C3C7CD" xlink:to="loc_us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperations_29DA8882FECF691B4A9D3991D1C4E0CC" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:label="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_E81E6416312850CA74DD3991D1C42BFF" xlink:type="locator" />
<link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_7DA3A40D7AED6D14B7D23991D1C3C7CD" xlink:to="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_E81E6416312850CA74DD3991D1C42BFF" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_69A4AD8E6323E5C556693991D1C4B4F0" xlink:type="locator" />
<link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_7DA3A40D7AED6D14B7D23991D1C3C7CD" xlink:to="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_69A4AD8E6323E5C556693991D1C4B4F0" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StateAndLocalIncomeTaxExpenseBenefitContinuingOperations" xlink:label="loc_us-gaap_StateAndLocalIncomeTaxExpenseBenefitContinuingOperations_669E6917CCAD67E4ACF639ED5BFF2E5A" xlink:type="locator" />
<link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_7DA3A40D7AED6D14B7D23991D1C3C7CD" xlink:to="loc_us-gaap_StateAndLocalIncomeTaxExpenseBenefitContinuingOperations_669E6917CCAD67E4ACF639ED5BFF2E5A" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CurrentForeignTaxExpenseBenefit" xlink:label="loc_us-gaap_CurrentForeignTaxExpenseBenefit_9B31FBE30D5FED7428E93991D1C53101" xlink:type="locator" />
<link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_7DA3A40D7AED6D14B7D23991D1C3C7CD" xlink:to="loc_us-gaap_CurrentForeignTaxExpenseBenefit_9B31FBE30D5FED7428E93991D1C53101" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredForeignIncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_DeferredForeignIncomeTaxExpenseBenefit_6CE221DEC27ACD6C2C933991D1C53753" xlink:type="locator" />
<link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_7DA3A40D7AED6D14B7D23991D1C3C7CD" xlink:to="loc_us-gaap_DeferredForeignIncomeTaxExpenseBenefit_6CE221DEC27ACD6C2C933991D1C53753" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ForeignIncomeTaxExpenseBenefitContinuingOperations" xlink:label="loc_us-gaap_ForeignIncomeTaxExpenseBenefitContinuingOperations_B38F76EE2AF2C46999193991D1C57C1A" xlink:type="locator" />
<link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_7DA3A40D7AED6D14B7D23991D1C3C7CD" xlink:to="loc_us-gaap_ForeignIncomeTaxExpenseBenefitContinuingOperations_B38F76EE2AF2C46999193991D1C57C1A" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_8D2D65F5D36806F720E13991D1C56400" xlink:type="locator" />
<link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_7DA3A40D7AED6D14B7D23991D1C3C7CD" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_8D2D65F5D36806F720E13991D1C56400" xlink:type="arc" />
</link:presentationLink>
<link:presentationLink xlink:role="http://www.immunomedics.com/role/IncomeTaxesNarrativeDetails" xlink:type="extended">
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_4A3B384AF74D4E19FA6A69B4D08BD89B" xlink:type="locator" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLossCarryforwardsTable" xlink:label="loc_us-gaap_OperatingLossCarryforwardsTable_D5E2B8D5F18698CC4D0769B4D08C4BA2" xlink:type="locator" />
<link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_4A3B384AF74D4E19FA6A69B4D08BD89B" xlink:to="loc_us-gaap_OperatingLossCarryforwardsTable_D5E2B8D5F18698CC4D0769B4D08C4BA2" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis_25F0DCD4BED95389B72769B4D08C2334" xlink:type="locator" />
<link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable_D5E2B8D5F18698CC4D0769B4D08C4BA2" xlink:to="loc_us-gaap_IncomeTaxAuthorityAxis_25F0DCD4BED95389B72769B4D08C2334" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_5447170E9FD17BB25EA869B4D08C85F6" xlink:type="locator" />
<link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_25F0DCD4BED95389B72769B4D08C2334" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_5447170E9FD17BB25EA869B4D08C85F6" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DomesticCountryMember" xlink:label="loc_us-gaap_DomesticCountryMember_5C4F00DB7A628B796DFD69B4D08C1B77" xlink:type="locator" />
<link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_5447170E9FD17BB25EA869B4D08C85F6" xlink:to="loc_us-gaap_DomesticCountryMember_5C4F00DB7A628B796DFD69B4D08C1B77" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="loc_us-gaap_StateAndLocalJurisdictionMember_E9C900CFABB8DF565C6369B4D08D7C82" xlink:type="locator" />
<link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_5447170E9FD17BB25EA869B4D08C85F6" xlink:to="loc_us-gaap_StateAndLocalJurisdictionMember_E9C900CFABB8DF565C6369B4D08D7C82" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLossCarryforwardsLineItems" xlink:label="loc_us-gaap_OperatingLossCarryforwardsLineItems_6D391C67D484970224E569B4D08D9F73" xlink:type="locator" />
<link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable_D5E2B8D5F18698CC4D0769B4D08C4BA2" xlink:to="loc_us-gaap_OperatingLossCarryforwardsLineItems_6D391C67D484970224E569B4D08D9F73" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="loc_us-gaap_OperatingLossCarryforwards_B76669AD0CFD82D881ED69B4D08DFD20" xlink:type="locator" />
<link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_6D391C67D484970224E569B4D08D9F73" xlink:to="loc_us-gaap_OperatingLossCarryforwards_B76669AD0CFD82D881ED69B4D08DFD20" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits_6AA7AE0201BAB005B2C869BEC0E2E51F" xlink:type="locator" />
<link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_6D391C67D484970224E569B4D08D9F73" xlink:to="loc_us-gaap_UnrecognizedTaxBenefits_6AA7AE0201BAB005B2C869BEC0E2E51F" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_BED917FFEAEC15E7399169B4D08DEF4F" xlink:type="locator" />
<link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_6D391C67D484970224E569B4D08D9F73" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_BED917FFEAEC15E7399169B4D08DEF4F" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:label="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_DE2B098A3984EFCF8F5469B4D08D930B" xlink:type="locator" />
<link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_6D391C67D484970224E569B4D08D9F73" xlink:to="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_DE2B098A3984EFCF8F5469B4D08D930B" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_91DAE56D75FD9E5EDA8069B4D08EB621" xlink:type="locator" />
<link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" priority="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_6D391C67D484970224E569B4D08D9F73" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_91DAE56D75FD9E5EDA8069B4D08EB621" xlink:type="arc" />
<link:loc xlink:href="immu-20191231.xsd#immu_OperatingLossCarryforwardResultingFromSale" xlink:label="loc_immu_OperatingLossCarryforwardResultingFromSale_88A679BA6BEAF27902C769B4D08EEE44" xlink:type="locator" />
<link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_6D391C67D484970224E569B4D08D9F73" xlink:to="loc_immu_OperatingLossCarryforwardResultingFromSale_88A679BA6BEAF27902C769B4D08EEE44" xlink:type="arc" />
<link:loc xlink:href="immu-20191231.xsd#immu_DeferredTaxAssetsTaxCreditCarryforwardsResearchAndDevelopment" xlink:label="loc_immu_DeferredTaxAssetsTaxCreditCarryforwardsResearchAndDevelopment_143E42E1965233B4991D69B4D08EF6E7" xlink:type="locator" />
<link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_6D391C67D484970224E569B4D08D9F73" xlink:to="loc_immu_DeferredTaxAssetsTaxCreditCarryforwardsResearchAndDevelopment_143E42E1965233B4991D69B4D08EF6E7" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_UndistributedEarningsOfForeignSubsidiaries" xlink:label="loc_us-gaap_UndistributedEarningsOfForeignSubsidiaries_E7C1E10D3C9DB8C5A65269B4D08E42F0" xlink:type="locator" />
<link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_6D391C67D484970224E569B4D08D9F73" xlink:to="loc_us-gaap_UndistributedEarningsOfForeignSubsidiaries_E7C1E10D3C9DB8C5A65269B4D08E42F0" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TaxCutsAndJobsActOf2017IncompleteAccountingProvisionalIncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_TaxCutsAndJobsActOf2017IncompleteAccountingProvisionalIncomeTaxExpenseBenefit_03817D2788B72BDC290169B4D08E4F10" xlink:type="locator" />
<link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_6D391C67D484970224E569B4D08D9F73" xlink:to="loc_us-gaap_TaxCutsAndJobsActOf2017IncompleteAccountingProvisionalIncomeTaxExpenseBenefit_03817D2788B72BDC290169B4D08E4F10" xlink:type="arc" />
</link:presentationLink>
<link:presentationLink xlink:role="http://www.immunomedics.com/role/IncomeTaxesReconciliationOfStatutoryTaxRatesAndEffectiveTaxRatesDetails" xlink:type="extended">
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_0DD13C1E4345EA2C40484551CE522B27" xlink:type="locator" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_34883BA79701873C6B914551CE521D4C" xlink:type="locator" />
<link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_0DD13C1E4345EA2C40484551CE522B27" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_34883BA79701873C6B914551CE521D4C" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_FC7932092496F100E2544551CE52B2EC" xlink:type="locator" />
<link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_0DD13C1E4345EA2C40484551CE522B27" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_FC7932092496F100E2544551CE52B2EC" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_D4FD5D1BAC5E1B4DDCAF4551CE527461" xlink:type="locator" />
<link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_0DD13C1E4345EA2C40484551CE522B27" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_D4FD5D1BAC5E1B4DDCAF4551CE527461" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_1F74F2029C26566E34774551CE530B8D" xlink:type="locator" />
<link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_0DD13C1E4345EA2C40484551CE522B27" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_1F74F2029C26566E34774551CE530B8D" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense_B9EAEE3246EBE3DAF49A4551CE5352BB" xlink:type="locator" />
<link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_0DD13C1E4345EA2C40484551CE522B27" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense_B9EAEE3246EBE3DAF49A4551CE5352BB" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent_2385AD64D3CA091EEA7A4551CE539978" xlink:type="locator" />
<link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_0DD13C1E4345EA2C40484551CE522B27" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent_2385AD64D3CA091EEA7A4551CE539978" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_0AC7867D3B56AE1E004E4551CE53200F" xlink:type="locator" />
<link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_0DD13C1E4345EA2C40484551CE522B27" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_0AC7867D3B56AE1E004E4551CE53200F" xlink:type="arc" />
</link:presentationLink>
<link:presentationLink xlink:role="http://www.immunomedics.com/role/IncomeTaxesTables" xlink:type="extended">
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_38FA6A2E3B6064AF76FDD1D0621680E3" xlink:type="locator" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_6B1182AF19D69F4DB860D1D06216872F" xlink:type="locator" />
<link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_38FA6A2E3B6064AF76FDD1D0621680E3" xlink:to="loc_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_6B1182AF19D69F4DB860D1D06216872F" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_FB6C7D616F9A8944FD0DD1D062166647" xlink:type="locator" />
<link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_38FA6A2E3B6064AF76FDD1D0621680E3" xlink:to="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_FB6C7D616F9A8944FD0DD1D062166647" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_C59383D24A93D2ABEAA5D1D06216C66B" xlink:type="locator" />
<link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_38FA6A2E3B6064AF76FDD1D0621680E3" xlink:to="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_C59383D24A93D2ABEAA5D1D06216C66B" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SummaryOfIncomeTaxContingenciesTextBlock" xlink:label="loc_us-gaap_SummaryOfIncomeTaxContingenciesTextBlock_185C06E4055FB7EAEA73D1D062163AB4" xlink:type="locator" />
<link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_38FA6A2E3B6064AF76FDD1D0621680E3" xlink:to="loc_us-gaap_SummaryOfIncomeTaxContingenciesTextBlock_185C06E4055FB7EAEA73D1D062163AB4" xlink:type="arc" />
</link:presentationLink>
<link:presentationLink xlink:role="http://www.immunomedics.com/role/IncomeTaxesTaxEffectsOfTemporaryDifferencesInDeferredTaxAssetsDetails" xlink:type="extended">
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_40CF5E65B790CDA841AC850F478105C1" xlink:type="locator" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_B03B37D208FBA0EA7B9D850F4781D6E1" xlink:type="locator" />
<link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_40CF5E65B790CDA841AC850F478105C1" xlink:to="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_B03B37D208FBA0EA7B9D850F4781D6E1" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_2C7C681892C109F3D820850F47816FA3" xlink:type="locator" />
<link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_40CF5E65B790CDA841AC850F478105C1" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_2C7C681892C109F3D820850F47816FA3" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxAssetsDeferredIncome" xlink:label="loc_us-gaap_DeferredTaxAssetsDeferredIncome_1E1159C8040E498516E9850F4782AC2A" xlink:type="locator" />
<link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_40CF5E65B790CDA841AC850F478105C1" xlink:to="loc_us-gaap_DeferredTaxAssetsDeferredIncome_1E1159C8040E498516E9850F4782AC2A" xlink:type="arc" />
<link:loc xlink:href="immu-20191231.xsd#immu_DeferredTaxAssetsDeferredRevenue" xlink:label="loc_immu_DeferredTaxAssetsDeferredRevenue_AE338F3CA479660BF6BC8523B2B7A602" xlink:type="locator" />
<link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_40CF5E65B790CDA841AC850F478105C1" xlink:to="loc_immu_DeferredTaxAssetsDeferredRevenue_AE338F3CA479660BF6BC8523B2B7A602" xlink:type="arc" />
<link:loc xlink:href="immu-20191231.xsd#immu_DeferredTaxAssetDisallowedInterestExpense" xlink:label="loc_immu_DeferredTaxAssetDisallowedInterestExpense_2AA5B510C68D23201E11850F47822E56" xlink:type="locator" />
<link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_40CF5E65B790CDA841AC850F478105C1" xlink:to="loc_immu_DeferredTaxAssetDisallowedInterestExpense_2AA5B510C68D23201E11850F47822E56" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxAssetsOther" xlink:label="loc_us-gaap_DeferredTaxAssetsOther_4E1038BE974242FF3C9A850F47829CD2" xlink:type="locator" />
<link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_40CF5E65B790CDA841AC850F478105C1" xlink:to="loc_us-gaap_DeferredTaxAssetsOther_4E1038BE974242FF3C9A850F47829CD2" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="loc_us-gaap_DeferredTaxAssetsGross_C23C24220BD35F543803850F47826162" xlink:type="locator" />
<link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_40CF5E65B790CDA841AC850F478105C1" xlink:to="loc_us-gaap_DeferredTaxAssetsGross_C23C24220BD35F543803850F47826162" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_3529FE8E2EF58B46AC95850F4783B4CE" xlink:type="locator" />
<link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_40CF5E65B790CDA841AC850F478105C1" xlink:to="loc_us-gaap_DeferredTaxAssetsValuationAllowance_3529FE8E2EF58B46AC95850F4783B4CE" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="loc_us-gaap_DeferredTaxAssetsNet_5B3CE593757A23F5015A850F4783E4A5" xlink:type="locator" />
<link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_40CF5E65B790CDA841AC850F478105C1" xlink:to="loc_us-gaap_DeferredTaxAssetsNet_5B3CE593757A23F5015A850F4783E4A5" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_A150D5EF00AA47927903850F47838C72" xlink:type="locator" />
<link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_40CF5E65B790CDA841AC850F478105C1" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_A150D5EF00AA47927903850F47838C72" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:label="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_F10777736338F6FF5662850F47831F48" xlink:type="locator" />
<link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_40CF5E65B790CDA841AC850F478105C1" xlink:to="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_F10777736338F6FF5662850F47831F48" xlink:type="arc" />
</link:presentationLink>
<link:presentationLink xlink:role="http://www.immunomedics.com/role/MarketableSecurities" xlink:type="extended">
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_EF3CA1C347F13D58F408D1D063341F63" xlink:type="locator" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:label="loc_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_BB276CE63601025F9CFCD1D0633433B0" xlink:type="locator" />
<link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_EF3CA1C347F13D58F408D1D063341F63" xlink:to="loc_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_BB276CE63601025F9CFCD1D0633433B0" xlink:type="arc" />
</link:presentationLink>
<link:presentationLink xlink:role="http://www.immunomedics.com/role/MarketableSecuritiesAmortizedCostToFairValueDetails" xlink:type="extended">
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_748DAAF2BA0ACA69FA3D3991D283D95D" xlink:type="locator" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_E415A2A1CBB006EF66073991D2837379" xlink:type="locator" />
<link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_748DAAF2BA0ACA69FA3D3991D283D95D" xlink:to="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_E415A2A1CBB006EF66073991D2837379" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="loc_us-gaap_FinancialInstrumentAxis_126BF9B58810F2D6D5483991D2844ACE" xlink:type="locator" />
<link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_E415A2A1CBB006EF66073991D2837379" xlink:to="loc_us-gaap_FinancialInstrumentAxis_126BF9B58810F2D6D5483991D2844ACE" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_F3B53A7162D06F4E67093991D2845899" xlink:type="locator" />
<link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentAxis_126BF9B58810F2D6D5483991D2844ACE" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_F3B53A7162D06F4E67093991D2845899" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember" xlink:label="loc_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember_B23B21643218C7FBF1EA3991D2847FAF" xlink:type="locator" />
<link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_F3B53A7162D06F4E67093991D2845899" xlink:to="loc_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember_B23B21643218C7FBF1EA3991D2847FAF" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_6012AD4D345BB19050CD3991D284B262" xlink:type="locator" />
<link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_E415A2A1CBB006EF66073991D2837379" xlink:to="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_6012AD4D345BB19050CD3991D284B262" xlink:type="arc" />
<link:loc xlink:href="immu-20191231.xsd#immu_AvailableForSaleSecuritiesDebtMaturitiesAfterOneYearormoreCarryingValue" xlink:label="loc_immu_AvailableForSaleSecuritiesDebtMaturitiesAfterOneYearormoreCarryingValue_9291349186795373BECD3991D285C6A2" xlink:type="locator" />
<link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_6012AD4D345BB19050CD3991D284B262" xlink:to="loc_immu_AvailableForSaleSecuritiesDebtMaturitiesAfterOneYearormoreCarryingValue_9291349186795373BECD3991D285C6A2" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_9A1324DB69BFCAE357D73991D28513EB" xlink:type="locator" />
<link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_6012AD4D345BB19050CD3991D284B262" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_9A1324DB69BFCAE357D73991D28513EB" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_E52421C5094607DC888F3991D285C18A" xlink:type="locator" />
<link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_6012AD4D345BB19050CD3991D284B262" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_E52421C5094607DC888F3991D285C18A" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_48DA9E2371A57265E2AE3991D285E536" xlink:type="locator" />
<link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_6012AD4D345BB19050CD3991D284B262" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_48DA9E2371A57265E2AE3991D285E536" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_6D436F18B75EBA986CE03991D28536B5" xlink:type="locator" />
<link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_6012AD4D345BB19050CD3991D284B262" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_6D436F18B75EBA986CE03991D28536B5" xlink:type="arc" />
</link:presentationLink>
<link:presentationLink xlink:role="http://www.immunomedics.com/role/MarketableSecuritiesTables" xlink:type="extended">
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_6054F35A592A74AC5F82DB5CE7AC796E" xlink:type="locator" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock_B48B161AC54FF4686A7CDB5CE7ADAE73" xlink:type="locator" />
<link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_6054F35A592A74AC5F82DB5CE7AC796E" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock_B48B161AC54FF4686A7CDB5CE7ADAE73" xlink:type="arc" />
</link:presentationLink>
<link:presentationLink xlink:role="http://www.immunomedics.com/role/PropertyAndEquipment" xlink:type="extended">
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_F33D3B185DA6624BDCFDD1D062E13EED" xlink:type="locator" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_EF688BF1BEF9AE53264DD1D062E16A3B" xlink:type="locator" />
<link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_F33D3B185DA6624BDCFDD1D062E13EED" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_EF688BF1BEF9AE53264DD1D062E16A3B" xlink:type="arc" />
</link:presentationLink>
<link:presentationLink xlink:role="http://www.immunomedics.com/role/PropertyAndEquipmentAdditionalInformationDetails" xlink:type="extended">
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_227081DD2E9093C61A44DB9A47EA6E1F" xlink:type="locator" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DepreciationAndAmortization" xlink:label="loc_us-gaap_DepreciationAndAmortization_E2D873D34008E91A9379DB9A47EAB776" xlink:type="locator" />
<link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_227081DD2E9093C61A44DB9A47EA6E1F" xlink:to="loc_us-gaap_DepreciationAndAmortization_E2D873D34008E91A9379DB9A47EAB776" xlink:type="arc" />
</link:presentationLink>
<link:presentationLink xlink:role="http://www.immunomedics.com/role/PropertyAndEquipmentSchedulesOfPropertyAndEquipmentDetails" xlink:type="extended">
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_99DD1D8194F88A7F9C97853A877BE8A0" xlink:type="locator" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_4D63321AB22AD9013453853A877B15FA" xlink:type="locator" />
<link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_99DD1D8194F88A7F9C97853A877BE8A0" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_4D63321AB22AD9013453853A877B15FA" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_22ED0A765BDCE7B68E05853A877C084C" xlink:type="locator" />
<link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_4D63321AB22AD9013453853A877B15FA" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_22ED0A765BDCE7B68E05853A877C084C" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_00365D813F93995C5903853A877C46F5" xlink:type="locator" />
<link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_22ED0A765BDCE7B68E05853A877C084C" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_00365D813F93995C5903853A877C46F5" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MachineryAndEquipmentMember" xlink:label="loc_us-gaap_MachineryAndEquipmentMember_3967AB313E1E39D325D4853A877CB73C" xlink:type="locator" />
<link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_00365D813F93995C5903853A877C46F5" xlink:to="loc_us-gaap_MachineryAndEquipmentMember_3967AB313E1E39D325D4853A877CB73C" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="loc_us-gaap_LeaseholdImprovementsMember_9F4A897E34D8546E22E3853A877C2955" xlink:type="locator" />
<link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_00365D813F93995C5903853A877C46F5" xlink:to="loc_us-gaap_LeaseholdImprovementsMember_9F4A897E34D8546E22E3853A877C2955" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="loc_us-gaap_FurnitureAndFixturesMember_F4F35E62B2B4487894B5853A877DB7AA" xlink:type="locator" />
<link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_00365D813F93995C5903853A877C46F5" xlink:to="loc_us-gaap_FurnitureAndFixturesMember_F4F35E62B2B4487894B5853A877DB7AA" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ComputerEquipmentMember" xlink:label="loc_us-gaap_ComputerEquipmentMember_81DDC19214490D9A4F70853A877DE79A" xlink:type="locator" />
<link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_00365D813F93995C5903853A877C46F5" xlink:to="loc_us-gaap_ComputerEquipmentMember_81DDC19214490D9A4F70853A877DE79A" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConstructionInProgressMember" xlink:label="loc_us-gaap_ConstructionInProgressMember_4E71809F704B96FAB51C853A877DD9D9" xlink:type="locator" />
<link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_00365D813F93995C5903853A877C46F5" xlink:to="loc_us-gaap_ConstructionInProgressMember_4E71809F704B96FAB51C853A877DD9D9" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_8DE427629B54A6D803EC853A877D3F17" xlink:type="locator" />
<link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_4D63321AB22AD9013453853A877B15FA" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentLineItems_8DE427629B54A6D803EC853A877D3F17" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_0D30A6F5EF78DAC1CFD5853A877D84F2" xlink:type="locator" />
<link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_8DE427629B54A6D803EC853A877D3F17" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_0D30A6F5EF78DAC1CFD5853A877D84F2" xlink:type="arc" />
<link:loc xlink:href="immu-20191231.xsd#immu_FinanceLeaseRightofUseAssetBeforeAccumulatedAmortization" xlink:label="loc_immu_FinanceLeaseRightofUseAssetBeforeAccumulatedAmortization_569A7945E7E440F96D6D853A877D8137" xlink:type="locator" />
<link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_8DE427629B54A6D803EC853A877D3F17" xlink:to="loc_immu_FinanceLeaseRightofUseAssetBeforeAccumulatedAmortization_569A7945E7E440F96D6D853A877D8137" xlink:type="arc" />
<link:loc xlink:href="immu-20191231.xsd#immu_PropertyPlantAndEquipmentAndFinanceLeaseRightofUseAssetBeforeAccumulatedDepreciationAndAmortization" xlink:label="loc_immu_PropertyPlantAndEquipmentAndFinanceLeaseRightofUseAssetBeforeAccumulatedDepreciationAndAmortization_97A5523681CEF27B4870853A877E8E40" xlink:type="locator" />
<link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_8DE427629B54A6D803EC853A877D3F17" xlink:to="loc_immu_PropertyPlantAndEquipmentAndFinanceLeaseRightofUseAssetBeforeAccumulatedDepreciationAndAmortization_97A5523681CEF27B4870853A877E8E40" xlink:type="arc" />
<link:loc xlink:href="immu-20191231.xsd#immu_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization" xlink:label="loc_immu_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization_6A46FF2408D8FB5A9BC4853A877E61C5" xlink:type="locator" />
<link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_8DE427629B54A6D803EC853A877D3F17" xlink:to="loc_immu_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization_6A46FF2408D8FB5A9BC4853A877E61C5" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_6A2AB5215C99F14E67EA853A877E331B" xlink:type="locator" />
<link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_8DE427629B54A6D803EC853A877D3F17" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_6A2AB5215C99F14E67EA853A877E331B" xlink:type="arc" />
<link:loc xlink:href="immu-20191231.xsd#immu_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization" xlink:label="loc_immu_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization_FB080B6EB50EF437BC7C853A877E5F59" xlink:type="locator" />
<link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_8DE427629B54A6D803EC853A877D3F17" xlink:to="loc_immu_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization_FB080B6EB50EF437BC7C853A877E5F59" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_6F5C9B295B3EA656C698853A877EF908" xlink:type="locator" />
<link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_8DE427629B54A6D803EC853A877D3F17" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_6F5C9B295B3EA656C698853A877EF908" xlink:type="arc" />
</link:presentationLink>
<link:presentationLink xlink:role="http://www.immunomedics.com/role/PropertyAndEquipmentTables" xlink:type="extended">
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_F28A057436C61B6FC6B4D1D062254A38" xlink:type="locator" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_107C98C8C33F9443645BD1D062250447" xlink:type="locator" />
<link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_F28A057436C61B6FC6B4D1D062254A38" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_107C98C8C33F9443645BD1D062250447" xlink:type="arc" />
</link:presentationLink>
<link:presentationLink xlink:role="http://www.immunomedics.com/role/QuarterlyResultsOfOperationsDetails" xlink:type="extended">
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_QuarterlyFinancialInformationDisclosureAbstract" xlink:label="loc_us-gaap_QuarterlyFinancialInformationDisclosureAbstract_24D20FFBF161D73746393991D16A146B" xlink:type="locator" />
<link:loc xlink:href="immu-20191231.xsd#immu_ConsolidatedStatementOfOperationsAbstract" xlink:label="loc_immu_ConsolidatedStatementOfOperationsAbstract_336915A68B8170F677E73991D16AB877" xlink:type="locator" />
<link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_QuarterlyFinancialInformationDisclosureAbstract_24D20FFBF161D73746393991D16A146B" xlink:to="loc_immu_ConsolidatedStatementOfOperationsAbstract_336915A68B8170F677E73991D16AB877" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_D0811422C28110D82DE53991D16A2D64" xlink:type="locator" />
<link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_immu_ConsolidatedStatementOfOperationsAbstract_336915A68B8170F677E73991D16AB877" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_D0811422C28110D82DE53991D16A2D64" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_1578A38BD35849A7E4CB3991D16A95B5" xlink:type="locator" />
<link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_immu_ConsolidatedStatementOfOperationsAbstract_336915A68B8170F677E73991D16AB877" xlink:to="loc_us-gaap_NetIncomeLoss_1578A38BD35849A7E4CB3991D16A95B5" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDiluted_DA385944638708B019A63991D16BE221" xlink:type="locator" />
<link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_immu_ConsolidatedStatementOfOperationsAbstract_336915A68B8170F677E73991D16AB877" xlink:to="loc_us-gaap_EarningsPerShareBasicAndDiluted_DA385944638708B019A63991D16BE221" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:label="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_00FFF77C7F658EE33C683991D16BCAF5" xlink:type="locator" />
<link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_immu_ConsolidatedStatementOfOperationsAbstract_336915A68B8170F677E73991D16AB877" xlink:to="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_00FFF77C7F658EE33C683991D16BCAF5" xlink:type="arc" />
</link:presentationLink>
<link:presentationLink xlink:role="http://www.immunomedics.com/role/QuarterlyResultsOfOperationsTables" xlink:type="extended">
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_QuarterlyFinancialInformationDisclosureAbstract" xlink:label="loc_us-gaap_QuarterlyFinancialInformationDisclosureAbstract_93B0DD1576A07FF91D283991D16D8E44" xlink:type="locator" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock_881AB52636EFC19CC43B3991D16E632E" xlink:type="locator" />
<link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_QuarterlyFinancialInformationDisclosureAbstract_93B0DD1576A07FF91D283991D16D8E44" xlink:to="loc_us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock_881AB52636EFC19CC43B3991D16E632E" xlink:type="arc" />
</link:presentationLink>
<link:presentationLink xlink:role="http://www.immunomedics.com/role/QuarterlyResultsOfOperationsUnaudited" xlink:type="extended">
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_QuarterlyFinancialInformationDisclosureAbstract" xlink:label="loc_us-gaap_QuarterlyFinancialInformationDisclosureAbstract_DD5FFBB2EAAFA86614743991D16F6B21" xlink:type="locator" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_QuarterlyFinancialInformationTextBlock" xlink:label="loc_us-gaap_QuarterlyFinancialInformationTextBlock_D5C66C068ECBEE4D8C723991D1703C1A" xlink:type="locator" />
<link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_QuarterlyFinancialInformationDisclosureAbstract_DD5FFBB2EAAFA86614743991D16F6B21" xlink:to="loc_us-gaap_QuarterlyFinancialInformationTextBlock_D5C66C068ECBEE4D8C723991D1703C1A" xlink:type="arc" />
</link:presentationLink>
<link:presentationLink xlink:role="http://www.immunomedics.com/role/RelatedPartyTransactions" xlink:type="extended">
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract_D8F9F2EECEA0152D6568D1D0627DF742" xlink:type="locator" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:label="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_39FC415335A195A0796CD1D0627DECE7" xlink:type="locator" />
<link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract_D8F9F2EECEA0152D6568D1D0627DF742" xlink:to="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_39FC415335A195A0796CD1D0627DECE7" xlink:type="arc" />
</link:presentationLink>
<link:presentationLink xlink:role="http://www.immunomedics.com/role/RelatedPartyTransactionsDetails" xlink:type="extended">
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract_3D6C85DC8F49F28F6BD2454D8573D34D" xlink:type="locator" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_D48F28D818B708A15DC3454D8573D6A8" xlink:type="locator" />
<link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract_3D6C85DC8F49F28F6BD2454D8573D34D" xlink:to="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_D48F28D818B708A15DC3454D8573D6A8" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_153CF61DAF92B99799B5454D8573B92F" xlink:type="locator" />
<link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_D48F28D818B708A15DC3454D8573D6A8" xlink:to="loc_us-gaap_AwardTypeAxis_153CF61DAF92B99799B5454D8573B92F" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_6227319A64CDCB10E44A454D85738E36" xlink:type="locator" />
<link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_153CF61DAF92B99799B5454D8573B92F" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_6227319A64CDCB10E44A454D85738E36" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaap_EmployeeStockOptionMember_F1C638CDE8C4BA1BF02C454D85746A52" xlink:type="locator" />
<link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_6227319A64CDCB10E44A454D85738E36" xlink:to="loc_us-gaap_EmployeeStockOptionMember_F1C638CDE8C4BA1BF02C454D85746A52" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_TitleOfIndividualAxis" xlink:label="loc_srt_TitleOfIndividualAxis_F700DD8D65AE796AA41A454D85746996" xlink:type="locator" />
<link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_D48F28D818B708A15DC3454D8573D6A8" xlink:to="loc_srt_TitleOfIndividualAxis_F700DD8D65AE796AA41A454D85746996" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_9AC367E14248D30B63B3454D8574AAD9" xlink:type="locator" />
<link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_TitleOfIndividualAxis_F700DD8D65AE796AA41A454D85746996" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_9AC367E14248D30B63B3454D8574AAD9" xlink:type="arc" />
<link:loc xlink:href="immu-20191231.xsd#immu_ChiefTechnologyOfficerMember" xlink:label="loc_immu_ChiefTechnologyOfficerMember_BC9C5329332BB6953973454D857408F5" xlink:type="locator" />
<link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_9AC367E14248D30B63B3454D8574AAD9" xlink:to="loc_immu_ChiefTechnologyOfficerMember_BC9C5329332BB6953973454D857408F5" xlink:type="arc" />
<link:loc xlink:href="immu-20191231.xsd#immu_ExecutiveDirectorMember" xlink:label="loc_immu_ExecutiveDirectorMember_0B166C8AE4059C13AAC5454D85758891" xlink:type="locator" />
<link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_9AC367E14248D30B63B3454D8574AAD9" xlink:to="loc_immu_ExecutiveDirectorMember_0B166C8AE4059C13AAC5454D85758891" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_BoardOfDirectorsChairmanMember" xlink:label="loc_srt_BoardOfDirectorsChairmanMember_8A65A3722CA02672053345546C13CCB2" xlink:type="locator" />
<link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_9AC367E14248D30B63B3454D8574AAD9" xlink:to="loc_srt_BoardOfDirectorsChairmanMember_8A65A3722CA02672053345546C13CCB2" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_A4A291188135E9662F04454D8575FA4A" xlink:type="locator" />
<link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_D48F28D818B708A15DC3454D8573D6A8" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_A4A291188135E9662F04454D8575FA4A" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain_33D9556EA95504090841454D8575CFE2" xlink:type="locator" />
<link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_A4A291188135E9662F04454D8575FA4A" xlink:to="loc_us-gaap_RelatedPartyDomain_33D9556EA95504090841454D8575CFE2" xlink:type="arc" />
<link:loc xlink:href="immu-20191231.xsd#immu_MRosenbergBioPharmaConsultingLlcMember" xlink:label="loc_immu_MRosenbergBioPharmaConsultingLlcMember_6D2D2530303492A8CE97454D857559F9" xlink:type="locator" />
<link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_33D9556EA95504090841454D8575CFE2" xlink:to="loc_immu_MRosenbergBioPharmaConsultingLlcMember_6D2D2530303492A8CE97454D857559F9" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_DirectorMember" xlink:label="loc_srt_DirectorMember_D281A408959672E55FEE454D8576E926" xlink:type="locator" />
<link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_33D9556EA95504090841454D8575CFE2" xlink:to="loc_srt_DirectorMember_D281A408959672E55FEE454D8576E926" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems_4F0A09EF5C1EB6170559454D85764216" xlink:type="locator" />
<link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_D48F28D818B708A15DC3454D8573D6A8" xlink:to="loc_us-gaap_RelatedPartyTransactionLineItems_4F0A09EF5C1EB6170559454D85764216" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProfessionalAndContractServicesExpense" xlink:label="loc_us-gaap_ProfessionalAndContractServicesExpense_8ED33DE68964D3F00940454D85767385" xlink:type="locator" />
<link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_4F0A09EF5C1EB6170559454D85764216" xlink:to="loc_us-gaap_ProfessionalAndContractServicesExpense_8ED33DE68964D3F00940454D85767385" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_26293CCD8B470D11936F454D85761674" xlink:type="locator" />
<link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_4F0A09EF5C1EB6170559454D85764216" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_26293CCD8B470D11936F454D85761674" xlink:type="arc" />
<link:loc xlink:href="immu-20191231.xsd#immu_PercentOfSharesForfeitedEmploymentCommencement" xlink:label="loc_immu_PercentOfSharesForfeitedEmploymentCommencement_23577B37F8BD73215F67454D85765860" xlink:type="locator" />
<link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_4F0A09EF5C1EB6170559454D85764216" xlink:to="loc_immu_PercentOfSharesForfeitedEmploymentCommencement_23577B37F8BD73215F67454D85765860" xlink:type="arc" />
<link:loc xlink:href="immu-20191231.xsd#immu_PercentOfSharesVestedEmploymentCommencement" xlink:label="loc_immu_PercentOfSharesVestedEmploymentCommencement_82E9E17024F7DCC0470E454D8576F058" xlink:type="locator" />
<link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_4F0A09EF5C1EB6170559454D85764216" xlink:to="loc_immu_PercentOfSharesVestedEmploymentCommencement_82E9E17024F7DCC0470E454D8576F058" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_4E6DDC8D7BB2E1A90B6D454D85777DEB" xlink:type="locator" />
<link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_4F0A09EF5C1EB6170559454D85764216" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_4E6DDC8D7BB2E1A90B6D454D85777DEB" xlink:type="arc" />
<link:loc xlink:href="immu-20191231.xsd#immu_SalaryandWageOfficerMonthlySalary" xlink:label="loc_immu_SalaryandWageOfficerMonthlySalary_F391BB5DBD3195381408454D8577BC52" xlink:type="locator" />
<link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_4F0A09EF5C1EB6170559454D85764216" xlink:to="loc_immu_SalaryandWageOfficerMonthlySalary_F391BB5DBD3195381408454D8577BC52" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SalariesWagesAndOfficersCompensation" xlink:label="loc_us-gaap_SalariesWagesAndOfficersCompensation_969D940F4822EEB5145D454D85775024" xlink:type="locator" />
<link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_4F0A09EF5C1EB6170559454D85764216" xlink:to="loc_us-gaap_SalariesWagesAndOfficersCompensation_969D940F4822EEB5145D454D85775024" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_0F3A51A99079A240ECF0454D8577A3B6" xlink:type="locator" />
<link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_4F0A09EF5C1EB6170559454D85764216" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_0F3A51A99079A240ECF0454D8577A3B6" xlink:type="arc" />
</link:presentationLink>
<link:presentationLink xlink:role="http://www.immunomedics.com/role/RevenueRecognition" xlink:type="extended">
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueFromContractWithCustomerAbstract" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_E1B4E902CBE10A762E483991D2985686" xlink:type="locator" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerTextBlock_5EB23711DC3E2FCBBA1C3991D298B575" xlink:type="locator" />
<link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_E1B4E902CBE10A762E483991D2985686" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerTextBlock_5EB23711DC3E2FCBBA1C3991D298B575" xlink:type="arc" />
</link:presentationLink>
<link:presentationLink xlink:role="http://www.immunomedics.com/role/RevenueRecognitionAdditionalInformationDetails" xlink:type="extended">
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueFromContractWithCustomerAbstract" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_C780D6F4F063FA7BD17B600A1650F4A0" xlink:type="locator" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_D1B50C3E582007C79188600A16526012" xlink:type="locator" />
<link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_C780D6F4F063FA7BD17B600A1650F4A0" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_D1B50C3E582007C79188600A16526012" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_A12BBBE3E798750CE14F600A1653163A" xlink:type="locator" />
<link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_D1B50C3E582007C79188600A16526012" xlink:to="loc_srt_RangeAxis_A12BBBE3E798750CE14F600A1653163A" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_90C878E15A2D5DA40382600A1653F34F" xlink:type="locator" />
<link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_A12BBBE3E798750CE14F600A1653163A" xlink:to="loc_srt_RangeMember_90C878E15A2D5DA40382600A1653F34F" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MinimumMember" xlink:label="loc_srt_MinimumMember_97A4131D6AA236B451FC600A1654A4F0" xlink:type="locator" />
<link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_90C878E15A2D5DA40382600A1653F34F" xlink:to="loc_srt_MinimumMember_97A4131D6AA236B451FC600A1654A4F0" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_0843F8EE82892DE4A556600A1654367F" xlink:type="locator" />
<link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_90C878E15A2D5DA40382600A1653F34F" xlink:to="loc_srt_MaximumMember_0843F8EE82892DE4A556600A1654367F" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MajorCustomersAxis" xlink:label="loc_srt_MajorCustomersAxis_D2B4966F6BB63CD66656600A16545DC6" xlink:type="locator" />
<link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_D1B50C3E582007C79188600A16526012" xlink:to="loc_srt_MajorCustomersAxis_D2B4966F6BB63CD66656600A16545DC6" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_NameOfMajorCustomerDomain" xlink:label="loc_srt_NameOfMajorCustomerDomain_F8E94BBB1CE4CD8FD11A600A165533EC" xlink:type="locator" />
<link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_MajorCustomersAxis_D2B4966F6BB63CD66656600A16545DC6" xlink:to="loc_srt_NameOfMajorCustomerDomain_F8E94BBB1CE4CD8FD11A600A165533EC" xlink:type="arc" />
<link:loc xlink:href="immu-20191231.xsd#immu_EverestMedicinesIILimitedMember" xlink:label="loc_immu_EverestMedicinesIILimitedMember_37EDB7656211658CA0FC600A16555470" xlink:type="locator" />
<link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_F8E94BBB1CE4CD8FD11A600A165533EC" xlink:to="loc_immu_EverestMedicinesIILimitedMember_37EDB7656211658CA0FC600A16555470" xlink:type="arc" />
<link:loc xlink:href="immu-20191231.xsd#immu_JanssenBiotechIncMember" xlink:label="loc_immu_JanssenBiotechIncMember_539D7A71C595FF03DE74600A16551E8A" xlink:type="locator" />
<link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_F8E94BBB1CE4CD8FD11A600A165533EC" xlink:to="loc_immu_JanssenBiotechIncMember_539D7A71C595FF03DE74600A16551E8A" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1DBDCC40AA7342E0D7D5600A1655AF53" xlink:type="locator" />
<link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_D1B50C3E582007C79188600A16526012" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1DBDCC40AA7342E0D7D5600A1655AF53" xlink:type="arc" />
<link:loc xlink:href="immu-20191231.xsd#immu_LicenseAgreementUpfrontFeesPaid" xlink:label="loc_immu_LicenseAgreementUpfrontFeesPaid_7370011645711C8646F9600A1656BD38" xlink:type="locator" />
<link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1DBDCC40AA7342E0D7D5600A1655AF53" xlink:to="loc_immu_LicenseAgreementUpfrontFeesPaid_7370011645711C8646F9600A1656BD38" xlink:type="arc" />
<link:loc xlink:href="immu-20191231.xsd#immu_LicenseAgreementMilestonePaymentUponAchievementofFDAApproval" xlink:label="loc_immu_LicenseAgreementMilestonePaymentUponAchievementofFDAApproval_1AB7EBD853E908205207600A16564630" xlink:type="locator" />
<link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1DBDCC40AA7342E0D7D5600A1655AF53" xlink:to="loc_immu_LicenseAgreementMilestonePaymentUponAchievementofFDAApproval_1AB7EBD853E908205207600A16564630" xlink:type="arc" />
<link:loc xlink:href="immu-20191231.xsd#immu_LicenseAgreementMilestoneDevelopmentTotalPayments" xlink:label="loc_immu_LicenseAgreementMilestoneDevelopmentTotalPayments_AF47BF19638BB147E1C6600A1656E37E" xlink:type="locator" />
<link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1DBDCC40AA7342E0D7D5600A1655AF53" xlink:to="loc_immu_LicenseAgreementMilestoneDevelopmentTotalPayments_AF47BF19638BB147E1C6600A1656E37E" xlink:type="arc" />
<link:loc xlink:href="immu-20191231.xsd#immu_LicenseAgreementMilestoneSalesTotalPayments" xlink:label="loc_immu_LicenseAgreementMilestoneSalesTotalPayments_8875A3B1139BEE577714600A16560AB1" xlink:type="locator" />
<link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1DBDCC40AA7342E0D7D5600A1655AF53" xlink:to="loc_immu_LicenseAgreementMilestoneSalesTotalPayments_8875A3B1139BEE577714600A16560AB1" xlink:type="arc" />
<link:loc xlink:href="immu-20191231.xsd#immu_RoyaltyPaymentsPercentage" xlink:label="loc_immu_RoyaltyPaymentsPercentage_3A3555046E5FA3205B54600A1656895B" xlink:type="locator" />
<link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1DBDCC40AA7342E0D7D5600A1655AF53" xlink:to="loc_immu_RoyaltyPaymentsPercentage_3A3555046E5FA3205B54600A1656895B" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_67C476BE482536C1CF8A600A16576498" xlink:type="locator" />
<link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1DBDCC40AA7342E0D7D5600A1655AF53" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_67C476BE482536C1CF8A600A16576498" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Revenues" xlink:label="loc_us-gaap_Revenues_140CA064DA642700FF98600A1657DB51" xlink:type="locator" />
<link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1DBDCC40AA7342E0D7D5600A1655AF53" xlink:to="loc_us-gaap_Revenues_140CA064DA642700FF98600A1657DB51" xlink:type="arc" />
</link:presentationLink>
<link:presentationLink xlink:role="http://www.immunomedics.com/role/RevenueRecognitionPerformanceObligationDetails" xlink:type="extended">
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueFromContractWithCustomerAbstract" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_9EB17A55A55658853EE860442EBDA248" xlink:type="locator" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable_F4694D1FF242B00E15A560442EBD23BA" xlink:type="locator" />
<link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_9EB17A55A55658853EE860442EBDA248" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable_F4694D1FF242B00E15A560442EBD23BA" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MajorCustomersAxis" xlink:label="loc_srt_MajorCustomersAxis_FA9E55C5BCAD54F286BE60442EBDF618" xlink:type="locator" />
<link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable_F4694D1FF242B00E15A560442EBD23BA" xlink:to="loc_srt_MajorCustomersAxis_FA9E55C5BCAD54F286BE60442EBDF618" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_NameOfMajorCustomerDomain" xlink:label="loc_srt_NameOfMajorCustomerDomain_32D104BBB2478BE035DC60442EBE18FE" xlink:type="locator" />
<link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_MajorCustomersAxis_FA9E55C5BCAD54F286BE60442EBDF618" xlink:to="loc_srt_NameOfMajorCustomerDomain_32D104BBB2478BE035DC60442EBE18FE" xlink:type="arc" />
<link:loc xlink:href="immu-20191231.xsd#immu_EverestMedicinesIILimitedMember" xlink:label="loc_immu_EverestMedicinesIILimitedMember_AACB2332F4046898F56260442EBEB9C6" xlink:type="locator" />
<link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_32D104BBB2478BE035DC60442EBE18FE" xlink:to="loc_immu_EverestMedicinesIILimitedMember_AACB2332F4046898F56260442EBEB9C6" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis_3AF2DADEDCA1E9A7621560442EBE7F0F" xlink:type="locator" />
<link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable_F4694D1FF242B00E15A560442EBD23BA" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis_3AF2DADEDCA1E9A7621560442EBE7F0F" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems_921FCF5FBA7D1E1CD70560442EBFEB5D" xlink:type="locator" />
<link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable_F4694D1FF242B00E15A560442EBD23BA" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems_921FCF5FBA7D1E1CD70560442EBFEB5D" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligation" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligation_094F2AF318DA8860924560442EBF48A0" xlink:type="locator" />
<link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems_921FCF5FBA7D1E1CD70560442EBFEB5D" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligation_094F2AF318DA8860924560442EBF48A0" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1_A2BAF008799865F61CB060442EBFA562" xlink:type="locator" />
<link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems_921FCF5FBA7D1E1CD70560442EBFEB5D" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1_A2BAF008799865F61CB060442EBFA562" xlink:type="arc" />
</link:presentationLink>
<link:presentationLink xlink:role="http://www.immunomedics.com/role/StockBasedCompensation" xlink:type="extended">
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_C71211AEAF1EE32A606BD1D062B96F6F" xlink:type="locator" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_07859EBC9F787C252994D1D062B9B28D" xlink:type="locator" />
<link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_C71211AEAF1EE32A606BD1D062B96F6F" xlink:to="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_07859EBC9F787C252994D1D062B9B28D" xlink:type="arc" />
</link:presentationLink>
<link:presentationLink xlink:role="http://www.immunomedics.com/role/StockBasedCompensationFairValueAssumptionsDetails" xlink:type="extended">
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_BA1E6FB6516A6799953ADB3A5B43E914" xlink:type="locator" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_5D6475A6855A9E99AE6EDB3A5B44149D" xlink:type="locator" />
<link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_BA1E6FB6516A6799953ADB3A5B43E914" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_5D6475A6855A9E99AE6EDB3A5B44149D" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_60F903A44F5DAF0A887BDB3A5B44FEC0" xlink:type="locator" />
<link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_5D6475A6855A9E99AE6EDB3A5B44149D" xlink:to="loc_srt_RangeAxis_60F903A44F5DAF0A887BDB3A5B44FEC0" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_58D440EBA43F1375F27CDB3A5B44EDB2" xlink:type="locator" />
<link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_60F903A44F5DAF0A887BDB3A5B44FEC0" xlink:to="loc_srt_RangeMember_58D440EBA43F1375F27CDB3A5B44EDB2" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MinimumMember" xlink:label="loc_srt_MinimumMember_8F2B3F58CF5F52576F46DB3A5B4533A0" xlink:type="locator" />
<link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_58D440EBA43F1375F27CDB3A5B44EDB2" xlink:to="loc_srt_MinimumMember_8F2B3F58CF5F52576F46DB3A5B4533A0" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_3C76837C63825C7DB32DDB3A5B457108" xlink:type="locator" />
<link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_58D440EBA43F1375F27CDB3A5B44EDB2" xlink:to="loc_srt_MaximumMember_3C76837C63825C7DB32DDB3A5B457108" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_BA0D1FFE5AFA1CDBEC74DB3A5B45C36C" xlink:type="locator" />
<link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_5D6475A6855A9E99AE6EDB3A5B44149D" xlink:to="loc_us-gaap_AwardTypeAxis_BA0D1FFE5AFA1CDBEC74DB3A5B45C36C" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_586D6A299E128D39D0ECDB3A5B4528D7" xlink:type="locator" />
<link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_BA0D1FFE5AFA1CDBEC74DB3A5B45C36C" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_586D6A299E128D39D0ECDB3A5B4528D7" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaap_EmployeeStockOptionMember_62719B727184CBF5A047DB3A5B46D42F" xlink:type="locator" />
<link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_586D6A299E128D39D0ECDB3A5B4528D7" xlink:to="loc_us-gaap_EmployeeStockOptionMember_62719B727184CBF5A047DB3A5B46D42F" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_FBBA194E86769ED2E37BDB3A5B46FC67" xlink:type="locator" />
<link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_5D6475A6855A9E99AE6EDB3A5B44149D" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_FBBA194E86769ED2E37BDB3A5B46FC67" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_9BDD3CBF16CEC1159BB5DB3A5B4658DD" xlink:type="locator" />
<link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_FBBA194E86769ED2E37BDB3A5B46FC67" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_9BDD3CBF16CEC1159BB5DB3A5B4658DD" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_D0587A8AAF695E71C278DB3A5B46557E" xlink:type="locator" />
<link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_FBBA194E86769ED2E37BDB3A5B46FC67" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_D0587A8AAF695E71C278DB3A5B46557E" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_9E0D51C039E5D2138D14DB3A5B477571" xlink:type="locator" />
<link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_FBBA194E86769ED2E37BDB3A5B46FC67" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_9E0D51C039E5D2138D14DB3A5B477571" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_59E1D67A98DAD414A740DB3A5B4734D7" xlink:type="locator" />
<link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_FBBA194E86769ED2E37BDB3A5B46FC67" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_59E1D67A98DAD414A740DB3A5B4734D7" xlink:type="arc" />
</link:presentationLink>
<link:presentationLink xlink:role="http://www.immunomedics.com/role/StockBasedCompensationNarrativeDetails" xlink:type="extended">
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_E71DBF2C1CA7C9565C323991D242A0CC" xlink:type="locator" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_8123148D82AE94D2BE083991D2439319" xlink:type="locator" />
<link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_E71DBF2C1CA7C9565C323991D242A0CC" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_8123148D82AE94D2BE083991D2439319" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_F042FBCC4465C45B9BCA3991D24376A1" xlink:type="locator" />
<link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_8123148D82AE94D2BE083991D2439319" xlink:to="loc_us-gaap_AwardTypeAxis_F042FBCC4465C45B9BCA3991D24376A1" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_30CFCC05505077EFAA7D3991D2436058" xlink:type="locator" />
<link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_F042FBCC4465C45B9BCA3991D24376A1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_30CFCC05505077EFAA7D3991D2436058" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaap_EmployeeStockOptionMember_C2E5B865773FA49F3A5D3991D243EE0F" xlink:type="locator" />
<link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_30CFCC05505077EFAA7D3991D2436058" xlink:to="loc_us-gaap_EmployeeStockOptionMember_C2E5B865773FA49F3A5D3991D243EE0F" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_64B19240C2B31C27EC4B3991D244179E" xlink:type="locator" />
<link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_30CFCC05505077EFAA7D3991D2436058" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_64B19240C2B31C27EC4B3991D244179E" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PerformanceSharesMember" xlink:label="loc_us-gaap_PerformanceSharesMember_2FBC58B100DE1FE4AE6039DC3FA70277" xlink:type="locator" />
<link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_30CFCC05505077EFAA7D3991D2436058" xlink:to="loc_us-gaap_PerformanceSharesMember_2FBC58B100DE1FE4AE6039DC3FA70277" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2FCEBC1E6F4075E1DA1A3991D2446CDA" xlink:type="locator" />
<link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_8123148D82AE94D2BE083991D2439319" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2FCEBC1E6F4075E1DA1A3991D2446CDA" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_235E7196232A4C4692833991D244DB40" xlink:type="locator" />
<link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2FCEBC1E6F4075E1DA1A3991D2446CDA" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_235E7196232A4C4692833991D244DB40" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_7EA07F7FC98927746BBF3991D245F8D3" xlink:type="locator" />
<link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2FCEBC1E6F4075E1DA1A3991D2446CDA" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_7EA07F7FC98927746BBF3991D245F8D3" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_976D676FE780709929473991D245D52B" xlink:type="locator" />
<link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2FCEBC1E6F4075E1DA1A3991D2446CDA" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_976D676FE780709929473991D245D52B" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_18F2D8F7019099C518D73991D2452561" xlink:type="locator" />
<link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2FCEBC1E6F4075E1DA1A3991D2446CDA" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_18F2D8F7019099C518D73991D2452561" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_2B5F295CD125034D9BA83991D2454A77" xlink:type="locator" />
<link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2FCEBC1E6F4075E1DA1A3991D2446CDA" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_2B5F295CD125034D9BA83991D2454A77" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_0F46A9630622E31D92463991D245C157" xlink:type="locator" />
<link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2FCEBC1E6F4075E1DA1A3991D2446CDA" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_0F46A9630622E31D92463991D245C157" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_7B4A8C45D0E991B0A64A3991D245AE8A" xlink:type="locator" />
<link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2FCEBC1E6F4075E1DA1A3991D2446CDA" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_7B4A8C45D0E991B0A64A3991D245AE8A" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_ADC8845C9F4891302D063991D24555BE" xlink:type="locator" />
<link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2FCEBC1E6F4075E1DA1A3991D2446CDA" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_ADC8845C9F4891302D063991D24555BE" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_B53655B1E376993F351939D4E372026B" xlink:type="locator" />
<link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2FCEBC1E6F4075E1DA1A3991D2446CDA" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_B53655B1E376993F351939D4E372026B" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StateAndLocalIncomeTaxExpenseBenefitContinuingOperations" xlink:label="loc_us-gaap_StateAndLocalIncomeTaxExpenseBenefitContinuingOperations_07F8B3BCC28D12D6EE0F39EC99A63F93" xlink:type="locator" />
<link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2FCEBC1E6F4075E1DA1A3991D2446CDA" xlink:to="loc_us-gaap_StateAndLocalIncomeTaxExpenseBenefitContinuingOperations_07F8B3BCC28D12D6EE0F39EC99A63F93" xlink:type="arc" />
</link:presentationLink>
<link:presentationLink xlink:role="http://www.immunomedics.com/role/StockBasedCompensationRestrictedStockUnitActivityDetails" xlink:type="extended">
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_533CE27E54B7486532863991D2274FB1" xlink:type="locator" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_D708CAB03C4F686D30603991D227FE04" xlink:type="locator" />
<link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_533CE27E54B7486532863991D2274FB1" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_D708CAB03C4F686D30603991D227FE04" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_4DDD91272168A84268C03991D227685D" xlink:type="locator" />
<link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_D708CAB03C4F686D30603991D227FE04" xlink:to="loc_us-gaap_AwardTypeAxis_4DDD91272168A84268C03991D227685D" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0D3AD342E7A26D3BD20F3991D2279672" xlink:type="locator" />
<link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_4DDD91272168A84268C03991D227685D" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0D3AD342E7A26D3BD20F3991D2279672" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_B9CAC079C1417D283B153991D2285C9B" xlink:type="locator" />
<link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0D3AD342E7A26D3BD20F3991D2279672" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_B9CAC079C1417D283B153991D2285C9B" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_415370AEF46F004DE3A43991D22802C9" xlink:type="locator" />
<link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_D708CAB03C4F686D30603991D227FE04" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_415370AEF46F004DE3A43991D22802C9" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_D87433532962FBD7B8803991D228186D" xlink:type="locator" />
<link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_415370AEF46F004DE3A43991D22802C9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_D87433532962FBD7B8803991D228186D" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_3EAD8D7715A3B29478A43991D229E6C6" xlink:type="locator" />
<link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_D87433532962FBD7B8803991D228186D" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_3EAD8D7715A3B29478A43991D229E6C6" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_21CAC48053750F29AEA53991D229E83E" xlink:type="locator" />
<link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_D87433532962FBD7B8803991D228186D" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_21CAC48053750F29AEA53991D229E83E" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_63BAD3AD7AB7CF1665E23991D2291875" xlink:type="locator" />
<link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_D87433532962FBD7B8803991D228186D" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_63BAD3AD7AB7CF1665E23991D2291875" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_8FC1F861EE84D69E18953991D229C39B" xlink:type="locator" />
<link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_D87433532962FBD7B8803991D228186D" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_8FC1F861EE84D69E18953991D229C39B" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_7AAE52D42DB09648E5083991D2295770" xlink:type="locator" />
<link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_D87433532962FBD7B8803991D228186D" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_7AAE52D42DB09648E5083991D2295770" xlink:type="arc" />
<link:loc xlink:href="immu-20191231.xsd#immu_WeightedaveragegrantdatefairvalueRollForward" xlink:label="loc_immu_WeightedaveragegrantdatefairvalueRollForward_0B159BB2FEE53AF19F863991D22AFE9F" xlink:type="locator" />
<link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_415370AEF46F004DE3A43991D22802C9" xlink:to="loc_immu_WeightedaveragegrantdatefairvalueRollForward_0B159BB2FEE53AF19F863991D22AFE9F" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_4E78933187C83BE24FB03991D22AAF26" xlink:type="locator" />
<link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_immu_WeightedaveragegrantdatefairvalueRollForward_0B159BB2FEE53AF19F863991D22AFE9F" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_4E78933187C83BE24FB03991D22AAF26" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_7BEAAC0017085B0D34E23991D22A815F" xlink:type="locator" />
<link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_immu_WeightedaveragegrantdatefairvalueRollForward_0B159BB2FEE53AF19F863991D22AFE9F" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_7BEAAC0017085B0D34E23991D22A815F" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_B05C97F255D7808305BF3991D22AC652" xlink:type="locator" />
<link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_immu_WeightedaveragegrantdatefairvalueRollForward_0B159BB2FEE53AF19F863991D22AFE9F" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_B05C97F255D7808305BF3991D22AC652" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_1B6AE5896B1AFD85B19D3991D22A7F29" xlink:type="locator" />
<link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_immu_WeightedaveragegrantdatefairvalueRollForward_0B159BB2FEE53AF19F863991D22AFE9F" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_1B6AE5896B1AFD85B19D3991D22A7F29" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_CA1DBE4B3C051AC6D7253991D22A7990" xlink:type="locator" />
<link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_immu_WeightedaveragegrantdatefairvalueRollForward_0B159BB2FEE53AF19F863991D22AFE9F" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_CA1DBE4B3C051AC6D7253991D22A7990" xlink:type="arc" />
</link:presentationLink>
<link:presentationLink xlink:role="http://www.immunomedics.com/role/StockBasedCompensationStockIncentivePlanDetails" xlink:type="extended">
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_B9536C6188F8051173523991D2493CEB" xlink:type="locator" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_7E51634C0597C526F08939D1BC31FBB2" xlink:type="locator" />
<link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_B9536C6188F8051173523991D2493CEB" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_7E51634C0597C526F08939D1BC31FBB2" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_2CF71EA8D879456B8F1B39D1BD38AACA" xlink:type="locator" />
<link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_7E51634C0597C526F08939D1BC31FBB2" xlink:to="loc_us-gaap_AwardTypeAxis_2CF71EA8D879456B8F1B39D1BD38AACA" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_138A2E1C48342EB2A7E939D1BD386D04" xlink:type="locator" />
<link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_2CF71EA8D879456B8F1B39D1BD38AACA" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_138A2E1C48342EB2A7E939D1BD386D04" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_6E1664D25DCF2A00F39139D1BE0E63A4" xlink:type="locator" />
<link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_138A2E1C48342EB2A7E939D1BD386D04" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_6E1664D25DCF2A00F39139D1BE0E63A4" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_64A8B36E0B9994CC2CC039D1BC3A79ED" xlink:type="locator" />
<link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_7E51634C0597C526F08939D1BC31FBB2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_64A8B36E0B9994CC2CC039D1BC3A79ED" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_893F440C627BD9A54F9D3991D249836E" xlink:type="locator" />
<link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_64A8B36E0B9994CC2CC039D1BC3A79ED" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_893F440C627BD9A54F9D3991D249836E" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_B2C9857716BCBF0E935C3991D2490D6F" xlink:type="locator" />
<link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_64A8B36E0B9994CC2CC039D1BC3A79ED" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_B2C9857716BCBF0E935C3991D2490D6F" xlink:type="arc" />
<link:loc xlink:href="immu-20191231.xsd#immu_AllocatedSharebasedCompensationExpenseAmountReversed" xlink:label="loc_immu_AllocatedSharebasedCompensationExpenseAmountReversed_3CF2C1FDEBA0F90A6B473991D2496AF7" xlink:type="locator" />
<link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_64A8B36E0B9994CC2CC039D1BC3A79ED" xlink:to="loc_immu_AllocatedSharebasedCompensationExpenseAmountReversed_3CF2C1FDEBA0F90A6B473991D2496AF7" xlink:type="arc" />
</link:presentationLink>
<link:presentationLink xlink:role="http://www.immunomedics.com/role/StockBasedCompensationStockOptionActivityDetails" xlink:type="extended">
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_28C92D356E98BBD49400DB3A1D3B826E" xlink:type="locator" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_03D95BA6414F33B86706DB3A1D3D476C" xlink:type="locator" />
<link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_28C92D356E98BBD49400DB3A1D3B826E" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_03D95BA6414F33B86706DB3A1D3D476C" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_AE7EEFC6F2FF16D804F7DB3A1D3E1BAC" xlink:type="locator" />
<link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_03D95BA6414F33B86706DB3A1D3D476C" xlink:to="loc_us-gaap_AwardTypeAxis_AE7EEFC6F2FF16D804F7DB3A1D3E1BAC" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_E10056EFAE86D5FAA212DB3A1D3E6953" xlink:type="locator" />
<link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_AE7EEFC6F2FF16D804F7DB3A1D3E1BAC" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_E10056EFAE86D5FAA212DB3A1D3E6953" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaap_EmployeeStockOptionMember_EA02E793F5BDFFFF3F38DB3A1D3F1E35" xlink:type="locator" />
<link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_E10056EFAE86D5FAA212DB3A1D3E6953" xlink:to="loc_us-gaap_EmployeeStockOptionMember_EA02E793F5BDFFFF3F38DB3A1D3F1E35" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PerformanceSharesMember" xlink:label="loc_us-gaap_PerformanceSharesMember_4342E3ADC48F2382FC9EDB3A1D3FF9C9" xlink:type="locator" />
<link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_E10056EFAE86D5FAA212DB3A1D3E6953" xlink:to="loc_us-gaap_PerformanceSharesMember_4342E3ADC48F2382FC9EDB3A1D3FF9C9" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_68F9E4B5E3E63931CF97DB3A1D3F583E" xlink:type="locator" />
<link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_03D95BA6414F33B86706DB3A1D3D476C" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_68F9E4B5E3E63931CF97DB3A1D3F583E" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_7988743A8E36D7DE7FB7DB3A1D403328" xlink:type="locator" />
<link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_68F9E4B5E3E63931CF97DB3A1D3F583E" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_7988743A8E36D7DE7FB7DB3A1D403328" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_B1563FEB14EC24B5F17BDB3A1D4065C3" xlink:type="locator" />
<link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_7988743A8E36D7DE7FB7DB3A1D403328" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_B1563FEB14EC24B5F17BDB3A1D4065C3" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_F086F89D242753A0C7AFDB3A1D4034AD" xlink:type="locator" />
<link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_7988743A8E36D7DE7FB7DB3A1D403328" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_F086F89D242753A0C7AFDB3A1D4034AD" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_BDD5713DA37532C8BC9ADB3A1D40C7CA" xlink:type="locator" />
<link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_7988743A8E36D7DE7FB7DB3A1D403328" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_BDD5713DA37532C8BC9ADB3A1D40C7CA" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_5960C6A3AC773CF31B77DB3A1D402C5E" xlink:type="locator" />
<link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_7988743A8E36D7DE7FB7DB3A1D403328" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_5960C6A3AC773CF31B77DB3A1D402C5E" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_C1F0722357D57805BDDEDB3A1D410C57" xlink:type="locator" />
<link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_7988743A8E36D7DE7FB7DB3A1D403328" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_C1F0722357D57805BDDEDB3A1D410C57" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_BF6FD067942DCFE09D5ADB3A1D415CD3" xlink:type="locator" />
<link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_68F9E4B5E3E63931CF97DB3A1D3F583E" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_BF6FD067942DCFE09D5ADB3A1D415CD3" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward_4B9F3FBBA60C48160F8ADB3A1D418DBB" xlink:type="locator" />
<link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_68F9E4B5E3E63931CF97DB3A1D3F583E" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward_4B9F3FBBA60C48160F8ADB3A1D418DBB" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_7C2B091AEAAD05CE0854DB3A1D412BFB" xlink:type="locator" />
<link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward_4B9F3FBBA60C48160F8ADB3A1D418DBB" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_7C2B091AEAAD05CE0854DB3A1D412BFB" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_ADA279D2706A72FF4EE0DB3A1D416B9C" xlink:type="locator" />
<link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward_4B9F3FBBA60C48160F8ADB3A1D418DBB" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_ADA279D2706A72FF4EE0DB3A1D416B9C" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_C548497D931A0EFC9286DB3A1D41B655" xlink:type="locator" />
<link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward_4B9F3FBBA60C48160F8ADB3A1D418DBB" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_C548497D931A0EFC9286DB3A1D41B655" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_C72156D9E6E28AD2A505DB3A1D4210CF" xlink:type="locator" />
<link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward_4B9F3FBBA60C48160F8ADB3A1D418DBB" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_C72156D9E6E28AD2A505DB3A1D4210CF" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_B5268C8D1DAA6FA9D625DB3A1D4283CF" xlink:type="locator" />
<link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward_4B9F3FBBA60C48160F8ADB3A1D418DBB" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_B5268C8D1DAA6FA9D625DB3A1D4283CF" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_7CE89DCD55E99B216EC8DB3A1D423EDB" xlink:type="locator" />
<link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_68F9E4B5E3E63931CF97DB3A1D3F583E" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_7CE89DCD55E99B216EC8DB3A1D423EDB" xlink:type="arc" />
<link:loc xlink:href="immu-20191231.xsd#immu_WeightedaverageremainingcontractualtermyearsRollForward" xlink:label="loc_immu_WeightedaverageremainingcontractualtermyearsRollForward_FBC1992349DF0CC00340DB3A1D42BB0C" xlink:type="locator" />
<link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_68F9E4B5E3E63931CF97DB3A1D3F583E" xlink:to="loc_immu_WeightedaverageremainingcontractualtermyearsRollForward_FBC1992349DF0CC00340DB3A1D42BB0C" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_B922E1ABDA68C98CBF59DB3A1D42CD9F" xlink:type="locator" />
<link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_immu_WeightedaverageremainingcontractualtermyearsRollForward_FBC1992349DF0CC00340DB3A1D42BB0C" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_B922E1ABDA68C98CBF59DB3A1D42CD9F" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_EE9E951C68225F1ECE98DB3A1D4314FC" xlink:type="locator" />
<link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_68F9E4B5E3E63931CF97DB3A1D3F583E" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_EE9E951C68225F1ECE98DB3A1D4314FC" xlink:type="arc" />
<link:loc xlink:href="immu-20191231.xsd#immu_IntrinsicvalueRollForward" xlink:label="loc_immu_IntrinsicvalueRollForward_4303B084DCECAA9F2D34DB3A1D43AD3C" xlink:type="locator" />
<link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_68F9E4B5E3E63931CF97DB3A1D3F583E" xlink:to="loc_immu_IntrinsicvalueRollForward_4303B084DCECAA9F2D34DB3A1D43AD3C" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_C7C792C30FEB260E2FB7DB3A1D4366B4" xlink:type="locator" />
<link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_immu_IntrinsicvalueRollForward_4303B084DCECAA9F2D34DB3A1D43AD3C" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_C7C792C30FEB260E2FB7DB3A1D4366B4" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_4C380E9857667B9DB0C4DB3A1D4374D9" xlink:type="locator" />
<link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_68F9E4B5E3E63931CF97DB3A1D3F583E" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_4C380E9857667B9DB0C4DB3A1D4374D9" xlink:type="arc" />
</link:presentationLink>
<link:presentationLink xlink:role="http://www.immunomedics.com/role/StockBasedCompensationTables" xlink:type="extended">
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_6DC2CAD38381C6CFF8DFDB9A48957F5D" xlink:type="locator" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_5FCEEB89B1C91F1F1A4CDB9A4895A776" xlink:type="locator" />
<link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_6DC2CAD38381C6CFF8DFDB9A48957F5D" xlink:to="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_5FCEEB89B1C91F1F1A4CDB9A4895A776" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_7DE8FF0E0CF04BD0A2D8DB9A4895CC13" xlink:type="locator" />
<link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_6DC2CAD38381C6CFF8DFDB9A48957F5D" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_7DE8FF0E0CF04BD0A2D8DB9A4895CC13" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock_D4A8EA6157C45FF13DA2DB9A4896FA4C" xlink:type="locator" />
<link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_6DC2CAD38381C6CFF8DFDB9A48957F5D" xlink:to="loc_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock_D4A8EA6157C45FF13DA2DB9A4896FA4C" xlink:type="arc" />
<link:loc xlink:href="immu-20191231.xsd#immu_ScheduleofSharebasedCompensationPerformanceStockandPerformanceStockUnitsActivityTableTextBlock" xlink:label="loc_immu_ScheduleofSharebasedCompensationPerformanceStockandPerformanceStockUnitsActivityTableTextBlock_44520D6A5C96AAF805D0DB9A4896F214" xlink:type="locator" />
<link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_6DC2CAD38381C6CFF8DFDB9A48957F5D" xlink:to="loc_immu_ScheduleofSharebasedCompensationPerformanceStockandPerformanceStockUnitsActivityTableTextBlock_44520D6A5C96AAF805D0DB9A4896F214" xlink:type="arc" />
</link:presentationLink>
<link:presentationLink xlink:role="http://www.immunomedics.com/role/StockholdersEquity" xlink:type="extended">
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="loc_us-gaap_StockholdersEquityNoteAbstract_25E889D9FB0CFB76B1A5E022A670FECB" xlink:type="locator" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_07575616F2AE72FB07B3E022A67005FA" xlink:type="locator" />
<link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_25E889D9FB0CFB76B1A5E022A670FECB" xlink:to="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_07575616F2AE72FB07B3E022A67005FA" xlink:type="arc" />
</link:presentationLink>
<link:presentationLink xlink:role="http://www.immunomedics.com/role/StockholdersEquityDetails" xlink:type="extended">
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="loc_us-gaap_StockholdersEquityNoteAbstract_5642A13E4F72333F884E850F47E3F3A3" xlink:type="locator" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfWarrantOrRightTable" xlink:label="loc_us-gaap_ClassOfWarrantOrRightTable_5A50C1824C482DD38108850F47E3B754" xlink:type="locator" />
<link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_5642A13E4F72333F884E850F47E3F3A3" xlink:to="loc_us-gaap_ClassOfWarrantOrRightTable_5A50C1824C482DD38108850F47E3B754" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_D10F3776ACAEEC5EE58D850F47E3D620" xlink:type="locator" />
<link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_5A50C1824C482DD38108850F47E3B754" xlink:to="loc_srt_RangeAxis_D10F3776ACAEEC5EE58D850F47E3D620" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_A6CE1182B46968E3B82A850F47E4953A" xlink:type="locator" />
<link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_D10F3776ACAEEC5EE58D850F47E3D620" xlink:to="loc_srt_RangeMember_A6CE1182B46968E3B82A850F47E4953A" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_WeightedAverageMember" xlink:label="loc_srt_WeightedAverageMember_F83CAA7750A045BD2246850F47E4511F" xlink:type="locator" />
<link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_A6CE1182B46968E3B82A850F47E4953A" xlink:to="loc_srt_WeightedAverageMember_F83CAA7750A045BD2246850F47E4511F" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueByLiabilityClassAxis" xlink:label="loc_us-gaap_FairValueByLiabilityClassAxis_24F069FDB21AD3A17EA2850F47E4792C" xlink:type="locator" />
<link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_5A50C1824C482DD38108850F47E3B754" xlink:to="loc_us-gaap_FairValueByLiabilityClassAxis_24F069FDB21AD3A17EA2850F47E4792C" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_93D0C374BB337497CBC4850F47E51B0E" xlink:type="locator" />
<link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByLiabilityClassAxis_24F069FDB21AD3A17EA2850F47E4792C" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_93D0C374BB337497CBC4850F47E51B0E" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaap_WarrantMember_33C4AFA262D511CBE402850F47E5C193" xlink:type="locator" />
<link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_93D0C374BB337497CBC4850F47E51B0E" xlink:to="loc_us-gaap_WarrantMember_33C4AFA262D511CBE402850F47E5C193" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_B077B03334465223E455850F47E52C46" xlink:type="locator" />
<link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_5A50C1824C482DD38108850F47E3B754" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_B077B03334465223E455850F47E52C46" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_88AA6A50083DA36A6D3D850F47E57C9B" xlink:type="locator" />
<link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_B077B03334465223E455850F47E52C46" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_88AA6A50083DA36A6D3D850F47E57C9B" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PrivatePlacementMember" xlink:label="loc_us-gaap_PrivatePlacementMember_37B4B2FC953837583FDF850F47E67F0C" xlink:type="locator" />
<link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_88AA6A50083DA36A6D3D850F47E57C9B" xlink:to="loc_us-gaap_PrivatePlacementMember_37B4B2FC953837583FDF850F47E67F0C" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IPOMember" xlink:label="loc_us-gaap_IPOMember_ED41F9D2B0B88E3F0F79850F47E67B88" xlink:type="locator" />
<link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_88AA6A50083DA36A6D3D850F47E57C9B" xlink:to="loc_us-gaap_IPOMember_ED41F9D2B0B88E3F0F79850F47E67B88" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OverAllotmentOptionMember" xlink:label="loc_us-gaap_OverAllotmentOptionMember_36AF5CD8640A31F20761850F47E6F069" xlink:type="locator" />
<link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_88AA6A50083DA36A6D3D850F47E57C9B" xlink:to="loc_us-gaap_OverAllotmentOptionMember_36AF5CD8640A31F20761850F47E6F069" xlink:type="arc" />
<link:loc xlink:href="immu-20191231.xsd#immu_ATMAgreementMember" xlink:label="loc_immu_ATMAgreementMember_F86213B8FBA8032424BE850F47E6D596" xlink:type="locator" />
<link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_88AA6A50083DA36A6D3D850F47E57C9B" xlink:to="loc_immu_ATMAgreementMember_F86213B8FBA8032424BE850F47E6D596" xlink:type="arc" />
<link:loc xlink:href="immu-20191231.xsd#immu_SalesAgreementMember" xlink:label="loc_immu_SalesAgreementMember_42C26528926A0DEFF5C5850F47E6DD22" xlink:type="locator" />
<link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_88AA6A50083DA36A6D3D850F47E57C9B" xlink:to="loc_immu_SalesAgreementMember_42C26528926A0DEFF5C5850F47E6DD22" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis_409ECE1F14A283FF61E2850F47E7FF68" xlink:type="locator" />
<link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_5A50C1824C482DD38108850F47E3B754" xlink:to="loc_us-gaap_TypeOfArrangementAxis_409ECE1F14A283FF61E2850F47E7FF68" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_838F02D6EE7005DB9632850F47E75B04" xlink:type="locator" />
<link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_409ECE1F14A283FF61E2850F47E7FF68" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_838F02D6EE7005DB9632850F47E75B04" xlink:type="arc" />
<link:loc xlink:href="immu-20191231.xsd#immu_SecuritiesPurchaseAgreementMember" xlink:label="loc_immu_SecuritiesPurchaseAgreementMember_AF223CF58A6E21D1AFDB850F47E743BC" xlink:type="locator" />
<link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_838F02D6EE7005DB9632850F47E75B04" xlink:to="loc_immu_SecuritiesPurchaseAgreementMember_AF223CF58A6E21D1AFDB850F47E743BC" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_CounterpartyNameAxis" xlink:label="loc_srt_CounterpartyNameAxis_C832E7872DE3F498858B850F47E7A497" xlink:type="locator" />
<link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_5A50C1824C482DD38108850F47E3B754" xlink:to="loc_srt_CounterpartyNameAxis_C832E7872DE3F498858B850F47E7A497" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_E82BF005FE97775E2BC8850F47E7A3DB" xlink:type="locator" />
<link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_C832E7872DE3F498858B850F47E7A497" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_E82BF005FE97775E2BC8850F47E7A3DB" xlink:type="arc" />
<link:loc xlink:href="immu-20191231.xsd#immu_SeattleGeneticsIncMember" xlink:label="loc_immu_SeattleGeneticsIncMember_092583072F73922BB441850F47E853B9" xlink:type="locator" />
<link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_E82BF005FE97775E2BC8850F47E7A3DB" xlink:to="loc_immu_SeattleGeneticsIncMember_092583072F73922BB441850F47E853B9" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_6D8CC3904CD88BFAAC9D850F47E87621" xlink:type="locator" />
<link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_5A50C1824C482DD38108850F47E3B754" xlink:to="loc_us-gaap_StatementClassOfStockAxis_6D8CC3904CD88BFAAC9D850F47E87621" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_3EF5DC41CDF892B40927850F47E855A0" xlink:type="locator" />
<link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_6D8CC3904CD88BFAAC9D850F47E87621" xlink:to="loc_us-gaap_ClassOfStockDomain_3EF5DC41CDF892B40927850F47E855A0" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConvertiblePreferredStockMember" xlink:label="loc_us-gaap_ConvertiblePreferredStockMember_3A02A184B09DF64DA62D850F47E908B1" xlink:type="locator" />
<link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_3EF5DC41CDF892B40927850F47E855A0" xlink:to="loc_us-gaap_ConvertiblePreferredStockMember_3A02A184B09DF64DA62D850F47E908B1" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfWarrantOrRightLineItems" xlink:label="loc_us-gaap_ClassOfWarrantOrRightLineItems_41B54B431001DB193B43850F47E921A5" xlink:type="locator" />
<link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_5A50C1824C482DD38108850F47E3B754" xlink:to="loc_us-gaap_ClassOfWarrantOrRightLineItems_41B54B431001DB193B43850F47E921A5" xlink:type="arc" />
<link:loc xlink:href="immu-20191231.xsd#immu_CommonAndPreferredSharesAuthorized" xlink:label="loc_immu_CommonAndPreferredSharesAuthorized_6AEE6862DE86A533B9E1850F47E9E292" xlink:type="locator" />
<link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_41B54B431001DB193B43850F47E921A5" xlink:to="loc_immu_CommonAndPreferredSharesAuthorized_6AEE6862DE86A533B9E1850F47E9E292" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_F1EC7734E7C61223B94F850F47E9FF23" xlink:type="locator" />
<link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_41B54B431001DB193B43850F47E921A5" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_F1EC7734E7C61223B94F850F47E9FF23" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_61733BD4016BB6C49831850F47EA843F" xlink:type="locator" />
<link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_41B54B431001DB193B43850F47E921A5" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_61733BD4016BB6C49831850F47EA843F" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_2BD9CCAC9820EB00AF42850F47EA0AA9" xlink:type="locator" />
<link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_41B54B431001DB193B43850F47E921A5" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_2BD9CCAC9820EB00AF42850F47EA0AA9" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="loc_us-gaap_PreferredStockSharesIssued_16E086653E6C9C058F10850F47EA2C6F" xlink:type="locator" />
<link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_41B54B431001DB193B43850F47E921A5" xlink:to="loc_us-gaap_PreferredStockSharesIssued_16E086653E6C9C058F10850F47EA2C6F" xlink:type="arc" />
<link:loc xlink:href="immu-20191231.xsd#immu_IssuanceofConvertiblePreferredStockPerShare" xlink:label="loc_immu_IssuanceofConvertiblePreferredStockPerShare_35BB2233F02AD1DD1A9A850F47EA6C11" xlink:type="locator" />
<link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_41B54B431001DB193B43850F47E921A5" xlink:to="loc_immu_IssuanceofConvertiblePreferredStockPerShare_35BB2233F02AD1DD1A9A850F47EA6C11" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock_78DEBE2E2AE2ADC57FBA850F47EAC9CF" xlink:type="locator" />
<link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_41B54B431001DB193B43850F47E921A5" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock_78DEBE2E2AE2ADC57FBA850F47EAC9CF" xlink:type="arc" />
<link:loc xlink:href="immu-20191231.xsd#immu_ConvertiblePreferredStockConversionRatio" xlink:label="loc_immu_ConvertiblePreferredStockConversionRatio_01A184EF89FCDA9C01FC850F47EAEAE6" xlink:type="locator" />
<link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_41B54B431001DB193B43850F47E921A5" xlink:to="loc_immu_ConvertiblePreferredStockConversionRatio_01A184EF89FCDA9C01FC850F47EAEAE6" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConversionOfStockSharesIssued1" xlink:label="loc_us-gaap_ConversionOfStockSharesIssued1_2CCF6829D25EC1EE1D8D850F47EB1F7A" xlink:type="locator" />
<link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_41B54B431001DB193B43850F47E921A5" xlink:to="loc_us-gaap_ConversionOfStockSharesIssued1_2CCF6829D25EC1EE1D8D850F47EB1F7A" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharePrice" xlink:label="loc_us-gaap_SharePrice_0C5CB3695874285C3B7C850F47EB932A" xlink:type="locator" />
<link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_41B54B431001DB193B43850F47E921A5" xlink:to="loc_us-gaap_SharePrice_0C5CB3695874285C3B7C850F47EB932A" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_21EA5940FFF38DC81306850F47EB2428" xlink:type="locator" />
<link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_41B54B431001DB193B43850F47E921A5" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_21EA5940FFF38DC81306850F47EB2428" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_2E41EC97CE61FF5D00BF850F47EB098A" xlink:type="locator" />
<link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_41B54B431001DB193B43850F47E921A5" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_2E41EC97CE61FF5D00BF850F47EB098A" xlink:type="arc" />
<link:loc xlink:href="immu-20191231.xsd#immu_GrossProceedsFromIssuanceOfCommonStock" xlink:label="loc_immu_GrossProceedsFromIssuanceOfCommonStock_90AED044F33BF1D4471D850F47EB1F30" xlink:type="locator" />
<link:presentationArc order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_41B54B431001DB193B43850F47E921A5" xlink:to="loc_immu_GrossProceedsFromIssuanceOfCommonStock_90AED044F33BF1D4471D850F47EB1F30" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentTerm" xlink:label="loc_us-gaap_DebtInstrumentTerm_A61474B9EB28143748BD850F47EC7EF6" xlink:type="locator" />
<link:presentationArc order="14" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_41B54B431001DB193B43850F47E921A5" xlink:to="loc_us-gaap_DebtInstrumentTerm_A61474B9EB28143748BD850F47EC7EF6" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_91DAEE9A6F7BF5DD4E41850F47ECD966" xlink:type="locator" />
<link:presentationArc order="15" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_41B54B431001DB193B43850F47E921A5" xlink:to="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_91DAEE9A6F7BF5DD4E41850F47ECD966" xlink:type="arc" />
<link:loc xlink:href="immu-20191231.xsd#immu_ClassOfWarrantOrRightFairValue" xlink:label="loc_immu_ClassOfWarrantOrRightFairValue_C54AF79D6DBE361D4E69850F47EC092E" xlink:type="locator" />
<link:presentationArc order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_41B54B431001DB193B43850F47E921A5" xlink:to="loc_immu_ClassOfWarrantOrRightFairValue_C54AF79D6DBE361D4E69850F47EC092E" xlink:type="arc" />
<link:loc xlink:href="immu-20191231.xsd#immu_ExerciseOfWarrants" xlink:label="loc_immu_ExerciseOfWarrants_CE9B4B113ACA7946DB04850F47ECBA61" xlink:type="locator" />
<link:presentationArc order="17" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_41B54B431001DB193B43850F47E921A5" xlink:to="loc_immu_ExerciseOfWarrants_CE9B4B113ACA7946DB04850F47ECBA61" xlink:type="arc" />
<link:loc xlink:href="immu-20191231.xsd#immu_AggregateOfferingPriceofCommonStock" xlink:label="loc_immu_AggregateOfferingPriceofCommonStock_DC155101CFD294A2A126850F47EC451F" xlink:type="locator" />
<link:presentationArc order="18" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_41B54B431001DB193B43850F47E921A5" xlink:to="loc_immu_AggregateOfferingPriceofCommonStock_DC155101CFD294A2A126850F47EC451F" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_4CD5E532202817ED8B59850F47EC6514" xlink:type="locator" />
<link:presentationArc order="19" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_41B54B431001DB193B43850F47E921A5" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_4CD5E532202817ED8B59850F47EC6514" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_EA6065A0DD062D619B48850F47EDE783" xlink:type="locator" />
<link:presentationArc order="20" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_41B54B431001DB193B43850F47E921A5" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_EA6065A0DD062D619B48850F47EDE783" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_30A04D579EC847712FAF850F47ED669E" xlink:type="locator" />
<link:presentationArc order="21" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_41B54B431001DB193B43850F47E921A5" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_30A04D579EC847712FAF850F47ED669E" xlink:type="arc" />
<link:loc xlink:href="immu-20191231.xsd#immu_IncreaseDecreaseinFairValueOfWarrantsExercised" xlink:label="loc_immu_IncreaseDecreaseinFairValueOfWarrantsExercised_B2503160710146E5BC59850F47ED07EC" xlink:type="locator" />
<link:presentationArc order="22" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_41B54B431001DB193B43850F47E921A5" xlink:to="loc_immu_IncreaseDecreaseinFairValueOfWarrantsExercised_B2503160710146E5BC59850F47ED07EC" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="loc_us-gaap_ClassOfWarrantOrRightOutstanding_60BB1972C4CF5556F1B1850F47EDDD06" xlink:type="locator" />
<link:presentationArc order="23" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_41B54B431001DB193B43850F47E921A5" xlink:to="loc_us-gaap_ClassOfWarrantOrRightOutstanding_60BB1972C4CF5556F1B1850F47EDDD06" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="loc_us-gaap_ProceedsFromWarrantExercises_5519F3305EA7F5D121A9850F47EDD92B" xlink:type="locator" />
<link:presentationArc order="24" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_41B54B431001DB193B43850F47E921A5" xlink:to="loc_us-gaap_ProceedsFromWarrantExercises_5519F3305EA7F5D121A9850F47EDD92B" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_3F447CF427C30BAD418F850F47ED51F6" xlink:type="locator" />
<link:presentationArc order="25" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_41B54B431001DB193B43850F47E921A5" xlink:to="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_3F447CF427C30BAD418F850F47ED51F6" xlink:type="arc" />
<link:loc xlink:href="immu-20191231.xsd#immu_PaymentsforStockIssuanceCostsPercentage" xlink:label="loc_immu_PaymentsforStockIssuanceCostsPercentage_BF07775D46C76641E8D3850F47EE3625" xlink:type="locator" />
<link:presentationArc order="26" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_41B54B431001DB193B43850F47E921A5" xlink:to="loc_immu_PaymentsforStockIssuanceCostsPercentage_BF07775D46C76641E8D3850F47EE3625" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_81D8410D64B54D860620850F47EEC435" xlink:type="locator" />
<link:presentationArc order="27" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_41B54B431001DB193B43850F47E921A5" xlink:to="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_81D8410D64B54D860620850F47EEC435" xlink:type="arc" />
<link:loc xlink:href="immu-20191231.xsd#immu_ProceedsfromIssuanceInitialPublicOfferingGross" xlink:label="loc_immu_ProceedsfromIssuanceInitialPublicOfferingGross_41A0652CC90FECF9C94C850F47EE0055" xlink:type="locator" />
<link:presentationArc order="28" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_41B54B431001DB193B43850F47E921A5" xlink:to="loc_immu_ProceedsfromIssuanceInitialPublicOfferingGross_41A0652CC90FECF9C94C850F47EE0055" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:label="loc_us-gaap_ProceedsFromIssuanceInitialPublicOffering_A037A04E8DABACBC5DCB850F47EE8D4D" xlink:type="locator" />
<link:presentationArc order="29" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_41B54B431001DB193B43850F47E921A5" xlink:to="loc_us-gaap_ProceedsFromIssuanceInitialPublicOffering_A037A04E8DABACBC5DCB850F47EE8D4D" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="loc_us-gaap_PaymentsOfStockIssuanceCosts_F9F32C6E033BDC7C221A850F47EE93BB" xlink:type="locator" />
<link:presentationArc order="30" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_41B54B431001DB193B43850F47E921A5" xlink:to="loc_us-gaap_PaymentsOfStockIssuanceCosts_F9F32C6E033BDC7C221A850F47EE93BB" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="loc_us-gaap_SaleOfStockPricePerShare_85E2B55364A04D8CC420850F47EEB8CD" xlink:type="locator" />
<link:presentationArc order="31" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_41B54B431001DB193B43850F47E921A5" xlink:to="loc_us-gaap_SaleOfStockPricePerShare_85E2B55364A04D8CC420850F47EEB8CD" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SaleOfStockConsiderationReceivedPerTransaction" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedPerTransaction_E0D0B4C26ECEE2C9F288850F47EFBC29" xlink:type="locator" />
<link:presentationArc order="32" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_41B54B431001DB193B43850F47E921A5" xlink:to="loc_us-gaap_SaleOfStockConsiderationReceivedPerTransaction_E0D0B4C26ECEE2C9F288850F47EFBC29" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="loc_us-gaap_SharesIssuedPricePerShare_C6D23EC728ECAF6F6D62850F47EFA06C" xlink:type="locator" />
<link:presentationArc order="33" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_41B54B431001DB193B43850F47E921A5" xlink:to="loc_us-gaap_SharesIssuedPricePerShare_C6D23EC728ECAF6F6D62850F47EFA06C" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TreasuryStockSharesAcquired" xlink:label="loc_us-gaap_TreasuryStockSharesAcquired_F7363FF27DF4F82D1479850F47EF3FE0" xlink:type="locator" />
<link:presentationArc order="34" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_41B54B431001DB193B43850F47E921A5" xlink:to="loc_us-gaap_TreasuryStockSharesAcquired_F7363FF27DF4F82D1479850F47EF3FE0" xlink:type="arc" />
<link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockRepurchasedAndRetiredDuringPeriodShares" xlink:label="loc_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares_9030732EFE2942362108850F47EFB2DF" xlink:type="locator" />
<link:presentationArc order="35" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_41B54B431001DB193B43850F47E921A5" xlink:to="loc_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares_9030732EFE2942362108850F47EFB2DF" xlink:type="arc" />
</link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>15
<FILENAME>a10kchecmicallinkerimage.jpg
<TEXT>
begin 644 a10kchecmicallinkerimage.jpg
M_]C_X 02D9)1@ ! 0$ 8 !@ #_X0""17AI9@ 34T *@ @ @$2 ,
M ! $ (=I 0 ! )@ 9*& < ! . !53DE#
M3T1% !, $4 00!$ " 5 !E &, : !N &\ ; !O &< :0!E ', ( !) &X
M8P N " 5@ Q "X , Q #__@ ?3$5!1"!496-H;F]L;V=I97,@26YC+B!6
M,2XP,0#_VP!# (! 0(! 0(" @(" @(" P4# P,# P8$! ,%!P8'!P<&!P<(
M"0L)" @*" <'"@T*"@L,# P,!PD.#PT,#@L,# S_VP!# 0(" @,# P8# P8,
M" <(# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,
M# P,# P,# S_P 1" 'A M,# 2( A$! Q$!_\0 'P 04! 0$! 0$
M $" P0%!@<("0H+_\0 M1 @$# P($ P4%! 0 %] 0(# 01!1(A
M,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*%A<8&1HE)B<H*2HT-38W
M.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U=G=X>7J#A(6&AXB)BI*3
ME)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&Q\C)RM+3U-76U]C9VN'B
MX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$ P$! 0$! 0$! 0 $" P0%
M!@<("0H+_\0 M1$ @$"! 0#! <%! 0 0)W $" Q$$!2$Q!A)!40=A<1,B
M,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF)R@I*C4V-S@Y.D-$149'
M2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$A8:'B(F*DI.4E9:7F)F:
MHJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4U=;7V-G:XN/DY>;GZ.GJ
M\O/T]?;W^/GZ_]H # ,! (1 Q$ /P#]_**** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHJCJFL6?A_3KB^OKR"QLK.-I)[BXD6.&)%Y
M9V8X"@=R>* +U><_M#?M1^"/V7O#$&I>,M8^PR:C)]GTS3+>)[S5-;N#]VWL
M[2(--<2G^Y&IQU. "1Y'?_M@>,_VJ=0DTC]GC1[.XT'S'M[SXF:_;R?\(];;
M?E;^SH%*2ZI*&W ,A2V!7_7/RM=W^SW^Q3X7^!GB:X\6WUWK'COXE:E'Y>H>
M,?$DBW6J2JW6&':HCM+?T@MU1 .H)Y(!!^S_ .,_C'\7O&W_ DWBK0=-^&O
M@'[.\>G>%[P+>^([UV(VW-[-&_D6H"]+>/S6^;+R C;7MU%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 5\O\ [<OP_P!'^,?[1O[/
MO@[Q3:'5_!^KZYJ]SJ&CW$C?V?JLMMIDTT"W,((2=$==X20%<KD@XKZ@KY[_
M &GO^3SOV:?^PYKO_ICN: />M.TZ'2K*&UM88;>WMXUCBBC39'&B\!5 X"@=
M!5JBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH *IZ?J=OJEOY]K/#<Q_<\R-U=..OS"KE?D;_P
M1!_X*M_L]_LP_L$V/@[XA_%KPWX7\6:;XH\127FGZA))Y\2R:Q=R1EL(>J,I
M'/2@#]9K?5+>YOIK:.:"2XMMIGC21=\6[E=R]5SVS6?XB^(.@^#KFM=T?
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %?
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MS=[B.L<<- &'H7Q[\??M2Z19Z!^S_IO_ AWP[L8$L_^%E^)=.;R[F)%V?\
M$GT^3:]W@*,7-P$M^Z"<5HZ]^S7X#_8W^$.O>(+CX?\ BKXV:EX@*6_C/5+R
M*/Q!XDU>U;B222.7'FPQ_+_H=LH4+_JX21@_3\<8B7:M.H ^+/@MHNK_ Z\
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MM#X%\ 2_NY/B/XDTUO.U%.[:/ILN&E7;TN;H)%GE(YUJKX__ &9?A/\ L?\
MP:UB[USX9>)?B]9>+9%MO'&OWEDOB;7;VW96W7=ZK_OI;>,]8K5"(@V8X0H.
M/K"B@#XW^%D'C#X'>![/Q=\!?$D/Q\^!]['YL?A.XU9;K5])B_B72=1E?]\J
M=/L=ZP9=NQ9DP$KW/]E;X]_#CXV?#_R/A[-:Z?;^'?\ 0[WP_)9-IE_X<EZ_
M9[FR<+);N/1E /520<GCOB?^PW_9GCB\\??!G7?^%5^/[Z3[1JD45MY_A_Q6
M_P#=U*P4A'<]/M,12X4?QLORGR/Q9JOACXY_]'^*&FZQ^SC^TG;Q_9_#G
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M\*_!WBF'Q%KFFZE\2_&$0X\0>.]1E\0:A'_UR%P3#;]?NV\<:CL*]\BBCM(
MJC9&GZ4 <O\ !GXNZ'\>?A3H/C'PS>?;M#\1V:7MI(5V/M;JKJ>4=&W*Z$ J
MRE2 01765\KRR#]@;]J;?_Q[?!SXV:O^\/\ RQ\)^*9F^]Z1VVI'CT6[7UN>
M/JB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH ^>?V\CYOB?X P_\]OBOIO/^[8:C)_[)BI/V8KV
M>Y_;$_:5C>::2WMM?T.*)#(Q2+_B0V3,JKT7[V3C^]FHOV[CN\;_ +.RC_HK
M%D/_ "E:J?Y5-^RM_P G:_M-_P#8TZ/_ .H_IU 'T#1110 5A^._A_HGQ0\'
MZAX?\1:/INO:'JD307FGZA;+/:W2-U5T<$,M;E% 'S7^T;H&G^"OVCOV4M#T
MNSAL]-T_Q1J5O9V\?"6T4?AS4E55]@-H%?2E?/?[5,4<W[7_ .S*7_Y9^)-:
M?_RW[^OH2@ HHHH *Y;XL?![PO\ '7P->>&?&6@:;XDT#4!^_LM0MUFA/HV&
M^ZXZAUPRGD$&NIHH ^<?C98IIG[>O[-]K K1V]OI?BE$4EGPHM+(*-QY_/FO
MHZOGCX]2[O\ @H=^SW%_=TKQ7+_Y L%_]FKZ'H **** .4^,GPAT#X]_"K7O
M!?BFS^W>'_$EF]G>09V/L;&&1ARCJVUE<<JRJP((%>5?L.?M;_#OXW6'B3X;
M^&?B%>>/_&'P/O%\)^+;C4[-K74)+V#="T\BLB*_F/%)^\C!1F5\&OH"OPO_
M &?_ 1K7[*WQ(_:$_; \ V>I7VI?#CX^>+]'^(^AV>Y_P#A(O"+W<;2LL?\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 ?._[=7_)4?V:?^RL1?\ I@URI/V3
M#YG[5/[3DG_+3_A,-*C_ . KX<TO;_Z%6Q^V=\!_%GQI\/>"=2\"ZGH.G>+O
MAQXHA\5Z7!K=O))IVI.EI=VC6L[1'S(EDBNY,2H&*,JG8XRIS_@+^V?X?\8?
M$'_A"/&'AN[^$_Q:O0;B?PYK'E_\3G8JJT]A>IB'4(PJK\T9\Q54;XX\8 ![
MY1110 4GW!7DG[0_[9?@[]G"_LM%OFU#Q)XVUF,R:1X1\/V_V[6]5_VHX 1L
MBW=9I2D2_P 3BO!?CEHVK>-O <GBW]JKQIIOPO\ A?(ZQV_PXT#56_XFK-_J
M[;4;V+$U]*_3['9A8V/RDW Z@'J'[4%WYO[8_P"S'&G^KDU_7)=_^[H-[_\
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M') /3OCI_P I'/V?/^P!XM_] TVOHJOB75M%^/7[27QG\%_%;P+X)\'_ ]\
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M]LW&L3K_ P6Q%NA^7S80-M>Z? _]A;0_ 'CB'QYXVUK4OBI\5 C)'XE\01I
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M#6C_ ^\<1>/O'&L:E\4?BL(VC_X2?7(UV:4C?>@TVT7]S80^T0WM_RTD<UX
MQ_P;^:K::[_P3XEOK&:&]L;[QYXLGM[B"3S(YXI-<NV5U;^)2&R#Z5]OT %%
M%% '&_%CX!^"?CQHW]G>-O!_A;Q=8_\ /OK.E0WT?U D0X/N.E?+?AC]D/X?
M_L=?\%'OA7-X9TB\L=!\6>&]<TC2-.N-1N[W3]!U2+R+EI+&&>1X[1Y[1;E&
M$ 4%+?& <_:U?.__!2,_P#"(_!GPW\1D;RY/A-XOTKQ/(_I9>=]BO\ \/L-
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M9A^&,'AGPY%=21^:]Y?ZA>2^?J&M7LK;I[VZE;F6>5_F9C] H '?U5L+Z'5
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110!Y_P#M'?&2_P#@+\,;CQ3:^%M8\76>
MDW$4FJVFE?/>VUCN_?W,,6,W#1+\YB3YF56"Y;"GH_A_X_T/XJ^"-(\2^&M2
ML]<T'7+=;S3[^SD\R"ZA<;E=6'8__KYK=KY-\?\ @[5/^"=7C?5/B#X+TV\U
M+X,:_</J'C?PI81---X5G;+2ZYIT2\M$>MU:1CGF>,;Q(L@!]945D^$_%>F>
M//"^G:WH>HV>K:3JUNEY9WMI*LT%U#(NY)$9>&4JP((ZBM:@ K'\;^#K#X@^
M"=7\/ZK'YVFZY93:?>1?\]8IHVCD7\58UL44 >"_\$V/&.H>(_V,O!VFZS-Y
MGB#P0EQX,U@G[YO-*N)-/D8_]=/L_F#VD!KRG]JOP!\6K:W^,GQ/\3?'#5_@
M_P"#O MI+>>#+/1/L4FGBWM[3S'N]3\^!WF:6XW#R590(U55RSDUZ!^RZ#\,
M/VS?C[X#D/E6^K7FF_$/2X_6+4+=K2YV_2[TZ9C[S#UKYJ_:>^*/C;XT?MO:
MO8_$GX$_'+Q3\$_AI?Q'POH?AS08[K3_ !?J,?S-J=_(TZ>;!$_$%L1L)7S7
M!.T Z_P3\8_BU^W=X^^&/@2[\2>)/@PO_"I],^(?C.?PW% FIW&I:A*T%O9
M1O<1RB&%/(N97'EEB6B4L &S[E_P3F^,_BGXM?!+7=.\;7D.K^+/AQXLU?P7
MJNJ1VZVHUE[*XVQ7?E)\D;2P-"[(O 9FQQQ7F?C3QYXH^#O[8&@_';_A6/Q(
MU?P7\1_A_:^'-7TO3-)6\UWPQJ%M>S7-M]IM$<OLD6[FC8QEA&\:[L*=P]"_
MX)G_ I\5_#OX(^)-:\;:/-X<\2?$SQIK7C2XT:619)M&BO;DM;VTK(2GFI;
MQP[]I(WE@#0!]'5\$^+_ [9_M$?\'!>D:/XJABU+1/@I\)T\3^&],N_GACU
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M67XM\36?@GPQJ6L:C-]FTW2;26\N9?\ GG%&A=V_!5)K\^_V?O"?[0__ 5;
M^',/QDF^.WB3X#_#WQ5(]YX$\+^#])M/MO\ 9OF,MO=ZC=722-++.BK(8HPJ
M ,,'DT ?HQ17QS^PC^TM\3O"O[5'C3]FOXX:EI?BCQKX1T.W\6>&_&.GV/\
M9Z>+]%FF:!I)[924BNH)ML;B,[6W!@.Y^QJ /DCQ%H]Y_P $QO%EYXET6"[O
M/V>==NVN?$&CV\9D?X=74K[I-3M(U&?[-D=F:X@4'[.<S1C89%'MGQD_:5T?
MX.>#O!_B)X9=<T'Q;K^E:'!J&GRQR06ZZA*L-O=,V<-"9)(AE,Y\Q2.*]#N+
M=+R$QR 21R#8Z/RKK7EOC;]C?P/XC_9AO/A+IMG-X3\(R;9+./1Y/)DTJ5;M
M;N.2WWAU3R[A5=5P57 4 * 7)/CV]E^UY#\+[K3HK>.^\)OXHT^_\ M/SW
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MBC\06GO;R3_EZ:.'SV;=Z"6]F^E?L70!\U1?\%+_ WX!_=_%CP3\1O@S)'Q
M)>>(-%:ZT7=NV_\ (2LO/M47WEDC^E>V_#OXR>$/B]X:&L>$_%7AOQ+I$B>8
M+S2M1AO;;;_>\R-BOZUU%?!_[;_[!'PCUG]LWX,Z]JW@G3=-TWQ_<:KX0\07
M&C22:-)J4\MM]OM/M,EJ\32[FLKB(B0L&%P5.0<4 =A]J/\ P5;UZ:.UF_XQ
MDT6]>*>2.3;_ ,+2O()=KQAE_P"81%(C!O\ G[=2O^I4^9];V5G'IEK%!!%#
M;V]O&$1$78J*O '0 "OG#_@G1IUG\)?^%L?"6RLX=-L?AIXWO?[(LH(_+AM
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MWO/+CV))=%?,N9 O;?.TK_\ J]4H ^/_P!L#_@EQI?Q!_8BU?X??#&[O-$\
M8:;KEIXX\-ZOKFI7>K2#7[*:.:":>:XDDD8/Y?EMSPKD@5R^F?\ !7'Q]I/@
M:'1_$7[)O[0T?Q>CM_L\FB:7X=^U>'[B]^[NAUA7^S"U9N1*Y!5>HSU^Z**
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MTY9NDLD<>XR2+\K,QQZD ^MZ*** "BBB@ HHHH **** "BBB@ HHHH ****
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M8ZE_:_BCQ1X6LM0U2\\J.'[3<21[F;9&JHN?0 #VH ^@:*** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HKQO_ (*#>.-7^&7[!/QL\2:#J$^DZWX?
M\":UJ.FWMO\ +-97$-A-)'*O^TKJK#W%1_\ !//QKJWQ+_80^#7B/Q!J%UJV
MMZYX,TJ_U"\N7WS75Q):1M)(S?WF9F)H ]HHKS_X9_M)^#?BQ\5_'G@?0]4^
MT>*?AI<VMKXAT^2VD@>R:YA\^!AO4"1)(\D/&67*L,Y!%>=^-_\ @IM\&_A]
MX'USQ!=>)+VYL]#\63^!#;Z?HUW=WFHZY#_K+*T@CC,ETX^;+1!D&UR6 4D
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M^<?V\S_PL?Q9\&_A3&/,C\=>-+?4]5CQ\ITK1U_M*?=_LO<0V4)]?M&*Y_\
M;'_;H\;^$OVAM!^!/P-\'Z1XU^+VMZ0WB'4+C6[U[70O"&E"7R5N[UXP9':2
M7*1Q1C<Q4G('->4Z]^UM\:OV(OC/X#UK]J+P5\*]<\&^(]0'A?3_ (A^ X[N
M%_"$]ZT:QPWMM=;G6WGECB0S1R8#*FY1\N0#]!*_$O\ X*T?\%WOBA_P2%_X
M+%WFARVJ^-OA#XC\.:5JESX<N)/+FLF;SH99K*?'[ISY>2C91CV!.ZOVTK\]
M_P#@JA_P;\?#W_@J-\7M6^(/B;7]:T_Q+!X+?PYH%O;[4M+*]62:2*]F/WI5
M4R &/@8R<DXP ?4W[#G[;?@?_@H-^SAH_P 3/A[+JC>']7WQ^7J%C)9W-O*G
M#QLK##8/&^,LA_A8U[%7PU_P0?\ VRK_ /:%_9/F^'7C2R@T#XO? .[/@?QA
MHZ1K#Y;V^8X+I$4 >7*D?4#!>.3'&,_<M !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 445YG^U=^T+;_LP_!+4O$WV.;5M6DDBT
MS0M(B/[_ %O5+EUBM+2/WDE903_"N]SPI- 'Q+XV\9>./V'?^"JOQ>\3?"GX
M>^)/C5X&\>:5I&J?$O0_#YA_M3PGJZQO!:3VRRR(MPUQ:QJTENI#*JQR$@,N
M=KQ_I7Q8_P""M_Q@^'.CZM\)O&'P9^ WP]\2V7C#7)/&I@M=>\5WMDWF6EE#
M:0R2[+=9MLDDDC?-Y8"^E?6?['G[/]Q^SW\(8[76KR'5_&WB2[EU_P 6:L@Q
M_:NJW.&G=?2)/EBB7^&&&)>U>LT ?-OC_P#8UUOX3>+]2\>?L_ZEIW@[Q%J4
MCWFL>$]0#?\ "*^*YF.YI)8DR;*[;_G[MQDG_61S#IY1^UO^VAH?QM_9IUCP
M+KFG:C\//BC'X@\,6VH>#];V_;=DOB'3X3<6DB_N[VU.[B> LN.'"-E1]TU\
ME_\ !7;X*>&_C7\#_ ECK-F8M1D^)/A.STO6+3]SJFB//K5I')-:7&-\,OE[
MAD?CGI0!]:45\H_\+R^+_P"Q8?[#^(/A;Q)\;/#4G^C^'_%G@_38Y-:EE^[#
M::I8@HB2OT%Y#BW)YD6W')M']G'XD?MDG[5\;]1_X0[P++^\B^&GAO46Q>I_
M"NL:C'M>X_VK:V*0=G:=>H!J>,OVW]0^)WBF\\'_ #T.S^)'B"QD:WU3Q)<
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MQ"UQ)(?"MBW\7V7;B;4Y!SQ;X@SPTX/%>(_\% ?V1_%_Q0_9FN_$GQR\8?\
M"2WLGB#P];Z?X,T#S++PKI+3ZY80MYD>X2ZA+LD9/,N3L&XE(4)S7Z Z?IUO
MI-E#:VL,-M;VZ+'%%%'LCC5>%55' ["@#YFN/\ @F;;:^/^$FUSXJ?$Z^^,
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M_!GPE\./#GB>W\>:-XDL_&0_XINT\/R?VMJ'B9]N[R[*VM]\L[^H5?EP=Y4
MD 'N5>)_';]N/PG\&/%P\'Z7:ZQ\0/B1<()+?P?X8B6\U/:WW9+EB5ALX/66
MY>-<="QX/$CPU\<OVQ/GUR[O/V??AW<=-+TNYCG\::K$W_/>[3=!IN>Z6YFF
M'_/:-NGLWP)_9O\ _[,G@_^P_ OAO3_ _8R2?:+GR@TES?2_Q33SN3+/*>
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MT/QAX<O)$EET[5+-;J#>C;DD"L/E=3R&&"#T- 'R%^PG\<OB9H7_ 4.\8?!
MWXO?\*G\=>,K;P);^)+?X@>#]-_L^\N+);WR%L-1AW/Y<F^226,!@I&\A:^G
M/B?%\:/^$PF_X0N;X8Q^']B>7_;<5_)>!]OS;O*<)MW=,=NM3?LZ?L?_ O_
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M\+V>I?%OQ=?VFN>$[FWCN983KETR^7)-#,GE2*RG[F2,8(K[8\+_ 0\/^&_
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M'.*][D_8Y\.R_MRP_'K[=JW_ E5OX+?P.+3S%^Q?9&O%N_,VXSYN]<9SC':
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M %?G%X2\*:7:_L=_!/7(]-TZ/6KGXYQ6<E_]F7[3)$OC#466-I,;R@9F(7.
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M[)O_ 36^$O@;Q-!]C\2:;I#7FJ6P_Y<[J[GENYH._S1O.R''&5..*^F***
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M:ZG):R;6*[E9$)9#U! YK_AY)X8_Z)Q\?_P#PUNM?_&*S]%^$/[55AINR
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M)M_!/[04?E2C.R.S\4V5O\C?W1]ML(=A]7TY/XI.0#Z4HHHH **** "BBB@
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M\C2>605)^\".GHO_ 5+_8/\!_&?]BKQA=:7H.C>%_&W@'2+CQ%X.\2:79QV
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M HHHH **** "BBB@ HHHH *\O_:\^ G_ TG\ -=\+P77]FZY^ZU#0-1Q\VE
M:I;2+/97*[>?W<\<;''5=RG@D5ZA7D7[9G[0MY^SW\(?.\/V<.L>.O%%Y%X?
M\(:0Y_Y".JW&1#N](8E5YY6_AA@E;M0!H_LD?'U/VE/@1H_B>XLVTG6LRZ?K
M^EO_ *S1M5MI&@O;1O\ KG/'(H/\2[6'!%>F5YE^R9^SM9?LN_!'3/"MO>2Z
MOJ7F2ZCKFKRQ[)]>U2YD::]O9?\ ;EG9WQ_""JC@"O3: "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#YJ_X*/_L:>(/VHO!_@_Q%
M\/=8T_PW\7OA+KJ^)_!FH:C&SV3W'EM%/97(3YOL]S SQOMY&Y6P<8/COQ _
M:(_;6^/'@B[^'^@_LXZ'\)_$FM6[:?=^.]5\<VFHZ1H*NNR6[MH($\^>0;BT
M2,%YV[N :^]Z* /*OV+_ -EC0_V)?V5?!'PK\.R33Z5X)TQ+,7$GRR7DOS/-
M.W^U)*TDA]VKU6BB@ HHHH **** "BBB@ HHHH ^,_\ @H=^S]\1/!_[1_PW
M_:8^#^@0^-O&/PWL+OPYXC\(?:%MIO$^@7;QR2K;3-A5NH)8Q+&C_*^Y@><
M^;_M0?M:_&3_ (*&?!G6/@W\(?@#\8/AYJ7C^W?0]<\8?$/3(-%TSPQILRF.
MYGC59I7NIS$71(XQC+9+<8/Z*44 <;\!_@UH_P"SM\#_ ?X!T#,>B^"='M-
M%LM_WS%;PK$I;_:*KD^]=E110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% "*N%I: ,"B@ K\0_^#L3Q!9^%_VT?V'-1U*^
MMM.TO3_%EQ=W=S=3+#;VT27VDL\DCL0JJJ@DL2 "3Q7[>5^&_\ P=P^"M,^
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M"69SA0 #DG<>6"FW9QJT+2>JUE=WLDG:RVMU0H2YJC@MI4ZVFWPQLK7U5
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M-_\ !PEI?[('[47_ H_X4_!OQQ^T9\7+&V6[UC0O#32QKI2,BR!&:*WN99)
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M:/;P:CK$: *B7-PJ"29555 #L0 !TIOP7_9X^'_ .S?X>NM)^'?@7P?X"TF
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M3(>K^5 BKN/KC-=911'2]NN_GZ@];7Z;'DQ_8(^!9\0:]JW_ I;X3?VKXJA
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M;97MJ?>G["?_ 6"^#W_ 5J_9[^(.K?"^X\06-_X7L98]6T77K..UU*Q66*
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M]IU7S(U5B3&P<[5#$?/?[%__ =+_LN_ML?M :7\-]+?Q]X+U[Q!=)8:--XI
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M=JW)XPPK[QKX@^+/PV\0:S\+OV]/#^FZ#J\EQKDCZAH:1V<G_$VED\*:<O\
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M=LMI-N!'E221QANGU%;/Q!_X*&7/[0/_ 1<^)WQD\$S7G@_QIH/A#5TO[,[
M5O?">NV<#K/;2*V=LL4J\!QRK(V,&LW_ (+JGR]&_97_ .SA/"W_ *#=U\Y_
M\%R?"=__ ,$ZO"_QL^(WA_3KR;X0_M)>$[WPYXXT^T'R:!XG:VDCL-855_AN
M?EMYO]KRW))(% 'Z9?LA>+-0\=?LH?##7-7NI+W5M:\)Z5?WES)]^XGELHI)
M)&]RS,37I%?,_P %K#XI7'[!'P-F^%NH^!;+5+7PAHTEY9^*;&YFM=1A_LZ
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 <E\2?@OX3^,XT-?%7A_3?$'_ C&JPZ[I?VRW63^S[^'
M=Y5S'G[LJ;VP>VXU8^*GPJ\-_&[P!J?A/Q=H6F>)/#6N1>1?Z9J%NL]K=)NW
M;71N&^90?8@&NEHH S?#7AS3_!WAS3](TNTAT_3-*MXK.SMX$V1VT4:JD<:K
M_"H4* /05I444 ?-O[?N@Z?JGCC]G?S[.TDO?^%J6'V>XDB5Y+?R[#49VVL>
M5SY/..M?25?//[9<?V_]H;]F.Q_ZJ)=7O_?KPUK7_P 57T-0 4444 %?&?\
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M$]30!Z/1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7S1XR_8EU;X.>+]0\:
M?L]ZQ9^!=:OI&N]7\(7D;/X2\3RM]YI($YLKIO\ GYML9/,D<U?2]% 'S/\
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M(XJ^E;.SCTZVCAACACBCC")&@V*BKP% [ 4 ?+G_ P'XZ\'WW_";^'?CCXV
MO_C$8\7FH>()//\ #>MQ+\PLI-'B*P6MN&9MCVVRX0R%FEFY#=?\$_VVX]:\
M>VOP[^)^@R?"_P"*DP)M]+O+GSM,\1JOWIM*O<!+I>YB(2X3^.(##'WRN/\
MC-\#/"/[0G@&Z\,^-=!T[Q!HEUM<V]RG^K=?NR1NN'BE0\K)&5=3RI!H ["B
MOEB.Y^+'[!R[;K^W_CA\(;;_ )>$'VGQIX4B_P"FBC']K6Z#JXQ=@=1<')KW
MSX0?&CPI\?? UGXF\%Z[IOB30;__ %5Y92;TW?Q(PZHZ]&1P&4\, : .KJKJ
MFEV^JZ?<6MQ&)+>ZC:*6,_\ +164JR_E5JB@#\X_V<]=^-7_ 1\\'S_ ?N
M_@SXV^.'PAT2\N'\ >)/!'V>ZU2RL)I'G6PU&TEDC=7A:1D69"5=0HX(Q7HG
M[&_P*^*'QW_;=UC]I;XT>%8?AS<6_AP^$/ '@B348[V]T73Y)OM%W>WLD68_
MM5PZQCRT8A$CP3FOMBO*/VK/V=+C]H'P/9_V'KUYX.\=>%[S^U_"_B"WR_\
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M>67=;R.RQA&F@; 7>:^N* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M*K-N\J3 WK[X%?0E?&7_ ;WR'_AS1\ MW_0O-_Z4S5]FT %%%% !7SU\*KG
M[?\ \%-?C4W_ $#_ 'X/M_^^KO7Y*^A:^=OV?F^U_\ !0_]HJ?_ )]]+\)V
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M7;&W.3SVKE/^":/_ 6@^#'_ 5=UGQ5IWPM_P"$JBOO!L%O<:A%K>GQV;^5
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M=F(S^\^SR*TEZW^[Y"M&3ZSJ.]?@##\!/'G_ 1\UC]D?]I/]],WC:W_ .$O
MM[?&SR_)NV5K0M_TULI(6.?^>[#M0!_9-7QUX2_X+=_!GQG_ ,%%[K]EVQM_
M&?\ PLRQO[C3Y9)-+C73/-@@:>3$WF[MNQ3@[.O&*^IOAE\0=+^+7PXT'Q1H
M<ZW6B^)-/M]4L)Q_RU@FC62-O^^6%?S0^)OVIO!G[%W_ =<?$SXG>/]2DTG
MPGX3\0:O<7DL43332%M+9(XHT7EG=V55' RW) R0 ?T^T5^+OA+_ (/-/AG_
M ,+?L]*\8?!GX@^"_!VI2)Y>N7%Q'/=11-_RV:T"#<G<^7(Q Z!CQ7[#?#WX
M@:+\5/ VD^)O#NHVNK:!X@LXM1T^]MY-\-U;RJ'CD4^C*V: -RBBB@ HHHH
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M,_\ J_/OQY^WK\4/V3/^"WWQR\5:QKVL:Q^S?X2D\*^&_&&EW%[--!X0_M6
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MS(XW8..N*]HHH _%W_@]E_Y,0^$W_8^?^XZ[KXD_X*<VUQ^Q[K'_ 3A_:/T
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M3#@_=.6A0>XV_P#@WZ_X)<:K^WS^WY\9?B[^TS\+=2O=(V7&H_V?XLTF:
M=5U&Y>3S%CG4>:(D67V4R)[5^Q>H_P#!"S]D&]T^:#_AGOX9Q^9&T>^/2421
M-W]UNQ]#VH ^8_\ @TG_ &UF_:5_X)IKX%U&X\S7O@[J+Z)AWR\NGR_OK23Z
M#=+%_P!L17YR:1\#?#?[0G_!X/KWAWQ9IMGK&A_\)Q>ZC+87$?F0W+VU@T\*
MNIX9?,C0E3P0N#P377_\$)?A)\5O^"3W_!</Q=\,M8\%^-IOASXHO+WP?+KB
M:+<OI\GER-+IUYYP39M<JJ%LX7[0V3@&N%_:7_9-_:6OO^#BKXM?$;X*>"=>
M_P"$D\'^(;KQ7HEW>:;-#I^M);0QF2TCF91'(9XO,C";AOW%002* /TN_P"#
MLG]G3PGXX_X)):]XINM)TU/$'@'5-/O-'O$MU2:V$MS';S1JW78Z2\KTRJ'&
M0*ZK_@U1\>ZIXX_X(Q?#^/4KR6Z_L35-5TNT,AWM';QW<C)'G^ZOF8'H !7Y
M=_\ !2W_ (*@?M5?\%J_"&A_LXZ#^SCXE\$WTNJ17'B"SCMKF22]N(?NK))+
M$B6]NCMO)<]50EL#G]T?^"4'[$!_X)V?L!?#OX4SSV]UJV@6;SZO<0?ZF2_N
M)&GN-O3<@DD**3R0JF@#Z1HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "HY8
MDGAVM\Z/Q]:DHH ^8O$/['7B7]F_Q#?>+/V=;S3=#%].][J_P\U25H_"NO2-
M\TDEML!.F73?\](%,+MS)"QR]=W^SC^V-X;^/^KWGAVXL]2\%_$;18E?6/!F
MOQK#JVG _P#+5-I*7%N3]VX@9XFX^8-\H]BKS']HS]E#P?\ M.:+9+X@M;RQ
MUK1)?M.B>(=(N&LM:T"?_GI:7*?/'G^).4<?*ZLO% 'H&L:S9^'-)N[V^NK6
MQL;&-I[BXN)5BAMT4;F=F; 50.23P*^:[S]MKQ1^TM?S:/\ LY^'+3Q)8K)Y
M=Q\0]?CEMO"5E_>^R;<3:I*/FP+?;#G&Z<=*7PY_P3PU#XCZA#=?'[XD:E\;
M+?29\Z7H5QIT6D>'HU1OW,UW80L4O;K;M+/.3$&YCACKZ7T_3H-)M(;>U@AM
M[>W01QQQQ[%C4=%4#H* /#_@U^PCH?A#QS!XZ\?:QJ7Q9^)EON-OX@\01KY.
MB[OO1Z;9+^XL4]XU\QA]^1Z[;]H;]F+P?^U)X0ATKQ9I\DDFG3_;-*U2SN'L
M]4T&Z7[MS97,>)+>8?WT(R/E8,I(/HE% 'RC'^T3X\_81N8=+^-]Q-XP^&^]
M8M/^*&GV.V335Z+'KMM$,0>GVV$>0>LBP=3]/:1K5GXCTBSU'3;RTOM-OHUG
MM[BWE6:&YB9<JZ,N0RE>00<$5/=6L=[;20S1K)#(-CHXW*ZGL:^8M<_97\7_
M +'^KWGB;]GK[)<^&Y9'N]5^%>H7/D:3>;MS/)H\QR--N&;GRL?99&ZK$29*
M /J:O+?$_P"U[X%\,?&[3?AO!J4VN>.-2D3S-'T:VDU"?2HF_P"7B]\H%;2'
M_;F*Y_A#&O*K;P_\<_VT8(9]?GU+]GGX=W0S_8VGW,4WC?54/\-S=QEX--4C
M^"V,LO\ TVC/ ]O^!O[//@K]F?P=_P (_P"!?#>G>'--:3SY_L\>Z:]E;[TT
M\K$R3RG^*25F<]R: /B?]EWX8Z'\:?\ @JY_P4"\'^)M.AU7P_XDT?P;I>H6
MDH^2YMYM,O8Y%_[Y;KV/(KYW_9AD\=? _P#X+5_LZ_LZ^._[0U1O@?H?C-/"
M?B6XW$>(_#=[:6G]G;F;[UQ;K:RV\O;,*\G.:_7S2/ 6A>'O%&K:Y8Z-I%CK
M6MB+^U-0MK*..YU'RE98_.D4;Y-BE@NXG 8@47_P_P! U3QAI_B2ZT+1[GQ!
MI,4MO9:I)91O>6<4G^LCCF*[T5_X@" >] 'DOQ@^./Q>^"7Q!U*\_P"%60_$
M3X;_ "/;W'A/4E_X233E\M?,\ZPNO+CN!YFX@V\^_;@>43S6M\!_VY/AA^T9
MK<NC^'O%$-OXHM1_I'AO6+>32=<M<==]E<*DV!C[P4K[U[!7C?[:G[(7A#]K
M[X$^(_#GB#PYH>K:M<Z7=1:/?W-JKW6E7;1,L4\$W$D3J[*0493[T 8O[9/[
M0.M^%M0T+X6?#>:S_P"%O?$:.4:9+)&)H_#5A'M6[UFXC_BC@#*(T/\ KIVB
MCZ%B/1/V>O@/H/[,WP?T?P=X<CF^PZ2C227%Q)ON=1N)&:2>[G?^.::5GD=S
MU9V-?"O[)OP;\-_!S7_V6?C?I>I>,-7U;XM6_P#PC?B#4/$FO3ZM>VR7>CM<
M0:<LTQ+K;P7MDP6,DX>9R22U?I)0 4444 %%%% !1110 4444 %%%% !1110
M 4444 ,\M8SNI]%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH CNO]2:(O]3110!)1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
84 %%%% !1110 4444 %%%% !1110!__9
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>16
<FILENAME>chart-e9c6128662635b0daca.jpg
<TEXT>
begin 644 chart-e9c6128662635b0daca.jpg
M_]C_X 02D9)1@ ! 0 0 ! #_VP!# $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P 1" &L ED# 2( A$! Q$!_\0
M'P 04! 0$! 0$ $" P0%!@<("0H+_\0 M1 @$# P($ P4%
M! 0 %] 0(# 01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$ P$! 0$!
M 0$! 0 $" P0%!@<("0H+_\0 M1$ @$"! 0#! <%! 0 0)W $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,! (1 Q$ /P#^_BBBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MJ>L%[>XMU2PN;.4ZP0#]F_VR/^"L7@?]G3XA?!#]GWX$? GXO?MM?M5?M#>
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MHO$6NW%S>V6EM;:7JZZ9X[9?$-O^"F__ 4'_:8_X*%?LX^!OB?8?L8_L]_\
M$E_CY^RMX=^-_C;X>^+OAQ9_M&?%CX@77BWQXVD_#3PWXPT/1O%.O^#_ AI
M&H7$NH7]QIEM+:>)+*P62TA36](^V 'UY^RC_P '%/P?_:6_X)X_MI?MYZK\
M!/%/PMG_ &-$T^77/@KJWQ!TG7]>\<6_C3PUHFI?"*XTCQ5!X4T>UTJ#XH>*
M-6G\':,\_A_4/LUYI\E\@U%9DLTXK3?^#BV\\5_L8_LJ_M1_#[]A3QOXO\>_
MM:?ME:]^Q5X _9];X[^"O#6MP?$C3A>VVCW%WX^\1>#+'PU%'KVMVL6C"UU2
MRT2UTF:=KK4=86V@9V_F^_9$^ GQKN9/^"/'[.GA[X;:@OP,_P""H/PT_97F
M_:L^WZ!K-LYF_P"":7[9_P ;_B[X@CU9)+!+:T.M?">Y\(:6CZP;<E(8+B 7
ML<L4(WO!'PI^)OQ%_P"";?\ P20\#>'M7^)GP<\8^)_^#@+QU%9_$;P?X5O'
M\:_"B3Q-XS\06FF?$G1M.UC3A9V]WX6NK^#6M+N=9BBT?[59Q_:Y1 DQ4 _L
M5_9)_P""H_BWXQ?M5:I^P_\ M5_L:?%?]A[]J)_@Q)\?_ _@SQI\1/A=\9?!
M?Q(^&6G^)?\ A%->U#PE\2OA1J=WHDVM:+JLD7VK0+NUBNFM8-4E\R*33)8)
M>&^ G_!;CX'_ ![_ ."H_P :_P#@F=HGP[\3:->_#)/B+H/@KX]7VNV=QX&^
M,'Q4^"UAX-OOC5\*O"NC1Z/#<6WB3X<Q>)M6EU%UUW51+:>$]2N[JTTR/4-)
M%S\Y^//V0?#?_!)+X>?M6?\ !63XQ_M+_M-?MX_M=_#O]EK7OA-\+?%WQ^O-
M$U>#P_;ZQK=JW@?X<?#[P%X#T"PM='M_&_Q7U'PU%X@U)VU6>TTZYUN[@%C'
MJ7B&XU#\!]>_88_X*_?L/_L0_L8_MF>(?AA^R)KDO[!'QMN/V_/$FL_#OQI\
M>M:_;:^),G[2^OZ#>?M%^"_BEH&M^";3X973ZSX5UO1_#WQ+MO#FI13:9X<^
M'T;:9J&JO;W[ZH ?TF?$O_@K]^TX_P"W1^U5^Q!^R=_P3$\=?M<:]^R-'\(+
MGXE^.-$_:I^!OP;LUL/C-X TCQSX9N[70/BQ8:2\I)O-7T8P6.MZG)Y^A37M
MY_9UM?V2OA:C_P %^?AG:_LI^'_VAX_V;OBAI?CG3O\ @H9X>_X)N?'#]G_Q
MOXI\+>&?&WP1^..HW>H0:_/JNO:7:^*O#_BK2- @M["XA_L<6AU:2^FLS/IM
MQIEX*_(KP]^RG\8O^"@G_!5[_@M7\3_V3_VS_P!J7]CW7_$'P-_8)^)'[/\
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M3[B[DT'PII<8;45?0[6\NM3BDC':?$S_ (+.?L[_ Z_8M_9Z_:['PR_:!\1
M^(?VK_$>G?#C]GS]E;3OAQ<V'[3?Q!^,5]J.JZ)>_#.+P%JUS:Q:=>^'-7T7
M48M>\2S7L_ADV*Z;J&@7VOCQ'X9M]8_![_@J%J?_ 3K@_X*#_M%Z[^VYX5_
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M])_X*6_L:_#C]K_1?AGJ?PCT[XAZU\1='A\":OXGLO&-_I3_ ]\?:_X$GFE
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MCIFL6.F@'Z&?%S_@O9\$?#7_ 3GT+_@H/\ !;X-_$'XOVU_\?/#/[,_BC]G
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M::5J=QJ"ZEX/TO7M*TZ+P_K%^TQM=3U"W:22\L(X;5U"QAB ?/\ _P % /\
M@J#\4/V1?VGOV6OV1/@3^Q;XG_;%^-?[5?A+XN>+/!7AKP]\<?AY\%196OP<
ML[76/$\%QJOQ)TF;P]*R^'FU'65ENM;TKY--:RMHKV]NH(J\R^*W_!6[]HW]
MF3X$> ?C%^U__P $VO&O[/&L_$K]L;X'_LH^$OA[<_M/?!?XG7NI6'QET[7[
MEOBI_P )'\--.U[2;73_ MJ.@RZ1/X0OXK/5]7FN([NVO[2S1I#\7_\%<?V
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MT70)Y&C2.S\%WD*RPB5_,XO_ (+)?LO_ 6_8U^!G_! +]G3QYKWQ-\&_L]_
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M"XM(UEFCN#; ']''[(__ 5&\8?&3]JW4_V'OVJOV,_BI^P_^U _P0;]HGP7
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MXEBGGEBF2QL;NWGTR[U _H=_:^_X+_?#G]D'XU_L ?"_P 6?L[>,-=\*?MP
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MHI]U@/#ZQM;+&_VS;*8XG_"+X%_MM_!3_@F/^S[_ ,%@_P#@GO\ M9Z+\;O
M?[2_Q9_:R_;M\=?L[^"M/^!/Q/\ &=K^T)X+_:'\"V&A_"36OAIXJ\'^&]8\
M)W:>()+2.XN7UG6-&M+"WO;=VNI9H=4MM-X_Q[83_P#!.KX=?\&HOB/]JO1?
M&_PWT7]G2P_:5\3_ !R ^'GCGQCKWPS/C/P#X"U6/2?$GA/P%X?\3>)[?6-/
MU#QE8:-?:1%I,VIVEY#?17%JKZ;J'V8 _NWEN88+=[J>1(((XC/-++(D<4,*
MKYDLLLCLJ1QPQAI)9'951$9V(4$U^*7_ 3'_P""VOP?_P""G?Q1_:D^%OPU
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M&O?#'1?^"D+:[^Q!XTF\<?\ !,SP=^QQXR^-?P]L?C9X1O\ 5M1LOVG_ GI
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MJ7B[X?:O<6;7MKX;^)6G:/J\$&L:4MEKL,%M-J\-E!J,%E<:B]['-&OY#_\
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MSU _M)^&_[?7A3XC_\ !0S]HO\ X)\67P]\2Z;XL_9W^#/PN^,FK_$:ZU;1
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M?V#WEO M[92;&,-W:&:VF7#PRNCHS 'V)^SA_P %8? O[1G_ 3Z_:-_;_TC
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MIT6IZ,]W[5X]_:;B_8L_X)%V7[2U_HU[JNK_ >_8N^&^O>&_"RZ9J%W>>(/
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MK/Q,_;M_X*1_MW_ ;P-XA\8ZS^S[^SM_P2#_ ."B?[-]Q>>&]>LHO$/_ JC
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M^":_@']@?X__ /_ &F/"?\ P4(_9^^!>K_LY1?L;VO[.?Q4\1^+?BUX\\,:
M9JO@_P -:CX"\7^'/"6J?#W6/"'Q">[TO6'\0R:\J10ZC?RV5IXBAET6Z\0_
M)@_X)U>(/!NG?\&MW[#'[7OPRN/%EK=>%?\ @HMX?_: \$ZK9W.L6?A2R^-_
M@.V\92^#-;U?3(I[+0]>\%P^,[71["_AOU;2O%>@/>Z'?7#Z7#=* ?U1Z_\
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M^E)KGA3P_P#$]/!&IP:?<W-QI+^!)O#]P;O4=!N+JZ]QT'_@I/I?[/'_ 31
M_9Z_8#\9?&W]M?\ X)M_\%%?V0O"!^%NK_!KX9?L>ZC\9O%OQ^UCX=Z%K_A7
MPK8^"/$&N_#CQA\+-=^'_P 1+Z?0/&%OXJTOQ'H]V+HSK;7NH:1/9:KK !_:
M!\#OC-X%_:(^#WPT^.?PRO=0U#P!\6?!7A[Q[X1NM6TC4/#^KOH7B73H=2L8
M]7T+5H+;4]%U:V28VNIZ5?P17>GW\%Q:S+OB+'U6OSD_X)(>(?VK?%O_ 3I
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MO\Z/B?3IY_\ @X[_ &MKY;,O;V?_ 0DD@N;OR$_<-??&VS6*&24KO7[2;-L
M1D[9/LP)4^6I'\LG[)/Q@^)?[!W_ 1@^*7@GXN^)+S6/V,O^"M'[''[6.H_
M CQ!<:?/<6/P3_;E^$.L^//AQK/PAU!K426^F:7\??A]X&\/:YX?U&Y9!JGB
MK3M-L[*QC?3?%^IL ?Z;^I?%7X8:1X#M/BEJOQ%\"Z;\,M0TC3-?L?B+?^,/
M#MCX%O-!UJWAN]'UJT\87.IP^'KC2=5M;B"YTW48=2>SU"WFBFM)IHI%8S^$
M/B7\.?B#X47QUX$\>^"_&G@AX[F5/&/A+Q7H/B3PL\-E"+B[E3Q%HFHWVD-'
M:P$37#B]Q!#^]E*(=U?QH?L[_";X:_MR?MJ_\$??V./VNM(B\=_LM?!7_@@1
M^SE^U3\(_@-XGU"XB^&?Q2_:#\16OA#X?:[XB\2>%[>ZM++QU)X.\$07,>G^
M&]0CNTTI- O+]K;^QK[6[?4?IC4?@I\*O^"?G_!:BX_9Y_8L\,6'PF^"/[6G
M_!,K]H;XG_M'_L\^![I[7X7:!XP^%\^NZ7\-?C-IW@)KB:S\&ZQJZ64G@83:
M/!8:=J$-[JCPVIN-1U&60 _IM\$?M"_ +XE>#_$WQ#^'/QO^$/C_ , ^"UOS
MXQ\<>"OB;X+\5^#_ FNDZ4FNZH?$OB70M<U#1-!&FZ&Z:SJ#:K?6GV/2G74
M;DQVC"8\K-^U]^R9;_#^U^+$_P"U!^SQ!\++[Q-+X,LOB3-\;OAI%X N_&$%
MA)JDWA2U\9/XI7PY/XDATV*74)=!AU)M4CL8WNWM!;HT@_S8O^"?7CC7O@'_
M ,$_OB)^QEX4UNZTKQ%_P6X_9Y_9JT#X"V]RK/I]Y\4O$G[>OQ,_85_:*T72
M2O U"?X+2P>*M3MR&46FGV4C*MN\K)Z9_P *WL?#O_!(']EOX4^"OAYX.^*]
MIHW_ <W:A\/_"?PN^(=U9V?@;XDP:9H>N^$]!\!^-]3U&PU6TM/"WC&TMK/
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M+ _8OQ'\4OAEX.\5>"_ GBWXB^!?"_C?XCSZE;?#WP=XC\7^']%\5>/+C1H
MH)]7M_!OA[5-2M=8\4S:5!=6TVI0Z'9W\EC%<0/<K$DL9:3_ (67\-Q\05^$
MO_"P/!7_ M1O"Q\<I\-#XMT+_A8#>"O[0_L@^+QX,.H_P#"2-X6_M4'3/\
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MC_@I_P#LRS_MQ:I_P6ELOVA89?VG_#G_ 4HL/ _AW]G*"W\?O=:I_P2DTGX
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M"\:W5O=I>%+34?LWZ!?MF_MCVG_!4;]AG_@AII.J^*=4\+_L_P#_ 4@_:^^
M$WPE_;6L_!WB*3PFNL:MX1TS5+'Q[^S[J6L65S:7^GZ%XT^+&A:_':P02VE]
MJ%IH.A7=N"7MDE /ZQ/A]\:/@Q\7I=53X6?%;X:?$R;P]<-;:VOP_P#'GA/Q
MK)H-V2]NUOJ@\,ZOJCZ1<EUDA:.Z^S2%PT9!?*UZ1?WEEIME=ZCJ-W;V&GZ?
M:W%[?7UY<QV=G9V=K$]Q=7=W=3R106]M;P1R37%Q/(D,,2/+*Z(K,/Y%/^"C
M'[,'[%/_ 3Z^-__ 3/_:/_ .";?@[X5? K]I+0O^"EG[/O[&GQ+\"_L^ZS
MIND+\2/A?\;=+U27XF?";XQ^"=#UBX34==_L"V\.ZE#?^*;!/$&E6NOVNKWL
MLK7.B7UI^P/_ 7%^"<7[2?_ 3>^-?P"3]I3X7_ ++FN_%75OASX:\(^-_C
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M4\)_LG?!C]D7]G;XCV\6K?"[X;?"3XC_ NO/%WC'QMH'PPDF30-1O?$GB&P
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MEU5;KPNO@:[\0_#72/"MOXXDM+#Q1]HU.XU'PC=_9([S2KV* _T9_B=^U;^
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M_P *_B;_ &B?'+6%TOBIK:'PGX=%S+>?:X(X0#^OK4OVW?V+]&T'PUXH
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M'@OX:^#_ Q\0?B--<:=%JT\OCGQAHVD6>O^*I)M54:G*^MW]ZTFH?Z6Q,P5
MP ?MX !TS^+,?YDUS6O>,_!_A2\\/Z?XF\5>'/#M_P"+=7BT#PM9:[KVE:1=
M^)-=G :'1= MM2O+:?6=5F4AHM-TR.ZO) 04@((K\\_C%_P5@_9:^!W[9WPY
M_82\:V7QJE^.'Q1U7X::-X9N/#GP8\7>(OATEY\5M2&E>%VU?X@Z?&VB:5:Q
MW1W:Y=W -OH=NLEQ?.D4$[1?G_\ \%SK21_VI?\ @@WJ#VZO96__ 5D^$UI
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M3PK!86&J6TVFZA=?VO';VM_;RV=T\=Q$\2_QV?\ !%_]J+]ESPMX>_X*^_\
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M.:[\</C5\<OCWX3/@/XK_M,_M*_%C5OC'\?_ !3X+%D+2W\*KXVUBSL[/0]
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MFH3.S:1K4-KJ,<<KP"-OE[X:_P#!M[^Q#\/_ ;X<^$&L?&O]OCXL?LW^&K^
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M]3\23^#_ OI7AV;7]1:[NKZZ:^UJ336U.\-S>WDYN+J3SKJXDW3/_-?_P %
M/?\ @M'^T7^RA^WWX?\ OP3\.^#?$/[&O['&F?LV^)?^"H/BS4]&MM2\2>!
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M="T@V^J7)FLKN\U>9W$.V[2.%8Z_*7P1^V_^WYX8_8 _X*4_'/X@_$#]C?\
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M[/5-<\3/=0:1I>HPW#G6;[6=,2)96:.2;G?^"$W_ 4U_:U_:]O/CO\ 3_@
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M 4*_P"">7P9_8[U7X?7/[,WQNO?V"Y_COX@\1>#;#Q/K=P/VZ?B-KM]X \-
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M1UU'28[Z?5;'A_V:_$?_ 6U^%O[4WP^^&_[8?A3]E3]IC]F3XJ^&?%FH>)O
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ML:#X<\7_ !1MO'F@GQQHMMXR@U73WUG1_#/V(>'V\.R7MG>SMJAL76X^7O\
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M_L4^#_V#-$U7QYXWTW7[/6/@KX(\0Z?XCT/5/%,%MX6TJ[UKXC_:M+L;6_\
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M?&3X)>!_C?\ GXI?L[>*H=0TKX<_%OX4^-/@WXB@\)W%OH>J:=X,\<^$]0\
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M>?:M)U&RN_[6L="N=%A\XPW&H17$<D2^&7W_ 2RM/CC_P %M?VJOVG?VJ_V
M2?@U\</V4?&/['OP6\!_"?Q!\9_#/PD^*NBGXO>%-6T&/Q#%I/@7Q/)KOB+P
M]JMEHD6JVK>(KCP]IMI=69EL[74[A+GR7_H=HP.N.?6@#^)7]H'_ ((P_M<P
M_LH_\%]O@+^SM^RMX2\*:)^UG^U/^RUXT_8U^&W@;Q+\&/ GA'Q)\+_AG\1-
M$UWQ/-X?T>V\4:-X<^'>G:#IEM>7D&A>)D\+7-RP>#3-/GGD5'_4;]C^;]HS
MP?\ &CX,PWO_ ;A?#+]E:&'5-)\,^(_VG/"OQW_ & ;SQ!\,]#U/37T#Q/X
MTBTWX7Z#8?$'5XFTNXO4U+1O#=VFJ:M97MS8 2Q32QM_1'@>@YZ\=:,#T'Y"
M@#\6O^"X?[)_[0'[7OP$_93\&_L[>!F\=>*/AM_P4'_9<^./C"P3Q-X6\+2:
M'\-/AS<^,Y?%WB=+WQ5K6AVEZ^C#5=/9=+TRXNM;O#-G3=/NFBE"?E_\:_\
M@C3^TU\+O^"X7[+O[7'[+WAV?Q+^PIJ7Q_\ '?[6WQJ^'MIXJ\$:/;_ _P#:
M(\6>!+WPA\5O$_A?PQXDUO1M7U6T^.L6D^"=:V^%QJ*6WB6WU2RUBST?1=(\
M/W#?US44 ?R _ W_ (((_M4?M1?!C]KKXG?MK?M9?M(_LJ?&W_@H?\4/B?XZ
M_:(_9E^%FM_ CQM\+;3P^GB;7-.^#'A/QEK"^&?&LWBFU\)^$DTJ33H/#?C6
MUM]'T2>QTS3VTO6[2]N*]4\+?"[_ (+3^!_V _V#/!GC_P#9,^#7[5'_ SM
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M:F9M;T[^P@ 8 '3 '&/3%+@#H * /YE/%?_!*S]K7]JW_@IW\;OVFO%OQN
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M[:O_ 5B^-/[=_[$7[/?Q5\,?'C]K/2?'_[,GBWXT^ O@M\:;_4OAO-H6LPZ
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M?Z/_ %7X'H.N?Q]?K1@#H,4 ?R&^!O\ @EQ_P4:_X=O_ %^ NI:!X8A_:I_
MX)#_ /!0.V^-G[!_B+XC>,O"5[X!_:N^ ?PM\3ZMJ_P_T'Q%JWA76-9O_AS#
MXF\-^)=1\-:9IOBBST"_T)/"?@W3M3_LBRO+W5M(_3/]G;XQ?\%E_P!IS]K?
MX3^(?B_^REX7_P""=/[&_P *_#'CAOC1X%\9?%7X/_M)_$_]I7Q_K%I;6/A/
M3/!6M^!+42?#;PEX%U*)-83Q%NTRXU^PDU>TN8];EU+1QX<_;^D Z #/)P
M,GUXH _BS_9$_9)_;2_9$/[4/@_XH_\ !OA\,_VX[OXG?MG?M"_'+P=\</%_
MQT_8'LM5/P[^(WB#3V\+>&DLOBDGBSQ9:65G!I5UKL5I/?VD,$GB.>$Z597J
MWHE^^_VL?@7^WGIW[27_ 3>_P""I7[._P"PIH?B[Q_\#/V=OB=\"/CW^P1'
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M:GJ7A_9<7=M'_9WB:TTC52925LBB.X_:\ 8 Z < ?A1@>E '\<7P;_P""
M._[<VA?\$Y/AO::=X(\'> OVWOV/_P#@JSX\_P""@_P ^'GQ"\9>%M3\#_%3
M0K3Q9%=V/@+Q)XN\&ZMXAT[PU;?$7P]/+/87=Q>VMQINL:-IMCKCZ!;7\VK:
M=^J'P*^-G_!9_P#:-_:D^'GC'XJ?LA:#^P%^R!\(/ OQ&NOBY\*O$GQ9^"G[
M1OQ=_:L^).H:6EOX-\-> /$/A);.T^&/AOPIJUO%>6GB6^O=#BURVNM5M=2D
MU5-3TN;PO^YN .@Q2 9P ,]< #/U]: /X^_@C_P0'_:G_:=^ /[5WC_ /;2
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MN>,8OC3=_!O3_P#@G)X1_:XM?@ ?V@H-03XM-H__ N?Q;=:A!XF_P"$I'Q)
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M^U=4_P"A<OO_ /T7_Y84?VKJG_0N7W_ ('Z+_\ +"MZB@#!_M75/^A<OO\
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MO_RPK>HH P?[5U3_ *%R^_\ _1?_EA1_:NJ?]"Y??\ @?HO_P L*WJ* ,'^
MU=4_Z%R^_P# _1?_ )84?VKJG_0N7W_@?HO_ ,L*WJ* ,'^U=4_Z%R^_\#]%
M_P#EA1_:NJ?]"Y??^!^B_P#RPK>HH P?[5U3_H7+[_P/T7_Y84?VKJG_ $+E
M]_X'Z+_\L*WJ* ,'^U=4_P"A<OO_ /T7_Y84?VKJG_0N7W_ ('Z+_\ +"MZ
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M1_:NJ?\ 0N7W_@?HO_RPK>HH P?[5U3_ *%R^_\ _1?_EA1_:NJ?]"Y??\
M@?HO_P L*WJ* ,'^U=4_Z%R^_P# _1?_ )84?VKJG_0N7W_@?HO_ ,L*WJ*
M,'^U=4_Z%R^_\#]%_P#EA1_:NJ?]"Y??^!^B_P#RPK>HH P?[5U3_H7+[_P/
MT7_Y84?VKJG_ $+E]_X'Z+_\L*WJ* ,'^U=4_P"A<OO_ /T7_Y84?VKJG_0
MN7W_ ('Z+_\ +"MZB@#!_M75/^A<OO\ P/T7_P"6%;PZ=,>WI[444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !7X>_\'(?_*%3]N7_ +%7X3?^M$?!
M^OW"K\/?^#D/_E"I^W+_ -BK\)O_ %HCX/T ?MS9_P#'K;_]<(/_ $3'5FJU
MG_QZV_\ UP@_]$QU9H **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M]J?=-%%%?*GU84444 %%%% !1110 4444 %%(2 "2< DD] !R2?I7B\O[1W
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MQ,)5<GP4Z<G&K1P4*<Z4\\Q].:=.='"UJ6 PM2-:&-S&EB\/_9]?\S?VL/\
M@G'\6O\ @I9X=OOBA\:CX0_9S^(>@>%;W2_V>/AWI-AI'BGQ#H4%U?Q:IY/[
M2_Q.T^UN[GQ ^LO%)!!X'^&[2>&/A7<:GJ&KZ?K/C[6)]06[^O?^"=7_ 3L
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MPIK6OV>G>(O&-MX?T_5G70GU:2/^;OX'I:^ /AM\3-,UOX*>,?@%^SK\ /\
M@OM\&_&/Q;/Q/\5?#/Q'I.@^%6^%WPTT]=8^)7B+P;\1?B%:R7_@GX]W'P?^
M+GQ9^)'BV]E\-7&M>+K7QT_BR]U.R\6ZCX6_KM(!X(R/0UF-HVD-;:G9MI>G
M&TUI[F35[8V-J;?57O+=+2\;4H?*\J_:ZM8X[:Y:[28W%NBP3%XE" _FE@\
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M88K>VMK>*."WM[>"-8H8((8E2*&&&)$CBBC18XHU6.-515 )Z_G(_X.&? 7
MQGTG_@C[^VOJOB7X[?\ "4^&X/#WPPEO?"W_ JGP=H?V^WE^/\ \*8[:V_M
MVPOY=1M/LT\MO/Y\,323?9O+<!96Q_1O7X>_\'(?_*%3]N7_ +%7X3?^M$?!
M^@#]FK33];-M;XU[_EA#_P P>Q7_ )9)V$F!]!P.@X JQ_9VM_\ 0>_\I-E_
M\<K7L_\ CUM_^N$'_HF.K- '/_V=K?\ T'O_ "DV7_QRC^SM;_Z#W_E)LO\
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M9?\ QRC^SM;_ .@]_P"4FR_^.5T%% '/_P!G:W_T'O\ RDV7_P <H_L[6_\
MH/?^4FR_^.5T%% '/_V=K?\ T'O_ "DV7_QRC^SM;_Z#W_E)LO\ XY7044 <
M_P#V=K?_ $'O_*39?_'*/[.UO_H/?^4FR_\ CE=!10!S_P#9VM_]![_RDV7_
M ,<H_L[6_P#H/?\ E)LO_CE=!10!S_\ 9VM_]![_ ,I-E_\ '*/[.UO_ *#W
M_E)LO_CE=!10!S_]G:W_ -![_P I-E_\<H_L[6_^@]_Y2;+_ ..5T%% '/\
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M\'(?_*%3]N7_ +%7X3?^M$?!^OW"K\/?^#D/_E"I^W+_ -BK\)O_ %HCX/T
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MBC6)E%QK7B;Q#J&I:[J]T6N-0O[B5MU>G ?YY/;D]2<#J>:*PS//JF,PZRW
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!117@O[2?[0W@C]F+X4:W\4?&J:AJ0MKBPT'PEX.T"'[;XO^(WC[Q!/_ &?X
M/^'G@K2D#3ZKXI\5ZL\5AIUM%&Z6T9N=3O3%IUA=S1]>!P.+S/&X7+\!AZF*
MQN-KTL-A<-1CS5*U>M-0ITX+O*32NVHQ5Y2:BFURX['83+<'B<PQ^(IX7!X.
MA4Q.)Q%67+3HT:,'.I4D][1BF[)-MZ13;2/G7]OWXK6<7@*S_9;\&^"/"_Q@
M^/7[4EEK/@7X>?"_Q991ZMX3T[03 L?C#XO_ !-M2LC:?\-?AA93+K5]=XBO
M-7\01Z1H&A2#4[EY['X;_9(_X(-? 'X!_$WQ-X[^+NO6_P"T=I46G6.F?#OP
MEXS\*V=GH.C27>BV\'B?Q#XKTE;F\T_Q+KKZF]_!X27RK>P\.Z8T6HS6]]XG
M^S:EI?W]^Q[^SSXV\)7GC#]I/]HN33]8_:N^/-MIT_CC[#*+W0_@]X$LW:]\
M(?L^?#R=GE2#PKX&282>(M1M'+>-/&SZGXBO[B]5=-E3[JK]*GQUF_!.5X_@
MO@G/J^'P.-A*'%&;Y?52_MS,VZ*K++,3R^VPF58"%!Y?@L1@YT,1FE*IC<;B
MJCPV.PV P/YK'@3)^-LTP'&?&V08?$X_ U(U.&,JS"ES?V)ER5;V3S'#-^RQ
M>9X^598[&8?&0KT,LJT\'A,-36)P6(QV-^.A^Q'\*]"C1?A9XQ^.WP0>-Q)'
M#\+?CE\1++0$<$[2/ ?B_6?&7PY8+DXC?P@T3 D.C G+_P#A47[6/A.5I/ _
M[6&F>-;*%=MOH_[0'P.\*^);F5%P$B?Q5\&]:^"5[&P7K=W6AZK.S -(DAW
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M1_PCGA[_ * 6C?\ @KL?_C%;-% &-_PCGA[_ * 6C?\ @KL?_C%'_".>'O\
MH!:-_P""NQ_^,5LT4 8W_".>'O\ H!:-_P""NQ_^,4?\(YX>_P"@%HW_ (*[
M'_XQ6S10!C?\(YX>_P"@%HW_ (*['_XQ1_PCGA[_ * 6C?\ @KL?_C%;-% &
M-_PCGA[_ * 6C?\ @KL?_C%'_".>'O\ H!:-_P""NQ_^,5LT4 8W_".>'O\
MH!:-_P""NQ_^,4?\(YX>_P"@%HW_ (*['_XQ6S10!C?\(YX>_P"@%HW_ (*[
M'_XQ1_PCGA[_ * 6C?\ @KL?_C%;-% &-_PCGA[_ * 6C?\ @KL?_C%'_".>
M'O\ H!:-_P""NQ_^,5LT4 8W_".>'O\ H!:-_P""NQ_^,4?\(YX>_P"@%HW_
M (*['_XQ6S10!C?\(YX>_P"@%HW_ (*['_XQ1_PCGA[_ * 6C?\ @KL?_C%;
M-% &-_PCGA[_ * 6C?\ @KL?_C%'_".>'O\ H!:-_P""NQ_^,5LT4 8W_".>
M'O\ H!:-_P""NQ_^,4?\(YX>_P"@%HW_ (*['_XQ6S10!C?\(YX>_P"@%HW_
M (*['_XQ1_PCGA[_ * 6C?\ @KL?_C%;-% &-_PCGA[_ * 6C?\ @KL?_C%'
M_".>'O\ H!:-_P""NQ_^,5LT4 8W_".>'O\ H!:-_P""NQ_^,4?\(YX>_P"@
M%HW_ (*['_XQ6S02!R?\_P")/8=2: .%\6W/PZ\">&/$'C3QBOA3PUX4\*:-
MJ7B'Q'X@UFVTVQTK1=$TBTEOM3U34;N:)8[>SLK2&6>>5SA40X#,54_G/^S5
M\.[[]KCXL6'[<7Q9\)-H/POT&'4++]B3X/ZWI$>G2:+X0U1?L]_^TIXYT.6)
M-OQ)^*=C''_P@UC>Q%O GP\DM);</K.N/?6]3Q-))_P4=^-FI_#BQE-S^PI^
MSSXQMX?BEJ=NSG2OVJOCOX5O8[R'X66%PJB#5_@K\(M6@MK[XB74<DVF^./'
M,%CX8@2[TG1KV]K]6HHHX8TAB1(XHD6...-51$1%"HB(H"HB* JHH"JH"J H
M 'WM;_C#,LJ8.*Y>+<\P?)F$]JO#>1XVBF\LBW[U+.L[PU3_ (5>7EGE^455
ME52;Q.99MA,%\'0OQEF<,9+WN%,DQG/E\=?9\0YW@JSC_:4UI&KDV38B#667
MYJ>/S6F\TII8?+LKQ6,R1X<\/ 8&@Z-@<#_B5V/_ ,8H_P"$<\/?] +1O_!7
M8_\ QBMFBO@C[PQO^$<\/?\ 0"T;_P %=C_\8H_X1SP]_P! +1O_ 5V/_QB
MMFB@#&_X1SP]_P! +1O_ 5V/_QBC_A'/#W_ $ M&_\ !78__&*V:* ,;_A'
M/#W_ $ M&_\ !78__&*/^$<\/?\ 0"T;_P %=C_\8K9HH QO^$<\/?\ 0"T;
M_P %=C_\8H_X1SP]_P! +1O_ 5V/_QBMFB@#&'ASP\&#C0M&#*<AETRR# C
MH0P@!'X&L7Q-\.?A_P"-+$Z9XP\#^$/%FG,,-8>)O#.B:_9,N"-K6NKV-Y 5
M ) 7R\ $C&":[.BKIU)TJD*M*<J=6FU*G4A)QJ0DMG"<6I1:Z---$3IPJPG2
MJPA4I5$XU*<XJ<)Q:LXSA).,DUHU)-6/RD_;/_X)0_ ?]H?X->+_ G\'?#_
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M5]"N_%VLVNI:I>Q:9J.K7-A8S&S@B /U-HHHH **** "OP]_P"#D/\ Y0J?
MMR_]BK\)O_6B/@_7[A5^'O\ P<A_\H5/VY?^Q5^$W_K1'P?H _;FS_X];?\
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MOVH_C7I5G8W/A^WG&H:+^SW\);>Y.H^%/@#X*NCE&726>+5_B3K]HL7_ F7
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M\$6J?_(U']OV_P#T#]=_\$6J?_(U &[16%_;]O\ ] _7?_!%JG_R-1_;]O\
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M_MRD(H(\*_";!"@$?\9#_!_N!7[B5^'O_!R'_P H5/VY?^Q5^$W_ *T1\'Z
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MQ,N3"X#"0DXQ=:O/XISE"AAJ,:V+Q56CA,/7K4_.OB'<W/\ P41^-&K_ (\
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M8*"1P&A?>)]3M-$\.?$OP%K^LW_F?8=*T;Q;H6IZC>>3!)=2_9;.SOIK
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M[.69M3UJ1 7RJN$C52J* 06/HMC\#_A3IZ+%#X)TB:!2"L&H?;=5@SDEB8=
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MBQ0QI%&H 5(E$2 !0 L850 J@ <#%3_:/$[N\)@.",HFKJG4Q&6Y]Q
M36Y=/XKQN>Y1EU2>[YEE%.-_LI:-<^,?P0P%!]'*EB,7+INYU\/3?77V*].W
MR2MQ%K<:/K7Q5_:#\8 ,"UIX$^'NN^!=(8$%RB77ASP/IVLA-I3F3Q9,^R6,
MJ[;MPLV'@WX=&Z-[#^SKX[\7:CRPU+Q_#I/B"\$@ )D%]\4/'5]=QN&9?GAC
M4,Q+0[A&P7ZQP.G7Z\_SH Z #Z #^5*6/X]K+DJ<:_V92E%QG1X5R+!Y!0G
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MQ^\9OVHOVJM&66W^(_PI\3?"^=(V,VHG]F#XF?�7!(,QUOX _%/XK1F-?
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M?%0:NW;WHK5/IJ^UQFKVBG;M5H;]M:J_KY'V929'J/S%?%/_ K?]MS_ *.(
M^'7_ (;.+_XU48^%G[8Y&9/C[X,=SR[KX7U*)6<\LRQ1J$B4G)6- $085> *
MY?JN9/X,/@5M=ULXRZ"Z:1]C6Q#;UOJHI*VK(M5Z4XK_ !5Z*[?RSGWZVV9]
ML[E'5E'XC_&C<IZ,I_$?XU\2GX3?M<R'=<_'#PA<, I73_%]@%49X\O3-0L
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M?V-9VR312;--M<^3'T?_ S1\0YR6OOVD_B2H8C>FAR7NCJ%7[BP27FOZ]/"
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M$S#<NYF)!_>;&38B-%(^3X::A='=J/Q1^)U[G[R0ZQH.A1D?=PO_ C?AG2)
M4S'\A*S [B9E*SA9%[7RO$O_ #^:'_X+]1_^6U'E>)?^?S0__!?J/_RVH_U2
MR9IJJ\XQ4&[NECN)>),?1;5MZ.-S;$4FM-N2UFT'U*@])>WFNU3%XNI'_P !
MJ5Y1_ XF;X/^$[F%DO[GQ?K,VQPKZ[\0?'NHPEF! $UI_P ))!;20MB-)H1%
M<2"-NK,?._"W[-VCZ-K<>I>(;[2/&6G^3<QS:/K?AB&Y@,LP!ANH'O=2OU
MBN+9U"QRR0SR?9WFAW@R>8/>O*\2_P#/YH?_ (+]1_\ EM1Y7B7_ )_-#_\
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M4DK))))))65DC9)+9)>BM^1N[1[_ /?3?XTN >HS6#Y7B7_G\T/_ ,%^H_\
MRVH\KQ+_ ,_FA_\ @OU'_P"6U59=E_7_ R^X9N;5Z[5SZX'^%+@#H /PK"\
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MVJ5--ODC;15JL82I1JU(TY.\J:G)0DW:[E!/E;=ENNB[&]16#Y7B7_G\T/\
M\%^H_P#RVH\KQ+_S^:'_ ."_4?\ Y;5YIF;U%8/E>)?^?S0__!?J/_RVH\KQ
M+_S^:'_X+]1_^6U &]16#Y7B7_G\T/\ \%^H_P#RVH\KQ+_S^:'_ ."_4?\
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MC+!SA6FU^9>)O"_B]Q#@\FP?"?&.3932_M>C_;;P>6YAE&(J975@Z5:7UO\
MMK,:U>E0C*<IX'#?4*N)<XR6+A*E!+ZK_9N^%WPK^#GP1^''@3X+Z5<:7\.M
M/\,Z=?\ A]M1MM0MM>UE-=@36[KQ-XI&L6ECK4_BWQ/=W\VN^)[K6[2VU>;6
M;Z[^WV]M,IMH?<: ,# [?B?Q)Y)]2>3WHK\;QN+KX_&8O'8FM7Q&(QF)K8JO
M7Q59XC$UJM>I*K4JXBNXQ=:M.4G*K5<8NI-RERQO9?LV"PE' 8/"8+#TJ%"A
MA,-1PU&CA:2H8:E3H4XTX4Z%!2DJ-&$8J-.GS2Y()1YI6NRBBBN4Z@HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "OP]
M_P"#D/\ Y0J?MR_]BK\)O_6B/@_7[A5^'O\ P<A_\H5/VY?^Q5^$W_K1'P?H
M _;FS_X];?\ ZX0?^B8ZLU6L_P#CUM_^N$'_ *)CJS0 4444 %%%% !1110
M4444 %96H:%HFK7.D7NJZ1I>I7F@:@VK:%=7^GVEY<Z+JK6-YIC:GI,]S#++
MINH-INH7^GM>V3P7+6-[=VAE-O<S1OJT5492@^:$I0E:2O%N+M*+C)733M*+
M<9+9Q;3NFT3*,9KEG&,XWB[22DKQDI1=FFKQDE*+W4DFK-)ATZ4445)04444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% '@7[0G[0_A;]GCP_X/U#6/#?C;Q]XL
M^)?Q T7X5_"KX8?#;2M-U?QY\2?B!K>FZWX@3P_X>BU[6O#7AC3H=)\)>%_%
MGC7Q/XB\6^)O#GA?PQX0\*Z]KNLZS:P62I//^SU^T)X,_:0\$ZGXP\)Z7XJ\
M+ZAX8\;>+_AI\0/A_P"/M+L]$\??#?XC>!-3.E^*/!7C'2],U37=(CU2Q9['
M4['4=!UW7O#7B3PYJ^A>*?#&NZSX>UO3-1N?G3]M[P?X[@\:_L:?M#>"O 7B
M_P"*EE^S!^T3XA\;_$+X?^ HK'4?&E_\._B7^SO\:_@/J_B?PAX;O[_35\5:
M]X#UKXE>'/%-SH&GW0\07_A&T\6)X8L]7U\6&BZE+^P#X!^(7A_1/VF_BK\0
M_!.N_#2Z_:?_ &M?B1\?O"OP\\7M8+XW\*> +SP1\+OA3X+3QK8:7>ZGI^@^
M(_%&C?">+QY=>%X]1N[[PM:>*[#P]KQM_$>FZQ9VP!]^5^'O_!R%EO\ @BK^
MW+@,?^*5^$_16[?M#_" ^GH"?H#Z5^X5?DM_P4<_8D^#WC_]C7X]^'#\/?'7
MQ)GUS0-(8>"KWXC?'/QU8Z[<0^-_#.HI$W@N;Q[JMCJPM)8/[2@M3I5Q':2V
M<5W%%']D5T /U4M-1L!;0 WMGD00CB[MCTB0=1*0>G;KU'%6/[1L/^?VT_\
M JW_ /CM?D&G_! +_@CB02?^"?7P !WN/^03XEZ!V //B?N #Z<\ # IW_#@
M'_@CA_TC[^ '_@I\2_\ S3T ?KU_:-A_S^VG_@5;_P#QVC^T;#_G]M/_ *M
M_P#X[7Y"_P##@'_@CA_TC[^ '_@I\2__ #3T?\. ?^".'_2/OX ?^"GQ+_\
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M6ULF\2P>';)II+B\M[.Z /Z O[1L/^?VT_\ JW_ /CM']HV'_/[:?\ @5;_
M /QVOR%'_! '_@CA@9_X)]? #I_T"?$O_P T]'_#@'_@CA_TC[^ '_@I\2__
M #3T ?KU_:-A_P _MI_X%6__ ,=H_M&P_P"?VT_\"K?_ ..U^0O_ X!_P""
M.'_2/OX ?^"GQ+_\T]'_ X!_P"".'_2/OX ?^"GQ+_\T] 'Z]?VC8?\_MI_
MX%6__P =H_M&P_Y_;3_P*M__ ([7Y"_\. ?^".'_ $C[^ '_ (*?$O\ \T]'
M_#@'_@CA_P!(^_@!_P""GQ+_ /-/0!^O7]HV'_/[:?\ @5;_ /QVC^T;#_G]
MM/\ P*M__CM?D+_PX!_X(X?](^_@!_X*?$O_ ,T]'_#@'_@CA_TC[^ '_@I\
M2_\ S3T ?KU_:-A_S^VG_@5;_P#QVC^T;#_G]M/_ *M_P#X[7Y"_P##@'_@
MCA_TC[^ '_@I\2__ #3T?\. ?^".'_2/OX ?^"GQ+_\ -/0!^O7]HV'_ #^V
MG_@5;_\ QVC^TM/SC[;9YQG'VJWSCUQYO3D5^0O_ X!_P"".'_2/OX ?^"G
MQ+_\T]?,NK?\$(?^"6D?[8G@/PO:_P#!/OX0CX3W?[-?Q9U[7%B\.>-&\*2?
M$/3_ (K?!33?"S7^HCQ"VFQ>(8?#.I^,?[(LGN8KVXTV;6YXH)[:UF>W /Z%
M/[1L/^?VT_\ JW_ /CM']HV'_/[:?\ @5;_ /QVOR%_X< _\$</^D??P _\
M%/B7_P":>C_AP#_P1P_Z1]_ #_P4^)?_ )IZ /UZ_M&P_P"?VT_\"K?_ ..T
M?VC8?\_MI_X%6_\ \=K\A?\ AP#_ ,$</^D??P _\%/B7_YIZ/\ AP#_ ,$<
M/^D??P _\%/B7_YIZ /UZ_M&P_Y_;3_P*M__ ([1_:-A_P _MI_X%6__ ,=K
M\A?^' /_ 1P_P"D??P _P#!3XE_^:>C_AP#_P $</\ I'W\ /\ P4^)?_FG
MH _7K^T;#_G]M/\ P*M__CM']HV'_/[:?^!5O_\ ':_(7_AP#_P1P_Z1]_ #
M_P %/B7_ .:>C_AP#_P1P_Z1]_ #_P %/B7_ .:>@#]>O[1L/^?VT_\ JW_
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M_CM?D+_PX!_X(X?](^_@!_X*?$O_ ,T]'_#@'_@CA_TC[^ '_@I\2_\ S3T
M?KU_:-A_S^VG_@5;_P#QVC^T;#_G]M/_ *M_P#X[7Y"_P##@'_@CA_TC[^
M'_@I\2__ #3T?\. ?^".'_2/OX ?^"GQ+_\ -/0!^O7]HV'_ #^VG_@5;_\
MQVC^T;#_ )_;3_P*M_\ X[7Y"_\ #@'_ ((X?](^_@!_X*?$O_S3T?\ #@'_
M ((X?](^_@!_X*?$O_S3T ?KU_:-A_S^VG_@5;__ !VC^T;#_G]M/_ JW_\
MCM?D+_PX!_X(X?\ 2/OX ?\ @I\2_P#S3T?\. ?^".'_ $C[^ '_ (*?$O\
M\T] 'Z]?VC8?\_MI_P"!5O\ _':!J6GGD7MF1SR+JW/0X/\ RU['@^]?D*?^
M" /_ 1P_P"D?7P ZC_F$^)?7G_F9Z^=OV6_^"#W_!*WQ'\*]3U/XE?\$^_@
M]_PDP^.'[4>EVR^)/#OC*QU&+P9H/[3GQ?T+X:P00:CXAANVT.W^'&F^%(/#
M%TRR0WWAJ/2+VUN;RTN(+N8 _H#_ +1L/^?VT_\ JW_ /CM']HV'_/[:?\
M@5;_ /QVOR%_X< _\$</^D??P _\%/B7_P":>C_AP#_P1P_Z1]_ #_P4^)?_
M )IZ /UZ_M&P_P"?VT_\"K?_ ..T?VC8?\_MI_X%6_\ \=K\A?\ AP#_ ,$<
M/^D??P _\%/B7_YIZ/\ AP#_ ,$</^D??P _\%/B7_YIZ /UZ_M&P_Y_;3_P
M*M__ ([1_:-A_P _MI_X%6__ ,=K\A?^' /_ 1P_P"D??P _P#!3XE_^:>C
M_AP#_P $</\ I'W\ /\ P4^)?_FGH _7K^T;#_G]M/\ P*M__CM']HV'_/[:
M?^!5O_\ ':_(7_AP#_P1P_Z1]_ #_P %/B7_ .:>C_AP#_P1P_Z1]_ #_P %
M/B7_ .:>@#]>O[1L/^?VT_\ JW_ /CM']HV'_/[:?\ @5;_ /QVOR%_X< _
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M'Z@\4 #@ # ] !TI:^2?CO^TSKOP<^-'[+GPHLOA'XC\3Z)^T/\5Y?
MAIK/Q2DUG0]%\&?#R;_A6GQ5^(6G6PM9KNX\3>+O%FMGX875G;:'I&AQ:-I6
MD7-SKVO^)].EBT?1M> /K:@C/'\B1^HYK\Z-4_;7\?\ PW^+U[X*^-_P;T/P
M7X6U7X5?M(?&KPROAKXD1>-?B5X5^&G[-^I:/:2^,/B_X6L?#UOX9\-:%\6-
M-UW3]0\&W?AWQCXA.@ZY<67@;7TN_$$^IR:$:;^V/\5])_:#^ ?P5^)OPA\
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M\+>&E^'O@'1+[4MFFV,EWXHL-,?QWX^U+PEI,WB&>6RL+&YT72-3\0 ^V:/
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M >\/::;O]G+X$?'[QO_ ,+I^)47PYT7X,:9\;K/Q7XCO/\ A9.HP>'M8O/L
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M ,1O 7@B*ZCM_!EA<?#R*77]=34/%-EI=E[W!^T_XBG_ &O_ 1^S%<_!;Q9
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M_P"R+^R%\./V-_!OQ \$?#6[UV\TGX@?&GXI_&:^;7]8US6;JRU#XE^*;SQ
M-#M[G7=;URYDL?#ME/:Z':7C7$=[J\-BFK:V;O7+S4+^Y^L*** "BBB@ HHH
MH *^6/B-^S7>>+OB]KOQQ\)_$_Q!\._B'=?LP_$7]G3PMJNE^'_#FO0>#KWQ
MQXMT'QIIOQ.LK'7H)[75?$?A#7/#UA/IFAZO%/X;U%5,>K6T\1:-OJ>B@#\Y
M_P!FC]A/Q%\";'X7^'_$?QIL/B%X5^$_C?7?B=I-C;?"/2_!OB'QC\3?$W@?
MQ=X,\0_$KXI^-&\;>+M=^(GC_P 1R^-]?\6>)/%FMO\ VOK/BRZ34YIXUMK6
M"W]/^$/[*>O>!?BU8?
?'/QG\;O$_@WX6:_\ !'X::AXL\,>"_#^M:1\-
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MXRF\%36SW<GCR_GNY/%C^#_+\$I]\ !0 .@ ^@X%+10 4444 %%%% "$!A@
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MN6W/?3FORZ'S3K7_ 41^#>E?$?6_A98>#/CCXL\5:/\7_$O[/5NWA+X4ZIJ
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M F0BBCN"9I_[!FTD>6$X3O/0;+_ (*/_LY77@[X@>,[A_B)I-K\+/@-\4?V
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MX8S=ZGJWA/0-1U"Z,,201&XO;S3YKF<Q011PQF65RD4:1KA$51G?\*:^$/\
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M2^(M=\%^%YM9UA[92IO]2F_LV0RW<PP97+L689)))K[O//\ B$/^K>1_V/\
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MBK5]>@U#X6?"3XZ6>GS_ @\ >*-"L-&T>U\[QYJ6N:OJ6L^/O#%S'X,M_"B
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M^#_&MYX4\*^&++3_ ]X(?PN 7-1_P""G7P%@\9:IX&T/P9\??&FLVWCKXR?
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M)?/?CC_P4GC^%%UX-FT7X/\ Q)\57_B[2_A(X^$&H> /$GA/XO:9-\2_VQ/
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M 51\4Z9HG[7%CXD^$V@^'?'WP._:)UCP-\&;2Z\1:M<^%_CM\"O#W[57@']
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M\/\ ]I/X!^+?A!X;U#7_ SX'^+OP[\=Z+I.N?$3POK-[;KX3\:?%7X5Z)IG
MA'PSXA2RNO"]QXZ\)>)='\3Q?8^C_P#!-+]G?0++X<:_HVE0:;\=_A_\;(OC
MY<?M.6/A'X?6/QW\<>.=:\=>(/%_Q2A\:^-;#PM:WNK>&OB[I'C7QU\/?%_A
M])(;.U\#>*)=,\.C2;G1]#N[#D/&O_!-'2/BEX-?X??%G]HCXR?$GPUX7^"_
MQO\ @E\'K_Q18?#>[\?_ XT'X[?"C7_ (*^(]>U7XDCP@/%OQ2\4:'\._$-
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M$\76B_%7XP?"3X[VGQ"\3^/M,^'R^,?BC\7_ #\2?@IX#U7POX\^)NJ^)X;
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M_CCQ]K/C#]E_XC>&?B9X9EM?B7XA^']UXO\ W@SQUXC\+VE]\2/AW\-KOP?
MX:U6\N]3ET!/#EEJFJZ7?@'UY^Q[\;]8_:3_ &8/@9\>/$&@Z;X7UOXK_#CP
M[XUU3P]H]W=W^F:/>ZS;M-/I]C>7\<-[<V]NZE(Y;F))G&2Z@U])5XQ^SM\$
M]!_9Q^!_PO\ @5X8U?6=>\/_ L\'Z3X-TC6?$/V ZWJ5CI$;1PW>J'2[2PT
MXWDH8F7['96T&1\D2]*]GH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
1HH **** "BBB@ HHHH __]D!
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>17
<FILENAME>immu20170630x10k002a01.jpg
<TEXT>
begin 644 immu20170630x10k002a01.jpg
M_]C_X 02D9)1@ ! 0$ 8 !@ #_X0!:17AI9@ 34T *@ @ !0,! 4
M ! 2@,# $ ! %$0 $ ! 0 %$1 0 ! .Q%$2
M 0 ! .Q 8:@ "QC__; $, " 8&!P8%" <'!PD)" H,% T,
M"PL,&1(3#Q0=&A\>'1H<'" D+B<@(BPC'!PH-RDL,#$T-#0?)SD].#(\+C,T
M,O_; $,!"0D)# L,& T-&#(A'"$R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,O_ !$( 94$*@,!(@ "$0$#$0'_
MQ ? !!0$! 0$! 0 0(#! 4&!P@)"@O_Q "U$ " 0,# @0#
M!04$! 7T! @, !!$%$B$Q008346$'(G$4,H&1H0@C0K'!%5+1\"0S8G*"
M"0H6%Q@9&B4F)R@I*C0U-C<X.3I#1$5&1TA)2E-455976%E:8V1E9F=H:6IS
M='5V=WAY>H.$A8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$
MQ<;'R,G*TM/4U=;7V-G:X>+CY.7FY^CIZO'R\_3U]O?X^?K_Q ? 0 # 0$!
M 0$! 0$! 0(#! 4&!P@)"@O_Q "U$0 " 0($! ,$!P4$! ! G<
M 0(#$00%(3$&$D%1!V%Q$R(R@0@40I&AL<$)(S-2\!5B<M$*%B0TX27Q%Q@9
M&B8G*"DJ-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U=G=X>7J"
M@X2%AH>(B8J2DY25EI>8F9JBHZ2EIJ>HJ:JRL[2UMK>XN;K"P\3%QL?(R<K2
MT]35UM?8V=KBX^3EYN?HZ>KR\_3U]O?X^?K_V@ , P$ A$#$0 _ /?Z*CN)
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M4'(Q0!IT444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% #)HDG@DAD&4D4JP]B,5\R:]\*/''@O6;S4_"CW,MI@E
M)K&7;,$8_<* [F(XZ U](:S!-=:)?6]N,S20.D8SC+$''->&Z1XU^*G@VW_L
M?5?"5[JYA51%*L;R;5YX,D88-V[\8H 9\-_B]XC_ .$KM?#'BB-I?,86P>6/
MRYH7 Q\_<DXYSSFN9/AAO%_QTUG1?MTEE%--,99(QEBH7.,>^*ZKP5X(\3^+
M?B-_PG/B6P;3+=9O.2"1=KNR_*J[#\P ') S[YJ;PEH>KP?M#:EJ,^E7T=B
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MXD:OXRT+6[:ZTC0FUK0Y8/*N;01^9E\GLN6''?&*\LTSP3KOC;QW87UOX/\
M^$7T^T:(W \IHE&UBVY0P!9CTX''&: )+6U'Q4^.-Y9ZW<2MI]NTWEQ*Q&(X
MS@*/3/4FEOK0?"GXXZ?:Z'<2I87)A\R%F)S'(VUE/KTR/?'I6OK_ (5\5?#K
MXF2^+/#NERZM8W3NQBA0NPW\LC*H)'/1@,4:%X7\5_$?XFV_BSQ#I4NDV%G(
MC"*="C'RSE456 8Y/))&.M %.?\ Y.GC_P"OP?\ HJG>,_\ DY;1O^OJT_\
M0JO3Z#K)_:4CU,:3?G3Q=!OM7V9_*QY6,[\8QGWJ'XQ>%O$]M\1+/Q3H.GW5
MTH$;1O:Q&5HY4.>5 ) Z>U #/C[_ ,E$\-_]<$_]&FJGQ_7?XJ\/KDKNM0,C
MJ/F%9'B?2?B-XAU[0]5\0:/>32.D91;:T8B&/?GYPH(4]3@\^M=1\;] US5/
M$VA2Z9H]]>K'; ,T%N[JK9'!(&!^- %/XQ_#+1?"'AZSUK1C<QS&Z$4QEF+E
MRP)#9/0@J?SJG\4=3GUGX6>";^Y8M/*C;V/<@8S^E6?%U]\0OBE/8:$_A*ZT
MN!)BSM)$XC+=-S.P P!GIUSQ6M\7_!NH6O@OPMHNCV%[J L 8V-M TA^[U.T
M'&30!'\8O^2-^#?]RW_]$4OCG_DW#PY_N6_\JO?%;1-6O_A-X3M+/2[VYN84
M@\V&&W9WCQ#@[E R.>.:/&>B:M<_ #0-/@TN]EO8T@$EM';LTB8'.5 R* ,'
M7=&LKS]FK0=4F1C=6.X0,&( WS$-D=^!6S\(?AMX<UGP59Z]=6TK:D[3)O\
M-;9U*CY>G2M6#PCJVL_LY6NA1VDL.J+'O6WG4QMN68M@AL8R/7VK(^$6O^+]
M#_L[PG>>$+V.P,[[KV:WE3RPQ).?EQU]Z ,+X7:\WP_U[QAHE^^T6]O+-'N_
MBDBSC'^\#FNC_9XT21K;5O$MR"7NI/)B=N20#EC^9Q^%<;\?]"73O'L5_ 0?
M[3A#LB]=Z_*>/<;?UKZ \ :#_P (WX&TG3"@66. -,!_ST;EOU)H Z6BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MN0\+>/+;Q/XCUS1XK5XFTN78)"V1(,XSCMS77T %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110!Y/XE^%VM>*/BE9^(KV^L?[(M)(O+MP7\S8GS8(
MVXR6SWZ5ZQ110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !17G
M'Q!^*D7A6]CT/2+)]3UZ8 K @.V,'INQR3WP.W<5SD&H?'&\3SCI^EVP;D1R
M C_ ,>- 'M5%>->=\</^>&C_P"?QH\[XX?\\-'_ ,_C0![+17C7G?'#_GAH
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M,$#Z@DCZD4 >Y45A^$_%>F>,="BU73)"8V^5XWX>)^ZL/6MR@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M@CKBNV\ ?\D^\/\ _7A#_P"@B@#HZ*** "BBB@ HHHH **** "BBB@ HHHH
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 (2 "2< =2:XJ^^*GA
MNTNI((C>WWE':\EG;&5%/<;J/BOJ-S8> KJ&SD,=S?RQ62.#@CS'"MCWV[JZ
M;1=(LM"TBVTZP@2&WAC"JJ@#/'4^I]Z &Z'K^F>(].6_TJ[2YMR<$KU4]P1U
M!K2KS2<VOA#XQV8@,=K8:_9R?:(A\J>=&1M?'0$YQ^->E@@C(Y!H 9,VR"1_
M[JD_I61X.B\CP3H,.,>7IUNN ?2-15_57\O2+Q_[L#G]#4>B1^5H.GQ_W;:-
M>GHHH OT444 %%%)O7?LW#>1G;GG% "T444 %%%% !7/.EY;>-+;&JW<EM=0
MRLUFXC\I-NT KA0W4]V-=#6!<N#X_P!,B[_V;=2?E) /_9J -^BBB@ HHHH
M**** "N*UC2+^X^+'AS58K9VL;6SN$FF&,(S#@?C7:UY9\2O$NO^'_&>AR:0
MTDMI%;2W-[:J ?,B4C<?J!GI0!W?BRTGU#P?K5G:QF2XGL9HHD'\3,A 'YU'
MX,L[C3_!6BV=W$T-Q!9Q1R1MU5@H!!J#6];2X^'6I:WI-S\K:;+<6TR]1^[)
M!^HJ;P7=SWW@G1+NZE:6XFLHGDD;JS%1DT ;M%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%<I\2KJXLOAWK5S:S20SQVY9)(V*LI]B*
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MG/&:Z155$5$4*JC & !61H%O*T<VJ72E;J^(<J3_JXQ]Q?P'\ZV* "BBB@#
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M:/QFZ6/_ B.KV>GG+>>;EHQN],;U/Z4 =W16?83R6VC6)U6ZA^U&%!-(7 5
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M JC IU '/:QJ]I>^"M7O+64,J6<Q8$<H0AR".Q%;=JGEVD*?W8U'Z5RWQ T
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M[R_(R+:'DCT+'^%<]S7/1:3<ZOXPD?771T2R!%E 2(E#-T?_ )Z=#D'Y3Z4
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MVT\:';^++I/#X!3[.8(S*(S_ "3&0.WKB@#L-(O;6]\.V5[IB%K66V1[="<
M';M^4'/0]JH_VOK_ /T+8_\ U?_ (FM>PLK?3=/M[&TC$=O;QK%&@[*!@58
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M,GOM(TE])NU@UC1BKV<\@RK$#!5AZ,* .RKQB,LFG?%>! !:I/(R[0 Q3YA
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MUIIL'DVD"1*3N8@<NW=F/4D^IYK,LVW^-]67_GG9VW_CS2__ !-;M<]IL?\
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MV586F$?VQKS=A(@S_P H K>$;&.[T73-=OF:[U2ZM8YGN)N=A902$'1![*!
MFNFK#\& CP1H0(P180Y'_ !6Y0 4444 %4;O1=+OKZWOKO3[6>ZMO]3-+$K/
M'_ND]*O44 %%%% !1110 4444 %%%% !1110 50UG3SJ6FO%&P2X0B6WD/\
M!(O*GZ=C[$BK]% %'2-0&IZ;%<[2DGW98R,%''# CMS5ZL'']C^) 1\MGJ9Y
M]$G Z^@W#\SBFW^CZU=7TLUIXLNK.!B-ENEI;N$X]60D^O)[T =!17+?\(_X
MC_Z'B]_\ +7_ .(J:/1O$$:;6\63RG^\]G #^B@4 ='6)JY_M/4;?14YB(%Q
M>X[1 _*A_P!]AT[JKU/$TVCZ9<7&J:D;L1@N9&C5,#T^4"FZ#:316LE[=J1>
MWK^=*#G*#HJ<]-JXX]2Q[T :W08%%%% !1110 4444 %%%% '#6O@K7=/U#4
MKRR\4-'+?W!FE9K.)V]%7<5SM4< =J[6!)([>-)I/-D50&? &X^N!4E% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5G:_;7E[X
M>U&UT^8PWLMNZ02*Q4JY!P<CISWK1HH \$N_#WQPU326T>]U"V^Q3((96$D(
M<IQG+ ;C[\Y//K7I7PX\!P^ ?#[6(G%Q=SOYEQ,!@,W0 #T%=C10 4444 %%
M%% !1110 4444 %%%% !1110!XA+I'QNLI[JWT[4H)+(S.8FFDB=]I)Q\S@L
M./?BM_X5?"^X\&S76LZQ="YUB\3:V#N$8)RV6_B8GJ?:O4** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** *VHO=Q:7=R6$:RWBPNT$;'
M9P#M!^IQ53PZEJN@VCVDAECE3S#*WWI&;EF/N3FM2L+3O^)5KMUIC<071:ZM
M23W/^L3\#S@= : -VBBB@ HHHH **** "BBB@ HHHH **** "BBB@!&&Y2IS
MR,<&LW2M#M-(FNI;=[F22Y*F1KB=Y3QG &XG &3P/6M.B@#D/%+-K'B#2?#"
MLP@ES>7V/XH4/RH?9F_]!KKE4*H50 H& .E45T>U37I=9 <W<ELML26X"*Q
M88';EC5^@ HHHH **** "BBB@ HHHH *YF/_ )*?<_\ 8&A_]'25TU<-JGCC
MP3HGBF>XNM77^TA;K;2K"&E"*K%@#M! .6/6@#>\+?\ (*F_Z^IO_0S6W63X
M<NM)O-(6XT6[CNK25VD$D;[OF)R0?0\]*UJ "BBB@ HHHH **** "BBB@ HH
MHH *Y_3O^/WQ%_UV'_HL5T%<P=;\-:9J5_;3^(M/CNKR3+0R7"!D(4#&,_SH
M T/"O_(I:/\ ]><7_H K7JII5I'8:19V<4OFQP0I&DG]X U;H **** "BB
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M-S=R3G3FB61MTD$4K)$Y]U'%=I10!7L;"TTRSBL[&WCM[:(;4BC7"J*L444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !117GGQH%R_
M@(16D[P3RWUO&LB,5()?':@#T.LV_P!.DU"_M/-9/L5NWFM'U,D@^[GV'7WK
M$\ ^([C6-*FT_5 (];TJ3[+?1]R1]V0>S#G\ZR?A5-+-_P )3YLLDFW69E7>
MY; ]!GH* /0Z*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MW9_Y]Y3_ _[K=O1N.XQMUB-J%O?^&KJ]U&#;8NK,J<[FC_A(_VCU&.>5[U;
MT-;Y-%M5U)@UWY8\S'4>Q/<^I&/I0!H4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110!!<(EU;3VX=270H><XR,5CW.B2S:)I=D]U''):75O,SD<.(W#%1]0,
M5Y7'J>H>%OBAXC\2^87T/^T$L=1B_P">0:-2DOT!)S]376?%:4/;^%7B?*/K
M,!!4\,#0!Z/1110 5AZPS:E?0Z)$2(W EO&4XQ$#POU8\<=JT]0OHM-L)KN;
M)2)<[5&2QZ!1ZDG ]36(K3Z+I$ES*JRZQJ$H^4<9D;A5'^RHXY["@">0+JV
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M@ 8_@% &+X?\8:G_ ,)%_P (UXJL(;'59(S+:RP,3#=(.NTGHP[BNVKSWXE
M1ZUX(N(@!=#7(HU(ZE&!WCZ8ZUZ%0 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M+>ZG;6%D+J=G\ML!0D;.S$] 37F?C;Q)#XJ^ NJ:E&OES;(X[F$]895E0,
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH *X'2?^2W>(O^P7;?S-=]7*6GB+S?B7J'A_[%"OD6
M4<YN1]]\_P )]A0!YC\8]+O/"MGK%SIL)?1_$*HEW$.D-RKJPD'LP4@^]>YV
MO_'G#_US7^58'C_6E\.^"M0U=K*&\^S!&$$P^5LNH_K710OYD$;XQN4' [<4
M /HHHH **** $.,'(R*Y_P %VT-MX>Q#$D8>\NG(10.MQ)C\A@?A70/PC'VK
M'\*C_BG+4_WC(WYNQ_K0!LT444 %%%% !6?JVFVNH6I:=662(%HYHSMDC(YR
MI_R/45H55U)_+TN[?^["Y_\ '30!6\.7$]WX9TNYNI/,N);2)Y7QC<Q4$G\Z
MTZS]"3R_#^G)_=MHQ_XZ*T* "BBB@ J"[M(+ZUDMKA-\;C!']0>Q]ZGHH Y3
M5-133=)GL=:2:Y=-@MY8L![C<ZHI!/ D5F7/YCJ0)K2#Q;<VT<=U<V%CMX9D
M1IWD7UYVA&_[ZI/'=NL_AQ"4#/'?V;(3V_TF,']":Z:@#!B\)6!D26_GN]2G
M0DK)=2YQGMM7 Q]0:V8+>"UB$=O#'#&.BQJ%'Y"I:* ,VXO9+76(;>X"&SNU
M\N)\?=E&3M;V8=/=<<Y%5=*)TJ_?19,^1@R6+DYS'WC^J_RQ6EJ-C'J5A+:R
MLRAQ\KI]Y&'*L/<'!'TK&"S:WIC0R;8=9T^3[V, 2#HP_P!AAS]#STH Z.BJ
M6EZ@NI6*3[/+D!*2Q9R8W'5?\]L&KM !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !144]Q!:PF:XFCAB'5Y&"@?B:+>Y@NXA+;3QS1DX#
MQN&!_$4 2T444 %%%(2%4LQ &23VH 6BJ]K?V=[N^R7<%QL^]Y4@?;]<58H
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M.?'?PEIOAC2;"\_M-[JVLH89F$ 8%U0!CDMSR#S0![317E/_ T)X)_NZI_X
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M]*J:SX8A^'GQGT6QTFZN'B6:WEC>9@7^9L$' (_#O0!UWC_ .*6I:;\5+6P
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MW%=6LGW9(SD'_"OF+X?_ ZM/&G@35]4O]2OD?33(MI!&X\M2$WG((/!)[8K
M0^$>O7NA^ /&UQ;O\UK;B:$'D+)@@'^7Y4 >[:OX_P#"F@WQLM3URUM[D#<8
MR2Q')'. <<@\5JV>MZ9J&E#5+.]AGL2GF><C9&WU]J^0O"VHZ%%9WDFN>$+[
MQ!=SRD_:ENW0)QS]U3ELDDDD]OQ[?X,W%_;#Q5I[6US!I\MC).B2J?E8<#G
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M\&7^AW%N^YG$\DP?'(/S+D$'WH ^KM:\8>'_ [=P6NKZI#:3W S$D@.6YQV
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M@B2WM[U1^[E"J W]QL#IT.">.E=+3)H8KB%X9XDEB<;71U#*P]"#UH >"",
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M;-% &-_PB/AK_H7=)_\ */_ .)H_P"$1\-?]"[I/_@%'_\ $ULT4 8W_"(^
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MXK=^%]=?]G&UT)=+N#JJGYK0+\X_?L>GT.:Y32O^%K^'_!!\+V/A9EMIE?\
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M?+ Y)((Z'GKFOHZB@#P7XG>"O%5O\2;3QAX;L#?;6C=40;BDB?WA_=-:/BS
M1/&/Q(^%JOJ6D16.N6EZ94M%4IYD03'&2?F.>.>U>TT4 >"^'+3XA:WX0G\$
M:OH0L-/73WBM[R2)E;>H^16.[&#TZ5A^%M-^)_AS0-3\,6'A6$0W@F\V[GB.
M[[A&%8, >!\N0>6]Z^EJ* /"?A1\/M3/A/Q+HOB/3KFPCU *JF1<'IU'T-96
M@:=\4_A;/>:5I.B1:O8ROYBMY;/'GIN&&4@D 9!SVKZ+HH \%\6>'?'>O_"Q
M5U6RFN]8N=1%S]GBY,,97A=O\..F*Z/5/#VL3?L]1Z)'IT[:H+:-#:@?.")
M2,?3FO5Z* /"=,\)>((?V?;[1)-)N5U-YV9;4K\Y&\'./I6KX8\-:U:? +5=
M%N--N(]2EBN%2V9?G8L.,#WKV&B@#QWX1>&M:T3X=>(+'4]-N+6ZGDE,44BX
M9\Q #'X\5E?"#P%JL.D^)]+\1:9=6-OJ, A!D4 D$$''N,U[O10!\\:+I'Q1
M^%5S=:;HNEPZUIT[F5"(RZ ]-W# JQ"C(R1TKL?"W_"P]<.MZEXIM?LMM+8R
M06FGI\NU^.0G).?4DUZM10!X[\!/#6M>'++6DUG3;BR::2(QB9<;@ V<?G65
M\(_".OZ-\0]8O=4TBZM;6:.0)+(N%;+Y'Z5[O10!\W1^&?B!\._B)JFJ>']#
M&IQ77F;&V%XS&[[@#@@AA@=Z^@]&N+R[T6RN-1MQ;WLD*M/"!@(Y'(ZGH:O4
M4 >1_%GX;ZOKNKV7BKPU,%U:Q49B)P6V$NC)VW \8/7(]*Q7\4?&K5K9-,C\
M-Q:?+-B,WP@*LGJQ+,5'UQ]*]VHH \$^*G@_Q-JVI^$VM=-N;][2U1+J:+YP
M'!7.2>O0\UN?'?PWK7B+1M&BT?39[V2&9VD6%<E05&,UZ_10!X;\0OAMJ_B'
MP#X=N;"V8ZKI=J(Y;4\.RD#('JP(''N:P?$B?%GQAX+32M1\-JL%K)%N*Q%9
MYR 0&QNP1ZX ZBOI"B@#D?ACIUYI/P[TBQU"VDMKJ*(B2*0893N/6NNHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ K,U#1H[J<7EM*UIJ"@ 7$0&6 _
MA<=&7KP>F3C!K3HH YX7/B6Y=K,6=O:,G$E]NWHP]8TZY^N0.^:O:=HEKI\I
MN27N;YAA[N<[I#TR ?X5X^ZN![5IT4 %%%% !4%Y9V]_;-;W4*2Q-@E6'0CH
M1Z$'D'M4]% &!YU]X>XG,M]I:CB;[TT _P!K^^H'\748))-27'B:U9A!I:'4
M[ME#+% ?E4$9!=NB@^IK;J*WM;>T1DMH(X49BY6- H+'J>.] &,FB7&I.)=>
MN%G7.5LH@5@7_>'5SC&=Q(R. *M:[H5IK^@W&CW&Z.UG38WE8! ]JU** (X8
MEAMXX1DJB!!GN ,5@>&O!.D^$[[4KG2UDC&H2^9)$3\J'T7T%='10 5BW7AC
M3Y97N;17L+MB6\^S8Q%F]74</_P(&MJB@#SAUUK4O#,.IZEJ4<L&G72386+R
MW=H;C#M)CY2-B,0 !R<]ACT8'*@CN,US-G8B\A\3Z'/M\J:5PB>D4L0'ZL)*
MU/#M\VI>'-.O64JTUNCLIZ@XY!H TZ*** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH PAMM?'3#!S?Z?DGM^Y< ?\ H\_E1X9W0Q:A8NP+
M6U], H_A1F+H/^^6%.\17NDZ.MKK6K:A'916;-AG8#S-RD;/?L<#GBLC0?'7
M@W4]8GCT[4$2]O75F$R-&9650HQN R< =* .RHHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@#SBTLX_%?Q<U>;452>S\/110VD#?,JS2
M#<TF/[P KI?&7AK3_$?AJ[M;J%=Z1M)!*!AHI ,AE/8Y%<Q<WZ^!?B=J%_J
MCF'0]?BBQ=L/W<-Q&"H5S_""IZFM;Q;X]T;3M!G2QOK?4=1N4,-I:6D@E>1V
M&!PN<#G.30!:^'.MS^(/ >EW]VQ:Z,9CF;'5E)4G\<5U-<WX"T*7PWX(TO2[
M@ 7,<6Z;']]B6/ZG'X5TE !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 07=G;7]J]M=P1SP2##QR+D$?2L[3?"N@:/<&?3M(M+:8C&^., T
M44 ;%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
..444 %%%% !1110!__]D!
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>18
<FILENAME>immu20170630x10k003a01.jpg
<TEXT>
begin 644 immu20170630x10k003a01.jpg
M_]C_X 02D9)1@ ! $ 8 !@ #_X0!V17AI9@ 34T *@ @ 8=I 0
M ! &@ 9*& < ! + !53DE#3T1% !, $4 00!$
M " 5 !E &, : !N &\ ; !O &< :0!E ', ( !) &X 8P N " 5@ Q "X
M, Q #__@ ?3$5!1"!496-H;F]L;V=I97,@26YC+B!6,2XP,0#_VP!# 4%
M!0@%" P'!PP,"0D)# T,# P,#0T-#0T-#0T-#0T-#0T-#0T-#0T-#0T-#0T-
M#0T-#0T-#0T-#0T-#0T-#0W_VP!# 04(" H'"@P'!PP-# H,#0T-#0T-#0T-
M#0T-#0T-#0T-#0T-#0T-#0T-#0T-#0T-#0T-#0T-#0T-#0T-#0T-#0W_P 1
M" #- M<# 1$ A$! Q$!_\0 'P 04! 0$! 0$ $" P0%!@<(
M"0H+_\0 M1 @$# P($ P4%! 0 %] 0(# 01!1(A,4$&$U%A!R)Q%#*!
MD:$((T*QP152T? D,V)R@@D*%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I3
M5%565UA96F-D969G:&EJ<W1U=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6F
MIZBIJK*SM+6VM[BYNL+#Q,7&Q\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T
M]?;W^/GZ_\0 'P$ P$! 0$! 0$! 0 $" P0%!@<("0H+_\0 M1$
M @$"! 0#! <%! 0 0)W $" Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S
M4O 58G+1"A8D-.$E\1<8&1HF)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC
M9&5F9VAI:G-T=79W>'EZ@H.$A8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.T
MM;:WN+FZPL/$Q<;'R,G*TM/4U=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H
M# ,! (1 Q$ /P#[+H * "@ H * "@ H * "@ H * "@ H S[W4X;#".2TK_
M .KAC&Z5_P#=0<X'=CA%ZLRCF@"[$S.BLZF-B 2I()4D<J2I()'3()'H30 ^
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@"I>7\&GH'G8+N.%4 EW;LJ(H+.Q[*H)]J '6D[W$8D>-H"<X1]N[&
M>"0I8 D<XSD=#@Y% %F@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * (IIX[9&EF98XT&69B H'J2>!0!B_:[O5
M.+(&VMS_ ,O$J_O&'_3&%N@/:28 =UB=<&@#0L=,@T_)C!:1_ORN2TLA]7<\
MGV4851PJJ,"@"_0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % 3CDT 8']IS:E\NEJ#&>#=2 ^2/\ KDN5:<^ZE8L_
M\M"05H N6>E16CF=BT]RPPTTN"^/[JX 6-/]B,*O<@G)(!IT % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 <
M[XL'_$LF^L7_ *.CH Z*@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H 9*-R,/4'^5 &1X:;?I-DW3-I;G\X4H
M VJ "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@!"0HR
M> /6@!: G')X H @DNH8$$DCHB-@!F8!26^Z 20#GMCKVH GH * "@ H *
M,'Q/_P @V;Z)_P"C$H OZE=364#2VT#WDJXQ#&T:,V2 2&E9$&!R<L,XXR:
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M]G2V,5_#"SLXMI#/)!+'$7+,L4N%D6/.U&#[ 2* .F\9:>NI:/=0.\L:>1*
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M;E)! 8=02#@\XH \3TVRCMM-M=/ +V?_ DMU%*LC-)NC6YO&02LY)DW3)%G
M>3O? .<XH [WP>BVTFIV\ 5+2#476!5P$0&"W>94 X51<-+E0 %8L * -=O$
M$.=T$<MQ;ID23Q+NC3Z<[Y0/XC"L@7^(CG !L6]Q'=1B:!EDC<95E((/;@CW
MX/H>#0!-0 4 4+[4H;#"R$M*^?+B0;I7_P!U!S@=V.$7J[*.: ,7PG.+?3[7
M3+@&"\M+6"*2%\!LQQJC,A!*R1Y'#QLR\@$AL@ #O"=A/9VLDUZACO+RYGN)
MP2&(+R%8ERI88C@6)% )P% XH Z>@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H H:K8C5+.>Q+%!<PRPE@,E1(C)N XR1NSC(S0!S^H>$DO\
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M+SPP W(W. ZD\<.C@ Y^U9[23R;/\ T2?DFPG/[F0=2;6500HZG]V&51_K
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M "@ H * "@#AK&ZDM);2&'"1W6H7ZR */F4+=RCMP?,16)&"<8/!- '<T %
M%:[LX;Z/RKA!(F<X/8CHRD8*L.S*01V- '/WUN+>\TR/+2>7+. \AW/C[+-U
M8C).."3R<?,2<D@'4T % !0!GPZ7#;3-/!F+S,^9&IQ$['^-H\;0_JR[2V?G
M+<8 ,WPE!';Z3:K$JQJ8E.$4*,GDG &2>2>I/)H Z*@ H YH:A8:'?QZ;+<
M)%+J9DDM;9@02Z#=<>6WW<'<)-AP=Q<KD'"@&J-5M?MITOS!]K$ N?*PV?)+
MF,/G&W&\%<9W=\8YH T* "@#SOXAJUQ912VRM<-I-_8W\\,2EY&A@F#R!5 .
MYP@,JQCYFV# ^89 ,+QOXGTSQ5I+:)HMQ%?WVJF**&*W82/$#(C-/.!DP1P(
M"[M*%(*A0-Y H ]A'% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 <+JMW)I\U[<6
MY"2>9ID9; )P\ZHX.0<YCD(!ZC.1@C- '=4 % #)(TF4QR*'1@0RL 00>H(/
M!![@T <QJ^GQ65AY$6XQFYM2J.Q<)BY@^5-V2JC&57.%)^7 P =50 4 % %
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MV(.TN<$)'G)();"*QH CTZ#SBK0EDM(R64Y.^YD/WI9&X)3/(_YZ'YO]6$!
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MU'E(=^]E .B\E _F;5WXQNP-V/3/7% $E !0 4 % !0 4 % !0 4 % !0 4
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MGM0!V<4R3KOB974]"I!'YC(H JWMY]E"I&OF3R9$<><9(ZLQ_A1<Y=NW +%
M5(!%%I<?FQ7EP%EO(4DC6;&TJLK*TB* <!"43&<MA1DDY) $CT2QAOWU9(46
M^FB6"2<##O$C;E1N<$ ]#C.,#. #4H X_6M(M8KNUO%C6/S)O(N#&JH98Y
M481I,P 9T$XB 0GEF ^Z6! .P QP* "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@#C;V*+[5<07I:"*ZEM9(ICCRV: HVPORJ,7C "OM+@_)N/0 [*@ H S+W
M58;-Q TUPPRL$0#2$>IR0L:?[<C(G^UGB@#GM5U*0Q+!,HDNA/!*T%J&F:*
M%98V+2D = &.=J[\;8U<CD ZRUNX;V,36[K(A[J>A'4$=58'AE(#*>" : +%
M #)94@0R2LJ(@RS,0JJ!U))P /<T 8?]M&7]^BK%8IR]S.3&''80H<,P)Q^\
M?:I_@$F> #(TK6H;-KEKE+B".:Z>2.22WE".C*@5MP4[0=I/[S80.2 "* .L
MM+ZWOD\RUECG0]&C=7'YJ2* %N[M+*/S),G)"JJC+.Q^ZB#NS=AT R20H) !
M133OMHCEU%4>6*87$2=5@<(R+M88+,JNX9SP2S8 7: 2W&CV=U=P:C-"CW=
MF)!!,1\\8E7;(%;KAUX(Z?C0!I4 <EXKTZ!K<7^T1S6<D<IF0!91"' N%60#
M> T#2# /7&,'! !U,,*6Z+%$ B( %4# '0 4 24 % !0!E:QKMAX>@^U:E/
M':Q9"AI#C<QZ*BC+.QZ[5!. 3CB@"MI?BG2M:MY+RPN8IX;<$S,K<Q *6/F*
M0'3Y03\RC(&10!;?6;*.Q.JM,@L1#]H,^?D\G;O\S/\ =V_-GTH T4=9%#J<
MJP!!'<'D'\J '4 % !0 4 % !0 4 % !0 4 5KNRAOH_)N$$B9S@]B.C*1@J
MP[,I##L: ,G;>Z3]W=?6P_A)'VF,>S'"S@>C%9<?Q2MU ,^^U2WOBJQW#M&P
MP;6W4BZD<$[EDY$D*+P&R(2ISOE"G:0"S;:1+<1B*<+9V@^[:6YQD?\ 3:9=
MI8GJR1;5)R&>5220#H8(([9!%"JQQH,*J@*H'H .!0!DMI!M7\W37%L2<O$1
MN@?)Y/E@CRW/]^(KD\NK\8 .5T[QYY_B6\\-W4/D)"46TN,DK<2"WCN)X6SP
MLJ)*KH/XT#D<H: -#2-3E\1F]=8H8KC3-0N+*"1PS@*BPDR[<@[V5R,*R@XQ
MN )% '0V>DQVK_:)"UQ<D8,TF"P!ZJ@ "Q)_L1A0>K;FRQ -0C/% &)-X<T^
M1BZQ""0Y^>!F@?)ZG="R')[DG- &'#.VB->,[-<-!-;$R3'+BTE\L$;@!GR3
MY[#CYL#>6<EB =O0 4 % &-XAA:?3YA'GS(T\V/ R?,A(ECP/[V]!CWQ0!J6
M\RW,23)RLBJZ_1@"/T- $M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % #)(TF4
MQR*'1@0RL 00>H(/!![@T 8?]GW&E_-IS>9".MK*QP/^N$IRT?LC[HNR^4,M
M0!5O-:AGC\OSVL9 V)8C'FZ.1PD*?-N+'I)&DH/\!SD@ ;9:=/*I2%3IULQR
MV#NO)C_>EE)?RR>A.Z2;'1XB!@ Z&SLH-/C\JW01KG)QU)/5F8Y9F/=F)8]S
M0!3NM(220W-LQM;DXS(@!#XZ"6,_+*,<9;#J/N.O6@#CM9\<R>'M;LM(OHE-
MK=V^Z:[0D)!,\HABWAB=L,LA$88DE79 QP<T :XU9M2UF\T1X8F2RM;2[C=\
MMF6=[E1N7H!&8%92/FR2>" : -BWTD>8MS>O]JN%.5)&V*(_],8LD*?]MB\I
M[OC !L4 95WH5C>OYLT$9EX_>*-DG'3]XFU^.WS4 8#6[:1>2"(R7#"SDFM
M5N)'F*O&V)E0L2YW^9""2S-CY5(7(H ZVUN%NX8YT^[*BN/HP##^= $] !0!
M!=6ZW<+P/]V5&0XZX8$''O@T 9^@7#7-A"S_ .L5/+DYSB6(F*49[XD1AGO0
M!KT % !0!YS,D<WC6,76#Y&DE[(-R!(]RRW;QY'^L$8MU8C+"-NP9L@&%XT5
M8-?4VH EGT/5/MNWJ88UA^S-)CN)6D6(L,X,@7@&@#BKS_A*?^%?/N_LK[!_
M8G./M?VCR?LO_?OS=G_ -WM0!]&:=_QZP_\ 7*/_ - % %R@ H * "@ H *
M"@ H * "@ H * (UA1':154.X 9@ &8#H">IQDXSTSQ0!)0 4 % 'D3^%)=<
MN-=C;?:2M?VMS8714CRYX;&V$<\9_B59%:.0#AE\R,]30!=^%::A]DU"?5K9
MK&ZN-5N96B8'',<"EXR?O1,RL48<%>YH ]0H * "@#EM6M%EO5B8E4U&UFM7
M('(9!YD3 ] 55I\=R2OI0!JZ+=F]L89GXD:,"09SB1?DD7/?;(K#/?% &I0
M4 9[Z@@F:)0"D(+3R$@)%QD*2>"Q'S$?PK\S$94, <WH^L1:5:);WB3P10[T
MBE:%O):!7(A8/'O$8\K8 LWEN<?=QS0!U=K>P7J^9;2),H."8V5@#Z':3@^H
M/(H LT % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % ##$C,)"JET!"L0-R@XR
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MD+;W==@8!03NH ZB@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@#-UFT-]93VZ9WO&VPC@AP,H0>Q#A2#V(!H S-#N[:\EENH)HS)<
MI TUN"!)%,J%6+J2'5F3RTVLJD",'G=0!TM &;>WC1L+:V >YD&0#]V->AED
MQSM!X500TC?*N &90#*MK07@:&)F-L6)N)S]^ZDZ,H88Q$,;69< @>3'A 30
M!TRJ$ 50%50 !@ #H .P'84 9][I%GJ&#<PQR,/NN5 =3C&4D&'0XXRK ^]
M %#^PY(>+2[N8$)Y1F69=O PIF5Y$('W2LF >2&Z4 ;%K:1648BA&U023U)+
M'DLS')9F/)8DDGJ: +% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
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MPNI[?T20BXB[?PS;I% P%CE11_=- %%OMLEVFGWODB*X21S-!OC>7RB@\AE
M;<4RLFXNLK%E5U"IUH ZM$6-0B *J@ # ' Z #@"@!U !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % #6=4(#$ L
M<+DXR<$X'J< G [ GM0 Z@ H * ,&^_T;4;2XZ"82VK=>K+Y\?MUA< GNP4<
MMR 2ZKK*:6T4(BFN9[DN(HH54L1&NYV9G9(T501DNZY+*JY)Q0!B2>.;+RT>
MWBN;DM%)/+'%&OF6\4+F*5IE=TPR2J\?EIOD9D?8K!2: .NM[B.[B2>%@\4J
MJZ,.C*P#*P]B""* .>\5Z^_A^U1K>,7%Y=SQ6EI$S%4>>8G;YC $K&BJ\DA
M)V(0OS$4 <K/J.N^#!#<ZJ]E>:9+/%!,+6W>U>S,[K%'(@,TRS0B5U60,(W
M8."<%2 >HT (Q(!(&3C@=,^U 'P_\9/BMXWL+EM-:UD\/V;L51XVWR7"^JW:
M_( PY*P[64<,QP: /=!XW\?8_P"13'_@XL__ (B@ _X3?Q]_T*8_\'%G_P#$
M4 '_ F_C[_H4Q_X.+/_ .(H /\ A-_'W_0IC_P<6?\ \10 ?\)OX^_Z%,?^
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M;CS?]K;0!W7[-30/::TUIM^SG5I#%L&%\LH-FT8&%VXP,# QQ0!],4 % !0
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M:I;YB>#3KJ*&%XCG<KVD$[;F#%21)(PXQ@ C(- '84 % !0 4 % !0 4 %
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MFJX/ RP)]Z /0Z "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@"M=VD=Y&8I,XR""#AE8<AD8<JRGD$?J"10!16XNH8I8W3S)X49HW P
MDW!V=/NN2,.G8G<ORD8 $M[NXO#%)& MM<6OF!L99)3L*@Y/(*L<#;U4Y/-
M''_$7Q')X,\-SZG+)NNTM_L\04 ++=3[8T8(5ZJ^9-HX"!\@CH ;6E>'+C2[
M*"WMKR>-X88HV$I%Q&65%4MMES(O0X6.5$&?N]* +_VC5;3_ %L$5VO]ZW?R
MI.O>&;Y, <DBXR3P$H SY?%D<G^CV\4Z7)F2!A-!(J0-)C:\CX\MA\RD+'(S
M-N7.U26 !TEG9I9(54EW8[G=OO.YZLQ&/H ,*J@*H"@"@"W0 4 % !0 4 %
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MT1!SMC3)V+GN68EV9B 7Z "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * #I0!\V?&K3]9\1:[H6DVMK.^DQWD,]S<*A:
M'S#*%"N5R%\N(.<N #YO!X- 'TG0 4 <5K%LWGWD,?#7-JEU%V'VBT?J2.3N
MQ; @?PICO0!UUK<+=PI/']R5%=<\'# ,/T- $] !0 4 % !0 4 % !0 4 %
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M6=W$<J^8)(WCV89=I!5L ]?H * .=U^:WTTP:I=S16L-HSB629@H,4J%3&"
M?XFE$+!1RQ3:.30!1\(:]I.I6_V/2[N.\-H,%02)$C+-Y>Y'P^ N%WXPQ!(Z
MXH ["@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M \F\0^*#X?\ %END_P!LEM9-)F/D6L,]R/-%U$!(T,*OC";E\PKQG;GF@#E[
MOQ_<+=Z[J-@+E!:Z?IXMH+R*:!4N)IIXA)Y$P0A2S1EWV@,$P3@4 =1K'@V7
M0M-FU:RO[]]6LH'N/.GNII(9WB4R-'+:LWV<0RX*E8XT,8(,;*5!H ](T?4!
MJUC;WZKL%U!%.%/51+&KX_#=B@#1H Q=>1!;"X>2. 6LD5P9)6"(JQN#)N<\
M*K1[T)]&(R,T 8/A;Q/HFI33VFF7L-R\DLEPD2Y5@K[6D*AL>:OFEY"Z9 #@
M'ID@'<4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0!S.CZ"^F:EJ6H,ZNNIRV\BH 08_)MHX"&.<'<4W C'!Q0!SA\ &6
MWOHGN/+GN=5;5;2>-<M;3 1"+*L<28,;+(O"O&[)QG- #IO#>M^()((M?GLQ
M8VLT<[0V<<H:[DA<20^<TSGRHTD5)6B3>6=0#)MR" >CT % 'FOB94F\4:)#
M> &UV7TD2L 4:]C2+R<@\>8D)N'BSR""5Y&0 'B]%AU[09K4 7KW4\3;<;FL
MC;2O<!^YC1UA89X639CYF&0#TJ@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H Y=] =O$$>NB11''8269BP=Q9YXY@^[., )MQC.
M3G- &7>^"(]4O]2N+QP]KJUE;V9C4$.GDF<F0/TSF4%,#Y67)S0!FW?AKQ)J
MUF=$U"^M38R+Y4]U%#(M[/#P&0J7,$,DJ9625-_4LD:$C !Z3! EK&D$*A(X
ME5$4=%50 H'L !0!+0!YQ\1467^RH;G'V"75K870;&Q@%E:!) >#&URL((/
M!;:,'.* &?$U$CLK*XA %_#J=@+(J/G\Q[B-)43'.U[8S>8OW2@.X8% 'I5
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0!DZUH5EX@M_LNH1B6,,'7ED>.1?NR1R(5>.1<G:Z,K#)&<$B
M@#.T?PAI^BW#7T8EN+QT\HW-U/+<SB/(/EJ\S,43(!*IM#$ MD@4 =/0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0!2U+3;;5[:2ROHTGMYEVO&XRK#.?P((!!&"K $$$ T <[IO@?3=,N$O!Y]
MS/;@B!KNYGN?LX(*D0"9W$9*DJ6 WE>-V"10!U] !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % 2 ,G@"@#XCLOVB]6F\6+;
MNT/]@R:@8 /*4,+=G\M7\SKD K*?;CI0!]K3W$5I&T\[K%%&"SN[!451U9F8
M@ #N20* ."MOBSX1O)_LD.JVC2DX \S:"?0.P"$\< ,<]LYH \F\)_'^+4O$
M=_IVL3Z?:Z1;>;]DN1YB--ME58\N\KHVZ,LWRHN<9&!Q0!T]WJFH2^-;?[/K
M]FFF3)%*NDY_?RQM;%MR?NCD.09E/F#Y1^% 'JFA>+-(\3&0:1=P7AMR!*(G
M#%"V<;AVSM./H: &Z7XOT;6IYK73[R"YFM 3.D;@F(*Q4E^R@,"#D]C0!@Q_
M%?PG+="Q35;,SEM@'F?*6SC DQY><\??H ]!H ^9OBQXVUGP_P"--"TK3KI[
M>SOGM1<1*J$2"2]\I\EE+#<GR\$<=.: /8M>^)/AOPQ<&RU74(+6Y4 M$Q8N
MH894E55B,CD9QQ0!NZ%XDTSQ-!]JTBYAO(0=I:%PVUO1AU4]\, 2.>E '/:O
M\3O"^@7)LM0U*U@N$.&C+[F0^C[ P0^H;!'?% 'D?Q!^/ \.ZUIUCHLVGW=A
M=^4UW,Q>0PH\J@LKQS(B_NB7^97P1R."* /<K+QEHFHV,NJVU[;26-N2LMP)
M%\J-@ 2&<D '#+QU.1CDT 9FB?$KPSXBN18Z9J-M<7+9VQ*Y5FQR=@<+OXY^
M7/&30!HWWC30],O?[+O+ZVM[S;O\F214<+L,FXAL #8I;)., F@"/P_XYT+Q
M5+)!H][!>2P#<Z1ME@N<;L$ E<\;ERN2!GD4 0:_\0O#OA:86NK7]O:SD ^6
MS9< ]"RH&90>Q8#CGI0!T.E:O9ZY;)>Z=-'=6TGW)8F#*?49'0CH0<$'@@4
M<9\4/'$?@+0KC40\:WA0I9QR'_63' "_P 6P'S&7(RJD9H \9^"6O\ B#Q7
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MH5LD?,2K 9)P>.* ))/B#X=AG-K)J-HDR1"=D:55(B:-9E<YQA3$RN/4,,=
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M 55L9550.P 'H* .>EU<?!3QOK<?\ J[34+*XGME_A,DBF>V ]EF\R 8Z
MGTH Q-/TN[\.?"V^UI-RW&OWL22R=&^R+(R8)ZXEE\P-C&Y7 /% $]G\/_$7
MB_PI9VFF:)I:P,J31:C'/&MW(<G>9&:3.7Y5T884C VC !]G^ +>]L_#UA;
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MC[[HZJ?,ZYDY)R* *?B72X/%GQ0TVSUF+S(KRTLVN(B67+?8FE*DJ5; =1D
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M_A3PYI^HS1R2&\OM1<Y9@WE,Z98&-2RD1A&R0-^U3D X7X7:G?:/X1\6-9.
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M[$M:J1@@G.,JZ)[$M$V>X- 'T#X=T.#PSIMMI-J7:"RB6%"Y!<JHQEB 2>^
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M@@CB@#N;WX56=[XMA\:-<3+<VRJJP!4\HA8GB&3C?T<G@]1Z4 '_ JNS'B[
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M*"<=SB@"S0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
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MQ$<4 ?2^L>!+/6/#/_")J[VUH;>&W#QA=ZK"8V! 8%26,8W$CG)/6@#A=4^
MVE:IX;M/#,EQ.#IKR26]UA/,4RL6=6081D.0,#:?E4AASD Q6_9RLKB2TN;W
M5=1N[FQ92))F5PRHR,D:(^_RHUVD85B3N))X& #K_B/\'-/^(=U!J+W$^GWU
MJH1)X,$E0Q=<@X(9&)*,K*1GG.!@ KWOP3TS6-!BT'5[FZOIK>66:*_D8?:4
M>4DMR=X9.@*-N!VJ>" 0 <WIG[/BVMU;S7VM:E?6UE+'-#;.V$#1.'0'<\B[
M05'"HAQT(H ^BZ /+)?A59R>+U\;FXF%T@"BWPGE<6QMNN-_W3NZ_>]J (/B
M%\(-.\?7$.I>=/INIVH"QW=L0'*J2RAQQDHQ)1E967.,D< J^ O@QI_@J_?
M6[BYN-6U212OVFY/*!@ Y5<L=[ ;2[.Q"Y48!.0#1^'_ ,*K/X>WE]?6EQ-<
M-J9#.LH0!,.[_+M )Y<CGL!0 0_"JS@\7OXV%Q,;F0;3!A/*'^CK;\'&_P"Z
MN[KU]J #P[\*[/PYXEO/%<-Q-)/J(E#PL$$:>;(DAVD -P4 &3T)S0 >!OA5
@9^!=4O\ 5[6XFGDU0L720(%3=*TORE0">6QSVH __]D!
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>19
<FILENAME>immupipeline21020.jpg
<TEXT>
begin 644 immupipeline21020.jpg
M_]C_X 02D9)1@ ! 0$ 8 !@ #_X2N 17AI9@ 34T *@ @ !@ + (
M F (8@$2 , ! $ $Q ( F (B $R ( 4 (KH=I
M 0 ! (PNH< < @, 5@ $48<Z@ @
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M %=I;F1O=W,@4&AO=&\@161I=&]R(#$P+C N,3 P
M,3$N,38S.#0 5VEN9&]W<R!0:&]T;R!%9&ET;W(@,3 N,"XQ,# Q,2XQ-C,X
M- R,#(P.C R.C$P(# Y.C4R.C,V &D , @ !0 !$<D 0 @ !0
M !$PDI$ @ ,Y,P DI( @ ,Y,P H $ P $ 0 ZAP !P
M" P D0 !SJ "
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M,C R,#HP,CHQ," P.3HU,3HQ,0 R,#(P.C R.C$P(# Y.C4Q.C$Q 8!
M P # 0 & !&@ % 0 $90!&P % 0 $9P!* # 0 "
M " 0 $ 0 $:0" @ $ 0 &=, 8 $ !@
M ?_8_]L 0P (!@8'!@4(!P<'"0D("@P4#0P+"PP9$A,/%!T:'QX=&AP<("0N
M)R B+",<'"@W*2PP,30T-!\G.3TX,CPN,S0R_]L 0P$)"0D,"PP8#0T8,B$<
M(3(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R_\ $0@ 5 $ P$A (1 0,1 ?_$ !\ $% 0$! 0$!
M ! @,$!08'" D*"__$ +40 (! P,"! ,%!00$ !?0$" P $$042(3%!
M!A-180<B<10R@9&A""-"L<$54M'P)#-B<H()"A87&!D:)28G*"DJ-#4V-S@Y
M.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@X2%AH>(B8J2DY25
MEI>8F9JBHZ2EIJ>HJ:JRL[2UMK>XN;K"P\3%QL?(R<K2T]35UM?8V=KAXN/D
MY>;GZ.GJ\?+S]/7V]_CY^O_$ !\! ,! 0$! 0$! 0$ ! @,$!08'
M" D*"__$ +41 (! @0$ P0'!00$ $"=P ! @,1! 4A,08205$'87$3(C*!
M"!1"D:&QP0DC,U+P%6)RT0H6)#3A)?$7&!D:)B<H*2HU-C<X.3I#1$5&1TA)
M2E-455976%E:8V1E9F=H:6IS='5V=WAY>H*#A(6&AXB)BI*3E)66EYB9FJ*C
MI*6FIZBIJK*SM+6VM[BYNL+#Q,7&Q\C)RM+3U-76U]C9VN+CY.7FY^CIZO+S
M]/7V]_CY^O_: P# 0 "$0,1 #\ U=;U_5T\4WMM'JMS#"LQ"A7X4>W(J)-2
MUN1D5?$K NP509CGGUKK45;8^:EB*KFUS=0_M+7,C/B7 VDY\\\>U57\1:W#
M?+"-9N95!7++(<'(!/\ A345V(EB*L5?F*W_ E.O?\ 06N_^_AH_P"$IU[_
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MM# 5.>.0,9QUQQ7%C94/9KV;U*AAJ:=^4ZN/[GXG^=/KRCI"FR?ZML>E '.
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M:>'DI/6Z%U.W_<_\\S_W[/\ A1^Y_P">9_[]G_"N748A\G*_NSU_YYG_ I?
MW/\ SS/_ '[/^%&H!^Y_YYG_ +]G_"D;RN,(0<C^ ^M)WL!4N+.\N+B-H;PP
M0 '<%&23N_P_E49TJ\\\R+J\X# 94J,9&.?;O^=--6 M6-I/:F0SWLER7QC>
M O7I_GM5J3B-C[4GJP,2^0;V9]6FA'F$[0O"CT_0TR%1&RHNJ[G5MIS&QSP
M1C[WO^G.:NVFP$X"21+&NHNK(0"RJ0#@GU)]<=:;8VYM]K2:I).ICV\K@')4
MY')YQ_.CIL U+*?9LCU:7EPW"$Y'7')^G^%-\F>6+":Y*"ORN?*[Y]">.GZ4
M?(!ZQR)<LS:NTB^6%\IEQR,%CG/< _3-/^Q7("_9M1E$>X'!0MQGG!S1\@'/
M8WA)*:E,F7+'$/48Z=?Y<>U!L+L[L:G<#/(/E<@_G2N@)+&VN;:8O<7DMP"F
MW!C(YXY_0_G4UX\)0^=(T2@JV[E>A)Q^0-+J!C""".-8FUB<A3RV&W''49SC
M'X5.J('B(U1S@A@=C$L!Z\X['M^=7KV M:=&([B9Q>R7'567:>#G/J?TQ7G_
M ,7K"/5%LXY-7MM+"C/FW3,H;GH, UMA6XUT[7\A2V/*?^$3M?\ H?=%_P"_
MTO\ \31_PB=K_P!#[HO_ '^E_P#B:^@^L/\ Y\_D96\QT?@^":5(H_'>BL[G
M:H\Z3DG_ (#7I?@3X7ZYX9\21:G>:Z&@1"#%;;SYN>S;AC'?\*Y<7C(JFX2I
MV;]"HQUW/6_,']U_^^32+(,?=?J?X37S]C07S!_=?_ODT>8/[K_]\FBP"&09
M7Y7Z_P!TTOF#^Z__ 'R:+ 'F#^Z__?)IK2 @#:W4=5/K0T Z/[GXG^=/I %-
MD_U;8]* ,.XETY&N,0R2L&?S@D;#G'S<D@'MT]:J61T=KN3[)!.C[LL^612,
MG/5QQGM^G'&BO8">>/1E MYD);!8_NW'HQ)8$#/3OZ4_[/ITT)D:&0JL94(S
MG[H 7IOP."!S@T78$45QHMLT48;:Z#>D1B9MFT#ZC@ '.?>EVZ%?I)>K^\5_
MON%D7/#>XR,!NGI1J!%*FB6\DT3PR1_9DW!@KX((!^7!Y/S"KEOK&EVD!@2\
M;;"F6W0/D#GD\>W^<T.[ U8)3<1"6.0%22 =OH<?TJ3$G]]?^^:G0 Q)_?7_
M +YK/U9(#;$7J>;#E<JHQZ\GD<>M"M<#)$FC2#<UK(7*[PDBG=M)V\9;@<].
MF*;,^BI-EK.1)B2NV($'!+ GY6Z?>^G'M5Z@;]KI\5FTC0?*9,;B2S9Q]3[U
MYI\8DT=H[(:[-=I!CY#:(I;=GOD]*WP;E[>+AN*6QY)Y/P]_Y_->_P"_,?\
MC7I&E_!+PSK6EV^HV&N7DMK<)OC<(O(_H>V*]K%8S%8=)R2U,U%,NQ_ '0TF
M0OJEZZ Y*X49'IFO5;:V%I:Q6T&U(8D"(H!X4# '6O&Q>-GB;<ZV-(QL2XD_
MOK_WS2*),??7J?X:X]!BXD_OK_WS1B3^^O\ WS1H A$F5^=>O]VEQ)_?7_OF
MC0 Q)_?7_OFFL'P,L,9'\/O0[ .C^Y^)_G3Z0!3)/]4V3C@\T 9-Q->$RB""
M)=K-M+ON\P8]!C&>/7H:K0SWDEU)YUE'$GF AMNXGD]\]?\ :[>G-:I("S<W
M$P;;]C61,<MYF><#^'ZX'7M3HY9A!*6@0OASL!VACQQGG.?7VZ4K 56N;X3\
M:?$%#;00^[(P 1GC'?GT[5-%-*%2/RE7#C+",@;<=AGCG/?BG9 /DN)7M_,^
MQ"1^/E:0#=D#)[XZD<^E53<7($F_2HF^?:NV7^'L>G/?TZBD@->V*&W0EO+)
MZJ&]_P#)J;,?_/;_ ,?J0#,?_/;_ ,?J-EA=R'<,, X+9]: $$%H%VC8%)S@
M$8SZT_9 >KCG_:IZ@.S'_P ]O_'Z\J^,5VEI%9.-,M]4R,>7<!V"\]?E8&NG
M!*]>*O84MCR3^VQ_T(^D_P#?FX_^.5U=O\9/%EK;QV]OH.GQ0QJ%1$MY@% Z
M #?7OUL#"LDIU&[&2E;8L6WQI\827<*MH-K(K. 4CBF#,">@)8X/X&O>+>99
M[:*5]\+N@9HW<;D)'0X.,BO'Q^#IX?EY'>YI&39+F/\ Y[?^/TU3'C_6]S_'
M7G6?8H=F/_GM_P"/T9C_ .>W_C] #28\K^][_P!^G9C_ .>W_C] !F/_ )[?
M^/TUC'@8ER<CC=[TGL @N8H@0Y8$$_P'U/M3A=1$D#><=<1M_A26PQ%NX6;:
MI<GT$;?X4LDRB-LK+T_YY-_A0(Q[BWNY[MF349%B&08Q%("N2<=".<$#FI(K
M>]2WEC:]D)9<*QA<D<8SGMSS5\R 8L-T+?R7OI#(V%+[) >!S@=OPYIX@U%9
M%"Z@_E+C@VS$D<=3CV/YT70"-#J_S[=0X(^7-F>.#[<TD4.KK*2]X&4@9_T9
MN3[#'%'-$"6UBU*.:)KF\>95)WJML5!&..U:?FK_ ')?^_3?X5+:Z##S5_N2
M_P#?IO\ "CS5_N2_]^F_PI70!YJ_W)?^_3?X54O/,G1DMWEBD!4[O*?W]!33
M0%,6FH;\M>RL".1Y+KWSV_$>M6[-;B%W-Q-+,K!0!Y##:0,'MWZTW)"+GFK_
M ')?^_3?X5Y?\6DN[G[&ECK$6E2!<M)<7#6P89Z9[_2NC!->WC?44MCRW^SO
M$'_0_P"F_P#@[:C^SO$'_0_Z;_X.VKZ7GI?\^W]QEKW$_L_Q #_R/VF_^#MJ
MO:?X=\9:O<?&=O>3!=QCM]7DD8#UP.U3.K1BN:4';T"S[FG_PKGXG_P#0
M:N/_ .G_P *?!\//B<)8W&NSJ P.[[;,<<^F.:YGC\#;8KED>[V1EAL8([I
MY)KA(U$DH@9=[8Y.,<58\U?[DO\ WZ;_ KYR33>AI8:TR K\DO7_GDW^%.\
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MA77@$UB(\NY,GH>-^7X/_P"?K7/_ 'B_P#BZ].TCX(:-K>DVVI67B&Z:VN$
M#H6M@#CZ9KZ#%XRMAHJ4H[F2BF7/^&>[#(']OW/_ 'X7_&MWPG\';#PKK\.K
MIJ<UU- #Y2.FU03QDX//&>*\VMF\ZE-PY=RU!)GI7FW7]^+_ +X/^--C>Z5,
M;XNI_@/^->-RHTN.\VZ_OQ?]\'_&CS;K^_%_WP?\:.5!<:[W1*_/%PV?N'_&
MG>;=?WXO^^#_ (T<J"X>;=?WXO\ O@_XTUI+@@;FC*Y&<(1W^M+E07)<)/
MSOC/3C_"D%F@.0[@^O'^%+G86%^QKG/F/D=^/\*#:@C!EDY]Q_A1SL+"&R0G
M)=S]<?X4GV&/.=S9SG.!_A3YV%ABZ9;K*TJ@B1@ 6 7)QT[4_P"P18QN; &.
M@_PH]I(+"_8H\YWOGZ#_ I1:*HP)9 !V&/\*.=A87[*/^>TGYC_ H^RC_G
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M ," @," @,# P,$ P,$!0@%!00$!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+
M$!80$1,4%145# \7&!84&!(4%13_VP!# 0,$! 4$!0D%!0D4#0L-%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!04%!04%!04%!04%!04%!04%!04%!3_
MP 1" &4!,<# 2( A$! Q$!_\0 'P 04! 0$! 0$ $" P0%
M!@<("0H+_\0 M1 @$# P($ P4%! 0 %] 0(# 01!1(A,4$&$U%A!R)Q
M%#*!D:$((T*QP152T? D,V)R@@D*%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(
M24I35%565UA96F-D969G:&EJ<W1U=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*C
MI*6FIZBIJK*SM+6VM[BYNL+#Q,7&Q\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ
M\O/T]?;W^/GZ_\0 'P$ P$! 0$! 0$! 0 $" P0%!@<("0H+_\0
MM1$ @$"! 0#! <%! 0 0)W $" Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!
M"2,S4O 58G+1"A8D-.$E\1<8&1HF)R@I*C4V-S@Y.D-$149'2$E*4U155E=8
M65IC9&5F9VAI:G-T=79W>'EZ@H.$A8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJ
MLK.TM;:WN+FZPL/$Q<;'R,G*TM/4U=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ
M_]H # ,! (1 Q$ /P#]1=0U:'3U)D8*/<UDMXUL%_Y;+^=>-_M>3,WP=\6Q
MD_+Y-L>O_3[;BOSO]Z]##X3ZQ%R3L?%YUQ$\IK*BJ7-=7WM^A^NG_";6'_/9
M?SH_X3:P_P">R_G7Y%T5U?V=_>_ \#_7A/:A_P"3?\ _73_A-K#_ )[+^='_
M FUA_SV7\Z_(NBC^SO[WX#_ -=_^G'_ )-_P#]=/^$VL/\ GLOYT?\ ";6'
M_/9?SK\BZ*/[._O?@'^N_P#TX_\ )O\ @'ZZ?\)M8?\ /9?SH_X3:P_Y[+^=
M?D711_9W][\ _P!=_P#IQ_Y-_P _73_ (3:P_Y[+^='_";6'_/9?SK\BZ*/
M[._O?@'^N_\ TX_\F_X!^NG_ FUA_SV7\Z/^$VL/^>R_G7Y%T4?V=_>_ /]
M=_\ IQ_Y-_P#]=/^$VL/^>R_G1_PFUA_SV7\Z_(NBC^SO[WX!_KO_P!./_)O
M^ ?KI_PFUA_SV7\Z/^$VL/\ GLOYU^1=%']G?WOP#_7?_IQ_Y-_P#]=/^$VL
M.?WR_P#?0H_X3:Q[RK^=?E[IX_XL[KI[_P!O:=W/_/O>UQG2I67WO[WX&M3C
M/V?*_8;K^;_@'ZZ_\)M8?\]E_.C_ (3:P_Y[+^=?D715?V=_>_ R_P!=_P#I
MQ_Y-_P _73_ (3:P_Y[+^='_";6'_/9?SK\BZ*/[._O?@'^N_\ TX_\F_X!
M^NG_ FUA_SV7\Z/^$VL/^>R_G7Y%T4?V=_>_ /]=_\ IQ_Y-_P#]=/^$VL/
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M_DW_ #]=/\ A-K#_GLOYT?\)M8?\]E_.OR+HH_L[^]^ ?Z[_P#3C_R;_@'Z
MZ?\ ";6'_/9?SH_X3:P_Y[+^=?D711_9W][\ _UW_P"G'_DW_ /UT_X3:P_Y
M[+^='_";6'_/9?SK\BZ*/[._O?@'^N__ $X_\F_X!^NG_";6'_/9?SH_X3:P
M_P">R_G7Y%T4?V=_>_ /]=_^G'_DW_ /UT_X3:P_Y[+^='_";6'_ #V7\Z_(
MNBC^SO[WX!_KO_TX_P#)O^ ?KI_PFUA_SV7\Z/\ A-K#_GLOYU^1=%']G?WO
MP#_7?_IQ_P"3?\ _73_A-K#_ )[+^='_ FUA_SV7\Z_(NBC^SO[WX!_KO\
M]./_ ";_ (!^NG_";6'_ #V7\Z/^$VL/^>R_G7Y%T4?V=_>_ /\ 7?\ Z<?^
M3?\ /UT_P"$VL/^>R_G1_PFUA_SV7\Z_(NBC^SO[WX!_KO_ -./_)O^ ?KI
M_P )M8?\]E_.C_A-K#_GLOYU^1=%']G?WOP#_7?_ *<?^3?\ _73_A-K#_GL
MOYT?\)M8?\]E_.OR+HH_L[^]^ ?Z[_\ 3C_R;_@'ZZ?\)M8?\]E_.C_A-K#_
M )[+^=?D711_9W][\ _UW_Z<?^3?\ _73_A-K#_GLOYT?\)M8?\ /9?SK\BZ
M*/[._O?@'^N__3C_ ,F_X!^NG_";6'_/9?SH_P"$VL/^>R_G7Y%T4?V=_>_
M/]=_^G'_ )-_P#]=/^$VL/\ GLOYT?\ ";6'_/9?SK\BZ*/[._O?@'^N_P#T
MX_\ )O\ @'ZZ?\)M8?\ /9?SH_X3:P_Y[+^=?D711_9W][\ _P!=_P#IQ_Y-
M_P _73_ (3:P_Y[+^='_";6'_/9?SK\BZ*/[._O?@'^N_\ TX_\F_X!^NG_
M FUA_SV7\Z/^$VL.?WR_P#?0K\BZ[+3Q_Q9[73W_M[3NY_Y][VIEE]OM?@:
MT^,W4YK4-E_-_P _4+_ (3:Q[RK^='_ FUA_SV7\Z_(KI2U?\ 9W][\#+_
M %W_ .G'_DW_ #]=/\ A-K#_GLOYT?\)M8?\]E_.OR+HI?V=_>_ /\ 7?\
MZ<?^3?\ /UT_P"$VL/^>R_G1_PFUA_SV7\Z_(NBC^SO[WX!_KO_ -./_)O^
M ?KI_P )M8?\]E_.C_A-K#_GLOYU^1=%']G?WOP#_7?_ *<?^3?\ _73_A-K
M#_GLOYT?\)M8?\]E_.OR+HH_L[^]^ ?Z[_\ 3C_R;_@'ZZ?\)M8?\]E_.C_A
M-K#_ )[+^=?D711_9W][\ _UW_Z<?^3?\ _73_A-K#_GLOYT?\)M8?\ /9?S
MK\BZ*/[._O?@'^N__3C_ ,F_X!^NG_";6'_/9?SH_P"$VL/^>R_G7Y%T4?V=
M_>_ /]=_^G'_ )-_P#]=/^$VL/\ GLOYT?\ ";6'_/9?SK\BZ*/[._O?@'^N
M_P#TX_\ )O\ @'ZZ?\)M8?\ /9?SH_X3:P_Y[+_WT*_(KWKM/C,-OQ5\4@=!
M?R=SZU/]GZVYOP-5QG[G/[#K_-_P#]0?^$VL/^>R_G1_PFUA_P ]E_.OR+HJ
MO[._O?@8_P"N_P#TX_\ )O\ @'ZZ?\)M8?\ /9?SH_X3:P_Y[+^=?D711_9W
M][\!_P"N_P#TX_\ )O\ @'ZZ?\)M8?\ /9?SH_X3:P_Y[+^=?D711_9W][\
M_P!=_P#IQ_Y-_P _73_ (3:P_Y[+^='_";6'_/9?SK\BZ*/[._O?@'^N_\
MTX_\F_X!^NG_ FUA_SV7\Z/^$VL/^>R_G7Y%T4?V=_>_ /]=_\ IQ_Y-_P#
M]=/^$VL/^>R_G1_PFUA_SV7\Z_(NBC^SO[WX!_KO_P!./_)O^ ?KI_PFUA_S
MV7\Z/^$VL.?WR^OWA7Y%UV7PA_Y'B+_KPU#_ -(IJ3R^R^+\#2GQI[2:C[#_
M ,F_X!^H/_";6'_/9?\ OJE_X3:P_P">R_G7Y%T4_P"SO[WX&;XVL[>P_P#)
MO^ ?KI_PFUA_SV7\Z/\ A-K#_GLOYU^1=%']G?WOP#_7?_IQ_P"3?\ _73_A
M-K#_ )[+^='_ FUA_SV7\Z_(NBC^SO[WX!_KO\ ]./_ ";_ (!^NG_";6'_
M #V7\Z/^$VL/^>R_G7Y%T4?V=_>_ /\ 7?\ Z<?^3?\ /UT_P"$VL/^>R_G
M1_PFUA_SV7\Z_(NBC^SO[WX!_KO_ -./_)O^ ?KI_P )M8?\]E_.C_A-K#C]
M\O/'WJ_(NNK^$O\ R57P9Z_VU9#O_P ]TI/+[*_-^!<.->>:C[#_ ,F_X!^I
M/_";6'_/9?SH_P"$VL/^>R_G7Y(WO%Y/_P!=&_G4-"R^ZOS?@*?&O+)Q]AM_
M>_X!^NG_ FUA_SV7\Z/^$VL/^>R_G7Y%T4_[._O?@3_ *[_ /3C_P F_P"
M?KI_PFUA_P ]E_.C_A-K#_GLOYU^1=%']G?WOP#_ %W_ .G'_DW_ #]=/\
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M*/[._O?@'^N__3C_ ,F_X!^NG_";6'_/9?SH_P"$VL/^>R_G7Y%T4?V=_>_
M/]=_^G'_ )-_P#]=/^$VL/\ GLOYT?\ ";6'_/9?SK\BZ*/[._O?@'^N_P#T
MX_\ )O\ @'ZZ?\)M8?\ /9?SH_X3:P_Y[+^=?D711_9W][\ _P!=_P#IQ_Y-
M_P _73_ (3:P_Y[+^='_";6'_/9?SK\BZ*/[._O?@'^N_\ TX_\F_X!^NG_
M FUA_SV7\Z?'XRL9& $J_G7Y$4?_KI/+K:\WX%0XVYI)>PZ_P W_ /V0M;Q
M+I-RFBN?\*S,YN%Z*LC* .@P:*\=Z.Q^FTY<T%+N>-_M=?\ )(O%O_7"V_\
M2VWK\\Z_0S]KK_DD?BW_ *X6W_I;;U^>=>_@?X;/QSC/_?H6_E"KFCZ/>^(-
M6M-,TZW>[O[N5888(_O.[$ =NIZG@53KU/]EZXM[7X[^%6N'2-6EFC1G( \
MQH)%3_QXJ/QKT)RY8\Q\3AZ4:U>%.?4WD_9[\+0ZN/#=[\5M)M_&.?).FQV$
MTELLYX$1NLA0<\<C.>,9KR#Q)X<U#PCX@OM&U2 VVH64K0S1YSAAZ'N#U![@
MYIVI:;J47B:ZL98;C^UEO&B:'DRF;S,8&/XMP_R:]W\%Z=K?PIT_XI>*M7@A
MU/Q_H)LX(;B\E%Y]F:X8AY\Y.6VD8+<CD$<L#S\TJ>K=[GL_5J6+ER4Z7(HM
MW>KT7?S]+'SI_/M[T#YNE?46A^)+KXN^$?!WB_Q'#;R^)M,\:V.EQ:K' L+W
M<#%7\MPH )4G(P!C'09.>GC^)UUXB^)7Q8\+ZCIFEWWA31[._P!0@TF>S01-
M<V\BL)78#<Q9P6;<3G/ %3]8ELHZFL,GI2M)U;)[::O2^NNFWF?&O8'M2U]0
M6_C?4OBM\+_"'B#Q&+>ZUG3?'-K807D4$<)6W9 _E_* ,9QT_NCJ1SOP?%/6
M?$O[16K_ WO=,L7\'7U]=V4^D?8D^?AW-R7(W%R1O)SC'09P:KV\MN7;S)6
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M0RQ& HX?#-J5YIJ^FVE['E5%%%=1\^=EI_\ R1W7?^P]I_\ Z3WM<;79:?\
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M<YP*Y<G&?;\Z^G]8\1:CXQTO]H*75[P3217=E91R^6J;(4OG1%P 0%]>3W-
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M&I-.F@^<"2,N%VLA0D[3CD#D_*!\VV=G<:C=06MI#)=74S+'%!"ID>1R0 H
MR223C YK:G4=2+=K'EXS!QPE50C)33MM;]&U?YGM&J?LX:?%;ZOI^D^/--UG
MQEH]LUQ?:#':R1JNP9E6.=CMD9>> >#G;7B/X?G7O\ ^SW?:6=1O_ #>'[K
M0O&>KV]W8?\ "3)(3/:D(S&,V[KA!A2K,N&Y['D>!21^3*Z';E3@[>G\O\_I
M4T92<FI,VQ]*A&E3JTH\M[I[[_/KWZ#:***Z3Q0KL?&W_(G_ ^_[!$__IPN
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M*>/?^@MX=_\ FX_^,4?\,*^/?\ H+>'?_ FX_\ C%>A[:GW/C/["S-.ZHNY
MS</[5WBE9H[Z;1/"]WXACC\M?$$^E*;\<8#;PP7([?+C%<9X*^,'B3P/XDU+
M6K:YCU";5%=-1MM2C\^"^#DEA*I^]R2<@@\D9P2#ZO\ \,*^/?\ H+>'?_ F
MX_\ C%'_ PKX]_Z"WAW_P ";C_XQ62=!;'H2P6>3<6XR]W8\\\2?'SQ#XDU
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MP1\F.P.<\YSS7HO_ PGX^_Z"WAW_P ";C_XQ1_PPKX]_P"@MX=_\";C_P",
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M_P"@MX=_\";C_P",4?\ #"OCW_H+>'?_ )N/_C%$9T8OF3)J9=G5:FJ=2#:
M1\YT5]&?\,*^/?\ H+>'?_ FX_\ C%'_ PKX]_Z"WAW_P ";C_XQ6GMZ?<X
M?[!S+_GRSR73_P#DCNN_]A[3O_2>]KC:^HK?]D+QC:^%+SPNVI:&=0OKZ#4H
MI!/-Y0B@2:-PQ\G(;-RF.,8#9(XSDC]A7QZW35O#O_@3/Z?]<*B-:FKZG36R
M/,9*-J+V2/G.BOHS_AA/Q]_T%O#O_@3<?_&*/^&$_'W_ $%O#G_@3/\ _&*K
MV]+N<_\ 869?\^6?.=%?1G_#"?C[./[6\. YQS<W _\ :%'_ PIX^_Z"WAW
MU_X^9Q_[0H]O3[A_869?\^6?.=%?1G_#"GC[_H+>',\_\O-QV_[84?\ #"?C
M[G_B;>'1];FX'_M"G[>GW#^PLR_Y\L^<Z*^C?^&$_'W(&K>'2?\ KYG_ /C-
M)_PPIX]_Z"_AP?6ZG_\ C%+V]+N+^P<R_P"?+/G.BOHS_AA3Q[G_ )"_AS'_
M %]3_P#QFC_AA3Q]_P!!;P[_ .!-Q_\ &*?MZ?<?]@YE_P ^6?.=%?1G_#"?
MC[C_ (FWAS_P)G_^,4O_ PGX^S@ZMX=!SC_ (^9Q_[0I>WI]Q?V%F7_ #Y9
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M[4WA?]I+Q3X5\.Z?I4-GHM_+IB/'IFJ:A8+->6"L,8A?( ]U/IR !7;?\,*
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MZ*+.UFRQ^;DY(P/85[1_PPKX]_Z"WAW_ ,";C_XQ1_PPKX]_Z"WAW_P)N/\
MXQ5*I13NF<LLJS><7&5-M.R^[8^<Z*^C/^&%?'O_ $%O#O\ X$W'_P 8H_X8
M5\>_]!;P[_X$W'_QBK]M3[G-_8.9?\^6?.=%?1G_ PKX]_Z"WAW_P ";C_X
MQ1_PPKX]_P"@MX=_\";C_P",4>WI]Q_V%F7_ #Y9\YT5]&?\,*^/?^@MX=_\
M";C_ .,4?\,*^/?^@MX=_P# FX_^,4>WI]P_L+,O^?+/G.BOHS_AA7Q[_P!!
M;P[_ .!-Q_\ &*/^&%?'O_06\._^!-Q_\8H]O3[A_869?\^6?.=%?1G_ PK
MX]_Z"WAW_P ";C_XQ1_PPKX]_P"@MX=_\";C_P",4>WI]P_L+,O^?+/G.BOH
MS_AA7Q[_ -!;P[_X$W'_ ,8H_P"&%?'O_06\._\ @3<?_&*/;T^X?V%F7_/E
MGSG17T9_PPKX]_Z"WAW_ ,";C_XQ1_PPKX]_Z"WAW_P)N/\ XQ1[>GW#^PLR
M_P"?+/G.BOHS_AA7Q[_T%O#O_@3<?_&*/^&%?'O_ $%O#O\ X$W'_P 8H]O3
M[A_869?\^6?.=%?1G_#"OCW_ *"WAW_P)N/_ (Q1_P ,*^/?^@MX=_\ FX_
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M5O#' EY?:0TTY5 N7,F>,5TW_#"OCW_ *"WAW_P)N/_ (Q1_P ,*^/?^@MX
M=_\ FX_^,5$JE&=KL[,/EN<86_L:;5]SR76OB]XKU[QY;^,)]4>/7+5T:UE
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MD\(_M'>)/"OA_3-(FTS0O$,&E,6TV;6['SYK+T$3AEP!VSDCIG ';_\,*^/
M?^@MX=_\";C_ .,4?\,*^/?^@MX=_P# FX_^,4^:A:PE@\\4N=0=SRB;XO>(
M;RQ\807TL.H2^*FA;4+JX0^:#$^]?+VD!1VQ@@ #&*S=;\>7^O>$/#GARXA
MMDL=!^T?9I(D82/YSAW#DL01GI@"O:?^&%?'O_06\._^!-Q_\8H_X85\>_\
M06\._P#@3<?_ !BJ]I16S.>65YQ--2IMW_X<^<_YT5]&?\,*^/?^@MX=_P#
MFX_^,4?\,*^/?^@MX=_\";C_ .,5?MJ?<YO["S+_ )\L^<J[3XT?\E6\5?\
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MC7=/^T-:;CN*QD,,#//.3^ JIHOQ\\7:/XXU;Q.US;ZC=:NICU"SOH?,M;F
M,C C://W5 &"" ,9()!]&_X86\>?]!CPW_X%3__ !BC_AA;QY_T&/#?_@5/
M_P#&*.:@'U//'RKEE[NQY;X^^+VK>/M-L]+>PTG0=%M96G32]"LQ:VWFG@R%
M<DEL9&<\9.,9KA>WO7T9_P ,+>//^@QX;_\ J?_ .,4?\,+>//^@QX;_P#
MJ?\ ^,5<:M**LCDK91FU>;G5I-L\8O\ QYJ&H>!=+\*216ZZ=IUU+=Q2*'\Y
MGD&&#'=@C\,^]<W7T7_PPMX\_P"@QX;_ / J?_XQ1_PPMX\_Z#'AO_P*G_\
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M*;<,?-SDY/3G JS>?M/>,-0\:0^)YXM+DO?[-&E75NUJ6MKV ,6(FC+')).
M?E*],#@G/8?\,+>//^@QX;_\"I__ (Q1_P ,+>//^@QX;_\ J?_ .,5G>A>
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M_P ,+>//^@QX;_\ J?_ .,4?\,+>//^@QX;_P# J?\ ^,5/M:27*;O*<VE4
M51TG=6_ \:T7XA:EH7AGQ+H5M';FUU]K=[F5U8RH89"ZF,AL#D\Y![5Z39?M
M=>+K&\@U%=&\,OKJ)'%+K;:9_IMPBX^620..& P0 ..F.#6Y_P ,+>//^@QX
M;_\ J?_ .,4?\,+>//^@QX;_P# J?\ ^,5#E0EN==+!YY1_AP:.&TC]HC7M
M-_MN&ZT;P_KFF:KJ#ZH^EZO8&XMH+AR2S1*6R.O0DX_$U3G^/WB^3XBVWC.*
M[AM-1MHA:PVUO"%M8[<<>0(SG]WR>"<YY!! (]%_X86\>?\ 08\-_P#@5/\
M_&*/^&%O'G_08\-_^!4__P 8HYJ G@L\:4>5V6IYWXT^.FL^,- FT2'2-!\,
MZ9<S+/=V_A^P^RBZ=3E3*=Q+8/./6O/+:YFL[B*XMY7@N(762.:-BK(P.5*G
MJ,'T]!7T/_PPMX\_Z#'AO_P*G_\ C%'_ PMX\_Z#'AO_P "I_\ XQ51J4HJ
MR.>ME>;UY^TJ4VV<MJ'[4WBV\L[[R=/T'3=9OH/L]SXAL-/$6HRIQG,H;&2
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M_E7T)X$^/MW=6/Q(\47[Z+8^))M-L88H&&%U!D<J^8G=MY9,*P7'&.G6F?\
M#"_CS_H,>&__ *G_P#C%(?V%_'G_07\-]/^?J?_ .,UG*5&22;._#8'.,--
MS5)_\'N<9<?&S5?'GBKP9:ZC%I/A_P /:3J<,\6G:5 MK9PMYHS*06(S@GDG
M YQC)SV'Q:_:8UR'QAXML="302)I9;.'Q)9VB-?/:EOE19U;!4#@'&0.^1FI
M?^&%_'G7^V/#>?\ KZGX]O\ 4=*3_AA?QY_T%_#8_P"WJ?\ ^,U/[BZU-_J^
M=J$X*#O+K\K'B^H>/-0U+P+I?A26*W&G:?=2W<4BJWFEY!A@Q+8QZ ?C79>
M$?VC_$GA30--TB73-"\0P:6Q;3IM<L?M$UE[1/N& #TSD@8 . .V_X86\>?
M]!CPW_X%3_\ QBC_ (86\>?]!CPW_P"!4_\ \8JY3H2T.6GE^=4I\\8-.UCR
MG0?B_P")-#^)!\<FY34=>=Y'F:\4F.;>A0JRJ5^4 \*" -J^E3^'?C3XC\-^
M/-7\5P&UN;S5O.6_M;N'S+:XCD.6C9,YVYQ@ YP ,]<^G_\ #"_CS_H,>&__
M *G_P#C%'_#"_CS_H+^'/3_ (^;C_XQ3YZ),<NSJ-FH/1W^?<XSQ/\ M(:_
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MYP5D1)5' PRCKNX_.'1K>XN?AKK2Z[?_ *LM8>:[?5+WQ0]\GBN"Z\UC(Y*
MCS1*KYV^4,' P#R*^S/C8NJ3_ #X='4)EO/$K:UX;831+(#)=?:8"[H'17!(
M\P_,JD G('(JY4%&25P/HG-%)V';VI:X@"BBB@ HHHH **** "BBB@ HHHH
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MAWX=>(5GBNM3@MKZX,?B+2DF5VMH7O;F4I,DJI(8XV!F ^3#=V*Q=95H2H
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M7B76M LS!-JVC" WUO\ 9F7R1,I:+YBH5MR@GY2<=\5M?V99<9M;<?\ %J;
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M']EV7_/I!_W[%3[@&7_PGWAC_H8M)_\ V+_ .*H_P"$^\,?]#%I/_@;%_\
M%5J?V79?\^D'_?L4?V79?\^D'_?L4>X!E_\ "?>&/^ABTG_P-B_^*H_X3[PQ
M_P!#%I/_ (&Q?_%5J?V79?\ /I!_W[%']EV7_/I!_P!^Q1[@&7_PGWAC_H8M
M)_\ V+_ .*H_P"$^\,?]#%I/_@;%_\ %5J?V79?\^D'_?L4?V79?\^D'_?L
M4>X!E_\ "?>&/^ABTG_P-B_^*H_X3[PQ_P!#%I/_ (&Q?_%5J?V79?\ /I!_
MW[%']EV7_/I!_P!^Q1[@&7_PGWAC_H8M)_\ V+_ .*H_P"$^\,?]#%I/_@;
M%_\ %5J?V79?\^D'_?L4?V79?\^D'_?L4>X!E_\ "?>&/^ABTG_P-B_^*H_X
M3[PQ_P!#%I/_ (&Q?_%5J?V79?\ /I!_W[%']EV7_/I!_P!^Q1[@&7_PGWAC
M_H8M)_\ V+_ .*H_P"$^\,?]#%I/_@;%_\ %5J?V79?\^D'_?L4?V79?\^D
M'_?L4>X!E_\ "?>&/^ABTG_P-B_^*H_X3[PQ_P!#%I/_ (&Q?_%5J?V79?\
M/I!_W[%']EV7_/I!_P!^Q1[@&7_PGWAC_H8M)_\ V+_ .*H_P"$^\,?]#%I
M/_@;%_\ %5J?V79?\^D'_?L4?V79?\^D'_?L4>X!E_\ "?>&/^ABTG_P-B_^
M*H_X3[PQ_P!#%I/_ (&Q?_%5J?V79?\ /I!_W[%']EV7_/I!_P!^Q1[@&7_P
MGWAC_H8M)_\ V+_ .*H_P"$^\,?]#%I/_@;%_\ %5J?V79?\^D'_?L4?V79
M?\^D'_?L4>X!E_\ "?>&/^ABTG_P-B_^*H_X3[PQ_P!#%I/_ (&Q?_%5J?V7
M9?\ /I!_W[%']EV7_/I!_P!^Q1[@&7_PGWAC_H8M)_\ V+_ .*H_P"$^\,?
M]#%I/_@;%_\ %5J?V79?\^D'_?L4?V79?\^D'_?L4>X!E_\ "?>&/^ABTG_P
M-B_^*H_X3[PQ_P!#%I/_ (&Q?_%5J?V79?\ /I!_W[%']EV7_/I!_P!^Q1[@
M&7_PGWAC_H8M)_\ V+_ .*K(F\<>'&\76,@U_2S&+&X4M]LCP#YD/'WOK75
M_P!EV7_/I!_W[%8UQIMG_P )A8+]EAVFPN"5\L8R)(?;W-'N>8$O_"?>&?\
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M?>&/^ABTG_P-B_\ BJ/^$^\,?]#%I/\ X&Q?_%5J?V79?\^D'_?L4?V79?\
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M?_)CSOW7F97_ P[\9/^A=TK_P *C2O_ )*H_P"&'?C)_P!"[I7_ (5&E?\
MR56K_P /"OC]_P!#S#_X(=-_^1J/^'A7Q^_Z'F'_ ,$.F_\ R-1_QD?_ $Y_
M\F#]UYF5_P ,._&3_H7=*_\ "HTK_P"2J/\ AAWXR?\ 0NZ5_P"%1I7_ ,E5
MJ_\ #PKX_?\ 0\P_^"'3?_D:C_AX5\?O^AYA_P#!#IO_ ,C4?\9'_P!.?_)@
M_=>9E?\ ##OQD_Z%W2__ J-)_\ DJC_ (8=^,?_ $+NE_\ A4:3_P#)5:Z_
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M_A4:3_\ )5'_ P[\8_^A=TO_P *C2?_ )*K6_X>$_'[_H>H?_!#IO\ \C4O
M_#PCX_8Y\<Q?^"#3?_D;_.*VYN(O^G/_ ),+]UYF1_PP[\8_^A=TO_PJ-)_^
M2J;+^Q#\8H87E?P[I81%+,1XFTHX &3TN:Z2/]O+]HV;2I]3C\6/)ID$J02W
MJ>&].,,<CAF1&?[-@,P1R%/)"-Z&J$W_ 4"^/=Q#)')XXA:-T*D?V%IHR".
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M-_$Q\M/LSR;_ (8?^,G_ $+NE_\ A4:3_P#)5*/V'_C)T_X1W2__ J-*_\
MDJO7]/\ CU^V%J7B[4?#<6MVL6IZ?';RSO=6.AV]H%G95MRMU)&L+^:77R]K
MGS,_)NKB[7_@H-\?_"?BI(];U^WO6TZZ\N]T?4-"L80Y1L20R^7 DBG@J<,&
M!';%:0Q6?5;^RE1DTKV3EMT?S%RTNMSE!^Q#\8^H\.Z61_V-&D__ "51_P ,
M/_&/_H7-+_\ "GTK_P"2J_87]G?XY>"?VDOA_;^)?#L<"3KMBU#3)E4W%C.1
MDQN,<CJ0_1@,]<@>I?V59?\ /G!_WZ7_ KXJMQIF="HZ52E!23U33_^2.E4
M(25TS\*/^&'_ (R9)_X1S2^?^IGTG_Y*IL?[$OQB9I%'AW3"4.#_ ,5/I0[
M_P#/SSUK]V!I5E_SZ6__ 'Z7_"L_3=,LVO\ 51]E@PLZ ?NP?^6,=8_Z]8]?
M8A]S_P#D@^KQ[GX<_P##$/QD_P"A<TO\?%&D_P#R52_\,0?&3_H7-+_'Q1I/
M_P E5^ZW]EV7_/G;_P#?I?\ "C^R[+_GSM_^_2_X4_\ 7K'_ ,D/N?\ \D'U
M>/<_"C_AA_XR<Y\.:6?^YGTG_P"2J/\ AA_XR?\ 0N:7_P"%/I/_ ,E5^Z_]
MEV7_ #YV_P#WZ7_"C^R[+_GSM_\ OTO^%+_7G'_R0^Y__)!]7CW/PH_X8?\
MC)@#_A'-+Q_V-&E?_)5!_8?^,AS_ ,4YI?\ X4^D_P#R57[K_P!EV7_/G;_]
M^E_PH_LNR_Y\[?\ []+_ (4_]>L?_)#[G_\ )!]6CW/PI_X8A^,N<_\ ".Z7
MGU_X2?2O_DJD_P"&(/C+V\.:6/\ N9])_P#DJOW7_LNR_P"?.W_[]+_A1_9=
ME_SYV_\ WZ7_ H_UZQ_\D/N?_R0?5X]S\*/^&(/C+C'_".Z7C_L9])_^2J7
M_AB'XR]O#NF9]O%&E>G_ %]5^ZW]EV7_ #YV_P#WZ7_"C^R[+_GS@_[]+_A1
M_KUF'\D/N?\ \D'U>/<_+G]C/]A&PTSQ:WBKXSW.AVUOILBM8>'&U:UN5N9!
M@^;,8Y&4QJ2,1YRS#YAM&'_3%?'GAA, >(=)4#L+V,?UK5_LNSX_T2#CI^['
M'Z4#2[)1@6< '_7,5\CF6:5LUK>VQ+N^W1>AO"$8*R,H>/O#&/\ D8M)_P#
MV/\ ^*I?^$^\,9_Y&+2?_ Z+_P"*K4_LNR_Y](/^_8H_LNR_Y](,=,>6*\GW
M/,OJ9OPQ8-HT1!R"N01R#^-%+\,_^01']**\Q[Z&I1\2?\CUX>_Z^9?_ $GF
MKJ:Y;Q)_R/7A[_KYE_\ 2>:NIKII?"1(****V)"BBB@ HHHH **** "BBB@
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MC'^<48_SB@ HHQ_G%&/\XH **,?YQ1C_ #B@ HHQ_G%&/\XH *Q;C_D<M/\
M^O"Y_P#1D%;6/\XK&N./&5@3T^P7'8_\](/_ *_Y4 :TLJPQO([!$0;F9CP,
M<Y/ITK\U-<_:8^'=Y?:S\3X?$H7XC0^+(=1TW2_L%PK/I4"&U%H9O+,:^;!)
M+(?FQN<=P37Z!_%/P;??$+X=Z_X:T[5QH-UJUHUI_:/V<W'DHXPY"!TR2A8
M[A@D'G&#I:+X1TW0O"=EX:M[96TBTLDL$MW4%3"J! I&.?E'ZUTT:D::;>[
M\K^-N@V/Q:TOX?W>@:UH#Z]!?)K^@Z7K[9M=7"P$D-$IW_*DH<.JL4(!(-<_
MJGC2:X\?>"X_C!\+5\/74.JQP^'O%6E:P+VT%\ZE51F012Q+)RH612C9&[ID
M:D/[*J#X2^'_ @_B_48-5\,7DMUX=\1Z?%Y%SIRLS[(BI=A*H1_+;.-Z@=#
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M=Q4$Y/.14MQ;YE+Y >(?L\?%CXSZ3\#_ 38:'\!?^$ATB#2XH[74_\ A,+.
MV^U1A>'\IU)3./NDY'ZUU7[1_A4_&/\ X4IHGB[29-"N-:U"Z6\L8KE9WL9C
MITY^251AGC;!# 8)4'FI/"?[,_QH\#>&=.\/:'^T.;+1].@6VMK;_A";.39&
MHPJ[GD)/U))]Z]&M?@WXAU!OAS>>*/&O_"1ZWX3U&YOY]0_LF.U_M#S8IHE3
MRXWVQ;%E49&[.SGKD:NI&,^>-OQ_41X5KGC[4?$4GPH\*^)Y%/CGPC\0]/TO
M5N5'VE?(F,%XH!X2>/#?[VX#I7L7[3G_ ![_ Q/_4\Z3U'^T]3_ !3_ &:]
M,^)'Q9\"?$"/46TG6/#5TDLX6V\T:A"C;DB<[AM*L6VM\V-[#!XQUWQ.^&O_
M L:/PNG]H?V?_8FNVFM9\CS?.\@L?*^\NW=N^]SCT-+VD+PDO.XSM>G3@44
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M+\@,K_A$=6_Z';7,=_W%A_\ (M'_ B.K=_&NN9Q_P \+#_Y%K$^"OBK5?%W
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M[?M/92><8(HMJ]U]W_ ^@3X1U7)_P"*VUSCC_46'_R-2?\ "(ZM_P!#MKG_
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M ,BT?\(CJW_0[:Y_WXL/_D6NIHHYG_2 Y;_A$=6_Z';7/^_%A_\ (M'_ B.
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MG_2 Y;_A$=6_Z';7/^_%A_\ (M'_ B.K?\ 0[:Y_P!^+#_Y%KJ:*.9_T@.6
M_P"$1U;_ *';7/\ OQ8?_(M'_"(ZM_T.VN?]^+#_ .1:ZFBCF?\ 2 Y;_A$=
M6_Z';7/^_%A_\BUE3>%=4'BRR3_A,=:+FQN")?)L0P&^'*C%MT/'OQP1S7?5
MBW'_ ".6G_\ 7A<_^C(*.=_TD!0;PCJW4^-M<_[\6'_R-1_PB.KCKXUUS_P'
ML?\ Y%K4\5:?JFK>&]3L]%U?^P=6N+=XK74_LRW'V60CY9/*8@/@X.TGG%?+
M#>&_CVOQDC\!?\- \MH3:U_:'_"%Z?QBX$/E>7GWW;MWMCO6L$ZE]5]W_ ^
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M?_0[ZW_WXL/_ )%I?^$2U/\ Z'?6_P#OQ8?_ "+7\Z&WZ?E1M^GY4?ZAU/\
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MR/Z+O^$1U+_H=M;_ ._%A_\ (M'_ B.I?\ 0[:W_P!^+#_Y%K^=';]/RHV_
M3\J?^H=3_H)7_@'_ -L'UKR/Z+_^$1U+_H=];_[\6'_R+2?\(CJ7_0[ZU_WX
ML/\ Y%K^=';]/RHV_3\J/]0ZG_02O_ /_M@^L^1_1=_PB.I?]#OK?_?BP_\
MD6C_ (1'4_\ H=]:_P"_%A_\BU_.CM^GY4;?I^5'^H=3_H)7_@'_ -L'UGR/
MZ+O^$1U/_H=];_[\6'_R+5+6_">I1Z-J#'QIK4@^SR$H8;'YOE/'%MGO7\[V
MWZ?E0*/]0ZG_ $$K_P _P#M@^L^1_1:GA'4O+7/C;6NF?\ 4V&/_26E_P"$
M1U+_ *'?6_\ OQ8?_(M?SHG_ #Q1M^GY4?ZAU/\ H)7_ (!_]L'UKR/Z+O\
MA$=3_P"AWUK_ +\6'_R+1_PB.I_]#OK?_?BP_P#D6OYT=OT_*C;]/RH_U#J?
M]!*_\ _^V#ZSY']%W_"(ZG_T.^M_]^+#_P"1:/\ A$=2_P"AWUO_ +\6'_R+
M7\Z.WZ?E1M^GY4?ZAU/^@E?^ ?\ VP?6O(_HN_X1#4O^AVUO_OQ8?_(M*OA#
M4V.!XVUL_P#;&P_^1:_G0V_3\JZ7X<_$/7_A3XPTSQ3X8U"33-:T^420S1]#
MV*,.C*PR"IX()K.IP'6C!N&(3?;EM^-V-8J[U1_07_PA^J8R/&NN?]^+#_Y%
MH_X0_5?^AUUS_OQ8?_(M>6?LC_M:>'_VHO!/VB 1Z9XKT]%&K:-OR8CT\V//
M+1,>AZ@_*>Q;WLC\Z_+L13K86JZ%:/+)>1V1:DKHY?\ X0_5?^AUUS_OQ8?_
M "+1_P (?JG_ $.FN?\ ?BP_^1:ZFBL/:,9RW_"'ZI_T.NN?]^+#_P"1:0^#
MM5/_ #.NM_0V^GG_ -M:ZJBCVC$<O_PB.K=O&VN?C#8'_P!MJ3_A$=6_Z';7
M/^_%A_\ (M=312YG_2&<O_PB.K]O&^NC_MC8<?\ DK6?I_A/57OM4QXSUI2)
MU!(@L?F/E1\G-MU^GI7<=ZS=+_Y"&K?]?"?^BHZ.=_T@,C_A$=6_Z';7/^_%
MA_\ (M'_ B.K?\ 0[:Y_P!^+#_Y%KJ:*.9_T@.6_P"$1U;_ *';7/\ OQ8?
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M7O?_ E&BKTU:Q'O]I3/\Z7_ (2G1<<:O8CT_P!)3_&DY:)1C^OX6 \;\/\
MP?\ C;I^OZ;=ZM^T!_;.FP7,<MUI_P#PAEE!]JB# O%YBON3<,C<.1G(I^O:
M;::A^VAX8EN;:*>2T\%7DT#R("8Y/MD";EST.UV&1@X)KV#_ (2G1?\ H+V/
M_@0G^-'_ E.B]?[6L<_]?"?XU//.]VOPL!\S>"/"NCP_#']IB9-*LUDNM;U
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MLO\ X2K1?^@O8_\ @2G^-'_"5:+_ -!>Q_\ E/\:GEEV U**R_^$JT7_H+V
M/_@2G^-'_"5:+_T%['_P)3_&CEEV U**R_\ A*M%_P"@O8_^!*?XT?\ "5:+
M_P!!>Q_\"4_QHY9=@-2BLO\ X2K1?^@O8_\ @2G^-'_"5:+_ -!>Q_\ E/\
M:.678#4HK+_X2K1?^@O8_P#@2G^-'_"5:+_T%['_ ,"4_P :.678#4HK+_X2
MK1?^@O8_^!*?XT?\)5HO_07L?_ E/\:.678#4HK+_P"$JT7_ *"]C_X$I_C1
M_P )5HO_ $%['_P)3_&CEEV U**R_P#A*M%_Z"]C_P"!*?XT?\)5HO\ T%['
M_P "4_QHY9=@-2BLO_A*M%_Z"]C_ .!*?XT?\)5HO_07L?\ P)3_ !HY9=@-
M2BLO_A*M%_Z"]C_X$I_C1_PE6B_]!>Q_\"4_QHY9=@-2BLO_ (2K1?\ H+V/
M_@2G^-'_ E6B_\ 07L?_ E/\:.678#4HK+_ .$JT7_H+V/_ ($I_C1_PE6B
M_P#07L?_ )3_&CEEV U**R_^$JT7_H+V/\ X$I_C1_PE6B_]!>Q_P# E/\
M&CEEV U**R_^$JT7_H+V/_@2G^-'_"5:+_T%['_P)3_&CEEV U**R_\ A*M%
M_P"@O8_^!*?XT?\ "5:+_P!!>Q_\"4_QHY9=@-2BLO\ X2K1?^@O8_\ @2G^
M-'_"5:+_ -!>Q_\ E/\:.678#4K%N/^1RT__KPN?_1D%3?\)3HO_07L?_ E
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MA>_\(!X0BO+@:]?VTENNHW<\7DK';I( [*B,S,Q7J /3/OG_ E6B\_\3>Q_
M\"5_QH_X2C1?^@O8C_MX3].?\_K4\VE^74#Y)^"_[.0^).C^*-:;XF_$;PSY
MWBG68SIOAW7_ +)9+MO91E8O+;!;&3SR:[GXI?#?0OA/X+^$_ASP]!)!80>/
M-,F+SRM+--*\CM)+(['<S,Q))_ #WW_A*=%_Z"]C_ .!"?XT?\)5HO_06
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M )3_&IY9=@,#XT_\D=\=_\ 8!OO_2>2ORX^,O\ RC#^&O\ V.TO_HO4*_3;
MXQ>(M)NOA'XWAAU.SEFDT.]1(TG0LS&!P #U.:_/?6/A1XG^,'_ 3S\ >%
M_"EC!?Z_:>*IK^>QN+Z"T=( +U"Y\]T[RIQU^;., D?3Y#.-'%4JE5\J4UJS
M.IK%I'YY4M?0'_#!/QP[^$;+_P */2__ ))H_P"&"?CA_P!"C9?^%'I?_P D
MU^^?VQEO_01#_P "1Y7LY]CY_HKZ _X8)^.'_0HV7_A1Z7_\DT?\,$_'#_H4
M;+_PH]+_ /DFG_;&6_\ 01#_ ,"0>SGV/G^BOH#_ (8)^.'_ $*-E_X4>E__
M "31_P ,$_'#_H4;+_PH]+_^2:/[8RW_ *"(?^!(/9S['S_17T!_PP3\</\
MH4;+_P */2__ ))H_P"&"?CA_P!"C9?^%'I?_P DT?VQEO\ T$0_\"0>SGV/
MG^BOH#_A@GXX?]"C9?\ A1Z7_P#)-'_#!/QP_P"A1LO_ H]+_\ DFC^V,M_
MZ"(?^!(/9S['S_17T!_PP3\</^A1LO\ PH]+_P#DFC_A@GXX?]"C9?\ A1Z7
M_P#)-']L9;_T$0_\"0>SGV/G^BOH#_A@GXX?]"C9?^%'I?\ \DTR7]@[XW0Q
MEW\)687(''B+3#U..US1_;&6_P#01#_P)![.?8\"HKZ _P"&"?CA_P!"C9'_
M +F/2_\ Y)H_X8)^.'_0HV7_ (4>E_\ R31_;&6_]!$/_ D'LY]CY_HKZ _X
M8)^.'_0HV7_A1Z7_ /)-'_#!/QP_Z%&R_P#"CTO_ .2:/[8RW_H(A_X$@]G/
ML?/]%?0'_#!/QP_Z%&R_\*/2_P#Y)H_X8)^.'_0HV7_A1Z7_ /)-']L9;_T$
M0_\ D'LY]CY_HKZ _X8)^.'_0HV7_A1Z7_\DT?\,$_'#_H4;+_PH]+_ /DF
MC^V,M_Z"(?\ @2#V<^Q\_P!%?0'_ P3\</^A1LO_"CTO_Y)H_X8)^.'_0HV
M7_A1Z7_\DT?VQEO_ $$0_P# D'LY]CY_HKZ _P"&"?CA_P!"C9?^%'I?_P D
MTR7]@WXW0Q/(_A*S"(,L?^$BTP\?^!-']L9;_P!!$/\ P)![.?8\"HKW_P#X
M8)^.!Y_X1&R_\*/2_P#Y)I?^&"?CA_T*-E_X4>E__)-']L9;_P!!$/\ P)![
M.?8^?Z*^@/\ A@GXX?\ 0HV7_A1Z7_\ )-'_ P3\</^A1LO_"CTO_Y)H_MC
M+?\ H(A_X$@]G/L?/]%?0'_#!/QP_P"A1LO_ H]+_\ DFC_ (8)^.'_ $*-
ME_X4>E__ "31_;&6_P#01#_P)![.?8^?N.]*H+?2OH#_ (8)^.'_ $*-E_X4
M>E__ "36]X'_ .">7Q8\0>*M,L/$-CIGA;19I<7>K3ZU87 MX^K$)%.S,V!@
M#&,D9(&3653.LMA%R]O%V[-.Y2IR;M8I_L&_"OXD?$#XWZ9J?P_OY?#T>BR)
M+J>NE"T$$#'#1,G E,@! C[XSP!D?N+STSR#BO-?@]X'^'WP+\!V/A/PI/I]
MEIUJ,NSW,;37$I&&EE;/S.<<^P [?_A*-&[ZO8^G_'RG^-?@F?9J\XQ?
MMHPY8+1::_,]*E#D6IJ45E_\)5HO_07L?_ E/\:/^$JT7_H+V/\ X$I_C7S7
M++L:FI167_PE6B_]!>Q_\"4_QH_X2K1?^@O8_P#@2G^-/EEV U**R_\ A*M%
M_P"@O8_^!*?XT?\ "5:+_P!!>Q_\"4_QHY9=@-3O6;I?_(0U;_KX3_T5'3?^
M$HT;_H+6/_@2G^-9^F^)M'6_U4G5K'#3J0?M"<_NH_>ERR[ =)167_PE.C?]
M!>Q_\"4_QH_X2K1?^@O8_P#@2G^-/EEV U**R_\ A*M%_P"@O8_^!*?XT?\
M"5:+_P!!>Q_\"4_QHY9=@-2BLO\ X2K1?^@O8_\ @2G^-'_"5:+_ -!>Q_\
M E/\:.678#4HK+_X2K1?^@O8_P#@2G^-'_"5:+_T%['_ ,"4_P :.678#4HK
M+_X2K1?^@O8_^!*?XT?\)5HO_07L?_ E/\:.678#4HK+_P"$JT7_ *"]C_X$
MI_C1_P )5HO_ $%['_P)3_&CEEV U**R_P#A*M%_Z"]C_P"!*?XTG_"5:+G_
M )"]C_X$I_C2Y7V#J0_#+_D#Q_2BCX8X.CQX.>**\]FI1\2?\CUX>_Z^9?\
MTGFKJ:Y;Q)_R/7A[_KYE_P#2>:NIKII?"1(****V)"BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@#G-4TNSU'QEIWVJT@N<6%QCSHP^/WD/K]3^=6[CP[H
M-K#)-/ING0PQJ7>22"-551R221Z9_*FW'_(Y:?\ ]>%S_P"C(*/&V?\ A#=>
MQQ_H$^/^_;546]KC(=-TWPOK.EV^I6%KI-]I]Q$)H;NV2*2*1",AE=>&4CN#
MBF:+9^$_$FEP:EI,&CZIIMPI:&\LEBEAD ."5=>" 01]17$_LX8;]F/P!@\?
M\(W:CO\ \\!S^G_ZZ\'^#_Q.\;>#O@7\"?#7@;2]'U#5O$T.HPJ=:\U(('A9
MY%D=HSD(!N)4 LV !CK6_)*5[/81]>_\(KHW3^R+'./^?9?\*1O"^B*H)TFQ
M ]3;I_A7A>I_$_XS>)/%EWX.\#:5X,DUKP[96A\1ZSK<ETM@;V6,2&"VCCS)
M@ AMS$\-@@'KYI\8OBI\0?B/\//"JV6EZ)H'BG1?'MGH^MZ?J,TTD0OTFB:U
M:-H^6MW+HS9^;:?EZ9+C2J2=N8#ZRMK'PI>:I?:;;P:/<:A8!#=VD2Q-+;AP
M2A=!RNX D9QD U>_X1;1?^@38_\ @.G^%?*]OK'Q:L_CM\4+/P3H_AJ\\2-8
M:)/J=[K$TZZ;&RVCAHH5CQ(S.Q;820%"_-R:U_$'[8E\OPK^'>IZ;9Z!H?BW
MQB)P#XIU+[+IFF_9R5FDFE.TL-X4+&"&.[VY'3G=),#Z+O-#\.Z;9S75WI^F
MVUM ADEFFAC1(U )9F8@ 9R>/6J%BW@O5+RVM+(Z#=W=S:"_@MX#"\DML2
M )E4<F,D@;@,<U\_>'OV@-0^(G@CXF>$/$E_X/U77['PQ=:A%J7@75/MFG7%
MNT;HR_,Q>-T.T$/U# BM;X3^,KC3=2\$Z3;>'=/U"XA^%MMJ<=RL2Q7\S*T:
MBV6=V"I$QYVM@!N<\4O9S2U8'T!_PBNB_P#0)L?_ &3_"J.EV/A36FNQI]O
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M6'# CD$&I7\,:+&K%M)L %!8DVZ =<].E?/$/QB^).K:GX"\(_#_0O"-M<:
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M-G7;N.-V,9XS5[_A%=&_Z!%B?^W9?\*\E^(7Q$N/"OQ<UV&TT?1Y+K3_ %=
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M,^^#5FLN:2Z@9?\ PBNB_P#0(L?_ &3_"C_ (171?\ H$6/_@,G^%:E%+FE
MW R_^$5T7_H$6/\ X#)_A1_PBNB_] BQ_P# 9/\ "M2BCFEW R_^$5T7_H$6
M/_@,G^%'_"*Z+_T"+'_P&3_"M2BCFEW R_\ A%=%_P"@18_^ R?X4?\ "*Z+
M_P! BQ_\!D_PK4HHYI=P,O\ X171?^@18_\ @,G^%'_"*Z+_ - BQ_\ 9/\
M*U**.:7<#+_X171?^@18_P#@,G^%'_"*Z+_T"+'_ ,!D_P *U**.:7<#+_X1
M71?^@18_^ R?X4?\(KHO_0(L?_ 9/\*U**.:7<#+_P"$5T7_ *!%C_X#)_A1
M_P (KHO_ $"+'_P&3_"M2BCFEW R_P#A%=%_Z!%C_P" R?X4?\(KHO\ T"+'
M_P !D_PK4HHYI=P,O_A%=%_Z!%C_ . R?X4?\(KHO_0(L?\ P&3_ K4HHYI
M=P,O_A%=%_Z!%C_X#)_A1_PBNB_] BQ_\!D_PK4HHYI=P,O_ (171?\ H$6/
M_@,G^%'_ BNB_\ 0(L?_ 9/\*U**.:7<#+_ .$5T7_H$6/_ (#)_A1_PBNB
M_P#0(L?_ &3_"M2BCFEW R_^$5T7_H$6/\ X#)_A1_PBNB_] BQ_P# 9/\
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M[M!C+1,S ..1R,CGK5GPGXD^&OCR6:+PSJGA;Q%)"-TBZ3<6]T4'J1&20*\
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M8_\ @.G^%'_"*Z+_ - BQ_\ 9/\*U/U^M%<_-+N!YW\8O#NE6OPC\;S0Z99
MQ31Z'>NDB0(&5A Y!!QP1BODSX%_'?P=^SW^Q/X.\9>-]%OM>AOM9N=+4V-M
M#<7'F-)/(I8S.GRA86&=Q()7CFOL3XU?\D=\=_\ 8!OO_2>2ORY^,G_*,/X:
M?]CM)_Z!J%?0Y/0CC*]/#U6[2DD[$3ERQN?0/_#U#X#_ /0A^*?QTBP_^2:/
M^'J'P'_Z$+Q1_P""BP_^2:_)[G-*HW _X5^M_P"I>6]Y7]3@^L3/U@_X>H?
M?_H0_%'_ (*+#_Y)H_X>H? ?./\ A O%'_@HL/\ Y)KX=U'6K/X%^"_AA)I7
MAO0=9NO$.F'7M9N/$.CVVH?:E-W-"MK'Y\;^1&J0$;H2CL9&);Y4"P>$_@GX
M9^)4FGZQ_;,_@*S\8>(Y]%\+:*+4ZHL<B^6<7-PTD12%6N(8Q($E<_,2GRY;
MQ%P]E45[6JIQIMV3O=NV^B5UMYZ;V-/:S;LMS[I_X>H? ?OX"\4C_N#V&?\
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M37 .V>PD:7%] &212W[H\(=NU\C.ID.0T(4Y5IRBYJZ5[]+]$P52H^A];?\
M#U#X#_\ 0A^*/_!18?\ R31_P]0^ _\ T(?BC_P46'_R37Q/H_[+?AWQ'=:%
M/I7Q#FET"].MQW>HW.AK$\$FF6R7$ICC%RPEC=7&URZ'U45FZ;^SGHVKZ7IL
M=EXRO/\ A(]>TO4-=T#2[C151)[*U,^TW$RW+>1-*MK.5C195&$!D&[(S_L7
MA_\ GG^/^7D/VE7L?=7_ ]0^ __ $(7B@?72+#_ .2:K:A_P5)^!=U:^7%X
M%\4(^]&#?V38#HRD]+GT%?-OC/X1:!XBTDZ-8:;INAW>J:SX%TV+4+>PCWVP
MO-'D,[KMVDAI"LCC<-[#+'/(XVP_9;\%:C=:4L7Q.U 07WB>3P:LA\+X;^TE
M\O:X7[7_ ,>I$G,C%900O[DY)7"CE&1RCSS<UY:O\D/GJ]C[-_X>H? ?_H0_
M%&/^P18?_)-!_P""J'P''_,A^*/_ 46'_R37Q;HO[%'B35O ,VM22ZJFIO9
MZAJ%LMKH4MQI'E6;R)(EQJ(8+!,_D3%$,; XCW,AD #;S]E_PQH]M<-/XZO+
MS4-+TC1_$.J6,.@@1QV=\]JK(DIN@6F3[4IV,J*P ^<$D+?]D<.^]:K)M::7
MW^X.>KV/M3_AZA\!_P#H0_%'_@GL/_DFC_AZA\!_^A#\4?\ @HL/_DFOSG_:
M0\)^'O _QT\;^'_"OVE=$TW5KBT@ANHBC0;)&7R@3+(SJN-H=FW, "54G N7
M7P@\.^'_ 'HFJ>)_&5QHGB+7M*FUG2]+316N+5H%>1(EFN5E#1O,T3A0L,B
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M(;_PEX<AL9K:\\/^$[R\U]O#.D'4;^\FAUF[M 8K=3&;B1F\I=S.N(T)+ (
M<JF3Y!"5G.:6NNMM%?MKVT#GJ]CZM7_@JA\"#_S(7BC/_8(L/_DFC_AZA\!_
M^A"\4?\ @HL/_DFOCCQ]^S3H/PO^&'CA-9N-2E\8V>NZ1#I$S::UOOM+RTGF
MCCGBDN%\AVV_O R.8GA50S!V9;?B3]@GQ3I=YI-C:W.J?;I-=MO#^H2:SH$V
MGV:S3(Q\^RG9V^V6Z&.4,X5&P$(0A^%#*>'I:NI)7=EKO9)W6FVH<]7L?7G_
M ]0^ YZ> O%'_@HL/\ Y)KZ(^#_ ,8OAM^T=\,=2\1^#;.WQ#'+%<V-Y9Q1
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M . R?X4?\(KHO_0(L?\ P&3_ K4HK+F?<9E_P#"*Z+_ - BQ_\ 9/\*/\
MA%=%_P"@18_^ R?X5J44<S[@97_"*Z+_ - FQ_\ 9/\*7_A%M%_Z!%C_P"
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M_P 9H]E+R^] =117+_VQXK_Z%NQ_\&I_^,T?VQXK_P"A;L?_ :G_P",T>RE
MY?>@.HHKE_[8\5_]"W8_^#4__&:/[8\5_P#0MV/_ (-3_P#&:/92\OO0'445
MR_\ ;'BO_H6['_P:G_XS1_;'BO\ Z%NQ_P#!J?\ XS1[*7E]Z ZBBN7_ +8\
M5_\ 0MV/_@U/_P 9H_MCQ7_T+=C_ .#4_P#QFCV4O+[T!U%%<O\ VQXK_P"A
M;L?_ :G_P",T?VQXK_Z%NQ_\&I_^,T>REY?>@.HHKE_[8\5_P#0MV/_ (-3
M_P#&:/[8\5_]"W8_^#4__&:/92\OO0'445R_]L>*_P#H6['_ ,&I_P#C-']L
M>*_^A;L?_!J?_C-'LI>7WH#J**Y?^V/%?_0MV/\ X-3_ /&:/[8\5_\ 0MV/
M_@U/_P 9H]E+R^] =117+_VQXK_Z%NQ_\&I_^,T?VQXK_P"A;L?_ :G_P",
MT>REY?>@.HHKE_[8\5_]"W8_^#4__&:/[8\5_P#0MV/_ (-3_P#&:/92\OO0
M'445R_\ ;'BO_H6['_P:G_XS1_;'BO\ Z%NQ_P#!J?\ XS1[*7E]Z ZBL6X_
MY'+3_P#KPN?_ $9!5'^V/%?_ $+=C_X-3_\ &:R9M6\4?\)79-_PCUEYHLK@
M!/[4."N^')SY/;C\Z7LI>7WH#O2,UY])\/=1/Q]B\<^=:_V2OAI](,.YO/\
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M\&I_^,T?VQXK_P"A;L?_ :G_P",U/+._-=7]5_F!SO[1'PUU/XL_"O4/#6D
MW%G;7\]S:3"2^=EB BN(I6W%%8_=0XXZX]<U-\?_ (=ZC\5?A7JWAG2IK6WO
M[N>T=9+YV6)?*NHI6W%59A\L;=NI'3/&Y_;'BL8QX;L>.G_$U/\ \8H_MCQ5
MQ_Q3=CQT_P")J?\ XS1RS5M5IYK_ #%8D\6?#7PCX^DMG\4>%M%\2/:AA VK
MZ=#=&(,06"^8IVYP,@=<"O,/B1\)/'VE_$"'QM\)=6\/Z9?RZ9'I.H:)XBMY
M3I]Q%$SM#(IA&Y'3S& &,8]*]+_ +8\5_\ 0MV/_@U/_P 9H_MCQ7_T+=C_
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M_A1VG_ROH_X=-^"_[_BG_P *.T_^5]*6>Y%*UZ;_ _S_ /9U.Y^?^N_'[6?
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M3>+X@T<G-X?+^0XD'[K]TO PW)^:OT#_ .'3G@O^_P"*?_"CM/\ Y7U7O_\
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M(3*80!Y,*ETB5V$2[F/.:GBSX^>(?&7_ G?VVTTV/\ X3"\L[Z_\B*0>5);
M;_+$69#@'><[MQZ8(K]!/^'3?@O^_P"*?_"CM/\ Y7TO_#IWP7_>\4_^%':?
M_*^LH9_D=/X8/\/\Q^SJ'R;<?M86]WX!EU/4?#_AK7/&UQXTD\0C3[^TN_(L
M]MI D5Q%LE4'YXV!BD=U;'S(?EKSZ3]I;Q3>WMM)K-EI7B"U_LF;1K^RU!)O
M*U2"6\DO&:<QRHXD$\F\-$T9!C3MN#?>?_#IWP7_ 'O%'_A1VG_ROH/_ 2=
M\%_W_%/_ (4=I_\ *^L(YWD<>9N+=_33TUT'[.H?GU<?'*^FT'Q5HB>&?#EG
MI.O7%G=):V5M+ --FM8WCADMBDH)?9(X9IC*7+%FRQ)-[6/VCM<U'Q!IWB.T
MT'P[HOBVWU*'6+KQ%86DAO=0NXP<22F61U0,2S/'"L<;LV64X4#[V_X=.>"_
M[_BG_P *.T_^5]'_ Z;\%_W_%/_ (4=I_\ *^MO[>R.]^1_AVMW_K?</9U#
M\^?B%\:KGQ]X3T_PW#X6\.>%=%L=1N=4CM]!AN%W3SHBR%FFFD)&(UP,X7H,
M "C\'_@YXF^.7C*'PWX7LFNKID:>YN'R(;2!<;YI6_A4?FQ( !) K]%5_X)
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M+=C_ .#4_P#QFCV4O+[T!U%%<O\ VQXK_P"A;L?_ :G_P",T?VQXK_Z%NQ_
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M'\)R**\MZ,U*7B3_ )'KP]_U\R_^D\U=37+>)/\ D>O#W_7S+_Z3S5U/'4G
MKII?"1(**\*\3?M>>'-&\3:GHVC^$O&WCAM*N&M-1OO"NA/>6MG.HR\3R;E&
MY>^,UZGX ^(&A?$_PI9^(O#EZ+[2[H-M?8R.C*VUHW0C<CJ0058#!%=,H2BM
M23HJ*.^.])N'//09J %HKBV^*^D:?!<S:S:ZGX?B374\/V[:G9M']MG=U2)X
M,9WQ.S@*YP.#G&*[/(]?K3:MN M%)WP1@T9';D^E(!:*/7N/4?7%'KSZ]:-
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MI_VNWCN/LE]'Y<\.]0VR1<G:XS@C/!!%7)IA##)*V2B*7..N *^1-,TWQ/\
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M?B!I<?C+7_'6E0>![CQ19Q^+;O[7/!>12E"OF!5Q&0!\H Q^-3[!]Q'T1\4
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M9YG.6D<1A2Q]SC)]R:](KFDG%M, S6-<?\CE8?\ 7A<?^C(*V:Q;C_D<M/\
M^O"Y_P#1D%2!M49HHI@&:,T44 &:,T44 &:,T44 &:,T44 &:,T44 &:,T44
M &:,T44 &:,T44 <9\:O^2.^._\ L WW_I._^%>-_P#!.G_DU3PU_P!?5[_Z
M4R5[)\:O^2.^._\ L WW_I/)7C?_ 3J_P"35/#7_7U>_P#I3)77'_=Y>J ^
ME\T9HHKD ,T9HHH ,T9HHH ,T9HHH ,T9HHH ,T9HHH *S?$'_(-/_76+_T:
ME:59OB#_ )!I_P"NL7_HQ:0&E1FDI:8!FC-%% !FC-%% !FBBB@ HS110!2U
MK6++P_H]]J>I7,=GI]E"]S<7$S;4BC12S,Q[ $GZ5^"O[5WQ_O/VCOC/K'B
MJ0R1Z2C?9-(M9./(M$8[,CLS$L[?[3GG %?I3_P54\3>+M!_9VAMM @8:#J5
M^EMKMY$WSQ0XS&A']QY S9[*O\ '7XZ]&YK]DX&RRFJ<L?+63=EY?\ #_D<
M&(D[\I],?L#?M*_\,\_&FW74[CRO!_B I8:J&)V0$D^3<>VQF()_N._4XK]O
MHV#HK*=RD9!'IV_2OYJ1C'XU^Y?_ 3\\2>+_%'[+/A*Z\80,EQ&KVVGW$C9
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MTL5S9WFY[A,( 4&,ACR>>F*'B;]E/PQXJ\2:;KEWKWBJ"^ATZ+2]1:RU=
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M-I__ B$<T.F6=F42W5)(1"592I.%0 +M(QWS5S^S?&?_0?T/_P23?\ R72?
MV;XS_P"@_H?_ ())O_DNM>:^\@.+^)_[-.@?$OQ4/$\7B#Q1X,\1- MK<:GX
M3U9K&6ZA4DK'+PP8#/!P#P!G HO/V7?!<WPD7X?6AU32]-2\74DU.SO2-16
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M5Y?_ &B]N-0N;W4&1KBXN)Y"\CN41%ZM@;5& /7)H?PQTSP[\1/$OC&RNKV
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M?V:O"'A_P!XD\*W4FJ^(HO$@(UC5=;OFN+^^.W:K/-@<H,!< 8SUR3D^!?V
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M+NVZ3?"!N 8XR%8#@8Q7J_\ 9OC/_H/Z'_X))O\ Y+H_LWQG_P!!_0__ 23
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MBN6_LWQG_P!!_0__ 23?_)=']F^,_\ H/Z'_P""2;_Y+I\L?YD!U-%<M_9O
MC/\ Z#^A_P#@DF_^2Z/[-\9_]!_0_P#P23?_ "71RQ_F ZFBN6_LWQG_ -!_
M0_\ P23?_)=']F^,_P#H/Z'_ ."2;_Y+HY8_S =317+?V;XS_P"@_H?_ ())
MO_DNC^S?&?\ T']#_P#!)-_\ET<L?Y@.IHKEO[-\9_\ 0?T/_P $DW_R71_9
MOC/_ *#^A_\ @DF_^2Z.6/\ ,!U-%<M_9OC/_H/Z'_X))O\ Y+H_LWQG_P!!
M_0__ 23?_)='+'^8#J:*Y;^S?&?_0?T/_P23?\ R71_9OC/_H/Z'_X))O\
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M\9?]#!H7_@DF_P#DNCE7\WY@=317+?V;XR_Z�O_!)-_P#)=']F^,O^A@T+
M_P $DW_R71RK^;\P.IHKEO[-\9?]#!H7_@DF_P#DNC^S?&7_ $,&A?\ @DF_
M^2Z.5?S?F!U-%<M_9OC+_H8-"_\ !)-_\ET?V;XR_P"A@T+_ ,$DW_R71RK^
M;\P.IHKEO[-\9?\ 0P:%_P""2;_Y+H_LWQE_T,&A?^"2;_Y+HY5_-^8'4UF^
M(/\ D&'_ *ZQ?^C4K(_LWQE_T,&A?^"2;_Y+JCK6G^,%T\E]>T1E\R/[NC3
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M!Q^\NEZ9::+IMKI]A!':V5K$L,$$*A4CC4 *J@<8 QTQBOE/\ 8=_9=\1?
M 'X20RM>Z5IWB7Q$L5_JD=YI4DT\'R9CMRZW"?ZL,<C;PSOR1BOH[^SO&9))
MU_0__!)-_P#)=<O%&:K-,8U3E^[AHOU8Z,.2.IU%%<M_9OC/_H/Z'_X))O\
MY+H_LWQG_P!!_0__ 23?_)=?(<L?YC<ZFBN6_LWQG_T']#_ /!)-_\ )=']
MF^,_^@_H?_@DF_\ DNCEC_,!U-%<M_9OC/\ Z#^A_P#@DF_^2Z/[-\9_]!_0
M_P#P23?_ "71RQ_F ZFBN6_LWQG_ -!_0_\ P23?_)=']F^,_P#H/Z'_ ."2
M;_Y+HY8_S =317+?V;XS_P"@_H?_ ())O_DNC^S?&?\ T']#_P#!)-_\ET<L
M?Y@.IHKEO[-\9_\ 0?T/_P $DW_R71_9OC/_ *#^A_\ @DF_^2Z.6/\ ,!U-
M%<M_9OC/_H/Z'_X))O\ Y+H_LWQG_P!!_0__ 23?_)='+'^8#J?U[UFZ9QJ
M&K_]?"_^B8ZR/[-\9<9U_0R,]/[$F_\ DNJ.GZ?XQ:^U/&O:(&$ZAB=%F.3Y
M4?(_TO@8QQ[4N6/\P';T5RW]F^,_^@_H?_@DF_\ DNC^S?&?_0?T/_P23?\
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MQ'K6J-)]BT/PW8F\O9EC ,D@CR %4$9)(Z\9YKYK_:6'[0?_ J2\_X3G_A6
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MC/0M/T[Q#EF\JQU#[.$MKT@<(LG$,C<#/EDGJ2_8QU6N^@SZL^%_Q$TWXL>
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M"./+W$JS2#D;>AR:W_A/\7/&'@;1_B*HTKXEWOAS2?#D^M:;>?%+3#'<I>1
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M+I]#\)Z:U_=PPDX$D@!"H/8MGD'I\)_CEX=^+\&I)IT.I:-K&E%5U+0]>
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M'[D>7S2[GI7_ TU\7_^BK^./_"CO/\ XY1_PTU\7_\ HJ_CC_PH[S_XY7FM
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M"_Y\Q^Y!S2[GI7_#3/Q?_P"BK>-__"BO/_CE'_#37Q?_ .BK^./_ H[S_XY
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M^(+;284AM9Y6>&>,*JJ=LL;*R[MBY .#@ ]*]'HKLE6G))=B3EOAS\+_ K\
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MT0!1@9DD8Y).7/. *_Q"^'NG?$C2+'3M2FN8(;/4K75(VM64,9;>42H#N5A
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M\]MXMO+N]OFDD0O&]P@1Q'\F ,;@Q![FN9\7_LO^&?%FA^%K./5_$7A[5/
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M5\UKXMN[N\OFD="\;7$81Q$=G 48W!N<YS7$^)_V2?#7B!O#T]EXE\7>%=2
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M&)EFC\M_-W LYQDYW DDDDUL_P#"0>)/^A6_\J$?^%'_ D'B3_H5O\ RH1_
MX4[56K7_ !7^87.9\6?L^^'O&3>.FO;W5(SXP2S2_P#(EC B%M_J_*S&=N?X
MMV[/;%=)X@^'.F^(_&7A7Q)<S727WAQKEK6.)D$4GGQ>4_F J2<+R,$<^HXI
MW_"0>)/^A6_\J$?^%'_"0>)/^A6_\J$?^%+EJ=U]Z_S"YYA_PQOX*_X2;[>-
M5\3)X>-[_:)\%IJ[C0C<;_,W_9<=-_S;=VW.1C'%>G:'\.].T'QMXH\4V\]T
M^H>(EM5NXY74Q)Y$;(FP;<C(8YW%OPI?^$@\2?\ 0K?^5"/_ H_X2#Q)_T*
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MMKFRU#372.4HZ[98'W(P:*08W+@'Y1@BKO\ PD'B3=C_ (17_P J,6?Y4?\
M"0>)./\ BE>?^PA'_A349I[_ (H#D/BA^S?X;^)VOQ>(5U/7O"'BA(A;MKWA
M346L+R:(=(Y& *NOID9'0$5?^$WP$\,_"&:^OK"74]<\0:@H2\\0>(+PWE_<
M(.B-*P'RC X R!GH*Z :_XDY_XI7@?]1&/_ H_X2#Q)W\*X/I_:,7^%5^\
MMRWT]4 ?#OX>Z=\--'O=.TR>ZN(+K4;K4W:\=682W$K2N 55?E#,<9YQU)H\
M=_#W3OB#'H*:A-<P#1]5M]8@^RLJ[IH22BME3\AW'(&#[BC^W_$G0>%<GT_M
M"//Y8H_X2#Q)P?\ A%N/^PA'^/:IY)WYKJ_J@..^*7[-?AOXG^(HO$:ZIX@\
M(>*$A%LVN>%=2:QNY81G$;MA@PYZD9P ,X K3^%'P&\+_"&'5'TYM0UG5]6(
M.I:WKUV;R^O<9"B61AC !QA0H/)(R:WO^$@\2?\ 0J_^5&+\NGX4O]O>)/\
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M2#Q(.#X5QZ_\3&/_ I?[?\ $@Z^%?\ RH1_X4U[5))27WK_ # YWX1_ 7P_
M\'YM3O;.^UCQ'KVIA4O=>\27S7M].B9V1F0@ (N> .@SG KTGO7,?V_XD_Z
M%7_RH1_X4G_"0>)/^A6_\J$?^%1*$Y.[:^]?YB.HHKE_^$@\2?\ 0K?^5"/_
M H_X2#Q)_T*W_E0C_PI>REY?>O\PN5/C5_R1WQW_P!@&^_])Y*_-3QOX%\2
M?$#_ ()J?#G3O"_A_5/$E_%XPFN)+72+*2ZE2(+?J7*1J2%!91DC&6'K7Z%?
M%S6M>N/A3XSCN/#OV6!]%O%DG^W1MY:F!P6VXR<#)P/2O)_V#]0U'3?V:?#T
M&E:4-:L5N+PI=FY6#<3.Y/R-R,$]?;MS7L8"M4P+CB8)-PDGNO\ ,F5I*S/R
M:_X9G^,!_P":4>./_"<O/_C='_#,WQ?_ .B4>./_ G+S_XW7[TGQ!XC_P"A
M67_P81_X4G_"0>(O^A67_P &$?\ A7V_^NV/_P"?4/O_ ."<OL(]S\%_^&9O
MB_\ ]$H\<?\ A.7G_P ;H_X9F^+_ /T2CQQ_X3EY_P#&Z_>C_A(/$7_0K+_X
M,(_\*/\ A(/$7_0K+_X,(_\ "C_7;'_\^H??_P $/81[GX+_ /#,WQ?_ .B4
M>./_ G+S_XW1_PS-\7_ /HE'CC_ ,)R\_\ C=?O1_PD'B+_ *%9?_!A'_A1
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M_P#/J'W_ /!#V$>Y^"__ S-\7_^B4>./_"<O/\ XW2/^S3\78UW/\*_&R#(
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M,D?L]\'O@]X9^!G@.P\)^%+$66G6H+-(_P TMQ*1AI96ZL[8&3TP -#_
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M2?\ 0K?^5"/_ H_X2#Q)_T*W_E0C_PH]E+R^]?YA<ZBBN7_ .$@\2?]"M_Y
M4(_\*/\ A(/$G_0K?^5"/_"CV4O+[U_F%SJ**Y?_ (2#Q)_T*W_E0C_PH_X2
M#Q)_T*W_ )4(_P#"CV4O+[U_F%SJ**Y?_A(/$G_0K?\ E0C_ ,*/^$@\2?\
M0K?^5"/_ H]E+R^]?YA<ZCO6;I?_(0U;_KX3_T5'65_PD'B//\ R*W_ )4(
M_P#"L_3M>\1+?:H1X7R3.I(_M"/@^5'QTI>REY?>O\PN=O17+_\ "0>)/^A5
M_P#*A'_A1_PD'B3_ *%;_P J$?\ A3]E+R^]?YA<ZBBN7_X2#Q)_T*W_ )4(
M_P#"C_A(/$G_ $*W_E0C_P */92\OO7^87.HHKE_^$@\2?\ 0K?^5"/_ H_
MX2#Q)_T*W_E0C_PH]E+R^]?YA<ZBBN7_ .$@\2?]"M_Y4(_\*/\ A(/$G_0K
M?^5"/_"CV4O+[U_F%SJ**Y?_ (2#Q)_T*W_E0C_PH_X2#Q)_T*W_ )4(_P#"
MCV4O+[U_F%SJ**Y?_A(/$G_0K?\ E0C_ ,*/^$@\2?\ 0K?^5"/_ H]E+R^
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M;[]ES2=62[OOLAU:XA36--2RN(QY!DAW6ZR2+&R IA0YQM4X4C J?VDC_
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M=*MR/]4[DYR2<^7_ =,\X7Z=K^8\70CAZ\Z4)\RB[774]:+NKL2BEHKD*$H
MI:*0"44M%,!*H>(/^0#J7_7K+G_O@UH5G^(/^0#J7_7M+_Z :0%Z//EK]*6D
MC_U:_2G4 )12T4P$HI:* $HI:* $HI:* $HI:* $HI:* $HI:* #VK.TSG4-
M7_Z^%_\ 1,=:/>LW2_\ D(:M_P!?"?\ HJ.D!I4E+13 2BEHH 2BEHH 2BEH
MH 2BEHH 2BEHH 2E]J*/_K4!U,3X9?\ ('B^E%'PR_Y \?THKSS4H^)/^1Z\
M/?\ 7S+_ .D\U=37+>)/^1Z\/?\ 7S+_ .D\U=3752^$B04445L2%%%% !11
M10 4444 %%%% !1110 4444 %%%% ')>(?$5KH7C'33<Q7T@:PN,?8[">Z_Y
M:0]?*1L=#UJ7_A8VD_\ /KKA]?\ B07Y_P#:-7KC_D<M/_Z\+C_T9!_]:MG]
M:I./8#F/^%C:5Q_HNN_^$_?^G_7&C_A8VE?\^NNY]O#]_P"G_7&NGX]/THZ
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M)I?#E^LBVP8^3&Y\H[V1-J;^-VW.!G%>F#'''!Z'%''''Z52<;6L!S'_ L;
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M8'/2E>';^ON Y?\ X6+I/_/KKO3_ *%^_P#_ (S2_P#"QM*_Y]==_P#!!?\
M_P 9KI\#T'Y4<<\#\J/<[?U]P',?\+&TG_GTUS_PG[__ .,TA^(FDGG[)KI.
M,<^'[\_^T:ZCC<00 1UZ<4<=P*/<[,#F#\1=)_Y]-= ]/^$?OS_[1H_X6-I/
M_/KKH_[@%_\ _&:Z?CT^O%'U _*E[G8#F/\ A8VD_P#/IKGH/^*?O_\ XS1_
MPL;2O^?771[C0+__ .,UT^!Z8^HHXXX _"G[G8#QWQ-:Z3XB^+/@OQJ+C7;8
M>&X+Z#["/#%^WVC[0B*#O\L;-FS^Z<Y[=:T?A_=Z-X'M=5=_[<U#5=6U"74K
M^^_X1J_C\V1\!5"^4=JI&L<:C)PJ#DG->H\>@_*C ]!^56YIJS_K\ .8_P"%
MC:3_ ,^NN_\ A/W_ /\ &:/^%C:3_P ^NN_^$_?_ /QFNGP/0?E1@>@_*IO'
MM_7W <Q_PL;2?^?77?\ PG[_ /\ C-'_ L;2?\ GUUW_P )^_\ _C-=/@>@
M_*C ]!^5*\.W]?<!S'_"QM)_Y]==_P#"?O\ _P",T?\ "QM)_P"?77?_ G[
M_P#^,UT_'7''THP/0?E1>';^ON YC_A8VD_\^NN_^$_?_P#QFC_A8VD_\^NN
M_P#A/W__ ,9KI\#T'Y48'H/RI^YV_K[@.8_X6-I/_/KKO_A/W_\ \9H_X6-I
M/_/KKO\ X3]__P#&:Z? ]!^5&!Z#\J/<[?U]P',?\+&TG_GUUW_PG[__ .,T
M?\+&TG_GUUW_ ,)^_P#_ (S73X'H/RHP/0?E1[G;^ON YC_A8VD_\^NN_P#A
M/W__ ,9H_P"%C:3_ ,^NN_\ A/W_ /\ &:Z? ]!^5&!Z#\J/<[?U]P',?\+&
MTG_GUUW_ ,)^_P#_ (S1_P +&TG_ )]==_\ "?O_ /XS73X'H/RHP/0?E1[G
M;^ON YC_ (6-I/\ SZZ[_P"$_?\ _P 9H_X6-I/_ #ZZ[_X3]_\ _&:Z? ]!
M^5&!Z#\J/<[?U]P',?\ "QM)_P"?77?_ G[_P#^,UDS?$#2SXLL9?LVM;5L
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MW_OTO_Q5?L[_ ,-0?!O_ **MX'_\**S_ /CE'_#4'P;_ .BK>!__ HK/_XY
M1_KEFO\ SX7W2_S'["'<_&+_ (8C^.G_ $3+7?\ OTO_ ,51_P ,1_'3_HF6
MN_\ ?I?_ (JOV=_X:@^#G_15_!'_ (45G_\ '*/^&H/@Y_T5?P1_X45G_P#'
M*/\ 7+-?^?"^Z7^8>PAW/QB_X8C^.G_1,M=_[]+_ /%4?\,1_'3_ *)EKO\
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MAI7AV_K[@,6/XC:3Y:_Z+KG3_H 7_P#\9IW_ L;2?\ GUUW_P )^_\ _C-=
M-'RBD]<4N!Z#\J+P[?U]P',?\+&TG_GUUW_PG[__ .,T?\+&TG_GUUW_ ,)^
M_P#_ (S73X'H/RHP/0?E3]SM_7W <Q_PL;2?^?77?_"?O_\ XS1_PL;2?^?7
M7?\ PG[_ /\ C-=/@>@_*C ]!^5'N=OZ^X#F/^%C:3_SZZ[_ .$_?_\ QFC_
M (6-I/\ SZZ[_P"$_?\ _P 9KI\#T'Y48'H/RH]SM_7W <Q_PL;2?^?77?\
MPG[_ /\ C-'_ L;2?\ GUUW_P )^_\ _C-=/@>@_*C ]!^5'N=OZ^X#F/\
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M==_\)^__ /C-'_"QM)_Y]==_\)^__P#C-=/@>GZ48'H/RI^YV YC_A8VD_\
M/KKO_A/W_P#\9H_X6-I/_/KKO_A/W_\ \9KI\#T'Y48'H/RH]SM_7W <Q_PL
M;2?^?77?_"?O_P#XS1_PL;2?^?77?_"?O_\ XS73X'H/RHP/0?E1[G;^ON Y
MC_A8VD_\^NN_^$_?_P#QFC_A8VD_\^NN_P#A/W__ ,9KI\#T'Y48'H/RH]SM
M_7W <Q_PL;2?^?77?_"?O_\ XS1_PL;2?^?77?\ PG[_ /\ C-=/@>@_*C ]
M!^5'N=OZ^X#F/^%C:3_SZZ[_ .$_?_\ QFC_ (6-I/\ SZZ[_P"$_?\ _P 9
MKI\#T'Y48'H/RH]SM_7W <Q_PL;2?^?77?\ PG[_ /\ C-'_ L?20?^/77?
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M9*ZHX"@A69^%R,T/ 6L?&_X1P^(="T[X&#Q/I\VOZEJ%MJ7_ EUC:^;'/=2
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MI7AMOXR_:4T/38O#+?#30->U2.);=/&0U^."Q?@ 32VA439QRP7'.0!BO6_
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MAV%[<2CR[8C.T;C\S A<]:P_AC\5K3]I[PIXV\+:WH/_ C>K:=BSU&SM=4A
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M:MK]C)I]TRCS8,^9YVT21JV2<%789YQ6;=/E44]5;_@]0/&M+\#_ 'L8+*W
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M/.OVCO\ A1__ U/JP^-I_T+_A&;#^S>+[B3S[GS.+7GIM^]QZ5N_LOQ>!O^
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M10 4444 %%%% ')^(/$VEZ!XRTW^T;^"SW6%QCSGQUDAQ_(_E4O_ LWPHP/
M_$^L#V_UHJ[<?\CEI_ _X\+@\COYD%;/'_ZZM."6J?\ 7R YG_A9OA3OKUB?
M^VPI!\3/"@_YCUCTQ_K174<<]B,YSQCBLKQ5KP\*^&]3U?\ LW4-7^PP//\
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M;Z?\+OB=KMK87L]A+J6D>'ENK1I(9&CD*R+-@@%3[^H%2H1E]E_?_P 1[!_
MPL[PKG)U^Q_[_?\ UZ0?$SPJ/^8]8 ?]=1^54=#^,WA#7OA>?B%#JR0>%4@D
MGFO+E3&81&2LBNI&0ZLI4KUR,#.1GS&#]M?PB+B"?4/"GCG0_#%PRK%XMU3P
M_)#I+A\"-_-R6"L2 &* #(S@<T_9IWM%_?\ \ 9Z[_PLSPI_T'['_O\ #_.*
M3_A9GA3_ *#UC_W]%=*LD<D0E1E>-AN5U(((['/H:PO OC.Q^(/AFVU[3H;B
M*PN9)DA-RJJTBQRO'Y@"L1M;9N7G.",@'BL_W>]G]_\ P (/^%F>% .->L?^
M_HH_X6;X4Y_XG]C_ -_A73<8SC_/>E.!GBE^[[/[_P#@ <Q_PLSPIT_M^QQ_
MUV'^>U'_ LSPK_T'['\9@:3P?\ $+3?&VK^*=.L8+J&?P[J/]F7;7"HJO)Y
M22[H\,25VR+R0#G/'>JN@_%31?$'BGQIH2)<6<WA)X$U"ZO B6Y\V'SE9&W$
M[0OWBP7%7:'\K^__ ( %O_A9WA7_ *#]CCC_ );"C_A9GA7_ *#]C_W]'\J\
MAN/VVO!X=KRR\)^.]6\*1D^9XNL?#LLFDH@)#R&3(?8N#DA.U>[:#KNG^)M%
ML=7TNZCOM-OH4N;>XA.5DC9=RL/P(H<8K5Q?W_\ Q_^%F>%?\ H/V/_?T4
M?\+.\*?]!ZQ_[^BI])\:6.M>,-?\.VT-P;G14MFNKAE7R=TRNRHI#;BRJH9L
MJ Z8)R0-_Y?I2_=]G]__ YC_A9GA3_ *#]C_W^%+_PLSPIU_M^QS_UU%=-
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M \WRB"2P5RT9) ^:-QT&3T''I4/V?9_?_P #F/^%G>%3G.OV/\ W^%+_P +
M.\*Y/_$^L>>O[T"F?$SXB:9\*O!E[XFU:"ZN+&T>%'BLD5I6,LJ1+M#,H/S2
M+GGIFNH^7_Z]'[O?E?W_ / YG_A9GA7@_V_8D\<^:N>*/\ A9GA3: =?L3U
M_P"6P[UTW'ISCI^7^?PKSOXQ?&[2/@U#HRWNCZYXCU/6)W@L='\.6/VN\G*(
M7D94RHVJHR><X/3KAKV<G91?W_\ W?^%F>%/\ H/V/_?U:/^%F>%-N/[?L
M3QCF8?Y_S^-6/!_BX>+H-1D_L75]%-G>/9[-6MA"T^T*?-BP3OB.[ 8=2IXX
MK?RO/_Z_Y4/V:T<7]_\ P .9_P"%F>%/^@]88]/-%9WB+Q9X%\6:'>:1JVL6
M5WIUY'Y5Q#]I*>:A.2C%2#M/0CN#@\$@]O\ +WKA['XL6$UCX8N[_1]:T!=?
MO'T^"+5K0026\XW[$F7<2GF>6VP\@Y4<%E!%R-Z)_?\ \ 1H1_$GPE#&J)KM
M@B* JJLH Z 4[_ (6;X4_Z#]C_ -_A73\>E''I2YJ?9_?_ , 9S'_"S?"G
M_0?L?^_PH_X6;X4_Z#]C_P!_A73\>E''I1>GV?W_ / YC_A9OA3_H/V/_?X
M4?\ "S?"G_0?L?\ O\*Z?CTHX]*+T^S^_P#X ',?\+-\*?\ 0?L?^_PH_P"%
MF^%/^@_8_P#?X5T_'I1QZ47I]G]__ YC_A9OA3_ *#]C_W^%'_"S?"G_0?L
M?^_PKI^/2CCTHO3[/[_^ !S'_"S?"G_0?L?^_P */^%F^%/^@_8_]_A73\>E
M''I1>GV?W_\ YC_A9OA3_H/V/_ '^%'_"S?"G_ $'['_O\*Z?CTHX]*+T^
MS^__ ( ',?\ "S?"G_0?L?\ O\*R+CXD>&/^$LL9O[<LO*6QN%+>:,;C)"0/
MR!_*N^X]*QKC'_"96'_7A<?^C(*+T^S^_P#X %'_ (69X4_Z#]C_ -_A1_PL
MSPI_T'['_OZ*Z;CTI>/2B]/L_O\ ^ !R_P#PLSPISC7[$?\ ;44O_"S/"G_0
M>L?^_P!_]>NGX]*./2B]/L_O_P" !S#?$[PJ?^8_8_\ ?X4?\+,\*<XUZQ'O
MYHS73\>E''I1>GV?W_\ YC_A9OA3/_ "'K''_74?Y[4?\ "S/"G_0>L?\
MOZ*Z?CTHX]*/W7\K^_\ X ',?\+-\*_]!^Q_[_"C_A9OA7G_ (G]C_W^%=/Q
MZ4<>E%Z?9_?_ , #ES\3/"AS_P 3^Q_[^BE/Q.\*LQ/]OV//_38?SKI^/2CC
MTHO3[/[_ /@ <Q_PLWPK_P!!^Q_[^BC_ (6;X4_Z#]C_ -_A73\>E''I1>GV
M?W_\ #F/^%F^%/\ H/V/_?X4?\+-\*?]!^Q_[_"NGX]*./2B]/L_O_X ',?\
M+-\*?]!^Q_[_ H_X6;X4_Z#]C_W^%=/QZ4<>E%Z?9_?_P #ROXN?$'PWJ7
MPI\9V=MK=G-<W&BWD4422@L[- ZJ /4DU\-1_!G4/C=^P;X'\!V&N:'X=\0Z
M?XEFU2>+Q!<20*(A]K3 \N-VW$S(0,8P#SQ7Z#?&GCX.^._^P#??^D\G^?QK
MXI^$_P"TR?V4_P!@OP/XL7PY_P ).;W7[G2OLGV[['LWO<R[]_ER9QY.-N!]
M[.>,'W,LE54X/"1;J<RMJM_FK$2M;WMCYF_X=K>.#_S4+X<_^#6Z_P#D6C_A
MVKXW_P"BA?#G_P &MU_\BU[I_P /F&_Z) /_ IO_N2C_A\PW_1(!_X4W_W)
M7Z/[?BS_ )]?C X[4.YX7_P[5\;_ /10OAS_ .#6Z_\ D6C_ (=J^-_^BA?#
MG_P:W7_R+7NG_#YAO^B0#_PIO_N2C_A\PW_1(!_X4W_W)1[?BS_GU^, _<'A
M?_#M7QO_ -%"^'/_ (-;K_Y%H'_!-7QQU'Q!^'9 Z_\ $TN__D6O=/\ A\PW
M_1(!_P"%-_\ <E'_ ^6;(_XM O_ (4O_P!R4>WXL_Y]?C /W!Z;^Q/^RUX%
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MCX_\*;_[CH_U5S7_ *!W_P"!1_S#VT.Y^A'_ LWPI_T'['_ +_"L_7/B3X6
MET\JFO6+-YL1QYP_YZ+7P1_P^8/_ $1__P N;_[CJMJ'_!8PWUL8?^%1>7EE
M;=_PDN?NL&_Y]/:C_57-?^@=_P#@4?\ ,/;0[GZ(?\+-\*?]!^Q_[_"C_A9O
MA3_H/V/_ '^%?GQ_P^6/_1( !_V,O_W)7UK^RC^UYX6_:H\-W%Q86_\ 87B2
MQ/\ I^@S3B:2%2<+*C[5\R,\?-M&#P1TSP8S(\;E]/VN)H-1[W3_ "N5&I&3
MM%GJ7_"S?"G_ $'['_OZ*/\ A9OA3_H/V/\ W^%=-QZ4O'I7@WI]G]__ #4
MYC_A9OA3_H/V/_?X4?\ "S?"G_0?L?\ O\*Z?CTHX]*+T^S^_P#X ',?\+-\
M*?\ 0?L?^_PH_P"%F^%/^@_8_P#?X5T_'I1QZ47I]G]__ YC_A9OA3_ *#]
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M_?X4?\+-\*?]!^Q_[_"NGX]*./2B]/L_O_X ',?\+-\*?]!^Q_[_ H_X6;X
M4_Z#]C_W^%=/QZ4<>E%Z?9_?_P #F/^%F^%/^@_8_\ ?X4?\+-\*?\ 0?L?
M^_PKI^/2CCTHO3[/[_\ @ <Q_P +-\*?]!^Q_P"_PH_X6;X4_P"@_8_]_A73
M\>E''I1>GV?W_P# YC_ (6;X4_Z#]C_ -_A1_PLWPI_T'['_O\ "NGX]*./
M2B]/L_O_ . !S'_"SO"G_0?L1Z9F%4-/^)7A:.^U0MKMD TZLN91R/*C']*[
M;CTK-TOG4-6_Z^%_]%1T7I]G]_\ P ,K_A9WA3_H/V/_ '^%'_"S?"G_ $'[
M'_O\*Z?CTHX]*+T^S^__ ( ',?\ "S?"G_0?L?\ O\*/^%F^%/\ H/V/_?X5
MT_'I1QZ47I]G]_\ P .8_P"%F^%/^@_8_P#?X4?\+-\*?]!^Q_[_ KI^/2C
MCTHO3[/[_P#@ <Q_PLWPI_T'['_O\*/^%F^%/^@_8_\ ?X5T_'I1QZ47I]G]
M_P#P .8_X6;X4_Z#]C_W^%'_ LWPI_T'['_ +_"NGX]*./2B]/L_O\ ^ !S
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M;6[_ / \_DR/VRH>N[_ (09SGZ7Z]?PKC_CQ\-]/^+'[0&@>&KYWM1<>#]2
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M.GZ/^SW>Z_X4(2TGT=(M#"PM TZ+%:@(P5D&Z2/AL8![5VO@?PS!X)\%Z'X
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MX/\ ACX6>#YO#6CVKSV5U))/>S:C+]HGOI9!B22=V_UC, <C& !C%3SP7O+
M78#?T%-'?PKIJZ4+5M!^QQBT6 #R/LVP;-N.-NS&/:L7X2:GX.U3X>Z9+X"6
M!?"<0E@LOLMN\,("2,K[%902NY6^8##=02#FO)Y_V'_!K&2RL_%7CC2_"<KY
MD\(67B&1-)=2<M&8B"VUCU <>Q%>W6W@_3--\'CPSI47]C:7'9FQMTL0JFWC
MV[1Y>X$ CJ,@].<\YRERVT8'$?L\_P#$W\*ZUXL?#-XJUJ[U6)^I-L'$-K_Y
M AC/XUQ?Q9TSQ%XZ_:*TCP78>,];\)Z)>>%+F\O7T6Y,4[;+N)08F.5CD)=0
M9-I;;N4$;LCW+PKX=LO!WAG2="TY2EAIEI%9VZL02(XT"+D^N *RIOA[IMQ\
M3;3QRT]T-6MM*DTA(5=/(\EYDE+%=N[?NC !W8QGCO34TIN0'RG8^#O'WBKX
M9_$:6\^,'BRT_P"%>ZAJ5CH\MA.L,]V;>/S5DOY -UQ]X)MRHPN3DL:UO$WA
M6/\ :!\:_#6SUZ=HK[6?AS/?C4+8^5):WGFV4J7$9_A99,,,?0\$Y^A=-^#^
MBZ5X?\;:/#<WK6OBV[N[V^9Y(]\;W,8201$(, C<&QWS3/#_P;T7PWKWA3
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M+3[)#<WL^H2KYC/NGFD,DKY8DC<S,<#@9XX&*MSBE)<MVP/+/VRO^3=_$?\
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M "-P;'?-,M?@UHEG=?#^X6[OFD\$VLEII^Z2,B9'@$#&;Y/F.U0<KMYY]JV
M]LKW2_#R ^<?%GB;QEJWA[6++2?&&JZ/J$WQ?71[;4%G>4V]JVT>4$8D-&,D
M^61L)[5UGA?P3KO@[XP>*?AG>?$SQAK/AO6_";:JFHZIJ@?4M-N!<>2[P3[!
ML 4[A@84CIZ^H/\ L^^'7+YO=3^?Q8/&)_?1G_3!CY/N?ZKC[OWO]JG?$OX
MZ%\4M1U:^U'5-8T^?4M#/A^9M-N8XO\ 1C,LS8RC'<Q7:<D@J2".<T.I!Z=
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M?#/P1\"V'A/PI8+8Z9:+DECNDGE(P\LK?QNV.2?0 8 KLLC_)K^6L7*C*O.
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M0 4444 <EX@T:;5O&6F>7JM]INVQN#_H9C&<20]=R-Z_I4O_ AMWG'_ EF
MN$_[\'_QFKUQ_P CEI__ %X7/_HR"IO%%[-I_AG5[J!_+GALYI8VQNPRH6!P
M>.H'6KC.6R R_P#A#;S_ *&O7,=_GMS_ .T:/^$-O.A\5Z[G'3?!_P#&:P_@
MKXJU7Q=\"_"'B'5[K[5K-_HD%W<W)C1#),\2LS;54*,DDXP![5X-:_%#XE^-
M_@?\#I-+\:_\(]XI\8:O)9W^M_V3;7/R+'=./W#*$_Y8I]W;TK>,:DG:X'TK
M_P (9>=/^$KUT_\ X/_ (S1_P (;>9Q_P )7KOM\\'_ ,9KS7PG\)?C/I'B
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M3W<-O&=DBXD9T)E;=R#+M7 JEXZM?CC\!O#<_CC4_B]9>/])TN2%[[0[WPQ
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M_A+-<'_ [?\ ^,URGPS_ &H?A?\ C1O"7BRWU75(8VE:V-O/ S*#@E/-
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M->N?]]P?_&:ZBBCVD@.7_P"$+O/^AKUS_ON#_P",T?\ "%WG_0UZY_WW!_\
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M_P#CM'_#+O[$7_0^>'O_ N8?_CM?E03[4GX5^M?ZN8W_H/G^/\ F</M8_RG
MZL?\,N_L1?\ 0^>'O_"YA_\ CM'_ R[^Q%_T/GA[_PN8?\ X[7Y3_A1^%'^
MKF-_Z#Y_C_F'MH_RGZL?\,N_L1?]#YX>_P#"YA_^.T?\,N_L1?\ 0^>'O_"Y
MA_\ CM?E/^%'X4?ZN8W_ *#Y_C_F'MH_RGZL?\,N_L1?]#YX>_\ "YA_^.T?
M\,N_L1?]#YX>_P#"YA_^.U^4_P"%'X4?ZN8W_H/G^/\ F'MH_P I^K'_ R[
M^Q%_T/GA[_PN8?\ X[1_PR[^Q%_T/GA[_P +F'_X[7Y3_A1^%'^KF-_Z#Y_C
M_F'MH_RGZL?\,N_L1?\ 0^>'O_"YA_\ CM'_ R[^Q%_T/GA[_PN8?\ X[7Y
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M73/\*_!K\*/PH_U%I_\ 00__ %!]:\C]Y?^%V_"?_HX/1?_ I=,_PH_P"%
MV_"?_HX/1?\ PI=,_P *_!K\*/PH_P!1:?\ T$/_ ,!0?6O(_>7_ (7;\)_^
MC@]%_P#"ETS_ JIJ_QJ^%3Z3>JGQ^T65C X5/\ A)-,^8[>G2OPE_"C\*/]
M1:?_ $$/_P !0?6O(_>-?C9\*-H_XR"T4>W_ DNF<?I3O\ A=OPG_Z.#T7_
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MO_PA=Y_T->N?]]P?_&:/^$+O/^AKUS_ON#_XS7444>TD!R__ A=Y_T->N?]
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ML4_!CQ=\"?"'B/5O!OVK5]0T2"\N+K^U+U!)*T09FVK,%&3DX ]J\WU9?!2
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MJ ,9QJI"RDCG< ,YS@ =.*^WNW8_C2_7G\:<\0Y6T ^>_"?BK3O#/[8GC?0
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M_N8R1DG:1D8P=7]GO3-?^!WQB\3_ W\5^(E\3R^)8V\5Z?JRV*V0FG9_+O(
M_)4E5;/EOA3CDG S7TS^OX]:4G=U.1TQD53JMKDMH,3]!V%+2=NHS]11^7YB
ML %HI/R_,4?E^8HL M%)^7YBC\OS%%@%HI/R_,4<>H_,46 XWXU?\D=\=_\
M8!OO_2>2ORZ^,G_*,/X:?]CM+_Z+U"OU%^-/_)'?'8_Z@-]_Z3R5\&>&/V<_
M$O[3G_!/GP%X7\*WNEV%_9^)KC4GDU>66.(QJ;R,@&..0[B9E(! X!YXKZ3(
MZ]/"XFE6JNT8S3?H9S5XM(_,S/O1^-?;_P#PZ)^,?/\ Q47@C_P.O/\ Y%H_
MX=$_&/\ Z&+P1_X'7G_R)7[A_K/E/_/]?B>;[&?8^(/QH_&OM_\ X=$_&/\
MZ&+P1_X'7G_R)1_PZ)^,?_0Q>"/_ .O/_D2C_6?*?\ G^OQ_P @]C/L?$'X
MT?C7V_\ \.B?C'_T,7@C_P #KS_Y$H_X=$_&/_H8O!'_ ('7G_R)1_K/E/\
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M'_+KZFC_ %FRG_G^OQ_R#V,^Q\3?C1^-?;__ Z)^,?_ $,7@C_P.O/_ )%H
M_P"'1/QC_P"AB\$?^!UY_P#(E'^L^4_\_P!?C_D'L9]CX@_&C\:^W_\ AT3\
M8_\ H8O!'_@=>?\ R)1_PZ)^,?\ T,7@C_P.O/\ Y$H_UGRG_G^OQ_R#V,^Q
M\0?C1^-?;_\ PZ)^,?\ T,7@C_P.O/\ Y$H_X=$_&/\ Z&+P1_X'7G_R)1_K
M/E/_ #_7X_Y![&?8^(/QH_&OM_\ X=$_&/\ Z&+P1_X'7G_R)1_PZ)^,?_0Q
M>"/_ .O/_D2C_6?*?\ G^OQ_P @]C/L?$'XT?C7V_\ \.B?C'_T,7@C_P #
MKS_Y$H_X=$_&/_H8O!'_ ('7G_R)1_K/E/\ S_7X_P"0>QGV/B#\:/QK[?\
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M2?\ 'S)GAXAC[W^U^E=&GP2T?8N5G_\ F7_ .*K>O/^1\L/^O&X_P#1D-7/
MB1XDG\'_ Y\3Z[:Q^;=:;I5U>Q1A=V]XX6=5QWR5Z4U6JMVYF*R/+O$VD_#
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M\+]0OO)@LI;Z2/73:>:8S>98B # +^7G<0, G@TG[=/67XA9'HW_ I31MQ7
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M-N; (4=J\O^"7[7OB?Q7\;M,\!^(]3^'WB5-6@GE@N? 5S=S?86B0R;9WF'
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M%53.T$@DD5Z\GW>M92K58OE<G]X[(\P_X4CH_P#<G_\ J7_ .*H_P"%(Z/_
M ')__ J7_P"*KU"BH]O5_F861Y?_ ,*1T?\ N3_^!4O_ ,51_P *1T?^Y/\
M^!4O_P 57J%%'MZO\[^\+(\O_P"%(Z/_ ')__ J7_P"*H_X4CH_]R?\ \"I?
M_BJ]0HH]O5_F?WA9'E__ I'1_[D_P#X%2__ !5'_"D='_N3_P#@5+_\57J%
M%'UBK_,PLCR__A2.C_W)_P#P*E_^*H_X4CH_]R?_ ,"I?_BJ]0HI_6*O\S"R
M/+_^%(Z/_<G_ / J7_XJC_A2.C_W)_\ P*E_^*KU"BE[>K_,PLCR_P#X4CH_
M]R?_ ,"I?_BJ/^%(Z/\ W)__ *E_P#BJ]0HH]O5_F861Y?_ ,*1T?\ N3_^
M!4O_ ,51_P *1T?^Y/\ ^!4O_P 57J%%'MZO\S#E1Y?_ ,*1T?\ N3_^!4O_
M ,51_P *1T?^Y/\ ^!4O_P 57J%%'MZO\S#E1Y?_ ,*1T?\ N3_^!4O_ ,51
M_P *1T?^Y/\ ^!4O_P 57J%%'MZO\S#E1Y?_ ,*1T?\ N3_^!4O_ ,51_P *
M1T?^Y/\ ^!4O_P 57J%%'MZO\S#E1Y?_ ,*1T?\ N3_^!4O_ ,51_P *1T?^
MY/\ ^!4O_P 57J%%'MZO\S#E1Y?_ ,*1T?\ N3_^!4O_ ,51_P *1T?^Y/\
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MJG?\*1T?^Y/_ .!4O_Q5>G1?ZL4ZCV]7^9A9'E__ I'1_[D_P#X%2__ !5'
M_"D='_N3_P#@5+_\57J%%'MZO\S"R/+_ /A2.C_W)_\ P*E_^*H_X4CH_P#<
MG_\ J7_ .*KU"BCV]7^9A9'E_\ PI'1_P"Y/_X%2_\ Q5'_ I'1_[D_P#X
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M /(U'_#SK0?^B/7'_A7R?_(U?!;4E?MW^JF4_P#/M_\ @4O\SS?;U.Y]Z_\
M#SK0?^B/7'_A7R?_ "-1_P /.M!_Z(]<?^%?)_\ (U?!5%/_ %5RG_GV_P#P
M*7^8_;U.Y]Z_\/.M!_Z(]<?^%?)_\C4?\/.M!_Z(]<?^%?)_\C5\%44?ZJY3
M_P ^W_X%+_,/;U.Y]Z_\/.M!_P"B/7'_ (5\G_R-1_P\ZT'_ *(]<?\ A7R?
M_(U?!5%'^JN4_P#/M_\ @4O\P]O4[GWK_P /.M!_Z(]<?^%?)_\ (U'_ \Z
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MO@^)^%Y86D\7EU^6*UC=OYJ_XHZ:->[Y9'W6/@EH_P#<G_\ J7_ .*H_P"%
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M (4CH_\ <G_\"I?_ (JO4**/;U?YF'*CR_\ X4CH_P#<G_\ J7_ .*H_P"%
M(Z/_ ')__ J7_P"*KU"BCV]7^9ARH\O_ .%(Z/\ W)__ *E_P#BJ/\ A2.C
M_P!R?_P*E_\ BJ]0HH]O5_F8<J/+_P#A2.C_ -R?_P "I?\ XJC_ (4CH_\
M<G_\"I?_ (JO4**/;U?YF'*CR_\ X4CH_P#<G_\ J7_ .*H_P"%(Z/_ ')_
M_ J7_P"*KU"BCV]7^9ARH\O_ .%(Z/\ W)__ )E_P#BJ@N/@SI$&&V3\?\
M3S)_\5]:]7JEJ@_=4>VJ/[3"R,+P!;+!X?L=O0PJ<9SV%%3>"/\ D :?_P!<
M$_\ 0116 S.\6L%USPYW_P!/<G_P%GKJ[>YC6(988 Y.>.E><_$1;^^UW0K3
M3KB&VN3=.R27$;.JD02\X##MD=>X/:JJ^'_'"J=NNZ2/^W"7'_HWTK>%)S6X
MFSBM:_9]\0W_ ,#OB_X.BO\ 2UU/Q?KVHZI8S/-((8HIYD=%F/EY5@$(.U6
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MD',C@E_9Q\2V_P ?ASX?TKQ'I^B_$'P/*E[8:I$C7%FTH61'B8%58QR)*5)
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M,)S&6! = "1N))/&-'^R[?-\'[_ $:;Q>\GQ!O=>'BUO$PM\1IJH961EASQ
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M*\J_L#QQ_P!!W2?_ E_P#CM']@>./^@]I/_@!+_P#':/J[_F7]?(.8Z&\G
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MD%U*[/;S8"R*I7RSN"Y!4X'1AZ9_PC_CC_H/:3_X 2_UEH_L'QQ_T'])_P#
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MN=<L?AQH&MZWH<^C65CX&T%+*TA,BMF22Y:/SY-QV93[@"YVD]/21H'C@?\
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M E_P#CM'U=_P R_KY!S'JWVE/[PH^TI_>%>4_V!XX_Z#ND_P#@!+_\=H_L
M#QQ_T'=)_P# "7_X[1]7?\R_KY!S'JWVE/[PH^TI_>%>4_V!XX_Z#ND_^ $O
M_P =H_L#QQ_T'=)_\ )?_CM'U=_S+^OD',>K?:4_O"C[2G]X5Y3_ &!XX_Z#
MND_^ $O_ ,=H_L#QQ_T'=)_\ )?_ ([1]7?\R_KY!S'JWVE/[PH^TI_>%>4_
MV!XX_P"@[I/_ ( 2_P#QVC^P/''_ $'=)_\ "7_ ..T?5W_ #+^OD',>K?:
M4_O"C[2G]X5Y3_8'CC_H.Z3_ . $O_QVC^P/''_0=TG_ , )?_CM'U=_S+^O
MD',>K?:4_O"C[2G]X5Y3_8'CC_H.Z3_X 2__ !VC^P/''_0=TG_P E_^.T?5
MW_,OZ^0<QZM]I3^\*/M*?WA7E/\ 8'CC_H.Z3_X 2_\ QVC^P/''_0=TG_P
ME_\ CM'U=_S+^OD',>K?:4_O"C[2G]X5Y3_8'CC_ *#ND_\ @!+_ /':/[ \
M<?\ 0=TG_P )?\ X[1]7?\ ,OZ^0<QZM]I3^\*/M*?WA7E/]@>./^@[I/\
MX 2__':/[ \<?]!W2?\ P E_^.T?5W_,OZ^0<QZM]I3^\*/M*?WA7E/]@>./
M^@[I/_@!+_\ ':/[ \<?]!W2?_ "7_X[1]7?\R_KY!S'JWVE/[PH^TI_>%>4
M_P!@>./^@[I/_@!+_P#':/[ \<?]!W2?_ "7_P".T?5W_,OZ^0<QZM]I3^\*
M/M*?WA7E/]@>./\ H.Z3_P" $O\ \=H_L#QQ_P!!W2?_ E_P#CM'U=_P R
M_KY!S'JK7";3\PKB[R=/^$\L.?\ EQN?_1D%<]_8'CC_ *#VD_\ @!+_ /':
MQ9_#/C#_ (2BT4ZWIAF:TF</]BEP%#Q C'F]\C\J?U=_S+^OD',>VQW";!\U
M/^TI_>%>4_\ "/\ CA>!KND\?].$O_QVC^P/''_0=TG_ , )?_CM+ZN_YE_7
MR#F/5OM*?WA1]I3^\*\I_L#QQ_T'=)_\ )?_ ([1_8'CC_H.Z3_X 2__ !VC
MZN_YE_7R#F/5OM*?WA1]I3^\*\I_L#QQ_P!!W2?_ E_P#CM']@>./^@[I/
M_@!+_P#':/J[_F7]?(.8]6^TI_>%'VE/[PKRG^P/''_0=TG_ , )?_CM']@>
M./\ H.Z3_P" $O\ \=H^KO\ F7]?(.8]6^TI_>%'VE/[PKRG^P/''_0=TG_P
M E_^.T?V!XX_Z#ND_P#@!+_\=H^KO^9?U\@YCU;[2G]X4?:4_O"O*?[ \<?]
M!W2?_ "7_P".T?V!XX_Z#ND_^ $O_P =H^KO^9?U\@YCU;[2G]X4?:4_O"O*
M?[ \<?\ 0=TG_P )?\ X[1_8'CC_H.Z3_X 2_\ QVCZN_YE_7R#F/5OM*?W
MA1]I3^\*\I_L#QQ_T'=)_P# "7_X[1_8'CC_ *#ND_\ @!+_ /':/J[_ )E_
M7R#F/5OM*?WA1]HC_O"O*?[ \<?]!W2?_ "7_P".T?\ "/\ CC_H.Z3_ . $
MO_QVCZN_YE_7R#F)/VCID;X.^- #D_V+>\#K_J'K\K_BXP/_ 36^'Z@Y)\;
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M ";1_P .ROAE_P!"WI'_ ($ZK_\ )M+_ %XR[^27X?YA]7D?CAM-&TU^Q_\
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M:CC:*.[ECOKEHPW4H)KEPI(XW X)&<$Y]D_L'QSWU[2?_ "7_X[7P_$?$LL
MU@L/A'RT^M]WY>ATT:/([L]56X11C=^M+]I3^\*\I_L#QQ_T'=)_\ )?_CM'
M]@>./^@[I/\ X 2__':_./JUMI?U]QU\QZM]I3^\*/M*?WA7E/\ 8'CC_H.Z
M3_X 2_\ QVC^P/''_0=TG_P E_\ CM+ZN_YE_7R#F/5OM$?]X5S_ (RG1M"U
M ;N?L\G_ *":XG^P/'/_ $'M)_\ "7_ ..U0UOPWXT_LN\DEUS2G1(78J+&
M4;L*>/\ 6T?5W_,OZ^0<QZKH]PGV6/YOX:T/M$?]X5Y+;^&O&T* +KND[>V;
M"7_X[4G_ C_ (X_Z#ND_P#@!+_\=H^KO^9?U\@YCU;[2G]X4?:4_O"O*?[
M\<?]!W2?_ "7_P".T?V!XX_Z#ND_^ $O_P =H^KO^9?U\@YCU;[2G]X4?:4_
MO"O*?[ \<?\ 0=TG_P )?\ X[1_8'CC_H.Z3_X 2_\ QVCZN_YE_7R#F/5O
MM*?WA1]I3^\*\I_L#QQ_T'=)_P# "7_X[1_8'CC_ *#ND_\ @!+_ /':/J[_
M )E_7R#F/5OM*?WA1]I3^\*\I_L#QQ_T'=)_\ )?_CM']@>./^@[I/\ X 2_
M_':/J[_F7]?(.8]6^TI_>%'VE/[PKRG^P/''_0=TG_P E_\ CM']@>./^@[I
M/_@!+_\ ':/J[_F7]?(.8]6^TI_>%'VE/[PKRG^P/''_ $'=)_\ "7_ ..T
M?V!XX_Z#ND_^ $O_ ,=H^KO^9?U\@YCU;[2G]X4?:4_O"O*?[ \<?]!W2?\
MP E_^.T?V!XX_P"@[I/_ ( 2_P#QVCZN_P"9?U\@YCU"ZN(_)/S"N:T&9!K&
MK9(YG4_^0HZY-O#OCAUQ_;NDX]K"7_X[6;I_A?QE]MOQ'KFEJ\<JJS?893N/
MEH<_ZWW _"CZN_YE_7R#F/:!<QX^\*7[2G]X5Y3_ &!XX_Z#VDG_ +<)?_CM
M']@>./\ H.Z3_P" $O\ \=H^KO\ F7]?(.8]6^TI_>%'VE/[PKRG^P/''_0=
MTG_P E_^.T?V!XX_Z#ND_P#@!+_\=H^KO^9?U\@YCU;[2G]X4?:4_O"O*?[
M\<?]!W2?_ "7_P".T?V!XX_Z#ND_^ $O_P =H^KO^9?U\@YCU;[2G]X4?:4_
MO"O*?[ \<?\ 0=TG_P )?\ X[1_8'CC_H.Z3_X 2_\ QVCZN_YE_7R#F/5O
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M;4$SVW368!'_ $\GUKU?90DGY/\ #J(V)/VJ/'*_ =/&(\+Z4OBEO%G_ CO
M]B%Y?+'[XQ[-^<^9D$;L8S_#7K?B+XV6]E\"[;X@Z5:#4'U*RMI=-L&DV^?<
MW)1(82<''[R0*QP>A]*^>F7_ (MK; X'QN4# Z8U0C J_X/BGOOB99_!R6%
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MP%HHHK HHHHL!BW'_(YZ?\ ]>%QV_Z:0U9\1:A+I&@:G?0JC36MM+.BN"5+
M*C$9 (XX'YU6N/\ D<M/_P"O"Y_]&04>-@?^$+U['/\ H$_3_KFW_P!>G&UT
MGW&8/PF\;7WCKX.^%O%>H0V\.HZGI4.H2Q6R,L*N\>XA 26QS_>)XZUB?!;X
MQ?\ "9? ?P_X^\7W6EZ&;RW>:[F$GV:SAQ*Z [I7.T84=6ZD]*\(^"O[+/\
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MPZ:].JW-NR'SHI@J.2IBR2;@ @$LO4D<.I)N]@/NU?B-X3DUR'15\3Z.VL3
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M*+ %8MQ_R.>G_P#7A<=O^FD-;58MQ_R.6G_]>%S_ .C(* -FEHHHL 44446
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M$$;RNJ(K.[':JJ,DD\ >IK]N?\ @GW\+_B-\*_@;;Z?\0=2D8W#B?3-$G7,
MVE0$9\IW)SDDY\O^#IGG"_C/&F4X7#M8VE)1G)ZQ[^:_7H=M";>C/IVBBBOR
ML[0HHHH *S?$'_(-/_76+_T8M:59OB#_ )!I_P"NL7_HQ:0&C2TE+3 ****
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M.C_W)_\ P*E_^*H_X4CH_P#<G_\ J7_ .*H]K3VN_N_X(<K.QSR3QGGOZU0
MFT/3;C6+;59;"UEU2VB>""^>%#/%&^-Z*Y&55MJY /.T9Z5SO_"D='_N3_\
M@5+_ /%4?\*1T?\ N3_^!4O_ ,52YZ7=_=_P0Y6==)&DT;)(%=&&UE;!##N#
M^%4K#0-*TO18]'L]-L[/28XOLZ6%O"B0)'C&P1@;0N.,8Q@FN>_X4CH_]R?_
M ,"I?_BJ/^%(Z/\ W)__ *E_P#BJ/:4N[^[_@ARLT_"O@/PSX%@GA\-^'M)
M\/PSL))H]*LXK99&'&Y@@&3[GFMWCVQ]17'_ /"D='_N3_\ @5+_ /%4?\*1
MT?\ N3_^!4O_ ,53]I2>K;^[_@ARL[#\OS%'Y?F*X_\ X4CH_P#<G_\ J7_
M .*H_P"%(Z/_ ')__ J7_P"*I>TI=W]W_!#E9V'Y?F*/R_,5Q_\ PI'1_P"Y
M/_X%2_\ Q5'_ I'1_[D_P#X%2__ !5'M*7=_=_P0Y6:]Q_R.6G_ /7A<=_^
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M)M/TS3SHVG&PTMXI+"U-M'Y=HT8Q&8EQA"HX7;C:.F*Q?^%(Z/\ W)__ *E
M_P#BJ/\ A2.C_P!R?_P*E_\ BJ/:T_YG]W_!#E9T3:#IDFL?VL^GVC:I]G^R
M&^:%#.8-P8Q;\;MA8 E<X) /7FN=T[X-^ -(9S8^!_#=D7GCN6-OI-O&3,C;
MDDX3[ZGD-U!YH_X4CH_]R?\ \"I?_BJ/^%(Z/_<G_P# J7_XJCVM-?:?W?\
M!#E9LP^#]!M_$5UK\.BZ;%KMW"+>XU-+6,7,T8QA&DQN*C:ORDXX'I5+PY\-
M/"'@_4[G4M \+:)H>HW6?/N].L(;>67)R=SHH)YYZ]>:I_\ "D='_N3_ /@5
M+_\ %4?\*1T?^Y/_ .!4O_Q5'M:>W,_Z^8<K-VW\+Z-:VVHV\.DZ?%!J,KSW
MD26T:I<R. '>0 8<L 2V<XYJEX4^'_A;P'%<1>&?#>D>'8[@[I5TFRAM@Y[
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M+_\ %5/M:=_B?W?\$.5FSIO@_0=%N+6?3M%TVPGM;1;"WEMK:.-H;8$%85(
MVQ@C(4<"IO$'AO2/%NER:;KFF66LZ=(1OM-0@2>)L=,HP(./I6!_PI'1_P"Y
M/_X%2_\ Q5'_ I'1_[D_P#X%2__ !5+VE+N_N_X(<K-?POX+\/>!]/>Q\.:
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M&WEER<G<Z*"<DDG)ZU4_X4CH_P#<G_\ J7_ .*H_P"%(Z/_ ')__ J7_P"*
MH]K3_F?W?\$.5G1Z;H>FZ*;PZ?86EB;R=KJY^SQ)'Y\S8W2/M W,<#+'DX%8
MVA_"_P &^&-;FUG1O">A:3J\^[S=0L=.@AN)"QRVZ15#')Z\U5_X4CH_]R?_
M ,"I?_BJ/^%(Z/\ W)__ *E_P#BJ/:4^[^[_@ARL[#C_)H_+\Q7'_\ "D='
M_N3_ /@5+_\ %4?\*1T?^Y/_ .!4O_Q5+VE+N_N_X(<K.P_+\Q1^7YBN/_X4
MCH_]R?\ \"I?_BJ/^%(Z/_<G_P# J7_XJCVE+N_N_P""'*SL/R_,4?E^8KC_
M /A2.C_W)_\ P*E_^*H_X4CH_P#<G_\ J7_ .*H]I2[O[O^"'*SL/R_,4?E
M^8KC_P#A2.C_ -R?_P "I?\ XJC_ (4CH_\ <G_\"I?_ (JCVE+N_N_X(<K.
MP_+\Q1^7YBN/_P"%(Z/_ ')__ J7_P"*H_X4CH_]R?\ \"I?_BJ/:4N[^[_@
MARL[#\OS%'Y?F*X__A2.C_W)_P#P*E_^*H_X4CH_]R?_ ,"I?_BJ/:4N[^[_
M ((<K.P_+\Q1^7YBN/\ ^%(Z/_<G_P# J7_XJC_A2.C_ -R?_P "I?\ XJCV
ME+N_N_X(<K.P_+\Q1^7YBN/_ .%(Z/\ W)__ *E_P#BJ/\ A2.C_P!R?_P*
ME_\ BJ/:4N[^[_@ARL[#\OS%'Y?F*X__ (4CH_\ <G_\"I?_ (JC_A2.C_W)
M_P#P*E_^*H]I2[O[O^"'*SL/R_,4?E^8KC_^%(Z/_<G_ / J7_XJC_A2.C_W
M)_\ P*E_^*H]I2[O[O\ @ARL[#\OS%'Y?F*X_P#X4CH_]R?_ ,"I?_BJ/^%(
MZ/\ W)__ *E_P#BJ/:4N[^[_@ARL[#\OS%'Y?F*X_\ X4CH_P#<G_\ J7_
M .*H_P"%(Z/_ ')__ J7_P"*H]I2[O[O^"'*SL/R_,4?E^8KC_\ A2.C_P!R
M?_P*E_\ BJ/^%(Z/_<G_ / J7_XJCVE+N_N_X(<K.P_+\Q1^7YBN/_X4CH_]
MR?\ \"I?_BJ/^%(Z/_<G_P# J7_XJCVE+N_N_P""'*SL/R_,5C7'_(Y:?_UX
M7'?_ *:05D?\*1T?^Y/_ .!4O_Q5,;X%Z(TJR&*8NH*AOM,N<$@D?>]A^5'M
M*7=_=_P0Y6=GG_.11^7YBN/_ .%(Z1_=G_\ F7_ .*H_P"%(Z/_ ')__ J7
M_P"*H]I2[O[O^"'*SL/R_,4?E^8KC_\ A2.C_P!R?_P*E_\ BJ/^%(Z/_<G_
M / J7_XJCVE+N_N_X(<K.P_+\Q1^7YBN/_X4CH_]R?\ \"I?_BJ/^%(Z/_<G
M_P# J7_XJCVE+N_N_P""'*SL/R_,4?E^8KC_ /A2.C_W)_\ P*E_^*H_X4CH
M_P#<G_\ J7_ .*H]I2[O[O^"'*SL/R_,4?E^8KC_P#A2.C_ -R?_P "I?\
MXJC_ (4CH_\ <G_\"I?_ (JCVE+N_N_X(<K.P_+\Q1^7YBN/_P"%(Z/_ ')_
M_ J7_P"*H_X4CH_]R?\ \"I?_BJ/:4N[^[_@ARL[#\OS%'Y?F*X__A2.C_W)
M_P#P*E_^*H_X4CH_]R?_ ,"I?_BJ/:4N[^[_ ((<K.P_+\Q1^7YBN/\ ^%(Z
M/_<G_P# J7_XJC_A2.C_ -R?_P "I?\ XJCVE+N_N_X(<K.P_+\Q1^7YBN/_
M .%(Z/\ W)__ *E_P#BJ/\ A2.C_P!R?_P*E_\ BJ/:4N[^[_@ARL;\:>?@
M[X[ _P"@#?\ _I/)7YXS_!/QG\>/^"<_P]T#P-HW]N:M;>*YKZ6W^U00;85^
MVH7W2NH/S2(, Y^;I@''Z%77P'T*^MI;>>&66&5&1T:YD(*D$$?>[@U6T?\
M9V\,^'[!++3K-[.T0L5ABN) H).3_%ZUZ>"S&&!G&K3UE&2:NM-/F*4.96/Q
M[;_@G#^T3_T3P_\ @[T[_P"2*3_AW#^T3_T3P_\ @[T[_P"2*_9/_A2.CG^"
M?_P*E_\ BJ/^%(:/_<G_ / J7_XJOLO]?,=VC_X"_P#Y(YOJJ/QL_P"'</[1
M/_1/#_X.]._^2*/^'</[1/\ T3P_^#O3O_DBOV3_ .%(:/\ W)__ *E_P#B
MJ/\ A2&C_P!R?_P*E_\ BJ/]?,=VC_X"_P#Y(/JL3\;/^'</[1/_ $3P_P#@
M[T[_ .2*!_P3@_:)/_-/#_X.M._^2*_9/_A2&C_W)_\ P*E_^*H_X4CH_P#<
MF_\ F3_ .*I?Z^X[M'_ ,!?_P D'U6/<^-OV$_^"><WPLOX_'?Q2T^$^++>
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M_P#Q5'M*7=_=_P $.5G8?E^8H_+\Q7'_ /"D='_N3_\ @5+_ /%4?\*1T?\
MN3_^!4O_ ,51[2EW?W?\$.5G8?E^8H_+\Q7'_P#"D='_ +D__@5+_P#%4?\
M"D='_N3_ /@5+_\ %4>TI=W]W_!#E9V'Y?F*/R_,5Q__ I'1_[D_P#X%2__
M !5'_"D='_N3_P#@5+_\51[2EW?W?\$.5G8?E^8JAX@_Y .I <G[-+T_W#7/
M?\*1T?\ N3_^!4O_ ,539/@=HTBLK),588(^TR__ !5'M*7=_=_P0Y6=C&P\
MM>>,<4N1Z_J*X[_A2.C_ -R?_P "I?\ XJE_X4CH_P#<G_\ J7_ .*H]I2[
MO[O^"'*SL/R_,4?E^8KC_P#A2.C_ -R?_P "I?\ XJC_ (4CH_\ <G_\"I?_
M (JCVE+N_N_X(<K.P_+\Q1^7YBN/_P"%(Z/_ ')__ J7_P"*H_X4CH_]R?\
M\"I?_BJ/:4N[^[_@ARL[#\OS%'Y?F*X__A2.C_W)_P#P*E_^*H_X4CH_]R?_
M ,"I?_BJ/:4N[^[_ ((<K.P_+\Q1^7YBN/\ ^%(Z/_<G_P# J7_XJC_A2.C_
M -R?_P "I?\ XJCVE+N_N_X(<K.P_+\Q1^7YBN/_ .%(Z/\ W)__ *E_P#B
MJ/\ A2.C_P!R?_P*E_\ BJ/:4N[^[_@ARL[#\OS%'Y?F*X__ (4CH_\ <G_\
M"I?_ (JC_A2.C_W)_P#P*E_^*H]I2[O[O^"'*SL/R_,4?E^8KC_^%(Z/_<G_
M / J7_XJC_A2.C_W)_\ P*E_^*H]I2[O[O\ @ARL['O_ /7%9NF'%_J__7PO
M_HJ.N?/P1T?&-L__ (%2_P#Q5-7X&Z,K$B.8%CDXN9>>W]ZCGI=W]W_!#E9V
M?'K^HH_+\Q7'_P#"D='_ +D__@5+_P#%4?\ "D='_N3_ /@5+_\ %4>TI=W]
MW_!#E9V'Y?F*/R_,5Q__ I'1_[D_P#X%2__ !5'_"D='_N3_P#@5+_\51[2
MEW?W?\$.5G8?E^8H_+\Q7'_\*1T?^Y/_ .!4O_Q5'_"D='_N3_\ @5+_ /%4
M>TI=W]W_ 0Y6=A^7YBC\OS%<?\ \*1T?^Y/_P"!4O\ \51_PI'1_P"Y/_X%
M2_\ Q5'M*7=_=_P0Y6=A^7YBC\OS%<?_ ,*1T?\ N3_^!4O_ ,51_P *1T?^
MY/\ ^!4O_P 51[2EW?W?\$.5G8?E^8H_+\Q7'_\ "D='_N3_ /@5+_\ %4?\
M*1T?^Y/_ .!4O_Q5'M*7=_=_P0Y6=A^7YBC(]?UKC_\ A2.C_P!R?_P*E_\
MBJ='\$]&5@2DQ'_7S+_\51[2EW?W?\$=F:WPSC*Z/$3D KD45TN@Z';:#I\-
MG:IY<$2A$7).%';)HKA=NA9I,?FQ1FBBD 9-&3113&&31DT44 &31DT44 &3
M1DT44 &31DT44 &31DT44 &31DT44 &31DT44 &31DT44 &31DT44 &31DT4
M4 &31DT44 &31DT44 &31DT44@%%%%%,0AHR:**!ADT9-%% !DT9-%% !DT9
M-%% !DT9-%% !DT9-%% !DT9-%% !DT9-%% !DT9-%% !DT9-%% !DT9-%%
M!DT9-%% !DT9-%% !DT9-%% !DT9-%% !DT9-%% !DT9-%% !DT9-%% !DT9
M-%% !DT9-%% !DT9-%% !DT9-%% !DT9-%% !DT9-%% !DT9-%% !DT9-%%
M!DT9-%% !DT9-%% !DT9-%% !DT9-%% !1Z445'4 QFEVT450!MHVT44 %%%
M% @HHHI@(:,FBB@89-&3110 9-&3110 9-&3110 9-&3110 9-&3110 9-&3
M110 9-&3110 9-&3110 9-&3110 9-&3110 9-&3110 9-&3110 9-&3110
M9-&3110 9-&3110 9-&3110 9-&3110 9-&3110 9-&3110 9-&3110 9-&3
;110 9-&3110 9-&3110 "@T44@%6BBB@1__9
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>20
<FILENAME>layout.jpg
<TEXT>
begin 644 layout.jpg
M_]C_X 02D9)1@ ! 0$ 8 !@ #_VP!# ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P 1" *C M0# 2( A$! Q$!_\0
M'P 04! 0$! 0$ $" P0%!@<("0H+_\0 M1 @$# P($ P4%
M! 0 %] 0(# 01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$ P$! 0$!
M 0$! 0 $" P0%!@<("0H+_\0 M1$ @$"! 0#! <%! 0 0)W $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,! (1 Q$ /P#]4Z*** "B
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M"XF[VHI:4-CM18=QG\/XT_(I&]>@I-PH$(5.3Q2@'TIRD8HR* &FY%&11N]
MLT@N.7I1D4#I24@N&*;M/I3P:,B@+@O2F,P7..M.Q1Y= Q5.5!I:.G%% PHH
MHH **3(HW \9IB G'6HI)&W+MY'>I)/NU#'EF(/2F%R7K2[C1TXI5Z4,!:**
M*D8F11D4E)3$&02<4N#34^\3VJ3(;D=* $'2EHIP-(8VBBG T -IM.HH ;Y>
M>:<%QQ3EZ49%,1')RM,5AT[U+3!'\Y)I#'+TI:*<#0 TVBB@ IPZ4+TI: "
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M.!DC+.)M*E9<=LJ%)!JU"^R(<K;L^J?/3./-0'.,%@*>LRE<[@>,]:^48?\
M@HQ\#E9 VLZP[ X!73GQ_/FI[C_@H!\#O(CF'B+4+L3#+"/3I-T>>@.1S^!-
M-TY=@YNESZJ:=(^&*@_6HDNHVDX*GOUKYLA_;=^ <EO'<2?$'[,9$!,,^G7>
M]#Z';$1GZ&I+/]N#X KNQ\2(#N'_ $#KS_XS1R::!=]6?2,=[&TI4.,_6G_;
M$9CALU\UWG[<'[/D<,4;?$B".5<')T^\^;Z?N:D_X;J^ !N$1/B/#&< M&VF
MWH)_.&DX7V3'S6ZGTBMW">.IZ42S(/NGGTKYON/VWO@*TRM!\1H50'+*-.O3
MG_R#4C?MW?L_%N/B-",G _XEM[U]!^YZTO9M=&'-?0^B5NDVY)7C@Y.*%FW;
MNBJ#][.*^=+C]N3X!+AD^(ENC9Q^]TV] )_&&I?^&W_@*Z(UQ\0(N1DC^SKP
M(?I^YZ4<K["YE'=GT1]J1UPKJV/>FM>+'&6W# ZU\[_\-M_L_P!NTC?\+#@1
M>H7[!>8_#]S4$O[;WP.NI%6'XB6T*8 !?3KP9_$PT<OD/F\SZ/%X9%&2%'8Y
MJ:+$?S%@1]:\._X:H^$31*?^%CZ&<<G+L#^6VI&_:H^#4R,)/B3HN,X(69O\
M*7(5SV/<I+J)5!++CZU6^T*S'#+Z]:\1/[57P>B58Q\2-#"@84-(V<?]\TG_
M U-\&\JS?$K01NR!F8CD?A2Y>47,Y,]J6Z61F4NI(. P)IDEXD1P>'_NGK
M^5>+P_M6?!OS-TWQ(T-XU&41IF/(]!M%?*^B?M@?%#XB?%WQ^/"GCOPU_P (
MWH&^?3=(O[2.-=3@7)(BD"B4MM1N,]ZN,)2?NH5^Y^B"S"Z;:KJKC^'//Y5)
M#<+'R7Y]&X-?+_PP_;;^%_Q&\-VFJZMK]GX0UJ,B*^TR]9D"N.Z-C[O^37:7
M'[5'P>E)Q\2M!4>\[']<<T.&MF@BTU>Y[=)=1C+' !]Q1'>([!0WTKQ)/VG/
MA)*J*OQ&T-^=H*RL<_IT]Z?%^TA\*%N@C_$C12Q^[&LYS^6*:I/L0ZB3W/9[
MB0')\Q5V]MPIUL0T9?(YY'->/W/[0OPGLX7>;QYH\/JTDQ_PIEC^T?\ #((S
M0?$+0ROKYIQ_*G[-[,:FGK?0]C67(R6 /UIOG;F=20>,#GK7C+?M2?"4$>9\
M2- WM_TV//Z4]OVBOA?=Y5?B)HX=0&7RY3D ].U2J;OL'/'N>T+-Y>"Q"@^I
MQ3OM*2'(<#'OUKQ63]I+X66L,8O/B+HNY<X=YB/Z5%)^TI\*O*+M\1M#"C&6
M$IQ_*J=)]@]HEK?0]S6\5F*@9(ZX']:@DN\R#:=W^[S_ "KXJ^,/_!0KP[\,
M_&D/A[P]X7@^(D;VR3C4M,UE(U7?U!Q$Y4CZUQJ_\%0S]HM[>7X6:A;2NPA\
MN3Q.50,3@$MY/\ZE49[V'*HNK/T(:<Y)(8?535A)!MP>HZUX);?M#75IHMI=
M:GI/AG3HY5#G[9XRM\)D9^\T?-3:?\?'UQ6ELX?"$MC&KEKF/Q9!+&N.G*K4
M>SD^WWE>TBM?T/=?.0\;A^=.C8,K8.:\3L_C9J$UK'(FF^&'W#.Z'Q9%M;W7
MY*MQ_&N[ ?3/#\;=Q_PDT!Q^.VDZ<E_PX_:QZ_D>NF0+P6 QZD5(LR[ =PQ
M7C__ NR_P!QVZ5H3)V8>*(?_B*D7XOW$CJ6T[0@O5O^*CA.#_WS1[*74?M(
MGKOG+G&:9N7=][OZ5XM<?M#:;I]]<6UY=>$K>11E8I?%=LK_ (@CBJ%[^TSH
MD,,C?VAX(D;:VR'_ (3.V!8@94?<^\:/9L7M(_TCW>.;+$8X!J7S%SC//TK\
M_H/^"IMO>:K+96WPJGNWC=HR]OKB.K%3@D$08(]ZMV__ 5$MM+UBW@\0?##
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MXY9?[W]FQG_VM4.E-=#2-6#5^8^N9'^3.W/K4:MNZ?I7R:O_ 4:^&,LB[=(
M\:0;B!N;38]H]S^^JW>?\%"/A9:><K)XDG"0[]T.FX$AS]Q<N,-[G ]ZKV4^
MQ/MH=SZF63<0 >O2C[0H.W=S7RO;?\%"/A3>6GF;/$4+8W?8SI9,N1T!8.5R
M?K5IO^"@WP@@@BENIM?L7D&XQRZ;("I]#@D?K2=.26J8XUH2^%GU$MTOW2P_
M.E5LN3C*]B*^5&_X**?!M6'_ !-]<"MT_P")9)C^=6[7_@H=\'+F,F+4]8E
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MS)+@D_-&S+G"8XQ[5?MKI%MU 7;.#GGTH4(7M8'5G\29974H[=G9M.TZ9-N
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MVV%3"3GJJX ]@*]1U"^F6V;S[*QG7 " 6D8"^U<;X=BECU35-Q\R4W!R^ N
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M NP Q]*]&NOLDC,PL(E"C:5%<CJW@V*:9[J/,08$LHZ5SU*/(N:QT4:WM)<
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M,\H^<C'U!K[7^"__ 44\.>+&MM'^(EK_P (CKWRQ_V@@+V,C'U)YCS[U\F7
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MKS),ICD9%0YQGCZ5TVER7%[J&F7%W''-IL5ROG*I 8KWS653$2Q248FM'"K
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M)&DD,L9R,KZ UTLT@DE,I8!E.3BN1N]8D\3>(K+5[>PBTZRFC\M,RHQD(ZG
M)(_$5U<-BD=B\AF#'IQ65&3:TV-ZT=5S;HM2_O%5R-IZU5N-Q:,.2XW9"^U3
MQ3FX7RXT(91RU(UV%7RW +] QJZF]A4FW=E:6X63$0'EKTJ-XX(9 I^<K_.I
M#!NWC'1N#2RVH7F5L^@ IRBU8(26J'M,)(U'W)#_ ^U00VB1Z@7<Y11U]ZM
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MP@2$_P"[7,^.IXU\B$\?-R/2LZN$C3@VG;4NCCI5:BBU<YM=9NC8BW:)BRC
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MK9KJH(X9&$>/+CS_ G)J**W66WWW'S2 XPW7%,A;+D$JNWIMZ4Z<?9^Z%:2
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M;+8D#!Z;JAY5 7R%]:-K26NP_, >E3,MK(@3S'4@9VU.O<J]E>PUHT: [FP
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MKWFE6\3V.FA)+B2X8?+DX S6$\73A/35G5#!5JD+O1'=Z;;KJ%S'YX96SB,
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MVM[7[+<B@,N-^5/(K]>4P%&.G:OBL5?VFK/OL&DJ*Y59$M%(O2EKC.T***
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M/S_(^ZR]WPJ/7.PI?PJ& 'R5SDG'.[K5@&OGSWAE%+13$9/B)=VCZE[VTO\
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M>6T[-\K[3L(4CC(STK]<H>(U (.!CBOSO%_Q6?J&#M[&(X=*6BBN([0HHHH
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M1_@E&UG=V\MO?121V=P%0PA;1@1)A0!(N5& /O<<<?(XZ=\1?U_(^YP,7'"
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MNOL<BDN[1D5%:1W,A"S;!N&<# JU#"O =U![*:]V%^7W3YRI\5K:(C&H?O\
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M->/_ QN-8L;6XBM49[0WC&0L.!R:]98?NUR<%A\P]*^WPTOW4%8^!QT>7$S
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M:MU*20V%Y/,RDF-PZ>M-:0>7@;EDW?,?6KMO:1);))RX#<@=A52X=990(!L
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M6-5JMC]+P?\ "3'T445P'<%%%% !1110 4444 %%%% "9%+3*<#0 M%)D4M
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M:2%DGM9IEBDE!/\ I^\?7%<U>LHI(Z\/2]H[HW_ 9-:S:'+# =\@N"2P8'
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M] N+<1-L)QQD4V%GAD,;+A2,;JM7 ^V$[>2J U6^RM-$6>3.T<@=167)U*4
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M1D4G[)+"@B:.88;<.",5VI1E5E%LX7*4:*<8C]2D?36DBN-2U%[B1F,<H8R
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M^D:C/"+>>[LX;B2$'(1G0,5SWP37R&,E[2:F?<86/)#D-0=*6BBO/.T****
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M!]'TF7PEX0^-?PLO-,\3Q:OH5O<>;<^)=0TNYL+=U0#(C,KLSD@@G &1ZUZ
ME^WU^TQ\-?BI\ ;WPWX9\1PZWK":E:RQK% PWJK99E)'((K=D^-'PQ_:-^.'
MP@\"VR2>)="M]'E:YL[BV9((KAHXP@)(4LZA&!XP,C'4TXREK)KN#A"+23NS
MNOC%_P %&_!'@6&2+PK:3>,KA5RT\+>7;1^Y)&3^%<YI_P"U;X\U'X[^&]"@
M-B-.\1):.MFZ^8(!(N2 WK7:_$G_ ()R_#GQK^]T62]\*RL272R(>%AZ;&X
MKRG4/V=?B=H?[6WAC5],T%[GPKI!M4CU154(T<28)<9X;KT%13=#D?<SG&O*
M:/T*B8^6N>N.:7UIL:[5 IP]:\QGIG-?$(A?!/B1FRP73;DD#_KFU?B-\+])
MGB^&FC>,IK^XN?""^*;G3KG16W"**X6V@D$R_-M+2(P4G .(1R>W[=^/UW^"
MO$B]VTVY'_D)J_ >PTT65G;6-M<2-+=WD:PVGF$1F9B$#$=,\XSZ5VX5N,DX
MG'72E!QEU/HZ&\M]2D7[&1'&"2D>>0O:HX;5KKS@T9RAY:O5_$'_ 3SO/AQ
MX6?Q%XL^.&F>$K2+:L]Q-II,$3,VU5$C3+NR2/X17$?\,Z^!X+<S']K7P[Y3
M@,9!IX*X/O\ ::^G6:4Y+6-SY!Y/5N[S,BTTN-K(SLCDC@,IZU:TOR( XDFV
M)(. /6O._C!H_AWX5_V3!X>^-EM\1Y+IF:>+3;+RHK>,="TGFL"Q/10.G)QQ
MF_\ GP<WQLU+5DD^(&C^"M'TJ,37-_JTRM*V[.!'#N4OT.3D <=R!5?VC2U
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M?Q+H?@709_$.OZK#HVCQJ!)<7!(V$G ]ZJ]OA9FN\EH?&GCK]@7P_JG[1'@
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M#V_EGE23C;ZU<4E>Q,F^I=&9%D8E21QFFW5TPC ..M#1F.!QG#$\"JOES?
M,)5) Q@=ZS>Y4;RC9(<99(XS&Z9+8J6ZLPI4EP!4]QY=]"OE_NV3@>IJM)&Z
M12 YWYX+4U*VQ3IW5QIA$9+YRRC%1")FQO3"YZTT+-(K[_F '5:EA4)(';:8
MU[,:+W,N72URY(R)#)QE=N%-5I$ECL4D W$U/>1I>0>8OR@'Y57I562>2./R
MI.-PR*UDU$TBE)(LK<%(%!BYI9KC#;O+\O _.JUK(4L_GY8]*+B:0A%X([TJ
MCL[&<4[$WVQOLS$A74^@Y%4[>,M()/+(4]ZM,S0P[,#GFF*V(PL<Y 8_,O\
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M 35?7--G\0?%KQ#=2^)=083>193AVC)SN+.?O-C%+9_O-@7O)\NYSOA[X/_
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ME5O2.B.NG36[U9%"A:,<$>Q%28VC%/5ABF,PW'GVKEU-VD?DI^UE;Q7?[?\
M96D\:O%+?:>&SW!(%?K;']P$C'>OR:_:DC$W_!0K3R.<7^G']17ZSK]T5O4^
M"),?B8M%%)D5@:"T444 %%%% !1110 4444 %%%% !1110 4444 ,D^[7D/[
M4K6\/[/WC^2Z$KPC2+C AZ[MHV_ANVY]@:]>D/%>2?M174-G\ /'TMP5\D:3
M,IW=,G 'ZD52)E;J?DQ\((G7P>0UL4@DE8"4'[Q'6N]AMA##"R;AMZ[N]>9?
M#!'O+8Q02-'"P) 4\!J])&G_ &JS;SM2GC"G'RK7W^'GR48W1^=8B$95YZVN
M2.QD3E-IZ%E%4ULY&NG4X_&I;?1[9K:0'Q!.C#YD18L@_6H3I1AS*-:=967O
M%WK6%5<K:1R3P_O).0KPS11AG9?(!VTPJL;;EC.QCZ56L=-ENEE^W:I*B)@Q
MLL7WC4FM6<D=N'M=1N'+#'W.F3UI*HEK8/9WNDR^+>ZX>-%C7;D-WJC=0F1%
M+29D/WFJFEO?PWLH%^9HU*JLLB>HYQ3[C3KBX9V&I$[<;OW7>E[7E>PU1NM9
M%M?/M;:.1R) 3C(ZBK=U(MSLR654'!Q56VL]RA9-1.W.?]75+4([SSG6"ZWQ
MJW8=JN-338B5-6OS&A<>9)&F&D'/7;4;7;0N?.&Y!QFHK.&^'GE[UMB@%?E[
MT7VFW-X(V74,#.6'ET<^JT",?<O%DR0&\A$D.5YX%+=6]PJ*65N:CBLYH9S&
MVK&&+JK)%4MW9M"[ ZS)(N 0QBI^T6Z0I4FT]="O#"[KM&0V"-OJ:DO+.6U4
M#[-M<C)W51U,75DH-AJ@=<_,QBJC9S:I?74_VK4=R8PG&,TXU$]T5[*T4^IU
M-I;RC3>0H)Y^E9MQ;S,VTL#CD'VI(M/N7MFW:J8@H("E*S[JVOX&1K:[69\8
M._@54II]"(TGU9LPQFZMB^T(JG&Y:?/")+7Y>6'.X]_>LRWMM;93'-<VUG%L
M9]^W.6'04H6]O(E,^K(A' VQ]!3E4BGJ4J$N2]RXL"S1JQ)+=*BN;-K<J1D+
MV--L-/O=TG_$TB:WC.0?+Y)]:9<0:E=N/.U:W.\Y1%3[H]Z(SU5D*W-'<L1M
M<3 I"P"]&S27.G3-Y>'RG0FJ5Q9ZDMP$;4+<JH^5E3K2>;K5I#&XN8)#G!39
MS]:M2T(5/H:'V1VA;^*)6QN6HV_=S*B\(>NZH[>SO[A#,^HPP=RBIU]ZDN--
MOYT\R+4[:95'\7#?@*2:OL*2?*XW'M#&TI5#FHKFU"@,JY9>OTJM#8ZQ';F6
M.X@^;J)#\U-&GZH#&_\ :-L-PYC*Y-9\W-NC6,+:W+<5NZQ22 83'6K,#3I$
MQSE<51C&JS0[#>6X[;#'4LUGK5C;;(KRWE##G;VIRDK;&BI]GJ4U+ S.R$-4
MRE(5SN=(R/FV^M9^W5UD"F:WD)'S56T^\U5]:CL[I[>UE?=MRN<CM6,:B@[F
MKHN26I)IT@;Q!-ELJ5X/K6S)M61"..>M<QX<NKD:K>Q7 \QXF()"\@>M=-%E
MF4!FV_2KB_=31C47+-J1)L^;S PR/[U2K<2-(1(^T9_"HYX661U.<$<$U(D;
M2KY;K\N,[AVK3F=[D:-6'7$T2@J1N*]2M0RR(MJQ7Y6(P,]:C%J89'P?,5AQ
M4PAZJ1E>N[TH3T:)Y?>4B*.3[/;[<_,U2-((XVP,D\FI(XPT.-RY!XI=A,FU
MQNB889AVJ8Z:%.*W#3SB.0R851TI94A^SB6+<9#UJDRONVH3L'%7+1RF59EQ
MV4U>KE9&<8JUR!8Q)%ED7.?6E:5Y?W8&P+QQ2RC,C$' S2,KH,A"?>B-32PW
M$:T3QX9Y,KU'J*9>W3JT2$[AV]33I-ZQL[C (X%)-(OEQ$QY8C\J4I^\D@C#
MW6VB?;OC4!Y$.[)XZ4^W1_WB1-O&>6:H5>56W.I,9]*ECG:+>X8"+H!WJXW;
MNS*7+RZF5XTT^6XFT*PMI9UN;R_MXD:%@'#F10"I) !],D?45^HOCZ_CA^._
MPQ@:%)7>'4,,QY3(AP?TK\O_ !W:[Y/"MQ<W']FV5WJUO&]\Q(%LF]0TG!!^
M4<\$=.HK]-_B+'<S_M ?"X+$6@CBOY-P'?\ <[OR 7\Z^4S#^,OF?;Y8W[!?
M(]O7I3ZC7H*?7S1](.IC9S3@:;G^=#'U.$^-V6^$_BY1Q_Q+9N?^ FOQXTNS
M.F_M(?!RU#Y!UG1Y=OUNX\U^Q?QJF2/X5^*VE&4&G39'MM-?CTM_#JG[3GP5
MN+<!8AJ>CJ>1U^V)Q7I4;>S=SS:U_;1L?HA_P42M1)^SE-=EI-]AK%C<I&AP
M)#YFS:WJ,.3]0*]N\.7_ -L\&>&)& C>?3;>0IZ%HU)'ZUX'_P %*-6&F_LT
MRP;HU:^UFSMPTF1C#-)D8'7$9ZX&,]\ ^8_$S]O:ST/P9X?\,_#6&/Q!XC_L
MNWMGU#:7B@D$2J1&O5GS_*HBI2BDC9\L6Y2/IOXP_&CP7\#=!DO_ !1?HMR1
MOATV%@]Q/Z +U KX>NKGXI_M\>,)A8HVC> [.91Y;/Y=O#'GD_[<F*ZKX&?L
M8^)?B;J$WCOXXW&H)YS++!I\DF+B?N"YZHO^R*^WM L+#2]-CT[2;*WTC2H5
MVK;P1! 0/7'6M5%0ORZON92]]:Z(Y+X*_ #P9\"]+^Q^'=/\R_;'VC595#3.
M<<D$]![5W"J&C+2RF1][;6Q@D>N*M:>=LGSKE1TV]!3)K>5IB5==LA^48Z5"
M=V[[EVLM")HV6']VYY^]O[U,UR+.W?'F8QD!&P0:6.W.T(#ND)PS=A7SI^TU
M^V=X:^ I?2=(MHO$_BW:KB'<?L\63CYG7/(_NU46Y^[%7#57DV8W_!2)C:_L
MGZS:7-[";F]O[3RHG8&0KY@+;!U) ].E?*.@_%[XG_M(>#=#^&O@RU;1O#&F
MV,5I>%'Q'Y:#YI;B0](^^VJ7QW^'_P 6?BA\/]6^-/CR5=-L()8EMM/F5H]R
MLP"^5'G"C!'S'K7W+\,O".C^'OV&X)-*TVVLC=>&7EGDB0+)*64DEF R>O>F
MKTWK9ZDZ5%9:&!^RY\!?A'\$M-M=6;Q)H7B3Q;-&SR7QGC9$]5A4GY<>O6OH
M:X^(7A)YL2^)=-MVC0.5:Y4E5]3S7SE^QC\+/"FM_LXZ%J%[X:TO4+^62827
M%U "[8;IGZ5[C%\(_!ZPGSO">CHS?*RBV_A]*)Q3DW)Z[ FTK16AV4?C7PTT
MD*+XCTMY' V@WD89L],#-=2C,<#JOK7P_P#MQ_#?0='^'OA&]T'P[:V&K'Q%
M9+%-:0@2,@D'RC'/3-?<$<B! 0!@ 8KDJ044GW.FG?E'><BY!;IUK,\0:]I
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MN<*/";<?\ ->._M_?%;POK'[(L#Z1JJZC!XDN[9]+;;G?Y<FY\^AK.FL_
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M**ILZ#]FO]JCP3\#_P!DCPY!J$PU'Q!(UP\.CVS9D)+<%_[HKC[7PO\ %_\
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M<LMV]FGE65I$H!=V&XK'&B@$XX IT-PD>M7!2YAAMI%\LIY(;?^)Z5JZFFG
M+8Q_:8HSY0!5D]/K64:4HOGYK&LJL7%0Y;C=+OM:U?7+VQN([>.>W=HY4B=9
M%W*2#M920PR.H.#7365P\<AMI1@XY],US?@NZLO[9=[%"/D(]:Z5&#;D)$C,
MWS'/2O:P]W&[=SPL2[3Y;;!'*(VD(7>0<8ILC+Y1_=J.>E6)K?RXV2(&3/\
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M><' &:^C?AS^V;K,EOX*D^,W@JT\/Z5XN@5M%\0:3<B2T=),!O.7>3& &C#
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M 3H^#T>#YWB3/\ V$5X_P#(=91QL(NZN:RP,Y*UD?"TWCB8PDQ:0X+#Y7W=
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M3XW0^ /"NM/X?^'FO>(_%.KQS"(ZD]WFTDR,%$1?F<Y[]*]>^"?_ 3_ /$W
MQ(M[#Q#X]U.;0M*FB9A9*"UX?[I._A?P_*M'CG%*4F<T,#S2<8(\EL?%$\D.
M]]&OBK#.^.(8/N*5O%+*LC/H^J1Q*,C]SG<:^Q6_X)Y>$F3 \9>)40<!1(
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M>&98/$EYIN@Z++/8>8\X^VP/EK9QN)'*J-@ P&P!W/ZR?M79;]G7XAKO9?\
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M2U9N.:[L7)<T?0XL'\#OW*OECMR*>"B@ I4RVS*HQV^YL'BN'F.ZUR,*A
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MM;-$+R2R, .YYKXK^-G[:FJ^(O$7_"$?!BQ.MW[[[>74HXFD*MG!,0Z$?[7
M2MZ4)57:/_ ,*C5)<\ONZGM/QT_:>\%? 6SWW^I+J&M[6^SZ39L'>0]BP'W!
MGN:^.=%^%_QP_;>\0?V]XDOYO#_@:27Y8IG:.%(P<XCA'WSC^(_F*]E_9[_X
M)_0Z7?Q^,?BA<-K7B,S"[BL3)YL:MU/G<?.<]@>/?I7V@NFHMJD,2")5&U%1
M0H7\JTE5A2?+3U??_(482JI2EHCS;X/_ )\(? W21:^%=+2*>10+B^D8-/*
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MD1*MYJ$^_P"?'4 =#7OEEI<6FZ<EG86JVMM -L4,8"1JOH%%36UNRW"LYSM
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MWXO^)&\L.!I$8SLSC]X,<XX_2KO_ 5%W2:Q\.%*$0@3DMVW<<5G?\$ZY)+C
MXSZ^B\1QZ0H8CI]\8SQ_4?C79'_<V<E27^V1TZ'Z/PJ?+ 8Y(J09QS21@JH!
MZ^U.KP3W!R]*8?O'BG@TG^-)AU/(?VKE'_#._P 0"&(;^RY,$<$=.E?FO\7+
M>;_AK[X"/.C)*MKX4#AFWD'S(\_-N;/UR?K7Z3_M69C_ &?/'K]/^)9)C!P>
MW(/8U^;?Q@O%D_;'^!4B&1X[BV\*RF268S'_ %D7)?<P/ '(8Y.3DYS7?1^
MXI:5&_(^I?\ @JKI]SJW[/OANRMG427/BNS@57XRS07(7GL,GTJK;?LY> ?V
M:M"T7QE\9?'FH>/KS0;2.'2=.U:1?(C>-0!':6S,=Y "87./EW'U'GG_ 4Y
M_: \,:_I>@^ _#^IKJ.O:3K,6J7;VP+0PLD;A8_,# %\R9*@''JIX.+\,_@%
M\3?VT/$ \9_$[4KW2-"VDVS%"F4W']U#&<;4Y//)/<D\U<$^3>R)GO>US*\9
M?&[XB?M=>)+SP?\ "S3=2T7PM=EX[B/$4,ES&S''VJ6-%"QJA"",%N%Y9B2:
M]F\&_P#!,WP38_#.XTGQ#J4DWBRZ/F?VM9G$=FP&0BH>"N>I/)]J^I/AO\-M
M!^%?A&#P[X9TY+/3K4;7FD4>9/[N0,L?>NE_LIYE7RU4-C/S$#/Y4I3TLM">
M7J^I\9?L]_L#ZA\'?C5:>,]8\1Z7XAT"QBE6*S$#^;O9,*Y!7 (//6OL6U\U
MIGE.9%<Y QR!4GV&Y4N@A5AC:0I[UY[\5_CKX/\ @#IL$_BC4"9YB?)T^WC\
MV<\<\#D+[TE*4_-E2C&'D=_JVI6&BZ?=:GJ=U%IUC;INFNKAPJH!W.>M?%7Q
MJ_;DOO$MX/"7P5M)M0O;DM'/J,=JQ;T'E)C/_ JXS6-0^+W[>&KRV6DV@TCP
M!;7(*@GRXL \,Y_C8#!QTK[%^ _[.7A7]G_3YK?2()+[69P#-JETJ^8[8Y53
M_"N>U:.*I_%JS.-1U/A5HG@?P%_83ECU9O&7Q@F'B/6;Q%E33YG,C(QYS*^<
M$CCC\*^P[.SCL[&.TM;=;6TC7RXX+4"-$3IP/6M(6]PTB-.0SXR=O2F7"F.1
M453GTK!RYG=FL8QAJB&XM+=HA&N[*KRQK/NM4LO#FESZCJM]%8:;:KNDNKAP
MBH#WR>PKSGXY_M)^#_@/8S3:I?+>:QLS:Z/;N&ED?'!8#[H_VCQ7R-I>G_&?
M]N;5@UZ[^&_ ;M\VQ-MN%ST7_GHW^>*WC2<XW;M%&=2LJ<^5*\F=)\</VU-?
M^(=]+X(^#6GWUTQ<QRZK;J6EE.<?NNR@]=Q[5UW[._[ ]KI-ZOB[XGM_;VN3
MD3KITA+0HY^;=)GEG!Z@\?6OH+X,_L]^&O@+H)T_PS:L9YPOVK4IS^]F8>OH
M/I7J&V211D'\JR=517)3V+]GSM2J:E*&&.&&*WBC6WM578L*J%5..,8I^V1I
M%(90BNO/<]*EEM78*!R::MONV,0/ED Z]>]8F]KM'Y)6Q _X*/:6_1/^$QB&
MX^N\?XU^P4<BLJX;.:_&/Q?XUM_ W[:EWXNU"W:YM=%\2?:KJ.%5)\M7'*^_
M2OU5^"7QHT/XZ>%I-:T&WO(+&*4V_P#ID7EDD#JOK6E5.48RZ!3:YFKZGI0.
M>E+3(_\ 5KSNXZT^N,Z HHHH **** "BBB@ HHHH **** "F4^B@""4%LXXY
M_I5;2X3#:HAZKQ5YN_TJ.W4JO(Q3OI876YY/^T9\(;[XT>"[+1;"[@T^XM=5
M@U'SKE6*%8]WR_*,Y.:\"_:B^'M]\+?V9?&LLD]C>W6I&T@FDM[5E.U95;))
M8G[R@9/K7VM)]VOG3]N^^6T_9G\5HX3;<-;VX9F8%6,RG/'T/6NFE5EI3Z'+
M5HQUGU/@O]D0)'^TA\,2S[!YTW4X'_'O-7ZWSEQ)D$[1WK\7O@K\+[_XM?&C
MP5H\&JWVBK(9)/MUA'NEMA&A<-C(X)^7_@5?H1<?LR^+--TV* _''Q,TZOEI
MOLJ_-^&_^M=V*UFK]CAPGNTV?2\GG?*><9-1*TJNH.<@9-?--Q^S+XJATN6X
MN/CYXD@CC#2O=O;*(D4=23O X_R*^+O&_P"T3X^^#_QF-EX%^*U[\2+.%5B5
MKJ$-!,[Y!4+GYL8."&YQ^%<48.;LCM<U%<S/T7^.W[27@WX%V)EUS4%GU<Q;
M[;1[<YN)>< D=ESQFOC"\T_XP?MX>)H-0ALY_#W@-9EC9)+A?LT0'WRHX\QS
M^-=A\%_V,?$_Q<U[_A8?QGN;JXFN]SC1YODFDR>-_38O<*/7M7W-I.DV7AFP
MLM*TJPBL+&% L4,,>Q4P,=*U<H4?@U9ERRK*[TB<)\%?@#X6^!^@V]GHUG'<
M:CY>V?5YHQYT[=_FY*CT'2O3D#*H&_Z8&/TI)$81XY)SZ4]1N3)XVURMN3O+
M4Z(14%RQT#YNYJ99<(.?J:JQSDL<J<>M-N)@JX'1FQ2TV+NT/GN#N #?>/%4
M+S5K71;*ZU+4KR.TLH5W27$S!5C4=>37'?&3XT>&?@IX5FU?7+E?/VD6]E%(
M!/<L!G:H/6OCZ34/BE^W-KGV2"&3P=\/82IESDI+\V>N/WC$>AX_6NBG2<DY
M/1(PG62?(OB-SX[?ME:I\2-0?P)\'K*ZU.ZOHVMYM2BRDF3Q^Z.1C'=ORK?_
M &8_V#8?"=Y:>,/B+*NKZ^P\]--D)DA@=N27R3O?ZY'H:]Z^$?P'\*? W39+
M7PMII:YD(,UY<.'GF/?+XX'M7J%K&^#O)P><$8JI5U&/+1T7XD1H2E+FK:L9
M;QI"D*1J(84&%CC7"BK2D!>6R?6@(,<4H"^M<>FYW7TL&,]Z6D+*O4X%,DGC
MB4L[JB@9+$X''6I >LR-P&!(.",UYU\8OC5X4^#.@G4_$VI"!)&VPVRKODF.
M,X11S^->(_M#_MN:1X!O&T#P%!#XN\57!,1\AM\,#YQ\Q7EF!_A'YBN$^%_[
M&GBSXL:U;^-_C1K%Q?"Z3SUT?S761<C(5E^[&!Z+SZUW4\.HI3K.R.2=?F?L
MZ>_<Y;4-0^*?[=6O)%I,,WA;X=V\S*\LDK;'&>"PX,C$?PC@5]<_ K]G7PS\
M!O#T5KH]LMYJ0!%QJ<\:B>8^F?X5]A7HF@^';'POI=KI^E6L.G6-NH6.WMH@
MJX QSCO6I&I5]N"5/)-14K.2Y8:1"G2<-9:ON1JKJ .GTH7<K9+8J8L-Q&>:
M8TR;2,9(ZU@;?#JQQVNO#Y/?%5V+#(+87MFGLJM&9"PB5>6+<"OE?]H+]M[1
MOAKJ<OASP?:IXE\2MF-I(9 T4$AXP<9);/85I3IRJNT414J*$>:6B/6/C?\
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M48+-Z5[5X/\ _Q5_P""@GBZ75?$^HWGACP%;,9HV6W<VQ)P!%!G E8#.6S@
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MB-6N) 89M6MU9^V"4/0 ?WN]=O\ K]B;2?"=\OBGQW<-XM\8SE;AS=$F."3
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M1L[GX6^*L2+@J9[?C_QZO+?VFOBUKVG_ &\<6=W\*O$T.G75@T<MW=/ T-L
M"0-SX;)7)'3-8\O\IT*KS:/8ZOX<_M>>&O'/[/\ K/Q+;2)+%].\R)]&^T(9
MI&4@*5Y[Y'ZTY/VBOB]):@K\ M:^[O4&YA!)QQP6X/\ *N<_8S_9[^''@;]G
M_P ,>/+S3C?7UWIL>M7=UJ#M/' RH7+1Q8V@*.1\I;Y1SD"N^T_]M?X:R?"6
MX^(]Y?:GIFAO?26%K:ZA:*EU=2H%R((U)WJ<_>S@8;)&,#*5DW97-;-K>Q^9
M_P"T1%\0I/BDUU\1-(US2(M1DEFTRSUB0.$B)&Y48$@[2>WJ*]R_X)GS12?M
M#Z\L2M&$T7 W?]=!UKPKX[?M#:M^T=\1X]?U]H=.TRR:2/2[&.--T$#-D*\@
M4%SQDD\9)P!FNG_9%\2?$:P^)'C2?X5:58:MJDFG(K_:9!OA3>/G1"?F;_9K
MLG3DJ/))HY(5$JSFE>Q^R@RJ[L[3GYB>E8.A^/O#GB35KS3=,UFVO=1M&*W%
MK#(#)$1_>%?FYX_\=>,&O/!\^O\ B3QO%\2&UB&&\TB>S^QZ<ENS'/E[&._G
M:,L<_>)4<9] _9?UB_T?]MCQMH^I10&_G2X\T6TV^--N& SWZBN)X91@WS;'
M='$.;TCH?H5&<H#T^HQ0:;&=T8(.1[4X=ZX#LZ'@?[;5W-IO[,_C^6" 7+-8
MLOS*6V@D9./;WK\F)(_$?Q(^+?@OPYXVN-1L]4U2;3-*1[VU$4L-I*R)"RI@
M#:$<,OK7Z\?MF2;?V7_B5_V")?Z5^:/C&18OVC/V=;EW1UBT7PC(6CQ&K8,1
MXSM 'UP/I7H8=6CS'#6]Z7*?2?[47[.O@SX2Z3\'M+\):%#ISGQ.@GUH[7O7
M&TMM>3&Y@>2!G:-@X'%?<&KWGV>95/)>/ Q7RK_P4:UBY\)^%_AMXEA241:3
MXFCFFG5&=(D,;9+ <9..,^^.M:D7_!2#X$W]Q'_Q-M5W?=5I-*E /OBG9SC
M&5K[B2C%RZ'T+8O<>9LC<,3_ BO'_C]^U=X4^ UD]N98]>\43'Y=)@F&Y/>
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M8?'?Q$X/8V-N!5K_ (4=X]5=W_"[/$/I_P >-O7LEO;JTA4@9SN..E7H\;6
MK/VDHZ+\C103>IX8GP-\>,Y7_A=WB%B.<?8;>G?\*-\>-\Q^-GB!<]OL5O7L
M^T1R$YP>N*YOQU\0_#OP[T675?$>J1Z9:+NV^8P!D8?PJO\ $?I3<Y-V7Y('
M3BM_S9YEJGP1^(T=L39?&G6/-!P6N+.$*!C))Q7RG\9OC9XX\/ZQ8Z#X&^+^
MH^,?%TUR+9;'3[-#"./F!;&3)].G>NY\8?&;XB?M::H_ACX3V=UH7AJVF*WN
MM2.8_-0\ ,<9 QS@'<:]W^ /[,/ACX*Z':EK"UU/Q65_TO6)D+%I#VC9N5'T
MY]:Z-::]^S9A%<[]S1'RMH/[ ?Q.^*BV_C#Q]XYDM/$%T4N?(NHVGEMR.=KK
MC:#Z@"OI+P_\"_BCX:L9+6#XEPQVY15CA@TU(TB_W0H[U]$1R)M&*D$GI6*K
M36G0VEAZ=^;J>'K\-_BXBA1\2K=0.QL,U/#\/?BNIPWQ'M9/^X?7L@SYC%ON
MYI68>FT=C2]M+LON)]C%*UV>&ZQ\-?C%+"SZ?\3+6WG&2%FTT&,^QQSBL34/
MAQ^T+)''-8_$OP\MPVUI4N-/?R@0>0F.<'WKV_Q3XPT?P+I$VJZ_J=OI>GQ'
MF:Y?:G)QU]3Z5\+_ !,_:G\=?M*Z]?> _@]I<UO92R%)=6CD\N1XP<9W=$4^
MN<FM*2J5G=6MZ$5?9THWN[F9\7_VF/BK\&UO-''Q2\->)O$,,X#6.E:5)(T9
MSRK.3@?2N8LOV8_CM^V&LWC#Q?X@C\/HSK]EM=4CFCA>,J#OBB4$*OOU-?2O
M[-_[#>A_"]3K?B_[/XJ\438<^<GF06S]2%W??)]6KZLM]IM0JC:H& N,8]L4
MYU81TAOW"%.=17JO1]#Y'\(_ 'X\^ ]#33= \=^#M'LHPFV*#2G5?E&,GN2?
M>NSM?!'[1GGNTGC_ ,(.I(/EC3I=H^E>_M#RO%3>6O1?O=ZQ]M)ZNWW&SIQV
MZ'A</AG]H,,X'C7P<>1\ITN8X_6F_P#"._M#;B/^$U\% >ATJ;_&O>H/EW@]
M:JR9:1L'-+GN^@<B75GS[<>#_P!H5OM7_%PO"<9?!.-.E C^@JMKMG\>O#.B
MW6I:O\1/ ^G:;%%NEN)M.E58L=\Y[UVOQG_:-\%? W3;Q]>U2V_MA8#+#I:R
M?Z1,#T 'I[U\=P^'?BO^WQK3:C>S2>$?A]&VV&%RWE.N>BJ/]:V.YXKIA%R7
M-+2)A*2@^6+NSE=9_:G^/'Q-\:7WP[\':[HOB+^T&^SIJ>CV;0H%(PS+(3E/
M=B/I7;?#W_@G[\5?A[KEMXC3Q3X9O]4EYGAU6WDN@A/)))'S-GC//6OL;X-_
ML^>#/@?HL5IX?TT)>^7LEU&50T\A/4D]@?2O3T;$8?.<?+P:SE647^ZV-%1Y
MH_O-SYI_X1/]I>1XX(_%OA*&T+#]]%8,NP#H ,]*T(/#O[1T<T;-XN\).'&'
M5K"3$?X ]?<5]%*^U<"J\BAG)[YK/VC?1#]CR[29\Y2>'/VCK>97'C#PJP9<
ME9;)RJGTQ7.>+O#/[3EUX5UF:/QEX7C;[/*[P0VC!DVJ<!6S@9&:^J+B,[EX
M3\17G/QQ^+WA3X1^!=6N?$NK6^G&:UEC@@S^\E=D8#"]35^TO9) H7>LF?GM
M^PW#\<;#P7X[UWP5JGA+1?#,.IO_ &K>^*&8*UPD8:0J45L*J,A+' ^88S@X
MF\8?MW?&%?%3^'_#&N>'/%2SHB0:AH^CRQ9D91E$\T*V5)(SMP<9KRG]G?X:
M_%'X[6NJ^$O#%_>6?@2;57O[Z1B5LHKEE !E Y8E%CP#P-HXK]%O@+^S-X1^
M .GV]O9V<7B+74<R3ZO<PC>KD=(O3FNR?LY)R>YSI3B[=#XUL_V(_CK\0=2B
M\8^)-0TU=7NIA</;ZW<;F8 Y 8#H/]FOJ#0]+_::\.Z9'96&H^ +2T@4*JVM
MD(E_[Y#5[]=A[B]+2DL6Y.1C;1'!'MV1$\GEGZ&I<=%?4I6UY5J>'1R?M1R;
M@^L^!6/91;?>_P#'J:J?M0LV4U;P"K*.5^R]/_'J]TN=-C@N894=_,7G:IX-
M8OCKQ9X;^&.CS:UXGU*VTZV6$R+%),JR2M_<5>^:F48K_A@UL>3QP_M8SQLT
M6K>!7"D#=]D.U/4_>KYI^)/[;GQN\!>))-%BU?PKKEWETEFTFP+E),X(^]P:
MUO&OQW^)W[8WB*'PG\+](O/#V@0N1<317!CWH> \TB_=QZ U] _ 7]CGPW\!
M[>UUC6_*\4^,I.?M4@+PQ2=RJL.?]XC-)Q4=)[B3;=XL^"['P?XO^)/[1'P\
M?XK6U],/&6HVY<W3[6FMC(%8)W0=N,'FOUCUKP_HGPK^$?B&W\-Z3:Z)IVG:
M5=3QVNGVZHH*PL<[1C<QQU/7N:\4_:!_9UUKXU_$;P3XTT'Q9'X7U3PWCR6:
MT$VR02;P><@C<!PPQ1XP^#_QH\:>&[_P_=_&]4M=0M6MKI8=$MXG9&&&"ND8
M901D<$'FLI>]9+0WCU9^:7AL#4M#>UF4&%R0/J*]T^!O[<'C[X'^$XO"G]BV
M/BK2;>1OL1O)I(YK92<F/<,@IGD#'&3SC '>:?\ \$S=1M--Q:_$R-(86VJO
MV)OO'J>:6W_X)UZA#,D#?$Z#SV;Y0;$\FO3=6E5C::T1Y,*5:G-RB[W/6OV9
M/VY/$WQX^+T/@[4/!-AI%LUI/=2W<-Z[O&$ P=I7YLL5'XY[5ZS^VEI'B7Q!
M^S+XWTOPEI4FLZS>VT< LX(O,D>%I4$Q1>["/>1C)XX&:^4XOV0_$O[-^LP?
M$4?&S3_"]U:HT#7$]H-KPL,%/+92'S@<$$9 /4"O#/B)^V%\:_%UMKVE6WC_
M %"^\.1,R/?:?ID-F[Q],M)%&K(#Z;AD5Q>S3FJE%:([XU'&-JFY[C;_ +;W
MACX8_LC^$O!/A^!?$7C0:/\ V5?V%W!+%!8$(4D\TL%WGG 5#V.2,<_&.E?"
M3Q#JGPKN/&\OV:W\.P:M'H_G3,YD:9D\QBH5"-JK@DDC[P !->P_LG_!?X:_
M$+0TO_'\WC'2[07JQB^MH84T@D./DDGPTBYR 3A0.?FZ8_6#P%\.?#/PWT:7
M1O#7AZRT'3/.,IAM4 $K$ %V/5FX R2> .>PKVD:+YN75B4955O8_)"\U3Q5
MX-U#XV:1\%+)-<^&%Q#%#J>L6]M]L:#3S%(0?-<93<K3!CC(VG[I7(] _P""
M6LRM^T!XA3=(N='.%7A9,,/O?3M7HW_!0SX=Z?I?CSP58^'!'X<A\26]Y_:M
MKI;+;1WK1M&5>9$ #G]XPW,3G&.,<_.O[(_PW\8_$7XF>*=$\$>+F\(W2612
M:0YQ/&&P(RR@GMV_.J?[V-[I#YO9R44KL_8/Q%?>&HKNR36[G3!>+(&MA>21
M[U?LR;N0:^4?V7?"/PKUGX^>*_$?AB^UZX\36<TQN5O7Q"=[D-C'WAD5X+\2
M/V</B7:7/A;P_>> KO4[Y-2BDNO&<>H2W[RQGY3%L;Y8TYWX()RO7'%=G^PW
M?67AK]J#QCX=ANH;F 13P)<X ,NQ\Y'\N/2LO8QA3ERSN:JLW447&Q^C\9_=
MC'Z4H[TU0%4#TXIPZ5Y5];'>?/G[==Y-:_LR>,UA9D,T*PL H.Y2PROXU^?G
MQKM[/PI^V=\'; 7RSVVEP^%X7P(P+=4,/RXC4 ?+A\8_CXXP!^A'[<%O)-^S
M/XZFC=%:UM/M!W]"%8''UK\L/CM\6K/XU?'73_&_A6'4[*_GATZ-&95BN3?Q
M1I'OC\LG!W*NT@YX!XX ]/#ZQ27=G%4:4G?L?IS^UA^T!\,_ /@G7O"7BZ>3
M5K_4[!H6T/3Q_I!20$!BY&V+U!;GH0IK\I-0U_Q-XZT'P?X6FUEIO#.F:C]F
ML;/>GFVGVAQNQP&8=^>!VQFO:?BS^RMXS\$Z!X;\0>-+Q;OQ3XMU4::FG75P
M97A9D++)-.&(9\CH,X ZGH/I/X0_LQ_%/X2Z-I&EI>_#KR[8^9+)>:.;B[4[
MMQS*>6/H1TK9*-*-H.]SDO4J2]Y62/>_@W^SCX/_ &?/#=O9Z!81WVJA")]8
MND7[0Y]0>WX5Z1#)-#IIC-RIDZIG)./QJC)B;R[E)M\KQ OQA<XYP.W-)#)M
MN4;'FSD8*GH*RY+ZLZ>=VLBY;WK^5$V]"4X)QUJ>29)%FFE*PQ1C<TSG"*HY
M))[5P7Q4^+WA?X+Z++J?BS4[>WD928-/A;,\WH%7M]:^.-<^*'QC_;6U+_A&
M?!NEOX6\%,^RXNHR_EA1G'G2]\_W5IJ+J+F6RZD2J*#4'NSU+]HG]N+1? MM
M'I7PWFL_%/BJ9VA:2(M)%;#V/\3>U? WQ(O/%?BOQQ%J_P 2HM2BU?4,.'U"
M,QXBZ80'@+TK],/V?_V3?#'P!M([B[@M_$GB\G)U*6+ B7 PL8/'!SR>:X;]
MLS]GWQU\5OB!X'\6^%8M+U6VT>)HKG3-1N%B4DL&R2_!!(QBE%TXS\NXYJ7*
M^_8_..^\N.<Q(8WA4D*1@\=NE=!H*JUF"(E*AN/W8->^7'[!OQ2.GZQKFO0>
M%_#T.]Y_+>\S#;H1T!':OF^*#6K?7I_"&A1?\)/J#3&&VDT=C*MP_'"'TYZ^
MU=].I"+<CRZM"KHMC=FOK>WMR7MT9B>/W8KE/$6H/=7406WC1<==N*]VM_V*
M/CI<Q6\TNC:3#(\8;R+K48HI4XZ,IZ&K%M^P[\=3>+(^B^'I=O\ ^J1$?SI
M2J0J1T=A1ISI2VN?.\6Q59@BF/H<=S4EM&TB[@^SGD5[SX]_93^+G@SP?J^N
MZGH.@VVG:;;/<736M]&[(BX^8 =^:\;TG5K.;2TF>(LA(0R%#L#'H,],XITX
M1?PR%4YEJXE62;[/(,)N!_BK0T^;=J$) Q\PXJ_?64O]G_:%MU\AAD.HXQ69
M:,(9/,V_-N!'%=2BUI<XN:,G:QZK^RG,3^V9X'4]KF3_ - K]F$^[7XW_L:3
M$_M;>#K^:)9VE>:-1_='EM\_UK]D%^Z*^>Q,>61]3AG>G=#J***Y#K"BBB@
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MQ6UI"ADDEF("HH]<U\;_ !%_:R\6_$SQ@?!_P5LDU%&_<W.LO =J,W&X$\*
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M 4=^:^,?CI^V5=>*-47P!\&K<ZG>7VZTN-4:(B23=P%@&1S_M4K75HO4F35
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M.63PQI22ZLR 2ZK=,))G;N5S]T>PKT32;.RTO2X+'3;>&QL+>/;%:VZ! ,#
MR/I1>0Q7'EC PHZJ,&AR<E:UD*$%'5N[)5G^VMYMS$IE*??\L$FDMXXX[H2[
M4W-QRN#2KYLDBPQ[8HU7 D8<FKMM:A)?+%Q'/*.HQR*B345H6O-G(?%CP%%\
M2/AQXH\)&6/3SK5A)9+=.GRJ7&.<<UX5\+_V)M&^'_[-_BCP+XPUG3[V34)9
M+IM;"E8[)@H$3KOQRO.?K7L_QI^+'AWX*Z#_ &WXLU!XK4/B"UMT\R>9L<
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M<^"OA^RJ\=I"I03+NR >7..YXKZ_P#A+\(_#'P=\-PZ1X>L5MT51YMPV#-.
M?[TC=Z[6)4V1K@;$ ITG^L!(^3M6<YN6FR-H04-7JQC8W$9S2MN=E':G+;
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M>M?'[]K/PK\"_M.F6>SQ+XR REJK?N8,\9=QQQ_=ZU^>_P"SCXM^)D&GZKX
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M;[!_$S\>8V/X.13/A]^PE\0_B7XPTKQY\7]?@\J:X$][I=Y*\EU+&.508RJ
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MG_8V6=OVX](\F&*Y43Z@\B/_ !\O\ 51S^%?L7"P:-2,<C-?BA^S/XXUK0
M_P!J32/$'A?07UB\O;FX6/3I!B00S$AF/T1LGZ5^UL>/+4@8!&:RKQ:Y6^QK
M1:=[$M%(O2EKF.@**** "BBB@ HHHH **** "BBB@ HHHH *2EIE !7P5_P5
M!TB"P\ ^'KD2RR&[UPNR32':"(L84=J^]:^(?^"IQ7_A6?@PD9/]M'"^IV5O
M0=JB,:RO3DCC_P#@F;#!-XI^(D@B!FBL[-%8GD M,<5]^V\>5D).3Q7Y]?\
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M3(=/0HB/-P9)<#&YV'4^]=DK&10"N[W]:J57W>2GI$N,7\4W=D@426X'5<\
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M BGPF-SJGB"64V\M\+9F !."L/9F_VN@K2E1E4?N??T,JE6%->^_EU/H#XU
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MQFFO;B5G\VWTF9L><IY 89^1?85]DZ?X;33](33]-L!HUA$/W-K9P",9''S
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M;67_ 4L^&B02"/:VC _9F64\0* "%!QD =2QVD-NP1C[%_;^GEM_P!G353'
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MGS.+\CII144TB2BD7I2USFX4444 %%%% !1110 4444 %%%% !1110 4444
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MV.%4#DDU\6?'[]MN:_U:\\#_ JTZYU?7)F^R-JENI8(S'!\E!]XC^\>!7!Z
MOXA^*_[<'B:]B\*"[\+_ ^@=4:.ZE,*.#U9RN"S?[.<8XYKZU^!O[._A/X
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M1WPP/TPV/O-GL*\D^%W[&?COXQ>(K'QK\8M2DCMG/G?8;B;?<2*>0N ,(O\
ML]:]"&'27/5=D<,\3>7LZ2NS'\4>/_BY^W+KJ:1X3L+CPOX*CD*2W8E=(F&.
MLK <G'\ R#[U]/?LZ_LA^'/@':17L\<6N^)R"7U1X_N@_P ,:]OK7L?A'PCH
MO@;0XM(\/:?#I>G6^!'!;C R>I-;OSR<[@<>E9U*S?NP5HEPII>]-WD-Y>,!
MAM/IG-.63RE""F33 ;6+X;H:%F"AR2JQ*N6E8XQ6&MC72]R1>'(K@OBM\:/"
MGP9TU[[Q'JL%J6!:&U+9EE;' ["O!_VF/VWM)^'<=QX:\#O_P )%XPGW6ZO
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M'[<9UOB#X)_X9W\%^$IOAM\?;S7_ IJ6L26=_-HL4;I9G".[[4E)9@I)V\9
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MT\<_&35;J=;P^;'I4SL+B;/\++T1?88J^=N-WHAV=_=W.?U[XQ_$O]LK4/\
MA%_ >CS>'O"ID*RW,3. 5S]Z:3'_ (Z,U]*?LU?LK^$_@E(QN'B\1>--FZ:_
MDCRD6?X8@1CCUZUZ+H_]A>$(H_"?A6VT72=-A7RHXK>\B!W>A3.XM]>:Z7PQ
M)/'K-U!+"A*Q B;9@CVJ'+W'RZ(<*;C-.6K.LM!)Y:[NO?%2F8,Q5?O#K6=J
MVL66BZ;<7VHW45G96ZF2:>9MBJ!ZFOA_X\?MI:CX^O'\"?!>UNM4U*YE\F76
M+8' .#Y?_Q5<<*4JCT.F=6,%S,]V_:(_:F\$_!33Y[?4)5UK7%.Y-)M'W2$
MG^\?X17QO)X=^,O[>7BF*]O8&\+>![<XC\S<+5 #_=_Y:/C\*]B^!_[!5O:S
M-XE^+,QUS6;AQ+]A\]C'N/)\Y^K'V_6OJEBELD5M"5@L+=1%';Q#"@ 8 ]!
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MEY ''=1;C%->?Z')5CJ[^1T/Q+_9Y\(_L<_%;X#>(=:UEM3GFU6XFUJ^F0+
M$A,.SRXN2H D8').<=J^[/!GQ<\*_&"&\G\%^([/7)8^6AC8B1%_W37S;_P4
M7^'+_%'XK_ ?PP9X[&'6[^[L&NPH,D8+6VXXV\X4Y )QGL.I[/XJ_LCMKWQ,
MC\0_#;Q*?A7?Z38Q6MR]GI.+>X)R1(NQU5C@A6!7^$5<6OBEN3)R6B/H62U8
MPJ%@E+8YSUK)\1>*O#_P]T7^U/%>KP:'IC':;BYF"+N_N\\D^PKXG\>-\?\
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MT_\ 9*_8-?NCZ5^1G_!.?3;>\_:ZU*Z+AWM;>_DAD4<'>S(2/P:OUQC_P!6
M*Y:MTTGV.FG:S:'T445@:!1110 4444 %%%% !1110 444E "T444 %%%% #
M)/NU\._\%3F'_"L?!JL-J?VRV3_P"ON+(R:^ _\ @J_=7</AOX=0HFZPFU&Z
M,[8_B")L_K6U%VJ)F%;^&Q?^"7NGBQ\._$&X@#&*;4(55V/<1C/'I7W./*ED
MY&#BOB3_ ()@K'<>$?'%S$#Y<FHQJ&(X.(Q7VO"-T?S#Y@>*ZL1_%E8Y<+?V
M,;DQ40QC;TZ4Z!UD'/3UKF_&7C;1OA[I-QKOB#4[?3=-A4EY)S@GV0?Q&OB_
MQ]^T-XZ_:E\2CP1\'8KS3-%+?Z;K&\1L8\\L6_@4=@.3_/*,'/T-95%#?<]=
M_:,_;&TOX8WUUX3\)(^N>.IBL%M!%$9((Y7^Z&(^\?8=.]>4_#G]C7Q9\9/%
M0\=?&[4+B:21E=-(+@2,@&55]O$:]L=>Q]:]G_9__8\T#X+QMK.K&/Q+XMG8
M/+J%Q%YB0GOY2MD@_P"T>:^B("JAF8#!YXK3VBIKEI_>3R.H^:I]QE>']!T[
MPOI-KI6D6$>G6-K'Y<,, Q&@/MZU?^QQS)E\D*>_6I%D+,2OW<\4-(?,/TK#
M4U".(*7'\&.!45K-$RR0!64\G+=*8UPRD[QM7UIUO,LC%P085SO9N,4-$ZWT
M&\* BX4M_$O>O/?B[\;?!OP0T;[;XKU-(7<$PV<>7EF/;"]1_*O(_CY^V=HW
M@>:Z\,>!4/B/Q?)+]D15C)A@D/!RP^\WL*\U^#_[$6N?$;6%\8_&O4+Z:XF<
M20Z5--O8Y.[YSGY1_L8K=4].:>B,95KRY(*[.<U[Q+\6OVZ-2ETWPU8R>&OA
M^DA)GFW1I)'GI(5^^<=A^M?7'P'_ &:_"O[/>@BWTF(WFK3K_I>J3J/-D/H/
M[JY[5Z7HGA_3?#6CP:7HUI#864*[(H+==JK^%76V1[2QW-_>%1*K?W8Z(TC3
M47>6K+%O*S *1CVZU=7[M4U8LR$'-66; KFD=:T0^F$]:&<#J:^8/VDOVU?#
MGPA6_P!'T)X]=\80E4%HN?)B)/.Y^F?:G"G*K+EBB9U(TU>3/<OB)\1O#OPP
M\/W&M^)=1AT[3HLDR2'!<]E4=S7P;XZ_:<^(W[5'BV^\$_">RFLO#TJ,DMVR
M[))(\89GDZ(I_,U8\/?L_P#Q4_:X\06_BCXE:I<Z'X2G_?VMG&HW ?*0$B;H
MI'\1YK[9^%_PG\+_ AT&+2?#6F06$4<:K-,.99<?Q.W<UW>Y0VUE^1QWG6\
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M[!_,MTMT6(!VD8*0Y>7&,8QSFOH_P/\ ?XZ?%#X;^$_AIXTLXO"7A'P[=O>
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MP7^,W@7QS<WWC?XG1>*_#3"3_B61Q$DR-_$2RC [#->D>,/$FE^!]#EUWQ1
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M?10 B]*6BB@ I*6H^YH CFQSM^]7P?\ \%6M2AC\!^ -+D?;=WFJRO!C_85
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M@.^:^'_%'[0'Q)_:L\41^#_A1:W?A[P^6>.[U3.-T1."\C8^48Z ')I_P_\
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MI_O"EN1M3/>H4.8<^]<EF=;9(Z&-C@Y%(K98$TBI)(QPHV]B:\U^-/QX\+?
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M#=D!],5U<KWD[)G+SK_EWJ<MKOQ@^+W[9GB;_A'_ !I5UX<\&KB.7R7*+M)
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MVH/"O[.UC)#/>1>(?$D@S#I%NP(A;LTK_P 'MS[5\]_&#]LSQ-\5M5E\$?!
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MZX4Q<ZU<1@SN#UV_W1["O2;6WM]/L[>RL+>*PTFV0)#;0*%55[ 4^XD.WI@
M^@JI5'4TBK(F--4]6[LB9I+N2-&4$QC&2V<T[5+AK?P_J#-&L,<-M+(UQ*?E
M7"FL^[UFW\.V<VJ:E?6NEZ=",O<W1 &!S@9[U\#_ +4W[>4'CS2]7\&^ XKB
MWTR:3R[C66< SH#\RH#_ GD5/+*;Y45*I&FN9G+_P#!-.X:\_:DU.X:193)
M87;^8@^4Y<]*_65?NCZ5^3?_ 31$+?M(2FUE6*)-*G#1-R6Y[?3I^%?K-']
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M75Y?WLDVX?Q"XD1>/H!7TQ'=><R#=Y:XYV]*RG[TW(TA90447MR1R&1A\[#
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M&%0J(!T X J6'\CZ4YBN2=^*XZE251^]L=E.E"DK00^HY69.12>9V0\UP'Q
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MZ =*MYEDD&3\G:EFC=I" ?EQ45*DZLO?94*<*:]T:LZM#\HPV:5IO+)##);
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M>H2PKK_C*-")+Z3#0Q.>@A4^G][^5>D^&_#.C>"=%MO#_A73HM!TB -##&
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MOV?X5CU^^:_UMU+0Z38G<['L7/\ "/;^=?+?[1W_ 41T^*+4?#?PUBD=9D:
M&7Q')\K$8Y\E>OXGTKA?V:O@EX"^(%U9^-?BS\2_#WV68B?^Q)M<0WEP>?\
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MC@@?,8\MCM7R_P#M$_#WP7X&L]/OO!'BO2;ZS9I(180ZBUW=,I.?.D^50!Z
M9K]3OC%\!/!/QI^R'Q;HZW\MF2L-P&*R1JW5 0>A//(K\]?^"A7[/_@[X"Z3
M\/I/"UM/;'4I;R.[>XN#*SK&D97M_P!-*]&G6<8J-]#@G052;DUJ?0__ 3)
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ME<_\\E]A7OO[.?[$_ASX)B'6-69?$7BHQ#=/+$/(@/<(ASDC^]U]A7TJ@ 8
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MM?._BSX6S^*?CCJ.N^.]+\:V-KJ,$MYJ4MQHB7$EO?<CR<(\:R1 $,H7@@8
MZM7'^(O!_P (X_"FKZGH/Q3U:75+5S%;Z%)X7:&61R"0=YN2JH",%LDC^Z>,
MYJFKJ3U9K.I+E<8HY*)UDT&YF2PNOL3$1&X6,^4K$':I8< G!X]C7O=I^VYK
M^B_ #PK\,_A_:7^E:K9V1M=0U^_D5I8_G)VVV#P,' 9@"HP .-U<9\!/@!\8
M/VBM%L-"CUZ]M/!.CR%X6U267[%$6+,?+BSAFR[<X_B/-=[XX_8:^)W@_P ?
MZ#X?T19?$.DWY!N=;@L6\FT&>C&M*U2G.2C/2QRT:-6$6X=3B?V3_P!G9?VB
M/BYKMKXIU'5)M*LH6NKZ\60-)<3NW\4ARV22<DY-?J9\+?@WX5^$5C]G\.6+
MQCREA:XN+@S2NJ\!"3V'ITKRO]D_]EG5/V>-1\27NJ^(X-6DU4JL<-NI"(JG
M[QR!S7TCMP,*.*\ZI)<UH/0]2"DH^_N)&LI;+-A3VQ2S!^ IXS2$;C_K,8[5
M2U*\CL[=I[BZBMK>,%FEF<(OOECT%<^M[&VD5YGP7^UMXF\9>!_VJ+CQ/8^!
M+[Q+H=EX6N+/[3;1';&9H)$9]^TXVLPSCDJ6'>O(O^";NI-=?M*:2CKM8:9>
M C!'\%>V?M;?M_>']+T?6/!7@8)K>IW,1M[C5HWWVL2D$.J_-DM[\"O*_P#@
MG7X!\:W'Q?TWQ:FB2Q^&8;2>"XU&:+;$^Y< (W7=7?3D_92;[6.6:M4B?I[=
M:M-;ZQ9V*V$T\5PI+72KF./'8^];"]*2$?NUY!^E.KR[W/2"D-+10)GR_P#M
MYK-#\/?#5]';27"6'B"TNI=D;N BN"20@)QQZ&OSP^(OQPMM0_;,U3XHM;6^
MN:7IGB*-[>VC)C2XAML10L"RD@E8D;)'6OVEG(82+M#=MN-P.1W%?BAX#M[/
MQ1^VII%CJFE6U]9W?C!X[BSF@S#(OGL"&3!R.,D$8]>,FN^C.+M"2VN<LTXM
MR3W-'Q-XJ\5_ML?M#:)#J\UGH[ZELL+580WDVUNI=L $DL<LQ)/4GMTK]%O@
MQ\ ?"/P)T%+;0+5+W6T&VZUNZC!F9NAV_P!T?2O*/BKH.D>#?VW_ (-Z3HL%
MKHUA;:-'#%9P0JL:*;BXVA<,.I+9X]^<\?3MU^YN[A4>(N7.Y0./I6T8IM<O
M4P;NM>A5CN&2W8L/-(!)8'.*EANH'N&N;16D01X8/T!Q487G9M8;AGY3Q^%5
MKZ]TWP_HTFJZSJ,6D6$9PUU>R>4@SV']XUH[0W%JU9$ZW4K3QJ4$\DW( _AK
MSKXQ?M$>!_@;!,-=U!=3UE5RFBV3AI6/;<?X1^->%_&[]NZ"UDD\.?"2TDU3
M5I7,!U@P&4D],0IU/L3^&:P?@_\ L0W.M32^,OC;?SH;X?:H=%2Y*WETS@DF
M=AS&!D?*.?7;C!%JKR_X<RYOY3C]4O?C-^WOXEDL=,2;1O"0'*.7BTZ! 0,/
M(%/F/R. #],#-?,^N>"G\!^+?$_AR_D5KO1KJ:Q),93S#&Y7=@\@'&?QK]DM
M+OK;1['2M/TRVAT308'CM[?3[0!%1=R@#_/6OR<^*4S3_M!?%%;BS:V/_"1W
MX$3[B1BX<9^;GGK^/'%1&*J5;6L5.3ITFT[GG\;17$"&2TB#*1G(KII+?2Y]
M-9FCB,V,; .G%4->4V]H4CC7+'TK/M+.^NKB"STS3Y=1U27B&WMADL3]*ZK^
MSO&QYO+[36^H]?LMH\4!M+?<. 2M=;\.?A?J?Q>^*.C>$--N[+39=15U$\T)
M94 &>,*3FN]_X8[^.MEHEMJ\W@OSX)/+98(+B.6<;N.8P2P'N17N/[-W[(7Q
M8\&_'?POXL\2Z)8Z9H]@2\K1WL3R %>!M4YK&<X\C:D=-*$XS2DCZ5^!?[&/
MP]^#_A6SL[O0]-\1ZTN6N=2U"V$OF,>H"OG KU*3X/\ @:2T>$^#= \MQ@B/
M3(D_]!6NSC7S(PV=V[D&D78K'->3?J>SI>UC@_\ A2GP^CM_+'@W1@#CAK-,
M_J*\Z_:"^%?@'1_@SXUOT\':49+'3)IT%O9JL@8(0I4@>]>S>+O$^D^$=/GU
M/6=2@TO3X1N>>Y<(@]B3U^E?G?\ M*?\%!)O%>H:EX0^'YM6T">VDM[O4;J
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M XQ4TTFZ4*GW1Q6<YN;MLNQ=*DJ2ONWU-*&<R<8I8Y$BF<U#"Y$!"<*#S4
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M #J0 <9)R<5"BZCTU9O?D2Z(^U/$&L6'A/39]7U:ZALM)MD:6XN)LA45>GS
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M Q@ "L+XB?&[XI_$+X2_$?4]+NM-^'EMX.T^ZLO$'A>XMDNKF1O+8*R2.N,
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M;C5I"9+RZV\99R,G/7 ^4$\ 5I9)V>K_ 1"E*?PZ+\6?/WP5_83T_P?<:5X
MH^)EVVK:[#)]K'ANSVO"DBMD"XFRPD[$JH SQEA7IG[4FI7>J?LW^*X9'2SM
MOMMC!%'"H5(XO/7 ' P.GI7J3VKZ;J"W$ZLD++R[##'W->:_M2:I;P_L[>
M*9()P\#7E@A+#CF=>#^-7S1NG)W=U^8U!<K45;<^<?A7^VYI?[.FGW7@Z30%
MUQ(+CS4U"SG$8D+ 9!!]*[F\_P""H]G=6=PMMX,N(9WA=(I?M:':Q&,_G@U\
M97VJ:%X>\3>*M1U**^3Q#$L<^@W>ER1B&"Z5U8M*K [D*@C _KQ@^,OB!K7Q
M"URXU_Q-J%B+B2R"(UI9Q6T0"#A2D:J-Q.3G'4FL)QC*H[JY5-SC!)'9K\9?
MBQ\1O$']C1>+?$&LWFL2F..PM;@C[Q^Z .!ZCBOK[]FW_@GHFDW5MXC^)YA
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MQN_;P\6_+WP1\'-+N/LUP/*74K96DNY\\,8P!A!COG/TKIOV?_P#@G"DD
MUEXJ^+5U)J=[.AGDT'S6=M^>/-D4Y8XQP#[9K7V?*KS)<V]('B4.C_'#_@H!
MXB.H$"T\+6]R41FD,5I:\_> YWL!]>:^V?V>_P!B?P/\"(YKF:)?%>O3Q[)K
MZ_@5T7U$:$';D]?45[UX;\-Z9X3TV+3]$TRUTS38QA;:SC$:@X Y K57;O(Z
M_+CBE*I?1:(%3C:[U9GZ3H.G:'$(M.T^UTU&7[EG:K$![?*!6O& L8;K4<@^
M[@5..E82[FT=-!RMN7-+2+TI:@L*;3J*!B#I2YIC Y^YFC\,4 +2CI0O2DH
M**5>E% "T444 .'2EIE)YF.* %-%,SGFEH8$-Q]X?2OSW_X*0?!7X@_$CXA>
M%-6\+>'-0\3:;;Z:UJ\-A$TA@E\V1RYP.,@Q_E7W;KNJ:E9WT4=CHTNH1/G?
M-',JA<=B":K'6];^RQO'H$K2LW,?VF/@>O6NF%XVD<TI)WCJ?F'X+^"'[4GP
MC\+G5/!=AJ^@VDWS_P!F0W$4L@)/)-N<G)^@-=?I_P"W)\?_ (R6/C#P*M[
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M,T'X&^'Y9?"'PSNSXXD@\K^W=5N&<*QV[MJ >W7WK]/?"O@_PUX;T>TTG3
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M">F^'H?"/AD2+<W-J;LWEQ>3J20TDQ5?D!P0JJ.1DD\ ?=3_ +._P0D1'O?
M$TT\CE6DF2Z9W.>22'[UG7G[,?P,CN)F'@>^L0Z>4$A%QMP.XY/6IO2>\6'[
MY?:1^:G@_2_AKHMO--X_T'Q7K5\LS",:)J=O;VS1%0 &5HB^X-DY#@=..N>U
M@\;?LWP^'CI-E\#O$>K:NL>P:A?>)I8996SR[&/]V&QZ18XZ5]XP_LP_ RYN
M([O_ (0BZC,(*>0HN/5AFB\_9S^"-U=RSOX1U2U9G('D13*H^@QTI_NV[
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M^LM(ADCSR(DP?PP,5]^_!O\ 99^'WP/M8O[!T9;C6 /WFK7H$UQG'.TX&!]
M#7=P^/--:#8EK?[4X"BQD ],8J;_A/],6-Y#%>J4'*BT?(_2N:I*K4^S9&T
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ML5 P0<&OS@\!^+(/#OQ?T/XA7.G116ECK*ZK+I^E1)#&/WF_RHE<,J+_ @=
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M5"@V(Q0-M8 C> P&ZOT8FPD<DTLD<42*/FE.%7'<D^U?ES\7O@[^TI\8;S3
M(O&?B#1=;;1IO.L?+U#3K;RF;:2V(PF3E4Z^E'C+X>_M277A>XTO7O$O]HZ+
M,Q2:VM]:M7+;AT8*=Q7V!KDE2;C&-ST%6AJVCZ0_:@_;\\/?!FY_L3PK##XI
M\0R*2SI(!;VO;YF'4Y[?RKYV^'GP#^-'[:]RGB+Q]XDO='\)M)OB^T1E1*NX
M?+! .#@#[S?G7>_L:_L;Z%X;,OBGXF?V=-J5NP:RTF:YBE2)<9$L@S@GCA>W
M6OOF#Q=H%M;B,ZMI\(B55*"= %!^Z,9XK%WIOE@M>Y<91J>])V1YY\%/V;O
MOP*TN./PSI2QW_E".?5)AOGFQWW'IGVKUBW8LH)&T^F<UFS>+-"A<B36+%&
MW$&X3IC/K[5'!XV\.7$BQQZYI[NW11<)S^M<_+.6K3.E2A'121NLH)S3/+"G
M.:R&\;>'D7)UNP"^OVA/4CU]0:L-XBTA;:2X;5+,01G#R>>N%YQR<U'LYKH/
MF@]FC15A^-(9.:S+'Q!I&HWR06FIVES<,GF+%%,K,5QG( -:J_=J91<=QQM+
M5,%.5S2'K3J*DL1>E+13ATH& Z4VBB@!PZ4VFTW?BF!,.E%19S13L*X^D\S'
M%+12 ,YYIADY-/HH!B+R*;ZT^DS3%:Y"S;,FD$P/-/E*^E5X2FY^.]-)$\SV
M'K.>?]ZI?,JNA3=TJ<>W2AI"NQXDX[4SS.:6F+]XTK(=V] ,AI?M&.,5(:@;
M[Q^M.*0._</,8\T>>1QBE7I1D?W\51.I&UP2<*,&I4D)49Z]ZB/4]ZD7;M&:
M5A78+)]^FK,VT8J)MSN0.F>*D4;6 /I3L@NQZW6[CO3EFVJY]*K[=HW4L;^8
MV*-!W8Z.5I#N' /-2[VHW=?]FF1R>8QI60QRLV&SUIL,C&3GTIWE?O#]*11M
M7%/0!X9J3S,=>M,_A_&G;,\TK#'1R?-39'.Y\?A28;H*-BGKUIB>JL-\YEZ4
MOF.:5-NUQBHHPV[CI0*.A,+C;P>M1-<?,3BF295BY]<4HCVC']ZGH#&-/(Q.
MREBO'SM(YJ2"/]XR^V*8BJC[?2C0G=W)M['FGJQ*@*/FI$^ZV.E)&&R,=*EF
MEQS,0HR.>]1_:".U22[>XYIIC#1C%)$O48UTZLH"9!J3>_IBH]OE\TL;*S9/
M6JT&+O>G"1Z4]>.E0J&\PX]:5D _?)3EN#O"$<XS2>9C@U&3DDT60MB19689
M'>HFFD\W';%-4-O]JD^5LYZK5*R%=BI<':,CFF?:'WGTH:3;\PIK-N*GUI:$
MO4F\QSVI//=:3S*>R[HP:>A2OT$$['M2^8_I4)5@ZXJWM7^+K4NQ23V(?.<<
M8IT<A;K3_+';I35&UB*3&EW%D;%+&V5%/J)?]8:G89)M!ZTBJ QJ2BBX]QOF
M8S1G/-.HHW&4-0MX+J,I<6\=P@.=LJJX_(UA1>#_ _#J$5_%H.EI?Q\QW"6
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M7)Y2NK;AFAF5V52*F6.+'3FI%V #I1<5B%0%W@4(?E%2%4S3<Q*?+Q][F@8
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M[OX4R/K0+8DDE.T5%'N9LBI&ZFF*NUBV: 2%9"#ZT_=C_@5$C;ES48W=J 1
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M$-+<FD\S%(8\DFE' Q2 ;Y8;G>11P.,YJ3=MX_O4GV?WIA:XJGY13&W;CBI
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4_P!8:>20>M%% (56..M%%% S_]D!
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>21
<FILENAME>signature1.jpg
<TEXT>
begin 644 signature1.jpg
M_]C_X 02D9)1@ ! 0$ 8 !@ #_X0!:17AI9@ 34T *@ @ !0,! 4
M ! 2@,# $ ! %$0 $ ! 0 %$1 0 ! .PU$2
M 0 ! .PP 8:@ "QC__; $, @$! @$! @(" @(" @(#!0,#
M P,#!@0$ P4'!@<'!P8'!P@)"PD(" H(!P<*#0H*"PP,# P'"0X/#0P."PP,
M#/_; $,! @(" P,#!@,#!@P(!P@,# P,# P,# P,# P,# P,# P,# P,# P,
M# P,# P,# P,# P,# P,# P,# P,# P,#/_ !$( *@!I0,!(@ "$0$#$0'_
MQ ? !!0$! 0$! 0 0(#! 4&!P@)"@O_Q "U$ " 0,# @0#
M!04$! 7T! @, !!$%$B$Q008346$'(G$4,H&1H0@C0K'!%5+1\"0S8G*"
M"0H6%Q@9&B4F)R@I*C0U-C<X.3I#1$5&1TA)2E-455976%E:8V1E9F=H:6IS
M='5V=WAY>H.$A8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$
MQ<;'R,G*TM/4U=;7V-G:X>+CY.7FY^CIZO'R\_3U]O?X^?K_Q ? 0 # 0$!
M 0$! 0$! 0(#! 4&!P@)"@O_Q "U$0 " 0($! ,$!P4$! ! G<
M 0(#$00%(3$&$D%1!V%Q$R(R@0@40I&AL<$)(S-2\!5B<M$*%B0TX27Q%Q@9
M&B8G*"DJ-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U=G=X>7J"
M@X2%AH>(B8J2DY25EI>8F9JBHZ2EIJ>HJ:JRL[2UMK>XN;K"P\3%QL?(R<K2
MT]35UM?8V=KBX^3EYN?HZ>KR\_3U]O?X^?K_V@ , P$ A$#$0 _ /W\HHHH
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M ;X46Z1Z+\*/"$?[L(6O+$7S<=/]>7KWBUACM+:.*)%CCC4(B(NU4 & .P'
MI0.E%9D!4?VJ,D+YBY89 SU%,R/^>B\>]?*O[<'_ 4;TS]F[6X? OA'3M0\
M9?%;78]NFZ-8VYF\N4CY7F*_>]=B\D"@-SO?VQOVZO ?[$WA)=3\4:DLFHW@
M*V6CP$/J&H/T&Q0<A?4XP*^9_ GP ^.G_!2#Q':^(OBM-??"?X4Q3--8^$;1
MC%JM^@SM:9NJ*>#\X&1TB7(:N^_8;_X)MWWA3QJWQ>^-VH)XV^+6KJL\<5T@
MFM/#.3N\N '*F0<#> I!"Y^\?L*_OH-+L9KFZFAM[>W1I)996")$H&2S,>
M .23TJKVV-).*5EOW.3\#_#;P=^S3\.YHM)L=/\ #^BZ3:F>[N6"J3'&N7EF
MD/+$*"2S'UKY1_X)?Q3?M*_'3XI?M):I#)#;^,KH:+X9AF4C[/I5M\J.,]#)
M@,<<$LV*X7]M_P#:_M?VXO[3^'_@W7&T'X+^';@R?$/QVTGDVM_;Q$@V%E(
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M_P!IC@5\E_M-?\%@O!OPW\47'@[X6Z=?_²'8FD^'H_/A@?.")9TW*Q'=
M5R1ZBOG'XZ>!]:UNVC^(W[:WCH:+HRG[3HOPN\.W0VSD<@2H"0[8X(9V(/\
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M5^#/^"E/_!4*S_:\^,OP3B^#_A+49)_#/C5!HOB_Q#HZ-IEU=R%(O*CCD4Y
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M;VL9/1]J)+(P_P"NAB^M=/\ L_>)OV\?BY\0K+5O%>C_ P^'7A?SX9KB"\M
MO-GN;4GYXXUCFED64#_GJ5'L*P]3_:S_ &KOA#IEU8>(-!_9R^'T>EPC[/\
MVWKUO:02N1E8(E^WEE9@,@R8&*D_84_X+D:?^T7K][H_Q(T/3?!=UH]E)>S:
MS:ZDWV&YVR;%2.(_,Y8<@!GR.E3[-@DWLC]"XY,JWS*Q8 9'0GVJ<2*J<L!M
M'/M7P_\ M%_\%:I?"_ARVU'X;^&-/U73]1293KNNZK#8Z=;2*/EW1(3,V?1S
M%]:\_P#^"<__ 5,^-'[7G[1D?AG5/!?@_5O!L,+&[UO0-/U"TATIP/E#22O
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M@FM3_@F'^Q._[)7_ 3@\,?#Q99_#WBC5](DOM9O[1 MU:ZE>1[G<;L@R0;D
MC!.1^X7C'% 'KG[*?[.EO^RE\#M)\#VGB;Q;XPM]):9EU3Q+?_;=0F\R5I"'
MDVJ-J[L* !@ 5Z(9E#;=R[O3-><_LF?!'Q!^SO\ _3/"?B;X@>(/B=JVGR3
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MM+&O]U[^Y(M4/U5#[US%G_P3O\)ZI):>,OVLOVFM/U-F87$6D66O/K-Z4QG
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M&P [M]PVU#WPH4'TQ6BE'[2+]M'L? ?_ 3R^+?[3&D^,?$NJ_"/P]XF^)T.
MJ11VT^H>*KAVL8IPSEVC<S1)S_O>GJ*^C_BM_P $P/C=^U'X&\2^(OC]\6=5
M_L^TTVXO;7PEX7=IH@R1%PA1ML+-P5P4D).,25]NZ#^VC\%+NRD73?BG\,S;
MV+M$Z0^(;-5B*Y!&!)TX[<'M1_PVI\&=0EFLV^*7PZD86XED1M>M=IC?(')?
M!S@\=?:L[]D8RJ>1\M_\$&O@AX!\(_L2>&?%VD:+I?\ PDVLS7']I:N]LAOY
M95D8,C2N-VQ>!M3I7TM^V9^UWX?_ &.?@[>>)]8VWEY*3%IFE+(/.U6<@;44
M'G:"1D@< BOB'PKXRL?V ?B=JUC\%OC)\)?$7P[UBY-Y_P (YKWB7R3H\LFY
MRL+QDJ8^4YSGG!'!-><_##]MGP_^T)_P4IU'Q/\ M >*OA_X=T7X16?D:)H^
MES/JMAJ-XQR+F&X7<)V!9OD0,>0.J\4'QL^GOV</V=;S3]7U3]I3]H:\MY/%
MBVC7]G8LX>Q\)V(&51(SPTA&/F SGCKDGS2Q_;8^.G_!4[QA?^'?@+8S?#7X
M=V(\O4O%6H8CNILMAEBD4.J/CG;$-X[NM;__ 4$_P""@W[/O[5W[&OCKP;H
M7QFT/2=8U"T,EO#?07MCYLD9W^4T;P"0JY&, '/2OG/X&_\ !QOX;_9[_9$\
M*^"=!^$MPWB?POI4&F!DNDATB=XT"O=<*)29&!D*;02SG+YY*]HAN2Z'VU^S
MM_P1N^%WP3D;Q)\0KBX^*'B:.-GGU'Q+)YUE;KU;;#(S*1W+2ESWXKH?B#_P
M4/\ #^CZ\GP_^!WA=OBCXNA B6TT4+!HND*<!9)[E5\L1C.?DRO!!937PRW_
M 4Y^!_Q^\K6?CM\8O&'B"UFM(;EO WA[P_?6.CI(%R8V;@S_/D!B4R>^.!J
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M ?0%-\Q?6O 1_P %)?A%_P!!KQ9_X1FM?_(E.'_!2CX2X_Y"WBC_ ,([6?\
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M^+'Q'\-_!_P/J'B7QEK6E>'_ _IJ9N[_4Y1#:6Z2,$ =F(4Y8JN#U) KK*A
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MM];_ 5\"S774276F?;%7_@$Q<5X3^T1_P %A_B5\*=%^*'C;1?@QILWPO\
MA/XD;PY?7VO:^^EZKK3QRQPS2V5N8&C>-9) 0?,)91T!.!V?[5W_ 5?\3?L
M\_M%_"OP-HOP5UCQA;_%S3GNM!O(]=M;62_N! )/LZQMD1B-I(1))(RX5V*J
M^T!@#ZO\-^!=(\$6 M=!T73]%M<8\BRLTMU_#85 K94R =_S'^-? 7PR_P""
MN_QF^(WQ.\=?">W_ &9KZ;XT>!Y(9+S2[?Q9:?V+:VLL*2I+-?. %9@Z[416
MW;AR,-CM_!G_ 6&T9_^":5]^T!XL\(R^'[[3-1GT*7PY_:,;&?4TNOLRP)<
M, H5FPQ=E&Q5<D$+D@'V2"^.G\J<$;'W6_3_ !KX%_9O_P""V0^('[:'AOX-
M>--%^']M?>+[:5=/U3P7XR3Q):VM]'O)L[K;#'Y3D1L 5W#<4Z@EE^JOV7?B
M]\0_BM-XXC\?_#=OA[_PCOB*?2]&?^U%ODU^Q0*8[Q"%4JK@]"/4<$$ ]2#
ML!]UOTH\UO[K?I4E1F@#X4_X*L?L(?"/QA\$O&'Q/F\ ^=XT\)Z;]IMY]'U!
MM'EN&,H?>^T&-G0NSB1HS*=NT-7#_![_ ()!_#/]I?X'^%/%6K?%3X]:MI&M
MZ9;W\=C>^+XYK58F (0;[8# /]W:?>JG_!9?]L3XV?#CX5>.O#-E\)K%O >J
M)_9G_"0WER95:&0'+@)QN?D!>JXS7,?L5?LA?%SXK^'?#/PY_:$N/B)I?@_2
M=)@CT?1/#<<4/AB^M%C1E2ZN[<EF?_9F4'T<5M\)O[-\FYX_^U5^S1^R%\*_
M$K>"/A?X=USXH?$BYD\BULH/$K6VE6LHSYCR71S&2F"6R25P<NN*^N_^"(?[
M%ND?LQ_"_P 0>(;3QEHOBS6/%$ZQWL>B:H+S2],5"Q2)6P/W@W8;G)X/3FOF
MG_@M)\+?A!^S=\8/V>_"\'A>Q\(>#VU/&OW=E" QTYIHTDW,,S%D02-N#DG?
MT/0]5^R?X\\#_P#!.G_@K%XC^&OA?Q3;S?";XC>&8->L+R?6XKBUL)QN!83.
MPCVEUES@G " T7'&"G"Q^K4URY7_ %D8QUS&>/UJ%GVG)>-5SC:=P)/TS7YZ
M?\$H/VD+;XT?\% OVI+/2]:M=7\.V^K1ZAI]S:W)EM[@---%YD;;BFP^7_#P
M:U?^"/WQ2U+]I/\ :#_:)^(+:[J5_P"&Y?$K:7I&G75]-<1V8C9F)02 !1A]
MOR\97':I,_9GZ +N*C#-_G\:^'?^"T'[0&K6?PW\/?!?P;=*WCKXOWZ:;!'"
M[I<VMD&_?3C!W !AC<.,9K[CAF23A65BO! /0U^=W["EDO[<G_!1;XE_'Z_M
MI)/"W@^4^%_!\MRI3)3Y99 C?=R ,D?Q$T$TCO?^";7[.6D?L&_%CQM\-+/6
M89H[^UM=7L--EU#[3>NI0++*Y**5^?.!D^V:^T4NO,95#+N89"[AG^=?!'_!
M2O\ X*'^"?V&OVFO">H6_@FR\9?$:XT][:6;^U)+.:PL7<%8B$$@9F;D90GT
MK#^*/[:/[47P$\+_ /"V_'GP]\*6'PSM_(>^TJ-PVIVT4T@C4ER7(/W,Y48W
M#( X5693IN6Y^B^]EDV?-S7RK\;O^"5W@KXM?&K5OB!I7B[XH_#7Q'X@B5-7
MD\%:\FEC6-GW7F#(^['H<9KY5^ W_!;_ .-'[8O[0NL^#OA5\-/!FH0R0RWF
MC#4IY+66"UC W-<.TP6;YF&%B"']37U%^P9_P4QL?VH+KQ%X5\8:.W@7XD>"
MVE.MZ3,"B,(N'D3=R%&,X)/&.33#V+@:GP7_ ."5?P/^"_C.+Q"?"_\ PEOB
MQ0K#6/%MT^J72-US&) T,;=3F)%-?2D<^Q-L<ENJK\H55&%QQCKVK\L_A[\!
M+[_@MKXP^+GC[5]>U[1O"OAZXG\/>"K.&[$<,%]&@83,-C!5&86;8<GS3R""
M*^?O&/\ P5S^,&I_L\^'_@YX>U;7O"GQ$\)WM]H?C'6+XQ&"2&$M"BK=2!W6
M0%6W$*A! Y% *G=V/M?_ (*-?\%8KSX>>-K3X/\ P.M8?&7Q;\070LOW$1FM
M]*>3@*2IPTW4DYVQ@%FQ@UXO\!?V1M+_ &1/$6H,WA_PU\>OVJ_'J.-3DNG_
M +0TWPE$6&6N6*$G#'YB%4G;M&U<L_QW^QY\:=:\/31Z!\'_ IXBU;XR^(C
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M=?1K*ZUV(1CQ J%@UQ /N?*.064AUPQY ]<J0=* "BBB@#X1_X+3WMQXB\(
M_!_P7:VM[<-XJ\=6#RR01-)+"D3@&0X&T@"1CM/4 ^E?<%G:"PTNWMU;<(8U
MC!QC.!BJ][I<5^\;7$$<[6[EHQ)$KE6[%3_#]:O*#M'!H+/SG_;U_8(\4?MC
M_P#!5KX1WOB#P>-8^#_AG1)'U2X,[+:N^Z0F)D'.\NT>!W537@/_ 6P_P""
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M?V%9_L]^%M ^%^G?#6X%L/$UWJ@M=;DM]NP,;2!6=U8C(DDF#DCJN6%>+_\
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M4VV�!*K BH[GE:2#AC]:=0 ]/N#Z44J]** "BBB@ HHHH **** "O/_P!J
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MBQ-G 4<-^WU^V?XCA_:<_91UGX1?&+3]4^&?Q&\?6WAK6+#0OL5]9:EMNH%
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M(J0=*AT^PM]*L(;6UAAMK6VC6*&&) D<2*,*JJ. . *FH **** (Z_*O
M]N75?'7_ 5Y_:(\4?#WX5^)I-.^%OP@T^2ZU;4HDF^S:MJZ!RD("8\Y@Z!$
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M[H<C&T[E^HQ7;:1I<&AZ3:V-K&(;:SA2") <[$4!5'X "K%% !1110 4444
M%%%% !1110 4;J-U1T %2#I2 \4NZ@ HHW4@8-T(H 90!DTX)FG#B@ P***
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M@_9U^(D/C"XAA>UO=6M"UE9/N1I?.7:J^7@2(K-(F25. 3MK&\7_ (_:B_9
MG_;PU[XO?#7X<Z#XTN/BOX?LX-7MKN_AC@T:^\F%IX<^>AVI);_*Y)1@X&XF
MOTT!XI:97M$MD?$/P;^'O[<'Q)\<^']8^(7C/X7^"_"ZWL4VK>'+#3EO9YK=
M0/,A)"NI\P$J<7'!Y&0 #Y5_P45UJ[_89_X*C_"?XZ7'@[4=:^'>G^%G\-+#
MH=NC26DP%U"D2IE4C_X^H0@) 8;E'(Q7Z7T50>TUV/S9\0)^T3_P66L!H=]X
M?NO@'\"[AUEO9KS>VLZ^B](E1@A9"V#RJ1_+G=(0%/WA\!?@?X7_ &9OA3I'
M@OP;IL>E:#HL7EPQ+\SRL>7ED;J\CMEF8]2?PKMJ!;YJ"92OIT&6\(7FG7'*
MTHXHH) =*KE/(/"G\*L!&]?UH'2@",'(IUMQ3J* )**!THH **** "BBB@ H
MHHH **** "BBB@".I!THHH CHJ2B@!@3-+'$(Q3J* "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH C#9HW5%<_N5^4;OI2@\
M4 /WCU%2*P(ZU4J:VXH =113P>* 'BEW5'10!)NHW5'10!)NHW5'10!)NI
MP;H13-U-MN* )J*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** #=1NJ.
MB@ HIX/%+NH KXJ0=*DW4@8-T(H 914E('5NC#\Z &45)4>Z@ HIZL".M,)Q
M0 44 ;JD'2@"OBI%&14E% .E%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110!'BEVDT44 &PTD,1CZXHHH DJ&&W:-N<=>U%% #_*/][]*00>]
M%% #DC6/I3B,T44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
6444 %%%% !1110 4444 %%%% '__V0$!
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>22
<FILENAME>signature2.jpg
<TEXT>
begin 644 signature2.jpg
M_]C_X 02D9)1@ ! 0$ 8 !@ #_X0!:17AI9@ 34T *@ @ !0,! 4
M ! 2@,# $ ! %$0 $ ! 0 %$1 0 ! .PU$2
M 0 ! .PP 8:@ "QC__; $, @$! @$! @(" @(" @(#!0,#
M P,#!@0$ P4'!@<'!P8'!P@)"PD(" H(!P<*#0H*"PP,# P'"0X/#0P."PP,
M#/_; $,! @(" P,#!@,#!@P(!P@,# P,# P,# P,# P,# P,# P,# P,# P,
M# P,# P,# P,# P,# P,# P,# P,# P,#/_ !$( &4!'0,!(@ "$0$#$0'_
MQ ? !!0$! 0$! 0 0(#! 4&!P@)"@O_Q "U$ " 0,# @0#
M!04$! 7T! @, !!$%$B$Q008346$'(G$4,H&1H0@C0K'!%5+1\"0S8G*"
M"0H6%Q@9&B4F)R@I*C0U-C<X.3I#1$5&1TA)2E-455976%E:8V1E9F=H:6IS
M='5V=WAY>H.$A8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$
MQ<;'R,G*TM/4U=;7V-G:X>+CY.7FY^CIZO'R\_3U]O?X^?K_Q ? 0 # 0$!
M 0$! 0$! 0(#! 4&!P@)"@O_Q "U$0 " 0($! ,$!P4$! ! G<
M 0(#$00%(3$&$D%1!V%Q$R(R@0@40I&AL<$)(S-2\!5B<M$*%B0TX27Q%Q@9
M&B8G*"DJ-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U=G=X>7J"
M@X2%AH>(B8J2DY25EI>8F9JBHZ2EIJ>HJ:JRL[2UMK>XN;K"P\3%QL?(R<K2
MT]35UM?8V=KBX^3EYN?HZ>KR\_3U]O?X^?K_V@ , P$ A$#$0 _ /W\ P**
MCA4J6]ZDH **** "BBB@ HHHH *:R4ZHY)!^M $%Y<):1M)(ZQQHI9F8X Y
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M,KV+%% Z44#"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ P** <BB@ H
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M//VS(?VU/COK/PO^&NB7&H1^%=,;7[?Q@TACM8=1MI0(4@X(DB=P\3/D YD
MW!6KZ=^&OQ[T7QG\&-/\:WEU:Z/IT]D+F[:[E$*V#+E94D+$!=CJRG..5KW,
MTR_$04*E6-IRM===5=.W]Y?BO,\/*\?1DY4:<KPC=Q?2R=FK_P!U]>S\CT#=
M@5A>-?B)H?P\T[[9KVM:3HMIG'GW]U';Q@^[.0*^=M9_:G\7?M6ZO<:)\"[=
M;31%<17OC[5[-O[-C4@@_8(CAKJ7@_,0(AQRW2NE^%__ 3S\$>%O$"^(/%#
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M*:<K9- "T4$X%!.!0 44 Y%% !@44Q9MV[C[M+')OH ^<OC3^V!\2/!7[8>
MG?"3PE\,?"/B:;6?#-SXGL=3U'QM-I0:&WDBAEBDB739]DGFS($P[*RG)*<@
M:_[,/_!0?P/^T'\(-+\2ZM>:?\/]1U#6KSPX=(US5;>.5M2M9O)F@MWW!;D;
MBNUH^H=> 3@>(_MG_"I_B3_P4=\*:UK/PE^(/Q \$^'_ %J&EW<VBQB"-;V
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M^?0\-_9K^/</[-ME)\8_&EM#XJ^,WQ*@B\/_ Y\'V"*J:;IRGRH?+4<06[M
ML X!* 8R78U]8>*_VJ]>_8 _9PT2Q\>:K)\2_CEXVOWETWP[:. \MU<ON^S1
M!02EK#]T.<YQQU 'GWQ7_P"";WC#X&^)_@WK7PKTG3?'VO\ A^]NY_$6I>(+
MA87N+HV:6]C<$XRMO;?O"L,6 $ &<%<[X@?\$OOC%H_QSTWXB>&_&?AW6?%
M5QH%U%K'B#6EGDU"TU&5G.[3H,&*-5B(BB#G$8+$ACC'H8RME&.JQK5:D5&5
MW;;X6U&&EW"%E=_:E?OMY^!I9K@Z;I0IMRC;5?WK.4K[3ET[1MV/L+PG^UWX
M;\0_'>/X7M-))XXM]$36-4MK5/.MM*SM!BEF' <LWRJ<$C!KP'_@I[^TIXH^
M(3I^S_\ !N)M:^(WBRWW:W):SK&GAS3&RKO--D+$[Y SN"DD DKGR7]A?\
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M_LSPI;S!M+FMKBXM-"NI-N;ZWA*F.\NS\Y,EP5 ;&T !=+1/^""7B7QAX6\
M76/C7XU:E<W'B36!JDMS86 9M6920'OVD;=,0N=L>X(A9B,U.(A@Y8BIB*F8
M>]-ZM*5WK;2R6ROM:U[+1:YTOK7L84(X)<L%HFUIIZ]7;>][7/HGXI_\%2_A
M)\%/BGX!\&VNI6=];^,K87D=_82QQZ;I%F5!AEE<G:$?G 7D!3QT!V/^"?'[
M27C+]K#4?B)XTOGMX_AK-K1L/!"BV6.:ZM8,QRW3, &*R2 E0W(PPP 3Y[H
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MH8A!G<I60-EMQ 7(&]<^%?\% /@PNE?%0?"KX6?L\ZE?7TFB#Q1-XET?78;
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M2-)ILG VH3ELD$<#J*OG]B?X2G_FGOA?_P EK\^+7]GC5OBG\5UU/XA_"WX
MW>+KKQI:>%=9\-W^EP)I5KIUS:6-G#+:ZE)-&EQI[0WMO+.2!@I*Q522 _ZL
M478(\O'[%'PE'3X?>&!]+-12+^Q/\)5DW#X>^%]W3/V-<UZC104>8_\ #%_P
MI_Z$'PS_ . :TT?L5?"=6R/A_P"&5;U%FH(_&O4** ([6UCL;:.&&-8XHU"J
MJC 4#H!4E%% #?+&[-*4W4M% ";1BD,2GM3J* #I1110!'CFG(,4W/-/5LT
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MY*P6.&)>KL21T''4X'-=37Y8Z1IVIGX2Z7>ZUXWUWQA-H_[6UI;W(U4V4/\
M8PAUV>$2,(XD<-*LD649RJ_N_+6- 5/K/P$_:C^,WQC_ &G5U?\ X3;P9I7@
M"U^(.N>#-1\-ZCJ-L;B06TT\%K%:P1V"W2W6V);AC+=R1NI/RQKP 7,??-%<
MG\#=/U/2?A3HUKK/C)?B#JEO$T=UXA6TM[4:G('8%O*M_P!TF/NX7^YSSFNL
M8X%!17U._M](L)KJZGAM;6V1I9IIG$<<2 9+,QX Y)/ KS7P_\ M<?"WQA<
MW2Z+\4OAWJYM1(\ZV?B6RG,"H,N6"RG:%'))Z#K7AG_!9/5GA^&GP;TW4V1?
M 7B#XM>'M.\:";_CUETMI)&,=QV\AID@#;OE/ /!KVGXP_!7X:WGC7PKK&K:
M=X?L_$^EV6HZ1X>4I##)=P2V4OVBS5,9DB$*-(8QPOE[L8!R ;7AO]H#X?\
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MM!\?'P9HK2ZIK]E/>'[3/]GBW/!&#)+<2"3"+@[IG3<,%J\MT_\ ;.^-VL^
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M/6-:BO=0N[K[9?(24N@9)6,<XSCS(RKX &< ==\#?V7OA_^S9#JR>!?">D^
M&3KTJSZC):(?-OY%!"O*[$L[#)Y8D\D]Z] VCUHV@T ?/,O_ 2N^!$^G:M9
MMX)N&M=>U--:U&+_ (2#4]M[?(Q9;F0?:/FE#'=O/.0ISE1C?OO^">7P=UH>
M,AJ7@JWU5?B%);S>(5U"_N[Q=4DMV5H'<2RL T91=K+@J% !QQ7LX4 T.<&@
M+'C\W[ 7P9F^+6G^.A\-_#$/B[2[:.TM=3AMO)FA2*,1Q,-I"F2-%54D(+H%
M4*PP,4[;_@G3\'+;X+3?#M?![?\ "&W&JKK;Z8=7OF3[8&WB8.9MZGS/GP&
MW_/C=S7MP.110!X7JO\ P37^"NN:=KEK>>#6N(?$FK6^NZGYFLWY:\OH 1#<
M,WG[MZ9X((^ZO]U<>@_#K]GKP;\)O&7B'Q#X=T.WTS6O%C1/K%W'+(TFH-$N
MV-I-S$%E7Y0<9P .@%=G10!Y3\1_V&_A'\7/B)+XL\1> = U+Q%=1K#=7S1&
M.2_15VJMP$($ZA> )0P P!T%+X[_ &(/A/\ $WQ?#K^N^!]'U#6+6S33[>Z8
M.K6ULH4+!'M8".,;1\B@+D9QGFO5:* /-;O]CKX7W_PHM_ \W@?09/"MG>MJ
M=O8F#BWNVD:0W,;YWI,7=SYBL'^8\\UM?![X >#?@%IU];>$/#]CHHU287-_
M-'NDN=0E"A1)/.Y:69PHQND9CCO7844 %%%% !1110 4444 %%%% !12.<"F
M[C0 OF4JMNHHH 6BBB@ HHHH **** &R4!\"BB@!K/EZ&.!110 Y6P*)***
M&TJG!HHH 3/-*QR:** $!P:>K;J** %HHHH **** "BBB@ HHHH **** "BB
/B@ HHHH :_2B.BB@#__9
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R63.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
function toggleNextSibling (e) {
if (e.nextSibling.style.display=='none') {
e.nextSibling.style.display='block';
} else { e.nextSibling.style.display='none'; }
}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6804343472">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Commitments and Contingencies - Maturities of Lease Liabilities (Details)<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear', window );">Year 1</a></td>
<td class="nump">$ 1,453<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo', window );">Year 2</a></td>
<td class="nump">1,465<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree', window );">Year 3</a></td>
<td class="nump">1,523<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour', window );">Year 4</a></td>
<td class="nump">1,531<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive', window );">Year 5</a></td>
<td class="nump">1,567<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive', window );">Thereafter</a></td>
<td class="nump">11,333<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Total lease payments</a></td>
<td class="nump">18,872<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount', window );">Less imputed interest</a></td>
<td class="num">(8,570)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Total</a></td>
<td class="nump">$ 10,302<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments for operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&oid=77888426&loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments for operating lease, due after fifth fiscal year following latest fiscal year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&oid=77888426&loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments for operating lease, due in fifth fiscal year following latest fiscal year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&oid=77888426&loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments for operating lease, due in fourth fiscal year following latest fiscal year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&oid=77888426&loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments for operating lease, due in third fiscal year following latest fiscal year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&oid=77888426&loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments for operating lease, due in second fiscal year following latest fiscal year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&oid=77888426&loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments for operating lease having an initial or remaining lease term in excess of one year due in remainder of fiscal year following latest fiscal year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&oid=77888426&loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&oid=77888426&loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&oid=77888419&loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
function toggleNextSibling (e) {
if (e.nextSibling.style.display=='none') {
e.nextSibling.style.display='block';
} else { e.nextSibling.style.display='none'; }
}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6805982128">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Estimated Fair Value of Financial Instruments - Debt Instruments (Details) - Senior Notes - Level 2 - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Carrying Amount</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</strong></a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConvertibleDebtFairValueDisclosures', window );">Convertible debt, fair value</a></td>
<td class="nump">$ 7,106<span></span>
</td>
<td class="nump">$ 7,055<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Estimated Fair Value</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</strong></a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConvertibleDebtFairValueDisclosures', window );">Convertible debt, fair value</a></td>
<td class="nump">$ 28,900<span></span>
</td>
<td class="nump">$ 20,100<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertibleDebtFairValueDisclosures">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of borrowing which can be exchanged for a specified number of another security at the option of the issuer or the holder, for example, but not limited to, the entity's common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertibleDebtFairValueDisclosures</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_CarryingReportedAmountFairValueDisclosureMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementBasisAxis=us-gaap_CarryingReportedAmountFairValueDisclosureMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_EstimateOfFairValueFairValueDisclosureMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementBasisAxis=us-gaap_EstimateOfFairValueFairValueDisclosureMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
function toggleNextSibling (e) {
if (e.nextSibling.style.display=='none') {
e.nextSibling.style.display='block';
} else { e.nextSibling.style.display='none'; }
}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6823291984">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Fair Value Assumptions (Details) - Employee Stock Option<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Jun. 30, 2018</div></th>
<th class="th"><div>Jun. 30, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Expected dividend yield</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected option term (years)</a></td>
<td class="text">4 years 9 months 3 days<span></span>
</td>
<td class="text">4 years 6 months 7 days<span></span>
</td>
<td class="text">4 years 10 months 2 days<span></span>
</td>
<td class="text">5 years 14 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected stock price volatility</a></td>
<td class="nump">69.00%<span></span>
</td>
<td class="nump">71.00%<span></span>
</td>
<td class="nump">70.00%<span></span>
</td>
<td class="nump">63.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="nump">2.69%<span></span>
</td>
<td class="nump">1.39%<span></span>
</td>
<td class="nump">1.72%<span></span>
</td>
<td class="nump">1.16%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="nump">3.06%<span></span>
</td>
<td class="nump">2.58%<span></span>
</td>
<td class="nump">2.89%<span></span>
</td>
<td class="nump">2.15%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -URI http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -URI http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -URI http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2)<br> -URI http://asc.fasb.org/extlink&oid=115993241&loc=d3e301413-122809<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
function toggleNextSibling (e) {
if (e.nextSibling.style.display=='none') {
e.nextSibling.style.display='block';
} else { e.nextSibling.style.display='none'; }
}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6723905088">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Debt - Schedule of Liability Related to Sale of Future Royalties (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Jun. 30, 2018</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Jun. 30, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MovementInDeferredRevenueRollForward', window );"><strong>Movement in Deferred Revenue [Roll Forward]</strong></a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_immu_LiabilitiesRelatedToTheSaleOfFutureRoyaltiesCurrent', window );">Liability related to sale of future royalties - current</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 3,455<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=immu_RpiFinanceTrustMember', window );">Rpi Finance Trust | Royalty Arrangement</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MovementInDeferredRevenueRollForward', window );"><strong>Movement in Deferred Revenue [Roll Forward]</strong></a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_immu_FairValueForLiabilityRelatedtoSaleofFutureRoyalties', window );">Fair value, liability related to sale of future royalties, beginning balance</a></td>
<td class="nump">202,007<span></span>
</td>
<td class="nump">$ 182,216<span></span>
</td>
<td class="nump">221,295<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_immu_NonCashInterestExpenseRelatedToSaleOfFutureRoyalties', window );">Non-cash interest expenses</a></td>
<td class="nump">19,288<span></span>
</td>
<td class="nump">19,791<span></span>
</td>
<td class="nump">39,929<span></span>
</td>
<td class="nump">$ 19,800<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_immu_FairValueForLiabilityRelatedtoSaleofFutureRoyalties', window );">Fair value, liability related to sale of future royalties, ending balance</a></td>
<td class="nump">$ 221,295<span></span>
</td>
<td class="nump">$ 202,007<span></span>
</td>
<td class="nump">261,224<span></span>
</td>
<td class="nump">$ 202,007<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_immu_LiabilitiesRelatedToTheSaleOfFutureRoyaltiesCurrent', window );">Liability related to sale of future royalties - current</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 3,455<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_immu_FairValueForLiabilityRelatedtoSaleofFutureRoyalties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair Value For Liability Related to Sale of Future Royalties</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">immu_FairValueForLiabilityRelatedtoSaleofFutureRoyalties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>immu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_immu_LiabilitiesRelatedToTheSaleOfFutureRoyaltiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Liabilities Related To The Sale Of Future Royalties, Current</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">immu_LiabilitiesRelatedToTheSaleOfFutureRoyaltiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>immu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_immu_NonCashInterestExpenseRelatedToSaleOfFutureRoyalties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Non Cash Interest Expense Related To Sale Of Future Royalties</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">immu_NonCashInterestExpenseRelatedToSaleOfFutureRoyalties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>immu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MovementInDeferredRevenueRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MovementInDeferredRevenueRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=immu_RpiFinanceTrustMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=immu_RpiFinanceTrustMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRevenueArrangementTypeAxis=us-gaap_RoyaltyArrangementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredRevenueArrangementTypeAxis=us-gaap_RoyaltyArrangementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
function toggleNextSibling (e) {
if (e.nextSibling.style.display=='none') {
e.nextSibling.style.display='block';
} else { e.nextSibling.style.display='none'; }
}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6805743168">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Defined Contribution Plans<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CompensationAndRetirementDisclosureAbstract', window );"><strong>Retirement Benefits [Abstract]</strong></a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock', window );">Defined Contribution Plans</a></td>
<td class="text">Defined Contribution Plans <div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Eligible employees are able to participate in the Company’s 401(k) plan. Effective January 1, 2019, the Company increased the employer non-discretionary matching contributions in an amount equal to </span><span style="font-family:inherit;font-size:10pt;"><span>100%</span></span><span style="font-family:inherit;font-size:10pt;"> of deferral contributions up to a maximum of </span><span style="font-family:inherit;font-size:10pt;"><span>5%</span></span><span style="font-family:inherit;font-size:10pt;"> of eligible compensation contributed to the 401(k) plan. Company contributions to the 401(k) plan totaled approximately $</span><span style="font-family:inherit;font-size:10pt;"><span>1.9 million</span></span><span style="font-family:inherit;font-size:10pt;"> for the year ended December 31, 2019, and </span><span style="font-family:inherit;font-size:10pt;"><span>$0.1 million</span></span><span style="font-family:inherit;font-size:10pt;"> for the Transition Period and for each of the fiscal years ended June 30, 2018 and 2017.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationAndRetirementDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationAndRetirementDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for pension and other postretirement benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -URI http://asc.fasb.org/topic&trid=2235017<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
function toggleNextSibling (e) {
if (e.nextSibling.style.display=='none') {
e.nextSibling.style.display='block';
} else { e.nextSibling.style.display='none'; }
}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6810002608">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Debt (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_immu_AllocationofFairValuetoLiabilityTableTextBlock', window );">Schedule of allocation of fair value to liability</a></td>
<td class="text">The Company allocated the transaction consideration on a relative fair value to the liability and common stock in accordance with ASC 470-10 as follows (in thousands):<div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="5"/></tr><tr><td style="width:2%;"/><td style="width:78%;"/><td style="width:1%;"/><td style="width:18%;"/><td style="width:1%;"/></tr><tr><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Units of Accounting:</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Allocated Consideration</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Liability related to sale of future royalties</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>182,216</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Common stock</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>67,784</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>250,000</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock', window );">Schedule of deferred revenue, by arrangement</a></td>
<td class="text"><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following table shows the activity within the liability related to sale of future royalties during the year ended </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;">, the Transition Period and at the fiscal year ended June 30, 2018 (in thousands):</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"/></tr><tr><td style="width:80%;"/><td style="width:1%;"/><td style="width:18%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Liability related to sale of future royalties at January 7, 2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>182,216</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Interest expense recognized</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>19,791</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Carrying value of liability related to sale of future royalties at June 30, 2018</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>202,007</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Interest expense recognized</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>19,288</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Carrying value of liability related to sale of future royalties at December 31, 2018 </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>221,295</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Interest expense recognized</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>39,929</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Carrying value of liability related to sale of future royalties at December 31, 2019 (includes current portion of $3,455)</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>261,224</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_immu_AllocationofFairValuetoLiabilityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Allocation of Fair Value to Liability [Table Text Block]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">immu_AllocationofFairValuetoLiabilityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>immu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of contract balances and changes in contract balances.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&oid=118956577&loc=SL49130551-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
function toggleNextSibling (e) {
if (e.nextSibling.style.display=='none') {
e.nextSibling.style.display='block';
} else { e.nextSibling.style.display='none'; }
}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6802520752">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Business Overview and Summary of Significant Accounting Polices<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock', window );">Business Overview and Summary of Significant Accounting Policies</a></td>
<td class="text">Business Overview and Summary of Significant Accounting Policies<div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Immunomedics, Inc., a Delaware corporation, together with its subsidiaries (collectively "we," "our," "us," "Immunomedics", or the "Company"), is a clinical-stage biopharmaceutical company that develops monoclonal antibody-based products for the targeted treatment of cancer. Immunomedics manages its operations as one line of business of researching, developing, manufacturing and marketing biopharmaceutical products, particularly antibody-based products for patients with difficult to treat solid tumor and blood cancers. The Company currently reports as a single industry segment with substantially all business conducted in the United States. Immunomedics conducts its research activities in the United States and runs its development studies in the United States and selected European countries. Our corporate objective is to become a fully-integrated biopharmaceutical company and a leader in the field of antibody-drug conjugates (“ADCs”). To that end, our immediate priority is to commercialize our most advanced ADC product candidate, sacituzumab govitecan ("IMMU-132"), beginning in the United States, with metastatic triple-negative breast cancer (“mTNBC”) as the first indication. </span><span style="font-family:inherit;font-size:10pt;">In May 2018, we submitted a Biologics License Application (“BLA”) to the United States Food and Drug Administration ("FDA") for sacituzumab govitecan for the treatment of patients with mTNBC who have received at least two prior therapies for metastatic disease. In July 2018, we received notification from the FDA that the BLA was accepted for filing and the original application was granted Priority Review with a Prescription Drug User Fee Act ("PDUFA") target action date in January 2019. In January 2019, we received a Complete Response Letter ("CRL") from the FDA for the BLA. We subsequently met with the FDA in May 2019 to review the FDA’s findings and discussed our BLA resubmission. Since then, we have developed a detailed plan to address the chemistry, manufacturing, and controls (“CMC”) matters raised in the CRL and in our pre-approval inspection. We held another meeting with the FDA in September 2019 to update the FDA on our progress in addressing these matters and to receive feedback from the FDA on our approach. On November 30, 2019, we resubmitted our BLA to the FDA and on December 23, 2019 we received notification from the FDA that the BLA was accepted for filing and further assigned a new PDUFA target action date as June 2, 2020. We have dedicated, and continue to commit, significant resources to address the CMC matters identified by the FDA, while, in parallel, preparing our manufacturing facility to be ready for re-inspection by the FDA. Our Phase 3 confirmatory ASCENT study for sacituzumab govitecan has reached its target enrollment for mTNBC patients previously treated with at least two systemic chemotherapy regimens. Top-line data for the ASCENT study is expected to be available around mid-2020. </span><span style="font-family:inherit;font-size:10pt;"> </span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company has a foreign subsidiary, Immunomedics GmbH in Rodermark, Germany, that assists the Company in managing sales and marketing efforts and coordinating clinical trials in Europe. The accompanying consolidated financial statements include results for its foreign subsidiary and its majority-owned United States subsidiary, IBC Pharmaceuticals, Inc. ("IBC"). </span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Immunomedics is subject to significant risks and uncertainties, including, without limitation, the Company's inability to further identify, develop and achieve commercial success for new products and technologies; the possibility of delays in the research and development necessary to select drug development candidates and delays in clinical trials; the risk that clinical trials may not result in marketable products; the risk that the Company may be unable to secure regulatory approval of and market its drug candidates; the development or regulatory approval of competing products; the Company's ability to protect its proprietary technologies; patent infringement claims; and risks of new, changing and competitive technologies, and regulations in the United States and internationally.</span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Since its inception in 1982, Immunomedics’ principal sources of funds have been the private and public sale of equity and debt securities, and revenues from licensing agreements, including up-front and milestone payments, funding of development programs, and other forms of funding from collaborations. </span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company expects to continue to fund its operations with its current financial resources. </span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Summary of Significant Accounting Policies:</span></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Basis of Presentation</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The consolidated financial statements include the accounts of Immunomedics and its subsidiaries. Noncontrolling interests in consolidated subsidiaries in the consolidated balance sheets represent minority stockholders' proportionate share of the equity (deficit) in such subsidiaries. All intercompany balances and transactions have been eliminated in consolidation. In this Annual Report, the periods presented are the year ended December 31, 2019, the six-month transition period from July 1, 2018 to December 31, 2018 (which we sometimes refer to as the "Transition Period") and our fiscal years ended June 30, 2018 and 2017 (which are referred to as “fiscal 2018,” and "fiscal 2017", as if we had not changed our fiscal year to a calendar year).</span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Use of Estimates</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The preparation of consolidated financial statements in conformity with United States generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reported period. Actual results could differ from those estimates. The Company’s significant estimates and assumptions relate to stock-based compensation expenses, the fair value for the liability related to sale of future royalties and related interest expense.</span></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Interest Expense on Liability Related to Sale of Future Royalties</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company accounts for the liability related to the sale of future royalties as a debt financing. The Company has a significant continuing involvement in the generation of related royalty streams. The Company accretes this liability and recognizes expected interest expense using the effective interest rate method over the life of the related royalty stream, based on our current estimates of future royalty payments. These estimates include projections the Company makes and projections from outside the Company and involves significant judgment and inherent uncertainties. The Company periodically re-assesses the projections and, to the extent our future projections are greater or less than its previous estimates or the estimated timing of such payments is materially different than its previous estimates, the Company will adjust the effective interest calculation.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Foreign Currencies</span><span style="font-family:inherit;font-size:10pt;font-style:italic;"> </span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">For our German subsidiary which operates in a local currency environment, income and expense items are translated to United States dollars at the monthly average rates of exchange prevailing during the year, assets and liabilities are translated at year-end exchange rates and equity accounts are translated at historical exchange rates. Translation adjustments are accumulated in a separate component of stockholders' equity in the consolidated balance sheets and the consolidated statements of changes in stockholders’ equity and are included in the determination of comprehensive (loss) income in the consolidated statements of comprehensive loss. Transaction gains and losses are included in the determination of net loss in the consolidated statements of comprehensive loss.</span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Financial Instruments</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The carrying amount of cash and cash equivalents, prepaid expenses, other current assets and current liabilities approximate fair value due to the short-term maturity of these instruments. The Company considers all highly liquid investments with an original maturity of three months or less when purchased to be cash equivalents.</span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Marketable Securities</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Marketable securities, all of which are available-for-sale, consist of United States Government sponsored agencies which are carried at fair value, with unrealized gains and losses, net of related income taxes, reported as accumulated other comprehensive loss, except for losses from impairments which are determined to be other-than-temporary. Realized gains and losses and declines in value judged to be other-than-temporary on available-for-sale securities are included in the determination of net loss and are included in interest and other income (net), at which time the average cost basis of these securities are adjusted to fair value. Fair values are based on quoted market prices at the reporting date. Interest and dividends on available-for-sale securities are included in interest and other income (net).</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Property and Equipment</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Property and equipment are stated at cost less accumulated depreciation and amortization. Depreciation expense is computed using the straight-line method over the estimated useful lives of the assets, including leasehold improvements and capital lease assets that are amortized over the shorter of their useful lives or the terms of the respective leases. The Company generally uses the following range of useful lives for its property and equipment categories: leasehold improvements—</span><span style="font-family:inherit;font-size:10pt;"><span>7</span></span><span style="font-family:inherit;font-size:10pt;"> to </span><span style="font-family:inherit;font-size:10pt;"><span>10 years</span></span><span style="font-family:inherit;font-size:10pt;">; computer equipment—</span><span style="font-family:inherit;font-size:10pt;"><span>5 years</span></span><span style="font-family:inherit;font-size:10pt;">; machinery and equipment—</span><span style="font-family:inherit;font-size:10pt;"><span>5</span></span><span style="font-family:inherit;font-size:10pt;"> to </span><span style="font-family:inherit;font-size:10pt;"><span>10 years</span></span><span style="font-family:inherit;font-size:10pt;">; and furniture and fixtures—</span><span style="font-family:inherit;font-size:10pt;"><span>10 years</span></span><span style="font-family:inherit;font-size:10pt;">. Depreciation expense includes amortization of assets related to capital leases. The Company charges repairs and maintenance costs to expense as incurred. </span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Concentration of Credit Risk</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Cash, cash equivalents, and marketable securities are financial instruments that potentially subject the Company to concentration of credit risk. Our investment policy is to invest only in institutions that meet high credit quality standards and establishes limits on the amount and time to maturity of investments with any individual counterparty. The policy also requires that investments are only entered into with corporate and financial institutions that meet high credit quality standards. Restricted cash represents funds the Company is required to set aside to cover vehicle operating leases and other purposes. </span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Revenue Recognition</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Pursuant to Topic 606, we recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. To achieve this core principle, Topic 606 includes provisions within a five step model that includes i) identifying the contract with a customer, ii) identifying the performance obligations in the contract, iii) determining the transaction price, iv) allocating the transaction price to the performance obligations, and v) recognizing revenue when, or as, an entity satisfies a performance obligation.</span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">At contract inception, we assess the goods or services promised within each contract and assess whether each promised good or service is distinct and determine those that are performance obligations. We then recognize as revenue the amount of the transaction price that is allocated to the respective performance obligation when the performance obligation is satisfied.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Research and Development Costs</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Research and development costs are expensed as incurred. Costs incurred for clinical trials for patients and investigators are expensed as services are performed in accordance with the agreements in place with the institutions. Research and development costs include salaries and benefits, costs associated with producing biopharmaceutical compounds, laboratory supplies, the costs of conducting clinical trials, and facilities costs. In addition, the Company uses clinical research organizations and contract manufacturing operations to outsource portions of our research and development activities.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Treasury Shares</span><span style="font-family:inherit;font-size:10pt;">    </span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company records treasury stock at the cost to acquire it and includes treasury stock as a component of Stockholders’ Equity. In determining the cost of the treasury shares when either sold or issued, the Company uses the first-in, first-out method ("FIFO"). If the proceeds from the sale of the treasury shares are greater than the cost of the shares sold, the excess proceeds are recorded as additional paid-in capital. If the proceeds from the sale of the treasury shares are less than the original cost of the shares sold, the excess cost reduces any additional paid-in capital arising from previous sales of treasury shares for that class of stock.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Fair Value Measurements</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"/><span style="font-family:inherit;font-size:10pt;">The Company categorizes its financial instruments measured at fair value into a three-level fair value hierarchy that prioritizes the inputs used in determining the fair value of the asset or liability. The three levels of the fair value hierarchy are as follows:</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">•</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Level 1 - </span><span style="font-family:inherit;font-size:10pt;">Financial instruments whose values are based on unadjusted quoted prices for identical assets or liabilities in an active market which the company has the ability to access at the measurement date (examples include active exchange-traded securities and most United States Government and agency securities).</span></div></td></tr></table><div style="line-height:120%;text-align:justify;padding-left:96px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><span style="font-family:inherit;font-size:10pt;">•</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Level 2 -</span><span style="font-family:inherit;font-size:10pt;"> Financial instruments whose value are based on quoted market prices in markets where trading occurs infrequently or whose values are based on quoted prices of instruments with similar attributes in active markets.</span></div></td></tr></table><div style="line-height:120%;text-align:justify;padding-left:96px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><span style="font-family:inherit;font-size:10pt;">•</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Level 3 -</span><span style="font-family:inherit;font-size:10pt;"> Financial instruments whose values are based on prices or valuation techniques that require inputs that are both unobservable and significant to the overall fair value measurement. These inputs reflect management's own assumptions about the assumptions a market participant would use in pricing the asset.</span></div></td></tr></table><div style="line-height:120%;text-align:justify;padding-left:72px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company’s financial instruments consist of cash and cash equivalents, marketable securities, prepaid expenses, other current assets, accounts payable and accrued expenses, convertible senior notes, liabilities related to the sale of future royalties and Convertible Senior Notes. The carrying amount of prepaid expenses, other current assets, accounts payable and accrued expenses and certain other liabilities are generally considered to be representative of their respective fair values because of the short-term nature of those instruments.</span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Income Taxes</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company uses the asset and liability method to account for income taxes, including the recognition of deferred tax assets and deferred tax liabilities for the anticipated future tax consequences attributable to differences between financial statements amounts and their respective tax bases. The Company reviews its deferred tax assets for recovery. A valuation allowance is established when the Company believes that it is more likely than not that its deferred tax assets will not be realized. Changes in valuation allowances from period to period are included in the Company’s tax provision in the period of change. The Company has recorded a full valuation allowance against its net deferred tax assets as of </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">2018</span><span style="font-family:inherit;font-size:10pt;">.</span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Tax Cuts and Jobs Act (the "Act") was signed into law on December 22, 2017. Among its numerous changes to the Internal Revenue Code, the Act reduces United States corporate rates from 35% to 21%. Additionally, the Act limits the use of net operating loss carry backs, however any future net operating losses will instead be carried forward indefinitely. Only 80% of current income will be able to be offset with a net operating loss carryforward, with the remainder of the net operating loss continuing to carry forward. As a result of the reduction in the U.S. corporate income tax rate, the Company revalued its ending net deferred tax assets as of June 30, 2018, which resulted in a provisional expense of </span><span style="font-family:inherit;font-size:10pt;"><span>$59.5 million</span></span><span style="font-family:inherit;font-size:10pt;"> which was offset by an associated change in valuation allowance. In the second quarter of the Transition Period, the Company completed its analysis to determine the effect of the Tax Act and recorded no further adjustments. </span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Net Loss Per Share Allocable to Common Stockholders</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net loss per basic and diluted common share allocable to common stockholders is based on the net loss for the relevant period, divided by the weighted-average number of common shares outstanding during the period. For purposes of the diluted net loss per common share calculations, the exercise or exchange of all potential common shares is not included because their effect would have been anti-dilutive, due to the net loss recorded for the year ended </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;">, the Transition Period and fiscal years ended June 2018, and 2017, respectively. The common stock equivalents excluded from the earnings per share calculation are </span><span style="font-family:inherit;font-size:10pt;"><span>8.2 million</span></span><span style="font-family:inherit;font-size:10pt;">, </span><span style="font-family:inherit;font-size:10pt;"><span>6.7 million</span></span><span style="font-family:inherit;font-size:10pt;">, </span><span style="font-family:inherit;font-size:10pt;"><span>10.0 million</span></span><span style="font-family:inherit;font-size:10pt;">, and </span><span style="font-family:inherit;font-size:10pt;"><span>66.1 million</span></span><span style="font-family:inherit;font-size:10pt;"> for the year ended </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;">, the Transition Period and the fiscal years ended June 2018, and 2017, respectively.</span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Net Comprehensive Loss</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net comprehensive loss consists of net loss, unrealized gain (loss) on available for sale securities and foreign exchange translation adjustments and is presented in the consolidated statements of comprehensive loss.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Stock-Based Compensation</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company utilizes stock-based compensation in the form of stock options, stock appreciation rights, stock awards, stock unit awards, performance shares, cash-based performance units and other stock-based awards, each of which may be granted separately or in tandem with other awards.</span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The grant-date fair value of stock awards is based upon the underlying price of the stock on the date of grant. The grant-date fair value of stock option awards must be determined using an option pricing model. Option pricing models require the use of estimates and assumptions as to (a) the expected term of the option, (b) the expected volatility of the price of the underlying stock and (c) the risk-free interest rate for the expected term of the option. The Company uses the Black-Scholes option pricing formula for determining the grant-date fair value of such awards. The fair value of option awards that vest based on achievement of certain market conditions are determined using a Monte Carlo simulation technique.</span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The expected term of the option is based upon the contractual term and expected employee exercise and expected post-vesting employment termination behavior. The expected volatility of the price of the underlying stock is based upon the historical volatility of the Company’s stock computed over a period of time equal to the expected term of the option. The risk-free interest </span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">rate is based upon the implied yields currently available from the United States Treasury yield curve in effect at the time of the grant. Forfeitures are recorded as incurred.</span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Recently Issued Accounting Pronouncements</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Accounting Pronouncements adopted during the year</span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) 2019-01, “Leases Topic 842,” requiring entities to recognize assets and liabilities on the balance sheet for all leases, with certain exceptions. Topic 842 allows for a modified retrospective application and is effective as of the first quarter of 2019. Entities are allowed to apply the new guidance using a modified retrospective approach at the beginning of the year in which new lease standard is adopted, rather than to the earliest comparative period presented in their financial statements. The modified retrospective approach includes a number of optional practical expedients that entities may elect to apply. We elected the modified retrospective approach under the new guidance and elected the available practical expedients on adoption. Upon adoption, we recognized additional operating lease liabilities of </span><span style="font-family:inherit;font-size:10pt;"><span>$8.4 million</span></span><span style="font-family:inherit;font-size:10pt;"> with a corresponding right-of-use assets of </span><span style="font-family:inherit;font-size:10pt;"><span>$8.4 million</span></span><span style="font-family:inherit;font-size:10pt;"> based on the present value of the remaining lease payments under existing operating leases. As of December 31, 2018, we had </span><span style="font-family:inherit;font-size:10pt;"><span>$2.1 million</span></span><span style="font-family:inherit;font-size:10pt;"> in deferred charges related to our real estate leases that were recorded against the lease liability asset as part of the transition, resulting in </span><span style="font-family:inherit;font-size:10pt;"><span>$10.5 million</span></span><span style="font-family:inherit;font-size:10pt;"> included in other long-term liabilities on our consolidated balance sheets. In addition, the new guidance resulted in additional lease-related disclosures in the footnotes to our consolidated financial statements. Our leasing portfolio is comprised entirely of operating leases, and we do not recognize right-of-use assets or related lease liabilities with a lease term of twelve months or less on our consolidated balance sheets. Adoption of Topic 842 has required changes to our business processes and controls to comply with the provisions of the standard. Refer to Note 14 "Commitments and Contingencies" for additional information.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In June 2018, the FASB issued ASU 2018-07, "Compensation-Stock Compensation," to improve the usefulness of information provided to users of financial statements while reducing cost and complexity in financial reporting and provide guidance aligning the measurement and classification for share-based payments to nonemployees with the guidance for share-based payments to employees. Under the guidance, the measurement of equity-classified nonemployee awards will be fixed at the grant date. This standard is effective for fiscal years beginning after December 15, 2018, and interim periods within those annual periods. Early adoption is permitted, but no earlier than an entity's adoption date of ASU 2014-09, “Revenue from Contracts with Customers (Topic 606).” We adopted ASU 2018-07 during the first quarter of 2019 and the adoption did not have a material impact to our consolidated financial statements.</span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Accounting Pronouncements yet to be adopted</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In November 2018, the FASB issued ASU 2018-18, "Collaborative Arrangements (Topic 808): Clarifying the Interaction between Topic 808 and Topic 606,"    to clarify when ASC 606 should be used for collaborative arrangements when the counterparty is a customer. The guidance precludes an entity from presenting consideration from a transaction in a collaborative arrangement as revenue from contracts with customers if the counterparty is not a customer for that transaction. The guidance is effective for public business entities in fiscal years beginning after December 15, 2019, and interim periods therein. Early adoption is permitted to entities that have adopted ASC 606. We are currently assessing the impact of ASU 2018-18.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In August 2018, the FASB issued ASU 2018-13, "Fair Value measurement (Topic 820): Disclosure Framework - Changes to the Disclosure Requirements for Fair Value Measurement," to no longer require public companies to disclose transfers between Level 1 and Level 2 of the fair value hierarchy, and to require disclosure about the range and weighted average used to develop significant unobservable inputs for Level 3 fair value measurements. The guidance is effective for fiscal years beginning after December 15, 2019, and for interim periods within those fiscal years. Entities are permitted to early adopt either the entire standard or only the provisions that eliminate or modify the requirements. We are currently assessing the impact of ASU 2018-13.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the business description and basis of presentation concepts. Business description describes the nature and type of organization including but not limited to organizational structure as may be applicable to holding companies, parent and subsidiary relationships, business divisions, business units, business segments, affiliates and information about significant ownership of the reporting entity. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI http://asc.fasb.org/topic&trid=2122369<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -URI http://asc.fasb.org/topic&trid=2122149<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -URI http://asc.fasb.org/topic&trid=2134479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
function toggleNextSibling (e) {
if (e.nextSibling.style.display=='none') {
e.nextSibling.style.display='block';
} else { e.nextSibling.style.display='none'; }
}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6802358000">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accounts Payable and Accrued Expenses (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock', window );">Schedule of Accounts Payable and Accrued Expenses</a></td>
<td class="text"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Accounts payable and accrued expenses consisted of the following as of December 31, (in thousands):</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"/></tr><tr><td style="width:73%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">2018 </span><span style="font-family:inherit;font-size:9pt;font-weight:bold;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(a)</sup></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Trade accounts payable</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>37,758</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>20,125</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Accrued contract manufacturing expenses</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>11,663</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Accrued employee related expenses</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>7,403</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>315</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Clinical trial accruals</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>2,225</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>5,114</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Executive severance liabilities</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>561</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>2,198</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Miscellaneous other current liabilities</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>1,250</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>3,970</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>60,860</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>31,722</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(a)</sup></span><span style="font-family:inherit;font-size:10pt;"> </span><span style="font-family:inherit;font-size:9pt;">Certain 2018 amounts have been reclassified to conform with current year presentation.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the (a) carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business (accounts payable); (b) other payables; and (c) accrued liabilities. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). An alternative caption includes accrued expenses.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
function toggleNextSibling (e) {
if (e.nextSibling.style.display=='none') {
e.nextSibling.style.display='block';
} else { e.nextSibling.style.display='none'; }
}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6824158672">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONSOLIDATED BALANCE SHEETS (Parenthetical) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent', window );">Allowances for doubtful accounts</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_immu_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization', window );">Accumulated depreciation</a></td>
<td class="nump">$ 7,925<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Accumulated depreciation</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 4,316<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value (in USD per share)</a></td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized (in shares)</a></td>
<td class="nump">10,000,000<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in USD per share)</a></td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized (in shares)</a></td>
<td class="nump">250,000,000<span></span>
</td>
<td class="nump">250,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued (in shares)</a></td>
<td class="nump">212,529,313<span></span>
</td>
<td class="nump">190,445,795<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding (in shares)</a></td>
<td class="nump">212,409,692<span></span>
</td>
<td class="nump">190,411,070<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockShares', window );">Treasury stock, shares (in shares)</a></td>
<td class="nump">119,621<span></span>
</td>
<td class="nump">34,725<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_ConvertiblePreferredStockMember', window );">Convertible preferred stock</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value (in USD per share)</a></td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized (in shares)</a></td>
<td class="nump">10,000,000<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_immu_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Property, Plant, And Equipment And Finance Lease Right-Of-Use Asset, Accumulated Depreciation And Amortization</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">immu_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>immu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.14)<br> -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of allowance for credit loss on accounts receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(4)<br> -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&oid=118936363&loc=d3e5074-111524<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&oid=118955202&loc=SL82895884-210446<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&oid=109259400&loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of common and preferred shares that were previously issued and that were repurchased by the issuing entity and held in treasury on the financial statement date. This stock has no voting rights and receives no dividends.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29,30)<br> -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&oid=6405813&loc=d3e23239-112655<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_ConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_ConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R9999.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
function toggleNextSibling (e) {
if (e.nextSibling.style.display=='none') {
e.nextSibling.style.display='block';
} else { e.nextSibling.style.display='none'; }
}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6810317088">
<tr>
<th class="tl" colspan="1">Label</th>
<th class="tl"><strong>Element</strong></th>
<th class="th" colspan="1">Value</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashCurrent', window );">Restricted Cash, Current</a></td>
<td class="th" style="border-bottom: 0px;">us-gaap_RestrictedCashCurrent</td>
<td class="nump">$ 3,413,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashCurrent', window );">Restricted Cash, Current</a></td>
<td class="th" style="border-bottom: 0px;">us-gaap_RestrictedCashCurrent</td>
<td class="nump">525,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashCurrent', window );">Restricted Cash, Current</a></td>
<td class="th" style="border-bottom: 0px;">us-gaap_RestrictedCashCurrent</td>
<td class="nump">$ 1,313,000<span></span>
</td>
</tr>
</table>
<div style="display: none;"><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&oid=98513485&loc=SL98516268-108586<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&oid=118951113&loc=d3e6676-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table></div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
function toggleNextSibling (e) {
if (e.nextSibling.style.display=='none') {
e.nextSibling.style.display='block';
} else { e.nextSibling.style.display='none'; }
}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6828266992">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Debt - Liability Related to Sale of Future Royalties (Details) - USD ($)<br> $ / shares in Units, shares in Millions</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jan. 01, 2019</div></th>
<th class="th"><div>Jan. 07, 2018</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Jun. 30, 2018</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Jun. 30, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Agreement purchase shares of common stock (in shares)</a></td>
<td class="nump">4.4<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_immu_PeriodWhichCompanyWillAccreteLiability', window );">Period which company will accrete liability</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">20 years<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_immu_AnnualInterestRateInCalculatingLiabilityRelatedToSaleOfFutureRoyalties', window );">Annual interest rate in calculating liability related to sale of future royalties</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">16.00%<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=immu_RpiFinanceTrustMember', window );">Rpi Finance Trust | Royalty Arrangement</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_immu_PaymentsForFutureRoyalties', window );">Collaborative arrangement purchase price</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 175,000,000.0<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_immu_RoyaltyPurchaseArrangementRoyaltyRateasPercentageofNetSales', window );">Collaborative arrangement royalty rate as percent of net sales</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">4.15%<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_immu_RoyaltyPurchaseArrangementAnnualSalesLimitMaximum', window );">Collaborative arrangement maximum royalty amount</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 2,000,000,000.0<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_immu_RoyaltyPurchaseArrangementRoyaltyRateasPercentageofExcessofGlobalAnnualSalesThresholdLimit', window );">Collaborative arrangement royalty rate as percentage of excess of global annual sales threshold limit</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">1.75%<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_immu_RoyaltyPurchaseArrangementExcessGlobalAnnualSalesLimitMinimum', window );">Collaborative arrangement excess of global annual sales threshold limit</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 6,000,000,000.0<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_immu_NonCashInterestExpenseRelatedToSaleOfFutureRoyalties', window );">Non-cash interest expenses</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 19,288,000<span></span>
</td>
<td class="nump">$ 19,791,000<span></span>
</td>
<td class="nump">$ 39,929,000<span></span>
</td>
<td class="nump">$ 19,800,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember', window );">Private placement | Rpi Finance Trust | Royalty Arrangement</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Share price (in USD per share)</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 17.15<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Sale of stock, consideration received on transaction</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 75,000,000.0<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_immu_AnnualInterestRateInCalculatingLiabilityRelatedToSaleOfFutureRoyalties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Annual Interest Rate In Calculating Liability Related To Sale Of Future Royalties</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">immu_AnnualInterestRateInCalculatingLiabilityRelatedToSaleOfFutureRoyalties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>immu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_immu_NonCashInterestExpenseRelatedToSaleOfFutureRoyalties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Non Cash Interest Expense Related To Sale Of Future Royalties</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">immu_NonCashInterestExpenseRelatedToSaleOfFutureRoyalties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>immu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_immu_PaymentsForFutureRoyalties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Payments For Future Royalties</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">immu_PaymentsForFutureRoyalties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>immu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_immu_PeriodWhichCompanyWillAccreteLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period Which Company Will Accrete Liability</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">immu_PeriodWhichCompanyWillAccreteLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>immu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_immu_RoyaltyPurchaseArrangementAnnualSalesLimitMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of collaborative arrangement royalty.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">immu_RoyaltyPurchaseArrangementAnnualSalesLimitMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>immu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_immu_RoyaltyPurchaseArrangementExcessGlobalAnnualSalesLimitMinimum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">immu_RoyaltyPurchaseArrangementExcessGlobalAnnualSalesLimitMinimum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>immu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_immu_RoyaltyPurchaseArrangementRoyaltyRateasPercentageofExcessofGlobalAnnualSalesThresholdLimit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The percentage of collaborative arrangement royalty rate on excess of global annual sales threshold limit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">immu_RoyaltyPurchaseArrangementRoyaltyRateasPercentageofExcessofGlobalAnnualSalesThresholdLimit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>immu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_immu_RoyaltyPurchaseArrangementRoyaltyRateasPercentageofNetSales">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The percentage of collaborative arrangement royalty rate on net sales.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">immu_RoyaltyPurchaseArrangementRoyaltyRateasPercentageofNetSales</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>immu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash received on stock transaction after deduction of issuance costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockConsiderationReceivedOnTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Price of a single share of a number of saleable stocks of a company.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&oid=109259400&loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=immu_RpiFinanceTrustMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=immu_RpiFinanceTrustMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRevenueArrangementTypeAxis=us-gaap_RoyaltyArrangementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredRevenueArrangementTypeAxis=us-gaap_RoyaltyArrangementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
function toggleNextSibling (e) {
if (e.nextSibling.style.display=='none') {
e.nextSibling.style.display='block';
} else { e.nextSibling.style.display='none'; }
}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6813287984">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Business Overview and Summary of Significant Accounting Polices - Recent Accounting Pronouncements (Details) - USD ($)<br> $ in Thousands, shares in Millions</strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Jun. 30, 2018</div></th>
<th class="th"><div>Jun. 30, 2017</div></th>
<th class="th"><div>Jan. 01, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxCutsAndJobsActOf2017IncompleteAccountingChangeInTaxRateDeferredTaxAssetProvisionalIncomeTaxExpense', window );">Provisional expense from revaluation in deferred tax asset due to TCJA</a></td>
<td class="nump">$ 59,500<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded from computation of earnings per share</a></td>
<td class="nump">6.7<span></span>
</td>
<td class="nump">8.2<span></span>
</td>
<td class="nump">10.0<span></span>
</td>
<td class="nump">66.1<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Operating lease, liability</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 10,302<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Right-of-use asset</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">8,105<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Other liabilities, noncurrent</a></td>
<td class="nump">$ 2,119<span></span>
</td>
<td class="nump">$ 9,965<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201602Member', window );">Accounting Standards Update 2016-02</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Operating lease, liability</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 8,400<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Right-of-use asset</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">8,400<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Other liabilities, noncurrent</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 10,500<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember', window );">Leasehold Improvements | Minimum</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property, plant and equipment, useful life</a></td>
<td class="text"> <span></span>
</td>
<td class="text">7 years<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember', window );">Leasehold Improvements | Maximum</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property, plant and equipment, useful life</a></td>
<td class="text"> <span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember', window );">Computer Equipment</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property, plant and equipment, useful life</a></td>
<td class="text"> <span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_MachineryAndEquipmentMember', window );">Machinery and Equipment | Minimum</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property, plant and equipment, useful life</a></td>
<td class="text"> <span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_MachineryAndEquipmentMember', window );">Machinery and Equipment | Maximum</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property, plant and equipment, useful life</a></td>
<td class="text"> <span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember', window );">Furniture and Fixtures</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property, plant and equipment, useful life</a></td>
<td class="text"> <span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeaseDescriptionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeaseDescriptionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&oid=77888419&loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&oid=77888419&loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.24)<br> -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCutsAndJobsActOf2017IncompleteAccountingChangeInTaxRateDeferredTaxAssetProvisionalIncomeTaxExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of reasonable estimate for income tax expense for which accounting for tax effect for remeasurement of deferred tax asset from change in tax rate is incomplete pursuant to Tax Cuts and Jobs Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2A<br> -Subparagraph (SAB Topic 5.EE.Q2(b))<br> -URI http://asc.fasb.org/extlink&oid=116825942&loc=SL116722634-122817<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCutsAndJobsActOf2017IncompleteAccountingChangeInTaxRateDeferredTaxAssetProvisionalIncomeTaxExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201602Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201602Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_MachineryAndEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_MachineryAndEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
function toggleNextSibling (e) {
if (e.nextSibling.style.display=='none') {
e.nextSibling.style.display='block';
} else { e.nextSibling.style.display='none'; }
}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6809621696">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accumulated Other Comprehensive (Loss) Income (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock', window );">Components of Accumulated Other Comprehensive (Loss) Income</a></td>
<td class="text"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The components of accumulated other comprehensive (loss) income were as follows (in thousands):</span></div><div style="line-height:120%;text-align:justify;padding-left:0px;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"/></tr><tr><td style="width:53%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Currency Translation Adjustments</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;"> Net Unrealized Gains (Losses) on Available-for-Sale Securities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Accumulated Other Comprehensive (Loss) Income</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Balance at June 30, 2016</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(172</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>40</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(132</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Other comprehensive loss before reclassifications</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(62</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(125</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(187</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">   Amounts reclassified from accumulated other comprehensive income</span><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(a)</sup></span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>16</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>16</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Net other comprehensive loss for the year</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(62</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(109</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(171</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Balance at June 30, 2017</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(234</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(69</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(303</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Other comprehensive income (loss) before reclassifications</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(105</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>55</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(50</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">  Amounts reclassified from accumulated other comprehensive income</span><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(a)</sup></span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Net other comprehensive (loss) income for the year</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(105</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>55</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(50</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Balance at June 30, 2018</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(339</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(14</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(353</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Other comprehensive income (loss) before reclassifications</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(8</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>10</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">  Amounts reclassified from accumulated other comprehensive income</span><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(a)</sup></span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Net other comprehensive (loss) income for the year</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(8</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>10</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Balance at December 31, 2018</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(347</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(4</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(351</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Other comprehensive loss before reclassifications</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(21</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(391</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(412</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">  Amounts reclassified from accumulated other comprehensive income</span><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(a)</sup></span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>195</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>195</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Net other comprehensive (loss) income for the year</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>174</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(391</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(217</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Balance at December 31, 2019</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(173</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(395</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(568</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td></tr></table></div></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:inherit;font-size:10pt;">(a)</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">For the year ended </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;">, the Transition Period ended December 31, 2018, and the fiscal years ended June 30, 2018 and 2017, </span><span style="font-family:inherit;font-size:10pt;"><span>$0.2 million</span></span><span style="font-family:inherit;font-size:10pt;">, </span><span style="font-family:inherit;font-size:10pt;"><span>$0</span></span><span style="font-family:inherit;font-size:10pt;">, </span><span style="font-family:inherit;font-size:10pt;"><span>$0</span></span><span style="font-family:inherit;font-size:10pt;">, and </span><span style="font-family:inherit;font-size:10pt;"><span>$16 thousand</span></span><span style="font-family:inherit;font-size:10pt;">, respectively, were reclassified from accumulated other comprehensive (loss) income to interest and other income.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of accumulated other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI http://asc.fasb.org/extlink&oid=118930883&loc=SL7669686-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
function toggleNextSibling (e) {
if (e.nextSibling.style.display=='none') {
e.nextSibling.style.display='block';
} else { e.nextSibling.style.display='none'; }
}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6802446880">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock', window );">Property and Equipment</a></td>
<td class="text">Property and Equipment<div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Property and equipment consisted of the following as of December 31, (in thousands):</span></div><div style="line-height:120%;text-align:justify;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"/></tr><tr><td style="width:73%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">2018</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Machinery and equipment</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>14,331</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>16,048</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Leasehold improvements</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>11,535</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>6,365</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Right-of-use asset</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>8,368</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">—</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Furniture and fixtures</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>1,190</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>291</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Computer equipment</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>2,596</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>1,850</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Construction in progress</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>2,667</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>3,231</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>40,687</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>27,785</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Accumulated depreciation and amortization</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(7,925</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(4,316</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>32,762</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>23,469</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Depreciation and amortization expense for the year ended </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;">, the Transition Period, and the fiscal years ended June 30, 2018 and 2017, was </span><span style="font-family:inherit;font-size:10pt;"><span>$3.8 million</span></span><span style="font-family:inherit;font-size:10pt;">, </span><span style="font-family:inherit;font-size:10pt;"><span>$2.1 million</span></span><span style="font-family:inherit;font-size:10pt;">, $</span><span style="font-family:inherit;font-size:10pt;"><span>1.3 million</span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>$0.9 million</span></span><span style="font-family:inherit;font-size:10pt;">, respectively. </span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for long-lived, physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, accounting policies and methodology, roll forwards, depreciation, depletion and amortization expense, including composite depreciation, accumulated depreciation, depletion and amortization expense, useful lives and method used, income statement disclosures, assets held for sale and public utility disclosures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -URI http://asc.fasb.org/topic&trid=2155823<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
function toggleNextSibling (e) {
if (e.nextSibling.style.display=='none') {
e.nextSibling.style.display='block';
} else { e.nextSibling.style.display='none'; }
}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6809621696">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">Income Taxes</a></td>
<td class="text">Income Taxes<div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Income tax expense for income taxes is as follows (in thousands):</span></div><div style="line-height:120%;text-align:justify;padding-left:0px;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"/></tr><tr><td style="width:31%;"/><td style="width:1%;"/><td style="width:15%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:15%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:14%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:14%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"> </span></div></td><td colspan="3" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Year Ended </span></div><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">December 31, 2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Transition Period Ended </span></div><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">December 31, 2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Fiscal Year Ended June 30,</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">2017</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Federal</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">    </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">    </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Current</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Deferred</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Total Federal</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">State</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Current</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Deferred</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Total State</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Foreign</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Current</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>154</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>19</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Deferred</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Total Foreign</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>154</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>19</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Total income tax expense</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>156</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>20</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">A reconciliation of the statutory tax rates and the effective tax rates for the year ended </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;">, the transition period ended December 31, 2018 and fiscal years ended June 30, 2018 and 2017 is as follows:</span></div><div style="line-height:120%;text-align:justify;padding-left:0px;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"/></tr><tr><td style="width:31%;"/><td style="width:16%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:16%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:15%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:15%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Year Ended </span></div><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">December 31, 2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Transition Period Ended </span></div><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">December 31, 2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Fiscal Year Ended June 30,</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">2017</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Statutory rate</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(21.0</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)%</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(21.0</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)%</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(28.0</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)%</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(34.0</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)%</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Foreign income tax</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"> %</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"> %</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"> %</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"> %</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Change in valuation allowance</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>29.9</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"> %</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>34.4</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"> %</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>21.1</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"> %</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>21.9</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"> %</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">State income taxes, (net of federal tax benefit)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(7.5</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(8.8</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(4.3</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(4.8</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)%</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Permanent differences, (primarily warrant-related expenses)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(1.4</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)%</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(4.2</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)%</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>11.3</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"> %</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>15.3</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"> %</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Other</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"> %</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(0.4</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"> %</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>1.6</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"> %</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Effective rate</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"> %</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"> %</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>0.1</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"> %</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"> %</span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The tax effects of temporary differences that give rise to significant portions of the Company’s deferred tax assets and liabilities as of December 31, (in thousands):</span></div><div style="line-height:120%;text-align:justify;padding-left:0px;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"/></tr><tr><td style="width:59%;"/><td style="width:1%;"/><td style="width:18%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:18%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">2018</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Deferred tax assets:</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">NOL carryforwards</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>203,928</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>132,841</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Research and development credits</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>28,535</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>23,118</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Liability related to sale of future royalties</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>49,228</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>49,217</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Deferred revenue</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>18,286</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Disallowed interest expense </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>13,474</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Other</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>5,807</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>3,088</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Total</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>319,258</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>208,264</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Valuation allowance</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(317,828</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(206,397</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Net deferred assets</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>1,430</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>1,867</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Deferred tax liabilities:</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Property and equipment</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(1,430</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(1,867</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Net deferred assets and liabilities</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"> </span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">A valuation allowance is provided when it is more likely than not that some portion or all of the deferred tax assets will not be realized. The valuation allowances for the year ended </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;">, and the Transition Period ended December 31, 2018 have been applied to offset the deferred tax assets in recognition of the uncertainty that such tax benefits will be realized as the Company continues to incur losses. The differences between book income and tax income primarily relate to the temporary differences from depreciation and stock compensation expenses, and deferred book income that is realized for tax.</span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">At </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;">, and the Transition Period ended December 31, 2018, the Company has available net operating loss carry forwards for federal income tax reporting purposes of approximately </span><span style="font-family:inherit;font-size:10pt;"><span>$769.1 million</span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>$516.6 million</span></span><span style="font-family:inherit;font-size:10pt;"> for state income tax reporting purposes of approximately </span><span style="font-family:inherit;font-size:10pt;"><span>$593.6 million</span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>$343.0 million</span></span><span style="font-family:inherit;font-size:10pt;">, respectively, which expire at various dates between 2020 and 2038. For tax years 2018 onward, Federal net operating losses have an indefinite life but are limited to annual utilization by 80% taxable income. </span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company accounts for uncertain tax benefits in accordance with the provisions of section 740-10 of the Accounting for Uncertainty in Income Taxes Topic of the FASB ASC. Of the total unrecognized tax benefits at </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;"> and 2018, approximately </span><span style="font-family:inherit;font-size:10pt;"><span>$2.5 million</span></span><span style="font-family:inherit;font-size:10pt;"> was recorded in both years as a reduction to deferred tax assets, which caused a corresponding reduction in the Company’s valuation allowance of </span><span style="font-family:inherit;font-size:10pt;"><span>$2.5 million</span></span><span style="font-family:inherit;font-size:10pt;"> in both years. The Company does not anticipate that the amount of unrecognized tax benefits as of </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;"> will change materially within the 12-month period following </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;">. The change in unrecognized tax benefits are presented below (in thousands):</span></div><div style="line-height:120%;text-align:left;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"/></tr><tr><td style="width:66%;"/><td style="width:1%;"/><td style="width:14%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:15%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Year Ended </span></div><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">December 31, 2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Transition Period Ended </span></div><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">December 31, 2018</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Change in unrecognized tax benefits</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Balance at beginning of year</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>2,521</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Gross increases related to current period tax positions</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Gross increases related to prior periods tax positions</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>2,521</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Gross decreases in tax positions</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Expiration of the statute of limitations</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Balance at end of year</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>2,521</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>2,521</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company will recognize potential interest and penalties related to income tax positions as a component of the provision for income taxes on the Consolidated Statements of Comprehensive Loss in any future periods in which the Company must record a liability. The Company is subject to examination for United States Federal and Foreign tax purposes for 2013 and forward and for New Jersey 2015 and forward. The Company conducts business and files tax returns in New Jersey.</span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">For fiscal year 2016, the Company sold certain State of New Jersey State Net Operating Losses (“NOL”) and Research and Development (“R&D”) tax credits through the New Jersey Economic Development Authority Technology Business Tax Certificate Transfer Program. Pursuant to such sale, for the year ended June 30, 2016, the Company recorded a tax benefit of </span><span style="font-family:inherit;font-size:10pt;"><span>$5.1 million</span></span><span style="font-family:inherit;font-size:10pt;">, as a result of its sale of approximately </span><span style="font-family:inherit;font-size:10pt;"><span>$66.2 million</span></span><span style="font-family:inherit;font-size:10pt;">, of New Jersey State NOL and </span><span style="font-family:inherit;font-size:10pt;"><span>$1.5 million</span></span><span style="font-family:inherit;font-size:10pt;"> of New Jersey R&D tax credits. There were </span><span style="font-family:inherit;font-size:10pt;"><span>no</span></span><span style="font-family:inherit;font-size:10pt;"> sales of NOL or R&D for the year ended </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;">, the Transition Period or 2018 or 2017 fiscal years.</span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Global Intangible Low-tax Income ("GILTI") provisions of the 2017 Tax Act require the Company to include in its United States income tax return foreign subsidiary earnings in excess of an allowable return on the foreign subsidiary’s tangible assets. The Company expects that it may be subject to incremental United States tax on GILTI income in the future but not for the for the year ended </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;">. The Company has elected to account for GILTI tax in the period in which it is incurred, and therefore has not provided any deferred tax impacts of GILTI in its consolidated financial statements. </span></div><div style="line-height:120%;padding-top:10px;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">As a result of U.S. tax reform legislation, distributions of profits from non-U.S. subsidiaries are not expected to cause a significant incremental U.S. tax impact in the future. However, distributions may be subject to non-U.S. withholding taxes if profits are distributed from certain jurisdictions. U.S. federal income taxes have not been provided on undistributed earnings of our international subsidiaries as it is our intention to reinvest any earnings into the respective subsidiaries. It is not practicable to estimate the amount of tax that might be payable if some or all of such earnings were to be repatriated due to the legal structure and complexity of U.S. and local tax laws. As of </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;">, and 2018, there are </span><span style="font-family:inherit;font-size:10pt;"><span>no</span></span><span style="font-family:inherit;font-size:10pt;"> undistributed earnings.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><span style="font-family:inherit;font-size:10pt;">As a result of the reduction in the U.S. corporate income tax rate, the Company revalued its ending net deferred tax assets as of June 30, 2018, which resulted in a provisional expense of </span><span style="font-family:inherit;font-size:10pt;"><span>$59.5 million</span></span> which was offset by an associated change in valuation allowance. In the second quarter of the Transition Period, the Company completed its analysis to determine the effect of the Tax Act and recorded no further adjustments.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -URI http://asc.fasb.org/topic&trid=2144680<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
function toggleNextSibling (e) {
if (e.nextSibling.style.display=='none') {
e.nextSibling.style.display='block';
} else { e.nextSibling.style.display='none'; }
}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6988947456">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Accounts Payable and Accrued Expenses (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableTradeCurrent', window );">Trade accounts payable</a></td>
<td class="nump">$ 37,758<span></span>
</td>
<td class="nump">$ 20,125<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_immu_AccruedContractManufacturingExpenses', window );">Accrued contract manufacturing expenses</a></td>
<td class="nump">11,663<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeRelatedLiabilitiesCurrent', window );">Accrued employee related expenses</a></td>
<td class="nump">7,403<span></span>
</td>
<td class="nump">315<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_immu_ClinicalTrials', window );">Clinical trial accruals</a></td>
<td class="nump">2,225<span></span>
</td>
<td class="nump">5,114<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SupplementalUnemploymentBenefitsSeveranceBenefits', window );">Executive severance liabilities</a></td>
<td class="nump">561<span></span>
</td>
<td class="nump">2,198<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_immu_OtherCurrentLiabilities', window );">Miscellaneous other current liabilities</a></td>
<td class="nump">1,250<span></span>
</td>
<td class="nump">3,970<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent', window );">Accounts payable and accrued expenses</a></td>
<td class="nump">$ 60,860<span></span>
</td>
<td class="nump">$ 31,722<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_immu_AccruedContractManufacturingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accrued Manufacturing Expenses</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">immu_AccruedContractManufacturingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>immu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_immu_ClinicalTrials">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Clinical Trials</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">immu_ClinicalTrials</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>immu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_immu_OtherCurrentLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Other Current Liabilities</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">immu_OtherCurrentLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>immu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableTradeCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&oid=118951113&loc=d3e6935-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableTradeCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeRelatedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeRelatedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalUnemploymentBenefitsSeveranceBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Liability for amount due employees, in addition to wages and any other money that employers owe employees, when their employment ends through a layoff or other termination. For example, a company may provide involuntarily terminated employees with a lump sum payment equal to one week's salary for every year of employment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalUnemploymentBenefitsSeveranceBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
function toggleNextSibling (e) {
if (e.nextSibling.style.display=='none') {
e.nextSibling.style.display='block';
} else { e.nextSibling.style.display='none'; }
}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6804659280">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Reconciliation of Statutory Tax Rates and Effective Tax Rates (Details)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Jun. 30, 2018</div></th>
<th class="th"><div>Jun. 30, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate', window );">Statutory rate</a></td>
<td class="num">(21.00%)<span></span>
</td>
<td class="num">(21.00%)<span></span>
</td>
<td class="num">(28.00%)<span></span>
</td>
<td class="num">(34.00%)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential', window );">Foreign income tax</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance', window );">Change in valuation allowance</a></td>
<td class="nump">34.40%<span></span>
</td>
<td class="nump">29.90%<span></span>
</td>
<td class="nump">21.10%<span></span>
</td>
<td class="nump">21.90%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes', window );">State income taxes, (net of federal tax benefit)</a></td>
<td class="num">(8.80%)<span></span>
</td>
<td class="num">(7.50%)<span></span>
</td>
<td class="num">(4.30%)<span></span>
</td>
<td class="num">(4.80%)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense', window );">Permanent differences, (primarily warrant-related expenses)</a></td>
<td class="num">(4.20%)<span></span>
</td>
<td class="num">(1.40%)<span></span>
</td>
<td class="nump">11.30%<span></span>
</td>
<td class="nump">15.30%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent', window );">Other</a></td>
<td class="num">(0.40%)<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">1.60%<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations', window );">Effective rate</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.10%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(h)(2))<br> -URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&oid=84230637&loc=d3e32687-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&oid=84230637&loc=d3e32698-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of domestic federal statutory tax rate applicable to pretax income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I)<br> -URI http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&oid=84230637&loc=d3e32687-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&oid=84230637&loc=d3e32698-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I)<br> -URI http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&oid=84230637&loc=d3e32687-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&oid=84230637&loc=d3e32698-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to statutory income tax expense (benefit) outside of the country of domicile.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&oid=84230637&loc=d3e32698-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I)<br> -URI http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&oid=84230637&loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to nondeductible expenses.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&oid=84230637&loc=d3e32687-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&oid=84230637&loc=d3e32698-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I)<br> -URI http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference, between reported income tax expense (benefit) and the expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations, that is attributable to tax exempt income, equity in earnings (loss) of an unconsolidated subsidiary, minority interest income (expense), tax holiday, disposition of a business, disposition of an asset, repatriation of foreign earnings, repatriation of foreign earnings jobs creation act of 2004, change in enacted tax rate, prior year income taxes, change in deferred tax asset valuation allowance, and other adjustments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&oid=84230637&loc=d3e32698-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I)<br> -URI http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&oid=84230637&loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R59.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
function toggleNextSibling (e) {
if (e.nextSibling.style.display=='none') {
e.nextSibling.style.display='block';
} else { e.nextSibling.style.display='none'; }
}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6804871824">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related Party Transactions (Details)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="1">8 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Nov. 19, 2019 </div>
<div>shares</div>
</th>
<th class="th">
<div>Mar. 05, 2019 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2018 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Jun. 30, 2018 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Jan. 06, 2018 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_immu_PercentOfSharesForfeitedEmploymentCommencement', window );">Percent of shares forfeited upon employment commencement</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">0.50<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_immu_PercentOfSharesVestedEmploymentCommencement', window );">Percent of shares vested upon employment commencement</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">0.50<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=immu_MRosenbergBioPharmaConsultingLlcMember', window );">M Rosenberg Bio Pharma Consulting Llc</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfessionalAndContractServicesExpense', window );">Professional and contract services expense | $</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 300,000<span></span>
</td>
<td class="nump">$ 800,000<span></span>
</td>
<td class="nump">$ 600,000<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=srt_DirectorMember', window );">Director</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_immu_SalaryandWageOfficerMonthlySalary', window );">Monthly salary | $</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 16,667<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 21,372<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SalariesWagesAndOfficersCompensation', window );">Salary and wage | $</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 400,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=immu_ExecutiveDirectorMember', window );">Executive Director</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Granted (in shares)</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">79,818<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">22,854<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Share-based payment award</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">7 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Employee Stock Option</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Granted (in shares)</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">2,002,000<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">3,614,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Employee Stock Option | M Rosenberg Bio Pharma Consulting Llc</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Granted (in shares)</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">45,000<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Employee Stock Option | Chief Technology Officer</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Stock issued during period, net of forfeitures (in shares)</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">104,389<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Employee Stock Option | Board of Directors Chairman</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Granted (in shares)</a></td>
<td class="nump">150,000<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_immu_PercentOfSharesForfeitedEmploymentCommencement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percent Of Shares Forfeited, Employment Commencement</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">immu_PercentOfSharesForfeitedEmploymentCommencement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>immu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_immu_PercentOfSharesVestedEmploymentCommencement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percent Of Shares Vested, Employment Commencement</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">immu_PercentOfSharesVestedEmploymentCommencement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>immu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_immu_SalaryandWageOfficerMonthlySalary">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Salary and Wage, Officer, Monthly Salary</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">immu_SalaryandWageOfficerMonthlySalary</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>immu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfessionalAndContractServicesExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Professional and contract service expense includes cost reimbursements for support services related to contracted projects, outsourced management, technical and staff support.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfessionalAndContractServicesExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SalariesWagesAndOfficersCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for salary and wage arising from service rendered by nonofficer and officer employees. Excludes allocated cost, labor-related nonsalary expense, and direct and overhead labor cost included in cost of good and service sold.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SalariesWagesAndOfficersCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&oid=109259400&loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=immu_MRosenbergBioPharmaConsultingLlcMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=immu_MRosenbergBioPharmaConsultingLlcMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=srt_DirectorMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=srt_DirectorMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=immu_ExecutiveDirectorMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=immu_ExecutiveDirectorMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=immu_ChiefTechnologyOfficerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=immu_ChiefTechnologyOfficerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=srt_BoardOfDirectorsChairmanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=srt_BoardOfDirectorsChairmanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
function toggleNextSibling (e) {
if (e.nextSibling.style.display=='none') {
e.nextSibling.style.display='block';
} else { e.nextSibling.style.display='none'; }
}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6813290000">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenue Recognition - Additional Information (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Apr. 29, 2019</div></th>
<th class="th"><div>Apr. 05, 2019</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityNoncurrent', window );">Deferred revenues</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 65,000<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_MajorCustomersAxis=immu_EverestMedicinesIILimitedMember', window );">Everest Medicines II Limited</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_immu_LicenseAgreementUpfrontFeesPaid', window );">Upfront fees paid</a></td>
<td class="nump">$ 65,000<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_immu_LicenseAgreementMilestonePaymentUponAchievementofFDAApproval', window );">Payment upon achievement of FDA approval</a></td>
<td class="nump">60,000<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_immu_LicenseAgreementMilestoneDevelopmentTotalPayments', window );">Development total payments</a></td>
<td class="nump">180,000<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_immu_LicenseAgreementMilestoneSalesTotalPayments', window );">Sales total payments</a></td>
<td class="nump">530,000<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityNoncurrent', window );">Deferred revenues</a></td>
<td class="nump">$ 65,000<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_MajorCustomersAxis=immu_JanssenBiotechIncMember', window );">Janssen Biotech Inc</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_immu_LicenseAgreementMilestoneSalesTotalPayments', window );">Sales total payments</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 15,000<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 300<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum | Everest Medicines II Limited</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_immu_RoyaltyPaymentsPercentage', window );">Royalty payments percentage</a></td>
<td class="nump">14.00%<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum | Everest Medicines II Limited</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_immu_RoyaltyPaymentsPercentage', window );">Royalty payments percentage</a></td>
<td class="nump">20.00%<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_immu_LicenseAgreementMilestoneDevelopmentTotalPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>License Agreement Milestone Development Total Payments</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">immu_LicenseAgreementMilestoneDevelopmentTotalPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>immu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_immu_LicenseAgreementMilestonePaymentUponAchievementofFDAApproval">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>License Agreement Milestone Payment Upon Achievement of FDA Approval</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">immu_LicenseAgreementMilestonePaymentUponAchievementofFDAApproval</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>immu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_immu_LicenseAgreementMilestoneSalesTotalPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>License Agreement Milestone Sales Total Payments</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">immu_LicenseAgreementMilestoneSalesTotalPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>immu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_immu_LicenseAgreementUpfrontFeesPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>License Agreement Upfront Fees Paid</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">immu_LicenseAgreementUpfrontFeesPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>immu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_immu_RoyaltyPaymentsPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Royalty Payments Percentage</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">immu_RoyaltyPaymentsPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>immu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&oid=118944033&loc=SL49130532-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&oid=118944033&loc=SL49130531-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&oid=118956577&loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&oid=115929826&loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -URI http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=immu_EverestMedicinesIILimitedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=immu_EverestMedicinesIILimitedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=immu_JanssenBiotechIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=immu_JanssenBiotechIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
function toggleNextSibling (e) {
if (e.nextSibling.style.display=='none') {
e.nextSibling.style.display='block';
} else { e.nextSibling.style.display='none'; }
}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6989160848">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock', window );">Schedule of Expense for Income Taxes</a></td>
<td class="text"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Income tax expense for income taxes is as follows (in thousands):</span></div><div style="line-height:120%;text-align:justify;padding-left:0px;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"/></tr><tr><td style="width:31%;"/><td style="width:1%;"/><td style="width:15%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:15%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:14%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:14%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"> </span></div></td><td colspan="3" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Year Ended </span></div><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">December 31, 2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Transition Period Ended </span></div><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">December 31, 2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Fiscal Year Ended June 30,</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">2017</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Federal</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">    </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">    </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Current</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Deferred</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Total Federal</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">State</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Current</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Deferred</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Total State</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Foreign</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Current</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>154</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>19</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Deferred</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Total Foreign</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>154</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>19</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Total income tax expense</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>156</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>20</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock', window );">Schedule of Reconciliation of Statutory Tax Rates and Effective Tax Rates</a></td>
<td class="text"><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">A reconciliation of the statutory tax rates and the effective tax rates for the year ended </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;">, the transition period ended December 31, 2018 and fiscal years ended June 30, 2018 and 2017 is as follows:</span></div><div style="line-height:120%;text-align:justify;padding-left:0px;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"/></tr><tr><td style="width:31%;"/><td style="width:16%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:16%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:15%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:15%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Year Ended </span></div><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">December 31, 2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Transition Period Ended </span></div><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">December 31, 2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Fiscal Year Ended June 30,</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">2017</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Statutory rate</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(21.0</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)%</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(21.0</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)%</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(28.0</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)%</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(34.0</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)%</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Foreign income tax</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"> %</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"> %</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"> %</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"> %</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Change in valuation allowance</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>29.9</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"> %</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>34.4</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"> %</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>21.1</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"> %</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>21.9</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"> %</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">State income taxes, (net of federal tax benefit)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(7.5</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(8.8</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(4.3</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(4.8</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)%</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Permanent differences, (primarily warrant-related expenses)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(1.4</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)%</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(4.2</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)%</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>11.3</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"> %</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>15.3</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"> %</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Other</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"> %</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(0.4</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"> %</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>1.6</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"> %</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Effective rate</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"> %</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"> %</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>0.1</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"> %</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"> %</span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock', window );">Schedule of Tax Effects of Temporary Differences in Deferred Tax Assets</a></td>
<td class="text"><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The tax effects of temporary differences that give rise to significant portions of the Company’s deferred tax assets and liabilities as of December 31, (in thousands):</span></div><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"/></tr><tr><td style="width:59%;"/><td style="width:1%;"/><td style="width:18%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:18%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">2018</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Deferred tax assets:</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">NOL carryforwards</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>203,928</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>132,841</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Research and development credits</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>28,535</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>23,118</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Liability related to sale of future royalties</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>49,228</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>49,217</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Deferred revenue</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>18,286</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Disallowed interest expense </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>13,474</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Other</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>5,807</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>3,088</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Total</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>319,258</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>208,264</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Valuation allowance</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(317,828</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(206,397</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Net deferred assets</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>1,430</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>1,867</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Deferred tax liabilities:</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Property and equipment</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(1,430</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(1,867</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Net deferred assets and liabilities</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SummaryOfIncomeTaxContingenciesTextBlock', window );">Summary of Unrecognized Tax Benefits</a></td>
<td class="text">The change in unrecognized tax benefits are presented below (in thousands):<div style="line-height:120%;text-align:left;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"/></tr><tr><td style="width:66%;"/><td style="width:1%;"/><td style="width:14%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:15%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Year Ended </span></div><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">December 31, 2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Transition Period Ended </span></div><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">December 31, 2018</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Change in unrecognized tax benefits</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Balance at beginning of year</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>2,521</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Gross increases related to current period tax positions</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Gross increases related to prior periods tax positions</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>2,521</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Gross decreases in tax positions</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Expiration of the statute of limitations</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Balance at end of year</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>2,521</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>2,521</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&oid=84230637&loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&oid=84230637&loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&oid=84230637&loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SummaryOfIncomeTaxContingenciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for tax positions taken in the tax returns filed or to be filed for which it is more likely than not that the tax position will not be sustained upon examination by taxing authorities and other income tax contingencies. Includes, but is not limited to, interest and penalties, reconciliation of unrecognized tax benefits, unrecognized tax benefits that would affect the effective tax rate, tax years that remain subject to examination by tax jurisdictions, and information about positions for which it is reasonably possible that amounts unrecognized will significantly change within 12 months.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -URI http://asc.fasb.org/extlink&oid=84230637&loc=SL6600010-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&oid=84230637&loc=d3e32718-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&oid=84230637&loc=d3e32840-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SummaryOfIncomeTaxContingenciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
function toggleNextSibling (e) {
if (e.nextSibling.style.display=='none') {
e.nextSibling.style.display='block';
} else { e.nextSibling.style.display='none'; }
}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6989220672">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Debt - Consideration Allocation (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Jun. 30, 2018</div></th>
<th class="th"><div>Jan. 07, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRevenueArrangementLineItems', window );"><strong>Deferred Revenue Arrangement [Line Items]</strong></a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock</a></td>
<td class="nump">$ 2,125<span></span>
</td>
<td class="nump">$ 1,905<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=immu_RpiFinanceTrustMember', window );">Rpi Finance Trust | Royalty Arrangement</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRevenueArrangementLineItems', window );"><strong>Deferred Revenue Arrangement [Line Items]</strong></a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_immu_FairValueForLiabilityRelatedtoSaleofFutureRoyalties', window );">Liability related to sale of future royalties</a></td>
<td class="nump">$ 261,224<span></span>
</td>
<td class="nump">$ 221,295<span></span>
</td>
<td class="nump">$ 202,007<span></span>
</td>
<td class="nump">$ 182,216<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">67,784<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_immu_RoyaltyPurchaseAgreementArrangementsConsideration', window );">Royalty purchase agreement arrangements consideration</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 250,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_immu_FairValueForLiabilityRelatedtoSaleofFutureRoyalties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair Value For Liability Related to Sale of Future Royalties</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">immu_FairValueForLiabilityRelatedtoSaleofFutureRoyalties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>immu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_immu_RoyaltyPurchaseAgreementArrangementsConsideration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Royalty Purchase Agreement Arrangements Consideration</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">immu_RoyaltyPurchaseAgreementArrangementsConsideration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>immu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRevenueArrangementLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredRevenueArrangementLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=immu_RpiFinanceTrustMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=immu_RpiFinanceTrustMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRevenueArrangementTypeAxis=us-gaap_RoyaltyArrangementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredRevenueArrangementTypeAxis=us-gaap_RoyaltyArrangementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
function toggleNextSibling (e) {
if (e.nextSibling.style.display=='none') {
e.nextSibling.style.display='block';
} else { e.nextSibling.style.display='none'; }
}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6802520752">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Estimated Fair Value of Financial Instruments<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">Estimated Fair Value of Financial Instruments</a></td>
<td class="text">Estimated Fair Value of Financial Instruments<div style="line-height:120%;padding-top:16px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Cash Equivalents and Marketable Securities</span></div><div style="line-height:120%;padding-top:16px;text-align:justify;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.609375%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"/></tr><tr><td style="width:53%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="15" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-style:italic;font-weight:bold;">($ in thousands)</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">As of December 31, 2019</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Level 1</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Level 2</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Level 3</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Total</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Money Market Funds Note (a)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>550,788</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>550,788</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Marketable Securities:</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">U.S. Government Sponsored Agencies</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>4,550</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>4,550</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Total</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>555,338</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>555,338</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"/></tr><tr><td style="width:53%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="15" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-style:italic;font-weight:bold;">($ in thousands)</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">As of December 31, 2018</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Level 1</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Level 2</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Level 3</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Total</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Money Market Funds Note (a)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>326,239</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>326,239</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Marketable Securities:</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">U.S. Government Sponsored Agencies</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>4,941</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>4,941</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Total</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>331,180</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>331,180</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;padding-left:4px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-left:0px;text-align:justify;text-indent:48px;"><span style="text-align:justify;font-family:inherit;font-size:10pt;padding-right:48px;">(a)</span><span style="font-family:inherit;font-size:10pt;">The money market funds noted above are included in cash and cash equivalents.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Convertible Senior Notes</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The carrying amounts and estimated fair values (Level 2) of debt instruments are as follows (in thousands):</span></div><div style="line-height:120%;text-align:justify;padding-left:0px;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"/></tr><tr><td style="width:47%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">As of December 31, 2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">As of December 31, 2018</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Carrying Amount</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Estimated Fair Value</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Carrying Amount</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Estimated Fair Value</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Convertible Senior Notes</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>7,106</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>28,900</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>7,055</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>20,100</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The fair value of the Convertible Senior Notes, which differs from their carrying values, is influenced by interest rates, the Company’s stock price and stock price volatility and is determined by prices for the Convertible Senior Notes observed in market trading which are Level 2 inputs.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Liability Related to the Sale of Future Royalties</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"/><span style="font-family:inherit;font-size:10pt;">The Company has determined the fair value of the liability related to the sale of future royalties is based on the Company's current estimates of future royalties expected to be paid to RPI, over the life of the arrangement, which are considered Level 3 (See Note 4 - "Debt").</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">There were no transfers between Level 1, Level 2, and Level 3 during the periods presented.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
function toggleNextSibling (e) {
if (e.nextSibling.style.display=='none') {
e.nextSibling.style.display='block';
} else { e.nextSibling.style.display='none'; }
}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6802542224">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accumulated Other Comprehensive (Loss) Income<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNoteTextBlock', window );">Accumulated Other Comprehensive (Loss) Income</a></td>
<td class="text">Accumulated Other Comprehensive (Loss) Income<div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The components of accumulated other comprehensive (loss) income were as follows (in thousands):</span></div><div style="line-height:120%;text-align:justify;padding-left:0px;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"/></tr><tr><td style="width:53%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Currency Translation Adjustments</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;"> Net Unrealized Gains (Losses) on Available-for-Sale Securities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Accumulated Other Comprehensive (Loss) Income</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Balance at June 30, 2016</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(172</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>40</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(132</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Other comprehensive loss before reclassifications</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(62</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(125</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(187</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">   Amounts reclassified from accumulated other comprehensive income</span><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(a)</sup></span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>16</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>16</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Net other comprehensive loss for the year</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(62</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(109</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(171</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Balance at June 30, 2017</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(234</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(69</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(303</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Other comprehensive income (loss) before reclassifications</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(105</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>55</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(50</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">  Amounts reclassified from accumulated other comprehensive income</span><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(a)</sup></span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Net other comprehensive (loss) income for the year</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(105</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>55</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(50</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Balance at June 30, 2018</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(339</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(14</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(353</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Other comprehensive income (loss) before reclassifications</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(8</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>10</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">  Amounts reclassified from accumulated other comprehensive income</span><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(a)</sup></span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Net other comprehensive (loss) income for the year</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(8</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>10</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Balance at December 31, 2018</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(347</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(4</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(351</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Other comprehensive loss before reclassifications</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(21</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(391</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(412</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">  Amounts reclassified from accumulated other comprehensive income</span><span style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(a)</sup></span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>195</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>195</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Net other comprehensive (loss) income for the year</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>174</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(391</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(217</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Balance at December 31, 2019</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(173</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(395</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(568</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td></tr></table></div></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><span style="font-family:inherit;font-size:10pt;">(a)</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">For the year ended </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;">, the Transition Period ended December 31, 2018, and the fiscal years ended June 30, 2018 and 2017, </span><span style="font-family:inherit;font-size:10pt;"><span>$0.2 million</span></span><span style="font-family:inherit;font-size:10pt;">, </span><span style="font-family:inherit;font-size:10pt;"><span>$0</span></span><span style="font-family:inherit;font-size:10pt;">, </span><span style="font-family:inherit;font-size:10pt;"><span>$0</span></span><span style="font-family:inherit;font-size:10pt;">, and </span><span style="font-family:inherit;font-size:10pt;"><span>$16 thousand</span></span><span style="font-family:inherit;font-size:10pt;">, respectively, were reclassified from accumulated other comprehensive (loss) income to interest and other income.</span></div></td></tr></table><div style="line-height:120%;padding-left:4px;text-align:justify;padding-left:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">All components of accumulated other comprehensive (loss) income are net of tax, except currency translation adjustments, which exclude income taxes related to indefinite investments in foreign subsidiaries.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNoteTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for comprehensive income, which includes, but is not limited to, 1) the amount of income tax expense or benefit allocated to each component of other comprehensive income, including reclassification adjustments, 2) the reclassification adjustments for each classification of other comprehensive income and 3) the ending accumulated balances for each component of comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -URI http://asc.fasb.org/topic&trid=2134417<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNoteTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R58.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
function toggleNextSibling (e) {
if (e.nextSibling.style.display=='none') {
e.nextSibling.style.display='block';
} else { e.nextSibling.style.display='none'; }
}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6721975232">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Change in Unrecognized Tax Benefits (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward', window );"><strong>Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]</strong></a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Balance at beginning of year</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 2,521<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions', window );">Gross increases related to current period tax positions</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions', window );">Gross increases related to prior periods tax positions</a></td>
<td class="nump">2,521<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions', window );">Gross decreases in tax positions</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations', window );">Expiration of the statute of limitations</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Balance at end of year</a></td>
<td class="nump">$ 2,521<span></span>
</td>
<td class="nump">$ 2,521<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of unrecognized tax benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10B<br> -URI http://asc.fasb.org/extlink&oid=116821951&loc=SL37586934-109318<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&oid=84230637&loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease in unrecognized tax benefits resulting from tax positions taken in prior period tax returns.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&oid=84230637&loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in unrecognized tax benefits resulting from tax positions that have been or will be taken in current period tax return.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&oid=84230637&loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in unrecognized tax benefits resulting from tax positions taken in prior period tax returns.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&oid=84230637&loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease in unrecognized tax benefits resulting from lapses of applicable statutes of limitations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)(4)<br> -URI http://asc.fasb.org/extlink&oid=84230637&loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
function toggleNextSibling (e) {
if (e.nextSibling.style.display=='none') {
e.nextSibling.style.display='block';
} else { e.nextSibling.style.display='none'; }
}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6810506944">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment - Additional Information (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Jun. 30, 2018</div></th>
<th class="th"><div>Jun. 30, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationAndAmortization', window );">Depreciation and amortization expense</a></td>
<td class="nump">$ 2,099<span></span>
</td>
<td class="nump">$ 3,822<span></span>
</td>
<td class="nump">$ 1,297<span></span>
</td>
<td class="nump">$ 923<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
function toggleNextSibling (e) {
if (e.nextSibling.style.display=='none') {
e.nextSibling.style.display='block';
} else { e.nextSibling.style.display='none'; }
}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6810819424">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Expense (Benefit) from Income Taxes (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="4">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Jun. 30, 2018</div></th>
<th class="th"><div>Jun. 30, 2017</div></th>
<th class="th"><div>Jun. 30, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CurrentFederalTaxExpenseBenefit', window );">Current</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredFederalIncomeTaxExpenseBenefit', window );">Deferred</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperations', window );">Total Federal</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CurrentStateAndLocalTaxExpenseBenefit', window );">Current</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit', window );">Deferred</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StateAndLocalIncomeTaxExpenseBenefitContinuingOperations', window );">Total State</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CurrentForeignTaxExpenseBenefit', window );">Current</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">154<span></span>
</td>
<td class="nump">19<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredForeignIncomeTaxExpenseBenefit', window );">Deferred</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ForeignIncomeTaxExpenseBenefitContinuingOperations', window );">Total Foreign</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">154<span></span>
</td>
<td class="nump">19<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Total income tax expense</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 156<span></span>
</td>
<td class="nump">$ 20<span></span>
</td>
<td class="num">$ (5,100)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentFederalTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current federal tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&oid=84230637&loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentFederalTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentForeignTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current foreign income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&oid=84230637&loc=d3e32639-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(h))<br> -URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentForeignTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentStateAndLocalTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current state and local tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&oid=84230637&loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentStateAndLocalTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredFederalIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred federal income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&oid=84230637&loc=d3e32639-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredFederalIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredForeignIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred foreign income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&oid=84230637&loc=d3e32639-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredForeignIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred state and local tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&oid=84230637&loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current and deferred federal income tax expense (benefit) attributable to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(h)(1))<br> -URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&oid=84230637&loc=d3e32672-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignIncomeTaxExpenseBenefitContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current and deferred foreign income tax expense (benefit) attributable to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(h)(1))<br> -URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignIncomeTaxExpenseBenefitContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&oid=109238882&loc=d3e38679-109324<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StateAndLocalIncomeTaxExpenseBenefitContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of state and local current and deferred income tax expense (benefit) attributable to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)-(b)<br> -URI http://asc.fasb.org/extlink&oid=84230637&loc=d3e32639-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(h)(1))<br> -URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StateAndLocalIncomeTaxExpenseBenefitContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R62.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
function toggleNextSibling (e) {
if (e.nextSibling.style.display=='none') {
e.nextSibling.style.display='block';
} else { e.nextSibling.style.display='none'; }
}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6988937088">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies - Supplemental Consolidated Balance Sheet Information Related to Leases (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use assets, net</a></td>
<td class="nump">$ 8,105<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Current portion of lease liabilities</a></td>
<td class="nump">337<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Non-current portion of lease liabilities</a></td>
<td class="nump">9,965<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Total operating lease liabilities</a></td>
<td class="nump">$ 10,302<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1', window );">Weighted average remaining lease term (years)</a></td>
<td class="text">11 years 9 months 18 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent', window );">Weighted average discount rate</a></td>
<td class="nump">11.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_immu_NonCashLeaseExpense', window );">Non-cash lease expense</a></td>
<td class="nump">$ 264<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_immu_ChangeinOperatingLeaseLiability', window );">Change in operating lease liabilities</a></td>
<td class="nump">$ 186<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_immu_ChangeinOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Change in Operating Lease Liability</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">immu_ChangeinOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>immu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_immu_NonCashLeaseExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Non Cash Lease Expense</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">immu_NonCashLeaseExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>immu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&oid=77888419&loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&oid=77888419&loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&oid=77888419&loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&oid=77888419&loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average discount rate for operating lease calculated at point in time.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(4)<br> -URI http://asc.fasb.org/extlink&oid=77888426&loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&oid=77888399&loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&oid=77888399&loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(3)<br> -URI http://asc.fasb.org/extlink&oid=77888426&loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
function toggleNextSibling (e) {
if (e.nextSibling.style.display=='none') {
e.nextSibling.style.display='block';
} else { e.nextSibling.style.display='none'; }
}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6813403040">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Stock Option Activity (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="5">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Jun. 30, 2018</div></th>
<th class="th"><div>Jun. 30, 2017</div></th>
<th class="th"><div>Jun. 30, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward', window );"><strong>Weighted Average Exercise Price [Roll Forward]</strong></a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Granted (in USD per share)</a></td>
<td class="nump">$ 0.00<span></span>
</td>
<td class="nump">$ 9.50<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 7.29<span></span>
</td>
<td class="nump">$ 0.00<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Employee Stock Option</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward', window );"><strong>Share Equivalent</strong></a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Options outstanding, start of year (in shares)</a></td>
<td class="nump">3,549,000<span></span>
</td>
<td class="nump">4,757,000<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Granted (in shares)</a></td>
<td class="nump">2,002,000<span></span>
</td>
<td class="nump">3,614,000<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise of stock options (in shares)</a></td>
<td class="num">(706,000)<span></span>
</td>
<td class="num">(1,207,000)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod', window );">Expired or forfeited (in shares)</a></td>
<td class="num">(88,000)<span></span>
</td>
<td class="num">(1,263,000)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Options outstanding, end of year (in shares)</a></td>
<td class="nump">4,757,000<span></span>
</td>
<td class="nump">5,901,000<span></span>
</td>
<td class="nump">4,757,000<span></span>
</td>
<td class="nump">3,549,000<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber', window );">Vested, end of year (in shares)</a></td>
<td class="nump">1,504,000<span></span>
</td>
<td class="nump">1,150,000<span></span>
</td>
<td class="nump">1,504,000<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward', window );"><strong>Weighted Average Exercise Price [Roll Forward]</strong></a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted average exercise price, options outstanding, start of year (in USD per share)</a></td>
<td class="nump">$ 7.58<span></span>
</td>
<td class="nump">$ 14.30<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Granted (in USD per share)</a></td>
<td class="nump">22.54<span></span>
</td>
<td class="nump">15.46<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Exercised (in USD per share)</a></td>
<td class="nump">3.71<span></span>
</td>
<td class="nump">3.17<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice', window );">Expired or forfeited (in USD per share)</a></td>
<td class="nump">15.57<span></span>
</td>
<td class="nump">17.78<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted average exercise price, options outstanding, end of year (in USD per share)</a></td>
<td class="nump">14.30<span></span>
</td>
<td class="nump">16.54<span></span>
</td>
<td class="nump">$ 14.30<span></span>
</td>
<td class="nump">$ 7.58<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice', window );">Vested, end of year (in USD per share)</a></td>
<td class="nump">$ 4.23<span></span>
</td>
<td class="nump">$ 14.72<span></span>
</td>
<td class="nump">$ 4.23<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_immu_WeightedaverageremainingcontractualtermyearsRollForward', window );"><strong>Weighted average remaining contractual term (years) [Roll Forward]</strong></a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted average remaining contractual term</a></td>
<td class="text">5 years 5 months 1 day<span></span>
</td>
<td class="text">5 years 10 months 24 days<span></span>
</td>
<td class="text">5 years 5 months 1 day<span></span>
</td>
<td class="text">4 years 5 months 4 days<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1', window );">Weighted average remaining contractual term, end of year</a></td>
<td class="text">3 years 4 months 28 days<span></span>
</td>
<td class="text">4 years 7 months 9 days<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_immu_IntrinsicvalueRollForward', window );"><strong>Intrinsic value [Roll Forward]</strong></a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Options, outstanding, intrinsic value</a></td>
<td class="nump">$ 18,618<span></span>
</td>
<td class="nump">$ 30,145<span></span>
</td>
<td class="nump">$ 18,618<span></span>
</td>
<td class="nump">$ 57,123<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue', window );">Options, vested, outstanding, intrinsic value end of year</a></td>
<td class="nump">$ 15,098<span></span>
</td>
<td class="nump">$ 8,276<span></span>
</td>
<td class="nump">$ 15,098<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember', window );">Performance Shares</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward', window );"><strong>Share Equivalent</strong></a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Options outstanding, start of year (in shares)</a></td>
<td class="nump">538,000<span></span>
</td>
<td class="nump">538,000<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Granted (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">800,000<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise of stock options (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod', window );">Expired or forfeited (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(501,000)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Options outstanding, end of year (in shares)</a></td>
<td class="nump">538,000<span></span>
</td>
<td class="nump">837,000<span></span>
</td>
<td class="nump">538,000<span></span>
</td>
<td class="nump">538,000<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber', window );">Vested, end of year (in shares)</a></td>
<td class="nump">38,000<span></span>
</td>
<td class="nump">50,000<span></span>
</td>
<td class="nump">38,000<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward', window );"><strong>Weighted Average Exercise Price [Roll Forward]</strong></a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted average exercise price, options outstanding, start of year (in USD per share)</a></td>
<td class="nump">$ 13.09<span></span>
</td>
<td class="nump">$ 13.09<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Granted (in USD per share)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">17.18<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Exercised (in USD per share)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice', window );">Expired or forfeited (in USD per share)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">13.05<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted average exercise price, options outstanding, end of year (in USD per share)</a></td>
<td class="nump">13.09<span></span>
</td>
<td class="nump">17.03<span></span>
</td>
<td class="nump">$ 13.09<span></span>
</td>
<td class="nump">$ 13.09<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice', window );">Vested, end of year (in USD per share)</a></td>
<td class="nump">$ 11.86<span></span>
</td>
<td class="nump">$ 18.74<span></span>
</td>
<td class="nump">$ 11.86<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_immu_WeightedaverageremainingcontractualtermyearsRollForward', window );"><strong>Weighted average remaining contractual term (years) [Roll Forward]</strong></a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted average remaining contractual term</a></td>
<td class="text">6 years 14 days<span></span>
</td>
<td class="text">6 years 3 months 3 days<span></span>
</td>
<td class="text">6 years 14 days<span></span>
</td>
<td class="text">6 years 6 months 14 days<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1', window );">Weighted average remaining contractual term, end of year</a></td>
<td class="text">5 years 11 months 8 days<span></span>
</td>
<td class="text">6 years 10 months 17 days<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_immu_IntrinsicvalueRollForward', window );"><strong>Intrinsic value [Roll Forward]</strong></a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Options, outstanding, intrinsic value</a></td>
<td class="nump">$ 772<span></span>
</td>
<td class="nump">$ 3,456<span></span>
</td>
<td class="nump">$ 772<span></span>
</td>
<td class="nump">$ 5,688<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue', window );">Options, vested, outstanding, intrinsic value end of year</a></td>
<td class="nump">$ 91<span></span>
</td>
<td class="nump">$ 121<span></span>
</td>
<td class="nump">$ 91<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_immu_IntrinsicvalueRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Intrinsic value [Roll Forward]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">immu_IntrinsicvalueRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>immu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_immu_WeightedaverageremainingcontractualtermyearsRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term (years) [Roll Forward]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">immu_WeightedaverageremainingcontractualtermyearsRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>immu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For presentations that combine terminations, the number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan or that expired.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)-(4)<br> -URI http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price of options that were either forfeited or expired.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)-(4)<br> -URI http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&oid=109259400&loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
function toggleNextSibling (e) {
if (e.nextSibling.style.display=='none') {
e.nextSibling.style.display='block';
} else { e.nextSibling.style.display='none'; }
}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6830051072">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Debt - Convertible Senior Notes (Details)<br> $ / shares in Units, shares in Millions</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Feb. 14, 2020 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Oct. 02, 2018 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Sep. 21, 2017 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Feb. 28, 2015 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2018 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($) </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Jun. 30, 2018 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2017 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRevenueArrangementLineItems', window );"><strong>Deferred Revenue Arrangement [Line Items]</strong></a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtConversionOriginalDebtAmount1', window );">Issuance of common shares for debt conversion</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 13,757,000<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 92,307,000<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpenseDebt', window );">Interest on non-recourse debt</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">19,288,000<span></span>
</td>
<td class="nump">39,929,000<span></span>
</td>
<td class="nump">19,791,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfFinancingCosts', window );">Amortization of debt issuance costs</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">179,000<span></span>
</td>
<td class="nump">$ 50,000<span></span>
</td>
<td class="nump">1,679,000<span></span>
</td>
<td class="nump">730,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=immu_FourPointSevenFivePercentConvertibleSeniorNotesMember', window );">Four Point Seven Five Percent Convertible Senior Notes</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRevenueArrangementLineItems', window );"><strong>Deferred Revenue Arrangement [Line Items]</strong></a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Debt instrument, face amount</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 100,000,000.0<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromDebtNetOfIssuanceCosts', window );">Proceeds from debt, net of issuance costs</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">96,300,000<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfDebtIssuanceCosts', window );">Payments of debt issuance costs</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 3,700,000<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Debt instrument, interest rate, stated percentage</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">4.75%<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage', window );">Debt instrument, interest rate, effective percentage</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">5.48%<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion', window );">Convertible preferred stock, shares issued upon conversion (in shares) | shares</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">19.6<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleConversionRatio1', window );">Conversion ratio</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">195.8336<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleConversionPrice1', window );">Conversion price (in USD per share) | $ / shares</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 5.11<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed', window );">Percentage of principal amount redeemed</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtConversionOriginalDebtAmount1', window );">Issuance of common shares for debt conversion</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 80,000,000.0<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtConversionConvertedInstrumentSharesIssued1', window );">Issuance of common stock due to debt conversion (in shares) | shares</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">16.8<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_immu_DebtInstrumentConvertibleBeneficialConversionFeatureAggregateNumberOfShares', window );">Convertible beneficial conversion feature (in shares) | shares</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">0.1<span></span>
</td>
<td class="nump">1.1<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InducedConversionOfConvertibleDebtExpense', window );">Induced conversion of convertible debt expense</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 900,000<span></span>
</td>
<td class="nump">$ 13,000,000.0<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_immu_DebtConversionOutstandingBalance', window );">Outstanding balance</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 7,100,000<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpenseDebt', window );">Interest on non-recourse debt</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">500,000<span></span>
</td>
<td class="nump">400,000<span></span>
</td>
<td class="nump">3,500,000<span></span>
</td>
<td class="nump">5,500,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfFinancingCosts', window );">Amortization of debt issuance costs</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">200,000<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="nump">1,700,000<span></span>
</td>
<td class="nump">$ 700,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_immu_AcceleratedAmortizationOfFinancingCosts', window );">Accelerated amortization of financing costs</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 1,400,000<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=immu_October2018ExchangeAgreementMember', window );">October 2018 Exchange Agreement</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRevenueArrangementLineItems', window );"><strong>Deferred Revenue Arrangement [Line Items]</strong></a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtConversionOriginalDebtAmount1', window );">Issuance of common shares for debt conversion</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 12,900,000<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtConversionConvertedInstrumentSharesIssued1', window );">Issuance of common stock due to debt conversion (in shares) | shares</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">2.6<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event | Four Point Seven Five Percent Convertible Senior Notes</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRevenueArrangementLineItems', window );"><strong>Deferred Revenue Arrangement [Line Items]</strong></a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleConversionPrice1', window );">Conversion price (in USD per share) | $ / shares</a></td>
<td class="nump">$ 5.11<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtConversionConvertedInstrumentSharesIssued1', window );">Issuance of common stock due to debt conversion (in shares) | shares</a></td>
<td class="nump">1.4<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_immu_DebtConversionOutstandingBalance', window );">Outstanding balance</a></td>
<td class="nump">$ 7,100,000<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_immu_AcceleratedAmortizationOfFinancingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accelerated amortization of financing costs attributable to debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">immu_AcceleratedAmortizationOfFinancingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>immu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_immu_DebtConversionOutstandingBalance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Conversion, Outstanding Balance</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">immu_DebtConversionOutstandingBalance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>immu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_immu_DebtInstrumentConvertibleBeneficialConversionFeatureAggregateNumberOfShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of shares by which the convertible debt's if-converted value exceeds its principle amount of shares at the balance sheet date, regardless of whether the instrument is currently convertible. This element applies to public companies only.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">immu_DebtInstrumentConvertibleBeneficialConversionFeatureAggregateNumberOfShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>immu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfFinancingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense attributable to debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(8))<br> -URI http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&oid=114775744&loc=d3e28555-108399<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfFinancingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued for each share of convertible preferred stock that is converted.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27))<br> -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&oid=109259400&loc=d3e21475-112644<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&oid=109259400&loc=d3e21506-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtConversionConvertedInstrumentSharesIssued1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued in exchange for the original debt being converted in a noncash (or part noncash) transaction. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or payments in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&oid=98513485&loc=d3e4332-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&oid=98513485&loc=d3e4304-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtConversionConvertedInstrumentSharesIssued1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtConversionOriginalDebtAmount1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of the original debt being converted in a noncash (or part noncash) transaction. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&oid=98513485&loc=d3e4304-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&oid=98513485&loc=d3e4332-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtConversionOriginalDebtAmount1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleConversionPrice1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The price per share of the conversion feature embedded in the debt instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&oid=109500613&loc=SL6031898-161870<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentConvertibleConversionPrice1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleConversionRatio1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Ratio applied to the conversion of debt instrument into equity with equity shares divided by debt principal amount.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&oid=109259400&loc=d3e21521-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&oid=109259400&loc=d3e21506-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(5))<br> -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&oid=109259400&loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentConvertibleConversionRatio1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&oid=114775744&loc=d3e28551-108399<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&oid=114775985&loc=d3e28878-108400<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Effective interest rate for the funds borrowed under the debt agreement considering interest compounding and original issue discount or premium.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&oid=109500613&loc=SL6036836-161870<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&oid=114775744&loc=d3e28551-108399<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateEffectivePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of principal amount of debt redeemed.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRevenueArrangementLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredRevenueArrangementLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InducedConversionOfConvertibleDebtExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Consideration given by issuer of convertible debt to provide an incentive for debt holders to convert the debt to equity securities. The expense is equal to the fair value of all securities and other consideration transferred in the transaction in excess of the fair value of securities issuable pursuant to the original conversion terms.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 40<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&oid=99385385&loc=d3e6835-112609<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InducedConversionOfConvertibleDebtExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpenseDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense for debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&oid=109500613&loc=SL6036836-161870<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.8)<br> -URI http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpenseDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfDebtIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow paid to third parties in connection with debt origination, which will be amortized over the remaining maturity period of the associated long-term debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfDebtIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromDebtNetOfIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from additional borrowings, net of cash paid to third parties in connection with debt origination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromDebtNetOfIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=immu_FourPointSevenFivePercentConvertibleSeniorNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=immu_FourPointSevenFivePercentConvertibleSeniorNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=immu_October2018ExchangeAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=immu_October2018ExchangeAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
function toggleNextSibling (e) {
if (e.nextSibling.style.display=='none') {
e.nextSibling.style.display='block';
} else { e.nextSibling.style.display='none'; }
}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6804302288">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Property and Equipment - Schedules of Property and Equipment (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 27,785<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_immu_FinanceLeaseRightofUseAssetBeforeAccumulatedAmortization', window );">Right-of-use asset</a></td>
<td class="nump">$ 8,368<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_immu_PropertyPlantAndEquipmentAndFinanceLeaseRightofUseAssetBeforeAccumulatedDepreciationAndAmortization', window );">Property, plant, and equipment and finance lease right-of-use asset, before accumulated depreciation and amortization</a></td>
<td class="nump">40,687<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_immu_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization', window );">Accumulated depreciation and amortization</a></td>
<td class="nump">7,925<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Accumulated depreciation and amortization</a></td>
<td class="text"> <span></span>
</td>
<td class="num">(4,316)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_immu_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization', window );">Property, plant, and equipment and finance lease right-of-use asset, after accumulated depreciation and amortization</a></td>
<td class="nump">32,762<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property, plant and equipment, net</a></td>
<td class="nump">32,762<span></span>
</td>
<td class="nump">23,469<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_MachineryAndEquipmentMember', window );">Machinery and equipment</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">14,331<span></span>
</td>
<td class="nump">16,048<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember', window );">Leasehold improvements</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">11,535<span></span>
</td>
<td class="nump">6,365<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember', window );">Furniture and fixtures</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">1,190<span></span>
</td>
<td class="nump">291<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember', window );">Computer equipment</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">2,596<span></span>
</td>
<td class="nump">1,850<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember', window );">Construction in progress</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">$ 2,667<span></span>
</td>
<td class="nump">$ 3,231<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_immu_FinanceLeaseRightofUseAssetBeforeAccumulatedAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Finance Lease, Right-of-Use Asset, Before Accumulated Amortization</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">immu_FinanceLeaseRightofUseAssetBeforeAccumulatedAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>immu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_immu_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Property, Plant, And Equipment And Finance Lease Right-Of-Use Asset, Accumulated Depreciation And Amortization</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">immu_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>immu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_immu_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Property, Plant, And Equipment And Finance Lease Right-Of-Use Asset, After Accumulated Depreciation And Amortization</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">immu_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>immu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_immu_PropertyPlantAndEquipmentAndFinanceLeaseRightofUseAssetBeforeAccumulatedDepreciationAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Property, Plant, And Equipment And Finance Lease Right-of-Use Asset, Before Accumulated Depreciation And Amortization</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">immu_PropertyPlantAndEquipmentAndFinanceLeaseRightofUseAssetBeforeAccumulatedDepreciationAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>immu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.14)<br> -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.13)<br> -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_MachineryAndEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_MachineryAndEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
function toggleNextSibling (e) {
if (e.nextSibling.style.display=='none') {
e.nextSibling.style.display='block';
} else { e.nextSibling.style.display='none'; }
}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6825062800">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Jun. 30, 2018</div></th>
<th class="th"><div>Jun. 30, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Cash flows from operating activities:</strong></a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="num">$ (157,749)<span></span>
</td>
<td class="num">$ (357,319)<span></span>
</td>
<td class="num">$ (273,887)<span></span>
</td>
<td class="num">$ (153,266)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used in operating activities:</strong></a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAdjustmentOfWarrants', window );">Changes in fair value of warrant liabilities</a></td>
<td class="num">(1,404)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">108,636<span></span>
</td>
<td class="nump">61,074<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentOfWarrantsGrantedForServices', window );">Warrant related expense</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">7,649<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">2,099<span></span>
</td>
<td class="nump">3,822<span></span>
</td>
<td class="nump">1,297<span></span>
</td>
<td class="nump">923<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainLossOnSaleOfPropertyPlantEquipment', window );">Loss on disposal of property and equipment</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,003<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpenseDebt', window );">Interest on non-recourse debt</a></td>
<td class="nump">19,288<span></span>
</td>
<td class="nump">39,929<span></span>
</td>
<td class="nump">19,791<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_immu_LossOnInducedExchangesOfDebt', window );">Loss on induced exchanges of debt</a></td>
<td class="nump">897<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">13,005<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityRevenueRecognized', window );">Amortization of deferred revenue</a></td>
<td class="num">(94)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(77)<span></span>
</td>
<td class="num">(64)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments', window );">Amortization of bond premiums</a></td>
<td class="nump">3<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">31<span></span>
</td>
<td class="nump">218<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfFinancingCosts', window );">Amortization of debt issuance costs</a></td>
<td class="nump">179<span></span>
</td>
<td class="nump">50<span></span>
</td>
<td class="nump">1,679<span></span>
</td>
<td class="nump">730<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInDeferredCharges', window );">Amortization of deferred rent</a></td>
<td class="nump">132<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">279<span></span>
</td>
<td class="nump">10<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseRightOfUseAssetAmortization', window );">Non-cash lease expense</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">264<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtAndEquitySecuritiesGainLoss', window );">Loss on sale of marketable securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">16<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProvisionForDoubtfulAccounts', window );">Decrease in allowance for doubtful accounts</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(9)<span></span>
</td>
<td class="num">(62)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Non-cash expense related to stock-based compensation</a></td>
<td class="nump">886<span></span>
</td>
<td class="nump">11,736<span></span>
</td>
<td class="nump">4,024<span></span>
</td>
<td class="nump">4,333<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNoncashExpense', window );">Non-cash financing expenses</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">347<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities</strong></a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsReceivable', window );">Accounts receivable, net</a></td>
<td class="nump">46<span></span>
</td>
<td class="num">(295)<span></span>
</td>
<td class="nump">452<span></span>
</td>
<td class="nump">103<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInInventories', window );">Inventories, net</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">580<span></span>
</td>
<td class="num">(196)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherReceivables', window );">Other receivables</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(30)<span></span>
</td>
<td class="nump">223<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">3,617<span></span>
</td>
<td class="num">(16,423)<span></span>
</td>
<td class="num">(7,679)<span></span>
</td>
<td class="num">(97)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities', window );">Accounts payable and accrued expenses</a></td>
<td class="nump">1,436<span></span>
</td>
<td class="nump">29,977<span></span>
</td>
<td class="num">(1,518)<span></span>
</td>
<td class="nump">15,809<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities', window );">Other liabilities</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(186)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInDeferredRevenue', window );">Deferred revenue</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">65,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="num">(130,664)<span></span>
</td>
<td class="num">(222,442)<span></span>
</td>
<td class="num">(133,426)<span></span>
</td>
<td class="num">(62,250)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Cash flows from investing activities:</strong></a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt', window );">Purchases of marketable securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(10,380)<span></span>
</td>
<td class="num">(131,610)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities', window );">Proceeds from sales/maturities of marketable securities</a></td>
<td class="nump">21,818<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">95,112<span></span>
</td>
<td class="nump">57,183<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchases of property and equipment</a></td>
<td class="num">(11,213)<span></span>
</td>
<td class="num">(6,849)<span></span>
</td>
<td class="num">(9,975)<span></span>
</td>
<td class="num">(1,837)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash (used in) provided by investing activities</a></td>
<td class="nump">10,605<span></span>
</td>
<td class="num">(6,849)<span></span>
</td>
<td class="nump">74,757<span></span>
</td>
<td class="num">(76,264)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash flows from financing activities:</strong></a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Exercise of stock options, net</a></td>
<td class="nump">176<span></span>
</td>
<td class="nump">2,553<span></span>
</td>
<td class="nump">2,261<span></span>
</td>
<td class="nump">4,290<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromWarrantExercises', window );">Exercise of warrants</a></td>
<td class="nump">1,688<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">78,226<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock', window );">Sale of preferred stock, net of related expenses</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">121,782<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering', window );">Proceeds from public offering of common stock</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">273,031<span></span>
</td>
<td class="nump">299,467<span></span>
</td>
<td class="nump">28,578<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_immu_ProceedsFromIssuanceOfNonRecourseDebt', window );">Proceeds from the issuance of non-recourse debt</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">182,216<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_immu_PaymentOfDebtConversionFees', window );">Debt conversion fees</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(530)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation', window );">Tax withholding payments for stock-based compensation</a></td>
<td class="num">(192)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(1,521)<span></span>
</td>
<td class="num">(546)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td>
<td class="nump">1,672<span></span>
</td>
<td class="nump">347,181<span></span>
</td>
<td class="nump">627,903<span></span>
</td>
<td class="nump">168,804<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations', window );">Effect of changes in exchange rates on cash, cash equivalents and restricted cash</a></td>
<td class="num">(22)<span></span>
</td>
<td class="num">(22)<span></span>
</td>
<td class="num">(46)<span></span>
</td>
<td class="num">(100)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net increase (decrease) in cash, cash equivalents and restricted cash</a></td>
<td class="num">(118,409)<span></span>
</td>
<td class="nump">117,868<span></span>
</td>
<td class="nump">569,188<span></span>
</td>
<td class="nump">30,190<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents, and restricted cash beginning of period</a></td>
<td class="nump">612,582<span></span>
</td>
<td class="nump">494,173<span></span>
</td>
<td class="nump">43,394<span></span>
</td>
<td class="nump">13,204<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents, and restricted cash end of period</a></td>
<td class="nump">494,173<span></span>
</td>
<td class="nump">612,041<span></span>
</td>
<td class="nump">612,582<span></span>
</td>
<td class="nump">43,394<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>Supplemental disclosure of cash flow information:</strong></a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestPaidNet', window );">Interest paid</a></td>
<td class="nump">475<span></span>
</td>
<td class="nump">338<span></span>
</td>
<td class="nump">2,850<span></span>
</td>
<td class="nump">4,750<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxesPaidNet', window );">Income taxes paid</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">24<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NoncashInvestingAndFinancingItemsAbstract', window );"><strong>Schedule of non-cash investing and financing activities:</strong></a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtConversionOriginalDebtAmount1', window );">Issuance of common shares for debt conversion</a></td>
<td class="nump">13,757<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">92,307<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CapitalExpendituresIncurredButNotYetPaid', window );">Accrued capital expenditures</a></td>
<td class="nump">795<span></span>
</td>
<td class="nump">101<span></span>
</td>
<td class="nump">2,173<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_immu_ReclassOfWarrantLiabilityToCapitalContributedInExcessOfPar', window );">Non-cash component of warrant exercise</a></td>
<td class="nump">7,569<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssued1', window );">Shares received in cashless exercise</a></td>
<td class="nump">2,450<span></span>
</td>
<td class="nump">1,271<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Total cash, cash equivalents and restricted cash</a></td>
<td class="nump">612,582<span></span>
</td>
<td class="nump">494,173<span></span>
</td>
<td class="nump">612,582<span></span>
</td>
<td class="nump">13,204<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=immu_MarketOfferingMember', window );">Market Offering</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash flows from financing activities:</strong></a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from private offering of common stock</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">71,597<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember', window );">Private placement</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash flows from financing activities:</strong></a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from private offering of common stock</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 67,784<span></span>
</td>
<td class="nump">$ 14,700<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_immu_LossOnInducedExchangesOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Loss On Induced Exchanges Of Debt</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">immu_LossOnInducedExchangesOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>immu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_immu_PaymentOfDebtConversionFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with debt conversion fees.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">immu_PaymentOfDebtConversionFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>immu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_immu_ProceedsFromIssuanceOfNonRecourseDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflows from amounts received from a non-recourse debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">immu_ProceedsFromIssuanceOfNonRecourseDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>immu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_immu_ReclassOfWarrantLiabilityToCapitalContributedInExcessOfPar">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Reclass of warrant liability to capital contributed in excess of par.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">immu_ReclassOfWarrantLiabilityToCapitalContributedInExcessOfPar</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>immu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The sum of the periodic adjustments of the differences between securities' face values and purchase prices that are charged against earnings. This is called accretion if the security was purchased at a discount and amortization if it was purchased at premium. As a noncash item, this element is an adjustment to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentOfWarrantsGrantedForServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Adjustment for noncash service expenses paid for by granting of warrants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentOfWarrantsGrantedForServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfFinancingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense attributable to debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(8))<br> -URI http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&oid=114775744&loc=d3e28555-108399<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfFinancingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalExpendituresIncurredButNotYetPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Future cash outflow to pay for purchases of fixed assets that have occurred.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&oid=98513485&loc=d3e4332-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&oid=98513485&loc=d3e4313-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&oid=98513485&loc=d3e4304-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalExpendituresIncurredButNotYetPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&oid=98513485&loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&oid=98513438&loc=d3e33268-110906<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityRevenueRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received or is due.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&oid=118956577&loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityRevenueRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtAndEquitySecuritiesGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of unrealized and realized gain (loss) on investment in debt and equity securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(9)(a))<br> -URI http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(7)(c))<br> -URI http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtAndEquitySecuritiesGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtConversionOriginalDebtAmount1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of the original debt being converted in a noncash (or part noncash) transaction. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&oid=98513485&loc=d3e4304-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&oid=98513485&loc=d3e4332-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtConversionOriginalDebtAmount1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&oid=98513438&loc=d3e33268-110906<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAdjustmentOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense (income) related to adjustment to fair value of warrant liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Section 25<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&oid=109262497&loc=d3e20148-110875<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAdjustmentOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseRightOfUseAssetAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense attributable to right-of-use asset from finance lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&oid=77888426&loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&oid=77888419&loc=SL77918638-209977<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&oid=77888399&loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseRightOfUseAssetAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnSaleOfPropertyPlantEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) on sale or disposal of property, plant and equipment assets, including oil and gas property and timber property.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnSaleOfPropertyPlantEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxesPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income, net of any cash received during the current period as refunds for the overpayment of taxes.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&oid=98513485&loc=d3e4297-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxesPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInDeferredCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the value of expenditures made during the current reporting period for benefits that will be received over a period of years. Deferred charges differ from prepaid expenses in that they usually extend over a long period of time and may or may not be regularly recurring costs of operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInDeferredCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInDeferredRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInDeferredRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInInventories">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInInventories</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in operating liabilities classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherOperatingLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in receivables classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpenseDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense for debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&oid=109500613&loc=SL6036836-161870<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.8)<br> -URI http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpenseDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&oid=98513485&loc=d3e4297-108586<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 17<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3367-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoncashInvestingAndFinancingItemsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NoncashInvestingAndFinancingItemsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNoncashExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense or loss included in net income that result in no cash flow, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNoncashExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow to satisfy grantee's tax withholding obligation for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow to acquire investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3213-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3151-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&oid=118954083&loc=d3e26853-111562<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from entity's first offering of stock to the public.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceInitialPublicOffering</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Proceeds from issuance of capital stock which provides for a specific dividend that is paid to the shareholders before any dividends to common stockholders and which takes precedence over common stockholders in the event of liquidation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from sale, maturity, prepayment and call of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3151-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3179-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&oid=118954083&loc=d3e26853-111562<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from exercise of option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&oid=116856206&loc=SL79508275-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromWarrantExercises">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from holders exercising their stock warrants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromWarrantExercises</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&oid=118930883&loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&oid=118930883&loc=SL7669625-108580<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&oid=116874947&loc=SL4591551-111686<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3000-108585<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&oid=108774443&loc=SL4569616-111683<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&oid=115929826&loc=d3e8933-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&oid=116874947&loc=SL4591552-111686<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProvisionForDoubtfulAccounts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense (reversal of expense) for expected credit loss on accounts receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&oid=119407570&loc=SL82919249-210447<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(5))<br> -URI http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProvisionForDoubtfulAccounts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssued1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The fair value of stock issued in noncash financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&oid=98513485&loc=d3e4304-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&oid=98513485&loc=d3e4332-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&oid=98513485&loc=d3e4313-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssued1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=immu_MarketOfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=immu_MarketOfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
function toggleNextSibling (e) {
if (e.nextSibling.style.display=='none') {
e.nextSibling.style.display='block';
} else { e.nextSibling.style.display='none'; }
}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6810430576">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">Summary of Property and Equipment</a></td>
<td class="text"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Property and equipment consisted of the following as of December 31, (in thousands):</span></div><div style="line-height:120%;text-align:justify;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"/></tr><tr><td style="width:73%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">2018</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Machinery and equipment</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>14,331</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>16,048</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Leasehold improvements</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>11,535</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>6,365</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Right-of-use asset</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>8,368</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">—</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Furniture and fixtures</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>1,190</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>291</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Computer equipment</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>2,596</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>1,850</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Construction in progress</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>2,667</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>3,231</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>40,687</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>27,785</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Accumulated depreciation and amortization</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(7,925</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(4,316</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>32,762</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>23,469</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
function toggleNextSibling (e) {
if (e.nextSibling.style.display=='none') {
e.nextSibling.style.display='block';
} else { e.nextSibling.style.display='none'; }
}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6823721840">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONSOLIDATED BALANCE SHEETS - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current Assets:</strong></a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 608,628<span></span>
</td>
<td class="nump">$ 492,860<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Marketable securities</a></td>
<td class="nump">4,550<span></span>
</td>
<td class="nump">4,941<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable, net of allowances of $0 at December 31, 2019</a></td>
<td class="nump">295<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseCurrent', window );">Prepaid expenses</a></td>
<td class="nump">21,818<span></span>
</td>
<td class="nump">5,354<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsCurrent', window );">Other current assets</a></td>
<td class="nump">3,413<span></span>
</td>
<td class="nump">1,348<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">638,704<span></span>
</td>
<td class="nump">504,503<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net of accumulated depreciation and amortization of $7,925 and $4,316 at December 31, 2019 and 2018, respectively</a></td>
<td class="nump">32,762<span></span>
</td>
<td class="nump">23,469<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other long-term assets</a></td>
<td class="nump">256<span></span>
</td>
<td class="nump">68<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total Assets</a></td>
<td class="nump">671,722<span></span>
</td>
<td class="nump">528,040<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current Liabilities:</strong></a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent', window );">Accounts payable and accrued expenses</a></td>
<td class="nump">60,860<span></span>
</td>
<td class="nump">31,722<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_immu_LiabilitiesRelatedToTheSaleOfFutureRoyaltiesCurrent', window );">Liability related to sale of future royalties - current</a></td>
<td class="nump">3,455<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Lease liability - current</a></td>
<td class="nump">337<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConvertibleDebtCurrent', window );">Convertible senior notes, net</a></td>
<td class="nump">7,106<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">71,758<span></span>
</td>
<td class="nump">31,722<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConvertibleDebtNoncurrent', window );">Convertible senior notes, net</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">7,055<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_immu_LiabilitiesRelatedToTheSaleOfFutureRoyaltiesNoncurrent', window );">Liability related to sale of future royalties - non-current</a></td>
<td class="nump">257,769<span></span>
</td>
<td class="nump">221,295<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityNoncurrent', window );">Deferred revenues</a></td>
<td class="nump">65,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Other long-term liabilities</a></td>
<td class="nump">9,965<span></span>
</td>
<td class="nump">2,119<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total Liabilities</a></td>
<td class="nump">404,492<span></span>
</td>
<td class="nump">262,191<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and Contingencies (Note 14)</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders' Equity:</strong></a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConvertiblePreferredStockNonredeemableOrRedeemableIssuerOptionValue', window );">Convertible preferred stock, $0.01 par value; authorized 10,000,000 shares; no shares issued and outstanding at December 31, 2019 and 2018</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, $0.01 par value; authorized 250,000,000 shares; issued 212,529,313 shares and outstanding 212,409,692 shares at December 31, 2019; issued 190,445,795 shares and outstanding 190,411,070 shares at December 31, 2018</a></td>
<td class="nump">2,125<span></span>
</td>
<td class="nump">1,905<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapitalCommonStock', window );">Capital contributed in excess of par</a></td>
<td class="nump">1,579,205<span></span>
</td>
<td class="nump">1,219,237<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockValue', window );">Treasury stock, at cost: 119,621 shares at December 31, 2019 and 34,725 shares at December 31, 2018</a></td>
<td class="num">(2,095)<span></span>
</td>
<td class="num">(824)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(1,310,406)<span></span>
</td>
<td class="num">(953,216)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive loss</a></td>
<td class="num">(568)<span></span>
</td>
<td class="num">(351)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total Immunomedics, Inc. stockholders' equity</a></td>
<td class="nump">268,261<span></span>
</td>
<td class="nump">266,751<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterest', window );">Noncontrolling interest in subsidiary</a></td>
<td class="num">(1,031)<span></span>
</td>
<td class="num">(902)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Total Stockholders' Equity</a></td>
<td class="nump">267,230<span></span>
</td>
<td class="nump">265,849<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total Liabilities and Stockholders' Equity</a></td>
<td class="nump">$ 671,722<span></span>
</td>
<td class="nump">$ 528,040<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_immu_LiabilitiesRelatedToTheSaleOfFutureRoyaltiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Liabilities Related To The Sale Of Future Royalties, Current</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">immu_LiabilitiesRelatedToTheSaleOfFutureRoyaltiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>immu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_immu_LiabilitiesRelatedToTheSaleOfFutureRoyaltiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Liabilities Related To The Sale Of Future Royalties, Noncurrent</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">immu_LiabilitiesRelatedToTheSaleOfFutureRoyaltiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>immu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&oid=118956577&loc=SL49130549-203045<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&oid=118952595&loc=d3e4428-111522<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3))<br> -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&oid=118951113&loc=d3e6676-107765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&oid=118952595&loc=d3e4531-111522<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&oid=118930883&loc=d3e637-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI http://asc.fasb.org/extlink&oid=118930883&loc=SL7669686-108580<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&oid=118930883&loc=d3e681-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapitalCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapitalCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&oid=118951113&loc=d3e6801-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.9)<br> -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&oid=118951113&loc=d3e6676-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&oid=118942338&loc=SL82898722-210454<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&oid=118954083&loc=d3e26626-111562<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&oid=118951113&loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.(a),19)<br> -URI http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -URI http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&oid=118942415&loc=d3e14326-108349<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&oid=118944033&loc=SL49130532-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&oid=118944033&loc=SL49130531-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&oid=118956577&loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertibleDebtCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of the carrying value of long-term convertible debt as of the balance sheet date that is scheduled to be repaid within one year or in the normal operating cycle if longer. Convertible debt is a financial instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19))<br> -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertibleDebtCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertibleDebtNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount of long-term convertible debt as of the balance sheet date, net of the amount due in the next twelve months or greater than the normal operating cycle, if longer. The debt is convertible into another form of financial instrument, typically the entity's common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertibleDebtNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertiblePreferredStockNonredeemableOrRedeemableIssuerOptionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of outstanding nonredeemable convertible preferred stock or outstanding convertible preferred stock that is redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&oid=109259400&loc=d3e21475-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertiblePreferredStockNonredeemableOrRedeemableIssuerOptionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which is directly or indirectly attributable to that ownership interest in subsidiary equity which is not attributable to the parent (that is, noncontrolling interest, previously referred to as minority interest).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(24))<br> -URI http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.31)<br> -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(22))<br> -URI http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MinorityInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&oid=77888419&loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.8)<br> -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.24)<br> -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&oid=118951113&loc=d3e6787-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&oid=118951113&loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section 05<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&oid=68074540&loc=d3e5879-108316<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&oid=27010918&loc=d3e74512-122707<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&oid=108774443&loc=SL4568740-111683<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4I<br> -URI http://asc.fasb.org/extlink&oid=116874947&loc=SL4590271-111686<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&oid=108774443&loc=SL4568447-111683<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount allocated to treasury stock. Treasury stock is common and preferred shares of an entity that were issued, repurchased by the entity, and are held in its treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&oid=6405834&loc=d3e23315-112656<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29,30)<br> -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&oid=6405813&loc=d3e23239-112655<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
function toggleNextSibling (e) {
if (e.nextSibling.style.display=='none') {
e.nextSibling.style.display='block';
} else { e.nextSibling.style.display='none'; }
}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6810545296">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Commitments and Contingencies</a></td>
<td class="text">Commitments and Contingencies<div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">a. Legal Matters</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Arbitration of Disputed Matters:</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">On January 15, 2019, the Company received an Arbitrator’s Findings of Fact and Conclusions of Law and Final Award (the “Final Award”) in the arbitration matter in which Dr. David M. Goldenberg, the Company’s former Chief Scientific Officer, Chief Patent Officer and Chairman of the Company’s Board of Directors, claimed entitlement to certain equity awards and severance payments, and Dr. Goldenberg and Ms. Cynthia Sullivan, a former director of the Company and former President and Chief Executive Officer, claimed rights to certain bonus payments. The Final Award (i) denied Dr. Goldenberg’s claim that he was entitled to an award of </span><span style="font-family:inherit;font-size:10pt;"><span>1.5 million</span></span><span style="font-family:inherit;font-size:10pt;"> restricted stock units, (ii) denied each of Dr. Goldenberg’s and Ms. Sullivan’s claims that they were entitled to certain discretionary cash bonuses relating to the Company’s 2017 fiscal year, and (iii) granted Dr. Goldenberg an award of approximately </span><span style="font-family:inherit;font-size:10pt;"><span>$1.0 million</span></span><span style="font-family:inherit;font-size:10pt;"> relating to certain claimed severance payments which was paid in March 2019. The arbitration took place pursuant to the Delaware Rapid Arbitration Act.  Although the Delaware Rapid Arbitration Act permits challenges to arbitration awards in limited circumstances, pursuant to that certain stipulation and agreement of settlement, compromise, and release dated November 2, 2017, the Company, Dr. Goldenberg and Ms. Sullivan agreed that the Final Award would be the sole and exclusive final and binding remedy between and among the parties with respect to the matters disputed in the arbitration. </span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Stockholder Complaints:</span></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Class Action Stockholder Federal Securities Cases</span></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Two purported class action cases were filed in the United States District Court for the District of New Jersey; namely, Fergus v. Immunomedics, Inc., et al., filed June 9, 2016; and Becker v. Immunomedics, Inc., et al., filed June 10, 2016. These cases arise from the same alleged facts and circumstances and seek class certification on behalf of purchasers of our common stock between April 20, 2016 and June 2, 2016 (with respect to the Fergus matter) and between April 20, 2016 and June 3, 2016 (with respect to the Becker matter). These cases concern the Company’s statements in press releases, investor conference calls, and filings with the U.S. Securities and Exchange Commission (the "SEC") beginning in April 2016 that the Company would present updated information regarding its IMMU-132 breast cancer drug at the 2016 American Society of Clinical Oncology (“ASCO”) conference in Chicago, Illinois. The complaints allege that these statements were false and misleading in light of June 2, 2016 reports that ASCO had canceled the presentation because it contained previously reported information. The complaints further allege that these statements resulted in artificially inflated prices for our common stock, and that the Company and certain of its officers are thus liable under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934, as amended (the "Exchange Act"). An order of voluntary dismissal without prejudice was entered on November 10, 2016 in the Becker matter. An order granting motion to consolidate cases, appoint lead plaintiff, and approve lead and liaison counsel was entered on February 7, 2017 in the Fergus matter. A consolidated complaint was filed on October 4, 2017. The Company filed a motion to dismiss the consolidated complaint on January 26, 2018. On March 31, 2019, the court granted the Company's motion to dismiss, without prejudice, and left plaintiffs with the ability to file an amended complaint within thirty (30) days. Counsel for the Company has consented to an extension of time for plaintiffs to file the proposed amended complaint for an additional thirty (30) days. On May 30, 2019, plaintiffs filed an amended complaint alleging many of the same allegations that were set forth in the previously filed complaints, and the Company has filed a motion to dismiss.</span><span style="font-family:inherit;font-size:10pt;"> </span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">A third purported class action case was filed in the United States District Court for the District of New Jersey; namely, Odeh v. Immunomedics, Inc., et al., filed December 27, 2018. The complaint in this action alleges that the Company failed to disclose the results of observations made by the FDA during an inspection of the Company’s manufacturing facility in Morris Plains, New Jersey in August 2018. The complaint alleges that Immunomedics misled investors by failing to disclose the Form 483 inspection report issued by the FDA which set forth the observations of the FDA inspector during the inspection. Such observations purportedly included, inter alia, manipulated bioburden samples, misrepresentation of an integrity test procedure in the batch record, and backdating of batch records. The complaint further alleges that the Company’s failure to disclose the Form 483 resulted in an artificially inflated price for our common stock, and that the Company and certain of its officers are thus liable under Sections 10(b) and 20(a) of the Exchange Act. </span><span style="font-family:inherit;font-size:10pt;"> </span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"/><span style="font-family:inherit;font-size:10pt;">On February 8, 2019, a purported class action case was filed in the United States District Court for the District of New Jersey; namely, Choi v. Immunomedics, Inc., et al. The complaint asserts violations of the federal securities laws based on claims that the Company violated the federal securities laws by making alleged misstatements in various press releases and securities filings from February 8, 2018 to November 7, 2018 and by failing to disclose the substance of its interactions with the FDA in connection with the Company's submission of its BLA for sacituzumab govitecan.</span><span style="font-family:inherit;font-size:10pt;">  </span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"/><span style="font-family:inherit;font-size:10pt;">Motions for the appointment of a lead plaintiff and lead counsel and to consolidate the Odeh and Choi actions were granted on September 10, 2019. Pursuant to a scheduling order entered by the court on October 7, 2019, the plaintiffs filed an amended complaint on November 18, 2019. The Company filed a motion to dismiss the consolidated, amended complaint on January 17, 2020. The motion has a return date of April 20, 2020. </span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"/><span style="font-family:inherit;font-size:10pt;">On April 8, 2019, a putative stockholder of the Company filed a derivative action purportedly on behalf of the Company and against the Company’s board of directors and certain Company current and former officers, in the Superior Court of New Jersey, Law Division (Morris County); namely, Crow v. Aghazadeh, et al. The Crow complaint alleges that the individual defendants breached their fiduciary duties and committed other violations of law based on the same core allegations in the Odeh and Choi actions. The Crow complaint was served on the Company and other defendants on July 18, 2019. On August 13, 2019, the parties submitted to the court a stipulation and proposed order to stay the action until either the entry of an order denying all motions to dismiss the now-consolidated federal actions or the entry of an order dismissing the federal actions with prejudice. That stipulation is currently pending court approval.</span><span style="font-family:inherit;font-size:10pt;"> </span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Stockholder Claim in the Court of Chancery of the State of Delaware</span></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">On February 13, 2017, venBio commenced an action captioned venBio Select Advisor LLC v. Goldenberg, et al., C.A. (Del. Ch.) (the “venBio Action”), alleging that Company’s Board breached their fiduciary duties when the Board (i) amended the Company’s Amended and Restated By-laws (the “By-Laws”) to call for a plurality voting regime for the election of directors instead of majority voting, and providing for mandatory advancement of attorneys’ fees and costs for the Company’s directors and officers, (ii) rescheduled the Company’s 2016 Annual Meeting of Stockholders (the “2016 Annual Meeting”) from December 14, 2016 to February 16, 2017, and then again to March 3, 2017, and (iii) agreed to the proposed Licensing Transaction with Seattle Genetics. venBio also named Seattle Genetics as a defendant and sought an injunction preventing the Company from closing the licensing transaction with Seattle Genetics. On March 6, 2017, venBio amended its complaint, adding further allegations. The Court of Chancery entered a temporary restraining order on March 9, 2017, enjoining the closing of the Licensing Transaction. venBio amended its complaint a second time on April 19, 2017, this time adding Greenhill & Co. Inc. and Greenhill & Co. LLC (together “Greenhill”), the Company’s financial advisor on the Licensing Transaction, as an additional defendant. On May 3, 2017, venBio and the Company and individual defendants Dr. Goldenberg, Ms. Sullivan and Mr. Brian A. Markison, a director of the Company (collectively, the “Individual Defendants”) entered into the Initial Term Sheet. On June 8, 2017, venBio the Company and Greenhill entered into the Greenhill Term Sheet. On February 9, 2018, the Court of Chancery approved the Settlement, and entered an order and partial judgment releasing all claims that were asserted by venBio against the Individual Defendants and Greenhill in the venBio Action and awarding venBio fees and expenses. On May 24, 2018 the remaining parties to the venBio Action participated in a mediation of the claims against Geoff Cox, Robert Forrester, Bob Oliver, and Jason Aryeh (the "Remaining Defendants"). The mediation was unsuccessful. The Remaining Defendants filed submitted motions to dismiss the claims against them in the venBio Action. On March 18, 2019, venBio amended its complaint, adding further allegations. The Remaining Defendants filed a motion to dismiss the claims against them on May 1, 2019. The Court of Chancery held oral arguments for the motion to dismiss on November 13, 2019 and following arguments, denied Defendants' motion to dismiss on that same date. The parties are now engaged in discovery activities.</span><span style="font-family:inherit;font-size:10pt;"> </span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Insurance Coverage Arbitration:</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"/><span style="font-family:inherit;font-size:10pt;">The Company has initiated an arbitration with two of its management liability insurers: Starr Indemnity & Liability Company (“Starr”), and Liberty Insurance Underwriters Inc. (“Liberty”) (collectively, “Insurers”).  The arbitration arises from </span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">the 2015 Insurers’ refusal to cover</span><span style="font-family:inherit;font-size:10pt;"> </span><span style="font-family:inherit;font-size:10pt;"><span>$3.4 million</span></span><span style="font-family:inherit;font-size:10pt;"> </span><span style="font-family:inherit;font-size:10pt;">in attorneys’ fees and expenses paid to venBio pursuant to a December 1, 2017, settlement agreement between venBio, the Company, Dr. Goldenberg, Ms. Sullivan, Mr. Markison, and Greenhill to partially settle the venBio Action and fully settle the Federal Action and the Delaware Section 225 Action (the “venBio Fee Award”).  </span><span style="font-family:inherit;font-size:10pt;"> </span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"/><span style="font-family:inherit;font-size:10pt;">The Insurers argue that the venBio Fee Award does not satisfy their policies’ definitions of covered “loss” because the policies only cover defense costs incurred by the Company.  The Company counters that the venBio Fee Award is a covered settlement, not a claim for defense costs.  Insurers also argue that they have no obligation to pay any defense costs or settlement incurred in the Federal Action or 225 Action because Immunomedics initiated those lawsuits.  The Company’s position is that the Federal Action and 225 Action were defensive in nature and therefore covered because they were initiated to further the defense of the venBio Action.  Additionally, Insurers argue the venBio Fee Award is not covered because the Company was required to obtain Insurers’ consent to enter into a binding term sheet in the venBio Action and to agree to pay the venBio Fee Award and that the Company failed to do so.  The Company takes the position that Insurers at all times were aware of the developments in the venBio Action, that they sought consent to enter into the settlement, and that Insurers cannot show they were prejudiced by an any alleged failure to obtain Insurers’ consent. </span><span style="font-family:inherit;font-size:10pt;"> </span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"/><span style="font-family:inherit;font-size:10pt;">Liberty also contends that the Company’s insurance claim is not covered by Liberty’s 2015-16 insurance policy and should be covered by another company’s policy in a later policy period. The Company takes the position that the policies treat the venBio Action as a related claim to the Fergus v. Immunomedics class action stockholder federal securities case, which was filed in 2016 and that because of the similar allegation in the venBio Action and Fergus, the policies deem the venBio Action claim to be made at the same time as Fergus and covered by the 2015-16 policies. In the arbitration, Starr contends it will have the benefit of any finding that the claim is covered in a later policy period, even though Starr had agreed with the Company’s position prior to the arbitration.</span><span style="font-family:inherit;font-size:10pt;"> </span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"/><span style="font-family:inherit;font-size:10pt;">In the event Insurers prevail on their argument that the venBio Fee Award is covered by a subsequent policy year, the Company will pursue coverage under its other insurance policies.</span><span style="font-family:inherit;font-size:10pt;"> </span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"/><span>Starr is presently advancing the costs to defend the remaining claims in the venBio Action, </span><span style="font-style:italic;">i.e., </span><span>those against the Company as Nominal Defendant and individual defendants Aryeh, Cox, Forrester, and Oliver.  However, all Insurers have reserved their rights to contest coverage for any potential settlement of those claims.</span><span style="font-family:inherit;font-size:10pt;"> </span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">b. Other Matters</span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Immunomedics is also a party to various claims and litigation arising in the normal course of business.</span><span style="font-family:inherit;font-size:10pt;"> </span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">c. Leases</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Our operating lease assets primarily represent manufacturing and research and development facilities, warehouses, and offices. Our finance leases primarily represent computer equipment and are not significant. For the year ended </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;">, cash payments against operating lease liabilities totaled </span><span style="font-family:inherit;font-size:10pt;"><span>$1.3 million</span></span><span style="font-family:inherit;font-size:10pt;">. The discount rate used to determine the net present value of the leases at inception was </span><span style="font-family:inherit;font-size:10pt;"><span>11.0%</span></span><span style="font-family:inherit;font-size:10pt;">. This is the incremental borrowing rate that represents the rate of interest that the Company would expect to pay to borrow an amount equal to the lease payments under similar terms. Our leases both share a remaining lease term of </span><span style="font-family:inherit;font-size:10pt;"><span>11.8 years</span></span><span style="font-family:inherit;font-size:10pt;">, some of which may include options to extend the leases further. The Company considers these options in determining the lease term used to establish the right-of-use assets and lease liabilities. </span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Supplemental consolidated balance sheet information related to leases are as follows (in thousands):</span></div><div style="line-height:120%;text-align:center;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="6"/></tr><tr><td style="width:3%;"/><td style="width:67%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:27%;"/><td style="width:1%;"/></tr><tr><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Operating leases:</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">December 31, 2019</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Operating lease right-of-use assets, net</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>8,105</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Current portion of lease liabilities</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>337</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Non-current portion of lease liabilities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>9,965</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Total operating lease liabilities</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>10,302</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Weighted average remaining lease term (years)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>11.8</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Weighted average discount rate</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>11.0</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">%</span></div></td></tr></table></div></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Operating lease right-of-use asset is a component of property and equipment on the consolidated balance sheet. The non-current portion of lease liabilities is a component of other long-term liabilities on the consolidated balance sheet.</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-indent:48px;font-size:11pt;"><span style="font-family:inherit;font-size:11pt;"/><span style="font-family:inherit;font-size:10pt;">Supplemental cash flow information related to leases are as follows (in thousands):</span></div><div style="line-height:120%;text-align:center;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="5"/></tr><tr><td style="width:67%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:30%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Year Ended December 31, 2019</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Non-cash lease expense</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>264</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Change in operating lease liabilities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>186</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-left:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-left:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Maturities of lease liabilities as of </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;"> are as follows (in thousands): </span></div><div style="line-height:120%;text-align:center;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="6"/></tr><tr><td style="width:3%;"/><td style="width:77%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:17%;"/><td style="width:1%;"/></tr><tr><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Year 1</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>1,453</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Year 2</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>1,465</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Year 3</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>1,523</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Year 4</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>1,531</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Year 5</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>1,567</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Thereafter</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>11,333</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Total lease payments</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>18,872</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Less imputed interest</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(8,570</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td></tr><tr><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Total</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>10,302</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Operating lease expense was approximately </span><span style="font-family:inherit;font-size:10pt;"><span>$1.4 million</span></span><span style="font-family:inherit;font-size:10pt;">, </span><span style="font-family:inherit;font-size:10pt;"><span>$0.7 million</span></span><span style="font-family:inherit;font-size:10pt;">, </span><span style="font-family:inherit;font-size:10pt;"><span>$1.3 million</span></span><span style="font-family:inherit;font-size:10pt;">, and </span><span style="font-family:inherit;font-size:10pt;"><span>$0.9 million</span></span><span style="font-family:inherit;font-size:10pt;"> for the year ended </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;">, the transition period ended December 31, 2018 and fiscal years ended June 30, 2018, and 2017, respectively.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">d. Purchase Obligations</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We have several commitments</span><span style="font-family:inherit;font-size:10pt;"> primarily to purchase commercial manufacturing services including minimum purchase commitments related to product supply contracts and e-sourcing software</span><span style="font-family:inherit;font-size:10pt;"> totaling </span><span style="font-family:inherit;font-size:10pt;"><span>$90.0 million</span></span><span style="font-family:inherit;font-size:10pt;"> in 2020, </span><span style="font-family:inherit;font-size:10pt;"><span>$59.8 million</span></span><span style="font-family:inherit;font-size:10pt;"> in 2021, </span><span style="font-family:inherit;font-size:10pt;"><span>$40.8 million</span></span><span style="font-family:inherit;font-size:10pt;"> in 2022, </span><span style="font-family:inherit;font-size:10pt;"><span>$40.8 million</span></span><span style="font-family:inherit;font-size:10pt;"> in 2023, </span><span style="font-family:inherit;font-size:10pt;"><span>$33.0 million</span></span><span style="font-family:inherit;font-size:10pt;"> in 2024 and </span><span style="font-family:inherit;font-size:10pt;"><span>$33.0 million</span></span><span style="font-family:inherit;font-size:10pt;"> thereafter. </span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">e. License</span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">On April 4, 2018, we entered into a license agreement with The Scripps Research Institute ("TSRI"). Pursuant to the license agreement, TSRI granted to us an exclusive, worldwide, sub-licensable, royalty-bearing license to use certain patent rights relating to our ADC sacituzumab govitecan. The license agreement expires on a country-by-country basis on the expiration date of the last to expire licensed patent rights in such country covering a licensed product. The license agreement may be terminated by the mutual written consent of us and TSRI, and TSRI may terminate the license agreement upon the occurrence of certain events, including but not limited to if we do not make a payment due pursuant to the license agreement and fail to cure such non-payment within </span><span style="font-family:inherit;font-size:10pt;"><span>30</span></span><span style="font-family:inherit;font-size:10pt;"> days after the date of TSRI's written notice of such non-payment. As consideration for the license granted, we made a cash payment of </span><span style="font-family:inherit;font-size:10pt;"><span>$0.3 million</span></span><span style="font-family:inherit;font-size:10pt;"> to TSRI. Additionally, we will pay TRSI (i) product development milestone payments that range from the </span><span style="font-family:inherit;font-size:10pt;">mid-six digit dollar figure</span><span style="font-family:inherit;font-size:10pt;"> to the </span><span style="font-family:inherit;font-size:10pt;">low-seven digit dollar figure</span><span style="font-family:inherit;font-size:10pt;"> and (ii) royalties on net sales of licensed products in the </span><span style="font-family:inherit;font-size:10pt;">low-single digit</span><span style="font-family:inherit;font-size:10pt;"> percentage figure range capped at an annual amount. We have agreed to use reasonable efforts to develop and market the licensed products. During the year ended December 31, 2019, we recognized a </span><span style="font-family:inherit;font-size:10pt;"><span>$0.5 million</span></span><span style="font-family:inherit;font-size:10pt;"> milestone payment expense.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">f. Michael Pehl Separation</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><span style="font-family:inherit;font-size:10pt;">On March 13, 2019, the Company entered into a separation agreement (the “Separation Agreement”) with Michael Pehl, the Company’s former Chief Executive Officer, President and member of the Company’s Board. Mr. Pehl resigned as Chief Executive Officer, President and member of the Company’s Board effective February 23, 2019. Pursuant to the Separation Agreement, Mr. Pehl will receive cash payments of approximately </span><span style="font-family:inherit;font-size:10pt;"><span>$1.0 million</span></span><span style="font-family:inherit;font-size:10pt;"> over an </span><span style="font-family:inherit;font-size:10pt;">eighteen-month</span><span style="font-family:inherit;font-size:10pt;"> period. During the year ended </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;">, the Company paid approximately </span><span style="font-family:inherit;font-size:10pt;"><span>$0.5 million</span></span><span style="font-family:inherit;font-size:10pt;"> to Mr. Pehl, and </span><span style="font-family:inherit;font-size:10pt;"><span>$0.6 million</span></span><span style="font-family:inherit;font-size:10pt;"> was accrued for as of </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span>. Mr. Pehl also released the Company from any and all claims with respect to all matters arising out of or related to Mr. Pehl’s employment by the Company and his resignation.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -URI http://asc.fasb.org/topic&trid=2127136<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -URI http://asc.fasb.org/topic&trid=2144648<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
function toggleNextSibling (e) {
if (e.nextSibling.style.display=='none') {
e.nextSibling.style.display='block';
} else { e.nextSibling.style.display='none'; }
}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6802389472">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Marketable Securities (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract', window );"><strong>Investments, Debt and Equity Securities [Abstract]</strong></a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock', window );">Schedule of Available-for-sale Securities</a></td>
<td class="text"><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following table summarizes the marketable securities held as of </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;"> and 2018 (in thousands):</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"/></tr><tr><td style="width:38%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"> December 31, 2019</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Amortized Cost</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Gross Unrealized Gain</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Gross Unrealized (Loss)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Fair Value</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">U.S. Government Sponsored Agencies</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>4,941</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(391</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>4,550</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;padding-left:0px;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"/></tr><tr><td style="width:38%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"> December 31, 2018</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Amortized Cost</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Gross Unrealized Gain</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Gross Unrealized (Loss)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Fair Value</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">U.S. Government Sponsored Agencies</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>4,941</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>4,941</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -URI http://asc.fasb.org/topic&trid=2196928<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>60
<FILENAME>0000722830-20-000003-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0000722830-20-000003-xbrl.zip
M4$L#!!0 ( ,& 6U#T_N@L(Y NC < 83$P:V-H96-M:6-A;&QI
M;FME<FEM86=E+FIP9]2[=UP3W]<N.H"(#:)4I44%1:D6B@HD(M+DBU%4.D2E
M@Q!!D A45$0$"*@H"!$142D1#H()$I'1#H(D9+0I 02@3"0=N+O\YYSSQ_G
MOO><>__XO7<G*S.?R0RSU]YKK>=Y-A/^3_X$L/N"N94Y("0D!%P7O ^%7A@
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MN&>'K*HN]1#SKVO_\NQ_S[$'_Z\\^Q^._5]^C0"[1(0$DR>R!X #7,[;^"/
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M(U:.Z95)P^^Q"L^;E[2:;2KUEPLV=]X6D7-4<?4U9- _RG9L9M/?9^:!=4+
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MF0TCT]W"DPZ]6BC/8>[�M4_R"T>7DDE=KZ1=S?I(\3-(D31U]D-X5!O?NT
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MZ"8;[,7V"RW^:W+LGV$%\J)B7 #&7N[O?\Y?6CC#!Q*,+.I\L'+=FJ31(O\
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MM'9^E+#^D,.2R ?U4RTF /Y0/EXSVK^&EZ"U^X&B6T9&2P*;J?AGB@?J<E8
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M&FT]:4Y 09=X7[J;E9+J*RS&RU)L4I3?[SMV1A[85&%I<O-(JMCA\9*D^LD
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M5(MY3ZAK9&"%S)$6"/8&%89W(VY/<ET-3 I-OL TPL]YSD;%\P$&6WQT C%
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M*=9Q\I%%YVCF*X<_5[_@]'9II(4EUWBA&NX9&39 &=:))R?48D-?(3<OQ
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MI==:$U]ZJB=<LXDA+?&^ QKBL EZ%K;6%\@E?674WXV?7(=_EYF<ILP9N\2
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M]20'Q">B.3<>)NS,Z\"5(AK'@5;%X^W41,FQL94._$VK$/OO-4]U E;*B7Q
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MT4G@ R4W>(U@-!4EB;G%Z"?\YD&9WM&K/Z<&<].7>_.CQXG$(V"9?0:I\Q
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M( BA>W9?#8"7URF4N"2#DUTT=DFK2#5V(9*+0[2DQ)7<5K,R)FVB]$7W8S&
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MD35CTR\1HL^K1G2F'/>%N7T^,KSSUQ*F3:1L0A[5C /\8$F_#"1>K%DDA@-
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M#7*:D2:6_-V\$-:!DX#_6L >QU'"6LCLPE(HYT/#Z2 @FBLHP)*: L=!AN,
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M'88TG-Q+4<X\UGUGE QKV9-'V?.;]%]N,OVGD+L'SCJ(#F-^ '!A;&-@X_8
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M'DXP#\YEB:4-LA,,O4,O03/%MFWP'![P:-;O[.PAU3N Q;1TW36+/HPHLU2
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M)A,UA7.#\D*!$-$Q3O(77 C^G'^8$<*-;C8H"5#LL+<WJAY1F))MJJ\*-P
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M/TQ:B14;3]@PABB2$9Y(P>^>PZHQ[,QVU123W)C _TVM^T?[,95!)1NW;+D
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M6[HSV7 ^8PM^*$RQS$7##:M&5"_$E'XQ_)("7WAY<@=8Y%^Y@(1GW?&$YLF
M=P5W-^ZI:]M!9C$/MVVI>LS2J,S4,9L&GLRZ@&!=*A5K*BH;-YOV>FNW7\KN
M5=,K7YNZE,5( '\'"'R.,0@"B-0)<@1;\%$*5GI "9A^EXR%O16^;GOJ9;#Z
M!.+PASTFC@Z1QB)]"G6VP-CRW$^YXIKZ1FXPAX. Z6+:4!I$UYBA8W+9&N!
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M8N -WK2+H!YP@5[3AHK,D >N!OI@I5%&6J#UC<:7S_(?%.!G3%+/5K>]J[M
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M-CS_W.9&1)6GGEWONIL$K<MR8%DBV#8O;;G!Y[#*MY!S[X52_R6C!'Z&Z&8
MX,MZEM8#MR!PHT.-GV"@?#]/6?:^+?PM/#RR^.E2]!9$;< 9ZXSQ!5<H?IP,
MW(.>B)H,#6"(&,.^PSBR; "'?LWKY&0&\:=_)&FI24UV@8ZE=RVPZ?]!YJ/X
M4X9F.Q$HY4HO;&ZDS.+NSZ5(<I$;[#S2%1R]<ML4LG*#+39+T5QTIKWQ@T;"
M1-EZU,;'-)UT[8:NP! 9BPTGM'K?E&F/J_^>$(\^[BYNK]%N3@X!9H.NX)E7
M)>P V@N,E\C,GE3_KIA2D$[T[_1_*#)N_14)G(<_L9'!?T(])V@L/ Y(*\%<
M <DRA),,DQ=>M#LKFCGU;V=B82>>JHI=T_8NNKMDGZZ5VM;/%L_BML,!!X30
M+RY_1<0%@+ATF'+F\HI][Z+\[8>.P]IOY>-U8,<>Y:W:?N\KXYM1$9A*/ M[
M7_D_ /+^[1!?,WE)O&]O2YF-7H<>Q/8\;L<_]2^<.[AB#3R?>LC=SS LWD@U
M%4U3S=F"X-,>.JTI^%KW_[;DYP7L_7#*Q\?*BT,L!3"1UMF!V EV4JMJ0OUW
M5S8&(A*Z4?CN!-.L.\6*+Q;KJP+>!GQ[ T>?S"H\N@'=C;$%MB!ML.?ZN!CM
M,Y=E;5L?5[]);<R>_KRV?V8H:TW"N-.N1)4.!T^K#!ML04"%GI=W4Q63C_F3
MH28*J V%2\/JXDG$47F=IZP3DST\U"%QWK,]66H+OA9;D#WDCCJ';%I/F&3*
M?NSRI'JQ4B9UG;M@:Q!4QC=\#.H=!=E,:2'7S+;BQ;!?Y*3!B9TS93S(1T2K
MJR_[?8R[G$&_UN@^UA6^H_*Y4_QTX)_S1PU9OG:7;=F!G'*SM9B5Q25@<I9[
MI^->'6.X4))EL3;F'M7*(F#H99&?I7# .?*?"SV+:UN0^R%$[K.A]7;(WT+:
M%/@V'/7*O -?(K4ZPO?#_ 8<-:BQ;/BURJ-KR+,K6)%UHL[C$_GXNZ\S?%\>
MS$)C""K8YGE'ABMSM@/U3+=SBJ&87DHRM*6^@<]Q28?@E8?/#=,FL+W\WQEF
M:V;(&WUG959:$9%<&? K)<:@S4%T1)N\S^W@1ZQG.A?_J*)5/_@DH_.\?EAS
M<TD4P1=,8HF1T<J=!U/BN#L7)'!0C&>>&3,&:5(;^1&HB4[CXCU%Y6[.5DT3
M1B,8?[[I6JM*LL5P[:DU+W) 5#9;C/&,**=6W$^W!#AMT="(RH7 --U*9V7
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M ZC(1ID' ;=,NAFBB$0$$Q !HR+;"9 IC@PB1D0D3&D4 1$!!9$-7H@8AJV
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M:@SGJK<QUD.,O'6U0N.4:,="\()#M8WN'#1VX< W?EM<R?O(W[::TF/74_Z
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M6C\,2^S?F2LK@_\ 4$L#!!0 ( ,& 6U!WT0SQ1RT! /E2 0 = 8VAA
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M,G65U@YCP=U3E&M48Z\ 6N(3 !C>)>!9=581?(L]1L8!$T10H?!0UU"KG&<
MPV+80\)=Q$CK P@[Z\@:>M94ZLG1CM'9:YK9_;/_";U^M^S8Z'W" YX-6=[(
MF\]TQS(ZT@'*[V-=562*[D# > #^)B%7D7/(T7,XRW%/7[& 0UVBWT*S;>S+
MJ&!Z(USKVA/*7 ^):"-44^SP'[<)KM2%/I'42#Q2VZ.L+'C$'1<,$C0"G8CE
MSCS4 +'5F[!SU,+<B03H*W[1V&ROH"4W15.M*R1M'8Q "ML.=JJKVQ<*TD76
M_[Q1'G/J.RT0AN_Q/G=$__?S M_VF-+V>#(OT:Z$A(./0O[HA;1FEI=$6L5
M<R/R'-J'1S:P4>MOKWA"WR;95<_"VR6?9=9,4XC:*EH?[R2)<(,=LD^<V/I
M@5_!2#-)^9!02/NM,RP$20Z[]IH.G%K7IO'5V@)BTA1EH+O980N\]+;VF/Z#
MK#H0Z?;MKO9+Y$K'-3S8H^V=D22V."[9-FTL M\UK78^P)',MFCWQR=Y[_SP
MZ.;7II_CPW>V+K_,G,-AB<3]C_HYJ+L!Q$X.TC!Y9*FU1GB:%J1?>Q3Q5XYP
MO)8I!'AF G(1.A(2BJZL$O9Y41:TEL).?OF2KDKDHM#^U*FZOBG!K0":<XR
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M.VV1<O,[E\JU";N,!7==*O^:*%EYMM76[^2%H[OW7%B]PQTIQII1&[8 4I2
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MT6P/#]*>B>.W"DS_L+UF'6S+&6[;0OL7X[KY@4BP=A\S05?',F"])WSGZH8
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MP\_P3#.81H#20QF1BA$NZ0<?V(*<-;RQ$UV0DBKWFZ;:OH:C?3M8:V3(]=1
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M:TM-3D_UH+O]5HW8W71;R[TVX->9.Y"K^H_\Y9+DF*B:NV>AOS]_?FN@<9K
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M@<%)CF>WAX2;]V8:5Y;.,T[#D5-0,MPOS^.PUC"X"GP&ZT?4!2:V $9A_WQ
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MC3/ 0U#S\+I.%6S*SK JL!L>O4V8O\1(31[G*40EN;OG6K)F]GSF?SF>"L7
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M5D^BYCQ%M#I,&Q4:<P&P$OW,6#.NX>CN _+[A:N1]/C[Z$6HML4$S/)\7")
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M^Z+@<\C/S"V12F%N8+ZI_=G/^_##--1?_>&E7CA/^,5)5*B]BVPS\!WQSC*
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M+1^D^"K *W0CZ@JLG6Z&&BH$*Y%L;/9'_1]4.ZR?Z@K1KW ]WZ)N+V[-J4]
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MS>GH_A,/;AT(UP2OL'[Q[_%4; <0!@P#S6+(CSB<AZU,U!UD@P?G"=>9=!A
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M;ET->Y\<5&9X[1J6=+W)=4Y#]SJ2:I\&OC87E\T3;,$SXB$,1.Q2-)E*P;!
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M=Z$1EC:3Z"3P-& -GLV["5>HVY@Q.TON:US9SLB/X]*?X!>!7")?7_W4GP>
MA8]:5D.C54_>O7ZX-^9^A%5;A2@G["*H?2[*A\,F%^E<V1W:]7QL!?P8\3PA
M#MM-78K+^*J9)[=/>]T1ID5W+D/B)3)NXKT(&9A*_O$/^QO3EZ,K@-9+7+OG
M3U_<;#C&M*V*85ZT.VBVL(1ALP^@J)97 Y,"O!NOZFY8 <5^"X6^T*W&I #T
MZAG8?!@]\YAA69>2BBX3U\A;K7DK$=OA[_M\QT<8L:&F4&+XZ*Y?*M.R"F/+
M\O<<,XQ<+N@6#]_6JI%F'8"-+E02GQKJ5 K0]4*Y$1@I3Y57>R13G>3,()N!
MJB>U&5"G4GZ=$J#<(_AJXE+03&9V^JQ'[HA:_N[=V-S? 5I6Q---PM\[=Q@\
M1?$TNW8*Z^03Q.'\9'H-*9GC"_-:Q98B"ZR-2M0GNOH&2 L\>F-T7F<4@FN4
M?:4(;U\_Y=A285)U62-3!<BJZZV#<2"V^4[FH/OA(/\'CUY:@O,MMAQ;7JRS
M8?\%# \?JA8C'0KZ$CPJWH50_Y3&!NIM"J7T3--3GB&#DMSW.:JM5'NVH62P
MP*1?K#1&KJI" FAUS^'DLJ4CVCP\02L"-'74A<*9O<#).VFIN]M_/-WX+ #(
M9OX;@WS QRD?])@H)XG(-^4249M!SB+;?-P6_L6H>D\$+'V%Q\QX>W(Z^()
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M&VCV,J-!_,097X]# U?Z[D-8,3-*.?;ARYF&GD^1%RYH/N@G'UP![ F$;%C
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M,+<;*Z_-?RQ"H#'7T=UH<BS3MV&YA_HE?"8(:IQ1:37^Q%,?_ITHN5".7VU
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M%Z4(.5$72/(\'[8&;@:S+,Z.5G@.XGJP2:?GOT%EX>AH1X$"L(]\3AJ%@-P
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MR>!'3AV%];M>R2YSP]C6W?/$ Y <6\.0DPF%<6UY^_F9YR!Y%DT3"NK*T\U
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MH>2S2P#T\KDR_-A;Q2E<L6 (=:LS_:Y[W1YJR[HT=X2QLQ>NJA<]6DL\4G?
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M/&TH;*9_$MY!4[@4!*PDU IABF'36TE*O / 2@HOA(V67D3+(1UNL/J_.*?
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MD;?3Y2E$S026 ^QNEPCN9F(_RJ@AD9U3?JGO&G6R<H86C_-O3F0%Q'<\CO6
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M: E-@+@SUB)SGL^F=1G@=Q7N .K)_Q#SF?(VP/U=^1OI=+]U%X,U^8?_Z3X
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M)MX_]K,M@<+HWAKQK;DLDF2P ',WG])MN<&] _\^!T(2P*N;MTN4A(]P<>2
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M'S\I[FN5(2 \39T DH&L@)HQQ+IK>+ /K)L>M'\\U>8P]91+YM'(O7?H$D5
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MJT#/5'[1;P^(HEJ6);.6-1D_&]9*9YN/]TCD!3?M__.4.UHQH8WY;/6*Y[N
MFYX7]ZG%:;NW:LGY72FW2=>[[.A2X5Q2+&&SI]&N)(/@IR]SIX-M]/+MCV<?
M3FFKO4QSW%D[:FZ\VRFVPKW*Z^U;A?F. UE_?<IRN?@-/3G'R6V$)%DD&7P0
MZV?B>2B=:T,('@L$=)>X0.DE:=TNE%&TRY5HMJ'<>U5X,<$$NE5N!&(Z,5O?
M#7B'-!D\F9!Z3%VUWS9/?$.I<: MS3 -'#5(G2X$:V@0/.A'82-Z:*F3:2B_
M*E"7[5ZYX0K#KT<=-ND11[ (O8O'M6DJ-<AYXL,ZQDQS_CC2D*N6WM5_C_B:
ML0&U(W1Z+ZB[?)>+";GR03"(5;J&_X'=C%]OU\6A< _RX,I!+L!*>\OFP-/W
MH!JG;#:(Z(;+M?U1$-&]E10P9:N963252AG82S[#/RQP6VW\;"ASCZG=X65]
MTS-UI-0GY>!%DQ.CI?F!U]2S]S9L3(J]4G'WPJAZNJKSI8RP^S;587I_IID@
M\PX99KX&_GRPJ*&Y]_UC-SHUR#U7>M;SSY,%9RH-.FTVE_FG%5F&S-UHWEGJ
M;J*EUNCGJ^=UX9R5G(L9ONY14>'GZ3'=PL_!5:QT>V3-ZS\Z4Q[6'+3;<_ST
M$ZFM[V"G[9AJS%5T*DG*V ._BDO6%!O63LO&XYJQ+&[(:#:OWF5#WNW\JZUN
M638GG^VXW=[SA@7@F\\T7GYYQE$'VYM8Y%[;NG E<X%<GZ:+CCF0"YV?_:5S
M4U%Q1HI[A+?G)<G0'I01PI)*D#LAEP[40?#L'W>_)3'HK9HCCZ[V["XYL>ZN
M=IH&>/(Q!6A4F^<$TS8+C!:]N/=('5N0)E)_L3#W9](].KAN-:H?/6:]S/9K
M.K0E#@IA'A&OA3!E_>YS_F'<4Y&ZMTLO":;4E_;XT&CE+IC*L47'*S[387=]
MPJ8)E:#EHQ3P.LCH2FWHS@50:V,'[[V &MC*L<:DW"=?4^E7\9.NY]=M/*E1
M_=I,<1]8DHNME9F!Z]I!%JS7']+R*5OPXUW?;1_LT5$GP2%358D=):X^)=*E
MY_?%J9X4T#N[^^H/ZA1+^;Z?N^&^<]HQ1UPYI1/[Q@EWR_!AM&1D@4JU8#*+
M)G'RJA#V!G.^J:G^>5UC2\O+F*&^/LGJZJ_5 2<,EJNJ9D+*7Q:&J/JGJ)RW
MS?&Z$'!BQOWZV8=WVX*Q*B@%/,6E=A!YL\Q;4D#[?2CPYV.Q3%'HS?2YS
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M39;8N9S@WN.ICAE_VA!LZO/I9I5>J%V@\<T(';6UQLLK";ZG?01SYM=AW
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MEEBJ/HL:=O1LF$,ZVL.';S, E4@ M)RRWT1@*G6=,CEH;6%)4?;%H#2%4-^
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MLE1',BKD@C%+JG:/SWWG2G).QEKT L=92]^',):GC_GGZM<OW&4E4:NP] '
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M[@GJ#;V*.,Q%LH58@UP[)ITZ&E1"G_]0E?,%?&U?9*!J6RZ#[K+)RFDM^GG
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M\R V?\XZHRPG68$'R>3P*7:RSX1YT_%'[_0R2 8+F3BBB1YUSS?=,V]7OOI
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MRTPR&K2YL:K-]ZYO%?=@*V,S:S6[R1.@C=#2'V%NX(3^ 4TFWM#)VLRD:*]
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M84N$#4V FER#,3-21> UH]BNEZ-&;R0NR,#E:00L.<>$(#D@[==2985S/X4
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M5P3J_Q"%%#.'&H\RC5N%5C"S<KT#2FEG+>?([J??Z*SV" 3=S9L!1:%]1
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M]">,)=>6S2:A'J.3&-GZ>NNP,8'C"&9 VCT 1]V2>5S3.DFT9B K-;R+$6.
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M=_PXOKK2I^*CZ"MF<4';)]/@:%:G9,EYRB!Q)*@5?TGLU%>3:B15KB';,MO
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M+5BNR6(Y(=$J;P(G.3\'TQ=3P6N 7$Y,_7G&WH]VA.D-L1TD:\@IBWROOBN
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M%4%HT),!F5W[;%(+8: ')41L[42<U'BBN$-590J92MQ0!B.I):'QB09EL(T
M+,NYPYN02!5UM5QE[%*PB_BA<@,U8X?-AD!X6%;F_V B^9^D6S=>>?RFE6P
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MPD(+#".W5'_Y.&P=NG5! J8-5^X"B]-:0\LN5U.6 *EP:56<6G"-9UR]#"5
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M9W^S>@UA@U]W0^%__V:G_Z$OROS _P)02P,$% @ P8!;4+[O]<];%0
M4.( !$ !I;6UU+3(P,3DQ,C,Q+GAS9.U=;7/;.)+^/K^"YZNZRE2M8LO.
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MLVO^ZE5^<)6ALY<F5+FN'I%:?S5)GC-M2C!M:B!-;,SCYW7A^(FYZ8DRP^\
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M+PGHUBJY>Z.2Y"*J.2R]W1E<X*9>0 7[$.L6!.*SKFAB>+@;H1!DE0H(=:R
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M\G]02P,$% @ P8!;4%&Z>)F,* /+4! !4 !I;6UU+3(P,3DQ,C,Q
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M!R4&_=$"48*5\&XQ\W]\G$U";.;G_[.L%]=[3V-[ER4F]M 0VGLZ3W4TZ"1
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MGQRDMQ.? [L![5_@[_7C>31#)HNL7A^_+N(T9/6UV >A>%V''D4-^.8S/P]
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M!R*N7:1:\54J)?NZ8I_G^?[+; 6L>YI.VC&88Z=)RAQY@$Y$1 622'X-C$"
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M7#C;2B$0Y<83#&+6I1Z,H- ]'H.M_B E=O^JUO6\PV>B[M7K0/SVL@%GFY6
M<<IE!$F'B.4>$1,"$LH;Q&C@5D<,*GX/9E!2A^AEH R,T0&80?=CX8?/5RYH
MP46(R"=/D4R,()>21#'@P#&AGHD>1FI)W: 7#0P%3K%2 D^DG[^Q>> ?XR+?
M:G5_:.,FP;];P,\V?N\R97/N8C+[<KAD^#R"!T;EMRN>UT;G_0_N/+G%QM^[
MWXJ2'"";,)(T:L2R<HE5 'HU0AI0,'GP![Q#Y=_^CZ[\IB 5/#-_R7U4MNNP
MCSY?29(,(\8B:6U$.H*"GE3 "'B_QD8;4/R.OK3EX6AH*$Q+^F7W1FIUY\KK
MJ<])<_$LKOZ_37XX_^H_VNF'^!:$UWE*T6\\I2HZD$I@RL#F8"AAKI$V,=\T
M"@L-*@TSE'(O4B?-;)Q5R3X3F"'HSI]KD.FOKG^?1YC>[1'VB5_4G[=%QG?O
MI/(1!Y6S12R3$CEO' ([+V=' W62R*E./<(%?@"Y,3(!S0JN3$&;.=6+G**V
MV4)>/U1I)S1E@)4%MHI\2 ZF(Q@*0AON.(W8]$@F+4-C8RW<]S;S_JB56O\+
M6S>M1G02_M]RWF877:9_Y%)KF[7\C>VJX!,S"K85=2ZBZ!)%-"@!4M@33Y-P
MUAQ]/F A*AD:R')E+KX?[M_SSQCR 5.^-,MO%&S=.JAH,IA[8,E268>"LP&!
MYBX0I\Q'2JRGOD?"3QGG2R%2&@W14C1U%C\UT=>K19J&DZN<=_O/]L\-A+2A
M5662<508CF*R%D62++PVN)REP"DEB3-Z]+>\%Z*>86$L13)_M_4TB]C+Z2IV
M^)ZC^M9+O8%ZNG50V8@EMR8B)0!>D2Q%1CB-7(HX28JE%CV20D29*BN%*&DT
M2$L1U4W^_?K0,\=';*"@1YZNI&("&Z:0,\PA;7U$+#B,"--!I,B]$3TNS2E3
M*:,0M0P#W_Z)(2VAOIZ&I6^ODVLMQ/EE>F+1M[:IG,"K(Q:JP)IT&&ODM5BG
M*9@ M,U[>-[4<UCZ,4 \BC3EM_%SG"[SC=RS#]/ZGS%L8!N[=50)Y5U0(2$5
MJ0 PG$ TVNR+])HJD[A+/<A*/RL!-#JT!2/=FM@NU1UM#+;(^O[+7%OB31.O
MZN75_/7T<UPI_QN-KKTZK Q/PK8A7[FH#4_:(\$( 7E-J75@B!+70_LQSXKX
MBD%<C COS>.BGMJI![A.9_/-I+:A646X"3)'#3F5-!*8YPMC%$?4R. X[#G=
M)\J*X.<@)4<"LIP2_= -?[:N\GOZT38?-OJ&MK:M8N">>!-0\#$B(B6H"C9R
MY,% =58*17B?6RG)LV))8\!9S$'=TGMLTSW?YA6Y3 !2&X;4T3_4L8<J2N>Y
M# 2EZ!62#BP/ >HGXC: A:J-5*9/::'GY;4>#=-ROD9W$\BXN/Z6_7#CN]CH
M;]S8LI*4)(;SK96"N)RG;@#<Q)$-/ 5IN [&]Z C]JQ8T_!@%CPY_5S/ <B+
M67,V6[I%6DYN\B8VGZ4^V:P"#9 8:Q*2(4J$E;"(>OAAA59!T^ALZ"/5GI6_
M>F @2Y'-.Y"X\16PS9!+Q<;I?)OX>KQ!E; S,!-0_. 7Q%0*B ?XTU##K19&
MZU[2JDRB0B%2&0S"HG'K.<@ZQ[>L_*+;HM;O/UVI)*GSE@-2.9/>*(V8E:#:
M$?@U:(Y58CW(XUEYH(?![W!VU??9>CN95M\WK[!QRG%B41*6(,]%1$&"_-5<
MII2XI!K3'M2CGI4*,Q*BAZ.G[)::PF)N#DS<V*Y*U#&>=$"4<X$(!:N2>JE1
MLM@+CDT0L8]X>E[^ZJ&A/!SIM*ST&]GO1C\/&U?2&!PB20@[EF_Z41*L1^<0
M=]A'HIR(O$] Z_/R.X^"Y^$H:9UW?..H6LME,!7OI*'M1%U=.JQ"\B[(?.$S
MRS$NV%/D@HE(>N%SRDCHI553_,PI;B2,#Z]:;:IFN9>RM:G#2OE<HSL?=QOA
MD<!.(X)CKHTF DFY))KL4Z#Z6459%X/XP$+U6^'#/2GOR5ZJH$*D6C.4(A@\
M,BH/"H:&-4@Q&FL99WWR#>FS<GR/B^OAS^;6T1%[G<VMVU;2)ZNIRI<Q,HNH
M-1(%B@/B,3!FO*&NC^^!/JN8[3'0+$5%3T"TBFKHF=_V2"<53EA9C26R-%@D
M0[X-25F#@@+[R&:VW>?NCQ\@I_4H\MN&69EBIS3VNHVO>3\[\0!D$S>70=MT
M<+-;3SGGB]@H$M*)<&1S(5J, 7^=>%1$)II,CX"]PP8H]*:!AV<YHV-;\%30
MQQCF%P!E'CALYU_M(H_]^C(]/:O-!X;[]%AIYI,45B C"4@E!?N?!.F1H0D[
M%:R,O;2Z0PKAP<FO&,0'8WM/%G#:A>,]V0F@KT.2./NS23YT30*L>\]0Y)B;
M &H1%\.43WR.S&Y(6 ^L^]U&)_;1_1[II"(Q!<,\:"[.8-"");!]8Q1B5F&;
MP)A*?>JPE3$I?GS=;YB5.8@LSE<P7G[*JS0__QH;7\\W9F=L;5LEQ31C/B"8
M)4>>!P$LP'-$B"!4FD2"[7/"?DCYVGN9-\G7@< \!!&MDZIOAMU5:WO8K+):
M1VM <*1(!,J7SZ.H<O$IS1/1'+0*=O07$!Z = ; \1!4\WH^7^9@V9P(N_;M
MM)M@E0@"'\1<FC!_TI&>NG=8!:%3THRC)&%?!:(2,C;'P8'AI!P6UN@>3.J@
MGK@Q*6U4A ])@Z^G )2=O%FZ2>TO04]H , =R>[1/D#;$);PG+]$+$4Q5P2E
M-H%!)*1(!I1B07M$/1\T<K4$I0T%ZF$97+ZB?#;=CY?=:9O-*Z-$D$@+C)&2
M%B.O>$(B7^X5@W:2]O#T'C2VM0S;Z@?FWLGTCP_FM]DT9]LNFR=+*71O7!E"
M%)C%$K%\&873&E#C^N860*HBZU/8\J!QK4.1QJAH[D\;*[?'*L%_=4]7&[T?
M']6CMS6I @<M#S.)VE)&0D8@:"_YS<B=5*3'Y2Z'C5 =EA &!;&T _/;[:#V
M:T[G_SB;9'=']L7NFDBQ;Y<55A$X)U4HT>"RLR\G(H&9X2@-T@5FF.A1\_"P
MH:R#BZ-R()<BQ94[[3+==;%=3GLY\V[==F?U_--L;B=_;V;+3]"BK1(P7=33
M90SK4(/9=).?X?"#JR0%TP?GI$[.#1+&<Z1XC*!IR!"32]H>?XVU'\@U^T.N
M^+>]6NS.AWNW+:R*"[U>:<29%X$07.6<WA]GP0L@@/DU\2/PO_ISO)MQ7/PB
M") ,0 P\"UYS_>>JR(HCCZ2B#RS&D4-RZ^UPUF1U"$H1P+I)!1',T__%<L:
M[[L^/V+EXF]SS2;.Z8I- 0_[QJ=>Q31KXNHY4$/B_/SKHK&P)J#S-->O <SV
M(IM<+&HV@?%]N"E%MSGZ<:RW5EP;)XF32'EF$.78(Y6D1L03J83SEKFCOPQW
M7]+Y/BSRB& NEO9[$US:B1\_\G2E@\,DR( L['\D*$L(L#9(6\?SO7R6TJ._
M N!HUOYAFO @>)>BI77X\ V$#\OA@?:X4OER4@[\"X#C!EK;H[?*:>VQQ EA
MXQAR$@Q*[L&VLTIYIZ,2T?<XY2Q#B[W7_+N+94K@6(K&VA)D.6!IE>>U\5:P
M!X]62@8JDF1(8BL1#]$AD@)&FEL6C$Y1ZQX:%RWC5!F:/ 9 J>3:7Z;MZ2+W
MGJL< ]O1,(\P)Q1%*SUB 50$3&( 936HQ'KX"@I=4=-KD1Y9\3[PE!,G\PCO
MRFZ$,QCL9-8&*&ZO3;*Q7143M=Y$F""6"3DN%6),&V2L]C%Z[F+L4>^H4$;'
MD.0P-%S%JAK%5L]J Z>;/^*B=7MMHXVG&U6*$4\-@.:IR'>).HNDLP9%SXA3
MGGJKW+''K0Q*&(-B58HJ_AZG(!\G.0,W7-73>K[(TO)SW$X:6UI60G-);>:1
M/E=2L30@;6Q -&A'?522]HDW+^1S'I(^A@>L%)'\X#=0C:E>'JLE_.\[JX[D
MSJI_1>+[X6^Y>G#AR49G\[TG*R*C21)D@Q"4@_WO"%*YJH!B,1HE"8Z^1^P3
M_]>FJ_Y@ER:@F[HZ*Z0ZT-']!I61226*@4=S$Q$6@F4>+1&Q3D9!8[3AZ*,L
MCYV:>D->3%>W]72><8SSRRE !$ LZ_G';Z%CF[3U;6VKP+0P2B<DL]+I8.*@
M?DJ+!(G&.4^9XCWR$,I$;1XKJ8V!_MY1GBVQWP:5K7GIDPQJ6Y.*.ZFHSMY3
M'A4,7RG$E93K>Z 2 Z/H^*,\CXUP1D"]))>ZG+Y:SNMIG,];%)IEFTSX>CI?
M-CG(.<<W?X[-]19^U;&7"CMI.*$2R9SD$Q)8,T8' WHD,=P;P$/UR&O1__*<
M:[QU*.; .3J#]/399/3PJ[?P[CGUN=9W-QBL$)W\PGK#KV %N&3I)(@@;5!
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MY[*EFJ. IXPD:]_]<38!)7*>-8G%=?DW;H=YK4OE'PYP^MN?_C]02P,$%
M @ P8!;4/<:1?#P=0 1*X% !4 !I;6UU+3(P,3DQ,C,Q7V1E9BYX;6SL
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MDS"!&9/*,N=5^!>%W.#MV*&'<LB;($=6R,:HY]W(WJO>)M^/Z^WI,TD,^-)
M2:>0=%HPBB"MQAZ0:>X>Z7S?TXG>6L@^6(3C+O)[Z?/B4_K[ON.T(R[XD_I)
M&*% >N,$5@CPS EJ,(".5/KVF1'.YZS.^/[1&XH%D4S_^)*S?(2CZ-[G[<>
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M^5PB %+* &HU0SP,UE G-^-S@/%*DMQ.;;LVL+E!IK+4=\R[S52Q-,YG_
MFLW3Y2I?I)>3A]NW-_DU6R;:"2?#A&0,Y=JS,"$)6LD09!KA'9@>--LY3CWJ
M^FM:W#;7=VR=0,^D%=0HY!%5C@2H5)"%2XZYYP(UUGEO)P5GT7D#K(;R]WU8
M3(N-JVOS[P^+;7V,)YZJ _OI.LT3JX'D+$B,(9=$:BRMJACOF6G.DM[.!_K9
M6O< UB"^0)/?WF:;R">UF)F\=/FEBT$\?7O?_.MDM3V.N[AZ=MJ2#55:YL#@
M#I?J>__>067#+ 85HX(J%B]MQ9^ )YPH*.P9JZ3T[QUTG"-FL63"RR"T=QSQ
MK>P$&C#D-K*-=["N!AMX!T]#J"?O8$=T6G];IO]8QT3^]]O;C\<JGKS=(M$&
M0TQ%@ )::\,>#0NP!84BV>)4= 2>Q-H*?TFF3K :RE)Z8[1'4XSL;9, !XRC
MG!D8K$*"E 585S)2#^$XO8Z=:>XX$UKA],?DQ*@\E..CPB@H<#3J_<WG$ZRA
M,$):I#Q@RFKND*AD4V),%R [U--AS3="IL_KD28&.Z3%W:18/7R:W!Y*#_#6
MHXG'2##/M-3*4L\DY]!5DG#&FKL^>\X4T(<)T!%(O5X\3^_6Q?0F["QW#IZ7
M(]X[UY_4/J'4"*YB!05M.6%.^\#XK<QA"D7CM 7:JS ?#JP_!U%&92",E!\=
MN=>_WJ1?8FS@W?)SNDQ#-S<?%LM5MEJO]B>KJ-<PL0 A$MV+QFG &7>,DJT$
MC'L]HFH=/6DF[Q&N/B>"CP'PS:IH(AS[S8/7#R84>VEM^"H@]]8J3*RJP&&*
MMO /]'R#OB_CH#5$PRGZX*[OT.,)QX J0^)5 (6T@)0#54FDG1QQQJ$VZMFK
MY=;(_!%T/KHU_-RJ[FC!#LO&.LQ/T]3D]VDQN4Y5\2U;;2)R#J_8QULF2B*#
MPEZ7"Q0O!TAG#=S*P*4>4Q72;E21]PG/4)X;'^%./V;WL>CE:K*XSL)B5=[-
M6>J'7R?_E1<FEK\YXO _H9>$>\4<U8)"#JU@1,)''!AFS2/+3S\(/_LBWS]^
M(^#1X_@/[@(;]I10B!D30FA" 8F9,ZV6%1Y<(S5.^Z%7S==G5X>(_C?31F6U
MO&>"G8=8[O9NGC]L]NZ+L'9/:V3&W]LF\9 #8Y5W1DEBK,-2XDI&*K@;CS74
MNQ;S?C ;+%]%+/%6(^KAV7-)/.71Q&D7)$ $.8EVP24<(-O\'//T&^"C,7/:
M(#3846;,6:'#EF 6LUH$M#;7%8HB9F$IX]STP^,SV]C64K!'Z1:SF(&HUAK4
MQ^N2&$OMN;/2:JW#YH594QT^AJ](C]PD:LB2EP>IXP'VOZG;'<*CM+'>,6,[
M<BQ]3I>K(INNTMEO ?GEW[+5S7^$7V6+ZU\GQ=_3N-+/2HWL-ZD:]9-0(DJI
M"&7$">8IQ[:2CVHV(J?3.-2<#P?V4-/>Y[0L1'L93]J^!A27P:*,@]8/3_]R
MQ'BKWTD"O=?*:T 4=]!;*8BH=DF2$]]\BCH]F\MH++O>X#L'B8ZN?*\?3J0W
M3AA'+*38$,T)T-5YOD3.N'&;7'VH[P!#6F'V1V'$*"V9<1*A(R/EEWP^2Q=A
M(;O>16D<MD;V-D@4A<H$F;T+TR*F0$%5V7@2>SQH'H5Z9D<;V/,>,.GSF/IK
MMHK+W(=@OMQGL_5D?B ,Y<UG$X*)!%8+(* /;#:$2U_)(JEK?D#-W]\:WQ5*
M@VH\&K,EY:/<-]G=U]PM5MF!F;Q!+XE4"#I"$/>><4.ME[CR@$HJ_4BSYG2@
MST/,Z 6S/Q]W1F4>C)LRPU'%W&3IE?N>3LMDR!=75]DT+0Z6BCK0(D%<<N["
MC"L#>$89A$PU$2MN^:"1S,<#9GK36MX'6J/QN>YSYL3:!*N'&,=;K$NO3YD:
M]>O-9'%1YEI=_A*7[^6'Q65:9/FLC1^VHR$$ \\":SW1P"*O+(<,/VJ BA'%
M9/=\_WN<@ ]&^32&N)6Q;LO5$AYBYO,G$\1 F>&)<:$%04A94VTXE$*VN;/V
M7-F1FA*H%2Y#Z?ECOEP^)O1XL)/;R76Z_)*OKV]6_S&9KP\ED3C:-C%(&B^M
MT@PAJZQT&E4R:X%%\Y+!Y\J:U) +72,U%#N>YW7?SG*'/.QO-T@4U]IR%9@O
M1:POR*FI8CXTU+QYQK1SY45JR(-.X#F/\O^6QJS^Z4QM0I]MMBQ3HL=J-6$A
MFQY)FW]B5PFB0 -D K@XNAF#Y6<J@#4/_QPPL&9$A.D<N%%0Z7,: :[^&#/(
M'3(W3NTJP8( @Y@7'&'#L?>:5>D9M (M*O?V5I?A#%1J#]Q@!DL<8#2I#ADF
MU3.)$U XI81'CB@@ !*L.C+73,(A7;SG-4 :(C*45B^W-VL?A;;K],/B4_I]
M]?7W='Z?_AJLIYM#ED?-'A)EL$:*,TI]S$#L$;=5>(.F&#<W1<3[8D0_>)V9
M+U_2:;Z8_6<Z.13.?;1MP@C'81$5GB!B)"-A,65;F0TRMOGM)?F'X$ACI,[,
MCJ\W6=&0'+NF"7062XQY^#\&D0SF%:O<-890W=PRA> /08ZF2)V9&SY?%ZN;
M9N1X;)L@XQ 4A'EJ(46,6F%VWX/2NL6!SSMSGW8-U;GID5TU9D?5-$%.,*69
M#=M[*7G8X3MC=Q\$<"U*.;PSUVC'2)V5&^IJE1:-Z?&\=5A.F9$X(!IC<!G7
M1H,J!9QA0#?WE\)WYC#M'JS& 655"0L[>0B"36/-91/=^K'.R7PSID_YXDA5
MB9,Z2<H*-\Y2A(4,HT%!PMW4*!5N<0;W3OREO6,VV)2Q&9W/BYW[/T;<+[-9
MNLD;L:N<^V%QOPG+5]-5=G^L&D&K?A.$F&+:($X]=XIPK=SC]*I=BYB$=^9>
M'1+&QA/0EON/D9A5S8UM!?A]<\ZQ=HD'&&KL!5'>(DL\!KM5UA)&FKM"X#MQ
MC?8!TV '].N[NTVB^,G\MT6ZNVZMTT50R6JY.WZN?G'H"/_4OA(."$9 >P"4
M%M)+P&'E1;3>JQ8W^-Z98[5OZ!K/&B</K$:MI#9])EX#B!S" %"'J2H/.G>?
MD<(MKDJ\$\_KT! .-A--YI,BK(=_BS$-:C';1O0MG\9-'9I\:C1/L$),Q#I!
MP!H+% P3,*HDIQ*1YN1Y9R[9'M :S8H517O8&&+KHZPYN;/$,AAV!$Q)CPUS
M4*F 484*$*9%5O)WYKGM';M'1IVG5M=3 :,YG\^S6;P7I8-@86K]<I.FJP^+
MJ[RX+:7;WIKZFI>GI.>OJ57>X.G__6_C<K;W7DZ* ,9-NLJFD_F>00PP2:W"
MP*)6/M:H'?;ZX40;(A6$\9(<=D8RPV/"4!S6:H?""EVKO$7/DAVM#?;LP<3%
M648@S1UTT'C#6<P]4$H$ 4%#7F X6 :LC3)>3I!M$)B,NLQ7)5F9Y^OBZLLJ
MG_[]6*&O?6T2HUW8#"OG 222(..#@5KA2S$<DAJG7:!LJ-]]-&D)S% &V--A
M'KWL_OKA!,&PX6#><B"<I<!(CE$E%?%.C_,F9(?:RGN"Z(]"@/,H_EC9KC'H
M_4SZSA?W:;&**1XO0[=I4:2S<M1'4UX>:1FV'E1"Y1P0BAC+':=<5/(BR <M
MX%9O*]5&:2_UWRDX0Y%!S>?Y[]'<]GEA\_6WU=5ZKJ9E /GR<SI-L_NX&)IU
M41R.Y3^IGP2%;:G @%L:4#&>:Q%+X&RPT @,60VT;NJN[NS(/J%J[!B^+/)@
M*JT>8G*Q5=AZQON*=^7MQ<7,9XLXW'(?_#D&B%]<_;;<I(<-XU[?KLN-LDWO
MBG2:;2Y$+F;J-@\?PS_W>6SZ?VFB 2?".\@),UCS,*?'$QHB-7->,]H\L*:W
MN)H.2#8Z7 >;R-X>?/AYGKXAQ5Z(#LUQ';TB 3I\NQ!+"0GUE!A):/5-X[#H
M-+>8>HOGZ7+Z.P^*@\5V/%O[+R?%15&"-RMO=%ZF17D__% 01ZT.$F=<L$P<
MTUPR;+UTQI!*>FE-<UNKMV"@#CG4"T;G84@YTJ5:KV[R(OMG>BC;P^&&":6$
M *D=<-IYCXR.,9%;::WUS8]2>PO?Z8T1+;$Y)Q,^+)?KDUFP:91HR)&GC"L@
MM, 6AVW%CN\$TN9)%GJ+W.F9 8UP.:?V+]:KY6JRF&6+ZQ,I\*1E$L3SGMNP
MQ03&"&UD&9NT93OWS<_%>PO#Z9D'S<$9SBES>YLOFMH,-5HG$E!O%?<,8(RL
M1MK:"D_L08N44[T%VG1(BNX!.@,Q3C 5#K1*I!7$4 Z\1)0@IH)HU6Q('+#-
M[ZKU%C33#Q%: G,V ARU$/:T2!CEWC!NC#1,:>N0BVG4-O)9B&N=0@]\2;%/
MS3="Y6Q:KV<9'&J68.,9!H !1:T#RAM(*N0("QNEYOI_#V[7#J$9B@1?BW2R
M7!</3P9]0/=O/)UX!8CS@G%*/?9(FV#Z5G)!PL=XN;!#E;='9*"8M<?@IYWT
MRXLK,UG>^'G^^[[@J_''/5DIM/26:HJ%YYH;9C?7KX1!@M6KES&NN">L-#&,
M68 -]X!0HK;!UL) BNR018I.C7NJK8S#<4^G(3#NN*?UMV4VRR9AAIC$!+>U
MXI[VM4F04#8 X\H,G0 :@0BI@,$8#%G9O$W<4VW]OHH?[@:8 2\H5*.,U90N
MKIX4O3A> .UHXP0Z@F!85BQB1BD-*675YP;#5I.,/"ZJO39?WU'H![(_"V'&
M&4<U1IYT%!.Q*85V<765%K$PVL%Z,6\]FR 'G<$*!H&A5I8H)ZNI%(6_C# >
MJDOP\V[A&<XMG]W'U)GSR?1PG:###9( CI?*$>F@-0)[3!"JI#/$-4\7UM_.
MJWOE=XK14 SXE*[BUNNRR.^SL,_2#[\M8UWL7:K,Q\O^ZMNRK&)]@!VG=Y90
M1:")AY5AJPH$Q\AH7*&B!!NT$&KC/7O3W4;O> TWC^17V2KF^#XX=U0/)1HJ
MR33P&F#F% A?QDX*+!5IX9WK2^M]JNK5_-$0I\'"SV;_M5YN+NY]S3_'5(C3
M;)Y^BC<*I_EM&D?^->]N5NGC=0GV(&A!<N"Y1,H"J< .629:!)#TMF(-R, 1
M(#X4E_TD*\JCT4>9+Z[^-BG*"B4'2'FP78(=8=H3)(F%4".*@*@6!!SV X->
M$ZG'KO.J/.\/W.$GQ<>AEG5NTIG/BR]I<9]-#QYIU.L@,<$,%93'Z"X!#;=>
M<%U)']/=CV_B&A6U>D%Y*(Z==NV@1JL$"LHH\Y1IQCFA6&)JMG(2"TSS;*V]
M16>/BDW=03L4A7X)&$>,+A:;'?"SD/,Z%P/J=9 :"G15#LD+ 4!561@)3WQ
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MY*; B3TE1 BBA")8!ZP!II(]VH,<@!8':WWQIT^EOSQP[17, 8_RIVDZ6_H
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M\B_KUX_A8'[(96485,?G^NO$Y9=8[I"$F$.+&7-$$Z@J+YDR C1WX_261F1
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MQ9_G?N6+(KL.HY^7F>UNXYU3>( W1]LF8:I4& /.3=.H[@YK3(J!NG1""M!
M]:#/-[(&=HG:<%N<\F)8><U]EJW685D,L^0Z1D7H]>I3OOK/M%PF#^YFZG61
M8 $0 9PS"(Q@V!ONJ^A2(]TH0Y]ZYTU/X#4^ _R<3N>3Y7)72&J7\#ZFG"J'
M6J;%S[ZM5]'W&[;R:7SZ<K*WLG+S'A/-@:&($ Q9(Q834$5\6P4Q\U+:O;G
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M]J?T3C!J[.C]=5+\/5U5]]/V*G3OLPD6W .,!) &>BXEG8W3F!Y\U#I_DX-
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MX53N+8O7,"3J$<51&."GUF0_O;,$&JNXIM@BHTT R%1;4LH=+Q%AI'W[[KN
M&\TQ6.D=46Q_7XECWN"PVQ5AYV(C'!Y51X34>M_B7N0?PV_=(YB#$NSQ_'E6
M%IQ99<5;'\XQ;M7L)D'*2^ D9PXHC*#2R%>A)]1(U>+([=UZM@? <5R,.I8C
M]X1>$B$X$<PJJ@VE@ $(=V9!P@T]U#!=^L)[Q_&45A93VH47/T6U-?8W?FJ
MH\2&3XI)!ICF0"@DN5=5K!.5 K18^]ZM[WP0),=@63V5X4EZA"_I-#P9*\)^
MB@F2GCAA&EI=)[\G"?L>[(TQ3FA!I#-*H&V$MV/A:VT1>_I']<8/ O10I'U>
MEV4K2:R.L%P5ZSCPIS$[]<OB'.LH@8)KXSEGA%N*/==25W<"F22NQ63X[OWX
MO2(Y&EZ=6FAI?Q>)]PAPB8.TT&K,H1.F"LI@"JOF51OAN_7I]XSA*$RU\I_Z
MI=NXL4?LS=X2PHSVU'$E-;96D?!U53LB1GR;H@GOUF<_')QCL-RZ8MF!SA)#
MH<8^_,](C2 DIB=::"!;3Z!H7?KTQ\,S6$CR>-Y:H#DZ^3[W[+5340KB!1^
M<3K+&G27$&\TXA [%+;A1%G+=>61YL[8YFX-]/[]^_WC.5PZF]VFXW-:7K[_
MFK<G7(M>$X4TD,A)8"%S2ADBJT22C@.EFQO[Z-U[_8>#=2CZ[<OT\#%?;C;%
M0;P#/*O3/-%68BN=,D!YA:10<N>GYLC(YE89>O?^_A[P&XHYET5^E:WB0 _P
MX_&A!(<MBD&,2R$!AX@;JW;3+["@!0O>O9>^,4J/NCY'B;.GM'W*@W=7V(P1
M 02B&%)&P_<5*XIR+"6TR#G)Z3LL;(:#.&&Z )@&(BJ'P__05J)@]K2(7>N_
ML%EM91PN;'8: I,!"YO52F<1IH39>KJZ*+ZDQ7TV/931YJU'$X3"-LHRKXB%
MDAJO8QF.K?B*#UI^J$U&F]I:S#O%H\]$)=OA+=5BMAW@\F!BDKW/)\&")$IX
MB3W2CGM)G1'5ET*@&&E-LO8J>JWKSL#Y8RC^/ H_D(%F!/KN*(9X.X!8?&=_
M#LH]3R:$*@8,\ A2"A$A+OQG-4;$AM7;\:PD'6"==XE'8YU]#$-?+%-?I&F0
MI=QR?4[OT\5Z?_;(6NT2H DQG,, 2*20VCA;OR.J!:>DG>@SX[1:7$G?YE.
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M("H]JISG,;G$D%?XZT:BI$]@\F [.S?#?%@',>?;/=/9OFV1$E;?T8O&8
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M_Y(8%\0]AD']QHF J-XQL.#Z$98;!C820U \["ET_>Q(S 5>@-N''39NS2<
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MI'C8?)OE^6.-:[!OMDF,-@ )X3@ "M'(".Z D8I,&22QA/OO;10\AOWG+I
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MU$EL' ,*D.$D69W8& ];'[I]KSYWVLKKF[^]]-P:FQB5K=^?5[43/.^OT4B
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M*>R(]ELA]$?CP2B]X6-0_WG4_B5=9'GQ*5^ERZ.N[E?/)@)*&O[G$0" RT9
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M!!]N+=[914P3MBYB^L#PP*=\453_61K"'T\)BNKB/0G44"@B@DV#C-04 ^D
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M7L2<1(\?Q_-/Y0#)ZG:1,*0PH2C6(G-$6TJLJCYJATR+8[_^G5QGY5A/ ]&
ML1*[TR:NO6T2KI44!"))O&<6!)/!5" Z;%H$??;O#3LOB3I"=%2A5X-D)/NP
M"#^F7R??AWR3N8GYYSXL?HM$R*\7V3_36?B#3A>A_V,IMWH8SS:[X?;]/I#\
MR1\''\UH0NXN[LK:FXOKC_ER609@7VU22M8*I*O1.F$62V@8MT00R0%"Q%$6
M<V,#8:6OE^M[:-F/!;T=:9E8ZI 6EGHHF!3&!&'Y5F9#M&I1A:_;4+9.]9?W
MB=&HP\YV'[9:KV[R8,L\'#D5>;M!@J@'UEBBG944"ZDYVD&",![R@/VD0Y'.
M5)WW --05N+KP1YU!.]KDE!"..2@O.[ M4;4*5%)**AGXSZ!:*NVHRQHA=(?
MD0^C=/*/A0;G47\87!HV =.R:E7Q<-3)^N;S"37$ V U5PP)S26SWE:R0<V'
MS#]:<[/87DTO:Z-T ,Q02B_O'L7]<5#$_-_71;8,.X"(_/%$<8=;)DX:"8")
M9V-AZTP9-0Q75A@W8L@B7><B0K<0#46)_;91H_U%HCEC3"H;!+4"62&@JX@?
M/H$6YRJ]S0CGV62<"-1@1W-ONT,.G;Z]W2)A2G'E0'B/5AH JI&)GY$SP"%'
M8?.X[=YFA#Z)T U*9V9!F#*+=+*,A1:6P6Z-MUH#B)=%EA>7:?AG?/8R7Y8*
M:T"9D[I/HGT&N?=..0.I*P\4*TTX3YKSJS<_]1GXU2>D0Y$QNJ<GI8[F\_SW
M>+&ZJB42%^_H=:]\N9O;^0>(=VI7B75( RD4EH(X;[SPE.S4@4'SPQ#R'DG6
M,WR#[WR?^]SK;'R?MT@DM"I 9SGU5CKJK!)@*Y_3##6/$J;OD1[=H'2<!7M*
M,NT5[=G<%\]WW]#TB3TD0BC&I59,.^41EP"9RDO@G"/-7:'L/6F^7]0:,^'E
MK+0,/YCPW]GJF=QA?&F\)Q'V;#;>;<CO;@^4Z6K5:0()=@0Y*!E%&&L2CW\K
MR3USS1TE_-WQ94@@AS.89]ER4]@JG;E)L0BXQ0"\O$BSZ\67];=E-LLFQ>$X
MG_J=)(X;Z""PV$BKA:$JH%&A0)!OOLL6[XE.O0,W6&!_^ +69>3*O^??EFJZ
MNK@*3_)R0;V;IZM43:?1H IR71;Y?1;]VS%.XU0[IM/W) +R"WB0FB.M#5(
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M$J$;E(9C01FS4>9J^; (N%P'WAZ?%@XU2XCC4 9Y"-:,J\TA3O'@I6V>7Q5
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ML;OC79MFUKU?'F \!XTA0"F."7+ <DL9 HR2I6GN,W^'#NUK7O<;_MTMY[?
M"!9J"@QV5" N.$2"K'#$54]01*Z)YL[9"=DF8-)<FG!3IDXU^H2Y*9:9D,H
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M.@X-XF*/,NV1@IIS+G,OIL^!#I,6^'\NJVZS5=[4.43^\Z\'Z8"ET L';4(
M8F%AK3)R3GGW;*><4["S$OJ]"#+)C7 S7_W#ET5QM5AOHC=3;H/7OAUH5%PM
MXTH*JRR!1'$":LPQZ6'ZY9Q5GL4F&( <9XSD^6U65B7[OQ5OD33-O(:\<=I
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MD2[9F 8'K:H= IN5KJYVU3M>P.#^*LK;^:IX'PWM7I$AP\TB($T]DM18B"C
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M]#;OT(29_I9JS-G)9%^=.,? M5/* Y$%0#B\E>]50"THQ.FTO87.-29_H[
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M);XVPHD441V?(&N-9VN,@FDVA^C%!>MH9*2@G$.FC?8@"@MJ:CH RS*ZN<J
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M(*5BA*?3/'HI_//# 3M/K2'06"\DTM&:0GS/WE2!/#6 :GU>KI6?X@NA0&R
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M% @ P8!;4+\K--'% $ >TH- !4 !I;6UU+3(P,3DQ,C,Q7VQA8BYX
M;6SDO6N3W#B6)?A]?@6WNFT[RRQ42? !DOT: PF@1M-*22LIJZ:W;,R-X<Z0
M..GAC";IDJ)^_0)\N<>+#H 2>7:]%0J0Y&\YYX+'-R+Y[_^]^^W>^MK5E9Y
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M(Z:K*,!5.1[16^-A6X?VFG?S\5'_>7B578LNRBS_?'@Z$D2Q"VA,7!O[E."
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M$8+&EW5U,+L64=+CS-,E7GT<R;P74YVN7,UV\?V'["8K,\;$I^Q['3/'?]L
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M<3_/S(CV3>5R'6HVV8O'UU]K845-<3[DG[^PG/O7*FN2Z WUJ4-BD,08^B[
M'HSC_C"J"W'LRQU5GV9+I@<IG59O +TJ;EX=JZR=:9FB/-)4JNB/20XGJM#
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MJR?3&!&^3SBMOJ##CO^#WU_\E94<!Z9E=9*6Y7U^^-Q,P&V@C]T HS@):9*
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M;PRBU6-\L#BR8%8O0MYXCJ^5_M5D_'J]>IK_&V!-ZH33F1J?&230\9W0A2Z
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MY .D#QYZ6NB1.RDB1U3(3$#6H2.&?"OF:-*2S^EF3&9X:M^\['%Z7(IZ/H6
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MN1![(]U8-__KZ+K:O7IRW[H)UC1UT9-"^"1VW G+C$H4D<(Y#TYF,_\.5>
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MXC9[4U35HQ(5N6'H4C_ # R@KN>2*, VPRH2V$BM4_,-!;#(LI!%H=FXR>?
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M3#TO YP<6\WLN7.WDZW9GB,8TA>;:=T.U,DB^7[\_(KE^:/W<Y[ K@*/3O!
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M_CRCEF0C^-T-6++^FQNKE"(QUS#U9WZW0_7Z\+X1ZS^7155MJ!U"&D;8\9S
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MTBA_'RG 7&3-O@M88XR%;K+O[75)_O R&XMC7:;;^ICN^>MLS=MLYYNM:)R
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MW=@./9R0!*&(.MCMSU:Y"+OBT_#J)@P/XP,PJT&F/E,[@42!:?)Y^),;Q-9
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M#O8;.S!QL50'F)_ '<.+]AT#[0O(EH&:-YO->CH \G[%A1M$KCH4D%V\+7=
MPE7MF6B_+Y<)?H( "&:8G\ 3<YGK,(H&]\%U^X*[:!/:19?6CER[ >ONV_R
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MHPP9%L&7V, 3D[NQC$IIG"3D2@G:B?XFTG0SI%T1L.T<+L,V=+C2FE@[(F)
M4_[XN%M]R]*FV6:_9476Y.N::>%P;W/D>A0B&(4QM0G[J^^X@RWHB,T.QUDP
M+$<]+C XW>\K?]Q 7[Y?_^?T'&L__;MM^1+^U?[OPD>#1])Z'EQFHY+.55Z
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M;-Y]'TCDV\2E['\1(HYM6<B+]BL3Q(JEJE8#YJ?0X5_?ZK#&C;N*M(]?()Z
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M,4IP9&&*'11BM#^:$C@1BE=,U6Y+41W78E)[1"8M"B[)=^=C#!'F+$_RR
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M%]EEDSW6*_;9KNW@$,8A=.+("I$3#38#"GV9)=MQE@SK[XD%1(X/M E5VE'
MTBJV/CL=HW("/8),(TNR9WDZLQBKA]]E+,-J\J4T,0(EZL,O.ZZ%Y=U79JOM
M>!E:#L:1Y<<$.@&3R,A/4&<CL3S7P\*%H?0G&U:D#D_;;[A'Q"\A7[-?SM?I
M%JQ?S*'X)N3AQP3/4BC2*5 Q&F523HD.) Y@C)(C41D:)4FM))0@2ZP0?.WC
MJ0I0F8L%E'[JV$L=HT%".O>S]Z]EP_[,T^WG?)O535ED_3G-%4G"!+G$BB(_
M(!1:GA?Z@U6&0FCSJ"Y;AN5U#PP\#LB&D\(2$JP%%G9A..8T]K-\=.-W#
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M@QXM:"\D!GP5/*L:EB5 AQ\<')!8@M(?#X%EOEE#(:=Z;Z+ P>Y#\89YE55
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MKBNU+*#+IF%Y&& RA7A\S)ONY>QFEP''<BPYQ=#&LIB>S$&PG-KLN3U O ,
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M3@X3 Y((=2B:!HGIPKWOS'!75JQV'^#SOQ[PJYX5,APBP>I^,=&1K/N/ G-
M#EY !WOL%V"/'AS@3SPE&,/TN<G")!%<R#1B&E]?3S F9%AHZM$GE4,WX'S+
MS)9%EOS@[32R%;5<F[@T]#"-G=BCKK5?V(D]Z GMS-1CR; ^[_& K ,D4<2.
M9U%@PC I@7(2.M2BAZ;?!S:3&=B4F 5,RJI:X3^&7;$Z_R,23I7VVLA;0#6O
MSY?2Q/"2;"RT>WK:M@;3[>]%MK^"DV1%=I<W];Z%R?"%56!YKF,1:EF8A(@B
M*["'_?\QI1C+G8K5;U_F,5,Z%GMHP7/;8Y+L4:2?<K&Z>UZNY1+%,59P#!8,
MX"[ (1#DHT"8:8<DR^>9BMI<;)9111OT[W73)<-,"E7+TB#Z>I^?HEQ18ME.
MXKB6Y2>NC]L6"'NEQZ[0_67F41BNLM^J+.@7Z]NCR6W_TL?V((9@_]()XB)0
MFR\F)%/(\;XW"[@Y=YI\ZC!)%/V+"9?:A,!HV,1F#&,8/#6;F"0J"YAI3.-G
M.?5XEYRAI-NTRK/Z7[P=&2XV?6/S^KB/Z\K%#@Q=.T!6',46MMG,R!E,^\CQ
M)"<E.DP:GX<,J/[&=_CL<4G.1;20*SC]F)I5R13'X3V#M-@ CO ")#_6V]V&
M+]_S<^_\=>IO9;EI?^!;5GUGV,&W<CMU"VP!$L]-,W3&8"$S"ZTNO9Y,Z.=+
MV\I,.UZ[MP.[#D@,;1CZ$"/J1C"Q,6:P!B!6&$E=[V[ O.D90_\ K]?5+CO]
M6$Y&MJ9%&;,\&Y@&=&$X1KRP99DWC(Y9EU$/ST+DTZ"#LBLS8[D4E5:\W99_
M\BJ6EE5<[FZ;N]T6K]LV=?5UML[R[WS33+2K*KY9QO%\-W2M(/9][$<T(*&=
MA+[+ZMO$(8XEU29.KV7#@KH'6[=;'C8]7JZP+6 YB=5,NIBZSL>WG+ .F, !
MU 78@^]VG%39)F\ ;]-\ 7K$TPJK%)EG--5,4)8AIX9\*Z<8UA+KVU^K\BFK
MFN>O;!0WK"[FMZ0\<2UG?Z=YP:&U'<.N><? J[O?ZPS7==8PC+O'W39MLDV<
M/579.N^N82DV^+&LFOR_.M4G5N"%-+$##T8N":P(\U>='B(PH03Z0J<.%P#3
MM#P?4(+-$4R)==:9PRBP7O[S1%!.\ >_+D#K&1/[8@/VSK7_ZMWKVIR#UL%?
MK^Y^_9UO\. ^LM\Y&@'';K:_?NSHSS,D)-;F?YZAH;9XOY A(K;,;S08I]X#
M+&,$+.!%P4*(*!?W=$K."]\WSOZ^S=Y!<=+%E458966["-F>3WTO0IX_5%QN
MF,1274HG [7H<F7Z$ E.,)<8'>FYY[LIX@+LO6A?>AS[P7+2Z^R4'F>GB2>F
MFH)P;LXZ=9P7,IV=W.W7,]UY>!<^\L9&<<9FV9MO_(KEKVEU57UK.-CVQJRO
M6=5>*KI*H@0%;@))@* ;4Y1$D3<81W%D2YUMTV/2L-KO47:73U^ I[0"WSG"
M=N?6[]]B?GU,=P.UY 74NC@7$_@9Z):=20Y,?^N89AB9,( .97=?'[^MN;O]
M>>+S9T+DG9%=S>PO0U1U._7ZZ)@)SM0$L;54XUWS4%;Y?V6;E>][GH5(8B4D
MH=2)"&_YTQN-8YK([=,9:<SX#ITW(MC*70W2/<96#+NOCE)!>:)5U,\HPR-5
MK\,&#N#F5+K71 DKG#+#2U0V=6?.*MI(CL8HV65=[YA!8@<.]6& K9"$;NPZ
M=K"73L_VX7@5$S0TFX+E+3Z]ZB5*KKIR&6!5CVIUP.97K Z'I%I)LKI<I9)U
M1$"EE+@9HU!7NZ9NTH)O6UTQ(Y0&<1+X5A2%)$+MB=%>%P,JN2EZK+79M*H\
M@-0K6%)<JZN6*9+U2-<1NOGUZPB,I(BID+Q<)5/R1D#.U%D2U;2H?'PLB_,S
M5V3Y-,8!A9;K.C%Q2!Q'@V5J!8Z<KNFP:%S;.I#ZU]*TT"TF;5/S+"=O/<'+
M6T(3H.V,U.DD?1ERI]6CTMP059:]-]-;%(=>Y <618[O.1 S(T/QZ"56+'D-
M_1A+$\N<QM6R4?Q*ZYM18L?HVLR+9&<H$M,P96(7IUWJGIS6K)'L*&M5/\F%
M?D C&$01BB F<>(D43!8BVW7':E3@E;FT:BQZV'*G"IJDP$RQ^O2Q2SK8">X
MD1$D2387*D:R7GPD1$JL*(O0\=34C2AT+0M:V(\3"]/(]H8:S8,H<&6V6XPR
M9'B3Q;M2I&6Y:QR]BJ)DBED=RC3;,M<YEF0T2H7<A0J5DBL?J94Z/Z*2=5-E
M:;VKGH^,KBBVO(2&,/!]ZE*'1(Z]%T?;"Z3N5U/Y?,,"-4!Z)5'*LJ1$H9@:
MF69/3H3VQ+V0H6F5YQU&S@C.&/Z6H3.C/"CUC2;)-B'KAVRSVV97=R?WOM[P
MPZ K+X:NZ]B8. Z.D66[_%0H-Q\$Q/:I7',074:-[T)]L4G]Y1YU\$>+\7])
M=@K1QK>8+LU"M>RKP3$LF^D!(LC:&4'33OPR5$Z_6Z^[?)CA350//Z?KA[S(
MJN=C@Y\S?CO.RD4PP,2UW<3F>UQ=QX^]WF)$ E?J!L@Q=@RKWAY:^R1F\YS)
M.<//F8=.!ZO+>,ZT>%+J'W-R3U-[1/.AW&XN'Y^J\GO;O*?N+2+JX1 %B>OQ
MHY<P<9QD>'XC!_E2?7'&V#'\-.VA@?P(V[0/TQEZSCQ,.DA=QL.DQ9-2_Y"3
M>YCHKBKR9E=E[1'H'_QO@T'J4==/H$,<XGEA$"*/^+W!F 18JC@?8<;PH[1'
MUB:FNQ[;M(_2:7;./$D:*%W&@Z3#D5+[<)->^G_:L='W.@.&=AQ'-G)LST-6
MC+!' VNPE@1(ZAE2M6%^P;^%-5=1=X*6\^O0HXA<QF,SVHNWJ\\:6!%_8(JZ
MJ79K?D#ZDA^1OF=#;'A&O22P0PLQ0QY!D&+BV]%@,D8QDGMJ1A@R_N@<L(&\
M $\].MGW8F.H%'TO-A&+LN_%7A(X -_=- F7N$YQ])9/=) [E)$28<K;Y1)
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M WZ=K5CU,:=1"[]6^3JS5] AL1]C!P:135SJ1*YM#?8IM(EF+12T.IT6/G%
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M-&FN-C_ B0KLKN<5=9_#+B$=POKD4,)QLZHE@G>ER$N1CPKS8]:N4?U*S/?
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M1516\:,-R^< !OS!T0CVQ%!EZ;SR34"0G*2)<B.B5\RY(ZUB_WJM4^][_XX
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MZT]I:J3)%:G)X].V?,ZRZVR;-MGF4Y[>YMNVR<^0B&(+.0&.HC#!$80TLL/
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M<QR*ZFA_.]WQY73\;KI^F;_ZG#;K!P;KQ?>[K;.\=2S[YBJ 0RI1X@=NZ'G
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M%H%QCR0(XH2LOF?5;2E\3,T IF']!BL\#/:@@9YBQIL6MA];Z8+4&1MSNKG
M4SO^ /^2%WT..WW?FIE34/+DGED(,1FJ9:R*&/7P]?DGXVP*E:'?TFU:/:?%
MYE_I?3;LSR^+YF'[W'UK15UD$^+')'9MY+NA[5GA8)1$OM!.3DVF3&^7ZL"
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M/>$J.6SU5&Q4;&10F925VZFD)IGILOO7+\!'/B0E!8 2>]V5]B2+><]]P X
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M'NIS*(V]!JM$*P3 $W"LIVD-O<>=!7ZQLW#[X+5'??U;">XHUHA])Z!Z\.7
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M9IOSI!1N?\I_U%4N'LK=,?Z7^ZRDK/:56 LY<S\M5A@[B=)$M$P)DD<AX"E
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M(4!2;NNSFS_6^T=RJ/;E4[%CWY>;@\R0C:JJ$/^M[O+OBSCP8T)0XF,8B^Y
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M17JZ(W%(<EHD(]=).B>A1TO,R)J';AAB?UGN: #Z@O'9JV*+M:JW3,U(3T1
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MLA!D*8A E!(81:F/.HL4AE2OGJ2Y'<=; KZ;?6MS"#*!VNT5;9'TM\IGM?T
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M?]LTSJ#FB$UO2C>=S?!BS&\U@.*TL?G2?I1F'( $XJ"F/H1CJ#?V >RP*-6
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M]YZ@6F716%2[/VANU"P R#*2.J'/@NS- (QRUJK$!&(!HFHIJV?8D_?#<N&
MBNF08 L*>?S#!M[$<GC)E8[\&;(\4[DS]>8]>1O$DM).\%63;2Z:!6)!D/*
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MHVI&G9K>N&=-3VS>)LS[LP$VLMR\24Z/U@PC<QY",]"'EP]/+3"B*C%R\[9
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M:?-Y3 @3^5[.8=2]G%;.>_='\=5__%OW)^*7^[PJ_N/?_B]02P,$% @
MP8!;4-T D4Z,H@ H04( !4 !I;6UU+3(P,3DQ,C,Q7W!R92YX;6SLO5N7
M&SF2)O@^OR*WYCDK<;_,F9XYN-9J1YFAE915,_OBAXKP4'@G@Q[M))6*_O4+
M..F,*TDGX>[TH#*[6@HQ !#VV0? 8# 8_OO__'X[_>E;7LV+<O9O?X-_!W_[
M*9]=EE?%[.N__>WW3S^K3^;=N[_]S__Q7_[[__7SS_];?WS_DRTOE[?Y;/&3
MJ?+)(K_ZZ<]B<?/3OZ[R^1\_75?E[4__*JL_BF^3GW]>5?JI_F%:S/[X;_&/
M+Y-Y_M/W>?'?YI<W^>WD?7DY6=3??;-8W/VW7W[Y\\\___[]2S7]>UE]_04!
M@'_9U-I:(O[KYZ;8S_&CGR'Z&<._?Y]?_>VG(.%L7G]WBR]IBG]_4?Y/7)>&
M4LI?ZM]NBLZ+UPJ&9N$O__O7]Y]J.7\N9O/%9':9_^U__)>??EK!4973_&-^
M_5/\^_>/[YXT4MS>+F?E;7Y57,[_?EG>_A(+_:(N+\OE;#'_,+F??)GF:G85
M/JF6^97[?I?/YOD\]*EN^J;*K__M;[&1 >4$*W ^*^M&UC<W^7_]K=Y<7LW
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M2:S[Z^3C^2O8G2ICR-1@SQ*C'[K\MFTBTTA8@0TA@ @3T!7<F&9W#XA.\;/
M489@GMK1THM>AF)F/8CT9)Y?14&"%"NHF@S9[VHO4I LNC'W'X(<T5J&+8'$
M,X"U]P1C31G1:UP<!S[)6OSK>.3YVPV]*V@HXNZX '_HU'IH4QF7SEI%!6"6
M.L YTYMC2R=Q4J@#_.L@I1Q4.X-%-9MR&KA7KCSRZFN5KV0X(EYYBY/I?7$9
M/5M!*5N^:D>0\6$-9%Q+#@62G"&BD41:"E\_X8*X]&&;>4P4\;%2[76AM6\A
M(]Y8A!VW- ;54Z>%Q(U<%NBD@3V><=V7LLLA0#_U>#W^I8S3#UM-G-8:4LBT
MIP)A"B7A 6@JK2.*M3H$Z\D,W;PI]8_EI)K,%GE^\65:?%T%L>U[QZ)%[<PX
M$A8=2Y#6P!FI9 "AD9W2I / MSNT6Q-BZQ-@70%^]-'*ZR)NR5BVIT9&$!30
M,1PV9(QB L+?#1Y>^Z0(P1&1I!<MEGT@W#$KMCX=L;=.QBV13BD= + N6*U4
M0]3TFRF5='(['F9TIKW];#@*U^/YH/_ARVI^>;.<?9W_X_;+_[TU.]BNXAD5
M1&EAL,%6<@HP),XWO<42G<G=L0ZU5G8.ZE#^A=>FQ/<MTG_MK)<%F3!$2K"P
MY476 "&1:63EGIU) M4^%Y@^<#YZ6OEM&1E<7G\(W_]X,_]\/GE>+A, *64
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M AJF@SY<QJO0P6A$[C+%FC*9$U#$Q,0>.:* $BP)G) ,PG/[*2@)Y/K2#2'
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M^[=[Y-@W\$?/5P=W;#T+QQ.I;7-92IN9UP BAS U&&JZH/_S2!4..E:VMG[
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M@'*Z1D1#)TA*+,4HKW&<@G^=JV$4Q.SY?E$P* 5UF%NO6,2$F]Q@TC,_WQ>
MUSI&0,MT)1P?HE&_9W!3]VK/X>0K1;,P<K0(3;+0.4*U9P:(II?&ZI1W[T9X
MD:-?JG0$\M%4,#<QXT Q:V]=M:F6.:_"+AAYAT% BO-R8;(CI(4C_H(3W(&
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M1@LIVF3YE\7#O_:?QA_84D9L?#[46*$<%Y(XA2EM\ B;A90K)TG&[YNC7[_
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MD^EN:AW;5*84I.$_+[!$1AOG#6QVL]I"<&9/275(J8$0?^NW9(%A&#,2AP[
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M.BTFH9X2(PEMY@,<C*0SNZK8Y;1[&@T,Q>&G=NZ'2751U>!=U8% '_+JTTU
M? =#VS60.>."%>Z8YI)AZZ4SAC322VM2]B1COZ?8(1E[ ?LT5*M[.E?+Q4W
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M7 :'PV0CC(@&EF5XBD6XR@WSR?AV/& GW UCI;$PZ XC&'/*V?Q#I,3 C*$
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MFP'"D4YYV#+I>;71^[7Z@'<H:CUU\YJX8N^\$O]J^<P[BS 5 )N2+SR!1C=
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MA.D$WZ-/(WZ=5'_DB^8._E8R;"V;8<$-X C 92!CFMI-_T$EJ?<?1KC<7SW
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M>U->[2;%SIH9@IARSY1"WE *,.DP4I["E-2WHTH^JI+CG2)9Z^4B:[2JP!*
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M#J33(P,C1%M"K/$L;CPL 06ZH@%9D%6(ZMI1TSI[K^<A4Z6*"] SRJV26AJ
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M. 85(8((XVK*+0>YN2-7AR>F@J];G.!9CP>)ES[;:TZ'*^."![ >,9[%XU&
M#:2W$*$]?4#2G*-NE$$0;1YU;7#T;-NY2G7VY:)F-X##(X)06C)KHIG'?:0;
MB]1#>+=F+ZY/DV1*KNR"J^=[4<_*>S_HL-UO4DKH9/D0WU_>ORM6Z>KJ(%0R
MI@R88!X/<P: M#BJ8:]=Y7V@Z+/F8>]SJ96.J/[1V 3<WGZ\ELLYBWTV_3
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MQOI11.,DLB;=R;_VBGP\^>K4Z YA-1#YZ(5@R0W0LF]/4,D&^P9K%= =HV9
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M\R\W8L XP85C% BN9"4,D<K.HWQ.8?PF"^6>\?5>?P>$E?X+%SM1@5%HR,M
M@3$0,>*I4P20BDYN8$XZ[)COBGO'U7G\[@U7+^\L3OD.KX\(D4V.>J6U$E9$
M&K%P9D>?%=K"*]53P_D'K<BA+YQM&M1&"29.?2P6/Z:WD0NO7YFE@.OE@<RX
M4_Y"FU\3*&(<2,^P!D9IXQB4?L])3J^LXU8VGLK1B*(O4/]9SHN??TX6_RI6
M?CV_.YU7\?J %(B@!+84D"L)HHY5)D<*>9VL!"6'OR(85#RHLA["V+I"W1_
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MJ]ZC#?*IB/;((A)6O0'=%LM7KL^O+^Z ..I8U1S"8Q5@D!E! 6>< $!-;6>
M9;JA]07SSTI4;#!+T !KS"T"PFL%(F"UM!4O+',Y3U079N#71L6!LG?M<[OO
M$HLUHUF;(._X3 $9;IB 0B(#@?38BLB:'3^85U>6A]T+^EKE^& (K'ZP95D3
MQ#T=&:"#D$HC &.2$$A<W)'+U(&Y=15O##+NS6$97&XO62*Z@<?BA_%?'TP
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M2[ZX72\VRQWPZ>M'](;3#ES:XG.U)5<_'Y96ZR6L[B3!I6L::##A'F)+A2=
M;-XO,2;0LP$CXQX1D9XH-V0\B.H%0?,[L^WU_FDQV32 W]Y,[=%=YX&]JZ\,
M6B/.C&.8 0@0]=)X4W$98WUEQ4*[@-^+RE&CD-2@.DI]*Q>K5%'0E,O5I])/
MIHOD@HR@^4N_*HP3897R2"N@C&+2*[QM%HL$MI+6RE?K.AI-_8@B2>+SY2+5
MHWH@XU23F-IS!$>BLX#B;M(: .8\2ZWI=WS@F,NAE,Q#A3$T HU3&RT'H]':
ME4-?EK.?SB?SVVE*,HR<6"=>G>@J<V!$@(AI+S45T1KTR#)+B=C11XC*NCP:
MX6'6@=R?=[%KA<^]%6Y:3.;+**%TJ'XL%C^FMRF[Y?X5(I:?XL*6K__J9%>:
M-K\F>*PI5APR% ]R3QSC0%:<I$(.IAF[06PVGIZ7:AI.%+T5POOX1_FC6,S3
M2C]^+^?+,HK3I:?)>'@MB\VA\K#=3[8X.6>ZH-/[.&0$(R@,]]I#IRK.<*\&
MR[OIX?@>!F'/2^IU+[3^LR .GUEO:_15:31/B!X34I983*C64 (*3&59$8VR
M7BFS(OMZ '#W1D*7HC@[ .?P4M)F^7.RJHSO^RB/FWGQW\5D42ZBVUIL(A7C
M)M\XK(?"<UJ:/D@D(282"L8EC5S6;L\-:MBU]='L""GEX(+I2WL^I^ZIXG]R
MZZ(GRZ,N5-.I@E00(V(UD]H;Y3#EME(/%&*7DS767(<^>H08B0X]'[<]260D
M&+V]77];S])CY2;.);4?F<P277]$"TD7]W$G?IK\?3YPZ\T?'$4$04.!)/&8
MLT8(X??[&XK!(K%_%31W(J:Q0SREX'0)\2?SAW2;*!W"'"K*$:,.11VQXYVC
M."<P^-QB:;]!GB^HH4#^U))Z^1Y= \>'I@C,$LP\%)I3IY44S#A0<0 SG1.R
ME17#?K5 ;4D2@SXR#EX*J-^W1 8H\9@J*I'B1!GJ!;*:&L>5X9+5>MOH*O+I
MB=9[!K7:Y2R:3!,T$1HR&-E O"=,,,7-CAM6N:R>N2-TG+N R8L(J<ZXWYN6
MJ$(&7XOX[%T_'(Q?K*$63HX-'F.+-134*L80T=94U2-<=/W<@)$%!]?>+."I
MR33!>2:$]E [+U6J5<?(GAM,X9R[B1%J@Q;14?;&]$&5@+J[VW0J38\RT>K^
MMIEZZ&"D;A4$0AP(:"UR$DALHK(FQ&JI"'>*N7K]F[LR%Z* ;W>]+.9WNXNM
MS1^/6@<'1P6'K. 1\00 X214$G-9T:HYS_%T&V__/OH!MRC]%U9 6UP>=+]7
M3M7RYOZU7U_WSI<RJ6$!)?%"*.ZED3PZ;TIPKIU0M2)ZNW[\/4A%_9C#XU,$
M8AG&""J-HL,L 8P>,ZZX *G/N> =>\Q"BQ Y^-3;*O?[NM(ZN&C],P5OG @Z
MK#$ZZEUG@>*,1I/+<<V$ W1'MP&BIT980U]DM86-NL;IV?P?''=IW2?C#6N,
M#E%<C,8-C7T****&;E+BMG03YG,N4,>.NU9A41=R9[.^+\C].8ELFQ>+)W;/
MR>C (Z,"EHPKC:/_"!V6%B-J246GYG@PU=8SJLZ1?-D5E_M"T]MBLBR^EK.[
M-]^^+\H?Q>8F\B2:CHP*TA,E)'>86$$)<W&'[GF'),U16&./R.L26NVQO+?D
MC_5B/EVE'-_YG9_^G?[O-+(.#PH^W7X[AC32A @N)-&5JK>:JVL.[.@26*UQ
MO"]<I?X&ZRB ^H??@1$AW:,8*!$D1 (K%?$<5/0Y+G,0E562[\(1U0Z[^X/3
M)IK_-@GPS3SRY4N4Z&E%=6Q8((Y# 62DCVC)O-(4FHI2*VU.[L\(*_=UBZ76
MV#RX3_BV1O;#Z<%!6$<09TAJ2A2S F"WIQI[.%@/DJN^B3B7_8.#[E3UO^,#
M [ 8J+@_G>?"*@.-MWL30! _6!K#D$?D&5BH"[-SF'YV)LTVGZW8>!8?IE^^
MKLK[OY;%IDS%-H3Q49CCB;>\K/D"95)Q2:CCCA#@);.1EQ6]$%]95Z4.<-4G
M^\^&V^''B^1XU%][LU?FOKXZ2*XH19@):)Q'7$>'J;)NG7 DI]S.""O =P7B
M\4FJ'[S?[$GI$>E-OS0P%6UUCU*]).$U55*;Z@[3,6AR[O8:.\R#AF/TB?*.
MI=1;UL'KBX__/RM>H>*<0I]M?47D((K.)(+42.EA2N=WJN(@QG"(+N]78?<.
M)*#>57A*01Y&C]?_YN U$$ SIREPGF"N#:^$Z*BG.9=4S?L"=%Y[=&RJO#-!
M#7[C<+PD[K%A(?J\1FHDJ<9.,<H,DZ*BU$N04P\WJ^? 96O=%ED^:.SGP&EA
M':=](*$ Y01'"4#-O&&:;&/N490VK@7]OF.<<I(]'G4S!=Q(883!V$L2&4"H
MKB@')*NG]B6%GS1'0NV0IC-9W=MF_[_KR2)R?O;S0[%<SU+/V%UORW(^>%O8
M_=H>5?]Z2#1ITBJVX4P!$8N 3^6]&+0<<\+PMJ889 J2>LV\:]JYZ96MG$WO
MDB7R,4IQ$UWR6 I'R&LV0<"824@5$UI #CR+QPROJ-+QT+FNW=Z9S,L>F-^7
M);GKX.<C]U+#Z[32?TY77\UZN8JJ8N'^OIVMJP+:\9^[XR4VSI@M6" @) @9
M%/\+K$#6T8HOR+*<WN6C2C/J"BYEWR+H"YK10MXVK7A[_!7UR><"I%S$@SKU
M]Q)$*NZ(T14MT="^QA#(GI"5P^>^,.,FBWD$]_)]L?CX-3(ME?2ZC?:8G<[6
MD3%'4'1B9+"16!KM-H;3BX6.7Z_8CE[M$,IIHC[6",B><-4NY_M"VC^+=*E4
MW*EX9DR^%._6*2KJYGY#P<UZM5Q-YDG-U@?@>1,&$$T6S[GAGE'A',:&B8H[
M1F7EJ(PUCK(G7/8BD%'X>0-?[@SGYDFL@;7Q*&,*<.^W57FWLK+"D5JV9]=)
MO4=IJET&Z*SY@A P/?4PS)PW4!I#<'7(.X;1E75^Z P]!_-]NY/%*/3*7_-)
M]#4>'7N_D&JQEGJO-7)*>248@X23G;@\T_7LQ0%X4D>7U)L@6&H8,X )9[1S
MQ*8FDEL.<( -'*Q6P#B41VU\E#TPOS=M\:'8O+B^CS3\W#2!F&RR"X:S/0XM
MJ(9&.#4T6.&E1\X9IP"DR#+*MKWN$+>>DUKQV_U2W:R86(-9 I;>$$@QI@I*
M&L]+R4S%B\B@*[MZ;@\:+V[WNF+YX"I@Z,>F+C4!MLP(:HWP)(I=1 5O$:$I
M8WA3^FD4'0L/$:%_/OE-[4I"#>8+EHC(%BM2A5P@%(RLPGO^,)75BWFDEQCM
M8^>@E]&=)'J+7_W/9'%7HYC0D\^%J/N,9] J+Y&6DLL4O+.C14LT6(.M;H#4
ML;R?1Y-F<+HOU%2WR:F[Q[?O1>3#5HJ1)5^V-1STSX?/O)_\W(2"),(>J)O?
MI9".=Y-OIRL*=?%U@2'$<;KQ)L8:#8$C1%6<%2ZKW< (,7PFJIYKON$%T=M[
MU[?OL_)G47Q<18OOYGNB\V3V_,$QP4/#L##6"4.T@MH#9'8T$J;HM?7-&A0F
MSQ_!6A+*F<!;+E:/0!?_]!QP\4?ATW25CI<W\[OIC^G=>C([<!H?_&SP' !K
M171WE(ONB%($JCTM4N9HLQ$FF_9S(K?%[5Z1DT)2-J0G+GR=?O]4NODJ&MH'
M#]DS9@E2&<RX@P0183'0#.N*DT2IK$H@(U)G+<C_&)):Y?'9R4#FZ[2X_U3<
M?IV7L_++SYO[^^EML3AXU)T<$[21AF(D,49:,TFQY/MU S%<:<<>L-&61,MN
M>'TV1MS?Q>UZ-?U1V.FBN(WB.@Z/ Q\/0$,6/6[E"*#20*Q2/X[M:JD0,B?0
M9T1G5&_(:(?-71Y.NHS6W,U]M;ZE^3J9+KY-#AO2IP<%H:+2Q1PAHP!B' &*
M(ZLH89%28W2.)3VB@@1]@*AU9O<765W'YCMQH55_DJ"(0A)"(2"F3C*&/"#5
MAO+QEU<8H#C,U5=G,AD"F2=OM5Y^.&!L):7,J?AO0( $@L"**N/=-=>EZD+V
M1^!U%L//-J#^_%!&F42-^D5/R_=?)U'%IBC+]6PUG7]Y.[L];D_5&QV81191
M#.+?1"(EC).\HH5*?R5.61O"++MF;I=&U4D;_.6'@D4B.JA 2"KC*>XH]<[M
M5L^<1%=V.]0"-+)Y.+ M]+9&4<Y30P/Q0 'I/#70:08YB$BO*"8(]M.0^1>V
M>\Z51(^U,NZ+Y7*:^M2I^5V5%/>Q6/R8WA9+]W>Z^C\6TE!O@B"<C?O7,2$9
ML=@#( FHJ.=87,F-4OM@>)E)WSZW1_/B?.A%:?OBL_PC?G"U?#-_7T3E<7>J
M?&P'WQ800S(ZS59HPH&%4&+F*[Y"QG.R<4=^!K>*XN%%<W[=K6)QNTFEVBQP
MZ<O%?9%B^+<OE&FAD:3XG]OB0$6X,V8)"%/.->9>:,LQ@M2SRG!E5+ K*^#9
M.NRZ9WE;</I'L<S%TK$I@D!.NL@P1#RWQH"X5?;VKP<T)Y(PRQJ\8""UR._>
MSN$41?%FN5P7=W:]B"[R5H]NZ7E=-Q\[9YO/%HACUAIA>4KQ@$H"S>R.+ZGC
M1C]5+'NLUMK=2=HY\\]6;1\GL\GBYV1^]\_)EZ)Z\HSVZM?9S^VO#BFTDP.#
MQQ)J3:VV&$J*!8PN?46!-EF16,WK0UZH&FN;R[TIK[2X:;%,RUY&%VBW]&5=
M;55C>)!,VN@Q>2(0<DY32.A^A]"HS#/PU;S8X^7AJT->]^JJ?C[MH7Q^[J%$
M#WRZS>_=:N)3#FH;WQ& QXI&32X!EPH1X(ROW'VNL,ZYY!._$EX'$DB/R66;
MZE<?BMORRWSZ6%,.D$]VM!!7K;2R6C,$!S5Q$B"C'4S]>)$CVSH$2 K*1*W-
M,0@/ZB69UILB4*<1YA!:@QWR1FL%3<4%3?G5W;^VC(UF9>3.9?N BD#=W6W^
M^S0Q?_"DT[Z4A.$"6.;CR<&P5UQ;R#4#0$%&HVFB:MVP=9V">GY&1OVTU,SO
M"!9J"B+6J8B[EALNH1 [/B(&X)7ER+2.KH-)JOW*I<O0AP]IQ4=28_:_#PHB
MK;7#CDL170'C(/&[-6/(\)552!E UF4^USM'RM$(F4>?"!(8P86#5"%+K2(
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M)C!/'> 1-3PN&]EJ[1R"G*B+$5WSM"+S#+[U=<&X/;+B5YYXNGSRN6A+@?2
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M<HS3$4)O P<?4!LQOW16),7\("(@?'& $H!!9P[KQ2W%6?9B][SEX[K,U'5
MQP-B,T%<Y@.B08YJP2CGV"LB4_O;/8W.9>5_CQ!LP\*D]@-B,Z'TET<8S9AI
MNEC8K/BO^72U_/#QKY/@.SHN,**A1 08I'&ZUW.&Z!VM!'+YJUW/]@G -@73
M%P@?Y2=N^+0\";\#(T(Z9ZC0$ #KH'=$.0:PM"8U^@2(7]M[\YB UXY(1F-3
M#APX@;QQVJ3$% (X== J6-E,A!E[);UOQN,']2ZRT0-]\Z]_Q--DFT!^HEA
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M!_#][__G!;?CRO_U?_[7[A?I7Y_CM_^?__7_ U!+ P04 " #!@%M0J9M
M T): !A< &@ &EM;74R,#$W,#8S,'@Q,&LP,#)A,#$N:G!GY+L%5%M?
MNR=\($!PBCL4IVBAN+<4+T6*:PNTN%O0("WN%&AQEV+%W;T4IZ'%"<4U:(IE
M^+_WO7-GYGN_^>Z=]<UZ1W;6+SDK9V?G_,Y^]F/[.:B?J%7@@:JBBB* AH8&
MO+Y_ :@UP$@!8OL. -35 2X + !3! :@'E_A'8/51#H;Y]_ =!Z\"_'?[UI
M$0,8__(]8;\6R;\=_]4/0 O+!8":>-0"( ]@8V&!L3"QP6 P#@XV+CX9 3X>
M'CXU"2D1&3T-(P,]#1W=0U8^CH?,/"QT=)RBCW@>"P@)"3%RB$N+"4KQ/1$2
M_&L0-!P<''P\?"H" BI!)CHFP?]P0W4#Q-AH*1A<(#1F )T8#42,ANH'&.^O
M%!/M;PWX>T-#!V%@8H&Q<7#Q[CLT/ #0T4 @= P0)B;&/46T@/OS 8Q)@F3
MP%,L4JTW8&97,L'@Q#QLEF<U/>3:4\>L3RS<0G!P*2BIJ&G8V#DX'W$)"8N(
MBHE+R#]74%125E%]I:.KIV]@:&1I]?:=M8VMG;N'IY<WQ,<W]/V'L/"(R*BD
MY(\IJ6F?/J?G%Q06%9>4EGVIK:MO:&QJ;FGM[>L?&!P:'ODV/3/[ S;W\]?\
M&GS]]\;FUO;.+N+D].S\XA+YY^HO7F@ ".U?VS_D17S/"QT# X0!_HL7&KKW
M7QV(,3"9!+!(GFJ!W[B2,@L&8Y,]2\RKZ<%A>:)]3&[A-H5+P2JTQH;XB]K?
MF/W[B(7\#S'[S\3^C=<\@'\OF.C$(&) %KB\XI*,G)Z?-_Q]G<CD=866;"YA
MB,P9RJ&4TO6TS=T]*+"]:"M\118F73;IQ'TJ(%NL#@0PJB1F6KUK#^VC8>Q?
MP8,,?B/0,$@SG.(SIB2E%/QC#09M_DEK8HG::*?K@=JJZW[^FE>%PWHLHPI<
ML4=]G[Y1RK=W4V%(*?^Y(B5':6S_(:%4^DGH@$:9W;Q7K/U%ULNK^6\$/?X+
MD<_MDQ?8@_BT=(0ZW%5A\"13;NWZSCB1^0-'P6&R*SH&KD?^*GD]7ZI2^&HL
M&?+WR1V-UIX79@?QN8\!=EIF[@AN.%OQAS7CR\F&)<GK=\NZ\2,DA7$E7E1D
M$R;6#1R]*Q$NR.0^D5!CV-G%'/OGF?T["R46(-#DX59) ^ K3:;_7= <.=._
M0M%@3FB;S3O+HW_PZH]Q52%V5.$Q>C8G:&>7>XN>99!!$.F#X.,G1*;I9.@T
MM*0*>:6_XOBVA;MMG$(M%6]G'=^00V[J;Y/6UZH1R;_/W)S$"==I\8P3'"9T
M*0Z22<QOCY:['X#H)0(S=K-@O<5I?^VSF;V[ZQ,<,@9]<%S ;MH ?U1Z0WB$
M?J\9J>E\-+E*L>YBSR>7"&D?:NE2T'QI-5@C?(72L1YY5(#(/%E^2(+'T9&P
MT=6J(JFQ/N!KWA=@:0B[H2>8B'A07)JL1K9K>3+,]=NM(PX3\*S/"!)C#?2,
MAH\%$A% WEV_2H<P0_+<L3_WAB>#[6+.62^J,Z30UL:>#%W%CA?!G2DR''6K
M$M]$J22,NLB!Q2R3)-#B[R>U->K[K/ 8;=]Q=WI5N;45E6/,TLN:HZ%B#6%K
MC=E]3WN%MIEJWL.#3PEL(7*[RGO#\"!>+4--2,:SUEFKF<KS#!QGRZ7.);X'
MPVV^&^Z)<>?6ZC_J#RQ^57F,[MD/DW^CYMT@X7PS:^7]6Q/S&Q=M6YL]GHK3
M$4?4\C+;$FMML^[37955/=/PZ!OA+\MLV3G5.VG>VM96CTU9VEY;K8*R0X)$
M2K\89=<5VWSEN2K.LW^+)_+#[[.>,,<,Z[1M^GA:I=S,CE%LY9GR@N%!L2$@
M\SX4%L3WVYJ:NJ@ZHX3CCB9;(!D%,(:B 7]S@FX.N&"KCI?@,4@[[-G7U*K
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M(*QA3S\FJGZ]8"$_9>\X+AABP(,Y"\OB2G]O_,3&7I/FT$-UVQMT:"&V31#
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M8HJC@-\[ZRB@N@<%Y)<M/T$!R:E377N[,RC@6?G,ML3(;1'+[&!RH ?"@_;
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MA[,?)KW7&S0!]:%+T '-M69[:)?_*T1YN$KAM,-VZQ->F^QIWI9+3KD&,S/
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M@@*C$!._CEYUS=Y(EX] ]R]=KS(C>#O$H*_N@C:_]S^?XMD0:G(\-PQ.#_&
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M\(1"X>+NW>/$\SFEY[48AG+*D?*B2O=Q:A;ATS\:18"#2M4$E-MX6V_/1>?
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M0/ZC4P-H]P(*H*_R8V [3GN/ FH\XPE_04+['O1JE=0$U%*%2T;=BL/;4 >
MTDOZ27>C+]N^Q;.+ 6?RKMC?(\DR+3P_@BG[EMXM:-#0=T7S)?>MDEV+ASSA
MC$$!0#(UJ*F*$_1UFM_1V5_RK5\QD[VA8^+!9"9]6Z"F^^3%%]GY*Q1PBW<O
M6R!]%!!9Z8?''2"JT513'Z/D[$PS0$/X#0O3()<0>FUN?A_6.T!7[5 0EB@
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MC^JETK%%^D,!#B:ID*1?U+JT:+^RZ$*EM]QG('=/=Y%;VI\UXI)I0,+QO
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MFLB J[^G/!ZL@UF86U YH*\X]J^/(DBP\G.L *HLO_331AXS11T'!-0SMA;
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M"^:3/T1"Z,"6A7 'G'7>:6VYY726N]"/2FVAU7U.Z>B <\#M#\X'YX"9J-)
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MSF"YG!&SJN;M]D(4J@'SR195%Z_N04F[I*R-+0Z56PT5&/=1$./OUYU5Q8O
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MD:$SX:5=U[P@)@'&^P8TP+P@W+;0O7FHJVS.CA[@' [P0.)/AR":49/X=D3
M[U0^%(UO3ZN)&H#253@OS;R/P,/<WS>@&^HT=%T$(CGCTA,HPP?*EMH #K=C
M/<MD,ZT;S:?D+(7#S-A/<1/?)?-ZXQ,!2(OM2&C5^@,NQ?[U+6>]A!7;*XI(
MHS> 1(X,;CB.\T[,%>=&*K8P7!7UAM*U]O%*;W2JY$?=5>VKD#L@]7VVT8M.
MV,_"'?0S3)OJ3*M;["V':QVN.AWX\$#(M%S8BP" F[(8;[W/A"AS-?Q*D^>=
M9F>_.XOECE?03GJ;$-,+ HI1BER\'P4:/SF)?.*?Q=T;=UK:[<TO5NHQ*@7
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M*4-E[G^U:/:_8B'GT_\&4$L#!!0 ( ,& 6U#Z>E*JKDH &]6 :
M:6UM=3(P,3<P-C,P>#$P:S P,V$P,2YJ<&?LNW=45,^V,'B:)F>0U&2A"9)I
M<FZB9%HD@XB2)6<0A 8D9Y"<6@$E"T@&D9R1C.2<<X,B"L+P^\U[\ZWUS?WF
MN_?-?6O-'U-GG=Z]ZE3M4SO6WE5U;F=O5P%2=14U%0!T=UG<7<#M&N"M[&MO
M P!:6@ 7 "X "C"'L"\^P>ZNVF!OPHH.1S N8/PNYOGKPI];35%'25E - $
ME %Y0 E@!O0 :\ 2L .< 1? \>ZV!>SO:CSNGJC=U5D"?'?_# #!.RAP]PO<
MW@!,FLKR2LQZUI9VSBZ.+K;VUA[,:LZ6?,P&@GP"@L#M J (8&%AX6+A$N+@
M$!+BX>$1$A'>%:)_H?R%!(2%BXN/@_\7$B)"_'^I^W\@:0?(<($1C&]@$!F
M008"DX%NNP&F.[9@@?XNP'\4$ 88$PL;!Q</G^"N01TI@ $"@S$PP5A8F'?\
M!+VZ>PY@DF&1WQ>4Q[[WZ!D.BQL%+#CI+2ZK0G4'I>[X*53HN7L('CX5-0V$
MEHV=@_,!E["(J)BXA*2BDK+*0U4U]<=Z^@:&1L8FEE;6-K9V]B\\/+V\?7S]
M7H:^#@N/B(R*3DYYDYJ6GI&9]:Z@L.C]A^*2TII/M77U#8U-S9U=W3V]??T#
M@Q.34],SWV;GYM?6-S:WMG=V]_;19^???US\O/SU^R^Z0 8])_E'])UQP00
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M7:FA<?^'CW2^-8T^/5=Q.XK@.X P;$ BO\> &A+"(."_WP0+3K;>T%H&^K%
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M92O]AJ2*/*$WG"#SC'ET'D1PVKW0R\ A,016"O?7F(7/BBA"?PAZ\"=)@UB
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M=70U$Z--LI-.@R2^S@.I_R?ZMEW;3#$>W1_ AOG]6Z: ;'T[N.:QZ@;V%
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M0]R>-P7L_ZW[="??G50F-E 9&B^67M;\0E]YA;5SM-S"3[S</VCM1L#RH
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M_421*/ZSPJCPL6?8M'D@%/NW7^NWNG-M>?),Q5 $%F5C<_@#2\]SCC!(@:M
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M4-F S$C7_'P+1<Q(M/&;@0<,^@;/W^)7N7<%Q[6#D>CZ[)+=^>TH?[^BV<M
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M9>39$(@7##:,@9.T#GVH ]7L[864$=LI+"&-(P3U(10H)QW.* +- !0 4 %
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MQ=) @5-TK2_*5 )Y;'/:@#__V5!+ P04 " #!@%M0&^A);K"D P!,NRH
M$ &EM;74R,#$Y,3 M:RYH=&WLO6EWHTB6,/QYGE_!Z^F>R3R/Y61?LJKS
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MN"%."L;1+V"VI+Z;7(;NBLN CL&7<<4-J-[K9C$U_J^RV)TX"3'O8E+C*Q1
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MAHUJBP4Q6Y:V /VV@8SJI7WDSW9':I-INAG85R2F]82A2YAW=&!0,_PEO\#
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MQ;/J2%[%D9>YZ9?XAL3WOEO=HD42XF"])+R0W),@FE4J)EO.$K"R]W4K._M
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M\:%AMNJ5+#]T!A_W?"3):I]7+'SX]7K/!\Z<U =^J'THNJ;Y]6U/?>=_?P\
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M,L6N@*Q]T*!$<0Q@_,S !HAC$)J6O@NU0,>F&J&H"@R416]]_"M9SMNVM,'
MNLX/54,U;5Z3S:'5%_2!, "S2K)DVQZ<<:J!'_/>#R,TPYH4)'> U9D1=
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M) 568K0RKYA67S7-OBQJJBP-=7M09,,&VG(V+)?Z3.AO2<._II16*U3%*4G
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M:IXB*O+6^W>90_7OY^A0LQ-4?0_J?V7L%D8I_/)'YJ- SE&*Z!CNN\AJ1-P
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M*I \$C0_+CG[8Z[BZ.'=%(,N0";AC#OGS601RGS7_^IBR+_4\,,Z57AI_-B
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M2L^W5:O(#P%V>(P\=WEY658X.>R9K& C2 ;- "'AZ2L".55,_O1B?VGEIK/
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M%_F?\D=1 J(_"3_1N\\6%[2S<[S!'R/,)H['A5&:HWAM.O3A''R#6<$W_ D
MAT<^N4ABL9\@OK)X%B4D.6</Q#;.01(!+;I!AFO)0B?S? 2BYZ0.-X:[MT"R
MTDJVA4+A&%+QRST6NI"'-J_[B83AY72:A<#*GN\"E29(?S 5ZM$D*1BBW,B/
M9A,GGCHNR:BGPX@QG',>N2=!-,,*(I JD1M$(5S%_N*CR)OW1DX"Q 8RT\M<
MD$$%(:9.?$>0/%.P<%,:)0?QY.*VSOB"^P(<X7CW^(W>.XM]0OOFIL2=A&#/
MW?E8JQ2 \YE"3*,BX\!3LBF3@CK\HH)X+ATXJ3X:&Y$8#1<(S[MUN/ 5*GX
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MCIG"_'F59A82H\!-+@7P0=21J/B0HL3N/31?C;.862L):FB*\Q"(BG)$'3_
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M7"+"SHBN3 DDM#/E<JFVB(8E$1 M:KF8I'1V0+VP3!948?!]@(FC#"M"1ZM
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MBI47YI9;,_QWHHH<T^ =8X"N$(1@:OG@MY2AOGRO=XY%BA$*>FI#L^"[R"]
M6<KWZMS>.&_9NYQB'FCUHVX"?X2Q&( $S]Q:Y&DP9NA%V8AJI3M_D1?!3 2"
M#9/ V12AC'SP&:3L#9WC&\""1\!Y6[A#-<A_B]> C=!:1C7"80"4FGO.%'=:
M%JH834\<L+)<_/1FE*]J%F$J&FN)0?P0$/WP% !.P&GJOT7RA\0","JG3].
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M?(*'1\#->0SFEL2 :#!N\U(1%XU5CU3RB12YR&(4NPTP+ W=:C+ #/N813D
MG+HX(.?!NZ7B-IN-8Z"IPJ:BX>?2_%^$77+##;UF==G40G_*IZG5*$8/GUF(
MK$0DSED\8H_#I<!*/6H%C0 <&-9/)H10*Q^>_6B[HSZL\.C'L;#*&E2Y7+PE
MU >CA$=_7K-,&9PJ\2B.E0!DLR+TONP(T%AZ814VQFN;9D6K7A936TC/C7-D
M>03 =XJYJA*]A3VM-\Q^@QO#',O:EX+OB+1<S.V\GFH7BV >T9YS5J3]Y[SR
M(IAGP3C4V9HZWP@71W-0F_/%)!B/5%ZP\+ H&6-4BCT8M7 =*L&)=<([&O;'
M.*4@_QD?"FJCTY1/4NQ8U95X+"HMEF$1OX<8TUU8799KA#RX"Z@4Y'-15\XU
M06D*2M*(X^J=>8*W$G?4+A2^&NB.25[PA\-9-'8I#HNBX;L/V"7@(_U)K$:Z
M+];YJO!*"QV*OY5+HTE"3N)[GC/G(I9M!F*;9;%+,TF,E\1S01;/=46KDEC#
MFBDAYCR)0%+/95$_5S0QOX%FW\ILX/KJ_B3J (]%T!94XEI85]2D"FM3EPJC
M8)F;%J&5<H'X X;:43@DI5V01W7I=TPK@=Q!G<4ZZN5:M$ 8G;"/+HC'6)T%
M@Y8FE><Q_60I(3%UP!*C&;R%OU\Q2[C R4)0EYC;0YL!C 9LUT<;3U4TP'FC
MV*@-R^&/-$=WOI3/A%46)0E%'=N2;,Z3%4FSOL'DY3V*PORMHSAR,/Y7^[@B
M@ 0014'$O6%EF+BVO'*+I\!G7V3^[6*V'H=UGZ27T<#@<K1N/7Y'48!9\"DM
M0J82^;P:)<3U/$3Q-^J$.#.?Z@IX#+I ,2W:*XY1* I(7X# /, DN*;"_T>;
M429EWK5RY4<_[[RH''[T$_ZD"M*%6 B2QX>Y@"-<)YF<T[\T#WB/M<JYP&%9
M0FI>)ZR5LO]#55P@CD;@[P.W%84@O[.\^+ALM+"H5, X/K#I'QDM(8F $=\^
MDS1ZX\.K'RV2*C6UC6_/7]04&V%5DV?3KQ86C4Y +*$MB:IH!@Y6#WC?I_'A
M-V=_O?Z_9V_?T<I9CLS0W9K"$T!7/8#J1ME#ZS#8?9RX*-"$.X?78N_L;74.
M*U6;9].^Q8I6B]P+UCZQ; =ED EP-D?KCN&=(4&O&D#GOSVR^'WCW[]=E<'<
M#\E@C-O#,PM!NRJ$8^23F(V^ ,?Z >8?G^>\1"VC168'%H?>,@:;&,PRM&_!
M1@++#*WAE%7]3YUY\=BJI8+>+2KRQS/XH^^\*O,5!4/"NO+YX%*3#/=1L!6#
MC1)XQ7X%RJB(0[@]IIXQ=>\7^8\JNI?#'5A#D>:YM;Q4B8;1<\R!Y8@!$;K%
M(L,,DC]CV9A%=0\.')%Y%'KU3$WU9Q"-,$B?(QH)=#$Y,'[N:9P +N7V;X%V
M)@V30EBA?;7BXQC@XU0:Q2?_S0UI9<5&)^?Q*/JQ!/XQ7)-MFK<U$\4=."Q)
MA]1$RWS)'>!ZQFI:BW1JD\"FA/Z^=:NJ,;^8]@:M&>2[+_]RQI_1[S#*+;[7
MO.26;@3#S/9U!$(3]TVLOFVY'\6#[Z63]X;*=KGG>^IW;E^11K/]DEU+^_&U
M?&_]WA 35DSF[2<X;)GE<4S:I;A:HQGSM"7HE;HBF-Y_)]A^N$P-F\5DKYQT
M\N#,&[OI%=T$]H3I$O:- [4-[=AG[[8'I\$^UIJOT!S/K'<=ZHR)CJ9?)$U+
MIT'3^7EPK,8)C9AZ3S1 FLZ36\QL2=YS'>'N1+B"+#\'Y<* 1Y*N<QJD6^[:
MRFV3ZD8-ZBOB_HIBZQW:$/G6D-OK+U>^==/CQ6)K1<C]]?K_OJ.A"V[:MPXM
MD3LR?A8R'IT8&3/RI1$B/V$E1.#9$7@?+5DJ+7!*VVXTP5X>8AGI\N]IQHD1
MN4B)_*__Y+[V>&%!Y=.O++11- (I=AT5W4!H%H?&1 2>+UXAK-C^*R5.+.U+
M-P!BPP"ZP=#]-HM\RH6T!6[5"_CIT%JC8ZYG82[W-)CK,@\F.F$U;D:^SP),
M>6%@-:?R)1=WX=<&SBQAY;=YKY>8!K]I3G.%!1:.[BA+N=#YK_\4)>.G>QKI
MIZP1]?*M!_/*6$P#X'8O#!8VQO7=:#KR\TX,C ?)= 3"PF=C<Z\"ZZ90>JRQ
M_FGHLY95-"M=1?-KKFCN%, 62'JGH0#R5F@^EHFQO#"U=$!DAEBQ,W7 V$&L
M<D%&4W-YCO+SC?71JC9^*)T&B<G4<]IQ#0PHL0=VFT_WC!>VUQ1>X?=RQ5(:
M7Q7EX7@$M ';'_Q'AH5[0#'XQG/<?N;E-3_NMWP^+,-$0@\;J\6+7"YM*79,
M)YP196=A/0N#K;8?:C>#U?L2>97SHA-#X8,OMS;(*Q?J%MS1\NF'0N73H.1A
M@GCTDPD:T3?.-$&-T/>CCZPKE!5=G',?4^^"%N?3NB,L<)SGA0U%'6B>("CZ
ML17&>9+-9L$<^SOZX:820[;9-F_<B.4N>9T$?4:E) 4GP"H0EAY]5!8Z8DS6
MJ[3-E:2!H<F"9$I]6Q$$R1 U31%L>2#;LCD0=F\4_,-3I5]7&D0"W*TB1(YJ
M^2HF9<C\*B_8ZMJO5&OTZ-XYNLMCT7^1NM>5)HF+TAF:),,6LK0F*&$=XVCG
MQ05/844K[FG>M_5BOM6?-F"L=(C,0O^/O%U+.0ULY84[DLAXC)V&[I?2X;1,
M/&'[3YPT==Q)D29?#,?)]M)LFO=HQ08]K!9I 00_R<NJ\^ZQM'<E,KH'D .I
M.,^#>\DRJ&CK$_HL]OC$QY(D"H 1:UN&W9&P9Q-MGS1Q**"P2(Q%/Y9W(MYB
MT?9B;6!A3B(/I^:1O+D4]DR %=.B*5H74)G+ Y -G33K@1)C#7I1@EXV/2+?
M9U&2Q:2,5>;Q^KS.?'UM9:K)(PP3P%_X>IP4[5/@4+&(^\!RB">YX,RKNXHI
MP+I=6C]69+AJWU<TJ*'@/%^B@8 6@]ZQCDL4MO ^X'5W?H!BNM8P:SM%"(I:
MM"W'4>!'B+Q<(=X5"9VR@VR1DN3,@97W=L5P796"<Y;"5D\Y<^#^I2!R/-:2
M855T<!YM[\UV+Y3$D5-92>9XY MZD"A27%;O5;X]2S*VAS])(C )%D*JRHO.
M<G_(DM_7IL,8XP+LDMH8(;-(EMO) C#*UM9(QS7]91_1";:V%>(3=:OL6.[(
ML[I=VJFS5)A.M6/%UEFIMFXR9_-&@TL;L/&YBRWSY1-=^,D9Y2'#Y#TC'Q-Y
MXW])"(_CKFB;M<HO>;.U4BSL$T+/>V&NI:K.<5\_1N3Q$6\NIV,__+=_TDU(
MWE*3BC@QF&,@"9@Q-.:*+H1EU?/Y0G34;1O 70.L@GK!F#1HA27]>;SLI[Q%
M7@"@3[@O>;KCG#:AP@YY]'>&-8:0)HS1QV CGED$(O2-.;CJQ6 V)>0M_06\
M+(PCO+DRKZ_>5G$79ZZ#+24!==?9*';<T^X?PU"WBIT\BQO=PT+1N%L$ QG<
MKB-WPM).-.J)9>AYX$48O2N*'MY\^G)]]=?AUYNWQ1D"A=GFC G8C33DF-LZ
MA>5492+4FBGY=YF$>G-+J*GE_W':$&=1V>;FU;0] .M=72J]FN[5"QZ)<(-+
M- .*Q2#16F<?IA^QU5&6+$-T%L OH3/JS1P7;=[OA.[G@\?B(1 >:XX?DPO.
M+#.;N!NA5N0ZR])U(0)_P:T](57[H(M_ ;T_ T;]I?]+P:4AZSK&@MIA;GJA
MD9RDO9" _?1[=L]ZP]86V^3$=F/>6)=FWGJ>;B7?DO5DG5N6(!R2AV#>\WSG
M+J0[E)?W%2UE;[V(GJ:1;W+'S<8.N#6TO7=^3 &MN(B+=L]OSF;6->W+76BE
M$LK5-99.TW/O36RG]? /PG;;8?"JV.Q$"0VW\GP".QCPD27@1B5 =FQ/U%^C
MA.V*>7/VZ9>_ @9P._.ZL&JL56<2J7S1U1BF$Y=]3% ]5+4#O,CY=Y3KAUOS
MX_\./W\V3UM<Y1V5URWNIK[$8<0"&S0N0'M)5&QOYFOD?8D;K/"?V%ZG?V(L
M\FN(3E5"N[XN$+<5:VM3GN%#DK38RA63XGR!AJ17OB$PKZ4NIS#F_H$[W</$
MKWE'926N4TBJ'H@ 'WF=[K;$RZ00**7+4FGYA"E#@C(QW]17]%2$$21<[*1D
MOF-9$U('G.JF+ZO<@6U5A?09.S'H"PU:+5U)SC"X%CT<K>G%TWD\;2KY4+N2
MC]=<\M$"'NE3KLZC.54/&WM5E7M4&RPFE[82J6RF7JW0WW.!L !_"I90[/[E
M# O8BGVRHH ]0'^?W9UA^[S&:_F;\I>(H@(@8NE+5<\SB>_@^2V"?GUL#<-C
M(]QGC7+;9XU>,>['"><\5LFNF)_HKY7Z55!H]T'6^ A;?>7#&P-YBSC<[>!9
M0VTTMX'OI3T4T:(KVN<T;!JDSX_Q; UO$2T\7XK!8J,9/( NSW$L;]_.#T9A
M[7V*[L=L>I4X;YXMJ6^DB@U_T>1!EROPQZ2'_6Q!K89Y#QRZW9"=V%7T!RH>
ME#A34F$==LK&FE?'PAW(@5@WU*NI&V)AD";LEK"D]%3 B35; AL *88>W[4X
MU&(7M!>3 G*G"2UJX-#YT&WL[%G#+ 8?%%ZP:%MH@LWB5CH3?EJ<;+3#6]?>
M]@*ZQASE&+V0L\DHKIP]Q(ZS*4YA+'@\]WG Y6'6[N[&<\[V!!N69[2 8=&-
M&DM+AN$=ME_D?@6E$K(G%T3 V)Q.Y WKO,;K>)[1[RRE5C[]+9=,HH><4/.<
M1^D\Q^P<"DZ2_KQVB@S6)F!Y$"S4N8]8"&0$IO/83]_%?O(->1L/,"U/GQB4
M9WZQ9;$J.C;/G2J):F&S=B#+CGN3D6&+:(%7V5]T\!-;.MZIF]72KBQZ!F5^
M=M1RZ*<BMVE\B1Y6^8W,N45#!G9.78&FO"/<187I*@?B;FCN4TV5]RH%G8Q*
ML29T%LUHF_5JC V;\ONAF])F-G02>2YYK:3@O.2S@MC1Z6QD..'/%Y2546]D
MBQ1B.1#[L&L7,D>/]DW.EQ,Z.1NRI^%(6?]S'M^G3RS<7O22QS'!$J;X'OLZ
MT<'JA9X_EO%F'C4NV+F 5EX$^T#Y*"Q\_'P?$0M0Y+N1DBZJ5C^KK[FZ6"NL
M7!#O]G +B]ZO[W2I(J(2*<*-8@].]=QE;#2*1@I-N],?<T.)E4[0\P%^ 4LK
MC; E$BH[BUFZW,U\BIVELBDCE&(9NR@4@1&D4Y!D+9%CCT7QPLBI$2<J*^7.
MG7<5)BU6?<'9^?EIN7;"<IU%7A/E^8-3D.5"E?JTS? 49N0$\\0OSX@ +@51
M)"D+J%(,E;OG5C;HL=TYO<K&O%QGYMS>E(*I*,H-*;--X!2-/Q>; )>"Y97X
M%NLD.8J0*I9W-RT=7+;;;K]YI]7JD^QHVB^;A%O,M+R%5,YQZ$#DAZ]X#=$_
M&JAD1$2)41;Y%:9W.,P>$A8U)3-_.=W;+&7RHC</8ZZ$M1XK2;/2!#2GP4(K
M+)1B48-%;5QZ#"C+!& !ZXJ"2"<1LO<(CW$A^3GT.&G4&8R[,&%6)K83UF\X
M/S_C@34]I98H>W-<=NY"TV!I!7F7XBQ%'RG$EN2ADX$%F)_&Z<3QA*QNBN^H
M.4_Z%%8.GESETR,X2YG%4JF,#/,#3I=;\DYH/C,WTB@1>,3U\WI(UN O7(L6
M-$K O&,;L_G![V5-6FC+OL:].B#=OI'Z73J/V)'3OJC[R;12*XXDI2<;@!"@
M)QN@S@T"<*$R5NXW(S$5)T51(/R4$M;TN*%%_$U>[<=RXXJ&8I!)0?27Z3F-
M&WK\@5;'-HNP]MK[7)1S^4%YK'LFDW#L*%0PYN<AEO/Y[&$9MM;EK+S3>O$\
MVG0Y+S'-V2@E6 )-CQ1V2\]X<GVC+2J@L_P WGI& +?39ZE_U"]:\_I8)IZ.
M9H-%B<IN]'XOL.E646E<66"YF/(\RX^BB65%WZ@K5K83WCH_]((>,!!&7YL?
M+F4T3W8Q,982JX,@*U]F3;F9<UC8+*4W=O.Y)^G5TG':(!3[CB*$MP&VZ((M
M\I)44WF!^6\L[DR#(N3);I@L#MG$T#YJ(#9]Z@ZR)N-CI'@:.\8#(NO/G&/&
M8DY"!6G2WMXQ[:G[)4MI5?3:C>=-A&]F*( #5'I@L3L>_LN._& APW/N,HD=
M/*WW5V>&)7V?R'??C98.\ZCT<L65Y?M2\D:7ZS*Q33D_K<OY=3F_Y[?BRLU/
M"C_09%Z0!H9J*NI [ZL#PX:OFL+SAJ .=M[\=(S9-^R'NBJZ+-\2=Q+2,BNR
MQQZHUV0M7[+S;KS8+QJ#T([1B^-'%R%IX)\\#)TLBOI&F1^D2V>R8X@Y3F$@
M"]'D]@'!TU0(-4[HD=*I[X('%@<TCC!#Q\^A84L,;:-1#6Y5BL8W*BE63X5%
M0&#-O+$&UV][=S%(/_SU3?D&VAP\/U;T;:%WSQ<SR)-VE63:-/<!S_-V*!A2
MP))!T)S3"(P\G" W\O.2X?)!A::F=\[P #>/[8_([V5&%JNTO(,IN=6+K&J=
M6505F+3/3F\GN?:!",)%>1V2;KY9KJ0(/&28_83F3@[B@CH6F_9\I.+*)L!E
M EHT:L_/V /2H5%PSV=N^M(^H+K-<,6N&WKJ11J59XMB^! #)LRWH($!/"O<
M*TQK1HKP$+I;KJ.+/9W^)'.Q\_TX"]91/E]@E55.8\HKY^-E>>9P<32"Z=+T
M7W%J?$9C"4@R>"YC56SAJ-S?2 N-\Z-%N9N@).P-)>$)</>X6;&O./P]UMWZ
M;IU21P!_9 N5?J\90MI+6N4P2HJP$+0[@&CZX(9%H1=)6I&T.?4FR[VOSXX
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M2E+&AUHH,D+%**/)6Z,?]J[OD57 BEGJ4I5?HD=8[NJ/4)7+&Z,J#B@KQDJ
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M8;)P?OP#[B5GK9 P3T6'#4SD]'>CNTF,Z88GI"8_XUI%+Y(_[>\]QN 76 K
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MC$$P.M%K_(9"6[^G(_73/)/D*AO5V9;N]OYTM^H/T)[CD+,M)6Y&', #VLB
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M&/G \@ <=WL21'V+?Q1W O%A0#IYL22Q, @YPAW.Y?+=5ML'!/R=24P:.Y:
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MV46JEM8=9^'[PM4]*%?A%09!4!T41'SZJ%LRY.C87)5\P2[&.*,-P(6GS!J
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M[SBH?2F0E1E G!@US..H:UA3<P:8M6$;;/W'PO&GCM*.&8Z9]K>;.$3FR_+
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MJB=%88@""O3,G];38.HZO"(V02C/BO!NVL^B)'V'VL,Y ; OT)5<7] @2]C
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M6V #_</]YW;5J.I?HBNWAJ=ZH(6="?E^H6BX"HZ>G99T[I"-;?K&QINOLA2
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M&\;M6\UT!PL/,]<VZY2*&18@> 6)"FA9(.%YEB7+3C:2Y AZIAT?BQE%HA:
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MOM(8*O,L@%AH>D8^P><O3NF0][.Q<"I?##H<Y('806<Z0S,<3&K8,L8]<DQ
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M1NHC<MVV[?25D';O=\1P;5T\4[K!PN2M=*>,XHA7_\>-ND 152^'0<9_+
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M#3A)FJ.1U"%EK9"\]_E\%N]Z%YJ\=Y/B;DVLH<R K:GK)8X5NT$;'9](88[
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M"_C>;T3>L# 3_]]FY6;_;-H/^#>2:T(ZKVW#NXLT, Y*_5-F-4W(["JML1R
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MR<8$5?H4-:\!#_&"+;R_%(O68ZN11 W<U.*C#[[%-KV"\'[:&ATU8X0 *"5
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M#,<_?VA\X,7I3/GD%2&T*#%"=4:*LYA<1?8-Y3[M9J;!OY7!O,->H3^?L"E
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M0K-P@->3(L[X1M=J32_Y[)6TF+"&*4Z66R<3998LT<Z#X3!LD2QFF52RD$+
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MI]1D#='MAC)U)7'=7;J@!K'8'=XOT>:];=R'2MOSJ.WF]@<.=L\[X?K8M
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MN24MJF=#C3(9@4V^XH&T@S=B?QKME^VGEVV _!!9*1[1>/<VVFL[&[K!!)1
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ME M5P AR_2;6D*-5":X5ZQS?M8#F>0XUT@I&V!1(3N:!'"WLEY6 XK(R(B[
MA10ADB[FW?T#)-SZ53DC]Z?;WCA\9>/ >\A@O+PW^7]\L/0LUMA>UW5SR1!'
M[%UQ*_F'W;6_#!6MNW?,1?B7=^X1#M=O$;B/_.%E;$KB3F/ZN=]Y%2"AF]FJ
M*=#UA,81:J(.]TW*ATB[,UO0"(RE#=CCQ&+X!1N>K:'.KM!'/0AB@EE+N"R
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M5(K1$N*(\=> MT*TMU_Y^Y7_^Z[\*X(J;UADJFP+CB>=D?>D2D/5YQ1045$
M#:F!CVVDB:ET#&7L&A9H9M@"L5C>H*N$2PT<CH[.,DUQ,6HPK4R5E"&36$@\
M-%O>T)&"PU?I0^@DVG !M)V?R\LY)WA8YB"[T_?CCZBJDCP0/,^GYV[&F5-
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MHBCT 95)*FIO9*J] &#@Y+/$8?0%TU"MQ^S7X&C/+D=Q=T;$=:MSW,NZJV@
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MO*& NP@'EP$0*=X)G7^T B!8@[U><H!'Z\?E@>!/-*[;7<2ZN_#T2?_GGB(
M6V9);N-RNI'9>#_AGVVYD6BM,"U%H*^J N7..N\89@&=\_*#J]2D!/Z7\%/]
M)1L4H'_,,@_M6*FZ3$YT/EM@L]O=&_#=OC=@WQNP/]^V?G%C:P."Y^QZJS+W
M\8^ 'B^)5!FZNM)B!$2F\-;1)>6>FCB5?\)!I<_U<%4.DGG9[%1APV P9F&C
MWF9;!KZA+8%+DA9Z&3[!Q*@+WGPE2]DR:4[RJ%RNEC.R'3.>U6B9@90$\-#
MG&EBM+W;=;-1O1J_Q&R\;O)J THTRH!T%Q%!RQ0K7=K^3=WBB$378Z)E[B9F
M4';;,,?YX4R\OLG#4.#'RANE*&4!XD3R:@,0"J,EBFGUN!2$RP_&*XW;.65]
M%D2UXM(&X?>$I570MQ $[?%T^YK!;ZA-6C=04.)FB?E&"(0WAB>&PL^\[6O1
M[MSH'LLK%;"43V<B<FV+!BR#>+#%,T3%A81H2$F);9.^Q<\#0N<6%[7W9LY%
MC[-N+G6/<CLVC$2^IF/%<!/)?['Z8Y;2!X!B,!D59!,I?_;.%\%-7+XS-
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MW8;)L[Y">^/#)P_L(TCK(2G,%_:!F60M6@5B$;4S) ^/[\KUP(\Q!!;C>!.
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M7T5#__'OR.$-65RR<GF?/&9IF25!TL/M930?HH;T&3[OK3!UWP0"D F$%;I
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M"\>,:K9Z0O_D$>5G^F%;-^CR2_!P"<4&)HR^B(;6Y\"_TT4A_TV%@<[C.9A
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M%:X2R7_(KLD#17-U6]6@V:"Y?FAV[&9[JT6H#)H-FE\)S;V![72VFN_9@-F
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MH$'@9@ALV6ZGRJT/@T"#P.W$ ]OM?I4(2@- T #0 / _0>@6S$+Z;X \$B.
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MQH)/>6A.EVOA8S)NRWI#RAE4N8UEX&3@M";JOULI2M R@#*;'D&4@92!E(&
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M3X<\MEJ.;;E-9V!O,$IGT&AM;Y3?8A8*'R6!]04>C49KAMS?<,C][0QY[ O
MKAH0CK]X%_^KO(O_&][%SS&D\75:??S-+5!\$_J]=O_.%I;/IN+LU<?0WA:$
M'N?-4KZP%[&'D\F_Z-D@G<2,>XE_QX/Y6_J932, YG^@CQ$?)I8O1,I"#W:N
M2(",VPB.SBO#T7UE./9>'8[-+8QA$SBN%]//@&GC,2O@(;5@05M!%:E$3UBT
M/O&AW2B*1B5\4"5T]T,E_(-;$W;'K9##B*P9\T>6Q\3$@I'X(\"[0'TP2F.0
MH--I%,J0AX;UM1#Y0%$IO?<Z_J&@4WZ<3M,PFO*1[PG;^AAZC?*0">08Y#BP
MB\X\&&$< 9.'M[D^X<LQB'0H_)'/XGE#.F?6NFCVDJ/H'V;YHY]/Q'GW\K)U
MW1Q\:+MNI]6\NNA>-B\&G;Y[V1KT+B\O3YYJ)>X"-O1Q,33I8\*G5J]172[+
MI;065[3*N.CQ=WX"<_;*1OJ)A>R63P&@"KC"N@)IG0J!DAZA>!ZR8"Y\LFRN
M_1 4"!]D.6B]([D;X#,W7*1!@H]4G_(N9_EYQJ6S0:Q@[(4E3#G0=^?5*"'&
M)4N1%" WR%"!Q;ME,;*T=1W%]_#GV:]1]!T_?TW W)TN^&*JD(V^\D%;"$&H
M]'<I,%Y[5-] ;'_]< FJD0<2&AA+X$X!K:!G((E@'Q%>$($I.%:4#A2E_1"^
MF1)$+1&!^&<HYN] VD<QM '#&/($Q+^5AKA7)*3=J[;G&><J9\0LCDC%$L2;
M4_:=J_9!79.-XIJ"3>#YR.6B87V; '^?AV$*G'W#9V UX$8'<)A:3O/LORW<
MAI@?"MASO(F%_;G-]\MS$!E:Z 'GO77O)Q/8K' SFW(@ CP$0@0_?HG].W@:
M#&8OC>F*LO4K_.=64N"&XVBM<R_!YYW!H(-#A&VTT ?,:PY$@?^,.- UAOD&
M<XMZ6YZ+K;?4.;W$ J"P?I/!+A\G<E@K-!CB_CV&31>-)EB^"-J(K5'DI7((
M8S\ DN(L:5*P\K9U/_&!1-#4]S"Z!^DH-+E\P$0\4T[/A:8;BEY[)IM>B*?^
MB.*1 EY.3%A'6U%-ZS[T/0M!C_1G )+2GP'Z_G3MCS^(:4I_ Y;Z<^V/J)B!
M;EC^8@!F4^DO0Q[XH&9FS((8O:>Y$EIY/*4M5_A 'B:UO82L]U00'R-3AFA(
M 9H(@B )2,"HO3MW3D9R]T/N0_^5WL+A6Q(ZV":+N26G(=V;J.WBBJX(JIP!
M&]9Y$#SP.[4Y754OE#YL27++7;DP6"!)J"07-@#31L+CF)@5IF1IPL.Q+[[+
MAU(8?HS"B80("4Z0O0$J[D H27'F)<C5L=)22!"/@?DLQ$(,M #),8ZC*;R.
MPGG$A1?[0TEE9.R'B"#ETKKQ -,'Z8C;Z(I!^I, 0:%X*][)L2V009OC49J
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M$S0H<1"V;$>C#8Q2D(Y*3# A(B ODC>PK?O86UOTX"!0C)':@5Z6#3=[&3$
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MX4B^:%A?2T,H,%8YQ1,:D>2;+<:#:+\)PKCLH!X'.V$BCX6Y0 >#YN9O4D:
MAHV$E$-444,R^.5E@VYJJCZ_-H-])A-&'RBKPWXZR22A16%58$6E ,8SW&YN
MU=G'6C50AMHB9'B<G3KY/"!6019K5+_$]3$$ZW.NW+;W%.TV]1-R&UH7/JF#
M'D;&>G1_]#R/NLDLT8M?<R-4\>;B>?%U%(UH#E<8+W"^R&&G)X#;D[>U"20C
MWRJY;C.29,V!I8F"JH3OB&_Q T8)W:.&Y.$Y#IJO%/"811Y1:%WLW_JAC/C*
MJ(DOW6+1)'CG"XX4584;CM:4BJV$KRDJD'0=2<O?!0#BFG.*4SX]^7+U^S72
M4AH =(X#3Y)@ =3\FX$9'-.\!G*6A2\6)\K(#1]P"LT7LPB7_E>YVYZ>7-[\
MBNM5)G9@]G0&EQ]*H:X 0\G.]_%I/X/<0+K8:9+JUT)H (62J:B>[-!5!QX6
M([1 "OL4'PTJ:.ZZ4L8336<$ZTP^?PR&)=5N-,*C+*F3@&Q'0,[MQ;A 6\5*
MT/VGW/-R^>DRP_N4(5$$A6D5HAQN?E5!$BJ$@Y]E431Y;")1:H)<S$*I!T^Y
M# Q9IM97A!)Y5#3-U,FD?B;2'46W-"L9?H1_*KU+\&RHA,)(K[4UYGR$R8@7
M%U0U2*,&99J.>7Z#S56Z=9IV$3.YQ-!KHZ0 -D3[7>&(R&TIO]*6^4H'L,'F
M+E4,1L>NQ!%E_ !-T3F%B\-QFW(M)&HHVI&/\M6G2"J*JIK"1&T+>Z#QAA0M
M!K/VY-V*(J@ )1G)552=+T]QU=QLJ;N0=85NM"#@8&H!5M 9BZI,&J\+4Z5M
MA)QG,@IU,>0U[T(:^U] G^!6"Z<R]O$,&D.5SK]>?OCM&^P4J6JC7/9*5000
M@.!&$T=2,@_@E%*4Q&\FD@L';22SM:*U((TS6Z1H_&#LD0_-HB47S<YP U]T
M.2X,&S94&;HL-4H@";L#+B>')*/<VF"GC,[D^CY32S@*2^ S"F*,#'0'Q5/
M+)J*;GN.9$ S4?_;)^M<Q]C)-;V,[CD)5+S9+RUV@6%@ C09+M:%7Q?OKMJ(
M?@M$([S^IMEH.NA,EN_;R)*2PT'?AHYO90#)F,<R?L[WR(1-9SB"-TX'7M<7
MTFTE2 !.)(_POR/)1Z1,\'BJ1[<P+3LSG5FX>*\C.8.'SV3XHW9>J2C,PI H
MI%+;K_EAMH@PC!-VL9C+&! 9GB*M:DG$>Q_#Y[Q$G_PN$TU9QN'HIPA%/>QX
M_HP%B]%RU ;84:I))F66/$8@*JF#^T;S[RH26)+@-HY ;F%&&63?R(--0<B
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M0]]>BE4#Y I#E_XP<IPTWOO0#JS&8@ 6E'(!D)W6!74Q:";/;'8_@"AEFD
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MOWV3M_X ')&'FK?><>Q.T^09KY?XVV]$]>QVTWBR#:*VZ *R!TWW4'Q QPG
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M^T&ST=Y\+,^6_22CK3?-AI,IUYFNBL1%O3=7F6&&7JX*K6X'F.U\Q(>@L[(
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MQ5G+8 ,)Z>(WL% -5CK*6)$BW-\[A3:U)ET[J/X.S[MJ<T\1CZ)=8C4OZ)[
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M V$"-FHX1W&RWKM.IN J5*6?+!T*?^2S@4[D^U.1;],DCKRT;%O0:_-&7
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MNKV>+=>O_.X_!%)#09*W>/_^JEQ4>V>YJ]RUFD0#6@%:.5U:46A+*Q(;YVS
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M&M>*+4V^_@L+141,MHY :#L2#$L;'Q)DO:&S;.<\7.Y%J"$1QZ2_[B6, <&
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M#U08\$5W^()5>U&00T(0@:6BQGL<D:7;\7X!*]HZ7_BR2/"_5Q.$O_?9%<5
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M"@!S@'DW8$ZK_F%*G2<D!,M<Q$Y[$M*7 N:"&\8."?-G>OU'4.OT.*.J .^
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MKS(UVZP]T?:E8(261 E@'*7N XE%2I%;IYR%+23AC//HF.R6H_%7X#*PV4*
M*<PX[G%B\6*Z6,V3A&6#>3:^O5S-%UD>ICC7J ^M+=/B(6E.8EQ"9\!44T^%
M+KU*9RE1C65:>=3G[=2N%N-IME@4*?[YZB[_E.U#?I]=Y<S[Y60<S<YJRW-2
MBJ>+)E&I/B<$%U(2HQ5G#+NH#=^4R'C9G".\-YH.LS12M]F? :@"5+T 54I5
MF0GG/*,\1Q!FR8;$1E>[,RAN3!=N 54'J!$50]'J<BO %^!K?WPQ5.$K1*NQ
M(U@2+1($I$9L&T;Q1+6KM2 '"#G _!_$6?+%?ID.KE;S>3:]^C)8)L%9K(7U
MER1AP\$T>ZF+]M2:SA.,Q#R%ZUH@Q@=/D^[4W&')C3<R)%SGOIT55B?-V9A>
M7!Z)6Y_(Q^I <L3GJ7Z;)?QE'T>?3\:WVUL".JM>(81ZGL!FE<)F5NM(C41*
M>"J%B 9MUVTX+5EKP#Z!O"3@&_#="WP+6650N O1>:-D$(A2[UG<9E"(,O(
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M';UKR?Z31\TE <"!P('GBP'JJI*%G.NJ8_8$FP5-]0+:C>]=0ZCQLB&9W/@
M3G'#EDB0'36-<?(DV*^RM[]F^2=EUX-1NHG1+UD9/%P,5HOTL^5LD.[J:C49
M+;.R.*X197PD:MC;[MNG"$+7MI?81 P*(R,")AX'S7G1?I>^2X0AXD."V!R#
M*4_AS>KV,IN_O2G@_7:U7"S3 T[WO$>PK#S//??7TZ' ;;+#KL(,.[;/LKW]
MVP"C21=6 \^TI,PQ)"(+^3Y>ADQMQS9JS"UO V#?#,R\!&=*#3EO,QP#. .<
MO0!GE&]QEJQ9+*,(S"CD%$$V^FUM8)X8/RS.OA$$> G>.!TRR0%O@+=NX(U7
M>/.,IQ^Z:!0)FFF-C=]&UY"VZ%!X>]KA? G@$!MRVF:)RJL![DQ*2MXN/Y6>
MWMT\^Y1-%^-?DZN7>X!_6"^Q' ZFV7(PN\D7:WRE3&0+7/I4+^79A@U[?.-P
M^G#Z</KG>>-P^GL&B55'S8'UHO3!U7I3^F"9KTJ?% O?!J/K?ZP6R]MLNNSO
M/.\G+'C,J]"O8%%@1:12"A/IC78A#_TR+ 0EW.&'%GQA:KFZI57;L??5!?7)
MEO]8G8'9'L&;;/GVIK&O_H4+MAZ:\Q)B52? 0?U WA-I68IE%10F##LGC99(
M4>,Q"HR(S2H<9IN-K,> WH$'H)WAO%3 ;2]PJRO<4LXT$@KGC>A*2B.1"!O<
M2MX,>AT7MX?L(\6HS3 T(!@0?#P$$URK=TC?6&:\DS$R';R*T6\1K)OIV&,A
M^!A#P\@9(KCM,'A7'=\_3^=9>K__S:X'OXS&TTT,/"]_RI(S/%Z.L\5@].MH
M/"G:+).8#!9)>&"XX+/)I#8GR_G A!$H(N,UDLDZL*+PH"5R"#=SSE\CD^KP
M_FLVR6_[/],1Y@SS=OIA>WIF/EZD7_GT[?27=^D.9M>M^= [C=S2,,,82M!A
M..G+ G"D-LZ*>.F-XT)I:;'$.J^_W)2&D1CTZ]!'.^NQ&^Y#%[BCLQ$\((/S
M) -9.2;*6<I"]);&*+"5A*GMH&+C$7MM,CC >FW>9D@!2 %(X31(X4D/H]Z>
M095$F%EI&$6**&(\VY@(V)+&)-[CL<(Q!D8A6*IT^'ZOKD8T'JOL*TOZUL&-
MYU3VO91F3I=-**[-C!,.!T(H"I%[IR,CU)3Q"FL,M8U-B]\*?AXU]D!:;>[:
M];"[#GC(3O0!P$_AEU;X538HY[0V&"<C082HY+J73##J4&,EVO/Q>Q#GO\V\
MPU/GW%EK'L!X"F!\4IO6PG<X.*.2<8ZY9L8I8Q':%O%$%)^52GS-U/Y1EXZ!
M;@4X=PC.LE*N00I/L%=.(ZZ\DT%M G#<<FZ?59/WNFZS/&:B[E0 ?2;]</<$
MLAB% @&XY[("0]40N8!%C,(J;*@)!G&-(RM<9B6$M*)A<C]""!LR2-]-5OD=
MOYO-B[*@KBPOSY=IM=OUVOM86Z=(Y%3MACY21VW@N-58"$Q8P%910BGF;CM[
MURG?J XZ*'4<?M^5/.!X-F 08)!S89#:]&X1/>8V>(R(LY0$C%783&]$G#8Z
M]([$((?>5Z4/N*\*F 28Y%R81-3FP"*G)0]>84<-EIIJYC=,$BUKC'D\.),<
M:=\4 RHYWY&QS5A(8]?4])ZX#L9K>86 Z=<X19%J&R]'FC$F# M$&.,<XZX(
MC6BL!9:-VJ1O<$IG0B&8'+/DZ%1H 9(AYX!MCBIL(^\M#XYK3WR@N:G@U,9>
MT)@>%ML'GD0 V1% ^)DBG%0(ITZ@Z(SWP1'C":8>QTUTDB'9&&5P((1#80,@
M'9#>/M(9K?(0(E(NK @.1RT<P4+R[:1>YQMMAJTC_1BS#0#J4/+P=3?_B972
ML$@+%FD]1J*BJ@[CE',C$WTZ$235R"-JRV!'(E3TK#J0H]5T)#,.%F9!(@6V
M!@+9[4!VJM8GYK4TFG+J;;'F02.[S3LKK1I;HW<FN\-7H0AQN#HVX#S@/."\
M'G&>0!7G(4$1CYCI2 /G3#"&_,9+UH0TNGGVX+Q#U\TH!?8><!]P'W#?+MQ'
MJSK#Z(CUUHA\@QYWE+/T==OZ)*-[$?<=J=*'2B"_9P<'_U1$R+8_+[[6+F0R
MGF;??RH6M_V0SN]?[]T*%NG":Y=ZE>4!X#9XZT.6#497^>2/T?1+7I8SG2VS
M1;'D>38M0K&C?!'TS7@ZFEZ-1Y/TYND'Q5Z//]Z_T^)+V;#]\-Z:5_[=M^^]
MA1OC^L%!%%\_S3=O<C?Z)?O^<IZ-_OG]Z"9=T@^CR6^C+XOT47_Z-%_?S:@
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M/# "&H)P S 6?;D+,^0ML5W@_GLMPX6,+9SV(\Y:[-I<7NYY_%NGMUD\WEV
M/2BH^\SA?8B=7%V"]SF=9=^I^LS.<LO13ZX./P!''_W<'V/MT=UX.9H4T=.B
MV#9Q]G@Z")^OLL4B#ZN^&\U!3 #R<)9PEMT[R[.G;W-UM;I=38I,:KEJX7X?
MQ<5ZU4(^SO3<^\@ ^W"6IW*6YQ,Q.1N1%6<2!;J]G4UK8?OS//6^W]^C1MAK
MQ#F[8(1]G&>CQ6K^!8*=(! -J]QG-^.K\5=FD?5=*OI^?R#U-:F_/TABL)DD
M 9(!GDH'Q/Z8)3MG2@ ?/HT2X 'O9WGXYG:VFIX[V0/RS_CP ?GG=_AP?W!_
M<']P?Z!<#A5;G2U'DQY,1=S3W[2CR6AZE0U&R\%_KZ;9@*+A(&_!?^TY&%^]
M[8?3#_:\[V\O52>$<9YA5IOL9PA1,7*J.6::!H>]I-YB0QG5F$CZ</A!:;%>
M+!:K[/K!*+^+_ '_#_O[^J5__[#I2W>3T6+Q]J:(\IO/X\7V%;72YVWE<_&J
MG[/;RVQ>&Y*P*#YVM_WK_YO-9]>CQ:><(13!Y,<V)R.\=(S'T3>OG^T8EWWN
M[\7'NR=L]YK2<HPA+ >E(55MDU<J.A.X0))%C9S0Q)J2AIB20C9F[M4[V\J^
MMA;VRQZ2P+XYY078"]BK]U9'?<$*5TH::16VAGNAA>=*EG#7@EC;6.VXC]51
MTD)>UCF;YO--'@ W+[=YN:WQ8!23YD,E%"#V'!$+]D;7":BV_T4Y@T4@43OA
M'56"$8-* HK,4M68=WE<>V-OZMK9RFCP%I 6D!:05@=)BU5K;)TU 3EO1(@J
M>A.-T;X@+6X09IIUF+1,>KKY!XXF[T;CZXOINGVR-0*C& \I:74-#I 8D!B0
MV&XD]M5QNQL6$]6X71>-9Y$2GIP]J;'AENN"Q03VWNG&+ID.L=BF8'T/XVN7
M0;[L.%98$]HOD:-V8 $#RH'O^L1WJK+:C%'")4\S$JD<\=AH5V;8A%<!(]YA
MOGN?+4?C:78=1O-I>N]%^Y1'A1IRQ('V@/: ]DZ>]@2J:$]RQ8D.@CDD>/ Q
M1N<*VI-4A. :>U<[1'NU-K1B-L0C"Q_:9T),"; @L""PX.FS(*E8D%*L>6"*
M<(84CH[R4.89I*.6.])A%GS\K=LG/HDQ$!\0WW&);UWV6^Q^:-3\]HP5][O7
MXU(FJU*SC!AI(TF>8?*:5>1<Q+(V1$:'HVC6AAR0,MOD.2Z'G'0WP/>:B/CJ
MAJ[>3'+*2Y>*@O39S>!N.^1YD8ON<##-CM4%UHF4IN!5W2>6REND*.6<.T24
MLJA,:2I"N.9F _;Q[>WJA_LEEF4UF%_-<Z"GJYE=EU5B;[+?BE\M=E[&]^H5
MZP]=P6'"7(M$T=F,90],EH,.*^\&7&6EFYU ,C+* K,Z,LR,(V4L6PD<B0S/
M@NM?1I-5UA&T[EMW@ &GIX'3D\/FMOH?Q*A#8G32= \B!2+U&A:$)+S*AE,=
MF$;14YK^H\C$8$L+0EFN&7L="^)5:Q<QP4,IV\S^ %P!KJ !0*1 I$"D0*1
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MM12T;G/I/* 3"/\%2*W5BA@G PO4(!4"%EH3+$2)5*^)"_Y9!GUG@+JO1T
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M+MYRLJ@G0N.#>SWM>"I,]F)XV)DTV!?QI.\O1XLL1]OM739=C);[915/JE0
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MV&YE8E.X7R(EL$7^7($-,1 0*1 I$"D0*1"ILQ*IG7Q/(JM68FZ,"-1K8ZG
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M 'B:3NE$*8E2!ARMQ:)C%$:,#4Z-U]IC!<-W&+N:49RVV.[HW0R%40Y>K $
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M)%$40X.5CQT\GDN"J*DPZ8702-Q771X>DX<NY<1CD2":(#J4^2%,H U&O1-
M41V0JI'7TCK*<<2HU%YJ08:#T0/7$P;+EJ>)0 G10T-T"G4DD4HBE40JB502
MJ6<E4O?R-GFOL=IA9H0!)GRUFN!@N]:6+**,6X-O+TO<BR6[C\3NF%)\"A[B
M,YEW%^6F&GBW/ ]2$2-Z30)WMAA=K<_FLTGXRWD>Q6K77.Y1'=Z6CA8\C9JI
MTSQ:,$GG:4CGZ4CDO:P; ;O\%N3.8R 4\ YC%?X'I W6C9"&2,6D>E#J^77^
MN?I3>;"D5O?^]5DYF\ZRXNO[8 ;=-EOOU=LW>TU1LS%!3U(AER@@*:@GI8->
M)0H/P'<0("^9%$)["Y&HZ,!90[2\O4W@&\[.X-E@Y[0X>Y(9 8D'$@\\*0^0
M;EHX 0 HJ)$UCC#K+:,R!CV$@EQ:1FZ?G_14//#=M/H/X@3$T5BP)YFIE'@A
M\4)R8)-T)NE,TIFD,TEGDLXDG4DZDW0>D73>RQ^5A';]UH(*$@^6-)I8 #AW
M%%;^J&9QHN_!XE)/[$/B,<!/,M1G^'G\HTC75_+P\BPK\XC4RZM\469QRTZD
MD3&57QVU2D@BE43J.;=82]D%M#4&EOEX%H .)H1VBM,8T);84ZDX<0]KL8Y?
M=61]TR/]H?=8[_,XE 3&Q.^)WY-(#87K!<!=[Z%4D%'H(<3:$>DH8(1'KB>(
M$$G)[6.YOU6Q?5"J_VXF<Q^5"G <G.;$^PFDB?>32"612B*51"J)5!*I)%))
MI(8K4O=R>&"O:IM@1Y&C&$(*I"'6$@\JAX>'GZC=/M1\?PY/<E)2DVJ_235;
MO5Q=Y"\OL^*/?)5Z58\U33LH 1ZJ[DC2F:1S6*FZHY+(^YDYO9ERUFB-O"*&
M6X>5$H Z !"S&'A(3S"7M79Y>7Z[[]5NO)-HRKWF?(C8X*?Y$R;Q 1)3STI
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MD/9<">&8!Z"M7Y,8; U(^!8G1$H0_X_\]WH.X$N;3S#<:TENH 9.$C4D:AC
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ML/GL8V>3T\#/'<XRA #T3L^D-L"&.0 P(\%/=HS7WC+03&O[" =./P^)H \
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MB>D>%_&D0D=%2 @$P)B= 5/AG@0KFMO-\N^$QYOP3-!,W[09.2KI.9.(.
M$IH+KZP.=F[0G34TD:9PZQROQT$SY?T21!-$[P-1WD$4$@2(Y\9+)""VE'@)
M&NO6$J7(OB"Z1Z_T>6'TQ))^[6&+T3$-6_8R#A-8%V4>=O[LL7[H\0)2=H"D
MU )CJ):>$P,TCWU-5=+/<4P]V>IG:A?4U66[-BSC09-]<BQ1RE*<F(X[6N00
MV,W-\0X81DW07='OP\I*Z=HL!?3;DSCO1,Y!LGQ0CI$0"4 )0,, $.YFTQEB
MB#500A#^CP&OA<5MF2:C_.&JY[#I/3GF<I]'RB<@)2 ] DBT Y+T5@K'G#.*
M!@/.028W/>D"6K\3D([$@QJ^HW0B:;W98KJ>5/UZDV;FRO)\'U[4Z<4["._-
M7_4 "*"@,!H89Q%U$E7NE8>2*+F)=\PN+]>_U(&.5_5"NW:=WYSOW<EZ7B&-
M%'9\GC"4W=@C1SCCR&$C@+7*<F ;#4D\$3N",.#>&QBKU5D"8X)CH. (X6]
M?G9NA7&,(:2,,T( #G@[<E@##!\-QT/X?W@, $W(3,@\.63BWG E!H#&RDFH
M)->0.X-H4RJJF1/^$<@\$H=R>+ \L91<OYRX]B'/\Z((GF61?\H7Z\=.@CE>
M&-+.7@T@1)HKZ!A$U.CP_XC5;J-6CH.MB(X)%XP?^[?9ZL*LR_!<>?%K,_GT
MZ[MZ7=_ED^7'1;BIZ='XDH/5A,])X0T74'?-[:2\4VS("0@M<4)2HKC5G&+5
M9NL(-&J?B#J(6RC3\,Z$PR/%H>P9F)83;Z'C"A%DC06*B!:'2FR?5;<?'![
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M=@>4!-UT;$.#YV:4"K#BG!HL.#8-H QB?*LP^Y& &OJ1$@E8"5B/ !;J@"6
ME@@#(+'1BFH,C8 UL&!UWO3>@'4D4V>&[V8=>1*P'6-:AIV-2<#+K/@C7V5G
MX:<RGZS#6V9Y:B3<@BSI((M]<,U<4(9<!SA130BO9M)X%+PW;VXY1?1LI1;3
M>$C+ZNO[S1JW)[JD5& *8:80YH/ R+K#)RBPT<$#E E$>3QP.PV%:BDW<K,
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MY7VW6=V##EJ3]!E6TB7O]QAP=Q?L>GE#"ACV6#L#M#9 (;<ICL#.G./P=UW
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MM%=1SCW1G$DEC8&0,Q'^QMIB6"_@5CO&0T$T?&<Q82EAZ1'6(\7=H=C X=(
M Y3SG'$H2";D6UQEMO^P'2 KGF\3^_N6.S$A,%CP.!=$.Q%68S7DD@ O#&$
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M9PR9=$C&L8E"!&2C .K*WZ-,!K6YU>!U&YQ?!03.LOG;:AO>-+MPT*).CL<
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M3]X_O&^>5,/'7.QUU'6">(+X$" N87_P%Z,.*^DE@\AS"I37F_GT%MZS&OE
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M3JV56%X'9_8U!CK>G,=E-IM5]GF:-)OBG2G>^4 4HFZ*D%/,N _;"37G",9
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MK#<XSGB@@A)3!F'CG"9,4+%I03#;??[[1AC?"\(('F.YS]KD!+ $L$< C'4
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MUB3/*#!J,8W_N$Y:U,ID1?$UK,3_9/-U?J/ZXE5=?;&'G"D#8LS07D\VWX<
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MM@@)!B$(T&, 8.T)?&43V685M)MS<-]U([NLF.F6:'-:^[<+7JHS;J,[<2!
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MD2!!2HG?KA&7B" _";"^.]<^92@8AK,@2B3R>1CXSU7P^V&RW$J[5W/D?0.
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M!STIE\ZRZA"S#J4KX@&:M]$_YU4AHZL1K)S:NF+@HC"8'\4%)-@L\RGPN;<
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M1LW^=O[MO+4<S<EL5F:Q- E XL?@$L BY)8;^W%]"DQ]3B4ZNKY3E^JRPZI
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M[ZBWX)?\KBE?^G5:3/2? QO4V#JV1Z,(T3A)$?=IQ#%1C$# CG L,0UDN^<
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ME-UD0 *D[8'\#,H>3R'&=3;-+^?:5 #3:'ZKW2+ J\E<33E$#JL)RJ[T!:_
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M6 +QA9BF5\Y-UUB-XU F8,^5_ZO9;DX]:[T/1TX=8LF#9B )_-+0*"8MGK%
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M=@>)TR+K?J"O9)#^G#$P*VY_>L2J$K>SDY_UKA#L)Q#X^>WSY_Y#ZY#Z6&O
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MV1]M@S@L0>I$BU9Y79';S*=:$$K (A\-<MA#WV[U0( ;#R^M]NEDGT@5K D
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M.3Y ]@ \FD9>[""=/-B'U#+@7&JWU'\NX2^0)S,YAH\@<W3$NV V;W>:2-I
MY8LDCEC(B$ J)BD1F/KV-&%A%-$59 +S/-:A6Z%^[\KI4'_AV_RB' U'6I/
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M&"&FC;> 1E(DB0C3B+J=XW.%G[)SDNIY']H\=93FY3?.UHQK_)RM5C?LOFV
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M5>/S8MGX=(=CK>S^RPF]LC+_%Y#C6$M\J@7^/T'>MSE&=VE4#\Z#0S:J'SH
M)%K<(%2Q1*;Z"$K\E%&9R"@RBQBQ@#'LKQQ+K[J(P3X7$3!.#T&7_'*KR%MM
MFKZ/18!)+%,?RUCIU["*,<=88+&26'OE523[W(KB SGK44\?%).\!:I>1B'
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M?X_+:&R>?S<00]7[3[[X ]!S[<Q0!P"G[!2L_KLX\+V!@;6]CC88F +41.U
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M2J784HFS4*%@[XG\[7C/R&OCAW(FWSR/P#LX'3JRN7OVD]WT%6EX&GFJ-52
MX@@E5$;<QT@&5E_12"3BD#R-3^8]VX<6VS&I+L[YVR=$Z179N\B(!Y0U9DNH
M<)*D/O/]U*<D(I' E1K %*VO0'[-)@3'>J;M4:S_$K/BK_,)1?#F03+AC/:9
M\-X.>&MV &_9 52$F/.$!M1'@B 1A:I2 )0%Z'59T/9T\C^O 5N<8G( 4*6.
M'?KO!+2A9T%[4^V;G8V.ON%)Z!^\?_!W\N#]?N]43F/A'CT+VMX< =GJ1$1)
MBA&)(S^6/$D0BM)45HY '%'QXBQHC:>/\%F<#RA^W60&.45HGWTU?9BO U59
MQ[MUF=^J14<!$B(.)&8I55)&^H7-/2J:T*?[\(<B0SO(EMXQLD_(?@&'^FU]
M1.''_OFZ:58?^[,>1U#M1<SJGA-M\=R6+3#S- P(0B$/4H413Y4(P\KD9NO@
M?W;D1.N:12W07OO >F*T(]66[YH83>_)Q@E/0\ '\Q%1A'&D NG3.AOGBS3H
M$C%:%XUY>B[VBIG<.="P]ZPC^@=_;P_>A^'?7QB^YT?;9"_XM &T20/N1V$8
M\B@2-"6QE+&U%W#(U/ZK>)_(C]8UAR,X0 WO1@D[=K?CV%7H>T@'$"0:.I50
M\CB)F(]$++0^D"C4BL$I!8FC]<#BW>!(ZZ)/@?DYWR?I<F=]AS>PT?OG.^[G
MZQ,$G4H0['QV]51I>SC;,9'UV8XC(4GJ*Z6")$*")5%L8.> &!E,_]=I,WYE
M8'!V*O9Z0O=4:4>C1WLZE..F0R&8-8X+43[RHRB(&6-Q+&*:^L(HMY3+5*J]
M8VKNTI/<#:!ONE<^A%ZM'8M:>_M4:03[K=KDF"<<D9 )'*DT].,(UUW*/A*R
MPUW*N\<Q'F%,8Z1G3.M-A#=O(K1BFRQ-M=L3(<XE#V7 DR2-P$00^JLT%='K
MMBN_)JPV#DY]O-?\1N?,@4XE0W>6_4<9TYX#LO9F&=,(EDW*$Q.1*C\,TR3$
M*$)!X..DL@5D'.^=,W$'QK17#XS@4X[V2J;<,Z9UU(CI64C>"PL)(:UZ42D$
MT[I049^S)&:"I@WJ)$/1*["0'&,@A9T? N?E83'L)A!,KT)[PC2C7TC36<I0
MR.*(,J)00@E1PO=5U5D:Q^G> R^'(DQ[D7@,/6<];UIOL?06RXI&8:U0;A!2
MG$@NE*(8QY$,0E&Y;ZEDO,N\::\<X.&G2!ZN@/5H[)0UQ&E[N?:2XFX]W'HZ
MKCW3G:U6PJ]3K1M'9=?@T+QLLV*6C;W+;#3U?AB.A.+2LW$*[X<-:RVAZAV$
M>DT^^W*GZPGB3CVM$KS+$>Q',^QRUW'_=3[)/8IV9(JSXWKVSP$H]]D_]NZR
M\OFWMN?#OVTZ($1S0- D\CF*(QZ#P2E#Q)6*PS!.1<1%A->W0.YL<E:ERJD6
M::/^#\&X^^ 1P.LCP'^\?^%\E4W!TPLP;I,:/5O&#K[(+<2:) J((KY*TEAQ
MY5.*A5[D!*62(J76@TT=?)$/57W^K+7&YZLQB>-9ZQ93+@8T,=\7B.C%YB3R
MTRB&M<8AU6M/UJ,3O>!:[P]'?.<U1P==\YW.D&W7O2%;YSB(5>IC%<L LT@O
M?R!AW0F7./&3]9;^BZR[<'M<_^DW"R]>=;.OIFGVM_#:+ /?9_0C']^?>XW]
M-JJ)KAHCKL6HJXV?"D>D;<ZUS*,CM^IZL^ZPVH"V^+%4*)D*!8M]B6.1 %B=
MT09<$.93OG=XR15@B^\@\H^Z^)TP\3 [7RUE/YISGZ+&QL.4LIB$>J45"[@B
MQ(\C6'$?4E;:DG_]%>^6O4>/V>"CN*&4P#'F/$W#F/H2$>G[L3!;701,"T&Z
M=RJ\71:^0\:?.%\-[AV5\4=QPRN4!EJG1Y%6[Q%%/)14;WF0@8!+/U!H[SW(
MSY.![AF"Y'P5$NU AN#1!!P?"-;"8HXF\\Q&P<W;]HO+XUYECSUY_+GV,&9!
ME@9L_KV>5A>YS:[RLXMIGOU^EEWJ(7W*QG?9?:EO]>_74_<T3YSZU5%G3QBR
M*_%TP7US>2V4A>WD!W',?SKQKJ<@V_^GO+P(?!&(;!!0Q(:7EQ<7[.(R%Y>7
M@\M,7'#V]!G;YO8_?X>8/W@ID.P%<+-ZCK-MQ/5 HEC==T'\EN33J,KO^JF^
MY>/<[.HS;0*G@> 4XXBK)%&QTFK1),*@ECD4D!=RE\B':O;DG[,-0K[WC(U]
M"5__--*Z=S30U_BJ??+I"-)NGM&6WF]:09;>AY.OWW[[<WGR\5FZYH )IE?7
M=N;E(C'UL_4]./IPFF:3>^\FN_>N +7;R^!,,S7'9@V\6>'E^J%&L+7THXQ^
MC(9S?6:=>VH"W]!GQJT^-F"W>9D1R(HSO;C0/[/2?7%O/._J9OJ20WW-'_E4
M_V1BJF-;"2*S?V]N],^L2.3_A*OIWYC@ J24;K+I[_FL"4K !W!PC2Y'6I!6
M+EC.+_Y7[XKJ$N8!3P$_"L9[<S&:V$$^/ *PC099>7WN00P)XAQ3/:C1U"(H
MFKD;30;C^3#W;O.I.;TG@]R[*O0\V9A#-IMEHPE\'2Z^\B7O;C2[;G:S5^;3
M'Z-!;@9Y4<STC7<2P\/LA<4BH0<\Y14[;G"=#^?C_,OE^G!>HQ#,U*O)<.D=
MHR 4V"BCV;U1^*#WPK'^Z&2-%L7:R6 X2)) 8!6D*4(*[$R" VV.<A2>-6X)
MC2A!<8*UB<=BJ9U2Q'SX*@D02J)(/*IN*8\"%0LB6$A12*+8IZ12M[Z,DS-T
MXN7:PKL%>V.J;<VG:;-#F$V?)];.!-F' H?IL(K@N7VJ-[]5 ?I[74W4>J,2
M.B0NB_&XN"L_/6N;.*-O=4I;OU\H-D)Z =HK J_;-YC O(X7:G,PLL56IBS!
M&^3CL?O4U)[":SWP0?5ZS0Q\']UHS?1+?N=]+;3F6!ZM5HE7HXD=7C:?%=4;
MMM++O',W&LZN];?UP[O"#6U4C;/;,O]4_;$B=R=U/TV-O!*</-QM8V]!@S_]
M5'UI^3/\\$=$/NMGS_N(;#?&[6%8#@ G^,(=1VM,BU^T9K-I$[M=&UUL7[=L
MMHY ,':LPG%[V.K7E9\5%;@O"3*GO)=H:TE;:_HF#RKHEQC,A]%$GV/%O-0&
M7?G>H0XW0N:^48FL"L0]5R'N&;(B+\YFN0=)8<_$ O<+R348Y/FQ0'*!SG<U
M>MG,^VLVF6?3>V_)3MNI3?B L]&I O9]/G@GZK09;E5O*"(E$4J%1 K)*"3R
M:E[P0.PO7PMGQ^S^\T1;'G/C;W_1KLCT^W4V<:%]+;!67G?HLUWG9&K?9Z^]
MMOR@O?=.MCK;'?9NU<!^X$.>N+RO"A^RM+"=UVJT24O&$:92(8I2$S67"9,U
MOTH2A?N##]E>JRTUM!EK!8R5NH#MH IO=P@RLEJ2_);TWMO"'(FN07#+=CG?
MK4F7?WKGWM(A@.$[]JQO_?EZ[.BWY:BN5J:TLLDVC^PHV[W>7GW7;JMLW-94
M!4S_#_?]&!$_3@4-PSC47JR*TCA\H-GD( ;>(D?V<TN-7\!QY8<%C7MM ^X]
M*X(=6#6/72EPU(#F(TC1LR 0U&<(\RC&#!NE$*4RDM'^(..>J!2>ZOKM76OL
MZOV1<[E7X*3.*8^WY?VM6E0V^?OONW!TOP$UN??G>QD-N(DHD+<"7SC 1*:(
MDH@APM.$:-/(J,"$<2J3%PSG+[9I=M@NVFM ?U7B=Q&CG@RPJS&?;M@^K$48
M% 1)Z*=I$C,:L%!1S"AL_ AQB7&T'L'M!3;^T=L^>XY\=]_$>6O1I'07=N$W
M[#2^-T=1-%92&"4RIHI%& <QU(<+RHVRQ$GJDS1Y.659"V<7#:5_Y=-BF)77
M($<!P>2G-^T#OF==\)X#2$'#.I(B@;4^2'VD;2:61"E40X%>H%S%*-U?-_.V
M>@&XEH_.@GI?:N-MA8X6JT:7V4J>4S?Z!K3C$^JK7Q7?^"75IH];5"T22484
M"^(0"2)BBA-EU":G?J3U49=J2&47:DCWFXH[3GC?7F]T1F_TN.@'UI6T@;WE
M*>$1D5)&" <HD"H6OM&5 )Q#T L6+NQ4F;H_-=JUW.1Q:M.N@*6_?>2.DY]5
M68%5=+"1WN!43/.7@'WT>0/[&..$\3#!"A$6A0)1DN XC!"B6L])O))WK+&U
M+$+&>BU7:RBC84H#]=7^/"K*V2_%[+]SK4D&Q=5$/\&PN9+]T;+6.[0NZQP>
ML)%5 P,[GTSK:0+$E'H>]8MR5GK3?)R!X]?&5RDMCBQ\ 2 :+O*104VI+U-8
M\)<[=X2<9:X9TU:;P[UW%,+'.8Q\WI0$1I*$,<1TE8A9RK4Z3K1#DL1A&*9A
M&JQ4_QQ,!!TP<3%U;\'WG@TSOT'T'B0I0@W2\ ,<14^7)(.IVU4,FPTP7%L
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MU"Q@CI$3P#H830;C.4#D_/_LO6ESXT:6+OQ7=,7:$I,E]L>\X(M=^W='M
MJG95WXG^-$&18(G7%*GAXK+FU[^96 A0H$1)!"F0@B.LDK@ R#SG/'GVD[:E
MR7>KEW8>2'I9^Y?^=4"KJUY86,"L@'(?@N F/4AZEY%1;\?+=.L#(P[#WU'/
M^9I,!^.X_-B6YW:6WF7=R>?J59K(V^M"S3Q!]F?\^ _C (GC0;A&X,QT=Z:#
MI)>U*,FYM_?=AT^?/_[[XL/WSW_B#8N7W/W1@DU\ZI$.IV&F?V[V4GBUW'RI
M8/)M_[[W->W!D)WT4:92*D712,*BQE%F(D+_/AZN@NQ?Y6]':<MP(7XE2DY
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MZ&-)H#URQJN.ES1HU.B(47R &:,MRU]\!X=#2P3[[9*]SP.K*I/R,*-4*0B
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M>%_W/*]4C7?2W&II[M9WVNOKYN.=N[MLG\$MC>Y%*\YFC$3I/8=&,$,T (Q
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M(JXXZ>96=PAZ 2M;T![\.41-PNEY5#?8%LA[KS"&$BKM5,<9VX69P436#?M
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MZH#IM<"$6-D86Y* 0 H#)R#D#O-UJ:@%?5&MF\(3+@#I@Z8.F Z9V BK#(8
M2=#8R]9BS&-7;2Q-&:G#&.T)3)WQM6_/ZH;Z<9Y<)S (0-<#[+W?J^L!UO4
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M#A5?BHJ57"^$A"' 6"=!MQ(BZ@J^D_$*$*SJ-A43/N"HW8T#VPG*AZH4==Y
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ME2ZH(PFL]8E]%1 V1AEZ',H<%PA9)2G;*209],A;C#$TSHCUL:0 VM*Y_75
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MJ'U@'8T[<*,* 4OQM4!RA*S1C BIH QXO2Y@0L#6,/I)@_"7Y%OZUA:TYO_
M@6@07*8__WLQ7_ZWB4[J9'[7GR_O?PDWJ;JCTHTI]B48&8=Q9>USFN.CEEP6
MJ33/JK?<$N8]CGM<P#*Z:Q AW NI+20$.A5T %94)A&V17=_7707MXF?]G:J
MDRMYH"AQRE,7J4I8EAX=+[ K8!G8Q3$"R" Q 1>\%P!C@HLF851@VTA@MY5X
M\VHMDQQ0S;R**9EY3]O)?7EHICG )<*4\',1SZE(A&7ANDA/LXW6*I/%+/!9
MV(<T$)/V%MC/T;F\"1=[];<O4^=&KG1M9#D=M11/H&KW$2*<\9)2#X!CS%N"
MU@7GP7 Z0M93J[!SG[-87#!*+P38.46UJ>2I=?+]ABW63 ;^P>,! I=12TR]
M(EQQ8H1E D=5$!2GM-&B9KV]5OTKT^]/G]L.K_FE14=/Z72';F4G<!EAE!X!
MP!BU+-@&& *H\;JGIPDO' &H(N^<!>L<':BVUF;DX87\;%^[(KZ+O7^&PW'1
MK3E5 K*KUJ]2*4N.^8:K^4NZO%S$ 'U,4UHMHK';OY[]GGR_D6:T+<LHZJYI
M5'Y6<P"P/)22=W08QSN%3_VU/RT_5/BS-^\3LT;RUD?A"Z_>_NW/LU\^0WRT
MV7S\=3P-HG*_L15!!L:3K5X0!$XLAT:0,O1(-??2AS5(Q[P3GE'#B]/(60+W
MS*%)]1W6$AAY=:HA.F >328;P_$H;\@6R+_\%F./:5.W"NM$_ES>'-6")**S
M(-MI06X-4<<4K&F18UKT^8NC4LKP]8LBUEE.5^X.*]"[R%S-;W.5>\9ZU79W
M9)MN'I^GYGZM.7Z_I$"8*>X59W'5_,WB:SLO'1YT//V?U7AQD\U6&,\K2;U%
M,\35VCU<\U!G6=QK@SJ=S)"%<<,C+AX<Y9N?2,_#; WIB9"F(6P_.N(7MT:9
M>'JH;+Y%BWVM[^,Z AGO7RAX\8_[WDTR2>D_6DTFZ7,.LG2[PZJSM+1X#%?"
M(T\%08P0'J $K0N-L?7B15'E+#J%PL8 ^DJ$."7-LEK0F;D2J]Z38]<2"5KI
M1B,A(%1);"DD'$!)2CN6\;*O;DI553SRQSS3/<V^GCU]'#1'YM=B.$%7=>HV
M=O)W%;9;F3_U\TR3'J1%-LRW>)I- P,,<H"+\Y^*NJM@!QV[J%:PTE:GB&EM
M')-0 T^] 9H[AI'%DGB!=#V:5\;0UQ9ZI8_"S],O,4LHN^U6D7C+DDEX00_O
MAXD4?;MX&J]D[E*GK73:<P($ULP2&TB+H><FV$9EI[\MI$WA[?$@VO[I%8_$
MO=!S&UB0@Q5'YCVN/ST(6*SKI9+YOR\R7>2A6R2.K T ,YDM,V]MFN;<^QJ5
M@*PA]6IQD?H8TB8SJ((.$0\R=T(UC-(OG2O]R8$1@9<FM2$8.*R#E%#GD,-6
M2QG8!FG*H>2\/N7NB(CP,6RQ*G8XRR-ON"LR1_3H )'J18'1XDB8@V,_+XUB
M9+2$A"*G(6/682 5#I2F"A!& :Z[\O>E=%-4PA?HL&3*O!H913;JF;/&]I62
MQYA!-)BLAD62[+- X:*1C+M=1X$H31@93G6,)7,4"*.$($S%HX )HA *]'].
M5>W/@73C_N13JJP4>O Q!/K5?B\IK^H%A\W5V#XLJSTT.2N=4+SR(,"T4(X
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MCFG$2EC6_$'BF5;(1D\%A-I T2@O0>48DOK,]F:I'UC4V<O"!(7E*/#V;/_
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M2[)_G@;+)/EEMDRBSJ0G:<ED785R#L5I3UC'-E>QS%8)5:A0P>A3EV5]$Y3
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MJT2:Y*-2^/?AK&8$Y?M#+/"$S]4. 5N-@#L L#(8//JS8, _J#V3FL1>7+@
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M"79(;.FJG;#80Z%++RXBIIT8<<I1FT?YJ;5612?TIR#TNS2#H#.7XS:=40)
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M'(*8.&P9,L@P1Z5C!; @3(\XNZA]9E"7NMT!2P<L+P$6@BIML"2 X7_$D,,
M*JZA7@.+I;6\E*, 2Z=<=.4;+2G?.-U^X;M @)7:!<44>,(A!\0PYH3T:AT_
M$0 W,"2@+>;(4T#!C]ECL[4Z07?TGX)P[W*=,E$>\9(P3123WD'KD:),25LD
M@#%'&A@&T#Z;X/BAD7.9+M#APWO !PY*?%#,0(<0!LY3:Z0G""O+(8%<*X7U
MBT(K1U7M$6PT3?Q,!+B=,99CUJG(O:F/ _6'L]7U)-E+UO>V!E^Y-W\ZQ ;L
M9)?V@QXJ.VT)J!WG1!+)($& !27)K94B'JO>CI23*D^@'@?RP_7^?@VGM1V"
M6X6\1U:N.I1][RA+2I25F@EF'%?:$ RTX<*H==L0+&OURNU$V3>P3 _GL^[P
MML/;#F_/"6]9B;<.4"\0<]P;I .*4*^8 ]!@2+WQ IP&WAZOTHJR)GLXG3_0
MIKZ%_TB98?UZ^K/R(+5,P\J311-E/+H_5'PCH^0OJ]OPE4&@5WS.WB"93/+=
M^\\/00+BW^%;@^+O+3?],KY-%KU?DF^]7V>W_>F/O?K=-QTLW\;#Y<T/1&14
MR9GEV?Z80.,/:;@NBM%XNNJOQ?Q+V+K/R21).?.2$BP- 00A(3"!2DB1VZR<
M*N_))<PD,5PB&:KEB[^./CQ-R >[L'%V@&SI+R9CEG?Z@(C5?=@E>S&YM9G=
MV[7\P_"QK\2J>\ETF Q[+T\!SJ]5.,(R?>&A-^S%E[M('RSU,8S33<W2-_*G
MK'6'N>CUI\/T*Z-QA.%T28O\TQLC?-,/QK'1%Z]?:W8X_FG7X2C+$@*J0:"W
M@$1)PAB#X5RTUE"@B3).VB.V*7V>/YRN3S/VO-,,7-5K"GIA%R?AEP>GVBMX
MX>"4*M.H#<=!?=$6.D*"E$),.,DHI8%!]6*/=C24!6MZ@:?)M$OE:"-Q*MW$
M,8 42T=)) 6U 3I])(X51'%JWJ3;[_-GT+\ED2+J'9A0HA+7PT'WIY1SPRR1
MG'+*,(R$<AQ3COF1V[[S7(K"KZRD%&_43<WJ\+>\F:T68>/WIUZP=.ZB*O%[
M,KF_Z'U+-JKQGUOCLYFGMIR%WS(;*F6.[!O9FU?/4HLV%/*GE)<-98T$96V+
M-K/YF:C,'D9/?Z&2E;XT#EK$M+FG4I-)2IG,$.W-1B^D7#]0?QIS$4>]9?^/
MBU[RQR"Y6_8&J2P,[GO+,C#3ZZ\C,XO -S?CP4W\>+"RUR,TPR626#&6W3WE
MBF$R&@?!B!\I_(V+\'MD_[!;8;&KZ\5X..[/Q\EB)ZNTPCI+?V0O/^2"RC,,
MDB@0/[[,$GG-$_*'W0S3GS?SXB)W_:_)Y?4\Z?]VV1^%1_JA/_G6OU]$\^YF
MGJ^FG\+O(J"JYA(R;HBE1#AMC.5$:>K""0D!B-_I;VS#W@3IOV"MN:LA]T&D
MEP^0.9NGS!'1,OGQ0^]F'B'XWQ:C:\&XX/V!P( ,1Z/K:W(]2OAH-!CU^34E
M+]_JY]S^IR^IJ1ZDR<1C(_#ZFCC]YZ#&@?P)N_CV*,*4_ODMN\GU;#(,EX#P
MJEIR^OR?_V?#0_*X3;*I&&3G?#C5;;#K @RNYDDTK?5D-OCMPQ9+6VF#B0[&
MM0!"">>1M&!M:3O,+RMEW4%[Q)Y+)X7AX?.>%@.OH-:.HB<=&COO$Y3U)*@0
M=Q%BYJODPT_92GI?(M[6W$4;M-_M3WC.W?=Y>/3AI]>1Z_/@)AFN)LG'4>EJ
M_3A:$]']<1>.M$0GTW#$+%/!>Y*:ABB 3-#L-: "!JN92UX\J!5.5JBIG0AK
ML=8BB@3EBEK*"FH:XO%#<K3F8'IK=>3GM1X05(.4/&D-PX9Z,%[T^HOP\F0R
M^[;H?1=T@4*W77S_PUXKJCGRJDL$6U=8N</.;U<?81JU]\F&=QOFKL/&O+4/
MGC;SS89C^,^%@SZ<2)/^W2+YH?BENBFI\[QT\*YS12'[\-.C#MWL'AC^N>+^
MW7SOJ;?HZ[YV C<C[;O9>=5#/2O-.>#N/&#&FZ4\OV!7<O5_SWW9HC+]*[K7
MW89[_1EF2///T42NZAED+72\6>&)>H2EA8SZ2//_=\.HO$VU(@>CNL\B=Q6T
M+ )W>U4:O*W@'OZH/7<I./?U58^C-G/RP>2^ _CW3'K^?LO(?!*(VI_LRQOO
M-L'XC!?>4;^C?MNH?R"M=DNDJ..&CAN>XH97^E%!2U>>9S$=20=N8:5,:^I=
M'LMP(T (DLA*[SHBF76 &J80QU 2)41,Z-4F%G-+6LM$S&F<JWRU4.C>/2N.
MU8CRN=S3]8YJ@:>C$_57BSJ#99Z(B#W_$08*2(X-,TB*(K. 6%_K?_LB46]F
MYG$G\9W$=Q*_G\17!GY82K%%1%LM!6(":^!BU8'75H'P:JV4]942__S*@4[R
M.\GO)/] D@\!*$5?(1+.=DL$H%0A!(#&+A-]$P6W-K'XQ:*_9RW*V<M^T[[_
MMAK]-ADE@76&.WP^70?YFK1"6M8#(L55^!]#KA2U,JKCF15N/?*^5F96;'HN
MKH_D)9^,,7YZ'>$[/VXGT]MD&I-*RVC!!<4"<11.88. !JHPM[UBM;Y=KY'I
M]EO=G6AWHGT>HDW+60_":"B]8Y;+8$4;:#33J7+M( 0.L&9%N^WF=2?BG8B?
MAXCSRC@7$RUH+[V57D&E)-*Y_:PQ)JX1C?R$S.C3D_'SJE'Z,EOV)[WG)=J=
M[C#K7?(I2_E4F(A@&@/",(-!O[86ZM1B5@P)Q6MQZZ?E,E;,CZ>KL.B/=TE6
M5;\X&>NYM<?H>SHM3U:H(*P,,@S*K)9>4\=],%^-HYH4)BNVIC;E:%^A:K_Y
MVLE6)UM[R!8NLR\DQ5!")''0(;E1BELB\U@L4]K4.E T)UMMMQ\[&>MD; \9
MHZ6,.2F#S"$$L!-6>:0I8)E?QL-@R!U$QD[$@&N_'7;:6=]I@_93RGMO4Y[(
M.2^\HWY'_8[Z[W/A'?7?4X73^>O:J!(#A9IKS%U,3W+"$6&H8YD#UBH,1"U
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M2AL58WY V)KS-<UAP:&%?H8IPIM)_09[521=#QQ&81*KS]G1>$U26?E=/R3
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MV[2,U-SF$X_88!U2E3BAYAJJY1+0?;ZKZI;NUVW@D]ELN9G5OHL%/9KF(]9
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M>&L)T 5N'\>XQ[Q)^.25/U&.(!B$U,S@2$,A<M;+BTGHV'3-1Z#8YH.T4$O
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M$8A:H.CR$@,H3L'FGLX:V3 ;. %3<6$4C8T(F+B=:,8C^P$M(&(&&+P<-1,
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MCJ0$5E7;R:,TZSU*<X_2O!=*L[X?2K/Q;JM1/%R@]APE@0^GO9<(G[,YT(;
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M>@B*E@6^QCQF^"%#]"K/\W5+"S 1_A'P4T=96SEM'BI;%VV+BKW ZPZ,T_E
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MOD6MP#;%@ONAQQY%U4Q2-?QIUBO.#D+>]M%6'-_+4940_52).<;%J52(#?C
M%GF4%@G?2- Z23:2HUQ%XK X[8QY:C^?32$OA*V(Y8A4<:4@,]R=@9+'Q1R+
M 6] 6ST"/^I4M?W>@Q ?\?)?$W WD^$Z0)31N?)MF0\GJ/LOKF O)RT>/G+
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M=AI!JI?@]\ 0[L[DG\I55"05*#6_6 G(S U NWPA8@*OBCB6>5+1BM#A;$7
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M?FCY ;.9:>G$4*W ]9AIF$PYFJD YPBB;U)ZTCJ@9SW%SG)UN_B%.)BS'_<
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M ;A0KQHD[J38OP=T?#)>M>L.D('E>J"SO9"QT%$#RPH]GDI&32OPB-;IH'1
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M)IHN\50.ODQ@ .,Q4 +,.(6-.E? X;[L[3\55R,6P./P6EN,YKJG3&NC?A3
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M8)\PCE+ VB/=7T<Y?V%-G<5C+9EC:XV7H\N^5'M9T4;-GY_0.4YAQZ2:4RZ
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MH?6LRC\UOW:_LE^5G\X+#C8B;=JDV3R+UD[>CA?S<^, !@@,(F8:]3 DQN]
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M3UT)H]SQ\/%:#/]"UZ.NP;^H57AQ[$$+P.#+LR%BIB2C,$ZF60)Y(&L)![/
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MYG/AU"?XCV6HJ [+4+%JBT;7L?F .2U408N2A:LF$#19ME4.!-70K-^5LH'
M-#$K+5I@P#4[/'=R)E 7[@^F>?U200>(]1#:^!W&@B@O,EHN*R[6PN*.C"7C
MQ%#A"=/B1&'AR*KBF!; PKFT#05883^6"(K&^/*6/"V<97>!YD+MO36_/HH\
M7U(LGAU[$LJOUY2_GN#2SC&I/A[F@.-5D1_ILU[F+%]PQ?ETSJJ+>].C%'BJ
M2T3P0%J>B[BBVL")Z):POP]8KW:84BW%UC7%@-\M4[F"&_Y>JC[>L*!Z&M%9
M;6O3^R@ET9B=N03:!L8L3*7HJ]_3Y(G2H#AQLM=_PZBZU";10R@U2 F^!?V
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M!#BZ ,YK@;.LT* S@D QU%LU='-##AFJ4&6_G+>+%"&::!B,PUT9A'#P/+;
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M\O3,Y5=,C8$4#&EN89>)I)6+M7M"4K%TCJ#3"CJI@DZ"3IQ.92[Y3NCT)0S
M7?>]OI>7=E@"J-47O36C5B[^;L HP9P5S-$$<P1S.'/*71+.F(/5J"+/328P
M^37 +/<"<%9<,:7-&88<O_;[\($HOFH-1WXXIC0^?R,,K5P2?FL,K2B+6ZDB
MM8XH4BN*U&[Z'(6K9S@LBM2^09': YG6T6;1A<TB;!9NLQB'9+-<>Q%UDS!Z
M,U/%J(JI<DSTV2HI_X!D$_!YN6:G[#B*PVIVZH;E_,Y6A=^D9B=6$1H&O&KG
M;-QE3=4@2MP!W@!1U,O9<R'19^JFC"=AYD1=L,OAMX1X0?X)(-80Y(+_E
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MJPH1$H4 7J1A<I]W.Z00VV"!'4.:608!@]%"%U(/VC0\$*XNT]=K*GUPXO#
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M$X@I<FD46UFU1U!L-XII:^/[@F6"97MFF6[(ZH1EMJQQEBGW5#;N[\MT"=,
MFVOE@F26;LF+@=BK\?6M<R.UO0##_M+W*(WWX4J^$F!8[=XY,7;I@EF"6>_+
M+-5T+<LN<XT2U9RE6Z'QM9@;]O8$*RNEXA0)9DBYI)M_W,GTE5EMR]16<%!P
ML)S#^)@?*LL\5X-AT.2I&D:9>X3R\ODO9)&9$]Z]G*O1Z';F#^J3NK51K;[%
M&J.Q,I)&>.78!?K]<E7?>CG@=!AH"@8*!AX# \NLOKWRA%(.P?HH\GQ)WY""
MW^'OKAMYHQ'F],>4%9"]">+$2]*$;D'"E=&X522\%"A\"856&2@49'J?$5 1
M4BF9UXI9M:A,#%5E5MK=,/N_2T=)MER@K/-6NV08I\&#U/#"V_#!<^,L-RSI
M;0$KI^R$6^O$:&6_EE:"4U7H^XIQJH IL\QUS4X4]E(WD;HCZF)R6%4X9<J"
M4_OEU'Q]+,$9P9E9>\@L,P]UFSRP*6Q4?1UL?B81'GT"]^GQ-/R-"5/6&N2I
M$D:3!6&JT'=5)DR9I=!7EP]>DJ7U-HB97R3\BX#+KG!1!%RJT'=5ADN9E6EV
M-%_,=6SY)04$U(->1)_6U;<J@J7T;=.GAA=5X*4*?5=EO)19M'PKVX6M]:\/
MP^R(EI5%Q]\2+0=0<-R9=W=ZHN"X*#@N"HZ+@N.OL4,T88=4H>^J;(>4F62X
MI$1X=A!\D\0#J1$&:;RV-OB<05'6EMN3]55T22PY5Q\R582*PVYN3)+V%/DQ
MF>RA+3-Q[XX$:1]$22-HLK5),9/,-\7:,)?OYW 0Q&SW1 )OC>>RF_%E>'3B
MQ]N6IS/G<_O^\E)6WQ8;;%6#2>:<#+2V.LM ,.?(F#,Q9#1-P6'/-KJ^VV:)
M.Y;JFVG@6K9T7>@ L'^"K;*"YU>77[_T,]T9=CK4V.KD 4&-$Z!&F2O(73HB
MT4)YM$5R9 <1K4?'G><."/6E#AWXNV\M%>C8!1V60(= QPPZJK(^7$\?TCC)
MPA;K*VO_&I,A 17VO<?=ZVH+ANS"$%M$6@2$7@$A\RJ[8;G>3B<*A^%+9@O?
M&+G*X5D2].5I;T$<P]L-+TRH.]@V=+)_!VB&FZ<#(4= 2$!H/Q JTWG::&^V
MZFS'H!;T'@6=O\,WO(#&TLV-=.L-/;CQ*\X_$BS:C46Z2/$7*.$H*=.9:H9!
MG/J)M[I&(3HCJKT=2_#@CF_A/?2A=$,"_*KW=*=.$""J4E/^6@4%$T?)[D:/
M;-G84>1'OFJL*DJI)_^D]['7\TB$!\*"UA<4\#041A,*<V0*HY6J,#AQ9@=C
MX7DO(\J22K,3BRGN8NND]S[N\G?=, W8#-OV8,YB.5G*3](OG;O/TNUMYR34
M2Q/ST9&IEU;N?-3$%IN<H)1-2)T(C$AO1'QIN@;PM0]7T4@:I5&<$M# !,^2
M<]G'-%D](^?YI[LDNB?@UUY^??;I&/22*:\J@ZM^(BJH"A4\+A54WU$%>3%G
M#WX3*KBI"JHP"PH=/"H=5*L_#3JR*10P5T!5*."1*6#U)T&A@-.%#>$&'J)P
M6,"Y'_I^^(1QC/YDU'M!'W?-LE'>C\(A&^/9-K9OB[LVX!X1NV1,221AR*0W
MW8&B*?DB [\GKA-X@703X"9=Z9^-;[?2&?UG0H/8P]VXC33&5<HX^QY\KEL2
M/*3D@9ZS18A^&@5>/("[L*/%HS# MO?'$LA(<:G@HW3FG6>1SB .?8\O>S2(
MSTXIZ0XH3>*?X*)E5W43^ =72V*^AWHXBN@ GPTFX]LPYI_;X(,#>&8:HZ"L
M%L$ 3SF/XFSCGM3Z(_62,=[KQ_I;X;;!-G01?#?*?Y9]Y$N8P!< CF8^.R77
M]"XU:<GP/3+^Z%OQ1ZRK5J;K$$$N-IJ$Y1[X?.K%Y<&&K5CZ:8^_@?>9+E(J
M,U2Z#MV4):%V:5);I4$KRFSD3?!238H2#Y'8K+*"L^T7\@_\E8_'U_]LL]7=
M'-NUMQ1AI0SMR>R2/]?L8^VM9(2TV(_+*CSH-E?"3-^W@?>';1IQAA99>8QM
M6_5/TN9]ORW-MA)FAV>_(P'@AZF["V^ADR(!9UPP &#V)TD8C:41&!#X(HDB
MG-W9Q1&%J1R7A6 BOJ=9P@+!+:Y2YN/PO(>7D5;T+FY@UI84XXR<GVDLPC:Y
M;"V$RBKLLN1HB-?\!(.E[^&R&IHI241)PIIR ,UVC]DG#UBP"9H100^^5T(
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M?^5_W(>]\:?__MO5(!GZG_X#4$L#!!0 ( ,& 6U"CVP5#4EX! $BR"@ 8
M :6UM=3(P,3DQ,&LQ,C,Q97@Q,#DN:'1M[+UK5]O8MB;\N?M7J#GO/@5C
M*"3<<JGLKC$H<*KH)B0-U*FN]YML+V-59,E;%PC[U_>\K9LD&Q++8(BKQJX-
MQI*6UF5>G_G,?_Z/XT]'EW]][@7C<I($G__X]?3D*-AX\?+EGWM'+U\>7QX'
MOU]^/ WVMU_M!)=YE!9Q&6=IE+Q\V3O;"#;&93G]^>7+FYN;[9N][2R_>GEY
M_A)OM?\RR;)";0_+X<8O__V?^-$O__V__7.LHB'\_W_[Y_]X\2(XS@;51*5E
M,,A55*IA4!5Q>A7\.53%EV G>/'"?/,HF][F\=6X#'9?[;X*_LSR+_%UI+]1
MQF6B?NE]'<?]N/SG2_X5'O92GO;/?C:\_>6?P_@Z*,K;1/W/C5&6EB]&T21.
M;G^^C">J",[437">3:+T/?VMB/^M?MYY-2W?X^CARE_^&05I-(%K"_5F]#K:
M?[4S.GB[M[_W+GJKWNZ]?O=F/SK84VIG!._[SY<1_(^NTO_13T[B5+T8*WR7
MGW=V7_VC^;A_XB=M XW3L<KCLN6*?@Z/PX_U4YUGT]_N'$6IOI8OHB2^2G].
MU,A[QNXWCVIWQJC6 U@/8#V ]0#6 [CG :@'%6^'L+C#&$:#8=@C[PHL^G/
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MI_62=!!2RS#V21+$623T/78>G&" ?. $:+2'0E C*50.!X%X1#)C?" P&":
M^7<>;!A,DTKP&1KGP4]".0MN&/WZ#7EQ^*Y(ZR]MW0FT8VT]TZ=6DGQ&L
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M$(-?N]SP[,K'V/A=&$3O($G^D13%JO!;[2W>/7*>E'L8@?Y_JAC.2R_].R-
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MU6F9VE3'7C['B3[#YKN*4W(Y<M+'_ O=E#*^Q @W3VL;6<&8EO]W.7O%%7_
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MQ8N?:\_!6"8Q<9Z 'A9K9PP*T96.,&<3<IJM?4TE84F>F]%Y>2<BDPUP*[
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M4#_(YB!)6=)(UXC5TC!Y;::%C$7>C+<"[K!38=F2= G)(AM$HX7HZ"=P4TL
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MDC-DEX% V^L1(PQT6"-LT05V<0%+]6B<BX+X8+UD\/]X<$K>,EG8B?=*Q'=
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MH$U*>D]WYRO&I-<HW6,M8D^_8M1=NI7436J2U7!B\VHJ56,U AI3X FB7(E
M&7GY#S[]>/2=%B8Z2,-7]-5M)O)0Y^-]QM'@S(NFDY TXQ*Y-# +G*LD!N?#
M5,GI +9/;O\\A,@ZS_YD\^SK%NZK>\)6>D /#CZ(=OM[>W"]0 =8KO[G?[S=
MW7GSWJD5"5WR3L-GPO)>4Y(9?N3@OJW&J!@!T;[DD.CN>'V\KL2H?PV7T J0
MR+%@ I56Q:EPYH#KWTK:W> AHD$IS@("$##"5B4>&,R\=*JNB)%Z0/8OFN?(
MX@I/U$2N6#?)A>O.5XFM3G_9_395?[C>B=.DWFM@3W?@SO9;H>/ A<%-1"FK
MW__K\,BI<T;'$?T["0+.+(;!X48&1%)/GFS1+%9I= VF/\T=F?("-) L=4Y\
M=9&+1($IKP:8T=:./;'1$"B$T-->A)2ZP[F$6*E?U2)%4Z&G^4-'[Y-U@M.I
MH0]20(^+B!O++KY0\$G9:RWVA\_1%<,,O#_8"MQ$5F%-"JI0<>JC!@I)>:RW
MW?X*>K]%V!29<"%Z>1CU,6/ E@%2>/'*4ND6E'!1EEQ+(J_*^0?=IUR^[N!
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MRYHB?)2B\DZW"J<N22/@R R63AI"VFL^'D6#:*A"[GM!O#B@=X9>+V3;\(+
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MX(J1*K+V);3L3QI[)FA' U+E*N>!KLH>-PPQSF+;8;">/L':4N_2LCQ+:9
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M9R6,.!MVHQ)L)K$#\TL]FXU\=2E>Z17Y^>TO2?RB8!P]YYSK*DN9)Q.H?K2
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MC#S#<JTPIR4@.#H;8J*PY42@0<NU>/C";&>#AW (",E-TW@[ZFL*T<X_0HA
MOEW]$MHPT=LQ$4==/0IP.%RC*V!%4/#>R]>OUM)V(6_V8?<HQ-$270&;]DKN
M1X^"$4SOZU+@K\,3*.$YC8ZY)X+Q=78PM#&M=&JZFWG; SBB&#GKYQA#&?Q@
M$\C2C1CI,SUK6AG0U;NFM=&!&^EZ$6M#CCPZ'W?B?+Q8C_/1NOW=>",=<(_U
M^27ONA =EDK?H,65RZB1^P#/W1W;[F^P321'Q_P(7=Z^GFUBC"N"X?NT@#6=
MF)JY ,?A+)LY\S1+_0Y$:U.H/%L'F0X88R$P WJ>,'<P<O'_66<*@:5GLNHK
MF@DADW*['%3<*',I=5+.E+@87I\ I%:@&\I+[Q!)K@48XH'?D5.!,_;9LS59
MSQ_7M%9V(65JLCS;FOKY&\,,;B">_EZ;]_(>!ER^+E%Q?,'EB?4_2^._/J$&
M 88\B<#2G']FO!=J=#S'\41;[L(3"F<F5'-P*R [=YX^8-56=5U?P/\-W'"?
MK.4ZR\WXC_^X\=>+<[?B,^FKW+8E*-*B*450K!+6P)FR!1JE&3JMVAQY\MXM
ML>,# =T][ $\XB)NLFGV8:^=I0>P?JJ2>S<E&V?A[K2)^!7\)T 5]X,N6H +
MWS0#P :?@AWZ"DD 7P#UHW+$JH2:&E)](U\OI5Y#0U&O))Z6KM@FG/!V[A+1
M63&,!DF5H=;F>GA^[GSKWN(R&.@R"'+ZQ G+-/]A#8L:HKPJ.7P+4D>5)HTJ
M\N>UU:J+GA=#];5R&:TE,[\Z7P\WV7&RNR>W719CY@B98$(Z*+/[9#7]2=+?
MQ;RL.QO.@DPV982Y*X/S D&2E755F\D"DT*7)"UTKK!,SG8T0 (\0Y7U7R:
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M$@F2]CM^OIN0:EOB()'@:JK;IZ NLK7WK<%BAF%$CIK<5]O7'$3M)AR?$8
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M@T6#KZ]Q6 +.^II#M(T7R!DUG$V$9."'&I6#46ZJ$QQK$'!JX(IAE&7J<$3
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MO J[>G$%MN7H&5V@O*MT31W;( 2]T^1XSZM5OXC]W_YDSA#4$H&?F5@D7 *
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M [1FQ5V596Z0G+Y9)8XE(%:'-"AQF=+4:#[T91+J 50J%?]M+U+=)ES"Y3G
M3 <7S0L7JV<Y=H'?[/#,J!MH63D<.OI"X@UFUF[<XN2#R?&Q'3Z="4S6%
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MV0 7AML@(T(<$AX8,P\T%)0YC+9:C8S!HC),:40021@3&.8\=SO$#>I=.DX
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M&M?=MG\G'^*GW<WQ(5[?4&?R+;H4)V)'L=@RGZ[_B0['@:<!QT=("&!BIL
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MVJ+TSG>Z8YN6[+\]<S':7'-Q@F0?_.:9@!G2Q4FGN45U_MPCO65-1,\=I
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MTA0S3I=@E,>ZX#Y#)P'MIGT7'K@9W.XK)DCT!L.ET=?-9' 3(\/="YT#RZJ
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MY3_=O& QL/YMJE[T <#,E(O"TW12>;B2@QI=<505!!X)[4%65CQ/S; %P#7
M==ZG-_2$%_R3[5\>L&/>[/9_?4,D6B(+B/]WZ&GV&0EV.D]*]V\K#P Q6D"^
MZ/F.MM09T.^Y"#YZ\KO\Z\DVTT7\@@WQ%%@'%-3B @[2/!UGZ+P,75B6N2]7
M;Z3Y'#AC<(1#%[2E%35?.I<MK3,1W%$6#,\>R?09MOT'QRNLF11S?LE18^@S
MQ(GHC,%^0\4:_-4V4;K@+P9)_K6<S^KA);*(%>5IDF?_%K T2 5E? #&2HP
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M;:JZ;[E+@\J*.P$FSF];55J*!G@5*'\M-P$M*3T+Z5AF/F+;4@E=B]#TY3N
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M3,L4DT[$[>R:($^I7:;G63%W+Z$$V,8#.;Y[L'\W?58OB1)[OBI*K-=56!M
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M"! X>BY7&S5R0 HY% P 7EX:F19B9"4%V[U Z_*+@)+9+VIJO%\ @$LO@"$
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M(@N>TNE93-5DV'-9'7N D4Z\HC26,65FKH(*;#)/6Y5>Z1,WX=+0+1!XM4W
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M:$!6!CTW;G<@BX85]Y2:T ECIT<;?#<V^/5]M<%![ T*7[ *;FS<K8Z>*:#
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M-!V>Y=C"31"V:9KDWU\G_ALOCK.K(P[#1$(L*&Q2A8'&&T!/N9V4A*8 Q H
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MKYUHHT?\NW/AQDDYP(/[MTF: JSS_:>-'O-+9_?>I]_<8JN=AR-V[]7NF7N
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MY/;L_OSZ5;3U8B_ZLO-YY^W.3O3JYV>[40KEBG^M:X&OZ4UMXQY,IDQN*9C
MMVXKE^D9H&#.FSO7S<$,GAX_Y#Y!<X!-[UDRR": KH&)L!/P\RN=@)W@EC<5
M9ER]#=KFZ+__XZ>]O=TWVVN:VG6$HG(M0_-'A?_,._EGEZ>9\[-=<!<\$02
M4F04@6[<B+C Y\0"D$PNJZS2$!'S;M,DGP.7P;Q,*;AT+B6$D\X,YMB4BZ$C
MM=XZCSYW_RIKQ=ETGA)BXP>I.VMVHI#DSZ<89\DE1Q"L= W6@6H,?I&YEUDR
MA'WJ(E40!21<@*]V2%LOFI0 =( EI/ $)+J.NAMIM5_6V7#5N,Z>2NLZE((9
MA#3/-(=R9170FQ?$,$U^"-2PW (HIT#1$8>LBY"<F$)'*+8RGXHV8E9+4)F5
MP@J!_H$+V-Q!CX;8.2OY,)OA:W8SZHP&%0UC#NO@IU$&;ZR 'P%-DN,OI^ET
M@#](^3F.QID+'#,74L(_2+@,3#6E32AHU,P)YZ%' =)0 'P3-D1XH5$R=5>H
MB#X33@C(L,!EAWQD.".63.BSN/)BX=>./76JET<WIX3X;I[8>TT+)5[7.C%:
M]/HH;O\.YDR2 H^(NR4A@660S*#"),)[W/LAZT%SJ+\O 6L(U+!N.U4%4C2;
MJN5%@NA+V'V\'NMI4<U@L6YKOSX2 +@UQ4H>^#J]VB>3%%&]<S9A$EI<CP/G
M],MA/YK7F=(,X:F4R7NW* #>Q> 4_D8<*9#[\KN<]T]]V?".55+$S=>(<.WN
MT>%;!6BCN0?,JC.>D?2IUJ-".VQ)5JGYI@>N!# *SIT0HT#C0HF;W=K[DO0*
M=H0@MK*JT1;-#V_5_55W3JQI2,K@X![,W)UH#SHO]BF2^)!J*C(#L12WIBE1
M&&7PU/YJ2Q2^H3^IP%CG$LL?>7I*U>"8.+2I5A]C568\QT,$^(F2"_>/;>\R
M$NO4!)2!W$_.'9,"2K-'04\3;_04=.H,T"@YQTU?IG2 *?\^.SJ3[&O:EE&
M:,VJ ')AQSWP>8H 7M\]-X _>!(HN.Z Q&9(_5S>MIR?/6=D4[I6%L5#KIPW
M 6<_K[51JW%4,D<4)>+!R62+CJ )='6F(,(,)4Y062>L!/D;W@ Q Y+L9U$(
MX5.',OUNL;F( P\+_ MQAIPBR$EVLJ=%*YRU%2X30TPR5DHVM\;FB\+YA<>1
MR>[#%;;P3N[$=JO./1(7#"!E(:L0\@Y)A4S.).!>GV&M@2J^B;.1X%]5*> T
MJ\L*A!01J]5CTG8,[8NO,V"P3*QR)AQD7G4HQ&;UY=(9A.#U^N*)O).NK2;A
MZ."2CKR:*R6&XHSJ+.XI"H"7*?%ZNR<!S(CXP.X/53&!F747&LW=__)"<%=(
MAG(NP:MUWK![ .](,_ZI8[ [4?B$6<Y.,3IC\BQ7/C(0Z\!R4,(]+"QT/Y-D
M<M(ZO?X+80VO.6QH"5+@> 1G:Y@V;.)424BNF()]?&288X0M>Q>@(3R>3;&H
M17A T5&][!PFP*[H91$XRW@/E_[T=/?^ M=RQB(K$]7=9314J[6@>SFZGQ;E
M7+Y[L<%*PCB.@S1TU&1-A;D6].:_(T.W@>FX9E$6-&N9L1$#Q8FH*C"3':8J
M! %^Y2$,V^2*_>&![*U*&ZF#,-E]SMZRD8A24,JFQ0F<9%Z1JNCUJV>OUCHL
MRLP%'%] (9J19I+A*73S_#"@-#='[/]8PEQI?-]7PKS[8ME&1 */ ]KH^J;@
M3H:3))M65E.&#SO2E;^4LB-#\J^'0M'P9)R554W]%1A+6P)A'U=KL@#3F 7@
MRM'!'8\+<B#U:ZV> S@/9K,T*2GE4)ZG>1KFG<(X2"0C27T6<N;=[7.A$!+1
M2>Z0$I5'T(:9 ]\6R_5?ZTA22$=H^Q/G4C:\1W((T4>KD_PKSNPX^U9CQIOP
MI:1;2ZW417<"P:K:^UL9C"K3_L24[?(D0 71/^ O!/L/,Q!W^N@/_/2]N31%
M)]@0G)P99+]HEP3LS,(XBO'\-K->(YL&L3DB).'I?!;3 K(4J4$2 K%^/@<A
M/C.S.V-O-06!(\X#0+( %@;V='"03"J88=Q 1;M%MTN^&&[/G6!OHDB%)/&
M*Z$%BJB>T[@M-X)S3EJR_I;#OG/Y6V-&66S.94)2$7<LPM&96_N2'ENJFG$T
M*:K*),8;"6N ;\*(!3X!?_0(^8Y]\H9 <-MCE@@DN/R%4<+C9SOJ0M7+CN%
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M;_W\_^V]>7/;2)(W_/?[?HH*S>Z.M$'+NGWTSDRP);J;&[*DD>3I[>>--R9
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M61)+0U_DSV6J:Z#QV(F:_&N_W@ <=[H71MQ532?US='O,!Z>9 /#^$FY%V:
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M'8'2'<GS.)3WLX? Y5OP] 5C64@> 171;$\-:F#7"IT:E4+E*7L"!3!G8<4
M*.C%\Z!*'6IWU@,E\AS@TP,A*PT<0N 0OJ\=E$.PI@[[MJIN1]V?!Y589]]
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M$[0WX/<(C( $(;YI+JI\A[X B_CJ7*>$[/K]9&A)M[H)? FX,8Z@80C3$TL
MX? E)RWM9(C-8/5*6B?%=,VE!$T*JW3.6VW.^^[O;.]NO9*X&Q&0,W,/&U,9
M#V*UVE&7S;_YQE_?+9LO>P@44J*:$G.;/@N5P];IZ;,;OL6[XY5L@ =UBWS\
MM I7KXMV+_W))9Y,T<%<>QB/ [+)!E2F$>I?S3D@'N56[.+I5CC0:5J7<CZM
MWD9=26-.=_45+^\TH?&Q?&7R V _--$51U<]3Z<BY9(#7'529C@_6"&$'H Y
M#^=8@S3LBP]P-EQN\1CG7&W5LO[$UC_>U@9&XKE"*KFLH,'@ (.EUR!A,2>C
M"T5%'C8(<WDOYDCGV]1FW;?OXP'6*>$D>@^'TZ*)- FI^@F$@;8BEF!L[G[<
M0N0-,,1,'MQBE6V;$-_N>:3U9@]D,^T;Q6HJWZG<0IO5)-U#S9-HF;.'P5"K
MC$@\U^:JM"YKP(H^P-+!NC;GMOAFUUEH$U 7U]RS7L:H1\$UONK\.$^IS,T*
M/96]=1R,1'L3_S&8:5W)N\,N2]#)WSNXU0PL9UW-%,#J@$SX?GBG36;7,HTS
M<_<!&X7])Z!"765K[YQGHTL M2_C8LW<''F>%SZB"B;&)R0QOZ%YE%F S++W
M]DUG<;4W8]UJ&+Y3<+MIG!UJ64QI[N2JGSAB8K/?:O0-[=@,B8#ASP))*)]X
M67QPY5NS[-74M:$>8>*]N$G7IN[>;.IN=[]@KG]:BWQ22_8K(+LTK"+SZ1+N
MK*/!DV'H*J2+#-!_@_)-G@EO8T4?>&@;HF18F+-$6EXXQJL6Q0[S<T#@,;J4
MU]%#BCTSU=F,BC0/N._$LTK4"I8*M_)E$!QYD_D*R_OXO.^B_XKPKSI!HLYD
M()R"S^R*/)@B/LJSNEF9A1"U452BS(P\#3U>'YQ*%:J)I]1THD:>DJ]5SAP&
MU(V:M40LSD>PU06W>M"]<CV3>NVX$*T4O"[&_7-5F=94[!$V.N=I-.Z&,>*<
M0,'F42\LL F1$1-$26+WD<%0O)$J@,V\NK[8^7>&+N&^9?[Z/(\I;Y<:P[08
M>Z!"936T=![%V72(JD!'/OML<7*-\>X;HNV.,VUG=(D54K?TD]JP:L>J+4LH
MJ=:2\9K-RYAG*]=1>=Y%,3*6<1O$AX(#:E:E23@P7&2HA7L!0"=ZVI&LZ!TV
MF7SJUW#BK)?%DGU=Z,PN%*X9NPK@-B"*J=B\XUA.P(T+- (D2$C,XW^E^."1
ME$GQZ7-US(^M+(Q([I*5OU-^6C7G.C18B@;J+?+$"#';-$:I2 ^LI/05-@$"
MLZCF\>) JKGU#/N*^-E6GHMVB;_U]8-7$H$NIV".=IZAT#:7:-F'C5Q3!>J[
ME=?1=K6<J;/=M@5L(7TE\O&PXNQ/*Y"995,4U;',. P#.TM<'>J!6Q! BE64
MK >;6[\R4YA,D8"N*A!6\8MJ+;&(U<K2ZDAARMD6X\(A-NEXZJE1;6(!S;K5
M5;TAA>?HU"&P4LQ9\TM3X%O%]?YL$BLFL/Z:[9+G$=O,"UNY,OH5="D-/#A7
MY32U%?)73R[+1L/P81K&L:>;H0C!$(4X5)/'#0RXT(64])$IHK2^4-H<@HYU
MAI/D38%I$IK^QL4WD9GS.R]19$_:F+MKL'UJJ ;QX(C0X*&8K3E;2)UE,97G
MX$MB]8 "OZ;BNWOBX=[(KN*++54"/Q2J?#0?:F6#9=,^RF KV6ND=2J3!3,[
M/[8H6:$+CJR\F)U3X5A!3F<9%_N67ZECC+:.&(=WV.)?I6Q1P?,+1 I;6=@H
M6NA^@_4<ZRG4E$PED9<\^=2(;_$57O717_+M5J)#CY]/AW+6!K:BZ-*9+=WZ
ME.@<PV5Q@=^^#CX@U ?O3 58Q7-$.8Z7=5BI79TK6<N5)#KJO0CQ>2KS2%7W
MT/(3U>AF[J7\@9"P6.N6"ZV4K@-5*CU3_GH+$N5ZNCC<%- &*DMF8W69DKGJ
M")2%G['46Y&O-S2A,&M@0GYL"%:7) Y-?K>@/^_8>XZ'7I";GZ9[<RMCI@O"
MAP29HN)OBI1<-2<VLM\J<A0V<1E4FE4KGIM &3;7J6B8I)E7V+)A-['#77'*
M$=[5TFF*?149Y$5GZ.*(H"K@KCY'JV1G2;"'P='.T:<ZP1Z\_":6S4M,MGG
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MUV46I%.Z=%8\L?*D6?,/\) /XJ[-OF@5F4[[!1C%<GFONJJ[%2J)'X3JHQS
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M$X^TO*]'"6(6!;,3_&6$\8*",@3"\_CM<T]EY#]G0F$\H( X#HXBT,^BK,:
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MFY"HJB\+CQY=FLD;#A*'R/!&\PD>.RY-D1U("7<-]3W-FP_3*$(*9K"K<1U
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M>22\)!;B5@9N&,7J$]=#ZW.0)O0KL'[)_+W%*GYN.\0&(; TN3G3T8UP"=C
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M80M@S"7 S:R7\_[SH6-9PT"'ACD#DTQ&CK:-^8B/Y$U(5XQ ^U-VFG8MG@-
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M2?"OJ!S<&T(C32.,8*+WXDLY)<=FX@0IV )P3T;U%X/9#G",&DD/-^7-W@7
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M<%6ML7I,62VX;;H	)UQ[K(/23G ZPO#/.UU'E!J621PHX6^5V50+72L=E
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MY8OW+S#DIWLXLO*. /*9@$R"NQS=6ZD<"+I" VWN!EO:53&6&8-N-L&^E!#
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MU2@+K#O$V3/32-Y*H O\ )O @^BKT22ZR7#D1Z>X07P=?Q(!K=>% 83N*QQ
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MW "K4%5"9881V$0.@H4,@1(,R]^402!J/GG?P&HP CJ"^FAKA'_4J;O,OA?
MS79LW^2^JS@F#YL'43:7UN[5S[VKZ_,K<7Q^=MWMG_7/?A$_?^N?GN _OG:O
M>Y?][NDK@1#[(X4-.)H]P^97J?(!&!CNK4=VP]A)6/=J=TM,'326O*G#,)!@
MBXAN/ E$<;B/$/"0G/]JX-I]8"B-!=1>!,Y$XZKT&WA0D=?"$;_K9R)B3-C
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M@S*)HSW17PA1/:HY"N"?.=.I@R"P8G,Z#W6E(D^WU1[G;^Q/PQW'YQ[8AXH
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M"ZL!T-K%[JF)P]D&'CK\@W_^5PI6"DVM +-X$J:83.@^J-OG,6F$QEL.+TG
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M9:AZQCS1S7]<X+?Z\)GY?8TVRJ:X2J3T.^(+C0\FB6K2J',!]@_JE^@2
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M]D]#(OO_C_YA$+JSO_Z___5^G$S\O_Y?4$L#!!0 ( ,& 6U E_"G%-0,
M )<0 9 :6UM=3(P,3DQ,&LQ,C,Q97@R,3$Q+FAT;>U8;4_;,!#^#+_B
MR+2)2:1)6MZ:ADIM$B 2;X(BMH].[!(/QZX<E]#]^CEIP\K;$ (VF/C0-'=G
MWSW/$_L:UUL*#OW!]Z,04I4Q.#KM[T4^&*9EG;5\RPH& >P.]O=@M6$[,)"(
MYU11P1&SK/# "-5:N1:5E$4C:+5$/+<&AQ;9:I5BPF1DP96V.@N>J6KN[C@
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M4$L#!!0 ( ,& 6U"3W_S1&P0 .X0 9 :6UM=3(P,3DQ,&LQ,C,Q
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MZ[O.9NP&W7K<<WR_"X0G:TU>N]UV '$F0N;PV?*K5]_&PGHT0^ %N_+7:
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M\EKU^L2M\O$QN/%6=]^#^J&Z^A^&U7\2@Z]02P,$% @ P8!;4,'CF$TG
M" MC$ !D !I;6UU,C Q.3$P:S$R,S%E>#,Q,3$N:'1M[5MM3QNY%O[<
M_@IOJMT+4D)>@(4;4J0"J2ZZNVV%6%7WHS/V,!8>>];V)&1__7WLF4DF)&F3
M6]#=M"!!XO&Q?8[]/#[G>,S@IZN/E[?_^30DB4LE^?3'Q6_7EZ31:K<_'UZV
MVU>W5^1?M[__1HX..EUR:ZBRP@FMJ&RWAQ\:I)$XE_7;[<ED<C Y/-#FKGU[
MT_9=';6EUI8?,,<:YZ\'_M'YZU>#A%.&SU>#GUHM<J6C/.7*D<APZC@CN17J
MCGQFW-Z3+FFU9I*7.IL:<9<XTNOT.N2S-O=B3"L))YSDY\.'1(R$&[2+(@9K
MEZ,-1II-SP=,C(EU4\G?-F*M7"NFJ9#3_JU(N24?^(3<Z)2JLU!GQ5^\W^UD
M[LQKCY;G TH43='6_O/J=-CM7'0Z%]WWQX?'1Q>G%U<G%YW#BZO+D^'PLM,X
M'[0I?D.KZD\ULA2*MQ+N;>EW>YV?EX<;^">K%!4JX4:X%2U&!L/YQ]6HM;%#
MW5>UR"ACF/O62#NG4]_QPYGC#ZY%I;A3_3#W9RW+HQ8>&AJYOLW3E)II79ON
MUOK[%J$X*709:<G01;F4Y+![T%TT[!MLB( T;IYBOB^'-[?7[Z\OW]U>?_SP
M;?I]LS:1EMKTW_0.NW&O@_;73?*'I2DEO\/J^R;YY4WWU\[9)R-4)#(JR?"!
M1[D38TX^QK&(N"$Z)M=IFBN=<B8BVR37*CIH$E0Y$4^)2ZCK+QKIZ$AR"$A9
MFO2VT6F$LLUH5)5+&]9:O89^9'E*'"#L6-7A1#"7]'M'Z,<SS3%?67YI!]$%
M\;&W(Z*R1('366,K0E;Z2QZ[?J<8]!O7J'OPB*V%#>LU/MM.Y?\%T]<DH0"%
MX6/!)]B*7<+).Z5R0.:&9]HXHA5YKTU*NIW6OU>#YFR%66%%V@$Q+\#9?EEZ
M?T.H7% +@ .Z93<*SV1G-WQ)A C+/ 3L,(TED9I>'8TID(1JJ8D5\[D'$/!
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M2$X;.XO5P@-TF:;".<Z_X#)'&M&@KV<"^H5.]D Q>"CK/2 ^?:96[07\SUQ
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M]2#\;\7Y?P%02P,$% @ P8!;4(]8_+(B" \"\ !D !I;6UU,C Q
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M_S\H4Q%U8WSN\-UG)DTM;235GH-$%])B.&#)AR+?!GJ3HJ2 YW;]+A2N#"5
M6\Y4!$ FSS =O*1LMX_0$HF?AS*\F:>I>Z=,JFY9T$9 <V W"P]%S4J>!GH
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MBT1F:'+WN ;K>%8^E9:4I87?3O+9L,K__/X@BR<!?4YH\%<^/#L?Q!;PX:*
MVC)DZ1RLS!9\2YT7_[&;>!<*T$P0Y!E!LA8-S8T7&^M00R\X,(K%8V&_YPBC
M,.C.DG (/F&O7Y KU0R <G]@1V=Y_E2XT&6WT"3B=AHNDI?P_)/"NT]O?>G:
M)DRK>ZG+T[L%^>83'LBVL&V[SAP.G_O,X06XMN$91'D X5]VB(JFS=DN3DZE
M3IO9AD[PWR!P7,J/IJIQY$C.9'8:J_D*#!G'RCDI_\)E#@VB06H7"OKY079
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MR[>K'[]7O7R[^.4O8SQR^_M-5?"7W]\._*W\TS\!4$L#!!0 ( ,& 6U >
M V#+$04 '\6 9 :6UM=3(P,3DQ,&LQ,C,Q97@S,C$Q+FAT;>U86V\:
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M2;6Y!WO]7DST"]=\MXNI]:,N(Y\T W<7^[3O+HD'?P-02P,$% @ P8!;
M4/0$MY8<!0 11< !D !I;6UU,C Q.3$P:S$R,S%E>#,R,C$N:'1M[5AM
M;]LV$/[<_HJK@Q4I8%DO=E)'=@TD=H(5ZQL:%\4^4A(5$:%(C:3B>+]^1]KR
M;"==Y]9!UJ$!DI:\X]US?.ZH(X?/)N_'T]\_G$-A2@X?/IV]>3V&EN?[G[MC
MWY],)_#K].T;Z'6"$*:*",T,DX)PWS]_UX)684P5^_YL-NO,NAVIKOSI1]^:
MZOE<2DT[F<E:HZ=#.S5Z^F184)+AOT^&SSP/)C*M2RH,I(H20S.H-1-7\#FC
M^AI"\+R5YEA6<\6N"@-1$ 7P6:IK=D,:#<,,IZ/SVX(ES S]Q1"=^4MOPT1F
M\]$P8S>@S9S35ZU<"N/EI&1\'D]9236\HS/X*$LB!DZFV9\T#H/*#"QZ7#D:
M$A"DQ+7Z++SH'9T&9Y/S_OBH>]0_.^V-SX+3WEDT.1X'O:@U&OH$?]VJYD_C
MF3-!O8+:6.(P"GZYZVYH9^X#RD1!%3/WK$@4NK/3C=<UWT[V5105R3+<>R^1
MQL@R[E>WJRDCJ_@8QX;>&H]P=B5B1\7 TS3U<%*1U,2Z+DNBYM\?CAO.%M 2
MR3,TL606NE$GVHQS?R&EF(=4+6:8R' 4A[T>ZNR!G^<'X7$P^/?([\+: X@Q
M58;E+"6V?A\9RX=:Z9K@(B/ADJ86$9P$QR!S, 6%2Z(2(JCVWM]R.H?3U%A)
M% 0[L/\@N \OZT0O\&HX)"^ B P.DQ<67A-'V#T*VC N2(5.X;AK95-[(D'8
M;\,GP>Q!=VGPO--XK&7TQ2/'=/?PV$=1+4NHU]]/!:TGC-XE8>!0?YDRO4%9
MND&9^2?*VLYKC3$JC6R@5.986K@85[XNRUK(DF8LU1UX+=).&PA,*"<SHBBD
M4E52N2J$0VOF^4$_BH+!6)85$7,W"@?H(I/H#O>#)G-(7?'.VR[^.BT:?U8[
M?#G0<"WDC-/LBEIHQ,3_>49_B+2;(CVG0M2$PT>*K&%:";B0JH0P\'Z#7"J7
M"#G3*:K,*5% $4$&360[>YS0E)8))E(W;'^SD><'W6@0!>')1H*M<#<IUE3/
M,O,@KSG'5,,19YAZ,V8*)U?TCYHI:CLUO7G2V7K"/0B/#K.5-936B,I:.+_%
MFA)7M"G(\*3;:[L"M(I,X/Z5BT)(,03";"$QX81KFTR80EB5HMH":%L-PCG@
M2HP>MQT%%2+2[247@HC4SJ/-S#6KSB-JU7R!7U9T47]Z:P<Z>TW(QRZ2L/LP
MH":V58^_/<4O:*)J;!4A>MEV[?SWY?DW?3XYS<UJ;^P@#K:.D.#>S5HS_]75
MZ_Z%S72^P49H=="D(0E^:%+*^5+ZJA6TW%A7)&W&N]];9BPS11Q%-C43J?!3
MY:62<U)I&C?_N;,E%@^FG,FP>JQ_\:KEKC,FLW_42KJ$L_#1.UE$XK2VA>'+
M_IKT'ALW]M.&Q^<2QB)Y-[F)MA)Y?;Q,]O4I=SMQ,YN,2725<SF+"Y8A2P_5
MV6]MPU9\B+^AHZG3ZA:TY"R#@\#]/$CPVTSO(7A?^Y\T*0F\1;O7]VS"3[8M
MVS\(FS^I_-]0.2X8S>%BU0F]7UP6OD2K[SY!=YZ.=KB&KG_Z3O;49NSZ:/*5
MCFQ/3SFGT%SXD$_<8+YH(1FVRZAOJ$!KV!^Y5\UEWYP!7N#67SD*HB&AJ%HI
M></L=0%O=>N-N.U79PQ[W,0VW\O&&(ULZ^2U$DP7?QM8Z[VM?-5_XZ*2:6T!
M8+O.L U&E'D.=84S%B;59H?F]Z$ZVR\\5M[-M]9C/:D^:0;N1?GIT#UUC_X"
M4$L#!!0 ( ,& 6U!!2;"#[ 4 .P= 3 :6UM=3(P,3DQ,&ME>#0Q
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M,Z%4N"2 4MI>I,?'E9B6P/L6&"=)Z;;>9U>W@ZXPJ*;LIN[A9O8"G._P%Q;
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MF>.CH[-Z<?'WD)/UKA1>^[GM>_WR]Z@<V!\^'_?L+[+]?P!02P,$% @
MP8!;4.))I2"2K@$ V5T" !4 !I;6UU<&EP96QI;F4R,3 R,"YJ<&?LO D\
ME-_[-W[+5B%D7T=19%^RA@E%$K*'D.QD)[M10LE2A+)6]H1D7T?V)?N^&V0?
M9JS#C)G_Z+-_/]_G^7R?Y_^\_J_G]_\Y#.<^]SGG?5WOZSK7N<X,-VX4-PM0
MW596508(" B !_@O ?C"[KI;6<- .KJ "\ *<!$H ,.(6O7<9?/"0X#Q#B
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M]KMB?^@U#I 3XIV0FI : -#P[M')K(Z?H[L>>[D?")GZ5!:\+:<6.WA!4L]
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MS4TM[ &^MSV7E%P8V)H)CG9_)6+,?=O%$J\>AX<&Y$RRII:NDPZF[_==!>5
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M/7JG!V3TR(N9_*LH!:%FM /=U*6F>@E*H@?LT) !@&S)6NC\TZ](J_35^Z?
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M#8ZI(A3ZOS <_9\R9!HHXK/E Z(\//DW0=@J3<&RFIDG=^>=["ZMR^ O#7W
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M \N)%4>A(Y\TP27,DG@^S(QBRKNQ:=PZS!)Y:?WS?U>^*)!9/*H)N,>T5
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MP536<0"BPXSR*)YLHCK_NJJGW%=5CDA! I'(>KA!VU14H%;;FLKPI:]1&3C
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M'UK9>$TF(]?6$TS6RL6\;O1XM[SV59D0\V1D?=R=!Y81L[M<9L-L<(M4:?Z
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M*QAHSXJ.LK:;_9T)T.UG=CIYMV7+J_PVM]=FWH_S?*S2I.4K0I9C7N 2N@Z
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M1\(/G5J;&7 @SP(Y= LSWU/4/R(NX7>UU_FDW&&IBLAW)WF$8'&0.BRL%Q[
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M&+4+3_MG[Z-.8:RS;,]-L-'+_>3),:[2[6'0]Q\,LX.O[$M!OK@+'6SU7!K
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M"/9MMRH-3YKVWD[U2S2I* Y(X_]5$9W62ASP"AHF@L^ =' ,A$,"Y$-^,OB
MS,83"]H[9X4#Y VW4^AV;##":='XI?*B/ R,N S!BJC]E&Q]=G6:C50*!T2_
M:\7V9N(',>S1_S(H[N>@[&AO\/@TVQ(V]=A<A'OX.!I@W)B.G3Z^9)].TP>-
M2B=@#FQ^M7?J+_8&_V%O_,(=+P\3FSCZI>5?Q#+#"!?BE16 37H>RX#7OUGH
M,5!\QE^H[I8EW]"MHWX#&OQ+PBR4WP&N+QY-JXVE'[1_3C@/JDZ*Q(BIX
MCLU_*%==/";(GPUN=:N;R!%H,?6>U[G'+-F:&KV,B9>(QG$UB26YM_)B_
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M4'*O!]&-\KM=(WT01,.T+#ZXM(;B 0OY*?SED>#ET5@4,S9X_3Y;IZV,8UL
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M8U4N9@_DV6?#8O:V]C'R6SIGSU2?NA_6KA'HE-65O0SG4^.%6% +Q$MW@WL
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MJTLCY8PRQ\<K8\XKC% 3^TV;W>:2[[[:#+Y ?XVW:?-!?K4S#W-PIT" )BG
MH;\S^^A136Z#*S) ]W&'(;49)25J7>Y,5I[? 0Y@!][T63N8R,B7_#XRZR,K
M1X472V2&Y)5[=DY+T[SJE_I-F",TVQ\5B7X1R3(,,%4'OH9(*L0)XT++Z5L-
M?UPMN)0REA;M_:8=N7C<5@FKN&2 IZO'H!@=S3DB"N?'IU9\GK8W@\ID
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M\)'M\RN8*7'H9&\>](]M<H.HNT3]L4DJ=3&S% P/@K.UWQ249!\YE"6JCHO
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MLAC"B,%'EUL(G#VLI <#'B=!._T0\ <ZQ^L,^?5#Z/SM(A5-GYYSG4 R,>8
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M\@,=@QVT1?_P.82M9E (Z>)5)&JXC&-)%^#<"?./? 7R,HEQ&TUD:_V/4G0
MD[$J0^J,2TK)Z_#%*TX(.1_[R2Q3[J$E)_<D@?C2#]1\FK>]AF7-O=C,%VOQ
M%7\UBS/T@T6@S<!WL[2/:N//!QI//9P_O7"5,^:$6L4D)(B+$((#Q66*V_AN
ME]:@@9'^X'!0V31B%O0:25;&T\=MJ-H7+_,H.Z2\F'I87"5>YA>"?> 2?][P
MDZ!Q^XNQ2['.)&_"S6*("1+7.@W$0TD7_$<C=T!K*BZZ1 E)LBU3/,?F5)(?
MFY?2TD"D8L##E<%M[A'(W9&K)!!NI8TGX^6TQF%FBI>'VQ4&HI"VV?"7QK!0
M^N-GP"IH+!7[,ZJ6LY*G"?;ME4$\EA:-)@?K>853#M>F57U.]'';1/^T7'UX
M.G<54#I1RS'U#'JBX4JW6\E#7Q16!^\:7^A@J@S]@<)P5'S=G$^2_SR!#42[
M&G2U>PR9:LS"0NF;&J[B%JH/RW91J]!3+1AHV>$;],*^*V)Q?=I[T57>>H<X
M+)6D;.13!AU](W 6$32D=HW@@U,P=&-S'#<GU'2U;?E>K].1"^-]\&!_?&=M
MKNOLS]!;YXEM+Y2CP&,SNUDN'G,C[V??-XB;D<PK1XK7!51F")KS_:[.PJ\5
M7HH:"KWJY)N'3$08<*RD1JYVN13Z0ELK#>;$)J[K&N+O-H@->@6J76 _L.LZ
MP<!YZ64PH-,CN'/>^KGC1@OHI9H2;N-U]@C)!6]OC/\^TE<GGWS- >]@HEO%
M5/>E6?M]._/ ?/BD;X^8O?+5JUT'1%0' XIY71A' :QQX]5;C&KYI0\&#?#L
MAMY1?K??Z)L>;I3E6/L([2'L$1<)Z@7PLY#;^+W6BV&KJ1FMRFJ)PM"1L7$Z
M.B-R5Z_0O,#R)\V;=/7/)9' ._.%^//GHJ3([IJ@'K%K#)?1^VW4>J_XX=B?
MYZAE-@::;@3;B@)<S@$NLMN2YH+_GQ[UV0*VSU=. 1S@J)*G_XW)"'5I/%@8
M]\.S@ZN<_##2=A@%@-@WI"O_^EFJ+J[I#-W"4U4FC\2E 92<7.^X+6;JYVX9
M7@W(%DZ(98F^,.0Y);G*R=";=R-BR)R[KHQG_XN.>.1"^R)_D]P!/=Z@"3G#
MVL"_0N89K'#_,.4X$NMPF+/KX3Z?$Z-TDE_ZSCG .I>0@'M87C9!2Z^O3L0.
M4Q1@YW)QX)LXV]00Q[5/QQDTE?:U5BQE'3537=8;-U&Q-:=A;<62F,/ID.)G
M+(B;D%1R6-[*6IKE(_'C;_JOS&SF9K5\*KU%<WX4],EWP D&]+T*B@$RFK:,
M&BZ7MF V.!S,&^O+.7ORC+G?:(CKBHB>T[@\QEOSQ%&=*/J!H(NA"E-0] Z7
M')C)2M<+,W-F">_'J?RB3*TC*N6QZ$NH1%GL,KUZMW 848%0] "O&?V)=)=0
M",4SC-ZNL3@$W=&[>%IZS)7S\%'"J]=;=P1,%9L$YGGT&>3=-*A)<W2:AJCR
M:U>YMY4E.E-BZ*(NC(.%_=&O]CEGV<H10R&;DV_A5>'ZFW0R56<[2M"&N,@P
M62"_+\RL/&&DJSUU.JIYH4?E \+K^*7@]$:6[YT/+Z1PM],YT<Z)K.X5K0C(
MU^)3@E4#/T(4J2F-_?GRO9NV'(<9FQ]$89?*J\#7)#N!JLR3"R40&0*-2)CK
M3G= :Y 8"H^.W2D"ESY:&7\IQJ !$'IEC52OO+SIPW%\?BO^WJ3%PKU]FCE@
M&;H-%G-@0.UUCO]X!J6!8BX,G!^8BQNE]B OFWLFUHS",:2">_<5B;GS017#
M0?UD#A"5=)@[SS*O#CSI*Y$KOK7D)FY3;3;=;EN@'Z3SX'&F?!,3W2E#OT)5
M$:(,Z1E.(<)S@^49M%SI:__VKW/CXQ-DUC0E><T<AMK,6P9#"8$K_<5!IPF1
MAFZ1"IF7\0B2D/_,RQW>M/T=EM5W:]!RU1_YK^]WQ>ZVE=H9Q=>J**W$%Q5R
M]6;*DZ!& APEOD0C/#N<055LSH^=L-@,8MT^E#3YJ35NVO&NR?># )LO;F;#
ME38O@'--B0(0H':6!H<&R@9&Y,$A"H"= GA:+S.GU08_!KD!,W(1>8@;'M!5
MM'"3=63-<=5.7^>]4^I2O&4;P"0@-0K1)SA1 (P\(,:"W<A=Z*YPK4.Q?<<6
M9.-\Z6;#YMI4[88'3%UW_!8N8:NJ9[1 _\11C%)CUI3U;[\9TF@<1>M1^ *,
MCJ*5&KX =S@/:CZ.L$%N5)@Y,+@4].BH:WS[F"3;T7'T[V+ AYP?39<5VJF-
M_SD?-'27IF&7 DCQ073!8^ *I+,LF'S0+Q]J%=58YMB!J B5EEN0/>WN8^Q;
MMLO3_0>L_4>W(U55<CK*^#44:$=B6,R5L)/B:".]QIT<VI$XWSU&*8^H719F
M.*&5 N #*!-J-;#D*3D>_$96 =U2.@^V=2#NHA1,[O,@\;V["]":@&Y2#D0V
M%_N;4K60$VX.2.=@FBF ?V#^2*K7IUBI<NL-^ 2;P16?>JV0W,<\[<^C?T;M
M=@%IJ9$),Y5:$3C6![F$(0+/^4)\9>X/;ON*6ZW[9$ (<YERIU_D"\IT?.ZY
M^.3&.9EP8.K-RG1\)GEG **)I_::K1N\R^0KPS:5849#/[?RX[K-;$P:N0R_
MMS+1#*7NZ\PG7;JJ868V8S5* 2"1@6"K\331UYYJ\"^#GI*G2))IK:6^%C<:
MAHO)?-!G&L)9>1:3B G>5C?7JV9"FJ9O-&_]#.DL&8QO\_)7""%)>F$EN<!+
M5IP16VTN!02;77Y.=9Q=9MV)^K90O0 A\R=?6]@$]1^SB'JPOCUQDN\+0>.=
M0$OQ^<<Q>T7)&B*<7'-R@2Y+^9@U2!QZ[C SNH!T'V^'B'3.'?14]%+"EG]-
M]2UX)LC&*KAU,>&V2[UT26/('LS\8&#:[40O4=W73F+[\,[,7!(B?%L%SFSI
MR%,'_3&:FKID4NQRO$^BIC,81W/VS>:)^^$V]"W6?57MB@@+CA1U3@;W)(,0
M.6AM;Y?QT*MO;=/H,?(Y''V$)P40PJK[D7#?:)BC/-:"S.: P;6]A14LX_4N
MQ]H/%U1'67!?'',T&3-\3<MZ3O-MU%0% ?38"<=I;L#^2QEB'HAX6=Y]9\9D
MH([?[3C-]-RX9N;,0[_8[I^-$5I;;T3>YG[]>>NCVTO";LYS] VQCF2=>SIY
MKY'U@2E3*&Q]N>QN=.D!,!"C8A?66B,2#;F4Y0O&.,//R#*Z7-Q%&T0T\ZOK
M2'@*>E?!Z.;."K03U<OXND1ZA[4NV.'6+6U6U$OQ,\&R;LP0C6'Z*&?9*08)
MNAD]A3=7T])$SG6\>AF=<[%-?JI'BZE- Z(&7NCEWLWQE@J^'*=U><U2DAH/
M+J.(Y[N96I/F!F%>,\<@@B-U"H\Q*D[@<V#258MN=5WXK5"+)2&]P%:8T(O;
M8/^;WSHF&\SE:6(92&M$D5"H RR<8-A"9A/C@Q$=Z]RM[E0)O'U:KRION7K%
MY.4GX66OBAJ+ZO0";U@6Q M'1*.>UB0#QS+=&+53M)<^JV<[#7"XR5J[U%8G
MGV-^GJO,ZF/MQ;'*,QI<KE.G@>'H)_%BJJ\^P<?!7/#G1GIZ>%]Y6E0S,20_
MIQ4X7QY/[@-VV3!ES4E4G/U.<'N^J)J^M6$AP((W'@V%F&7[1C0K7FH8<,L:
M.J\;+BR?<(5CZ-IQ_MR/'<?Y?/B=DGYZV=Z1,JZ():[,;XA0 #3+IN5Z\.=-
MN,7;57BY#%0K@O99)LO(V3;S#%2XL[.G6,#3H37;TJ3BP=79]I1^QJ2R,^4E
MTP%W^M]SR3 L5AB<6)*8TS,K!QW[)M+V3)4GY9P_705&C%$FT&NWGR_E5+:6
M.%YHY2G7OCA<?O!:= XP9J?8W#+ ?$A.9T1Q7=)5J#K>YOAE>YO6RT*S3_ C
MA>LB0IL&A27/GB2=O>\U,E)13MIP73Z C?L!'SE^(921V27;+ 5-<'&O/TQ;
M$")O-HQL3W%JE]L63-3G-7^3$:5W,IDL33;>).4G:#!R^:C_RE2A2M+FWK9I
MGB\C$"5Y^.PN/C:V(;I$%[/"S].^HGMY#+;VVGO0\;EV$2UOP=W\AV4%[\XU
MT(I+!RYYU"INMU]W,GOR=>%>;( 8,GL]8<,+.?6AOB">*M_Y[><F0&,;S<\)
MO<WR:DPCG&T'7RS56K0B=4]SCJT=J[W)\&FGLVBMZ^*5+GOW=:@]-5.[+T/I
MM\?D8,P._LG1GP@^%@U$.T386DE\[L/U<V?</^M>2V;,2[[P=7J,I?.C=I<*
M2R2295=[)^<YAT<G;[,6"T.G?-)Z"HF?=MPI .A@Y9"<DBDU(FO Y"O2,CHM
MW*\&=#"=%ABPP>WDM::,CK(^U/%1T?IYUN]RA,Z4[1MM.O[AF_12OH.S:XBH
M;02' YD;YY*!CEG=J),(*%[RUPOE'.2QX*8 RHV,-"^\?,2^9<NE/0$(/RF%
M3U[+/1,E,Q,S OWQ54_1=.QJ!A0G45=;WS(.SCH '$B&DU3P]UNF@94X@W#A
MTM$&B17_2V,U?6LBH+&.W4^5_9PQ^]JJ \9O"N]"<NFL7P2=(GAC=?HA8NX8
M$(.#SS0;O%G@0F! ZX"#H8Z7TZ>3DJ;?G-H%G,4_2@P_9LH:N-5FX2Z(L9PN
M=UV48^O8X T(V*LA^4QY LLWKWOL&@^6KUE@XUZ[%3EX*W>_*A^R2T#?"]8[
MGB=^E8_^_A"=8> +FN/N5DNS$\5B[>/0Y@F7^TW39V:P0&9"&-%F;K0EV613
M>Z1Y;[67,X7+PAYFDX$3E>%SDPQ'MQ'K?W6H)2W-;?ZP6?:H21X\6-G:9\T?
M55^+1AQO*4 C]*C=0A,/\!7)B:/@Y;B>\*)Z98-NH)JEA%!-S4.A>T4U4'%=
M1<L.+K:NJ@IW"H ;<E[5DFCA6ZN/"T(BS"%&=7CG+PZ5\B:G^#\_Z2*7K75Y
M+0@/3;:^TC]VN([]&3CE;UA<CG-*87G;RR(B!S8I_KHYO6&</^Z?M*8*0Y8#
M3R]3E0K)#K,1ODOFQ3/'9G<YE8R/$6"M_D_&W7:G43[Y7<XPUT'1??<G&NRZ
M&8M!"RUJG,(L(4'7\ TILP:TC[002U!<+$%IG627OR3_HC<H>=/1AU.^4G-8
M<['J>;^T^GD::?XO[*F$&1_7T!BL(A;)D?#MDZ2_7(H<\N=*2>7"EK_/A![M
M> EZ3+D$AH7%"/#C9\*V4<>7R?SXZ\D%F+(\@LGRN+;724^+9R4NC[V9LN9_
M##0.Z,1^^(;Z:80.)@^,3V?,&8PSS@D4Y'9SC&1XE%C6*;"^N6>\I3V=^UR=
M5?MZ4Z__UHV9.\C<)9^:W0*'_*7*1#!XZLX7B_&)K 2=)[;A&H;2.D),S NU
M7QXR^'+7]&175%;4@DUFW%*\[^8O9FOE!WU'<9(\<$YS[8F%!(8K%?SFFP_*
M \_)V>OI<4>N,S#KB+S1$O7;Z=W(C_;R@.;\>#3]H_*]G^R9;W*)VE]Y?409
M-<U\77+CXYO0')L^JV)$YC%RK[]JD!C^@1&8=+OA)1VZ5R")E^:=[76FE\_7
M05-6-!([NRSW0'=(3E%E=Z_:QC3P*&OINRU0 ,'>_=%10RHCKM3:<^&T!;GA
M+%63:9F#K<14[M(3U4VP9"M.Y*%T7,/E)=EG.?2DHX;M[O_U%A"X>45E>R_W
M:KYDB^0^+7H[&Q8!W3P)N^ZN\9R7':)# 0B.1J)6%L"'(JDUJ3_K_G)B.0\7
M?SX[2LSF5M1EZK3__F#6;576F"[$2BBLC@_OOM$(;P]J?R._JL,"EA?9.10U
M(-SV<@ZA $Y55L_ +K;L!R8C)O_Q<^CY>(W5<6B$5\!'8%<FKU)>;&DMT\>'
M? +*(2.?I ,D.Y@0U G<#O@KOOL<MD52 !?[J4U97/%,>\T"-8Y4Q4'[YTK5
M& A%QGB?1M1)WTC3&J)5&33[IH^'Q\]L;F'?I/>[G\*YA=*M61QQ%FY10#:2
M"PXT"TD%QT(Q GBMZ!T'\8T=U&J:$R+>ML:=&'$#OME&WX7,<^/JKG788SHP
M)9_AMT#&5K10 *Z[(%*T[F_S%(!Z);5A#CHRWQ"$-UYL/_K_ 4:X]K(YEFA_
M^U9^$:,1%]G";95>E@F'LN]EG8*2SKA2:>W:/9=?[&S^IGV9(/P"'#?3DF,V
ME%V=.31E/K9:H2'1X#? +NAQN=&!1G6[AV9)IU"XV!XJ23A&S<0G(Q#_:#3Q
M:%FHV(HF"L#YZ.\T_/UV("Z8I(@'OC)\&JC6;I9E62UY58H-.]4):Z]R"V\0
MQ3^"<ZK>Q(!8E]%&,!W<0JP*-*<U>*I3A)/-[DP0/@:"\K0-5OGNEUO]N6%6
M!46%_?%H^_B"%GCR(17IA')HLV 1FQ36Y3D%,,'+0M8@&S=-0VZ-8@YS*JA]
MSM6L6+K!)H>BF\\NP.9K%*Y&Z$WX )-NC.N G4??041P*>C>*# 326END'B3
M K"C+MM,R]N9VA<R?DGIG)1!!IEZ7W^NEI0=4^PGVP#& 0YDCG980!(>7[R+
M/Q&)/%2Y=[0 Y@;Y4=#&;R*,PDA6\#G[\#HE7%ESJGTKO(Q08#$RH3^D:GP8
M[DQ^<?*J<.^8Q>6Z]K"?CP>52J!MIG NJ#V1 CCMI':>@,PGW1SP.NTX> >N
M7H<[K$Q3[5+-EA[I963;O+I&-+ 32;>.DBB:"IRA+N4X0<OX&P40-?$("]LY
M!R3%ZOP+">JVYH"19%G?E?;Q6'@XR<P!U]N<ZLQZF&A$[D(.VP_G>TW.Y\:^
M,E(T:GPJE'F3:^(PH^&\$XI5E04"T=N]4C'%:5+7M[XAV]<\O:[K\^-IC, -
M-P-#?T_60:,:AY"AHZU#^]9*H#/15.1SCJ A1[IXD$D/H9L27K3Y-SI*..<X
MT9*TD"O)#TEF<R<]3>,ZEH_KLL/>W0Y5+6E320N@*7V!3HPYYLB>)_($!9"E
M(G]F&/7+^V]H#OQ&UR"VXCMTE)%JH^2LR>&7(.9?->?"/UOY+C>)RWUI;\/&
M.? W5X[8:]SJ!S2&/F&@H>\;X6R/M4=G7B*4S8)/$>CG&'Q%>TT&W"J4-G(&
M7'8NI=_N<Z:QHP6\-A!MP1<+<B.?%F]2LQ_]9ZJY3_,40)M+,;[IL#L23#KQ
M>U<B9+&_;<L/U()BA6CA@.U=DI'3,OB,@E:+P/M:\ >11I%W8/K57YX]N3TA
MY"X%EB#U)M6LTP]\+:^WF-M88SI(KI[=X#6#2.(><'X=6[H'M=$HG'9\?99K
M/O6FC',L8Y$+P!6;F=Y@)KQC0JX+WITY2E$40,??X/U 4#<1!.+2G-YM;Q[Y
M]DL0XS*85>CK2#GLE;?W@*._7E_HA%7I3?Z&8IH;)H\%YFR?O^ +[/,WS1EY
MD1A="0_F0Y(N*E.9\7[B48_*S<?4J<O_V8$E^5&9]H?GE=S^S&V]1/R_'Z4$
MWP[^B?IG3_7_"_EJ4B\O0 =HDZFR4LN$ LB:>$0!H*@\C=:BK@-YR#R^>$CX
M0@',FR\_RWE/ 6@S6_PS@8"X5\LSVRI.\+TY:IJ+=RK,COL_J_O_Q>KL]#"6
MAKY?OX$P4B/1:;RAES:=U6D:^#ZV(=71*+XSW3[#T?_\1JW2S/]B[SW#FFJ;
M<-$@*BI-.M*B@()4D5XC(EU$1'J)BG0!Z2T0$0&I41!0$*+21)ITI(5>1$!Z
M+PDB'1)J@)"<A;[-]_WV]WW7/OM<YUQG[Q_KSV*M-3/WS-PS\[#RK,UGC.P-
M<N7Z,[\]0_+0PIF":,]N D7AH:A^G"'R@\,D>__RI@5TG\*PHMPGSQ-2+-PZ
M<I]G-N[S/?+IZ16^UT8=U&@4PA$7"R&#-UY9'V5PA(Z"L2$+A'O3*K.^OCL3
M5=YE\H,?;V1L0;T)(*4XZ(G%5J*MA3M?^?,[NL387A+H!V)+^70KQ\)F2""1
M4@R<S@A3Y;.&+F]<H<5D;8ND>;Z#6CHD[1!XRA*/;!NS':/>]I9!*#D^S--;
MJ)QK%@V&LU2??.-3A;%,QH&OXPR:!FT&-NTDQI;4-"Q54R6?/,,]?GEO0II_
MK=FMRD)R!UY'/O:#%0\_T)Q/OG8L;)8$XBK)05,;1R'9E@X=O$$"(4S7=?R;
MD Q*XCXS37[@1B2],9Z\48FMBLUSZFEF'\/-3U4U)[@TWH5>I;NE6"?.I0D1
MML#21E7#@0$!8Y.,W<>HI5EC2@97LC[UP RL[(0F[<\U:KNX@LX;-'#691T]
M(A?#(I37.^WG\KN'.>&N/T((A7WJ4#>-'S,';S?4P>5-=V?JY""MX*C3^&"+
MOEI9 ##)NS0UV?;;H\"MAD:!UQ^:M],';J[8H-7UQF(U\I/K2"!F!=4<'\/1
M[N9:@6+LSE,/!'M!J/-:R8K0N'(>T[D$IENTL=9&-WMI*S[[>=#<GNW)/(!,
MDRV3-\@5+LPXN63"^P\#@A+-:4P"?5G)0^S?/=1LX%O27'@@'\P!-Q3A 0FK
MY2W"!Z 1U!;42G--# OVV1:64\?HM1GU-.J9>6G>%.Z6>_"]]IBB7*N]Z&-K
MB#L>--/-U\*<(!7NG^E3?*-46Q\>6[\R^TC,X.5IL8].8U&OMU)-S,R@I8]6
MX.C3 _OXH=\!@/R:/4-=*.HMVN@I=@51VI@2T<A:]EZN.[U9P4XEK"(K*UAC
MX9K.>K@LQPS-I5//7'MK7V"YLO.7N&A[UA1TTT6",2>=^J?L"[OBA,1I6 5S
M3G_6:*M7H$MUU])L+#Z2C8W)K8$Y :DYE4Q+5'L#] -G^%I&I[FVMX%<M-2;
MB?;&M1<JM!2N!?2J[Z]A<0E:$K?L]PR7:MLZL.N<S5C\4<CO](8A1S*4F
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MJF!?CUI>FDO[T\T-JVYA!JZP]Y"+RV:3;82E]655N6'3_!"[]79?SN<.6O-
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M!N/I:6V56KLWC7XB IG7 WS8@ B^5O2OWC. VO4)ATMX21%,=)J;D]PGA9_
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MT< 1,.C!2+3>DUM(<ZA>Z:\F1)R=)[(5HWC,;:+6_2N;.K+3V873@N-8$+0
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M<ZE1\&PJ=^,:1=N2]DB_H5/0*@H;,8_:/'%8=#T.-]4 ('/TQU28SN1R46G
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MVSOO69Z:/-PWVEDEW%T)1R^"R?;QE,T\Q.GM,\ GP0Y/$,"S5_%72&!*A3#
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M1F%YWS(:Q[F2EQ>=Z\BHQU_AJ=&C=N0]:^L#HX\.4Q]OE&8XLM$DNWY8'+P
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M1>X)R)GWKI+_8M0_IVC8?RO[+U:E_76\!V 9N7_ F_M0S#_%^'PJR[LD/4_
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MP:9/4<Y]==Y*7KDQ41K:G[3DU-SX6>7E@!%$^HK,0ISEQD$AYBU LOJ!\T:
M)- H$(:6@EUP-/L?V5ESX#7423:[AZPG@=CQQ1;50Z4=*4>$#0&N3>1BJ]11
MTFPZ0C2A=+[29M:^PUL&?S*86HAU-.M7XH#Q8S>]#2_ZHQ75-:MJGJ>[<H0[
M!%G3<;[BW3[*KXBSF!]4,$+L,B_[61&O D'>8G>(@PNU<="\Y"$;V1,W=(PF
M'^UV-$\5>4=X -(==U+I>@*9?<+4AUQF^ZWC6OTHS:>&VP6=GW/',^[F5!3S
MNXGM^+GYBX:GGHJKAQ?K9#7*FSQ8W4*<9JV&L!L;J]RE*AIOK\3<?LQT6U7C
MR_JSXP]?Q[HY#I) 90I&4;34PXC]"" *#+*2FUB,!LMC\>I:L:M#\)$Y)W51
M&ESH\*2:T=D[,V<R9V_IN)OI2E#H9PVW9MIOE[D>IS-K^IBY>H,1!(DWSH<"
MWK/*"EV&8QV 3 (#>4T"O74&F.5X%L N@TI=EE _\O?O/L%7$#_#G 0*UO_-
M?N@!I1<$+PDAV""L145KR/KUS%% 4/[.E]E_\F45F,!V&+)%B8F3CQ;Y?T@]
MC!D@H?M)(%P2!+ )&.,F$$1J71+H3-J(=L?:%4]&(U' XZ@]YO^!=CW+&;,[
M;^0B!!-_5>;OJF[?6M__RJG*U/&CAOVIS=]U];_H&S!/\RYB]@?&?]7G;^HJ
MOJ@&Z$9/U8T$^KM*ORC,]?E_/_0*?_W=S6WXK\KEOBIU 9HZH_M36(2)[[O/
MTT>)_3*"M1RO=Q4K" L_G[$9-834Q.[H0<#W<-TIC@>QM6P!9QL_ 1V^S'AN
M56&Y<V?:F2XW=:;2?V6?P^_V#?!KR4ON%&R0,T#QWN\7D1P*YV=8OY=:"&KV
M2E(K8<YP/NGD72.[^D:D-^WS@]F@;P_=3;@NX]4_9+70TA*N8>]O2\GE3RU/
MT8U::N":/]C//=.\9C77-,S_\/+EC$=,(_^"C7_ P34U>L@/]NO=E2N5)- E
MA8X6Z,G <WBC5K;N2"5ZQTK.]*3]]-':(,S+"XXG\^FN!F1*!\^I"QQ'1TF1
M27JC"QK +)TS);B=9FKO&X,P?4>';3_GY+?7< N5]]U.W[<C--9J@LE%#B@X
MQ6)(H'UH,W13V'AN:/\V />UWD,?Y4:!@:K0MW][!C@S$+@^V(<E9YB&-W:J
MH[-"MBRD]1,&_2/SW&_U]^29O+KFS2(J<,3D]NJI.KJO'(_L Z5A"OV!YWUL
M-?I*1O+N)/69]WG*LJV\%%1U>1A;&?VAJ=#@[.&+7C&E_Q+]/Z*K?[V+,&2T
M!?U.(;]_#2;93Q0B"/8K2*:/FXQ!N]WM+\7NCMP[(O@TPZF9"3&A$B,W,R0I
M#=P;YH=HAH;XE8=Z9.<YK:W.E7@>7@@56+QHYFI@ Q9R&LOF%&^9 \!N$4-7
M<<G!FPXS( +( (-6@KZ7 L"\X3^BT:W3S" KB002,XYK1E+#>&86A)'-7,P]
M,(WMMT^H<Q:^3K &GS86?9GE_/ RA?FI#=IP\$F%@ S"E;"6J9.>+K0+B>L+
MSQ?D0L,Q@KXWD*Z,UU>H(NZR/^_[<@?$VJ(HV/N?*,(U:F8@8-X621#!BV..
M#U3K8UPBAI)$PZM5,(+&'B,E*TK]9:^<K+C6A7NLCZ53]8J+P>:"C!3@^[)X
MN!&6:I3O<:X$BLS!%3JV.,@RJI;,>)%SF;KR(F\T(P7G[;G78OE]_YH$!G[3
M)_,@8S<?(*E7!$4\%"=HBG^>X=.':2E&CZQZL-OG;0:(-O1T"<=_)[.NB,_<
MC5QF?RAS9J8BOQ$3UCBAWE++AW?/'M%QI$:%;A5G3^0U?K2-&NUD'L9F"5<:
MR/!2D7>SYG7_3A3XQ2_ /' 8 . -X>&Y?'CI#?BFSH7,V<XL@*YDUP8C9D,+
M,!D+Z!PZ$LCU1[7\&RF\_\$Q3$J2\'9.W-3!(Q?49JH6X=/A9S3X&_'V))!5
M"7)/]&9!+S32+RO\ EY_1F.UA%W>T:;'A=DD[I9(6R@%53WL;450UV7Q)>A%
M&/L!<AEN3SO<VL!%7Q.SYW2DPZ2B?QI5V,]35.%KJ#DSVL[+ *J(/V@_Y286
ML4>5FOO0<P$C0!!+\B_8$'__*>U^H/Y7]GG'+6DBI_PT:@T/!/0I>2C1J(<$
MHDG&0G<(@!$AG,!9P:6M[JU&D0T"Y,OT-KT2"%O0&EE#V>@G%9;KH]NH)%GX
M=<Y^$X'7N%/A]5'DN[KJNLU337;9\7LO-5YU,3H_6)J'E]I&ENRW]DOZ<[(T
M5S;Y]:=R%_9OO3\O;C_Z).+MW!-57COWV89K;H)-5)I/6)L#_JG!/) T.GC1
M?>)%8**- 8@W?NM[MU+;HM0L14$207%%='!L2W2D'P)Q@MO1TIN-V_4E!\C9
MEZ!HI_#.?+&R)V,GE\=?61 #[X,=XX[>56,1>.CNM[$=.[2F<'G/M:=$IM1D
M<TF':Z-)KUFF7_2!4Y)4Z.15&[%C7-<%3'C4[](_;OT^L9-%D'.IAT_A=(F,
M7DA"01J14_H/V'2)1KT)_L^UAC))(-H- OE(_VH@? D%+D4RF!)4R@<D IA7
M1=D6L_,LG&.LI:0=>I^?+S11YM#EQNA>.NU+D>?;G-$W,J$B=\PF?/!*WM=G
MRG-C$0?J_S!Z$]Z826 Y^+%],%H=")G/>XM93;NJK!57A?EJ)_*F/M9$3<Y]
M1\8HN,)GUC@= X50&DZEBJ9$"S7/8JKGZ44:]^7)>!^QOKZ/S/,[BBP9_#AY
MJ:?:!!P"$W3!1'(:4CNL&<5TV50,B,P093NN7SU^KVO!^9R:3;M^R-B.[;^W
M?]!3)N["AW=9+*LYPF4K%0,"3PD$;'?KU&F\46-9DF1&:N+YO(^#1R1ZVLRC
MM0:$\\FXE7?T&+,X.%;'97+D*%88\O'P!BE3"5.E<-?W]J,!W^,R\1&8BS%O
M[]IZ?O?]VF*H1T?1]5I0X<;\!:=<E(C2WG^#3O/<"&-Y\%H?H75Y$7RB?$49
MDUE96K%_/(9KZF:/).^1,Z[?[;U:)D=TUY26SG7$I$=EWXB/SX+YXVB2#Q)G
M3>VS]N6;=3#X8'4^Z;".71I><.5!+_;2.#()=060T9=*222!(N#8M!(2:#;
M"$4"/=;'BW3U=Z":>:ARXC""*@./%@Z0:T9<9]LP>6Q>^Z@OEI_3%F%,[PF!
M_:4UIQRIH8U*[(,N!L[HPH&"/.O8N1NAWXT2C-]"I=O/*A05212VX5ZQYAQA
M>2 ]!:Y6#7#%G.S,?\58.1B>-:]?\A"U.EV\+Q8RT_%:5NJY,]_9V8]I/. W
M2.P"ZA@)!&^&X/5&X>NU<7]S5'_N/G>Q9>?('OSE08K*AC\FL<D,&3$I.Z!@
MY)]A7ZGV-ONSLPBZ-\'@L>;+V/656/6SA;)G3W^:/^9B"G.K0=27L=&\1<.I
M'7?DK%_O!;[*<]B.[?:U<A$49^V!]9"OV//>M[_G=77.GM4\,(@$^H=+(.B^
MP%]@<Q+A;9\[T>?J%3,&1Q)DE3YGK,*H<P)[3%<+T.PIG)M.--1:&]JE/:(P
M=2I]ZJOK+1-I8LKG+K^\ F2G!;?17?I5JRX'G^*9N:<P:Q+HY-28DP10+]"7
MJHMK4>O<SWQOF;FL-YD\F^:<DR_G>LF-4OZ'!J($.>]Z^.3OD9W[%OG-@\@*
M:?P1-1?& P>9=P+)$O7[81!TGGO+$)=$7!./+JJD:EUH>_3*<W/5(@.*N>B@
M"'7/!["V0-.-!8B]"^/DY)AF[HB]Y=E28GNR&JJHG]Y%\/9CLW;1,UEBGV-X
M&=JK)73.')=8J9">A&,7I@"'^3>#?SHLF 0ZFO(K 9^8\^7P38[TWNSKLZ
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MJE6VJAUTH;'QSD;P$&L^HS$^;7HJNI;;1T\!CM%EM/=6(J_$4>=UU?C/68P
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MQ!/.X..;EQNK?N=]P5FO44U%C5;SYQ$[!ZVX!3PPN-? RF<$D=$HL 0+5JD
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M7)K-<M*@ $!?+R/U#+K5M[PO9'!JK>\]Y:WZZ;6O/8]IL%1PL<\7YH)F>\S
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M[WEX^!25%TC !"8_TV:<^O[C6<^IC?*GFMS82X*Y'^ 0;:";H-^004UH'>K
MIV."5G_JJS.I=DC>'USK<HE+P79:M81EGU/F"U^,LXD=&D('H &V ->X)4CO
M[MZ0NM/:6IM.?>7'$E)_?01=_$17S^WZ/B$3,_75IK6+/.IR"5#^-GSW@T_
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M(K'U_ZRQ[]M*=?,*_PEOB%,X'H5U>.C<83MO+U1J4PC6<1-8X_',_<"&%"
M..1V_(4.3'=J"P2NK. DT;K\ISM:9)6H->Z(YDM_;;M5M,>P5X)#MA@H3;<]
MV8KE7&2QMG0<>^TJ(@,]G=U)72S0>.?)#Z/+\-8[(VK.=F^ 5\W5#!^_&044
MZ:DTSKY/#+\7UKZAJ\\@_=V&2C4=CM7=!']%DPR0#;Y3!TDN^\AL_;2Q/C)H
M.N_@;:UFP$XA0CI+,T>GYD6%N?1V^*?U'VV. X,CJM'9(W?E->00+@/U)Q;'
M%+K7@M'PF "+G17.)$'^4OV"5)&-,4-AJ>SHO.^R 05Q>-0JA1X=AX:7?N>G
M@&MN5D"U5_#^%3/\9)PCK!*_T3&7'J;ZVGW]#K(,311!C4..(7$LI,-#V!)(
M;/$NF'+BY*>U?8X.#?ODS1F^^G6$=^$D%1G4?!79=">7#&JB]&,G/L.=);=[
M5YA7P>6N7[UW V%KFS5N'E@E?[/7G[8=?][UUPZ Y\POMR(L_7',?,"R'C Z
MG5(O#F"NP.B7]UXY^+FE!OP8Q]X-MQO5N%D:Q\9QU?)I'ATH26% ,7,Z=DRX
M=8(9_WI"<1C!DQU[=!2>1H+16]%;+B^_"AD-DAHH5AC3NZ$\(:MRUU.@8OP1
M!5J:*!!3VLL%[VTE\914U,10WMFTU/0562A@CU:S<?)]("-R=+E2NMSYPVK&
MMY_;9!"D$*'^SMGF+"!JOZ^C1Q>N73,M;KG*UC32PO7IW0)Q829$^2'(59I-
MMR9&X^'U%[):/AI">*5P,LA>W;0QXWP9D#O=RQVM;U/<]],5W%)1X.[J72']
M(ZD\UF$CE2?R23:^4A3THS.FW(1":^F&&#=^T@2R5RH+TV34,HRTJ52$$FUG
MEJ'1%M,( X).J! ^L"I/(\X^VYI[9I+C@ZDK"GY6UQ=T63&O*\/#] #5QBN/
MI".=FT3HC$B72;,OC=F]R\'ANP0CRG?<XTW$[VJ878^=D'EXL9>]+IAT5Z.^
M1R,=OO7!U1YKH1/ZLYM>!U/+N1=3(9^TS>+Z4$[-7;[H(O\]%M0K<!>$ 2B8
M]HE0"R#0895&8(3.8UOI#^<-^Z8!QUSA1>/"&A?:AR(!F5WY#\VPLC?Y!54"
M_*]0/FK$$MC#VQ91!N6&*[4HK0?8^3LZ"CO&MXIP;GY*O6=W5OG,: A6NTWL
MP@6GNN>H.B&-[F$OZ94 P;W#IYQ*V&$ZU$JY^VY"=YG>*"^AJN<"W6,MN<M#
MR IY XBQ8K*%>VU%S-2=2:T?5E>JKKC$09YC'^G<%_]AS:5#D ZCP\;RVAQN
MFV#5P44;697T>UJJ&TP7WY LYM7:[[E9>2[SR>54$)LS?5O&60)SE#PDI!X\
M4*M%X#*I3VA2]$O<3IQ2C!E>Z#I]3C^R^YK][JW.2M95D<2'HF]R5@1'J)?6
M!1&7!^H%BYZ-12F9,MJ:5?05DCK?>W?+G.*ID,7!YWDTL.5JFFA'$M>7];)H
MLS55244L765E90K.-MK<0X8H/HTZ"J!;2,* Y=0XE-,HSRA_ <E96/J<-%2E
M'UDY$UTLG.9YXJR71#.<?[H^Z""OZ SR!*"CS2;OG389*5^HL@DC--BSR=KV
MU7X\MF7[>NNMIR]OY)'<&(R3,Q+4:J?>VRP=-I:>CDWES#\SEYPI@;? +MW.
M[O?---&BEI"]//M@:/T9M#0=@V6\/]'9BUN/14 <W9W<<,,*!^R6M]M33#+M
MV!3U:8]>XI^N 4<]87ZFH4CI..MF2%\/%Y8?^!'0@LL6Z%#(/0,EDSZ%XZ6%
M%LQ,CC9:WVL+3V);+(NN2!VCN[C<+I_%W<GG[$^U533EJ'-Q9\J\RT8*#PTG
M0HK@7+B V)9U#NR$=-6@@K5M2W+R^YW]NR&2P^4NYBXG[NR LF9//-*=?F4/
M#B.=@,^T"E)3H&?>FA 3G0=7W+$NKAY9J^_+=ZQ@^1A%.KBEKTVZB]6A56/P
M2%R!E5 OW?6(\HAK/3]#)'$0J+X@?'#2H[V7@;% :2!^OX5312$I]VR"OR=3
MG >L3 XF(L*V45P^(//X\[PP350 &P9,C;@6V=B&FXP]%G\S"@CRO+Y([7EO
MA^\)&>3I-F8XP<UZ[>9K;Q_JQ"&,*^RHHTIA.ZF)X+4>(NEFT3^/-?,3[WC;
MM#0.5J(JOES1>2V?9S&NV_][X:!YTL=OS:>[8+*A,5>5S4WD7OA'F?=B6,H
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M(_*?.VW'?EM:;7($RN%,!N$C )CI,*3$BQ&ZHK@.^2I?J;:<OQVU$BZKI+Q
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M1NM.U>B/>7M8743L-/3PA(Y\$@O2/HP,JJCO>'^ Z<1A2HBQR8&0X)[1$I^
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MC<=NX1\_/K)AY$*U",:_.*P:?^328= ;HO 1?X1Y=MU[GSFB^6[$/ INM&V
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M831^[,!<8S^;T08B7[1%DJK ?Y<<X\<,/T'J[H]T(.@WJOYGJ:G>;72@*R>
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MQ:?H-(% > L'*W"OU@FN0JINA((\H7Q.X#T47[>DN4QYMKKHEDP73>GL_
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M7/(MIO>9OR-]L^P@M1[_\?A&I>B]Y&/S.J?&L/XD_R;!JHDVM- S$^)JSH/
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M[A^$@1C*R(%IFOI_]-HV>W"8<I,ABP1YBD$B/S(B L,@D2VF=&"//JF7%I;
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M.G!0\)U@8@>J]KZ6:B\:.6*P$D5BQ<T7Y,+E/M?PV:F-O(NU<7KGEYJ!O'?
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MB*-T V-Y-(RF8=!*5KFK71@V:1.A.'._ADZ$,,HM2'.Y%%:N& 3FG+@&W)1
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MND>1<^!.HH/;4^%(]B,)21P?N$Y?V2<\*<[Y&9!JJI,MZUYG]A[WCPW6+ ,
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MOSX#!\ZL]U(A]&%_+!?<YS9-X\>N>FGM1_^=P>*$U$F=A D3U34;8!V\Q9+
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M%-4@2I'_8MWI*1Y5PS[5PF\X[%&TO_$NG%RUS0@;N/D/[*K]8)<5$+5L586
MR/5WRT?\A]UOFZ=.\S"DD?Q_MPZP_K\#&T\0TO;@G,MLU1$G?+7CO71J#&5_
M^;*Q3W=\'M_[71(RF_[LJS/'C[><!C(E8VTN#HRB;A]3JFM+H33 BMMB=%2#
M#=X2+R:OKX23%? +I1EN@9^VO+4Z<$GNGG>;0R8_O-2Z:VA.LJGP$%1H.[7C
MRMH0>J!;1P! F!!6(GV&0\0->J\='+8^47D:XCV8>,Y(.D TT:CPF6K\V*.B
M)N^/$SG>T1NKE]]:BTU-!RK/D90UHL_NP'X@$X'Y/U-=V_W^RF,@'BRJI33_
M?O#4&.51VYEZ9U.C!(HA+2S+_S^-X%3(P(\W +STXB)K64K<^%3RG<EMTW.
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M*9+$4<DH)*RO-;H%379#LP(C2,I(#QCX<O<';%-(Y>%2KD,0HA/*W5:P+8
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M.]V1.3371F^S.L, .KGU%/0B%-0>BJ8]7OA:2LPYTK-I@_V9Y$- S$1'$1>
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M53]L2S6)=J$9];$B$T,*Z$=M*:+7)V6&4Q!@L22_78-K$ZQ[Z*9"@H*ETWO
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M =D3+@+6(OSL:,:YM#SP6LP>1K@L<<9NG:F6]( B=^>Q/_GZ:5+UF/9@/!-
M1M5HY+IL-'Q<QJS=H%MZNL='Z&,2FZO&5;!TEQR#Z04?\91-U&8H#>"0KD+R
MZKA"-(D9+Z\EWX?SBMSATLLYC7UX\#@;>L*S?[%0 !PTAIP_/@8/PTB8[/4W
MT._P'KZABCNR.!6_/I7%WI.1,E6?H#H$4!5W8IKY""F"W<+;_G =L &F(%T
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M222['0N8_;,68>>"S[[#V2B_R1Z<&1KZXXR#!#.HYIZ4L&AD%R:0'N)B7=T
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M5J )>=9RO7@0WZPQ-/A<-Z2')V!OLN^) ';UR=F*<>)"O6BLKVRBL-LC5:'
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M,EM3,E6P1XNK>3Q(QFFL,*)@T8=_,;_F>"Y.Z6LTX_&^Y7++[FH3H:=[WM,
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MTNV7G:<G[^-XHYX#%0FBGE^>RTF]%4OSDK.3HUC >#Y;N*-P=&X) ,HZ:G0
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M7F*A"<NM7F(:8!@V@/UG8BH[#+\>!(M"DK0Z^S%76]1'Z7X,S:C'?)JS#
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M2XMT31)^,51.*(AV'9OJ<.A2))<JQ=577?7MS"^*6S7E%_)<B,D:@T2*<A%
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M[[_#E96=+F>+F",9>K2/_P=02P$"% ,4 " #!@%M0]/[H+".0 +HP
M' @ $ 83$P:V-H96-M:6-A;&QI;FME<FEM86=E+FIP
M9U!+ 0(4 Q0 ( ,& 6U!WT0SQ1RT! /E2 0 = " 5V0
M !C:&%R="UE.6,V,3(X-C8R-C,U8C!D86-A+FIP9U!+ 0(4 Q0 ( ,&
M6U"^[_7/6Q4 %#B 1 " =^] 0!I;6UU+3(P,3DQ,C,Q
M+GAS9%!+ 0(4 Q0 ( ,& 6U!1NGB9C"@ #RU 0 5 "
M 6G3 0!I;6UU+3(P,3DQ,C,Q7V-A;"YX;6Q02P$"% ,4 " #!@%M0]QI%
M\/!U !$K@4 %0 @ $H_ $ :6UM=2TR,#$Y,3(S,5]D968N
M>&UL4$L! A0#% @ P8!;4+\K--'% $ >TH- !4 ( !
M2W(" &EM;74M,C Q.3$R,S%?;&%B+GAM;%!+ 0(4 Q0 ( ,& 6U#= )%.
MC*( *$%" 5 " 4-S P!I;6UU+3(P,3DQ,C,Q7W!R92YX
M;6Q02P$"% ,4 " #!@%M0J9M T): !A< &@ @ $"
M%@0 :6UM=3(P,3<P-C,P>#$P:S P,F$P,2YJ<&=02P$"% ,4 " #!@%M0
M^GI2JJY* !O5@ &@ @ %\< 0 :6UM=3(P,3<P-C,P>#$P
M:S P,V$P,2YJ<&=02P$"% ,4 " #!@%M0&^A);K"D P!,NRH $
M @ %BNP0 :6UM=3(P,3DQ,"UK+FAT;5!+ 0(4 Q0 ( ,& 6U"C
MVP5#4EX! $BR"@ 8 " 4!@" !I;6UU,C Q.3$P:S$R,S%E
M>#$P.2YH=&U02P$"% ,4 " #!@%M0)?PIQ34# "7$ &0
M @ '(O@D :6UM=3(P,3DQ,&LQ,C,Q97@R,3$Q+FAT;5!+ 0(4 Q0 (
M ,& 6U"3W_S1&P0 .X0 9 " 33""0!I;6UU,C Q.3$P
M:S$R,S%E>#(S,3$N:'1M4$L! A0#% @ P8!;4,'CF$TG" MC$ !D
M ( !AL8) &EM;74R,#$Y,3!K,3(S,65X,S$Q,2YH=&U02P$"
M% ,4 " #!@%M0CUC\LB(( #P+P &0 @ 'DS@D :6UM
M=3(P,3DQ,&LQ,C,Q97@S,3(Q+FAT;5!+ 0(4 Q0 ( ,& 6U > V#+$04
M '\6 9 " 3W7"0!I;6UU,C Q.3$P:S$R,S%E>#,R,3$N
M:'1M4$L! A0#% @ P8!;4/0$MY8<!0 11< !D ( !
MA=P) &EM;74R,#$Y,3!K,3(S,65X,S(R,2YH=&U02P$"% ,4 " #!@%M0
M04FP@^P% #L'0 $P @ '8X0D :6UM=3(P,3DQ,&ME>#0Q
M+FAT;5!+ 0(4 Q0 ( ,& 6U#B2:4@DJX! -E= @ 5 "
M ?7G"0!I;6UU<&EP96QI;F4R,3 R,"YJ<&=02P4& !, $P B!0 NI8+
#
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
function toggleNextSibling (e) {
if (e.nextSibling.style.display=='none') {
e.nextSibling.style.display='block';
} else { e.nextSibling.style.display='none'; }
}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6810481440">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Debt<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureTextBlock', window );">Debt</a></td>
<td class="text">Debt<div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Liability related to sale of future royalties</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"/><span style="font-family:inherit;font-size:10pt;">On </span><span style="font-family:inherit;font-size:10pt;">January 7, 2018</span><span style="font-family:inherit;font-size:10pt;">, the Company entered into a funding agreement (the "Funding Agreement") with RPI Finance Trust, a Delaware statutory trust ("RPI"). Pursuant to the Funding Agreement, the Company issued to RPI the right to receive certain royalty amounts, subject to certain reductions, based on the net sales of the ADC sacituzumab govitecan, for each calendar quarter during the term of the Funding Agreement ("Revenue Participation Right"), in exchange for </span><span style="font-family:inherit;font-size:10pt;"><span>$175.0 million</span></span><span style="font-family:inherit;font-size:10pt;"> in cash (the "Purchase Price"). Specifically, the royalty rate commences at </span><span style="font-family:inherit;font-size:10pt;"><span>4.15 percent</span></span><span style="font-family:inherit;font-size:10pt;"> on net annual sales of up to </span><span style="font-family:inherit;font-size:10pt;"><span>$2.0 billion</span></span><span style="font-family:inherit;font-size:10pt;">, declining step-wise based on sales tiers to </span><span style="font-family:inherit;font-size:10pt;"><span>1.75 percent</span></span><span style="font-family:inherit;font-size:10pt;"> on net global annual sales exceeding </span><span style="font-family:inherit;font-size:10pt;"><span>$6.0 billion</span></span><span style="font-family:inherit;font-size:10pt;">.</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">On </span><span style="font-family:inherit;font-size:10pt;">January 7, 2018</span><span style="font-family:inherit;font-size:10pt;">, in connection with the Funding Agreement, the Company entered into a common stock purchase agreement (the "Purchase Agreement") with RPI, pursuant to which the Company, in a private placement, issued and sold to RPI approximately </span><span style="font-family:inherit;font-size:10pt;"><span>4.4 million</span></span><span style="font-family:inherit;font-size:10pt;"> unregistered shares (the "Shares") of the Company's Common Stock, at a price of </span><span style="font-family:inherit;font-size:10pt;"><span>$17.15</span></span><span style="font-family:inherit;font-size:10pt;"> per share for gross proceeds to the Company of </span><span style="font-family:inherit;font-size:10pt;"><span>$75.0 million</span></span><span style="font-family:inherit;font-size:10pt;"> before deducting fees and expenses (the "Financing").</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company concluded that there were two units of accounting in the transaction. The Company allocated the transaction consideration on a relative fair value to the liability and common stock in accordance with ASC 470-10 as follows (in thousands):</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="5"/></tr><tr><td style="width:2%;"/><td style="width:78%;"/><td style="width:1%;"/><td style="width:18%;"/><td style="width:1%;"/></tr><tr><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Units of Accounting:</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Allocated Consideration</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Liability related to sale of future royalties</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>182,216</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Common stock</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>67,784</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>250,000</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Interest will be recognized using the effective interest method over a period of </span><span style="font-family:inherit;font-size:10pt;"><span>20 years</span></span><span style="font-family:inherit;font-size:10pt;">. The effective interest rate under the Funding Agreement, including issuance costs, is approximately </span><span style="font-family:inherit;font-size:10pt;"><span>16.0%</span></span><span style="font-family:inherit;font-size:10pt;"> as of </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;">. During the year ended </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;">, the Transition Period, and the fiscal year ended </span><span style="font-family:inherit;font-size:10pt;">June 30, 2018</span><span style="font-family:inherit;font-size:10pt;">, the Company recognized </span><span style="font-family:inherit;font-size:10pt;"><span>$39.9 million</span></span><span style="font-family:inherit;font-size:10pt;">, </span><span style="font-family:inherit;font-size:10pt;"><span>$19.3 million</span></span><span style="font-family:inherit;font-size:10pt;">, and </span><span style="font-family:inherit;font-size:10pt;"><span>$19.8 million</span></span><span style="font-family:inherit;font-size:10pt;"> in interest expense, respectively.</span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following table shows the activity within the liability related to sale of future royalties during the year ended </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;">, the Transition Period and at the fiscal year ended June 30, 2018 (in thousands):</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"/></tr><tr><td style="width:80%;"/><td style="width:1%;"/><td style="width:18%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Liability related to sale of future royalties at January 7, 2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>182,216</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Interest expense recognized</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>19,791</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Carrying value of liability related to sale of future royalties at June 30, 2018</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>202,007</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Interest expense recognized</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>19,288</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Carrying value of liability related to sale of future royalties at December 31, 2018 </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>221,295</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Interest expense recognized</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>39,929</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Carrying value of liability related to sale of future royalties at December 31, 2019 (includes current portion of $3,455)</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>261,224</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Convertible Senior Notes</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In February 2015, the Company issued </span><span style="font-family:inherit;font-size:10pt;"><span>$100.0 million</span></span><span style="font-family:inherit;font-size:10pt;"> of Convertible Senior Notes (the "Convertible Senior Notes") (net proceeds of approximately </span><span style="font-family:inherit;font-size:10pt;"><span>$96.3 million</span></span><span style="font-family:inherit;font-size:10pt;"> after deducting the initial purchasers’ fees and offering expenses) in a private offering exempt from registration under the Securities Act of 1933, as amended (the “Securities Act”), in reliance upon Rule 144A under the Securities Act. The Convertible Senior Notes had a maturity date of </span><span style="font-family:inherit;font-size:10pt;">February 15, 2020</span><span style="font-family:inherit;font-size:10pt;">, unless earlier purchased or converted. The debt issuance costs of approximately </span><span style="font-family:inherit;font-size:10pt;"><span>$3.7 million</span></span><span style="font-family:inherit;font-size:10pt;">, primarily consisting of underwriting, legal and other professional fees, and are amortized over the term of the Convertible Senior Notes. The Convertible Senior Notes are senior unsecured obligations of the Company. Interest at </span><span style="font-family:inherit;font-size:10pt;"><span>4.75%</span></span><span style="font-family:inherit;font-size:10pt;"> is payable semiannually on </span><span style="font-family:inherit;font-size:10pt;">February 15</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">August 15</span><span style="font-family:inherit;font-size:10pt;"> of each year. The effective interest rate on the Convertible Senior Notes was </span><span style="font-family:inherit;font-size:10pt;"><span>5.48%</span></span><span style="font-family:inherit;font-size:10pt;"> for the period from the date of issuance through the year ended </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;">.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Convertible Senior Notes are convertible at the option of holders into approximately </span><span style="font-family:inherit;font-size:10pt;"><span>19.6 million</span></span><span style="font-family:inherit;font-size:10pt;"> shares of common stock at any time prior to the close of business on the day immediately preceding the maturity date. The exchange rate will initially be </span><span style="font-family:inherit;font-size:10pt;"><span>195.8336</span></span><span style="font-family:inherit;font-size:10pt;"> shares of common stock per </span><span style="font-family:inherit;font-size:10pt;"><span>$1,000</span></span><span style="font-family:inherit;font-size:10pt;"> principal amount of Convertible Senior Notes (equivalent to an initial conversion price of approximately </span><span style="font-family:inherit;font-size:10pt;"><span>$5.11</span></span><span style="font-family:inherit;font-size:10pt;"> per share of common stock).</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">If the Company undergoes a fundamental change (as defined in the indenture governing the Convertible Senior Notes), holders may require Immunomedics to purchase for cash all or part of the Convertible Senior Notes at a purchase price equal to </span><span style="font-family:inherit;font-size:10pt;"><span>100%</span></span><span style="font-family:inherit;font-size:10pt;"> of the principal amount of the Convertible Senior Notes to be purchased, plus accrued and unpaid interest, if any, to, but excluding, the fundamental change purchase date, subject to certain exceptions. In addition, if certain make-whole fundamental changes (as defined in the indenture governing the Convertible Senior Notes) occur, Immunomedics will, in certain circumstances, increase the conversion rate for any Convertible Note converted in connection with such make-whole fundamental change.</span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The indenture does not limit the amount of debt which may be issued by the Company under the indenture or otherwise, does not contain any financial covenants or restrict the Company from paying dividends, selling or disposing of assets, or issuing or repurchasing its other securities, provided that such event is not deemed to be a fundamental change (as defined in the indenture governing the Convertible Senior Notes). The indenture contains customary terms and covenants and events of default.</span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">If an event of default with respect to the Convertible Senior Notes occurs, holders may, upon satisfaction of certain conditions, accelerate the principal amount of the Convertible Senior Notes plus premium, if any, and accrued and unpaid interest, if any. In addition, the principal amount of the Convertible Senior Notes plus premium, if any, and accrued and unpaid interest, if any, will automatically become due and payable in the case of certain types of bankruptcy or insolvency events of default involving the Company.</span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">On </span><span style="font-family:inherit;font-size:10pt;">September 21, 2017</span><span style="font-family:inherit;font-size:10pt;">, the Company entered into separate, privately negotiated exchange agreements, (the "September Exchange Agreements") with certain holders of the Convertible Senior Notes. Under the Exchange Agreements, such holders agreed to convert an aggregate </span><span style="font-family:inherit;font-size:10pt;"><span>$80.0 million</span></span><span style="font-family:inherit;font-size:10pt;"> of Convertible Senior Notes held by them. In total, the Company issued an aggregate </span><span style="font-family:inherit;font-size:10pt;"><span>16.8</span></span><span style="font-family:inherit;font-size:10pt;"> million shares of common stock in the September Exchange Agreements. The shares represent an aggregate of </span><span style="font-family:inherit;font-size:10pt;"><span>1.1</span></span><span style="font-family:inherit;font-size:10pt;"> million shares more than the number of shares into which the exchanged Convertible Senior Notes were convertible under their original terms. As a result of the September Exchange Agreements, the Company recognized a loss on induced exchanges of debt of </span><span style="font-family:inherit;font-size:10pt;"><span>$13.0 million</span></span><span style="font-family:inherit;font-size:10pt;"> representing the fair value of the incremental consideration paid to induce the holders to exchange their Convertible Senior Notes for equity (i.e., </span><span style="font-family:inherit;font-size:10pt;"><span>1.1</span></span><span style="font-family:inherit;font-size:10pt;"> million shares of common stock), based on the closing market price of the Company's Common Stock on the date of the September 2017 Exchange Agreements.</span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">On October 2, 2018, the Company entered into privately negotiated exchange agreements (the "October 2018 Exchange Agreements"), with a limited number of holders of the Convertible Senior Notes. Under the Exchange Agreements, such holders agreed to convert an aggregate </span><span style="font-family:inherit;font-size:10pt;"><span>$12.9 million</span></span><span style="font-family:inherit;font-size:10pt;"> of Convertible Senior Notes held by them. In total, the Company issued an aggregate </span><span style="font-family:inherit;font-size:10pt;"><span>2.6 million</span></span><span style="font-family:inherit;font-size:10pt;"> shares of common stock in the October 2018 Exchange Agreements. The shares represent an aggregate of </span><span style="font-family:inherit;font-size:10pt;"><span>0.1 million</span></span><span style="font-family:inherit;font-size:10pt;"> shares more than the number of shares into which the exchanged Convertible Senior Notes were convertible under their original terms. As a result of the October 2018 Exchange Agreements, the Company recognized a loss on induced exchanges of debt of </span><span style="font-family:inherit;font-size:10pt;"><span>$0.9 million</span></span><span style="font-family:inherit;font-size:10pt;"> representing the fair value of the incremental consideration paid to induce the holders to exchange their Convertible Senior Notes for equity (i.e., </span><span style="font-family:inherit;font-size:10pt;"><span>0.1 million</span></span><span style="font-family:inherit;font-size:10pt;"> shares of common stock), based on the closing market price of the Company's Common Stock on the date of the October 2018 Exchange Agreements. As a result of the October 2018 Exchange Agreements, the balance of the outstanding Convertible Senior Notes was </span><span style="font-family:inherit;font-size:10pt;"><span>$7.1 million</span></span><span style="font-family:inherit;font-size:10pt;"> at </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">2018</span><span style="font-family:inherit;font-size:10pt;">. As of February 14, 2020, the remaining </span><span style="font-family:inherit;font-size:10pt;"><span>$7.1 million</span></span><span style="font-family:inherit;font-size:10pt;"> of Convertible Senior Notes converted into </span><span style="font-family:inherit;font-size:10pt;"><span>1.4 million</span></span><span style="font-family:inherit;font-size:10pt;"> shares of common stock based on the initial conversion price of approximately </span><span style="font-family:inherit;font-size:10pt;"><span>$5.11</span></span><span style="font-family:inherit;font-size:10pt;"> per share of common stock.</span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total interest expense for the Convertible Senior Notes were </span><span style="font-family:inherit;font-size:10pt;"><span>$0.4 million</span></span><span style="font-family:inherit;font-size:10pt;">, </span><span style="font-family:inherit;font-size:10pt;"><span>$0.5 million</span></span><span style="font-family:inherit;font-size:10pt;">, </span><span style="font-family:inherit;font-size:10pt;"><span>$3.5 million</span></span><span style="font-family:inherit;font-size:10pt;">, and </span><span style="font-family:inherit;font-size:10pt;"><span>$5.5 million</span></span><span style="font-family:inherit;font-size:10pt;">, for the year ended </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;">, the Transition Period and the fiscal years ended 2018 and 2017, respectively. Included in interest expense is the amortization of debt issuance costs of </span><span style="font-family:inherit;font-size:10pt;"><span>$0.1 million</span></span><span style="font-family:inherit;font-size:10pt;"> for the year ended </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;">, </span><span style="font-family:inherit;font-size:10pt;"><span>$0.2 million</span></span><span style="font-family:inherit;font-size:10pt;"> in the Transition Period (</span><span style="font-family:inherit;font-size:10pt;"><span>$0.1 million</span></span><span style="font-family:inherit;font-size:10pt;"> of which related to the accelerated amortization of debt issuance costs associated with the October 2018 Exchange Agreements), </span><span style="font-family:inherit;font-size:10pt;"><span>$1.7 million</span></span><span style="font-family:inherit;font-size:10pt;"> in fiscal 2018 (</span><span style="font-family:inherit;font-size:10pt;"><span>$1.4 million</span></span><span style="font-family:inherit;font-size:10pt;"> of which related to the accelerated amortization of debt issuance costs associated with the September Exchange Agreements), and </span><span style="font-family:inherit;font-size:10pt;"><span>$0.7 million</span></span><span style="font-family:inherit;font-size:10pt;"> in fiscal 2017.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -URI http://asc.fasb.org/topic&trid=2208564<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
function toggleNextSibling (e) {
if (e.nextSibling.style.display=='none') {
e.nextSibling.style.display='block';
} else { e.nextSibling.style.display='none'; }
}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6805743168">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accounts Payable and Accrued Expenses<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock', window );">Accounts Payable and Accrued Expenses</a></td>
<td class="text">Accounts Payable and Accrued Expenses<div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Accounts payable and accrued expenses consisted of the following as of December 31, (in thousands):</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"/></tr><tr><td style="width:73%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">2018 </span><span style="font-family:inherit;font-size:9pt;font-weight:bold;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(a)</sup></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Trade accounts payable</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>37,758</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>20,125</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Accrued contract manufacturing expenses</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>11,663</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Accrued employee related expenses</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>7,403</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>315</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Clinical trial accruals</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>2,225</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>5,114</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Executive severance liabilities</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>561</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>2,198</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Miscellaneous other current liabilities</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>1,250</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>3,970</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>60,860</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>31,722</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(a)</sup></span><span style="font-family:inherit;font-size:10pt;"> </span><span style="font-family:inherit;font-size:9pt;">Certain 2018 amounts have been reclassified to conform with current year presentation.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a),20,24)<br> -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
function toggleNextSibling (e) {
if (e.nextSibling.style.display=='none') {
e.nextSibling.style.display='block';
} else { e.nextSibling.style.display='none'; }
}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6810545296">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related Party Transactions<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsAbstract', window );"><strong>Related Party Transactions [Abstract]</strong></a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock', window );">Related Party Transactions</a></td>
<td class="text">Related Party Transactions<div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">On </span><span style="font-family:inherit;font-size:10pt;">January 8, 2018</span><span style="font-family:inherit;font-size:10pt;">, Morris Rosenberg joined the Company as Chief Technology Officer and became a full-time employee. Between </span><span style="font-family:inherit;font-size:10pt;">May 5, 2017</span><span style="font-family:inherit;font-size:10pt;">, and </span><span style="font-family:inherit;font-size:10pt;">January 7, 2018</span><span style="font-family:inherit;font-size:10pt;">, Mr. Rosenberg was engaged by the Company as an independent consultant pursuant to a consulting agreement between the Company and Mr. Rosenberg’s consulting company, M Rosenberg BioPharma Consulting LLC. The Company paid M Rosenberg BioPharma Consulting LLC </span><span style="font-family:inherit;font-size:10pt;"><span>$0.6 million</span></span><span style="font-family:inherit;font-size:10pt;"> during this time and Morris Rosenberg was also granted stock options to purchase </span><span style="font-family:inherit;font-size:10pt;"><span>45,000</span></span><span style="font-family:inherit;font-size:10pt;"> shares of the Company's common stock pursuant to the Immunomedics, Inc. 2014 Long-Term Incentive Plan. From </span><span style="font-family:inherit;font-size:10pt;">January 8, 2018</span><span style="font-family:inherit;font-size:10pt;">, through </span><span style="font-family:inherit;font-size:10pt;">June 30, 2018</span><span style="font-family:inherit;font-size:10pt;">, the Company paid M Rosenberg BioPharma </span><span style="font-family:inherit;font-size:10pt;"><span>$0.8 million</span></span><span style="font-family:inherit;font-size:10pt;">, and from July 1, 2018, through the transition period ending December 31, 2018, the Company paid M Rosenberg BioPharma </span><span style="font-family:inherit;font-size:10pt;"><span>$0.3 million</span></span><span style="font-family:inherit;font-size:10pt;"> for services agreed upon prior to Mr. Rosenberg becoming a full-time employee. As part of his employment contract, </span><span style="font-family:inherit;font-size:10pt;"><span>50%</span></span><span style="font-family:inherit;font-size:10pt;"> of the </span><span style="font-family:inherit;font-size:10pt;"><span>45,000</span></span><span style="font-family:inherit;font-size:10pt;"> shares granted to Mr. Rosenberg as a consultant were forfeited, the remaining </span><span style="font-family:inherit;font-size:10pt;"><span>50%</span></span><span style="font-family:inherit;font-size:10pt;"> continue to vest. Mr. Rosenberg received </span><span style="font-family:inherit;font-size:10pt;"><span>104,389</span></span><span style="font-family:inherit;font-size:10pt;"> stock options and was permitted to continue to provide certain limited outside consulting services through M Rosenberg BioPharma Consulting LLC based on certain restrictions outlined in the contract. Additionally, during his employment period, except with the prior written consent of the Board of Directors, Mr. Rosenberg is not permitted to enter into any contract, agreement or other transaction arrangement to provide goods and/or services to the Company through M Rosenberg BioPharma Consulting LLC.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">On March 5, 2019, the Company appointed Scott Canute, a member of the Company’s Board, as the Company’s Executive Director. Upon recommendation of the Compensation Committee, the Board approved that Mr. Canute will be paid </span><span style="font-family:inherit;font-size:10pt;"><span>$16,667</span></span><span style="font-family:inherit;font-size:10pt;"> per month for his service as Executive Director and was granted a nonqualified stock option to purchase </span><span style="font-family:inherit;font-size:10pt;"><span>79,818</span></span><span style="font-family:inherit;font-size:10pt;"> shares of the Company’s common stock (the “Initial Canute Compensation”). The Compensation Committee determined that in order to reflect the scope of his role and the significant time that Mr. Canute will be devoting to his role as Executive Director, Mr. Canute’s cash compensation shall be increased to </span><span style="font-family:inherit;font-size:10pt;"><span>$21,372</span></span><span style="font-family:inherit;font-size:10pt;"> per month, and Mr. Canute was granted an additional nonqualified stock option to purchase </span><span style="font-family:inherit;font-size:10pt;"><span>22,854</span></span><span style="font-family:inherit;font-size:10pt;"> shares of the Company’s common stock (the “Revised Canute Compensation”). The options have a </span><span style="font-family:inherit;font-size:10pt;">seven</span><span style="font-family:inherit;font-size:10pt;">-year term and an exercise price equal to the fair market value of the Company’s common stock based on the closing price of the Company’s common stock on each date of grant and will be subject to the terms of a nonqualified stock option agreement (the “Canute NQSO Agreement”). Such options will vest in full upon the Company’s receipt of approval from the FDA for the Company’s BLA resubmission for sacituzumab govitecan for the treatment of patients with mTNBC who have received at least two prior therapies for metastatic disease under the PDUFA. The Company and Mr. Canute entered into a letter agreement (the “Canute Letter Agreement”) to memorialize his appointment as the Company’s Executive Director, and the Initial Canute Compensation. The Canute Letter Agreement may be terminated by either party at any time upon written notice to the other party. During the year ended </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;">, the Company paid Mr. Canute </span><span style="font-family:inherit;font-size:10pt;"><span>$0.4 million</span></span><span style="font-family:inherit;font-size:10pt;"> for such services. </span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">On November 19, 2019, pursuant to the Plan, the Board of Directors approved a stock option grant to Behzad Aghazadeh, Executive Chairman of the Board of Directors of the Company, to purchase </span><span style="font-family:inherit;font-size:10pt;"><span>150,000</span></span><span style="font-family:inherit;font-size:10pt;"> shares of the Company's common stock (the "Performance-Based Option") for certain duties performing this role; including providing consulting and advisory services to the Company. The Performance-Based Option will be a nonqualified stock option and one third vested upon FDA acceptance of the BLA resubmission in December 2019, and two thirds shall vest upon approval from the FDA for the Company’s BLA for sacituzumab govitecan.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -URI http://asc.fasb.org/topic&trid=2122745<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
function toggleNextSibling (e) {
if (e.nextSibling.style.display=='none') {
e.nextSibling.style.display='block';
} else { e.nextSibling.style.display='none'; }
}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6804066592">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Marketable Securities - Amortized Cost to Fair Value (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_immu_AvailableForSaleSecuritiesDebtMaturitiesAfterOneYearormoreCarryingValue', window );">Fair Value</a></td>
<td class="nump">$ 4,500<span></span>
</td>
<td class="nump">$ 4,900<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember', window );">U.S. Government Sponsored Agencies</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">4,941<span></span>
</td>
<td class="nump">4,941<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gain</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized (Loss)</a></td>
<td class="num">(391)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value</a></td>
<td class="nump">$ 4,550<span></span>
</td>
<td class="nump">$ 4,941<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_immu_AvailableForSaleSecuritiesDebtMaturitiesAfterOneYearormoreCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Available For Sale Securities Debt Maturities After One Year or more Carrying Value</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">immu_AvailableForSaleSecuritiesDebtMaturitiesAfterOneYearormoreCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>immu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&oid=118939692&loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&oid=118939692&loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&oid=118939692&loc=d3e27161-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&oid=118942338&loc=SL82898722-210454<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&oid=118942338&loc=SL82898722-210454<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&oid=118954083&loc=d3e26610-111562<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -URI http://asc.fasb.org/extlink&oid=118939692&loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
function toggleNextSibling (e) {
if (e.nextSibling.style.display=='none') {
e.nextSibling.style.display='block';
} else { e.nextSibling.style.display='none'; }
}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6802535200">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Quarterly Results of Operations (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_QuarterlyFinancialInformationDisclosureAbstract', window );"><strong>Quarterly Financial Information Disclosure [Abstract]</strong></a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock', window );">Summarized Unaudited Quarterly Financial Data</a></td>
<td class="text"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following table summarizes unaudited quarterly financial data:</span></div><div style="line-height:120%;text-align:justify;padding-left:0px;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"/></tr><tr><td style="width:37%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:14%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"> </span></div></td><td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Three Months Ended</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-style:italic;"> </span><span style="font-family:inherit;font-size:9pt;font-style:italic;font-weight:bold;">($ in thousands, except for per share amounts)</span></div></td><td colspan="3" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">December 31, 2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">September 30, 2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">June 30, 2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">March 31, 2019</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Consolidated Statements of Comprehensive Loss Data:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">    </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">    </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Revenues</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>295</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Net loss attributable to Immunomedics, Inc. stockholders </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(99,608</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(94,292</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(75,953</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(87,337</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Loss per common share attributable to Immunomedics Inc. stockholders – (basic and diluted) </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(0.50</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(0.49</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(0.40</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(0.46</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Weighted average shares used to calculate loss per common share – (basic and diluted)</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>199,614</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>191,981</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>191,745</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>191,052</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;padding-left:0px;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"/></tr><tr><td style="width:37%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:14%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"> </span></div></td><td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Three Months Ended</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-style:italic;"> </span><span style="font-family:inherit;font-size:9pt;font-style:italic;font-weight:bold;">($ in thousands, except for per share amounts)</span></div></td><td colspan="3" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">December 31, 2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">September 30, 2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">June 30, 2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">March 31, 2018</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Consolidated Statements of Comprehensive Loss Data:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">    </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">    </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Revenues</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>387</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>482</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Net loss attributable to Immunomedics, Inc. stockholders </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(93,499</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(64,169</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(117,032</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(35,546</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Loss per common share attributable to Immunomedics Inc. stockholders – (basic and diluted) </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(0.50</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(0.34</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(0.68</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(0.21</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Weighted average shares used to calculate loss per common share – (basic and diluted)</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>190,171</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>186,937</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>171,124</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>166,054</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_QuarterlyFinancialInformationDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_QuarterlyFinancialInformationDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of quarterly financial data. Includes, but is not limited to, financial information for fiscal quarters, cumulative effect of a change in accounting principle and earnings per share data.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 270<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&oid=118952077&loc=d3e1280-108306<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
function toggleNextSibling (e) {
if (e.nextSibling.style.display=='none') {
e.nextSibling.style.display='block';
} else { e.nextSibling.style.display='none'; }
}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6832214000">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders’ Equity (Details)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Dec. 09, 2019 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Mar. 29, 2019 </div>
<div>USD ($) </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Jan. 01, 2019 </div>
<div>shares</div>
</th>
<th class="th">
<div>Jun. 15, 2018 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 05, 2017 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Jul. 31, 2017 </div>
<div>shares</div>
</th>
<th class="th">
<div>May 10, 2017 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Feb. 10, 2017 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Oct. 11, 2016 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2018 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Jun. 30, 2018 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Jun. 30, 2017 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 29, 2017 </div>
<div>shares</div>
</th>
<th class="th">
<div>Jun. 28, 2017 </div>
<div>shares</div>
</th>
<th class="th">
<div>Feb. 16, 2017 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_immu_CommonAndPreferredSharesAuthorized', window );">Common and preferred shares authorized (in shares)</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">260,000,000<span></span>
</td>
<td class="nump">165,000,000<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized (in shares)</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">250,000,000<span></span>
</td>
<td class="nump">250,000,000<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">250,000,000<span></span>
</td>
<td class="nump">155,000,000<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized (in shares)</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value (in USD per share) | $ / shares</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Agreement purchase shares of common stock (in shares)</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">4,400,000<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in USD per share) | $ / shares</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromWarrantExercises', window );">Exercise of warrants | $</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 1,688<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 78,226<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Number of shares issued in transaction (in shares)</a></td>
<td class="nump">16,428,572<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">13,225,000<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering', window );">Proceeds from public offering of common stock | $</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">273,031<span></span>
</td>
<td class="nump">299,467<span></span>
</td>
<td class="nump">28,578<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Payments for stock issuance costs | $</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">17,400<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedPerTransaction', window );">Consideration received per transaction | $</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 71,600<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares', window );">Retired treasury stock (in shares)</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">105,959<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_ConvertiblePreferredStockMember', window );">Convertible preferred stock</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized (in shares)</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value (in USD per share) | $ / shares</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued (in shares)</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=immu_SeattleGeneticsIncMember', window );">Seattle Genetics, Inc., (“SGEN”)</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_immu_ExerciseOfWarrants', window );">Exercise of warrants (in shares)</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">8,655,804<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_immu_AggregateOfferingPriceofCommonStock', window );">Aggregate purchase price of common stock | $</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 42,400<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=immu_SecuritiesPurchaseAgreementMember', window );">Securities Purchase Agreement | Seattle Genetics, Inc., (“SGEN”)</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Agreement purchase shares of common stock (in shares)</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">3,000,000<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">3,000,000<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in USD per share) | $ / shares</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 4.90<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_immu_GrossProceedsFromIssuanceOfCommonStock', window );">Gross proceeds from sale of common stock | $</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 14,700<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentTerm', window );">Warrants term</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Shares that warrants can purchase (in shares)</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">8,655,804<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">8,655,804<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_immu_ClassOfWarrantOrRightFairValue', window );">Fair value of warrants | $</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 22,300<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember', window );">Private placement</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Net proceeds from sale of common stock | $</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">67,784<span></span>
</td>
<td class="nump">$ 14,700<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember', window );">Private placement | Convertible preferred stock</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued (in shares)</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">1,000,000<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_immu_IssuanceofConvertiblePreferredStockPerShare', window );">Issuance of convertible preferred stock (in USD per share) | $ / shares</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 125<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock', window );">Proceeds from issuance of convertible preferred stock | $</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 125,000<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_immu_ConvertiblePreferredStockConversionRatio', window );">Convertible preferred stock, shares issued upon conversion (in shares)</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">23.10536<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConversionOfStockSharesIssued1', window );">Conversion of shares (in shares)</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">23,105,348<span></span>
</td>
<td class="nump">23,105,348<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Share price (in USD per share) | $ / shares</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 5.41<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember', window );">IPO</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in USD per share) | $ / shares</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 3.00<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_immu_GrossProceedsFromIssuanceOfCommonStock', window );">Gross proceeds from sale of common stock | $</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 30,000<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Shares that warrants can purchase (in shares)</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_immu_ExerciseOfWarrants', window );">Exercise of warrants (in shares)</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">450,000<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Net proceeds from sale of common stock | $</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 28,600<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price of warrant (in USD per share) | $ / shares</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 3.75<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_immu_IncreaseDecreaseinFairValueOfWarrantsExercised', window );">Increase in fair value of warrants exercised | $</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 102,100<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants outstanding (in shares)</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">450,000<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromWarrantExercises', window );">Exercise of warrants | $</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 1,700<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Number of shares issued in transaction (in shares)</a></td>
<td class="nump">14,285,715<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">11,500,000<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering', window );">Proceeds from public offering of common stock | $</a></td>
<td class="nump">$ 250,000<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Sale of stock (in USD per share) | $ / shares</a></td>
<td class="nump">$ 17.50<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 24.00<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember', window );">IPO | Securities Purchase Agreement</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_immu_ClassOfWarrantOrRightFairValue', window );">Fair value of warrants | $</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 7,300<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember', window );">Over-Allotment Option [Member]</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Number of shares issued in transaction (in shares)</a></td>
<td class="nump">2,142,857<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">1,725,000<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_immu_ProceedsfromIssuanceInitialPublicOfferingGross', window );">Proceeds from initial public offering, gross | $</a></td>
<td class="nump">$ 287,500<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering', window );">Proceeds from public offering of common stock | $</a></td>
<td class="nump">$ 273,000<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 299,500<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=immu_ATMAgreementMember', window );">ATM Agreement</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in USD per share) | $ / shares</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Sale of stock, consideration received on transaction | $</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 150,000<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_immu_PaymentsforStockIssuanceCostsPercentage', window );">Payments for stock issuance costs percentage (as percent)</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">3.00%<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Number of shares issued in transaction (in shares)</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">4,432,416<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=immu_SalesAgreementMember', window );">Sales Agreement</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockSharesAcquired', window );">Treasury stock, acquired (in shares)</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">84,896<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByLiabilityClassAxis=us-gaap_WarrantMember', window );">Warrant | IPO</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Warrants exercised (in shares)</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">9,550,000<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_WeightedAverageMember', window );">Weighted Average</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Shares issued, price (USD per share) | $ / shares</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 16.40<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_immu_AggregateOfferingPriceofCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of aggregate offering price of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">immu_AggregateOfferingPriceofCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>immu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_immu_ClassOfWarrantOrRightFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of warrants during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">immu_ClassOfWarrantOrRightFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>immu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_immu_CommonAndPreferredSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Common and preferred shares authorized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">immu_CommonAndPreferredSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>immu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_immu_ConvertiblePreferredStockConversionRatio">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Convertible Preferred Stock, Conversion Ratio</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">immu_ConvertiblePreferredStockConversionRatio</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>immu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_immu_ExerciseOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of warrants exercised.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">immu_ExerciseOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>immu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_immu_GrossProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents gross proceeds from issuance of common stock before deducting underwriting discounts and commissions and estimated expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">immu_GrossProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>immu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_immu_IncreaseDecreaseinFairValueOfWarrantsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Increase (Decrease) in Fair Value Of Warrants Exercised</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">immu_IncreaseDecreaseinFairValueOfWarrantsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>immu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_immu_IssuanceofConvertiblePreferredStockPerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Issuance of Convertible Preferred Stock, Per Share</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">immu_IssuanceofConvertiblePreferredStockPerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>immu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_immu_PaymentsforStockIssuanceCostsPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Payments for Stock Issuance Costs Percentage</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">immu_PaymentsforStockIssuanceCostsPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>immu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_immu_ProceedsfromIssuanceInitialPublicOfferingGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Proceeds from Issuance Initial Public Offering, Gross</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">immu_ProceedsfromIssuanceInitialPublicOfferingGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>immu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(i)(4))<br> -URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(i)(2))<br> -URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(i))<br> -URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConversionOfStockSharesIssued1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of new shares issued in the conversion of stock in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&oid=98513485&loc=d3e4332-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&oid=98513485&loc=d3e4313-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&oid=98513485&loc=d3e4304-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConversionOfStockSharesIssued1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period of time between issuance and maturity of debt instrument, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfStockIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for cost incurred directly with the issuance of an equity security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfStockIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from entity's first offering of stock to the public.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceInitialPublicOffering</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from issuance of preferred stocks identified as being convertible into another form of financial instrument, typically the entity's common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromWarrantExercises">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from holders exercising their stock warrants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromWarrantExercises</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash received on stock transaction after deduction of issuance costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockConsiderationReceivedOnTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockConsiderationReceivedPerTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of consideration received by subsidiary or equity investee in exchange for shares of stock issued or sold. Includes amount of cash received, fair value of noncash assets received, and fair value of liabilities assumed by the investor.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockConsiderationReceivedPerTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Price of a single share of a number of saleable stocks of a company.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssuedPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share or per unit amount of equity securities issued.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssuedPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&oid=109259400&loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&oid=109259400&loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares that have been repurchased and retired during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&oid=109259400&loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRepurchasedAndRetiredDuringPeriodShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockSharesAcquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares that have been repurchased during the period and are being held in treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&oid=109259400&loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockSharesAcquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_ConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_ConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=immu_SeattleGeneticsIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=immu_SeattleGeneticsIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=immu_SecuritiesPurchaseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=immu_SecuritiesPurchaseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=immu_ATMAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=immu_ATMAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=immu_SalesAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=immu_SalesAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByLiabilityClassAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByLiabilityClassAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_WeightedAverageMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_WeightedAverageMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R56.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
function toggleNextSibling (e) {
if (e.nextSibling.style.display=='none') {
e.nextSibling.style.display='block';
} else { e.nextSibling.style.display='none'; }
}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6810647408">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Income Taxes - Tax Effects of Temporary Differences in Deferred Tax Assets (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards', window );">NOL carryforwards</a></td>
<td class="nump">$ 203,928<span></span>
</td>
<td class="nump">$ 132,841<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch', window );">Research and development credits</a></td>
<td class="nump">28,535<span></span>
</td>
<td class="nump">23,118<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsDeferredIncome', window );">Liability related to sale of future royalties</a></td>
<td class="nump">49,228<span></span>
</td>
<td class="nump">49,217<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_immu_DeferredTaxAssetsDeferredRevenue', window );">Deferred revenue</a></td>
<td class="nump">18,286<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_immu_DeferredTaxAssetDisallowedInterestExpense', window );">Disallowed interest expense</a></td>
<td class="nump">13,474<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOther', window );">Other</a></td>
<td class="nump">5,807<span></span>
</td>
<td class="nump">3,088<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGross', window );">Total</a></td>
<td class="nump">319,258<span></span>
</td>
<td class="nump">208,264<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Valuation allowance</a></td>
<td class="num">(317,828)<span></span>
</td>
<td class="num">(206,397)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsNet', window );">Net deferred assets</a></td>
<td class="nump">1,430<span></span>
</td>
<td class="nump">1,867<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment', window );">Property and equipment</a></td>
<td class="num">(1,430)<span></span>
</td>
<td class="num">(1,867)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsLiabilitiesNet', window );">Net deferred assets and liabilities</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_immu_DeferredTaxAssetDisallowedInterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Deferred Tax Asset, Disallowed Interest Expense</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">immu_DeferredTaxAssetDisallowedInterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>immu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_immu_DeferredTaxAssetsDeferredRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Deferred Tax Assets, Deferred Revenue</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">immu_DeferredTaxAssetsDeferredRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>immu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsDeferredIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from deferred income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&oid=84230637&loc=d3e32632-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 25<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&oid=117330534&loc=d3e28680-109314<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&oid=84230637&loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsDeferredIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&oid=84230637&loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsLiabilitiesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&oid=84230637&loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsLiabilitiesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b),(c)<br> -URI http://asc.fasb.org/extlink&oid=84230637&loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&oid=84230637&loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&oid=84230637&loc=d3e32632-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 25<br> -Paragraph 20<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&oid=117330534&loc=d3e28680-109314<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 25<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&oid=117330534&loc=d3e28680-109314<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&oid=84230637&loc=d3e32632-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&oid=84230637&loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible research tax credit carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&oid=84230637&loc=d3e32632-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&oid=84230637&loc=d3e32559-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&oid=84230637&loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&oid=84230637&loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences from property, plant, and equipment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 25<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&oid=117330534&loc=d3e28680-109314<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&oid=84230637&loc=d3e32621-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&oid=84230637&loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
function toggleNextSibling (e) {
if (e.nextSibling.style.display=='none') {
e.nextSibling.style.display='block';
} else { e.nextSibling.style.display='none'; }
}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6989880880">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Estimated Fair Value of Financial Instruments - Narrative (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Financial assets</a></td>
<td class="nump">$ 555,338<span></span>
</td>
<td class="nump">$ 331,180<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_MoneyMarketFundsMember', window );">Money Market Funds</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash and cash equivalents</a></td>
<td class="nump">550,788<span></span>
</td>
<td class="nump">326,239<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember', window );">U.S. Government Sponsored Agencies</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Marketable Securities</a></td>
<td class="nump">4,550<span></span>
</td>
<td class="nump">4,941<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Level 1</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Financial assets</a></td>
<td class="nump">555,338<span></span>
</td>
<td class="nump">331,180<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Level 1 | Money Market Funds</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash and cash equivalents</a></td>
<td class="nump">550,788<span></span>
</td>
<td class="nump">326,239<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Level 1 | U.S. Government Sponsored Agencies</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Marketable Securities</a></td>
<td class="nump">4,550<span></span>
</td>
<td class="nump">4,941<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Financial assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2 | Money Market Funds</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash and cash equivalents</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2 | U.S. Government Sponsored Agencies</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Marketable Securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Level 3</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Financial assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Level 3 | Money Market Funds</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash and cash equivalents</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Level 3 | U.S. Government Sponsored Agencies</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Marketable Securities</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&oid=118942338&loc=SL82898722-210454<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&oid=118954083&loc=d3e26610-111562<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -URI http://asc.fasb.org/extlink&oid=118939692&loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_MoneyMarketFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_MoneyMarketFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
function toggleNextSibling (e) {
if (e.nextSibling.style.display=='none') {
e.nextSibling.style.display='block';
} else { e.nextSibling.style.display='none'; }
}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6806436768">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Narrative (Details) - USD ($)<br> $ / shares in Units, shares in Thousands, $ in Thousands</strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Jun. 30, 2018</div></th>
<th class="th"><div>Jun. 30, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions', window );">Nonvested, compensation not yet recognized, stock options</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 40,600<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Nonvested, compensation not yet recognized, period</a></td>
<td class="text"> <span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Arrangement by share-based payment award (in USD per share)</a></td>
<td class="nump">$ 12.90<span></span>
</td>
<td class="nump">$ 8.81<span></span>
</td>
<td class="nump">$ 8.76<span></span>
</td>
<td class="nump">$ 2.21<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Granted (in USD per share)</a></td>
<td class="nump">$ 0.00<span></span>
</td>
<td class="nump">$ 9.50<span></span>
</td>
<td class="nump">$ 7.29<span></span>
</td>
<td class="nump">$ 0.00<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StateAndLocalIncomeTaxExpenseBenefitContinuingOperations', window );">Total State</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 2<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Employee Stock Option</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period</a></td>
<td class="text">4 years<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Granted (in USD per share)</a></td>
<td class="nump">$ 22.54<span></span>
</td>
<td class="nump">$ 15.46<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1', window );">Fair value of shares vested</a></td>
<td class="nump">$ 1,300<span></span>
</td>
<td class="nump">$ 8,900<span></span>
</td>
<td class="nump">300<span></span>
</td>
<td class="nump">1,400<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue', window );">Intrinsic value of stock-options exercised</a></td>
<td class="nump">$ 13,300<span></span>
</td>
<td class="nump">$ 14,700<span></span>
</td>
<td class="nump">$ 7,800<span></span>
</td>
<td class="nump">$ 2,600<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted Stock Units (RSUs)</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Nonvested, compensation not yet recognized, period</a></td>
<td class="text">1 year 2 months 4 days<span></span>
</td>
<td class="text">4 months 24 days<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions', window );">Unrecognized compensation costs</a></td>
<td class="nump">$ 300<span></span>
</td>
<td class="nump">$ 300<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod', window );">RSUs forfeited in period (in shares)</a></td>
<td class="nump">1,500<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember', window );">Performance Shares</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Nonvested, compensation not yet recognized, period</a></td>
<td class="text">3 years 18 days<span></span>
</td>
<td class="text">9 months 18 days<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Granted (in USD per share)</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 17.18<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1', window );">Fair value of shares vested</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 1,100<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions', window );">Unrecognized compensation costs</a></td>
<td class="nump">$ 3,000<span></span>
</td>
<td class="nump">$ 4,900<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cost to be recognized for nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cost to be recognized for option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)<br> -URI http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -URI http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average grant-date fair value of non-vested options outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of options vested. Excludes equity instruments other than options, for example, but not limited to, share units, stock appreciation rights, restricted stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StateAndLocalIncomeTaxExpenseBenefitContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of state and local current and deferred income tax expense (benefit) attributable to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)-(b)<br> -URI http://asc.fasb.org/extlink&oid=84230637&loc=d3e32639-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(h)(1))<br> -URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StateAndLocalIncomeTaxExpenseBenefitContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
<Version>3.19.3.a.u2</Version>
<ProcessingTime/>
<ReportFormat>html</ReportFormat>
<ContextCount>300</ContextCount>
<ElementCount>475</ElementCount>
<EntityCount>1</EntityCount>
<FootnotesReported>false</FootnotesReported>
<SegmentCount>63</SegmentCount>
<ScenarioCount>0</ScenarioCount>
<TuplesReported>false</TuplesReported>
<UnitCount>6</UnitCount>
<MyReports>
<Report instance="immu201910-k.htm">
<IsDefault>false</IsDefault>
<HasEmbeddedReports>false</HasEmbeddedReports>
<HtmlFileName>R1.htm</HtmlFileName>
<LongName>0001000 - Document - COVER PAGE</LongName>
<ReportType>Sheet</ReportType>
<Role>http://www.immunomedics.com/role/CoverPage</Role>
<ShortName>COVER PAGE</ShortName>
<MenuCategory>Cover</MenuCategory>
<Position>1</Position>
</Report>
<Report instance="immu201910-k.htm">
<IsDefault>false</IsDefault>
<HasEmbeddedReports>false</HasEmbeddedReports>
<HtmlFileName>R2.htm</HtmlFileName>
<LongName>1001000 - Statement - CONSOLIDATED BALANCE SHEETS</LongName>
<ReportType>Sheet</ReportType>
<Role>http://www.immunomedics.com/role/ConsolidatedBalanceSheets</Role>
<ShortName>CONSOLIDATED BALANCE SHEETS</ShortName>
<MenuCategory>Statements</MenuCategory>
<Position>2</Position>
</Report>
<Report instance="immu201910-k.htm">
<IsDefault>false</IsDefault>
<HasEmbeddedReports>false</HasEmbeddedReports>
<HtmlFileName>R3.htm</HtmlFileName>
<LongName>1001501 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical)</LongName>
<ReportType>Sheet</ReportType>
<Role>http://www.immunomedics.com/role/ConsolidatedBalanceSheetsParenthetical</Role>
<ShortName>CONSOLIDATED BALANCE SHEETS (Parenthetical)</ShortName>
<MenuCategory>Statements</MenuCategory>
<Position>3</Position>
</Report>
<Report instance="immu201910-k.htm">
<IsDefault>false</IsDefault>
<HasEmbeddedReports>false</HasEmbeddedReports>
<HtmlFileName>R4.htm</HtmlFileName>
<LongName>1002000 - Statement - CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS</LongName>
<ReportType>Sheet</ReportType>
<Role>http://www.immunomedics.com/role/ConsolidatedStatementsOfComprehensiveLoss</Role>
<ShortName>CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS</ShortName>
<MenuCategory>Statements</MenuCategory>
<Position>4</Position>
</Report>
<Report instance="immu201910-k.htm">
<IsDefault>false</IsDefault>
<HasEmbeddedReports>false</HasEmbeddedReports>
<HtmlFileName>R5.htm</HtmlFileName>
<LongName>1003000 - Statement - CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS??? EQUITY</LongName>
<ReportType>Sheet</ReportType>
<Role>http://www.immunomedics.com/role/ConsolidatedStatementsOfChangesInStockholdersEquity</Role>
<ShortName>CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS??? EQUITY</ShortName>
<MenuCategory>Statements</MenuCategory>
<Position>5</Position>
</Report>
<Report instance="immu201910-k.htm">
<IsDefault>false</IsDefault>
<HasEmbeddedReports>false</HasEmbeddedReports>
<HtmlFileName>R6.htm</HtmlFileName>
<LongName>1004000 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS</LongName>
<ReportType>Sheet</ReportType>
<Role>http://www.immunomedics.com/role/ConsolidatedStatementsOfCashFlows</Role>
<ShortName>CONSOLIDATED STATEMENTS OF CASH FLOWS</ShortName>
<MenuCategory>Statements</MenuCategory>
<Position>6</Position>
</Report>
<Report instance="immu201910-k.htm">
<IsDefault>false</IsDefault>
<HasEmbeddedReports>false</HasEmbeddedReports>
<HtmlFileName>R7.htm</HtmlFileName>
<LongName>2101100 - Disclosure - Business Overview and Summary of Significant Accounting Polices</LongName>
<ReportType>Sheet</ReportType>
<Role>http://www.immunomedics.com/role/BusinessOverviewAndSummaryOfSignificantAccountingPolices</Role>
<ShortName>Business Overview and Summary of Significant Accounting Polices</ShortName>
<MenuCategory>Notes</MenuCategory>
<Position>7</Position>
</Report>
<Report instance="immu201910-k.htm">
<IsDefault>false</IsDefault>
<HasEmbeddedReports>false</HasEmbeddedReports>
<HtmlFileName>R8.htm</HtmlFileName>
<LongName>2102100 - Disclosure - Revenue Recognition</LongName>
<ReportType>Sheet</ReportType>
<Role>http://www.immunomedics.com/role/RevenueRecognition</Role>
<ShortName>Revenue Recognition</ShortName>
<MenuCategory>Notes</MenuCategory>
<Position>8</Position>
</Report>
<Report instance="immu201910-k.htm">
<IsDefault>false</IsDefault>
<HasEmbeddedReports>false</HasEmbeddedReports>
<HtmlFileName>R9.htm</HtmlFileName>
<LongName>2103100 - Disclosure - Marketable Securities</LongName>
<ReportType>Sheet</ReportType>
<Role>http://www.immunomedics.com/role/MarketableSecurities</Role>
<ShortName>Marketable Securities</ShortName>
<MenuCategory>Notes</MenuCategory>
<Position>9</Position>
</Report>
<Report instance="immu201910-k.htm">
<IsDefault>false</IsDefault>
<HasEmbeddedReports>false</HasEmbeddedReports>
<HtmlFileName>R10.htm</HtmlFileName>
<LongName>2105100 - Disclosure - Debt</LongName>
<ReportType>Sheet</ReportType>
<Role>http://www.immunomedics.com/role/Debt</Role>
<ShortName>Debt</ShortName>
<MenuCategory>Notes</MenuCategory>
<Position>10</Position>
</Report>
<Report instance="immu201910-k.htm">
<IsDefault>false</IsDefault>
<HasEmbeddedReports>false</HasEmbeddedReports>
<HtmlFileName>R11.htm</HtmlFileName>
<LongName>2106100 - Disclosure - Stock-Based Compensation</LongName>
<ReportType>Sheet</ReportType>
<Role>http://www.immunomedics.com/role/StockBasedCompensation</Role>
<ShortName>Stock-Based Compensation</ShortName>
<MenuCategory>Notes</MenuCategory>
<Position>11</Position>
</Report>
<Report instance="immu201910-k.htm">
<IsDefault>false</IsDefault>
<HasEmbeddedReports>false</HasEmbeddedReports>
<HtmlFileName>R12.htm</HtmlFileName>
<LongName>2107100 - Disclosure - Estimated Fair Value of Financial Instruments</LongName>
<ReportType>Sheet</ReportType>
<Role>http://www.immunomedics.com/role/EstimatedFairValueOfFinancialInstruments</Role>
<ShortName>Estimated Fair Value of Financial Instruments</ShortName>
<MenuCategory>Notes</MenuCategory>
<Position>12</Position>
</Report>
<Report instance="immu201910-k.htm">
<IsDefault>false</IsDefault>
<HasEmbeddedReports>false</HasEmbeddedReports>
<HtmlFileName>R13.htm</HtmlFileName>
<LongName>2108100 - Disclosure - Property and Equipment</LongName>
<ReportType>Sheet</ReportType>
<Role>http://www.immunomedics.com/role/PropertyAndEquipment</Role>
<ShortName>Property and Equipment</ShortName>
<MenuCategory>Notes</MenuCategory>
<Position>13</Position>
</Report>
<Report instance="immu201910-k.htm">
<IsDefault>false</IsDefault>
<HasEmbeddedReports>false</HasEmbeddedReports>
<HtmlFileName>R14.htm</HtmlFileName>
<LongName>2109100 - Disclosure - Accounts Payable and Accrued Expenses</LongName>
<ReportType>Sheet</ReportType>
<Role>http://www.immunomedics.com/role/AccountsPayableAndAccruedExpenses</Role>
<ShortName>Accounts Payable and Accrued Expenses</ShortName>
<MenuCategory>Notes</MenuCategory>
<Position>14</Position>
</Report>
<Report instance="immu201910-k.htm">
<IsDefault>false</IsDefault>
<HasEmbeddedReports>false</HasEmbeddedReports>
<HtmlFileName>R15.htm</HtmlFileName>
<LongName>2110100 - Disclosure - Stockholders??? Equity</LongName>
<ReportType>Sheet</ReportType>
<Role>http://www.immunomedics.com/role/StockholdersEquity</Role>
<ShortName>Stockholders??? Equity</ShortName>
<MenuCategory>Notes</MenuCategory>
<Position>15</Position>
</Report>
<Report instance="immu201910-k.htm">
<IsDefault>false</IsDefault>
<HasEmbeddedReports>false</HasEmbeddedReports>
<HtmlFileName>R16.htm</HtmlFileName>
<LongName>2111100 - Disclosure - Accumulated Other Comprehensive (Loss) Income</LongName>
<ReportType>Sheet</ReportType>
<Role>http://www.immunomedics.com/role/AccumulatedOtherComprehensiveLossIncome</Role>
<ShortName>Accumulated Other Comprehensive (Loss) Income</ShortName>
<MenuCategory>Notes</MenuCategory>
<Position>16</Position>
</Report>
<Report instance="immu201910-k.htm">
<IsDefault>false</IsDefault>
<HasEmbeddedReports>false</HasEmbeddedReports>
<HtmlFileName>R17.htm</HtmlFileName>
<LongName>2112100 - Disclosure - Income Taxes</LongName>
<ReportType>Sheet</ReportType>
<Role>http://www.immunomedics.com/role/IncomeTaxes</Role>
<ShortName>Income Taxes</ShortName>
<MenuCategory>Notes</MenuCategory>
<Position>17</Position>
</Report>
<Report instance="immu201910-k.htm">
<IsDefault>false</IsDefault>
<HasEmbeddedReports>false</HasEmbeddedReports>
<HtmlFileName>R18.htm</HtmlFileName>
<LongName>2113100 - Disclosure - Related Party Transactions</LongName>
<ReportType>Sheet</ReportType>
<Role>http://www.immunomedics.com/role/RelatedPartyTransactions</Role>
<ShortName>Related Party Transactions</ShortName>
<MenuCategory>Notes</MenuCategory>
<Position>18</Position>
</Report>
<Report instance="immu201910-k.htm">
<IsDefault>false</IsDefault>
<HasEmbeddedReports>false</HasEmbeddedReports>
<HtmlFileName>R19.htm</HtmlFileName>
<LongName>2114100 - Disclosure - Collaboration Agreements</LongName>
<ReportType>Sheet</ReportType>
<Role>http://www.immunomedics.com/role/CollaborationAgreements</Role>
<ShortName>Collaboration Agreements</ShortName>
<MenuCategory>Notes</MenuCategory>
<Position>19</Position>
</Report>
<Report instance="immu201910-k.htm">
<IsDefault>false</IsDefault>
<HasEmbeddedReports>false</HasEmbeddedReports>
<HtmlFileName>R20.htm</HtmlFileName>
<LongName>2115100 - Disclosure - Commitments and Contingencies</LongName>
<ReportType>Sheet</ReportType>
<Role>http://www.immunomedics.com/role/CommitmentsAndContingencies</Role>
<ShortName>Commitments and Contingencies</ShortName>
<MenuCategory>Notes</MenuCategory>
<Position>20</Position>
</Report>
<Report instance="immu201910-k.htm">
<IsDefault>false</IsDefault>
<HasEmbeddedReports>false</HasEmbeddedReports>
<HtmlFileName>R21.htm</HtmlFileName>
<LongName>2116100 - Disclosure - Defined Contribution Plans</LongName>
<ReportType>Sheet</ReportType>
<Role>http://www.immunomedics.com/role/DefinedContributionPlans</Role>
<ShortName>Defined Contribution Plans</ShortName>
<MenuCategory>Notes</MenuCategory>
<Position>21</Position>
</Report>
<Report instance="immu201910-k.htm">
<IsDefault>false</IsDefault>
<HasEmbeddedReports>false</HasEmbeddedReports>
<HtmlFileName>R22.htm</HtmlFileName>
<LongName>2117100 - Disclosure - Quarterly Results of Operations (Unaudited)</LongName>
<ReportType>Sheet</ReportType>
<Role>http://www.immunomedics.com/role/QuarterlyResultsOfOperationsUnaudited</Role>
<ShortName>Quarterly Results of Operations (Unaudited)</ShortName>
<MenuCategory>Notes</MenuCategory>
<Position>22</Position>
</Report>
<Report instance="immu201910-k.htm">
<IsDefault>false</IsDefault>
<HasEmbeddedReports>false</HasEmbeddedReports>
<HtmlFileName>R23.htm</HtmlFileName>
<LongName>2201201 - Disclosure - Business Overview, Summary of Significant Accounting Polices (Policies)</LongName>
<ReportType>Sheet</ReportType>
<Role>http://www.immunomedics.com/role/BusinessOverviewSummaryOfSignificantAccountingPolicesPolicies</Role>
<ShortName>Business Overview, Summary of Significant Accounting Polices (Policies)</ShortName>
<MenuCategory>Policies</MenuCategory>
<ParentRole>http://www.immunomedics.com/role/BusinessOverviewAndSummaryOfSignificantAccountingPolices</ParentRole>
<Position>23</Position>
</Report>
<Report instance="immu201910-k.htm">
<IsDefault>false</IsDefault>
<HasEmbeddedReports>false</HasEmbeddedReports>
<HtmlFileName>R24.htm</HtmlFileName>
<LongName>2303301 - Disclosure - Marketable Securities (Tables)</LongName>
<ReportType>Sheet</ReportType>
<Role>http://www.immunomedics.com/role/MarketableSecuritiesTables</Role>
<ShortName>Marketable Securities (Tables)</ShortName>
<MenuCategory>Tables</MenuCategory>
<ParentRole>http://www.immunomedics.com/role/MarketableSecurities</ParentRole>
<Position>24</Position>
</Report>
<Report instance="immu201910-k.htm">
<IsDefault>false</IsDefault>
<HasEmbeddedReports>false</HasEmbeddedReports>
<HtmlFileName>R25.htm</HtmlFileName>
<LongName>2305301 - Disclosure - Debt (Tables)</LongName>
<ReportType>Sheet</ReportType>
<Role>http://www.immunomedics.com/role/DebtTables</Role>
<ShortName>Debt (Tables)</ShortName>
<MenuCategory>Tables</MenuCategory>
<ParentRole>http://www.immunomedics.com/role/Debt</ParentRole>
<Position>25</Position>
</Report>
<Report instance="immu201910-k.htm">
<IsDefault>false</IsDefault>
<HasEmbeddedReports>false</HasEmbeddedReports>
<HtmlFileName>R26.htm</HtmlFileName>
<LongName>2306301 - Disclosure - Stock-Based Compensation (Tables)</LongName>
<ReportType>Sheet</ReportType>
<Role>http://www.immunomedics.com/role/StockBasedCompensationTables</Role>
<ShortName>Stock-Based Compensation (Tables)</ShortName>
<MenuCategory>Tables</MenuCategory>
<ParentRole>http://www.immunomedics.com/role/StockBasedCompensation</ParentRole>
<Position>26</Position>
</Report>
<Report instance="immu201910-k.htm">
<IsDefault>false</IsDefault>
<HasEmbeddedReports>false</HasEmbeddedReports>
<HtmlFileName>R27.htm</HtmlFileName>
<LongName>2307301 - Disclosure - Estimated Fair Value of Financial Instruments (Tables)</LongName>
<ReportType>Sheet</ReportType>
<Role>http://www.immunomedics.com/role/EstimatedFairValueOfFinancialInstrumentsTables</Role>
<ShortName>Estimated Fair Value of Financial Instruments (Tables)</ShortName>
<MenuCategory>Tables</MenuCategory>
<ParentRole>http://www.immunomedics.com/role/EstimatedFairValueOfFinancialInstruments</ParentRole>
<Position>27</Position>
</Report>
<Report instance="immu201910-k.htm">
<IsDefault>false</IsDefault>
<HasEmbeddedReports>false</HasEmbeddedReports>
<HtmlFileName>R28.htm</HtmlFileName>
<LongName>2308301 - Disclosure - Property and Equipment (Tables)</LongName>
<ReportType>Sheet</ReportType>
<Role>http://www.immunomedics.com/role/PropertyAndEquipmentTables</Role>
<ShortName>Property and Equipment (Tables)</ShortName>
<MenuCategory>Tables</MenuCategory>
<ParentRole>http://www.immunomedics.com/role/PropertyAndEquipment</ParentRole>
<Position>28</Position>
</Report>
<Report instance="immu201910-k.htm">
<IsDefault>false</IsDefault>
<HasEmbeddedReports>false</HasEmbeddedReports>
<HtmlFileName>R29.htm</HtmlFileName>
<LongName>2309301 - Disclosure - Accounts Payable and Accrued Expenses (Tables)</LongName>
<ReportType>Sheet</ReportType>
<Role>http://www.immunomedics.com/role/AccountsPayableAndAccruedExpensesTables</Role>
<ShortName>Accounts Payable and Accrued Expenses (Tables)</ShortName>
<MenuCategory>Tables</MenuCategory>
<ParentRole>http://www.immunomedics.com/role/AccountsPayableAndAccruedExpenses</ParentRole>
<Position>29</Position>
</Report>
<Report instance="immu201910-k.htm">
<IsDefault>false</IsDefault>
<HasEmbeddedReports>false</HasEmbeddedReports>
<HtmlFileName>R30.htm</HtmlFileName>
<LongName>2311301 - Disclosure - Accumulated Other Comprehensive (Loss) Income (Tables)</LongName>
<ReportType>Sheet</ReportType>
<Role>http://www.immunomedics.com/role/AccumulatedOtherComprehensiveLossIncomeTables</Role>
<ShortName>Accumulated Other Comprehensive (Loss) Income (Tables)</ShortName>
<MenuCategory>Tables</MenuCategory>
<ParentRole>http://www.immunomedics.com/role/AccumulatedOtherComprehensiveLossIncome</ParentRole>
<Position>30</Position>
</Report>
<Report instance="immu201910-k.htm">
<IsDefault>false</IsDefault>
<HasEmbeddedReports>false</HasEmbeddedReports>
<HtmlFileName>R31.htm</HtmlFileName>
<LongName>2312301 - Disclosure - Income Taxes (Tables)</LongName>
<ReportType>Sheet</ReportType>
<Role>http://www.immunomedics.com/role/IncomeTaxesTables</Role>
<ShortName>Income Taxes (Tables)</ShortName>
<MenuCategory>Tables</MenuCategory>
<ParentRole>http://www.immunomedics.com/role/IncomeTaxes</ParentRole>
<Position>31</Position>
</Report>
<Report instance="immu201910-k.htm">
<IsDefault>false</IsDefault>
<HasEmbeddedReports>false</HasEmbeddedReports>
<HtmlFileName>R32.htm</HtmlFileName>
<LongName>2315301 - Disclosure - Commitments and Contingencies (Tables)</LongName>
<ReportType>Sheet</ReportType>
<Role>http://www.immunomedics.com/role/CommitmentsAndContingenciesTables</Role>
<ShortName>Commitments and Contingencies (Tables)</ShortName>
<MenuCategory>Tables</MenuCategory>
<ParentRole>http://www.immunomedics.com/role/CommitmentsAndContingencies</ParentRole>
<Position>32</Position>
</Report>
<Report instance="immu201910-k.htm">
<IsDefault>false</IsDefault>
<HasEmbeddedReports>false</HasEmbeddedReports>
<HtmlFileName>R33.htm</HtmlFileName>
<LongName>2317301 - Disclosure - Quarterly Results of Operations (Tables)</LongName>
<ReportType>Sheet</ReportType>
<Role>http://www.immunomedics.com/role/QuarterlyResultsOfOperationsTables</Role>
<ShortName>Quarterly Results of Operations (Tables)</ShortName>
<MenuCategory>Tables</MenuCategory>
<ParentRole>http://www.immunomedics.com/role/QuarterlyResultsOfOperationsUnaudited</ParentRole>
<Position>33</Position>
</Report>
<Report instance="immu201910-k.htm">
<IsDefault>false</IsDefault>
<HasEmbeddedReports>false</HasEmbeddedReports>
<HtmlFileName>R34.htm</HtmlFileName>
<LongName>2401402 - Disclosure - Business Overview and Summary of Significant Accounting Polices - Recent Accounting Pronouncements (Details)</LongName>
<ReportType>Sheet</ReportType>
<Role>http://www.immunomedics.com/role/BusinessOverviewAndSummaryOfSignificantAccountingPolicesRecentAccountingPronouncementsDetails</Role>
<ShortName>Business Overview and Summary of Significant Accounting Polices - Recent Accounting Pronouncements (Details)</ShortName>
<MenuCategory>Details</MenuCategory>
<Position>34</Position>
</Report>
<Report instance="immu201910-k.htm">
<IsDefault>false</IsDefault>
<HasEmbeddedReports>false</HasEmbeddedReports>
<HtmlFileName>R35.htm</HtmlFileName>
<LongName>2402401 - Disclosure - Revenue Recognition - Additional Information (Details)</LongName>
<ReportType>Sheet</ReportType>
<Role>http://www.immunomedics.com/role/RevenueRecognitionAdditionalInformationDetails</Role>
<ShortName>Revenue Recognition - Additional Information (Details)</ShortName>
<MenuCategory>Details</MenuCategory>
<Position>35</Position>
</Report>
<Report instance="immu201910-k.htm">
<IsDefault>false</IsDefault>
<HasEmbeddedReports>false</HasEmbeddedReports>
<HtmlFileName>R36.htm</HtmlFileName>
<LongName>2402402 - Disclosure - Revenue Recognition - Performance Obligation (Details)</LongName>
<ReportType>Sheet</ReportType>
<Role>http://www.immunomedics.com/role/RevenueRecognitionPerformanceObligationDetails</Role>
<ShortName>Revenue Recognition - Performance Obligation (Details)</ShortName>
<MenuCategory>Details</MenuCategory>
<Position>36</Position>
</Report>
<Report instance="immu201910-k.htm">
<IsDefault>false</IsDefault>
<HasEmbeddedReports>false</HasEmbeddedReports>
<HtmlFileName>R37.htm</HtmlFileName>
<LongName>2403402 - Disclosure - Marketable Securities - Amortized Cost to Fair Value (Details)</LongName>
<ReportType>Sheet</ReportType>
<Role>http://www.immunomedics.com/role/MarketableSecuritiesAmortizedCostToFairValueDetails</Role>
<ShortName>Marketable Securities - Amortized Cost to Fair Value (Details)</ShortName>
<MenuCategory>Details</MenuCategory>
<Position>37</Position>
</Report>
<Report instance="immu201910-k.htm">
<IsDefault>false</IsDefault>
<HasEmbeddedReports>false</HasEmbeddedReports>
<HtmlFileName>R38.htm</HtmlFileName>
<LongName>2405402 - Disclosure - Debt - Liability Related to Sale of Future Royalties (Details)</LongName>
<ReportType>Sheet</ReportType>
<Role>http://www.immunomedics.com/role/DebtLiabilityRelatedToSaleOfFutureRoyaltiesDetails</Role>
<ShortName>Debt - Liability Related to Sale of Future Royalties (Details)</ShortName>
<MenuCategory>Details</MenuCategory>
<Position>38</Position>
</Report>
<Report instance="immu201910-k.htm">
<IsDefault>false</IsDefault>
<HasEmbeddedReports>false</HasEmbeddedReports>
<HtmlFileName>R39.htm</HtmlFileName>
<LongName>2405403 - Disclosure - Debt - Consideration Allocation (Details)</LongName>
<ReportType>Sheet</ReportType>
<Role>http://www.immunomedics.com/role/DebtConsiderationAllocationDetails</Role>
<ShortName>Debt - Consideration Allocation (Details)</ShortName>
<MenuCategory>Details</MenuCategory>
<Position>39</Position>
</Report>
<Report instance="immu201910-k.htm">
<IsDefault>false</IsDefault>
<HasEmbeddedReports>false</HasEmbeddedReports>
<HtmlFileName>R40.htm</HtmlFileName>
<LongName>2405404 - Disclosure - Debt - Schedule of Liability Related to Sale of Future Royalties (Details)</LongName>
<ReportType>Sheet</ReportType>
<Role>http://www.immunomedics.com/role/DebtScheduleOfLiabilityRelatedToSaleOfFutureRoyaltiesDetails</Role>
<ShortName>Debt - Schedule of Liability Related to Sale of Future Royalties (Details)</ShortName>
<MenuCategory>Details</MenuCategory>
<Position>40</Position>
</Report>
<Report instance="immu201910-k.htm">
<IsDefault>false</IsDefault>
<HasEmbeddedReports>false</HasEmbeddedReports>
<HtmlFileName>R41.htm</HtmlFileName>
<LongName>2405405 - Disclosure - Debt - Convertible Senior Notes (Details)</LongName>
<ReportType>Notes</ReportType>
<Role>http://www.immunomedics.com/role/DebtConvertibleSeniorNotesDetails</Role>
<ShortName>Debt - Convertible Senior Notes (Details)</ShortName>
<MenuCategory>Details</MenuCategory>
<Position>41</Position>
</Report>
<Report instance="immu201910-k.htm">
<IsDefault>false</IsDefault>
<HasEmbeddedReports>false</HasEmbeddedReports>
<HtmlFileName>R42.htm</HtmlFileName>
<LongName>2406402 - Disclosure - Stock-Based Compensation - Stock Incentive Plan (Details)</LongName>
<ReportType>Sheet</ReportType>
<Role>http://www.immunomedics.com/role/StockBasedCompensationStockIncentivePlanDetails</Role>
<ShortName>Stock-Based Compensation - Stock Incentive Plan (Details)</ShortName>
<MenuCategory>Details</MenuCategory>
<Position>42</Position>
</Report>
<Report instance="immu201910-k.htm">
<IsDefault>false</IsDefault>
<HasEmbeddedReports>false</HasEmbeddedReports>
<HtmlFileName>R43.htm</HtmlFileName>
<LongName>2406403 - Disclosure - Stock-Based Compensation - Narrative (Details)</LongName>
<ReportType>Sheet</ReportType>
<Role>http://www.immunomedics.com/role/StockBasedCompensationNarrativeDetails</Role>
<ShortName>Stock-Based Compensation - Narrative (Details)</ShortName>
<MenuCategory>Details</MenuCategory>
<Position>43</Position>
</Report>
<Report instance="immu201910-k.htm">
<IsDefault>false</IsDefault>
<HasEmbeddedReports>false</HasEmbeddedReports>
<HtmlFileName>R44.htm</HtmlFileName>
<LongName>2406404 - Disclosure - Stock-Based Compensation - Fair Value Assumptions (Details)</LongName>
<ReportType>Sheet</ReportType>
<Role>http://www.immunomedics.com/role/StockBasedCompensationFairValueAssumptionsDetails</Role>
<ShortName>Stock-Based Compensation - Fair Value Assumptions (Details)</ShortName>
<MenuCategory>Details</MenuCategory>
<Position>44</Position>
</Report>
<Report instance="immu201910-k.htm">
<IsDefault>false</IsDefault>
<HasEmbeddedReports>false</HasEmbeddedReports>
<HtmlFileName>R45.htm</HtmlFileName>
<LongName>2406405 - Disclosure - Stock-Based Compensation - Stock Option Activity (Details)</LongName>
<ReportType>Sheet</ReportType>
<Role>http://www.immunomedics.com/role/StockBasedCompensationStockOptionActivityDetails</Role>
<ShortName>Stock-Based Compensation - Stock Option Activity (Details)</ShortName>
<MenuCategory>Details</MenuCategory>
<Position>45</Position>
</Report>
<Report instance="immu201910-k.htm">
<IsDefault>false</IsDefault>
<HasEmbeddedReports>false</HasEmbeddedReports>
<HtmlFileName>R46.htm</HtmlFileName>
<LongName>2406406 - Disclosure - Stock-Based Compensation - Restricted Stock Unit Activity (Details)</LongName>
<ReportType>Sheet</ReportType>
<Role>http://www.immunomedics.com/role/StockBasedCompensationRestrictedStockUnitActivityDetails</Role>
<ShortName>Stock-Based Compensation - Restricted Stock Unit Activity (Details)</ShortName>
<MenuCategory>Details</MenuCategory>
<Position>46</Position>
</Report>
<Report instance="immu201910-k.htm">
<IsDefault>false</IsDefault>
<HasEmbeddedReports>false</HasEmbeddedReports>
<HtmlFileName>R47.htm</HtmlFileName>
<LongName>2407402 - Disclosure - Estimated Fair Value of Financial Instruments - Narrative (Details)</LongName>
<ReportType>Sheet</ReportType>
<Role>http://www.immunomedics.com/role/EstimatedFairValueOfFinancialInstrumentsNarrativeDetails</Role>
<ShortName>Estimated Fair Value of Financial Instruments - Narrative (Details)</ShortName>
<MenuCategory>Details</MenuCategory>
<Position>47</Position>
</Report>
<Report instance="immu201910-k.htm">
<IsDefault>false</IsDefault>
<HasEmbeddedReports>false</HasEmbeddedReports>
<HtmlFileName>R48.htm</HtmlFileName>
<LongName>2407403 - Disclosure - Estimated Fair Value of Financial Instruments - Debt Instruments (Details)</LongName>
<ReportType>Sheet</ReportType>
<Role>http://www.immunomedics.com/role/EstimatedFairValueOfFinancialInstrumentsDebtInstrumentsDetails</Role>
<ShortName>Estimated Fair Value of Financial Instruments - Debt Instruments (Details)</ShortName>
<MenuCategory>Details</MenuCategory>
<Position>48</Position>
</Report>
<Report instance="immu201910-k.htm">
<IsDefault>false</IsDefault>
<HasEmbeddedReports>false</HasEmbeddedReports>
<HtmlFileName>R49.htm</HtmlFileName>
<LongName>2408402 - Disclosure - Property and Equipment - Schedules of Property and Equipment (Details)</LongName>
<ReportType>Sheet</ReportType>
<Role>http://www.immunomedics.com/role/PropertyAndEquipmentSchedulesOfPropertyAndEquipmentDetails</Role>
<ShortName>Property and Equipment - Schedules of Property and Equipment (Details)</ShortName>
<MenuCategory>Details</MenuCategory>
<Position>49</Position>
</Report>
<Report instance="immu201910-k.htm">
<IsDefault>false</IsDefault>
<HasEmbeddedReports>false</HasEmbeddedReports>
<HtmlFileName>R50.htm</HtmlFileName>
<LongName>2408403 - Disclosure - Property and Equipment - Additional Information (Details)</LongName>
<ReportType>Sheet</ReportType>
<Role>http://www.immunomedics.com/role/PropertyAndEquipmentAdditionalInformationDetails</Role>
<ShortName>Property and Equipment - Additional Information (Details)</ShortName>
<MenuCategory>Details</MenuCategory>
<Position>50</Position>
</Report>
<Report instance="immu201910-k.htm">
<IsDefault>false</IsDefault>
<HasEmbeddedReports>false</HasEmbeddedReports>
<HtmlFileName>R51.htm</HtmlFileName>
<LongName>2409402 - Disclosure - Accounts Payable and Accrued Expenses (Details)</LongName>
<ReportType>Sheet</ReportType>
<Role>http://www.immunomedics.com/role/AccountsPayableAndAccruedExpensesDetails</Role>
<ShortName>Accounts Payable and Accrued Expenses (Details)</ShortName>
<MenuCategory>Details</MenuCategory>
<ParentRole>http://www.immunomedics.com/role/AccountsPayableAndAccruedExpensesTables</ParentRole>
<Position>51</Position>
</Report>
<Report instance="immu201910-k.htm">
<IsDefault>false</IsDefault>
<HasEmbeddedReports>false</HasEmbeddedReports>
<HtmlFileName>R52.htm</HtmlFileName>
<LongName>2410401 - Disclosure - Stockholders??? Equity (Details)</LongName>
<ReportType>Sheet</ReportType>
<Role>http://www.immunomedics.com/role/StockholdersEquityDetails</Role>
<ShortName>Stockholders??? Equity (Details)</ShortName>
<MenuCategory>Details</MenuCategory>
<ParentRole>http://www.immunomedics.com/role/StockholdersEquity</ParentRole>
<Position>52</Position>
</Report>
<Report instance="immu201910-k.htm">
<IsDefault>false</IsDefault>
<HasEmbeddedReports>false</HasEmbeddedReports>
<HtmlFileName>R53.htm</HtmlFileName>
<LongName>2411402 - Disclosure - Accumulated Other Comprehensive (Loss) Income (Details)</LongName>
<ReportType>Sheet</ReportType>
<Role>http://www.immunomedics.com/role/AccumulatedOtherComprehensiveLossIncomeDetails</Role>
<ShortName>Accumulated Other Comprehensive (Loss) Income (Details)</ShortName>
<MenuCategory>Details</MenuCategory>
<ParentRole>http://www.immunomedics.com/role/AccumulatedOtherComprehensiveLossIncomeTables</ParentRole>
<Position>53</Position>
</Report>
<Report instance="immu201910-k.htm">
<IsDefault>false</IsDefault>
<HasEmbeddedReports>false</HasEmbeddedReports>
<HtmlFileName>R54.htm</HtmlFileName>
<LongName>2412402 - Disclosure - Income Taxes - Expense (Benefit) from Income Taxes (Details)</LongName>
<ReportType>Sheet</ReportType>
<Role>http://www.immunomedics.com/role/IncomeTaxesExpenseBenefitFromIncomeTaxesDetails</Role>
<ShortName>Income Taxes - Expense (Benefit) from Income Taxes (Details)</ShortName>
<MenuCategory>Details</MenuCategory>
<Position>54</Position>
</Report>
<Report instance="immu201910-k.htm">
<IsDefault>false</IsDefault>
<HasEmbeddedReports>false</HasEmbeddedReports>
<HtmlFileName>R55.htm</HtmlFileName>
<LongName>2412403 - Disclosure - Income Taxes - Reconciliation of Statutory Tax Rates and Effective Tax Rates (Details)</LongName>
<ReportType>Sheet</ReportType>
<Role>http://www.immunomedics.com/role/IncomeTaxesReconciliationOfStatutoryTaxRatesAndEffectiveTaxRatesDetails</Role>
<ShortName>Income Taxes - Reconciliation of Statutory Tax Rates and Effective Tax Rates (Details)</ShortName>
<MenuCategory>Details</MenuCategory>
<Position>55</Position>
</Report>
<Report instance="immu201910-k.htm">
<IsDefault>false</IsDefault>
<HasEmbeddedReports>false</HasEmbeddedReports>
<HtmlFileName>R56.htm</HtmlFileName>
<LongName>2412404 - Disclosure - Income Taxes - Tax Effects of Temporary Differences in Deferred Tax Assets (Details)</LongName>
<ReportType>Sheet</ReportType>
<Role>http://www.immunomedics.com/role/IncomeTaxesTaxEffectsOfTemporaryDifferencesInDeferredTaxAssetsDetails</Role>
<ShortName>Income Taxes - Tax Effects of Temporary Differences in Deferred Tax Assets (Details)</ShortName>
<MenuCategory>Details</MenuCategory>
<Position>56</Position>
</Report>
<Report instance="immu201910-k.htm">
<IsDefault>false</IsDefault>
<HasEmbeddedReports>false</HasEmbeddedReports>
<HtmlFileName>R57.htm</HtmlFileName>
<LongName>2412405 - Disclosure - Income Taxes - Narrative (Details)</LongName>
<ReportType>Sheet</ReportType>
<Role>http://www.immunomedics.com/role/IncomeTaxesNarrativeDetails</Role>
<ShortName>Income Taxes - Narrative (Details)</ShortName>
<MenuCategory>Details</MenuCategory>
<Position>57</Position>
</Report>
<Report instance="immu201910-k.htm">
<IsDefault>false</IsDefault>
<HasEmbeddedReports>false</HasEmbeddedReports>
<HtmlFileName>R58.htm</HtmlFileName>
<LongName>2412406 - Disclosure - Income Taxes - Change in Unrecognized Tax Benefits (Details)</LongName>
<ReportType>Sheet</ReportType>
<Role>http://www.immunomedics.com/role/IncomeTaxesChangeInUnrecognizedTaxBenefitsDetails</Role>
<ShortName>Income Taxes - Change in Unrecognized Tax Benefits (Details)</ShortName>
<MenuCategory>Details</MenuCategory>
<Position>58</Position>
</Report>
<Report instance="immu201910-k.htm">
<IsDefault>false</IsDefault>
<HasEmbeddedReports>false</HasEmbeddedReports>
<HtmlFileName>R59.htm</HtmlFileName>
<LongName>2413401 - Disclosure - Related Party Transactions (Details)</LongName>
<ReportType>Sheet</ReportType>
<Role>http://www.immunomedics.com/role/RelatedPartyTransactionsDetails</Role>
<ShortName>Related Party Transactions (Details)</ShortName>
<MenuCategory>Details</MenuCategory>
<ParentRole>http://www.immunomedics.com/role/RelatedPartyTransactions</ParentRole>
<Position>59</Position>
</Report>
<Report instance="immu201910-k.htm">
<IsDefault>false</IsDefault>
<HasEmbeddedReports>false</HasEmbeddedReports>
<HtmlFileName>R60.htm</HtmlFileName>
<LongName>2414401 - Disclosure - Collaboration Agreements (Details)</LongName>
<ReportType>Sheet</ReportType>
<Role>http://www.immunomedics.com/role/CollaborationAgreementsDetails</Role>
<ShortName>Collaboration Agreements (Details)</ShortName>
<MenuCategory>Details</MenuCategory>
<ParentRole>http://www.immunomedics.com/role/CollaborationAgreements</ParentRole>
<Position>60</Position>
</Report>
<Report instance="immu201910-k.htm">
<IsDefault>false</IsDefault>
<HasEmbeddedReports>false</HasEmbeddedReports>
<HtmlFileName>R61.htm</HtmlFileName>
<LongName>2415402 - Disclosure - Commitments and Contingencies - Narrative (Details)</LongName>
<ReportType>Sheet</ReportType>
<Role>http://www.immunomedics.com/role/CommitmentsAndContingenciesNarrativeDetails</Role>
<ShortName>Commitments and Contingencies - Narrative (Details)</ShortName>
<MenuCategory>Details</MenuCategory>
<Position>61</Position>
</Report>
<Report instance="immu201910-k.htm">
<IsDefault>false</IsDefault>
<HasEmbeddedReports>false</HasEmbeddedReports>
<HtmlFileName>R62.htm</HtmlFileName>
<LongName>2415403 - Disclosure - Commitments and Contingencies - Supplemental Consolidated Balance Sheet Information Related to Leases (Details)</LongName>
<ReportType>Sheet</ReportType>
<Role>http://www.immunomedics.com/role/CommitmentsAndContingenciesSupplementalConsolidatedBalanceSheetInformationRelatedToLeasesDetails</Role>
<ShortName>Commitments and Contingencies - Supplemental Consolidated Balance Sheet Information Related to Leases (Details)</ShortName>
<MenuCategory>Details</MenuCategory>
<Position>62</Position>
</Report>
<Report instance="immu201910-k.htm">
<IsDefault>false</IsDefault>
<HasEmbeddedReports>false</HasEmbeddedReports>
<HtmlFileName>R63.htm</HtmlFileName>
<LongName>2415404 - Disclosure - Commitments and Contingencies - Maturities of Lease Liabilities (Details)</LongName>
<ReportType>Sheet</ReportType>
<Role>http://www.immunomedics.com/role/CommitmentsAndContingenciesMaturitiesOfLeaseLiabilitiesDetails</Role>
<ShortName>Commitments and Contingencies - Maturities of Lease Liabilities (Details)</ShortName>
<MenuCategory>Details</MenuCategory>
<Position>63</Position>
</Report>
<Report instance="immu201910-k.htm">
<IsDefault>false</IsDefault>
<HasEmbeddedReports>false</HasEmbeddedReports>
<HtmlFileName>R64.htm</HtmlFileName>
<LongName>2416401 - Disclosure - Defined Contribution Plans (Details)</LongName>
<ReportType>Sheet</ReportType>
<Role>http://www.immunomedics.com/role/DefinedContributionPlansDetails</Role>
<ShortName>Defined Contribution Plans (Details)</ShortName>
<MenuCategory>Details</MenuCategory>
<ParentRole>http://www.immunomedics.com/role/DefinedContributionPlans</ParentRole>
<Position>64</Position>
</Report>
<Report instance="immu201910-k.htm">
<IsDefault>false</IsDefault>
<HasEmbeddedReports>false</HasEmbeddedReports>
<HtmlFileName>R65.htm</HtmlFileName>
<LongName>2417402 - Disclosure - Quarterly Results of Operations (Details)</LongName>
<ReportType>Sheet</ReportType>
<Role>http://www.immunomedics.com/role/QuarterlyResultsOfOperationsDetails</Role>
<ShortName>Quarterly Results of Operations (Details)</ShortName>
<MenuCategory>Details</MenuCategory>
<ParentRole>http://www.immunomedics.com/role/QuarterlyResultsOfOperationsTables</ParentRole>
<Position>65</Position>
</Report>
<Report instance="immu201910-k.htm">
<IsDefault>false</IsDefault>
<HasEmbeddedReports>false</HasEmbeddedReports>
<HtmlFileName>R9999.htm</HtmlFileName>
<LongName>Uncategorized Items - immu201910-k.htm</LongName>
<ReportType>Sheet</ReportType>
<Role>http://xbrl.sec.gov/role/uncategorizedFacts</Role>
<ShortName>Uncategorized Items - immu201910-k.htm</ShortName>
<MenuCategory>Cover</MenuCategory>
<Position>66</Position>
</Report>
<Report>
<IsDefault>false</IsDefault>
<HasEmbeddedReports>false</HasEmbeddedReports>
<LongName>All Reports</LongName>
<ReportType>Book</ReportType>
<ShortName>All Reports</ShortName>
</Report>
</MyReports>
<InputFiles>
<File doctype="10-K" original="immu201910-k.htm">immu201910-k.htm</File>
<File>immu-20191231.xsd</File>
<File>immu-20191231_cal.xml</File>
<File>immu-20191231_def.xml</File>
<File>immu-20191231_lab.xml</File>
<File>immu-20191231_pre.xml</File>
<File>immu201910k1231ex109.htm</File>
<File>immu201910k1231ex2111.htm</File>
<File>immu201910k1231ex2311.htm</File>
<File>immu201910k1231ex3111.htm</File>
<File>immu201910k1231ex3121.htm</File>
<File>immu201910k1231ex3211.htm</File>
<File>immu201910k1231ex3221.htm</File>
<File>immu201910kex41.htm</File>
</InputFiles>
<SupplementalFiles>
<File>a10kchecmicallinkerimage.jpg</File>
<File>chart-e9c6128662635b0daca.jpg</File>
<File>immu20170630x10k002a01.jpg</File>
<File>immu20170630x10k003a01.jpg</File>
<File>immupipeline21020.jpg</File>
</SupplementalFiles>
<BaseTaxonomies>
<BaseTaxonomy>http://xbrl.sec.gov/dei/2019-01-31</BaseTaxonomy>
<BaseTaxonomy>http://fasb.org/srt/2019-01-31</BaseTaxonomy>
<BaseTaxonomy>http://fasb.org/us-gaap/2019-01-31</BaseTaxonomy>
</BaseTaxonomies>
<HasPresentationLinkbase>true</HasPresentationLinkbase>
<HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R60.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
function toggleNextSibling (e) {
if (e.nextSibling.style.display=='none') {
e.nextSibling.style.display='block';
} else { e.nextSibling.style.display='none'; }
}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6989415184">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaboration Agreements (Details)<br> € in Millions</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2019 </div>
<div>EUR (€) </div>
<div>patient</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GuaranteeObligationsLineItems', window );"><strong>Guarantor Obligations [Line Items]</strong></a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_immu_AgreementPotentialMilestonePayment', window );">Potential milestone payment</a></td>
<td class="nump">€ 33.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_immu_AgreementPotentialMilestonePaymentTerm', window );">Potential milestone payment terms (in years)</a></td>
<td class="text">6 years<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedLiabilities', window );">Accrued expenses</a></td>
<td class="nump">€ 0.5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_immu_CollaborationAgreementAxis=immu_CBGForschungsGmbHMember', window );">CBG Forschungs GmbH</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GuaranteeObligationsLineItems', window );"><strong>Guarantor Obligations [Line Items]</strong></a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_immu_NumberofPatients', window );">Number of patients in clinical collaboration (in patients) | patient</a></td>
<td class="nump">1,200<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_immu_AgreementPotentialMilestonePayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Agreement Potential Milestone Payment</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">immu_AgreementPotentialMilestonePayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>immu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_immu_AgreementPotentialMilestonePaymentTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Agreement, Potential Milestone Payment Term</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">immu_AgreementPotentialMilestonePaymentTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>immu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_immu_NumberofPatients">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of Patients</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">immu_NumberofPatients</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>immu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GuaranteeObligationsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GuaranteeObligationsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_immu_CollaborationAgreementAxis=immu_CBGForschungsGmbHMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">immu_CollaborationAgreementAxis=immu_CBGForschungsGmbHMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R64.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
function toggleNextSibling (e) {
if (e.nextSibling.style.display=='none') {
e.nextSibling.style.display='block';
} else { e.nextSibling.style.display='none'; }
}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6804764768">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Defined Contribution Plans (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Jun. 30, 2018</div></th>
<th class="th"><div>Jun. 30, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CompensationAndRetirementDisclosureAbstract', window );"><strong>Retirement Benefits [Abstract]</strong></a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch', window );">Employer matching contribution (as percent)</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent', window );">Employer matching contribution, percent of employee's pay (as percent)</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanContributionsByEmployer', window );">Aggregate company contributions to its benefit plans</a></td>
<td class="nump">$ 0.1<span></span>
</td>
<td class="nump">$ 1.9<span></span>
</td>
<td class="nump">$ 0.1<span></span>
</td>
<td class="nump">$ 0.1<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationAndRetirementDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationAndRetirementDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanContributionsByEmployer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of contribution received by defined benefit plan from employer which increases plan assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&oid=118257860&loc=d3e4179-114921<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(iv)(01)<br> -URI http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(ii)<br> -URI http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&oid=118255775&loc=d3e2709-114920<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -URI http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanContributionsByEmployer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of employees' gross pay for which the employer contributes a matching contribution to a defined contribution plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage employer matches of the employee's percentage contribution matched.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
function toggleNextSibling (e) {
if (e.nextSibling.style.display=='none') {
e.nextSibling.style.display='block';
} else { e.nextSibling.style.display='none'; }
}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6823477232">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS - USD ($)<br> shares in Thousands, $ in Thousands</strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Jun. 30, 2018</div></th>
<th class="th"><div>Jun. 30, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 295<span></span>
</td>
<td class="nump">$ 2,156<span></span>
</td>
<td class="nump">$ 3,091<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingCostsAndExpensesAbstract', window );"><strong>Costs and expenses:</strong></a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostOfRevenue', window );">Costs of goods sold</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">613<span></span>
</td>
<td class="nump">483<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">93,887<span></span>
</td>
<td class="nump">254,871<span></span>
</td>
<td class="nump">99,283<span></span>
</td>
<td class="nump">51,776<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SellingAndMarketingExpense', window );">Sales and marketing</a></td>
<td class="nump">19,834<span></span>
</td>
<td class="nump">26,459<span></span>
</td>
<td class="nump">6,822<span></span>
</td>
<td class="nump">873<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="nump">30,814<span></span>
</td>
<td class="nump">43,803<span></span>
</td>
<td class="nump">36,485<span></span>
</td>
<td class="nump">29,109<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostsAndExpenses', window );">Total costs and expenses</a></td>
<td class="nump">144,535<span></span>
</td>
<td class="nump">325,133<span></span>
</td>
<td class="nump">143,203<span></span>
</td>
<td class="nump">82,241<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Operating loss</a></td>
<td class="num">(144,535)<span></span>
</td>
<td class="num">(324,838)<span></span>
</td>
<td class="num">(141,047)<span></span>
</td>
<td class="num">(79,150)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAdjustmentOfWarrants', window );">Changes in fair market value of warrant liabilities</a></td>
<td class="nump">1,404<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(108,636)<span></span>
</td>
<td class="num">(61,074)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentOfWarrantsGrantedForServices', window );">Warrant related expenses</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(7,649)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense</a></td>
<td class="num">(20,017)<span></span>
</td>
<td class="num">(40,337)<span></span>
</td>
<td class="num">(23,255)<span></span>
</td>
<td class="num">(5,480)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestAndOtherIncome', window );">Interest and other income</a></td>
<td class="nump">6,106<span></span>
</td>
<td class="nump">7,856<span></span>
</td>
<td class="nump">5,493<span></span>
</td>
<td class="nump">431<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Loss on induced exchanges of debt</a></td>
<td class="num">(897)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(13,005)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_immu_OtherFinancingExpenseIncome', window );">Other financing expenses</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(347)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainOnBusinessInterruptionInsuranceRecovery', window );">Insurance reimbursement</a></td>
<td class="nump">190<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">6,638<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax', window );">Foreign currency transaction gain, net</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">81<span></span>
</td>
<td class="nump">23<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Loss before income tax</a></td>
<td class="num">(157,749)<span></span>
</td>
<td class="num">(357,319)<span></span>
</td>
<td class="num">(273,731)<span></span>
</td>
<td class="num">(153,246)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax expense</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(156)<span></span>
</td>
<td class="num">(20)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="num">(157,749)<span></span>
</td>
<td class="num">(357,319)<span></span>
</td>
<td class="num">(273,887)<span></span>
</td>
<td class="num">(153,266)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest', window );">Net loss attributable to noncontrolling interest</a></td>
<td class="num">(81)<span></span>
</td>
<td class="num">(129)<span></span>
</td>
<td class="num">(50)<span></span>
</td>
<td class="num">(60)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss attributable to Immunomedics, Inc. stockholders</a></td>
<td class="num">$ (157,668)<span></span>
</td>
<td class="num">$ (357,190)<span></span>
</td>
<td class="num">$ (273,837)<span></span>
</td>
<td class="num">$ (153,206)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDiluted', window );">Loss per common share attributable to Immunomedics, Inc. stockholders (basic and diluted) (in USD per share)</a></td>
<td class="num">$ (0.84)<span></span>
</td>
<td class="num">$ (1.84)<span></span>
</td>
<td class="num">$ (1.78)<span></span>
</td>
<td class="num">$ (1.47)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted', window );">Weighted average shares used to calculate loss per common share (basic and diluted) (in shares)</a></td>
<td class="nump">188,554<span></span>
</td>
<td class="nump">193,617<span></span>
</td>
<td class="nump">153,475<span></span>
</td>
<td class="nump">104,536<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract', window );"><strong>Other comprehensive (loss) income, net of tax:</strong></a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax', window );">Foreign currency translation adjustments</a></td>
<td class="num">$ (8)<span></span>
</td>
<td class="nump">$ 174<span></span>
</td>
<td class="num">$ (105)<span></span>
</td>
<td class="num">$ (62)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax', window );">Unrealized gain (loss) on securities available for sale</a></td>
<td class="nump">10<span></span>
</td>
<td class="num">(391)<span></span>
</td>
<td class="nump">55<span></span>
</td>
<td class="num">(109)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other comprehensive income (loss), net of tax:</a></td>
<td class="nump">2<span></span>
</td>
<td class="num">(217)<span></span>
</td>
<td class="num">(50)<span></span>
</td>
<td class="num">(171)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest', window );">Comprehensive loss</a></td>
<td class="num">(157,747)<span></span>
</td>
<td class="num">(357,536)<span></span>
</td>
<td class="num">(273,937)<span></span>
</td>
<td class="num">(153,437)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest', window );">Comprehensive loss attributable to noncontrolling interest</a></td>
<td class="num">(81)<span></span>
</td>
<td class="num">(129)<span></span>
</td>
<td class="num">(50)<span></span>
</td>
<td class="num">(60)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Comprehensive loss attributable to Immunomedics, Inc. stockholders</a></td>
<td class="num">(157,666)<span></span>
</td>
<td class="num">(357,407)<span></span>
</td>
<td class="num">(273,887)<span></span>
</td>
<td class="num">(153,377)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=immu_ProductSalesMember', window );">Product sales</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,501<span></span>
</td>
<td class="nump">2,443<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=immu_LicenseFreeAndOtherRevenueMember', window );">License fee and other revenues</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">295<span></span>
</td>
<td class="nump">330<span></span>
</td>
<td class="nump">284<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=immu_ResearchandDevelopmentMember', window );">Research and development</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 325<span></span>
</td>
<td class="nump">$ 364<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_immu_OtherFinancingExpenseIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of other financing expenses.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">immu_OtherFinancingExpenseIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>immu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentOfWarrantsGrantedForServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Adjustment for noncash service expenses paid for by granting of warrants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentOfWarrantsGrantedForServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&oid=118930883&loc=d3e557-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&oid=118930883&loc=SL7669625-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&oid=118930883&loc=SL7669619-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income (loss) and other comprehensive income (loss), attributable to noncontrolling interests. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&oid=118930883&loc=SL7669625-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&oid=116874947&loc=SL4591552-111686<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&oid=118930883&loc=SL7669619-108580<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 21<br> -URI http://asc.fasb.org/extlink&oid=108774443&loc=SL4613674-111683<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&oid=108774443&loc=SL4569643-111683<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&oid=116874947&loc=SL4591552-111686<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&oid=118930883&loc=SL7669619-108580<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&oid=108774443&loc=SL4569616-111683<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&oid=118930883&loc=SL7669625-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate cost of goods produced and sold and services rendered during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.2)<br> -URI http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostsAndExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total costs of sales and operating expenses for the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03)<br> -URI http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostsAndExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements. Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period. Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&oid=117326831&loc=d3e1337-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAdjustmentOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense (income) related to adjustment to fair value of warrant liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Section 25<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&oid=109262497&loc=d3e20148-110875<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAdjustmentOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before tax of foreign currency transaction realized and unrealized gain (loss) recognized in the income statement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&oid=6450222&loc=d3e30840-110895<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&oid=109240200&loc=d3e30700-110894<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&oid=109240200&loc=d3e30690-110894<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyTransactionGainLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainOnBusinessInterruptionInsuranceRecovery">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net amount (to the extent disclosed within this portion of the income statement) by which an insurance settlement exceeds incremental costs incurred from the event causing an interruption of business, plus the insurance award for earnings lost from the event, such as a natural catastrophe, explosion or fire.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&oid=114868897&loc=SL114872001-224240<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainOnBusinessInterruptionInsuranceRecovery</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainsLossesOnExtinguishmentOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&oid=117329964&loc=d3e12355-112629<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&oid=117329964&loc=d3e12317-112629<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainsLossesOnExtinguishmentOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 940<br> -SubTopic 20<br> -Section 25<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&oid=68072869&loc=d3e41242-110953<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -URI http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(8))<br> -URI http://asc.fasb.org/extlink&oid=116637232&loc=SL114874131-224263<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -URI http://asc.fasb.org/extlink&oid=116637391&loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&oid=109238882&loc=d3e38679-109324<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestAndOtherIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of interest income and other income recognized during the period. Included in this element is interest derived from investments in debt securities, cash and cash equivalents, and other investments which reflect the time value of money or transactions in which the payments are for the use or forbearance of money and other income from ancillary business-related activities (that is, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestAndOtherIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&oid=6450988&loc=d3e26243-108391<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&oid=114775744&loc=d3e28555-108399<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (210.5-03(11))<br> -URI http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.9)<br> -URI http://asc.fasb.org/extlink&oid=116637391&loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&oid=118930883&loc=SL7669619-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&oid=116637391&loc=SL114874048-224260<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&oid=118930883&loc=SL7669625-108580<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&oid=116637232&loc=SL114874131-224263<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3602-108585<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of Net Income (Loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&oid=118930883&loc=SL7669625-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&oid=118930883&loc=SL7669619-108580<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&oid=116874947&loc=SL4591551-111686<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingCostsAndExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingCostsAndExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&oid=118930883&loc=SL7669646-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (b,c)<br> -URI http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&oid=118930883&loc=SL7669619-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&oid=109259400&loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&oid=118951672&loc=d3e1436-108581<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&oid=118930883&loc=SL7669625-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax, before reclassification adjustments, of unrealized holding gain (loss) on available-for-sale securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&oid=118930883&loc=SL7669646-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&oid=118930883&loc=d3e637-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&oid=118930883&loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&oid=118930883&loc=SL7669625-108580<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&oid=116874947&loc=SL4591551-111686<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3000-108585<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&oid=108774443&loc=SL4569616-111683<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&oid=115929826&loc=d3e8933-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&oid=116874947&loc=SL4591552-111686<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&oid=118956577&loc=SL49130543-203045<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&oid=118956577&loc=SL49130545-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingAndMarketingExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total amount of expenses directly related to the marketing or selling of products or services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingAndMarketingExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=immu_ProductSalesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=immu_ProductSalesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=immu_LicenseFreeAndOtherRevenueMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=immu_LicenseFreeAndOtherRevenueMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=immu_ResearchandDevelopmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=immu_ResearchandDevelopmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
function toggleNextSibling (e) {
if (e.nextSibling.style.display=='none') {
e.nextSibling.style.display='block';
} else { e.nextSibling.style.display='none'; }
}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6810553552">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Quarterly Results of Operations (Unaudited)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_QuarterlyFinancialInformationDisclosureAbstract', window );"><strong>Quarterly Financial Information Disclosure [Abstract]</strong></a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_QuarterlyFinancialInformationTextBlock', window );">Quarterly Results of Operations (Unaudited)</a></td>
<td class="text">Quarterly Results of Operations (Unaudited)<div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following table summarizes unaudited quarterly financial data:</span></div><div style="line-height:120%;text-align:justify;padding-left:0px;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"/></tr><tr><td style="width:37%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:14%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"> </span></div></td><td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Three Months Ended</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-style:italic;"> </span><span style="font-family:inherit;font-size:9pt;font-style:italic;font-weight:bold;">($ in thousands, except for per share amounts)</span></div></td><td colspan="3" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">December 31, 2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">September 30, 2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">June 30, 2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">March 31, 2019</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Consolidated Statements of Comprehensive Loss Data:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">    </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">    </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Revenues</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>295</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Net loss attributable to Immunomedics, Inc. stockholders </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(99,608</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(94,292</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(75,953</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(87,337</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Loss per common share attributable to Immunomedics Inc. stockholders – (basic and diluted) </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(0.50</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(0.49</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(0.40</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(0.46</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Weighted average shares used to calculate loss per common share – (basic and diluted)</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>199,614</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>191,981</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>191,745</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>191,052</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;padding-left:0px;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"/></tr><tr><td style="width:37%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:14%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"> </span></div></td><td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Three Months Ended</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-style:italic;"> </span><span style="font-family:inherit;font-size:9pt;font-style:italic;font-weight:bold;">($ in thousands, except for per share amounts)</span></div></td><td colspan="3" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">December 31, 2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">September 30, 2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">June 30, 2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">March 31, 2018</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Consolidated Statements of Comprehensive Loss Data:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">    </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">    </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Revenues</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>387</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>482</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Net loss attributable to Immunomedics, Inc. stockholders </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(93,499</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(64,169</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(117,032</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(35,546</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Loss per common share attributable to Immunomedics Inc. stockholders – (basic and diluted) </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(0.50</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(0.34</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(0.68</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(0.21</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Weighted average shares used to calculate loss per common share – (basic and diluted)</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>190,171</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>186,937</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>171,124</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>166,054</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_QuarterlyFinancialInformationDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_QuarterlyFinancialInformationDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_QuarterlyFinancialInformationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for quarterly financial data. Includes, but is not limited to, tabular presentation of financial information for fiscal quarters, effect of year-end adjustments, and an explanation of matters or transactions that affect comparability of the information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 270<br> -URI http://asc.fasb.org/topic&trid=2126967<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_QuarterlyFinancialInformationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
function toggleNextSibling (e) {
if (e.nextSibling.style.display=='none') {
e.nextSibling.style.display='block';
} else { e.nextSibling.style.display='none'; }
}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6810481440">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenue Recognition<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerAbstract', window );"><strong>Revenue from Contract with Customer [Abstract]</strong></a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerTextBlock', window );">Revenue Recognition</a></td>
<td class="text">Revenue Recognition<div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Everest Medicines II Limited</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">On April 29, 2019, we entered into a license agreement (the "License Agreement") with Everest Medicines II Limited, a China limited company ("Everest"). Pursuant to the License Agreement, we granted Everest an exclusive license to develop and commercialize sacituzumab govitecan in the People's Republic of China, Taiwan, Hong Kong, Macao, Indonesia, Philippines, Vietnam, Thailand, South Korea, Malaysia, Singapore and Mongolia (the "Territory"). In consideration for entering into the License Agreement, Everest made a one-time, non-refundable upfront payment to us in the aggregate amount of </span><span style="font-family:inherit;font-size:10pt;"><span>$65.0 million</span></span><span style="font-family:inherit;font-size:10pt;"> which is recorded as deferred revenue on the consolidated balance sheet as of </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;">. The License Agreement contains a development milestone payment of </span><span style="font-family:inherit;font-size:10pt;"><span>$60.0 million</span></span><span style="font-family:inherit;font-size:10pt;"> based upon our achievement of FDA approval for sacituzumab govitecan. The </span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">License Agreement also contains additional development milestone payments in a total amount of up to </span><span style="font-family:inherit;font-size:10pt;"><span>$180.0 million</span></span><span style="font-family:inherit;font-size:10pt;"> based upon the achievement of certain other development milestones. In addition, the License Agreement contains sales milestone payments in a total amount of up to </span><span style="font-family:inherit;font-size:10pt;"><span>$530.0 million</span></span><span style="font-family:inherit;font-size:10pt;"> based upon the achievement of certain sales milestones. Everest will make royalty payments to us based upon percentages of net sales of sacituzumab govitecan, ranging from </span><span style="font-family:inherit;font-size:10pt;"><span>14%</span></span><span style="font-family:inherit;font-size:10pt;"> to </span><span style="font-family:inherit;font-size:10pt;"><span>20%</span></span><span style="font-family:inherit;font-size:10pt;">. </span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company assessed the arrangement in accordance with ASC 606 and concluded that the contract counterparty, Everest, is a customer based on the arrangement structure. The Company identified two material promises to deliver under the contract: (1) grant of license and the (2) clinical and commercial supply of the product. However, given the nature of the manufacturing of the product the license is not considered to be distinct from the clinical and commercial supply promise. The Company therefore concluded that there is one combined performance obligation.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company initially deferred and will recognize the </span><span style="font-family:inherit;font-size:10pt;"><span>$65.0 million</span></span><span style="font-family:inherit;font-size:10pt;"> over the performance obligation period of the combined performance obligation. As it relates to the upfront consideration, the </span><span style="font-family:inherit;font-size:10pt;"><span>$65.0 million</span></span><span style="font-family:inherit;font-size:10pt;"> is recorded as deferred revenue and will be recognized over the term of the of the contract performance obligation period, which the Company has concluded to be </span><span style="font-family:inherit;font-size:10pt;"><span>15 years</span></span><span style="font-family:inherit;font-size:10pt;"> after initial sale of the product in the territory. As concluded above, the Company has a combined performance obligation, which includes delivering the license and clinical and commercial supply to Everest. As such, because the clinical and commercial supply obligation occur throughout the period of the License Agreement, the </span><span style="font-family:inherit;font-size:10pt;"><span>$65.0 million</span></span><span style="font-family:inherit;font-size:10pt;"> fixed consideration is recognized over the period in which commercial and clinical supply of product is delivered (over-time). </span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The future potential milestone payments are excluded from the transaction price, as the achievement of the milestone events require considerable judgment in determining whether it is probable of being achieved, and that a significant revenue reversal would not occur. As such, all milestone payments are fully constrained. The Company will reevaluate the transaction price at the end of each reporting period and as uncertain events are resolved or other changes in circumstances occur, and, if necessary, adjust its estimate of the transaction price.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Janssen Biotech Inc.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><span style="font-family:inherit;font-size:10pt;">On April 5, 2019, the Company entered into a promotion agreement (the "Promotion Agreement") with Janssen Biotech Inc., ("Janssen") pursuant to which the Company will provide non-exclusive product detailing services to Janssen for erdafitinib (the "Product"). Pursuant to the Promotion Agreement, the Company will provide a dedicated sales team to detail the Product to oncologists and other targeted health care providers in the United States. Under the terms of the Promotion Agreement, Janssen maintains ownership of the New Drug Application for the Product as well as legal, regulatory, distribution, commercialization and manufacturing responsibilities for the Product, while the Company will provide product detailing services to Janssen.  Following the achievement of certain sales targets in 2019 and 2020, Janssen will pay the Company (a) a service fee equal to a percentage in the low double digits of the portion of Cumulative Net Sales (as defined in the Promotion Agreement) in excess of a baseline amount during each of 2019 and 2020, and (b) potential milestone payments of up to </span><span style="font-family:inherit;font-size:10pt;"><span>$15.0 million</span></span><span style="font-family:inherit;font-size:10pt;"> when Cumulative Net Sales exceed certain thresholds during each of 2019 and 2020. On April 12, 2019, the Company was informed that the FDA granted accelerated approval to Janssen's Balversa</span><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">® </sup></span><span style="font-family:inherit;font-size:10pt;">(erdafitinib) for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma that has a type of susceptible genetic alteration known as FGFR3 or FGFR2, and that has progressed during or following prior platinum-containing chemotherapy. During the year ended </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;">, </span><span style="font-family:inherit;font-size:10pt;"><span>$0.3 million</span></span> of service fee revenues were recorded relating to the Promotion Agreement.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -URI http://asc.fasb.org/topic&trid=49130388<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
function toggleNextSibling (e) {
if (e.nextSibling.style.display=='none') {
e.nextSibling.style.display='block';
} else { e.nextSibling.style.display='none'; }
}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6721975232">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-based Payment Arrangement [Abstract]</strong></a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions</a></td>
<td class="text"><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We estimated the fair value of options granted using a Black-Scholes option pricing model with the following assumptions:</span></div><div style="line-height:120%;text-align:center;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:98.6328125%;border-collapse:collapse;text-align:left;"><tr><td colspan="10"/></tr><tr><td style="width:31%;"/><td style="width:1%;"/><td style="width:16%;"/><td style="width:1%;"/><td style="width:16%;"/><td style="width:1%;"/><td style="width:16%;"/><td style="width:1%;"/><td style="width:16%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Year Ended </span></div><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">December 31, 2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Transition Period December 31, 2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="4" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Fiscal Years Ended June 30,</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">2017</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Expected dividend yield</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>—%</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>—%</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>—%</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>—%</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Expected option term (years)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>4.52</span></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>4.76</span></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>4.84</span></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>5.04</span></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Expected stock price volatility</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>71%</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>69%</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>70%</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>63%</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Risk-free interest rate</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">1.39% - 2.58%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">2.69% - 3.06%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">1.72% - 2.89%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">1.16% - 2.15%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Share-based Compensation, Stock Options, Activity</a></td>
<td class="text"><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following table summarizes all stock option activity for the ended </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;">:</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="13"/></tr><tr><td style="width:27%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:16%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:21%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:16%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Options</span></div><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">(in thousands)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Weighted Average Exercise Price Per Option</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Weighted Average Remaining Contractual Term (Years)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Aggregate Intrinsic Value (in thousands)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Options outstanding, January 1, 2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>4,757</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>14.30</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>5.42</span></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>18,618</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">   Changes during the year:</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">   Granted</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>3,614</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>15.46</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">   Exercised</span></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(1,207</span></span></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>3.17</span></span></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">   Expired or forfeited</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(1,263</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>17.78</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Options outstanding, end of year</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>5,901</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#bfe4ff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#bfe4ff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>16.54</span></span></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>5.90</span></span></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#bfe4ff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>30,145</span></span></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Vested as of December 31, 2019</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>1,150</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>14.72</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>4.61</span></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>8,276</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following table summarizes all stock option activity for the Transition Period ended </span><span style="font-family:inherit;font-size:10pt;">December 31, 2018</span><span style="font-family:inherit;font-size:10pt;">:</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="13"/></tr><tr><td style="width:27%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:16%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:21%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:16%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Options</span></div><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">(in thousands)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Weighted Average Exercise Price Per Option</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Weighted Average Remaining Contractual Term (Years)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Aggregate Intrinsic Value (in thousands)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Options outstanding, July 1, 2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>3,549</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>7.58</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>4.43</span></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>57,123</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">   Changes during the year:</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">   Granted</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>2,002</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>22.54</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">   Exercised</span></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(706</span></span></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>3.71</span></span></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">   Expired or forfeited</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(88</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>15.57</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Options outstanding, end of year</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>4,757</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#bfe4ff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#bfe4ff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>14.30</span></span></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>5.42</span></span></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#bfe4ff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>18,618</span></span></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Vested as of December 31, 2018</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>1,504</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>4.23</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>3.41</span></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>15,098</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock', window );">Schedule of Share-based Compensation, Restricted Stock and Restricted Stock Units Activity</a></td>
<td class="text"><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Information regarding the Company's RSU's for the year ended </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;"> is as follows:</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"/></tr><tr><td style="width:38%;"/><td style="width:1%;"/><td style="width:29%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:28%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Non-Vested Restricted Stock Units</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Share Equivalent</span></div><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">(in thousands)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Weighted Average Grant Date Fair Value</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Non-vested at January 1, 2019</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>15</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>14.29</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Changes during the period:</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">   Restricted Units Granted </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>58</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>12.93</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">   Vested/Exercised</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(15</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>14.29</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">   Forfeited</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Non-vested at December 31, 2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>58</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>12.93</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Information regarding the Company's RSU's for the Transition Period ended </span><span style="font-family:inherit;font-size:10pt;">December 31, 2018</span><span style="font-family:inherit;font-size:10pt;"> is as follows:</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"/></tr><tr><td style="width:38%;"/><td style="width:1%;"/><td style="width:29%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:28%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Non-Vested Restricted Stock Units</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Share Equivalent</span></div><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">(in thousands)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Weighted Average Grant Date Fair Value</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Non-vested at July 1, 2018</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>1,535</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>2.83</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Changes during the period:</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">   Restricted Units Granted </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>15</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>14.29</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">   Vested/Exercised</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(35</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>8.46</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">   Forfeited</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(1,500</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>2.28</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Non-vested at December 31, 2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>15</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>14.29</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_immu_ScheduleofSharebasedCompensationPerformanceStockandPerformanceStockUnitsActivityTableTextBlock', window );">Schedule of Share-based Compensation, Performance Stock and Performance Stock Units Activity</a></td>
<td class="text"><div style="line-height:120%;padding-left:4px;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following table summarizes the Company's performance-based stock option activity for the year ended </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;"> is as follows:</span><span style="font-family:inherit;font-size:10pt;font-weight:bold;"> </span></div><div style="line-height:120%;padding-left:4px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:98.4375%;border-collapse:collapse;text-align:left;"><tr><td colspan="13"/></tr><tr><td style="width:28%;"/><td style="width:13%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:15%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:20%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:16%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Options</span></div><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">(in thousands)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Weighted Average Exercise Price Per Option</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Weighted Average Remaining Contractual Term (Years)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Aggregate Intrinsic Value (in thousands)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Options outstanding, January 1, 2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>538</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>13.09</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>6.04</span></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>772</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">   Changes during the year:</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">   Granted</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>800</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>17.18</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">   Exercised</span></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">   Expired or forfeited</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(501</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>13.05</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Options outstanding, end of year</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>837</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#bfe4ff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#bfe4ff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>17.03</span></span></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>6.26</span></span></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#bfe4ff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>3,456</span></span></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Vested as of December 31, 2019</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>50</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>18.74</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>6.88</span></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>121</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-left:4px;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following table summarizes the Company's performance-based stock option activity for the Transition Period ended </span><span style="font-family:inherit;font-size:10pt;">December 31, 2018</span><span style="font-family:inherit;font-size:10pt;"> is as follows:</span><span style="font-family:inherit;font-size:10pt;font-weight:bold;"> </span></div><div style="line-height:120%;padding-left:4px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:98.4375%;border-collapse:collapse;text-align:left;"><tr><td colspan="13"/></tr><tr><td style="width:28%;"/><td style="width:13%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:15%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:20%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:16%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Options</span></div><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">(in thousands)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Weighted Average Exercise Price Per Option</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Weighted Average Remaining Contractual Term (Years)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Aggregate Intrinsic Value (in thousands)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Options outstanding, July 1, 2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>538</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>13.09</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>6.54</span></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>5,688</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">   Changes during the year:</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">   Granted</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">   Exercised</span></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">   Expired or forfeited</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Options outstanding, end of year</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>538</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#bfe4ff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#bfe4ff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>13.09</span></span></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>6.04</span></span></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#bfe4ff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>772</span></span></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Vested as of December 31, 2018</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>38</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>11.86</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>5.94</span></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>91</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_immu_ScheduleofSharebasedCompensationPerformanceStockandPerformanceStockUnitsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Schedule of Share-based Compensation, Performance Stock and Performance Stock Units Activity [Table Text Block]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">immu_ScheduleofSharebasedCompensationPerformanceStockandPerformanceStockUnitsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>immu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of the number and weighted-average grant date fair value for restricted stock and restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock and restricted stock units that were granted, vested, or forfeited during the year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>77
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
function toggleNextSibling (e) {
if (e.nextSibling.style.display=='none') {
e.nextSibling.style.display='block';
} else { e.nextSibling.style.display='none'; }
}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6988942272">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Restricted Stock Unit Activity (Details) - Restricted Stock Units (RSUs) - $ / shares<br> shares in Thousands</strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward', window );"><strong>Share Equivalent</strong></a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Non-vested, start of year (in shares)</a></td>
<td class="nump">1,535<span></span>
</td>
<td class="nump">15<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Granted (in shares)</a></td>
<td class="nump">15<span></span>
</td>
<td class="nump">58<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Vested/Exercised (in shares)</a></td>
<td class="num">(35)<span></span>
</td>
<td class="num">(15)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod', window );">Forfeited (in shares)</a></td>
<td class="num">(1,500)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Non-vested, end of year (in shares)</a></td>
<td class="nump">15<span></span>
</td>
<td class="nump">58<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_immu_WeightedaveragegrantdatefairvalueRollForward', window );"><strong>Weighted Average Grant Date Fair Value</strong></a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Nonvested, weighted average grant date fair value, start of year (in USD per share)</a></td>
<td class="nump">$ 2.83<span></span>
</td>
<td class="nump">$ 14.29<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Grants in period, weighted average grant date fair value (in USD per share)</a></td>
<td class="nump">14.29<span></span>
</td>
<td class="nump">12.93<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue', window );">Vested/exercised, weighted average grant date fair value (in USD per share)</a></td>
<td class="nump">8.46<span></span>
</td>
<td class="nump">14.29<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue', window );">Forfeited, weighted average grant fate fair value (in USD per share)</a></td>
<td class="nump">2.28<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Nonvested, weighted average grant date fair value, end of year (in USD per share)</a></td>
<td class="nump">$ 14.29<span></span>
</td>
<td class="nump">$ 12.93<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_immu_WeightedaveragegrantdatefairvalueRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average grant date fair value [Roll Forward]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">immu_WeightedaveragegrantdatefairvalueRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>immu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)<br> -URI http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(3)<br> -URI http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(2)<br> -URI http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(2)<br> -URI http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>78
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
function toggleNextSibling (e) {
if (e.nextSibling.style.display=='none') {
e.nextSibling.style.display='block';
} else { e.nextSibling.style.display='none'; }
}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6804954576">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Stock Incentive Plan (Details) - USD ($)<br> shares in Thousands, $ in Millions</strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Jun. 30, 2018</div></th>
<th class="th"><div>Jun. 30, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock compensation expense</a></td>
<td class="nump">$ 0.9<span></span>
</td>
<td class="nump">$ 11.7<span></span>
</td>
<td class="nump">$ 4.0<span></span>
</td>
<td class="nump">$ 4.3<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_immu_AllocatedSharebasedCompensationExpenseAmountReversed', window );">Reversed stock based compensation expense</a></td>
<td class="nump">$ 3.4<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted Stock Units (RSUs)</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod', window );">RSUs forfeited in period (in shares)</a></td>
<td class="nump">1,500<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_immu_AllocatedSharebasedCompensationExpenseAmountReversed">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Allocated Share-based Compensation Expense, Amount Reversed</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">immu_AllocatedSharebasedCompensationExpenseAmountReversed</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>immu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&oid=116856206&loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&oid=115993241&loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)<br> -URI http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>79
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>80
<FILENAME>R61.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
function toggleNextSibling (e) {
if (e.nextSibling.style.display=='none') {
e.nextSibling.style.display='block';
} else { e.nextSibling.style.display='none'; }
}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6813406224">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies - Narrative (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jan. 15, 2019</div></th>
<th class="th"><div>Apr. 04, 2018</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Jun. 30, 2018</div></th>
<th class="th"><div>Jun. 30, 2017</div></th>
<th class="th"><div>Mar. 13, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GuaranteeObligationsLineItems', window );"><strong>Guarantor Obligations [Line Items]</strong></a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasePayments', window );">Operating lease, liability</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 1,300<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent', window );">Weighted average discount rate, percent</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">11.00%<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1', window );">Weighted average remaining lease term</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">11 years 9 months 18 days<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseCost', window );">Lease cost</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 700<span></span>
</td>
<td class="nump">$ 1,400<span></span>
</td>
<td class="nump">$ 1,300<span></span>
</td>
<td class="nump">$ 900<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PurchaseObligationDueInNextTwelveMonths', window );">Purchase commitments due 2020</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">90,000<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PurchaseObligationDueInSecondYear', window );">Purchase commitments due 2021</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">59,800<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PurchaseObligationDueInThirdYear', window );">Purchase commitments due 2022</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">40,800<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PurchaseObligationDueInFourthYear', window );">Purchase commitments due 2023</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">40,800<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PurchaseObligationDueInFifthYear', window );">Purchase commitments due 2024</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">33,000<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PurchaseObligationDueAfterFifthYear', window );">Purchase commitments due thereafter</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">33,000<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentForContingentConsiderationLiabilityInvestingActivities', window );">Payment for contingent consideration liability</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 300<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SupplementalUnemploymentBenefitsSeveranceBenefits', window );">Severance benefits</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 2,198<span></span>
</td>
<td class="nump">$ 561<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=srt_ChiefExecutiveOfficerMember', window );">Chief Executive Officer</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GuaranteeObligationsLineItems', window );"><strong>Guarantor Obligations [Line Items]</strong></a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SupplementalUnemploymentBenefitsSeveranceBenefits', window );">Severance benefits</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 1,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_immu_SupplementalUnemploymentBenefitsSeveranceBenefitsPaymentTerm', window );">Severance benefits payment term (in months)</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">18 months<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SalariesWagesAndOfficersCompensation', window );">Officers' compensation</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 500<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SupplementalUnemploymentBenefitsSalaryContinuation', window );">Salary accrued</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">600<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=immu_RestrictedUnitsWithVestingMarketConditionsMember', window );">Restricted Units Vesting Based on Certain Market Conditions | Goldenberg Agreement</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GuaranteeObligationsLineItems', window );"><strong>Guarantor Obligations [Line Items]</strong></a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Restricted stock units granted (in shares)</a></td>
<td class="nump">1,500,000<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_EmploymentContractsMember', window );">Employment Agreement | Goldenberg Agreement</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GuaranteeObligationsLineItems', window );"><strong>Guarantor Obligations [Line Items]</strong></a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SeveranceCosts1', window );">Severance costs</a></td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_LitigationCaseAxis=immu_InsuranceCoverageArbitrationMember', window );">Insurance Coverage Arbitration</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GuaranteeObligationsLineItems', window );"><strong>Guarantor Obligations [Line Items]</strong></a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingencyDamagesSoughtValue', window );">Legal fees</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">3,400<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=immu_TheScrippsResearchInstituteMember', window );">TSRI</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GuaranteeObligationsLineItems', window );"><strong>Guarantor Obligations [Line Items]</strong></a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_immu_NumberofDaysLicenseCancellableAfterNonPayment', window );">Number of days license cancellable after non-payment</a></td>
<td class="text"> <span></span>
</td>
<td class="text">30 days<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_immu_LicenseAgreementMilestoneExpense', window );">Milestone expense</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 500<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_immu_LicenseAgreementMilestoneExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>License Agreement Milestone Expense</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">immu_LicenseAgreementMilestoneExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>immu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_immu_NumberofDaysLicenseCancellableAfterNonPayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of Days License Cancellable After Non-Payment</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">immu_NumberofDaysLicenseCancellableAfterNonPayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>immu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>us-types:durationStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_immu_SupplementalUnemploymentBenefitsSeveranceBenefitsPaymentTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Supplemental Unemployment Benefits, Severance Benefits, Payment Term</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">immu_SupplementalUnemploymentBenefitsSeveranceBenefitsPaymentTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>immu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GuaranteeObligationsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GuaranteeObligationsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lease cost recognized by lessee for lease contract.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&oid=77888426&loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&oid=77888399&loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencyDamagesSoughtValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The value (monetary amount) of the award the plaintiff seeks in the legal matter.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&oid=118942415&loc=d3e14557-108349<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&oid=118942415&loc=d3e14435-108349<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&oid=118942415&loc=d3e14326-108349<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencyDamagesSoughtValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&oid=77888419&loc=SL77918643-209977<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -URI http://asc.fasb.org/extlink&oid=77888426&loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average discount rate for operating lease calculated at point in time.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(4)<br> -URI http://asc.fasb.org/extlink&oid=77888426&loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&oid=77888399&loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&oid=77888399&loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(3)<br> -URI http://asc.fasb.org/extlink&oid=77888426&loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentForContingentConsiderationLiabilityInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow, made soon after acquisition date of business combination, to settle contingent consideration liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentForContingentConsiderationLiabilityInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PurchaseObligationDueAfterFifthYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Minimum amount of purchase arrangement maturing after the fifth fiscal year following the latest fiscal year. Includes, but not limited to, recorded and unrecorded purchase obligations, long-term purchase commitments, and short-term purchase commitments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PurchaseObligationDueAfterFifthYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PurchaseObligationDueInFifthYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Minimum amount of purchase arrangement maturing in the fifth fiscal year following the latest fiscal year. Includes, but not limited to, recorded and unrecorded purchase obligations, long-term purchase commitments, and short-term purchase commitments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PurchaseObligationDueInFifthYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PurchaseObligationDueInFourthYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Minimum amount of purchase arrangement maturing in the fourth fiscal year following the latest fiscal year. Includes, but not limited to, recorded and unrecorded purchase obligations, long-term purchase commitments, and short-term purchase commitments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PurchaseObligationDueInFourthYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PurchaseObligationDueInNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Minimum amount of purchase arrangement maturing in the next fiscal year following the latest fiscal year. Includes, but not limited to, recorded and unrecorded purchase obligations, long-term purchase commitments, and short-term purchase commitments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PurchaseObligationDueInNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PurchaseObligationDueInSecondYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Minimum amount of purchase arrangement maturing in the second fiscal year following the latest fiscal year. Includes, but not limited to, recorded and unrecorded purchase obligations, long-term purchase commitments, and short-term purchase commitments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PurchaseObligationDueInSecondYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PurchaseObligationDueInThirdYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Minimum amount of purchase arrangement maturing in the third fiscal year following the latest fiscal year. Includes, but not limited to, recorded and unrecorded purchase obligations, long-term purchase commitments, and short-term purchase commitments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PurchaseObligationDueInThirdYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SalariesWagesAndOfficersCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for salary and wage arising from service rendered by nonofficer and officer employees. Excludes allocated cost, labor-related nonsalary expense, and direct and overhead labor cost included in cost of good and service sold.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SalariesWagesAndOfficersCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SeveranceCosts1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses for special or contractual termination benefits provided to current employees involuntarily terminated under a benefit arrangement associated exit or disposal activities pursuant to an authorized plan. Excludes expenses related to one-time termination benefits, a discontinued operation or an asset retirement obligation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 5.P.3)<br> -URI http://asc.fasb.org/extlink&oid=115931487&loc=d3e140864-122747<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4(b))<br> -URI http://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SeveranceCosts1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalUnemploymentBenefitsSalaryContinuation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Liability for agreement to continue an employee's salary after termination of employment (but before retirement) including death, disability, or other event. For example, a company may agree to continue a disabled employee's salary for six months.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalUnemploymentBenefitsSalaryContinuation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalUnemploymentBenefitsSeveranceBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Liability for amount due employees, in addition to wages and any other money that employers owe employees, when their employment ends through a layoff or other termination. For example, a company may provide involuntarily terminated employees with a lump sum payment equal to one week's salary for every year of employment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalUnemploymentBenefitsSeveranceBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=srt_ChiefExecutiveOfficerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=srt_ChiefExecutiveOfficerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=immu_RestrictedUnitsWithVestingMarketConditionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=immu_RestrictedUnitsWithVestingMarketConditionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=immu_GoldenbergAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=immu_GoldenbergAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_EmploymentContractsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_EmploymentContractsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_LitigationCaseAxis=immu_InsuranceCoverageArbitrationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_LitigationCaseAxis=immu_InsuranceCoverageArbitrationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=immu_TheScrippsResearchInstituteMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=immu_TheScrippsResearchInstituteMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>81
<FILENAME>R65.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
function toggleNextSibling (e) {
if (e.nextSibling.style.display=='none') {
e.nextSibling.style.display='block';
} else { e.nextSibling.style.display='none'; }
}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6721345584">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Quarterly Results of Operations (Details) - USD ($)<br> $ / shares in Units, shares in Thousands, $ in Thousands</strong></div></th>
<th class="th" colspan="8">3 Months Ended</th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Mar. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Sep. 30, 2018</div></th>
<th class="th"><div>Jun. 30, 2018</div></th>
<th class="th"><div>Mar. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Jun. 30, 2018</div></th>
<th class="th"><div>Jun. 30, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_immu_ConsolidatedStatementOfOperationsAbstract', window );"><strong>Consolidated Statements of Comprehensive Loss Data:</strong></a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">$ 295<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 387<span></span>
</td>
<td class="nump">$ 482<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 295<span></span>
</td>
<td class="nump">$ 2,156<span></span>
</td>
<td class="nump">$ 3,091<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss attributable to Immunomedics, Inc. stockholders</a></td>
<td class="num">$ (99,608)<span></span>
</td>
<td class="num">$ (94,292)<span></span>
</td>
<td class="num">$ (75,953)<span></span>
</td>
<td class="num">$ (87,337)<span></span>
</td>
<td class="num">$ (93,499)<span></span>
</td>
<td class="num">$ (64,169)<span></span>
</td>
<td class="num">$ (117,032)<span></span>
</td>
<td class="num">$ (35,546)<span></span>
</td>
<td class="num">$ (157,668)<span></span>
</td>
<td class="num">$ (357,190)<span></span>
</td>
<td class="num">$ (273,837)<span></span>
</td>
<td class="num">$ (153,206)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDiluted', window );">Loss per common share attributable to Immunomedics, Inc. stockholders (basic and diluted) (in USD per share)</a></td>
<td class="num">$ (0.50)<span></span>
</td>
<td class="num">$ (0.49)<span></span>
</td>
<td class="num">$ (0.40)<span></span>
</td>
<td class="num">$ (0.46)<span></span>
</td>
<td class="num">$ (0.50)<span></span>
</td>
<td class="num">$ (0.34)<span></span>
</td>
<td class="num">$ (0.68)<span></span>
</td>
<td class="num">$ (0.21)<span></span>
</td>
<td class="num">$ (0.84)<span></span>
</td>
<td class="num">$ (1.84)<span></span>
</td>
<td class="num">$ (1.78)<span></span>
</td>
<td class="num">$ (1.47)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted', window );">Weighted average shares used to calculate loss per common share (basic and diluted) (in shares)</a></td>
<td class="nump">199,614<span></span>
</td>
<td class="nump">191,981<span></span>
</td>
<td class="nump">191,745<span></span>
</td>
<td class="nump">191,052<span></span>
</td>
<td class="nump">190,171<span></span>
</td>
<td class="nump">186,937<span></span>
</td>
<td class="nump">171,124<span></span>
</td>
<td class="nump">166,054<span></span>
</td>
<td class="nump">188,554<span></span>
</td>
<td class="nump">193,617<span></span>
</td>
<td class="nump">153,475<span></span>
</td>
<td class="nump">104,536<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_immu_ConsolidatedStatementOfOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Consolidated Statement Of Operations [Abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">immu_ConsolidatedStatementOfOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>immu_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements. Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period. Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&oid=117326831&loc=d3e1337-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&oid=118930883&loc=SL7669619-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&oid=116637391&loc=SL114874048-224260<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&oid=118930883&loc=SL7669625-108580<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&oid=116637232&loc=SL114874131-224263<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3602-108585<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&oid=118956577&loc=SL49130543-203045<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&oid=118956577&loc=SL49130545-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>82
<FILENAME>immu201910-k_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
xmlns="http://www.xbrl.org/2003/instance"
xmlns:dei="http://xbrl.sec.gov/dei/2019-01-31"
xmlns:immu="http://www.immunomedics.com/20191231"
xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
xmlns:link="http://www.xbrl.org/2003/linkbase"
xmlns:srt="http://fasb.org/srt/2019-01-31"
xmlns:us-gaap="http://fasb.org/us-gaap/2019-01-31"
xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
xmlns:xlink="http://www.w3.org/1999/xlink"
xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<link:schemaRef xlink:href="immu-20191231.xsd" xlink:type="simple"/>
<context id="FD2019Q4YTD">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0000722830</identifier>
</entity>
<period>
<startDate>2019-01-01</startDate>
<endDate>2019-12-31</endDate>
</period>
</context>
<context id="I2020Q1SharesOutstanding">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0000722830</identifier>
</entity>
<period>
<instant>2020-02-21</instant>
</period>
</context>
<context id="FI2019Q2">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0000722830</identifier>
</entity>
<period>
<instant>2019-06-30</instant>
</period>
</context>
<context id="FI2018Q4">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0000722830</identifier>
</entity>
<period>
<instant>2018-12-31</instant>
</period>
</context>
<context id="FI2019Q4">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0000722830</identifier>
</entity>
<period>
<instant>2019-12-31</instant>
</period>
</context>
<context id="FI2018Q4_us-gaap_StatementClassOfStockAxis_us-gaap_ConvertiblePreferredStockMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0000722830</identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant>2018-12-31</instant>
</period>
</context>
<context id="FI2019Q4_us-gaap_StatementClassOfStockAxis_us-gaap_ConvertiblePreferredStockMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0000722830</identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant>2019-12-31</instant>
</period>
</context>
<context id="D2018Q4Jul01-Dec31">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0000722830</identifier>
</entity>
<period>
<startDate>2018-07-01</startDate>
<endDate>2018-12-31</endDate>
</period>
</context>
<context id="FD2019Q4YTD_srt_ProductOrServiceAxis_immu_ResearchandDevelopmentMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0000722830</identifier>
<segment>
<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">immu:ResearchandDevelopmentMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate>2019-01-01</startDate>
<endDate>2019-12-31</endDate>
</period>
</context>
<context id="FD2019Q4YTD_srt_ProductOrServiceAxis_immu_LicenseFreeAndOtherRevenueMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0000722830</identifier>
<segment>
<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">immu:LicenseFreeAndOtherRevenueMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate>2019-01-01</startDate>
<endDate>2019-12-31</endDate>
</period>
</context>
<context id="D2018Q4Jul12017toJun302018_srt_ProductOrServiceAxis_immu_ProductSalesMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0000722830</identifier>
<segment>
<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">immu:ProductSalesMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate>2017-07-01</startDate>
<endDate>2018-06-30</endDate>
</period>
</context>
<context id="D2018Q4Jul12017toJun302018">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0000722830</identifier>
</entity>
<period>
<startDate>2017-07-01</startDate>
<endDate>2018-06-30</endDate>
</period>
</context>
<context id="D2017Q4Jul012016toJun302017">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0000722830</identifier>
</entity>
<period>
<startDate>2016-07-01</startDate>
<endDate>2017-06-30</endDate>
</period>
</context>
<context id="D2018Q4Jul12017toJun302018_srt_ProductOrServiceAxis_immu_LicenseFreeAndOtherRevenueMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0000722830</identifier>
<segment>
<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">immu:LicenseFreeAndOtherRevenueMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate>2017-07-01</startDate>
<endDate>2018-06-30</endDate>
</period>
</context>
<context id="D2018Q4Jul01-Dec31_srt_ProductOrServiceAxis_immu_ProductSalesMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0000722830</identifier>
<segment>
<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">immu:ProductSalesMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate>2018-07-01</startDate>
<endDate>2018-12-31</endDate>
</period>
</context>
<context id="D2017Q4Jul012016toJun302017_srt_ProductOrServiceAxis_immu_ResearchandDevelopmentMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0000722830</identifier>
<segment>
<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">immu:ResearchandDevelopmentMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate>2016-07-01</startDate>
<endDate>2017-06-30</endDate>
</period>
</context>
<context id="D2017Q4Jul012016toJun302017_srt_ProductOrServiceAxis_immu_ProductSalesMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0000722830</identifier>
<segment>
<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">immu:ProductSalesMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate>2016-07-01</startDate>
<endDate>2017-06-30</endDate>
</period>
</context>
<context id="D2018Q4Jul01-Dec31_srt_ProductOrServiceAxis_immu_ResearchandDevelopmentMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0000722830</identifier>
<segment>
<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">immu:ResearchandDevelopmentMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate>2018-07-01</startDate>
<endDate>2018-12-31</endDate>
</period>
</context>
<context id="D2017Q4Jul012016toJun302017_srt_ProductOrServiceAxis_immu_LicenseFreeAndOtherRevenueMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0000722830</identifier>
<segment>
<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">immu:LicenseFreeAndOtherRevenueMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate>2016-07-01</startDate>
<endDate>2017-06-30</endDate>
</period>
</context>
<context id="D2018Q4Jul01-Dec31_srt_ProductOrServiceAxis_immu_LicenseFreeAndOtherRevenueMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0000722830</identifier>
<segment>
<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">immu:LicenseFreeAndOtherRevenueMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate>2018-07-01</startDate>
<endDate>2018-12-31</endDate>
</period>
</context>
<context id="FD2019Q4YTD_srt_ProductOrServiceAxis_immu_ProductSalesMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0000722830</identifier>
<segment>
<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">immu:ProductSalesMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate>2019-01-01</startDate>
<endDate>2019-12-31</endDate>
</period>
</context>
<context id="D2018Q4Jul12017toJun302018_srt_ProductOrServiceAxis_immu_ResearchandDevelopmentMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0000722830</identifier>
<segment>
<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">immu:ResearchandDevelopmentMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate>2017-07-01</startDate>
<endDate>2018-06-30</endDate>
</period>
</context>
<context id="D2018Q4Jul01-Dec31_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0000722830</identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate>2018-07-01</startDate>
<endDate>2018-12-31</endDate>
</period>
</context>
<context id="D2017Q4Jul012016toJun302017_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0000722830</identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate>2016-07-01</startDate>
<endDate>2017-06-30</endDate>
</period>
</context>
<context id="D2017Q4Jul012016toJun302017_srt_CounterpartyNameAxis_immu_SeattleGeneticsIncMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0000722830</identifier>
<segment>
<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">immu:SeattleGeneticsIncMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate>2016-07-01</startDate>
<endDate>2017-06-30</endDate>
</period>
</context>
<context id="FI2017Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0000722830</identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant>2017-06-30</instant>
</period>
</context>
<context id="D2017Q4Jul012016toJun302017_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0000722830</identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate>2016-07-01</startDate>
<endDate>2017-06-30</endDate>
</period>
</context>
<context id="FI2019Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0000722830</identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant>2019-12-31</instant>
</period>
</context>
<context id="FI2016Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0000722830</identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant>2016-06-30</instant>
</period>
</context>
<context id="D2018Q4Jul12017toJun302018_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0000722830</identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate>2017-07-01</startDate>
<endDate>2018-06-30</endDate>
</period>
</context>
<context id="FD2019Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0000722830</identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate>2019-01-01</startDate>
<endDate>2019-12-31</endDate>
</period>
</context>
<context id="FI2019Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0000722830</identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant>2019-12-31</instant>
</period>
</context>
<context id="D2018Q4Jul01-Dec31_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0000722830</identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate>2018-07-01</startDate>
<endDate>2018-12-31</endDate>
</period>
</context>
<context id="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0000722830</identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant>2018-12-31</instant>
</period>
</context>
<context id="D2018Q4Jul12017toJun302018_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0000722830</identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate>2017-07-01</startDate>
<endDate>2018-06-30</endDate>
</period>
</context>
<context id="FI2016Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0000722830</identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant>2016-06-30</instant>
</period>
</context>
<context id="D2017Q4Jul012016toJun302017_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0000722830</identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate>2016-07-01</startDate>
<endDate>2017-06-30</endDate>
</period>
</context>
<context id="D2018Q4Jul01-Dec31_srt_CounterpartyNameAxis_immu_RpiFinanceTrustMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0000722830</identifier>
<segment>
<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">immu:RpiFinanceTrustMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate>2018-07-01</startDate>
<endDate>2018-12-31</endDate>
</period>
</context>
<context id="FI2016Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0000722830</identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant>2016-06-30</instant>
</period>
</context>
<context id="FI2019Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0000722830</identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant>2019-12-31</instant>
</period>
</context>
<context id="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0000722830</identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant>2018-12-31</instant>
</period>
</context>
<context id="FI2018Q2_us-gaap_StatementClassOfStockAxis_us-gaap_ConvertiblePreferredStockMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0000722830</identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant>2018-06-30</instant>
</period>
</context>
<context id="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0000722830</identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant>2018-12-31</instant>
</period>
</context>
<context id="D2018Q4Jul12017toJun302018_us-gaap_StatementClassOfStockAxis_us-gaap_ConvertiblePreferredStockMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0000722830</identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate>2017-07-01</startDate>
<endDate>2018-06-30</endDate>
</period>
</context>
<context id="FD2019Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0000722830</identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate>2019-01-01</startDate>
<endDate>2019-12-31</endDate>
</period>
</context>
<context id="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0000722830</identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant>2018-12-31</instant>
</period>
</context>
<context id="D2018Q4Jul12017toJun302018_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0000722830</identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate>2017-07-01</startDate>
<endDate>2018-06-30</endDate>
</period>
</context>
<context id="FD2019Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0000722830</identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate>2019-01-01</startDate>
<endDate>2019-12-31</endDate>
</period>
</context>
<context id="D2018Q4Jul12017toJun302018_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0000722830</identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate>2017-07-01</startDate>
<endDate>2018-06-30</endDate>
</period>
</context>
<context id="FI2018Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0000722830</identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant>2018-06-30</instant>
</period>
</context>
<context id="D2017Q4Jul012016toJun302017_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0000722830</identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate>2016-07-01</startDate>
<endDate>2017-06-30</endDate>
</period>
</context>
<context id="FI2017Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0000722830</identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant>2017-06-30</instant>
</period>
</context>
<context id="FI2018Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0000722830</identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant>2018-06-30</instant>
</period>
</context>
<context id="FI2019Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0000722830</identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant>2019-12-31</instant>
</period>
</context>
<context id="FI2017Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0000722830</identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant>2017-06-30</instant>
</period>
</context>
<context id="FI2016Q4_us-gaap_StatementClassOfStockAxis_us-gaap_ConvertiblePreferredStockMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0000722830</identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant>2016-06-30</instant>
</period>
</context>
<context id="FI2017Q2">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0000722830</identifier>
</entity>
<period>
<instant>2017-06-30</instant>
</period>
</context>
<context id="FI2016Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0000722830</identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant>2016-06-30</instant>
</period>
</context>
<context id="D2017Q4Jul012016toJun302017_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0000722830</identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate>2016-07-01</startDate>
<endDate>2017-06-30</endDate>
</period>
</context>
<context id="D2017Q4Jul012016toJun302017_srt_CounterpartyNameAxis_immu_SeattleGeneticsIncMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0000722830</identifier>
<segment>
<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">immu:SeattleGeneticsIncMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate>2016-07-01</startDate>
<endDate>2017-06-30</endDate>
</period>
</context>
<context id="D2017Q4Jul012016toJun302017_srt_CounterpartyNameAxis_immu_SeattleGeneticsIncMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0000722830</identifier>
<segment>
<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">immu:SeattleGeneticsIncMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate>2016-07-01</startDate>
<endDate>2017-06-30</endDate>
</period>
</context>
<context id="FI2018Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0000722830</identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant>2018-06-30</instant>
</period>
</context>
<context id="FD2019Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0000722830</identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate>2019-01-01</startDate>
<endDate>2019-12-31</endDate>
</period>
</context>
<context id="FI2017Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0000722830</identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant>2017-06-30</instant>
</period>
</context>
<context id="FD2019Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_us-gaap_SubsidiarySaleOfStockAxis_immu_MarketOfferingMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0000722830</identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">immu:MarketOfferingMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate>2019-01-01</startDate>
<endDate>2019-12-31</endDate>
</period>
</context>
<context id="D2018Q4Jul01-Dec31_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0000722830</identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate>2018-07-01</startDate>
<endDate>2018-12-31</endDate>
</period>
</context>
<context id="FI2017Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0000722830</identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant>2017-06-30</instant>
</period>
</context>
<context id="FD2019Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0000722830</identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate>2019-01-01</startDate>
<endDate>2019-12-31</endDate>
</period>
</context>
<context id="D2018Q4Jul01-Dec31_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0000722830</identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate>2018-07-01</startDate>
<endDate>2018-12-31</endDate>
</period>
</context>
<context id="FI2017Q2_us-gaap_StatementClassOfStockAxis_us-gaap_ConvertiblePreferredStockMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0000722830</identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant>2017-06-30</instant>
</period>
</context>
<context id="D2018Q4Jul01-Dec31_srt_CounterpartyNameAxis_immu_RpiFinanceTrustMember_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0000722830</identifier>
<segment>
<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">immu:RpiFinanceTrustMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate>2018-07-01</startDate>
<endDate>2018-12-31</endDate>
</period>
</context>
<context id="D2018Q4Jul01-Dec31_srt_CounterpartyNameAxis_immu_RpiFinanceTrustMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0000722830</identifier>
<segment>
<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">immu:RpiFinanceTrustMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate>2018-07-01</startDate>
<endDate>2018-12-31</endDate>
</period>
</context>
<context id="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0000722830</identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant>2018-12-31</instant>
</period>
</context>
<context id="FD2019Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_us-gaap_SubsidiarySaleOfStockAxis_immu_MarketOfferingMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0000722830</identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">immu:MarketOfferingMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate>2019-01-01</startDate>
<endDate>2019-12-31</endDate>
</period>
</context>
<context id="D2018Q4Jul12017toJun302018_srt_CounterpartyNameAxis_immu_RpiFinanceTrustMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0000722830</identifier>
<segment>
<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">immu:RpiFinanceTrustMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate>2017-07-01</startDate>
<endDate>2018-06-30</endDate>
</period>
</context>
<context id="FD2019Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0000722830</identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate>2019-01-01</startDate>
<endDate>2019-12-31</endDate>
</period>
</context>
<context id="D2017Q4Jul012016toJun302017_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0000722830</identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate>2016-07-01</startDate>
<endDate>2017-06-30</endDate>
</period>
</context>
<context id="D2018Q4Jul01-Dec31_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0000722830</identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate>2018-07-01</startDate>
<endDate>2018-12-31</endDate>
</period>
</context>
<context id="D2017Q4Jul012016toJun302017_us-gaap_StatementClassOfStockAxis_us-gaap_ConvertiblePreferredStockMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0000722830</identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate>2016-07-01</startDate>
<endDate>2017-06-30</endDate>
</period>
</context>
<context id="FD2019Q4YTD_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0000722830</identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate>2019-01-01</startDate>
<endDate>2019-12-31</endDate>
</period>
</context>
<context id="FI2017Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0000722830</identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant>2017-06-30</instant>
</period>
</context>
<context id="FI2016Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0000722830</identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant>2016-06-30</instant>
</period>
</context>
<context id="D2018Q4Jul12017toJun302018_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0000722830</identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate>2017-07-01</startDate>
<endDate>2018-06-30</endDate>
</period>
</context>
<context id="FI2018Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0000722830</identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant>2018-06-30</instant>
</period>
</context>
<context id="D2017Q4Jul012016toJun302017_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0000722830</identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate>2016-07-01</startDate>
<endDate>2017-06-30</endDate>
</period>
</context>
<context id="D2018Q4Jul01-Dec31_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0000722830</identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate>2018-07-01</startDate>
<endDate>2018-12-31</endDate>
</period>
</context>
<context id="FI2018Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0000722830</identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant>2018-06-30</instant>
</period>
</context>
<context id="FD2019Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0000722830</identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate>2019-01-01</startDate>
<endDate>2019-12-31</endDate>
</period>
</context>
<context id="D2018Q4Jul12017toJun302018_srt_CounterpartyNameAxis_immu_RpiFinanceTrustMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0000722830</identifier>
<segment>
<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">immu:RpiFinanceTrustMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate>2017-07-01</startDate>
<endDate>2018-06-30</endDate>
</period>
</context>
<context id="FI2018Q2">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0000722830</identifier>
</entity>
<period>
<instant>2018-06-30</instant>
</period>
</context>
<context id="FD2019Q4YTD_us-gaap_SubsidiarySaleOfStockAxis_immu_MarketOfferingMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0000722830</identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">immu:MarketOfferingMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate>2019-01-01</startDate>
<endDate>2019-12-31</endDate>
</period>
</context>
<context id="D2018Q4Jul12017toJun302018_srt_CounterpartyNameAxis_immu_RpiFinanceTrustMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0000722830</identifier>
<segment>
<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">immu:RpiFinanceTrustMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate>2017-07-01</startDate>
<endDate>2018-06-30</endDate>
</period>
</context>
<context id="FI2018Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0000722830</identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant>2018-06-30</instant>
</period>
</context>
<context id="D2018Q4Jul01-Dec31_srt_CounterpartyNameAxis_immu_RpiFinanceTrustMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0000722830</identifier>
<segment>
<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">immu:RpiFinanceTrustMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate>2018-07-01</startDate>
<endDate>2018-12-31</endDate>
</period>
</context>
<context id="D2018Q4Jul12017toJun302018_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0000722830</identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate>2017-07-01</startDate>
<endDate>2018-06-30</endDate>
</period>
</context>
<context id="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0000722830</identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant>2018-12-31</instant>
</period>
</context>
<context id="D2017Q4Jul012016toJun302017_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0000722830</identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate>2016-07-01</startDate>
<endDate>2017-06-30</endDate>
</period>
</context>
<context id="D2018Q4Jul12017toJun302018_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0000722830</identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate>2017-07-01</startDate>
<endDate>2018-06-30</endDate>
</period>
</context>
<context id="FI2019Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0000722830</identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant>2019-12-31</instant>
</period>
</context>
<context id="FI2016Q4">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0000722830</identifier>
</entity>
<period>
<instant>2016-06-30</instant>
</period>
</context>
<context id="D2018Q4Jul12017toJun302018_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0000722830</identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate>2017-07-01</startDate>
<endDate>2018-06-30</endDate>
</period>
</context>
<context id="FI2019Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0000722830</identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant>2019-12-31</instant>
</period>
</context>
<context id="FI2016Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0000722830</identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant>2016-06-30</instant>
</period>
</context>
<context id="FD2019Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0000722830</identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate>2019-01-01</startDate>
<endDate>2019-12-31</endDate>
</period>
</context>
<context id="D2018Q4Jul12017toJun302018_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0000722830</identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate>2017-07-01</startDate>
<endDate>2018-06-30</endDate>
</period>
</context>
<context id="D2017Q4Jul012016toJun302017_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0000722830</identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate>2016-07-01</startDate>
<endDate>2017-06-30</endDate>
</period>
</context>
<context id="D2017Q4Jul012016toJun302017_us-gaap_SubsidiarySaleOfStockAxis_immu_MarketOfferingMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0000722830</identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">immu:MarketOfferingMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate>2016-07-01</startDate>
<endDate>2017-06-30</endDate>
</period>
</context>
<context id="D2018Q4Jul01-Dec31_us-gaap_SubsidiarySaleOfStockAxis_immu_MarketOfferingMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0000722830</identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">immu:MarketOfferingMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate>2018-07-01</startDate>
<endDate>2018-12-31</endDate>
</period>
</context>
<context id="D2018Q4Jul01-Dec31_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0000722830</identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate>2018-07-01</startDate>
<endDate>2018-12-31</endDate>
</period>
</context>
<context id="FD2019Q4YTD_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0000722830</identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate>2019-01-01</startDate>
<endDate>2019-12-31</endDate>
</period>
</context>
<context id="D2018Q4Jul12017toJun302018_us-gaap_SubsidiarySaleOfStockAxis_immu_MarketOfferingMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0000722830</identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">immu:MarketOfferingMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate>2017-07-01</startDate>
<endDate>2018-06-30</endDate>
</period>
</context>
<context id="I2019Q1Jan01_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201602Member">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0000722830</identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201602Member</xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant>2019-01-01</instant>
</period>
</context>
<context id="FD2019Q4YTD_srt_RangeAxis_srt_MaximumMember_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_LeaseholdImprovementsMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0000722830</identifier>
<segment>
<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate>2019-01-01</startDate>
<endDate>2019-12-31</endDate>
</period>
</context>
<context id="FD2019Q4YTD_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_ComputerEquipmentMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0000722830</identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate>2019-01-01</startDate>
<endDate>2019-12-31</endDate>
</period>
</context>
<context id="FD2019Q4YTD_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_FurnitureAndFixturesMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0000722830</identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate>2019-01-01</startDate>
<endDate>2019-12-31</endDate>
</period>
</context>
<context id="FD2019Q4YTD_srt_RangeAxis_srt_MinimumMember_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_MachineryAndEquipmentMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0000722830</identifier>
<segment>
<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:MachineryAndEquipmentMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate>2019-01-01</startDate>
<endDate>2019-12-31</endDate>
</period>
</context>
<context id="FD2019Q4YTD_srt_RangeAxis_srt_MinimumMember_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_LeaseholdImprovementsMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0000722830</identifier>
<segment>
<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate>2019-01-01</startDate>
<endDate>2019-12-31</endDate>
</period>
</context>
<context id="FD2019Q4YTD_srt_RangeAxis_srt_MaximumMember_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_MachineryAndEquipmentMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0000722830</identifier>
<segment>
<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:MachineryAndEquipmentMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate>2019-01-01</startDate>
<endDate>2019-12-31</endDate>
</period>
</context>
<context id="I2019Q2Apr29_srt_MajorCustomersAxis_immu_EverestMedicinesIILimitedMember_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain_2019-04-30">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0000722830</identifier>
<segment>
<xbrldi:explicitMember dimension="srt:MajorCustomersAxis">immu:EverestMedicinesIILimitedMember</xbrldi:explicitMember>
<xbrldi:typedMember dimension="us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis">
<us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain>2019-04-30</us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain>
</xbrldi:typedMember>
</segment>
</entity>
<period>
<instant>2019-04-29</instant>
</period>
</context>
<context id="D2019Q2Apr29_srt_MajorCustomersAxis_immu_EverestMedicinesIILimitedMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0000722830</identifier>
<segment>
<xbrldi:explicitMember dimension="srt:MajorCustomersAxis">immu:EverestMedicinesIILimitedMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate>2019-04-29</startDate>
<endDate>2019-04-29</endDate>
</period>
</context>
<context id="D2019Q2Apr29_srt_MajorCustomersAxis_immu_EverestMedicinesIILimitedMember_srt_RangeAxis_srt_MaximumMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0000722830</identifier>
<segment>
<xbrldi:explicitMember dimension="srt:MajorCustomersAxis">immu:EverestMedicinesIILimitedMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate>2019-04-29</startDate>
<endDate>2019-04-29</endDate>
</period>
</context>
<context id="I2019Q2Apr29_srt_MajorCustomersAxis_immu_EverestMedicinesIILimitedMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0000722830</identifier>
<segment>
<xbrldi:explicitMember dimension="srt:MajorCustomersAxis">immu:EverestMedicinesIILimitedMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant>2019-04-29</instant>
</period>
</context>
<context id="D2019Q1Apr5-Apr5_srt_MajorCustomersAxis_immu_JanssenBiotechIncMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0000722830</identifier>
<segment>
<xbrldi:explicitMember dimension="srt:MajorCustomersAxis">immu:JanssenBiotechIncMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate>2019-04-05</startDate>
<endDate>2019-04-05</endDate>
</period>
</context>
<context id="D2019Q2Apr29_srt_MajorCustomersAxis_immu_EverestMedicinesIILimitedMember_srt_RangeAxis_srt_MinimumMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0000722830</identifier>
<segment>
<xbrldi:explicitMember dimension="srt:MajorCustomersAxis">immu:EverestMedicinesIILimitedMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate>2019-04-29</startDate>
<endDate>2019-04-29</endDate>
</period>
</context>
<context id="FD2019Q4YTD_srt_MajorCustomersAxis_immu_JanssenBiotechIncMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0000722830</identifier>
<segment>
<xbrldi:explicitMember dimension="srt:MajorCustomersAxis">immu:JanssenBiotechIncMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate>2019-01-01</startDate>
<endDate>2019-12-31</endDate>
</period>
</context>
<context id="FI2018Q4_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0000722830</identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant>2018-12-31</instant>
</period>
</context>
<context id="FI2019Q4_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0000722830</identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant>2019-12-31</instant>
</period>
</context>
<context id="D2018Q3Jan07_srt_CounterpartyNameAxis_immu_RpiFinanceTrustMember_us-gaap_DeferredRevenueArrangementTypeAxis_us-gaap_RoyaltyArrangementMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0000722830</identifier>
<segment>
<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">immu:RpiFinanceTrustMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:DeferredRevenueArrangementTypeAxis">us-gaap:RoyaltyArrangementMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate>2018-01-07</startDate>
<endDate>2018-01-07</endDate>
</period>
</context>
<context id="FD2019Q4YTD_us-gaap_DebtInstrumentAxis_immu_FourPointSevenFivePercentConvertibleSeniorNotesMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0000722830</identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">immu:FourPointSevenFivePercentConvertibleSeniorNotesMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate>2019-01-01</startDate>
<endDate>2019-12-31</endDate>
</period>
</context>
<context id="D2019Q1Jan7">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0000722830</identifier>
</entity>
<period>
<startDate>2019-01-01</startDate>
<endDate>2019-01-01</endDate>
</period>
</context>
<context id="D2018Q4Jul12017toJun302018_us-gaap_DebtInstrumentAxis_immu_FourPointSevenFivePercentConvertibleSeniorNotesMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0000722830</identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">immu:FourPointSevenFivePercentConvertibleSeniorNotesMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate>2017-07-01</startDate>
<endDate>2018-06-30</endDate>
</period>
</context>
<context id="D2015Q3Feb01-Feb28_us-gaap_DebtInstrumentAxis_immu_FourPointSevenFivePercentConvertibleSeniorNotesMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0000722830</identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">immu:FourPointSevenFivePercentConvertibleSeniorNotesMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate>2015-02-01</startDate>
<endDate>2015-02-28</endDate>
</period>
</context>
<context id="D2020Q1Feb14-Feb14_us-gaap_DebtInstrumentAxis_immu_FourPointSevenFivePercentConvertibleSeniorNotesMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0000722830</identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">immu:FourPointSevenFivePercentConvertibleSeniorNotesMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate>2020-02-14</startDate>
<endDate>2020-02-14</endDate>
</period>
</context>
<context id="D2018Q1Sept21_us-gaap_DebtInstrumentAxis_immu_FourPointSevenFivePercentConvertibleSeniorNotesMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0000722830</identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">immu:FourPointSevenFivePercentConvertibleSeniorNotesMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate>2017-09-21</startDate>
<endDate>2017-09-21</endDate>
</period>
</context>
<context id="FI2019Q4_us-gaap_DebtInstrumentAxis_immu_FourPointSevenFivePercentConvertibleSeniorNotesMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0000722830</identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">immu:FourPointSevenFivePercentConvertibleSeniorNotesMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant>2019-12-31</instant>
</period>
</context>
<context id="I2020Q1Feb14_us-gaap_DebtInstrumentAxis_immu_FourPointSevenFivePercentConvertibleSeniorNotesMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0000722830</identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">immu:FourPointSevenFivePercentConvertibleSeniorNotesMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant>2020-02-14</instant>
</period>
</context>
<context id="D2018Q4Jul01-Dec31_us-gaap_DebtInstrumentAxis_immu_FourPointSevenFivePercentConvertibleSeniorNotesMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0000722830</identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">immu:FourPointSevenFivePercentConvertibleSeniorNotesMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate>2018-07-01</startDate>
<endDate>2018-12-31</endDate>
</period>
</context>
<context id="I2015Q3Feb28_us-gaap_DebtInstrumentAxis_immu_FourPointSevenFivePercentConvertibleSeniorNotesMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0000722830</identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">immu:FourPointSevenFivePercentConvertibleSeniorNotesMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant>2015-02-28</instant>
</period>
</context>
<context id="D2018Q4Oct02_us-gaap_DebtInstrumentAxis_immu_October2018ExchangeAgreementMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0000722830</identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">immu:October2018ExchangeAgreementMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate>2018-10-02</startDate>
<endDate>2018-10-02</endDate>
</period>
</context>
<context id="D2018Q4Oct02_us-gaap_DebtInstrumentAxis_immu_FourPointSevenFivePercentConvertibleSeniorNotesMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0000722830</identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">immu:FourPointSevenFivePercentConvertibleSeniorNotesMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate>2018-10-02</startDate>
<endDate>2018-10-02</endDate>
</period>
</context>
<context id="I2018Q3Jan07_srt_CounterpartyNameAxis_immu_RpiFinanceTrustMember_us-gaap_DeferredRevenueArrangementTypeAxis_us-gaap_RoyaltyArrangementMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0000722830</identifier>
<segment>
<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">immu:RpiFinanceTrustMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:DeferredRevenueArrangementTypeAxis">us-gaap:RoyaltyArrangementMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant>2018-01-07</instant>
</period>
</context>
<context id="FD2019Q4YTD_srt_CounterpartyNameAxis_immu_RpiFinanceTrustMember_us-gaap_DeferredRevenueArrangementTypeAxis_us-gaap_RoyaltyArrangementMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0000722830</identifier>
<segment>
<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">immu:RpiFinanceTrustMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:DeferredRevenueArrangementTypeAxis">us-gaap:RoyaltyArrangementMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate>2019-01-01</startDate>
<endDate>2019-12-31</endDate>
</period>
</context>
<context id="D2017Q4Jul012016toJun302017_us-gaap_DebtInstrumentAxis_immu_FourPointSevenFivePercentConvertibleSeniorNotesMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0000722830</identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">immu:FourPointSevenFivePercentConvertibleSeniorNotesMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate>2016-07-01</startDate>
<endDate>2017-06-30</endDate>
</period>
</context>
<context id="D2018Q3Jan07_srt_CounterpartyNameAxis_immu_RpiFinanceTrustMember_us-gaap_DeferredRevenueArrangementTypeAxis_us-gaap_RoyaltyArrangementMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0000722830</identifier>
<segment>
<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">immu:RpiFinanceTrustMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:DeferredRevenueArrangementTypeAxis">us-gaap:RoyaltyArrangementMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate>2018-01-07</startDate>
<endDate>2018-01-07</endDate>
</period>
</context>
<context id="D2018Q4Jul01-Dec31_srt_CounterpartyNameAxis_immu_RpiFinanceTrustMember_us-gaap_DeferredRevenueArrangementTypeAxis_us-gaap_RoyaltyArrangementMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0000722830</identifier>
<segment>
<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">immu:RpiFinanceTrustMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:DeferredRevenueArrangementTypeAxis">us-gaap:RoyaltyArrangementMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate>2018-07-01</startDate>
<endDate>2018-12-31</endDate>
</period>
</context>
<context id="D2018Q4Jul12017toJun302018_srt_CounterpartyNameAxis_immu_RpiFinanceTrustMember_us-gaap_DeferredRevenueArrangementTypeAxis_us-gaap_RoyaltyArrangementMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0000722830</identifier>
<segment>
<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">immu:RpiFinanceTrustMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:DeferredRevenueArrangementTypeAxis">us-gaap:RoyaltyArrangementMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate>2017-07-01</startDate>
<endDate>2018-06-30</endDate>
</period>
</context>
<context id="FI2018Q4_srt_CounterpartyNameAxis_immu_RpiFinanceTrustMember_us-gaap_DeferredRevenueArrangementTypeAxis_us-gaap_RoyaltyArrangementMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0000722830</identifier>
<segment>
<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">immu:RpiFinanceTrustMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:DeferredRevenueArrangementTypeAxis">us-gaap:RoyaltyArrangementMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant>2018-12-31</instant>
</period>
</context>
<context id="FI2018Q2_srt_CounterpartyNameAxis_immu_RpiFinanceTrustMember_us-gaap_DeferredRevenueArrangementTypeAxis_us-gaap_RoyaltyArrangementMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0000722830</identifier>
<segment>
<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">immu:RpiFinanceTrustMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:DeferredRevenueArrangementTypeAxis">us-gaap:RoyaltyArrangementMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant>2018-06-30</instant>
</period>
</context>
<context id="I2018Q3Jan07_srt_CounterpartyNameAxis_immu_RpiFinanceTrustMember_us-gaap_DeferredRevenueArrangementTypeAxis_us-gaap_RoyaltyArrangementMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0000722830</identifier>
<segment>
<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">immu:RpiFinanceTrustMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:DeferredRevenueArrangementTypeAxis">us-gaap:RoyaltyArrangementMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant>2018-01-07</instant>
</period>
</context>
<context id="D2018Q3Jan08-Jun30_srt_CounterpartyNameAxis_immu_RpiFinanceTrustMember_us-gaap_DeferredRevenueArrangementTypeAxis_us-gaap_RoyaltyArrangementMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0000722830</identifier>
<segment>
<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">immu:RpiFinanceTrustMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:DeferredRevenueArrangementTypeAxis">us-gaap:RoyaltyArrangementMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate>2018-01-08</startDate>
<endDate>2018-06-30</endDate>
</period>
</context>
<context id="FI2019Q4_srt_CounterpartyNameAxis_immu_RpiFinanceTrustMember_us-gaap_DeferredRevenueArrangementTypeAxis_us-gaap_RoyaltyArrangementMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0000722830</identifier>
<segment>
<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">immu:RpiFinanceTrustMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:DeferredRevenueArrangementTypeAxis">us-gaap:RoyaltyArrangementMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant>2019-12-31</instant>
</period>
</context>
<context id="FI2018Q2_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0000722830</identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant>2018-06-30</instant>
</period>
</context>
<context id="D2018Q4Jul01-Dec31_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0000722830</identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate>2018-07-01</startDate>
<endDate>2018-12-31</endDate>
</period>
</context>
<context id="FI2018Q4_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0000722830</identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant>2018-12-31</instant>
</period>
</context>
<context id="FD2019Q4YTD_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0000722830</identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate>2019-01-01</startDate>
<endDate>2019-12-31</endDate>
</period>
</context>
<context id="FI2019Q4_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0000722830</identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant>2019-12-31</instant>
</period>
</context>
<context id="FI2018Q4_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0000722830</identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant>2018-12-31</instant>
</period>
</context>
<context id="FD2018Q4YTD_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0000722830</identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate>2018-01-01</startDate>
<endDate>2018-12-31</endDate>
</period>
</context>
<context id="FI2018Q2_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0000722830</identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant>2018-06-30</instant>
</period>
</context>
<context id="D2018Q4Jul01-Dec31_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0000722830</identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate>2018-07-01</startDate>
<endDate>2018-12-31</endDate>
</period>
</context>
<context id="D2018Q4Jul12017toJun302018_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0000722830</identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate>2017-07-01</startDate>
<endDate>2018-06-30</endDate>
</period>
</context>
<context id="FD2019Q4YTD_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0000722830</identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate>2019-01-01</startDate>
<endDate>2019-12-31</endDate>
</period>
</context>
<context id="FI2019Q4_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0000722830</identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant>2019-12-31</instant>
</period>
</context>
<context id="D2017Q4Jul012016toJun302017_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0000722830</identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate>2016-07-01</startDate>
<endDate>2017-06-30</endDate>
</period>
</context>
<context id="D2018Q4Jul01-Dec31_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0000722830</identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate>2018-07-01</startDate>
<endDate>2018-12-31</endDate>
</period>
</context>
<context id="FD2019Q4YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0000722830</identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate>2019-01-01</startDate>
<endDate>2019-12-31</endDate>
</period>
</context>
<context id="D2018Q4Jul12017toJun302018_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0000722830</identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate>2017-07-01</startDate>
<endDate>2018-06-30</endDate>
</period>
</context>
<context id="FI2019Q4_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0000722830</identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant>2019-12-31</instant>
</period>
</context>
<context id="FD2018Q4YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0000722830</identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate>2018-01-01</startDate>
<endDate>2018-12-31</endDate>
</period>
</context>
<context id="FI2018Q4_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0000722830</identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant>2018-12-31</instant>
</period>
</context>
<context id="FI2018Q2_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0000722830</identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant>2018-06-30</instant>
</period>
</context>
<context id="D2018Q4Jul12017toJun302018_srt_RangeAxis_srt_MaximumMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0000722830</identifier>
<segment>
<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate>2017-07-01</startDate>
<endDate>2018-06-30</endDate>
</period>
</context>
<context id="D2017Q4Jul012016toJun302017_srt_RangeAxis_srt_MinimumMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0000722830</identifier>
<segment>
<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate>2016-07-01</startDate>
<endDate>2017-06-30</endDate>
</period>
</context>
<context id="D2018Q4Jul01-Dec31_srt_RangeAxis_srt_MaximumMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0000722830</identifier>
<segment>
<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate>2018-07-01</startDate>
<endDate>2018-12-31</endDate>
</period>
</context>
<context id="D2018Q4Jul12017toJun302018_srt_RangeAxis_srt_MinimumMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0000722830</identifier>
<segment>
<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate>2017-07-01</startDate>
<endDate>2018-06-30</endDate>
</period>
</context>
<context id="D2017Q4Jul012016toJun302017_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0000722830</identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate>2016-07-01</startDate>
<endDate>2017-06-30</endDate>
</period>
</context>
<context id="D2017Q4Jul012016toJun302017_srt_RangeAxis_srt_MaximumMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0000722830</identifier>
<segment>
<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate>2016-07-01</startDate>
<endDate>2017-06-30</endDate>
</period>
</context>
<context id="FD2019Q4YTD_srt_RangeAxis_srt_MaximumMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0000722830</identifier>
<segment>
<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate>2019-01-01</startDate>
<endDate>2019-12-31</endDate>
</period>
</context>
<context id="D2018Q4Jul01-Dec31_srt_RangeAxis_srt_MinimumMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0000722830</identifier>
<segment>
<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate>2018-07-01</startDate>
<endDate>2018-12-31</endDate>
</period>
</context>
<context id="FD2016Q4YTD_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0000722830</identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate>2015-07-01</startDate>
<endDate>2016-06-30</endDate>
</period>
</context>
<context id="FD2019Q4YTD_srt_RangeAxis_srt_MinimumMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0000722830</identifier>
<segment>
<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate>2019-01-01</startDate>
<endDate>2019-12-31</endDate>
</period>
</context>
<context id="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0000722830</identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant>2018-12-31</instant>
</period>
</context>
<context id="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FinancialInstrumentAxis_us-gaap_MoneyMarketFundsMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0000722830</identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant>2018-12-31</instant>
</period>
</context>
<context id="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0000722830</identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant>2018-12-31</instant>
</period>
</context>
<context id="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0000722830</identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant>2018-12-31</instant>
</period>
</context>
<context id="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FinancialInstrumentAxis_us-gaap_MoneyMarketFundsMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0000722830</identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant>2018-12-31</instant>
</period>
</context>
<context id="FI2018Q4_us-gaap_FinancialInstrumentAxis_us-gaap_MoneyMarketFundsMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0000722830</identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant>2018-12-31</instant>
</period>
</context>
<context id="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0000722830</identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant>2018-12-31</instant>
</period>
</context>
<context id="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FinancialInstrumentAxis_us-gaap_MoneyMarketFundsMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0000722830</identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant>2018-12-31</instant>
</period>
</context>
<context id="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0000722830</identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant>2018-12-31</instant>
</period>
</context>
<context id="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0000722830</identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant>2018-12-31</instant>
</period>
</context>
<context id="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FinancialInstrumentAxis_us-gaap_MoneyMarketFundsMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0000722830</identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant>2019-12-31</instant>
</period>
</context>
<context id="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FinancialInstrumentAxis_us-gaap_MoneyMarketFundsMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0000722830</identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant>2019-12-31</instant>
</period>
</context>
<context id="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FinancialInstrumentAxis_us-gaap_MoneyMarketFundsMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0000722830</identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant>2019-12-31</instant>
</period>
</context>
<context id="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0000722830</identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant>2019-12-31</instant>
</period>
</context>
<context id="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0000722830</identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant>2019-12-31</instant>
</period>
</context>
<context id="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0000722830</identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant>2019-12-31</instant>
</period>
</context>
<context id="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0000722830</identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant>2019-12-31</instant>
</period>
</context>
<context id="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0000722830</identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant>2019-12-31</instant>
</period>
</context>
<context id="FI2019Q4_us-gaap_FinancialInstrumentAxis_us-gaap_MoneyMarketFundsMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0000722830</identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant>2019-12-31</instant>
</period>
</context>
<context id="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0000722830</identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant>2019-12-31</instant>
</period>
</context>
<context id="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_EstimateOfFairValueFairValueDisclosureMember_us-gaap_LongtermDebtTypeAxis_us-gaap_SeniorNotesMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0000722830</identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant>2018-12-31</instant>
</period>
</context>
<context id="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_CarryingReportedAmountFairValueDisclosureMember_us-gaap_LongtermDebtTypeAxis_us-gaap_SeniorNotesMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0000722830</identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant>2018-12-31</instant>
</period>
</context>
<context id="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_EstimateOfFairValueFairValueDisclosureMember_us-gaap_LongtermDebtTypeAxis_us-gaap_SeniorNotesMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0000722830</identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant>2019-12-31</instant>
</period>
</context>
<context id="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_CarryingReportedAmountFairValueDisclosureMember_us-gaap_LongtermDebtTypeAxis_us-gaap_SeniorNotesMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0000722830</identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant>2019-12-31</instant>
</period>
</context>
<context id="FI2018Q4_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_MachineryAndEquipmentMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0000722830</identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:MachineryAndEquipmentMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant>2018-12-31</instant>
</period>
</context>
<context id="FI2019Q4_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_FurnitureAndFixturesMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0000722830</identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant>2019-12-31</instant>
</period>
</context>
<context id="FI2018Q4_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_ConstructionInProgressMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0000722830</identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant>2018-12-31</instant>
</period>
</context>
<context id="FI2018Q4_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_FurnitureAndFixturesMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0000722830</identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant>2018-12-31</instant>
</period>
</context>
<context id="FI2019Q4_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_LeaseholdImprovementsMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0000722830</identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant>2019-12-31</instant>
</period>
</context>
<context id="FI2019Q4_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_ComputerEquipmentMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0000722830</identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant>2019-12-31</instant>
</period>
</context>
<context id="FI2019Q4_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_ConstructionInProgressMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0000722830</identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant>2019-12-31</instant>
</period>
</context>
<context id="FI2018Q4_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_LeaseholdImprovementsMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0000722830</identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant>2018-12-31</instant>
</period>
</context>
<context id="FI2018Q4_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_ComputerEquipmentMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0000722830</identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant>2018-12-31</instant>
</period>
</context>
<context id="FI2019Q4_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_MachineryAndEquipmentMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0000722830</identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:MachineryAndEquipmentMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant>2019-12-31</instant>
</period>
</context>
<context id="I2017Q4May10_us-gaap_StatementClassOfStockAxis_us-gaap_ConvertiblePreferredStockMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0000722830</identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant>2017-05-10</instant>
</period>
</context>
<context id="D2019Q4Dec09-Dec09_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_OverAllotmentOptionMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0000722830</identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate>2019-12-09</startDate>
<endDate>2019-12-09</endDate>
</period>
</context>
<context id="I2017Q4June28">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0000722830</identifier>
</entity>
<period>
<instant>2017-06-28</instant>
</period>
</context>
<context id="D2018Q2Dec05_srt_CounterpartyNameAxis_immu_SeattleGeneticsIncMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0000722830</identifier>
<segment>
<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">immu:SeattleGeneticsIncMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate>2017-12-05</startDate>
<endDate>2017-12-05</endDate>
</period>
</context>
<context id="D2017Q4May10_us-gaap_StatementClassOfStockAxis_us-gaap_ConvertiblePreferredStockMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0000722830</identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate>2017-05-10</startDate>
<endDate>2017-05-10</endDate>
</period>
</context>
<context id="D2018Q2_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_OverAllotmentOptionMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0000722830</identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate>2018-06-15</startDate>
<endDate>2018-06-15</endDate>
</period>
</context>
<context id="I2017Q2Oct11_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0000722830</identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant>2016-10-11</instant>
</period>
</context>
<context id="D2019Q4Dec09-Dec09_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0000722830</identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate>2019-12-09</startDate>
<endDate>2019-12-09</endDate>
</period>
</context>
<context id="I2017Q4June29">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0000722830</identifier>
</entity>
<period>
<instant>2017-06-29</instant>
</period>
</context>
<context id="D2018Q2">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0000722830</identifier>
</entity>
<period>
<startDate>2018-06-15</startDate>
<endDate>2018-06-15</endDate>
</period>
</context>
<context id="D2018Q1July31_srt_CounterpartyNameAxis_immu_SeattleGeneticsIncMember_us-gaap_TypeOfArrangementAxis_immu_SecuritiesPurchaseAgreementMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0000722830</identifier>
<segment>
<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">immu:SeattleGeneticsIncMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">immu:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate>2017-07-31</startDate>
<endDate>2017-07-31</endDate>
</period>
</context>
<context id="I2017Q3Feb10_srt_CounterpartyNameAxis_immu_SeattleGeneticsIncMember_us-gaap_TypeOfArrangementAxis_immu_SecuritiesPurchaseAgreementMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0000722830</identifier>
<segment>
<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">immu:SeattleGeneticsIncMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">immu:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant>2017-02-10</instant>
</period>
</context>
<context id="FI2019Q4_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0000722830</identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant>2019-12-31</instant>
</period>
</context>
<context id="I2017Q1Jul31_srt_CounterpartyNameAxis_immu_SeattleGeneticsIncMember_us-gaap_TypeOfArrangementAxis_immu_SecuritiesPurchaseAgreementMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0000722830</identifier>
<segment>
<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">immu:SeattleGeneticsIncMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">immu:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant>2017-07-31</instant>
</period>
</context>
<context id="D2016Q1Oct11-Oct11_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0000722830</identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate>2016-10-11</startDate>
<endDate>2016-10-11</endDate>
</period>
</context>
<context id="I2017Q3Feb16_srt_CounterpartyNameAxis_immu_SeattleGeneticsIncMember_us-gaap_TypeOfArrangementAxis_immu_SecuritiesPurchaseAgreementMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0000722830</identifier>
<segment>
<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">immu:SeattleGeneticsIncMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">immu:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant>2017-02-16</instant>
</period>
</context>
<context id="FI2018Q4_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0000722830</identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant>2018-12-31</instant>
</period>
</context>
<context id="D2018Q1July31_us-gaap_StatementClassOfStockAxis_us-gaap_ConvertiblePreferredStockMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0000722830</identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate>2017-07-31</startDate>
<endDate>2017-07-31</endDate>
</period>
</context>
<context id="D2017Q3Feb10-Feb10_srt_CounterpartyNameAxis_immu_SeattleGeneticsIncMember_us-gaap_TypeOfArrangementAxis_immu_SecuritiesPurchaseAgreementMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0000722830</identifier>
<segment>
<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">immu:SeattleGeneticsIncMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">immu:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate>2017-02-10</startDate>
<endDate>2017-02-10</endDate>
</period>
</context>
<context id="I2018Q4_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0000722830</identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant>2018-06-15</instant>
</period>
</context>
<context id="I2019Q4Dec09_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0000722830</identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant>2019-12-09</instant>
</period>
</context>
<context id="D2018Q4Jul01-Dec31_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0000722830</identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate>2018-07-01</startDate>
<endDate>2018-12-31</endDate>
</period>
</context>
<context id="I2019Q1Mar29_us-gaap_SubsidiarySaleOfStockAxis_immu_ATMAgreementMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0000722830</identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">immu:ATMAgreementMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant>2019-03-29</instant>
</period>
</context>
<context id="D2018Q2_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0000722830</identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate>2018-06-15</startDate>
<endDate>2018-06-15</endDate>
</period>
</context>
<context id="FI2019Q4_srt_RangeAxis_srt_WeightedAverageMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0000722830</identifier>
<segment>
<xbrldi:explicitMember dimension="srt:RangeAxis">srt:WeightedAverageMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant>2019-12-31</instant>
</period>
</context>
<context id="D2019Q1Mar29-29_us-gaap_SubsidiarySaleOfStockAxis_immu_ATMAgreementMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0000722830</identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">immu:ATMAgreementMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate>2019-03-29</startDate>
<endDate>2019-03-29</endDate>
</period>
</context>
<context id="D2018Q4Jul12017toJun302018_us-gaap_FairValueByLiabilityClassAxis_us-gaap_WarrantMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0000722830</identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate>2017-07-01</startDate>
<endDate>2018-06-30</endDate>
</period>
</context>
<context id="I2017Q2Oct11_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember_us-gaap_TypeOfArrangementAxis_immu_SecuritiesPurchaseAgreementMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0000722830</identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">immu:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant>2016-10-11</instant>
</period>
</context>
<context id="D2019Q4Dec09-Dec09">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0000722830</identifier>
</entity>
<period>
<startDate>2019-12-09</startDate>
<endDate>2019-12-09</endDate>
</period>
</context>
<context id="I2018Q2Dec05_srt_CounterpartyNameAxis_immu_SeattleGeneticsIncMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0000722830</identifier>
<segment>
<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">immu:SeattleGeneticsIncMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant>2017-12-05</instant>
</period>
</context>
<context id="FD2019Q4YTD_us-gaap_SubsidiarySaleOfStockAxis_immu_ATMAgreementMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0000722830</identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">immu:ATMAgreementMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate>2019-01-01</startDate>
<endDate>2019-12-31</endDate>
</period>
</context>
<context id="FD2019Q4YTD_us-gaap_SubsidiarySaleOfStockAxis_immu_SalesAgreementMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0000722830</identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">immu:SalesAgreementMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate>2019-01-01</startDate>
<endDate>2019-12-31</endDate>
</period>
</context>
<context id="D2018Q4Jul12017toJun302018_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0000722830</identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate>2017-07-01</startDate>
<endDate>2018-06-30</endDate>
</period>
</context>
<context id="FD2019Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0000722830</identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate>2019-01-01</startDate>
<endDate>2019-12-31</endDate>
</period>
</context>
<context id="FD2019Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedTranslationAdjustmentMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0000722830</identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate>2019-01-01</startDate>
<endDate>2019-12-31</endDate>
</period>
</context>
<context id="D2018Q4Jul01-Dec31_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0000722830</identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate>2018-07-01</startDate>
<endDate>2018-12-31</endDate>
</period>
</context>
<context id="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0000722830</identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant>2018-12-31</instant>
</period>
</context>
<context id="FI2017Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedTranslationAdjustmentMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0000722830</identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant>2017-06-30</instant>
</period>
</context>
<context id="D2017Q4Jul012016toJun302017_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedTranslationAdjustmentMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0000722830</identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate>2016-07-01</startDate>
<endDate>2017-06-30</endDate>
</period>
</context>
<context id="D2018Q4Jul12017toJun302018_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedTranslationAdjustmentMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0000722830</identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate>2017-07-01</startDate>
<endDate>2018-06-30</endDate>
</period>
</context>
<context id="FI2019Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedTranslationAdjustmentMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0000722830</identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant>2019-12-31</instant>
</period>
</context>
<context id="D2018Q4Jul01-Dec31_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedTranslationAdjustmentMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0000722830</identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate>2018-07-01</startDate>
<endDate>2018-12-31</endDate>
</period>
</context>
<context id="D2017Q4Jul012016toJun302017_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0000722830</identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate>2016-07-01</startDate>
<endDate>2017-06-30</endDate>
</period>
</context>
<context id="FI2016Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0000722830</identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant>2016-06-30</instant>
</period>
</context>
<context id="FI2016Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedTranslationAdjustmentMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0000722830</identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant>2016-06-30</instant>
</period>
</context>
<context id="FI2017Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0000722830</identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant>2017-06-30</instant>
</period>
</context>
<context id="FI2018Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedTranslationAdjustmentMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0000722830</identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant>2018-06-30</instant>
</period>
</context>
<context id="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedTranslationAdjustmentMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0000722830</identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant>2018-12-31</instant>
</period>
</context>
<context id="FI2019Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0000722830</identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant>2019-12-31</instant>
</period>
</context>
<context id="FI2018Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0000722830</identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant>2018-06-30</instant>
</period>
</context>
<context id="FD2016Q4YTD">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0000722830</identifier>
</entity>
<period>
<startDate>2015-07-01</startDate>
<endDate>2016-06-30</endDate>
</period>
</context>
<context id="FI2019Q4_us-gaap_IncomeTaxAuthorityAxis_us-gaap_DomesticCountryMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0000722830</identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant>2019-12-31</instant>
</period>
</context>
<context id="FI2019Q4_us-gaap_IncomeTaxAuthorityAxis_us-gaap_StateAndLocalJurisdictionMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0000722830</identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant>2019-12-31</instant>
</period>
</context>
<context id="FI2018Q4_us-gaap_IncomeTaxAuthorityAxis_us-gaap_StateAndLocalJurisdictionMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0000722830</identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant>2018-12-31</instant>
</period>
</context>
<context id="FI2018Q4_us-gaap_IncomeTaxAuthorityAxis_us-gaap_DomesticCountryMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0000722830</identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant>2018-12-31</instant>
</period>
</context>
<context id="I2018Q1Jan06">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0000722830</identifier>
</entity>
<period>
<instant>2018-01-06</instant>
</period>
</context>
<context id="D2019Q4Nov19-Nov19_srt_TitleOfIndividualAxis_srt_BoardOfDirectorsChairmanMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0000722830</identifier>
<segment>
<xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:BoardOfDirectorsChairmanMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate>2019-11-19</startDate>
<endDate>2019-11-19</endDate>
</period>
</context>
<context id="D2019Q1Mar5-Mar5_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_srt_DirectorMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0000722830</identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:DirectorMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate>2019-03-05</startDate>
<endDate>2019-03-05</endDate>
</period>
</context>
<context id="D2018Q3Jan08-Jun30_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_immu_MRosenbergBioPharmaConsultingLlcMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0000722830</identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">immu:MRosenbergBioPharmaConsultingLlcMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate>2018-01-08</startDate>
<endDate>2018-06-30</endDate>
</period>
</context>
<context id="FD2019Q4YTD_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_srt_DirectorMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0000722830</identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:DirectorMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate>2019-01-01</startDate>
<endDate>2019-12-31</endDate>
</period>
</context>
<context id="D2018Q3May05-Jan06_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_immu_MRosenbergBioPharmaConsultingLlcMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0000722830</identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">immu:MRosenbergBioPharmaConsultingLlcMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate>2017-05-05</startDate>
<endDate>2018-01-06</endDate>
</period>
</context>
<context id="D2019Q1Mar5-Mar5_srt_TitleOfIndividualAxis_immu_ExecutiveDirectorMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0000722830</identifier>
<segment>
<xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">immu:ExecutiveDirectorMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate>2019-03-05</startDate>
<endDate>2019-03-05</endDate>
</period>
</context>
<context id="D2018Q4Jul01-Dec31_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_immu_MRosenbergBioPharmaConsultingLlcMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0000722830</identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">immu:MRosenbergBioPharmaConsultingLlcMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate>2018-07-01</startDate>
<endDate>2018-12-31</endDate>
</period>
</context>
<context id="D2018Q3Jan08-Jun30_srt_TitleOfIndividualAxis_immu_ChiefTechnologyOfficerMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0000722830</identifier>
<segment>
<xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">immu:ChiefTechnologyOfficerMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate>2018-01-08</startDate>
<endDate>2018-06-30</endDate>
</period>
</context>
<context id="D2018Q3Jan08-Jun30">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0000722830</identifier>
</entity>
<period>
<startDate>2018-01-08</startDate>
<endDate>2018-06-30</endDate>
</period>
</context>
<context id="FD2019Q4YTD_srt_TitleOfIndividualAxis_immu_ExecutiveDirectorMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0000722830</identifier>
<segment>
<xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">immu:ExecutiveDirectorMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate>2019-01-01</startDate>
<endDate>2019-12-31</endDate>
</period>
</context>
<context id="D2018Q3May05-Jan06_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_immu_MRosenbergBioPharmaConsultingLlcMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0000722830</identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">immu:MRosenbergBioPharmaConsultingLlcMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate>2017-05-05</startDate>
<endDate>2018-01-06</endDate>
</period>
</context>
<context id="FD2019Q4YTD_immu_CollaborationAgreementAxis_immu_CBGForschungsGmbHMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0000722830</identifier>
<segment>
<xbrldi:explicitMember dimension="immu:CollaborationAgreementAxis">immu:CBGForschungsGmbHMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate>2019-01-01</startDate>
<endDate>2019-12-31</endDate>
</period>
</context>
<context id="D2018Q2Apr04-Apr04_srt_CounterpartyNameAxis_immu_TheScrippsResearchInstituteMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0000722830</identifier>
<segment>
<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">immu:TheScrippsResearchInstituteMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate>2018-04-04</startDate>
<endDate>2018-04-04</endDate>
</period>
</context>
<context id="FD2019Q4YTD_srt_LitigationCaseAxis_immu_InsuranceCoverageArbitrationMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0000722830</identifier>
<segment>
<xbrldi:explicitMember dimension="srt:LitigationCaseAxis">immu:InsuranceCoverageArbitrationMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate>2019-01-01</startDate>
<endDate>2019-12-31</endDate>
</period>
</context>
<context id="D2018Q2Apr04-Apr04">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0000722830</identifier>
</entity>
<period>
<startDate>2018-04-04</startDate>
<endDate>2018-04-04</endDate>
</period>
</context>
<context id="D2019Q1Jan015_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_EmploymentContractsMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_immu_GoldenbergAgreementMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0000722830</identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:EmploymentContractsMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">immu:GoldenbergAgreementMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate>2019-01-15</startDate>
<endDate>2019-01-15</endDate>
</period>
</context>
<context id="FD2019Q4YTD_srt_TitleOfIndividualAxis_srt_ChiefExecutiveOfficerMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0000722830</identifier>
<segment>
<xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate>2019-01-01</startDate>
<endDate>2019-12-31</endDate>
</period>
</context>
<context id="D2019Q1Jan015_us-gaap_AwardTypeAxis_immu_RestrictedUnitsWithVestingMarketConditionsMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_immu_GoldenbergAgreementMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0000722830</identifier>
<segment>
<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">immu:RestrictedUnitsWithVestingMarketConditionsMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">immu:GoldenbergAgreementMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate>2019-01-15</startDate>
<endDate>2019-01-15</endDate>
</period>
</context>
<context id="I2019Q1Mar13_srt_TitleOfIndividualAxis_srt_ChiefExecutiveOfficerMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0000722830</identifier>
<segment>
<xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant>2019-03-13</instant>
</period>
</context>
<context id="FD2019Q4YTD_srt_CounterpartyNameAxis_immu_TheScrippsResearchInstituteMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0000722830</identifier>
<segment>
<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">immu:TheScrippsResearchInstituteMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<startDate>2019-01-01</startDate>
<endDate>2019-12-31</endDate>
</period>
</context>
<context id="FI2019Q4_srt_TitleOfIndividualAxis_srt_ChiefExecutiveOfficerMember">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0000722830</identifier>
<segment>
<xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember>
</segment>
</entity>
<period>
<instant>2019-12-31</instant>
</period>
</context>
<context id="FD2019Q2QTD">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0000722830</identifier>
</entity>
<period>
<startDate>2019-04-01</startDate>
<endDate>2019-06-30</endDate>
</period>
</context>
<context id="FD2019Q3QTD">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0000722830</identifier>
</entity>
<period>
<startDate>2019-07-01</startDate>
<endDate>2019-09-30</endDate>
</period>
</context>
<context id="FD2019Q4QTD">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0000722830</identifier>
</entity>
<period>
<startDate>2019-10-01</startDate>
<endDate>2019-12-31</endDate>
</period>
</context>
<context id="FD2019Q1QTD">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0000722830</identifier>
</entity>
<period>
<startDate>2019-01-01</startDate>
<endDate>2019-03-31</endDate>
</period>
</context>
<context id="FD2018Q3QTD">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0000722830</identifier>
</entity>
<period>
<startDate>2018-07-01</startDate>
<endDate>2018-09-30</endDate>
</period>
</context>
<context id="FD2018Q4QTD">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0000722830</identifier>
</entity>
<period>
<startDate>2018-10-01</startDate>
<endDate>2018-12-31</endDate>
</period>
</context>
<context id="FD2018Q1QTD">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0000722830</identifier>
</entity>
<period>
<startDate>2018-01-01</startDate>
<endDate>2018-03-31</endDate>
</period>
</context>
<context id="FD2018Q2QTD">
<entity>
<identifier scheme="http://www.sec.gov/CIK">0000722830</identifier>
</entity>
<period>
<startDate>2018-04-01</startDate>
<endDate>2018-06-30</endDate>
</period>
</context>
<unit id="usdPerShare">
<divide>
<unitNumerator>
<measure>iso4217:USD</measure>
</unitNumerator>
<unitDenominator>
<measure>shares</measure>
</unitDenominator>
</divide>
</unit>
<unit id="usd">
<measure>iso4217:USD</measure>
</unit>
<unit id="shares">
<measure>shares</measure>
</unit>
<unit id="number">
<measure>pure</measure>
</unit>
<unit id="eur">
<measure>iso4217:EUR</measure>
</unit>
<unit id="patient">
<measure>immu:patient</measure>
</unit>
<dei:AmendmentFlag
contextRef="FD2019Q4YTD"
id="Fact-A7ED97D1522841A5D150D1D0180BC50D-wk-Fact-A7ED97D1522841A5D150D1D0180BC50D">false</dei:AmendmentFlag>
<dei:CurrentFiscalYearEndDate
contextRef="FD2019Q4YTD"
id="Fact-6D26DEC0D558C2419AAAD1D0182AA2F8-wk-Fact-6D26DEC0D558C2419AAAD1D0182AA2F8">--12-31</dei:CurrentFiscalYearEndDate>
<dei:DocumentFiscalPeriodFocus
contextRef="FD2019Q4YTD"
id="Fact-34211CACF3D3AE7AFCAED1D0182ADA02-wk-Fact-34211CACF3D3AE7AFCAED1D0182ADA02">FY</dei:DocumentFiscalPeriodFocus>
<dei:DocumentFiscalYearFocus
contextRef="FD2019Q4YTD"
id="Fact-61FC478C35788B3FF839D1D0183CD355-wk-Fact-61FC478C35788B3FF839D1D0183CD355">2019</dei:DocumentFiscalYearFocus>
<dei:EntityCentralIndexKey
contextRef="FD2019Q4YTD"
id="Fact-5178AE335880E3EBF516D1D0181BF030-wk-Fact-5178AE335880E3EBF516D1D0181BF030">0000722830</dei:EntityCentralIndexKey>
<immu:LiabilitiesRelatedToTheSaleOfFutureRoyaltiesCurrent
contextRef="FI2019Q4_srt_CounterpartyNameAxis_immu_RpiFinanceTrustMember_us-gaap_DeferredRevenueArrangementTypeAxis_us-gaap_RoyaltyArrangementMember"
decimals="-3"
id="Fact-39ECAF244C156AB47C9179F5015E81CE-wk-Fact-39ECAF244C156AB47C9179F5015E81CE"
unitRef="usd">3455000</immu:LiabilitiesRelatedToTheSaleOfFutureRoyaltiesCurrent>
<immu:OperatingLossCarryforwardResultingFromSale
contextRef="D2017Q4Jul012016toJun302017"
decimals="-3"
id="Fact-D4FFF04AA2D0FAACC69CD1D0180B787C-wk-Fact-D4FFF04AA2D0FAACC69CD1D0180B787C"
unitRef="usd">0</immu:OperatingLossCarryforwardResultingFromSale>
<immu:OperatingLossCarryforwardResultingFromSale
contextRef="D2018Q4Jul01-Dec31"
decimals="-3"
id="Fact-57923928CEC3D2FA06FDD1D0180BCB12-wk-Fact-57923928CEC3D2FA06FDD1D0180BCB12"
unitRef="usd">0</immu:OperatingLossCarryforwardResultingFromSale>
<immu:SupplementalUnemploymentBenefitsSeveranceBenefitsPaymentTerm
contextRef="FD2019Q4YTD_srt_TitleOfIndividualAxis_srt_ChiefExecutiveOfficerMember"
id="Fact-2AFBE0F36BDB270D9B2E7D11E460BCF3-wk-Fact-2AFBE0F36BDB270D9B2E7D11E460BCF3">P18M</immu:SupplementalUnemploymentBenefitsSeveranceBenefitsPaymentTerm>
<us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent
contextRef="FI2019Q4"
decimals="-3"
id="Fact-F22614965E2A8C15D444D705B07F4628-wk-Fact-F22614965E2A8C15D444D705B07F4628"
unitRef="usd">0</us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent>
<us-gaap:CommonStockParOrStatedValuePerShare
contextRef="FI2018Q4"
decimals="INF"
id="Fact-72A1C5BDA1F915B4856BD1D0184BB1F5-wk-Fact-72A1C5BDA1F915B4856BD1D0184BB1F5"
unitRef="usdPerShare">0.01</us-gaap:CommonStockParOrStatedValuePerShare>
<us-gaap:CommonStockParOrStatedValuePerShare
contextRef="FI2019Q4"
decimals="INF"
id="Fact-B296A6C9EE4BAE19647ED1D0184BADAE-wk-Fact-B296A6C9EE4BAE19647ED1D0184BADAE"
unitRef="usdPerShare">0.01</us-gaap:CommonStockParOrStatedValuePerShare>
<us-gaap:CommonStockSharesAuthorized
contextRef="FI2018Q4"
decimals="INF"
id="Fact-07FCE8C270B3BDB90324D1D0184BCE6A-wk-Fact-07FCE8C270B3BDB90324D1D0184BCE6A"
unitRef="shares">250000000</us-gaap:CommonStockSharesAuthorized>
<us-gaap:CommonStockSharesAuthorized
contextRef="FI2019Q4"
decimals="INF"
id="Fact-07E34C26D1D09BC194A7D1D0184BEC81-wk-Fact-07E34C26D1D09BC194A7D1D0184BEC81"
unitRef="shares">250000000</us-gaap:CommonStockSharesAuthorized>
<us-gaap:CommonStockSharesIssued
contextRef="FI2018Q4"
decimals="INF"
id="Fact-6F0B1B4EAE9E268D14D4D1D0184B55F2-wk-Fact-6F0B1B4EAE9E268D14D4D1D0184B55F2"
unitRef="shares">190445795</us-gaap:CommonStockSharesIssued>
<us-gaap:CommonStockSharesIssued
contextRef="FI2019Q4"
decimals="INF"
id="Fact-082991A6B0F12CC2258FD1D0184B7DE9-wk-Fact-082991A6B0F12CC2258FD1D0184B7DE9"
unitRef="shares">212529313</us-gaap:CommonStockSharesIssued>
<us-gaap:CommonStockSharesOutstanding
contextRef="FI2018Q4"
decimals="INF"
id="Fact-352369FBB236E3001FABD1D0184BD16E-wk-Fact-352369FBB236E3001FABD1D0184BD16E"
unitRef="shares">190411070</us-gaap:CommonStockSharesOutstanding>
<us-gaap:CommonStockSharesOutstanding
contextRef="FI2019Q4"
decimals="INF"
id="Fact-16ECE8B36A54E6116210D1D0184BD7C9-wk-Fact-16ECE8B36A54E6116210D1D0184BD7C9"
unitRef="shares">212409692</us-gaap:CommonStockSharesOutstanding>
<us-gaap:DebtInstrumentTerm
contextRef="D2017Q3Feb10-Feb10_srt_CounterpartyNameAxis_immu_SeattleGeneticsIncMember_us-gaap_TypeOfArrangementAxis_immu_SecuritiesPurchaseAgreementMember"
id="Fact-BE9B8FFC929585B1D7CA454A8E13CBDA-wk-Fact-BE9B8FFC929585B1D7CA454A8E13CBDA">P3Y</us-gaap:DebtInstrumentTerm>
<us-gaap:DefinedBenefitPlanContributionsByEmployer
contextRef="D2017Q4Jul012016toJun302017"
decimals="-5"
id="Fact-5CBE9B8D3ABAB124085E63716174017B-wk-Fact-5CBE9B8D3ABAB124085E63716174017B"
unitRef="usd">100000</us-gaap:DefinedBenefitPlanContributionsByEmployer>
<us-gaap:DefinedBenefitPlanContributionsByEmployer
contextRef="D2018Q4Jul12017toJun302018"
decimals="-5"
id="Fact-CE1461802A0C335E9D3D63715629B431-wk-Fact-CE1461802A0C335E9D3D63715629B431"
unitRef="usd">100000</us-gaap:DefinedBenefitPlanContributionsByEmployer>
<us-gaap:PreferredStockParOrStatedValuePerShare
contextRef="FI2018Q4_us-gaap_StatementClassOfStockAxis_us-gaap_ConvertiblePreferredStockMember"
decimals="INF"
id="Fact-3404D2B2E98069147F8CD1D0184BFDB1-wk-Fact-3404D2B2E98069147F8CD1D0184BFDB1"
unitRef="usdPerShare">0.01</us-gaap:PreferredStockParOrStatedValuePerShare>
<us-gaap:PreferredStockParOrStatedValuePerShare
contextRef="FI2019Q4_us-gaap_StatementClassOfStockAxis_us-gaap_ConvertiblePreferredStockMember"
decimals="INF"
id="Fact-647522B2D6A369FBC5DDD1D0184BD8B1-wk-Fact-647522B2D6A369FBC5DDD1D0184BD8B1"
unitRef="usdPerShare">0.01</us-gaap:PreferredStockParOrStatedValuePerShare>
<us-gaap:PreferredStockSharesAuthorized
contextRef="FI2018Q4_us-gaap_StatementClassOfStockAxis_us-gaap_ConvertiblePreferredStockMember"
decimals="INF"
id="Fact-872AACA4AA08EDB0198ED1D0184B41D4-wk-Fact-872AACA4AA08EDB0198ED1D0184B41D4"
unitRef="shares">10000000</us-gaap:PreferredStockSharesAuthorized>
<us-gaap:PreferredStockSharesAuthorized
contextRef="FI2019Q4_us-gaap_StatementClassOfStockAxis_us-gaap_ConvertiblePreferredStockMember"
decimals="INF"
id="Fact-23A5205ADADE42E75B15D1D0184B2452-wk-Fact-23A5205ADADE42E75B15D1D0184B2452"
unitRef="shares">10000000</us-gaap:PreferredStockSharesAuthorized>
<us-gaap:PreferredStockSharesIssued
contextRef="FI2018Q4_us-gaap_StatementClassOfStockAxis_us-gaap_ConvertiblePreferredStockMember"
decimals="INF"
id="Fact-CBEC72BB42FF73F5F8A1D704C1894CCA-wk-Fact-CBEC72BB42FF73F5F8A1D704C1894CCA"
unitRef="shares">0</us-gaap:PreferredStockSharesIssued>
<us-gaap:PreferredStockSharesIssued
contextRef="FI2019Q4_us-gaap_StatementClassOfStockAxis_us-gaap_ConvertiblePreferredStockMember"
decimals="INF"
id="Fact-CA34D697574D6AC492CAD704C160E73D-wk-Fact-CA34D697574D6AC492CAD704C160E73D"
unitRef="shares">0</us-gaap:PreferredStockSharesIssued>
<us-gaap:PreferredStockSharesOutstanding
contextRef="FI2018Q4_us-gaap_StatementClassOfStockAxis_us-gaap_ConvertiblePreferredStockMember"
decimals="INF"
id="Fact-5F6B7F3669A30E367ABCD704D7B0FE5B-wk-Fact-5F6B7F3669A30E367ABCD704D7B0FE5B"
unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
<us-gaap:PreferredStockSharesOutstanding
contextRef="FI2019Q4_us-gaap_StatementClassOfStockAxis_us-gaap_ConvertiblePreferredStockMember"
decimals="INF"
id="Fact-180D1B7715506AE0A952D704D7B07073-wk-Fact-180D1B7715506AE0A952D704D7B07073"
unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
contextRef="D2017Q4Jul012016toJun302017_srt_RangeAxis_srt_MaximumMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember"
decimals="4"
id="Fact-F04A0F79EE45EBF5D04CD1D0181BDBA0-wk-Fact-F04A0F79EE45EBF5D04CD1D0181BDBA0"
unitRef="number">0.0215</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
contextRef="D2017Q4Jul012016toJun302017_srt_RangeAxis_srt_MinimumMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember"
decimals="4"
id="Fact-A9D5BFA60F5C865B14CDD1D0181B6103-wk-Fact-A9D5BFA60F5C865B14CDD1D0181B6103"
unitRef="number">0.0116</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
contextRef="D2018Q4Jul01-Dec31_srt_RangeAxis_srt_MaximumMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember"
decimals="4"
id="Fact-5CE7C6AED3E35887862ED1D0182A4C71-wk-Fact-5CE7C6AED3E35887862ED1D0182A4C71"
unitRef="number">0.0306</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
contextRef="D2018Q4Jul01-Dec31_srt_RangeAxis_srt_MinimumMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember"
decimals="4"
id="Fact-CD5262D1B993A1AEC157D1D0181B1C0F-wk-Fact-CD5262D1B993A1AEC157D1D0181B1C0F"
unitRef="number">0.0269</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
contextRef="D2018Q4Jul12017toJun302018_srt_RangeAxis_srt_MaximumMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember"
decimals="4"
id="Fact-08CF791FF5DE3B4673F6D1D0181B9D67-wk-Fact-08CF791FF5DE3B4673F6D1D0181B9D67"
unitRef="number">0.0289</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
contextRef="D2018Q4Jul12017toJun302018_srt_RangeAxis_srt_MinimumMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember"
decimals="4"
id="Fact-29339EDF21FB4F9C3678D1D0181B2FC7-wk-Fact-29339EDF21FB4F9C3678D1D0181B2FC7"
unitRef="number">0.0172</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
contextRef="FD2019Q4YTD_srt_RangeAxis_srt_MaximumMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember"
decimals="4"
id="Fact-C4487818F169E75E5052D1D0180BC5A7-wk-Fact-C4487818F169E75E5052D1D0180BC5A7"
unitRef="number">0.0258</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
contextRef="FD2019Q4YTD_srt_RangeAxis_srt_MinimumMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember"
decimals="4"
id="Fact-85F70D3379BD181B66F2D1D0181BCC77-wk-Fact-85F70D3379BD181B66F2D1D0181BCC77"
unitRef="number">0.0139</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
contextRef="D2017Q4Jul012016toJun302017_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember"
decimals="INF"
id="Fact-15EB1D31C1405747630ED1D0182A4F45-wk-Fact-15EB1D31C1405747630ED1D0182A4F45"
unitRef="shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
contextRef="FD2016Q4YTD_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember"
decimals="INF"
id="Fact-0BFF1F8D7CCB6AF211D6D1D0182A6F87-wk-Fact-0BFF1F8D7CCB6AF211D6D1D0182A6F87"
unitRef="shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod
contextRef="FD2019Q4YTD_srt_TitleOfIndividualAxis_immu_ExecutiveDirectorMember"
id="Fact-3A2872FE26E015689271454D4CF53C5B-wk-Fact-3A2872FE26E015689271454D4CF53C5B">P7Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
<us-gaap:TreasuryStockShares
contextRef="FI2018Q4"
decimals="INF"
id="Fact-7A32521110195736DBB1D1D0184B9B9A-wk-Fact-7A32521110195736DBB1D1D0184B9B9A"
unitRef="shares">34725</us-gaap:TreasuryStockShares>
<us-gaap:TreasuryStockShares
contextRef="FI2019Q4"
decimals="INF"
id="Fact-0F5FE4FA3BFAAF62BA34D1D0184B7AE2-wk-Fact-0F5FE4FA3BFAAF62BA34D1D0184B7AE2"
unitRef="shares">119621</us-gaap:TreasuryStockShares>
<us-gaap:UndistributedEarningsOfForeignSubsidiaries
contextRef="FI2018Q4"
decimals="INF"
id="Fact-4F75A8AB5D78ADF4FD5CD1D0181B2B8E-wk-Fact-4F75A8AB5D78ADF4FD5CD1D0181B2B8E"
unitRef="usd">0</us-gaap:UndistributedEarningsOfForeignSubsidiaries>
<dei:DocumentType
contextRef="FD2019Q4YTD"
id="d22891554e658-wk-Fact-8D880E696AF074AECB18D1D0183C4FFD">10-K</dei:DocumentType>
<dei:DocumentAnnualReport
contextRef="FD2019Q4YTD"
id="d22891554e664-wk-Fact-E8F3E2EFF3D2176ED5B0D1D0184BE6D0">true</dei:DocumentAnnualReport>
<dei:DocumentPeriodEndDate
contextRef="FD2019Q4YTD"
id="d22891554e677-wk-Fact-F43B970BBDC8137EBCFCD1D01865A1CE">2019-12-31</dei:DocumentPeriodEndDate>
<dei:DocumentTransitionReport
contextRef="FD2019Q4YTD"
id="d22891554e684-wk-Fact-39CA96C5C50B426B4792D1D0180B050E">false</dei:DocumentTransitionReport>
<dei:EntityFileNumber
contextRef="FD2019Q4YTD"
id="d22891554e707-wk-Fact-9E00E8740D5527690EABD1D0181B88C3">0-12104</dei:EntityFileNumber>
<dei:EntityRegistrantName
contextRef="FD2019Q4YTD"
id="d22891554e723-wk-Fact-924FBFFC01ED5426B20FD1D0185BC3D3">IMMUNOMEDICS, INC.</dei:EntityRegistrantName>
<dei:EntityIncorporationStateCountryCode
contextRef="FD2019Q4YTD"
id="d22891554e743-wk-Fact-E8897AE4B1A115298312D1D0183C85C8">DE</dei:EntityIncorporationStateCountryCode>
<dei:EntityTaxIdentificationNumber
contextRef="FD2019Q4YTD"
id="d22891554e748-wk-Fact-81EFE41CF3E73B7B57D0D1D0181BDB67">61-1009366</dei:EntityTaxIdentificationNumber>
<dei:EntityAddressAddressLine1
contextRef="FD2019Q4YTD"
id="d22891554e765-wk-Fact-6F31DAEAAFD9B8F2AE66D1D0185B493E">300 The American Road</dei:EntityAddressAddressLine1>
<dei:EntityAddressCityOrTown
contextRef="FD2019Q4YTD"
id="d22891554e770-wk-Fact-CEE899471446EB3A86C7D1D0184A3DEE">Morris Plains,</dei:EntityAddressCityOrTown>
<dei:EntityAddressStateOrProvince
contextRef="FD2019Q4YTD"
id="d22891554e775-wk-Fact-DB90F9AAF7BAA240526CD1D0184B2147">NJ</dei:EntityAddressStateOrProvince>
<dei:EntityAddressPostalZipCode
contextRef="FD2019Q4YTD"
id="d22891554e780-wk-Fact-CC63824FC2E413391553D1D01865C580">07950</dei:EntityAddressPostalZipCode>
<dei:CityAreaCode
contextRef="FD2019Q4YTD"
id="d22891554e793-wk-Fact-F2132F534FF1C5C4F24DD1D0185BE5CB">973</dei:CityAreaCode>
<dei:LocalPhoneNumber
contextRef="FD2019Q4YTD"
id="d22891554e798-wk-Fact-493A8845D49FC88373E2D1D0184B9656">605-8200</dei:LocalPhoneNumber>
<dei:Security12bTitle
contextRef="FD2019Q4YTD"
id="d22891554e855-wk-Fact-D0F0E7216C9C5EE29217D1D0182A6217">Common Stock, $0.01 par value</dei:Security12bTitle>
<dei:TradingSymbol
contextRef="FD2019Q4YTD"
id="d22891554e865-wk-Fact-405ACB6AAB427643E8FDD1D0183CD7C8">IMMU</dei:TradingSymbol>
<dei:SecurityExchangeName
contextRef="FD2019Q4YTD"
id="d22891554e875-wk-Fact-E2E91DB403C166A30CABD1D0180B2289">NASDAQ</dei:SecurityExchangeName>
<dei:EntityWellKnownSeasonedIssuer
contextRef="FD2019Q4YTD"
id="d22891554e890-wk-Fact-CBD06DCFBFF4999A8EC0D1D01865D34E">Yes</dei:EntityWellKnownSeasonedIssuer>
<dei:EntityVoluntaryFilers
contextRef="FD2019Q4YTD"
id="d22891554e912-wk-Fact-9F1A13D425AB33E79F94D1D0180B79A4">No</dei:EntityVoluntaryFilers>
<dei:EntityCurrentReportingStatus
contextRef="FD2019Q4YTD"
id="d22891554e927-wk-Fact-E37AD66695F22F24A9AAD1D0181BB219">Yes</dei:EntityCurrentReportingStatus>
<dei:EntityInteractiveDataCurrent
contextRef="FD2019Q4YTD"
id="d22891554e945-wk-Fact-B8B70F444047D76CFB3FD1D0180B6E6B">Yes</dei:EntityInteractiveDataCurrent>
<dei:EntityFilerCategory
contextRef="FD2019Q4YTD"
id="d22891554e982-wk-Fact-632F198FD0F017624DFDD1D0180B8518">Large Accelerated Filer</dei:EntityFilerCategory>
<dei:EntitySmallBusiness
contextRef="FD2019Q4YTD"
id="d22891554e1018-wk-Fact-C67912C6396CF5857F46D1D0185BAF72">false</dei:EntitySmallBusiness>
<dei:EntityEmergingGrowthCompany
contextRef="FD2019Q4YTD"
id="d22891554e1039-wk-Fact-2D08B5685A9AF5CB3E4BD1D0184B285A">false</dei:EntityEmergingGrowthCompany>
<dei:EntityShellCompany
contextRef="FD2019Q4YTD"
id="d22891554e1058-wk-Fact-51683AD76CA4F6BA2EBA7E5C6C9ED1AF">false</dei:EntityShellCompany>
<dei:EntityPublicFloat
contextRef="FI2019Q2"
decimals="0"
id="d22891554e1072-wk-Fact-DE2D71583DA959E9E373D1D0184BCBF6"
unitRef="usd">2660996949</dei:EntityPublicFloat>
<dei:EntityCommonStockSharesOutstanding
contextRef="I2020Q1SharesOutstanding"
decimals="INF"
id="d22891554e1076-wk-Fact-7B6132A1C663422099D0D1D0186574B2"
unitRef="shares">213929505</dei:EntityCommonStockSharesOutstanding>
<dei:DocumentsIncorporatedByReferenceTextBlock
contextRef="FD2019Q4YTD"
id="TextSelection-8C352722E0F9DBD6CEF1D1D01865AD4E-0-wk-Fact-D432D860F1049290B4D0D1D018658445"><div style="line-height:120%;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">Specified portions of the registrant’s proxy statement, which will be filed with the Commission pursuant to Regulation 14A within 120 days of the end of the fiscal year ended </span><span style="font-family:inherit;font-size:8pt;">December 31, 2019</span><span style="font-family:inherit;font-size:8pt;"> in connection with the registrant’s 2020 Annual Meeting of Stockholders, are incorporated by reference into Part III of this annual report on Form 10-K.</span></div></dei:DocumentsIncorporatedByReferenceTextBlock>
<us-gaap:CashAndCashEquivalentsAtCarryingValue
contextRef="FI2019Q4"
decimals="-3"
id="d22909209e861-wk-Fact-DC4AE9A8FE4AE0112236D1D0184B774F"
unitRef="usd">608628000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
<us-gaap:CashAndCashEquivalentsAtCarryingValue
contextRef="FI2018Q4"
decimals="-3"
id="d22909209e880-wk-Fact-71ACCBE1F94A85D78382D1D0184B1F30"
unitRef="usd">492860000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
<us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
contextRef="FI2019Q4"
decimals="-3"
id="d22909209e900-wk-Fact-A83535AA97BD4D1198A0D1D0184B1567"
unitRef="usd">4550000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
<us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
contextRef="FI2018Q4"
decimals="-3"
id="d22909209e919-wk-Fact-E55C8926040E78940F72D1D0184BA09B"
unitRef="usd">4941000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
<us-gaap:AccountsReceivableNetCurrent
contextRef="FI2019Q4"
decimals="-3"
id="d22909209e944-wk-Fact-A1469DD4CFE6B9712277D1D0180B0BAB"
unitRef="usd">295000</us-gaap:AccountsReceivableNetCurrent>
<us-gaap:AccountsReceivableNetCurrent
contextRef="FI2018Q4"
decimals="-3"
id="d22909209e963-wk-Fact-1D5DCD038A71F97E0153D1D0181BE42A"
unitRef="usd">0</us-gaap:AccountsReceivableNetCurrent>
<us-gaap:PrepaidExpenseCurrent
contextRef="FI2019Q4"
decimals="-3"
id="d22909209e988-wk-Fact-A4208F98B347CFB27FA6D1D0184BEF32"
unitRef="usd">21818000</us-gaap:PrepaidExpenseCurrent>
<us-gaap:PrepaidExpenseCurrent
contextRef="FI2018Q4"
decimals="-3"
id="d22909209e1007-wk-Fact-7135DAEA87FF6F71EE6BD1D0184B74D8"
unitRef="usd">5354000</us-gaap:PrepaidExpenseCurrent>
<us-gaap:OtherAssetsCurrent
contextRef="FI2019Q4"
decimals="-3"
id="d22909209e1032-wk-Fact-5FD8820299B30BE9B4C2D1D0185BF435"
unitRef="usd">3413000</us-gaap:OtherAssetsCurrent>
<us-gaap:OtherAssetsCurrent
contextRef="FI2018Q4"
decimals="-3"
id="d22909209e1051-wk-Fact-9555C1EB841AAC68D155D1D0185B86B4"
unitRef="usd">1348000</us-gaap:OtherAssetsCurrent>
<us-gaap:AssetsCurrent
contextRef="FI2019Q4"
decimals="-3"
id="d22909209e1076-wk-Fact-1C8D17C3369AE885A18AD1D0185BC208"
unitRef="usd">638704000</us-gaap:AssetsCurrent>
<us-gaap:AssetsCurrent
contextRef="FI2018Q4"
decimals="-3"
id="d22909209e1095-wk-Fact-4F67B160758AA362C8A5D1D0184B4028"
unitRef="usd">504503000</us-gaap:AssetsCurrent>
<us-gaap:PropertyPlantAndEquipmentNet
contextRef="FI2019Q4"
decimals="-3"
id="d22909209e1120-wk-Fact-E3C75C1700F42C00467BD1D0184B9605"
unitRef="usd">32762000</us-gaap:PropertyPlantAndEquipmentNet>
<us-gaap:PropertyPlantAndEquipmentNet
contextRef="FI2018Q4"
decimals="-3"
id="d22909209e1139-wk-Fact-10C952140E4204F13D7BD1D0184B37BF"
unitRef="usd">23469000</us-gaap:PropertyPlantAndEquipmentNet>
<us-gaap:OtherAssetsNoncurrent
contextRef="FI2019Q4"
decimals="-3"
id="d22909209e1165-wk-Fact-7051C4AAC3558AAC8642D1D0184B472D"
unitRef="usd">256000</us-gaap:OtherAssetsNoncurrent>
<us-gaap:OtherAssetsNoncurrent
contextRef="FI2018Q4"
decimals="-3"
id="d22909209e1184-wk-Fact-1A2763FDD1D0DD9F0C6CD1D0184B4C83"
unitRef="usd">68000</us-gaap:OtherAssetsNoncurrent>
<us-gaap:Assets
contextRef="FI2019Q4"
decimals="-3"
id="d22909209e1214-wk-Fact-80C553DD9A54032E3C78D1D0184BC218"
unitRef="usd">671722000</us-gaap:Assets>
<us-gaap:Assets
contextRef="FI2018Q4"
decimals="-3"
id="d22909209e1233-wk-Fact-47299FFA8AE4C494972ED1D0185BB94A"
unitRef="usd">528040000</us-gaap:Assets>
<us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent
contextRef="FI2019Q4"
decimals="-3"
id="d22909209e1396-wk-Fact-7C2A859B877F0F655F76D6F43C09A49D"
unitRef="usd">60860000</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent>
<us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent
contextRef="FI2018Q4"
decimals="-3"
id="d22909209e1415-wk-Fact-228C40E00DEB07C9D25AD1D0185B2721"
unitRef="usd">31722000</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent>
<immu:LiabilitiesRelatedToTheSaleOfFutureRoyaltiesCurrent
contextRef="FI2019Q4"
decimals="-3"
id="d22909209e1435-wk-Fact-43384EACEC23B8D45E88D6F43C5C946E"
unitRef="usd">3455000</immu:LiabilitiesRelatedToTheSaleOfFutureRoyaltiesCurrent>
<immu:LiabilitiesRelatedToTheSaleOfFutureRoyaltiesCurrent
contextRef="FI2018Q4"
decimals="-3"
id="d22909209e1454-wk-Fact-B0F60D4AEBFD1B158EF5D1D0184B60FE"
unitRef="usd">0</immu:LiabilitiesRelatedToTheSaleOfFutureRoyaltiesCurrent>
<us-gaap:OperatingLeaseLiabilityCurrent
contextRef="FI2019Q4"
decimals="-3"
id="d22909209e1479-wk-Fact-F784E40002191509ACB0D6EF61131A61"
unitRef="usd">337000</us-gaap:OperatingLeaseLiabilityCurrent>
<us-gaap:ConvertibleDebtCurrent
contextRef="FI2019Q4"
decimals="-3"
id="d22909209e1523-wk-Fact-C99BB883EF6A99D6095639991F3EDE2D"
unitRef="usd">7106000</us-gaap:ConvertibleDebtCurrent>
<us-gaap:ConvertibleDebtCurrent
contextRef="FI2018Q4"
decimals="-3"
id="d22909209e1542-wk-Fact-06BBEA18318A0EE351D43999452EAD94"
unitRef="usd">0</us-gaap:ConvertibleDebtCurrent>
<us-gaap:LiabilitiesCurrent
contextRef="FI2019Q4"
decimals="-3"
id="d22909209e1567-wk-Fact-85F2508459CCE488A4FBD6F43DA928A8"
unitRef="usd">71758000</us-gaap:LiabilitiesCurrent>
<us-gaap:LiabilitiesCurrent
contextRef="FI2018Q4"
decimals="-3"
id="d22909209e1586-wk-Fact-BEF0B9381A2BF0D5D374D1D0183C3C08"
unitRef="usd">31722000</us-gaap:LiabilitiesCurrent>
<us-gaap:ConvertibleDebtNoncurrent
contextRef="FI2019Q4"
decimals="-3"
id="d22909209e1611-wk-Fact-ABFE52DA7DA2682A9E4A3998D248E88A"
unitRef="usd">0</us-gaap:ConvertibleDebtNoncurrent>
<us-gaap:ConvertibleDebtNoncurrent
contextRef="FI2018Q4"
decimals="-3"
id="d22909209e1630-wk-Fact-3A1B4E3AF80548BB44BFD1D0184BA3DD"
unitRef="usd">7055000</us-gaap:ConvertibleDebtNoncurrent>
<immu:LiabilitiesRelatedToTheSaleOfFutureRoyaltiesNoncurrent
contextRef="FI2019Q4"
decimals="-3"
id="d22909209e1656-wk-Fact-187BAD387A11001FED70D6F43E165A34"
unitRef="usd">257769000</immu:LiabilitiesRelatedToTheSaleOfFutureRoyaltiesNoncurrent>
<immu:LiabilitiesRelatedToTheSaleOfFutureRoyaltiesNoncurrent
contextRef="FI2018Q4"
decimals="-3"
id="d22909209e1675-wk-Fact-527EDD58BB7E9BE310DAD1D0184B1531"
unitRef="usd">221295000</immu:LiabilitiesRelatedToTheSaleOfFutureRoyaltiesNoncurrent>
<us-gaap:ContractWithCustomerLiabilityNoncurrent
contextRef="FI2019Q4"
decimals="-3"
id="d22909209e1700-wk-Fact-B0756F150582F0979660D6F06A9A83B3"
unitRef="usd">65000000</us-gaap:ContractWithCustomerLiabilityNoncurrent>
<us-gaap:ContractWithCustomerLiabilityNoncurrent
contextRef="FI2018Q4"
decimals="-3"
id="d22909209e1719-wk-Fact-82FD8FE0EB15FA74DD07D1D0184BB963"
unitRef="usd">0</us-gaap:ContractWithCustomerLiabilityNoncurrent>
<us-gaap:OtherLiabilitiesNoncurrent
contextRef="FI2019Q4"
decimals="-3"
id="d22909209e1744-wk-Fact-D2CEE59A32500E97367CD6F43EA9ECCC"
unitRef="usd">9965000</us-gaap:OtherLiabilitiesNoncurrent>
<us-gaap:OtherLiabilitiesNoncurrent
contextRef="FI2018Q4"
decimals="-3"
id="d22909209e1763-wk-Fact-58CDC7E3063990F900ADD1D0184B597C"
unitRef="usd">2119000</us-gaap:OtherLiabilitiesNoncurrent>
<us-gaap:Liabilities
contextRef="FI2019Q4"
decimals="-3"
id="d22909209e1788-wk-Fact-214265571E5A5CEB1964D6F43EFF16E6"
unitRef="usd">404492000</us-gaap:Liabilities>
<us-gaap:Liabilities
contextRef="FI2018Q4"
decimals="-3"
id="d22909209e1807-wk-Fact-53110366302F72C99EA1D1D0184B0A93"
unitRef="usd">262191000</us-gaap:Liabilities>
<us-gaap:CommitmentsAndContingencies
contextRef="FI2019Q4"
id="d22909209e1832-wk-Fact-741E6098A5A97DC4C6BAD1D0184ACEE5"
unitRef="usd"
xsi:nil="true"/>
<us-gaap:CommitmentsAndContingencies
contextRef="FI2018Q4"
id="d22909209e1850-wk-Fact-680F6FE3AF52F300BE34D1D0184A42DB"
unitRef="usd"
xsi:nil="true"/>
<us-gaap:ConvertiblePreferredStockNonredeemableOrRedeemableIssuerOptionValue
contextRef="FI2019Q4"
decimals="-3"
id="d22909209e1920-wk-Fact-DA59FC4E132BEC863F12D1D0184BC4EB"
unitRef="usd">0</us-gaap:ConvertiblePreferredStockNonredeemableOrRedeemableIssuerOptionValue>
<us-gaap:ConvertiblePreferredStockNonredeemableOrRedeemableIssuerOptionValue
contextRef="FI2018Q4"
decimals="-3"
id="d22909209e1939-wk-Fact-CC17A2E44C85903DED4CD1D0184B0057"
unitRef="usd">0</us-gaap:ConvertiblePreferredStockNonredeemableOrRedeemableIssuerOptionValue>
<us-gaap:CommonStockValue
contextRef="FI2019Q4"
decimals="-3"
id="d22909209e1964-wk-Fact-B8CA1105BAA6A50FB566D1D0184BD52E"
unitRef="usd">2125000</us-gaap:CommonStockValue>
<us-gaap:CommonStockValue
contextRef="FI2018Q4"
decimals="-3"
id="d22909209e1983-wk-Fact-E6B46C8E9F9421C7E93CD1D0185B44F2"
unitRef="usd">1905000</us-gaap:CommonStockValue>
<us-gaap:AdditionalPaidInCapitalCommonStock
contextRef="FI2019Q4"
decimals="-3"
id="d22909209e2008-wk-Fact-0B2E5AE6FF9EEFB4D148D1D0184B8831"
unitRef="usd">1579205000</us-gaap:AdditionalPaidInCapitalCommonStock>
<us-gaap:AdditionalPaidInCapitalCommonStock
contextRef="FI2018Q4"
decimals="-3"
id="d22909209e2027-wk-Fact-5238DE08BC981CFA2DB6D1D0184BFCBE"
unitRef="usd">1219237000</us-gaap:AdditionalPaidInCapitalCommonStock>
<us-gaap:TreasuryStockValue
contextRef="FI2019Q4"
decimals="-3"
id="d22909209e2052-wk-Fact-6832AA0BD09019B3A452D1D0184BD7E5"
unitRef="usd">2095000</us-gaap:TreasuryStockValue>
<us-gaap:TreasuryStockValue
contextRef="FI2018Q4"
decimals="-3"
id="d22909209e2072-wk-Fact-837F7A4A4EFC4A029988D1D0184BC8F8"
unitRef="usd">824000</us-gaap:TreasuryStockValue>
<us-gaap:RetainedEarningsAccumulatedDeficit
contextRef="FI2019Q4"
decimals="-3"
id="d22909209e2098-wk-Fact-38CD3235136A96B5013ED1D0185BE7F9"
unitRef="usd">-1310406000</us-gaap:RetainedEarningsAccumulatedDeficit>
<us-gaap:RetainedEarningsAccumulatedDeficit
contextRef="FI2018Q4"
decimals="-3"
id="d22909209e2118-wk-Fact-816A33B8BEF48FA4F723D1D0184B19AE"
unitRef="usd">-953216000</us-gaap:RetainedEarningsAccumulatedDeficit>
<us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
contextRef="FI2019Q4"
decimals="-3"
id="d22909209e2145-wk-Fact-49954B6AB2E9E8F572FED1D0184B71CA"
unitRef="usd">-568000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
<us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
contextRef="FI2018Q4"
decimals="-3"
id="d22909209e2165-wk-Fact-B2259B9501A45FF8FFA3D1D0184BF8F0"
unitRef="usd">-351000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
<us-gaap:StockholdersEquity
contextRef="FI2019Q4"
decimals="-3"
id="d22909209e2191-wk-Fact-B8A81A216826F9E8600DD1D0184B17BF"
unitRef="usd">268261000</us-gaap:StockholdersEquity>
<us-gaap:StockholdersEquity
contextRef="FI2018Q4"
decimals="-3"
id="d22909209e2210-wk-Fact-958C727F7AC1A85077B4D1D0185B081F"
unitRef="usd">266751000</us-gaap:StockholdersEquity>
<us-gaap:MinorityInterest
contextRef="FI2019Q4"
decimals="-3"
id="d22909209e2235-wk-Fact-5625D0ABF40EF7CE6A44D1D0184B42D7"
unitRef="usd">-1031000</us-gaap:MinorityInterest>
<us-gaap:MinorityInterest
contextRef="FI2018Q4"
decimals="-3"
id="d22909209e2255-wk-Fact-4875B5458E2F189891CAD1D0184B9A42"
unitRef="usd">-902000</us-gaap:MinorityInterest>
<us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
contextRef="FI2019Q4"
decimals="-3"
id="d22909209e2281-wk-Fact-506CDA3CCB6716A29946D1D0184B0B3B"
unitRef="usd">267230000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
<us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
contextRef="FI2018Q4"
decimals="-3"
id="d22909209e2300-wk-Fact-82C9BC65B21B97B100C5D1D0184B8D2C"
unitRef="usd">265849000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
<us-gaap:LiabilitiesAndStockholdersEquity
contextRef="FI2019Q4"
decimals="-3"
id="d22909209e2330-wk-Fact-AE58C2CD0AA2D69AF270D1D0183C7921"
unitRef="usd">671722000</us-gaap:LiabilitiesAndStockholdersEquity>
<us-gaap:LiabilitiesAndStockholdersEquity
contextRef="FI2018Q4"
decimals="-3"
id="d22909209e2349-wk-Fact-B97BD1E8CA270EA60E13D1D0184B0E07"
unitRef="usd">528040000</us-gaap:LiabilitiesAndStockholdersEquity>
<us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
contextRef="FD2019Q4YTD_srt_ProductOrServiceAxis_immu_ProductSalesMember"
decimals="-3"
id="d22912578e928-wk-Fact-849307BE2C2CD3186A6ED71306A09326"
unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
<us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
contextRef="D2018Q4Jul01-Dec31_srt_ProductOrServiceAxis_immu_ProductSalesMember"
decimals="-3"
id="d22912578e947-wk-Fact-0C066261783ADD1F0B3ED1D0184BE183"
unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
<us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
contextRef="D2018Q4Jul12017toJun302018_srt_ProductOrServiceAxis_immu_ProductSalesMember"
decimals="-3"
id="d22912578e966-wk-Fact-6FC762CDD646E7C09EF0D1D0185B1329"
unitRef="usd">1501000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
<us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
contextRef="D2017Q4Jul012016toJun302017_srt_ProductOrServiceAxis_immu_ProductSalesMember"
decimals="-3"
id="d22912578e986-wk-Fact-6BAED3D9F7E84118916BD1D0185B2530"
unitRef="usd">2443000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
<us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
contextRef="FD2019Q4YTD_srt_ProductOrServiceAxis_immu_LicenseFreeAndOtherRevenueMember"
decimals="-3"
id="d22912578e1001-wk-Fact-8BCE2A850F609D812959D713090D74E0"
unitRef="usd">295000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
<us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
contextRef="D2018Q4Jul01-Dec31_srt_ProductOrServiceAxis_immu_LicenseFreeAndOtherRevenueMember"
decimals="-3"
id="d22912578e1020-wk-Fact-E620504A2B4D663BB59ED1D0185BA0EE"
unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
<us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
contextRef="D2018Q4Jul12017toJun302018_srt_ProductOrServiceAxis_immu_LicenseFreeAndOtherRevenueMember"
decimals="-3"
id="d22912578e1039-wk-Fact-33CD22EEB4CF1C9D2EC9D1D01865A44E"
unitRef="usd">330000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
<us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
contextRef="D2017Q4Jul012016toJun302017_srt_ProductOrServiceAxis_immu_LicenseFreeAndOtherRevenueMember"
decimals="-3"
id="d22912578e1059-wk-Fact-954F00B17E6FF93F9AD9D1D0184BC7C4"
unitRef="usd">284000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
<us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
contextRef="FD2019Q4YTD_srt_ProductOrServiceAxis_immu_ResearchandDevelopmentMember"
decimals="-3"
id="d22912578e1079-wk-Fact-B967A541E52B74E1F92DD7130AD3A9AD"
unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
<us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
contextRef="D2018Q4Jul01-Dec31_srt_ProductOrServiceAxis_immu_ResearchandDevelopmentMember"
decimals="-3"
id="d22912578e1098-wk-Fact-96102BA3DFA71F2AC990D1D0185B5DEC"
unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
<us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
contextRef="D2018Q4Jul12017toJun302018_srt_ProductOrServiceAxis_immu_ResearchandDevelopmentMember"
decimals="-3"
id="d22912578e1117-wk-Fact-6338BB5F750EA369909DD1D0185B97AB"
unitRef="usd">325000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
<us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
contextRef="D2017Q4Jul012016toJun302017_srt_ProductOrServiceAxis_immu_ResearchandDevelopmentMember"
decimals="-3"
id="d22912578e1137-wk-Fact-84B823585AAADDB57909D1D0180BDFC6"
unitRef="usd">364000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
<us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
contextRef="FD2019Q4YTD"
decimals="-3"
id="d22912578e1157-wk-Fact-BE0339946F50338D197BD7130D1D6330"
unitRef="usd">295000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
<us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
contextRef="D2018Q4Jul01-Dec31"
decimals="-3"
id="d22912578e1176-wk-Fact-2E4FA2FEB6C1E00677A8D1D0185B2147"
unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
<us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
contextRef="D2018Q4Jul12017toJun302018"
decimals="-3"
id="d22912578e1195-wk-Fact-6AA171CFEB17092C01B8D1D0185B165F"
unitRef="usd">2156000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
<us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
contextRef="D2017Q4Jul012016toJun302017"
decimals="-3"
id="d22912578e1215-wk-Fact-B9CB6F1C411F3D42094ED1D018642B18"
unitRef="usd">3091000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
<us-gaap:CostOfRevenue
contextRef="FD2019Q4YTD"
decimals="-3"
id="d22912578e1399-wk-Fact-D96853E3535829A15A7ED713D1E90369"
unitRef="usd">0</us-gaap:CostOfRevenue>
<us-gaap:CostOfRevenue
contextRef="D2018Q4Jul01-Dec31"
decimals="-3"
id="d22912578e1418-wk-Fact-D7A81EF6C3BBFF9ABDD8D1D0185BD9F0"
unitRef="usd">0</us-gaap:CostOfRevenue>
<us-gaap:CostOfRevenue
contextRef="D2018Q4Jul12017toJun302018"
decimals="-3"
id="d22912578e1437-wk-Fact-F91439BB83BA1B1BF2F0D1D0185BAA11"
unitRef="usd">613000</us-gaap:CostOfRevenue>
<us-gaap:CostOfRevenue
contextRef="D2017Q4Jul012016toJun302017"
decimals="-3"
id="d22912578e1457-wk-Fact-30B02726B27AF75E5B85D1D0185B7765"
unitRef="usd">483000</us-gaap:CostOfRevenue>
<us-gaap:ResearchAndDevelopmentExpense
contextRef="FD2019Q4YTD"
decimals="-3"
id="d22912578e1477-wk-Fact-B11FDF4ADA5C9F46A3E2D713D2BF53AF"
unitRef="usd">254871000</us-gaap:ResearchAndDevelopmentExpense>
<us-gaap:ResearchAndDevelopmentExpense
contextRef="D2018Q4Jul01-Dec31"
decimals="-3"
id="d22912578e1496-wk-Fact-E7B9D3701A1EC92A4331D1D018659239"
unitRef="usd">93887000</us-gaap:ResearchAndDevelopmentExpense>
<us-gaap:ResearchAndDevelopmentExpense
contextRef="D2018Q4Jul12017toJun302018"
decimals="-3"
id="d22912578e1515-wk-Fact-1658CE7B1021821A9ED4D1D0184BB922"
unitRef="usd">99283000</us-gaap:ResearchAndDevelopmentExpense>
<us-gaap:ResearchAndDevelopmentExpense
contextRef="D2017Q4Jul012016toJun302017"
decimals="-3"
id="d22912578e1535-wk-Fact-8DD50C65D904A7967D5BD1D0180BDBB9"
unitRef="usd">51776000</us-gaap:ResearchAndDevelopmentExpense>
<us-gaap:SellingAndMarketingExpense
contextRef="FD2019Q4YTD"
decimals="-3"
id="d22912578e1556-wk-Fact-3910843FD69E0648ED42D713D3A776AB"
unitRef="usd">26459000</us-gaap:SellingAndMarketingExpense>
<us-gaap:SellingAndMarketingExpense
contextRef="D2018Q4Jul01-Dec31"
decimals="-3"
id="d22912578e1575-wk-Fact-BA56985542020B20470ED1D018650FED"
unitRef="usd">19834000</us-gaap:SellingAndMarketingExpense>
<us-gaap:SellingAndMarketingExpense
contextRef="D2018Q4Jul12017toJun302018"
decimals="-3"
id="d22912578e1594-wk-Fact-7D85183C7160CAF5FF77D1D0184B150F"
unitRef="usd">6822000</us-gaap:SellingAndMarketingExpense>
<us-gaap:SellingAndMarketingExpense
contextRef="D2017Q4Jul012016toJun302017"
decimals="-3"
id="d22912578e1614-wk-Fact-ECA0FE7699DA13B71737D1D0185B6DC3"
unitRef="usd">873000</us-gaap:SellingAndMarketingExpense>
<us-gaap:GeneralAndAdministrativeExpense
contextRef="FD2019Q4YTD"
decimals="-3"
id="d22912578e1634-wk-Fact-2BC47F20F787BA724609D713D45A454C"
unitRef="usd">43803000</us-gaap:GeneralAndAdministrativeExpense>
<us-gaap:GeneralAndAdministrativeExpense
contextRef="D2018Q4Jul01-Dec31"
decimals="-3"
id="d22912578e1653-wk-Fact-A8429C6D7C690F620C60D1D0184B8513"
unitRef="usd">30814000</us-gaap:GeneralAndAdministrativeExpense>
<us-gaap:GeneralAndAdministrativeExpense
contextRef="D2018Q4Jul12017toJun302018"
decimals="-3"
id="d22912578e1672-wk-Fact-02E40748F19333AA1661D1D0185B7B1D"
unitRef="usd">36485000</us-gaap:GeneralAndAdministrativeExpense>
<us-gaap:GeneralAndAdministrativeExpense
contextRef="D2017Q4Jul012016toJun302017"
decimals="-3"
id="d22912578e1692-wk-Fact-0BAE8D6BF3442F357E3FD1D0185BFF20"
unitRef="usd">29109000</us-gaap:GeneralAndAdministrativeExpense>
<us-gaap:CostsAndExpenses
contextRef="FD2019Q4YTD"
decimals="-3"
id="d22912578e1712-wk-Fact-88AD0497CD31D47BCF2AD713D57AEA2E"
unitRef="usd">325133000</us-gaap:CostsAndExpenses>
<us-gaap:CostsAndExpenses
contextRef="D2018Q4Jul01-Dec31"
decimals="-3"
id="d22912578e1731-wk-Fact-EF12E63A7E33163ADE83D1D0184BD97E"
unitRef="usd">144535000</us-gaap:CostsAndExpenses>
<us-gaap:CostsAndExpenses
contextRef="D2018Q4Jul12017toJun302018"
decimals="-3"
id="d22912578e1750-wk-Fact-74E82701703D0AB64498D1D0184B68C6"
unitRef="usd">143203000</us-gaap:CostsAndExpenses>
<us-gaap:CostsAndExpenses
contextRef="D2017Q4Jul012016toJun302017"
decimals="-3"
id="d22912578e1770-wk-Fact-7D884864882DD0188911D1D0185B6D18"
unitRef="usd">82241000</us-gaap:CostsAndExpenses>
<us-gaap:OperatingIncomeLoss
contextRef="FD2019Q4YTD"
decimals="-3"
id="d22912578e1790-wk-Fact-2568334275D383D7F60FD713D620B870"
unitRef="usd">-324838000</us-gaap:OperatingIncomeLoss>
<us-gaap:OperatingIncomeLoss
contextRef="D2018Q4Jul01-Dec31"
decimals="-3"
id="d22912578e1810-wk-Fact-6A7566400D8A7373C6A9D1D0185BF0A5"
unitRef="usd">-144535000</us-gaap:OperatingIncomeLoss>
<us-gaap:OperatingIncomeLoss
contextRef="D2018Q4Jul12017toJun302018"
decimals="-3"
id="d22912578e1830-wk-Fact-2D77134220E2B92918C3D1D0185BD470"
unitRef="usd">-141047000</us-gaap:OperatingIncomeLoss>
<us-gaap:OperatingIncomeLoss
contextRef="D2017Q4Jul012016toJun302017"
decimals="-3"
id="d22912578e1851-wk-Fact-8494A2DF4A52A832E0A6D1D01865C60C"
unitRef="usd">-79150000</us-gaap:OperatingIncomeLoss>
<us-gaap:FairValueAdjustmentOfWarrants
contextRef="FD2019Q4YTD"
decimals="-3"
id="d22912578e1872-wk-Fact-D2E66984117CBB450CBED713D6D0FE4C"
unitRef="usd">0</us-gaap:FairValueAdjustmentOfWarrants>
<us-gaap:FairValueAdjustmentOfWarrants
contextRef="D2018Q4Jul01-Dec31"
decimals="-3"
id="d22912578e1891-wk-Fact-1D5D4506E00364D1DE67D1D0180B6BBD"
unitRef="usd">-1404000</us-gaap:FairValueAdjustmentOfWarrants>
<us-gaap:FairValueAdjustmentOfWarrants
contextRef="D2018Q4Jul12017toJun302018"
decimals="-3"
id="d22912578e1910-wk-Fact-E26CFE363B06D151ED08D1D0185B3F62"
unitRef="usd">108636000</us-gaap:FairValueAdjustmentOfWarrants>
<us-gaap:FairValueAdjustmentOfWarrants
contextRef="D2017Q4Jul012016toJun302017"
decimals="-3"
id="d22912578e1931-wk-Fact-F37ECCDD6B19E07A84DED1D0184BF9B9"
unitRef="usd">61074000</us-gaap:FairValueAdjustmentOfWarrants>
<us-gaap:AdjustmentOfWarrantsGrantedForServices
contextRef="FD2019Q4YTD"
decimals="-3"
id="d22912578e1952-wk-Fact-19C533DBB7AA881D2E4ED713D76EE172"
unitRef="usd">0</us-gaap:AdjustmentOfWarrantsGrantedForServices>
<us-gaap:AdjustmentOfWarrantsGrantedForServices
contextRef="D2018Q4Jul01-Dec31"
decimals="-3"
id="d22912578e1971-wk-Fact-02AC75F1B59F9F5CF65BD1D0180B5321"
unitRef="usd">0</us-gaap:AdjustmentOfWarrantsGrantedForServices>
<us-gaap:AdjustmentOfWarrantsGrantedForServices
contextRef="D2018Q4Jul12017toJun302018"
decimals="-3"
id="d22912578e1990-wk-Fact-98B95CF860F0B356D8DDD1D0185B395E"
unitRef="usd">0</us-gaap:AdjustmentOfWarrantsGrantedForServices>
<us-gaap:AdjustmentOfWarrantsGrantedForServices
contextRef="D2017Q4Jul012016toJun302017"
decimals="-3"
id="d22912578e2010-wk-Fact-797C88AEF9ED2C7F4EE3D1D0184B05E0"
unitRef="usd">7649000</us-gaap:AdjustmentOfWarrantsGrantedForServices>
<us-gaap:InterestExpense
contextRef="FD2019Q4YTD"
decimals="-3"
id="d22912578e2031-wk-Fact-30DB59B73DB242E363E4D713D8165D09"
unitRef="usd">40337000</us-gaap:InterestExpense>
<us-gaap:InterestExpense
contextRef="D2018Q4Jul01-Dec31"
decimals="-3"
id="d22912578e2051-wk-Fact-72BD364920F18DA1D99FD1D0184BF821"
unitRef="usd">20017000</us-gaap:InterestExpense>
<us-gaap:InterestExpense
contextRef="D2018Q4Jul12017toJun302018"
decimals="-3"
id="d22912578e2071-wk-Fact-3B66A61233A9BCBFD3C6D1D0184B14CE"
unitRef="usd">23255000</us-gaap:InterestExpense>
<us-gaap:InterestExpense
contextRef="D2017Q4Jul012016toJun302017"
decimals="-3"
id="d22912578e2092-wk-Fact-64CD7BD68675331EA7D7D1D0184BC04E"
unitRef="usd">5480000</us-gaap:InterestExpense>
<us-gaap:InterestAndOtherIncome
contextRef="FD2019Q4YTD"
decimals="-3"
id="d22912578e2113-wk-Fact-E6EFA523230B1891F546D713D8C5C87B"
unitRef="usd">7856000</us-gaap:InterestAndOtherIncome>
<us-gaap:InterestAndOtherIncome
contextRef="D2018Q4Jul01-Dec31"
decimals="-3"
id="d22912578e2132-wk-Fact-CD1DEAA5D3CB0A9A2D0CD1D0185B05F9"
unitRef="usd">6106000</us-gaap:InterestAndOtherIncome>
<us-gaap:InterestAndOtherIncome
contextRef="D2018Q4Jul12017toJun302018"
decimals="-3"
id="d22912578e2151-wk-Fact-E3CC4A7B8168960651CDD1D0184BD62C"
unitRef="usd">5493000</us-gaap:InterestAndOtherIncome>
<us-gaap:InterestAndOtherIncome
contextRef="D2017Q4Jul012016toJun302017"
decimals="-3"
id="d22912578e2171-wk-Fact-22FC6DDEA7D24B3DFE08D1D018653AB2"
unitRef="usd">431000</us-gaap:InterestAndOtherIncome>
<us-gaap:GainsLossesOnExtinguishmentOfDebt
contextRef="FD2019Q4YTD"
decimals="-3"
id="d22912578e2191-wk-Fact-CA82D7B93B7BC5D63761D713D96D415C"
unitRef="usd">0</us-gaap:GainsLossesOnExtinguishmentOfDebt>
<us-gaap:GainsLossesOnExtinguishmentOfDebt
contextRef="D2018Q4Jul01-Dec31"
decimals="-3"
id="d22912578e2210-wk-Fact-9369F26ACFE94B195D3AD1D0184B6189"
unitRef="usd">-897000</us-gaap:GainsLossesOnExtinguishmentOfDebt>
<us-gaap:GainsLossesOnExtinguishmentOfDebt
contextRef="D2018Q4Jul12017toJun302018"
decimals="-3"
id="d22912578e2230-wk-Fact-AF53D3B24B925925A685D1D0184B9F0E"
unitRef="usd">-13005000</us-gaap:GainsLossesOnExtinguishmentOfDebt>
<us-gaap:GainsLossesOnExtinguishmentOfDebt
contextRef="D2017Q4Jul012016toJun302017"
decimals="-3"
id="d22912578e2251-wk-Fact-ABDED49C91AE1FDB5EEED1D0185B4263"
unitRef="usd">0</us-gaap:GainsLossesOnExtinguishmentOfDebt>
<immu:OtherFinancingExpenseIncome
contextRef="FD2019Q4YTD"
decimals="-3"
id="d22912578e2271-wk-Fact-9FF5F26A0EBF2991A6EDD713DA20D6E6"
unitRef="usd">0</immu:OtherFinancingExpenseIncome>
<immu:OtherFinancingExpenseIncome
contextRef="D2018Q4Jul01-Dec31"
decimals="-3"
id="d22912578e2290-wk-Fact-8B448EE696535CF40EFBD1D0180B65F2"
unitRef="usd">0</immu:OtherFinancingExpenseIncome>
<immu:OtherFinancingExpenseIncome
contextRef="D2018Q4Jul12017toJun302018"
decimals="-3"
id="d22912578e2309-wk-Fact-94AA403DF954FBF14CEAD1D0185B029B"
unitRef="usd">0</immu:OtherFinancingExpenseIncome>
<immu:OtherFinancingExpenseIncome
contextRef="D2017Q4Jul012016toJun302017"
decimals="-3"
id="d22912578e2329-wk-Fact-6F29950E9C7A54D4FC47D1D0184BD95B"
unitRef="usd">347000</immu:OtherFinancingExpenseIncome>
<us-gaap:GainOnBusinessInterruptionInsuranceRecovery
contextRef="FD2019Q4YTD"
decimals="-3"
id="d22912578e2350-wk-Fact-5E4FB2AC018E1393D369D713DACB3286"
unitRef="usd">0</us-gaap:GainOnBusinessInterruptionInsuranceRecovery>
<us-gaap:GainOnBusinessInterruptionInsuranceRecovery
contextRef="D2018Q4Jul01-Dec31"
decimals="-3"
id="d22912578e2369-wk-Fact-C6656772A985441CF9A5D1D01865D74C"
unitRef="usd">190000</us-gaap:GainOnBusinessInterruptionInsuranceRecovery>
<us-gaap:GainOnBusinessInterruptionInsuranceRecovery
contextRef="D2018Q4Jul12017toJun302018"
decimals="-3"
id="d22912578e2388-wk-Fact-ACCD4355D74144BD1A93D1D0185BD31D"
unitRef="usd">6638000</us-gaap:GainOnBusinessInterruptionInsuranceRecovery>
<us-gaap:GainOnBusinessInterruptionInsuranceRecovery
contextRef="D2017Q4Jul012016toJun302017"
decimals="-3"
id="d22912578e2408-wk-Fact-EFB91C217296D207904AD1D0185BD28C"
unitRef="usd">0</us-gaap:GainOnBusinessInterruptionInsuranceRecovery>
<us-gaap:ForeignCurrencyTransactionGainLossBeforeTax
contextRef="FD2019Q4YTD"
decimals="-3"
id="d22912578e2429-wk-Fact-DED3ACC95C175ADA7E4AD713DB6B9BD3"
unitRef="usd">0</us-gaap:ForeignCurrencyTransactionGainLossBeforeTax>
<us-gaap:ForeignCurrencyTransactionGainLossBeforeTax
contextRef="D2018Q4Jul01-Dec31"
decimals="-3"
id="d22912578e2448-wk-Fact-4B99F3A7086D3766FA07D1D0180BC974"
unitRef="usd">0</us-gaap:ForeignCurrencyTransactionGainLossBeforeTax>
<us-gaap:ForeignCurrencyTransactionGainLossBeforeTax
contextRef="D2018Q4Jul12017toJun302018"
decimals="-3"
id="d22912578e2467-wk-Fact-65CEFCDA87E6033DD4F7D1D0184B28A7"
unitRef="usd">81000</us-gaap:ForeignCurrencyTransactionGainLossBeforeTax>
<us-gaap:ForeignCurrencyTransactionGainLossBeforeTax
contextRef="D2017Q4Jul012016toJun302017"
decimals="-3"
id="d22912578e2487-wk-Fact-BCB0F6F64A867205F2ECD1D0184B9E46"
unitRef="usd">23000</us-gaap:ForeignCurrencyTransactionGainLossBeforeTax>
<us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
contextRef="FD2019Q4YTD"
decimals="-3"
id="d22912578e2507-wk-Fact-2A0CA103AC2C49597E93D713DBFF3115"
unitRef="usd">-357319000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
<us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
contextRef="D2018Q4Jul01-Dec31"
decimals="-3"
id="d22912578e2527-wk-Fact-44EE05DB67B05FD87789D1D0184B91BD"
unitRef="usd">-157749000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
<us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
contextRef="D2018Q4Jul12017toJun302018"
decimals="-3"
id="d22912578e2547-wk-Fact-5CE89222731660B2B1BFD1D0184B3DBE"
unitRef="usd">-273731000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
<us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
contextRef="D2017Q4Jul012016toJun302017"
decimals="-3"
id="d22912578e2568-wk-Fact-EF5770EEDA0F69E63917D1D01864AC18"
unitRef="usd">-153246000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
<us-gaap:IncomeTaxExpenseBenefit
contextRef="FD2019Q4YTD"
decimals="-3"
id="d22912578e2589-wk-Fact-3CC832BF5EF3C97185F1D713DCC31FBC"
unitRef="usd">0</us-gaap:IncomeTaxExpenseBenefit>
<us-gaap:IncomeTaxExpenseBenefit
contextRef="D2018Q4Jul01-Dec31"
decimals="-3"
id="d22912578e2608-wk-Fact-32780205060E315B26CED1D0185B11B7"
unitRef="usd">0</us-gaap:IncomeTaxExpenseBenefit>
<us-gaap:IncomeTaxExpenseBenefit
contextRef="D2018Q4Jul12017toJun302018"
decimals="-3"
id="d22912578e2627-wk-Fact-5584AB2B0AA443CB47F2D1D0180B2C0B"
unitRef="usd">156000</us-gaap:IncomeTaxExpenseBenefit>
<us-gaap:IncomeTaxExpenseBenefit
contextRef="D2017Q4Jul012016toJun302017"
decimals="-3"
id="d22912578e2648-wk-Fact-B3DF2F8B547FC4AC0F35D1D0184B2343"
unitRef="usd">20000</us-gaap:IncomeTaxExpenseBenefit>
<us-gaap:ProfitLoss
contextRef="FD2019Q4YTD"
decimals="-3"
id="d22912578e2669-wk-Fact-29F9B6EF360FC370699FD713DDBDA593"
unitRef="usd">-357319000</us-gaap:ProfitLoss>
<us-gaap:ProfitLoss
contextRef="D2018Q4Jul01-Dec31"
decimals="-3"
id="d22912578e2689-wk-Fact-5ACF8E8FD2F7A88E6F00D1D0184B9305"
unitRef="usd">-157749000</us-gaap:ProfitLoss>
<us-gaap:ProfitLoss
contextRef="D2018Q4Jul12017toJun302018"
decimals="-3"
id="d22912578e2709-wk-Fact-6CE3D07A35B1D83DEB81D1D0184B1FFE"
unitRef="usd">-273887000</us-gaap:ProfitLoss>
<us-gaap:ProfitLoss
contextRef="D2017Q4Jul012016toJun302017"
decimals="-3"
id="d22912578e2730-wk-Fact-AC988A2DC8A22FB48CBDD1D018651B52"
unitRef="usd">-153266000</us-gaap:ProfitLoss>
<us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
contextRef="FD2019Q4YTD"
decimals="-3"
id="d22912578e2751-wk-Fact-299E907197C83C6AC3A5D713DEA358C6"
unitRef="usd">-129000</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
<us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
contextRef="D2018Q4Jul01-Dec31"
decimals="-3"
id="d22912578e2771-wk-Fact-E993EB3C6C253F4641ECD1D0184BBB7B"
unitRef="usd">-81000</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
<us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
contextRef="D2018Q4Jul12017toJun302018"
decimals="-3"
id="d22912578e2791-wk-Fact-8809DF416D0B3AF3681DD1D0184B3665"
unitRef="usd">-50000</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
<us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
contextRef="D2017Q4Jul012016toJun302017"
decimals="-3"
id="d22912578e2812-wk-Fact-8457D6CBD4E1DE0EBDB0D1D0184B4095"
unitRef="usd">-60000</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
<us-gaap:NetIncomeLoss
contextRef="FD2019Q4YTD"
decimals="-3"
id="d22912578e2838-wk-Fact-3F7D94E4DE1AC85D3DD4D713DFB524CA"
unitRef="usd">-357190000</us-gaap:NetIncomeLoss>
<us-gaap:NetIncomeLoss
contextRef="D2018Q4Jul01-Dec31"
decimals="-3"
id="d22912578e2858-wk-Fact-9C21D92CEF83CA62B07BD1D0184B6F86"
unitRef="usd">-157668000</us-gaap:NetIncomeLoss>
<us-gaap:NetIncomeLoss
contextRef="D2018Q4Jul12017toJun302018"
decimals="-3"
id="d22912578e2878-wk-Fact-3D5D8EF8B296CD34AF8AD1D0184B6D05"
unitRef="usd">-273837000</us-gaap:NetIncomeLoss>
<us-gaap:NetIncomeLoss
contextRef="D2017Q4Jul012016toJun302017"
decimals="-3"
id="d22912578e2899-wk-Fact-AB40936ABCF6162B822DD1D0185B6E17"
unitRef="usd">-153206000</us-gaap:NetIncomeLoss>
<us-gaap:EarningsPerShareBasicAndDiluted
contextRef="FD2019Q4YTD"
decimals="2"
id="d22912578e2920-wk-Fact-1E182124567E5A939773D713E086B425"
unitRef="usdPerShare">-1.84</us-gaap:EarningsPerShareBasicAndDiluted>
<us-gaap:EarningsPerShareBasicAndDiluted
contextRef="D2018Q4Jul01-Dec31"
decimals="2"
id="d22912578e2940-wk-Fact-503C5F49D656E570EF19D1D0184B3CD7"
unitRef="usdPerShare">-0.84</us-gaap:EarningsPerShareBasicAndDiluted>
<us-gaap:EarningsPerShareBasicAndDiluted
contextRef="D2018Q4Jul12017toJun302018"
decimals="2"
id="d22912578e2960-wk-Fact-6152D000FB974A9716FED1D0184B167D"
unitRef="usdPerShare">-1.78</us-gaap:EarningsPerShareBasicAndDiluted>
<us-gaap:EarningsPerShareBasicAndDiluted
contextRef="D2017Q4Jul012016toJun302017"
decimals="2"
id="d22912578e2981-wk-Fact-15593DF1B21B85A3D63BD1D01865C103"
unitRef="usdPerShare">-1.47</us-gaap:EarningsPerShareBasicAndDiluted>
<us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted
contextRef="FD2019Q4YTD"
decimals="-3"
id="d22912578e2997-wk-Fact-2B1B8810A6E12D1E9555D713E12B856F"
unitRef="shares">193617000</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
<us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted
contextRef="D2018Q4Jul01-Dec31"
decimals="-3"
id="d22912578e3016-wk-Fact-B9734C406F4E5C1740AAD1D0185BD208"
unitRef="shares">188554000</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
<us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted
contextRef="D2018Q4Jul12017toJun302018"
decimals="-3"
id="d22912578e3035-wk-Fact-C1017F6E4A80C820BFDBD1D0184BDD1D"
unitRef="shares">153475000</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
<us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted
contextRef="D2017Q4Jul012016toJun302017"
decimals="-3"
id="d22912578e3055-wk-Fact-D45257CFA82E94991ADED1D0184B09B0"
unitRef="shares">104536000</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
<us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
contextRef="FD2019Q4YTD"
decimals="-3"
id="d22912578e3157-wk-Fact-64F61827888127DA9CE5D714166325C1"
unitRef="usd">174000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
<us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
contextRef="D2018Q4Jul01-Dec31"
decimals="-3"
id="d22912578e3176-wk-Fact-241CC7A97083AD10E426D1D0180B4B86"
unitRef="usd">-8000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
<us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
contextRef="D2018Q4Jul12017toJun302018"
decimals="-3"
id="d22912578e3196-wk-Fact-354906819C21877A706ED1D0180B75B0"
unitRef="usd">-105000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
<us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
contextRef="D2017Q4Jul012016toJun302017"
decimals="-3"
id="d22912578e3217-wk-Fact-2217B4ADC7FF49ED8FFDD1D0180B7908"
unitRef="usd">-62000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
<us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
contextRef="FD2019Q4YTD"
decimals="-3"
id="d22912578e3238-wk-Fact-CDE46A60F0AD907354B6D714170C011D"
unitRef="usd">-391000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
<us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
contextRef="D2018Q4Jul01-Dec31"
decimals="-3"
id="d22912578e3258-wk-Fact-2D7DAC56897B17192D1ED1D0185B2FE9"
unitRef="usd">10000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
<us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
contextRef="D2018Q4Jul12017toJun302018"
decimals="-3"
id="d22912578e3277-wk-Fact-8CB34EFDB3FF61B72480D1D0184BAD04"
unitRef="usd">55000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
<us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
contextRef="D2017Q4Jul012016toJun302017"
decimals="-3"
id="d22912578e3297-wk-Fact-2387014B7A4308282AD4D1D0185B1B2A"
unitRef="usd">-109000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
<us-gaap:OtherComprehensiveIncomeLossNetOfTax
contextRef="FD2019Q4YTD"
decimals="-3"
id="d22912578e3319-wk-Fact-A6C1E2230EF5DC9F423AD71417BAA3B2"
unitRef="usd">-217000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
<us-gaap:OtherComprehensiveIncomeLossNetOfTax
contextRef="D2018Q4Jul01-Dec31"
decimals="-3"
id="d22912578e3339-wk-Fact-8BE8CC99A112976EF87AD1D018643C0B"
unitRef="usd">2000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
<us-gaap:OtherComprehensiveIncomeLossNetOfTax
contextRef="D2018Q4Jul12017toJun302018"
decimals="-3"
id="d22912578e3358-wk-Fact-1ECA80141594AC8AB006D1D0180BF0F8"
unitRef="usd">-50000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
<us-gaap:OtherComprehensiveIncomeLossNetOfTax
contextRef="D2017Q4Jul012016toJun302017"
decimals="-3"
id="d22912578e3379-wk-Fact-E76D21D8C9058DC7E880D1D0185B55B6"
unitRef="usd">-171000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
<us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
contextRef="FD2019Q4YTD"
decimals="-3"
id="d22912578e3400-wk-Fact-E16FF6B81A3AEA0591F4D71418667B6B"
unitRef="usd">-357536000</us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest>
<us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
contextRef="D2018Q4Jul01-Dec31"
decimals="-3"
id="d22912578e3420-wk-Fact-B9166124E1B8323315C9D1D0184BC8DD"
unitRef="usd">-157747000</us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest>
<us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
contextRef="D2018Q4Jul12017toJun302018"
decimals="-3"
id="d22912578e3440-wk-Fact-6FD15BED102CB32E118ED1D018650531"
unitRef="usd">-273937000</us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest>
<us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
contextRef="D2017Q4Jul012016toJun302017"
decimals="-3"
id="d22912578e3461-wk-Fact-10C975ED81C3A179394DD1D01865FB4F"
unitRef="usd">-153437000</us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest>
<us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest
contextRef="FD2019Q4YTD"
decimals="-3"
id="d22912578e3482-wk-Fact-95094446A4E26AACC45CD7141919617A"
unitRef="usd">-129000</us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest>
<us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest
contextRef="D2018Q4Jul01-Dec31"
decimals="-3"
id="d22912578e3502-wk-Fact-0DDB5EC59D2DE3DD1DC8D1D01865913A"
unitRef="usd">-81000</us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest>
<us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest
contextRef="D2018Q4Jul12017toJun302018"
decimals="-3"
id="d22912578e3522-wk-Fact-3C60FCADDEC2AD213D1FD1D0184B4070"
unitRef="usd">-50000</us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest>
<us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest
contextRef="D2017Q4Jul012016toJun302017"
decimals="-3"
id="d22912578e3543-wk-Fact-B6F356B6EC1F96C21675D1D0184B0CD9"
unitRef="usd">-60000</us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest>
<us-gaap:ComprehensiveIncomeNetOfTax
contextRef="FD2019Q4YTD"
decimals="-3"
id="d22912578e3569-wk-Fact-5355A796CC6E7390D03BD71419C2106B"
unitRef="usd">-357407000</us-gaap:ComprehensiveIncomeNetOfTax>
<us-gaap:ComprehensiveIncomeNetOfTax
contextRef="D2018Q4Jul01-Dec31"
decimals="-3"
id="d22912578e3589-wk-Fact-AD97A9353DBD452590BED1D018658987"
unitRef="usd">-157666000</us-gaap:ComprehensiveIncomeNetOfTax>
<us-gaap:ComprehensiveIncomeNetOfTax
contextRef="D2018Q4Jul12017toJun302018"
decimals="-3"
id="d22912578e3609-wk-Fact-06305F149F3E5546440DD1D0184B9228"
unitRef="usd">-273887000</us-gaap:ComprehensiveIncomeNetOfTax>
<us-gaap:ComprehensiveIncomeNetOfTax
contextRef="D2017Q4Jul012016toJun302017"
decimals="-3"
id="d22912578e3630-wk-Fact-FC2BDBA6017F5C354F5CD1D0185B57FC"
unitRef="usd">-153377000</us-gaap:ComprehensiveIncomeNetOfTax>
<us-gaap:SharesIssued
contextRef="FI2016Q4_us-gaap_StatementClassOfStockAxis_us-gaap_ConvertiblePreferredStockMember"
decimals="-3"
id="d22922455e1469-wk-Fact-A228FF53951493EC1D73DB1A34391273"
unitRef="shares">0</us-gaap:SharesIssued>
<us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
contextRef="FI2016Q4_us-gaap_StatementClassOfStockAxis_us-gaap_ConvertiblePreferredStockMember"
decimals="-3"
id="d22922455e1488-wk-Fact-88FCAE56074F90C692BADB1A34487677"
unitRef="usd">0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
<us-gaap:SharesIssued
contextRef="FI2016Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"
decimals="-3"
id="d22922455e1502-wk-Fact-5887A7B81BA5D696D587DB1A34962BB1"
unitRef="shares">95868000</us-gaap:SharesIssued>
<us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
contextRef="FI2016Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"
decimals="-3"
id="d22922455e1522-wk-Fact-8CA16E2F9C6DC38642A0DB1A34F4B388"
unitRef="usd">958000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
<us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
contextRef="FI2016Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember"
decimals="-3"
id="d22922455e1541-wk-Fact-CBAE0CDA6EF8FDAFAA9DDB1A35A01494"
unitRef="usd">311320000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
<us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
contextRef="FI2016Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember"
decimals="-3"
id="d22922455e1560-wk-Fact-CFAD4F325349791A5B59DB1A361DDC9B"
unitRef="usd">-458000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
<us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
contextRef="FI2016Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember"
decimals="-3"
id="d22922455e1581-wk-Fact-AA86C2F9F278C2D1A9C3DB1A36D8E105"
unitRef="usd">-368505000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
<us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
contextRef="FI2016Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
decimals="-3"
id="d22922455e1601-wk-Fact-758529E64C065EDFFFCCDB1A3736EEC9"
unitRef="usd">-132000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
<us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
contextRef="FI2016Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember"
decimals="-3"
id="d22922455e1621-wk-Fact-33195E48254081FC35E0DB1A37C3B5C2"
unitRef="usd">-711000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
<us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
contextRef="FI2016Q4"
decimals="-3"
id="d22922455e1642-wk-Fact-42A7BF2368C2F8F556F7DB1A37FC1F61"
unitRef="usd">-57528000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
<immu:PreferredStockIssuedDuringPeriodSharesNewIssues
contextRef="D2017Q4Jul012016toJun302017_us-gaap_StatementClassOfStockAxis_us-gaap_ConvertiblePreferredStockMember"
decimals="-3"
id="d22922455e1658-wk-Fact-178DB0833555C0288B0DDB1A3822595A"
unitRef="shares">1000000</immu:PreferredStockIssuedDuringPeriodSharesNewIssues>
<immu:PreferredStockIssuedDuringPeriodValueNewIssues
contextRef="D2017Q4Jul012016toJun302017_us-gaap_StatementClassOfStockAxis_us-gaap_ConvertiblePreferredStockMember"
decimals="-3"
id="d22922455e1672-wk-Fact-C607F434E4B9F414AC23DB1A3861F27E"
unitRef="usd">10000</immu:PreferredStockIssuedDuringPeriodValueNewIssues>
<immu:PreferredStockIssuedDuringPeriodValueNewIssues
contextRef="D2017Q4Jul012016toJun302017_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember"
decimals="-3"
id="d22922455e1725-wk-Fact-A39E490FD33D3330AFEBDB1A388B5944"
unitRef="usd">121772000</immu:PreferredStockIssuedDuringPeriodValueNewIssues>
<immu:PreferredStockIssuedDuringPeriodValueNewIssues
contextRef="D2017Q4Jul012016toJun302017"
decimals="-3"
id="d22922455e1822-wk-Fact-46D11CF9762BEF05FA0FDB1A3926079B"
unitRef="usd">121782000</immu:PreferredStockIssuedDuringPeriodValueNewIssues>
<us-gaap:StockIssuedDuringPeriodSharesNewIssues
contextRef="D2017Q4Jul012016toJun302017_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember"
decimals="-3"
id="d22922455e1875-wk-Fact-61D43C9ACDD32C666934DB1A398DF64C"
unitRef="shares">10000000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
<us-gaap:StockIssuedDuringPeriodValueNewIssues
contextRef="D2017Q4Jul012016toJun302017_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember"
decimals="-3"
id="d22922455e1890-wk-Fact-6DFE38B0335E3293E171DB1A32771D27"
unitRef="usd">100000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
<us-gaap:StockIssuedDuringPeriodValueNewIssues
contextRef="D2017Q4Jul012016toJun302017_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember"
decimals="-3"
id="d22922455e1909-wk-Fact-D4FBDDEDF3125F850D0EDB1A325CC4A2"
unitRef="usd">28478000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
<us-gaap:StockIssuedDuringPeriodValueNewIssues
contextRef="D2017Q4Jul012016toJun302017_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember"
decimals="-3"
id="d22922455e2006-wk-Fact-0E9D2971ACD3649EAEA4DB1A336B9CD4"
unitRef="usd">28578000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
<immu:AdjustmentstoAdditionalPaidinCapitalProceedsFromOfferingWarrants
contextRef="D2017Q4Jul012016toJun302017_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember"
decimals="-3"
id="d22922455e2093-wk-Fact-D3F52AFB4CB6876B471DDB1A33A0CE85"
unitRef="usd">6966000</immu:AdjustmentstoAdditionalPaidinCapitalProceedsFromOfferingWarrants>
<immu:AdjustmentstoAdditionalPaidinCapitalProceedsFromOfferingWarrants
contextRef="D2017Q4Jul012016toJun302017"
decimals="-3"
id="d22922455e2191-wk-Fact-7485F83B70501FF6525CDB1A33B8D288"
unitRef="usd">6966000</immu:AdjustmentstoAdditionalPaidinCapitalProceedsFromOfferingWarrants>
<us-gaap:StockIssuedDuringPeriodSharesNewIssues
contextRef="D2017Q4Jul012016toJun302017_srt_CounterpartyNameAxis_immu_SeattleGeneticsIncMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember"
decimals="-3"
id="d22922455e2245-wk-Fact-41AB8B902A7BCB26A2AADB1A340AD9E0"
unitRef="shares">3000000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
<us-gaap:StockIssuedDuringPeriodValueNewIssues
contextRef="D2017Q4Jul012016toJun302017_srt_CounterpartyNameAxis_immu_SeattleGeneticsIncMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember"
decimals="-3"
id="d22922455e2260-wk-Fact-76ADFB0ECD5D445C28EEDB1A3429C50E"
unitRef="usd">30000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
<us-gaap:StockIssuedDuringPeriodValueNewIssues
contextRef="D2017Q4Jul012016toJun302017_srt_CounterpartyNameAxis_immu_SeattleGeneticsIncMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember"
decimals="-3"
id="d22922455e2279-wk-Fact-355DB0ED5AB07F4D315CDB1A3439F48B"
unitRef="usd">14670000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
<us-gaap:StockIssuedDuringPeriodValueNewIssues
contextRef="D2017Q4Jul012016toJun302017_srt_CounterpartyNameAxis_immu_SeattleGeneticsIncMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember"
decimals="-3"
id="d22922455e2376-wk-Fact-C109A21874BBFBA10134DB1A3513A124"
unitRef="usd">14700000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
<immu:AdjustmentstoAdditionalPaidinCapitalProceedsFromOfferingWarrants
contextRef="D2017Q4Jul012016toJun302017_srt_CounterpartyNameAxis_immu_SeattleGeneticsIncMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember"
decimals="-3"
id="d22922455e2463-wk-Fact-5C126682E18BB29EF614DB1A37B32D38"
unitRef="usd">14670000</immu:AdjustmentstoAdditionalPaidinCapitalProceedsFromOfferingWarrants>
<immu:AdjustmentstoAdditionalPaidinCapitalProceedsFromOfferingWarrants
contextRef="D2017Q4Jul012016toJun302017_srt_CounterpartyNameAxis_immu_SeattleGeneticsIncMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember"
decimals="-3"
id="d22922455e2561-wk-Fact-6E2BF2CC1D827777EAFADB1A38327B75"
unitRef="usd">14670000</immu:AdjustmentstoAdditionalPaidinCapitalProceedsFromOfferingWarrants>
<us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
contextRef="D2017Q4Jul012016toJun302017_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"
decimals="-3"
id="d22922455e2615-wk-Fact-E43519A3C4571190A20EDB1A38A55797"
unitRef="shares">1279000</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
<us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
contextRef="D2017Q4Jul012016toJun302017_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"
decimals="-3"
id="d22922455e2630-wk-Fact-53D83D0B495E49ED89EBDB1A38BFA027"
unitRef="usd">13000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
<us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
contextRef="D2017Q4Jul012016toJun302017_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember"
decimals="-3"
id="d22922455e2649-wk-Fact-D28335E6EDA15C68767BDB1A39159649"
unitRef="usd">4277000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
<us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
contextRef="D2017Q4Jul012016toJun302017"
decimals="-3"
id="d22922455e2746-wk-Fact-BCBD0953759B0069EFB2DB1A39597D43"
unitRef="usd">4290000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
<us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
contextRef="D2017Q4Jul012016toJun302017_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"
decimals="-3"
id="d22922455e2800-wk-Fact-52A752F8BD553FE392DBDB1A328E5246"
unitRef="shares">198000</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
<us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
contextRef="D2017Q4Jul012016toJun302017_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"
decimals="-3"
id="d22922455e2815-wk-Fact-AC7E4E3A08EE16992166DB1A32D92CED"
unitRef="usd">2000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
<us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
contextRef="D2017Q4Jul012016toJun302017_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember"
decimals="-3"
id="d22922455e2834-wk-Fact-B9B7EE813175781F3F6BDB1A32E48DC5"
unitRef="usd">3785000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
<us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
contextRef="D2017Q4Jul012016toJun302017"
decimals="-3"
id="d22922455e2931-wk-Fact-FAD7653E8F7629F6C063DB1A33768A4B"
unitRef="usd">3787000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
<us-gaap:OtherComprehensiveIncomeLossNetOfTax
contextRef="D2017Q4Jul012016toJun302017_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
decimals="-3"
id="d22922455e3076-wk-Fact-41522A8060540A8B032ADB1A33C9BB3D"
unitRef="usd">-171000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
<us-gaap:OtherComprehensiveIncomeLossNetOfTax
contextRef="D2017Q4Jul012016toJun302017"
decimals="-3"
id="d22922455e3116-wk-Fact-E76D21D8C9058DC7E880D1D0185B55B6"
unitRef="usd">-171000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
<us-gaap:ProfitLoss
contextRef="D2017Q4Jul012016toJun302017_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember"
decimals="-3"
id="d22922455e3243-wk-Fact-E6166577EACDCD72D74CDB1A35FE9B28"
unitRef="usd">-153206000</us-gaap:ProfitLoss>
<us-gaap:ProfitLoss
contextRef="D2017Q4Jul012016toJun302017_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember"
decimals="-3"
id="d22922455e3283-wk-Fact-5415C1BB72020B1D990FDB1A36B95436"
unitRef="usd">-60000</us-gaap:ProfitLoss>
<us-gaap:ProfitLoss
contextRef="D2017Q4Jul012016toJun302017"
decimals="-3"
id="d22922455e3304-wk-Fact-AC988A2DC8A22FB48CBDD1D018651B52"
unitRef="usd">-153266000</us-gaap:ProfitLoss>
<us-gaap:SharesIssued
contextRef="FI2017Q2_us-gaap_StatementClassOfStockAxis_us-gaap_ConvertiblePreferredStockMember"
decimals="-3"
id="d22922455e3325-wk-Fact-DC232591C496E06AD56ADB1A37E283AE"
unitRef="shares">1000000</us-gaap:SharesIssued>
<us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
contextRef="FI2017Q2_us-gaap_StatementClassOfStockAxis_us-gaap_ConvertiblePreferredStockMember"
decimals="-3"
id="d22922455e3344-wk-Fact-569D07F8B7886CC3E641DB1A380BF04D"
unitRef="usd">10000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
<us-gaap:SharesIssued
contextRef="FI2017Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"
decimals="-3"
id="d22922455e3358-wk-Fact-4F60F980CD721D1943F7DB1A3849F952"
unitRef="shares">110345000</us-gaap:SharesIssued>
<us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
contextRef="FI2017Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"
decimals="-3"
id="d22922455e3378-wk-Fact-6006DC0666129A72781BDB1A3859FED1"
unitRef="usd">1103000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
<us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
contextRef="FI2017Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember"
decimals="-3"
id="d22922455e3397-wk-Fact-14247BDA1650AF255671DB1A386911F7"
unitRef="usd">462666000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
<us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
contextRef="FI2017Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember"
decimals="-3"
id="d22922455e3416-wk-Fact-1268BDE9E2F8E4BD25F9DB1A389D4837"
unitRef="usd">-458000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
<us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
contextRef="FI2017Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember"
decimals="-3"
id="d22922455e3437-wk-Fact-1700F63F6A0812A161D9DB1A38AE1709"
unitRef="usd">-521711000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
<us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
contextRef="FI2017Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
decimals="-3"
id="d22922455e3457-wk-Fact-C250495353646701D3F8DB1A38D1AAF4"
unitRef="usd">-303000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
<us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
contextRef="FI2017Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember"
decimals="-3"
id="d22922455e3477-wk-Fact-77973AB87400221D4B8DDB1A38F45A1E"
unitRef="usd">-771000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
<us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
contextRef="FI2017Q2"
decimals="-3"
id="d22922455e3498-wk-Fact-894520B5C9B760872CA6DB1A39372D98"
unitRef="usd">-59464000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
<immu:ReclassificationofWarrantLiabilitytoEquity
contextRef="D2018Q4Jul12017toJun302018_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember"
decimals="-3"
id="d22922455e3581-wk-Fact-5A9E010A0A5AD759B13FDB1A323BFCA8"
unitRef="usd">190369000</immu:ReclassificationofWarrantLiabilitytoEquity>
<immu:ReclassificationofWarrantLiabilitytoEquity
contextRef="D2018Q4Jul12017toJun302018"
decimals="-3"
id="d22922455e3678-wk-Fact-AD9715B1063DB2C6B6E9DB1A32EF5E80"
unitRef="usd">190369000</immu:ReclassificationofWarrantLiabilitytoEquity>
<immu:SharebasedCompensationArrangementbySharebasedPaymentAwardWarrantsExercisesinPeriod
contextRef="D2018Q4Jul12017toJun302018_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"
decimals="-3"
id="d22922455e3731-wk-Fact-EA7169FC780F2B95CEA1DB1A33824448"
unitRef="shares">18206000</immu:SharebasedCompensationArrangementbySharebasedPaymentAwardWarrantsExercisesinPeriod>
<immu:StockIssuedDuringPeriodValueWarrantsExercised
contextRef="D2018Q4Jul12017toJun302018_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"
decimals="-3"
id="d22922455e3746-wk-Fact-5D744DC9B2C5678D6C81DB1A3388D819"
unitRef="usd">182000</immu:StockIssuedDuringPeriodValueWarrantsExercised>
<immu:StockIssuedDuringPeriodValueWarrantsExercised
contextRef="D2018Q4Jul12017toJun302018_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember"
decimals="-3"
id="d22922455e3765-wk-Fact-73EA3BF187A2A7FC7FE1DB1A3394B13C"
unitRef="usd">78044000</immu:StockIssuedDuringPeriodValueWarrantsExercised>
<immu:StockIssuedDuringPeriodValueWarrantsExercised
contextRef="D2018Q4Jul12017toJun302018"
decimals="-3"
id="d22922455e3862-wk-Fact-EB0DD7A8AD727D836DB1DB1A33C42F2D"
unitRef="usd">78226000</immu:StockIssuedDuringPeriodValueWarrantsExercised>
<us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
contextRef="D2018Q4Jul12017toJun302018_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"
decimals="-3"
id="d22922455e3915-wk-Fact-DAA6963965024C43DB1ADB1A340AF299"
unitRef="shares">586000</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
<us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
contextRef="D2018Q4Jul12017toJun302018_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"
decimals="-3"
id="d22922455e3930-wk-Fact-85A94CE600AA631703F6DB1A341A3EA6"
unitRef="usd">6000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
<us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
contextRef="D2018Q4Jul12017toJun302018_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember"
decimals="-3"
id="d22922455e3949-wk-Fact-1AE04C6BB6CC860B338EDB1A341A9655"
unitRef="usd">2255000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
<us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
contextRef="D2018Q4Jul12017toJun302018"
decimals="-3"
id="d22922455e4046-wk-Fact-20AEEE871EDC933B6758DB1A34B6345F"
unitRef="usd">2261000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
<us-gaap:StockIssuedDuringPeriodSharesNewIssues
contextRef="D2018Q4Jul12017toJun302018_srt_CounterpartyNameAxis_immu_RpiFinanceTrustMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"
decimals="-3"
id="d22922455e4099-wk-Fact-CCAD31FE206AD598FA06DB1A369AADBE"
unitRef="shares">4373000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
<us-gaap:StockIssuedDuringPeriodValueNewIssues
contextRef="D2018Q4Jul12017toJun302018_srt_CounterpartyNameAxis_immu_RpiFinanceTrustMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"
decimals="-3"
id="d22922455e4114-wk-Fact-6A2E27CBBDEE9C0716A5DB1A371758B1"
unitRef="usd">44000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
<us-gaap:StockIssuedDuringPeriodValueNewIssues
contextRef="D2018Q4Jul12017toJun302018_srt_CounterpartyNameAxis_immu_RpiFinanceTrustMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember"
decimals="-3"
id="d22922455e4133-wk-Fact-C956E00647699D663DDADB1A373664D2"
unitRef="usd">67740000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
<us-gaap:StockIssuedDuringPeriodValueNewIssues
contextRef="D2018Q4Jul12017toJun302018_srt_CounterpartyNameAxis_immu_RpiFinanceTrustMember"
decimals="-3"
id="d22922455e4230-wk-Fact-26FD7DE1205BED40DB8FDB1A381B7E38"
unitRef="usd">67784000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
<us-gaap:StockIssuedDuringPeriodSharesNewIssues
contextRef="D2018Q4Jul12017toJun302018_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember"
decimals="-3"
id="d22922455e4283-wk-Fact-D674818A4088772D2118DB1A37A4EC45"
unitRef="shares">13225000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
<us-gaap:StockIssuedDuringPeriodValueNewIssues
contextRef="D2018Q4Jul12017toJun302018_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember"
decimals="-3"
id="d22922455e4298-wk-Fact-B9D6690BFA9A5EA6A0C0DB1A34D530D2"
unitRef="usd">132000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
<us-gaap:StockIssuedDuringPeriodValueNewIssues
contextRef="D2018Q4Jul12017toJun302018_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember"
decimals="-3"
id="d22922455e4317-wk-Fact-B4DEC0C5BF902A7FE251DB1A339AD6D6"
unitRef="usd">299335000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
<us-gaap:StockIssuedDuringPeriodValueNewIssues
contextRef="D2018Q4Jul12017toJun302018_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember"
decimals="-3"
id="d22922455e4414-wk-Fact-7B7D779FA7A8362A15CADB1A3879A8D5"
unitRef="usd">299467000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
<us-gaap:StockIssuedDuringPeriodSharesConversionOfUnits
contextRef="D2018Q4Jul12017toJun302018_us-gaap_StatementClassOfStockAxis_us-gaap_ConvertiblePreferredStockMember"
decimals="-3"
id="d22922455e4434-wk-Fact-C6D124497FC01429C75BDB1A38C88B3C"
unitRef="shares">1000000</us-gaap:StockIssuedDuringPeriodSharesConversionOfUnits>
<us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecuritiesNetOfAdjustments
contextRef="D2018Q4Jul12017toJun302018_us-gaap_StatementClassOfStockAxis_us-gaap_ConvertiblePreferredStockMember"
decimals="-3"
id="d22922455e4449-wk-Fact-43A49EA247EB0D8F7B62DB1A38E2CFD3"
unitRef="usd">-10000</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecuritiesNetOfAdjustments>
<us-gaap:StockIssuedDuringPeriodSharesConversionOfUnits
contextRef="D2018Q4Jul12017toJun302018_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"
decimals="-3"
id="d22922455e4469-wk-Fact-946688E43C4E7119208FDB1A392E8D2D"
unitRef="shares">23105000</us-gaap:StockIssuedDuringPeriodSharesConversionOfUnits>
<us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecuritiesNetOfAdjustments
contextRef="D2018Q4Jul12017toJun302018_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"
decimals="-3"
id="d22922455e4484-wk-Fact-82FA74FAB817852BC51DDB1A390C8A69"
unitRef="usd">231000</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecuritiesNetOfAdjustments>
<us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecuritiesNetOfAdjustments
contextRef="D2018Q4Jul12017toJun302018_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember"
decimals="-3"
id="d22922455e4503-wk-Fact-65585779EDCE8CD3F870DB1A39DC783A"
unitRef="usd">-221000</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecuritiesNetOfAdjustments>
<us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecuritiesNetOfAdjustments
contextRef="D2018Q4Jul12017toJun302018"
decimals="-3"
id="d22922455e4601-wk-Fact-66E21C8357F68E5819E2DB1A3A14975F"
unitRef="usd">0</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecuritiesNetOfAdjustments>
<us-gaap:DebtConversionConvertedInstrumentSharesIssued1
contextRef="D2018Q4Jul12017toJun302018_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"
decimals="-3"
id="d22922455e4654-wk-Fact-A979096C24D5C23D858EDB1A35718257"
unitRef="shares">16800000</us-gaap:DebtConversionConvertedInstrumentSharesIssued1>
<us-gaap:DebtConversionConvertedInstrumentAmount1
contextRef="D2018Q4Jul12017toJun302018_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"
decimals="-3"
id="d22922455e4669-wk-Fact-0EFB495985B9843D8A5CDB1A367B1E61"
unitRef="usd">168000</us-gaap:DebtConversionConvertedInstrumentAmount1>
<us-gaap:DebtConversionConvertedInstrumentAmount1
contextRef="D2018Q4Jul12017toJun302018_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember"
decimals="-3"
id="d22922455e4688-wk-Fact-142EB4D1395EF0F43CFFDB1A36F87EB1"
unitRef="usd">92307000</us-gaap:DebtConversionConvertedInstrumentAmount1>
<us-gaap:DebtConversionConvertedInstrumentAmount1
contextRef="D2018Q4Jul12017toJun302018"
decimals="-3"
id="d22922455e4785-wk-Fact-BB66D9AB8A69F82D7FC0DB1A37D26911"
unitRef="usd">92475000</us-gaap:DebtConversionConvertedInstrumentAmount1>
<us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
contextRef="D2018Q4Jul12017toJun302018_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"
decimals="-3"
id="d22922455e4839-wk-Fact-8BFB71AD64D0ADFBACF6DB1A383A00B0"
unitRef="shares">331000</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
<us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
contextRef="D2018Q4Jul12017toJun302018_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"
decimals="-3"
id="d22922455e4854-wk-Fact-04266B8D16D7A205BABCDB1A3851BC12"
unitRef="usd">3000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
<us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
contextRef="D2018Q4Jul12017toJun302018_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember"
decimals="-3"
id="d22922455e4873-wk-Fact-5384D2B3252F547402A4DB1A3871AE61"
unitRef="usd">4024000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
<us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
contextRef="D2018Q4Jul12017toJun302018"
decimals="-3"
id="d22922455e4970-wk-Fact-415E090F48B97C9D0BFCDB1A39059A07"
unitRef="usd">4027000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
<us-gaap:SharesPaidForTaxWithholdingForShareBasedCompensation
contextRef="D2018Q4Jul12017toJun302018_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"
decimals="-3"
id="d22922455e5023-wk-Fact-CAC084D54571C6A20004DB1A397BBF8B"
unitRef="shares">170000</us-gaap:SharesPaidForTaxWithholdingForShareBasedCompensation>
<us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
contextRef="D2018Q4Jul12017toJun302018_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"
decimals="-3"
id="d22922455e5039-wk-Fact-46AA6B63E82EDC39D36CDB1A398340BA"
unitRef="usd">1000</us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation>
<us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
contextRef="D2018Q4Jul12017toJun302018_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember"
decimals="-3"
id="d22922455e5059-wk-Fact-79251B9941D8DAF2EFF2DB1A3997B07B"
unitRef="usd">1521000</us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation>
<us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
contextRef="D2018Q4Jul12017toJun302018"
decimals="-3"
id="d22922455e5157-wk-Fact-23CE170113E776D71EBEDB1A363C6226"
unitRef="usd">1522000</us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation>
<us-gaap:OtherComprehensiveIncomeLossNetOfTax
contextRef="D2018Q4Jul12017toJun302018_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
decimals="-3"
id="d22922455e5303-wk-Fact-AB5E70C4483A1DE69C98DB1A3813DD50"
unitRef="usd">-50000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
<us-gaap:OtherComprehensiveIncomeLossNetOfTax
contextRef="D2018Q4Jul12017toJun302018"
decimals="-3"
id="d22922455e5343-wk-Fact-1ECA80141594AC8AB006D1D0180BF0F8"
unitRef="usd">-50000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
<us-gaap:ProfitLoss
contextRef="D2018Q4Jul12017toJun302018_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember"
decimals="-3"
id="d22922455e5470-wk-Fact-18A6CED1342045E12F6ADB1A391D44FA"
unitRef="usd">-273837000</us-gaap:ProfitLoss>
<us-gaap:ProfitLoss
contextRef="D2018Q4Jul12017toJun302018_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember"
decimals="-3"
id="d22922455e5509-wk-Fact-CBA95FC35F2D22807768DB1A3947B9FB"
unitRef="usd">-50000</us-gaap:ProfitLoss>
<us-gaap:ProfitLoss
contextRef="D2018Q4Jul12017toJun302018"
decimals="-3"
id="d22922455e5530-wk-Fact-6CE3D07A35B1D83DEB81D1D0184B1FFE"
unitRef="usd">-273887000</us-gaap:ProfitLoss>
<us-gaap:SharesIssued
contextRef="FI2018Q2_us-gaap_StatementClassOfStockAxis_us-gaap_ConvertiblePreferredStockMember"
decimals="-3"
id="d22922455e5551-wk-Fact-C134259EB5AB2C48EBA3DB1A3A2C2F71"
unitRef="shares">0</us-gaap:SharesIssued>
<us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
contextRef="FI2018Q2_us-gaap_StatementClassOfStockAxis_us-gaap_ConvertiblePreferredStockMember"
decimals="-3"
id="d22922455e5570-wk-Fact-FE2899D8184CA487BC44DB1A3552C90B"
unitRef="usd">0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
<us-gaap:SharesIssued
contextRef="FI2018Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"
decimals="-3"
id="d22922455e5584-wk-Fact-9E1FB3DAAA6BBBFF3457DB1A35333466"
unitRef="shares">186801000</us-gaap:SharesIssued>
<us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
contextRef="FI2018Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"
decimals="-3"
id="d22922455e5604-wk-Fact-AD60146677BD42CE81FEDB1A35CF1BC1"
unitRef="usd">1868000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
<us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
contextRef="FI2018Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember"
decimals="-3"
id="d22922455e5623-wk-Fact-0CEB8110D18C8F6FBC41DB1A365B3B35"
unitRef="usd">1194998000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
<us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
contextRef="FI2018Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember"
decimals="-3"
id="d22922455e5642-wk-Fact-DB323081C326F2ED0571DB1A37275A21"
unitRef="usd">-458000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
<us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
contextRef="FI2018Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember"
decimals="-3"
id="d22922455e5663-wk-Fact-3E9BA2F69F795113AB2ADB1A37B36E81"
unitRef="usd">-795548000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
<us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
contextRef="FI2018Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
decimals="-3"
id="d22922455e5683-wk-Fact-7CD7C9D8D384C483DBEADB1A37C32986"
unitRef="usd">-353000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
<us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
contextRef="FI2018Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember"
decimals="-3"
id="d22922455e5703-wk-Fact-3F6901B10BA605A59DABDB1A37E2E6A0"
unitRef="usd">-821000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
<us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
contextRef="FI2018Q2"
decimals="-3"
id="d22922455e5724-wk-Fact-8D06FCED55F03AC4C6F8DB1A37F288CE"
unitRef="usd">399686000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
<immu:ReclassificationofWarrantLiabilitytoEquity
contextRef="D2018Q4Jul01-Dec31_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember"
decimals="-3"
id="d22922455e5806-wk-Fact-6338A29699F3B14BDB39DB1A38D9A838"
unitRef="usd">7569000</immu:ReclassificationofWarrantLiabilitytoEquity>
<immu:ReclassificationofWarrantLiabilitytoEquity
contextRef="D2018Q4Jul01-Dec31"
decimals="-3"
id="d22922455e5903-wk-Fact-207AD62C3915B0E6A8ADDB1A38FDA626"
unitRef="usd">7569000</immu:ReclassificationofWarrantLiabilitytoEquity>
<immu:SharebasedCompensationArrangementbySharebasedPaymentAwardWarrantsExercisesinPeriod
contextRef="D2018Q4Jul01-Dec31_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"
decimals="-3"
id="d22922455e5956-wk-Fact-79494612ECA232A37878DB1A3950C5E2"
unitRef="shares">450000</immu:SharebasedCompensationArrangementbySharebasedPaymentAwardWarrantsExercisesinPeriod>
<immu:StockIssuedDuringPeriodValueWarrantsExercised
contextRef="D2018Q4Jul01-Dec31_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"
decimals="-3"
id="d22922455e5971-wk-Fact-33A86064B144A57F390DDB1A39698BEE"
unitRef="usd">5000</immu:StockIssuedDuringPeriodValueWarrantsExercised>
<immu:StockIssuedDuringPeriodValueWarrantsExercised
contextRef="D2018Q4Jul01-Dec31_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember"
decimals="-3"
id="d22922455e5990-wk-Fact-F32DB8ABBA658C7761CCDB1A3972202A"
unitRef="usd">1683000</immu:StockIssuedDuringPeriodValueWarrantsExercised>
<immu:StockIssuedDuringPeriodValueWarrantsExercised
contextRef="D2018Q4Jul01-Dec31"
decimals="-3"
id="d22922455e6088-wk-Fact-A08C1E79F200350364F2DB1A35BFC13C"
unitRef="usd">1688000</immu:StockIssuedDuringPeriodValueWarrantsExercised>
<us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
contextRef="D2018Q4Jul01-Dec31_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"
decimals="-3"
id="d22922455e6141-wk-Fact-C3CCC4713C0B9C83CFF0DB1A37276675"
unitRef="shares">706000</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
<us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
contextRef="D2018Q4Jul01-Dec31_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"
decimals="-3"
id="d22922455e6156-wk-Fact-FD6FDFCC2691C135115FDB1A3803FDA2"
unitRef="usd">7000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
<us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
contextRef="D2018Q4Jul01-Dec31_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember"
decimals="-3"
id="d22922455e6175-wk-Fact-33C7A1EDE6F65E7C34ACDB1A37A495F1"
unitRef="usd">2619000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
<us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
contextRef="D2018Q4Jul01-Dec31_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember"
decimals="-3"
id="d22922455e6194-wk-Fact-7BDC108E4B64649C8035DB1A37D26358"
unitRef="usd">-2450000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
<us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
contextRef="D2018Q4Jul01-Dec31"
decimals="-3"
id="d22922455e6273-wk-Fact-5AA6E3D9AB361B4991A6DB1A382AE3C5"
unitRef="usd">176000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
<us-gaap:StockRepurchasedAndRetiredDuringPeriodShares
contextRef="D2018Q4Jul01-Dec31_srt_CounterpartyNameAxis_immu_RpiFinanceTrustMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"
decimals="-3"
id="d22922455e6326-wk-Fact-434E0C0454C92A056EC7DB1A3881E7F1"
unitRef="shares">106000</us-gaap:StockRepurchasedAndRetiredDuringPeriodShares>
<us-gaap:StockRepurchasedAndRetiredDuringPeriodValue
contextRef="D2018Q4Jul01-Dec31_srt_CounterpartyNameAxis_immu_RpiFinanceTrustMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"
decimals="-3"
id="d22922455e6342-wk-Fact-F888A5BA91B92D45A04FDB1A38936529"
unitRef="usd">1000</us-gaap:StockRepurchasedAndRetiredDuringPeriodValue>
<us-gaap:StockRepurchasedAndRetiredDuringPeriodValue
contextRef="D2018Q4Jul01-Dec31_srt_CounterpartyNameAxis_immu_RpiFinanceTrustMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember"
decimals="-3"
id="d22922455e6362-wk-Fact-89B276ADEC1EAA74C155DB1A38B67080"
unitRef="usd">2083000</us-gaap:StockRepurchasedAndRetiredDuringPeriodValue>
<us-gaap:StockRepurchasedAndRetiredDuringPeriodValue
contextRef="D2018Q4Jul01-Dec31_srt_CounterpartyNameAxis_immu_RpiFinanceTrustMember_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember"
decimals="-3"
id="d22922455e6382-wk-Fact-64CDA05FBBF3A1A0533EDB1A38EBD3D1"
unitRef="usd">-2084000</us-gaap:StockRepurchasedAndRetiredDuringPeriodValue>
<us-gaap:StockRepurchasedAndRetiredDuringPeriodValue
contextRef="D2018Q4Jul01-Dec31_srt_CounterpartyNameAxis_immu_RpiFinanceTrustMember"
decimals="-3"
id="d22922455e6460-wk-Fact-9441FEBA9D0985FE39BDDB1A393E015C"
unitRef="usd">0</us-gaap:StockRepurchasedAndRetiredDuringPeriodValue>
<us-gaap:DebtConversionConvertedInstrumentSharesIssued1
contextRef="D2018Q4Jul01-Dec31_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"
decimals="-3"
id="d22922455e6513-wk-Fact-9AB29318C83AC9004B93DB1A39BD2C4E"
unitRef="shares">2568000</us-gaap:DebtConversionConvertedInstrumentSharesIssued1>
<us-gaap:DebtConversionConvertedInstrumentAmount1
contextRef="D2018Q4Jul01-Dec31_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"
decimals="-3"
id="d22922455e6528-wk-Fact-A47C1EA74E813F829D3ADB1A39F5C5A5"
unitRef="usd">26000</us-gaap:DebtConversionConvertedInstrumentAmount1>
<us-gaap:DebtConversionConvertedInstrumentAmount1
contextRef="D2018Q4Jul01-Dec31_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember"
decimals="-3"
id="d22922455e6547-wk-Fact-AB087089441F773BD023DB1A32A8DFA6"
unitRef="usd">13757000</us-gaap:DebtConversionConvertedInstrumentAmount1>
<us-gaap:DebtConversionConvertedInstrumentAmount1
contextRef="D2018Q4Jul01-Dec31"
decimals="-3"
id="d22922455e6644-wk-Fact-44E6D0030383E00EA8CFDB1A32F47F95"
unitRef="usd">13783000</us-gaap:DebtConversionConvertedInstrumentAmount1>
<us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
contextRef="D2018Q4Jul01-Dec31_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"
decimals="-3"
id="d22922455e6697-wk-Fact-7337E6AE1F691C0AD237DB1A337C8817"
unitRef="shares">36000</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
<us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
contextRef="D2018Q4Jul01-Dec31_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember"
decimals="-3"
id="d22922455e6731-wk-Fact-9C61C9CE4F0F1D661676DB1A338DFB5F"
unitRef="usd">886000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
<us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
contextRef="D2018Q4Jul01-Dec31"
decimals="-3"
id="d22922455e6828-wk-Fact-9B9ED98A693589C5AA9EDB1A33AC7080"
unitRef="usd">886000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
<us-gaap:SharesPaidForTaxWithholdingForShareBasedCompensation
contextRef="D2018Q4Jul01-Dec31_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"
decimals="-3"
id="d22922455e6882-wk-Fact-06D88D1F562BF86AB490DB1A33CFCA7C"
unitRef="shares">9000</us-gaap:SharesPaidForTaxWithholdingForShareBasedCompensation>
<us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
contextRef="D2018Q4Jul01-Dec31_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember"
decimals="-3"
id="d22922455e6917-wk-Fact-7631E684054514533642DB1A33EF3175"
unitRef="usd">192000</us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation>
<us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
contextRef="D2018Q4Jul01-Dec31"
decimals="-3"
id="d22922455e7015-wk-Fact-A0F40B8EFDEF0171E27FDB1A344864FE"
unitRef="usd">192000</us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation>
<us-gaap:OtherComprehensiveIncomeLossNetOfTax
contextRef="D2018Q4Jul01-Dec31_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
decimals="-3"
id="d22922455e7161-wk-Fact-6412DDF91EE459E13C19DB1A3365D6EE"
unitRef="usd">2000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
<us-gaap:OtherComprehensiveIncomeLossNetOfTax
contextRef="D2018Q4Jul01-Dec31"
decimals="-3"
id="d22922455e7200-wk-Fact-8BE8CC99A112976EF87AD1D018643C0B"
unitRef="usd">2000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
<us-gaap:ProfitLoss
contextRef="D2018Q4Jul01-Dec31_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember"
decimals="-3"
id="d22922455e7326-wk-Fact-B3465BD810D5EBC02921DB1A33A6F84E"
unitRef="usd">-157668000</us-gaap:ProfitLoss>
<us-gaap:ProfitLoss
contextRef="D2018Q4Jul01-Dec31_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember"
decimals="-3"
id="d22922455e7366-wk-Fact-97BAEE797D6938FA7468DB1A33B21718"
unitRef="usd">-81000</us-gaap:ProfitLoss>
<us-gaap:ProfitLoss
contextRef="D2018Q4Jul01-Dec31"
decimals="-3"
id="d22922455e7387-wk-Fact-5ACF8E8FD2F7A88E6F00D1D0184B9305"
unitRef="usd">-157749000</us-gaap:ProfitLoss>
<us-gaap:SharesIssued
contextRef="FI2018Q4_us-gaap_StatementClassOfStockAxis_us-gaap_ConvertiblePreferredStockMember"
decimals="-3"
id="d22922455e7408-wk-Fact-34276AFB4FC86A1178A4DB1A33D6CF8B"
unitRef="shares">0</us-gaap:SharesIssued>
<us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
contextRef="FI2018Q4_us-gaap_StatementClassOfStockAxis_us-gaap_ConvertiblePreferredStockMember"
decimals="-3"
id="d22922455e7427-wk-Fact-D8BD7D786A88E93487EBDB1A33E97150"
unitRef="usd">0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
<us-gaap:SharesIssued
contextRef="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"
decimals="-3"
id="d22922455e7441-wk-Fact-67214A7B1CE5ABF3EA11DB1A33FC4ACF"
unitRef="shares">190446000</us-gaap:SharesIssued>
<us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
contextRef="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"
decimals="-3"
id="d22922455e7461-wk-Fact-A7FC0995A8AEBEE92D15DB1A341A815B"
unitRef="usd">1905000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
<us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
contextRef="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember"
decimals="-3"
id="d22922455e7480-wk-Fact-76A2D1DFA701CA8C6880DB1A34295F72"
unitRef="usd">1219237000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
<us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
contextRef="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember"
decimals="-3"
id="d22922455e7499-wk-Fact-6F1E8115D1B5B1C86E92DB1A34481A84"
unitRef="usd">-824000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
<us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
contextRef="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember"
decimals="-3"
id="d22922455e7520-wk-Fact-20814BF9D248359A344EDB1A347716B1"
unitRef="usd">-953216000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
<us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
contextRef="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
decimals="-3"
id="d22922455e7540-wk-Fact-562F6001069369D84768DB1A32C37129"
unitRef="usd">-351000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
<us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
contextRef="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember"
decimals="-3"
id="d22922455e7560-wk-Fact-EDF8707C7ABB7E2C3D9ADB1A32DFCE05"
unitRef="usd">-902000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
<us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
contextRef="FI2018Q4"
decimals="-3"
id="d22922455e7581-wk-Fact-82C9BC65B21B97B100C5D1D0184B8D2C"
unitRef="usd">265849000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
<us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
contextRef="FD2019Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"
decimals="-3"
id="d22922455e7629-wk-Fact-6ADB63583FDC17EED36AE0171C999F3D"
unitRef="shares">1207000</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
<us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
contextRef="FD2019Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"
decimals="-3"
id="d22922455e7644-wk-Fact-91E6D8158AAD11676781E0171E19DA1C"
unitRef="usd">12000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
<us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
contextRef="FD2019Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember"
decimals="-3"
id="d22922455e7663-wk-Fact-4A531C3AF5ABFF79425CE0171F88B28D"
unitRef="usd">3812000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
<us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
contextRef="FD2019Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember"
decimals="-3"
id="d22922455e7682-wk-Fact-FE80A5BA53B2FB9DE573E0179BF9B84D"
unitRef="usd">-1271000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
<us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
contextRef="FD2019Q4YTD"
decimals="-3"
id="d22922455e7761-wk-Fact-E36C8C0C6C8DB4384D73E0172567DC39"
unitRef="usd">2553000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
<us-gaap:StockIssuedDuringPeriodSharesNewIssues
contextRef="FD2019Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember"
decimals="-3"
id="d22922455e7814-wk-Fact-17EF308A0FE33AE3309DE0189C49A69A"
unitRef="shares">16429000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
<us-gaap:StockIssuedDuringPeriodValueNewIssues
contextRef="FD2019Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember"
decimals="-3"
id="d22922455e7829-wk-Fact-789CE102F96988BFD128E0189EDC4B95"
unitRef="usd">164000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
<us-gaap:StockIssuedDuringPeriodValueNewIssues
contextRef="FD2019Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember"
decimals="-3"
id="d22922455e7848-wk-Fact-4000A1B2DCE46DFD6593E018A179D642"
unitRef="usd">272867000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
<us-gaap:StockIssuedDuringPeriodValueNewIssues
contextRef="FD2019Q4YTD_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember"
decimals="-3"
id="d22922455e7945-wk-Fact-885847366CB4D0077E51E018AB642955"
unitRef="usd">273031000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
<us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
contextRef="FD2019Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"
decimals="-3"
id="d22922455e7998-wk-Fact-B30D6F1CA8BCB4BEA753E0193F59A74E"
unitRef="shares">15000</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
<us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
contextRef="FD2019Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember"
decimals="-3"
id="d22922455e8032-wk-Fact-9A1651F113BE49E50647E01942449541"
unitRef="usd">11736000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
<us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
contextRef="FD2019Q4YTD"
decimals="-3"
id="d22922455e8129-wk-Fact-43E52E5311509C4DD4F0E019479C45DF"
unitRef="usd">11736000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
<us-gaap:StockIssuedDuringPeriodSharesNewIssues
contextRef="FD2019Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_us-gaap_SubsidiarySaleOfStockAxis_immu_MarketOfferingMember"
decimals="-3"
id="d22922455e8182-wk-Fact-DCBB2FA4C7DE3AA80401E0226E38F11A"
unitRef="shares">4432000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
<us-gaap:StockIssuedDuringPeriodValueNewIssues
contextRef="FD2019Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_us-gaap_SubsidiarySaleOfStockAxis_immu_MarketOfferingMember"
decimals="-3"
id="d22922455e8197-wk-Fact-A821D07063F18F3FA45EE0227161BE54"
unitRef="usd">44000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
<us-gaap:StockIssuedDuringPeriodValueNewIssues
contextRef="FD2019Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_us-gaap_SubsidiarySaleOfStockAxis_immu_MarketOfferingMember"
decimals="-3"
id="d22922455e8216-wk-Fact-F222BE7870F9D334374FE022746DC81A"
unitRef="usd">71553000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
<us-gaap:StockIssuedDuringPeriodValueNewIssues
contextRef="FD2019Q4YTD_us-gaap_SubsidiarySaleOfStockAxis_immu_MarketOfferingMember"
decimals="-3"
id="d22922455e8313-wk-Fact-7BA23B140E9B754F2274E02283833BAB"
unitRef="usd">71597000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
<us-gaap:OtherComprehensiveIncomeLossNetOfTax
contextRef="FD2019Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
decimals="-3"
id="d22922455e8458-wk-Fact-DD9474BEB6B88C2EC211E01B9DDAC906"
unitRef="usd">-217000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
<us-gaap:OtherComprehensiveIncomeLossNetOfTax
contextRef="FD2019Q4YTD"
decimals="-3"
id="d22922455e8498-wk-Fact-A6C1E2230EF5DC9F423AD71417BAA3B2"
unitRef="usd">-217000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
<us-gaap:ProfitLoss
contextRef="FD2019Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember"
decimals="-3"
id="d22922455e8625-wk-Fact-D59B78AAE5CA59EF330BE01BD5405CD4"
unitRef="usd">-357190000</us-gaap:ProfitLoss>
<us-gaap:ProfitLoss
contextRef="FD2019Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember"
decimals="-3"
id="d22922455e8664-wk-Fact-1DA3F7A5EE15BA97FD65E01BD810D643"
unitRef="usd">-129000</us-gaap:ProfitLoss>
<us-gaap:ProfitLoss
contextRef="FD2019Q4YTD"
decimals="-3"
id="d22922455e8685-wk-Fact-29F9B6EF360FC370699FD713DDBDA593"
unitRef="usd">-357319000</us-gaap:ProfitLoss>
<us-gaap:SharesIssued
contextRef="FI2019Q4_us-gaap_StatementClassOfStockAxis_us-gaap_ConvertiblePreferredStockMember"
decimals="-3"
id="d22922455e8706-wk-Fact-4D91E5BC752B0EF014B4E01C2724CAD4"
unitRef="shares">0</us-gaap:SharesIssued>
<us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
contextRef="FI2019Q4_us-gaap_StatementClassOfStockAxis_us-gaap_ConvertiblePreferredStockMember"
decimals="-3"
id="d22922455e8725-wk-Fact-2EF83A51D107D60EA816E01C289606F8"
unitRef="usd">0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
<us-gaap:SharesIssued
contextRef="FI2019Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"
decimals="-3"
id="d22922455e8739-wk-Fact-351E87437DA2C208F602E01C2A121598"
unitRef="shares">212529000</us-gaap:SharesIssued>
<us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
contextRef="FI2019Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"
decimals="-3"
id="d22922455e8759-wk-Fact-F378FDBF492BA0B35961E01C2B82A3EF"
unitRef="usd">2125000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
<us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
contextRef="FI2019Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember"
decimals="-3"
id="d22922455e8778-wk-Fact-0153367734B82FD76113E01C2CFE5025"
unitRef="usd">1579205000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
<us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
contextRef="FI2019Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember"
decimals="-3"
id="d22922455e8797-wk-Fact-943E06949CDDB37031D5E01C2E71A7D8"
unitRef="usd">-2095000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
<us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
contextRef="FI2019Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember"
decimals="-3"
id="d22922455e8818-wk-Fact-E4C7EC056A034D54D906E01C2FEE1F96"
unitRef="usd">-1310406000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
<us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
contextRef="FI2019Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
decimals="-3"
id="d22922455e8838-wk-Fact-E05F826E7FC2B3955FA6E01C315FCF80"
unitRef="usd">-568000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
<us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
contextRef="FI2019Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember"
decimals="-3"
id="d22922455e8858-wk-Fact-012C9C92FE5184C3BED0E01C32DDBA4E"
unitRef="usd">-1031000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
<us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
contextRef="FI2019Q4"
decimals="-3"
id="d22922455e8879-wk-Fact-506CDA3CCB6716A29946D1D0184B0B3B"
unitRef="usd">267230000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
<us-gaap:ProfitLoss
contextRef="FD2019Q4YTD"
decimals="-3"
id="d22927408e922-wk-Fact-29F9B6EF360FC370699FD713DDBDA593"
unitRef="usd">-357319000</us-gaap:ProfitLoss>
<us-gaap:ProfitLoss
contextRef="D2018Q4Jul01-Dec31"
decimals="-3"
id="d22927408e942-wk-Fact-5ACF8E8FD2F7A88E6F00D1D0184B9305"
unitRef="usd">-157749000</us-gaap:ProfitLoss>
<us-gaap:ProfitLoss
contextRef="D2018Q4Jul12017toJun302018"
decimals="-3"
id="d22927408e962-wk-Fact-6CE3D07A35B1D83DEB81D1D0184B1FFE"
unitRef="usd">-273887000</us-gaap:ProfitLoss>
<us-gaap:ProfitLoss
contextRef="D2017Q4Jul012016toJun302017"
decimals="-3"
id="d22927408e983-wk-Fact-AC988A2DC8A22FB48CBDD1D018651B52"
unitRef="usd">-153266000</us-gaap:ProfitLoss>
<us-gaap:FairValueAdjustmentOfWarrants
contextRef="FD2019Q4YTD"
decimals="-3"
id="d22927408e1081-wk-Fact-D2E66984117CBB450CBED713D6D0FE4C"
unitRef="usd">0</us-gaap:FairValueAdjustmentOfWarrants>
<us-gaap:FairValueAdjustmentOfWarrants
contextRef="D2018Q4Jul01-Dec31"
decimals="-3"
id="d22927408e1100-wk-Fact-1D5D4506E00364D1DE67D1D0180B6BBD"
unitRef="usd">-1404000</us-gaap:FairValueAdjustmentOfWarrants>
<us-gaap:FairValueAdjustmentOfWarrants
contextRef="D2018Q4Jul12017toJun302018"
decimals="-3"
id="d22927408e1120-wk-Fact-E26CFE363B06D151ED08D1D0185B3F62"
unitRef="usd">108636000</us-gaap:FairValueAdjustmentOfWarrants>
<us-gaap:FairValueAdjustmentOfWarrants
contextRef="D2017Q4Jul012016toJun302017"
decimals="-3"
id="d22927408e1140-wk-Fact-F37ECCDD6B19E07A84DED1D0184BF9B9"
unitRef="usd">61074000</us-gaap:FairValueAdjustmentOfWarrants>
<us-gaap:AdjustmentOfWarrantsGrantedForServices
contextRef="FD2019Q4YTD"
decimals="-3"
id="d22927408e1160-wk-Fact-19C533DBB7AA881D2E4ED713D76EE172"
unitRef="usd">0</us-gaap:AdjustmentOfWarrantsGrantedForServices>
<us-gaap:AdjustmentOfWarrantsGrantedForServices
contextRef="D2018Q4Jul01-Dec31"
decimals="-3"
id="d22927408e1179-wk-Fact-02AC75F1B59F9F5CF65BD1D0180B5321"
unitRef="usd">0</us-gaap:AdjustmentOfWarrantsGrantedForServices>
<us-gaap:AdjustmentOfWarrantsGrantedForServices
contextRef="D2018Q4Jul12017toJun302018"
decimals="-3"
id="d22927408e1198-wk-Fact-98B95CF860F0B356D8DDD1D0185B395E"
unitRef="usd">0</us-gaap:AdjustmentOfWarrantsGrantedForServices>
<us-gaap:AdjustmentOfWarrantsGrantedForServices
contextRef="D2017Q4Jul012016toJun302017"
decimals="-3"
id="d22927408e1218-wk-Fact-797C88AEF9ED2C7F4EE3D1D0184B05E0"
unitRef="usd">7649000</us-gaap:AdjustmentOfWarrantsGrantedForServices>
<us-gaap:DepreciationAndAmortization
contextRef="FD2019Q4YTD"
decimals="-3"
id="d22927408e1238-wk-Fact-796F20817C8F559229CAE03DED5163C9"
unitRef="usd">3822000</us-gaap:DepreciationAndAmortization>
<us-gaap:DepreciationAndAmortization
contextRef="D2018Q4Jul01-Dec31"
decimals="-3"
id="d22927408e1257-wk-Fact-5E7A83E518B41047DEE3D1D0182AC33E"
unitRef="usd">2099000</us-gaap:DepreciationAndAmortization>
<us-gaap:DepreciationAndAmortization
contextRef="D2018Q4Jul12017toJun302018"
decimals="-3"
id="d22927408e1276-wk-Fact-61ABE4EE1D9A402E6FEBD1D0181BFFC5"
unitRef="usd">1297000</us-gaap:DepreciationAndAmortization>
<us-gaap:DepreciationAndAmortization
contextRef="D2017Q4Jul012016toJun302017"
decimals="-3"
id="d22927408e1296-wk-Fact-2BC04E4166F6D3520588D1D0183CB85C"
unitRef="usd">923000</us-gaap:DepreciationAndAmortization>
<us-gaap:GainLossOnSaleOfPropertyPlantEquipment
contextRef="FD2019Q4YTD"
decimals="-3"
id="d22927408e1316-wk-Fact-72005A0951F951DF966EE047E5F650F8"
unitRef="usd">-1003000</us-gaap:GainLossOnSaleOfPropertyPlantEquipment>
<us-gaap:GainLossOnSaleOfPropertyPlantEquipment
contextRef="D2018Q4Jul01-Dec31"
decimals="-3"
id="d22927408e1335-wk-Fact-352C2491E5806EE9148BE047E6078AE1"
unitRef="usd">0</us-gaap:GainLossOnSaleOfPropertyPlantEquipment>
<us-gaap:GainLossOnSaleOfPropertyPlantEquipment
contextRef="D2018Q4Jul12017toJun302018"
decimals="-3"
id="d22927408e1354-wk-Fact-A4EC20A8B78FADB20566E047E602B51B"
unitRef="usd">0</us-gaap:GainLossOnSaleOfPropertyPlantEquipment>
<us-gaap:GainLossOnSaleOfPropertyPlantEquipment
contextRef="D2017Q4Jul012016toJun302017"
decimals="-3"
id="d22927408e1374-wk-Fact-14204F7CF92813D54F90E047E5FD4AA4"
unitRef="usd">0</us-gaap:GainLossOnSaleOfPropertyPlantEquipment>
<us-gaap:InterestExpenseDebt
contextRef="FD2019Q4YTD"
decimals="-3"
id="d22927408e1394-wk-Fact-55D0CC5B9F74C0B7E003E03DEE735F4D"
unitRef="usd">39929000</us-gaap:InterestExpenseDebt>
<us-gaap:InterestExpenseDebt
contextRef="D2018Q4Jul01-Dec31"
decimals="-3"
id="d22927408e1413-wk-Fact-FE0C65C47E78AE3AD99ED1D0181B1F93"
unitRef="usd">19288000</us-gaap:InterestExpenseDebt>
<us-gaap:InterestExpenseDebt
contextRef="D2018Q4Jul12017toJun302018"
decimals="-3"
id="d22927408e1432-wk-Fact-C4C4DC191010160FB8D3D1D0185B657D"
unitRef="usd">19791000</us-gaap:InterestExpenseDebt>
<us-gaap:InterestExpenseDebt
contextRef="D2017Q4Jul012016toJun302017"
decimals="-3"
id="d22927408e1452-wk-Fact-9FD98E6EECA57E0E1697D1D0180B81DF"
unitRef="usd">0</us-gaap:InterestExpenseDebt>
<immu:LossOnInducedExchangesOfDebt
contextRef="FD2019Q4YTD"
decimals="-3"
id="d22927408e1472-wk-Fact-6F0080A18CB0CED25E92E03DEF194A94"
unitRef="usd">0</immu:LossOnInducedExchangesOfDebt>
<immu:LossOnInducedExchangesOfDebt
contextRef="D2018Q4Jul01-Dec31"
decimals="-3"
id="d22927408e1491-wk-Fact-E47672E3C80DDAD70C01D1D0180B0F49"
unitRef="usd">897000</immu:LossOnInducedExchangesOfDebt>
<immu:LossOnInducedExchangesOfDebt
contextRef="D2018Q4Jul12017toJun302018"
decimals="-3"
id="d22927408e1510-wk-Fact-17D8CE6622ACEC880707D1D01865B031"
unitRef="usd">13005000</immu:LossOnInducedExchangesOfDebt>
<immu:LossOnInducedExchangesOfDebt
contextRef="D2017Q4Jul012016toJun302017"
decimals="-3"
id="d22927408e1530-wk-Fact-E600B3AE91A97B17EC25D1D0183B6E8F"
unitRef="usd">0</immu:LossOnInducedExchangesOfDebt>
<us-gaap:ContractWithCustomerLiabilityRevenueRecognized
contextRef="FD2019Q4YTD"
decimals="-3"
id="d22927408e1551-wk-Fact-00B2B7A1E6125CB5CB26E03DEFBAE70F"
unitRef="usd">0</us-gaap:ContractWithCustomerLiabilityRevenueRecognized>
<us-gaap:ContractWithCustomerLiabilityRevenueRecognized
contextRef="D2018Q4Jul01-Dec31"
decimals="-3"
id="d22927408e1570-wk-Fact-2E811D4E8954A7DB753AD1D0181B41CA"
unitRef="usd">94000</us-gaap:ContractWithCustomerLiabilityRevenueRecognized>
<us-gaap:ContractWithCustomerLiabilityRevenueRecognized
contextRef="D2018Q4Jul12017toJun302018"
decimals="-3"
id="d22927408e1590-wk-Fact-ED74FD1E7A242DCD0A48D1D0181BA805"
unitRef="usd">77000</us-gaap:ContractWithCustomerLiabilityRevenueRecognized>
<us-gaap:ContractWithCustomerLiabilityRevenueRecognized
contextRef="D2017Q4Jul012016toJun302017"
decimals="-3"
id="d22927408e1611-wk-Fact-10CF2DF7F9BC2B6D2ED9D1D0182A2F0A"
unitRef="usd">64000</us-gaap:ContractWithCustomerLiabilityRevenueRecognized>
<us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments
contextRef="FD2019Q4YTD"
decimals="-3"
id="d22927408e1632-wk-Fact-315F871BAE6F3E575D65E03DF0665C28"
unitRef="usd">0</us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments>
<us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments
contextRef="D2018Q4Jul01-Dec31"
decimals="-3"
id="d22927408e1651-wk-Fact-363F775B1E771FE6569BD1D0180BE83C"
unitRef="usd">-3000</us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments>
<us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments
contextRef="D2018Q4Jul12017toJun302018"
decimals="-3"
id="d22927408e1670-wk-Fact-9C9400B76971994CA4FFD1D0182A0F22"
unitRef="usd">-31000</us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments>
<us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments
contextRef="D2017Q4Jul012016toJun302017"
decimals="-3"
id="d22927408e1690-wk-Fact-9BC21C1D3C9C418CC1A4D1D0183C27C7"
unitRef="usd">-218000</us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments>
<us-gaap:AmortizationOfFinancingCosts
contextRef="FD2019Q4YTD"
decimals="-3"
id="d22927408e1710-wk-Fact-38085602BB09E587F549E03DF1079925"
unitRef="usd">50000</us-gaap:AmortizationOfFinancingCosts>
<us-gaap:AmortizationOfFinancingCosts
contextRef="D2018Q4Jul01-Dec31"
decimals="-3"
id="d22927408e1729-wk-Fact-269E3818309893EB8304D1D0186540E4"
unitRef="usd">179000</us-gaap:AmortizationOfFinancingCosts>
<us-gaap:AmortizationOfFinancingCosts
contextRef="D2018Q4Jul12017toJun302018"
decimals="-3"
id="d22927408e1748-wk-Fact-07AF50940B45C6D84A2FD1D0181B8B7F"
unitRef="usd">1679000</us-gaap:AmortizationOfFinancingCosts>
<us-gaap:AmortizationOfFinancingCosts
contextRef="D2017Q4Jul012016toJun302017"
decimals="-3"
id="d22927408e1768-wk-Fact-A2FDABF98AFACA5099E8D1D0181B22CF"
unitRef="usd">730000</us-gaap:AmortizationOfFinancingCosts>
<us-gaap:IncreaseDecreaseInDeferredCharges
contextRef="FD2019Q4YTD"
decimals="-3"
id="d22927408e1788-wk-Fact-427E98B389C0E980DDF4E03DF1AEC5C9"
unitRef="usd">0</us-gaap:IncreaseDecreaseInDeferredCharges>
<us-gaap:IncreaseDecreaseInDeferredCharges
contextRef="D2018Q4Jul01-Dec31"
decimals="-3"
id="d22927408e1807-wk-Fact-687B1B63DE151E2F3C2BD1D0183C5FB5"
unitRef="usd">-132000</us-gaap:IncreaseDecreaseInDeferredCharges>
<us-gaap:IncreaseDecreaseInDeferredCharges
contextRef="D2018Q4Jul12017toJun302018"
decimals="-3"
id="d22927408e1826-wk-Fact-7AA6FA362DCD7A43235FD1D01865632E"
unitRef="usd">-279000</us-gaap:IncreaseDecreaseInDeferredCharges>
<us-gaap:IncreaseDecreaseInDeferredCharges
contextRef="D2017Q4Jul012016toJun302017"
decimals="-3"
id="d22927408e1846-wk-Fact-6DE7623FEC6B072E7251D1D0182AA220"
unitRef="usd">-10000</us-gaap:IncreaseDecreaseInDeferredCharges>
<us-gaap:FinanceLeaseRightOfUseAssetAmortization
contextRef="FD2019Q4YTD"
decimals="-3"
id="d22927408e1866-wk-Fact-0461DCA6A3DFAFDA7C1AE0477722A0F8"
unitRef="usd">264000</us-gaap:FinanceLeaseRightOfUseAssetAmortization>
<us-gaap:FinanceLeaseRightOfUseAssetAmortization
contextRef="D2018Q4Jul01-Dec31"
decimals="-3"
id="d22927408e1885-wk-Fact-29E3D6D1AF209B06B96BE04777274B72"
unitRef="usd">0</us-gaap:FinanceLeaseRightOfUseAssetAmortization>
<us-gaap:FinanceLeaseRightOfUseAssetAmortization
contextRef="D2018Q4Jul12017toJun302018"
decimals="-3"
id="d22927408e1904-wk-Fact-C5656CAAE3D775C3873CE047772C267C"
unitRef="usd">0</us-gaap:FinanceLeaseRightOfUseAssetAmortization>
<us-gaap:FinanceLeaseRightOfUseAssetAmortization
contextRef="D2017Q4Jul012016toJun302017"
decimals="-3"
id="d22927408e1924-wk-Fact-80B9230093CBA5B31C81E047771DED51"
unitRef="usd">0</us-gaap:FinanceLeaseRightOfUseAssetAmortization>
<us-gaap:DebtAndEquitySecuritiesGainLoss
contextRef="FD2019Q4YTD"
decimals="-3"
id="d22927408e1944-wk-Fact-3FA7CECAA7B0125B4476E03DF2DCAFCC"
unitRef="usd">0</us-gaap:DebtAndEquitySecuritiesGainLoss>
<us-gaap:DebtAndEquitySecuritiesGainLoss
contextRef="D2018Q4Jul01-Dec31"
decimals="-3"
id="d22927408e1963-wk-Fact-50D9B060540A9217ABE4D1D0183CA9D9"
unitRef="usd">0</us-gaap:DebtAndEquitySecuritiesGainLoss>
<us-gaap:DebtAndEquitySecuritiesGainLoss
contextRef="D2018Q4Jul12017toJun302018"
decimals="-3"
id="d22927408e1982-wk-Fact-C4E935E5407DC22D5D36D1D0185B42D1"
unitRef="usd">0</us-gaap:DebtAndEquitySecuritiesGainLoss>
<us-gaap:DebtAndEquitySecuritiesGainLoss
contextRef="D2017Q4Jul012016toJun302017"
decimals="-3"
id="d22927408e2002-wk-Fact-BCFDF14072B79812794BD1D0181B639C"
unitRef="usd">-16000</us-gaap:DebtAndEquitySecuritiesGainLoss>
<us-gaap:ProvisionForDoubtfulAccounts
contextRef="FD2019Q4YTD"
decimals="-3"
id="d22927408e2022-wk-Fact-C476D201DD89814BC935E03DF3881200"
unitRef="usd">0</us-gaap:ProvisionForDoubtfulAccounts>
<us-gaap:ProvisionForDoubtfulAccounts
contextRef="D2018Q4Jul01-Dec31"
decimals="-3"
id="d22927408e2041-wk-Fact-525457B19BBC6B61A1B5D1D0181B3E7A"
unitRef="usd">0</us-gaap:ProvisionForDoubtfulAccounts>
<us-gaap:ProvisionForDoubtfulAccounts
contextRef="D2018Q4Jul12017toJun302018"
decimals="-3"
id="d22927408e2060-wk-Fact-A499D78C396F5BB9AA1ED1D0182A5F1F"
unitRef="usd">-9000</us-gaap:ProvisionForDoubtfulAccounts>
<us-gaap:ProvisionForDoubtfulAccounts
contextRef="D2017Q4Jul012016toJun302017"
decimals="-3"
id="d22927408e2081-wk-Fact-6E7F0983A9E2CB2CD08DD1D0185BC28F"
unitRef="usd">-62000</us-gaap:ProvisionForDoubtfulAccounts>
<us-gaap:ShareBasedCompensation
contextRef="FD2019Q4YTD"
decimals="-3"
id="d22927408e2102-wk-Fact-3153A3E94C9F98F8B14BE03DF428872E"
unitRef="usd">11736000</us-gaap:ShareBasedCompensation>
<us-gaap:ShareBasedCompensation
contextRef="D2018Q4Jul01-Dec31"
decimals="-3"
id="d22927408e2121-wk-Fact-2357B96370D886723F5CD1D0182A5C6F"
unitRef="usd">886000</us-gaap:ShareBasedCompensation>
<us-gaap:ShareBasedCompensation
contextRef="D2018Q4Jul12017toJun302018"
decimals="-3"
id="d22927408e2140-wk-Fact-28AABABF5E384C3D2AE9D1D0181B4266"
unitRef="usd">4024000</us-gaap:ShareBasedCompensation>
<us-gaap:ShareBasedCompensation
contextRef="D2017Q4Jul012016toJun302017"
decimals="-3"
id="d22927408e2160-wk-Fact-6B4B93CD6EF7A42B450FD1D0183CC8E7"
unitRef="usd">4333000</us-gaap:ShareBasedCompensation>
<us-gaap:OtherNoncashExpense
contextRef="FD2019Q4YTD"
decimals="-3"
id="d22927408e2180-wk-Fact-A069CC3B7ADE1506E2BBE03DF6C54057"
unitRef="usd">0</us-gaap:OtherNoncashExpense>
<us-gaap:OtherNoncashExpense
contextRef="D2018Q4Jul01-Dec31"
decimals="-3"
id="d22927408e2199-wk-Fact-1962DED19E8A8AB89DCFD1D0180B059C"
unitRef="usd">0</us-gaap:OtherNoncashExpense>
<us-gaap:OtherNoncashExpense
contextRef="D2018Q4Jul12017toJun302018"
decimals="-3"
id="d22927408e2218-wk-Fact-C7C5B57B5CCB58A0932BD1D0182A1881"
unitRef="usd">0</us-gaap:OtherNoncashExpense>
<us-gaap:OtherNoncashExpense
contextRef="D2017Q4Jul012016toJun302017"
decimals="-3"
id="d22927408e2238-wk-Fact-B08B0B44F05FA383581ED1D0183C3753"
unitRef="usd">347000</us-gaap:OtherNoncashExpense>
<us-gaap:IncreaseDecreaseInAccountsReceivable
contextRef="FD2019Q4YTD"
decimals="-3"
id="d22927408e2340-wk-Fact-1F3E892E630ADCC147D7E03DF7DD26EE"
unitRef="usd">295000</us-gaap:IncreaseDecreaseInAccountsReceivable>
<us-gaap:IncreaseDecreaseInAccountsReceivable
contextRef="D2018Q4Jul01-Dec31"
decimals="-3"
id="d22927408e2360-wk-Fact-5063F3BEC0BBC08062E5D1D0181B1EC5"
unitRef="usd">-46000</us-gaap:IncreaseDecreaseInAccountsReceivable>
<us-gaap:IncreaseDecreaseInAccountsReceivable
contextRef="D2018Q4Jul12017toJun302018"
decimals="-3"
id="d22927408e2379-wk-Fact-93D84D449AE5A845E444D1D01865EB58"
unitRef="usd">-452000</us-gaap:IncreaseDecreaseInAccountsReceivable>
<us-gaap:IncreaseDecreaseInAccountsReceivable
contextRef="D2017Q4Jul012016toJun302017"
decimals="-3"
id="d22927408e2399-wk-Fact-48B029B0A4DA7B0EED00D1D0181BD835"
unitRef="usd">-103000</us-gaap:IncreaseDecreaseInAccountsReceivable>
<us-gaap:IncreaseDecreaseInInventories
contextRef="FD2019Q4YTD"
decimals="-3"
id="d22927408e2420-wk-Fact-1E70C9B811B92D4A7B43E03DF90A300E"
unitRef="usd">0</us-gaap:IncreaseDecreaseInInventories>
<us-gaap:IncreaseDecreaseInInventories
contextRef="D2018Q4Jul01-Dec31"
decimals="-3"
id="d22927408e2439-wk-Fact-CF5D647F10C26F0968F0D1D0181BF89B"
unitRef="usd">0</us-gaap:IncreaseDecreaseInInventories>
<us-gaap:IncreaseDecreaseInInventories
contextRef="D2018Q4Jul12017toJun302018"
decimals="-3"
id="d22927408e2458-wk-Fact-764FCBE86670B845D7FAD1D0182A6446"
unitRef="usd">-580000</us-gaap:IncreaseDecreaseInInventories>
<us-gaap:IncreaseDecreaseInInventories
contextRef="D2017Q4Jul012016toJun302017"
decimals="-3"
id="d22927408e2478-wk-Fact-6031D805A7BC190787CAD1D0185B36DE"
unitRef="usd">196000</us-gaap:IncreaseDecreaseInInventories>
<us-gaap:IncreaseDecreaseInOtherReceivables
contextRef="FD2019Q4YTD"
decimals="-3"
id="d22927408e2499-wk-Fact-A33B6E7F9AF4E6D507B7E03DF9CDE4E0"
unitRef="usd">0</us-gaap:IncreaseDecreaseInOtherReceivables>
<us-gaap:IncreaseDecreaseInOtherReceivables
contextRef="D2018Q4Jul01-Dec31"
decimals="-3"
id="d22927408e2518-wk-Fact-7F4B769A9CC117685186D1D0183CF81C"
unitRef="usd">0</us-gaap:IncreaseDecreaseInOtherReceivables>
<us-gaap:IncreaseDecreaseInOtherReceivables
contextRef="D2018Q4Jul12017toJun302018"
decimals="-3"
id="d22927408e2537-wk-Fact-0F0E243CF6AEE727184ED1D0182A9D78"
unitRef="usd">30000</us-gaap:IncreaseDecreaseInOtherReceivables>
<us-gaap:IncreaseDecreaseInOtherReceivables
contextRef="D2017Q4Jul012016toJun302017"
decimals="-3"
id="d22927408e2558-wk-Fact-CFB94900FCC471373741D1D0180BF7E3"
unitRef="usd">-223000</us-gaap:IncreaseDecreaseInOtherReceivables>
<us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
contextRef="FD2019Q4YTD"
decimals="-3"
id="d22927408e2578-wk-Fact-0E53CE49A7C9D148358BE03DFAA27027"
unitRef="usd">16423000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
<us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
contextRef="D2018Q4Jul01-Dec31"
decimals="-3"
id="d22927408e2598-wk-Fact-BAA4E071CF39ABFE6912D1D0181B2BC5"
unitRef="usd">-3617000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
<us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
contextRef="D2018Q4Jul12017toJun302018"
decimals="-3"
id="d22927408e2617-wk-Fact-31681F45B63E4BD6FB52D1D0182AB5C3"
unitRef="usd">7679000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
<us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
contextRef="D2017Q4Jul012016toJun302017"
decimals="-3"
id="d22927408e2638-wk-Fact-6D3CBF9B31E69EC49082D1D0185BD770"
unitRef="usd">97000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
<us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
contextRef="FD2019Q4YTD"
decimals="-3"
id="d22927408e2659-wk-Fact-85C04B9330B2518EF98FE03DFC9CF2AA"
unitRef="usd">29977000</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
<us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
contextRef="D2018Q4Jul01-Dec31"
decimals="-3"
id="d22927408e2678-wk-Fact-E3FC29AC548FFA912DEFD1D0183CD5B5"
unitRef="usd">1436000</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
<us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
contextRef="D2018Q4Jul12017toJun302018"
decimals="-3"
id="d22927408e2697-wk-Fact-C43717E4AD0EF0E50A22D1D0185B052A"
unitRef="usd">-1518000</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
<us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
contextRef="D2017Q4Jul012016toJun302017"
decimals="-3"
id="d22927408e2718-wk-Fact-63343A911680AED40207D1D0182ABF4E"
unitRef="usd">15809000</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
<us-gaap:IncreaseDecreaseInOtherOperatingLiabilities
contextRef="FD2019Q4YTD"
decimals="-3"
id="d22927408e2738-wk-Fact-8165F26AFB80EE0B36BAE042DA252EC1"
unitRef="usd">-186000</us-gaap:IncreaseDecreaseInOtherOperatingLiabilities>
<us-gaap:IncreaseDecreaseInOtherOperatingLiabilities
contextRef="D2018Q4Jul01-Dec31"
decimals="-3"
id="d22927408e2758-wk-Fact-1A4A8BB9759CDACDE464E042DA2F4F43"
unitRef="usd">0</us-gaap:IncreaseDecreaseInOtherOperatingLiabilities>
<us-gaap:IncreaseDecreaseInOtherOperatingLiabilities
contextRef="D2018Q4Jul12017toJun302018"
decimals="-3"
id="d22927408e2777-wk-Fact-35337C344C0CBC544DD8E042DA2AA3C9"
unitRef="usd">0</us-gaap:IncreaseDecreaseInOtherOperatingLiabilities>
<us-gaap:IncreaseDecreaseInOtherOperatingLiabilities
contextRef="D2017Q4Jul012016toJun302017"
decimals="-3"
id="d22927408e2797-wk-Fact-186B5C23720975FA2405E042DA1F28CB"
unitRef="usd">0</us-gaap:IncreaseDecreaseInOtherOperatingLiabilities>
<us-gaap:IncreaseDecreaseInDeferredRevenue
contextRef="FD2019Q4YTD"
decimals="-3"
id="d22927408e2817-wk-Fact-E9A7481E9DA23DB31181E04382CCF9F0"
unitRef="usd">65000000</us-gaap:IncreaseDecreaseInDeferredRevenue>
<us-gaap:IncreaseDecreaseInDeferredRevenue
contextRef="D2018Q4Jul01-Dec31"
decimals="-3"
id="d22927408e2836-wk-Fact-7BEBA1D145A1EB5C429EE043842AED24"
unitRef="usd">0</us-gaap:IncreaseDecreaseInDeferredRevenue>
<us-gaap:IncreaseDecreaseInDeferredRevenue
contextRef="D2018Q4Jul12017toJun302018"
decimals="-3"
id="d22927408e2855-wk-Fact-3E2F6328F2929A42A10FE04385E527C9"
unitRef="usd">0</us-gaap:IncreaseDecreaseInDeferredRevenue>
<us-gaap:IncreaseDecreaseInDeferredRevenue
contextRef="D2017Q4Jul012016toJun302017"
decimals="-3"
id="d22927408e2875-wk-Fact-F3031886EC60F9A6448AE04387B6A345"
unitRef="usd">0</us-gaap:IncreaseDecreaseInDeferredRevenue>
<us-gaap:NetCashProvidedByUsedInOperatingActivities
contextRef="FD2019Q4YTD"
decimals="-3"
id="d22927408e2895-wk-Fact-105F176A1DB59041C3C1E03DFE41A474"
unitRef="usd">-222442000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
<us-gaap:NetCashProvidedByUsedInOperatingActivities
contextRef="D2018Q4Jul01-Dec31"
decimals="-3"
id="d22927408e2915-wk-Fact-9881C2E57624659D5270D1D0182AE11A"
unitRef="usd">-130664000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
<us-gaap:NetCashProvidedByUsedInOperatingActivities
contextRef="D2018Q4Jul12017toJun302018"
decimals="-3"
id="d22927408e2935-wk-Fact-4035B20C58F079D3A7C7D1D0182A3DC9"
unitRef="usd">-133426000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
<us-gaap:NetCashProvidedByUsedInOperatingActivities
contextRef="D2017Q4Jul012016toJun302017"
decimals="-3"
id="d22927408e2956-wk-Fact-E728F2285F609C16FC95D1D0181B4F7A"
unitRef="usd">-62250000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
<us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt
contextRef="FD2019Q4YTD"
decimals="-3"
id="d22927408e3059-wk-Fact-DC22795EE41646A9F03FE03DFFB12850"
unitRef="usd">0</us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt>
<us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt
contextRef="D2018Q4Jul01-Dec31"
decimals="-3"
id="d22927408e3078-wk-Fact-DFF5F997DED8A72F25FCD1D0180B60C1"
unitRef="usd">0</us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt>
<us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt
contextRef="D2018Q4Jul12017toJun302018"
decimals="-3"
id="d22927408e3097-wk-Fact-90CCB689DA444C4657FCD1D0185BB712"
unitRef="usd">10380000</us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt>
<us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt
contextRef="D2017Q4Jul012016toJun302017"
decimals="-3"
id="d22927408e3118-wk-Fact-0AE8125908315C0960FFD1D0181B6A73"
unitRef="usd">131610000</us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt>
<us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
contextRef="FD2019Q4YTD"
decimals="-3"
id="d22927408e3139-wk-Fact-A2F9302707D8DCDDA31DE03E0058CB9E"
unitRef="usd">0</us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities>
<us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
contextRef="D2018Q4Jul01-Dec31"
decimals="-3"
id="d22927408e3158-wk-Fact-3F5A7910746DAAA9BBD0D1D0181B8A7F"
unitRef="usd">21818000</us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities>
<us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
contextRef="D2018Q4Jul12017toJun302018"
decimals="-3"
id="d22927408e3177-wk-Fact-1B33929C329F74A06CAED1D0183BA628"
unitRef="usd">95112000</us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities>
<us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
contextRef="D2017Q4Jul012016toJun302017"
decimals="-3"
id="d22927408e3197-wk-Fact-BB7F696DDC4C1CF56302D1D01865F0B9"
unitRef="usd">57183000</us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities>
<us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
contextRef="FD2019Q4YTD"
decimals="-3"
id="d22927408e3217-wk-Fact-D501140860E88A996C8DE03E0108D380"
unitRef="usd">6849000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
<us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
contextRef="D2018Q4Jul01-Dec31"
decimals="-3"
id="d22927408e3237-wk-Fact-DF901A1823C5EC6B4AC1D1D018646EA5"
unitRef="usd">11213000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
<us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
contextRef="D2018Q4Jul12017toJun302018"
decimals="-3"
id="d22927408e3257-wk-Fact-0DD4A17A158FD0FD55CFD1D018655460"
unitRef="usd">9975000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
<us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
contextRef="D2017Q4Jul012016toJun302017"
decimals="-3"
id="d22927408e3278-wk-Fact-5BAB0E3555C5B8798566D1D0180B3584"
unitRef="usd">1837000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
<us-gaap:NetCashProvidedByUsedInInvestingActivities
contextRef="FD2019Q4YTD"
decimals="-3"
id="d22927408e3300-wk-Fact-127C2563439CE49154B5E03E026B0AC8"
unitRef="usd">-6849000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
<us-gaap:NetCashProvidedByUsedInInvestingActivities
contextRef="D2018Q4Jul01-Dec31"
decimals="-3"
id="d22927408e3320-wk-Fact-AE7D93389679985B1D1CD1D0180B6614"
unitRef="usd">10605000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
<us-gaap:NetCashProvidedByUsedInInvestingActivities
contextRef="D2018Q4Jul12017toJun302018"
decimals="-3"
id="d22927408e3339-wk-Fact-9A06E4822D7686C58CBFD1D0182A5ACA"
unitRef="usd">74757000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
<us-gaap:NetCashProvidedByUsedInInvestingActivities
contextRef="D2017Q4Jul012016toJun302017"
decimals="-3"
id="d22927408e3359-wk-Fact-0A3444E6989A87FB4A5ED1D0181BE447"
unitRef="usd">-76264000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
<us-gaap:ProceedsFromStockOptionsExercised
contextRef="FD2019Q4YTD"
decimals="-3"
id="d22927408e3462-wk-Fact-855876B006BD995C61BCE03E0373EC35"
unitRef="usd">2553000</us-gaap:ProceedsFromStockOptionsExercised>
<us-gaap:ProceedsFromStockOptionsExercised
contextRef="D2018Q4Jul01-Dec31"
decimals="-3"
id="d22927408e3481-wk-Fact-68CF32679C55162FF6D5D1D01865F663"
unitRef="usd">176000</us-gaap:ProceedsFromStockOptionsExercised>
<us-gaap:ProceedsFromStockOptionsExercised
contextRef="D2018Q4Jul12017toJun302018"
decimals="-3"
id="d22927408e3500-wk-Fact-E5FC720EEA81334A98BAD1D0180BE418"
unitRef="usd">2261000</us-gaap:ProceedsFromStockOptionsExercised>
<us-gaap:ProceedsFromStockOptionsExercised
contextRef="D2017Q4Jul012016toJun302017"
decimals="-3"
id="d22927408e3520-wk-Fact-8DFD961D07AD6B5F0541D1D0183CA52F"
unitRef="usd">4290000</us-gaap:ProceedsFromStockOptionsExercised>
<us-gaap:ProceedsFromWarrantExercises
contextRef="FD2019Q4YTD"
decimals="-3"
id="d22927408e3540-wk-Fact-35B39B3B4A1E85D292EAE03E0418D5EB"
unitRef="usd">0</us-gaap:ProceedsFromWarrantExercises>
<us-gaap:ProceedsFromWarrantExercises
contextRef="D2018Q4Jul01-Dec31"
decimals="-3"
id="d22927408e3559-wk-Fact-4278239C42C56611E0A2D1D0182A0A9D"
unitRef="usd">1688000</us-gaap:ProceedsFromWarrantExercises>
<us-gaap:ProceedsFromWarrantExercises
contextRef="D2018Q4Jul12017toJun302018"
decimals="-3"
id="d22927408e3578-wk-Fact-0F29532860D2209B0E4DD1D0182A5123"
unitRef="usd">78226000</us-gaap:ProceedsFromWarrantExercises>
<us-gaap:ProceedsFromWarrantExercises
contextRef="D2017Q4Jul012016toJun302017"
decimals="-3"
id="d22927408e3598-wk-Fact-4B0F366850EEBC0595AAD1D0181B803A"
unitRef="usd">0</us-gaap:ProceedsFromWarrantExercises>
<us-gaap:ProceedsFromIssuanceOfPreferredStockAndPreferenceStock
contextRef="FD2019Q4YTD"
decimals="-3"
id="d22927408e3618-wk-Fact-62CE1B148A156791E279E03E04C2795E"
unitRef="usd">0</us-gaap:ProceedsFromIssuanceOfPreferredStockAndPreferenceStock>
<us-gaap:ProceedsFromIssuanceOfPreferredStockAndPreferenceStock
contextRef="D2018Q4Jul01-Dec31"
decimals="-3"
id="d22927408e3637-wk-Fact-DCA1AA1912B5933CD947D1D0182A7185"
unitRef="usd">0</us-gaap:ProceedsFromIssuanceOfPreferredStockAndPreferenceStock>
<us-gaap:ProceedsFromIssuanceOfPreferredStockAndPreferenceStock
contextRef="D2018Q4Jul12017toJun302018"
decimals="-3"
id="d22927408e3656-wk-Fact-70713572B3E7DCF81F14D1D0182A763F"
unitRef="usd">0</us-gaap:ProceedsFromIssuanceOfPreferredStockAndPreferenceStock>
<us-gaap:ProceedsFromIssuanceOfPreferredStockAndPreferenceStock
contextRef="D2017Q4Jul012016toJun302017"
decimals="-3"
id="d22927408e3676-wk-Fact-94E2B71FAA90A5537401D1D0181B0EA0"
unitRef="usd">121782000</us-gaap:ProceedsFromIssuanceOfPreferredStockAndPreferenceStock>
<us-gaap:ProceedsFromIssuanceInitialPublicOffering
contextRef="FD2019Q4YTD"
decimals="-3"
id="d22927408e3696-wk-Fact-3169E29DE0388E2B20A5E03E05697637"
unitRef="usd">273031000</us-gaap:ProceedsFromIssuanceInitialPublicOffering>
<us-gaap:ProceedsFromIssuanceInitialPublicOffering
contextRef="D2018Q4Jul01-Dec31"
decimals="-3"
id="d22927408e3715-wk-Fact-324654F3E82C89488BF5D1D0181BF1DE"
unitRef="usd">0</us-gaap:ProceedsFromIssuanceInitialPublicOffering>
<us-gaap:ProceedsFromIssuanceInitialPublicOffering
contextRef="D2018Q4Jul12017toJun302018"
decimals="-3"
id="d22927408e3734-wk-Fact-4B0DE5A19551B9C48F61D1D0182A9BB0"
unitRef="usd">299467000</us-gaap:ProceedsFromIssuanceInitialPublicOffering>
<us-gaap:ProceedsFromIssuanceInitialPublicOffering
contextRef="D2017Q4Jul012016toJun302017"
decimals="-3"
id="d22927408e3754-wk-Fact-90A2B33FCB01F079D047D1D0183A06DA"
unitRef="usd">28578000</us-gaap:ProceedsFromIssuanceInitialPublicOffering>
<us-gaap:ProceedsFromIssuanceOfCommonStock
contextRef="FD2019Q4YTD_us-gaap_SubsidiarySaleOfStockAxis_immu_MarketOfferingMember"
decimals="-3"
id="d22927408e3774-wk-Fact-570DE8390E8718F4222EE03E060FFE72"
unitRef="usd">71597000</us-gaap:ProceedsFromIssuanceOfCommonStock>
<us-gaap:ProceedsFromIssuanceOfCommonStock
contextRef="D2018Q4Jul01-Dec31_us-gaap_SubsidiarySaleOfStockAxis_immu_MarketOfferingMember"
decimals="-3"
id="d22927408e3793-wk-Fact-C3DAC846230131E426CF39BAC1CFCA81"
unitRef="usd">0</us-gaap:ProceedsFromIssuanceOfCommonStock>
<us-gaap:ProceedsFromIssuanceOfCommonStock
contextRef="D2018Q4Jul12017toJun302018_us-gaap_SubsidiarySaleOfStockAxis_immu_MarketOfferingMember"
decimals="-3"
id="d22927408e3812-wk-Fact-5AB400EA4B3A3C2A43BC39BACD3314B1"
unitRef="usd">0</us-gaap:ProceedsFromIssuanceOfCommonStock>
<us-gaap:ProceedsFromIssuanceOfCommonStock
contextRef="D2017Q4Jul012016toJun302017_us-gaap_SubsidiarySaleOfStockAxis_immu_MarketOfferingMember"
decimals="-3"
id="d22927408e3832-wk-Fact-3E8897258591B299137C39BAD7B9CFBF"
unitRef="usd">0</us-gaap:ProceedsFromIssuanceOfCommonStock>
<us-gaap:ProceedsFromIssuanceOfCommonStock
contextRef="FD2019Q4YTD_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember"
decimals="-3"
id="d22927408e3852-wk-Fact-F5D27E2C267B2BBAEEE739B36007FDBE"
unitRef="usd">0</us-gaap:ProceedsFromIssuanceOfCommonStock>
<us-gaap:ProceedsFromIssuanceOfCommonStock
contextRef="D2018Q4Jul01-Dec31_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember"
decimals="-3"
id="d22927408e3871-wk-Fact-F010E73EE4CF54D14A36D1D0181B7C91"
unitRef="usd">0</us-gaap:ProceedsFromIssuanceOfCommonStock>
<us-gaap:ProceedsFromIssuanceOfCommonStock
contextRef="D2018Q4Jul12017toJun302018_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember"
decimals="-3"
id="d22927408e3890-wk-Fact-08CF94FD00BFEDF1F28BD1D0183CC149"
unitRef="usd">67784000</us-gaap:ProceedsFromIssuanceOfCommonStock>
<us-gaap:ProceedsFromIssuanceOfCommonStock
contextRef="D2017Q4Jul012016toJun302017_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember"
decimals="-3"
id="d22927408e3910-wk-Fact-E565E3A9F9612F750AFBD1D0181BED10"
unitRef="usd">14700000</us-gaap:ProceedsFromIssuanceOfCommonStock>
<immu:ProceedsFromIssuanceOfNonRecourseDebt
contextRef="FD2019Q4YTD"
decimals="-3"
id="d22927408e3930-wk-Fact-C430B25CDD13101E63CBE03E06B5D264"
unitRef="usd">0</immu:ProceedsFromIssuanceOfNonRecourseDebt>
<immu:ProceedsFromIssuanceOfNonRecourseDebt
contextRef="D2018Q4Jul01-Dec31"
decimals="-3"
id="d22927408e3949-wk-Fact-CE3E5AE84C4DDBB2A3CCD1D0182A9C2C"
unitRef="usd">0</immu:ProceedsFromIssuanceOfNonRecourseDebt>
<immu:ProceedsFromIssuanceOfNonRecourseDebt
contextRef="D2018Q4Jul12017toJun302018"
decimals="-3"
id="d22927408e3968-wk-Fact-D7A5F0F5003D6359599ED1D0182A304A"
unitRef="usd">182216000</immu:ProceedsFromIssuanceOfNonRecourseDebt>
<immu:ProceedsFromIssuanceOfNonRecourseDebt
contextRef="D2017Q4Jul012016toJun302017"
decimals="-3"
id="d22927408e3988-wk-Fact-B2FD821B5351485AB039D1D0181BCD1E"
unitRef="usd">0</immu:ProceedsFromIssuanceOfNonRecourseDebt>
<immu:PaymentOfDebtConversionFees
contextRef="FD2019Q4YTD"
decimals="-3"
id="d22927408e4008-wk-Fact-C8EB7029A2C48C158D62E03E075DD939"
unitRef="usd">0</immu:PaymentOfDebtConversionFees>
<immu:PaymentOfDebtConversionFees
contextRef="D2018Q4Jul01-Dec31"
decimals="-3"
id="d22927408e4027-wk-Fact-EA6CE8C13C97B7729570D1D0182A80FB"
unitRef="usd">0</immu:PaymentOfDebtConversionFees>
<immu:PaymentOfDebtConversionFees
contextRef="D2018Q4Jul12017toJun302018"
decimals="-3"
id="d22927408e4046-wk-Fact-55AE829804B9A5A60AE5D1D0185B1F9F"
unitRef="usd">530000</immu:PaymentOfDebtConversionFees>
<immu:PaymentOfDebtConversionFees
contextRef="D2017Q4Jul012016toJun302017"
decimals="-3"
id="d22927408e4067-wk-Fact-9A050A083EE9207883E3D1D0185B3A55"
unitRef="usd">0</immu:PaymentOfDebtConversionFees>
<us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation
contextRef="FD2019Q4YTD"
decimals="-3"
id="d22927408e4087-wk-Fact-516CB4AB5F6B90908F93E03E0808C15F"
unitRef="usd">0</us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation>
<us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation
contextRef="D2018Q4Jul01-Dec31"
decimals="-3"
id="d22927408e4106-wk-Fact-D514A232A8B9A92B0B61D1D0183A25B4"
unitRef="usd">192000</us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation>
<us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation
contextRef="D2018Q4Jul12017toJun302018"
decimals="-3"
id="d22927408e4126-wk-Fact-2D985B48416D06503477D1D0182A9EA9"
unitRef="usd">1521000</us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation>
<us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation
contextRef="D2017Q4Jul012016toJun302017"
decimals="-3"
id="d22927408e4147-wk-Fact-DA230C32032D17FE1704D1D0182AC248"
unitRef="usd">546000</us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation>
<us-gaap:NetCashProvidedByUsedInFinancingActivities
contextRef="FD2019Q4YTD"
decimals="-3"
id="d22927408e4169-wk-Fact-15AA4D7D8B6FBCF6193EE03E08D30F81"
unitRef="usd">347181000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
<us-gaap:NetCashProvidedByUsedInFinancingActivities
contextRef="D2018Q4Jul01-Dec31"
decimals="-3"
id="d22927408e4188-wk-Fact-E3A215C08CCA35FF7B0DD1D0182A4CE2"
unitRef="usd">1672000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
<us-gaap:NetCashProvidedByUsedInFinancingActivities
contextRef="D2018Q4Jul12017toJun302018"
decimals="-3"
id="d22927408e4207-wk-Fact-85FB1EB10DCB43C77CB2D1D0182A1988"
unitRef="usd">627903000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
<us-gaap:NetCashProvidedByUsedInFinancingActivities
contextRef="D2017Q4Jul012016toJun302017"
decimals="-3"
id="d22927408e4227-wk-Fact-1B7E58CF0D22542D9DF1D1D01865F893"
unitRef="usd">168804000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
<us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
contextRef="FD2019Q4YTD"
decimals="-3"
id="d22927408e4247-wk-Fact-CD00A591E3EA6681559439B35FFFB72F"
unitRef="usd">-22000</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
<us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
contextRef="D2018Q4Jul01-Dec31"
decimals="-3"
id="d22927408e4267-wk-Fact-F5F2479C60AE1BD47CE9D1D0180B27FB"
unitRef="usd">-22000</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
<us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
contextRef="D2018Q4Jul12017toJun302018"
decimals="-3"
id="d22927408e4287-wk-Fact-505C4B84AA5D4C316DAED1D01865F32C"
unitRef="usd">-46000</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
<us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
contextRef="D2017Q4Jul012016toJun302017"
decimals="-3"
id="d22927408e4308-wk-Fact-6E437A14B2B947BF9690D1D0185BB818"
unitRef="usd">-100000</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
<us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
contextRef="FD2019Q4YTD"
decimals="-3"
id="d22927408e4329-wk-Fact-B95CAAC91F70AA1E1AD2E03E0A476FC3"
unitRef="usd">117868000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
<us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
contextRef="D2018Q4Jul01-Dec31"
decimals="-3"
id="d22927408e4348-wk-Fact-6EC15A1D90930728ED44D1D0180BDEC2"
unitRef="usd">-118409000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
<us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
contextRef="D2018Q4Jul12017toJun302018"
decimals="-3"
id="d22927408e4368-wk-Fact-B1510DCB162D7F3BEDBFD1D018651E70"
unitRef="usd">569188000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
<us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
contextRef="D2017Q4Jul012016toJun302017"
decimals="-3"
id="d22927408e4388-wk-Fact-742881101562FF38427BD1D0180B7FCE"
unitRef="usd">30190000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
<us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
contextRef="FI2018Q4"
decimals="-3"
id="d22927408e4408-wk-Fact-6D5B14D1F6D6938CB26AD1D018659C29"
unitRef="usd">494173000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
<us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
contextRef="FI2018Q2"
decimals="-3"
id="d22927408e4427-wk-Fact-718066546B34804E2C42D1D0185B0EC6"
unitRef="usd">612582000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
<us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
contextRef="FI2017Q2"
decimals="-3"
id="d22927408e4446-wk-Fact-CF0AB14AC23CEEB46858D1D0182A1CA9"
unitRef="usd">43394000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
<us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
contextRef="FI2016Q4"
decimals="-3"
id="d22927408e4466-wk-Fact-9CB258C2A7D45DE20F36D1D01865A3D6"
unitRef="usd">13204000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
<us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
contextRef="FI2019Q4"
decimals="-3"
id="d22927408e4491-wk-Fact-AF9460368D0650E51B54E03E0BB96189"
unitRef="usd">612041000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
<us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
contextRef="FI2018Q4"
decimals="-3"
id="d22927408e4510-wk-Fact-6D5B14D1F6D6938CB26AD1D018659C29"
unitRef="usd">494173000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
<us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
contextRef="FI2018Q2"
decimals="-3"
id="d22927408e4529-wk-Fact-718066546B34804E2C42D1D0185B0EC6"
unitRef="usd">612582000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
<us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
contextRef="FI2017Q2"
decimals="-3"
id="d22927408e4549-wk-Fact-CF0AB14AC23CEEB46858D1D0182A1CA9"
unitRef="usd">43394000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
<us-gaap:InterestPaidNet
contextRef="FD2019Q4YTD"
decimals="-3"
id="d22927408e4651-wk-Fact-2D3BE16986E793E84712E03E0CE3EC33"
unitRef="usd">338000</us-gaap:InterestPaidNet>
<us-gaap:InterestPaidNet
contextRef="D2018Q4Jul01-Dec31"
decimals="-3"
id="d22927408e4670-wk-Fact-454B7204524D8B3874AFD1D0183CB9AE"
unitRef="usd">475000</us-gaap:InterestPaidNet>
<us-gaap:InterestPaidNet
contextRef="D2018Q4Jul12017toJun302018"
decimals="-3"
id="d22927408e4689-wk-Fact-98A3EC35F0430866D085D1D0180B4AE4"
unitRef="usd">2850000</us-gaap:InterestPaidNet>
<us-gaap:InterestPaidNet
contextRef="D2017Q4Jul012016toJun302017"
decimals="-3"
id="d22927408e4709-wk-Fact-BCFC44F6B49818AA74D5D1D018653E0F"
unitRef="usd">4750000</us-gaap:InterestPaidNet>
<us-gaap:IncomeTaxesPaidNet
contextRef="FD2019Q4YTD"
decimals="-3"
id="d22927408e4729-wk-Fact-A155B91EE56DE38B9B1FE03E0D8EE85D"
unitRef="usd">0</us-gaap:IncomeTaxesPaidNet>
<us-gaap:IncomeTaxesPaidNet
contextRef="D2018Q4Jul01-Dec31"
decimals="-3"
id="d22927408e4748-wk-Fact-613BC2F958AC56B30B96D1D0183BBD5C"
unitRef="usd">0</us-gaap:IncomeTaxesPaidNet>
<us-gaap:IncomeTaxesPaidNet
contextRef="D2018Q4Jul12017toJun302018"
decimals="-3"
id="d22927408e4767-wk-Fact-A5674B8510B9356F6766D1D0181BC1C6"
unitRef="usd">0</us-gaap:IncomeTaxesPaidNet>
<us-gaap:IncomeTaxesPaidNet
contextRef="D2017Q4Jul012016toJun302017"
decimals="-3"
id="d22927408e4787-wk-Fact-8DA866395C026C8C94E8D1D0183C12E8"
unitRef="usd">24000</us-gaap:IncomeTaxesPaidNet>
<us-gaap:DebtConversionOriginalDebtAmount1
contextRef="FD2019Q4YTD"
decimals="-3"
id="d22927408e4889-wk-Fact-BC4B5D3A1BFFD83CDBFDE03E0EA706EF"
unitRef="usd">0</us-gaap:DebtConversionOriginalDebtAmount1>
<us-gaap:DebtConversionOriginalDebtAmount1
contextRef="D2018Q4Jul01-Dec31"
decimals="-3"
id="d22927408e4908-wk-Fact-FD40D3203A3AB49C3046D1D0182A2315"
unitRef="usd">13757000</us-gaap:DebtConversionOriginalDebtAmount1>
<us-gaap:DebtConversionOriginalDebtAmount1
contextRef="D2018Q4Jul12017toJun302018"
decimals="-3"
id="d22927408e4927-wk-Fact-BCAAA96C0D98FB904106D1D0181BD813"
unitRef="usd">92307000</us-gaap:DebtConversionOriginalDebtAmount1>
<us-gaap:DebtConversionOriginalDebtAmount1
contextRef="D2017Q4Jul012016toJun302017"
decimals="-3"
id="d22927408e4947-wk-Fact-50000F7DEF97E0D0282AD1D0185B96FE"
unitRef="usd">0</us-gaap:DebtConversionOriginalDebtAmount1>
<us-gaap:CapitalExpendituresIncurredButNotYetPaid
contextRef="FD2019Q4YTD"
decimals="-3"
id="d22927408e4967-wk-Fact-19B9A5D46FC6F777A6EBE03E0F4C1447"
unitRef="usd">101000</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
<us-gaap:CapitalExpendituresIncurredButNotYetPaid
contextRef="D2018Q4Jul01-Dec31"
decimals="-3"
id="d22927408e4986-wk-Fact-723D145BA68A07E35DD7D1D0183C1642"
unitRef="usd">795000</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
<us-gaap:CapitalExpendituresIncurredButNotYetPaid
contextRef="D2018Q4Jul12017toJun302018"
decimals="-3"
id="d22927408e5005-wk-Fact-C2DEE5DE86402AA98AFBD1D0181B2590"
unitRef="usd">2173000</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
<us-gaap:CapitalExpendituresIncurredButNotYetPaid
contextRef="D2017Q4Jul012016toJun302017"
decimals="-3"
id="d22927408e5025-wk-Fact-F38C0A5F93FFB6DA4F51D1D0182A5984"
unitRef="usd">0</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
<immu:ReclassOfWarrantLiabilityToCapitalContributedInExcessOfPar
contextRef="FD2019Q4YTD"
decimals="-3"
id="d22927408e5046-wk-Fact-CB87C24A0EC65ED46208E03E0FF7BBD7"
unitRef="usd">0</immu:ReclassOfWarrantLiabilityToCapitalContributedInExcessOfPar>
<immu:ReclassOfWarrantLiabilityToCapitalContributedInExcessOfPar
contextRef="D2018Q4Jul01-Dec31"
decimals="-3"
id="d22927408e5065-wk-Fact-624BA810BAA5A6534EC6D1D0182A59C0"
unitRef="usd">7569000</immu:ReclassOfWarrantLiabilityToCapitalContributedInExcessOfPar>
<immu:ReclassOfWarrantLiabilityToCapitalContributedInExcessOfPar
contextRef="D2018Q4Jul12017toJun302018"
decimals="-3"
id="d22927408e5084-wk-Fact-A1D735BEFD4BBC202CD2D1D0185BACB7"
unitRef="usd">0</immu:ReclassOfWarrantLiabilityToCapitalContributedInExcessOfPar>
<immu:ReclassOfWarrantLiabilityToCapitalContributedInExcessOfPar
contextRef="D2017Q4Jul012016toJun302017"
decimals="-3"
id="d22927408e5104-wk-Fact-0E7A2A6E3E242813BB52D1D0180B2540"
unitRef="usd">0</immu:ReclassOfWarrantLiabilityToCapitalContributedInExcessOfPar>
<us-gaap:StockIssued1
contextRef="FD2019Q4YTD"
decimals="-3"
id="d22927408e5124-wk-Fact-5DF0496CE18BDE23074AE03E109ECBE3"
unitRef="usd">1271000</us-gaap:StockIssued1>
<us-gaap:StockIssued1
contextRef="D2018Q4Jul01-Dec31"
decimals="-3"
id="d22927408e5143-wk-Fact-EF398E3D05DEB45E6BB4D1D0186499B4"
unitRef="usd">2450000</us-gaap:StockIssued1>
<us-gaap:StockIssued1
contextRef="D2018Q4Jul12017toJun302018"
decimals="-3"
id="d22927408e5162-wk-Fact-2791EAB3155BFB730D33D1D0180BC1C1"
unitRef="usd">0</us-gaap:StockIssued1>
<us-gaap:StockIssued1
contextRef="D2017Q4Jul012016toJun302017"
decimals="-3"
id="d22927408e5182-wk-Fact-AA31417070BFC2CCAF4FD1D0181BFF42"
unitRef="usd">0</us-gaap:StockIssued1>
<us-gaap:CashAndCashEquivalentsAtCarryingValue
contextRef="FI2019Q4"
decimals="-3"
id="d22927408e5350-wk-Fact-DC4AE9A8FE4AE0112236D1D0184B774F"
unitRef="usd">608628000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
<us-gaap:CashAndCashEquivalentsAtCarryingValue
contextRef="FI2018Q4"
decimals="-3"
id="d22927408e5369-wk-Fact-71ACCBE1F94A85D78382D1D0184B1F30"
unitRef="usd">492860000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
<us-gaap:CashAndCashEquivalentsAtCarryingValue
contextRef="FI2018Q2"
decimals="-3"
id="d22927408e5388-wk-Fact-80EF5A48784EB236CEFBD1D0181B2035"
unitRef="usd">612057000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
<us-gaap:RestrictedCashCurrent
contextRef="FI2019Q4"
decimals="-3"
id="d22927408e5404-wk-Fact-9D7DA728DDC623261698E03EB93965FE"
unitRef="usd">3413000</us-gaap:RestrictedCashCurrent>
<us-gaap:RestrictedCashCurrent
contextRef="FI2018Q4"
decimals="-3"
id="d22927408e5423-wk-Fact-35E0C66E965F74B667ABD1D0182A2292"
unitRef="usd">1313000</us-gaap:RestrictedCashCurrent>
<us-gaap:RestrictedCashCurrent
contextRef="FI2018Q2"
decimals="-3"
id="d22927408e5442-wk-Fact-BA12B45D4859B1EE014DD1D0182A8274"
unitRef="usd">525000</us-gaap:RestrictedCashCurrent>
<us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
contextRef="FI2019Q4"
decimals="-3"
id="d22927408e5468-wk-Fact-AF9460368D0650E51B54E03E0BB96189"
unitRef="usd">612041000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
<us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
contextRef="FI2018Q4"
decimals="-3"
id="d22927408e5487-wk-Fact-6D5B14D1F6D6938CB26AD1D018659C29"
unitRef="usd">494173000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
<us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
contextRef="FI2018Q2"
decimals="-3"
id="d22927408e5506-wk-Fact-718066546B34804E2C42D1D0185B0EC6"
unitRef="usd">612582000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
<us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock
contextRef="FD2019Q4YTD"
id="TextSelection-233697280A886946CB74D1D0186581DF-0-wk-Fact-2CB3DE235F0C10149D15D1D0182A1681">Business Overview and Summary of Significant Accounting Policies<div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Immunomedics, Inc., a Delaware corporation, together with its subsidiaries (collectively "we," "our," "us," "Immunomedics", or the "Company"), is a clinical-stage biopharmaceutical company that develops monoclonal antibody-based products for the targeted treatment of cancer. Immunomedics manages its operations as one line of business of researching, developing, manufacturing and marketing biopharmaceutical products, particularly antibody-based products for patients with difficult to treat solid tumor and blood cancers. The Company currently reports as a single industry segment with substantially all business conducted in the United States. Immunomedics conducts its research activities in the United States and runs its development studies in the United States and selected European countries. Our corporate objective is to become a fully-integrated biopharmaceutical company and a leader in the field of antibody-drug conjugates (“ADCs”). To that end, our immediate priority is to commercialize our most advanced ADC product candidate, sacituzumab govitecan ("IMMU-132"), beginning in the United States, with metastatic triple-negative breast cancer (“mTNBC”) as the first indication. </span><span style="font-family:inherit;font-size:10pt;">In May 2018, we submitted a Biologics License Application (“BLA”) to the United States Food and Drug Administration ("FDA") for sacituzumab govitecan for the treatment of patients with mTNBC who have received at least two prior therapies for metastatic disease. In July 2018, we received notification from the FDA that the BLA was accepted for filing and the original application was granted Priority Review with a Prescription Drug User Fee Act ("PDUFA") target action date in January 2019. In January 2019, we received a Complete Response Letter ("CRL") from the FDA for the BLA. We subsequently met with the FDA in May 2019 to review the FDA’s findings and discussed our BLA resubmission. Since then, we have developed a detailed plan to address the chemistry, manufacturing, and controls (“CMC”) matters raised in the CRL and in our pre-approval inspection. We held another meeting with the FDA in September 2019 to update the FDA on our progress in addressing these matters and to receive feedback from the FDA on our approach. On November 30, 2019, we resubmitted our BLA to the FDA and on December 23, 2019 we received notification from the FDA that the BLA was accepted for filing and further assigned a new PDUFA target action date as June 2, 2020. We have dedicated, and continue to commit, significant resources to address the CMC matters identified by the FDA, while, in parallel, preparing our manufacturing facility to be ready for re-inspection by the FDA. Our Phase 3 confirmatory ASCENT study for sacituzumab govitecan has reached its target enrollment for mTNBC patients previously treated with at least two systemic chemotherapy regimens. Top-line data for the ASCENT study is expected to be available around mid-2020. </span><span style="font-family:inherit;font-size:10pt;"> </span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company has a foreign subsidiary, Immunomedics GmbH in Rodermark, Germany, that assists the Company in managing sales and marketing efforts and coordinating clinical trials in Europe. The accompanying consolidated financial statements include results for its foreign subsidiary and its majority-owned United States subsidiary, IBC Pharmaceuticals, Inc. ("IBC"). </span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Immunomedics is subject to significant risks and uncertainties, including, without limitation, the Company's inability to further identify, develop and achieve commercial success for new products and technologies; the possibility of delays in the research and development necessary to select drug development candidates and delays in clinical trials; the risk that clinical trials may not result in marketable products; the risk that the Company may be unable to secure regulatory approval of and market its drug candidates; the development or regulatory approval of competing products; the Company's ability to protect its proprietary technologies; patent infringement claims; and risks of new, changing and competitive technologies, and regulations in the United States and internationally.</span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Since its inception in 1982, Immunomedics’ principal sources of funds have been the private and public sale of equity and debt securities, and revenues from licensing agreements, including up-front and milestone payments, funding of development programs, and other forms of funding from collaborations. </span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company expects to continue to fund its operations with its current financial resources. </span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Summary of Significant Accounting Policies:</span></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Basis of Presentation</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The consolidated financial statements include the accounts of Immunomedics and its subsidiaries. Noncontrolling interests in consolidated subsidiaries in the consolidated balance sheets represent minority stockholders' proportionate share of the equity (deficit) in such subsidiaries. All intercompany balances and transactions have been eliminated in consolidation. In this Annual Report, the periods presented are the year ended December 31, 2019, the six-month transition period from July 1, 2018 to December 31, 2018 (which we sometimes refer to as the "Transition Period") and our fiscal years ended June 30, 2018 and 2017 (which are referred to as “fiscal 2018,” and "fiscal 2017", as if we had not changed our fiscal year to a calendar year).</span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Use of Estimates</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The preparation of consolidated financial statements in conformity with United States generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reported period. Actual results could differ from those estimates. The Company’s significant estimates and assumptions relate to stock-based compensation expenses, the fair value for the liability related to sale of future royalties and related interest expense.</span></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Interest Expense on Liability Related to Sale of Future Royalties</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company accounts for the liability related to the sale of future royalties as a debt financing. The Company has a significant continuing involvement in the generation of related royalty streams. The Company accretes this liability and recognizes expected interest expense using the effective interest rate method over the life of the related royalty stream, based on our current estimates of future royalty payments. These estimates include projections the Company makes and projections from outside the Company and involves significant judgment and inherent uncertainties. The Company periodically re-assesses the projections and, to the extent our future projections are greater or less than its previous estimates or the estimated timing of such payments is materially different than its previous estimates, the Company will adjust the effective interest calculation.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Foreign Currencies</span><span style="font-family:inherit;font-size:10pt;font-style:italic;"> </span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">For our German subsidiary which operates in a local currency environment, income and expense items are translated to United States dollars at the monthly average rates of exchange prevailing during the year, assets and liabilities are translated at year-end exchange rates and equity accounts are translated at historical exchange rates. Translation adjustments are accumulated in a separate component of stockholders' equity in the consolidated balance sheets and the consolidated statements of changes in stockholders’ equity and are included in the determination of comprehensive (loss) income in the consolidated statements of comprehensive loss. Transaction gains and losses are included in the determination of net loss in the consolidated statements of comprehensive loss.</span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Financial Instruments</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The carrying amount of cash and cash equivalents, prepaid expenses, other current assets and current liabilities approximate fair value due to the short-term maturity of these instruments. The Company considers all highly liquid investments with an original maturity of three months or less when purchased to be cash equivalents.</span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Marketable Securities</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Marketable securities, all of which are available-for-sale, consist of United States Government sponsored agencies which are carried at fair value, with unrealized gains and losses, net of related income taxes, reported as accumulated other comprehensive loss, except for losses from impairments which are determined to be other-than-temporary. Realized gains and losses and declines in value judged to be other-than-temporary on available-for-sale securities are included in the determination of net loss and are included in interest and other income (net), at which time the average cost basis of these securities are adjusted to fair value. Fair values are based on quoted market prices at the reporting date. Interest and dividends on available-for-sale securities are included in interest and other income (net).</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Property and Equipment</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Property and equipment are stated at cost less accumulated depreciation and amortization. Depreciation expense is computed using the straight-line method over the estimated useful lives of the assets, including leasehold improvements and capital lease assets that are amortized over the shorter of their useful lives or the terms of the respective leases. The Company generally uses the following range of useful lives for its property and equipment categories: leasehold improvements—</span><span style="font-family:inherit;font-size:10pt;"><span>7</span></span><span style="font-family:inherit;font-size:10pt;"> to </span><span style="font-family:inherit;font-size:10pt;"><span>10 years</span></span><span style="font-family:inherit;font-size:10pt;">; computer equipment—</span><span style="font-family:inherit;font-size:10pt;"><span>5 years</span></span><span style="font-family:inherit;font-size:10pt;">; machinery and equipment—</span><span style="font-family:inherit;font-size:10pt;"><span>5</span></span><span style="font-family:inherit;font-size:10pt;"> to </span><span style="font-family:inherit;font-size:10pt;"><span>10 years</span></span><span style="font-family:inherit;font-size:10pt;">; and furniture and fixtures—</span><span style="font-family:inherit;font-size:10pt;"><span>10 years</span></span><span style="font-family:inherit;font-size:10pt;">. Depreciation expense includes amortization of assets related to capital leases. The Company charges repairs and maintenance costs to expense as incurred. </span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Concentration of Credit Risk</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Cash, cash equivalents, and marketable securities are financial instruments that potentially subject the Company to concentration of credit risk. Our investment policy is to invest only in institutions that meet high credit quality standards and establishes limits on the amount and time to maturity of investments with any individual counterparty. The policy also requires that investments are only entered into with corporate and financial institutions that meet high credit quality standards. Restricted cash represents funds the Company is required to set aside to cover vehicle operating leases and other purposes. </span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Revenue Recognition</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Pursuant to Topic 606, we recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. To achieve this core principle, Topic 606 includes provisions within a five step model that includes i) identifying the contract with a customer, ii) identifying the performance obligations in the contract, iii) determining the transaction price, iv) allocating the transaction price to the performance obligations, and v) recognizing revenue when, or as, an entity satisfies a performance obligation.</span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">At contract inception, we assess the goods or services promised within each contract and assess whether each promised good or service is distinct and determine those that are performance obligations. We then recognize as revenue the amount of the transaction price that is allocated to the respective performance obligation when the performance obligation is satisfied.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Research and Development Costs</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Research and development costs are expensed as incurred. Costs incurred for clinical trials for patients and investigators are expensed as services are performed in accordance with the agreements in place with the institutions. Research and development costs include salaries and benefits, costs associated with producing biopharmaceutical compounds, laboratory supplies, the costs of conducting clinical trials, and facilities costs. In addition, the Company uses clinical research organizations and contract manufacturing operations to outsource portions of our research and development activities.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Treasury Shares</span><span style="font-family:inherit;font-size:10pt;">    </span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company records treasury stock at the cost to acquire it and includes treasury stock as a component of Stockholders’ Equity. In determining the cost of the treasury shares when either sold or issued, the Company uses the first-in, first-out method ("FIFO"). If the proceeds from the sale of the treasury shares are greater than the cost of the shares sold, the excess proceeds are recorded as additional paid-in capital. If the proceeds from the sale of the treasury shares are less than the original cost of the shares sold, the excess cost reduces any additional paid-in capital arising from previous sales of treasury shares for that class of stock.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Fair Value Measurements</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"/><span style="font-family:inherit;font-size:10pt;">The Company categorizes its financial instruments measured at fair value into a three-level fair value hierarchy that prioritizes the inputs used in determining the fair value of the asset or liability. The three levels of the fair value hierarchy are as follows:</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">•</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Level 1 - </span><span style="font-family:inherit;font-size:10pt;">Financial instruments whose values are based on unadjusted quoted prices for identical assets or liabilities in an active market which the company has the ability to access at the measurement date (examples include active exchange-traded securities and most United States Government and agency securities).</span></div></td></tr></table><div style="line-height:120%;text-align:justify;padding-left:96px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><span style="font-family:inherit;font-size:10pt;">•</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Level 2 -</span><span style="font-family:inherit;font-size:10pt;"> Financial instruments whose value are based on quoted market prices in markets where trading occurs infrequently or whose values are based on quoted prices of instruments with similar attributes in active markets.</span></div></td></tr></table><div style="line-height:120%;text-align:justify;padding-left:96px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><span style="font-family:inherit;font-size:10pt;">•</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Level 3 -</span><span style="font-family:inherit;font-size:10pt;"> Financial instruments whose values are based on prices or valuation techniques that require inputs that are both unobservable and significant to the overall fair value measurement. These inputs reflect management's own assumptions about the assumptions a market participant would use in pricing the asset.</span></div></td></tr></table><div style="line-height:120%;text-align:justify;padding-left:72px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company’s financial instruments consist of cash and cash equivalents, marketable securities, prepaid expenses, other current assets, accounts payable and accrued expenses, convertible senior notes, liabilities related to the sale of future royalties and Convertible Senior Notes. The carrying amount of prepaid expenses, other current assets, accounts payable and accrued expenses and certain other liabilities are generally considered to be representative of their respective fair values because of the short-term nature of those instruments.</span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Income Taxes</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company uses the asset and liability method to account for income taxes, including the recognition of deferred tax assets and deferred tax liabilities for the anticipated future tax consequences attributable to differences between financial statements amounts and their respective tax bases. The Company reviews its deferred tax assets for recovery. A valuation allowance is established when the Company believes that it is more likely than not that its deferred tax assets will not be realized. Changes in valuation allowances from period to period are included in the Company’s tax provision in the period of change. The Company has recorded a full valuation allowance against its net deferred tax assets as of </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">2018</span><span style="font-family:inherit;font-size:10pt;">.</span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Tax Cuts and Jobs Act (the "Act") was signed into law on December 22, 2017. Among its numerous changes to the Internal Revenue Code, the Act reduces United States corporate rates from 35% to 21%. Additionally, the Act limits the use of net operating loss carry backs, however any future net operating losses will instead be carried forward indefinitely. Only 80% of current income will be able to be offset with a net operating loss carryforward, with the remainder of the net operating loss continuing to carry forward. As a result of the reduction in the U.S. corporate income tax rate, the Company revalued its ending net deferred tax assets as of June 30, 2018, which resulted in a provisional expense of </span><span style="font-family:inherit;font-size:10pt;"><span>$59.5 million</span></span><span style="font-family:inherit;font-size:10pt;"> which was offset by an associated change in valuation allowance. In the second quarter of the Transition Period, the Company completed its analysis to determine the effect of the Tax Act and recorded no further adjustments. </span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Net Loss Per Share Allocable to Common Stockholders</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net loss per basic and diluted common share allocable to common stockholders is based on the net loss for the relevant period, divided by the weighted-average number of common shares outstanding during the period. For purposes of the diluted net loss per common share calculations, the exercise or exchange of all potential common shares is not included because their effect would have been anti-dilutive, due to the net loss recorded for the year ended </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;">, the Transition Period and fiscal years ended June 2018, and 2017, respectively. The common stock equivalents excluded from the earnings per share calculation are </span><span style="font-family:inherit;font-size:10pt;"><span>8.2 million</span></span><span style="font-family:inherit;font-size:10pt;">, </span><span style="font-family:inherit;font-size:10pt;"><span>6.7 million</span></span><span style="font-family:inherit;font-size:10pt;">, </span><span style="font-family:inherit;font-size:10pt;"><span>10.0 million</span></span><span style="font-family:inherit;font-size:10pt;">, and </span><span style="font-family:inherit;font-size:10pt;"><span>66.1 million</span></span><span style="font-family:inherit;font-size:10pt;"> for the year ended </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;">, the Transition Period and the fiscal years ended June 2018, and 2017, respectively.</span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Net Comprehensive Loss</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net comprehensive loss consists of net loss, unrealized gain (loss) on available for sale securities and foreign exchange translation adjustments and is presented in the consolidated statements of comprehensive loss.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Stock-Based Compensation</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company utilizes stock-based compensation in the form of stock options, stock appreciation rights, stock awards, stock unit awards, performance shares, cash-based performance units and other stock-based awards, each of which may be granted separately or in tandem with other awards.</span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The grant-date fair value of stock awards is based upon the underlying price of the stock on the date of grant. The grant-date fair value of stock option awards must be determined using an option pricing model. Option pricing models require the use of estimates and assumptions as to (a) the expected term of the option, (b) the expected volatility of the price of the underlying stock and (c) the risk-free interest rate for the expected term of the option. The Company uses the Black-Scholes option pricing formula for determining the grant-date fair value of such awards. The fair value of option awards that vest based on achievement of certain market conditions are determined using a Monte Carlo simulation technique.</span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The expected term of the option is based upon the contractual term and expected employee exercise and expected post-vesting employment termination behavior. The expected volatility of the price of the underlying stock is based upon the historical volatility of the Company’s stock computed over a period of time equal to the expected term of the option. The risk-free interest </span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">rate is based upon the implied yields currently available from the United States Treasury yield curve in effect at the time of the grant. Forfeitures are recorded as incurred.</span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Recently Issued Accounting Pronouncements</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Accounting Pronouncements adopted during the year</span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) 2019-01, “Leases Topic 842,” requiring entities to recognize assets and liabilities on the balance sheet for all leases, with certain exceptions. Topic 842 allows for a modified retrospective application and is effective as of the first quarter of 2019. Entities are allowed to apply the new guidance using a modified retrospective approach at the beginning of the year in which new lease standard is adopted, rather than to the earliest comparative period presented in their financial statements. The modified retrospective approach includes a number of optional practical expedients that entities may elect to apply. We elected the modified retrospective approach under the new guidance and elected the available practical expedients on adoption. Upon adoption, we recognized additional operating lease liabilities of </span><span style="font-family:inherit;font-size:10pt;"><span>$8.4 million</span></span><span style="font-family:inherit;font-size:10pt;"> with a corresponding right-of-use assets of </span><span style="font-family:inherit;font-size:10pt;"><span>$8.4 million</span></span><span style="font-family:inherit;font-size:10pt;"> based on the present value of the remaining lease payments under existing operating leases. As of December 31, 2018, we had </span><span style="font-family:inherit;font-size:10pt;"><span>$2.1 million</span></span><span style="font-family:inherit;font-size:10pt;"> in deferred charges related to our real estate leases that were recorded against the lease liability asset as part of the transition, resulting in </span><span style="font-family:inherit;font-size:10pt;"><span>$10.5 million</span></span><span style="font-family:inherit;font-size:10pt;"> included in other long-term liabilities on our consolidated balance sheets. In addition, the new guidance resulted in additional lease-related disclosures in the footnotes to our consolidated financial statements. Our leasing portfolio is comprised entirely of operating leases, and we do not recognize right-of-use assets or related lease liabilities with a lease term of twelve months or less on our consolidated balance sheets. Adoption of Topic 842 has required changes to our business processes and controls to comply with the provisions of the standard. Refer to Note 14 "Commitments and Contingencies" for additional information.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In June 2018, the FASB issued ASU 2018-07, "Compensation-Stock Compensation," to improve the usefulness of information provided to users of financial statements while reducing cost and complexity in financial reporting and provide guidance aligning the measurement and classification for share-based payments to nonemployees with the guidance for share-based payments to employees. Under the guidance, the measurement of equity-classified nonemployee awards will be fixed at the grant date. This standard is effective for fiscal years beginning after December 15, 2018, and interim periods within those annual periods. Early adoption is permitted, but no earlier than an entity's adoption date of ASU 2014-09, “Revenue from Contracts with Customers (Topic 606).” We adopted ASU 2018-07 during the first quarter of 2019 and the adoption did not have a material impact to our consolidated financial statements.</span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Accounting Pronouncements yet to be adopted</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In November 2018, the FASB issued ASU 2018-18, "Collaborative Arrangements (Topic 808): Clarifying the Interaction between Topic 808 and Topic 606,"    to clarify when ASC 606 should be used for collaborative arrangements when the counterparty is a customer. The guidance precludes an entity from presenting consideration from a transaction in a collaborative arrangement as revenue from contracts with customers if the counterparty is not a customer for that transaction. The guidance is effective for public business entities in fiscal years beginning after December 15, 2019, and interim periods therein. Early adoption is permitted to entities that have adopted ASC 606. We are currently assessing the impact of ASU 2018-18.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In August 2018, the FASB issued ASU 2018-13, "Fair Value measurement (Topic 820): Disclosure Framework - Changes to the Disclosure Requirements for Fair Value Measurement," to no longer require public companies to disclose transfers between Level 1 and Level 2 of the fair value hierarchy, and to require disclosure about the range and weighted average used to develop significant unobservable inputs for Level 3 fair value measurements. The guidance is effective for fiscal years beginning after December 15, 2019, and for interim periods within those fiscal years. Entities are permitted to early adopt either the entire standard or only the provisions that eliminate or modify the requirements. We are currently assessing the impact of ASU 2018-13.</span></div></us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock>
<us-gaap:BasisOfAccountingPolicyPolicyTextBlock
contextRef="FD2019Q4YTD"
id="TextSelection-F568666CD837EE6DD33AE082EED1E298-0-wk-Fact-64F3FC42E2475FF77D57E08540066094"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Basis of Presentation</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The consolidated financial statements include the accounts of Immunomedics and its subsidiaries. Noncontrolling interests in consolidated subsidiaries in the consolidated balance sheets represent minority stockholders' proportionate share of the equity (deficit) in such subsidiaries. All intercompany balances and transactions have been eliminated in consolidation. In this Annual Report, the periods presented are the year ended December 31, 2019, the six-month transition period from July 1, 2018 to December 31, 2018 (which we sometimes refer to as the "Transition Period") and our fiscal years ended June 30, 2018 and 2017 (which are referred to as “fiscal 2018,” and "fiscal 2017", as if we had not changed our fiscal year to a calendar year).</span></div></us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
<us-gaap:UseOfEstimates
contextRef="FD2019Q4YTD"
id="TextSelection-9924BB4C5C3E3B324110E085A64A6CE7-0-wk-Fact-FB3E568B33BA58DB06EFE085E3AE746E"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Use of Estimates</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The preparation of consolidated financial statements in conformity with United States generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reported period. Actual results could differ from those estimates. The Company’s significant estimates and assumptions relate to stock-based compensation expenses, the fair value for the liability related to sale of future royalties and related interest expense.</span></div></us-gaap:UseOfEstimates>
<us-gaap:DebtPolicyTextBlock
contextRef="FD2019Q4YTD"
id="TextSelection-0FDD55E87D2C7D9876E8E0868B22A197-0-wk-Fact-08DC171E09D825D2FF9BE086BBC11B25"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Interest Expense on Liability Related to Sale of Future Royalties</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company accounts for the liability related to the sale of future royalties as a debt financing. The Company has a significant continuing involvement in the generation of related royalty streams. The Company accretes this liability and recognizes expected interest expense using the effective interest rate method over the life of the related royalty stream, based on our current estimates of future royalty payments. These estimates include projections the Company makes and projections from outside the Company and involves significant judgment and inherent uncertainties. The Company periodically re-assesses the projections and, to the extent our future projections are greater or less than its previous estimates or the estimated timing of such payments is materially different than its previous estimates, the Company will adjust the effective interest calculation.</span></div></us-gaap:DebtPolicyTextBlock>
<us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock
contextRef="FD2019Q4YTD"
id="TextSelection-429E2D8ACA2E24608CC0E08709083661-0-wk-Fact-D1DF11012F863A0CD9EBE0873CFBD47C"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Foreign Currencies</span><span style="font-family:inherit;font-size:10pt;font-style:italic;"> </span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">For our German subsidiary which operates in a local currency environment, income and expense items are translated to United States dollars at the monthly average rates of exchange prevailing during the year, assets and liabilities are translated at year-end exchange rates and equity accounts are translated at historical exchange rates. Translation adjustments are accumulated in a separate component of stockholders' equity in the consolidated balance sheets and the consolidated statements of changes in stockholders’ equity and are included in the determination of comprehensive (loss) income in the consolidated statements of comprehensive loss. Transaction gains and losses are included in the determination of net loss in the consolidated statements of comprehensive loss.</span></div></us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock>
<us-gaap:FairValueOfFinancialInstrumentsPolicy
contextRef="FD2019Q4YTD"
id="TextSelection-C01A23B1A896230BB137E0877EE5F10B-0-wk-Fact-FB925445C0A043C534CEE087AF5646CA"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Financial Instruments</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The carrying amount of cash and cash equivalents, prepaid expenses, other current assets and current liabilities approximate fair value due to the short-term maturity of these instruments. The Company considers all highly liquid investments with an original maturity of three months or less when purchased to be cash equivalents.</span></div></us-gaap:FairValueOfFinancialInstrumentsPolicy>
<us-gaap:MarketableSecuritiesPolicy
contextRef="FD2019Q4YTD"
id="TextSelection-2F7F988F2BD860CF39E3E088021956F0-0-wk-Fact-F61B0426AD862C779CD0E088321D26BC"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Marketable Securities</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Marketable securities, all of which are available-for-sale, consist of United States Government sponsored agencies which are carried at fair value, with unrealized gains and losses, net of related income taxes, reported as accumulated other comprehensive loss, except for losses from impairments which are determined to be other-than-temporary. Realized gains and losses and declines in value judged to be other-than-temporary on available-for-sale securities are included in the determination of net loss and are included in interest and other income (net), at which time the average cost basis of these securities are adjusted to fair value. Fair values are based on quoted market prices at the reporting date. Interest and dividends on available-for-sale securities are included in interest and other income (net).</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></us-gaap:MarketableSecuritiesPolicy>
<us-gaap:PropertyPlantAndEquipmentPolicyTextBlock
contextRef="FD2019Q4YTD"
id="TextSelection-AB78A56E0E619C2EE54BE0894ED7CDFF-0-wk-Fact-3458984F52CDF6898AD0E08A91C08FAF"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Property and Equipment</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Property and equipment are stated at cost less accumulated depreciation and amortization. Depreciation expense is computed using the straight-line method over the estimated useful lives of the assets, including leasehold improvements and capital lease assets that are amortized over the shorter of their useful lives or the terms of the respective leases. The Company generally uses the following range of useful lives for its property and equipment categories: leasehold improvements—</span><span style="font-family:inherit;font-size:10pt;"><span>7</span></span><span style="font-family:inherit;font-size:10pt;"> to </span><span style="font-family:inherit;font-size:10pt;"><span>10 years</span></span><span style="font-family:inherit;font-size:10pt;">; computer equipment—</span><span style="font-family:inherit;font-size:10pt;"><span>5 years</span></span><span style="font-family:inherit;font-size:10pt;">; machinery and equipment—</span><span style="font-family:inherit;font-size:10pt;"><span>5</span></span><span style="font-family:inherit;font-size:10pt;"> to </span><span style="font-family:inherit;font-size:10pt;"><span>10 years</span></span><span style="font-family:inherit;font-size:10pt;">; and furniture and fixtures—</span><span style="font-family:inherit;font-size:10pt;"><span>10 years</span></span><span style="font-family:inherit;font-size:10pt;">. Depreciation expense includes amortization of assets related to capital leases. The Company charges repairs and maintenance costs to expense as incurred. </span></div></us-gaap:PropertyPlantAndEquipmentPolicyTextBlock>
<us-gaap:PropertyPlantAndEquipmentUsefulLife
contextRef="FD2019Q4YTD_srt_RangeAxis_srt_MinimumMember_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_LeaseholdImprovementsMember"
id="d22928294e768-wk-Fact-8FA34FA0C0400679BA48D78245CDFFC8">P7Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
<us-gaap:PropertyPlantAndEquipmentUsefulLife
contextRef="FD2019Q4YTD_srt_RangeAxis_srt_MaximumMember_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_LeaseholdImprovementsMember"
id="d22928294e772-wk-Fact-97639741B319D8ED7BD0D7825672E2B8">P10Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
<us-gaap:PropertyPlantAndEquipmentUsefulLife
contextRef="FD2019Q4YTD_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_ComputerEquipmentMember"
id="d22928294e776-wk-Fact-233486708D76020C2BD4D783AC6BA9E6">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
<us-gaap:PropertyPlantAndEquipmentUsefulLife
contextRef="FD2019Q4YTD_srt_RangeAxis_srt_MinimumMember_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_MachineryAndEquipmentMember"
id="d22928294e780-wk-Fact-4445C8DE7C0D5D4025B9D7826578D31B">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
<us-gaap:PropertyPlantAndEquipmentUsefulLife
contextRef="FD2019Q4YTD_srt_RangeAxis_srt_MaximumMember_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_MachineryAndEquipmentMember"
id="d22928294e784-wk-Fact-39C4BCE463D50DAA8242D78273110DBA">P10Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
<us-gaap:PropertyPlantAndEquipmentUsefulLife
contextRef="FD2019Q4YTD_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_FurnitureAndFixturesMember"
id="d22928294e789-wk-Fact-31F8CD64AC14C1F56995D78282EDF70A">P10Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
<us-gaap:ConcentrationRiskCreditRisk
contextRef="FD2019Q4YTD"
id="TextSelection-743447A55CDBC1F7B754E08AE6AA57D3-0-wk-Fact-A6CA0098CCCCD110EFFCE08B13FF58D6"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Concentration of Credit Risk</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div>Cash, cash equivalents, and marketable securities are financial instruments that potentially subject the Company to concentration of credit risk. Our investment policy is to invest only in institutions that meet high credit quality standards and establishes limits on the amount and time to maturity of investments with any individual counterparty. The policy also requires that investments are only entered into with corporate and financial institutions that meet high credit quality standards. Restricted cash represents funds the Company is required to set aside to cover vehicle operating leases and other purposes.</us-gaap:ConcentrationRiskCreditRisk>
<us-gaap:RevenueRecognitionPolicyTextBlock
contextRef="FD2019Q4YTD"
id="TextSelection-0AA05DB69DDE3F3D223FE08B736A8951-0-wk-Fact-F01D59D6DDBFD1242367E08B9C16A639"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Revenue Recognition</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Pursuant to Topic 606, we recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. To achieve this core principle, Topic 606 includes provisions within a five step model that includes i) identifying the contract with a customer, ii) identifying the performance obligations in the contract, iii) determining the transaction price, iv) allocating the transaction price to the performance obligations, and v) recognizing revenue when, or as, an entity satisfies a performance obligation.</span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">At contract inception, we assess the goods or services promised within each contract and assess whether each promised good or service is distinct and determine those that are performance obligations. We then recognize as revenue the amount of the transaction price that is allocated to the respective performance obligation when the performance obligation is satisfied.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></us-gaap:RevenueRecognitionPolicyTextBlock>
<us-gaap:ResearchAndDevelopmentExpensePolicy
contextRef="FD2019Q4YTD"
id="TextSelection-DAA1BDD14BDF506F3E27E08BE5135173-0-wk-Fact-818754D466F57B953B14E08C0F43AE7D"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Research and Development Costs</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Research and development costs are expensed as incurred. Costs incurred for clinical trials for patients and investigators are expensed as services are performed in accordance with the agreements in place with the institutions. Research and development costs include salaries and benefits, costs associated with producing biopharmaceutical compounds, laboratory supplies, the costs of conducting clinical trials, and facilities costs. In addition, the Company uses clinical research organizations and contract manufacturing operations to outsource portions of our research and development activities.</span></div></us-gaap:ResearchAndDevelopmentExpensePolicy>
<immu:TreasuryStockPolicyPolicyTextBlock
contextRef="FD2019Q4YTD"
id="TextSelection-FDD722EF0D0558D5B46AE08C728F3260-0-wk-Fact-90206E810195C16B7417E08CE9065B86"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Treasury Shares</span><span style="font-family:inherit;font-size:10pt;">    </span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company records treasury stock at the cost to acquire it and includes treasury stock as a component of Stockholders’ Equity. In determining the cost of the treasury shares when either sold or issued, the Company uses the first-in, first-out method ("FIFO"). If the proceeds from the sale of the treasury shares are greater than the cost of the shares sold, the excess proceeds are recorded as additional paid-in capital. If the proceeds from the sale of the treasury shares are less than the original cost of the shares sold, the excess cost reduces any additional paid-in capital arising from previous sales of treasury shares for that class of stock.</span></div></immu:TreasuryStockPolicyPolicyTextBlock>
<us-gaap:FairValueMeasurementPolicyPolicyTextBlock
contextRef="FD2019Q4YTD"
id="TextSelection-60B6D4B40A9A28330841E08D4BFDDF04-0-wk-Fact-489D80FCC3957FF3D0DDE08D7B322C6B"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Fair Value Measurements</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"/><span style="font-family:inherit;font-size:10pt;">The Company categorizes its financial instruments measured at fair value into a three-level fair value hierarchy that prioritizes the inputs used in determining the fair value of the asset or liability. The three levels of the fair value hierarchy are as follows:</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">•</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Level 1 - </span><span style="font-family:inherit;font-size:10pt;">Financial instruments whose values are based on unadjusted quoted prices for identical assets or liabilities in an active market which the company has the ability to access at the measurement date (examples include active exchange-traded securities and most United States Government and agency securities).</span></div></td></tr></table><div style="line-height:120%;text-align:justify;padding-left:96px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><span style="font-family:inherit;font-size:10pt;">•</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Level 2 -</span><span style="font-family:inherit;font-size:10pt;"> Financial instruments whose value are based on quoted market prices in markets where trading occurs infrequently or whose values are based on quoted prices of instruments with similar attributes in active markets.</span></div></td></tr></table><div style="line-height:120%;text-align:justify;padding-left:96px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><span style="font-family:inherit;font-size:10pt;">•</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Level 3 -</span><span style="font-family:inherit;font-size:10pt;"> Financial instruments whose values are based on prices or valuation techniques that require inputs that are both unobservable and significant to the overall fair value measurement. These inputs reflect management's own assumptions about the assumptions a market participant would use in pricing the asset.</span></div></td></tr></table><div style="line-height:120%;text-align:justify;padding-left:72px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company’s financial instruments consist of cash and cash equivalents, marketable securities, prepaid expenses, other current assets, accounts payable and accrued expenses, convertible senior notes, liabilities related to the sale of future royalties and Convertible Senior Notes. The carrying amount of prepaid expenses, other current assets, accounts payable and accrued expenses and certain other liabilities are generally considered to be representative of their respective fair values because of the short-term nature of those instruments.</span></div></us-gaap:FairValueMeasurementPolicyPolicyTextBlock>
<us-gaap:IncomeTaxPolicyTextBlock
contextRef="FD2019Q4YTD"
id="TextSelection-C472F536E842E5DD5AA2E08F369FE541-0-wk-Fact-2D61EA321E24D3F2072AE08F9DA82BD9"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Income Taxes</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company uses the asset and liability method to account for income taxes, including the recognition of deferred tax assets and deferred tax liabilities for the anticipated future tax consequences attributable to differences between financial statements amounts and their respective tax bases. The Company reviews its deferred tax assets for recovery. A valuation allowance is established when the Company believes that it is more likely than not that its deferred tax assets will not be realized. Changes in valuation allowances from period to period are included in the Company’s tax provision in the period of change. The Company has recorded a full valuation allowance against its net deferred tax assets as of </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">2018</span><span style="font-family:inherit;font-size:10pt;">.</span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><span style="font-family:inherit;font-size:10pt;">The Tax Cuts and Jobs Act (the "Act") was signed into law on December 22, 2017. Among its numerous changes to the Internal Revenue Code, the Act reduces United States corporate rates from 35% to 21%. Additionally, the Act limits the use of net operating loss carry backs, however any future net operating losses will instead be carried forward indefinitely. Only 80% of current income will be able to be offset with a net operating loss carryforward, with the remainder of the net operating loss continuing to carry forward. As a result of the reduction in the U.S. corporate income tax rate, the Company revalued its ending net deferred tax assets as of June 30, 2018, which resulted in a provisional expense of </span><span style="font-family:inherit;font-size:10pt;"><span>$59.5 million</span></span> which was offset by an associated change in valuation allowance. In the second quarter of the Transition Period, the Company completed its analysis to determine the effect of the Tax Act and recorded no further adjustments.</us-gaap:IncomeTaxPolicyTextBlock>
<us-gaap:TaxCutsAndJobsActOf2017IncompleteAccountingChangeInTaxRateDeferredTaxAssetProvisionalIncomeTaxExpense
contextRef="D2018Q4Jul01-Dec31"
decimals="-5"
id="d22928294e934-wk-Fact-597DF60237726C170D565EE29F497720"
unitRef="usd">59500000</us-gaap:TaxCutsAndJobsActOf2017IncompleteAccountingChangeInTaxRateDeferredTaxAssetProvisionalIncomeTaxExpense>
<us-gaap:EarningsPerSharePolicyTextBlock
contextRef="FD2019Q4YTD"
id="TextSelection-F86ED3B13D2DD92F6C39E08FEFA33C64-0-wk-Fact-762F6B4A3C46090FAC66E0907829B65C"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Net Loss Per Share Allocable to Common Stockholders</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net loss per basic and diluted common share allocable to common stockholders is based on the net loss for the relevant period, divided by the weighted-average number of common shares outstanding during the period. For purposes of the diluted net loss per common share calculations, the exercise or exchange of all potential common shares is not included because their effect would have been anti-dilutive, due to the net loss recorded for the year ended </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;">, the Transition Period and fiscal years ended June 2018, and 2017, respectively. The common stock equivalents excluded from the earnings per share calculation are </span><span style="font-family:inherit;font-size:10pt;"><span>8.2 million</span></span><span style="font-family:inherit;font-size:10pt;">, </span><span style="font-family:inherit;font-size:10pt;"><span>6.7 million</span></span><span style="font-family:inherit;font-size:10pt;">, </span><span style="font-family:inherit;font-size:10pt;"><span>10.0 million</span></span><span style="font-family:inherit;font-size:10pt;">, and </span><span style="font-family:inherit;font-size:10pt;"><span>66.1 million</span></span><span style="font-family:inherit;font-size:10pt;"> for the year ended </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;">, the Transition Period and the fiscal years ended June 2018, and 2017, respectively.</span></div></us-gaap:EarningsPerSharePolicyTextBlock>
<us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
contextRef="FD2019Q4YTD"
decimals="-5"
id="d22928294e956-wk-Fact-9E9427FA31C2403FBD09D7785EBE8E5A"
unitRef="shares">8200000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
<us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
contextRef="D2018Q4Jul01-Dec31"
decimals="-5"
id="d22928294e960-wk-Fact-50F0ADE9DE987807177AD77591DCE286"
unitRef="shares">6700000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
<us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
contextRef="D2018Q4Jul12017toJun302018"
decimals="-5"
id="d22928294e964-wk-Fact-1CB44CED46CEAD38C394D775A11E96AB"
unitRef="shares">10000000.0</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
<us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
contextRef="D2017Q4Jul012016toJun302017"
decimals="-5"
id="d22928294e968-wk-Fact-3CD8CEB572B3D9E4F999D775B239AEA9"
unitRef="shares">66100000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
<us-gaap:ComprehensiveIncomePolicyPolicyTextBlock
contextRef="FD2019Q4YTD"
id="TextSelection-901D758F3758E3CB05ADE090F58C2D75-0-wk-Fact-EA6E7F890E7DD6BA9A60E0912BBF02FD"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Net Comprehensive Loss</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net comprehensive loss consists of net loss, unrealized gain (loss) on available for sale securities and foreign exchange translation adjustments and is presented in the consolidated statements of comprehensive loss.</span></div></us-gaap:ComprehensiveIncomePolicyPolicyTextBlock>
<us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy
contextRef="FD2019Q4YTD"
id="TextSelection-15910446B6FF1333E6E5E09168889018-0-wk-Fact-D0072F6BDBDBD39E1C46E09192221961"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Stock-Based Compensation</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company utilizes stock-based compensation in the form of stock options, stock appreciation rights, stock awards, stock unit awards, performance shares, cash-based performance units and other stock-based awards, each of which may be granted separately or in tandem with other awards.</span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The grant-date fair value of stock awards is based upon the underlying price of the stock on the date of grant. The grant-date fair value of stock option awards must be determined using an option pricing model. Option pricing models require the use of estimates and assumptions as to (a) the expected term of the option, (b) the expected volatility of the price of the underlying stock and (c) the risk-free interest rate for the expected term of the option. The Company uses the Black-Scholes option pricing formula for determining the grant-date fair value of such awards. The fair value of option awards that vest based on achievement of certain market conditions are determined using a Monte Carlo simulation technique.</span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The expected term of the option is based upon the contractual term and expected employee exercise and expected post-vesting employment termination behavior. The expected volatility of the price of the underlying stock is based upon the historical volatility of the Company’s stock computed over a period of time equal to the expected term of the option. The risk-free interest </span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">rate is based upon the implied yields currently available from the United States Treasury yield curve in effect at the time of the grant. Forfeitures are recorded as incurred.</span></div></us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy>
<us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock
contextRef="FD2019Q4YTD"
id="TextSelection-3CC03DEF0563C512A420E09251913891-0-wk-Fact-009A7727F41E28CBE744E092848F04AA"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Recently Issued Accounting Pronouncements</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Accounting Pronouncements adopted during the year</span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) 2019-01, “Leases Topic 842,” requiring entities to recognize assets and liabilities on the balance sheet for all leases, with certain exceptions. Topic 842 allows for a modified retrospective application and is effective as of the first quarter of 2019. Entities are allowed to apply the new guidance using a modified retrospective approach at the beginning of the year in which new lease standard is adopted, rather than to the earliest comparative period presented in their financial statements. The modified retrospective approach includes a number of optional practical expedients that entities may elect to apply. We elected the modified retrospective approach under the new guidance and elected the available practical expedients on adoption. Upon adoption, we recognized additional operating lease liabilities of </span><span style="font-family:inherit;font-size:10pt;"><span>$8.4 million</span></span><span style="font-family:inherit;font-size:10pt;"> with a corresponding right-of-use assets of </span><span style="font-family:inherit;font-size:10pt;"><span>$8.4 million</span></span><span style="font-family:inherit;font-size:10pt;"> based on the present value of the remaining lease payments under existing operating leases. As of December 31, 2018, we had </span><span style="font-family:inherit;font-size:10pt;"><span>$2.1 million</span></span><span style="font-family:inherit;font-size:10pt;"> in deferred charges related to our real estate leases that were recorded against the lease liability asset as part of the transition, resulting in </span><span style="font-family:inherit;font-size:10pt;"><span>$10.5 million</span></span><span style="font-family:inherit;font-size:10pt;"> included in other long-term liabilities on our consolidated balance sheets. In addition, the new guidance resulted in additional lease-related disclosures in the footnotes to our consolidated financial statements. Our leasing portfolio is comprised entirely of operating leases, and we do not recognize right-of-use assets or related lease liabilities with a lease term of twelve months or less on our consolidated balance sheets. Adoption of Topic 842 has required changes to our business processes and controls to comply with the provisions of the standard. Refer to Note 14 "Commitments and Contingencies" for additional information.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In June 2018, the FASB issued ASU 2018-07, "Compensation-Stock Compensation," to improve the usefulness of information provided to users of financial statements while reducing cost and complexity in financial reporting and provide guidance aligning the measurement and classification for share-based payments to nonemployees with the guidance for share-based payments to employees. Under the guidance, the measurement of equity-classified nonemployee awards will be fixed at the grant date. This standard is effective for fiscal years beginning after December 15, 2018, and interim periods within those annual periods. Early adoption is permitted, but no earlier than an entity's adoption date of ASU 2014-09, “Revenue from Contracts with Customers (Topic 606).” We adopted ASU 2018-07 during the first quarter of 2019 and the adoption did not have a material impact to our consolidated financial statements.</span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Accounting Pronouncements yet to be adopted</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In November 2018, the FASB issued ASU 2018-18, "Collaborative Arrangements (Topic 808): Clarifying the Interaction between Topic 808 and Topic 606,"    to clarify when ASC 606 should be used for collaborative arrangements when the counterparty is a customer. The guidance precludes an entity from presenting consideration from a transaction in a collaborative arrangement as revenue from contracts with customers if the counterparty is not a customer for that transaction. The guidance is effective for public business entities in fiscal years beginning after December 15, 2019, and interim periods therein. Early adoption is permitted to entities that have adopted ASC 606. We are currently assessing the impact of ASU 2018-18.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In August 2018, the FASB issued ASU 2018-13, "Fair Value measurement (Topic 820): Disclosure Framework - Changes to the Disclosure Requirements for Fair Value Measurement," to no longer require public companies to disclose transfers between Level 1 and Level 2 of the fair value hierarchy, and to require disclosure about the range and weighted average used to develop significant unobservable inputs for Level 3 fair value measurements. The guidance is effective for fiscal years beginning after December 15, 2019, and for interim periods within those fiscal years. Entities are permitted to early adopt either the entire standard or only the provisions that eliminate or modify the requirements. We are currently assessing the impact of ASU 2018-13.</span></div></us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
<us-gaap:OperatingLeaseLiability
contextRef="I2019Q1Jan01_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201602Member"
decimals="-5"
id="d22928294e1035-wk-Fact-0747AF242BA734722F96D751F0F78EE3"
unitRef="usd">8400000</us-gaap:OperatingLeaseLiability>
<us-gaap:OperatingLeaseRightOfUseAsset
contextRef="I2019Q1Jan01_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201602Member"
decimals="-5"
id="d22928294e1039-wk-Fact-EF41DE1A18F5412A868DD752629C1DD9"
unitRef="usd">8400000</us-gaap:OperatingLeaseRightOfUseAsset>
<us-gaap:OtherLiabilitiesNoncurrent
contextRef="FI2018Q4"
decimals="-5"
id="d22928294e1043-wk-Fact-D5D48CC33AC413899C9AD752D5A45019"
unitRef="usd">2100000</us-gaap:OtherLiabilitiesNoncurrent>
<us-gaap:OtherLiabilitiesNoncurrent
contextRef="I2019Q1Jan01_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201602Member"
decimals="-5"
id="d22928294e1047-wk-Fact-9E74F6CE672198B62B81D75335774656"
unitRef="usd">10500000</us-gaap:OtherLiabilitiesNoncurrent>
<us-gaap:RevenueFromContractWithCustomerTextBlock
contextRef="FD2019Q4YTD"
id="TextSelection-8C8F6DD7313BA9FA5DCED78E963BBAAD-0-wk-Fact-7D67033580E8C63EE616D78FB71D14AF">Revenue Recognition<div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Everest Medicines II Limited</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">On April 29, 2019, we entered into a license agreement (the "License Agreement") with Everest Medicines II Limited, a China limited company ("Everest"). Pursuant to the License Agreement, we granted Everest an exclusive license to develop and commercialize sacituzumab govitecan in the People's Republic of China, Taiwan, Hong Kong, Macao, Indonesia, Philippines, Vietnam, Thailand, South Korea, Malaysia, Singapore and Mongolia (the "Territory"). In consideration for entering into the License Agreement, Everest made a one-time, non-refundable upfront payment to us in the aggregate amount of </span><span style="font-family:inherit;font-size:10pt;"><span>$65.0 million</span></span><span style="font-family:inherit;font-size:10pt;"> which is recorded as deferred revenue on the consolidated balance sheet as of </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;">. The License Agreement contains a development milestone payment of </span><span style="font-family:inherit;font-size:10pt;"><span>$60.0 million</span></span><span style="font-family:inherit;font-size:10pt;"> based upon our achievement of FDA approval for sacituzumab govitecan. The </span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">License Agreement also contains additional development milestone payments in a total amount of up to </span><span style="font-family:inherit;font-size:10pt;"><span>$180.0 million</span></span><span style="font-family:inherit;font-size:10pt;"> based upon the achievement of certain other development milestones. In addition, the License Agreement contains sales milestone payments in a total amount of up to </span><span style="font-family:inherit;font-size:10pt;"><span>$530.0 million</span></span><span style="font-family:inherit;font-size:10pt;"> based upon the achievement of certain sales milestones. Everest will make royalty payments to us based upon percentages of net sales of sacituzumab govitecan, ranging from </span><span style="font-family:inherit;font-size:10pt;"><span>14%</span></span><span style="font-family:inherit;font-size:10pt;"> to </span><span style="font-family:inherit;font-size:10pt;"><span>20%</span></span><span style="font-family:inherit;font-size:10pt;">. </span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company assessed the arrangement in accordance with ASC 606 and concluded that the contract counterparty, Everest, is a customer based on the arrangement structure. The Company identified two material promises to deliver under the contract: (1) grant of license and the (2) clinical and commercial supply of the product. However, given the nature of the manufacturing of the product the license is not considered to be distinct from the clinical and commercial supply promise. The Company therefore concluded that there is one combined performance obligation.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company initially deferred and will recognize the </span><span style="font-family:inherit;font-size:10pt;"><span>$65.0 million</span></span><span style="font-family:inherit;font-size:10pt;"> over the performance obligation period of the combined performance obligation. As it relates to the upfront consideration, the </span><span style="font-family:inherit;font-size:10pt;"><span>$65.0 million</span></span><span style="font-family:inherit;font-size:10pt;"> is recorded as deferred revenue and will be recognized over the term of the of the contract performance obligation period, which the Company has concluded to be </span><span style="font-family:inherit;font-size:10pt;"><span>15 years</span></span><span style="font-family:inherit;font-size:10pt;"> after initial sale of the product in the territory. As concluded above, the Company has a combined performance obligation, which includes delivering the license and clinical and commercial supply to Everest. As such, because the clinical and commercial supply obligation occur throughout the period of the License Agreement, the </span><span style="font-family:inherit;font-size:10pt;"><span>$65.0 million</span></span><span style="font-family:inherit;font-size:10pt;"> fixed consideration is recognized over the period in which commercial and clinical supply of product is delivered (over-time). </span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The future potential milestone payments are excluded from the transaction price, as the achievement of the milestone events require considerable judgment in determining whether it is probable of being achieved, and that a significant revenue reversal would not occur. As such, all milestone payments are fully constrained. The Company will reevaluate the transaction price at the end of each reporting period and as uncertain events are resolved or other changes in circumstances occur, and, if necessary, adjust its estimate of the transaction price.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Janssen Biotech Inc.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><span style="font-family:inherit;font-size:10pt;">On April 5, 2019, the Company entered into a promotion agreement (the "Promotion Agreement") with Janssen Biotech Inc., ("Janssen") pursuant to which the Company will provide non-exclusive product detailing services to Janssen for erdafitinib (the "Product"). Pursuant to the Promotion Agreement, the Company will provide a dedicated sales team to detail the Product to oncologists and other targeted health care providers in the United States. Under the terms of the Promotion Agreement, Janssen maintains ownership of the New Drug Application for the Product as well as legal, regulatory, distribution, commercialization and manufacturing responsibilities for the Product, while the Company will provide product detailing services to Janssen.  Following the achievement of certain sales targets in 2019 and 2020, Janssen will pay the Company (a) a service fee equal to a percentage in the low double digits of the portion of Cumulative Net Sales (as defined in the Promotion Agreement) in excess of a baseline amount during each of 2019 and 2020, and (b) potential milestone payments of up to </span><span style="font-family:inherit;font-size:10pt;"><span>$15.0 million</span></span><span style="font-family:inherit;font-size:10pt;"> when Cumulative Net Sales exceed certain thresholds during each of 2019 and 2020. On April 12, 2019, the Company was informed that the FDA granted accelerated approval to Janssen's Balversa</span><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">® </sup></span><span style="font-family:inherit;font-size:10pt;">(erdafitinib) for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma that has a type of susceptible genetic alteration known as FGFR3 or FGFR2, and that has progressed during or following prior platinum-containing chemotherapy. During the year ended </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;">, </span><span style="font-family:inherit;font-size:10pt;"><span>$0.3 million</span></span> of service fee revenues were recorded relating to the Promotion Agreement.</us-gaap:RevenueFromContractWithCustomerTextBlock>
<immu:LicenseAgreementUpfrontFeesPaid
contextRef="D2019Q2Apr29_srt_MajorCustomersAxis_immu_EverestMedicinesIILimitedMember"
decimals="-5"
id="d22928493e862-wk-Fact-DF8A068B5B59AE38C63CD79478C3190F"
unitRef="usd">65000000.0</immu:LicenseAgreementUpfrontFeesPaid>
<immu:LicenseAgreementMilestonePaymentUponAchievementofFDAApproval
contextRef="D2019Q2Apr29_srt_MajorCustomersAxis_immu_EverestMedicinesIILimitedMember"
decimals="-5"
id="d22928493e870-wk-Fact-6E2E1A990ADCC8E055B5D795B988BFE8"
unitRef="usd">60000000.0</immu:LicenseAgreementMilestonePaymentUponAchievementofFDAApproval>
<immu:LicenseAgreementMilestoneDevelopmentTotalPayments
contextRef="D2019Q2Apr29_srt_MajorCustomersAxis_immu_EverestMedicinesIILimitedMember"
decimals="-5"
id="d22928493e877-wk-Fact-3BFC0B35EBF03F09DDF2D79758641AD0"
unitRef="usd">180000000.0</immu:LicenseAgreementMilestoneDevelopmentTotalPayments>
<immu:LicenseAgreementMilestoneSalesTotalPayments
contextRef="D2019Q2Apr29_srt_MajorCustomersAxis_immu_EverestMedicinesIILimitedMember"
decimals="-5"
id="d22928493e881-wk-Fact-6750CE1BFAD2A176AC2FD79692ECEC6C"
unitRef="usd">530000000.0</immu:LicenseAgreementMilestoneSalesTotalPayments>
<immu:RoyaltyPaymentsPercentage
contextRef="D2019Q2Apr29_srt_MajorCustomersAxis_immu_EverestMedicinesIILimitedMember_srt_RangeAxis_srt_MinimumMember"
decimals="INF"
id="d22928493e885-wk-Fact-FC466D5D97B0FF2027DAD79871424F17"
unitRef="number">0.14</immu:RoyaltyPaymentsPercentage>
<immu:RoyaltyPaymentsPercentage
contextRef="D2019Q2Apr29_srt_MajorCustomersAxis_immu_EverestMedicinesIILimitedMember_srt_RangeAxis_srt_MaximumMember"
decimals="INF"
id="d22928493e889-wk-Fact-A61CB577CE92CFD0570BD798A1DD9F46"
unitRef="number">0.20</immu:RoyaltyPaymentsPercentage>
<us-gaap:RevenueRemainingPerformanceObligation
contextRef="I2019Q2Apr29_srt_MajorCustomersAxis_immu_EverestMedicinesIILimitedMember_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain_2019-04-30"
decimals="-5"
id="d22928493e905-wk-Fact-EBC5624C00CF3A375C4CD79BE3CB0AF5"
unitRef="usd">65000000.0</us-gaap:RevenueRemainingPerformanceObligation>
<us-gaap:ContractWithCustomerLiabilityNoncurrent
contextRef="I2019Q2Apr29_srt_MajorCustomersAxis_immu_EverestMedicinesIILimitedMember"
decimals="-5"
id="d22928493e909-wk-Fact-C733B02AD5739BEBEBE1D79B2A61513A"
unitRef="usd">65000000.0</us-gaap:ContractWithCustomerLiabilityNoncurrent>
<us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1
contextRef="I2019Q2Apr29_srt_MajorCustomersAxis_immu_EverestMedicinesIILimitedMember_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain_2019-04-30"
id="d22928493e913-wk-Fact-8BBA9930F39910216520D79C9F7C2BC0">P15Y</us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1>
<us-gaap:RevenueRemainingPerformanceObligation
contextRef="I2019Q2Apr29_srt_MajorCustomersAxis_immu_EverestMedicinesIILimitedMember_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain_2019-04-30"
decimals="-5"
id="d22928493e917-wk-Fact-EBC5624C00CF3A375C4CD79BE3CB0AF5"
unitRef="usd">65000000.0</us-gaap:RevenueRemainingPerformanceObligation>
<immu:LicenseAgreementMilestoneSalesTotalPayments
contextRef="D2019Q1Apr5-Apr5_srt_MajorCustomersAxis_immu_JanssenBiotechIncMember"
decimals="-5"
id="d22928493e939-wk-Fact-1BD245C692593D058017D79DAEE061BF"
unitRef="usd">15000000.0</immu:LicenseAgreementMilestoneSalesTotalPayments>
<us-gaap:Revenues
contextRef="FD2019Q4YTD_srt_MajorCustomersAxis_immu_JanssenBiotechIncMember"
decimals="-5"
id="d22928493e951-wk-Fact-4274AA58226EFA569EC3D79E7E695F6E"
unitRef="usd">300000</us-gaap:Revenues>
<us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock
contextRef="FD2019Q4YTD"
id="TextSelection-5626F08A98EB97B4E60ED1D018754DA3-0-wk-Fact-748190D6F5C93AB98E63D1D0185B6734">Marketable Securities<div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Immunomedics considers all of its current investments to be available-for-sale. Marketable securities are carried at fair value, with unrealized gains and losses, net of related income taxes, reported as accumulated other comprehensive (loss) income, except for losses from impairments which are determined to be other-than-temporary. Realized gains and losses and declines in value judged to be other-than-temporary on available-for-sale securities are included in the determination of net loss and are included in interest and other income (net), at which time the average cost basis of these securities are adjusted to fair value. Fair values are based on quoted market prices at the reporting date. Interest and dividends on available-for-sale securities are included in interest and other income (net). As of December 31, 2019, and 2018, the carrying value of our current investments due after one year or more are </span><span style="font-family:inherit;font-size:10pt;"><span>$4.5 million</span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>$4.9 million</span></span><span style="font-family:inherit;font-size:10pt;">, respectively. </span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following table summarizes the marketable securities held as of </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;"> and 2018 (in thousands):</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"/></tr><tr><td style="width:38%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"> December 31, 2019</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Amortized Cost</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Gross Unrealized Gain</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Gross Unrealized (Loss)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Fair Value</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">U.S. Government Sponsored Agencies</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>4,941</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(391</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>4,550</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;padding-left:0px;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"/></tr><tr><td style="width:38%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"> December 31, 2018</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Amortized Cost</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Gross Unrealized Gain</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Gross Unrealized (Loss)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Fair Value</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">U.S. Government Sponsored Agencies</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>4,941</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>4,941</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div></us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock>
<immu:AvailableForSaleSecuritiesDebtMaturitiesAfterOneYearormoreCarryingValue
contextRef="FI2019Q4"
decimals="-5"
id="d22929044e648-wk-Fact-AFDAF810C5E432B1D5D7D7B2F62CFE04"
unitRef="usd">4500000</immu:AvailableForSaleSecuritiesDebtMaturitiesAfterOneYearormoreCarryingValue>
<immu:AvailableForSaleSecuritiesDebtMaturitiesAfterOneYearormoreCarryingValue
contextRef="FI2018Q4"
decimals="-5"
id="d22929044e652-wk-Fact-94AAC381CD95D9A0CBE4D7B31883B655"
unitRef="usd">4900000</immu:AvailableForSaleSecuritiesDebtMaturitiesAfterOneYearormoreCarryingValue>
<us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock
contextRef="FD2019Q4YTD"
id="TextSelection-E1B11B24340238329CDDD1D01875D4D6-0-wk-Fact-D4694B111840E3AF5ADAD1D0180B85D0"><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following table summarizes the marketable securities held as of </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;"> and 2018 (in thousands):</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"/></tr><tr><td style="width:38%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"> December 31, 2019</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Amortized Cost</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Gross Unrealized Gain</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Gross Unrealized (Loss)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Fair Value</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">U.S. Government Sponsored Agencies</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>4,941</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(391</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>4,550</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;padding-left:0px;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"/></tr><tr><td style="width:38%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"> December 31, 2018</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Amortized Cost</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Gross Unrealized Gain</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Gross Unrealized (Loss)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Fair Value</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">U.S. Government Sponsored Agencies</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>4,941</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>4,941</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div></us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock>
<us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
contextRef="FI2019Q4_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember"
decimals="-3"
id="d22929044e789-wk-Fact-4A58C57EDEE8BFB85293D1D0182A55F6"
unitRef="usd">4941000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
<us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
contextRef="FI2019Q4_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember"
decimals="-3"
id="d22929044e808-wk-Fact-700D19C87CCD90549255D1D0182A376E"
unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
<us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
contextRef="FI2019Q4_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember"
decimals="-3"
id="d22929044e827-wk-Fact-EE281F4CA618BB5D0122D1D0182AE5A0"
unitRef="usd">391000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
<us-gaap:AvailableForSaleSecuritiesDebtSecurities
contextRef="FI2019Q4_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember"
decimals="-3"
id="d22929044e848-wk-Fact-6925F06F6C4C9B1C7110D1D0182AFD14"
unitRef="usd">4550000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
<us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
contextRef="FI2018Q4_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember"
decimals="-3"
id="d22929044e989-wk-Fact-3CD83E68B6B15BFE491AD7AF42DA449B"
unitRef="usd">4941000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
<us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
contextRef="FI2018Q4_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember"
decimals="-3"
id="d22929044e1008-wk-Fact-486C56E6EC78B9BE4107D7AF42F9514F"
unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
<us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
contextRef="FI2018Q4_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember"
decimals="-3"
id="d22929044e1027-wk-Fact-99CBEA59ABF5FD6173C4D7AF42EAFE35"
unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
<us-gaap:AvailableForSaleSecuritiesDebtSecurities
contextRef="FI2018Q4_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember"
decimals="-3"
id="d22929044e1047-wk-Fact-19DDF8199E1F6CF08D52D7AF42EA193E"
unitRef="usd">4941000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
<us-gaap:DebtDisclosureTextBlock
contextRef="FD2019Q4YTD"
id="TextSelection-58784F48271978614545D1D0187553FD-0-wk-Fact-49800ED299C7EABF4DDED1D0181BB9E6">Debt<div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Liability related to sale of future royalties</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"/><span style="font-family:inherit;font-size:10pt;">On </span><span style="font-family:inherit;font-size:10pt;">January 7, 2018</span><span style="font-family:inherit;font-size:10pt;">, the Company entered into a funding agreement (the "Funding Agreement") with RPI Finance Trust, a Delaware statutory trust ("RPI"). Pursuant to the Funding Agreement, the Company issued to RPI the right to receive certain royalty amounts, subject to certain reductions, based on the net sales of the ADC sacituzumab govitecan, for each calendar quarter during the term of the Funding Agreement ("Revenue Participation Right"), in exchange for </span><span style="font-family:inherit;font-size:10pt;"><span>$175.0 million</span></span><span style="font-family:inherit;font-size:10pt;"> in cash (the "Purchase Price"). Specifically, the royalty rate commences at </span><span style="font-family:inherit;font-size:10pt;"><span>4.15 percent</span></span><span style="font-family:inherit;font-size:10pt;"> on net annual sales of up to </span><span style="font-family:inherit;font-size:10pt;"><span>$2.0 billion</span></span><span style="font-family:inherit;font-size:10pt;">, declining step-wise based on sales tiers to </span><span style="font-family:inherit;font-size:10pt;"><span>1.75 percent</span></span><span style="font-family:inherit;font-size:10pt;"> on net global annual sales exceeding </span><span style="font-family:inherit;font-size:10pt;"><span>$6.0 billion</span></span><span style="font-family:inherit;font-size:10pt;">.</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">On </span><span style="font-family:inherit;font-size:10pt;">January 7, 2018</span><span style="font-family:inherit;font-size:10pt;">, in connection with the Funding Agreement, the Company entered into a common stock purchase agreement (the "Purchase Agreement") with RPI, pursuant to which the Company, in a private placement, issued and sold to RPI approximately </span><span style="font-family:inherit;font-size:10pt;"><span>4.4 million</span></span><span style="font-family:inherit;font-size:10pt;"> unregistered shares (the "Shares") of the Company's Common Stock, at a price of </span><span style="font-family:inherit;font-size:10pt;"><span>$17.15</span></span><span style="font-family:inherit;font-size:10pt;"> per share for gross proceeds to the Company of </span><span style="font-family:inherit;font-size:10pt;"><span>$75.0 million</span></span><span style="font-family:inherit;font-size:10pt;"> before deducting fees and expenses (the "Financing").</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company concluded that there were two units of accounting in the transaction. The Company allocated the transaction consideration on a relative fair value to the liability and common stock in accordance with ASC 470-10 as follows (in thousands):</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="5"/></tr><tr><td style="width:2%;"/><td style="width:78%;"/><td style="width:1%;"/><td style="width:18%;"/><td style="width:1%;"/></tr><tr><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Units of Accounting:</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Allocated Consideration</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Liability related to sale of future royalties</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>182,216</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Common stock</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>67,784</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>250,000</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Interest will be recognized using the effective interest method over a period of </span><span style="font-family:inherit;font-size:10pt;"><span>20 years</span></span><span style="font-family:inherit;font-size:10pt;">. The effective interest rate under the Funding Agreement, including issuance costs, is approximately </span><span style="font-family:inherit;font-size:10pt;"><span>16.0%</span></span><span style="font-family:inherit;font-size:10pt;"> as of </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;">. During the year ended </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;">, the Transition Period, and the fiscal year ended </span><span style="font-family:inherit;font-size:10pt;">June 30, 2018</span><span style="font-family:inherit;font-size:10pt;">, the Company recognized </span><span style="font-family:inherit;font-size:10pt;"><span>$39.9 million</span></span><span style="font-family:inherit;font-size:10pt;">, </span><span style="font-family:inherit;font-size:10pt;"><span>$19.3 million</span></span><span style="font-family:inherit;font-size:10pt;">, and </span><span style="font-family:inherit;font-size:10pt;"><span>$19.8 million</span></span><span style="font-family:inherit;font-size:10pt;"> in interest expense, respectively.</span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following table shows the activity within the liability related to sale of future royalties during the year ended </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;">, the Transition Period and at the fiscal year ended June 30, 2018 (in thousands):</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"/></tr><tr><td style="width:80%;"/><td style="width:1%;"/><td style="width:18%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Liability related to sale of future royalties at January 7, 2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>182,216</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Interest expense recognized</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>19,791</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Carrying value of liability related to sale of future royalties at June 30, 2018</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>202,007</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Interest expense recognized</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>19,288</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Carrying value of liability related to sale of future royalties at December 31, 2018 </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>221,295</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Interest expense recognized</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>39,929</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Carrying value of liability related to sale of future royalties at December 31, 2019 (includes current portion of $3,455)</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>261,224</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Convertible Senior Notes</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In February 2015, the Company issued </span><span style="font-family:inherit;font-size:10pt;"><span>$100.0 million</span></span><span style="font-family:inherit;font-size:10pt;"> of Convertible Senior Notes (the "Convertible Senior Notes") (net proceeds of approximately </span><span style="font-family:inherit;font-size:10pt;"><span>$96.3 million</span></span><span style="font-family:inherit;font-size:10pt;"> after deducting the initial purchasers’ fees and offering expenses) in a private offering exempt from registration under the Securities Act of 1933, as amended (the “Securities Act”), in reliance upon Rule 144A under the Securities Act. The Convertible Senior Notes had a maturity date of </span><span style="font-family:inherit;font-size:10pt;">February 15, 2020</span><span style="font-family:inherit;font-size:10pt;">, unless earlier purchased or converted. The debt issuance costs of approximately </span><span style="font-family:inherit;font-size:10pt;"><span>$3.7 million</span></span><span style="font-family:inherit;font-size:10pt;">, primarily consisting of underwriting, legal and other professional fees, and are amortized over the term of the Convertible Senior Notes. The Convertible Senior Notes are senior unsecured obligations of the Company. Interest at </span><span style="font-family:inherit;font-size:10pt;"><span>4.75%</span></span><span style="font-family:inherit;font-size:10pt;"> is payable semiannually on </span><span style="font-family:inherit;font-size:10pt;">February 15</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">August 15</span><span style="font-family:inherit;font-size:10pt;"> of each year. The effective interest rate on the Convertible Senior Notes was </span><span style="font-family:inherit;font-size:10pt;"><span>5.48%</span></span><span style="font-family:inherit;font-size:10pt;"> for the period from the date of issuance through the year ended </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;">.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Convertible Senior Notes are convertible at the option of holders into approximately </span><span style="font-family:inherit;font-size:10pt;"><span>19.6 million</span></span><span style="font-family:inherit;font-size:10pt;"> shares of common stock at any time prior to the close of business on the day immediately preceding the maturity date. The exchange rate will initially be </span><span style="font-family:inherit;font-size:10pt;"><span>195.8336</span></span><span style="font-family:inherit;font-size:10pt;"> shares of common stock per </span><span style="font-family:inherit;font-size:10pt;"><span>$1,000</span></span><span style="font-family:inherit;font-size:10pt;"> principal amount of Convertible Senior Notes (equivalent to an initial conversion price of approximately </span><span style="font-family:inherit;font-size:10pt;"><span>$5.11</span></span><span style="font-family:inherit;font-size:10pt;"> per share of common stock).</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">If the Company undergoes a fundamental change (as defined in the indenture governing the Convertible Senior Notes), holders may require Immunomedics to purchase for cash all or part of the Convertible Senior Notes at a purchase price equal to </span><span style="font-family:inherit;font-size:10pt;"><span>100%</span></span><span style="font-family:inherit;font-size:10pt;"> of the principal amount of the Convertible Senior Notes to be purchased, plus accrued and unpaid interest, if any, to, but excluding, the fundamental change purchase date, subject to certain exceptions. In addition, if certain make-whole fundamental changes (as defined in the indenture governing the Convertible Senior Notes) occur, Immunomedics will, in certain circumstances, increase the conversion rate for any Convertible Note converted in connection with such make-whole fundamental change.</span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The indenture does not limit the amount of debt which may be issued by the Company under the indenture or otherwise, does not contain any financial covenants or restrict the Company from paying dividends, selling or disposing of assets, or issuing or repurchasing its other securities, provided that such event is not deemed to be a fundamental change (as defined in the indenture governing the Convertible Senior Notes). The indenture contains customary terms and covenants and events of default.</span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">If an event of default with respect to the Convertible Senior Notes occurs, holders may, upon satisfaction of certain conditions, accelerate the principal amount of the Convertible Senior Notes plus premium, if any, and accrued and unpaid interest, if any. In addition, the principal amount of the Convertible Senior Notes plus premium, if any, and accrued and unpaid interest, if any, will automatically become due and payable in the case of certain types of bankruptcy or insolvency events of default involving the Company.</span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">On </span><span style="font-family:inherit;font-size:10pt;">September 21, 2017</span><span style="font-family:inherit;font-size:10pt;">, the Company entered into separate, privately negotiated exchange agreements, (the "September Exchange Agreements") with certain holders of the Convertible Senior Notes. Under the Exchange Agreements, such holders agreed to convert an aggregate </span><span style="font-family:inherit;font-size:10pt;"><span>$80.0 million</span></span><span style="font-family:inherit;font-size:10pt;"> of Convertible Senior Notes held by them. In total, the Company issued an aggregate </span><span style="font-family:inherit;font-size:10pt;"><span>16.8</span></span><span style="font-family:inherit;font-size:10pt;"> million shares of common stock in the September Exchange Agreements. The shares represent an aggregate of </span><span style="font-family:inherit;font-size:10pt;"><span>1.1</span></span><span style="font-family:inherit;font-size:10pt;"> million shares more than the number of shares into which the exchanged Convertible Senior Notes were convertible under their original terms. As a result of the September Exchange Agreements, the Company recognized a loss on induced exchanges of debt of </span><span style="font-family:inherit;font-size:10pt;"><span>$13.0 million</span></span><span style="font-family:inherit;font-size:10pt;"> representing the fair value of the incremental consideration paid to induce the holders to exchange their Convertible Senior Notes for equity (i.e., </span><span style="font-family:inherit;font-size:10pt;"><span>1.1</span></span><span style="font-family:inherit;font-size:10pt;"> million shares of common stock), based on the closing market price of the Company's Common Stock on the date of the September 2017 Exchange Agreements.</span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">On October 2, 2018, the Company entered into privately negotiated exchange agreements (the "October 2018 Exchange Agreements"), with a limited number of holders of the Convertible Senior Notes. Under the Exchange Agreements, such holders agreed to convert an aggregate </span><span style="font-family:inherit;font-size:10pt;"><span>$12.9 million</span></span><span style="font-family:inherit;font-size:10pt;"> of Convertible Senior Notes held by them. In total, the Company issued an aggregate </span><span style="font-family:inherit;font-size:10pt;"><span>2.6 million</span></span><span style="font-family:inherit;font-size:10pt;"> shares of common stock in the October 2018 Exchange Agreements. The shares represent an aggregate of </span><span style="font-family:inherit;font-size:10pt;"><span>0.1 million</span></span><span style="font-family:inherit;font-size:10pt;"> shares more than the number of shares into which the exchanged Convertible Senior Notes were convertible under their original terms. As a result of the October 2018 Exchange Agreements, the Company recognized a loss on induced exchanges of debt of </span><span style="font-family:inherit;font-size:10pt;"><span>$0.9 million</span></span><span style="font-family:inherit;font-size:10pt;"> representing the fair value of the incremental consideration paid to induce the holders to exchange their Convertible Senior Notes for equity (i.e., </span><span style="font-family:inherit;font-size:10pt;"><span>0.1 million</span></span><span style="font-family:inherit;font-size:10pt;"> shares of common stock), based on the closing market price of the Company's Common Stock on the date of the October 2018 Exchange Agreements. As a result of the October 2018 Exchange Agreements, the balance of the outstanding Convertible Senior Notes was </span><span style="font-family:inherit;font-size:10pt;"><span>$7.1 million</span></span><span style="font-family:inherit;font-size:10pt;"> at </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">2018</span><span style="font-family:inherit;font-size:10pt;">. As of February 14, 2020, the remaining </span><span style="font-family:inherit;font-size:10pt;"><span>$7.1 million</span></span><span style="font-family:inherit;font-size:10pt;"> of Convertible Senior Notes converted into </span><span style="font-family:inherit;font-size:10pt;"><span>1.4 million</span></span><span style="font-family:inherit;font-size:10pt;"> shares of common stock based on the initial conversion price of approximately </span><span style="font-family:inherit;font-size:10pt;"><span>$5.11</span></span><span style="font-family:inherit;font-size:10pt;"> per share of common stock.</span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total interest expense for the Convertible Senior Notes were </span><span style="font-family:inherit;font-size:10pt;"><span>$0.4 million</span></span><span style="font-family:inherit;font-size:10pt;">, </span><span style="font-family:inherit;font-size:10pt;"><span>$0.5 million</span></span><span style="font-family:inherit;font-size:10pt;">, </span><span style="font-family:inherit;font-size:10pt;"><span>$3.5 million</span></span><span style="font-family:inherit;font-size:10pt;">, and </span><span style="font-family:inherit;font-size:10pt;"><span>$5.5 million</span></span><span style="font-family:inherit;font-size:10pt;">, for the year ended </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;">, the Transition Period and the fiscal years ended 2018 and 2017, respectively. Included in interest expense is the amortization of debt issuance costs of </span><span style="font-family:inherit;font-size:10pt;"><span>$0.1 million</span></span><span style="font-family:inherit;font-size:10pt;"> for the year ended </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;">, </span><span style="font-family:inherit;font-size:10pt;"><span>$0.2 million</span></span><span style="font-family:inherit;font-size:10pt;"> in the Transition Period (</span><span style="font-family:inherit;font-size:10pt;"><span>$0.1 million</span></span><span style="font-family:inherit;font-size:10pt;"> of which related to the accelerated amortization of debt issuance costs associated with the October 2018 Exchange Agreements), </span><span style="font-family:inherit;font-size:10pt;"><span>$1.7 million</span></span><span style="font-family:inherit;font-size:10pt;"> in fiscal 2018 (</span><span style="font-family:inherit;font-size:10pt;"><span>$1.4 million</span></span><span style="font-family:inherit;font-size:10pt;"> of which related to the accelerated amortization of debt issuance costs associated with the September Exchange Agreements), and </span><span style="font-family:inherit;font-size:10pt;"><span>$0.7 million</span></span><span style="font-family:inherit;font-size:10pt;"> in fiscal 2017.</span></div></us-gaap:DebtDisclosureTextBlock>
<immu:PaymentsForFutureRoyalties
contextRef="D2018Q3Jan07_srt_CounterpartyNameAxis_immu_RpiFinanceTrustMember_us-gaap_DeferredRevenueArrangementTypeAxis_us-gaap_RoyaltyArrangementMember"
decimals="-5"
id="d22929576e658-wk-Fact-54CD9DC64C87871AA5A4D1D0180BC084"
unitRef="usd">175000000.0</immu:PaymentsForFutureRoyalties>
<immu:RoyaltyPurchaseArrangementRoyaltyRateasPercentageofNetSales
contextRef="D2018Q3Jan07_srt_CounterpartyNameAxis_immu_RpiFinanceTrustMember_us-gaap_DeferredRevenueArrangementTypeAxis_us-gaap_RoyaltyArrangementMember"
decimals="4"
id="d22929576e662-wk-Fact-2E6529BC8E40A640C9F3D1D0181B0B67"
unitRef="number">0.0415</immu:RoyaltyPurchaseArrangementRoyaltyRateasPercentageofNetSales>
<immu:RoyaltyPurchaseArrangementAnnualSalesLimitMaximum
contextRef="D2018Q3Jan07_srt_CounterpartyNameAxis_immu_RpiFinanceTrustMember_us-gaap_DeferredRevenueArrangementTypeAxis_us-gaap_RoyaltyArrangementMember"
decimals="INF"
id="d22929576e666-wk-Fact-7035369352B29A4829ACD1D0181B59AC"
unitRef="usd">2000000000.0</immu:RoyaltyPurchaseArrangementAnnualSalesLimitMaximum>
<immu:RoyaltyPurchaseArrangementRoyaltyRateasPercentageofExcessofGlobalAnnualSalesThresholdLimit
contextRef="D2018Q3Jan07_srt_CounterpartyNameAxis_immu_RpiFinanceTrustMember_us-gaap_DeferredRevenueArrangementTypeAxis_us-gaap_RoyaltyArrangementMember"
decimals="4"
id="d22929576e670-wk-Fact-7306D996BED6BEF995C9D1D0185B771B"
unitRef="number">0.0175</immu:RoyaltyPurchaseArrangementRoyaltyRateasPercentageofExcessofGlobalAnnualSalesThresholdLimit>
<immu:RoyaltyPurchaseArrangementExcessGlobalAnnualSalesLimitMinimum
contextRef="D2018Q3Jan07_srt_CounterpartyNameAxis_immu_RpiFinanceTrustMember_us-gaap_DeferredRevenueArrangementTypeAxis_us-gaap_RoyaltyArrangementMember"
decimals="INF"
id="d22929576e675-wk-Fact-87F4C65FAA17A28EE9CAD1D0181BB86D"
unitRef="usd">6000000000.0</immu:RoyaltyPurchaseArrangementExcessGlobalAnnualSalesLimitMinimum>
<us-gaap:StockIssuedDuringPeriodSharesNewIssues
contextRef="D2019Q1Jan7"
decimals="-5"
id="d22929576e689-wk-Fact-994FDD5EFB1015822490DCE2318AC1DB"
unitRef="shares">4400000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
<us-gaap:SharePrice
contextRef="I2018Q3Jan07_srt_CounterpartyNameAxis_immu_RpiFinanceTrustMember_us-gaap_DeferredRevenueArrangementTypeAxis_us-gaap_RoyaltyArrangementMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember"
decimals="INF"
id="d22929576e693-wk-Fact-A7EDC4B4270AD2F27136D1D0184BCC30"
unitRef="usdPerShare">17.15</us-gaap:SharePrice>
<us-gaap:SaleOfStockConsiderationReceivedOnTransaction
contextRef="D2018Q3Jan07_srt_CounterpartyNameAxis_immu_RpiFinanceTrustMember_us-gaap_DeferredRevenueArrangementTypeAxis_us-gaap_RoyaltyArrangementMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember"
decimals="-5"
id="d22929576e697-wk-Fact-9F481AFA117AD3963C89D1D0181BE8B3"
unitRef="usd">75000000.0</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
<immu:AllocationofFairValuetoLiabilityTableTextBlock
contextRef="FD2019Q4YTD"
id="TextSelection-B87D5A5A9A886F981391D1D018759849-0-wk-Fact-82200CF6ABB08D69E1E0D1D0180BB5F3">The Company allocated the transaction consideration on a relative fair value to the liability and common stock in accordance with ASC 470-10 as follows (in thousands):<div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="5"/></tr><tr><td style="width:2%;"/><td style="width:78%;"/><td style="width:1%;"/><td style="width:18%;"/><td style="width:1%;"/></tr><tr><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Units of Accounting:</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Allocated Consideration</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Liability related to sale of future royalties</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>182,216</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Common stock</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>67,784</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>250,000</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div></immu:AllocationofFairValuetoLiabilityTableTextBlock>
<immu:FairValueForLiabilityRelatedtoSaleofFutureRoyalties
contextRef="I2018Q3Jan07_srt_CounterpartyNameAxis_immu_RpiFinanceTrustMember_us-gaap_DeferredRevenueArrangementTypeAxis_us-gaap_RoyaltyArrangementMember"
decimals="-3"
id="d22929576e773-wk-Fact-FAFCEA6073D4F0B07F2039CD1FA246BA"
unitRef="usd">182216000</immu:FairValueForLiabilityRelatedtoSaleofFutureRoyalties>
<us-gaap:CommonStockValue
contextRef="I2018Q3Jan07_srt_CounterpartyNameAxis_immu_RpiFinanceTrustMember_us-gaap_DeferredRevenueArrangementTypeAxis_us-gaap_RoyaltyArrangementMember"
decimals="-3"
id="d22929576e793-wk-Fact-26E7614FCD07D4FE2F7E39CD1AADA641"
unitRef="usd">67784000</us-gaap:CommonStockValue>
<immu:RoyaltyPurchaseAgreementArrangementsConsideration
contextRef="I2018Q3Jan07_srt_CounterpartyNameAxis_immu_RpiFinanceTrustMember_us-gaap_DeferredRevenueArrangementTypeAxis_us-gaap_RoyaltyArrangementMember"
decimals="-3"
id="d22929576e823-wk-Fact-C68B680BFE5A0D97535D39CD1A81B842"
unitRef="usd">250000000</immu:RoyaltyPurchaseAgreementArrangementsConsideration>
<immu:PeriodWhichCompanyWillAccreteLiability
contextRef="FD2019Q4YTD"
id="d22929576e840-wk-Fact-C53187AE1E129F63E002DCE15344F553">P20Y</immu:PeriodWhichCompanyWillAccreteLiability>
<immu:AnnualInterestRateInCalculatingLiabilityRelatedToSaleOfFutureRoyalties
contextRef="FD2019Q4YTD"
decimals="INF"
id="d22929576e844-wk-Fact-9F79ABF09422AA9A2C88DCE3F9D7CC30"
unitRef="number">0.160</immu:AnnualInterestRateInCalculatingLiabilityRelatedToSaleOfFutureRoyalties>
<immu:NonCashInterestExpenseRelatedToSaleOfFutureRoyalties
contextRef="FD2019Q4YTD_srt_CounterpartyNameAxis_immu_RpiFinanceTrustMember_us-gaap_DeferredRevenueArrangementTypeAxis_us-gaap_RoyaltyArrangementMember"
decimals="-5"
id="d22929576e861-wk-Fact-AD81B21DC8736B2EE80BD7B45C5561AA"
unitRef="usd">39900000</immu:NonCashInterestExpenseRelatedToSaleOfFutureRoyalties>
<immu:NonCashInterestExpenseRelatedToSaleOfFutureRoyalties
contextRef="D2018Q4Jul01-Dec31_srt_CounterpartyNameAxis_immu_RpiFinanceTrustMember_us-gaap_DeferredRevenueArrangementTypeAxis_us-gaap_RoyaltyArrangementMember"
decimals="-5"
id="d22929576e865-wk-Fact-D2938A39563021AFDE71D1D0180B89C8"
unitRef="usd">19300000</immu:NonCashInterestExpenseRelatedToSaleOfFutureRoyalties>
<immu:NonCashInterestExpenseRelatedToSaleOfFutureRoyalties
contextRef="D2018Q4Jul12017toJun302018_srt_CounterpartyNameAxis_immu_RpiFinanceTrustMember_us-gaap_DeferredRevenueArrangementTypeAxis_us-gaap_RoyaltyArrangementMember"
decimals="-5"
id="d22929576e869-wk-Fact-29B17B74BB3F7D6D53A3D7B46B57B0C8"
unitRef="usd">19800000</immu:NonCashInterestExpenseRelatedToSaleOfFutureRoyalties>
<us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock
contextRef="FD2019Q4YTD"
id="TextSelection-FC74E42A79BA51350E60D1D01875C061-0-wk-Fact-45CFEF396EA1B9D77574D1D0180BA8E8"><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following table shows the activity within the liability related to sale of future royalties during the year ended </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;">, the Transition Period and at the fiscal year ended June 30, 2018 (in thousands):</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"/></tr><tr><td style="width:80%;"/><td style="width:1%;"/><td style="width:18%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Liability related to sale of future royalties at January 7, 2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>182,216</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Interest expense recognized</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>19,791</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Carrying value of liability related to sale of future royalties at June 30, 2018</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>202,007</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Interest expense recognized</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>19,288</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Carrying value of liability related to sale of future royalties at December 31, 2018 </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>221,295</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Interest expense recognized</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>39,929</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Carrying value of liability related to sale of future royalties at December 31, 2019 (includes current portion of $3,455)</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>261,224</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div></us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock>
<immu:FairValueForLiabilityRelatedtoSaleofFutureRoyalties
contextRef="I2018Q3Jan07_srt_CounterpartyNameAxis_immu_RpiFinanceTrustMember_us-gaap_DeferredRevenueArrangementTypeAxis_us-gaap_RoyaltyArrangementMember"
decimals="-3"
id="d22929576e913-wk-Fact-FAFCEA6073D4F0B07F2039CD1FA246BA"
unitRef="usd">182216000</immu:FairValueForLiabilityRelatedtoSaleofFutureRoyalties>
<immu:NonCashInterestExpenseRelatedToSaleOfFutureRoyalties
contextRef="D2018Q3Jan08-Jun30_srt_CounterpartyNameAxis_immu_RpiFinanceTrustMember_us-gaap_DeferredRevenueArrangementTypeAxis_us-gaap_RoyaltyArrangementMember"
decimals="-3"
id="d22929576e928-wk-Fact-A56EA7DB28E612D6D02539CD1FA90A38"
unitRef="usd">19791000</immu:NonCashInterestExpenseRelatedToSaleOfFutureRoyalties>
<immu:FairValueForLiabilityRelatedtoSaleofFutureRoyalties
contextRef="FI2018Q2_srt_CounterpartyNameAxis_immu_RpiFinanceTrustMember_us-gaap_DeferredRevenueArrangementTypeAxis_us-gaap_RoyaltyArrangementMember"
decimals="-3"
id="d22929576e953-wk-Fact-1F2A4EDC36D7468DDC4939CD1F45CA08"
unitRef="usd">202007000</immu:FairValueForLiabilityRelatedtoSaleofFutureRoyalties>
<immu:NonCashInterestExpenseRelatedToSaleOfFutureRoyalties
contextRef="D2018Q4Jul01-Dec31_srt_CounterpartyNameAxis_immu_RpiFinanceTrustMember_us-gaap_DeferredRevenueArrangementTypeAxis_us-gaap_RoyaltyArrangementMember"
decimals="-3"
id="d22929576e968-wk-Fact-1E5DF9BF77803116D17FD1D0183CFDF3"
unitRef="usd">19288000</immu:NonCashInterestExpenseRelatedToSaleOfFutureRoyalties>
<immu:FairValueForLiabilityRelatedtoSaleofFutureRoyalties
contextRef="FI2018Q4_srt_CounterpartyNameAxis_immu_RpiFinanceTrustMember_us-gaap_DeferredRevenueArrangementTypeAxis_us-gaap_RoyaltyArrangementMember"
decimals="-3"
id="d22929576e993-wk-Fact-1B74D96A73D100729493D1D0183C4E06"
unitRef="usd">221295000</immu:FairValueForLiabilityRelatedtoSaleofFutureRoyalties>
<immu:NonCashInterestExpenseRelatedToSaleOfFutureRoyalties
contextRef="FD2019Q4YTD_srt_CounterpartyNameAxis_immu_RpiFinanceTrustMember_us-gaap_DeferredRevenueArrangementTypeAxis_us-gaap_RoyaltyArrangementMember"
decimals="-3"
id="d22929576e1008-wk-Fact-5036BB16364A99C9849DDCE73F5999E7"
unitRef="usd">39929000</immu:NonCashInterestExpenseRelatedToSaleOfFutureRoyalties>
<immu:FairValueForLiabilityRelatedtoSaleofFutureRoyalties
contextRef="FI2019Q4_srt_CounterpartyNameAxis_immu_RpiFinanceTrustMember_us-gaap_DeferredRevenueArrangementTypeAxis_us-gaap_RoyaltyArrangementMember"
decimals="-3"
id="d22929576e1033-wk-Fact-CDEE26BEC02196546FE3DCE9C68463B8"
unitRef="usd">261224000</immu:FairValueForLiabilityRelatedtoSaleofFutureRoyalties>
<us-gaap:DebtInstrumentFaceAmount
contextRef="I2015Q3Feb28_us-gaap_DebtInstrumentAxis_immu_FourPointSevenFivePercentConvertibleSeniorNotesMember"
decimals="INF"
id="d22929576e1057-wk-Fact-39BB0540D0441A880594D1D0184B807B"
unitRef="usd">100000000.0</us-gaap:DebtInstrumentFaceAmount>
<us-gaap:ProceedsFromDebtNetOfIssuanceCosts
contextRef="D2015Q3Feb01-Feb28_us-gaap_DebtInstrumentAxis_immu_FourPointSevenFivePercentConvertibleSeniorNotesMember"
decimals="-5"
id="d22929576e1061-wk-Fact-F6012EF370623FA1E236D1D0180B04D2"
unitRef="usd">96300000</us-gaap:ProceedsFromDebtNetOfIssuanceCosts>
<us-gaap:PaymentsOfDebtIssuanceCosts
contextRef="D2015Q3Feb01-Feb28_us-gaap_DebtInstrumentAxis_immu_FourPointSevenFivePercentConvertibleSeniorNotesMember"
decimals="-5"
id="d22929576e1069-wk-Fact-9D35B69BCD759D85B301D1D0181B3A94"
unitRef="usd">3700000</us-gaap:PaymentsOfDebtIssuanceCosts>
<us-gaap:DebtInstrumentInterestRateStatedPercentage
contextRef="I2015Q3Feb28_us-gaap_DebtInstrumentAxis_immu_FourPointSevenFivePercentConvertibleSeniorNotesMember"
decimals="INF"
id="d22929576e1073-wk-Fact-8250E54BFDC25F74BBBDD1D0181B6405"
unitRef="number">0.0475</us-gaap:DebtInstrumentInterestRateStatedPercentage>
<us-gaap:DebtInstrumentInterestRateEffectivePercentage
contextRef="FI2019Q4_us-gaap_DebtInstrumentAxis_immu_FourPointSevenFivePercentConvertibleSeniorNotesMember"
decimals="4"
id="d22929576e1086-wk-Fact-D00436D83C97EE7BFC3DD1D01865A105"
unitRef="number">0.0548</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
<us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion
contextRef="I2015Q3Feb28_us-gaap_DebtInstrumentAxis_immu_FourPointSevenFivePercentConvertibleSeniorNotesMember"
decimals="-5"
id="d22929576e1101-wk-Fact-E684A61F74EF22FCC9F8D1D0180BD27A"
unitRef="shares">19600000</us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion>
<us-gaap:DebtInstrumentConvertibleConversionRatio1
contextRef="D2015Q3Feb01-Feb28_us-gaap_DebtInstrumentAxis_immu_FourPointSevenFivePercentConvertibleSeniorNotesMember"
decimals="INF"
id="d22929576e1105-wk-Fact-520C77FA6382008E685CD1D0184B1A46"
unitRef="number">195.8336</us-gaap:DebtInstrumentConvertibleConversionRatio1>
<us-gaap:DebtInstrumentConvertibleConversionPrice1
contextRef="FI2019Q4_us-gaap_DebtInstrumentAxis_immu_FourPointSevenFivePercentConvertibleSeniorNotesMember"
decimals="INF"
id="d22929576e1109-wk-Fact-1807AD01AB36B644D601D1D0181B2496"
unitRef="usdPerShare">1000</us-gaap:DebtInstrumentConvertibleConversionPrice1>
<us-gaap:DebtInstrumentConvertibleConversionPrice1
contextRef="I2015Q3Feb28_us-gaap_DebtInstrumentAxis_immu_FourPointSevenFivePercentConvertibleSeniorNotesMember"
decimals="2"
id="d22929576e1113-wk-Fact-9FECAE8EFECD0D11FDF1D1D0181BC2C1"
unitRef="usdPerShare">5.11</us-gaap:DebtInstrumentConvertibleConversionPrice1>
<us-gaap:DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed
contextRef="D2015Q3Feb01-Feb28_us-gaap_DebtInstrumentAxis_immu_FourPointSevenFivePercentConvertibleSeniorNotesMember"
decimals="INF"
id="d22929576e1123-wk-Fact-1818B8F9CF2B9E5F8945D1D0181B76B0"
unitRef="number">1</us-gaap:DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed>
<us-gaap:DebtConversionOriginalDebtAmount1
contextRef="D2018Q1Sept21_us-gaap_DebtInstrumentAxis_immu_FourPointSevenFivePercentConvertibleSeniorNotesMember"
decimals="-5"
id="d22929576e1146-wk-Fact-07FB96E283FB3E3A3CC0D1D0181BCE74"
unitRef="usd">80000000.0</us-gaap:DebtConversionOriginalDebtAmount1>
<us-gaap:DebtConversionConvertedInstrumentSharesIssued1
contextRef="D2018Q1Sept21_us-gaap_DebtInstrumentAxis_immu_FourPointSevenFivePercentConvertibleSeniorNotesMember"
decimals="-5"
id="d22929576e1150-wk-Fact-5E7A89197A99C4ABB80DD1D0181B9856"
unitRef="shares">16800000</us-gaap:DebtConversionConvertedInstrumentSharesIssued1>
<immu:DebtInstrumentConvertibleBeneficialConversionFeatureAggregateNumberOfShares
contextRef="D2018Q1Sept21_us-gaap_DebtInstrumentAxis_immu_FourPointSevenFivePercentConvertibleSeniorNotesMember"
decimals="-5"
id="d22929576e1154-wk-Fact-1C2C74F160B55BC0F822D1D0181BB64E"
unitRef="shares">1100000</immu:DebtInstrumentConvertibleBeneficialConversionFeatureAggregateNumberOfShares>
<us-gaap:InducedConversionOfConvertibleDebtExpense
contextRef="D2018Q1Sept21_us-gaap_DebtInstrumentAxis_immu_FourPointSevenFivePercentConvertibleSeniorNotesMember"
decimals="-5"
id="d22929576e1158-wk-Fact-9A7F6E65C187B9C0DFD7D1D0185B24F9"
unitRef="usd">13000000.0</us-gaap:InducedConversionOfConvertibleDebtExpense>
<immu:DebtInstrumentConvertibleBeneficialConversionFeatureAggregateNumberOfShares
contextRef="D2018Q1Sept21_us-gaap_DebtInstrumentAxis_immu_FourPointSevenFivePercentConvertibleSeniorNotesMember"
decimals="-5"
id="d22929576e1163-wk-Fact-1C2C74F160B55BC0F822D1D0181BB64E"
unitRef="shares">1100000</immu:DebtInstrumentConvertibleBeneficialConversionFeatureAggregateNumberOfShares>
<us-gaap:DebtConversionOriginalDebtAmount1
contextRef="D2018Q4Oct02_us-gaap_DebtInstrumentAxis_immu_October2018ExchangeAgreementMember"
decimals="-5"
id="d22929576e1172-wk-Fact-1FC5C224F9D44C28F682D1D0185B6A0D"
unitRef="usd">12900000</us-gaap:DebtConversionOriginalDebtAmount1>
<us-gaap:DebtConversionConvertedInstrumentSharesIssued1
contextRef="D2018Q4Oct02_us-gaap_DebtInstrumentAxis_immu_October2018ExchangeAgreementMember"
decimals="-5"
id="d22929576e1176-wk-Fact-A57E91C0980A95BAA732D1D0180B595B"
unitRef="shares">2600000</us-gaap:DebtConversionConvertedInstrumentSharesIssued1>
<immu:DebtInstrumentConvertibleBeneficialConversionFeatureAggregateNumberOfShares
contextRef="D2018Q4Oct02_us-gaap_DebtInstrumentAxis_immu_FourPointSevenFivePercentConvertibleSeniorNotesMember"
decimals="-5"
id="d22929576e1180-wk-Fact-61F1B77ADC72EE70E6FED1D0186528DF"
unitRef="shares">100000</immu:DebtInstrumentConvertibleBeneficialConversionFeatureAggregateNumberOfShares>
<us-gaap:InducedConversionOfConvertibleDebtExpense
contextRef="D2018Q4Oct02_us-gaap_DebtInstrumentAxis_immu_FourPointSevenFivePercentConvertibleSeniorNotesMember"
decimals="-5"
id="d22929576e1184-wk-Fact-139F0177BEE2CC86F759D1D0180BCC4A"
unitRef="usd">900000</us-gaap:InducedConversionOfConvertibleDebtExpense>
<immu:DebtInstrumentConvertibleBeneficialConversionFeatureAggregateNumberOfShares
contextRef="D2018Q4Oct02_us-gaap_DebtInstrumentAxis_immu_FourPointSevenFivePercentConvertibleSeniorNotesMember"
decimals="-5"
id="d22929576e1188-wk-Fact-61F1B77ADC72EE70E6FED1D0186528DF"
unitRef="shares">100000</immu:DebtInstrumentConvertibleBeneficialConversionFeatureAggregateNumberOfShares>
<immu:DebtConversionOutstandingBalance
contextRef="FI2019Q4_us-gaap_DebtInstrumentAxis_immu_FourPointSevenFivePercentConvertibleSeniorNotesMember"
decimals="-5"
id="d22929576e1193-wk-Fact-79D2B5AF41A7A8552383D1D0181BD3A2"
unitRef="usd">7100000</immu:DebtConversionOutstandingBalance>
<immu:DebtConversionOutstandingBalance
contextRef="I2020Q1Feb14_us-gaap_DebtInstrumentAxis_immu_FourPointSevenFivePercentConvertibleSeniorNotesMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember"
decimals="-5"
id="d22929576e1205-wk-Fact-F3415A8ECEABE24D0B4A456402C6EA70"
unitRef="usd">7100000</immu:DebtConversionOutstandingBalance>
<us-gaap:DebtConversionConvertedInstrumentSharesIssued1
contextRef="D2020Q1Feb14-Feb14_us-gaap_DebtInstrumentAxis_immu_FourPointSevenFivePercentConvertibleSeniorNotesMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember"
decimals="-5"
id="d22929576e1209-wk-Fact-62F311FED758F5A6D7C145624F9A4714"
unitRef="shares">1400000</us-gaap:DebtConversionConvertedInstrumentSharesIssued1>
<us-gaap:DebtInstrumentConvertibleConversionPrice1
contextRef="I2020Q1Feb14_us-gaap_DebtInstrumentAxis_immu_FourPointSevenFivePercentConvertibleSeniorNotesMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember"
decimals="2"
id="d22929576e1213-wk-Fact-C8021A098E040EFCA0844565BCA3E985"
unitRef="usdPerShare">5.11</us-gaap:DebtInstrumentConvertibleConversionPrice1>
<us-gaap:InterestExpenseDebt
contextRef="FD2019Q4YTD_us-gaap_DebtInstrumentAxis_immu_FourPointSevenFivePercentConvertibleSeniorNotesMember"
decimals="-5"
id="d22929576e1224-wk-Fact-F73063966F9C5B35271ED7B3ECE002B7"
unitRef="usd">400000</us-gaap:InterestExpenseDebt>
<us-gaap:InterestExpenseDebt
contextRef="D2018Q4Jul01-Dec31_us-gaap_DebtInstrumentAxis_immu_FourPointSevenFivePercentConvertibleSeniorNotesMember"
decimals="-5"
id="d22929576e1228-wk-Fact-0051548EE71F5854037ED1D0181B152A"
unitRef="usd">500000</us-gaap:InterestExpenseDebt>
<us-gaap:InterestExpenseDebt
contextRef="D2018Q4Jul12017toJun302018_us-gaap_DebtInstrumentAxis_immu_FourPointSevenFivePercentConvertibleSeniorNotesMember"
decimals="-5"
id="d22929576e1232-wk-Fact-75F25B0545B713219A54D1D0180B2222"
unitRef="usd">3500000</us-gaap:InterestExpenseDebt>
<us-gaap:InterestExpenseDebt
contextRef="D2017Q4Jul012016toJun302017_us-gaap_DebtInstrumentAxis_immu_FourPointSevenFivePercentConvertibleSeniorNotesMember"
decimals="-5"
id="d22929576e1236-wk-Fact-6C3E7BC71A9DDC8DFF07D1D0181BCD00"
unitRef="usd">5500000</us-gaap:InterestExpenseDebt>
<us-gaap:AmortizationOfFinancingCosts
contextRef="FD2019Q4YTD_us-gaap_DebtInstrumentAxis_immu_FourPointSevenFivePercentConvertibleSeniorNotesMember"
decimals="-5"
id="d22929576e1245-wk-Fact-59956610D69A082D1769DB3BBABC2EB5"
unitRef="usd">100000</us-gaap:AmortizationOfFinancingCosts>
<us-gaap:AmortizationOfFinancingCosts
contextRef="D2018Q4Jul01-Dec31_us-gaap_DebtInstrumentAxis_immu_FourPointSevenFivePercentConvertibleSeniorNotesMember"
decimals="-5"
id="d22929576e1253-wk-Fact-3C2F714F899E7BA3051BD1D0181B8DC7"
unitRef="usd">200000</us-gaap:AmortizationOfFinancingCosts>
<immu:AcceleratedAmortizationOfFinancingCosts
contextRef="D2018Q4Jul01-Dec31_us-gaap_DebtInstrumentAxis_immu_FourPointSevenFivePercentConvertibleSeniorNotesMember"
decimals="-5"
id="d22929576e1257-wk-Fact-F29D16C394FC1AF7CBCAD1D0185B4552"
unitRef="usd">100000</immu:AcceleratedAmortizationOfFinancingCosts>
<us-gaap:AmortizationOfFinancingCosts
contextRef="D2018Q4Jul12017toJun302018_us-gaap_DebtInstrumentAxis_immu_FourPointSevenFivePercentConvertibleSeniorNotesMember"
decimals="-5"
id="d22929576e1261-wk-Fact-ACAA2614C19DCA975C47D1D0181B6BA6"
unitRef="usd">1700000</us-gaap:AmortizationOfFinancingCosts>
<immu:AcceleratedAmortizationOfFinancingCosts
contextRef="D2018Q4Jul12017toJun302018_us-gaap_DebtInstrumentAxis_immu_FourPointSevenFivePercentConvertibleSeniorNotesMember"
decimals="-5"
id="d22929576e1265-wk-Fact-03784594C491DD1B94E6D1D0180B068B"
unitRef="usd">1400000</immu:AcceleratedAmortizationOfFinancingCosts>
<us-gaap:AmortizationOfFinancingCosts
contextRef="D2017Q4Jul012016toJun302017_us-gaap_DebtInstrumentAxis_immu_FourPointSevenFivePercentConvertibleSeniorNotesMember"
decimals="-5"
id="d22929576e1270-wk-Fact-A7900FB0625568436B32D1D0181B38B3"
unitRef="usd">700000</us-gaap:AmortizationOfFinancingCosts>
<us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock
contextRef="FD2019Q4YTD"
id="TextSelection-E7DF875311C5AEEADAA0D1D0187552B7-0-wk-Fact-EE129F5E60CC1E22C1CCD1D0182AEC98">Stock-Based Compensation<div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Stock Incentive Plan</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company has a stock incentive plan, the Immunomedics, Inc. 2014 Long-Term Incentive Plan (the “Plan”). The Plan was established to promote the long-term financial interests and growth of the Company, by attracting and retaining management and other personnel and key service providers with the training, experience and ability to enable them to make a substantial contribution to the success of the Company's business. The Plan is designed to motivate management personnel by means of growth-related incentives to achieve long-range goals and further the alignment of interests with those of the stockholders of the Company through opportunities for increased stock or stock-based ownership in the Company. Toward these objectives, the Company may grant stock options, stock appreciation rights, stock awards, stock units, performance shares, performance options, performance units, and other stock-based awards to eligible individuals on the terms and subject to the conditions set forth in the Plan. There have been no significant modifications to the Plan during the year ended December 31, 2019, the Transition Period or fiscal years ended June 30, 2018, or 2017.</span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Stock-based compensation expense was </span><span style="font-family:inherit;font-size:10pt;"><span>$11.7 million</span></span><span style="font-family:inherit;font-size:10pt;">, </span><span style="font-family:inherit;font-size:10pt;"><span>$0.9 million</span></span><span style="font-family:inherit;font-size:10pt;">, </span><span style="font-family:inherit;font-size:10pt;"><span>$4.0 million</span></span><span style="font-family:inherit;font-size:10pt;">, and </span><span style="font-family:inherit;font-size:10pt;"><span>$4.3 million</span></span><span style="font-family:inherit;font-size:10pt;"> for the year ended </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;">, the Transition Period, and fiscal years ended </span><span style="font-family:inherit;font-size:10pt;">June 30, 2018</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">2017</span><span style="font-family:inherit;font-size:10pt;">, respectively. On January 15, 2019, the Company received a final award finding from an arbitrator that denied Dr. Goldenberg </span><span style="font-family:inherit;font-size:10pt;"><span>1.5 million</span></span><span style="font-family:inherit;font-size:10pt;"> of RSU's. As a result, during the Transition Period, </span><span style="font-family:inherit;font-size:10pt;"><span>$3.4 million</span></span><span style="font-family:inherit;font-size:10pt;"> of the stock-based compensation expense was reversed. Refer to "Note 14 - Commitments and Contingencies" for more information.</span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Stock Options</span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Stock option grants provide the right to purchase a specified number of shares of Common Stock from the Company at a specified price during a specified period of time. The stock option exercise price per share is the fair market value of one share of Common Stock on the date of the grant of the stock option and generally have a vesting period of </span><span style="font-family:inherit;font-size:10pt;"><span>four years</span></span><span style="font-family:inherit;font-size:10pt;">. </span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">As of December 31, 2019</span><span style="font-family:inherit;font-size:10pt;">, there was </span><span style="font-family:inherit;font-size:10pt;"><span>$40.6 million</span></span><span style="font-family:inherit;font-size:10pt;"> of total unrecognized compensation cost related to non-vested stock-based compensation arrangements granted under the plan. That cost is being recognized over a weighted-average period of </span><span style="font-family:inherit;font-size:10pt;"><span>3 years</span></span><span style="font-family:inherit;font-size:10pt;">. </span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The weighted average grant date fair value of the stock options granted during the year ended </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;">, the Transition Period, and fiscal years ended </span><span style="font-family:inherit;font-size:10pt;">June 30, 2018</span><span style="font-family:inherit;font-size:10pt;">, and </span><span style="font-family:inherit;font-size:10pt;">2017</span><span style="font-family:inherit;font-size:10pt;"> was </span><span style="font-family:inherit;font-size:10pt;"><span>$8.81</span></span><span style="font-family:inherit;font-size:10pt;"> per share, </span><span style="font-family:inherit;font-size:10pt;"><span>$12.90</span></span><span style="font-family:inherit;font-size:10pt;"> per share, </span><span style="font-family:inherit;font-size:10pt;"><span>$8.76</span></span><span style="font-family:inherit;font-size:10pt;"> per share, and </span><span style="font-family:inherit;font-size:10pt;"><span>$2.21</span></span><span style="font-family:inherit;font-size:10pt;"> per share, respectively. The weighted average grant date fair value of the performance-based stock options granted during the year ended December 31, 2019, the Transition Period, and fiscal years ended </span><span style="font-family:inherit;font-size:10pt;">June 30, 2018</span><span style="font-family:inherit;font-size:10pt;">, and 2017 was </span><span style="font-family:inherit;font-size:10pt;"><span>$9.50</span></span><span style="font-family:inherit;font-size:10pt;">, </span><span style="font-family:inherit;font-size:10pt;"><span>$0.00</span></span><span style="font-family:inherit;font-size:10pt;">, </span><span style="font-family:inherit;font-size:10pt;"><span>$7.29</span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>$0.00</span></span><span style="font-family:inherit;font-size:10pt;"> per share, respectively. There were no performance-based stock options granted during the Transition Period, or for the fiscal year ended </span><span style="font-family:inherit;font-size:10pt;">June 30, 2017</span><span style="font-family:inherit;font-size:10pt;">. </span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We estimated the fair value of options granted using a Black-Scholes option pricing model with the following assumptions:</span></div><div style="line-height:120%;text-align:center;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:98.6328125%;border-collapse:collapse;text-align:left;"><tr><td colspan="10"/></tr><tr><td style="width:31%;"/><td style="width:1%;"/><td style="width:16%;"/><td style="width:1%;"/><td style="width:16%;"/><td style="width:1%;"/><td style="width:16%;"/><td style="width:1%;"/><td style="width:16%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Year Ended </span></div><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">December 31, 2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Transition Period December 31, 2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="4" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Fiscal Years Ended June 30,</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">2017</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Expected dividend yield</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>—%</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>—%</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>—%</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>—%</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Expected option term (years)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>4.52</span></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>4.76</span></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>4.84</span></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>5.04</span></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Expected stock price volatility</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>71%</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>69%</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>70%</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>63%</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Risk-free interest rate</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">1.39% - 2.58%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">2.69% - 3.06%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">1.72% - 2.89%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">1.16% - 2.15%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">    </span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following table summarizes all stock option activity for the ended </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;">:</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="13"/></tr><tr><td style="width:27%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:16%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:21%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:16%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Options</span></div><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">(in thousands)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Weighted Average Exercise Price Per Option</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Weighted Average Remaining Contractual Term (Years)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Aggregate Intrinsic Value (in thousands)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Options outstanding, January 1, 2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>4,757</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>14.30</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>5.42</span></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>18,618</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">   Changes during the year:</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">   Granted</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>3,614</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>15.46</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">   Exercised</span></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(1,207</span></span></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>3.17</span></span></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">   Expired or forfeited</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(1,263</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>17.78</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Options outstanding, end of year</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>5,901</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#bfe4ff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#bfe4ff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>16.54</span></span></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>5.90</span></span></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#bfe4ff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>30,145</span></span></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Vested as of December 31, 2019</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>1,150</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>14.72</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>4.61</span></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>8,276</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following table summarizes all stock option activity for the Transition Period ended </span><span style="font-family:inherit;font-size:10pt;">December 31, 2018</span><span style="font-family:inherit;font-size:10pt;">:</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="13"/></tr><tr><td style="width:27%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:16%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:21%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:16%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Options</span></div><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">(in thousands)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Weighted Average Exercise Price Per Option</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Weighted Average Remaining Contractual Term (Years)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Aggregate Intrinsic Value (in thousands)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Options outstanding, July 1, 2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>3,549</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>7.58</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>4.43</span></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>57,123</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">   Changes during the year:</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">   Granted</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>2,002</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>22.54</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">   Exercised</span></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(706</span></span></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>3.71</span></span></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">   Expired or forfeited</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(88</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>15.57</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Options outstanding, end of year</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>4,757</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#bfe4ff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#bfe4ff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>14.30</span></span></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>5.42</span></span></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#bfe4ff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>18,618</span></span></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Vested as of December 31, 2018</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>1,504</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>4.23</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>3.41</span></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>15,098</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">    </span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The total fair value of shares vested during the year ended </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;">, the Transition Period, and fiscal years ended </span><span style="font-family:inherit;font-size:10pt;">June 30, 2018</span><span style="font-family:inherit;font-size:10pt;">, and </span><span style="font-family:inherit;font-size:10pt;">2017</span><span style="font-family:inherit;font-size:10pt;"> was </span><span style="font-family:inherit;font-size:10pt;"><span>$8.9 million</span></span><span style="font-family:inherit;font-size:10pt;">, </span><span style="font-family:inherit;font-size:10pt;"><span>$1.3 million</span></span><span style="font-family:inherit;font-size:10pt;">, </span><span style="font-family:inherit;font-size:10pt;"><span>$0.3 million</span></span><span style="font-family:inherit;font-size:10pt;">, and </span><span style="font-family:inherit;font-size:10pt;"><span>$1.4 million</span></span><span style="font-family:inherit;font-size:10pt;">, respectively. The total intrinsic value of stock options exercised during the fiscal year ended </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;">, the Transition Period, and fiscal years ended </span><span style="font-family:inherit;font-size:10pt;">June 30, 2018</span><span style="font-family:inherit;font-size:10pt;">, and </span><span style="font-family:inherit;font-size:10pt;">2017</span><span style="font-family:inherit;font-size:10pt;"> was </span><span style="font-family:inherit;font-size:10pt;"><span>$14.7 million</span></span><span style="font-family:inherit;font-size:10pt;">, </span><span style="font-family:inherit;font-size:10pt;"><span>$13.3 million</span></span><span style="font-family:inherit;font-size:10pt;">, </span><span style="font-family:inherit;font-size:10pt;"><span>$7.8 million</span></span><span style="font-family:inherit;font-size:10pt;">, and </span><span style="font-family:inherit;font-size:10pt;"><span>$2.6 million</span></span><span style="font-family:inherit;font-size:10pt;">, respectively.    </span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Restricted Stock Units ("RSU's")</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"/><span style="font-family:inherit;font-size:10pt;">The Company may grant awards of RSU's to eligible individuals. An RSU represents a contractual obligation by the Company to deliver a number of shares of Common Stock equal to the fair market value of the specified number of shares subject to the award, or a combination of shares of Common Stock and cash. Vesting requirements may include performance goals, the attainment of performance goals with continued service, or both. </span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Information regarding the Company's RSU's for the year ended </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;"> is as follows:</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"/></tr><tr><td style="width:38%;"/><td style="width:1%;"/><td style="width:29%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:28%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Non-Vested Restricted Stock Units</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Share Equivalent</span></div><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">(in thousands)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Weighted Average Grant Date Fair Value</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Non-vested at January 1, 2019</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>15</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>14.29</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Changes during the period:</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">   Restricted Units Granted </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>58</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>12.93</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">   Vested/Exercised</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(15</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>14.29</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">   Forfeited</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Non-vested at December 31, 2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>58</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>12.93</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">As of the year ended </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;">, there was </span><span style="font-family:inherit;font-size:10pt;"><span>$0.3 million</span></span><span style="font-family:inherit;font-size:10pt;"> of total unrecognized compensation costs related to the awards. The cost is being recognized over a weighted-average period of </span><span style="font-family:inherit;font-size:10pt;"><span>0.4</span></span><span style="font-family:inherit;font-size:10pt;"> years. </span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Information regarding the Company's RSU's for the Transition Period ended </span><span style="font-family:inherit;font-size:10pt;">December 31, 2018</span><span style="font-family:inherit;font-size:10pt;"> is as follows:</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"/></tr><tr><td style="width:38%;"/><td style="width:1%;"/><td style="width:29%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:28%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Non-Vested Restricted Stock Units</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Share Equivalent</span></div><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">(in thousands)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Weighted Average Grant Date Fair Value</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Non-vested at July 1, 2018</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>1,535</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>2.83</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Changes during the period:</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">   Restricted Units Granted </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>15</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>14.29</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">   Vested/Exercised</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(35</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>8.46</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">   Forfeited</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(1,500</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>2.28</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Non-vested at December 31, 2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>15</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>14.29</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">As of </span><span style="font-family:inherit;font-size:10pt;">December 31, 2018</span><span style="font-family:inherit;font-size:10pt;">, there was </span><span style="font-family:inherit;font-size:10pt;"><span>$0.3 million</span></span><span style="font-family:inherit;font-size:10pt;"> of total unrecognized compensation costs related to the awards. The cost was being recognized over a weighted-average period of </span><span style="font-family:inherit;font-size:10pt;"><span>1.18 years</span></span><span style="font-family:inherit;font-size:10pt;">. During the Transition Period, the Company received a final award finding from an arbitrator that denied Dr. Goldenberg </span><span style="font-family:inherit;font-size:10pt;"><span>1.5 million</span></span><span style="font-family:inherit;font-size:10pt;"> of RSU's that are included as forfeited in the table above. Refer to "Note 14 - Commitments and Contingencies" for more information.</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Performance Stock Options ("PSO's")</span></div><div style="line-height:120%;padding-left:4px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-left:4px;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"/><span style="font-family:inherit;font-size:10pt;">The Company may grant awards of PSO's to eligible individuals. PSO's are shares of Common Stock that vest based on performance measured against predetermined objectives that could include performance goals, continued employment, or a combination of both over a specified performance period. PSO's may be settled in shares of Common Stock, cash, or both as determined on the settlement date. </span></div><div style="line-height:120%;padding-left:4px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">On March 14, 2019, performance stock options were granted to certain individuals that vest upon the Company’s receipt of approval from the FDA for the Company’s BLA for sacituzumab govitecan for the treatment of patients with metastatic triple-negative breast cancer who have received at least two prior therapies for metastatic disease under the Prescription Drug User Fee Act. There were additional stock options that were granted to certain eligible individuals that vest on the second anniversary of the date of grant. In addition, on April 17, 2019 performance stock options were granted to certain individuals that vest upon achievement of defined sales performance milestones.</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-left:4px;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">    </span></div><div style="line-height:120%;padding-left:4px;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following table summarizes the Company's performance-based stock option activity for the year ended </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;"> is as follows:</span><span style="font-family:inherit;font-size:10pt;font-weight:bold;"> </span></div><div style="line-height:120%;padding-left:4px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:98.4375%;border-collapse:collapse;text-align:left;"><tr><td colspan="13"/></tr><tr><td style="width:28%;"/><td style="width:13%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:15%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:20%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:16%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Options</span></div><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">(in thousands)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Weighted Average Exercise Price Per Option</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Weighted Average Remaining Contractual Term (Years)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Aggregate Intrinsic Value (in thousands)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Options outstanding, January 1, 2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>538</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>13.09</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>6.04</span></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>772</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">   Changes during the year:</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">   Granted</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>800</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>17.18</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">   Exercised</span></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">   Expired or forfeited</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>(501</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>13.05</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Options outstanding, end of year</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>837</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#bfe4ff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#bfe4ff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>17.03</span></span></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>6.26</span></span></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#bfe4ff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>3,456</span></span></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Vested as of December 31, 2019</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>50</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>18.74</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>6.88</span></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>121</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The total fair value of shares vested during the year ended </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;"> was </span><span style="font-family:inherit;font-size:10pt;"><span>$1.1 million</span></span><span style="font-family:inherit;font-size:10pt;">. As of the year ended </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;">, there was </span><span style="font-family:inherit;font-size:10pt;"><span>$4.9 million</span></span><span style="font-family:inherit;font-size:10pt;"> of total unrecognized compensation costs related to the awards. The cost is being recognized over a remaining weighted-average period of </span><span style="font-family:inherit;font-size:10pt;"><span>0.8</span></span><span style="font-family:inherit;font-size:10pt;"> years. </span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-left:4px;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following table summarizes the Company's performance-based stock option activity for the Transition Period ended </span><span style="font-family:inherit;font-size:10pt;">December 31, 2018</span><span style="font-family:inherit;font-size:10pt;"> is as follows:</span><span style="font-family:inherit;font-size:10pt;font-weight:bold;"> </span></div><div style="line-height:120%;padding-left:4px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:98.4375%;border-collapse:collapse;text-align:left;"><tr><td colspan="13"/></tr><tr><td style="width:28%;"/><td style="width:13%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:15%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:20%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:16%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Options</span></div><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">(in thousands)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Weighted Average Exercise Price Per Option</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Weighted Average Remaining Contractual Term (Years)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Aggregate Intrinsic Value (in thousands)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Options outstanding, July 1, 2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>538</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>13.09</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>6.54</span></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>5,688</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">   Changes during the year:</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">   Granted</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">   Exercised</span></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">   Expired or forfeited</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Options outstanding, end of year</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>538</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#bfe4ff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#bfe4ff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>13.09</span></span></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>6.04</span></span></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#bfe4ff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>772</span></span></div></td><td style="vertical-align:bottom;background-color:#bfe4ff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Vested as of December 31, 2018</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>38</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>11.86</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>5.94</span></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><span>91</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">As of </span><span style="font-family:inherit;font-size:10pt;">December 31, 2018</span><span style="font-family:inherit;font-size:10pt;">, there was </span><span style="font-family:inherit;font-size:10pt;"><span>$3.0 million</span></span>&